<SEC-DOCUMENT>0001193125-21-239461.txt : 20210809
<SEC-HEADER>0001193125-21-239461.hdr.sgml : 20210809
<ACCEPTANCE-DATETIME>20210806174143
ACCESSION NUMBER:		0001193125-21-239461
CONFORMED SUBMISSION TYPE:	S-4/A
PUBLIC DOCUMENT COUNT:		60
FILED AS OF DATE:		20210809
DATE AS OF CHANGE:		20210806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Roivant Sciences Ltd.
		CENTRAL INDEX KEY:			0001635088
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				981173944
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		S-4/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-256165
		FILM NUMBER:		211154020

	BUSINESS ADDRESS:	
		STREET 1:		CLARENDON HOUSE, 2 CHURCH STREET
		CITY:			HAMILTON HM11
		STATE:			D0
		ZIP:			HM11
		BUSINESS PHONE:		441-295-5950

	MAIL ADDRESS:	
		STREET 1:		CLARENDON HOUSE
		STREET 2:		2 CHURCH STREET
		CITY:			HAMILTON
		STATE:			D0
		ZIP:			HM11
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4/A
<SEQUENCE>1
<FILENAME>d65062ds4a.htm
<DESCRIPTION>S-4/A
<TEXT>
<HTML><HEAD>
<TITLE>S-4/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on August 6, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-256165</FONT> </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:1pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Amendment
No. 4 to </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">S-4</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>ROIVANT SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Its Charter) </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Bermuda</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">98-1173944</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State or Other Jurisdiction of<BR>Incorporation or Organization)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Primary Standard Industrial<BR>Classification Code Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer<BR>Identification Number)</B></TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Suite 1, 3rd Floor </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">11-12</FONT> St. James&#146;s Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>London SW1Y 4LB </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>United
Kingdom </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Telephone: +44 207 400 3347 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#146;s Principal Executive Offices) </B></P>
<P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:1pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Derek J. Dostal</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Lee Hochbaum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Brian
Wolfe</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Davis Polk&nbsp;&amp; Wardwell LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>450 Lexington Avenue</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New
York, New York 10017</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">450-4000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Sophia Hudson, P.C.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tamar Donikyan</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Alla
Digilova</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Kirkland&nbsp;&amp; Ellis LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>601 Lexington Avenue</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New
York, New York 10022</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">446-4800</FONT></B></P></TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:7pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public:</B> As soon as practicable after this
Registration Statement is declared effective and all other conditions to the business combination described in the enclosed proxy statement/prospectus have been satisfied or waived. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:7pt; font-family:Times New Roman">If the securities being registered on this form are being offered in connection with the formation of a holding company and there is compliance
with General Instruction G, check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:7pt; font-family:Times New Roman">If this form is filed to register additional securities for an
offering pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the
same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:7pt; font-family:Times New Roman">If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check
the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:7pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 as amended (the &#147;Exchange Act&#148;). </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744; (Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">Emerging&nbsp;Growth&nbsp;Company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:3%; font-size:7pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:3%; font-size:7pt; font-family:Times New Roman">If applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction: </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:3%; font-size:7pt; font-family:Times New Roman">Exchange Act Rule <FONT STYLE="white-space:nowrap">13e-4(i)</FONT> (Cross-Border Issuer Tender Offer)&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:3%; font-size:7pt; font-family:Times New Roman">Exchange Act Rule <FONT STYLE="white-space:nowrap">14d-l(d)</FONT> (Cross-Border Third-Party Tender Offer)&nbsp;&nbsp;&#9744; </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Title of Each Class<BR>of Securities to be Registered</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount to be<BR>Registered<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed<BR>Maximum<BR>Offering Price<BR>Per Unit<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed<BR>Maximum<BR>Aggregate<BR>Offering Price</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount&nbsp;of<BR>Registration&nbsp;Fee<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Roivant Common Shares<SUP
STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">51,339,779</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$9.89</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$507,750,414.31</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$55,395.57</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Warrants to purchase Roivant Common Shares<SUP
STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">30,750,276</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$12.825</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$394,372,289.70</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$43,026.02</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$902,122,704.01</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$98,421.59<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman; " ALIGN="left">The number of common shares, par value $0.000000007 per share (&#147;Roivant Common Shares&#148;), of Roivant
Sciences Ltd. (&#147;Roivant&#148;) and Roivant Common Shares issuable upon the exercise of warrants to purchase Roivant Common Shares (&#147;Roivant Warrants&#148;) being registered is based upon an estimate of the sum of (a)&nbsp;the maximum
number of shares of Class&nbsp;A common stock, par value $0.0001 per share (&#147;MAAC Class<U></U>&nbsp;A Shares&#148;), of Montes Archimedes Acquisition Corp. (&#147;MAAC&#148;) that will be outstanding immediately prior to the Business
Combination (as defined herein) and exchanged for an equal number of Roivant Common Shares (including the maximum number of shares of Class&nbsp;B common stock, par value $0.0001 per share (&#147;MAAC Class&nbsp;B Shares&#148; and, together with the
MAAC Class&nbsp;A Shares, the &#147;MAAC Shares&#148;), of MAAC that will be converted to MAAC Class&nbsp;A Shares immediately prior to the Business Combination); and (b)&nbsp;the maximum number of MAAC Class&nbsp;A Shares underlying each warrant of
MAAC entitling the holder to purchase one MAAC Class&nbsp;A Share per warrant at a price of $11.50 per share (&#147;MAAC Warrants&#148;), which will be assumed by Roivant and will become Roivant Warrants. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman; " ALIGN="left">Pursuant to Rule 416(a), there are also being registered an indeterminable number of additional securities as
may be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman; " ALIGN="left">In accordance with Rule 457(f)(1) and Rule 457(c), as applicable, based on (i)&nbsp;in respect of Roivant Common
Shares issued to MAAC securityholders, the average of the high ($9.90) and low ($9.88) prices of the MAAC Class&nbsp;A Shares on the Nasdaq Stock Market LLC (&#147;Nasdaq&#148;) on May 12, 2021 and (ii) in respect of Roivant Common Shares underlying
Roivant Warrants issued to MAAC security holders, the sum of (a) the average of the high ($1.40) and low ($1.25) prices of the MAAC Warrants on Nasdaq on May 12, 2021 and (b) $11.50, the exercise price of the MAAC Warrants, resulting in a combined
maximum offering price per warrant of $12.825. The maximum number of Roivant Common Shares issuable upon exercise of the Roivant Warrants are being simultaneously registered hereunder. Consistent with the response to Question 240.06 of the
Securities Act Rules Compliance and Disclosure Interpretations, the registration fee with respect to the Roivant Warrants has been allocated to the underlying Roivant Common Shares and those Roivant Common Shares are included in the registration
fee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman; " ALIGN="left">Determined in accordance with Section&nbsp;6(b) of the Securities Act at a rate equal to $109.10 per $1,000,000
of the proposed maximum aggregate offering price. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman; " ALIGN="left">Represents Roivant Common Shares issuable in exchange for outstanding MAAC Shares upon the merger of Rhine
Merger Sub, Inc., a wholly owned subsidiary of Roivant, with and into MAAC pursuant to the Business Combination. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman; " ALIGN="left">Represents Roivant Common Shares underlying Roivant Warrants. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman; " ALIGN="left">Previously paid. </P></TD></TR></TABLE>
<P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:1pt; margin-bottom:0pt; text-indent:3%; font-size:7pt; font-family:Times New Roman"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the Registration Statement shall
become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>The information in this preliminary proxy statement/prospectus is
not complete and may be changed. The registrant may not sell the securities described in this preliminary proxy statement/prospectus until the registration statement filed with the Securities and Exchange Commission is declared effective. This
preliminary proxy statement/prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>PRELIMINARY&#151;SUBJECT TO COMPLETION, DATED AUGUST 6, 2021 </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Montes Archimedes Acquisition Corp. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>724 Oak Grove Ave, Suite 130 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Menlo Park, CA 94025 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dear
Montes Archimedes Acquisition Corp. stockholders: </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You are cordially invited to attend the special meeting (the &#147;MAAC Special
Meeting&#148;) of Montes Archimedes Acquisition Corporation, a Delaware corporation (&#147;MAAC&#148;), at 10:00 a.m. Eastern Time, on September 28, 2021, unless postponed or adjourned to a later date or time. In light of the novel coronavirus
disease (referred to as <FONT STYLE="white-space:nowrap">&#147;COVID-19&#148;)</FONT> pandemic and to support the well-being of MAAC&#146;s stockholders and employees, the MAAC Special Meeting will be completely virtual. All MAAC stockholders as of
the record date, or their duly appointed proxies, may attend the MAAC Special Meeting virtually. Registration will begin at 9:00 a.m. Eastern Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the MAAC Special Meeting, MAAC stockholders are being asked to consider and vote upon a proposal, which is referred to herein as the
&#147;Business Combination Proposal,&#148; to approve and adopt the Business Combination Agreement, dated as of May 1, 2021 (as amended on June 9, 2021 to reflect the execution of the lock-up agreements entered into by MAAC&#146;s independent
directors and Roivant Sciences Ltd., a Bermuda exempted limited company (&#147;Roivant&#148;), and as may be further amended, supplemented or otherwise modified from time to time, the &#147;Business Combination Agreement&#148;; the Business
Combination Agreement and the transactions contemplated thereby, collectively, the &#147;Business Combination&#148;) among MAAC, Roivant and Rhine Merger Sub, Inc., a Delaware corporation (&#147;Merger Sub&#148;), a copy of which is attached to the
accompanying proxy statement/prospectus as Annex A. The Business Combination will not occur unless MAAC stockholders approve the Business Combination Proposal. In connection with the Business Combination, outstanding shares and warrants of MAAC will
be automatically canceled and extinguished and converted into shares and warrants of Roivant that are expected to be listed on Nasdaq under the new ticker symbols &#147;ROIV&#148; and &#147;ROIVW,&#148; in each case in accordance with the terms of
the Business Combination Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, MAAC and Roivant entered into subscription agreements (collectively, the
&#147;Subscription Agreements&#148;) with certain institutional and accredited investors (collectively, the &#147;PIPE Investors&#148;), pursuant to which PIPE Investors agreed to subscribe for and purchase, and MAAC agreed to issue and sell to PIPE
Investors, prior to and substantially concurrently with the closing of the Business Combination (the &#147;Closing&#148;), an aggregate of 22,000,000 MAAC Class A Shares at a purchase price of $10.00 per share, for aggregate gross proceeds of
$220,000,000 (the &#147;PIPE Financing&#148;). The MAAC Class A Shares to be offered and sold pursuant to the Subscription Agreements and the Roivant Common Shares into which such MAAC Class&nbsp;A Shares are converted in connection with the Merger
have not been registered under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), in reliance upon the exemption provided in Section 4(a)(2) thereof. Each MAAC Class&nbsp;A Share issued in the PIPE Financing will be
automatically canceled and extinguished and converted into one Roivant Common Share in the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The closing of the PIPE Financing is
subject to customary conditions for a financing of this nature, including the substantially concurrent consummation of the Business Combination. The Subscription Agreements provide that Roivant will grant the PIPE Investors certain customary
registration rights with respect to their Roivant Common Shares following the closing of the Business Combination. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, certain related agreements were entered into in
connection with the signing of the Business Combination Agreement, including the Subscription Agreements, the Transaction Support Agreements, the Sponsor Support Agreement and the Lock-Up Agreements (as defined and each described in more detail in
the accompanying proxy statement/prospectus). See the section entitled &#147;The Business Combination Proposal&#151;Related Agreements&#148; in the accompanying proxy statement/prospectus for more information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC&#146;s units, consisting of one MAAC Class A Share and one-half of one MAAC Warrant (the &#147;MAAC Units&#148;), MAAC Class A Shares and
MAAC Warrants are currently listed on the Nasdaq Capital Market LLC (&#147;Nasdaq&#148;) under the symbols &#147;MAACU,&#148; &#147;MAAC&#148; and &#147;MAACW,&#148; respectively. MAAC will apply for listing, to be effective at the time of the
Closing, of Roivant Common Shares and Roivant Warrants on Nasdaq under the symbols &#147;ROIV&#148; and &#147;ROIVW,&#148; respectively. It is a condition of the consummation of the Business Combination that Roivant&#146;s initial listing
application with Nasdaq shall have been approved. If such listing condition is not met or if such confirmation is not obtained, the Business Combination may not be consummated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You will be also asked to vote upon (a) a proposal herein referred to as the &#147;Nasdaq Proposal&#148; to approve, for the purposes of
complying with Nasdaq Listing Rule 5635(a), (b) and (d), the issuance of more than 20% of the issued and outstanding MAAC Shares upon the completion of the Business Combination and (b) a proposal herein referred to as the &#147;Adjournment
Proposal&#148; to consider and vote upon a proposal to adjourn the MAAC Special Meeting to a later date or time, if necessary, to permit further solicitation of proxies if, based upon the tabulated vote at the time of the MAAC Special Meeting, there
are not sufficient votes to approve the Business Combination Proposal, or holders of MAAC Class A Shares have elected to redeem an amount of MAAC Class A Shares such that (i) MAAC would have less than $5,000,001 of net tangible assets or (ii) the
aggregate cash proceeds from the Trust Account are not equal to or greater than $210,000,000 and the related closing condition has not been waived by Roivant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MAAC board of directors has unanimously approved the Business Combination Agreement and the transactions contemplated thereby and
recommends that MAAC stockholders vote &#147;FOR&#148; each of the proposals to be considered at the MAAC Special Meeting. The Business Combination Agreement and the transactions contemplated thereby (collectively, the &#147;Business
Combination&#148;) were approved by the boards of directors of each of MAAC, Roivant and Merger Sub, the requisite shareholders of Roivant and Roivant in its capacity as the sole shareholder of Merger Sub. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">YOUR VOTE IS VERY IMPORTANT, REGARDLESS OF THE NUMBER OF MAAC CLASS A SHARES YOU OWN. To ensure your representation at the MAAC Special
Meeting, please complete and return the enclosed proxy card or submit your proxy by following the instructions contained in the accompanying proxy statement/prospectus and on your proxy card. Please submit your proxy promptly whether or not you
expect to attend the MAAC Special Meeting. Submitting a proxy now will NOT prevent you from being able to vote online at the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You
may attend the meeting and vote your shares electronically during the meeting via live audio webcast by visiting https://www.cstproxy.com/montesarchimedes/2021. You will need the control number that is printed on your proxy card to enter the MAAC
Special Meeting. MAAC recommends that you log in at least 15 minutes before the meeting to ensure you are logged in when the MAAC Special Meeting starts. Please note that you will not be able to attend the MAAC Special Meeting in person. If your
shares are held in &#147;street name&#148; in a stock brokerage account or by a broker, bank or other nominee, you will need to contact Continental Stock Transfer&nbsp;&amp; Trust Company (&#147;CST&#148;) to receive a control number. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying proxy statement/prospectus provides you with detailed information about the proposed Business Combination. It also contains
or references information about MAAC, Roivant and certain related matters. You are encouraged to read the accompanying proxy statement/prospectus carefully. In particular, you should read the &#147;Risk Factors&#148; section beginning on
page&nbsp;34 for a discussion of the risks you should consider in evaluating the proposed Business Combination and how it will affect you. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you have any questions regarding the accompanying proxy statement/prospectus, you may
contact Okapi Partners LLC, MAAC&#146;s proxy solicitor, toll-free at (877) 279-2311 (banks and brokers call (212) 297-0720)) or email info@okapipartners.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">James C. Momtazee </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairman of the Board </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the
Securities and Exchange Commission (the &#147;SEC&#148;) nor any state securities commission has approved or disapproved of the Business Combination, the issuance of Roivant Common Shares in connection with the Business Combination or the other
transactions described in the accompanying proxy statement/prospectus, or passed upon the adequacy or accuracy of the disclosure in the accompanying proxy statement/prospectus. Any representation to the contrary is a criminal offense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying proxy statement/prospectus is dated August 6, 2021, and is first being mailed to MAAC&#146;s stockholders on or about August
13, 2021. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Montes Archimedes Acquisition Corp. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>724 Oak Grove Ave, Suite 130 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Menlo Park, CA 94025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>NOTICE OF THE SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON SEPTEMBER 28, 2021 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOTICE IS HEREBY GIVEN that a special meeting of the stockholders of Montes Archimedes Acquisition Corp., a Delaware corporation, will be held
virtually, conducted via live audio webcast at 10:00 a.m. Eastern Time on September 28, 2021, unless postponed or adjourned to a later date or time. In light of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and to support the
well-being of MAAC&#146;s stockholders and employees, the MAAC Special Meeting will be completely virtual. All MAAC stockholders as of the record date, or their duly appointed proxies, may attend the MAAC Special Meeting. Registration will begin at
9:00 a.m. Eastern Time. You may attend the meeting and vote your shares electronically during the meeting via live audio webcast by visiting https://www.cstproxy.com/montesarchimedes/2021. You will need the control number that is printed on your
proxy card to enter the MAAC Special Meeting. MAAC recommends that you log in at least 15 minutes before the meeting to ensure you are logged in when the MAAC Special Meeting starts. Please note that you will not be able to attend the MAAC Special
Meeting in person. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;1, 2021, Montes Archimedes Acquisition Corp., a Delaware corporation (&#147;MAAC&#148;), entered into
a Business Combination Agreement (as amended on June 9, 2021 to reflect the execution of the lock-up agreements entered into by MAAC&#146;s independent directors (the &#147;MAAC Independent Directors&#148; and each, a &#147;MAAC Independent
Director&#148;) and Roivant Sciences Ltd., a Bermuda exempted limited company (&#147;Roivant&#148;), and as may be further amended, supplemented or otherwise modified from time to time, the &#147;Business Combination Agreement&#148;) with Roivant,
and Rhine Merger Sub, Inc., a Delaware corporation (&#147;Merger Sub&#148;), a copy of which is attached to the accompanying proxy statement/prospectus as Annex A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement and the transactions contemplated thereby (collectively, the &#147;Business Combination&#148;) were
approved by the boards of directors of each of MAAC, Roivant and Merger Sub. The Business Combination Agreement provides for, among other things, the following transactions: (i)&nbsp;the <FONT STYLE="white-space:nowrap">bye-laws</FONT> of Roivant
will be amended and restated; (ii)&nbsp;Merger Sub will merge with and into MAAC, with MAAC surviving the merger as a wholly-owned subsidiary of Roivant (the &#147;Merger&#148;); and (iii)&nbsp;in connection with the aforementioned transactions and
the other transactions contemplated by the Business Combination Agreement, the PIPE Financing and the Transaction Support Agreements (each as defined and described in more detail in the accompanying proxy statement/prospectus) will be completed. As
described in the accompanying proxy statement/prospectus, MAAC&#146;s stockholders are being asked to consider a vote on the Business Combination, among other proposals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the effective time of the Merger (the &#147;Effective Time&#148;), (a)&nbsp;each share of MAAC Class&nbsp;A common stock (the &#147;MAAC
Class&nbsp;A Shares&#148;) and each share of MAAC Class&nbsp;B common stock (the &#147;MAAC Class&nbsp;B Shares,&#148; together with the MAAC Class&nbsp;A Shares, the &#147;MAAC Shares&#148;) that is outstanding immediately before the Effective Time
(other than treasury shares and any shares held by the MAAC Sponsor, any affiliate of the MAAC Sponsor or any MAAC Independent Director or its transferee) will be automatically canceled and extinguished and converted into one Roivant Common Share,
(b) each MAAC Class B Share that is outstanding immediately before the Effective Time and held by the MAAC Sponsor, any affiliate of the MAAC Sponsor or any MAAC Independent Director or its transferee will be automatically canceled and extinguished
and converted into a number of Roivant Common Shares based on an exchange ratio (the &#147;MAAC Sponsor Exchange Ratio&#148;), with a portion of such Roivant Common Shares issued to the MAAC Sponsor, any affiliate of the MAAC Sponsor, any MAAC
Independent Director or its transferee by virtue of the Merger being subject to the vesting and other terms and conditions set forth in the Sponsor Support Agreement (as defined and more fully described in the accompanying proxy
statement/prospectus), and (c)&nbsp;each warrant to purchase MAAC Class&nbsp;A Shares (the &#147;MAAC Warrants&#148;) that is outstanding immediately before the Effective Time will be converted automatically into the right to acquire Roivant Common
Shares on the terms and subject to the conditions set forth in the MAAC Warrant Agreement, dated as of October&nbsp;6, 2020, by and between MAAC and the Continental Stock Transfer&nbsp;&amp; Trust Company. Pursuant to the Sponsor Support Agreement,
the MAAC Sponsor Exchange Ratio is 1.0, subject to reduction in an amount equal to <FONT STYLE="white-space:nowrap">one-half</FONT> of the percentage of MAAC Class&nbsp;A Shares redeemed in </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
connection with the Business Combination (i.e., if 10% of the MAAC Class&nbsp;A Shares are so redeemed, then the MAAC Sponsor Exchange Ratio will be equal to 0.95), provided that in no event will
the MAAC Sponsor Exchange Ratio be less than 0.75. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The Business Combination Proposal &#151;</I>&nbsp;To consider and vote upon a
proposal to approve the Business Combination Agreement, certain related agreements and the transactions contemplated thereby (including the Business Combination, as defined in the accompanying proxy statement/prospectus). The Business Combination
Agreement provides for, among other things, that the Business Combination shall be effectuated through Merger Sub merging with and into MAAC, with MAAC surviving the merger as a wholly-owned subsidiary of Roivant. As described in the accompanying
proxy statement/prospectus, MAAC&#146;s stockholders are being asked to consider a vote on the Business Combination, among other proposals. A copy of the Business Combination Agreement is attached to the accompanying proxy statement/prospectus as
Annex A (Proposal No.&nbsp;1). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The Nasdaq Proposal &#151; </I>To consider and vote upon a proposal to approve, for the purposes of
complying with Nasdaq Listing Rule 5635(a), (b) and (d), the issuance of more than 20% of the issued and outstanding MAAC Shares upon the completion of the Business Combination (Proposal No. 2). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The Adjournment Proposal &#151;</I>&nbsp;To consider and vote upon a proposal to adjourn the MAAC Special Meeting to a later date or time,
if necessary, to permit further solicitation of proxies if, based upon the tabulated vote at the time of the MAAC Special Meeting, there are not sufficient votes to approve the Business Combination Proposal, or holders of MAAC Class&nbsp;A Shares
have elected to redeem an amount of MAAC Class&nbsp;A Shares such that (i) MAAC would have less than $5,000,001 of net tangible assets or (ii) the aggregate cash proceeds from the Trust Account not being equal to or greater than $210,000,000 would
not be satisfied or waived by Roivant. The Business Combination is not conditioned upon the approval of the Adjournment Proposal (Proposal No.&nbsp;3). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only holders of record of MAAC Shares at the close of business on August 10, 2021 are entitled to notice of the MAAC Special Meeting and to
vote at the MAAC Special Meeting and any adjournments or postponements thereof. A complete list of MAAC stockholders of record entitled to vote at the MAAC Special Meeting will be available for ten days before the MAAC Special Meeting at the
principal executive offices of MAAC for inspection by stockholders during ordinary business hours for any purpose germane to the MAAC Special Meeting. The eligible MAAC stockholder list will also be available on the MAAC Special Meeting website for
examination by any stockholder attending the MAAC Special Meeting live audio webcast. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of MAAC Class&nbsp;A Shares have the
right to redeem such shares for a pro rata portion of the cash held in a trust account (the &#147;Trust Account&#148;), which holds the net proceeds of MAAC&#146;s initial public offering, as of two business days prior to the consummation of the
transactions contemplated by the Business Combination Agreement (including interest earned on the funds held in the Trust Account and not previously released to MAAC to pay taxes, if any) upon the closing of the transactions contemplated by the
Business Combination Agreement. Notwithstanding the foregoing, a holder of MAAC Class&nbsp;A Shares, together with any affiliate of such holder or any other person with whom such holder is acting in concert or as a &#147;group&#148; (as defined in
Section&nbsp;13(d)(3) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), will be restricted from seeking redemption with respect to more than 15% of the MAAC Class&nbsp;A Shares. Holders of the outstanding MAAC
Warrants do not have redemption rights with respect to such warrants in connection with the transactions contemplated by the Business Combination Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval of the Business Combination Proposal requires that the initial Business Combination be approved by the affirmative vote of the
holders of a majority of MAAC Shares outstanding as of the date of the stockholder meeting held to consider such initial Business Combination. Approval of the Adjournment Proposal requires the affirmative vote of a majority of MAAC Shares present in
person or represented by proxy at the MAAC Special Meeting and entitled to vote at the meeting, regardless of whether a quorum is present. Broker <FONT STYLE="white-space:nowrap">non-votes,</FONT> while considered present for the purposes of
establishing a quorum, will not count as shares entitled to vote or votes cast at the MAAC Special Meeting, and otherwise will have no effect on the Nasdaq Proposal and Adjournment Proposal. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT>
will have the same effect as a vote &#147;<B>AGAINST</B>&#148; the Business Combination Proposal. The MAAC board of directors has approved each of the proposals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of August 5, 2021, there was $410,769,443.71 in the Trust Account, which MAAC intends to use for the purposes of consummating the Business
Combination within the time period described in the accompanying proxy statement/prospectus and to pay $14,375,138 in deferred underwriting commissions to the underwriters </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">of MAAC&#146;s initial public offering. Each redemption of MAAC Class&nbsp;A Shares by its
public stockholders will decrease the amount in the Trust Account. MAAC will not consummate the Business Combination if the redemption of MAAC Class&nbsp;A Shares would result in MAAC&#146;s failure to have at least $5,000,001 of net tangible assets
(as determined in accordance with <FONT STYLE="white-space:nowrap">Rule&nbsp;3a51-1(g)(1)</FONT> of the Exchange Act) (or any successor rule). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If MAAC stockholders fail to approve the Business Combination Proposal, the Business Combination will not occur. The proxy
statement/prospectus accompanying this notice explains the Business Combination Agreement and the transactions contemplated thereby, as well as the proposals to be considered at the MAAC Special Meeting. Please review the proxy statement/prospectus
carefully. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>YOUR VOTE IS VERY IMPORTANT, REGARDLESS OF THE NUMBER OF MAAC CLASS A SHARES YOU OWN. To ensure your representation at the
MAAC Special Meeting, please complete and return the enclosed proxy card or submit your proxy by following the instructions contained in the accompanying proxy statement/prospectus and on your proxy card. Please submit your proxy promptly whether or
not you expect to attend the meeting. Submitting a proxy now will NOT prevent you from being able to vote online at the MAAC Special Meeting. If your shares are held in &#147;street name&#148; in a stock brokerage account or by a broker, bank or
other nominee, you will need to contact CST to receive a control number. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MAAC board of directors has unanimously approved the
Business Combination Agreement and the transactions contemplated thereby and recommends that you vote &#147;<B>FOR&#148; the Business Combination Proposal, &#147;FOR&#148; the Nasdaq Proposal and, if required, &#147;FOR&#148; the Adjournment
Proposal. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you plan to vote at the MAAC Special Meeting you will need to have a legal proxy from your bank, broker, or other
nominee or if you would like to join and not vote CST will issue you a guest control number with proof of ownership. In either case, you must contact CST for specific instructions on how to receive the control number. Please allow up to 72 hours
prior to the meeting for processing your control number. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you do not have internet capabilities, you can listen only to the meeting by
dialing +1 888-965-8995 (toll-free) inside the U.S. and Canada or +1 415-655-0243 (standard rates apply), and when prompted enter the pin number 46620368#. This is listen-only, you will not be able to vote or enter questions during the meeting. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BY ORDER OF THE BOARD OF DIRECTORS:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">James C. Momtazee,</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chairman of the Board</TD></TR>
</TABLE></DIV>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES REGULATORY AGENCY HAS
APPROVED OR DISAPPROVED THE TRANSACTIONS DESCRIBED IN THE ACCOMPANYING PROXY STATEMENT/PROSPECTUS OR ANY OF THE SECURITIES TO BE ISSUED IN CONNECTION WITH THE BUSINESS COMBINATION, PASSED UPON THE MERITS OR FAIRNESS OF THE BUSINESS COMBINATION OR
RELATED TRANSACTIONS OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THE ACCOMPANYING PROXY STATEMENT/PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><A HREF="#rom65062_1">Basis of Presentation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><A HREF="#rom65062_2">Market, Industry and Other Data</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><A HREF="#rom65062_3">Trademarks</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><A HREF="#rom65062_4">Cautionary Note Regarding Forward-Looking Statements</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom65062_5">Certain Defined Terms</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><A HREF="#rom65062_6">Questions and Answers</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><A HREF="#rom65062_7">Summary of the Proxy Statement/Prospectus</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom65062_8">Summary Unaudited Pro Forma Condensed Combined Financial
Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><A HREF="#rom65062_9">Ticker Symbol and Dividend Information</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><A HREF="#rom65062_10">Risk Factors</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><A HREF="#rom65062_11">Special Meeting of MAAC Stockholders</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><A HREF="#rom65062_12">Material United States Tax Considerations</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><A HREF="#rom65062_13">Material United Kingdom Tax Considerations</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><A HREF="#rom65062_14">Proposal No. 1 - The Business Combination Proposal</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><A HREF="#rom65062_15">Proposal No. 2 - The Nasdaq Proposal</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><A HREF="#rom65062_16">Proposal No. 3 - The Adjournment Proposal</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom65062_17">Unaudited Pro Forma Condensed Combined Financial
Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom65062_18">Business of MAAC</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom65062_19">Management&#146;s Discussion and Analysis of Financial Condition and Results
 of Operations of MAAC</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom65062_20">Business of Roivant</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom65062_21">Management&#146;s Discussion and Analysis of Financial Condition and Results
 of Operations of Roivant </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom65062_22">Management after the Business Combination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom65062_23">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom65062_24">Director Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom65062_25">Beneficial Ownership of Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom65062_26">Certain MAAC Relationships and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom65062_27">Certain Roivant Relationships and Related Party
Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom65062_28">Description of Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><A HREF="#rom65062_29">Roivant Common Shares Eligible for Future Sale</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><A HREF="#rom65062_30">Appraisal Rights</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><A HREF="#rom65062_31">Future Shareholder Proposals</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><A HREF="#rom65062_32">Stockholder Communications</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom65062_33">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom65062_34">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom65062_35">Householding Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom65062_36">Where You Can Find Additional Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom65062_37">Index To Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ANNEXES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom65062_39">Annex A &#150; Business Combination Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom65062_39a">Annex AA &#150; Amendment No. 1 to the Business Combination Agreement
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">AA-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom65062_40">Annex B &#150; Form of Subscription Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">B-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom65062_41">Annex C &#150; Registration Rights Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">C-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom65062_42">Annex D &#150; Form of Transaction Support Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">D-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom65062_43">Annex E &#150; Sponsor Support Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">E-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom65062_43a">Annex EE &#150; Amendment No. 1 to the Sponsor Support Agreement
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">EE-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom65062_44">Annex F &#150; Form of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC and Roivant are responsible for the information contained in this proxy
statement/prospectus. Neither MAAC nor Roivant has authorized anyone to provide you with different information, and neither MAAC nor Roivant take responsibility for any other information others may give you. MAAC and Roivant are not making an offer
to sell these securities in any jurisdiction where the offer or sale is not permitted. You should not assume that the information contained in this proxy statement/prospectus is accurate as of any date other than its date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For investors outside of the United States, neither MAAC nor Roivant has done anything that would permit this offering or possession or
distribution of this proxy statement/prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourselves about, and to observe any restrictions relating to, this offering
and the distribution of this proxy statement/prospectus outside of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_1"></A>BASIS OF PRESENTATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proxy statement/prospectus includes references to the clinical trials that Roivant has conducted with respect to its product candidates.
Where reference is made to a clinical trial being &#147;successful,&#148; that indicates that the product candidate under evaluation in that clinical trial met its pre-specified primary endpoint(s). The eight successful Phase 3 clinical trials
referenced in this proxy statement/prospectus evaluated four distinct drug candidates or combination therapies: tapinarof, vibegron, relugolix monotherapy, and a combination of relugolix, estradiol, and norethindrone acetate. The one unsuccessful
Phase 3 clinical trial evaluated intepirdine for the treatment of Alzheimer&#146;s disease. With respect to the drug candidates that have completed successful Phase 3 clinical trials: (i) our subsidiary, Dermavant Sciences, has submitted an NDA to
the FDA for tapinarof, for which a decision on its approval is expected in mid-2022; (ii) our former subsidiary, Myovant Sciences, has received FDA approval for relugolix (marketed as Orgovyx) for the treatment of prostate cancer and the combination
of relugolix, estradiol and norethindrone acetate (marketed as Myfembree) for the treatment of uterine fibroids; (iii) our former subsidiary, Urovant Sciences, has received FDA approval for vibegron (marketed as Gemtesa) for the treatment of
overactive bladder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain summary statistics and other information presented in proxy statement/prospectus, including our clinical
trial count, the number of Vant launches and the return on our investment in publicly-listed Vants, include three entities in which we retain both an economic interest and have representation on the entities&#146; boards of directors: Arbutus
Biopharma, Sio Gene Therapies and Datavant. Other than the potential appreciation in the value of our equity interests in these entities, we do not have any further economic interests in the product candidates they are developing or their marketed
technology products, as applicable. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_2"></A>MARKET, INDUSTRY AND OTHER DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proxy statement/prospectus contains estimates, projections and other information concerning Roivant&#146;s industry, Roivant&#146;s
business and the markets for Roivant&#146;s products. Some market data and statistical information contained in this proxy statement/prospectus are also based on Roivant&#146;s management&#146;s estimates and calculations, which are derived from
their review and interpretation of the independent sources listed below, internal research and knowledge of Roivant&#146;s market. While we are not aware of any misstatements regarding the market, industry or other data presented herein, such
projections, assumptions and estimates of the future performance of the industry in which Roivant operates and Roivant&#146;s future performance are necessarily subject to uncertainty and risk due to a variety of factors, including those described
in the sections titled &#147;Cautionary Note Regarding Forward-Looking Statements&#148; and &#147;Risk Factors.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise
expressly stated, we obtained industry, business, market and other data from the reports, publications and other materials and sources listed below. In some cases, we do not expressly refer to the sources from which this data is derived. In that
regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context
otherwise requires. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_3"></A>TRADEMARKS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document contains references to trademarks, trade names and service marks belonging to other entities. Solely for convenience,
trademarks, trade names and service marks referred to in this proxy statement/consent solicitation statement/prospectus may appear without the&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, <SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP> or <SUP STYLE="font-size:85%; vertical-align:top">SM </SUP>symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent
under applicable law, its rights to these trademarks and trade names. MAAC and Roivant do not intend that use or display of other companies&#146; trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship
of us, by any other companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_4"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proxy statement/prospectus may contain &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities
Act and Section&nbsp;21E of the Exchange Act. Our forward-looking statements include, but are not limited to, statements regarding our or our management team&#146;s expectations, hopes, beliefs, intentions or strategies regarding the future, and
statements that are not historical facts, including statements about the Business Combination. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying
assumptions, are forward-looking statements. The words &#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;might,&#148;
&#147;plan,&#148; &#147;possible,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;would&#148; and similar expressions may identify forward-looking statements, but the absence of these words does not
mean that a statement is not forward-looking. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The forward-looking statements contained in this proxy statement/prospectus are based on
our current expectations and beliefs concerning future developments and their potential effects on us taking into account information currently available to us. There can be no assurance that future developments affecting us will be those that we
have anticipated. Should one or more of these risks or uncertainties materialize, they could cause our actual results to differ materially from the forward-looking statements. Some factors that could cause actual results to differ include, but are
not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing to complete the Business Combination; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the occurrence of any event, change or other circumstances that could give rise to the termination of the
Business Combination Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome of any legal proceedings that may be instituted against MAAC or Roivant in connection with the
Business Combination and related transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to complete the Business Combination and the other transactions contemplated by the Business
Combination Agreement due to the failure to obtain the requisite approval of our shareholders, or other conditions to closing in the Business Combination Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to obtain the listing of Roivant Common Shares and Roivant Warrants on Nasdaq following the Business
Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that the Business Combination disrupts Roivant&#146;s current operations as a result of the announcement
and consummation of the transactions described herein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among
other things, competition, and the ability of the combined business to grow and manage growth profitably; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to the Business Combination; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in applicable laws or regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility that MAAC or Roivant may be adversely affected by other economic, business and/or competitive
factors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks and uncertainties, including those described under the heading &#147;Risk Factors.&#148;
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not undertaking any obligation to update or revise any forward-looking statements whether as a result of new
information, future events or otherwise. You should not take any statement regarding past trends or activities as a representation that the trends or activities will continue in the future. Accordingly, you should not put undue reliance on these
statements in deciding how to grant your proxy or instruct how your vote should be cast on the proposals set forth in this proxy statement/prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_5"></A>CERTAIN DEFINED TERMS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Unless the context otherwise requires, references in this proxy statement/prospectus to: </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Basic&#148; means, when referring to Roivant&#146;s ownership interest in an entity, and unless otherwise indicated, Roivant&#146;s
percentage ownership of the issued and outstanding shares of the entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Business Combination&#148; means the merger pursuant to
the Business Combination Agreement, whereby, among other things, (a)&nbsp;the <FONT STYLE="white-space:nowrap">bye-laws</FONT> of Roivant will be amended and restated, (ii)&nbsp;Merger Sub will merge with and into MAAC, with MAAC surviving the
merger as a wholly-owned subsidiary of Roivant, and (iii)&nbsp;and the other transactions contemplated by the Business Combination Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Business Combination Agreement&#148; means the Business Combination Agreement, dated as of May&nbsp;1, 2021, by and among MAAC, Roivant
and Merger Sub, as amended on June 9, 2021 to reflect the execution of the lock-up agreements entered into by the MAAC Independent Directors and Roivant and as may be further amended, supplemented or otherwise modified from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Closing&#148; means the closing of the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Effective Time&#148; means the effective time of the Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;FDA&#148; means the U.S. Food and Drug Administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Founder Shares&#148; means 10,267,956 MAAC Class&nbsp;B Shares outstanding as of the date of this proxy statement/prospectus that were
issued to the MAAC Sponsor in a private placement prior to MAAC&#146;s initial public offering, which immediately prior to the Effective Time will automatically convert, on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, into 10,267,956 MAAC Class&nbsp;A Shares subject to the terms of the Sponsor Support Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Fully Diluted&#148; means, when referring to Roivant&#146;s ownership interest in an entity, and unless otherwise indicated,
Roivant&#146;s percentage ownership of all outstanding equity interests, whether vested or unvested, of the entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;HSR Act&#148;
means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;MAAC&#148;
means Montes Archimedes Acquisition Corp., a Delaware corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;MAAC Class&nbsp;A Shares&#148; means each share of Class&nbsp;A
common stock of MAAC, par value $0.0001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;MAAC Class&nbsp;B Shares&#148; means each share of Class&nbsp;B common stock of
MAAC, par value $0.0001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;MAAC Shares&#148; means, collectively, the MAAC Class&nbsp;A Shares and the MAAC Class&nbsp;B
Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;MAAC Sponsor&#148; means Patient Square Capital LLC, a limited liability company organized under the State of Delaware.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;MAAC Unit&#148; means each issued and outstanding unit of MAAC, consisting of one MAAC Class&nbsp;A Share and <FONT
STYLE="white-space:nowrap">one-half</FONT> of one MAAC Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;MAAC Warrant&#148; means each whole warrant of MAAC entitling the
holder to purchase one MAAC Class&nbsp;A Share per warrant at a price of $11.50 per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;MAAC Warrant Agreement&#148; means the Warrant Agreement, dated as of October 6, 2020,
by and between MAAC and the Continental Stock Transfer &amp; Trust Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Merger&#148; means the merger between MAAC and Merger
Sub. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Merger Sub&#148; means Rhine Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Roivant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;NDA&#148; means a New Drug Application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;PIPE Financing&#148; means the commitment by the PIPE Investors to purchase an aggregate of 22,000,000 MAAC Class&nbsp;A Shares at a
purchase price of $10.00 per share, for aggregate gross proceeds to MAAC of $220,000,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;PIPE Investors&#148; means those certain
institutional and accredited investors that entered into the Subscription Agreements in connection with the PIPE Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Roivant&#148; means Roivant Sciences Ltd., a Bermuda exempted limited company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Roivant Common Shares&#148; means each common share of Roivant either, as context requires, prior to or following the consummation of
the Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Roivant Warrants&#148; means each warrant to be issued by Roivant to MAAC Warrant holders and the Roivant
Common Shares underlying such warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Sponsor Support Agreement&#148; means the agreement, dated as of May 1, 2021, as amended by
Amendment No. 1, dated as of June 9, 2021, pursuant to which the MAAC Sponsor agreed to undertake certain actions in support of the Business Combination, including, but not limited to, delivering a voting proxy pursuant to which the MAAC Sponsor
will vote in favor of the proposals presented for approval herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Subscription Agreements&#148; means the subscription agreements
entered into among MAAC, Roivant and the PIPE Investors, pursuant to which such investors have agreed to subscribe for and purchase, and MAAC has agreed to issue and sell to such investors, an aggregate of 22,000,000 MAAC Class&nbsp;A Shares at a
price of $10.00 per share, for aggregate gross proceeds of $220,000,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Transaction Support Agreements&#148; means, collectively,
the agreements pursuant to which certain shareholders of Roivant entered into with MAAC and Roivant, pursuant to which such shareholders of Roivant have agreed to, among other things, certain covenants and agreements, to support, or that are
otherwise related to, the Business Combination, including an agreement to terminate certain existing agreements between Roivant and such shareholders, an agreement to not transfer his, her or its Roivant Common Shares prior to Closing and, in the
case of certain Roivant shareholders also participating in the PIPE Financing, certain covenants related to the expiration or termination of the waiting period under the HSR Act, to the extent applicable, with respect to the issuance of Roivant
Common Shares to such shareholder in connection with the Business Combination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_6"></A>QUESTIONS AND ANSWERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following are answers to certain questions that you, as a stockholder of MAAC, may have regarding the Business Combination and the
stockholder meeting. We urge you to carefully read the remainder of this proxy statement/prospectus because the information in this section may not provide all the information that might be important to you in determining how to vote. Additional
important information is also contained in the annexes to this proxy statement/prospectus. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>QUESTIONS AND ANSWERS ABOUT THE BUSINESS COMBINATION
</U></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WHAT IS THE BUSINESS COMBINATION? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">MAAC, Roivant and Merger Sub have entered into a Business Combination Agreement, dated as of May&nbsp;1, 2021
(as amended on June 9, 2021 to reflect the execution of the lock-up agreements entered into by the MAAC Independent Directors and Roivant and as may be further amended, supplemented or otherwise modified from time to time), pursuant to which, among
other things: (i)&nbsp;the <FONT STYLE="white-space:nowrap">bye-laws</FONT> of Roivant will be amended and restated; (ii)&nbsp;Merger Sub will merge with and into MAAC, with MAAC surviving the merger as a wholly-owned subsidiary of Roivant; and
(iii)&nbsp;in connection with the aforementioned transactions and the other transactions contemplated by the Business Combination Agreement, the PIPE Financing and the Transaction Support Agreements will be completed. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">MAAC will hold the MAAC Special Meeting of stockholders to consider matters relating to the proposed Business Combination. See &#147;The
Business Combination Proposal&#151;Business Combination.&#148; In addition, a copy of the Business Combination Agreement is attached to this proxy statement/prospectus as Annex A. We urge you to carefully read this proxy statement/prospectus and the
Business Combination Agreement in their entirety. MAAC and Roivant cannot complete the Business Combination unless MAAC&#146;s stockholders approve the Business Combination Agreement and the transactions contemplated thereby. MAAC is sending you
this proxy statement/prospectus to ask you to vote in favor of these and the other matters described in this proxy statement/prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WHY AM I RECEIVING THIS DOCUMENT? </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">MAAC is sending this proxy statement/prospectus to its stockholders to help them decide how to vote their MAAC
Shares with respect to the matters to be considered at the MAAC Special Meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Business Combination cannot be
completed unless MAAC&#146;s stockholders approve the Business Combination Proposal, as set forth in this proxy statement/prospectus. Information about the MAAC Special Meeting, the Business Combination and the other business to be considered by
stockholders at the MAAC Special Meeting is contained in this proxy statement/prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">This document constitutes a proxy statement of
MAAC and a prospectus of Roivant. It is a proxy statement because the board of directors of MAAC is soliciting proxies using this proxy statement/prospectus from its stockholders. It is a prospectus because Roivant, in connection with the Merger, is
offering Roivant Common Shares in exchange for the outstanding MAAC Class&nbsp;A Shares and MAAC Class&nbsp;B Shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WHAT WILL HAPPEN TO MAAC&#146;S SECURITIES UPON CONSUMMATION OF THE BUSINESS COMBINATION?
</B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">MAAC Units, the MAAC Class&nbsp;A Shares and the MAAC Warrants are publicly traded on Nasdaq under the symbols
&#147;MAACU,&#148; &#147;MAAC&#148; and &#147;MAACW,&#148; respectively. At the effective time of the Merger, outstanding MAAC Class&nbsp;A Shares and MAAC Warrants will be exchanged for newly issued Roivant Common Shares and Roivant Warrants,
respectively, which are expected to be listed on Nasdaq under the new ticker symbols &#147;ROIV&#148; and &#147;ROIVW.&#148; MAAC warrant holders and those stockholders who do not elect to have their shares redeemed need not deliver their MAAC
Class&nbsp;A Shares or warrant certificates to MAAC or MAAC&#146;s transfer agent and they will remain outstanding. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WHAT WILL MAAC STOCKHOLDERS RECEIVE IN THE BUSINESS COMBINATION? </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At the effective time of the Merger, (a)&nbsp;each MAAC Class&nbsp;A Share and each MAAC Class B Share that is
outstanding immediately before the effective time (other than treasury shares and any shares held by the MAAC Sponsor, any affiliate of the MAAC Sponsor or any MAAC Independent Director or its transferee) will be automatically canceled and
extinguished and converted into one Roivant Common Share, (b)&nbsp;each MAAC Class&nbsp;B Share that is outstanding immediately before the effective time held by the MAAC Sponsor, any affiliate of the MAAC Sponsor or any MAAC Independent Director or
its transferee will be automatically canceled and extinguished and converted into a number of Roivant Common Shares based on an exchange ratio, with a portion of such Roivant Common Shares issued to the MAAC Sponsor , any affiliate of the MAAC
Sponsor or any MAAC Independent Director or its transferee by virtue of the Merger being subject to the vesting and other terms and conditions set forth in the Sponsor Support Agreement (as more fully described in the section entitled &#147;Summary
of the Proxy Statement/Prospectus&#151;Sponsor Support Agreement&#148; below), and (c)&nbsp;each MAAC Warrant that is outstanding immediately before the effective time will be converted automatically into the right to acquire Roivant Common Shares
on the terms and subject to the conditions set forth in the MAAC Warrant Agreement, dated as of October&nbsp;6, 2020, by and between MAAC and the Continental Stock Transfer&nbsp;&amp; Trust Company. Pursuant to the Sponsor Support Agreement, the
MAAC Sponsor Exchange Ratio is 1.0, subject to reduction in an amount equal to <FONT STYLE="white-space:nowrap">one-half</FONT> of the percentage of MAAC Class&nbsp;A Shares redeemed in connection with the Business Combination (i.e., if 10% of the
MAAC Class&nbsp;A Shares are so redeemed, then the MAAC Sponsor Exchange Ratio will be equal to 0.95), provided that in no event will the MAAC Sponsor Exchange Ratio be less than 0.75. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WHEN WILL THE BUSINESS COMBINATION BE COMPLETED? </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">MAAC and Roivant currently expect that the Business Combination will be completed during the third calendar
quarter of 2021. However, MAAC cannot assure you of when or if the Business Combination will be completed, and it is possible that factors outside of the control of MAAC could result in the Business Combination being completed at a different time or
not at all. MAAC must first obtain the approval of MAAC stockholders for each of the proposals set forth in this proxy statement/prospectus (other than the Adjournment Proposal) and certain other closing conditions must be fulfilled. See &#147;The
Business Combination Proposal&#151;Business Combination&#151;Conditions to the Closing of the Business Combination.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WHAT ARE THE U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE MERGER TO U.S. HOLDERS OF MAAC CLASS A SHARES
AND/OR MAAC WARRANTS? </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the limitations and qualifications described in &#147;Material United States Tax
Considerations&#151;Tax Consequences of the Merger&#148; below, the Merger is generally intended to be tax-deferred to U.S. Holders (as defined in &#147;Material United States Tax Considerations&#148;) of MAAC Class A Shares and MAAC Warrants for
U.S. federal income tax purposes, except to the extent that such U.S. Holders of MAAC Class A Shares receive cash pursuant to the exercise of redemption rights. However, there are significant factual and legal uncertainties as to whether the Merger
qualifies for tax-deferred treatment as a &#147;reorganization&#148; under Section 368(a) of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;). If any requirement for Section 368(a) of the Code is not met, then a U.S. Holder of
MAAC Class A Shares or MAAC Warrants may recognize gain or loss in an amount equal to the difference, if any, between the fair market value (as of the date of the Closing) of Roivant Common Shares received in the Merger or MAAC Warrants assumed by
Roivant in the Merger, over such U.S. Holder&#146;s aggregate tax basis in the corresponding MAAC Class A Shares surrendered by such U.S. Holder in the Merger or MAAC Warrants assumed by Roivant in the Merger, respectively. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section 367(a) of the Code and the Treasury regulations promulgated thereunder, in certain circumstances, may impose additional requirements
for certain U.S. Holders to qualify for tax-deferred treatment with respect to the exchange of MAAC Class A Shares and/or the assumption of MAAC Warrants by Roivant in the Merger. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The tax consequences of the Merger are complex and will depend on your particular
circumstances. For a more complete discussion of the U.S. federal income tax considerations of the Merger, including the application of Section 367(a) of the Code, see the sections entitled &#147;Material United States Tax Considerations&#151;Tax
Consequences of the Merger&#148;, and &#147;Material United States Tax Considerations&#151;Additional Requirements for Tax Deferral.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you are a U.S. Holder whose MAAC Class A Shares are exchanged, or whose MAAC Warrants are assumed by Roivant, in the Merger, you are urged
to consult your tax advisor to determine the tax consequences thereof. The summary above is qualified in its entirety by the more detailed discussion provided in the section entitled &#147;Material United States Tax Considerations.&#148; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WHAT ARE THE U.S. FEDERAL INCOME TAX CONSEQUENCES OF EXERCISING MY REDEMPTION RIGHTS?
</B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Whether the redemption is subject to U.S. federal income tax depends on the particular facts and circumstances.
Please see the section entitled &#147;Material United States Tax Considerations&#151;Tax Consequences of Exercising Redemption Rights.&#148; We urge you to consult your tax advisors regarding the tax consequences of exercising your redemption
rights. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>QUESTIONS AND ANSWERS ABOUT THE MAAC SPECIAL MEETING </U></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WHAT AM I BEING ASKED TO VOTE ON AND WHY IS THIS APPROVAL NECESSARY? </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">MAAC stockholders are being asked to vote on the following proposals: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Business Combination Proposal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Nasdaq Proposal; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Adjournment Proposal. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Business Combination will not occur unless MAAC stockholders approve each of the proposals specified in this proxy statement/prospectus,
other than the Adjournment Proposal. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WHY IS MAAC PROPOSING THE BUSINESS COMBINATION? </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">MAAC is a blank check company incorporated to effect a merger, capital stock exchange, asset acquisition, share
purchase, reorganization or other similar business combination with one or more businesses. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;9, 2020,
MAAC completed its initial public offering, generating gross proceeds of $410,718,230 (which includes the gross proceeds from the partial exercise of the underwriters&#146; over-allotment option on November&nbsp;10, 2020), which were placed in the
Trust Account. All of MAAC&#146;s activity since its initial public offering has related to identifying a target company for a business combination. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Based on its due diligence investigations of Roivant and the industry in which Roivant operates, including the financial and other information
provided by Roivant in the course of the negotiations of the Business Combination Agreement, MAAC believes that Roivant aligns well with the objectives laid out in MAAC&#146;s investment thesis. As a result, MAAC believes that a business combination
with Roivant will provide MAAC stockholders with an opportunity to participate in the ownership of a publicly-listed company with significant growth potential at an attractive valuation. See &#147;The Business Combination Proposal&#151;Business
Combination&#151;The MAAC Board of Directors&#146; Reasons for the Business Combination.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DID THE MAAC BOARD OBTAIN A THIRD-PARTY VALUATION OR FAIRNESS OPINION IN DETERMINING WHETHER OR NOT TO
PROCEED WITH THE BUSINESS COMBINATION? </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">MAAC&#146;s board of directors did not obtain a third-party valuation or fairness opinion in connection with
its determination to approve the Business Combination. MAAC&#146;s officers have more than 50 years of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
combined investing experience during which they have conducted diligence on a broad set of private and publicly held health care companies. MAAC&#146;s directors also have significant operating
experience, acquisition experience and relationships in the health care industry. MAAC&#146;s officers and directors, together with their advisors, employed a disciplined and highly selective investment process that focused on accessing
differentiated opportunities through deep relationships with executives, advisors, and intermediaries to enhance the growth potential and value of a target business and provide opportunities for an attractive return to our stockholders. They
concluded that their experience and backgrounds, together with the experience and sector expertise of MAAC&#146;s advisors, enabled them to make the necessary analyses and determinations regarding the Business Combination. Accordingly, investors
will be relying solely on the judgment of MAAC&#146;s board of directors in valuing Roivant&#146;s business. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DO I HAVE REDEMPTION RIGHTS? </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you are a holder of MAAC Class&nbsp;A Shares, you have the right to redeem such shares for a pro rata
portion of the cash held in the Trust Account, which holds the net proceeds of MAAC&#146;s initial public offering, as of two business days prior to the consummation of the transactions contemplated by the Business Combination Agreement (including
interest earned on the funds held in the Trust Account and not previously released to MAAC to pay taxes, if any) upon the closing of the transactions contemplated by the Business Combination Agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a holder of MAAC Class&nbsp;A Shares, together with any affiliate of such holder or any other person with whom
such holder is acting in concert or as a &#147;group&#148; (as defined in Section&nbsp;13(d)(3) of the Exchange Act), will be restricted from seeking redemption with respect to more than 15% of the MAAC Class&nbsp;A Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Holders of the outstanding MAAC Warrants do not have redemption rights with respect to such warrants in connection with the transactions
contemplated by the Business Combination Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Under the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> MAAC Certificate of
Incorporation, the Business Combination may be consummated only if MAAC has at least $5,000,001 of net tangible assets after giving effect to redemptions by all holders of MAAC Class&nbsp;A Shares that properly demand redemption of their MAAC
Class&nbsp;A Shares for cash. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WILL MY VOTE AFFECT MY ABILITY TO EXERCISE MY REDEMPTION RIGHTS? </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No. You may exercise your redemption rights whether you vote your MAAC Class&nbsp;A Shares for or against, or
whether you abstain from voting on, the Business Combination Proposal or any other proposal described in this proxy statement/prospectus. As a result, the Business Combination Proposal can be approved by stockholders who will redeem their MAAC
Class&nbsp;A Shares and will no longer be stockholders and the Business Combination may be consummated even though the funds available from the Trust Account and the number of public stockholders are substantially reduced as a result of redemptions
by public stockholders. With fewer MAAC Class&nbsp;A Shares and public stockholders, the trading market for MAAC Class&nbsp;A Shares may be less liquid than the market for MAAC Class&nbsp;A Shares prior to the Business Combination and MAAC may not
be able to meet the listing standards of a national securities exchange, including Nasdaq. In addition, with fewer funds available from the Trust Account, the capital infusion from the Trust Account into Roivant&#146;s business will be reduced and
the amount of working capital available to Roivant following the Business Combination may be reduced. Your decision to exercise your redemption rights with respect to MAAC Class&nbsp;A Shares will have no effect on the MAAC Warrants you may also
hold. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>HOW DO I EXERCISE MY REDEMPTION RIGHTS? </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you are a holder of MAAC Class&nbsp;A Shares and wish to exercise your redemption rights, you are required
to tender your share certificates or deliver your shares to the transfer agent electronically using The Depository Trust Company&#146;s DWAC (Deposit/Withdrawal at Custodian) system, at your option, in each
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
case by the date that is two business days prior to the initially scheduled vote to approve the Business Combination. Accordingly, you have until two days prior to the initial vote on the
Business Combination to tender your shares if you wish to exercise your redemption rights. Given the relatively short period in which to exercise redemption rights, it is advisable for you to use electronic delivery of your shares. If you exercise
your redemption right, your shares will be redeemed for a pro rata portion of the amount then in the Trust Account (which, for illustrative purposes, was $410,769,443.71, or $10.00 per MAAC Class A Share, as of August 5, 2021). Such amount,
including interest earned on the funds held in the Trust Account and not previously released to MAAC to pay its taxes, if any, will be paid promptly upon consummation of the Business Combination. However, under Delaware law, the proceeds held in the
Trust Account could be subject to claims that could take priority over those of MAAC&#146;s public stockholders exercising redemption rights, regardless of whether such holders vote for or against the Business Combination Proposal. The per share
distribution from the Trust Account in such a situation may be less than originally anticipated due to such claims. Your vote on any proposal other than the Business Combination Proposal will have no impact on the amount you will receive if you
exercise your redemption rights. </TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Any request for redemption, once made by a holder of MAAC Class&nbsp;A Shares, may be
withdrawn at any time up to two days prior to the vote on the Business Combination Proposal at the MAAC Special Meeting. If you deliver your shares for redemption to MAAC&#146;s transfer agent and later decide, prior to the MAAC Special Meeting, not
to redeem your shares, you may request that MAAC&#146;s transfer agent return the shares electronically. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">No demand will be effectuated
unless the holder&#146;s MAAC Class&nbsp;A Shares have been delivered electronically to the transfer agent prior to the vote on the Business Combination Proposal at the MAAC Special Meeting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If a holder of MAAC Class&nbsp;A Shares properly makes a request for redemption and the MAAC Class&nbsp;A Shares are delivered to MAAC&#146;s
transfer agent no later than two business days prior to the initially scheduled vote to approve the Business Combination, then, if the Business Combination is consummated, MAAC will redeem these shares for a pro rata portion of funds deposited in
the Trust Account. If you exercise your redemption rights, then you will be exchanging your MAAC Class&nbsp;A Shares for cash. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For a
discussion of the material U.S. federal income tax considerations for holders of MAAC Class&nbsp;A Shares with respect to the exercise of these redemption rights, see &#147;Material United States Tax Considerations&#151;Tax Consequences of
Exercising Redemption Rights.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WHAT HAPPENS TO THE FUNDS DEPOSITED IN THE TRUST ACCOUNT AFTER CONSUMMATION OF THE BUSINESS COMBINATION?
</B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The net proceeds of MAAC&#146;s initial public offering, together with funds raised from the sale of the
private placement warrants simultaneously with the consummation of MAAC&#146;s initial public offering, were placed in the Trust Account immediately following MAAC&#146;s initial public offering. After consummation of the Business Combination, the
funds in the Trust Account will be used to pay holders of the MAAC Class&nbsp;A Shares who exercise redemption rights, to pay fees and expenses incurred in connection with the Business Combination (including aggregate fees of $14,375,138 as deferred
underwriting commissions related to MAAC&#146;s initial public offering) and for Roivant&#146;s working capital and general corporate purposes, which may include future strategic transactions. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WHAT HAPPENS IF THE BUSINESS COMBINATION IS NOT CONSUMMATED? </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If MAAC does not complete the Business Combination with Roivant for any reason, MAAC intends to search for
another target business with which to complete a business combination. If MAAC does not complete the Business Combination with Roivant or another target business by October&nbsp;9, 2022, MAAC will (i)&nbsp;cease all operations except for the purpose
of winding up; (ii)&nbsp;as promptly as reasonably possible but not more than ten business days thereafter, redeem the MAAC Class A Shares at a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to us to pay its taxes, if
any (less up to $100,000 of interest to pay dissolution expenses), divided by the number of the then outstanding MAAC Class A Shares, which redemption will completely extinguish public stockholders&#146; rights as stockholders (including the right
to receive further liquidation distributions, if any), subject to applicable law; and (iii)&nbsp;as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the board of directors,
liquidate and dissolve, subject in each case, to our obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>HOW DOES THE MAAC SPONSOR INTEND TO VOTE ON THE PROPOSALS? </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The MAAC Sponsor owns of record, and is entitled to vote, an aggregate of approximately 20% of the outstanding
MAAC Shares. The MAAC Sponsor has agreed to vote any MAAC Class&nbsp;B Shares, and any MAAC Class&nbsp;A Shares held by it as of the record date, in favor of the Business Combination Proposal. Further, the MAAC Sponsor intends to vote in favor of
all of the proposals. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WHAT CONSTITUTES A QUORUM AT THE MAAC SPECIAL MEETING? </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A majority of the voting power of the issued and outstanding MAAC Shares entitled to vote at the MAAC Special
Meeting as of the MAAC record date must be present virtually or by proxy, at the MAAC Special Meeting to constitute a quorum and in order to conduct business at the MAAC Special Meeting. Abstentions and broker
<FONT STYLE="white-space:nowrap">non-votes</FONT> will be counted as present for the purpose of determining a quorum. The holders of the MAAC Class&nbsp;B Shares, who currently own approximately 20% of the issued and outstanding MAAC Class&nbsp;A
Shares, will count towards this quorum. In the absence of a quorum, the holders of a majority of the MAAC Shares present in person or represented by proxy at the meeting, and entitled to vote at the meeting, may adjourn the MAAC Special Meeting.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of the MAAC record date, 25,669,890 MAAC Shares would be required to achieve a quorum. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WHAT VOTE IS REQUIRED TO APPROVE EACH PROPOSAL AT THE MAAC SPECIAL MEETING? </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>The Business Combination Proposal</I>: MAAC shall consummate the proposed initial Business Combination only
if it is approved by the affirmative vote of the holders of a majority of MAAC Shares outstanding as of the date of the stockholder meeting held to consider such initial Business Combination. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>The Nasdaq Proposal:</I> The affirmative vote of a majority of MAAC Shares present in person or represented by proxy at the MAAC Special
Meeting and entitled to vote at the meeting is required to approve the Nasdaq Proposal. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>The Adjournment Proposal</I>: The affirmative
vote of a majority of MAAC Shares present in person or represented by proxy at the MAAC Special Meeting and entitled to vote at the meeting, regardless of whether a quorum is present, is required to approve the Adjournment Proposal. The Business
Combination is not conditioned upon the approval of the Adjournment Proposal. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DO ANY OF MAAC&#146;S DIRECTORS OR OFFICERS HAVE INTERESTS IN THE BUSINESS COMBINATION THAT DIFFER FROM OR
ARE IN ADDITION TO THE INTERESTS OF MAAC&#146;S PUBLIC STOCKHOLDERS? </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each of MAAC&#146;s directors and officers owns MAAC Class&nbsp;B Shares and/or MAAC Warrants and therefore may
have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination. MAAC&#146;s board of directors was aware of and considered this, among other
matters, in approving the Business Combination Agreement and in </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
recommending that the Business Combination be approved by MAAC&#146;s stockholders of MAAC. See &#147;The Business Combination Proposal&#151;Business Combination&#151;Interests of Certain MAAC
Persons in the Business Combination.&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WHAT DO I NEED TO DO NOW? </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">After carefully reading and considering the information contained in this proxy statement/prospectus, please
submit your proxies as soon as possible so that your shares will be represented at the MAAC Special Meeting. Please follow the instructions set forth on the proxy card or on the voting instruction card provided by your broker, bank or other nominee
if your shares are held in the name of your broker, bank or other nominee. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>HOW DO I VOTE? </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you are a stockholder of record of MAAC as of August 10, 2021, the record date, you may submit your proxy
before the MAAC Special Meeting in any of the following ways, if available: </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">use the toll-free number shown on your proxy card; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">visit the website shown on your proxy card to vote via the Internet; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complete, sign, date and return your proxy card in the enclosed postage-paid envelope. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Stockholders who choose to participate in the MAAC Special Meeting can vote their shares electronically during the meeting via live audio
webcast by visiting https://www.cstproxy.com/montesarchimedes/2021. You will need the control number that is printed on your proxy card to enter the MAAC Special Meeting. MAAC recommends that you log in at least 15 minutes before the meeting to
ensure you are logged in when the MAAC Special Meeting starts. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If your shares are held in &#147;street name&#148; through a broker, bank
or other nominee, your broker, bank or other nominee will send you separate instructions describing the procedure for voting your shares. &#147;Street name&#148; stockholders who wish to vote at the MAAC Special Meeting will need to obtain a legal
proxy from their broker, bank or other nominee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WHEN AND WHERE IS THE MAAC SPECIAL MEETING? </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The MAAC Special Meeting of stockholders will be held on September 28, 2021, unless postponed or adjourned to a
later date. In light of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and to support the well-being of MAAC&#146;s stockholders and employees, the MAAC Special Meeting will be completely virtual. All MAAC stockholders as of the
record date, or their duly appointed proxies, may attend the MAAC Special Meeting. Registration will begin at 9:00 a.m. Eastern Time. </P></TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>HOW CAN MAAC&#146;S STOCKHOLDERS ATTEND THE SPECIAL MEETING? </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you are a registered stockholder, you will receive a proxy card from MAAC&#146;s transfer agent, CST. Your
proxy card contains instructions on how to attend the virtual MAAC Special Meeting including the URL address, along with your control number. You will need your control number to vote at the MAAC Special Meeting. If you do not have your control
number, contact CST at the phone number or <FONT STYLE="white-space:nowrap">e-mail</FONT> address below. CST&#146;s contact information is as follows: (917) 262-2373, or email proxy@continentalstock.com. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">You can <FONT STYLE="white-space:nowrap">pre-register</FONT> to attend the virtual MAAC Special Meeting three days prior to the meeting date
starting on September 25, 2021 at 9:00 a.m. Eastern Time. Enter the URL address into your browser https://www.cstproxy.com/montesarchimedes/2021, enter your control number, name and email address. Once you
<FONT STYLE="white-space:nowrap">pre-register</FONT> you can vote or enter questions in the chat box. At the start of the meeting you will need to <FONT STYLE="white-space:nowrap">re-log</FONT> in using your control number and will also be prompted
to enter your control number if you vote during the meeting. MAAC recommends that you log in at least 15 minutes before the meeting to ensure you are logged in when the MAAC Special Meeting starts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If your shares are held in &#147;street name&#148; in a stock brokerage account or by a
broker, bank or other nominee, you will need to contact CST to receive a control number. If you plan to vote at the MAAC Special Meeting you will need to have a legal proxy from your bank, broker, or other nominee or if you would like to join and
not vote CST will issue you a guest control number with proof of ownership. In either case, you must contact CST for specific instructions on how to receive the control number. Please allow 72 hours prior to the meeting for processing your control
number. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you do not have internet capabilities, you can listen only to the meeting by dialing +1 888-965-8995 <FONT
STYLE="white-space:nowrap">(toll-free)</FONT> inside the U.S. and Canada or +1 415-655-0243 (standard rates apply), and when prompted enter the pin number 46620368#. This is listen-only, you will not be able to vote or enter questions during the
meeting. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WHY IS THE SPECIAL MEETING A VIRTUAL MEETING? </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">MAAC has decided to hold the MAAC Special Meeting virtually due to the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. MAAC is sensitive to the public health and travel concerns of MAAC&#146;s stockholders and employees and the protocols that federal, state and local governments may impose. MAAC believes
that hosting a virtual meeting will enable greater stockholder attendance and participation from any location around the world. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WHAT IF DURING THE <FONT STYLE="white-space:nowrap">CHECK-IN</FONT> TIME OR DURING THE SPECIAL MEETING I
HAVE TECHNICAL DIFFICULTIES OR TROUBLE ACCESSING THE VIRTUAL MEETING WEBSITE? </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you encounter any difficulties accessing the virtual meeting during the
<FONT STYLE="white-space:nowrap">check-in</FONT> or meeting time, please call the technical support number that will be posted on the virtual stockholder meeting log in page. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>IF MY SHARES ARE HELD IN &#147;STREET NAME&#148; BY A BROKER, BANK OR OTHER NOMINEE, WILL MY BROKER, BANK OR
OTHER NOMINEE VOTE MY SHARES FOR ME? </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If your shares are held in &#147;street name&#148; in a stock brokerage account or by a broker, bank or other
nominee, you must provide the record holder of your shares with instructions on how to vote your shares. Please follow the voting instructions provided by your broker, bank or other nominee. Please note that you may not vote shares held in
&#147;street name&#148; by returning a proxy card directly to MAAC or by voting online at the MAAC Special Meeting unless you provide a &#147;legal proxy,&#148; which you must obtain from your broker, bank or other nominee. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Pursuant to applicable rules, brokers who hold shares in &#147;street name&#148; for a beneficial owner of those shares typically have the
authority to vote in their discretion on &#147;routine&#148; proposals when they have not received instructions from beneficial owners. However, brokers are not permitted to exercise their voting discretion with respect to the approval of matters
that the Nasdaq determines to be <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> without specific instructions from the beneficial owner. It is expected that all proposals to be voted on at the MAAC Special Meeting will be <FONT
STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you are a holder of MAAC Shares holding your shares in &#147;street
name&#148; and you do not instruct your broker, bank or other nominee on how to vote your shares, your broker, bank or other nominee will not vote your shares on any of the proposals presented in this proxy statement/prospectus. The failure of your
broker to vote will have no effect on the vote count for such proposals. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WHAT HAPPENS IF I SELL MY MAAC CLASS A SHARES BEFORE THE MAAC SPECIAL MEETING? </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The record date for the MAAC Special Meeting will be earlier than the date of the consummation of the Business
Combination. If you transfer your MAAC Class&nbsp;A Shares after the record date, but before the MAAC Special Meeting, unless the transferee obtains from you a proxy to vote those shares, you will retain
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
your right to vote at the MAAC Special Meeting. However, you will not be able to seek redemption of your MAAC Class&nbsp;A Shares because you will no longer be able to deliver them for
cancellation upon the consummation of the Business Combination in accordance with the provisions described herein. If you transfer your MAAC Class&nbsp;A Shares prior to the record date, you will have no right to vote those shares at the MAAC
Special Meeting or redeem those shares for a pro rata portion of the proceeds held in the Trust Account. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WHAT IF I ATTEND THE MAAC SPECIAL MEETING AND ABSTAIN OR DO NOT VOTE? </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For purposes of the MAAC Special Meeting, an abstention occurs when a stockholder attends the meeting online
and does not vote or returns a proxy with an &#147;abstain&#148; vote. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you are a holder of MAAC Shares that attends
the MAAC Special Meeting virtually and fails to vote, or if you vote abstain, your failure to vote or abstention will have the same effect as a vote &#147;<B>AGAINST</B>&#148; the Business Combination Proposal, the Nasdaq Proposal and the
Adjournment Proposal. Broker <FONT STYLE="white-space:nowrap">non-votes,</FONT> while considered present for the purposes of establishing a quorum, will not count as shares entitled to vote or votes cast at the MAAC Special Meeting, and otherwise
will have no effect on the Nasdaq Proposal and Adjournment Proposal. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have the same effect as a vote &#147;<B>AGAINST</B>&#148; the Business Combination Proposal. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WHAT WILL HAPPEN IF I RETURN MY PROXY CARD WITHOUT INDICATING HOW TO VOTE? </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you sign and return your proxy card without indicating how to vote on any particular proposal, the MAAC
Shares represented by your proxy will be voted as recommended by MAAC&#146;s board of directors with respect to that proposal. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MAY I CHANGE MY VOTE AFTER I HAVE DELIVERED MY PROXY OR VOTING INSTRUCTION CARD? </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Yes. You may change your vote at any time before your proxy is voted at the MAAC Special Meeting (provided that
you do not hold your shares through a broker, bank or other nominee). </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">You may do this in one of two ways: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mailing a new, subsequently dated proxy card; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by attending the MAAC Special Meeting virtually and electing to vote your shares online at the meeting.
</P></TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Any proxy that you submitted may also be revoked by submitting a new proxy by mail, or online or by telephone, not
later than 11:59 p.m., Eastern Time, on September 27, 2021, or by voting online at the MAAC Special Meeting. Simply attending the MAAC Special Meeting will not revoke your proxy. If you have instructed a broker, bank or other nominee to vote your
MAAC Shares, you must follow the directions you receive from your broker, bank or other nominee in order to change or revoke your vote. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WHAT HAPPENS IF I FAIL TO TAKE ANY ACTION WITH RESPECT TO THE MAAC SPECIAL MEETING?
</B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you fail to take any action with respect to the MAAC Special Meeting and the Business Combination is
approved by stockholders and consummated, you will continue to be a stockholder of MAAC and your shares will be automatically cancelled and extinguished and converted into Roivant Common Shares at the consummation of the Business Combination.
Failure to take any action with respect to the MAAC Special Meeting will not affect your ability to exercise your redemption rights. If you fail to take any action with </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
respect to the MAAC Special Meeting and the Business Combination is not approved, you will continue to be a stockholder of MAAC while MAAC searches for another target business with which to
complete a business combination. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WHAT SHOULD I DO IF I RECEIVE MORE THAN ONE SET OF VOTING MATERIALS? </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Stockholders may receive more than one set of voting materials, including multiple copies of this proxy
statement/prospectus and multiple proxy cards or voting instruction cards. For example, if you hold your shares in more than one brokerage account, you will receive a separate voting instruction card for each brokerage account in which you hold
shares. If you are a holder of record and your shares are registered under more than one name, you will receive more than one proxy card. Please complete, sign, date and return each proxy card and voting instruction card that you receive in order to
cast a vote with respect to all of your shares. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WHOM SHOULD I CONTACT IF I HAVE ANY QUESTIONS ABOUT THE PROXY MATERIALS OR VOTING?
</B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you have any questions about the proxy materials, need assistance submitting your proxy or voting your
shares or need additional copies of this proxy statement/prospectus or the enclosed proxy card, you should contact Okapi Partners LLC, the proxy solicitation agent for MAAC, toll-free at (877) 279-2311 (banks and brokers call (212) 297-0720) or
email info@okapipartners.com<I>.</I> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_7"></A>SUMMARY OF THE PROXY STATEMENT/PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary highlights selected information from this proxy statement/prospectus and does not contain all of the information that is
important to you. To better understand the Business Combination and the proposals to be considered at the MAAC Special Meeting, you should read this entire proxy statement/prospectus carefully, including the attached annexes. See also the section
entitled &#147;Where You Can Find Additional Information.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Parties to the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Montes Archimedes Acquisition Corp. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC
is a blank check company incorporated as a Delaware corporation in July 2020 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses
or entities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MAAC Class A Shares and warrants are currently listed on Nasdaq under the symbols &#147;MAAC&#148; and
&#147;MAACW,&#148; respectively. Certain MAAC Class A Shares and MAAC Warrants currently trade as units consisting of one share of a MAAC Class A Share and one-half of one MAAC Warrant, and are listed on Nasdaq under the symbol &#147;MAACU.&#148;
The units will automatically separate into their component securities upon consummation of the Business Combination and, as a result, will no longer trade as an independent security. Upon the Closing, the Roivant Common Shares and Roivant Warrants
received in exchange for the MAAC Class A Shares and MAAC Warrants will be listed on Nasdaq under the symbols &#147;ROIV&#148; and &#147; ROIVW,&#148; respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC&#146;s principal executive offices are located at 724 Oak Grove Ave, Suite 130, Menlo Park, California 94025 and its phone number is
(650) 384-6558. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Roivant Sciences Ltd. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are building the next-generation &#147;big pharma&#148; company, organized to harness modern technologies and the entrepreneurial spirit of
nimble biotechnology companies at scale. Our mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a diverse team of experienced drug developers, scientists, physicians, company builders, data scientists and engineers, biopharma
investors, physicists and business development professionals dedicated to improving the lives of patients. At Roivant, we combine our team&#146;s extensive experience and multi-disciplinary expertise with innovative technologies to identify and
advance potentially transformative medicines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We deploy a hypothesis-driven approach to identify novel or clinically-validated targets
and biological pathways in areas of high unmet medical need. We then seek to acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or discover promising drug candidates against those targets or pathways. Our small molecule discovery engine is
powered by a unique combination of leading computational physics and machine learning capabilities for <I>in silico</I> drug design. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
develop drug candidates in subsidiary companies we call &#147;Vants&#148; with a distinct approach to sourcing talent, aligning incentives and deploying technology. Each of our Vant teams is built with deep relevant expertise to promote successful
execution of our development strategy. Our Vants continue to benefit from the support of the Roivant platform and technologies that are built to address inefficiencies in the drug discovery, development and commercialization process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our agile Vant model has allowed us to rapidly add capabilities in diverse therapeutic areas, including immunology, dermatology, hematology
and oncology, and modalities, including biologics, topicals, gene </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
therapies and bifunctional small molecules. We currently have 16 Vants and, together, we are advancing a deep and diversified pipeline of over 30 drug candidates. The Vant model also enables a
modular approach to the monetization of therapies we advance through development, allowing us to pursue commercialization of some products independently, while selectively establishing partnerships for other Vants or divesting of the Vants entirely.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our founding in 2014, we have: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conducted nine international Phase 3 trials, the last eight of which have been successful; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consummated a $3&nbsp;billion upfront partnership with Sumitomo Dainippon Pharma (&#147;Sumitomo&#148;) (see
&#147;Business of Roivant&#151;Platform Recognition&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developed three drugs that received FDA approval shortly after their transfer to Sumitomo; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launched and taken public multiple Vants, resulting in an aggregate ownership stake of $732&nbsp;million in
public Vants as of July&nbsp;30, 2021, based on a $289&nbsp;million aggregate investment in those Vants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">built a pipeline of over 30 drug candidates ranging from early discovery to registration; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">created innovative software tools to optimize each stage of the drug discovery, development and commercialization
process. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception in 2014, we have focused substantially all of our efforts and financial resources on
acquiring and developing our product candidates and expanding our platform and technologies. For the years ended March&nbsp;31, 2021 and 2020, we incurred losses from continuing operations of $900.2&nbsp;million and $568.1&nbsp;million,
respectively. As of March&nbsp;31, 2021, we had cash and cash equivalents of approximately $2.1 billion and our accumulated deficit was approximately $1.9 billion. We have not generated any revenues to date from the sale of our product candidates.
Our revenue, primarily generated through license agreements as well as from subscription and service-based fees, has not been significant to date. Our operations to date have been financed primarily through the sale of equity securities, sale of
subsidiary interests, debt financings and revenue generated from licensing and collaboration arrangements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roivant&#146;s principal
executive office is located at Suite 1, 3rd Floor, <FONT STYLE="white-space:nowrap">11-12</FONT> St. James&#146;s Square, London SW1Y 4LB, United Kingdom. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rhine Merger Sub, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Merger Sub is a
Delaware corporation and wholly-owned subsidiary of Roivant formed for the purpose of effecting the Business Combination. Merger Sub owns no material assets and does not operate any business. In the Business Combination, Merger Sub will merge with
and into MAAC, with MAAC continuing as the surviving entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Merger Sub&#146;s principal executive office is located at 151 West 42nd
Street, 15th Floor, New York, New York 10036. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Business Combination </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May 1, 2021, MAAC entered into a Business Combination Agreement with Roivant and Merger Sub and was subsequently amended on June 9, 2021 to
reflect the execution of the lock-up agreements entered into by the MAAC Independent Directors and Roivant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination
Agreement provides for, among other things, the following transactions: (i)&nbsp;Roivant&#146;s bye-laws will be amended and restated, each outstanding share of Roivant will be subdivided (and </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the case of certain non-voting shares of Roivant, converted) into Roivant Common Shares based on a fixed exchange ratio of 2.9262:1 (the &#147;Roivant Exchange Ratio&#148;), and each
outstanding equity award of Roivant will be subdivided and adjusted into comparable equity awards of Roivant, based on the Roivant Exchange Ratio (the steps contemplated by this clause (i), collectively, the &#147;Pre-Closing Steps&#148;); and (ii)
Merger Sub will merge with and into MAAC, with MAAC surviving the Merger. At the Effective Time, (a) each outstanding MAAC Class A Share and MAAC Class B Share (other than treasury shares and any shares held by the MAAC Sponsor, any affiliate of the
MAAC Sponsor or any MAAC Independent Director or its transferee) will be automatically canceled and extinguished and converted into one Roivant Common Share, (b) each outstanding MAAC Class B Share held by the MAAC Sponsor, any affiliate of the MAAC
Sponsor or any MAAC Independent Director or its transferee will be automatically canceled and extinguished and converted into a number of Roivant Common Shares based on the MAAC Sponsor Exchange Ratio, with a portion of such Roivant Common Shares
issued to the MAAC Sponsor, any affiliate of the MAAC Sponsor or any MAAC Independent Director or its transferee by virtue of the Merger being subject to the vesting and other terms and conditions set forth in the Sponsor Support Agreement, and (c)
each outstanding warrant to purchase MAAC Class A Shares will be converted automatically into the right to acquire Roivant Common Shares on the terms and subject to the conditions set forth in the MAAC Warrant Agreement. The MAAC Sponsor Exchange
Ratio is 1.0, subject to reduction in an amount equal to one-half of the percentage of MAAC Class A Shares redeemed in connection with the Business Combination (i.e., if 10% of MAAC Class A Shares are so redeemed, then the MAAC Sponsor Exchange
Ratio will be equal to 0.95), provided that in no event will the MAAC Sponsor Exchange Ratio be less than 0.75. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All Roivant Common Shares
that are outstanding and held by Roivant equityholders immediately prior to the Closing (including Roivant Common Shares issued after the Closing upon the exercise or settlement of incentive equity awards that were held by Roivant equityholders
immediately prior to the Closing) will be subject to restrictions on transfer for six months following the Closing, subject to customary exceptions. In addition, the MAAC Sponsor, the MAAC Independent Directors and certain Roivant equityholders have
entered into Lock-Up Agreements and are subject to extended transfer restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information about the Business Combination
Agreement and the Business Combination, see the section entitled &#147;The Business Combination Proposal&#151;Business Combination.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendment
No. 1 to the Business Combination Agreement</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;9, 2021, MAAC entered into an amendment (the &#147;BCA Amendment&#148;) to
the Business Combination Agreement.&nbsp;Pursuant to the BCA Amendment, the Business Combination Agreement was revised to reflect the execution of the Lock-Up Agreements described in this proxy statement/prospectus. In particular, the BCA Amendment
revised the Business Combination Agreement to reflect the MAAC Independent Directors and Roivant entering into respective lock-up agreement substantially in the form attached to this proxy statement/prospectus as Annex F. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Conditions to the Closing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The respective obligations of each party to the Business Combination Agreement to consummate the Business Combination are subject to the
satisfaction, or written waiver by the party for whose benefit such condition exists, at or prior to the Closing of the following conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there being no order or law issued by any court of competent jurisdiction or other governmental entity
(i)&nbsp;in the United States or any other jurisdiction in which the Roivant and its subsidiaries conduct material operations or (ii)&nbsp;that is otherwise material, in each case, preventing the consummation of the transactions contemplated by the
Business Combination Agreement in effect; </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the registration statement &#151; of which this proxy statement/prospectus forms a part &#151; must have become
effective in accordance with the provisions of the Securities Act, no stop order has been issued by the SEC and remains in effect with respect to the registration statement of which this proxy statement/prospectus forms a part, and no proceeding
seeking such a stop order has been threatened or initiated by the SEC and remains pending; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval of the Business Combination Agreement by the affirmative vote of the holders of the requisite number
MAAC Shares being obtained in accordance with MAAC&#146;s governing documents and applicable law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval by Nasdaq of Roivant&#146;s initial listing application in connection with the Business Combination
and, immediately following the effective time of the Merger, Roivant satisfying any applicable initial and continuing listing requirements of Nasdaq, and Roivant not having received any notice of
<FONT STYLE="white-space:nowrap">non-compliance</FONT> in connection therewith that has not been cured or would not be cured at or immediately following the effective time of Merger, and Roivant Common Shares to be issued in connection with the
Business Combination, being approved for listing on Nasdaq; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate cash proceeds from the Trust Account (after, for the avoidance of doubt, giving effect to any
redemptions by MAAC stockholders in connection with the Business Combination) being equal to or greater than $210,000,000; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after giving effect to the transactions contemplated by the Business Combination Agreement (including the PIPE
Financing), Roivant having at least $5,000,001 of net tangible assets (as determined in accordance with Rule <FONT STYLE="white-space:nowrap">3a51-1(g)(1)</FONT> of the Exchange Act). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of the parties to the Business Combination Agreement to consummate the Business Combination are subject to additional
conditions, as described more fully below in the section entitled &#147;The Business Combination Proposal&#151;Business Combination Agreement&#151;Conditions to the Closing of the Business Combination.&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Other Agreements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following agreements were entered into or will be entered into in connection with the Business Combination, the Business Combination Agreement and the other transactions contemplated thereby: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Support Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the
signing of the Business Combination Agreement, certain shareholders of Roivant entered into a Transaction Support Agreement (collectively, the &#147;Transaction Support Agreements&#148;) with MAAC and Roivant, pursuant to which such shareholders of
Roivant have agreed to, among other things, certain covenants and agreements to support, or that are otherwise related to, the Business Combination, including an agreement to terminate certain existing agreements between Roivant and such
shareholders, an agreement to not transfer his, her or its Roivant Common Shares prior to the Closing and, in the case of certain Roivant shareholders also participating in the PIPE Financing, certain covenants related to the expiration or
termination of the waiting period under the HSR Act, to the extent applicable, with respect to the issuance of Roivant Common Shares to such shareholder in connection with the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the section entitled The Business Combination Proposal&#151;Related Agreements.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lock-Up Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May 1, 2021 and
June 9, 2021, Roivant, on the one hand, and the MAAC Sponsor, both of MAAC&#146;s independent directors (the &#147;MAAC Independent Directors&#148;) and certain Roivant equityholders, on the other </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
hand, entered into lock-up agreements substantially in the form attached to this proxy statement/prospectus as Annex F (the &#147;Lock-Up Agreements&#148;), pursuant to which, among other things,
the MAAC Sponsor, the MAAC Independent Directors and such Roivant equityholders have agreed not to, subject to, and conditioned upon the effectiveness of, the Closing, effect any sale or distribution of the Roivant Common Shares (including those
underlying incentive equity awards or Roivant Warrants) held by the MAAC Sponsor, the MAAC Independent Directors or such equityholders as of immediately following the Closing during the applicable lock-up period, subject to customary exceptions. The
lock-up period applicable to Roivant Common Shares held by the MAAC Sponsor and MAAC Independent Directors as of immediately following the Closing will be (i)&nbsp;with respect to 25% of the Roivant Common Shares held by the MAAC Sponsor and MAAC
Independent Directors, six months following the Closing, (ii)&nbsp;with respect to an additional 25% of the Roivant Common Shares held by the MAAC Sponsor and MAAC Independent Directors, the earlier of twelve months following the achievement of
certain price-based vesting restrictions or six years from the Closing and (iii)&nbsp;with respect to 50% of the Roivant Common Shares held by the MAAC Sponsor and MAAC Independent Directors, thirty-six months following the Closing. The Roivant
warrants and the Roivant Common Shares underlying warrants held by the MAAC Sponsor as of immediately following the Closing will be subject to a corresponding lock-up period for (a)&nbsp;with respect to 25% of such warrants held by the MAAC Sponsor,
six months from the Closing, (b)&nbsp;with respect to an additional 25% of such warrants held by the MAAC Sponsor, twelve months from Closing and (c)&nbsp;with respect to 50% of such warrants held by the MAAC Sponsor, thirty-six months from the
Closing. The lock-up period applicable to Roivant Common Shares held by certain Roivant equityholders as of immediately following the Closing (including those underlying incentive equity awards) will be (x)&nbsp;with respect to 25% of the Roivant
Common Shares held by such Roivant equityholders (including those underlying incentive equity awards), six months following the Closing, (y)&nbsp;with respect to an additional 25% of the Roivant Common Shares held by such Roivant equityholders
(including those underlying incentive equity awards), twelve months following the Closing and (z)&nbsp;with respect to 50% of the Roivant Common Shares (including those underlying incentive equity awards) held by such Roivant equityholders,
thirty-six months following the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the section entitled &#147;The Business Combination Proposal&#151;Related
Agreements&#151;Lock-Up Agreements.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sponsor Support Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Business Combination Agreement, MAAC, MAAC Sponsor, Roivant and each of James C. Momtazee, George
Barrett, Stephen Oesterle and Maria C. Walker, each of whom is a member of MAAC&#146;s board of directors and/or management (collectively, the &#147;MAAC Insiders&#148;), entered into the Sponsor Support Agreement (the &#147;Sponsor Support
Agreement&#148;), pursuant to which, among other things: (i) the MAAC Sponsor and the MAAC Insiders have each reaffirmed his, her or its obligations in existing arrangements with MAAC to vote in favor of each of the proposals to be voted upon at the
meeting of MAAC stockholders in connection with the Business Combination, including approval of the Business Combination Agreement and the transactions contemplated thereby; (ii) the MAAC Sponsor has waived any adjustment to the conversion ratio set
forth in the governing documents of MAAC or any other anti-dilution or similar protection with respect to the MAAC Class B Common Shares that may result from the transactions contemplated by the Business Combination; (iii) subject to, and
conditioned upon, the occurrence of and effective as of, the Effective Time, the MAAC Sponsor and the MAAC Insiders have each agreed to terminate certain existing arrangements with MAAC, including existing registration rights and the existing
lock-up obligations with respect to his, her or its MAAC Shares; (iv) the MAAC Sponsor and the MAAC Insiders that hold Roivant Common Shares immediately following the Effective Time will be granted the right to include his, her or its Roivant Common
Shares in a resale registration statement to be filed in connection with the transactions contemplated by the Subscription Agreements following the Effective Time; (v) MAAC Sponsor, Roivant and MAAC have each agreed to certain covenants related to
the expiration or termination of the waiting period under the HSR Act with respect to the issuance of Roivant Common Shares to the MAAC Sponsor in connection with the Business </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Combination; and (vi) subject to, and conditioned upon the occurrence of, and effective as of immediately after, the Effective Time, (a) twenty percent of the Roivant Common Shares issued to the
MAAC Sponsor in respect of its MAAC Class B Common Shares will be subject to the vesting conditions described below and the other restrictions set forth in the Sponsor Support Agreement (the &#147;$15 Earn-Out Shares&#148;) and (b) ten percent of
the Roivant Common Shares issued to the MAAC Sponsor in respect of its MAAC Class B Common Shares will be subject to the vesting conditions described below and the other restrictions set forth in the Sponsor Support Agreement (the &#147;$20 Earn-Out
Shares&#148; and, together with the $15 Earn-Out Shares, the &#147;Earn-Out Shares&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $15 Earn-Out Shares will vest if the
closing price of the Roivant Common Shares is greater than or equal to $15.00 over any twenty out of thirty trading day period during the five year period following the Closing, and the $20 Earn-Out Shares will vest if the closing price of the
Roivant Common Shares is greater than or equal to $20.00 over any twenty out of thirty trading day period during the five year period following the Closing. The five year vesting period described in the preceding sentence will, if a definitive
purchase agreement with respect to a Sale (as defined in the Sponsor Support Agreement) is entered into on or prior to the end of such period, be extended to the earlier of one day after the consummation of such Sale and the termination of such
definitive transaction agreement, and if a Sale occurs during such five year (or, as applicable, longer) vesting period, then all of the Earn-Out Shares unvested as of such time will automatically vest immediately prior to the consummation of such
Sale. If any Earn-Out Shares have not vested on or prior to the end of the five year (or, as applicable, longer) vesting period, then such Earn-Out Shares will be forfeited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June 9, 2021, MAAC, the MAAC Sponsor, Roivant and the MAAC Insiders entered into Amendment No. 1 to the Sponsor Support Agreement
(&#147;SSA Amendment&#148;) pursuant to which the Sponsor Support Agreement was revised to reflect the MAAC Independent Directors and Roivant entering into respective Lock-Up Agreements. In particular, among other things, the SSA Amendment revised
the Sponsor Support Agreement to subject the Roivant Common Shares issued to each MAAC Independent Director in respect of his or her MAAC Class B Shares to the same vesting conditions applicable to the Roivant Common Shares issued to the MAAC
Sponsor. Specifically, (a) twenty percent of the Roivant Common Shares issued to each MAAC Independent Director will be treated as $15 Earn-Out Shares (as defined in the Sponsor Support Agreement) and (b) ten percent of the Roivant Common Shares
issued to each MAAC Independent Director will be treated as $20 Earn-Out Shares (as defined in the Sponsor Support Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the
section entitled &#147;The Business Combination Proposal&#151;Related Agreements&#151;Sponsor Support Agreement.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights Agreement
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Business Combination Agreement, certain Roivant shareholders entered into the Third Amended and
Restated Registration Rights Agreement pursuant to which, among other things, Roivant will be obligated to file a registration statement to register the resale of certain Roivant Common Shares within 30 days after the consummation of the Business
Combination and certain Roivant shareholders party thereto, subject to certain exceptions, will be granted certain customary registration rights as of the effective date of the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the section entitled &#147;The Business Combination Proposal&#151;Related Agreements&#151;Registration Rights Agreement.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Subscription Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC and Roivant
entered into Subscription Agreements with certain institutional and accredited investors, pursuant to which such investors agreed to subscribe for and purchase, and MAAC agreed to issue and </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sell to such investors, prior to and substantially concurrently with the Closing, an aggregate of 22,000,000 MAAC Class A Shares at a purchase price of $10.00 per share, for aggregate gross
proceeds of $220,000,000. The MAAC Class A Shares to be offered and sold pursuant to the Subscription Agreements and the Roivant Common Shares (into which such MAAC Class A Shares are converted in connection with the Merger) have not been registered
under the Securities Act, in reliance upon the exemption provided in Section&nbsp;4(a)(2) thereof. Each MAAC Class A Share issued in the PIPE Financing will be converted into one Roivant Common Share in the Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The closing of the PIPE Financing is subject to customary conditions for a financing of this nature, including the substantially concurrent
consummation of the Business Combination. The Subscription Agreements provide that Roivant will grant the investors in the PIPE Financing certain customary registration rights with respect to their Roivant Common Shares following the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the section entitled &#147;The Business Combination Proposal&#151;Related Agreements.&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Interests of Certain MAAC Persons in the Business Combination </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When considering the recommendation of the MAAC board of directors to vote in favor of the Business Combination, you should be aware that,
aside from their interests as stockholders, the MAAC Sponsor and the holders of the Founder Shares have other interests in the Business Combination that are different from, or in addition to, those of other MAAC stockholders generally. The MAAC
board of directors was aware of and considered these interests, among other matters, in evaluating and unanimously approving the Business Combination and in recommending to MAAC stockholders that they approve the Business Combination. MAAC
stockholders should take these interests into account in deciding whether to approve the Business Combination. These interests include, among other things, the interests listed below: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">MAAC&#146;s directors and officers and the MAAC Sponsor have waived their right to redeem any Founder Shares and
MAAC Class&nbsp;A Shares held by them (if any) in connection with a stockholder vote to approve a proposed initial business combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the MAAC Sponsor paid an aggregate of $25,000 for the Founder Shares, which will convert into
10,267,956 MAAC Class&nbsp;A Shares held by the MAAC Sponsor and the MAAC Independent Directors in accordance with the terms of MAAC&#146;s amended and restated certificate of incorporation and such securities will have a significantly higher value
at the time of the Business Combination when such shares convert into shares in the combined company, as described further below: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Class<BR>A Stock<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value of Class<BR>A Stock<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MAAC Sponsor<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,167,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,679,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">George Barrett</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Oesterle</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Interests shown consist solely of Founder Shares, classified as Class B common stock. Such shares will
automatically convert into Class&nbsp;A common stock concurrently with or immediately following the consummation of the Business Combination on a one-for-one basis, subject to adjustment pursuant to the MAAC Sponsor Exchange Ratio. Share amounts are
subject to the terms and conditions set forth in the Sponsor Support Agreement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Patient Square Capital LLC is the record holder of the shares reported herein. James C. Momtazee is the
managing member of Patient Square Capital LLC and has voting and dispositive power over such securities. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes a value of $10.00 per share, the deemed value of the Class&nbsp;A Stock in the Business Combination.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the MAAC Sponsor and MAAC&#146;s directors and officers have agreed to waive their rights to
liquidating distributions from the Trust Account with respect to the Founder Shares if we fail to complete an initial business combination by October&nbsp;9, 2022; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the MAAC Sponsor, in which certain of MAAC&#146;s officers and directors hold a direct or indirect
interest, purchased an aggregate of 10,214,365 warrants in a private placement from MAAC for an aggregate purchase price of $10,214,365 (or $1.00 per warrant), each of such private placement warrants is exercisable commencing on the later of 12
months from the closing of MAAC&#146;s initial public offering and 30 days following the Closing for one MAAC Class&nbsp;A Share at $11.50 per share; if we do not consummate an initial business combination by October&nbsp;9, 2022, then the proceeds
from the sale of the private placement warrants will be part of the liquidating distribution to the public stockholders and the private placement warrants held by the MAAC Sponsor will be worthless; the warrants held by the MAAC Sponsor had an
aggregate market value of approximately $13,278,674.50 based upon the closing price of $1.30 per warrant on Nasdaq on August 5, 2021; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">James C. Momtazee, Chairman, Chief Executive Officer and President of MAAC, is expected to be a director of
Roivant after the consummation of the Business Combination. As such, in the future, he may receive cash fees, stock options, stock awards or other remuneration that the Roivant board of directors determines to pay to him and any applicable
compensation as described under section &#147;Executive Compensation&#151;Director Compensation&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the Trust Account is liquidated, including in the event we are unable to complete an initial business
combination within the required time period, the MAAC Sponsor has agreed that it will be liable to us if and to the extent any claims by a third-party (other than MAAC&#146;s independent public accountants) for services rendered or products sold to
us, or a prospective target business with which we have entered into a transaction agreement, reduce the amount of funds in the trust account to below: (i) $10.00 per public share; or (ii)&nbsp;such lesser amount per public share held in the trust
account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets, in each case, net of the interest which may be withdrawn to pay taxes, except as to any claims by a third-party who executed a waiver
of any and all rights to seek access to the trust account and except as to any claims under our indemnity of the underwriters of MAAC&#146;s initial public offering against certain liabilities, including liabilities under the Securities Act; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the MAAC Sponsor and MAAC&#146;s officers and directors will lose their entire investment in us,
which investment amount totaled $10,239,365, and will not be reimbursed for any out-of-pocket expenses, which totaled $23,418 as of June 17, 2021, if the Business Combination, or an alternative initial business combination, is not consummated by
October 9, 2022. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time prior to the Special Meeting, during a period when they are not then aware of any material
<FONT STYLE="white-space:nowrap">non-public</FONT> information regarding MAAC or its securities, the MAAC Sponsor, MAAC&#146;s directors and officers, Roivant and/or their respective affiliates may purchase shares and/or warrants from investors, or
they may enter into transactions with such investors and others to provide them with incentives to acquire shares of MAAC Shares or vote their shares in favor of the Business Combination Proposal. The purpose of such share purchases and other
transactions would be to increase the likelihood that the proposals presented to stockholders for approval at the Special Meeting are approved or to provide additional equity financing. Any such share purchases and other transactions may thereby
increase the likelihood of obtaining stockholder approval of the Business Combination. This may result in the completion of our Business Combination that may not otherwise have been possible. While the exact nature of any such incentives has not
been determined as of the date of this proxy statement/prospectus, they might include, without limitation, arrangements to protect such investors or holders against potential loss in value of their shares, including the granting of put options. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Entering into any such incentive arrangements may have a depressive effect on MAAC Shares.
For example, as a result of these arrangements, an investor or holder may have the ability to effectively purchase shares at a price lower than market and may therefore be more likely to sell the shares he owns, either prior to or immediately after
the Special Meeting. If such transactions are effected, the consequence could be to cause the Business Combination to be approved in circumstances where such approval could not otherwise be obtained. Purchases of shares by the persons described
above would allow them to exert more influence over the approval of the proposals to be presented at the Special Meeting and would likely increase the chances that such proposals would be approved. As of the date of this proxy statement/prospectus,
there have been no such discussions and no agreements to such effect have been entered into with any such investor or holder. MAAC will file a Current Report <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;8-K&nbsp;to&nbsp;disclose</FONT> any
arrangements entered into or significant purchases made by any of the aforementioned persons that would affect the vote on the proposals to be voted on at the Special Meeting. Any such report will include descriptions of any arrangements entered
into or significant purchases by any of the aforementioned persons. The existence of financial and personal interests of our directors and officers may result in conflicts of interest, including a conflict between what may be in the best interests
of MAAC and its stockholders and what may be best for a director&#146;s personal interests when determining to recommend that stockholders vote for the proposals. See the sections entitled &#147;Risk Factors,&#148; &#147;The Business Combination
Proposal&#151;Interests of Certain MAAC Persons in the Business Combination&#148; and &#147;Beneficial Ownership of Securities&#148; for more information and other risks. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Reasons for Approval of the Business Combination </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC&#146;s board of directors considered a wide variety of factors in connection with its evaluation of the Business Combination. In light of
the complexity of those factors, MAAC&#146;s board of directors, as a whole, did not consider it practicable to, nor did it attempt to, quantify or otherwise assign relative weights to the specific factors it took into account in reaching its
decision. Individual members of MAAC&#146;s board of directors may have given different weight to different factors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a more complete
description of MAAC&#146;s reasons for the approval of the Business Combination and the recommendation of MAAC&#146;s board of directors, see the section entitled &#147;The Business Combination&#151;MAAC Board of Directors&#146; Reasons for the
Business Combination.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Redemption Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a holder of MAAC Class A Shares, you have the right to redeem such shares for a pro rata portion of the cash held in the Trust
Account, which holds the net proceeds of MAAC&#146;s initial public offering, as of two business days prior to the consummation of the transactions contemplated by the Business Combination Agreement (including interest earned on the funds held in
the Trust Account and not previously released to MAAC to pay taxes, if any) upon the closing of the transactions contemplated by the Business Combination Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a holder of MAAC Class A Shares, together with any affiliate of such holder or any other person with whom such
holder is acting in concert or as a &#147;group&#148; (as defined in Section 13(d)(3) of the Exchange Act), will be restricted from seeking redemption with respect to more than 15% of the MAAC Class A Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of the outstanding MAAC Warrants do not have redemption rights with respect to such warrants in connection with the transactions
contemplated by the Business Combination Agreement. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Pre-Closing MAAC Certificate of Incorporation, the Business Combination may be
consummated only if MAAC has at least $5,000,001 of net tangible assets after giving effect to redemptions by all holders of MAAC Class A Shares that properly demand redemption of their MAAC Class A Shares for cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may exercise your redemption rights whether you vote your MAAC Class A Shares for or against, or whether you abstain from voting on, the
Business Combination Proposal or any other proposal described in this proxy statement/prospectus. As a result, the Business Combination Proposal can be approved by stockholders who will redeem their MAAC Class A Shares and will no longer be
stockholders and the Business Combination may be consummated even though the funds available from the Trust Account and the number of public stockholders are substantially reduced as a result of redemptions by public stockholders. With fewer MAAC
Class A Shares and public stockholders, the trading market for MAAC Class A Shares may be less liquid than the market for MAAC Class A Shares prior to the Business Combination and MAAC may not be able to meet the listing standards of a national
securities exchange, including Nasdaq. In addition, with fewer funds available from the Trust Account, the capital infusion from the Trust Account into Roivant&#146;s business will be reduced and the amount of working capital available to Roivant
following the Business Combination may be reduced. Your decision to exercise your redemption rights with respect to MAAC Class A Shares will have no effect on the MAAC Warrants you may also hold. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a holder of MAAC Class A Shares and wish to exercise your redemption rights, you are required to tender your share certificates or
deliver your shares to the transfer agent electronically using The Depository Trust Company&#146;s DWAC (Deposit/Withdrawal at Custodian) system, at your option, in each case until the date that is two business days prior to the initially scheduled
vote to approve the Business Combination. Accordingly, you have until two days prior to the initial vote on the Business Combination to tender your shares if you wish to exercise your redemption rights. Given the relatively short period in which to
exercise redemption rights, it is advisable for you to use electronic delivery of your shares. If you exercise your redemption right, your shares will be redeemed for a pro rata portion of the amount then in the Trust Account (which, for
illustrative purposes, was $410,769,443.71, or $10.00 per MAAC Class A Share, as of August 5, 2021). Such amount, including interest earned on the funds held in the Trust Account and not previously released to MAAC to pay its taxes, if any, will be
paid promptly upon consummation of the Business Combination. However, under Delaware law, the proceeds held in the Trust Account could be subject to claims that could take priority over those of MAAC&#146;s public stockholders exercising redemption
rights, regardless of whether such holders vote for or against the Business Combination Proposal. The per share distribution from the Trust Account in such a situation may be less than originally anticipated due to such claims. Your vote on any
proposal other than the Business Combination Proposal will have no impact on the amount you will receive if you exercise your redemption rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MAAC&#146;s transfer agent can be contacted at the following address: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Continental Stock Transfer &amp; Trust Company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">One State Street, 30th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New
York, NY 10004 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn: Mark Zimkind </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email: mzimkind@continentalstock.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any request for redemption, once made by a holder of MAAC Class A Shares, may be withdrawn at any time up to two days prior to the vote on the
Business Combination Proposal at the MAAC Special Meeting. If you deliver your shares for redemption to MAAC&#146;s transfer agent and later decide, prior to the MAAC Special Meeting, not to redeem your shares, you may request that MAAC&#146;s
transfer agent return the shares electronically. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No demand will be effectuated unless the holder&#146;s MAAC Class A Shares have been
delivered electronically to the transfer agent not later than two business days prior to the initially scheduled vote to approve the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a holder of MAAC Class A Shares properly makes a request for redemption and the MAAC Class A Shares are delivered to MAAC&#146;s transfer
agent no later than two business days prior to the initially scheduled vote to approve the Business Combination, then, if the Business Combination is consummated, MAAC will redeem these shares for a pro rata portion of funds deposited in the Trust
Account. If you exercise your redemption rights, then you will be exchanging your MAAC Class A Shares for cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a discussion of the
material U.S. federal income tax considerations for holders of MAAC Class A Shares with respect to the exercise of these redemption rights, see &#147;Material United States Tax Considerations&#151;Tax Consequences of a Redemption of MAAC Public
Shares.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Board of Directors of Roivant Following the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Closing, it is expected that the Roivant Board will consist of nine directors determined by Roivant (upon reasonable prior
consultation with MAAC) prior to the Effective Time, with one director, James C. Momtazee, being designated by MAAC, and the other directors being determined by Roivant (upon reasonable prior consultation with MAAC). See &#147;Management After The
Business Combination&#151;Executive Officers and Directors.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information about the current MAAC directors and executive officers can
be found in the section entitled &#147;Where You Can Find Additional Information.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Accounting Treatment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination is a capital transaction in substance whereby MAAC will be treated as the acquired company for financial reporting
purposes. Accordingly, for accounting purposes, the Business Combination will be treated similar to an equity contribution in exchange for the issuance of Roivant shares. The net assets of MAAC, which are primarily comprised of cash and cash
equivalents, will be stated at historical cost with no goodwill or other intangible assets recorded. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Appraisal Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Appraisal rights are not available to MAAC stockholders in connection with the Business Combination. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Proposals to be Put to the Stockholders of MAAC at the MAAC Special Meeting </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the proposals to be put to the MAAC Special Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination Proposal. MAAC shall consummate the proposed initial Business Combination only if the Business Combination Proposal
is approved by the affirmative vote of the holders of a majority of MAAC Shares outstanding as of the date of the stockholder meeting held to consider such initial Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nasdaq Proposal. MAAC shall consummate the proposed initial Business Combination only if the Nasdaq Proposal is approved by the
affirmative vote of a majority of MAAC Shares present in person or represented by proxy at the MAAC Special Meeting and entitled to vote at the meeting. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Adjournment Proposal. The affirmative vote of a majority of MAAC Shares present in
person or represented by proxy at the MAAC Special Meeting and entitled to vote at the meeting, regardless of whether a quorum is present, is required to approve the Adjournment Proposal. The Business Combination is not conditioned upon the approval
of the Adjournment Proposal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Date, Time and Place of MAAC Special Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MAAC Special Meeting will be held on September 28, 2021, at 10:00 a.m., Eastern Time, via a virtual meeting. In light of COVID-19 pandemic
and to support the well-being of MAAC&#146;s stockholders and employees, the MAAC Special Meeting will be completely virtual. MAAC stockholders may attend the MAAC Special Meeting and vote their shares electronically during the meeting via live
audio webcast by visiting https://www.cstproxy.com/montesarchimedes/2021. MAAC Stockholders will need the control number that is printed on their proxy card to enter the MAAC Special Meeting. MAAC recommends that stockholders log in at least 15
minutes before the meeting to ensure they are logged in when the MAAC Special Meeting starts. MAAC stockholders will not be able to attend the MAAC Special Meeting in person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Power; Record Date </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You will
be entitled to vote or direct votes to be cast at the MAAC Special Meeting if you owned MAAC Shares at the close of business on August 10, 2021, which is the record date for the MAAC Special Meeting. You are entitled to one vote for each MAAC Share
that you owned as of the close of business on the MAAC record date. If your shares are held in &#147;street name&#148; through a broker, bank or other nominee, your broker, bank or other nominee will send you separate instructions describing the
procedure for voting your shares. On the MAAC record date, there were 51,339,779 MAAC Shares outstanding. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Proxy Solicitation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC is soliciting proxies on behalf of its board of directors. This solicitation is being made by mail but also may be made by telephone. MAAC
and its directors, officers and employees may also solicit proxies online. MAAC will file with the SEC all scripts and other electronic communications as proxy soliciting materials. MAAC will bear the cost of the solicitation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC has hired Okapi Partners LLC to assist in the proxy solicitation process. MAAC will pay to Okapi Partners LLC a fee of $19,500, plus
disbursements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC will ask banks, brokers and other institutions, nominees and fiduciaries to forward the proxy materials to their
principals and to obtain their authority to execute proxies and voting instructions. MAAC will reimburse them for their reasonable expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quorum
and Required Vote for Proposals for the MAAC Special Meeting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A quorum of MAAC stockholders is necessary to hold a valid meeting. A
quorum will be present at the MAAC Special Meeting if a majority of the outstanding MAAC Shares as of the MAAC record date at the MAAC Special Meeting is represented virtually or by proxy. Abstentions and broker non-votes will be counted as present
for the purpose of determining a quorum. The holders of the MAAC Class B Common Shares, who currently own 20% of the issued and outstanding MAAC Shares, will count towards this quorum. As of the MAAC record date for the MAAC Special Meeting,
25,669,890 MAAC Shares would be required to achieve a quorum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval of the Business Combination Proposal requires that the initial
Business Combination be approved by the affirmative vote of the holders of a majority of MAAC Shares outstanding as of the date of the stockholder </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
meeting held to consider such initial Business Combination. Approval of the Adjournment Proposal requires the affirmative vote of a majority of shares present in person or represented by proxy at
the MAAC Special Meeting and entitled to vote thereon, regardless of whether a quorum is present. The MAAC board of directors has approved each of the proposals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recommendation to MAAC Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After careful consideration, MAAC&#146;s board of directors recommends that MAAC&#146;s stockholders vote &#147;FOR&#148; each proposal being
submitted to a vote of MAAC&#146;s stockholders at the MAAC Special Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a more complete description of MAAC&#146;s reasons for
the approval of the Business Combination and the recommendation of MAAC&#146;s board of directors, see the section entitled &#147;The Business Combination&#151;MAAC Board of Directors&#146; Reasons for the Business Combination.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When you consider the recommendation of the board of directors to vote in favor of approval of the proposals, you should keep in mind that our
sponsor and certain of our directors and officers have interests have interests in the Business Combination that are different from or in addition to (and which may conflict with) your interests as a stockholder. Please see the section entitled
&#147;The Business Combination&#151;Interests of Certain MAAC Persons in the Business Combination.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of Corporate Governance and
Shareholder Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a summary of the material differences among the rights of holders of Roivant Common Shares and holders of MAAC
Shares see &#147;The Business Combination Proposal&#151;The Business Combination&#151;Comparison of Corporate Governance and Shareholder Rights.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulatory Matters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business
Combination and the transactions contemplated by the Business Combination Agreement are not subject to any federal or state regulatory requirements or approvals. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary of Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should consider carefully the risks described under &#147;Risk Factors&#148; in this proxy statement/prospectus. A summary of the risks
that could materially and adversely affect our business, financial condition, operating results and prospects include the following: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to
Roivant&#146;s Business and Industry </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Unless the context otherwise requires, references in this subsection to &#147;we,&#148; &#147;us,&#148;
&#147;our&#148; and the &#147;Company&#148; refer to Roivant and its subsidiaries and affiliates in the present tense or from and after the consummation of the Business Combination, as the context requires. </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our limited operating history and the inherent uncertainties and risks involved in biopharmaceutical product
development may make it difficult for us to execute on our business model and for you to assess our future viability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will likely incur significant operating losses for the foreseeable future and may never achieve or maintain
profitability. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ongoing global pandemic resulting from the outbreak of the novel strain of coronavirus, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> which causes <FONT STYLE="white-space:nowrap">COVID-19,</FONT> could adversely impact our business, including our clinical trials and <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may not be successful in our efforts to acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or
discover new product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Because we have multiple programs and product candidates in our development pipeline and are pursuing a variety
of target indications and treatment approaches, we may expend our limited resources to pursue a particular product candidate and fail to capitalize on development opportunities or product candidates that may be more profitable or for which there is
a greater likelihood of success. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We face risks associated with the Vant structure. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinical trials and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies are very expensive,
time-consuming, difficult to design and implement and involve uncertain outcomes. We may encounter substantial delays in clinical trials, or may not be able to conduct or complete clinical trials or
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies on the expected timelines, if at all. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our approach to the discovery and development of product candidates from our targeted protein degradation
platform is unproven, which makes it difficult to predict the time, cost of development and likelihood of successfully developing any product candidates from this platform. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may not be successful in our efforts to acquire, in-license or discover new product candidates.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Certain of our product candidates, including our gene therapy product candidates, are novel, complex and
difficult to manufacture. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Obtaining approval of a new drug is an extensive, lengthy, expensive and inherently uncertain process, and the
FDA or another regulator may delay, limit or deny approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of product candidates
that we may identify and pursue for their intended uses, which would prevent, delay or limit the scope of regulatory approval and commercialization. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our product candidates may cause adverse effects or have other properties that could delay or prevent their
regulatory approval, cause us to suspend or discontinue clinical trials, abandon further development or limit the scope of any approved label or market acceptance. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We depend on the knowledge and skills of our senior leaders, and may not be able to manage our business
effectively if we are unable to attract and retain key personnel. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Changes in funding for, or disruptions to the operations of, the FDA, the SEC and other government agencies could
hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the
operation of our business may rely, which could negatively impact our business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will need to expand our organization and may experience difficulties in managing this growth, which could
disrupt operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to obtain and maintain patent and other intellectual property protection for our technology and
product candidates or if the scope of the intellectual property protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the patent applications we hold or have <FONT STYLE="white-space:nowrap">in-licensed</FONT> with respect to
our product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our product candidates or any future product candidate, it could dissuade companies from
collaborating with us to develop product candidates, and threaten our ability to commercialize, future drugs. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patent terms and their scope may be inadequate to protect our competitive position on current and future product
candidates for an adequate amount of time. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to MAAC and the Business Combination </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The MAAC Sponsor and MAAC&#146;s officers and directors have agreed to vote in favor of the Business Combination,
regardless of how MAAC&#146;s public stockholders vote. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The MAAC Sponsor, MAAC&#146;s directors and officers and their respective affiliates may elect to purchase shares
from public stockholders in connection with the Business Combination, which may influence the vote on the Business Combination and reduce the public &#147;float&#148; of the Roivant Common Shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If third parties bring claims against MAAC, the proceeds held in the Trust Account could be reduced and the per
share redemption amount received by stockholders may be less than $10.00 per share (which was the offering price in MAAC&#146;s initial public offering). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">MAAC has not obtained an opinion from an independent investment banking firm or from an independent accounting
firm, and consequently, you may have no assurance from an independent source that the price MAAC is paying for the business is fair to MAAC&#146;s stockholders from a financial point of view. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Since holders of MAAC&#146;s founder shares and private placement warrants will lose their entire investment in
us if MAAC&#146;s initial business combination is not completed, a conflict of interest may arise in determining whether Roivant is an appropriate target for the Business Combination. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Roivant Following the Consummation of the Business Combination and Related to Ownership of Roivant Common Shares Following the Business
Combination </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Roivant will incur increased costs as a result of operating as a public company, and its management will devote
substantial time to new compliance initiatives. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Roivant&#146;s failure to timely and effectively implement controls and procedures required by
Section&nbsp;404(a) of the Sarbanes-Oxley Act that will be applicable to it after the Business Combination is consummated could have a material adverse effect on its business. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Anti-takeover provisions in Roivant&#146;s memorandum of association, proposed
<FONT STYLE="white-space:nowrap">bye-laws</FONT> and Bermuda law could delay or prevent a change in control, limit the price investors may be willing to pay in the future for Roivant Common Shares and could entrench management.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Roivant&#146;s largest shareholders and certain members of Roivant&#146;s management own a significant percentage
of our stock and will be able to exert significant control over matters subject to shareholder approval. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roivant is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act, as modified by the Jumpstart
Our Business Startups Act of 2012, as amended (the &#147;JOBS Act&#148;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth
companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended (the &#147;Sarbanes-Oxley Act&#148;), reduced disclosure obligations
regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not
previously approved. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, section 102(b)(1) of the JOBS Act exempts emerging growth companies from being
required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the
Exchange Act) are required to comply with the new or revised financial accounting standards. Roivant intends to irrevocably elect not to avail itself of this extended transition period, and, as a result, will adopt new or revised accounting
standards on the relevant dates on which adoption of such standards is required for other public companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roivant will remain an
emerging growth company until the earlier of (1)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth anniversary of the date of the first sale of Roivant Common Shares pursuant to an effective registration statement or (b)&nbsp;in
which it has total annual gross revenue of at least $1.07&nbsp;billion (as adjusted for inflation pursuant to SEC rules from time to time), and (2)&nbsp;the date on which (x)&nbsp;it is deemed to be a large accelerated filer, which means the market
value of Roivant Common Shares that are held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior September 30th, or (y)&nbsp;the date on which it has issued more than $1.0&nbsp;billion in
nonconvertible debt during the prior three-year period. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_8"></A>SUMMARY UNAUDITED PRO FORMA </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED COMBINED FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary unaudited pro forma condensed combined financial information has been derived from the unaudited pro forma condensed
combined balance sheet as of March 31, 2021 and the unaudited pro forma condensed combined statements of operations for the year ended March 31, 2021, included in &#147;Unaudited Pro Forma Condensed Combined Financial Information.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The summary unaudited pro forma condensed combined financial information should be read in conjunction with the unaudited pro forma condensed
combined balance sheet and the unaudited pro forma condensed combined statements of operations, and the accompanying notes. In addition, the unaudited condensed combined pro forma financial information was based on and should be read in conjunction
with the historical financial statements of Roivant and MAAC, including the accompanying notes, which are included elsewhere in this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As MAAC does not represent a business for accounting purposes and its primary asset represents cash and cash equivalents, the Business
Combination will be treated similar to an equity contribution in exchange for the issuance of Roivant Common Shares. The net assets of MAAC will be stated at historical cost, with no goodwill or other intangible assets recorded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information has been prepared using the assumptions below with respect to the potential
redemption of MAAC Class A Shares into cash: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Assuming No Redemptions</B>: This presentation of the no redemption scenario assumes that no MAAC stockholders
exercise redemption rights with respect to their MAAC Class A Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Assuming Maximum Redemptions</B>: This presentation assumes that the maximum possible number of MAAC&#146;s
public stockholders exercise redemption rights with respect to their MAAC Class A Shares. This scenario assumes that 20,075,542 MAAC Class A Shares are redeemed for an aggregate redemption payment of approximately $200.8 million. The maximum
redemption scenario is based on the maximum number of redemptions that may occur, but which would still provide the minimum proceeds consisting of Trust Account funds of $210 million to be contributed at Closing of the Business Combination.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(in thousands, except per share amounts)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Roivant</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>MAAC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No&nbsp;Redemptions<BR>Scenario</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum<BR>Redemptions<BR>Scenario</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Operations Data&#151;For the Year Ended March 31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,094,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,570,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,570,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,070,898</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,469</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,546,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,546,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss from continuing operations attributable to Roivant Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(809,234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,275,230</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,276,133</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3.76</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.76</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.81</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(in thousands)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Roivant</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>MAAC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No&nbsp;Redemptions<BR>Scenario</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum<BR>Redemptions<BR>Scenario</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data&#151;As of March 31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,186,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,767,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,567,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,589,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">412,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,168,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,967,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">218,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">223,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">223,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">527,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">578,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">573,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class A common stock subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">362,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable non-controlling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,039,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,567,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,371,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_9"></A>TICKER SYMBOL AND DIVIDEND INFORMATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MAAC </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC Units, MAAC Class&nbsp;A Shares
and MAAC&#146;s public warrants are currently listed on Nasdaq under the symbols &#147;MAACU,&#148; &#147;MAAC&#148; and &#147;MAACW,&#148; respectively. The MAAC Units will automatically separate into their component securities upon consummation of
the Business Combination and, as a result, will no longer trade as an independent security. Upon the Closing, Roivant Common Shares and Roivant Warrants will be listed on Nasdaq under the symbols &#147;ROIV&#148; and &#147;ROIVW,&#148; respectively.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;10, 2021,
there was one holder of record of MAAC Units, one holder of record of MAAC Class&nbsp;A Shares, three holders of record of MAAC Class&nbsp;B Shares and two holders of record of MAAC public warrants. The number of holders of record does not include a
substantially greater number of &#147;street name&#148; holders or beneficial holders whose MAAC Units, MAAC Class A Shares and MAAC Warrants are held of record by banks, brokers and other financial institutions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividend Policy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC has not paid any
cash dividends on the MAAC Class&nbsp;A Shares to date and does not intend to pay cash dividends prior to the completion of the business combination. The payment of cash dividends in the future will be dependent upon the Company&#146;s revenues and
earnings, if any, capital requirements and general financial condition subsequent to completion of the Business Combination. The payment of any cash dividends subsequent to a Business Combination will be within the discretion of the Board at such
time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Roivant </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historical market
price information for Roivant Common Shares is not provided because there is no public market for Roivant Common Shares. See &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations of Roivant.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_10"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should carefully consider all the following risk factors, together with all of the other information in this proxy
statement/prospectus, including the financial statements and other financial information included herein, before deciding how to vote or instruct your vote to be cast to approve the proposals described in this proxy statement/prospectus. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in the Roivant Common Shares involves a high degree of risk. You should consider carefully the following risks, together with all
the other information in this proxy statement/prospectus, including the combined and consolidated financial statements and notes thereto, as well as the risks, uncertainties and other information set forth in the reports and other materials filed or
furnished by MAAC and by Roivant&#146;s majority-controlled subsidiary Immunovant, Inc. (&#147;Immunovant&#148;), with the U.S. Securities and Exchange Commission (the &#147;SEC&#148;), before you invest in the Roivant Common Shares. The value of
your investment following the completion of the Business Combination will be subject to significant risks affecting, among other things, Roivant&#146;s business, financial condition, results of operations and prospects. If any of the following risks
or the risks included in the public filings of Immunovant actually materializes following the Business Combination, Roivant&#146;s operating results, financial condition and liquidity could be materially adversely affected. As a result, the trading
price of the Roivant Common Shares could decline and you could lose part or all of your investment. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Roivant&#146;s Business and
Industry </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Unless the context otherwise requires, references in this subsection &#147;&#151;Risks Related to Roivant&#146;s Business and
Industry&#148; to &#147;we,&#148; &#147;us,&#148; &#147;our&#148; and the &#147;Company&#148; refer to Roivant and its subsidiaries and affiliates in the present tense or from and after the consummation of the Business Combination, as the context
requires. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to Our Financial Position and Strategy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our limited operating history and the inherent uncertainties and risks involved in biopharmaceutical product development may make it difficult for us to
execute on our business model and for you to assess our future viability. We have never generated product revenue from the commercialization of our drug product candidates, and there is no guarantee that we will do so in the future. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical and healthcare technology company with a limited operating history upon which you can evaluate our business and
prospects. We were formed in April 2014, and our operations to date have been limited to acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> product candidates or developing technologies for the discovery, development, and
commercialization of product candidates, starting or acquiring subsidiary businesses, which we refer to as the Vants, in which to house those product candidates or technologies, and hiring management teams to operate the Vants and oversee the
development of our product candidates and technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to execute on our business model and generate revenues depends on a
number of factors including our ability to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identify new acquisition or <FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully identify new product candidates through our computational discovery and targeted protein degradation
platforms and advance those product candidates into <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully complete ongoing <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials
and obtain regulatory approvals for our current and future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully market our healthcare technology products and services; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">raise additional funds when needed and on terms acceptable to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract and retain experienced management and advisory teams; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add operational, financial and management information systems and personnel, including personnel to support
clinical, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> manufacturing and planned future commercialization efforts and operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launch commercial sales of product candidates, whether alone or in collaboration with others, including
establishing sales, marketing and distribution systems; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate and continue relationships with third-party suppliers and manufacturers and have commercial quantities
of product candidates manufactured at acceptable cost and quality levels and in compliance with the FDA and other regulatory requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">set acceptable prices for product candidates and obtain coverage and adequate reimbursement from third-party
payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achieve market acceptance of product candidates in the medical community and with third-party payors and
consumers; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand and protect our intellectual property portfolio. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we cannot successfully execute any one of the foregoing, our business may not succeed and the price of our common shares may be negatively
impacted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biopharmaceutical product development, which represents the core of our business model, is a highly speculative undertaking and
involves a significant degree of risk. Our product candidates will require substantial development time &#150; including extensive clinical, and in some cases <FONT STYLE="white-space:nowrap">pre-clinical,</FONT> research and development &#150; and
resources before we would be able to apply for or receive applicable regulatory approvals and begin generating revenue from product sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not yet demonstrated an ability to successfully acquire regulatory clearance, develop or manufacture a commercial scale product, or
arrange for a third-party to do so on our behalf, or conduct sales and marketing activities necessary for successful biopharmaceutical product commercialization. We have generated minimal revenues to date, and no revenues from the commercialization
of our drug product candidates. Consequently, we have limited operations upon which to evaluate our business and predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a
history of successfully developing and commercializing biopharmaceutical product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and
uncertainties associated with biopharmaceutical product development, we are unable to predict the timing or amount of increased expenses, or when we will be able to generate any meaningful revenue or achieve or maintain profitability, if ever. Our
expenses could increase beyond expectations if we are required by the FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities to perform studies or clinical trials in addition to those that are currently anticipated
or to otherwise provide data beyond that which we currently believe is necessary to support an application for marketing approval or to continue clinical development, or if there are any delays in any of our or our future collaborators&#146;
clinical trials or the development of our product candidates that we may identify. Even if a product is approved for commercial sale, we could incur significant costs associated with the commercial launch of any such product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may never be able to develop or commercialize a marketable drug or achieve profitability. Revenue from the sale of any product candidate
for which regulatory approval is obtained will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to obtain reimbursement at any price, the
strength and term of patent exclusivity for the product, the competitive landscape of the product market, and whether we own the commercial rights for that territory. Even if we achieve profitability in the future, we may not be able to sustain
profitability in subsequent periods. Our failure to achieve sustained profitability would depress the value of our company and could impair our ability to raise capital, expand our business, expand our pipeline, market our product candidates, if
approved, and pursue or continue our operations. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our shareholders&#146; equity and working capital. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will likely incur significant operating losses for the foreseeable future and may never achieve or
maintain profitability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investment in biopharmaceutical product development is highly speculative because it entails substantial
upfront capital expenditures and significant risk that a product candidate will fail to gain regulatory approval or become commercially viable. None of our current product candidates has received marketing approval anywhere in the world and we have
not generated any product revenues from the commercial sale of our biopharmaceutical products. We cannot estimate with precision the extent of our future losses. We may never generate product revenue from the commercial sales of our product
candidates or achieve profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to incur substantial operating losses through the projected commercialization
of our product candidates. Our ability to generate product revenue and achieve profitability is dependent on the ability to complete the development of our product candidates, obtain necessary regulatory approvals and manufacture and successfully
market product candidates alone or in collaboration with others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we do successfully obtain regulatory approval to market product
candidates, our revenue will be dependent upon, in part and among other things, the size of the markets in the territories for which we gain regulatory approval, the number of competitors in such markets, the accepted price for product candidates
and whether we own the commercial rights for those territories. If the indication approved by regulatory authorities is narrower than expected, or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may
not generate significant revenue from sales of our product candidates, even if approved. We cannot assure you that we will be profitable even if we successfully commercialize our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The ongoing global pandemic resulting from the outbreak of the novel strain of coronavirus, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> which causes <FONT STYLE="white-space:nowrap">COVID-19,</FONT> could adversely impact our business, including our clinical trials and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Public health crises such as pandemics or similar outbreaks could adversely impact our business. In December 2019, a novel strain
of coronavirus, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> which causes <FONT STYLE="white-space:nowrap">COVID-19,</FONT> emerged. <FONT STYLE="white-space:nowrap">COVID-19</FONT> has since spread
globally, including to the countries in which we and our other business partners conduct business. Governments in affected regions have implemented, and may continue to implement or <FONT STYLE="white-space:nowrap">re-implement,</FONT> safety
precautions, including quarantines, travel restrictions, business closures, cancellations of public gatherings and other measures they deem necessary. Like many other organizations and individuals, we and our employees have taken additional steps to
avoid or reduce infection, including limiting travel and implementing remote work arrangements. We will continue to actively monitor the situation and may take further actions that could alter our business operations as may be required by national,
state or local authorities, or that we determine are in the best interests of our employees and shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic and policy responses to it, in April and May 2020 we initially observed a decrease in both patient screening and patient enrollment in certain of our ongoing clinical trials. Patient screening and
the number of patients eligible for enrollment in our clinical trials has since returned to expected levels. However, some of our development programs have been delayed. Together with our investigators and clinical sites, we continue to assess the
impact of the coronavirus pandemic on enrollment and the ability to maintain patients enrolled in our clinical trials and the corresponding impact on the timing of the completion of our ongoing clinical trials. We have experienced, or may in the
future experience, disruptions as a result of <FONT STYLE="white-space:nowrap">COVID-19</FONT> or future pandemics that severely impact our business, clinical trials and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or difficulties in enrolling patients in our clinical trials, and the consequences of such delays or
difficulties, including terminating clinical trials prematurely; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site
investigators and clinical site staff; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or disruptions in <FONT STYLE="white-space:nowrap">non-clinical</FONT> experiments due to unforeseen
circumstances at contract research organizations (&#147;CROs&#148;), and vendors along their supply chain; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting <FONT
STYLE="white-space:nowrap">COVID-19,</FONT> being forced to quarantine or not accepting home health visits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals
serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on
travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures (particularly any procedures that may be deemed
<FONT STYLE="white-space:nowrap">non-essential),</FONT> which may impact the integrity of subject data and clinical study endpoints; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption or delays in the operations of the FDA and comparable
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory agencies, which may impact review and approval timelines; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing
organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations on employee resources that would otherwise be focused on the conduct of our clinical trials and <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies, including because of sickness of employees or their families, the desire of employees to avoid contact with large groups of people, an increased reliance on working from home or mass transit
disruptions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other disruptions to our business generally, including from the transition to remote working for the majority of
our employees and the implementation of new health and safety requirements for our employees; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waiver or suspension of patent or other intellectual property rights. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These and other factors arising from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including risks relating to the emergence
of new variants, the efficacy and availability of vaccines and rates of vaccination, the pandemic worsening in countries that are already afflicted with <FONT STYLE="white-space:nowrap">COVID-19</FONT> or the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic continuing to spread to additional countries or returning to countries where the pandemic has been partially contained, could further adversely impact our ability to conduct clinical trials
and our business generally, and could have a material adverse impact on our operations and financial condition and results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
continuing to monitor potential delays or other impacts on our business, our clinical trials, healthcare systems and the global economy as a whole. These effects could have a material impact on our business, operations and financial results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic adversely affects our business, operations and financial results,
it may also have the effect of heightening many of the other risks described elsewhere in &#147;Risk Factors,&#148; such as those relating to our clinical development operations, the supply chain for our ongoing and planned clinical trials and our
ability to seek and receive regulatory approvals for our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to acquire, <FONT
STYLE="white-space:nowrap">in-license</FONT> or discover new product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of our business is highly dependent
on our ability to successfully identify new product candidates, whether through acquisitions or <FONT STYLE="white-space:nowrap">in-licensing</FONT> transactions, or through our internal discovery capabilities. Our acquisition and <FONT
STYLE="white-space:nowrap">in-licensing</FONT> efforts focus on identifying assets in development by third parties across a diverse range of therapeutic areas that, in our view, are underutilized or undervalued. Our strategy often entails designing <FONT
STYLE="white-space:nowrap">low-cost</FONT> studies that result in quick <FONT STYLE="white-space:nowrap">&#147;go/no-go&#148;</FONT> decisions when deciding whether or how to proceed with future development for a given asset, once acquired. We may
decide to proceed with the development of a drug candidate on this basis </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and later determine that the more costly and time intensive trials do not support the initial value the product was thought to hold. Even if a product candidate does prove to be valuable, its
value may be less than anticipated at the time of investment. We may also face competition for attractive investment opportunities. A number of entities compete with us for such opportunities, many of which have considerably greater financial and
technical resources. If we are unable to identify a sufficient number of such product candidates, or if the product candidates that we identify do not prove to be as valuable as anticipated, we will not be able to generate returns and implement our
investment strategy and our business and results of operations may suffer materially. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our drug discovery efforts are centered on our
targeted protein degradation platform and our computational discovery technology. As a company we have relatively limited experience in drug discovery generally, with targeted protein degradation as an approach to target inhibition and with
computational discovery as a technology. Our future success depends, in part, on our ability to successfully use targeted protein degradation and computational discovery technology to identify promising new product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Very few small molecule product candidates using targeted protein degradation, such as the product candidates which may be generated by our
targeted protein degradation platform, have been tested in humans and none has been approved in the United States or Europe. The data underlying the feasibility of developing therapeutic products based on protein degradation technology is both
preliminary and limited. We have not yet succeeded and may not succeed in advancing any product candidates developed using our targeted protein degradation platform into clinical trials, demonstrating the efficacy and safety of such product
candidates or obtain marketing approval thereafter. As a result, it is difficult to predict the time and cost of protein degrader product candidate development and we cannot predict whether the application of our targeted protein degradation
platform will result in the development and marketing approval of any products. Any problems we experience in the future related to this platform or any of our related development programs may cause significant delays or unanticipated costs or may
prevent the development of a commercially viable product. Any of these factors may prevent us from completing our preclinical studies or any clinical trials that we may initiate or commercializing any internally discovered product candidates we may
develop on a timely or profitable basis, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we believe that our computational discovery platform has the potential to
identify more promising molecules than traditional research methods and to accelerate drug discovery efforts, our focus on using our platform technology to discover and design molecules with therapeutic potential may not result in the discovery and
development of commercially viable products for us. Computational discovery is a relatively new approach to drug development. As an organization, we have not yet developed any product candidates using this technology that have advanced into clinical
trials and we may fail to identify potential product candidates for clinical development. Even if we are able to advance product candidates identified through our computational discovery platform into clinical trials, those trials may not be
successful in demonstrating the efficacy and safety of such product candidates and, as a result, we may not be able to obtain regulatory approvals for those product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any such failure to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire new product candidates from third parties, or to discover
new product candidates using our targeted protein degradation or computational discovery platforms would have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we have multiple programs and product candidates in our development pipeline and are pursuing a variety of target indications and treatment
approaches, we may expend our limited resources to pursue a particular product candidate and fail to capitalize on development opportunities or product candidates that may be more profitable or for which there is a greater likelihood of success.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have limited financial and management resources. As a result, we may forego or delay pursuit of opportunities with potential
target indications or product candidates that later prove to have greater commercial potential than our current and planned development programs and product candidates. Our resource allocation decisions may cause us to fail to capitalize on viable
commercial product candidates or profitable market </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
opportunities. Our spending on current and future research and development programs and other future product candidates for specific indications may not yield any commercially viable future
product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may be required to relinquish valuable rights to that product candidate through collaboration, licensing or other
royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we may pursue additional <FONT STYLE="white-space:nowrap">in-licenses</FONT> or acquisitions of product candidates or programs,
which entails additional risk to us. Identifying, selecting and acquiring promising product candidates requires substantial technical, financial and human resources expertise. Efforts to do so may not result in the actual acquisition or license of a
successful product candidate, potentially resulting in a diversion of our management&#146;s time and the expenditure of our resources with no resulting benefit. For example, if we are unable to identify programs that ultimately result in approved
products, we may spend material amounts of our capital and other resources evaluating, acquiring and developing products that ultimately do not provide a return on our investment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face risks associated with the Vant structure. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We develop our product candidates in the Vants, which operate similarly to independent biopharmaceutical companies. While we believe that there
are significant competitive advantages to this structure, as compared to traditional pharmaceutical companies or smaller biopharma companies, the Vant structure also poses certain risks for our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating the Vants independently, rather than under a centralized, consolidated management team, may result in increased costs at the Vants,
as certain functions or processes, including clinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> personnel, business development, finance, accounting, human resources and legal functions, are replicated across the Vants. There may also
be certain <FONT STYLE="white-space:nowrap">start-up</FONT> costs, associated with the establishment of a new Vant or integration of a newly acquired business into a Vant, which are greater under the Vant model than they would be under a centralized
model. The use of the Vant model may also entail increased costs at Roivant centrally, including the time and expenses associated with hiring Vant CEOs and management teams, overseeing Vant equity incentive arrangements and managing
compliance-related risks, including the internal controls, reporting systems and procedures necessary for Roivant to operate as a public company. We may also be exposed to increased &#147;key employee&#148; risks, in the event a Vant CEO were to
depart, including the loss of other senior Vant personnel, potentially resulting in significant delays to the development programs at the Vant. These increased expenses, complexities and other challenges may make using and scaling the Vant model
more challenging and costly than it would be for a traditional pharmaceutical company to both operate and expand the number of product candidates under development, which could have a material adverse effect on our consolidated business, financial
condition, results of operations or prospects. This decentralized model could also make compliance with applicable laws and regulations more challenging to monitor and may expose us to increased costs that could, in turn, harm our business,
financial condition, results of operations or prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, a single or limited number of the Vants may, now or in the future,
comprise a large proportion of our value. Similarly, a large proportion of our consolidated revenues may in the future be derived from one or a small number of Vants. Any adverse development at those Vants, including the termination of a key license
agreement or other loss of the intellectual property underlying a product candidate or the failure of a clinical trial for a product candidate under development at the Vant, could have a material adverse effect on our consolidated business,
financial condition, results of operations or prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We manage the Vants in part through Roivant designees who serve on the Vant
boards of directors. In their capacities as directors, those individuals owe fiduciary duties to the Vants and its shareholders under applicable law, which may at times require them to take actions that are not directly in Roivant&#146;s interest.
To the extent any such actions have an adverse effect on the value of Roivant&#146;s ownership interest in the Vant, it could further adversely impact our consolidated business, financial condition, results of operations or prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business may suffer reputational harm due to failures of our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure of any of our product candidates could have a lasting negative impact on our reputation, which could, in turn, impact our ability
to successfully enter into future licensing arrangements or other transactions with potential counterparties, raise future capital or attract key personnel to join us. As a result, our business and prospects would be materially harmed and our
results of operations and financial condition would likely suffer materially. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face risks associated with potential future payments related to
our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our model for asset <FONT STYLE="white-space:nowrap">in-licensing</FONT> transactions typically involves a
low upfront payment combined with milestone and royalty payments contingent upon the achievement of certain future development and commercial events. These arrangements generally involve a payment or payments upon certain regulatory milestones,
including regulatory approval, and then upon achieving specified levels of sales, with ongoing royalty payments which can extend for up to the life of a product. These payments may become due before a product is generating revenues, in which case we
may not have sufficient funds available to meet our obligations. If this were to occur, we would default on our payment obligations and could face penalties, delays in development or reputational damage. Even if a product is commercialized and
generating revenue, payments could become due that are so large that the investment is not profitable or is less profitable than anticipated. For example, this could occur if at the time of the initial investment, we overestimated the value of the
product and agreed to a payment schedule using these inflated estimates. If we are unable to make milestone and royalty payments related to our product candidates when due, our business and prospects could suffer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our investment strategy and future growth relies on a number of assumptions, some or all which may not be realized. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our investment strategy and plans for future growth rely on a number of assumptions, including, in the case of our biopharmaceutical product
candidates, assumptions related to adoption of a particular therapy, incidence of an indication, use of a product candidate versus competitor therapies and size of patient populations. Some or all of these assumptions may be incorrect. We cannot
accurately predict whether our product candidates will achieve significant market acceptance in line with these assumptions or whether there will be a market for our product candidates that reaches that which is anticipated. If any of these
assumptions are incorrect or overstated, our results and future prospects will be materially and adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we enter into acquisitions
or strategic partnerships, this may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities and subject us to other risks. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may engage in various acquisitions and strategic partnerships in the future, including licensing or acquiring new product candidates,
intellectual property rights, technologies or businesses. Any acquisition or strategic partnership may entail numerous risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased operating expenses and cash requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the assumption of indebtedness or contingent liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance of our or our subsidiaries&#146; equity securities which would result in dilution to our
shareholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assimilation of operations, intellectual property, products and product candidates of an acquired company,
including difficulties associated with integrating new personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the diversion of our management&#146;s attention from our existing product programs and initiatives in pursuing
such an acquisition or strategic partnership; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business
relationships; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that
party and their existing products or product candidates, intellectual property, and regulatory approvals; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to generate revenue from acquired intellectual property, technology and/or products sufficient to
meet our objectives or even to offset the associated transaction and maintenance costs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if we undertake
such a transaction, we may issue dilutive securities, assume or incur debt obligations, incur large <FONT STYLE="white-space:nowrap">one-time</FONT> expenses and acquire intangible assets that could result in significant future amortization expense.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face risks associated with our ongoing strategic alliance with Sumitomo Dainippon Pharma Co., Ltd. (&#147;Sumitomo&#148;), as well as other
acquisitions, partnerships, alliances or strategic transactions we may undertake in the future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, Roivant and
Sumitomo completed various transactions in connection with the formation of a strategic alliance between the companies, including (i)&nbsp;Sumitomo indirectly acquiring from us our controlling equity interests in five affiliates, (ii)&nbsp;our
granting Sumitomo options to purchase, subject to certain exceptions, our existing equity interests in six other privately-held Roivant affiliates, (iii)&nbsp;our granting Sumitomo access to key elements of our proprietary technology platforms and
(iv)&nbsp;issuing our common shares to Sumitomo. In exchange, Sumitomo made a $3.0&nbsp;billion upfront cash payment to us upon the closing of the transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face a number of risks in connection with our transactions with Sumitomo, including, but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of management time and focus away from operating our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reliance on certain employees of the alliance with Sumitomo who will continue to provide key services for us,
including information technology services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in relationships with strategic partners as a result of product acquisitions or strategic positioning
resulting from these transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks arising from technological and data platforms shared between us and the alliance with Sumitomo, such as
DrugOme, including data or other security breaches at Sumitomo or its affiliates that could, in turn, impact us, or disputes over ownership of intellectual property between us and the alliance with Sumitomo, which could impact our access to those
platforms; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">non-competition</FONT> obligations arising from the formation of the alliance
with Sumitomo; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coordination of research and development efforts; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">litigation or other claims, including claims from terminated employees, customers, former shareholders or other
third parties. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also face similar risks in connection with any other mergers, acquisitions, divestitures or
strategic alliances that we have undertaken in the past or may undertake in the future, including our acquisition of Oncopia Therapeutics, which closed in November 2020, and of Silicon Therapeutics, which closed in March 2021. If we acquire
businesses with promising technologies, we may not be able to realize the benefits of acquiring such businesses, including any anticipated synergies between the acquired business and our existing business, if we are unable to successfully integrate
them with our existing operations, technology and company culture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, any such mergers, acquisitions, divestitures or strategic
alliances may be complex, time consuming and expensive to execute and may be subject to regulatory requirements that could impact our business. There can be no guarantee that we will be able to successfully consummate such acquisitions or other
transactions, which could result in a significant diversion of management and other employee time, as well as substantial <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs. For example, on
March&nbsp;8, 2021, we filed an amendment to our Schedule 13D </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
relating to our ownership interest in Immunovant announcing our intention to propose to Immunovant that Roivant and Immunovant evaluate a potential transaction pursuant to which Roivant or an
affiliate would acquire all of the issued and outstanding shares of Immunovant&#146;s common stock not currently owned by Roivant (the &#147;Potential Immunovant Transaction&#148;). Following such filing, we explored a range of possible transactions
involving Immunovant, which included discussions with Immunovant with respect to the Potential Immunovant Transaction, but, as disclosed in the amendment to our Schedule 13D relating to our ownership interest in Immunovant filed on August 2, 2021,
we and Immunovant ultimately agreed on a significant cash primary equity investment by us in Immunovant, and we made such cash primary equity investment on August 2, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any acquisitions or other transactions are not completed for any reason, we may incur significant costs and the market price of our common
shares may decline. In addition, even if an acquisition is consummated, the integration of the acquired business, product or other assets into our Company may be complex and time-consuming, and we may not achieve the anticipated benefits,
cost-savings or growth opportunities we expect. Potential difficulties that may be encountered in the integration process include the following: integrating personnel, operations and systems; coordinating geographically dispersed organizations;
distracting management and employees from current operations; maintaining the existing business relationships of the acquired company; and managing inefficiencies associated with integrating the operations of the Company and the acquired business,
product or other assets. For biopharmaceutical businesses we have acquired or may acquire in the future, or alliances or joint ventures in the biopharmaceutical industry, we may encounter numerous difficulties in developing, manufacturing and
marketing any new drugs related to such businesses, which may delay or prevent us from realizing the expected benefits or enhancing our business. We cannot assure you that, following any such acquisition, alliance or partnership, we will achieve the
expected synergies to justify the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our failure to address these risks or other problems encountered in connection with the
strategic alliance with Sumitomo, or other past or future acquisitions, partnerships or strategic alliances could cause us to fail to realize the anticipated benefits of these transactions, incur unanticipated liabilities and harm our business
generally. There is also a risk that current or future acquisitions will result in the shareholder litigation, incurrence of debt, contingent liabilities, amortization expenses or incremental operating expenses, any of which could harm our financial
condition or results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we obtain a controlling interest in additional companies in the future, it could adversely affect our
operating results and the value of our common shares, thereby disrupting our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of our strategy, we expect to form
and invest in additional wholly-owned and majority-owned subsidiaries. Investments in our existing and any future subsidiaries involve numerous risks, including, but not necessarily limited to, risks related to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conducting research and development activities in new therapeutic areas or treatment approaches in which we have
little to no experience; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of financial and managerial resources from existing operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or potential conflicts among new and existing Vants to the extent they have overlapping or competing areas
of focus or pipeline products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully negotiating a proposed acquisition, <FONT STYLE="white-space:nowrap">in-license</FONT> or investment
in a timely manner and at a price or on terms and conditions favorable to us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully combining and integrating a potential acquisition into our existing business to fully realize the
benefits of such acquisition; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of regulatory reviews on a proposed acquisition, <FONT STYLE="white-space:nowrap">in-license</FONT> or
investment; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome of any legal proceedings that may be instituted with respect to the proposed acquisition, <FONT
STYLE="white-space:nowrap">in-license</FONT> or investment. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to properly evaluate potential acquisitions, <FONT
STYLE="white-space:nowrap">in-licenses,</FONT> investments or other transactions associated with the creation of new research and development programs or the maintenance of existing ones, we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
might not achieve the anticipated benefits of any such transaction, we might incur costs in excess of what we anticipate, and management resources and attention might be diverted from other
necessary or valuable activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may
not be able to complete the development and commercialization of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to spend substantial capital to
complete the development of, seek regulatory approvals for and commercialize our biopharmaceutical product candidates, as well as to advance the development of our healthcare technologies. Because the length of time and activities associated with
successful development of our biopharmaceutical product candidates is highly uncertain, and due to the inherent challenges and uncertainties associated with the development of novel healthcare technologies, we are unable to estimate with certainty
the actual funds we will require to execute on our strategy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future funding requirements, both near- and long-term, will depend on
many factors, including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">with respect to our biopharmaceutical product candidates: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost and timing of newly launched product candidates or Vants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress, costs and results of <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
studies and clinical trials for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome, timing and cost of meeting regulatory requirements established by the FDA and other comparable <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities globally; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property
rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of defending potential intellectual property disputes, including patent infringement actions brought by
third parties against us or any of our current or future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost and timing of completion of <FONT STYLE="white-space:nowrap">pre-clinical,</FONT> clinical and
commercial manufacturing activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of establishing sales, marketing and distribution capabilities for our product candidates in regions
where we choose to commercialize our product candidates on our own; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, progress, timing and results of our commercialization of our product candidate, if approved for
commercial sale; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other costs associated with preparing the commercial launch of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for our healthcare and drug discovery technologies: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs related to hiring and retaining employees with the expertise necessary to manage these technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investments in wet labs, computational resources and other facilities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs needed to update, maintain and improve these technologies and the infrastructure underlying these
technologies, including with respect to data protection and cybersecurity. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be certain that additional capital
will be available on acceptable terms, or at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of
any product candidate, delay the launch or expansion of a given healthcare technology product or potentially discontinue our operations altogether. In addition, attempting to secure additional capital may divert the time and attention of our
management from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and harm our business. Because of the numerous risks and uncertainties associated with our business, we are unable to estimate the
amounts of increased capital outlays, operating expenditures and capital requirements associated with our current product development programs and technology products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that significant additional capital will be needed in the future to continue our
planned operations, including with respect to fulfilling our and the Vants&#146; human resources needs, which may be costly. Until such time, if ever, that we can generate substantial revenues, we expect to continue to finance our cash needs through
a combination of equity offerings, debt financings, strategic alliances and license and development agreements or other collaborations both at our parent and at certain affiliates. To the extent that we raise additional capital by issuing equity
securities at the parent or subsidiary level, our existing shareholders&#146; ownership, or our ownership in our subsidiaries, may experience substantial dilution, and the terms of these securities may include liquidation or other preferences that
could harm the rights of a common shareholder. Additionally, any agreements for future debt or preferred equity financings, if available, may involve covenants limiting or restricting our ability to take specific actions, such as incurring
additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable
rights to our product candidates, future revenue streams, research programs or technologies, or grant licenses on terms that may not be favorable to us. The foregoing restrictions associated with potential sources of additional capital may make it
more difficult for us to raise additional capital or to pursue business opportunities, including potential acquisitions. If we are unable to obtain adequate financing or financing on terms satisfactory to us, if and when we require it, our ability
to grow or support our business and to respond to business challenges could be significantly limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to the Development of Our
Product Candidates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical trials and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies are very expensive, time-consuming,
difficult to design and implement and involve uncertain outcomes. We may encounter substantial delays in clinical trials, or may not be able to conduct or complete clinical trials or <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies on
the expected timelines, if at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our biopharmaceutical product candidates are in clinical development or <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies and will require extensive clinical testing before an Investigational New Drug (&#147;IND&#148;), New Drug Application (&#147;NDA&#148;) or other similar application for regulatory approval,
such as a Biologics License Application (&#147;BLA&#148;), may be submitted. We cannot provide you any assurance that we will submit an IND, NDA or other similar application for regulatory approval for our product candidates within projected
timeframes or whether any such application will be approved by the relevant regulatory authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials and <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies are very expensive, time-consuming and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. For instance, the FDA, an institutional review
board (&#147;IRB&#148;) or other regulatory authorities may not agree with the proposed analysis plans or trial design for the clinical trials of our product candidates, and during any such review, may identify unexpected efficacy or safety
concerns, which may delay the approval of an NDA or similar application. The FDA may also find that the benefits of any product candidate in any applicable indication do not outweigh its risks in a manner sufficient to grant regulatory approval.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA or other regulatory authorities may also not agree with the scope of our proposed investigational plan. For example, they may
find that our proposed development program is not sufficient to support a marketing authorization application, or that the proposed indication is considered to be too broad. Moreover, the FDA or other regulatory authorities may also refuse or impose
certain restrictions on our reliance on data supporting our marketing authorization application should such data originate from studies outside of the relevant jurisdiction. In each case, this could delay the clinical development timeline for a
given product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failures can occur at any stage of clinical trials or <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
studies, and we could encounter problems that cause us to abandon or repeat clinical trials or <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies. In addition, results from clinical trials or
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies may require further evaluation, delaying the next stage of development or submission of an NDA or similar application. Further, product candidates in later stages of clinical trials may
fail to show the desired safety and efficacy traits despite having progressed through nonclinical studies and initial clinical trials, and such product candidates may exhibit safety signals in later stage clinical trials that they did not exhibit in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> or early-stage clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in or the
discontinuation of advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials or studies. Likewise, the results of early clinical trials or
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies of our product candidates may not be predictive of the results of planned development programs, and there can be no assurance that the results of studies conducted by collaborators or
other third parties will be viewed favorably or are indicative of our own future trial results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The commencement and completion of <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials may be delayed by several factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to obtain regulatory authorization to commence a trial or reaching consensus with regulatory authorities
regarding the design or implementation of our studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other regulatory issues, including the receipt of any inspectional observations on FDA&#146;s <FONT
STYLE="white-space:nowrap">Form-483,</FONT> Warning or Untitled Letters, clinical holds, or complete response letters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unforeseen safety issues, or subjects experience severe or unexpected adverse events; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of serious adverse events in trials of the same class of agents conducted by other sponsors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of effectiveness during clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">resolving any dosing issues, including those raised by the FDA or other regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of
which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">slower than expected rates of patient recruitment or failure to recruit suitable patients to participate in a
trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to add a sufficient number of clinical trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated impact from changes in or modifications to protocols or clinical trial design, including those that
may be required by the FDA or other regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability or unwillingness of clinical investigators or study participants to follow our clinical and other
applicable protocols or applicable regulatory requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an IRB or ethics committee (&#147;EC&#148;) refusing to approve, suspending, or terminating the trial at an
investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">premature discontinuation of study participants from clinical trials or missing data; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to manufacture or release sufficient quantities of our product candidate or failure to obtain sufficient
quantities of active comparator medications for our clinical trials, if applicable, that in each case meet our quality standards, for use in clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to monitor patients adequately during or after treatment; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inappropriate unblinding of trial results. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, disruptions caused by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic increase the likelihood that we encounter
such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials.&nbsp;Further, we, the FDA or other regulatory authorities may suspend our clinical trials in an entire country at any time, or an
IRB/EC may suspend our clinical trial sites within any country, if it appears that we or our collaborators are failing to conduct a trial in accordance with applicable regulatory requirements, including GCP regulations, that we are exposing
participants to unacceptable health risks, or if the FDA or other regulatory authority finds deficiencies in our IND or equivalent applications for other countries or in the manner in which clinical trials are conducted. Therefore, we cannot predict
with any certainty the schedule for commencement and completion of future clinical trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we experience delays in the commencement or completion of our clinical trials, or if we
terminate a clinical trial prior to completion, the commercial prospects of our product candidates could be harmed, and our ability to generate product revenue from any of our product candidates, if approved, may be delayed. In addition, any delays
in our clinical trials could increase our costs, cause a decline in our share price, slow down the approval process, and jeopardize our ability to commence product sales and generate revenue. Any of these occurrences may harm our business, financial
condition and results of operations. In addition, many of the factors that cause or lead to a termination or suspension of, or delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval
of our product candidates. We may make formulation or manufacturing changes to our product candidates, in which case we may need to conduct additional <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical studies to bridge our modified
product candidates to earlier versions. Any delays to our clinical trials that occur as a result could shorten any period during which we may have the exclusive right to commercialize our product candidates and our competitors may be able to bring
product candidates to market before we do, and the commercial viability of our product candidates could be significantly reduced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive
compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or other regulatory authorities. The FDA or other regulatory authorities may conclude that a financial
relationship between us and a principal investigator has created a conflict of interest or otherwise affected the integrity of the study. The FDA or other regulatory authority may therefore question the integrity of the data generated at the
applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or other regulatory authority, as the case may be, and
may ultimately lead to the denial of marketing approval of any of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, for our product candidates in
clinical development, prior to our acquisition of the rights to those product candidates we had no involvement with or control over the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical development of those product candidates. We are
therefore dependent on our licensing and other transaction partners having conducted such research and development in accordance with the applicable protocol and legal, regulatory and scientific standards, having accurately reported the results of
all clinical trials and other research they conducted prior to our acquisition of the rights to product candidates, having correctly collected and interpreted the data from these trials and other research and having supplied us with complete
information, data sets and reports required to adequately demonstrate the results reported through the date of our acquisition of these product candidates. Problems associated with the <FONT STYLE="white-space:nowrap">pre-acquisition</FONT>
development of our product candidates could result in increased costs and delays in the development of our product candidates, which could harm our ability to generate any future revenue from sales of product candidates, if approved. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our approach to the discovery and development of product candidates from our targeted protein degradation platform is unproven, which makes it difficult
to predict the time, cost of development and likelihood of successfully developing any product candidates from this platform. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Treating diseases using targeted protein degradation is a new treatment approach. Our future success depends in part on the successful
development of this novel therapeutic approach. Very few small molecule product candidates using targeted protein degradation have been tested in humans. None have been approved in the United States or Europe, and the data underlying the feasibility
of developing these types of therapeutic products is both preliminary and limited. If any adverse learnings are made by other developers of chimeric targeting molecules, development of these product candidates could be materially impacted, which
could in turn adversely impact our financial condition and future growth. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The scientific research that forms the basis of our efforts to
develop our degrader product candidates is ongoing and the scientific evidence to support the feasibility of developing these treatments is both preliminary and limited. In addition, we may be unable to replicate the scientific evidence supporting
our protein degrader candidates observed by our academic collaborators in commercial laboratories. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, certain cancer patients have shown inherent primary resistance to approved drugs
that inhibit disease-causing proteins and other patients have developed acquired secondary resistance to these inhibitors. Although we believe our products candidates may have the ability to degrade the specific mutations that confer resistance to
currently marketed inhibitors of disease-causing enzymes, any inherent primary or acquired secondary resistance to our product candidates in patients, or if the research proves to be contradicted, would prevent or diminish their clinical benefit.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not yet completed <FONT STYLE="white-space:nowrap">IND-enabling</FONT> work for, or initiated a clinical trial of, any product
candidate associated with our targeted protein degradation platform and we have not yet assessed the safety of any of these product candidates in humans. Although some of our product candidates have produced observable results in animal studies,
there is a limited safety data set for their effects in animals. In addition, these product candidates may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen,
ineffective or harmful ways. As a result, there could be adverse effects from treatment with any of our current or future product candidates that we cannot predict at this time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the regulatory approval process for novel product candidates such as those associated with our targeted protein degradation
platform is uncertain and can be more expensive and take longer than for other, better-known or extensively studied classes of product candidates. Although other companies are also developing therapeutics based on targeted protein degradation, no
product candidates of this type have been approved in the United States or Europe. As a result, it is difficult for us to predict the time and cost of developing our product candidates and we cannot predict whether any of these product candidates
will receive marketing approval or achieve commercial acceptance. Any development problems we experience in the future related to our targeted protein degradation platform or any of our related research programs may cause significant delays or
unanticipated costs or may prevent the development of a commercially viable product. Any of these factors may prevent us from completing our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or any clinical trials that we may initiate, as
well as from commercializing any product candidates we may develop on a timely or profitable basis, if at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain of our product candidates,
including our gene therapy product candidates, are novel, complex and difficult to manufacture. We could experience manufacturing problems that result in delays in our development or commercialization programs or otherwise harm our business.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manufacturing processes our contract manufacturing organizations (&#147;CMOs&#148;) use to produce our product candidates are
complex, novel and have not necessarily been validated for commercial use. Several factors could cause production interruptions, including equipment malfunctions, facility contamination, raw material shortages or contamination, natural disasters,
disruption in utility services, human error or disruptions in the operations of our suppliers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our gene therapy product candidates may
require processing steps that are more complex than those required for most small molecule drugs. Moreover, unlike small molecules, the physical and chemical properties of biologics generally cannot be fully characterized. As a result, assays of the
finished product may not be sufficient to ensure that the product is consistent from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">lot-to-lot</FONT></FONT> or will perform in the intended manner. Accordingly, our CMOs must employ
multiple steps to control the manufacturing process to assure that the process is reproducible and the product candidate is made strictly and consistently in compliance with the process. Problems with the manufacturing process, even minor deviations
from the normal process, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims or insufficient inventory to conduct clinical trials or supply commercial markets. We may
encounter problems achieving adequate quantities and quality of clinical-grade materials that meet the FDA, the EU or other applicable standards or specifications with consistent and acceptable production yields and costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the FDA, the European Medicines Agency (the &#147;EMA&#148;) and other comparable regulatory authorities may require us to submit
samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
comparable regulatory authorities may require that we not distribute a lot until the agency authorizes its release. Slight deviations in the manufacturing process, including those affecting
quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us to delay product launches or clinical trials, which could be
costly to us and otherwise harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our CMOs also may encounter
problems hiring and retaining the experienced scientific, quality assurance, quality-control and manufacturing personnel needed to operate our manufacturing processes, which could result in delays in production or difficulties in maintaining
compliance with applicable regulatory requirements. Any problems in our CMOs&#146; manufacturing process or facilities could result in delays in planned clinical trials and increased costs, and could make us a less attractive collaborator for
potential partners, including larger biotechnology companies and academic research institutions, which could limit access to additional attractive development programs. Problems in our manufacturing process could restrict our ability to meet
potential future market demand for products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may encounter difficulties enrolling and retaining patients in clinical trials, and clinical
development activities could thereby be delayed or otherwise adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may encounter delays or difficulties in
enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials for our product candidates on current timelines, or at all, and even once enrolled we may be unable to retain a sufficient number of patients
to complete any of our clinical trials for these product candidates. Enrollment in our clinical trials may also be slower than we anticipate, or be stopped, leading to delays in the development timelines for our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient enrollment and retention in clinical trials depends on many factors, including the size of the patient population, the nature of the
trial protocol, our ability to recruit clinical trial investigators with the appropriate competencies and experience, delays in enrollment due to travel or quarantine policies, or other factors, related to
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> the existing body of safety and efficacy data with respect to the study drug, the number and nature of competing treatments and ongoing clinical trials of competing drugs for the same indication, the
proximity of patients to clinical sites, the eligibility criteria for the trial and the proportion of patients screened that meets those criteria, our ability to obtain and maintain patient consents, our ability to successfully complete prerequisite
studies before enrolling certain patient populations. For certain of our product candidates, including IMVT-1401, which targets certain rare autoimmune indications, there are limited patient pools from which to draw in order to complete our clinical
trials in a timely and cost-effective manner. In addition, for certain of our early-stage development programs, there may be a limited number of sites where it is feasible to run clinical trials, making such programs particularly susceptible to
delays caused by issues at those sites. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, any negative results or new safety signals we may report in clinical trials of our
product candidates may make it difficult or impossible to recruit and retain patients in other clinical trials we are conducting or to resume enrolling patients once a paused clinical trial has been resumed. For example, in February 2021, our
subsidiary, Immunovant, voluntarily paused dosing in its clinical trials for IMVT-1401 globally due to elevated total cholesterol and LDL levels observed in patients treated with IMVT-1401, resulting in a delay in Immunovant&#146;s development of
IMVT-1401. If Immunovant commences a future trial of <FONT STYLE="white-space:nowrap">IMVT-1401,</FONT> it may be more difficult to recruit and retain patients for such clinical trials. Similarly, negative results reported by our competitors about
their drug candidates may negatively affect patient recruitment in our clinical trials. Also, marketing authorization of competitors in this same class of drugs may impair our ability to enroll patients into our clinical trials, delaying or
potentially preventing us from completing recruitment of one or more of our trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delays or failures in planned patient enrollment or
retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop our product candidates, or could render further development impossible. In addition, we expect to rely on CROs and clinical
trial sites to ensure proper </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and timely conduct of our future clinical trials, and, while we intend to enter into agreements governing their services, we will be limited in our ability to compel their actual performance.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The results of our clinical trials may not support our proposed claims for our product candidates, or regulatory approvals on a timely basis or at
all, and the results of earlier studies and trials may not be predictive of future trial results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Success in <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> testing and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the results of later clinical trials will replicate the results of prior <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> testing and clinical trials. In particular, we cannot assure you that the reductions in IgG antibodies that we have observed to date in our clinical trials of IMVT-1401 will be observed in any future
clinical trials. Likewise, promising results in interim analyses or other preliminary analyses do not ensure that the clinical trial as a whole will be successful. A number of companies in the pharmaceutical industry, including biotechnology
companies, have suffered significant setbacks in, or the discontinuation of, clinical trials, even after promising results in earlier <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials. These setbacks have been caused
by, among other things, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unreported adverse events. In February
2021, our subsidiary, Immunovant, voluntarily paused dosing in its clinical trials for IMVT-1401 globally due to elevated total cholesterol and LDL levels observed in patients treated with IMVT-1401, resulting in a delay in Immunovant&#146;s
development of IMVT-1401. Immunovant plans to progress discussions with regulatory authorities, with the intent to continue development of IMVT-1401. While the ASCEND GO-2 trial was terminated and the efficacy results, based on approximately half
the anticipated number of subjects who had reached the week 13 primary efficacy analysis at the time of the termination of the trial, were inconclusive, further discussions with external experts are ongoing to determine whether a specific population
can be identified to optimize the clinical performance of IMVT-1401. Based on these analyses, Immunovant is likely to design another Phase 2 trial in TED or another thyroid-related disease as its next study in this therapeutic area and initiate
discussions with regulatory authorities before the end of the calendar year 2021. Failure to successfully complete clinical trials of IMVT-1401 and to demonstrate the efficacy and safety necessary to obtain regulatory approval to market IMVT-1401
would significantly harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and early clinical
trials of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> and initial clinical trials. A future failure of a clinical trial to meet its <FONT STYLE="white-space:nowrap">pre-specified</FONT> endpoints would likely cause us to abandon our product candidates. Any
delay in, or termination of, our clinical trials will delay the submission of an NDA or other similar applications to the FDA or other relevant comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities and, ultimately, our
ability to commercialize our product candidates, if approved, and generate product revenues. Even if our clinical trials are completed as planned, we cannot be certain that their results will support our claims for differentiation or the
effectiveness or safety of our product candidates. The FDA has substantial discretion in the review and approval process and may disagree that our data support the differentiated claims we propose. In addition, only a small percentage of product
candidates under development result in the submission of an NDA or other similar application to the FDA and other comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities and even fewer are approved for commercialization.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interim, <FONT STYLE="white-space:nowrap">top-line</FONT> or preliminary data from our clinical trials that we announce or publish from time to
time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may publicly disclose preliminary or <FONT STYLE="white-space:nowrap">top-line</FONT> data from our clinical trials,
which is based on a preliminary analysis of then-available <FONT STYLE="white-space:nowrap">top-line</FONT> data, and the results and related findings and conclusions are subject to change following a full analysis of all data related to the
particular trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
received or had the opportunity to fully and carefully evaluate all data. As a result, the preliminary and <FONT STYLE="white-space:nowrap">top-line</FONT> results that we report may differ from
future results of the same trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. <FONT STYLE="white-space:nowrap">Top-line</FONT> data also remain subject to audit
and verification procedures that may result in the final data being materially different from the <FONT STYLE="white-space:nowrap">top-line</FONT> data we previously published. As a result, preliminary and
<FONT STYLE="white-space:nowrap">top-line</FONT> data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our clinical trials. Interim data from clinical trials that we may
complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary,
<FONT STYLE="white-space:nowrap">top-line</FONT> or interim data and final data could significantly harm our business prospects. Further, disclosure of preliminary or interim data by us or by our competitors could result in increased volatility in
the price of our shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates,
calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our
business in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the
material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding
a particular product, product candidate or our business. If the <FONT STYLE="white-space:nowrap">top-line</FONT> data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached,
our ability to obtain approval for and commercialize product candidates, our business, operating results, prospects or financial condition may be harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in methods of product manufacturing or formulation may result in additional costs or delay. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As product candidates proceed through <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies to pivotal clinical trials towards potential
approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that
they will not achieve these intended objectives. Any of these changes could cause product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. Such
changes may also require additional testing, FDA notification or FDA approval. Similar requirements apply in other jurisdictions. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of
one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commence sales and generate revenues. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to conduct, supervise and monitor our clinical trials, and if those third parties perform in an unsatisfactory manner or fail
to comply with applicable requirements, it may harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on CROs and clinical trial sites to ensure the proper
and timely conduct of our clinical trials, and we expect to have limited influence over their actual performance. In addition, we rely upon CROs to monitor and manage data for our clinical programs, as well as the execution of future <FONT
STYLE="white-space:nowrap">non-clinical</FONT> studies. We expect to control only certain aspects of our CROs&#146; activities. Nevertheless, we will be responsible for ensuring that each of our studies is conducted in accordance with the applicable
protocol, legal, regulatory and scientific standards and that clinical trial sites meet applicable protocol and regulatory requirements, and our reliance on the CROs does not relieve us of our regulatory responsibilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our CROs will be required to comply with the Good Laboratory Practices (&#147;GLPs&#148;) and GCPs, which are regulations and
guidelines enforced by the FDA and other comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities, which also require compliance with the International Council for Harmonization of Technical Requirements for Pharmaceuticals
for Human Use (&#147;ICH&#148;) guidelines for any of our product candidates that are in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical development. The regulatory authorities enforce GCP regulations through periodic inspections of trial sponsors, principal investigators and clinical trial sites. Although we may rely on
CROs to conduct our <FONT STYLE="white-space:nowrap">GLP-compliant</FONT> nonclinical studies and <FONT STYLE="white-space:nowrap">GCP-compliant</FONT> clinical trials, we remain responsible for ensuring that each of our GLP nonclinical studies and
GCP clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations, and our expected reliance on the CROs does not relieve us of our regulatory responsibilities. If we or our CROs fail to
comply with GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities may reject our marketing applications and require us to
perform additional clinical trials before approving our marketing applications. Accordingly, if our CROs fail to comply with these regulations or other applicable laws, regulations or standards, or fail to recruit a sufficient number of subjects, we
may be required to repeat clinical trials, which would delay the regulatory approval process. Failure by any future CROs to properly execute study protocols in accordance with applicable law could also create product liability and healthcare
regulatory risks for us as sponsors of those studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our CROs will not be our employees, and we will not control whether or not they
devote sufficient time and resources to our future clinical and nonclinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other
drug development activities which could harm our competitive position. We face the risk of potential unauthorized disclosure or infringement, misappropriation or other violation of our intellectual property by CROs, which may reduce our trade secret
and intellectual property protection and allow our potential competitors to access and exploit our proprietary technology. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the
quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may
not be able to obtain regulatory approval for, or successfully commercialize any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs
could increase, and our ability to generate revenues could be delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our relationships with these CROs terminate, we may not be able
to enter into arrangements with alternative CROs or do so on commercially reasonable terms or in a timely manner. Switching or adding additional CROs involves substantial cost and requires management time and focus. In addition, there is a natural
transition period when a new CRO commences work. As a result, delays occur, which can adversely impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with the CROs, there can be
no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not have our own manufacturing capabilities and will rely on third parties to produce clinical supplies and commercial supplies of our product
candidates and any future product candidate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not own or operate, and do not expect to own or operate, facilities for product
manufacturing, storage and distribution, or testing. We will rely on third parties to produce clinical and commercial supplies of our product candidates and any future product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party vendors may be difficult to identify for our product process and formulation development and manufacturing due to special
capabilities required, and they may not be able to meet our quality standards. In addition, certain of our third-party manufacturers and suppliers may encounter delays in providing their services as a result of supply chain constraints. If any
third-party manufacturers or third parties in the supply chain for materials used in the production of our product candidates or any future product candidates are adversely impacted by supply chain constraints, our supply chain may be disrupted,
limiting our ability to manufacture product candidates for our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, clinical trials, research and development operations and commercialization. Any significant delay in the supply of a product
candidate, or the raw material components </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
thereof, for an ongoing clinical trial due to the need to replace a third- party manufacturer could considerably delay completion of our clinical trials, product testing and potential regulatory
approval of our product candidate. If our manufacturers or we are unable to purchase these raw materials after regulatory approval has been obtained for our product candidates, the commercial launch of our product candidates would be delayed or
there would be a shortage in supply, which would impair our ability to generate revenue from the sale of our product candidates. Moreover, as a result of projected supply constraints for certain materials used in the production of our product
candidates, we have in the past and may in the future reserve manufacturing capacity in advance of receiving required efficacy or safety results from our clinical trials, which may involves committing substantial financial resources to current or
future potential product candidates that may never be approved or achieve commercialization at scale or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The facilities used by
our contract manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will be conducted after we submit an NDA or other similar application to the FDA. Similar requirements apply in other
jurisdictions. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with cGMP requirements for manufacture of drug product candidates. If our contract manufacturers
cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities, we will not be able to secure or
maintain regulatory approval for our product candidates. In addition, we have limited control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or comparable <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities do not approve these facilities for the manufacture of our product candidates or if they withdraw any such approval in the future, we may need to find alternative manufacturing
facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured product candidates
ourselves, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to meet our product specifications and quality requirements consistently; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay or inability to procure or expand sufficient manufacturing capacity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing and product quality issues related to <FONT STYLE="white-space:nowrap">scale-up</FONT> of
manufacturing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs and validation of new equipment and facilities required for
<FONT STYLE="white-space:nowrap">scale-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to comply with applicable laws, regulations and standards, including cGMP and similar standards;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">deficient or improper record-keeping; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to negotiate manufacturing agreements with third parties under commercially reasonable terms;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly
or damaging to us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reliance on a limited number of sources, and in some cases, single sources for product components, such that if
we are unable to secure a sufficient supply of these product components, we will be unable to manufacture and sell our product candidates in a timely fashion, in sufficient quantities or under acceptable terms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of qualified backup suppliers for those components that are currently purchased from a sole or single source
supplier; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our
business or operations, including the bankruptcy of the manufacturer or supplier or other regulatory sanctions related to the manufacturer of another company&#146;s product candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">carrier disruptions or increased costs that are beyond our control; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to deliver our product candidates under specified storage conditions and in a timely manner.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could lead to clinical trial delays, cost overruns, delay or failure to obtain regulatory approval
or impact our ability to successfully commercialize our product candidates as well as potential product liability litigation, product recalls or product withdrawals. Some of these events could be the basis for FDA or other regulatory authority
action, including injunction, recall, seizure, or total or partial suspension of production. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the contract manufacturing facilities on which we
rely do not continue to meet regulatory requirements or are unable to meet our requirements, including providing an adequate supply, our business will be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All entities involved in the preparation of product candidates for clinical trials or commercial sale, including our existing CMOs for all of
our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with cGMP, or similar regulatory
requirements outside the United States. These regulations govern manufacturing processes and procedures, including recordkeeping, and the implementation and operation of quality systems to control and assure the quality of investigational products
and products approved for sale. Poor control of production processes can lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our product candidates. Our failure, or the failure of third-party
manufacturers, to comply with applicable regulations could result in the issuance of inspectional observations on FDA&#146;s <FONT STYLE="white-space:nowrap">Form-483,</FONT> Warning or Untitled Letters, public safety alerts identifying our company
or products and sanctions being imposed on us, including clinical holds, import alerts, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, suspension of production, seizures or recalls of product
candidates or marketed drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect clinical or commercial supplies of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or our CMOs must supply all necessary documentation in support of an NDA or similar regulatory application on a timely basis, and must
adhere to regulations enforced by the FDA and other regulatory agencies through their facilities inspection program. Some of our CMOs have never produced a commercially approved pharmaceutical product and therefore have not obtained the requisite
regulatory authority approvals to do so. The facilities and quality systems of some or all of our third-party contractors must pass a <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection for compliance with the applicable regulations as a
condition of regulatory approval of our product candidates or any of our other potential products. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product
candidates or our other potential products or the associated quality systems for compliance with the regulations applicable to the activities being conducted. Although we oversee the CMOs, we cannot control the manufacturing process of, and are
completely dependent on, our CMO partners for compliance with the regulatory requirements. If these facilities do not pass a <FONT STYLE="white-space:nowrap">pre-approval</FONT> plant inspection, regulatory approval of the products may not be
granted or may be substantially delayed until any violations are corrected to the satisfaction of the regulatory authority, if ever. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
regulatory authorities also may, at any time following approval of a product for sale, audit the manufacturing facilities of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or
if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time consuming for us or a
third party to implement, and that may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom
we contract could materially harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if supply from one approved manufacturer is interrupted, an alternative
manufacturer would need to be qualified through an NDA or similar regulatory filing, which could result in further delay. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. In some cases, the technical skills required to manufacture our product
candidates may be unique or proprietary to the original CMO and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a <FONT STYLE="white-space:nowrap">back-up</FONT> or alternate
supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and
with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product candidate according to the specifications previously submitted to the FDA
or another regulatory authority. The delays associated with the verification of a new CMO could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. In addition, changes in
manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be
unsuccessful in demonstrating the comparability of clinical supplies, which could require the conduct of additional clinical trials. Accordingly, switching manufacturers may involve substantial costs and is likely to result in a delay in our desired
clinical and commercial timelines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These factors could cause us to incur higher costs and could cause the delay or termination of
clinical trials, regulatory submissions, required approvals, or commercialization of our product candidates. Furthermore, if our suppliers fail to meet contractual requirements and we are unable to secure one or more replacement suppliers capable of
production at a substantially equivalent cost, our clinical trials may be delayed or we could lose potential revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If malignancies arise in
patients treated with our gene therapy product candidates, including <FONT STYLE="white-space:nowrap">ARU-1801,</FONT> or if there are other safety events that require us to halt or delay clinical development of
<FONT STYLE="white-space:nowrap">ARU-1801</FONT> or other gene therapies, the development of those therapies would be delayed and the commercial potential of those therapies would be materially and negatively impacted. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A potentially significant risk in any gene therapy product candidate using viral vectors is that the vector will insert in or near
cancer-causing oncogenes leading to uncontrolled clonal proliferation of mature cancer cells in the patient, known as insertional oncogenesis, which can lead to certain forms of cancer. In early 2021, a company developing a gene therapy for the
treatment of sickle cell disease announced that one of its patients has developed acute myelogenous leukemia following treatment.&nbsp;While Aruvant has not experienced any similar safety events to date, any such events arising in patients treated
with <FONT STYLE="white-space:nowrap">ARU-1801</FONT> could result in delays to the clinical development timeline, the suspension of clinical development altogether or, following approval by the FDA, if received, the product being removed from the
market or its market opportunity being significantly reduced. In addition, the sickle cell disease population has an elevated underlying risk of malignancy. As a result, if patients treated with <FONT STYLE="white-space:nowrap">ARU-1801</FONT>
develop a malignancy, it may be difficult for us to determine the underlying cause of the malignancy and the link, if any, to <FONT STYLE="white-space:nowrap">ARU-1801,</FONT> potentially causing further delays to our clinical development timeline.
Any of the foregoing issues arising in relation to <FONT STYLE="white-space:nowrap">ARU-1801</FONT> or other gene therapy product candidates could lead to adverse publicity and have a material adverse effect on our business and the price of the
Roivant Common Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to Regulatory Approval and Commercialization of Our Product Candidates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining approval of a new drug is an extensive, lengthy, expensive and inherently uncertain process, and the FDA or another regulator may delay, limit
or deny approval. If we are unable to obtain regulatory approval in one or more jurisdictions for any product candidates, our business will be substantially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot commercialize a product until the appropriate regulatory authorities have reviewed and approved the product candidate. Approval by
the FDA and comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities is lengthy and unpredictable, and depends upon numerous factors, including substantial discretion of the regulatory authorities. Approval policies,
regulations, or the type and amount of <FONT STYLE="white-space:nowrap">non-clinical</FONT> or clinical data necessary to gain approval may change during the course of a product candidate&#146;s development and may vary among jurisdictions, which
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may cause delays in the approval or the decision not to approve an application. To date, we have not obtained regulatory approval for any product candidates, and it is possible that our current
product candidates and any other product candidates which we may seek to develop in the future will not ever obtain regulatory approval. We cannot be certain that any of our product candidates will receive regulatory approval or be successfully
commercialized even if we receive regulatory approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining marketing approval of a new drug is an extensive, lengthy, expensive and
inherently uncertain process and the FDA or other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities may delay, limit or deny approval of a product candidate for many reasons, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to demonstrate that a product candidate is safe and effective as a treatment for the targeted
indications, and in the case of our product candidates regulated as biological products, that the product candidate is safe, pure, and potent for use in its targeted indication, to the satisfaction of the FDA or other relevant regulatory
authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other relevant regulatory authorities may require additional
<FONT STYLE="white-space:nowrap">pre-approval</FONT> studies or clinical trials, which would increase costs and prolong development timelines; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of clinical trials may not meet the level of statistical or clinical significance required by the FDA
or other relevant regulatory authorities for marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other relevant regulatory authorities may disagree with the number, design, size, conduct or
implementation of clinical trials, including the design of proposed <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and early clinical trials of any future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the CROs that we retain to conduct clinical trials may take actions outside of our control, or otherwise commit
errors or breaches of protocols, that adversely impact the clinical trials and ability to obtain marketing approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other relevant regulatory authorities may not find the data from nonclinical, <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials sufficient to demonstrate that the clinical and other benefits of a product candidate outweigh its safety risks; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other relevant regulatory authorities may disagree with an interpretation of data or significance of
results from nonclinical, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials or may require additional studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other relevant regulatory authorities may not accept data generated at clinical trial sites;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if an NDA or BLA is reviewed by an advisory committee, the FDA or other relevant regulatory authority, as the
case may be, may have difficulties scheduling an advisory committee meeting in a timely manner or the advisory committee may recommend against approval of our application or may recommend that the FDA or other relevant regulatory authority, as the
case may be, require, as a condition of approval, additional nonclinical, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials, limitations on approved labeling or distribution and use restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other relevant regulatory authorities may require development of a risk evaluation and mitigation
strategy (&#147;REMS&#148;) or its equivalent, as a condition of approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other relevant regulatory authorities may require additional post-marketing studies and/or patient
registries for product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other relevant regulatory authorities may find the chemistry, manufacturing and controls data
insufficient to support the quality of our product candidate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other relevant regulatory authorities may identify deficiencies in the manufacturing processes or
facilities of third-party manufacturers; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other relevant regulatory authorities may change their approval policies or adopt new regulations.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future success depends significantly on our ability to successfully complete clinical
trials for our product candidates, obtain regulatory approval and then successfully commercialize those product candidates. Any inability to successfully initiate, conduct or complete clinical trials could result in additional costs to us or impair
our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to or we may elect to conduct additional <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies or
clinical trials to bridge data obtained from our modified product candidates to data obtained from <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical research conducted using earlier versions of these product candidates. Clinical
trial delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize product candidates and
may harm our business and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delays in the initiation, conduct or completion of any clinical trial of our product
candidates will increase our costs, slow down the product candidate development and approval process and delay or potentially jeopardize our ability to receive regulatory approvals, commence product sales and generate revenue. In addition, many of
the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Any of these events could have a material adverse effect on our
business, prospects, financial condition and results of operations and have a negative impact on the price of our common shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our clinical
trials may fail to demonstrate substantial evidence of the safety and efficacy of product candidates that we may identify and pursue for their intended uses, which would prevent, delay or limit the scope of regulatory approval and commercialization.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through
lengthy, complex and expensive <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials that the applicable product candidate is both safe and effective for use in
each target indication, and in the case of our product candidates regulated as biological products, that the product candidate is safe, pure, and potent for use in its targeted indication. Each product candidate must demonstrate an adequate risk
versus benefit profile in its intended patient population and for its intended use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive and can take many years
to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical development process. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. We
have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be certain that our current clinical trials or any other future clinical trials will be successful. Additionally, any safety
concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business,
financial condition and results of operations. In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities will
interpret the results as we do, and more trials could be required before we submit our product candidates for approval. Moreover, results acceptable to support approval in one jurisdiction may be deemed inadequate by another regulatory authority to
support regulatory approval in that other jurisdiction. To the extent that the results of the trials are not satisfactory to the FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities for support of a marketing
application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for a product
candidate, the terms of such approval may limit the scope and use of the specific product candidate, which may also limit its commercial potential. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates may cause adverse effects or have other properties that could delay or prevent
their regulatory approval, cause us to suspend or discontinue clinical trials, abandon further development or limit the scope of any approved label or market acceptance. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adverse events caused by our product candidates could cause us, other reviewing entities, clinical trial sites or regulatory authorities to
interrupt, delay or halt clinical trials and could result in the denial of regulatory approval. If an unacceptable frequency or severity of adverse events or new safety signals are reported in our clinical trials for our product candidates or any
future product candidates, our ability to obtain regulatory approval for such product candidates may be negatively impacted. Treatment-related side effects arising from, or those perceived to arise from, our product candidates or those from other
companies targeting similar diseases, could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately
recognized or managed by the treating medical staff. For example, in February 2021, our subsidiary Immunovant voluntarily paused dosing in its ongoing trials for IMVT-1401 globally due to elevated total cholesterol and LDL levels observed in
patients treated with IMVT-1401, resulting in a delay in Immunovant&#146;s development of IMVT-1401. Any of these occurrences may harm our business, financial condition and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, if any of our product candidates are approved and then cause serious or unexpected side effects, a number of potentially
significant negative consequences could result, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may withdraw, suspend or limit their approval of the product or require a REMS (or
equivalent outside the United States) to impose restrictions on its distribution or other risk management measures; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require that we recall a product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additional restrictions being imposed on the marketing or manufacturing processes of product candidates or any
components thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require the addition of labeling statements, such as warnings or contraindications,
require other labeling changes of a product or require field alerts or other communications to physicians, pharmacies or the public; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to change the way a product is administered or to conduct additional clinical trials, change
the labeling of a product or conduct additional post-marketing studies or surveillance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to repeat <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials or
terminate programs for a product candidate, even if other studies or trials related to the program are ongoing or have been successfully completed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be sued and held liable for harm caused to patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could elect to discontinue the sale of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our product candidates may become less competitive; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidate and could substantially
increase the costs of commercializing our product candidates and have a negative impact on the price of our common shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory approval
processes of the FDA and comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities are lengthy, time consuming and inherently unpredictable, and even if we obtain approval for a product candidate in one country or
jurisdiction, we may never obtain approval for or commercialize it in any other jurisdiction, which would limit our ability to realize our full market potential. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to obtaining approval to commercialize a product candidate in any jurisdiction, we or our collaborators must demonstrate with substantial
evidence from well-controlled clinical trials, and to the satisfaction of the FDA or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory agencies, that such product candidate is safe and effective for its intended use. Results from <FONT
STYLE="white-space:nowrap">non-clinical</FONT> studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for a product candidate are promising, such data may not be sufficient to support
approval by the FDA and other regulatory authorities. In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis regarding safety and efficacy. Approval by the FDA does not ensure approval by regulatory authorities in any other country or jurisdiction outside the United States. In addition,
clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. Approval processes vary among countries
and can involve additional product testing and validation, as well as additional administrative review periods. Seeking regulatory approval could result in difficulties and costs for us and require additional nonclinical studies or clinical trials,
which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any
jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if
regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our failure to maintain or continuously improve our quality management program could have an adverse effect upon our business, subject us to regulatory
actions, cause a loss of patient confidence in us or our products, among other negative consequences. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Quality management plays an
essential role in contract manufacturing of drugs or drug products, conducting clinical trials, preventing defects, improving our product candidates and services and assuring the safety and efficacy of our product candidates. Our goal is to maintain
a robust quality management program which includes the following broad pillars of quality: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitoring and assuring regulatory compliance for clinical trials, manufacturing and testing of GxP products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitoring and providing oversight of all GxP suppliers (e.g., contract development manufacturing organizations
and CROs); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing and maintaining an integrated, robust quality management system for clinical, manufacturing, supply
chain and distribution operations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cultivating a proactive, preventative quality culture and employee and supplier training to ensure quality.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future success depends on our ability to maintain and continuously improve our quality management program. A
quality or safety issue may result in adverse inspection reports, warning letters, monetary sanctions, injunction to halt manufacture and distribution of drugs or drug products, civil or criminal sanctions, costly litigation, refusal of a government
to grant approvals and licenses, restrictions on operations or withdrawal of existing approvals and licenses. An inability to address a quality or safety issue in an effective and timely manner may also cause negative publicity, or a loss of patient
confidence in us or our future products, which may result in difficulty in successfully launching product candidates and the loss of potential future sales, which could have an adverse effect on our business, financial condition, and results of
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain FDA approval for a product candidate in the United States, we may never obtain approval for or commercialize our
product candidates in any other jurisdiction, which would limit our ability to realize the drug candidate&#146;s full market potential. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of
other countries regarding safety and effectiveness. Clinical trials </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any
other country. Approval processes vary among countries and can involve additional product testing and validation and additional or different administrative review periods from those in the United States, including additional <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a
product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Seeking regulatory approval outside of the United States could result in difficulties and costs and require additional nonclinical studies or
clinical trials which could be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our product candidates in those countries. The regulatory approval outside of
the United States process may include all of the risks associated with obtaining FDA approval. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining
regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approval in international markets is delayed, our target market
will be reduced and our ability to realize the full market potential of our products will be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain regulatory approval for our
product candidates, we will still face extensive ongoing quality and regulatory obligations and continued regulatory review, which may result in significant additional expense, and our product may face future development and quality or regulatory
compliance difficulties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product candidate for which we obtain marketing approval will be subject to extensive and ongoing
regulatory requirements, including for manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, conduct of potential post-market studies and post-market submission
requirements, export, import, advertising and promotional activities for such product, among other things, will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include
submissions of safety and other post-marketing information and reports, establishment of registration and drug listing requirements, continued compliance with current cGMP, requirements relating to manufacturing, quality control, quality assurance
and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians, recordkeeping and GCP requirements for any clinical trials that we conduct post-approval. Even if marketing approval of a
product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including any requirement to implement a REMS. If a product candidate receives
marketing approval, the accompanying label may limit the approved use of the drug or the FDA or other regulatory authorities may require that contraindications, warnings or precautions, including in some cases, a boxed warning, be included in the
product labeling, which could limit sales of the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may also impose requirements for costly post-marketing studies or
clinical trials and surveillance to monitor the safety or efficacy of the product. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the
provisions of the approved labeling and that promotional and advertising materials and communications are truthful and <FONT STYLE="white-space:nowrap">non-misleading.</FONT> Although the FDA and other regulatory agencies do not regulate a
physician&#146;s choice of drug treatment made in the physician&#146;s independent medical judgment, regulatory authorities impose stringent restrictions on manufacturers&#146; communications and if we do not market our product candidates for their
approved indications or in a manner which regulators believe to be truthful and <FONT STYLE="white-space:nowrap">non-misleading,</FONT> we may be subject to enforcement action. Violations of the Federal Food, Drug, and Cosmetic Act in the United
States and other comparable regulations in other jurisdictions relating to the promotion of prescription drugs may lead to enforcement actions and investigations by the FDA, Department of Justice, State Attorneys General and other comparable <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> regulatory agencies alleging violations of United States federal and state health care fraud and abuse laws, as well as state consumer protection laws and comparable laws in other jurisdictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, later discovery of previously unknown adverse events or other problems with our
product candidates, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may negatively impact our business and the price of our common shares and may yield various results, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the manufacture such product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the labeling or marketing of such product candidates, including a &#147;black box&#148; warning
or contraindication on the product label or communications containing warnings or other safety information about the product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on product distribution or use; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements to conduct post-marketing studies or clinical trials, or any regulatory holds on our clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirement of a REMS (or equivalent outside the United States); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Warning or Untitled Letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of the product candidates from the market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to approve pending applications or supplements to approved applications that we submit;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recall of product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, restitution or disgorgement of profits or revenues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspension or withdrawal of marketing approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to permit the import or export of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lawsuits, injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Non-compliance by us or any current or future collaborator with regulatory requirements, including safety monitoring or pharmacovigilance can
also result in significant financial penalties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Breakthrough Therapy Designation, Fast Track Designation, Regenerative Medicine Advanced Therapy
Designation or orphan drug designation by the FDA, even if granted for any product candidate, may not lead to a faster development, regulatory review or approval process, and does not necessarily increase the likelihood that any product candidate
will receive marketing approval in the United States. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have sought, or may in the future seek, Breakthrough Therapy Designation,
Fast Track Designation, Regenerative Medicine Advanced Therapy Designation or orphan drug designation for certain of our product candidates. <FONT STYLE="white-space:nowrap">ARU-1801,</FONT> a gene therapy in development by Aruvant for the treatment
of sickle cell disease, has received orphan drug designation and rare pediatric designation by the FDA, as well as priority review and orphan designation by the EMA. In addition, two gene therapies under development by Sio Gene Therapies, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">AXO-AAV-GM1,</FONT></FONT> in development for the treatment of GM1 gangliosidosis, and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">AXO-AAV-GM2,</FONT></FONT> in
development for the treatment of GM2 gangliosidosis, also known as <FONT STYLE="white-space:nowrap">Tay-Sachs</FONT> and Sandhoff diseases, have received rare pediatric designation and orphan drug designation (in the case of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">AXO-AAV-GM1)</FONT></FONT> and rare pediatric designation (in the case of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">AXO-AAV-GM2)</FONT></FONT> from the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A breakthrough therapy is defined as a therapy that is intended, alone or in combination with one or more other therapies, to treat a serious
or life-threatening disease or condition, and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment
effects observed early in clinical development. For therapies that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical
development while minimizing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the number of patients placed in potentially less efficacious control regimens. Therapies designated as breakthrough therapies by the FDA may also be eligible for priority review and accelerated
approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe a product candidate meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to
make such designation. In any event, the receipt of a Breakthrough Therapy Designation for a product candidate may not result in a faster development process, review or approval compared to therapies considered for approval under conventional FDA
procedures and does not assure ultimate approval by the FDA. In addition, even if a product candidate qualifies as a breakthrough therapy, the FDA may later decide that such product candidate no longer meets the conditions for qualification or
decide that the time period for FDA review or approval will not be shortened. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a therapy is intended for the treatment of a serious or
life-threatening condition and the therapy demonstrates the potential to address unmet medical needs for this condition, the therapy sponsor may apply for Fast Track Designation. The FDA has broad discretion whether or not to grant this designation,
so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not necessarily experience a faster development
process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track Designation if we believe that the designation is no longer supported by data from our clinical development program. Fast Track Designation alone
does not guarantee qualification for the FDA&#146;s priority review procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory authorities in some jurisdictions, including
the United States and the EEA, may designate drugs and biologics for relatively small patient populations as orphan drugs. In the United States, the FDA may designate a drug or biologic as an orphan drug if it is intended to treat a rare disease or
condition, which is defined as a disease or condition that affects fewer than 200,000 individuals annually in the United States or for which there is no reasonable expectation that costs of research and development of the drug for the disease or
condition can be recovered by sales of the drug in the United States. Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is
entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug or biologic for that time period. In the United States, in order for a product to receive orphan drug exclusivity,
FDA must not have previously approved a drug considered the same drug for the same orphan indication, or the subsequent drug must be shown to be clinically superior to such a previously approved sane drug. The applicable period is seven years in the
United States. A similar data exclusivity scheme exists in the EEA, whereby no company can make reference to (rely on) the innovator drug company&#146;s <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical data in order to obtain a
marketing authorization for eight years from the date of the first approval of the innovator drug in the EEA and no generic drug can be marketed for ten years from the first approval of the innovator drug in the EEA; the innovator drug may qualify
for an extra year&#146;s protection. This additional one year of marketing exclusivity may be obtained in a number of circumstances, such as where the innovator company is granted a marketing authorization for a significant new indication for the
relevant medicinal product. In such a situation, the generic company can only market their product after 11 years from the first grant of the innovator company&#146;s marketing authorization for the product in the EEA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the
manufacturer is unable to assure sufficient quantity of the drug or biologic to meet the needs of patients with the rare disease or condition. In the EEA, orphan drug designation, and the related benefits, may be lost if it is established before the
market authorization is granted that the designation criteria are no longer met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we obtain orphan drug exclusivity for a product, that
exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA or the EMA can subsequently approve the same drug for the same
condition if the FDA or the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
EMA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In the EEA, a marketing authorization may
also be granted, for the same therapeutic indication, to a competitor with a similar medicinal product during the exclusivity period if we are unable to supply sufficient quantities of the medicinal product for which we received marketing
authorization. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain of our gene therapy product candidates are based on novel technologies and the regulatory landscape that governs these
product candidates we may develop is rigorous, complex, uncertain and subject to change, which makes it difficult to predict the time and cost of developing the product candidates and subsequently obtaining regulatory approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical study requirements of the FDA, the EMA and other regulatory agencies and the criteria these regulators use to determine the safety
and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential product candidates. The regulatory approval process for novel product candidates such as our gene
therapies can be more expensive and take longer than for other, better known or more extensively studied pharmaceutical or other product candidates. Currently, a limited number of gene therapy products have been approved by the FDA, the EMA and the
European Commission. Given the few precedents of approved gene therapy products, it is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates in the United States, the EU or
other jurisdictions. Approvals by the EMA and the European Commission may not be indicative of what the FDA may require for approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory requirements governing the development of gene therapy products have changed frequently and may continue to change in the future.
The FDA has established the Office of Tissues and Advanced Therapies within the CBER, to consolidate the review of gene therapy and related products, and to advise the CBER on its review. The FDA can put an IND on clinical hold if the information in
an IND is not sufficient to assess the risks in pediatric patients. In addition to FDA oversight and oversight by IRBs, under guidelines promulgated by the National Institutes of Health (&#147;NIH&#148;) gene therapy clinical trials funded by NIH
are also subject to review and oversight by an institutional biosafety committee (&#147;IBC&#148;), a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution.
Before a clinical study can begin at any institution, that institution&#146;s IRB, and, where applicable, its IBC assesses the safety of the research and identifies any potential risk to public health or the environment. While the NIH guidelines are
not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH
Guidelines voluntarily follow them. Moreover, serious adverse events or developments in clinical trials of gene therapy product candidates conducted by others may cause the FDA or other regulatory bodies to initiate a clinical hold on our clinical
trials or otherwise change the requirements for approval of any of our product candidates. Although the FDA decides whether individual gene therapy protocols may proceed, the review process and determinations of other reviewing bodies can impede or
delay the initiation of a clinical trial, even if the FDA has reviewed the trial and approved its initiation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adverse developments in <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials conducted by others in the field of gene therapy and gene regulation products may cause the FDA, the EMA and other regulatory bodies to revise the requirements for approval of
any product candidates we may develop or limit the use of products utilizing gene regulation technologies, either of which could harm our business. In addition, the clinical trial requirements of the FDA, the EMA and other regulatory authorities and
the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty, and intended use and market of the potential products. The regulatory approval process for
novel product candidates such as our gene therapies can be more expensive and take longer than for other, better known, or more extensively studied pharmaceutical or other product candidates. In addition, because of the evolving regulatory landscape
for novel product candidates such as our gene therapies, there is a heightened risk relating to changes in regulatory requirements, such as the required trial size, the size of safety databases and duration of clinical
<FONT STYLE="white-space:nowrap">follow-up</FONT> required for approval, which could develop in a manner that adversely impacts our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, as we are developing novel potential treatments for diseases in which there is
little clinical experience with new endpoints and methodologies, there is heightened risk that the FDA, the EMA or other regulatory bodies may not consider the clinical trial endpoints to provide clinically meaningful results, and the resulting
clinical data and results may be more difficult to analyze. The prospectively designed natural history studies with the same endpoints as our corresponding clinical trials may not be accepted by the FDA, EMA or other regulatory authorities.
Regulatory agencies administering existing or future regulations or legislation may not allow production and marketing of products utilizing gene regulation technology in a timely manner or under technically or commercially feasible conditions. In
addition, regulatory action or private litigation could result in expenses, delays, or other impediments to our research programs or the commercialization of resulting products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if our product candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payors or
others in the medical community necessary for commercial success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The commercial success of our product candidates will depend
upon their degree of market acceptance by physicians, patients, third-party payors and others in the medical community. Even if any product candidates we may develop receive marketing approval, they may nonetheless fail to gain sufficient market
acceptance by physicians, patients, healthcare payors and others in the medical community. The degree of market acceptance for any product candidates we may develop, if approved for commercial sale, will depend on a number of factors, including:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy and safety of such product candidates as demonstrated in pivotal clinical trials and published in
peer-reviewed journals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential and perceived advantages compared to alternative treatments, including any similar generic
treatments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to offer these products for sale at competitive prices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to offer appropriate patient financial assistance programs, such as commercial insurance <FONT
STYLE="white-space:nowrap">co-pay</FONT> assistance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">convenience and ease of dosing and administration compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical indications for which the product candidate is approved by FDA or comparable <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> regulatory agencies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product labeling or product insert requirements of the FDA or other comparable
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities, including any limitations, contraindications or warnings contained in a product&#146;s approved labeling; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on how the product is dispensed or distributed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction of competitive products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicity concerning these products or competing products and treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strength of marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">favorable third-party coverage and sufficient reimbursement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of any side effects or AEs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of medical products also depend on the willingness of physicians to prescribe the treatment, which is likely to be based on a
determination by these physicians that the products are safe, therapeutically effective and cost effective. In addition, the inclusion or exclusion of products from treatment guidelines established by various physician groups and the viewpoints of
influential physicians can affect the willingness of other physicians to prescribe such products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If approved, our products candidates regulated as biologics may face competition from biosimilars
approved through an abbreviated regulatory pathway. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Patient Protection and Affordable Care Act, as amended by the Health Care
and Education Reconciliation Act of 2010 (the &#147;ACA&#148;), includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (the &#147;BPCIA&#148;), which created an abbreviated approval pathway under section 351(k) of the
Public Health Service Act (&#147;PHSA&#148;) for biological products that are biosimilar to or interchangeable with <FONT STYLE="white-space:nowrap">an&nbsp;FDA-licensed&nbsp;reference</FONT> biological product. Under the BPCIA, a section 351(k)
application for a biosimilar or interchangeable product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar or interchangeable
product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During <FONT STYLE="white-space:nowrap">this&nbsp;12-year&nbsp;period</FONT> of exclusivity, another company may still
market a competing version of the reference product if the FDA approves a full BLA for the competing product submitted under section 351(a) of the PHSA containing the competing sponsor&#146;s own <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of the other company&#146;s product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its
ultimate impact, implementation, and meaning are subject to uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether approval of a biological product qualifies for reference
product exclusivity turns on whether FDA consider the approval a &#147;first licensure.&#148; Not every licensure of a biological product is considered a &#147;first licensure&#148; that gives rise to its own exclusivity period. We believe that our
product candidates approved as a biological product under a BLA should qualify for <FONT STYLE="white-space:nowrap">the&nbsp;12-year&nbsp;period</FONT> of exclusivity. However, there is a risk that this exclusivity could be shortened due to
congressional action or otherwise. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once licensed, will be substituted
for any one of our reference products in a way that is similar to traditional generic substitution <FONT STYLE="white-space:nowrap">for&nbsp;non-biological&nbsp;products</FONT> is not yet clear, and will depend on a number of marketplace and
regulatory factors that are still developing. If competitors are able to obtain marketing approval for biosimilars referencing our products, our products may become subject to competition from such biosimilars, with the attendant competitive
pressure and consequences. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If, in the future, we are unable to establish sales, marketing and distribution capabilities or enter into agreements
with third parties to sell, market and distribute any product candidates we may develop, we may not be successful in commercializing those product candidates if and when they are approved. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently have any infrastructure for the sales, marketing or distribution of any product, and the cost of establishing and
maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market any product that may be approved, we must build our sales, distribution, marketing, compliance, managerial and other non-technical capabilities or
make arrangements with third parties to perform these services. To achieve commercial success for any product for which we obtain marketing approval, we will need a sales and marketing organization or outsource these functions to third parties. In
the future, we may choose to build a focused sales, marketing, and commercial support infrastructure to market and sell our product candidates, if and when they are approved. We may also elect to enter into collaborations or strategic partnerships
with third parties to engage in commercialization activities with respect to selected product candidates, indications or geographic territories, including territories outside the United States, although there is no guarantee we will be able to enter
into these arrangements even if the intent is to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are risks involved with both establishing our own commercial capabilities
and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force or reimbursement specialists is expensive and time consuming and could delay any product launch. If the commercial launch
of a product candidate for which we recruit a sales force and establish marketing and other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization
expenses. This may be costly, and our investment would be lost if we cannot retain or reposition commercialization personnel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors that may inhibit our efforts to commercialize any approved product on our own
include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, customer
service, medical affairs, and other support personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to
prescribe any future approved products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement, and
other acceptance by payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to price products at a sufficient price point to ensure an adequate and attractive level of
profitability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restricted or closed distribution channels that make it difficult to distribute our products to segments of the
patient population; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive
disadvantage relative to companies with more extensive product lines; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unforeseen costs and expenses associated with creating an independent commercialization organization.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to build our own sales force or negotiate a collaborative relationship for the commercialization of
any product candidate, we may be forced to delay potential commercialization or reduce the scope of our sales or marketing activities. If we elect to increase our expenditures to fund commercialization activities ourselves, we will need to obtain
additional capital, which may not be available to us on acceptable terms, or at all. If we do not have sufficient funds, we will not be able to bring any product candidate to market or generate product revenue. We could enter into arrangements with
collaborative partners at an earlier stage than otherwise would be ideal and we may be required to relinquish certain rights to our product candidate or otherwise agree to terms unfavorable to us, any of which may have an adverse effect on our
business, operating results and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we enter into arrangements with third parties to perform sales, marketing, commercial
support, and distribution services, our product revenue or the profitability of product revenue may be lower than if we were to market and sell any products we may develop internally. In addition, we may not be successful in entering into
arrangements with third parties to commercialize our product candidates or may be unable to do so on terms that are favorable to us or them. We may have little control over such third parties, and any of them may fail to devote the necessary
resources and attention to sell and market our products effectively or may expose us to legal and regulatory risk by not adhering to regulatory requirements and restrictions governing the sale and promotion of prescription drug products, including
those restricting <FONT STYLE="white-space:nowrap">off-label</FONT> promotion. If we do not establish commercialization capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing
our product candidates, if approved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our current and future relationships with investigators, health care professionals, consultants, third-party
payors, patient support, charitable organizations, customers, and others are subject to applicable healthcare regulatory laws, which could expose us to penalties and other risks. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business operations and current and potential future arrangements with investigators, healthcare professionals, consultants, third-party
payors, patient support, charitable organizations, customers, and others, expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws regulate the business or financial arrangements and relationships through
which we conduct our operations, including how we research, market, sell and distribute our product candidates for which we obtain marketing approval. Such laws include, without limitation: </P>
<P STYLE="font-size:11pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which is a criminal law that prohibits, among other things, persons and
entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good,
facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare program (such as Medicare and Medicaid). The term &#147;remuneration&#148; has been broadly interpreted by the federal government to include
anything of value. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain activities from prosecution, the exceptions and safe harbors are drawn narrowly, and arrangements may be subject to scrutiny or
penalty if they do not fully satisfy all elements of an available exception or safe harbor. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they
do not qualify for an exception or safe harbor. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation; in addition, the government may assert
that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. Violations of the federal Anti-Kickback Statute may result in
civil monetary penalties up to $100,000 for each violation. Civil penalties for such conduct can further be assessed under the federal False Claims Act. Violations can also result in criminal penalties, including criminal fines and imprisonment of
up to 10 years. Similarly, violations can result in exclusion from participation in government healthcare programs, including Medicare and Medicaid; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal false claims laws, including the False Claims Act, which imposes civil penalties, including through
civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent, knowingly making, using or causing to be made
or used, a false record or statement material to a false or fraudulent claim, or knowingly making or causing to be made, a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. When an entity is
determined to have violated the federal civil False Claims Act, the government may impose civil fines and penalties currently ranging from $11,665 to $23,331 for each false claim or statement for penalties assessed after June&nbsp;19, 2020, with
respect to violations occurring after November&nbsp;2, 2015, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal health care fraud statute (established by Health Insurance Portability and Accountability Act of 1996
(&#147;HIPAA&#148;)), which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or making false or fraudulent statements
relating to healthcare matters; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#147;HITECH&#148;),
and their implementing regulations, which also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information on health plans, health
care clearing houses, and most providers and their business associates, defined as independent contractors or agents of covered entities that create, receive or obtain protected health information in connection with providing a service for or on
behalf of a covered entity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a variety of privacy, cybersecurity and data protection laws, rules and regulations at the international,
federal, state and local level imposes obligations with respect to safeguarding the privacy, security, and transmission of personal data and health information generally; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Civil Monetary Penalties Law, which authorizes the imposition of substantial civil monetary penalties
against an entity that engages in activities including, among others (1)&nbsp;knowingly presenting, or causing to be presented, a claim for services not provided as claimed or that is otherwise false or fraudulent in any way; (2)&nbsp;arranging for
or contracting with an individual or entity that is excluded from participation in federal health care programs to provide items or services reimbursable by a federal health care program; (3)&nbsp;violations of the federal Anti-Kickback Statute; or
(4)&nbsp;failing to report and return a known overpayment; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics,
and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to the government information related to payments or other &#147;transfers of
value&#148; made to physicians, certain other healthcare providers, and teaching hospitals, and requires applicable manufacturers and group purchasing organizations to report annually to the government ownership and investment interests held by the
physicians described above and their immediate family members and payments or other &#147;transfers of value&#148; to such physician owners (covered manufacturers are required to submit reports to the government by the 90th day of each calendar
year); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state and national laws and regulations, such as state anti-kickback and false claims laws, which may
apply to our business practices, including but not limited to, research, distribution, sales, and marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT>
third-party payors, including private insurers, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws that require pharmaceutical companies to comply with the pharmaceutical
industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, and state laws that require drug manufacturers to report information related to payments and other transfers of value to
physicians and other healthcare providers or marketing expenditures; and several recently passed state laws that require disclosures related to state agencies and/or commercial purchasers with respect to certain price increases that exceed a certain
level as identified in the relevant statutes, some of which contain ambiguous requirements that government officials have not yet clarified. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and
regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable
healthcare laws. If our operations are found to be in violation of any of these or any other applicable health regulatory laws that may apply to us, we may be subject to significant penalties, including the imposition of significant civil, criminal
and administrative penalties, damages, monetary fines, disgorgement, individual imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished
profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement and curtailment or restructuring of our operations, any of which could adversely affect our
ability to operate our business and our results of operations. Even the mere issuance of a subpoena, civil investigative demand or the fact of an investigation alone, regardless of the merit, may result in negative publicity, a drop in our share
price and other harm to our business, financial condition and our results of operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are
successful in defending against any such actions that may be brought against us, our business may be impaired. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare legislative measures
aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The United States
and many other jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our product candidates or any future product candidates, restrict or regulate
post-approval activities and affect our ability to profitably sell any product for which we obtain marketing approval. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by
requiring, for example: (i)&nbsp;changes to our manufacturing arrangements; (ii)&nbsp;additions or modifications to product labeling; (iii)&nbsp;the recall or discontinuation of our products; or (iv)&nbsp;additional record-keeping requirements. If
any such changes were to be imposed, they could adversely affect the operation of our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, there have been and continue to be a number of legislative initiatives
to contain healthcare costs, including costs for pharmaceuticals. For example, in March 2010, the ACA was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the
U.S. pharmaceutical industry. The ACA, among other things, subjects biological products to potential competition by lower-cost biosimilars, addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are
calculated for drugs that are inhaled, infused, instilled, implanted or injected, increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid
managed care organizations, establishes annual fees and taxes on manufacturers of certain branded prescription drugs, and creates a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s
outpatient drugs to be covered under Medicare Part D. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been numerous judicial, administrative, executive,
and legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. Various portions of the ACA are currently undergoing legal and constitutional challenges in the
United States Supreme Court; the former Trump Administration issued various Executive Orders which eliminated cost sharing subsidies and various provisions that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden
on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices; and Congress has introduced several pieces of legislation aimed at significantly revising or repealing the ACA. The United States Supreme
Court is expected to rule on a legal challenge to the constitutionality of the ACA in the coming months. The implementation of the ACA is ongoing, the law appears likely to continue the downward pressure on pharmaceutical pricing, especially under
the Medicare program, and may also increase our regulatory burdens and operating costs. Litigation and legislation related to the ACA are likely to continue, with unpredictable and uncertain results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the
Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013
through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went
into effect in 2013, and, due to subsequent legislative amendments, will remain in effect through 2029 unless additional Congressional action is taken. Pursuant to the CARES Act and subsequent legislation, these reductions were suspended from
May&nbsp;1, 2020 through December&nbsp;31, 2021 due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. As the legislation currently stands, the reductions will go back into effect as of January 2022 and will remain in effect through
2030 unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012 further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period
for the government to recover overpayments to providers from three to five years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There has been increasing legislative and enforcement
interest in the United States with respect to drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to
drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, including the
former administration&#146;s budget for fiscal year 2020 contained further drug price control measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under
Medicaid, and to eliminate cost sharing for generic drugs for <FONT STYLE="white-space:nowrap">low-income</FONT> patients. Additionally, the former Trump administration released a &#147;Blueprint&#148; to lower drug prices and reduce out of pocket
costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of
pocket costs of drug products paid by consumers. The U.S. Department of Health </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and Human Services (&#147;HHS&#148;), has already implemented several of these provisions to date. In May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step
therapy, a type of prior authorization, for Part B drugs beginning January&nbsp;1, 2020. Additionally, on November&nbsp;20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to
plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">point-of-sale,</FONT></FONT> as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. These modifications to the safe harbors are being challenged in court and HHS
has delayed their implementation until January&nbsp;1, 2023. Although a number of these and other proposed measures will require authorization through additional legislation to become effective, it is unclear whether the Biden administration will
challenge, reverse, revoke or otherwise modify these recent executive and administrative actions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been, and likely will
continue to be, legislative and regulatory proposals at the national and state levels in jurisdictions around the world directed at containing or lowering the cost of healthcare, including prescription drugs. The implementation of cost containment
measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may
successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates. We cannot predict the initiatives that may be adopted in the future. The continuing
efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the demand for our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to receive or set a price that we believe is fair for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to generate revenue and achieve or maintain profitability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of taxes that we are required to pay; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of capital. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in
Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement and new payment methodologies. This could lower the price that we receive for any approved product. Any denial in coverage or reduction in reimbursement from
Medicare or other government-funded programs may result in a similar denial or reduction in payments from private payors, which may prevent us from being able to generate sufficient revenue, attain profitability or commercialize our product
candidates, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recent federal legislation and actions by state and local governments in the United States may permit
reimportation of drugs from foreign countries into the United States, including foreign countries where the drugs are sold at lower prices than in the United States, which could materially adversely affect our operating results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coverage and adequate reimbursement may not be available for our product candidates, which could make it difficult for us to sell our product candidates
profitably. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market acceptance and sales of any approved product candidates that we develop will depend in part on the extent to
which coverage and adequate reimbursement for these product candidates and related treatments will be available from third-party payors, including government health administration authorities and private health insurers. The target patient
populations for our drugs are often relatively small, as a result of which the pricing and reimbursement of our product candidates, if approved, must be adequate to support commercial infrastructure. If we are unable to obtain adequate levels of
reimbursement, our ability to successfully market and sell our product candidates will be adversely affected. The manner and level at which reimbursement is provided for services related to our product candidates (e.g., for administration of our
product to patients) is also </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
important. Inadequate reimbursement for such services may lead to physician resistance and adversely affect our ability to market or sell our product candidates. There is no assurance that our
product candidates, if approved, would achieve adequate coverage and reimbursement levels. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, no uniform policy of
coverage and reimbursement for product candidates exists among third-party payors. Third-party payors decide which drugs they will pay for and establish reimbursement levels. Third-party payors often rely upon Medicare coverage policy and payment
limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any product candidates that we develop will be made on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">plan-by-plan</FONT></FONT> basis. One payor&#146;s determination to provide coverage for a product does not assure that other payors will also provide coverage, and adequate reimbursement,
for the product. Additionally, a third-party payor&#146;s decision to provide coverage for a drug does not imply that an adequate reimbursement rate will be approved. Each plan determines whether or not it will provide coverage for a drug, what
amount it will pay the manufacturer for the drug, on what tier of its formulary the drug will be placed and whether to require step therapy. The position of a drug on a formulary generally determines the
<FONT STYLE="white-space:nowrap">co-payment</FONT> that a patient will need to make to obtain the drug and can strongly influence the adoption of a drug by patients and physicians. Patients who are prescribed treatments for their conditions and
providers prescribing such services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to
cover a significant portion of the cost of the product candidates. Further, from time to time, typically on an annual basis, payment rates are updated and revised by third-party payors. Such updates could impact the demand for our product
candidates, to the extent that patients who are prescribed our product candidates, if approved, are not separately reimbursed for the cost of the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the
price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Even if we obtain adequate levels of reimbursement, third-party payors, such as government or private healthcare insurers, carefully review and
increasingly question the coverage of, and challenge the prices charged for, product candidates. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Increasingly, third-party payors are requiring that pharmaceutical
companies provide them with predetermined discounts from list prices and are challenging the prices for product candidates. We may also be required to conduct expensive pharmacoeconomic studies to justify the coverage and the amount of reimbursement
for particular medications. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Inadequate coverage and reimbursement
may impact the demand for, or the price of, any product for which we obtain marketing approval. If coverage and adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize any
product candidates that we develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, there have been a number of legislative and regulatory proposals to change the
healthcare system in the United States and in some other jurisdictions that could affect our ability to sell any future drugs profitably. These legislative and regulatory changes may negatively impact the reimbursement for any future drugs,
following approval. There can be no assurance that our candidates, if approved, will be considered medically reasonable and necessary, that they will be considered cost-effective by third-party payors, that coverage or an adequate level of
reimbursement will be available, or that reimbursement policies and practices in the United States and in other countries where our product candidates are sold will not harm our ability to sell our product candidates profitably, if they are approved
for sale. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent federal legislation and actions by state and local governments may permit reimportation of drugs from foreign countries into the
United States, including foreign countries where the drugs are sold at lower prices than in the United States, which could materially adversely affect our operating results. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may face competition in the United States for our product candidates, if approved, from therapies sourced from foreign countries that have
placed price controls on pharmaceutical products. In the United States, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Medicare Modernization Act (&#147;MMA&#148;) contains provisions that may change U.S. importation laws and expand pharmacists&#146; and wholesalers&#146; ability to import cheaper versions of an
approved drug and competing products from Canada, where there are government price controls. These changes to U.S. importation laws will not take effect unless and until the Secretary of the HHS certifies that the changes will pose no additional
risk to the public&#146;s health and safety and will result in a significant reduction in the cost of products to consumers. On September&nbsp;23, 2020, the Secretary of HHS made such certification to Congress, and on October&nbsp;1, 2020, the FDA
published a final rule that allows for the importation of certain prescription drugs from Canada. Under the final rule, States and Indian Tribes, and in certain future circumstances pharmacists and wholesalers, may submit importation program
proposals to the FDA for review and authorization. Since the issuance of the final rule, on November&nbsp;23, 2020, several industry groups filed federal lawsuits in the U.S. District Court for the District of Columbia, requesting injunctive relief
to prevent implementation of the rule. Further, authorities in Canada have passed rules designed to safeguard the Canadian drug supply from shortages. On September&nbsp;25, 2020, CMS stated drugs imported by States under this rule will not be
eligible for federal rebates under Section&nbsp;1927 of the Social Security Act and manufacturers would not report these drugs for &#147;best price&#148; or Average Manufacturer Price purposes. Since these drugs are not considered covered outpatient
drugs, CMS further stated it will not publish a National Average Drug Acquisition Cost for these drugs. Separately, the FDA also issued a final guidance document outlining a pathway for manufacturers to obtain an additional National Drug Code
(&#147;NDC&#148;), for an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug that was originally intended to be marketed in a foreign country and that was authorized for sale in that foreign country. If implemented, importation of drugs from
Canada may materially and adversely affect the price we receive for any of our product candidates. The regulatory and market implications of the final rule and guidance are unknown at this time. Proponents of drug reimportation may attempt to pass
legislation that would directly allow reimportation under certain circumstances. Legislation or regulations allowing the reimportation of drugs, if enacted, could decrease the price we receive for any products that we may develop and adversely
affect our future revenues and prospects for profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Risks Related to Our Business and Industry </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend on the knowledge and skills of our senior leaders, and may not be able to manage our business effectively if we are unable to attract and
retain key personnel. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have benefited substantially from the leadership, performance and vision of our senior leaders, in
particular, our founder and Executive Chairman, Vivek Ramaswamy, our Chief Executive Officer and Chief Financial Officer, Matthew Gline, and other senior executives at Roivant and the Vants. We rely greatly on the investment experience and medical
and scientific expertise of our senior leadership team to identify product candidates and guide future investments and opportunities, as well as the drug development expertise of our and the Vants&#146; senior leadership to guide the pre-clinical
and clinical development of our product candidates. Our success will depend on our ability to retain our current management team. In addition, while we expect to engage in an orderly transition process as we integrate newly appointed officers and
managers, we face a variety of risks and uncertainties relation to management transition, including diversion of management attention from business concerns, failure to retain other key personnel or loss of institutional knowledge. Competition for
senior leadership in the healthcare investment industry is intense, and we cannot guarantee that we will be able to retain key personnel at Roivant or the Vants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our senior leaders and key employees may terminate their positions with us at any time. Due to the small number of employees at some of the
Vants, the loss of key employee may have a larger impact on our business. In particular, we rely on a limited number of employees in certain key jurisdictions, including the UK, Switzerland and Bermuda. If we lose one or more members of our or the
Vants&#146; senior leadership teams or other key employees, our ability to successfully implement our business strategies could be adversely impacted. Replacing these individuals may be difficult, cause disruption and may take an extended period of
time due to the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of, and commercialize product candidates successfully. Competition to hire from this limited pool
is intense, and we may be unable to hire, train, retain or motivate additional key personnel. We do not maintain &#147;key person&#148; insurance for any members of our senior leadership team or other employees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To encourage valuable employees to remain at our company, in addition to salary and cash
incentives, we have provided certain equity awards that vest over time. The value to employees of equity awards that vest over time may be significantly affected by movements in our share price that are beyond our control and may at any time be
insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain invaluable employees, members of our management, scientific and development teams may terminate their employment with us at any time. Although we
have employment agreements with our key employees, certain of these employment agreements provide for <FONT STYLE="white-space:nowrap">at-will</FONT> employment, which means that any of our employees could leave our employment at any time. Our
success also depends on our ability to continue to attract, retain and motivate high skilled junior, <FONT STYLE="white-space:nowrap">mid-level</FONT> and senior managers as well as junior, <FONT STYLE="white-space:nowrap">mid-level</FONT> and
senior scientific and medical personnel. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in funding for, or disruptions to the operations of, the FDA, the SEC and other government
agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal
functions on which the operation of our business may rely, which could negatively impact our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the FDA to
review and approve new products or take action with respect to other regulatory matters can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user
fees, the availability of personnel and other resources in light of governmental &#147;stay at home&#148; orders in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, and statutory, regulatory and policy changes. Average
review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is
subject to the political process, which is inherently fluid and unpredictable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disruptions at the FDA and other agencies may also slow
the time necessary for new drugs to be reviewed and/or approved, or for other actions to be taken, by relevant government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning
on December&nbsp;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. Since March
2020, foreign and domestic inspections by the FDA have largely been on hold due to impacts of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, with the FDA announcing plans in July 2020 to resume prioritized domestic inspections. With
respect to <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections, FDA has been using other tools and approaches where possible, including requesting existing inspection reports from other foreign regulatory partners, requesting
information from applicants, and requesting records and other information directly from facilities and other inspected entities. Should FDA determine that an inspection is necessary for approval of a marketing application and an inspection cannot be
completed during the review cycle due to restrictions on travel, the FDA has stated that it generally intends to issue a complete response letter. Further, if there is inadequate information to make a determination on the acceptability of a
facility, the FDA may defer action on the application until an inspection can be completed. In 2020, several companies announced receipt of complete response letters due to the FDA&#146;s inability to complete required inspections for their
applications. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and may experience delays in their regulatory
activities. Additionally, as of June&nbsp;23, 2020, the FDA noted it is continuing to ensure timely reviews of applications for medical products during the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic in line with its user fee
performance goals. On July&nbsp;16, 2020, the FDA noted that it is continuing to expedite oncology product development with its staff teleworking full-time. However, the FDA may not be able to continue its current pace and approval timelines could
be extended, including where a <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection or an inspection of clinical sites is required and due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and travel restrictions the FDA is
unable to complete such required inspections during the review period. If a prolonged government shutdown or disruption to the operations of the FDA occurs, it could significantly impact the ability of the FDA to timely review and process our
regulatory submissions, which could have a material adverse effect on our business. Similarly, a prolonged </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
government shutdown or disruption to the operations of the USPTO could prevent the timely review of our patent applications, which could delay the issuance of any U.S. patents to which we might
otherwise be entitled. Future government shutdowns and similar events could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to expand our organization and may experience difficulties in managing this growth, which could disrupt operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with our continued growth and the Business Combination, we expect to hire, either directly or through our current or future
affiliates, additional employees for our managerial, finance and accounting, clinical, scientific and engineering, regulatory, operational, manufacturing, sales and marketing teams. We may have difficulties in connection with identifying, hiring and
integrating new personnel. Future growth would impose significant additional responsibilities on management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors. Also,
management may need to divert a disproportionate amount of its attention away from our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and devote a substantial amount of time to managing these
growth activities. We may not be able to effectively manage the expansion of operations across our entities, which may result in weaknesses in infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and
reduced productivity among remaining employees. Our future growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of product candidates. If our management is unable to
effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and ability to
commercialize product candidates and new technologies and compete effectively will partly depend on our ability to effectively manage any future growth. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the other pharmaceutical and healthcare technology companies that we compete against for qualified personnel and consultants have
greater financial and other resources, different risk profiles and a longer operating history in the industry than us. They also may provide more diverse opportunities and better chances for career advancement. Some of these opportunities may be
more appealing to high-quality candidates and consultants than what we have to offer. If we are unable to continue to attract and retain high-quality personnel and consultants, the rate and success at which we can discover and develop product
candidates and our business will be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our international operations may expose us to business, legal, regulatory, political, operational,
financial and economic risks associated with conducting business globally. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Part of our business strategy involves potential
expansion internationally with third-party collaborators to seek regulatory approval for our product candidates globally. Doing business internationally involves a number of risks, including but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">multiple conflicting and changing laws and regulations such as tax laws, export and import restrictions,
employment laws, anti-bribery and anti-corruption laws, regulatory requirements and other governmental approvals, permits and licenses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by us or our collaborators to obtain appropriate licenses or regulatory approvals for the sale or use of
our product candidate, if approved, in various countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties in managing operations in different jurisdictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complexities associated with managing multiple payor-reimbursement regimes or
<FONT STYLE="white-space:nowrap">self-pay</FONT> systems; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial risks, such as longer payment cycles, difficulty enforcing contracts and collecting accounts receivable
and exposure to currency exchange rate fluctuations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">varying protection for intellectual property rights; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak
of disease, boycotts, curtailment of trade and other business restrictions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to comply with the United States Foreign Corrupt Practices Act (the &#147;FCPA&#148;), including its
books and records provisions and its anti-bribery provisions, the United Kingdom Bribery Act 2010 (the &#147;U.K. Bribery Act&#148;), and similar anti-bribery and anti-corruption laws in other jurisdictions, for example by failing to maintain
accurate information and control over sales or distributors&#146; activities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these risks, if encountered, could
significantly harm our future international expansion and operations and, consequently, negatively impact our financial condition, results of operations and cash flows. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to invest in and expand our business and meet our financial obligations, to attract and retain third-party contractors and
collaboration partners and to raise additional capital depends on our operating and financial performance, which, in turn, is subject to numerous factors, including the prevailing economic and political conditions and financial, business and other
factors beyond our control, such as the rate of unemployment, the number of uninsured persons in the United States, political influences and inflationary pressures. For example, an overall decrease in or loss of insurance coverage among individuals
in the United States as a result of unemployment, underemployment or the repeal of certain provisions of the ACA may decrease the demand for healthcare services and pharmaceuticals. If fewer patients are seeking medical care because they do not have
insurance coverage, we may experience difficulties in any eventual commercialization of our product candidates and our business, results of operations, financial condition and cash flows could be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our results of operations could be adversely affected by general conditions in the global economy and in the global financial
markets upon which pharmaceutical and biopharmaceutical companies such as us are dependent for sources of capital. In the past, global financial crises have caused extreme volatility and disruptions in the capital and credit markets. A severe or
prolonged economic downturn could result in a variety of risks to our business, including a reduced ability to raise additional capital when needed on acceptable terms, if at all, and weakened demand for our product candidates. A weak or declining
economy could also strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could
adversely impact our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face significant competition in an environment of rapid technological and scientific change, and there is a
possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer, more advanced or more effective than ours, which may negatively impact our ability to successfully market or commercialize any product
candidates we may develop and ultimately harm our financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development and commercialization of new drug products
is highly competitive. We may face competition with respect to any product candidates that we seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies
worldwide. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research,
development, manufacturing, and commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are a number of large pharmaceutical and biotechnology companies that are
currently pursuing the development and commercialization of products for the treatment of the indications that we are pursuing, including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Roflumilast, a PDE4 inhibitor, a potential competitor to tapinarof, in development by Dermavant for the topical
treatment of psoriasis; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Teprotumumab, an insulin-like growth <FONT STYLE="white-space:nowrap">factor-1</FONT> receptor inhibitor, a
potential competitor to IMVT-1401, in development by Immunovant for the treatment of thyroid eye disease; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Efgartigimod, an anti-FcRn antibody fragment, and nipocalimab, an anti-FcRn antibody, both potential competitors
to IMVT-1401, in development by Immunovant for the treatment of myasthenia gravis; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CTX001, a gene-editing therapy and LentiGlobin, a gene therapy delivering a modified form of adult hemoglobin,
both potential competitors to <FONT STYLE="white-space:nowrap">ARU-1801,</FONT> in development by Aruvant for the treatment of sickle cell disease. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of these or other competitors, including competitors for our other product candidates, receive FDA approval before we do, our product
candidates would not be the first treatment on the market, and our market share may be limited. In addition to competition from other companies targeting our target indications, any products we may develop may also face competition from other types
of therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our current or potential competitors, either alone or with their strategic partners, have significantly greater
financial resources and expertise in research and development, manufacturing, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a
smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in
recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we
may develop. Furthermore, currently approved products could be discovered to have application for treatment of our targeted disease indications or similar indications, which could give such products significant regulatory and market timing
advantages over our product candidates. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours and may obtain orphan product exclusivity from the FDA for indications that
we are targeting, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, products or technologies developed by our competitors may render our potential product candidates
uneconomical or obsolete and we may not be successful in marketing any product candidates we may develop against competitors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, we could face litigation or other proceedings with respect to the scope, ownership, validity and/or enforceability of our patents relating to our competitors&#146; products and our competitors may allege that our products infringe,
misappropriate or otherwise violate their intellectual property. The availability of our competitors&#146; products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The markets in which our healthcare technology Vants participate are competitive, and if we do not compete effectively, our business and operating
results could be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The overall market for healthcare technologies and software is global, rapidly evolving,
competitive and subject to changing technology and shifting customer focus. Our healthcare technology Vants, including Datavant, a healthcare data infrastructure company, Lokavant, a clinical trial technology company, and Alyvant, a salesforce
technology company, face competition from well-established providers of these solutions, certain of which may have long-standing relationships with many of our current and potential customers, including large biopharmaceutical companies. We also
face competition from solutions that biopharmaceutical companies develop internally and from smaller companies that offer products and services directed at more specific markets </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
than we target, enabling these smaller competitors to focus a greater proportion of their efforts and resources on these markets, as well as a large number of companies that have been founded
with the goal of applying machine learning technologies to drug discovery. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our competitors are able to devote greater resources
to the development, promotion, and sale of their software solutions and services. Third parties with greater available resources and the ability to initiate or withstand substantial price competition could acquire our current or potential
competitors. Our competitors may also establish cooperative relationships among themselves or with third parties that may further enhance their product offerings or resources. If our competitors&#146; products, services or technologies become more
accepted than our solutions, if our competitors are successful in bringing their products or services to market earlier than ours, if our competitors are able to respond more quickly and effectively to new or changing opportunities, technologies, or
customer requirements, or if their products or services are more technologically capable than ours, then the business and prospects of these Vants could be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Roivant and its subsidiaries are subject to litigation and investigation risks which could adversely affect their business, results of operations and
financial condition and could cause the market value of the Roivant Common Shares to decline. Insurance coverage may not be available for, or adequate to cover, all potential exposure for litigation and other business risks. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roivant and its subsidiaries are from time to time subject to various litigation matters and claims, including regulatory proceedings,
administrative proceedings, securities litigation and other lawsuits, and governmental investigations. In addition, Roivant and its subsidiaries may receive requests for information from governmental agencies in connection with their regulatory or
investigatory authority or from private third parties pursuant to subpoena. These proceedings may be complex and prolonged, and may occupy the resources of Roivant&#146;s and its subsidiaries&#146; management and employees. These proceedings are
also costly to prosecute and defend and may involve substantial awards or damages payable by Roivant or its subsidiaries if not favorably resolved. Roivant and its subsidiaries may be required to pay substantial amounts or grant certain rights on
unfavorable terms in order to settle such proceedings. We also face risks relating to litigation arising from judgments made by us and the Vants&#146; as to the materiality of any developments in our businesses, including with respect to <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> and clinical data, and the resulting disclosure (or lack thereof) may give rise to securities litigation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain insurance policies for litigation and various business risks, but such policies may not be adequate to compensate us for potential
losses. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and defending a suit, regardless of its merit, could be costly
and divert management&#146;s attention. Because of the uncertain nature of litigation, investigations and insurance coverage decisions, it is not possible to predict the outcome of these matters, which could have a material adverse effect on the
business, results of operations, and financial condition of Roivant and its subsidiaries, as applicable, could impact the ability to consummate a transaction that is challenged or otherwise subject to such litigation and could cause the market value
of the Roivant Common Shares to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage
public perception of our gene therapy product candidates and any future products or adversely affect our ability to conduct our business or obtain and maintain marketing approvals for our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Public perception may be influenced by claims that gene therapy, including gene editing technologies, is unsafe or unethical, and research
activities and adverse events in the field, even if not ultimately attributable to us or our product candidates, could result in increased governmental regulation, unfavorable public perception, challenges in recruiting patients to participate in
our clinical studies, potential regulatory delays in the testing or approval of our potential products, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product. More restrictive
government regulations or negative public </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any approved
products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not hold a controlling stake in certain of our subsidiaries and thus may not be able to direct our business or the development of
our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For certain of the Vants, including Arbutus, Datavant and Sio Gene Therapies, we hold less than a majority
ownership interest or are otherwise limited in our ability to direct or control the business and the development of the product candidates or technologies at the Vant. In addition, for certain other Vants, including Immunovant, we may in the future
come to hold less than a majority ownership interest in the Vant. Furthermore, even if we own a majority ownership interest in a Vant, we may not necessarily be able to control the outcome of certain corporate actions. If the business or development
of a product candidate at one of these Vants were to face challenges, we would be adversely affected as a result and would be limited in our ability to cause or influence the Vant in question to take appropriate remediative actions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business and operations would suffer in the event of system failures, cyber-attacks or a deficiency in our cyber-security. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our computer systems, as well as those of various third parties on which we presently rely, or may rely on in the future, including our CROs
and other contractors, consultants and law and accounting firms, may sustain damage from computer viruses, unauthorized access, data breaches, phishing attacks, cybercriminals, natural disasters (including hurricanes and earthquakes), terrorism, war
and telecommunication and electrical failures. Such information technology systems are additionally vulnerable to security breaches from inadvertent or intentional actions by our employees, third-party vendors, contractors, consultants, business
partners, and/or other third parties. Any of the foregoing may compromise our system infrastructure, or that of our third-party vendors and other contractors and consultants, or lead to data leakage. The risk of a security breach or disruption,
particularly through cyber-attacks or cyber intrusion, including by computer hackers, sovereign governments and cyber terrorists, has generally increased along with the number, intensity and sophistication of attempted attacks and intrusions from
around the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on our third-party providers to implement effective security measures and to identify and correct for any such
failures, deficiencies or breaches. Although we seek to supervise such third parties&#146; security measures, our ability to do so is limited. If the information technology systems of our third-party vendors and other contractors and consultants
become subject to disruptions or security breaches, we may have insufficient recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to
prevent future events of this nature from occurring. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to anticipate all types of security threats and we cannot assure
you that our data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages, breaches in our systems, or those of our third-party vendors and other contractors and consultants, or other cyber
incidents that could have a material adverse effect upon our reputation, business, operations, or financial condition. If any of the aforementioned security events were to occur, it could result in a material disruption of our drug development
programs and business operations. For example, the loss of nonclinical or clinical trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or
reproduce the data. Similarly, we rely on third parties to supply components for and manufacture our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect
on our business. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and
reputational damage and the further development of any product candidate could be delayed. The costs related to significant security breaches or disruptions could be material and exceed the limits of the cybersecurity insurance we maintain against
such risks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to stringent privacy laws, information security laws, regulations, policies and
contractual obligations related to data privacy and security and changes in such laws, regulations, policies and contractual obligations could adversely affect our business, including in particular our healthcare technology businesses. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of
personally-identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information. The legislative and regulatory landscape for privacy and data protection continues
to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business, including in particular our healthcare technology businesses. Failure to comply with these
laws and regulations could result in enforcement action against us, including fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could
have a material adverse effect on our business, financial condition, results of operations or prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are numerous U.S. federal
and state laws and regulations related to the privacy and security of personal information. In particular, regulations promulgated pursuant to HIPAA establish privacy and security standards for covered entities that limit the use and disclosure of
individually identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the
confidentiality, integrity and availability of electronic protected health information. While we generally do not receive protected health information subject to HIPAA in our business, we do business with various entities that are subject to HIPAA
or that process protected health information, and as HIPAA obligations or our business evolves, we may have to expend resources to understand our obligations, adjust contractual relationships, or change business practices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, many states in which we operate have laws that protect the privacy and security of sensitive and personal information. Certain
state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to sensitive and personal information than federal, international or other state laws, and such laws may differ from each other, which may
complicate compliance efforts. For example, the California Confidentiality of Medical Information Act (the &#147;CMIA&#148;), a statute similar to HIPAA that expressly applies to pharmaceutical companies, imposes stringent data privacy and security
requirements and obligations with respect to the personal health information of California residents. Among other things, the CMIA requires that a patient or employee provide a signed, written authorization for disclosure of his or her personal
health information, with limited exceptions, and requires security measures to protect the information. The CMIA authorizes administrative fines and civil penalties of up to $25,000 for willful violations and up to $250,000 if the violation is for
purposes of financial gain, as well as criminal fines. In addition, the California Consumer Privacy Act of 2018 (the &#147;CCPA&#148;), which went into effect on January&nbsp;1, 2020, requires covered businesses to provide substantial disclosures to
California residents and honor such residents&#146; data protection and privacy rights, including the right to <FONT STYLE="white-space:nowrap">opt-out</FONT> of certain sales of personal information. The CCPA provides for civil penalties for
violations, as well as a private right of action for certain data breaches that result in the compromise of highly sensitive personal information, which may increase the likelihood of, and risks associated with, data breach litigation. The CCPA has
been amended several times, and will be significantly updated from the California Privacy Rights Act (the &#147;CPRA&#148;), a ballot initiative that passed in November 2020. Effective in most material aspects starting on January&nbsp;1, 2023, the
CPRA&#146;s amendments to the CCPA will expand California residents&#146; rights with respect to certain sensitive personal information and give California residents&#146; a right to opt out of the sharing of certain personal information for
targeted online advertising. The CPRA also created a new state agency vested with authority to implement and enforce the CCPA and the CPRA. Virginia also recently enacted a CCPA/CPRA-like law, the Virginia Consumer Data Privacy Act (the
&#147;VDCPA&#148;), to provide its residents with similar rights. New legislation enacted in various other states will continue to shape the data privacy environment nationally. Certain state laws may be more stringent or broader in scope, or offer
greater individual rights, with respect to confidential, sensitive and personal information than federal, international or other state laws, and such laws may differ from each other, which may complicate compliance efforts. The effects on our
business of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
CMIA, CCPA, CPRA, VDCPA and other similar state laws and general consumer protection authorities are potentially significant, and may require us to modify our data processing practices and
policies and to incur substantial costs and expenses in an effort to comply. Privacy laws are changing rapidly and there is discussion in Congress of a new federal data protection and privacy law to which we may be subject. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside of the United States, laws, regulations and standards in many jurisdictions apply broadly to the collection, use, retention, security,
disclosure, transfer and other processing of personal information. For example, in the European Economic Area (the &#147;EEA&#148;), the collection and use of personal data is governed by the provisions of the General Data Protection Regulation (the
&#147;GDPR&#148;). The GDPR came into effect in May 2018, superseding the European Union Data Protection Directive, and imposing more stringent data privacy and security requirements on companies in relation to the processing of personal data. The
GDPR, together with national legislation, regulations and guidelines of the EU member states governing the processing of personal data, impose strict obligations on controllers, including <I>inter alia</I>: (i)&nbsp;accountability and transparency
requirements, and enhanced requirements for obtaining valid consent; (ii)&nbsp;obligations to consider data protection as any new products or services are developed and to limit the amount of personal data processed; (iii)&nbsp;obligations to comply
with data protection rights of data subjects; and (iv)&nbsp;reporting of certain personal data breaches to the supervisory authority without undue delay (and no later than 72 hours where feasible). The GDPR also prohibits the transfer of personal
data from the EEA to countries outside of the EEA unless made to a country deemed to have adequate data privacy laws by the European Commission or a data transfer mechanism has been put in place. Until recently, one such data transfer mechanism was
the <FONT STYLE="white-space:nowrap">EU-US</FONT> Privacy Shield, but the Privacy Shield was invalidated for international transfers of personal data in July 2020 by the Court of Justice of the European Union (&#147;CJEU&#148;). The CJEU upheld the
validity of standard contractual clauses (&#147;<B>SCCs</B>&#148;) as a legal mechanism to transfer personal data but companies relying on SCCs will, subject to additional guidance from regulators in the EEA and the UK, need to evaluate and
implement supplementary measures that provide privacy protections additional to those provided under SCCs. It remains to be seen whether SCCs will remain available and whether additional means for lawful data transfers will become available. The
GDPR authorizes fines for certain violations of up to 4% of global annual revenue or &#128;20&nbsp;million, whichever is greater. Such fines are in addition to any civil litigation claims by customers and data subjects. European data protection
authorities may interpret the GDPR and national laws differently and impose additional requirements, which contributes to the complexity of processing personal data in or from the EEA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, as of January&nbsp;1, 2021, and the expiry of transitional arrangements agreed to between the United Kingdom and EU (<I>i.e</I>.,
following the United Kingdom&#146;s exit from the EU &#150; otherwise known as Brexit), data processing in the United Kingdom is governed by a United Kingdom version of the GDPR (combining the GDPR and the Data Protection Act 2018), exposing us to
two parallel regimes, each of which potentially authorizes similar fines and other potentially divergent enforcement actions for certain violations. With respect to transfers of personal data from the EEA to the United Kingdom, on June 28, 2021 the
European Commission issued an adequacy decision in respect of the United Kingdom&#146;s data protection framework, enabling data transfers from EU member states to the United Kingdom to continue without requiring organizations to put in place
contractual or other measures in order to lawfully transfer personal data between the territories. While it is intended to last for at least four years, the European Commission may unilaterally revoke the adequacy decision at any point, and if this
occurs it could lead to additional costs and increase our overall risk exposure. Moreover, other countries have also passed or are considering passing laws requiring local data residency or restricting the international transfer of data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or our third party service providers are unable to properly protect the privacy and security of personal information, or other sensitive
data we process in our business, we could be found to have breached our contracts. Further, if we fail to comply with applicable privacy laws, we could face civil and criminal penalties. Enforcement activity from state Attorneys General, the FTC, EU
Data Protection Authorities and other regulatory authorities in relation to privacy and cybersecurity matters can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal
resources. We cannot be sure how these privacy laws and regulations will be interpreted, enforced or applied to our operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state
level may be costly and require ongoing modifications to our policies, procedures and systems. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Data privacy remains an evolving landscape
at both the domestic and international level, with new regulations coming into effect. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices and our efforts to comply with the evolving data
protection rules may be unsuccessful. Significant resources are needed to understand and comply with this changing landscape. Failure to comply with federal, state and international laws regarding privacy and security of personal information could
expose us to penalties under such laws. Any such failure to comply with data protection and privacy laws could result in government-imposed fines or orders requiring that we change our practices or unwind certain lines of business, claims for
damages or other liabilities, regulatory investigations and enforcement action, litigation and significant costs for remediation, any of which could adversely affect our business. Even if we are not determined to have violated these laws, government
investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our business, financial condition, results of operations or prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our or our affiliates&#146; employees, independent contractors, principal investigators, consultants, commercial collaborators, service providers and
other vendors or potential collaborators may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could harm our results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk that our or our affiliates&#146; employees and contractors, including principal investigators, CROs, CMOs,
consultants, commercial collaborators, service providers and other vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless or negligent conduct or other unauthorized activities that
violate the laws and regulations of the FDA and other similar regulatory bodies, including those laws that require the reporting of true, complete and accurate information to such regulatory bodies; manufacturing and the FDA&#146;s GCP, GLP and GMP
standards; federal, state and foreign healthcare fraud and abuse laws and data privacy; or laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and other business arrangements
in the healthcare industry are subject to extensive laws intended to prevent fraud, kickbacks, self-dealing, bribery, corruption, antitrust violations and other abusive practices. These laws may restrict or prohibit a wide range of business
activities, including research, manufacturing, distribution, pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use
or misrepresentation of information obtained in the course of clinical trials, creating fraudulent data in our nonclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and serious
harm to our reputation. It is not always possible to identify and deter employee or third-party misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or
in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we are subject to the risk that a person, including any person who may have engaged in any fraud or misconduct, or government
agency could allege such fraud or other misconduct, even if none occurred. Furthermore, we rely on our CROs and clinical trial sites to adequately report data from our ongoing clinical trials. Moreover, in some instances, our licensing partners
conduct clinical trials with respect to product candidates in different territories and we rely on any such partners to share data from their ongoing clinical trials as required under our agreements with such partners. For example, any failure by
such parties to adequately report safety signals to us in a timely manner from any such trials may also affect the approvability of our product candidates or cause delays and disruptions for the approval of our product candidates, if at all. If our
or our affiliates&#146; employees, independent contractors, principal investigators, consultants, commercial collaborators, service providers or other vendors are alleged or found to be in violation of any such regulatory standards or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requirements, or become subject to a corporate integrity agreement or similar agreement and curtailment of our operations, it could have a significant impact on our business and financial
results, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, suspension or delay in our clinical trials, possible exclusion from participation in Medicare, Medicaid and other federal
healthcare programs, FDA debarment, contractual damages, reputational harm, diminished profits and future earnings, and additional reporting requirements and oversight, any of which could harm our ability to operate our business and our results of
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any
product candidates that we may develop. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The use of existing product candidates in clinical trials and the sale of any product
candidates for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, health care providers, other pharmaceutical companies or others taking or
otherwise coming into contact with our product candidates. On occasion, large judgments have been awarded in class action lawsuits where drugs have had unanticipated harmful effects. If we cannot successfully defend against product liability claims,
it could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impairment of our business reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay or termination of clinical trials, or withdrawal of participants from our clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distraction of management&#146;s attention from our primary business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to patients or other claimants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to commercialize existing product candidates or any future product candidate, if approved;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for existing product candidates or any future product candidate, if approved; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The product liability insurance we currently carry, and any additional product liability insurance coverage we acquire in the future, may not
be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts
to protect us against losses due to liability. If we obtain marketing approval for product candidates, we intend to acquire insurance coverage to include the sale of commercial product candidates; however, it may be unable to obtain product
liability insurance on commercially reasonable terms or in adequate amounts. A successful product liability claim or series of claims brought against us could adversely affect our results of operations and business, including preventing or limiting
the commercialization of any product candidates, if approved, that we develop. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with environmental, health and safety laws and
regulations, we could become subject to fines or penalties or incur costs that could harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to numerous
environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Certain of our operations may involve the use of
hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of
contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for
failure to comply with such laws and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we maintain workers&#146; compensation insurance to cover us for costs and
expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic
tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations.
These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We or the third parties upon whom we depend may be adversely affected by earthquakes, outbreak of disease&nbsp;or other natural disasters and our
business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Earthquakes or other
natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from
using all or a significant portion of our offices, that damaged critical infrastructure, such as the manufacturing facilities of our third-party CMOs, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for
us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may
incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The increasing use of social media platforms presents new risks and challenges. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Social media is increasingly being used to communicate about our research, product candidates, investigational medicines and the diseases our
product candidates and investigational medicines are being developed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty
and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us. For example, patients may use social media channels to comment on their experience in an ongoing blinded clinical study or
to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend our business or the public&#146;s legitimate
interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our development candidates and investigational medicines. There is also a risk of inappropriate disclosure of
sensitive information or negative or inaccurate posts or comments about us on any social networking website. Furthermore, our employees, affiliates and/or business partners may use social media for their personal use, and their activities on social
media or in other forums could result in adverse publicity for us. Any negative publicity as a result of social media posts, whether or not such claims are accurate, could adversely impact us. If any of these events were to occur or we otherwise
fail to comply with applicable regulations, we could incur liability, face regulatory actions, or incur other harm to our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The United
Kingdom&#146;s withdrawal from the European Union may adversely impact our ability to obtain regulatory approvals of our product candidates in the European Union and may require us to incur additional expenses in order to develop, manufacture and
commercialize our product candidates in the European Union. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our headquarters are located in the United Kingdom. The United Kingdom
formally exited the EU, commonly referred to as Brexit, on January&nbsp;31, 2020. Under the terms of its departure, the United Kingdom </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
entered a transition period (the &#147;Transition Period&#148;), during which it continued to follow all EU rules. The Transition Period ended on December&nbsp;31, 2020. On December&nbsp;30,
2020, the United Kingdom and European Union signed the Trade and Cooperation Agreement, which includes an agreement on free trade between the two parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is considerable uncertainty resulting from a lack of precedent and the complexity of the United Kingdom and the EU&#146;s intertwined
legal regimes as to how Brexit (following the Transition Period) will impact the life sciences industry in Europe, including our company, including with respect to ongoing or future clinical trials. The impact will largely depend on the model and
means by which the United Kingdom&#146;s relationship with the EU is governed post-Brexit and the extent to which the United Kingdom chooses to diverge from the EU regulatory framework. For example, following the Transition Period, Great Britain
will no longer be covered by the centralized procedures for obtaining <FONT STYLE="white-space:nowrap">EU-wide</FONT> marketing authorizations and our products will therefore require a separate marketing authorization to allow us to market such
products in Great Britain. It is unclear as to whether the relevant authorities in the EU and the United Kingdom are adequately prepared for the additional administrative burden caused by Brexit. Any delay in obtaining, or an inability to obtain,
any marketing approvals, as a result of Brexit or otherwise, would prevent us from or delay us commercializing our product candidates in the United Kingdom and/or the EEA and restrict our ability to generate revenue and achieve and sustain
profitability. In the short term, following the expiry of the Transition Period there is a risk of disrupted import and export processes due to a lack of administrative processing capacity by the respective United Kingdom and EU customs agencies
that may delay time-sensitive shipments and may negatively impact our product supply chain. Further, under current plans, orphan designation in the United Kingdom (or Great Britain, depending on whether there is a prior centralized marketing
authorization in the EEA) following Brexit is to be based on the prevalence of the condition in Great Britain as opposed to the current position where prevalence in the EU is the determinant. It is therefore possible that conditions that are
currently designated as orphan conditions in the United Kingdom will no longer be and that conditions are not currently designated as orphan conditions in the European Union will be designated as such in the United Kingdom. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom and/or EEA for
our product candidates, which could significantly and materially harm our business. There is a degree of uncertainty regarding the overall impact that Brexit will have on (i)&nbsp;the marketing of pharmaceutical products, (ii)&nbsp;the process to
obtain regulatory approval in the United Kingdom for product candidates or (iii)&nbsp;the award of exclusivities that are normally part of the EU legal framework (for instance Supplementary Protection Certificates, Pediatric Extensions or Orphan
exclusivity). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Brexit may also result in a reduction of funding to the EMA once the United Kingdom no longer makes financial contributions
to European institutions, such as the EMA. If funding to the EMA is so reduced, it could create delays in the EMA issuing regulatory approvals for our product candidates and, accordingly, have a material adverse effect on our business, financial
condition, results of operations or prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may be required to pay taxes or duties or be subjected to other hurdles in
connection with the importation of our product candidates into the EU, or we may incur expenses in establishing a manufacturing facility in the EU in order to circumvent such hurdles. If any of these outcomes occur, we may be forced to restrict or
delay efforts to seek regulatory approval in the United Kingdom or the EU for our product candidates, or incur significant additional expenses to operate our business, which could significantly and materially harm or delay our ability to generate
revenues or achieve profitability of our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of Brexit, other EU Member States may seek to conduct referenda with
respect to their continuing membership with the EU. Given these possibilities and others we may not anticipate, as well as the absence of comparable precedent, it is unclear what financial, regulatory and legal implications the withdrawal of the
United Kingdom from the EU will have and how such withdrawal will affect us, and the full extent to which our business could be adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to Our Intellectual Property </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain and maintain patent and other intellectual property protection for our technology and product candidates or if the scope of
the intellectual property protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely, and will continue to rely, upon a combination of patents, trademarks, trade secret protection and confidentiality agreements with
employees, consultants, collaborators, advisors and other third parties to protect the intellectual property related to our brand, current and future drug development programs and product candidates. Our success depends in large part on our ability
to obtain and maintain patent protection in the United States and other countries with respect to our product candidates and any future product candidates. We seek to protect our proprietary position by
<FONT STYLE="white-space:nowrap">in-licensing</FONT> or acquiring intellectual property and filing patent applications in the United States and abroad related to our current and future development programs and product candidates, defending our
intellectual property rights against third-party challenges and enforcing our intellectual property rights to prevent third-party infringement. The patent prosecution process is expensive and time-consuming, and we may not be able to file and
prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. Furthermore, there is always a risk that our licensed or owned issued patents and any pending and future patent applications may not protect our
product candidates, in whole or in part, and may not effectively prevent others from commercializing competitive product candidates, or that an alteration to product candidates or processes may provide sufficient basis for a competitor to avoid
infringing our patent claims. The risks associated with patent rights generally apply to patent rights that we <FONT STYLE="white-space:nowrap">in-license</FONT> now or in the future, as well as patent rights that we may own now or in the future.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to
obtain patent protection. Although we enter into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to confidential or patentable aspects of their research and development output, such
as employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application
is filed, thereby jeopardizing our ability to obtain patent protection. In addition, while we have <FONT STYLE="white-space:nowrap">pre-publication</FONT> review procedures in effect, premature or inadvertent publication of potentially patentable
subject matter could preclude our ability to obtain patent protection. We may choose not to seek patent protection for certain innovations or product candidates and may choose not to pursue patent protection in certain jurisdictions, and under the
laws of certain jurisdictions, patents or other intellectual property rights may be unavailable or limited in scope and, in any event, any patent protection we obtain may be limited. As a result, product candidates may not be protected by patents in
all jurisdictions. We generally apply for patents in those countries where we intend to make, have made, use, offer for sale, or sell product candidates and where we assess the risk of infringement to justify the cost of seeking patent protection.
However, we do not seek protection in all countries where we intend to sell product candidates and we may not accurately predict all the countries where patent protection would ultimately be desirable. If we fail to timely file a patent application
in any such country or major market, we may be precluded from doing so at a later date. The patent applications that we own or <FONT STYLE="white-space:nowrap">in-license</FONT> may fail to result in issued patents with claims that cover product
candidates in the United States or in other countries. We may also inadvertently make statements to regulatory agencies during the regulatory approval process that may be inconsistent with positions that have been taken during prosecution of our
patents, which may result in such patents being narrowed, invalidated or held unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent applications that we own or <FONT
STYLE="white-space:nowrap">in-license</FONT> may fail to result in issued patents with claims that cover our product candidates or any future product candidate in the United States or in other countries. Our pending PCT patent applications are not
eligible to become issued patents until, among other things, we file a national stage patent application within 30 months in the countries in which we seek patent protection. If we do not timely file any national stage patent applications, we may
lose our priority date with respect to our PCT patent applications and any patent protection on the inventions disclosed in such PCT patent applications. We cannot guarantee any current or future patents will provide us with any meaningful
protection or competitive advantage. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
For example, any issued patents might not cover the pharmaceutical composition of the product candidate that is ultimately commercialized. There is no assurance that all of the potentially
relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from issuing from a pending patent application or be used to invalidate an issued patent. The examination process may require us to narrow
our claims, which may limit the scope of patent protection that we may ultimately obtain. Even if patents do successfully issue and even if such patents cover our product candidates or any future product candidate, third parties may challenge their
validity, enforceability or scope, which may result in such patents being narrowly construed, invalidated, or held unenforceable, any of which could limit our ability to prevent competitors and other third parties from developing and marketing
similar product candidates or limit the length of terms of patent protection we may have for our product candidates and technologies. Other companies may also design around technologies we have patented, licensed or developed. In addition, the
issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing product candidates or practicing our own patented technology or impose a substantial
royalty burden to do so. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if
we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. If any of our patents are challenged, invalidated, circumvented by third parties or otherwise
limited or expire prior to the commercialization of our product candidates, and if we do not own or have exclusive rights to other enforceable patents protecting our product candidates or other technologies, competitors and other third parties could
market product candidates and use processes that are substantially similar to, or superior to, ours and our business would suffer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the patent
applications we hold or have <FONT STYLE="white-space:nowrap">in-licensed</FONT> with respect to our product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for
our product candidates or any future product candidate, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize, future drugs. Any such outcome could have a materially adverse
effect on our business. Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions
and has in recent years been the subject of much litigation. The standards that the U.S. Patent and Trademark Office (the &#147;USPTO&#148;) and its counterparts in other countries use to grant patents are not always applied predictably or
uniformly. In addition, the laws of countries other than the United States may not protect our rights to the same extent as the laws of the United States, and many companies have encountered significant problems in protecting and defending such
rights in such jurisdictions. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other parties have developed technologies that may be related or competitive to our own technologies and such parties may have filed or may
file patent applications, or may have received or may receive patents, claiming inventions that may overlap or conflict with those claimed in our own or licensed patent applications or issued patents. Furthermore, publications of discoveries in
scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with
certainty whether we or our licensors were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions. As a
result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or product
candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and product candidates. Changes in either the patent laws or interpretation of the patent laws in the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patent reform legislation in the United States, including the Leahy-Smith America Invents Act (&#147;the Leahy-Smith Act&#148;), could
increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act was signed into law on September&nbsp;16, 2011 and includes a number of
significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents.
These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to challenge the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, <I>inter
partes</I> review, and derivation proceedings. After March&nbsp;15, 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first
inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. The Leahy-Smith Act and its implementation could increase the uncertainties and
costs surrounding the prosecution of our patent applications, our ability to obtain future patents, and the enforcement or defense of our issued patents, all of which could harm our business, financial condition, results of operations and prospects.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents
may be challenged in the courts or patent offices in the United States and abroad. We are currently and may in the future be subject to third-party <FONT STYLE="white-space:nowrap">pre-issuance</FONT> submissions of prior art to the USPTO or its
equivalents and we or our licensors have in the past, and may in the future, become involved in opposition, derivation, reexamination, <I>inter partes</I> review, post-grant review or interference proceedings in the U.S. or in other jurisdictions
challenging our patent rights or the patent rights of others. A third party may also claim that our owned or licensed patent rights are invalid or unenforceable in a litigation. For example, three U.S. patents (U.S. Patent Nos. 8,058,069 , 9,364,435
and 9,404,127) relating to lipid nanoparticle molar ratios and the aggregation of lipid nanoparticles that Genevant exclusively licenses from Arbutus Biopharma Corp. (&#147;Arbutus&#148;) were the subject of <I>inter partes </I>review proceedings
brought by Moderna Therapeutics, Inc. (&#147;Moderna&#148;) before the Patent Trial and Appeal Board of the USPTO (&#147;PTAB&#148;). The PTAB upheld all claims of U.S. Patent No.&nbsp;8,058,069, invalidated some of the claims of U.S. Patent
No.&nbsp;9,364,435 and invalidated all claims of U.S. Patent No.&nbsp;9,404,127. The PTAB&#146;s decisions with respect to U.S. Patent Nos. 8,058,069 and 9,364,435 are currently on appeal at the United States Court of Appeals for the Federal
Circuit. The Federal Circuit vacated and remanded the PTAB&#146;s decision on U.S. Patent No.&nbsp;9,494,127, and the PTAB&#146;s decision with respect to U.S. Patent No.&nbsp;9,494,127 patent is currently held in administrative abeyance, pending a
review following a recent Supreme Court ruling in an unrelated case. Additionally, one European patent (EU patent no. EP2279254) relating to lipid nanoparticle molar ratios that Genevant exclusively licenses from Arbutus is the subject of an
opposition proceeding brought by Merck Sharp&nbsp;&amp; Dohme Corporation and Moderna at the European Patent Office Opposition Division. The outcome following legal assertions of invalidity and unenforceability is unpredictable. An adverse
determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to
us, result in our inability to manufacture or commercialize product candidates without infringing third-party patent rights or result in our breach of agreements pursuant to which we license such rights to our collaborators or licensees. In
addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Such
challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or
identical technology and product candidates, or limit the duration of the patent protection of our technology and product candidates. Such challenges also may result in substantial cost and require significant time from our scientists and
management, even if the eventual outcome is favorable to us. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if they are unchallenged, our owned and licensed patents and pending patent
applications, if issued, may not provide us with any meaningful protection or prevent competitors from designing around our patent claims to circumvent our owned or licensed patents by developing similar or alternative technologies or therapeutics
in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. For example, a third party may develop a competitive product that provides benefits similar to one or more of our product candidates but that falls outside the scope of our patent
protection. Moreover, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however the life of a patent, and the protection it
affords, is limited. Without patent protection for our current or future product candidates, it may be open to competition from generic versions of such product candidates. Given the amount of time required for the development, testing and
regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights
to exclude others from commercializing product candidates similar or identical to our own and, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent terms and their scope may be inadequate to protect our competitive position on current and future product candidates for an adequate amount of
time. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a
patent is generally 20 years from its earliest U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. In certain instances, the patent term may be adjusted to add additional days to compensate for delays incurred by the USPTO in
issuing the patent. Also, the patent term may be extended for a period of time to compensate for at least a portion of the time a product candidate was undergoing FDA regulatory review. However, the life of a patent, and the protection it affords,
is limited. Even if patents covering product candidates are obtained, once the patent life has expired, we may be open to competition from competitive product candidates, including generics or biosimilars. Given the amount of time required for the
development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. For example, the patent covering the use of tapinarof as an active
ingredient to treat psoriasis and atopic dermatitis, but not limited to any formulation, expired in December 2020. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing
product candidates similar or identical to ours. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not currently and may not in the future own or license any issued composition of matter
patents covering certain of our product candidates, including tapinarof, and we cannot be certain that any of our other issued patents will provide adequate protection for such product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Composition-of-matter</FONT></FONT> patents on the active pharmaceutical
ingredient (&#147;API&#148;) in prescription drug products are generally considered to be the strongest form of intellectual property protection for drug products because those types of patents provide protection without regard to any particular
method of use or manufacture or formulation of the API used. While we generally seek composition of matter patents for our product candidates, such patents may not be available for all of our product candidates. For example, we do not own or <FONT
STYLE="white-space:nowrap">in-license</FONT> any issued composition of matter patents in the United States or any other jurisdiction with respect to tapinarof. Instead, we rely on an issued U.S. patent claiming topical formulations of tapinarof,
including the formulation studied in Phase 3, and an issued U.S. patent covering methods of using the patented topical formulations to treat inflammatory diseases, including psoriasis and atopic dermatitis. The formulation and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">method-of-use</FONT></FONT> patents have natural expiration dates in 2036. We additionally rely on a drug substance (&#147;DS&#148;) patent covering the high purity commercial crystal form
of the DS, the commercial DS synthesis and several novel intermediates that are formed in the synthesis, which has a natural expiration date in 2038. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Method-of-use</FONT></FONT> patents protect the use of a product for the
specified method and formulation patents cover formulations of the API. These types of patents do not prevent a competitor or other third party from developing or marketing an identical product for an indication that is outside the scope of the
patented method or from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
developing a different formulation that is outside the scope of the patented formulation. Moreover, with respect to <FONT STYLE="white-space:nowrap">method-of-use</FONT> patents, even if
competitors or other third parties do not actively promote their product for our targeted indications or uses for which we may obtain patents, physicians may recommend that patients use these products
<FONT STYLE="white-space:nowrap">off-label,</FONT> or patients may do so themselves. Although <FONT STYLE="white-space:nowrap">off-label</FONT> use may infringe or contribute to the infringement of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">method-of-use</FONT></FONT> patents, the practice is common, and this type of infringement is difficult to prevent or prosecute. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our owned and licensed patents and pending patent applications, if issued, may not adequately protect our intellectual property or prevent
competitors or others from designing around our patent claims to circumvent our owned or licensed patents by developing similar or alternative technologies or therapeutics in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. If the
breadth or strength of protection provided by the patents and patent applications we own or license with respect to our product candidates is not sufficient to impede such competition or is otherwise threatened, it could dissuade companies from
collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain protection under the Hatch-Waxman Amendments by extending the patent term, our business may be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success will largely depend on our ability to obtain and maintain patent and other intellectual property in the United States
and other countries with respect to our proprietary technology, product candidates and our target indications. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting our
product candidates might expire before or shortly after such candidate begins to be commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we are prosecuting patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of FDA marketing approval of product candidates, one or more of our U.S. patents may be
eligible for a limited patent term extension (&#147;PTE&#148;) under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up
to five years beyond the normal expiration of the patent as compensation for patent term lost during development and the FDA regulatory review process, which is limited to the approved indication (and potentially additional indications approved
during the period of extension) covered by the patent. This extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and is limited to only one patent that covers the approved product, the
approved use of the product, or a method of manufacturing the product. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our
assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. We may not be granted an extension because of, for example, failing to apply within
applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time-period or the scope of patent protection afforded could be less than we request.
Even if we are able to obtain an extension, the patent term may still expire before or shortly after we receive FDA marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to extend the expiration date of our existing patents or obtain new patents with longer expiry dates, our competitors may be
able to take advantage of our investment in development and clinical trials by referencing our clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data to obtain approval of competing product candidates following our patent expiration
and launch their product earlier than might otherwise be the case. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural,
document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated as a result of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and other patent agencies in other jurisdictions in
several stages over the lifetime of the patent. The USPTO and various national or international patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application
process. In certain circumstances, we rely on our licensing partners to pay these fees due to U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent agencies and to take the necessary action to comply with these requirements with respect
to our licensed intellectual property. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or
lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> events that could result in abandonment or lapse of patent rights
include, but are not limited to, failure to timely file national and regional stage patent applications based on our international patent applications, failure to respond to official actions within prescribed time limits, <FONT
STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering our product candidates or any future product
candidate, our competitors might be able to enter the market earlier than anticipated, which would have an adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely
on certain <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and other intellectual property rights in connection with our development of certain product candidates and, if we fail to comply with our obligations under our existing and any
future intellectual property licenses with third parties, we could lose license rights that are important to our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
ability to develop and commercialize product candidates is dependent on licenses to patent rights and other intellectual property granted to it by third parties. Further, development and commercialization of our current product candidates, and
development of any future product candidates, may require us to enter into additional license or collaboration agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current
license agreements impose, and future agreements may impose, various development, diligence, commercialization and other obligations on us and require us to meet development timelines, or to exercise commercially reasonable efforts to develop and
commercialize licensed products, in order to maintain the licenses. If we fail to comply with our obligations under these licenses, our licensors may have the right to terminate these license agreements, in which event we may not be able to market
our product candidates. Termination of any of our license agreements or reduction or elimination of our licensed rights may also result in our having to negotiate new or reinstated licenses with less favorable terms. Additionally, certain provisions
in our intellectual property agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or
technology, or affect financial or other obligations under the relevant agreement, either of which could harm our business, financial condition, results of operations and prospects. For example, disputes may arise with respect to our current or
future licensing agreement include disputes relating to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial or other obligations under the license agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which our technology and product candidates infringe on intellectual property of the licensor that
is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sublicensing of patent and other rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations under the license agreements and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inventorship or ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from
the joint creation or use of intellectual property by our licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on
acceptable terms, we may be unable to successfully develop and commercialize our product candidates. If our licenses are terminated, we may lose our rights to develop and market our technology and product candidates, lose patent protection for our
product candidates and technology, experience significant delays in the development and commercialization of our product candidates, or incur liability for damages. In addition, we may need to obtain additional licenses from our licensors and, in
connection with obtaining such licenses, we may agree to amend our existing licenses in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable third parties, including our competitors, to receive
licenses to a portion of the intellectual property that is subject to our existing licenses and to compete with our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, if our licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third
parties would have the freedom to seek regulatory approval of, and to market, products identical or competitive to ours and we may be required to cease our development and commercialization of certain of our product candidates. Moreover, if disputes
over intellectual property that we license prevent or impair our ability to maintain other licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. In
addition, certain of these license agreements, may not be assignable by us without the consent of the respective licensor, which may have an adverse effect on our ability to engage in certain transactions. Any of the foregoing could have a material
adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in some circumstances, we may not
have the right to control the preparation, filing and prosecution of patent applications, or to maintain or enforce the patents, covering technology that it licenses from third parties. For example, pursuant to the CCHMC License Agreement, as
defined below, CCHMC controls such activities for certain patents licensed to ASG under such agreement, subject to ASG&#146;s right to review and comment. Therefore, we cannot be certain that these or other patents will be prosecuted, maintained and
enforced in a manner consistent with the best interests of our business. Additionally, we may not have sufficient ability to provide input into the patent prosecution, maintenance and defense process with respect to such patents, and our licensors
may fail to take the steps that we believe are necessary or desirable in order to obtain, maintain, defend and enforce the licensed patents. If our current or future licensors or collaboration partners fail to obtain, maintain, defend, protect or
enforce any patents or patent applications licensed to us, our rights to such patents and patent applications may be reduced or eliminated and our right to develop and commercialize product candidates that are the subject of such licensed rights
could be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, certain of our current and future licenses may not provide us with exclusive rights to use the
licensed intellectual property and technology, or may not provide us with rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology
and product candidates in the future. The intellectual property portfolio licensed to us by our licensors at least in some respects, may therefore be used by such licensors or licensed to third parties, and such third parties may have certain
enforcement rights with respect to such intellectual property. For example, Immunovant does not have rights to develop, manufacture, use or commercialize IMVT-1401 or file or enforce patents relating to these assets in territories other than the
United States, Canada, Mexico, the E.U., the U.K., Switzerland, the Middle East, North Africa and Latin America, as such rights in other jurisdictions have been retained by HanAll or licensed by HanAll to third parties. Additionally, Dermavant does
not have the right to develop, manufacture, use or commercialize tapinarof in China, including Hong Kong, Macau or Taiwan, as such rights were retained by Welichem. Patents licensed to us could be put at risk of being invalidated or interpreted
narrowly in litigation filed by or against our licensors or another licensee or in administrative </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proceedings brought by or against our licensors or another licensee in response to such litigation or for other reasons. As a result, we may not be able to prevent competitors or other third
parties from developing and commercializing competitive products, including in territories covered by our licenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third party claims or
litigation alleging infringement, misappropriation or other violations of third-party patents or other proprietary rights or seeking to invalidate our patents or other proprietary rights, may delay or prevent the development and commercialization of
our product candidates and any future product candidate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on our avoidance of infringement,
misappropriation and other violations of the patents and proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe, misappropriate or otherwise violate patents
or other intellectual property rights owned or controlled by third parties. Our competitors or other third parties may assert infringement claims against us, alleging that our product candidates are covered by their patents. We cannot be certain
that we do not infringe existing patents or that we will not infringe patents that may be granted in the future. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property
rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, derivation and administrative law proceedings,<I> inter partes</I> review, and post-grant review before the USPTO, as well as
oppositions and similar processes in other jurisdictions. Numerous U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our
collaborators are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility, the risk increases that our product candidates or other business activities
may be subject to claims of infringement of the patent and other proprietary rights of third parties. Third parties may assert that we are infringing their patents or employing their proprietary technology without authorization. There may be
third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. For example, we are aware of third-party patents that, if
issued as patents, patent applications, could be construed in a manner that negatively impacts the commercialization of <FONT STYLE="white-space:nowrap">ARU-1801.</FONT> If any such patents were held by a court of competent jurisdiction to cover <FONT
STYLE="white-space:nowrap">ARU-1801,</FONT> we may be required to cease development or commercialization of <FONT STYLE="white-space:nowrap">ARU-1801</FONT> unless we obtain a license under the applicable patents, or until such patents expire. Such
a license may not be available on commercially reasonable terms, may only be available on a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> basis or may not be available at all. We could also be required to pay damages, which could be
significant, including treble damages and attorneys&#146; fees if we are found to have willfully infringed such patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally,
because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the
future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover any of our product candidates, the holders of any such patents may be able to block our
ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our
formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or
until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar
negative impact on our business. In addition, we may be subject to claims that we are infringing other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our
employees, consultants or contractors use intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or resulting <FONT STYLE="white-space:nowrap">know-how</FONT> and
inventions, which could be time-consuming and divert the attention of senior management. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making claims against us may obtain injunctive or other equitable relief, which
could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of
employee resources from our business. In the event of a successful infringement or other intellectual property claim against it, we may have to pay substantial damages, including treble damages and attorneys&#146; fees for willful infringement,
obtain one or more licenses from third parties, pay royalties or redesign our affected product candidates, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at
all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates,
and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates,
which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our product candidates, resulting in either an injunction prohibiting our sales, or, with respect to
our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our competitors may be
able to sustain the costs of complex intellectual property litigation more effectively than we can because the competitors have substantially greater resources. In addition, intellectual property litigation, regardless of its outcome, may cause
negative publicity, adversely impact prospective customers, cause product shipment delays, or prohibit us from manufacturing, marketing or otherwise commercializing our product candidates, services, and technology. Any uncertainties resulting from
the initiation and continuation of any litigation could adversely impact our ability to raise additional funds or otherwise harm our business, results of operation, financial condition or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that
some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, which could adversely
impact the price of our common shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or
expiration of a third-party patent, which might harm our ability to develop and market our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot guarantee
that any of our or our licensors&#146; patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have
identified each and every third-party patent and pending application in the United States and abroad that is or may be relevant to or necessary for the commercialization of product candidates in any jurisdiction. Patent applications in the United
States and elsewhere are not published until approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. In addition, U.S. patent applications filed
before November&nbsp;29, 2000 and certain U.S. patent applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Therefore, patent applications covering our product candidates could
have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates, any future product
candidates, or the use thereof, provided such pending patent applications result in issued patents. Our ability to develop and market our product candidate or any future product candidates can be adversely affected in jurisdictions where such
patents are issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the
patent&#146;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our product candidates. We may incorrectly determine that
our product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#146;s pending application will issue with claims of relevant scope. Our determination of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect and we may incorrectly conclude that a third-party patent is invalid or unenforceable.
Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our product candidates or any future product candidates, if approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to identify and correctly interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be
able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our product candidates
that are held to be infringing. We might, if possible, also be forced to redesign product candidates or services so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail,
could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be
involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time consuming and unsuccessful. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe, misappropriate or otherwise violate our patents, the patents of our licensors or our other intellectual property
rights. To counter infringement or unauthorized use, we may be required to file and prosecute legal claims against one or more third parties, which can be expensive and time-consuming, even if ultimately successful. In addition, in an infringement
proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question.
The standards that courts use to interpret patents are not always applied predictably or uniformly and can change, particularly as new technologies develop. As a result, we cannot predict with certainty how much protection, if any, will be given to
our patents if we attempt to enforce them and they are challenged in court. Further, even if we prevail against an infringer in U.S. district court, there is always the risk that the infringer will file an appeal and the district court judgment will
be overturned at the appeals court and/or that an adverse decision will be issued by the appeals court relating to the validity or enforceability of our patents. An adverse result in any litigation or defense proceedings could put one or more of our
patents at risk of being invalidated or interpreted narrowly in a manner insufficient to achieve our business objectives, or could put our patent applications at risk of not issuing. The initiation of a claim against a third party may also cause the
third party to bring counter claims against us such as claims asserting that our patents are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace.
Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, <FONT STYLE="white-space:nowrap">non-enablement</FONT> or lack of written description or statutory
subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during
prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte reexaminations, <I>inter partes</I> review, or post-grant review, or oppositions or similar proceedings outside the United
States, in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art, of which it and
the patent examiner were unaware during prosecution. For the patents and patent applications that we have licensed, we may have limited or no right to participate in the defense of any licensed patents against challenge by a third party. If a
defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future product candidates. Such a loss of patent protection could harm
our business. Additionally, any adverse outcome could allow third parties to commercialize our products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing
third-party patent rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we establish infringement, the court may decide not to grant an injunction against further infringing
activity and instead award only monetary damages, which may or may not be an adequate remedy. We may not be able to detect or prevent, alone or with our licensors, misappropriation of our intellectual property rights,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a
license on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that
some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts
or investors perceive these results to be negative, it could have an adverse effect on the price of our common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not have
sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors or other third parties may be able to sustain the costs of such litigation or proceedings more effectively than we can because of
their greater financial resources and more mature and developed intellectual property portfolios. Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our issued patent, any patents that may
be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our
shareholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other <FONT STYLE="white-space:nowrap">non-litigious</FONT> action or solution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because many of the patents we own are owned by our subsidiaries, and in certain cases by subsidiaries that are not or will not be directly
commercializing products, we may not be in a position to obtain a permanent injunction against a third party that is found to infringe our patents. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many patents that we own are assigned to our subsidiaries or to their respective subsidiaries. For example, any patents that Immunovant owns
are assigned to its wholly-owned subsidiary Immunovant Sciences GmbH and any patents that Dermavant owns are assigned to its wholly-owned subsidiary Dermavant Sciences GmbH. If a third party is found to be infringing such patents, we and our direct
subsidiaries may not be able to permanently enjoin the third party from making, using, offering for sale or selling the infringing product or activity for the remaining life of such patent in the United States or other jurisdictions when the patent
is assigned to a subsidiary, which is not the entity that is or would be commercializing a potentially competitive product or service. In such a circumstance, such third party may be able to compete with us or our subsidiaries, which could have a
material adverse effect on our competitive position, business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in U.S. patent
law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property. Obtaining and enforcing
patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States
or USPTO rules and regulations could increase the uncertainties and costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The United States has recently enacted and implemented
wide-ranging patent reform legislation. In addition, patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and pending
patent applications. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In
addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. For example, the Biden administration
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recently indicated its support for a proposal at the World Trade Organization to waive patent rights with respect to <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccines. Any waiver of our
patent or other intellectual property protection by the U.S. and other foreign governments, including with respect to Genevant&#146;s licensed LNP delivery technology as used in connection with mRNA vaccine delivery, could have a material adverse
effect on our competitive position, business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending on actions by the U.S.
Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we have licensed or that we might obtain in the
future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken
our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by
United States and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the United States federal government retains certain rights in inventions produced with its financial assistance under the
Bayh-Dole Act. The federal government retains a &#147;nonexclusive, nontransferable, irrevocable, <FONT STYLE="white-space:nowrap">paid-up</FONT> license&#148; for its own benefit. The Bayh-Dole Act also provides federal agencies with <FONT
STYLE="white-space:nowrap">&#147;march-in</FONT> rights.&#148; <FONT STYLE="white-space:nowrap">March-in</FONT> rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a
&#147;nonexclusive, partially exclusive, or exclusive license&#148; to a &#147;responsible applicant or applicants.&#148; For example, the research resulting in certain of our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights and
technology for certain product candidates was funded in part by the U.S. federal government. As a result, the federal government may have certain rights to such patent rights and technology, which include
<FONT STYLE="white-space:nowrap">march-in</FONT> rights. If the federal government decides to exercise these rights, it is not required to engage us as its contractor in connection with doing so. The federal government&#146;s rights may also permit
it to disclose our confidential information to third parties and to exercise <FONT STYLE="white-space:nowrap">march-in</FONT> rights to use or allow third parties to use our licensed technology. The federal government can exercise its <FONT
STYLE="white-space:nowrap">march-in</FONT> rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, or because action is necessary to alleviate health or safety needs, to
meet requirements of federal regulations, or to give preference to U.S. industry. Further, the recipient of U.S. government funding is required to comply with certain other requirements, including timely disclosing the inventions claimed in such
patent rights to the U.S. government and timely electing title to such inventions. The U.S. government has the right to take title to such intellectual property rights if we, or the applicable licensor, fail to disclose the invention to the
government and fail to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which
may require us or the applicable licensor to expend substantial resources. In addition, our rights in such inventions may be subject to certain requirements to manufacture product candidates embodying such inventions in the United States. We cannot
be certain that our current or future licensors will comply with the disclosure or reporting requirements of the Bayh-Dole Act at all times, or be able to rectify any lapse in compliance with these requirements. Any exercise by the government of any
of the foregoing rights or by any third party of its reserved rights could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The validity, scope and enforceability of any patents listed in the Orange Book that cover our product candidates or patents that cover our biologic
product candidates can be challenged by third parties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If one of our product candidates is approved by the FDA and if a third
party files an application under Section&nbsp;505(b)(2) or an abbreviated new drug application (&#147;ANDA&#148;) under Section&nbsp;505(j) for a generic product containing any of our product candidates, including tapinarof (which, following the
natural expiration of our method of use patent family, will be protected only by our formulation patent), and relies in whole or in part on studies conducted by or for us, the third party will be required to certify to the FDA that either:
(1)&nbsp;there is no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patent information listed in the Orange Book with respect to our NDA for the applicable approved product candidate; (2)&nbsp;the patents listed in the Orange Book have expired; (3)&nbsp;the
listed patents have not expired, but will expire on a particular date and approval is sought after patent expiration; or (4)&nbsp;the listed patents are invalid or will not be infringed by the manufacture, use or sale of the third party&#146;s
generic product. A certification under 21 CFR &#167;&nbsp;314.94(a)(12)(i)(A)(4) that the new product will not infringe the Orange Book-listed patents for the applicable approved product candidate, or that such patents are invalid, is called a
paragraph IV certification. If the third party submits a paragraph IV certification to the FDA, a notice of the paragraph IV certification must also be sent to us once the third party&#146;s ANDA is accepted for filing by the FDA. We may then
initiate a lawsuit to defend the patents identified in the notice. The filing of a patent infringement lawsuit within 45 days of receipt of the notice automatically prevents the FDA from approving the third party&#146;s ANDA until the earliest of 30
months or the date on which the patent expires, the lawsuit is settled, or the court reaches a decision in the infringement lawsuit in favor of the third party. If we do not file a patent infringement lawsuit within the required <FONT
STYLE="white-space:nowrap">45-day</FONT> period, the third party&#146;s ANDA will not be subject to the <FONT STYLE="white-space:nowrap">30-month</FONT> stay of FDA approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, a third party may challenge the current patents, or patents that may issue in the future, within our portfolio, which could result
in the invalidation of some or all of the patents that might otherwise be eligible for listing in the Orange Book for one of our products. If a third party successfully challenges all of the patents that might otherwise be eligible for listing in
the Orange Book for one of our products before an ANDA or 505(b)(2) NDA is filed we will be unable to obtain a <FONT STYLE="white-space:nowrap">30-month</FONT> stay of FDA approval of a 505(b)(2) or ANDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, our three issued U.S. patents covering tapinarof may not provide adequate protection from competitive products developed by
505(b)(1) NDA, 505(b)(2) NDA or 505(j) ANDA applicants containing paragraph IV certifications if such applicants are able to design around the three patents. One or more competitors may circumvent these patents by filing a marketing application with
the FDA under Sections 505(b)(2) or 505(j) of the Federal Food, Drug and Cosmetic Act containing a paragraph IV certification for a competitive product containing the active moiety in tapinarof and successfully challenging the validity of the three
patents or successfully designing around the three patents. Any successful challenge against the three patents and/or designing around one or more of the patents could result in a generic version of tapinarof being commercialized before the
expiration of the three patents. If the three patents are successfully challenged or designed around, our business, results of operations, financial condition and prospects would be harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For biologics, the BPCIA provides a mechanism for one or more third parties to seek FDA approval to manufacture or sell a biosimilar or
interchangeable versions of brand name biological product candidates. Due to the large size and complexity of biological product candidates, as compared to small molecules, a biosimilar must be &#147;highly similar&#148; to the reference product
with &#147;no clinically meaningful differences between the two.&#148; The BPCIA does not require reference product sponsors to list patents in the FDA&#146;s Orange Book and does not include an automatic
<FONT STYLE="white-space:nowrap">30-month</FONT> stay of FDA approval upon the timely filing of a lawsuit. The BPCIA, however, does require a formal <FONT STYLE="white-space:nowrap">pre-litigation</FONT> process which includes the exchange of
information between a biosimilar applicant and a reference biologic sponsor that includes the identification of relevant patents and each parties&#146; basis for infringement and invalidity. After the exchange of this information, we may then
initiate a lawsuit within 30 days to defend the patents identified in the exchange. If the biosimilar applicant successfully challenges the asserted patent claims, it could result in the invalidation of, or render unenforceable, some or all of the
relevant patent claims or result in a finding of <FONT STYLE="white-space:nowrap">non-infringement.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unsuccessful in
enforcing our patents against generics or biosimilars, our products could face competition prior to the expiration of the patents which cover such products, which could have a material adverse effect on our business, financial condition, results of
operations and prospects. Furthermore, any such litigation or other proceedings to enforce or defend intellectual property rights are often very complex in nature, may be very expensive and time-consuming, may divert management&#146;s attention from
our core business, and may result in unfavorable results that could limit our ability to prevent third parties from competing with product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our intellectual property rights throughout the world. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our
intellectual property rights in some countries outside the United States can be less extensive than those in the United States. The requirements for patentability may differ in certain countries, particularly developing countries, and the breadth of
patent claims allowed can be inconsistent. In addition, the laws of some countries do not protect intellectual property rights to the same extent as laws of the United States. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from
selling or importing product candidates made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own product
candidates and may also export infringing product candidates to territories where we have patent protection, but enforcement is not as strong as that in the United States. These product candidates may compete with our product candidates and our
patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have patent
rights in all countries in which a market may exist. Moreover, in jurisdictions where we do have patent rights, proceedings to enforce such rights could result in substantial costs and divert our efforts and attention from other aspects of our
business, could put our patents at risk of being invalidated or interpreted narrowly, and our patent applications at risk of not issuing. Additionally, such proceedings could provoke third parties to assert claims against us. We may not prevail in
any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Thus, we may not be able to stop a competitor from marketing and selling in other countries product candidates and services that are
the same as or similar to our product candidates and services, and our competitive position would be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have
encountered significant problems in protecting and defending intellectual property rights in other jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade
secrets, and other intellectual property protection, particularly those relating to biotechnology product candidates, which could make it difficult for us to stop the infringement of our patents or marketing of competing product candidates in
violation of our proprietary rights generally. Proceedings to enforce our patent rights in other jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business,
could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the
damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual
property that we develop or license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many countries, including European Union countries, India, Japan and China, have compulsory
licensing laws under which a patent owner may be compelled under specified circumstances to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In
those countries, we may have limited remedies, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world
may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to
protect the confidentiality of any trade secrets, our business and competitive position would be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to seeking
patents for any product candidates, we may rely on trade secrets, including unpatented software, <FONT STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary information, to maintain our competitive position. We seek to protect
this software and information, in part, by entering into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our
employees and consultants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we rely and expect to continue to rely on third parties to manufacture our product candidates and
future product candidates, and we collaborate and expect to continue to collaborate with third parties on the development of current and future product candidates, we must, at times, share trade secrets with them. We also conduct joint research and
development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. We seek to protect our proprietary technology in part by entering into confidentiality agreements
and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These
agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and
other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Any disclosure,
either intentional or unintentional, by our employees, the employees of third parties with whom we share facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or
misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in the
market. Further, adequate remedies may not exist in the event of unauthorized use or disclosure. Given that our proprietary position is based, in part, on our <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets, a competitor&#146;s
discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish
data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Policing unauthorized use of our or our licensors&#146; intellectual property is difficult, expensive and time-consuming, and we
may be unable to determine the extent of any unauthorized use. Moreover, enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition,
some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Despite our efforts to protect our trade secrets, our competitors and other third parties may discover our trade secrets, including our
proprietary software, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#146;s or other third party&#146;s discovery of our trade
secrets, including our proprietary software, would impair our competitive position and have an adverse impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot
guarantee that we have entered into <FONT STYLE="white-space:nowrap">non-disclosure,</FONT> confidentiality agreements, material transfer agreements or consulting agreements with each party that may have or have had access to our trade secrets or
proprietary software, technology and processes. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets and proprietary software, and we may not be able to obtain
adequate remedies for such breaches. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In addition, we
may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some
courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets, including our proprietary software, were to be lawfully obtained or independently developed by a competitor or other
third party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets, including our proprietary software, were to be disclosed to or
independently developed by a competitor or other third party, our competitive position would be harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain software utilized in our computational drug discovery efforts may include third party open
source software. Any failure to comply with the terms of one or more open source software licenses could adversely affect our business, subject us to litigation, or create potential liability. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain software utilized in our computational drug discovery efforts may include third party open source software and we expect to continue to
incorporate open source software in the future. The use of open source software involves a number of risks, many of which cannot be eliminated and could negatively affect our business. For example, we cannot ensure that we have effectively monitored
our use of open source software or that we are in compliance with the terms of the applicable open source licenses or our current policies and procedures. There have been claims against companies that use open source software asserting that the use
of such open source software infringes the claimants&#146; intellectual property rights. As a result, we could be subject to suits by third parties claiming infringement on such third parties&#146; intellectual property rights. Litigation could be
costly for us to defend, have a negative effect on our business, financial condition and results of operations, or require us to devote additional research and development resources to modify our computational drug discovery platform. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Use of open source software may entail greater risks than use of third-party commercial software, as open source licensors generally do not
provide warranties, controls on the origin of the software or other contractual protections regarding infringement claims or the quality of the code, including with respect to security vulnerabilities. In addition, certain open source licenses
require that source code for software programs that interact with such open source software be made available to the public at no cost and that any modifications or derivative works to such open source software continue to be licensed under the same
terms as the open source software license. The terms of various open source licenses have not been interpreted by courts in the relevant jurisdictions, and there is a risk that such licenses could be construed in a manner that imposes unanticipated
conditions or restrictions on our ability to market our solutions. By the terms of certain open source licenses, if portions of our proprietary software are determined to be subject to an open source license or if we combine our proprietary software
with open source software in a certain manner, we could be required to release the source code of our proprietary software and to make our proprietary software available under open source licenses, each of which could reduce or eliminate the
effectiveness of our computational discovery efforts. We may also face claims alleging noncompliance with open source license terms or misappropriation or other violation of open source technology. Any of these events could create liability for us
and damage our reputation, which could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of
their former employers or other third parties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We employ individuals who were previously employed at universities or other
software, biotechnology or pharmaceutical companies, including our licensors, competitors or potential competitors. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees,
collaborators and other third parties with whom we do business include provisions requiring such parties to not use the confidential information of their former employer, we may be subject to claims that we or our employees, consultants, independent
contractors or other third parties have inadvertently or otherwise used or disclosed confidential information of our employees&#146; former employers or other third parties. We may also be subject to claims that former employers or other third
parties have an ownership interest in our owned or licensed patents or patent applications. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we fail in defending any such
claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property, which could limit our ability to stop others from using or
commercializing similar technology and therapeutics, without payment to us, could limit the duration of the patent protection covering our technology and product candidates and could result in our inability to develop, manufacture or commercialize
our product candidates without infringing third-party patent rights. Such intellectual property rights could be awarded </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to a third party, and we could be required to obtain a license from such third party to commercialize our current or future product candidates. Such a license may not be available on commercially
reasonable terms or at all. Even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees. Moreover, any such litigation or the threat thereof may harm our reputation, our ability
to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would harm our business, results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on a combination of internally developed and <FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property rights and we or
our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, trade secrets, or other intellectual property as an
inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or other third parties who are involved in developing
product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#146; ownership of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, trade secrets or
other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property
that is important to product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could harm our business,
financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, while it is our policy to require our employees, contractors and
other third parties who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops
intellectual property that we regard as our own. Our invention assignment agreements may not be self-executing or may be breached, and we may not have adequate remedies for any such breach. Additionally, we may be forced to bring claims against
third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Furthermore, individuals executing agreements with us may have preexisting or competing obligations to a third
party, such as an academic institution, and thus an agreement with us may be ineffective in perfecting ownership of inventions developed by that individual. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal
responsibilities, and have a harmful effect on the success of our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if resolved in our favor, litigation or other
legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of
the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could adversely impact the price of our common shares. Such litigation or proceedings
could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such
litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating our intellectual
property. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials and internal research programs, or <FONT STYLE="white-space:nowrap">in-license</FONT>
needed technology or other future product candidates. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace, including compromising our
ability to raise the funds necessary to continue our clinical trials, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
continue our research programs, license necessary technology from third parties, or enter into development collaborations that would help us commercialize product candidates, if approved. Any of
the foregoing could harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in obtaining necessary
intellectual property rights to future product candidates through acquisitions and <FONT STYLE="white-space:nowrap">in-licenses.</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A third party may hold intellectual property, including patent rights, that are important or necessary to the development of our product
candidates. Accordingly, we may seek to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> patented or proprietary technologies to develop such product candidates or to grow our product offerings and technology portfolio. However, we may
be unable to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> intellectual property rights relating to, or necessary for, any such product candidate or technology from third parties on commercially reasonable terms or at all. Even if we
are able to <FONT STYLE="white-space:nowrap">in-license</FONT> any such necessary intellectual property, it could be on <FONT STYLE="white-space:nowrap">non-exclusive</FONT> terms, thereby giving our competitors and other third parties access to the
same intellectual property licensed to us, and it could require us to make substantial licensing and royalty payments. In that event, we may be unable to develop or commercialize such product candidates or technology. We may also be unable to
identify product candidates or technology that we believe are an appropriate strategic fit for our company and protect intellectual property relating to, or necessary for, such product candidate and technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">in-licensing</FONT> and acquisition of third-party intellectual property rights for any future product
candidate is a competitive area, and a number of more established companies are also pursuing strategies to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire third-party intellectual property rights for product candidates that we may
consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. Furthermore, companies that perceive us to
be a competitor may be unwilling to assign or license rights to us. If we are unable to successfully obtain rights to additional technologies or product candidates, our business, financial condition, results of operations and prospects for growth
could suffer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we expect that competition for the <FONT STYLE="white-space:nowrap">in-licensing</FONT> or acquisition of
third-party intellectual property rights for any future product candidate and technologies that are attractive to us may increase in the future, which may mean fewer suitable opportunities for us as well as higher acquisition or licensing costs. We
may be unable to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire the third-party intellectual property rights for product candidates or technology on terms that would allow us to make an appropriate return on our investment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any trademarks we have obtained or may obtain may be infringed or successfully challenged, resulting in harm to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on trademarks as one means to distinguish product candidates that are approved for marketing from the product candidates of our
competitors. Our current and future trademark applications in the United States and in other jurisdictions may not be allowed or may subsequently be opposed, challenged, infringed, circumvented, declared generic or determined to be infringing other
marks. Additionally, once we select new trademarks and apply to register them, our trademark applications may not be approved. Third parties have in the past opposed, are currently opposing and may in the future oppose or attempt to cancel our
trademark applications or trademarks, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand product candidates, which could result in loss of brand recognition
and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks and we may not have adequate resources to enforce our trademarks. If we attempt to enforce our trademarks and assert
trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we
could ultimately be forced to cease use of such trademarks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to protect our rights to these trademarks and trade names,
which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or
trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition
based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names,
copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and
prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once granted, patents may remain open to invalidity challenges including opposition, interference,
<FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review, <I>inter partes</I> review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during
which time third parties can raise objections against such grant. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus
attacked, or may lose the allowed or granted claims altogether. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the degree of future protection afforded by our intellectual
property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive
advantage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, if a third party has intellectual property rights that cover the practice of our technology, we may not be able to
fully exercise or extract value from our intellectual property rights. The following examples are illustrative: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make formulations or compositions that are the same as or similar to product candidates,
but that are not covered by the claims of the patents that we own; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make product candidates that are similar to product candidates that we intend to
commercialize that are not covered by the patents that we exclusively licensed and have the right to enforce; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, our licensor or any collaborators might not have been the first to make or reduce to practice the inventions
covered by the issued patents or pending patent applications that we own or have exclusively licensed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or our licensor or any collaborators might not have been the first to file patent applications covering
certain of our inventions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our pending patent applications will not lead to issued patents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents that we own or have exclusively licensed may not provide us with any competitive advantages, or
may be held invalid or unenforceable as a result of legal challenges; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors might conduct research and development activities in the United States and other countries that
provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and then use the information learned from such activities to develop competitive
product candidates for sale in our major commercial markets; and we may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third parties performing manufacturing or testing for us using our product candidates or technologies could use
the intellectual property of others without obtaining a proper license; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">parties may assert an ownership interest in our intellectual property and, if successful, such disputes may
preclude us from exercising exclusive rights over that intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop or <FONT STYLE="white-space:nowrap">in-license</FONT> additional proprietary technologies that
are patentable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to obtain and maintain necessary licenses on commercially reasonable terms, or at all;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may harm our business; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may choose not to file a patent application in order to maintain certain trade secrets or <FONT
STYLE="white-space:nowrap">know-how,</FONT> and a third party may subsequently file a patent application covering such intellectual property. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could significantly harm our business and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to MAAC and the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>For purposes of this subsection only, &#147;we,&#148; &#147;us&#148; or &#147;our&#148; refer to (i) MAAC prior to the consummation of the Business
Combination or (ii) Roivant following the consummation of the Business Combination, unless the context otherwise requires. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The MAAC Sponsor and
MAAC&#146;s officers and directors have agreed to vote in favor of the Business Combination, regardless of how MAAC&#146;s public stockholders vote. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unlike certain blank check companies in which the initial stockholders agree to vote their founder shares in accordance with the majority of
the votes cast by the public stockholders in connection with an initial Business Combination, the MAAC Sponsor and MAAC&#146;s officers and directors have agreed (and their permitted transferees will agree), pursuant to the terms of a letter
agreement entered into with MAAC, to vote any founder shares, placement shares or MAAC Class A Shares held by them, in favor of MAAC&#146;s Business Combination. As of the date of this proxy statement/prospectus, MAAC&#146;s initial stockholders own
approximately 20% of MAAC&#146;s issued and outstanding shares. As a result, in addition to MAAC&#146;s initial stockholders&#146; shares, MAAC would need only 15,401,934, or 37.50%, of the 41,071,823 MAAC Class A Shares outstanding as of the date
of this proxy statement/prospectus to be voted in favor of the Business Combination (assuming all outstanding shares are voted) in order to have the Business Combination approved. Accordingly, it is more likely that the necessary stockholder
approval will be received than would be the case if such persons agreed to vote their shares in accordance with the affirmative vote of the holders of a majority of MAAC Shares outstanding as of the date of the stockholder meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The MAAC Sponsor, MAAC&#146;s directors and officers and their respective affiliates may elect to purchase shares from public stockholders in connection
with the Business Combination, which may influence the vote on the Business Combination and reduce the public &#147;float&#148; of the Roivant Common Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC&#146;s Sponsor, directors, officers or their affiliates may purchase shares in privately negotiated transactions or in the open market
either prior to or following the completion of the Business Combination, although they are under no obligation to do so. Please see &#147;Information about MAAC&#151;Permitted Purchases of MAAC&#146;s Securities&#148; for a description of how such
persons will determine which stockholders to seek to acquire shares from. Such purchases may include a contractual acknowledgement that such stockholder, although still the record holder of MAAC&#146;s shares, is no longer the beneficial owner
thereof and therefore agrees not to exercise its redemption rights. In the event that MAAC&#146;s Sponsor, directors, officers or their affiliates purchase shares in privately negotiated transactions from public stockholders who have already elected
to exercise their redemption rights, such selling stockholders would be required to revoke their prior elections to redeem their shares. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
price per share paid in any such transaction may be different than the amount per share a public stockholder would receive if it elected to redeem its shares in connection with the Business
Combination. The purpose of such purchases could be to vote such shares in favor of the Business Combination and thereby increase the likelihood of obtaining stockholder approval or to satisfy the closing condition that requires MAAC to have a
minimum amount of cash at the Closing of the Business Combination, where it appears that such requirement would otherwise not be met. This may result in the completion of the Business Combination although it may not otherwise have been possible. Any
such purchases will be reported pursuant to Sections&nbsp;13 and 16 of the Exchange Act to the extent such purchasers are subject to such reporting requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if such purchases are made, the public float of MAAC Class&nbsp;A Shares or public warrants and the number of beneficial holders
of MAAC securities may be reduced, possibly making it difficult to maintain the quotation, listing or trading of MAAC securities on a national securities exchange, including Nasdaq. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If third parties bring claims against MAAC, the proceeds held in the Trust Account could be reduced and the per share redemption amount
received by stockholders may be less than $10.00 per share (which was the offering price in MAAC&#146;s initial public offering). </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC&#146;s placing of funds in the Trust Account may not protect those funds from third-party claims against MAAC. Although MAAC has sought
and will seek to have all vendors, service providers (other than its independent registered public accounting firm), prospective target businesses or other entities with which MAAC does business execute agreements with MAAC waiving any right, title,
interest or claim of any kind in or to any monies held in the Trust Account, there is no guarantee that they will execute such agreements or even if they execute such agreements that they would be prevented from bringing claims against the Trust
Account, including, but not limited to, fraudulent inducement, breach of fiduciary responsibility or other similar claims, as well as claims challenging the enforceability of the waiver, in each case in order to gain advantage with respect to a
claim against MAAC&#146;s assets, including the funds held in the Trust Account. If any third party refuses to execute an agreement waiving such claims to the monies held in the Trust Account, MAAC&#146;s management will perform an analysis of the
alternatives available to it and will only enter into an agreement with a third party that has not executed a waiver if management believes that such third party&#146;s engagement would be significantly more beneficial to MAAC than any alternative.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Examples of possible instances where MAAC may engage a third party that refuses to execute a waiver include the engagement of a third
party consultant whose particular expertise or skills are believed by management to be significantly superior to those of other consultants that would agree to execute a waiver or in cases where management is unable to find a service provider
willing to execute a waiver. In addition, there is no guarantee that such entities will agree to waive any claims they may have in the future as a result of, or arising out of, any negotiations, contracts or agreements with MAAC and will not seek
recourse against the Trust Account for any reason. Upon redemption of MAAC Class A Shares, if MAAC is unable to complete its business combination within the prescribed time frame, or upon the exercise of a redemption right in connection with its
business combination, MAAC will be required to provide for payment of claims of creditors that were not waived that may be brought against it within the ten years following redemption. Accordingly, the per share redemption amount received by public
stockholders could be less than the $10.00 per share initially held in the Trust Account, due to claims of such creditors. In order to protect the amounts held in the Trust Account, Sponsor has agreed to be liable to MAAC if and to the extent any
claims by a vendor for services rendered or products sold to MAAC, or a prospective target business with which MAAC has discussed entering into a transaction agreement, reduces the amount of funds in the Trust Account. This liability will not apply
with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account or to any claims under our indemnity of the underwriters of MAAC&#146;s initial public
offering against certain liabilities, including liabilities under the Securities Act. Moreover, even in the event that an executed waiver is deemed to be unenforceable against a third party, Sponsor will not be responsible to the extent of any
liability for such third party claims. MAAC has not independently verified whether Sponsor has sufficient funds to satisfy its indemnity obligations and has not asked Sponsor to reserve for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such indemnification obligations. Therefore, MAAC cannot assure you that Sponsor would be able to satisfy those obligations. None of MAAC&#146;s officers will indemnify it for claims by third
parties including, without limitation, claims by vendors and prospective target businesses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if MAAC is forced to file a
bankruptcy case or an involuntary bankruptcy case is filed against it that is not dismissed, or if MAAC otherwise enters compulsory or court supervised liquidation, the proceeds held in the Trust Account could be subject to applicable bankruptcy
law, and may be included in MAAC&#146;s bankruptcy estate and subject to the claims of third parties with priority over the claims of its stockholders. To the extent any bankruptcy claims deplete the Trust Account, MAAC may not be able to return to
its public stockholders $10.00 per share (which was the offering price in its initial public offering). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>MAAC has not obtained an opinion from an
independent investment banking firm or from an independent accounting firm, and consequently, you may have no assurance from an independent source that the price MAAC is paying for the business is fair to MAAC&#146;s stockholders from a financial
point of view. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the Business Combination is not with an affiliated entity, MAAC is not required to obtain an opinion from an
independent investment banking firm or another independent firm that commonly renders valuation opinions for the type of company MAAC is seeking to acquire or from an independent accounting firm that the price MAAC is paying for a target is fair to
MAAC&#146;s stockholders from a financial point of view, unless MAAC&#146;s Board of Directors cannot independently determine the fair market value of the target business or businesses. Since no opinion has been obtained, MAAC&#146;s stockholders
are relying on the judgment of MAAC&#146;s Board of Directors, who determined fair market value based on standards generally accepted by the financial community. Such standards are disclosed in this proxy statement/prospectus under &#147;The
Business Combination&#151;Satisfaction of 80% Test.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>MAAC&#146;s stockholders will experience immediate dilution due to the issuance of common
shares to the MAAC stockholders as consideration in the Business Combination. Having a minority share position likely reduces the influence that MAAC&#146;s current stockholders have on its management following the Business Combination. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on MAAC&#146;s current capitalization, MAAC anticipates Roivant issuing (or reserving for issuance) an aggregate of 41,071,823 Roivant
Common Shares, subject to adjustment, to the MAAC stockholders as consideration in the Business Combination. It is anticipated that, upon completion of the Business Combination, assuming no redemptions MAAC&#146;s public stockholders will own
approximately 5.7% outstanding of Roivant Common Shares, assuming that no shares are elected to be redeemed in connection with the Business Combination. In addition, this does not take into account: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">warrants to purchase common shares that will remain outstanding immediately following the Business Combination;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance of any shares upon completion of the Business Combination under the 2021 EIP (as defined herein).
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of MAAC&#146;s shares are redeemed in connection with the Business Combination, the percentage of Roivant&#146;s
outstanding common shares held by public stockholders will decrease and the percentages of Roivant&#146;s outstanding common shares held immediately following the Closing of the Business Combination by each of Roivant&#146;s initial shareholders
will increase. See the section entitled &#147;Summary&#151;Impact of the Business Combination on the Company&#146;s Public Float&#148; and &#147;Unaudited Pro Forma Combined Financial Information&#148; for further information. To the extent that any
of the outstanding warrants or options are exercised for Roivant Common Shares, or awards are issued under the 2021 EIP, MAAC&#146;s existing stockholders may experience substantial dilution. Such dilution could, among other things, limit the
ability of MAAC&#146;s current stockholders to influence management through the election of directors following the Business Combination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the issuance of additional common stock will significantly dilute the equity
interests of existing holders of MAAC securities, and may adversely affect prevailing market prices for Roivant Common Shares and/or Roivant Warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Since holders of MAAC&#146;s founder shares and private placement warrants will lose their entire investment in us if MAAC&#146;s initial business
combination is not completed, a conflict of interest may arise in determining whether Roivant is an appropriate target for the Business Combination. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC&#146;s initial holders currently own 10,267,956 Founder Shares, which will be worthless if MAAC does not consummate its initial business
combination. Sponsor has purchased 10,214,365 private placement warrants for an aggregate purchase price of $10,214,365. There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Founder Shares,
shares underlying the private placement warrants or private placement warrants, which will expire worthless if MAAC does not consummate a business combination prior to October&nbsp;9, 2022. If MAAC does not consummate the Business Combination or
another initial business combination, Sponsor will realize a loss on the private placement warrants it purchased. As a result, the personal and financial interests of certain of MAAC&#146;s officers and directors, directly or as members of Sponsor,
in consummating the Business Combination or another initial business combination, may have influenced their motivation in identifying and selecting Roivant as the target for the Business Combination and, if the Business Combination is not
consummated, may in the future influence their motivation in identifying and selecting a target business for an alternative initial business combination and completing an initial business combination that is not in the best interests of MAAC&#146;s
stockholders. Consequently, the discretion of MAAC&#146;s officers and directors, in identifying and selecting Roivant or another suitable target business combination may result in a conflict of interest when determining whether the terms,
conditions and timing of the Business Combination or another initial business combination are appropriate and in the best interest of MAAC&#146;s public stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Since the MAAC Sponsor and MAAC&#146;s officers and directors will not be eligible to be reimbursed for their <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses if MAAC&#146;s initial business combination is not completed, a conflict of interest may arise in determining whether the Business Combination or an alternative initial business
combination target is appropriate for MAAC&#146;s initial business combination. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Closing of the Business Combination or, if
the Business Combination is not consummated, at the closing of an alternative initial business combination, Sponsor and MAAC&#146;s officers and directors, or any entities with which they are affiliated, will be reimbursed for any <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with activities on MAAC&#146;s behalf such as identifying Roivant or any alternative target businesses and performing due
diligence on suitable business combinations. As of June 17, 2021, the MAAC Sponsor had incurred approximately $23,418 of out-of-pocket expenses eligible for reimbursement if the Business Combination, or an alternative initial business combination,
is consummated. There is no cap or ceiling on the reimbursement of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with activities on MAAC&#146;s behalf. These financial
interests of Sponsor and MAAC&#146;s officers and directors may influence their motivation in identifying and selecting Roivant or an alternative target business combination and completing the Business Combination or an alternative initial business
combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The exercise of MAAC&#146;s directors&#146; and executive officers&#146; discretion in agreeing to changes or waivers in the terms of
the Business Combination may result in a conflict of interest when determining whether such changes to the terms of the Business Combination or waivers of conditions are appropriate and in MAAC&#146;s stockholders&#146; best interest. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the period leading up to the closing of the Business Combination, events may occur that, pursuant to the Business Combination Agreement,
would require MAAC to agree to amend the Business Combination Agreement, to consent to certain actions taken by Roivant or to waive rights that MAAC is entitled to under the Business Combination Agreement. Such events could arise because of changes
in the course of Roivant&#146;s business, a request by Roivant to undertake actions that would otherwise be prohibited by the terms of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Business Combination Agreement or the occurrence of other events that would have a material adverse effect on Roivant&#146;s business and would entitle MAAC to terminate the Business Combination
Agreement. In any of such circumstances, it would be at MAAC&#146;s discretion, acting through its board of directors, to grant its consent or waive those rights. The existence of financial and personal interests of one or more of the directors
described in the preceding risk factors may result in a conflict of interest on the part of such director(s) between what he or they may believe is best for MAAC and its stockholders and what he or they may believe is best for himself or themselves
in determining whether or not to take the requested action. As of the date of this proxy statement/prospectus, MAAC does not believe there will be any changes or waivers that MAAC&#146;s directors and executive officers would be likely to make after
stockholder approval of the Business Combination Proposal has been obtained. While certain changes could be made without further stockholder approval, MAAC intends to circulate a new or amended proxy statement/prospectus and resolicit MAAC&#146;s
stockholders if changes to the terms of the transaction that would have a material impact on its stockholders are required prior to the vote on the Business Combination Proposal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Subsequent to consummation of the Business Combination, MAAC may be required to subsequently take write-downs or write-offs, restructuring and
impairment or other charges that could have a significant negative effect on MAAC&#146;s financial condition, results of operations and the share price of its securities, which could cause you to lose some or all of your investment. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC cannot assure you that the due diligence conducted in relation to Roivant has identified all material issues or risks associated with
Roivant, its business or the industry in which it competes. As a result of these factors, MAAC may incur additional costs and expenses and MAAC may be forced to later write-down or <FONT STYLE="white-space:nowrap">write-off</FONT> assets,
restructure its operations, or incur impairment or other charges that could result in MAAC reporting losses. Even if MAAC&#146;s due diligence has identified certain risks, unexpected risks may arise and previously known risks may materialize in a
manner not consistent with its preliminary risk analysis. If any of these risks materialize, this could have a material adverse effect on MAAC&#146;s financial condition and results of operations and could contribute to negative market perceptions
about MAAC&#146;s securities or Roivant. Accordingly, any stockholders of MAAC who choose to remain shareholders of Roivant following the Business Combination could suffer a reduction in the value of their investment. Such stockholders are unlikely
to have a remedy for such reduction in value unless they are able to successfully pursue claims under applicable state law or federal securities laws. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The listing of Roivant securities on Nasdaq will not benefit from the process undertaken in connection with an&nbsp;underwritten initial public
offering. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC and Roivant will apply to list the Roivant Common Shares and Roivant Warrants on Nasdaq under the symbols
&#147;ROIV&#148; and &#147;ROIVW,&#148; respectively, to be effective at Closing. Unlike an underwritten initial public offering&nbsp;of the Roivant securities, the initial listing of Roivant&#146;s securities as a result of the Business Combination
will not benefit from the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the book-building process undertaken by underwriters that helps to inform efficient price discovery with respect
to opening trades of newly listed securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">underwriter support to help stabilize, maintain or affect the public price of the new issue immediately after
listing; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">underwriter due diligence review of the offering and potential liability for material misstatements or omissions
of fact in a prospectus used in connection with the securities being offered or for statements made by its securities analysts or other personnel. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The lack of such a process in connection with the listing of Roivant&#146;s securities could result in diminished investor demand,
inefficiencies in pricing and a more volatile public price for Roivant&#146;s securities during the period immediately following the listing than in connection with an underwritten initial public offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Termination of the Business Combination Agreement could negatively impact Roivant and MAAC.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Business Combination is not completed for any reason, including as a result of MAAC&#146;s stockholders declining to
approve the proposals required to effect the Business Combination, the ongoing business of MAAC may be adversely impacted and, without realizing any of the anticipated benefits of completing the Business Combination, MAAC would be subject to a
number of risks, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">MAAC may experience negative reactions from the financial markets, including negative impacts on its share price
(including to the extent that the current market price reflects a market assumption that the merger will be completed); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">MAAC will have incurred substantial expenses, to the extent not reimbursable by Roivant, and will be required to
pay certain costs relating to the Business Combination, whether or not the Business Combination is completed; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">since the Business Combination Agreement restricts the conduct of MAAC&#146;s businesses prior to completion of
the Business Combination, MAAC may not have been able to take certain actions during the pendency of the Business Combination that would have benefitted it as an independent company, and the opportunity to take such actions may no longer be
available. See &#147;The Business Combination Proposal&#151;Business Combination&#151;Covenants of the Parties&#148; for a description of the restrictive covenants applicable to Roivant and MAAC. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Roivant and the Vants will be subject to business uncertainties and contractual restrictions while the Business Combination is pending. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Uncertainty about the effect of the Business Combination on employees and other stakeholders may have an adverse effect on Roivant and
consequently on MAAC. These uncertainties may impair Roivant&#146;s ability to attract, retain and motivate key personnel until the Business Combination is completed, and could cause Roivant&#146;s counterparties to seek to change existing business
relationships. Retention of certain employees may be challenging during the pendency of the Business Combination, as certain employees may experience uncertainty about their future roles. If key employees depart because of issues relating to the
uncertainty and difficulty of integration or a desire not to remain with the business, Roivant&#146;s business following the Business Combination could be negatively impacted. In addition, the Business Combination Agreement restricts Roivant from
taking certain specified actions without the consent of MAAC until the Business Combination occurs. These restrictions may prevent Roivant from pursuing attractive business opportunities that may arise prior to the completion of the Business
Combination. See &#147;The Business Combination Proposal&#151;Business Combination&#151;Covenants of the Parties.&#148; Additionally, Roivant is a clinical stage biopharmaceutical and healthcare technology company with a limited operating history
and has never generated any revenue from the sale of its product candidates. Roivant has not yet demonstrated an ability to manufacture a commercial scale product or arrange for a third party to do so on its behalf or conduct sales and marketing
activities necessary for successful product commercialization. Accordingly, there is no guarantee that Roivant will be profitable, continue to grow or otherwise execute its business strategy successfully in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>MAAC is attempting to complete the Business Combination with a private company about which little information is available, which may result in a
business combination that is not as profitable as MAAC suspected, if at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC is seeking to effectuate the Business
Combination with a privately held company. MAAC cannot assure that the due diligence conducted in relation to Roivant has identified all material issues or risks associated with Roivant and its business, because little public information generally
exists about private companies, including Roivant. MAAC&#146;s board of directors was required, and MAAC&#146;s stockholders will be required to evaluate the Business Combination on the basis of limited information, which may result in the Business
Combination being less profitable than MAAC suspected, if at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nasdaq may not list Roivant&#146;s securities on its exchange, and if they are listed Roivant may be
unable to satisfy listing requirements in the future, which could limit investors&#146; ability to effect transactions in Roivant securities and subject Roivant to additional trading restrictions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the Business Combination, Nasdaq rules require that MAAC and Roivant apply for the listing of the Roivant Common Shares and
Roivant Warrants. While MAAC and Roivant will apply to have the Roivant Common Shares and Roivant Warrants listed on the Nasdaq at the Closing of the Business Combination, Roivant will be required to meet Nasdaq&#146;s initial listing requirements.
Roivant may be unable to meet those requirements. Even if Roivant&#146;s securities are listed on the Nasdaq immediately following the Business Combination, it may be unable to maintain the listing of its securities in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Roivant fails to meet the initial listing requirements and Nasdaq does not list Roivant&#146;s securities on its exchange, or if Roivant is
delisted, there could be significant material adverse consequences, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a limited availability of market quotations for Roivant&#146;s securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a limited amount of news and analyst coverage; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a decreased ability to obtain capital or pursue acquisitions by issuing additional equity or convertible
securities. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Roivant&#146;s performance following the Business Combination does not meet market expectations, the price of its
securities may decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Roivant&#146;s performance following the Business Combination does not meet market expectations, the
price of the Roivant Common Shares may decline from the price of MAAC Class&nbsp;A Shares prior to the Closing of the Business Combination. The market value of MAAC Class&nbsp;A Shares prior to the Business Combination may vary significantly from
the price of the Roivant Common Shares on the date the Business Combination is consummated, the date of this proxy statement/prospectus, or the date on which our shareholders vote on the Business Combination. Because the number of Roivant Common
Shares issued as consideration in the Business Combination will not be adjusted to reflect any changes in the market price of MAAC Class&nbsp;A Shares, the value of the Roivant Common Shares issued in the Business Combination may be higher or lower
than the value of the same number of MAAC Class&nbsp;A Shares on earlier&nbsp;dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if an active market for the Roivant
Common Shares develops and continues, the trading price of the Roivant Common Shares following the Business Combination could be volatile and subject to wide fluctuations in response to various factors, some of which are beyond its control. Prior to
the Business Combination, there has not been a public market for the Roivant Common Shares, and trading in the Roivant Common Shares has not been active. Accordingly, the valuation ascribed to the Roivant Common Shares in the Business Combination
may not be indicative of the price that will prevail in the trading market following the Business Combination. Any of the factors listed below could have a material adverse effect on the price of the Roivant Common Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors affecting the trading price of the Roivant Common Shares following the closing of the Business Combination may include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated fluctuations in Roivant&#146;s quarterly and annual financial results or the quarterly and
annual financial results of companies perceived to be similar to it; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the market&#146;s expectations about operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Roivant&#146;s operating results failing to meet market expectations in a particular period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a Vant&#146;s operating results failing to meet market expectations in a particular period, which could impact
the market prices of shares of a public Vant or the valuation of a private Vant, and in turn adversely impact the trading price of the Roivant Common Shares; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of clinical trials or pre-clinical studies at Roivant and the Vants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in financial estimates and recommendations by securities analysts concerning Roivant, the Vants or the
biopharmaceutical industry and market in general; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operating and stock price performance of other companies that investors deem comparable to Roivant;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in laws and regulations affecting Roivant&#146;s and the Vants&#146; businesses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commencement of, or involvement in, litigation involving MAAC or Roivant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in Roivant&#146;s capital structure, such as future issuances of securities or the incurrence of debt;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the volume of Roivant Common Shares available for public sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any significant change in Roivant&#146;s board of directors or management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of substantial amounts of Roivant Common Shares directors, executive officers or significant shareholders
or the perception that such sales could occur; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic and political conditions such as recessions, interest rates, fuel prices, international currency
fluctuations and acts of war or terrorism. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Broad market and industry factors may depress the market price of Roivant
Common Shares irrespective of Roivant&#146;s or the Vants&#146; operating performance. The stock market in general has experienced price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of the
particular companies affected. The trading prices and valuations of these stocks, and of Roivant&#146;s securities, may not be predictable. A loss of investor confidence in the market for companies engaging in digital payments or the stocks of other
companies which investors perceive to be similar to Roivant could depress our stock price regardless of its business, prospects, financial conditions or results of operations. A decline in the market price of Roivant Common Shares also could
adversely affect Roivant&#146;s ability to issue additional securities and Roivant&#146;s ability to obtain additional financing in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions in MAAC&#146;s amended and restated Certificate of Incorporation and Delaware law may have the effect of discouraging lawsuits against its
directors and officers. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC&#146;s amended and restated Certificate of Incorporation requires, unless it consents in writing to
the selection of an alternative forum, that (i)&nbsp;any derivative action or proceeding brought on its behalf, (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee to MAAC or its
stockholders, (iii)&nbsp;any action asserting a claim against MAAC, its directors, officers or employees arising pursuant to any provision of the DGCL or MAAC&#146;s amended and restated Certificate of Incorporation or amended and restated bylaws,
or (iv)&nbsp;any action asserting a claim against MAAC, its directors, officers or employees governed by the internal affairs doctrine may be brought only in the Court of Chancery in the State of Delaware, except any claim (A)&nbsp;as to which the
Court of Chancery of the State of Delaware determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery
within ten days following such determination), (B)&nbsp;which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or (C)&nbsp;for which the Court of Chancery does not have subject matter jurisdiction. If an
action is brought outside of Delaware, the stockholder bringing the suit will be deemed to have consented to service of process on such stockholder&#146;s counsel. Although MAAC believes this provision benefits it by providing increased consistency
in the application of Delaware law in the types of lawsuits to which it applies, a court may determine that this provision is unenforceable, and to the extent it is enforceable, the provision may have the effect of discouraging lawsuits against
MAAC&#146;s directors and officers, although MAAC&#146;s stockholders will not be deemed to have waived our compliance with federal securities laws and the rules&nbsp;and regulations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, MAAC&#146;s amended and restated Certificate of Incorporation provides that the exclusive forum provision will
not apply to suits brought to enforce a duty or liability created by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Section&nbsp;27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to
enforce any duty or liability created by the Exchange Act or the rules&nbsp;and regulations thereunder. Although MAAC believes this provision benefits it by providing increased consistency in the application of Delaware law in the types of lawsuits
to which it applies, the provision may have the effect of discouraging lawsuits against MAAC&#146;s directors and officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our warrant agreement
designates the courts of the State of New York or the United States District Court for the Southern District of New York as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by holders of our warrants,
which could limit the ability of warrant holders to obtain a favorable judicial forum for disputes with our company. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our warrant
agreement provides that, subject to applicable law, (i)&nbsp;any action, proceeding or claim against us arising out of or relating in any way to the warrant agreement, including under the Securities Act, will be brought and enforced in the courts of
the State of New York or the United States District Court for the Southern District of New York, and (ii)&nbsp;that we irrevocably submit to such jurisdiction, which jurisdiction shall be the exclusive forum for any such action, proceeding or claim.
We waive any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the
foregoing, these provisions of the warrant agreement do not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal district courts of the United States of America are the sole and
exclusive forum. Any person or entity purchasing or otherwise acquiring any interest in any of our warrants shall be deemed to have notice of and to have consented to the forum provisions in our warrant agreement. If any action, the subject matter
of which is within the scope the forum provisions of the warrant agreement, is filed in a court other than a court of the State of New York or the United States District Court for the Southern District of New York (a &#147;foreign action&#148;) in
the name of any holder of our warrants, such holder shall be deemed to have consented to: (x)&nbsp;the personal jurisdiction of the state and federal courts located in the State of New York in connection with any action brought in any such court to
enforce the forum provisions (an &#147;enforcement action&#148;) and (y) having service of process made upon such warrant holder in any such enforcement action by service upon such warrant holder&#146;s counsel in the foreign action as agent for
such warrant holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">choice-of-forum</FONT></FONT> provision may
limit a warrant holder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with our company, which may discourage such lawsuits. Warrant holders who do bring a claim in a court of the State of New York or the
United States District Court for the Southern District of New York could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near the State of New York. Alternatively, if a court were to find this
provision of our warrant agreement inapplicable or unenforceable with respect to one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could
materially and adversely affect our business, financial condition and results of operations and result in a diversion of the time and resources of our management and board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You do not have any rights or interests in funds from the Trust Account, except under certain limited circumstances. If MAAC does not complete the
Business Combination, to liquidate your investment, therefore, you may be forced to sell your MAAC Class A Shares or MAAC Warrants, potentially at a loss. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC&#146;s public stockholders will be entitled to receive funds from the Trust Account only upon the earlier to occur of: (i)&nbsp;the
completion of MAAC&#146;s initial business combination, (ii)&nbsp;the redemption of any MAAC Class A Shares properly tendered in connection with a stockholder vote to amend MAAC&#146;s amended and restated certificate of incorporation to
(A)&nbsp;modify the substance or timing of MAAC&#146;s obligation to redeem 100% of MAAC Class A Shares if MAAC does not complete its initial business combination by October&nbsp;9, 2022 or (B)&nbsp;with respect to any other provision relating to
stockholders&#146; rights and (iii)&nbsp;the redemption of all MAAC Class A Shares if MAAC is unable to complete MAAC&#146;s initial business combination by October&nbsp;9, 2022, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to applicable law and as further described herein. In no other circumstances will a public stockholder have any right or interest of any kind in the Trust Account. Holders of warrants
will not have any right to the proceeds held in the Trust Account with respect to the warrants. Accordingly, to liquidate your investment, you may be forced to sell your MAAC Class A Shares or MAAC Warrants, potentially at a loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The ability of MAAC&#146;s stockholders to exercise redemption rights with respect to MAAC Class A Shares may prevent MAAC from completing the Business
Combination or optimizing its capital structure. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC does not know how many stockholders will ultimately exercise their
redemption rights in connection with the Business Combination. As such, the Business Combination is structured based on MAAC&#146;s expectations (and those of the other parties to the Business Combination Agreement) as to the number of shares that
will be submitted for redemption. In addition, if a larger number of shares are submitted for redemption than MAAC initially expected, MAAC may need to seek to arrange for additional third party financing to be able to satisfy the Aggregate Trust
Account Proceeds Condition (or such lower amount designated by the seller if the seller waives the condition). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If too many public
stockholders elect to redeem their shares and additional third-party financing is not available to MAAC, MAAC may not be able to complete the Business Combination. Even if such third-party financing is available, MAAC&#146;s ability to obtain such
financing is subject to restrictions set forth in the Business Combination Agreement. For information regarding the parameters of such restrictions, please see the sections of this proxy statement/prospectus entitled &#147;Business Combination
Proposal&#151;Conditions to the Closing of the Business Combination.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, raising such additional financing may involve
dilutive equity issuances or the incurrence of indebtedness at higher than desirable levels. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The unaudited pro forma condensed combined financial
information included in this proxy statement/prospectus is preliminary, and the actual financial condition and results of operations after the merger may differ materially. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information included in this proxy statement/prospectus is presented for illustrative
purposes only and is not necessarily indicative of what Roivant&#146;s actual financial position or results of operations would have been had the Business Combination been completed on the date(s) indicated. The preparation of the unaudited pro
forma condensed combined financial information is based upon available information and certain assumptions and estimates that MAAC and Roivant currently believe are reasonable. See&nbsp;&#147;Unaudited Pro Forma Condensed Combined Financial
Information&#148;&nbsp;in this proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>MAAC has identified a material weakness in its internal controls over financial
reporting. This material weakness could continue to adversely affect its ability to report its results of operations and financial condition accurately and in a timely manner. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC&#146;s management is responsible for establishing and maintaining adequate internal control over financial reporting designed to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. MAAC&#146;s management also evaluates the effectiveness of its internal controls and
will disclose any changes and material weaknesses identified through such evaluation in those internal controls. A material weakness is a deficiency, or a combination of deficiencies, in internal controls over financial reporting, such that there is
a reasonable possibility that a material misstatement of MAAC&#146;s annual or interim financial statements will not be prevented or detected on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC identified a material weakness in its internal control over financial reporting related to the classification of its warrants as equity
instead of liabilities. On May 11, 2021, its audit committee authorized </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
management to restate its audited financial statements for the year ended December 31, 2020, and, accordingly, management concluded that the control deficiency that resulted in the incorrect
classification of its warrants constituted a material weakness as of December 31, 2020. This material weakness resulted in a material misstatement of MAAC&#146;s warrant liabilities, change in fair value of warrant liabilities, additional paid-in
capital, accumulated deficit and related financial disclosures for the affected periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC has implemented a remediation plan to
remediate the material weakness surrounding its historical presentation of its warrants but can give no assurance that the measures MAAC has taken will prevent any future material weaknesses or deficiencies in internal control over financial
reporting. Even though MAAC has strengthened its controls and procedures, in the future those controls and procedures may not be adequate to prevent or identify irregularities or errors or to facilitate the fair presentation of its financial
statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The MAAC Warrants are accounted for as derivative liabilities with changes in fair value each period included in earnings, which may
have an adverse effect on the market price of our securities or may make it more difficult for it to consummate an initial business combination. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The MAAC Warrants are accounted for as derivative warrant liabilities. At each reporting period (1)&nbsp;the accounting treatment of the warrants will be <FONT
STYLE="white-space:nowrap">re-evaluated</FONT> for proper accounting treatment as a liability or equity and (2)&nbsp;the fair value of the liability of the public warrants and private placement warrants will be remeasured and the change in the fair
value of the liability will be recorded as other income (expense) in our income statement. The impact of changes in fair value on earnings may have an adverse effect on the market price of our securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The provisions of MAAC&#146;s amended and restated Certificate of Incorporation that relate to our <FONT STYLE="white-space:nowrap">pre-Business</FONT>
Combination activity (and corresponding provisions of the agreement governing the release of funds from its Trust Account) may be amended with the approval of holders of at least 60% of MAAC Shares, which is a lower amendment threshold than that of
some other blank check companies. It may be easier for MAAC, therefore, to amend its amended and restated Certificate of Incorporation to facilitate the completion of an initial business combination that some of its stockholders may not support.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some other blank check companies have a provision in their charter which prohibits the amendment of certain of its provisions,
including those which relate to a company&#146;s <FONT STYLE="white-space:nowrap">pre-Business</FONT> Combination activity, without approval by a certain percentage of the company&#146;s stockholders. In those companies, amendment of these
provisions typically requires approval by 90% of the company&#146;s stockholders attending and voting at an annual meeting. MAAC&#146;s amended and restated Certificate of Incorporation provides that any of its provisions related to <FONT
STYLE="white-space:nowrap">pre-Business</FONT> Combination activity (including the requirement to deposit proceeds of MAAC&#146;s initial public offering and the private placement of warrants into the Trust Account and not release such amounts
except in specified circumstances, and to provide redemption rights to Public Stockholders as described herein) may be amended if approved by holders of 60% of MAAC Shares entitled to vote thereon and corresponding provisions of the trust agreement
governing the release of funds from its Trust Account may be amended if approved by holders of at least 60% of MAAC Shares entitled to vote thereon. In all other instances, MAAC&#146;s amended and restated Certificate of Incorporation may be amended
by holders of a majority of outstanding MAAC Shares entitled to vote thereon, subject to applicable provisions of the DGCL or applicable stock exchange rules. The MAAC Sponsor and its permitted transferees, if any, who collectively beneficially own,
on an as converted basis, 20% of MAAC Class&nbsp;A Shares upon the closing of MAAC&#146;s initial public offering (assuming they did not purchase any units), will participate in any vote to amend MAAC&#146;s amended and restated Certificate of
Incorporation and/or trust agreement and have the discretion to vote in any manner they choose. As a result, MAAC may be able to amend the provisions of MAAC&#146;s amended and restated Certificate of Incorporation which govern MAAC&#146;s <FONT
STYLE="white-space:nowrap">pre-Business</FONT> Combination behavior more easily than some other blank check companies, and this may increase its ability to complete a business combination with which you do not agree. MAAC&#146;s stockholders may
pursue remedies against us for any breach of its amended and restated Certificate of Incorporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MAAC Sponsor, executive officers and directors have agreed, pursuant to a written
agreement with MAAC, that they will not propose any amendment to MAAC&#146;s amended and restated Certificate of Incorporation that would affect the substance or timing of MAAC&#146;s obligation to allow redemption in connection with MAAC&#146;s
initial Business Combination or to redeem 100% of MAAC Class A Shares if MAAC does not complete an initial business combination within 24&nbsp;months from the closing of its initial public offering, unless MAAC provides holders of MAAC Class A
Shares with the opportunity to redeem their MAAC Class&nbsp;A Shares upon approval of any such amendment at a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount then on deposit in the Trust
Account, including interest earned on the funds held in the Trust Account and not previously released to us to pay MAAC&#146;s taxes, if any (less up to $100,000 of interest to pay dissolution expenses) divided by the number of then outstanding MAAC
Class A Shares. These agreements are contained in letter agreements that MAAC entered into with the MAAC Sponsor, MAAC&#146;s directors and each member of MAAC&#146;s management team. MAAC&#146;s stockholders are not parties to, or third-party
beneficiaries of, these agreements and, as a result, do not have the ability to pursue remedies against the MAAC Sponsor, executive officers or directors for any breach of these agreements. As a result, in the event of a breach, MAAC&#146;s
stockholders would need to pursue a stockholder derivative action, subject to applicable law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Business Combination may give rise to a taxable
event for U.S. Holders of MAAC Class A Shares or MAAC Warrants. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the limitations and qualifications described in
&#147;Material United States Tax Considerations&#151;Tax Consequences of the Merger&#148; below, the Business Combination is generally intended to be tax-deferred to U.S. Holders (as defined in &#147;Material United States Tax Considerations&#148;)
of MAAC Class A Shares and MAAC Warrants for U.S. federal income tax purposes, except to the extent that such U.S. Holders of MAAC Class A Shares receive cash pursuant to the exercise of redemption rights. However, there are significant factual and
legal uncertainties as to whether the Merger qualifies for tax-deferred treatment as a reorganization under Section 368(a) of the Code. Under Section 368(a) of the Code, the acquiring corporation must continue, either directly or indirectly through
certain controlled corporations, either a significant line of the acquired corporation&#146;s historic business or use a significant portion of the acquired corporation&#146;s historic business assets in a business. However, there is an absence of
guidance directly on point as to how the provisions of Section 368(a) of the Code apply in the case of an acquisition of a corporation with investment-type assets, such as MAAC. There are significant factual and legal uncertainties concerning the
determination of this requirement. Moreover, qualification of the Merger for tax-deferred treatment is based on facts which will not be known until or following the closing of the Merger, and the closing of the Merger is not conditioned upon the
receipt of an opinion of counsel that the Merger qualifies for tax-deferred treatment, and neither MAAC nor Roivant intends to request a ruling from the United States Internal Revenue Service (the &#147;IRS&#148;) regarding the U.S. federal income
tax treatment of the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any requirement for Section 368(a) of the Code is not met, then a U.S. Holder of MAAC Class A Shares or
MAAC Warrants may recognize gain or loss in an amount equal to the difference, if any, between the fair market value (as of the Closing Date) of Roivant Common Shares received in the Merger or MAAC Warrants assumed by Roivant in the Merger, over
such U.S. Holder&#146;s aggregate tax basis in the corresponding MAAC Class A Shares surrendered by such U.S. Holder in the Merger or MAAC Warrants assumed by Roivant in the Merger, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section 367(a) of the Code and the Treasury Regulations promulgated thereunder, in certain circumstances, may impose additional requirements
for certain U.S. Holders to qualify for tax-deferred treatment with respect to the exchange of MAAC Class A Shares and/or the assumption of MAAC Warrants by Roivant in the Merger. The requirements for tax-deferred treatment, including Section 367(a)
of the Code, and the U.S. federal income tax consequences to U.S. Holders if such requirements are not met are discussed in more detail under the sections entitled &#147;Material United States Tax Considerations&#151;Tax Consequences of the
Merger&#148; and &#147;Material United States Tax Considerations&#151;Additional Requirements for Tax Deferral.&#148; If you are a U.S. Holder exchanging </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
MAAC Class A Shares in the Merger or holding MAAC Warrants at the time of the consummation of the Merger, you are urged to consult your tax advisor to determine the tax consequences thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, if a U.S. Holder exercises its redemption rights to receive cash from the trust account in exchange for a portion or, if such
U.S. Holder maintains its ownership of MAAC Warrants, all of its MAAC Class A Shares, such redemption may be treated as integrated with the Merger rather than as a separate transaction. In such case, cash received by such U.S. Holder in the
redemption may also be treated as taxable boot received in a &#147;reorganization&#148; which, depending on the circumstances applicable to such U.S. Holder, may be treated as capital gain (but not loss) or dividend income. If the IRS were to
assert, and a court were to sustain such a contrary position, such U.S. Holder may be required to recognize more gain or income than if the redemption of MAAC Class A Shares was treated as a separate transaction from the exchanges pursuant to the
Merger. For further discussion on the tax implications of such treatment, please see the discussion under the headings &#147;Material United States Tax Considerations&#151;Tax Consequences of Exercising Redemption Rights.&#148; If you are a U.S.
Holder exercising your redemption rights with respect to the MAAC Class A Shares, you are urged to consult your tax advisor to determine the tax consequences if the Merger and the redemption of MAAC Class A Shares are to be treated as an integrated
transaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The IRS may not agree that Roivant should be treated as a non-U.S. corporation for U.S. federal income tax purposes. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under current U.S. federal income tax law, a corporation generally will be considered to be a U.S. corporation for U.S. federal income tax
purposes only if it is created or organized in the United States or under the law of the United States or of any State. Accordingly, under generally applicable U.S. federal income tax rules, Roivant, which is not created or organized in the United
States or under the law of the United States or of any State but is instead a Bermuda incorporated entity and tax resident of the UK, would generally be classified as a non-U.S. corporation. Section 7874 of the Code and the Treasury regulations
promulgated thereunder, however, contain specific rules that may cause a non-U.S. corporation to be treated as a U.S. corporation for U.S. federal income tax purposes. If it were determined that Roivant is treated as a U.S. corporation for U.S.
federal income tax purposes under Section 7874 of the Code and the Treasury regulations promulgated thereunder, Roivant would be liable for U.S. federal income tax on its income just like any other U.S. corporation and certain distributions made by
Roivant to its shareholders that are not U.S. Holders (as defined in &#147;Material United States Tax Considerations&#148;) of Roivant would be subject to U.S. withholding tax. As more fully described in &#147;Material United States Tax
Considerations&#151;Treatment of Roivant as a Non-U.S. Corporation for U.S. Federal Income Tax Purposes,&#148; Roivant believes it should not be treated as a U.S. corporation for U.S. federal income tax purposes under Section 7874 of the Code.
However, whether the requirements for such treatment have been satisfied must be finally determined after the completion of the Business Combination, by which time there could be adverse changes to the relevant facts and circumstances. Furthermore,
the interpretation of Treasury regulations relating to the required ownership of Roivant is subject to uncertainty and there is limited guidance regarding their application. Accordingly, there can be no assurance that the IRS will not take a
contrary position to those described above or that a court will not agree with a contrary position of the IRS in the event of litigation. You are urged to consult your tax advisor to determine the tax consequences if the classification of Roivant as
a non-U.S. corporation is not respected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may amend the terms of the warrants in a manner that may be adverse to holders of public warrants with
the approval by the holders of at least 50% of the then outstanding public warrants. As a result, the exercise price of your warrants could be increased, the exercise period could be shortened and the number of shares purchasable upon exercise of a
warrant could be decreased, all without your approval. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our warrants were issued in registered form under a warrant agreement
between Continental Stock Transfer&nbsp;&amp; Trust Company, as warrant agent, and us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrant agreement provides that the terms of
the warrants may be amended without the consent of any holder for the purpose of (i)&nbsp;curing any ambiguity or correct any mistake or defective provision (ii)&nbsp;amending the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provisions relating to cash dividends on common stock as contemplated by and in accordance with the warrant agreement or (iii)&nbsp;adding or changing any provisions with respect to matters or
questions arising under the warrant agreement as the parties to the warrant agreement may deem necessary or desirable and that the parties deem to not adversely affect the rights of the registered holders of the warrants, provided that the approval
by the holders of at least 50% of the then-outstanding public warrants is required to make any change that adversely affects the interests of the registered holders of public warrants. Accordingly, we may amend the terms of the public warrants in a
manner adverse to a holder if holders of at least 50% of the then outstanding public warrants approve of such amendment. Although our ability to amend the terms of the public warrants with the consent of at least 50% of the then outstanding public
warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the warrants, convert the warrants into cash, shorten the exercise period or decrease the number of MAAC Class&nbsp;A
Shares purchasable upon exercise of a warrant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The MAAC Sponsor may have interests in the Merger different from the interests of MAAC&#146;s public
stockholders. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MAAC Sponsor has financial interests in the Business Combination that are different from, or in addition to,
those of other MAAC stockholders generally. See the section entitled &#147;The Business Combination Proposal&#151;Interests of Certain MAAC Persons in the Business Combination&#148; for more information. In addition, the MAAC Sponsor may be
incentivized to complete the Business Combination, or an alternative initial business combination with a less favorable company or on terms less favorable to shareholders, rather than to liquidate, in which case the MAAC Sponsor would lose its
entire investment. As a result, the MAAC Sponsor may have a conflict of interest in determining whether Roivant is an appropriate business with which to effectuate a business combination and/or in evaluating the terms of the Business Combination.
See the section entitled &#147;Business of MAAC&#151;Directors and Executive Officers&#151;Conflicts of Interest&#148; for more information. The MAAC board of directors was aware of and considered these interests, among other matters, in evaluating
and unanimously approving the Business Combination and in recommending to MAAC stockholders that they approve the Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The MAAC
Sponsor and its affiliates may receive a positive return on the 10,167,956 Founder Shares and 10,214,365 private placement warrants even if MAAC&#146;s public stockholders experience a negative return on their investment after consummation of the
Merger. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If MAAC is able to complete a business combination within the required time period, the MAAC Sponsor may receive a
positive return on the 10,167,956 Founder Shares (after giving effect to the MAAC Sponsor&#146;s surrender of 1,232,044 Founder Shares to the Company for no consideration), which were acquired by the MAAC Sponsor for an aggregate purchase price of
$25,000 prior to MAAC&#146;s initial public offering, and the 10,214,365 private placement warrants, which were acquired for an aggregate purchase price of $10,214,365 (or $1.00 per warrant) concurrently with completion of MAAC&#146;s initial public
offering, even if MAAC&#146;s public stockholders experience a negative return on their investment in MAAC Class A Shares and private placement warrants after consummation of the Merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Redemption </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Unless the context otherwise requires, any reference in this section to &#147;MAAC,&#148; the &#147;Company,&#148; &#147;we,&#148;
&#147;us&#148; or &#147;our&#148; refers to MAAC prior to the Business Combination and to Roivant and its subsidiaries and affiliates in the present tense or from and after the consummation of the Business Combination. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Public Stockholders who wish to redeem their MAAC Class A Shares for a pro rata portion of the Trust
Account must comply with specific requirements for redemption that may make it more difficult for them to exercise their redemption rights prior to the deadline. If stockholders fail to comply with the redemption requirements specified in this proxy
statement/prospectus, they will not be entitled to redeem their MAAC Class A Shares for a pro rata portion of the funds held in the Trust Account. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A public stockholder will be entitled to receive cash for any MAAC Class A Shares to be redeemed only if such public stockholder: (i)(a) holds
MAAC Class A Shares, or (b)&nbsp;if the public stockholder holds MAAC Class A Shares through units, the public stockholder elects to separate its units into the underlying MAAC Class A Shares and public warrants prior to exercising its redemption
rights with respect to the MAAC Class A Shares; (ii)&nbsp;submits a written request to Continental, MAAC&#146;s transfer agent, in which it (a)&nbsp;requests that Roivant redeem all or a portion of its MAAC Class A Shares for cash, and
(b)&nbsp;identifies itself as a beneficial holder of the MAAC Class A Shares and provides its legal name, phone number and address; and (iii)&nbsp;delivers its MAAC Class A Shares to Continental, MAAC&#146;s transfer agent, physically to Continental
or electronically through DWAC. Holders must complete the procedures for electing to redeem their MAAC Class A Shares in the manner described above prior to September 24, 2021 (two business days prior to the initial vote on the Business Combination)
in order for their shares to be redeemed. In order to obtain a physical share certificate, a stockholder&#146;s broker and/or clearing broker, DTC and Continental, MAAC&#146;s transfer agent, will need to act to facilitate this request. It is
MAAC&#146;s understanding that stockholders should generally allot at least two weeks to obtain physical certificates from the transfer agent. However, because MAAC does not have any control over this process or over DTC, it may take significantly
longer than two weeks to obtain a physical stock certificate. If it takes longer than anticipated to obtain a physical certificate, public stockholders who wish to redeem their MAAC Class A Shares may be unable to obtain physical certificates by the
deadline for exercising their redemption rights and thus will be unable to redeem their shares. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Business Combination is
consummated, and if a public stockholder properly exercises its right to redeem all or a portion of the MAAC Class A Shares that it holds and timely delivers its shares to Continental, MAAC&#146;s transfer agent, Roivant will redeem such MAAC Class
A Shares for a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the pro rata portion of the Trust Account established at the consummation of our initial public offering, calculated as of two business days prior to
the consummation of the Business Combination. Please see the section entitled &#147;Special Meeting of MAAC Stockholders&#151;Redemption Rights&#148; for additional information on how to exercise your redemption rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If a public stockholder fails to receive notice of MAAC&#146;s offer to redeem MAAC Class A Shares in connection with the Business Combination, or fails
to comply with the procedures for tendering its shares, such shares may not be redeemed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, despite MAAC&#146;s compliance with
the proxy rules, a public stockholder fails to receive MAAC&#146;s proxy materials, such public stockholder may not become aware of the opportunity to redeem his, her or its MAAC Class A Shares. In addition, the proxy materials that MAAC is
furnishing to holders of MAAC Class A Shares in connection with the Business Combination describes the various procedures that must be complied with in order to validly redeem the MAAC Class A Shares. In the event that a public stockholder fails to
comply with these procedures, its MAAC Class A Shares may not be redeemed. Please see the section entitled &#147;<I>Special Meeting of MAAC Stockholders&#151;Redemption Rights</I>&#148; for additional information on how to exercise your redemption
rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the minimum Trust Account condition is waived, MAAC does not have a specified maximum redemption threshold. The absence of such a
redemption threshold may make it possible for us to complete the Business Combination with which a substantial majority of MAAC&#146;s stockholders do not agree. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Existing Governing Documents do not provide a specified maximum redemption threshold, except that MAAC will not redeem MAAC Class A Shares
in an amount that would cause MAAC&#146;s net tangible assets to be less than $5,000,001 after giving effect to the transactions contemplated by the Business Combination </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement, the PIPE Financing and all of the MAAC stockholder redemptions (as determined in accordance with Rule <FONT STYLE="white-space:nowrap">3a51-1(g)(1)</FONT> of the Exchange Act). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, MAAC may be able to complete the Business Combination even though a substantial portion of public stockholders do not agree with
the transaction and have redeemed their shares or have entered into privately negotiated agreements to sell their shares to Sponsor, directors or officers or their affiliates. As of the date of this proxy statement/prospectus, no agreements with
respect to the private purchase of MAAC Class A Shares by MAAC or the persons described above have been entered into with any such investor or holder. MAAC will file or submit a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> to
disclose any material arrangements entered into or significant purchases made by any of the aforementioned persons that would affect the vote on the proposals to be put to the extraordinary general meeting or the redemption threshold. Any such
report will include descriptions of any arrangements entered into or significant purchases by any of the aforementioned persons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you or a
&#147;group&#148; of stockholders of which you are a part are deemed to hold an aggregate of more than 15% of the MAAC Class A Shares, you (or, if a member of such a group, all of the members of such group in the aggregate) will lose the ability to
redeem all such shares in excess of 15% of the MAAC Class A Shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A public stockholder, together with any of his, her or its
affiliates or any other person with whom it is acting in concert or as a &#147;group&#148; (as defined under Section&nbsp;13 of the Exchange Act), will be restricted from redeeming in the aggregate his, her or its shares or, if part of such a group,
the group&#146;s shares, in excess of 15% of the MAAC Class A Shares. In order to determine whether a stockholder is acting in concert or as a group with another stockholder, MAAC will require each public stockholder seeking to exercise redemption
rights to certify to MAAC whether such stockholder is acting in concert or as a group with any other stockholder. Such certifications, together with other public information relating to stock ownership available to MAAC at that time, such as
Section&nbsp;13D, Section&nbsp;13G and Section&nbsp;16 filings under the Exchange Act, will be the sole basis on which MAAC makes the above-referenced determination. Your inability to redeem any such excess shares will reduce your influence over
MAAC&#146;s ability to consummate the Business Combination and you could suffer a material loss on your investment in MAAC if you sell such excess shares in open market transactions. Additionally, you will not receive redemption distributions with
respect to such excess shares if MAAC consummates the Business Combination. As a result, you will continue to hold that number of shares aggregating to more than 15% of the MAAC Class A Shares and, in order to dispose of such excess shares, would be
required to sell your stock in open market transactions, potentially at a loss. MAAC cannot assure you that the value of such excess shares will appreciate over time following the Business Combination or that the market price of the MAAC Class A
Shares will exceed the <FONT STYLE="white-space:nowrap">per-share</FONT> redemption price. Notwithstanding the foregoing, stockholders may challenge MAAC&#146;s determination as to whether a stockholder is acting in concert or as a group with
another stockholder in a court of competent jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, MAAC&#146;s stockholders&#146; ability to vote all of their shares
(including such excess shares) for or against the Business Combination is not restricted by this limitation on redemption. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There is no guarantee
that a stockholder&#146;s decision whether to redeem its shares for a pro rata portion of the Trust Account will put the stockholder in a better future economic position. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC can give no assurance as to the price at which a stockholder may be able to sell its MAAC Class A Shares in the future following the
completion of the Business Combination or any alternative business combination. Certain events following the consummation of any initial business combination, including the Business Combination, may cause an increase in MAAC share price, and may
result in a lower value realized now than a stockholder of MAAC might realize in the future had the stockholder not redeemed its shares. Similarly, if a stockholder does not redeem its shares, the stockholder will bear the risk of ownership of the
MAAC Class A Shares after the consummation of any initial business combination, and there can be no assurance that a stockholder can sell its shares in the future for a greater amount than the redemption price set forth in this proxy
statement/prospectus. A stockholder should consult the stockholder&#146;s own financial advisor for assistance on how this may affect his, her or its individual situation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The securities in which we invest the funds held in the Trust Account could bear a negative rate of
interest, which could reduce the value of the assets held in trust such that the <FONT STYLE="white-space:nowrap">per-share</FONT> redemption amount received by public stockholders may be less than $10.00 per share. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proceeds held in the Trust Account will be invested only in U.S. government treasury obligations with a maturity of 185 days or less or in
money market funds meeting certain conditions under Rule <FONT STYLE="white-space:nowrap">2a-7</FONT> under the Investment Company Act, which invest only in direct U.S. government treasury obligations. While short-term U.S. government treasury
obligations currently yield a positive rate of interest, they have briefly yielded negative interest rates in recent years. Central banks in Europe and Japan pursued interest rates below zero in recent years, and the Open Market Committee of the
Federal Reserve has not ruled out the possibility that it may in the future adopt similar policies in the United States. In the event that we are unable to complete our initial business combination or make certain amendments to our amended and
restated memorandum and articles of association, our public stockholders are entitled to receive their <FONT STYLE="white-space:nowrap">pro-rata</FONT> share of the proceeds held in the Trust Account, plus any interest income, net of income taxes
paid or payable (less, in the case we are unable to complete our initial business combination, $100,000 of interest to pay dissolution expenses). Negative interest rates could reduce the value of the assets held in trust such that the <FONT
STYLE="white-space:nowrap">per-share</FONT> redemption amount received by public stockholders may be less than $10.00 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks if the
Adjournment Proposal is Not Approved </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the Adjournment Proposal is not approved, and an insufficient number of votes have been obtained to
authorize the consummation of the Business Combination, the MAAC Board will not have the ability to adjourn the special MAAC meeting to a later date in order to solicit further votes, and, therefore, the Business Combination will not be approved,
and, therefore, the Business Combination may not be consummated. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The MAAC Board is seeking approval to adjourn the special MAAC meeting to a later
date or dates if, at the extraordinary general meeting, based upon the tabulated votes, there are insufficient votes to approve each of the Condition Precedent Proposals. If the Adjournment Proposal is not approved, the MAAC Board will not have the
ability to adjourn the extraordinary general meeting to a later date and, therefore, will not have more time to solicit votes to approve the proposals. In such events, the Business Combination would not be completed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Roivant Following the Consummation of the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Unless the context otherwise requires, references in this subsection &#147;&#151;Risks Related to Roivant Following the Consummation of the Business
Combination&#148; to &#147;we,&#148; &#147;us,&#148; &#147;our&#148; and the &#147;Company&#148; refer to Roivant and its subsidiaries and affiliates from and after the consummation of the Business Combination. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Roivant will incur increased costs as a result of operating as a public company, and its management will devote substantial time to new compliance
initiatives. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Business Combination is completed and Roivant becomes a public company, it will incur significant legal,
accounting and other expenses that it did not incur as a private company, and these expenses may increase even more after Roivant is no longer an emerging growth company, as defined in Section&nbsp;2(a) of the Securities Act. In addition, we expect
to record incremental share-based compensation expense in connection with the consummation of the Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public
company, Roivant will be subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the Dodd-Frank Act, as well as rules adopted, and to be adopted, by the SEC and the Nasdaq. Roivant&#146;s management and other personnel
will need to devote a substantial amount of time to these compliance initiatives. Moreover, Roivant expects these rules and regulations to substantially increase its legal and financial compliance costs and to make some activities more
time-consuming and costly. For example, Roivant expects these rules and regulations to make it more difficult and more expensive for it to obtain director and officer liability insurance and it may be forced to accept reduced policy limits or incur
substantially higher </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
costs to maintain the same or similar coverage. Roivant cannot predict or estimate the amount or timing of additional costs it may incur to respond to these requirements. The impact of these
requirements could also make it more difficult for Roivant to attract and retain qualified persons to serve on its board of directors, its board committees or as executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Roivant&#146;s failure to timely and effectively implement controls and procedures required by Section&nbsp;404(a) of the Sarbanes-Oxley Act that will
be applicable to it after the Business Combination is consummated could have a material adverse effect on its business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roivant is
currently not subject to Section&nbsp;404 of the Sarbanes-Oxley&nbsp;Act. However, following the consummation of the Business Combination, Roivant will be required to provide management&#146;s attestation on internal controls. The standards required
for a public company under Section&nbsp;404(a) of the Sarbanes-Oxley&nbsp;Act are significantly more stringent than those required of Roivant as a privately-held&nbsp;company. Management may not be able to effectively and timely implement controls
and procedures that adequately respond to the increased regulatory compliance and reporting requirements that will be applicable after the Business Combination. If Roivant is not able to implement the additional requirements of Section&nbsp;404(a)
in a timely manner or with adequate compliance, it may not be able to assess whether its internal controls over financial reporting are effective, which may subject it to adverse regulatory consequences and could harm investor confidence and the
market price of its securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to properly implement internal controls on a timely basis may lead to the identification of one
or more material weaknesses or control deficiencies in the future, which may prevent us from being able to report our financial results accurately on a timely basis or help prevent fraud, and could cause our reported financial results to be
materially misstated and result in the loss of investor confidence or delisting and cause the market price of our common shares to decline. If we have material weaknesses in the future, it could affect the financial results that we report or create
a perception that those financial results do not fairly state our financial position or results of operations. Either of those events could have an adverse effect on the value of our common shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, even if we conclude that our internal control over financial reporting provides reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, because of its inherent limitations, internal control over financial reporting may not prevent or detect fraud or misstatements. Failure
to implement required new or improved controls, or difficulties encountered in their implementation, could harm our results of operations or cause us to fail to meet our future reporting obligations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Roivant may redeem your unexpired warrants prior to their exercise at a time that is disadvantageous to you, thereby making your warrants worthless.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Business Combination, Roivant has the ability to redeem outstanding warrants at any time after they become
exercisable and prior to their expiration, at a price of $0.01 per warrant, provided that the last reported sales price of Roivant Common Shares is equal to or exceeds $18.00 per share (as adjusted for share sub divisions, share capitalizations,
rights issuances, subdivisions, reorganizations, recapitalizations and the like) for any 20 trading days within a 30 <FONT STYLE="white-space:nowrap">trading-day</FONT> period ending on the third trading day prior to the date they send the notice of
redemption to the warrant holders. If and when the warrants become redeemable by Roivant, they may not exercise their redemption right if the issuance of shares upon exercise of the warrants is not exempt from registration or qualification under
applicable state blue sky laws or Roivant is unable to effect such registration or qualification. Roivant will use its best efforts to register or qualify such shares under the blue sky laws of the state of residence in those states in which the
warrants were offered by us in this offering. Redemption of the outstanding warrants could force you (i)&nbsp;to exercise your warrants and pay the exercise price therefor at a time when it may be disadvantageous for you to do so, (ii)&nbsp;to sell
your warrants at the then-current market price when you might otherwise wish to hold your warrants or (iii)&nbsp;to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accept the nominal redemption price which, at the time the outstanding warrants are called for redemption, is likely to be substantially less than the market value of your warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, following the Business Combination, Roivant may redeem your warrants at any time after they become exercisable and prior to their
expiration at a price of $0.10 per warrant upon a minimum of 30 days&#146; prior written notice of redemption provided that holders will be able to exercise their warrants prior to redemption for a number of common shares determined based on the
redemption date and the fair market value of Roivant Common Shares. Please see &#147;Description of Securities&#151;Redeemable Warrants&#151;Public Shareholders&#146; Warrants&#151;Redemption of warrants for common shares when the price per common
share equals or exceeds $10.00.&#148; The value received upon exercise of the warrants (1)&nbsp;may be less than the value the holders would have received if they had exercised their warrants at a later time where the underlying share price is
higher and (2)&nbsp;may not compensate the holders for the value of the warrants, including because the number of shares received is capped at 0.361 common shares per warrant (subject to adjustment) irrespective of the remaining life of the
warrants. None of the private placement warrants will be redeemable by us (except as set forth under &#147;Description of Securities&#151;Warrants&#151;Public Shareholders&#146; Warrants&#151;Redemption of warrants for common shares when the price
per common share equals or exceeds $10.00&#148;) so long as they are held by the MAAC Sponsor or its permitted transferees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Following the Business
Combination, Roivant&#146;s management will have the ability to require holders of Roivant&#146;s warrants to exercise such warrants on a cashless basis, which will cause holders to receive fewer common shares upon their exercise of the warrants
than they would have received had they been able to exercise their warrants for cash. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Roivant calls the public warrants for
redemption after the redemption criteria described elsewhere in this prospectus have been satisfied, Roivant&#146;s management will have the option to require any holder that wishes to exercise their warrant (including any warrants held by the MAAC
Sponsor, MAAC&#146;s former officers or directors, other purchasers of MAAC&#146;s founders&#146; units, or their permitted transferees) to do so on a &#147;cashless basis.&#148; If Roivant&#146;s management chooses to require holders to exercise
their warrants on a cashless basis, the number of common shares received by a holder upon exercise will be fewer than it would have been had such holder exercised his warrant for cash. This will have the effect of reducing the potential
&#147;upside&#148; of the holder&#146;s investment in Roivant&#146;s company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in laws or regulations, or a failure to comply with any laws
and regulations, may adversely affect Roivant&#146;s business, investments and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roivant is subject to laws
and regulations enacted by national, regional and local governments. In particular, it will be required to comply with certain SEC and other legal requirements. Compliance with, and monitoring of, applicable laws and regulations may be difficult,
time consuming and costly. Those laws and regulations and their interpretation and application may also change from time to time and those changes could have a material adverse effect on Roivant&#146;s business, investments and results of
operations. In addition, a failure to comply with applicable laws or regulations, as interpreted and applied, could have a material adverse effect on Roivant&#146;s business and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Ownership of Roivant Common Shares Following the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Unless the context otherwise requires, references in this subsection &#147;&#151;Risks Related to Roivant Following the Consummation of the Business
Combination&#148; to &#147;we,&#148; &#147;us,&#148; &#147;our&#148; and the &#147;Company&#148; refer to Roivant and its subsidiaries and affiliates from and after the consummation of the Business Combination. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions in Roivant&#146;s memorandum of association, proposed <FONT
STYLE="white-space:nowrap">bye-laws</FONT> and Bermuda law could delay or prevent a change in control, limit the price investors may be willing to pay in the future for Roivant Common Shares and could entrench management. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roivant&#146;s memorandum of association and proposed <FONT STYLE="white-space:nowrap">bye-laws</FONT> contain provisions that could make it
more difficult for a third-party to acquire us without the consent of our board of directors. These provisions provide for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a classified board of directors with staggered three-year terms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of Roivant&#146;s Board of Directors to determine the powers, preferences and rights of preference
shares and to cause us to issue the preference shares without shareholder approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of Roivant&#146;s Board of Directors to prevent the transfer of capital stock, or the exercise of
rights with respect to Roivant&#146;s capital stock, if the effect of such transfer or exercise of rights would result in a shareholder holding more than 9.9% of the total issued and outstanding shares of Roivant capital stock on a fully diluted
basis; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requiring advance notice for shareholder proposals and nominations and placing limitations on convening
shareholder meetings. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions may make more difficult the removal of management and may discourage
transactions that otherwise could involve payment of a premium over prevailing market prices for Roivant&#146;s securities. These provisions could also discourage proxy contests and make it more difficult for you and other shareholders to elect
directors of your choosing and cause us to take corporate actions other than those you desire, any of which could harm Roivant&#146;s share price. See &#147;Description of Securities Post-Business Combination<I>.</I>&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Roivant&#146;s largest shareholders and certain members of Roivant&#146;s management own a significant percentage of our stock and will be able to exert
significant control over matters subject to shareholder approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roivant&#146;s founder and certain of our largest shareholders
are expected to hold approximately 77.7% of our common shares following the Business Combination (assuming no MAAC Class A Shares are redeemed). As a result, these holders will have the ability to substantially influence Roivant and exert
significant control through this ownership position and, in the case of certain holders, service on Roivant&#146;s board of directors. For example, these holders may be able to control elections of directors, issuance of equity, including to
Roivant&#146;s employees under equity incentive plans, amendments of Roivant&#146;s organizational documents, or approval of any merger, amalgamation, sale of assets or other major corporate transaction. These holders&#146; interests may not always
coincide with Roivant&#146;s corporate interests or the interests of other shareholders, and it may exercise its voting and other rights in a manner with which you may not agree or that may not be in the best interests of Roivant&#146;s other
shareholders. So long as these holders continue to own a significant amount of Roivant&#146;s equity, they will continue to be able to strongly influence and effectively control Roivant&#146;s decisions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales and issuances of our or the Vants&#146; equity securities or rights to purchase equity securities, including pursuant to our or the
Vants&#146; equity incentive and other compensatory plans, will result in additional dilution of the percentage ownership of our shareholders and could cause our share price to fall. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the Vants will need additional capital in the future to continue our planned operations. To the extent we raise additional capital by
issuing equity securities, including in our subsidiaries, our shareholders may experience substantial dilution. We or the Vants may sell common shares, convertible securities or other equity securities in one or more transactions at prices and in a
manner we determine from time to time. If we sell common shares, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. In addition, new investors could gain rights
superior to our existing shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our 2021 Equity Incentive Plan (the &#147;2021 EIP&#148;), we are authorized to grant
options and other share-based awards to our employees, directors and consultants. The aggregate number of shares initially </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reserved for issuance under the 2021 EIP will be increased annually on the first day of each fiscal year during the term of the plan in an amount equal to the lesser of (i) 5% of the number of
Roivant Common Shares outstanding as of the day of the immediately preceding fiscal year and (ii)&nbsp;such number of Roivant Common Shares as determined by our board of directors in its discretion. As a result of this annual increase, or if our
board of directors elects in the future to make any additional increase in the number of shares available for future grant under the 2021 EIP, and if our shareholders approve of any such additional increase, our shareholders may experience
additional dilution, and our share price may fall. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Issuance of options and other share-based awards pursuant to equity incentive plans at
the Vants may indirectly have a similar effect of diluting your ownership in Roivant since a portion of the value of Roivant Common Shares is tied to the value of the Vants, which would be diluted in the event of a grant of options or other similar
equity grants to the employees of the Vants. &nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities analysts do not publish research or reports about our business
or if they publish negative evaluations of our shares, the price of our shares could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for
Roivant&#146;s securities will be influenced by the research and reports that industry or securities analysts may publish about Roivant, its business, market or competitors. Securities and industry analysts do not currently, and may never, publish
research on Roivant. If no securities or industry analysts commence coverage of Roivant, Roivant&#146;s share price and trading volume would likely be negatively impacted. If any of the analysts who may cover Roivant change their recommendation
regarding Roivant Common Shares adversely, or provide more favorable relative recommendations about its competitors, the price of Roivant Common Shares would likely decline. If any analyst who may cover Roivant were to cease coverage or fail to
regularly publish reports, Roivant could lose visibility in the financial markets, which in turn could cause its share price or trading volume to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Roivant&#146;s founder and certain of our largest shareholders will own a substantial portion of our common shares. As a result, there may
be&nbsp;limited&nbsp;liquidity&nbsp;for our common shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roivant&#146;s founder and certain of our largest shareholders are
expected to hold approximately 77.7% of our common shares following the Business Combination (assuming no MAAC Class A Shares are redeemed). Such shareholders are subject to the <FONT STYLE="white-space:nowrap">lock-ups</FONT> described elsewhere in
this prospectus, and as a result there may initially be limited liquidity in the trading market for our common shares. In addition, even once the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> periods expire, the liquidity for our common
shares may remain limited given the substantial holdings of such shareholders, which could make the price of our common shares more volatile and may make it more difficult for investors to buy or sell large amounts of our common shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because there are no current plans to pay cash dividends on Roivant Common Shares for the foreseeable future, you may not receive any return on
investment unless you sell Roivant Common Shares for a price greater than that which you paid for it. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roivant may retain future
earnings, if any, for future operations, expansion and debt repayment and has no current plans to pay any cash dividends for the foreseeable future. Any decision to declare and pay dividends as a public company in the future will be made at the
discretion of Roivant&#146;s board of directors and will depend on, among other things, Roivant&#146;s results of operations, financial condition, cash requirements, contractual restrictions, applicable law and other factors that Roivant&#146;s
board of directors may deem relevant. In addition, Roivant&#146;s ability to pay dividends may be limited by covenants of any existing and future outstanding indebtedness it or its subsidiaries incur. As a result, you may not receive any return on
an investment in Roivant Common Shares unless you sell your shares of for a price greater than that which you paid for it. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an exempted company limited by shares incorporated under the laws of Bermuda and following the
completion of the Business Combination it may be difficult for you to enforce judgments against us or our directors and executive officers. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an exempted company limited by shares incorporated under the laws of Bermuda. As a result, the rights of our shareholders following the
completion of the Business Combination will be governed by Bermuda law and our memorandum of association and proposed bye-laws. The rights of shareholders under Bermuda law may differ from the rights of shareholders of companies incorporated in
another jurisdiction. It may be difficult for investors to enforce in the U.S. judgments obtained in U.S. courts against us based on the civil liability provisions of the U.S. securities laws. It is doubtful whether courts in Bermuda will enforce
judgments obtained in other jurisdictions, including the U.S., against us or our directors or officers under the securities laws of those jurisdictions or entertain actions in Bermuda against us or our directors or officers under the securities laws
of other jurisdictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bermuda law differs from the laws in effect in the U.S. and may afford less protection to our shareholders. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are incorporated under the laws of Bermuda. As a result, our corporate affairs are governed by the Bermuda Companies Act 1981, as amended,
(the &#147;Companies Act&#148;) which differs in some material respects from laws typically applicable to U.S. corporations and shareholders, including the provisions relating to interested directors, amalgamations, mergers and acquisitions,
takeovers, shareholder lawsuits and indemnification of directors. Generally, the duties of directors and officers of a Bermuda company are owed to the company only. Shareholders of Bermuda companies typically do not have rights to take action
against directors or officers of the company and may only do so in limited circumstances. Shareholder class actions are not available under Bermuda law. The circumstances in which shareholder derivative actions may be available under Bermuda law are
substantially more proscribed and less clear than they would be to shareholders of U.S. corporations. The Bermuda courts, however, would ordinarily be expected to permit a shareholder to commence an action in the name of a company to remedy a wrong
to the company where the act complained of is alleged to be beyond the corporate power of the company or illegal or would result in the violation of the company&#146;s memorandum of association or <FONT STYLE="white-space:nowrap">bye-laws.</FONT>
Furthermore, consideration would be given by a Bermuda court to acts that are alleged to constitute a fraud against the minority shareholders or, for instance, where an act requires the approval of a greater percentage of the company&#146;s
shareholders than those who actually approved it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When the affairs of a company are being conducted in a manner that is oppressive or
prejudicial to the interests of some shareholders, one or more shareholders may apply to the Supreme Court of Bermuda, which may make such order as it sees fit, including an order regulating the conduct of the company&#146;s affairs in the future or
ordering the purchase of the shares of any shareholders by other shareholders or by the company. Additionally, under our proposed <FONT STYLE="white-space:nowrap">bye-laws</FONT> that will be in effect from the completion of the Business
Combination, and as permitted by Bermuda law, each shareholder will waive any claim or right of action against our directors or officers for any action taken by directors or officers in the performance of their duties, except for actions involving
fraud or dishonesty. In addition, the rights of our shareholders and the fiduciary responsibilities of our directors under Bermuda law are not as clearly established as under statutes or judicial precedent in existence in jurisdictions in the U.S.,
particularly the State of Delaware. Therefore, following the completion of the Business Combination, our shareholders may have more difficulty protecting their interests than would shareholders of a corporation incorporated in a jurisdiction within
the U.S. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There are regulatory limitations on the ownership and transfer of our common shares. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Common shares may be offered or sold in Bermuda only in compliance with the provisions of the Companies Act and the Bermuda Investment Business
Act 2003, which regulates the sale of securities in Bermuda. In addition, the Bermuda Monetary Authority must approve all issues and transfers of shares of a Bermuda exempted company. However, the Bermuda Monetary Authority has, pursuant to its
statement of June&nbsp;1, 2005, given its general permission under the Exchange Control Act 1972 and related regulations for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issue and free transfer of our common shares to and among persons who are <FONT STYLE="white-space:nowrap">non-residents</FONT> of Bermuda for exchange control purposes as long as the shares are
listed on an appointed stock exchange, which includes Nasdaq. Additionally, we have sought and have obtained a specific permission from the Bermuda Monetary Authority for the issue and transfer of our common shares up to the amount of our authorized
capital from time to time, and options, warrants, depository receipts, rights, loan notes, debt instruments and our other securities to persons resident and <FONT STYLE="white-space:nowrap">non-resident</FONT> for exchange control purposes with the
need for prior approval of such issue or transfer. The general permission or the specific permission would cease to apply if we were to cease to be listed on the Nasdaq or another appointed stock exchange. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legislation enacted in Bermuda as to economic substance may affect our operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Economic Substance Act 2018 of Bermuda, as amended (the &#147;Economic Substance Act&#148;) that came into force on
January&nbsp;1, 2019, a registered entity other than an entity which is resident for tax purposes in certain jurisdictions outside Bermuda (a <FONT STYLE="white-space:nowrap">&#147;non-resident</FONT> entity&#148;) that carries on as a business any
one or more of the &#147;relevant activities&#148; referred to in the Economic Substance Act must comply with economic substance requirements. The Economic Substance Act may require <FONT STYLE="white-space:nowrap">in-scope</FONT> Bermuda entities
which are engaged in such &#147;relevant activities&#148; to be directed and managed in Bermuda, have an adequate level of qualified employees in Bermuda, incur an adequate level of annual expenditure in Bermuda, maintain physical offices and
premises in Bermuda or perform core income-generating activities in Bermuda. The list of &#147;relevant activities&#148; includes carrying on any one or more of: banking, insurance, fund management, financing, leasing, headquarters, shipping,
distribution and service centre, intellectual property and holding entities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the Economic Substance Act currently, for so long
as we are a <FONT STYLE="white-space:nowrap">non-resident</FONT> entity, we are not required to satisfy any such economic substance requirements other than providing the Bermuda Registrar of Companies annually information on the jurisdiction in
which it claims to be resident for tax purposes together with sufficient evidence to support that tax residence. We currently do not anticipate material impact on our business or operations from the Economic Substance Act. However, since such
legislation is new and remains subject to further clarification and interpretation, it is not currently possible to ascertain the precise impact of the Economic Substance Act on us. If we ceased to be a
<FONT STYLE="white-space:nowrap">non-resident</FONT> entity, we may be unable to comply with the Economic Substance Act or may have to restructure our business to comply with the Economic Substance Act, either of which may have a material adverse
effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become subject to unanticipated tax liabilities and higher effective tax rates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are incorporated under the laws of Bermuda. We are centrally managed and controlled in the U.K., and under current U.K. tax law, a company
which is centrally managed and controlled in the U.K. is regarded as resident in the U.K. for taxation purposes. Accordingly, we expect to be subject to U.K. taxation on our income and gains, and subject to U.K.&#146;s controlled foreign company
rules, except where an exemption applies. We may be treated as a dual resident company for U.K. tax purposes. As a result, our right to claim certain reliefs from U.K. tax may be restricted, and changes in law or practice in the U.K. could result in
the imposition of further restrictions on our right to claim U.K. tax reliefs. We may also become subject to income, withholding or other taxes in certain jurisdictions by reason of our activities and operations, and it is also possible that taxing
authorities in any such jurisdictions could assert that we are subject to greater taxation than we currently anticipate. Any such additional tax liability could materially adversely affect our results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The intended tax effects of our corporate structure and intercompany arrangements depend on the application of the tax laws of various jurisdictions and
on how we operate our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are incorporated under the laws of Bermuda. We currently have subsidiaries in the U.S., U.K.,
Switzerland, China and certain other jurisdictions. If we succeed in growing our business, we expect to conduct increased operations through our subsidiaries in various countries and tax jurisdictions, in part through intercompany service agreements
between our subsidiaries and us. In that case, our corporate structure and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
intercompany transactions, including the manner in which we develop and use our intellectual property, will be organized so that we can achieve our business objectives in a tax-efficient manner
and in compliance with applicable transfer pricing rules and regulations. If two or more affiliated companies are located in different countries or tax jurisdictions, the tax laws and regulations of each country generally will require that transfer
prices be the same as those between unrelated companies dealing at arm&#146;s length and that appropriate documentation be maintained to support the transfer prices. While we believe that we operate in compliance with applicable transfer pricing
laws and intend to continue to do so, our transfer pricing procedures are not binding on applicable taxing authorities. If taxing authorities in any of these countries were to successfully challenge Roivant&#146;s transfer prices as not reflecting
arm&#146;s length transactions, they could require it to adjust its transfer prices and thereby reallocate its income to reflect these revised transfer prices, which could result in a higher tax liability to Roivant. In addition, if the country from
which the income is reallocated does not agree with the reallocation, both countries could tax the same income, resulting in double taxation. If taxing authorities were to allocate income to a higher tax jurisdiction, subject Roivant&#146;s income
to double taxation or assess interest and penalties, it would increase its consolidated tax liability, which could adversely affect Roivant&#146;s financial condition, results of operations and cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant judgment is required in evaluating our tax positions and determining our provision for income taxes. During the ordinary course of
business, there are many transactions and calculations for which the ultimate tax determination is uncertain. For example, our effective tax rates could be adversely affected by changes in foreign currency exchange rates or by changes in the
relevant tax, accounting, and other laws, regulations, principles, and interpretations. As we intend to operate in numerous countries and taxing jurisdictions, the application of tax laws can be subject to diverging and sometimes conflicting
interpretations by tax authorities of these jurisdictions. It is not uncommon for taxing authorities in different countries to have conflicting views, for instance, with respect to, among other things, the manner in which the arm&#146;s length
standard is applied for transfer pricing purposes, or with respect to the valuation of intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, tax laws are
dynamic and subject to change as new laws are passed and new interpretations of the law are issued or applied. We continue to assess the impact of such changes in tax laws and interpretations on our business and may determine that changes to our
structure, practice, tax positions or the manner in which we conduct our business are necessary in light of such changes and developments in the tax laws of other jurisdictions in which we operate. Such changes may nevertheless be ineffective in
avoiding an increase in our consolidated tax liability, which could adversely affect our financial condition, results of operations and cash flows. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in our effective tax rate may reduce our net income in future periods. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our tax position could be adversely impacted by changes in tax rates, tax laws, tax practice, tax treaties or tax regulations or changes in the
interpretation thereof by the tax authorities in Europe (including the U.K. and Switzerland), the U.S., Bermuda, China and other jurisdictions, as well as being affected by certain changes currently proposed by the Organization for Economic
Co-operation and Development and their action plan on Base Erosion and Profit Shifting. Such changes may become more likely as a result of recent economic trends in the jurisdictions in which we operate, particularly if such trends continue. If such
a situation were to arise, it could adversely impact our tax position and our effective tax rate. Failure to manage the risks associated with such changes, or misinterpretation of the laws providing such changes, could result in costly audits,
interest, penalties, and reputational damage, which could adversely affect our business, results of our operations, and our financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our actual effective tax rate may vary from our expectation and that variance may be material. A number of factors may increase our future
effective tax rates, including: (1) the jurisdictions in which profits are determined to be earned and taxed; (2) the resolution of issues arising from any future tax audits with various tax authorities; (3) changes in the valuation of our deferred
tax assets and liabilities; (4) increases in expenses not deductible for tax purposes, including transaction costs and impairments of goodwill in connection with acquisitions; (5) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
changes in the taxation of stock-based compensation; (6) changes in tax laws or the interpretation of such tax laws, and changes in U.S. generally accepted accounting principles; and (7)
challenges to the transfer pricing policies related to our structure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. holders that own 10% or more of the combined voting power or value of
our common shares may suffer adverse tax consequences because we and our non-U.S. subsidiaries may be characterized as &#147;controlled foreign corporations&#148; (&#147;CFCs&#148;), under Section 957(a) of the Code. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A non-U.S. corporation is considered a CFC if more than 50% of (1) the total combined voting power of all classes of stock of such corporation
entitled to vote, or (2) the total value of the stock of such corporation, is owned, or is considered as owned by applying certain constructive ownership rules, by U.S. shareholders (U.S. persons who own stock representing 10% or more of the
combined voting power or value of all outstanding stock of such non-U.S. corporation) on any day during the taxable year of such non-U.S. corporation. Certain U.S. shareholders of a CFC generally are required to include currently in gross income
such shareholders&#146; share of the CFC&#146;s &#147;Subpart F income&#148;, a portion of the CFC&#146;s earnings to the extent the CFC holds certain U.S. property, and a portion of the CFC&#146;s &#147;global intangible low-taxed income&#148; (as
defined under Section 951A of the Code). Such U.S. shareholders are subject to current U.S. federal income tax with respect to such items, even if the CFC has not made an actual distribution to such shareholders. &#147;Subpart F income&#148;
includes, among other things, certain passive income (such as income from dividends, interests, royalties, rents and annuities or gain from the sale of property that produces such types of income) and certain sales and services income arising in
connection with transactions between the CFC and a person related to the CFC. &#147;Global intangible low-taxed income&#148; may include most of the remainder of a CFC&#146;s income over a deemed return on its tangible assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that we will not be classified as a CFC in the current taxable year. However, it is possible that our non-U.S. subsidiaries could
be classified as CFCs in the current taxable year. For U.S. holders who hold 10% or more of the combined voting power or value of our common shares, this may result in adverse U.S. federal income tax consequences, such as current U.S. taxation of
Subpart F income (regardless of whether we make any distributions), taxation of amounts treated as global intangible low-taxed income under Section 951A of the Code with respect to such shareholder, and being subject to certain reporting
requirements with the IRS. Any such U.S. holder who is an individual generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a U.S. corporation. If you are a U.S. holder who holds 10% or more of the
combined voting power or value of our common shares, you should consult your own tax advisors regarding the U.S. tax consequences of acquiring, owning, or disposing of our common shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. holders of our common shares may suffer adverse tax consequences if we are characterized as a passive foreign investment company. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, if, for any taxable year, at least 75% of our gross income is passive income, or at least 50% of the average quarterly value of our
assets is attributable to assets that produce passive income or are held for the production of passive income, including cash, we would be characterized as a passive foreign investment company (a &#147;PFIC&#148;) for U.S. federal income tax
purposes. For purposes of these tests, passive income generally includes dividends, interest, gains from the sale or exchange of investment property and rents and royalties other than rents and royalties which are received from unrelated parties in
connection with the active conduct of a trade or business. Additionally, a look-through rule generally applies with respect to 25% or more owned subsidiaries. If we are characterized as a PFIC, U.S. holders of our common shares may suffer adverse
tax consequences, including having gains realized on the sale of our common shares treated as ordinary income rather than capital gain, the loss of the preferential tax rate applicable to dividends received on our common shares by individuals who
are U.S. holders, and having interest charges apply to certain distributions by us and the proceeds of sales or other dispositions of our common shares that result in a gain to the U.S. holder. In addition, special information reporting may be
required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our status as a PFIC will depend on the nature and composition of our income and the nature, composition and value of our
assets from time to time. The 50% passive asset test described above is generally based on the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fair market value of each asset. If we are a CFC (determined by disregarding certain downward attribution rules) and not publicly traded for the relevant taxable year, however, the test shall be
applied based on the adjusted basis of our assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recently adopted Treasury regulations (the &#147;New Regulations&#148;), modify
certain of the rules described above. Such modifications include, for example, permitting asset value to be determined more frequently than on a quarterly basis and treating a non-U.S. corporation as publicly traded for a taxable year if the stock
of such corporation is publicly traded, other than in de minimis quantities, for at least twenty trading days during such taxable year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The New Regulations generally apply to taxable years of shareholders beginning on or after January 14, 2021. A shareholder, however, may
choose to apply such rules for any open taxable year beginning before January 14, 2021, provided that, with respect to a non-U.S. corporation being tested for PFIC status, the shareholder consistently applies certain of the provisions of the New
Regulations and certain other Treasury regulations for such year and all subsequent years. Investors who are U.S. holders should consult their own tax advisors regarding the impact and applicability of the New Regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are considered &#147;publicly traded&#148; for the current taxable year that ends on March 31, 2022 (i.e., the Business Combination
closes within such current taxable year and Roivant Common Shares are publicly traded, other than in de minimis quantities, for at least twenty days during the current taxable year) we would apply the 50% passive asset test using the fair market
value of our assets. This determination, however, is subject to uncertainty. In addition, our status may also depend, in part, on how quickly we utilize our cash on-hand and cash from future financings in our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the foregoing, with respect to the taxable year that ended on March 31, 2021, we believe that we were not a PFIC (based in part on
our belief that we were not classified as a CFC in the taxable year that ended on March 31, 2021) and presently do not anticipate that we will be a PFIC based upon the expected value of our assets, including any goodwill and intangible property, and
the expected nature and composition of our income and assets. However, our status as a PFIC is a fact-intensive determination made on an annual basis, and we cannot provide any assurances regarding our PFIC status for the current or future taxable
years. Our U.S. counsel expresses no opinion with respect to our PFIC status for the current or future taxable years. We will determine our PFIC status for each taxable year and make such determination available to U.S. holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have implemented structures and arrangements intended to mitigate the possibility that we will be classified as a PFIC. There can be no
assurance that the IRS will not successfully challenge these structures and arrangements, which may result in an adverse impact on the determination of whether we are classified as a PFIC in the current and future taxable years. In addition,
recently finalized U.S. Treasury regulations, of which we are continuing to assess the impact, may also adversely affect the treatment of these structures and arrangements with respect to our PFIC status. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_11"></A>SPECIAL MEETING OF MAAC STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC is furnishing this
proxy statement/prospectus to its stockholders as part of the solicitation of proxies by the MAAC board of directors for use at the MAAC Special Meeting to be held on September 28, 2021 and at any adjournment or postponement thereof. This proxy
statement/prospectus is first being furnished to MAAC&#146;s stockholders on or about August 13, 2021 in connection with the vote on the proposals described in this proxy statement/prospectus. This proxy statement/prospectus provides MAAC&#146;s
stockholders with information they need to know to be able to vote or direct their vote to be cast at the MAAC Special Meeting. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Date, Time and
Place </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MAAC Special Meeting will be held on September 28, 2021, at 10:00 a.m., Eastern Time, via a virtual meeting. In light of
COVID-19 pandemic and to support the well-being of MAAC&#146;s stockholders and employees, the MAAC Special Meeting will be completely virtual. MAAC stockholders may attend the MAAC Special Meeting and vote their shares electronically during the
meeting via live audio webcast by visiting https://www.cstproxy.com/montesarchimedes/2021. MAAC Stockholders will need the control number that is printed on their proxy card to enter the MAAC Special Meeting. MAAC recommends that stockholders log in
at least 15 minutes before the meeting to ensure they are logged in when the MAAC Special Meeting starts. MAAC stockholders will not be able to attend the MAAC Special Meeting in person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Purpose of MAAC Special Meeting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC
stockholders are being asked to consider and vote upon: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Business Combination Proposal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Nasdaq Proposal; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Adjournment Proposal (if necessary). </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Power; Record Date </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You will
be entitled to vote or direct votes to be cast at the MAAC Special Meeting if you owned MAAC Shares at the close of business on August 10, 2021, which is the record date for the MAAC Special Meeting. You are entitled to one vote for each MAAC Share
that you owned as of the close of business on the MAAC record date. If your shares are held in &#147;street name&#148; through a broker, bank or other nominee, your broker, bank or other nominee will send you separate instructions describing the
procedure for voting your shares. On the MAAC record date, there were 51,339,779 MAAC Shares outstanding. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote of the MAAC Sponsor and
MAAC&#146;s Directors and Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MAAC Sponsor has agreed to vote any MAAC Class B Shares, and any MAAC Class&nbsp;A Shares held
by it as of the record date, in favor of the Business Combination Proposal. Further, the MAAC Sponsor intends to vote in favor of all of the proposals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MAAC Sponsor has waived any redemption rights in connection with Business Combination. The MAAC Class B Shares held by the MAAC Sponsor
has no redemption rights upon MAAC&#146;s liquidation and will be worthless if no business combination is effected by MAAC by October&nbsp;9, 2022. However, the MAAC Sponsor is entitled to redemption rights upon MAAC&#146;s liquidation with respect
to any MAAC Class&nbsp;A Shares it may own. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MAAC Sponsor owns 10,167,956 MAAC Class B Shares as of the record date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quorum and Required Vote for Proposals for the MAAC Special Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A quorum of MAAC stockholders is necessary to hold a valid meeting. A quorum will be present at the MAAC Special Meeting if a majority of the
outstanding MAAC Shares as of the MAAC record date at the MAAC Special Meeting is represented virtually or by proxy. Abstentions and broker non-votes will be counted as present for the purpose of determining a quorum. The holders of the MAAC Class B
Shares, who currently own 20% of the issued and outstanding MAAC Shares, will count towards this quorum. As of the MAAC record date for the MAAC Special Meeting, 25,669,890 MAAC Shares would be required to achieve a quorum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval of the Business Combination Proposal requires that the initial Business Combination be approved by the affirmative vote of the
holders of a majority of MAAC Shares outstanding as of the date of the stockholder meeting held to consider such initial Business Combination. Approval of the Nasdaq Proposal requires the affirmative vote of a majority of MAAC Shares present in
person or represented by proxy at the MAAC Special Meeting and entitled to vote at the meeting. Approval of the Adjournment Proposal requires the affirmative vote of a majority of shares present in person or represented by proxy at the MAAC Special
Meeting and entitled to vote thereon, regardless of whether a quorum is present. The MAAC board of directors has approved each of the proposals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If MAAC stockholders fail to approve the Business Combination Proposal or the Nasdaq Proposal, then the Business Combination will not occur.
The Business Combination is not conditioned upon the Adjournment Proposal. It is important for you to note that, in the event that the Business Combination Proposal or the Nasdaq Proposal does not receive the requisite vote for approval, then the
Business Combination will not be consummated. If MAAC does not consummate the Business Combination and fails to otherwise complete a business combination by October&nbsp;9, 2022, MAAC will be required to dissolve and liquidate its Trust Account by
returning the then remaining funds in such account to the public stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recommendation of the MAAC Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>MAAC&#146;s board of directors unanimously determined that the Business Combination Agreement and the transactions contemplated thereby,
including the Merger, were advisable and in the best interests of, MAAC and its stockholders. Accordingly, MAAC&#146;s board of directors unanimously recommends that its stockholders vote &#147;</I><B><I>FOR</I></B><I>&#148; the Business Combination
Proposal, &#147;</I><B><I>FOR</I></B><I>&#148; the Nasdaq Proposal and, if required, &#147;</I><B><I>FOR</I></B><I>&#148; the Adjournment Proposal</I>.<I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When you consider the recommendation of MAAC&#146;s board of directors in favor of approval of these proposals, you should keep in mind that
MAAC&#146;s directors and officers have interests in the Business Combination that are different from or in addition to (and which may conflict with) your interests as a stockholder. These interests include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the Business Combination or another business combination is not consummated by October&nbsp;9, 2022, MAAC will
cease all operations except for the purpose of winding up, redeeming 100% of the outstanding MAAC Class&nbsp;A Shares for cash and, subject to the approval of its remaining stockholders and its board of directors, dissolving and liquidating. In such
event, the 10,167,956 MAAC Class B Shares held by the MAAC Sponsor, which were acquired for an aggregate purchase price of $25,000, would be worthless because the holders of MAAC Class B Shares are not entitled to participate in any redemption or
distribution with respect to such shares. Such shares had an estimated aggregate market value of $100,662,764.40 based upon the closing price of $9.90 per MAAC Class A Share on Nasdaq on August 5, 2021. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The MAAC Sponsor purchased an aggregate of 10,214,365 private placement warrants from MAAC for an aggregate
purchase price of $10,214,365 (or $1.00 per warrant) in a private placement. This purchase took place on a private placement basis simultaneously with the consummation of MAAC&#146;s initial public offering. A portion of the proceeds MAAC received
from this purchase was placed in the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Trust Account. Such warrants had an estimated aggregate value of $13,278,674.50 based on the closing price of $1.30 per public warrant on Nasdaq on August 5, 2021. The private placement warrants
will become worthless if MAAC does not consummate a business combination by October&nbsp;9, 2022. </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If MAAC is unable to complete a business combination within the required time period, its executive officers will
be personally liable under certain circumstances described herein to ensure that the proceeds in the Trust Account are not reduced by the claims of target businesses or claims of vendors or other entities that are owed money by MAAC for services
rendered or contracted for or products sold to MAAC. If MAAC consummates a business combination, on the other hand, MAAC will be liable for all such claims. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">MAAC&#146;s&nbsp;officers and directors, and their affiliates are entitled to reimbursement of out-of-pocket
expenses incurred by them in connection with certain activities on MAAC&#146;s behalf, such as identifying and investigating possible business targets and business combinations. However, if MAAC fails to consummate a business combination within the
required period, they will not have any claim against the Trust Account for reimbursement. Accordingly, MAAC may not be able to reimburse these expenses if the Business Combination or another business combination, are not completed by
October&nbsp;9, 2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The continued indemnification of current directors and officers and the continuation of directors&#146; and
officers&#146; liability insurance. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MAAC Placement Agents and Advisory Fees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon consummation of the closing of the purchase of the applicable securities and the Business Combination, (i)&nbsp;J.P. Morgan Securities
LLC, SVB Leerink LLC, Citigroup Global Markets Inc. and Truist Securities, Inc. (collectively, the &#147;Placement Agents&#148;) will be entitled to customary fees in connection with their role as MAAC&#146;s joint placement agents for the PIPE
Financing. If the Business Combination is not consummated, the Placement Agents will not be entitled to such fees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Abstentions and Broker Non-Votes
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a holder of MAAC Shares that attends the MAAC Special Meeting virtually and fails to vote, or if you vote abstain, your
failure to vote or abstention will have the same effect as a vote &#147;<B>AGAINST</B>&#148; the Business Combination Proposal, the Nasdaq Proposal and the Adjournment Proposal. Broker non-votes, while considered present for the purposes of
establishing a quorum, will not count as shares entitled to vote or votes cast at the MAAC Special Meeting, and otherwise will have no effect on the Nasdaq Proposal and the Adjournment Proposal. Broker non-votes will have the same effect as a vote
&#147;<B>AGAINST</B>&#148; the Business Combination Proposal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Your Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a stockholder of record of MAAC as of August 10, 2021, the record date, you may submit your proxy before the MAAC Special Meeting in
any of the following ways, if available: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">use the toll-free number shown on your proxy card; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">visit the website shown on your proxy card to vote via the Internet; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complete, sign, date and return your proxy card in the enclosed postage-paid envelope. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders who choose to participate in the MAAC Special Meeting can vote their shares electronically during the meeting via live audio
webcast by visiting https://www.cstproxy.com/montesarchimedes/2021. You will need the control number that is printed on your proxy card to enter the MAAC Special Meeting. MAAC recommends that you log in at least 15 minutes before the meeting to
ensure you are logged in when the MAAC Special Meeting starts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If your shares are held in &#147;street name&#148; through a broker, bank or other nominee,
your broker, bank or other nominee will send you separate instructions describing the procedure for voting your shares. &#147;Street name&#148; stockholders who wish to vote at the MAAC Special Meeting will need to obtain legal proxy form from their
broker, bank or other nominee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revoking Your Proxy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may change your vote at any time before your proxy is voted at the MAAC Special Meeting (provided that you do not hold your shares through
a broker, bank or other nominee). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may do this in one of two ways: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mailing a new, subsequently dated proxy card; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by attending the MAAC Special Meeting virtually and electing to vote your shares online at the meeting.
</P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any proxy that you submitted may also be revoked by submitting a new proxy by mail, or online or by telephone, not
later than 11:59 p.m., Eastern Time, on September 27, 2021, or by voting online at the MAAC Special Meeting. Simply attending the MAAC Special Meeting will not revoke your proxy. If you have instructed a broker, bank or other nominee to vote your
MAAC Shares, you must follow the directions you receive from your broker, bank or other nominee in order to change or revoke your vote. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Who Can
Answer Your Questions About Voting Your Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If have any questions about how to vote or direct a vote in respect of your MAAC
Shares, you may call , the proxy solicitation agent for MAAC, toll-free at (877) 279-2311 (banks and brokers call (212) 297-0720) or email info@okapipartners.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redemption Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a holder of
MAAC Class&nbsp;A Shares, you have the right to redeem such shares for a pro rata portion of the cash held in the Trust Account, which holds the net proceeds of MAAC&#146;s initial public offering, as of two business days prior to the consummation
of the transactions contemplated by the Business Combination Agreement (including interest earned on the funds held in the Trust Account and not previously released to MAAC to pay taxes, if any) upon the closing of the transactions contemplated by
the Business Combination Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a holder of MAAC Class&nbsp;A Shares, together with any affiliate of
such holder or any other person with whom such holder is acting in concert or as a &#147;group&#148; (as defined in Section&nbsp;13(d)(3) of the Exchange Act), will be restricted from seeking redemption with respect to more than 15% of the MAAC
Class&nbsp;A Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of the outstanding MAAC Warrants do not have redemption rights with respect to such warrants in connection
with the transactions contemplated by the Business Combination Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Pre-Closing MAAC Certificate of Incorporation, the
Business Combination may be consummated only if MAAC has at least $5,000,001 of net tangible assets after giving effect to redemptions by all holders of MAAC Class&nbsp;A Shares that properly demand redemption of their MAAC Class&nbsp;A Shares for
cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may exercise your redemption rights whether you vote your MAAC Class&nbsp;A Shares for or against, or whether you abstain from
voting on, the Business Combination Proposal or any other proposal described in this proxy statement/prospectus. As a result, the Business Combination Proposal can be approved by stockholders </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
who will redeem their MAAC Class&nbsp;A Shares and will no longer be stockholders and the Business Combination may be consummated even though the funds available from the Trust Account and the
number of public stockholders are substantially reduced as a result of redemptions by public stockholders. With fewer MAAC Class&nbsp;A Shares and public stockholders, the trading market for MAAC Class&nbsp;A Shares may be less liquid than the
market for MAAC Class&nbsp;A Shares prior to the Business Combination and MAAC may not be able to meet the listing standards of a national securities exchange, including Nasdaq. In addition, with fewer funds available from the Trust Account, the
capital infusion from the Trust Account into Roivant&#146;s business will be reduced and the amount of working capital available to Roivant following the Business Combination may be reduced. Your decision to exercise your redemption rights with
respect to MAAC Class&nbsp;A Shares will have no effect on the MAAC Warrants you may also hold. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a holder of MAAC
Class&nbsp;A Shares and wish to exercise your redemption rights, you are required to tender your share certificates or deliver your shares to the transfer agent electronically using The Depository Trust Company&#146;s DWAC (Deposit/Withdrawal at
Custodian) system, at your option, in each case no later than two business days prior to the initially scheduled vote to approve the Business Combination. Accordingly, you have until two days prior to the initial vote on the Business Combination to
tender your shares if you wish to exercise your redemption rights. Given the relatively short period in which to exercise redemption rights, it is advisable for you to use electronic delivery of your shares. If you exercise your redemption right,
your shares will be redeemed for a pro rata portion of the amount then in the Trust Account (which, for illustrative purposes, was $410,769,443.71, or $10.00 per share, as of August 5, 2021). Such amount, including interest earned on the funds held
in the Trust Account and not previously released to MAAC to pay its taxes, if any, will be paid promptly upon consummation of the Business Combination. However, under Delaware law, the proceeds held in the Trust Account could be subject to claims
that could take priority over those of MAAC&#146;s public stockholders exercising redemption rights, regardless of whether such holders vote for or against the Business Combination Proposal. The per share distribution from the Trust Account in such
a situation may be less than originally anticipated due to such claims. Your vote on any proposal other than the Business Combination Proposal will have no impact on the amount you will receive if you exercise your redemption rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC&#146;s transfer agent can be contacted at the following address: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Continental Stock Transfer&nbsp;&amp; Trust Company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">One State Street, 30th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New
York, NY 10004 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn: Mark Zimkind </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email: mzimkind@continentalstock.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any request for redemption, once made by a holder of MAAC Class&nbsp;A Shares, may be withdrawn at any time up to two days prior to the vote
on the Business Combination Proposal at the MAAC Special Meeting. If you deliver your shares for redemption to MAAC&#146;s transfer agent and later decide, prior to the MAAC Special Meeting, not to redeem your shares, you may request that
MAAC&#146;s transfer agent return the shares electronically. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No demand will be effectuated unless the holder&#146;s MAAC Class&nbsp;A
Shares have been delivered electronically to the transfer agent prior to the vote on the Business Combination Proposal at the MAAC Special Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a holder of MAAC Class&nbsp;A Shares properly makes a request for redemption and the MAAC Class&nbsp;A Shares are delivered to MAAC&#146;s
transfer agent no later than two business days prior to the initially scheduled vote to approve the Business Combination, then, if the Business Combination is consummated, MAAC will redeem these shares for a pro rata portion of funds deposited in
the Trust Account. If you exercise your redemption rights, then you will be exchanging your MAAC Class&nbsp;A Shares for cash. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a discussion of the material U.S. federal income tax considerations for holders of MAAC
Class&nbsp;A Shares with respect to the exercise of these redemption rights, see &#147;Material United States Tax Considerations&#151;Tax Consequences of a Redemption of MAAC Public Shares.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Appraisal Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Appraisal rights are
not available to holders of MAAC Shares in connection with the Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Proxy Solicitation Costs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC is soliciting proxies on behalf of its board of directors. This solicitation is being made by mail but also may be made by telephone. MAAC
and its directors, officers and employees may also solicit proxies online. MAAC will file with the SEC all scripts and other electronic communications as proxy soliciting materials. MAAC will bear the cost of the solicitation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC has hired Okapi Partners LLC to assist in the proxy solicitation process. MAAC will pay to Okapi Partners LLC a fee of $19,500, plus
disbursements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC will ask banks, brokers and other institutions, nominees and fiduciaries to forward the proxy materials to their
principals and to obtain their authority to execute proxies and voting instructions. MAAC will reimburse them for their reasonable expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_12"></A>MATERIAL UNITED STATES TAX CONSIDERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion is a description of material U.S. federal income tax considerations to U.S. Holders (as defined below) of MAAC
Class&nbsp;A Shares or MAAC Warrants (each, a &#147;MAAC Security&#148;), the Roivant Common Shares and/or Roivant Warrants, as the case may be, as a consequence of (i)&nbsp;electing to have their MAAC Class&nbsp;A Shares redeemed for cash if the
Merger is completed, (ii)&nbsp;the Merger, and (iii)&nbsp;the ownership and disposition of Roivant Common Shares or Roivant Warrants after the Merger. Based upon and subject to the assumptions, qualifications and limitations set forth herein and in
the opinions filed as Exhibits 8.2 and 8.3, respectively, to this Registration Statement, the statements of law and legal conclusions set forth below represent the opinion of Davis Polk &amp; Wardwell LLP, except for the statements of law and legal
conclusions under the headings &#147;Tax Consequences of Exercising Redemption Rights,&#148; &#147;Tax Consequences of the Merger&#148; and &#147;Additional Requirements for Tax Deferral,&#148; which represent the opinion of Kirkland &amp; Ellis
LLP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion applies only to a U.S. Holder that holds MAAC Securities, the Roivant Common Shares and/or Roivant Warrants, as the
case may be, as capital assets for U.S. federal income tax purposes (generally, property held for investment). In addition, it does not describe all of the U.S. federal income tax consequences that may be relevant in light of a U.S. Holder&#146;s
particular circumstances, including any alternative minimum tax considerations, the potential application of the provisions of the Code known as the Medicare contribution tax and tax considerations applicable to U.S. Holders subject to special
rules, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dealers or traders in securities that use
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of tax accounting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding MAAC Securities, the Roivant Common Shares and/or Roivant Warrants, as the case may be, as part
of a straddle, wash sale, hedging transaction, conversion transaction or integrated transaction or entering into a constructive sale with respect to such securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons whose functional currency for U.S. federal income tax purposes is not the U.S. dollar;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that are subject to the &#147;applicable financial statement&#148; rules under Section&nbsp;451(b) of the
Code; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">entities classified as partnerships for U.S. federal income tax purposes and their partners;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> entities, &#147;individual retirement accounts&#148; or
&#147;Roth IRAs&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons actually or constructively owning five percent (measured by vote or value) or more of MAAC Class&nbsp;A
shares, or, following the Merger, Roivant Common Shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons owning shares in connection with a trade or business conducted outside of the United States;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who purchase MAAC Class&nbsp;A Shares as part of the PIPE Financing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who acquire MAAC Class&nbsp;A Shares or, following the Merger, Roivant Common Shares pursuant to an
exercise of employee share options, in connection with employee share incentive plans or otherwise as compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons subject to special tax accounting rules as a result of any item of gross income with respect to MAAC
Securities, Roivant Common Shares, or Roivant Warrants, as the case may be, being taken into account in an applicable financial statement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">founders, sponsors, officers or directors of MAAC or holders of private placement warrants.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership (or other entity that is classified as a partnership for U.S. federal income tax purposes) holds MAAC
Securities, the Roivant Common Shares and/or Roivant Warrants, as the case may be, the tax treatment of a partner in such partnership will generally depend upon the status of the partner and the activities of the partnership. Partnerships holding
MAAC Securities, the Roivant Common Shares and/or Roivant Warrants and partners in such partnerships should consult their tax advisor as to the particular tax consequences of the exercise of redemption rights with respect to MAAC Class&nbsp;A
Shares, the Merger and/or the ownership and disposition of Roivant Common Shares or Roivant Warrants by the partnership. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used here in, a &#147;U.S. Holder&#148; is a person that for U.S. federal income tax
purposes is a beneficial owner of MAAC Securities, Roivant Common Shares and/or Roivant Warrants, as the case may be, and: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a citizen or individual resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United
States, any state therein or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust that (1)&nbsp;is subject to the primary supervision of a U.S. court and the control of one or more
&#147;United States persons&#148; (within the meaning of Section&nbsp;7701(a)(30) of the Code) or (2)&nbsp;has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is based on the Code, administrative pronouncements, judicial decisions, and final, temporary and proposed Treasury
regulations, all as of the date hereof, and of which is subject to change, possibly with retroactive effect. We have not sought, and will not seek, a ruling from the IRS as to any U.S. federal income tax consequences described herein. The IRS may
disagree with the discussion herein, and its determination may be upheld by a court. Moreover, there can be no assurance that future legislation, regulations, administrative rulings or court decisions will not adversely affect the accuracy of the
statements in this discussion. This discussion does not address any U.S. federal taxes (such as estate or gift taxes) other than income taxes, nor does it address any state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax
considerations. U.S. Holders should consult their tax advisors concerning the U.S. federal, state, local and foreign tax consequences of (i)&nbsp;electing to have their MAAC Class&nbsp;A Shares redeemed for cash if the Merger is completed,
(ii)&nbsp;the Merger, and (iii)&nbsp;the ownership and disposition of Roivant Common Shares or Roivant Warrants after the Merger in their particular circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>EACH U.S. HOLDER SHOULD CONSULT ITS TAX ADVISOR WITH RESPECT TO THE PARTICULAR TAX CONSEQUENCES TO SUCH HOLDER OF (I) ELECTING TO HAVE ITS
MAAC CLASS A SHARES REDEEMED FOR CASH IF THE MERGER IS COMPLETED, (II) THE MERGER AND (III) THE OWNERSHIP AND DISPOSITION OF ROIVANT COMMON SHARES OR ROIVANT WARRANTS AFTER THE MERGER.</B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Treatment of Roivant as a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Corporation for U.S. Federal Income Tax Purposes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under current U.S. federal income tax law, a corporation generally will be considered to be a U.S. corporation for U.S. federal income tax
purposes only if it is created or organized in the United States or under the law of the United States or of any State. Accordingly, under generally applicable U.S. federal income tax rules, Roivant, which is not created or organized in the United
States or under the law of the United States or of any State but is instead a Bermuda incorporated entity and tax resident of the UK, would generally be classified as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation. Section&nbsp;7874
of the Code and the Treasury regulations promulgated thereunder, however, contain specific rules (more fully discussed below) that may cause a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation to be treated as a U.S. corporation for U.S.
federal income tax purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Section&nbsp;7874 rules are complex and require analysis of all relevant facts, and there is limited
guidance as to their application. Under Section&nbsp;7874 of the Code, a corporation created or organized outside the United States (i.e., a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation) will nevertheless be treated as a U.S.
corporation for U.S. federal income tax purposes (and, therefore, be subject to U.S. federal income tax on its worldwide income) if (1)&nbsp;the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation directly or indirectly acquires
substantially all of the assets held directly or indirectly by a U.S. corporation (including through the acquisition of all of the outstanding stock of the U.S. corporation), (2) the <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
corporation&#146;s &#147;expanded affiliated group&#148; does not have substantial business activities in the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation&#146;s country of organization or incorporation relative to the expanded
affiliated group&#146;s worldwide activities, and (3)&nbsp;the shareholders of the acquired U.S. corporation before the acquisition hold at least 80% (by either vote or value) of the shares of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
acquiring corporation after the acquisition by reason of holding shares in the acquired U.S. corporation (the &#147;Ownership Test&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the complex rules for determining share ownership under Section&nbsp;7874 of the
Code and certain factual assumptions, Roivant expects that former MAAC stockholders will be treated as holding less than 80% (by both vote and value) of Roivant by reason of their former ownership of MAAC Shares, and therefore Roivant does not
expect to satisfy the Ownership Test. As a result, Roivant believes, and the remainder of this discussion assumes that, it will not be treated as a U.S. corporation for U.S. federal income tax purposes under Section&nbsp;7874 of the Code. However,
whether the Ownership Test has been satisfied must be finally determined after the completion of the Business Combination, by which time there could be adverse changes to the relevant facts and circumstances. Furthermore, the interpretation of
Treasury regulations relating to the Ownership Test is subject to uncertainty, and there is limited guidance regarding their application. In addition, changes to the rules in Section&nbsp;7874 of the Code or the Treasury regulations promulgated
thereunder, or other changes in law, could adversely affect Roivant&#146;s status as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entity for U.S. federal income tax purposes. Accordingly, there can be no assurance that the IRS will not take a
contrary position to those of Roivant described above or that a court would not agree with a contrary position taken by the IRS in the event of litigation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If it were determined that Roivant is treated as a U.S. corporation for U.S. federal income tax purposes under Section&nbsp;7874 of the Code
and the Treasury regulations promulgated thereunder, Roivant would be liable for U.S. federal income tax on its income in the same manner as any other U.S. corporation, and U.S. Holders of the Roivant Common Shares and Roivant Warrants would be
treated as holders of stock and warrants of a U.S. corporation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax Consequences of Exercising Redemption Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below under the heading &#147;&#151;Tax Consequences of the Merger,&#148; the U.S. federal income tax consequences to
a U.S. Holder of MAAC Class&nbsp;A Shares that exercises its redemption rights to receive cash from the trust account in exchange for all or a portion of its MAAC Class&nbsp;A Shares will depend on whether the redemption qualifies as a sale of the
MAAC Class&nbsp;A Shares redeemed under Section&nbsp;302 of the Code or is treated as a distribution under Section&nbsp;301 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Treatment of Redemptions</I>. The redemption of MAAC Class&nbsp;A Shares generally qualifies as a sale of the MAAC Class&nbsp;A Shares
redeemed if such redemption (i)&nbsp;is &#147;substantially disproportionate&#148; with respect to the redeeming U.S. Holder, (ii)&nbsp;results in a &#147;complete termination&#148; of such U.S. Holder&#146;s interest in MAAC or (iii)&nbsp;is
&#147;not essentially equivalent to a dividend&#148; with respect to such U.S. Holder. These tests are explained more fully below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
purposes of such tests, a U.S. Holder takes into account not only MAAC Shares actually owned by such U.S. Holder, but also MAAC Shares that are constructively owned by such U.S. Holder. A redeeming U.S. Holder may constructively own, in addition to
MAAC Class&nbsp;A Shares owned directly, MAAC Shares owned by certain related individuals and entities in which such U.S. Holder has an interest or that have an interest in such U.S. Holder, as well as any MAAC Class&nbsp;A Shares such U.S. Holder
has a right to acquire by exercise of an option, which would generally include MAAC Class&nbsp;A Shares which could be acquired pursuant to the exercise of the MAAC Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The redemption of MAAC Class&nbsp;A Shares generally will be &#147;substantially disproportionate&#148; with respect to a redeeming U.S.
Holder if the percentage of MAAC&#146;s outstanding voting shares that such U.S. Holder actually or constructively owns immediately after the redemption is less than 80&nbsp;percent of the percentage of MAAC&#146;s outstanding voting shares that
such U.S. Holder actually or constructively owned immediately before the redemption, and such U.S. Holder immediately after the redemption actually and constructively owned less than 50&nbsp;percent of the total combined voting power of MAAC Shares.
There will be a complete termination of such U.S. Holder&#146;s interest if either (i)&nbsp;all of the MAAC Shares actually or constructively owned by such U.S. Holder are redeemed or (ii)&nbsp;all of the MAAC Shares actually owned by such U.S.
Holder are redeemed and such U.S. Holder is eligible to waive, and effectively waives in accordance with specific rules, the attribution of MAAC Shares owned by certain family members and such U.S. Holder does not constructively own any other MAAC
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Shares (including any stock constructively owned by the U.S. Holder as a result of owning warrants). The redemption of MAAC Class&nbsp;A Shares will not be essentially equivalent to a dividend if
it results in a &#147;meaningful reduction&#148; of such U.S. Holder&#146;s proportionate interest in MAAC. Whether the redemption will result in a &#147;meaningful reduction&#148; in such U.S. Holder&#146;s proportionate interest in MAAC will
depend on the particular facts and circumstances applicable to it. The IRS has indicated in a published ruling that even a small reduction in the proportionate interest of a small minority shareholder in a publicly held corporation who exercises no
control over corporate affairs may constitute such a &#147;meaningful reduction.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If none of the above tests is satisfied, a
redemption will be treated as a distribution and the tax effects will be as described under &#147;&#151;Taxation of Redemptions Treated as Distributions&#148; below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Taxation of Redemptions Treated as Distributions.</I><I></I>&nbsp;A redemption treated as a distribution generally will be taxable as a
dividend for U.S. federal income tax purposes to the extent paid from MAAC&#146;s current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions in excess of MAAC&#146;s current and accumulated
earnings and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the U.S. Holder&#146;s adjusted tax basis in its MAAC Class&nbsp;A Shares. Any remaining excess will be treated as gain realized on
the sale or other disposition of the MAAC Class&nbsp;A Shares and will be treated as described under &#147;&#151;Taxation of Gain or Loss on Redemptions Treated as a Sale or Exchange of MAAC Class&nbsp;A Shares&#148; below. Amounts treated as
dividends that MAAC pays to a U.S. Holder that is treated as a taxable corporation generally qualifies for the dividends received deduction if the requisite holding period is satisfied. With certain exceptions (including, but not limited to,
dividends treated as investment income for purposes of investment interest deduction limitations), and provided certain holding period requirements are met, amounts treated as dividends that MAAC pays to
<FONT STYLE="white-space:nowrap">a&nbsp;non-corporate&nbsp;U.S.</FONT> Holder may be taxed as &#147;qualified dividend income&#148; at the preferential tax rate accorded to long-term capital gains. It is unclear whether the redemption rights
described herein with respect to the MAAC Class&nbsp;A Shares may have suspended the running of the applicable holding period for these purposes. If the holding period requirements are not satisfied, then a corporation may not be able to qualify for
the dividends received deduction and would have taxable income equal to the entire dividend amount, <FONT STYLE="white-space:nowrap">and&nbsp;non-corporate&nbsp;U.S.</FONT> Holders may be subject to tax on such dividend at regular ordinary income
tax rates instead of the preferential rate that applies to &#147;qualified dividend income.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the application of those rules,
any remaining tax basis of the U.S. Holder in the redeemed Class&nbsp;A Shares will be added to the U.S. Holder&#146;s adjusted tax basis in its remaining MAAC Class&nbsp;A Shares, or, if it has none, to the U.S. Holder&#146;s adjusted tax basis in
its MAAC Warrants or possibly in other shares of common stock constructively owned by it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Taxation of Gain or Loss on Redemptions
Treated as a Sale or Exchange of MAAC Class</I><I></I><I>&nbsp;A Shares.</I><I></I>&nbsp;If a redemption qualifies as a sale of such U.S. Holder&#146;s MAAC Class&nbsp;A Shares redeemed, such U.S. Holder generally will recognize capital gain or
loss. Any such capital gain or loss generally will be long-term capital gain or loss if the U.S. Holder&#146;s holding period for the MAAC Class&nbsp;A Shares so redeemed exceeds one year. It is unclear, however, whether the redemption rights
described herein with respect to the MAAC Class&nbsp;A Shares may have suspended the running of the applicable holding period for this purpose. Long-term capital gains recognized
<FONT STYLE="white-space:nowrap">by&nbsp;non-corporate&nbsp;U.S.</FONT> Holders generally will be eligible to be taxed at reduced rates. The deductibility of capital losses is subject to limitations. Generally, the amount of gain or loss recognized
by a U.S. Holder is an amount equal to the difference between (i)&nbsp;the sum of the amount of cash and the fair market value of any property received in such disposition and (ii)&nbsp;the U.S. Holder&#146;s adjusted tax basis in its MAAC
Class&nbsp;A Shares so redeemed. See &#147;&#151;Exercise, Lapse or&nbsp;Redemption of MAAC Warrants&#148; below for a discussion regarding a U.S. Holder&#146;s tax basis in Roivant Common Shares acquired pursuant to the exercise of a MAAC Warrant.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IF YOU ARE A U.S. HOLDER OF MAAC CLASS A SHARES CONTEMPLATING EXERCISE OF YOUR REDEMPTION RIGHTS, WE URGE
YOU TO CONSULT YOUR TAX ADVISOR CONCERNING THE U.S. FEDERAL, STATE, LOCAL, AND FOREIGN INCOME AND OTHER TAX CONSEQUENCES THEREOF. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax Consequences
of the Merger </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is intended that the Merger qualifies as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of
the Code. To qualify as a reorganization, a transaction must satisfy certain requirements, including, among others, that the acquiring corporation (or, in the case of certain reorganizations structured similarly to the Merger, its corporate parent),
either directly or indirectly through certain controlled corporations, either continue a significant line of the acquired corporation&#146;s historic business or use a significant portion of the acquired corporation&#146;s historic business assets
in a business, in each case, within the meaning of Treasury regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.368-1(d).</FONT> However, due to the absence of guidance bearing directly on how the above rules apply in the case of an
acquisition of a corporation with investment-type assets, such as MAAC, the qualification of the Merger as a reorganization is not &#147;free from doubt&#148;. Moreover, the closing of the Merger is not conditioned upon the receipt of, and neither
MAAC nor Roivant has received or sought, an opinion of counsel that the Merger qualifies as a reorganization, and neither MAAC nor Roivant intends to request a ruling from the IRS regarding the U.S. federal income tax treatment of the Merger.
Accordingly, no assurance can be given that the IRS will not challenge the Merger&#146;s qualification as a reorganization or that a court will not sustain such a challenge by the IRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Merger qualifies as a reorganization under Section&nbsp;368(a) of the Code, subject to the discussion below under the heading
&#147;&#151;Additional Requirements for Tax Deferral,&#148; a U.S. Holder generally should not recognize gain or loss if, pursuant to the Merger, the U.S. Holder exchanges only MAAC Class&nbsp;A Shares for Roivant Common Shares. In such a case, the
aggregate tax basis of the Roivant Common Shares received by a U.S. Holder in the Merger should be equal to the aggregate adjusted tax basis of the MAAC Class&nbsp;A Shares surrendered in exchange therefor. The holding period of the Roivant Common
Shares received by a U.S. Holder in the Merger should include the period during which the MAAC Class&nbsp;A Shares exchanged therefor were held by such U.S. Holder. It is unclear whether the redemption rights with respect to the MAAC Class&nbsp;A
Shares have suspended the running of the applicable holding period for this purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Every &#147;significant transferor&#148; pursuant to
the exchange must include a statement on or with such transferor&#146;s income tax return for the taxable year of the exchange. For this purpose, a significant transferor is generally a person that transferred property to a corporation and received
stock of the transferee corporation if, immediately after the exchange, such person&#151;(i) owned at least five percent (by vote or value) of the total outstanding stock of the transferee corporation if the stock owned by such person is publicly
traded, or (ii)&nbsp;owned at least one percent (by vote or value) of the total outstanding stock of the transferee corporation if the stock owned by such person is not publicly traded. We expect that Roivant Common Shares will be treated as
publicly traded for this purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, notwithstanding the above, any requirement for Section&nbsp;368(a) is not met, the Merger will not
qualify as a reorganization and will be a taxable transaction to U.S. Holders of MAAC Class A Shares. In such case, a U.S. Holder of MAAC Class&nbsp;A Shares would generally recognize gain or loss with respect to its MAAC Class&nbsp;A Shares in an
amount equal to the difference, if any, between the fair market value as of the Closing Date of Roivant Common Shares received by such U.S. Holder in the Merger over such U.S. Holder&#146;s tax basis in the MAAC Class&nbsp;A Shares surrendered by
such U.S. Holder in the Merger. Any gain or loss so recognized would generally be long-term capital gain or loss if the U.S. Holder had held the MAAC Class&nbsp;A Shares for more than one year (or short-term capital gain or loss otherwise). It is
unclear, however, whether certain redemption rights (described above) may suspend the running of the applicable holding period for this purpose. Long-term capital gains of <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders (including
individuals) currently are eligible for preferential U.S. federal income tax rates. However, the deductibility of capital losses is subject to limitations. A U.S. Holder should have a tax basis in Roivant Common Shares received equal to the fair
market value on the date of exchange, and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
U.S. Holder&#146;s holding period in the Roivant Common Shares received in the Merger, if any, would not include the holding period for the MAAC Class&nbsp;A Shares surrendered in exchange
therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, if a U.S. Holder exercises its redemption rights to receive cash from the trust account in
exchange for a portion of its MAAC Class&nbsp;A Shares, such redemption may be treated as integrated with the Merger rather than as a separate transaction. In such case, cash received by such U.S. Holder in the redemption may also be treated as
taxable boot received in a &#147;reorganization&#148; (which, depending on the circumstances applicable to such U.S. Holder, may be treated as capital gain or dividend income to the extent of MAAC&#146;s accumulated earnings and profits, in each
case, taxable as described above under the heading &#147;&#151;Tax Consequences of Exercising Redemption Rights&#148;). Under this characterization, such U.S. Holder may be required to recognize more gain or income than if the redemption of MAAC
Class&nbsp;A Shares was treated as a separate transaction from the exchange pursuant to the Merger, and would not be entitled to recognize any loss with respect to its redeemed MAAC Class&nbsp;A Shares. In addition, if a U.S. Holder that elects to
participate in a redemption with respect to all its MAAC Class&nbsp;A Shares maintains its ownership of MAAC Warrants, such redemption also may be treated as integrated with the Merger rather than as a separate transaction (with the same taxation
effects described above). Under this characterization, such U.S. Holder generally is expected to recognize capital gain (but not loss) on such exchange in an amount equal to the difference between the amount of cash received and such U.S.
Holder&#146;s adjusted basis in the MAAC Class&nbsp;A Shares exchanged therefor. If the IRS were to assert, and a court were to sustain such a contrary position, such U.S. Holder may be required to recognize more gain or income than if the
redemption of MAAC Class&nbsp;A Shares was treated as a separate transaction from the exchanges pursuant to the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is intended
that the MAAC Warrants becoming exercisable for Roivant Common Shares, and the MAAC warrant agreements being assigned to, and assumed by, Roivant, also constitutes a <FONT STYLE="white-space:nowrap">tax-deferred</FONT> transaction in which no gain
or loss is recognized by the U.S. Holders of MAAC Warrants if the Merger qualifies as a reorganization as discussed above. It is also possible the transaction is treated as <FONT STYLE="white-space:nowrap">tax-deferred</FONT> on the basis that the
terms of the MAAC Warrants are not otherwise being changed pursuant to the Merger, and because the terms of the MAAC Warrants, when originally issued, contemplated, among other things, the MAAC Warrants becoming exercisable into shares of another
corporation under circumstances similar to the Merger. Accordingly, in that case, the adjusted tax basis of the Roivant Warrants of such a U.S. Holder immediately after the Merger should be the same as the adjusted tax basis of such U.S.
Holder&#146;s MAAC Warrants immediately prior to the Merger. In addition, in that case, the holding period of the Roivant Warrants of such a U.S. Holder immediately after the Merger should include the period during which such U.S. Holder held such
U.S. Holder&#146;s MAAC Warrants immediately prior to the Merger. However, due to a lack of clear authority, the issue is not free from doubt, and there is a risk that the warrant exchange transaction would be treated as a taxable exchange of MAAC
Warrants for Roivant Warrants, and no assurance can be given that the IRS would not assert, or that a court would not sustain, such a contrary position. In that case, a U.S. Holder of MAAC Warrants would recognize gain or loss equal to the
difference between the fair market value of the Roivant Warrants treated as having been received by such U.S. Holder and such U.S. Holder&#146;s tax basis in the MAAC Warrants treated as having been exchanged. Any such gain would generally be
long-term capital gain if the U.S. Holder&#146;s holding period in the MAAC Warrants is more than one year at the time of the Merger. In that case, the U.S. Holder&#146;s tax basis in the Roivant Warrants after the Merger would be equal to the fair
market value of such MAAC Warrants at the time of the Merger and the U.S. Holder would start a new holding period in the Roivant Warrants at such time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Requirements for Tax Deferral </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;367(a) of the Code and the Treasury regulations promulgated thereunder, in certain circumstances described below, may impose
additional requirements for a U.S. Holder to qualify <FONT STYLE="white-space:nowrap">for&nbsp;tax-deferred&nbsp;treatment</FONT> under Section&nbsp;368 of the Code with respect to the exchange of MAAC Class&nbsp;A Shares and/or the assumption of
the MAAC Warrants by Roivant in the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;367(a) of the Code potentially may apply to the exchange by a U.S. Holder of
MAAC Class&nbsp;A Shares for Roivant Common Shares pursuant to the Merger. Section&nbsp;367(a) of the Code generally requires a U.S. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Holder of stock in a U.S. corporation to recognize gain (but not loss) when such stock is exchanged for stock of <FONT STYLE="white-space:nowrap">a&nbsp;non-U.S.&nbsp;corporation</FONT> in an
exchange that would otherwise qualify <FONT STYLE="white-space:nowrap">for&nbsp;tax-deferred&nbsp;treatment</FONT> (such as pursuant to a reorganization under Section&nbsp;368 of the Code) and any of the following is true: (i)&nbsp;the U.S.
corporation fails to comply with certain reporting requirements; (ii)&nbsp;U.S. Holders of stock of the acquired U.S. corporation receive more than 50% (by vote or value) of the stock of
<FONT STYLE="white-space:nowrap">the&nbsp;non-U.S.&nbsp;corporation;</FONT> (iii)&nbsp;U.S. persons that are officers, directors, or 5% or greater shareholders of the acquired U.S. corporation own more than 50% (by vote or value) of the stock of <FONT
STYLE="white-space:nowrap">the&nbsp;non-U.S.&nbsp;corporation</FONT> immediately after the acquisition; (iv)&nbsp;such U.S. Holder is a 5% or greater shareholder of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation immediately after
the acquisition and fails to enter into <FONT STYLE="white-space:nowrap">a&nbsp;5-year&nbsp;gain</FONT> recognition agreement with the IRS to recognize gain in certain circumstances with respect to the acquired U.S. corporation stock exchanged in
the acquisition; or (v)&nbsp;the U.S. <FONT STYLE="white-space:nowrap">and&nbsp;non-U.S.&nbsp;corporations</FONT> (and other relevant parties) fail to meet the &#147;active trade or business test.&#148; A holder of an acquired U.S. corporation is
presumed to be a U.S. person unless that person signs an ownership statement certifying certain information, including its residency. The &#147;active trade or business test&#148; generally requires (A)&nbsp;that
<FONT STYLE="white-space:nowrap">the&nbsp;non-U.S.&nbsp;corporation</FONT> (and its qualified subsidiaries, including for this purpose Roivant and its subsidiaries) be engaged in an &#147;active trade or business&#148; outside of the U.S. for the <FONT
STYLE="white-space:nowrap">36-month</FONT> period immediately before the exchange and that neither the transferors nor <FONT STYLE="white-space:nowrap">the&nbsp;non-U.S.&nbsp;corporation</FONT> has an intention to substantially dispose of or
discontinue such trade or business, and (B)&nbsp;that the fair market value of <FONT STYLE="white-space:nowrap">the&nbsp;non-U.S.&nbsp;corporation</FONT> be at least equal to the fair market value of the U.S. corporation, as specifically determined
for purposes of Section&nbsp;367 of the Code, as of the closing of the exchange (the &#147;substantiality test&#148;). For purposes of applying the substantiality test to the Merger, the fair market value of MAAC generally will be deemed to include
the value of <FONT STYLE="white-space:nowrap">any&nbsp;non-ordinary&nbsp;course</FONT> distributions, as determined under applicable Treasury regulations, made by MAAC during <FONT STYLE="white-space:nowrap">the&nbsp;36-month&nbsp;period</FONT>
ending on the closing of the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that U.S. Holders of MAAC Class&nbsp;A Shares and/or MAAC Warrants are required to
recognize gain under Section&nbsp;367(a) of the Code for any of the foregoing reasons, a U.S. Holder generally would recognize gain, if any, in an amount equal to the excess of (i)&nbsp;the sum of the fair market value of the Roivant Common Shares
received and/or Roivant Warrants deemed received by such U.S. Holder, over (ii)&nbsp;such U.S. Holder&#146;s adjusted tax basis in the MAAC Class&nbsp;A Shares exchanged and/or MAAC Warrants deemed exchanged therefor. Any such gain would generally
be capital gain, and would be long-term capital gain if the U.S. Holder&#146;s holding period for the MAAC Class&nbsp;A Shares and/or MAAC Warrants was more than one year at the time of the Merger. In either case described in the previous sentence,
the U.S. Holder&#146;s tax basis in the Roivant Common Shares and/or Roivant Warrants received in the exchange would be equal to the fair market value of such Roivant Common Shares and/or Roivant Warrants at the time of the Merger (determined in
U.S. dollars at the spot rate in effect at the time of the Merger). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rules dealing with Section&nbsp;367(a) of the Code discussed
above are very complex and are affected by various factors in addition to those described above. Accordingly, U.S. Holders are strongly urged to consult their tax advisor concerning the application of these rules to the exchange of MAAC Class&nbsp;A
Shares and/or deemed exchange of MAAC Warrants under your particular circumstances, including, if a U.S. Holder believes that it will be a 5% or greater shareholder of Roivant, the possibility of entering into a &#147;gain recognition
agreement&#148; under applicable Treasury regulations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ownership and Disposition of the Roivant Common Shares or Roivant Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Dividends and Other Distributions on the Roivant Common Shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the PFIC rules discussed below under the heading &#147;&#151;Passive Foreign Investment Company Rules,&#148; distributions
(including, for the avoidance of doubt and for the purpose of the balance of this discussion, deemed distributions) on Roivant Common Shares will generally be taxable as a dividend for U.S. federal income tax purposes to the extent paid from
Roivant&#146;s current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions in excess of Roivant&#146;s current and accumulated earnings </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the U.S. Holder&#146;s adjusted tax basis in its Roivant Common Shares. Any remaining
excess will be treated as gain realized on the sale or other disposition of the Roivant Common Shares and will be treated as described below under the heading &#147;&#151;Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Roivant
Common Shares or Roivant Warrants.&#148; The amount of any such distribution will include any amounts withheld by us (or another applicable withholding agent). Subject to applicable limitations, dividends paid to certain <FONT
STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders generally will be taxed at the lower applicable long-term capital gains rate if the Roivant Common Shares are readily tradable on an established securities market in the United States
(such as the Nasdaq, where the Roivant Common Shares are intended to be listed) or Roivant is eligible for benefits under an applicable tax treaty with the United States, and, in each case, Roivant is not treated as a PFIC with respect to such U.S.
Holder at the time the dividend was paid or in the preceding year and provided certain holding period requirements are met. The amount of any dividend distribution paid in foreign currency will be the U.S. dollar amount calculated by reference to
the applicable exchange rate in effect on the date of actual or constructive receipt, regardless of whether the payment is in fact converted into U.S. dollars at that time. A U.S. Holder may have foreign currency gain or loss if the dividend is
converted into U.S. dollars after the date of receipt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amounts taxable as dividends generally will be treated as income from sources
outside the U.S. and will, depending on the circumstances of the U.S. Holder, be &#147;passive&#148; or &#147;general&#148; category income which, in either case, is treated separately from other types of income for purposes of computing the foreign
tax credit allowable to such U.S. Holder. The rules governing foreign tax credits are complex and U.S. Holders are urged to consult their tax advisors regarding the creditability of foreign taxes in their particular circumstances. In lieu of
claiming a foreign tax credit, a U.S. Holder may, in certain circumstances, deduct foreign taxes in computing their taxable income, subject to generally applicable limitations under U.S. law. Generally, an election to deduct foreign taxes instead of
claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable year. Notwithstanding the foregoing, if (a)&nbsp;Roivant is 50% or more owned, by vote or value, by U.S. persons and (b)&nbsp;at least 10% of Roivant&#146;s
earnings and profits are attributable to sources within the U.S., then for foreign tax credit purposes, a portion of Roivant&#146;s dividends would be treated as derived from sources within the U.S. In such case, with respect to any dividend paid
for any taxable year, the U.S.-source ratio of such dividends for foreign tax credit purposes would be equal to the portion of Roivant&#146;s earnings and profits from sources within the U.S. for such taxable year, divided by the total amount of
Roivant&#146;s earnings and profits for such taxable year. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of
Roivant Common Shares or Roivant Warrants </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the PFIC rules discussed below under the heading &#147;&#151;Passive Foreign
Investment Company Rules,&#148; upon any sale, exchange or other taxable disposition of Roivant Common Shares or Roivant Warrants, a U.S. Holder generally will recognize gain or loss in an amount equal to the difference between (i)&nbsp;the sum of
(x)&nbsp;the amount of cash and (y)&nbsp;the fair market value of any other property, received in such sale, exchange or other taxable disposition and (ii)&nbsp;the U.S. Holder&#146;s adjusted tax basis in such Roivant Common Shares or Roivant
Warrants (determined as described above or below), in each case as calculated in U.S. dollars. Any such gain or loss generally will be capital gain or loss and will be long-term capital gain or loss if the U.S. Holder&#146;s holding period for such
Roivant Common Shares or Roivant Warrants exceeds one year. Long-term capital gain realized by a <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holder generally will be taxable at a reduced rate. The deductibility of capital losses is
subject to limitations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any gain or loss recognized on the sale, exchange or other taxable disposition of Roivant Common Shares or
Roivant Warrants generally will be U.S.-source income or loss for purposes of computing the foreign tax credit allowable to a U.S. Holder. Consequently, a U.S. Holder may not be able to claim a credit for any
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax imposed upon a disposition of Roivant Common Shares or Roivant Warrants unless such credit can be applied (subject to applicable limitations) against tax due on other income treated as derived
from foreign sources. Prospective U.S. Holders should consult their tax advisors as to the foreign tax credit implications of such sale, exchange or other taxable disposition of Roivant Common Shares or Roivant Warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Exercise, Lapse or Redemption of Roivant Warrants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the PFIC rules discussed below and except as discussed below with respect to the cashless exercise of a Roivant Warrant, a U.S.
Holder generally will not recognize taxable gain or loss on the exercise of a Roivant Warrant. The U.S. Holder&#146;s tax basis in the Roivant Common Share received upon exercise of a Roivant Warrant generally will be an amount equal to the sum of
the U.S. Holder&#146;s initial investment in the MAAC Warrant in respect of which the exercised Roivant Warrant was received (assuming the Merger is a <FONT STYLE="white-space:nowrap">tax-deferred</FONT> transaction, as discussed above) and the
exercise price of such Roivant Warrant. It is unclear whether the U.S. Holder&#146;s holding period for the Roivant Common Share received upon exercise of the Roivant Warrant will begin on the date following the date of exercise or on the date of
exercise of the Roivant Warrant; in either case, the holding period will not include the period during which the U.S. Holder held the Roivant Warrant. If a Roivant Warrant is allowed to lapse unexercised, a U.S. Holder generally will recognize a
capital loss equal to such U.S. Holder&#146;s tax basis in the Roivant Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The tax consequences of a cashless exercise of a Roivant
Warrant are not clear under current tax law. Subject to the PFIC rules discussed below, a cashless exercise may be <FONT STYLE="white-space:nowrap">tax-free,</FONT> either because the exercise is not a realization event or because the exercise is
treated as a recapitalization for U.S. federal income tax purposes. In either <FONT STYLE="white-space:nowrap">tax-free</FONT> situation, a U.S. Holder&#146;s basis in the Roivant Common Shares received generally should equal the U.S. Holder&#146;s
basis in the Roivant Warrants exercised therefor. If the cashless exercise were treated as not being a realization event (and not a recapitalization), it is unclear whether a U.S. Holder&#146;s holding period in the Roivant Common Shares would be
treated as commencing on the date following the date of exercise or on the date of exercise of the Roivant Warrant; in either case, the holding period would not include the period during which the U.S. Holder held the Roivant Warrants. If the
cashless exercise were treated as a recapitalization, the holding period of the Roivant Common Shares would include the holding period of the Roivant Warrants exercised therefor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is also possible that a cashless exercise could be treated in part as a taxable exchange in which gain or loss would be recognized. In such
event, a U.S. Holder could be deemed to have surrendered a number of Roivant Warrants with an aggregate fair market value equal to the exercise price for the total number of Roivant Warrants deemed exercised. Subject to the PFIC rules discussed
below, the U.S. Holder would recognize capital gain or loss in an amount equal to the difference between the total exercise price for the total number of Roivant Warrants to be exercised and the U.S. Holder&#146;s adjusted tax basis in the Roivant
Warrants deemed surrendered. In this case, a U.S. Holder&#146;s tax basis in the Roivant Common Shares received would equal the sum of the U.S. Holder&#146;s tax basis in the Roivant Warrants exercised (i.e., the sum of the U.S. Holder&#146;s
initial investment in the MAAC Warrants in respect of which the exercised Roivant Warrants were received, assuming the Merger is a <FONT STYLE="white-space:nowrap">tax-free</FONT> transaction as discussed above) and the exercise price of such
Roivant Warrants. It is unclear whether a U.S. Holder&#146;s holding period for Roivant Common Shares would commence on the date following the date of exercise or on the date of exercise of the Roivant Warrants; in either case, the holding period
would not include the period during which the U.S. Holder held the Roivant Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the absence of authority on the U.S. federal
income tax treatment of a cashless exercise, including when a U.S. Holder&#146;s holding period would commence with respect to the Roivant Common Shares received, there can be no assurance which, if any, of the alternative tax consequences and
holding periods described above would be adopted by the IRS or a court of law. Accordingly, U.S. Holders should consult their tax advisors regarding the tax consequences of a cashless exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the PFIC rules discussed below, if we redeem Roivant Warrants for cash pursuant to the redemption provisions described in the
section of this proxy statement/prospectus entitled &#147;Description of Securities&#151;Roivant Warrants&#151;Redemption of Roivant Warrants When the Price per Roivant Common Share Equals or Exceeds $18.00&#148; or the redemption provisions
described in the section of this proxy statement/prospectus entitled &#147;Description of Securities&#151;Roivant Warrants&#151;Redemption of Roivant Warrants When the Price per Roivant Common Share Equals or Exceeds $10.00&#148; or if we purchase
Roivant Warrants in an open </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
market transaction, such redemption or purchase generally will be treated as a taxable disposition to the U.S. Holder, taxed as described above under &#147;&#151;Gain or Loss on Sale, Taxable
Exchange or Other Taxable Disposition of Roivant Common Shares or Roivant Warrants.&#148; The tax consequences of a cashless exercise of a Roivant Warrant occurring after our giving notice of an intention to redeem the Roivant Warrant for $0.01 as
described in the section of this proxy statement/prospectus entitled &#147;Description of Securities&#151;Roivant Warrants&#151;Redemption of Roivant Warrants When the Price per Roivant Common Share Equals or Exceeds $18.00&#148; or for $0.10 as
described in the section of this proxy statement/prospectus entitled &#147;Description of Securities&#151;Roivant Warrants&#151;Redemption of Roivant Warrants When the Price per Roivant Common Share Equals or Exceeds $10.00&#148; are unclear under
current law. Such cashless exercise may be treated either as if we redeemed such Roivant Warrant for Roivant Common Shares or as an exercise of the Roivant Warrant. If the cashless exercise of a Roivant Warrant for Roivant Common Shares is treated
as a redemption, then such redemption generally should be treated as a <FONT STYLE="white-space:nowrap">tax-deferred</FONT> recapitalization for U.S. federal income tax purposes, in which case a U.S. Holder should not recognize any gain or loss on
such redemption, and accordingly, a U.S. Holder&#146;s basis in the Roivant Common Shares received should equal the U.S. Holder&#146;s basis in the Roivant Warrant and the holding period of the Roivant Common Share should include the holding period
of the Roivant Warrant. If the cashless exercise of a Roivant Warrant is treated as such, the tax consequences generally should be as described under the heading &#147;&#151;Exercise, Lapse or Redemption of Roivant Warrants.&#148; Due to the lack of
clarity under current law regarding the treatment of a cashless exercise of a Roivant Warrant after our giving notice of an intention to redeem the Roivant Warrant for $0.01 or $0.10, there can be no assurance as to which, if any, of the alternative
tax consequences described above would be adopted by the IRS or a court of law. Accordingly, U.S. Holders should consult their tax advisors regarding the tax consequences of the exercise of a Roivant Warrant occurring after our giving notice of an
intention to redeem the Roivant Warrant as described above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Possible Constructive Distributions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of each Roivant Warrant provide for an adjustment to the number of Roivant Common Shares for which the Roivant Warrant may be
exercised or to the exercise price of the Roivant Warrant in certain events, as discussed in the section of this proxy statement/prospectus entitled &#147;Description of Securities&#151;Roivant Warrants&#151;Anti-Dilution Adjustments.&#148; An
adjustment which has the effect of preventing dilution generally is not taxable. The U.S. Holders of the Roivant Warrants would, however, be treated as receiving a constructive distribution from us if, for example, the adjustment to the number of
such Roivant Common Shares received upon exercise of the Roivant Warrants or to the exercise price of the Roivant Warrants increases the proportionate interest of the U.S. Holder of Roivant Warrants in our assets or earnings and profits (e.g.,
through an increase in the number of Roivant Common Shares that would be obtained upon exercise or through a decrease in the exercise price of a Roivant Warrant) as a result of a distribution (or a transaction treated as a distribution) of cash or
other property, such as other securities, to the holders of Roivant Common Shares, which is taxable to the holders of such shares as a distribution as described under &#147;&#151;Dividends and Other Distributions on the Roivant Common Shares.&#148;
Such constructive distribution would be subject to tax as described under that section in the same manner as if the U.S. Holders of the Roivant Warrants received a cash distribution from us equal to the fair market value of such increased interest.
For certain information reporting purposes, we are required to determine the date and amount of such constructive distributions. Proposed Treasury regulations, on which we may rely prior to the issuance of final regulations, specify how the date and
amount of constructive distributions are determined. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Passive Foreign Investment Company Rules </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The treatment of U.S. Holders of Roivant Common Shares or Roivant Warrants could be materially different from that described above if Roivant
is treated as a <U>PFIC</U> for U.S. federal income tax purposes<I>.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A foreign (i.e.,
<FONT STYLE="white-space:nowrap">non-U.S.)</FONT> corporation will be classified as a PFIC for U.S. federal income tax purposes if either (i)&nbsp;at least 75% of its gross income in a taxable year, including its pro rata share of the gross income
of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
corporation in which it is considered to own at least 25% of the shares by value, is passive income or (ii)&nbsp;at least 50% of its assets in a taxable year (ordinarily determined based on fair
market value and averaged quarterly over the year), including its pro rata share of the assets of any corporation in which it is considered to own at least 25% of the shares by value, are held for the production of, or produce, passive income.
Passive income generally includes, among other things, dividends, interest, rents and royalties (other than rents or royalties derived from the active conduct of a trade or business) and gains from the disposition of passive assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roivant&#146;s status as a PFIC will depend on the nature and composition of its income and the nature, composition and value of its assets
from time to time. The 50% passive asset test described above is generally based on the fair market value of each asset. If Roivant is a CFC (determined by disregarding certain downward attribution rules) and not publicly traded for the relevant
taxable year, however, the test will be applied based on the adjusted basis of Roivant&#146;s assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The New Regulations modify certain
of the rules described above. Such modifications include, for example, permitting asset value to be determined more frequently than on a quarterly basis and treating a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation as publicly traded
for a taxable year if the stock of such corporation is publicly traded, other than in de minimis quantities, for at least twenty trading days during such taxable year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The New Regulations generally apply to taxable years of shareholders beginning on or after January&nbsp;14, 2021. A shareholder, however, may
choose to apply such rules for any open taxable year beginning before January&nbsp;14, 2021, provided that, with respect to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation being tested for PFIC status, the shareholder consistently
applies certain of the provisions of the New Regulations and certain other Treasury regulations for such year and all subsequent years. Investors who are U.S. Holders should consult their own tax advisors regarding the impact and applicability of
the New Regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Roivant is considered &#147;publicly traded&#148; for the current taxable year that ends on March&nbsp;31, 2022,
assuming that the Business Combination closes within such current taxable year and that Roivant Common Shares are publicly traded, other than in de minimis quantities, for at least twenty days during the current taxable year, Roivant would apply the
50% passive asset test using the fair market value of its assets. This determination, however, is subject to uncertainty. In addition, Roivant&#146;s status may also depend, in part, on how quickly it utilizes its cash
<FONT STYLE="white-space:nowrap">on-hand</FONT> and cash from future financings in its business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the foregoing, with respect to
the taxable year that ended on March&nbsp;31, 2021, Roivant believes that it was not a PFIC (based in part on its belief that it was not classified as a CFC in the taxable year that ended on March&nbsp;31, 2021) and presently does not anticipate
that it will be a PFIC based upon the expected value of its assets, including any goodwill and intangible assets, and the expected nature and composition of its income and assets. However, Roivant&#146;s status as a PFIC is a fact-intensive
determination made on an annual basis, and it cannot provide any assurances regarding its PFIC status for the current or future taxable years. Roivant&#146;s U.S. counsel expresses no opinion with respect to Roivant&#146;s PFIC status for the
current or future taxable years. Roivant will determine its PFIC status for each taxable year and make such determination available to U.S. Holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roivant has implemented structures and arrangements intended to mitigate the possibility that it will be classified as a PFIC. There can be no
assurance that the IRS will not successfully challenge these structures and arrangements, which may result in an adverse impact on the determination of whether Roivant is classified as a PFIC in the current and future taxable years. In addition,
recently finalized U.S. Treasury regulations, the impact of which Roivant is continuing to assess, may also adversely affect the treatment of these structures and arrangements with respect to its PFIC status.Although Roivant&#146;s PFIC status is
determined annually, an initial determination that Roivant is a PFIC will generally apply for subsequent years to a U.S. Holder who held Roivant Common Shares or Roivant Warrants while Roivant was a PFIC, whether or not Roivant meets the test for
PFIC status in those subsequent years. If Roivant is determined to be a PFIC for any taxable year (or portion thereof) that is included in the holding period of a U.S. Holder of Roivant Common Shares or Roivant Warrants
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and, in the case of Roivant Common Shares, the U.S. Holder did not make an applicable PFIC election (or elections), as further described below under the heading &#147;&#151;PFIC Elections,&#148;
for the first taxable year of Roivant in which it was treated as a PFIC, and in which the U.S. Holder held (or was deemed to hold) such Roivant Common Shares, such U.S. Holder generally will be subject to special and adverse rules. Such rules apply
to (i)&nbsp;any gain recognized by the U.S. Holder on the sale or other disposition of its Roivant Common Shares or Roivant Warrants (which may include gain realized by reason of transfers of Roivant Common Shares or Roivant Warrants that would
otherwise qualify as nonrecognition transactions for U.S. federal income tax purposes) and (ii)&nbsp;any &#147;excess distribution&#148; made to the U.S. Holder (generally, any distributions to such U.S. Holder during a taxable year of the U.S.
Holder that are greater than 125% of the average annual distributions received by such U.S. Holder in respect of the Roivant Common Shares during the three preceding taxable years of such U.S. Holder or, if shorter, the portion of such U.S.
Holder&#146;s holding period for the Roivant Common Shares that preceded the taxable year of the distribution). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under these rules: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. Holder&#146;s gain or excess distribution will be allocated ratably over the U.S. Holder&#146;s holding
period for the Roivant Common Shares or Roivant Warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount allocated to the U.S. Holder&#146;s taxable year in which the U.S. Holder recognized the gain or
received the excess distribution, or to the period in the U.S. Holder&#146;s holding period before the first day of Roivant&#146;s first taxable year in which Roivant is a PFIC, will be taxed as ordinary income; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount allocated to other taxable years (or portions thereof) of the U.S. Holder and included in its holding
period will be taxed at the highest tax rate in effect for that year and applicable to the U.S. Holder without regard to the U.S. Holder&#146;s other items of income and loss for such year; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an additional tax equal to the interest charge generally applicable to underpayments of tax will be imposed on
the U.S. Holder with respect to the tax attributable to each such other taxable year of the U.S. Holder. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>PFIC
Elections </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Roivant is a PFIC and Roivant Common Shares constitute &#147;marketable stock,&#148; a U.S. Holder may avoid the adverse
PFIC tax consequences discussed above with respect to its Roivant Common Shares if such U.S. Holder makes a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election with respect to such shares for the
first taxable year in which it holds (or is deemed to hold) Roivant Common Shares and each subsequent taxable year. Such U.S. Holder generally will include for each of its taxable years as ordinary income the excess, if any, of the fair market value
of its Roivant Common Shares at the end of such year over its adjusted basis in its Roivant Common Shares. These amounts of ordinary income would not be eligible for the favorable tax rates applicable to qualified dividend income or long-term
capital gains. The U.S. Holder also will recognize an ordinary loss in respect of the excess, if any, of its adjusted basis of its Roivant Common Shares over the fair market value of its Roivant Common Shares at the end of its taxable year (but only
to the extent of the net amount of previously included income as a result of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election). The U.S. Holder&#146;s basis in its Roivant Common Shares will
be adjusted to reflect any such income or loss amounts, and any further gain recognized on a sale or other taxable disposition of its Roivant Common Shares will be treated as ordinary income. Currently, a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election likely may not be made with respect to Roivant Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election is available only for &#147;marketable stock,&#148; generally, stock that is regularly traded on a national securities exchange that is registered with
the Securities and Exchange Commission, including the Nasdaq (on which Roivant Common Shares are intended to be listed), or on a foreign exchange or market that the IRS determines has rules sufficient to ensure that the market price represents a
legitimate and sound fair market value. If made, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election would be effective for the taxable year for which the election was made and for all subsequent
taxable years unless the Roivant Common Shares cease to qualify as &#147;marketable stock&#148; for purposes of the PFIC rules or the IRS consents to the revocation of the election. U.S. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Holders are urged to consult their tax advisors regarding the availability and tax consequences of a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT>
election with respect to Roivant Common Shares under their particular circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Alternatively, if Roivant is determined to be a
PFIC, a U.S. Holder may avoid the adverse PFIC tax consequences described above in respect of Roivant Common Shares (but not Roivant Warrants) by making and maintaining a timely and valid qualified electing fund (&#147;QEF&#148;) election (if
eligible to do so). If a U.S. Holder makes a QEF election with respect to a PFIC, the U.S. Holder will be taxed on its pro rata share of the PFIC&#146;s ordinary earnings and net capital gain (at ordinary income and capital gain rates, respectively)
for each taxable year that the entity is a PFIC. If a U.S. Holder makes a QEF election with respect to the Roivant Common Shares, any distributions paid by Roivant out of its earnings and profits that were previously included in the U.S.
Holder&#146;s income under the QEF election would not be taxable to the U.S. Holder. A U.S. Holder will increase its tax basis in its Roivant Common Shares by an amount equal to any income included under the QEF election and will decrease its tax
basis by any amount distributed on the Roivant Common Shares that is not included in the U.S. Holder&#146;s income. In addition, a U.S. Holder will recognize capital gain or loss on the disposition of Roivant Common Shares in an amount equal to the
difference between the amount realized and the U.S. Holder&#146;s adjusted tax basis in the Roivant Common Shares, as determined in U.S. dollars. U.S. Holders should note that if they make QEF elections with respect to Roivant, they may be required
to pay U.S. federal income tax with respect to their Roivant Common Shares for any taxable year significantly in excess of any cash distributions received on the Roivant Common Shares for such taxable year. U.S. Holders should consult their tax
advisers regarding making QEF elections in their particular circumstances. A U.S. Holder generally may make a separate election to defer the payment of taxes on undistributed income inclusions under the QEF rules, but if deferred, any such taxes
will be subject to an interest charge. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. Holder must make the QEF election for each PFIC by attaching a separate properly completed
IRS Form 8621 for each PFIC to the U.S. Holder&#146;s timely filed U.S. federal income tax return. However, Roivant currently does not intend to provide information necessary for U.S. Holders to make QEF elections with respect to Roivant Common
Shares, and the QEF election would be unavailable with respect to the Roivant Warrants in all cases under current law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Related PFIC
Rules </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Roivant is a PFIC and, at any time, has a foreign subsidiary that is classified as a PFIC, a U.S. Holder generally would be
deemed to own a proportionate amount of the shares of such lower-tier PFIC, and generally could incur liability for the deferred tax and interest charge described above if Roivant receives a distribution from, or disposes of all or part of its
interest in, the lower-tier PFIC, or the U.S. Holder otherwise was deemed to have disposed of an interest in the lower-tier PFIC. Roivant currently does not intend to cause any lower-tier PFIC to provide to a U.S. Holder the information that may be
required to make or maintain a QEF election with respect to the lower-tier PFIC. A <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election generally would not be available with respect to such
lower-tier PFIC. U.S. Holders are urged to consult their tax advisors regarding the tax issues raised by lower-tier PFICs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. Holder
that owns (or is deemed to own) shares in a PFIC during any taxable year of the U.S. Holder, may have to file an IRS Form 8621 (whether or not a QEF or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT>
election is made) and to provide such other information as may be required by the U.S. Treasury Department. Failure to do so, if required, will extend the statute of limitations applicable to such U.S. Holder until such required information is
furnished to the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rules dealing with PFICs and with the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> and QEF elections are very complex and are affected by various factors in addition to those described above. Accordingly, U.S. Holders of Roivant Common
Shares or Roivant Warrants are urged to consult their own tax advisors concerning the application of the PFIC rules to Roivant securities under their particular circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Additional Reporting</I><B><I> </I></B><I>Requirements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain U.S. Holders may be required to file an IRS Form 926 (Return by a U.S. Transferor of Property to a Foreign Corporation) to report a
transfer of property to Roivant. Substantial penalties may be imposed on a U.S. Holder that fails to comply with this requirement and the period of limitations on assessment and collection of U.S. federal income taxes will be extended in the event
of a failure to comply. In addition, certain U.S. Holders holding specified foreign financial assets with an aggregate value in excess of the applicable dollar thresholds are required to report information to the IRS relating to Roivant Common
Shares, subject to certain exceptions (including an exception for Roivant Common Shares held in accounts maintained by U.S. financial institutions), by attaching a complete IRS Form 8938 (Statement of Specified Foreign Financial Assets) with their
tax return for each year in which they hold Roivant Common Shares. Substantial penalties apply to any failure to file IRS Form 8938 and the period of limitations on assessment and collection of U.S. federal income taxes will be extended in the event
of a failure to comply. U.S. Holders are urged to consult their tax advisors regarding the effect, if any, of these rules on the ownership and disposition of Roivant Common Shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments of dividends and sales proceeds that are made within the United States or through certain U.S.-related financial intermediaries are
subject to information reporting, and may be subject to backup withholding. Backup withholding generally will not apply, however, to a U.S. Holder if (i)&nbsp;the U.S. Holder is a corporation or other exempt recipient or (ii)&nbsp;the U.S. Holder
provides a correct taxpayer identification number and certifies that it is not subject to backup withholding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not
an additional tax. The amount of any backup withholding from a payment to a holder will be allowed as a credit against such holder&#146;s U.S. federal income tax liability and may entitle it to a refund, provided that the required information is
timely furnished to the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE U.S. FEDERAL INCOME TAX DISCUSSION SET FORTH ABOVE MAY NOT BE APPLICABLE TO YOU DEPENDING UPON YOUR
PARTICULAR SITUATION. YOU ARE URGED TO CONSULT YOUR OWN TAX ADVISOR WITH RESPECT TO THE TAX CONSEQUENCES TO YOU OF THE DISPOSITION OF MAAC CLASS A SHARES OR MAAC WARRANTS IN CONNECTION WITH THE MERGER, OF THE EXERCISE OF REDEMPTION RIGHTS, AND OF
THE ACQUISITION, OWNERSHIP AND DISPOSITION OF ROIVANT COMMON SHARES OR ROIVANT WARRANTS INCLUDING THE TAX CONSEQUENCES UNDER STATE, LOCAL, ESTATE, FOREIGN AND OTHER TAX LAWS AND TAX TREATIES AND THE POSSIBLE EFFECTS OF CHANGES IN U.S. OR OTHER TAX
LAWS. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_13"></A>MATERIAL UNITED KINGDOM TAX CONSIDERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the opinion of Davis Polk &amp; Wardwell London LLP, the following is a description of material United Kingdom tax considerations relating
to the Business Combination and the ownership and disposal of Roivant Common Shares and Roivant Warrants applicable to a non-UK Holder. The comments set out below are based on current United Kingdom tax law as applied in England and Wales and HM
Revenue &amp; Customs, or HMRC, practice (which may not be binding on HMRC) as at the date of this summary, both of which are subject to change, possibly with retrospective effect. They are intended as a general guide and, save where expressly
stated otherwise, apply only to absolute beneficial owners of the Roivant Common Shares or Roivant Warrants who are (i) individuals not resident in the United Kingdom for United Kingdom tax purposes who do not hold Roivant Common Shares or Roivant
Warrants for the purposes of a trade, profession, or vocation which they carry on in the United Kingdom through a branch or agency, or (ii) companies not resident in the United Kingdom for United Kingdom tax purposes which do not hold the Roivant
Common Shares or Roivant Warrants for the purpose of a trade carried on in the United Kingdom through a permanent establishment in the United Kingdom, together, &#147;non-UK Holders.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary does not address all possible tax consequences relating to an investment in the Roivant Common Shares or Roivant Warrants.
Certain categories of holders, including those falling outside the category described above (such as those who are resident in the United Kingdom for United Kingdom tax purposes), those carrying on certain financial activities, those subject to
specific tax regimes or benefitting from certain reliefs or exemptions, those connected with Roivant and those for whom the shares are employment-related securities may be subject to special rules and this summary does not apply to such holders and
any general statements made in this disclosure do not take them into account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Potential investors should satisfy themselves prior to
investing as to the overall tax consequences, including, specifically, the consequences under United Kingdom tax law and HMRC practice of the acquisition, ownership and disposal of the Roivant Common Shares or Roivant Warrants in their own
particular circumstances by consulting their own tax advisors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>EACH HOLDER SHOULD CONSULT ITS OWN TAX ADVISOR WITH RESPECT TO THE
PARTICULAR TAX</B><B> </B><B>CONSEQUENCES TO SUCH HOLDER OF THE OWNERSHIP AND DISPOSAL OF </B><B>ROIVANT COMMON </B><B>SHARES AND </B><B>ROIVANT </B><B>WARRANTS, AND OF THE BUSINESS COMBINATION AND AN EXERCISE OF REDEMPTION R</B><B>IGHTS, INCLUDING
THE EFFECTS OF UNITED KINGDOM </B><B>TAX LAWS.</B><B> </B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>United Kingdom Taxation of Dividends</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roivant will not be required to withhold amounts on account of United Kingdom tax at source when paying a dividend in respect of Roivant Common
Shares to a non-UK Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Non-UK Holders who hold their Roivant Common Shares as an investment should not be subject to United Kingdom
tax in respect of any dividends. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>United Kingdom Taxation of Capital Gains</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Effect of the Business Combination </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An individual who is a non-UK Holder will generally not be liable to United Kingdom capital gains tax on capital gains (if any) realized on
either the cancellation of his or her MAAC Class A Shares and their conversion into Roivant Common Shares, or the conversion of his or her MAAC Warrants into Roivant Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A company that is a non-UK Holder will generally not be liable for United Kingdom corporation tax on chargeable gains realized (if any) on
either the cancellation of its MAAC Class A Shares and their conversion into Roivant Common Shares, or the conversion of its MAAC Warrants into Roivant Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An individual non-UK Holder who is only temporarily a non-UK resident for United Kingdom tax purposes may, in certain circumstances, become
liable to UK tax on capital gains in respect of gains realized (if any) while he or she was not resident in the United Kingdom. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Acquisition of Roivant Common Shares on exercise of the Roivant Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An individual that is a non-UK Holder will generally not be liable to United Kingdom capital gains tax on capital gains realized (if any) on
the exercise of Roivant Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A company that is a non-UK Holder will generally not be liable to United Kingdom corporation tax on
chargeable gains realized (if any) on the exercise of Roivant Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An individual non-UK Holder who is only temporarily a non-UK
resident for United Kingdom tax purposes, may, in certain circumstances, become liable to United Kingdom tax on capital gains in respect of gains realized (if any) while he or she was not resident in the United Kingdom. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disposal of Roivant Common Shares or Roivant Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An individual who is a non-UK Holder will generally not be liable to United Kingdom capital gains tax on capital gains realized on the disposal
of his or her Roivant Common Shares or Roivant Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A company that is a non-UK Holder will generally not be liable for United
Kingdom corporation tax on chargeable gains realized on the disposal of its Roivant Common Shares or Roivant Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An individual
non-UK Holder who is only temporarily a non-UK resident for United Kingdom tax purposes will, in certain circumstances, become liable to United Kingdom tax on capital gains in respect of gains realized while he or she was not resident in the United
Kingdom. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>United Kingdom Stamp Duty (&#147;stamp duty&#148;) and Stamp Duty Reserve Tax (&#147;SDRT&#148;) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No stamp duty or SDRT is expected to be payable on the issue, grant or transfer of Roivant Common Shares or Roivant Warrants, subject to the
comments below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stamp duty will in principle be payable on any instrument that vests or transfers Roivant Common Shares or Roivant
Warrants that is executed in the United Kingdom or that relates to any property situated, or to any matter or thing done or to be done, in the United Kingdom. Holders of Roivant Common Shares or Roivant Warrants should be aware that, even where such
an instrument is in principle subject to stamp duty, stamp duty is not required to be paid unless it is necessary to rely on the instrument for legal purposes, for example to register a change of ownership or in litigation in a United Kingdom court.
Provided that the Roivant Common Shares and the Roivant Warrants are not registered in any register maintained in the United Kingdom, any agreement to transfer Roivant Common Shares or Roivant Warrants will not be subject to SDRT. Roivant currently
does not intend that any register of its Roivant Common Shares or the Roivant Warrants will be maintained in the United Kingdom. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_14"></A>PROPOSAL NO.&nbsp;1 &#151; THE BUSINESS COMBINATION PROPOSAL
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are asking our
stockholders to adopt and approve the Business Combination Agreement, certain related agreements and the transactions contemplated thereby (including the Business Combination). MAAC stockholders should read carefully this proxy statement/prospectus
in its entirety for more detailed information concerning the Business Combination Agreement, which is attached as Annex A to this proxy statement/prospectus, and the transactions contemplated thereby. Please see the section entitled &#147;<I>The
Business Combination Agreement</I>&#148; for additional information and a summary of certain terms of the Business Combination Agreement. You are urged to read carefully the Business Combination Agreement in its entirety before voting on this
proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we are holding a stockholder vote on the Business Combination, we may consummate the Business Combination only if such
initial Business Combination is approved by the affirmative vote of the holders of a majority of MAAC Shares that are voted at a stockholder meeting held to consider such initial Business Combination. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Business Combination </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Business Combination Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This subsection of this proxy statement/prospectus describes the material provisions of the Business Combination Agreement, but does not
purport to describe all of the terms of the Business Combination Agreement. The following summary is qualified in its entirety by reference to the complete text of the Business Combination Agreement, which is attached as Annex A to this proxy
statement/prospectus. You are urged to read the Business Combination Agreement in its entirety because it is the primary legal document that governs the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement contains representations, warranties and covenants that the respective parties made to each other as of the
date of the Business Combination Agreement or other specific dates. The assertions embodied in those representations, warranties and covenants were made for purposes of the contract among the respective parties and are subject to important
qualifications and limitations agreed to by the parties in connection with negotiating the Business Combination Agreement. The representations, warranties and covenants in the Business Combination Agreement are also modified in part by the
underlying disclosure schedules (the&nbsp;&#147;disclosure schedules&#148;), which are not filed publicly and which are subject to a contractual standard of materiality different from that generally applicable to stockholders and were used for the
purpose of allocating risk among the parties rather than establishing matters as facts. We do not believe that the disclosure schedules contain information that is material to an investment decision. Additionally, the representations and warranties
of the parties to the Business Combination Agreement may or may not have been accurate as of any specific date and do not purport to be accurate as of the date of this proxy statement/prospectus. Accordingly, no person should rely on the
representations and warranties in the Business Combination Agreement or the summaries thereof in this proxy statement/prospectus as characterizations of the actual state of facts about MAAC, Sponsor, Roivant, Merger Sub or any other matter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Description of the Business Combination; Structure of the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;1, 2021, MAAC, Merger Sub, and Roivant entered into the Business Combination Agreement, as amended, which provides for, among other
things, the following transactions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Prior to the Pre-Closing Steps (defined below), the non-voting common shares of Roivant will be converted and
redesignated into voting shares of Roivant, subject to the expiration or termination of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
any applicable waiting period under the HSR Act with respect to such conversion, provided that if such expiration or termination of any applicable waiting period under the HSR Act does not occur,
then the parties shall, prior to the Effective Time, appropriately modify Roivant&#146;s post-closing bye-laws to provide for a separate class of common shares of Roivant that are identical to the common shares of Roivant (the &#147;Roivant Common
Shares&#148;), except that they will not be entitled to voting rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On the date of Closing (defined below) prior to the Effective Time, Roivant will amend and restate its existing
bye-laws to be in the form of the Roivant&#146;s post-closing bye-laws, each outstanding share of Roivant will be subdivided into the Roivant Common Shares based on a fixed exchange ratio of 2.9262:1 (the &#147;Roivant Exchange Ratio&#148;), and
each outstanding equity award of Roivant will be subdivided and adjusted into comparable equity awards of Roivant, based on the Roivant Exchange Ratio (the steps contemplated by this clause (b), collectively, the &#147;Pre-Closing Steps&#148;);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On the date of Closing, the parties to the Business Combination Agreement will cause a certificate of merger to
be executed and filed with the Secretary of State of the State of Delaware, pursuant to which Merger Sub will merge with and into MAAC, with MAAC surviving the Merger; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At the Effective Time, (i) each outstanding MAAC Class A Share and each outstanding MAAC Class B Share (other
than treasury shares and any shares held by the MAAC Sponsor or its affiliates) will be automatically canceled and extinguished and converted into one Roivant Common Share, (ii) each outstanding MAAC Class B Share held by the MAAC Sponsor or any of
its affiliates will be automatically canceled and extinguished and converted into a number of Roivant Common Shares based on the MAAC Sponsor Exchange Ratio, with a portion of such Roivant Common Shares issued to the MAAC Sponsor or any of its
affiliates by virtue of the Merger being subject to the vesting and other terms and conditions set forth in the Sponsor Support Agreement (as more fully described in the section entitled &#147;&#151;Related Agreements&#148;) and (iii) each
outstanding MAAC Warrant to purchase MAAC Class A Shares will automatically convert into the right to acquire Roivant Common Shares on the terms and subject to the conditions set forth in the MAAC Warrant Agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Sponsor Exchange Ratio is 1.0, subject to reduction in an amount equal to one-half of the percentage of MAAC Class A Shares redeemed in
connection with the Business Combination (i.e., if 10% of the MAAC Class A Shares are so redeemed, then the Sponsor Exchange Ratio will be equal to 0.95), provided that in no event will the Sponsor Exchange Ratio be less than 0.75. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, MAAC and Roivant entered into Subscription Agreements with certain institutional and accredited investors, pursuant to which such
investors have agreed to subscribe for and purchase, and MAAC has agreed to issue and sell to such investors, an aggregate of 22,000,000 MAAC Class&nbsp;A Shares at a price of $10.00 per share, for aggregate gross proceeds of $220,000,000, which we
refer to as the &#147;PIPE Financing.&#148; The MAAC Class A Shares to be offered and sold pursuant to the Subscription Agreements and the Roivant Common Shares into which such MAAC Class A Shares are converted in connection with the Merger have not
been registered under the Securities Act, in reliance upon the exemption provided in Section 4(a)(2) thereof. Each MAAC Class&nbsp;A Share issued in the PIPE Financing will be converted into one Roivant Common Share in the Merger. Roivant will grant
the investors certain registration rights in connection with the PIPE Financing. The PIPE Financing is contingent upon, among other things, the substantially concurrent Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proceeds from MAAC&#146;s Trust Account (after, for the avoidance of doubt, giving effect to any redemptions by MAAC stockholders in
connection with the Business Combination) and the PIPE Financing will be used for general capital purposes of Roivant following the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, certain related agreements have been, or will be entered into substantially concurrently with, or
prior to the Closing, including the Transaction Support Agreements, the Sponsor Support Agreement, the Registration Rights Agreement and the Lock-Up Agreement (each as defined in this proxy statement/prospectus). See &#147;&#151;Related
Agreements&#148; for more information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Closing and Effective Time of the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Closing is required to take place electronically by exchange of the closing deliverables as promptly as reasonably practicable, but in no
event later than the third business day, following the satisfaction (or, to the extent permitted by applicable law, waiver) of the conditions described below under the section entitled &#147;&#151;Conditions to the Closing of the Business
Combination,&#148; (other than those conditions that by their nature are to be satisfied at the closing of the Business Combination, but subject to satisfaction or waiver of such conditions) or at such other place, date and/or time as MAAC and
Roivant may agree in writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Effective Time will occur at the time that the parties file a certificate of merger with the Secretary
of State of the State of Delaware on the date of the Closing or at such other time mutually agreed to by the parties and set forth in the certificate of merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conditions to the Closing of the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Conditions to Each Party&#146;s Obligations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The respective obligations of each party to the Business Combination Agreement to consummate the transactions contemplated by the Business
Combination are subject to the satisfaction or, if permitted by applicable law, written waiver by all of the parties to the Business Combination Agreement of the following conditions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no order or law issued by any court of competent jurisdiction or other governmental entity (i)&nbsp;in the United
States or any other jurisdiction in which the Group Companies (as defined below) conduct material operations or (ii)&nbsp;that is otherwise material, in each case, preventing the consummation of the transactions contemplated by the Business
Combination Agreement being in effect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the registration statement of which this proxy statement/prospectus forms a part becoming effective in accordance
with the provisions of the Securities Act, no stop order being issued by the SEC and remaining in effect, and no proceeding seeking such a stop order being threatened or initiated by the SEC and remaining pending; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval of each of the Business Combination Approval and the Nasdaq Approval by the affirmative vote of the
holders of the requisite number of MAAC Shares being obtained in accordance with MAAC&#146;s governing documents and applicable law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Roivant&#146;s initial listing application with Nasdaq in connection with the transactions contemplated by the
Business Combination Agreement being approved and, immediately following the Effective Time, Roivant satisfying any applicable initial and continuing listing requirements of Nasdaq, and Roivant not having received any notice of non-compliance in
connection therewith that has not been cured or would not be cured at or immediately following the Effective Time, and the Roivant Common Shares to be issued in connection with the Business Combination, being approved for listing on Nasdaq; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after giving effect to the transactions contemplated by the Business Combination Agreement (including the PIPE
Financing), Roivant having at least $5,000,001 of net tangible assets (as determined in accordance with Rule 3a51-1(g)(1) of the Exchange Act) immediately after the Effective Time. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other Conditions to the Obligations of MAAC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of MAAC to consummate the transactions contemplated by the Business Combination Agreement are subject to the satisfaction or,
if permitted by applicable law, waiver by MAAC of the following further conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the representations and warranties of Roivant regarding its organization and qualification, the authority of
Roivant to execute and deliver the Business Combination Agreement and each of the ancillary documents thereto to which it is or will be a party and to consummate the transactions contemplated
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
thereby and Roivant brokers&#146; fees and certain representations and warranties of Roivant regarding its capitalization, being true and correct (without giving effect to any limitation of
&#147;materiality&#148; or Company Material Adverse Effect (as defined in the Business Combination Agreement) or any similar limitation set forth in the Business Combination Agreement) in all material respects as of the date of Closing, as though
made on and as of the date of Closing (or, if given as of an earlier date, as of such earlier date); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the representation and warranty regarding the absence of a Company Material Adverse Effect since July 6, 2020
being true and correct in all respects as of the date of Closing, provided that such representation and warranty will be deemed satisfied if there is no Company Material Adverse Effect that is continuing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain representations and warranties of Roivant regarding its capitalization being true and correct (without
giving effect to any limitation of &#147;materiality&#148; or Company Material Adverse Effect or any similar limitation set forth in the Business Combination Agreement) as of the date of Closing, as though made on and as of the date of Closing, (or,
if given as of an earlier date, as of such earlier date), except where the failure of such representations and warranties to be true and correct would not be material to the Group Companies, taken as a whole; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the other representations and warranties of Roivant being true and correct (without giving effect to any
limitation of &#147;materiality&#148; or Company Material Adverse Effect or any similar limitation set forth in the Business Combination Agreement) in all respects as of the date of Closing, as though made on and as of the date of Closing (or, if
given as of an earlier date, as of such earlier date), except where the failure of such representations and warranties to be true and correct would not have a Company Material Adverse Effect; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Roivant and Merger Sub having performed and complied in all material respects with the covenants and agreements
required to be performed or complied with by Roivant and Merger Sub under the Business Combination Agreement at or prior to the Closing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">since the date of the Business Combination Agreement, no Company Material Adverse Effect has occurred that is
continuing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as of immediately after the Effective Time, the Roivant Board shall include the MAAC director designee as a
director; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Pre-Closing Steps having been consummated on the date of Closing prior to the Effective Time in accordance
with the applicable terms of the Business Combination Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the waiting period under the HSR Act with respect to the Notification and Report Form to be filed by the MAAC
Sponsor as an acquiring person (as that term is defined by 16 C.F.R. 801.2) in connection with the transactions contemplated by the Business Combination Agreement having been expired or terminated; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">MAAC must have received a certificate executed by an authorized officer of Roivant confirming that the conditions
set forth in the first six bullet points in this section have been satisfied. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other Conditions to the Obligations
of Roivant </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of Roivant to consummate the transactions contemplated by the Business Combination Agreement are
subject to the satisfaction or, if permitted by applicable law, waiver by Roivant of the following further conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the representations and warranties regarding organization and qualification of MAAC, the authority of MAAC to
execute and deliver the Business Combination Agreement, and each of the ancillary documents thereto to which it is or will be a party and to consummate the transactions contemplated thereby, the absence of a MAAC Material Adverse Effect (as defined
in the Business Combination </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Agreement), MAAC&#146;s brokers&#146; fees and MAAC&#146;s Trust Account and certain representations and warranties regarding the capitalization of MAAC being true and correct in all material
respects as of the date of Closing, as though made on and as of such date of Closing (or, if given as of an earlier date, as of such earlier date), provided that the representation and warranty related to the absence of a MAAC Material Adverse
Effect since July 6, 2020 will be deemed satisfied if there is no MAAC Material Adverse Effect that is continuing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the other representations and warranties of MAAC being true and correct (without giving effect to any limitation
as to &#147;materiality&#148; or MAAC Material Adverse Effect or any similar limitation set forth in the Business Combination Agreement) in all respects as of the date of Closing, as though made on and as of the date of Closing (or, if given as of
an earlier date, as of such earlier date), except where the failure of such representations and warranties to be true and correct would not have a MAAC Material Adverse Effect; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">MAAC having performed and complied in all material respects with the covenants and agreements required to be
performed or complied with by it under the Business Combination Agreement at or prior to the Closing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">since the date of the Business Combination Agreement, no MAAC Material Adverse Effect has occurred that is
continuing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate proceeds from the Trust Account (after, for the avoidance of doubt, giving effect to any
redemptions by MAAC stockholders in connection with the Business Combination) being equal to or greater than $210,000,000; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sponsor having complied in all material respects with its covenants and agreements required to be performed or
complied with by it under the Sponsor Support Agreement at or prior to the Closing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">MAAC having delivered to Roivant a certificate duly executed by an authorized officer of MAAC dated as of the
date of Closing confirming that the conditions set forth in the first four bullet points of this section have been satisfied; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">MAAC having delivered to Roivant a certificate prepared in a manner consistent and in accordance with the
requirements of the Treasury Regulations Sections 1.897-2(g), (h)&nbsp;and 1.1445-2(c)(3), certifying that no interest in MAAC is, or has been during the relevant period specified in Section&nbsp;897(c)(1)(A)(ii) of the Code, a &#147;United States
real property interest&#148; within the meaning of Section&nbsp;897(c) of the Code, and a form of notice to the Internal Revenue Service prepared in accordance with the provisions of Treasury Regulations Section&nbsp;1.897-2(h)(2).
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Representations and Warranties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Business Combination Agreement, Roivant and Merger Sub made customary representations and warranties to MAAC relating to, among other
things: organization and qualification; capitalization; authorization; financial statements; absence of undisclosed liabilities; consents and approvals; permits; material contracts; absence of certain changes; the absence of a Company Material
Adverse Effect; litigation; compliance with law; Merger Sub activities; employee plans; environmental matters; intellectual property; labor matters; insurance; tax matters; brokers; real and personal property; transactions with affiliates and other
related parties; data privacy and security; compliance with international trade and anti-corruption laws; information supplied; investigation; regulatory compliance; investment company act; and SEC filings and others matters relating to
Roivant&#146;s subsidiaries that are public companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Business Combination Agreement, MAAC made customary representations and
warranties to Roivant relating to, among other things: organization and qualification; authorization; consent and approvals; brokers; information supplied; capitalization; SEC filings; the Trust Account; the absence of a MAAC Material Adverse
Effect; material contracts; transactions with affiliates and other related parties; litigation; compliance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with law; MAAC&#146;s activities; internal controls, listing and financial statements; absence of undisclosed liabilities; employees; tax matters; compliance with international trade and
anti-corruption laws; PIPE Financing; and investigation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material Adverse Effect </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Business Combination Agreement, certain representations and warranties of Roivant and MAAC are qualified in whole or in part by
materiality thresholds. In addition, certain representations and warranties of Roivant and MAAC are qualified in whole or in part by a material adverse effect standard for purposes of determining whether a breach of such representations and
warranties has occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Business Combination Agreement, a &#147;Company Material Adverse Effect&#148; means any change,
event, development, effect or occurrence that, individually or in the aggregate with any other change, event, development, effect or occurrence, has had or would reasonably be expected to have a material adverse effect on (a)&nbsp;the business,
results of operations, assets or financial conditions of the Group Companies, taken as a whole, or (b)&nbsp;the ability of Roivant or Merger Sub to consummate the transactions contemplated by the Business Combination Agreement on the date of Closing
(including the Merger and the Pre-Closing Steps); provided, however, that, in the case of clause (a), none of the following shall be taken into account in determining whether a Company Material Adverse Effect has occurred or is reasonably likely to
occur: any adverse change, event, development, effect or occurrence arising after the date of the Business Combination Agreement from or related to (i)&nbsp;general business or economic conditions in or affecting the United States, or changes
therein, or the global economy generally, (ii)&nbsp;any national or international political or social conditions in the United States or any other country, including the engagement by the United States or any other country in hostilities, whether or
not pursuant to the declaration of a national emergency or war, or the occurrence in any place of any military or terrorist attack, sabotage or cyberterrorism, (iii)&nbsp;changes in conditions of the financial, banking, capital or securities markets
generally in the United States or any other country or region in the world, or changes therein, including changes in interest rates in the United States or any other country and changes in exchange rates for the currencies of any countries,
(iv)&nbsp;changes in any applicable Laws, (v)&nbsp;any change, event, development, effect or occurrence that is generally applicable to the industries or markets in which any of Roivant or any of its Subsidiaries (each a &#147;Group Company&#148;)
operates, (vi)&nbsp;the execution or public announcement of the Business Combination Agreement or the pendency or consummation of the transactions contemplated by the Business Combination Agreement, including the impact thereof on the relationships,
contractual or otherwise, of any Group Company with employees, customers, investors, contractors, lenders, suppliers, vendors, partners, licensors, licensees, payors or other third parties related thereto (provided that the exception in this clause
(vi)&nbsp;shall not apply to the representations and warranties set forth in Section&nbsp;3.5(b) of the Business Combination Agreement to the extent that its purpose is to address the consequences resulting from the public announcement or pendency
or consummation of the transactions contemplated by the Business Combination Agreement or the condition set forth in Section&nbsp;6.2(a) of the Business Combination Agreement to the extent it relates to such representations and warranties),
(vii)&nbsp;any failure by any Group Company to meet, or changes to, any internal or published budgets, projections, forecasts, estimates or predictions (although the underlying facts and circumstances resulting in such failure may be taken into
account to the extent not otherwise excluded from this definition, (viii)&nbsp;any hurricane, tornado, flood, earthquake, tsunami, natural disaster, mudslides, wild fires, epidemics, pandemics (including COVID-19) or quarantines, acts of God or
other natural disasters or comparable events in the United States or any other country or region in the world, or any escalation of the foregoing, or (ix)&nbsp;any regulatory, preclinical, clinical, pricing or reimbursement changes, effects,
developments or occurrences arising after the date of the Business Combination Agreement and relating to or affecting any product candidate, product or platform that is being or has been researched, tested, developed, manufactured, distributed,
sold, promoted, advertised or marketed by or on behalf of the Group Companies (&#147;Company Product&#148;) (including (A) any suspension, rejection, refusal of, request to refile or any delay in obtaining or making any regulatory application or
filing relating to any Company Product, (B)&nbsp;any negative regulatory actions, requests, recommendations or decisions of any Governmental Entity (as defined in the Business Combination Agreement) relating to any Company Product or the manufacture
thereof, or any other regulatory or preclinical or clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development relating to any Company Product, (C)&nbsp;any preclinical or clinical studies, trials, tests, results or adverse events, or announcements of any of the foregoing, with respect to any
Company Product, (D)&nbsp;any delay, hold or termination of any preclinical or clinical study, trial or test or any delay, hold or termination of any planned application for investigational new drug application or application for marketing approval
with respect to any Company Product, (E)&nbsp;any preclinical or clinical studies, trials, tests, results or adverse events, or announcements of any of the foregoing, with respect to any product or product candidate competitive with or related to
any Company Product, (F)&nbsp;FDA approval (or other preclinical or clinical or regulatory developments), market entry or threatened market entry of any product or product candidate competitive with or related to any Company Product or (G)&nbsp;any
recommendations, statements, decisions or other pronouncements made, published or proposed by professional medical organizations, payors, Governmental Entities or representatives of the foregoing, or any panel or advisory body empowered or appointed
thereby, relating to any Company Product or any products or product candidates of any competitors of the Company), in each case, as applicable and solely to the extent not resulting from or arising out of any fraud or intentional and material
violation of any applicable Public Health Law or Order (each as defined in the Business Combination Agreement) by any Group Company; provided, however, that (A)&nbsp;any change, event, development, effect or occurrence resulting from a matter
described in any of the foregoing clauses&nbsp;(i) through (v)&nbsp;may be taken into account in determining whether a Company Material Adverse Effect has occurred or is reasonably likely to occur to the extent such change, event, development,
effect or occurrence has or has had a disproportionate adverse effect on the Group Companies, taken as a whole, relative to other participants operating in the industries or markets in which the Group Companies operate and (B)&nbsp;in no event shall
(x)&nbsp;any change, event, development, effect or occurrence to the extent relating to MAAC, (y)&nbsp;any MAAC stockholder redemption, in and of itself, or (z)&nbsp;any failure, in and of itself, by a PIPE Investor to fulfill its obligations under
the Subscription Agreement constitute a Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Business Combination Agreement, certain
representations and warranties of MAAC are qualified in whole or in part by a material adverse effect standard for purposes of determining whether a breach of such representations and warranties has occurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Business Combination Agreement, a &#147;MAAC Material Adverse Effect&#148; means any change, event, development, effect or
occurrence that, individually or in the aggregate with any other change, event, development, effect or occurrence, has had or would reasonably be expected to have a material adverse effect on (a)&nbsp;the business, results of operations, assets or
financial condition of MAAC, taken as a whole, or (b)&nbsp;the ability of MAAC to consummate the transactions contemplated by the Business Combination Agreement to occur on the date of Closing (including the Merger); provided, however, that, in the
case of clause (a), none of the following shall be taken into account in determining whether a MAAC Material Adverse Effect has occurred or is reasonably likely to occur: any adverse change, event, development, effect or occurrence arising after the
date of this Agreement from or related to (i)&nbsp;general business or economic conditions in or affecting the United States, or changes therein, or the global economy generally, (ii)&nbsp;any national or international political or social conditions
in the United States or any other country, including the engagement by the United States or any other country in hostilities, whether or not pursuant to the declaration of a national emergency or war, or the occurrence in any place of any military
or terrorist attack, sabotage or cyberterrorism, (iii)&nbsp;changes in conditions of the financial, banking, capital or securities markets generally in the United States or any other country or region in the world, or changes therein, including
changes in interest rates in the United States or any other country and changes in exchange rates for the currencies of any countries, (iv)&nbsp;changes in any applicable Laws, (v)&nbsp;any change, event, development, effect or occurrence that is
generally applicable to the industries or markets in which MAAC operates, (vi)&nbsp;the execution or public announcement of the Business Combination Agreement or the pendency or consummation of the transactions contemplated by the Business
Combination Agreement, including the impact thereof on the relationships, contractual or otherwise, of MAAC with investors, contractors, lenders, suppliers, vendors, partners, licensors, licensees, payors or other third parties related thereto
(provided that the exception in this clause&nbsp;(vi) shall not apply to the representations and warranties set forth in Section&nbsp;4.3(b) of the Business Combination Agreement to the extent that its purpose is to address the consequences
resulting from the public announcement or pendency or consummation of the transactions contemplated by this Agreement or the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
condition set forth in Section&nbsp;6.3(a) of the Business Combination Agreement to the extent it relates to such representations and warranties), (vii)&nbsp;any failure by MAAC to meet, or
changes to, any internal or published budgets, projections, forecasts, estimates or predictions (although the underlying facts and circumstances resulting in such failure may be taken into account to the extent not otherwise excluded from this
definition), (viii)&nbsp;any hurricane, tornado, flood, earthquake, tsunami, natural disaster, mudslides, wild fires, epidemics, pandemics (including COVID-19) or quarantines, acts of God or other natural disasters or comparable events in the United
States or any other country or region in the world, or any escalation of the foregoing or (ix)&nbsp;any change, event, development, effect or occurrence that is generally applicable to &#147;SPACs&#148;; provided, however, that (A)&nbsp;any change,
event, development, effect or occurrence resulting from a matter described in any of the foregoing clauses&nbsp;(i) through (v)&nbsp;or clause (ix)&nbsp;may be taken into account in determining whether a MAAC Material Adverse Effect has occurred or
is reasonably likely to occur to the extent such change, event, development, effect or occurrence has or has had a disproportionate adverse effect on MAAC relative to other &#147;SPACs,&#148; and (B)&nbsp;in no event shall (x)&nbsp;any change,
event, development, effect or occurrence to the extent relating to any of the Group Companies, (y)&nbsp;any MAAC stockholder redemption, in and of itself, or (z)&nbsp;any failure, in and of itself, by a PIPE Investor to fulfill its obligations under
each Subscription Agreement constitute a MAAC Material Adverse Effect. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Covenants of the Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Covenants of Roivant and Merger Sub </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roivant and Merger Sub made certain covenants under the Business Combination Agreement, including, among others, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, as required by law or as consented to in writing by MAAC (such consent not to be
unreasonably withheld, conditioned or delayed), prior to the Closing, Roivant will, and will cause the other non-public Group Companies to, use commercially reasonable efforts to (i)&nbsp;operate the non-public Group Companies in the ordinary course
of business in all material respects and (ii)&nbsp;maintain and preserve intact in all material respects the business organization, assets, properties and material business relations of the non-public Group Companies, taken as a whole.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions (including those set forth in the applicable subsections of Section&nbsp;5.1(b) of
the Business Combination Agreement or in the disclosure schedules) or as consented to in writing by MAAC (such consent not to be unreasonably withheld, conditioned or delayed), prior to the Closing, Roivant will, and will cause the other non-public
Group Companies to, not do any of the following: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">declare, set aside, make or pay dividend on, or make any other distribution payment in respect of, any equity
securities of Roivant or repurchase, redeem or otherwise acquire any outstanding equity securities of Roivant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) merge, consolidate, combine or amalgamate Roivant with any person or (ii)&nbsp;purchase or otherwise acquire
any corporation, partnership, association or other business entity or organization or division thereof, except, in the case of this clause (ii)&nbsp;for any such transaction that would not be material to the business of all of the Group Companies,
taken as a whole; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adopt any amendments, supplements, restatements or modifications to Roivant&#146;s governing documents or
Roivant&#146;s shareholder agreements that are material and adverse to the holders of MAAC Shares or that would adversely affect the ability of Roivant to perform, or otherwise comply with, any of its covenants, agreements or obligations under the
Business Combination Agreement or any ancillary document or any holder of Roivant common shares prior to the Effective Time to perform, or otherwise comply with, any of its covenants, agreements or obligations under the Transaction Support
Agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) sell, assign, abandon, lease, exclusively license or otherwise dispose of any assets or properties of the
non-public Group Companies that are material to the business of all of the Group </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Companies, taken as a whole or (ii)&nbsp;create, subject or incur any lien (other than any Permitted Liens (as defined in the Business Combination Agreement)) on any assets or properties of the
non-public Group Companies that are material to the business of all of the Group Companies, taken as a whole; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur, create or assume any indebtedness for borrowed money to a third party in excess of $200 million in the
aggregate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) enter into, or amend or modify in any manner that would be adverse to the existing MAAC stockholders in any
material respect following the Closing (including, for the avoidance of doubt, by reason of any additional payments or consideration that occur prior to the Closing) or that would adversely affect the ability of Roivant to perform, or otherwise
comply with, any of its covenants, agreements or obligations under the Business Combination Agreement or any ancillary document, any related party contract required to be or that, if existing on the date of the Business Combination Agreement, would
be required to be, disclosed on the disclosure schedules or (ii)&nbsp;consummate any other related party transaction or make any other payments to a related party that, if reflected in a contract and existing on the date of the Business Combination
Agreement, would be required to be disclosed on the disclosure schedules; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into or provide for, or amend or modify in a manner that would result in material additional payments or
other amounts under (either individually or in the aggregate), any retention, transaction bonus or other similar payments or amounts that become payable as a result of the transactions contemplated by the Business Combination Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any loans, advances or capital contributions to, or guarantees for the benefit of, any person in an amount
in excess of $25 million in the aggregate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any settlement agreement or similar contract the performance of which would involve the payment in
excess of $2 million individually or $10 million in the aggregate, or that imposes or will impose any material, non-monetary obligations on any non-public Group Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize, recommend, propose or announce an intention to adopt, or otherwise effect, a plan of (A)&nbsp;complete
or partial liquidation, dissolution or restructuring involving any non-public Group Company (other than a non-public Group Company with no material operations) or (B)&nbsp;recapitalization, reorganization or similar transaction involving any
non-public Group Company (other than the Pre-Closing Steps); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change any non-public Group Company&#146;s methods of accounting in any material respect; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into a contract with any broker, finder, investment banker or other person that would entitle such person
to a brokerage fee, finders&#146; fee or other commission in connection with the transactions contemplated by the Business Combination Agreement or any ancillary documents; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any contract to take any of the above actions prohibited under the Business Combination Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Roivant will not, and will cause the other non-public Group Companies that may hold equity securities of Datavant
Holdings, Inc. and its subsidiaries (&#147;Datavant&#148;) not to, take any action in furtherance of, approve or consent to any dividend, distribution or other payment by Datavant to any Roivant related party (including, if applicable, by voting its
equity securities of Datavant against any proposal to make any such dividend, distribution or other payment), except for a dividend, distribution or other payment to the direct holders of equity securities of Datavant that is made in accordance with
the governing documents of Datavant and applicable contracts governing such equity securities (in each case, as in effect as of the date of the Business Combination Agreement), without the prior written consent of MAAC. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Merger Sub will not take any action, engage in any activities or business, or incur any liabilities or
obligations, other than (i)&nbsp;those incident to its organization, (ii)&nbsp;the execution of the Business Combination Agreement or any ancillary documents to which it is or will be a party, (iii)&nbsp;those contemplated by the Business
Combination Agreement or any ancillary document or (iv)&nbsp;those that are consented to in writing by MAAC. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Prior to the Effective Time, Roivant will cause the conversion and redesignation of non-voting common shares of
Roivant into Roivant Common Shares to occur, subject to the expiration or termination of any applicable waiting period under the HSR Act with respect to such conversion. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As promptly as reasonably practicable (and in any event within one business day) following the date of the
Business Combination Agreement, Roivant, as the sole shareholder of Merger Sub, will approve and adopt the Business Combination Agreement, the ancillary documents to which Merger Sub is or will be a party and the transactions contemplated hereby and
thereby (including the Merger). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Roivant will use its reasonable best efforts to cause: (i)&nbsp;Roivant to satisfy any applicable initial and
continuing listing requirements of Nasdaq, in each case, as promptly as reasonably practicable after the date of the Business Combination Agreement and in any event prior to the Effective Time, and (ii)&nbsp;the Roivant Common Shares issuable in
accordance with the Business Combination Agreement, including the Merger, to be approved for listing on Nasdaq, subject to official notice of issuance thereof. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As promptly as reasonably practicable following the date of the Business Combination Agreement, Roivant will
deliver to MAAC (i)&nbsp;Roivant audited financial statements for the fiscal years ended March&nbsp;31, 2019 and March&nbsp;31, 2020, (ii)&nbsp;Roivant audited financial statements for the fiscal year ended March&nbsp;31, 2021 and
(iii)&nbsp;customary pro forma financial statements (after giving effect to the transactions contemplated by the Business Combination Agreement). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Roivant will use reasonable best efforts to terminate at or prior to the Closing the Roivant shareholders
agreements set forth in the disclosure schedules without any further liabilities to Roivant or any of its affiliates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Following the Effective Time, Roivant will maintain the rights to indemnification or exculpation in favor of the
current or former directors and officers of both MAAC and Roivant for a period of six&nbsp;years after the Effective Time and will maintain in effect for six years after the Effective Time a &#147;tail&#148; policy obtained by MAAC providing
liability insurance covered for MAAC directors and officers with respect to matters occurring at or prior to the Effective Time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Roivant will, subject to certain exceptions, at or prior to the Closing, obtain a &#147;tail&#148; policy
providing liability insurance coverage for Roivant directors and officers with respect to matters occurring on or prior to the Effective Time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Prior to the earlier of the Closing or termination of the Business Combination Agreement in accordance with its
terms, Roivant will not and will cause the non-public Group Companies and its and their respective officers and directors to not, and will use their reasonable best efforts to cause its and their affiliates and the other representatives to not,
directly or indirectly: (i)&nbsp;solicit, initiate, knowingly encourage (including by means of furnishing or disclosing information), knowingly facilitate, discuss or negotiate, directly or indirectly, any inquiry, proposal or offer (written or
oral) with respect to a Company Acquisition Proposal (as defined in the Business Combination Agreement); (ii)&nbsp;furnish or disclose any non-public information to any person in connection with, or that would reasonably be expected to lead to, a
Company Acquisition Proposal; (iii)&nbsp;enter into any contract or other arrangement or understanding regarding a Company Acquisition Proposal; (iv)&nbsp;make any filings with the SEC in connection with a public offering of any securities of
Roivant, other than in connection with the transactions contemplated by, and in accordance with, the Business Combination Agreement and the ancillary documents; or (v)&nbsp;otherwise cooperate in any way with, or assist or participate in, or
knowingly facilitate or knowingly encourage any effort or attempt by any person to do or seek to do any of the foregoing. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Roivant will take all such actions as may be necessary or appropriate such that effective as of the Effective
Time the Roivant Board will consist of a number of directors determined by Roivant (upon reasonable prior consultation with MAAC) prior to the Effective Time, with one director being an individual designated by MAAC, who is currently expected to be
James C. Momtazee, and the other directors being determined by Roivant (upon reasonable prior consultation with MAAC). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Prior to the effectiveness of the registration statement of which this proxy statement/prospectus forms a part,
the board of directors of Roivant (i)&nbsp;will approve and adopt the Roivant Sciences Ltd. Amended and Restated 2021 Equity Incentive Plan, with any changes or modifications thereto as Roivant and MAAC may mutually agree (such agreement not to be
unreasonably withheld, conditioned or delayed by either Roivant or MAAC, as applicable) and (ii)&nbsp;may approve and adopt an employee stock purchase plan, with any changes or modifications thereto as Roivant and MAAC may mutually agree (such
agreement not to be unreasonably withheld, conditioned or delayed by either Roivant or MAAC, as applicable). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Roivant will, and will cause its representatives to, reasonably consult with and reasonably cooperate with MAAC
and its representatives in connection with the Pre-Closing Steps and otherwise keep MAAC and its representatives apprised, in reasonable detail, of the status of the Pre-Closing Steps. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) within a reasonable time prior to the Closing (and in any event ten business days prior to the date of
Closing), Roivant will provide, or cause to be provided, drafts of all agreements, documents and instruments related to the Pre-Closing Steps, and give MAAC and its representatives a reasonable amount of time to review all such agreements, documents
and instruments and will consider in good faith all comments provided by MAAC and its Representatives and (ii)&nbsp;none of Roivant or the other Group Companies will enter into any agreement, document or instrument related to the Pre-Closing Steps
that is not in a form and substance reasonably satisfactory to MAAC. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Covenants of MAAC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC made certain covenants under the Business Combination Agreement, including, among others, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions (including the ability of MAAC to use funds held by MAAC outside the Trust Account
to pay any MAAC expenses or liabilities to distribute or pay over any funds held by MAAC outside the Trust Account to the MAAC Sponsor or any of its affiliates, in each case, prior to the Closing)&nbsp;or as consented to in writing by Roivant (such
consent not to be unreasonably withheld, conditioned or delayed), prior to the Closing, MAAC will, and will cause its subsidiaries to, not do any of the following: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adopt any amendments, supplements, restatements or modifications to the Trust Agreement (as defined in the
Business Combination Agreement), the MAAC Warrant Agreement or the governing documents of MAAC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">create or form any subsidiary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire any corporation, partnership, other business organization or enter into any strategic joint ventures,
partnerships or alliances with any other person, or make any loans, advances or capital contributions to, or guarantees for the benefit of, or any investments in, any person or entity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">declare, set aside, make or pay any dividend or distribution or payment in respect of, or repurchase any
outstanding, any equity securities of MAAC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">split, combine or reclassify any of its capital stock or other equity securities or issue any other security in
respect of, in lieu of or in substitution for shares of its capital stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) incur, create or assume any indebtedness for borrowed money (other than working capital loans from the MAAC
Sponsor in an amount not to exceed $3 million) or (ii)&nbsp;guarantee any liability of any person or entity; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any loans or advances to, or capital contributions in, any other person; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue any equity securities of MAAC or grant any options, warrants or stock appreciation rights with respect to
its equity securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into, amend, renew, modify or revise any MAAC related party transaction or make any material payment to any
MAAC related party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">engage in any activities or business, or incur any liabilities, other than any activities, businesses or
liabilities that are contemplated by, incurred in connection with or that are otherwise incidental or attendant to the Business Combination Agreement or any ancillary document; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into, amend or modify any material term of (in a manner adverse to MAAC), terminate, or waive or release
any material rights, claims or benefits under, certain material contracts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any collective bargaining agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize, recommend, propose or announce an intention to adopt a plan of complete or partial liquidation,
dissolution, restructuring, recapitalization, reorganization or similar transaction involving MAAC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make, change or revoke any material election concerning taxes, enter into any material tax closing agreement,
settle any material tax claim or assessment, or consent to any extension or waiver of the limitation period applicable to or relating to any material tax claim or assessment </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any changes to the methods of accounting of MAAC in any material respect; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into or amend any contract providing for the payment of any brokerage fee, finders&#146; fee or other
commission in connection with the transactions contemplated by the Business Combination Agreement or any ancillary document; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) establish, adopt, modify, amend or terminate any &#147;employee benefit plan&#148; (as such term is defined
in Section&nbsp;3(3) of the Employee Retirement Income Security Act of 1974 (&#147;ERISA&#148;), whether or not subject to ERISA), equity or equity-based, deferred compensation, severance, retention, bonus, incentive, retirement, retiree or
post-employment welfare, vacation, and other benefit or compensatory plan, program, policy, arrangement or contract, (ii)&nbsp;grant or increase (or accelerate the timing of payment or funding of) any compensation or benefits (including, without
limitation, any severance or change in control or retention payments) to any employee or independent contractor or (iii)&nbsp;(A)&nbsp;hire any employee or (B)&nbsp;engage any individual independent contractor or consultant for fees;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any change of control payments that become payable as a result of or in connection with the Business
Combination or the ancillary documents; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any contract to take any of the above actions prohibited under the Business Combination Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As promptly as reasonably practicable following the effectiveness of the registration statement of which this
proxy statement/prospectus forms a part, MAAC will (i)&nbsp;duly give notice of and use reasonable best efforts to duly convene and hold a meeting of its stockholders to approve the Business Combination Proposal, the Nasdaq Proposal, the Adjournment
Proposal, any proposal that either the SEC or Nasdaq indicates is necessary in its comments to the proxy statement/prospectus or in correspondence related hereto, and any proposal reasonably agreed by MAAC and Roivant to be appropriate in connection
with the consummation of the Business Combination (the &#147;Transaction Proposals&#148;), (ii)&nbsp;use reasonable best efforts to solicit proxies from the holders of MAAC&#146;s outstanding shares to vote in favor of the Transaction Proposals and
(iii)&nbsp;provide MAAC stockholders with the opportunity to elect to effect an MAAC stockholder redemption in accordance with MAAC&#146;s governing documents. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Except as otherwise required by applicable law, none of the MAAC board of directors, MAAC or any committee of the
MAAC board of directors will (i)&nbsp;change, withdraw, withhold, qualify, amend or modify, or publicly propose to change, withdraw, withhold, qualify, amend or modify, in a manner adverse to Roivant, the recommendation of MAAC&#146;s board of
directors or any other recommendation by the MAAC board of directors or MAAC of the proposals set forth in this proxy statement/prospectus, (ii)&nbsp;adopt, approve, recommend or declare advisable to the existing MAAC stockholders, or publicly
propose to adopt, approve, recommend or declare advisable, any MAAC Acquisition Proposal (as defined in the Business Combination Agreement or (iii)&nbsp;fail to include the recommendation of MAAC&#146;s board of directors in the registration
statement of which this proxy statement/prospectus forms a part. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Upon the satisfaction of the conditions to closing, MAAC will deliver to the Trust Account trustee all documents,
certificates or other notices required to be delivered to the trustee pursuant to the Trust Agreement and will cause the trustee to (i)&nbsp;pay all amounts (if any) payable to the holders of MAAC Class&nbsp;A Shares in connection with the MAAC
stockholder redemption, (ii)&nbsp;pay the deferred underwriting expenses as set forth in the Trust Agreement, (iii)&nbsp;pay all remaining amounts to MAAC in accordance with the Trust Agreement and (iv)&nbsp;terminate the Trust Account following the
completion of the actions described in clauses (i)&nbsp;through (iii). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">MAAC will use its reasonable best efforts to obtain the PIPE Financing, enforce the obligations of the PIPE
Investors and satisfy and comply with all the conditions to each Subscription Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Subject to certain exceptions, MAAC will not amend, modify or waiver any provision of any Subscription Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">MAAC will also promptly notify Roivant of any material breach or termination under any Subscription Agreement and
will deliver a Closing Notice (as defined in the Subscription Agreements) to the PIPE </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top">Investors promptly (and in any event within two (2)&nbsp;business days) following Roivant&#146;s reasonable request once all the conditions to Closing have been satisfied. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Prior to the earlier of the Closing or termination of the Business Combination Agreement in accordance with its
terms, MAAC will not, and will cause Sponsor and its and their respective officers and directors to not, and will use their reasonable best efforts to cause its and their other representatives to not, directly or indirectly: (i)&nbsp;solicit,
initiate, knowingly encourage (including by means of furnishing or disclosing information), knowingly facilitate, discuss or negotiate, directly or indirectly, any inquiry, proposal or offer (written or oral) with respect to a MAAC Acquisition
Proposal (as first referenced above); (ii)&nbsp;furnish or disclose any non-public information to any person in connection with, or that could reasonably be expected to lead to, a MAAC Acquisition Proposal; (iii)&nbsp;enter into any contract or
other arrangement or understanding regarding a MAAC Acquisition Proposal; or (iv)&nbsp;otherwise cooperate in any way with, or assist or participate in, or knowingly facilitate or knowingly encourage any effort or attempt by any person to do or seek
to do any of the foregoing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Prior to the earlier of the Closing or termination of the Business Combination Agreement in accordance with its
terms, MAAC will use its reasonable best efforts to keep current and timely file all reports required to be filed or furnished with the SEC and otherwise comply in all material respects with its reporting obligations under applicable securities
laws. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">MAAC will, and will cause its Representatives to, reasonably cooperate with the Roivant and its representatives
in connection with approval of the Roivant Common Shares for listed on Nasdaq. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">MAAC will, subject to certain exceptions, at or prior to the Closing, obtain a &#147;tail&#148; policy providing
liability insurance coverage for MAAC directors and officers with respect to matters occurring on or prior to the Effective Time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">MAAC will use its reasonable best efforts to cooperate with Roivant in connection with the preparation of
customary pro forma financial statements that are required to be included in this proxy statement/prospectus. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">MAAC will (i)&nbsp;reasonably assist Roivant in preparing in a timely manner any financial information or
statements that involve financial information or statements of MAAC required to be included in this proxy statement/prospectus and any other SEC filings in connection with the transactions contemplated hereby and (ii)&nbsp;obtain the consents of its
auditors as may be required by applicable law or requested by the SEC. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Mutual Covenants of the Parties
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties made certain covenants under the Business Combination Agreement, including, among others, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">using reasonable best efforts to consummate the Business Combination; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">notifying the other party in writing promptly after learning of any shareholder demands or other shareholder
proceedings (including derivative claims) relating to the Business Combination Agreement, any ancillary documents or any matters relating thereto, and reasonably cooperating with one another in connection therewith; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not settling any shareholder demands or other shareholder proceedings (including derivative claims) relating to
the Business Combination Agreement, any ancillary documents or any matters relating thereto without the written consent of the other party (such consent not to be unreasonably withheld, conditioned or delayed); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">keeping certain information confidential in accordance with the existing confidentiality agreement between
Roivant and MAAC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, providing the other party reasonable access to the directors, officers, books and
records; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">agreeing to, and making the appropriate SEC filings with respect to, a signing and a closing press release;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, refraining from making public announcements or press releases;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">using reasonable best efforts to cause the Merger to constitute a transaction treated as a
&#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the IRS Code or otherwise use commercially reasonable efforts to restructure the Merger to so qualify; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cooperating in connection with certain tax matters and filings. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, MAAC and Roivant agreed that MAAC and Roivant will prepare and mutually agree upon and Roivant will file with the SEC, the
registration statement on Form S-4, of which this proxy statement/prospectus forms a part, relating to the Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Closing, it is expected that the current management of Roivant will remain the management of Roivant, and the Roivant
Board will consist of nine directors determined by Roivant (upon reasonable consultation with MAAC) prior to the Closing, with one director, James C. Momtazee, being designated by MAAC, and the remaining directors being designated by Roivant. See
&#147;Management After The Business Combination&#151;Executive Officers and Directors.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Survival of Representations, Warranties and Covenants
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representations, warranties, agreements and covenants in the Business Combination Agreement terminate at the Effective Time,
except for the covenants and agreement which by their terms contemplate performance after the Effective Time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Termination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement may be terminated under certain customary circumstances prior to the Closing, including, but not limited to,
the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by the mutual written consent of MAAC and Roivant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by MAAC, subject to certain exceptions, if any of the representations or warranties made by Roivant or Merger Sub
are not true and correct or if Roivant or Merger Sub fails to perform any covenant or agreement set forth in the Business Combination Agreement (including an obligation to consummate the Closing) such that certain conditions to closing, as described
in the section entitled &#147;&#151;Conditions to the Closing of the Business Combination&#148; above, would not (assuming that the Closing occurred as of such date) be satisfied and the breach (or breaches) of such representations or warranties not
to be true and correct, or the failures to perform any such covenant or agreements is (or are) not cured or cannot be cured within the earlier of (i)&nbsp;thirty days after written notice thereof is delivered to MAAC by the Company, and
(ii)&nbsp;November&nbsp;30, 2021 (the &#147;Termination Date&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Roivant, subject to certain exceptions, if any of the representations or warranties made by MAAC are not true
and correct or if MAAC has failed to perform any covenant or agreement on the part of MAAC set forth in the Business Combination Agreement (including an obligation to consummate the Closing) such that certain conditions to Closing, as described in
the section entitled &#147;&#151;Conditions to the Closing of the Business Combination&#148; above, would not (assuming that the Closing occurred as of such date) be satisfied and the breach or breaches causing such representations or warranties not
to be true and correct, or the failures to perform any covenant or agreement, as applicable, is (or are) not cured or cannot be cured within the earlier of (i)&nbsp;thirty (30)&nbsp;days after written notice thereof is delivered to MAAC by the
Company and (ii)&nbsp;the Termination Date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by either MAAC or Roivant, subject to certain exceptions, if the transactions contemplated by the Business
Combination Agreement are not consummated on or prior to the Termination Date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by either MAAC or Roivant, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if any governmental entity of competent jurisdiction has issued an order or taken any other action permanently
enjoining, restraining or otherwise prohibiting the transactions contemplated by the Business Combination Agreement and such order has become final and nonappealable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the MAAC Special Meeting has been held (including and adjournment or postponement thereof), has concluded, the
MAAC stockholders have duly voted and the approval of the Business Combination Proposal was not obtained; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by MAAC, if Roivant does not deliver, or cause to be delivered to MAAC, the Merger Sub shareholder approval, when
required under the Business Combination Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Business Combination Agreement is validly terminated, none of
the parties to the Business Combination Agreement will have any liability or any further obligation under the Business Combination Agreement, except in the case of Willful Breach or Fraud (each as defined in the Business Combination Agreement) and
for customary provisions and obligations that survive the termination thereof (such as confidentiality obligations). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fees and Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fees and expenses incurred in connection with the Business Combination Agreement and the ancillary documents thereto, and the transactions
contemplated thereby, including the fees and disbursements of counsel, financial advisors and accountants, will be paid by the party incurring such fees or expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination
Agreement is governed by and construed in accordance with the laws of the State of Delaware, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would
cause the application of the law of any jurisdiction other than the State of Delaware (except that the Bermuda Companies Act 1981 shall also apply to the Pre-Closing Steps). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement may be amended or modified only by a written agreement executed and delivered by MAAC and Roivant, provided
that the amendment of certain provisions also require the prior written consent of the MAAC Sponsor following the Closing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ownership of Roivant
Immediately Following the Business Combination </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this proxy statement/prospectus, there are 41,071,823 MAAC
Class&nbsp;A Shares, 10,267,956 shares of MAAC Class B Shares, and 30,750,267 MAAC Warrants issued and outstanding. Therefore, as of the date of this proxy statement/prospectus (without giving effect to the Business Combination and assuming that
none of the outstanding MAAC Class&nbsp;A Shares are redeemed in connection with the Business Combination), assuming that each outstanding warrant is exercised and one MAAC Class&nbsp;A Share is issued as a result of such exercise, MAAC&#146;s
fully-diluted capital stock would consist of 82,090,046 MAAC Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the pro forma Roivant Common Shares
outstanding as of June 25, 2021 based on the varying levels of redemptions by the public stockholders, excluding the potential dilutive effect of outstanding stock options, unvested RSUs and common stock warrants. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No redemption scenario</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum redemption<BR>scenario</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Roivant Stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">651,576,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">651,576,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MAAC&#146;s Public Shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,071,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,996,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Founder Shares<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,267,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,758,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PIPE Investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>724,916,109</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>100.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>702,331,124</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>100.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An aggregate of 30% of the MAAC Class B Shares held by the holders are subject to those certain earn-out
provisions in the Sponsor Support Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Related Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section describes certain additional agreements entered into or to be entered into pursuant to the Business Combination Agreement, but
does not purport to describe all of the terms thereof. The following summary is qualified in its entirety by reference to the complete text of each of the agreements. The form of Subscription Agreement, the Registration Rights Agreement, the form of
the Transaction Support Agreement, the Sponsor Support Agreement and the form of the Lock-Up Agreement are attached hereto as Annex B, Annex C, Annex D, Annex E and Annex F, respectively. You are urged to read such agreements in their entirety prior
to voting on the proposals presented at the special meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PIPE Financing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC and Roivant entered into the Subscription Agreements with certain institutional and accredited investors, pursuant to which such investors
agreed to subscribe for and purchase, and MAAC agreed to issue and sell to such investors, prior to and substantially concurrently with the Closing, an aggregate of 22,000,000 MAAC Class&nbsp;A Shares at a purchase price of $10.00 per share, for
aggregate gross proceeds of $220,000,000. The MAAC Class A Shares to be offered and sold pursuant to the Subscription Agreements and the Roivant Common Shares into which such MAAC Class A Shares are converted into in the Merger have not been
registered under the Securities Act in reliance upon the exemption provided in Section 4(a)(2) thereof. Each MAAC Class&nbsp;A Share issued in the PIPE Financing will be converted into one Roivant Common Share in the Merger. The closing of the PIPE
Financing is contingent upon, among other things, the substantially concurrent consummation of the Business Combination. The Subscription Agreements provide that Roivant will grant the investors in the PIPE Financing certain customary registration
rights with respect to their Roivant Common Shares following the Closing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Business Combination Agreement, certain Roivant shareholders entered into the Third Amended and Restated
Registration Rights Agreement (the &#147;Registration Rights Agreement&#148;) pursuant to which, among other things, certain Roivant shareholders party thereto, subject to certain exceptions, will be granted certain customary registration rights as
of the effective date of the Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Registration Rights Agreement, Roivant will be obligated
to file a registration statement to register the resale of certain Roivant Common Shares within 30 days after the consummation of the Business Combination. In addition, pursuant to the terms of the Registration Rights Agreement and subject to
certain requirements and customary conditions, including with regard to the number of demand rights that may be exercised and other requirements, at any time beginning 180 days following the consummation of the Business Combination, certain
significant shareholders (as provided in the Registration Rights Agreement), if any, holding at least five percent (5.0%)&nbsp;of the then-outstanding number of registrable securities of Roivant who is party to the Registration Rights Agreement may
request that Roivant file a registration statement to register the registrable securities of Roivant held by such significant shareholder. The Registration Rights Agreement will also provide certain shareholders with &#147;piggy-back&#148;
registration rights, subject to certain requirements and customary conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transaction Support Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the signing of the Business Combination Agreement, certain shareholders of Roivant entered into a Transaction Support
Agreement (collectively, the &#147;Transaction Support Agreements&#148;) with MAAC and Roivant, pursuant to which such shareholders of Roivant have agreed to, among other things, certain covenants and agreements, to support, or that are otherwise
related to, the Business Combination, including an agreement to terminate certain existing agreements between Roivant and such shareholders, an agreement to not transfer his, her or its Roivant shares prior to the Closing and, in the case of certain
Roivant shareholders also participating in the PIPE Financing, certain covenants related to the expiration or termination of the waiting period under the HSR Act, to the extent applicable, with respect to the issuance of Roivant Common Shares to
such shareholder in connection with the Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lock-Up Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May 1, 2021 and June 9, 2021, Roivant, on the one hand, and the MAAC Sponsor, both of MAAC&#146;s independent directors (the &#147;MAAC
Independent Directors&#148;) and certain Roivant equityholders, on the other hand, entered into lock-up agreements substantially in the form attached to this proxy statement/prospectus as Annex F (the &#147;Lock-Up Agreements&#148;), pursuant to
which, among other things, the MAAC Sponsor, MAAC Independent Directors and such Roivant equityholders have agreed not to, subject to, and conditioned upon the effectiveness of, the Closing, effect any sale or distribution of the Roivant Common
Shares (including those underlying incentive equity awards or Roivant Warrants) held by the MAAC Sponsor, MAAC Independent Directors or such equityholders as of immediately following the Closing during the applicable lock-up period, subject to
customary exceptions. The lock-up period applicable to Roivant Common Shares held by the MAAC Sponsor and MAAC Independent Directors as of immediately following the Closing will be (i) with respect to 25% of the Roivant Common Shares held by the
MAAC Sponsor, six months following the Closing, (ii) with respect to an additional 25% of the Roivant Common Shares held by the MAAC Sponsor, the earlier of twelve months following the achievement of certain price-based vesting restrictions or six
years from the Closing and (iii) with respect to 50% of the Roivant Common Shares held by the MAAC Sponsor, thirty-six months following the Closing. The Roivant warrants and the Roivant Common Shares underlying warrants held by the MAAC Sponsor as
of immediately following the Closing will be subject to a corresponding lock-up period for (a) with respect to 25% of such warrants held by the MAAC Sponsor, six months from the Closing, (b) with respect to an additional 25% of such warrants held by
the MAAC Sponsor, twelve months from Closing and (c) with respect to 50% of such warrants held by the MAAC Sponsor, thirty-six months from the Closing. The lock-up period applicable to Roivant Common Shares (including those underlying incentive
equity awards) held by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain Roivant equityholders as of immediately following the Closing will be (x) with respect to 25% of the Roivant Common Shares (including those underlying incentive equity awards) held by
such Roivant equityholders, six months following the Closing, (y) with respect to an additional 25% of the Roivant Common Shares (including those underlying incentive equity awards) held by such Roivant equityholders, twelve months following the
Closing and (z) with respect to 50% of the Roivant Common Shares (including those underlying incentive equity awards) held by such Roivant equityholders, thirty-six months following the Closing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sponsor Support Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently
with the execution of the Business Combination Agreement, MAAC, the MAAC Sponsor, Roivant and each of the MAAC Insiders, entered into the Sponsor Support Agreement, pursuant to which, among other things: (i)&nbsp;the MAAC Sponsor and the MAAC
Insiders have each reaffirmed his, her or its obligations in existing arrangements with MAAC to vote in favor of each of the proposals to be voted upon at the meeting of MAAC stockholders in connection with the Business Combination, including
approval of the Business Combination Agreement and the transactions contemplated thereby; (ii)&nbsp;the MAAC Sponsor has waived any adjustment to the conversion ratio set forth in the governing documents of MAAC or any other anti-dilution or similar
protection with respect to the MAAC Class B Shares that may result from the transactions contemplated by the Business Combination; (iii)&nbsp;subject to, and conditioned upon, the occurrence of and effective as of, the Effective Time, the MAAC
Sponsor and the MAAC Insiders have each agreed to terminate certain existing arrangements with MAAC, including existing registration rights and the existing lock-up obligations with respect to his, her or its MAAC Shares; (iv)&nbsp;the MAAC Sponsor
and the MAAC Insiders that hold Roivant Common Shares immediately following the Effective Time will be granted the right to include his, her or its Roivant Common Shares in a resale registration statement to be filed in connection with the
transactions contemplated by the Subscription Agreements following the Effective Time; (v)&nbsp;the MAAC Sponsor, Roivant and MAAC have each agreed to certain covenants related to the expiration or termination of the waiting period under the HSR Act
with respect to the issuance of Roivant Common Shares to the MAAC Sponsor in connection with the Business Combination; and (vi)&nbsp;subject to, and conditioned upon the occurrence of, and effective as of immediately after, the Effective Time,
(a)&nbsp;twenty percent of the Roivant Common Shares issued to the MAAC Sponsor in respect of its MAAC Class B Shares will be subject to the vesting conditions described below and the other restrictions set forth in the Sponsor Support Agreement
with respect to the $15 Earn-Out Shares and (b)&nbsp;ten percent of the Roivant Common Shares issued to the MAAC Sponsor in respect of its MAAC Class B Shares will be subject to the vesting conditions described below and the other restrictions set
forth in the Sponsor Support Agreement with respect to the $20 Earn-Out Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $15 Earn-Out Shares will vest if the closing price of
the Roivant Common Shares is greater than or equal to $15.00 over any twenty out of thirty trading day period during the five year period following the Closing, and the $20 Earn-Out Shares will vest if the closing price of the Roivant Common Shares
is greater than or equal to $20.00 over any twenty out of thirty trading day period during the five year period following the Closing. The five year vesting period described in the preceding sentence will, if a definitive purchase agreement with
respect to a Sale (as defined in the Sponsor Support Agreement) is entered into on or prior to the end of such period, be extended to the earlier of one day after the consummation of such Sale and the termination of such definitive transaction
agreement, and if a Sale occurs during such five year (or, as applicable, longer) vesting period, then all of the Earn-Out Shares unvested as of such time will automatically vest immediately prior to the consummation of such Sale. If any Earn-Out
Shares have not vested on or prior to the end of the five year (or, as applicable, longer) vesting period, then such Earn-Out Shares will be forfeited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June 9, 2021, MAAC, the MAAC Sponsor, Roivant and the MAAC Insiders entered into Amendment No. 1 to the Sponsor Support Agreement
(&#147;SSA Amendment&#148;) pursuant to which the Sponsor Support Agreement was revised to reflect the MAAC Independent Directors and Roivant entering into respective Lock-Up Agreements. In particular, among other things, the SSA Amendment revised
the Sponsor Support Agreement to subject the Roivant Common Shares issued to each MAAC Independent Director in respect of his or her MAAC Class B Shares to the same vesting conditions applicable to the Roivant Common Shares issued to the MAAC
Sponsor. Specifically, (a) twenty percent of the Roivant Common Shares issued to each MAAC </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Independent Director will be treated as $15 Earn-Out Shares (as defined in the Sponsor Support Agreement) and (b) ten percent of the Roivant Common Shares issued to each MAAC Independent Director
will be treated as $20 Earn-Out Shares (as defined in the Sponsor Support Agreement).</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a summary of the material differences among the
rights of holders of Roivant Common Shares and holders of MAAC Shares see &#147;The Business Combination Proposal&#151;The Business Combination&#151;Comparison of Corporate Governance and Shareholder Rights.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Background of the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC is a blank check company incorporated on July&nbsp;6, 2020 as a Delaware corporation and formed for the purpose of effecting a merger,
capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. MAAC&#146;s management team have more than 50 years of combined investing experience during which they have
conducted diligence on a broad set of privately and publicly held health care companies. MAAC&#146;s directors also have significant operating experience, acquisition experience and relationships in the health care industry. MAAC&#146;s management
and directors, together with their advisors, employed an investment process that focused on accessing differentiated opportunities through relationships with executives, advisors, and intermediaries in an effort to enhance the growth potential and
value of a target business and provide opportunities for an attractive return to our shareholders. The terms of the Business Combination Agreement and the related ancillary documents are the result of extensive negotiations among MAAC, Roivant and
their respective representatives and advisors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the pricing of MAAC&#146;s initial public offering, neither MAAC, nor any
authorized person on its behalf, initiated any substantive discussions, formal or otherwise, with respect to a business combination involving MAAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;6, 2020, MAAC priced its initial public offering of 40,000,000 units at an offering price of $10.00 per unit. Each unit
consists of one MAAC Class&nbsp;A Share and <FONT STYLE="white-space:nowrap">one-half</FONT> of one redeemable MAAC Warrant. Each whole MAAC Warrant entitles the holder to purchase one MAAC Class&nbsp;A Share at an exercise price of $11.50 per
share. On October&nbsp;9, 2020, MAAC closed its initial public offering, generating gross proceeds of $400,000,000 before underwriting discounts and expenses. Simultaneously with the closing of the initial public offering, MAAC completed the private
sale of an aggregate of 10,000,000 private placement warrants at a price of $1.00 per warrant, or $10,000,000 in the aggregate, in a private placement to MAAC Sponsor. Each whole private placement warrant issued to MAAC Sponsor entitles the holder
thereof to purchase one MAAC Class&nbsp;A Share at a price of $11.50 per share, subject to certain adjustments. Subsequently, on November&nbsp;10, 2020, the underwriters exercised their over-allotment option in part for the sale of an additional
1,071,823 units. In connection with the partial exercise of the underwriters&#146; over-allotment option, MAAC issued an additional 214,365 private placement warrants to MAAC Sponsor at a price of $1.00 per warrant, or $214,365 in the aggregate.
Following the expiration of the remainder of the underwriters&#146; over-allotment option, MAAC Sponsor owned 10,167,956 MAAC Class&nbsp;B Shares and 10,214,365 warrants to purchase MAAC Class&nbsp;A Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the consummation of its initial public offering, MAAC&#146;s management and directors commenced an active, targeted search for
potential business combination targets, leveraging its management&#146;s and directors&#146; relationship network built over decades of investing in and growing health care businesses. The focus of this search was potential business combination
targets in the health care industry, which MAAC&#146;s directors and officers believed, based on their experiences, were likely to satisfy several of the key criteria for a business combination target, including, among others: serving a critical
role in the health care ecosystem; being family or founder-owned, venture or investor-backed, or a corporate divestiture; being growth-oriented companies led by strong management teams; having durable revenue or the potential to develop a durable
revenue base; having the ability to drive innovation in their product or service offering; would benefit from MAAC&#146;s management and directors network and expertise including acquisition strategy, capital structure optimization and operational
enhancements to drive growth; would benefit from being a public company by utilizing broader access to capital; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and having the ability to generate attractive returns on capital and a compelling use for capital to achieve a growth strategy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During this search, MAAC and MAAC Sponsor initiated contact with or were contacted by various representatives regarding more than 70 potential
business combination targets that represent a broad array of potential targets across the healthcare industry, which encompasses, among other things, biopharmaceuticals, pharmaceutical value chain, medical devices, diagnostics, providers, digital
health and consumer health. Notably, on October&nbsp;7, 2020, Mr. Matthew Gline, then Roivant&#146;s Chief Financial Officer and currently Roivant&#146;s Chief Executive Officer, contacted Mr. James C. Momtazee, the Chairman and Chief Executive
Officer of MAAC, by email to congratulate Mr. Momtazee on the pricing of the MAAC initial public offering. Mr. Gline also expressed an interest in scheduling a time at a future date for Mr. Vivek Ramaswamy, then Roivant&#146;s Chief Executive
Officer and currently Roivant&#146;s Executive Chairman, Mr. Gline and Mr. Momtazee to discuss Roivant and its business. Mr. Momtazee had known Mr.&nbsp;Ramaswamy and Mr.&nbsp;Gline for a number of years prior to Mr.&nbsp;Gline reaching out and
proposing a discussion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC Sponsor provided support to MAAC throughout its evaluation, analysis and due diligence regarding potential
business combination targets and a potential business combination (including the potential business combination with Roivant). This support included assistance in the initial identification of potential business combination targets, business and
financial due diligence of such potential business combination targets (including Roivant) and the management and coordination of third party advisors. These third party advisors include KPMG LLP (MAAC&#146;s accounting and tax advisors), Kirkland
&amp; Ellis LLP (MAAC&#146;s corporate counsel), Sidley Austin LLP (MAAC&#146;s intellectual property and regulatory counsel), Ropes &amp; Gray LLP (MAAC&#146;s special intellectual property counsel) and Aon Risk Services Northeast, Inc.
(MAAC&#146;s insurance and benefits advisor). MAAC, with the assistance of MAAC Sponsor, engaged in varying levels of preliminary evaluation, analysis and due diligence with respect to these 70 potential business combination targets based on a
multitude of factors, including, (a)&nbsp;interest from, and due diligence access granted by, the potential targets, (b)&nbsp;which potential targets could best satisfy MAAC&#146;s key criteria for a business combination target, and (c)&nbsp;the
receptivity to, and preparedness of, the potential targets with respect to a business combination and the terms on which such targets were willing to consider a potential business combination (including the valuation expectations of the potential
business combination targets). This evaluation, analysis and due diligence included, among other things, a review of publicly available information and other market research available to MAAC and presentations and discussions with each potential
target&#146;s management. The focus of this evaluation, analysis and due diligence was on each potential target&#146;s business, product pipeline or services, as applicable, technology, historical performance, management team (including that
team&#146;s ability to lead a public company) and competitive positioning. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on its preliminary analysis and due diligence of
potential business combination targets, MAAC and its representatives, including Mr.&nbsp;Momtazee, with the assistance of MAAC Sponsor, determined to focus MAAC&#146;s evaluation, analysis and due diligence efforts on seven potential targets
(including Roivant) that, in their belief, could best satisfy MAAC&#146;s key criteria for a business combination target and were receptive to a potential business combination. The other potential business combination targets were not further
pursued because such targets did not, in the judgment of MAAC&#146;s management, including Mr.&nbsp;Momtazee, satisfy MAAC&#146;s investment criteria, the valuation expectations of such targets were, in the judgment of MAAC&#146;s management,
including Mr.&nbsp;Momtazee, too high, or such targets were not receptive to a potential business combination with MAAC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
October&nbsp;20, 2020, Mr.&nbsp;Gline had a virtual meeting with Mr.&nbsp;Momtazee. During the course of their meeting, Mr.&nbsp;Gline indicated to Mr.&nbsp;Momtazee that Roivant was in the process of considering financing transactions and
Mr.&nbsp;Momtazee indicated that MAAC would potentially be interested in exploring a business combination involving MAAC and Roivant. Mr.&nbsp;Gline and Mr.&nbsp;Momtazee determined that additional discussions and the exploration of a potential
business combination were warranted and that, in order to facilitate them, MAAC and Roivant should enter into a <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreement. Specific terms of a potential business combination were not discussed
during this conversation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between October&nbsp;25, 2020 and December&nbsp;11, 2020, MAAC entered into <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> agreements with the seven potential business combination targets, including entering into a <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreement with Roivant on October&nbsp;26, 2020, for
purposes of performing additional due diligence and further evaluating and analyzing these companies as potential business combination targets. These seven potential targets were businesses that operate in the health care industry and included
biopharmaceutical companies, multi-site health care services companies, diagnostics companies, health care technology companies and medical device companies, with equity values ranging from approximately $1&nbsp;billion to $10&nbsp;billion, based on
preliminary due diligence and financial analysis conducted by MAAC, with the assistance of MAAC Sponsor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning on October&nbsp;26,
2020, MAAC, with the assistance of MAAC Sponsor, engaged in varying levels of further due diligence, evaluation and analysis and discussions with these seven potential business combination targets. This additional due diligence, evaluation and
analysis included access to materials in online data rooms and additional presentations and discussions with these potential business combination targets&#146; management and included, in addition to the general business and financial due diligence
described in this section with respect to the potential business combination targets, a review and evaluation of certain financial and operating information of each business combination target, a comparable company analysis and other financial
analyses to better understand and evaluate various entry and exit valuations, and market research to better understand potential growth opportunities of each business combination target. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the additional due diligence, evaluation and analysis of these seven potential targets conducted between October&nbsp;26, 2020 and
December&nbsp;24, 2020, MAAC further focused its resources and efforts on three potential targets, including Roivant, which MAAC&#146;s management and board of directors believed were most suitable for a potential business combination due to the
strength of the following factors relative to other potential targets: the ability to drive innovation, strong growth opportunities, being led by strong management teams and having the ability to achieve a strong revenue base. In addition to
Roivant, the other potential targets included a multi-site health care services company (&#147;Company A&#148;) and a technology-based consumer health company (&#147;Company B&#148;). Like other potential business combination opportunities, MAAC
Sponsor assisted MAAC as they further explored a potential business combination with each of these three potential targets, including Roivant, which further exploration included additional business and financial due diligence, market research and
analysis and evaluation of the extent to which each of these potential targets satisfied MAAC&#146;s investment criteria. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While MAAC,
with the assistance of MAAC Sponsor, continued its evaluation, analysis and due diligence review of potential targets, including Company A and Company B, between November&nbsp;10, 2020 and December&nbsp;17, 2020, representatives of Roivant and MAAC
held numerous video conferences and calls to discuss Roivant&#146;s business, including its product pipeline, technology, acquisition pipeline and corporate and tax structure, and a potential business combination between Roivant and MAAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;24, 2020, Roivant provided MAAC with access to an online data room for purposes of conducting business and financial due
diligence with respect to Roivant. Thereafter, MAAC, with the assistance of MAAC Sponsor engaged by MAAC to assist in business and financial due diligence, conducted additional business and financial due diligence, including with respect to
Roivant&#146;s product pipeline, technology, industry dynamics, competitive positioning and historical performance. MAAC, with the assistance of MAAC Sponsor, reviewed information available in the online data room, asked <FONT
STYLE="white-space:nowrap">follow-up</FONT> questions of, and received written responses from, Roivant&#146;s management and participated in due diligence calls with Roivant&#146;s management and advisors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;24, 2020, MAAC, including MAAC Sponsor, met to discuss and evaluate business and financial due diligence findings with
respect to and financial analysis prepared by MAAC, with the assistance of MAAC Sponsor, regarding Roivant, Company A and Company B. Based on this discussion, MAAC management determined that the valuation expectations of Company A were not supported
by the results of MAAC&#146;s business and financial due diligence and that Company A&#146;s primary revenue generating asset was insufficient to support </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company A&#146;s valuation. Accordingly, after further review, analysis and discussion of the three targets, MAAC concluded that Company A did not represent an attractive business combination
target for MAAC and narrowed its search to Roivant and Company B. MAAC ceased its discussions with Company A on December&nbsp;24, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;31, 2020, MAAC and Roivant held a virtual meeting to introduce MAAC&#146;s management and directors, including
Mr.&nbsp;Momtazee, Ms.&nbsp;Maria Walker, MAAC&#146;s Chief Financial Officer, and Mr.&nbsp;George Barrett and Dr.&nbsp;Steve Oesterle, each a director of MAAC, to members of Roivant&#146;s management team, including Mr.&nbsp;Ramaswamy,
Mr.&nbsp;Gline, Dr.&nbsp;Eric Venker, Roivant&#146;s Chief Operating Officer, Dr.&nbsp;Mayukh Sukhatme, Roivant&#146;s Chief Investment Officer, Dr.&nbsp;Frank Torti, Roivant&#146;s Vant Chair, and Dr.&nbsp;Roger Sidhu, then Roivant&#146;s Chief
Medical Officer and Head of Research and Development, to further discuss and explore a potential business combination. During this meeting, Roivant&#146;s management team presented a management presentation that included an overview of
Roivant&#146;s business, including its product pipeline and technical capabilities. At the conclusion of the meeting, the representatives of both MAAC and Roivant expressed an interest in further exploring a potential business combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between the pricing of its initial public offering and January&nbsp;4, 2021, the MAAC board of directors met several times both informally and
in formal board meetings to discuss MAAC&#146;s ongoing evaluation, analysis and business and financial diligence, analysis and evaluation with respect to potential business combination targets. On January&nbsp;4, 2021, a virtual meeting of the MAAC
board of directors was held with MAAC and its representatives present. Members of MAAC management provided the MAAC board of directors with an overview of its evaluation and analysis of potential business combination targets, including an overview
of its discussions with Roivant&#146;s management with respect to due diligence on Roivant <FONT STYLE="white-space:nowrap">to-date.</FONT> The MAAC board of directors reviewed the merits of a potential business combination with Company B. Based on
those discussions, the MAAC board of directors determined that Company B did not, in the judgment of the MAAC board of directors, meet MAAC&#146;s key investment criteria, including due to certain shortcomings in the performance of Company B&#146;s
main product offerings and due to the excessive valuation expectations of Company B. MAAC ceased its discussions with Company B on January&nbsp;4, 2021. Following further discussions among the MAAC board of directors on the merits of a potential
business combination transaction with Roivant, the MAAC board of directors directed MAAC to pursue and negotiate a term sheet with respect to such a potential business combination with Roivant and further discussed a work plan for completing due
diligence, including the potential advisors who would assist in those efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;5, 2021, Mr.&nbsp;Momtazee and
Mr.&nbsp;Gline held a call to discuss the potential business combination and MAAC&#146;s ongoing due diligence with respect to Roivant and its business. During this call, Mr.&nbsp;Momtazee informed Mr.&nbsp;Gline that the MAAC board of directors was
supportive of further pursuing a potential business combination with Roivant, and provided a high-level overview of, and the participants discussed, MAAC&#146;s remaining due diligence and its due diligence work plan (including outstanding key
business, financial, legal and other diligence matters). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;6, 2021, MAAC, Roivant, Kirkland&nbsp;&amp; Ellis LLP
(&#147;Kirkland&#148;), counsel to MAAC, and Davis Polk&nbsp;&amp; Wardwell LLP (&#147;Davis Polk&#148;), counsel to Roivant, held a virtual meeting during which the parties and their respective advisors discussed the potential business combination
and related process (including the potential delivery of a draft term sheet by MAAC based on economic terms to be proposed by Roivant). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;7, 2021, Roivant provided MAAC&#146;s representatives and advisors with access to the online data room for purposes of
conducting additional financial, legal, regulatory, insurance, tax and accounting due diligence with respect to Roivant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between
January&nbsp;7, 2021 and April&nbsp;14, 2021, including after January&nbsp;21, 2021, when Roivant provided MAAC&#146;s advisors access to a new data room, MAAC engaged legal, tax and other advisors to review information available in the online data
room, ask follow up questions of, and receive written responses from, Roivant&#146;s management and participate in due diligence calls with Roivant&#146;s management and advisors. This due </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
diligence focused on an assessment of Roivant&#146;s business as a whole, as well as various individual &#147;Vants,&#148; the prospects of certain of the technologies and drug products being
developed by Roivant and its Vants, Roivant&#146;s tax profile and corporate structure, Roivant&#146;s intellectual property protection and regulatory interactions, as well as general legal diligence. MAAC and its advisors also analyzed the
competitive environment for certain of the individual &#147;Vants&#148; and certain of Roivant&#146;s technologies and drug products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
January&nbsp;10, 2021, Mr.&nbsp;Gline sent an email to Mr.&nbsp;Momtazee proposing certain key terms with respect to a potential business combination, which included the following: (a)&nbsp;each Roivant Common Share having a fixed value of $40.00
per Roivant Common Share (or a fixed exchange ratio of 4.0 MAAC shares per Roivant Common Share); (b) certain MAAC Class&nbsp;B Shares held by MAAC Sponsor and Roivant shares held by certain Roivant Shareholders would be subject to vesting and
become vested if the price of the Roivant Common Shares exceeded certain price thresholds; (c)&nbsp;forfeiture by MAAC Sponsor and the Roivant shareholders of a portion of the vesting shares described in the preceding clause (b)&nbsp;proportionately
to any MAAC stockholder redemptions in connection with the Business Combination; (d)&nbsp;all of the private placement warrants held by MAAC Sponsor being forfeited at the closing of the Business Combination; and (e)&nbsp;MAAC Sponsor waiving any
applicable anti-dilution rights with respect to its MAAC Class&nbsp;B Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;11, 2021, Mr.&nbsp;Gline and
Mr.&nbsp;Momtazee held a call to discuss the email proposal sent on January&nbsp;10, 2021 and next steps, including the delivery by MAAC of a <FONT STYLE="white-space:nowrap">non-binding</FONT> term sheet reflecting a response to Roivant&#146;s
proposed terms as well as other terms and conditions with respect to a potential business combination. Mr.&nbsp;Gline and Mr.&nbsp;Momtazee also discussed general guiding principles and themes with respect to a potential business combination,
including alignment among the parties, long-term commitment to Roivant and the terms of the potential transaction being market-based. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
January&nbsp;12, 2021, Mr.&nbsp;Momtazee, on behalf of MAAC, provided Roivant with a draft <FONT STYLE="white-space:nowrap">non-binding</FONT> (except for the exclusivity provision described below) term sheet (the &#147;Initial Term Sheet&#148;)
setting forth the key terms with respect to a potential business combination transaction involving MAAC and Roivant. Between January&nbsp;12, 2021 and January&nbsp;20, 2021, representatives of MAAC and Kirkland, on the one hand, and representatives
of Roivant and Davis Polk, on the other hand, exchanged multiple drafts of the Initial Term Sheet, the details of which are more fully described below, and had numerous telephone conversations concerning the key terms with respect to a potential
business combination that are more fully described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The first draft of the Initial Term Sheet provided by Mr.&nbsp;Momtazee to
Roivant on January&nbsp;12, 2021 proposed certain key terms with respect to a potential business combination, which included the following: (a)&nbsp;each Roivant Common Share having a value of $40.00, with such value per share (and the exchange
ratio derived therefrom) being subject to adjustment based on any changes to the capitalization of Roivant since a specified date and subject to confirmatory due diligence by MAAC and its advisors and appropriate representations, warranties and
covenants; (b)&nbsp;certain MAAC Class&nbsp;B Shares held by MAAC Sponsor would be subject to vesting and become vested if the price of the Roivant Common Shares exceeds certain price thresholds; (c)&nbsp;no forfeiture of any MAAC Class&nbsp;B
Shares or private placement warrants by MAAC Sponsor; (d)&nbsp;MAAC Sponsor waiving any applicable anti-dilution rights with respect to its MAAC Class&nbsp;B Shares; (e)&nbsp;the <FONT STYLE="white-space:nowrap">lock-up</FONT> periods that would be
applicable to the shares held by MAAC Sponsor and key Roivant shareholders following the closing of the Business Combination, with 25% of such shares held by MAAC Sponsor and such key Roivant shareholders being subject to a <FONT
STYLE="white-space:nowrap">6-month</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period, 25% of such shares held by such key Roivant shareholders being subject to a <FONT STYLE="white-space:nowrap">12-month</FONT> <FONT
STYLE="white-space:nowrap">lock-up</FONT> period, 25% of the such shares held by MAAC sponsor being subject to a <FONT STYLE="white-space:nowrap">12-month</FONT> period following the vesting of the MAAC Class&nbsp;B Shares that are subject to
vesting and the remaining 50% of such shares held by MAAC Sponsor and such key Roivant shareholders being subject to a <FONT STYLE="white-space:nowrap">3-year</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period; (f)&nbsp;that the parties
would seek $250&nbsp;million of committed PIPE financing at signing (the &#147;PIPE Financing&#148;); (g) the implementation of a post-closing incentive equity plan with the sizes and terms to be agreed by the parties; (h)&nbsp;the initial size of
the post-closing Roivant board of directors being mutually agreed to by the parties, with one director being designated by MAAC Sponsor and the other directors being designated by Roivant and MAAC Sponsor having a continuing right to designate one
director following the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
closing, subject to a specified sell-down threshold; (i)&nbsp;representations, warranties and <FONT STYLE="white-space:nowrap">pre-closing</FONT> covenants not surviving the closing of the
Business Combination; (j)&nbsp;the Business Combination being subject to customary closing conditions, including a <FONT STYLE="white-space:nowrap">two-way</FONT> condition that the aggregate cash proceeds from the Trust Account (after giving effect
to any redemptions by MAAC stockholders) are no less than $210&nbsp;million; and (k)&nbsp;a mutual exclusivity period expiring on the later of 30 days following the execution of the Initial Term Sheet and the time at which either party gives written
notice to the other party of termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;14, 2021, Mr.&nbsp;Gline, on behalf of Roivant, provided MAAC with a revised
draft of the Initial Term Sheet that included the following terms: (a)&nbsp;the value per Roivant Common Share would not be subject to adjustment based on changes to capitalization of Roivant following a specified date (i.e., the value per Roivant
Common Share would be fixed at $40.00 per share); (b) certain MAAC Class&nbsp;B Shares held by MAAC Sponsor would be forfeited at the closing of the Business Combination; (c)&nbsp;certain MAAC Class&nbsp;B Shares held by MAAC Sponsor would be
subject to vesting and become vested if the price of the Roivant Common Shares exceeded certain revised price thresholds; (d)&nbsp;forfeiture by MAAC Sponsor of a portion of its remaining MAAC Class&nbsp;B Shares (including the shares subject to
vesting) proportional to any MAAC stockholder redemptions in connection with the Business Combination, with MAAC Sponsor forfeiting <FONT STYLE="white-space:nowrap">one-half</FONT> of the percentage of MAAC Class&nbsp;A Shares redeemed, provided
that in no event would MAAC Sponsor forfeit more than 25% of its Class&nbsp;B Shares; (e)&nbsp;the <FONT STYLE="white-space:nowrap">lock-up</FONT> period applicable to the Roivant shareholders (including the key Roivant shareholders) being subject
to discussions with key Roivant shareholders; (f)&nbsp;the private placement warrants and any shares underlying such warrants would be subject to a <FONT STYLE="white-space:nowrap">3-year</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period
following the closing of the Business Combination; (g)&nbsp;the implementation of a post-closing employee stock purchase plan and incentive equity plan; (h)&nbsp;the initial size of the post-closing Roivant board of directors being determined by
Roivant in consultation with MAAC, with the directors serving staggered <FONT STYLE="white-space:nowrap">3-year</FONT> terms, and MAAC Sponsor not having a continuing right to designate one director following the closing; (i)&nbsp;a <FONT
STYLE="white-space:nowrap">one-way</FONT> condition in favor of Roivant that the aggregate cash proceeds from the Trust Account (after giving effect to any redemptions by MAAC stockholders) are no less than $300&nbsp;million; and (j)&nbsp;a mutual
exclusivity period that expires on the later of (1)&nbsp;February&nbsp;19, 2021 and 30 days following the execution of the term sheet and (2)&nbsp;the time at which either party gives written notice to the other party of termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;15, 2021, representatives of MAAC and Roivant held a call to discuss certain business and financial due diligence matters,
including the potential transaction that Roivant planned to pursue with Silicon Therapeutics. During this call, representatives of Roivant provided an overview of, and the participants discussed, the potential key terms of the Silicon Therapeutics
transaction, Roivant&#146;s and its advisors&#146; due diligence to date with respect to such transaction and the timeline and process for completion of such transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;15, 2021, Mr.&nbsp;Momtazee, on behalf of MAAC, provided Roivant with a revised draft of the Initial Term Sheet that proposed
terms which included the following: (a)&nbsp;the value per Roivant Common Share would be subject to adjustment based on changes to capitalization of Roivant following a specified date; (b)&nbsp;none of MAAC Sponsor&#146;s MAAC Class&nbsp;B Shares
would be forfeited at the closing of the Business Combination; (c)&nbsp;certain MAAC Class&nbsp;B Shares held by MAAC Sponsor would be subject to vesting and become vested if the price of the Roivant Common Shares exceeds certain revised price
thresholds; (d)&nbsp;reinstated the <FONT STYLE="white-space:nowrap">lock-up</FONT> periods applicable to key Roivant shareholders that had been proposed in the initial January&nbsp;12, 2021 draft of the Initial Term Sheet; (e)&nbsp;private
placement warrants and any shares underlying such warrants being subject to the same lock-periods and in the same proportion as those applicable to the key Roivant shareholders; (f)&nbsp;the initial size of the post-closing Roivant board of
directors being mutually agreed to by the parties and MAAC having a consultation right with respect to the directors designated by Roivant prior to the signing; and (g)&nbsp;the deletion of the <FONT STYLE="white-space:nowrap">one-way</FONT>
condition in favor of Roivant that the aggregate cash proceeds from the Trust Account (after giving effect to any redemptions by MAAC stockholders) would be no less than $300&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;16, 2021, Mr.&nbsp;Gline, on behalf of Roivant, provided MAAC with a revised draft of the Initial Term Sheet that proposed
terms which included the following: (a)&nbsp;the value per Roivant Common Share would not be subject to adjustment based on changes to capitalization of Roivant following a specified date (i.e., the </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
value per Roivant Common Share would be fixed at $40 per share); (b) certain MAAC Class&nbsp;B Shares held by MAAC Sponsor would be subject to vesting and become vested if the price of the
Roivant Common Shares exceeds certain revised price thresholds; and <FONT STYLE="white-space:nowrap">(c)&nbsp;one-way</FONT> condition in favor of Roivant that the aggregate cash proceeds from the Trust Account (after giving effect to any
redemptions by MAAC stockholders) would be no less than $210&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;17, 2021, Mr.&nbsp;Momtazee, on behalf of
MAAC, provided Roivant with a revised draft of the Initial Term Sheet that proposed a revision to the quantity of MAAC Class&nbsp;B Shares held by MAAC Sponsor that would be subject to vesting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between January&nbsp;17, 2021 and early March 2021, representatives of MAAC, Roivant, Kirkland, Davis Polk, KPMG, LLP, tax advisor to MAAC,
White&nbsp;&amp; Case LLP, special tax counsel to Roivant, and PricewaterhouseCoopers LLP, tax advisor to Roivant, held numerous calls and virtual meetings to discuss and determine the transaction structure of the proposed business combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;18, 2021, a virtual meeting of the MAAC board of directors was held with representatives of MAAC and Kirkland present.
Representatives of Kirkland provided the MAAC board of directors with an overview regarding certain legal considerations related to a potential business combination, including directors&#146; fiduciary duties in connection therewith. MAAC&#146;s
management and representatives then provided the MAAC directors with an update on the due diligence of Roivant and the evaluation and analysis of a potential business combination with Roivant. They discussed the terms of the proposed Initial Term
Sheet to be entered into by MAAC and Roivant. The MAAC board of directors engaged in discussion and asked representatives of MAAC various questions regarding Roivant, including questions regarding Roivant&#146;s management and track record, certain
of the &#147;Vant&#148; businesses, and an analysis of the value of publicly traded companies that are comparable to certain of the Vants, as well as their competitive environments. They also engaged MAAC&#146;s management and representatives in a
discussion of why Roivant was a superior potential target compared to the other potential targets that MAAC had considered to date. Following discussion, the MAAC board of directors determined that it was supportive of continuing to pursue a
potential business combination with Roivant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;20, 2021, a virtual meeting of the Roivant board of directors was held with
representatives of Roivant management in attendance. Mr.&nbsp;Gline presented the terms of the proposed Initial Term Sheet to be entered into by MAAC and Roivant. Following discussion, the Roivant board of directors determined that it was supportive
of continuing to pursue a potential business combination with MAAC and approved the Initial Term Sheet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;20, 2021, MAAC
and Roivant executed the Initial Term Sheet, which provided for, among other things, a binding exclusivity period ending on the later of (a) 5:00 p.m. Eastern Time on February&nbsp;19, 2021 and (b)&nbsp;the time at which either party gave written
notice to the other party of termination thereof, and otherwise included the terms described above and exchanged between MAAC and Roivant between January&nbsp;10, 2021 and January&nbsp;20, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;2, 2021, Roivant entered into a definitive agreement to acquire Silicon Therapeutics, which subsequently closed on
March&nbsp;19, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;2, 2021, Immunovant, Inc. (&#147;IMVT&#148;), a publicly listed biopharmaceutical company of which
Roivant owned approximately 58% of the outstanding common stock as of such date, announced a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401, its lead product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between February&nbsp;2, 2021 and February&nbsp;29, 2021, MAAC&#146;s management, representatives and advisors (including Sidley Austin LLP
(&#147;Sidley&#148;), MAAC&#146;s outside intellectual property and regulatory counsel) conducted due diligence with respect to the IMVT-1401 clinical trial pause, including numerous calls and meetings with management and advisors of Roivant and
IMVT, and analyzed and evaluated the information </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
gathered in the due diligence process. MAAC also engaged new and existing third party consultants and advisors to evaluate the clinical findings released by IMVT to form an internal view as to
the probability of technical success of IMVT-1401. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;5, IMVT&#146;s management and Roivant&#146;s management held a call
with MAAC management, the MAAC board of directors and representatives and advisors of MAAC, including MAAC Sponsor, to discuss the voluntary pause of dosing in its ongoing clinical trials for IMVT-1401, its lead product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;16, 2021, Mr.&nbsp;Momtazee and Mr.&nbsp;Gline held a call in which they discussed the IMVT-1401 clinical trial pause, and
the Silicon Therapeutics acquisition and their respective effects on Roivant, its business and its valuation. Following this discussion, Mr.&nbsp;Momtazee and Mr.&nbsp;Gline agreed that amendments to the Initial Term Sheet were warranted and to work
in good faith to memorialize any necessary amendments in light of recent developments and events affecting Roivant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;17,
2021, Mr.&nbsp;Momtazee, on behalf of MAAC, provided Roivant with a draft of an amended and restated <FONT STYLE="white-space:nowrap">non-binding</FONT> (except for the exclusivity provision and fee reimbursement provision therein) term sheet (the
&#147;A&amp;R Term Sheet&#148;) that proposed the following material revisions to the Initial Term Sheet: (a)&nbsp;the value of each Roivant Common Share and the related <FONT STYLE="white-space:nowrap">pre-transaction</FONT> equity value and
exchange ratio would be subject to diligence and discussion among the parties; (b)&nbsp;the exclusivity period would be extended to the later of 5:00 pm Eastern Time on March&nbsp;19, 2021 and the time at which either party gives written notice of
termination thereof; and (c)&nbsp;a binding provision that Roivant would reimburse MAAC and its affiliates for transaction fees and expenses incurred on or after February&nbsp;16, 2021 (subject to a cap of $1.5 million) if the parties did not
execute a definitive transaction agreement prior to the end of the exclusivity period. Between February&nbsp;17, 2021 and February&nbsp;19, 2021, MAAC and MAAC Sponsor, on the one hand, and Roivant, on the other hand, also held numerous calls
regarding the revised drafts of the A&amp;R Term Sheet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;19, 2021, MAAC and MAAC Sponsor, on the one hand, and Roivant,
on the other hand, exchanged multiple revised drafts of the A&amp;R Term Sheet containing revisions to the MAAC fee reimbursement provision, with the parties ultimately agreeing that MAAC would not be entitled to the contemplated fee reimbursement
if the parties did not enter into a definitive transaction agreement by May&nbsp;19, 2021 on terms and conditions consistent with the A&amp;R Term Sheet following the successful marketing of a PIPE financing resulting in aggregate PIPE financing
commitments of $250&nbsp;million and at a price per share of $10.00, and MAAC and Roivant executed the A&amp;R Term Sheet, which superseded the Initial Term Sheet. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;3, 2021, MAAC management, MAAC Sponsor, the MAAC board of directors and Roivant held a call in which Roivant provided
MAAC&#146;s management, advisors and directors with an update on, and the participants discussed, the IMVT-1401 clinical trial pause, including Roivant management&#146;s perspective and evaluation of the clinical trial data around the implications
of the clinical pause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;5, 2021, a virtual meeting of the MAAC board of directors was held with MAAC&#146;s management and
representatives, including Kirkland, present. MAAC&#146;s management and representatives provided the MAAC board of directors with an update on their due diligence with respect to the IMVT-1401 clinical trial pause. The directors asked questions and
engaged in a discussion of the reasons for the clinical trial pause, the potential consequences of the safety signal that led to the clinical trial pause and the competitive landscape for IMVT-1401. MAAC management discussed the pending acquisition
by Roivant of Silicon Therapeutics that was expected to bolster Roivant&#146;s technological capabilities in physics computational driven drug discovery. They also discussed the other potential targets that MAAC had considered and concluded that
Roivant continued to be a superior target for a potential business combination because of the overall strength of its pipeline. Following discussion, the MAAC board of directors determined that it was supportive of continuing to pursue a potential
business combination with Roivant and agreed with MAAC&#146;s management&#146;s recommendation to modify the existing term sheet to take into account both the decline in the stock price of Immunovant and the increase in value resulting from the
anticipated acquisition of Silicon Therapeutics. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;8, 2021, Roivant filed a Schedule 13D/A with the Securities and Exchange
Commission that disclosed that Roivant intended to propose to IMVT that Roivant and IMVT evaluate a potential transaction pursuant to which Roivant or an affiliate would acquire all of the issued and outstanding shares of common stock of IMVT not
currently owned by Roivant and that Roivant had engaged investment banks as financial advisors in connection with the evaluation of a potential transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to, among other factors, the IMVT-1401 clinical trial pause and the decrease in the trading price of Immunovant common stock, which
reduced the value of Roivant&#146;s holdings of Immunovant, Roivant and MAAC agreed to reduce the <FONT STYLE="white-space:nowrap">pre-transaction</FONT> equity value of Roivant from the value reflected in the Initial Term Sheet and the A&amp;R Term
Sheet. Accordingly, on March&nbsp;9, 2021, representatives and MAAC and Roivant agreed on, and executed, a second amended and restated <FONT STYLE="white-space:nowrap">non-binding</FONT> (except for the exclusivity provisions described below) term
sheet (the &#147;Second A&amp;R Term Sheet&#148;), which superseded the A&amp;R Term Sheet and provided for the following changes to the A&amp;R Term Sheet: the transaction would value each outstanding Roivant Common Share at $38.50 per share (or a
fixed exchange ratio of 3.85 per Roivant Common Share), which would, based on the December&nbsp;31, 2020 Roivant capitalization, on a pro forma basis taking into account the pending acquisition of Silicon Therapeutics, equate to an approximately
$9.4&nbsp;billion pro forma equity value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning in <FONT STYLE="white-space:nowrap">mid-March,</FONT> representatives of the
Placement Agents commenced conversations with prospective investors in the PIPE Financing (the &#147;PIPE Investors&#148;) to provide an overview of Roivant&#146;s business and the potential business combination. MAAC&#146;s management and
Roivant&#146;s senior management met with prospective investors to discuss Roivant and the rationale for the business combination and investment in Roivant, as well as address questions from such prospective investors with respect to Roivant and the
potential business combination and the related PIPE financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;11, 2021, the PIPE investor presentation was distributed to
prospective PIPE Investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between early March 2021 and late April 2021, MAAC and Roivant, along with their respective advisors, held
numerous conversations with JPMorgan and SVB Leerink (the &#147;Placement Agents&#148;) to determine the aggregate amount of the PIPE Financing and the proposed allocations among prospective PIPE Investors. During this same time period, the
prospective PIPE Investors conveyed their initial proposed subscription amounts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;11, 2021, Kirkland provided the initial
draft of the Business Combination Agreement to Davis Polk. Between March&nbsp;11, 2021 and May&nbsp;1, 2021, Kirkland and Davis Polk exchanged numerous drafts of the Business Combination Agreement, the details of which are more fully described
below, and, over the same time period, Kirkland and other representatives and advisors for MAAC, on the one hand, and Davis Polk and other representatives and advisors for Roivant, on the other hand, held numerous conference calls regarding certain
terms and conditions of the Business Combination Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between March&nbsp;11, 2021 and May&nbsp;1, 2021, Kirkland, on the one hand,
and Davis Polk, on the other hand, exchanged multiple drafts of the other transaction documents, including the Transaction Support Agreements, the Sponsor Support Agreement and the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements, each of
which was executed on May&nbsp;1, 2021, concurrently with the execution of the Business Combination Agreement. Over this same time period, Kirkland and other representatives and advisors for MAAC, on the one hand, and Davis Polk and other
representatives and advisors for Roivant, on the other hand, held numerous conference calls regarding certain terms and conditions of these other transaction documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;18, 2021, a draft of the form of subscription agreement for the PIPE Financing was distributed to prospective PIPE Investors.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;22, 2021, Davis Polk provided Kirkland with a revised draft of the Business Combination Agreement that, in addition to
proposed revisions to the overall suite of representations, warranties and covenants to be provided by each party under the Business Combination Agreement, proposed the following material revisions: </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(a)&nbsp;representations and warranties with respect to the organization and qualification of Roivant&#146;s subsidiaries, capitalization of Roivant&#146;s subsidiaries and the authorized capital
structure of Roivant following the transaction brought down to a Company Material Adverse Effect standard, rather than an &#147;in all material respects&#148; standard for purposes of the &#147;bring-down&#148; closing condition in favor of MAAC;
(b)&nbsp;representations and warranties with respect to MAAC&#146;s Trust Account brought down to an &#147;in all material respects&#148; standard, rather than a MAAC Material Adverse Effect standard, for purposes of the &#147;bring-down&#148;
closing condition in favor of Roivant; (c)&nbsp;the addition of&nbsp;qualifications and exceptions to the definition of Company Material Adverse Effect, including (i)&nbsp;that the definition does not apply to adverse effects on the assets of
Roivant and its subsidiaries and (ii)&nbsp;a <FONT STYLE="white-space:nowrap">carve-out</FONT> for regulatory or similar events related to Roivant&#146;s and its subsidiaries products and product candidates; (d)&nbsp;the deletion or qualification of
certain interim operating covenants of Roivant, including the deletion of, among other covenants, those restricting (i)&nbsp;the transfer or sale of equity securities, (ii)&nbsp;amendments to subsidiary governing documents, (iii)&nbsp;taking
material actions with respect to certain types of &#147;materials contracts&#148; (e.g., material partnership or similar agreements, related party contracts, etc.), (iv) entering into or providing for change of control or similar payments,
(v)&nbsp;entering into brokers&#146; arrangements related to the transactions, and (vi)&nbsp;material changes to tax elections or similar items; (e)&nbsp;a <FONT STYLE="white-space:nowrap">carve-out</FONT> to the exclusivity provision for equity or
similar investments in Roivant; (f)&nbsp;the deletion of the right of MAAC to designate its director designee to serve on Roivant board committees following closing; and (g)&nbsp;the addition of covenants, agreements and obligations of MAAC with
respect to the PIPE Financing and the Subscription Agreements (including, among other things, covenants with respect to the required efforts by MAAC to comply with its obligations, and enforce its rights, under the Subscription Agreements and
Roivant&#146;s right, in certain circumstances, to cause MAAC to enforce its rights under the Subscription Agreements on the terms and subject to the conditions set forth in the Subscription Agreements and the Business Combination Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;23, 2021, a virtual meeting of the Roivant board of directors was held with representatives of Roivant management in attendance.
Mr.&nbsp;Momtazee also attended a portion of this meeting and was introduced to the members of the Roivant board of directors and answer questions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between March&nbsp;25, 2021 and May&nbsp;1, 2021, Kirkland, Davis Polk and Latham&nbsp;&amp; Watkins LLP, counsel to the Placement Agents,
collectively negotiated the terms and exchanged drafts of the Subscription Agreements with prospective PIPE Investors and their respective representatives and responded to <FONT STYLE="white-space:nowrap">follow-up</FONT> questions and comments
related thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;31, 2021, Kirkland provided Davis Polk with a revised draft of the Business Combination Agreement that, in
addition to proposed revisions to the overall suite of representations, warranties and covenants to be provided by each party under the Business Combination Agreement, proposed the following material revisions: (a)&nbsp;certain representations and
warranties with respect to capitalization of Roivant&#146;s subsidiaries and the authorized capital structure of Roivant being brought down to an &#147;in all material respects&#148; standard for purposes of the &#147;bring-down&#148; closing
condition in favor of MAAC; (b)&nbsp;representations and warranties with respect to MAAC&#146;s Trust Account being brought down to a MAAC Material Adverse Effect standard for purposes of the &#147;bring-down&#148; closing condition in favor of
Roivant; (c)&nbsp;the definition of Company Material Adverse Effect also including adverse effects on the assets of Roivant and its subsidiaries; (d)&nbsp;the Company Material Adverse Effect <FONT STYLE="white-space:nowrap">carve-out</FONT> for
regulatory or similar events subject to an exception for regulatory or similar events arising out of fraud or wrongdoing by Roivant or its subsidiaries; (e)&nbsp;certain revisions to Roivant&#146;s interim operating covenants, including the addition
of covenants restricting (i)&nbsp;taking material actions with respect to related party contracts, (ii)&nbsp;entering into or providing for change of control or similar payments, (iii)&nbsp;material changes to tax elections or similar items and
(iv)&nbsp;entering into brokers&#146; arrangements related to the transactions; and (f)&nbsp;the <FONT STYLE="white-space:nowrap">carve-out</FONT> to the exclusivity provision for equity or similar issuances of Roivant being qualified by a
requirement for any such issuance to be consistent with past valuation practices of Roivant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;2, 2021, Davis Polk provided
Kirkland with a revised draft of the Business Combination Agreement that, in addition to proposed revisions to the overall suite of representations, warranties and covenants to be provided by each party under the Business Combination Agreement,
proposed the following material </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
revisions: (a)&nbsp;certain representations and warranties with respect to capitalization of Roivant&#146;s subsidiaries and the authorized capital structure of Roivant being brought down to an
&#147;material to Roivant and its subsidiaries, taken as a whole&#148; standard, rather than an &#147;in all material respects&#148; standard, for purposes of the &#147;bring-down&#148; closing condition in favor of MAAC; (b)&nbsp;representations
and warranties with respect to MAAC&#146;s Trust Account being brought down to an &#147;in all material respects&#148; standard, rather than MAAC Material Adverse Effect standard, for purposes of the &#147;bring-down&#148; closing condition in favor
of Roivant; (c)&nbsp;the exception to the Company Material Adverse Effect <FONT STYLE="white-space:nowrap">carve-out</FONT> for regulatory or similar event being limited to fraud of Roivant and its subsidiaries, rather than fraud or wrongdoing of
the Group Companies; (d)&nbsp;certain exceptions and qualifications to Roivant&#146;s interim operating covenants; and (e)&nbsp;a proposed outside date for completing the Business Combination by December&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between April&nbsp;2, 2021 and May&nbsp;1, 2021, Kirkland, on the one hand, and Davis Polk, on the other hand, exchanged revised drafts of the
Business Combination Agreement and the parties came to agreement on the outstanding issues and other matters in the Business Combination Agreement, including, among other things: (a)&nbsp;the overall suite of other representations, warranties and
covenants to be provided by each party under the Business Combination Agreement (including the suite of Roivant interim operating covenants); (b) the standard for the &#147;bring-down&#148; at the closing for certain representations and warranties
(including those related to certain representations and warranties with respect to Roivant&#146;s capitalization and the Trust Account); (c) the definition of Company Material Adverse Effect and Roivant Material Adverse Effect; (d)&nbsp;the
mechanics for determining the post-closing Roivant board of directors; (e)&nbsp;the size, terms and establishment of the 2021 incentive equity plan and employee stock purchase plan; (f)&nbsp;an outside date for completing the Business Combination
(by November&nbsp;30, 2021); and (g)&nbsp;as more fully described below, the value per Roivant Common Share and the exchange ratio based thereon. For further information related to the final resolution of items (a)&nbsp;through (g) and the other
material terms of the Business Combination Agreement, please see the section entitled &#147;Business Combination Proposal&#151;The Business Combination Agreement.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;14, 2021, a virtual meeting of the MAAC board of directors was held, with members of MAAC management and representatives of MAAC
Sponsor, Kirkland, Sidley, and Ropes&nbsp;&amp; Gray LLP (&#147;Ropes&#148;), special intellectual property counsel to MAAC, present. Members of MAAC management provided the MAAC directors with an update with respect to the transaction process,
including an update with respect to the PIPE Financing process and an overview of the business, financial, tax, insurance and accounting due diligence process and findings with respect thereto. Representatives from Kirkland again advised the MAAC
board of directors of their fiduciary duties in connection with the potential business combination, and representatives from Kirkland, Sidley and Ropes each provided an overview of its due diligence findings with respect to Roivant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;29, 2021, Mr.&nbsp;Momtazee and Mr.&nbsp;Gline held a call to discuss the proposed business combination, including the status of
the PIPE process. Mr.&nbsp;Momtazee and Mr.&nbsp;Gline evaluated whether a transaction at the agreed-upon valuation of $38.50 per Roivant Common Share was preferable to a transaction with a lower valuation that would allow additional selected
investors to participate in the PIPE Financing. After discussion regarding the benefits of allowing such additional investors to participate in the PIPE Financing, Mr.&nbsp;Momtazee and Mr.&nbsp;Gline agreed to reduce the value per outstanding
Roivant Common Share from $38.50 per share to $29.26 per share (or from a fixed exchange ratio of 3.85 to 2.9262 per Roivant Common Share), which would, based on the December&nbsp;31, 2020 Roivant capitalization, pro forma for the acquisition of
Silicon Therapeutics, equate to an approximately $7.3&nbsp;billion pro forma equity value. The parties also agreed to adjust the vesting terms applicable to the portion of the MAAC Class&nbsp;B Shares held by MAAC Sponsor, with the parties agreeing
that (a)&nbsp;twenty percent of the Roivant Common Shares issued to MAAC Sponsor in respect of its MAAC Class&nbsp;B Shares would vest based on a $15.00 per share trigger price within five years of the closing of the Business Combination and
(b)&nbsp;ten percent of the Roivant Common Shares issued to MAAC Sponsor in respect of its MAAC Class&nbsp;B Shares would vest based on a $20.00 per share trigger price within 5 years of the closing of the Business Combination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between April&nbsp;29, 2021 and May&nbsp;1, 2021, the final investment allocations of the
PIPE Investors that executed and delivered Subscription Agreements were determined and PIPE Investors delivered executed signature pages to the Subscription Agreements, which contemplated a $200&nbsp;million PIPE Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;30, 2021, a virtual meeting of the MAAC board of directors was held, with members of MAAC management and representatives of MAAC
Sponsor, Kirkland, Sidley and Ropes present. At the meeting, members of MAAC management and the MAAC board of directors discussed the strategic rationale for the proposed Business Combination (including the potential benefits and the risks related
thereto) and the valuation of the combined company as implied by the terms of the Business Combination, including the PIPE Financing (see &#147;Certain Financial Analysis&#148; for more information). Representatives from Kirkland also provided the
MAAC board of directors with an overview of the material terms of the Business Combination Agreement, the other key transaction documents and an overview of directors&#146; fiduciary duties in connection with approving the Business Combination.
Representatives of Kirkland also held, prior to the making of a motion to adopt and approve the transaction, an executive session with MAAC&#146;s independent directors only in which the independent directors and Kirkland discussed certain aspects
of the transaction and Kirkland answered certain questions from the independent directors. Based on the factors cited in &#147;&#151;Reasons for the Business Combination&#148;, the MAAC board of directors then unanimously adopted and approved, among
other resolutions, resolutions (a)&nbsp;that it was fair to and in the best interests of MAAC and its stockholders, and that it was advisable, to enter into the Business Combination Agreement and the ancillary documents to which MAAC is or will be a
party and to consummate the transactions contemplated thereby (including the Merger and the PIPE Financing), (b) to adopt and approve the Business Combination Agreement, the ancillary documents to which MAAC is or will be a party and the
transactions contemplated thereby (including the Merger and the PIPE Financing), (c) to recommend that the MAAC stockholders vote in favor of the Business Combination Proposal, the Adjournment Proposal, any proposal that either the SEC or Nasdaq
indicates is necessary in its comments to the proxy statement/prospectus or in correspondence related hereto, and any proposal reasonably agreed by MAAC and Roivant to be appropriate in connection with the consummation of the Business Combination,
and (d)&nbsp;to direct that each of the Business Combination Proposal, the Adjournment Proposal, any proposal that either the SEC or Nasdaq indicates is necessary in its comments to the proxy statement/prospectus or in correspondence related hereto,
and any proposal reasonably agreed by MAAC and Roivant to be appropriate in connection with the consummation of the Business Combination to be submitted to the MAAC stockholders for approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;30, 2021, a virtual meeting of the Roivant board of directors was held, with Roivant management in attendance, to discuss the
final negotiated terms of the Business Combination. Following discussions among the Roivant board of directors, the Roivant board of directors (a)&nbsp;unanimously approved the Business Combination Agreement, the ancillary documents to which Roivant
is or will be a party and the consummation of the transactions contemplated thereby (including the Roivant <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps (as defined in the Business Combination Agreement) and the Merger) and
(b)&nbsp;recommended, among other things, the entry into the Business Combination Agreement and the ancillary documents to which Roivant is or will be a party and the consummation of the transactions contemplated thereby (including the Roivant <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Steps (as defined in the Business Combination Agreement) and the Merger) to the holders of the Roivant Common Shares entitled to vote thereon for their approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;1, 2021, the parties entered into the Business Combination Agreement and the related ancillary documents. Also, on May&nbsp;1,
2021, the PIPE Investors executed and delivered the Subscription Agreements. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;3, 2021, MAAC and Roivant issued a joint press release announcing
the execution and delivery of the Business Combination Agreement, and MAAC filed a Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> which filed as an exhibit (a)&nbsp;the Business Combination Agreement, (b)&nbsp;the Sponsor
Support Agreement, (c)&nbsp;the form of Subscription Agreement, (d)&nbsp;the form of Transaction Support Agreement, (e)&nbsp;the form of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, (f)&nbsp;a joint press release, dated May&nbsp;3,
2021, (g) an investor presentation providing information on Roivant and a summary of certain key terms of the Business Combination and (h)&nbsp;a transcript of the investor presentation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The MAAC Board of Directors&#146; Reasons for the Business Combination </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MAAC board of directors, in evaluating the Business Combination, consulted with its management and legal, tax, insurance, accounting and
other advisors. In reaching its unanimous resolution (a)&nbsp;that it was fair to and in the best interests of MAAC and its stockholders, and that it was advisable, to enter into the Business Combination Agreement and the ancillary documents to
which MAAC is or will be a party and to consummate the transactions contemplated thereby (including the Merger and the PIPE Financing), (b) to adopt and approve the Business Combination Agreement, the ancillary documents to which MAAC is or will be
a party and the transactions contemplated thereby (including the Merger and the PIPE Financing), (c) to recommend that the MAAC stockholders vote in favor of the Business Combination Proposal, the Nasdaq Proposal, the Adjournment Proposal, any
proposal that either the SEC or Nasdaq indicates is necessary in its comments to the proxy statement/prospectus or in correspondence related hereto, and any proposal reasonably agreed by MAAC and Roivant to be appropriate in connection with the
consummation of the Business Combination, and (d) to direct that each of the Business Combination Proposal, the Nasdaq Proposal, the Adjournment Proposal, any proposal that either the SEC or Nasdaq indicates is necessary in its comments to the proxy
statement/prospectus or in correspondence related hereto, and any proposal reasonably agreed by MAAC and Roivant to be appropriate in connection with the consummation of the Business Combination be submitted to the MAAC stockholders for approval,
the MAAC board of directors considered and evaluated a number of factors, including, but not limited to, the factors discussed below. In light of the number and wide variety of factors considered in connection with its evaluation of the Business
Combination, the MAAC board of directors did not consider it practicable, and did not attempt, to quantify or otherwise assign relative weights to the specific factors that it considered in reaching its determination and supporting its decision. The
MAAC board of directors viewed its decision as being based on all of the information available and the factors presented to and considered by it. In addition, individual directors may have given different weight to different factors. This
explanation of MAAC board of directors&#146; reasons for the Business Combination and all other information presented in this section is forward-looking in nature and, therefore, should be read in light of the factors discussed under
&#147;Cautionary Note Regarding Forward-Looking Statements.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of the MAAC board of directors are well qualified to
evaluate the Business Combination with Roivant, as each of such directors has decades of operating and acquisition experience as well as relationships in the health care industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MAAC board of directors considered a number of factors pertaining to Roivant and the Business Combination as generally supporting its
decision to enter into the Business Combination Agreement and the transactions contemplated thereby, including, but not limited to, the following material factors: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A.<B><I> </I></B><B><I>Satisfies Certain Key MAAC Acquisition Criteria</I></B><I>. </I>The MAAC board of directors believes that Roivant meets
many of the key acquisition criteria that MAAC established at its initial public offering, namely that Roivant drives innovation, is growth oriented, is led by an outstanding team and has the potential to develop a durable revenue base. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B<I>.</I><B><I> Strong Management T</I></B><B><I>eam</I></B>. The MAAC board of directors believes that Roivant has a strong management team,
as evidenced by their individual experience and skill sets, as well as their strong track record at Roivant, further discussed below. This management team, led by Roivant&#146;s Chief Executive Officer and Chief Financial Officer, Chief Operating
Officer, Chief Investment Officer, Chief Accounting Officer and President of Roivant Health, many of whom have successfully worked together for most of Roivant&#146;s existence, has guided Roivant through a number of significant milestones over
recent years, including eight consecutive positive Phase 3 trials and a $3.0 billion upfront transaction with Sumitomo Dainippon Pharma. Together with Roivant&#146;s founder Vivek Ramaswamy, who will continue to serve Roivant as Executive Chairman,
this team intends to remain with Roivant and will provide important continuity in advancing Roivant&#146;s strategic and growth goals. James C. Momtazee, the Chief Executive Officer, President and Chairman of MAAC&#146;s board of directors, will
join Roivant&#146;s board of directors after completion of the Business Combination. Mr. Momtazee brings over 23 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
years of broad operational and transaction experience in the healthcare industry that make him well qualified to serve on Roivant&#146;s board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C<I>.</I><B><I> Roivant&#146;s Track Record</I></B>. Founded in 2014, Roivant is a next-generation &#147;big pharma&#148; company, organized
to harness modern technologies and the entrepreneurial spirit of nimble biotechnology companies at scale. The Company has brought over 40 medicines into development, conducted nine international Phase 3 trials, the last eight of which have been
successful, and developed two drugs that received FDA approval shortly after their transfer to Sumitomo. Roivant&#146;s return on investment from inception to March 31, 2021, based on the realized return associated with the partnership with Sumitomo
Dainippon Pharma and the value of Roivant&#146;s ownership stakes in its public Vants as of April 29, 2021, has far exceeded average research and development returns for select large cap biopharmaceutical companies based on average cost to develop
assets and projected revenues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">D. <B><I>Proprietary Technology Assets</I></B>. Roivant has differentiated capabilities in computational
drug discovery, organized in its small molecule discovery engine. The combination of both machine-learning and physics driven computational drug discovery capabilities may accelerate the hit-to-lead and lead optimization stages of the drug discovery
process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">E. <B><I>Promising Development Pipeline</I></B>. Roivant has a deep and diversified pipeline of over 30 drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">F. <B><I>Recent Targeted Acquisitions</I></B>. The recent acquisition of Silicon Therapeutics will expand Roivant&#146;s computational physics
capabilities, potentially providing distinct advantages in drug discovery. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">G. <B><I>Attractive Entry Valuation</I></B>. After the close
of the Business Combination, Roivant will have an anticipated initial equity value of approximately $7.3 billion assuming that the MAAC Shares are trading at $10.00 per share. The MAAC board of directors reviewed and considered valuations of private
and publicly traded companies in similar and adjacent sectors as Roivant and its material Vants. Based on these valuations, the MAAC board of directors conducted a sum of the parts analysis and determined that the anticipated initial market
capitalization represents an attractive discount as compared to such comparable private and public companies. For additional information, see &#147;&#151;Certain Financial Analyses.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">H. <B><I>P</I></B><B><I>ost-</I></B><B><I>C</I></B><B><I>losing </I></B><B><I>Economic I</I></B><B><I>nterest in Roivant</I></B>. If the
Business Combination were consummated, MAAC stockholders (other than MAAC stockholders that redeem their MAAC Class A Shares) would have a continuing economic interest in Roivant and as a result would have a continuing opportunity to benefit from
the success of Roivant following the consummation of the Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I. <B><I>Due Diligence</I></B>. The MAAC board of
directors reviewed and discussed in detail the results of the due diligence examination of Roivant conducted by MAAC&#146;s officers and MAAC&#146;s legal, tax, insurance, accounting and other advisors which included virtual meetings with the
management team and advisors of Roivant regarding Roivant&#146;s business and business plan, operations, prospects and other material matters, as well as financial, legal, intellectual property, regulatory, cyber, insurance, tax and accounting due
diligence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">J. <B><I>Support of Key S</I></B><B><I>hareholders</I></B>. The fact that (i) key Roivant shareholders representing
approximately 90% of the currently issued and outstanding Roivant Common Shares entered into Transaction Support Agreements, demonstrating their support for the Business Combination, and (ii) certain Roivant shareholders and their affiliates
committed to invest an aggregate of over $100 million in the PIPE Financing, demonstrating their continued conviction in Roivant&#146;s business and prospects for growth following the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">K. <B><I>Roivant Shareholder and Sponsor Lock-Up</I></B>. Certain Roivant shareholders and the MAAC Sponsor have agreed to subject 75% of
their holdings to an extended lock-up, further demonstrating their conviction in Roivant&#146;s long-term success. For additional information, see &#147;The Business Combination Proposal&#151;Related Agreements.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">L. <B><I>Financial Condition</I></B>. The MAAC board of directors reviewed certain factors
related to Roivant&#146;s financial condition, such as Roivant&#146;s historical financial results, outlook and business and financial plans. The MAAC board of directors took note of the fact that Roivant had over $2.0 billion of consolidated cash
and cash equivalents on its balance sheet as of December 31, 2020, and that the Business Combination is expected to provide up to approximately $611 million of gross proceeds to Roivant, assuming no redemptions by the MAAC shareholders of their MAAC
Class A Shares. In reviewing these factors, the MAAC board of directors concluded that Roivant will be well-capitalized with sufficient funding to advance its development plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">M. <B><I>Other Alternatives</I></B>. The MAAC board of directors&#146; belief that, after a thorough review of other business combination
opportunities reasonably available to MAAC, based upon the process utilized to diligence, evaluate and analyze other potential business combination targets, that the Business Combination represents the best potential business combination for MAAC.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">N. <B><I>Negotiated Transaction</I></B>. The financial and other terms of the Business Combination Agreement and the fact that such terms
and conditions were the product of arm&#146;s-length negotiations between MAAC and Roivant, as well as feedback on valuation from the investors who participated in the PIPE Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MAAC board of directors also considered a variety of uncertainties and risks and other potentially negative factors related to
Roivant&#146;s business and prospects and related to the Business Combination including, but not limited to, the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A.
<B><I>Roivant Business Plan Execution</I></B>. The risk that the potential benefits of the Business Combination may not be fully achieved or may not be achieved within the expected timeframe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. <B><I>Liquidation of MAAC</I></B>. The risks and costs to MAAC if the Business Combination is not completed, including the risk of
diverting management focus and resources from other business combination opportunities, which could result in MAAC being unable to effect a business combination by October 9, 2022 and force MAAC to liquidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. <B><I>Redemption Risk</I></B>. The potential that a significant number of MAAC stockholders elect to redeem their shares prior to the
consummation of the Business Combination and pursuant to MAAC&#146;s Pre-Closing Certificate of Incorporation, and that Roivant&#146;s obligation to consummate the Business Combination is conditioned on there being at least $210 million remaining in
MAAC&#146;s trust account to be released to MAAC on the closing date after giving effect to any such redemptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">D.
<B><I>Exclusivity</I></B>. The fact that the Business Combination Agreement includes an exclusivity provision that prohibits MAAC from soliciting other business combination proposals, which restricts MAAC&#146;s ability, so long as the Business
Combination Agreement is in effect, to consider other potential business combinations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">E. <B><I>Stockholder Vote</I></B>. The risk that
MAAC&#146;s stockholders may fail to provide the votes necessary to effect the Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">F. <B><I>Macroeconomic
Risks</I></B>. The risk that the future financial performance of Roivant may not meet the MAAC board of directors&#146; expectations due to factors in Roivant&#146;s control or out of its control, including economic cycles or other macroeconomic
factors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">G. <B><I>Limitations of Review</I></B>. The MAAC board of directors considered that they were not obtaining an opinion from any
independent investment banking or accounting firm that the consideration to be received by the MAAC Stockholders is fair to MAAC or its stockholders from a financial point of view. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">H. <B><I>Closing Conditions</I></B>. The fact that completion of the Business Combination is conditioned on the satisfaction of certain
closing conditions that are not within MAAC&#146;s or Roivant&#146;s control, including approval by MAAC stockholders and approval by Nasdaq of the initial listing application in connection with the Business Combination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I. <B><I>Post-Business Combination Corporate Governance</I></B>. The fact that the board of
directors of Roivant will be classified and that all Roivant directors will not be elected annually. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">J. <B><I>Litigation</I></B>. The
possibility of litigation challenging the Business Combination or that an adverse judgment granting permanent injunctive relief could indefinitely enjoin consummation of the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">K. <B><I>Fees and Expenses</I></B>. The expected fees and expenses associated with the Business Combination, some of which would be payable
regardless of whether the Business Combination is ultimately consummated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to considering the factors described above, the
MAAC board of directors also considered other factors including, without limitation: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. <B><I>Interests of Certain Persons</I></B>. The
MAAC Sponsor, each member of the MAAC board of directors, MAAC&#146;s officers and certain of MAAC&#146;s advisors directly or indirectly own MAAC Class B Shares and warrants to purchase MAAC Class A Shares and, accordingly, may have a conflict of
interest in determining whether a particular target business is an appropriate business with which to effectuate our business combination. The MAAC board of directors reviewed and considered this during the negotiation of the Business Combination
and in evaluating and unanimously approving, as members of the MAAC board of directors, the Business Combination Agreement and the transactions contemplated therein, including the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. <B><I>Other Risks</I></B>. The various risks associated with the Business Combination, the business of Roivant, and the business of MAAC,
as described in the section entitled &#147;Risk Factors&#148; of this proxy statement/ prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MAAC board of directors concluded
that the potential benefits expected to be received by MAAC and its stockholders as a result of the Business Combination outweighed the potentially negative factors and other risks associated with the Business Combination. Accordingly, the MAAC
board of directors unanimously resolved that (a) that it was fair to and in the best interests of MAAC and its stockholders, and that it was advisable, to enter into the Business Combination Agreement and the ancillary documents to which MAAC is or
will be a party and to consummate the transactions contemplated thereby (including the Merger and the PIPE Financing), (b) to adopt and approve the Business Combination Agreement, the ancillary documents to which MAAC is or will be a party and the
transactions contemplated thereby (including the Merger and the PIPE Financing), (c) to recommend that the MAAC stockholders vote in favor of the Business Combination Proposal, the Nasdaq Proposal, the Adjournment Proposal, any proposal that either
the SEC or Nasdaq indicates is necessary in its comments to the proxy statement/prospectus or in correspondence related hereto, and any proposal reasonably agreed by MAAC and Roivant to be appropriate in connection with the consummation of the
Business Combination, and (d) to direct that each of the Business Combination Proposal, the Nasdaq Proposal, the Adjournment Proposal, any proposal that either the SEC or Nasdaq indicates is necessary in its comments to the proxy
statement/prospectus or in correspondence related hereto, and any proposal reasonably agreed by MAAC and Roivant to be appropriate in connection with the consummation of the Business Combination to be submitted to the MAAC stockholders for approval.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary of MAAC Financial Analysis </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material financial analyses prepared and reviewed by MAAC&#146;s management in connection with the valuation
of Roivant. The summary set forth below does not purport to be a complete description of the financial analyses performed or factors considered by MAAC nor does the order of the financial analyses described represent the relative importance or
weight given to those financial analyses by the Board. MAAC may have deemed various assumptions more or less probable than other assumptions, so the valuations resulting from any particular portion of the analyses summarized below should not be
taken to be MAAC&#146;s view of the actual value of Roivant. Some of the summaries of the financial analyses set forth below include information presented in tabular format. Considering the data in the tables below without considering all financial
analyses or factors or the full narrative description of such analyses or factors, including the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
methodologies and assumptions underlying such analyses or factors, could create a misleading or incomplete view of the processes underlying MAAC&#146;s financial analyses and the Board&#146;s
recommendation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In performing analyses, MAAC&#146;s management made numerous material assumptions with respect to, among other things,
timing of clinical trials, patient enrollment, timing of receipt of regulatory approvals that may be needed, characterization of the product candidates, the timing of, and amounts of, any royalty payments, milestone payments or other payments due to
third parties by Roivant, the entry by Roivant into license or collaboration agreements, market size, commercial efforts, industry performance, general business and economic conditions and numerous other matters, many of which are beyond the control
of MAAC, Roivant or any other parties to the Business Combination. None of Roivant, MAAC, or any other person assumes responsibility if future results are materially different from those discussed. Any estimates contained in these analyses are not
necessarily indicative of actual values or predictive of future results or values, which may be significantly more or less favorable than as set forth below. In addition, analyses relating to the value of Roivant do not purport to be appraisals or
reflect the prices at which Roivant shares may actually be valued. Accordingly, the assumptions and estimates used in, and the results derived from, the financial analyses are inherently subject to substantial uncertainty. Except as otherwise noted,
the following quantitative information, to the extent that it is based on market data, is based on market data as it existed on or before&nbsp;April 29, 2021 and is not necessarily indicative of current market conditions. For companies reviewed in
the precedent transaction analysis, selected valuation figures were sourced from certain financial databases and other publicly available information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>General Approach </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In performing its financial analysis, MAAC&#146;s management reviewed certain quantitative and qualitative financial and operating information
of Roivant and deployed a number of different valuation methodologies, as discussed below, selected based on the experience and the professional judgment of MAAC&#146;s management. On this basis, MAAC&#146;s management determined a range of equity
values that could reasonably be ascribed to Roivant and which would represent an attractive investment opportunity for MAAC. Upon that determination, the mandate for MAAC was to achieve a transaction value that was less than that assessment of value
and which attempted to maximize shareholder value for MAAC, but which was also acceptable to Roivant. The range of values developed through the process described below was greater than the approximately $7.3&nbsp;billion pro forma equity value
agreed upon in the Business Combination Agreement and validated by the PIPE Financing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Sum of the Parts </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC&#146;s management utilized a sum of the parts approach in its evaluation of Roivant that focused on certain more advanced or material
Vants, taking into account the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the value of Roivant&#146;s ownership stake in the public Vants (Arbutus, Immunovant and Sio Gene Therapies) and
certain other public companies (Poxel and Myovant Sciences (in the case of Myovant, with respect to Roivant&#146;s right to receive certain Myovant shares pursuant to the Share Return Agreement, dated as of December 27 2019, by and between Roivant
and Sumitomo Dainippon Pharma Co., Ltd., as further described in Roivant&#146;s Schedule 13D filing on December 31, 2019)), as of April 29, 2021; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the value of Roivant&#146;s ownership stake in certain material private Vants (Dermavant, Aruvant, the targeted
protein degrader platform and the computational small molecule discovery engine). </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given the large number and range of
Roivant&#146;s clinical and pre-clinical programs, MAAC&#146;s management did not assign a specific value to each private Vant. Instead, MAAC&#146;s management reviewed the market values of companies that are comparable to each of the material
private Vants as an indicator of the range of potential market values for each of these Vants. MAAC&#146;s management determined that the sum of (x) the market values for the investments in the public Vants and other public companies and (y) the
comparable company market values for each private Vant was in excess of the pro forma equity value of approximately $7.3 billion (which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
includes approximately $2.3 billion of net cash and cash equivalents held by Roivant at December 31, 2020) ultimately agreed upon in the Business Combination Agreement and validated in the PIPE
Financing. MAAC&#146;s management thus concluded that it was an attractive valuation for MAAC&#146;s stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This analysis did not
take into account any potential additional value of certain other private Vants where there were not comparable publicly traded companies or precedent transactions, however, MAAC&#146;s management believed that such private Vants represented
additional value, further bolstering their conclusion regarding Roivant&#146;s equity value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Interests in Publicly Traded Vants
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the Vants that are publicly traded and the other investments in public companies, MAAC&#146;s management evaluated the
value of Roivant&#146;s ownership stake in each such company. As of April 29, 2021, the market value of such investments was approximately $1.2&nbsp;billion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Interests in Material Private Vants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the material private Vants, MAAC&#146;s management reviewed the market capitalizations of comparable publicly traded companies
and, with respect to Dermavant, performed a selected precedent transaction analysis for two comparators (Otezla and Anacor Pharmaceuticals), in each case selected based on the experience and the professional judgment of MAAC&#146;s management. While
more companies could have been included, MAAC management selected the companies below based on the targeted disease of the Vant&#146;s development program, comparable stage of drug development, comparable drug mechanism of action, comparable target
indications or comparable technologies. In particular, MAAC selected publicly traded companies that are oriented towards (a)&nbsp;atopic dermatitis and plaque psoriasis treatment, (b)&nbsp;sickle cell gene therapy, (c)&nbsp;targeted protein degrader
platforms, and (d)&nbsp;computational small molecule discovery engines, in each case that MAAC deemed relevant for analysis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the
selected companies has characteristics identical to Roivant or any one of the Vants. Companies were selected because they have a combination of comparable stage of drug development, comparable drug mechanism of action, comparable target indications
or comparable technologies to the assets at one or more of the material private Vants. An analysis of selected publicly traded companies and precedent transaction values is not purely quantitative; rather it involves complex consideration and
judgments concerning differences in financial and operating characteristics of the selected companies and other factors that could affect the valuations of the companies reviewed. MAAC believed that it was inappropriate to, and therefore did not,
rely solely on the quantitative results of the selected public company and precedent transaction analysis. Accordingly, MAAC also made qualitative judgments, based on the experience and professional judgment of its management team and advisors,
concerning differences between the operational, business and/or financial characteristics of Roivant and the Vants and the selected companies to provide a context in which to consider the results of the quantitative analysis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC reviewed the market capitalization as of April&nbsp;29, 2021 of the selected comparable
companies and the enterprise value of the companies that it analyzed on the basis of precedent transactions (demarcated with a *) as shown below: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dermavant&#151;Atopic Dermatitis and Plaque Psoriasis Treatment </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stage(s)&nbsp;of&nbsp;Comparable<BR>Program(s)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market&nbsp;Cap&nbsp;($BN)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arcutis Biotherapeutics</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Clinical&nbsp;Stage</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Enterprise&nbsp;Value&nbsp;($BN)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Otezla*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>On Market</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;13.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anacor Pharmaceuticals*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>On&nbsp;Market&nbsp;and&nbsp;Clinical&nbsp;Stage</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 5.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Precedent transaction analysis </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aruvant&#151;Sickle Cell Gene Therapy </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stage(s)&nbsp;of&nbsp;Comparable<BR>Program(s)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market&nbsp;Cap&nbsp;($BN)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CRISPR Therapeutics</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Clinical&nbsp;Stage</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intellia Therapeutics</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Clinical Stage</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">bluebird bio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>On&nbsp;Market&nbsp;and&nbsp;Clinical&nbsp;Stage</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sangamo Therapeutics</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Clinical Stage</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Targeted Protein Degradation Platform </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stage(s)&nbsp;of&nbsp;Comparable<BR>Program(s)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market&nbsp;Cap&nbsp;($BN)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arvinas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Pre-Clinical&nbsp;and&nbsp;Clinical&nbsp;Stage</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kymera Therapeutics</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Pre-Clinical</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nurix Therapeutics</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Pre-Clinical</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">C4 Therapeutics</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Pre-Clinical</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Silicon Therapeutics / VantAI&#151;Small Molecule Discovery Engine </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stage(s)&nbsp;of&nbsp;Comparable<BR>Program(s)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market&nbsp;Cap&nbsp;($BN)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schr&ouml;dinger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Discovery</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Relay Therapeutics</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Clinical&nbsp;Stage&nbsp;and&nbsp;Discovery</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Historical Equity Financings of Roivant </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the sum of the parts analysis described above, MAAC&#146;s management derived an implied equity value of Roivant based on the
previous equity financings of Roivant, taking into account various financial and operational developments since the latest such financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From September to December 2018, several large institutional asset managers and existing Roivant shareholders subscribed for approximately
$200&nbsp;million in Roivant Common Shares at a price of $32.25 per share. On October&nbsp;31, 2019, Sumitomo agreed to subscribe for $1.0&nbsp;billion in Roivant Common Shares at a price of $37.10 per share. Sumitomo&#146;s subscription closed on
December&nbsp;27, 2019. &nbsp;&nbsp;&nbsp;&nbsp; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From October&nbsp;31, 2019 through April&nbsp;29, 2021, the market value of Roivant&#146;s
ownership interests in the publicly traded Vants increased by an amount in excess of $500&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the same period, Roivant:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">received positive Phase 3 trial results in the PSOARING 1 and PSOARING 2 trials and positive data in the PSOARING
3 long-term open-label study, each at Dermavant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">implemented improvements to the manufacturing process of <FONT STYLE="white-space:nowrap">ARU-1801</FONT> at
Aruvant and observed that the first patient treated under this new manufacturing process had the highest levels of fetal hemoglobin achieved to date and experienced no VOEs at twelve months; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launched its small molecule discovery engine and targeted protein degradation platform, including through the
acquisitions of Silicon Therapeutics and Oncopia Therapeutics. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding achieving such milestones, each of which
MAAC&#146;s management concluded was indicative of Roivant&#146;s increasing value, as well as various other achievements and developments across the various Vants since its most recent equity financing transactions, the valuation implied by such
prior equity financing transactions was greater than the approximately $7.3&nbsp;billion pro forma equity value ultimately agreed upon in the Business Combination Agreement and validated by the PIPE Financing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Satisfaction of 80% Test </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is a requirement under MAAC&#146;s existing organizational documents and Nasdaq listing requirements that the business or assets acquired
in MAAC&#146;s initial business combination have a fair market value equal to at least 80% of the balance of the funds in the Trust Account (excluding the deferred underwriting commissions and taxes payable on the income earned on the Trust Account)
at the time of the execution of a definitive agreement for the initial business combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of the execution of the
Business Combination Agreement, the balance of the funds in the Trust Account was approximately $396.4 million (excluding the deferred underwriting amount) and 80% thereof represents approximately $317.1 million. In reaching its conclusion that the
business combination meets the 80% asset test, MAAC&#146;s board of directors looked at the enterprise value of Roivant of approximately $7.3 billion (calculated on a debt and cash free basis). In determining whether the enterprise value described
above represents the fair market value of Roivant, MAAC&#146;s board of directors considered all of the factors described above in this section and the fact that the purchase price for Roivant was the result of an arm&#146;s-length negotiation. As a
result, MAAC&#146;s board of directors concluded that the fair market value of the business acquired was significantly in excess of 80% of the assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on the
income earned on the Trust Account). In light of the financial background and experience of the members of MAAC&#146;s management team and the board of directors, MAAC&#146;s board of directors believes that the members of its management team and
the board of directors are qualified to determine whether the business combination meets the 80% asset test. MAAC&#146;s board of directors did not seek or obtain an opinion of an outside financial advisor as to whether the 80% asset test has been
met. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Interests of Certain MAAC Persons in the Business Combination </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When considering the recommendation of the MAAC board of directors to vote in favor of the Business Combination, you should be aware that,
aside from their interests as stockholders, the MAAC Sponsor and the holders of the Founder Shares have other interests in the Business Combination that are different from, or in addition to, those of other MAAC stockholders generally. The MAAC
board of directors was aware of and considered these interests, among other matters, in evaluating and unanimously approving the Business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Combination and in recommending to MAAC stockholders that they approve the Business Combination. MAAC stockholders should take these interests into account in deciding whether to approve the
Business Combination. These interests include, among other things, the interests listed below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">MAAC&#146;s directors and officers and the MAAC Sponsor have waived their right to redeem any Founder Shares and
MAAC Class&nbsp;A Shares held by them (if any) in connection with a stockholder vote to approve a proposed initial business combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the MAAC Sponsor paid an aggregate of $25,000 for the Founder Shares, which will convert into
10,267,956 MAAC Class&nbsp;A Shares held by the MAAC Sponsor and the MAAC Independent Directors in accordance with the terms of MAAC&#146;s amended and restated certificate of incorporation and such securities will have a significantly higher value
at the time of the Business Combination when such shares convert into shares in the combined company, as described further below: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Class&nbsp;A<BR>Stock<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value&nbsp;of&nbsp;Class&nbsp;A<BR>Stock<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MAAC Sponsor<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,167,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,679,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">George Barrett</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Oesterle</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Interests shown consist solely of Founder Shares, classified as Class B common stock. Such shares will
automatically convert into Class&nbsp;A common stock concurrently with or immediately following the consummation of the Business Combination on a one-for-one basis, subject to adjustment pursuant to the MAAC Sponsor Exchange Ratio. Share amounts are
subject to the terms and conditions set forth in the Sponsor Support Agreement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Patient Square Capital LLC is the record holder of the shares reported herein. James C. Momtazee is the
managing member of Patient Square Capital LLC and has voting and dispositive power over such securities. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes a value of $10.00 per share, the deemed value of the Class&nbsp;A Stock in the Business Combination.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the MAAC Sponsor and MAAC&#146;s directors and officers have agreed to waive their rights to
liquidating distributions from the Trust Account with respect to the Founder Shares if we fail to complete an initial business combination by October&nbsp;9, 2022; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the MAAC Sponsor, in which certain of MAAC&#146;s officers and directors hold a direct or indirect
interest, purchased an aggregate of 10,214,365 warrants in a private placement from MAAC for an aggregate purchase price of $10,214,365 (or $1.00 per warrant), each of such private placement warrants is exercisable commencing on the later of 12
months from the closing of MAAC&#146;s initial public offering and 30 days following the Closing for one MAAC Class&nbsp;A Share at $11.50 per share; if we do not consummate an initial business combination by October&nbsp;9, 2022, then the proceeds
from the sale of the private placement warrants will be part of the liquidating distribution to the public stockholders and the private placement warrants held by the MAAC Sponsor will be worthless; the warrants held by the MAAC Sponsor had an
aggregate market value of approximately $13,278,674.50 based upon the closing price of $1.30 per warrant on Nasdaq on August 5, 2021; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">James C. Momtazee, Chairman, Chief Executive Officer and President of MAAC, is expected to be a director of
Roivant after the consummation of the Business Combination. As such, in the future, he may receive cash fees, stock options, stock awards or other remuneration that the Roivant board of directors determines to pay to him and any applicable
compensation as described under section &#147;Executive Compensation&#151;Director Compensation&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the Trust Account is liquidated, including in the event we are unable to complete an initial business
combination within the required time period, the MAAC Sponsor has agreed that it will be liable to us if and to the extent any claims by a third-party (other than MAAC&#146;s independent public accountants) for services rendered or products sold to
us, or a prospective target business with which we have </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
entered into a transaction agreement, reduce the amount of funds in the trust account to below: (i) $10.00 per public share; or (ii)&nbsp;such lesser amount per public share held in the trust
account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets, in each case, net of the interest which may be withdrawn to pay taxes, except as to any claims by a third-party who executed a waiver
of any and all rights to seek access to the trust account and except as to any claims under our indemnity of the underwriters of MAAC&#146;s initial public offering against certain liabilities, including liabilities under the Securities Act; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the MAAC Sponsor and MAAC&#146;s officers and directors will lose their entire investment in us,
which investment amount totaled $10,239,365, and will not be reimbursed for any out-of-pocket expenses, which totaled $23,418 as of June 17, 2021, if the Business Combination, or an initial business combination, is not consummated by October 9,
2022. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time prior to the Special Meeting, during a period when they are not then aware of any material <FONT
STYLE="white-space:nowrap">non-public</FONT> information regarding MAAC or its securities, the MAAC Sponsor, MAAC&#146;s directors and officers, Roivant and/or their respective affiliates may purchase shares and/or warrants from investors, or they
may enter into transactions with such investors and others to provide them with incentives to acquire shares of MAAC Shares or vote their shares in favor of the Business Combination Proposal. The purpose of such share purchases and other
transactions would be to increase the likelihood that the proposals presented to stockholders for approval at the Special Meeting are approved or to provide additional equity financing. Any such share purchases and other transactions may thereby
increase the likelihood of obtaining stockholder approval of the Business Combination. This may result in the completion of our Business Combination that may not otherwise have been possible. While the exact nature of any such incentives has not
been determined as of the date of this proxy statement/prospectus, they might include, without limitation, arrangements to protect such investors or holders against potential loss in value of their shares, including the granting of put options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Entering into any such incentive arrangements may have a depressive effect on MAAC Shares. For example, as a result of these arrangements, an
investor or holder may have the ability to effectively purchase shares at a price lower than market and may therefore be more likely to sell the shares he owns, either prior to or immediately after the Special Meeting. If such transactions are
effected, the consequence could be to cause the Business Combination to be approved in circumstances where such approval could not otherwise be obtained. Purchases of shares by the persons described above would allow them to exert more influence
over the approval of the proposals to be presented at the Special Meeting and would likely increase the chances that such proposals would be approved. As of the date of this proxy statement/prospectus, there have been no such discussions and no
agreements to such effect have been entered into with any such investor or holder. MAAC will file a Current Report <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;8-K&nbsp;to&nbsp;disclose</FONT> any arrangements entered into or significant
purchases made by any of the aforementioned persons that would affect the vote on the proposals to be voted on at the Special Meeting. Any such report will include descriptions of any arrangements entered into or significant purchases by any of the
aforementioned persons. The existence of financial and personal interests of our directors and officers may result in conflicts of interest, including a conflict between what may be in the best interests of MAAC and its stockholders and what may be
best for a director&#146;s personal interests when determining to recommend that stockholders vote for the proposals. See the sections entitled &#147;Risk Factors,&#148; &#147;The Business Combination Proposal&#151;Interests of Certain MAAC Persons
in the Business Combination&#148; and &#147;Beneficial Ownership of Securities&#148; for more information and other risks. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sources and
Uses for the Business Combination </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the sources and uses for funding the Business Combination assuming
that no MAAC Class&nbsp;A Shares are redeemed in connection with the Business Combination. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="4" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Sources</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Uses</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash in the Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Cash to Roivant&#146;s balance sheet</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="4" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Sources</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Uses</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PIPE Financing proceeds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Transaction expenses<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Sources</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>$631</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Total Uses</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>$631</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Transaction expenses includes fees and expenses incurred by both Roivant and MAAC in connection with the
Business Combination, including deferred underwriting fees, fees related to the PIPE Financing and advisory, legal and other fees. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Board of Directors of Roivant Following the Business Combination </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Closing, it is expected that the Roivant Board will consist of nine directors determined by Roivant (upon reasonable prior
consultation with MAAC) prior to the Effective Time, with one director, James C. Momtazee, being designated by MAAC, and the other directors being determined by Roivant (upon reasonable prior consultation with MAAC). See &#147;Management After The
Business Combination&#151;Executive Officers and Directors.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information about the current MAAC directors and executive officers can
be found in the section entitled &#147;Where You Can Find Additional Information.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Redemption Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption Rights for Public Stockholders upon Completion of MAAC&#146;s Initial Business Combination </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC is providing the MAAC stockholders with the opportunity to redeem all or a portion of their MAAC Class&nbsp;A Shares prior to the
consummation of the transactions contemplated by the Business Combination Agreement at a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of
two business days prior to the consummation of the transactions contemplated by the Business Combination Agreement, including interest earned on the funds held in the Trust Account and not previously released to MAAC to pay its taxes, if any divided
by the number of then outstanding MAAC Class&nbsp;A Share, subject to the limitations described herein. The amount in the Trust Account is initially anticipated to be approximately $10.00 per MAAC Class&nbsp;A Share. The <FONT
STYLE="white-space:nowrap">per-share</FONT> amount MAAC will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting commissions MAAC will pay to the underwriters of its initial public offering. The
redemption rights will include the requirement that a beneficial holder must identify itself in order to validly redeem its shares. There will be no redemption rights upon the completion of MAAC&#146;s initial Business Combination with respect to
the MAAC Warrants. The MAAC Sponsor, MAAC&#146;s directors and each member of MAAC&#146;s management team have entered into a letter agreement with MAAC, pursuant to which they have agreed to waive their redemption rights with respect to any Founder
Shares and any MAAC Class&nbsp;A Shares in connection with (i)&nbsp;the completion of the Business Combination and (ii)&nbsp;a stockholder vote to approve an amendment to MAAC&#146;s amended and restated Certificate of Incorporation that would
affect the substance or timing of MAAC&#146;s obligation to allow redemption in connection with MAAC&#146;s initial business combination or to redeem 100% of the MAAC Class&nbsp;A Shares if MAAC has not completed an initial business combination
within 24 months from the closing of MAAC&#146;s initial public offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitations on Redemptions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC&#146;s amended and restated Certificate of Incorporation provides that in no event will MAAC redeem its MAAC Class&nbsp;A Shares in an
amount that would cause its net tangible assets to be less than $5,000,001 (so that MAAC is not subject to the SEC&#146;s &#147;penny stock&#148; rules). However, the proposed Business Combination may require: (i)&nbsp;cash consideration to be paid
to the target or its owners; (ii)&nbsp;cash to be transferred to the target for working capital or other general corporate purposes; or (iii)&nbsp;the retention of cash to satisfy other conditions in accordance with the terms of the proposed
Business Combination. In the event the aggregate cash consideration </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
MAAC would be required to pay for all MAAC Class&nbsp;A Shares that are validly submitted for redemption plus any amount required to satisfy cash conditions pursuant to the terms of the proposed
Business Combination exceed the aggregate amount of cash available to MAAC, MAAC will not complete the Business Combination or redeem any shares, and all MAAC Class&nbsp;A Shares submitted for redemption will be returned to the holders thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption of Public Shares and Liquidation If No Initial Business Combination </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MAAC Sponsor, MAAC&#146;s officers and directors have agreed that MAAC has only 24 months from the closing of MAAC&#146;s initial public
offering to complete MAAC&#146;s initial business combination. If MAAC has not completed an initial business combination within <FONT STYLE="white-space:nowrap">24-months</FONT> from the closing of MAAC&#146;s initial public offering, MAAC will:
(i)&nbsp;cease all operations except for the purpose of winding up; (ii)&nbsp;as promptly as reasonably possible but not more than ten business days thereafter, redeem the MAAC Class&nbsp;A Shares, at a
<FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to MAAC to pay
its taxes, if any (less up to $100,000 of interest to pay dissolution expenses), divided by the number of the then outstanding MAAC Class&nbsp;A Shares, which redemption will completely extinguish Public Stockholders&#146; rights as stockholders
(including the right to receive further liquidation distributions, if any), subject to applicable law; and (iii)&nbsp;as promptly as reasonably possible following such redemption, subject to the approval of MAAC&#146;s remaining stockholders and
MAAC&#146;s board of directors, liquidate and dissolve, subject in each case, to MAAC&#146;s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or
liquidating distributions with respect to the MAAC Warrants, which will expire worthless if MAAC does not complete an initial business combination within 24 months from the closing of MAAC&#146;s initial public offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MAAC Sponsor, directors and each member of its management team have entered into a letter agreement with MAAC, pursuant to which they have
waived their rights to liquidating distributions from the Trust Account with respect to their Founder Shares if MAAC does not complete an initial business combination within 24 months from the closing of MAAC&#146;s initial public offering. However,
if MAAC&#146;s Sponsor, director or members of MAAC&#146;s management team acquire MAAC Class&nbsp;A Shares in or after MAAC&#146;s initial public offering, they will be entitled to liquidating distributions from the Trust Account with respect to
such MAAC Class&nbsp;A Shares if MAAC does not complete an initial business combination within 24 months from the closing of MAAC&#146;s initial public offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC&#146;s Sponsor, executive officers and directors have agreed, pursuant to a written agreement with MAAC, that they will not propose any
amendment to MAAC&#146;s amended and restated Certificate of Incorporation that would affect the substance or timing of MAAC&#146;s obligation to allow redemption in connection with MAAC&#146;s initial business combination or to redeem 100% of the
MAAC Class&nbsp;A Shares if MAAC does not complete an initial business combination within 24 months from the closing of MAAC&#146;s initial public offering, unless MAAC provides its stockholders with the opportunity to redeem their MAAC Class&nbsp;A
Shares upon approval of any such amendment at a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust
Account and not previously released to MAAC to pay its taxes, if any (less up to $100,000 of interest to pay dissolution expenses) divided by the number of the then outstanding MAAC Class&nbsp;A Shares. However, MAAC may not redeem the MAAC
Class&nbsp;A Shares in an amount that would cause MAAC&#146;s net tangible assets to be less than $5,000,001 (so that MAAC is not subject to the SEC&#146;s &#147;penny stock&#148; rules). If this optional redemption right is exercised with respect
to an excessive number of MAAC Class&nbsp;A Shares such that MAAC cannot satisfy the net tangible asset requirement, MAAC would not proceed with the amendment or the related redemption of the MAAC Class&nbsp;A Shares at such time. This redemption
right shall apply in the event of the approval of any such amendment, whether proposed by MAAC&#146;s Sponsor, any executive officer, director, or any other person. MAAC expects that all costs and expenses associated with implementing MAAC&#146;s
plan of dissolution, as well as payments to any creditors, will be funded from amounts remaining out of the approximately $1,700,000 of proceeds held outside </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Trust Account as of March 31, 2021 plus up to $100,000 of funds from the Trust Account available to MAAC to pay dissolution expenses, although MAAC cannot assure you that there will be
sufficient funds for such purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If MAAC were to expend all of the net proceeds of its initial public offering and the sale of the
Private Placement warrants, other than the proceeds deposited in the Trust Account, and without taking into account interest, if any, earned on the Trust Account, the <FONT STYLE="white-space:nowrap">per-share</FONT> redemption amount received by
stockholders upon MAAC&#146;s dissolution would be approximately $10.00. The proceeds deposited in the Trust Account could, however, become subject to the claims of MAAC&#146;s creditors which would have higher priority than the claims of
MAAC&#146;s Public Stockholders. MAAC cannot assure you that the actual <FONT STYLE="white-space:nowrap">per-share</FONT> redemption amount received by stockholders will not be substantially less than $10.00. Under Section&nbsp;281(b) of the
Delaware General Corporation Law (&#147;DGCL&#148;), MAAC&#146;s plan of dissolution must provide for all claims against MAAC to be paid in full or make provision for payments to be made in full, as applicable, if there are sufficient assets. These
claims must be paid or provided for before MAAC makes any distribution of MAAC&#146;s remaining assets to MAAC&#146;s stockholders. While MAAC intends to pay such amounts, if any, MAAC cannot assure you that MAAC will have funds sufficient to pay or
provide for all creditors&#146; claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although MAAC will seek to have all vendors, service providers (other than MAAC&#146;s
independent auditors), prospective target businesses and other entities with which MAAC does business execute agreements with MAAC waiving any right, title, interest or claim of any kind in or to any monies held in the Trust Account for the benefit
of MAAC&#146;s Public Stockholders, there is no guarantee that they will execute such agreements or even if they execute such agreements that they would be prevented from bringing claims against the Trust Account including, but not limited, to
fraudulent inducement, breach of fiduciary responsibility or other similar claims, as well as claims challenging the enforceability of the waiver, in each case in order to gain an advantage with respect to a claim against MAAC&#146;s assets,
including the funds held in the Trust Account. If any third party refuses to execute an agreement waiving such claims to the monies held in the Trust Account, MAAC&#146;s management will perform an analysis of the alternatives available to it and
will only enter into an agreement with a third party that has not executed a waiver if management believes that such third party&#146;s engagement would be significantly more beneficial to MAAC than any alternative. Examples of possible instances
where MAAC may engage a third party that refuses to execute a waiver include the engagement of a third-party consultant whose particular expertise or skills are believed by management to be significantly superior to those of other consultants that
would agree to execute a waiver or in cases where management is unable to find a service provider willing to execute a waiver. In addition, there is no guarantee that such entities will agree to waive any claims they may have in the future as a
result of, or arising out of, any negotiations, contracts or agreements with MAAC and will not seek recourse against the Trust Account for any reason. In order to protect the amounts held in the Trust Account, the MAAC Sponsor has agreed that it
will be liable to MAAC if and to the extent any claims by a third party for services rendered or products sold to MAAC (other than MAAC&#146;s independent registered public accounting firm), or a prospective target business with which MAAC has
discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i) $10.00 per Public Share and (ii)&nbsp;the actual amount per Public Share held in the Trust Account as of the date of the liquidation
of the Trust Account if less than $10.00 per share, due to reductions in the value of the trust assets, in each case net of the interest that may be withdrawn to pay MAAC&#146;s taxes, if any, provided that such liability will not apply to any
claims by a third party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under MAAC&#146;s indemnity of the underwriters of MAAC&#146;s initial public
offering against certain liabilities, including liabilities under the Securities Act. In the event that an executed waiver is deemed to be unenforceable against a third party, the MAAC Sponsor will not be responsible to the extent of any liability
for such third party claims. However, MAAC has not asked the MAAC Sponsor to reserve for such indemnification obligations, nor has MAAC independently verified whether MAAC&#146;s Sponsor has sufficient funds to satisfy its indemnity obligations and
MAAC believes that the MAAC Sponsor&#146;s only assets are securities of MAAC&#146;s company. Therefore, MAAC cannot assure you that the MAAC Sponsor would be able to satisfy those obligations. None of MAAC&#146;s officers or directors will
indemnify MAAC for claims by third parties including, without limitation, claims by vendors and prospective target businesses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the proceeds in the Trust Account are reduced below the lesser of (i)
$10.00 per Public Share and (ii)&nbsp;the actual amount per MAAC Class&nbsp;A Share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per share, due to reductions in the value of the trust assets,
in each case net of the interest which may be withdrawn to pay MAAC&#146;s taxes, if any, and MAAC&#146;s Sponsor asserts that it is unable to satisfy its indemnification obligations or that they have no indemnification obligations related to a
particular claim, MAAC&#146;s independent directors would determine whether to take legal action against the MAAC Sponsor to enforce its indemnification obligations. While MAAC currently expects that MAAC&#146;s independent directors would take
legal action on MAAC&#146;s behalf against the MAAC Sponsor to enforce its indemnification obligations to MAAC, it is possible that MAAC&#146;s independent directors in exercising their business judgment may choose not to do so in any particular
instance. Accordingly, MAAC cannot assure you that due to claims of creditors the actual value of the <FONT STYLE="white-space:nowrap">per-share</FONT> redemption price will not be less than $10.00 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC will seek to reduce the possibility that the MAAC Sponsor will have to indemnify the Trust Account due to claims of creditors by
endeavoring to have all vendors, service providers (other than MAAC&#146;s independent auditors), prospective target businesses or other entities with which MAAC does business execute agreements with MAAC waiving any right, title, interest or claim
of any kind in or to monies held in the Trust Account. MAAC&#146;s Sponsor will also not be liable as to any claims under MAAC&#146;s indemnity of the underwriters of MAAC&#146;s initial public offering against certain liabilities, including
liabilities under the Securities Act. MAAC will have access to up to approximately $1,700,000 from the proceeds held outside the Trust Account as of March 31, 2021 with which to pay any such potential claims (including costs and expenses incurred in
connection with MAAC&#146;s liquidation, currently estimated to be no more than approximately $100,000). In the event that MAAC liquidates and it is subsequently determined that the reserve for claims and liabilities is insufficient, stockholders
who received funds from the Trust Account could be liable for claims made by creditors, however such liability will not be greater than the amount of funds from the Trust Account received by any such stockholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the DGCL, stockholders may be held liable for claims by third parties against a corporation to the extent of distributions received by
them in a dissolution. The pro rata portion of the Trust Account distributed to MAAC&#146;s stockholders upon the redemption of the MAAC Class&nbsp;A Shares in the event MAAC does not complete MAAC&#146;s initial business combination within 24
months from the closing of the initial public offering may be considered a liquidating distribution under Delaware law. If the corporation complies with certain procedures set forth in Section&nbsp;280 of the DGCL intended to ensure that it makes
reasonable provision for all claims against it, including a <FONT STYLE="white-space:nowrap">60-day</FONT> notice period during which any third-party claims can be brought against the corporation, a <FONT STYLE="white-space:nowrap">90-day</FONT>
period during which the corporation may reject any claims brought, and an additional <FONT STYLE="white-space:nowrap">150-day</FONT> waiting period before any liquidating distributions are made to stockholders, any liability of stockholders with
respect to a liquidating distribution is limited to the lesser of such stockholder&#146;s pro rata share of the claim or the amount distributed to the stockholder, and any liability of the stockholder would be barred after the third anniversary of
the dissolution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, if the pro rata portion of the Trust Account distributed to MAAC&#146;s Public Stockholders upon the
redemption of the MAAC Class&nbsp;A Shares in the event MAAC does not complete MAAC&#146;s initial business combination within 24 months from the closing of the initial public offering, is not considered a liquidating distribution under Delaware law
and such redemption distribution is deemed to be unlawful (potentially due to the imposition of legal proceedings that a party may bring or due to other circumstances that are currently unknown), then pursuant to Section&nbsp;174 of the DGCL, the
statute of limitations for claims of creditors could then be six years after the unlawful redemption distribution, instead of three years, as in the case of a liquidating distribution. If MAAC does not complete MAAC&#146;s initial business
combination within 24 months from the closing of MAAC&#146;s initial public offering, MAAC will: (i)&nbsp;cease all operations except for the purpose of winding up, (ii)&nbsp;as promptly as reasonably possible but not more than ten business days
thereafter, redeem the MAAC Class&nbsp;A Shares, at a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the
Trust Account that may be released to MAAC to pay </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
its taxes, if any (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding MAAC Class&nbsp;A Shares, which redemption will completely extinguish
Public Stockholders&#146; rights as stockholders (including the right to receive further liquidating distributions, if any) and (iii)&nbsp;as promptly as reasonably possible following such redemption, subject to the approval of MAAC&#146;s remaining
stockholders and MAAC&#146;s board of directors, dissolve and liquidate, subject in each case to MAAC&#146;s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. Accordingly, it is
MAAC&#146;s intention to redeem the MAAC Class&nbsp;A Shares as soon as reasonably possible following MAAC&#146;s 24th month and, therefore, MAAC does not intend to comply with those procedures. As such, MAAC&#146;s stockholders could potentially be
liable for any claims to the extent of distributions received by them (but no more) and any liability of MAAC&#146;s stockholders may extend well beyond the third anniversary of such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because MAAC will not be complying with Section&nbsp;280, Section&nbsp;281(b) of the DGCL requires MAAC to adopt a plan, based on facts known
to MAAC at such time that will provide for MAAC&#146;s payment of all existing and pending claims or claims that may be potentially brought against MAAC within the subsequent 10 years. However, because MAAC is a blank check company, rather than an
operating company, and MAAC&#146;s operations will be limited to searching for prospective target businesses to acquire, the only likely claims to arise would be from MAAC&#146;s vendors (such as lawyers, investment bankers, etc.) or prospective
target businesses. As described above, pursuant to the obligation contained in MAAC&#146;s underwriting agreement, MAAC will seek to have all vendors, service providers, prospective target businesses or other entities with which MAAC does business
execute agreements with MAAC waiving any right, title, interest or claim of any kind in or to any monies held in the Trust Account. As a result of this obligation, the claims that could be made against MAAC are significantly limited and the
likelihood that any claim that would result in any liability extending to the Trust Account is remote. Further, MAAC&#146;s Sponsor may be liable only to the extent necessary to ensure that the amounts in the Trust Account are not reduced below (i)
$10.00 per Public Share or (ii)&nbsp;such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, due to reductions in value of the trust assets, in each case net of the amount of interest
withdrawn to pay taxes and will not be liable as to any claims under MAAC&#146;s indemnity of the underwriters of MAAC&#146;s initial public offering against certain liabilities, including liabilities under the Securities Act. In the event that an
executed waiver is deemed to be unenforceable against a third party, MAAC&#146;s Sponsor will not be responsible to the extent of any liability for such third-party claims. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If MAAC files a bankruptcy or <FONT STYLE="white-space:nowrap">winding-up</FONT> petition or an involuntary bankruptcy or <FONT
STYLE="white-space:nowrap">winding-up</FONT> petition is filed against MAAC that is not dismissed, the proceeds held in the Trust Account could be subject to applicable bankruptcy or insolvency law, and may be included in MAAC&#146;s bankruptcy
estate and subject to the claims of third parties with priority over the claims of MAAC&#146;s stockholders. To the extent any bankruptcy claims deplete the Trust Account, MAAC cannot assure you MAAC will be able to return $10.00 per share to
MAAC&#146;s Public Stockholders. Additionally, if MAAC files a bankruptcy or <FONT STYLE="white-space:nowrap">winding-up</FONT> petition or an involuntary bankruptcy or <FONT STYLE="white-space:nowrap">winding-up</FONT> petition is filed against
MAAC that is not dismissed, any distributions received by stockholders could be viewed under applicable debtor/creditor and/or bankruptcy or insolvency laws as either a &#147;preferential transfer&#148; or a &#147;fraudulent conveyance.&#148; As a
result, a bankruptcy or insolvency court could seek to recover some or all amounts received by MAAC&#146;s stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore,
MAAC&#146;s board of directors may be viewed as having breached its fiduciary duty to MAAC&#146;s creditors and/or may have acted in bad faith, and thereby exposing itself and MAAC&#146;s company to claims of punitive damages, by paying Public
Stockholders from the Trust Account prior to addressing the claims of creditors. MAAC cannot assure you that claims will not be brought against MAAC for these reasons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC&#146;s Public Stockholders will be entitled to receive funds from the Trust Account only (i)&nbsp;in the event of the redemption of the
MAAC Class&nbsp;A Shares if MAAC does not complete an initial business combination within 24 months from the closing of MAAC&#146;s initial public offering, (ii)&nbsp;in connection with a stockholder vote to amend MAAC&#146;s amended and restated
Certificate of Incorporation (A)&nbsp;to modify the substance or timing of MAAC&#146;s obligation to allow redemption in connection with MAAC&#146;s initial business combination or to redeem </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
100% of MAAC Class&nbsp;A Shares if MAAC does not complete an initial business combination within 24 months from the closing of MAAC&#146;s initial public offering or (B)&nbsp;with respect to any
other provisions relating to the rights of holders of MAAC Class&nbsp;A Shares, or (iii)&nbsp;if they redeem their respective shares for cash upon the completion of the initial business combination. Public Stockholders who redeem their MAAC
Class&nbsp;A Shares in connection with a stockholder vote described in clause (ii)&nbsp;in the preceding sentence shall not be entitled to funds from the Trust Account upon the subsequent completion of an initial business combination or liquidation
if MAAC has not completed an initial business combination within 24 months from the closing of MAAC&#146;s initial public offering, with respect to such MAAC Class&nbsp;A Shares so redeemed. In no other circumstances will a stockholder have any
right or interest of any kind to or in the Trust Account. In the event MAAC seeks stockholder approval in connection with MAAC&#146;s initial business combination, a stockholder&#146;s voting in connection with the business combination alone will
not result in a stockholder&#146;s redeeming its shares to MAAC for an applicable pro rata share of the Trust Account. Such stockholder must have also exercised its redemption rights described above. These provisions of MAAC&#146;s amended and
restated Certificate of Incorporation, like all provisions of MAAC&#146;s amended and restated Certificate of Incorporation, may be amended with a stockholder vote. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Appraisal Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Appraisal rights are not available to MAAC stockholders in connection with the Business Combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required for Approval </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval of
the Business Combination Proposal requires that the initial Business Combination be approved by the affirmative vote of the holders of a majority of MAAC Shares outstanding as of the date of the stockholder meeting held to consider such initial
Business Combination. Abstentions are considered present for the purposes of establishing a quorum and will have the same effect as a vote &#147;<B>AGAINST</B>&#148; the Business Combination Proposal. Broker non-votes, while considered present for
the purposes of establishing a quorum, are not considered as entitled to vote on the Business Combination Proposal and therefore will have no effect on the Business Combination Proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination is conditioned upon the approval of the Business Combination Proposal, subject to the terms of the Business
Combination Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MAAC Sponsor and MAAC&#146;s directors and officers have agreed to vote any shares of MAAC common stock held
by them as of the record date in favor of the Business Combination Proposal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recommendation of the Board of Directors </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT OUR STOCKHOLDERS VOTE &#147;FOR&#148; THE BUSINESS COMBINATION PROPOSAL. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_15"></A>PROPOSAL NO. 2 &#151; THE NASDAQ PROPOSAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business
Combination, MAAC intends to effect the issuance of up to 22,000,000 MAAC Class A Shares in the PIPE Financing. We are seeking stockholder approval in order to comply with Nasdaq Listing Rule&nbsp;5635(a), (b) and (d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Nasdaq Listing Rule 5635(a)(1), stockholder approval is required prior to the issuance of common stock, or of securities convertible
into or exercisable for common stock, in connection with the acquisition of another company if such securities are not issued in a public offering for cash and (i) the common stock has, or will have upon issuance, voting power equal to or in excess
of 20% of the voting power outstanding before the issuance of such securities (or securities convertible into or exercisable for common stock); or (ii) the number of shares of common stock to be issued is or will be equal to or in excess of 20% of
the number of shares of common stock outstanding before the issuance of the stock or securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Nasdaq Listing Rule 5635(b),
stockholder approval is required prior to the issuance of securities when the issuance or potential issuance will result in a &#147;change of control&#148; of the registrant. Although Nasdaq has not adopted any rule on what constitutes a
&#147;change of control&#148; for purposes of Rule 5635(b), Nasdaq has previously indicated that the acquisition of, or right to acquire, by a single investor or affiliated investor group, as little as 20% of the common stock (or securities
convertible into or exercisable for common stock) or voting power of an issuer could constitute a change of control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Nasdaq Listing
Rule 5635(d), stockholder approval is required for a transaction other than a public offering involving the sale, issuance or potential issuance by an issuer of common stock (or securities convertible into or exercisable for common stock) at a price
that is less than the lesser of the official Nasdaq closing price immediately before signing of the binding agreement and the average official Nasdaq closing price for the five trading days immediately preceding the signing of the binding agreement
for the stock if the number of shares of common stock to be issued is or may be equal to 20% or more of the common stock, or 20% or more of the voting power, outstanding before the issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, pursuant to Nasdaq Listing Rule 5635(a)(2), when a Nasdaq-listed company proposes to issue securities in connection with the
acquisition of the stock or assets of another company, shareholder approval is required if any director, officer or substantial shareholder of such company has a 5% or greater interest (or such persons collectively have a 10% or greater interest),
directly or indirectly, in such company or the assets to be acquired or in the consideration to be paid in the transaction or series of related transactions and the present or potential issuance of common stock (or securities convertible into or
exercisable for common stock) could result in an increase in outstanding shares of common stock or voting power of 5% or more. Nasdaq Listing Rule 5635(e)(3) defines a substantial stockholder as the holder of an interest of 5% or more of either the
number of shares of common stock or the voting power outstanding of a Nasdaq-listed company. Based on Schedule 13Gs filed with the SEC, certain stockholders of MAAC to whom securities will be issued in the PIPE Financing and in the Business
Combination may be considered substantial shareholders of MAAC under Nasdaq Listing Rule&nbsp;5635(e)(3). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholder approval of the
Nasdaq Proposal is also a condition to the closing under the Business Combination Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required for Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote of a majority of MAAC Shares present in person or represented by proxy at the MAAC Special Meeting and entitled to vote at
the meeting is required to approve the Nasdaq Proposal. Abstentions are considered present for the purposes of establishing a quorum and will have the same effect as a vote </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;AGAINST&#148; the Nasdaq Proposal. Broker non-votes, while considered present for the purposes of establishing a quorum, are not considered as entitled to vote on the Nasdaq Proposal and
therefore will have no effect on the Nasdaq Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination is conditioned upon the approval of the Nasdaq Proposal,
subject to the terms of the Business Combination Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MAAC Sponsor and MAAC&#146;s directors and officers have agreed to vote
any shares of MAAC common stock held by them as of the record date in favor of the Nasdaq Proposal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recommendation of the MAAC Board of Directors
</B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE MAAC BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT ITS STOCKHOLDERS VOTE &#147;FOR&#148; THE NASDAQ PROPOSAL. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_16"></A>PROPOSAL NO. 3 &#151; THE ADJOURNMENT PROPOSAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Adjournment Proposal, if
adopted, will allow MAAC&#146;s board of directors to adjourn the MAAC Special Meeting to a later date or dates, if necessary, to permit further solicitation of proxies if, based upon the tabulated vote at the time of the MAAC Special Meeting, there
are not sufficient votes to approve the Business Combination Proposal, or holders of MAAC Class&nbsp;A Shares have elected to redeem an amount of MAAC Class&nbsp;A Shares such that (i) MAAC would have less than $5,000,001 of net tangible assets or
(ii) the aggregate cash proceeds from the Trust Account not being equal to or greater than $210,000,000 (unless waived by Roivant). In no event will MAAC&#146;s board of directors adjourn the MAAC Special Meeting or consummate the Business
Combination beyond the date by which it may properly do so under its existing charter and Delaware law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consequences if the Adjournment Proposal is
Not Approved </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Adjournment Proposal is not approved by MAAC&#146;s stockholders, MAAC&#146;s board of directors may not be able
to adjourn the MAAC Special Meeting to a later date in the event that there are insufficient votes for the approval of the Business Combination Proposal, or holders of MAAC Class&nbsp;A Shares have elected to redeem an amount of MAAC Class&nbsp;A
Shares such that (i) MAAC would have less than $5,000,001 of net tangible assets or (ii) the aggregate cash proceeds from the Trust Account not being equal to or greater than $210,000,000 (unless waived by Roivant), and may be unable to consummate
the Business Combination. If MAAC does not consummate the Business Combination and fails to complete an initial business combination by October&nbsp;9, 2022 (subject to the requirements of law), it will be required to dissolve and liquidate its
Trust Account by returning the then remaining funds in such account to the public stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required for Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote of a majority of MAAC Shares present in person or represented by proxy at the MAAC Special Meeting and entitled to vote at
the meeting is required to approve the Adjournment Proposal. Abstentions are considered present for the purposes of establishing a quorum and will have the same effect as a vote &#147;<B>AGAINST</B>&#148; the Adjournment Proposal. Broker non-votes,
while considered present for the purposes of establishing a quorum, are not considered as entitled to vote on the Adjournment Proposal and therefore will have no effect on the Adjournment Proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination is not conditioned upon the approval of the Adjournment Proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MAAC Sponsor and MAAC&#146;s directors and officers have agreed to vote any MAAC Shares held by them as of the record date in favor of the
Adjournment Proposal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recommendation of the MAAC Board of Directors </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MAAC&#146;S BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT ITS STOCKHOLDERS VOTE &#147;FOR&#148; THE APPROVAL OF THE ADJOURNMENT PROPOSAL.
</B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_17"></A>UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following unaudited pro forma condensed combined balance sheet of the Combined Company as of March&nbsp;31, 2021 and the
unaudited pro forma condensed combined statement of operations of the Combined Company for the year ended March&nbsp;31, 2021 are based on the historical financial statements of MAAC and Roivant after giving effect to the Business Combination and
PIPE Financing, as outlined below. MAAC and Roivant are collectively referred to herein as the &#147;Companies,&#148; and the Companies, subsequent to the Business Combination, are referred to herein as the &#147;Combined Company.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation <FONT
STYLE="white-space:nowrap">S-X,</FONT> Pro Forma Financial Information, as amended by Release <FONT STYLE="white-space:nowrap">No.&nbsp;33-10786</FONT> &#147;Amendments to Financial Disclosures about Acquired and Disposed Businesses.&#148; The
unaudited pro forma condensed combined statement of operations for the year ended March&nbsp;31, 2021 gives pro forma effect to the Business Combination and PIPE Financing as if they had occurred on April&nbsp;1, 2020. The unaudited pro forma
condensed combined balance sheet as of March&nbsp;31, 2021 gives pro forma effect to the Business Combination and PIPE Financing as if they were completed on March&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information is based on and should be read in conjunction with the audited historical
financial statements of Roivant as of and for the year ended March&nbsp;31, 2021; and the audited historical financial statements of MAAC for the period from July&nbsp;6, 2020 (inception) through December&nbsp;31, 2020, and the unaudited historical
financial statements of MAAC as of and for the three months ended March&nbsp;31, 2021 and the notes thereto, as well as the disclosures contained in the sections titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and
Results of Operations of MAAC&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations of Roivant.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information has been presented for illustrative purposes only and do not necessarily
reflect what the Combined Company&#146;s financial condition or results of operations would have been had the Business Combination and PIPE Financing occurred on the dates indicated. Further, the unaudited pro forma condensed combined financial
information also may not be useful in predicting the future financial condition and results of operations of the Combined Company. The actual financial position and results of operations may differ significantly from the pro forma amounts reflected
herein due to a variety of factors. The unaudited pro forma transaction accounting adjustments represent management&#146;s estimates based on information available as of the date of this unaudited pro forma condensed combined financial information
and are subject to change as additional information becomes available and analyses are performed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;1, 2021, MAAC entered into
the Business Combination Agreement with Roivant and Merger Sub, under which Merger Sub will merge with and into MAAC, with MAAC surviving the Business Combination as a wholly owned subsidiary of Roivant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information contained herein assumes that MAAC&#146;s stockholders approve the proposed
Business Combination. MAAC&#146;s stockholders may elect to redeem their MAAC Class&nbsp;A Shares for cash even if they approve the proposed Business Combination. MAAC cannot predict how many of its public stockholders will exercise their right to
have their MAAC Class&nbsp;A Shares redeemed for cash. As a result, the Combined Company has elected to provide the unaudited pro forma condensed combined financial information under two different redemption scenarios, which produce different
allocations of total Combined Company equity between holders of the common stock. As described in greater detail in Note 2 of the &#147;Notes to Unaudited Pro Forma Condensed Combined Financial Information&#148;, the first scenario, or &#147;no
redemption scenario&#148;, assumes that none of MAAC&#146;s public stockholders will exercise their right to have their MAAC Class&nbsp;A Shares redeemed for cash, and the second scenario, or &#147;maximum redemption scenario&#148;, assumes that
holders of the maximum number of MAAC Class&nbsp;A Shares that could be redeemed for cash while still leaving sufficient cash available to consummate the Business Combination, will exercise their right to have their MAAC Class&nbsp;A Shares redeemed
for cash. The actual results will likely be within the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
parameters described by the two scenarios, however, there can be no assurance regarding which scenario will be closest to the actual results. Under both scenarios, Roivant is considered the
accounting acquirer, as further discussed in Note 2 of the &#147;Notes to Unaudited Pro Forma Condensed Combined Financial Information&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMBINED COMPANY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNAUDITED PRO FORMA CONDENSED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMBINED BALANCE SHEET </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS OF MARCH&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(in thousands) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No redemptions scenario</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum redemptions scenario</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Roivant<BR>(Historical)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>MAAC<BR>(Historical)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Current Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 2,055,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 579,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(a),(b)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 2,635,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 378,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(a),(b)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,434,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Due from underwriters</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,186,995</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,700</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>579,190</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,767,885</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>378,399</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,567,094</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Restricted cash, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash and Marketable Securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">410,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(410,791</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(c)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(410,791</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(c)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Investments measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Long-term investment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,329</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(b)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,329</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(b)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> 2,589,692</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>412,491</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> 166,070</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> 3,168,253</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(34,721</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,967,462</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Liabilities, Redeemable Noncontrolling Interest and Shareholders&#146; Equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 20,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 20,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 20,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deferred consideration liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total Current Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>218,961</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,203</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>223,164</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>223,164</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Liability instruments measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(d)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(d)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Operating lease liability, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deferred underwriting commissions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(b)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(b)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Long term debt</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>527,687</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>44,716</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,832</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>578,235</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>894</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>573,297</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Class&nbsp;A common stock subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">362,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(362,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(e)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(362,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(e)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Redeemable noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Shareholders&#146; Equity:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Class&nbsp;A common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(e)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(e)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Class&nbsp;B common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(e)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(e)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,814,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">836,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(e)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,651,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">641,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(e)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,456,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Subscription receivable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Retained earnings (accumulated deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,918,462</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(313,286</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(e)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,226,749</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(314,189</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(e)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,227,652</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accumulated other comprehensive (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Noncontrolling interests</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">241,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">241,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">241,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total Shareholders&#146; Equity (Deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,039,514</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>523,013</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,567,527</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>327,160</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,371,674</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total liabilities, redeemable noncontrolling interest and shareholders&#146; equity</B></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> 2,589,692</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>412,491</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> 166,070</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> 3,168,253</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(34,721</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,967,462</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to unaudited pro forma condensed combined financial information. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMBINED COMPANY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNAUDITED PRO FORMA CONDENSED COMBINED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENT OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE YEAR ENDED MARCH&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(in thousands, except share and per share amounts) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No redemptions scenario</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum redemptions scenario</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(A)</B><br><B>Roivant<BR>(Historical)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(B)</B><br><B>MAAC<BR>(Historical)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Revenue, net</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Operating expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cost of revenues</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">832,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(f)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">871,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(f)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">871,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">259,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">432,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(f)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">696,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">432,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(f)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">696,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Administrative expenses&#151;related party</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,094,693</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,469</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>471,193</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,570,355</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>471,193</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,570,355</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,070,898</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(4,469</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(471,193</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,546,560</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(471,193</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,546,560</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Change in fair value of investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(95,533</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(95,533</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(95,533</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Change in fair value of debt and liability instruments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,372</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(115,364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(115,364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(115,364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Financing costs&#151;derivative warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Unrealized gain on marketable securities held in trust account</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(g)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(g)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other (income) expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(172</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(g),(h)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(g),(h)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Net Income (Loss) from continuing operations before income</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(898,547</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,281</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(474,277</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,364,543</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(475,180</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,365,446</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(g)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(g)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Income (loss) from continuing operations, net of tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(900,233</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,245</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(474,241</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,366,229</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(475,144</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,367,132</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss attributable to noncontrolling interests</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(90,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(90,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(90,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Net Income (loss) from continuing operations attributable to Roivant Sciences
Ltd.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(809,234</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,245</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(474,241</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,275,230</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(475,144</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,276,133</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Earnings per Share</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Weighted average shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215,312,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">725,529,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">703,696,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3.76</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(i</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.76</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(i</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.81</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to unaudited pro forma condensed combined financial information. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMBINED COMPANY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(in thousands, except share and per share amounts) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 1&#151;Description of the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;1, 2021, MAAC entered into a Business Combination Agreement with Roivant and Merger Sub and was subsequently amended on June 9,
2021 to reflect the execution of the lock-up agreements entered into by the MAAC Independent Directors and Roivant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business
Combination Agreement provides for, among other things, the following transactions: (i)&nbsp;Roivant&#146;s <FONT STYLE="white-space:nowrap">bye-laws</FONT> will be amended and restated, each outstanding share of Roivant will be subdivided (and in
the case of certain <FONT STYLE="white-space:nowrap">non-voting</FONT> shares of Roivant, converted) into Roivant Common Shares based on a fixed exchange ratio of 2.9262:1 (the &#147;Roivant Exchange Ratio&#148;), and each outstanding equity award
of Roivant will be subdivided and adjusted into comparable equity awards of Roivant, based on the Roivant Exchange Ratio (the steps contemplated by this clause (i), collectively, the &#147;Pre-Closing Steps&#148;); and (ii)&nbsp;Merger Sub will
merge with and into MAAC, with MAAC surviving the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Effective Time (a) each outstanding MAAC Class&nbsp;A Share and MAAC
Class&nbsp;B Share (other than treasury shares and any shares held by the MAAC Sponsor, any affiliate of the MAAC Sponsor or any MAAC Independent Director or its transferee) will be automatically canceled and extinguished and converted into one
Roivant Common Share, (b)&nbsp;each outstanding MAAC Class&nbsp;B Share held by the MAAC Sponsor, any affiliate of the MAAC Sponsor or any MAAC Independent Director or its transferee will be automatically canceled and extinguished and converted into
a number of Roivant Common Shares based on the MAAC Sponsor Exchange Ratio, with a portion of such Roivant Common Shares issued to the MAAC Sponsor, any affiliate of the MAAC Sponsor or any MAAC Independent Director or its transferee by virtue of
the Merger being subject to the vesting and other terms and conditions set forth in the Sponsor Support Agreement (as more fully described below), and (c)&nbsp;each outstanding warrant to purchase MAAC Class&nbsp;A Shares will be converted
automatically into the right to acquire Roivant Common Shares on the terms and subject to the conditions set forth in the MAAC Warrant Agreement. The MAAC Sponsor Exchange Ratio is 1.0, subject to reduction in an amount equal to <FONT
STYLE="white-space:nowrap">one-half</FONT> of the percentage of MAAC Class&nbsp;A Shares redeemed in connection with the Business Combination (i.e., if 10% of MAAC Class&nbsp;A Shares are so redeemed, then the MAAC Sponsor Exchange Ratio will be
equal to 0.95), provided that in no event will the MAAC Sponsor Exchange Ratio be less than 0.75. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Sponsor Support
Agreement entered into concurrently with the execution of the Business Combination Agreement, (a)&nbsp;twenty percent of the Roivant Common Shares issued to the MAAC Sponsor in respect of its shares of MAAC Class&nbsp;B common stock will be subject
to the vesting conditions described below and the other restrictions set forth in the Sponsor Support Agreement (the &#147;$15 <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares&#148;) and (b)&nbsp;ten percent of the Roivant Common Shares
issued to the MAAC Sponsor in respect of its shares of MAAC Class&nbsp;B common stock will be subject to the vesting conditions described below and the other restrictions set forth in the Sponsor Support Agreement (the &#147;$20 <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Shares&#148; and, together with the $15 <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares, the <FONT STYLE="white-space:nowrap">&#147;Earn-Out</FONT> Shares&#148;). The remaining seventy percent of
the number of Roivant Common Shares issued to the MAAC Sponsor in respect of its shares of MAAC Class&nbsp;B common stock will not be subject to the vesting conditions described above (the &#147;Retained Shares&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $15 <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares will vest if the closing price of the Roivant Common Shares is greater than or
equal to $15.00 over any twenty out of thirty trading day period during the five year period following the Closing, and the $20 <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares will vest if the closing price of the Roivant Common Shares is
greater than or equal to $20.00 over any twenty out of thirty trading day period during the five year period following the Closing. The five year vesting period described in the preceding sentence will, if a definitive purchase agreement with
respect to a Sale (as defined in the Sponsor Support Agreement) is entered into on or prior to the end of such period, be extended to the earlier of one day after the consummation of such Sale and the termination of such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
definitive transaction agreement, and if a Sale occurs during such five year (or, as applicable, longer) vesting period, then all of the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares
unvested as of such time will automatically vest immediately prior to the consummation of such Sale. If any <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares have not vested on or prior to the end of the five year (or, as applicable, longer)
vesting period, then such <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares will be forfeited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June 9, 2021, MAAC, the MAAC
Sponsor, Roivant and the MAAC Insiders entered into Amendment No. 1 to the Sponsor Support Agreement (&#147;SSA Amendment&#148;) pursuant to which the Sponsor Support Agreement was revised to reflect the MAAC Independent Directors and Roivant
entering into respective Lock-Up Agreements. In particular, among other things, the SSA Amendment revised the Sponsor Support Agreement to subject the Roivant Common Shares issued to each MAAC Independent Director in respect of his or her MAAC Class
B Shares to the same vesting conditions applicable to the Roivant Common Shares issued to the MAAC Sponsor. Specifically, (a) twenty percent of the Roivant Common Shares issued to each MAAC Independent Director will be treated as $15 Earn-Out Shares
(as defined in the Sponsor Support Agreement) and (b) ten percent of the Roivant Common Shares issued to each MAAC Independent Director will be treated as $20 Earn-Out Shares (as defined in the Sponsor Support Agreement). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2&#151;Basis of Presentation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
historical financial information of MAAC and Roivant has been adjusted in the unaudited pro forma condensed combined financial information to reflect transaction accounting adjustments related to the Business Combination and PIPE Financing in
accordance with U.S. GAAP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination is a capital transaction in substance whereby MAAC will be treated as the acquired
company for financial reporting purposes. This determination was primarily based on the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Roivant stockholders will own the majority of the issued and outstanding common shares of the Combined Company.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The current executive officers of Roivant will manage the Combined Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The majority of the board of directors of the Combined Company will be comprised of the current members of the
board of directors of Roivant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Roivant&#146;s operations will be the operations of the Combined Company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, because MAAC does not represent a business for accounting purposes and its primary asset represents cash and cash equivalents,
the Business Combination will be treated similar to an equity contribution in exchange for the issuance of Roivant Common Shares. The net assets of MAAC will be stated at historical cost, with no goodwill or other intangible assets recorded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information has been prepared using the assumptions below with respect to the potential
redemption of MAAC Class&nbsp;A Shares into cash: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Assuming No Redemptions</B>: This presentation of the no redemption scenario assumes that no MAAC stockholders
exercise redemption rights with respect to their MAAC Class&nbsp;A Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Assuming Maximum Redemptions</B>: This presentation assumes that the maximum possible number of MAAC&#146;s
public stockholders exercise redemption rights with respect to their MAAC Class&nbsp;A Shares. This scenario assumes that 20,075,542 MAAC Class&nbsp;A Shares are redeemed for an aggregate redemption payment of approximately $200.8&nbsp;million. The
maximum redemption scenario is based on the maximum number of redemptions that may occur, but which would still provide the minimum proceeds consisting of Trust Account funds of $210&nbsp;million to be contributed at Closing of the Business
Combination. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roivant and MAAC have different fiscal years. As Roivant&#146;s fiscal year ends on
March&nbsp;31 and MAAC&#146;s fiscal year ends on December&nbsp;31, the unaudited pro forma condensed combined statement of operations for the fiscal year ended March&nbsp;31, 2021 combines the historical results of Roivant for its fiscal year ended
March&nbsp;31, 2021 and the historical results of MAAC for the period ended March&nbsp;31, 2021, derived by combining MAAC&#146;s unaudited condensed statement of operations for the three months ended March&nbsp;31, 2021 and MAAC&#146;s audited
statement of operations for the period from July&nbsp;6, 2020 (inception) through December&nbsp;31, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3&#151;Pro Forma Adjustments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adjustments to the Unaudited Pro Forma Condensed Combined Balance Sheet as of March&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transaction accounting adjustments included in the unaudited pro forma condensed combined balance sheet as of March&nbsp;31, 2021 are as
follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Cash and cash equivalents. </I>Represents the impact of the Business Combination and PIPE Financing on the
cash and cash equivalents balance of the Combined Company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below reflects the pro forma adjustments related
to cash and cash equivalents under the no redemption scenario and the maximum redemption scenario <I>(in thousands)</I>: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No<BR>redemption<BR>scenario</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum<BR>redemption<BR>scenario</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash balance of Roivant prior to Business Combination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,055,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,055,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash balance of MAAC prior to Business Combination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total pre Business Combination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,056,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,056,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MAAC Cash and Marketable Securities in Trust</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">410,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">410,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PIPE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">220,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">220,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment to redeeming MAAC Class&nbsp;A stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(200,791</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of deferred underwriting commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of estimated transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(37,226</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(37,226</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Business Combination adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">579,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">378,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Post Business Combination cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,635,697</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,434,906</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the amount of the restricted cash and marketable securities held in the Trust Account upon
consummation of the Business Combination at Closing (see Note 3(c) <I>Trust Account</I>). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the issuance, in a private placement to be consummated concurrently with the Closing, to third-party
PIPE Investors of up to 22,000,000 ordinary shares assuming a stock price of $10.00 per share (see Note 3(e)(5) <I>Impact on equity</I>). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the amount paid to MAAC public stockholders who are assumed to exercise redemption rights under the
maximum redemption scenario, including accrued interest (see Note 3(e)(10) <I>Impact on equity</I>). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents payment of deferred underwriting fees payable by MAAC (see Note 3(b)(1) <I>Transaction costs</I>).
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents payment of other transaction costs (see Note 3(b)(2) <I>Transaction costs</I>).
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3(b) <I>Transaction costs</I>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Payment of deferred underwriting commissions incurred by MAAC in the amount of $14.4&nbsp;million (See Note
3(a)(4) <I>Cash and cash equivalents</I>). The unaudited pro forma condensed combined balance sheet reflects payment of these costs as a reduction of cash, with a corresponding decrease in deferred underwriting fee payable. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the recognition of $39.5&nbsp;million of incremental transaction costs. Of the $39.5&nbsp;million,
$2.3&nbsp;million was capitalized within other assets on Roivant&#146;s balance sheet as of March&nbsp;31, 2021. An additional $37.2&nbsp;million of incremental transaction expenses are estimated to be incurred through the Business Combination and
PIPE Financing (see Note 3(a)(5) <I></I><I>Cash and cash equivalents</I><I></I>). The unaudited pro forma condensed combined balance sheet reflects costs allocated to the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares and warrants, which
will be liability classified subsequent to the Business Combination, as a reduction of cash and other assets, with a corresponding charge to accumulated deficit. The remaining costs are reflected as a reduction of cash and other assets, with a
corresponding decrease in additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital (see Note 3(e)(8) <I></I><I>Impact on equity</I><I></I>). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Trust Account</I>. Represents release of the restricted cash and marketable securities held in the Trust
Account upon consummation of the Business Combination to fund the Closing of the Business Combination (See Note 3(a)(1) <I></I><I>Cash and cash equivalents</I><I></I>). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I><FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares. </I>Represents recognition of the preliminary
estimated fair values of the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares as derivatives that will not qualify for equity classification. These amounts are classified as liabilities in the unaudited pro forma condensed combined balance
sheet. The preliminary estimated fair values of the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares were determined using a Monte Carlo simulation valuation model using a distribution of potential outcomes based on certain underlying
assumptions such as stock price, volatility and risk-free interest rates. These assumptions reflect the most reliable information available. The actual fair values could change materially once the final valuation is determined at the Closing.
Following the Business Combination, these liabilities will be remeasured to fair value at each reporting date and subsequent changes in the fair value will be recognized in the Combined Company&#146;s consolidated statement of operations. See Note 1
&#147;Description of the Business Combination&#148; for more information. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Impact on equity. </I>The following table represents the impact of the Business Combination and PIPE
Financing on the number of MAAC Class&nbsp;A Shares and represents the total equity section assuming <B>no redemptions</B> by MAAC&#146;s stockholders: </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>(in thousands, except share amounts) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Roivant/Combined<BR>Company Common<BR>Shares</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>MAAC Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD COLSPAN="2" ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Roivant/Combined<BR>Company<BR>Temporary Equity</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>MAAC Temporary<BR>Equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note<BR>3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Par<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR>paid-in<BR>capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Subscription<BR>receivable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>other<BR>comprehensive<BR>loss</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Noncontrolling<BR>interests</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>stockholders&#146;<BR>equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable non-<BR>controlling<BR>interest</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Roivant equity as of March&nbsp;31, 2021&#151;pre Business Combination</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">222,669,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,814,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,918,462</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">241,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,039,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">MAAC equity as of March&nbsp;31, 2021&#151;pre Business Combination</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,794,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,267,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,277,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">362,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Total equity balance pre Business Combination</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">222,669,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,794,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,267,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,814,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,913,463</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">241,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,044,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,277,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">362,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Subdivision of Roivant shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">651,576,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Transaction Accounting Adjustments:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Reclassification of MAAC Class&nbsp;A common stock to Roivant Common Shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,277,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">362,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">362,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,277,487</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(362,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Reclassification of MAAC Class&nbsp;A common stock to Roivant Common Shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,794,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,794,336</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Reclassification of MAAC Class&nbsp;B common stock to Roivant Common Shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,267,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,267,956</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Reclassification to MAAC Sponsor <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,080,386</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">PIPE Investment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">220,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">220,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Recognition of <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares as a liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,207</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,207</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Liquidity vesting of certain stock-based awards at Close of the Business Combination</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,502,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">305,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(305,381</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Payment of incremental transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,649</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,906</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(39,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Elimination of the historical accumulated deficit of MAAC</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Total Transaction Accounting Adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,762,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,794,336</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,267,956</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">836,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(313,286</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">523,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,277,487</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(362,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Post-Business Combination</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>724,338,719</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,651,105</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(100,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(2,226,749</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,445</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>241,726</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,567,527</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>22,491</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case of <B>maximum redemption</B> by MAAC&#146;s stockholders, the following table
represents the impact of the Business Combination and PIPE Financing on the number of MAAC Class&nbsp;A Shares and represents the total equity section: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>(in thousands, except share amounts) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Roivant/Combined</B><br><B>Company Common<BR>Shares</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>MAAC Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Roivant/Combined<BR>Company</B><br><B>Temporary Equity</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>MAAC Temporary<BR>Equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class A Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note<BR>3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Par<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR>paid-in<BR>capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Subscription<BR>receivable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>other<BR>comprehensive<BR>loss</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Noncontrolling<BR>interests</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total </B><br><B>stockholders&#146;<BR>equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable non-<BR>controlling<BR>interest</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Roivant equity as of March 31, 2021&#151;pre Business Combination</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">222,669,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,814,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,918,462</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">241,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,039,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">MAAC equity as of March 31, 2021 &#151;pre Business Combination</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,794,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,267,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,277,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">362,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Total equity balance pre Business Combination</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">222,669,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,794,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,267,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,814,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,913,463</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">241,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,044,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,277,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">362,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Subdivision of Roivant shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(1)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">651,576,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Transaction Accounting Adjustments:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Reclassification of MAAC Class A common stock to Roivant Common Shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(2)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,277,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">362,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">362,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,277,487</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(362,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Reclassification of MAAC Class A common stock to Roivant Common Shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(2)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,794,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,794,336</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Reclassification of MAAC Class B common stock to Roivant Common Shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(3)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,267,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,267,956</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Reclassification to MAAC Sponsor Earn-Out Shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(4)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,327,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">PIPE Investment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(5)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">220,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">220,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Redemption of MAAC Class A common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(10)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,075,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(200,791</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(200,791</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Forfeited MAAC Class B common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(11)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,509,443</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Recognition of Earn-Out Shares as a liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(6)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,269</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,269</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Liquidity vesting of certain stock-based awards at Close of the Business Combination</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(7)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,502,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">305,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(305,381</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Payment of incremental transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35,746</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,809</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(39,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Elimination of the historical accumulated deficit of MAAC</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(9)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Total Transaction Accounting Adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,930,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,794,336</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,267,956</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">641,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(314,189</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">327,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,277,487</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(362,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Post-Business Combination</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>702,506,567</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,456,155</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(100,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(2,227,652</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,445</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>241,726</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,371,674</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>22,491</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents the subdivision of <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Roivant Common Shares using
the 2.9262:1 Roivant Exchange Ratio. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents the conversion of all MAAC Class&nbsp;A Shares of capital stock into post-Closing Roivant Common
Shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents the conversion of all MAAC Class&nbsp;B Shares of capital stock into post-Closing Roivant Common
Shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents the conversion of a portion of the MAAC Class&nbsp;B Shares into
<FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares (See Note 1 &#150; Description of the Business Combination). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents the issuance, in a private placement to be consummated concurrently with the Closing, to third-party
PIPE Investors of up to 22,000,000 ordinary shares assuming a stock price of $10.00 per share (see Note 3(a)(2) <I>Cash and cash equivalents</I>). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents the recognition of the preliminary estimated fair value of the
<FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares as a liability (see Note 3(d) <I><FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares</I>). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents the estimated <FONT STYLE="white-space:nowrap">catch-up</FONT> expense related to prior service for
certain Roivant share-based compensation awards, which contain a performance condition tied to achievement of a liquidity event (see Note 3(f) <I>Share-based compensation</I>). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents payment of estimated other transaction costs (see Note 3(b)(2) <I>Transaction costs</I>).
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents the elimination of the historical accumulated deficit of MAAC. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents the redemption of MAAC Class&nbsp;A Shares under the maximum redemption scenario (see Note 3(a)(3)
<I>Cash and cash equivalents</I>). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents the forfeiture of Retained Shares and <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares each
equal to <FONT STYLE="white-space:nowrap">one-half</FONT> of the percentage of MAAC Class&nbsp;A Shares redeemed under the maximum redemption scenario based on the MAAC Sponsor Exchange Ratio, but provided that in no event will the MAAC Sponsor
Exchange Ratio be less than 0.75 (See Note 1 &#150; Description of the Business Combination). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Adjustments to the Unaudited Pro
Forma Condensed Combined Statements of Operations for the year ended March&nbsp;31, 2021 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed
combined statements of operations for the year ended March&nbsp;31, 2021 is derived from the following historical financial information: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The audited consolidated statement of operations of Roivant for the year ended March&nbsp;31, 2021.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The combination of the audited statement of operations of MAAC for the period from July&nbsp;6, 2020
(inception) through December&nbsp;31, 2020 and the unaudited condensed statement of operations of MAAC for the three months ended March&nbsp;31, 2021. See Note 2 &#150; Basis of Presentation for more information. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transaction accounting adjustments included in the unaudited pro forma condensed combined statement of operations for the year ended
March&nbsp;31, 2021 are as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3(f)<I> Share-based compensation.</I> Certain Roivant restricted stock units, performance options, and
capped value appreciation rights (&#147;CVARs&#148;) granted in the years prior to the Business Combination are subject to (i)&nbsp;service-vesting conditions and (ii)&nbsp;a performance condition tied to the achievement of a liquidity event.
Historically, Roivant did not record share-based compensation expense related to these awards as the liquidity event requirement had not been met and was deemed not probable of being met. Upon consummation of the Business Combination, the liquidity
event requirement is expected to be met, resulting in the recognition of a <FONT STYLE="white-space:nowrap">one-time</FONT> <FONT STYLE="white-space:nowrap">catch-up</FONT> expense relating to cumulative service rendered between the grant date of
the respective awards and completion of the Business Combination. As such, this adjustment reflects, using the accelerated attribution method, the estimated <FONT STYLE="white-space:nowrap">catch-up</FONT> expense and estimated expense to be
recognized in the period following the Business Combination related to these awards, assuming that the Business Combination had been consummated on April&nbsp;1, 2020. Any remaining expense will be recognized over the awards&#146; applicable
requisite service period. For the year ended March&nbsp;31, 2021, pro forma share-based compensation expense reflects an estimated total of $471.2&nbsp;million, consisting of an estimated $305.4&nbsp;million of
<FONT STYLE="white-space:nowrap">catch-up</FONT> expense relating to prior service and an estimated $165.8&nbsp;million of expense to be recognized in the twelve months following the Closing. Of this amount, $432.5&nbsp;million is presented in
general and administrative expenses and $38.7&nbsp;million is presented in research and development expenses. The income tax effects, to be reflected at the statutory tax rate for pro forma financial presentation purposes, have been offset by a
valuation allowance as the Combined Company expects to incur continuing losses. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3(g)<I> Interest income and unrealized gain.
</I>Represents an adjustment to eliminate interest income and unrealized gains/losses on marketable securities held in the Trust Account as of the beginning of the period. The associated income tax expense was eliminated as a result of the
elimination of the Trust Account income. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3(h)<I> Transaction costs allocated to <FONT STYLE="white-space:nowrap">Earn-Out</FONT>
Shares and warrants.</I> Represents incremental expenses allocated to the Earnout Shares and warrants, which will be liability classified subsequent to the Business Combination. These costs are reflected in the unaudited pro forma condensed combined
statement of operations for the year ended March&nbsp;31, 2021 within other (income) expense. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3(i) <I>Net loss per share.</I> Represents
pro forma net loss per share based on pro forma net loss and, for the year ended March&nbsp;31, 2021, pro forma weighted-average shares outstanding of 725,529,015 and 703,696,863 for the no redemption scenario and maximum redemption scenario,
respectively, after giving effect to the pro forma adjustments for such periods. There is no difference between basic and diluted pro forma net loss per share as the inclusion of all potential common shares of the Combined Company outstanding would
have been anti-dilutive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_18"></A>BUSINESS OF MAAC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>References to the &#147;Company,&#148; &#147;Montes Archimedes Acquisition Corp.,&#148; &#147;our,&#148; &#147;us&#148; or &#147;we&#148;
in the following section refer to Montes Archimedes Acquisition Corp.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC is a blank check company incorporated in July 2020 as a Delaware corporation whose business purpose is to effect a merger, capital stock
exchange, asset acquisition, stock purchase, reorganization or similar Business Combination with one or more businesses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC is an early
stage and emerging growth company and, as such, MAAC is subject to all of the risks associated with early stage and emerging growth companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Initial Public Offering and Private Placement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021, we had not commenced any operations. All of our activity through March&nbsp;31, 2021 related to our formation, the
initial public offering, and identifying a target company for a Business Combination. We will not generate any operating revenues until after the completion of an initial Business Combination, at the earliest. We generate <FONT
STYLE="white-space:nowrap">non-operating</FONT> income in the form of interest income from the proceeds derived from our initial public offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;9, 2020, we consummated our initial public offering of 40,000,000 MAAC Units. The MAAC Units sold in the initial public
offering were sold at an offering price of $10.00 per unit, generating total gross proceeds of $400,000,000. We granted the underwriters a <FONT STYLE="white-space:nowrap">45-day</FONT> option to purchase up to an additional 6,000,000 MAAC Units at
the initial public offering price to cover over-allotments, if any. Citigroup Global Markets Inc. and Jefferies LLC acted as the book-running managers in the offering. The securities in the offering were registered under the Securities Act on a
registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (No. <FONT STYLE="white-space:nowrap">333-248802).</FONT> The Securities and Exchange Commission declared the registration statement effective on October&nbsp;6, 2020. On
November&nbsp;10, 2020, the underwriters exercised the Over-Allotment option in part, and the closing of the issuance and sale of the additional 1,071,823 MAAC Units (the &#147;Over-Allotment Option Units&#148;) and the additional private placement
warrants (as defined below), which resulted in total gross proceeds of $10,932,595 and net proceeds of $10,356,918. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Simultaneous with the
consummation of the initial public offering, we consummated the Private Placement (as defined below) of an aggregate of 10,000,000 warrants at a price of $1.00 per Private Placement Warrant (as defined below), generating total proceeds of
$10,000,000. In addition, on November&nbsp;12, 2020, following the exercise of the Over-Allotment option in part, we consummated the additional sale of 214,365 private placement warrants (the &#147;additional private placement warrants&#148;). The
issuance was made pursuant to the exemption from registration contained in Section&nbsp;4(a)(2) of the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The private
placement warrants are substantially similar to the warrants underlying the MAAC Units sold in the initial public offering, except that the private placement warrants, if held by the MAAC Sponsor or its permitted transferees, (i)&nbsp;may be
exercised for cash or on a cashless basis, (ii)&nbsp;are not subject to being called for redemption under certain redemption scenarios and (iii)&nbsp;subject to certain limited exceptions, will be subject to transfer restrictions until 30 days
following the consummation of the company&#146;s initial Business Combination. If the private placement warrants are held by holders other than the MAAC Sponsor or its permitted transferees, the private placement warrants will be redeemable by us
under all redemption scenarios and exercisable by holders on the same basis as the Public Warrants. The private placement warrants have been issued pursuant to, and are governed by the MAAC Warrant Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Effecting a Business Combination </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not presently
engaged in, and we will not engage in, any substantive business activities until we complete the Business Combination with Roivant and Merger Sub or another target business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Market Value of Target Business </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nasdaq Listing Rules require that our business combination must be with one or more target businesses that together have a fair market
value equal to at least 80% of the balance in the Trust Account (less any deferred underwriting commissions and taxes payable on interest earned) at the time of our signing a definitive agreement in connection with our initial business combination.
The MAAC Board determined that this test was met in connection with the proposed Business Combination with Roivant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation if No Business
Combination </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Sponsor, officers and directors have agreed that we have a period of 24 months from the closing of our initial
public offering to complete our initial Business Combination. If we have not completed an initial Business Combination within 24 months from the closing of our initial public offering, we will: (i)&nbsp;cease all operations except for the purpose of
winding up; (ii)&nbsp;as promptly as reasonably possible but not more than ten business days thereafter, redeem the MAAC Class A Shares, at a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount
then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to us to pay our taxes, if any (less up to $100,000 of interest to pay dissolution expenses), divided by the number of
the then outstanding MAAC Class A Shares, which redemption will completely extinguish Public Stockholders&#146; rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law; and
(iii)&nbsp;as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and our board of directors, liquidate and dissolve, subject in each case, to our obligations under Delaware law to provide
for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to our warrants, which will expire worthless if we do not complete an initial Business Combination
within 24 months from the closing of our initial public offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Sponsor, officers and directors and each member of our management
team have entered into a letter agreement with us, pursuant to which they have waived their rights to liquidating distributions from the Trust Account with respect to their Founder Shares if we do not complete an initial Business Combination within
24 months from the closing of our initial public offering. However, if our Sponsor, director or members of our management team acquire MAAC Class A Shares in or after our initial public offering, they will be entitled to liquidating distributions
from the Trust Account with respect to such MAAC Class A Shares if we do not complete an initial Business Combination within 24 months from the closing of our initial public offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Sponsor, executive officers and directors have agreed, pursuant to a written agreement with us, that they will not propose any amendment
to our amended and restated Certificate of Incorporation that would affect the substance or timing of our obligation to allow redemption in connection with our initial Business Combination or to redeem 100% of the MAAC Class A Shares if we do not
complete an initial Business Combination within 24 months from the closing of our initial public offering, unless we provide our Public Stockholders with the opportunity to redeem their MAAC Class A Shares upon approval of any such amendment at a <FONT
STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to us to pay our
taxes, if any (less up to $100,000 of interest to pay dissolution expenses) divided by the number of the then outstanding MAAC Class A Shares. However, we may not redeem the MAAC Class A Shares in an amount that would cause our net tangible assets
to be less than $5,000,001 (so that we are not subject to the SEC&#146;s &#147;penny stock&#148; rules). If this optional redemption right is exercised with respect to an excessive number of MAAC Class A Shares such that we cannot satisfy the net
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
tangible asset requirement, we would not proceed with the amendment or the related redemption of the MAAC Class A Shares at such time. This redemption right shall apply in the event of the
approval of any such amendment, whether proposed by our Sponsor, any executive officer, director, or any other person. We expect that all costs and expenses associated with implementing our plan of dissolution, as well as payments to any creditors,
will be funded from amounts remaining out of the approximately $1,700,000 of proceeds held outside the Trust Account as of March&nbsp;31, 2021 plus up to $100,000 of funds from the Trust Account available to us to pay dissolution expenses, although
we cannot assure you that there will be sufficient funds for such purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we were to expend all of the net proceeds of our initial
public offering and the sale of the private placement warrants, other than the proceeds deposited in the Trust Account, and without taking into account interest, if any, earned on the Trust Account, the
<FONT STYLE="white-space:nowrap">per-share</FONT> redemption amount received by stockholders upon our dissolution would be approximately $10.00. The proceeds deposited in the Trust Account could, however, become subject to the claims of our
creditors which would have higher priority than the claims of our Public Stockholders. We cannot assure you that the actual <FONT STYLE="white-space:nowrap">per-share</FONT> redemption amount received by stockholders will not be substantially less
than $10.00. Under Section&nbsp;281(b) of the DGCL, our plan of dissolution must provide for all claims against us to be paid in full or make provision for payments to be made in full, as applicable, if there are sufficient assets. These claims must
be paid or provided for before we make any distribution of our remaining assets to our stockholders. While we intend to pay such amounts, if any, we cannot assure you that we will have funds sufficient to pay or provide for all creditors&#146;
claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we will seek to have all vendors, service providers (other than our independent auditors), prospective target businesses
and other entities with which we do business execute agreements with us waiving any right, title, interest or claim of any kind in or to any monies held in the Trust Account for the benefit of our Public Stockholders, there is no guarantee that they
will execute such agreements or even if they execute such agreements that they would be prevented from bringing claims against the Trust Account including, but not limited, to fraudulent inducement, breach of fiduciary responsibility or other
similar claims, as well as claims challenging the enforceability of the waiver, in each case in order to gain an advantage with respect to a claim against our assets, including the funds held in the Trust Account. If any third party refuses to
execute an agreement waiving such claims to the monies held in the Trust Account, our management will perform an analysis of the alternatives available to it and will only enter into an agreement with a third party that has not executed a waiver if
management believes that such third party&#146;s engagement would be significantly more beneficial to us than any alternative. Examples of possible instances where we may engage a third party that refuses to execute a waiver include the engagement
of a third-party consultant whose particular expertise or skills are believed by management to be significantly superior to those of other consultants that would agree to execute a waiver or in cases where management is unable to find a service
provider willing to execute a waiver. In addition, there is no guarantee that such entities will agree to waive any claims they may have in the future as a result of, or arising out of, any negotiations, contracts or agreements with us and will not
seek recourse against the Trust Account for any reason. In order to protect the amounts held in the Trust Account, our Sponsor has agreed that it will be liable to us if and to the extent any claims by a third party for services rendered or products
sold to us (other than our independent registered public accounting firm), or a prospective target business with which we have discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i) $10.00
per MAAC Class A Share and (ii)&nbsp;the actual amount per MAAC Class A Share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per share, due to reductions in the value of the trust assets, in each
case net of the interest that may be withdrawn to pay our taxes, if any, provided that such liability will not apply to any claims by a third party or prospective target business that executed a waiver of any and all rights to seek access to the
Trust Account nor will it apply to any claims under our indemnity of the underwriters of our initial public offering against certain liabilities, including liabilities under the Securities Act. In the event that an executed waiver is deemed to be
unenforceable against a third party, our Sponsor will not be responsible to the extent of any liability for such third party claims. However, we have not asked our Sponsor to reserve for such indemnification obligations, nor have we independently
verified whether our Sponsor has sufficient funds to satisfy its indemnity obligations and we believe that our Sponsor&#146;s only assets are securities of our company. Therefore, we cannot assure you that our Sponsor would be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
able to satisfy those obligations. None of our officers or directors will indemnify us for claims by third parties including, without limitation, claims by vendors and prospective target
businesses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the proceeds in the Trust Account are reduced below the lesser of (i) $10.00 per MAAC Class A Share and
(ii)&nbsp;the actual amount per MAAC Class A Share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per share, due to reductions in the value of the trust assets, in each case net of the interest
which may be withdrawn to pay our taxes, if any, and our Sponsor asserts that it is unable to satisfy its indemnification obligations or that they have no indemnification obligations related to a particular claim, our independent directors would
determine whether to take legal action against our Sponsor to enforce its indemnification obligations. While we currently expect that our independent directors would take legal action on our behalf against our Sponsor to enforce its indemnification
obligations to us, it is possible that our independent directors in exercising their business judgment may choose not to do so in any particular instance. Accordingly, we cannot assure you that due to claims of creditors the actual value of the <FONT
STYLE="white-space:nowrap">per-share</FONT> redemption price will not be less than $10.00 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will seek to reduce the
possibility that our Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than our independent auditors), prospective target businesses or other entities with which
we do business execute agreements with us waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. Our Sponsor will also not be liable as to any claims under our indemnity of the underwriters of our initial
public offering against certain liabilities, including liabilities under the Securities Act. We will have access to up to approximately $1,700,000 from the proceeds held outside the Trust Account as of March&nbsp;31, 2021 with which to pay any such
potential claims (including costs and expenses incurred in connection with our liquidation, currently estimated to be no more than approximately $100,000). In the event that we liquidate and it is subsequently determined that the reserve for claims
and liabilities is insufficient, stockholders who received funds from our Trust Account could be liable for claims made by creditors, however such liability will not be greater than the amount of funds from our Trust Account received by any such
stockholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the DGCL, stockholders may be held liable for claims by third parties against a corporation to the extent of
distributions received by them in a dissolution. The pro rata portion of our Trust Account distributed to our Public Stockholders upon the redemption of the MAAC Class A Shares in the event we do not complete our initial Business Combination within
24 months from the closing of the initial public offering may be considered a liquidating distribution under Delaware law. If the corporation complies with certain procedures set forth in Section&nbsp;280 of the DGCL intended to ensure that it makes
reasonable provision for all claims against it, including a <FONT STYLE="white-space:nowrap">60-day</FONT> notice period during which any third-party claims can be brought against the corporation, a <FONT STYLE="white-space:nowrap">90-day</FONT>
period during which the corporation may reject any claims brought, and an additional <FONT STYLE="white-space:nowrap">150-day</FONT> waiting period before any liquidating distributions are made to stockholders, any liability of stockholders with
respect to a liquidating distribution is limited to the lesser of such stockholder&#146;s pro rata share of the claim or the amount distributed to the stockholder, and any liability of the stockholder would be barred after the third anniversary of
the dissolution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, if the pro rata portion of our Trust Account distributed to our Public Stockholders upon the redemption of
the MAAC Class A Shares in the event we do not complete our initial Business Combination within 24 months from the closing of the initial public offering, is not considered a liquidating distribution under Delaware law and such redemption
distribution is deemed to be unlawful (potentially due to the imposition of legal proceedings that a party may bring or due to other circumstances that are currently unknown), then pursuant to Section&nbsp;174 of the DGCL, the statute of limitations
for claims of creditors could then be six years after the unlawful redemption distribution, instead of three years, as in the case of a liquidating distribution. If we do not complete our initial Business Combination within 24 months from the
closing of our initial public offering, we will: (i)&nbsp;cease all operations except for the purpose of winding up, (ii)&nbsp;as promptly as reasonably possible but not more than ten business days thereafter, redeem the MAAC Class A Shares, at a <FONT
STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Trust Account that may be released to us to pay our taxes, if any (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding MAAC Class A Shares,
which redemption will completely extinguish Public Stockholders&#146; rights as stockholders (including the right to receive further liquidating distributions, if any) and (iii)&nbsp;as promptly as reasonably possible following such redemption,
subject to the approval of our remaining stockholders and our board of directors, dissolve and liquidate, subject in each case to our obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.
Accordingly, it is our intention to redeem the MAAC Class A Shares as soon as reasonably possible following our 24th month and, therefore, we do not intend to comply with those procedures. As such, our stockholders could potentially be liable for
any claims to the extent of distributions received by them (but no more) and any liability of our stockholders may extend well beyond the third anniversary of such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we will not be complying with Section&nbsp;280, Section&nbsp;281(b) of the DGCL requires us to adopt a plan, based on facts known to
us at such time that will provide for our payment of all existing and pending claims or claims that may be potentially brought against us within the subsequent 10 years. However, because we are a blank check company, rather than an operating
company, and our operations will be limited to searching for prospective target businesses to acquire, the only likely claims to arise would be from our vendors (such as lawyers, investment bankers, etc.) or prospective target businesses. As
described above, pursuant to the obligation contained in our underwriting agreement, we will seek to have all vendors, service providers, prospective target businesses or other entities with which we do business execute agreements with us waiving
any right, title, interest or claim of any kind in or to any monies held in the Trust Account. As a result of this obligation, the claims that could be made against us are significantly limited and the likelihood that any claim that would result in
any liability extending to the Trust Account is remote. Further, our Sponsor may be liable only to the extent necessary to ensure that the amounts in the Trust Account are not reduced below (i) $10.00 per MAAC Class A Share or (ii)&nbsp;such lesser
amount per MAAC Class A Share held in the Trust Account as of the date of the liquidation of the Trust Account, due to reductions in value of the trust assets, in each case net of the amount of interest withdrawn to pay taxes and will not be liable
as to any claims under our indemnity of the underwriters of our initial public offering against certain liabilities, including liabilities under the Securities Act. In the event that an executed waiver is deemed to be unenforceable against a third
party, our Sponsor will not be responsible to the extent of any liability for such third-party claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we file a bankruptcy or <FONT
STYLE="white-space:nowrap">winding-up</FONT> petition or an involuntary bankruptcy or <FONT STYLE="white-space:nowrap">winding-up</FONT> petition is filed against us that is not dismissed, the proceeds held in the Trust Account could be subject to
applicable bankruptcy or insolvency law, and may be included in our bankruptcy estate and subject to the claims of third parties with priority over the claims of our stockholders. To the extent any bankruptcy claims deplete the Trust Account, we
cannot assure you we will be able to return $10.00 per share to our Public Stockholders. Additionally, if we file a bankruptcy or <FONT STYLE="white-space:nowrap">winding-up</FONT> petition or an involuntary bankruptcy or <FONT
STYLE="white-space:nowrap">winding-up</FONT> petition is filed against us that is not dismissed, any distributions received by stockholders could be viewed under applicable debtor/creditor and/or bankruptcy or insolvency laws as either a
&#147;preferential transfer&#148; or a &#147;fraudulent conveyance.&#148; As a result, a bankruptcy or insolvency court could seek to recover some or all amounts received by our stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, our board of directors may be viewed as having breached its fiduciary duty to our creditors and/or may have acted in bad faith,
and thereby exposing itself and our company to claims of punitive damages, by paying Public Stockholders from the Trust Account prior to addressing the claims of creditors. We cannot assure you that claims will not be brought against us for these
reasons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Public Stockholders will be entitled to receive funds from the Trust Account only (i)&nbsp;in the event of the redemption of
the MAAC Class A Shares if we do not complete an initial Business Combination within 24 months from the closing of our initial public offering, (ii)&nbsp;in connection with a stockholder vote to amend our amended and restated Certificate of
Incorporation (A)&nbsp;to modify the substance or timing of our obligation to allow redemption in connection with our initial Business Combination or to redeem 100% of the MAAC Class A Shares if we do not complete an initial Business Combination
within 24 months from the closing of our initial public offering or (B)&nbsp;with respect to any other provisions relating to the rights of holders of MAAC Class&nbsp;A </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Shares, or (iii)&nbsp;if they redeem their respective shares for cash upon the completion of the initial Business Combination. Public Stockholders who redeem their MAAC Class&nbsp;A Shares in
connection with a stockholder vote described in clause (ii)&nbsp;in the preceding sentence shall not be entitled to funds from the Trust Account upon the subsequent completion of an initial Business Combination or liquidation if we have not
completed an initial Business Combination within 24 months from the closing of our initial public offering, with respect to such MAAC Class&nbsp;A Shares so redeemed. In no other circumstances will a stockholder have any right or interest of any
kind to or in the Trust Account. In the event we seek stockholder approval in connection with our initial Business Combination, a stockholder&#146;s voting in connection with the Business Combination alone will not result in a stockholder&#146;s
redeeming its shares to us for an applicable pro rata share of the Trust Account. Such stockholder must have also exercised its redemption rights described above. These provisions of our amended and restated Certificate of Incorporation, like all
provisions of our amended and restated Certificate of Incorporation, may be amended with a stockholder vote. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employees </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have two executive officers. These individuals are not obligated to devote any specific number of hours to our matters but they
intend to devote as much of their time as they deem necessary to our affairs until we have completed our initial Business Combination. The amount of time they will devote in any time period will vary based on whether a target business has been
selected for our initial Business Combination and the stage of the Business Combination process we are in. We do not intend to have any full-time employees prior to the completion of our initial Business Combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Facilities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain our
executive offices at 724 Oak Grove Ave, Suite 130, Menlo Park, CA 94025. The cost for our use of this space is included in the $10,000 per month fee we pay to an affiliate of our Sponsor for office space, utilities, secretarial and administrative
support services. We consider our current office space adequate for our current operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal Proceedings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to legal proceedings, investigations and claims incidental to the conduct of our business from time to time. To the knowledge
of our management, there is no litigation currently pending or contemplated against us, any of our officers or directors in their capacity as such or against any of our property. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Periodic Reporting and Audited Financial Statements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC has registered its securities under the Exchange Act and has reporting obligations, including the requirement to file annual and quarterly
reports with the Securities and Exchange Commission. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Directors and Executive Officers </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC&#146;s current directors and executive officers are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="55%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Age&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James C. Momtazee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer and President, Chairman of the Board of Directors and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maria C. Walker</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">George Barrett</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Oesterle</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Our Founder James C. Momtazee</B> has over 23 years of investment and acquisition experience. He has served
as the Chief Executive Officer and President of our Company and Chairman of the Board of Directors </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
since July 2020. Mr.&nbsp;Momtazee initially joined KKR&nbsp;&amp; Co., Inc. (&#147;KKR&#148;), in 1996. He helped form KKR&#146;s health care industry group in 2001 and was promoted to
KKR&#146;s Head of the Heath Care Team for the Americas Private Equity platform in January 2009. He was a member of KKR&#146;s Americas Private Equity Investment Committee and was Chairman of the Health Care Strategic Growth and the Health Care
Royalty&nbsp;&amp; Income Investment Committees. During the period between 2001 and 2019, KKR was one of the most active investors on Wall Street, committing over $50&nbsp;billion in capital across the health care sector. The largest of these
investments was its $33&nbsp;billion acquisition of HCA, Inc. in 2006, which at the time, was the largest cash buyout in history. During this same period, KKR made several other notable investments across the health care sector, including: Jazz
Pharmaceuticals plc in 2004; PRA Health Sciences, Inc. in 2013; and BridgeBio Pharma, Inc. in 2016. Mr.&nbsp;Momtazee currently serves on the Board of Directors of BridgeBio, Apollo Therapeutics, Kriya Therapeutics and the Medical Device
Manufacturers Association and has previously served on the Board of Directors of multiple other health care companies, including PRA Health Sciences, Inc. (lead independent director), Envision Healthcare, Heartland Dental, Ajax Health, Global
Medical Response, BrightSpring Health Services, Covenant Surgical Partners, Entellus Medical, Inc. (acquired by Stryker Corporation), EchoNous, Spirox, Inc., Arbor Pharmaceuticals, Lake Region Medical, HCA Healthcare, Jazz Pharmaceuticals, and
Alliance Imaging. We believe that Mr.&nbsp;Momtazee&#146;s broad operational and transactional experience make him well qualified to serve on our board of directors. Four of the companies where Mr.&nbsp;Momtazee had his longest serving Board of
Directors roles are summarized below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Jazz Pharmaceuticals plc:</B> Jazz is a biopharmaceutical company focused on developing and commercializing
products to treat various unmet medical needs, including narcolepsy, hematology and oncology. Mr.&nbsp;Momtazee served on the company&#146;s Board of Directors from February 2004 until January 2014. During that period of time, Jazz went public
through an IPO, raising approximately $108&nbsp;million and placing a valuation of approximately $434&nbsp;million on the company, and completed four transactions, including the acquisitions of Azur Pharma in 2011 and EUSA Pharma in 2012, the
divestiture of its Women&#146;s Health business in 2012 and the acquisition of Gentium in 2013. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>HCA Holdings, Inc.:</B> HCA is an acute care and health care services company that currently operates 179
hospitals with over 44,000 beds across 20 states and Europe. Mr.&nbsp;Momtazee served on the company&#146;s Board of Directors from November 2006, coinciding with HCA&#146;s take private transaction, until February 2014. During that period of time,
HCA went public through an IPO, raising $4.4&nbsp;billion and placing a valuation of approximately $17.1&nbsp;billion on the company, which at the time, represented the largest IPO of a Sponsor-backed company in history. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>PRA Health Sciences, Inc.: </B>PRA Health is a global contract research organization (CRO) that provides
outsourced clinical development services to the biotechnology and pharmaceutical industries. In September 2013, Mr.&nbsp;Momtazee joined PRA Health Sciences&#146; Board of Directors and is currently Lead Independent Director. During this period of
time, PRA Health went public through an IPO, raising approximately $351&nbsp;million and placing a valuation of $1.1&nbsp;billion on the company, and completed four acquisitions, including CRI Worldwide in 2013, Symphony Health Solutions in 2017,
Parallel6 in 2017 and Care Innovations in 2020. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>BridgeBio Pharma, Inc.: </B>BridgeBio is a clinical biotechnology company focused on developing therapies for
Mendelian disease and cancers with clear genetic drivers. The company has a diversified pipeline of more than 20 assets that has been gradually built through internal development, licensing deals and acquisitions. In March 2016, Mr.&nbsp;Momtazee
joined BridgeBio&#146;s Board of Directors, coinciding with a Series B investment from private investors in BridgeBio, and is currently still a member. During this period of time, BridgeBio went public through an IPO, raising approximately
$401&nbsp;million and placing a valuation of approximately $2.1&nbsp;billion on the company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Our Founder Maria C.
Walker </B>has over 30 years of operational and investment experience. She has served as the Chief Financial Officer of our Company since July 2020. Most recently, Ms.&nbsp;Walker <FONT STYLE="white-space:nowrap">co-founded,</FONT> and served as
Chief Executive Officer of, Recuerdo Therapeutics, a biotechnology startup that focused on the postponement of Alzheimer&#146;s disease. Prior to her time with Recuerdo, Ms.&nbsp;Walker spent the majority of her career with KPMG where, over two
separate periods between 1993 to 2000 and 2008 to 2018, she advanced to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the role of senior partner and served as global lead partner of private equity leading a global, cross-functional team of 70+ partners advising a bulge bracket private equity firm. During the
time period between 2000 and 2005, Ms.&nbsp;Walker served as the Administrative Partner, Chief Operating Officer and Chief Financial Officer for Forward Ventures, and between 2005 and 2008, she served as the Chief Financial Officer of Lightspeed
Venture Partners, where she was a key member of the team establishing units in India, China and Israel. At KPMG and as an investment executive, Ms.&nbsp;Walker advised over a dozen public companies on operations, financial reporting, debt and equity
offerings, mergers and acquisitions, take public and take private transactions. Ms.&nbsp;Walker currently serves on the Board of Directors of ForgeRock, Inc., a private cyber security company where she also serves as the audit committee Chairman,
the Boys and Girls Club of Greater Tarrant County, and StepUp. Ms.&nbsp;Walker has previously served on the Board of Directors of the KPMG Foundation Board of Trustees and MedicineNet (acquired by WebMD). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>George Barrett</B> is a director since October 2020 and the former Chairman of the Board of Directors and Chief Executive Officer of
Cardinal Health, Inc., a role he held from August 2009 through end of 2017, when he became Executive Chairman of the Board of Directors until November 2018. He helped transform Cardinal Health into a global, integrated health care company,
delivering 189% total shareholder return during his eight-year CEO tenure from August 2009 to December 2017. Prior to joining Cardinal Health, Mr.&nbsp;Barrett spent a decade at global pharmaceutical manufacturer Teva Pharmaceutical Industries Ltd.,
most recently as President and Chief Executive Officer of its North American business and corporate executive vice president for Global Pharmaceuticals. Mr.&nbsp;Barrett serves on the boards of Target Corporation, health care-focused artificial
intelligence company Olive, Digital Diagnostics, Inc., National Resilience, Inc., and InStride, a public benefit corporation that provides workforce education. Additionally, Barrett serves on the boards of Nationwide Children&#146;s Hospital, and a
National Academy of Medicine&#146;s President&#146;s Advisory Council. He is vice chair of the board of trustees of The Conference Board, and a former director of the Federal Reserve Bank of Cleveland. Barrett earned his bachelor&#146;s degree from
Brown University, and his MBA from New York University. Barrett is an Adjunct Assistant Professor at Columbia University Mailman School of Public Health, a trustee emeritus of Brown University, and a frequent lecturer at other leading American
universities on the topics of leadership and health care. We believe that Mr.&nbsp;Barrett&#146;s broad operational and transactional experience make him well qualified to serve on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Dr.</B><B></B><B>&nbsp;Stephen Oesterle</B> is a director since October 2020 and currently serves as a consultant to several private equity
and venture capital groups and numerous public operating companies in the health care industry. Previously, Dr.&nbsp;Oesterle served as Medtronic&#146;s Senior Vice President for Medicine and Technology and was a member of the Medtronic Executive
Committee for 14 years. By forging relationships with global technology partners and technical universities, he oversaw long term internal technology investments while participating in strategic corporate investments in emerging private companies.
He also served as a member of the Business Development and Strategy Committee that approved all corporate acquisitions. During his tenure at Medtronic Dr.&nbsp;Oesterle served on more than 20 boards as a director or observer and built a strong and
enduring profile for Medtronic in the global venture capital and private equity communities. Prior to joining Medtronic, he was an associate professor at Harvard Medical School and practicing interventional cardiologist. Dr.&nbsp;Oesterle currently
serves on the boards of three public companies, Baxter (NYSE: BAX), Peijia Medical (HKG: 9996), and Siglon Therapeutics (Nasdaq: SGTX) in addition to the board of certain private companies. Dr.&nbsp;Oesterle graduated <I>summa cum laude</I> from
Harvard and received his medical degree from Yale; he completed his internship and residency at Massachusetts General Hospital. Following medical school, he completed a fellowship in Interventional Cardiology at Stanford and then served on the
faculty at Stanford and Harvard Medical School and directed the Invasive Cardiology Services at Massachusetts General Hospital and Stanford. We believe that Dr.&nbsp;Oesterle&#146;s broad operational and transactional experience make him well
qualified to serve on our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Number, Terms of Office and Election of Officers and Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is divided into three classes, with only one class of directors being elected in each year, and with each class (except
for those directors appointed prior to our first annual meeting of stockholders) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
serving a three-year term. In accordance with the Nasdaq corporate governance requirements, we are not required to hold an annual meeting until one year after our first fiscal year end following
our listing on Nasdaq. The term of office of the first class of directors, consisting of Stephen Oesterle, will expire at our first annual meeting of stockholders. The term of office of the second class of directors, consisting of George Barrett,
will expire at our second annual meeting of the stockholders. The term of office of the third class of directors, consisting of James C. Momtazee, will expire at our third annual meeting of stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the completion of an initial Business Combination, any vacancy on the board of directors may be filled by a nominee chosen by holders
of a majority of our Founder Shares. In addition, prior to the completion of an initial Business Combination, holders of a majority of our Founder Shares may remove a member of the board of directors for any reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of
office. Our board of directors is authorized to nominate persons to the offices set forth in our amended and restated Certificate of Incorporation as it deems appropriate. Our amended and restated Certificate of Incorporation provides that our
officers may consist of one or more chairman of the board of directors, chief executive officer, president, chief financial officer, vice presidents, secretary, treasurer and such other offices as may be determined by the board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nasdaq listing
standards require that a majority of our board of directors be independent, subject to applicable <FONT STYLE="white-space:nowrap">phase-in</FONT> rules. An &#147;independent director&#148; is defined generally as a person other than an officer or
employee of the company or its subsidiaries or any other individual having a relationship which in the opinion of the company&#146;s board of directors, would interfere with the director&#146;s exercise of independent judgment in carrying out the
responsibilities of a director. Our board of directors has determined that George Barrett, and Stephen Oesterle are &#147;independent directors&#148; as defined in the Nasdaq listing standards and applicable SEC rules. Our independent directors will
have regularly scheduled meetings at which only independent directors are present. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of the Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has three standing committees: an audit committee, a compensation committee and a corporate governance and nominating
committee. Subject to <FONT STYLE="white-space:nowrap">phase-in</FONT> rules and a limited exception, the rules of Nasdaq and Rule 10A of the Exchange Act require that the audit committee of a listed company be comprised solely of independent
directors. Subject to <FONT STYLE="white-space:nowrap">phase-in</FONT> rules and a limited exception, the rules of Nasdaq require that the compensation committee of a listed company be comprised solely of independent directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Audit Committee </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established an
audit committee of our board of directors. The audit committee is not fully independent but complies with Nasdaq listing standards, specifically applicable <FONT STYLE="white-space:nowrap">phase-in</FONT> rules, and applicable SEC rules. Our board
of directors has determined that both George Barrett and Stephen Oesterle are independent under Nasdaq listing standards and applicable rules. George Barrett serves as the chairman of the audit committee. Each member of the audit committee is
financially literate and our board of directors has determined that George Barrett qualifies as an &#147;audit committee financial expert&#148; as defined in applicable SEC rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary functions of the audit committee include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing, compensating and overseeing our independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the annual audit plan for the Company; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing the integrity of our financial statements and our compliance with legal and regulatory requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing the annual audited financial statements and unaudited quarterly financial statements with management
and the independent registered public accounting firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> all audit services and permitted <FONT
STYLE="white-space:nowrap">non-audit</FONT> services to be performed by our independent registered public accounting firm, including the fees and terms of the services to be performed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing or replacing the independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing procedures for the receipt, retention and treatment of complaints (including anonymous complaints)
we receive concerning accounting, internal accounting controls, auditing matters or potential violations of law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitoring our environmental sustainability and governance practices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing procedures for the receipt, retention and treatment of complaints received by us regarding
accounting, internal accounting controls or reports which raise material issues regarding our financial statements or accounting policies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> services provided by our independent
registered public accounting firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing earnings press releases and financial information provided to analysts and rating agencies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing with management our policies and practices with respect to risk assessment and risk management;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing any material transaction between our Chief Financial Officer that has been approved in accordance with
our Code of Ethics for our officers, and providing prior written approval of any material transaction between us and our President; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">producing an annual report for inclusion in our proxy statement, in accordance with applicable rules and
regulations. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee is a separately designated standing committee established in accordance with
Section&nbsp;3 (a)(58)(A) of the Exchange Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Compensation Committee </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established a compensation committee of our board of directors. The members of our compensation committee are George Barrett and
Dr.&nbsp;Stephen Oesterle, with Dr.&nbsp;Stephen Oesterle serving as chairman. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Nasdaq listing standards and applicable SEC
rules and subject to applicable phase in rules, we are required to have a compensation committee composed entirely of independent directors. Our board of directors has determined that George Barrett and Dr.&nbsp;Stephen Oesterle are independent. We
adopted a compensation committee charter, which details the principal functions of the compensation committee, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving corporate goals and objectives relevant to our President&#146;s compensation, evaluating
our President&#146;s performance in light of those goals and objectives, and setting our President&#146;s compensation level based on this evaluation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">setting salaries and approving incentive compensation and equity awards, as well as compensation policies, for
all other officers who file reports of their ownership, and changes in ownership, of the Company&#146;s common stock under Section&nbsp;16(a) of the Exchange Act (the &#147;Section&nbsp;16 Officers&#148;), as designated by our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making recommendations to the board with respect to incentive compensation programs and equity-based plans that
are subject to board approval; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving any employment or severance agreements with our Section&nbsp;16 Officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">granting any awards under equity compensation plans and annual bonus plans to our President and the
Section&nbsp;16 Officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving the compensation of our directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">producing an annual report on executive compensation for inclusion in our proxy statement, in accordance with
applicable rules and regulations. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The charter also provides that the compensation committee may, in its sole
discretion, retain or obtain the advice of a compensation consultant, legal counsel or other adviser and will be directly responsible for the appointment, compensation and oversight of the work of any such adviser. However, before engaging or
receiving advice from a compensation consultant, external legal counsel or any other adviser, the compensation committee will consider the independence of each such adviser, including the factors required by Nasdaq and the SEC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of our executive officers currently serves, and in the past year has not served, as a member of the compensation committee of any entity
that has one or more executive officers serving on our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Corporate Governance and Nominating Committee </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established a corporate governance and nominating committee of our board of directors. The members of our corporate governance and
nominating committee are George Barrett and Dr.&nbsp;Stephen Oesterle, and Dr.&nbsp;Stephen Oesterle serves as chairman of the corporate governance and nominating committee. Under the Nasdaq listing standards, we are required to have a corporate
governance and nominating committee composed entirely of independent directors, subject to applicable <FONT STYLE="white-space:nowrap">phase-in</FONT> rules. Our board of directors has determined that both George Barrett and Dr.&nbsp;Stephen
Oesterle are independent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary function of the corporate governance and nominating committee include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying individuals qualified to become members of the board of directors and making recommendations to the
board of directors regarding nominees for election; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the independence of each director and making a recommendation to the board of directors with respect to
each director&#146;s independence; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and recommending to the board of directors the corporate governance principles applicable to us and
reviewing our corporate governance guidelines at least annually; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making recommendations to the board of directors with respect to the membership of the audit, compensation and
corporate governance and nominating committees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing the evaluation of the performance of the board of directors and its committees on a continuing basis,
including an annual self- evaluation of the performance of the corporate governance and nominating committee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considering the adequacy of our governance structures and policies, including as they relate to our environmental
sustainability and governance practices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considering director nominees recommended by stockholders; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing our overall corporate governance and reporting to the board of directors on its findings and any
recommendations. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Ethics and How to Obtain the Code of Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a Code of Ethics applicable to our directors, officers and employees. A copy of the Code of Ethics will be provided without
charge upon written request to our principal executive offices. We intend to disclose any amendments to or waivers of certain provisions of our Code of Ethics in a Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conflicts of Interest </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general,
officers and directors of a corporation incorporated under the laws of the State of Delaware are required to present business opportunities to a corporation if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the corporation could financially undertake the opportunity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the opportunity is within the corporation&#146;s line of business; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it would not be fair to our company and its stockholders for the opportunity not to be brought to the attention
of the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our officers and directors presently have, and any of them in the future may have
additional, fiduciary or contractual obligations to other entities, including entities that are affiliates of our Sponsor, pursuant to which such officer or director is or will be required to present a Business Combination opportunity to such
entity. Accordingly, if any of our officers or directors becomes aware of a Business Combination opportunity which is suitable for an entity to which he or she has then-current fiduciary or contractual obligations, he or she will honor his or her
fiduciary or contractual obligations to present such Business Combination opportunity to such entity, subject to their fiduciary duties under Delaware law. We do not believe, however, that the fiduciary duties or contractual obligations of our
officers or directors will materially affect our ability to complete our initial Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Potential investors should also be
aware of the following other potential conflicts of interest: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our executive officers and directors are not required to, and will not, commit their full time to our affairs,
which may result in a conflict of interest in allocating their time between our operations and our search for a Business Combination and their other businesses. We do not intend to have any full-time employees prior to the completion of our initial
Business Combination. Each of our executive officers and directors is engaged in several other business endeavors for which he may be entitled to substantial compensation, and our executive officers and directors are not obligated to contribute any
specific number of hours per week to our affairs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Sponsor subscribed for Founder Shares and purchased private placement warrants in a transaction that closed
simultaneously with the closing of our initial public offering. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Sponsor and each member of our management team have entered into agreements with us, pursuant to which they
have agreed to waive their redemption rights with respect to their Founder Shares and MAAC Class A Shares in connection with (i)&nbsp;the completion of our initial Business Combination and (ii)&nbsp;a stockholder vote to approve an amendment to our
amended and restated Certificate of Incorporation that would affect the substance or timing of our obligation to allow redemption in connection with our initial Business Combination or to redeem 100% of the MAAC Class A Shares if we have not
completed an initial business combination within 24 months from the closing of our initial public offering. Additionally, our Sponsor has agreed to waive its rights to liquidating distributions from the Trust Account with respect to its Founder
Shares if we do not complete our initial Business Combination within the prescribed time frame. If we do not complete our initial Business Combination within the prescribed time frame, the private placement warrants will expire worthless. Except as
described herein, our Sponsor and our directors and executive officers have agreed not to transfer, assign or sell any of their Founder Shares until the earliest of (A)&nbsp;one year after
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
the completion of our initial Business Combination or (B)&nbsp;subsequent to our initial Business Combination, (x)&nbsp;if the last reported sale price of MAAC Class&nbsp;A Shares equals or
exceeds $12.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any <FONT STYLE="white-space:nowrap">30-trading</FONT> day period commencing at least 150
days after our initial Business Combination, or (y)&nbsp;the date on which we complete a liquidation, merger, capital stock exchange or other similar transaction that results in all of our stockholders having the right to exchange their common stock
for cash, securities or other property. The private placement warrants will not be transferable until 30 days following the completion of our initial Business Combination. Because each of our executive officers and directors own common stock or
warrants directly or indirectly, they may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial Business Combination. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our officers and directors may have a conflict of interest with respect to evaluating a particular Business
Combination if the retention or resignation of any such officers and directors is included by a target business as a condition to any agreement with respect to our initial Business Combination. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, in no event will our Sponsor or any of our existing officers or directors, or any of their respective affiliates, be paid by the
company any finder&#146;s fee, consulting fee or other compensation prior to, or for any services they render in order to effectuate, the completion of our initial Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure you that any of the above mentioned conflicts will be resolved in our favor. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitation on Liability and Indemnification of Officers and Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated Certificate of Incorporation provides that our officers and directors will be indemnified by us to the fullest extent
authorized by Delaware law, as it now exists or may in the future be amended. In addition, our amended and restated Certificate of Incorporation provides that our directors will not be personally liable for monetary damages to us or our stockholders
for breaches of their fiduciary duty as directors, unless they violated their duty of loyalty to us or our stockholders, acted in bad faith, knowingly or intentionally violated the law, authorized unlawful payments of dividends, unlawful stock
purchases or unlawful redemptions, or derived an improper personal benefit from their actions as directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into agreements
with our officers and directors to provide contractual indemnification in addition to the indemnification provided for in our amended and restated Certificate of Incorporation. Our amended and restated
<FONT STYLE="white-space:nowrap">bye-laws</FONT> also permit us to secure insurance on behalf of any officer, director or employee for any liability arising out of his or her actions, regardless of whether Delaware law would permit such
indemnification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have purchased a policy of directors&#146; and officers&#146; liability insurance that insures our officers and
directors against the cost of defense, settlement or payment of a judgment in some circumstances and insures us against our obligations to indemnify our officers and directors. Our officers and directors have agreed to waive any right, title,
interest or claim of any kind in or to any monies in the Trust Account, and have agreed to waive any right, title, interest or claim of any kind they may have in the future as a result of, or arising out of, any services provided to us and will not
seek recourse against the Trust Account for any reason whatsoever (except to the extent they are entitled to funds from the Trust Account due to their ownership of MAAC Class A Shares). Accordingly, any indemnification provided will only be able to
be satisfied by us if (i)&nbsp;we have sufficient funds outside of the Trust Account or (ii)&nbsp;we complete an initial Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our indemnification obligations may discourage stockholders from bringing a lawsuit against our officers or directors for breach of their
fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against our officers and directors, even though such an action, if successful, might otherwise benefit us and our stockholders.
Furthermore, a stockholder&#146;s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against our officers and directors pursuant to these indemnification provisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that these provisions, the insurance and the indemnity agreements are necessary
to attract and retain talented and experienced officers and directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_19"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS OF MAAC </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>References to the &#147;Company,&#148; &#147;Montes Archimedes Acquisition Corp.,&#148;
&#147;our,&#148; &#147;us&#148; or &#147;we&#148; refer to Montes Archimedes Acquisition Corp. The following discussion and analysis of the Company&#146;s financial condition and results of operations should be read in conjunction with the financial
statements and the notes thereto contained elsewhere in this proxy. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a blank check company
incorporated in Delaware on July&nbsp;6, 2020 for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. We are an emerging growth company
and, as such, we are subject to all of the risks associated with emerging growth companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our sponsor is Patient Square Capital LLC
(the &#147;Sponsor&#148;). On October&nbsp;9, 2020, we consummated our initial public offering of 40,000,000 MAAC Units at $10.00 per Unit, generating gross proceeds of $400.0&nbsp;million, and incurring offering costs of approximately
$22.1&nbsp;million (net of reimbursement of offering costs of $520,000 from the underwriters), inclusive of $14.0&nbsp;million in deferred underwriting commissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Simultaneously with the closing of the initial public offering, we consummated the private placement (&#147;Private Placement&#148;) of
10,000,000 warrants (each, a &#147;private placement warrant&#148; and collectively, the &#147;private placement warrants&#148;) at a price of $1.00 per Private Placement Warrant to the MAAC Sponsor, generating proceeds of $10.0&nbsp;million. The
underwriters exercised the over-allotment option in part and on November&nbsp;12, 2020 purchased an additional 1,071,823 MAAC Units (the &#147;Over-Allotment Units&#148;), generating gross proceeds of approximately $10.7&nbsp;million, and incurred
additional offering costs of approximately $576,000 in underwriting fees (net of reimbursement of offering costs of approximately $14,000 from the underwriters and inclusive of approximately $0.4&nbsp;million in deferred underwriting fees) (the
&#147;Over-Allotment&#148;). Simultaneously with the closing of the Over-allotment on November&nbsp;12, 2020, we consummated the second closing of the Private Placement, resulting in the purchase of an aggregate of an additional 214,365 private
placement warrants by our Sponsor, generating gross proceeds to us of approximately $214,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of the initial public
offering, the Private Placement and part of the Over-Allotment option, $410.7&nbsp;million ($10.00 per Unit) of the net proceeds of the initial public offering and certain of the proceeds of the Private Placement was placed in a trust account
(&#147;Trust Account&#148;) with Continental Stock Transfer&nbsp;&amp; Trust Company acting as trustee and invested in United States &#147;government securities&#148; within the meaning of Section&nbsp;2(a)(16) of the Investment Company Act having a
maturity of 185 days or less or in money market funds meeting certain conditions under Rule <FONT STYLE="white-space:nowrap">2a-7</FONT> promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations,
as determined by the Company, until the earlier of: (i)&nbsp;the completion of a business combination and (ii)&nbsp;the distribution of the Trust Account as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to complete a business combination within 24 months from the closing of the initial public offering, or October&nbsp;9, 2022
(as such period may be extended pursuant to the Certificate of Incorporation, the &#147;Combination Period&#148;), we will (i)&nbsp;cease all operations except for the purpose of winding up; (ii)&nbsp;as promptly as reasonably possible but not more
than ten business days thereafter, redeem the MAAC Class&nbsp;A Shares sold in the initial public offering, at a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount then on deposit in the Trust
Account including interest earned on the funds held in the Trust Account and not previously released to us to pay its taxes, if any (less up to $100,000 of interest to pay dissolution expenses), divided by the number of the then outstanding MAAC
Class A Shares, which redemption will completely extinguish Public Stockholders&#146; rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law; and (iii)&nbsp;as promptly as
reasonably possible following such redemption, subject to the approval of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">226 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
remaining stockholders and the board of directors, liquidate and dissolve, subject in each case, to our obligations under Delaware law to provide for claims of creditors and the requirements of
other applicable law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Proposed Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;1, 2021, we entered into the Business Combination Agreement with Roivant and Merger Sub, which was subsequently amended on June 9,
2021 to reflect the execution of the lock-up agreements entered into by MAAC&#146;s independent directors and Roivant. In connection with the Business Combination, we also entered into the Subscription Agreements, Sponsor Support Agreement, and the
Transaction Support Agreements, as further described in &#147;<I></I>The Business Combination Proposal&#151;Related Agreements.<I></I>&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results
of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our entire activity from July 6, 2020 (inception) through December 31, 2020, was in preparation for an Initial Public
Offering, and since our Initial Public Offering, our activity has been limited to the search for a prospective initial Business Combination. We will not generate any operating revenues until the closing and completion of our initial Business
Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three months ended March 31, 2021, we had a net income of approximately $19 million, which consisted of
approximately $23 million gain from change in fair value of warrant liabilities, an approximately $93,000 gain on investment (net), dividends and interest held in Trust Account, which were partially offset by approximately $3.9 million in general
and administrative expenses (including $3.5 million related to due diligence), approximately $30,000 in general and administrative expenses for costs incurred with our Sponsor, an approximately of $20,000 in income tax expense, and approximately
$49,000 of franchise tax expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the period from July 6, 2020 (inception) through December 31, 2020, we had a net loss of
approximately $10.8 million, which consisted of approximately $3.6 million loss from changes in fair value of derivative warrant liabilities, approximately $6.8 million of financing cost - derivative warrant liabilities, approximately $0.3 million
of general and administrative expenses, approximately $28,000 general and administrative expense - related party, franchise tax expense of approximately $89,000, income tax expense of approximately $17,000 offset by approximately $85,000 of interest
income and unrealized gain on marketable securities held in the Trust Account. The $6.8 million in financing cost - derivative liability is primarily related to the non-cash financing cost recognized as a result of the fair value of the private
placement warrants being in excess of the amount paid by the MAAC Sponsor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the restatement described in Note 2 of the
notes to the financial statements included herein, we allocated approximately $1.7 million of offering costs to the warrant liabilities and recognized $5.1 million related to the excess fair value of the private placement warrants over the proceeds
received as a financing cost. Both of these charges have been presented as financing cost - derivative warrant liability on the statement of operations. In addition, we classify the warrants issued in connection with our Initial Public Offering and
Private Placement as liabilities at their fair value and adjust the warrant instruments to fair value at each reporting period. These liabilities are subject to re-measurement at each balance sheet date until exercised, and any change in fair value
is recognized in our statement of operations. For the periods from July 6, 2020 (inception) through December 31, 2020, the change in fair value of warrants was an increase of approximately $3.6 million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
March 31, 2021, the Company had approximately $1.5&nbsp;million in cash and a working capital deficit of approximately $2.4&nbsp;million (not taking into account approximately $69,000 of taxes that may be paid using interest income from the Trust
Account). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our liquidity needs up to March 31, 2021 had been satisfied through the payment of $25,000 from our Sponsor to cover for
certain expenses on behalf of us in exchange for the issuance of the Founder Shares, a loan </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">227 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of $200,000 pursuant to the Note issued to our Sponsor, and the net proceeds from the consummation of the Private Placement not held in the Trust Account. We fully repaid the Note to our Sponsor
on October&nbsp;9, 2020. In addition, in order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, our Sponsor may, but is not obligated to, provide us Working Capital Loans. To date, there
are no amounts outstanding under any Working Capital Loan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the foregoing, management believes that we will have sufficient
working capital and borrowing capacity to meet our needs through the consummation of the Business Combination. Over this time period, we will be using these funds for paying existing accounts payable, identifying and evaluating prospective initial
Business Combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the Business
Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management continues to evaluate the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and has
concluded that the specific impact is not readily determinable as of the date of the financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Registration and
Stockholder Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the Founder Shares, private placement warrants and warrants that may be issued upon conversion
of Working Capital Loans (and any MAAC Class&nbsp;A Shares issuable upon the exercise of the private placement warrants and warrants that may be issued upon conversion of Working Capital Loans) are entitled to registration rights pursuant to the
registration rights agreement. The holders of these securities are entitled to make up to three demands, excluding short form demands, that we register such securities. In addition, the holders have certain &#147;piggy-back&#148; registration rights
with respect to registration statements filed subsequent to the completion of the initial Business Combination. We will bear the expenses incurred in connection with the filing of any such registration statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Underwriting Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
underwriters were entitled to an underwriting discount of $0.20 per unit, or $8.0&nbsp;million in the aggregate, paid upon the closing of the initial public offering. In addition, $0.35 per unit, or $14.0&nbsp;million in the aggregate will be
payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that we complete a Business Combination, subject to the terms
of the underwriting agreement. The underwriters agreed to make a payment to us in an amount of 0.13% of the gross proceeds of the initial public offering, or $520,000, to reimburse certain offering expenses. We received such reimbursement on
October&nbsp;27, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon closing of the Over-allotment on November&nbsp;12, 2020, the underwriters received approximately $214,000 in
fees paid upfront and eligible for an additional deferred underwriting commissions of approximately $375,000. In addition, the underwriters agreed to make an additional payment to us in an amount of 0.13% of the gross proceeds of the Over-allotment,
or approximately $14,000, to reimburse certain offering expenses. As of December&nbsp;31, 2020, approximately $5,000 is included as a receivable for such reimbursements on the accompanying balance sheet. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This management&#146;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which
have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">228 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to
fair value of financial instruments and accrued expenses. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We have identified the following as
our critical accounting policies: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>MAAC Class&nbsp;A Shares Subject to Possible Redemption </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for MAAC Class&nbsp;A Shares subject to possible redemption in accordance with the guidance in ASC Topic 480 &#147;Distinguishing
Liabilities from Equity.&#148; MAAC Class&nbsp;A Shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Shares of conditionally redeemable MAAC Class&nbsp;A Shares (including MAAC
Class&nbsp;A Shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control) are classified as temporary equity. At all other
times, MAAC Class&nbsp;A Shares are classified as stockholders&#146; equity. MAAC Class&nbsp;A Shares feature certain redemption rights that are considered to be outside of our control and subject to the occurrence of uncertain future events.
Accordingly, at March&nbsp;31, 2021, 36,277,487 MAAC Class&nbsp;A Shares subject to possible redemption are presented as temporary equity, outside of the stockholders&#146; equity section of the accompanying balance sheets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Income Per Share </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We comply
with accounting and disclosure requirements of FASB ASC Topic 260, &#147;Earnings Per Share.&#148; Net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of MAAC Shares outstanding during the
period. We have not considered the effect of the warrants sold in the initial public offering and Private Placement to purchase an aggregate of 30,750,276 MAAC Class&nbsp;A Shares in the calculation of diluted earnings per share, since the exercise
of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We apply
the <FONT STYLE="white-space:nowrap">two-class</FONT> method in calculating income (loss) per common share. Net income (loss) per common share, basic and diluted for MAAC Class&nbsp;A Shares subject to possible redemption is calculated by dividing
the proportionate share of income or loss on marketable securities held by the Trust Account, net of applicable franchise and income taxes, by the weighted average number of MAAC Class&nbsp;A Shares subject to possible redemption outstanding since
original issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net income (loss) per common share, basic and diluted for <FONT STYLE="white-space:nowrap">non-redeemable</FONT>
common stock is calculated by dividing net income (loss) less income attributable to MAAC Class&nbsp;A Shares subject to possible redemption by the weighted average number of shares of <FONT STYLE="white-space:nowrap">non-redeemable</FONT> common
stock outstanding for the period presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Derivative Warrant Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. We evaluate all of our financial
instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC 815-15. The classification of derivative instruments,
including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
issued 20,535,912 MAAC Warrants to investors in our initial public offering and issued 10,214,365 private placement warrants. All of our outstanding warrants are recognized as derivative liabilities in accordance with ASC 815-40. Accordingly, we
recognize the warrant instruments as liabilities at fair value and adjust the instruments to fair value at each reporting period. The liabilities are subject to re-measurement at each balance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">229 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sheet date until exercised, and any change in fair value is recognized in our statement of operations. The fair value of the public placement warrants (if not market observed) and private
placement warrants is estimated using a Binomial Lattice in a risk-neutral framework. Our future stock price is modeled assuming a Geometric Brownian Motion in a risk-neutral framework. For each modeled future price, the warrant payoff is calculated
based on the contractual terms (incorporating any optimal early exercise / redemption), and then discounted at the term-matched risk-free rate. The value of the warrants is calculated as the probability-weighted present value over all future modeled
payoffs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a
material impact on our financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021, we did not have any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements as defined in Item
303(a)(4)(ii) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> and did not have any commitments or contractual obligations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JOBS Act </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The JOBS Act contains provisions that, among other things, relax certain reporting requirements for qualifying public companies. We will
qualify as an &#147;emerging growth company&#148; and under the JOBS Act will be allowed to comply with new or revised accounting pronouncements based on the effective date for private (not publicly traded) companies. We are electing to delay the
adoption of new or revised accounting standards, and as a result, we may not comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for
<FONT STYLE="white-space:nowrap">non-emerging</FONT> growth companies. As such, our financial statements may not be comparable to companies that comply with public company effective dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to certain conditions set forth in the JOBS Act, if, as an &#147;emerging growth company,&#148; we choose to rely on such exemptions
we may not be required to, among other things, (i)&nbsp;provide an auditor&#146;s attestation report on our system of internal controls over financial reporting pursuant to Section&nbsp;404, (ii) provide all of the compensation disclosure that may
be required of <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii)&nbsp;comply with any requirement that may be adopted by the PCAOB regarding
mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements (auditor discussion and analysis) and (iv)&nbsp;disclose certain executive compensation related
items such as the correlation between executive compensation and performance and comparisons of the CEO&#146;s compensation to median employee compensation. These exemptions will apply for a period of five years following the completion of our
initial public offering or until we are no longer an &#147;emerging growth company,&#148; whichever is earlier. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">230 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_20"></A>BUSINESS OF ROIVANT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>References to &#147;Roivant,&#148; &#147;the Company,&#148; &#147;we,&#148; &#147;us&#148; or &#147;our&#148; in the following section
refer to Roivant Sciences Ltd. and its subsidiaries, unless the context otherwise requires. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are building the next-generation &#147;big pharma&#148; company, organized to harness modern technologies and the entrepreneurial spirit of
nimble biotechnology companies at scale. Our mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a diverse team of experienced drug developers, scientists, physicians, company builders, data scientists and engineers, biopharma
investors, physicists and business development professionals dedicated to improving the lives of patients. At Roivant, we combine our team&#146;s extensive experience and multi-disciplinary expertise with innovative technologies to identify and
advance potentially transformative medicines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We deploy a hypothesis-driven approach to identify novel or clinically-validated targets
and biological pathways in areas of high unmet medical need. We then seek to acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or discover promising drug candidates against those targets or pathways. Our small molecule discovery engine is
powered by a unique combination of leading computational physics and machine learning (&#147;ML&#148;) capabilities for <I>in silico</I> drug design. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We develop drug candidates in subsidiary companies we call &#147;Vants&#148; with a distinct approach to sourcing talent, aligning incentives
and deploying technology. Each of our Vant teams is built with deep relevant expertise to promote successful execution of our development strategy. Our Vants continue to benefit from the support of the Roivant platform and technologies that are
built to address inefficiencies in the drug discovery, development and commercialization process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our agile Vant model has allowed us to
rapidly add capabilities in diverse therapeutic areas, including immunology, dermatology, hematology and oncology, and modalities, including biologics, topicals, gene therapies and bifunctional small molecules. We currently have 16 Vants and,
together, we are advancing a deep and diversified pipeline of over 30 drug candidates. The Vant model also enables a modular approach to the monetization of therapies we advance through development, allowing us to pursue commercialization of some
products independently, while selectively establishing partnerships for other Vants or divesting of the Vants entirely. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our
founding in 2014, we have: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conducted nine international Phase 3 trials, the last eight of which have been successful; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consummated a $3&nbsp;billion upfront partnership with Sumitomo (see &#147;&#151;Platform Recognition&#148;);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developed three drugs that received FDA approval shortly after their transfer to Sumitomo; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launched and taken public multiple Vants, resulting in an aggregate ownership stake of $732 million in public
Vants as of July 30, 2021, based on a $289&nbsp;million aggregate investment in those Vants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">built a pipeline of over 30 drug candidates ranging from early discovery to registration; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">created innovative software tools to optimize each stage of the drug discovery, development and commercialization
process. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">231 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our Vants: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vants </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Roivant<BR>Ownership</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Vant</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Basic</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Diluted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Lead Program / Mechanism</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Modality</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Indication(s) / Phase</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Upcoming Milestones</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Dermavant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>100%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>85%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Developing treatments for unmet needs in immuno-dermatology</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Tapinarof / Therapeutic aryl hydrocarbon receptor modulating agent</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Topical</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;Psoriasis&nbsp;/&nbsp;Phase 3 complete</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;Atopic dermatitis / Phase 2b complete</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">&#149;&#8195;&#8202;Mid-22:</FONT> FDA approval decision on
Tapinarof for psoriasis</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;2H&#146;21: Tapinarof Phase 3 initiation in atopic dermatitis</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Immunovant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>58%*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>53%*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Developing an anti-FcRn monoclonal antibody for <FONT STYLE="white-space:nowrap">IgG-mediated</FONT> autoimmune diseases</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>IMVT-1401 / Anti-FcRn monoclonal antibody</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Biologic</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;Myasthenia gravis, thyroid eye disease, and warm autoimmune hemolytic
anemia / Phase 2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;Late &#145;21/early &#145;22: IMVT-1401 Phase 3 initiation in myasthenia
gravis</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;Late &#145;21/early &#145;22: IMVT-1401 Phase 2a restart in warm autoimmune hemolytic anemia</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;1H&#146;22: Two new indications for IMVT-1401 to be announced</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Aruvant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>88%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>80%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Developing transformative gene therapies for severe blood disorders</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="white-space:nowrap">ARU-1801</FONT> / Ex vivo lentiviral gene therapy delivering a novel, highly potent variant of fetal hemoglobin (HbF)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Gene&nbsp;therapy</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;Sickle cell disease / Phase 1/2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;2H&#146;21: First patient dosed with
<FONT STYLE="white-space:nowrap">ARU-1801</FONT> manufacturing process III</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;2H&#146;21: Clinical data from additional <FONT STYLE="white-space:nowrap">ARU-1801</FONT> Phase
1/2 patients</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;2H&#146;22: ARU-1801 Phase 3 initiation</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proteovant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>60%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>60%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Developing heterobifunctional protein degraders for oncology, neurology, and immunology</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>AR Degrader</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Small Molecule</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;Prostate cancer / Preclinical</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;2022: AR degrader Phase 1 initiation</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Lysovant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>100%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>99%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Developing a novel endolysin for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">hard-to-treat</FONT></FONT> Staph aureus infection</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>LSVT-1701 / Endolysin</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Biologic</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;Staph aureus bacteremia and infective endocarditis / Phase 1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;1H&#146;22: LSVT-1701 MAD initiation</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Kinevant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>88%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>88%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Developing an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-GM-CSF</FONT></FONT> monoclonal antibody for autoimmune diseases</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Namilumab / <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-GM-CSF</FONT></FONT> monoclonal antibody</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Biologic</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;Sarcoidosis / Phase 1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;1H&#146;22: Namilumab Phase 2
initiation</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">232 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Roivant<BR>Ownership</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Vant</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Basic</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Diluted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Lead Program / Mechanism</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Modality</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Indication(s) / Phase</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Upcoming Milestones</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Affivant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>100%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>100%&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Developing bispecific antibodies for oncology indications with unmet medical need</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>AFM32 / Bispecific antibody</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Biologic</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;Solid Tumors / Preclinical</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;1H&#146;23: File IND</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cytovant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>72%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>68%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Developing cellular medicines uniquely suited to Asian patients</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CVT-TCR-01</FONT></FONT> / <FONT STYLE="white-space:nowrap">TCR-T</FONT> targeting
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NY-ESO-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Cell therapy</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;Oncologic malignancies / Preclinical</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;2H&#146;21: Initiation of CMC activities</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Arbutus</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>33%*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>29%*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Developing a potential cure for chronic HBV infection</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="white-space:nowrap">AB-729</FONT> / RNAi inhibiting HBV replication</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>RNA therapy</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;Hepatitis B / Phase 2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;2H&#146;21: Initiation of two additional combination Phase 2
trials</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Sio Gene Therapies</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>27%*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>25%*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Developing gene therapies for neurodegenerative diseases</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">AXO-AAV-GM1</FONT></FONT> In vivo AAV9 gene therapy</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Gene therapy</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;GM1 gangliosidosis / Phase 1/2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;2H&#146;21: <FONT STYLE="white-space:nowrap">12-month</FONT> topline
data from <FONT STYLE="white-space:nowrap">low-dose</FONT> cohort</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Genevant</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>83%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>69%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Advancing delivery of nucleic acid therapeutics</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&#151;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Silicon Therapeutics</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>100%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>100%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Advancing a physics-driven approach for computational drug design; part of small molecule discovery engine</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&#151;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">VantAI</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>100%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>100%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Advancing a machine-learning approach for computational design and optimization of protein degraders; part of small molecule discovery engine</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&#151;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Lokavant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>90%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>85%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Optimizing trial operations with an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> risk monitoring solution</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&#151;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Datavant**</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>52%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>48%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Connecting patient-level health data through privacy-first, HIPAA-compliant tokens</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&#151;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Alyvant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>97%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>95%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Leveraging data and artificial intelligence to connect patients to therapies</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&#151;&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">233 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Note: Excludes early-stage pipeline of protein degraders and inhibitors being developed through our small
molecule discovery engine. All drugs in current pipeline are investigational and subject to health authority approval. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Ownership figures as of March 31,
2021. Arbutus Basic and Fully Diluted ownership includes the conversion of preferred shares held by Roivant into common shares. Roivant ownership in Cytovant includes both direct and indirect ownership. Roivant ownership in Kinevant refers to
ownership of Pharmavant 3, which holds the rights to namilumab. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">* Denotes entities that are publicly traded. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">** In June 2021, Datavant entered into a definitive merger agreement to combine with Ciox Health. The transaction closed on July 27, 2021. The implied
enterprise value of the combined company at the conversion price cap of the new preferred equity investment made concurrently with closing of the merger was $7.0 billion. This enterprise value implies an equity value of $6.1 billion (after netting
out approximately $900 million of debt and other adjustments). No assurance can be given that the implied enterprise or equity value is an accurate reflection of the value of the combined business at closing or in the future. At closing of the
merger and assuming a $7.0 billion enterprise value, Roivant&#146;s ongoing, fully diluted equity ownership in the combined entity was approximately 12% (without giving effect to certain liquidation preferences held by the preferred equity
shareholders). For more information, see <I>&#147;</I>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations of Roivant&#151;Recent Developments&#151;Datavant.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">234 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our development-stage product candidate pipeline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Development Pipeline </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Product Candidate</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Indication</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Vant</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Modality</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Phase</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Tapinarof</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Psoriasis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Dermavant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Topical</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Registration</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Tapinarof</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Atopic Dermatitis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Dermavant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Topical</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cerdulatinib</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Vitiligo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Dermavant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Topical</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">IMVT-1401</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Myasthenia Gravis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Immunovant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Biologic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">IMVT-1401</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Warm Autoimmune Hemolytic Anemia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Immunovant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Biologic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">IMVT-1401</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Thyroid Eye Disease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Immunovant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Biologic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ARU-1801</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Sickle Cell Disease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Aruvant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Gene Therapy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Gimsilumab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">COVID-19</FONT> Associated ARDS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Kinevant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Biologic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Namilumab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Sarcoidosis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Kinevant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Biologic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">LSVT-1701</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Staph Aureus Bacteremia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Lysovant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Biologic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cerdulatinib</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Atopic Dermatitis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Dermavant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Topical</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">DMVT-504</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Hyperhidrosis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Dermavant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Small Molecule</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">DMVT-503</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Acne</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Dermavant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Topical</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Preclinical</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ARU-2801</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Hypophosphatasia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Aruvant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Gene&nbsp;Therapy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Preclinical</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AFM32</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Solid Tumors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Affivant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Biologic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Preclinical</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CVT-TCR-01</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Oncologic&nbsp;Malignancies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cytovant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cell Therapy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Preclinical</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Note: All drugs in current pipeline are investigational and subject to health authority approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of our mission to redefine &#147;big pharma,&#148; we aim to develop transformative medicines faster for diseases for which there are
no approved therapies or the current standard of care treatment has significant limitations or drawbacks. We believe we are uniquely positioned to accomplish this by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Relentlessly pursuing opportunities to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire drugs that
we believe can deliver successful outcomes on accelerated timelines; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Designing creative deal structures to balance risk and the potential for future value creation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Using our computational drug discovery technologies to design and identify compounds with the greatest
probability of success early in the discovery process; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Creating nimble, entrepreneurial Vants that operate similar to independent biotechnology companies where each
management team, comprised of world-class drug developers and clinical operators, is solely focused on their respective Vant&#146;s mission; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Incentivizing employees with equity in their Vants, which encourages focus and calculated risk-taking;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Providing operational support from our centralized functions to accelerate Vant formation and operational
maturation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Developing proprietary computational technologies that leverage our unique position at the intersection of
biopharma and technology; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Providing Vants with access to our team of scientific experts, physicians and technologists to help optimize
their clinical development and commercial strategies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Leveraging our business development engine and vast network of industry relationships for the identification of
value-creating collaborations and synergistic partnerships. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, the return on our investment from inception to
March&nbsp;31, 2021, based on our realized return associated with our partnership with Sumitomo Dainippon Pharma (the &#147;Sumitomo Transaction&#148;) and the value of our ownership stakes in our public Vants as of June 30, 2021, has far exceeded
average R&amp;D returns for select large cap biopharmaceutical companies based on average cost to develop assets and projected revenues. See &#147;Platform Recognition&#148; for additional information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">235 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through continued investment in our model, we believe we are well-positioned to advance our
current pipeline through regulatory approval and commercialization, expand our pipeline through novel drug discovery and <FONT STYLE="white-space:nowrap">in-licensing</FONT> and acquisition transactions, and execute on our vision of transforming the
delivery of healthcare to patients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Process </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g15a20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Discover </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We focus on developing potentially transformative medicines that address areas of significant unmet medical need. We take a hypothesis-driven
approach, focusing on compelling pathways, targets and drug classes that we believe lack established leaders, and we proactively pursue or discover drugs that align with our hypotheses. We focus on building diversification and varied risk profiles
into our pipeline and are agnostic to therapeutic area, stage of development and drug modality. We leverage internally developed technologies as well as a multi-disciplinary team with diverse backgrounds to evaluate the universe of targets and
biological pathways that we deem compelling. Once we have built conviction around a specific target or biological pathway, we look for assets to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire, and/or design novel drugs through our
small molecule discovery engine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to rapidly identify and execute <FONT STYLE="white-space:nowrap">in-licensing</FONT>
opportunities is underpinned by our diverse business development team, which consists of former investment professionals and experienced R&amp;D and data scientists. A suite of tools that we built <FONT STYLE="white-space:nowrap">in-house</FONT>
supports our business development team by bringing a computationally driven approach to the identification of <FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities as well as supporting our R&amp;D decision-making across all stages of
the drug discovery and development process. Our track record in R&amp;D and our ability to implement creative deal structures ensures that we are a favored development partner and are able to acquire assets on attractive terms with shared risk and
aligned incentives. We have been successful <FONT STYLE="white-space:nowrap">in-licensing</FONT> drugs from global pharmaceutical companies, small biotech startups and academic centers around the world, and we are proud of our deep network of
academic and industry partners. Our goal is to add multiple potentially category-creating or category-leading drugs to our pipeline each year through this <FONT STYLE="white-space:nowrap">in-licensing</FONT> strategy, a pace which is consistent with
our track record over the past several years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a complement to our <FONT STYLE="white-space:nowrap">in-licensing</FONT> strategy, we
also apply our hypothesis-driven approach to our small molecule discovery engine, ensuring we direct our efforts toward high value pathways, targets and drug classes. Our discovery engine is defined by the distinctive combination of capabilities in
computational physics and ML. Through the acquisition of Silicon Therapeutics, we have world-leading capabilities in computational physics for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">236 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
drug design. Silicon Therapeutics has built an advanced computational physics platform integrated with a proprietary supercomputing cluster and a <FONT STYLE="white-space:nowrap">wet-lab</FONT>
facility equipped for generating a broad range of experimental data. We have also built a ML platform, VantAI, tailored to the <I>in silico</I> design and optimization of novel protein degraders. We believe the unique combination of both
computational physics and ML capabilities will position us as the leader in computational drug discovery and establish a sustainable source of future small molecule drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our discovery engine has broad capabilities across multiple categories of small molecules and an initial special focus on targeted protein
degradation, a therapeutic approach with broad potential applicability to diseases associated with protein overactivity and with no incumbent leader. Our capabilities in targeted protein degradation include a long-term partnership with a leading
academic lab, the ability to optimize our degraders using both computational physics and ML and our well-established clinical development capabilities. Based on promising early-stage preclinical data for our first computationally-designed degrader
candidates, we believe that our computational approach can generate candidates that achieve real-world degradation against relevant targets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that our discovery engine will expand our clinical-stage pipeline by generating candidates to advance through the launch of
potential new Vants, or to integrate with existing Vants if there is appropriate therapeutic area overlap, in either case taking advantage of Roivant&#146;s established clinical development capabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Develop </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the Vant model
accelerates successful execution due to three key factors: nimble teams, incentive alignment and robust governance. We build Vant teams with deep, relevant expertise to promote successful execution of development strategy. By keeping Vant teams
focused and generally small, we strive to eliminate excessive bureaucracy, thereby facilitating rapid decision-making and ultimately accelerating outcomes. Vants are built as entrepreneurial biotech companies, where each Vant leader is compensated
with significant upside potential in the form of Vant equity. By aligning employee incentives with successful Vant outcomes, we encourage Vant leaders to take calculated risks and implement strategies that we believe differentiate the speed and
creativity of development capabilities from legacy large pharmaceutical companies, where drug developers may face asymmetric downside in the event of failure and where upside equity, if granted, is diluted by many diverse projects. Vants are also
supported through a robust governance structure that is centralized at Roivant. Our governance team ensures accountability for execution at Vants and allows us to capture synergies through shared technology and certain future shared commercial
functions, while at the same time providing access to a broad range of Roivant resources when Vants face critical strategic questions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Commercialize
or monetize </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Vant model is designed to maximize the value of each drug that we successfully develop and generate returns for
shareholders through the independent commercialization of products, partnerships with pharmaceutical and biotechnology companies or the selective sale of Vants. Our primary objective is to launch commercial products ourselves, but we may sell or
partner Vants or specific drugs based on the facts and circumstances, including, without limitation, the strategic rationale and financial return potential. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Technologies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our platform leverages
technologies that are designed to optimize each stage of the drug discovery, development and commercialization process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">237 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g15b23.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Roivant retains a license to DrugOme, which is owned by Sumitomo and managed by Sumitovant.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our small molecule discovery engine powers <I>in silico</I> drug discovery through the combination of two distinct
approaches to computational drug design: the physics approach and the ML approach. The physics approach applies quantum mechanics and statistical thermodynamics to model the behavior of and interactions between molecules in a biological system. This
includes molecular dynamics simulations, which predict how potential drug molecules bind to and modulate therapeutic protein targets. ML approaches for drug design, meanwhile, use pattern-recognition algorithms to discern mathematical relationships
from empirical observations of small molecules and extrapolate to predict chemical, biological and physical properties of novel compounds. ML techniques are very efficient in terms of computing power consumed compared to physics-based approaches and
can be scaled to large datasets without the need for extensive computational resources. To effectively build a leadership position in computational drug discovery, we deliberately built and assembled capabilities in both computational physics and
ML, creating a combined platform that we believe to be significantly differentiated from others. <I></I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The key components of our small
molecule discovery engine include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>A quantum mechanics-based molecular dynamics software platform to predict the interactions, energies and
conformational behavior of targets and generate novel drug candidates.</I></B> We can simulate hundreds of molecules per day and make predictions for drug design, enabling the optimization of properties such as binding affinity, selectivity,
membrane permeability and solubility. We also have a suite of molecular dynamics and simulation tools to generate additional insights regarding individual atomic contributions to binding properties and conformational dynamics. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>A supercomputing cluster composed of over 500 graphics processing units (&#147;GPUs&#148;)</I></B><I>.
</I>Our supercomputing cluster allows us to run molecular simulations at biologically meaningful timescales predicting not only affinity but also how biomolecules will respond at an atomic level to perturbations such as mutation, phosphorylation,
protonation, or the addition or removal of a ligand and functionally important structural changes in proteins. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>A suite of degrader-specific ML tools.</I></B> We have developed a novel protein contact-first workflow
that utilizes information about known protein-protein interactions to build new degraders that can effectively stabilize <FONT STYLE="white-space:nowrap">target-E3</FONT> interfaces; a degron knowledge graph, which we believe to be industry-leading,
to map the ubiquitin proteasome system; and a unique model, based on millions of carefully curated protein </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">238 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
stability datapoints, to predict degradation. See &#147;Roivant&#146;s Targeted Protein Degradation Platform&#148; for further detail. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>A wet lab fully equipped for synthetic chemistry, crystallography, biophysics, biochemistry and
biology</I></B><B>.</B> Our <FONT STYLE="white-space:nowrap">in-house</FONT> laboratories are tightly integrated with our computational physics platform to directly augment simulations with biophysical data as well as validate simulation
predictions. Certain experimental techniques enable more accurate and efficient simulations on targets where we lack crystal structures. Combined with homology modeling and <FONT STYLE="white-space:nowrap">X-ray</FONT> crystallography, this allows
for the simultaneous design of chemical matter against a target while refining atomistic structural models and solving high-resolution crystal structures. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our computational physics capabilities, which we obtained through the acquisition of Silicon Therapeutics, allow us to predict how molecules
will interact by using principles of quantum physics to computationally model the forces and energies of the atomic and <FONT STYLE="white-space:nowrap">sub-atomic</FONT> particles that comprise the molecule system. Based on internal and published
benchmarks, we believe that the speed and accuracy of binding free energy calculations made by our programs are on par with the best commercially available tool, Schr&ouml;dinger&#146;s FEP+, and superior to open-source methods. Further, we believe
our ability to rapidly validate and constrain simulations with experimental data generated <FONT STYLE="white-space:nowrap">in-house</FONT> creates a sustainable advantage compared to competitors. These capabilities power <I>in silico</I> assays
that allow us to potentially predict binding affinity of a ligand and protein, predict conformational dynamics of a protein as it shifts from active to inactive state, and identify binding sites on a protein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">VantAI combines cutting-edge ML techniques with deep systems biology expertise to power the discovery of novel protein degraders.
VantAI&#146;s distinctive degrader platform includes a novel &#147;protein contact-first&#148; workflow that uses graph representations of known protein-protein interactions to design new degraders that can effectively stabilize <FONT
STYLE="white-space:nowrap">target-E3</FONT> interfaces; an industry-leading ubiquitin proteasome system map allowing for the identification of degron motifs; and complex models for protein degradation and prediction of key chemical properties,
trained on over five years of proprietary degrader-specific experimental data and millions of carefully curated protein stability datapoints. Our VantAI-designed degrader candidates have produced promising early-stage preclinical data that suggests
our computational approach can generate candidates that achieve real-world degradation against multiple relevant targets. The use of VantAI&#146;s computational technology on compounds for the inducement of protein degradation will be dedicated
exclusively to Proteovant until at least early 2026, other than certain pre-specified work on designated targets being conducted for third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our small molecule discovery engine may allow us to replace experimental assays with <I>in silico</I> assays, resulting in
decreased time and costs, ultimately accelerating the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">hit-to-lead</FONT></FONT> and lead optimization stages of the drug discovery process. Further, we expect to increase our
likelihood of identifying novel binding pockets on previously &#147;undruggable&#148; targets. We plan to direct our expanding capabilities in computational drug discovery towards targets selected with the same &#147;investment lens&#148; we use for
our <FONT STYLE="white-space:nowrap">in-licensing</FONT> strategy, and we expect it to produce candidates for continued clinical development within our existing clinical trial infrastructure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The hypothesis generation for both our internal discovery engine and <FONT STYLE="white-space:nowrap">in-licensing</FONT> strategies is
supported by a tool we developed <FONT STYLE="white-space:nowrap">in-house</FONT> called DrugOme, which we sold as part of the Sumitomo Transaction but retain a perpetual license to. DrugOme is a comprehensive map of targets and drug candidates in
development that enables differentiated analysis of development strategies and potential business development opportunities. DrugOme employs natural language processing to extract, ingest and harmonize data across diverse structured and unstructured
sources to construct a centralized database that captures available data regarding clinical trials, company financials, prescriptions and intellectual property. This database informs R&amp;D decision-making across all stages of the drug discovery
and development process. DrugOme supports our business development by rapidly defining the competitive and therapeutic landscape for a specific asset, predicting clinical trial costs, identifying trends in treatment patterns, optimizing clinical
trial site and investigator selection and providing other customized analyses. We believe our computational approach to identifying assets for <FONT STYLE="white-space:nowrap">in-licensing</FONT> and the creative drug development strategies that
accompany those assets are key advantages unique to the Roivant platform. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">239 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we have developed drugs in clinical trials, we have built technologies to improve the
process of running such trials. We have aggregated many of these at our subsidiary Lokavant. Lokavant&#146;s software integrates real-time data from ongoing clinical trials and monitors risks related to time, cost and quality. Its proprietary data
model serves as a &#147;common language&#148; for trial operational data and ensures that all trial data sources are ingested, harmonized and aggregated into a central database, allowing the trial sponsor to access operational trial data in
near-real time. This approach is a substantial departure from traditional operations which typically share different types of trial data asynchronously and on multi-week delays. Algorithms trained on a proprietary dataset of operational metadata
from over 1,300 trials are designed to identify the most important risks with sufficient time to empower researchers to implement interventions to mitigate those risks and deliver trial results on budget and on time. In addition to being deployed in
Roivant trials, Parexel, a leading global contract research organization (&#147;CRO&#148;), is using Lokavant&#146;s software as its remote monitoring platform, and we intend to grow Lokavant&#146;s customer base with other CROs and trial sponsors.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In designing development and commercialization strategies for our pipeline of drugs, we also identified significant shortcomings with
commercially available patient data. Today, healthcare data is siloed across multiple fragmented data sources, limiting the ability to generate a comprehensive understanding of patient health. Datavant, a company which we founded and in which we
maintain a <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest, is working to address this problem. Datavant recently merged with Ciox Health, LLC (as described below). The combined company seeks to power every exchange of health data,
unlocking a massive ecosystem of companies using linked, longitudinal data to improve patient outcomes. Datavant linking technology enables the advanced use of real-world evidence, patient finding, outcomes research, and commercial analytics.
Datavant&#146;s customers and partners include Janssen/J&amp;J and other top 20 pharmaceutical companies, ZS, Medidata, Cigna, Parexel, Symphony Health, Komodo Health and the NIH. We can also use Datavant&#146;s technology to better understand the
real-world health outcomes of subjects who participate in our trials beyond the duration of the trials themselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2021, Datavant
entered into a definitive merger agreement with CIOX Health, LLC. (&#147;Ciox Health&#148;), a leader in clinical data exchange. The transaction closed on July 27, 2021. The combined entity, named Datavant, is the nation&#146;s largest health data
ecosystem, enabling patients, providers, payers, health data analytics companies, patient-facing applications, government agencies, and life science companies to securely exchange their patient-level data. The implied enterprise value of the
combined company at the conversion price cap of the new preferred equity investment made concurrently with closing of the merger was $7.0 billion. This enterprise value implies an equity value of $6.1 billion (after netting out approximately $900
million of debt and other adjustments). No assurance can be given that the implied enterprise or equity value is an accurate reflection of the value of the combined business at closing or in the future. At closing of the merger and assuming a
$7.0&nbsp;billion enterprise value, the ongoing, fully diluted equity ownership in the combined entity of the former Datavant shareholders was approximately 24% including Roivant ownership of approximately 12% (without giving effect to certain
liquidation preferences held by the new preferred equity shareholders). At closing of the merger, former Datavant shareholders also received approximately $557&nbsp;million in cash of which Roivant received approximately $320 million in cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have begun to build technology to support our transition from a development-stage biopharmaceutical company into a commercial one. Alyvant
is an early-stage technology product for physician and patient segmentation, targeting and engagement. Alyvant generates dynamic call plans uniquely prioritized on likelihood to prescribe by integrating patient and payor data with physician
behavioral characteristics and presents those call plans through a salesforce app that drives adherence to call plans and reprioritizes physician outreach based on feedback from the field. In a 2019 pilot
<FONT STYLE="white-space:nowrap">co-promotion</FONT> of three products, Alyvant increased total prescriptions by 223% compared to the same period in the prior year and generated a &gt;2x increase in the number of activated prescribers. As we deliver
products to market, we expect to expand the suite of technology tools available to accelerate and optimize commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will
continue to execute against our goal of building the next-generation pharmaceutical company by fully integrating modern technologies at each stage of the drug discovery, development and commercialization
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">240 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
process. We believe that there is significant opportunity to address inefficiencies within these processes, and we expect to build technologies where we find commercially available tools
nonexistent or insufficient for our needs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Roivant&#146;s Targeted Protein Degradation Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Protein degraders </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Protein degraders are a
novel class of small molecules that target and destroy cellular proteins, rather than inhibiting them. Degraders are small molecules engineered to induce the degradation of specific disease-causing proteins through the ubiquitin-proteasome system
(&#147;UPS&#148;), which ordinarily tags and degrades proteins that have been misfolded or have already fulfilled their biological function. In heterobifunctional degraders, the protein ligand domain, commonly referred to as a &#147;warhead,&#148;
targets the specific protein of interest. At the other end of the complex, the ligase ligand recruits a specific E3 ubiquitin ligase. Both ends of the complex are connected by a linker that orients the target protein and E3 ligase in a cooperative
ternary complex, driving ubiquitination. Similar to heterobifunctional degraders, molecular-glue-type degraders are small molecules that induce a novel interaction between a substrate receptor of an E3 ubiquitin ligase and a target protein leading
to proteolysis of the target via UPS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe degraders represent a promising new approach to drug previously &#147;undruggable&#148;
targets and transform the treatment of diseases with significant unmet medical need. Degraders open a new set of opportunities for small molecule drug development, with multiple distinct potential advantages over inhibitors: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Not bound by &#147;active site&#148; requirements, allowing degraders to target historically
&#147;undruggable&#148; proteins, including transcription factors and scaffolding proteins that lack a catalytic pocket </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Achieve efficacy at lower doses to decrease dose-limiting toxicities (which have similar but not identical
function to the target protein) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Efficacy in tumors that are resistant to inhibitors, as a function of protein depletion </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our degrader strategy </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe we are
positioned for leadership in the field of targeted protein degradation given our long-term partnership with a leading academic lab, our degrader-specific ML capabilities, and our well-established clinical development capabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have access to leading medicinal chemistry capabilities via our long-term partnership with the lab of Dr.&nbsp;Shaomeng Wang, a
world-renowned scientist focused on the discovery of protein degraders, at the University of Michigan. Over 15 years, Dr.&nbsp;Wang and his team have developed an initial pipeline of degraders for over 10 targets and have over 50 U.S. patents and
hundreds of international patents related to degrader technology. Through our acquisition of Oncopia Therapeutics, which was co-founded by Dr. Wang, we obtained Oncopia&#146;s pipeline, ongoing work on new targets, broad patent estate and deep
knowledge and experience in the degrader space. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to initiate a Phase 1 trial for our first degrader candidate in 2022 and
rapidly build upon the early pipeline of degraders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our medicinal chemistry and degrader biology expertise are complemented by our
degrader-specific ML capabilities. VantAI, through its focus on the <I>in silico</I> design and optimization of targeted protein degraders, has developed a number of powerful and distinctive tools, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A novel protein contact-first workflow that utilizes information about known protein-protein interactions to
build new degraders that can effectively stabilize <FONT STYLE="white-space:nowrap">target-E3</FONT> interfaces </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">241 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A degron knowledge graph, which we believe to be industry-leading, that maps the ubiquitin proteasome system and
enables the analysis of interactions between E3 ligases and degrons, the protein components that bind to E3 ligases and regulate degradation </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A unique model for predicting degradation based on millions of carefully curated protein stability datapoints
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These techniques may enable quick and effective generation of degrader candidates and facilitate drugging targets with
little or no structural information and recruiting novel E3 ligases with no known ligands. We believe that degrader drug development will uniquely benefit from the application of computational approaches because of the combinatorial nature of target
binder, linker, and E3 ligase, as well as the ability to bind to the protein of interest outside the active site. Computational techniques can also help predict protein surface conformation changes in the identification of novel molecular glues. Our
first VantAI-designed degraders have generated early-stage preclinical data that suggests our computational approach can generate candidates that achieve real-world degradation against multiple relevant targets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to face competition within a growing class of degrader-focused companies. We believe that our computational capabilities provide
critical differentiation in an area that is uniquely suited to the application of computational techniques. The combinatorial nature and modularity of degrader structures allows for computational techniques to provide meaningful acceleration in the
identification, design and optimization of protein degraders. To our knowledge, no competitor has a computational platform as advanced or robust as the capabilities we have built through our small molecule discovery engine. Today, our preclinical
and clinical development organizations, initial pipeline, and long-term access to a leading academic lab are integrated with our computational capabilities. Further, VantAI algorithms have incorporated over five years of real-world laboratory data
generated by Dr.&nbsp;Wang&#146;s lab, in turn informing the identification of targets and discovery of novel degraders to further evaluate in the lab and ultimately advance into the clinic. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">242 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unique Features of the Roivant Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our model allows each Vant to rapidly scale given full access to shared technologies that address inefficiencies in the drug discovery,
development and commercialization process. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g16a35.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">All trademarks are property of their respective owners. Altavant, Enzyvant, Myovant, Spirovant and Urovant were transferred
to Sumitovant, a wholly-owned subsidiary of Sumitomo, in December 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We aim to redefine &#147;big pharma&#148; by rapidly developing
and commercializing transformative medicines in areas of high unmet medical need where there are no approved therapies or there are significant limitations associated with current standards of care. We believe our platform is uniquely positioned to
accomplish this by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Leveraging complementary approaches to identify or discover promising drug candidates:</I></B> We assembled
our current late-stage product candidate pipeline by relentlessly pursuing opportunities to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire programs where we believe we can deliver successful outcomes on accelerated timelines. In
addition, our computational drug discovery engine allows us to design, optimize and validate our own novel product candidates, providing us with another avenue to pursue compelling targets or pathways and further expand our pipeline.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Creating nimble, entrepreneurial Vants</I></B><I>:</I> Vants generally operate similar to independent
biotechnology companies where each management team is focused on their respective mission and are economically incentivized to maximize value through Vant-specific equity grants. Each of our Vant teams is built with deep relevant expertise to ensure
successful execution of their specific development strategy. The Vant model is designed to facilitate rapid decision making and calculated risk taking, by empowering, aligning and incentivizing Vant teams around the specific outcomes of their
product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Developing and deploying proprietary technologies:</I></B><B> </B>We believe we are able to develop
transformative medicines faster by building and applying computational tools to drug discovery, development and commercialization. We occupy a unique position at the intersection of biopharma and technology, having built our capabilities in
parallel, optimizing each for synergy with the other, in contrast to big pharma who have added software tools to legacy workflows or technology startups that lack experience developing drugs. Vants have access to, and are supported by, these
technologies. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">243 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Allocating capital to maximize R&amp;D efficiency:</I></B><B> </B>We apply an objective, rigorous decision
framework across the drug development process designed to ensure resources and capital are continuously directed towards programs we believe have a higher probability of success and away from those that fail to meet our internal hurdles. We
centralize capital allocation decisions at the Roivant level, while distributing operational decisions to the Vants, allowing us to strategically deploy capital in high growth areas, regardless of potentially competing operational priorities.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Maintaining a diversified pipeline with various risk profiles:</I></B><B> </B>We have built a pipeline of
over 30 drugs across different therapeutic areas, phases of development, modalities and geographies. This approach limits our exposure to several concentrated scientific and biological risks and allows us to pursue multiple innovative hypotheses
across our portfolio as we seek to develop therapies for patient populations with high unmet need. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Designing creative <FONT STYLE="white-space:nowrap">&#147;win-win&#148;</FONT> deal structures:</I></B> We
structure our partnerships to balance risk and the potential for future value creation. We ensure that a significant proportion of near-term expenses go toward development, allowing us to stage our investment and align incentives as well as limit
losses in the event of a setback. Our scale and track record of developing product candidates assures partners that we are uniquely capable of maximizing value for patients and investors. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Providing operating leverage through centralized support functions:</I></B><B> </B>Our model allows us to
accelerate Vant formation and maturation by centralizing and sharing certain support functions across various Vants. Vants also benefit from access to our vast network of scientific experts, physicians and technologists to help optimize their
clinical development and plans for commercialization. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Platform Recognition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, we entered into a $3&nbsp;billion upfront partnership with Sumitomo. There were four key components of this transaction: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><SUB STYLE="font-size:85%; vertical-align:bottom"></SUB>Sumitomo acquired 100% of Roivant&#146;s ownership
interest in five Vants: Urovant, Myovant, Enzyvant, Altavant and Spirovant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><SUB STYLE="font-size:85%; vertical-align:bottom"></SUB>Sumitomo acquired options to purchase Roivant&#146;s
ownership interest in six additional Vants (the &#147;Option Vants&#148;), in each case at a purchase price calculated by reference to a specified multiple. In June 2021, Sumitomo and Roivant completed a transaction which included the termination of
Sumitomo&#146;s outstanding options to acquire Roivant&#146;s ownership interest in the Option Vants. See the section titled &#147;Recent Events&#151;Option Vants Transaction&#148; for additional information. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><SUB STYLE="font-size:85%; vertical-align:bottom"></SUB>Roivant and Sumitomo agreed to share access to two
technology platforms: DrugOme and Digital Innovation, an approach to integrating technologists into business operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><SUB STYLE="font-size:85%; vertical-align:bottom"></SUB>Sumitomo acquired 26,952,143 shares of Roivant at a per
share price of $37.10. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ROI for Sumitomo Transaction and Publicly-Listed Vants </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><I>Total&nbsp;Investment&nbsp;($M)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><I>Value&nbsp;($M)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><I>Return&nbsp;Multiple</I></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Sumitomo Transaction</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">433</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,868</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Public Vants</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">732</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Includes aggregate Roivant investments in tech assets and in the five transferred Vants from Vant inception to
transaction close. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Includes aggregate proceeds received at closing of the Sumitomo transaction, excluding (i)&nbsp;any potential
future proceeds from the exercise of Sumitomo&#146;s options to acquire Roivant&#146;s ownership interest in the Option Vants, (ii)&nbsp;a $1&nbsp;billion allocation of the proceeds received by Roivant to Sumitomo&#146;s purchase of Roivant equity
and (iii) $99.1&nbsp;million liability related to the Option Vants. Excludes investment in Sinovant and any proceeds received from the termination of Sumitomo&#146;s options to purchase Roivant&#146;s ownership interest in certain Vants.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Includes cash capital contributions, purchases of equity securities, items paid on behalf of the Vant and
allocations for unreimbursed services provided by Roivant employees to Arbutus, Immunovant and Sio Gene Therapies as of March 31, 2021. Excludes subsequent $200 million common equity investment by Roivant in Immunovant, which was made on August 2,
2021. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">244 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Based the market values of Roivant&#146;s ownership interest in Arbutus, Immunovant and Sio Gene Therapies as of
July 30, 2021. Values Arbutus preferred stock as common stock. Excludes value of shares received in subsequent common equity investment by Roivant in Immunovant, which was made on August 2, 2021. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Growth Strategies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe we are
on our way to building the next generation &#147;big pharma&#148; company by leveraging our unique platform to transform the delivery of healthcare to patients. To support this goal and mission, we are executing on 5 key pillars of growth: </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Deliver successes across our current pipeline:</I></B> Our current pipeline is comprised of multiple
potentially transformative drug candidates across all stages of development, modalities and therapeutic areas. Our ability to successfully develop promising drug candidates has been evidenced through 3 FDA approvals from Vants sold to Sumitomo. We
will continue to advance our diverse pipeline through to late-stage development and ultimately, if successful, regulatory approval, expanding our track record of pipeline successes to date. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a robust calendar of potential near-term catalysts, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g16b45.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>All catalyst timings are based on current expectations but may be subject to change. All trademarks are property of their
respective owners. </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Expand our pipeline through acquisitions or <FONT STYLE="white-space:nowrap">in-licensing</FONT>
transactions:</I></B> We intend to continue to expand our existing pipeline through acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> additional transformative drug candidates. Our goal is to add multiple potentially
category-creating or category-leading drugs to our pipeline each year on average via this <FONT STYLE="white-space:nowrap">in-licensing</FONT> strategy, a pace which is consistent with our track record over the past several years. We will continue
to manage our pipeline like a portfolio and build diversified risk profiles across therapeutic area, target, modality and stage of development. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Expand our pipeline through drug discovery:</I></B> In parallel with our
<FONT STYLE="white-space:nowrap">in-licensing</FONT> strategy, we intend to expand our pipeline through computational discovery of novel drug candidates. Thus far, we have focused our discovery efforts towards novel protein degraders. We plan to
initiate a Phase 1 trial for our first degrader candidate in 2022 and rapidly build upon our early pipeline of degraders. We expect that the significant investments we have made in our small molecule discovery engine will allow us to generate novel
drug candidates internally and initiate multiple <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies each year starting in 2022. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">245 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Power our entire platform by technology:</I></B> We have built leading capabilities in computational drug
discovery with our distinctive combination of ML and computational physics platforms. Our investment in computational discovery bolsters our existing technology platform that seeks to address inefficiencies across each stage of the drug discovery,
development and commercialization process. We expect to continue to make strategic investments in technology to power the entire Roivant platform, ultimately accelerating the delivery of transformative medicines to patients. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Commercialize medicines independently where optimal:</I></B> While the Roivant platform ensures flexibility
on our path to value creation from each asset, we believe independently commercializing our drug candidates will unlock maximal value over the long run. Our plan for building commercial capabilities will be informed by the identification of
specific, targeted opportunities to create additional value across Vants. We are presently evaluating which commercial functions to potentially build <FONT STYLE="white-space:nowrap">in-house</FONT> and centralize across the Vants. Based on our
current pipeline, we expect to market our first drug, tapinarof, in 2022. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Management Team </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are led by a management team of leaders with diverse backgrounds, bringing together an expansive set of capabilities across healthcare
investing, clinical development, technology, medicine, venture capital, operations, finance and data science. We believe we are well-positioned to redefine what it means to be a large pharmaceutical company today based on our ability to leverage
experience from within and beyond the world of pharmaceuticals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management team is led by our Chief Executive Officer, Matthew Gline,
with strategic guidance from our Founder and Executive Chairman, Vivek Ramaswamy. Our Chief Operating Officer, Eric Venker, M.D., Pharm.D., oversees the operations of the Roivant platform and provides oversight to our Vants as a board member. Our
Chief Investment Officer, Mayukh Sukhatme, M.D., is responsible for generating hypotheses for potential new drugs, ultimately guiding target selection for our small molecule discovery engine and overseeing the evaluation of new assets to bring into
our pipeline through our <FONT STYLE="white-space:nowrap">in-licensing</FONT> strategy. As President, Roivant Health, Benjamin Zimmer leads the launch, growth and oversight of Roivant&#146;s technology platform Vants. Our Chief Computational
Scientist, Woody Sherman, Ph.D., manages our computational physics platform. Our Vant Chair, Frank Torti, M.D., serves as chair of the board for certain of our Vants and, in that capacity, is responsible for ensuring successful execution of Vant
strategy. We created the role of Vant Chair to establish clear accountability for our Vant CEOs, ensuring each Vant maintains the freedom to deploy their relevant expertise while maintaining connectivity to the Roivant platform. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We build impressive teams across all levels of the organization. We hire and develop world-class talent from diverse backgrounds in biopharma,
academia, technology and finance to ensure we have all of the capabilities to design and deliver creative solutions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our team is united
by our core values: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Create value:</I></B><B> </B>We maximize value for patients and for shareholders. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Be contrarian:</I></B><B> </B>We question convention, others, and ourselves. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Climb the wall:</I></B><B> </B>If an obstacle arises, we focus on finding the best solution to overcome
that obstacle. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Sweat the details:</I></B><B> </B>We are thorough, we follow facts not stories, and we accept and learn
from mistakes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Evolve or die:</I></B><B> </B>&#147;It&#146;s working now&#148; is never satisfactory.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">246 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Vants and Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our Vants. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Roivant&nbsp;Ownership</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Vant</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Basic</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Diluted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Lead Program / Mechanism</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Modality</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Indication(s) / Phase</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Upcoming Milestones</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Dermavant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">85%</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Developing treatments for unmet needs in immuno-dermatology</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Tapinarof / Therapeutic aryl hydrocarbon receptor modulating agent</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Topical</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;Psoriasis / Phase 3 complete</P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;Atopic dermatitis / Phase 2b
complete</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;Mid-22: FDA approval decision on Tapinarof for psoriasis</P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;2H&#146;21: Tapinarof Phase 3
initiation in atopic dermatitis</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Immunovant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">58%*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">53%</TD>
<TD NOWRAP VALIGN="top">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Developing an anti-FcRn monoclonal antibody for IgG-mediated autoimmune diseases</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>IMVT-1401 / Anti-FcRn monoclonal antibody</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Biologic</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;Myasthenia gravis, thyroid eye disease, and warm autoimmune hemolytic
anemia / Phase 2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;Late &#145;21/early &#145;22: IMVT-1401 Phase 3 initiation in myasthenia
gravis</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;Late &#145;21/early
&#145;22: IMVT-1401 Phase 2a restart in warm autoimmune hemolytic anemia</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;1H&#146;22: Two new indications for IMVT-1401 to be announced</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Aruvant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">88%</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">80%</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Developing transformative gene therapies for severe blood disorders</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>ARU-1801 / Ex vivo lentiviral gene therapy delivering a novel, highly potent variant of fetal hemoglobin (HbF)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Gene&nbsp;therapy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;Sickle cell disease / Phase 1/2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;2H&#146;21: First patient dosed with ARU-1801 manufacturing process
III</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;2H&#146;21: Clinical
data from additional ARU-1801 Phase 1/2 patients</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;2H&#146;22: ARU-1801 Phase&nbsp;3 initiation</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proteovant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top">60%</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top">60%</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Developing heterobifunctional protein degraders for oncology, neurology, and immunology</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>AR Degrader</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Small Molecule</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;Prostate cancer / Preclinical</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;2022: AR degrader Phase 1 initiation</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Lysovant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">99%</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Developing a novel endolysin for hard-to-treat Staph aureus infection</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>LSVT-1701 / Endolysin</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Biologic</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;Staph aureus bacteremia and infective endocarditis / Phase 1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;1H&#146;22: LSVT-1701 MAD initiation</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Kinevant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">88%</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">88%</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Developing an anti-GM-CSF monoclonal antibody for autoimmune diseases</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Namilumab / Anti-GM-CSF monoclonal antibody</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Biologic</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;Sarcoidosis / Phase 1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;1H&#146;22: Namilumab Phase 2
initiation</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">247 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Roivant&nbsp;Ownership</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Vant</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Basic</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Diluted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Lead Program / Mechanism</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Modality</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Indication(s) / Phase</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Upcoming Milestones</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Affivant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Developing bispecific antibodies for oncology indications with unmet medical need</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>AFM32 / Bispecific antibody</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Biologic</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;Solid Tumors / Preclinical</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;1H&#146;23: File IND</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cytovant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">72%</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">68%</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Developing cellular medicines uniquely suited to Asian patients</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>CVT-TCR-01 / TCR-T targeting NY-ESO-1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Cell therapy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;Oncologic malignancies / Preclinical</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;2H&#146;21: Initiation of CMC activities</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Arbutus</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">33%</TD>
<TD NOWRAP VALIGN="top">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">29%</TD>
<TD NOWRAP VALIGN="top">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Developing a potential cure for chronic HBV infection</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>AB-729 / RNAi inhibiting HBV replication</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>RNA&nbsp;therapy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;Hepatitis B / Phase 2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;2H&#146;21: Initiation of two additional combination Phase 2
trials</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Sio Gene Therapies</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">27%</TD>
<TD NOWRAP VALIGN="top">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">25%</TD>
<TD NOWRAP VALIGN="top">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Developing gene therapies for neurodegenerative diseases</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>AXO-AAV-GM1 In vivo AAV9 gene therapy</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Gene therapy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;GM1 gangliosidosis / Phase 1/2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:9pt; font-family:Times New Roman">&#149;&#8195;&#8202;2H&#146;21: 12-month topline data from low-dose cohort</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Genevant</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">83%</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">69%</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Advancing delivery of nucleic acid therapeutics</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Silicon Therapeutics</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top">100%</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top">100%</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Advancing a physics-driven approach for computational drug design; part of small molecule discovery engine</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">VantAI</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top">100%</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top">100%</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Advancing a machine-learning approach for computational design and optimization of protein degraders; part of small molecule discovery engine</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Lokavant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">90%</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">85%</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Optimizing trial operations with an end-to-end risk monitoring solution</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Datavant**</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">52%</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">48%</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Connecting patient-level health data through privacy-first, HIPAA-compliant tokens</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Alyvant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">97%</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">95%</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Leveraging data and artificial intelligence to connect patients to therapies</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">Note:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Excludes early-stage pipeline of protein degraders and inhibitors being developed through our small molecule
discovery engine. All drugs in current pipeline are investigational and subject to health authority approval. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">248 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Ownership figures as of March 31, 2021. Arbutus Basic and Fully Diluted ownership includes the conversion of
preferred shares held by Roivant into common shares. Roivant ownership in Cytovant includes both direct and indirect ownership. Roivant ownership in Kinevant refers to ownership of Pharmavant 3, which holds the rights to namilumab. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">* Denotes entities that are publicly traded. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">** In June 2021,
Datavant entered into a definitive merger agreement to combine with Ciox Health. The transaction closed on July 27, 2021. The implied enterprise value of the combined company at the conversion price cap of the new preferred equity investment made
concurrently with closing of the merger was $7.0 billion. This enterprise value implies an equity value of $6.1 billion (after netting out approximately $900 million of debt and other adjustments). No assurance can be given that the implied
enterprise or equity value is an accurate reflection of the value of the combined business at closing or in the future. At closing of the merger and assuming a $7.0 billion enterprise value, Roivant&#146;s ongoing, fully diluted equity ownership in
the combined entity was approximately 12% (without giving effect to certain liquidation preferences held by the new preferred equity shareholders). For more information, see <I>&#147;</I>Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations of Roivant&#151;Recent Developments&#151;Datavant.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">249 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our development-stage product candidate pipeline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Development Pipeline </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Product Candidate</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Indication</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Vant</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Modality</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Phase</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Tapinarof</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Psoriasis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Dermavant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Topical</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Registration</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Tapinarof</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Atopic Dermatitis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Dermavant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Topical</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cerdulatinib</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Vitiligo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Dermavant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Topical</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">IMVT-1401</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Myasthenia Gravis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Immunovant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Biologic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">IMVT-1401</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Warm Autoimmune Hemolytic Anemia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Immunovant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Biologic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">IMVT-1401</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Thyroid Eye Disease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Immunovant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Biologic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ARU-1801</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Sickle Cell Disease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Aruvant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Gene Therapy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Gimsilumab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">COVID-19</FONT> Associated ARDS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Kinevant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Biologic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Namilumab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Sarcoidosis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Kinevant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Biologic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">LSVT-1701</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Staph Aureus Bacteremia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Lysovant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Biologic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cerdulatinib</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Atopic Dermatitis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Dermavant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Topical</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">DMVT-504</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Hyperhidrosis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Dermavant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Small&nbsp;Molecule</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">DMVT-503</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Acne</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Dermavant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Topical</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Preclinical</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ARU-2801</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Hypophosphatasia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Aruvant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Gene&nbsp;Therapy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Preclinical</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AFM32</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Solid Tumors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Affivant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Biologic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Preclinical</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CVT-TCR-01</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Oncologic&nbsp;Malignancies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cytovant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cell Therapy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Preclinical</P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Note: All drugs in current pipeline are investigational and subject to health authority approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the pipeline of our small molecule discovery engine. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Discovery Pipeline </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g78m56.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Proteovant logo indicates that Proteovant, which is 60% owned by Roivant, has rights to a program for that target or has
initiated discovery projects for that project. Roivant logo indicates other 100% Roivant owned entities have rights to a program for that target or have initiated discovery projects for that target. Degraders designated in purple text. Inhibitors
designated in green text. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">250 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>Dermavant Overview</U> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Overview</U>: </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dermavant is developing tapinarof for the treatment of psoriasis and atopic dermatitis, alongside an
earlier-stage development pipeline focused on multiple unmet medical needs in immuno-dermatology. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Lead program</U>: </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tapinarof is a novel, once daily, steroid-free topical cream for the treatment of plaque psoriasis and atopic
dermatitis. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tapinarof is a therapeutic aryl hydrocarbon receptor (AhR) modulating agent (TAMA) that directly targets the AhR,
a key regulator of skin homeostasis and inflammation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Disease overview</U>: </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Plaque psoriasis is a chronic, inflammatory disease with skin lesions characterized by red patches and plaques
with silvery scales. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Atopic dermatitis, the most common type of eczema, is a chronic condition characterized by dry, itchy skin.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Psoriasis and atopic dermatitis affect approximately 8&nbsp;million and 26&nbsp;million people in the United
States, respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Limitations of current treatment</U>: </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Topical corticosteroids (TCS) are the most common first-line therapy but use typically cannot exceed four weeks
due to risk of significant side effects. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">While oral and biologic therapies have become increasingly available, they are often limited to <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> psoriasis and atopic dermatitis patients that comprise the smallest percentage of the affected populations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Clinical data</U>: </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We recently completed two pivotal Phase 3 clinical trials, PSOARING 1 and PSOARING 2, for the use of tapinarof in
treating mild, moderate, and severe plaque psoriasis in adults. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In both pivotal Phase 3 trials, which enrolled over 500 patients each, tapinarof met its primary endpoint and
secondary endpoints with clinically meaningful and statistically significant responses. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An interim analysis from our long-term open-label PSOARING 3 study provides supportive evidence of
tapinarof&#146;s increased therapeutic effect beyond the <FONT STYLE="white-space:nowrap">12-week</FONT> double blind treatment periods, suggesting treatment durability over time, as well as supportive evidence of a remittive effect, measured by
time until disease worsening following treatment discontinuation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Development plan and upcoming milestones</U>: </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have submitted an NDA to the FDA for tapinarof cream for the treatment of adults with plaque psoriasis and are
expecting a decision on tapinarof&#146;s approval in <FONT STYLE="white-space:nowrap">mid-2022.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If approved, tapinarof would be the first novel topical therapy approved by the FDA for plaque psoriasis in over
20 years, potentially offering a favorable mix of treatment effect, safety, durability of therapy, and remittive effect. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We anticipate initiating pivotal Phase 3 clinical trials in atopic dermatitis in the second half of 2021.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Roivant ownership</U>: </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As of March 31, 2021, we own 100% of the issued and outstanding common shares of Dermavant and 85% on a Fully
Diluted basis. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">251 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Pipeline</U>: </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g48l79.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tapinarof for the Treatment of Psoriasis and Atopic Dermatitis </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tapinarof is a novel, once daily, cosmetically elegant, steroid-free topical cream TAMA. Tapinarof directly targets the AhR, a key regulator of
skin homeostasis and inflammation, to help reduce Th17 and Th2 cytokines, two <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> pathways implicated in plaque psoriasis and atopic dermatitis, increase antioxidant activity, and promote skin
barrier restoration. Tapinarof cream is designed to be easy to apply, <FONT STYLE="white-space:nowrap">non-greasy</FONT> and odorless, which we believe makes it cosmetically elegant. To date, over 2,200 subjects have been enrolled in 18 clinical
trials of tapinarof and predecessor formulations of tapinarof cream. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Psoriasis and atopic dermatitis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Psoriasis and atopic dermatitis (&#147;AD&#148;) affect hundreds of millions of people globally each year, impacting their quality of life,
including their physical health, psychological state, and overall well-being. While topical therapies are the foundation of treatment, many patients fail to achieve their desired outcome due to subpar efficacy, tolerability and safety concerns,
application site restrictions and limits on duration of therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Psoriasis is a chronic, inflammatory disease with skin lesions
characterized by red patches and plaques with silvery scale that affects an estimated 8&nbsp;million people in the United States. Its most common form, psoriasis vulgaris or plaque psoriasis, constitutes approximately 80 to 90% of all cases of
psoriasis. Psoriasis severity is typically classified by body surface area (&#147;BSA&#148;) involvement: mild (less than 3% BSA), moderate (3% to 10% BSA) and severe (greater than 10% BSA). Based on this guideline, approximately 80% of patients
with psoriasis in the United States have mild to moderate disease, which is most often amenable to topical treatment. Common signs and symptoms of psoriasis include itching and burning, which can be very intense and frequent. Other symptoms can
include cracking and bleeding of the skin. Psoriasis can cause significant social and emotional distress. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Atopic dermatitis is the most
common type of eczema, affecting more than 9.6&nbsp;million children and about 16.5&nbsp;million adults in the United States. It is a chronic condition characterized by dry, itchy skin that often turns into a red rash. Atopic dermatitis can come and
go for years or throughout life and can overlap with other types of eczema. Atopic dermatitis has a complex pathophysiology involving genetic, immunologic and environmental factors, culminating in skin barrier dysfunction and immune system
dysregulation. The condition occurs most frequently in children (15 to 30% worldwide). Approximately 60% of those who develop atopic dermatitis show symptoms in the first year of life and up to 90% show symptoms by five years of age. While more
prevalent in infancy and adolescence, one in ten people will develop atopic dermatitis. Approximately 89% of adult patients have mild to moderate atopic dermatitis, while 11% have severe atopic dermatitis. Atopic dermatitis is associated with
several comorbidities, including asthma, allergies depression, and sleep disruption, and could negatively impact quality of life. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While
topical therapies are the foundation of treatment, many patients fail to achieve their desired outcome due to subpar efficacy, tolerability and safety concerns, application site restrictions and limits on duration of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">252 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
therapy. Topical corticosteroids (&#147;TCS&#148;) are commonly used as the first-line therapy for the treatment of inflammatory skin conditions, such as psoriasis and atopic dermatitis. They are
broadly available in generic form and carry FDA class labeling that restrict their duration of use, typically to no more than four weeks, and their location of use, prohibiting use in sensitive skin areas such as the face, groin, or axillae
(armpit). While many people experience improvement with TCS, the continual long-term use of TCS has the potential to cause significant side effects including skin atrophy. As a result, healthcare professionals and patients are limited to
intermittent treatment cycles of TCS therapy, leading to frequent disease flares and recurrence of disease, providing an inadequate solution for chronic conditions in immuno-dermatology. Topical calcineurin inhibitors (&#147;TCI&#148;) are an
additional non-steroidal option for the topical treatment of atopic dermatitis, but their use is limited by safety concerns, including boxed warnings of malignancy reported in patients treated with TCIs. Oral and biologic therapies have become
increasingly available but are often limited to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> psoriasis and atopic dermatitis patients which comprise the smallest percentage of the affected
populations. While biologics have proven to be very effective, their use has also been limited by concerns with systemic side effects, high cost, and reimbursement and access restrictions. Oral therapies are functionally limited to <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> psoriasis patients. Oral therapies also have significant side effects and have not achieved the same level of efficacy as biologics. Given the limitations
associated with TCS, other topicals, orals, and biologics therapies, patients with inflammatory skin conditions often report dissatisfaction with their current treatment options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Psoriasis and atopic dermatitis represent two of the largest markets in immuno-dermatology and are expected to reach total sales of
approximately $25 billion in the U.S. and $37 billion globally by 2027. Topical treatments serve as the foundation of dermatologic treatment, representing 83% of all U.S. prescriptions written by dermatologists in 2020. Additionally, we believe that
tapinarof has the potential to be prescribed alongside biologics and oral therapies. Annual U.S. prescriptions for both psoriasis and atopic dermatitis are outlined below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TCS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vitamin&nbsp;D&nbsp;/&nbsp;Combos</B><br><B>/ Retinoids</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Biologics</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Otezla</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Other&nbsp;Oral</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Annual Scripts for PsO (2020)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B>~2.35M</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">~508K</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">~1.05M</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">~258K</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">~241K</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TCS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TCI</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Eucrisa</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dupixent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Annual Scripts for AD (2020)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B>~16.4M</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">~996K</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">~352K</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">~344K</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">253 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g13m19.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Source: EvaluatePharma </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tapinarof for the Treatment of Psoriasis </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical
data </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recently completed two pivotal Phase 3 clinical trials, PSOARING 1 and PSOARING 2, evaluating the use of tapinarof in treating
mild, moderate and severe plaque psoriasis in adults. In both of these trials, which enrolled over 500 patients each, tapinarof met its primary endpoint and all secondary endpoints with clinically meaningful and statistically significant responses
as well as favorable safety and tolerability findings. At week 12, 35.4% and 40.2% of patients treated with tapinarof in PSOARING 1 and PSOARING 2, respectively, achieved the primary efficacy endpoint of a Physician Global Assessment (PGA) score of
clear (0)&nbsp;or almost clear (1)&nbsp;with a minimum <FONT STYLE="white-space:nowrap">2-grade</FONT> improvement from baseline as compared to 6.0% and 6.3% of patients treated with vehicle cream (p&lt;0.0001; p&lt;0.0001). When this endpoint was
evaluated over time, rapid onset of activity was observed with separation emerging by the first evaluation trial visit (week 2) and statistically significant differences between tapinarof and vehicle cream at week 4 and continuing at all measured
time points thereafter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tapinarof met all secondary endpoints with statistical significance in PSOARING 1 and PSOARING 2, including a key
secondary endpoint, the proportion of subjects with <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>75% improvement in Psoriasis Area and Severity Index (PASI75). In PSOARING 1 and 2, 36.1% &amp; 47.6% of patients achieved PASI75 at Week 12 with
tapinarof 1% cream QD vs 10.2% &amp; 6.9% for vehicle, respectively. The PASI assessment is a more quantitative assessment of disease activity relative to the PGA and provides additional insight into a drug&#146;s impact on disease modification.
Similar to what was observed with PGA, evaluating reduction in the burden of disease via a PASI assessment confirms rapid onset of action with separation of tapinarof from vehicle cream control at week 2, and statistically significant differences
were noted as early as week 4 and each evaluation thereafter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, tapinarof was observed to be well-tolerated, consistent with
previous trials, and had low discontinuation rates due to adverse events (&#147;AEs&#148;), no treatment related serious adverse events (&#147;SAEs&#148;), and minimal severe application site reactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tapinarof was observed to be well-tolerated in both trials, with AEs generally mild to moderate in nature and the majority consisting of
localized skin reactions. Overall trial discontinuations due to adverse events were 5.6% in PSOARING 1 and 5.8% in PSOARING 2. Trial discontinuation rates due to folliculitis were 1.8% in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">254 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
PSOARING 1 and 0.9% in PSOARING 2. No tapinarof-related severe adverse events were observed, and over 90% of eligible patients enrolled in the long-term extension study. To date, over 2,200
subjects have been enrolled in 18 clinical trials of tapinarof and predecessor formulations of tapinarof cream. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g14w92.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Patients with PGA of 2 (mild) and PGA of 4 (severe) limited to ~10% each of the total randomized population;~80%
of the total randomized population with PGA of 3 (moderate); &#134;Patients electing not to participate in LTE had <FONT STYLE="white-space:nowrap">follow-up</FONT> visit 4 weeks after completion of treatment period. BSA, body surface area; LTE,
long-term extension; PASI75, <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 75% improvement in Psoriasis Area and Severity Index; PASI90, <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 90% improvement in Psoriasis Area and Severity Index; PGA,
Physician Global Assessment; QD, once daily. 1. Clinicaltrials.gov; NCT03956355. 2. Clinicaltrials.gov; NCT03983980. 3. Clinicaltrials.gov; NCT04053387. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g15q63.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">255 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g97p21.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g16a22.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The below figure shows rapid and complete clearance of plaque psoriasis in a patient achieving the defined
trial endpoint. At baseline, this patient&#146;s PGA score was 3, indicative of moderate disease, and the PASI score was 17.6. The baseline image demonstrates classic plaque psoriasis with well demarcated erythematous scaling plaques. At week 4, the
PGA had decreased from 3 to 2 and the PASI from 17.6 to 4, the latter having passed the threshold 75% reduction in PASI (PASI75). The target plaques on the forearm are completely resolved. At week </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">256 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
12, both the PGA and PASI scores were 0, indicating complete clearance of disease. PGA and PASI are global efficacy assessments. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g67t12.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2021, we reported data from the planned interim analysis of our long-term open-label study,
PSOARING 3. While the PSOARING 3 long-term open-label study remains ongoing, we conducted the preplanned interim analysis once at least 100 subjects had received tapinarof for 52 weeks, and a further 300 subjects had received tapinarof for 26 weeks.
The interim analysis showed that, as of a cutoff date of November&nbsp;25, 2020, 57.3% of subjects who entered the PSOARING 3 study with a PGA score of <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 2 achieved a PGA score of 0 or 1 at least once
during the study. Although PSOARING 3 was not a vehicle-controlled study unlike the prior two PSOARING studies, we believe these interim data provide supportive evidence regarding tapinarof&#146;s potential therapeutic effect beyond the <FONT
STYLE="white-space:nowrap">12-week</FONT> double blind treatment periods utilized in PSOARING 1 and PSOARING 2. In addition, 299 out of 763 subjects (39.2%) included in the interim analysis achieved complete disease clearance (PGA score of 0) at
least once during the study. We observed no evidence of tachyphylaxis as of the cutoff date, which we believe suggests treatment durability over time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the time of the interim analysis of PSOARING 3 open-label study results, we completed an integrated summary of efficacy (ISE) that included
data from PSOARING 1, PSOARING 2 and the PSOARING 3 interim analysis summary. In the integrated analysis, we identified a PGA response of clear (0)&nbsp;or almost clear (1), plus at least a <FONT STYLE="white-space:nowrap">2-grade</FONT> improvement
from baseline, at any time point, in 57% of subjects, PASI75, at any time point, in 63.5% of subjects, and PASI90, at any time point, in 44.2% of subjects, providing evidence of improvement beyond the 12 week double-blind treatment period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our pivotal Phase 3 clinical trials, we observed that tapinarof&#146;s treatment effect did not decline with continued use over the
duration of the trials, which we refer to as durability on therapy. Additionally, in our interim data analysis for our open-label, <FONT STYLE="white-space:nowrap">single-arm</FONT> PSOARING 3 long-term study, we observed continued improvement in
efficacy assessments, including PGA and PASI scores beyond twelve weeks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Relatedly, in our clinical trials we have also observed,
including in early interim data from our PSOARING 3 long-term open-label study, that some patients treated with tapinarof maintained clinically meaningful disease clearance for an extended period of time after therapy had been discontinued. In
PSOARING 3, subjects discontinued applying tapinarof when they achieved complete clearance of their disease (PGA=0). These subjects </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">257 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
were then followed, and the time to first worsening (defined as PGA <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 2) was utilized to determine the maintenance of clinical benefit off therapy,
and we refer to maintenance of clear/almost clear (PGA 0/1) while off therapy as remittive effect. At the completion of the Week 12 visit of the PSOARING 1 and PSOARING 2 trials, subjects were offered enrollment in the PSOARING 3 long-term
open-label study. Subjects with a PGA <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 1 began treatment with tapinarof cream applied QD until they achieved a PGA score of 0. Treatment was discontinued when a subject achieved a PGA score of 0 and <FONT
STYLE="white-space:nowrap">re-initiated</FONT> for subsequent worsening disease (PGA&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 2). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the PSOARING 3 interim analysis, for subjects entering PSOARING 3 with a PGA score of 0 (78/763), the median time to disease worsening
(defined as a PGA score of <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 2) following treatment discontinuation was approximately 115 days as of November&nbsp;25, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Development plan </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have submitted an
NDA to the FDA for tapinarof cream for the treatment of adults with plaque psoriasis and are expecting a decision on tapinarof&#146;s approval in <FONT STYLE="white-space:nowrap">mid-2022.</FONT> Tapinarof has the potential to be the first novel
topical therapy approved by the FDA for plaque psoriasis in over 20 years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tapinarof for the Treatment of Atopic Dermatitis </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical data </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2017, GSK completed a
multicenter randomized, double-blind, vehicle cream-controlled Phase 2b clinical trial of tapinarof for the treatment of atopic dermatitis in 247 adult (aged 18 to 65 years) and adolescent (aged 12 to 17 years) patients. Patients were randomized
equally to six treatment groups: tapinarof cream 0.5%, tapinarof cream 1% or vehicle cream, each applied to atopic dermatitis lesions either QD or BID. The primary endpoint was the percentage of patients who achieved a minimum <FONT
STYLE="white-space:nowrap">two-point</FONT> improvement in IGA score and resulted in an assessment of &#147;clear&#148; or &#147;almost clear&#148; skin at week 12. These cases were considered a &#147;treatment success.&#148; Secondary endpoints
included the percentage of patients with at least 75% improvement in Eczema Area and Severity Index (EASI) from baseline. Efficacy was evaluated in the intent to treat (ITT) population. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Overall, the percentage of patients achieving treatment success at week 12 was much higher than vehicle cream for both tapinarof
concentrations, with a robust dose response. Treatment success at week 12 was higher for both tapinarof concentrations when compared with vehicle cream. 53% of patients who applied tapinarof cream 1% BID and 46% of those who applied it QD were
considered a treatment success at week 12. This compares favorably to the 24% and 28% levels for vehicle cream BID and QD, respectively. At week 12, 60% and 51% of patients treated with tapinarof cream 1% BID and QD, respectively, achieved EASI75.
The treatment effect across adults and adolescents was observed to be consistent. Patient-reported outcome data was collected during the Phase 2b clinical trial, including data on reduction in severity of pruritus. At week 12, most patients treated
with tapinarof cream 1% (78% of patients treated BID and 87% of patients treated QD) reported &#147;moderately improved&#148; to &#147;very improved&#148; pruritus, compared to patients treated with vehicle cream (47% of patients treated BID and 64%
of patients treated QD). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">258 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IGA score 0 or 1 and </B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B>2-grade
improvement at Week 8 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Primary Endpoint was at 12 Weeks: Assessed in ITT Population (NRI Analysis) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g13o68.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">IGA response: IGA score of 0 or 1 and a
<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><FONT STYLE="white-space:nowrap">2-grade</FONT> improvement from baseline. </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><I>Difference versus vehicle cream is statistically significant at p=0.05 level (the 95% confidence interval
excludes 0). </I></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tapinarof was observed to be well-tolerated in this Phase 2b trial for atopic dermatitis, with the
majority of AEs reported as mild or moderate in intensity. In the trial, TEAEs were considered treatment-related in 10% to 19% of dosed patients across the treatment arms. The most commonly reported TEAEs were folliculitis, application-site pain and
atopic dermatitis. TEAEs led to permanent discontinuation of trial treatment in 4% of dosed patients (seven patients from treatment groups total) compared to 7% of patients receiving vehicle cream (six patients total). Only one patient (tapinarof 1%
BID) experienced a SAE of anxiety and hyperactive disorder, which was not considered to be related to treatment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Development plan
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently planning for development of tapinarof for the treatment of atopic dermatitis and anticipate initiating pivotal Phase
3 clinical trials for the treatment of atopic dermatitis in the second half of 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Potential Benefits of Tapinarof&#151;Limitations of Current
Treatments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tapinarof&#146;s potential in psoriasis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While TCS, especially high potency TCS, are the most commonly prescribed first line topical agents for plaque psoriasis treatment, continual
and long-term TCS treatment carries the risk of a variety of significant side effects, as well as the inability to utilize them in sensitive skin areas (e.g., areas such as the face, groin, or axillae), and is associated with HPA axis suppression,
skin atrophy (thinning), striae (stretch marks), and telangiectasia (spider veins), among other side effects. Furthermore, some of these side effects are irreversible, persisting even after therapy is discontinued. Consequently, high-potency TCS are
not recommended for chronic use, and physicians generally will not prescribe them for treatment on the face or in the intertriginous regions where skin opposes skin, such as skin folds. For example, the label for clobetasol propionate, the most
commonly used high-potency steroid, limits use to two consecutive weeks, and use on the face or intertriginous regions is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">259 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contraindicated. Facial psoriasis affects <FONT STYLE="white-space:nowrap">33%-50%</FONT> of psoriasis patients, and between <FONT STYLE="white-space:nowrap">21%-30%</FONT> of people living with
psoriasis develop intertriginous psoriasis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Oral and biologic therapies are also available but are only indicated for a small percentage
of the affected population, are expensive and often face access and reimbursement restrictions. While highly efficacious, biologic therapies may require frequent injections and regular physician appointments, have potential systemic toxicities and
often require laboratory monitoring. As a result, use of biologics remains limited to patients with significant disease burden. Patients on biologics often continue to use TCS on resistant patches and plaques. Oral therapies have not yet achieved
the same level of efficacy as biologics, but also have potential systemic side-effects, often requiring dose titration to mitigate adverse reactions. Systemic exposure to PDE4 inhibitors has been linked to depression and suicidal ideation. For
example, the FDA labeling for both Otezla, the leading branded oral PDE4 inhibitor, and roflumilast, recommends advising patients to be alert for the emergence or worsening of suicidal thoughts or other mood changes, and indicates that instances of
suicidal ideation and behavior were observed in clinical trials. In addition, Otezla requires dosing twice daily (BID), which can compromise adherence to the treatment regimen. Despite inferior efficacy compared to biologics, oral therapies comprise
significant market share. According to EvaluatePharma, Otezla is forecasted to generate over $1.9&nbsp;billion in worldwide sales in psoriasis and psoriatic arthritis in 2020, indicating a need for more convenient treatment options with efficacy
across the disease spectrum of mild to severe. In two Phase 3 trials in psoriasis patients, 20% and 22% of patients on oral Otezla achieved a PGA response at week 16, vs. 4% and 4% for placebo, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe tapinarof&#146;s differentiated clinical profile has five key attributes that will position it favorably over current standard of
care treatments in psoriasis, including TCS therapies, if approved. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g33c40.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have commissioned robust qualitative and quantitative prescriber, payor and patient third party market
research, involving more than 510 clinicians, 56 patients, and 58 payors. Based on this market research, we believe that an unmet need exists in psoriasis for a safe and conveniently administered <FONT STYLE="white-space:nowrap">non-steroidal</FONT>
topical therapy that can be applied without interruption or long-term safety concerns and has potential efficacy similar to that of TCS and some systemically administered products. If approved, such a treatment could provide a significant
improvement for those patients who do not receive adequate relief from current topical therapies or who have reservations about the safety and cost of oral medications or biologics or are unable to access these therapies. Our market research
indicates that payors perceive tapinarof as a novel therapy that, if approved, could provide the potential to arrest the increasing cost trend of the psoriasis category, based on a survey of 15 payors.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">260 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
If approved, tapinarof could give national payors the opportunity to reduce spend in the overall psoriasis therapeutic class while allowing physicians and patients access to a potentially highly
potent, safe, and tolerable treatment option for plaque psoriasis before moving to more costly oral and biologic therapies. TCS, due to their FDA label safety limitations, do not allow payors the versatility to aggressively manage a chronic
condition in a manner that can effectively control the psoriasis therapeutic category cost trend. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based the clinically meaningful and
statistically significant reduction in psoriasis symptoms tapinarof demonstrated in both Phase 3 trials, coupled with safety data, we believe tapinarof could be used broadly without restriction on skin application sites, or duration of use if
approved. We believe the Phase 3 data we have generated and the data observed in the interim analysis of our open-label, long-term extension study support the chronic use of tapinarof, potentially in place of other topical and oral treatments, for
the treatment of mild, moderate and severe plaque psoriasis, if approved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tapinarof&#146;s potential in atopic dermatitis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TCS, especially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">low-to-mid</FONT></FONT> potency TCS, represent the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> for atopic dermatitis treatment. Although they are used commonly, TCS pose a specific concern in pediatric patients due to the risk of systemic absorption,
HPA axis suppression, skin thinning and other potential side effects. The increased body surface area to mass ratio in children results in increased absorption and systemic exposure. The American Academy of Dermatology guidelines suggest limiting
long-term use of TCS in children to avoid the risk of systemic side effects. As such, 86% of U.S. patients report dissatisfaction with current treatment options for atopic dermatitis according to the National Eczema Association. There is also
considerable concern among many parents about treating their children with steroids, which can be an obstacle to treatment for physicians. Due to these risks and patient dissatisfaction, health care providers are less likely to use them long-term in
children and also in sensitive skin areas such as the face or diaper/groin area. In addition, topical PDE4 inhibitors developed to treat atopic dermatitis have been associated with side effects including application site burning and stinging.
Topical calcineurin inhibitors are an additional <FONT STYLE="white-space:nowrap">non-steroidal</FONT> option for the topical treatment of atopic dermatitis; however, their use has been limited by safety including boxed warnings of malignancy (e.g.,
skin and lymphoma) having been reported in patients treated with topical calcineurin inhibitors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients whose disease flares despite
topical treatments may be prescribed systemic agents such as oral corticosteroids or oral cyclosporine to rapidly relieve severe signs and symptoms of the disease. While these are effective as temporary treatments of
<FONT STYLE="white-space:nowrap">flare-ups,</FONT> extended use has been associated with many potential side effects or adverse events. Systemic steroids, such as prednisone, can lead to symptom relief, but their use is not recommended to induce
stable remission due to numerous side effects associated with steroids and the propensity of severe disease flares upon abrupt treatment cessation. Cyclosporine is also generally not recommended for use lasting longer than one to two years, as it
has been associated with renal toxicity, hirsutism, nausea and lymphoma. Based on data from the 2014 Adelphi U.S. AD Disease Specific Program, over 58% of adults with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> atopic dermatitis have disease which physicians consider to be inadequately controlled by these therapeutic modalities. While biologic therapies are
more efficacious, as is the case in psoriasis, use of therapies such as the recently approved Dupixent is limited to patients with significant disease burden as they are expensive, necessitate frequent injections, entail regular physician
appointments, have potential systemic toxicities and often require laboratory monitoring. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe tapinarof has the potential to fill
the need for a long-term treatment option for atopic dermatitis. We also believe that tapinarof has the potential to offer significant clinical advancement to address the incessant flare cycle experienced by atopic dermatitis patients that is the
result of the short-term use limitation of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> TCS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since acquiring tapinarof in 2018, we have expanded our intellectual property with multiple patents, which are expected to expire beginning in
2036. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">261 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tapinarof sales and marketing </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If tapinarof is approved by the FDA for the treatment of mild, moderate or severe plaque psoriasis, we intend to commercialize it in the United
States by building a highly specialized commercial sales organization focused on high value dermatology healthcare providers and their patients and implementing a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;best-in-class&#148;</FONT></FONT> payor reimbursement and patient point of sale access strategy, which we believe will ensure broad patient access at launch. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As psoriasis patients are predominantly managed by dermatologists, we intend to deploy a specialty sales team focused on a core target base of
<FONT STYLE="white-space:nowrap">top-decile</FONT> dermatologists who write more than 80% of all commercial prescriptions in the psoriasis market. We believe a scientifically oriented, customer-focused team of approximately 60 to 75 sales
representatives will allow us to reach the approximately 5,000 highest value dermatology healthcare providers. For markets outside of the U.S., we may opportunistically seek strategic collaborations to maximize the commercial opportunities for
tapinarof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If tapinarof or topical cerdulatinib are approved by the FDA for the treatment of atopic dermatitis, we plan to expand our
psoriasis sales team to be able to reach additional specialists who see a significant amount of atopic dermatitis patients, such as pediatric dermatologists and allergists. Based on our commercial team&#146;s experience developing and launching
dermatology products in U.S., we believe we can effectively reach the psoriasis and atopic dermatitis core target base with a highly specialized sales team of 120 to 130 total sales representatives. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Earlier-Stage Pipeline </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beyond tapinarof,
Dermavant&#146;s pipeline consists of three novel product candidates targeting an array of significant unmet medical needs in the field of dermatology. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cerdulatinib <FONT STYLE="white-space:nowrap">(DMVT-502)</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are evaluating topical cerdulatinib as a differentiated dual inhibitor of the JAK and Syk pathways. Given its unique mechanism of action, we
believe that topical cerdulatinib, if approved, could provide a differentiated treatment option for vitiligo, a condition for which there are no FDA approved treatments that suppress vitiligo disease activity, as well as other inflammatory skin
conditions that have already been validated for JAK inhibition, such as atopic dermatitis. We initiated a Phase 2a clinical trial of topical cerdulatinib for the treatment of vitiligo in 2019 and received
<FONT STYLE="white-space:nowrap">top-line</FONT> results in the first half of 2021 that met the primary endpoints of safety and tolerability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Vitiligo is an inflammatory skin condition characterized by skin depigmentation resulting from the loss of skin melanocytes. It usually
involves the face, digits, arms, inguinal area, anogenital area, umbilicus and nipples, and can also affect the hair. Affected patches of skin are sharply demarcated and noticeable, particularly among patients with a darker natural skin color.
Vitiligo is the most common skin depigmentation (color loss) disorder, affecting up to 1% of people of all ages, sexes, and ethnicities, worldwide. Vitiligo can severely impact patients&#146; quality of life and psychological well-being due to its
appearance and visibility, which can each persist for the duration of a patient&#146;s life. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on preclinical data observed to date,
we believe topical cerdulatinib&#146;s dual JAK/Syk inhibition has the potential to be a powerful combination for the treatment of vitiligo. In a mouse model of vitiligo, the effect of topical cerdulatinib (dosed orally QD) on epidermal
depigmentation and melanocyte-specific immunity was evaluated versus placebo over a five-week span. We observed a significant decrease in vitiligo scores compared with vehicle gel at doses of 30 mg/kg (<I>p</I>=0.0003) and 60 mg/kg
(<I>p</I>=0.0001). The drug prevented epidermal depigmentation in the mice and was associated with a significant reduction of melanocyte-specific T cells in skin tissues. Topical administration has the potential to avoid systemic toxicities that are
often associated with oral JAK inhibitors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">262 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given topical cerdulatinib&#146;s unique dual JAK/Syk inhibitor mechanism of action, we
believe it also has the potential to offer particular advantages for the treatment of atopic dermatitis. In a preclinical mouse model of atopic dermatitis, contact sensitization is experimentally induced via the application of dinitrochlorobenzene.
Syk knockout mice are resistant to this chemically-induced contact dermatitis. By blocking Syk activity, topical cerdulatinib may suppress the role that exogenous contact antigens play in the activity and flares associated with atopic dermatitis.
Inhibiting both pathways simultaneously has the potential to not only control inflammatory disease activity but also to reduce flare frequency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a Phase 1 trial to investigate the safety, tolerability and PK profile of topical cerdulatinib over a <FONT
STYLE="white-space:nowrap">14-day</FONT> trial period in healthy volunteers and adults with atopic dermatitis. The results showed reductions in atopic dermatitis disease activity and evidence of drug-target engagement via biomarkers. Measures of
epidermal hyperplasia showed improvements from treatment with topical cerdulatinib. Gene expression of immune markers was also reduced, which correlated with improvement in clinical response. Topical cerdulatinib gel 0.37% was generally observed to
be well-tolerated among patients in this trial, with no serious AEs reported or trial discontinuations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">DMVT-504</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">DMVT-504</FONT> is an investigational oral candidate that we are developing for the treatment of primary focal
hyperhidrosis (PFH). <FONT STYLE="white-space:nowrap">DMVT-504</FONT> combines an immediate-release muscarinic antagonist, oxybutynin, with a delayed-release muscarinic agonist, pilocarpine, designed to mitigate dry mouth typically observed with
anticholinergic therapies for better long-term tolerability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Primary focal hyperhidrosis is a condition characterized by excessive
sweating&#151;beyond what is physiologically required by the body or what is expected given the local environment and temperature. The most common focal areas affected by the disease are the underarms, palms of hands, soles of feet, and face.
Approximately 80% of patients experience symptoms in multiple areas of the body, with 70% of patients reporting excessive sweating in multiple areas. Hyperhidrosis results in substantial impairments for patients; excessive sweating, which can range
from mild to &#147;dripping,&#148; can severely limit social interactions, work productivity and physical activity. Hyperhidrosis has an estimated prevalence in the United States of 4.8%, representing approximately 15.3&nbsp;million people, half of
whom are reportedly undiagnosed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a Phase 2a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> clinical trial conducted by TheraVida, Inc. (TheraVida) in patients with PFH, <FONT STYLE="white-space:nowrap">THVD-102</FONT> (a predecessor
formulation of <FONT STYLE="white-space:nowrap">DMVT-504)</FONT> significantly reduced Hyperhidrosis Disease Severity Score (HDSS) compared with placebo (p=0.04) and was also able to provide a statistically significant reduction (p=0.027) in dry
mouth symptoms. In connection with additional formulation work, we have completed a Phase 1 clinical trial to investigate the safety, tolerability and PK profile of multiple formulations of <FONT STYLE="white-space:nowrap">DMVT-504.</FONT> All
formulations of <FONT STYLE="white-space:nowrap">DMVT-504</FONT> assessed in the study were observed to be generally well-tolerated, and mean PK results showed a relationship between formulation and delayed-release characteristics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given the site-specific nature of treating hyperhidrosis, we believe patients would benefit from an oral therapy that provides a <FONT
STYLE="white-space:nowrap">non-invasive</FONT> treatment approach with a simple dosing regimen, efficacy across multiple focal sites of excessive sweating, and limited side effects commonly associated with oral and biologic anti-cholinergic
therapies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">DMVT-503</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to its clinical pipeline, Dermavant is developing <FONT STYLE="white-space:nowrap">DMVT-503,</FONT> a topical DGAT1 inhibitor, as a
treatment for acne vulgaris. We are conducting a <FONT STYLE="white-space:nowrap">pre-clinical</FONT> mouse model study to explore the potential for <FONT STYLE="white-space:nowrap">DMVT-503</FONT> to induce dose-dependent atrophy of sebum-producing
sebaceous glands, a similar effect to and potential biomarker of isotretinoin efficacy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">263 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>Immunovant Overview</U> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Overview: </U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Immunovant is developing IMVT-1401 for the treatment of Myasthenia Gravis (&#147;MG&#148;), Warm Autoimmune
Hemolytic Anemia (&#147;WAIHA&#148;) and Thyroid Eye Disease (&#147;TED&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Lead program:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">IMVT-1401 is a novel, fully human monoclonal antibody that selectively binds to and inhibits the neonatal
fragment crystallizable receptor (&#147;FcRn&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Designed to be a fixed-dose, self-administered subcutaneous (&#147;SC&#148;) injection on a convenient weekly, or
less frequent, dosing schedule. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In nonclinical studies and in clinical trials conducted to date, IMVT-1401 has been observed to reduce
immunoglobulin G (&#147;IgG&#148;) antibody levels. High levels of pathogenic IgG antibodies drive a variety of autoimmune diseases and, as a result, we believe IMVT-1401 has the potential for broad application in related disease areas.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Disease overview: </U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Advanced <FONT STYLE="white-space:nowrap">IgG-mediated</FONT> autoimmune diseases had an aggregate prevalence of
approximately 758,000 patients in 2020 in the United States and Europe. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">MG is a rare autoimmune disorder characterized by weakness of muscles including ocular, head, oropharyngeal, limb
and respiratory muscles and affected an estimated 66,000 people in the U.S. in 2020. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">WAIHA is a rare hematologic disease in which autoantibodies mediate hemolysis, or the destruction of red blood
cells (&#147;RBCs&#148;), affecting approximately 42,000 patients in the U.S. and 67,000 patients in Europe. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">TED is most commonly caused by IgG autoantibodies that active cell types present in tissues surrounding the eye
and can ultimately be sight-threatening and has an estimated annual incidence of 16 in 100,000 women and 2.9 in 100,000 men in North America and Europe. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Limitations of current treatments:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Early-stage disease: corticosteroids and immunosuppressants </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Later-stage disease: intravenous immunoglobulin (&#147;IVIg&#148;), or plasma exchange </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Approaches are limited by delayed onset of action, waning therapeutic benefit over time and unfavorable safety
profiles </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Clinical data: </U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In February 2021, we voluntarily paused dosing in our clinical trials for IMVT-1401 due to elevated total
cholesterol and low-density lipoprotein (&#147;LDL&#148;) levels observed in some trial subjects treated with IMVT-1401 and informed regulatory authorities and trial subjects and investigators of this voluntary pause of dosing in our studies that
were ongoing at that time. Following a program-wide data review from February 2021 through May 2021 suggesting that lipid elevations are predictable, manageable, and appear to be driven by reductions in albumin, we plan to resume clinical
development of IMVT-1401 in MG and WAIHA. We are likely to design another Phase 2 trial in TED or another thyroid-related disease as their next study in this therapeutic area. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Statistically significant improvements on the Myasthenia Gravis Activities of Daily Living <FONT
STYLE="white-space:nowrap">(&#147;MG-ADL&#148;)</FONT> scale and Myasthenia Gravis Composite (&#147;MGC&#148;) scale in ASCEND MG Phase 2a trial of IMVT-1401 in patients with MG. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">264 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In the ASCEND GO-2 Phase 2b trial in TED, treatment with IMVT-1401 reduced both IgG and disease specific
pathogenic IgG over the 12-week treatment period. However, the efficacy results, based on approximately half the anticipated number of subjects who had reached the week 13 primary efficacy analysis at the time of the termination of the trial, were
inconclusive. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Development plan and upcoming milestones:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Contingent upon FDA feedback, we plan to initiate a pivotal trial in MG late in the calendar year 2021 or early
part of calendar year 2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Contingent upon FDA feedback, we plan to re-initiate our Phase 2a trial in WAIHA late in the calendary year 2021
or early part of calendar year 2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are likely to design another Phase 2 trial in TED or another thyroid-related disease as the next study in this
therapeutic area and initiate discussions with regulatory authorities before the end of calendar year 2021. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We plan to announce two new indications and submit INDs and our trial designs to the FDA by May 2022.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Roivant ownership:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As of March 31, 2021, we owned 58% of the issued and outstanding shares of Immunovant common stock and 53% on a
Fully Diluted basis. On August 2, 2021, we entered into a Share Purchase Agrement with Immunovant and purchased 17,021,276 additional shares of Immunovant common stock for an aggregate purchase price of $200,000,000, in cash, representing a per
share price of $11.75. Following such purchase, we own approximately 64% of the issued and outstanding shares of Immunovant common stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Pipeline:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g87g13.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IMVT-1401 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IMVT-1401 is a novel, fully human monoclonal antibody that selectively binds to and inhibits FcRn. In nonclinical studies and in clinical
trials conducted to date, IMVT-1401 has been observed to reduce IgG antibody levels. High levels of pathogenic IgG antibodies drive a variety of autoimmune diseases and, as a result, we believe IMVT-1401 has the potential for broad application in
these disease areas.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to generating clinically meaningful IgG reductions, IMVT-1401 has been designed from inception to be a
fixed-dose, self-administered SC injection on a convenient weekly, or less frequent, dosing schedule. We believe that IMVT-1401, if developed and approved for commercial sale, would be differentiated from currently available, more invasive
treatments for advanced <FONT STYLE="white-space:nowrap">IgG-mediated</FONT> autoimmune diseases. The patent family directed to the composition of matter of IMVT-1401 has a natural projected expiration date in 2035 in the U.S. and in foreign
jurisdictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Mechanism of action </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The neonatal fragment crystallizable receptor, or FcRn plays a pivotal role in preventing the degradation of IgG antibodies. The physiologic
function of FcRn is to modulate the catabolism of IgG antibodies. FcRn </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">265 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
intercepts IgG, which would otherwise be degraded in lysosomes. The <FONT STYLE="white-space:nowrap">FcRn-IgG</FONT> complex is then recycled to the cell surface and free IgG is released back
into circulation. Anti-FcRn antibodies bind to FcRn, thereby preventing it from recycling IgG antibodies back to circulation. As a result, IgG is increasingly delivered to lysosomes for degradation. The inhibition of FcRn, such as through use of an
anti-FcRn antibody, has been shown to reduce levels of pathogenic IgG antibodies, suggesting utility in the many autoimmune diseases associated with high levels of such IgG antibodies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Autoimmune Diseases </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Autoimmune diseases
are conditions where an immune response is inappropriately directed against the body&#146;s own healthy cells and tissues. Many of these diseases are associated with high levels of pathogenic IgG antibodies, which are the most abundant type of
antibody produced by the human immune system, accounting for approximately 75% of antibodies in the plasma of healthy people. IgG antibodies are important in the defense against pathogens, such as viruses and bacteria. In many autoimmune diseases,
IgG antibodies inappropriately develop against normal proteins found in the body, directing the immune system to attack specific organs or organ systems. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unfortunately, safe and effective treatment options for patients suffering from autoimmune diseases are inadequate. Currently available
treatments are generally limited in early-stage disease to corticosteroids and immunosuppressants, and in later-stage disease to IVIg or plasma exchange. These approaches often fail to address patients&#146; needs since they are limited by delayed
onset of action, waning therapeutic benefit over time and unfavorable safety profiles. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g69h00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:8pt; font-family:Times New Roman"><I>Europe includes all E.U. countries, the U.K. and Switzerland. MG: Myasthenia Gravis; WAIHA: Warm
Autoimmune Hemolytic Anemia; TED: Thyroid Eye Disease; ITP: Idiopathic Thrombocytopenic Purpura; PV: Pemphigus Vulgaris; CIDP: Chronic Inflammatory Demyelinating Polyneuropathy; BP: Bullous Pemphigoid; NMO: Neuromyelitis Optica; PF: Pemphigus
Foliaceus; GBS: Guillain-Barr&eacute; Syndrome; PMN: PLA2R+ Membranous Nephropathy. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the rational design of IMVT-1401,
we believe that IMVT-1401, if approved for use, could provide the following benefits: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Subcutaneous delivery</I></B><B>.</B> Based on pharmacokinetics (&#147;PK&#148;) and pharmacodynamics
(&#147;PD&#148;) and clinical data, we believe that we will be able to obtain therapeutically relevant levels of IgG reduction <FONT STYLE="white-space:nowrap">using&nbsp;2-mL&nbsp;or</FONT> lesser volume SC injections. The current formulation is
concentrated at 170 mg/mL. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">266 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Simple dosing schedule</I></B><B>.</B> We are developing IMVT-1401 as a fixed-dose subcutaneously
administered regimen without the need for preceding intravenous induction doses or lengthy SC infusions. If approved, we intend to market IMVT-1401 as a <FONT STYLE="white-space:nowrap">fixed-dose&nbsp;pre-filled&nbsp;syringe</FONT> or
auto-injector, which would allow for convenient self-administration, eliminating the need for frequent and costly clinic visits, and reduce complexity and errors associated with calculating individual doses. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Low immunogenicity risk</I></B><I>.</I><I></I>&nbsp;IMVT-1401 is a fully human monoclonal antibody, and
therefore contains only amino acid sequences native to humans, hypothesizing a lower risk of immunogenicity development. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Low effector function.</I></B><I></I>&nbsp;IMVT-1401 has been engineered to prevent activation of other
components of the immune system, and, as a result, unintended immune response to IMVT-1401 is not expected. Specifically, well-characterized and validated mutations introduced into the fragment crystallizable domain of IMVT-1401 have reduced its
ability to cause antibody-dependent cell-mediated cytotoxicity (&#147;ADCC&#148;) and complement-dependent cytotoxicity (&#147;CDC&#148;). </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments in Our Clinical Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2021, we voluntarily paused dosing in our clinical trials for IMVT-1401 due to elevated total cholesterol and LDL levels observed
in some trial subjects treated with IMVT-1401. We have informed regulatory authorities and trial subjects and investigators of this voluntary pause of dosing in our studies that were ongoing at that time, ASCEND
<FONT STYLE="white-space:nowrap">GO-2,</FONT> a Phase 2b trial in Thyroid Eye Disease and ASCEND-WAIHA, a Phase 2 trial in Warm Autoimmune Hemolytic Anemia. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Program-Wide Review </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to better
characterize the observed lipid findings, we conducted from February 2021 through May 2021 a program-wide data review (including both clinical and nonclinical data) with input from external scientific and medical experts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our ASCEND <FONT STYLE="white-space:nowrap">GO-2</FONT> trial, lipid parameters were assessed at baseline, at week 12, and at week 20
following eight weeks off drug. Based on preliminary, unblinded data, median LDL cholesterol at week 12 was increased by approximately 12 mg/dL in the 255 mg dose group (corresponding to an increase from baseline of approximately 15%), by
approximately 33 mg/dL in the 340 mg dose group (corresponding to an increase from baseline of approximately 37%), by approximately 62 mg/dL in the 680mg dose group (corresponding to an increase from baseline of approximately 52%) and did not
increase in the control group. The data analysis indicates a dose-dependent increase in lipids. Average high-density lipoprotein (&#147;HDL&#148;) and triglyceride levels also increased but to a much lesser degree. We also observed correlated
decreases in albumin levels and the rate and extent of albumin reductions were dose-dependent. Subjects receiving the 255 mg weekly dose (&#147;QW&#148;) experienced the smallest reductions in albumin through week 12, with a median reduction of
about 16% from baseline, while subjects receiving the 340 mg or 680 mg QW dose experienced median reductions of albumin of 26% or 40%, respectively. At week 20, both lipids and albumin returned to baseline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our open label ASCEND WAIHA trial, only two subjects completed 12 weeks of dosing prior to the program-wide pause in dosing, with three
additional subjects partially completing the dosing period. Pre-specified and post-hoc lipid test results from these five subjects were analyzed along with post-hoc lipid test results performed on frozen samples from ASCEND MG subjects (where
available) and post-hoc lipid test results from our Phase 1 Injection Site study. LDL elevations observed in the ASCEND WAIHA and ASCEND MG subject populations and in healthy subjects in the Phase 1 Injection Site Study also appeared to be
dose-dependent and were generally consistent in magnitude with the elevations observed in ASCEND GO-2 subjects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No major adverse
cardiovascular events have been reported to date in IMVT-1401 clinical trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">267 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Integrated Safety Assessment and Regulatory Interactions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is our intent to resume development across multiple indications for IMVT-1401. We are in the process of drafting multiple study protocols
and updating our program-wide safety strategy for discussions with regulatory agencies. The elements of our development program will include extensive PK and PD modeling to select dosing regimens for IMVT-1401 which optimize reductions in total IgG
levels while minimizing the impact on albumin and LDL levels, particularly for clinical studies containing long-term treatment extensions. These protocols will likely include protocol-directed guidelines for the management of any observed lipid
abnormalities. While increases in LDL over an 8 to 12 week treatment duration would not be expected to pose a safety concern for patients, the risk-benefit profile of long-term administration of IMVT-1401 will need to incorporate any unfavorable
effects on lipid profiles. Discussions with regulatory agencies, including the FDA, are expected to commence during the second half of the calendar year 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Phase 1 Clinical Trials of IMVT-1401 in Healthy Volunteers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have completed a multi-part, placebo-controlled Phase 1 clinical trial involving 99 healthy volunteers in Australia and Canada,
administering IMVT-1401 both as an intravenous infusion and as a SC injection. In this trial, 77 subjects received at least one dose of IMVT-1401 and 22 subjects received placebo. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Program-Wide Data Review </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pharmacokinetics and
Pharmacodynamics </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PK and PD (including serum concentrations of total IgG, albumin, and lipids) of IMVT-1401 were evaluated in
healthy subjects in our Phase 1 clinical trial and Phase 1 Injection Site Study, and in patients with MG, TED and WAIHA in our ASCEND MG, ASCEND GO-1, ASCEND GO-2 and ASCEND WAIHA trials. To date, single doses of IMVT-1401 ranged from 100 mg to 1530
mg IV and 1.5 mg/kg to 765 mg SC and were administered to healthy subjects. Multiple doses of 255 mg, 340 mg and 680 mg SC QW have been studied in healthy subjects (up to 4 weeks of dosing) and patients with TED, MG or WAIHA (up to 12 weeks of
dosing). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pharmacokinetics </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IMVT-1401
exhibited a non-linear PK profile which was typical of that characterized by target-mediated drug disposition (&#147;TMDD&#148;). The elimination of IMVT-1401 can be divided into three phases according to the concentrations. The first phase shows
linear elimination; when drug concentrations are high enough to saturate targets, drug elimination is governed by linear non-target-related routes, together with a fixed rate of target-mediated elimination, which is negligible in this phase. At the
second phase, the drug concentrations become lower, the targets are not all saturated and both non-target-mediated and target-mediated elimination routes are important, resulting in nonlinear PK. At the last phase, the drug concentrations are so low
that targets are not saturated, the target mediated elimination becomes the main route of elimination, and the PK becomes linear again. The drug concentrations achieved after 680 mg SC QW dose were mainly in the linear elimination phase of the PK
profile, may maintain target saturation during the dosing intervals for most of the subjects. However, the drug concentrations achieved after the 340 mg or 255 mg SC QW dose may not always maintain target saturation during the dosing intervals for
majority of the subjects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pharmacodynamics </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, ASCEND GO-2 in TED is the largest study (total of 65 subjects, including 18 subjects on placebo) which evaluated placebo and 3-dose
levels of IMVT-1401 at 255 mg, 340 mg and 680 mg administered SC weekly for 12 weeks (&#147;QW*12&#148;). The preliminary PD results of total IgG by time and treatment group is presented in the below figure. The baseline serum levels of total IgG,
albumin, LDL, and HDL were comparable across all treatment groups. After active treatment, the levels of total IgG and albumin started to decrease, but the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">268 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
levels of LDL and HDL started to increase; both the rate and extent of reductions in total IgG and albumin or elevations of LDL and HDL were dose dependent. After 255 mg, 340 mg or 680 mg QW*12,
the median Emax of total IgG reduction was 62%, 69% or 80%, respectively. For Groups 255 mg and 340 mg, total IgG levels continued to decrease as of week 12 (the last injection). For Group 680 mg, total IgG reached maximum reduction around week 7,
and maintained in a plateau-like manner between weeks 7 to 12. The median Emax of albumin reduction was 16%, 26% or 40% for the 255 mg, 340 mg or 680 mg QW*12 doses, respectively. For Groups 340 mg and 680 mg, albumin levels continued to decrease as
of week 12 (the last injection). For Group 255 mg, albumin reduction reached maximum around week 8, and maintained in a plateau-like manner between weeks 8 to 12. After 255 mg, 340 mg or 680 mg QW*12, the median elevation at Week 12 was 15%, 37% or
52%, respectively for LDL, and 14%, 10% or 25%, respectively for HDL. For all three active dose groups, the levels of total IgG, albumin, LDL and HDL returned to baseline within 8 weeks after the last dose of the 12-week treatment. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Mean (&plusmn;SD) Percentage Change from Baseline of Serum Concentrations of Total IgG in Subjects in ASCEND GO-2 (Preliminary Results)
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g92p74.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The relationships of the PD effects in total LDL vs. albumin indicate that the time course and extent of LDL
elevations were highly correlated with albumin reductions. The reductions in both IgG and albumin were also highly correlated, with a coefficient of determination of R<SUP STYLE="font-size:85%; vertical-align:top">2</SUP> = 0.793. It was also noted
that the lipid elevations were not correlated with changes in thyroid hormone levels (no correlations to changes in T3, T4 or TSH was observed). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within the dose range studied, the rate and extent of total IgG reductions, albumin reductions and lipid elevations were dose dependent across
different populations and the shoulder region of the dose-response curve for total IgG reductions was covered and observed. However, the shoulder region of the dose-response curve for albumin reductions or lipid elevations was not clearly observed.
The extent of PD response was much larger in reductions of total IgG than reductions of albumin or elevations of lipids. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive
understanding of the PK and PD characteristics of IMVT-1401 has enabled creation of robust mathematical models to support the selection of future dosing regimens. The discordance between the PK/PD response relationship for IgG and that of albumin or
LDL suggests options for dosing regimens that provide potentially effective reductions in total IgG (and pathologic autoantibodies) while minimizing effects on albumin and LDL levels. Optimized dosing regimens, if shown to be effective, could
improve the risk/benefit profile of IMVT-1401 while the ease of administration of our current formulation could enhance the overall patient experience. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">269 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Safety data </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted, from February 2021 through May 2021, a program-wide data review, including safety data review, with input from external
scientific and medical experts. The safety data review for each of the studies is described below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">270 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our multi-part, placebo-controlled Phase 1 clinical trial, IMVT-1401 was observed to be
generally well-tolerated with no Grade 3 or Grade 4 treatment-emergent AEs and no discontinuations due to AEs. The most commonly reported AEs were mild erythema and swelling at the injection site, which typically resolved within hours and had a
similar incidence between subjects receiving IMVT-1401 and placebo. These reactions at the injection site were not considered dose-related and did not increase with multiple administrations of IMVT-1401 in the multiple-dose cohorts. As previously
disclosed, two serious AEs were reported, both of which were assessed as unrelated to IMVT-1401 by the study investigator. There were no treatment-related serious AEs reported. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of the most commonly reported AEs, defined as the AE reported occurred in more than one subject, is set forth in the table below:
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Most Common Adverse Events Reported in Phase 1 Clinical Trial of IMVT-1401 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="50" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Single Ascending Dose</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Intravenous Infusion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Subcutaneous Injection</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Multiple&nbsp;Ascending&nbsp;Dose</B><br><B>Subcutaneous Injection</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number of<BR>Subjects</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>0.1</B><br><B>MG/KG</B><br><B>N=4</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>100</B><br><B>MG</B><br><B>N=6</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>340</B><br><B>MG</B><br><B>N=6</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>765</B><br><B>MG</B><br><B>N=6</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1530</B><br><B>MG</B><br><B>N=6</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Placebo</B><br><B>N=8</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>0.5</B><br><B>MG/KG</B><br><B>N=3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1.5</B><br><B>MG/KG</B><br><B>N=6</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>5</B><br><B>MG/KG</B><br><B>N=6</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>340</B><br><B>MG</B><br><B>N=6</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>500</B><br><B>MG</B><br><B>N=6</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>765</B><br><B>MG</B><br><B>N=6</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Placebo</B><br><B>N=10</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>340</B><br><B>MG</B><br><B>N=8</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>680</B><br><B>MG</B><br><B>N=8</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Placebo</B><br><B>N=4</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>MedDRA Preferred Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Abdominal pain</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Abdominal pain upper</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Abnormal sensation in eye</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Back pain</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Constipation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cough</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Diarrhea</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Dizziness</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Dry skin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Erythema</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Fatigue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Headache</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Injection site erythema</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Injection site pain</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Injection site swelling</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Insomnia</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Myalgia</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Nasal congestion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Nausea</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Ocular hyperaemia</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Oropharyngeal pain</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Pain in extremity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Procedural complication</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Procedural dizziness</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Pyrexia</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Rash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Rhinorrhoea</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Sinusitis</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Somnolence</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Upper respiratory tract infection</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Vision blurred</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">271 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2018, one serious AE (malpighian carcinoma) occurred in a 51-year-old subject
who had received a single 765 mg subcutaneous administration of IMVT-1401. Fifty-five days after study drug administration, the subject presented to his personal physician with a left-sided neck mass. Biopsy results determined the mass to be a
poorly differentiated malpighian carcinoma, which was assessed as unrelated to IMVT-1401 by the study investigator. In February 2019, a 25-year-old subject who received a single dose 1530 mg of IMVT-1401 by intravenous infusion presented five days
later with uncomplicated acute appendicitis and the presence of an appendiceal stone. The subject underwent laparoscopic appendectomy and recovered with an uneventful post-operative course. The event was considered unrelated to study drug by the
study investigator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dose-dependent and reversible albumin reductions were observed in the single-ascending and multiple-ascending dose
cohorts. In the 680 mg multiple-ascending dose cohort, most subjects appeared to reach nadir before administration of the final dose. Mean reduction in albumin levels at day 28 were 20% in the 340 mg multiple-dose cohort, and 31% in the 680 mg
multiple-dose cohort. For subjects in the 340 mg and 680 mg cohorts, the mean albumin levels at day 28 were 37.5 g/L and 32.4 g/L, respectively (normal range 36-51 g/L). These reductions were not associated with any AEs or clinical symptoms and did
not lead to any study discontinuations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Phase 1 Injection Site study, a randomized, double-blinded, placebo-controlled, crossover
study to characterize the PK, PD, safety and tolerability of IMVT-1401 was administered as single subcutaneous doses in three different injection sites in healthy participants (N = 21). In this trial, IMVT-1401 was generally well tolerated with no
serious AEs reported and there were no discontinuations due to AEs. All AEs were assessed to be unrelated to IMVT-1401 by the study investigator. Mild headache was reported in 33% of the overall group as compared with 25% of the placebo group. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our <FONT STYLE="white-space:nowrap">ASCEND&nbsp;GO-1&nbsp;clinical</FONT> trial, where seven participants completed the&nbsp;treatment
period of the study and five of those participants completed the follow-up, off treatment period (the two discontinuations were not related to the study), the safety and tolerability profile observed was consistent with the Phase 1 clinical trials.
In this trial, no serious AEs were observed and there were no discontinuations due to AEs. <FONT STYLE="white-space:nowrap">IMVT-1401</FONT> was generally well-tolerated, with the reported AEs, ranging from mild to moderate, being increase in
weight, cough, fatigue, palpitations, light-headedness, and low blood pressure. One participant had a pre-existing condition of hypertension with borderline low platelets at baseline and a low platelet count after week 18. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our ASCEND MG clinical trial, which included five participants in the 340 mg dose group, six participants in the 680 mg dose group and six
participants in the placebo group, two serious AEs were reported but determined to be unrelated to IMVT-1401 by the study investigator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our ASCEND GO-2 clinical trial, five out of 18 participants in the 680 mg dose group reported peripheral edema with no such events noted in
the other treatment groups. The events were Grade 1 or 2 (on a scale of 1 to&nbsp;5), were limited in duration, and did not require permanent discontinuation of study drug. There were no reported cardiac events and injection site erythema was more
common in the treated groups as compared with the placebo group. In the 255 mg dose group, one AE, optic neuropathy, was considered serious due to hospitalization, but was ultimately determined to be unrelated to the study and the participant later
recovered. Triglycerides were elevated in the 340 mg and 680 mg dose groups with two participants reporting levels above 300 mg/dL and &lt;400 mg/dL. No other serious AEs were reported. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ASCEND WAIHA study is an ongoing, open-label trial that has been evaluated with interim results. To date, one of the five trial subjects
discontinued therapy after three 680 mg SC QW doses due to a serious AE (Immune thrombocytopenia). In January 2021, a 59-year-old subject presented for the scheduled week 4 study visit and reported gingival bleeding. The week 4 dose was not
administered and laboratory results revealed decreases in platelet count. Platelet count was already at a decreased level at the time of enrollment. The subject received multiple platelet transfusions over the following few weeks. In February 2021,
the AE was considered as resolved and no further transfusions were needed at that time. The study investigator considered the event related to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">272 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
aggravation of underlying disease activity (hemolytic anemia with immune thrombocytopenia) since the subject had decreased platelet counts at initial diagnosis; however, the study investigator
stated that the investigational product&#146;s role in causing or aggravating thrombocytopenia cannot be ruled out. The adverse event was determined to be possibly related to study drug. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As previously disclosed, lipid levels were not measured contemporaneously during these Phase 1, ASCEND MG and ASCEND GO-1 clinical trials of
IMVT-1401. See &#147;<I>Recent Developments in Our Clinical Programs</I>&#148; for further discussion about lipid and albumin changes noted in our clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Across all the clinical trial groups to date, we believe the safety profile of IMVT-1401 at the doses studied over a treatment interval of at
least 12 weeks is acceptable and supports further development of these dosing regimens. As discussed in &#147;<I>Recent Developments in Our Clinical Programs,</I>&#148; dose-dependent decreases in albumin levels have been observed with IMVT-1401;
however, these decreases were generally asymptomatic except for the potentially expected AE of peripheral edema which was observed only in the 680 mg dose group and resolved without permanent discontinuation of IMVT-1401. Dose-related increases in
LDL and total cholesterol have also been observed with IMVT-1401. While increases in LDL of this magnitude over a 12-week treatment duration would not be expected to pose a safety concern for patients, the risk-benefit profile of long-term
administration of IMVT-1401 will need to incorporate any unfavorable effects on lipid profiles. Future study designs which include long-term treatment extensions will employ extensive PK/PD modeling to select dosing regimens that optimize reductions
in total IgG while minimizing effects on albumin and LDL. These protocols will likely include protocol-directed guidelines for the management of any observed lipid abnormalities. The indications that we are pursuing with IMVT-1401 are associated
with substantial morbidity and currently available treatments (e.g., high dose intravenous methylprednisolone) associated with significant side effects. Therefore, we believe that, if IMVT-1401 is found to be effective in these diseases, the safety
profile observed to date should result in a favorable risk-benefit profile for IMVT-1401. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No major adverse cardiovascular events have
been reported to date in IMVT clinical trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Immunogenicity Data</I></B><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development of anti-drug antibodies (&#147;ADA&#148;) to IMVT-1401 was assessed across all dosed cohorts following single (IV and SC
formulations) and multiple (SC formulation) administrations of IMVT-1401. Preliminary data show a similar frequency of treatment-emergent ADA development among subjects who received at least one administration of IMVT-1401 or placebo (8% and 6%,
respectively). The antibody titers were low (<FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT> 1:16) consistent with the high sensitivity of the ADA assay. No subjects in either the 340 mg or 680 mg multiple ascending dose cohorts developed ADAs with
treatment. ADAs will continue to be monitored throughout the development program. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IMVT-1401 for the Treatment of Myasthenia Gravis </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>MG overview and limitations of current treatments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Myasthenia Gravis is a rare autoimmune disorder, characterized by weakness of muscles including ocular, head, oropharyngeal, limb and
respiratory muscles. The prevalence of MG is estimated to be one in 5,000, with up to 66,000 cases expected in the United States. Existing therapies are associated with significant side effects and an unmet medical need persists. Approximately 10%
of MG patients are refractory to current treatments, while up to 80% fail to achieve complete stable remission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Very early-stage MG is
symptomatically treated with acetylcholinesterase inhibitors such as pyridostigmine, which block the breakdown of acetylcholine at the neuromuscular junction, thereby increasing its concentration and capacity to activate the muscle. As the disease
progresses, patients are typically treated with immunosuppressive agents such as glucocorticoids, azathioprine, mycophenolate mofetil and cyclosporine. As </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">273 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
MG becomes more advanced, patients can be treated during exacerbations with IVIg, which provides therapeutic benefit through multiple potential mechanisms including the saturation of FcRn.
However, IVIg requires recurrent, burdensome infusions to obtain significant reductions in symptoms, and the large volumes of intravenous fluid associated with the administration of IVIg can lead to significant side effects, including pulmonary
edema and renal complications and treatment can be complicated by events associated with intravascular thrombosis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Physicians direct patients with more
advanced chronic disease and patients in times of crisis to therapies that reduce levels of circulating IgG antibodies. One method of reducing IgG levels is to take blood from a patient and physically remove the patient&#146;s plasma before
returning the red blood cells as well as outside obtained albumin or plasma to the patient in a process called plasma exchange. This is a slow process that typically takes several hours and often requires multiple treatment sequences due to limited
daily tolerance (a reported mean of 6 treatments in MG) over a number of days in order to achieve a significant reduction in IgG antibody levels. A variant of this procedure is immunoadsorption in which bacterial proteins are used to selectively
remove IgG antibodies from serum. The table below sets forth an overview of these treatments for MG. The most recent agent approved for MG is eculizumab, a complement C5 inhibitor, the use of which is limited to patients refractory to available
therapy with anti-AChR-positive MG. Anti-MuSK antibodies have a low propensity to activate complement proteins, thus C5 inhibition may not be therapeutically relevant in anti-MuSK-positive patients. Studies indicating that patients with
MuSK-positive disease are more likely to become treatment refractory thus presenting an additional unmet need. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical data </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2020, we reported topline results from an interim analysis of 15 participants in our ASCEND MG trial. Results from the <FONT
STYLE="white-space:nowrap">six-week</FONT> treatment period included three arms: 340 mg IMVT-1401 weekly (N=5), 680 mg IMVT-1401 weekly (N=5), and placebo (N=5). Initially, the trial had a target enrollment of 21 subjects, however, after taking into
consideration the impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> as well as recent data from other anti-FcRn programs that have supported this mechanism in MG, we elected to unblind and report the study with 15 subjects enrolled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As evaluated in a <FONT STYLE="white-space:nowrap">pre-specified,</FONT> pooled analysis of 15 subjects who completed Day 42,
IMVT-1401-treated subjects (N=10) showed a mean <FONT STYLE="white-space:nowrap">3.8-point</FONT> improvement on the MG Activities of Daily Living, or <FONT STYLE="white-space:nowrap">MG-ADL,</FONT> scale vs. a mean decline of +0.6 for placebo, a
result that was statistically significant (p=0.039). IMVT-1401-treated subjects also showed a statistically significant improvement on the MG Composite, or MGC, scale, with an average improvement of 8.0 points vs. a mean decline of +1.4 for placebo
(p=0.009). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">MG-ADL</FONT> responder rates, defined as the percentage of subjects showing a <FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> <FONT STYLE="white-space:nowrap">2-point</FONT> improvement, were 60% for IMVT-1401-treated subjects vs. 20% for placebo. <FONT STYLE="white-space:nowrap">MG-ADL</FONT> deep responder rates, defined in the
study as the percentage of subjects showing a <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> <FONT STYLE="white-space:nowrap">6-point</FONT> improvement, were 40% for IMVT-1401-treated subjects vs. 0% for placebo. MGC deep responder rates, defined
in the study as the percentage of subjects showing a <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> <FONT STYLE="white-space:nowrap">10-point</FONT> improvement, were 40% for IMVT-1401-treated subjects vs. 0% for placebo. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consistent with previously reported Phase 1 results, IMVT-1401 was observed to be generally well-tolerated with no SAEs, no withdrawals due to
AEs, and no imbalance in headaches; as previously disclosed, lipid levels were not measured contemporaneously during the Phase 1 and ASCEND MG Phase 2a clinical trials of IMVT-1401. Mean reductions in total serum IgG from baseline to Day 42 for the
340 mg and 680 mg cohorts were 59% and 76%, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the interim analysis, two additional participants enrolled and were
randomized. The ASCEND MG trial is now completed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">274 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Development plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before the voluntary pause of dosing, we had a favorable end of Phase 2 meeting with the FDA on the design of our Phase 3 registrational
program in MG and we are planning on advancing our clinical trials for this indication. Based on our integrated safety analysis, we plan to meet with the FDA to propose further development to evaluate additional dosing levels and regimens as well as
to include additional safety monitoring and considerations such as lipid and albumin monitoring and incorporating an independent safety monitoring committee. Contingent upon FDA feedback, we plan to initiate a pivotal study in MG late in the
calendar year 2021 or early part of the calendar year 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IMVT-1401 for the Treatment of Warm Autoimmune Hemolytic Anemia </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>WAIHA overview and limitations of current treatments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WAIHA is a rare hematologic disease in which autoantibodies mediate hemolysis, or the destruction of RBCs. The clinical presentation is
variable and most commonly includes <FONT STYLE="white-space:nowrap">non-specific</FONT> symptoms of anemia such as fatigue, weakness, skin paleness and shortness of breath. Symptoms typically develop chronically over several weeks to months,
however, rapid progression over a span of days has also been observed. In severe cases, hemoglobin levels are unable to meet the body&#146;s oxygen demand, which can lead to heart attacks, heart failure and even death. Though the exact causes of
WAIHA are unknown, roughly half of cases occur in patients with an underlying lymphoproliferative or autoimmune disease, most commonly chronic lymphocytic leukemia, rheumatoid arthritis or systemic lupus erythematosus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In WAIHA, autoantibodies react with surface proteins on RBCs at temperatures at or above 37 degrees Celsius, or normal body temperature. These
antibodies are of the IgG subtype in the majority of patients. WAIHA is differentiated from cold autoimmune hemolytic anemia, or cold agglutinin disease, which shares a similar clinical presentation but is triggered by autoantibodies that react at
temperatures below 37 degrees Celsius. In WAIHA, antibody-coated RBCs are removed from circulation primarily in the spleen, where they are destroyed by macrophages. Studies have suggested the severity of WAIHA correlates with the amount and potency
of autoantibodies present. The laboratory evaluation of WAIHA begins with a peripheral blood analysis revealing evidence of extravascular hemolysis (spherocytes, low haptoglobin, elevated bilirubin and elevated LDH). In over 97% of cases, patients
have a positive direct antiglobulin test, which detects the presence of IgG or complement proteins bound to the surface of RBCs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
annual incidence of WAIHA in the United States and Europe is estimated at one to three in 100,000 persons. Based on published estimates, we believe that there are approximately 42,000 patients in the United States and 67,000 patients in Europe
living with WAIHA. The disease may be more common in females, with some sources suggesting a 2:1 female predominance. Peak incidence occurs during the sixth and seventh decades of life, however, WAIHA can occur in children as well. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">High doses of corticosteroids (&gt;1 mg/kg of prednisone) are typically the first-line treatment option for WAIHA and lead to initial disease
control in approximately <FONT STYLE="white-space:nowrap">70-85%</FONT> of cases. Once initial disease control is achieved, doses of steroids are tapered. However, only 33% of patients maintain sustained disease control once steroids are
discontinued and, as a result, the majority of patients will require either long-term steroid treatment or additional therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There
are few studies to guide which treatment options to use in patients failing corticosteroids. Until recently, splenectomy had been a common second-line treatment option for patients not responding adequately to corticosteroids. The therapeutic
benefit of splenectomy is thought to be twofold: first, it eliminates the major site of RBC destruction in WAIHA; second, removal of the spleen reduces the total lymphoid tissue capable of producing autoantibodies. However, because of the lack of
reliable predictors of the outcome, morbidity and potential operative complications of splenectomy, rituximab has become the default second-line option despite not being approved for use in WAIHA. In case studies looking at patients with relapsed
disease after treatment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">275 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with steroids, single-agent rituximab led to responses in 65% to 90% of patients. In such a course of treatment, maximal therapeutic effect is not immediate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients with persistent disease despite use of corticosteroids and rituximab may be offered a course of other immunosuppressive drugs, such
as cyclophosphamide, mycophenolate mofetil or azathioprine sirolimus. IVIg is not routinely used alone for the treatment of WAIHA, however, small case series have suggested some evidence for a therapeutic effect in patients suffering from
life-threatening complications of the disease. In these reports, IVIg has been given at high doses (greater than or equal to 1 g/kg per day), and the results have been inconsistent, requiring repeated courses of treatment in at least one case. RBC
transfusions are indicated in patients who require immediate stabilization. Such patients are monitored closely for evidence of a transfusion reaction. In contrast to other treatment modalities that lead to nonspecific suppression of the immune
system, IMVT-1401 may offer a more targeted approach for reducing levels of the causative IgG species responsible for most cases of WAIHA. We believe this could provide a favorable therapeutic window and avoid the significant side effects associated
with less targeted immunosuppression. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Development plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2019, we submitted our IND to the FDA for WAIHA and, in December 2019, our IND was cleared for Phase 2 trial initiation. The ASCEND
WAIHA trial will explore the potential of IMVT-1401 to increase hemoglobin levels and assess the safety and tolerability of IMVT-1401 in this population. Subjects in this trial will be treated with one of two doses of IMVT-1401 (680 mg or 340 mg)
administered weekly by subcutaneous injection for 12 weeks. The primary endpoint of this trial is the proportion of responders, defined as subjects achieving a hemoglobin level of at least 10 g/dL and at least a 2 g/dL increase from baseline.
Secondary endpoints include change from baseline in other hematologic and chemistry parameters, time to response, patient reported outcome measures, total IgG antibodies and IgG antibodies by subclasses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ASCEND WAIHA trial is an open label design, so the program-wide pause in dosing resulted in this trial being suspended. During the fall of
2021, we plan to commence discussions with the FDA on re-initiating this study, incorporating safety considerations and risk management as well as additional dosing regimens. We anticipate re-initiating this study based on a favorable outcome from
these meetings late in the calendar year 2021 or early part of the calendar year 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IMVT-1401 for the Treatment of Thyroid Eye Disease </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>TED overview and limitations of current treatments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TED is an autoimmune inflammatory disorder that affects the muscles and other tissues around the eyes and can ultimately be sight-threatening.
TED has an estimated annual incidence of 16 in 100,000 women and 2.9 in 100,000 men in North America and Europe. The natural history of TED begins with an inflammatory phase lasting between six and 24 months. Treatment of patients with
immunosuppressive therapies during this active inflammatory phase can lead to reduction in symptoms and can alter the course of the disease. However, once the initial inflammatory phase is over, immunosuppressive therapies are ineffective and levels
of fibrosis that have developed as the result of acute inflammation are only reversible by surgery. We estimate that 15,000 to 20,000 patients in the United States have active inflammatory TED and are eligible for treatment. There are few treatment
options currently available for TED patients. As a first option, patients with active TED are treated with immunosuppressive therapy such as high doses of corticosteroids, typically administered intravenously or orally. Corticosteroids are not
effective in all patients, and approximately one-third of patients will relapse. This therapy is associated with an increased risk of acute and severe organ damage, bone thinning, weight gain, diabetes, hypertension, osteoporosis and depression. In
January 2020, the FDA approved Horizon Therapeutics&#146; Tepezza (teprotumumab), an anti-IGF-1R antibody, for the treatment of TED. Orbital radiation therapy may reduce the infiltration of lymphocytes and can be used in conjunction with
corticosteroids or immunosuppressive therapy. Similar to these anti-inflammatory and immunosuppressive drugs, radiation therapy is most effective in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">276 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the active stage of TED. Patients with moderate-to-severe active TED which is still in the active stage and who do not respond adequately to corticosteroids can be treated with cyclosporine or
mycophenolate mofetil, two broad immunosuppressive drugs. These powerful drugs are associated with numerous general immunosuppressive side effects as well as inherent toxicities, such as hypertension, kidney disease, and gastrointestinal toxicity.
Small case studies have identified Roche&#146;s Rituxan (rituximab) as an alternate way of inducing immunosuppression in patients with TED. However, rituximab is associated with the potential for serious side effects, such as infusion-related
reactions. Surgery is considered to be a treatment option in patients with a high Clinical Activity Score (&#147;CAS&#148;), a measure of disease activity in TED patients, who have been treated with corticosteroids or immunosuppressive therapy but
continue to have progressive disease. The goal of surgery is to reduce the pressure causing proptosis, reduced eye movement and loss of visual acuity. Due to its invasive nature, surgery is typically reserved for inactive disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that a therapy for TED focused on addressing the cause of the disease, namely the presence of autoimmune antibodies, represents an
attractive approach that has the potential to avoid many of the serious side effects of current therapies. Because the mode of action of IMVT-1401 is independent of the antigen recognized by the autoimmune antibodies, we believe that IMVT-1401 can
address TED that arises through any IgG autoantibody mechanism whether it be anti-TSHR, anti-IGF1R, or any other IgG autoantibodies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical data
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2020, we announced initial results from our ASCEND GO-1 trial, an open label single-arm Phase 2a clinical trial of IMVT-1401
in Canada in patients with TED. Subjects recruited for this trial have moderate-to-severe active TED with confirmed autoantibodies to TSHR. A total of seven subjects were dosed weekly with SC injections for six weeks. Subjects received a 680 mg dose
for the first two administrations of the study followed by a 340 mg dose for the final four administrations. The primary endpoints of this trial were safety and tolerability of IMVT-1401 over the six-week treatment period, as well as the change from
baseline in levels of anti-TSHR antibodies, total IgG antibodies and IgG antibodies by subclasses. Secondary clinical endpoints included mean changes in proptosis, or protrusion of the eyeball, the proptosis responder rate, defined as the percentage
of subjects with a greater than or equal to 2 mm reduction in proptosis in the study eye without deterioration in the fellow eye, PK and anti-drug antibodies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Trial Design of ASCEND GO-1 Trial </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g59s49.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All seven subjects completed the six-week treatment phase of the trial and entered the 12-week follow-up
phase. Mean reduction in total IgG levels from baseline to end of treatment was 65%. As evaluated at the end of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">277 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
treatment, four of seven subjects (57%) improved by <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>2 points on the CAS. Of six subjects with baseline diplopia, four subjects (67%) demonstrated
improvement in diplopia. Three of seven subjects (43%) were proptosis responders. The safety and tolerability profile observed was consistent with the prior Phase 1 trial of IMVT-1401 in 99 healthy volunteers; as previously disclosed, lipid levels
were not measured contemporaneously during the Phase 1 and ASCEND GO-1 Phase 2a clinical trials of IMVT-1401. Mean albumin reduction from baseline to end of treatment was 24%. All AEs were mild or moderate and there were no headaches reported. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2019, we initiated dosing in our ASCEND GO-2 trial, a randomized, masked, placebo-controlled Phase 2b clinical trial in 77 subjects
with moderate-to-severe active TED with confirmed autoantibodies to TSHR. The ASCEND GO-2 trial explored the potential of IMVT-1401 to improve proptosis and assesses the safety and tolerability of IMVT-1401 in this population. Subjects in this trial
were treated with one of three doses of IMVT-1401 (680 mg, 340 mg or 255 mg) or placebo administered weekly by subcutaneous injection for 12 weeks. The primary endpoints of this trial were the proptosis responder rate measured at week 13, defined as
the percentage of subjects with a greater than or equal to 2 mm reduction in proptosis in the study eye without deterioration in the fellow eye, and safety and tolerability. Secondary endpoints included the proptosis responder rate measured at weeks
2, 3, 4, 5, 6, 8, 10, 12, 14, 16 and 20, the proportion of subjects with a CAS of 0 or 1, the mean change from baseline in proptosis, CAS, diplopia, ophthalmic improvement and GO-QOL and PK, PD, defined as anti-TSHR antibodies and total IgG and IgG
antibodies by subclasses, and anti-drug antibodies. Exploratory endpoints included assessment of CT-measured muscle volume, fat volume, total orbital volume and proptosis, as well as multiple biomarkers including gene expression profiles,
pro-inflammatory markers and receptor occupancy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Trial Design of ASCEND GO-2 Trial </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g77d58.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our voluntary pause in dosing resulted in unblinding the ASCEND GO-2 trial. As a result, following the last
patient last visit of the post-treatment follow-up period, the ASCEND GO-2 trial was terminated. Treatment with IMVT-1401 reduced both IgG and disease specific pathogenic IgG over the 12-week treatment period. However, the efficacy results, based on
approximately half the anticipated number of subjects who had reached the week 13 primary efficacy analysis at the time of the termination of the trial, were inconclusive. The primary endpoint of the proportion of proptosis responders was not met,
and although not tested statistically, post hoc evaluation of other endpoints measured (CAS and diplopia scores) indicated the desired magnitude of treatment effect likely would not have been achieved. However, levels of IgG were reduced across
IMVT-1401 dosing groups, and analysis of the receptor occupancy data suggest binding of IMVT-1401 to the Fc receptor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">278 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Development plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional exploratory work on other disease biomarkers is under evaluation. Further discussions with external experts are ongoing to determine
whether a specific population can be identified to optimize the clinical performance of IMVT1401. Based on these analyses, we are likely to design another Phase 2 trial in TED or another thyroid-related disease as our next study in this therapeutic
area and initiate discussions with regulatory authorities before the end of the calendar year 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">279 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>Aruvant Overview </U></B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Overview: </U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Aruvant is developing <FONT STYLE="white-space:nowrap">ARU-1801</FONT> as a
<FONT STYLE="white-space:nowrap">one-time,</FONT> potentially curative gene therapy for the treatment of sickle cell disease (&#147;SCD&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Lead program:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">ARU-1801</FONT> is an <I>ex vivo</I> lentiviral gene therapy that contains a
proprietary <SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></SUP>-globin gene for a novel, highly potent variant of fetal hemoglobin (&#147;HbF&#148;) and has been observed in preliminary clinical
studies to engraft with only reduced intensity conditioning (&#147;RIC&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Disease overview: </U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">SCD results from a defect in the gene that encodes beta-globin, a component of hemoglobin, the protein that
carries oxygen in the blood. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The abnormal beta sickle globin can cause red blood cells to sickle, leading to obstruction of small blood
vessels, resulting in pain crises, progressive damage to bones, joints and major organs, and mortality in the <FONT STYLE="white-space:nowrap">mid-40s.</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">SCD is predominantly concentrated among individuals of African, Middle Eastern, South American and South Asian
descent. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An estimated 100,000 people in the U.S. and 125,000 people in the E.U. suffer from SCD, with approximately
100,000 of these patients experiencing severe disease. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Limitations of current treatments: </U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Common treatment for patients with SCD is the oral cytotoxic agent hydroxyurea which is required to be taken
daily. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For patients experiencing a vaso-occlusive crisis, only palliative therapy is currently available; treatment
typically consists of hydration, oxygenation and analgesia for pain often requiring intravenous or oral opioids. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">One potentially curative treatment available for patients with sickle cell disease is allogeneic hematopoietic
stem cell transplant, in which a patient&#146;s own bone marrow is replaced by that of a healthy donor. According to an analysis of data from the National Marrow Donor Program, fewer than 20% of sickle cell patients have a matched donor.
Additionally, allogeneic transplant comes with the risk of graft rejection and graft versus host disease. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Other gene therapies are in development as a potential cure; however, unlike
<FONT STYLE="white-space:nowrap">ARU-1801,</FONT> they require the use of myeloablative chemotherapy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Clinical data: </U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">All three study participants for whom sufficient <FONT STYLE="white-space:nowrap">follow-up</FONT> has been
completed have realized clinically meaningful reductions in disease burden, as seen with significant reductions in hospitalized VOEs and total VOEs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">These patients have experienced durable engraftment and improvement in SCD burden without the use of
myeloablative chemotherapy. Patient 3 has experienced potentially curative levels of HbF and has had complete resolution of vaso-occlusive events out to 12 months post-treatment. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Development plan and upcoming milestones: </U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are currently conducting the MOMENTUM Phase 1/2 study of <FONT STYLE="white-space:nowrap">ARU-1801</FONT> in
patients with severe sickle cell disease. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We expect to initiate a pivotal trial in the second half of 2022. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">280 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Roivant ownership: </U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As of March&nbsp;31, 2021, we own 88% of the issued and outstanding common shares of Aruvant and 80% on a Fully
Diluted basis. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Pipeline: </U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g40x97.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">ARU-1801</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ARU-1801</FONT> is an <I>ex vivo</I> gene therapy with the ability to engraft with only reduced intensity
conditioning (&#147;RIC&#148;). <FONT STYLE="white-space:nowrap">ARU-1801</FONT> uses a self-inactivating lentiviral vector that contains a proprietary
<SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></SUP>-globin gene for a novel, highly potent variant of fetal hemoglobin (HbF): HbF<SUP STYLE="font-size:85%; vertical-align:top">G16D</SUP>. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g42i82.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HbF is a more potent anti-sickling globin compared to adult hemoglobin (&#147;HbA&#148;), with mechanistic and clinical
benefits observed in SCD, which makes it suitable for the treatment of SCD. HbF disrupts both axial and lateral contacts that cause polymerization of sickle hemoglobin (&#147;HbS&#148;) polymers, and has an approximately 1.5 times higher affinity
for oxygen than HbA. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g19q45.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical benefits of increasing HbF have been well-described in scientific literature. HbF levels
greater than 8.6% improve survival by approximately 16 years in patients with SCD. HbF levels greater than 20% reduce </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">281 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
hospitalizations by two to four-fold for vaso-occlusive events and acute chest syndrome. Further, HbF levels greater than 30% result in asymptomatic disease and patients do not develop sickle
cell complications, as demonstrated in patients with SCD who also inherit Hereditary Persistence of Fetal Hemoglobin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">ARU-1801</FONT> originated in the laboratory of Punam Malik, MD, director of the Cincinnati Comprehensive Sickle Cell Center at Cincinnati Children&#146;s Hospital Medical Center (&#147;Cincinnati Children&#146;s&#148;).
Dr.&nbsp;Malik previously served as the director of the Cincinnati Children&#146;s Translational Core Services, which developed and manufactured viral vectors for multiple clinical trials. A leading expert in lentiviral gene therapy, stem cell
biology and clinical care of hemoglobinopathies, Dr.&nbsp;Malik remains a key scientific advisor to Aruvant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Potential benefits of <FONT
STYLE="white-space:nowrap">ARU-1801</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are several unique attributes of <FONT STYLE="white-space:nowrap">ARU-1801</FONT>
that we believe enable the use of reduced intensity conditioning for engraftment, and potential clinical efficacy at lower vector copy number (&#147;VCN&#148;). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Proprietary G16D modification drives higher HbF payload per vector copy.</I></B> A proprietary G16D point
mutation that changes glycine (G)&nbsp;at position 16 to aspartic acid (D)&nbsp;drives higher HbF payload per vector copy. <SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></SUP>-globin<SUP
STYLE="font-size:85%; vertical-align:top">G16D </SUP>has a higher affinity for <FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>-globin and is thus more likely to form HbF, as compared to unmodified <SUP STYLE="font-size:85%; vertical-align:top"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></SUP>-globin. In well- established SCD mouse models, vector encoding <SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></SUP>-globin<SUP
STYLE="font-size:85%; vertical-align:top">G16D </SUP>led to 1.5x to 2x more HbF per vector than vector encoding unmodified <SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></SUP>-globin.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g19f83.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">282 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>High HbF</I></B><B><I><SUP STYLE="font-size:85%; vertical-align:top">G16D</SUP></I></B><B><I> payload may
have a more potent clinical anti-sickling effect than endogenous HbF.</I></B> HbF<SUP STYLE="font-size:85%; vertical-align:top">G16D</SUP> may have a more potent anti-sickling effect than endogenous HbF. In preclinical studies, a lower percentage of
reticulocytes indicates less sickling and hemolysis. At the same level percentage of HbF, highlighted below, HbF<SUP STYLE="font-size:85%; vertical-align:top">G16D</SUP> is superior to endogenous HbF at reducing reticulocyte count.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Hemolysis in SCD mice </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g34f97.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Our proprietary stemness enhancer facilitates engraftment</I></B><B>.</B> Our cellular manufacturing
process leverages a proprietary stemness enhancer to facilitate the transduction and engraftment of more true stem cells. Stemness enhancers allow for a higher chance of engraftment for a given VCN compared to engraftment without a stemness
enhancer, as illustrated below. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g86u75.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Ability to engraft using only reduced intensity conditioning</I></B>. In preliminary clinical studies, <FONT
STYLE="white-space:nowrap">ARU-1801</FONT> demonstrated engraftment and the ability to deliver potentially curative treatment without fully myeloablative chemotherapy. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">We believe that the RIC regimen used for <FONT STYLE="white-space:nowrap">ARU-1801,</FONT> melphalan 140mg/m<SUP
STYLE="font-size:85%; vertical-align:top">2</SUP>, may provide significant clinical benefits compared to the higher intensity myeloablative busulfan-based regimen used by the other investigational SCD gene therapy candidates, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced duration of neutropenia and thrombocytopenia; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">283 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential for outpatient administration, which would significantly reduce resource utilization in the health care
setting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced intensity conditioning with melphalan for autologous transplants has required a median hospital stay
between zero and five days within 30 days of infusion, which represents a significant improvement in both patient experience and reduction in health care cost compared to myeloablative conditioning regimens that require a median hospital stay of 44
days; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced likelihood to result in infertility, with a risk of ovarian failure around
<FONT STYLE="white-space:nowrap">30-40%</FONT> compared to <FONT STYLE="white-space:nowrap">70-80%</FONT> with myeloablative regimens. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">High-intensity myeloablative conditioning regimens have been associated with increased risk of malignancy. The reduced intensity conditioning
melphalan-based conditioning regimens for autologous transplants in the setting of multiple myeloma have been associated with a 0.2% risk of AML and a 1-1.4% combined risk of AML and other secondary hematologic malignancies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARU-1801 with reduced intensity conditioning (melphalan 140mg/m2) has the potential to provide benefit to patients, providers and payors
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g90l00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Table reflects combination of gene therapy protocols, reported results from gene therapy trials, and literature on the use
of these conditioning agents in other settings. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">*Dose adjusted to a targeted AUC for busulfan of 4200 &micro;M*min. 1. bluebird bio ASGCT 2020. Resolution
of Sickle Cell Disease (SCD) Manifestations in Patients Treated with LentiGlobin Gene Therapy: Updated Results of Phase 1/2 <FONT STYLE="white-space:nowrap">HGB-206</FONT> Group C Study. 2. Based on data from 3
<FONT STYLE="white-space:nowrap">ARU-1801</FONT> patients. 3. Busulfan label; seizure prophylaxis required but not with phenytoin due to PK interaction with busulfan. 4. ALKERAN label. 5. Estimated based on Kaplan-Meier plot in post-pubescent female
children based on time to elevated FSH level with up to 8 years follow up (Panasuik et al. BJH 2015). 6. ZYNTEGLO EPAR. 7. Boston Medical Center. B Freeman et al. (2014)&nbsp;Bone Marrow Transplantation and Guru Murthy GS et al. (2019)&nbsp;Biol.
Blood Marrow Transplant; outpatient autologous HSCT are already performed for multiple myeloma and AL amyloidosis 8. Rescue cell collection required per bluebird bio protocol. 9. Based on Aruvant protocol. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">ARU-1801</FONT> for the Treatment of SCD </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sickle cell disease and limitations of current treatments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SCD results from a defect in the gene that encodes beta-globin, a component of hemoglobin, the protein that carries oxygen in the blood.<B>
</B>A proportion of sickled cells rising relative to <FONT STYLE="white-space:nowrap">non-sickled</FONT> cells can obstruct small blood vessels and reduce blood flow to bones, joints and major organs. This obstruction can cause intense pain and
lasting tissue damage. Patients can suffer additional complications such as stroke and frequent infections because of inadequate oxygen delivery to the brain and spleen.<B> </B>Over time repeated tissue damage leads to a loss of vital organ function
and a vastly reduced life expectancy; mean age of death in the US for patients with sickle cell disease is 44 years.<B> </B>SCD is predominantly concentrated among individuals of African, Middle Eastern, South American and South Asian descent. An
estimated 100,000 people in the U.S. and 125,000 people in the E.U. suffer from SCD, with approximately 100,000 patients experiencing severe disease. Based on a survey of over </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">284 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
100 physicians conducted in 2020, we believe approximately 15% of those patients, or approximately 35,000 in the U.S. and E.U., meet the inclusion/exclusion criteria for SCD gene therapy trials.
Market research suggests that use of busulfan conditioning is a major barrier to adoption, restricting patient groups eligible or willing to receive treatment. The same survey of physicians suggests that of the patients who meet the
inclusion/exclusion criteria for SCD gene therapy, 49% would be eligible for myeloablative gene therapy, versus 70% that would be eligible for gene therapy with a reduced intensity conditioning regimen. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The oral cytotoxic agent hydroxyurea is a mainstay in the overall management of individuals with SCD since it reduces the incidence of
vaso-occlusive crises, decreases hospitalization rates, and prolongs survival. However, its use is significantly limited by its side effect profile, variable patient response and long-term toxicity. For patients experiencing a vaso-occlusive crisis,
only palliative therapy is currently available; treatment typically consists of hydration, oxygenation and analgesia for pain, usually using intravenous or oral opioids. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2019, the FDA approved ADAKVEO to reduce the frequency of vaso-occlusive crises in adults and pediatric patients aged 16 years and
older with SCD. In November 2019, the FDA also approved Oxbryta for the treatment of SCD in adults and pediatric patients aged 12 years and older. Oxbryta is a once-daily oral therapy that inhibits sickle hemoglobin polymerization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One curative treatment available for some patients with SCD is allogeneic hematopoietic stem cell transplant (&#147;HSCT&#148;), in which a
patient&#146;s own bone marrow is replaced by that of a healthy donor. However, it requires identification of a suitable donor and carries significant morbidity and mortality risks, including an approximately 7% mortality rate. Ideal sibling matches
are only available to approximately 14% of patients. Furthermore, according to the Center for International Blood and Marrow Transplant Research, only 737 HSCTs were performed for the treatment of SCD in the U.S. between 2013 and 2017, highlighting
the need to bring alternative curative therapies to the remainder of the estimated 100,000 patients in the U.S. as well as the millions of patients worldwide. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical data </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently
conducting the MOMENTUM Phase 1/2 study of <FONT STYLE="white-space:nowrap">ARU-1801</FONT> in patients with severe SCD. Eligible patients include those between the age of <FONT STYLE="white-space:nowrap">18-45</FONT> that have failed hydroxyurea
and are not candidates for allogeneic transplant. After enrollment, patients are transfused to reduce HbS below 30%, stem cells are collected, and patients receive RIC consisting of a single dose of melphalan 140 mg/m<SUP
STYLE="font-size:85%; vertical-align:top">2</SUP>. <FONT STYLE="white-space:nowrap">ARU-1801</FONT> is manufactured in a <FONT STYLE="white-space:nowrap">two-day</FONT> period and administered via intravenous infusion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">285 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have collected data on three patients. Patient 1 and Patient 2 were treated in
July 2017 and November 2017, respectively, under our first manufacturing process (&#147;Process I&#148;). Since our first two patients were dosed, we have completed several improvements to our cell collection methods and transduction conditions as
part of our transition to new manufacturing process (&#147;Process II&#148;). Below are the results from all three patients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">ARU-1801:</FONT> Hemoglobin Levels over Time </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g48y51.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ARU-1801</FONT> has demonstrated durable engraftment through 36 months and
potentially curative HbF levels, without the use of myeloablative chemotherapy. Patient 1 has demonstrated durable engraftment through 36 months, with high, stable levels of anti-sickling hemoglobin and HbF<SUP
STYLE="font-size:85%; vertical-align:top">G16D</SUP>. Patient 2 has demonstrated durable total anti-sickling Hb levels through 30 months. Patient 3, the first patient treated under Process II, has achieved the highest levels of HbF<SUP
STYLE="font-size:85%; vertical-align:top">G16D</SUP>, total HbF and total anti-sickling globins, which already exceed the 30% threshold required for complete symptom resolution. At 12 months post-dosing, Patient 3 has 38% total HbF expression and
96% F cells, a pancellular distribution of HbF. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the durable engraftment and potentially curative HbF levels observed, all
patients have realized clinically meaningful reductions in disease burden, as seen with significant reductions in hospitalized VOEs and total VOEs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">ARU-1801:</FONT> Reduction in VOEs </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g29a02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our process improvements have resulted in a significantly improved drug product profile, with improvement
across multiple metrics. Patient 1 had maintained a consistent peripheral VCN of approximately 0.2 out to 36 months, as of August 2020. Patient 3, the first patient dosed with Process II, has plateaued at a peripheral VCN of 0.7 and has demonstrated
the strongest engraftment through 12 months. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">286 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Durable Engraftment Post Treatment </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g02u44.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A comparison of all three patients at post-treatment highlights the improvements observed with Process II.
At 12 months, Patient 3 achieved the highest levels of HbF<SUP STYLE="font-size:85%; vertical-align:top">G16D</SUP> and total HbF, both as a percentage and in absolute levels, and achieved pancellular distribution of HbF. At 12 months, HbF was
detected in 96% of Patient 3&#146;s blood cells. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Process II Results in Significantly Improved Drug Product Profile </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g24x49.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Vector copy number; Hb electrophoresis monitored monthly in Year 1. F-cells and F-retics are collected at 6
months and 12 months post-infusion; DP = drug product, PB = peripheral blood. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">287 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ARU-1801</FONT> was generally well tolerated, with no <FONT
STYLE="white-space:nowrap">ARU-1801</FONT> or chemotherapy related serious adverse events reported to date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Adverse Events </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="23%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1px solid #000000"><B>Patient 1</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1px solid #000000"><B>Patient 2</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1px solid #000000"><B>Patient 3</B></TD></TR>
<TR STYLE="font-size:1pt" BGCOLOR="#f2f2f2">
<TD HEIGHT="1" COLSPAN="7" STYLE="BORDER-LEFT:1px solid #bfbfbf; padding-left:8pt">&nbsp;</TD></TR>
<TR BGCOLOR="#f2f2f2" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="7" STYLE="BORDER-LEFT:1px solid #bfbfbf; BORDER-BOTTOM:1px solid #000000; padding-left:8pt; padding-right:2pt"><B><FONT STYLE="white-space:nowrap">ARU-1801</FONT> Related</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:4pt ;BORDER-LEFT:1px solid #bfbfbf; BORDER-BOTTOM:1px solid #bfbfbf; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;Infusion AEs</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #bfbfbf; BORDER-BOTTOM:1px solid #bfbfbf">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:4pt ;BORDER-BOTTOM:1px solid #bfbfbf">None</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #bfbfbf; BORDER-BOTTOM:1px solid #bfbfbf">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:4pt ;BORDER-BOTTOM:1px solid #bfbfbf">None</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #bfbfbf; BORDER-BOTTOM:1px solid #bfbfbf">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:4pt ;BORDER-RIGHT:1px solid #bfbfbf; BORDER-BOTTOM:1px solid #bfbfbf; padding-right:2pt">None</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:4pt ;BORDER-LEFT:1px solid #bfbfbf; BORDER-BOTTOM:1px solid #bfbfbf; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;Late AEs</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #bfbfbf; BORDER-BOTTOM:1px solid #bfbfbf">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:4pt ;BORDER-BOTTOM:1px solid #bfbfbf">None&nbsp;to&nbsp;date&nbsp;(at&nbsp;36&nbsp;months)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #bfbfbf; BORDER-BOTTOM:1px solid #bfbfbf">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:4pt ;BORDER-BOTTOM:1px solid #bfbfbf">None&nbsp;to&nbsp;date&nbsp;(at&nbsp;36&nbsp;months)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #bfbfbf; BORDER-BOTTOM:1px solid #bfbfbf">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:4pt ;BORDER-RIGHT:1px solid #bfbfbf; BORDER-BOTTOM:1px solid #bfbfbf; padding-right:2pt">None&nbsp;to&nbsp;date&nbsp;(at&nbsp;12&nbsp;months)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:4pt ;BORDER-LEFT:1px solid #bfbfbf; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;Vector
insertion</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #bfbfbf">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" NOWRAP ALIGN="center" STYLE="padding-bottom:4pt ;BORDER-RIGHT:1px solid #bfbfbf; padding-right:2pt">Polyclonal engraftment with no evidence of clonal expansion</TD></TR>
<TR STYLE="font-size:1pt" BGCOLOR="#f2f2f2">
<TD HEIGHT="1" COLSPAN="7" STYLE="BORDER-LEFT:1px solid #bfbfbf; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #bfbfbf; padding-left:8pt">&nbsp;</TD></TR>
<TR BGCOLOR="#f2f2f2" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7" STYLE="BORDER-LEFT:1px solid #bfbfbf; BORDER-RIGHT:1px solid #bfbfbf; BORDER-BOTTOM:1px solid #000000; padding-left:8pt; padding-right:2pt"><B>Chemotherapy Related</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:4pt ;BORDER-LEFT:1px solid #bfbfbf; BORDER-BOTTOM:1px solid #bfbfbf; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;Serious</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #bfbfbf; BORDER-BOTTOM:1px solid #bfbfbf">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:4pt ;BORDER-BOTTOM:1px solid #bfbfbf">None</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #bfbfbf; BORDER-BOTTOM:1px solid #bfbfbf">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:4pt ;BORDER-BOTTOM:1px solid #bfbfbf">None</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #bfbfbf; BORDER-BOTTOM:1px solid #bfbfbf">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:4pt ;BORDER-RIGHT:1px solid #bfbfbf; BORDER-BOTTOM:1px solid #bfbfbf; padding-right:2pt">None</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:4pt ;BORDER-LEFT:1px solid #bfbfbf; BORDER-BOTTOM:1px solid #bfbfbf; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">&nbsp;Non-serious</FONT></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #bfbfbf; BORDER-BOTTOM:1px solid #bfbfbf">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:4pt ;BORDER-BOTTOM:1px solid #bfbfbf">Cytopenias, mucositis, nausea,&nbsp; vomiting, cellulitis, elevated RFT&nbsp;<BR>and LFTs, alopecia&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #bfbfbf; BORDER-BOTTOM:1px solid #bfbfbf">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:4pt ;BORDER-BOTTOM:1px solid #bfbfbf">Cytopenias, mucositis, <FONT STYLE="white-space:nowrap">c-line</FONT> infection, elevated LFTs</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #bfbfbf; BORDER-BOTTOM:1px solid #bfbfbf">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:4pt ;BORDER-RIGHT:1px solid #bfbfbf; BORDER-BOTTOM:1px solid #bfbfbf; padding-right:2pt">Cytopenias, mucositis, nausea, vomiting, febrile neutropenia, alopecia</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are also several CMC process improvements scheduled for the second half of 2021 to prepare for
commercial supply, as shown below. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g49g49.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Development plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are continuing to screen additional patients who may be eligible for <FONT STYLE="white-space:nowrap">ARU-1801</FONT> and gathering <FONT
STYLE="white-space:nowrap">follow-up</FONT> data on our patients dosed to date, and we expect to share new patient and <FONT STYLE="white-space:nowrap">follow-up</FONT> data from five total patients by
<FONT STYLE="white-space:nowrap">year-end</FONT> 2021. We also continue to evolve our manufacturing process to improve product VCNs in preparation for our pivotal trial of <FONT STYLE="white-space:nowrap">ARU-1801</FONT> in SCD, which we expect to
initiate in the second half of 2022. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">ARU-2801</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also developing ARU-2801, a preclinical adeno-associated virus (&#147;AAV&#148;) gene therapy designed to deliver potentially curative
efficacy without chronic administration for patients with hypophosphatasia (&#147;HPP&#148;). This devastating, ultra-orphan disorder can result in multi-organ damage and high mortality when left untreated. HPP is caused by mutations in the gene
encoding the tissue non-specific alkaline phosphatase (&#147;TNS-ALP&#148;) enzyme and is wide-ranging in severity. This genetic and chronic disease is most often characterized by limited hydroxyapatite formation resulting in limited bone
mineralization that can lead to destruction and deformity of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">288 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
bones, profound muscle weakness, seizures, respiratory failure and premature death. There are five types of HPP, including perinatal, infantile, childhood, adult and odontohypophosphatasia. There
is currently an approved chronic therapy available for perinatal, infantile and juvenile-onset HPP, the enzyme replacement therapy Strensiq. Chronic administration, injection site reactions, and poor durability of Strensiq leave high unmet need that
we believe ARU-2801 could potentially address. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical research shows that treatment of HPP disease model mice with ARU-2801 results
in sustained elevation of TNS-ALP at levels that ameliorated disease symptoms. In a murine model of HPP, ARU-2801 resulted in durable, high levels of ALP and survival to 18 months, as shown below. There was no evidence of ectopic calcifications at
these therapeutic doses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>High ALP levels in HPP murine model (Akp2-/-) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g75y58.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Durable 18-month OS of 70% in HPP murine model (Akp2-/-) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g22m63.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investigational new drug application-enabling studies are currently underway. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">289 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>Discovery Pipeline</U> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g78m56.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Proteovant logo indicates that Proteovant, which is 60% owned by Roivant, has rights to a program for that target or has
initiated discovery projects for that project. Roivant logo indicates other 100% Roivant owned entities have rights to a program for that target or have initiated discovery projects for that target. Degraders designated in purple text. Inhibitors
designated in green text. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AR Degrader </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead degrader candidate, <FONT STYLE="white-space:nowrap">ARD-1671,</FONT> is an orally-administered androgen receptor (&#147;AR&#148;)
protein degrader currently undergoing <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. <FONT STYLE="white-space:nowrap">ARD-1671</FONT> is designed to shut down the AR pathway by targeting and degrading the AR protein, the primary
driver of prostate cancer. Based on its <I>in vitro</I> potency and selectivity, as well as its encouraging safety and tolerability demonstrated to date in canine and rat <FONT STYLE="white-space:nowrap">non-GLP</FONT> dose range finding studies
described below, we believe <FONT STYLE="white-space:nowrap">ARD-1671</FONT> has the potential to provide meaningful clinical benefit to prostate cancer patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Prostate cancer overview </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prostate cancer
is the second most common form of cancer in men, with nearly 200,000 annual new cases in the US alone. Additionally, with over 30,000 annual U.S. deaths, prostate cancer is the second most common cause of cancer death in the US. Prostate cancer
occurs more frequently in older men and is associated with various other risk factors, including a family history of prostate, breast, or ovarian cancer, <FONT STYLE="white-space:nowrap">high-fat</FONT> diets or obesity, smoking and maintenance of a
sedentary lifestyle. While prostate cancer can be slow-growing, such that some men die of other causes before their cancer, many patients experience metastases to other parts of the body. Prostate cancer that continues to progress following androgen
deprivation therapy (&#147;ADT&#148;) is considered to be castration-resistant. It is estimated that over 40,000 cases of metastatic castration-resistant prostate cancer (&#147;mCRPC&#148;) occur annually in the US, with over 20% of all prostate
cancer deaths occurring in men with mCRPC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The AR signaling axis is critical to the development, function and homeostasis of the normal
prostate. After binding androgen, cytoplasmic AR translocates to the nucleus, where it activates transcription of target genes. The AR also plays a role in prostate carcinogenesis and progression to androgen-resistant disease and is expressed in
nearly all primary prostate cancers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">290 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Limitations of current treatments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current prostate cancer treatment paradigm involves the use of <FONT STYLE="white-space:nowrap">AR-targeted</FONT> therapies throughout the
progression of the disease. For more advanced forms of prostate cancer, ADT is one of the primary treatment options. Among the most common ADTs are AR antagonists such as Xtandi (enzalutamide), which functions by blocking AR, and androgen synthesis
inhibitors, including Zytiga (abiraterone acetate). While these treatments have been successful in improving patient outcomes, resistance remains a major concern. At least 10% of patients whose disease has spread beyond the prostate on first-line
ADT do not experience suppression of prostate-specific antigen (&#147;PSA&#148;), an <FONT STYLE="white-space:nowrap">AR-regulated</FONT> gene. Additionally, while dramatic initial responses to ADT are often observed, these responses are often not
sustained, with median duration of response of up to 18 months, and virtually all patients treated with ADTs ultimately progressing to castration resistance. For patients who do not respond, chemotherapy is often chosen as the next line of
treatment, although its use is often postponed due to its severe side effects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of patients with mCRPC, including those whose cancer
progresses following treatment with androgen receptor signaling inhibitors, between 40% and 50% have alterations involving the AR, suggesting that their tumors may still be driven by AR signaling. Furthermore, progressive disease experienced by
patients while undergoing treatment with Xtandi or Zytiga is often accompanied by increase in serum PSA, further suggesting continued <FONT STYLE="white-space:nowrap">AR-driven</FONT> cellular proliferation. We believe that AR degraders have the
potential to improve the response rates and durability achieved with existing AR antagonists and inhibitors by degrading the AR, thereby fully shutting down the AR pathway, both in refractory and earlier-line prostate cancer patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical data </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In preclinical testing,
<FONT STYLE="white-space:nowrap">ARD-1671</FONT> has demonstrated high potency and selectivity and has produced encouraging tolerability data in toxicology studies completed to date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ARD-1671</FONT> has shown <I>in vitro </I>activity in wild type AR as well as multiple clinically relevant AR
cell lines with known mutations. The table below shows the DC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB>, or the concentration at which half-maximal degradation is achieved at 24 hours, of
<FONT STYLE="white-space:nowrap">ARD-1671</FONT> in four different cell lines: vertebral cancer of the prostate (&#147;VCaP&#148;), which exhibits wild-type AR; and three cell lines exhibiting mutant AR: lymph node cancer of the prostate
(&#147;LNCaP&#148;), 22RV1 and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">MDA-PCa-2b.</FONT></FONT> Each of these cell lines are well defined populations of cells that have been immortalized from human prostate cancer
patients. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="29%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cell Line</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>AR Variant</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB>&nbsp;(nM)</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">VCaP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Wild&nbsp;type</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0.05</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">LNCaP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">T878A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0.082</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">22RV1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">H875Y</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0.9</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">MDA-PCa-2b</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">L702H/T878A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">6</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">291 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The western blots below demonstrate <FONT STYLE="white-space:nowrap">ARD-1671&#146;s</FONT>
degradation ability in each of these cell lines. As the concentration of <FONT STYLE="white-space:nowrap">ARD-1671</FONT> increases to the right across each blot, the presence of AR, as indicated by the size and opacity of each band, decreases. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g12a21.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> study
with an intact VCaP xenograft model in severe combined immunodeficient (&#147;SCID&#148;) mice, which has high AR expression and in which enzalutamide is inactive, <FONT STYLE="white-space:nowrap">ARD-1671</FONT> demonstrated tumor growth inhibition
(64%) compared to enzlutamide <FONT STYLE="white-space:nowrap">(-1%)</FONT> on treatment day 25. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Antitumor Activity in VCaP </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Xenograft Tumor Model </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g74i25.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a <FONT STYLE="white-space:nowrap">21-day</FONT> <FONT STYLE="white-space:nowrap">non-GLP</FONT> dose
range finding canine study, maximal prostate weight reduction was achieved at the lowest dose of 1 mg/kg, consistent with the expected pharmacodynamic effect. No significant adverse events were observed at dose levels up to 10 mg/kg. In a <FONT
STYLE="white-space:nowrap">21-day</FONT> <FONT STYLE="white-space:nowrap">non-GLP</FONT> dose range finding rat study, no significant adverse events were observed at dose levels up to 300 mg/kg and prostate weight reduction was also attained. These
results indicate that <FONT STYLE="white-space:nowrap">ARD-1671</FONT> may have a wide therapeutic window, which is currently being assessed in GLP toxicology studies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">292 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Development plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead AR candidate <FONT STYLE="white-space:nowrap">ARD-1671</FONT> is in IND enabling development. We intend to pursue the development of
our AR program in refractory prostate cancer and to explore its potential in early-line settings, such as mCRPC or <FONT STYLE="white-space:nowrap">non-metastatic</FONT> castration-resistant prostate cancer, as well as in a combination therapy. We
expect to initiate a Phase 1 study for our AR program in 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>STAT3 Degrader </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing signal transducer and activator of transcription 3 (&#147;STAT3&#148;) degraders for the treatment of STAT3-driven
hematologic malignancies and immuno-oncology indications. Due to potency and selectivity challenges, STAT3 has traditionally been considered to lack an easily druggable pocket. We believe that preclinical data we have generated to date suggest the
potential of STAT3 degraders to overcome these challenges. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>STAT3-Implicated diseases </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">STAT3 is a transcription factor that regulates many biological processes and has been implicated as a direct driver of multiple tumor types.
STAT3 controls, among other processes, differentiation, survival, proliferation and angiogenesis, typically in response to growth factors and cytokines. Activation of STAT3 normally involves Janus kinase (JAK)-mediated phosphorylation and
dimerization of STAT3 following binding of <FONT STYLE="white-space:nowrap">IL-6</FONT> to its receptor. Aberrant constitutive activation of STAT3 has been observed in many different cancers and has been associated with poor prognosis and tumor
progression. STAT3 activation is also reported as a mechanism of resistance to inhibitors of the receptor tyrosine kinases EGFR and ALK. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">STAT3 contributes to an immunosuppressive microenvironment (&#147;TME&#148;), suggesting STAT3 degraders have significant potential as
immune-oncology agents. Phosphorylated STAT3 (&#147;pSTAT3&#148;) acts to negatively regulate neutrophils, natural killer, effector T and dendritic cells. STAT3 also promotes myeloid-derived suppressor cells (&#147;MDSCs&#148;) and regulatory T
cells and has been shown to mediate the <FONT STYLE="white-space:nowrap">up-regulation</FONT> of immunosuppressive factors such as <FONT STYLE="white-space:nowrap">IL-10</FONT> and <FONT STYLE="white-space:nowrap">TGF-&szlig;.</FONT> Additionally, a
STAT3 antisense oligonucleotide inhibitor demonstrated early evidence of clinical activity in lymphoma and lung cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given the broad
activity of STAT3, we believe a STAT3 degrader has significant potential in numerous solid tumors and hematologic malignancies, including <FONT STYLE="white-space:nowrap">non-Hodgkin</FONT> lymphoma, multiple myeloma, and breast, lung,
hepatocellular and head and neck cancer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Limitations of current STAT3 approaches </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to STAT3&#146;s lack of an easily druggable pocket, previous attempts to target STAT3 have been largely unsuccessful. One common approach,
inhibition of dimerization with small molecules targeting the SH2 domain of STAT3, has been limited by the transcriptional activity of monomeric STAT3 and by specificity challenges due to the high homology of SH2 domains across STAT proteins.
Another common approach, attempting to regulate STAT3 via inhibition of JAK, which is upstream of STAT3, has demonstrated significant <FONT STYLE="white-space:nowrap">off-target</FONT> effects and STAT3 activation and homodimerization can occur
independently of JAK. A third common approach, the use of STAT3 antisense oligonucleotides, has been limited by low cell penetration due to large size, low bioavailability and poor pharmacokinetics, and short half-life <I>in vivo</I>. We believe
that the degrader modality has the potential to address many of the historical challenges associated with STAT3 targeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical data </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our STAT3 degrader discovery program has identified a lead compound, <FONT STYLE="white-space:nowrap">SD-436,</FONT> that potently and rapidly
degrades the target with high specificity with respect to degradation of other STAT proteins. <FONT STYLE="white-space:nowrap">SD-436</FONT> exhibits </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">293 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
promising potency against wild type STAT3 in human peripheral blood mononuclear cells (&#147;PBMCs&#148;) as well as a mutated STAT3 protein (K658R) in the Pfeiffer cell line, with degradation
achieved at low nM concentrations. Furthermore, in an unbiased proteomics analysis in which megakaryoblastic leukemia cell line <FONT STYLE="white-space:nowrap">MOLM-16</FONT> cells were treated with <FONT STYLE="white-space:nowrap">SD-436,</FONT>
STAT3 was the only protein observed to be degraded with statistical significance among the approximately 5,000 proteins analyzed, indicating <FONT STYLE="white-space:nowrap">SD-436&#146;s</FONT> high specificity. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g75k22.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a leukemia xenograft tumor model with an activated STAT3 pathway, IV administration of <FONT
STYLE="white-space:nowrap">SD-436</FONT> resulted in deep reductions in tumor volume. The lowest dose tested, 5 mg/kg weekly, achieved rapid and complete tumor regression. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Effect of IV <FONT STYLE="white-space:nowrap">SD-436</FONT> on Tumor Volume in MOLM16 Xenograft Model </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g48r17.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Development plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to explore the potential use of a STAT3 degrader as monotherapy, combination therapy, or, in sequence with chemotherapy or radiation,
in tumors that are driven by the STAT3 pathway. In addition, we are exploring the potential for the STAT3 degrader as a potentially important immuno-oncology program both alone and in combination studies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">294 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Discovery Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to AR and STAT3, we are pursuing numerous additional targets with strong scientific rationale and potentially attractive market
opportunities. We do not expect to ultimately advance programs for all of these targets into clinical development. We are also discovering drug candidates for additional undisclosed targets and plan to continue to add new discovery programs over
time. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>
<TR STYLE="font-size:1pt" BGCOLOR="#2d1e3d">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1.50pt solid #ffffff; BORDER-RIGHT:1.50pt solid #ffffff">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#2d1e3d" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:2pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ffffff"><B>Target &amp;</B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ffffff"><B>MoA</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #ffffff">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:2pt ;BORDER-RIGHT:1.50pt solid #ffffff"><FONT COLOR="#ffffff"><B>Opportunity Profile</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:2pt ;"><FONT COLOR="#ffffff"><B>Potential Indications/Patient Populations</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center"><B>BRD4<BR>Degrader</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Specific degrader of BRD4, an epigenetic reader and transcriptional
regulator</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Aim to
significantly improve efficacy compared to BETi by fully abrogating BRD4 function</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Myelofibrosis (treatment-na&iuml;ve and Jakafi-experienced)</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Other hematologic
malignancies</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center"><B>CBP/P300 Degrader</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;CBP/P300 control expression of oncogenic factors (e.g., AR, c-Myc) in
prostate cancer</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Synthetic
lethality target (LOF mutations) with precision medicine approach</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;AR+ prostate cancer (including AR mutants and splice variant subsets),
tumors with CBP or P300 LOF (e.g., DLBCL, FL, NSCLC, bladder cancer)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center"><B>SHP2<BR>Degrader</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Difficult-to-drug protein tyrosine phosphatase and central node downstream of
RTKs</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Precision medicine
and I/O opportunities with mono and combination therapy</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Broad potential application across a variety of solid tumors</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Combination opportunities
with EGFR inhibitors, KRAS inhibitors and anti-PD1s</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center"><B>SMARCA2/4 Degrader</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Synthetic lethality target in multiple tumor types (e.g., SMARCA4
LOF)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;SMARCA4-mutated NSCLC (~10% of NSCLC overall)</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Tumor agonistic indication:
SMARCA4-mutated solid tumors</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center"><B>KRAS G12D Degrader</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Historically undruggable oncogene variant G12D</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Most frequently mutated
oncogene in human cancers</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;KRAS G12D mutant tumors</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Highest rates in PDAC, CRC,
endometrial and lung cancer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center"><B>mHTT<BR>Degrader</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;<B></B>Neurodegenerative disease target characterized by CAG repeats and
toxic mHTT protein aggregation; no approved therapies known to reduce level of toxic mHTT</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Huntington&#146;s disease</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center"><B>NLRP3 Degrader</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;<B></B>Inflammasome; innate immune pathway target; central regulator of
IL-1&szlig; and IL-18 cytokine secretion</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Drives inflammation across a broad range of chronic disorders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Autoimmune and inflammatory diseases such as Cryoporin-associated periodic
syndromes (CAPS), gout, SLE, IBD, Behcet&#146;s, and asthma</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">295 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>

<TR STYLE="font-size:1pt" BGCOLOR="#2d1e3d">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1.50pt solid #ffffff; BORDER-RIGHT:1.50pt solid #ffffff">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#2d1e3d" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:2pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ffffff"><B>Target &amp;</B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ffffff"><B>MoA</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #ffffff">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:2pt ;BORDER-RIGHT:1.50pt solid #ffffff"><FONT COLOR="#ffffff"><B>Opportunity Profile</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:2pt ;"><FONT COLOR="#ffffff"><B>Potential Indications/Patient Populations</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center"><B>ADAR1 Inhibitor</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;<B></B>Intracellular innate immune checkpoint target and biomarker defined tumor cell
dependency</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Potential to
overcome PD1/PDL1 resistance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Type I IFN-high solid tumors including lung, colon, breast,
ovarian</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center"><B>WRN<BR>Inhibitor</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;<B></B>Synthetic lethal target required in tumors with DNA damage repair
deficiency</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;MSI colorectal and gastric cancers</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;PARP inhibitor
combinations</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center"><B>JAK2-617F Inhibitor</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;<B></B>Potential for precision medicine approach</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Selective for mutants of
blood neoplasm driver</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;V617F driven myeloproliferative neoplasms: polycythemia vera, essential
thrombocythemia, primary myelofibrosis and AML</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center"><B>CRAF<BR>Inhibitor</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;<B></B>Synthetic lethal target required in KRAS and NRAS mutant tumors</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;CRAF mutant tumors</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;NRAS mutant melanoma</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;KRASG12X (non G12C) tumors:
lung, colon, many other GIs</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;CRAF mutant GI cancers: gastric, colon, lung and other</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center"><B>HIF2A<BR>Degrader</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;<B></B>Synthetic lethal target required specifically in tumors with
&#147;Achilles&#146; heel&#148; mutation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;VHL mutant RCC</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Pheochromocytoma</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">296 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>Genevant Overview</U> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Overview:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Genevant is a technology-focused nucleic acid delivery and development company with a lipid nanoparticle
(&#147;LNP&#148;) platform, an expansive intellectual property portfolio and deep scientific expertise, currently focused on partnering with other pharmaceutical or biotechnology companies to enable the development of nucleic acid therapeutics for
unmet medical needs. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Delivery platforms:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Genevant has two delivery platforms: LNP and ligand conjugate. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">LNP platform: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Proven technology as demonstrated by
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> <I>in vivo </I>ionizable lipid study assessing LNP potency and immune stimulation </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinically validated for hepatocyte and vaccine use and under development for other traditionally <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">hard-to-reach</FONT></FONT> tissues and cell types, including lung, eye, central nervous system, and hepatic stellate and immune cells </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Over 600 issued patents and pending patent applications </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ligand conjugate platform: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Novel GalNAc ligands with demonstrated ability to deliver to the liver in preclinical studies
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In preclinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT>
testing, demonstrated equal or better preclinical potency, assessed by duration and magnitude of knockdown, compared to a current industry benchmark </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Applying delivery expertise to design of novel extrahepatic ligands to expand therapeutic reach
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Collaboration-based business model: </U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Genevant uses its expertise in the delivery of nucleic acid therapeutics to develop optimal delivery systems for
its collaborators&#146; identified payloads or target tissues. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Genevant collaboration-based business model is to seek some or all of upfront payments, R&amp;D reimbursements,
and milestones and royalties (or profit share) upon success, while also retaining certain rights in the delivery-related intellectual property developed in the context of the collaboration for potential use in other
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> <FONT STYLE="white-space:nowrap">out-licenses.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Some current collaboration partners include BioNTech, Takeda, Sarepta and Gritstone. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Clinical data:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Genevant LNP technology has been in clinical testing in over a dozen distinct product candidates, representing
hundreds of subjects of clinical experience. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Genevant LNP technology is included in the first <FONT STYLE="white-space:nowrap">siRNA-LNP</FONT> product to
receive <FONT STYLE="white-space:nowrap">FDA-approval,</FONT> Alnylam&#146;s Onpattro (patisiran). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Roivant ownership: </U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As of March 31, 2021, we own 83% of the issued and outstanding common shares of Genevant and 69% on a
Fully-Diluted basis. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">297 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nucleic Acid Therapeutics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nucleic acid therapeutics represent an attractive, novel modality that we believe may overcome challenges associated with traditional small
molecule drug development in the treatment of genetically defined disease. The vast majority of human proteins are considered &#147;undruggable&#148; by small molecules based on their protein structure. Nucleic acid therapeutics circumvent the
question of whether or not a target is undruggable by impacting protein expression itself. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The field of nucleic acid therapeutics has
gained significant momentum in recent years, with FDA approval of Alnylam&#146;s Onpattro and Givlaari (givosiran), and emergency use authorization of multiple mRNA <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccines. There is a substantial
pipeline of nucleic acid therapeutics in clinical development that further underscores the transformative potential of nucleic acid therapeutics in the near term. However, nucleic acid therapeutics remain challenged by obstacles in the delivery of
nucleic acids to specific cell types. RNA molecules cannot passively cross most cell membranes given their large size and negative charge, and therefore must be administered in conjunction with a delivery technology to ensure transport to target
cell types. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We work with two proprietary technologies, an LNP delivery system and a ligand conjugate delivery system, to improve the
likelihood of clinical success of nucleic acid therapeutics. The intellectual property with respect to each of these technologies was licensed from Arbutus Biopharma in 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have continued to advance our platforms, expanding into novel tissue types by leveraging the scientific expertise of several members of the
technical team that originally developed or advanced the technologies at Arbutus and its predecessors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">298 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lipid Nanoparticle Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our LNP technology platform is designed to deliver nucleic acids, including mRNA, siRNA, antisense and gene editing constructs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some key features of our LNP technology are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Multi-component formulations that contain specialized lipids optimized for potency and tolerability, are
capable of encapsulating a broad range of nucleic acid payloads, and have limited constraints on nucleic acid composition, structure or size </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A manufacturing process developed and scaled to produce stable uniform dispersion of colloidal nanoparticles
with particle size appropriate for parenteral or intramuscular administration </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Efficient intracellular delivery of nucleic acids to cell cytoplasm via engineered active endosomal escape
mechanism </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g59y90.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> study comparing multiple LNP formulations varying only the key ionizable lipid, a newer Genevant formulation outperformed third party formulations. In
particular, our formulation showed superior potency and avoidance of immune stimulation relative to others, including when compared with the LNP utilized in the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> <FONT
STYLE="white-space:nowrap">RNA-LNP</FONT> therapeutic, Alnylam&#146;s Onpattro (&#147;MC3&#148; in figure below). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">299 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Genevant LNP Outperformed Third Party LNPs in <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Head-to-Head</FONT></FONT> Study </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g46g30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*Key lipid of first <FONT STYLE="white-space:nowrap">FDA-approved</FONT>
<FONT STYLE="white-space:nowrap">RNAi-LNP</FONT> (Alnylam&#146;s Onpattro) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Genevant LNP technology has entered the clinic in
more than a dozen distinct product candidates, representing hundreds of subjects of clinical experience. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Substantial clinical
experience with Genevant LNP technology </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g23k88.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">300 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With this track record of success, we are now also focusing our LNP capabilities on
historically challenging cell and tissue types, including hepatic stellate cells and the lung. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have demonstrated our ability to
deliver nucleic acid therapeutics to challenging targets through our efforts to access hepatic stellate cells (&#147;HSCs&#148;) in preclinical studies. Historically, attempts to address certain diseases have been limited by the inability to access
specific cell types outside of the hepatocyte. The activation of HSCs is well established as a central driver of fibrosis, and thus technologies that target activated HSCs may be key to address certain liver diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In preclinical studies, delivery of RNAis to HSCs via Genevant&#146;s LNP technology demonstrated selective knockdown of an HSC target with
minimal activity in hepatocytes, as shown below. Additional preclinical studies support our ability to design LNPs to deliver nucleic acids to the lung, and we believe that our scientific expertise will allow us to direct LNPs toward additional cell
and tissue types, such as the central nervous system and eye. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LNP delivery of siRNA to HSCs demonstrated selective knockdown of target
mRNA in mice with minimal activity in hepatocytes </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g80i80.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">301 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ligand Conjugate Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our LNP platform, we also have a proprietary RNAi ligand conjugate platform. Novel ligands can successfully deliver siRNA and
certain other oligonucleotides to the liver, and our delivery expertise enables the design of novel ligands potentially to expand therapeutic reach to hepatic stellate cells. Our ligand conjugate technology has demonstrated equal or better
preclinical potency, assessed by duration and magnitude of knockdown compared to current industry benchmark. We currently have multiple patents pending with respect to our ligand conjugate platform. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g75q31.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g07z79.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing a next-generation ligand conjugate (&#147;RNAi 2.0&#148;) platform. Our RNAi 2.0 platform
has demonstrated superior strength and duration of knockdown compared to legacy ligand conjugates (&#147;RNAi 1.0&#148;) in a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> nonclinical study in nonhuman
primates. In addition, our RNAi 2.0 platform: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Contains intrinsic endosomolytic properties </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Has demonstrated marked <I>in vivo</I> enhancement in potency </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Has maintained a subcutaneous dosing regimen and would be dosed subcutaneously in clinical trials
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Remains compatible with other ligand types </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">302 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Next Generation RNAi 2.0 Conjugate Platform Shows Improved Potency, Magnitude and Duration
of Knockdown </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g01t65.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Genevant seeks to partner with other pharmaceutical or biotechnology companies in the development of RNA therapeutics, crafting mutually
beneficial collaborations that allow collaboration partners to access innovative technologies while providing Genevant the opportunity to leverage our expertise to expand the technology and corresponding therapeutic reach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This provides the following benefits to collaborators: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Access to validated technology to deliver nucleic acid therapeutics to hepatocytes or for vaccine applications
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Potential to deliver RNA payloads to historically
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">challenging-to-reach</FONT></FONT> tissue or cell types, as well as nucleic acid design capabilities </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No need to build internal delivery expertise or build intellectual property estate from scratch in an
increasingly complex field </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This provides the following benefits to Genevant: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Opportunity to expand core delivery technology and capabilities, maintaining leadership position in nucleic acid
delivery </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Typically, certain rights to delivery-related intellectual property developed in the context of collaboration and
ability to exploit through other nonexclusive <FONT STYLE="white-space:nowrap">out-licenses</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">303 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Opportunity to generate revenue through deal structures including some combination of upfront payments, R&amp;D
reimbursements and additional milestones and royalties upon successful outcomes </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, Genevant has partnered with
leading companies with a shared vision of advancing innovative nucleic acid medicines to transform the lives of patients. Our collaborations currently include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Gritstone</B><FONT STYLE="white-space:nowrap">&#151;Non-exclusive</FONT> access to Genevant&#146;s LNP
technology for use in Gritstone&#146;s self-amplifying RNA <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccine program </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Gritstone</B>&#151;<B></B>Exclusive access to LNP technology for use with self-amplifying RNA for an
unspecified indication </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Sarepta</B>&#151;Research collaboration and option agreement for the delivery of <FONT
STYLE="white-space:nowrap">LNP-gene</FONT> editing therapeutics for specified neuromuscular diseases; Genevant will design and collaborate with Sarepta in the development of muscle targeted LNPs to be applied to gene editing targets in multiple
indications, including Duchenne muscular dystrophy </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>BioNTech</B><FONT STYLE="white-space:nowrap">&#151;Co-development</FONT> in up to five rare diseases with high
unmet medical need, and exclusive access to LNP technology for use with BioNTech&#146;s mRNA for a specified number of oncology targets </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Takeda</B>&#151;Exclusive access to LNP technology to develop nucleic acid therapeutics directed to specified
targets in hepatic stellate cells to treat liver fibrosis </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>ST Pharm</B>&#151;Non-exclusive access to Genevant&#146;s LNP technology for use in specified territories in
an mRNA COVID-19 vaccine </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Potential Benefits of Genevant&#146;s Delivery Platforms </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Robust and expansive patent estate.</I> Over 600 issued patents and pending patent applications for our LNP
platform, including coverage of individual lipid structure, particle composition, particle morphology, manufacturing and <FONT STYLE="white-space:nowrap">mRNA-LNP</FONT> formulations. As we continue to develop these technologies, we expect to have
the opportunity to expand intellectual property protection further, to enhance protection and support additional licensing opportunities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Experienced leadership team.</I> Our leadership team has deep technical expertise in nucleic acid drug
development and a track record of executing successfully in innovative areas. We believe this positions Genevant to expand delivery to historically challenging tissues and cell types, thereby creating potential opportunities for creative
collaboration. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Manufacturing know-how.</I> Since inception, we have made strategic investments in expanding our manufacturing
know-how. Our manufacturing process is rapid and reproducible, has intellectual property protection and is capable of commercial scale. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Expansive Patent Portfolio </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our LNP
platform is protected with a robust patent portfolio, covering a wide range of aspects required for successful nucleic acid delivery. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
patents are directed to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Structures and individual lipid compositions, including cationic and
<FONT STYLE="white-space:nowrap">PEG-lipids</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Particle compositions, including commonly used, most active ranges of lipid ratios for nucleic acid-containing
particles </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nucleic acid-containing particles with certain structural characteristics </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mRNA-containing LNP formulations </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Various aspects of our manufacturing process </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">304 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>Lysovant Overview</U> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Overview:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Lysovant is developing LSVT-1701, a novel endolysin, for the treatment of <I>Staph aureus</I> bacteremia
(&#147;SAB&#148;) to potentially address significant unmet medical need in the treatment of serious bacterial infections. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Lead program:</U><U> </U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>LSVT-1701: </I>Novel bacteriophage-derived biologic candidate with potent, selective and rapid bactericidal
anti-staphylococcal activity including multi-resistant strains via cell wall hydrolysis. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Disease overview:</U><U> </U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Staph aureus</I> is a major cause of infections in the United States and can be serious or fatal by causing
bacteremia or sepsis when the bacteria enter the bloodstream. Unless promptly treated, SAB can metastasize to deep tissues and significantly increase the risk of mortality. The most common complications include infective endocarditis
(&#147;IE&#148;), vertebral osteomyelitis and pulmonary infections. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In the United States, there are an estimated 226,000 patients with SAB and 50,000 with IE per year. The incidence
of SAB is increasing<B> </B>due to the growth of invasive procedures, expansion of implanted medical devices and rise in number of immunocompromised patients. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Limitations of current treatments:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Current standard of care antibiotics for SAB are vancomycin and daptomycin for MRSA, and beta-lactam antibiotics
for MSSA, and there has been no innovation for decades. Current antibiotic treatments take days to suppress the bacteria in hospitalized SAB patients. There exists significant unmet need for rapid bactericidal antibiotics for complicated SAB and IE,
as patients require more effective treatments to reduce the high mortality of these diseases. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Clinical data:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Results from Phase 1/2a clinical trials suggest that LSVT-1701 is generally well-tolerated with an adequate
safety profile on top of standard of care antibiotics. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Development plan and upcoming milestones:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We anticipate initiating a Multiple Ascending Dose (MAD) study of LSVT-1701 in patients with complicated SAB
including IE in the first half of 2022. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Roivant ownership:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As of March&nbsp;31, 2021, we own 100% of the issued and outstanding common shares of Lysovant and 99% on a
Fully-Diluted basis. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Pipeline:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g65062g58k78.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">305 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LSVT-1701 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">LSVT-1701 is a selective and efficient bactericide due to its unique endolysin mechanism. Where other antibiotics and treatments inhibit the
synthesis or function of the bacteria&#146;s cell wall, nucleic acid, membrane, and protein, LSVT-1701 directly cleaves the bacteria&#146;s cell wall leading to rapid bacterial lysis. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g99z87.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe LSVT-1701 may be the most effective lysin due to its use of two catalytic domains, called
amidase and endopeptidase. These domains provide peptidoglycan (cell wall) hydrolysis. While the amidase cuts between the sugar stands and stem peptides, the endopeptidase cleaves the bonds between the stem peptide and the pentaglycine bridge. As
shown below, this novel endolysin mechanism potentially allows for more rapid bactericidal effect. Additionally, endolysin target binding sites are highly conserved and essential to <I>S. aureus</I> bacteria viability<I>.</I> We believe this may
contribute to lower propensity for resistance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LSVT-1701 Mechanism of Action </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g48q33.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LSVT-1701 for the Treatment of </B><B><I>Staph aureus</I></B><B> Bacteremia </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Staph aureus</I><I> bacteremia and limitations of current treatments</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Staph aureus</I> is a major cause of infections in the United States and can be serious or fatal by causing bacteremia or sepsis when the
bacteria enter the bloodstream. Other complications from infection include infective endocarditis, where the infection reaches heart valves and may cause heart failure or stroke, and osteomyelitis, where the bone becomes infected.<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP>Common strains of <I>Staph aureus</I> are either methicillin-resistant (&#147;MRSA&#148;) or methicillin-susceptible (&#147;MSSA&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">306 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, there are an estimated 226,000 patients with <I>S. aureus</I>
bacteremia and 50,000 with infective endocarditis per year.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>Of all SAB cases, around 45% are caused by MRSA and 55% by MSSA. Complicated bacteremia due to sepsis, comorbidities or dialysis
accounts for approximately 32% of SAB cases per year and refractory bacteremia accounts for approximately 28% of SAB cases per year. In addition to being a leading cause of infections, SAB is also a major cost driver to U.S. hospitals and results in
high mortality rates. Average <FONT STYLE="white-space:nowrap">30-day</FONT> mortality of <I>S. aureus </I>infections is around 20% with current antibiotic treatment. Complicated bacteremia is associated with higher mortality rates of up to 30%.
MRSA and MSSA bacteremia is associated with long hospital stays and high ICU utilization, particularly for complicated bacteremia and IE. Cost of care for SAB across MRSA and MSSA is around $7.4&nbsp;billion annually, with sepsis due to the bacteria
accounting for 79% of this annual cost. These burdens are in part due to rising resistance of infections to current standard of care antibiotics. Consequently, there is a great need for new therapies efficacious for both <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">hard-to-treat</FONT></FONT> MRSA and MSSA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that if approved for
commercial sale, LSVT-1701 would be differentiated from both current standard of care and emerging endolysin treatments for SAB and IE. Endolysins have been clinically validated as a novel class of bacterial treatment by results from
ContraFect&#146;s Phase 2 trial of exebacase, which showed efficacy in MRSA but not MSSA and in right-sided infective endocarditis compared to standard of care antibiotics alone. While exebacase&#146;s endolysin mechanism only cleaves at one site in
the cell wall, LSVT-1701 cleaves at two, potentially increasing its bactericidal capability. Based on preclinical and clinical trials, we believe that if approved, LSVT-1701 can also be given in multiple doses and at higher dosing levels compared to
exebacase, which cannot be dosed twice and has a compound-specific dose-limiting toxicology signal (vasculitis). If approved, we believe that LSVT-1701 could be an attractive treatment on top of standard of care for populations with high medical
needs, such as those with complicated MRSA and MSSA bacteremia, and left-sided infective endocarditis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the novel endolysin
mechanism of LSVT-1701, we believe that LSVT-1701, if approved for use, could provide the following potential benefits: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Rapid antibacterial activity.</I> Where current antibiotic treatments take a long time to suppress the
bacteria, LSVT-1701 has the potential to provide rapid and highly effective lytic action. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Species specificity. </I>Anti-staphylococcal endolysins provide pathogen-targeted bacteriolysis and preserve
normal flora </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Low propensity for resistance.</I> Target binding sites are highly conserved and essential to bacteria
viability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Synergy with standard of care. </I>LSVT-1701 has the potential to be used to treat antibiotic-resistant
bacteria and administered concurrently with antibiotics. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Effective against biofilms. </I>In animal models,<I> </I>LSVT-1701 eradicated and cleared biofilm where
standard of care is ineffective. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Effective against all strains.</I> <I>In vitro </I>susceptibility data demonstrate an activity profile for
both MRSA and MSSA, and multi-resistant clinical isolates<I>.</I> </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical data </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Phase 1 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2019,
iNtRON Biotechnology completed Phase 1 studies evaluating the safety, pharmocokinetics and pharmacodynamics of LSVT-1701. In these double-blind, placebo-controlled studies, 51 healthy subjects were given single or multiple ascending doses. All
adverse events reported were mild or moderate and included chills or rigors, infusion site reaction, pyrexia, headache, myalgia and fatigue. These adverse events appeared dose-dependently but were not frequency-dependent. There were no reported
severe adverse events reported. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">307 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Phase 2a </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2019, Lysovant completed a randomized, placebo-controlled Phase 2a clinical trial evaluating the safety of LSVT-1701 in <I>S.
aureus</I> bacteremia. In this trial, 12 subjects with persistent MRSA or MSSA bacteremia received a single IV dose of LSVT-1701 3 mg/kg in addition to standard of care antibiotics. 13 subjects received placebo, alongside standard of care
antibiotics. LSVT-1701 was generally well-tolerated, with similar proportion of subjects reporting adverse events in both placebo and LSVT-1701 arms. Additionally, there was also no evidence of cytokine storm or anaphylaxis. The safety profile
observed potentially allows for higher dosing in future trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical data </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a <FONT STYLE="white-space:nowrap">non-neutropenic</FONT> murine bacteremia (i.e., MSSA sepsis) model, postantibiotic effect
(&#147;PAE&#148;) occurred after 48 hours. PAE occurs when bacterial growth is successfully suppressed after drug administration. There were no dose-limiting toxicities like vascular lesions or immunogenicity following administration of multiple
doses, which suggests safety and tolerability within the model. In a rabbit infectious endocarditis model, a multi-dose regimen of LSVT-1701 demonstrated complete sterilization of tissues. The data also suggest the ability to dissolve bacterial
vegetations, as LSVT-1701 achieved complete experimental sterilization on top of daptomycin, whereas the daptomycin antibiotic regimen alone and exebacase on top of daptomycin did not (not a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">head-to-head</FONT></FONT> study). <I>In vitro</I>, LSVT-1701 has demonstrated a narrow and well-defined minimum inhibitory concentration (MIC) range (MIC<SUB STYLE="font-size:85%; vertical-align:bottom">90</SUB> 2 ug/ml)
across a diverse collection of current clinical <I>S. aureus </I>isolates including MRSA, MSSA, vancomycin-intermediate <I>S. aureus</I> (VISA), and glycopeptide-intermediate <I>S. aureus</I> (GISA). LSVT-1701 also exhibited a comparable MIC range
in 82 coagulase negative staphylococci (CoNS) isolates. MIC measures the lowest concentration of drug necessary to prevent visible bacterial growth, and a narrower MIC range suggests that LSVT-1701 is an efficient bactericide against multi-resistant
clinical isolates. LSVT-1701 was also not adversely affected by decreased susceptibility or resistance to various antibiotics, further confirming its bactericidal activity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Development plan </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">LSVT-1701 is being
developed for the treatment of SAB and IE, and we plan to initiate a Multiple Ascending Dose (MAD) study in the first half of 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">308 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>Kinevant Overview </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Overview:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Kinevant is focused on developing namilumab for pulmonary sarcoidosis and other autoimmune diseases.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Lead program:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Namilumab: </I>Fully human
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-GM-CSF</FONT></FONT> monoclonal antibody with broad potential in autoimmune diseases. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Disease overview:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sarcoidosis is a multisystem autoimmune disease that affects approximately 200,000 people in the United States,
with 95% of cases presenting with pulmonary involvement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Limitations of current treatments:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Corticosteroids are the most widely used treatment for sarcoidosis, but they carry significant side effects when
used longer-term. Second- and third-line treatment options, including immunosuppressive therapies and biologics, are limited by slow onset, safety risk, inconsistent effectiveness, and reimbursement challenges, leaving significant unmet medical need
that could be met by a novel biologic. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Clinical data:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Early clinical data in pharmacokinetic/pharmacodynamic (PK/PD) and subsequent Phase 2 studies showed namilumab to
be well tolerated with a single subcutaneous injection given up to every four weeks. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Development plan and upcoming milestones:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We plan to initiate a Phase 2 trial to test for the safety and efficacy of namilumab in pulmonary sarcoidosis in
the first half of 2022. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Roivant ownership:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As of March&nbsp;31, 2021, we own 88% of the issued and outstanding common shares of Pharmavant 3 (which we refer
to here as Kinevant), and 88% on a Fully-Diluted basis. As of March&nbsp;31, 2021, we own 100% of the issued and outstanding common shares of the entity that owns the rights to gimsilumab, and 99% on a Fully-Diluted basis. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Pipeline:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g98u77.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Namilumab </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Namilumab is a fully human monoclonal antibody that neutralizes granulocyte-macrophage colony-stimulating factor
<FONT STYLE="white-space:nowrap">(&#147;GM-CSF&#148;)</FONT> activity by preventing it from binding to high-affinity cell surface receptors, neutralizing the otherwise pathogenic cytokine in conditions such as pulmonary sarcoidosis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">309 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">GM-CSF</FONT> provides key functions as a <FONT
STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokine and growth factor. Following antigen stimulation or activation by cytokines, <FONT STYLE="white-space:nowrap">GM-CSF</FONT> can be secreted by a variety of cell types, including activated B
and T cells. <FONT STYLE="white-space:nowrap">GM-CSF</FONT> is <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> as it activates macrophages and other cells to drive inflammation and tissue damage.
<FONT STYLE="white-space:nowrap">GM-CSF</FONT> also acts as a growth factor; for example, recombinant <FONT STYLE="white-space:nowrap">GM-CSF</FONT> is used for the treatment of low white blood cell counts in cancer patients undergoing chemotherapy
to increase white blood cells and mobilize them into peripheral blood. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">GM-CSF&#146;s</FONT> Role in
Sarcoid Pathogenesis </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g22r19.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to its targeting of a common <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokine, we
intend to evaluate the development of namilumab for the treatment of a number of potential autoimmune indications. <FONT STYLE="white-space:nowrap">GM-CSF</FONT> administration has been found to drive disease progression in a variety of preclinical
models, including inflammatory arthritis, multiple sclerosis, interstitial lung disease, nephritis, myocarditis, and giant cell arteritis, among others, suggesting broad utility of the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-GM-CSF</FONT></FONT> mechanism. Macrophages have been implicated in the progression of fibrosis in lung injury, which indicates a potential role of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-GM-CSF</FONT></FONT> as an antifibrotic. Numerous other cytokine inhibitors, including those targeting <FONT STYLE="white-space:nowrap">TNF-&#945;,</FONT> <FONT
STYLE="white-space:nowrap">IL-6,</FONT> <FONT STYLE="white-space:nowrap">IL-23,</FONT> and <FONT STYLE="white-space:nowrap">IL-17,</FONT> have been successfully clinically validated across a broad range of indications, which we believe suggests
potentially broad and flexible application of namilumab. Targeting <FONT STYLE="white-space:nowrap">GM-CSF</FONT> has been clinically validated in two other autoimmune diseases, rheumatoid arthritis and giant cell arteritis, where Phase 2 trials
have shown <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-GM-CSFs</FONT></FONT> to be generally well tolerated and to have demonstrated the potential for symptom resolution. Additionally, namilumab is being developed with
potentially the least frequent dosing schedule of other subcutaneous <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-GM-CSFs</FONT></FONT> in Phase 2 or Phase&nbsp;3 clinical trials, with a single dose every four weeks after
an initial loading period, and has been studied in approximately 300 patients to date. Based on the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-GM-CSF</FONT></FONT> development landscape, we believe that namilumab has
potential for pulmonary sarcoidosis and multiple avenues for expansion across both clinically validated indications and indications with no known <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-GM-CSF</FONT></FONT>
development. The three other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-GM-CSFs</FONT></FONT> currently in Phase 2 or Phase 3 clinical trials are GlaxoSmithKline&#146;s otilimab, which is subcutaneous, dosed weekly, and
currently undergoing Phase 3 trials in rheumatoid arthritis and a Phase 2 trial in <FONT STYLE="white-space:nowrap">COVID-19;</FONT> Kiniksa&#146;s mavrilumab, which is subcutaneous, dosed every two weeks, and last completed a positive Phase 2 trial
in giant cell arteritis and is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">310 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
undergoing a Phase 3 trial in <FONT STYLE="white-space:nowrap">COVID-19</FONT> pneumonia and hyperinflammation; and Humanigen&#146;s lenzilumab, which is intravenous, dosed every four weeks, and
reported positive topline results in a Phase 3 trial in <FONT STYLE="white-space:nowrap">COVID-19</FONT> pneumonia. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Namilumab for the Treatment of
Sarcoidosis </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sarcoidosis overview and limitations of current treatments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sarcoidosis is a multi-organ autoimmune disease characterized by the presence of granulomas believed to form via an exaggerated immune response
to unidentified antigens. Sarcoidosis primarily affects the lungs and lymphatic system, though sarcoidosis may damage any organ. Granulomas are compact, centrally organized collections of macrophages and epithelioid cells encircled by lymphocytes
and form during a normal immune response to trap foreign pathogens, restrict inflammation, and protect the surrounding tissue. The hallmark of sarcoidosis is the presence of CD4+ T cells that interact with antigen-presenting cells to initiate the
formation, maintenance, and accumulation of granulomas. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sarcoidosis affects approximately 200,000 patients in the United States alone and
can present itself acutely or subacutely with lymph node enlargement, shortness of breath, dry cough, skin, joint or eye lesions, or abnormalities on chest <FONT STYLE="white-space:nowrap">x-ray</FONT> or CT. Approximately 95% of sarcoidosis
patients have lung involvement, and around 20 to 30% of patients develop permanent lung damage from the disease. An estimated 54% of pulmonary sarcoidosis patients are diagnosed, and approximately 90% of these patients receive some form of
treatment. The annual incidence of sarcoidosis in African-Americans is threefold that of Caucasian Americans. Some studies report a slight predominance of sarcoidosis among females compared to males, while others show no gender predilection. Age at
onset ranges from 20s to over the age of 50. Corticosteroids are the most widely used treatment for sarcoidosis, but they carry significant side effects when used longer-term, and relapses are common when attempting to taper. There are multiple
second- and third-line treatment options, including immunosuppressive therapies such as methotrexate and azathioprine as well as biologics such as TNF inhibitors, but their use is limited by slow onset, safety risk, inconsistent effectiveness, and
reimbursement challenges. There remains significant unmet medical need for patients who are not well-controlled by steroids or immunosuppressants (patients may remain symptomatic or may not be able to tolerate effective doses) that could be met by a
novel biologic. Market research with HCPs and third-party analysis of claims data suggest that approximately 25% of diagnosed and treated pulmonary sarcoidosis would be eligible for treatment with <FONT STYLE="white-space:nowrap">second-line</FONT>
or later therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The granulomatous response is believed to begin when an antigen chronically stimulates and activates antigen-presenting
cells, including alveolar macrophages. Macrophages process and present the antigen, leading to the activation of CD4+ helper T cells, which form and maintain the granuloma by the production of <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT>
cytokines such as <FONT STYLE="white-space:nowrap">TNF-&#945;,</FONT> <FONT STYLE="white-space:nowrap">GM-CSF,</FONT> and <FONT STYLE="white-space:nowrap">IL-12</FONT> that in turn recruit inflammatory cells such as peripheral blood monocytes. The
activated immune environment of the granuloma may lead to significant damage to the surrounding tissue, and the development of advanced fibrosis permanently alters organ structure and function. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">GM-CSF,</FONT> a key pathogenic cytokine, has been critically implicated in multiple parts of the
granulomatous response. <FONT STYLE="white-space:nowrap">GM-CSF</FONT> is involved in the activation and fusion of alveolar macrophages into multinucleated giant cells, the priming and maintenance of T cell activation and the interactions between
lymphoid and myeloid cells that promote granuloma formation. Further, <FONT STYLE="white-space:nowrap">GM-CSF</FONT> production appears to amplify cellular immunity mediated by helper T cells (Th1, Th2, and Th17) that are also believed to be
critical during the granulomatous response and thereby driving the local immune response. In patients with sarcoidosis, GM-CSF has been shown to be increased in serum and broncho-alveolar fluid and correlated with disease activity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical data </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a Phase 1 study of
healthy volunteers with a single subcutaneous injection, namliumab was observed to be generally well-tolerated. In a Phase 2 trial in patients with moderate to severe rheumatoid arthritis (RA) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">311 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conducted by Takeda, namilumab demonstrated decreased disease activity compared to placebo. In this trial, patients were given a subcutaneous injection of either 20, 80, or 150 mg of namilumab
four times over a <FONT STYLE="white-space:nowrap">ten-week</FONT> period. Results showed a dose-dependent response to treatment, with a statistically significant difference for the 150 mg dose in the <FONT STYLE="white-space:nowrap">28-joint</FONT>
Disease Activity Score, <FONT STYLE="white-space:nowrap">C-reactive</FONT> protein version <FONT STYLE="white-space:nowrap">(DAS28-CRP),</FONT> the primary endpoint, at week 12. Compared to placebo, namilumab also increased patients&#146; ACR score,
which measures RA signs and symptom improvement. Over the <FONT STYLE="white-space:nowrap">12-week</FONT> study period, 14 of 27 (52%) subjects receiving placebo and 45 of 81 (56%) receiving namilumab experienced a treatment-emergent adverse event
(TEAE). The most common TEAEs, shown in the table below, were nasopharyngitis, dyspnoea, bronchitis, and headache. One serious adverse event, a myocardial infarction, was reported in the 150 mg arm. The patient, a
<FONT STYLE="white-space:nowrap">63-year</FONT> old smoker, was withdrawn from the trial and recovered after cardiac catheterization. Although we believe namilumab has significant potential in RA, we believe we can deliver greater value to patients
if we pursue development in sarcoidosis first, where the unmet medical need is greater. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-LEFT:1px solid #a5a5a5; BORDER-TOP:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5; padding-left:8pt"><B>Preferred term</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-TOP:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" ALIGN="center" STYLE="BORDER-TOP:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5"><B>Placebo&nbsp;(</B><B><I>N</I></B><B>&nbsp;=&nbsp;27)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-TOP:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="BORDER-TOP:1px solid #a5a5a5; BORDER-RIGHT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5; padding-right:2pt"><B>Namilumab</B></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #a5a5a5"><B>20&nbsp;mg&nbsp;(</B><I></I><B><I>N</I></B><I></I><B>&nbsp;=&nbsp;28)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #a5a5a5"><B>80&nbsp;mg&nbsp;(</B><I></I><B><I>N</I></B><I></I><B>&nbsp;=&nbsp;25)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5; padding-right:2pt"><B>150&nbsp;mg&nbsp;(</B><I></I><B><I>N</I></B><I></I><B>&nbsp;=&nbsp;28)</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;Nasopharyngitis</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #a5a5a5">5(18.5)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #a5a5a5">5(17.9)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #a5a5a5">1(4.0)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5; padding-right:2pt">4(14.3)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;Dyspnoea</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #a5a5a5">0</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #a5a5a5">1(3.6)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #a5a5a5">2(8.0)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5; padding-right:2pt">3(10.7)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;Bronchitis</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #a5a5a5">2(7.4)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #a5a5a5">1(3.6)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #a5a5a5">1(4.0)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5; padding-right:2pt">1(3.6)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;Headache</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #a5a5a5">1(3.7)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #a5a5a5">1(3.6)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #a5a5a5">3(12.0)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5; padding-right:2pt">0</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;Upper respiratory tract infection</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #a5a5a5">0</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #a5a5a5">0</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #a5a5a5">2(8.0)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5; padding-right:2pt">1(3.6)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;Rheumatoid arthritis</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #a5a5a5">0</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #a5a5a5">2(7.1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #a5a5a5">2(8.0)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5; padding-right:2pt">0</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;Hypertension</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #a5a5a5">0</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #a5a5a5">0</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #a5a5a5">0</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5; padding-right:2pt">2(7.1)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;Laryngitis</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #a5a5a5">0</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #a5a5a5">0</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #a5a5a5">2(8.0)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5; padding-right:2pt">0</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;Menorrhagia</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #a5a5a5">0</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #a5a5a5">2(7.1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #a5a5a5">0</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5; padding-right:2pt">0</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:2pt ;BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;Urticaria</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1px solid #a5a5a5">0</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1px solid #a5a5a5">2(7.1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1px solid #a5a5a5">0</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:2pt ;BORDER-RIGHT:1px solid #a5a5a5; BORDER-BOTTOM:1px solid #a5a5a5; padding-right:2pt">0</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Values are <I>n</I> (%). <I>TEAE</I> treatment-emergent adverse event </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Development plan </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to initiate a
Phase 2 trial to test the safety and efficacy of namilumab in pulmonary sarcoidosis in the first half of 2022. We believe the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-GM-CSF</FONT></FONT> mechanism has potential for
broad application due to the numerous disease functions of <FONT STYLE="white-space:nowrap">GM-CSF,</FONT> giving the opportunity to expand autoimmune disease indications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">312 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>Affivant Overview </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Overview:</U><U> </U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Affivant is focused on the future development and commercialization of AFM32 and other bispecific antibodies
through its licensing and strategic collaboration agreement with Affimed to develop and commercialize novel innate cell engagers for multiple cancer targets. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Lead program: </U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">AFM32 is a preclinical immune-engaging bispecific antibody licensed from Affimed with potential applicability to
several solid tumor indications. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Preclinical data:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> preclinical
study, AFM32&#146;s potency exceeded that of a monoclonal antibody (&#147;mAb&#148;) that has been clinically validated against the same tumor target. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">AFM32&#146;s potency also exceeded the potency of antibody-drug conjugate (&#147;ADC&#148;) agents that have been
clinically validated against the same tumor target, as reported in published preclinical studies. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Development plan and upcoming milestones: </U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We expect to file an IND for AFM32 in the first half of 2023. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Roivant ownership: </U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As of March&nbsp;31, 2021, we own 100% of the issued and outstanding common shares of Affivant and 100% on a
Fully-Diluted basis. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Pipeline:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g64e05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bispecific Innate Cell Engagers and Affimed&#146;s ROCK Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Bispecific innate cell engagers (&#147;ICE&#148;) are a novel class of drugs that activate the innate immune system and trigger a concerted
anti-tumoral immune response. These bispecific antibodies consist of tumor-associated antigen binding domains, which cause high affinity and high specificity binding to the tumor surface, and immune cell binding domains, which bind and activate
specific immune cell subsets able to kill the tumor cell. The Fc region of the antibody links the two domains together and improves pharmaceutical properties. The cross-linking of tumor and immune cells acts as a bridge that increases their
proximity and creates a spatial stimulus, enabling the immune cell to kill the tumor cell. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Affimed&#146;s Redirected Optimized Cell
Killing (&#147;ROCK&#148;) platform technology generates diverse, tetravalent, bispecific antibodies known as ICE, which can be customized to target specific binding domains on hematologic and solid tumor cells. The immune cell binding domain of ICE
includes a high affinity CD16A-directed domain that binds to CD16A receptors on natural killer (&#147;NK&#148;) cells with a unique epitope. CD16A is sufficient to fully activate cell killing by NK cells and macrophages, differentiating ICE from
other platforms that can engage NK cells. In addition, there is no dilution or sink effect through neutrophils (CD16B+) as the molecules are highly selective for CD16A. These ICE antibodies are superior to mAbs and
<FONT STYLE="white-space:nowrap">Fc-enhanced</FONT> mAbs in their ability to bind with high affinity to CD16A with minimal serum IgG competition. The ROCK<I> </I>platform has generated clinical proof of concept through clinical trials of AFM13 in
patients with peripheral <FONT STYLE="white-space:nowrap">T-cell</FONT> lymphoma, where AFM13 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">313 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
was well-tolerated and demonstrated tumor shrinkage or slowing of tumor growth. Our goal is to develop CD16A NK antibodies with the potential for targeted immune activation and tumor destruction,
along with a safety profile more like traditional antibody-based products. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g52a40.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AFM32 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AFM32 is an ICE program currently in the preclinical stage of development. AFM32&#146;s Fc region is fused to two high affinity CD16A binding
single chain variable regions to maximize NK cell and macrophage engagement. The biological target of AFM32&#146;s tumor-associated antigen binding domain has been clinically validated via other targeted agents (mAb and ADC), including both evidence
of single agent activity and a generally well-tolerated safety profile of the corresponding mAb in published studies. We believe AFM32 has potential applicability across several highly prevalent solid tumor types, providing the optionality to pursue
multiple large-market indications. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical data </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> preclinical study, AFM32 potency, as measured
by target cell killing, exceeded that of a mAb, and in preclinical studies, AFM32&#146;s potency exceeded the potency (as reported in published preclinical studies) of ADC agents that have been clinically validated against the same tumor target.
Furthermore, based on preclinical and clinical experiences with other ICE antibodies in separate studies, we believe that the tolerability of AFM32 has the potential to be superior to that observed to date with antibody-drug conjugates in published
literature. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Development plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to a collaboration and licensing agreement between Affivant and Affimed, Affimed is conducting a significant portion of the AFM32
preclinical work for the collaboration under the governance of a Joint Steering Committee controlled by Affivant. Pursuant to the agreement Affivant will be responsible for submitting any IND or equivalent for AFM32, and will be responsible for all
future clinical development and commercialization worldwide, with Affimed retaining an option for <FONT STYLE="white-space:nowrap">co-promotion.</FONT> We also have the option to license from Affimed additional ICE molecules directed against targets
that are not (a)&nbsp;currently licensed or optioned to third parties or (b)&nbsp;directed against targets included in Affimed&#146;s current pipeline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">314 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>Cytovant Overview </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Overview: </U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cytovant&#146;s mission is to discover, develop and commercialize cell therapies that are uniquely suited to
Asian patients. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Lead program:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CVT-TCR-01:</FONT></FONT></I> <FONT
STYLE="white-space:nowrap">TCR-T</FONT> therapeutic targeting <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NY-ESO-1,</FONT></FONT> an intracellular cancer testis antigen whose expression is nearly exclusive to malignant tissue,
being developed in Asia for the treatment of soft tissue sarcoma and other tumors with high disease burden in the region. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Disease overview:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NY-ESO-1</FONT></FONT> is expressed in many
tumor types associated with substantial unmet need in Asia, including soft tissue sarcoma, ovarian cancer, esophageal cancer and lung cancer. In 2020, the estimated incidences of colorectal, lung and esophageal cancer in China were 38.4, 56.3 and
22.4 cases per 100,000 individuals; these tumors are associated with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NY-ESO-1</FONT></FONT> positivity rates of 17%, 19% and 21%, respectively. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Limitations of current treatments:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The current treatment options for soft tissue sarcoma leave significant unmet need, as chemotherapy for systemic
treatment has an overall survival of approximately 12 months, and up to 40% of patients who receive surgery and radiotherapy eventually recur at distant sites. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Preclinical data:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CVT-TCR-01</FONT></FONT> has demonstrated
strong activity against <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NY-ESO-1-positive</FONT></FONT></FONT> cell lines in preclinical experiments and has further demonstrated highly specific <FONT
STYLE="white-space:nowrap">on-target</FONT> activity by sparing cell lines that are <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NY-ESO-1-negative.</FONT></FONT></FONT> Moreover, in preclinical
experiments, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CVT-TCR-01</FONT></FONT> has been shown to induce strong proinflammatory cytokine secretion upon exposure to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">NY-ESO-1</FONT></FONT> positive cell lines, further supporting its antitumor activity. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Development plan and upcoming milestones:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We expect to initiate CMC activities for
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CVT-TCR-01</FONT></FONT> in the second half of 2021. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Roivant ownership:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As of March&nbsp;31, 2021, we own 72% of the issued and outstanding common shares of Cytovant and 68% on a
Fully-Diluted basis, in each case including both direct and indirect ownership in Cytovant. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Pipeline: </U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g65x96.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cytovant holds development and commercialization rights for Greater China (includes People&#146;s Republic
of China, Hong Kong, Taiwan, and Macau), Japan, and the Republic of Korea. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">TCR-T</FONT> Background </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of normal immune surveillance, the body identifies diseased cells through the <FONT STYLE="white-space:nowrap">T-cell</FONT> receptor
(&#147;TCR&#148;), which binds and recognizes the HLA peptide complex. The HLA peptide complex is comprised of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">315 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
short fragments of cellular proteins bound to HLA; this complex is then trafficked to the cell surface for presentation to T cells. When a T cell binds to a specific HLA peptide complex on a
diseased cell, that cell is targeted for destruction. Importantly, peptide fragments that are bound to HLA are derived from intracellular, extracellular and transmembrane proteins, meaning that TCRs can target the entire array of cellular proteins.
Notably, HLA types vary substantially across global populations, with markedly different HLA types commonly observed in Asian populations relative to Caucasian populations. For example, two high-frequency alleles in Southern Chinese people, <FONT
STYLE="white-space:nowrap">HLA-A*02:07</FONT> (20%) and <FONT STYLE="white-space:nowrap">HLA-A*02:03</FONT> (10%), are not addressed by any current <FONT STYLE="white-space:nowrap">TCR-based</FONT> therapy. The ability of a specific TCR to bind and
recognize an HLA peptide complex is limited to matched HLA types; thus, a TCR that recognizes an HLA peptide complex found in Caucasian patients may not recognize an HLA peptide complex found in Asian patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of T cells to recognize and kill diseased cells via the TCR can be manipulated to target specific cells, including cancerous
cells. This constitutes the basis of <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapeutics, in which affinity- or specificity-enhanced T cell receptors are genetically engineered into a patient&#146;s own T cells and then used as a direct
anti-cancer treatment. This technology affords several advantages compared to other forms of adoptive cell therapy (&#147;ACT&#148;), including chimeric antigen receptor <FONT STYLE="white-space:nowrap">T-cells</FONT>
<FONT STYLE="white-space:nowrap">(&#147;CAR-T&#148;).</FONT> Two key advantages include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Greater range of target antigens</B>: Unlike <FONT STYLE="white-space:nowrap">CAR-T,</FONT> which relies upon
antibody fragment binding to cell surface proteins for cell recognition and destruction, <FONT STYLE="white-space:nowrap">TCR-T</FONT> can recognize intracellular antigens as well. As most cancerous cells express cancer-specific intracellular
antigens, this widens the range of addressable targets for <FONT STYLE="white-space:nowrap">TCR-T</FONT> relative to <FONT STYLE="white-space:nowrap">CAR-T.</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Specificity for malignant tissue</B>: To date, all approved <FONT STYLE="white-space:nowrap">CAR-T</FONT>
products are specific to targets expressed on both healthy and diseased tissue. By contrast, <FONT STYLE="white-space:nowrap">TCR-T</FONT> targets can be specific exclusively or nearly exclusively to malignant tissue, potentially limiting <FONT
STYLE="white-space:nowrap">off-target</FONT> toxicities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because <FONT STYLE="white-space:nowrap">TCR-T</FONT>
therapeutics must be specific to both an antigen (which discriminates specific tumor types) and an HLA type (which discriminates specific addressable populations), we believe that Cytovant&#146;s focus on the unique medical needs of Asian patients
will give the company an advantage relative to organizations that lack an explicit focus on Asian markets. Similarly, because of the complexity of cell therapy manufacturing as well as China&#146;s comprehensive regulatory regime regarding human
tissue, we believe that Cytovant&#146;s local focus and the team&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">on-the-ground</FONT></FONT> manufacturing experience represent a key competitive advantage over global
competitors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cell therapy landscape in China is saturated with <FONT STYLE="white-space:nowrap">CAR-T</FONT> treatments, primarily
for hematologic oncology. Cytovant&#146;s <FONT STYLE="white-space:nowrap">TCR-T</FONT> approach will face fewer <FONT STYLE="white-space:nowrap">TCR-T</FONT> competitors and may better enable solid tumor targeting, a larger market opportunity than
blood cancers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Development-Stage Cellular Therapeutics in China </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g86u89.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Clarivate Analytics as of January 2021 </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CVT-TCR-01</FONT></FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CVT-TCR-01</FONT></FONT> is a preclinical
<FONT STYLE="white-space:nowrap">TCR-T</FONT> therapeutic candidate being developed to target cancer testis antigen <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NY-ESO-1</FONT></FONT> presented by
<FONT STYLE="white-space:nowrap">HLA-A*02.</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NY-ESO-1</FONT></FONT> has several characteristics that make it well-suited to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">316 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">ACT-based</FONT> immunotherapeutic approaches. First, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NY-ESO-1</FONT></FONT> is an oncofetal
protein expressed primarily in malignant tissue; in particular, it is highly expressed in soft tissue sarcoma, ovarian cancer, esophageal cancer and lung cancer, among other common tumors. Second, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">NY-ESO-1</FONT></FONT> is highly immunogenic and its expression is associated with decreased survival. Finally, because <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NY-ESO-1</FONT></FONT> is expressed
only intracellularly, we believe it is a suitable target for a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">TCR-T-based</FONT></FONT> approach. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NY-ESO-1</FONT></FONT> positive cancers and limitations of current treatments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NY-ESO-1</FONT></FONT> positive cancers represent a substantial health burden
in East Asia. The estimated incidences of colorectal, lung and esophageal cancer in China are 38.4, 56.3 and 22.4 cases per 100,000 individuals; these tumors are associated with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NY-ESO-1</FONT></FONT> positivity rates of 17%, 19% and 21%, respectively. Among certain less common tumors,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NY-ESO-1</FONT></FONT> positivity increases significantly, with 35% of bladder cancers, 43% of ovarian cancers and more than 80% of soft tissue sarcomas expressing the antigen. The
estimated incidences of these tumor types in China are 5.9, 7.8 and 3.2 cases per 100,000 individuals. In aggregate, these six tumor types represent a prevalent population of more than 3,000,000 patients in China alone, of which we estimate more
than 600,000 are likely to be <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NY-ESO-1</FONT></FONT> positive. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NY-ESO-1</FONT></FONT> is Highly Expressed Across Many Fatal Cancers in Asia </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g20e67.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While local control of soft tissue sarcoma is achievable through surgery and radiotherapy, up to 40% of
patients eventually recur at distant sites, of whom over 90% ultimately die of this malignancy. For patients with locally advanced or metastatic sarcoma, conventional chemotherapy with doxorubicin and/or ifosfamide used sequentially or in
combination represents the backbone of systemic treatment, for which overall survival is approximately 12 months. The high mortality and limited development of novel treatment options leaves significant unmet need for patients suffering from soft
tissue sarcoma. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical data </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
preclinical testing, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CVT-TCR-01</FONT></FONT> demonstrated specific and potent killing of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">NY-ESO-1-positive</FONT></FONT></FONT> cell lines as assessed by <FONT STYLE="white-space:nowrap">IFN-g</FONT> release. Moreover, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CVT-TCR-01</FONT></FONT>
was shown to spare <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NY-ESO-1</FONT></FONT> negative cell lines, indicating the candidate&#146;s specificity for
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NY-ESO-1.</FONT></FONT> In subsequent cytotoxicity assays, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CVT-TCR-01&#146;s</FONT></FONT> activity was shown to be
dependent on both <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NY-ESO-1</FONT></FONT> and <FONT STYLE="white-space:nowrap">HLA-A2</FONT> expression, consistent with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CVT-TCR-01&#146;s</FONT></FONT> specificity for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NY-ESO-1</FONT></FONT> presented by
<FONT STYLE="white-space:nowrap">HLA-A2.</FONT> Finally, cytokine release assays indicated that <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CVT-TCR-01</FONT></FONT> induces strongly proinflammatory <FONT
STYLE="white-space:nowrap">Th1-type</FONT> cytokine secretion upon exposure to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NY-ESO-1</FONT></FONT> positive cell lines, further supporting <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">CVT-TCR-01&#146;s</FONT></FONT> antitumor activity. Additionally, preliminary clinical results from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NY-ESO-1</FONT></FONT> directed TCR therapy demonstrate
promising overall response rates in a wide variety of tumor types, including synovial sarcoma, multiple myeloma and myxoid round cell liposarcoma. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">317 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CVT-TCR-01</FONT></FONT>
Shows Comparable Cytotoxic Activity in Three Donors </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g98g89.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CVT-TCR-01</FONT></FONT> Transduced
Effector Cells Secrete <FONT STYLE="white-space:nowrap">Th1-Type</FONT> Cytokines </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g97g79.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">318 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g65062g55g55.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are multiple competing cellular therapeutics targeting <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">NY-ESO-1</FONT></FONT> in development both globally and in Asia specifically. Among global programs, the most advanced is letetresgene autoleucel, which GlaxoSmithKline is currently developing in multiple solid tumor types
in several Phase 1 and 2 studies. Prior studies of letetresgene autoleucel demonstrated strong antitumor activity in patients with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NY-ESO-1-positive</FONT></FONT></FONT> soft tissue sarcoma, in which overall response rates of up to 50% were observed. Among Asia- and China-specific
programs, competing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NY-ESO-1-targeting</FONT></FONT></FONT> <FONT STYLE="white-space:nowrap">TCR-Ts</FONT> include TAEST-16001, which is being
developed by Xiangxue Life Sciences; <FONT STYLE="white-space:nowrap">TBI-1301,</FONT> which is being developed by Takara Bio and Otsuka Pharmaceutical Co.; and a program in development by Shenzhen Binde Bio. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Development plan </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cytovant is developing <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CVT-TCR-01</FONT></FONT> for the treatment of tumors with high disease burden in Asia. We expect to initiate CMC activities for <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">CVT-TCR-01</FONT></FONT> in the second half of 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">319 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>Arbutus Overview </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Overview: </U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Arbutus is a clinical-stage biopharmaceutical company primarily focused on advancing a Hepatitis B virus
(&#147;HBV&#148;) product pipeline that includes RNA interference (&#147;RNAi&#148;) therapeutics, oral capsid inhibitors, oral compounds that inhibit <FONT STYLE="white-space:nowrap">PD-L1</FONT> and oral HBV RNA destabilizers.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Lead programs:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap">AB-729:</FONT></I> Subcutaneously-delivered RNAi therapeutic targeted to
hepatocytes using Arbutus&#146;s proprietary covalently conjugated GalNAc delivery technology that inhibits viral replication. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>AB-836:</I> Proprietary next-generation oral capsid inhibitor that suppresses HBV DNA replication.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Disease overview: </U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Hepatitis B is a potentially life-threatening liver infection caused by HBV. HBV can cause chronic infection
which leads to a higher risk of death from cirrhosis and liver cancer. The World Health Organization estimates that over 250&nbsp;million people worldwide suffer from chronic HBV infection, while other estimates indicate that approximately
2&nbsp;million people in the United States suffer from chronic HBV infection. Approximately 900,000 people die every year from complications related to chronic HBV infection despite the availability of effective vaccines and current treatment
options. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Limitations of current treatments:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Current treatment options include nucleos(t)ide analogs (&#147;NA&#148;) and pegylated interferon regimens.
However, fewer than 5% of patients are functionally cured by these current treatment options after a finite treatment duration. With such low cure rates, most patients with chronic HBV infection are required to take NA therapy daily for the rest of
their lives. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Clinical data:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Preliminary data from ongoing single- and multi-dose Phase 1a/1b clinical trials for <FONT
STYLE="white-space:nowrap">AB-729</FONT> demonstrate robust hepatitis B surface antigen (HBsAg) reductions in multiple patient cohorts. <FONT STYLE="white-space:nowrap">AB-729</FONT> has been observed to be well-tolerated after single and repeat
doses based on results to date. These data support dosing intervals of up to 8 weeks. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Repeat dosing of <FONT STYLE="white-space:nowrap">AB-729</FONT> 60 mg every 8 weeks results in comparable mean
HBsAg declines relative to 60 mg every 4 weeks at week 44 <FONT STYLE="white-space:nowrap">(-1.87</FONT> log10 IU/mL vs <FONT STYLE="white-space:nowrap">-1.81</FONT> log10 IU/mL, p=0.8). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In HBV DNA positive chronic hepatitis B subjects, a single 90 mg <FONT STYLE="white-space:nowrap">AB-729</FONT>
dose resulted in robust mean HBsAg <FONT STYLE="white-space:nowrap">(-1.02</FONT> log10 IU/mL) and HBV DNA <FONT STYLE="white-space:nowrap">(-1.53</FONT> log10 IU/mL) declines at week 12, as well as decreases in HBV RNA and core-related antigen.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Development plan and upcoming milestones:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Arbutus expects to report data from the 90 mg every 12 weeks cohort and 90 mg every 8 weeks cohort in HBV DNA
positive subjects, in the second half of 2021. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Arbutus announced plans to evaluate a triple combination of AB-729, Antios Therapeutics&#146;s proprietary active
site polymerase inhibitor nucleuotide ATI-2173, and Viread (tenofovir disoproxil fumarate) in a single cohort in the ongoing Antios Phase 2a ANTT201 clinical trial. The multi-center, double-blinded, placebo-controlled, multiple-dose cohort will
evaluate the safety, pharmacokinetics, immunogenicity, and antiviral activity of this triple combination and is expected to initiate in the second half of 2021. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">320 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Arbutus expects to initiate a Phase 2a trial evaluating a combination of AB-729 and Vaccitech&#146;s VTP-300, an
immunotherapeutic designed to elicit an HBV specific immune response, in subjects with chronic HBV infection in the second half of 2021. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Arbutus received authorization from the FDA to proceed with its IND application for AB-729 in a Phase 2a clinical
trial. The Phase 2a proof-of-concept clinical trial will evaluate the safety and efficacy of AB-729 in combination with ongoing NA therapy and short courses of Peg-IFN<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>-2a in subjects with chronic HBV
infection. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Arbutus expects to provide initial data from the Phase 1a/1b clinical trial of
<FONT STYLE="white-space:nowrap">AB-836</FONT> in the second half of 2021. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Roivant ownership:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As of March&nbsp;31, 2021, we own 33% of the issued and outstanding common shares of Arbutus and 29% on a
Fully-Diluted basis, in each case including the conversion of preferred shares held by Roivant into common shares. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">321 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>Sio Gene Therapies Overview </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Overview: </U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sio Gene Therapies is a clinical-stage company focused on developing gene therapies for neurodegenerative
diseases, with a pipeline of innovative product candidates for the treatment of GM1 gangliosidosis, GM2 gangliosidosis (including <FONT STYLE="white-space:nowrap">Tay-Sachs</FONT> disease and Sandhoff disease) and Parkinson&#146;s disease.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Lead programs:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">AXO-AAV-GM1:</FONT></FONT></I>
Investigational gene therapy currently being developed as a potential <FONT STYLE="white-space:nowrap">one-time</FONT> disease modifying treatment for GM1 gangliosidosis, a rare disease caused by <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">loss-of-function</FONT></FONT> mutations in the GLB1 gene. The program utilizes an adeno-associated virus (AAV) vector to deliver a functional copy of the GLB1 gene with the goals of restoring <FONT
STYLE="white-space:nowrap">&szlig;-gal</FONT> enzyme activity in the CNS and reducing GM1 ganglioside accumulation, to ultimately improve neurological function and extend survival. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">AXO-AAV-GM2:</FONT></FONT></I>
Investigational gene therapy currently being developed as a potential <FONT STYLE="white-space:nowrap">one-time</FONT> disease modifying treatment for GM2 gangliosidosis (including <FONT STYLE="white-space:nowrap">Tay-Sachs</FONT> disease and
Sandhoff disease). The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">AXO-AAV-GM2</FONT></FONT> program utilizes AAV dual vectors to deliver functional copies of both the HEXA gene and the HEXB gene, with the goal of restoring
normal Hex A enzyme function in the central nervous system. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">AXO-Lenti-PD:</FONT></FONT> In vivo
</I>lentiviral gene therapy investigational product candidate currently being developed as a potential <FONT STYLE="white-space:nowrap">one-time</FONT> treatment of Parkinson&#146;s disease. <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">AXO-Lenti-PD</FONT></FONT> delivers a construct of three genes that encode the critical enzymes required for the biochemical synthesis of dopamine from endogenous tyrosine. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Disease overview:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">GM1 gangliosidosis is a rare, inherited neurodegenerative lysosomal storage disorder characterized by the
accumulation of GM1 ganglioside with an estimated incidence of approximately one in 100,000 live births worldwide. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">GM2 gangliosidosis, also known as <FONT STYLE="white-space:nowrap">Tay-Sachs</FONT> or Sandhoff diseases, is a
rare, inherited neurodegenerative lysosomal storage disorder characterized by buildup of GM2 ganglioside in lysosomes with an estimated incidence of approximately one in 150,000 live births worldwide. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Parkinson&#146;s disease is a chronic neurodegenerative disorder that primarily results in progressive and
debilitating motor symptoms. It is estimated that up to 1&nbsp;million people in the U.S. and 7 to 10&nbsp;million people worldwide suffer from Parkinson&#146;s disease. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Limitations of current treatments:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">AXO-AAV-GM1:</FONT></FONT></I> GM1
gangliosidosis is uniformly fatal, and there are no disease-modifying treatment options. Management is limited to symptomatic treatment and palliative care. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">AXO-AAV-GM2:</FONT></FONT></I> There are no
disease-modifying treatment options for either <FONT STYLE="white-space:nowrap">Tay-Sachs</FONT> disease or Sandhoff disease, and management is limited to symptomatic treatment and palliative care. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">AXO-Lenti-PD:</FONT></FONT> </I>The
treatment of Parkinson&#146;s disease is limited to symptomatic treatments, as no therapies have proven effective in altering the course of the disease or addressing the underlying pathophysiological processes.
<FONT STYLE="white-space:nowrap">One-time</FONT> gene therapy has the potential to reduce reliance on levodopa-based therapies, reduce troublesome side effects such as dyskinesia, and slow the course of disease progression. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">322 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Clinical data:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">AXO-AAV-GM1:</FONT></FONT></I> <FONT
STYLE="white-space:nowrap">Six-month</FONT> <FONT STYLE="white-space:nowrap">follow-up</FONT> data from ongoing Phase 1/2 trial have shown <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">AXO-AAV-GM1</FONT></FONT> to be generally
well-tolerated, with all five children dosed demonstrating signs of clinical disease stability, with serum &szlig;-galactosidase enzyme activity restored to an average of 38% of normal reference levels in the
<FONT STYLE="white-space:nowrap">low-dose</FONT> cohort. Additionally, 18-49% reductions from baseline in accumulated substrate, GM1 ganglioside, were observed in the cerebrospinal fluid in 4 out of 5 children in the low-dose cohort at six months.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">AXO-AAV-GM2:</FONT></FONT> </I>Clinically
meaningful improvement in motor skills and disease stabilization were observed in two infants with <FONT STYLE="white-space:nowrap">Tay-Sachs</FONT> disease following administration under expanded access protocol. An IND was cleared by FDA in
November 2020 and the first patient was dosed in January 2021. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">AXO-Lenti-PD:</FONT></FONT> </I>Preliminary
data from ongoing Phase 2 trial have shown <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">AXO-Lenti-PD</FONT></FONT> to be generally well-tolerated and to demonstrate dose-dependent improvements in motor function. To date, 21
patients have received gene therapy in dose-escalation studies spanning 5 dose cohorts. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Development plan and upcoming milestones:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">AXO-AAV-GM1:</FONT></FONT></I> Sio expects
to report <FONT STYLE="white-space:nowrap">12-month</FONT> safety, biomarker and efficacy from the <FONT STYLE="white-space:nowrap">low-dose</FONT> cohort of its ongoing Phase 1/2 trial in the second half of 2021. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">AXO-AAV-GM2:</FONT></FONT> </I>Sio expects
to continue patient identification, screening and enrollment in Stage 1 of its ongoing Phase 1/2 trial throughout 2021. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">AXO-Lenti-PD:</FONT></FONT> </I>Sio and its
manufacturing partner, Oxford Biomedica, are currently working on the development of a suspension-based manufacturing process at scale. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>Roivant ownership:</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As of March&nbsp;31, 2021, we own 27% of the issued and outstanding shares of Sio common stock and 25% on a
Fully-Diluted basis. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Asset Acquisition and License Agreements; Other Vant Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Immunovant </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>License Agreement with HanAll
Biopharma Co., Ltd.</I><B><I> </I></B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2017, our wholly owned subsidiary, Roivant Sciences GmbH (&#147;RSG&#148;),
entered into a license agreement with HanAll Biopharma Co., Ltd. (&#147;HanAll&#148;) (the &#147;HanAll Agreement&#148;). Under the HanAll Agreement, RSG received (i)&nbsp;the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> right to
manufacture and (ii)&nbsp;the exclusive, royalty-bearing right to develop, import and use the antibody referred to as IMVT-1401 and certain <FONT STYLE="white-space:nowrap">back-up</FONT> and next-generation antibodies, and products containing such
antibodies, and to commercialize such products, in the United States, Canada, Mexico, the E.U., the U.K., Switzerland, the Middle East, North Africa and Latin America (the &#147;HanAll Licensed Territory&#148;), for all human and animal uses. RSG
also received the right to grant a sublicense, with prior written notice to HanAll of such sublicense, to: (i)&nbsp;a third party in any country in the HanAll Licensed Territory outside of the United States and E.U.; (ii) an affiliate of RSG in any
country in the HanAll Licensed Territory; and (iii)&nbsp;a third party in the United States and E.U. only after submission of a biologics license application in the United States or a Marketing Authorization Application in the E.U. Pursuant to the
HanAll Agreement, RSG granted to HanAll an exclusive, royalty-free license under certain RSG patents, <FONT STYLE="white-space:nowrap">know-how</FONT> and other intellectual property relating to such antibodies and products to develop, manufacture
and commercialize such antibodies and products for use outside of the HanAll Licensed Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2018, Immunovant Sciences
GmbH, (&#147;ISG&#148;) obtained and assumed all rights, title, interest and obligations under the HanAll Agreement from RSG, including all rights to IMVT-1401 in the HanAll Licensed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">323 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Territory, for an aggregate purchase price of $37.8&nbsp;million plus Swiss value-added tax of $2.9&nbsp;million. HanAll and RSG have agreed that neither they nor certain of their affiliates will
clinically develop or commercialize certain competitive products in the HanAll Licensed Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the HanAll Agreement, the
parties may choose to collaborate on a research program directed to the research and development of next generation FcRn inhibitors in accordance with an agreed plan and budget. ISG is obligated to reimburse HanAll for half of such research and
development expenses incurred by HanAll, up to an aggregate reimbursement amount of $20.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the HanAll Agreement,
RSG made an upfront payment of $30.0&nbsp;million to HanAll in December 2017. In May 2019, ISG achieved its first development and regulatory milestone, which resulted in a $10.0&nbsp;million milestone payment that ISG subsequently paid to HanAll in
August 2019. ISG will be responsible for future contingent payments and royalties, including up to a maximum of $442.5&nbsp;million upon the achievement of certain development, regulatory and sales milestone events. ISG is also obligated to pay
HanAll tiered royalties ranging from the <FONT STYLE="white-space:nowrap">mid-single</FONT> digits to <FONT STYLE="white-space:nowrap">mid-teens</FONT> on net sales of licensed products, subject to standard offsets and reductions as set forth in the
HanAll Agreement. These royalty obligations apply on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis and end upon the latest of (i)&nbsp;the date on which the last valid claim of the licensed patents that cover such licensed product in such
country expires, (ii)&nbsp;the date on which the data or market exclusivity for such licensed product in such country expires or (iii) 11 years after the first commercial sale of such licensed product in such country. The HanAll Agreement will
expire on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis on the expiration of the last royalty term with respect to a given licensed product, unless earlier terminated. ISG may terminate
the HanAll Agreement in its entirety without cause upon 180 days&#146; written notice following 30 days of discussion. Either party may terminate the HanAll Agreement upon 60 days&#146; written notice for uncured material breach (or 30 days in the
case <FONT STYLE="white-space:nowrap">of&nbsp;non-payment),&nbsp;or</FONT> immediately upon written notice if the other party files a voluntary petition, is subject to a substantiated involuntary petition or for certain other solvency events. HanAll
may terminate the HanAll Agreement if ISG or its affiliates challenge the validity or enforceability of any of the licensed patents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Proteovant
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Michigan Research Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2018, our subsidiary Oncopia Therapeutics, Inc. (&#147;Oncopia&#148;) entered into a research agreement with the Regents of the
University of Michigan (the &#147;University of Michigan&#148;) (the &#147;Michigan Research Agreement&#148;). Pursuant to the Michigan Research Agreement, Oncopia and the University of Michigan are collaborating to discover and optimize small
molecule protein degraders. Any intellectual property developed under the Michigan Research Agreement that is directed to certain targets will be licensed by the University of Michigan to Oncopia pursuant to the Michigan License Agreement, as
described below. Pursuant to the Michigan Research Agreement, Oncopia is obligated to provide a low eight-digit amount in funding between 2021 and 2023. Unless earlier terminated based on customary termination rights or extended by mutual agreement,
the Research Agreement continues until December 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Michigan License Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2020, Oncopia entered into an amended and restated patent license agreement with the University of Michigan (the &#147;Michigan
License Agreement&#148;), pursuant to which the University of Michigan granted Oncopia an exclusive, worldwide, sublicensable license under certain patents related to certain existing small molecule protein degraders and certain future small
molecule protein degraders that may be developed under the Michigan Research Agreement to make, use and commercialize certain products covered by such patents. Such license grant is subject to, among other things, certain rights required to be
granted under prior research or sponsorship agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Michigan License Agreement, Oncopia is obligated to pay the University
of Michigan a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">low-to-mid</FONT></FONT> single-digit royalty on net sales of each licensed product. Oncopia&#146;s royalty obligations apply on
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">324 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product,</FONT></FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis and end upon the expiration of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> valid claim of
the licensed patents under the University of Michigan Agreement which covers such licensed product in such country. The patents and pending patent applications, if granted, currently licensed under the Michigan License Agreement are expected to
expire as early as 2037, and as late as 2042, without giving effect to any potential patent term extensions or patent term adjustments. Oncopia is obligated to pay the University of Michigan minimum annual royalties in the low five-digit range from
March 2021 until the first commercial sale of a licensed product, at which time such minimum annual royalties will increase to a low <FONT STYLE="white-space:nowrap">six-digit</FONT> amount. Oncopia may also be obligated to pay up to a maximum of a
high seven-digit amount in development and commercial milestone payments on a per product basis. Unless earlier terminated based on customary termination rights, the term of the Michigan License Agreement will continue until the expiration of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> valid claim of the licensed patents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dermavant</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Agreements Relating to Tapinarof </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July
2018, our subsidiary Dermavant Sciences GmbH (&#147;DSG&#148;) acquired the worldwide rights (other than for China) with respect to certain intellectual property rights retained by Welichem Biotech Inc. (&#147;Welichem&#148;) to tapinarof and
related compounds from Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Ltd. (collectively, &#147;GSK&#148;) pursuant to an asset purchase agreement (the &#147;GSK Agreement&#148;). GSK previously acquired rights to a
predecessor formulation of tapinarof from Welichem pursuant to an asset purchase agreement between GSK and Welichem entered into in May 2012 (the &#147;Welichem Agreement&#148;). Under the GSK Agreement, DSG made an upfront payment of &pound;150.0
million (approximately $191 million) to GSK. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DSG is also obligated to pay GSK &pound;100.0 million (approximately $133 million) within 70
days following the receipt of marketing approval of tapinarof in the United States. The GSK Agreement does not require DSG to pay any royalties on sales of tapinarof following commercialization or make any commercial milestone payments, except for
milestones owed to Welichem as described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the GSK Agreement, DSG assumed all obligations under the Welichem
Agreement, including payment of up to C$80.0 million (approximately $61 million) in potential development milestone payments and up to C$100.0 million (approximately $76 million) in potential commercial milestone payments. Following the commencement
of the two pivotal Phase 3 clinical trials of tapinarof for the treatment of psoriasis in May 2019, on June 5, 2019, DSG paid to Welichem a milestone payment of C$30.0 million (approximately $23&nbsp;million). In the future DSG may seek to enter
into a royalty financing or similar transaction to fund its milestone payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2018, in connection with the GSK Agreement, DSG
and GlaxoSmithKline Trading Services Limited (&#147;GSK Trading&#148;) entered into a clinical manufacturing and supply agreement for tapinarof pursuant to which DSG obtained an existing supply of tapinarof drug product and drug substance as well as
additional supply of tapinarof drug product for clinical trials on a cost plus basis. As required under the GSK Agreement, in April 2019, DSG and GSK Trading also entered into a commercial manufacturing and supply agreement (the &#147;Commercial
Supply Agreement&#148;) pursuant to which DSG will obtain tapinarof drug product and drug substance from GSK Trading. Under the Commercial Supply Agreement, GSK Trading will provide development services to prepare for the manufacture and supply of
tapinarof at commercial scale. DSG will obtain commercial supply of tapinarof on a cost plus basis under the commercial supply agreement. As required under the GSK Agreement, DSG entered into a letter agreement with GSK whereby GSK has agreed to
make certain planned capital improvements, including design work, the purchase and modification of additional equipment items, and the reconfiguration of the existing production modules at GSK&#146;s manufacturing site in Cork, Ireland with DSG
agreeing to reimburse GSK an anticipated aggregate capital expenditure amount, which is not expected to exceed approximately &#128;11.4 million (approximately $13 million). DSG is not required to reimburse GSK for any actual amounts incurred in
excess of 110% of the anticipated aggregate capital expenditure amount and the letter agreement will terminate at the later of (i) the completion of the Planned Capital Improvements and (ii) reimbursement by DSG of GSK&#146;s actual capital
expenditures related to such planned capital improvements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">325 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration and License Agreement with Japan Tobacco Inc. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2020, DSG entered into a collaboration and license agreement with Japan Tobacco Inc. (&#147;Japan Tobacco&#148;) (the &#147;Japan
Tobacco Agreement&#148;). Pursuant to the Japan Tobacco Agreement, DSG granted Japan Tobacco exclusive rights to develop, register and market tapinarof in Japan for the treatment of dermatological diseases and conditions, including psoriasis and
atopic dermatitis. In connection with the Japan Tobacco Agreement, Japan Tobacco has signed an exclusive license with its subsidiary, Torii, for <FONT STYLE="white-space:nowrap">co-development</FONT> and commercialization of tapinarof in Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Japan Tobacco Agreement, in January 2020, DSG received an upfront payment of $60.0&nbsp;million and may receive up to an additional
$53.0&nbsp;million upon the achievement of certain development milestones for tapinarof in psoriasis and atopic dermatitis. In addition, DSG will be entitled to tiered purchase prices specified in the Japan Tobacco Agreement in consideration of
DSG&#146;s commercial supply of tapinarof to Japan Tobacco under the terms of a separate commercial supply agreement to be negotiated by the parties. DSG also has the right to receive royalties, to be negotiated by the parties and consistent with
the purchase prices, based on product sales of tapinarof in the indications to the extent that DSG is no longer responsible for supplying tapinarof to Japan Tobacco. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Japan Tobacco Agreement will remain in effect until expiration of the obligation to pay royalties, unless terminated in accordance with
the following: (1)&nbsp;for any reason by Japan Tobacco upon written notice to DSG, which notice must be provided (x) at least 90 days in advance, if the termination is prior to regulatory approval of tapinarof in Japan for any dermatological
disease or condition, and (y) at least 180 days in advance, if the termination is subsequent to regulatory approval of tapinarof in Japan for any dermatological disease or condition; (2)&nbsp;by either party upon written notice for the other
party&#146;s material breach if such party fails to cure such breach within the specified cure period; or (3)&nbsp;by DSG if Japan Tobacco or its affiliates or sublicenses participate in a challenge to certain of our patents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dermavant Financing Agreements&#151;Dermavant Revenue Interest Purchase and Sale Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2021, DSG, as seller, entered into a Revenue Interest Purchase and Sale Agreement (the &#147;RIPSA&#148;) with XYQ Luxco S.&#192; R.L.
(&#147;XYQ Luxco&#148;), NovaQuest Co-Investment Fund XVII, L.P., an affiliate of NovaQuest Capital Management, LLC, and MAM Tapir Lender, LLC, an affiliate of Marathon Asset Management, L.P. (collectively, the &#147;Purchasers&#148;), together with
U.S. Bank National Association, as collateral agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following satisfaction of the funding conditions set forth in the RIPSA, including
receipt of marketing approval from the FDA for tapinarof, the Purchasers are obligated to pay DSG a total of $160.0 million in accordance with the terms and conditions set forth in the RIPSA (the &#147;Purchase Price&#148;). In consideration
therefor, each of the Purchasers will have the right to receive a low single-digit to high single-digit tiered percentage of quarterly revenues based on the achievement of specified net sales thresholds for tapinarof in the U.S., up to a cap set at
a multiple of the Purchase Price paid to DSG by the Purchasers. Payments of such quarterly revenues to the Purchasers under the RIPSA are secured by a security interest in certain tapinarof-related assets, including intellectual property rights and
certain other assets that are owned by, licensed to or otherwise controlled by DSG related to the development and commercialization of tapinarof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The RIPSA contains certain representations and warranties and covenants applicable to DSL and its subsidiaries. The RIPSA also contains
certain Events of Default (as defined in the RIPSA) such as the breach of payment and other obligations, bankruptcy-related events and cross-defaults with respect to other related documents and agreements creating indebtedness. The occurrence of an
Event of Default following the Purchasers&#146; funding of the Purchase Price triggers DSG&#146;s obligation to pay an Event of Default Fee (as defined in the RIPSA) of $160.0 million, less revenue payments previously paid, as liquidated damages. In
addition, the occurrence of a change of control of DSG prior to the Purchasers funding the Purchase Price triggers DSG&#146;s right, but not the obligation, to terminate the RIPSA by payment of the Pre-Funding Change of Control Option Price (as
defined in the RIPSA) to all of the Purchasers, which varies based on the date of termination and certain milestones with respect to tapinarof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">326 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dermavant Financing Agreements&#151;Dermavant Credit Agreement with XYQ Luxco </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2021, our subsidiaries Dermavant Sciences Ltd. (&#147;DSL&#148;), Dermavant Holdings Limited, Dermavant Sciences IRL Limited and DSG, as
borrowers (the &#147;Borrowers&#148;), and certain other subsidiaries of DSL, as initial guarantors, entered into a credit agreement (the &#147;Credit Agreement&#148;) with XYQ Luxco, as lender, and U.S. Bank National Association, as collateral
agent. The Credit Agreement provides for a term loan of $40.0 million (the &#147;Term Loan&#148;), the proceeds of which were used by the Borrowers to repay in full and terminate an existing credit facility with Hercules Capital Inc., with the
remaining proceeds to be used for working capital and other general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Term Loan bears interest at a fixed interest
rate of 10.0% per annum, with interest paid quarterly in arrears until maturity in May 2026, at which time the principal amount is due. The Borrowers have the option to prepay the Term Loan in whole or in part, subject to (i) until May 2023, a
prepayment premium of 5.0% of the principal amount being repaid (plus the present value of all future scheduled interest on the principal being prepaid that would accrue through May 2023 calculated based on a discount rate equal to the treasury rate
plus 100 basis points, except in the event the prepayment is due to a change of control), (ii) from May 2023 to May 2024, a prepayment premium of 5.0% of the principal amount being repaid, and (iii) from May 2024 to May 2025, a prepayment premium of
2.5% of the principal amount being repaid. From May 2025 through maturity, the Term Loan may be prepaid in whole or part without a prepayment premium. Optional and mandatory prepayment of the Term Loan, as well as other forms of prepayment,
repayment, applications or reductions, will also require that DSL pays an Exit Fee (as defined in the Credit Agreement), calculated based on the amount so prepaid, repaid, applied or reduced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Borrowers&#146; obligations under the Credit Agreement are unconditionally guaranteed by the initial guarantors and secured by first
priority security interests in substantially all of the tangible and intangible assets of the Borrowers and guarantors, including certain intellectual property rights, bank accounts, any and all insurance receivables, intercompany receivables and/or
trade receivables and certain quotas and/or participation rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Credit Agreement contains certain representations and warranties,
affirmative covenants, negative covenants and conditions that are customarily required for similar financings, including a covenant against the occurrence of a &#147;change in control&#148; (subject to the Borrowers&#146; right to prepay the Term
Loan), financial reporting obligations and certain limitations on indebtedness, liens (including on intellectual property and other assets), investments, distributions (including dividends), collateral, transfers, mergers or acquisitions, taxes,
corporate changes and deposit accounts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Credit Agreement contains a minimum cash covenant that requires the initial Borrowers and the
guarantors thereunder to maintain a minimum cash balance of $10.0 million until the earlier of (a) a Qualified IPO (as defined in the Credit Agreement), (b) an Ultimate Parent Spinout (as defined in the Credit Agreement), and (c) the date that XYQ
Luxco, in its capacity as a purchaser under the RIPSA, has received cumulative payments from DSG under the RIPSA in an aggregate amount equal to its pro rata portion of the funding amount thereunder. The Credit Agreement also contains customary
events of default (subject, in certain instances, to specified grace periods) including, but not limited to, the failure to make payments of interest, premium, fees, indemnity or principal under the Term Loan, the failure to comply with certain
covenants and agreements specified in the Credit Agreement, defaults in respect of certain other indebtedness and certain events relating to bankruptcy or insolvency. If any event of default occurs, the principal, premium, if any, interest and any
other monetary obligations on all the then outstanding amounts under the Term Loan may become due and payable immediately. Upon the occurrence of an event of default, a default interest rate of an additional 2% per year may be applied to the
outstanding principal balance, and the lender may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Credit Agreement. Upon the occurrence of certain bankruptcy and insolvency events, the
obligations under the Credit Agreement would automatically become due and payable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">327 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the closing date of the Term Loan and in accordance with the Credit Agreement, DSL issued
to XYQ Luxco a warrant to purchase an aggregate of 1,199,072 common shares of DSL. The warrant is exercisable at any time until the earlier of (x) seven years from the date of issuance and (y) three years from the closing of an underwritten initial
public offering of DSL&#146;s common shares pursuant to an effective registration statement. The warrant includes customary registration rights and customary anti-dilution provisions for the common shares underlying the warrant in respect of certain
corporate events (including share splits, share combinations, share dividends and other recapitalization transactions). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Genevant </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cross-License Agreement with Arbutus Biopharma Corporation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2018, our subsidiary, Genevant Sciences Ltd (&#147;Genevant&#148;), entered into a cross-license agreement with our affiliate, Arbutus
Biopharma Corporation (&#147;Arbutus&#148;), which the parties amended twice in June 2018 (as amended, the &#147;Arbutus Cross-License Agreement&#148;). Pursuant to the Arbutus Cross-License Agreement Arbutus granted Genevant an exclusive,
sublicensable, worldwide, transferable, irrevocable and perpetual license under certain patents and <FONT STYLE="white-space:nowrap">know-how</FONT> relating to Arbutus&#146;s lipid nanoparticle and GaINAc technology for <FONT
STYLE="white-space:nowrap">RNA-based</FONT> applications other than hepatitis B virus (&#147;HBV&#148;), and certain other excluded fields. The license is subject to certain rights which have previously licensed by Arbutus to other third parties.
Under the Arbutus Cross-License Agreement, Genevant granted back to Arbutus an exclusive, sublicensable, worldwide, irrevocable, perpetual, royalty-free license under the intellectual property licensed under the Arbutus Cross-License Agreement and
certain intellectual property acquired by Genevant after the effective date of the Arbutus Cross-License Agreement for applications involving the treatment and prevention of HBV. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Genevant is obligated to pay Arbutus tiered low single-digit percentage royalties on sales of products covered by the licensed patents. If
Genevant sublicenses intellectual property licensed from Arbutus or collaborates with any third party to develop, manufacture or commercialize any products covered by the intellectual property licensed by Arbutus, it will be required to pay Arbutus
the lesser of (i)&nbsp;up to 20% of the Royalty-Related Receipts (as defined in the Arbutus Cross-License Agreement) received by Genevant from such sublicensees or collaborators and (ii)&nbsp;tiered low single-digit royalties on net sales by
sublicensees. Genevant&#146;s royalty obligations apply on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product,</FONT></FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis and end on the date on which the last valid claim of the licensed patents in such country that covers such licensed product expires. The patents
and pending patent applications, if granted, currently licensed under the Arbutus Cross-License Agreement are expected to expire as early as 2023, and as late as 2039, without giving effect to any potential patent term extensions or patent term
adjustments. Unless earlier terminated based on customary termination rights, the Arbutus Cross-License Agreement will continue until the expiration of Genevant&#146;s royalty obligations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Aruvant </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>License Agreement with Cincinnati
Children&#146;s Hospital Medical Center</I><B> </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2018, our subsidiary Aruvant Sciences Ltd. (&#147;Aruvant&#148;),
through its wholly owned subsidiary Aruvant Sciences GmbH (&#147;ASG&#148;), entered into a license agreement with Cincinnati Children&#146;s Hospital Medical Center (&#147;CCHMC&#148;), pursuant to which CCHMC granted ASG (i)&nbsp;an exclusive,
royalty-bearing, worldwide license for the use of certain patents, <FONT STYLE="white-space:nowrap">know-how</FONT> and data relating to certain gene therapies for sickle cell anemia and certain other hemoglobinopathies, including <FONT
STYLE="white-space:nowrap">ARU-1801,</FONT> and for related manufacturing processes, and (ii)&nbsp;a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> royalty-bearing, worldwide license for the use of relevant future CCHMC&#146;s patents and
general manufacturing <FONT STYLE="white-space:nowrap">know-how</FONT> (the &#147;CCHMC License Agreement&#148;). The license is subject to, among other things, a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license previously granted by
CCHMC to another party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration for entering into the CCHMC License Agreement, Aruvant issued nine million common shares to
CCHMC. Aruvant is obligated to issue additional shares to CCHMC upon the earliest of (i)&nbsp;immediately prior to a change of control event, (ii)&nbsp;immediately following Aruvant&#146;s issuance, in the aggregate, of equity
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">328 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities, convertible or exchangeable securities, or other securities in exchange for cash equal to or in excess of $150.0&nbsp;million or (iii)&nbsp;immediately prior to the effectiveness of a
registration statement in connection with an initial public offering by Aruvant. When such a triggering event occurs, Aruvant must issue CCHMC additional shares equal to the difference between 12% of Aruvant&#146;s fully-diluted share capital, less
the closing shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ASG has paid CCHMC approximately $25.0&nbsp;million in upfront licensing fees and is obligated to pay up to
$30.0&nbsp;million in the aggregate in sales, development and regulatory milestones for the first licensed product to reach certain specified milestones. Additionally, ASG is obligated to pay to CCHMC a low to mid single-digit royalty on net sales
of licensed products subject to certain potential downward adjustments for third-party licenses, expiration of certain patent claims or the entry into the market of a competing generic product. ASG&#146;s royalty obligations continue on <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until the latest to occur of (i)&nbsp;the date
on which the last valid claim of the licensed patents covering such licensed product in such country expires, (ii)&nbsp;the <FONT STYLE="white-space:nowrap">ten-year</FONT> anniversary of the first commercial sale of such licensed product in such
country or (iii)&nbsp;the expiration of regulatory exclusivity for such licensed product in such country. Unless earlier terminated based on customary termination rights, the CCHMC License Agreement will continue on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis until the expiration of the royalty term for such licensed product. In the event of termination, the license granted to ASG under the agreement
will terminate and, in the case of ASG&#146;s termination for convenience or CCHMC termination for ASG&#146;s material breach or bankruptcy, ASG will be deemed to grant CCHMC a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide,
perpetual license under ASG&#146;s patents and <FONT STYLE="white-space:nowrap">know-how</FONT> that relate to the licensed products and any patents for jointly developed inventions to develop and commercialize any product. Such license is
royalty-free in the case of termination for ASG&#146;s material breach or bankruptcy, and will be royalty-bearing on terms to be negotiated in good faith in the case of termination by ASG for convenience. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lysovant </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>License Agreement with iNtRON
Biotechnology, Inc. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2018, our subsidiary, Lysovant Sciences GmbH (&#147;LSG&#148;), entered into a license agreement with
iNtRON Biotechnology, Inc. (&#147;iNtRON&#148;), which the parties amended in March 2019 and August 2019 (the &#147;iNtRON License Agreement&#148;). Pursuant to the iNtRON License Agreement, iNtRON granted LSG an exclusive, worldwide, sublicensable,
royalty-bearing license under certain patents and <FONT STYLE="white-space:nowrap">know-how</FONT> to develop and commercialize certain antimicrobial bacteriophage-derived endolysins for any use other than uses involving topical administration.
iNtRON also granted LSG an exclusive option during a specified exclusivity period extending until the expiration of a certain evaluation period to obtain an exclusive license to develop, manufacture and commercialize products containing certain
other endolysins. LSG granted iNtRON a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, sublicensable, royalty-free, license under certain patents and <FONT STYLE="white-space:nowrap">know-how</FONT> to develop and commercialize
products containing the endolysins licensed under the iNtRON License Agreement formulated for topical administration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">LSG paid iNtRON an
upfront fee of $10.0&nbsp;million and is obligated to pay an option exercise fee to iNtRON upon each exercise of its option to obtain a license to additional endolysins. LSG may also be obligated up pay up to a maximum of $42.5&nbsp;million in
development and regulatory milestone payments (with respect to the originally licensed endolysin), up to a maximum of $37.5&nbsp;million in development and regulatory milestone payments (with respect to each of any new endolysins) and a maximum of
$940.0&nbsp;million in commercial milestone payments. LSG may also be obligated to pay a tiered <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">low-to-mid</FONT></FONT> teens percentage royalty, subject to certain customary
reductions, on net sales of products covered by licensed patents. LSG&#146;s royalty obligations apply on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis and end upon the latest of (i)&nbsp;the date on which the last valid claim of the licensed patents that covers such licensed product in such country expires, (ii)&nbsp;ten years after
the first commercial sale of such licensed product in such country and (iii)&nbsp;the date on which the regulatory exclusivity for such licensed product in such country expires. Unless earlier terminated based on customary termination rights, the
iNtRON License Agreement will continue in effect on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis until the expiration of all royalty obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">329 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on our ability to obtain and maintain proprietary protection for current and future products and product
candidates, technologies and <FONT STYLE="white-space:nowrap">know-how;</FONT> to operate without infringing, misappropriating or otherwise violating the proprietary rights of others; and to prevent others from infringing our proprietary rights. Our
policy is to seek to protect our proprietary position by, among other methods, filing or <FONT STYLE="white-space:nowrap">in-licensing</FONT> U.S. and foreign patents and patent applications related to our proprietary technology, inventions and
improvements that are important to the development and implementation of our business. We may also rely on trade secrets, <FONT STYLE="white-space:nowrap">know-how,</FONT> continuing technological innovation and potential <FONT
STYLE="white-space:nowrap">in-licensing</FONT> opportunities to develop and maintain our proprietary position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions of
companies like us are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in patents in the fields of genetic therapy, cell therapy, biologics or pharmaceutical products
generally has emerged in the United States or in Europe, among other countries. Changes in the patent laws and rules, either by legislation, judicial decisions, or regulatory interpretation in other countries may diminish our ability to protect our
inventions and enforce our intellectual property rights, and more generally could affect the value of our intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell, importing or otherwise
commercializing any of our patented inventions, either directly or indirectly, will depend in part on our success in obtaining, defending and enforcing patent claims that cover our technology, inventions, and improvements. We cannot be sure that any
patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the
future will be commercially useful in protecting our product candidates and technology. Moreover, our issued patents and those that may issue in the future may not guarantee us the right to practice our technology in relation to the
commercialization of our product candidates or technology. The area of patents and other intellectual property rights in biotechnology is an evolving one with many risks and uncertainties, which may prevent us from commercializing our current and
future products and product candidates and practicing our proprietary technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our issued patents and those that may issue in the
future may be challenged, narrowed, circumvented or invalidated, which could limit our ability to stop competitors from marketing related products or technologies or limit the length of the term of patent protection that we may have for our current
and future products and product candidates and technologies. In addition, the rights granted under any issued patents may not provide us with complete protection or competitive advantages against competitors or other third parties with similar
technology. Furthermore, our competitors may independently develop similar technologies that achieve similar outcomes but with different approaches. For these reasons, we may have competition for our product candidates. Moreover, the time required
for development, testing and regulatory review of our product candidates may shorten the length of effective patent protection following commercialization. For this and other risks related to our proprietary technology, inventions, improvements,
platforms and product candidates, please see the section entitled &#147;Risk Factors&#151;Risks Related to Roivant&#146;s Business and Industry&#151;Risks Related to Our Intellectual Property.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Patents and Patent Applications </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">ARU-1801</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of May&nbsp;1, 2021, ASG has licensed rights to six patent families containing at least 18 issued patents and 21 pending patent applications
in numerous foreign jurisdictions, including the European Union and Japan, with claims relating to a mutant human <FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>-Globin gene and lentiviral vectors. These patents and pending applications, if issued,
are expected to expire as early as 2035, in each case without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">330 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Tapinarof </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of May&nbsp;1, 2021, DSG is the exclusive owner of patent families that include six issued U.S. patents and at least 10 pending U.S. patent
applications, as well as more than 20 issued patents and at least 50 pending patent applications in numerous foreign jurisdictions, including the European Union and Japan, relating to tapinarof, the synthesis of tapinarof, intermediates made in the
synthesis, the drug substance crystal form, topical formulations of tapinarof and uses thereof in certain diseases and disorders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of
these patent families is directed to the topical formulation of tapinarof, and its use to treat plaque psoriasis, that Dermavant has evaluated in Phase 3 clinical trials, as well as its use to treat atopic dermatitis which has been evaluated in
Phase 2b clinical trials, which includes a patent that was issued in the United States and has a natural expiration date in 2036, without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate
maintenance, renewal, annuity, or other governmental fees. This formulation patent includes 113 claims directed to topical, homogeneous, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">oil-in-water</FONT></FONT> micro-emulsions
containing tapinarof, an oil phase, a surfactant and other specific ingredients. DSG also owns an issued patent in the United States covering methods of using the patented formulations to treat inflammatory diseases, including psoriasis and atopic
dermatitis. Like the formulation patent, the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">method-of-use</FONT></FONT> patent has a natural expiration date in 2036 in the United States, without taking into account any possible
patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. The foreign counterpart formulation and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">method-of-use</FONT></FONT> applications are pending, and if patents issue from these applications, they will also have a natural expiration date in 2036, without taking into account
any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DSG also owns a drug substance (&#147;DS&#148;) patent in the United States covering the high purity crystal form of tapinarof, as DS, the DS
synthesis and several novel intermediates that are formed in the synthesis. This DS patent has a natural expiration date in 2038, without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate
maintenance, renewal, annuity, or other governmental fees. DSG has also filed foreign counterpart DS applications that are still pending in foreign jurisdictions and, if patents issue from these applications, they will similarly have a natural
expiration date in 2038, without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Genevant </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of May 1,
2021, we own or co-own 16 patent families containing at least 43 issued patents and at least 42 pending patent applications in the U.S., European Union and numerous other jurisdictions with claims relating to lipid nanoparticle delivery technology
and polymers. These patents and pending applications, if issued, are expected to expire between 2024 and 2039, in each case without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate
maintenance, renewal, annuity or other governmental fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of May 1, 2021, we have licensed 40 patent families containing at least 405
issued patents and at least 237 pending patent applications in the U.S., European Union and numerous other jurisdictions with claims relating to delivery systems. These patents and pending applications, if issued, are expected to expire between 2021
and 2031,&nbsp;in each case without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>IMVT-1401 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
May&nbsp;1, 2021, ISG exclusively licenses from HanAll in certain territories one patent family containing patent applications pending in the United States and numerous foreign jurisdictions, including the European
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">331 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Union, with claims relating to IMVT-1401, and certain <FONT STYLE="white-space:nowrap">back-up</FONT> and next generation antibodies, and products containing such antibodies. This patent family
includes patent applications that disclose the antibody, pharmaceutical composition of IMVT-1401, methods of treating autoimmune disease using the same, polynucleotide encoding the antibody, expression vector including such polynucleotide, host cell
transfected with such recombinant expression vector, methods of manufacturing the antibody and methods of detecting FcRn in vivo or in vitro using the antibody. This patent family additionally includes an issued U.S. patent with claims directed to
an isolated anti-FcRn antibody or antigen-binding fragment thereof, and a pharmaceutical composition comprising such antibody or antigen-binding fragment thereof and a second issued U.S. patent with claims directed to an isolated anti-FcRn antibody
or antigen-binding fragment thereof, a pharmaceutical composition comprising such antibody or antigen-binding fragment thereof as well as methods of treating various autoimmune diseases using the antibody, polynucleotides and expression vectors
encoding the antibody, host cells capable of expressing the antibody and methods of producing the antibody. These patents and pending applications, if issued, are expected to expire as early as 2035, in each case without taking into account any
possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. For information regarding ISG&#146;s license agreement with HanAll, please see &#147;&#151;Asset
Acquisitions and License Arrangements.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, as of May&nbsp;1, 2021, ISG owns an additional patent family that includes an
internationally filed patent application and patent application pending in Argentina. This patent family is directed to methods of treating thyroid eye disease using anti-FcRn antibodies, and any patent issued from this patent family is expected to
expire in 2039, exclusive of any patent term adjustment or extension. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>LSVT-1701 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of May&nbsp;1, 2021, we have licensed rights to six patent families containing at least 47 issued patents and at least 33 pending patent
applications in numerous jurisdictions, including the U.S. and European Union, with claims relating to LSVT-1701, formulations thereof and methods of treatment. These patents and pending applications, if issued, are expected to expire as early as
2027, in each case without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Targeted Protein Degradation Platform </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of May 1, 2021, we have licensed rights to 21 patent families containing three issued U.S. patents, one issued European patent, one issued
South African patent and at least 66 pending patent applications in the U.S., European Union and a number of other jurisdictions.&nbsp;These patents and pending applications, if issued, are expected to expire as early as 2037, without taking into
account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict whether the patent applications we pursue or license will issue as patents in any particular jurisdiction. Even if our
pending patent applications are granted as issued patents, those patents, as well as any patents we license from third parties now or in the future, may be challenged, circumvented or invalidated by third parties. While we seek broad coverage under
our existing patent applications, there is always a risk that an alteration to the products or technologies may provide sufficient basis for a competitor or other third party to avoid infringing our patent claims. In addition, patents, if granted,
expire and we cannot provide any assurance that any patents will be issued from our pending or any future applications or that any potentially issued patents will adequately protect our products or product candidates. Consequently, we may not obtain
or maintain adequate patent protection for any of our products or product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Individual patents extend for varying periods
depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, patents issued for regularly filed applications in the United States are
granted a term of 20 years from the earliest </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">332 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effective <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also
20 years from the earliest effective <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. A U.S. patent also may be accorded patent term adjustment, or PTA, under certain circumstances to compensate for delays in obtaining the patent
from the USPTO. In some instances, such a PTA may result in a U.S. patent term extending beyond 20 years from the earliest date of filing a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application related to the U.S. patent. In
addition, in the United States, the term of a U.S. patent that covers an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug may also be eligible for PTE, which permits patent term restoration as compensation for the patent term lost during
the FDA regulatory review process. The Hatch-Waxman Act permits a PTE of up to five years beyond the expiration of the patent. The length of the PTE is related to the length of time the drug is under regulatory review. PTE cannot extend the
remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent applicable to an approved drug may be extended and only those claims covering the approved drug, a method for using it, or a method for
manufacturing it may be extended. Similar provisions are available in Europe and certain other jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our products receive FDA approval, we expect to
apply for PTEs on patents covering products eligible for PTE. We plan to seek PTEs for any of our issued patents in any jurisdiction where these are available; however, there is no guarantee that the applicable authorities, including the USPTO in
the United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions. The actual protection afforded by a patent varies on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis, from country to country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability
of legal remedies in a particular country and the validity and enforceability of the patent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success will also depend in
part on not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require us to alter our development or<B> </B>commercial strategies for our products or processes, or to obtain
licenses or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future products may have an adverse impact on us. If third parties
prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference or derivation proceedings in the USPTO to determine priority of invention. For more information,
please see &#147;Risk Factors&#151;Risks Related to Roivant&#146;s Business and Industry&#151;Risks Related to Our Intellectual Property.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Trade Secrets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition to our reliance on patent protection for our inventions, product candidates and research programs, we also rely on trade secrets, <FONT STYLE="white-space:nowrap">know-how,</FONT> continuing technological innovation and potential <FONT
STYLE="white-space:nowrap">in-licensing</FONT> opportunities to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality and invention assignment agreements with our commercial
partners, collaborators, employees and consultants. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a
relationship with an employee or a third party. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors or other
third parties. As a result, we may not be able to meaningfully protect our trade secrets. For more information regarding the risks related to our intellectual property, see &#147;Risk Factors&#151;Risks Related to Roivant&#146;s Business and
Industry&#151;Risks Related to Our Intellectual Property.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States at the federal, state and local level and in other countries regulate, among other things, the
research, development, manufacture, testing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and
biological products, including gene therapies, as well as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">333 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
diagnostics, and any future product candidates. Generally, before a new drug, biologic or diagnostic can be marketed, considerable data demonstrating its quality, safety and efficacy must be
obtained, organized into a format specific for each regulatory authority, submitted for review and approved, authorized, or cleared by the applicable regulatory authority. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Government Regulation of Drug and Biological Products </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act (the &#147;FDCA&#148;) and its implementing
regulations and biologics under the FDCA and the Public Health Service Act (the &#147;PHSA&#148;), and their implementing regulations. Both drugs and biologics also are subject to other federal, state and local statutes and regulations, such as
those related to competition. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources.
Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or following approval may subject an applicant to administrative actions or judicial sanctions. These actions and sanctions
could include, among other actions, the FDA&#146;s refusal to approve pending applications, withdrawal of an approval, license revocation, a clinical hold, untitled or warning letters, voluntary or mandatory product recalls or market withdrawals,
product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, debarment from producing or marketing drug products or biologics, disqualification from
conducting research, and civil or criminal fines or penalties. Any agency or judicial enforcement action could have a material adverse effect on our business, the market acceptance of our products and our reputation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates must be approved by the FDA through either an NDA or a Biologics License Application (a &#147;BLA&#148;), process
before they may be legally marketed in the United States. The process generally involves the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of extensive preclinical studies in accordance with applicable regulations, including studies
conducted in accordance with Good Laboratory Practice (&#147;GLP&#148;), requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an Institutional Review Boar (&#147;IRB&#148;), or independent ethics committee at each clinical
trial site before each human trial may be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations,
Good Clinical Practices (&#147;GCP&#148;), requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an NDA or BLA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a determination by the FDA within 60 days of its receipt of an NDA or BLA to accept the filing for review;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of one or more FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections of
the manufacturing facility or facilities where the drug or biologic will be produced to assess compliance with Current Good Manufacturing Practices (&#147;cGMP&#148;), requirements to assure that the facilities, methods and controls are adequate to
preserve the drug or biologic&#146;s identity, strength, quality and purity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential FDA inspection of the clinical trial sites that generated the data in support of the NDA or BLA;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payment of user fees for FDA review of the NDA or BLA; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the NDA or BLA, including consideration of the views of any FDA advisory committee,
prior to any commercial marketing or sale of the drug or biologic in the United States. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">334 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preclinical and clinical testing and approval process requires substantial time, effort
and financial resources, and the regulatory scheme for drugs and biologics is evolving and subject to change at any time. We cannot be certain that any approvals for our product candidates will be granted on a timely basis, or at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical Studies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before testing any drug, biological or gene therapy candidate in humans, the product candidate must undergo rigorous preclinical testing.
Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as in vitro and animal studies to assess safety and in some cases to establish a rationale for therapeutic use. In the U.S., the conduct of preclinical
studies is subject to federal and state regulations and requirements, including GLP regulations for safety/toxicology studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
U.S., an IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, to the FDA as part of an
IND. An IND is a request for authorization from the FDA to administer an investigational product to humans, and must become effective before human clinical trials may begin. Some long-term preclinical testing, such as animal tests of reproductive
AEs and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time, the FDA raises concerns or questions related to one or more proposed clinical trials
and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to
commence. Additionally, the review of information in an IND submission may prompt FDA to, among other things, scrutinize existing INDs or marketed products and could generate requests for information or clinical holds on other product candidates or
programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Trials </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the
supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#146;s control, in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for
their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used
to monitor subject safety and assess efficacy. In the U.S., each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for
each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed
consent form that must be provided to each clinical trial subject or his or her legal representative, and must monitor the clinical trial until completed. There also are requirements governing the reporting of ongoing clinical trials and completed
clinical trial results to public registries. Information about certain clinical trials, including clinical trial results, must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the submission of an IND to the FDA before initiation of a clinical trial in the United States, certain human clinical trials
involving recombinant or synthetic nucleic acid molecules had historically been subject to review by the NIH Recombinant DNA Advisory Committee (the &#147;RAC&#148;), of the NIH Office of Biotechnology Activities (the &#147;OBA&#148;), pursuant to
the NIH Guideline. On August&nbsp;17, 2018, the NIH issued a notice in the Federal Register and issued a public statement proposing changes to the oversight framework for gene therapy trials, including changes to the applicable NIH Guidelines to
modify the roles and responsibilities of the RAC with respect to human clinical trials of gene therapy products, and requesting public comment on its proposed modifications. During the public comment period, which closed October&nbsp;16, 2018, the
NIH announced that it will no longer accept new human gene transfer protocols for review as a part of the protocol registration </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">335 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
process or convene the RAC to review individual clinical protocols. In April 2019, NIH announced the updated guidelines, which reflect these proposed changes, and clarify that these trials will
remain subject to the FDA&#146;s oversight and other clinical trial regulations, and oversight at the local level will continue as set forth in the NIH Guidelines. Specifically, under the NIH Guidelines, supervision of human gene transfer trials
includes evaluation and assessment by an Institutional Biosafety Committee (an &#147;IBC&#148;), a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The
IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the
research in question being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily
follow them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to
conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of an NDA or BLA. The FDA will accept a well-designed and well-conducted
foreign clinical study not conducted under an IND if the study was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials generally are conducted in three sequential phases, known as Phase 1, Phase 2 and Phase 3, and may overlap. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who
are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action, side effect tolerability and safety of the product candidate.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 2 clinical trials involve studies in disease-affected patients to evaluate proof of concept and/or
determine the dose required to produce the desired benefits. At the same time, safety and further PK and PD information is collected, possible adverse effects and safety risks are identified, and a preliminary evaluation of efficacy is conducted.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 3 clinical trials generally involve a large number of patients at multiple sites and are designed to
provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product labeling.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2018, the FDA released a draft guidance entitled &#147;Expansion Cohorts: Use in <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-In-Human</FONT></FONT> Clinical Trials to Expedite Development of Oncology Drugs and Biologics,&#148; which outlines how drug developers can utilize an adaptive trial design commonly
referred to as a seamless trial design in early stages of oncology drug development, i.e., the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical trial, to compress the traditional three phases of
trials into one continuous trial called an expansion cohort trial. Information to support the design of individual expansion cohorts are included in IND applications and assessed by FDA. Expansion cohort trials can potentially bring efficiency to
drug development and reduce developmental costs and time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be
conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication and are commonly intended to generate additional safety data regarding use of the
product in a clinical setting. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA or BLA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA and
written IND safety reports must be submitted to the FDA and the investigators 15 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">336 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
days after the trial sponsor determines the information qualifies for reporting for serious and unexpected suspected AEs, findings from other studies or animal or in vitro testing that suggest a
significant risk for human subjects and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must also notify the FDA of any unexpected fatal or
life-threatening suspected adverse reaction as soon as possible but in no case later than seven calendar days after the sponsor&#146;s initial receipt of the information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Phase 1, Phase 2, Phase 3 and other types of clinical trials may not be completed successfully within any specified period, if at all. The FDA
or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval
of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the drug or biologic has been associated with unexpected serious harm to patients. Additionally, some clinical
trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated
check points based on access to certain data from the trial. Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry and physical characteristics of the
drug or biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among
other things, companies must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that
the product candidates do not undergo unacceptable deterioration over their shelf life. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>FDA Review Process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following completion of the clinical trials, data are analyzed to assess whether the investigational product is safe and effective for the
proposed indicated use or uses. The results of preclinical studies and clinical trials are then submitted to the FDA as part of an NDA or BLA, along with proposed labeling, chemistry and manufacturing information to ensure product quality and other
relevant data. The NDA or BLA is a request for approval to market the drug or biologic for one or more specified indications and must contain proof of safety and efficacy for a drug or safety, purity and potency for a biologic. The application may
include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#146;s use or from a
number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the
satisfaction of FDA. FDA approval of an NDA or BLA must be obtained before a drug or biologic may be marketed in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under
the Prescription Drug User Fee Act (the &#147;PDUFA&#148;), as amended, each NDA or BLA must be accompanied by a user fee. FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances,
including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs or BLAs for products designated as orphan drugs, unless the product also includes a <FONT
STYLE="white-space:nowrap">non-orphan</FONT> indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA reviews all submitted NDAs and BLAs before it accepts them for filing,
and may request additional information rather than accepting the NDA or BLA for filing. The FDA must make a decision on accepting an NDA or BLA for filing within 60 days of receipt, and such decision could include a refusal to file by the FDA. Once
the submission is accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> review of the NDA or BLA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA targets ten months, from the filing date, in
which to complete its initial review of a new molecular entity NDA or original BLA and respond to the applicant, and six months from the filing date of a new molecular entity NDA or original BLA designated for
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">337 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
priority review. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs or BLAs, and the review process is often extended by FDA requests for additional information or
clarification. During the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, because of travel and other restrictions, the FDA has significantly curtailed its inspection program. The reduction in
<FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections has resulted in delays to some product approvals. There may be delays to product approvals in the future based on continuing problems with respect to the FDA&#146;s ability to conduct
inspections and then, even after a resumption of the FDA&#146;s normal inspection program, a possible backlog in applications under review by the agency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has developed the Oncology Center of Excellence RTOR pilot program to facilitate a more efficient review process for certain oncology
product candidates. Although this program allows FDA to begin reviewing clinical data prior to submission of a complete NDA or BLA, the program is not intended to change the PDUFA review timelines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an NDA or BLA, the FDA will conduct a <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing
facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate
to assure consistent production of the product within required specifications. The FDA also may audit data from clinical trials to ensure compliance with GCP requirements. Additionally, the FDA may refer applications for novel products or products
which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under
what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making decisions on approval. The FDA likely will reanalyze the clinical trial data, which could result in
extensive discussions between the FDA and the applicant during the review process. After the FDA evaluates an NDA or BLA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug
or biologic with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response
Letter usually describes all of the specific deficiencies in the NDA or BLA identified by the FDA. The Complete Response Letter may require the applicant to obtain additional clinical data, including the potential requirement to conduct additional
pivotal Phase 3 clinical trial(s) and/or to complete other significant and time-consuming requirements related to clinical trials, or to conduct additional preclinical studies or manufacturing activities. If a Complete Response Letter is issued, the
applicant may either resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, or withdraw the application or request an opportunity for a hearing. Even if such data and information are submitted, the FDA may decide that
the NDA or BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Orphan Drug Designation and Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition,
which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making
the product available in the United States for this type of disease or condition will be recovered from sales of the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Orphan drug
designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not
convey any advantage in or shorten the duration of the regulatory review and approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product that has orphan drug
designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">338 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing
of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or in instances of drug supply issues. Competitors, however, may receive approval of
either a different product for the same indication or the same product for a different indication but that could be used <FONT STYLE="white-space:nowrap">off-label</FONT> in the orphan indication. Orphan drug exclusivity also could block the
approval of one of our products for seven years if a competitor obtains approval before we do for the same product, as defined by the FDA, for the same indication we are seeking approval, or if our product is determined to be contained within the
scope of the competitor&#146;s product for the same indication or disease. If we pursue marketing approval for an indication broader than the orphan drug designation we have received, we may not be entitled to orphan drug exclusivity. Orphan drug
status in the European Union has similar, but not identical, requirements and benefits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Rare Pediatric Disease Designation and
Priority Review Vouchers </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the FDCA, as amended, the FDA incentivizes the development of drugs and biologics that meet the
definition of a &#147;rare pediatric disease,&#148; defined to mean a serious or life-threatening disease in which the serious of life-threatening manifestations primarily affect individuals aged from birth to 18 years and the disease affects fewer
than 200,000 individuals in the United States or affects more than 200,000 in the United States and for which there is no reasonable expectation that the cost of developing and making in the United States a drug for such disease or condition will be
received from sales in the United States of such drug. The sponsor of a product candidate for a rare pediatric disease may be eligible for a voucher that can be used to obtain a priority review for a subsequent human drug or biologic application
after the date of approval of the rare pediatric disease drug product, referred to as a priority review voucher (a &#147;PRV&#148;). A sponsor may request rare pediatric disease designation from the FDA prior to the submission of its NDA or BLA. A
rare pediatric disease designation does not guarantee that a sponsor will receive a PRV upon approval of its NDA or BLA. Moreover, a sponsor who chooses not to submit a rare pediatric disease designation request may nonetheless receive a PRV upon
approval of their marketing application if they request such a voucher in their original marketing application and meet all of the eligibility criteria. If a PRV is received, it may be sold or transferred an unlimited number of times. Congress has
extended the PRV program through September&nbsp;30, 2024, with the potential for PRVs to be granted through September&nbsp;30, 2026. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Expedited Development and Review Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A sponsor may seek to develop and obtain approval of its product candidates under programs designed to accelerate the development, FDA review
and approval of new drugs and biologics that meet certain criteria. For example, the FDA has a fast-track program that is intended to expedite or facilitate the process for reviewing new drugs and biologics that are intended to treat a serious or
life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied. For a fast
track-designated product, the FDA may consider sections of the NDA or BLA for review on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA
agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application. The sponsor can request the FDA to designate the
product for fast-track status any time before receiving NDA or BLA approval, but ideally no later than the <FONT STYLE="white-space:nowrap">pre-NDA</FONT> or <FONT STYLE="white-space:nowrap">pre-BLA</FONT> meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A product submitted to the FDA for marketing, including under a fast-track program, may be eligible for other types of FDA programs intended
to expedite development or review, such as priority review and accelerated approval. Priority review means that, for a new molecular entity or original BLA, the FDA sets a target date for FDA action on the marketing application at six months after
accepting the application for filing as opposed to ten months. A product is eligible for priority review if it is designed to treat a serious or life-threatening disease condition and, if approved, would provide a significant improvement in safety
and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">339 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug or biologic designated for priority review in
an effort to facilitate the review. If criteria are not met for priority review, the application for a new molecular entity or original BLA is subject to the standard FDA review period of ten months after FDA accepts the application for filing.
Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A product may also be eligible for accelerated approval if it is designed to treat a serious or life-threatening disease or condition and
demonstrates an effect on either a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (&#147;IMM&#148;), that is reasonably likely
to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the disease or condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a
sponsor of a drug or biologic receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval
<FONT STYLE="white-space:nowrap">pre-approval</FONT> of promotional materials, which could adversely impact the timing of the commercial launch of the product. FDA may withdraw approval of a drug or indication approved under accelerated approval if,
for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, a drug or biologic may
be eligible for designation as a breakthrough therapy if the product is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that
the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. If the FDA designates a breakthrough
therapy, it may take actions appropriate to expedite the development and review of the application, which may include holding meetings with the sponsor and the review team throughout the development of the therapy; providing timely advice to, and
interactive communication with, the sponsor regarding the development of the drug to ensure that the development program to gather the nonclinical and clinical data necessary for approval is as efficient as practicable; involving senior managers and
experienced review staff, as appropriate, in a collaborative, cross-disciplinary review; assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific
liaison between the review team and the sponsor; and considering alternative clinical trial designs when scientifically appropriate, which may result in smaller trials or more efficient trials that require less time to complete and may minimize the
number of patients exposed to a potentially less efficacious treatment. Breakthrough therapy designation comes with all of the benefits of fast-track designation, which means that the sponsor may file sections of the BLA for review on a rolling
basis if certain conditions are satisfied, including an agreement with the FDA on the proposed schedule for submission of portions of the application and the payment of applicable user fees before the FDA may initiate a review. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the 21st Century Cures Act, Congress amended the FDCA to facilitate an efficient development program for, and expedite review of
regenerative medicine advanced therapies (&#147;RMATs&#148;), which include cell and gene therapies, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products. RMATs do not
include those human cells, tissues, and cellular and tissue-based products regulated solely under section 361 of the PHSA and 21 CFR Part 1271. This program is intended to facilitate efficient development and expedite review of regenerative medicine
therapies, which are intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition and qualify for RMAT designation. A drug sponsor may request that the FDA designate a drug as a RMAT concurrently with or at any time
after submission of an IND. The FDA has 60 calendar days to determine whether the drug meets the criteria, including whether there is preliminary clinical evidence indicating that the drug has the potential to address unmet medical needs for a
serious or life-threatening disease or condition. A BLA for a regenerative medicine therapy that has received RMAT designation may be eligible for priority review or accelerated approval through use of surrogate or intermediate endpoints reasonably
likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites. Benefits of RMAT designation also include early interactions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">340 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with FDA to discuss any potential surrogate or intermediate endpoint to be used to support accelerated approval. A regenerative medicine therapy with RMAT designation that is granted accelerated
approval and is subject to post-approval requirements may fulfill such requirements through the submission of clinical evidence from clinical studies, patient registries, or other sources of real-world evidence, such as electronic health records;
the collection of larger confirmatory data sets; or post-approval monitoring of all patients treated with such therapy prior to its approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has also announced the availability of the RTOR pilot program for oncology product candidates that are likely to demonstrate
substantial improvements over available therapy, which may include drugs previously granted breakthrough therapy designation for the same or other indications and candidates meeting other criteria for other expedited programs, such as fast track and
priority review. Submissions for RTOR consideration should also have straightforward study designs and endpoints that can be easily interpreted (such as overall survival or progression free survival). Acceptance into the RTOR pilot does not
guarantee or influence approvability of the application, which is subject to the usual benefit-risk evaluation by FDA reviewers, but the program allows FDA to review data earlier, before an applicant formally submits a complete application. The RTOR
pilot program does not affect FDA&#146;s PDUFA timelines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if a product qualifies for one or more of these programs, the FDA may
later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, fast track designation, priority review, accelerated approval, breakthrough therapy and
RMAT designation do not change the standards for approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Pediatric Information and Pediatric Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Pediatric Research Equity Act (the &#147;PREA&#148;), certain NDAs and BLAs and certain supplements to an NDA or BLA must contain
data to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA
may grant deferrals for submission of pediatric data or full or partial waivers. The Food and Drug Administration Safety and Innovation Act (the &#147;FDASIA&#148;), amended the FDCA to require that a sponsor who is planning to submit a marketing
application for a drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan (&#147;PSP&#148;), within 60 days of an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-Phase</FONT></FONT> 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 study. The initial PSP must include an
outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any
request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit
amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials and/or other clinical development programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A drug or biologic product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six
months to existing exclusivity periods and patent terms. This <FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of
a pediatric study in accordance with an <FONT STYLE="white-space:nowrap">FDA-issued</FONT> &#147;Written Request&#148; for such a study. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Post-Marketing Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following approval of a new product, the manufacturer and the approved product are subject to continuing regulation by the FDA, including,
among other things, monitoring and record-keeping activities, reporting of adverse experiences and certain problems in the manufacturing process, complying with promotion and advertising requirements, which include restrictions on promoting products
for unapproved uses or patient </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">341 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
populations (known as <FONT STYLE="white-space:nowrap">&#147;off-label</FONT> use&#148;) and limitations on industry-sponsored scientific and educational activities. Although physicians may
prescribe legally available products for <FONT STYLE="white-space:nowrap">off-label</FONT> uses, manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <FONT
STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant liability, including investigation by federal and state
authorities. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use or first publication. Further, if there are any modifications to the drug or biologic, including changes in indications, labeling
or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA/BLA or NDA/BLA supplement, which may require the development of additional data or preclinical studies and clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may also place other conditions on approvals including the requirement for a REMS, to assure the safe use of the product. If the FDA
concludes a REMS is needed, the sponsor of the NDA or BLA must submit a proposed REMS. The FDA will not approve the NDA or BLA without an approved REMS, if required. A REMS could include medication guides, physician communication plans or elements
to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of
products. Product approvals may be withdrawn for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards or if problems occur following initial marketing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMP regulations. We rely, and
expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. These manufacturers must comply with cGMP regulations that require, among other things,
quality control and quality assurance, the maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved
drugs or biologics are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP requirements and other laws.
Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. The discovery of violative conditions, including failure to conform to cGMP regulations, could
result in enforcement actions, and the discovery of problems with a product after approval may result in restrictions on a product, manufacturer or holder of an approved NDA or BLA, including recall. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once an approval is granted, the FDA may issue enforcement letters or withdraw the approval of the product if compliance with regulatory
requirements and standards is not maintained or if problems occur after the drug or biologic reaches the market. Corrective action could delay drug or biologic distribution and require significant time and financial expenditures. Later discovery of
previously unknown problems with a drug or biologic, including AEs of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add
new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the drug or biologic, suspension of the approval, complete
withdrawal of the drug from the market or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters or holds on post-approval clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve applications or supplements to approved applications, or suspension or revocation
of drug or biologic approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">drug or biologic seizure or detention, or refusal to permit the import or export of drugs; or
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">342 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">debarment from producing or marketing drug products or biologics. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Regulation of Companion Diagnostics </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Success of certain product candidates may depend, in part, on the development and commercialization of a companion diagnostic. A companion
diagnostic is a medical device, often an <I>in vitro</I> device, which provides information that is essential for the safe and effective use of a corresponding drug or biological product. Companion diagnostics can identify patients who are most
likely to benefit from a particular therapeutic product; identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product; or monitor response to treatment with a particular
therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness. Companion diagnostics are generally regulated as medical devices by the FDA. In the United States, the FDCA and its implementing regulations, and
other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage,
advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption or FDA exercise of enforcement discretion applies, diagnostic tests generally require marketing clearance through the premarket
notification process (&#147;510(k) clearance&#148;) or premarket approval from the FDA prior to commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To obtain 510(k)
clearance for a medical device, or for certain modifications to devices that have received 510(k) clearance, a manufacturer must submit a premarket notification demonstrating that the proposed device is substantially equivalent to a previously
cleared 510(k) device or to a preamendment device that was in commercial distribution before May&nbsp;28, 1976, or a predicate device, for which the FDA has not yet called for the submission of a PMA. In making a determination that the device is
substantially equivalent to a predicate device, the FDA compares the proposed device to the predicate device or predicate devices and assesses whether the subject device is comparable to the predicate device or predicate devices with respect to
intended use, technology, design and other features which could affect safety and effectiveness. If the FDA determines that the subject device is substantially equivalent to the predicate device or predicate devices, the subject device may be
cleared for marketing. The 510(k) premarket notification pathway generally takes from three to twelve months from the date the application is completed, but can take significantly longer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PMA applications must be supported by valid scientific evidence, which typically requires extensive data, including technical, preclinical,
clinical and manufacturing data, to demonstrate to the FDA&#146;s satisfaction the safety and effectiveness of the device. For diagnostic tests, a premarket approval application, or &#147;PMA&#148;, typically includes data regarding analytical and
clinical validation studies. As part of its review of the PMA, the FDA will typically conduct a <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing facility or facilities to ensure compliance with the Quality System
Regulation (the &#147;QSR&#148;), which requires manufacturers to follow design, testing, control, corrective and preventative action, documentation, and other quality assurance procedures. The FDA&#146;s review of an initial PMA application is
required by statute to take between six to ten months, although the process typically takes longer, and may require several years to complete. If the FDA evaluations of both the PMA application and the manufacturing facilities are favorable, the FDA
will either issue an approval letter or an approvable letter, which usually contains a number of conditions that must be met in order to secure the final approval of the PMA. If the FDA&#146;s evaluation of the PMA or manufacturing facilities is not
favorable, the FDA will deny the approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. Once
granted, PMA approval may be withdrawn by the FDA if compliance with post-approval requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing. Once cleared or approved,
the companion diagnostic device must adhere to post-marketing requirements including the requirements of FDA&#146;s quality system regulation, adverse event reporting, recalls and corrections along with product marketing requirements and
limitations. Like drug and biologic makers, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">343 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
companion diagnostic makers are subject to unannounced FDA inspections at any time during which the FDA is able to conduct an inspection of the product(s) and the company&#146;s facilities for
compliance with its authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FDA has taken the position that developers of companion diagnostic tests associated with novel
therapeutic products should seek clearance or approval at the same time that the therapeutic developer seeks approval. FDA has recognized that contemporaneous clearance or approval of a companion diagnostic with a therapeutic is not always possible,
though FDA has indicated that coordination of contemporaneous clearances/approvals is a policy goal. In October 2018, FDA issued a safety alert warning against the use of unapproved or uncleared genetic tests to predict patient response to specific
medications. While FDA has historically exercised enforcement discretion against laboratory developed tests&#151;tests which are developed and performed in a single Clinical Laboratory Improvement Amendments (CLIA) certified laboratory&#151;the 2018
alert and a subsequent 2019 Warning Letter against Inova Genomics Laboratory suggest that FDA may prioritize for enforcement certain uncleared or unapproved tests marketed as companion diagnostic tests. Subsequently, FDA has attempted to encourage
collaboration between <I>in vitro </I>diagnostic test developers and therapeutic developers and to clarify FDA expectations as to companion diagnostic labeling, particularly through guidance in the oncology area. In March 2020, the Verifying
Accurate Leading-edge IVCT Development Act of 2020 (the &#147;VALID Act&#148;) was introduced in the U.S. House of Representatives. Among other things, the VALID Act would classify all companion diagnostic tests as high-complexity tests requiring
FDA premarket review and would formalize and arguably expand FDA&#146;s regulatory authority over diagnostic testing. Though passage of the VALID Act is unlikely this year, strong bipartisan support remains for some kind of diagnostic testing
legislative reform in the near term. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Biosimilars and Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our product candidates, including IMVT-1401 and <FONT STYLE="white-space:nowrap">ARU-1801,</FONT> are regulated as biologics. An
abbreviated approval pathway for biological products shown to be similar to, or interchangeable with, an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product was created by the Biologics Price Competition and Innovation
Act of 2009 (the &#147;BPCI Act&#148;), as part of the Affordable Care Act (the &#147;ACA&#148;). This amendment to the PHSA, in part, attempts to minimize duplicative testing. Biosimilarity, which requires that the biological product be highly
similar to the reference product notwithstanding minor differences in clinically inactive components and that there be no clinically meaningful differences between the product and the reference product in terms of safety, purity and potency, can be
shown through analytical studies, animal studies and a clinical trial or trials. Interchangeability requires that a biological product be biosimilar to the reference product and that the product can be expected to produce the same clinical results
as the reference product in any given patient and, for products administered multiple times to an individual, that the product and the reference product may be alternated or switched after one has been previously administered without increasing
safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product without such alternation or switch. Complexities associated with the larger, and often more complex, structure of biological products as
compared to small molecule drugs, as well as the processes by which such products are manufactured, pose significant hurdles to implementation that are still being worked out by the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reference biological product is granted four and twelve year exclusivity periods from the time of first licensure of the product. The FDA
will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product, and the FDA will not approve an application for a
biosimilar or interchangeable product based on the reference biological product until twelve years after the date of first licensure of the reference product. &#147;First licensure&#148; typically means the initial date the particular product at
issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the licensure is for a supplement for the biological product or
for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest, or other related entity) for a change (not including a modification to the structure of the biological product) that
results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">344 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
strength, or for a modification to the structure of the biological product that does not result in a change in safety, purity, or potency. Therefore, one must determine whether a new product
includes a modification to the structure of a previously licensed product that results in a change in safety, purity, or potency to assess whether the licensure of the new product is a first licensure that triggers its own period of exclusivity.
Whether a subsequent application, if approved, warrants exclusivity as the &#147;first licensure&#148; of a biological product is determined on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis with
data submitted by the sponsor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Other Regulatory Matters </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturing, sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory
authorities in the United States in addition to the FDA, including the Centers for Medicare and Medicaid Services (the &#147;CMS&#148;), the Office of Inspector General and Office for Civil Rights, other divisions of the Department of HHS, the
Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety&nbsp;&amp; Health Administration, the Environmental Protection Agency and state and local
governments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers, physicians, and third-party payors will play a primary role in the recommendation and prescription of
any products for which we obtain marketing approval. Our current and future arrangements with healthcare providers and physicians and any future arrangements with third party payers, may expose us to broadly applicable fraud and abuse and other
healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any drugs for which we obtain marketing approval. In the United States, these laws include: the
federal Anti-Kickback Statute, the False Claims Act, and HIPAA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Anti-Kickback Statute makes it illegal for any person, including a
prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration, directly or indirectly, in cash or in kind, that is intended to induce or reward referrals, including the
purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Violations of this law are punishable by imprisonment, criminal fines,
administrative civil money penalties and exclusion from participation in federal healthcare programs. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it. Moreover, the ACA provides
that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drug manufacturers can be held liable under the federal civil False Claims Act, which imposes civil penalties, including through civil
whistleblower or qui tam actions, against individuals or entities (including manufacturers) for, among other things, knowingly presenting, or causing to be presented to federal programs (including Medicare and Medicaid) claims for items or services,
including drugs, that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. Penalties for a False Claims Act violation include three times the actual damages sustained
by the government, plus mandatory civil penalties for each separate false claim, the potential for exclusion from participation in federal healthcare programs and, although the federal False Claims Act is a civil statute, conduct that results in a
False Claims Act violation may also implicate various federal criminal statutes. The government may deem manufacturers to have &#147;caused&#148; the submission of false or fraudulent claims by, for example, providing certain billing or coding
information to customers or promoting a product <FONT STYLE="white-space:nowrap">off-label.</FONT> Claims which include items or services resulting from a violation of the federal Anti-Kickback Statute are false or fraudulent claims for purposes of
the False Claims Act. Our future marketing and activities relating to federal, state, and commercial reimbursement for our products, and the sale and marketing of our product candidates, are subject to scrutiny under this law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">345 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HIPAA created federal criminal statutes that prohibit among other things, knowingly and
willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit
program, including private third party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying,
concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the federal
Anti-Kickback Statute a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented
or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to data privacy and security regulations administered and enforced by the federal government as well as statutes and
regulations adopted in the states in which we conduct our business. At the federal level, the data privacy and security regulations implementing HIPAA, as amended by the Health Information and Technology for Economic and Clinical Health Act,
mandate, among other things, compliance with standards relating to the privacy and security of individually identifiable health information, which requires, among other things, the adoption of administrative, physical and technical safeguards to
protect such information. Civil and criminal penalties may be imposed on entities subject to HIPAA, both by the HHS Office for Civil Rights and by state attorneys general, who have the authority to file civil actions for damages or injunctions in
federal courts to enforce the HIPAA privacy and security regulations and to seek attorney&#146;s fees and costs associated with pursuing such actions. In addition, certain state laws govern the privacy and security of health information in certain
circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can
result in the imposition of significant civil and criminal penalties. Further, the states are rapidly expanding their data privacy and security laws and we may be subject to a variety of different restrictions and requirements under such laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the federal Physician Payments Sunshine Act (the &#147;Sunshine Act&#148;), within the ACA, and its implementing regulations,
require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) report annually to CMS
information related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, physicians, certain other healthcare
professionals, and teaching hospitals and to report annually certain ownership and investment interests held by physicians, certain other healthcare professionals, and their immediate family members. Effective January&nbsp;1, 2022, these reporting
obligations will extend to include transfers of value made to certain <FONT STYLE="white-space:nowrap">non-physician</FONT> providers such as physician assistants and nurse practitioners. In addition, many states also govern the reporting of
payments or other transfers of value, many of which differ from each other in significant ways, are often not preempted, and may have a more prohibitive effect than the Sunshine Act, thus further complicating compliance efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar federal, state and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, may apply to sales
or marketing arrangements and claims involving healthcare items or services. Such laws are generally broad and are enforced by various state agencies and private actions. Also, many states have similar fraud and abuse statutes or regulations that
may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#146;s
voluntary compliance guidelines and the relevant federal government compliance guidance, and require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing
expenditures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">346 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to distribute products commercially, we must comply with state laws that require
the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no
place of business within the state. Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on
sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and
biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform,
especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of
investigations, prosecutions, convictions and settlements in the healthcare industry. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law
involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil,
criminal and administrative penalties, damages, fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, individual imprisonment, exclusion of drugs from government funded healthcare programs, such as
Medicare and Medicaid, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results. If any of the physicians or other healthcare providers or entities with
whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Ensuring business arrangements
comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#146;s attention from the business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Current and Future Legislation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and some foreign jurisdictions, there have been, and likely will continue to be, a number of legislative and regulatory
changes and proposed changes regarding the healthcare system directed at broadening the availability of healthcare, improving the quality of healthcare, and containing or lowering the cost of healthcare. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, in March 2010, the ACA was enacted in the United States. The ACA includes measures that have significantly changed, and are
expected to continue to significantly change, the way healthcare is financed by both governmental and private insurers. Among the changes made by the ACA to preexisting law of importance to the pharmaceutical industry are that the ACA: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers&#146;
rebate liability by raising the minimum basic Medicaid rebate on most branded prescription drugs to 23.1% of average manufacturer price (&#147;AMP&#148;), and adding a new rebate calculation for &#147;line extensions&#148; (i.e., new formulations,
such as extended release formulations) of solid oral dosage forms of branded products, as well as potentially impacting their rebate liability by modifying the statutory definition of AMP. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposed a requirement on manufacturers of branded drugs to provide a 70% (increased pursuant to the Bipartisan
Budget Act of 2018, effective as of 2019) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discount off the negotiated price of branded drugs dispensed to Medicare Part D beneficiaries in the coverage gap
(i.e., &#147;donut hole&#148;) as a condition for a manufacturer&#146;s outpatient drugs being covered under Medicare Part D. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">347 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extended a manufacturer&#146;s Medicaid rebate liability to covered drugs dispensed to individuals who are
enrolled in Medicaid managed care organizations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expanded the entities eligible for discounts under the 340B Drug Discount Program. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">established a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are
calculated for drugs that are inhaled, infused, instilled, implanted, or injected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposed an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription
drugs, apportioned among these entities according to their market share in certain government healthcare programs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct
comparative clinical effectiveness research, along with funding for such research. The research conducted by the Patient-Centered Outcomes Research Institute may affect the market for certain pharmaceutical products. The ACA established the Center
for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA,
and we expect there will be additional challenges and amendments to the ACA in the future. Various portions of the ACA are currently undergoing legal and constitutional challenges in the United States Supreme Court; the Trump Administration issued
various Executive Orders which eliminated cost sharing subsidies and various provisions that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or
manufacturers of pharmaceuticals or medical devices; and Congress has introduced several pieces of legislation aimed at significantly revising or repealing the ACA. The United States Supreme Court is expected to rule on a legal challenge to the
constitutionality of the ACA in 2021. The implementation of the ACA is ongoing, and the law may continue to exert significant pressure on pharmaceutical pricing and our profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, in May 2018, the Trump administration released its &#147;Blueprint to Lower Drug Prices and Reduce <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs,&#148; or the Blueprint, and former President Trump also issued a number of Executive Orders in 2020 that were aimed at lowering the prices of prescription drugs. Some rules enacted under
the Trump Administration have been stayed as a result of pending litigation or are under review by the Biden Administration. For example, a rule enacted under the Trump Administration known as the &#147;Most Favored Nations&#148; rule would set
Medicare Part B reimbursement at an amount no higher than the lowest price that a drug manufacturer receives on a particular product in an index of foreign countries. This rule currently is the subject of litigation, and it is unclear whether it
will be implemented by the Biden Administration. Other initiatives under the Trump administration have taken effect. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy, a form of drug
utilization management, for Part B drugs beginning January&nbsp;1, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted in the
United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted
deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions of
Medicare payments to providers up to 2% per fiscal year, which went into effect in April 2013, following passage of the Bipartisan Budget Act of 2013, and will remain in effect through 2029 unless additional congressional action is taken. Pursuant
to the CARES Act and subsequent legislation, these reductions were suspended from May&nbsp;1, 2020 through December&nbsp;31, 2021 due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. As the legislation currently stands, the
reductions will go back into effect as of January 2022 and remain in effect through 2030 unless additional Congressional action is take, The American Rescue Plan Act of 2021 eliminates the Medicaid unit rebate cap effective as of January&nbsp;1,
2024, and the removal of this rebate cap could significantly impact our Medicaid rebate liability beginning in 2024. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">348 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, there have been several recent U.S. Congressional inquiries and proposed bills
designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. For example, Senator Tammy
Baldwin and three cosponsors have introduced legislation that would require transparency in any price increases for prescription drugs. Senator Bernie Sanders also introduced the three drug pricing bills, including the Medicare Drug Price
Negotiation Act, which would direct the Secretary HHS to negotiate lower prices for prescription drugs under Medicare Part D. H.R. 3, which was passed by the House of Representatives in 2020, also contains a provision requiring the federal
government to negotiate the pricing for certain prescription drugs, and manufacturers also would face fines if their drug prices increase faster than the rate of inflation. We cannot predict whether these or other drug pricing initiatives will be
adopted in the future. Further federal, state and foreign legislative and regulatory developments are likely, and we expect ongoing initiatives to increase pressure on drug pricing. The Biden administration has indicated that lowering prescription
drug prices is a priority. Reforms could have an adverse effect on anticipated revenues from product candidates and may affect our overall financial condition and ability to develop product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Packaging and Distribution in the United States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws
and requirements apply. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state
consumer protection and unfair competition laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of pharmaceutical products is subject to additional requirements and
regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure to comply with any of these laws or regulatory requirements subjects firms to possible legal or regulatory action. Depending on
the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, exclusion from federal healthcare programs, requests for recall, seizure of products, total or partial
suspension of production, denial or withdrawal of product approvals, or refusal to allow a firm to enter into supply contracts, including government contracts. Any action against us for violation of these laws, even if we successfully defend against
it, could cause us to incur significant legal expenses and divert our management&#146;s attention from the operation of our business. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our
business in an adverse way. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in
the future by requiring, for example: (i)&nbsp;changes to our manufacturing arrangements; (ii)&nbsp;additions or modifications to product labeling; (iii)&nbsp;the recall or discontinuation of our products; or (iv)&nbsp;additional record-keeping
requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Other U.S.
Environmental, Health and Safety Laws and Regulations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to numerous environmental, health and safety laws and
regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable
materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of
contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our
resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">349 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain workers&#146; compensation insurance to cover us for costs and expenses we may
incur due to injuries to our employees, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations.
Current or future environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Patent Term Restoration and Marketing Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of FDA approval of our future product candidates, some of our U.S. patents may be eligible
for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit restoration of the patent term of up to five years as
compensation for patent term lost during the FDA regulatory review process. Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#146;s approval date and only those claims
covering such approved drug product, a method for using it or a method for manufacturing it may be extended. The patent-term restoration period is generally <FONT STYLE="white-space:nowrap">one-half</FONT> the time between the effective date of an
IND and the submission date of an NDA or BLA plus the time between the submission date of an NDA or BLA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due
diligence. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the
application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length
of the clinical trials and other factors involved in the filing of the relevant NDA or BLA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Marketing exclusivity provisions under the
FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year period of <FONT STYLE="white-space:nowrap">non-patent</FONT> marketing exclusivity within the United States to the first applicant to gain
approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance.
During the exclusivity period, the FDA may not accept for review an ANDA, or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required
for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or <FONT STYLE="white-space:nowrap">non-infringement.</FONT> The FDCA also provides three years of marketing exclusivity for
an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application,
for example, new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs
containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the
preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>European
Union Drug Development </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Union and European Economic Area, our future products also may be subject to extensive
regulatory requirements. As in the United States, medicinal products can be marketed only if a marketing authorization from the competent regulatory agencies has been obtained. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">350 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to the United States, the various phases of preclinical and clinical research in the
European Union and European Economic Area are subject to significant regulatory controls. Although the EU Clinical Trials Directive 2001/20/EC (the &#147;Directive&#148;), has sought to harmonize the EU clinical trials regulatory framework, setting
out common rules for the control and authorization of clinical trials in the EU, the EU Member States have transposed and applied the provisions of the Directive differently into their national laws. This has led to significant variations in the
Member State regimes. Under the current regime, before a clinical trial can be initiated it must be approved in each of the EU countries where the trial is to be conducted by two distinct bodies: the National Competent Authority (the
&#147;NCA&#148;), and one or more Ethics Committees (&#147;ECs&#148;). Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial have to be reported to the NCA and ECs
of the Member State where they occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The EU clinical trials legislation currently is undergoing a transition process mainly aimed at
harmonizing and streamlining clinical trial authorization, simplifying adverse-event reporting procedures, improving the supervision of clinical trials and increasing their transparency. In April 2014, the EU adopted a new Clinical Trials Regulation
(EU) No 536/2014 (the &#147;Regulation&#148;), which is set to replace the current Directive. Specifically, the new Regulation, which will be directly applicable in all Member States without the need for EU Member States to transpose it into
national law, aims at simplifying and streamlining the approval of clinical trials in the EU. For instance, the new Regulation provides for a streamlined application procedure via a single entry point and strictly defined deadlines for the
assessment of clinical trial applications. It is expected that the new Regulation will apply following confirmation of full functionality of the Clinical Trials Information System, the centralized EU portal and database for clinical trials foreseen
by the Regulation, through an independent audit; the System is expected to go live in December 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>European Union Drug Marketing
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Much like the federal Anti-Kickback Statue prohibition in the United States, the provision of benefits or advantages to physicians
to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the European Union and European Economic Area. The provision of benefits or advantages to induce or
reward improper performance generally is governed by the national anti-bribery laws of the European Union Member States, and the Bribery Act 2010 in the UK, as well as the industry Codes of Practice that are based on the European Federation of
Pharmaceutical Industries and Associations (EFPIA) Code of Practice. Infringement of these laws could result in substantial fines and imprisonment. EU Directive 2001/83/EC, which is the EU Directive governing medicinal products for human use,
further provides that, where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to such persons unless they are inexpensive
and relevant to the practice of medicine or pharmacy. This provision has been transposed into the Human Medicines Regulations 2012 and so remains applicable in the UK despite its departure from the EU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments made to physicians in EU Member States and Member States of the European Economic Area must be publicly disclosed. Moreover,
agreements with physicians often must be the subject of prior notification and approval by the physician&#146;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These
requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative
penalties, fines or imprisonment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>European Union Drug Review and Approval </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Economic Area (the &#147;EEA&#148;), which is comprised of the Member States of the European Union plus Norway, Iceland and
Liechtenstein, medicinal products can only be commercialized after obtaining a marketing authorization (&#147;MA&#148;). There are two types of marketing authorizations. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The centralized MA is issued by the European Commission through the centralized procedure, based on the opinion
of the Committee for Medicinal Products for Human Use (the &#147;CHMP&#148;), of the EMA, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">351 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
and is valid throughout the entire territory of the EEA. The centralized procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products,
advanced-therapy medicinal products (gene-therapy, somatic cell-therapy or tissue-engineered medicines) and medicinal products containing a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, diabetes,
auto-immune and other immune dysfunctions and viral diseases. The centralized procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific
or technical innovation or which are in the interest of public health in the EEA. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Under the centralized procedure the
maximum timeframe for the evaluation of a marketing authorization application (a &#147;MAA&#148;), by the EMA is 210 days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions
asked by the CHMP. Clock stops may extend the timeframe of evaluation of a MAA considerably beyond 210 days. Where the CHMP gives a positive opinion, it provides the opinion together with supporting documentation to the European Commission, who make
the final decision to grant a marketing authorization, which is issued within 67 days of receipt of the EMA&#146;s recommendation. Accelerated assessment might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be
of major public health interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of a MAA under the accelerated assessment procedure is 150 days, excluding clock stops, but it is possible that the CHMP
may revert to the standard time limit for the centralized procedure if it determines that the application is no longer appropriate to conduct an accelerated assessment. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their
respective territory, are available for products not falling within the mandatory scope of the centralized procedure. If a product is to be authorized in more than one Member State, the assessment procedure is coordinated at <FONT
STYLE="white-space:nowrap">EU-level.</FONT> Where a product has already been authorized for marketing in a Member State of the EEA, the national MA can be recognized in another Member States through the mutual recognition procedure. If the product
has not received a national MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the decentralized procedure. Under the decentralized procedure an identical dossier is submitted to the
competent authorities of each of the Member States in which the MA is sought, one of which is selected by the applicant as the Reference Member State (the &#147;RMS&#148;). The competent authority of the RMS coordinates the preparation of a draft
assessment report, a draft summary of the product characteristics (the &#147;SmPC&#148;), and a draft of the labeling and package leaflet, which are sent to the other Member States (referred to as the Concerned Member States) for their final
approval. If the Concerned Member States raise no objections, based on a potential serious risk to public health, to the assessment, SmPC, labeling, or packaging circulated by the RMS, the coordinated procedures is closed, and the product is
subsequently granted a national MA in all the Member States (i.e., in the RMS and the Concerned Member States). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under
the above-described procedures, during the assessment of the documents submitted in the MAA and before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the
product on the basis of scientific criteria concerning its quality, safety and efficacy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Now that the United Kingdom (which comprises
Great Britain and Northern Ireland) has left the European Union, Great Britain will no longer be covered by centralized MAs (under the Northern Irish Protocol of the Withdrawal Agreement, centralized MAs will continue to apply in Northern Ireland).
All medicinal products with a valid centralized MA as of December&nbsp;31, 2020, were automatically converted to Great Britain MAs on January, 1 2021 (unless the MA holder opted out of this procedure). For a period of two years from January&nbsp;1,
2021, the Medicines and Healthcare products Regulatory Agency (the &#147;MHRA&#148;), the UK medicines regulator, may rely on a decision taken by the European Commission on the approval of a new MA in the centralized
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">352 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
procedure, in order to more quickly grant a new Great Britain MA. A separate application will, however, still be required. The MHRA also has the power to have regard to MAs approved in EEA Member
States through decentralized or mutual recognition procedures with a view to more quickly granting a MA in the United Kingdom or Great Britain. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>European Union New Chemical Entity Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EEA, innovative medicinal products, approved on the basis of a full dossier of preclinical and clinical data as part of the MAA, qualify
for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. The data exclusivity, if granted, prevents generic or biosimilar applicants from referencing the innovator&#146;s <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trial data contained in the dossier of the reference innovative product when applying for a generic or biosimilar MA in the EEA, for a period of eight years from the date of authorization
of the reference product. During the additional <FONT STYLE="white-space:nowrap">two-year</FONT> period of market exclusivity, a generic or biosimilar marketing authorization application can be submitted, and the innovator&#146;s data may be
referenced, but no generic or biosimilar product can be marketed until the expiration of the market exclusivity. The overall <FONT STYLE="white-space:nowrap">ten-year</FONT> period can be extended to a maximum of 11 years if, during the first eight
years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are determined to bring a significant clinical
benefit in comparison with currently approved therapies. Even if an innovative medicinal product gains the prescribed period of data exclusivity, however, another company may market another version of the product if such company obtained a MA based
on a marketing authorization application with a complete independent data package of pharmaceutical tests, preclinical tests and clinical trials (i.e. without cross-referencing to the data within the reference innovative product). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>European Union Orphan Designation and Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EEA, the EMA&#146;s Committee for Orphan Medicinal Products grants orphan drug designation to promote the development of products that
are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions and either (i)&nbsp;such condition affects not more than five in 10,000 persons in the EEA, or (ii)&nbsp;it is unlikely that the
development of the medicine would generate sufficient return to justify the necessary investment in its development. In either case, the applicant must also demonstrate that no satisfactory method of diagnosis, prevention or treatment has been
authorized (or, if a method exists, the product would be a significant benefit to those affected compared to the product available). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
the EEA, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers. In addition, if the criteria for orphan designation are found to be maintained at the time of authorization of the product, ten years
of market exclusivity is granted following grant of an orphan marketing authorization. During this market exclusivity period, neither the EMA nor the European Commission nor any of the competent authorities in the EEA Members States can accept an
application or grant a marketing authorization for a &#147;similar medicinal product&#148; for the same indication. A &#147;similar medicinal product&#148; is defined as a medicinal product containing a similar active substance or substances as
contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. This orphan exclusivity period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it
is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. Market exclusivity may also be broken, so a similar product may be authorized for the same indication, in very select cases, such as if
(i)&nbsp;it is established that a similar medicinal product is safer, more effective or otherwise clinically superior to the authorized product; (ii)&nbsp;the marketing authorization holder consents to the grant of the similar product; or
(iii)&nbsp;the marketing authorization holder cannot supply enough orphan medicinal product. Orphan drug designation must be requested before submitting an application for marketing approval. Orphan drug designation does not convey any advantage in,
or shorten the duration of, the regulatory review and approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From January&nbsp;1, 2021, a separate process for orphan drug
designation will apply in Great Britain. There will be no <FONT STYLE="white-space:nowrap">pre-marketing</FONT> authorization orphan designation (as there is in the EEA) and the application for orphan
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">353 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
designation will be reviewed by the MHRA at the time of the marketing authorization application. The criteria are the same as in the EEA, save that they apply to Great Britain only (e.g., there
must be no satisfactory method of diagnosis, prevention or treatment of the condition concerned in Great Britain). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>European
Pediatric Investigation Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EEA, MAAs for new medicinal products have to include the results of studies conducted in the
pediatric population, in compliance with a pediatric investigation plan (a &#147;PIP&#148;), agreed with the EMA&#146;s Pediatric Committee (a &#147;PDCO&#148;). The PIP sets out the timing and measures proposed to generate data to support a
pediatric indication of the drug for which marketing authorization is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and
safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when this data is not needed or appropriate because the product is likely to be ineffective or unsafe in children, the
disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. If a marketing authorization is
obtained and trial results are included in the product information, even when negative, and the product is approved in all Member States, <FONT STYLE="white-space:nowrap">non-orphan</FONT> products are eligible for six months&#146; supplementary
protection certificate extension. In the case of orphan medicinal products, a <FONT STYLE="white-space:nowrap">two-year</FONT> extension of the orphan market exclusivity may be available. This pediatric reward is subject to specific conditions and
is not automatically available when data in compliance with the PIP are developed and submitted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Brexit and the Regulatory
Framework in the United Kingdom </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;23, 2016, the electorate in the United Kingdom voted in favor of leaving the European
Union (commonly referred to as Brexit). Thereafter, on March&nbsp;29, 2017, the country formally notified the European Union of its intention to withdraw pursuant to Article 50 of the Lisbon Treaty. The United Kingdom formally left the European
Union on January&nbsp;31, 2020. A transition period began on February&nbsp;1, 2020, during which EU pharmaceutical law remained applicable in the United Kingdom. However this ended on December&nbsp;31, 2020. On December 30, 2020, the United Kingdom
and European Union signed the Trade and Cooperation Agreement, which includes an agreement on free trade between the two parties. Since the regulatory framework in the United Kingdom covering the quality, safety and efficacy of pharmaceutical
products, clinical trials, marketing authorizations, commercial sales, and distribution of pharmaceutical products is derived from EU Directives and Regulations, Brexit could materially impact the future regulatory regime which applies to products
and the approval of product candidates in the United Kingdom, as the UK legislation now has the potential to diverge from EU legislation. It remains to be seen how Brexit will impact regulatory requirements for medicinal products and devices in the
United Kingdom in the long term. The MHRA has recently published detailed guidance for industry and organizations to follow now the transition period is over, which will be updated as the United Kingdom&#146;s regulatory position on medicinal
products and medical devices evolves over time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>European Data Collection </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The collection and use of personal data, including health data, in the EEA is governed by the General Data Protection Regulation (the
&#147;GDPR&#148;), which became effective May&nbsp;25, 2018. The GDPR applies to any company established in the EEA and to companies established outside the EEA that process personal data in connection with the offering of goods or services to data
subjects in the European Union or EEA or the monitoring of the behavior of data subjects in the European Union or EEA. The GDPR enhances data protection obligations for data controllers of personal data, including stringent requirements relating to
the consent of data subjects, expanded disclosures about how personal data is used, requirements to conduct privacy impact assessments for &#147;high risk&#148; processing, limitations on retention of personal data, mandatory data breach
notification and &#147;privacy by design&#148; requirements, and creates direct obligations on service providers acting as data processors. The GDPR also imposes strict rules on the transfer of personal data outside of the EEA to countries that do
not ensure an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">354 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adequate level of protection, like the United States. Failure to comply with the requirements of the GDPR and the related national data protection laws of the EEA Member States may result in
fines up to &#128;20&nbsp;million or 4% of a company&#146;s global annual revenues for the preceding financial year, whichever is higher. Moreover, the GDPR grants data subjects the right to claim material and
<FONT STYLE="white-space:nowrap">non-material</FONT> damages resulting from infringement of the GDPR. Given the breadth and depth of changes in data protection obligations, maintaining compliance with the GDPR will require significant time,
resources and expense, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. This may be onerous and adversely affect our business, financial condition, results of operations and
prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, further to the United Kingdom&#146;s exit from the European Union on January&nbsp;31, 2020, the GDPR ceased to
apply in the United Kingdom at the end of the transition period on December&nbsp;31, 2020. However, as of January&nbsp;1, 2021, the United Kingdom&#146;s European Union (Withdrawal) Act 2018 incorporated the GDPR (as it existed on December&nbsp;31,
2020 but subject to certain UK specific amendments) into UK law, referred to as the UK GDPR. The UK GDPR and the UK Data Protection Act 2018 set out the United Kingdom&#146;s data protection regime, which is independent from but aligned to the
European Union&#146;s data protection regime. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> with the UK GDPR may result in monetary penalties of up to &pound;17.5&nbsp;million or 4% of worldwide revenue, whichever is higher. With respect to
transfers of personal data from the EEA to the United Kingdom, on June&nbsp;28, 2021 the European Commission issued an adequacy decision in respect of the UK&#146;s data protection framework, enabling data transfers from EU member states to the UK
to continue without requiring organizations to put in place contractual or other measures in order to lawfully transfer personal data between the territories. While it is intended to last for at least four years, the European Commission may
unilaterally revoke the adequacy decision at any point, and if this occurs it could lead to additional costs and increase our overall risk exposure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Rest of the World Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For other countries outside of the European Union and the United States, such as countries in Eastern Europe, Latin America or Asia, the
requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. Additionally, the clinical trials must be conducted in accordance with GCP requirements and the applicable regulatory
requirements and the ethical principles that have their origin in the Declaration of Helsinki. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to comply with applicable
foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Additional Laws and Regulations Governing International Operations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we further expand our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and
regulations in each jurisdiction in which we plan to operate. The U.S. Foreign Corrupt Practices Act (the &#147;FCPA&#148;), prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value,
directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also
obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including
international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the
FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in
connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">355 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Further, other anti-corruption laws, such as the UK Bribery Act, are broader and can regulate payments to <FONT STYLE="white-space:nowrap">non-governmental</FONT> entities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with
certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United
States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit
our growth potential and increase our development costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure to comply with laws governing international business practices may
result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#146;s accounting provisions.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Coverage and Reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Successful commercialization of new drug products depends in part on the extent to which reimbursement for those drug products will be
available from government health administration authorities, private health insurers, and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drug
products they will pay for and establish reimbursement levels. The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford a drug product. Sales of drug products depend
substantially, both domestically and abroad, on the extent to which the costs of drugs products are covered or paid for by the federal or national government as well as commercial managed care organizations, pharmacy benefit managers, and similar
healthcare management organizations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government
authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular drug products. In many countries, the prices of drug products are subject to varying price control mechanisms as
part of national health systems. In general, the prices of drug products under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for drug products, but monitor and control company
profits. Accordingly, in markets outside the United States, the acquisition costs and reimbursement for drug products may lower than within the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the decisions about reimbursement for new drug products under the Medicare program are made by CMS, an agency within
HHS. CMS determines coverage standards for products reimbursed by Medicare, and private payors often adopt coverage standards established by CMS for the commercial marketplace. However, no uniform policy of coverage and reimbursement for drug
products exists among third-party payors and coverage and reimbursement levels for drug products can differ significantly from payor to payor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party payors may limit coverage to specific products on an approved list or formulary, which might not include all of the <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> products for a particular indication. Also, third-party payors may refuse to include a particular branded drug on their formularies or otherwise restrict patient access to a branded drug when a less
costly generic equivalent or another alternative is available. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity, and reviewing the cost-effectiveness of medical
products and services and imposing controls to manage costs. Further, due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, millions of individuals have lost or are expected to lose employer-based insurance coverage, which may
adversely affect our ability to successfully commercialize our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Medicare Prescription Drug, Improvement, and Modernization
Act of 2003 (the &#147;MMA&#148;), established the Medicare Part D program to provide a voluntary prescription drug benefit to Medicare beneficiaries. Under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">356 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. Unlike Medicare Parts A and B, Part D
coverage is not standardized. Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level.
While all Medicare drug plans must give at least a standard level of coverage set by Medicare, Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that
identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each
category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for drugs for which
we obtain marketing approval. Any negotiated prices for any of our products covered by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare
beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from <FONT
STYLE="white-space:nowrap">non-governmental</FONT> payors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a drug product to receive federal reimbursement under the Medicaid or
Medicare Part B programs, a manufacturer must enter into agreements with the Secretary of HHS to participate in the Medicaid Drug Rebate Program and the 340B drug discount program. Under the Medicaid Drug Rebate Program, manufacturers are obligated
to pay rebates to the State Medicaid Programs on each unit of the manufacturer&#146;s drugs that are dispensed to Medicaid beneficiaries&#151;both with regard to Medicaid Fee for Service and Medicaid Managed Care. Additionally, under the 340B drug
discount program, manufacturers extend discounts to entities eligible to participate in the 340B program, including various hospital providers. The required 340B discount on a given product is calculated based on the average manufacturer price (the
&#147;AMP&#148;), and Medicaid rebate amounts reported and paid by the manufacturer under the Medicaid Drug Rebate Program. As of 2010, the ACA expanded the types of entities eligible to receive discounted 340B pricing, although under current law
these newly eligible entities (with the exception of children&#146;s hospitals) will not be eligible to receive discounted 340B pricing on drugs that receive an orphan designation by the FDA. As 340B drug pricing is determined based on AMP and
Medicaid rebate data, revisions to the statute and regulations governing the Medicaid Drug Rebate Program may cause the required 340B discount to increase. Additional legislation surrounding the 340B program, including which providers are eligible
for the program, may be enacted in the future. These developments could affect our profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The American Recovery and Reinvestment
Act of 2009 provides funding for the federal government to compare the effectiveness of different treatments for the same illness. The plan for the research was published in 2012 by the Department of HHS, the Agency for Healthcare Research and
Quality and the National Institutes for Health, and periodic reports on the status of the research and related expenditures are made to Congress. Although the results of the comparative effectiveness studies are not intended to mandate coverage
policies for public or private payors, it is not clear what effect, if any, the research will have on the sales of our drug candidates, if any such drug or the condition that they are intended to treat are the subject of a trial. It is also possible
that comparative effectiveness research demonstrating benefits in a competitor&#146;s drug could adversely affect the sales of our drug candidate. If third-party payors do not consider our drugs to be cost-effective compared to other available
therapies, they may not cover our drugs after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our drugs on a profitable basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These laws, and future state and federal healthcare reform measures may be adopted in the future, any of which may result in additional
reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside of the United States, the pricing of pharmaceutical products and medical devices is subject to governmental control in many
countries. For example, in the European Union, pricing and reimbursement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">357 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of
additional studies that compare the cost effectiveness of a particular therapy to currently available therapies or <FONT STYLE="white-space:nowrap">so-called</FONT> health technology assessments, in order to obtain reimbursement or pricing approval.
Other countries may allow companies to fix their own prices for products, but monitor and control product volumes or the amount of profit made on those profits, and issue guidance to physicians to limit prescriptions. Efforts to control prices and
utilization of pharmaceutical products and medical devices will likely continue as countries attempt to manage healthcare expenditures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Human Capital
Management </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021, we and our subsidiaries had approximately 620 full-time employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our human capital objectives include sourcing, recruiting, retaining, incentivizing and developing our existing and future employees. We seek
to create nimble, entrepreneurial Vants that operate similar to independent biotechnology companies where each management team, comprised of world-class drug developers and clinical operators, is solely focused on their respective Vant&#146;s
mission. Our and our Vants&#146; equity incentive plans are designed to attract, retain and motivate selected employees, consultants and directors through the granting of share-based compensation awards to encourage focus and calculated risk-taking.
In connection with becoming a public company, we expect to hire additional personnel and to implement procedures and processes to address public company regulatory requirements and customary practices. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate and Other Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were
registered as an exempted limited company in Bermuda in 2014, under the name Valor Biotechnology Ltd. In November 2014 we changed our name to Roivant Sciences Ltd. Our principal executive offices are located at Suite 1, 3rd Floor, <FONT
STYLE="white-space:nowrap">11-12</FONT> St. James&#146;s Square, London SW1Y 4LB, United Kingdom. Our telephone number is +44 207 400 3347. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our web page address is https://roivant.com. Our investor relations website will be located at https://investor.roivant.com/. We will make
available free of charge on our investor relations website under &#147;SEC Filings&#148; our Annual Reports on Form&nbsp;10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, our directors&#146; and officers&#146; Section&nbsp;16
Reports and any amendments to those reports after filing or furnishing such materials to the SEC. References to our website address do not constitute incorporation by reference of the information contained on the website, and the information
contained on the website is not part of this document or any other document that we file with or furnish to the SEC. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an
&#147;emerging growth company&#148; (an &#147;EGC&#148;), as defined in the Jumpstart Our Business Startups Act of 2012. As an EGC, we are eligible for exemptions from various reporting requirements applicable to other public companies that are not
emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 and reduced disclosure obligations regarding executive
compensation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consider it in
the ordinary course of our business that our patents may become subject to inter partes review and opposition proceedings. Three U.S. patents (U.S. Patent Nos. 8,058,069, 9,364,435 and 9,404,127) relating to lipid nanoparticle molar ratios and the
aggregation of lipid nanoparticles that Genevant exclusively licenses from Arbutus were the subject of inter partes review proceedings brought by Moderna before the PTAB. The PTAB upheld all claims of U.S. Patent No. 8,058,069, invalidated some of
the claims of U.S. Patent No. 9,364,435 and invalidated all claims of U.S. Patent No. 9,404,127. The PTAB&#146;s decisions with respect to U.S. Patent Nos. 8,058,069 and 9,364,435 are currently on appeal at the United States Court of Appeals for the
Federal Circuit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">358 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The Federal Circuit vacated and remanded the PTAB&#146;s decision on U.S. Patent No. 9,494,127, and the PTAB&#146;s decision with respect to U.S. Patent No. 9,494,127 patent is currently held in
administrative abeyance, pending a review following a recent Supreme Court ruling in an unrelated case. Additionally, one European patent (EU patent no. EP2279254) relating to lipid nanoparticle molar ratios that Genevant exclusively licenses from
Arbutus is the subject of an opposition proceeding brought by Merck Sharp &amp; Dohme Corporation and Moderna at the European Patent Office Opposition Division. There can be no assurance that these patents will be found to be valid or sufficiently
broad to protect our technology or to provide us with a competitive advantage. For more information on risks associated with the inter partes review proceedings and the pending European patent opposition proceeding, see &#147;Risk Factors&#151;Risks
Related to Roivant&#146;s Business and Industry&#151;Risks Related to Our Intellectual Property.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may be subject to other
legal proceedings, investigations and claims incidental to the conduct of our business. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us
because of defense and settlement costs, diversion of management resources, and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">359 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_21"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS OF ROIVANT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following discussion and analysis of Roivant&#146;s financial condition and results of
operations should be read in conjunction with Roivant&#146;s consolidated financial statements and notes to those statements included in this proxy statement/prospectus. Certain information contained in the discussion and analysis set forth below
includes forward-looking statements that involve risks and uncertainties. Roivant&#146;s actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors. Please see &#147;Cautionary
Statement Regarding Forward-Looking Statements&#148; and &#147;Risk Factors&#148; in this proxy statement/prospectus. Our fiscal year ends on March&nbsp;31 and our fiscal quarters end on June&nbsp;30, September&nbsp;30 and December 31. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>For purposes of this subsection only, &#147;Roivant,&#148; &#147;the Company,&#148; &#147;we,&#148; &#147;us&#148; or &#147;our&#148; refer
to Roivant Sciences Ltd. and its subsidiaries, unless the context otherwise requires. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are building the next-generation &#147;big pharma&#148; company, organized to harness modern technologies and the entrepreneurial spirit of
nimble biotechnology companies at scale. Our mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a diverse team of experienced drug developers, scientists, physicians, company builders, data scientists and engineers, biopharma
investors, physicists and business development professionals dedicated to improving the lives of patients. At Roivant, we combine our team&#146;s extensive experience and multi-disciplinary expertise with innovative technologies to identify and
advance potentially transformative medicines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We deploy a hypothesis-driven approach to identify novel or clinically-validated targets
and biological pathways in areas of high unmet medical need. We then seek to acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or discover promising drug candidates against those targets or pathways. Our small molecule discovery engine is
powered by a unique combination of leading computational physics and machine learning (&#147;ML&#148;) capabilities for <I>in silico</I> drug design. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We develop drug candidates in subsidiary companies we call &#147;Vants&#148; with a distinct approach to sourcing talent, aligning incentives
and deploying technology. Each of our Vant teams is built with deep relevant expertise to promote successful execution of our development strategy. Our Vants continue to benefit from the support of our platform and technologies that are built to
address inefficiencies in the drug discovery, development and commercialization process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our agile Vant model has allowed us to rapidly
add capabilities in diverse therapeutic areas, including immunology, dermatology, hematology and oncology, and modalities, including biologics, topicals, gene therapies and bifunctional small molecules. The Vant model also enables a modular approach
to the monetization of therapies we advance through development, allowing us to pursue commercialization of some products independently, while selectively establishing partnerships for other Vants or divesting of the Vants entirely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception in 2014, we have focused substantially all of our efforts and financial resources on acquiring and developing our product
candidates and expanding our platform and technologies. For the years ended March&nbsp;31, 2021 and 2020, we incurred losses from continuing operations of $900.2&nbsp;million and $568.1&nbsp;million, respectively. As of March&nbsp;31, 2021, we had
cash and cash equivalents of approximately $2.1&nbsp;billion and our accumulated deficit was approximately $1.9&nbsp;billion. We have not generated any revenues to date from the sale of our product candidates. Our revenue, primarily generated
through license agreements as well as from subscription and service-based fees, has not been significant to date. Our operations to date have been financed primarily through the sale of equity securities, sale of subsidiary interests, debt
financings and revenue generated from licensing and collaboration arrangements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">360 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Business Combination and Public Company Costs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;1, 2021, we entered into the Business Combination Agreement with MAAC and Merger Sub. Pursuant to the Business Combination
Agreement, and assuming a favorable vote of the MAAC stockholders at the MAAC Special Meeting and satisfaction or waiver of all other closing conditions, Merger Sub will merge with and into MAAC, with MAAC surviving the merger as our wholly owned
subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For financial accounting and reporting purposes, MAAC will be treated as the acquired company. Accordingly, because MAAC does
not represent a business for accounting purposes and its primary asset represents cash and cash equivalents, the Business Combination will be treated as an equity contribution in exchange for the issuance of Roivant shares. The net assets of MAAC
will be stated at historical cost, with no goodwill or other intangible assets recorded. We will be deemed both the accounting predecessor and the successor SEC registrant, which means that our financial statements for previous periods will be
disclosed in our future periodic reports filed with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The most significant change in our future reported financial position is
expected to be an estimated increase in cash (as compared to our consolidated balance sheet at March 31, 2021) of between approximately $378.4&nbsp;million, assuming maximum stockholder redemptions permitted under the Business Combination Agreement,
and $579.2&nbsp;million, assuming no stockholder redemptions and, in each case, after deducting estimated expenses. See &#147;Unaudited Pro Forma Condensed Combined Financial Information.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with becoming a public company, we expect to hire additional personnel and to implement procedures and processes to address
public company regulatory requirements and customary practices. We expect to incur additional annual expenses as a public company for, among other things, hiring of new personnel and fees to outside consultants, and costs related to implementation
of an appropriate internal control framework, insurance, and investor relations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Option Vants Transaction </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;1, 2021, we entered into an Asset Purchase Agreement with Sumitomo Dainippon Pharma Co., Ltd. (&#147;Sumitomo&#148;) and its
subsidiary Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. (&#147;SPC&#148;) (the &#147;Asset Purchase Agreement&#148;). The transactions contemplated by the Asset Purchase Agreement closed in June 2021. Pursuant to the Asset Purchase Agreement:
(i)&nbsp;Sumitomo terminated all of its existing options to acquire our equity interests in Genevant Sciences Ltd. (&#147;Genevant&#148;), Lysovant Sciences Ltd. (&#147;Lysovant&#148;), Metavant Sciences Ltd. (&#147;Metavant&#148;), Roivant Asia
Cell Therapy Holdings Ltd. (&#147;Cytovant Parent&#148;), and Sinovant Sciences HK Limited (&#147;Sinovant&#148;); (ii) we transferred and assigned to SPC all of our intellectual property, development and commercialization rights for
(a)&nbsp;lefamulin in Mainland China, Taiwan, Hong Kong, and Macau (collectively, &#147;Greater China&#148;), (b) vibegron in Mainland China, (c)&nbsp;rodatristat ethyl in Greater China and South Korea, and
<FONT STYLE="white-space:nowrap">(d)&nbsp;RVT-802</FONT> in Greater China and South Korea; (iii)&nbsp;we will receive a $5.0&nbsp;million cash payment; and (iv)&nbsp;Sumitomo entered into an agreement with us to pursue future collaborations with
Genevant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dermavant </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May 14, 2021, Dermavant Sciences Ltd. (&#147;Dermavant&#148;) entered into a $160.0 million revenue interest purchase and sale agreement
(the &#147;RIPSA&#148;) for its investigational product tapinarof with three institutional investors. Under the terms of the RIPSA, the participants purchased a capped single-digit revenue interest in net sales of tapinarof for all dermatological
indications in the United States in exchange for $160.0 million in committed funding to be paid to Dermavant, subject to approval of tapinarof by the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dermavant and certain of its subsidiaries concurrently entered into a $40.0 million senior secured credit facility (the &#147;Credit
Facility&#148;) with one of the institutional investors. The Credit Facility has a five-year maturity </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">361 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and bears an interest rate of 10% per annum. In connection with the funding of the Credit Facility, Dermavant issued to the institutional investor a warrant to purchase 1,199,072 common shares of
Dermavant at an exercise price of $0.01 per common share. The proceeds from the Credit Facility were used to repay all amounts outstanding under the loan and security agreement with Hercules Capital, Inc. (&#147;Hercules&#148;), with the remainder
of net proceeds used for working capital and general corporate purposes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Datavant </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2021, Datavant Holdings, Inc. (&#147;Datavant&#148;) and CIOX Health, LLC entered into a definitive agreement to merge the two
companies. The merger closed on July 27, 2021. At closing, Roivant received approximately $320 million in cash. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Impact of <FONT
STYLE="white-space:nowrap">COVID-19</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have been actively monitoring the impact of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our employees and our business. Based on guidance issued by federal, state and local authorities, we transitioned to a remote work model for our employees in March 2020 and our workforce
continues to primarily work remotely. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has had a variable impact on our
clinical trials by disrupting certain study sites. In the conduct of our business activities, we continue to take actions designed to protect the safety and well-being of our patients and employees. Although some of our clinical development
timelines have been impacted by delays related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, we have not experienced material financial impacts on our business and operations as a result of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. However, the impact on our future results will largely depend on future developments related to <FONT STYLE="white-space:nowrap">COVID-19,</FONT> which are highly uncertain and cannot be
predicted with confidence, such as the emergence of new variants, the ultimate duration and spread of the outbreak, the continuing impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on financial markets and the global economy,
travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain, treat, and prevent the disease,
including the availability and effectiveness of vaccines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional information about risks and uncertainties related to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic that may impact our business, financial condition and results of operations, see the section titled &#147;Risk Factors&#148; included elsewhere in this proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Components of Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue, net </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
have not generated any revenues to date from the sale of our product candidates and do not anticipate generating any revenues from the sale of product candidates unless and until we successfully complete development and obtain regulatory approval to
market our product candidates. Our revenue to date primarily includes the recognition of upfront payments received in connection with license agreements. Revenue is also generated by subscription and service-based fees. Our revenue recognized from
inception to date has not been significant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cost of revenues </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our cost of revenues primarily relates to subscription and service-based revenue recognized for the use of technology developed and consists
primarily of employee, hosting, and third-party data costs. Our cost of revenues has not been significant to date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">362 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and development expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist mainly of costs incurred in connection with the discovery and development of our product candidates.
Research and development expenses primarily include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Program-specific costs, including: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">direct third-party costs, which include expenses incurred under agreements with contract research organizations
(&#147;CROs&#148;) and contract manufacturing organizations (&#147;CMOs&#148;), the cost of consultants who assist with the development of our product candidates on a program-specific basis, investigator grants, sponsored research, manufacturing
costs in connection with producing materials for use in conducting nonclinical and clinical studies, and any other third-party expenses directly attributable to the development of our product candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payments made in connection with asset acquisitions and license agreements upon the achievement of development
milestones. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Consideration for the purchase of <FONT STYLE="white-space:nowrap">in-process</FONT> research and development
(&#147;IPR&amp;D&#148;) through asset acquisitions and license agreements, including: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cash upfront payments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares and other liability instruments issued; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fair value of future contingent consideration payments. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Unallocated internal costs, including: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">employee-related expenses, such as salaries, share-based compensation, and benefits, for research and development
personnel; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other expenses, including consulting costs, that are not allocated to a specific program. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development activities, including asset acquisitions and license agreements, will continue to be central to our business model.
We anticipate that our research and development expenses will increase for the foreseeable future as we advance our product candidates through <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials, as well as acquire new
product candidates. Research and development expenses will also be driven by the number of small molecules from our discovery engine that we advance through preclinical studies and clinical trials. In addition, we expect our research and development
expenses to increase in the future, including as a result of our small molecule discovery engine through which we utilize our computational platform for <I>in silico</I> design of novel drug candidates. We expect higher employee-related expenses,
including higher share-based compensation expenses, as well as higher consulting costs as we hire additional resources to support increasing development activity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The duration, costs and timing of pre-clinical studies and clinical trials of our product candidates will depend on a variety of factors that
include, but are not limited to, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, rate of progress, expense and results of our preclinical development activities, any future clinical
trials of our product candidates, and other research and development activities that we may conduct; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and scope of preclinical and clinical programs we decide to pursue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the uncertainties in clinical trial design and patient enrollment or drop out or discontinuation rates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of doses that patients receive; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the countries in which the trials are conducted; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to secure and leverage adequate CRO support for the conduct of clinical trials;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">363 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish an appropriate safety and efficacy profile for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, receipt and terms of any approvals from applicable regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential additional safety monitoring or other studies requested by regulatory agencies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the significant and changing government regulation and regulatory guidance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish clinical and commercial manufacturing capabilities, or make arrangements with
third-party manufacturers in order to ensure that we or our third-party manufacturers are able to make product successfully; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of any business interruptions to our operations due to the COVID-19 pandemic; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain a continued acceptable safety profile of our product candidates following approval, if
any, of our product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the probability of success for our product candidates will depend on
numerous factors, including competition, manufacturing capability and commercial viability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>General and administrative expenses
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of employee-related expenses for general and administrative personnel,
including those responsible for the identification and acquisition or <FONT STYLE="white-space:nowrap">in-license</FONT> of new drug candidates as well as for overseeing Vant operations and facilitating the use of our platform and technologies at
Vants. General and administrative expenses also consist of legal and accounting fees, consulting services and other operating costs relating to corporate matters and daily operations. General and administrative expenses also include costs incurred
relating to the identification, acquisition or <FONT STYLE="white-space:nowrap">in-license</FONT> and technology transfer of promising drug candidates along with costs incurred relating to the integration of new technologies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that our general and administrative expenses will increase in the future to support our continued research and development
activities, potential commercialization efforts, and increased costs associated with being a public company. These increases will likely include additional costs related to the hiring of new personnel, including higher share-based compensation
expenses, and fees to outside consultants, as well as other expenses. As a public company, we anticipate incurring expenses related to maintaining compliance with the rules and regulations promulgated by the SEC, the applicable Nasdaq listing rules
and the requirements of the Sarbanes-Oxley Act of 2002, as amended (the &#147;Sarbanes-Oxley Act&#148;). If any of our current or future product candidates receives regulatory approval in the U.S. or another jurisdiction, we expect that we would
incur significantly increased expenses associated with building a sales and marketing team. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Change in fair value of investments
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Change in fair value of investments includes the unrealized (gain) loss on equity investments in publicly-traded companies,
including Sio Gene Therapies Inc. (&#147;Sio&#148;) and Arbutus Biopharma Corporation (&#147;Arbutus&#148;). We have elected the fair value option to account for these investments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Change in fair value of debt and liability instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Change in fair value of debt and liability instruments primarily includes the unrealized loss (gain) relating to the measurement and
recognition of fair value on a recurring basis of certain liabilities, including debt issued by Dermavant to NovaQuest <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Fund VIII, L.P. (the &#147;NovaQuest Facility&#148;), and other liability
instruments, including options granted to Sumitomo to purchase our ownership interests in certain subsidiaries (the &#147;Sumitomo Options&#148;) under the Sumitomo Transaction Agreement (as defined below). In May 2021, we entered into an Asset
Purchase Agreement with Sumitomo pursuant to which Sumitomo will terminate all of its existing options to acquire our equity interests in certain subsidiaries. See &#147;Recent Developments&#151;Option Vants Transaction&#148; above for additional
information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">364 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain on deconsolidation of subsidiary resulted from the determination that we no longer had a controlling financial interest in
Sio as of February 2020 and Datavant as of April 2020. Gain on consolidation of unconsolidated entity resulted from the remeasurement of our previously held interest in Genevant following the consolidation of Genevant as of July 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other expense, net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other expense, net consists of losses from our equity method investment, interest income on our cash and cash equivalents, interest expense
resulting from interest accrued on long-term debt and the amortization of debt discount and issuance costs, and other miscellaneous expense. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Income tax expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income tax expense is recorded for the jurisdictions in which we do business. Deferred tax assets and liabilities are recognized for the future
tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply
to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment
date. A valuation allowance is recorded when, after consideration of all positive and negative evidence, it is not more likely than not that our deferred tax assets will be realizable. When uncertain tax positions exist, we recognize the tax benefit
of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as
consideration of the available facts and circumstances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Income from discontinued operations, net of tax </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income from discontinued operations, net of tax represents the gain on sale of business that resulted from the completion of transactions
contemplated by a transaction agreement entered into with Sumitomo on October&nbsp;31, 2019 (the &#147;Sumitomo Transaction Agreement&#148;) that closed on December&nbsp;27, 2019 (the &#147;Sumitomo Transaction&#148;), partially offset by the
financial results of the Vants for which we transferred our ownership interest to Sumitomo. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Net loss attributable to noncontrolling
interests </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net loss attributable to noncontrolling interests consists of the portion of net loss of those consolidated entities
that is not allocated to us. Changes in the amount of net loss attributable to noncontrolling interests are directly impacted by the net loss of our consolidated entities and changes in ownership percentages. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">365 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Comparison of the years ended March&nbsp;31, 2021 and 2020 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our results of operations for the years ended March&nbsp;31, 2021 and 2020: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><I></I><B><I>(in thousands)</I></B><I></I></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 23,795</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 67,689</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(43,894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">832,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">263,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">569,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">259,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">335,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(75,888</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,094,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">600,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">494,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,070,898</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(532,425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(538,473</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(95,533</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(231,538</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of debt and liability instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(115,364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(107,344</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,020</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,921</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from continuing operations before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(898,547</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(560,986</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(337,561</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,438</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from continuing operations, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(900,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(568,110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(332,123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from discontinued operations, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,578,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,578,426</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(900,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,010,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,910,549</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to noncontrolling interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(90,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(190,193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income attributable to Roivant Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(809,234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,200,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,009,743</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Variance analysis for years ended March&nbsp;31, 2021 and 2020 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue, net </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;March&nbsp;31, </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020 </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><I></I><B><I>(in thousands)</I></B><I></I></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,795</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,689</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(43,894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue, net decreased by $43.9 million to $23.8 million for the year ended March&nbsp;31, 2021 compared to
$67.7 million for the year ended March&nbsp;31, 2020. The decrease was primarily driven by a nonrefundable, upfront payment of $60.0 million received by Dermavant during the year ended March 31, 2020 from Japan Tobacco Inc., parent company of Torii
Pharmaceutical Co., Ltd., for the exclusive rights to develop, register, and market tapinarof in Japan, partially offset by $19.8 million of revenue generated by Genevant during the year ended March 31, 2021 following consolidation in July 2020.
Revenue generated by subscription and service-based fees was not significant in either period presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cost of revenues
</I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020 </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B></B><B><I>(in thousands)</I></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">366 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenues increased by $0.9&nbsp;million to $2.1&nbsp;million for the year ended
March&nbsp;31, 2021 compared to $1.1&nbsp;million for the year ended March&nbsp;31, 2020. Cost of revenues was not significant in either period presented and reflects cost of revenues generated by subscription and service-based fees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and development expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended March 31, 2021 and 2020, our research and development expenses consisted of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended March 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B></B><B><I>(in thousands)</I></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Program-specific costs:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IMVT-1401 (Immunovant)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,230</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,006</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tapinarof (Dermavant)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69,394</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35,392</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ARU-1801</FONT> (Aruvant)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,064</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,283</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gimsilumab (Kinevant)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">RVT-1601</FONT> (Respivant)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,935</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">AXO-LENTI-PD</FONT></FONT>
(Sio)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21,219</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other program-specific costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,402</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,612</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total program-specific costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(31,404</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consideration for the purchase of IPR&amp;D through asset acquisitions and license
agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">591,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,250</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">581,666</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Unallocated internal costs:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,738</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,899</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel-related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,865</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,401</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total research and development expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">832,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">263,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">569,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses increased by $569.5&nbsp;million to $832.8&nbsp;million for the year ended
March&nbsp;31, 2021 compared to $263.2&nbsp;million for the year ended March&nbsp;31, 2020 primarily due to an increase of $581.7&nbsp;million in consideration for the purchase of IPR&amp;D through asset acquisitions and license agreements,
partially offset by a decrease in program-specific costs of $31.4&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase of $581.7&nbsp;million in consideration for
the purchase of IPR&amp;D was primarily due to multiple asset acquisitions and license agreements entered into during the year ended March&nbsp;31, 2021, including consideration of $399.6 million attributed to IPR&amp;D relating to the acquisition
of the business of Silicon Therapeutics, LLC (&#147;SiTX&#148;); consideration of $116.5&nbsp;million relating to the stock purchase agreement to acquire Oncopia Therapeutics, Inc. (&#147;Oncopia&#148;); $41.4&nbsp;million attributed to IPR&amp;D as
part of the consolidation of Genevant, which was previously accounted for as an equity method investment; and consideration relating to the licensing and strategic collaboration agreement with Affimed N.V. (&#147;Affimed&#148;), pursuant to which
Affimed received consideration that included $40.0&nbsp;million in upfront cash and <FONT STYLE="white-space:nowrap">pre-paid</FONT> research and development funding and $20.0&nbsp;million of our common shares. During the year ended March&nbsp;31,
2020, we made a <FONT STYLE="white-space:nowrap">one-time</FONT> upfront payment of $10.0&nbsp;million related to our multi-program license and collaboration agreement with Medigene AG. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The decrease of $31.4&nbsp;million in program-specific costs was mainly due to a decrease of $35.4&nbsp;million relating to Dermavant&#146;s
tapinarof program primarily as a result of the completion of two pivotal Phase 3 clinical trials, PSOARING 1 AND PSOARING 2, and a <FONT STYLE="white-space:nowrap">one-time</FONT> milestone payment of C$30.0&nbsp;million (approximately $23 million)
made upon the achievement of a development milestone during the year ended March&nbsp;31, 2020; decrease of $21.2&nbsp;million relating to Sio&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">AXO-LENTI-PD</FONT></FONT>
program as a result of the deconsolidation of Sio in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">367 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
February 2020; and decrease of $10.2&nbsp;million for Respivant Sciences Ltd.&#146;s (&#147;Respivant&#148;) <FONT STYLE="white-space:nowrap">RVT-1601</FONT> program as a result of its
termination. These decreases were partially offset by increases of $14.7&nbsp;million for Kinevant Sciences Ltd.&#146;s (&#147;Kinevant&#148;) gimsilumab program, including $3.0&nbsp;million resulting from the achievement of development milestones,
$13.3 million for Aruvant Sciences Ltd.&#146;s (&#147;Aruvant&#148;) ARU-1801 program, and $10.0 million for Immunovant, Inc.&#146;s (&#147;Immunovant&#148;) IMVT-1401 program. These increases in program-specific costs were primarily due to
increases in clinical development costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>General and administrative expenses </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended March 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B><I>(in thousands)</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">259,878</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">335,766</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(75,888</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses decreased by $75.9&nbsp;million to $259.9&nbsp;million for the year ended
March&nbsp;31, 2021 compared to $335.8&nbsp;million for the year ended March&nbsp;31, 2020. The decrease was primarily due to decreases in personnel-related expenses of $38.5&nbsp;million and professional and transaction fees of $27.9&nbsp;million.
The decrease in personnel-related expenses is partially driven by the deconsolidation of Sio in February 2020 and Datavant in April 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Change in fair value of investments </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended March 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B><I>(in thousands)</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(95,533</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136,005</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(231,538</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Change in fair value of investments was an unrealized gain of $95.5&nbsp;million and unrealized loss of
$136.0&nbsp;million for the years ended March&nbsp;31, 2021 and 2020, respectively. The change of $231.5&nbsp;million was primarily driven by changes in the share prices of Arbutus and Sio. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Change in fair value of debt and liability instruments </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended March 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B><I>(in thousands)</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of debt and liability instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Change in fair value of debt and liability instruments was an unrealized loss of $29.8&nbsp;million and
unrealized gain of $13.7&nbsp;million for the years ended March&nbsp;31, 2021 and 2020, respectively. Change in fair value of debt and liability instruments for the year ended March&nbsp;31, 2021 primarily consisted of an unrealized loss of
$61.0&nbsp;million relating to the NovaQuest Facility, partially offset by an unrealized gain of $33.5&nbsp;million relating to the Sumitomo Options. Change in fair value of debt and liability instruments for the year ended March&nbsp;31, 2020
primarily consisted of an unrealized gain of $9.9&nbsp;million relating to the NovaQuest Facility and an unrealized gain of $3.2 million relating to the Sumitomo Options. Changes in the fair value of the NovaQuest Facility primarily resulted from
updates to the estimated timing of amounts payable to NovaQuest and discount rates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Gain on deconsolidation of subsidiary and
consolidation of unconsolidated entity </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended March 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B><I>(in thousands)</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(115,364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(107,344)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,020</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">368 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity was
$115.4&nbsp;million and $107.3&nbsp;million for the years ended March&nbsp;31, 2021 and 2020, respectively. Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity for the year ended March 31, 2021 primarily related to a
gain of $86.5&nbsp;million on the deconsolidation of Datavant in April 2020 and a gain of $28.8&nbsp;million resulting from the remeasurement of our previously held interest in Genevant upon its consolidation in July 2020. Gain on deconsolidation of
subsidiary was $107.3 million for the year ended March 31, 2020 due to the deconsolidation Sio in February 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other expense, net
</I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended March 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B><I>(in thousands)</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,921</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other expense, net was $8.7&nbsp;million and $13.6&nbsp;million for the years ended March&nbsp;31, 2021 and
2020, respectively. The change in other expense, net was primarily driven by reduced losses from our equity method investment in Genevant of $17.6&nbsp;million incurred through July 2020 until we consolidated Genevant and lower interest expense of
$4.9&nbsp;million, partially offset by lower interest income of $16.6&nbsp;million for the year ended March&nbsp;31, 2021 as compared to the year ended March&nbsp;31, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Income tax expense </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended March 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B><I>(in thousands)</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,438</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income tax expense decreased by $5.4&nbsp;million to $1.7&nbsp;million for the year ended March&nbsp;31, 2021,
compared to $7.1&nbsp;million for the year ended March&nbsp;31, 2020. Income tax expense was not significant in either period presented and reflects the income tax expense computed in jurisdictions in which we operate. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Income from discontinued operations, net of tax </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right"><B><I>(in thousands)</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from discontinued operations, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,578,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,578,426</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income from discontinued operations, net of tax was $1,578.4&nbsp;million for the year ended March&nbsp;31,
2020 and consisted of a $1,985.9&nbsp;million gain on sale of business resulting from the Sumitomo Transaction, partially offset by the net losses of the entities for which we transferred our entire ownership interest to Sumitomo. Refer to Note 5,
&#147;Sumitomo Transaction Agreement&#148; of our consolidated financial statements included elsewhere in this prospectus for additional information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the
years ended March&nbsp;31, 2021 and 2020, we incurred losses from continuing operations of $900.2&nbsp;million and $568.1 million, respectively. As of March&nbsp;31, 2021, we had cash and cash equivalents of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">369 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approximately $2.1&nbsp;billion and our accumulated deficit was approximately $1.9&nbsp;billion. We have not generated any revenues to date from the sale of our product candidates. Our revenue,
primarily generated through license agreements as well as from subscription and service-based fees, has not been significant to date. Our operations to date have been financed primarily through the sale of equity securities, sale of subsidiary
interests, debt financings and revenue generated from licensing and collaboration arrangements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Sources of Liquidity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>RSL Equity Financing Transactions </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, we have completed multiple equity financing transactions, including the following financing transaction completed during the
year ended March&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, in connection with the Sumitomo Transaction, we raised net proceeds of approximately
$999.2&nbsp;million in connection with the sale of our common shares to Sumitomo. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Sumitomo Transaction </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, we closed the Sumitomo Transaction, including the transfer of our ownership interest in five Vants &#150; Myovant Sciences
Ltd., Urovant Sciences Ltd., Enzyvant Therapeutics Ltd., Altavant Sciences Ltd., and Spirovant Sciences Ltd. &#150; to Sumitovant Biopharma Ltd. (&#147;Sumitovant&#148;), a wholly-owned subsidiary of Sumitomo. In addition, in connection with the
Sumitomo Transaction, we (i)&nbsp;granted Sumitomo options to purchase all, or in the case of Dermavant, 75%, of our ownership interests in six other subsidiaries (Dermavant, Genevant, Lysovant, Metavant, Cytovant Parent, and Sinovant), and
(ii)&nbsp;provided Sumitomo and Sumitovant with certain rights over and access to our proprietary technology platforms, DrugOme and Digital Innovation. In exchange for these components of the Sumitomo Transaction, we received approximately
$1.9&nbsp;billion in cash, which was in addition to the $999.2&nbsp;million from the sale of our common shares to Sumitomo as discussed above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2021, we completed a transaction with Sumitomo pursuant to which Sumitomo terminated its existing options to acquire our equity
interests in certain of our subsidiaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Consolidated Vant Equity Financing Transactions </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, we have completed multiple Vant equity financing transactions, including the following financing transactions completed during
the years ended March&nbsp;31, 2021 and 2020: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Immunovant </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended March 31, 2021 and 2020, Immunovant issued shares of common stock for an aggregate net proceeds of $384.9&nbsp;million
(including an aggregate of $27.5&nbsp;million of shares of common stock purchased by us) in private financings, underwritten public offerings, and warrant exercises. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, in December 2019, Immunovant Sciences Ltd. (&#147;ISL&#148;) completed a business combination with Health Sciences Acquisition
Corporation (&#147;HSAC&#148;), a special purpose acquisition company, pursuant to which HSAC acquired 100% of the outstanding shares of ISL (the &#147;HSAC Transaction&#148;). Following the HSAC Transaction, ISL became a wholly owned subsidiary of
HSAC, which was renamed &#147;Immunovant, Inc.&#148; HSAC was treated as the &#147;acquired&#148; company for accounting purposes. Immunovant received $111.0&nbsp;million in cash as a result of the HSAC Transaction, consisting of the funds held in
HSAC&#146;s trust account. The proceeds included $5.1 million related to common shares purchased by us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Proteovant </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2020, following Proteovant Sciences, Inc&#146;s (&#147;Proteovant&#148;) acquisition of Oncopia in November 2020, SK, Inc.
(formerly known as SK Holdings Co., Ltd.) (&#147;SK&#148;) entered into a subscription </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">370 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement (the &#147;Subscription Agreement&#148;) pursuant to which SK agreed to make a $200.0 million equity investment in Proteovant, representing an ownership interest of 40.0% on the closing
date. In January 2021, in accordance with the terms of the Subscription Agreement, SK made the first payment of $100.0 million to Proteovant. A second $100.0 million payment is expected to be made by SK to Proteovant on or about July 12, 2021, the
date six months from the closing date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Consolidated Vant Debt Financings </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, we have completed multiple Vant debt financings, including the following debt financing completed during the year ended March
31, 2020: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Dermavant </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2019, Dermavant entered into a loan and security agreement (the &#147;Hercules Loan Agreement&#148;) with Hercules, pursuant to which
Dermavant borrowed an aggregate of $20.0&nbsp;million. In May 2021, all amounts outstanding under the Hercules Loan Agreement were repaid using the proceeds from the $40.0 million senior secured credit facility entered into by Dermavant in May 2021,
and Dermavant terminated the Hercules Loan Agreement. See &#147;Recent Developments&#151;Dermavant&#148; above for additional information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Funding Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to incur significant and increasing operating losses at least for the foreseeable future. We do not expect to generate
product revenue until we successfully complete development and obtain regulatory approval for any of our current or future product candidates, which may never occur. Our operating results, including our net losses, may fluctuate significantly from <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year,</FONT></FONT> depending on the timing of our planned clinical trials,
our expenditures on other research and development activities and our <FONT STYLE="white-space:nowrap">pre-commercialization</FONT> efforts. We anticipate that our expenses will increase substantially as we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fund preclinical studies and clinical trials for our product candidates, which we are pursuing or may choose to
pursue in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fund the manufacturing of drug substance and drug product of our products candidates in development;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to identify, acquire, develop and commercialize additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">integrate acquired technologies into a comprehensive regulatory and product development strategy;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hire scientific, clinical, quality control and administrative personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add operational, financial and management information systems and personnel, including personnel to support our
drug development efforts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achieve milestones under our agreements with third parties that will require us to make substantial payments to
those parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory approvals for any product candidates that successfully complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ultimately establish a sales, marketing and distribution infrastructure and scale up external manufacturing
capabilities to commercialize any drug candidates for which we may obtain regulatory approval; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">begin to operate as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to finance our cash needs through a combination of our cash on hand and future equity offerings, debt financings, sales
of subsidiaries, and collaborations, strategic alliances or marketing, distribution, licensing or similar arrangements with third parties. To the extent that we raise additional capital </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">371 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely
affect your rights as a common shareholder. Any agreements for future debt or preferred equity financings, if available, may involve covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making
capital expenditures or declaring dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we raise additional funds through collaborations, strategic alliances or marketing,
distribution, licensing or similar arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be
favorable to us. Adequate additional funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or
discontinue the development or commercialization of our product candidates, grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves or potentially discontinue operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table sets forth a summary of our cash flows for the years ended March&nbsp;31, 2021 and 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(</B><B><I>in thousands)</I></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(552,138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(758,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(31,702</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,694,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">456,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">214,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cash flows from discontinued operations have not been segregated and are included in the statements of
cash flows for the year ended March&nbsp;31, 2020. Refer to Note 6, &#147;Discontinued Operations&#148; of our financial statements included elsewhere in this prospectus for further information regarding our discontinued operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash flow from operating activities represents the cash receipts and disbursements related to all of our activities other than investing and
financing activities. Cash flow from operating activities is derived from adjusting our net loss (income) for <FONT STYLE="white-space:nowrap">non-cash</FONT> items and changes in working capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended March&nbsp;31, 2021, cash used in operating activities decreased by $206.6&nbsp;million to $552.1&nbsp;million compared to
the year ended March&nbsp;31, 2020. This decrease was primarily driven by the reduction in cash required to fund the operations of Vants sold to Sumitomo in December 2019, partially offset by an increase in upfront cash consideration for IPR&amp;D
relating to asset acquisitions and license agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Investing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash flow from investing activities includes cash used for acquisitions, net of cash acquired; dispositions, net of cash disposed; capital
expenditures; and purchases of equity securities and other investments. Cash flow from investing activities also includes cash provided by sale of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended March&nbsp;31, 2021, cash flow from investing activities changed by $1,726.5&nbsp;million to net cash used in investing
activities of $31.7&nbsp;million from net cash provided by investing activities of $1,694.8&nbsp;million for the year ended March&nbsp;31, 2020. This change in cash flow from investing activities is primarily attributed to proceeds from the sale of
business, net of cash disposed, in December 2019, resulting from the Sumitomo Transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">372 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Financing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended March&nbsp;31, 2021, cash provided by financing activities increased by $242.2 million to $456.3 million compared to the
year ended March&nbsp;31, 2020. This change was primarily driven by higher net proceeds from the issuance of subsidiary equity, resulting from the issuance of Immunovant common stock upon completing two underwritten public offerings and warrant
exercises and the issuance of Proteovant common stock to SK, during the year ended March 31, 2021 as compared to net proceeds from the issuance of subsidiary equity during the year ended March 31, 2020. During the year ended March 31, 2020, proceeds
were also generated from the issuance of our common shares and the Sumitomo Options pursuant to the Sumitomo Transaction as well as from subsidiary debt financings. However, these proceeds were largely offset by cash used to repurchase certain of
our common shares and equity awards along with cash used to purchase subsidiary equity and repay certain subsidiary long-term debt and convertible debt during the year ended March 31, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Outlook </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect
our existing cash and cash equivalents will be sufficient to fund our committed operating expenses and capital expenditure requirements for at least the next twelve months based on current operating plans and financial forecasts. However, we have
based this estimate on assumptions that may prove to be wrong, which may require us to use our capital resources sooner than expected. See &#147;Cautionary Note Regarding Forward-Looking Statements&#148; and &#147;Risk Factors&#148; in this proxy
statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Commitments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have certain payment obligations under various asset acquisition and license agreements. Under these agreements we are required to make
milestone payments upon successful completion and achievement of certain development, regulatory and commercial milestones. The payment obligations under the asset acquisition and license agreements are contingent upon future events such as our
achievement of specified development, regulatory and commercial milestones, and we will be required to make milestone payments and royalty payments in connection with the sale of products developed under these agreements. The achievement and timing
of these future milestone payments are not probable or reasonably estimable, and therefore such amounts have not been included on our consolidated balance sheet as of March&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We enter into agreements in the normal course of business with CROs and other vendors for clinical trials and with vendors for preclinical
studies and other services and products for operating purposes, which are generally cancelable upon written notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our contractual
obligations also include operating lease liabilities, primarily relating to real estate leases. Refer to Note 13, &#147;Leases&#148; of our audited financial statements included elsewhere in this prospectus for further information regarding our
leases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Loan and Security Agreement between Dermavant and Hercules </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2019, Dermavant entered into the Hercules Loan Agreement with Hercules as agent and lender, under which Dermavant, borrowed an aggregate
of $20.0&nbsp;million (the &#147;2019 Term Loan&#148;). The 2019 Term Loan was fully drawn in May 2019. In May 2021, Dermavant repaid all amounts outstanding under the Hercules Loan Agreement using the proceeds from the $40.0 million Credit Facility
entered into by Dermavant and certain of its subsidiaries in May 2021, and Dermavant terminated the Hercules Loan Agreement. See &#147;Recent Developments&#151;Dermavant&#148; above and &#147;Dermavant Senior Secured Credit Facility&#148; below for
additional information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Funding Agreement between Dermavant and NovaQuest </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2018, as a result of Dermavant&#146;s acquisition of tapinarof from GlaxoSmithKline Intellectual Property Development Ltd. and Glaxo
Group Limited (collectively &#147;GSK&#148;), Dermavant entered into the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">373 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
NovaQuest Facility, pursuant to which Dermavant is required to make milestone and other quarterly interest payments to NovaQuest <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Fund VIII,
L.P. (&#147;NovaQuest&#148;) upon the achievement of certain regulatory and commercial milestones for tapinarof in either psoriasis or atopic dermatitis in the United States, the European Union and Japan. These obligations terminate upon marketing
approval revocation or withdrawal of tapinarof for health and safety reasons by either (x) the U.S. Food and Drug Administration (the &#147;FDA&#148;) or (y) Dermavant, Dermavant&#146;s affiliates, or any sublicensee. The aggregate maximum amount of
regulatory milestone payments Dermavant could be required to make under the NovaQuest Facility is $440.6&nbsp;million and the maximum aggregate amount of commercial milestone payments Dermavant could be required to make under the NovaQuest Facility
is $141.0&nbsp;million. In some circumstances, Dermavant may be able to offset certain of the regulatory milestone payments with up to $88.1&nbsp;million of the commercial milestone payments. Dermavant is also required to make significant payments
to NovaQuest if development of tapinarof is terminated or if Dermavant terminates development of tapinarof for one indication and receives approval for the other. NovaQuest is not obligated to refund to Dermavant any payments previously made under
the NovaQuest Facility. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dermavant Senior Secured Credit Facility </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2021, DSL, Dermavant Holdings Limited, Dermavant Sciences IRL Limited and DSG, as borrowers and certain other subsidiaries of DSL, as
initial guarantors, entered into a $40.0 million senior secured credit facility (the &#147;Credit Facility&#148;) with XYQ Luxco, as lender, and U.S. Bank National Association, as collateral agent. The Credit Facility has a five-year maturity and
bears an interest rate of 10.0% per annum. Interest is payable quarterly in arrears on the last day of each calendar quarter through the maturity date. A lump sum principal payment is due on the maturity date. See &#147;Recent
Developments&#151;Dermavant&#148; above for additional information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Acquisition of Silicon Therapeutics </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2021, we completed the acquisition of the business of SiTX for consideration of approximately $450.0&nbsp;million, with additional
cash payments payable subject to the satisfaction of certain regulatory and commercial milestones. A remaining balance of approximately $100.0&nbsp;million is payable to former SiTX equity holders on the earlier of (x)&nbsp;approximately 30 to 60
days following the public listing of our common shares, in either cash or our common shares (at our election), and (y) 12 months following the closing of the acquisition, in cash. For accounting purposes, the fair value of consideration transferred
was $402.4 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Palantir Master Subscription Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2021, we entered into a master subscription agreement with Palantir Technologies Inc. (&#147;Palantir&#148;) for access to
Palantir&#146;s proprietary software for a five-year period. The remaining minimum payments for this software subscription are $39.0 million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We did not have any material <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements, as defined under SEC rules, during the
periods presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management&#146;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which
have been prepared in accordance with generally accepted accounting principles in the United States of America (&#147;U.S. GAAP&#148;). The process of preparing financial statements in conformity with U.S. GAAP requires us to make estimates and
assumptions that affect the reported amounts of certain assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">374 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reported amounts of expense during the period. Any references to applicable accounting guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification
(the &#147;ASC&#148;), and Accounting Standards Updates (&#147;ASU&#148;), issued by the Financial Accounting Standards Board (the &#147;FASB&#148;). The consolidated financial statements include the accounts of Roivant and our subsidiaries in which
we have a controlling financial interest, most often through a majority voting interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are
described in more detail in Note 2, &#147;Summary of Significant Accounting Policies&#148; in our consolidated financial statements included elsewhere in this prospectus, we believe that the following accounting policies are those most critical to
the judgments and estimates used in the preparation of our financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist primarily of costs incurred in connection with the discovery and development of our product
candidates. We expense research and development costs as incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We accrue expense for preclinical studies and clinical trial
activities performed by vendors based upon estimates of the proportion of work completed. We determine such estimates by reviewing contracts, vendor agreements and purchase orders, and through discussions with our internal personnel and external
service providers as to the progress or stage of completion and the agreed-upon fee to be paid for such services. However, actual costs and timing of preclinical studies and clinical trials are highly uncertain, subject to risks, and may change
depending upon a number of factors, including our clinical development plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We make estimates of our accrued expenses as of each balance
sheet date in our financial statements based on facts and circumstances known at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the accrual is adjusted accordingly. Nonrefundable
advance payments for goods and services are deferred and recognized as expense in the period that the related goods are consumed or services are performed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We evaluate license agreements and asset acquisitions for IPR&amp;D projects to determine if it meets the definition of a business and thus
should be accounted for as a business combination. If the IPR&amp;D does not meet the definition of a business and the assets have not reached technological feasibility and therefore have no alternative future use, we expense payments made under
such license agreements as research and development expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize compensation costs related to share-based awards granted to employees, directors, and consultants based on the estimated fair
value of the awards on the date of grant. The grant date fair value of the stock-based awards is recognized over the requisite service period, which is generally the vesting period of the respective awards. We may grant awards with graded-vesting
features. When such awards have only service vesting requirements, we elected to record share-based compensation expense on a straight-line basis. If awards with graded-vesting features contain performance or market conditions, then we record
share-based compensation expense using the accelerated attribution method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate the fair value of stock options using the
Black-Scholes option-pricing model, which requires assumptions, including the fair value of our common shares prior to our initial public offering, volatility, the expected term of our stock options, the risk-free interest rate for a period that
approximates the expected term of our stock options, and our expected dividend yield. Certain assumptions used in our Black-Scholes option-pricing model represent management&#146;s best estimates and involve a number of variables, uncertainties and
assumptions and the application of management&#146;s judgment, as they are inherently subjective. If any assumptions change, our stock-based compensation expense could be materially different in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">375 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These subjective assumptions are estimated as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Fair value of common share</I>&#151;As a privately held company, we estimate the fair value of the shares of common stock underlying our
share-based awards on each grant date. To determine the fair value of our common shares underlying option grants, we considered, among other things, valuations of our common share prepared by an unrelated third-party valuation firm in accordance
with the guidance provided by the American Institute of Certified Public Accountants Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. The estimation of the fair value of the common shares considered
factors including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prices of our common shares sold to investors in arm&#146;s length transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the estimated present value of our future cash flows; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our business, financial condition and results of operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our forecasted operating performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the illiquid nature of our common shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">industry information such as market size and growth; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market capitalization of comparable companies and the estimated value of transactions such companies have engaged
in; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">macroeconomic conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We apply similar methodology to estimate the fair value of the shares of common stock underlying share-based awards at our privately held
Vants. Once our common shares are publicly traded, we will determine the fair value of each common share underlying share-based awards based on the closing price of our common shares as reported by the Nasdaq on the date of grant and therefore it
will not be necessary to determine the fair value of the new stock-based award pursuant to the methodology described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expected
term</I>&#151;We have generally elected to use the &#147;simplified method&#148; for estimating the expected term of options, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option
(generally 10 years). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expected volatility</I>&#151;As a privately held company, we do not have any trading history for our common
share; accordingly, the expected volatility was estimated based on the average volatility for comparable publicly traded biotechnology companies over a period equal to the expected term of the stock option grants. The comparable companies were
chosen based on their similar size, stage in the life cycle or area of specialty. We apply similar methodology to estimate the expected volatility at our privately held Vants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Risk-free interest rate</I>&#151;The risk-free rate assumption is based on the U.S. Treasury instruments with maturities similar to the
expected term of our stock options at the time of the grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expected dividend yield</I>&#151;We have not issued any dividends in our
history and do not expect to issue dividends over the life of the options; therefore, we have estimated the dividend yield to be zero. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Recently Adopted Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is
disclosed in Note 2, &#147;Summary of Significant Accounting Policies&#148; in our consolidated financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>JOBS Act </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2012,
the Jumpstart Our Business Startups Act of 2012 (the &#147;JOBS Act&#148;) was enacted. Section&nbsp;107(b) of the JOBS Act provides that an emerging growth company can take advantage of an extended </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">376 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would
otherwise apply to private companies. We have elected not to avail ourselves of this extended transition period, and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is
required for other public companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under SEC rules and regulations, because we are considered to be a &#147;smaller reporting company,&#148; we are not required to provide the
information required by this item in this report. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company and Smaller Reporting Company
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; within the meaning of the JOBS Act. As an emerging growth company, we may take advantage
of certain exemptions from various public company reporting requirements, including the requirement that our internal control over financial reporting be audited by our independent registered public accounting firm pursuant to Section&nbsp;404 of
the Sarbanes-Oxley Act, certain requirements related to the disclosure of executive compensation in this prospectus and in our periodic reports and proxy statements, and the requirement that we hold a nonbinding advisory vote on executive
compensation and any golden parachute payments. We have also taken advantage of the ability to provide reduced disclosure of financial information in this prospectus, such as being permitted to include only two years of audited financial information
and two years of selected financial information in addition to any required unaudited interim financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148;
disclosure. We may take advantage of these exemptions until we are no longer an emerging growth company. Section&nbsp;107 of the JOBS Act provides that an &#147;emerging growth company&#148; can take advantage of the extended transition period
provided in Section&nbsp;7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. In other words, an &#147;emerging growth company&#148; can delay the adoption of certain accounting standards until those standards
would otherwise apply to private companies. We have elected not to avail ourselves of this extended transition period, and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is
required for other public companies. However, because we have taken advantage of certain reduced reporting requirements, the information contained herein may be different from the information you receive from other public companies in which you hold
shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earlier of (1)&nbsp;the last day of the fiscal year (a)&nbsp;following the
fifth anniversary of the date of the first sale of Roivant Common Shares pursuant to an effective registration statement or (b)&nbsp;in which we have total annual gross revenue of at least $1.07&nbsp;billion (as adjusted for inflation pursuant to
SEC rules from time to time), and (2)&nbsp;the date on which (x)&nbsp;we are deemed to be a large accelerated filer, which means the market value of Roivant Common Shares that are held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT>
exceeds $700&nbsp;million as of the prior September 30th, or (y)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt during the prior three-year period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we are a &#147;smaller reporting company&#148; as defined in Item 10(f)(1) of Regulation
<FONT STYLE="white-space:nowrap">S-K.</FONT> Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller
reporting company until the last day of the fiscal year in which (i)&nbsp;the market value of our common shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $250&nbsp;million as of the end of that year&#146;s second fiscal
quarter, or (ii)&nbsp;our annual revenues exceeded $100&nbsp;million during such completed fiscal year and the market value of our common shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the end
of that year&#146;s second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies more difficult. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">377 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_22"></A>MANAGEMENT AFTER THE BUSINESS COMBINATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Unless the context otherwise requires, references in this section to &#147;we,&#148; &#147;us,&#148; &#147;our&#148; and the
&#147;Company&#148; refer to Roivant and its subsidiaries and affiliates in the present tense or from and after the consummation of the Business Combination, as the context requires. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC
and Roivant anticipate that the current executive officers and directors of Roivant, as of June&nbsp;30, 2021, will remain as the executive officers and directors of Roivant following the Business Combination and one additional director from the
Board will join the Roivant board of directors at such time. The following persons are expected to serve as Roivant&#146;s executive officers and directors following the Business Combination. The executive officers of Roivant are employees of
Roivant Sciences Inc., a wholly owned subsidiary of Roivant, and provide services pursuant to an inter-company agreement. For biographical information concerning the executive officers and directors, see below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="54%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Age&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew Gline</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">37</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Executive Officer and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Venker</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">34</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>President and Chief Operating Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mayukh Sukhatme</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">45</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>President and Chief Investment Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benjamin Zimmer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">35</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>President, Roivant Health</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rakhi Kumar</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">41</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Accounting Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vivek Ramaswamy</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">35</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Founder and Executive Chairman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Lo</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">61</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Machado</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">57</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Keith Manchester</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">52</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ilan Oren</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">37</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Gold</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">53</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Masayo Tada</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">76</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James C. Momtazee</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">49</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Matthew Gline</I></B><I> </I>has served as our Chief Executive Officer since January 2021 and is expected to be appointed as a Director
of Roivant at the closing of the Business Combination. Mr. Gline joined Roivant in March 2016 and previously served as Chief Financial Officer, from September 2017 through his appointment as Chief Executive Officer, and as Senior VP, Finance and
Business Operations. Prior to joining Roivant, Mr.&nbsp;Gline was a Vice President at Goldman Sachs, Fixed Income Digital Structuring, from 2014 to 2016, and <FONT STYLE="white-space:nowrap">co-founded</FONT> Fourthree, a risk analytics technology
and consulting company, from 2012 to 2014. Mr.&nbsp;Gline earned his A.B. in Physics from Harvard College. Our board of directors believes that Mr. Gline&#146;s experience in various roles at our company and his prior professional experience qualify
him to serve as a member of our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Eric Venker</I></B> has served as our President and Chief Operating Officer
since January 2021 and, prior to that role, as Chief Operating Officer, from November 2018. From October 2017 to October 2018, Dr.&nbsp;Venker served as Chief of Staff to our Chief Executive Officer, and from 2014 to 2015, as an Analyst at Roivant.
From 2015 to 2017, Dr.&nbsp;Venker was a physician at New York Presbyterian Hospital/Columbia University Medical Center, where he trained in internal medicine, and also served as Chair of the Housestaff Quality Council leading operational
initiatives to improve efficiencies. From 2011 to 2015, Dr.&nbsp;Venker was a Clinical Pharmacist at <FONT STYLE="white-space:nowrap">Yale-New</FONT> Haven Hospital. Dr.&nbsp;Venker also serves on the boards of directors of Immunovant, Arbutus
Biopharma, Sio Gene Therapies and several private biopharmaceutical companies. He received his Pharm.D. from St. Louis College of Pharmacy and his M.D. from Yale School of Medicine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">378 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Mayukh Sukhatme </I></B>has served as our President and Chief Investment Officer since
January 2021, overseeing the creation and support of biopharmaceutical companies in the Roivant family. Dr.&nbsp;Sukhatme joined Roivant in 2015 and previously served as President of Roivant Pharma and as our Chief Business Officer. From 2000 to
2015, Dr.&nbsp;Sukhatme was a healthcare-focused analyst and portfolio manager for several large institutional investment firms, including both public markets and venture capital firms. His principal focus was on development-stage biotechnology and
pharmaceutical companies, where he led diligence and investment decisions on numerous companies and pharmaceutical compounds across a wide variety of therapeutic areas. Dr.&nbsp;Sukhatme earned his M.D. from Harvard Medical School and his B.S. in
Biology and B.S. in Literature from MIT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Benjamin Zimmer </I></B>has served as President, Roivant Health since 2018, where he leads
the launch, growth and oversight of Roivant&#146;s technology platform Vants. Mr.&nbsp;Zimmer joined Roivant in 2015, was a member of the founding team and has held multiple leadership roles across the organization, including serving as
Roivant&#146;s Chief Operating Officer, from 2017 to 2018, and as Head of Public Affairs, from 2016 to 2017. Mr.&nbsp;Zimmer began his career as a business analyst at McKinsey&nbsp;&amp; Company. Mr.&nbsp;Zimmer earned an A.B. <I>magna cum laude
</I>in history and economics from Harvard College and a J.D. from Yale Law School. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Rakhi Kumar</I></B> has served as our Chief
Accounting Officer since August 2018, leading the accounting and financial operations and related internal controls functions. Ms. Kumar joined Roivant in September 2015, and previously served as Vice President, Finance and External Reporting. Prior
to joining Roivant, Ms. Kumar was responsible for external reporting, corporate and technical accounting at The Medicines Company from 2013 to 2015. Earlier in her career, Ms. Kumar was in the assurance services at Ernst and Young. Ms. Kumar also
serves as a director and as chair of the audit committee for NeuroPace (Nasdaq: NPCE), a medical device company. She is a licensed Certified Public Accountant and a Chartered Professional Accountant in Ontario, Canada. She received her M.S. in
Accounting and Taxation from the University of Hartford. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Vivek Ramaswamy </I></B>is our Founder and following the closing of the Business Combination will serve as Chair of our board of
directors. He has served as our Executive Chairman since January 2021 and, prior to taking that role, as Chief Executive Officer, from May 2014. Mr.&nbsp;Ramaswamy previously served as a member of the investment team at QVT Financial, from 2007 to
2014. Mr.&nbsp;Ramaswamy was previously as a director of Myovant Sciences, Axovant Sciences and Arbutus Biopharma. Mr.&nbsp;Ramaswamy received his A.B. in Biology from Harvard College and his J.D. from Yale Law School, where he was a Paul&nbsp;&amp;
Daisy Soros Fellow. Our board of directors believes that Mr.&nbsp;Ramaswamy&#146;s status as our Founder and Executive Chairman, and his extensive prior experience in the biopharmaceutical industry qualify him to serve as a member of our board of
directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Andrew Lo</I></B> has served as Director of Roivant since 2016. He is a Charles E. and Susan T. Harris Professor at MIT
Sloan School of Management since 1988, Founder and Chairman of QLS Advisors since 2019, Member of Thal&#275;s Advisory Board since 2019, Chairman Emeritus and Senior Advisor of AlphaSimplex Group since 2018 and member of the Competitive Market
Advisory Counsel of the Chicago Mercantile Exchange since 2013. Dr. Lo has served as Director of BridgeBio Pharma since 2020 and advisor of the same company from 2015 to 2020. Our board of directors believes that Dr.&nbsp;Lo&#146;s extensive
experience as director and advisor of various companies, including in the biopharmaceutical industry, qualifies him to serve as a member of our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Patrick Machado</I></B> has served as Director of Roivant since 2017. He is a <FONT STYLE="white-space:nowrap">co-founder</FONT> of
Medivation, Inc., a biopharmaceutical company, and has served on its Board of Directors since April 2014. Prior to his retirement in April 2014, Mr.&nbsp;Machado served as Medivation&#146;s Chief Financial Officer since its inception in September
2003 and as its Chief Business Officer since December 2009 through its acquisition by Pfizer in 2016. From 1998 until 2001, Mr.&nbsp;Machado was employed by ProDuct Health, Inc., a privately-held medical device company, as Vice President, Chief
Financial Officer and General Counsel from 1998 to 2000, and as Senior Vice President and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">379 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Chief Financial Officer from 2000 to 2001. From 2001 until 2002, Mr.&nbsp;Machado served as a consultant to Cytyc Corporation, to assist with transitional matters related to Cytyc
Corporation&#146;s acquisition of ProDuct Health, Inc. Mr.&nbsp;Machado received a J.D. from Harvard Law School and a B.A. and B.S. in German and Economics, respectively, from Santa Clara University. Our board of directors believes that
Mr.&nbsp;Machado&#146;s extensive experience as director and officer in the biopharmaceutical industry qualifies him to serve as a member of our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Keith Manchester </I></B>has served as Director of Roivant since 2014. He serves as a Partner and the Head of Life Sciences at QVT
Financial, New York, USA, an investment firm, where he has been employed since 2005. He focuses on investments in both publicly traded and privately owned life science companies. Prior to joining QVT, Dr.&nbsp;Manchester was Vice President of
Business Development from 2002 to 2004 and Director of Business Development from 2000 to 2002 at Applied Molecular Evolution, a biotechnology company. From 1999 to 2000, Dr.&nbsp;Manchester was an associate at Vestar Capital Partners, a private
equity firm. From 1997 to 1999, Dr.&nbsp;Manchester was an investment banker in the healthcare group at Goldman, Sachs&nbsp;&amp; Co. He received his A.B. from Harvard College and his M.D. from Harvard Medical School. Dr.&nbsp;Manchester serves as a
director for the following companies: Roivant Sciences Ltd., Roivant Sciences, Inc., Arbutus Biopharma Corporation, and Kriya Therapeutics. Dr.&nbsp;Manchester also sits on the Supervisory Board of Medigene AG. Our board of directors believes that
Dr.&nbsp;Manchester&#146;s extensive experience investing in the life sciences industry qualifies him to serve as a member of our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Ilan Oren </I></B>has served as Director of Roivant since 2014. He has served as <FONT STYLE="white-space:nowrap">Co-Chief</FONT>
Executive Officer of Dexcel Pharma, a privately-owned Israeli group of pharmaceutical companies, since November 2019. Prior to serving as <FONT STYLE="white-space:nowrap">Co-CEO,</FONT> Ilan served as Vice President for the group and led corporate
and business development activities, including formation of strategic ventures, product partnerships, product portfolio selection, product acquisitions, strategic investments, and mergers and acquisitions. He holds an A.B. in Economics from Harvard
College. Our board of directors believes that Mr.&nbsp;Oren&#146;s extensive experience as an high-level executive in the pharmaceutical industry qualifies him to serve as a member of our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Daniel Gold</I></B> has served as Director of Roivant since 2020. Mr. Gold serves as the CEO, managing partner and founder of QVT
Financial LP, an asset management company with offices in New York and New Delhi. QVT Financial, through its managed and affiliated multi-strategy funds, is an experienced global investor in multiple industries, including biotech, financial,
shipping and offshore industries. Mr. Gold founded QVT Financial LP in 2003. Mr. Gold holds an A.B. in Physics from Harvard College. Mr. Gold also currently serves on the board of public companies MP Materials, Okeanis Eco Tankers Corp. and Awilco
Drilling PLC, in addition to various private companies. Our board of directors believes that Mr.&nbsp;Gold&#146;s extensive experience investing in the life sciences industry qualifies him to serve as a member of our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Masayo Tada </I></B>has served as Director of Roivant since 2019. He has served as Chairman of the Board of Sumitomo Dainippon Pharma
Co., Ltd. since April 2018 and Director since April 2021, having previously served as Representative Director from April 2018 to April 2021. Prior to serving as Chairman of the Board and Representative Director, he served as President and CEO of
Sumitomo Dainippon Pharma Co., Ltd. since June 2008, as well as other positions in said company since 1968. Our board of directors believes that Mr.&nbsp;Tada&#146;s extensive experience as a director and high-level executive in the pharmaceutical
industry qualifies him to serve as a member of our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>James C. Momtazee </I></B>is expected to be appointed as a
Director of Roivant in connection with the consummation of the Business Combination. He has held various positions at KKR&nbsp;&amp; Co., Inc. (&#147;KKR&#148;) since 1996. He helped form KKR&#146;s health care industry group in 2001 and was
promoted to KKR&#146;s Head of the Heath Care Team for the Americas Private Equity platform in January 2009. He was a member of KKR&#146;s Americas Private Equity Investment Committee and was Chairman of the Health Care Strategic Growth and the
Health Care Royalty&nbsp;&amp; Income Investment Committees. During the period between 2001 and 2019, KKR was one of the most active investors on Wall Street, committing over $50&nbsp;billion in capital across the health care sector. The
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">380 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
largest of these investments was its $33&nbsp;billion acquisition of HCA, Inc. in 2006, which at the time, was the largest cash buyout in history. During this same period, KKR made several other
notable investments across the health care sector, including: Jazz Pharmaceuticals plc in 2004, PRA Health Sciences, Inc. in 2013, and BridgeBio Pharma, Inc. in 2016. Mr.&nbsp;Momtazee currently serves on the Board of Directors of BridgeBio, Apollo
Therapeutics, Kriya Therapeutics and the Medical Device Manufacturers Association and has previously served on the Board of Directors of multiple other health care companies, including PRA Health Sciences, Inc. (lead independent director), Envision
Healthcare, Heartland Dental, Ajax Health, Global Medical Response, BrightSpring Health Services, Covenant Surgical Partners, Entellus Medical, Inc. (acquired by Stryker Corporation), EchoNous, Spirox, Inc., Arbor Pharmaceuticals, Lake Region
Medical, HCA Healthcare, Jazz Pharmaceuticals, and Alliance Imaging. Our board of directors believes that Mr.&nbsp;Momtazee&#146;s extensive experience investing in the biopharmaceutical industry qualifies him to serve as a member of our board of
directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Family Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships between our board of directors and our executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business and
affairs will be managed under the direction of our board of directors. Following the consummation of the Business Combination, our board of directors is expected to initially consist of nine members, with Vivek Ramaswamy serving as Chair. Our
amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> provide for a classified board of directors divided into three classes serving staggered three-year terms as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;I directors are expected to be Mr. Machado, Dr. Manchester and Mr. Gline, and they will serve until
our annual meeting of shareholders in 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;II directors are expected to be Mr. Gold, Dr. Lo and Mr. Ramaswamy, and they will serve until our
annual meeting of shareholders in 2023; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;III directors are expected to be Mr. Tada, Mr. Oren and Mr. Momtazee, and they will serve until our
annual meeting of shareholders in 2024; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At each annual meeting of shareholders, directors will be elected to succeed the class of
directors whose terms have expired. This classification of our board of directors could have the effect of increasing the length of time necessary to change the composition of a majority of the board of directors. Our amended and restated <FONT
STYLE="white-space:nowrap">bye-laws</FONT> provide that the authorized number of directors (being no less than 5 directors and no more than 15 directors) may be changed only by resolution approved by a majority of our board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of
directors has undertaken a review of the independence of the directors and has considered whether any director has a material relationship with us that could compromise his or her ability to exercise independent judgment in carrying out his or her
responsibilities. As a result of this review, our board of directors has determined that each of Mr. Machado, Dr. Manchester, Mr. Gold, Dr. Lo, Mr. Oren and Mr. Momtazee, representing six of the nine individuals expected to serve as members of our
board of directors following the Business Combination, are independent, as that term is defined under the applicable rules and regulations of the SEC and the Nasdaq listing rules. We plan to comply with the corporate governance requirements of the
SEC and the Nasdaq listing rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to comply with the requirements of Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> of the
Exchange Act and the Nasdaq listing rules, which rules require that our audit committee be composed of at least three members. Under Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> of the Exchange Act, we are permitted to phase in our compliance
with the independent audit committee requirements set forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> of the Exchange Act as follows: (1)&nbsp;one independent member at the time of listing, (2)&nbsp;a majority of independent members
within 90 days of listing and (3)&nbsp;all independent members within one year of listing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">381 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of the Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective upon the consummation of the business combination, our board of directors will establish an audit committee, a compensation
committee, and a nominating and corporate governance committee, each of which will have the composition and responsibilities described below. From time to time, the board may establish other committees to facilitate the management of our business.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our audit committee are expected to be Mr. Momtazee, Mr. Machado and Mr. Oren. Mr.&nbsp;Momtazee is expected to be the chair of
our audit committee. The composition of our audit committee will meet the requirements for independence under the current Nasdaq listing standards and SEC rules and regulations. Each member of our audit committee will be financially literate. In
addition, our board of directors has determined that Mr. Momtazee is an &#147;audit committee financial expert&#148; as defined in Item 407(d)(5)(ii) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> promulgated under the Securities Act.
This designation will not impose any duties, obligations or liabilities that are greater than are generally imposed on members of our audit committee and our board of directors. Our audit committee will be directly responsible for, among other
things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selecting a firm to serve as the independent registered public accounting firm to audit our financial statements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ensuring the independence of the independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing the scope and results of the audit with the independent registered public accounting firm and
reviewing, with management and that firm, our interim and <FONT STYLE="white-space:nowrap">year-end</FONT> operating results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing procedures for employees to anonymously submit concerns about questionable accounting or audit
matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considering the adequacy of our internal controls and internal audit function; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing material related party transactions or those that require disclosure; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving or, as permitted, <FONT STYLE="white-space:nowrap">pre-approving</FONT> all audit and <FONT
STYLE="white-space:nowrap">non-audit</FONT> services to be performed by the independent registered public accounting firm. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our compensation committee are expected to be Mr. Gold, Mr. Machado and Mr. Oren. Mr.&nbsp;Gold is expected to be the chair of
our compensation committee. Each member of this committee will be a <FONT STYLE="white-space:nowrap">non-employee</FONT> director, as defined by Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act, and an outside
director, as defined pursuant to Section&nbsp;162(m) of the Code, and will meet the requirements for independence under the current Nasdaq listing standards and SEC rules and regulations. Our compensation committee will be responsible for, among
other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the compensation of our Principal Executive Officer, each of our other executive officers
and Mr. Ramaswamy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to our board of directors the compensation of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administering our stock and equity incentive plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving, or making recommendations to our board of directors with respect to, incentive
compensation and equity plans; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing our overall compensation philosophy. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">382 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our nominating and governance committee are expected to be Dr. Lo, Dr. Manchester and Mr. Momtazee. Dr. Lo is expected to be the
chair of our nominating and governance committee. Dr. Lo, Dr.&nbsp;Manchester and Mr. Momtazee will meet the requirements for independence under the current Nasdaq listing standards. Our nominating and governance committee will be responsible for,
among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying and recommending candidates for membership on our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and recommending our corporate governance guidelines and policies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing proposed waivers of the code of conduct for directors, executive officers and other senior financial
officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing the process of evaluating the performance of our board of directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assisting our board of directors on corporate governance matters. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics for Employees, Executive Officers and Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has adopted a Code of Business Conduct and Ethics (the &#147;Code of Conduct&#148;), that will be applicable following
the closing of the transaction to all of our employees, executive officers and directors. The Code of Conduct will be available on our website at www.roivant.com. The nominating and corporate governance committee of our board of directors will be
responsible for overseeing the Code of Conduct and must approve any waivers of the Code of Conduct for employees, executive officers and directors. We intend to disclose any amendments to the Code of Conduct, or any waivers of its requirements, on
our website. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of our directors who will serve as a member of our compensation committee is, or has at any time during the past year been, one of our
officers or employees. None of our executive officers currently serves, or in the past year has served, as a member of the board of directors or compensation committee of any other entity that has one or more executive officers serving on our board
of directors or compensation committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;Executive Compensation&#148; for information regarding compensation paid to our directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">383 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_23"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MAAC </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following disclosure
concerns the compensation of MAAC&#146;s officers and directors for the three months ended March&nbsp;31, 2021 (i.e., before the Business Combination). </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of our executive officers or directors have received any cash compensation for services rendered to us. In addition, the MAAC Sponsor,
our executive officers and directors, and any of their respective affiliates will be reimbursed for any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with activities on
our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee reviews on a quarterly basis all payments that were made to the MAAC Sponsor, our executive officers or
directors, or our or their affiliates. Any such payments prior to an initial business combination will be made using funds held outside the Trust Account. Other than quarterly audit committee review of such reimbursements, we do not have any
additional controls in place governing our reimbursement payments to our directors and executive officers for their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with
our activities on our behalf in connection with identifying and completing an initial business combination. Other than these payments and reimbursements, no compensation of any kind, including finder&#146;s and consulting fees, will be paid by MAAC
to the MAAC Sponsor, MAAC&#146;s executive officers and directors, or any of their respective affiliates, prior to completion of our initial business combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Roivant </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This discussion may contain
forward-looking statements that are based on Roivant&#146;s current plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that it adopts following the completion of the business
combination may differ materially from the currently planned programs summarized in this discussion. All share counts in this section are shown on a <FONT STYLE="white-space:nowrap">pre-business</FONT> combination basis. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roivant&#146;s named executive officers (&#147;NEOs&#148;) for Roivant&#146;s fiscal year ended March&nbsp;31, 2021 (&#147;Fiscal 2020&#148;),
each of whom is an employee of Roivant Sciences, Inc. (&#147;RSI&#148;), a wholly owned subsidiary of Roivant, are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Matthew Gline, Chief Executive Officer and Chief Financial Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Eric Venker, President and Chief Operating Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Benjamin Zimmer, President of Roivant Health; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Vivek Ramaswamy, Founder, Executive Chair and former Chief Executive Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table sets forth information regarding the compensation paid to the NEOs in respect of Fiscal 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman"><B>Name and Principal<BR>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal<BR>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive<BR>Plan<BR>Compensation</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Matthew Gline <BR>Chief Executive Officer and Chief Financial Officer&nbsp;<SUP
STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">455,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,497,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,310,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Eric Venker <BR>President and Chief Operating Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">275,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">455,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,734,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,748,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,296,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">384 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman"><B>Name and Principal<BR>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal<BR>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive<BR>Plan<BR>Compensation</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Benjamin Zimmer <BR>President of Roivant Health</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">455,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,247,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,052,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Vivek Ramaswamy<BR>Founder, Executive Chairman and Former Chief Executive Officer<SUP
STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">361,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">The amounts reported in this column reflect the annual cash discretionary performance bonus paid to each of the
NEOs in respect of Fiscal 2020, which were earned and paid based on an assessment by the board of directors of Roivant (the &#147;Roivant Board&#148;) of overall company and individual performance for Fiscal 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">The amounts reported in this column represent the aggregate grant date fair value of the awards of restricted
stock units (&#147;RSUs&#148;) and nonqualified stock options granted to each of the NEOs during Fiscal 2020 under the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan (&#147;2015 EIP&#148;) and as described in further detail
below. The grant date fair value was calculated in accordance with FASB ASC Topic 718, excluding the effect of estimated forfeitures. The amounts reported for any awards subject to performance conditions were calculated based on the probable outcome
of the performance conditions as of the grant date, consistent with the estimate of aggregate compensation cost to be recognized over the service period determined as of the grant date under FASB ASC Topic 718, excluding the effect of estimated
forfeitures. The assumptions used in calculating such grant date fair value are set forth in the notes to Roivant&#146;s audited consolidated financial statements included elsewhere in this prospectus. Amounts reported do not reflect the actual
economic value that may be realized by the applicable NEO. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">The grant date fair value of the RSUs granted to Dr.&nbsp;Venker in Fiscal 2020, if the maximum level of the
applicable performance conditions were achieved, is $5,734,500. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">The following are the grant date fair values of the stock options granted to the NEOs in Fiscal 2020, if the
maximum level of the applicable performance conditions were achieved: Mr.&nbsp;Gline ($7,497,000), Dr.&nbsp;Venker ($3,748,500) and Mr.&nbsp;Zimmer ($5,247,900). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">The amounts reported for Fiscal 2020 in this column reflect the following: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">For Mr.&nbsp;Gline, reflects company matching contributions under RSI&#146;s 401(k) plan ($8,550);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">For Dr.&nbsp;Venker, reflects (i)&nbsp;company matching contributions under RSI&#146;s 401(k) plan ($8,550) and
(ii)&nbsp;fees received by Dr.&nbsp;Venker in Fiscal 2020 for his service on the board of directors of certain private company affiliates of Roivant ($75,000); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">For Mr.&nbsp;Ramaswamy, reflects company matching contributions under RSI&#146;s 401(k) plan ($11,800).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Effective January&nbsp;26, 2021, Mr.&nbsp;Ramaswamy ceased serving as Roivant&#146;s Chief Executive Officer and
transitioned to his current role as Executive Chairman. In addition, effective as of such date, Mr.&nbsp;Gline, Roivant&#146;s then-current Chief Financial Officer, was appointed to also serve as Chief Executive Officer. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">385 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at Fiscal Year End </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information concerning outstanding equity awards for the NEOs as of the end of Fiscal 2020. Upon the
consummation of the Business Combination, each outstanding equity award reflected in the table below will be equitably adjusted in accordance with the terms of the business combination agreement and the 2015 EIP. For additional details regarding the
treatment of outstanding equity awards held by the NEOs in connection with the Business Combination, see &#147;Treatment of Equity Awards in Connection with the Business Combination&#148; below. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OUTSTANDING EQUITY AWARDS AT 2020 FISCAL YEAR END </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Numbers of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Numbers of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration&nbsp;Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>shares&nbsp;or&nbsp;units&nbsp;of<BR>stock that have<BR>not&nbsp;vested (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market&nbsp;value&nbsp;of<BR>shares&nbsp;or&nbsp;units&nbsp;of<BR>stock&nbsp;that&nbsp;have&nbsp;not<BR>vested ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Matthew Gline</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/20/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/19/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/21/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,152</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/20/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/20/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,625,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/26/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">466,035</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/31/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/26/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">776,725</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/31/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/26/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">466,035</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.70</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/31/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/26/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">776,725</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33.63</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/31/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/20/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/19/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Eric Venker</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/20/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,564</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/19/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/21/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,652</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/20/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/20/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,160</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/19/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/26/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">403,897</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/31/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/20/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/19/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/20/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,775,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Benjamin Zimmer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12/30/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12/29/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/20/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/19/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/20/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">229,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">270,830</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/19/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/20/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,625,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/26/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,138</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/31/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/26/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144,545</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/31/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/26/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,138</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33.63</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/31/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/20/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">210,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/19/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Vivek Ramaswamy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/26/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,126,118</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/31/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/26/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,343,002</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/31/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/26/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">599,380</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/31/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/26/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,021,411</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/31/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/26/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,343,002</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.70</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/31/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/26/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,126,118</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33.63</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/31/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Reflects the grant of nonqualified stock options to purchase Roivant Common Shares outstanding under the 2015
EIP that vest and become exercisable as follows: (i) 25% of the stock options vest and become exercisable on the first anniversary of the vesting commencement date and (ii)&nbsp;the remaining 75% vest in 36 successive equal monthly installments
thereafter, in each case, subject to the holder&#146;s continuous service through the applicable vesting date. For stock options held by Messrs. Gline and Venker that were granted in 2017 or 2018, immediately prior to (and contingent upon) the
occurrence of a &#147;change in control&#148; (as defined in the 2015 EIP), the stock options will become fully vested. For stock options held by the NEOs that were granted after 2018, in the event the NEO&#146;s employment is involuntarily
terminated without &#147;cause&#148; (as defined in the 2015 EIP and the applicable award agreement) within 12 months following the consummation of a &#147;change in control,&#148; the stock options will become fully vested. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Reflects the grant of RSUs outstanding under the 2015 EIP that vest upon the satisfaction of both a
&#147;service requirement&#148; and a &#147;liquidity event requirement.&#148; The service requirement applicable to the RSUs is satisfied as follows: (i) 25% of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">386 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
the RSUs satisfy the service requirement on the first anniversary of the vesting commencement date and (ii)&nbsp;the remaining 75% of the RSUs satisfy the service requirement in 36 successive
equal monthly installments thereafter, in each case, subject to the holder&#146;s continuous service through the applicable vesting date. The liquidity event requirement will be satisfied upon the first to occur of a &#147;change in control&#148; or
&#147;initial public offering&#148; of Roivant (as defined in the 2015 EIP and the applicable award agreement) prior to the expiration date of the RSUs, which is eight years from the grant date. If the liquidity event requirement is not satisfied
before the expiration date, the RSUs will be forfeited. The number of RSUs reflected in the table above assumes full attainment of the liquidity event requirement. The market value of the RSUs reflected in the table above is based on a share price
of $38.50 per share, the fair market value of Roivant Common Shares as of March&nbsp;31, 2021. In the event the NEO&#146;s employment is involuntarily terminated for any reason other than for &#147;cause&#148; within 12 months following the
consummation of a &#147;change in control,&#148; the RSUs will become fully vested. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Reflects the grant of nonqualified performance-based stock options to purchase Roivant Common Shares outstanding
under the 2015 EIP (&#147;Performance Options&#148;) that vest and become exercisable upon the satisfaction of both a &#147;service requirement&#148; and a &#147;liquidity event requirement.&#148; The service requirement applicable to the
Performance Options is satisfied as follows: (i) 25% of the Performance Options satisfy the service requirement on December&nbsp;27, 2020 and (ii)&nbsp;the remaining 75% of the Performance Options satisfy the service requirement in 36 successive
equal monthly installments thereafter, in each case, subject to the holder&#146;s continuous service through the applicable vesting date. The liquidity event requirement will be satisfied upon the first to occur of a &#147;change in control&#148; or
&#147;public listing&#148; of Roivant (as defined in the 2015 EIP and the applicable award agreement) prior to the expiration date of the Performance Options. If the liquidity event requirement is not satisfied before the expiration date, the
Performance Options will be forfeited. The number of Performance Options reflected in the table above assumes full attainment of the liquidity event requirement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Reflects the grant of capped value appreciation rights (&#147;CVARs&#148;) with respect to Roivant Common Shares
outstanding under the 2015 EIP that vest upon the satisfaction of both a &#147;service requirement&#148; and a &#147;liquidity event requirement.&#148; The service requirement applicable to the CVARs is satisfied as follows: (i) 25% of the CVARs
satisfy the service requirement on December&nbsp;27, 2020 and (ii)&nbsp;the remaining 75% of the CVARs satisfy the service requirement in 36 successive equal monthly installments thereafter, in each case, subject to the holder&#146;s continuous
service through the applicable vesting date. The liquidity event requirement will be satisfied upon the first to occur of a &#147;change in control&#148; or &#147;public listing&#148; of Roivant (as defined in the 2015 EIP and the applicable award
agreement) prior to the expiration date of the CVARs. If the liquidity event requirement is not satisfied before the expiration date, the CVARs will be forfeited. Upon vesting, the CVARs will entitle the holder to a payment equal to the product of
(i)&nbsp;the number of vested CVARs <I>multiplied by</I> (ii)&nbsp;the excess (if any) of (A)&nbsp;the fair market value of a Roivant Common Share as of the relevant date of determination (capped at $37.10 per share) <I>over</I> (B)&nbsp;the
applicable hurdle price (as described in the footnote 5 below) (the &#147;CVAR Amount&#148;). However, for CVARs with a hurdle price of $18.70 per share, no CVAR Amount will be payable in respect of vested CVARs if the fair market value of a Roivant
Common Share is less than $26.90 per share as of the relevant date of determination (the <FONT STYLE="white-space:nowrap">&#147;knock-in</FONT> condition&#148;); instead, such CVARs will remain outstanding unless and until the <FONT
STYLE="white-space:nowrap">knock-in</FONT> condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs. Once payable, the CVARs will be settled in a number of Roivant Common Shares determined by
dividing (i)&nbsp;the applicable CVAR Amount by (ii)&nbsp;the fair market value of a Roivant Common Share as of the applicable payment date. The number of CVARs reflected in the table above assumes full attainment of the liquidity event requirement.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">This amount reflects the per share hurdle price applicable to this award of CVARs. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Matthew Gline</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr. Gline is party to an employment agreement with RSI, dated May 14, 2021, which provides for at-will employment and no specified term of
employment. Pursuant to Mr. Gline&#146;s employment agreement, Mr. Gline&#146;s annual base salary is $725,000, which is subject to adjustment at the discretion of the Roivant Board or the compensation committee thereof. In addition, Mr. Gline is
eligible to receive a discretionary annual performance bonus, with a target annual bonus equal to 100% of his annual base salary. The actual amount of any annual bonus will be based on an assessment by the compensation committee of the Roivant Board
of Mr. Gline&#146;s performance, as well as business conditions at the company. Mr. Gline will also be eligible to receive discretionary periodic or annual equity incentive awards, based on Mr. Gline&#146;s performance and business conditions at the
company, as determined in the sole discretion of the compensation committee of the Roivant Board. Mr. Gline is also entitled to participate in the employee benefit plans and programs (including any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">387 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
medical, dental, vision, life and disability insurance benefit plans and 401(k) plan) as provided by RSI to similarly situated full-time employees from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Mr. Gline&#146;s employment agreement, in the event Mr. Gline&#146;s employment is terminated by RSI without &#147;cause&#148;
(other than due to Mr. Gline&#146;s death or &#147;disability&#148;) or Mr. Gline resigns for &#147;good reason&#148; (each as defined in Mr. Gline&#146;s employment agreement), then, subject to Mr. Gline&#146;s timely execution and non-revocation
of a release of claims and continued compliance with applicable restrictive covenants, Mr. Gline will be entitled to receive (i) continued payment of his base salary for 12 months following the date of his termination, payable in accordance with
RSI&#146;s customary payroll procedures, (ii) an amount equal to his target annual bonus for the year of termination, payable in 12 equal monthly installments following the date of his termination and (iii) monthly reimbursement of COBRA premiums
(less active employee rates) for 12 months following the date of his termination (or, if earlier, until the date Mr. Gline becomes eligible for coverage under a subsequent employer&#146;s group health insurance plan). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Mr. Gline&#146;s employment agreement, in the event of a termination of Mr. Gline&#146;s employment due to his death or
disability, to the extent not already provided under the applicable award agreements and subject to the execution and non-revocation of a release of claims and continued compliance with applicable restrictive covenants, all service-based vesting
conditions with respect to 50% of Mr. Gline&#146;s then-outstanding equity awards granted prior to March 31, 2021 will be immediately waived, and will thereafter otherwise remain subject to the other existing terms and conditions of such awards
(including the achievement of any applicable performance-based vesting conditions and any liquidity event vesting conditions, as the case may be). In addition, pursuant to the terms of Mr. Gline&#146;s outstanding Performance Options and CVARs
granted prior to March 31, 2021, in the event Mr. Gline&#146;s employment is terminated by RSI without cause, due to Mr. Gline&#146;s death or disability or Mr. Gline resigns for any reason (with or without good reason), subject to Mr. Gline&#146;s
timely execution and non-revocation of a release of claims and continued compliance with applicable restrictive covenants, all service-based vesting conditions with respect to 50% of Mr. Gline&#146;s then-outstanding Performance Options and CVARs
will be immediately waived, and will thereafter otherwise remain subject to the other existing terms and conditions of such awards (including the achievement of any applicable performance-based vesting conditions and any liquidity event vesting
conditions, as the case may be). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Eric Venker</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr. Venker is party to an employment agreement with RSI, dated May 14, 2021, which provides for at-will employment and no specified term of
employment. Pursuant to Dr. Venker&#146;s employment agreement, Dr.&nbsp;Venker&#146;s annual base salary is $620,000, which is subject to adjustment at the discretion of the compensation committee of the Roivant Board. In addition, Dr. Venker is
entitled to receive quarterly board fees in the amount of $3,125 per fiscal quarter (or such other amount as may be determined by Roivant) in respect of each private company affiliate of Roivant based in the United Kingdom for which Dr. Venker
serves as a member of the board of directors. Dr. Venker&#146;s annual base salary is reduced by the aggregate annual amount of such board fees payable to Dr. Venker. Dr. Venker is also eligible to receive a discretionary annual performance bonus,
with a target annual bonus equal to 55% of his annual base salary (without giving effect to any reductions in such base salary for board fees). The actual amount of any annual bonus will be based on an assessment by the compensation committee of the
Roivant Board of Dr. Venker&#146;s performance, as well as business conditions at the company. Dr. Venker will also be eligible to receive discretionary periodic or annual equity incentive awards, based on Dr. Venker&#146;s performance and business
conditions at the company, as determined in the sole discretion of the compensation committee of the Roivant Board. Dr. Venker is also entitled to participate in the employee benefit plans and programs (including any medical, dental, vision, life
and disability insurance benefit plans and 401(k) plan) as provided by RSI to similarly situated full-time employees from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Dr. Venker&#146;s employment agreement, in the event Dr. Venker&#146;s employment is terminated by RSI without &#147;cause&#148;
(other than due to Dr. Venker&#146;s death or &#147;disability&#148;) or Dr. Venker resigns for &#147;good reason&#148; (each as defined in Dr. Venker&#146;s employment agreement), then, subject to Dr. Venker&#146;s timely execution
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">388 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and non-revocation of a release of claims and continued compliance with applicable restrictive covenants, Dr.&nbsp;Venker will be entitled to receive (i) continued payment of his base salary
(without giving effect to any reductions in such base salary for board fees) for 12 months following the date of his termination, payable in accordance with RSI&#146;s customary payroll procedures, (ii) an amount equal to his target annual bonus for
the year of termination, payable in 12 equal monthly installments following the date of his termination and (iii) monthly reimbursement of COBRA premiums (less active employee rates) for 12 months following the date of his termination (or, if
earlier, until the date Dr. Venker becomes eligible for coverage under a subsequent employer&#146;s group health insurance plan). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, in the event of a termination of Dr. Venker&#146;s employment due to his death or disability, subject to the execution and non-revocation of a release of claims and continued compliance with applicable restrictive covenants, all
service-based vesting conditions with respect to 50% of Dr. Venker&#146;s then-outstanding equity awards granted prior to March 31, 2021 will be immediately waived, and will thereafter otherwise remain subject to the other existing terms and
conditions of such awards (including the achievement of any applicable performance-based vesting conditions and any liquidity event vesting conditions, as the case may be). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Benjamin Zimmer</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr. Zimmer is party to
an employment agreement with RSI, dated May 14, 2021, which provides for at-will employment and no specified term of employment. Pursuant to Mr. Zimmer&#146;s employment agreement, Mr.&nbsp;Zimmer&#146;s annual base salary is $350,000, which is
subject to adjustment at the discretion of the compensation committee of the Roivant Board. In addition, Mr. Zimmer is eligible to receive a discretionary annual performance bonus, with a target annual bonus equal to 100% of his annual base salary.
The actual amount of any annual bonus will be based on an assessment by the compensation committee of the Roivant Board of Mr. Zimmer&#146;s performance, as well as business conditions at the company. Mr. Zimmer will also be eligible to receive
discretionary periodic or annual equity incentive awards, based on Mr. Zimmer&#146;s performance and business conditions at the company, as determined in the sole discretion of the compensation committee of the Roivant Board. Mr. Zimmer is also
entitled to participate in the employee benefit plans and programs (including any medical, dental, vision, life and disability insurance benefit plans and 401(k) plan) as provided by RSI to similarly situated full-time employees from time to time.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Mr. Zimmer&#146;s employment agreement, in the event Mr. Zimmer&#146;s employment is terminated by RSI without
&#147;cause&#148; (other than due to Mr. Zimmer&#146;s death or &#147;disability&#148;) or Mr. Zimmer resigns for &#147;good reason&#148; (each as defined in Mr. Zimmer&#146;s employment agreement), then, subject to Mr. Zimmer&#146;s timely
execution and non-revocation of a release of claims and continued compliance with applicable restrictive covenants, Mr. Zimmer will be entitled to receive (i) continued payment of his base salary for 12 months following the date of his termination,
payable in accordance with RSI&#146;s customary payroll procedures, (ii) an amount equal to his target annual bonus for the year of termination, payable in 12 equal monthly installments following the date of his termination and (iii) monthly
reimbursement of COBRA premiums (less active employee rates) for 12 months following the date of his termination (or, if earlier, until the date Mr. Zimmer becomes eligible for coverage under a subsequent employer&#146;s group health insurance
plan). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the event of a termination of Mr. Zimmer&#146;s employment due to his death or disability, subject to the
execution and non-revocation of a release of claims and continued compliance with applicable restrictive covenants, all service-based vesting conditions with respect to 50% of Mr. Zimmer&#146;s then-outstanding equity awards granted prior to March
31, 2021 will be immediately waived, and will thereafter otherwise remain subject to the other existing terms and conditions of such awards (including the achievement of any applicable performance-based vesting conditions and any liquidity event
vesting conditions, as the case may be). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Vivek Ramaswamy</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr. Ramaswamy is party to an employment agreement with RSI, dated May 14, 2021, which provides for at-will employment and no specified term of
employment. Pursuant to Mr. Ramaswamy&#146;s employment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">389 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement, Mr. Ramaswamy&#146;s annual base salary is $350,000, which is subject to increase at the discretion of the Roivant Board. In addition, Mr. Ramaswamy is entitled to receive an annual
bonus for each fiscal year of employment, with a target annual bonus equal to 100% of his annual base salary. Mr. Ramaswamy is also entitled to participate in the employee benefit plans and programs provided by RSI to its employees from time to
time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Mr. Ramaswamy&#146;s employment agreement, in the event Mr. Ramaswamy&#146;s employment is&nbsp;terminated by RSI
without &#147;cause&#148; or Mr. Ramaswamy resigns for &#147;good reason&#148; (each as defined in Mr.&nbsp;Ramaswamy&#146;s employment agreement), then, subject to Mr. Ramaswamy&#146;s timely execution and non-revocation of a release of claims, Mr.
Ramaswamy will be entitled to receive (i) continued payment of his base salary for two years following the date of his termination, payable in accordance with RSI&#146;s customary payroll procedures, (ii) a lump sum payment equal to the average of
his target annual bonus for the three years prior to the termination date and (iii) monthly payment (or reimbursement) of COBRA premiums (less active employee rates) for 18 months following the date of his termination (or, if earlier, until the date
Mr. Ramaswamy becomes eligible for coverage under a subsequent employer&#146;s group health insurance plan). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, with respect to
equity awards granted to Mr. Ramaswamy prior to March 31, 2021, subject to his timely execution and non-revocation of a release of claims, (i) in the event Mr. Ramaswamy&#146;s employment is terminated by RSI without cause, by Mr. Ramaswamy for good
reason or by mutual agreement between him and RSI, then all service-based vesting conditions with respect to 100% of such awards then outstanding will be immediately waived and (ii) in the event Mr. Ramaswamy&#146;s employment is terminated due to
his death or disability, then all service-based vesting conditions with respect to 50% of such awards then outstanding will be immediately waived, in each case provided that all such awards will thereafter otherwise remain subject to the other
existing terms and conditions of such awards (including the achievement of any applicable performance-based vesting conditions and any liquidity event vesting conditions, as the case may be). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Restrictive Covenants </U></I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
employment agreements for each of the NEOs provide for customary non-competition and non-solicitation covenants that apply during the term of the NEO&#146;s employment and at least 12 months thereafter. In addition, the employment agreements contain
standard confidentiality and non-disparagement provisions that apply during the term of the NEO&#146;s employment and perpetually thereafter. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Benefit
Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roivant&#146;s NEOs participate in employee benefit programs available to its employees generally, including health, dental and
vision insurance and a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> 401(k) plan maintained by RSI. Neither Roivant nor its subsidiaries maintained any executive-specific benefit or perquisite programs in Fiscal 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under RSI&#146;s 401(k) plan, eligible employees (including the NEOs) are able to defer up to 90% of their eligible compensation subject to
applicable annual limits under the Internal Revenue Code. All participants are 100% vested in their deferrals when contributed. Currently, RSI provides matching contributions for employees&#146; <FONT STYLE="white-space:nowrap">pre-tax</FONT>
contributions on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">dollar-for-dollar</FONT></FONT> basis up to $8,550 annually per employee. These matching contributions generally become vested after two years of service by an
employee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Incentive Compensation Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amended and Restated 2015 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roivant maintains the Amended and Restated Roivant Sciences Ltd. 2015 Equity Incentive Plan (the &#147;2015 EIP&#148;), which provides for the
discretionary grant of equity awards to eligible participants. Effective as of, and contingent on the consummation of the Business Combination, the 2015 EIP will be terminated and no further </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">390 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
awards will be granted under the 2015 EIP. Any awards outstanding under the 2015 EIP as of such time will remain subject to the terms of the 2015 EIP and the applicable award agreement, subject
to adjustment at the closing of the Business Combination as described in more detail below. There are currently awards of nonqualified stock options (including Performance Options), RSUs and CVARs outstanding under the 2015 EIP. The following sets
forth a summary of certain material features of the 2015 EIP, and is qualified in its entirety by the text of the 2015 EIP, a form of which is filed as an exhibit to the registration statement of which this proxy statement/prospectus forms a part.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purpose </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2015 EIP is intended to
help Roivant secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Roivant and its affiliates and provide a means by which the eligible recipients may benefit
from increases in value of Roivant&#146;s shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Administration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2015 EIP is administered by the Roivant Board, which may delegate its duties and responsibilities to one or more committees of its
directors (referred to collectively as the &#147;plan administrator&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Roivant Board has the authority to, among other things
and subject to the limitations imposed under the 2015 EIP, stock exchange rules and other applicable law, determine the eligible participants to be granted awards and the terms and conditions of such awards; construe and interpret the 2015 EIP and
awards granted thereunder and to establish, amend and revoke rules for the administration of the 2015 EIP and awards granted thereunder; settle all controversies regarding the 2021 EIP and awards granted under it; accelerate, in whole or in part,
the time at which an award may be exercised or vest; approve forms of award agreements for use under the 2015 EIP; amend the terms of any one or more awards; effect, with the consent of any adversely affected participant, the reduction of the
exercise price of any outstanding award, the cancellation of any outstanding award and the grant in substitution therefor of a new award, cash and/or other valuable consideration, or any other action that is treated as a repricing under generally
accepted accounting principles; and exercise such powers and perform such acts as the Roivant Board deems necessary or expedient to promote the best interests of Roivant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent permitted by applicable law, the Roivant Board may also delegate its authority under the 2015 EIP to one or more officers to
designate employees to be recipients of awards and to determine the number of shares to be granted pursuant to awards, subject to specified limits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eligibility </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Employees, consultants and
directors of Roivant and certain of its affiliates are eligible to receive awards under the 2015 EIP to the extent the Roivant Board determines that the grant of such award furthers the purpose of the 2015 EIP (as described above). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Awards </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2015 EIP provides for the
grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021, there were 12,503,608 Roivant Common Shares underlying outstanding awards under the 2015 EIP. Upon the consummation
of the Business Combination, any awards outstanding under the 2015 EIP as of such time will remain subject to the terms of the 2015 EIP and the applicable award agreement, subject to adjustment at the closing of the Business Combination as described
in more detail below and no further awards will be granted under the 2015 EIP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">391 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Capitalization Adjustments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event there is a specified type of change in Roivant&#146;s capital structure, such as a merger, consolidation, reorganization,
recapitalization, reincorporation, share dividend, dividend in property other than cash, large nonrecurring cash dividend, share split, reverse share split, liquidating dividend, combination of shares, exchange of shares, change in corporate
structure, or any similar equity restructuring transaction, appropriate adjustments will be made to the class and maximum number of shares reserved for issuance under the 2015 EIP, the class and maximum number of shares that may be issued upon the
exercise of incentive stock options, and the class and number of shares and exercise price, strike price, <FONT STYLE="white-space:nowrap">knock-in</FONT> price measure, threshold, target or maximum price measure or other price measure, if
applicable, of all outstanding awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Change in Control </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2015 EIP provides that, in the event of a change in control of Roivant (as described below), the Roivant Board may take one or more of the
following actions with respect to outstanding awards, contingent upon the closing or completion of the change in control: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">arrange for the assumption, continuation or substitution of the award by the successor or acquiring corporation
(or its parent); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">arrange for lapse of, or the assignment to the successor or acquiring corporation (or its parent) of, any
reacquisition or repurchase rights held by Roivant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">accelerate the vesting (in whole or in part) of the award and provide for its termination prior to the effective
time of the change in control; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cancel the award prior to the effective time of the change in control in exchange for a cash payment, which may
be reduced by the exercise price payable in connection with the award; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make a payment, in such form as determined by the Roivant, equal to the excess, if any, of the value of the
property that would have been received if such award was exercised immediately prior to the effective time of the change in control over any exercise price payable (which may be $0 if the value of the property is equal to or less than the exercise
price), which such payments may be delayed to the same extent that payment of consideration to Roivant shareholders in connection with the change in control is delayed as a result of escrows, earn outs, holdbacks or any other contingencies).
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Roivant Board is not obligated to treat all awards or portions of awards in the same manner. The Roivant Board may
take different actions with respect to the vested and unvested portions of an award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A &#147;change in control&#148; is generally defined
under the 2015 EIP to include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a transaction or series of related transactions in which a person, or a group of related persons, acquires from
Roivant shares representing a majority of the voting power or economic interests of Roivant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a merger, amalgamation or scheme of arrangement in which Roivant is a constituent party and Roivant issues shares
pursuant to such transaction, except in circumstances where, Roivant shares outstanding immediately prior to such transaction continue to represent, or are converted into or exchanged for shares that represent, immediately following such
transaction, at least a majority of the voting power of the surviving or amalgamated corporation or Roivant (or, if such surviving or amalgamated corporation or Roivant is a wholly owned subsidiary of another corporation immediately following such
transaction, the parent corporation of such surviving or amalgamated corporation or Roivant); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related
transactions, by Roivant or any subsidiary of Roivant of all or substantially all the assets of Roivant and its subsidiaries taken as a whole; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sale or disposition (whether by merger, amalgamation, scheme of arrangement or otherwise) of one or more
subsidiaries of Roivant if substantially all of the assets of Roivant and its subsidiaries taken as </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">392 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
a whole are held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of Roivant.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Plan Amendment, Suspension or Termination </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Roivant Board has the authority to amend, suspend, or terminate the 2015 EIP at any time; <I>provided</I> that such action does not
materially impair the existing rights of any participant without such participant&#146;s written consent. No awards may be granted under the 2015 EIP while the 2015 EIP is suspended or after it is terminated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2021 Equity Incentive Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior
to consummation of the Business Combination, the Roivant Board is expected to approve and adopt, subject to Roivant shareholder approval, the Roivant Sciences Ltd. 2021 Equity Incentive Plan (the &#147;2021 EIP&#148;), effective as of and contingent
on the consummation of the Business Combination. The following sets forth a summary of certain material features of the 2021 EIP, and is qualified in its entirety by the text of the 2021 EIP, a form of which is filed as an exhibit to the
registration statement of which this proxy statement/prospectus forms a part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purpose </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2021 EIP is intended to help Roivant secure and retain the services of eligible award recipients, provide incentives for such persons to
exert maximum efforts for the success of the Roivant and its affiliates and provide a means by which the eligible recipients may benefit from increases in value of Roivant&#146;s shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Administration </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2021 EIP is
administered by the Roivant Board, which may delegate its duties and responsibilities to one or more committees of its directors (referred to collectively as the &#147;plan administrator&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Roivant Board has the authority to, among other things and subject to the limitations imposed under the 2021 EIP, stock exchange rules and
other applicable law: determine the eligible participants to be granted awards and the terms and conditions of such awards; construe and interpret the 2021 EIP and awards granted thereunder; settle all controversies regarding the 2021 EIP and awards
granted under it; accelerate, in whole or in part, the time at which an award may be exercised or vest; approve forms of award agreements for use under the 2021 EIP; amend the terms of any one or more awards; effect, with the consent of any
adversely affected participant, the reduction of the exercise price of any outstanding award, the cancellation of any outstanding award and the grant in substitution therefor of a new award, cash and/or other valuable consideration, or any other
action that is treated as a repricing under generally accepted accounting principles; and exercise such powers, perform such acts and make any other determinations as the Roivant Board deems necessary, expedient or desirable to promote the best
interests of Roivant and for due compliance with applicable law, stock market or exchange rules and regulations or accounting or tax rules and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent permitted by applicable law, the Roivant Board may also delegate its authority under the 2021 EIP to one or more officers to
designate employees to be recipients of awards and to determine the number of shares to be granted pursuant to awards, subject to specified limits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to certain
adjustments as described below, the aggregate number of Roivant Common Shares that initially may be issued under the 2021 EIP will be equal to 10% of the aggregate outstanding Roivant Common Shares as of the consummation of the Business Transaction.
In addition, on the first day of each fiscal year of Roivant following the effective date of the 2021 EIP and prior to the termination of the 2021 EIP, the number of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">393 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Roivant Common Shares reserved for issuance under the 2021 EIP will automatically increase by an amount equal to the lesser of (i) 5% of the Roivant Common Shares outstanding as of the last day
of the immediately preceding fiscal year and (ii)&nbsp;such number of Roivant Common Shares as determined by the Roivant Board in its discretion. The maximum number of Roivant Common Shares that may be issued pursuant to the exercise of incentive
stock options under the 2021 EIP will be equal to the initial share reserve under the 2021 EIP as described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The maximum number of
Roivant Common Shares subject to any awards granted under the 2021 EIP during any fiscal year to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director, taken together with any cash fees paid by Roivant to such director during such fiscal
year, will not exceed $750,000 (or $1,000,000 for such director&#146;s first fiscal year of service on the Roivant Board) in total value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roivant Common Shares subject to awards granted under the 2021 EIP that expire or terminate without being exercised in full, or that are paid
out in cash rather than in shares, will not reduce the number of Roivant Common Shares available for issuance under the 2021 EIP. Additionally, Roivant Common Shares issued pursuant to awards under the 2021 EIP that are repurchased by Roivant or are
forfeited, as well as Roivant Common Shares reacquired by Roivant as consideration for the exercise or purchase price of an award or to satisfy tax withholding obligations related to an award, will become available for future grant under the 2021
EIP. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eligibility </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Employees,
consultants and directors of Roivant and certain of its affiliates (including individuals who has accepted an offer of employment or service from Roivant and certain of its affiliates) are eligible to receive awards under the 2021 EIP to the extent
the Roivant Board determines that the grant of such award furthers the purpose of the 2021 EIP (as described above). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2021 EIP provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards,
restricted stock units and other stock awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Capitalization Adjustments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event there is a specified type of change in Roivant&#146;s capital structure, such as a merger, consolidation, amalgamation,
reorganization, recapitalization, reincorporation, share dividend, dividend in property other than cash, large nonrecurring cash dividend, share split, reverse share split, liquidating dividend, combination of shares, exchange of shares, change in
corporate structure, or any similar equity restructuring transaction, appropriate adjustments will be made to the class and maximum number of shares reserved for issuance under the 2021 EIP, the class and maximum number of shares that may be issued
upon the exercise of incentive stock options, and the class and number of shares and exercise price, strike price, <FONT STYLE="white-space:nowrap">knock-in</FONT> price measure, threshold, target or maximum price measure or other price measure, if
applicable, of all outstanding awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Change in Control </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2021 EIP provides that in the event of a change in control of Roivant (as described below), the Roivant Board may take one or more of the
following actions with respect to outstanding awards upon the closing of the change in control: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">arrange for the assumption, continuation or substitution of the award by the successor or acquiring corporation
(or its parent); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">394 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">arrange for the assignment of any reacquisition or repurchase rights held by Roivant to the successor or
acquiring corporation (or its parent); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">accelerate the vesting of the award and provide for its termination prior to the effective time of the change in
control; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">arrange for the lapse, in whole or in part, of any reacquisition or repurchase right held by Roivant;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determine the level of attainment of any performance conditions applicable to the award; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cancel the award prior to the effective time of the change in control in exchange for a cash payment, which may
be reduced by the exercise price payable in connection with the award; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cancel the award in exchange for a payment, in such form as determined by the Roivant Board, equal to the excess,
if any, of the value of the property that would have been received if such award was exercised immediately prior to the effective time of the change in control over any exercise price payable (which may be $0 if the value of the property is equal to
or less than the exercise price), which such payments may be delayed to the same extent that payment of consideration to Roivant shareholders in connection with the change in control is delayed as a result of escrows, earn outs, holdbacks or any
other contingencies). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Roivant Board is not obligated to treat all awards or portions of awards in the same manner.
The Roivant Board may take different actions with respect to the vested and unvested portions of an award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A &#147;change in
control&#148; is generally defined under the 2021 EIP to include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any person, entity or group is (or becomes during any <FONT STYLE="white-space:nowrap">12-month</FONT> period)
the beneficial owner of 50% or more of the total voting power of Roivant shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a change in the composition of the Roivant Board such that, during any
<FONT STYLE="white-space:nowrap">12-month</FONT> period, the individuals who, as of the beginning of such period, constitute the Roivant Board (&#147;Existing Board&#148;) cease for any reason to constitute a majority of the Roivant Board (with any
individuals whose appointment to the Roivant Board<I> </I>was approved by a vote of at least a majority of the members of the Existing Board being considered a member of the Existing Board); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the consummation of a merger, amalgamation or consolidation of Roivant with any another corporation or entity, or
the issuance of voting securities in connection with such a transaction pursuant to applicable stock exchange requirements, except in circumstances where, immediately following such transaction, the voting securities of Roivant continue to represent
50% or more of the total voting power and total fair market value of the surviving entity or its parent; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sale or disposition by Roivant of all or substantially all of its assets in which any person, entity or group
acquires (or has acquiring during a <FONT STYLE="white-space:nowrap">12-month</FONT> period) more than 50% of the total gross fair market value of all of the assets of Roivant. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clawback </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Awards granted under the 2021
EIP Plan are subject to recoupment in accordance with any clawback policy that Roivant is required to adopt pursuant to the listing standards of any national securities exchange or association on which Roivant&#146;s securities are listed or as is
otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Roivant Board may impose such other clawback, recovery or recoupment provisions in an award agreement as the Roivant Board
determines necessary or appropriate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Effective Date </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2021 EIP will become effective upon the consummation of the Business Combination, subject to approval of the Roivant Board and
Roivant&#146;s shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">395 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Plan Amendment, Suspension or Termination </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Roivant Board has the authority to amend, suspend, or terminate the 2021 EIP at any time; <I>provided</I> that such action does not
materially impair the existing rights of any participant without such participant&#146;s written consent. Unless terminated sooner by the Roivant Board, the 2021 EIP will automatically terminate on the day before the tenth anniversary of the
effective date of the 2021 EIP. No awards may be granted under the 2021 EIP while the 2021 EIP is suspended or after it is terminated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Treatment of
Equity Awards in Connection with the Business Combination </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, equity incentive awards
then-outstanding under the 2015 EIP will be equitably adjusted in accordance with the terms of the 2015 EIP and the business combination agreement. Specifically, on the date of the consummation of the Business Combination and prior to such
consummation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each outstanding Roivant option, whether vested or unvested, will be adjusted as follows: (i)&nbsp;the number of
post-closing Roivant Common Shares subject to such Roivant option will be equal to the product of (a)&nbsp;the number of Roivant Common Shares subject to the Roivant option before such adjustment,<I>&nbsp;multiplied by</I><I></I>&nbsp;(b)&nbsp;the
&#147;exchange ratio,&#148; rounded down to the nearest whole share, and (ii)&nbsp;the per share exercise price of such Roivant option will equal the quotient of (x)&nbsp;the per share exercise price at which the Roivant option was exercisable
before such adjustment,<I>&nbsp;divided by</I>&nbsp;(y)&nbsp;the exchange ratio, rounded up to the nearest whole cent. Following such adjustment, the Roivant options will otherwise remain subject to the same terms and conditions (including the
applicable vesting, expiration and forfeiture provisions) as applied before such adjustment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each outstanding and vested Roivant RSU will be adjusted by multiplying (i)&nbsp;the number of Roivant Common
Shares that were subject to the vested Roivant RSU before the adjustment<I>&nbsp;by</I><I></I>&nbsp;(ii)&nbsp;the exchange ratio, <I>minus</I> (iii)&nbsp;that number of post-closing Roivant Common Shares with a fair market value equal to all
required withholding taxes due upon settlement of such vested Roivant RSU, which such vested Roivant RSUs will be settled (including as to timing) in accordance with the terms of the 2015 EIP and the applicable award agreement thereunder.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each outstanding unvested Roivant RSU will be adjusted as follows: the number of post-closing Roivant Common
Shares subject to such unvested Roivant RSU will be equal to the product of (i)&nbsp;the number of Roivant Common Shares that were subject to the unvested Roivant RSU before the adjustment<I>&nbsp;multiplied by</I><I></I>&nbsp;(ii) the exchange
ratio, rounded down to the nearest whole share. Following such adjustment, the unvested Roivant RSUs will otherwise remain subject to the same terms and conditions (including the applicable vesting, expiration and forfeiture provisions) as applied
before such adjustment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each outstanding Roivant CVAR, whether vested or unvested, will be adjusted as follows: (i)&nbsp;the number of
post-closing Roivant Common Shares subject to such CVAR will be equal to the product of (a)&nbsp;the number of Roivant Common Shares that were subject to the Roivant CVAR before the adjustment,<I>&nbsp;multiplied by</I><I></I>&nbsp;(b)&nbsp;the
exchange ratio, rounded down to the nearest whole share, and (ii)&nbsp;the per share hurdle price, <FONT STYLE="white-space:nowrap">&#147;knock-in&#148;</FONT> price and value cap price, as applicable, of such CVAR will be equal to the quotient of
(x)&nbsp;the per share hurdle price, <FONT STYLE="white-space:nowrap">&#147;knock-in&#148;</FONT> price and value cap price, as applicable, applicable to the Roivant CVAR before the adjustment,<I>&nbsp;divided by</I>&nbsp;(y)&nbsp;the exchange
ratio, rounded up to the nearest whole cent. Following such adjustment, the Roivant CVARs will otherwise remain subject to the same terms and conditions (including the applicable vesting, expiration and forfeiture provisions) as applied before such
adjustment. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">396 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_24"></A>DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fiscal 2020 Director Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the annual cash retainer paid to directors of the Roivant Board in respect of Fiscal 2020.
Roivant did not grant equity incentive compensation to directors in respect of Fiscal 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During Fiscal 2020, only Messrs. Ramaswamy,
Lo and Machado were provided compensation for their services on the Roivant Board. During Fiscal 2020, Mr.&nbsp;Ramaswamy served as both an executive officer and a director of Roivant and his compensation for his service as executive officer is set
forth above in &#147;Executive Compensation&#151;Summary Compensation Table.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned<BR>or Paid<BR>in&nbsp;Cash</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vivek Ramaswamy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Lo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Machado</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Ramaswamy&#146;s equity incentive awards as of March&nbsp;31, 2021 are set forth above in
&#147;Executive Compensation&#151;Outstanding Equity Awards at Fiscal Year End.&#148; As of March&nbsp;31, 2021, each of Messrs. Lo and Machado held the following Roivant equity incentive awards granted under the 2015 EIP: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Lo holds 236,000 stock options granted on October&nbsp;20, 2016 with an exercise price of $15.17 per
share, all of which were vested and exercisable. Following this grant of stock options, Dr.&nbsp;Lo has not been eligible to receive any other equity compensation for his services on the Roivant Board. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Machado holds (i) 58,153 stock options granted on October&nbsp;20, 2016 with an exercise price of
$15.17 per share, all of which were vested and exercisable, (ii) 37,500 stock options granted on December&nbsp;20, 2017 with an exercise price of $21.72 per share, all of which were vested and exercisable, (iii) 37,500 stock options granted on
January&nbsp;22, 2019 with an exercise price of $32.72 per share, of which 29,172 were vested and exercisable and the remaining will vest and become exercisable in equal monthly installments through the period ending on November&nbsp;30, 2021, and
(iv) 37,500 stock options granted on January&nbsp;20, 2020 with an exercise price of $37.10 per share, of which 16,668 were vested and exercisable and the remaining will vest and become exercisable in equal monthly installments through the period
ending on November&nbsp;30, 2022. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Annual cash retainers payable to directors are calculated based upon the prorated
number of quarterly periods each <FONT STYLE="white-space:nowrap">non-employee</FONT> director served in their respective capacity as a board and/or committee member in a given fiscal year. Except for Dr.&nbsp;Lo, who is not eligible to receive any
expense reimbursement in connection with his service on the Roivant Board, directors are also eligible to be reimbursed for actual expenses incurred in attending meetings of the Roivant Board and any of its committees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Post-Business Combination Director Compensation Program </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the consummation of the Business Combination, Roivant intends to develop a <FONT STYLE="white-space:nowrap">non-employee</FONT>
director compensation program that is designed to align compensation with Roivant&#146;s business objectives and the creation of shareholder value, while enabling Roivant to attract, retain, incentivize and reward directors who contribute to the
long-term success of Roivant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company Status </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an emerging growth company, Roivant will be exempt from certain requirements related to executive compensation, including the requirements
to hold a nonbinding advisory vote on executive compensation and to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">397 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provide information relating to the ratio of total compensation of Roivant&#146;s chief executive officer to the median of the annual total compensation of all of Roivant&#146;s employees, each
as required by the Investor Protection and Securities Reform Act of 2010, which is part of the Dodd-Frank Wall Street Reform and Consumer Protection Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">398 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_25"></A>BENEFICIAL OWNERSHIP OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding (i)&nbsp;the actual beneficial ownership of MAAC Class&nbsp;A Shares and MAAC
Class&nbsp;B Shares at June&nbsp;25, 2021 and (ii)&nbsp;the expected beneficial ownership of Roivant Common Shares immediately following the consummation of the Business Combination and related transactions (including the PIPE Financing), assuming
that no MAAC Class&nbsp;A Shares are redeemed and, alternatively, that the maximum number of MAAC Class&nbsp;A Shares are redeemed, in each case, by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person who (i)&nbsp;is known to be the beneficial owner of more than 5% of MAAC&#146;s outstanding common
stock or (ii)&nbsp;is expected to be the beneficial owner of more than 5% of Roivant Common Shares following the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of the current named executive officers and directors of MAAC, and all directors and executive officers of
MAAC as a group; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person who is expected to be a named executive officer or director of Roivant, and all directors and
executive officers of Roivant as a group, in each case following the Business Combination. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is
determined according to the rules and regulations of the SEC. A person is a &#147;beneficial owner&#148; of a security if that person has or shares &#147;voting power,&#148; which includes the power to vote or to direct the voting of the security,
or &#147;investment power,&#148; which includes the power to dispose of or to direct the disposition of the security or has the right to acquire such powers within 60 days. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The beneficial ownership of MAAC Shares <FONT STYLE="white-space:nowrap">pre-Business</FONT> Combination is based on 51,339,779 issued and
outstanding MAAC Shares, which includes an aggregate of 41,071,823 MAAC Class&nbsp;A Shares and 10,267,956 MAAC Class&nbsp;B Shares. Immediately prior to the Effective Time, each MAAC Class&nbsp;B Share will automatically be converted into one MAAC
Class&nbsp;A Share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expected beneficial ownership of the Roivant Common Shares immediately following consummation of the Business
Combination and the related transactions assumes two redemption scenarios as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Assuming no redemptions: this presentation assumes that no MAAC Class&nbsp;A Shares are redeemed and the PIPE
Financing is fully subscribed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Assuming maximum redemptions: this presentation assumes that all 41,071,823 MAAC Class&nbsp;A Shares are
redeemed, the PIPE Financing is fully subscribed and the minimum cash condition is not satisfied and is waived by Roivant. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">399 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the footnotes to the following table and subject to applicable
community property laws, we believe that all persons named in the table below have, or may be deemed to have, sole voting and investment power with respect to all MAAC Shares beneficially owned, or Roivant Common Shares to be beneficially owned, by
them. Additionally, the following table does not reflect record or beneficial ownership of any (i) Roivant Common Shares issuable upon exercise of public warrants or private placement warrants and (ii) certain equity incentive awards that are
subject to vesting conditions that have not yet been satisfied, as such securities are not exercisable or convertible within 60 days of June&nbsp;25, 2021. However, shares that a person has the right to acquire within 60 days of June&nbsp;25, 2021
are deemed issued and outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not deemed issued and outstanding for purposes of computing the percentage ownership of any other person, except with
respect to the percentage ownership of all directors and executive officers as a group. Except as otherwise noted below, the address for persons or entities listed in the table is c/o Roivant Sciences Ltd., Suite 1, 3rd Floor, <FONT
STYLE="white-space:nowrap">11-12</FONT> St. James&#146;s Square, London SW1Y 4LB, United Kingdom. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="10" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Post-Business Combination**</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Pre-Business</FONT> Combination</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Assuming No Redemption</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Assuming Maximum<BR>Redemption</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>MAAC<BR>Class&nbsp;A<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>MAAC<BR>Class&nbsp;B<BR>Shares<BR>Beneficially<BR>Owned<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>of<BR>Outstanding<BR>MAAC<BR>Shares<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Roivant<BR>Common<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>of Total<BR>Voting<BR>Power</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Roivant<BR>Common<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>of Total<BR>Voting<BR>Power</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>MAAC Officers, Directors and 5% Holders <FONT STYLE="white-space:nowrap">Pre-Business</FONT>
Combination</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patient Square Capital LLC<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP><SUP
STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp; </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,167,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,167,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,682,953</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BlueCrest Capital Management
Limited<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp; </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Integrated Core Strategies (US) LLC<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp; </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citadel Advisors LLC<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,081,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,081,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,081,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James C. Momtazee<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP><SUP
STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp; <BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,167,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,167,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,682,953</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">George Barrett<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp; </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,780</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr. Stephen Oesterle<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp; </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,780</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maria C. Walker</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp; </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp; </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All directors and executive officers of MAAC as a group pre-Business Combination (four
individuals)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,267,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,267,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,758,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Roivant Officers, Directors and 5% Holders Post-Business Combination</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVF Investments<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,875,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,875,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">QVT Entities<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,660,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,660,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dexxon Holdings<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98,809,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98,809,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Viking Global Entities<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,238,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,238,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sumitomo Chemical Co., Ltd.<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,367,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,367,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vivek Ramaswamy</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,409,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,409,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Lo</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">690,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">690,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Machado</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">438,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">438,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Keith Manchester</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ilan Oren</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Gold</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Masayo Tada</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew Gline</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">684,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">684,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Venker</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">598,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">598,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">400 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="10" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Post-Business Combination**</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Pre-Business</FONT> Combination</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Assuming No<BR>Redemption</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Assuming Maximum<BR>Redemption</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>MAAC<BR>Class&nbsp;A<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>MAAC<BR>Class&nbsp;B<BR>Shares<BR>Beneficially<BR>Owned<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>of<BR>Outstanding<BR>MAAC<BR>Shares<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Roivant<BR>Common<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>of Total<BR>Voting<BR>Power</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Roivant<BR>Common<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>of Total<BR>Voting<BR>Power</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benjamin Zimmer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,190,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,190,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All directors and executive officers of Roivant as a group post-Business Combination (thirteen
individuals)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77,703,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,218,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than one percent. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The information set forth in the table above and in the corresponding notes below reflects the Roivant Exchange
Ratio of 2.9262:1. The amounts reported in the table above do not reflect certain equity incentive awards held by our executive officers which are subject to performance-based vesting conditions and/or for which the number of Roivant shares
underlying such awards cannot be determined until a future payment date. For information regarding these equity incentive awards held by Roivant&#146;s NEOs, please see &#147;Executive Compensation&#151;Outstanding Equity Awards at 2020 Fiscal Year
End.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents percentage of voting power of the holders of MAAC Class A Shares and MAAC Class B Shares, voting
together as a single class. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes MAAC Class B Shares beneficially held by the MAAC Sponsor. James C. Momtazee is the managing member of
MAAC Sponsor and the Chief Executive Officer and a Director of MAAC. This information is based solely on the Schedule 13G filed jointly by the MAAC Sponsor and Mr. Momtazee with the SEC on February 11, 2021. The principal address of the MAAC Sponsor
is 724 Oak Grove Ave, Suite 130, Menlo Park, CA 94025. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on the Schedule 13G filed jointly by BlueCrest Capital Management Limited (the &#147;Investment
Manager&#148;) and Michael Platt (&#147;Mr. Platt&#148;) with the SEC on February 26, 2021, Investment Manager, which serves as investment manager to Millais Limited, a Cayman Islands exempted company (the &#147;Fund&#148;), and Michael Platt, who
serves as principal, director, and control person of the Investment Manager, may be deemed the beneficial owner of 500,000 MAAC Class A Shares and 2,500,000 MAAC Class A Shares underlying MAAC Units held for the account of the Fund. The address of
the Investment Manager and Mr.&nbsp;Platt is Ground Floor, Harbour Reach, La Rue de Carteret, St. Helier, Jersey, Channel Islands, JE2 4HR. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on the Schedule 13G/A filed jointly by Integrated Core Strategies (US) LLC (&#147;Integrated Core
Strategies&#148;), ICS Opportunities, Ltd. (&#147;ICS Opportunities&#148;), Millennium International Management LP (&#147;Millennium International Management&#148;), Millennium Management LLC (&#147;Millennium Management&#148;), Millennium Group
Management LP (&#147;Millennium Group Management&#148;), and Israel A. Englander (&#147;Mr.&nbsp;Englander&#148;), with the SEC on January 22, 2021 (i) Integrated Core Strategies, a Delaware limited liability company, beneficially owned 2,050,000
MAAC Class A Shares as a result of holding 1,900,000 MAAC Class A Shares and 150,000 MAAC Units; and (ii) ICS Opportunities, an exempted company organized under the laws of the Cayman Islands, beneficially owned 1,300,000 MAAC Class A Shares as a
result of holding 1,300,000 MAAC Units, which together with the MAAC Class A Shares beneficially owned by Integrated Core Strategies represented 3,350,000 MAAC Class A Shares. Millennium International Management, a Delaware limited partnership, is
the investment manager to ICS Opportunities and may be deemed to have shared voting control and investment discretion over securities owned by ICS Opportunities. Millennium Management, a Delaware limited liability company, is the general partner of
the managing member of Integrated Core Strategies and may be deemed to have shared voting control and investment discretion over securities owned by Integrated Core Strategies. Millennium Management is also the general partner of the 100% owner of
ICS Opportunities and may also be deemed to have shared voting control and investment discretion over securities owned by ICS Opportunities. Millennium Group Management, a Delaware limited liability company, is the managing member of Millennium
Management </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">401 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
and may also be deemed to have shared voting control and investment discretion over securities owned by Integrated Core Strategies. Millennium Group Management is also the general partner of
Millennium International Management and may also be deemed to have shared voting control and investment discretion over securities owned by ICS Opportunities. The managing member of Millennium Group Management is a trust of which Mr. Englander, a
United States citizen, currently serves as the sole voting trustee. Therefore, Mr. Englander may also be deemed to have shared voting control and investment discretion over securities owned by Integrated Core Strategies and ICS Opportunities. The
business address of each of Integrated Core Strategies, ICS Opportunities, Millennium International Management, Millennium Management, Millennium Group Management, and Mr. Englander is 666 Fifth Avenue, New York, NY 10103. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on the Schedule 13G filed jointly by Citadel Advisors LLC, a Delaware limited liability company
(&#147;Citadel Advisors&#148;), Citadel Advisors Holdings LP, a Delaware limited partnership (&#147;CAH&#148;), Citadel GP LLC, a Delaware limited liability company (&#147;CGP&#148;), Citadel Securities LLC, a Delaware limited liability company
(&#147;Citadel Securities&#148;), CALC IV LP, a Delaware limited partnership (&#147;CALC4&#148;), Citadel Securities GP LLC, a Delaware limited liability company (&#147;CSGP&#148;) and Kenneth Griffin (&#147;Mr. Griffin&#148;), with the SEC on May
17, 2021: (i)&nbsp;each of Citadel Advisors, CAH and CGP beneficially owned 2,050,006 MAAC Class A Shares; (ii)&nbsp;each of Citadel Securities, CALC4 and CSGP beneficially owned 31,535 MAAC Class A Shares; and (iii)&nbsp;Mr. Griffin beneficially
owned 2,081,541 MAAC Class A Shares. Citadel Advisors is the portfolio manager for Citadel Multi-Strategy Equities Master Fund Ltd., a Cayman Islands company. CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is
the non-member manager of Citadel Securities. CSGP is the general partner of CALC4. Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP. The business address of each of Citadel Advisors,
CAH, CGP, Citadel Securities, CALC4, CSGP and Mr. Griffin is 131 S. Dearborn Street, 32nd Floor, Chicago, Illinois 60603. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of Roivant Common Shares held by SVF Investments (UK) Limited (&#147;SVF Investments&#148;). SVF
Investment is a wholly owned subsidiary of SVF Holdings (UK) LLP (&#147;SVF Holdings&#148;). SoftBank Vision Fund L.P. (&#147;SoftBank Vision Fund&#148;) is the managing member of SVF Holdings. SVF GP (Jersey) Limited is the general partner of
Softbank Vision Fund. Includes 2,500,000 Roivant Common Shares issuable to SB Northstar LP, an affiliate of SVF Holdings, in connection with the PIPE Financing. The principal address of SVF Investments is 69 Grosvenor Street, London, United Kingdom
W1K 3JP. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of Roivant Common Shares held by QVT Financial Investment Cayman Ltd., QVT Roiv Hldgs Offshore Ltd.,
QVT Roiv Hldgs Onshore Ltd., QVT Deferred Compensation Holdings Ltd., QVT P&amp;E Roiv Hldgs Ltd. and Fourth Avenue Capital Partners LP (together, the &#147;QVT Entities&#148;). Fourth Avenue Capital Partners GP LLC may be deemed to share beneficial
ownership of the Roivant Common Shares held by Fourth Avenue Capital Partners LP. Each of QVT Financial LP and QVT Financial GP LLC may be deemed to share beneficial ownership of the Roivant Common Shares held by the QVT Entities. The Managing
Members of QVT Financial GP LLC and Fourth Avenue Capital Partners GP LLC are Daniel Gold, Nicholas Brumm, Arthur Chu and Tracy Fu, each of whom disclaims beneficial ownership of the securities held by the QVT Entities except to the extent of any
pecuniary interest. The principal business address for the QVT Entities, QVT Financial LP, QVT Financial GP LLC, Fourth Avenue Capital Partners GP LLC and the Managing Members is 888 Seventh Avenue, 27th Floor, New York, NY 10106.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of Roivant Common Shares held by Dexxon Holdings Ltd. (&#147;Dexxon Holdings&#148;) and Dexcel Pharma
Technologies Ltd. (&#147;Dexcel Pharma&#148;). Dan Oren is the sole shareholder and sole director of Dexxon Holdings and the ultimate (indirect) sole shareholder and the Executive Chairman of Dexcel Pharma. As such, each of Dexxon Holdings, Dexcel
Pharma and Dan Oren may be deemed to share beneficial ownership of the Roivant Common Shares. The principal business address of Dexxon Holdings and Dan Oren is 1 Dexcel Street, Or Akiva, 3060000, Israel. The principal business address of Dexcel
Pharma is 21 Nahum Haftzadi Street, Jerusalem, 9548402. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of Roivant Common Shares held by Viking Global Equities Master Ltd. (&#147;VGEM&#148;), Viking Global
Equities II LP (&#147;VGEII&#148;), Viking Long Fund Master Ltd. (&#147;VLFM&#148;) and Viking Global Opportunities Illiquid Investments <FONT STYLE="white-space:nowrap">Sub-Master</FONT> LP (&#147;Opportunities Fund,&#148; and together with all of
the preceding entities, the &#147;Viking Global Entities&#148;). VGEM has the power to dispose of and vote the shares directly owned by it, which power may be exercised by its investment manager, Viking Global Performance LLC (&#147;VGP&#148;), and
by Viking Global Investors LP (&#147;VGI&#148;), which provides managerial services to VGEM. VGEII has the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">402 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
authority to dispose of and vote the shares directly owned by it, which power may be exercised by its general partner, VGP, and by VGI, which provides managerial services to VGEII. VLFM has the
authority to dispose of and vote the shares directly owned by it, which power may be exercised by its investment manager, Viking Long Fund GP LLC (&#147;VLFGP&#148;), and by VGI, which provides managerial services to VLFM. Opportunities Fund has the
authority to dispose of and vote the shares directly owned by it, which power may be exercised by its general partner, Viking Global Opportunities Portfolio GP LLC (&#147;Opportunities GP&#148;), and by VGI, which provides managerial services to
Opportunities Fund. O. Andreas Halvorsen, David C. Ott and Rose Shabet, as Executive Committee members of Viking Global Partners LLC (the general partner of VGI), VGP, VLFGP and Viking Global Opportunities GP LLC (the sole member of Opportunities
GP) have shared authority to direct the voting and disposition of investments beneficially owned by VGI, VGP, VLFGP and Opportunities GP. Includes an aggregate of 1,000,000 Roivant Common Shares issuable to affiliates of the Viking Global Entities
in connection with the PIPE Financing. The business address of each of the Viking Global Entities is 55 Railroad Avenue, Greenwich, Connecticut 06830. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of Roivant Common Shares held by Sumitomo Dainippon Pharma Co., Ltd. (&#147;Sumitomo Dainippon
Pharma&#148;), which is a majority-owned subsidiary of Sumitomo Chemical Co., Ltd. (&#147;Sumitomo Chemical&#148;). Includes 7,500,000 Roivant Common Shares issuable to Sumitomo Dainippon Pharma in connection with the PIPE Financing. The principal
business address of Sumitomo Chemical is <FONT STYLE="white-space:nowrap">27-1,</FONT> Shinkawa <FONT STYLE="white-space:nowrap">2-chome,</FONT> <FONT STYLE="white-space:nowrap">Chuo-ku,</FONT> Tokyo <FONT STYLE="white-space:nowrap">104-8260</FONT>
Japan. The principal business address of Sumitomo Dainippon Pharma is <FONT STYLE="white-space:nowrap">6-8</FONT> Doshomachi <FONT STYLE="white-space:nowrap">2-chome,</FONT> <FONT STYLE="white-space:nowrap">Chuo-ku,</FONT> Osaka <FONT
STYLE="white-space:nowrap">541-0045</FONT> Japan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An aggregate of 30% of the MAAC Class B Shares held by the holders are subject to those certain earn-out
provisions in the Sponsor Support Agreement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the reduction in the MAAC Sponsor Exchange Ratio from 1.0 to 0.76. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">403 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_26"></A>CERTAIN MAAC RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MAAC Related Person Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Founder
Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;23, 2020, an affiliate of our Sponsor paid an aggregate of $25,000 for certain expenses on behalf of the
Company in exchange for issuance of 14,375,000 MAAC Class&nbsp;B Shares, with such shares subsequently transferred to our Sponsor. On October&nbsp;6, 2020, our Sponsor surrendered 2,875,000 MAAC Class&nbsp;B Shares to the Company for no
consideration, resulting in a decrease of the Founder Shares from 14,375,000 shares to 11,500,000 shares. All shares and associated amounts have been retroactively restated to reflect the share surrender. The initial stockholders agreed to forfeit
up to 1,500,000 Founder Shares to the extent that the Over-Allotment option was not exercised in full by the underwriters, so that the Founder Shares would represent 20.0% of the Company&#146;s issued and outstanding MAAC Shares after our initial
public offering. The underwriters exercised their Over-Allotment option in part on November&nbsp;12, 2020; and the remaining over-allotment expired unexercised on November&nbsp;20, 2020 resulting in a forfeiture of 1,232,044 MAAC Class&nbsp;B
Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Sponsor, directors, and officers have entered into certain lockup agreements which restrict their ability to take certain
actions with respect to covered securities that they may own at the time of the effective date of the Business Combination. These restrictions are more fully explained in &#147;The Business Combination Proposal&#151;Related Agreements.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our officers or directors becomes aware of a Business Combination opportunity that falls within the line of business of any entity
to which he or she has then-current fiduciary or contractual obligations, he or she will honor his or her fiduciary or contractual obligations to present such opportunity to such entity. Our officers and directors currently have certain relevant
fiduciary duties or contractual obligations that may take priority over their duties to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No compensation of any kind, including
finder&#146;s and consulting fees, will be paid to our Sponsor, officers and directors, or any of their respective affiliates, for services rendered prior to or in connection with the completion of an initial Business Combination. However, these
individuals will be reimbursed for any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with activities on our behalf such as identifying potential target businesses and
performing due diligence on suitable Business Combinations. Our audit committee will review on a quarterly basis all payments that were made to our Sponsor, officers, directors or our or their affiliates and will determine which expenses and the
amount of expenses that will be reimbursed. There is no cap or ceiling on the reimbursement of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by such persons in connection with
activities on our behalf. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Private Placement Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Simultaneously with the closing of our initial public offering, the Company consummated the Private Placement of 10,000,000 private placement
warrants at a price of $1.00 per Private Placement warrant to the MAAC Sponsor, generating proceeds of $10.0&nbsp;million. Simultaneously with the closing of the Over-Allotment on November&nbsp;12, 2020, the Company consummated the second closing of
the Private Placement, resulting in the purchase of an aggregate of an additional 214,365 private placement warrants by the MAAC Sponsor, generating gross proceeds to the Company of approximately $214,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each whole Private Placement Warrant is exercisable for one whole MAAC Class&nbsp;A Shares at a price of $11.50 per share, subject to
adjustment. A portion of the proceeds from the sale of the private placement warrants to the MAAC Sponsor was added to the proceeds from our initial public offering held in the Trust Account. If the Company does not complete a Business Combination
within the Combination Period, the private placement warrants will expire worthless. The private placement warrants will be <FONT STYLE="white-space:nowrap">non-redeemable</FONT> for cash (except as described below) and exercisable on a cashless
basis so long as they are held by the MAAC Sponsor or its permitted transferees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">404 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MAAC Sponsor agreed, subject to limited exceptions, not to transfer, assign or sell the
private placement warrants until 30 days after the completion of the initial Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Related Party Loans </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;23, 2020, the MAAC Sponsor agreed to loan the Company an aggregate of up to $300,000 to cover expenses related to our initial
public offering pursuant to a promissory note (the &#147;Note&#148;). This loan was <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing and payable upon the completion of our initial public offering. The Company borrowed $200,000 under the
Note and fully repaid this amount on October&nbsp;9, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in order to fund working capital deficiencies or finance
transaction costs in connection with a Business Combination, the MAAC Sponsor or an affiliate of the MAAC Sponsor, or certain of the Company&#146;s officers and directors may, but are not obligated to, loan the Company funds as may be required
(&#147;Working Capital Loans&#148;). If the Company completes a Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans could be
repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the
Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination or, at the lender&#146;s discretion, up to $1,500,000 of such Working Capital Loans may be
convertible into warrants of the post Business Combination entity at a price of $1.00 per warrant. The warrants would be identical to the private placement warrants. Except for the foregoing, the terms of such Working Capital Loans, if any, have not
been determined and no written agreements exist with respect to such loans. We do not expect to seek loans from parties other than our Sponsor or an affiliate of our Sponsor as we do not believe third parties will be willing to loan such funds and
provide a waiver against any and all rights to seek access to funds in our Trust Account. To date, the Company had no borrowings under the Working Capital Loans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After our initial Business Combination, members of our management team who remain with us may be paid consulting, management or other fees
from the combined company with any and all amounts being fully disclosed to our stockholders, to the extent then known, in the tender offer or proxy solicitation materials, as applicable, furnished to our stockholders. It is unlikely the amount of
such compensation will be known at the time of distribution of such tender offer materials or at the time of a stockholder meeting held to consider our initial Business Combination, as applicable, as it will be up to the directors of the
post-combination business to determine executive and director compensation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Administrative Services Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commencing October&nbsp;7, 2020 through the earlier of consummation of the initial Business Combination and the liquidation, the Company has
agreed to pay the MAAC Sponsor a total of $10,000 per month for office space, utilities, secretarial and administrative support services. For the three months ended March 31, 2021, the Company incurred $30,000 for such services. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Registration Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered
into a registration and stockholders rights agreement pursuant to which our Sponsor is entitled to certain registration rights with respect to the private placement warrants, the warrants issuable upon conversion of working capital loans (if any)
and the MAAC Class&nbsp;A Shares issuable upon exercise of the foregoing and upon conversion of the Founder Shares, and, upon completion of our initial Business Combination, to nominate individuals for election to our board of directors, as long as
our Sponsor holds any securities covered by the registration and stockholder rights agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">405 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Policy for Approval of Related Party Transactions </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee of our board of directors adopted a charter, providing for the review, approval and/or ratification of &#147;related party
transactions,&#148; which are those transactions required to be disclosed pursuant to Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> as promulgated by the SEC, by the audit committee. At its meetings, the audit committee will be
provided with the details of each new, existing or proposed related party transaction, including the terms of the transaction, any contractual restrictions that the company has already committed to, the business purpose of the transaction and the
benefits of the transaction to the company and to the relevant related party. Any member of the committee who has an interest in the related party transaction under review by the committee shall abstain from voting on the approval of the related
party transaction, but may, if so requested by the chairman of the committee, participate in some or all of the committee&#146;s discussions of the related party transaction. Upon completion of its review of the related party transaction, the
committee may determine to permit or to prohibit the related party transaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lock-Up Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May 1, 2021 and June 9, 2021, Roivant, on the one hand, and the MAAC Sponsor, both of the MAAC Independent Directors and certain Roivant
equityholders, on the other hand, entered into lock-up agreements substantially in the form attached to this proxy statement/prospectus as Annex F (the &#147;Lock-Up Agreements&#148;), pursuant to which, among other things, the MAAC Sponsor, MAAC
Independent Directors and such Roivant equityholders have agreed not to, subject to, and conditioned upon the effectiveness of, the Closing, effect any sale or distribution of the Roivant Common Shares (including those underlying incentive equity
awards or Roivant Warrants) held by the MAAC Sponsor, MAAC Independent Directors or such equityholders as of immediately following the Closing during the applicable lock-up period, subject to customary exceptions. The lock-up period applicable to
Roivant Common Shares held by the MAAC Sponsor and MAAC Independent Directors as of immediately following the Closing will be (i)&nbsp;with respect to 25% of the Roivant Common Shares held by the MAAC Sponsor, six months following the Closing,
(ii)&nbsp;with respect to an additional 25% of the Roivant Common Shares held by the MAAC Sponsor, the earlier of twelve months following the achievement of certain price-based vesting restrictions or six years from the Closing and (iii)&nbsp;with
respect to 50% of the Roivant Common Shares held by the MAAC Sponsor, thirty-six months following the Closing. The Roivant warrants and the Roivant Common Shares underlying warrants held by the MAAC Sponsor as of immediately following the Closing
will be subject to a corresponding lock-up period for (a)&nbsp;with respect to 25% of such warrants held by the MAAC Sponsor, six months from the Closing, (b)&nbsp;with respect to an additional 25% of such warrants held by the MAAC Sponsor, twelve
months from Closing and (c)&nbsp;with respect to 50% of such warrants held by the MAAC Sponsor, thirty-six months from the Closing. The lock-up period applicable to Roivant Common Shares (including those underlying incentive equity awards) held by
certain Roivant equityholders as of immediately following the Closing will be (x)&nbsp;with respect to 25% of the Roivant Common Shares (including those underlying incentive equity awards) held by such Roivant equityholders, six months following the
Closing, (y)&nbsp;with respect to an additional 25% of the Roivant Common Shares (including those underlying incentive equity awards) held by such Roivant equityholders, twelve months following the Closing and (z)&nbsp;with respect to 50% of the
Roivant Common Shares (including those underlying incentive equity awards) held by such Roivant equityholders, thirty-six months following the Closing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sponsor Support Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Business Combination Agreement, MAAC, the MAAC Sponsor, Roivant and each of James C. Momtazee, George
Barrett, Stephen Oesterle and Maria C. Walker, each of whom is a member of MAAC&#146;s board of directors and/or management (collectively, the &#147;MAAC Insiders&#148;), entered into the Sponsor Support Agreement (the &#147;Sponsor Support
Agreement&#148;), pursuant to which, among other things: (i)&nbsp;the MAAC Sponsor and the MAAC Insiders have each reaffirmed his, her or its obligations in existing arrangements with MAAC to vote in favor of each of the proposals to be voted upon
at the meeting of MAAC stockholders in connection with the Business Combination, including approval of the Business Combination Agreement and the transactions contemplated thereby; (ii)&nbsp;the MAAC Sponsor has waived any adjustment to the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">406 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conversion ratio set forth in the governing documents of MAAC or any other anti-dilution or similar protection with respect to the MAAC Class&nbsp;B Shares that may result from the transactions
contemplated by the Business Combination; (iii)&nbsp;subject to, and conditioned upon, the occurrence of and effective as of, the effective time of the Merger, the MAAC Sponsor and the MAAC Insiders have each agreed to terminate certain existing
arrangements with MAAC, including existing registration rights and the existing <FONT STYLE="white-space:nowrap">lock-up</FONT> obligations with respect to his, her or its MAAC Shares; (iv)&nbsp;the MAAC Sponsor and the MAAC Insiders that hold
Roivant Common Shares immediately following the effective time of the Merger will be granted the right to include his, her or its Roivant Common Shares in a resale registration statement to be filed in connection with the transactions contemplated
by the Subscription Agreements following the effective time of the Merger; (v)&nbsp;the MAAC Sponsor, Roivant and MAAC have each agreed to certain covenants related to the expiration or termination of the waiting period under the HSR Act with
respect to the issuance of Roivant Common Shares to the MAAC Sponsor in connection with the Business Combination; and (vi)&nbsp;subject to, and conditioned upon the occurrence of, and effective as of immediately after, the effective time of the
Merger, (a)&nbsp;twenty percent of the Roivant Common Shares issued to the MAAC Sponsor in respect of its MAAC Class&nbsp;B Shares will be subject to the vesting conditions described below and the other restrictions set forth in the Sponsor Support
Agreement (the &#147;$15 <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares&#148;) and (b)&nbsp;ten percent of the Roivant Common Shares issued to the MAAC Sponsor in respect of its MAAC Class&nbsp;B Shares will be subject to the vesting
conditions described below and the other restrictions set forth in the Sponsor Support Agreement (the &#147;$20 <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares&#148; and, together with the $15 <FONT STYLE="white-space:nowrap">Earn-Out</FONT>
Shares, the <FONT STYLE="white-space:nowrap">&#147;Earn-Out</FONT> Shares&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $15
<FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares will vest if the closing price of the Roivant Common Shares is greater than or equal to $15.00 over any twenty out of thirty trading day period during the five year period following the
Closing, and the $20 <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares will vest if the closing price of the Roivant Common Shares is greater than or equal to $20.00 over any twenty out of thirty trading day period during the five year period
following the Closing. The five year vesting period described in the preceding sentence will, if a definitive purchase agreement with respect to a Sale (as defined in the Sponsor Support Agreement) is entered into on or prior to the end of such
period, be extended to the earlier of one day after the consummation of such Sale and the termination of such definitive transaction agreement, and if a Sale occurs during such five year (or, as applicable, longer) vesting period, then all of the <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Shares unvested as of such time will automatically vest immediately prior to the consummation of such Sale. If any <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares have not vested on or prior to the
end of the five year (or, as applicable, longer) vesting period, then such <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares will be forfeited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June 9, 2021, MAAC, the MAAC Sponsor, Roivant and the MAAC Insiders entered into Amendment No. 1 to the Sponsor Support Agreement
(&#147;SSA Amendment&#148;) pursuant to which the Sponsor Support Agreement was revised to reflect the MAAC Independent Directors and Roivant entering into respective Lock-Up Agreements. In particular, among other things, the SSA Amendment revised
the Sponsor Support Agreement to subject the Roivant Common Shares issued to each MAAC Independent Director in respect of his or her shares of MAAC Class B common stock to the same vesting conditions applicable to the Roivant Common Shares issued to
the MAAC Sponsor. Specifically, (a) twenty percent of the Roivant Common Shares issued to each MAAC Independent Director will be treated as $15 Earn-Out Shares (as defined in the Sponsor Support Agreement) and (b) ten percent of the Roivant Common
Shares issued to each MAAC Independent Director will be treated as $20 Earn-Out Shares (as defined in the Sponsor Support Agreement). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director
Independence </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nasdaq listing standards require that a majority of our board of directors be independent. Our board of directors has
determined that George Barrett and Dr.&nbsp;Stephen Oesterle are &#147;independent directors&#148; as defined in the Nasdaq listing standards. Our independent directors conduct regularly scheduled sessions at which only independent directors are
present. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">407 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification of Directors and Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amended and restated Certificate of Incorporation provides that we will indemnify our directors and officers to the fullest extent
permitted by the DGCL. In addition, the amended and restated Certificate of Incorporation provides that our directors will not be liable for monetary damages for breach of fiduciary duty to the fullest extent permitted by the DGCL. There is no
pending litigation or proceeding naming any of MAAC&#146;s respective directors or officers to which indemnification is being sought, and we are not aware of any pending or threatened litigation that may result in claims for indemnification by any
director or officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">408 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_27"></A>CERTAIN ROIVANT RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Unless the context otherwise requires, references in this section to &#147;we,&#148; &#147;us,&#148; &#147;our&#148; and the &#147;Company&#148;
refer to Roivant and its subsidiaries and affiliates in the present tense or from and after the consummation of the Business Combination, as the context requires. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a description of transactions occurring during our last three fiscal years or currently proposed, to which (i)&nbsp;Roivant
Sciences Ltd. has been a participant, (ii)&nbsp;the amount involved exceeded or will exceed $120,000 and (iii)&nbsp;any of Roivant&#146;s directors, executive officers or holders of more than 5% of Roivant&#146;s share capital, or any members of
their immediate family (collectively &#147;Roivant Related Parties&#148;), had or will have a direct or indirect material interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other
than as described below, there have not been, nor are there any currently proposed, transactions or series of similar transactions meeting these criteria to which we have been or will be a party other than compensation arrangements, which are
described where required under &#147;Executive Compensation&#151;Director Compensation&#148; and &#147;Executive Compensation&#151;Post-Business Combination Director Compensation Program.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transactions with Sumitomo Dainippon Pharma Co., Ltd. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;31, 2019, we entered into a transaction agreement with Sumitomo (the &#147;Sumitomo Transaction Agreement&#148;), which closed
on December&nbsp;27, 2019 (the &#147;Sumitomo Closing Date&#148;). Pursuant to the Sumitomo Transaction Agreement, we transferred our entire ownership interest in Myovant, Urovant, Enzyvant, Altavant and Spirovant (collectively &#147;Sumitovant
Vants&#148;) to a newly formed, wholly-owned entity (&#147;Sumitovant&#148;). Our ownership interest in Sumitovant was then transferred to Sumitomo, such that following the Sumitomo Closing Date, Sumitovant and its subsidiaries, including the
Sumitovant Vants, were each directly or indirectly owned by Sumitomo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, in connection with the Sumitomo Transaction
Agreement, we (i)&nbsp;granted Sumitomo options to purchase all, or in the case of Dermavant, 75%, of our ownership interests in six other subsidiaries (Dermavant, Genevant, Lysovant, Metavant, Cytovant and Sinovant (collectively the &#147;Option
Vants&#148;)), (ii) provided Sumitomo and Sumitovant with certain rights over and access to our proprietary technology platforms, DrugOme and Digital Innovation, and (iii)&nbsp;transferred 26,952,143 of our common shares to Sumitomo. On the Sumitomo
Closing Date, the Company received approximately $3.0&nbsp;billion in cash, resulting in a gain of $2.0&nbsp;billion after taking into account all of the components of the transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the Sumitomo Transaction Agreement, (i)&nbsp;Roivant, Sumitomo and Sumitovant entered into a transition services agreement,
whereby each of the parties thereto agreed to provide certain services to one another at cost for a period of time following the Sumitomo Closing Date and (ii)&nbsp;Roivant and Sumitomo entered into a strategic cooperation agreement relating to
certain ongoing technology-related collaborations between the parties. Pursuant to the terms of the transition services agreement and strategic cooperation agreement, we billed Sumitovant $1.4&nbsp;million and $0.2&nbsp;million, net of amounts
billed by Sumitovant to RSL, respectively, during the years ended March 31, 2021 and 2020 for costs incurred on behalf of Sumitovant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, on the Sumitomo Closing Date, Sumitomo deposited $75.0&nbsp;million of the consideration payable pursuant to the Sumitomo
Transaction Agreement in a segregated escrow account for the purpose of fulfilling our indemnification obligations that may become due to Sumitomo. Upon the expiration of the escrow period, being 18 months from the Sumitomo Closing Date, any
remaining escrow funds will be disbursed to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the Sumitomo Closing Date, we also entered into an agreement with Sumitomo, pursuant
to which we granted Sumitomo a right of first refusal with respect to potential transfers of Roivant&#146;s ownership interest in common shares of Sio Gene Therapies (formerly Axovant Gene Therapies) (the &#147;ROFR&#148;). Among other things, such
agreement provides that Roivant must promptly deliver notice to Sumitomo if it desires to transfer equity </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">409 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interests of Sio Gene Therapies and provide Sumitomo with an opportunity to make a matching offer for the subject shares in accordance with the terms and conditions set forth therein. The ROFR
terminates on October&nbsp;31, 2024. The ROFR also includes certain notification rights in favor of Sumitomo, in the event Roivant takes certain specified corporate actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the foregoing transactions with Sumitomo, our board of directors approved an exchange and offer to repurchase equity
securities for up to $1.0&nbsp;billion of the proceeds received from Sumitomo. See &#147;&#151;Equity Exchange and Offer to Purchase.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended March 31, 2021 and 2020, we paid Sumitomo a $1.0 million access fee pursuant to the strategic cooperation agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May&nbsp;2021, we entered into an Asset Purchase Agreement with Sumitomo and its subsidiary Sumitomo Pharmaceuticals (Suzhou) Co.,
Ltd. (&#147;SPC&#148;) (the &#147;Asset Purchase Agreement&#148;). The transactions contemplated by the Asset Purchase Agreement closed in June 2021. Pursuant to the Asset Purchase Agreement: (i)&nbsp;Sumitomo terminated all of its existing options
to acquire our equity interests in the Option Vants; (ii)&nbsp;we transferred and assigned to SPC all of our intellectual property, development, regulatory and commercialization rights to (a)&nbsp;lefamulin in Mainland China, Taiwan, Hong Kong, and
Macau (collectively &#147;Greater China&#148;), (b) vibegron in Mainland China, (c)&nbsp;rodatristat ethyl in Greater China and South Korea, and <FONT STYLE="white-space:nowrap">(d)&nbsp;RVT-802</FONT> in Greater China and South Korea; (iii)&nbsp;we
will receive a $5&nbsp;million cash payment; and (iv)&nbsp;Sumitomo entered into an agreement with us in respect of certain future collaborations with Genevant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Exchange and Offer to Purchase </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
February 2020, we commenced (i)&nbsp;an offer to purchase our common shares from our eligible shareholders (including certain of our eligible employees and former employees) at a price per share of $37.10, (ii) an offer to surrender for cash
performance options and capped value appreciation rights (&#147;CVARs&#148;) issued in exchange for certain performance restricted stock units (&#147;pRSUs&#148;) held by certain of our eligible employees and former employees, whereby such
holder&#146;s eligible pRSUs were exchanged at a rate of approximately 0.7 performance options per eligible pRSU and, if applicable, approximately 0.7 CVARs per eligible pRSU (the &#147;Exchange&#148;) and, immediately thereafter, 11.23% of such
performance options and CVARs were surrendered to us for cash and (iii)&nbsp;an offer to purchase outstanding options from certain of our eligible employees and former employees, the maximum aggregate repurchase value being equal to the lesser of
(a)&nbsp;the fair market value of approximately 11.23% of the eligible holder&#146;s outstanding vested and unvested unexercised options held as of December&nbsp;27, 2019 and (b)&nbsp;the fair market value of 100% of the eligible holder&#146;s
outstanding options that were vested and exercisable as of December&nbsp;27, 2019 (subject to certain adjustments). The foregoing transactions are referred to herein as the &#147;2020 Equity Exchange and Offer to Purchase.&#148; We additionally
entered into an agreement with our Founder to repurchase a portion of his common stock held and exchange his Performance RSUs for performance options and capped value appreciation rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In total, in the 2020 Equity Exchange and Offer to Purchase, including participation by certain Roivant Related Parties, we purchased
25,625,933 Roivant Common Shares, exchanged 18,016,310 primarily for pRSUs for performance options and CVARs, received 631,527 surrendered performance options, received 518,893 surrendered CVARs and purchased 895,923 options in connection with the
various offers to exchange and purchase, for an aggregate purchase price of approximately $1.0 billion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2018 Equity Financing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From September through December 2018, Roivant completed an equity financing in which certain Roivant Related Parties participated: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Viking Global Entities (as defined herein) and certain of their affiliates purchased 155,038 Roivant Common
Shares for an aggregate purchase price of $4,999,975. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">410 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dexxon Holdings Ltd. purchased 775,194 Roivant Common Shares for an aggregate purchase price of $25,000,006.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">SVF Investments (as defined herein) purchased 1,085,271 Roivant Common Shares for an aggregate purchase price of
$34,999,989. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the QVT Entities (as defined herein) and certain of their affiliates purchased 62,015 Roivant Common Shares for
an aggregate purchase price of $1,999,983. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Employment and Compensatory Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Brett Venker, currently Director, Compensation and Data, is the brother of Eric Venker, Roivant&#146;s President and Chief Operating Officer.
During the fiscal year ended March&nbsp;31, 2019, Brett Venker earned total cash compensation, consisting of salary and bonus, of $205,048 and was granted incentive equity awards with an aggregate grant date fair value, as computed in accordance
with FASB ASC 718, of $1,025,505. During the fiscal year ended March&nbsp;31, 2020, Dr.&nbsp;Venker earned total cash compensation, consisting of salary and bonus, of $338,273 and was granted incentive equity awards with an aggregate grant date fair
value, as computed in accordance with FASB ASC 718, of $64,140. During the fiscal year ended March&nbsp;31, 2021, Dr.&nbsp;Venker earned total cash compensation, consisting of salary and bonus, of $360,634 and was granted incentive equity awards
with an aggregate grant date fair value, as computed in accordance with FASB ASC 718, of $400,039. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted and intend to continue to grant equity awards to our executive officers and certain of our directors. For a description of
these equity awards, see the sections titled &#147;Executive Compensation&#151;Director Compensation&#148; and &#147;Executive Compensation&#151;Post-Business Combination Director Compensation Program.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection
with this offering, we will enter into indemnification agreements with each of our directors and executive officers. These indemnification agreements will provide the directors and executive officers with contractual rights to indemnification and
expense advancement that are, in some cases, broader than the specific indemnification provisions contained under Bermuda law. See the section titled &#147;Description of Securities&#151;Indemnification of Directors and Officers&#148; for additional
information regarding indemnification under Bermuda law and our amended and restated <FONT STYLE="white-space:nowrap">bye-laws.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Person
Transaction Policy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to adopt a related person transaction policy that sets forth our procedures for the identification,
review, consideration and approval or ratification of related person transactions. The policy will become effective immediately upon the consummation of the Business Combination. For purposes of our policy only, a related person transaction is a
transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we and any related person are, were or will be participants in which the amount involved exceeds $120,000. Transactions
involving compensation for services provided to us as an employee or director are not covered by this policy. A related person is any executive officer, director or beneficial owner of more than 5% of any class of Roivant&#146;s voting securities,
and any of their respective immediate family members and any entity owned or controlled by such persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the policy, if a
transaction has been identified as a related person transaction, including any transaction that was not a related person transaction when originally consummated or any transaction that was not initially identified as a related person transaction
prior to consummation, our management must present information regarding the related person transaction to our audit committee, or, if audit committee approval would be inappropriate, to another independent body of our board of directors, for
review, consideration and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">411 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval or ratification. The presentation must include a description of, among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to us of
the transaction and whether the transaction is on terms that are comparable to the terms available to or from, as the case may be, an unrelated third party or to or from employees generally. Under the policy, we will collect information that we deem
reasonably necessary from each director, executive officer and, to the extent feasible, significant shareholder to enable us to identify any existing or potential related-person transactions and to effectuate the terms of the policy. In addition,
under our Code of Conduct that we expect to adopt prior to the closing of this offering, our employees and directors will have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise
to a conflict of interest. In considering related person transactions, our audit committee, or other independent body of our board of directors, will take into account the relevant available facts and circumstances including, but not limited to:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risks, costs and benefits to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact on a director&#146;s independence in the event that the related person is a director, immediate family
member of a director or an entity with which a director is affiliated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of other sources for comparable services or products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms available to or from, as the case may be, unrelated third parties or to or from employees generally.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The policy requires that, in determining whether to approve, ratify or reject a related person transaction, our audit
committee, or other independent body of our board of directors, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our shareholders, as our audit committee, or
other independent body of our board of directors, determines in the good faith exercise of its discretion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Post-Business Combination Arrangements
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the business combination, certain agreements with certain Roivant Related Parties were entered into or will be
entered into pursuant to the merger agreement. The agreements described in this section, or forms of such agreements as they will be in effect substantially concurrently with the completion of the business combination, are filed as exhibits to the
registration statement of which this prospectus forms a part, and the following descriptions are qualified by reference thereto. These agreements include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shareholder support agreements (see the section titled &#147;The Business Combination&#151;Related
Agreements&#151;Support Agreements&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sponsor support agreement (see the section titled &#147;The Business Combination&#151;Related
Agreements&#151;Sponsor Support Agreement&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">PIPE subscription agreements (see the sections titled &#147;The Business Combination Proposal&#151;Related
Agreements&#151;Subscription Agreements&#148; and &#147;Beneficial Ownership of Securities&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our amended and restated registration rights agreement (see the section titled &#147;The Business Combination
Proposal&#151;Related Agreements&#151;Restated Registration Rights Agreement&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the MAAC Sponsor and certain Roivant
equityholders and our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> which include <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions applicable to other Roivant equityholders (see the section titled &#147;Roivant
Common Shares Eligible For Future <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Sale&#151;Lock-up-Periods</FONT></FONT> and Registration Rights&#151;Roivant, the MAAC Sponsor and Certain Roivant Equityholders <FONT
STYLE="white-space:nowrap">Lock-ups&#148;</FONT> and <FONT STYLE="white-space:nowrap">&#147;&#151;Bye-laws</FONT> <FONT STYLE="white-space:nowrap">Lock-up&#148;).</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">412 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPARISON OF CORPORATE GOVERNANCE AND SHAREHOLDER RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Comparison of Shareholder Rights under Applicable Corporate Law Before and After the Business Combination </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roivant&#146;s corporate affairs are governed by its memorandum of association
<FONT STYLE="white-space:nowrap">and&nbsp;bye-laws&nbsp;and</FONT> by the laws of Bermuda. The provisions of the Companies Act, which apply to Roivant, differ in certain material respects from laws generally applicable to U.S. companies incorporated
in the State of Delaware, including MAAC, and their stockholders. The following is a summary of significant differences between the Companies Act (including modifications adopted pursuant to Roivant&#146;s&nbsp;amended and restated <FONT
STYLE="white-space:nowrap">bye-laws</FONT> to be adopted upon closing of the Merger)&nbsp;and Bermuda common law applicable to Roivant and its shareholders and the provisions of the Delaware General Corporation Law applicable to U.S. companies
organized under the laws of Delaware, including MAAC, and their stockholders. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bermuda</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Shareholder Meetings</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;May be called by the principal executive officer, the chairman of the board of
directors, any two directors or a director and the secretary or the board of directors and must be called upon the request of shareholders holding not less than 10% of <FONT STYLE="white-space:nowrap">the&nbsp;paid-up&nbsp;capital</FONT> of the
company carrying the right to vote at general meetings.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;May be held in or outside Bermuda.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Notice:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Shareholders must be given at
least five days&#146; advance notice of a general meeting, but the unintentional failure to give notice to any person does not invalidate the proceedings at a meeting.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Notice of general meetings must specify the place, the day and hour of the meeting and in the case
of special general meetings, the general nature of the business to be considered.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">&#149;&#8195;&#8202;Our&nbsp;bye-laws&nbsp;provide</FONT> that at least 14 days&#146;
notice of an annual general meeting</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;May be held at such time or place as designated in the certificate of
incorporation or the bylaws, or if not so designated, as determined by the board of directors.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;May be held in or outside of Delaware.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Notice:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Written notice shall be given
not less than ten nor more than 60 days before the meeting.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Whenever stockholders are required to take any action at a meeting, a written notice of the
meeting shall be given, which shall state the place, if any, date and hour of the meeting, and the means of remote communication, if any.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">413 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bermuda</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.00em; font-size:10pt; font-family:Times New Roman">and 10 days&#146; notice of a special general meeting must be given to each shareholder entitled to vote at such
meeting.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Shareholders&#146; Voting Rights</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Shareholders may act by written consent to elect directors. Shareholders may not
act by written consent to remove a director or auditor.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Generally, except as otherwise provided in
<FONT STYLE="white-space:nowrap">the&nbsp;bye-laws,&nbsp;or</FONT> the Companies Act, any action or resolution requiring approval of the shareholders may be passed by a simple majority of votes cast. Any person authorized to vote may authorize
another person or persons to act for him or her by proxy.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;The voting rights of shareholders are regulated by a
<FONT STYLE="white-space:nowrap">company&#146;s&nbsp;bye-laws&nbsp;and,</FONT> in certain circumstances, by the Companies Act. <FONT STYLE="white-space:nowrap">The&nbsp;bye-laws&nbsp;may</FONT> specify the number to constitute a quorum and if <FONT
STYLE="white-space:nowrap">the&nbsp;bye-laws&nbsp;permit,</FONT> a general meeting of the shareholders of a company may be held with only one individual present if the requirement for a quorum is satisfied.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">&#149;&#8195;&#8202;Roivant&#146;s&nbsp;bye-laws&nbsp;provide</FONT> that the quorum
required for a general meeting of shareholders is two or more persons present in person and representing in person or by proxy in excess of 50% of all issued and outstanding voting shares.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">&#149;&#8195;&#8202;The&nbsp;bye-laws&nbsp;may</FONT> provide for cumulative voting,
although Roivant&#146;s <FONT STYLE="white-space:nowrap">bye-laws&nbsp;do</FONT> not.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Unless otherwise provided in the certificate of incorporation, stockholders may
act by written consent to elect directors.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Any person authorized to vote may authorize another person or persons to act for him or her by
proxy.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Quorum is a
majority of shares entitled to vote at the meeting unless otherwise set in the constitutional documents, but cannot be less <FONT STYLE="white-space:nowrap">than&nbsp;one-third&nbsp;of</FONT> shares entitled to vote at the meeting.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;When a quorum is once present
to organize a meeting, it is not broken by the subsequent withdrawal of any stockholders.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;The certificate of incorporation may provide for cumulative voting.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Any two or more corporations
existing under the laws of the state may merge into a single corporation pursuant to a board resolution and upon the majority vote by stockholders of each constituent corporation at an annual or special meeting.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Every corporation may at any
meeting of the board sell, lease or exchange all or substantially all of its property and assets as its board deems expedient and for the best interests of the corporation when so authorized by a resolution adopted by the holders of a majority of
the</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">414 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bermuda</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;The
amalgamation or merger of a Bermuda company with another company or corporation (other than certain affiliated companies) requires the amalgamation or merger agreement to be approved by the company&#146;s board of directors and by its shareholders.
Unless the company&#146;s <FONT STYLE="white-space:nowrap">bye-laws</FONT> provide otherwise, the approval of 75% of the shareholders voting at such meeting is required to approve the amalgamation or merger agreement, and the quorum for such meeting
must be two or more persons holding or representing more <FONT STYLE="white-space:nowrap">than&nbsp;one-third&nbsp;of</FONT> the issued shares of the company.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Any company that is the wholly owned subsidiary of a holding company, or one or more companies
which are wholly owned subsidiaries of the same holding company, may amalgamate or merge without the vote or consent of shareholders provided that the approval of the board of directors is obtained and that a director or officer of each such company
signs a statutory solvency declaration in respect of the relevant company.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Any mortgage, charge or pledge of a company&#146;s property and assets may be authorized without
the consent of shareholders subject to any restrictions under <FONT STYLE="white-space:nowrap">the&nbsp;bye-laws.</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:0.00em; font-size:10pt; font-family:Times New Roman">outstanding stock of a corporation entitled to vote.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Any corporation owning at
least 90% of the outstanding shares of each class of another corporation may merge the other corporation into itself and assume all of its obligations without the vote or consent of stockholders; however, in case the parent corporation is not the
surviving corporation, the proposed merger shall be approved by a majority of the outstanding stock of the parent corporation entitled to vote at a duly called stockholder meeting.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Any mortgage or pledge of a
corporation&#146;s property and assets may be authorized without the vote or consent of stockholders, except to the extent that the certificate of incorporation otherwise provides.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Directors</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;The board of directors must consist of at least one director.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;The number of directors is
fixed by <FONT STYLE="white-space:nowrap">the&nbsp;bye-laws,&nbsp;and</FONT> any changes to such number must be approved by the board of directors and/or the</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;The board of directors must consist of at least one member.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Number of board members shall
be fixed by the bylaws, unless the certificate of incorporation fixes the number of directors, in which case a</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">415 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bermuda</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:0.00em; font-size:10pt; font-family:Times New Roman">shareholders in accordance with the <FONT STYLE="white-space:nowrap">company&#146;s&nbsp;bye-laws.</FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Removal:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Under Roivant&#146;s <FONT
STYLE="white-space:nowrap">bye-laws,</FONT> the members entitled to vote for the election of directors may, at any special general meeting convened and held in accordance with the <FONT STYLE="white-space:nowrap">bye-laws,</FONT> by the affirmative
vote of at least 66 and 2/3% of the issued and outstanding voting shares entitled to vote for the election of directors, remove a director only with cause. &#147;Cause&#148; for these purposes means (i)&nbsp;a conviction for a criminal offence
involving dishonesty or (ii)&nbsp;engaging in conduct which brings the director or Roivant into disrepute and which results in material financial detriment to Roivant.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:0.00em; font-size:10pt; font-family:Times New Roman">change in the number shall be made only by amendment of the certificate of incorporation. The bylaws may provide that the
board may increase the size of the board and fill any vacancies.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Removal:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Any or all of the directors may be removed, with or without cause, by the holders of a majority of
the shares entitled to vote at an election of directors unless the certificate of incorporation otherwise provides.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;In the case of a classified board, stockholders may effect removal of any or all directors only
for cause.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;In the case of
a corporation having cumulative voting, if less than the entire board is to be removed, no director may be removed without cause if the votes cast against such director&#146;s removal would be sufficient to elect such director if then cumulatively
voted at an election of the entire board.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Duties of Directors</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;The Companies Act authorizes the directors of a company, subject to <FONT
STYLE="white-space:nowrap">its&nbsp;bye-laws,&nbsp;to</FONT> exercise all powers of the company except those that are required by the Companies Act or the <FONT STYLE="white-space:nowrap">company&#146;s&nbsp;bye-laws&nbsp;to</FONT> be exercised by
the shareholders of the company. <FONT STYLE="white-space:nowrap">Roivant&#146;s&nbsp;bye-laws&nbsp;provide</FONT> that Roivant&#146;s business is to be managed and conducted by</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Under Delaware law, the business and affairs of a corporation are managed by
or under the direction of its board of directors. In exercising their powers, directors are charged with a fiduciary duty of care to protect the interests of the corporation and a fiduciary duty of loyalty to act in the best interests of its
stockholders. The duty of care</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">416 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bermuda</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:0.00em; font-size:10pt; font-family:Times New Roman">Roivant&#146;s board of directors. At common law, members of a board of directors owe a fiduciary duty to the company to
act in good faith in their dealings with or on behalf of the company and exercise their powers and fulfill the duties of their office honestly. This duty includes the following essential elements:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;a duty to act in good faith
in the best interests of the company;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;a duty not to make a personal profit from opportunities that arise from the office of
director;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;a duty to avoid
conflicts of interest; and</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;a duty to exercise powers for the purpose for which such powers were intended.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;The Companies Act imposes a
duty on directors and officers of a Bermuda company:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;to act honestly and in good faith with a view to the best interests of the company; and</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;to exercise the care,
diligence and skill that a reasonably prudent person would exercise in comparable circumstances.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;The Companies Act also imposes various duties on directors and officers of a company with respect
to certain matters of management and administration of the company. Under Bermuda law, directors and officers generally owe fiduciary duties to the</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:0.00em; font-size:10pt; font-family:Times New Roman">requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar
circumstances. Under this duty, a director must inform himself of, and disclose to stockholders, all material information reasonably available regarding a significant transaction. The duty of loyalty requires that a director act in a manner he
reasonably believes to be in the best interests of the corporation. He must not use his corporate position for personal gain or advantage. This duty prohibits self-dealing by a director and mandates that the best interest of the corporation and its
stockholders take precedence over any interest possessed by a director, officer or controlling shareholder and not shared by the stockholders generally.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;In general, actions of a director are presumed to have been made on an informed basis, in good
faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties. Should such evidence be presented concerning a
transaction by a director, a director must prove the procedural fairness of the transaction, and that the transaction was of fair value to the corporation.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">417 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bermuda</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:0.00em; font-size:10pt; font-family:Times New Roman">company itself, not to the company&#146;s individual shareholders, creditors or any class thereof. Roivant&#146;s
shareholders may not have a direct cause of action against Roivant&#146;s directors.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Takeovers</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;An acquiring party is generally able to acquire compulsorily the common shares
of minority holders of a company in the following ways:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;By a procedure under the Companies Act known as a &#147;scheme of arrangement.&#148; A scheme of
arrangement could be effected by obtaining the agreement of the company and of holders of common shares, representing in the aggregate a majority in number and at least 75% in value of the common shareholders present and voting at a court ordered
meeting held to consider the scheme of arrangement. The scheme of arrangement must then be sanctioned by the Bermuda Supreme Court. If a scheme of arrangement receives all necessary agreements and sanctions, upon the filing of the court order with
the Registrar of Companies in Bermuda, all holders of common shares could be compelled to sell their shares under the terms of the scheme of arrangement.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;By acquiring pursuant to a tender offer 90% of the shares or class of shares not already owned by,
or by a nominee for, the</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Delaware law provides that a parent corporation, by resolution of its board of
directors and without any stockholder vote, may merge with any subsidiary of which it owns at least 90% of each class of its capital stock. Upon any such merger, and in the event the parent corporate does not own all of the stock of the subsidiary,
dissenting stockholders of the subsidiary are entitled to certain appraisal rights.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Delaware law also provides, subject to certain exceptions, that if a person acquires 15% of voting
stock of a company, the person is an &#147;interested stockholder&#148; and may not engage in &#147;business combinations&#148; with the company for a period of three years from the time the person acquired 15% or more of voting stock, unless the
corporation opts out of the statutory provision in its certificate of incorporation.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">418 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bermuda</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:0.00em; font-size:10pt; font-family:Times New Roman">acquiring party (the offeror), or any of its subsidiaries. If an offeror has, within four months after the making of an
offer for all the shares or class of shares not owned by, or by a nominee for, the offeror, or any of its subsidiaries, obtained the approval of the holders of 90% or more of all the shares to which the offer relates, the offeror may, at any time
within two months beginning with the date on which the approval was obtained, by notice compulsorily acquire the shares of any nontendering shareholder on the same terms as the original offer unless the Supreme Court of Bermuda (on application made
within <FONT STYLE="white-space:nowrap">a&nbsp;one-month&nbsp;period</FONT> from the date of the offeror&#146;s notice of its intention to acquire such shares) orders otherwise.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Where the acquiring party or
parties hold not less than 95% of the shares or a class of shares of the company, by acquiring, pursuant to a notice given to the remaining shareholders or class of shareholders, the shares of such remaining shareholders or class of shareholders.
When this notice is given, the acquiring party is entitled and bound to acquire the shares of the remaining shareholders on the terms set out in the notice, unless a remaining</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">419 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bermuda</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.00em; font-size:10pt; font-family:Times New Roman">shareholder, within one month of receiving such notice, applies to the Supreme Court of Bermuda for an appraisal of the
value of their shares. This provision only applies where the acquiring party offers the same terms to all holders of shares whose shares are being acquired.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Dissenters&#146; Rights of Appraisal</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;A dissenting shareholder (that did not vote in favor of the amalgamation or
merger) of a Bermuda exempted company is entitled to apply to the Bermuda Court within one month of the notice of the shareholder meeting to approve the amalgamation or merger for an appraisal of the fair value of his or her shares.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;With limited exceptions, appraisal rights shall be available for the shares of
any class or series of stock of a corporation in a merger or consolidation.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;The certificate of incorporation may provide that appraisal rights are available for shares as a
result of an amendment to the certificate of incorporation, any merger or consolidation or the sale of all or substantially all of the assets.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Dissolution</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Under Bermuda law, a solvent company may be wound up by way of a
shareholders&#146; voluntary liquidation. Prior to the company entering liquidation, a majority of the directors shall each make a statutory declaration, which states that the directors have made a full enquiry into the affairs of the company and
have formed the opinion that the company will be able to pay its debts within a period of 12 months of the commencement of the winding up and must file the statutory declaration with the Registrar of Companies in Bermuda. The general meeting will be
convened primarily for the purposes of passing a resolution that the company be</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Under Delaware law, a corporation may voluntarily dissolve (1)&nbsp;if a
majority of the board of directors adopts a resolution to that effect and the holders of a majority of the issued and outstanding shares entitled to vote thereon vote for such dissolution; or (2)&nbsp;if all stockholders entitled to vote thereon
consent in writing to such dissolution.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">420 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bermuda</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.00em; font-size:10pt; font-family:Times New Roman">wound up voluntarily and appointing a liquidator. The winding up of the company is deemed to commence at the time of
the passing of the resolution.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Shareholders&#146; Derivative Actions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Class&nbsp;actions and derivative actions are generally not available to
shareholders under Bermuda law. Bermuda courts, however, would ordinarily be expected to permit a shareholder to commence an action in the name of a company to remedy a wrong to the company where the act complained of is alleged to be beyond the
corporate power of the company or illegal, or would result in the violation of the company&#146;s memorandum of association or&nbsp;bye-laws.&nbsp;Furthermore, consideration would be given by a Bermuda court to acts that are alleged to constitute a
fraud against the minority shareholders or, for instance, where an act requires the approval of a greater percentage of the company&#146;s shareholders than that which actually approved it.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;In any derivative suit instituted by a stockholder of a corporation, it shall
be averred in the complaint that the plaintiff was a stockholder of the corporation at the time of the transaction of which he complains or that such stockholder&#146;s stock thereafter devolved upon such stockholder by operation of
law.</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">421 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_28"></A>DESCRIPTION OF SECURITIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Unless the context otherwise requires, references in this section to &#147;we,&#148; &#147;us,&#148; &#147;our&#148; and the &#147;Company&#148; refer to
Roivant and its subsidiaries and affiliates in the present tense or from and after the consummation of the Business Combination, as the context requires. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following description of our share capital and provisions of our memorandum of association and amended and restated
<FONT STYLE="white-space:nowrap">bye-laws</FONT> are summaries. You should also refer to the memorandum of association and the amended and restated <FONT STYLE="white-space:nowrap">bye-laws,</FONT> which are filed as exhibits to the registration
statement of which this proxy statement/prospectus is part. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an exempted company incorporated under the laws of Bermuda. We are registered with the Registrar of Companies in Bermuda under
registration number 48931. We were incorporated on 7&nbsp;April 2014 under the name Valor Biotechnology Ltd. We changed our name to Roivant Sciences Ltd. on 5&nbsp;November 2014. Our registered office is located at Clarendon House, 2 Church Street,
Hamilton HM11, Bermuda. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The objects of our business are unrestricted, and Roivant Sciences Ltd. has the capacity of a natural person. We
can therefore undertake activities without restriction on our capacity. Prior to the consummation of the Business Combination, our shareholders will approve certain amendments to our <FONT STYLE="white-space:nowrap">bye-laws</FONT> that will become
effective upon the closing of this offering. The following description assumes that such amendments have become effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have
been no public takeover offers by third parties for our shares nor any public takeover offers by us for the shares of another company that have occurred during the last or current financial years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Capital </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately following
the closing of the Business Combination and after giving effect to the subdivision of Roivant Common Shares, our authorized share capital will consist of 7,000,000,000 Roivant Common Shares, $0.000000007 par value per common share. As of March 31,
2021, we had 222,669,799 Roivant Common Shares issued and outstanding. All of the issued Roivant Common Shares prior to the closing of this offering are fully paid. Pursuant to our amended and restated
<FONT STYLE="white-space:nowrap">bye-laws,</FONT> subject to the requirements of Nasdaq, and to any resolution of the shareholders to the contrary, our board of directors is authorized to issue any of our authorized but unissued shares. There are no
limitations on the right of <FONT STYLE="white-space:nowrap">non-Bermudians</FONT> or <FONT STYLE="white-space:nowrap">non-residents</FONT> of Bermuda to hold or vote our shares provided Roivant Common Shares remain listed on an appointed stock
exchange, which includes Nasdaq. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of Roivant Common Shares have no <FONT STYLE="white-space:nowrap">pre-emptive,</FONT> redemption, conversion or sinking fund rights.
Holders of Roivant Common Shares are entitled to one vote per share on all matters submitted to a vote of holders of Roivant Common Shares. Unless a different majority is required by law or by our amended and restated
<FONT STYLE="white-space:nowrap">bye-laws,</FONT> resolutions to be approved by holders of Roivant Common Shares require approval by a simple majority of votes cast at a meeting at which a quorum is present. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of our liquidation, dissolution or winding up, the holders of Roivant Common Shares are entitled to share equally and ratably in
our assets, if any, remaining after the payment of all of our debts and liabilities, subject to any liquidation preference on any issued and outstanding preference shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preference Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Bermuda
law and our amended and restated <FONT STYLE="white-space:nowrap">bye-laws,</FONT> our board of directors may, by resolution, establish one or more series of preference shares having such number of shares, designations, dividend rates,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">422 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
relative voting rights, conversion or exchange rights, redemption rights, liquidation rights, rights to elect or appoint directors and other relative participation, optional or other special
rights, qualifications, limitations or restrictions as may be fixed by the board of directors without any further shareholder approval. Such rights, preferences, powers and limitations, as may be established, could have the effect of discouraging an
attempt to obtain control of our company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividend Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Bermuda law, a company may not declare or pay dividends if there are reasonable grounds for believing that (1)&nbsp;the company is, or
would after the payment be, unable to pay its liabilities as they become due; or (2)&nbsp;that the realizable value of its assets would thereby be less than its liabilities. Under our amended and restated
<FONT STYLE="white-space:nowrap">bye-laws,</FONT> each common share is entitled to dividends if, as and when dividends are declared by our board of directors, subject to any preferred dividend right of the holders of any preference shares. We do not
anticipate paying cash dividends in the foreseeable future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Variation of Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If at any time we have more than one class of shares, the rights attaching to any class, unless otherwise provided for by the terms of issue of
the relevant class, may be varied either: (1)&nbsp;with the consent in writing of the holders of 66<SUP STYLE="font-size:85%; vertical-align:top">2/3</SUP>% of the issued shares of that class; or (2)&nbsp;with the sanction of a resolution passed by
a majority of the votes cast at a general meeting of the relevant class of shareholders at which a quorum consisting of at least one person holding or representing a majority of the issued shares of the relevant class is present. Our amended and
restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> specify that the creation or issue of shares ranking equally with existing shares will not, unless expressly provided by the terms of issue of existing shares, vary the rights attached to
existing shares. In addition, the creation or issue of preference shares ranking prior to Roivant Common Shares will not be deemed to vary the rights attached to Roivant Common Shares or, subject to the terms of any other class or series of
preference shares, to vary the rights attached to any other class or series of preference shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer of Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors may, in its absolute discretion and without assigning any reason, refuse to register the transfer of a share on the
basis that it is not fully paid. Our board of directors may also refuse to recognize an instrument of transfer of a share unless it is accompanied by the relevant share certificate and such other evidence of the transferor&#146;s right to make the
transfer as our board of directors shall reasonably require or unless all applicable consents, authorizations and permissions of any governmental agency or body in Bermuda have been obtained. Subject to these restrictions, a holder of Roivant Common
Shares may transfer the title to all or any of his or her Roivant Common Shares by completing an instrument of transfer in writing in such form as our board of directors may accept. The instrument of transfer must be signed by the transferor and
transferee, although in the case of a fully paid share our board of directors may accept the instrument signed only by the transferor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Meetings of
Shareholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Bermuda law, a company is required to convene at least one general meeting of shareholders each calendar year,
which we refer to as the annual general meeting. While Bermuda law permits the shareholders to waive the requirement to hold an annual general meeting by resolution (either for a specific year or a period of time or indefinitely), our amended and
restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> provide that, notwithstanding, an annual general meeting shall be held in each year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Bermuda law provides that a special general meeting of shareholders may be called by the board of directors of a company and must be called
upon the request of shareholders holding not less than 10% of the <FONT STYLE="white-space:nowrap">paid-up</FONT> capital of the company carrying the right to vote at general meetings. Bermuda law also requires that shareholders be given at least
five days&#146; advance notice of a general meeting, but the accidental omission to give </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">423 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
notice to any person does not invalidate the proceedings at a meeting. Our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> provide that our principal executive officer or
the chairperson of our board of directors or any two directors or any director and the secretary or our board of directors may convene an annual general meeting and our principal executive officer or the chairperson of our board of directors or our
board of directors may convene a special general meeting. Under our amended and restated <FONT STYLE="white-space:nowrap">bye-laws,</FONT> at least 14 days&#146; notice of an annual general meeting or 10 days&#146; notice of a special general
meeting must be given to each shareholder entitled to vote at such meeting. This notice requirement is subject to the ability to hold such meetings on shorter notice if such notice is agreed: (1)&nbsp;in the case of an annual general meeting by all
of the shareholders entitled to attend and vote at such meeting; or (2)&nbsp;in the case of a special general meeting by a majority in number of the shareholders entitled to attend and vote at the meeting holding not less than 95% in nominal value
of the shares entitled to vote at such meeting. The quorum required for a general meeting of shareholders is two or more persons present in person at the start of the meeting and representing in person or by proxy in excess of 50% of all issued and
outstanding Roivant Common Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Access to Books and Records and Dissemination of Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Members of the general public have a right to inspect the public documents of a company available at the office of the Registrar of Companies
in Bermuda. These documents include a company&#146;s memorandum of association, including its objects and powers, and certain alterations to the memorandum of association. The shareholders have the additional right to inspect the <FONT
STYLE="white-space:nowrap">bye-laws</FONT> of the company, minutes of general meetings and the company&#146;s audited financial statements, which must be presented in the annual general meeting. The register of members of a company is also open to
inspection by shareholders and by members of the general public without charge. The register of members is required to be open for inspection for not less than two hours in any business day (subject to the ability of a company to close the register
of members for not more than thirty days in a year). A company is required to maintain its share register in Bermuda but may, subject to the provisions of the Companies Act establish a branch register outside of Bermuda. A company is required to
keep at its registered office a register of directors and officers that is open for inspection for not less than two hours in any business day by members of the public without charge. Bermuda law does not, however, provide a general right for
shareholders to inspect or obtain copies of any other corporate records. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Election and Removal of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> will provide that our board of directors shall consist of not less
than five (5)&nbsp;Directors and not more than such maximum number of Directors as the Board may from time to time determine, being initially fifteen (15)&nbsp;Directors. Upon the closing of this offering, our board of directors will consist of six
directors. Our board of directors will be divided into three classes that are, as nearly as possible, of equal size. Each class of directors will be elected for a three-year term of office, but the terms will be staggered so that the term of only
one class of directors expires at each annual general meeting. The initial terms of the Class&nbsp;I, Class&nbsp;II and Class&nbsp;III directors will expire in 2022, 2023 and 2024, respectively. At each succeeding annual general meeting, successors
to the class of directors whose term expires at the annual general meeting will be elected for a three-year term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A shareholder holding
any percentage of the Roivant Common Shares in issue may propose for election as a director someone who is not an existing director or is not proposed by our board of directors. Where a director is to be elected at an annual general meeting, notice
of any such proposal for election must be given not less than 90 days nor more than 120 days before the anniversary of the last annual general meeting prior to the giving of the notice or, in the event the annual general meeting is called for a date
that is not less than 30 days before or after such anniversary the notice must be given not later than 10 days following the earlier of the date on which notice of the annual general meeting was posted to shareholders or the date on which public
disclosure of the date of the annual general meeting was made. Where a director is to be elected at a special general meeting; provided, that our board of directors has determined that shareholders may nominate persons for election at such special
general meeting, that notice must be given not later than seven days following the earlier of the date on which notice of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">424 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the special general meeting was posted to shareholders or the date on which public disclosure of the date of the special general meeting was made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A director may be removed, only with cause, by the shareholders by the affirmative vote of at least 66<SUP
STYLE="font-size:85%; vertical-align:top">2/3</SUP>% of the issued and outstanding voting shares entitled to vote for the election of directors, provided notice of the shareholders meeting convened to remove the director is given to the director.
The notice must contain a statement of the intention to remove the director and a summary of the facts justifying the removal and must be served on the director not less than 14 days before the meeting. The director is entitled to attend the meeting
and be heard on the motion for his or her removal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Proceedings of Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> provide that our business is to be managed and conducted by our board
of directors. Bermuda law permits individual and corporate directors and there is no requirement in our <FONT STYLE="white-space:nowrap">bye-laws</FONT> or Bermuda law that directors hold any of our shares. There is also no requirement in our
amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> or Bermuda law that our directors must retire at a certain age. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
compensation of our directors will be determined by the board of directors, and there is no requirement that a specified number or percentage of &#147;independent&#148; directors must approve any such determination. Our directors may also be paid
all travel, hotel and other reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses properly incurred by them in connection with our business or their duties as directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A director who discloses a direct or indirect interest in any contract or arrangement with us as required by Bermuda law may be entitled to be
counted in the quorum for such meeting and to vote in respect of any such contract or arrangement in which he or she is interested unless the chairman of the relevant meeting of the Board of Directors determines that such director is disqualified
from voting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification of Directors and Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;98 of the Companies Act provides generally that a Bermuda company may indemnify its directors, officers and auditors against any
liability which by virtue of any rule of law would otherwise be imposed on them in respect of any negligence, default, breach of duty or breach of trust, except in cases where such liability arises from fraud or dishonesty of which such director,
officer or auditor may be guilty in relation to the company. Section&nbsp;98 further provides that a Bermuda company may indemnify its directors, officers and auditors against any liability incurred by them in defending any proceedings, whether
civil or criminal, in which judgment is awarded in their favor or in which they are acquitted or granted relief by the Supreme Court of Bermuda pursuant to Section&nbsp;281 of the Companies Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> provide that we shall indemnify our officers and directors in
respect of their actions and omissions, except in respect of their fraud or dishonesty, and that we shall advance funds to our officers and directors for expenses incurred in their defense upon receipt of an undertaking to repay the funds if any
allegation of fraud or dishonesty is proved. Our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> provide that the shareholders waive all claims or rights of action that they might have, individually or in right of the company,
against any of the company&#146;s directors or officers for any act or failure to act in the performance of such director&#146;s or officer&#146;s duties, except in respect of any fraud or dishonesty of such director or officer. Section&nbsp;98A of
the Companies Act permits us to purchase and maintain insurance for the benefit of any officer or director in respect of any loss or liability attaching to him in respect of any negligence, default, breach of duty or breach of trust, whether or not
we may otherwise indemnify such officer or director. We have purchased and maintain a directors&#146; and officers&#146; liability policy for such purpose. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendment of Memorandum of Association and <FONT STYLE="white-space:nowrap">Bye-laws</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Bermuda law provides that the memorandum of association of a company may be amended by a resolution passed at a general meeting of
shareholders. Our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> provide that no <FONT STYLE="white-space:nowrap">bye-law</FONT> shall be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">425 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rescinded, altered or amended, and no new <FONT STYLE="white-space:nowrap">bye-law</FONT> shall be made, unless it shall have been approved by a resolution of our board of directors and by a
resolution of our shareholders holding at least 66<SUP STYLE="font-size:85%; vertical-align:top">2/3</SUP>% of all votes cast on the resolution. The memorandum or association shall not be rescinded, altered or amended without a resolution of our
board of directors and a resolution of our shareholders holding at least 66<SUP STYLE="font-size:85%; vertical-align:top">2/3</SUP>% of all votes cast on the resolution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Bermuda law, the holders of an aggregate of not less than 20% in par value of a company&#146;s issued share capital or any class thereof
have the right to apply to the Supreme Court of Bermuda for an annulment of any amendment of the memorandum of association adopted by shareholders at any general meeting, other than an amendment that alters or reduces a company&#146;s share capital
as provided in the Companies Act. Where such an application is made, the amendment becomes effective only to the extent that it is confirmed by the Supreme Court of Bermuda. An application for an annulment of an amendment of the memorandum of
association must be made within 21 days after the date on which the resolution altering the company&#146;s memorandum of association is passed and may be made on behalf of persons entitled to make the application by one or more of their number as
they may appoint in writing for the purpose. No application may be made by shareholders voting in favor of the amendment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amalgamations and Mergers
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amalgamation or merger of a Bermuda company with another company or corporation (other than certain affiliated companies) requires
the amalgamation or merger agreement to be approved by the company&#146;s board of directors and by its shareholders. Unless the company&#146;s <FONT STYLE="white-space:nowrap">bye-laws</FONT> provide otherwise, the approval of 75% of the
shareholders voting at such meeting is required to approve the amalgamation or merger agreement, and the quorum for such meeting must be two or more persons holding or representing more than <FONT STYLE="white-space:nowrap">one-third</FONT> of the
issued shares of the company. Our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> provide that the approval of a 66<SUP STYLE="font-size:85%; vertical-align:top">2/3</SUP>% of shareholders voting at a meeting to approve the
amalgamation or merger agreement shall be sufficient (other than in respect of an amalgamation or merger constituting a &#147;business combination&#148;), and the quorum for such meeting shall be two or more Persons present in person and
representing in person or by proxy in excess of 50% of the total voting rights of all issued and outstanding shares of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under
Bermuda law, in the event of an amalgamation or merger of a Bermuda company with another company or corporation, a shareholder of the Bermuda company who did not vote in favor of the amalgamation or merger and who is not satisfied that fair value
has been offered for such shareholder&#146;s shares may, within one month of notice of the shareholders meeting, apply to the Supreme Court of Bermuda to appraise the fair value of those shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Combinations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the
Companies Act does not contain specific provisions regarding &#147;business combinations&#148; between companies organized under the laws of Bermuda and &#147;interested shareholders,&#148; we have included these provisions in our <FONT
STYLE="white-space:nowrap">bye-laws.</FONT> Specifically, our <FONT STYLE="white-space:nowrap">bye-laws</FONT> contain provisions which prohibit us from engaging in a business combination with an interested shareholder for a period of three years
after the date of the transaction in which the person became an interested shareholder, unless, in addition to any other approval that may be required by applicable law: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to the date of the transaction that resulted in the shareholder becoming an interested shareholder, our
board of directors approved either the business combination or the transaction that resulted in the shareholder becoming an interested shareholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon consummation of the transaction that resulted in the shareholder becoming an interested shareholder, the
interested shareholder owned at least 85% of our issued and voting shares outstanding at the time the transaction commenced; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">426 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after the date of the transaction that resulted in the shareholder becoming an interested shareholder, the
business combination is approved by our board of directors and authorized at an annual or special meeting of shareholders by the affirmative vote of at least 66<SUP STYLE="font-size:85%; vertical-align:top">2/3</SUP>% of our issued and outstanding
voting shares that are not owned by the interested shareholder. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of these provisions, a &#147;business
combination&#148; includes recapitalizations, mergers, amalgamations, consolidations, exchanges, asset sales, leases, certain issues or transfers of shares or other securities and other transactions resulting in a financial benefit to the interested
shareholder. An &#147;interested shareholder&#148; is any person or entity that beneficially owns 15% or more of our issued and outstanding voting shares and any person or entity affiliated with or controlling or controlled by that person or entity.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shareholder Suits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Class&nbsp;actions and derivative actions are generally not available to shareholders under Bermuda law. The Bermuda courts, however, would
ordinarily be expected to permit a shareholder to commence an action in the name of a company to remedy a wrong to the company where the act complained of is alleged to be beyond the corporate power of the company or illegal, or would result in the
violation of the company&#146;s memorandum of association or <FONT STYLE="white-space:nowrap">bye-laws.</FONT> Furthermore, consideration would be given by a Bermuda court to acts that are alleged to constitute a fraud against the minority
shareholders or, for instance, where an act requires the approval of a greater percentage of the company&#146;s shareholders than that which actually approved it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When the affairs of a company are being conducted in a manner that is oppressive or prejudicial to the interests of some part of the
shareholders, one or more shareholders may apply to the Supreme Court of Bermuda, which may make such order as it sees fit, including an order regulating the conduct of the company&#146;s affairs in the future or ordering the purchase of the shares
of any shareholders by other shareholders or by the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT>
contain a provision by virtue of which our shareholders waive any claim or right of action that they have, both individually and on our behalf, against any director or officer in relation to any action or failure to take action by such director or
officer, except in respect of any fraud or dishonesty of such director or officer. We have been advised by the SEC that in the opinion of the SEC, the operation of this provision as a waiver of the right to sue for violations of federal securities
laws would likely be unenforceable in U.S. courts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capitalization of Profits and Reserves </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our amended and restated <FONT STYLE="white-space:nowrap">bye-laws,</FONT> our board of directors may (1)&nbsp;capitalize any part
of the amount of our share premium or other reserve accounts or any amount credited to our profit and loss account or otherwise available for distribution by applying such sum in paying up unissued shares to be allotted as fully paid bonus shares
pro rata (except in connection with the conversion of shares) to the shareholders; or (2)&nbsp;capitalize any sum standing to the credit of a reserve account or sums otherwise available for dividend or distribution by paying up in full, partly paid
or nil paid shares of those shareholders who would have been entitled to such sums if they were distributed by way of dividend or distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Untraced Shareholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and
restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> provide that our board of directors may forfeit any dividend or other monies payable in respect of any shares that remain unclaimed for six years from the date when such monies became due for
payment. In addition, we are entitled to cease sending dividend warrants and checks by post or otherwise to a shareholder if such instruments have been returned undelivered to, or left uncashed by, such shareholder on at least two consecutive
occasions or, following one such occasion, reasonable enquires have failed to establish the shareholder&#146;s new address. This entitlement ceases if the shareholder claims a dividend or cashes a dividend check or a warrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">427 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Roivant Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Public Roivant Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each whole
Roivant Warrant entitles the registered holder to purchase one Roivant Common Share at a price of $11.50 per share, subject to adjustment as discussed below, at any time commencing on the later of one year from the closing of the initial public
offering and 30&nbsp;days after the completion of an initial business combination, provided in each case that Roivant has an effective registration statement under the Securities Act covering the Roivant Common Shares issuable upon exercise of the
Roivant Warrants and a current prospectus relating to them is available (or Roivant permits holders to exercise their Roivant Warrants on a cashless basis under the circumstances specified in the warrant agreement) and such shares are registered,
qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder. Pursuant to the warrant agreement, a holder of Roivant Warrants may exercise its Roivant Warrants only for a whole number of
Roivant Common Shares. This means only a whole Roivant Warrant may be exercised at a given time by a warrant holder. No fractional Roivant Warrants will be issued upon separation of the units and only whole Roivant Warrants will trade. Accordingly,
unless you purchase at least two units, you will not be able to receive or trade a whole warrant. The Roivant Warrants will expire five years after the completion of an initial business combination, at 5:00&nbsp;p.m., New York City time, or earlier
upon redemption or liquidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roivant will not be obligated to deliver any Roivant Common Shares pursuant to the exercise of a Roivant
Warrant and will have no obligation to settle such Roivant Warrant exercise unless a registration statement under the Securities Act with respect to the Roivant Common Shares underlying the Roivant Warrants is then effective and a prospectus
relating thereto is current, subject to our satisfying our obligations described below with respect to registration, or a valid exemption from registration is available. No Roivant Warrant will be exercisable and Roivant will not be obligated to
issue a Roivant Common Share upon exercise of a Roivant Warrant unless the Roivant Common Shares issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the
registered holder of the Roivant Warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a warrant, the holder of such Roivant Warrant will not be entitled to exercise such Roivant
Warrant and such Roivant Warrant may have no value and expire worthless. In no event will Roivant be required to net cash settle any warrant. In the event that a registration statement is not effective for the exercised Roivant Warrants, the
purchaser of a unit containing such Roivant Warrant will have paid the full purchase price for the unit solely for the share of Roivant Common Shares underlying such unit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As soon as practicable, but in no event later than twenty business days after the Closing, Roivant will use its commercially reasonable
efforts to file with the SEC a registration statement for the registration, under the Securities Act, of the Roivant Common Shares issuable upon exercise of the Roivant Warrants. Roivant will use its commercially reasonable efforts to cause the same
to become effective and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration or redemption of the Roivant Warrants in accordance with the provisions of the warrant agreement.
If a registration statement covering the issuance of the Roivant Common Shares issuable upon exercise of the Roivant Warrants is not effective by the 60th&nbsp;business day after the Closing, warrant holders may, until such time as there is an
effective registration statement and during any period when Roivant will have failed to maintain an effective registration statement, exercise Roivant Warrants on a &#147;cashless basis&#148; in accordance with Section&nbsp;3(a)(9)&nbsp;of the
Securities Act or another exemption. In addition, if Roivant Common Shares are at the time of any exercise of a Roivant Warrant not listed on a national securities exchange such that they satisfy the definition of a &#147;covered security&#148;
under Section&nbsp;18(b)(1)&nbsp;of the Securities Act, Roivant may, at its option, require holders of its public Roivant Warrants who exercise their Roivant Warrants to do so on a &#147;cashless basis&#148; in accordance with
Section&nbsp;3(a)(9)&nbsp;of the Securities Act and, in the event Roivant elects to do so, Roivant will not be required to file or maintain in effect a registration statement, but Roivant will use its best efforts to register or qualify the shares
under applicable blue sky laws to the extent an exemption is not available. In such event, each holder would pay the exercise price by surrendering each such Roivant Warrant for that number of Roivant Common Shares equal to the lesser of
(A)&nbsp;the quotient obtained by dividing (x)&nbsp;the product of the number of Roivant Common Shares </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">428 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
underlying the Roivant Warrants, multiplied the excess of the &#147;fair market value&#148; less the exercise price of the Roivant Warrants by (y)&nbsp;the fair market value and (B)&nbsp;0.361.
The &#147;fair market value&#148; shall mean the volume weighted average price of Roivant Common Shares for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Redemption of Roivant Warrants When the Price per Roivant Common Share Equals or Exceeds $18.00 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once the Roivant Warrants become exercisable, Roivant may redeem the outstanding Roivant Warrants (except as described herein with respect to
the private placement Roivant Warrants): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in whole and not in part; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a price of $0.01 per warrant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon not less than 30&nbsp;days&#146; prior written notice of redemption to each warrant holder; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the last reported sale price of the Roivant Common Shares for any 20 trading days within a <FONT
STYLE="white-space:nowrap">30-trading</FONT> day period ending three business days before Roivant sends to the notice of redemption to the warrant holders (which Roivant refers to as the &#147;Reference Value&#148;) equals or exceeds $18.00 per
share (as adjusted for share subdivisions, share capitalizations, dividends, reorganizations, recapitalizations and the like). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If and when the Roivant Warrants become redeemable by us, Roivant may exercise its redemption right even if Roivant is unable to register or
qualify the underlying securities for sale under all applicable state securities laws. However, Roivant will not redeem the Roivant Warrants unless an effective registration statement under the Securities Act covering the Roivant Common Shares
issuable upon exercise of the Roivant Warrants is effective and a current prospectus relating to those Roivant Common Shares is available throughout the <FONT STYLE="white-space:nowrap">30-day</FONT> redemption period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roivant has established the last of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the
call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and Roivant issues a notice of redemption of the Roivant Warrants, each warrant holder will be entitled to exercise his, her or its Roivant Warrant
prior to the scheduled redemption date. Any such exercise would not be done on a &#147;cashless&#148; basis and would require the exercising warrant holder to pay the exercise price for each warrant being exercised. However, the price of the Roivant
Common Shares may fall below the $18.00 redemption trigger price (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) as well as the $11.50 (for whole shares) Roivant Warrant exercise price
after the redemption notice is issued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption of Roivant Warrants When the Price per Roivant Common Share Equals or Exceeds $10.00 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once the Roivant Warrants become exercisable, Roivant may redeem the outstanding Roivant Warrants: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in whole and not in part;</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at $0.10 per Roivant Warrant upon a minimum of 30&nbsp;days&#146; prior written notice of redemption; provided
that holders will be able to exercise their Roivant Warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to the table below, based on the redemption date and the &#147;fair market value&#148; of
Roivant Common Shares (as defined below); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the Reference Value (as defined above under&#151;&#148;Redemption of Roivant Warrants When the
Price per Roivant Common Share Equals or Exceeds $18.00&#148;) equals or exceeds $10.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the Reference Value is less than $18.00 per share (as adjusted for share subdivisions, share capitalizations,
reorganizations, recapitalizations and the like) the private placement Roivant Warrants </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">429 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
must also be concurrently called for redemption on the same terms (except as described above with respect to a holder&#146;s ability to cashless exercise its Roivant Warrants) as the outstanding
public Roivant Warrants, as described above. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The numbers in the table below represent the number of Roivant Common
Shares that a warrant holder will receive upon exercise in connection with a redemption by Roivant pursuant to this redemption feature, based on the &#147;fair market value&#148; of Roivant Common Shares on the corresponding redemption date
(assuming holders elect to exercise their Roivant Warrants and such Roivant Warrants are not redeemed for $0.10 per warrant), determined based on volume-weighted average price of Roivant Common Shares as reported during the 10 trading days
immediately following the date on which the notice of redemption is sent to the holders of Roivant Warrants, and the number of months that the corresponding redemption date precedes the expiration date of the Roivant Warrants, each as set forth in
the table below. Roivant provides its warrant holders with the final fair market value no later than one business day after the <FONT STYLE="white-space:nowrap">10-trading</FONT> day period described above ends. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the warrant agreement, references above to Roivant Common Shares shall include a security other than Roivant Common Shares into
which the Roivant Common Shares have been converted or exchanged for in the event Roivant is not the surviving company in an initial business combination. The numbers in the table below will not be adjusted when determining the number of Roivant
Common Shares to be issued upon exercise of the Roivant Warrants if Roivant is not the surviving entity following an initial business combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The share prices set forth in the column headings of the table below will be adjusted as of any date on which the number of shares issuable
upon exercise of a Roivant Warrant is adjusted as set forth under the heading &#147;&#151;<I>Anti-dilution Adjustments</I>&#148; below. The adjusted share prices in the column headings will equal the share prices immediately prior to such
adjustment, multiplied by a fraction, the numerator of which is the number of shares deliverable upon exercise of a Roivant Warrant immediately prior to such adjustment and the denominator of which is the number of shares deliverable upon exercise
of a Roivant Warrant as so adjusted. The number of shares in the table below shall be adjusted in the same manner and at the same time as the number of shares issuable upon exercise of a warrant. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="34" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Market Value of Roivant Common Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Redemption Date<BR>(period to expiration of Roivant
Warrants)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT><B></B><B>$10.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$11.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$12.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$13.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$14.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$15.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$16.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$17.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B>$18.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">60&nbsp;months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">57&nbsp;months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">54&nbsp;months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">51&nbsp;months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">48&nbsp;months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">45&nbsp;months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">42&nbsp;months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">39&nbsp;months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">36&nbsp;months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">33&nbsp;months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">30&nbsp;months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">27&nbsp;months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">24&nbsp;months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21&nbsp;months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18&nbsp;months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15&nbsp;months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12&nbsp;months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9&nbsp;months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6&nbsp;months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3&nbsp;months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">0&nbsp;months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">430 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exact fair market value and redemption date may not be set forth in the table above, in
which case, if the fair market value is between two values in the table or the redemption date is between two redemption dates in the table, the number of Roivant Common Shares to be issued for each warrant exercised will be determined by a
straight-line interpolation between the number of shares set forth for the higher and lower fair market values and the earlier and later redemption dates, as applicable, based on a 365 or <FONT STYLE="white-space:nowrap">366-day</FONT> year, as
applicable. For example, if the volume-weighted average price of Roivant Common Shares as reported during the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of the Roivant Warrants is $11.00
per share, and at such time there are 57&nbsp;months until the expiration of the Roivant Warrants, holders may choose to, in connection with this redemption feature, exercise their Roivant Warrants for 0.277 Roivant Common Shares for each whole
warrant. For an example where the exact fair market value and redemption date are not as set forth in the table above, if the volume-weighted average price of Roivant Common Shares as reported during the 10 trading days immediately following the
date on which the notice of redemption is sent to the holders of the Roivant Warrants is $13.50 per share, and at such time there are 38&nbsp;months until the expiration of the Roivant Warrants, holders may choose to, in connection with this
redemption feature, exercise their Roivant Warrants for 0.298 Roivant Common Shares for each whole warrant. In no event will the Roivant Warrants be exercisable in connection with this redemption feature for more than 0.361 Roivant Common Shares per
Roivant Warrant (subject to adjustment). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This redemption feature differs from the typical warrant redemption features used in some other
blank check offerings, which typically only provide for a redemption of Roivant Warrants for cash (other than the private placement Roivant Warrants) when the trading price for the Roivant Common Shares exceeds $18.00 per share for a specified
period of time. This redemption feature is structured to allow for all of the outstanding Roivant Warrants to be redeemed when the Roivant Common Shares are trading at or above $10.00 per share, which may be at a time when the trading price of
Roivant Common Shares is below the exercise price of the Roivant Warrants. Roivant has established this redemption feature to provide Roivant with the flexibility to redeem the Roivant Warrants without the Roivant Warrants having to reach the $18.00
per share threshold set forth above under &#147;&#151;Redemption of Roivant Warrants When the Price per Roivant Common Share Equals or Exceeds $18.00.&#148; Holders choosing to exercise their Roivant Warrants in connection with a redemption pursuant
to this feature will, in effect, receive a number of shares for their Roivant Warrants based on an option pricing model with a fixed volatility input as of the date of this prospectus. This redemption right provides Roivant with an additional
mechanism by which to redeem all of the outstanding Roivant Warrants, and therefore have certainty as to our capital structure as the Roivant Warrants would no longer be outstanding and would have been exercised or redeemed. Roivant will be required
to pay the applicable redemption price to warrant holders if Roivant<U> </U>chooses to exercise this redemption right and it will allow Roivant to quickly proceed with a redemption of the Roivant Warrants if Roivant determines it is in our best
interest to do so. As such, Roivant would redeem the Roivant Warrants in this manner when Roivant believes it is in our best interest to update our capital structure to remove the Roivant Warrants and pay the redemption price to the warrant holders.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As stated above, Roivant can redeem the Roivant Warrants when the Roivant Common Shares are trading at a price starting at $10.00, which
is below the exercise price of $11.50, because it provides certainty with respect to our capital structure and cash position while providing warrant holders with the opportunity to exercise their Roivant Warrants on a cashless basis for the
applicable number of shares. If Roivant chooses to redeem the Roivant Warrants when the Roivant Common Shares are trading at a price below the exercise price of the Roivant Warrants, this could result in the warrant holders receiving fewer Roivant
Common Shares than they would have received if they had chosen to wait to exercise their Roivant Warrants for Roivant Common Shares if and when such Roivant Common Shares were trading at a price higher than the exercise price of $11.50. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional Roivant Common Shares will be issued upon exercise. If, upon exercise, a holder would be entitled to receive a fractional
interest in a share, Roivant will round down to the nearest whole number of the number of Roivant Common Shares to be issued to the holder. If, at the time of redemption, the Roivant Warrants are exercisable for a security other than the Roivant
Common Shares pursuant to the warrant agreement (for instance, if Roivant is not the surviving company in an initial business combination), the Roivant Warrants </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">431 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may be exercised for such security. At such time as the Roivant Warrants become exercisable for a security other than the Roivant Common Shares, Roivant (or surviving company) will use its
commercially reasonable efforts to register under the Securities Act the security issuable upon the exercise of the Roivant Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Redemption Procedures.</I> A holder of a Roivant Warrant may notify Roivant in writing in the event it elects to be subject to a
requirement that such holder will not have the right to exercise such warrant, to the extent that after giving effect to such exercise, such person (together with such person&#146;s affiliates), to the warrant agent&#146;s actual knowledge, would
beneficially own in excess of 4.9% or 9.8% (as specified by the holder) of the Roivant Common Shares issued and outstanding immediately after giving effect to such exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Anti-dilution Adjustments.</I> If the number of outstanding Roivant Common Shares is increased by a share subdivisions, share
capitalization or dividend payable in Roivant Common Shares, or by a <FONT STYLE="white-space:nowrap">split-up</FONT> of common shares or other similar event, then, on the effective date of such share subdivision, share capitalization, <FONT
STYLE="white-space:nowrap">split-up</FONT> or similar event, the number of Roivant Common Shares issuable on exercise of each Roivant Warrant will be increased in proportion to such increase in the outstanding shares of common shares. A rights
offering to holders of common shares entitling holders to purchase Roivant Common Shares at a price less than the &#147;historical fair market value&#148; (as defined below) will be deemed a dividend of a number of Roivant Common Shares equal to the
product of (i)&nbsp;the number of Roivant Common Shares actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for Roivant Common Shares) and
(ii)&nbsp;one minus the quotient of (x)&nbsp;the price per Roivant Common Share paid in such rights offering and (y)&nbsp;the historical fair market value. For these purposes, (i)&nbsp;if the rights offering is for securities convertible into or
exercisable for Roivant Common Shares, in determining the price payable for Roivant Common Shares, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and
(ii)&nbsp;&#148;historical fair market value&#148; means the volume-weighted average price of Roivant Common Shares as reported during the 10 trading day period ending on the trading day prior to the first date on which the Roivant Common Shares
trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if we,
at any time while the Roivant Warrants are outstanding and unexpired, pay a dividend or make a distribution in cash, securities or other assets to the holders of Roivant Common Shares on account of such Roivant Common Shares (or other securities
into which the Roivant Warrants are convertible), other than (a)&nbsp;as described above, (b)&nbsp;any cash dividends or cash distributions which, when combined on a per share basis with all other cash dividends and cash distributions paid on the
Roivant Common Shares during the <FONT STYLE="white-space:nowrap">365-day</FONT> period ending on the date of declaration of such dividend or distribution does not exceed $0.50 (as adjusted to appropriately reflect any other adjustments and
excluding cash dividends or cash distributions that resulted in an adjustment to the exercise price or to the number of Roivant Common Shares issuable on exercise of each warrant) but only with respect to the amount of the aggregate cash dividends
or cash distributions equal to or less than $0.50 per share, (c)&nbsp;to satisfy the redemption rights of the holders of Roivant Common Shares in connection with a proposed initial business combination, (d)&nbsp;to satisfy the redemption rights of
the holders of Roivant Common Shares in connection with a shareholder vote to amend our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> (A)&nbsp;to modify the substance or timing of our obligation to allow redemption in
connection with an initial business combination or to redeem 100% of Roivant Common Shares if Roivant does not complete an initial business combination within 24&nbsp;months from the closing of the initial public offering or (B)&nbsp;with respect to
any other provision relating to shareholders&#146; rights or <FONT STYLE="white-space:nowrap">pre-initial</FONT> business combination activity, or (e)&nbsp;in connection with the redemption of Roivant Common Shares upon our failure to complete an
initial business combination, then the warrant exercise price will be decreased, effective immediately after the effective date of such event, by the amount of cash and/or the fair market value of any securities or other assets paid on each Roivant
Common Share in respect of such event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the number of outstanding Roivant Common Shares is decreased by a consolidation, combination,
reverse share split or reclassification of Roivant Common Shares or other similar event, then, on the effective date of such consolidation, combination, reverse share split, reclassification or similar event, the number of Roivant
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">432 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Common Shares issuable on exercise of each Roivant Warrant will be decreased in proportion to such decrease in outstanding Roivant Common Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever the number of Roivant Common Shares purchasable upon the exercise of the Roivant Warrants is adjusted, as described above, the
warrant exercise price will be adjusted by multiplying the warrant exercise price immediately prior to such adjustment by a fraction (x)&nbsp;the numerator of which will be the number of Roivant Common Shares purchasable upon the exercise of the
Roivant Warrants immediately prior to such adjustment and (y)&nbsp;the denominator of which will be the number of Roivant Common Shares so purchasable immediately thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if (x)&nbsp;Roivant issues additional Roivant Common Shares or equity-linked securities for capital raising purposes in
connection with the closing of an initial business combination at an issue price or effective issue price of less than $9.20 per Roivant Common Share (with such issue price or effective issue price to be determined in good faith by our board of
directors and, in the case of any such issuance to our sponsor or its affiliates, without taking into account any shares held by the MAAC Sponsor or its affiliates, as applicable, prior to such issuance (the &#147;Newly Issued Price&#148;),
(y)&nbsp;the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of an initial business combination on the date of the completion of an initial business
combination (net of redemptions), and (z)&nbsp;the volume-weighted average trading price of Roivant Common Shares during the 20 trading day period starting on the trading day prior to Closing (such price, the &#147;Market Value&#148;) is below $9.20
per share, the exercise price of the Roivant Warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $10.00 and $18.00 per share redemption trigger prices described
adjacent to &#147;Redemption of Roivant Warrants When the Price per Roivant Common Share Equals or Exceeds $18.00&#148; and &#147;Redemption of Roivant Warrants When the Price per Roivant Common Share Equals or Exceeds $10.00&#148; will be adjusted
(to the nearest cent) to be equal to 100% and 180% of the higher of the Market Value and the Newly Issued Price, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case of
any reclassification or reorganization of the outstanding Roivant Common Shares (other than those described above or that solely affects the par value of such Roivant Common Shares), or in the case of any merger or consolidation of Roivant with or
into another corporation (other than a consolidation or merger in which Roivant is the continuing corporation and that does not result in any reclassification or reorganization of our outstanding Roivant Common Shares), or in the case of any sale or
conveyance to another corporation or entity of the assets or other property of Roivant as an entirety or substantially as an entirety in connection with which Roivant is dissolved, the holders of the Roivant Warrants will thereafter have the right
to purchase and receive, upon the basis and upon the terms and conditions specified in the Roivant Warrants and in lieu of the Roivant Common Shares immediately theretofore purchasable and receivable upon the exercise of the rights represented
thereby, the kind and amount of Roivant Common Shares or other securities or property (including cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that
the holder of the Roivant Warrants would have received if such holder had exercised their Roivant Warrants immediately prior to such event. If less than 70% of the consideration receivable by the holders of Roivant Common Shares in such a
transaction is payable in the form of Roivant Common Shares in the successor entity that is listed for trading on a national securities exchange or is quoted in an established
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, or is to be so listed for trading or quoted immediately following such event, and if the registered holder of the Roivant Warrant properly
exercises the Roivant Warrant within thirty days following public disclosure of such transaction, the warrant exercise price will be reduced as specified in the warrant agreement based on the Black-Scholes value (as defined in the warrant agreement)
of the warrant. The purpose of such exercise price reduction is to provide additional value to holders of the Roivant Warrants when an extraordinary transaction occurs during the exercise period of the Roivant Warrants pursuant to which the holders
of the Roivant Warrants otherwise do not receive the full potential value of the Roivant Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Roivant Warrants are issued in
registered form under a warrant agreement between American Stock Transfer&nbsp;&amp; Trust Company, LLC as warrant agent, and us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">433 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrant agreement provides that the terms of the Roivant Warrants may be amended without
the consent of any holder for the purpose of (i)&nbsp;curing any ambiguity or correct any mistake, including to conform the provisions of the warrant agreement to the description of the terms of the Roivant Warrants and the warrant agreement set
forth in this prospectus, or defective provision (ii)&nbsp;amending the provisions relating to cash dividends on common shares as contemplated by and in accordance with the warrant agreement or (iii)&nbsp;adding or changing any provisions with
respect to matters or questions arising under the warrant agreement as the parties to the warrant agreement may deem necessary or desirable and that the parties deem to not adversely affect the rights of the registered holders of the Roivant
Warrants, provided that the approval by the holders of at least 50% of the then-outstanding public Roivant Warrants is required to make any change that adversely affects the interests of the registered holders of public Roivant Warrants. You should
review a copy of the warrant agreement for a complete description of the terms and conditions applicable to the Roivant Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Roivant Warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as
indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by certified or official bank check payable to us, for the number of Roivant Warrants being exercised. The warrant holders do not have the rights
or privileges of holders of common shares and any voting rights until they exercise their Roivant Warrants and receive Roivant Common Shares. After the issuance of Roivant Common Shares upon exercise of the Roivant Warrants, each holder will be
entitled to one vote for each share held of record on all matters to be voted on by shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional shares will be issued
upon exercise of the Roivant Warrants. If, upon exercise of the Roivant Warrants, a holder would be entitled to receive a fractional interest in a share, Roivant will, upon exercise, round down to the nearest whole number, the number of Roivant
Common Shares to be issued to the warrant holder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Private Roivant Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The private placement Roivant Warrants (including the Roivant Common Shares issuable upon exercise of the Private placement Roivant Warrants)
will not be transferable, assignable or salable until 30&nbsp;days after the completion of an initial business combination (except pursuant to limited exceptions) and they will not be redeemable by Roivant so long as they are held by our sponsor or
its permitted transferees (except as otherwise set forth herein). Our sponsor, or its permitted transferees, have the option to exercise the private placement Roivant Warrants on a cashless basis. Except as described below, the private placement
Roivant Warrants have terms and provisions that are identical to those of the Roivant Warrants sold as part of the units in the initial public offering. If the private placement Roivant Warrants are held by holders other than our sponsor or its
permitted transferees, the private placement Roivant Warrants will be redeemable by Roivant in all redemption scenarios and exercisable by the holders on the same basis as the Roivant Warrants included in the units being sold in the initial public
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If holders of the private placement Roivant Warrants elect to exercise them on a cashless basis, they would pay the exercise
price by surrendering his, her or its Roivant Warrants for that number of Roivant Common Shares equal to the quotient obtained by dividing (x)&nbsp;the product of the number of Roivant Common Shares underlying the Roivant Warrants, multiplied by the
excess of the &#147;historical fair market value&#148; (defined below) over the exercise price of the Roivant Warrants by (y)&nbsp;the historical fair market value. For these purposes, the &#147;historical fair market value&#148; shall mean the
average last reported sale price of the Roivant Common Shares for the 10 trading days ending on the third trading day prior to the date on which the notice of warrant exercise is sent to the warrant agent. The reason that Roivant has agreed that
these Roivant Warrants will be exercisable on a cashless basis so long as they are held by our sponsor and its permitted transferees is because it is not known at this time whether they will be affiliated with Roivant following a business
combination. If they remain affiliated with us, their ability to sell our securities in the open market will be significantly limited. Roivant expects to have policies in place that restrict insiders from selling our securities except during
specific periods of time. Even during such periods of time when insiders will be permitted to sell our securities, an insider cannot trade in our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">434 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities if he or she is in possession of material <FONT STYLE="white-space:nowrap">non-public</FONT> information. Accordingly, unlike public shareholders who could exercise their Roivant
Warrants and sell the Roivant Common Shares received upon such exercise freely in the open market in order to recoup the cost of such exercise, the insiders could be significantly restricted from selling such securities. As a result, Roivant
believes that allowing the holders to exercise such Roivant Warrants on a cashless basis is appropriate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Provisions of Bermuda Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have been designated by the Bermuda Monetary Authority as a <FONT STYLE="white-space:nowrap">non-resident</FONT> for Bermuda exchange
control purposes. This designation allows us to engage in transactions in currencies other than the Bermuda dollar, and there are no restrictions on our ability to transfer funds (other than funds denominated in Bermuda dollars) in and out of
Bermuda or to pay dividends to U.S. residents who are holders of Roivant Common Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bermuda Monetary Authority has given its
consent for the issue and free transferability of all of the Roivant Common Shares that are the subject of this offering to and between residents and <FONT STYLE="white-space:nowrap">non-residents</FONT> of Bermuda for exchange control purposes,
provided our shares remain listed on an appointed stock exchange, which includes Nasdaq. Approvals or permissions given by the Bermuda Monetary Authority do not constitute a guarantee by the Bermuda Monetary Authority as to our performance or our
creditworthiness. Accordingly, in giving such consent or permissions, neither the Bermuda Monetary Authority nor the Registrar of Companies in Bermuda shall be liable for the financial soundness, performance or default of our business or for the
correctness of any opinions or statements expressed in this prospectus. Certain issues and transfers of Roivant Common Shares involving persons deemed resident in Bermuda for exchange control purposes require the specific consent of the Bermuda
Monetary Authority. We have sought and have obtained a specific permission from the Bermuda Monetary Authority for the issue and transfer of Roivant Common Shares up to the amount of our authorized capital from time to time, and options, warrants,
depository receipts, rights, loan notes, debt instruments and our other securities to persons resident and <FONT STYLE="white-space:nowrap">non-resident</FONT> for exchange control purposes with the need for prior approval of such issue or transfer.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with Bermuda law, share certificates are only issued in the names of companies, partnerships or individuals. In the case of
a shareholder acting in a special capacity (for example as a trustee), certificates may, at the request of the shareholder, record the capacity in which the shareholder is acting. Notwithstanding such recording of any special capacity, we are not
bound to investigate or see to the execution of any such trust. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exchange Controls </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The permission of the Bermuda Monetary Authority is required, pursuant to the provisions of the Exchange Control Act 1972 and related
regulations, for all issuances and transfers of shares (which includes Roivant Common Shares) of Bermuda companies to or from a <FONT STYLE="white-space:nowrap">non-resident</FONT> of Bermuda for exchange control purposes, other than in cases where
the Bermuda Monetary Authority has granted a general permission. The Bermuda Monetary Authority, in its notice to the public dated June&nbsp;1, 2005, has granted a general permission for the issue and subsequent transfer of any securities of a
Bermuda company from or to a <FONT STYLE="white-space:nowrap">non-resident</FONT> of Bermuda for exchange control purposes for so long as any &#147;Equity Securities&#148; of the company (which would include Roivant Common Shares) are listed on an
&#147;Appointed Stock Exchange&#148; (which would include Nasdaq). Certain issues and transfers of Roivant Common Shares involving persons deemed resident in Bermuda for exchange control purposes require the specific consent of the Bermuda Monetary
Authority. We have sought and have obtained a specific permission from the Bermuda Monetary Authority for the issue and transfer of Roivant Common Shares up to the amount of our authorized capital from time to time, and options, warrants, depository
receipts, rights, loan notes, debt instruments and our other securities to persons resident and <FONT STYLE="white-space:nowrap">non-resident</FONT> for exchange control purposes with the need for prior approval of such issue or transfer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">435 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent, Warrant Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A register of holders of Roivant Common Shares will be maintained by Conyers Corporate Services (Bermuda) Limited in Bermuda, and a branch
register will be maintained in the United States by American Stock Transfer &amp; Trust Company, LLC, which will also serve as transfer agent and warrant agent. The transfer and warrant agent&#146;s address is 6201 15th Avenue, Brooklyn, NY 11219.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to apply to list
the Roivant Common Shares and the Roivant Warrants on Nasdaq under the trading symbols &#147;ROIV&#148; and &#147;ROIVW,&#148; respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">436 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_29"></A>ROIVANT COMMON SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of the Business Combination, Roivant will have 7,000,000,000 Roivant Common Shares authorized and, based on the assumptions
set out elsewhere in this proxy statement/prospectus, up to 724,916,109 Roivant Common Shares issued and outstanding, assuming no MAAC Shares are redeemed in connection with the Business Combination. All Roivant Common Shares issued in connection
with the Business Combination to MAAC stockholders will be freely transferable by persons other than by Roivant&#146;s &#147;affiliates&#148; without restriction or further registration under the Securities Act, except 10,267,956 Roivant Common
Shares issued to the MAAC Sponsor and the MAAC Independent Directors, which are subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> described below. The remaining 651,576,330 shares held by existing Roivant shareholders are subject to the
<FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions described below and may only be resold pursuant to Rule 144. Sales of substantial amounts of Roivant Common Shares in the public market could adversely affect prevailing market price of
Roivant Common Shares. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Periods and Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Roivant, the MAAC Sponsor and Certain Roivant Equityholders <FONT STYLE="white-space:nowrap">Lock-ups</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the signing of the Business Combination Agreement and on June&nbsp;9, 2021, Roivant, on the one hand, and the MAAC Sponsor,
both of the MAAC Independent Directors and certain Roivant equityholders, on the other hand, entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements substantially in the form attached to this proxy statement/prospectus as Annex F
(the <FONT STYLE="white-space:nowrap">&#147;Lock-up</FONT> Agreements&#148;), pursuant to which, among other things, the MAAC Sponsor, both of the MAAC Independent Directors and such Roivant equityholders have agreed not to, subject to, and
conditioned upon the effectiveness of, the Closing, effect any sale or distribution of Roivant Common Shares (including Roivant Common Shares underlying incentive equity awards) held by such equityholders as of immediately following the Closing
during the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> period, subject to customary exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT
STYLE="white-space:nowrap">lock-up</FONT> period applicable to Roivant Common Shares held by the MAAC Sponsor and the MAAC Independent Directors will be (i)&nbsp;with respect to 25% of the Roivant Common Shares held by the MAAC Sponsor and the MAAC
Independent Directors, six months following the Closing, (ii)&nbsp;with respect to an additional 25% of the Roivant Common Shares held by the MAAC Sponsor and the MAAC Independent Directors, the earlier of twelve months following the achievement of
certain price-based vesting restrictions or six years from the Closing and (iii)&nbsp;with respect to 50% of the Roivant Common Shares held by the MAAC Sponsor and the MAAC Independent Directors, <FONT STYLE="white-space:nowrap">thirty-six</FONT>
months following the Closing. The Roivant warrants and the Roivant Common Shares underlying warrants held by the MAAC Sponsor as of immediately following the Closing will be subject to a corresponding <FONT STYLE="white-space:nowrap">lock-up</FONT>
period for (i)&nbsp;with respect to 25% of such warrants held by the MAAC Sponsor, six months from the Closing, (ii)&nbsp;with respect to an additional 25% of such warrants held by the MAAC Sponsor, twelve months from Closing and (iii)&nbsp;with
respect to 50% of such warrants held by the MAAC Sponsor, <FONT STYLE="white-space:nowrap">thirty-six</FONT> months from the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
<FONT STYLE="white-space:nowrap">lock-up</FONT> period applicable to Roivant Common Shares (including Roivant Common Shares underlying incentive equity awards) held by certain Roivant equityholders will be (i)&nbsp;with respect to 25% of the Roivant
Common Shares (including those underlying incentive equity awards) held by such Roivant equityholders, six months following the Closing, (ii)&nbsp;with respect to an additional 25% of the Roivant Common Shares (including Roivant Common Shares
underlying incentive equity awards) held by such Roivant equityholders, twelve months following the Closing and (iii)&nbsp;with respect to 50% of the Roivant Common Shares (including those underlying incentive equity awards) held by such Roivant
equityholders, <FONT STYLE="white-space:nowrap">thirty-six</FONT> months following the Closing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Bye-laws</FONT> <FONT
STYLE="white-space:nowrap">Lock-up</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the consummation of the Business Combination, Roivant will adopt the
amended and restated <FONT STYLE="white-space:nowrap">bye-laws.</FONT> The amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> contain a <FONT STYLE="white-space:nowrap">lock-up</FONT> provision (the
<FONT STYLE="white-space:nowrap">&#147;Bye-laws</FONT> <FONT STYLE="white-space:nowrap">Lock-up&#148;)</FONT> which provides that, without the prior consent of the board of directors of Roivant and subject to certain
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">437 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
customary exceptions, each holder will not, for a period ending 180 calendar days following the effective time of the Merger, lend, offer, pledge, sell, contract to sell, sell any option or
contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any (a)&nbsp;Roivant Common Shares or (b)&nbsp;any securities convertible
into or exercisable or exchangeable (directly or indirectly) for Roivant Common Shares (including Roivant Common Shares underlying incentive equity awards), in each case that are outstanding immediately prior to the Effective Time. For the avoidance
of doubt, such restriction will not apply to any Roivant Common Shares or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Roivant Common Shares held by or on behalf of any stockholder of MAAC (other than a
stockholder of MAAC who is also a Roivant shareholder that did not purchase MAAC Shares directly from MAAC) prior to, or received in connection with, the closing of the transactions contemplated by the Business Combination Agreement, including
Roivant Common Shares issuable in connection with the PIPE Financing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Registration Rights Agreement <FONT STYLE="white-space:nowrap">Lock-up</FONT>
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the signing of the Business Combination Agreement, Roivant and certain Roivant equityholders entered into the
Registration Rights Agreement. The Registration Rights Agreement contains a <FONT STYLE="white-space:nowrap">lock-up</FONT> provision agreements (the &#147;Registration Rights Agreement <FONT STYLE="white-space:nowrap">Lock-up&#148;</FONT> and,
together with the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements and the <FONT STYLE="white-space:nowrap">Bye-laws</FONT> <FONT STYLE="white-space:nowrap">Lock-up,</FONT> the <FONT STYLE="white-space:nowrap">&#147;Lock-ups&#148;),</FONT>
which provides that, without the prior consent of the board of directors of Roivant and subject to certain customary exceptions, each holder will not, for a period ending 180 calendar days following the effective time of the Merger, lend, offer,
pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Roivant Common Shares
or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Roivant Common Shares (including Roivant Common Shares underlying incentive equity awards), in each case that are outstanding immediately prior to the
Effective Time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>PIPE Financing Resale Shelf </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Subscription Agreements relating to the PIPE, Roivant has agreed that, within 30 calendar days after the consummation of the
Business Combination, it will file with the SEC (at Roivant&#146;s sole cost and expense) a registration statement registering the resale of Roivant Common Shares issuable in connection with the PIPE Financing (the &#147;Resale Registration
Statement&#148;), and Roivant will use its commercially reasonable efforts to have the Resale Registration Statement declared effective as soon as practicable after the filing thereof, subject to certain conditions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Registration Rights Agreement Registration Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> periods described above, certain shareholders are also entitled to registration
rights pursuant to the terms of the Registration Rights Agreement. Roivant has agreed to file a registration statement promptly following a request from certain significant shareholders of Roivant to register certain registrable securities under the
Securities Act (such request, a &#147;demand registration&#148;), subject to required notice provisions to other shareholders party thereto. Roivant has also agreed to provide customary &#147;piggy-back&#148; registration rights with respect to any
valid demand registration request. Subject to certain circumstances, Roivant is also required to file a resale shelf registration statement to register the resale under the Securities Act of such registrable securities. The Registration Rights
Agreement provides that Roivant will pay certain expenses relating to such registrations and indemnify the securityholders against certain liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Rule 144 under the
Securities Act (&#147;Rule 144&#148;), a person who has beneficially owned restricted Roivant Common Shares for at least six months would, subject to the restrictions noted in the section below, be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">438 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
entitled to sell their securities provided that (i)&nbsp;such person is not deemed to have been an affiliate of Roivant at the time of, or at any time during the three months preceding, a sale
and (ii)&nbsp;Roivant has been subject to the Exchange Act periodic reporting requirements for at least three months before the sale and has filed all required reports under Section&nbsp;13 or 15(d) of the Exchange Act during the twelve months (or
such shorter period as Roivant was required to file reports) preceding the sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Persons who have beneficially owned restricted Roivant
Common Shares for at least six months but who are affiliates of Roivant at the time of, or at any time during the three months preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any
three-month period only a number of securities that does not exceed the greater of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the total number of Roivant Common Shares then outstanding; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly reported trading volume of Roivant Common Shares during the four calendar weeks preceding the
filing of a notice on Form 144 with respect to the sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales by affiliates of Roivant under Rule 144 are also limited
by manner of sale provisions and notice requirements and to the availability of current public information about Roivant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">439 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_30"></A>APPRAISAL RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither MAAC stockholders nor MAAC warrant holders have appraisal rights in connection with the Business Combination under the DGCL. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">440 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_31"></A>FUTURE SHAREHOLDER PROPOSALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For any proposal to be considered for inclusion in our proxy statement and form of proxy for submission to the stockholders at Roivant&#146;s
2022 annual meeting of stockholders, assuming consummation of the Business Combination, it must be submitted in writing and comply with the requirements of Rule 14a-8 of the Exchange Act and Roivant&#146;s bye-laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Roivant&#146;s bye-laws provide notice procedures for shareholders to nominate a person as a director and to propose business to
be considered by stockholders at a meeting. To be timely, a shareholder&#146;s notice must be delivered to Roivant at its offices at Suite 1, 3rd Floor, 11-12 St. James&#146;s Square, London SW1Y 4LB, United Kingdom, not later than the close of
business on the 90th&nbsp;day nor earlier than the opening of business on the 120th day before the anniversary date of the immediately preceding annual meeting of shareholders; provided, however, that in the event that the annual meeting is called
for a date that is not within 30 days before or after such anniversary date, which we anticipate will be the case for the 2022 annual meeting, notice by the shareholder to be timely must be so received no earlier than the opening of business on the
120th day before the meeting and not later than the later of (x) the close of business on the 90th day before the meeting and (y) the close of business on the 10th day following the day on which public announcement of the date of the annual meeting
was first made by Roivant. Nominations and proposals also must satisfy other requirements set forth in Roivant&#146;s bye-laws. The Chairman of the Board may refuse to acknowledge the introduction of any shareholder proposal not made in compliance
with the foregoing procedures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">441 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_32"></A>STOCKHOLDER COMMUNICATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders and interested parties may communicate with MAAC&#146;s board of directors, any committee chairperson or the <FONT
STYLE="white-space:nowrap">non-management</FONT> directors as a group by writing to the board or committee chairperson in care of Montes Archimedes Acquisition Corp., 724 Oak Grove Ave, Suite 130, Menlo Park, CA 94025. Following the Business
Combination, such communications should be sent to Roivant Sciences Ltd., Suite 1, 3rd Floor, <FONT STYLE="white-space:nowrap">11-12</FONT> St. James&#146;s Square, London SW1Y 4LB, United Kingdom. Each communication will be forwarded, depending on
the subject matter, to the board of directors, the appropriate committee chairperson or all <FONT STYLE="white-space:nowrap">non-management</FONT> directors. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_33"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conyers Dill &amp; Pearman Limited have passed upon the validity of the Roivant Common Shares offered by this proxy statement/prospectus and
certain other legal matters related to this proxy statement/prospectus. Davis Polk &amp; Wardwell LLP have passed upon the validity of the Roivant Warrants under New York law. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_34"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of MAAC as of December&nbsp;31, 2020 and for the period from July&nbsp;6, 2020 (inception) through December&nbsp;31,
2020, have been audited by Marcum LLP, an independent registered public accounting firm, as stated in their report thereon, and have been included in this proxy statement/prospectus in reliance upon such reports and upon the authority of such firm
as experts in accounting and auditing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Roivant Sciences Ltd. at March 31, 2021 and 2020, and for
each of the two years in the period ended March 31, 2021, appearing in this proxy statement/prospectus have been audited by Ernst &amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon appearing
elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">442 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_35"></A>HOUSEHOLDING INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless MAAC has received contrary instructions, MAAC may send a single copy of this proxy statement/prospectus to any household at which two
or more stockholders reside if we believe the stockholders are members of the same family. This process, known as &#147;householding,&#148; reduces the volume of duplicate information received at any one household and helps to reduce our expenses.
However, if stockholders prefer to receive multiple sets of MAAC&#146;s disclosure documents at the same address this year or in future years, the stockholders should follow the instructions described below. We will promptly provide separate copies
upon written or oral request. Similarly, if an address is shared with another stockholder and together both of the stockholders would like to receive only a single set of MAAC&#146;s disclosure documents, the stockholders should follow these
instructions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the shares are registered in the name of the stockholder, the stockholder should contact MAAC at its offices
at 724 Oak Grove Ave., Suite 130, Menlo Park, California 94025 to inform MAAC of his or her request; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If a bank, broker or other nominee holds the shares, the stockholder should contact the bank, broker or other
nominee directly. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_36"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC files reports, proxy statements and other information with the SEC. You can obtain such documents free of charge through the SEC&#146;s
website (www.sec.gov). In addition, you can request such documents by writing to MAAC at the following address: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Montes Archimedes
Acquisition Corp. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">724 Oak Grove Ave, Suite&nbsp;130 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Menlo Park, California 94025 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAC has supplied all information contained in this proxy statement/prospectus relating to MAAC. Roivant has supplied all information
contained in this document relating to Roivant. Information provided by MAAC or Roivant does not constitute any representation, estimate or projection of any other party. Information and statements contained in this proxy statement/prospectus or any
annex to this proxy statement/prospectus are qualified in all respects by reference to the copy of the relevant contract or other annex filed as an exhibit to this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you would like additional copies of this proxy statement/prospectus or if you have questions about the Business Combination or the
proposals to be presented at the MAAC Special Meeting, you should contact MAAC&#146;s proxy solicitation agent at the following address and telephone number: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone: (877) 279-2311 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email:
info@okapipartners.com </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a MAAC stockholders and would like to request documents, please do so by September 21, 2021, in
order to receive them before the MAAC Special Meeting. If you request any documents from MAAC, MAAC or its proxy solicitation agent will mail them to you by first class mail, or another equally prompt means. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document is a proxy statement/prospectus of MAAC for the MAAC Special Meeting. MAAC and Roivant have not authorized anyone to provide you with any
information or make any representation about the Business Combination, MAAC or Roivant that is different from, or in addition to, that contained in this proxy statement/prospectus. Therefore, if anyone does give you information of this sort, you
should not rely on it. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">443 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
information contained in this proxy statement/prospectus speaks only as of the date of this proxy statement/prospectus unless the information specifically indicates that another date applies.
Neither our mailing of this document to MAAC stockholders, nor the issuance of any securities by Roivant in connection with the Business Combination and the transactions related thereto, subsequent to that date will create any implication to the
contrary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">444 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_37"></A>INDEX TO FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page&nbsp;No.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Audited Financial Statements for Montes Archimedes Acquisition Corp.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin65062_15">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin65062_16">Balance Sheet as of December 31, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin65062_17">Statement of Operations for the period from July 6, 2020 (inception) through December
 31, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin65062_18">Statement of Changes in Stockholders&#146; Equity for the period from July 6,
 2020 (inception) through December 31, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin65062_19">Statement of Cash Flows for the period from July 6, 2020 (inception) through December
 31, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin65062_20">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unaudited Interim Financial Statements for Montes Archimedes Acquisition Corp.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin65062_21">Condensed Balance Sheet as of March 31, 2021 (Unaudited) and December 31, 2020
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin65062_22">Unaudited Condensed Statement of Operations for the three months ended March 31,
 2021</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin65062_23">Unaudited Condensed Statement of Changes in Stockholders&#146; Equity or the three
 months ended March&nbsp;31, 2021</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin65062_24">Unaudited Condensed Statement of Cash Flows for the three months ended March 31,
 2021</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin65062_25">Notes to Unaudited Condensed Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Audited Consolidated Financial Statements for Roivant Sciences Ltd.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin65062_ff1">Report of Independent Registered Public Accounting Firm </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin65062_ff2">Consolidated Balance Sheets as of March&nbsp;31, 2021 and
2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin65062_ff3">Consolidated Statements of Operations for the Years Ended March&nbsp;
31, 2021 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin65062_ff4">Consolidated Statements of Comprehensive (Loss) Income for the Years Ended March&nbsp;31,
2021 and&nbsp;2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin65062_ff5">Consolidated Statements of Shareholders&#146; Equity and Redeemable Noncontrolling
 Interest for the Years Ended March&nbsp;31, 2021 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin65062_ff6">Consolidated Statements of Cash Flows for the Years Ended March&nbsp;
31, 2021 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin65062_ff7">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin65062_15"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Stockholders and Board of Directors of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Montes Archimedes
Acquisition Corp. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying balance sheet of Montes Archimedes Acquisition Corp. (the &#147;Company&#148;) as of December&nbsp;31, 2020, the related
statements of operations, changes in stockholders&#146; equity and cash flows for the period from July&nbsp;6, 2020 (inception) through December&nbsp;31, 2020, and the related notes (collectively referred to as the &#147;financial statements&#148;).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2020, and the results of its operations and its cash flows for the period from July&nbsp;6, 2020
(inception) through December&nbsp;31, 2020, in conformity with accounting principles generally accepted in the United States of America. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Restatement
of the 2020 Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed in Note 2 to the financial statements, the accompanying financial statements as of December&nbsp;31,
2020 and for period from July&nbsp;6, 2020 (inception) through December&nbsp;31, 2020, have been restated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial
statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#147;PCAOB&#148;) and are required to be independent with respect to the Company in accordance with the
U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audit in
accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The
Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the
purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and
performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and
significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Marcum&nbsp;<SMALL>LLP</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marcum&nbsp;<SMALL>LLP</SMALL> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the
Company&#146;s auditor since 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Houston, Texas </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;22, 2021 except for the effects of the restatement discussed in Note 2 and subsequent events discussed in Note 11 as to which the date is
May&nbsp;13, 2021 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin65062_16"></A>MONTES ARCHIMEDES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BALANCE SHEET </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31, 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Restated&#151;See Note 2) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,696,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">276,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Due from underwriters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,977,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and Marketable Securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">410,803,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>412,780,872</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and Stockholders&#146; Equity:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">207,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">240,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Franchise tax payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">552,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,097,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,375,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,025,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Commitments and Contingencies</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A common stock, $0.0001 par value; 34,375,578 shares subject to possible redemption at
$10.00 per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">343,755,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Stockholders&#146; Equity:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and
outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A common stock, $0.0001 par value; 400,000,000 shares authorized; 6,696,245 shares
issued and outstanding (excluding 34,375,578 shares subject to possible redemption)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;B common stock, $0.0001 par value; 40,000,000 shares authorized; 10,267,956 shares
issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,772,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,774,318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total stockholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Liabilities and Stockholders&#146; Equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>412,780,872</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin65062_17"></A>MONTES ARCHIMEDES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENT OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Period From July&nbsp;6, 2020 (Inception) Through December&nbsp;31, 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Restated&#151;See Note 2) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">338,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses&#151;related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Franchise tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(454,875</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of derivative warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,587,890</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing costs&#151;derivative warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,800,025</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain on marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss before taxes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,757,609</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,774,318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted average shares outstanding of common stock subject to redemption, basic and
diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,386,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic and diluted net income per share, common stock subject to redemption</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted average shares outstanding of common stock, basic and diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,324,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic and diluted net loss per share, common stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.81</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin65062_18"></A>MONTES ARCHIMEDES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENT OF CHANGES IN STOCKHOLDERS&#146; EQUITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Period From July&nbsp;6, 2020 (Inception) Through December&nbsp;31, 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Restated&#151;See Note 2) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="3" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Equity</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance&#151;July 6, 2020 (inception)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Class&nbsp;B common stock to initial stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,500,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,150</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23,850</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>25,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Sale of units in initial public offering, gross</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>41,071,823</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,107</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>380,526,333</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>380,530,440</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(21,025,341</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(21,025,341</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Common stock subject to possible redemption</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(34,375,578</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3,437</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(343,752,343</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(343,755,780</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeiture <B>of Class</B><B></B>&nbsp;B common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,232,044</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(123</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>123</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(10,774,318</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(10,774,318</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance&#151;December 31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>6,696,245</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>670</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>10,267,956</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,027</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>15,772,622</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(10,774,318</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,000,001</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin65062_19"></A>MONTES ARCHIMEDES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENT OF CASH FLOWS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>For the Period From July&nbsp;6, 2020 (Inception) Through December&nbsp;31, 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Restated&#151;See Note 2) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Cash Flows from Operating Activities:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,774,318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net (loss) income to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,587,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing cost&#151;derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,800,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(79,568</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain on marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,613</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(260,093</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">207,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Franchise tax payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(248,954</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Investing Activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash deposited in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(410,718,230</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(410,718,230</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Financing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from note payable to related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of note payable to related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(200,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds received from initial public offering, gross</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">410,718,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds received from private placement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,214,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering costs paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,797,978</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reimbursement of offering costs from underwriters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">529,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash provided by financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">412,663,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase in cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,696,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash&#151;beginning of the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash&#151;end of the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B><B></B><B></B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B><B></B><B>1,696,491</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of noncash activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeiture of Class B common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering costs paid by Sponsor in exchange for issuance of Class B common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses paid by Sponsor in exchange for issuance of Class B common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering costs included in accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin65062_20"></A>Note 1&#151;Description of Organization, Business Operations and Basis of
Presentation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Montes Archimedes Acquisition Corp, (the &#147;Company&#148;) is a blank check company incorporated in Delaware on
July&nbsp;6, 2020. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the &#147;Business
Combination&#148;). The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the Company had not commenced any operations. All activity for the period from July&nbsp;6, 2020 (inception)
through December&nbsp;31, 2020 relates to the Company&#146;s formation and the initial public offering (the &#147;Initial Public Offering&#148;) described below, and the search for a target for its initial Business Combination. The Company will not
generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate <FONT STYLE="white-space:nowrap">non-operating</FONT> income in the form of interest income on cash and cash
equivalents from the proceeds derived from the Initial Public Offering and placed in Trust Account (as defined below). The Company has selected December&nbsp;31 as its fiscal year end. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s sponsor is Patient Square Capital LLC (the &#147;Sponsor&#148;). The registration statement for the Company&#146;s Initial
Public Offering was declared effective on October&nbsp;6, 2020. On October&nbsp;9, 2020, the Company consummated its Initial Public Offering of 40,000,000 units (the &#147;Units&#148;) at $10.00 per Unit, generating gross proceeds of
$400.0&nbsp;million, and incurring offering costs of approximately $22.1&nbsp;million (net of reimbursement of offering costs of $520,000 from the underwriters), inclusive of $14.0&nbsp;million in deferred underwriting commissions (Note 6). The
underwriters exercised the over-allotment option in part and on November&nbsp;12, 2020 purchased an additional 1,071,823 Units (the &#147;Over-Allotment Units&#148;), generating gross proceeds of approximately $10.7&nbsp;million, and incurred
additional offering costs of approximately $576,000 in underwriting fees (net of reimbursement of offering costs of approximately $14,000 from the underwriters and inclusive of approximately $375,000 in deferred underwriting fees) (the
&#147;Over-Allotment&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Simultaneously with the closing of the Initial Public Offering, the Company consummated the private
placement (&#147;Private Placement&#148;) of 10,000,000 warrants (each, a &#147;Private Placement Warrant&#148; and collectively, the &#147;Private Placement Warrants&#148;) at a price of $1.00 per Private Placement Warrant to the Sponsor,
generating proceeds of $10.0&nbsp;million (Note 5). Simultaneously with the closing of the Over-allotment on November&nbsp;12, 2020, the Company consummated the second closing of the Private Placement, resulting in the purchase of an aggregate of an
additional 214,365 Private Placement Warrants by the Sponsor, generating gross proceeds to the Company of approximately $214,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon
the closing of the Initial Public Offering, the Over-Allotment, and the Private Placement, approximately $410.7&nbsp;million ($10.00 per Unit) of the net proceeds of the sale of the Units in the Initial Public Offering and of the Private Placement
Warrants in the Private Placement were placed in a trust account (&#147;Trust Account&#148;) located in the United States with Continental Stock Transfer&nbsp;&amp; Trust Company acting as trustee, and invested only in U.S. &#147;government
securities,&#148; within the meaning set forth in Section&nbsp;2(a)( 16) of the Investment Company Act, with a maturity of 185 days or less, or in money market funds meeting certain conditions under Rule <FONT STYLE="white-space:nowrap">2a-7</FONT>
under the Investment Company Act, which invest only in direct U.S. government treasury obligations, as determined by the Company, until the earlier of: (i)&nbsp;the completion of a Business Combination and (ii)&nbsp;the distribution of the Trust
Account as described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s management has broad discretion with respect to the specific application of the net
proceeds of the Initial Public Offering and the sale of Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the
Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (as defined
below) (excluding the amount of deferred underwriting discounts held in Trust and taxes payable on the income earned on the Trust Account) at the time of the agreement to enter </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
into the initial Business Combination. However, the Company only intends to complete a Business Combination if the post-transaction company owns or acquires 50% or more of the issued and
outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act 1940, as amended (the &#147;Investment
Company Act&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will provide holders (the &#147;Public Stockholders&#148;) of the Company&#146;s outstanding shares of
Class&nbsp;A common stock sold in the Initial Public Offering (the &#147;Public Shares&#148;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&nbsp;in connection with a
stockholder meeting called to approve the Business Combination or (ii)&nbsp;by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the
Company, solely in its discretion. The Public Stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then held in the Trust Account (initially anticipated to be $10.00 per Public Share), calculated as of two
business days prior to the initial Business Combination, including interest earned on the funds held in the trust account and not previously released to the Company to pay the Company&#146;s taxes, net of taxes payable. The <FONT
STYLE="white-space:nowrap">per-share</FONT> amount to be distributed to Public Stockholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note
6). The Company will proceed with a Business Combination if a majority of the shares voted are voted in favor of the Business Combination. The Company will not redeem the Public Shares in an amount that would cause its net tangible assets to be less
than $5,000,001. If a stockholder vote is not required by applicable law or stock exchange rule and the Company does not decide to hold a stockholder vote for business or other reasons, the Company will, pursuant to its amended and restated
certificate of incorporation (the &#147;Certificate of Incorporation&#148;), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (&#147;SEC&#148;) and file tender offer documents with the SEC
prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by applicable law or stock exchange rule, or the Company decides to obtain stockholder approval for business or reasons, the Company will
offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Stockholder may elect to redeem their Public Shares without voting, and if they do
vote, irrespective of whether they vote for or against the proposed transaction. If the Company seeks stockholder approval in connection with a Business Combination, the initial stockholders (as defined below) agreed to vote any Founder Shares (as
defined below in Note 5) and any Public Shares held by them in favor of a Business Combination. In addition, the initial stockholders agreed to waive their redemption rights with respect to any Founder Shares and any Public Shares held by them in
connection with the completion of a Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation will provide that a Public Stockholder,
together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a &#147;group&#148; (as defined under Section&nbsp;13 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange
Act&#148;)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Public Shares, without the prior consent of the Company. The Sponsor and the Company&#146;s officers and directors (the
&#147;initial stockholders&#148;) agreed, pursuant to a letter agreement with the Company, that they will not propose any amendment to the Certificate of Incorporation (A)&nbsp;to modify the substance or timing of the Company&#146;s obligation to
allow redemption in connection with the initial Business Combination or to redeem 100% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (B)&nbsp;with respect to any
other provision relating to stockholders&#146; rights or <FONT STYLE="white-space:nowrap">pre-initial</FONT> Business Combination activity, unless the Company provides the Public Stockholders with the opportunity to redeem their Public Shares upon
approval of any such amendment at a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable)
divided by the number of then outstanding Public Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Company is unable to complete a Business Combination within 24 months
from the closing of the Initial Public Offering, or October&nbsp;9, 2022, (as such period may be extended pursuant to the Certificate of Incorporation, the &#147;Combination Period&#148;), the Company will (i)&nbsp;cease all operations except for
the purpose of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
winding up, (ii)&nbsp;as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a <FONT STYLE="white-space:nowrap">per-share</FONT> price,
payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes, if any (less up to $100,000 of interest
to pay dissolution expenses), divided by the number of the then outstanding Public Shares, which redemption will completely extinguish Public Stockholders&#146; rights as stockholders (including the right to receive further liquidation
distributions, if any), subject to applicable law, and (iii)&nbsp;as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the board of directors, liquidate and dissolve, subject in each
case, to the Company&#146;s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial stockholders agreed to waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares
held by them if the Company fails to complete a Business Combination within the Combination Period. However, if the initial stockholders acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating
distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters agreed to waive their rights to the deferred underwriting commission (see
Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be
available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be only, or less
than, $10.00. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party (except for the Company&#146;s independent registered public accounting
firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement (a &#147;Target&#148;), reduce the amount of funds in the Trust Account to below
the lesser of (i) $10.00 per Public Share and (ii)&nbsp;the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per Public Share due to reductions in the value of the
trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or Target that executed a waiver of any and all rights to the monies held in the Trust Account nor will it apply to any claims under the
Company&#146;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). Moreover, in the event that an executed
waiver is deemed to be unenforceable against a third party, then the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify
the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers, prospective target businesses and other entities with which the Company does business, execute agreements with the Company waiving any right, title,
interest or claim of any kind in or to monies held in the Trust Account. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Basis of Presentation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying financial statements of the Company have been prepared in accordance with United States generally accepted accounting
principles (&#147;U.S. GAAP&#148;) and pursuant to the rules and regulations of the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described in Note 2&#151;Restatement of
Previously Issued Financial Statements, the Company&#146;s financial statements for the period as of December&nbsp;31, 2020, and the period from July&nbsp;6, 2020 (inception) through December&nbsp;31, 2020 (collectively, the &#147;Affected
Period&#148;), are restated in this Annual Report on Form <FONT STYLE="white-space:nowrap">10-K/A</FONT> (Amendment No.&nbsp;1) (this &#147;Annual Report&#148;) to correct the misapplication of accounting guidance related to the Company&#146;s
warrants in the Company&#146;s previously issued audited and unaudited condensed financial statements for such periods. The restated financial statements are indicated as &#147;Restated&#148; in the audited and unaudited condensed financial
statements and accompanying notes, as applicable. See Note 2&#151;Restatement of Previously Issued Financial Statements for further discussion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Emerging Growth Company </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act, as modified by the Jumpstart Our
Business Startups Act of 2012 (the &#147;JOBS Act&#148;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not
limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its
periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, Section&nbsp;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial
accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or
revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to <FONT STYLE="white-space:nowrap">non-emerging</FONT>
growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public
or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This may make comparison of the Company&#146;s financial statements with another public company that is neither an emerging growth company nor
an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Liquidity and Capital Resources </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the Company had approximately $1.7&nbsp;million in its operating bank account and working capital of
approximately $1.5&nbsp;million (not taking into account approximately $ 105,000 of taxes that may be paid using interest income from the Trust Account). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s liquidity needs prior to the consummation of the Initial Public Offering were satisfied through a payment of $25,000 from
the Sponsor to cover certain expenses on behalf of the Company in exchange for the issuance of the Founder Shares (as defined below), the loan under the Note from the Sponsor of $200,000 (see Note 5) to the Company. The Company folly repaid the Note
on October&nbsp;9, 2020. Subsequent to the consummation of the Initial Public Offering, the Company&#146;s liquidity has been satisfied through the portion of the proceeds of the Initial Public Offering and the Private Placement held outside of the
Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company&#146;s officers and directors may, but are not obligated to, provide
the Company Working Capital Loans (see Note 5). To date, there were no amounts outstanding under any Working Capital Loans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the
foregoing, management believes that the Company will have sufficient working capital and borrowing capacity to meet its needs through the earlier of the consummation of a Business Combination or one year from this filing. Over this time period, the
Company will be using these funds for paying existing accounts payable, identifying and evaluating prospective initial Business Combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures,
selecting the target business to merge with or acquire, and structuring, negotiating and consummating the Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Risks
and uncertainties </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management continues to evaluate the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the
industry and has concluded that while it is reasonably possible that the virus could have an effect on the Company&#146;s financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do
not include any adjustments that might result from the outcome of this uncertainty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2 &#151;Restatement of Previously Issued Financial Statements
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2021, the Audit Committee of the Company, in consultation with management, concluded that, because of a misapplication of the
accounting guidance related to its public and private placement warrants to purchase common stock that the Company issued in October 2020 (the &#147;Warrants&#148;), the Company&#146;s previously issued financial statements for the Affected Period
should no longer be relied upon. As such, the Company is restating its financial statements for the Affected Period included in this Annual Report. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;12, 2021, the staff of the Securities and Exchange Commission (the &#147;SEC Staff&#146;) issued a public statement entitled
&#147;Staff Statement on Accounting and Reporting Considerations for Warrants issued by Special Purpose Acquisition Companies (&#147;SPACs&#148;)&#148; (the &#147;Public Statement&#148;). In the Public Statement, the SEC Staff expressed its view
that certain terms and conditions common to SPAC warrants may require the warrants to be classified as liabilities on the SPAC&#146;s balance sheet and, based on our application of Financial Accounting Standards Board (&#147;FASB&#148;) Accounting
Standard Codification (&#147;ASC&#148;) Topic <FONT STYLE="white-space:nowrap">815-40,</FONT> Derivatives and Hedging, Contracts in Entity&#146;s Own Equity (&#147;ASC <FONT STYLE="white-space:nowrap">815-40&#148;),</FONT> our statement of
operations did not include subsequent <FONT STYLE="white-space:nowrap">non-cash</FONT> changes in estimated fair value of the Warrants. The views expressed in the Public Statement were not consistent with our historical interpretation of specific
provisions within our warrant agreement, dated as of October&nbsp;6, 2021 (&#147;warrant agreement&#148;), and our application of ASC <FONT STYLE="white-space:nowrap">815-40</FONT> to the warrant agreement. Since issuance on October&nbsp;9, 2020,
the Company&#146;s warrants were accounted for as equity within the Company&#146;s previously reported balance sheets. After discussion and evaluation, including with the Company&#146;s independent registered public accounting firm and the
Company&#146;s audit committee, management concluded that the warrants should be presented as liabilities with subsequent fair value remeasurement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Therefore, the Company, in consultation with its Audit Committee, concluded that its previously issued Financial Statements as of
December&nbsp;31, 2020, and for the period from July&nbsp;6, 2020 (inception) through December&nbsp;31, 2020 should be restated because of a reclassification of of our outstanding warrants to purchase common stock (the &#147;Warrants&#148;) and,
solely as a result of this material weakness, should no longer be relied upon. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impact of the Restatement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The impact of the restatement on the balance sheets, statements of operations and statements of cash flows for the Affected Period is presented
below. The restatement had no impact on net cash flows from operating, investing or financing activities. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As Previously</B><br><B>Reported</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Restatement<BR>Adjustment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="12"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet</B></P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">412,780,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">412,780,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">552,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">552,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,375,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,375,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,097,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,097,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,927,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,097,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,025,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A common stock, $0.0001 par value; shares subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">392,853,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49,097,230</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">343,755,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="12"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock- $0.0001 par value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A common stock&#151;$0.0001 par value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;B common stock&#151;$0.0001 par value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-capital</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,385,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,387,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,772,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(386,403</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,387,915</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,774,318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">412,780,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">412,780,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period From July&nbsp;6, 2020 (Inception) Through<BR>December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;Previously<BR>Reported</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Restatement<BR>Adjustment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="12"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Operations</B></P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(454,875</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(454,875</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="12"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense) income:</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing costs&#151;derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,800,025</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,800,025</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,587,890</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,587,890</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain on marketable securtities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other (expense) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,387,915</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,302,734</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(386,403</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,387,915</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,774,318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding of common stock subject to redemption, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,896,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,510,304</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34.386,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share, common stock subject to redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding of common stock, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,985,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,338,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,324,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share, common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.04&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">) $&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.77&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">) $&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.81</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period From July&nbsp;6, 2020 (Inception) Through<BR>December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As Previously</B><br><B>Reported</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Restatement<BR>Adjustment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="12"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Cash Flows</B></P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(248,954</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(248,954</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(410,718,230</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(410,718,230</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,663,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,663,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net change in cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,696,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,696,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the impact to the balance sheet dated October&nbsp;9, 2020, filed on <FONT
STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> on October&nbsp;16, 2020 related to the impact of accounting for the Public Warrants and Private Placement Warrants as liabilities at fair value resulted in a $44.4&nbsp;million increase to the
derivative warrant liabilities line item at October&nbsp;9, 2020 and offsetting decrease to the Class&nbsp;A common stock subject to possible redemption mezzanine equity line item. There was no change to total stockholders&#146; equity at the
reported balance sheet date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3&#151;Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Use of Estimates </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
preparation of the financial statements in conformity with U.S. GAAP requires the Company&#146;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the
estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future
confirming events. Accordingly, the actual results could differ significantly from those estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Cash and Cash Equivalents </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Cash and Marketable Securities Held in Trust Account </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s portfolio of investments held in the Trust Account is comprised of cash and U.S. government securities, within the meaning
set forth in Section&nbsp;2(a)(16) of the Investment Company Act. with a maturity of 185 days or less. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Concentration of Credit Risk
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial
institution, which, at times, may exceed the Federal Depository Insurance Coverage limit of $250,000. and any investments held in Trust Account. As of December&nbsp;31, 2020. the Company had not experienced losses on these accounts and management
believes the Company is not exposed to significant risks on such accounts. The Company&#146;s investments held in the Trust Account as of December&nbsp;31, 2020 is comprised of investments in U.S. Treasury securities with an original maturity of 185
days or less. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Fair Value of Financial Instruments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction
between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The hierarchy gives the highest priority to unadjusted quoted prices in active markets for
identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;1, defined as observable inputs such as quoted prices for identical instruments in active markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly
observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an
entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In
those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the Company&#146;s assets and liabilities, which qualify as financial instruments under ASC 820, &#147;Fair Value
Measurements and Disclosures,&#148; approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the Public Warrants (if not market observed) and Private Placement Warrants is estimated using a Binomial Lattice in a
risk-neutral framework. The future stock price of the Company is modeled assuming a Geometric Brownian Motion in a risk-neutral framework. For each modeled future price, the warrant payoff is calculated based on the contractual terms (incorporating
any optimal early exercise / redemption), and then discounted at the term-matched risk-free rate. The value of the Warrants is calculated as the probability-weighted present value over all future modeled payoffs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Offering Costs Associated with the Initial Public Offering </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Offering costs consisted of legal, accounting, underwriting fees and other costs incurred that were directly related to the Initial Public
Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with warrant liabilities are
expensed as incurred, presented as <FONT STYLE="white-space:nowrap">non-operating</FONT> expenses in the statement of operations. Offering costs associated with the Public Shares were charged to stockholders&#146; equity upon the completion of the
Initial Public Offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Class&nbsp;A Common Stock Subject to Possible Redemption </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for its Class&nbsp;A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480
&#147;Distinguishing Liabilities from Equity.&#148; Shares of Class&nbsp;A common stock subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable shares of Class&nbsp;A
common stock (including shares of Class&nbsp;A common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#146;s
control) are classified as temporary equity. At all other times, shares of Class&nbsp;A common stock are classified as stockholders&#146; equity. Shares of Class&nbsp;A common stock of the Company feature certain redemption rights that are
considered to be outside of the Company&#146;s control and subject to the occurrence of uncertain future events. Accordingly, as of December&nbsp;31, 2020, 34,375,578 shares of Class&nbsp;A common stock subject to possible redemption were presented
as temporary equity, outside of the stockholders&#146; equity section of the Company&#146;s balance sheet. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Derivative Warrant
Liabilities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The
Company evaluates all of its financial instruments, including issued stock purchase warrants, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC <FONT STYLE="white-space:nowrap">815-15.</FONT> The
classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is <FONT STYLE="white-space:nowrap">re-assessed</FONT> at the end of each reporting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company issued 20,535,912 warrants in connection with the Initial Public Offering (the &#147;Public Warrants&#148;) 10,214,365 warrants in
a Private Placement Placement (the &#147;Private Placement Warrants&#148;). These warrants are recognized as derivative liabilities in accordance with ASC <FONT STYLE="white-space:nowrap">815-40.</FONT> The excess of the fair value of the Private
Placement Warrants over the proceeds received is recognized as a financing cost of the derivative liability. Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjust the instruments to fair value at each
reporting period. The liabilities are subject to <FONT STYLE="white-space:nowrap">re-measurement</FONT> at each balance sheet date until exercised, and any change in fair value is recognized in the Company&#146;s statement of operations. The fair
value of the Public Warrants (if not market observed) and Private Placement Warrants is estimated using a Binomial Lattice in a risk-neutral framework. The future stock price of the Company is modeled assuming a Geometric Brownian Motion in a
risk-neutral framework. For each modeled future price, the Warrant payoff is calculated based on the contractual terms (incorporating any optimal early exercise / redemption), and then discounted at the term-matched risk-free rate. The value of the
Warrants is calculated as the probability-weighted present value over all future modeled payoffs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Income Taxes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company complies with the accounting and reporting requirements of FASB ASC 740, &#147;Income Taxes,&#148; which requires an asset and
liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future
taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the
amount expected to be realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement
recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> to be sustained upon examination by
taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Net Income (Loss) Per Common Share </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#147;Earnings Per Share.&#148; Net income (loss) per
common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. The Company has not considered the effect of the warrants sold in the Initial Public Offering and Private Placement
to purchase an aggregate of 30,750,277 shares of the Company&#146;s common stock in the calculation of diluted loss per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants
would be anti-dilutive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s statement of operations includes a presentation of income (loss) per common share for
Class&nbsp;A common shares subject to possible redemption in a manner similar to the <FONT STYLE="white-space:nowrap">two-class</FONT> method of income (loss) per common share. Net income (loss) per common share, basic and diluted, for Class&nbsp;A
common stock subject to possible redemption is calculated by dividing the proportionate share of income or loss on marketable securities held by the Trust Account, net of applicable franchise and income taxes, by the weighted average number of
shares of Class&nbsp;A common stock subject to possible redemption outstanding since original issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net income (loss) per common
share, basic and diluted, for <FONT STYLE="white-space:nowrap">non-redeemable</FONT> common stock is calculated by dividing the net income (loss), adjusted for income or loss on marketable securities attributable to common stock
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to possible redemption, by the weighted average number of <FONT STYLE="white-space:nowrap">non-redeemable</FONT> common stock outstanding for the period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-redeemable</FONT> common stock includes Founder Shares and
<FONT STYLE="white-space:nowrap">non-redeemable</FONT> shares of Class&nbsp;A common stock as these shares do not have any redemption features. <FONT STYLE="white-space:nowrap">Non-redeemable</FONT> common stock participates in the income or loss on
marketable securities based on <FONT STYLE="white-space:nowrap">non-redeemable</FONT> shares&#146; proportionate interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table reflects the calculation of basic and diluted net income (loss) per common share: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Period<BR>from July&nbsp;6,<BR>2020<BR>(inception)<BR>through<BR>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Class&nbsp;A Common stock subject to possible redemption</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator: Earnings allocable to Common stock subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from investments held in trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Company&#146;s portion available to be withdrawn to pay taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(71,296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator: Weighted average Class&nbsp;A common stock subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted weighted average shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>34,386,548</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net income per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I><FONT STYLE="white-space:nowrap">Non-Redeemable</FONT> Common Stock</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator: Net Loss minus Net Earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,774,318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income allocable to Class&nbsp;A common stock subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-redeemable</FONT> net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(10,774,318</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator: weighted average <FONT STYLE="white-space:nowrap">Non-redeemable</FONT> common
stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted weighted average shares outstanding,
<FONT STYLE="white-space:nowrap">Non-redeemable</FONT> common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13,324,191</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share, <FONT STYLE="white-space:nowrap">Non-redeemable</FONT>
common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(0.81</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Recent Accounting Pronouncements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management does not believe that any recently issued, but not yet effective, accounting pronouncement if currently adopted would have a
material effect on the Company&#146;s financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4&#151;Initial Public Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;9, 2020, the Company consummated its Initial Public Offering of 40,000,000 Units at $ 10.00 per Unit, generating gross proceeds
of $400.0&nbsp;million, and incurring offering costs of approximately $22.1&nbsp;million (net of reimbursement of offering costs of $520,000 from the underwriters), inclusive of $14.0&nbsp;million in deferred underwriting commissions. The
Underwriters exercised the over-allotment option in part and on November&nbsp;12, 2020 purchased an additional 1,071,823 Over-Allotment Units, generating gross proceeds of approximately $10.7&nbsp;million, and incurred additional offering costs of
approximately $576,000 in underwriting fees (net of reimbursement of offering costs of approximately $14,000 from the underwriters and inclusive of approximately $375,000 in deferred underwriting fees). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Unit consists of one share of Class&nbsp;A common stock, and <FONT STYLE="white-space:nowrap">one-half</FONT> of one redeemable warrant
(each, a &#147;Public Warrant&#148;). Each whole Public Warrant entitles the holder to purchase one share of Class&nbsp;A common stock at a price of $ 11.50 per share, subject to adjustment (see Note 7). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5&#151;Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Founder Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;23,
2020, an affiliate of the Sponsor paid an aggregate of $25,000 for certain expenses on behalf of the Company in exchange for issuance of 14,375,000 shares of the Company&#146;s Class&nbsp;B common stock, par value $0.0001 per share (the
&#147;Founder Shares&#148;), with such shares subsequently transferred to the Sponsor. On October&nbsp;6, 2020, the Sponsor surrendered 2,875,000 shares of Class&nbsp;B common stock to the Company for no consideration, resulting in a decrease of the
Founder Shares from 14,375,000 shares to 11,500,000 shares. All shares and associated amounts have been retroactively restated to reflect the share surrender. The initial stockholders agreed to forfeit up to 1,500,000 Founder Shares to the extent
that the over-allotment option was not exercised in full by the underwriters, so that the Founder Shares will represent 20.0% of the Company&#146;s issued and outstanding shares of common stock after the Initial Public Offering. The underwriters
partially exercised their over-allotment option in part on November&nbsp;12, 2020; and the remaining over-allotment expired unexercised on November&nbsp;20, 2020 resulting in the forfeiture of 1,232,044 share of Class&nbsp;B common stock. At
December&nbsp;31, 2020, there were 10,267,956 shares of Class&nbsp;B common stock outstanding, none subject to forfeiture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Initial
Stockholders agreed, subject to limited exceptions, not to transfer, assign or sell any of the Founder Shares until the earlier to occur of: (A)&nbsp;one year after the completion of the initial Business Combination or (B)&nbsp;subsequent to the
initial Business Combination; (x)&nbsp;if the last reported sale price of Class&nbsp;A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20
trading days within any <FONT STYLE="white-space:nowrap">30-trading</FONT> day period commencing at least 150 days after the initial Business Combination; or (y)&nbsp;the date on which the Company completes a liquidation, merger, capital stock
exchange or other similar transaction that results in all of the stockholders having the right to exchange their common stock for cash, securities or other property. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Private Placement Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Simultaneously with the closing of the Initial Public Offering, the Company consummated the Private Placement of 10,000,000 Private Placement
Warrants at a price of $1.00 per Private Placement Warrant to the Sponsor, generating proceeds of $10.0&nbsp;million. Simultaneously with the closing of the Over-allotment on November&nbsp;12, 2020, the Company consummated the second closing of the
Private Placement, resulting in the purchase of an aggregate of an additional 214,365 Private Placement Warrants by the Sponsor, generating gross proceeds to the Company of approximately $214,000. The excess of fair value of the Private Placement
Warrants of $5.1&nbsp;million has been recognized as financing costs&#151;derivative warrant liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each whole Private Placement
Warrant is exercisable for one whole share of Class&nbsp;A common stock at a price of $ 11.50 per share, subject to adjustment. A portion of the proceeds from the sale of the Private Placement Warrants to the Sponsor was added to the proceeds from
the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the Private Placement Warrants will expire worthless. The Private Placement Warrants will be <FONT
STYLE="white-space:nowrap">non-redeemable</FONT> for cash (except as described below) and exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Sponsor agreed, subject to limited exceptions, not to transfer, assign or sell the Private Placement Warrants until 30 days after the
completion of the initial Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Related Party Loans </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;23, 2020, the Sponsor agreed to loan the Company an aggregate of up to $300,000 to cover expenses related to the Initial Public
Offering pursuant to a promissory note (the &#147;Note&#148;). This loan was <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing and payable upon the completion of the Initial Public Offering. The Company borrowed $200,000 under the Note
and fully repaid on October&nbsp;9, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in order to fund working capital deficiencies or finance transaction costs in
connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company&#146;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#147;Working Capital Loans&#148;).
If the Company completes a Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans could be repaid only out of funds held outside
the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay
the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination or, at the lender&#146;s discretion, up to $1,500,000 of such Working Capital Loans may be convertible into warrants of the post
Business Combination entity at a price of $1.00 per warrant. The warrants would be identical to the Private Placement Warrants. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written
agreements exist with respect to such loans. As of December&nbsp;31, 2020, the Company had no borrowings under the Working Capital Loans. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Administrative Services Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commencing October&nbsp;7, 2020 through the earlier of consummation of the initial Business Combination and the liquidation, the Company has
agreed to pay the Sponsor a total of $10,000 per month for office space, utilities, secretarial and administrative support services. The Company incurred and paid $28,065 for such services for the period from October&nbsp;7, 2020 through
December&nbsp;31, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 6&#151;Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Registration Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of
the Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any Class&nbsp;A common stock issuable upon the exercise of the Private Placement Warrants and warrants that may be issued
upon conversion of Working Capital Loans) are entitled to registration rights pursuant to the registration rights agreement. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company
registers such securities. In addition, the holders have certain &#147;piggy-back&#148; registration rights with respect to registration statements filed subsequent to the completion of the initial Business Combination. The Company will bear the
expenses incurred in connection with the filing of any such registration statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Underwriting Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters were entitled to an underwriting discount of $0.20 per unit, or $8.0&nbsp;million in the aggregate, paid upon the closing of
the Initial Public Offering. In addition, $0.35 per unit, or $14.0&nbsp;million in the aggregate will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts
held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. The underwriters agreed to make a payment to the Company in an amount of 0.13% of the gross proceeds
of the Initial Public Offering, or $520,000, to reimburse certain of offering expenses. The Company received such reimbursement on October&nbsp;27, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon closing of the Over-allotment on November&nbsp;12, 2020, the underwriters received approximately $214,000 in fees paid upfront and
eligible for an additional deferred underwriting commissions of approximately $375,000. In addition, the underwriters agreed to make an addition payment to the Company in an amount of 0.13% of the gross proceeds of the Over-allotment, or
approximately $14,000, to reimburse certain of offering expenses. As of December&nbsp;31, 2020, approximately $5,000 remained unpaid. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 7&#151;Derivative Warrant Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Public Warrants may only be exercised for a whole number of shares. No fractional Public Warrants will be issued upon separation of the Units
and only whole Public Warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination and (b) 12 months from the closing of the Initial Public Offering; provided in each
case that the Company has an effective registration statement under the Securities Act covering the shares of Class&nbsp;A common stock issuable upon exercise of the warrants and a current prospectus relating to them is available and such shares are
registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder (or holders are permitted to exercise their warrants on a cashless basis under the circumstances specified in the
warrant agreement as a result of (i)&nbsp;the Company&#146;s failure to have an effective registration statement by the 60th business day after the closing of the initial Business Combination or (ii)&nbsp;a notice of redemption described below under
&#147;Redemption of warrants when the price per Class&nbsp;A common stock equals or exceeds $10.00&#148;). If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if the Company is unable to
register or qualify the underlying securities for sale under all applicable state securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is not registering the
shares of Class&nbsp;A common stock issuable upon exercise of the warrants at this time. However, the Company has agreed that as soon as practicable, but in no event later than twenty business days after the closing of the initial Business
Combination, the Company will use its commercially reasonable efforts to file with the SEC and have an effective registration statement covering the shares of Class&nbsp;A common stock issuable upon exercise of the warrants and to maintain a current
prospectus relating to those shares of Class&nbsp;A common stock until the warrants expire or are redeemed. If a registration statement covering the Class&nbsp;A common stock issuable upon exercise of the warrants is not effective by the 60th
business day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration
statement, exercise warrants on a &#147;cashless basis&#148; in accordance with Section&nbsp;3(a)&nbsp;(9) of the Securities Act or another exemption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants will have an exercise price of $ 11.50 per share and will expire five years after the completion of a Business Combination or
earlier upon redemption or liquidation. If (x)&nbsp;the Company issues additional shares of Class&nbsp;A common stock or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an
issue price or effective issue price of less than $9.20 per share of Class&nbsp;A common stock (with such issue price or effective issue price to be determined in good faith by the Company and, (i)&nbsp;in the case of any such issuance to the
Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance, and (ii)&nbsp;to the extent that such issuance is made to the Sponsor or its affiliates, without
taking into account the transfer of Founder Shares or Private Placement Warrants (including if such transfer is effectuated as a surrender to the Company and subsequent reissuance by the Company) by the Sponsor in connection with such issuance) (the
&#147;Newly Issued Price&#148;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the
completion of the initial Business Combination (net of redemptions), and (z)&nbsp;the volume-weighted average trading price of Class&nbsp;A common stock during the 20 trading day period starting on the trading day prior to the day on which the
Company completes its initial Business Combination (such price, the &#147;Market Value&#148;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value
and the Newly Issued Price, and the $10.00 and $18.00 per share redemption trigger prices described under &#147;Redemption of warrants when the price per Class&nbsp;A common stock equals or exceeds $18.00&#148; and &#147;Redemption of warrants when
the price per Class&nbsp;A common stock equals or exceeds $10.00&#148; will be adjusted (to the nearest cent) to be equal to 100% and 180% of the higher of the Market Value and the Newly Issued Price, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Private Placement Warrants will be identical to the Public Warrants, except that the Private Placement Warrants (including the
Class&nbsp;A common stock issuable upon exercise of the Private Placement Warrants) will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not be transferable, assignable or salable until 30 days after the completion of the initial Business Combination and they will not be redeemable by the Company so long as they are held by the
Sponsor or its permitted transferees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Redemption of warrants when the price per share of Class&nbsp;A common stock equals or exceeds
$18.00. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once the warrants become exercisable, the Company may redeem the outstanding warrants for cash (except as described herein
with respect to the Private Placement Warrants): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in whole and not in part; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a price of $0.01 per warrant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon a minimum of 30 days&#146; prior written notice of redemption; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the last reported sale price of Class&nbsp;A common stock for any 20 trading days within a <FONT
STYLE="white-space:nowrap">30-trading</FONT> day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders (the &#147;Reference Value&#148;) equals or exceeds $18.00 per share
(as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, in this
case, the Company will not redeem the warrants unless an effective registration statement under the Securities Act covering the Class&nbsp;A common stock issuable upon exercise of the warrants is effective and a current prospectus relating to those
shares of Class&nbsp;A common stock is available throughout the <FONT STYLE="white-space:nowrap">30-day</FONT> redemption period. Any such exercise would not be on a &#147;cashless&#148; basis and would require the exercising warrant holder to pay
the exercise price for each warrant being exercised. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Redemption of warrants when the price per share of Class&nbsp;A common stock
equals or exceeds $10.00. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once the warrants become exercisable, the Company may redeem the outstanding warrants (except as described
herein with respect to the Private Placement Warrants): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in whole and not in part; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at $0.10 per warrant upon a minimum of 30 days&#146; prior written notice of redemption provided that holders
will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to an agreed table based on the redemption date and the &#147;fair market value&#148; of the Shares of
Class&nbsp;A common stock; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the Reference Value equals or exceeds $10.00 per share (as adjusted for stock splits, stock
dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the Reference Value is less than $18.00 per share (as adjusted for stock splits, stock dividends, rights
issuances, subdivisions, reorganizations, recapitalizations and the like), the Private Placement Warrants must also concurrently be called for redemption on the same terms (except as described herein with respect to a holder&#146;s ability to
cashless exercise its warrants) as the outstanding Public Warrants, as described above. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The &#147;fair market
value&#148; of Class&nbsp;A common stock shall mean the volume-weighted average price of Class&nbsp;A common stock for the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of warrants. In no
event will the warrants be exercisable in connection with this redemption feature for more than 0.361 shares of Class&nbsp;A common stock per warrant (subject to adjustment). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In no event will the Company be required to net cash settle any warrant. If the Company is unable to complete a Business Combination within
the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#146;s assets held
outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 8&#151;Stockholders&#146; Equity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Class</I></B><B><I></I></B><B><I>&nbsp;A Common Stock&#151;</I></B>The Company is authorized to issue 400,000,000 shares of Class&nbsp;A
common stock with a par value of $0.0001 per share. As of December&nbsp;31, 2020, there were 41,071,823 shares of Class&nbsp;A common stock outstanding, including 34,375,578 shares of Class&nbsp;A common stock subject to possible redemption that
were classified as temporary equity in the accompanying balance sheet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Class</I></B><B><I></I></B><B><I>&nbsp;B Common
Stock&#151;</I></B>The Company is authorized to issue 40,000,000 shares of Class&nbsp;B common stock with a par value of $0.0001 per share. On July&nbsp;23, 2020, an affiliate of the Sponsor paid an aggregate of $25,000 for certain expenses on
behalf of the Company in exchange for issuance of 14,375,000 shares of Class&nbsp;B common stock, with such shares subsequently transferred to the Sponsor. On October&nbsp;6, 2020, the Sponsor surrendered 2,875,000 shares of Class&nbsp;B common
stock to the Company for no consideration, resulting in a decrease of the outstanding Class&nbsp;B common stock from 14,375,000 shares to 11,500,000 shares. All shares and associated amounts have been retroactively restated to reflect the share
surrender. Of these, an aggregate of up to 1,500,000 shares of Class&nbsp;B common stock that are subject to forfeiture to the Company by the initial stockholders for no consideration to the extent that the underwriters&#146; over-allotment option
is not exercised in full or in part, so that the number of Founder Shares will equal 20% of the Company&#146;s issued and outstanding shares of common stock after the Initial Public Offering. The underwriters partially exercised their over-allotment
option on November&nbsp;12, 2020, and the remaining over-allotment expired unexercised on November&nbsp;20, 2020 resulting in the forfeiture of 1,232,044 Class&nbsp;B common shares. As of December&nbsp;31, 2020, 10,267,956 shares of Class&nbsp;B
common stock were outstanding with no shares subject to forfeiture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders of record are entitled to one vote for each share held
on all matters to be voted on by stockholders. Holders of our Class&nbsp;A common stock and holders of our Class&nbsp;B common stock will vote together as a single class on all matters submitted to a vote of our stockholders except as required by
law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Class&nbsp;B common stock will automatically convert into Class&nbsp;A common stock on the first business day following the
completion of the initial Business Combination at a ratio such that the number of shares of Class&nbsp;A common stock issuable upon conversion of all Founder Shares will equal, in the aggregate, on an
<FONT STYLE="white-space:nowrap">as-converted</FONT> basis, 20% of the sum of (i)&nbsp;the total number of shares of Class&nbsp;A common stock issued and outstanding upon completion of the Initial Public Offering, plus (ii)&nbsp;the sum of
(a)&nbsp;the total number of shares of Class&nbsp;A common stock issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to
the completion of the initial Business Combination, excluding any shares of Class&nbsp;A common stock or equity-linked securities exercisable for or convertible into shares of Class&nbsp;A common stock issued, or to be issued, to any seller in the
initial Business Combination and any Private Placement Warrants issued to the Sponsor upon conversion of Working Capital Loans, minus (b)&nbsp;the number of Public Shares redeemed by Public Stockholders in connection with the initial Business
Combination. In no event will the shares of Class&nbsp;B common stock convert into shares of Class&nbsp;A common stock at a rate of less than one to one. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock&#151;</I></B>The Company is authorized to issue 1,000,000 shares of preferred stock, par value $0.0001 per share, with
such designations, voting and other rights and preferences as may be determined from time to time by the Company&#146;s board of directors. As of December&nbsp;31, 2020, there were no shares of preferred stock issued or outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 9&#151;Fair Value Measurements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents information about the Company&#146;s assets that are measured at fair value on a recurring basis as of
December&nbsp;31, 2020 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted Prices<BR>in Active<BR>Markets</B><br><B>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant Other<BR>Observable&nbsp;Inputs</B><br><B>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant&nbsp;Other</B><br><B>Unobservable&nbsp;Inputs</B><br><B>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash and Marketable Securities held in Trust Accounting:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Treasury securities maturing on April&nbsp;8, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">410,803,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">410,803,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 32,652,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,445,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Transfers to/from Levels 1. 2. and 3 are recognized at the end of the reporting period. The estimated fair
value of the Public Warrants transferred from a Level&nbsp;3 measurement to a Level&nbsp;1 fair value measurement as of December 2020 as the Public Warrants were separately listed and traded beginning in November 2020. The amount transferred to
Level&nbsp;1 was $30.2&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level&nbsp;1 instruments include investments in mutual funds invested in government securities. The
Company uses inputs such as actual trade data, benchmark yields, quoted market prices from dealers or brokers, and other similar sources to determine the fair value of its investments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the Public Warrants (if not market observed) and Private Placement Warrants is estimated using a Binomial Lattice in a
risk-neutral framework. Specifically, the future stock price of the Company is modeled assuming a Geometric Brownian Motion in a risk-neutral framework. For each modeled future price, the Warrant payoff is calculated based on the contractual terms
(incorporating any optimal early exercise / redemption), and then discounted at the term-matched risk-free rate. The value of the Warrants is calculated as the probability-weighted present value over all future modeled payoffs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides quantitative information regarding Level&nbsp;3 fair value measurements inputs at their measurement dates: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;October&nbsp;9,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected date of Business Combination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">Mar-21</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.39</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in the fair value of the derivative warrant liabilities for the period from July&nbsp;6, 2020
(inception) through December&nbsp;31, 2020 is summarized as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative warrant liabilities at July&nbsp;6, 2020 (inception)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Public and Private Placement Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,509,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,587,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative warrant liabilities at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,097,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 10&#151;Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company does not currently have taxable income but will generate taxable income in the future primarily consisting of interest income
earned on the Trust Account. The Company&#146;s general and administrative costs are generally considered <FONT STYLE="white-space:nowrap">start-up</FONT> costs and are not currently deductible. The income tax provision (benefit) consists of the
following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the<BR>Period from<BR>July&nbsp;6, 2020<BR>(inception)<BR>through<BR>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="4"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation on allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(94,345</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s net deferred tax assets are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred tax assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Start-up/Organization</FONT> costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(94,345</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred tax asset, net of allowance</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="4"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred tax liabilities:</B></P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain on marketable securities held in the Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,179</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,179</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net Deferred tax assets/(liabilities), net of valuation allowance</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In assessing the realization of deferred tax assets, management considers whether it is more likely than not
that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing net
future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax assets, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the information
available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the statutory federal income tax rate (benefit) to the Company&#146;s
effective tax rate (benefit) is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the<BR>Period from<BR>July&nbsp;6, 2020<BR>(inception)<BR>through<BR>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Statutory Federal income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing Cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in Valuation Allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.9</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income Taxes Benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no unrecognized tax benefits as of December&nbsp;31, 2020. No amounts were accrued for the payment
of interest and penalties as of December&nbsp;31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax
examinations by major taxing authorities since inception. The Company&#146;s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 11&#151;Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management has evaluated subsequent events to determine if events or transactions occurring through March&nbsp;22, 2021, the date the financial
statements were available for issuance, require potential adjustment to or disclosure in the financial statements and has concluded that all such events that would require recognition or disclosure have been recognized or disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MONTES ARCHIMEDES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin65062_21"></A>UNAUDITED CONDENSED BALANCE SHEET </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARCH&nbsp;31, 2021 AND DECEMBER&nbsp;31, 2020</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BALANCE SHEET </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,463,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,696,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">236,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">276,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Due from underwriters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,699,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,977,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and Marketable Securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">410,790,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">410,803,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>412,490,902</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>412,780,872</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and Stockholders&#146; Equity:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">207,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,020,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">240,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Franchise tax payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,203,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">552,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,137,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,097,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,375,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,375,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,716,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,025,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Commitments and Contingencies</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A common stock, $0.0001 par value;&nbsp;36,277,487 and 34,375,578 shares subject to
possible redemption at $10.00 per share as of March&nbsp;31, 2021 and December&nbsp;31,2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">362,774,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">343,755,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Stockholders&#146; Equity:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and
outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A common stock, $0.0001 par value; 400,000,000 shares authorized; 4,794,336 and
6,696,245 shares issued and outstanding (excluding 36,277,487 and 34,375,578 shares subject to possible redemption) as of March&nbsp;31, 2021 and December&nbsp;31,2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;B common stock, $0.0001 par value; 40,000,000 shares authorized; 10,267,956 shares
issued and outstanding as of March&nbsp;31, 2021 and December, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,772,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retained earnings (accumulated deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,998,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,774,318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total stockholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Liabilities and Stockholders&#146; Equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>412,490,902</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>412,780,872</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MONTES ARCHIMEDES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin65062_22"></A>UNAUDITED CONDENSED STATEMENT OF INCOME </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE THREE MONTHS ENDED MARCH&nbsp;31, 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,934,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses&#151;related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Franchise tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,013,773</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,959,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income before taxes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,038,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,019,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted average shares outstanding of common stock subject to redemption, basic and
diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,396,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic and diluted net income per share, common stock subject to redemption</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted average shares outstanding of common stock, basic and diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,943,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic and diluted net income per share, common stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MONTES ARCHIMEDES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin65062_23"></A>UNAUDITED CONDENSED STATEMENT OF&nbsp;CHANGES IN STOCKHOLDERS&#146; EQUITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE THREE MONTHS ENDED MARCH&nbsp;31, 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Additional&nbsp;Paid-In</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Retained&nbsp;Earnings</B><br><B>(Accumulated&nbsp;Deficit)</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Equity</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance&#151;December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>6,696,245</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>670</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>10,267,956</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,027</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>15,772,622</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(10,774,318</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,000,001</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A common stock subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,901,909</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(191</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,772,622</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,246,278</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,019,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,019,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,019,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance&#151;March&nbsp;31, 2021 (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,794,336</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>479</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>10,267,956</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,027</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,998,504</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,000,010</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MONTES ARCHIMEDES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin65062_24"></A>UNAUDITED CONDENSED STATEMENT OF&nbsp;CASH FLOWS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE THREE MONTHS ENDED MARCH&nbsp;31, 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Operating Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,019,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net income to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(92,877</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in FV of derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22,959,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(93,569</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,780,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Franchise tax payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(237,983</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Financing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reimbursement of offering costs from underwriters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash provided by financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net decrease in cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(233,106</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash&#151;beginning of the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,696,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash&#151;end of the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,463,385</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of noncash activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in Value of Class&nbsp;A common stock subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,019,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MONTES ARCHIMEDES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin65062_25"></A>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note&nbsp;1&#151;Description of Organization, Business Operations and Basis of Presentation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Montes Archimedes Acquisition Corp. (the &#147;Company&#148;) was incorporated in Delaware on July&nbsp;6, 2020. The Company was formed for the purpose of
effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the &#147;Business Combination&#148;). The Company is an emerging growth company and, as such,
the Company is subject to all of the risks associated with emerging growth companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021, the Company had not commenced any
operations. All activity for the period from July&nbsp;6, 2020 (inception) through March&nbsp;31, 2021 relates to the Company&#146;s formation and the preparation for the initial public offering (the &#147;Initial Public Offering&#148;) described
below. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate <FONT STYLE="white-space:nowrap">non-operating</FONT> income in the form of
interest income on cash and cash equivalents from the proceeds derived from the Initial Public Offering. The Company has selected December&nbsp;31 as its fiscal year end. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s sponsor is Patient Square Capital LLC (the &#147;Sponsor&#148;). The registration statement for the Company&#146;s Initial Public Offering
was declared effective on October&nbsp;6, 2020. On October&nbsp;9, 2020, the Company consummated its Initial Public Offering of 40,000,000 units (the &#147;Units&#148;) at $10.00 per Unit, generating gross proceeds of $400.0&nbsp;million, and
incurring offering costs of approximately $22.1&nbsp;million (net of reimbursement of offering costs of $520,000 from the underwriters), inclusive of $14.0&nbsp;million in deferred underwriting commissions (Note 5). The underwriters exercised the
over-allotment option in full and on November&nbsp;12, 2020 purchased an additional 1,071,823 Units (the &#147;Over-Allotment Units&#148;), generating gross proceeds of approximately $10.7&nbsp;million, and incurred additional offering costs of
approximately $576,000 in underwriting fees (net of reimbursement of offering costs of approximately $14,000 from the underwriters and inclusive of approximately $375,000 in deferred underwriting fees) (the &#147;Over-Allotment&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (&#147;Private Placement&#148;) of 10,000,000
warrants (each, a &#147;Private Placement Warrant&#148; and collectively, the &#147;Private Placement Warrants&#148;) at a price of $1.00 per Private Placement Warrant to the Sponsor, generating proceeds of $10.0&nbsp;million (Note 4).
Simultaneously with the closing of the Over-allotment on November&nbsp;12, 2020, the Company consummated the second closing of the Private Placement, resulting in the purchase of an aggregate of&nbsp;an additional&nbsp;214,365 Private Placement
Warrants&nbsp;by the Sponsor, generating gross proceeds to the Company of approximately $214,000.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the closing of the Initial Public Offering, the
Over-Allotment, and the Private Placement, approximately $410.7&nbsp;million ($10.00 per Unit) of the net proceeds of the sale of the Units in the Initial Public Offering and of the Private Placement Warrants in the Private Placement were placed in
a trust account (&#147;Trust Account&#148;) located in the United States with Continental Stock Transfer&nbsp;&amp; Trust Company acting as trustee, and invested only in U.S. &#147;government securities,&#148; within the meaning set forth in
Section&nbsp;2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or in money market funds meeting certain conditions under Rule <FONT STYLE="white-space:nowrap">2a-7</FONT> under the Investment Company Act, which invest only
in direct U.S. government treasury obligations, as determined by the Company, until the earlier of: (i)&nbsp;the completion of a Business Combination and (ii)&nbsp;the distribution of the Trust Account as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of
the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination
successfully. The Company must complete an initial Business Combination with one or more operating businesses or assets with a fair market </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
value equal to at least 80% of the net assets held in the Trust Account (as defined below) (excluding the deferred underwriting commissions and taxes payable on the interest earned on the Trust
Account). However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target
business sufficient for it not to be required to register as an investment company under the Investment Company Act 1940, as amended (the &#147;Investment Company Act&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will provide holders (the &#147;Public Stockholders&#148;) of the Company&#146;s outstanding shares of Class&nbsp;A common stock sold in the
Initial Public Offering (the &#147;Public Shares&#148;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&nbsp;in connection with a stockholder meeting called to approve
the Business Combination or (ii)&nbsp;by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The
Public Stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then held in the Trust Account (initially anticipated to be $10.00 per Public Share), calculated as of two business days prior to the initial
Business Combination, including interest earned on the funds held in the trust account and not previously released to the Company to pay the Company&#146;s taxes, net of taxes payable. The <FONT STYLE="white-space:nowrap">per-share</FONT> amount to
be distributed to Public Stockholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note&nbsp;5). The Company will proceed with a Business
Combination if a majority of the shares voted are voted in favor of the Business Combination. The Company will not redeem the Public Shares in an amount that would cause its net tangible assets to be less than $5,000,001. If a stockholder vote is
not required by applicable law or stock exchange rule and the Company does not decide to hold a stockholder vote for business or other reasons, the Company will, pursuant to its amended and restated certificate of incorporation (the
&#147;Certificate of Incorporation&#148;), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (&#147;SEC&#148;) and file tender offer documents with the SEC prior to completing a Business
Combination. If, however, stockholder approval of the transaction is required by applicable law or stock exchange rule, or the Company decides to obtain stockholder approval for business or reasons, the Company will offer to redeem shares in
conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Stockholder may elect to redeem their Public Shares without voting, and if they do vote, irrespective of whether
they vote for or against the proposed transaction. If the Company seeks stockholder approval in connection with a Business Combination, the initial stockholders (as defined below) agreed to vote any Founder Shares (as defined below in Note&nbsp;4)
and any Public Shares held by them in favor of a Business Combination. In addition, the initial stockholders agreed to waive their redemption rights with respect to any Founder Shares and any Public Shares held by them in connection with the
completion of a Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation will provide that a Public Stockholder, together with any affiliate of such
stockholder or any other person with whom such stockholder is acting in concert or as a &#147;group&#148; (as defined under Section&nbsp;13 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;)), will be restricted from
redeeming its shares with respect to more than an aggregate of 15% or more of the Public Shares, without the prior consent of the Company. The Sponsor and the Company&#146;s officers and directors (the &#147;initial stockholders&#148;) agreed,
pursuant to a letter agreement with the Company, that they will not propose any amendment to the Certificate of Incorporation (A)&nbsp;to modify the substance or timing of the Company&#146;s obligation to allow redemption in connection with the
initial Business Combination or to redeem 100% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (B)&nbsp;with respect to any other provision relating to
stockholders&#146; rights or <FONT STYLE="white-space:nowrap">pre-initial</FONT> Business Combination activity, unless the Company provides the Public Stockholders with the opportunity to redeem their Public Shares upon approval of any such
amendment at a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable) divided by the number of
then outstanding Public Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MONTES ARCHIMEDES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company is unable to complete a Business Combination within 24&nbsp;months from the closing of the
Initial Public Offering, or October&nbsp;9, 2022, (as such period may be extended pursuant to the Certificate of Incorporation, the &#147;Combination Period&#148;), the Company will (i)&nbsp;cease all operations except for the purpose of winding up;
(ii)&nbsp;as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount then on deposit in
the Trust Account including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes, if any (less up to $100,000 of interest to pay dissolution expenses), divided by the number of the then
outstanding Public Shares, which redemption will completely extinguish Public Stockholders&#146; rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law; and (iii)&nbsp;as promptly
as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the board of directors, liquidate and dissolve, subject in each case, to the Company&#146;s obligations under Delaware law to provide for
claims of creditors and the requirements of other applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The initial stockholders agreed to waive their rights to liquidating distributions from
the Trust Account with respect to any Founder Shares held by them if the Company fails to complete a Business Combination within the Combination Period. However, if the initial stockholders acquire Public Shares in or after the Initial Public
Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters agreed to waive their
rights to the deferred underwriting commission (see Note&nbsp;5) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the
other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution
(including Trust Account assets) will be only, or less than, $10.00. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party (except for the
Company&#146;s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement (a &#147;Target&#148;),
reduce the amount of funds in the Trust Account to below the lesser of (i)&nbsp;$10.00 per Public Share and (ii)&nbsp;the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than
$10.00 per Public Share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or Target that executed a waiver of any and all rights to the monies held in
the Trust Account nor will it apply to any claims under the Company&#146;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the
&#147;Securities Act&#148;). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, then the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will
seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers, prospective target businesses and other entities with which the Company does
business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Proposed Business Combination </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;1, 2021, we
entered into a business combination agreement (the &#147;<I>Business Combination Agreement</I>&#148;) with Roivant Sciences Ltd., a Bermuda exempted limited company (&#147;<I>Roivant</I>&#148;), and Rhine Merger Sub, Inc., a Delaware corporation
(&#147;<I>Merger Sub&#148;</I>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement and the transactions contemplated thereby (collectively, the
&#147;<I>Transaction</I>&#148;) were approved by the boards of directors of each of MAAC, Roivant and Merger Sub, the requisite shareholders of Roivant and Roivant in its capacity as the sole stockholder of Merger Sub. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MONTES ARCHIMEDES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement provides for, among other things, the following transactions:
(i)&nbsp;Roivant&#146;s <FONT STYLE="white-space:nowrap">bye-laws</FONT> will be amended and restated, each outstanding share of Roivant will be subdivided (and in the case of certain <FONT STYLE="white-space:nowrap">non-voting</FONT> shares of
Roivant, converted) into common shares of Roivant (the &#147;<I>Roivant Common Shares</I>&#148;) based on a fixed exchange ratio of 2.9262 (the &#147;<I>Roivant Exchange Ratio</I>&#148;), and each outstanding equity award of Roivant will be
subdivided and adjusted into comparable equity awards of Roivant, based on the Roivant Exchange Ratio (the steps contemplated by this clause (i), collectively, the &#147;<I><FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps</I>&#148;); and
(ii)&nbsp;Merger Sub will merge with and into MAAC, with MAAC surviving the merger as a wholly-owned subsidiary of Roivant (the &#147;<I>Merger</I>&#148;). At the effective time of the Merger (the &#147;<I>Effective Time</I>&#148;), (a) each
outstanding share of MAAC Class&nbsp;A common stock and MAAC Class&nbsp;B common stock (other than treasury shares and any shares held by Patient Square Capital LLC, a Delaware limited liability company (the &#147;<I>MAAC Sponsor</I>&#148;), or its
affiliates) will be exchanged for one Roivant Common Share, (b)&nbsp;each outstanding share of MAAC Class&nbsp;B common stock held by the MAAC Sponsor or its affiliates will be exchanged for a number of Roivant Common Shares based on an exchange
ratio (the &#147;<I>MAAC Sponsor Exchange Ratio</I>&#148;), with a portion of such Roivant Common Shares issued to the MAAC Sponsor by virtue of the Merger being subject to the vesting and other terms and conditions set forth in the Sponsor Support
Agreement (as more fully described in the section entitled &#147;Sponsor Support Agreement&#148; below), and (c)&nbsp;each outstanding warrant to purchase shares of MAAC Class&nbsp;A common stock will be converted into a comparable warrant to
purchase Roivant Common Shares on the terms and subject to the conditions set forth in the Warrant Agreement, dated as of October&nbsp;6, 2020, by and between MAAC and the Continental Stock Transfer&nbsp;&amp; Trust Company. The MAAC Sponsor
Exchange Ratio is 1.0, subject to reduction in an amount equal to <FONT STYLE="white-space:nowrap">one-half</FONT> of the percentage of shares of MAAC Class&nbsp;A common stock redeemed in connection with the Business Combination (i.e., if 10% of
the shares of MAAC Class&nbsp;A common stock are so redeemed, then the MAAC Sponsor Exchange Ratio will be equal to 0.95), provided that in no event will the MAAC Sponsor Exchange Ratio be less than 0.75. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Transaction is expected to close (the &#147;<I>Closing</I>&#148;) in the third quarter of 2021, subject to the required approvals by MAAC&#146;s
stockholders and the fulfillment of other closing conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Refer to the Company&#146;s current report on Form
<FONT STYLE="white-space:nowrap">8-K,</FONT> filed with the SEC on May 01, 2021, for more information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021, the Company had approximately $1,463,000 cash and a working capital deficit of approximately $2,434,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s liquidity needs prior to the consummation of the Initial Public Offering were satisfied through a payment of $25,000 from the Sponsor to
cover certain expenses on behalf of the Company in exchange for the issuance of the Founder Shares (as defined below), the loan under the Note from the Sponsor of $200,000 (see Note 4) to the Company.&nbsp;The Company fully repaid the Note on
October&nbsp;9, 2020. Subsequent to the consummation of the Initial Public Offering, the Company&#146;s liquidity has been satisfied through the portion of the proceeds of the Initial Public Offering and the Private Placement held outside of the
Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination,&nbsp;the Sponsor or an affiliate of the Sponsor, or certain of the Company&#146;s officers and directors may, but are not obligated to,
provide the Company Working Capital Loans (see Note 4). To date, there were no amounts outstanding under any Working Capital Loans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with
our assessment of going concern considerations in accordance with ASU <FONT STYLE="white-space:nowrap">2014-15,</FONT> &#147;Disclosures of Uncertainties about an Entity&#146;s Ability to Continue as a Going Concern,&#148; as of March&nbsp;31, 2021,
we do not have sufficient liquidity to meet our obligations in the next twelve months. However, management has determined that we have access to funds from the Sponsor that are sufficient to fund our working capital needs until the earlier of the
consummation of an Business Combination or a minimum one year from the date of issuance of these financial statements.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MONTES ARCHIMEDES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management continues to evaluate the impact of
<FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic</FONT> and has concluded that the specific impact is not readily determinable as of the date of the financial statements. The financial statements do not include any adjustments that
might result from the outcome of this uncertainty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis of Presentation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the
United States of America (&#147;GAAP&#148;) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP. In the opinion of management, the
unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the period presented. Operating results for the three months ended
March&nbsp;31, 2021 are not necessarily indicative of the results that may be expected through December&nbsp;31, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act, as modified by the Jumpstart Our
Business Startups Act of 2012 (the &#147;JOBS Act&#148;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not
limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic
reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, Section&nbsp;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting
standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised
financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth
companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or
private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This may make comparison of the Company&#146;s financial statements with another public company that is neither an emerging growth company nor an emerging
growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note&nbsp;2&#151;Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Concentration of Credit Risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that
potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage limit of $250,000. At March&nbsp;31, 2021, the Company has
not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MONTES ARCHIMEDES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash and Cash Equivalents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no
cash equivalents as of March&nbsp;31, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash and Marketable Securities Held in Trust Account </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s portfolio of investments held in the Trust Account is comprised of cash and U.S. government securities, within the meaning set forth in
Section&nbsp;2(a)(16) of the Investment Company Act, with a maturity of 185&nbsp;days or less. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fair Value of Financial Instruments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market
participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level&nbsp;1 measurements) and the
lowest priority to unobservable inputs (Level&nbsp;3 measurements). These tiers include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;1, defined as observable inputs such as quoted prices for identical instruments in active markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly
observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an
entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy.&nbsp;In those
instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the Company&#146;s assets and liabilities, which qualify as financial instruments under ASC 820, &#147;Fair Value Measurements and
Disclosures,&#148; approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of
Estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of the financial statements in conformity with U.S.&nbsp;GAAP requires the Company&#146;s management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could
differ from those estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Offering Costs Associated with the Initial Public Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Offering costs consisted of legal, accounting, underwriting fees and other costs incurred that were directly related to the Initial Public Offering. Offering
costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MONTES ARCHIMEDES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MONTES ARCHIMEDES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
associated with warrant liabilities are expensed as incurred, presented as <FONT STYLE="white-space:nowrap">non-operating</FONT> expenses in the statement of operations. Offering costs associated
with the Public Shares were charged to stockholders&#146; equity upon the completion of the Initial Public Offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Class&nbsp;A Common Stock Subject
to Possible Redemption </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for its Class&nbsp;A common stock subject to possible redemption in accordance with the guidance in ASC
Topic 480 &#147;Distinguishing Liabilities from Equity.&#148; Shares of Class&nbsp;A common stock subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable shares of
Class&nbsp;A common stock (including shares of Class&nbsp;A common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the
Company&#146;s control) are classified as temporary equity. At all other times, shares of Class&nbsp;A common stock are classified as stockholders&#146; equity. Shares of Class&nbsp;A common stock of the Company feature certain redemption rights
that are considered to be outside of the Company&#146;s control and subject to the occurrence of uncertain future events. Accordingly, as of March&nbsp;31, 2021, 36,277,487 shares of Class&nbsp;A common stock subject to possible redemption were
presented as temporary equity, outside of the stockholders&#146; equity section of the Company&#146;s balance sheet. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Net Income Per Common Share
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#147;Earnings Per Share.&#148; Net income (loss) per common
share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. The Company has not considered the effect of the warrants sold in the Initial Public Offering and Private
Placement to purchase an aggregate of 30,750,277 shares of the Company&#146;s common stock in the calculation of diluted income per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of
such warrants would be anti-dilutive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s statement of operations includes a presentation of income (loss) per common share for
Class&nbsp;A common shares subject to possible redemption in a manner similar to the <FONT STYLE="white-space:nowrap">two-class</FONT> method of income (loss) per common share. Net income (loss) per common share, basic and diluted, for Class&nbsp;A
common stock subject to possible redemption is calculated by dividing the proportionate share of income or loss on marketable securities held by the Trust Account, net of applicable franchise and income taxes, by the weighted average number of
shares of Class&nbsp;A common stock subject to possible redemption outstanding since original issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net income per common share, basic and diluted,
for <FONT STYLE="white-space:nowrap">non-redeemable</FONT> common stock is calculated by dividing the net income, adjusted for income or loss on marketable securities attributable to common stock subject to possible redemption, by the weighted
average number of <FONT STYLE="white-space:nowrap">non-redeemable</FONT> common stock outstanding for the period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-redeemable</FONT> common stock includes Founder Shares and <FONT STYLE="white-space:nowrap">non-redeemable</FONT> shares
of Class&nbsp;A common stock as these shares do not have any redemption features. <FONT STYLE="white-space:nowrap">Non-redeemable</FONT> common stock participates in the income or loss on marketable securities based on
<FONT STYLE="white-space:nowrap">non-redeemable</FONT> shares&#146; proportionate interest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MONTES ARCHIMEDES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table reflects the calculation of basic and diluted net income per common share: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the</B><br><B>Three</B><br><B>Months<BR>Ended<BR>March&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Class&nbsp;A Common stock subject to possible redemption</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator: Earnings allocable to Common stock subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from investments held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Company&#146;s portion available to be withdrawn to pay taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(60,788</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>21,250</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator: Weighted average Class&nbsp;A common stock subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted weighted average shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>34,396,710</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net income per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0.00</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Redeemable</FONT> Common Stock</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator: Net Loss minus Net Earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net gain</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,019,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less:&nbsp;Net income allocable to Class&nbsp;A common stock subject to possible
redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-redeemable</FONT> net gain</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>18,997,850</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator: weighted average <FONT STYLE="white-space:nowrap">Non-redeemable</FONT> common
stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted weighted average shares outstanding,
<FONT STYLE="white-space:nowrap">Non-redeemable</FONT> common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>16,943,069</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net income per share, <FONT STYLE="white-space:nowrap">Non-redeemable</FONT>
common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1.12</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Income Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
complies with the accounting and reporting requirements of FASB ASC 740, &#147;Income Taxes,&#148; which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are
computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are
expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or
expected to be taken in a tax return. For those benefits to be recognized, a tax position must be <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> to be sustained upon examination by taxing authorities. The Company recognizes accrued
interest and penalties related to unrecognized tax benefits as income tax expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MONTES ARCHIMEDES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Derivative warrant liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial
instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC <FONT STYLE="white-space:nowrap">815-15.</FONT> The
classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is <FONT STYLE="white-space:nowrap">re-assessed</FONT> at the end of each reporting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for its 30,750,277 warrants issued in connection with its Initial Public Offering (20,535,912) and Private Placement (10,214,365) as
derivative warrant liabilities in accordance with ASC <FONT STYLE="white-space:nowrap">815-40.</FONT> Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each
reporting period. The liabilities are subject to <FONT STYLE="white-space:nowrap">re-measurement</FONT> at each balance sheet date until exercised, and any change in fair value is recognized in the Company&#146;s statement of operations. The fair
value of the Public Warrants (if not market observed) and Private Placement Warrants is estimated using a Binomial Lattice in a risk-neutral framework. Specifically, the future stock price of the Company is modeled assuming a Geometric Brownian
Motion in a risk-neutral framework. For each modeled future price, the Warrant payoff is calculated based on the contractual terms (incorporating any optimal early exercise / redemption), and then discounted at the term-matched risk-free rate. The
value of the Warrants is calculated as the probability-weighted present value over all future modeled payoffs.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Issued Accounting Standards
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s management does not believe that any recently issued, but not yet effective, accounting standards updates, if currently adopted,
would have a material effect on the accompanying financial statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note&nbsp;3&#151;Initial Public Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;9, 2020, the Company consummated its Initial Public Offering of 40,000,000 Units at $10.00 per Unit, generating gross proceeds of
$400.0&nbsp;million, and incurring offering costs of approximately $22.1&nbsp;million (net of reimbursement of offering costs of $520,000 from the underwriters), inclusive of $14.0&nbsp;million in deferred underwriting commissions. The Underwriters
exercised the over-allotment option in full and on November&nbsp;12, 2020 purchased an additional 1,071,823 Over-Allotment Units, generating gross proceeds of approximately $10.7&nbsp;million, and incurred additional offering costs of approximately
$576,000 in underwriting fees (net of reimbursement of offering costs of approximately $14,000 from the underwriters and inclusive of approximately $375,000 in deferred underwriting fees). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Unit consists of one share of Class&nbsp;A common stock, and <FONT STYLE="white-space:nowrap">one-half</FONT> of one redeemable warrant (each, a
&#147;Public Warrant&#148;). Each whole Public Warrant entitles the holder to purchase one share of Class&nbsp;A common stock at a price of $11.50 per share, subject to adjustment (see Note&nbsp;6). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note&nbsp;4&#151;Related Party Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Founder
Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;23, 2020, an affiliate of the Sponsor paid an aggregate of $25,000 for certain expenses on behalf of the Company in exchange for
issuance of 14,375,000 shares of the Company&#146;s Class&nbsp;B common stock, par value $0.0001 per share (the &#147;Founder Shares&#148;), with such shares subsequently transferred to the Sponsor. On October&nbsp;6, 2020, the Sponsor surrendered
2,875,000 shares of Class&nbsp;B common stock to the Company for no consideration, resulting in a decrease of the Founder Shares from 14,375,000 shares to 11,500,000 shares. All </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MONTES ARCHIMEDES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares and associated amounts have been retroactively restated to reflect the share surrender. The initial stockholders agreed to forfeit up to 1,500,000 Founder Shares to the extent that the
over-allotment option is not exercised in full by the underwriters, so that the Founder Shares will represent 20.0% of the Company&#146;s issued and outstanding shares of common stock after the Initial Public Offering. The underwriters exercised
their Over-Allotment option in part on November&nbsp;12, 2020; and the remaining over-allotment expired unexercised on November&nbsp;20, 2020 resulting in a forfeiture of 1,232,044 shares of Class&nbsp;B common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Initial Stockholders agreed, subject to limited exceptions, not to transfer, assign or sell any of the Founder Shares until the earlier to occur of:
(A)&nbsp;one year after the completion of the initial Business Combination or (B)&nbsp;subsequent to the initial Business Combination; (x)&nbsp;if the last reported sale price of Class&nbsp;A common stock equals or exceeds $12.00 per share (as
adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any <FONT STYLE="white-space:nowrap">30-trading</FONT> day period commencing at least 150&nbsp;days after the initial
Business Combination; or (y)&nbsp;the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the stockholders having the right to exchange their common stock for cash,
securities or other property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Private Placement Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with the closing of the Initial Public Offering, the Company consummated the Private Placement of 10,000,000 Private Placement Warrants at a
price of $1.00 per Private Placement Warrant to the Sponsor, generating proceeds of $10.0&nbsp;million. Simultaneously with the closing of the Over-allotment on November&nbsp;12, 2020, the Company consummated the second closing of the Private
Placement, resulting in the purchase of an aggregate of&nbsp;an additional&nbsp;214,365 Private Placement Warrants&nbsp;by the Sponsor, generating gross proceeds to the Company of approximately $214,000.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each whole Private Placement Warrant is exercisable for one whole share of Class&nbsp;A common stock at a price of $11.50 per share, subject to adjustment. A
portion of the proceeds from the sale of the Private Placement Warrants to the Sponsor was added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the
Combination Period, the Private Placement Warrants will expire worthless. The Private Placement Warrants will be <FONT STYLE="white-space:nowrap">non-redeemable</FONT> for cash (except as described below) and exercisable on a cashless basis so long
as they are held by the Sponsor or its permitted transferees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor agreed, subject to limited exceptions, not to transfer, assign or sell the
Private Placement Warrants until 30&nbsp;days after the completion of the initial Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Party Loans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On&nbsp;July&nbsp;23, 2020, the Sponsor agreed to loan the Company an aggregate of up to $300,000 to cover expenses related to the Initial Public Offering
pursuant to a promissory note (the &#147;Note&#148;). This loan was <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing and payable upon the completion of the Initial Public Offering. As of September&nbsp;30, 2020, the Company borrowed
$200,000 under the Note. The Note was fully repaid on October&nbsp;9, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in order to fund working capital deficiencies or finance
transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company&#146;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#147;Working
Capital Loans&#148;). If the Company completes a Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans could be repaid only out of
funds held outside the Trust Account. In the event that a Business Combination does not close, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MONTES ARCHIMEDES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital
Loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination or, at the lender&#146;s discretion, up to $1,500,000 of such Working Capital Loans may be convertible into warrants of the post Business Combination
entity at a price of $1.00 per warrant. The warrants would be identical to the Private Placement Warrants. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with
respect to such loans. To date, the Company had no borrowings under the Working Capital Loans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Administrative Services Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company entered into an agreement that will provide that, commencing on October&nbsp;7, 2020 through the earlier of consummation of the Business
Combination and the liquidation, the Company will pay an affiliate of the Sponsor $10,000 per month for office space and administrative support services. For the three months ended March&nbsp;31, 2021, the Company incurred approximately $30,000
within General and administrative expenses &#150; related party. As of March&nbsp;31, 2021 there was $0 in accounts payable &#150; related party outstanding, as reflected in the accompanying unaudited condensed balance sheets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note&nbsp;5&#151;Commitments&nbsp;&amp; Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration and Stockholder Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of the
Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any Class&nbsp;A common stock issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon
conversion of Working Capital Loans) are entitled to registration rights pursuant to the registration rights agreement. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company
registers such securities. In addition, the holders have certain &#147;piggy-back&#148; registration rights with respect to registration statements filed subsequent to the completion of the Business Combination. The Company will bear the expenses
incurred in connection with the filing of any such registration statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Underwriting Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters were entitled to an underwriting discount of $0.20 per unit, or $8.0&nbsp;million in the aggregate, paid upon the closing of the Initial
Public Offering. In addition, $0.35 per unit, or $14.0&nbsp;million in the aggregate will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the
Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. The underwriters agreed to make a payment to the Company in an amount of 0.13% of the gross proceeds of the
Initial Public Offering, or $520,000, to reimburse certain of offering expenses. The Company received such reimbursement on October&nbsp;27, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon
closing of the Over-allotment on November&nbsp;12, 2020, the underwriters received approximately $214,000 in fees paid upfront and eligible for an additional deferred underwriting commissions of approximately $375,000. In addition, the underwriters
agreed to make an addition payment to the Company in an amount of 0.13% of the gross proceeds of the Over-allotment, or approximately $14,000, to reimburse certain of offering expenses. As of March&nbsp;31, 2021, there was no outstanding balance.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MONTES ARCHIMEDES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note&nbsp;6&#151;Stockholders&#146; Equity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock</I></B>&#151;The Company is authorized to issue 1,000,000 shares of preferred stock, par value $0.0001 per share, with such designations,
voting and other rights and preferences as may be determined from time to time by the Company&#146;s board of directors. As of March&nbsp;31, 2021, there were no shares of preferred stock issued or outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Class</I></B><B><I></I></B><B><I>&nbsp;A Common Stock</I></B><B><I></I></B>&nbsp;&#151; The Company is authorized to issue 400,000,000&nbsp;shares of
Class&nbsp;A common stock with a par value of $0.0001 per share. As of March&nbsp;31, 2021, there were 41,071,823 shares of Class&nbsp;A common stock outstanding, including 36,277,487 shares of Class&nbsp;A common stock subject to possible
redemption that were classified as temporary equity in the accompanying balance sheet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Class</I></B><B><I></I></B><B><I>&nbsp;B Common
Stock</I></B><B><I></I></B>&nbsp;&#151; The Company is authorized to issue 40,000,000&nbsp;shares of Class&nbsp;B common stock with a par value of $0.0001 per share. On July&nbsp;23, 2020, an affiliate of the Sponsor paid an aggregate of $25,000 for
certain expenses on behalf of the Company in exchange for issuance of 14,375,000 shares of Class&nbsp;B common stock, with such shares subsequently transferred to the Sponsor. On October&nbsp;6, 2020, the Sponsor surrendered 2,875,000 shares of
Class&nbsp;B common stock to the Company for no consideration, resulting in a decrease of the outstanding Class&nbsp;B common stock from 14,375,000 shares to 11,500,000 shares. All shares and associated amounts have been retroactively restated to
reflect the share surrender. Of these, an aggregate of up to 1,500,000 shares of Class&nbsp;B common stock that are subject to forfeiture to the Company by the initial stockholders for no consideration to the extent that the underwriters&#146;
over-allotment option is not exercised in full or in part, so that the number of Founder Shares will equal 20% of the Company&#146;s issued and outstanding shares of common stock after the Initial Public Offering. The underwriters partially
exercised their over-allotment option on November&nbsp;12, 2020, and the remaining over-allotment expired unexercised on November&nbsp;20, 2020 resulting in the forfeiture of 1,232,044 Class&nbsp;B common shares. As of March&nbsp;31, 2021,
10,267,956 shares of Class&nbsp;B common stock were outstanding with no shares subject to forfeiture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders of record are entitled to one vote for
each share held on all matters to be voted on by stockholders. Holders of our Class&nbsp;A common stock and holders of our Class&nbsp;B common stock will vote together as a single class on all matters submitted to a vote of our stockholders except
as required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Class&nbsp;B common stock will automatically convert into Class&nbsp;A common stock on the first business day following the
completion of the Business Combination at a ratio such that the number of shares of Class&nbsp;A common stock issuable upon conversion of all Founder Shares will equal, in the aggregate, on an <FONT STYLE="white-space:nowrap">as-converted</FONT>
basis, 20% of the sum of (i)&nbsp;the total number of shares of Class&nbsp;A common stock issued and outstanding upon completion of the Initial Public Offering, plus (ii)&nbsp;the sum of (a)&nbsp;the total number of shares of Class&nbsp;A common
stock issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the completion of the Business Combination, excluding any
shares of Class&nbsp;A common stock or equity-linked securities exercisable for or convertible into shares of Class&nbsp;A common stock issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Warrants
issued to the Sponsor upon conversion of Working Capital Loans, minus (b)&nbsp;the number of Public Shares redeemed by Public Stockholders in connection with the initial Business Combination. In no event will the shares of Class&nbsp;B common stock
convert into shares of Class&nbsp;A common stock at a rate of less than one to one. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B><B></B><B>&nbsp;7&#151;</B><B><I>Warrant</I></B>s </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Public Warrants may only be exercised for a whole number of shares. No fractional Public Warrants will be issued upon separation of the Units and only whole
Public Warrants will trade. The Public Warrants will become </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MONTES ARCHIMEDES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercisable on the later of (a)&nbsp;30&nbsp;days after the completion of a Business Combination and (b)&nbsp;12&nbsp;months from the closing of the Initial Public Offering; provided in each case
that the Company has an effective registration statement under the Securities Act covering the shares of Class&nbsp;A common stock issuable upon exercise of the warrants and a current prospectus relating to them is available and such shares are
registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder (or holders are permitted to exercise their warrants on a cashless basis under the circumstances specified in the
warrant agreement as a result of (i)&nbsp;the Company&#146;s failure to have an effective registration statement by the 60th&nbsp;business day after the closing of the initial Business Combination or (ii)&nbsp;a notice of redemption described below
under &#147;Redemption of warrants when the price per Class&nbsp;A common stock equals or exceeds $10.00&#148;). If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if the Company is unable
to register or qualify the underlying securities for sale under all applicable state securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is not registering the shares of
Class&nbsp;A common stock issuable upon exercise of the warrants at this time. However, the Company has agreed that as soon as practicable, but in no event later than twenty business days after the closing of the initial Business Combination, the
Company will use its commercially reasonable efforts to file with the SEC and have an effective registration statement covering the shares of Class&nbsp;A common stock issuable upon exercise of the warrants and to maintain a current prospectus
relating to those shares of Class&nbsp;A common stock until the warrants expire or are redeemed. If a registration statement covering the Class&nbsp;A common stock issuable upon exercise of the warrants is not effective by the 60th&nbsp;business day
after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement,
exercise warrants on a &#147;cashless basis&#148; in accordance with Section&nbsp;3(a)(9) of the Securities Act or another exemption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The warrants will
have an exercise price of $11.50 per share and will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. If (x)&nbsp;the Company issues additional shares of Class&nbsp;A common stock or
equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per share of Class&nbsp;A common stock (with such issue price or
effective issue price to be determined in good faith by the Company and, (i)&nbsp;in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as
applicable, prior to such issuance, and (ii)&nbsp;to the extent that such issuance is made to the Sponsor or its affiliates, without taking into account the transfer of Founder Shares or Private Placement Warrants (including if such transfer is
effectuated as a surrender to the Company and subsequent reissuance by the Company) by the Sponsor in connection with such issuance) (the &#147;Newly Issued Price&#148;), (y)&nbsp;the aggregate gross proceeds from such issuances represent more than
60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the completion of the initial Business Combination (net of redemptions), and (z)&nbsp;the volume-weighted average
trading price of Class&nbsp;A common stock during the 20 trading day period starting on the trading day prior to the day on which the Company completes its initial Business Combination (such price, the &#147;Market Value&#148;) is below $9.20 per
share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $10.00 and $18.00 per share redemption trigger prices described under
&#147;Redemption of warrants when the price per Class&nbsp;A common stock equals or exceeds $18.00&#148; and &#147;Redemption of warrants when the price per Class&nbsp;A common stock equals or exceeds $10.00&#148; will be adjusted (to the nearest
cent) to be equal to 100% and 180% of the higher of the Market Value and the Newly Issued Price, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Private Placement Warrants will be
identical to the Public Warrants, except that the Private Placement Warrants (including the Class&nbsp;A common stock issuable upon exercise of the Private Placement Warrants) will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MONTES ARCHIMEDES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not be transferable, assignable or salable until 30&nbsp;days after the completion of the initial Business Combination and they will not be redeemable by the Company so long as they are held by
the Sponsor or its permitted transferees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Redemption of warrants when the price per share of our Class&nbsp;A common stock equals or exceeds $18.00:
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once the warrants become exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the Private
Placement Warrants): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in whole and not in part; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a price of $0.01 per warrant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon a minimum of 30&nbsp;days&#146; prior written notice of redemption; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the last reported sale price of Class&nbsp;A common stock for any 20 trading days within a <FONT
STYLE="white-space:nowrap">30-trading</FONT> day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders (the &#147;Reference Value&#148;) equals or exceeds $18.00 per share
(as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, in this case, the
Company will not redeem the warrants unless an effective registration statement under the Securities Act covering the Class&nbsp;A common stock issuable upon exercise of the warrants is effective and a current prospectus relating to those shares of
Class&nbsp;A common stock is available throughout the <FONT STYLE="white-space:nowrap">30-day</FONT> redemption period. Any such exercise would not be on a &#147;cashless&#148; basis and would require the exercising warrant holder to pay the
exercise price for each warrant being exercised. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Redemption of warrants when the price per share of our Class&nbsp;A common stock equals or exceeds
$10.00 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once the warrants become exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the Private
Placement Warrants): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in whole and not in part; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at $0.10 per warrant upon a minimum of 30&nbsp;days&#146; prior written notice of redemption, provided that
holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to an agreed table based on the redemption date and the &#147;fair market value&#148; of Class&nbsp;A
common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the Reference Value equals or exceeds $10.00 per share (as adjusted for stock splits, stock
dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the Reference Value is less than $18.00 per share (as adjusted for stock splits, stock dividends, rights
issuances, subdivisions, reorganizations, recapitalizations and the like), the Private Placement Warrants must also concurrently be called for redemption on the same terms (except as described herein with respect to a holder&#146;s ability to
cashless exercise its warrants) as the outstanding Public Warrants, as described above. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;fair market value&#148; of
Class&nbsp;A common stock shall mean the volume-weighted average price of Class&nbsp;A common stock for the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of warrants. In no event will the
warrants be exercisable in connection with this redemption feature for more than 0.361 shares of Class&nbsp;A common stock per warrant (subject to adjustment). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MONTES ARCHIMEDES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In no event will the Company be required to net cash settle any warrant. If the Company is unable to complete
a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from
the Company&#146;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note
8&#151;Fair Value Measurements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents information about the Company&#146;s financial assets and liabilities that are measured at
fair value on a recurring basis as of March&nbsp;31, 2021 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measured as of March&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;Prices&nbsp;in</B><br><B>Active Markets</B><br><B>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant&nbsp;Other<BR>Observable&nbsp;Inputs<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant&nbsp;Other<BR>Unobservable&nbsp;Inputs</B><br><B>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investment held in Trust Account</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Treasury securties maturing on April&nbsp;8, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">410,790,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative warrant liabilities&#151;public warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,455,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative warrant liabilities&#151;private warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,682,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Fair Value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">428,246,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,682,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents information about the Company&#146;s financial assets and liabilities that are measured at fair
value on a recurring basis as of December&nbsp;31, 2020 by level within the fair value hierarchy: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measured as of December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;Prices&nbsp;in</B><br><B>Active Markets</B><br><B>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant&nbsp;Other</B><br><B>Observable&nbsp;Inputs</B><br><B>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant&nbsp;Other</B><br><B>Unobservable&nbsp;Inputs</B><br><B>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investment held in Trust Account</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Treasury securties maturing on April&nbsp;8, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">410,803,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative warrant liabilities&#151;public warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,652,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative warrant liabilities&#151;private warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,445,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Fair Value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">443,455,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,445,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transfers to/from Levels 1, 2, and 3 are recognized at the end of the reporting period. The estimated fair value of the Public
Warrants transferred from a Level&nbsp;3 measurement to a Level&nbsp;1 fair value measurement as of December 2020 as the Public Warrants were separately listed and traded beginning in November 2020. The amount transferred to Level&nbsp;1 was
$30.2&nbsp;million. There were no transfers between levels for the three months ended March&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the Public Warrants (if not
market observed) and Private Placement Warrants is estimated using a Binomial Lattice in a risk-neutral framework. Specifically, the future stock price of the Company is modeled </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MONTES ARCHIMEDES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assuming a Geometric Brownian Motion in a risk-neutral framework. For each modeled future price, the Warrant payoff is calculated based on the contractual terms (incorporating any optimal early
exercise / redemption), and then discounted at the term-matched risk-free rate. The value of the Warrants is calculated as the probability-weighted present value over all future modeled payoffs with changes in fair value recognized in the statement
of operations. For the three months ended March&nbsp;31, 2021, the Company recognized change in the fair value of warrant liabilities of approximately $22,959,500 presented on the accompanying statement of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The change in the fair value of the level 3 derivative warrant liabilities for three months ended March&nbsp;31, 2021 is summarized as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative warrant liabilities at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,445,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of derivative warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,762,920</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative warrant liabilities at March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,682,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides quantitative information regarding Level&nbsp;3 fair value measurements inputs as their
measurement dates: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;March&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;11.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock Price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.01</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note&nbsp;9&#151;Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management has evaluated subsequent events and transactions that occurred after the balance sheet date through the date the balance sheet was available for
issuance. Based on this evaluation, the Company identified the following subsequent events for disclosure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;1, 2021, the Company entered into
a business combination agreement (the &#147;<I>Business Combination Agreement</I>&#148;) with Roivant Sciences Ltd., a Bermuda exempted limited company (&#147;<I>Roivant</I>&#148;), and Rhine Merger Sub, Inc., a Delaware corporation (&#147;<I>Merger
Sub&#148;</I>). The Business Combination Agreement and the transactions contemplated thereby (collectively, the &#147;<I>Business Combination</I>&#148;) were approved by the boards of directors of each of MAAC, Roivant and Merger Sub, the requisite
shareholders of Roivant and Roivant in its capacity as the sole stockholder of Merger Sub. The Business Combination is expected to close (the &#147;<I>Closing</I>&#148;) in the third quarter of 2021, subject to the required approvals by MAAC&#146;s
stockholders and the fulfillment of other closing conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin65062_ff1"></A>Report of Independent Registered Public Accounting Firm
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Shareholders and the Board of Directors of Roivant Sciences Ltd. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the
accompanying consolidated balance sheets of Roivant Sciences Ltd. (the Company) as of March&nbsp;31, 2021 and 2020, the related consolidated statements of operations, comprehensive (loss) income, shareholders&#146; equity and redeemable
noncontrolling interest and cash flows for each of the two years in the period ended March&nbsp;31, 2021, and the related notes (collectively referred to as the &#147;consolidated financial statements&#148;). In our opinion, the consolidated
financial statements present fairly, in all material respects, the financial position of the Company at March&nbsp;31, 2021 and 2020, and the results of its operations and its cash flows for each of the two years in the period ended March&nbsp;31,
2021, in conformity with U.S. generally accepted accounting principles. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance
with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not
required to have, nor were we engaged to perform, an audit of internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of
expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test
basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the
financial statements. We believe that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2016. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Iselin, New Jersey </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June 30, 2021 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin65062_ff2"></A>ROIVANT SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(in thousands, except share and per share data) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,055,044</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,183,207</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77,701</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,275</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,250</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,763</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,186,995</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,219,245</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,749</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,962</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,279</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,970</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,931</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83,770</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investments measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188,978</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93,445</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,563</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,197</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,659</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,589,692</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,477,051</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Redeemable Noncontrolling Interest and Shareholders&#146; Equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,550</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,306</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76,936</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68,621</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,313</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,839</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred consideration liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,162</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,352</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">218,961</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,118</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liability instruments measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,893</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102,373</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,384</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,452</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt (includes $150,100 and $89,100 accounted for under the fair value option at
March&nbsp;31, 2021 and 2020, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170,280</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108,592</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,169</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">821</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">527,687</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">368,356</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,491</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,491</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common shares, par value $0.0000001 per share, 100,000,000,000 shares authorized and 222,669,799
and 214,879,058 shares issued and outstanding at March&nbsp;31, 2021 and 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,814,805</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,143,739</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subscription receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,918,462</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,109,228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,445</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,349</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#146; equity attributable to Roivant Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,797,788</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,032,162</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncontrolling interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">241,726</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,042</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,039,514</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,086,204</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, redeemable noncontrolling interest and shareholders&#146;<B>
</B>equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,589,692</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,477,051</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin65062_ff3"></A>ROIVANT SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Operations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(in thousands, except share and per share data) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,795</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,689</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,057</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,131</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">832,758</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">263,217</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">259,878</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">335,766</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,094,693</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">600,114</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,070,898</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(532,425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(95,533</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136,005</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of debt and liability instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,845</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(115,364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(107,344</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,701</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,622</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from continuing operations before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(898,547</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(560,986</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,686</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,124</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from continuing operations, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(900,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(568,110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from discontinued operations, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,578,426</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(900,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,010,316</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to noncontrolling interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(90,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(190,193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income attributable to Roivant Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(809,234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,200,509</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amounts attributable to Roivant Sciences Ltd.:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from continuing operations, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(809,234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(519,394</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from discontinued operations, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,719,903</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income attributable to Roivant Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(809,234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,200,509</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net (loss) income per common share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted loss from continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3.76</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2.72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted income from discontinued operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.85</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net (loss) income per common share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3.76</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.13</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted weighted average shares outstanding:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215,312,273</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">219,036,630</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215,312,273</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">219,036,630</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin65062_ff4"></A>ROIVANT SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Comprehensive (Loss) Income </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(in thousands) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(900,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,010,316</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income (loss):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,826</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,536</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,826</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,536</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(896,407</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,004,780</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss attributable to noncontrolling interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(90,967</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(190,862</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive (loss) income attributable to Roivant Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(805,440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,195,642</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin65062_ff5"></A>ROIVANT SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statement of Shareholders&#146; Equity and Redeemable Noncontrolling Interest </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(in thousands, except share data) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="30" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shareholders&#146; Equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable<BR>Noncontrolling<BR>Interest</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Subscription<BR>Receivable</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Income (Loss)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Noncontrolling<BR>Interests</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Shareholders&#146;<BR>Equity</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance at March&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,130</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">213,555,119</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,024,172</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,518</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,309,737</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170,216</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">887,169</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of subsidiary common shares, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,052</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,606</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117,658</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of subsidiary common shares to the Company</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,962</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,962</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Purchase of subsidiary common shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(62,913</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,631</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(65,544</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of subsidiary convertible and redeemable preferred stock, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,491</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Purchase of subsidiary convertible and redeemable preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55,130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(77,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(77,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of subsidiary warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">907</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">907</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise of subsidiary stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">875</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">532</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,407</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of the Company&#146;s common shares, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,952,143</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">999,193</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">999,193</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Repurchase of common shares and other equity instruments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,625,933</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(990,014</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(990,014</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Sale of interests in subsidiaries</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(43,398</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(43,398</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of equity by subsidiary upon Business Combination and recapitalization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69,379</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,307</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104,686</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of equity by subsidiary to the Company upon Business Combination and
recapitalization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,559</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,559</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Conversion of subsidiary convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,928</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,159</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,087</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of equity instruments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,842</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,842</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Settlement in equity of liability-classified instruments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,119</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,119</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deconsolidation of subsidiary</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,483</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,483</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Capital contributions to majority-owned subsidiaries</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,699</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,699</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,271</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,103</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,469</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122,572</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Foreign currency translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,867</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(669</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,536</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,200,509</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(190,193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,010,316</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance at March&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,491</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">214,879,058</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,143,739</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,349</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,109,228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,042</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,086,204</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of the Company&#146;s common shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,202,917</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">301,744</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">301,744</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of subsidiary common shares, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">324,995</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">231,102</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">456,097</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of subsidiary common shares to the Company</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,692</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,692</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise of subsidiary stock options and vesting of subsidiary restricted stock units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">522</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">907</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deconsolidation of subsidiary</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,054</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,054</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Consolidation of unconsolidated entity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,178</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,178</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Repurchase of equity awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash contribution to majority-owned subsidiaries</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,642</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,642</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">587,824</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,252</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,706</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84,958</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Foreign currency translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,794</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,826</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(809,234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(90,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(900,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance at March&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,491</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">222,669,799</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,814,805</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,445</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,918,462</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">241,726</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,039,514</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin65062_ff6"></A>ROIVANT SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(in thousands) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(900,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,010,316</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Adjustments to reconcile net (loss) income to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">351,523</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,405</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Unrealized foreign currency translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,826</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,536</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84,958</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122,572</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Gain on sale of business</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,985,949</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Change in fair value of investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(95,533</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136,005</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Change in fair value of debt and liability instruments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,845</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(115,364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(107,344</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Loss from equity method investment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,750</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,386</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,152</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,821</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Changes in assets and liabilities, net of effects from acquisition and divestiture:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,752</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,598</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,225</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,845</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Deferred consideration liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,272</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(552,138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(758,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from sale of business, net of cash disposed</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,772,191</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Cash disposed upon deconsolidation of subsidiary</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,085</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,049</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Cash acquired upon consolidation of unconsolidated entity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,439</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Investments in unconsolidated entities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Purchase of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,076</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Maturity of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,440</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Acquisitions, net of cash acquired</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,806</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net cash (used in) provided by investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(31,702</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,694,790</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from issuance of the Company&#146;s common shares, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">999,193</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Repurchase of common stock and equity awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(990,014</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from issuance of liability instruments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,567</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from issuance of subsidiary common shares, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">455,756</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117,658</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from issuance of equity by subsidiary upon Business Combination and
recapitalization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105,930</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Purchase of subsidiary common shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(65,544</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from issuance of subsidiary convertible and redeemable preferred stock, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,455</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Purchase of subsidiary convertible and redeemable preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(132,907</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from subsidiary debt financings, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83,781</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Repayment of long-term debt and convertible debt by subsidiary</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,063</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Payment of deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(286</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,082</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Payment for debt maintenance fee by subsidiary</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from exercise of subsidiary stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">907</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,407</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">456,264</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">214,081</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net change in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(127,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,150,121</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,269,252</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,119,131</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,141,676</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,269,252</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ROIVANT SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Cash Flows (Continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(in thousands) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-cash</FONT> investing and financing
activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets obtained and exchanged for operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,491</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56,025</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and operating lease liabilities, including amounts reclassified from other current liabilities and other liabilities to operating lease liabilities,
recognized upon the adoption of ASC 842, Leases, on April&nbsp;1, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,026</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subscription receivable related to issuance of subsidiary common shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of subsidiary convertible promissory notes to common shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,500</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(960</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,601</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of cash paid:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income taxes paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,076</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,936</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,017</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,158</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin65062_ff7"></A>ROIVANT SCIENCES LTD. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 1&#151;Description of Business and Liquidity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(A)
Description of Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roivant Sciences Ltd., inclusive of its consolidated subsidiaries (the &#147;Company&#148; or &#147;RSL&#148;), aims to
improve health by rapidly delivering innovative medicines and technologies to patients. The Company does this by building biotech and healthcare technology companies (&#147;Vants&#148;) and deploying technology to drive greater efficiency in
research and development and commercialization.&nbsp;In addition to biopharmaceutical subsidiaries, the Company also builds technology Vants focused on improving the process of developing and commercializing medicines. The Company was founded on
April&nbsp;7, 2014 as a Bermuda exempted limited company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has determined that it has one operating and reporting segment as it allocates
resources and assesses financial performance on a consolidated basis. The Company&#146;s subsidiaries are wholly owned subsidiaries and majority-owned or controlled subsidiaries. Refer to Note 3, &#147;Investments&#148; for further discussion of the
Company&#146;s investments in unconsolidated entities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(B) Liquidity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has incurred significant losses and negative cash flows from operations since its inception. As of March&nbsp;31, 2021, the Company had cash and
cash equivalents of approximately $2.1&nbsp;billion and its accumulated deficit was approximately $1.9&nbsp;billion. For the years ended March&nbsp;31, 2021 and 2020, the Company incurred losses from continuing operations of $900.2&nbsp;million and
$568.1&nbsp;million, respectively. The Company has historically financed its operations primarily through the sale of equity securities, sale of subsidiary interests, debt financings and revenue generated from licensing and collaboration
arrangements. The Company has not generated any revenues to date from the sale of its product candidates and does not anticipate generating any revenues from the sale of its product candidates unless and until it successfully completes development
and obtains regulatory approval to market its product candidates. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to
fully implement its business plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company intends to raise such additional capital through the issuance of equity securities, debt financings or
other sources in order to further implement its business plan. However, if such financing is not available at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product
candidates or take other steps to conserve capital. The Company expects its existing cash and cash equivalents will be sufficient to fund its committed operating expenses and capital expenditure requirements for at least the next 12 months from the
date of issuance of these consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2&#151;Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(A) Basis of Presentation and Principles of Consolidation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s fiscal year ends on March&nbsp;31, and its fiscal quarters end on June&nbsp;30, September&nbsp;30, and December 31. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying audited consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in
the United States (&#147;U.S. GAAP&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any references in these notes to applicable accounting guidance are meant to refer to the authoritative U.S.
GAAP as found in the Accounting Standards Codification (&#147;ASC&#148;) and Accounting Standards Updates </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(&#147;ASU&#148;) of the Financial Accounting Standards Board (&#147;FASB&#148;). The consolidated financial statements include the accounts of RSL and the subsidiaries in which it has a
controlling financial interest, most often through a majority voting interest. All intercompany balances and transactions have been eliminated in consolidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling
interests in its consolidated statements of operations equal to the percentage of the economic or ownership interest retained in the respective operations by the noncontrolling parties. The Company presents noncontrolling interests as a component of
shareholders&#146; equity on its consolidated balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for changes in its ownership interest in its subsidiaries while
control is retained as equity transactions. The carrying amount of the noncontrolling interest is adjusted to reflect the change in RSL&#146;s ownership interest in the subsidiary. Any difference between the fair value of the consideration received
or paid and the amount by which the noncontrolling interest is adjusted is recognized within shareholders&#146; equity attributable to RSL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally,
the Company concluded that the disposition of RSL&#146;s ownership interests in Myovant Sciences Ltd. (&#147;Myovant&#148;), Urovant Sciences Ltd. (&#147;Urovant&#148;), Enzyvant Therapeutics Ltd. (&#147;Enzyvant&#148;), Altavant Sciences Ltd.
(&#147;Altavant&#148;), and Spirovant Sciences Ltd. (&#147;Spirovant&#148;) (collectively, the &#147;Sumitovant Vants&#148;), pursuant to the transaction agreement entered into with Sumitomo Dainippon Pharma Co., Ltd. (&#147;Sumitomo&#148;) on
October&nbsp;31, 2019 (the &#147;Sumitomo Transaction Agreement&#148;) that closed on December&nbsp;27, 2019 (the &#147;Sumitomo Transaction&#148;), met the requirements to be presented as discontinued operations. As such, results relating to the
transferred interests prior to disposition are classified as discontinued operations in prior period consolidated financial statements. See Note 5, &#147;Sumitomo Transaction Agreement&#148; and Note 6, &#147;Discontinued Operations&#148; for
further discussion. Certain prior year amounts were reclassified to conform to current year presentation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2012, the Jumpstart Our Business
Startups Act of 2012 (the &#147;JOBS Act&#148;) was enacted. Section&nbsp;107(b) of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards.
Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has irrevocably elected not to avail itself of this extended transition period,
and, as a result, the Company will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(B) Use of Estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to
assets, liabilities, costs, expenses, contingent liabilities, share-based compensation and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be
reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the Company assessed the impact that the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has had on its operations and financial
results as of March&nbsp;31, 2021 and through the issuance of these consolidated financial statements. The Company&#146;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact <FONT
STYLE="white-space:nowrap">COVID-19</FONT> may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(C) Risks and Uncertainties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization
of products, regulatory approvals, dependence on key products, dependence on third-party service providers, such as contract research organizations, and protection of intellectual property rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(D) Concentrations of Credit Risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments
that potentially subject the Company to concentration of credit risk include cash and cash equivalents. The Company maintains cash deposits and cash equivalents in highly-rated, federally-insured financial institutions in excess of federally insured
limits. The Company has established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company has not experienced any credit losses related to these financial instruments and does not believe that it is
exposed to any significant credit risk related to these instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(E) Cash, Cash Equivalents, and Restricted Cash </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents include cash deposits in banks and all highly liquid investments that are readily convertible to cash. The Company considers all
highly liquid investments purchased with original maturities of three months or less to be cash equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted cash classified as a current
asset consists of the amount held in escrow relating to the Sumitomo Transaction (see Note 5, &#147;Sumitomo Transaction Agreement&#148;) and the legally restricted <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing deposit account
relating to the Company&#146;s corporate credit card program. Restricted cash classified as a long-term asset consists of restricted deposit accounts related to irrevocable standby letters of credit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash as reported in the accompanying consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted cash as
presented on the accompanying consolidated balance sheets as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,055,044</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,183,207</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,632</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,045</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,141,676</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,269,252</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(F) Trade Receivables, Net </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in customer credit
profiles. The Company reserves against trade receivables for estimated losses that may arise from a customer&#146;s inability to pay and any amounts determined to be uncollectible are written off against the reserve when it is probable that the
receivable will not be collected. The reserve amount for estimated losses was de minimis as of March&nbsp;31, 2021 and 2020. Trade receivables, net is included in &#147;Other current assets&#148; on the accompanying consolidated balance sheets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(G) Contingencies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may be, from time to time,
a party to various disputes and claims arising from normal business activities. The Company continually assesses any litigation or other claims it may confront to determine if an unfavorable outcome would lead to a probable loss or reasonably
possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the
estimate of a probable loss </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is a range and no amount within the range is more likely than another, the Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss
exists, the Company discloses the facts and circumstances of the litigation, including an estimable range, if possible. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(H) Property and Equipment
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, consisting primarily of computers, equipment, furniture and fixtures, software, and leasehold improvements, is recorded at
cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon disposal, retirement or sale, the related cost and accumulated depreciation is
removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation of property and equipment is recorded using the straight-line method over the estimated useful lives of the related assets once the asset
has been placed in service. Leasehold improvements are amortized using the straight-line method over the estimated useful life or remaining lease term, whichever is shorter. The following table provides the range of estimated useful lives used for
each asset type: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="66%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Property and Equipment</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Estimated Useful Life</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Lesser of estimated useful life or remaining lease term</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company reviews the recoverability of all long-lived assets, including the related useful lives, whenever events or
changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable. Recoverability is measured by comparison of the book values of the assets to the future net undiscounted cash flows that the assets are
expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future
net cash flows arising from the assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(I) Investments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For investments in entities over which the Company has significant influence but do not meet the requirements for consolidation and for which the Company has
not elected the fair value option, the Company applies the equity method of accounting with the Company&#146;s share of the underlying income or loss of such entities reported in &#147;Other expense, net&#148; on the consolidated statements of
operations. The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#146;s common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investments in equity securities may also be accounted for using (i)&nbsp;the fair value option if elected, (ii)&nbsp;fair value through earnings if fair
value is readily determinable or (iii)&nbsp;for equity investments without readily determinable fair values, the measurement alternative to measure at cost adjusted for any impairment and observable price changes, as applicable. The election to use
the measurement alternative is made for each eligible investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has elected the fair value option to account for certain investments over
which the Company has significant influence. The Company believes the fair value option best reflects the underlying economics of the investment. See Note 3, &#147;Investments.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(J) Research and Development Expenses </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and
development (&#147;R&amp;D&#148;) costs are expensed as incurred. Preclinical and clinical study costs are accrued over the service periods specified in the contracts and adjusted as necessary based upon an ongoing
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
review of the level of effort and costs actually incurred. Payments for a product license prior to regulatory approval of the product and payments for milestones achieved prior to regulatory
approval of the product are expensed in the period incurred as R&amp;D. Milestone payments made in connection with regulatory approvals are capitalized and amortized to cost of revenue over the remaining useful life of the asset. R&amp;D costs
primarily consist of the intellectual property and R&amp;D materials acquired and expenses from third parties who conduct R&amp;D activities on behalf of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluates <FONT STYLE="white-space:nowrap">in-licensed</FONT> agreements for <FONT STYLE="white-space:nowrap">in-process</FONT> research and
development projects (&#147;IPR&amp;D&#148;) to determine if it meets the definition of a business and thus should be accounted for as a business combination. If the <FONT STYLE="white-space:nowrap">in-licensed</FONT> agreement for IPR&amp;D does
not meet the definition of a business and the assets have not reached technological feasibility and therefore have no alternative future use, the Company expenses payments made under such license agreements as R&amp;D expense in its consolidated
statements of operations. The Company initially recognizes contingent consideration in an asset acquisition at fair value. The carrying value of contingent consideration is subsequently adjusted when the contingency is resolved and is paid or
becomes payable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(K) General and Administrative Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative (&#147;G&amp;A&#148;) expenses consist primarily of employee-related expenses for G&amp;A personnel, including those responsible for
the identification and acquisition or <FONT STYLE="white-space:nowrap">in-license</FONT> of new drug candidates as well as for overseeing Vant operations and facilitating the use of the Company&#146;s platform and technologies at Vants. G&amp;A
expenses also consist of legal and accounting fees, consulting services and other operating costs relating to corporate matters and daily operations. G&amp;A expenses include costs incurred relating to the identification, acquisition or <FONT
STYLE="white-space:nowrap">in-license</FONT> and technology transfer of promising drug candidates along with costs incurred relating to the integration of new technologies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(L) Income Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred tax assets and liabilities are
recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases. Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period
that includes the enactment date. A valuation allowance is recorded when, after consideration of all positive and negative evidence, it is not more likely than not that the Company&#146;s deferred tax assets will be realizable. If the Company
determines that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income
taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than
not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(M) Share-Based Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share-based awards to
employees, directors, and consultants, including stock options, restricted stock units, performance options and capped value appreciation rights, are measured at fair value on the date of the grant and that fair value is recognized as share-based
compensation expense in the Company&#146;s consolidated statements of operations over the requisite service period of the respective award. The estimated fair value of awards that contain performance conditions is expensed when the Company concludes
that it is probable that the performance condition will be achieved. The Company may grant awards with graded-vesting features. When such awards have only service vesting requirements, the Company elected to record share-based compensation
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expense on a straight-line basis. If awards with graded-vesting features contain performance or market conditions, then the Company records share-based compensation expense using the accelerated
attribution method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company measures the fair value of its stock options that only have service vesting requirements or performance-based options
without market conditions using the Black-Scholes option pricing model. For performance-based awards with market conditions, the Company determines the fair value of the awards as of the grant date using a Monte Carlo simulation model. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain assumptions need to be made with respect to utilizing the Black-Scholes option pricing model, including the expected life of the award, volatility of
the underlying shares, the risk-free interest rate and the fair value of the Company&#146;s common shares. Since the Company has no option exercise history, it has generally elected to estimate the expected life of an award based upon the
&#147;simplified method&#148; with the continued use of this method extended until such time the Company has sufficient exercise history. The risk-free interest rate is based on the rates paid on securities issued by the U.S. Treasury with a term
approximating the expected life of the equity award. The expected share price volatility for the Company&#146;s common shares is estimated by taking the average historical price volatility for industry peers. The Company accounts for <FONT
STYLE="white-space:nowrap">pre-vesting</FONT> award forfeitures when they occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the valuation of share-based compensation under the
Black-Scholes option pricing model, it is necessary for the Company to estimate the fair value of its common shares for RSL and privately held Vants. Given the absence of a public trading market, and in accordance with the American Institute of
Certified Public Accountants&#146; Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, the Company exercises reasonable judgment and considers numerous objective and subjective factors to determine its best
estimate of the fair value of its common shares. The estimation of the fair value of the common shares considers factors including the following: the prices of the Company&#146;s common shares sold to investors in arm&#146;s length transactions, the
estimated present value of the Company&#146;s future cash flows; the Company&#146;s business, financial condition and results of operations; the Company&#146;s forecasted operating performance; the illiquid nature of the Company&#146;s common
shares; industry information such as market size and growth; market capitalization of comparable companies and the estimated value of transactions such companies have engaged in; and macroeconomic conditions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(N) Fair Value Measurements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company utilizes fair
value measurement guidance prescribed by accounting standards to value its financial instruments. The guidance establishes a fair value hierarchy for financial instruments measured at fair value that distinguishes between assumptions based on market
data (observable inputs) and the Company&#146;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the
Company. Unobservable inputs are inputs that reflect the Company&#146;s assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the
circumstances. Fair value is defined as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the reporting date.
As a basis for considering market participant assumptions in fair value measurements, the guidance establishes a three-tier fair value hierarchy that distinguishes among the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>Level <FONT STYLE="white-space:nowrap">1-Valuations</FONT> are based on unadjusted quoted prices in active
markets for identical assets or liabilities that the Company has the ability to access. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>Level <FONT STYLE="white-space:nowrap">2-Valuations</FONT> are based on quoted prices for similar assets
or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>Level <FONT STYLE="white-space:nowrap">3-Valuations</FONT> are based on inputs that are unobservable
(supported by little or no market activity) and significant to the overall fair value measurement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent the valuation is based on models or inputs that are less observable or unobservable in the
market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&nbsp;3. A financial instrument&#146;s level
within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s financial
instruments include shares of common stock of Arbutus Biopharma Corporation (&#147;Arbutus&#148;); shares of Arbutus&#146;s Series A participating convertible preferred shares (&#147;Arbutus Preferred Shares&#148;); shares of common stock of Sio
Gene Therapies Inc. (&#147;Sio&#148;); liability instruments issued, including options granted to Sumitomo (the &#147;Sumitomo Options&#148;) to purchase all, or 75% in one case, of RSL&#146;s ownership interests in certain subsidiaries under the
Sumitomo Transaction Agreement; deferred consideration liability; its investments in other entities; cash and cash equivalents consisting of money market funds; accounts payable; and long-term debt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of Arbutus and Sio common stock and investments in common stock with a readily determinable fair value are classified as Level&nbsp;1, and their
fair value is determined based upon quoted market prices in an active market. The Arbutus Preferred Shares held by the Company are classified as Level&nbsp;2 as the fair value of such preferred shares is determined based upon the quoted market price
of Arbutus common stock into which such preferred shares are convertible. The liability instruments issued, including the Sumitomo Options, are classified as Level&nbsp;3 within the fair value hierarchy as the assumptions and estimates used in the
valuations are unobservable in the market. Cash, accounts payable, and deferred consideration liability are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature. The deferred
consideration liability is based on a fixed monetary amount, and payment is based solely on the passage of time. Money market funds are included in Level&nbsp;1 of the fair value hierarchy and are valued at the closing price reported by an actively
traded exchange. The carrying value of long-term debt issued by Dermavant Sciences Ltd. (together with its wholly owned subsidiaries, &#147;Dermavant&#148;), which is stated at amortized cost, approximates fair value&nbsp;based on current interest
rates for similar types of borrowings and therefore is included in Level&nbsp;2 of the fair value hierarchy. Long-term debt issued by Dermavant for which the fair value option has been elected is included in Level&nbsp;3 of the fair value hierarchy
as the assumptions and estimates used in the valuation are unobservable in the market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(O) Foreign Currency </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assets and liabilities of foreign operations are translated using exchange rates in effect at the balance sheet date and their results of operations are
translated using average exchange rates for the year. Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Adjustments resulting from the translation of the financial statements
of the Company&#146;s foreign functional currency subsidiaries into U.S. dollars are excluded from the determination of net loss and are accumulated in a separate component of shareholders&#146; equity. Foreign exchange transaction gains and losses
are included in &#147;Other expense, net&#148; in the Company&#146;s statements of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(P) Revenue Recognition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company
expects to receive in exchange for those goods or services. To determine revenue recognition for its arrangements, the Company performs the following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance
obligations in the contract; (iii)&nbsp;determine the transaction price; (iv)&nbsp;allocate the transaction price to the performance obligations in the contract; and (v)&nbsp;recognize revenue when or as the Company satisfies a performance
obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company applies significant judgment when evaluating whether contractual obligations represent distinct performance obligations,
allocating transaction price to performance obligations within a contract, determining </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
when performance obligations have been met, assessing the recognition and future reversal of variable consideration, and determining and applying appropriate methods of measuring progress for
performance obligations satisfied over time. These judgments are discussed in more detail below. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B><I>Licenses of intellectual property:</I> If the licenses to intellectual property are determined to be
distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from <FONT STYLE="white-space:nowrap">non-refundable,</FONT> upfront fees allocated to the license when the license is transferred to the
licensee and the licensee is able to use and benefit from the license. For licenses that are not distinct from other promises, the Company applies judgment to assess the nature of the combined performance obligation to determine whether the combined
performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from <FONT STYLE="white-space:nowrap">non-refundable,</FONT> upfront fees. The
Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition accordingly. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I></I></B><I>Milestone payments: </I>At the inception of each arrangement that includes research, development
or regulatory milestone payments, the Company<I> </I>evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not
considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the
performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company <FONT STYLE="white-space:nowrap">re-evaluates</FONT> the probability of achievement of such development milestones and any related
constraint, and if necessary, adjusts its estimate of the overall transaction price on a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> basis in earnings in the period of the adjustment. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I></I></B><I>Royalties and commercial milestone payments: </I>For arrangements that include sales-based
royalties, including commercial milestone payments<I> </I>based on a <FONT STYLE="white-space:nowrap">pre-specified</FONT> level of sales, the Company recognizes revenue at the later of (i)&nbsp;when the related sales occur, or (ii)&nbsp;when the
performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon performance of the licensee.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue is also generated by certain technology-focused Vants from subscription and service-based fees recognized for the use of
certain technology developed by these Vants. Subscription revenue is recognized ratably over the contract period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Q) Recently Adopted Accounting
Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-13,</FONT> &#147;Financial Instruments-Credit Losses
(Topic 326): Measurement of Credit Losses on Financial Instruments&#148; (&#147;ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-13&#148;),</FONT> which requires the measurement and recognition of expected credit losses for financial assets held
at amortized cost. ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-13</FONT> replaces the existing incurred loss impairment model with an expected loss model that requires the use of forward-looking information to calculate credit loss estimates.
It also eliminates the concept of other-than-temporary impairment and requires credit losses on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities to be recorded through an allowance
for credit losses instead of as a reduction in the amortized cost basis of the securities. ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-13</FONT> is effective for fiscal years beginning after December&nbsp;15, 2019 and interim periods within
those fiscal years. The adoption of ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-13</FONT> on April&nbsp;1, 2020 did not have a material impact on the Company&#146;s consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(R) Recently Issued Accounting Pronouncements Not Yet Adopted </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2020, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2020-06,</FONT> &#147;Debt&#151;Debt with Conversion and Other Options (Subtopic <FONT
STYLE="white-space:nowrap">470-20)</FONT> and Derivatives and Hedging&#151;Contracts in Entity&#146;s Own Equity (Subtopic <FONT STYLE="white-space:nowrap">815-40):</FONT> Accounting for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Convertible Instruments and Contracts in an Entity&#146;s Own Equity&#148; (&#147;ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2020-06&#148;).</FONT> ASU
<FONT STYLE="white-space:nowrap">No.&nbsp;2020-06</FONT> will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting
models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2020-06</FONT> also removes certain settlement conditions that
are required for equity contracts to qualify for the derivatives scope exception, which will permit more equity contracts to qualify for it. Either a modified retrospective transition method or a fully retrospective transition method is permissible
for the adoption of this standard. Update <FONT STYLE="white-space:nowrap">No.&nbsp;2020-06</FONT> is effective for fiscal years beginning after December&nbsp;15, 2021, including interim periods within those fiscal years. Early adoption is permitted
no earlier than the fiscal year beginning after December&nbsp;15, 2020. The adoption of ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2020-06</FONT> is not expected to have a material impact on the Company&#146;s consolidated financial statements.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3&#151;Investments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(A) Investments Measured
at Fair Value </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investment in Arbutus </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RSL owns
16,013,540 shares of common stock of Arbutus and 1,164,000 Arbutus Preferred Shares that are mandatorily convertible into shares of Arbutus common stock on October&nbsp;18, 2021 subject to conversion earlier upon a sale, merger or other transaction
considered a fundamental change of control of Arbutus. The Arbutus Preferred Shares are <FONT STYLE="white-space:nowrap">non-voting</FONT> and are convertible into common shares of Arbutus based on the subscription price plus 8.75% per annum,
compounded annually, divided by a conversion price of $7.13 per share (which represented a 15% premium to the closing price of $6.20 per share on September&nbsp;29, 2017). RSL&#146;s investments in Arbutus have been measured using the fair value
option. Due to the Company&#146;s significant influence over operating and financial policies, Arbutus is considered a related party of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After conversion of the Arbutus Preferred Shares into common shares, based on the number of Arbutus&#146;s common shares outstanding on October&nbsp;2, 2017,
the Company would hold&nbsp;49.90%&nbsp;of Arbutus&#146;s common shares. In addition, the Company agreed to a four-year standstill to not acquire greater than 49.99% of common shares or securities convertible into common shares of Arbutus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At March&nbsp;31, 2021 and 2020, the aggregate fair value of the Company&#146;s investment in Arbutus was $129.4&nbsp;million and $39.2&nbsp;million,
respectively, with the Company recognizing an unrealized gain on its investments in Arbutus of $90.2&nbsp;million and an unrealized loss of $99.9&nbsp;million in the accompanying consolidated statements of operations for the years ended
March&nbsp;31, 2021 and 2020, respectively. The fair value of the common stock and preferred shares held by the Company was determined using the closing price of Arbutus&#146;s common stock on March&nbsp;31, 2021 and 2020 of $3.33 and $1.01,
respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investment in Sio </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the
completion of Sio&#146;s underwritten public offering in February 2020, RSL&#146;s ownership interest fell below 50.0%. As such, the Company no longer has a controlling financial interest in Sio. Accordingly, the Company deconsolidated Sio in
February 2020. Due to the Company&#146;s significant influence over operating and financial policies, Sio remains a related party of the Company following deconsolidation. As the Company still has the ability to exercise significant influence over
the operating and financial policies of Sio, the Company has determined that its retained interest represents an equity method investment after the date of deconsolidation. Upon deconsolidation, the retained interest was recorded at fair market
value based on the closing price of Sio&#146;s common stock. The Company recognized a gain on deconsolidation of $107.3&nbsp;million in the accompanying consolidated statements of operations for the year ended March&nbsp;31, 2020. The fair value
option was elected to continuously remeasure the investment to fair value each reporting period after the initial measurement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At March&nbsp;31, 2021 and
2020, the fair value of the Company&#146;s investment in Sio was $48.5&nbsp;million<B> </B>and<B> </B>$45.3&nbsp;million, respectively, with the Company recognizing an unrealized gain on its investment in Sio of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$3.2&nbsp;million and an unrealized loss of $31.6&nbsp;million in the accompanying consolidated statements of operations for the years ended March&nbsp;31, 2021 and 2020, respectively. The fair
value of common shares held by the Company was determined using the closing price of Sio&#146;s common stock on March&nbsp;31, 2021 and 2020 of $2.61 and $2.44, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Investment </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company holds an additional equity
investment that is measured using the fair value option. The fair value of this investment was $11.1&nbsp;million and $8.9&nbsp;million as of March&nbsp;31, 2021 and 2020, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(B) Investment Accounted for Using Measurement Alternative </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investment in Datavant </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2020, Datavant Holdings,
Inc. (&#147;Datavant&#148;) completed an initial round of a Series B equity raise by which 13,411,311 Series B preferred shares were issued in April 2020 for gross proceeds of $27.2&nbsp;million, including 1,065,234 Series B preferred shares issued
and sold to RSL for a total purchase price of $2.5&nbsp;million and 1,800,253 Series B shares issued relating to the conversion of certain liability instruments. As a result of this transaction, along with a restructuring of Datavant&#146;s equity
classes, RSL no longer controls Datavant. As such, the Company deconsolidated Datavant as of April 2020. Due to the Company&#146;s significant influence over operating and financial policies, Datavant remains a related party of the Company following
deconsolidation. Upon deconsolidation, the Company recorded its investment in Datavant based on the fair value of Datavant preferred shares held of $99.0&nbsp;million. The Company accounts for its investment in Datavant using the measurement
alternative to fair value. The investment will be remeasured upon future observable price changes in orderly transactions or upon impairment, if any. The Company recognized a gain on deconsolidation of $86.5&nbsp;million in the accompanying
consolidated statements of operations for the year ended March&nbsp;31, 2021. In July 2020, Datavant issued and sold 639,140 Series B preferred shares to RSL at a price consistent with that of the initial round of Datavant&#146;s Series B equity
raise. At March&nbsp;31, 2021, the carrying value of the Company&#146;s investment in Datavant was $100.6&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4&#151;Asset Acquisitions
and License Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the years ended March&nbsp;31, 2021 and 2020, the Company, directly or indirectly through Vants, completed the following
key asset acquisitions and license agreements. The Company evaluated the below agreements, except the collaboration and license agreement entered into between Dermavant and Japan Tobacco Inc. that is evaluated separately below, and determined that
the acquired assets did not meet the definition of a business as substantially all the fair value of the assets acquired were concentrated in a single asset or group of similar assets and/or the acquired assets were not capable of producing outputs
due to the lack of an assembled workforce and early stage of development and thus, each transaction was accounted for as an asset acquisition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company then evaluated whether each <FONT STYLE="white-space:nowrap">in-process</FONT> research and development asset had an alternative future use and concluded it did not. As a result, the Company recorded the consideration attributable to <FONT
STYLE="white-space:nowrap">in-process</FONT> research and development under the below agreements as research and development expense in the accompanying consolidated statements of operations for the years ended March&nbsp;31, 2021 and 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dermavant </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2018, Dermavant acquired the
worldwide rights (other than with respect to certain rights in China) to tapinarof, an investigational therapeutic aryl hydrocarbon receptor modulating agent for the treatment of psoriasis and atopic dermatitis, from GlaxoSmithKline Intellectual
Property Development Ltd. and Glaxo Group Limited (collectively &#147;GSK&#148;) pursuant to an asset purchase agreement (the &#147;GSK Agreement&#148;). GSK previously acquired rights to a predecessor formulation of tapinarof from Welichem Biotech
Inc. (&#147;Welichem&#148;) pursuant to an asset </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchase agreement between GSK and Welichem entered into in May 2012 (the &#147;Welichem Agreement&#148;). Under the GSK Agreement, Dermavant made an upfront payment of &pound;150.0&nbsp;million
(approximately $191 million) and agreed to a contingent payment of &pound;100.0&nbsp;million (approximately $133 million) upon the first approval of an NDA by the FDA for a product that contains tapinarof. Dermavant assumed responsibility for all
obligations under the Welichem Agreement, including payment of up to C$180.0&nbsp;million (approximately $137 million) in potential development and commercial milestones. The purchase was funded in part by a $117.5&nbsp;million borrowing from
NovaQuest <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Fund VIII, L.P. (&#147;NovaQuest&#148;), an affiliate of NovaQuest Capital Management, LLC, as described in Note 8, &#147;Long-Term Debt.&#148; In connection with the GSK Agreement,
Dermavant and GSK have entered into a clinical manufacturing and supply agreement for tapinarof pursuant to which Dermavant will obtain supply of tapinarof for clinical trials on a cost-plus basis. In May 2019, Dermavant achieved a development and
regulatory milestone under the GSK Agreement, which resulted in a C$30.0&nbsp;million (approximately $23 million) milestone payment that Dermavant subsequently paid to Welichem in August 2019. The milestone payment was recorded as research and
development expense in the accompanying consolidated statements of operations for the year ended March&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2020, Dermavant entered
into a collaboration and license agreement with Japan Tobacco Inc. (&#147;JT&#148;) for exclusive rights to develop, register, and market tapinarof in Japan for the treatment of dermatological diseases and conditions, including psoriasis and atopic
dermatitis. In conjunction with this agreement, JT executed an exclusive license agreement with its subsidiary, Torii Pharmaceutical Co., Ltd., for <FONT STYLE="white-space:nowrap">co-development</FONT> and commercialization of tapinarof in Japan.
Under the terms of the license agreement, Dermavant received a nonrefundable, upfront payment of $60.0&nbsp;million in January 2020 and may receive up to $53.0&nbsp;million upon the achievement of certain development milestones for tapinarof for the
treatment of psoriasis and atopic dermatitis. In addition, Dermavant will have the right to receive royalties based on product sales of tapinarof in the indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluated the collaboration and license agreement and concluded that JT is a customer. The Company&#146;s performance obligations under the
agreement are the following: (i)&nbsp;an exclusive license to JT of the right to develop, register and market tapinarof in Japan and (ii)&nbsp;the associated transfer to JT of technology and <FONT STYLE="white-space:nowrap">know-how</FONT> related
to the license. The Company determined that the monetary value of participation in the Joint Steering Committee under the agreement was immaterial in the context of the contract and therefore was disregarded when identifying the performance
obligations. The Company determined that the exclusive license is not capable of being distinct from the associated technology transfer because the customer cannot benefit from or utilize the license without the technology and <FONT
STYLE="white-space:nowrap">know-how</FONT> transfer and as such does not have standalone value as JT cannot benefit from the exclusive license without the associated technology and <FONT STYLE="white-space:nowrap">know-how</FONT> transfer.
Accordingly, the Company concluded that these performance obligations should be combined into a single performance obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on management&#146;s
evaluation, the <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">up-front</FONT> payment of $60.0&nbsp;million constituted the amount of consideration to be included in the transaction price. The remaining
$53.0&nbsp;million of consideration related to potential development and regulatory approval milestones constitutes variable consideration and has not been recognized because of the inherent uncertainty of the occurrence of the future events and
because it is highly susceptible to factors outside of the Company&#146;s control. Any consideration related to potential royalty payments will be recognized when the related sales occur, since these amounts have been determined to relate
predominantly to the license granted to JT and therefore are recognized at the later of when the performance obligations are satisfied or the related sales occur.&nbsp;The Company will <FONT STYLE="white-space:nowrap">re-evaluate</FONT> the
transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. Upon transfer of the technology and <FONT STYLE="white-space:nowrap">know-how</FONT> related to the license, the Company
recognized the $60.0&nbsp;million <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payment as license revenue in the accompanying consolidated statements of operations for the year ended March&nbsp;31, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Genevant </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2020, RSL increased its investment in Genevant Sciences Ltd. (&#147;Genevant&#148;) as part of a recapitalization transaction (the
&#147;Recapitalization&#148;). Genevant, an entity focused on the discovery, development, and commercialization of a broad range of <FONT STYLE="white-space:nowrap">RNA-based</FONT> therapeutics enabled by Arbutus&#146; proprietary lipid
nanoparticle and ligand conjugate delivery technologies, was created in April 2018 as part of an agreement between RSL and Arbutus. As part of the initial transaction entered into in April 2018, RSL contributed $38.7&nbsp;million in cash, including
transaction costs, for an equity ownership interest in Genevant. Prior to the Recapitalization, RSL accounted for its investment in Genevant under the equity method of accounting as it had determined that it was not the primary beneficiary of
Genevant since it did not have the power to direct its most significant activities. Additionally, RSL made additional investments in the form of promissory notes issued by Genevant amounting to $20.1&nbsp;million aggregate principal amount
outstanding (the &#147;Genevant Outstanding Notes&#148;) prior to the Recapitalization. RSL applied its share of losses relating to its equity method investment in Genevant against the Company&#146;s carrying value of its investment in
Genevant&#146;s common shares and against the carrying value of the Genevant Outstanding Notes. The carrying value of RSL&#146;s investment in Genevant was reduced to zero prior to the Recapitalization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Recapitalization, the following transactions were completed: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Genevant issued 74,272,043 common shares to RSL for an aggregated purchase price of $20.5&nbsp;million;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$15.1&nbsp;million aggregate principal amount of the Genevant Outstanding Notes were converted into 54,526,549
common shares; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Genevant issued 9,057,566 common shares to Arbutus for an aggregated purchase price of $2.5&nbsp;million.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Recapitalization, RSL held an 82.9% controlling interest in Genevant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrent with the Recapitalization, the composition of Genevant&#146;s Board of Directors was restructured to include two directors designated by RSL and
one director who is a senior officer of Genevant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the Recapitalization and changes to the
<FONT STYLE="white-space:nowrap">bye-laws,</FONT> RSL determined that it controls the most significant activities of Genevant and is the primary beneficiary of Genevant following the Recapitalization. As such, RSL began consolidating Genevant into
the Company&#146;s consolidated financial statements from the date of the Recapitalization. The Company evaluated the acquired set of assets and activities and determined that the acquired set did not meet the definition of a business and thus the
transaction was not considered a business combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transactions completed as part of the Recapitalization represent an acquisition achieved in
stages, which required the remeasurement of RSL&#146;s previously held interest in Genevant. As such, RSL&#146;s investments in Genevant were remeasured to fair value of $28.8&nbsp;million, also resulting in a gain of $28.8&nbsp;million in the
accompanying consolidated statements of operations for the year ended March&nbsp;31, 2021. Along with the fair value of noncontrolling interests in Genevant of $9.2&nbsp;million and cash paid of $20.5&nbsp;million for common shares of Genevant as
part of the Recapitalization, total consideration paid was $58.5&nbsp;million. Of this amount, $41.4&nbsp;million was attributed to <FONT STYLE="white-space:nowrap">in-process</FONT> research and development, which was determined by the Company to
have not reached technological feasibility and therefore have no alternative future use. Accordingly, the Company recorded $41.4&nbsp;million as research and development expense in the accompanying consolidated statements of operations for the year
ended March&nbsp;31, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Proteovant </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
November 2020, Proteovant Sciences, Inc. (formerly known as Pharmavant 5, Inc.) (&#147;ProteoVant&#148;) entered into a stock purchase agreement to acquire Oncopia Therapeutics, Inc. (&#147;Oncopia&#148;), a preclinical biotechnology
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
company developing small molecule protein degraders primarily against certain oncology targets. Upfront proceeds to Oncopia&#146;s shareholders were $105.0&nbsp;million, prior to certain
adjustments in accordance with the terms of the agreement. Proteovant is also obligated to make future development and commercial milestone payments of up to $100.0&nbsp;million for the first product targeting each of the two specified initial
targets, and up to $51.0&nbsp;million for the first product targeting each of certain specified additional molecular targets. Additionally, the Company&#146;s investments in promissory notes issued by Oncopia for an aggregate principal amount of
$11.5&nbsp;million were settled through either conversion to equity or cancellation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oncopia&#146;s intellectual property was developed by the University
of Michigan laboratory run by Oncopia&#146;s <FONT STYLE="white-space:nowrap">co-founder</FONT> (the <FONT STYLE="white-space:nowrap">&#147;Co-Founder&#148;).</FONT> In connection with Proteovant&#146;s acquisition, Oncopia amended and restated its
existing license agreements with the University of Michigan. Under the new license agreement, Oncopia will be obligated to make future development and commercial milestone payments of up to $8.6&nbsp;million for the first product for each molecular
target covered by intellectual property included in the agreement, in addition to paying tiered royalties on net sales ranging from <FONT STYLE="white-space:nowrap">low-</FONT> to <FONT STYLE="white-space:nowrap">mid-single</FONT> digits, subject to
certain adjustments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">Co-Founder&#146;s</FONT> lab at the University of Michigan had been providing <FONT
STYLE="white-space:nowrap">on-going</FONT> discovery and optimization services to Oncopia under a sponsored research agreement (the &#147;SRA&#148;). Immediately after closing the acquisition, Oncopia extended the SRA through at least
December&nbsp;31, 2023, and expanded the potential molecular targets to be pursued under the SRA. As revised, Oncopia is obligated to pay the University of Michigan approximately $15.5&nbsp;million under the SRA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lastly, in connection with the acquisition of Oncopia, the <FONT STYLE="white-space:nowrap">Co-Founder</FONT> entered into an agreement with the Company to
serve as a consultant. In exchange for these services, the Company has agreed to grant the <FONT STYLE="white-space:nowrap">Co-Founder</FONT> RSL restricted stock units for which the majority will vest upon achievement of development milestones for
products directed to targets for which no milestones are payable to Oncopia shareholders and the remaining portion will be subject to time-based service requirements. All of these restricted stock units are subject to a liquidity requirement to
vest. The Company will also make a cash payment to the <FONT STYLE="white-space:nowrap">Co-Founder</FONT> upon achievement of development milestones for each such product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended March&nbsp;31, 2021, the Company recorded $116.5&nbsp;million, relating to the net upfront cash payment of $101.2&nbsp;million,
settlement of promissory notes receivable, including accrued interest, of $11.9&nbsp;million, and fair value of future contingent consideration payments of $3.4&nbsp;million, as research and development expense in the accompanying consolidated
statements of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2020, RSL, Proteovant and SK, Inc. (formerly known as SK Holdings Co., Ltd.) (&#147;SK&#148;) entered into a
subscription agreement (the &#147;Subscription Agreement&#148;) pursuant to which SK agreed to make a $200.0&nbsp;million equity investment in Proteovant, representing an ownership interest of 40.0% on the closing date. In January 2021, in
accordance with the terms of the Subscription Agreement, SK made the first payment of $100.0&nbsp;million to Proteovant. A second $100.0&nbsp;million payment is expected to be made by SK to Proteovant on or about July&nbsp;12, 2021, the date six
months from the closing date. The second $100.0&nbsp;million payment is classified as a subscription receivable in the accompanying consolidated balance sheets and consolidated statements of shareholders&#146; equity and redeemable noncontrolling
interest as of March&nbsp;31, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Affivant </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2020, RSL and its indirect subsidiary Affivant Sciences GmbH (&#147;Affivant&#148;) entered into a licensing and strategic collaboration agreement
with Affimed N.V. (&#147;Affimed&#148;) to develop and commercialize novel innate cell engagers for multiple cancer targets in exchange for consideration that includes $40.0&nbsp;million in upfront cash and
<FONT STYLE="white-space:nowrap">pre-paid</FONT> R&amp;D funding and $20.0&nbsp;million of newly issued shares in RSL. Affimed could receive further short-term proceeds in the form of option fees contingent on the commencement of additional programs
contemplated under the agreement. Affimed is eligible to receive up to an additional approximately $2.0&nbsp;billion in milestones over time upon achievement of specified development, regulatory and commercial milestones, as well as tiered royalties
on net sales. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Acquisition of Silicon Therapeutics </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2021, the Company completed the acquisition of the business of Silicon Therapeutics, LLC (&#147;SiTX&#148;), a physics-driven computational drug
discovery company, for total consideration of approximately $450.0&nbsp;million, with additional cash payments payable subject to the satisfaction of certain regulatory and commercial milestones. This acquisition did not include one of SiTX&#146;s
subsidiaries, Silicon SWAT, Inc. Approximately $350.0&nbsp;million of the consideration was payable primarily in the Company&#146;s common stock at or near closing of the acquisition (the &#147;First Tranche&#148;). At closing of the acquisition,
the Company issued 7,316,583 common shares and paid approximately $14.0&nbsp;million in cash, net of cash received, to SiTX after giving effect to certain transaction adjustments and holdbacks. The remainder of the First Tranche is expected to be
paid in a combination of common shares and cash as certain holdbacks are released. Approximately $100.0&nbsp;million (the &#147;Second Tranche Consideration&#148;) is payable to SiTX on the earlier of (x)&nbsp;approximately 30 to 60 days following
the public listing of the Company&#146;s common shares, in either cash or common shares (at the Company&#146;s election), and (y) 12 months following the closing of the acquisition, in cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transaction was accounted for as an asset acquisition as substantially all of the fair value of the assets acquired were concentrated in a single asset,
IPR&amp;D related to the computational drug discovery platform that designs and develops small molecule therapeutics. For accounting purposes, the fair value of consideration transferred was $402.4&nbsp;million, consisting of $281.7&nbsp;million
relating to the fair value of common shares issued upfront and expected to be issued shortly thereafter; $105.1&nbsp;million relating to the fair value of liabilities due to the sellers, including the Second Tranche Consideration, future contingent
consideration payments, and closing consideration to be paid in cash; and cash of $15.6&nbsp;million paid at closing. Of this amount, $399.6&nbsp;million was attributed to IPR&amp;D, which was determined to have no alternative future use.
Accordingly, the Company recorded $399.6&nbsp;million as research and development expense in the accompanying consolidated statement of operations for the year ended March&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the transaction, the vesting of certain outstanding SiTX share-based compensation awards held by employees of SiTX was discretionarily
accelerated at closing. As a result, the Company recorded share-based compensation expense of $23.5&nbsp;million in the accompanying consolidated statements of operations for the year ended March&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, certain share-based compensation awards of SiTX were exchanged with restricted common stock of the Company, subject to certain service-based
vesting requirements, with a fair value of $22.6&nbsp;million. Of this amount, $15.6 million was attributed to precombination service and therefore included in the total fair value of consideration transferred. Refer to Note 11, &#147;Share-Based
Compensation,&#148; for additional detail regarding this restricted common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5&#151;Sumitomo Transaction Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;27, 2019 (the &#147;Sumitomo Closing Date&#148;), RSL and Sumitomo completed the transactions contemplated by the Sumitomo Transaction
Agreement. Pursuant to the Sumitomo Transaction Agreement, RSL transferred its entire ownership interest in Myovant, Urovant, Enzyvant, Altavant, and Spirovant to a newly formed, wholly-owned entity (&#147;Sumitovant&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RSL&#146;s ownership interest in Sumitovant was then transferred to Sumitomo, such that following the Sumitomo Closing Date, Sumitovant and its subsidiaries,
including the Sumitovant Vants, were each directly or indirectly owned by Sumitomo. Additionally, in connection with the Sumitomo Transaction Agreement, RSL (i)&nbsp;granted Sumitomo options to purchase all, or in the case of Dermavant, 75%, of
RSL&#146;s ownership interests in six other subsidiaries (Dermavant, Genevant, Lysovant Sciences Ltd. (&#147;Lysovant&#148;), Metavant Sciences Ltd. (&#147;Metavant&#148;), Roivant Asia Cell Therapy Holdings Ltd. (&#147;Cytovant Parent&#148;), and
Sinovant Sciences HK Limited (&#147;Sinovant&#148;)), (ii) provided Sumitomo and Sumitovant with certain rights over and access to RSL&#146;s proprietary technology platforms, DrugOme and Digital Innovation, and (iii)&nbsp;transferred 26,952,143
common shares of RSL to Sumitomo. On the Sumitomo Closing Date, the Company received approximately $2.9&nbsp;billion in cash, resulting in a gain of $2.0&nbsp;billion after taking into account all of the components of the transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, on the Sumitomo Closing Date, $75.0&nbsp;million of the consideration was deposited into a
segregated escrow account for the purpose of fulfilling indemnification obligations of RSL that may become due to Sumitomo. Upon the expiration of the escrow period, being 18 months from the Sumitomo Closing Date, any remaining escrow funds will be
disbursed to RSL. As of March&nbsp;31, 2021, the Company does not believe that a reasonably possible loss of the funds in the escrow account exists. As such, the full escrow amount of $75.0&nbsp;million was recorded by the Company as restricted cash
on the accompanying consolidated balance sheets as of March&nbsp;31, 2021. In connection with the Sumitomo Transaction, RSL&#146;s board of directors approved a repurchase of RSL&#146;s equity securities for up to $1.0&nbsp;billion of the proceeds
received from Sumitomo. Refer to Note 10, &#147;Shareholders&#146; Equity and Redeemable Noncontrolling Interest&#148; for further detail. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In conjunction
with the Sumitomo Transaction, certain employees of the Company became employees of Sumitovant or its subsidiaries. The Company issued certain instruments with an aggregate fair value of $39.1&nbsp;million to these employees, of which
$24.8&nbsp;million was classified within shareholders&#146; equity and $14.3&nbsp;million was classified as a liability. The liability classified awards were subsequently surrendered and exchanged for cash and other newly issued equity as part of
the repurchase in March 2020. The remaining instruments vest based on the achievement of time-based, performance or liquidity event requirements. As of March&nbsp;31, 2021 and 2020, there were 1,865,416 and 1,880,980 outstanding instruments,
respectively, held by Sumitovant employees for which aggregate fair value was recorded against the gain on sale of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2021, RSL completed
a transaction with Sumitomo pursuant to which Sumitomo terminated its existing options to acquire RSL&#146;s equity interests in certain of its subsidiaries. See Note 19, &#147;Subsequent Events&#148; for additional information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 6&#151;Discontinued Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the
Sumitomo Transaction Agreement, see Note 5, &#147;Sumitomo Transaction Agreement,&#148; the financial results of the Sumitovant Vants are presented as &#147;Income from discontinued operations, net of tax&#148; in the accompanying consolidated
statements of operations for the year ended March&nbsp;31, 2020. There were no operating results from discontinued operations for the year ended March&nbsp;31, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents components of discontinued operations included in &#147;Income from
discontinued operations, net of tax&#148; for the year ended March&nbsp;31, 2020 (in thousands). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>March&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">265,452</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119,885</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">385,337</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(385,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on sale of business</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,985,949</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,305</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,733</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,866</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from discontinued operations before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,580,318</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,892</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from discontinued operations, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,578,426</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from discontinued operations before income taxes attributable to noncontrolling
interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(141,783</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from discontinued operations before income taxes attributable to Roivant Sciences
Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,722,101</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from discontinued operations before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,580,318</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Interest expense consists of interest payments related to outstanding debt held by Myovant and Urovant as well
as the associated <FONT STYLE="white-space:nowrap">non-cash</FONT> amortization of debt discounts and issuance costs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the
accompanying consolidated statements of cash flows, the cash flows from discontinued operations are not separately classified. The significant cash flow items from discontinued operations were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>March&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on sale of business</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,985,949</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,821</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,405</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 7&#151;Balance Sheet Components </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(A) Other Current Assets </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other current assets at
March&nbsp;31, 2021 and 2020 consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,544</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,344</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receivables for value added tax (VAT) paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">807</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,978</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Note receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade receivables, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,222</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,669</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,803</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">632</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">874</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,140</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,250</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,763</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(B) Accrued Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses at March&nbsp;31, 2021 and 2020 consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,755</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,607</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation-related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,552</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,113</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional services expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,267</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,135</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,362</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,766</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76,936</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68,621</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(C) Other Current Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other current liabilities at March&nbsp;31, 2021 and 2020 consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,918</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,621</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">207</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,497</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,037</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">234</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,162</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,352</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 8&#151;Long-Term Debt </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(A) Long-Term Debt </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Long-term debt, net consists of the
following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal amount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">171,490</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110,490</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: unamortized debt discount and issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,210</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,898</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total debt, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170,280</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108,592</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total long-term debt, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170,280</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108,592</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dermavant </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May
2019, Dermavant and certain of its subsidiaries entered into a loan and security agreement (the &#147;Hercules Loan Agreement&#148;) with Hercules Capital, Inc. (&#147;Hercules&#148;), pursuant to which Dermavant borrowed an aggregate of
$20.0&nbsp;million which bears interest at a variable per annum rate at the greater of (i)&nbsp;9.95%&nbsp;or (ii)&nbsp;the prime rate plus 4.45%. Dermavant is obligated to pay an end of term charge of&nbsp;$1.4&nbsp;million with the debt maturing
36 months from closing, subject to extension with the achievement of a clinical milestone. Dermavant is obligated to make monthly payments of accrued interest for the first 15 months after closing (the &#147;Interest-only Period&#148;), followed by
monthly installments of principal and interest through the maturity date, subject to extension upon certain milestone achievements. In January 2020, the Interest-only Period was extended through June 2021 upon Dermavant&#146;s receipt of net
proceeds from equity or debt financings, capital contributions, and proceeds from business development or similar transaction of at least $110.0&nbsp;million. In July 2020, the clinical milestone was achieved and the term loan maturity was extended
to June&nbsp;1, 2023 and the Interest-only Period was further extended through December 2021. As of March&nbsp;31, 2021 and March&nbsp;31, 2020, an aggregate principal amount of $20.0&nbsp;million and end of term charge of $1.4&nbsp;million remained
outstanding. In May 2021, Dermavant repaid all amounts outstanding under the Hercules Loan Agreement using the proceeds from the $40.0&nbsp;million Credit Facility entered into by Dermavant and certain of its subsidiaries in May 2021. Refer to Note
19, &#147;Subsequent Events&#148; for additional detail. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with Dermavant&#146;s acquisition of tapinarof from GSK, Dermavant and NovaQuest <FONT
STYLE="white-space:nowrap">Co-Investment</FONT> Fund VIII, L.P. (&#147;NovaQuest&#148;) entered into a funding agreement (the &#147;NovaQuest Agreement&#148;). Pursuant to the NovaQuest Agreement, Dermavant borrowed $100.0&nbsp;million in August
2018 and $17.5&nbsp;million in October 2018 in exchange for an obligation to make certain variable future payments calculated as a function of the achievement of regulatory and commercial milestones or events of termination. The aggregate maximum
amount of regulatory milestone payments that Dermavant could be required to make under the NovaQuest Agreement is $440.6&nbsp;million, and the maximum aggregate amount of commercial milestone payments is $141.0&nbsp;million. In some circumstances,
Dermavant may be able to offset certain of the regulatory milestone payments with up to $88.1&nbsp;million of the commercial milestone payments. At issuance, the Company concluded that certain features of the long-term debt would be considered
derivatives that would require bifurcation. In lieu of bifurcating various features in the agreement, the Company has elected the fair value option for this financial instrument and will record the changes in the fair value within the statements of
operations at the end of each reporting period. Direct costs and fees related to the debt issued under the NovaQuest Agreement were recognized in earnings. As of March&nbsp;31, 2021 and 2020, the fair value of the debt was $150.1&nbsp;million and
$89.1&nbsp;million, respectively. Refer to Note 15, &#147;Fair Value Measurements&#148; for additional details regarding the fair value measurement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(B) Debt Maturities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annual maturities, including the end
of term charge, of debt outstanding as of&nbsp;March&nbsp;31, 2021&nbsp;are as follows (in thousands). Long-term debt held by Dermavant for which the fair value option has been elected is excluded from the below as the repayment terms are variable.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Years Ending March&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,129</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,306</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,955</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,390</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 9&#151;Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transition Services Agreement and Strategic Cooperation Agreement with Sumitomo </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the Sumitomo Transaction Agreement, (i)&nbsp;RSL, Sumitomo and Sumitovant entered into a transition services agreement, whereby each of the
parties thereto agreed to provide certain services to one another at cost for a period of time following the Sumitomo Closing Date and (ii)&nbsp;RSL and Sumitomo entered into a strategic cooperation agreement relating to certain ongoing
technology-related collaborations between the parties. Pursuant to the terms of the transition services agreement and strategic cooperation agreement, RSL billed Sumitovant $1.4&nbsp;million and $0.2&nbsp;million, net of amounts billed by Sumitovant
to RSL, respectively, during the years ended March&nbsp;31, 2021 and 2020 for costs incurred on behalf of Sumitovant, which were recorded as offsets to the general and administrative expenses initially charged. Additionally, during the years ended
March&nbsp;31, 2021 and 2020, the Company paid Sumitomo a $1.0&nbsp;million access fee pursuant to the strategic cooperation agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note
10&#151;Shareholders&#146; Equity and Redeemable Noncontrolling Interest </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(A) Sumitomo Transaction Agreement and Roivant Equity Repurchase </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2019, RSL and Sumitomo completed the transactions contemplated by the Sumitomo Transaction Agreement; see Note 5, &#147;Sumitomo Transaction
Agreement.&#148; Pursuant to the Sumitomo Transaction Agreement, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
RSL issued 26,952,143 common shares to Sumitomo at closing at a price per share of $37.10 for allocated net proceeds of approximately $999.2&nbsp;million, after offering expenses incurred. In
connection with the Sumitomo Closing Date, RSL&#146;s board of directors approved a repurchase of up to $1.0&nbsp;billion of the Company&#146;s equity securities using the proceeds received from Sumitomo. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2020, the Company launched <FONT STYLE="white-space:nowrap">one-time</FONT> offers to purchase up to $1.0&nbsp;billion of issued and outstanding
equity securities of the Company (the &#147;Roivant Equity Repurchase&#148;). The offers included (i)&nbsp;an offer to repurchase up to approximately 11.23% of the common stock held by each holder (and its affiliates) of the Company&#146;s common
stock as of December&nbsp;26, 2019, at a price per share of $37.10 representing fair value of the common stock, (ii)&nbsp;an offer to purchase vested stock options whose fair market value (as determined as of December&nbsp;27, 2019) was less than or
equal to the fair market value of approximately 11.23% of the earliest-granted of such holder&#146;s outstanding vested and unvested stock options, at a purchase price equal to such vested option&#146;s fair market value, and (iii)&nbsp;an offer to
holders of performance restricted stock units (&#147;pRSUs&#148;) to surrender 100% of their existing pRSUs in exchange for newly issued performance stock options and capped value appreciation rights. The offer to the holders of pRSUs included an
offer by the Company to immediately purchase approximately 11.23% of the newly issued performance stock options and capped value appreciation rights for cash. The Company additionally entered into an agreement with the Company&#146;s Founder to
repurchase a portion of his common stock held and exchange his pRSUs for performance stock options and capped value appreciation rights. A summary of payments made during the year ended March&nbsp;31, 2020 relating to the purchase of equity
securities by the Company is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cash&nbsp;Payment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">950,722</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other equity instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,292</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">990,014</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(B) Consolidated Vant Equity Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cytovant Sciences HK Limited </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2020,
Cytovant Sciences HK Limited (&#147;Cytovant&#148;), a subsidiary of the Company, issued and sold 20,085,301 Series <FONT STYLE="white-space:nowrap">A-1</FONT> preference shares at a purchase price of $1.17 per share to third party investors for
aggregate net proceeds of $22.5&nbsp;million after deducting offering costs. The preferred stock is convertible into ordinary shares of Cytovant at any time at the option of the investor, or automatically upon a qualified initial public offering
(&#147;Qualified IPO&#148;) as defined in the subscription agreement. If a Qualified IPO is not completed within five years of the initial investment, Series A preference shareholders can force a sale or liquidation of Cytovant. The Series <FONT
STYLE="white-space:nowrap">A-1</FONT> preference shares are classified as redeemable noncontrolling interest in the accompanying consolidated balance sheets and consolidated statements of shareholders&#146; equity and redeemable noncontrolling
interest as the Company can be obligated to repurchase the Series A-1 preference shares upon the occurrence of certain contingent events outside the Company&#146;s control. No dividends shall accrue or be payable on the convertible and redeemable
preferred stock unless otherwise determined by the board of directors of Cytovant. The Company did not accrete changes in the redemption value as of March&nbsp;31, 2021 as the Company considers the events leading to a redemption of the convertible
and redeemable preferred stock as not probable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Immunovant </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2019, Immunovant Sciences Ltd. (&#147;ISL&#148;) entered into a share exchange agreement (the &#147;Share Exchange Agreement&#148;) with Health
Sciences Acquisitions Corporation (&#147;HSAC&#148;), and in December 2019, ISL and HSAC completed the transactions contemplated by the Share Exchange Agreement (the &#147;Business Combination&#148;). At closing, HSAC acquired 100% of the issued and
outstanding common shares of ISL in exchange for 42,080,376 shares of HSAC&#146;s common stock issued to HSAC, ISL, and the shareholders of ISL (together, the &#147;Sellers&#148;) and 10,000 shares of HSAC Series A preferred shares issued to RSL.
Additionally, as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
part of its initial public offering in May 2019, HSAC issued common stock warrants, which are classified in equity. Upon completion of the Business Combination, 11,500,000 warrants were
outstanding for the purchase of <FONT STYLE="white-space:nowrap">one-half</FONT> of one share of common stock (an aggregate of 5,750,000 common shares) at a price of $11.50 per whole share. Upon closing, ISL became a wholly owned subsidiary of HSAC
and HSAC was renamed &#147;Immunovant, Inc.&#148; The Business Combination was accounted for as a reverse recapitalization and HSAC was treated as the &#147;acquired&#148; company for accounting purposes. Accordingly, for accounting purposes, the
Business Combination was treated as the equivalent of ISL issuing equity for the net assets of HSAC, accompanied by a recapitalization. Immunovant, Inc. received $111.0&nbsp;million in cash as a result of the Business Combination, consisting of the
funds held in HSAC&#146;s trust account. The proceeds included $5.1&nbsp;million related to common shares purchased by RSL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sellers were entitled to
receive an additional 20,000,000 shares of Immunovant, Inc.&#146;s common stock (the &#147;Earnout Shares&#148;) if the volume-weighted average price of Immunovant, Inc.&#146;s shares equaled or exceeded the following prices for any 20 trading days
within any 30 <FONT STYLE="white-space:nowrap">trading-day</FONT> period (the &#147;Trading Period&#148;) following the closing of the Business Combination: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(i) during any Trading Period prior to March&nbsp;31, 2023, 10,000,000 Earnout Shares upon the achievement of a volume-weighted average price
of at least $17.50 per share; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(ii) during any Trading Period prior to March&nbsp;31, 2025, 10,000,000 Earnout Shares upon the
achievement of a volume-weighted average price of at least $31.50 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2020 and September 2020, Immunovant, Inc. achieved the first earnout
milestone and second earnout milestone, respectively, under the Share Exchange Agreement and, as a result, all of the 20,000,000 earnout shares of Immunovant, Inc.&#146;s common stock were issued to former stockholders of ISL, including 17,547,938
shares of common stock issued to RSL. In addition, upon the achievement of the first earnout milestone and second earnout milestone and pursuant to the restricted stock agreement entered into between HSAC and Health Sciences Holdings, LLC (the
&#147;Sponsor&#148;), all of the 1,800,000 shares of the Sponsor&#146;s restricted shares vested and are no longer subject to forfeiture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately
prior to the closing of the Business Combination, as described above, ISL&#146;s convertible promissory notes were automatically converted into an aggregate of 7,156,495 common shares of ISL, which were then exchanged for an aggregate of 3,499,995
shares of Immunovant, Inc. common stock upon the closing of transactions contemplated by the Share Exchange Agreement. The conversion of ISL&#146;s convertible promissory notes resulted in an increase to equity by $35.6&nbsp;million, the carrying
amount of the convertible promissory notes. The conversion included a convertible promissory note held by RSL for $2.5&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2020,
Immunovant, Inc. completed an underwritten public offering of 9,613,365 shares of its common stock, including 1,034,483 shares of common stock purchased by RSL, at a price of $14.50 per share for net proceeds to Immunovant, Inc. of approximately
$131.0&nbsp;million, after deducting underwriting discounts and commissions and offering expenses. The proceeds included $15.0&nbsp;million received from RSL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2020, Immunovant, Inc.&#146;s 11,500,000 outstanding warrants became exercisable for an aggregate of 5,750,000 shares of Immunovant, Inc.&#146;s common
stock at a price of $11.50 per share. An aggregate of 11,438,290 outstanding warrants were exercised for an aggregate of 5,719,145 shares of Immunovant, Inc.&#146;s common stock at a price of $11.50 per share, for net proceeds of approximately
$65.8&nbsp;million. The remaining 61,710 warrants were cancelled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2020, Immunovant, Inc. completed an underwritten public offering of
6,060,606 shares of its common stock, including 380,000 shares of common stock purchased by RSL, at a price of $33.00 per share for net proceeds to Immunovant, Inc. of approximately $188.1&nbsp;million, after deducting underwriting discounts and
commissions and offering expenses. The proceeds included $12.5&nbsp;million received from RSL. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sinovant </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sinovant, a subsidiary of the Company, previously issued and sold preferred stock convertible into ordinary shares of Sinovant at any time at the option of the
investors or automatically upon a qualified initial public offering (&#147;Qualified IPO&#148;) as defined in the subscription agreement relating to the sale of the preferred stock. The convertible preferred stock was redeemable at the option of the
investor if a Qualified IPO was not completed within five years of the initial investment and was payable in cash equal to the investment amount plus an annualized return of 12%. As such events are not within the control of the Company, the
preferred stock was previously classified as redeemable noncontrolling interest in the accompanying consolidated balance sheets and consolidated statements of shareholders&#146; equity and redeemable noncontrolling interest. No dividends accrued or
were payable on the convertible preferred stock. In January 2020, Sinovant&#146;s parent company, Roivant China Holdings Ltd. (&#147;RCHL&#148;), purchased all preferred stock of Sinovant held by third parties at a purchase price of $12.26 per
preferred share for an aggregate purchase price of $132.9&nbsp;million. Consideration paid in excess of the carrying value for the repurchase of redeemable noncontrolling interest of $77.8&nbsp;million is considered a deemed dividend. See Note 18,
&#147;Earnings per Common Share&#148; for resulting impact to earnings per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 11&#151;Share-Based Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(A) RSL 2015 Equity Incentive Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31,
2021, 22,800,000 of the Company&#146;s common shares (the &#147;Share Reserve&#148;) are reserved for issuance under the RSL Amended and Restated 2015 Equity Incentive Plan (the &#147;RSL 2015 EIP&#148;). At March&nbsp;31, 2021, a total of
10,296,392 common shares are available for future grants under the RSL 2015 EIP. The Company&#146;s employees, directors, and consultants are eligible to receive nonstatutory and incentive stock options, stock appreciation rights, restricted stock
awards, restricted stock unit awards, and other stock awards under the RSL 2015 EIP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021, an aggregate of 26,558,238 of the
Company&#146;s common shares (the &#147;Special Reserve&#148;) were reserved for the granting under RSL 2015 EIP of performance stock options (&#147;Performance Options&#148;) and capped value appreciation rights (&#147;CVARs&#148;) to the
Company&#146;s employees, directors and consultants. At March&nbsp;31, 2021, there are no common shares available for future grant under the Special Reserve. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the years ended March&nbsp;31,
2021 and 2020, the Company recorded share-based compensation expense related to stock options issued under the RSL 2015 EIP to employees and directors of approximately $32.3&nbsp;million and $31.8&nbsp;million, respectively, and was included in
research and development and general and administrative expenses in the accompanying consolidated statements of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At March&nbsp;31, 2021, total
unrecognized compensation expense related to <FONT STYLE="white-space:nowrap">non-vested</FONT> stock options was approximately $70.8&nbsp;million and is expected to be recognized over the remaining weighted-average service period of 2.96 years.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company estimated the fair value of each stock option on the date of grant using the Black-Scholes closed form option-pricing model applying the
weighted average assumptions in the following table. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt"><B>Assumptions</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2021&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2020&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected stock price volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74.84</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66.47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected risk free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.43</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.27</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term, in years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.25</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.72</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A summary of stock option activity and data under the RSL 2015 EIP for the year ended March&nbsp;31, 2021 is
as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Stock<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average Grant<BR>Date&nbsp;Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Remaining<BR>Contractual&nbsp;Life</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options outstanding at March&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,176,814</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24.52</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.53</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,482,604</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38.71</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25.37</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/Canceled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(270,047</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29.89</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19.85</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options outstanding at March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,389,371</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26.61</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17.90</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options exercisable at March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,533,848</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.52</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.95</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At March&nbsp;31, 2021 and 2020, there were 5,533,848 and 4,123,953 vested stock options, respectively. Additional information
regarding stock options is set forth below (in thousands, except per share data). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant date fair value of stock options vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,711</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,789</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average grant date fair value per share of stock options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25.37</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20.63</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock Units </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted stock units will vest upon the achievement of both time-based service requirements and liquidity requirements on or before the grant expiration
date. Restricted stock units expire eight years after the date of grant. During the year ended March&nbsp;31, 2021, the Company recorded no share-based compensation expense related to these restricted stock units as the liquidity event requirement
had not been met and was deemed not probable of being met. At March&nbsp;31, 2021, there was approximately $83.8&nbsp;million of unrecognized compensation expense related to <FONT STYLE="white-space:nowrap">non-vested</FONT> restricted stock units.
The Company will recognize the expense upon achievement of both the time-based service requirement and liquidity requirements through the requisite service period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A summary of restricted stock units under the RSL 2015 EIP is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Restricted&nbsp;Stock<BR>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;Average<BR>Grant Date Fair<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> balance at March&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,008,175</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32.50</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,454,199</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39.19</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(169,636</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36.36</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> balance at March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,292,738</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36.53</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Performance Options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Performance Options will vest upon the achievement of both time-based service requirements and liquidity requirements on or before the grant expiration date of
March&nbsp;31, 2026. During the year ended March&nbsp;31, 2021, the Company recorded no share-based compensation expense related to these Performance Options as the liquidity event requirement had not been met and was deemed not probable of being
met. At March&nbsp;31, 2021, there was approximately $337.8&nbsp;million of unrecognized compensation expense related to <FONT STYLE="white-space:nowrap">non-vested</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Performance Options. The Company will recognize the expense upon achievement of both the time-based service requirement and liquidity requirements through the requisite service period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company estimated the fair value of each Performance Option on the date of grant using the Black-Scholes closed form option-pricing model applying the
weighted average assumptions in the following table. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="22%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt"><B>Assumptions</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected stock price volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73.60</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected risk free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.62</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A summary of Performance Option activity and data under the RSL 2015 EIP for the year ended March&nbsp;31, 2021 is as follows:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average Grant<BR>Date&nbsp;Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Remaining<BR>Contractual&nbsp;Life</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Performance Options outstanding at March&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,518,870</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38.97</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23.78</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.00</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(93,207</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46.38</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22.18</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Performance Options outstanding at March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,425,663</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38.93</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23.42</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No Performance Options were exercisable at March&nbsp;31, 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>CVARs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CVARs will vest upon the achievement of
both time-based service requirements and liquidity requirements on or before the grant expiration date of March&nbsp;31, 2026. At settlement, each CVAR pays in common shares the excess of (a)&nbsp;the lesser of (i)&nbsp;the fair market value of a
common share as of the settlement date or (ii)&nbsp;the cap of $37.10, over (b)&nbsp;the hurdle price of either $18.70 or $33.63, as applicable to each grant. During the year ended March&nbsp;31, 2021, the Company recorded no share-based
compensation expense related to these CVARs as the liquidity event requirement had not been met and was deemed not probable of being met. At March&nbsp;31, 2021, there was approximately $23.0&nbsp;million of unrecognized compensation expense related
to <FONT STYLE="white-space:nowrap">non-vested</FONT> CVARs. The Company will recognize the expense upon achievement of both the time-based service requirement and liquidity requirements through the requisite service period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A summary of CVARs under the RSL 2015 EIP is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;CVARs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;Average<BR>Grant Date Fair<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> balance at March&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,088,658</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.07</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> balance at March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,088,658</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.07</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(B) RSL 2015 Restricted Stock Unit Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Amended and Restated RSL 2015 Restricted Stock Unit Plan (the &#147;pRSU Plan&#148;), as of March&nbsp;31, 2021, there are 200,000 of the
Company&#146;s common shares reserved for issuance in connection with pRSUs that may be granted to employees, officers, directors and consultants of the Company under the pRSU Plan. The pRSUs expire eight years after the date of grant. At
March&nbsp;31, 2021, none of the Company&#146;s common shares were reserved for future grants under this plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the Roivant Equity Repurchase,
17,044,465 existing pRSUs were surrendered and exchanged for newly issued Performance Options and CVARs issued under an amended and restated RSL 2015 EIP (see above), of which approximately 11.23% were then immediately purchased by the Company,
during the year ended March&nbsp;31, 2020. Refer to Note 10, &#147;Shareholders&#146; Equity and Redeemable Noncontrolling Interest&#148; for additional detail regarding the Roivant Equity Repurchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A summary of pRSU activity under the pRSU Plan is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>pRSUs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;Average<BR>Grant Date Fair<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> balance at March&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">266,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.92</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(66,845</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.92</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> balance at March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.92</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These pRSUs will vest to the extent certain performance criteria are achieved and certain liquidity conditions are satisfied
within specified years of the grant date, provided that the recipient has provided continued service through such date. As of&nbsp;March&nbsp;31, 2021, the performance conditions had not been met and were deemed not probable of being met. During the
year ended March&nbsp;31, 2021, the Company recorded&nbsp;no share-based compensation expense related to these pRSUs. During the year ended March&nbsp;31, 2020, the Company recorded $12.3&nbsp;million of share-based compensation expense relating to
cash payments made for the purchase of a portion of the Performance Options and CVARs issued in replacement of pRSUs. At March&nbsp;31, 2021, there was approximately $2.8&nbsp;million of unrecognized compensation expense related to <FONT
STYLE="white-space:nowrap">non-vested</FONT> pRSUs. The Company will recognize the expense upon achievement of the performance and liquidity conditions through the requisite service period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(C) RSL Restricted Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A summary of RSL
restricted common stock activity as of March&nbsp;31, 2021 is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Restricted<BR>Common<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;Average<BR>Grant Date Fair<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> balance at March&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">587,824</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38.50</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> balance at March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">587,824</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38.50</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended March&nbsp;31, 2021, the Company recorded share-based compensation expense of $0.1&nbsp;million in relation
to the RSL restricted common stock. At March&nbsp;31, 2021, total unrecognized compensation expense related to <FONT STYLE="white-space:nowrap">non-vested</FONT> restricted common stock was approximately $6.9&nbsp;million and is expected to be
recognized over the remaining weighted-average service period of 3.39 years. $15.6&nbsp;million of the fair value associated with these restricted common stock was attributed to precombination service. Refer to Note 4, &#147;Asset Acquisitions and
License Agreements.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(D) Subsidiary Equity Incentive Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain wholly owned and majority-owned or controlled subsidiaries of RSL adopt their own equity incentive plan (&#147;EIP&#148;). Each EIP is generally
structured so that the applicable subsidiary, and its affiliates&#146; employees, directors, officers and consultants are eligible to receive <FONT STYLE="white-space:nowrap">non-qualified</FONT> and incentive stock options, stock appreciation
rights, restricted share awards, restricted stock unit awards, and other share awards under their respective EIP. Standard option grants have time-based vesting requirements, generally vesting over a period of four years with a contractual term of
ten years. Such time-based stock options use the Black-Scholes option pricing model. The grant date fair value of awards subject to market conditions is estimated using a Monte Carlo valuation model. For the years ended March&nbsp;31, 2021 and 2020,
the Company recorded share-based compensation expense of $29.1&nbsp;million and $22.1&nbsp;million, respectively, in relation to subsidiary EIPs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(E)
Share-Based Compensation Expense </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share-based compensation expense from continuing operations was as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expense recognized as:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R&amp;D expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,637</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,738</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">G&amp;A expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,321</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,013</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84,958</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,751</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The classification of share-based compensation expense between R&amp;D and G&amp;A expenses in the accompanying consolidated
statements of operations is consistent with the classification of grantee&#146;s salary expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 12&#151;Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The loss before income taxes and the related expense/(benefit) are as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(212,921</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(69,264</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Switzerland</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(424,494</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(355,422</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bermuda</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(227,471</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(105,604</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(33,661</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,696</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(898,547</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(560,986</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Primarily Greater China and United Kingdom activity </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current taxes:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,365</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,327</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Switzerland</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bermuda</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">321</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">797</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,686</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,124</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred taxes:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Switzerland</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bermuda</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,686</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,124</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Primarily Greater China, United States state and local and United Kingdom activity </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of income tax provision/(benefit) computed at the Bermuda statutory rate to income tax expense reflected in the consolidated financial
statements is as follows (in thousands, except percentages): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended March&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>March&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit at Bermuda statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign rate differential<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(150,778</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.78</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(74,922</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.36</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permanent disallowed IPR&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111,432</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12.40</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nondeductible changes in the fair value of investments and loss from equity method
investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22,472</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,840</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3.72</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nontaxable (loss) gain on deconsolidation of business</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,438</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.83</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,041</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5.18</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permanent adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,923</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.33</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.64</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R&amp;D tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.17</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,990</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.07</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rate changes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,443</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.27</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85,046</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9.46</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87,677</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15.63</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.02</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,686</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.19</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,124</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.27</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Primarily related to operations in Switzerland, the United Kingdom, and other jurisdictions with statutory tax
rates different than the Bermuda rate. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s effective tax rates were (0.19)% and (1.27)% for the years ended
March&nbsp;31, 2021 and 2020, respectively, driven by the Company&#146;s jurisdictional earnings by location and a valuation allowance that eliminates the Company&#146;s global net deferred tax assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred taxes reflect the tax effects of the differences between the amounts recorded as assets and
liabilities for financial reporting purposes and the comparable amounts recorded for income tax purposes. Significant components of the deferred tax assets (liabilities) at March&nbsp;31, 2021 and 2020 are as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred tax assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,063</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,303</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,564</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,626</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202,906</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116,619</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,623</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,413</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,638</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,194</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,303</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,060</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subtotal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">323,097</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">209,215</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(303,287</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(187,831</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred tax liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,908</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,409</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,688</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets (liabilities)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has Federal net operating losses in Switzerland, the United States, the United Kingdom and other jurisdictions in
the amount of $1,181.1&nbsp;million, $122.2&nbsp;million, $28.6&nbsp;million, and $75.8&nbsp;million, respectively. The Switzerland net operating losses will expire in varying amounts between March&nbsp;31, 2025 and March&nbsp;31, 2028. The United
States net operating losses can be carried forward indefinitely with utilization limited to 80% of future taxable income for tax years beginning on or after January&nbsp;1, 2021, while the United Kingdom and other net operating losses can be carried
forward indefinitely as well, with an annual limitation on utilization. The Company has generated net operating losses from United States state and local jurisdictions in the amount of $69.7&nbsp;million which will expire in varying amounts between
March&nbsp;31, 2035 and March&nbsp;31, 2041. The Company has generated $19.1&nbsp;million of research tax credit carryforwards primarily in the United States, which will expire in varying amounts between March&nbsp;31, 2035 and March&nbsp;31, 2041.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company assesses the realizability of the deferred tax assets at each balance sheet date based on available positive and negative evidence in order
to determine the amount which is more likely than not to be realized and record a valuation allowance as necessary. Due to the Company&#146;s cumulative loss position which provides significant negative evidence difficult to overcome, the Company
has recorded a valuation allowance of $303.3&nbsp;million as of March&nbsp;31, 2021, representing the portion of the deferred tax asset that is not more likely than not to be realized. The amount of the deferred tax asset considered realizable could
be adjusted for future factors that would impact the assessment of the objective and subjective evidence of the Company. For the period April&nbsp;1, 2020 through March&nbsp;31, 2021, the valuation allowance increased by $115.5&nbsp;million
primarily as a result of corresponding increases in our global net operating losses, as well as our Research Tax Credits. For the period April&nbsp;1, 2019 through March&nbsp;31, 2020, the valuation allowance decreased by $168.0&nbsp;million
primarily as a result of the Sumitomo Transaction and the deconsolidation of Sio. The Company will continue to assess the realizability of deferred tax assets at each balance sheet date in order to determine the amount, if any, required for a
valuation allowance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are outside basis differences related to the Company&#146;s investment in subsidiaries for which no deferred taxes have been
recorded as these would not be subject to tax on repatriation as Bermuda has no tax regime for Bermuda exempted limited companies, and the United Kingdom tax regime relating to company distributions and sales generally provides for exemption from
tax for most overseas profits, subject to certain exceptions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to tax and is required to file United States, United Kingdom, and Switzerland federal
income tax returns, as well as income tax returns in various state, local, and foreign jurisdictions. The Company is subject to tax examinations for tax years ended March&nbsp;31, 2018 and forward in major taxing jurisdictions. Tax audits and
examinations can involve complex issues, interpretations and judgments. The resolution of matters may span multiple years particularly if subject to litigation or negotiation. The Company believes it has appropriately recorded its tax position using
reasonable estimates and assumptions, however, the potential tax benefits may impact the results of operations or cash flows in the period of resolution, settlement or when the statutes of limitations expire. There are no unrecognized tax benefits
recorded as of March&nbsp;31, 2021 and 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 13&#151;Leases </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s operating leases consist primarily of real estate leases, including those entered into by certain wholly owned and majority-owned or
controlled subsidiaries of RSL. The Company determines if an agreement is or contains a lease at inception. Leases with an initial term of 12 months or less are not recorded on the balance sheet. For real estate leases, the Company&nbsp;elected the
expedient to account for lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components as a single component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Right-of-use</FONT></FONT> (&#147;ROU&#148;) assets represent the Company&#146;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#146;s obligation to make lease payments
arising from the lease. ROU assets and liabilities are based on the estimated present value of fixed lease payments over the expected lease term and are recognized at the lease commencement date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As most of the Company&#146;s leases do not provide an implicit rate, the Company uses an estimated incremental borrowing rate in determining the present
value of fixed lease payments based on information available at the lease commencement date. The Company&#146;s incremental borrowing rates are determined based on the term of the lease, the economic environment of the lease, and the effect of
collateralization. Certain leases include one or more renewal options, generally for the same period as the initial term of the lease. The exercise of lease renewal options is generally at the Company&#146;s sole discretion and, as such, the Company
typically determines that exercise of these renewal options is not reasonably certain. As a result, the Company does not include the renewal option period in the expected lease term and the associated lease payments are not included in the
measurement of the ROU asset and lease liability. Certain leases also contain termination options with an associated penalty. Generally, the Company is reasonably certain not to exercise these options and as such, they are not included in the
determination of the expected lease term. The Company recognizes operating lease expense on a straight-line basis over the lease term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leases generally
provide for payments of nonlease components, such as common area maintenance, real estate taxes and other costs associated with the leased property. For lease agreements entered into or modified after April&nbsp;1, 2019, the Company accounts for
lease components and nonlease components together as a single lease component and, as such, includes fixed payments of nonlease components in the measurement of the ROU assets and lease liabilities. Variable lease payments, such as periodic
adjustments for inflation, reimbursement of real estate taxes, any variable common area maintenance and any other variable costs associated with the leased property are expensed as incurred as variable lease costs and are not recorded on the balance
sheet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s lease agreements do not contain any material residual value guarantees or material restrictions or covenants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of operating lease expense for the Company were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,931</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,515</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">872</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Variable lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">704</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">379</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,872</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,766</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information related to the Company&#146;s operating lease ROU assets and operating lease liabilities was as follows (in
thousands, except periods and percentages): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>During the Year<BR>Ended March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,830</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,108</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease ROU assets obtained in exchange for operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,491</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56,025</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average remaining lease term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.6</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.2</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021, maturities of operating lease liabilities were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Years Ending March&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,386</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,814</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,718</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,734</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,617</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,674</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106,943</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: present value adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: tenant improvement allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,898</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,697</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 14&#151;Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(A) Significant Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company, primarily through
its subsidiaries has entered into commitments under various asset acquisition and license agreements including those described in Note 4, &#147;Asset Acquisitions and License Agreements.&#148; Additionally, the Company through its subsidiaries
enters into agreements with contract service providers to assist in the performance of its R&amp;D activities. Expenditures to contract research organizations and contract manufacturing organizations represent significant costs in the clinical
development of its product candidates. Subject to required notice periods and certain obligations under binding purchase orders, the Company can elect to discontinue the work under these agreements at any time. The Company expects to enter into
additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require upfront payments and long-term commitments of capital resources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(B) Loss Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company accrues for loss
contingencies when available information indicates that it is probable that a liability has been incurred and the amount of such loss can be reasonably estimated, and if the Company believes that a reasonably possible loss exists, the Company
discloses the facts and circumstances of the litigation or claim, including an estimable range, if possible. The Company is currently not involved in any legal proceedings with a probable and estimable material loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(C) Intellectual Property Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
March&nbsp;31, 2021, the Company did not have any ongoing material financial commitments, other than pursuant to various asset acquisition and license agreements including those described in Note 4, &#147;Asset Acquisitions and License
Agreements.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(D) <FONT STYLE="white-space:nowrap">COVID-19</FONT> Pandemic </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has been actively monitoring the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on its employees and business. Based on
guidance issued by federal, state and local authorities, the Company transitioned to a remote work model for its employees in March 2020 and its workforce continues to primarily work remotely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has had a variable impact on clinical trials by disrupting certain study sites. In the conduct
of business activities, the Company continues to take actions designed to protect the safety and well-being of its patients and employees. Although some of the Company&#146;s clinical development timelines have been impacted by delays related to the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the Company has not experienced material financial impacts on its business and operations as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. However, the impact on
the Company&#146;s future results will largely depend on future developments related to <FONT STYLE="white-space:nowrap">COVID-19,</FONT> which are highly uncertain and cannot be predicted with confidence, such as the emergence of new variants, the
ultimate duration and spread of the outbreak, the continuing impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on financial markets and the global economy, travel restrictions and social distancing in the United States and
other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain, treat, and prevent the disease, including the availability and effectiveness of vaccines. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 15&#151;Fair Value Measurements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recurring Fair Value Measurements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table
sets forth the Company&#146;s assets and liabilities that are measured at fair value on a recurring basis as of&nbsp;March&nbsp;31, 2021 and 2020, by level, within the fair value hierarchy (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of March&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of March&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Balance&nbsp;as&nbsp;of<BR>March&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Balance&nbsp;as&nbsp;of<BR>March&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,420,597</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,420,597</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,874,662</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,874,662</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Investment in Sio common shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,487</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,487</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,329</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,329</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Investment in Arbutus common shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,325</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,325</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,174</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,174</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Investment in Arbutus convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76,037</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76,037</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,062</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,062</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,129</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,129</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,880</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,880</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total assets at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,533,538</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76,037</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,609,575</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,945,045</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,062</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,968,107</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Debt held by Dermavant with NovaQuest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150,100</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150,100</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89,100</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89,100</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Liability instruments measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,893</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,893</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102,373</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102,373</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total liabilities at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">217,993</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">217,993</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191,473</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191,473</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no transfers of assets between Level&nbsp;1 and Level&nbsp;2 of the fair value measurement hierarchy that occurred
during the years ended March&nbsp;31, 2021 and 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Level&nbsp;3 Disclosures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company measures its Level&nbsp;3 liabilities, including debt issued by Dermavant to NovaQuest and the Sumitomo Options, at fair value based on significant
inputs not observable in the market, which causes them to be classified as a Level&nbsp;3 measurement within the fair value hierarchy. The valuation of the Level&nbsp;3 liabilities uses assumptions and estimates the Company believes would be made by
a market participant in making the same valuation. The Company assesses these assumptions and estimates on an ongoing basis as additional data impacting the assumptions and estimates are obtained. Changes in the fair value related to updated
assumptions and estimates are recorded within the statements of operations at the end of each reporting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of Level&nbsp;3
liabilities may change significantly as additional data are obtained, impacting the Company&#146;s assumptions regarding probabilities of potential scenarios used to estimate fair value. In evaluating this information, considerable judgment is
required to interpret the data used to develop the assumptions and estimates. Accordingly, the use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts, and such changes
could materially impact the Company&#146;s results of operations in future periods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The changes in fair value of the Level&nbsp;3 liabilities during the&nbsp;years ended March&nbsp;31, 2021
and 2020 were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at March&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">103,628</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of liability instruments measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,567</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in fair value of debt and liability instruments, included in net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at March&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191,473</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in fair value of debt and liability instruments, included in net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,845</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liability instruments disposed due to deconsolidation of subsidiary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,325</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">217,993</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Debt issued by Dermavant to NovaQuest </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the debt instrument as of&nbsp;March&nbsp;31, 2021 and 2020 represents the fair value of amounts payable to NovaQuest using a Monte Carlo
simulation model under the income approach determined by using probability assessments of the expected future payments through 2032 and applying discount rates ranging from 6% to 17%. The future payments are based on significant inputs that are not
observable in the market which are subject to remeasurement at each reporting date. The estimates of fair value may not be indicative of the amounts that could ultimately be paid by Dermavant to NovaQuest. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sumitomo Options </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the options to
acquire the Company&#146;s interest in Dermavant, Genevant, Lysovant, Metavant, Cytovant Parent, and Sinovant (collectively, the &#147;Option Vants&#148;) granted to Sumitomo under the Sumitomo Transaction Agreement as of March&nbsp;31, 2021 and
2020 was calculated using significant unobservable inputs including the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Range&nbsp;or&nbsp;Point&nbsp;Estimate&nbsp;Used</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Input</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;March&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;March&nbsp;31,&nbsp;2020</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Time to expiration (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3.59</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0.49&nbsp;-&nbsp;4.59</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0.52%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0.15%&nbsp;-&nbsp;0.35%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">89.0%&nbsp;-&nbsp;95.0%</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">91.0%&nbsp;-&nbsp;110.0%</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021 and 2020, the fair value of the Sumitomo Options was $62.4&nbsp;million and $95.9&nbsp;million,
respectively. Sumitomo Options are included in &#147;Liability instruments measured at fair value&#148; in the accompanying consolidated balance sheets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2021, the Company completed a transaction with Sumitomo pursuant to which Sumitomo terminated all of its existing options to acquire the
Company&#146;s equity interests in certain subsidiaries. See Note 19, &#147;Subsequent Events&#148; for additional information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 16&#151;Defined
Contribution Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company and certain of its subsidiaries sponsor defined contribution plans pursuant to Section&nbsp;401(k) of the U.S. Internal
Revenue Code. Employee contributions are voluntary and subject to the maximum allowable under federal tax regulations. For the years ended March&nbsp;31, 2021 and 2020, the Company recorded total expense for employer matching contributions of
$1.7&nbsp;million and $1.7&nbsp;million, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 17&#151;Other Expense, Net </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other expense, net from continuing operations was as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from equity method investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,750</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,386</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,418</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,990</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,809</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,683</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,560</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,543</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,701</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,622</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 18&#151;Earnings per Common Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The computations of the numerator to derive the basic and diluted earnings per share amounts presented on the face of the accompanying consolidated statements
of operations are as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from continuing operations, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(900,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(568,110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss from continuing operations, net of tax, attributable to noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(90,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(48,716</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from continuing operations, net of tax, attributable to Roivant Sciences Ltd.</B></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(809,234</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(519,394</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend on repurchase of redeemable noncontrolling interest relating to subsidiary
convertible and redeemable preferred stock<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(77,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic and diluted loss from continuing operations, net of tax, attributable to Roivant Sciences
Ltd.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(809,234</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(597,171</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from discontinued operations, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,578,426</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss from discontinued operations, net of tax, attributable to noncontrolling
interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(141,477</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income from discontinued operations, net of tax, attributable to Roivant Sciences
Ltd.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,719,903</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted income from discontinued operations, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,719,903</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic and diluted net (loss) income attributable to Roivant Sciences</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(809,234</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,122,732</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consideration paid in excess of carrying value for the repurchase of redeemable noncontrolling interest
relating to subsidiary convertible and redeemable preferred stock of $77.8&nbsp;million is considered a deemed dividend and, for purposes of calculating net loss per share, increases the loss from continuing operations, net of tax, attributable to
Roivant Sciences Ltd. for the year ended March&nbsp;31, 2020. See Note 10, &#147;Shareholders&#146; Equity and Redeemable Noncontrolling Interest.&#148; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net (loss) income per common share is computed by dividing net (loss) income attributable to Roivant Sciences Ltd. by the weighted-average number of
common stock outstanding during the period. Diluted net (loss) income per common share is computed by dividing the net income (loss) attributable to Roivant Sciences Ltd. by the diluted weighted-average number of common stock outstanding during the
period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For periods of loss from continuing operations, diluted loss per share is calculated similar to basic loss per share as the effect of including
all potentially dilutive common share equivalents is anti-dilutive. All outstanding common stock equivalents have been excluded from the computation of diluted loss per share because their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effect was anti-dilutive due to the loss from continuing operations. Refer to Note 11, &#147;Share-Based Compensation&#148; and Note 5, &#147;Sumitomo Transaction Agreement&#148; for additional
detail regarding outstanding common stock equivalents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 19&#151;Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events for appropriate disclosures through June 30, 2021, the date that the consolidated financial statements were
available to be issued. All subsequent events requiring recognition as of March&nbsp;31, 2021 have been incorporated in these financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Option Vants Transaction </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;1, 2021, the
Company entered into an Asset Purchase Agreement with Sumitomo and its subsidiary Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. (&#147;SPC&#148;) (the &#147;Asset Purchase Agreement&#148;). The transactions contemplated by the Asset Purchase Agreement
closed in June 2021. Pursuant to the Asset Purchase Agreement: (i)&nbsp;Sumitomo terminated all of its existing options to acquire the Company&#146;s equity interests in the Option Vants; (ii)&nbsp;the Company transferred and assigned to SPC all of
its intellectual property, development and commercialization rights for (a)&nbsp;lefamulin in Mainland China, Taiwan, Hong Kong, and Macau (collectively &#147;Greater China&#148;), (b) vibegron in Mainland China, (c)&nbsp;rodatristat ethyl in
Greater China and South Korea and <FONT STYLE="white-space:nowrap">(d)&nbsp;RVT-802</FONT> in Greater China and South Korea; (iii)&nbsp;we will receive a $5.0&nbsp;million cash payment; and (iv)&nbsp;Sumitomo entered into an agreement with the
Company to pursue future collaborations with Genevant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dermavant </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;14, 2021, Dermavant entered into a $160.0&nbsp;million revenue interest purchase and sale agreement (the &#147;RIPSA&#148;) for its investigational
product tapinarof with three institutional investors. Under the terms of the RIPSA, the participants purchased a capped single-digit revenue interest in net sales of tapinarof for all dermatological indications in the United States in exchange for
$160.0&nbsp;million in committed funding to be paid to Dermavant, subject to approval of tapinarof by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dermavant concurrently entered into a
$40.0&nbsp;million senior secured credit facility (the &#147;Credit Facility&#148;) with one of the institutional investors. The Credit Facility has a five-year maturity and bears an interest rate of 10% per annum. In connection with the funding of
the Credit Facility, Dermavant issued to the institutional investor a warrant to purchase 1,199,072 common shares of Dermavant at an exercise price of $0.01 per common share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proceeds from the Credit Facility were used to repay all amounts outstanding under the loan and security agreement with Hercules, with the remainder of
net proceeds used for working capital and general corporate purposes. The Company reclassified $3.1&nbsp;million on the consolidated balance sheets as of March&nbsp;31, 2021 from current to long-term given that Dermavant had the intent and ability
to refinance the short-term obligation on a long-term basis after March&nbsp;31, 2021 and before the financial statements were issued. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Datavant</I></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2021, Datavant and CIOX Health,
LLC entered into a definitive agreement to merge the two companies. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The merger closed on July 27, 2021. At closing, Roivant received approximately $320
million in cash. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom65062_39"></A><U>ANNEX A &#150; BUSINESS COMBINATION AGREEMENT</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BUSINESS COMBINATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BY AND AMONG </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MONTES
ARCHIMEDES ACQUISITION CORP., </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RHINE MERGER SUB, INC., </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ROIVANT SCIENCES
LTD. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DATED AS OF MAY&nbsp;1, 2021 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TABLE OF CONTENTS </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">P<SMALL>AGE</SMALL></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE&nbsp;1 CERTAIN DEFINITIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">A-3</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Definitions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE&nbsp;2 MERGER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">A-19</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Closing Transactions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-19</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Closing of the Transactions Contemplated by this Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-21</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Fractional Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-21</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Treatment of Company Equity Awards</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-21</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Transfer Agent Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-23</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Withholding</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-23</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE&nbsp;3 REPRESENTATIONS AND WARRANTIES RELATING TO THE GROUP
COMPANIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">A-23</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Organization and Qualification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-23</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Capitalization of the Group Companies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-24</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authority</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-26</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Financial Statements; Undisclosed Liabilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-27</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Consents and Requisite Governmental Approvals; No&nbsp;Violations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-28</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Permits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-29</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Material Contracts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-29</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Absence of Changes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-30</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Litigation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-31</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance with Applicable Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-31</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Merger Sub Activities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-31</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Employee Plans</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-31</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Environmental Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-32</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.14</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Intellectual Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-32</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.15</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Labor Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-34</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.16</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-35</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.17</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tax Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-35</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.18</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Brokers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-36</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.19</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Real and Personal Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-36</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.20</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Transactions with Affiliates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-37</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.21</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Data Privacy and Security</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-37</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.22</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certain Business Practices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-38</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.23</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Information Supplied</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-38</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.24</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Regulatory Compliance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-39</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.25</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Investment Company Act</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-40</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.26</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>SEC Filings and Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-40</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.27</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Other Representations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-41</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.28</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>EXCLUSIVITY OF REPRESENTATIONS AND WARRANTIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-41</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE&nbsp;4 REPRESENTATIONS AND WARRANTIES RELATING TO MAAC</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">A-42</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Organization and Qualification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-42</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authority</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-42</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Consents and Requisite Governmental Approvals; No Violations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-42</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Brokers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-43</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Information Supplied</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-43</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Capitalization of MAAC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-43</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>SEC Filings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-44</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Trust Account</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-45</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No MAAC Material Adverse Effect</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-45</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Material Contracts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-45</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Transactions with Affiliates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-46</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Litigation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-46</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance with Applicable Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-46</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.14</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>MAAC&#146;s Business Activities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-46</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.15</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Internal Controls; Listing; Financial Statements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-47</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.16</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Undisclosed Liabilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-48</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.17</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Employees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-48</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.18</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tax Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-48</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.19</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certain Business Practices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-49</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.20</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>PIPE Financing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-50</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.21</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Investigation; No Other Representations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-50</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.22</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>EXCLUSIVITY OF REPRESENTATIONS AND WARRANTIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-51</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE&nbsp;5 COVENANTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">A-51</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conduct of Business of the Group Companies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-51</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Efforts to Consummate; Transaction Litigation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-54</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Confidentiality and Access to Information</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-55</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Public Announcements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-57</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tax Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-58</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Exclusive Dealing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-59</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preparation of Registration Statement / Proxy Statement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-60</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>MAAC Shareholder Approval</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-61</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Merger Sub Shareholder Approval</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-62</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conduct of Business of MAAC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-62</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Nasdaq Listing; MAAC Public Filings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-64</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Trust Account</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-64</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Company Shareholder Approval</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-64</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.14</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>MAAC Indemnification; Directors&#146; and Officers&#146; Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-65</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.15</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Company Indemnification; Directors&#146; and Officers&#146; Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-66</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.16</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Post-Closing Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-67</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.17</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>PCAOB Financials</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-68</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.18</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Company Post-Closing Incentive Equity Plan; Company Post-Closing Employee Stock Purchase Plan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-68</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.19</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-68</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.20</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Company Related Party Transactions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-69</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.21</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conduct of Business of Merger Sub</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-69</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.22</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notice of Certain Events</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-69</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.23</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>PIPE Subscription Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-69</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE&nbsp;6 CONDITIONS TO CONSUMMATION OF THE TRANSACTIONS CONTEMPLATED BY THIS
AGREEMENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">A-70</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conditions to the Obligations of the Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-70</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Other Conditions to the Obligations of MAAC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-71</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Other Conditions to the Obligations of the Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-72</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE&nbsp;7 TERMINATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">A-73</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-73</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effect of Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-74</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE&nbsp;8 MISCELLANEOUS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">A-74</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Non-Survival</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-74</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Entire Agreement; Assignment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-74</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Amendment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-74</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-75</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Governing Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-76</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Fees and Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-76</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Construction; Interpretation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-76</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Exhibits and Schedules</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-77</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Parties in Interest</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-77</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-78</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Counterparts; Electronic Signatures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-78</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Knowledge of Company; Knowledge of MAAC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-78</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Recourse</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-78</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.14</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Extension; Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-78</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.15</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Waiver of Jury Trial</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-79</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.16</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Submission to Jurisdiction</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-79</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.17</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Remedies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-80</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.18</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Trust Account Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ANNEXES AND EXHIBITS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Annex A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">PIPE Investors</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of PIPE Subscription Agreement</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit B</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Transaction Support Agreement</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit C</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Registration Rights Agreement</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit D</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit E</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Company Post-Closing <FONT STYLE="white-space:nowrap">Bye-laws</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit F</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Company Shareholder Written Consent</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit G</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Roivant Sciences Ltd. 2021 Equity Incentive Plan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit H</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Company Post-Closing Employee Stock Purchase Plan Term Sheet</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BUSINESS COMBINATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This BUSINESS COMBINATION AGREEMENT (this &#147;<U>Agreement</U>&#148;), dated as of May&nbsp;1, 2021, is made by and among Montes Archimedes
Acquisition Corp., a Delaware corporation (&#147;<U>MAAC</U>&#148;), Roivant Sciences Ltd., a Bermuda exempted limited company (the &#147;<U>Company</U>&#148;), and Rhine Merger Sub, Inc., a Delaware corporation and a direct wholly owned Subsidiary
of the Company (&#147;<U>Merger Sub</U>&#148;). MAAC, the Company and Merger Sub shall be referred to herein from time to time collectively as the &#147;<U>Parties</U>.&#148; Capitalized terms used but not otherwise defined herein have the meanings
set forth in <U>Section</U><U></U><U>&nbsp;1.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, (a)&nbsp;MAAC is a blank check company incorporated as a Delaware
corporation on July&nbsp;6, 2020 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses,&nbsp;and (b)&nbsp;Merger Sub is, as of the
date of this Agreement, a direct wholly owned Subsidiary of the Company formed for purposes of consummating the transactions contemplated by this Agreement and the applicable Ancillary Documents; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to the Governing Documents of MAAC, MAAC is required to provide an opportunity for the holders of MAAC Class&nbsp;A Shares
to have their outstanding MAAC Class&nbsp;A Shares redeemed on the terms and subject to the conditions set forth therein in connection with obtaining the MAAC Shareholder Approval; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as of the date of this Agreement, Patient Square Capital LLC, a Delaware limited liability company (the &#147;<U>MAAC
Sponsor</U>&#148;), owns 10,167,956 MAAC Class&nbsp;B Shares and 10,214,365 MAAC Warrants; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution of
this Agreement, the MAAC Sponsor, MAAC and the Company are entering into the sponsor support agreement (the &#147;<U>Sponsor Support Agreement</U>&#148;), pursuant to which (i)&nbsp;the MAAC Sponsor has agreed to, among other things, (a)&nbsp;vote
in favor of this Agreement and the transactions contemplated hereby (including the Merger), (b) subject to, and conditioned upon the occurrence of and effective as of immediately prior to, the Effective Time, waive any adjustment to the conversion
ratio set forth in the Governing Documents of MAAC or any other anti-dilution or similar protection, in each case, with respect to the MAAC Class&nbsp;B Shares (whether resulting from the transactions contemplated by the PIPE Subscription Agreements
or otherwise), and (c)&nbsp;subject to, and conditioned upon the occurrence of and effective as of immediately after, the Effective Time, subject a number Company Post-Closing Common Shares determined pursuant to the Sponsor Support Agreement to
vesting requirements that are tied to the share price of the Company Post-Closing Common Shares following the Effective Time, in each case, on the terms and subject to the conditions set forth in the Sponsor Support Agreement and (ii)&nbsp;the MAAC
Sponsor will, subject to, and conditioned upon the occurrence of and effective as of, the Effective Time, be granted certain registration rights with respect to its Company Post-Closing Common Shares; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, prior to the Closing Date or on the Closing Date prior to the Effective Time&nbsp;and prior to the consummation of the matters
described in the following recital, the Company <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Shares shall be converted and redesignated into Company Voting Common Shares, in accordance with the Company
<FONT STYLE="white-space:nowrap">Bye-Laws,</FONT> on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis (the &#147;<U><FONT STYLE="white-space:nowrap">Non-Voting</FONT> </U><U>Share
Conversion</U>&#148;), subject to the expiration or termination of any applicable waiting period under the HSR Act with respect to the <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Share Conversion; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the Closing Date prior to the Effective Time, the Company shall (a)&nbsp;cause each Company
<FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Share to be divided into a number of Company Post-Closing Common Shares equal to the Exchange Ratio and (b)&nbsp;amend and restate the Company
<FONT STYLE="white-space:nowrap">Bye-Laws,</FONT> in each case, on the terms and subject to the terms and conditions set forth in this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution of this Agreement, each of the investors set forth on <U>Annex A</U> hereto (collectively, the
&#147;<U>PIPE Investors</U>&#148;) is entering into a subscription agreement, substantially in the form attached hereto as <U>Exhibit A</U> (collectively, the &#147;<U>PIPE</U><U></U><U>&nbsp;Subscription Agreements</U>&#148;), pursuant to which,
among other things, each PIPE Investor has agreed to subscribe for and purchase on the Closing Date immediately prior to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Effective Time, and MAAC has agreed to issue and sell to each such PIPE Investor on the Closing Date immediately prior to the Effective Time, the number of MAAC Class&nbsp;A Shares set forth in
the applicable PIPE Subscription Agreement in exchange for the purchase price set forth therein (the equity financing under all PIPE Subscription Agreements, collectively, the &#147;<U>PIPE Financing</U>&#148;), in each case, on the terms and
subject to the conditions set forth in the applicable PIPE Subscription Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the Closing Date, promptly following the
Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps and at the Effective Time, Merger Sub will merge with and into MAAC, with MAAC continuing as the surviving corporation in the merger and, after giving effect to such merger,
(a)&nbsp;MAAC will be a wholly owned Subsidiary of the Company, (b)&nbsp;each MAAC Class&nbsp;A Share and each MAAC Class&nbsp;B Share not held by the MAAC Sponsor or its Affiliates, in each case, issued and outstanding as of immediately prior to
the Effective Time (including, for the avoidance of doubt, each MAAC Class&nbsp;A Share issued to the PIPE Investors pursuant to the PIPE Subscription Agreements (but excluding, for the avoidance of doubt, (i)&nbsp;any MAAC Class&nbsp;A Shares and
MAAC Class&nbsp;B Shares held by MAAC as treasury stock or by the MAAC Sponsor or its Affiliates and (ii)&nbsp;any MAAC Class&nbsp;A Shares redeemed in a MAAC Shareholder Redemption)), will be automatically converted as of the Effective Time into
one Company Post-Closing Common Share, and (c)&nbsp;each MAAC Class&nbsp;B Share held by the MAAC Sponsor and its Affiliates issued and outstanding as of immediately prior to the Effective Time will be automatically converted as of the Effective
Time into the number of Company Post-Closing Common Shares equal to the Sponsor Exchange Ratio, in each case, on the terms and subject to the conditions set forth in this Agreement and the applicable Ancillary Documents; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution of this Agreement, the Significant Company Shareholders will duly execute and deliver to MAAC and the
Company a transaction support agreement, substantially in the form attached hereto as <U>Exhibit B</U> (collectively, the &#147;<U>Transaction Support Agreements</U>&#148;), pursuant to which, in the case of each such Transaction Support Agreement,
each such Significant Company Shareholder will agree to, among other things, (i)&nbsp;be bound by and subject to certain covenants and agreements related to, or in furtherance of, the transactions contemplated by this Agreement and the Ancillary
Documents, including the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps and (ii)&nbsp;take, or cause to be taken, any actions necessary or advisable to cause certain existing Company agreements to be terminated effective as of the
Closing;<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution of this Agreement, the
Significant Company Shareholders are entering into the Third Amended and Restated Registration Rights Agreement, substantially in the form attached hereto as <U>Exhibit C</U> (the &#147;<U>Registration Rights Agreement</U>&#148;), pursuant to which,
among other things, certain Company Shareholders will, subject to, and conditioned upon and effective as of, the Effective Time, be granted certain registration rights with respect to their respective Company Post-Closing Common Shares, in each
case, on the terms and subject to the conditions set forth therein; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution of this Agreement, each of
the Company, certain Company Shareholders and the MAAC Sponsor are entering into a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, substantially in the form attached hereto as <U>Exhibit D</U> (the
&#147;<U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</U>&#148;), pursuant to which, among other things, subject to, and conditioned upon and effective as of, the Effective Time, such Company Shareholders and the MAAC Sponsor will agree
not to effect any sale or distribution of all or a portion of, as applicable, the Equity Securities of the Company held by any of them during the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> periods described therein; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the board of directors of MAAC (the &#147;<U>MAAC Board</U>&#148;) has (a)&nbsp;determined that it is in the best interests of MAAC
and its stockholders, and declared it advisable, to enter into this Agreement and the Ancillary Documents to which MAAC is or will be a party and to consummate the transactions contemplated hereby and thereby (including the Merger), (b) approved
this Agreement, the Ancillary Documents to which MAAC is or will be a party and the consummation of the transactions contemplated hereby and thereby (including the Merger) and (c)&nbsp;recommended, among other things, approval and adoption of this
Agreement, the Ancillary Documents to which MAAC is or will be a party and the consummation of the transactions contemplated by hereby or thereby (including the Merger) by the holders of MAAC Shares entitled to vote thereon; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the board of directors of Merger Sub has approved this Agreement, the Ancillary
Documents to which Merger Sub is or will be a party and the transactions contemplated hereby and thereby (including the Merger); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,
the Company, as the sole stockholder of Merger Sub, will as promptly as reasonably practicable (and in any event within one (1)&nbsp;Business Day) following the date of this Agreement, approve and adopt this Agreement, the Ancillary Documents to
which Merger Sub is or will be a party and the transactions contemplated hereby and thereby (including the Merger); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently
with the execution hereof, the Company is delivering to MAAC the Company Shareholder Written Consent duly executed by the Significant Company Shareholders; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the board of directors of the Company (the &#147;<U>Company Board</U>&#148;) has (a)&nbsp;unanimously approved this Agreement, the
Ancillary Documents to which the Company is or will be a party and the consummation of the transactions contemplated hereby and thereby (including the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps and the Merger),
(b)&nbsp;recommended, among other things, the entry into this Agreement and the Ancillary Documents to which the Company is or will be a party and the consummation of the transactions contemplated hereby and thereby (including the Company <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Steps and the Merger) to the holders of the Company Pre-Closing Common Shares entitled to vote thereon for their approval and (c)&nbsp;given reasonable advance written notice of the Company <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Steps and the Merger in accordance with the Company <FONT STYLE="white-space:nowrap">Bye-Laws</FONT> to the Company Shareholders (including the &#147;Lot Large Shareholders&#148; (as defined therein));
and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, each of the Parties intends for U.S. federal income tax purposes that (a)&nbsp;this Agreement constitutes a &#147;plan of
reorganization&#148; within the meaning of Section&nbsp;368 of the Code and Treasury Regulations promulgated thereunder, (b)&nbsp;the Merger qualifies as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code and
(c)&nbsp;the exchange of MAAC Class&nbsp;A Shares or MAAC Class&nbsp;B Shares for Company Post-Closing Common Shares pursuant to <U>Section</U><U></U><U>&nbsp;2.1(b)(vii)</U>, other than with respect to any
<FONT STYLE="white-space:nowrap">Pre-Closing</FONT> MAAC Shareholders who are U.S. persons and who will be &#147;five-percent transferee shareholders&#148; within the meaning of Treasury Regulations
<FONT STYLE="white-space:nowrap">Section&nbsp;1.367(a)-3(c)(5)(ii)</FONT> but who do not enter into gain recognition agreements within the meaning of Treasury Regulations Sections <FONT STYLE="white-space:nowrap">1.367(a)-3(c)(1)(iii)(B)</FONT> and <FONT
STYLE="white-space:nowrap">1.367(a)-8,</FONT> qualifies for an exception to Section&nbsp;367(a)(1) of the Code (<U>clauses (a)</U>&nbsp;through <U>(c)</U>, collectively, the &#147;<U>Intended Tax Treatment</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises and the mutual promises set forth herein and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Parties, each intending to be legally bound, hereby agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTAIN
DEFINITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section 1.1 <U>Definitions</U></B>. As used in this Agreement, the following terms have the respective meanings set
forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Additional MAAC SEC Reports</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.7</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Adjusted CVAR Award</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.4(d)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Adjusted Option</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.4(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Adjusted RSU Award</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.4(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Affiliate</U>&#148; means, with respect to any Person, any other Person who directly or indirectly, through one or more
intermediaries, controls, is controlled by, or is under common control with, such Person; <U>provided</U> that no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Public Group Company shall be deemed to be an Affiliate of any Private Group Company for purposes hereof. The term &#147;<U>control</U>&#148; means the possession, directly or indirectly, of the
power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise, and the terms &#147;<U>controlled</U>&#148; and &#147;<U>controlling</U>&#148; have
meanings correlative thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Aggregate Trust Account Proceeds</U>&#148; means the aggregate cash proceeds that are or would be
(assuming that the Closing occurs) released to MAAC (or any designees thereof) from the Trust Account on the Closing Date in connection with the transactions contemplated hereby (for the avoidance of doubt, (i)&nbsp;after giving effect to the MAAC
Shareholder Redemption and (ii)&nbsp;excluding the proceeds of the PIPE Financing). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Agreement</U>&#148; has the meaning set
forth in the introductory paragraph to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Ancillary Documents</U>&#148; means the Registration Rights Agreement,
the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, the Sponsor Support Agreement, the PIPE Subscription Agreements, the Transaction Support Agreements, the Certificate of Merger and each other agreement, document, instrument and/or
certificate contemplated by this Agreement executed or to be executed in connection with the transactions contemplated hereby (including those entered into in connection with the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Anti-Corruption Laws</U>&#148; means, collectively, (a)&nbsp;the U.S. Foreign Corrupt Practices Act of 1977, (b) the UK Bribery
Act 2010 and (c)&nbsp;any other applicable anti-bribery or anti-corruption Laws or Orders related to combatting bribery, corruption and money laundering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Business Combination Proposal</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.8</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Business Day</U>&#148; means a day, other than a Saturday or Sunday, on which commercial banks in Hamilton, Bermuda, London, England,
New York, New York and San Francisco, California are open for the general transaction of business; <U>provided</U> that banks shall be deemed to be generally open for the general transaction of business in the event of a &#147;shelter in place&#148;
or similar closure of physical branch locations at the direction of any governmental authority if such banks&#146; electronic funds transfer system (including for wire transfers) are open for use by customers on such day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>CBA</U>&#148; means any collective bargaining agreement or other Contract with any labor union, labor organization, or works council.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Certificate of Merger</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.1(b)(ii)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Certificates</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.1(b)(vii)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing Company Financial Statements</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.4(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing Date</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing Filing</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.4(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing Press Release</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.4(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>COBRA</U>&#148; means Part 6 of Subtitle B of Title I of ERISA, Section&nbsp;4980B of the Code and any similar state Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Code</U>&#148; means the U.S. Internal Revenue Code of 1986. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Companies Act</U>&#148; means the Bermuda Companies Act, 1981. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company</U>&#148; has the meaning set forth in the introductory paragraph to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Acquisition Proposal</U>&#148; means any transaction or series of related transactions under which any Person(s), directly or
indirectly, acquires or otherwise purchases the Company or all or substantially all of the assets, Equity Securities or businesses of the Company and its controlled Affiliates on a consolidated basis (whether by merger, consolidation,
recapitalization, purchase or issuance of Equity Securities, purchase of assets, tender offer or otherwise). Notwithstanding the foregoing or anything to the contrary herein, (i)&nbsp;none of this Agreement, the Ancillary Documents or the
transactions contemplated hereby or thereby shall constitute a Company Acquisition Proposal and (ii)&nbsp;the Company&#146;s or one of its Affiliates&#146; acquisition of Equity Securities of a Public Group Company that are not already owned by the
Company or any issuance of Equity Securities of the Company in connection therewith shall not constitute a Company Acquisition Proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Additional Capitalization Representations</U>&#148; means the representations and warranties set forth in the first two
sentences of <U>Section</U><U></U><U>&nbsp;3.2(a)</U> and <U>Section</U><U></U><U>&nbsp;3.2(c)</U> (Capitalization of the Group Companies). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Board</U>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company <FONT STYLE="white-space:nowrap">Bye-Laws</FONT></U>&#148; means the eighth amended and restated <FONT
STYLE="white-space:nowrap">bye-laws</FONT> of the Company, adopted on June&nbsp;17, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Common Shares</U>&#148; means
(a)&nbsp;prior to the consummation of the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps, the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares, and (b)&nbsp;from and after the consummation of the Company <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Steps, means the Company Post-Closing Common Shares. Any reference to the Company Common Shares in this Agreement or any Ancillary Document shall be deemed to refer to <U>clause (a)</U>&nbsp;and/or
<U>clause (b)</U>&nbsp;of this definition, as the context so requires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company CVAR Award</U>&#148; means, as of any
determination time, each capped value appreciation right with respect to Company Common Shares that is outstanding and granted under a Company Equity Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company D&amp;O Persons</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.15(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Designee</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.16(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Disclosure Schedules</U>&#148; means the disclosure schedules to this Agreement delivered to MAAC by the Company on the date
of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Equity Award</U>&#148; means, as of any determination time, each Company Option, each Company RSU
Award, each Company Restricted Common Share, each Company CVAR Award and each other award to any current or former director, manager, officer, employee, individual independent contractor or other service provider of any Group Company of rights of
any kind to receive any Equity Security of the Company under any Company Equity Plan or otherwise that is outstanding as of such time of determination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Equity Plan</U>&#148; means each of (a)&nbsp;the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan,
(b)&nbsp;the Roivant Sciences Ltd. Amended and Restated 2015 Restricted Stock Unit Plan and (c)&nbsp;each other plan that provides for the award to any current or former director, manager, officer, employee, individual independent contractor or
other service provider of any Group Company of rights of any kind to receive Equity Securities of the Company or benefits measured in whole or in part by reference to Equity Securities of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Equityholders</U>&#148; means, collectively, the Company Shareholders and the holders of Company Equity Awards as of any
determination time prior to the Effective Time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Expenses</U>&#148; means, as of any determination time and without
duplication, the aggregate amount of fees, expenses, costs, disbursements, commissions or other amounts incurred by or on behalf of, and that are due and payable by (and not otherwise expressly allocated to MAAC pursuant to the terms of this
Agreement or any Ancillary Document) any Group Company in connection with the negotiation, preparation or execution of this Agreement or any Ancillary Documents, the performance of its covenants or agreements in this Agreement or any Ancillary
Document or the consummation of the transactions contemplated hereby or thereby, including (a)&nbsp;the fees and expenses of outside legal counsel, accountants, advisors, brokers, placement agents, investment bankers, consultants, or other agents or
service providers of any Group Company, (b)&nbsp;any other fees, expenses, commissions or other amounts that are expressly allocated to any Group Company pursuant to this Agreement or any Ancillary Document and (c)&nbsp;fifty percent (50%) of the
expenses incurred in connection with the filing of the Registration Statement / Proxy Statement with the SEC and the printing and mailing of the Registration Statement / Proxy Statement to holders of MAAC Shares. Notwithstanding the foregoing or
anything to the contrary herein, Company Expenses shall not include any MAAC Expenses or any fees, expenses, commissions or other amounts that are expressly contemplated to be allocated to and paid by MAAC pursuant to this Agreement or any Ancillary
Document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Financial Statements</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.4(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Fundamental Representations</U>&#148; means the representations and warranties set forth in
<U>Section</U><U></U><U>&nbsp;3.1(a)</U> and <U>Section</U><U></U><U>&nbsp;3.1(b)</U> (Organization and Qualification), <U>Section</U><U></U><U>&nbsp;3.2(a)</U> and <U>Section</U><U></U><U>&nbsp;3.2(d)</U> (Capitalization of the Group Companies),
<U>Section</U><U></U><U>&nbsp;3.3</U>&nbsp;(Authority), <U>Section</U><U></U><U>&nbsp;3.8(a)</U> (No Company Material Adverse Effect) and <U>Section</U><U></U><U>&nbsp;3.18</U> (Brokers). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company IT Systems</U>&#148; means all computer systems, Software and hardware, communication systems, servers, network equipment and
related documentation, in each case, owned, licensed or leased by a Private Group Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Licensed Intellectual
Property</U>&#148; means Intellectual Property Rights owned by any Person (other than a Group Company) that are licensed to any Group Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Material Adverse Effect</U>&#148; means any change, event, development, effect or occurrence that, individually or in the
aggregate with any other change, event, development, effect or occurrence, has had or would reasonably be expected to have a material adverse effect on (a)&nbsp;the business, results of operations, assets or financial condition of the Group
Companies, taken as a whole, or (b)&nbsp;the ability of the Company or Merger Sub to consummate the transactions contemplated by this Agreement to occur on the Closing Date (including the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT>
Steps and the Merger); <U>provided</U>, <U>however</U>, that, in the case of <U>clause (a)</U>, none of the following shall be taken into account in determining whether a Company Material Adverse Effect has occurred or is reasonably likely to occur:
any adverse change, event, development, effect or occurrence arising after the date of this Agreement from or related to (i)&nbsp;general business or economic conditions in or affecting the United States, or changes therein, or the global economy
generally, (ii)&nbsp;any national or international political or social conditions in the United States or any other country, including the engagement by the United States or any other country in hostilities, whether or not pursuant to the
declaration of a national emergency or war, or the occurrence in any place of any military or terrorist attack, sabotage or cyberterrorism, (iii)&nbsp;changes in conditions of the financial, banking, capital or securities markets generally in the
United States or any other country or region in the world, or changes therein, including changes in interest rates in the United States or any other country and changes in exchange rates for the currencies of any countries, (iv)&nbsp;changes in any
applicable Laws, (v)&nbsp;any change, event, development, effect or occurrence that is generally applicable to the industries or markets in which any Group Company operates, (vi)&nbsp;the execution or public announcement of this Agreement or the
pendency or consummation of the transactions contemplated by this Agreement, including the impact thereof on the relationships, contractual or otherwise, of any Group Company with employees, customers, investors, contractors, lenders, suppliers,
vendors, partners, licensors, licensees, payors or other third parties related thereto (<U>provided</U> that the exception in this <U>clause</U><U></U><U>&nbsp;(vi)</U> shall not apply to the representations and warranties set forth in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<U>Section</U><U></U><U>&nbsp;3.5(b)</U> to the extent that its purpose is to address the consequences resulting from the public announcement or pendency or consummation of the transactions
contemplated by this Agreement or the condition set forth in <U>Section</U><U></U><U>&nbsp;6.2(a)</U> to the extent it relates to such representations and warranties), (vii) any failure by any Group Company to meet, or changes to, any internal or
published budgets, projections, forecasts, estimates or predictions (although the underlying facts and circumstances resulting in such failure may be taken into account to the extent not otherwise excluded from this definition), (viii) any
hurricane, tornado, flood, earthquake, tsunami, natural disaster, mudslides, wild fires, epidemics, pandemics (including <FONT STYLE="white-space:nowrap">COVID-19)</FONT> or quarantines, acts of God or other natural disasters or comparable events in
the United States or any other country or region in the world, or any escalation of the foregoing, or (ix)&nbsp;any regulatory, preclinical, clinical, pricing or reimbursement changes, effects, developments or occurrences arising after the date
hereof and relating to or affecting any Company Product (including (A)&nbsp;any suspension, rejection, refusal of, request to refile or any delay in obtaining or making any regulatory application or filing relating to any Company Product,
(B)&nbsp;any negative regulatory actions, requests, recommendations or decisions of any Governmental Entity relating to any Company Product or the manufacture thereof, or any other regulatory or preclinical or clinical development relating to any
Company Product, (C)&nbsp;any preclinical or clinical studies, trials, tests, results or adverse events, or announcements of any of the foregoing, with respect to any Company Product, (D)&nbsp;any delay, hold or termination of any preclinical or
clinical study, trial or test or any delay, hold or termination of any planned application for investigational new drug application or application for marketing approval with respect to any Company Product, (E)&nbsp;any preclinical or clinical
studies, trials, tests, results or adverse events, or announcements of any of the foregoing, with respect to any product or product candidate competitive with or related to any Company Product, (F)&nbsp;FDA approval (or other preclinical or clinical
or regulatory developments), market entry or threatened market entry of any product or product candidate competitive with or related to any Company Product or (G)&nbsp;any recommendations, statements, decisions or other pronouncements made,
published or proposed by professional medical organizations, payors, Governmental Entities or representatives of the foregoing, or any panel or advisory body empowered or appointed thereby, relating to any Company Product or any products or product
candidates of any competitors of the Company), in each case, as applicable and solely to the extent not resulting from or arising out of any fraud or intentional and material violation of any applicable Public Health Law or Order by any Group
Company; <U>provided</U>, <U>however</U>, that (A)&nbsp;any change, event, development, effect or occurrence resulting from a matter described in any of the foregoing <U>clauses</U><U></U><U>&nbsp;(i)</U> through <U>(v)</U>&nbsp;may be taken into
account in determining whether a Company Material Adverse Effect has occurred or is reasonably likely to occur to the extent such change, event, development, effect or occurrence has or has had a disproportionate adverse effect on the Group
Companies, taken as a whole, relative to other participants operating in the industries or markets in which the Group Companies operate and (B)&nbsp;in no event shall (x)&nbsp;any change, event, development, effect or occurrence to the extent
relating to MAAC, (y)&nbsp;any MAAC Shareholder Redemption, in and of itself, or (z)&nbsp;any failure, in and of itself, by a PIPE Investor to fulfill its obligations under a PIPE Subscription Agreement constitute a Company Material Adverse Effect.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates</U>&#148; means, collectively, each Company Related Party
and each former, current or future Affiliate, Representative, equityholder, successor, heir or permitted assign of any Company Related Party (other than, for the avoidance of doubt, the Company). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Shares</U>&#148; means
<FONT STYLE="white-space:nowrap">non-voting</FONT> common shares, par value $0.0000001 per share, of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company
Option</U>&#148; means, as of any determination time, each option to purchase Company Common Shares (including, for the avoidance of doubt, each option subject to any performance-based or liquidity-based vesting conditions) that is outstanding and
unexercised and granted under a Company Equity Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Owned Intellectual Property</U>&#148; means all Intellectual
Property Rights that are owned by any of the Group Companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Post-Closing
<FONT STYLE="white-space:nowrap">Bye-Laws</FONT></U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.1(a)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Post-Closing Common Shares</U>&#148; means common shares of the Company,
with a par value equal to the par value of the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares<I> divided by</I> the Exchange Ratio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Post-Closing Employee Stock Purchase Plan</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.18</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Post-Closing Incentive Equity Plan</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.18</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares</U>&#148; means, collectively, the Company <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Common Shares and the Company Voting Common Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Steps</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.1(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Product</U>&#148; means each product candidate, product or platform that is being or has been researched, tested, developed,
manufactured, distributed, sold, promoted, advertised or marketed by or on behalf of the Group Companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Registered
Intellectual Property</U>&#148; means all Registered Intellectual Property owned or purported to be owned by any Group Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Related Party</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.20</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Related Party Transactions</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.20</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Restricted Common Shares</U>&#148; means restricted Company Common Shares outstanding and granted under a Company Equity Plan
or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company RSU Award</U>&#148; means, as of any determination time, each restricted stock unit award with respect to
Company Common Shares outstanding and granted under a Company Equity Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Shareholder Written Consent</U>&#148; has the
meaning set forth in <U>Section</U><U></U><U>&nbsp;5.13</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Shareholders</U>&#148; means, collectively, the holders of
Company Common Shares as of any determination time prior to the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Shareholders Agreements</U>&#148; means,
collectively, (a)&nbsp;the Sixth Amended and Restated Shareholders Agreement, dated June&nbsp;17, 2020, by and among the Company and the Company Shareholders party thereto, (b)&nbsp;the Second Amended and Restated Registration Rights Agreement,
dated September&nbsp;6, 2017, by and among the Company and the Company Shareholders party thereto, and (c)&nbsp;the Agreement Regarding 2018 Equity Raise, dated as of September&nbsp;26, 2018, by and among the Company and the Company Shareholders
party thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Voting Common Shares</U>&#148; means common shares, par value $0.0000001 per share, of the Company
(including, for the avoidance of doubt, the Company Restricted Common Shares). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Warrant</U>&#148; has the meaning set
forth in <U>Section</U><U></U><U>&nbsp;2.1(b)(viii)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Confidentiality Agreement</U>&#148; means that certain Nondisclosure
Agreement, dated October&nbsp;26, 2020, between Roivant Sciences, Inc. and MAAC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Consent</U>&#148; means any notice,
authorization, qualification, registration, filing, notification, waiver, order, consent, grant, clearance, permission or approval to be obtained from, filed with or delivered to, a Governmental Entity or other Person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Contract</U>&#148; or &#147;<U>Contracts</U>&#148; means any agreement, contract,
license, lease, obligation, undertaking or other commitment or arrangement that is legally binding upon a Person or any of his, her or its properties or assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Copyrights</U>&#148; has the meaning set forth in the definition of Intellectual Property Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">COVID-19</FONT></U>&#148; means
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> or <FONT STYLE="white-space:nowrap">COVID-19</FONT> and any evolutions thereof or related or associated epidemics, pandemics or disease outbreaks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Datavant</U>&#148; has the meaning set forth in the definition of &#147;Subsidiary.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Designated Individuals</U>&#148; means the individuals listed on <U>Section</U><U></U><U>&nbsp;1.1</U> of the Company Disclosure
Schedules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>DGCL</U>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Disclosed Subscription Agreements</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.20</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Effective Time</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.1(b)(ii)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Employee Benefit Plan</U>&#148; means each &#147;<U>employee benefit plan</U>&#148; (as such term is defined in Section&nbsp;3(3) of
ERISA, whether or not subject to ERISA), each equity or equity-based, deferred compensation, severance, retention, bonus, incentive, retirement, retiree or post-employment welfare, vacation, and other benefit or compensatory plan, program, policy or
Contract that any Private Group Company maintains, sponsors or contributes to, or under or with respect to which any Private Group Company has any Liability, other than (i)&nbsp;any plan, program, policy or Contract sponsored, maintained or entered
into by a Public Group Company or (ii)&nbsp;any plan sponsored or maintained by a Governmental Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Environmental
Laws</U>&#148; means all Laws and Orders concerning pollution, protection of the environment, or human health or safety. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Equity
Securities</U>&#148; means any share, share capital, capital stock, partnership, membership, joint venture or similar interest in any Person (including any stock appreciation, phantom stock, profit participation or similar rights), and any option,
warrant, right or security (including debt securities) convertible, exchangeable or exercisable therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>ERISA</U>&#148; means
the Employee Retirement Income Security Act of 1974. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Ex-Im</FONT> Laws</U>&#148; means all
applicable Laws and Orders relating to export, <FONT STYLE="white-space:nowrap">re-export,</FONT> transfer and import controls, including the U.S. Export Administration Regulations, the International Traffic in Arms Regulations, and Laws
administered by the U.S. Customs and Border Protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Act</U>&#148; means the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Ratio</U>&#148; means 2.9262. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>FDA</U>&#148; means the U.S. Food and Drug Administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Federal Securities Laws</U>&#148; means the Exchange Act, the Securities Act and the other U.S. federal securities laws and the rules
and regulations of the SEC promulgated thereunder or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Foreign and Domestic Approval Laws</U>&#148; has the meaning set
forth in <U>Section</U><U></U><U>&nbsp;3.5(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Foreign Benefit Plan</U>&#148; means each Employee Benefit Plan maintained by
any of the Private Group Companies for its current or former employees, officers, directors or other individual service providers located outside of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Fraud</U>&#148; means an act or omission by a Party, and requires: (a)&nbsp;a false
or incorrect representation or warranty expressly made by such Party in this Agreement, (b)&nbsp;with actual knowledge (as opposed to constructive, imputed or implied knowledge) by the Party making such representation or warranty that such
representation or warranty expressly set forth in this Agreement is false or incorrect, (c)&nbsp;an intention to deceive another Party to induce it to enter into this Agreement, (d)&nbsp;another Party, in justifiable or reasonable reliance upon such
false or incorrect representation or warranty expressly set forth in this Agreement, entering into this Agreement, and (e)&nbsp;another Party suffering damage by reason of such reliance. For the avoidance of doubt, &#147;Fraud&#148; does not include
any equitable fraud, promissory fraud, unfair dealings fraud or any torts (including a claim for fraud or alleged fraud) based on negligence or recklessness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>GAAP</U>&#148; means United States generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Governing Documents</U>&#148; means the legal document(s) by which any Person (other than an individual) establishes its legal
existence or which govern its internal affairs. For example, the &#147;Governing Documents&#148; of a U.S. corporation are its certificate or articles of incorporation and <FONT STYLE="white-space:nowrap">by-laws,</FONT> the &#147;Governing
Documents&#148; of a U.S. limited partnership are its limited partnership agreement and certificate of limited partnership, the &#147;Governing Documents&#148; of a U.S. limited liability company are its operating or limited liability company
agreement and certificate of formation and the &#147;Governing Documents&#148; of a Bermuda exempted company are its certificate of incorporation, memorandum of association and <FONT STYLE="white-space:nowrap">bye-laws.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Governmental Entity</U>&#148; means any United States or <FONT STYLE="white-space:nowrap">non-United</FONT> States (a)&nbsp;federal,
state, local, municipal or other government, (b)&nbsp;governmental or quasi-governmental entity of any nature (including any governmental agency, branch, department, official, or entity and any court or other tribunal) or (c)&nbsp;body exercising or
entitled to exercise any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature, including any arbitrator or arbitral tribunal (public or private). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Group Companies</U>&#148; means, collectively, the Company and each of its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Hazardous Substance</U>&#148; means any hazardous, toxic, explosive or radioactive material, substance or waste that is regulated by,
or may give rise to standards of conduct or Liability pursuant to, any Environmental Law, including any petroleum products or byproducts, asbestos, lead, polychlorinated biphenyls, <FONT STYLE="white-space:nowrap">per-</FONT> and poly-fluoroalkyl
substances, or radon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>HSR Act</U>&#148; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and
regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Incentive Stock Option</U>&#148; means a Company Option intended to be an &#147;incentive
stock option&#148; (as defined in Section&nbsp;422 of the Code). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intellectual Property Rights</U>&#148; means all intellectual
property rights created or arising under the Laws of the United States or any other jurisdiction or under any international convention, including all (a)&nbsp;patents and patent applications, industrial designs and design patent rights, including
any continuations, divisionals, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part</FONT></FONT> and provisional applications and statutory invention registrations, and any patents issuing on any of the foregoing
and any reissues, reexaminations, substitutes, supplementary protection certificates, extensions of any of the foregoing (collectively, &#147;<U>Patents</U>&#148;); (b)&nbsp;trademarks, service marks, trade names, service names, brand names, trade
dress rights, logos, Internet domain names, corporate names and other source or business identifiers, together with the goodwill associated with any of the foregoing, and all applications, registrations, extensions and renewals of any of the
foregoing (collectively, &#147;<U>Marks</U>&#148;); (c) copyrights and works of authorship, database and design rights, mask work rights and moral rights, whether or not registered or published, and all registrations, applications, renewals,
extensions and reversions of any of the foregoing (collectively, &#147;<U>Copyrights</U>&#148;); (d) trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and confidential proprietary information, including inventions and formulae, whether
patentable or not; (e)&nbsp;intellectual property rights in or to Software; and (f)&nbsp;any other intellectual property or proprietary rights protectable or arising under any Law anywhere in the world. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intended Tax Treatment</U>&#148; has the meaning set forth in the recitals to this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Investment Company Act</U>&#148; means the Investment Company Act of 1940. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>IPO</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.18</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>JOBS Act</U>&#148; means the Jumpstart Our Business Startups Act of 2012. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Latest Balance Sheet</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.4(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Law</U>&#148; means any federal, state, local, foreign, national or supranational statute, law (including common law), act, statute,
ordinance, treaty, rule, code, Order, regulation or other legally binding directive or guidance issued, promulgated or enforced by a Governmental Entity having jurisdiction over a given matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Leased Real Property</U>&#148; has the meaning set forth in the definition of &#147;Real Property Leases.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Liability</U>&#148; or &#147;<U>liability</U>&#148; means any and all debts, liabilities and obligations, whether accrued or fixed,
absolute or contingent, known or unknown, matured or unmatured or determined or determinable, including those arising under any Law (including any Environmental Law), Proceeding or Order and those arising under any Contract, agreement, arrangement,
commitment or undertaking. Notwithstanding the foregoing or anything to the contrary herein, Liability shall not include any Company Expenses or MAAC Expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Lien</U>&#148; means any mortgage, pledge, security interest, encumbrance, lien, license or
<FONT STYLE="white-space:nowrap">sub-license,</FONT> charge, or other similar encumbrance or interest (including, in the case of any Equity Securities, any voting, transfer or similar restrictions). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</U>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC</U>&#148; has the meaning set forth in the introductory paragraph to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Acquisition Proposal</U>&#148; means any transaction or series of related transactions constituting a &#147;Business
Combination&#148; (as defined in MAAC&#146;s Governing Documents). Notwithstanding the foregoing or anything to the contrary herein, none of this Agreement, the Ancillary Documents or the transactions contemplated hereby or thereby shall constitute
a MAAC Acquisition Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Board</U>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Board Recommendation</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.8</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Class</U><U></U><U>&nbsp;A Shares</U>&#148; means shares of Class&nbsp;A common stock, par value $0.0001 per share, of MAAC.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Class</U><U></U><U>&nbsp;B Shares</U>&#148; means shares of Class&nbsp;B common stock, par value $0.0001 per share, of
MAAC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC D&amp;O Persons</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.14(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Designee</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.16(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Disclosure Schedules</U>&#148; means the disclosure schedules to this Agreement delivered to the Company by MAAC on the date of
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Expenses</U>&#148; means, as of any determination time and without duplication, the aggregate amount of
fees, expenses, costs, disbursements, commissions or other amounts incurred by or on behalf of, and that are due </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and payable by (and not otherwise expressly allocated to the Company or any Company Equityholder pursuant to the terms of this Agreement or any Ancillary Document) MAAC in connection with the
negotiation, preparation or execution of this Agreement or any Ancillary Documents, the performance of its covenants or agreements in this Agreement or any Ancillary Document or the consummation of the transactions contemplated hereby or thereby,
including (a)&nbsp;the fees and expenses of outside legal counsel, accountants, advisors, brokers, placement agents, investment bankers, consultants, or other agents or service providers of MAAC (including with respect to the PIPE Financing),
(b)&nbsp;any other fees, expenses, commissions or other amounts that are expressly allocated to MAAC pursuant to this Agreement or any Ancillary Document and (c)&nbsp;fifty percent (50%) of the expenses incurred in connection with the filing of the
Registration Statement / Proxy Statement with the SEC and the printing and mailing of the Registration Statement / Proxy Statement to holders of MAAC Shares. Notwithstanding the foregoing or anything to the contrary herein, MAAC Expenses shall not
include any Company Expenses or any fees, expenses, commissions or other amounts that are expressly contemplated to be allocated to and paid by the Company, Merger Sub or any Company Equityholder pursuant to this Agreement or any Ancillary Document.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Financial Statements</U>&#148; means all of the financial statements of MAAC included in the MAAC SEC Reports. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Fundamental Representations</U>&#148; means the representations and warranties set forth in
<U>Section</U><U></U><U>&nbsp;4.1</U> (Organization and Qualification), <U>Section</U><U></U><U>&nbsp;4.2</U> (Authority), <U>Section</U><U></U><U>&nbsp;4.4</U> (Brokers), <U>Section</U><U></U><U>&nbsp;4.6</U> (Capitalization of MAAC),
<U>Section</U><U></U><U>&nbsp;4.8</U> (Trust Account) and <U>Section</U><U></U><U>&nbsp;4.9</U> (No MAAC Material Adverse Effect). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Material Adverse Effect</U>&#148; means any change, event, development, effect or occurrence that, individually or in the
aggregate with any other change, event, development, effect or occurrence, has had or would reasonably be expected to have a material adverse effect on (a)&nbsp;the business, results of operations, assets or financial condition of MAAC, taken as a
whole, or (b)&nbsp;the ability of MAAC to consummate the transactions contemplated by this Agreement to occur on the Closing Date (including the Merger); <U>provided</U>, <U>however</U>, that, in the case of <U>clause (a)</U>, none of the following
shall be taken into account in determining whether a MAAC Material Adverse Effect has occurred or is reasonably likely to occur: any adverse change, event, development, effect or occurrence arising after the date of this Agreement from or related to
(i)&nbsp;general business or economic conditions in or affecting the United States, or changes therein, or the global economy generally, (ii)&nbsp;any national or international political or social conditions in the United States or any other
country, including the engagement by the United States or any other country in hostilities, whether or not pursuant to the declaration of a national emergency or war, or the occurrence in any place of any military or terrorist attack, sabotage or
cyberterrorism, (iii)&nbsp;changes in conditions of the financial, banking, capital or securities markets generally in the United States or any other country or region in the world, or changes therein, including changes in interest rates in the
United States or any other country and changes in exchange rates for the currencies of any countries, (iv)&nbsp;changes in any applicable Laws, (v)&nbsp;any change, event, development, effect or occurrence that is generally applicable to the
industries or markets in which MAAC operates, (vi)&nbsp;the execution or public announcement of this Agreement or the pendency or consummation of the transactions contemplated by this Agreement, including the impact thereof on the relationships,
contractual or otherwise, of MAAC with investors, contractors, lenders, suppliers, vendors, partners, licensors, licensees, payors or other third parties related thereto (<U>provided</U> that the exception in this
<U>clause</U><U></U><U>&nbsp;(vi)</U> shall not apply to the representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;4.3(b)</U> to the extent that its purpose is to address the consequences resulting from the public announcement or
pendency or consummation of the transactions contemplated by this Agreement or the condition set forth in <U>Section</U><U></U><U>&nbsp;6.3(a)</U> to the extent it relates to such representations and warranties), (vii) any failure by MAAC to meet,
or changes to, any internal or published budgets, projections, forecasts, estimates or predictions (although the underlying facts and circumstances resulting in such failure may be taken into account to the extent not otherwise excluded from this
definition), (viii) any hurricane, tornado, flood, earthquake, tsunami, natural disaster, mudslides, wild fires, epidemics, pandemics (including <FONT STYLE="white-space:nowrap">COVID-19)</FONT> or quarantines, acts of God or other natural disasters
or comparable events in the United States or any other country or region in the world, or any escalation of the foregoing or (ix)&nbsp;any change, event, development, effect or occurrence that is generally applicable to &#147;SPACs&#148;;
<U>provided</U>, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<U>however</U>, that (A)&nbsp;any change, event, development, effect or occurrence resulting from a matter described in any of the foregoing <U>clauses</U><U></U><U>&nbsp;(i)</U> through
<U>(v)</U>&nbsp;or <U>clause (ix)</U>&nbsp;may be taken into account in determining whether a MAAC Material Adverse Effect has occurred or is reasonably likely to occur to the extent such change, event, development, effect or occurrence has or has
had a disproportionate adverse effect on MAAC relative to other &#147;SPACs,&#148; and (B)&nbsp;in no event shall (x)&nbsp;any change, event, development, effect or occurrence to the extent relating to any of the Group Companies, (y)&nbsp;any MAAC
Shareholder Redemption, in and of itself, or (z)&nbsp;any failure, in and of itself, by a PIPE Investor to fulfill its obligations under a PIPE Subscription Agreement constitute a MAAC Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates</U>&#148; means, collectively, MAAC, the MAAC Sponsor and each of
their respective former, current or future Affiliates and Representatives and any former, current or future equityholders, successors, heirs or permitted assigns of any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Related Party</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.11</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Related Party Transactions</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.11</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC SEC Reports</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.7</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Shareholder Approval</U>&#148; means, collectively, the Required MAAC Shareholder Approval and the Other MAAC Shareholder
Approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Shareholder Redemption</U>&#148; means the right of the holders of MAAC Class&nbsp;A Shares to redeem all or a
portion of their MAAC Class&nbsp;A Shares (in connection with the transactions contemplated by this Agreement or otherwise) as set forth in Governing Documents of MAAC, which shall be effected solely out of the Trust Account. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Shareholders Meeting</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.8</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Shares</U>&#148; means, collectively, the MAAC Class&nbsp;A Shares and the MAAC Class&nbsp;B Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Sponsor</U>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Sponsor Consent</U>&#148; means that certain letter agreement, dated as of the date hereof, by and between MAAC and the MAAC
Sponsor, pursuant to which the MAAC Sponsor consented to the entry by MAAC into this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Sponsor Specified
Provisions</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.3</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Warrant Agreement</U>&#148; means
the Warrant Agreement, dated as of October&nbsp;6, 2020, by and between MAAC and the Continental Stock Transfer&nbsp;&amp; Trust Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Warrants</U>&#148; means each warrant (or fraction of a warrant) to purchase one MAAC Class&nbsp;A Share at an exercise price of
$11.50 per share, subject to adjustment in accordance with the MAAC Warrant Agreement (including, for the avoidance of doubt, each such warrant held by the MAAC Sponsor). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Marks</U>&#148; has the meaning set forth in the definition of Intellectual Property Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Material Contracts</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.7(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Material Permits</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.6</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.1(b)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Sub</U>&#148; has the meaning set forth in the introductory paragraph to
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Sub Shareholder Approval</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.9</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Sub Shareholder Approval Deadline</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.9</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Multiemployer Plan</U>&#148; has the meaning set forth in Section (3)37 or Section&nbsp;4001(a)(3) of ERISA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Nasdaq</U>&#148; means the Nasdaq Capital Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Nasdaq Proposal</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.8</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;8.13</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Non-Voting</FONT> Share Conversion</U>&#148; has the
meaning set forth in the recitals to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Order</U>&#148; means any outstanding writ, order, judgment, injunction,
decision, determination, award, ruling, subpoena, verdict or decree entered, issued or rendered by any Governmental Entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Other MAAC Shareholder Approval</U>&#148; means the approval of each Other Transaction Proposal by the affirmative vote of the
holders of the requisite number of MAAC Shares entitled to vote thereon, whether in person or by proxy at the MAAC Shareholders Meeting (or any adjournment or postponement thereof), in accordance with the Governing Documents of MAAC and applicable
Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Other Transaction Proposal</U>&#148; means each Transaction Proposal, other than the Required Transaction Proposals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parties</U>&#148; has the meaning set forth in the introductory paragraph to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Patents</U>&#148; has the meaning set forth in the definition of Intellectual Property Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>PCAOB</U>&#148; means the Public Company Accounting Oversight Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permits</U>&#148; means any approvals, authorizations, clearances, consents, exemptions, licenses, qualifications, registrations,
permits or certificates of a Governmental Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permitted Liens</U>&#148; means (a)&nbsp;mechanic&#146;s, materialmen&#146;s,
carriers&#146;, repairers&#146; and other similar statutory Liens arising or incurred in the ordinary course of business for amounts that are not yet due and payable or are being contested in good faith by appropriate proceedings and for which
sufficient reserves have been established in accordance with GAAP; (b)&nbsp;Liens for Taxes, assessments or other governmental charges not yet due and payable as of the Closing Date or which are being contested in good faith by appropriate
proceedings and for which sufficient reserves have been established in accordance with GAAP; (c)&nbsp;encumbrances and restrictions on real property (including easements, covenants, conditions, rights of way and similar restrictions) that do not
prohibit or materially interfere with any of the Group Companies&#146; use or occupancy of such real property; (d)&nbsp;zoning, building codes and other land use Laws regulating the use or occupancy of real property or the activities conducted
thereon which are imposed by any Governmental Entity having jurisdiction over such real property and which are not violated by the current use or occupancy of such real property or the operation of the businesses of the Group Company and do not
prohibit or materially interfere with any of the Group Companies&#146; use or occupancy of such real property; (e)&nbsp;cash deposits or cash pledges to secure the payment of workers&#146; compensation, unemployment insurance, social security
benefits or obligations arising under similar Laws or to secure the performance of public or statutory obligations, surety or appeal bonds, and other obligations of a like nature, in each case in the ordinary course of business and which are not yet
due and payable; (f)&nbsp;grants by any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Group Company of <FONT STYLE="white-space:nowrap">non-exclusive</FONT> rights in Intellectual Property Rights in the ordinary course of business; (g)&nbsp;Liens arising under the Governing
Documents of the Group Companies or the Company Shareholders Agreements; (h)&nbsp;Liens in favor of any Group Company and (i)&nbsp;other Liens that do not materially and adversely affect the value, use or operation of the asset subject thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Person</U>&#148; means an individual, partnership, corporation, limited liability company, joint stock company, unincorporated
organization or association, trust, joint venture or other similar entity (including a Governmental Entity), whether or not a legal entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Personal Data</U>&#148; means any data or information that (a)&nbsp;can, alone or when combined with other information, identify a
natural person, or (b)&nbsp;is otherwise considered &#147;personally identifiable information,&#148; &#147;personal information,&#148; or &#147;personal data&#148; as those terms are defined under applicable Laws relating to data privacy or data
protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>PIPE Financing</U>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>PIPE Investors</U>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>PIPE Subscription Agreements</U>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Pre-Closing</FONT> MAAC Shareholders</U>&#148; means the holders of MAAC Shares as of any
determination time prior to the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Privacy and Data Security Policies</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.21(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Privacy and Security Requirements</U>&#148; means any of the following to the extent
relating to the collection, processing, use, protection, security, transfer, distribution, or disposition of Personal Data or otherwise relating to data-related notifications: (a)&nbsp;all applicable Laws; (b)&nbsp;each Private Group Company&#146;s
own external-facing privacy policies; (c)&nbsp;any other industry standard to which any Private Group Company is bound; and (d)&nbsp;applicable provisions of Contracts to which any Private Group Company is a party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Private Group Companies</U>&#148; means, collectively, the Company and its Subsidiaries, other than the Public Group Companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Proceeding</U>&#148; means any lawsuit, litigation, action, audit, examination or investigation, claim, complaint (including a <I>qui
tam</I> complaint), charge, subpoena, civil investigative demand, inquiry, proceeding, suit or arbitration (in each case, whether civil, criminal or administrative and whether public or private) pending by or before or otherwise involving or on
behalf of any Governmental Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Process</U>&#148; (or &#147;<U>Processing</U>&#148; or &#147;<U>Processes</U>&#148;) means
the collection, use, storage, processing, recording, distribution, transfer, import, export, protection (including security measures), disposal or disclosure or other activity regarding data (whether electronically or in any other form or medium).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Prospectus</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.18(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Group Companies</U>&#148; means, collectively, each Subsidiary of the Company whose common stock (or similar Equity
Securities) is listed on a U.S. national securities exchange and each of their respective Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Group Company SEC
Reports</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.26(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Health Laws</U>&#148; means all
applicable Laws relating to the research, development, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> testing, clinical testing, manufacture, production, analysis, distribution, importation, exportation, use, handling, quality,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sale or promotion of any drug, biological product or medical device (including any ingredient or component of the foregoing products), including (a)&nbsp;the Federal Food, Drug, and Cosmetic Act
(21 U.S.C. &#167; 301 <I>et seq</I>.), (b) the Public Health Service Act (42 U.S.C. &#167; 201 et seq.), and the regulations administered, issued, or promulgated by FDA thereunder, (c)&nbsp;the Medicare statute (Title XVIII of the Social Security
Act), the Medicaid statute (Title XIX of the Social Security Act), and any other foreign, federal, and state Laws relating to governmental healthcare programs, (d)&nbsp;foreign, federal, and state criminal or civil healthcare Laws related to fraud
and abuse, false claims and anti-kickback Laws (including the federal Anti-Kickback Statute (42 U.S.C. &#167;1320a- 7(b)), the civil False Claims Act (31 U.S.C. &#167;&#167; 3729 et seq.), the criminal False Claims Law (42 U.S.C. <FONT
STYLE="white-space:nowrap">&#167;1320a-7b(a)),</FONT> criminal Laws relating to healthcare fraud and abuse, including 18 U.S.C. &#167;&#167; 286, 287 and 1001, Physician Payment Sunshine Act (42 U.S.C. &#167;
<FONT STYLE="white-space:nowrap">1320a-7h),</FONT> the exclusion laws (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7),</FONT> and the civil monetary penalties law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7a)),</FONT> (e)
the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, (f) the Health Insurance Portability and Accountability Act of 1996 (&#147;<U>HIPAA</U>&#148;) (42 U.S.C. &#167;1320d et
seq.), as amended by the Health Information and Technology for Economic and Clinical Health Act of 2009, and any comparable foreign and state Laws related to privacy, data protection and information security, and (g)&nbsp;each similar applicable
federal, state or foreign Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Software</U>&#148; means any Software that contains, includes or incorporates any Software
that is distributed as free software, open source software (<I>e.g.</I>, Linux) or similar licensing or distribution models, including under any terms or conditions that impose any requirement that any Software using, linked with, incorporating,
distributed with or derived from such Public Software (a)&nbsp;be made available or distributed in source code form, (b)&nbsp;be licensed for purposes of making derivative works, or (c)&nbsp;be redistributable at no, or a nominal, charge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Real Property Leases</U>&#148; means all leases, <FONT STYLE="white-space:nowrap">sub-leases,</FONT> licenses, concessions or other
agreements, in each case, pursuant to which any Private Group Company leases, <FONT STYLE="white-space:nowrap">sub-leases</FONT> or otherwise occupies any real property leased, subleased, licensed, or similarly used or occupied by any of the Private
Group Companies (the &#147;<U>Leased Real Property</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Registered Intellectual Property</U>&#148; means all issued
Patents, pending Patent applications, registered Marks, pending applications for registration of Marks, registered Copyrights, pending applications for registration of Copyrights and Internet domain name registrations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Registration Rights Agreement</U>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Registration Statement / Proxy Statement</U>&#148; means a registration statement of the Company on Form <FONT
STYLE="white-space:nowrap">S-4</FONT> relating to the transactions contemplated by this Agreement and the Ancillary Documents and containing a prospectus of the Company to be used as a proxy statement of MAAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Representatives</U>&#148; means, with respect to any Person, such Person&#146;s Affiliates and its and such Affiliates&#146;
respective directors, officers, employees, accountants, consultants, advisors, attorneys, agents and other representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Required MAAC Shareholder Approval</U>&#148; means the approval of each Required Transaction Proposal by the affirmative vote of the
holders of the requisite number of MAAC Shares entitled to vote thereon, whether in person or by proxy at the MAAC Shareholders Meeting (or any adjournment or postponement thereof), in accordance with the Governing Documents of MAAC and applicable
Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Required Transaction Proposals</U>&#148; means, collectively, the Business Combination Proposal and the Nasdaq Proposal.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sanctioned Person</U>&#148; means a Person (a)&nbsp;named on any Sanctions- or <FONT STYLE="white-space:nowrap">Ex-Im</FONT>
Laws-related list of designated or blocked Persons maintained by a Governmental Entity, (b)&nbsp;located, organized or resident in a country or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
territory which is itself the subject of or target of any comprehensive Sanctions (at the time of this Agreement, the Crimea region of Ukraine, Cuba, Iran, North Korea, and Syria), or (c)&nbsp;an
entity owned, directly or indirectly, or controlled by one or more of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sanctions</U>&#148; means any Law or Order
imposing or relating to economic sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury, the U.S. Department of State, the European Union, any European Union Member State, the United Nations, or Her
Majesty&#146;s Treasury of the United Kingdom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sarbanes-Oxley Act</U>&#148; means the Sarbanes-Oxley Act of 2002. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Schedules</U>&#148; means, collectively, the Company Disclosure Schedules and the MAAC Disclosure Schedules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>SEC</U>&#148; means the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Securities Act</U>&#148; means the U.S. Securities Act of 1933. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Securities Laws</U>&#148; means Federal Securities Laws and other applicable foreign and domestic securities or similar Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Significant Company Shareholders</U>&#148; means the Large Lot Shareholders (as defined in the Company
<FONT STYLE="white-space:nowrap">Bye-Laws)</FONT> and Vivek Ramaswamy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Signing Filing</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;5.4(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Signing Press Release</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;5.4(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Software</U>&#148; shall mean any and all (a)&nbsp;computer programs, including any
and all software implementations of algorithms, models and methodologies, whether in source code or object code; and (b)&nbsp;documentation, including user manuals and other training documentation, related to any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sponsor Exchange Ratio</U>&#148; shall have the meaning set forth in the Sponsor Support Agreement.<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sponsor Support Agreement</U>&#148; has the meaning set forth in the recitals
to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subsidiary</U>&#148; means, with respect to any Person, any corporation, limited liability company,
partnership or other legal entity of which (a)&nbsp;if a corporation, a majority of the total voting power of shares of stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees
thereof is at the time owned or controlled, directly or indirectly, by such Person or one or more of the other Subsidiaries of such Person or a combination thereof, or (b)&nbsp;if a limited liability company, partnership, association or other
business entity (other than a corporation), a majority of the partnership or other similar ownership interests thereof is at the time owned or controlled, directly or indirectly, by such Person or one or more Subsidiaries of such Person or a
combination thereof and, for this purpose, a Person or Persons own a majority ownership interest in such a business entity (other than a corporation) if such Person or Persons shall be allocated a majority of such business entity&#146;s gains or
losses or shall be a, or control any, managing director or general partner of such business entity (other than a corporation); <U>provided</U> that Datavant Holdings, Inc. and each of its Subsidiaries (collectively, &#147;<U>Datavant</U>&#148;)
shall not be deemed a Subsidiary of the Company. The term &#147;<U>Subsidiary</U>&#148; shall include all Subsidiaries of such Subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Surviving Company</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.1(b)(i)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax</U>&#148; means any federal, state, local or <FONT STYLE="white-space:nowrap">non-United</FONT> States income, gross receipts,
franchise, estimated, alternative minimum, sales, use, transfer, value added, excise, stamp, customs, duties, ad valorem, real property, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
personal property (tangible and intangible), capital stock, social security, unemployment, payroll, wage, employment, severance, occupation, registration, environmental, communication, mortgage,
profits, license, lease, service, goods and services, withholding, premium, unclaimed property, escheat, turnover, windfall profits or other taxes, charges, imposts, fees, levies or assessments of any kind whatsoever, in each case in the nature of a
tax, together with any interest, deficiencies, penalties, additions to tax, or additional amounts imposed by any Tax Authority with respect thereto, and including any Liability for any of the aforementioned as transferee or successor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax Authority</U>&#148; means any Governmental Entity responsible for the collection or administration of Taxes or Tax Returns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax Return</U>&#148; means returns, information returns, statements, declarations, claims for refund, schedules, attachments and
reports relating to Taxes that are filed or required to be filed with any Governmental Entity, including any amendment of any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Termination Date</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;7.1(d)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transaction Payment</U>&#148; means (a)&nbsp;when used in reference to any Group Company, any success, change of control, retention,
transaction bonus or other similar payment or amount to any current or former officer, director or employee of any Group Company or any other Company Related Party that would (either alone or when combined with one or more additional circumstances,
matters or events) become payable as a result of or in connection with the transactions contemplated by this Agreement or the Ancillary Documents or (b)&nbsp;when used in reference to MAAC, any success, change of control, retention, transaction
bonus or other similar payment or amount to any current or former officer, director or employee of MAAC or any other MAAC Related Party that would (either alone or when combined with one or more additional circumstances, matters or events) become
payable as a result of or in connection with the transactions contemplated by this Agreement or the Ancillary Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transaction Proposals</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.8</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transaction Support Agreements</U>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transfer Agent</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.5</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transfer Agent Agreement</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.5</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Treasury Regulations</U>&#148; means the Treasury regulations promulgated under the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trust Account</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.18</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trust Account Released Claims</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.18</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trust Agreement</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.8</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trustee</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.8</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Unvested Company CVAR Award</U>&#148; means each Company CVAR Award outstanding as of immediately prior to the Company <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Steps that is not a Vested Company CVAR Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Unvested Company Option</U>&#148;
means each Company Option outstanding as of immediately prior to the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps that is not a Vested Company Option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Unvested Company RSU Award</U>&#148; means each Company RSU Award outstanding as of
immediately prior to the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps that is not a Vested Company RSU Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Vested Company CVAR Award</U>&#148; means each Company CVAR Award outstanding as of immediately prior to the Company <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Steps that is vested as of such time or will vest in connection with the consummation of the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Vested Company Option</U>&#148; means each Company Option outstanding as of immediately prior to the Company <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Steps that is vested as of such time or will vest in connection with the consummation of the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Vested Company RSU Award</U>&#148; means each Company RSU Award outstanding as of immediately prior to the Company <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Steps that is vested as of such time or will vest in connection with the consummation of the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>WARN</U>&#148; means the Worker Adjustment Retraining and Notification Act of 1988 as well as similar foreign, state or local Laws.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Willful Breach</U>&#148; means a material breach of this Agreement by a Party that is a consequence of an act undertaken or a
failure to act by the breaching Party with the knowledge that the taking of such act or such failure to act would, or would reasonably be expected to, constitute or result in a breach of this Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;2 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MERGER
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.1</B> <B><U>Closing Transactions</U></B>. On the terms and subject to the conditions set forth in
this Agreement,<B> </B>the following transactions shall occur in the order set forth in this <U>Section</U><U></U><U>&nbsp;2.1</U>: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps and Share Conversion</U>. On the Closing Date prior to the Effective Time, the Company shall cause (i)&nbsp;a subdivision of the Company
<FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares to be consummated such that each Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Share shall be divided into a number of Company Post-Closing Common Shares equal to
the Exchange Ratio and the par value of each Company Post-Closing Common Share shall be equal to the then-current par value <I>divided by</I> the Exchange Ratio, (ii)&nbsp;the Company <FONT STYLE="white-space:nowrap">Bye-Laws</FONT> to be amended
and restated to be in substantially the form attached hereto as <U>Exhibit E</U> (the &#147;<U>Company Post-Closing <FONT STYLE="white-space:nowrap">Bye-Laws</FONT></U>&#148;) and (iii)&nbsp;the transactions set forth in
<U>Section</U><U></U><U>&nbsp;2.4</U> to occur (the transactions described in the foregoing <U>clauses</U><U></U><U>&nbsp;(i)</U> through <U>(iii)</U>, collectively, the &#147;<U>Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT>
Steps</U>&#148;). The Company shall also cause the <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Share Conversion to occur prior to the Effective Time, subject to the expiration or termination of any applicable waiting period under the HSR Act
with respect to the <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Share Conversion. In the event that any applicable waiting period under the HSR Act with respect to the <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Share Conversion has
not expired or been terminated as of the date of satisfaction (or, to the extent permitted by applicable Law, waiver) of the conditions set forth in <U>Article</U><U></U><U>&nbsp;6</U> (other than those conditions that by their nature are to be
satisfied at the Closing), then the Parties shall appropriately modify the Company Post-Closing <FONT STYLE="white-space:nowrap">Bye-Laws</FONT> that will become effective on the Closing Date immediately prior to the Effective Time in accordance
herewith to provide for a separate class of common shares of the Company that are identical to the Company Post-Closing Common Shares, except that they are not entitled to voting rights, with such modified Company Post-Closing <FONT
STYLE="white-space:nowrap">Bye-Laws</FONT> being in a form mutually agreed to by MAAC and the Company (such agreement not to be unreasonably withheld, conditioned or delayed). For the avoidance of doubt, the
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Share Conversion shall not be a condition to any Party&#146;s obligation to consummate the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>The Merger</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) On
the terms and subject to the conditions set forth in this Agreement and in accordance with the DGCL, on the Closing Date promptly following the consummation of the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Merger Sub shall merge with and into MAAC (the &#147;<U>Merger</U>&#148;) at the Effective Time. Following the Effective Time, the separate existence of Merger Sub shall cease and MAAC shall
continue as the surviving corporation of the Merger (the &#147;<U>Surviving Company</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) On the terms and subject to the
conditions set forth in this Agreement, at the Closing, the Parties shall cause a certificate of merger relating to the Merger, in a form reasonably satisfactory to the Company and MAAC (the &#147;<U>Certificate of Merger</U>&#148;), to be executed
and filed with the Secretary of State of the State of Delaware. The Merger shall become effective on the date and time at which the Certificate of Merger is accepted for filing by the Secretary of State of the State of Delaware or at such later date
and/or time as is agreed by the Company and MAAC and specified in the Certificate of Merger (the time the Merger becomes effective being referred to herein as the &#147;<U>Effective Time</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) From and after the Effective Time, the Merger shall have the effects set forth in this Agreement, in the Certificate of Merger and in
Section&nbsp;251 of the DGCL. Without limiting the generality of the foregoing, and subject thereto, at the Effective Time, all of the assets, properties, rights, privileges, powers and franchises of MAAC and Merger Sub shall vest in the Surviving
Company and all debts, liabilities, obligations, restrictions, disabilities and duties of each of MAAC and Merger Sub shall become the debts, liabilities, obligations and duties of the Surviving Company, in each case, in accordance with the DGCL.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) At the Effective Time, by virtue of the Merger, the certificate of incorporation of MAAC shall be amended and restated to be
identical to the certificate of incorporation of Merger Sub as in effect immediately prior to the Effective Time and, as so amended and restated, shall be the certificate of incorporation of the Surviving Company until thereafter amended in
accordance with its terms as provided therein and by the DGCL, except that the name of the Surviving Company reflected therein shall be a name that is determined by the Company prior to the Closing (which name does not reference &#147;Montes
Archimedes&#148;). At the Effective Time, the bylaws of MAAC shall be amended to be identical to the bylaws of Merger Sub as in effect immediately prior to the Effective Time and, as so amended, shall be the bylaws of the Surviving Company until
thereafter amended in accordance with their terms as provided therein, the Governing Documents of the Surviving Company and the DGCL, except that the name of the Surviving Company reflected therein shall be a name that is determined by the Company
prior to the Closing (which name does not reference &#147;Montes Archimedes&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) At the Effective Time, the persons serving as
the directors and officers of Merger Sub immediately prior to the Effective Time shall be the initial directors and officers of the Surviving Company, each to hold office in accordance with the Governing Documents of the Surviving Company from and
after the Effective Time until such director&#146;s or officer&#146;s successor is duly elected or appointed and qualified, or until the earlier of their death, resignation or removal in accordance with the Governing Documents of the Surviving
Company, or as otherwise provided by the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) At the Effective Time, by virtue of the Merger and without any action on the part of
any Party or any other Person, each share of capital stock of Merger Sub issued and outstanding immediately prior to the Effective Time shall be automatically canceled and extinguished and converted into one share of common stock, par value $0.0001,
of the Surviving Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) At the Effective Time, by virtue of the Merger and without any action on the part of any Party or any
other Person, (A)&nbsp;each (x) MAAC Class&nbsp;A Share and (y)&nbsp;each MAAC Class&nbsp;B Share that is not held by the MAAC Sponsor or any of its Affiliates (other than the MAAC Class&nbsp;A Shares and MAAC Class&nbsp;B Shares canceled and
extinguished pursuant to <U>Section</U><U></U><U>&nbsp;2.1(b)(ix)</U>) issued and outstanding as of immediately prior to the Effective Time shall be automatically canceled and extinguished and converted into one Company Post-Closing Common Share and
(B)&nbsp;each MAAC Class&nbsp;B Share issued and outstanding and held by the MAAC Sponsor or any of its Affiliates as of immediately prior to the Effective Time shall be automatically canceled and extinguished and converted into the number of
Company Post-Closing Common Shares equal to the Sponsor Exchange Ratio; <U>provided</U> that for the avoidance of doubt, a number of Company Post-Closing Common Shares </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
owned by the MAAC Sponsor or any of its Affiliates, determined pursuant to the Sponsor Support Agreement, shall become subject to the vesting and other terms and conditions set forth in the
Sponsor Support Agreement at the Effective Time. As of the Effective Time, all MAAC Shares shall no longer be outstanding and shall automatically be canceled and shall cease to exist, and shall thereafter represent the number of Company Post-Closing
Common Shares into which such MAAC Shares were converted pursuant to this Agreement. From and after the Effective Time, each <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> MAAC Shareholder&#146;s certificate(s) (the
&#147;<U>Certificates</U>&#148;), if any, evidencing ownership of MAAC Shares and MAAC Shares held in book-entry form issued and outstanding immediately prior to the Effective Time shall each cease to have any rights with respect to such MAAC
Shares, except as otherwise expressly provided for herein or under applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) At the Effective Time, each MAAC Warrant that
is outstanding immediately prior to the Effective Time shall, by its terms, convert automatically into the right to acquire Company Post-Closing Common Shares on the terms and subject conditions set forth in the MAAC Warrant Agreement as in effect
immediately prior to the Effective Time (each, a &#147;<U>Company Warrant</U>&#148;); <U>provided</U> that, for the avoidance of doubt, each Company Warrant shall, from and after the Effective Time, (x)&nbsp;represent the right to acquire the number
of Company Post-Closing Common Shares equal to the number of MAAC Shares subject to the underlying MAAC Warrant immediately prior to the Effective Time, and (y)&nbsp;have an exercise price of $11.50 per whole warrant to purchase one Company
Post-Closing Common Share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) At the Effective Time, by virtue of the Merger and without any action on the part of any Party or any
other Person, each MAAC Share held immediately prior to the Effective Time by MAAC as treasury stock shall be automatically canceled and extinguished, and no consideration shall be paid with respect thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.2</B> <B><U>Closing of the Transactions Contemplated by this Agreement</U></B>. On the terms and subject to
the conditions set forth in this Agreement, the closing of the transactions contemplated by this Agreement (the &#147;<U>Closing</U>&#148;) shall take place electronically by exchange of the closing deliverables by the means provided in
<U>Section</U><U></U><U>&nbsp;8.11</U> as promptly as reasonably practicable, but in no event later than the third (3rd) Business Day, following the satisfaction (or, to the extent permitted by applicable Law, waiver) of the conditions set forth in
<U>Article</U><U></U><U>&nbsp;6</U> (other than those conditions that by their nature are to be satisfied at the Closing, but subject to satisfaction or waiver of such conditions) or at such other place, date and/or time as MAAC and the Company may
agree in writing (the date on which the Closing actually occurs is referred to in this Agreement as the &#147;<U>Closing Date</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.3</B> <B><U>Fractional Shares</U></B><U>. </U>Notwithstanding the foregoing or anything to the contrary
herein, no fractional Company Post-Closing Common Shares shall be issued in connection with the transactions contemplated hereby. Except with respect to Company Equity Awards, all fractional Company Post-Closing Common Shares that each Company
Equityholder will have a right to receive in connection with the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps, as well as all fractional Company Post-Closing Common Shares that the MAAC Sponsor and its Affiliates as holders of
MAAC Class&nbsp;B Shares will have a right to receive in connection with the Merger, shall be aggregated and, if a fractional share results from such aggregation, such fractional share shall be rounded down to the nearest whole share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.4</B> <B><U>Treatment of Company </U></B><B><U>Equity Awards</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) On the Closing Date prior to the Closing (and as part of, for the avoidance of doubt, the Company
<FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps), each Company Option (whether a Vested Company Option or an Unvested Company Option) shall be adjusted in accordance with the applicable Company Equity Plan into an option to purchase
Company Post-Closing Common Shares (each, an &#147;<U>Adjusted Option</U>&#148;) in an amount and at an exercise price determined pursuant to this <U>Section</U><U></U><U>&nbsp;2.4(a)</U>. Each Adjusted Option shall: (i)&nbsp;be exercisable for, and
represent the right to purchase, a number of Company Post-Closing Common Shares (rounded down to the nearest whole share) equal to the product obtained by <I>multiplying</I> (A)&nbsp;the number of Company
<FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares subject to the corresponding Company Option immediately prior to the consummation of the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps, <I>by</I> (B)&nbsp;the
Exchange Ratio, and (ii)&nbsp;have an exercise price per Company Post-Closing Common Share (rounded up to the nearest whole cent) subject </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to such Adjusted Option equal to the quotient obtained by dividing (A)&nbsp;the exercise price per Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Share applicable to the
corresponding Company Option immediately prior to the consummation of the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps, <I>by</I> (B)&nbsp;the Exchange Ratio. Such conversion shall occur in a manner intended to comply with
(x)&nbsp;the requirements of Section&nbsp;409A of the Code and (y)&nbsp;in the case of any Adjusted Option that is an Incentive Stock Option, the requirements of Section&nbsp;424 of the Code. Except as otherwise set forth in this
<U>Section</U><U></U><U>&nbsp;2.4(a)</U>, each Adjusted Option shall continue to have, and be subject to, the same terms and conditions (including applicable vesting, expiration and forfeiture provisions) as applied to the corresponding Company
Option immediately prior to such adjustment. For the avoidance of doubt, the rounding of any shares pursuant to this <U>Section</U><U></U><U>&nbsp;2.4(a)</U> shall be determined on an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">award-by-award</FONT></FONT> basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) On the Closing Date prior to
the Closing (and as part of, for the avoidance of doubt, the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps), each Vested Company RSU Award shall be adjusted in accordance with the applicable Company Equity Plan into a number of
Company Post-Closing Common Shares (rounded down to the nearest whole share) equal to (i)&nbsp;the product obtained by <I>multiplying</I> (A)&nbsp;the number of Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares subject to the
corresponding Vested Company RSU Award immediately prior to the consummation of the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps, <I>by</I> (B)&nbsp;the Exchange Ratio, <I>minus</I> (ii)&nbsp;that number of Company Post-Closing
Common Shares with a fair market value equal to all required withholding taxes due upon settlement of such Vested Company RSU Award, as determined in accordance with the applicable Company Equity Plan and award (or similar) agreement. For the
avoidance of doubt, the rounding of any shares pursuant to this <U>Section</U><U></U><U>&nbsp;2.4(b)</U> shall be determined on an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">award-by-award</FONT></FONT> basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) On the Closing Date prior to the Closing (and as part of, for the avoidance of doubt, the Company
<FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps), each Unvested Company RSU Award shall be adjusted in accordance with the applicable Company Equity Plan into a restricted stock unit award (each, an &#147;<U>Adjusted RSU Award</U>&#148;)
with respect to a number of Company Post-Closing Common Shares (rounded down to the nearest whole share) equal to the product obtained by <I>multiplying</I> (A)&nbsp;the number of Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common
Shares subject to the corresponding Unvested Company RSU Award immediately prior to the consummation of the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps, <I>by</I> (B)&nbsp;the Exchange Ratio. Except as otherwise set forth in
this <U>Section</U><U></U><U>&nbsp;2.4(c)</U>, each Adjusted RSU Award shall continue to have, and be subject to, the same terms and conditions (including applicable vesting, expiration and forfeiture provisions) as applied to the corresponding
Unvested Company RSU Award immediately prior to such adjustment. For the avoidance of doubt, the rounding of any shares pursuant to this <U>Section</U><U></U><U>&nbsp;2.4(c)</U> shall be determined on an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">award-by-award</FONT></FONT> basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) On the Closing Date prior to the Closing (and as part of, for the
avoidance of doubt, the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps), each Company CVAR Award (whether a Vested Company CVAR Award or an Unvested Company CVAR Award) shall be adjusted in accordance with the applicable Company
Equity Plan into a capped value appreciation right with respect to Company Post-Closing Common Shares (each, an &#147;<U>Adjusted CVAR Award</U>&#148;) in an amount and at a hurdle price determined pursuant to this
<U>Section</U><U></U><U>&nbsp;2.4(d)</U>. Each Adjusted CVAR Award shall (i)&nbsp;be with respect to a number of Company Post-Closing Common Shares (rounded down to the nearest whole share) equal to the product obtained by <I>multiplying</I>
(A)&nbsp;the number of Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares subject to the corresponding Company CVAR Award immediately prior to the consummation of the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT>
Steps, <I>by</I> (B)&nbsp;the Exchange Ratio, and (ii)&nbsp;have a (A)&nbsp;hurdle price per Company Post-Closing Common Share, (B)&nbsp;a <FONT STYLE="white-space:nowrap">&#147;knock-in&#148;</FONT> price per Company Post-Closing Common Share (if
applicable) and (C)&nbsp;value cap price per Company Post-Closing Common Share (in each case, rounded up to the nearest whole cent) subject to such Adjusted CVAR Award equal to the quotient obtained by <I>dividing</I> (A)&nbsp;the hurdle price per
Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Share, <FONT STYLE="white-space:nowrap">&#147;knock-in&#148;</FONT> price per Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Share (if&nbsp;applicable) and value
cap price per Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Share applicable to the corresponding Company CVAR Award immediately prior to the consummation of the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps,
respectively, <I>by</I> (B)&nbsp;the Exchange Ratio. Except as otherwise set forth in this <U>Section</U><U></U><U>&nbsp;2.4(d)</U>, each Adjusted CVAR Award shall continue to have, and be subject to, the same terms and conditions (including
applicable vesting, expiration and forfeiture provisions) as applied to the corresponding Company CVAR Award </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
immediately prior to such adjustment. For the avoidance of doubt, the rounding of any shares pursuant to this <U>Section</U><U></U><U>&nbsp;2.4(d)</U> shall be determined on an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">award-by-award</FONT></FONT> basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) After giving effect to this
<U>Section</U><U></U><U>&nbsp;2.4</U>, and upon the approval of the Company Post-Closing Incentive Equity Plan in accordance with <U>Section</U><U></U><U>&nbsp;5.18</U> of this Agreement, effective as of the Closing, no further grants or issuances
shall be made under any of the Company Equity Plans (other than, for the avoidance of doubt, (x)&nbsp;issuances pursuant to awards outstanding as of the Closing Date under the Company Equity Plans (as adjusted pursuant to this
<U>Section</U><U></U><U>&nbsp;2.4</U>) and (y)&nbsp;grants or issuances pursuant to the Company Post-Closing Incentive Equity Plan and the Company Post-Closing Employee Stock Purchase Plan). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Prior to the Closing, the Company shall take, or cause to be taken, all necessary actions under the Company Equity Plans, under the
underlying grant, award or similar agreement and otherwise to give effect to the provisions of this <U>Section</U><U></U><U>&nbsp;2.4</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.5</B> <B><U>Transfer Agent Matters</U></B>. At least three (3)&nbsp;Business Days prior to the effectiveness
of the Registration Statement / Proxy Statement, the Company shall appoint a transfer agent (the &#147;<U>Transfer Agent</U>&#148;) and, if required by the Transfer Agent, enter into a transfer agent agreement with the Transfer Agent (the
&#147;<U>Transfer Agent Agreement</U>&#148;) in a form and substance that is reasonably acceptable to MAAC (it being understood and agreed, for the avoidance of doubt, that Continental Stock Transfer&nbsp;&amp; Trust Company (or any of its
Affiliates) shall be deemed to be acceptable to MAAC and any Transfer Agent Agreement in substantially the same form as the transfer agent agreement between MAAC and Continental Stock Transfer<U></U>&nbsp;&amp; Trust Company as of the date hereof
shall be deemed to be acceptable to MAAC). The Company and MAAC shall each take, or cause to be taken, all necessary or reasonably advisable actions in order to appropriately reflect the Company Post-Closing Common Shares issued pursuant to, or as a
result of, the transactions contemplated by this Agreement and the Ancillary Documents and outstanding immediately after the Effective Time, including taking any necessary or reasonably advisable actions <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> MAAC&#146;s existing transfer agent or the Transfer Agent, and the Company and MAAC shall each reasonably cooperate with the other and the Transfer Agent in connection with the foregoing.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.6</B> <B><U>Withholding</U></B>. MAAC, the Company and the Transfer Agent (and their respective
Representatives) shall be entitled to deduct and withhold (or cause to be deducted and withheld) from any consideration payable pursuant to this Agreement such amounts as are required to be deducted and withheld under applicable Tax Law. To the
extent that amounts are so deducted and withheld and duly paid over to the appropriate Tax Authority, such withheld amounts shall be treated for all purposes of this Agreement as having been paid to the Person in respect of which such deduction and
withholding was made. The Parties shall cooperate in good faith to eliminate or reduce any such deduction or withholding (including through the request and provision of any statements, forms or other documents to reduce or eliminate any such
deduction or withholding), as reasonably requested by the relevant Party. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;3 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES RELATING </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO&nbsp;THE&nbsp;GROUP&nbsp;COMPANIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to <U>Section</U><U></U><U>&nbsp;8.8</U>, except (a)&nbsp;as set forth in the Company Disclosure Schedules, or (b)&nbsp;solely in the
case of the Public Group Companies, as set forth in any Public Group Company SEC Reports publicly available as of the date hereof (excluding any disclosures in any &#147;risk factors&#148; section that do not constitute statements of fact,
disclosures in any forward-looking statements disclaimers and other disclosures that are generally cautionary, predictive or forward-looking in nature), the Company and Merger Sub each hereby represents and warrants to MAAC as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.1</B> <B><U>Organization and Qualification</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company is an exempted limited company duly organized or formed, as applicable, validly existing and in good standing (or the
equivalent thereof, if applicable, in each case, with respect to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
jurisdictions that recognize the concept of good standing or any equivalent thereof) under the Laws of Bermuda. The Company has the requisite exempted company or other applicable business entity
power and authority to own, lease and operate its properties and to carry on its businesses as presently conducted, except where the failure to have such power or authority would not have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) True and complete copies of the Governing Documents of the Company and the Company Shareholders Agreements have been made available to
MAAC, in each case, as amended and in effect as of the date of this Agreement. The Governing Documents of the Company and the Company Shareholders Agreements are in full force and effect, the Company is not in material breach or violation of any
provision set forth in its Governing Documents and the Company is not in material breach or violation of the Company Shareholders Agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each Group Company (other than the Company) is a corporation, limited liability company or other applicable business entity duly organized
or formed, as applicable, validly existing and in good standing (or the equivalent thereof, if applicable, in each case, with respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof) under the Laws of its
jurisdiction of formation or organization (as applicable). Each Group Company (other than the Company) has the requisite corporate, limited liability company or other applicable business entity power and authority to own, lease and operate its
properties and to carry on its businesses as presently conducted, except where the failure to have such power or authority would not have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) True and complete copies of the Governing Documents of each Private Group Company (other than the Company) have been made available to
MAAC, in each case, as amended and in effect as of the date of this Agreement. The Governing Documents of each Group Company (other than the Company) are in full force and effect and none of the Group Companies is in material breach or material
violation of any provision set forth in its Governing Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Each Group Company is duly qualified or licensed to transact
business and is in good standing (or the equivalent thereof, if applicable, in each case, with respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof) in each jurisdiction in which the property and assets
owned, leased or operated by it, or the nature of the business conducted by it, makes such qualification or licensing necessary, except where the failure to be so duly qualified or licensed and in good standing would not have a Company Material
Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.2</B> <B><U>Capitalization of the Group Companies</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Section</U><U></U><U>&nbsp;3.2(a)</U> of the Company Disclosure Schedules sets forth a true and complete statement as of April&nbsp;30,
2021 (the &#147;<U>Designated Capitalization Date</U>&#148;) of (i)&nbsp;the aggregate number and class, series or type (as applicable) of all of the Equity Securities of the Company issued and outstanding and (ii)&nbsp;the identity of the Persons
that are the owners of one percent (1.0%) or more of the issued and outstanding Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares. Except for (x)&nbsp;the aggregate number of Equity Securities of the Company and the Company
Equity Awards outstanding as set forth on <U>Section</U><U></U><U>&nbsp;3.2(a)</U> of the Company Disclosure Schedules, (y)&nbsp;those Equity Securities of the Company issued or granted during the period beginning on the day after the Designated
Capitalization Date and ending on the date of this Agreement that would, assuming such issuance or grant occurred during the period from the date of this Agreement until the Closing, be permitted by <U>Section</U><U></U><U>&nbsp;5.1(b)(v)</U> or
<U>Section</U><U></U><U>&nbsp;5.1(b)(vi)</U> (provided that, for purposes of <U>clause (3)</U>&nbsp;and <U>(4)</U> of Section&nbsp;5.1(b)(vi), no such issuances or grants are to any Designated Individual or Affiliated Shareholder), and (z)&nbsp;the
exercise, vesting, settlement or forfeiture of any Company Equity Awards outstanding as of the Designated Capitalization Date during the period beginning on the day after Designated Capitalization Date and ending on the date of this Agreement, the
Company has no outstanding Equity Securities as of the date hereof. All of the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares have been duly authorized and validly issued and are fully paid and <FONT
STYLE="white-space:nowrap">non-assessable.</FONT> The Equity Securities of the Company (1)&nbsp;were not issued in violation of the Governing Documents of the Company, the Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Shareholders Agreements or any other Contract to which any Group Company is party or by which any Group Company is otherwise bound and (2)&nbsp;were not issued in violation of any preemptive
rights, call option, right of first refusal or first offer, subscription rights, transfer restrictions or similar rights of any Person. Other than (A)&nbsp;as set forth above and pursuant to the Governing Documents of the Company or the Company
Shareholders Agreement and (B)&nbsp;pursuant to offer letters or similar Contracts with service providers who are not Designated Individuals or Affiliated Shareholders entered into in the ordinary course of business providing for the grant or
issuance of Equity Securities, as of the date hereof, the Company has no outstanding purchase rights, subscription rights, conversion rights, exchange rights, calls, puts or rights of first refusal or first offer or other Contracts that could
require the Company to issue, sell or otherwise cause to become outstanding or to acquire, repurchase or redeem any Equity Securities or securities convertible into or exchangeable for Equity Securities of the Company. Except for the Governing
Documents of the Company and the Company Shareholders Agreements, there are no voting trusts, proxies or other Contracts to which the Company is a party or otherwise bound with respect to the voting or transfer of the Equity Securities of the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Section</U><U></U><U>&nbsp;3.2(b)</U> of the Company Disclosure Schedules sets forth a true and complete statement as of
the Designated Capitalization Date of (i)&nbsp;the aggregate number and class, series or type (as applicable) of all of the Equity Securities (other than equity incentive awards) of each Private Group Company (other than the Company) and Datavant
issued and outstanding, (ii)&nbsp;the aggregate pool of allocated and unallocated equity incentive awards of each Private Group Company (other than the Company) and Datavant and (iii)&nbsp;the aggregate number and class, series or type (as
applicable) of all of the Equity Securities of each Private Group Company (other than the Company) that are owned by another Group Company and the aggregate number and class, series or type (as applicable) of all of the Equity Securities of Datavant
that are owned by a Group Company. Except for (x)&nbsp;the aggregate number of Equity Securities of each Private Company Vant (other than the Company) and Datavant outstanding as set forth on <U>Section</U><U></U><U>&nbsp;3.2(b)</U> of the Company
Disclosure Schedules, (y)&nbsp;those Equity Securities of a Private Group Company or Datavant issued or granted during the period beginning on the day after the Designated Capitalization Date and ending on the date of this Agreement that would,
assuming such issuance or grant occurred during the period from the date of this Agreement until the Closing, either be permitted by <U>Section</U><U></U><U>&nbsp;5.1(b)(v)</U> or <U>Section</U><U></U><U>&nbsp;5.1(b)(vi)</U> (provided that, for
purposes of <U>clause (3)</U>&nbsp;and <U>(4)</U> of <U>Section</U><U></U><U>&nbsp;5.1(b)(vi)</U>, no such issuances or grants are to any Designated Individual or Affiliated Shareholder), and (z)&nbsp;the exercise, vesting, settlement or forfeiture
of any equity incentive awards outstanding as of the Designated Capitalization Date during the period beginning on the day after Designated Capitalization Date and ending on the date of this Agreement, each Private Group Company (other than the
Company) and Datavant has no outstanding Equity Securities as of the date hereof. Other than (A)&nbsp;as set forth above and pursuant to the Governing Documents of the Private Group Companies (other than the Company) and (B)&nbsp;pursuant to offer
letters or similar Contracts with service providers who are not Designated Individuals or Affiliated Shareholders entered into in the ordinary course of business providing for the grant or issuance of Equity Securities of a Private Group Company, as
of the date hereof, no Private Group Company has any outstanding purchase rights, subscription rights, conversion rights, exchange rights, calls, puts or rights of first refusal or first offer or other Contracts that could require any Private Group
Company (other than the Company) to issue, sell or otherwise cause to become outstanding or to acquire, repurchase or redeem any Equity Securities or securities convertible into or exchangeable for Equity Securities of any Private Group Company
(other than the Company), in each case other than to another Group Company. Except for the Governing Documents of the applicable Private Group Company or shareholders agreements or similar Contracts to which the applicable Private Group Company is a
party and that has, in the case of each such material agreement or Contract, been made available to MAAC, there are no voting trusts, proxies or other Contracts to which a Private Group Company is a party with respect to the voting or transfer of
any Equity Securities of any Private Group Company (other than the Company), in each case other than in favor of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
<U>Section</U><U></U><U>&nbsp;3.2(c)</U> of the Company Disclosure Schedules sets forth a true and complete statement as of the date hereof of the number and class or series (as applicable) of all of the capital stock of each Public Group Company
owned by the Company (whether of record, beneficially, legally or otherwise). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Immediately after the Effective Time, (i)&nbsp;the authorized share capital of the
Company will consist of 7,000,000,000 Company Post-Closing Common Shares and (ii)&nbsp;all of the issued and outstanding Company Post-Closing Common Shares (A)&nbsp;will be duly authorized, validly issued, fully paid and nonassessable and
(B)&nbsp;will not have been issued in breach or violation of any preemptive rights, call option, right of first refusal or first offer, subscription rights, transfer restrictions or similar rights of any Person or any Contract to which the Company
is a party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Equity Securities of the Company have been offered, sold and issued by the Company in compliance with applicable Law,
including Securities Laws, in all material respects. Immediately after the Effective Time, all of the issued and outstanding Company Post-Closing Common Shares will have been offered, sold and issued in compliance with applicable Law, including
Securities Laws, in all material respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Except as set forth on <U>Section&nbsp;3.2(b)</U> and <U>Section&nbsp;3.2(c)</U> of the
Company Disclosure Schedules or for any changes to the extent permitted by <U>Section</U><U></U><U>&nbsp;5.1(b)</U> or resulting from the acquisition of Equity Securities of any Person permitted by <U>Section</U><U></U><U>&nbsp;5.1(b)(ii)</U>, none
of the Private Group Companies owns or holds (of record, beneficially, legally or otherwise), directly or indirectly, any Equity Securities in any other Person (other than Merger Sub) or the right to acquire any such Equity Securities, and none of
the Private Group Companies are a partner, member or similar participant of or in any partnership, limited liability company or similar business entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Section</U><U></U><U>&nbsp;3.2(g)</U> of the Company Disclosure Schedules sets forth any agreements evidencing indebtedness to third
parties for borrowed money of the Private Group Companies as of the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Section</U><U></U><U>&nbsp;3.2(h)</U>
of the Company Disclosure Schedules sets forth a list of all Transaction Payments of the Private Group Companies as of the date of this Agreement and, to the knowledge of the Company, of the Public Group Companies and Datavant as of the date of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The Company has made available to MAAC a schedule that sets forth, with respect to each Company Equity Award outstanding
as of the Designated Capitalization Date (i)&nbsp;the date of grant and (ii)&nbsp;any applicable exercise, hurdle cap, <FONT STYLE="white-space:nowrap">&#147;knock-in&#148;</FONT> or similar price (in the case of Company Options and Company CVAR
Awards). Each Company Option and Company CVAR Award was granted with an exercise price equal to or greater than the fair market value of the underlying Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Share on the date of grant.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.3</B> <B><U>Authority</U></B>. The Company and Merger Sub each have the requisite corporate, limited
liability company or other similar power and authority to execute and deliver this Agreement and each Ancillary Document to which it is or will be a party, to perform its obligations hereunder and thereunder and to consummate the transactions
contemplated hereby and thereby. The execution and delivery of this Agreement, the Ancillary Documents to which the Company or Merger Sub is or will be a party and the consummation of the transactions contemplated hereby and thereby have been (or,
in the case of any Ancillary Document entered into after the date of this Agreement, will be upon execution thereof) duly authorized by all necessary corporate (or other similar) action on the part of the Company or Merger Sub. This Agreement and
each Ancillary Document to which the Company or Merger Sub is or will be a party has been or will be, upon execution thereof, as applicable, duly and validly executed and delivered by the Company and/or Merger Sub, as applicable, and constitutes or
will constitute, upon execution and delivery thereof, as applicable, a valid, legal and binding agreement of the Company and/or Merger Sub, as applicable (assuming that this Agreement and the Ancillary Documents to which the Company and/or Merger
Sub is or will be a party are or will be upon execution thereof, as applicable, duly authorized, executed and delivered by the other Persons party thereto), enforceable against the Company and/or Merger Sub, as applicable, in accordance with its
terms (subject to applicable bankruptcy, insolvency, reorganization, moratorium or other Laws affecting generally the enforcement of creditors&#146; rights and subject to general principles of equity). The Company Shareholder Written Consent and the
approval to be obtained by Merger Sub pursuant to <U>Section</U><U></U><U>&nbsp;5.9</U> are the only votes or consents of the holders of any class or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
series of Equity Securities of the Company or Merger Sub required to approve and adopt this Agreement, the Ancillary Documents to which the Company or Merger Sub is or is contemplated to be a
party, the performance of the obligations of the Company and Merger Sub hereunder and thereunder and the consummation of the transactions contemplated hereby (including the Merger and the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT>
Steps). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.4</B> <B><U>Financial Statements; Undisclosed Liabilities</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company has made available to MAAC a true and complete copy of (i)&nbsp;the audited consolidated balance sheet of the Company as of
March&nbsp;31, 2019 and March&nbsp;31, 2020 and the related audited consolidated statements of operations, comprehensive income (loss), shareholders&#146; equity and redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest and
cash flows of the Company for the years then ended and (ii)&nbsp;the unaudited consolidated balance sheet of the Company as of December&nbsp;31, 2020 (the &#147;<U>Latest Balance Sheet</U>&#148;) and the related unaudited consolidated statements of
operations, comprehensive income (loss), shareholders&#146; equity and redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest and cash flows of the Company for the period then ended (<U>clauses (i)</U>&nbsp;and <U>(ii)</U>,
collectively, the &#147;<U>Company Financial Statements</U>&#148;). Each of the Company Financial Statements (including the notes thereto)&nbsp;(A) were prepared in accordance with GAAP applied on a consistent basis throughout the periods indicated
(except as may be indicated in the notes thereto), (B) fairly presents, in all material respects in accordance with GAAP, the consolidated financial position, results of operations and cash flows of the Company as at the date thereof and for the
period indicated therein (except as may be indicated therein and subject to, in the case of any unaudited financial statements, normal year end audit adjustments (none of which are, individually or in the aggregate, material)), and (C)&nbsp;in the
case of the Company Financial Statements described in <U>clause</U><U></U><U>&nbsp;(i)</U> of the preceding sentence, contain an unqualified report of the Company&#146;s auditors and comply in all material respects with the applicable accounting
requirements and with the rules and regulations of the SEC, the Exchange Act and the Securities Act (including Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> or Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> as applicable) in effect
as of the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The financial statements or similar reports required to be included in the Registration Statement /
Proxy Statement (including (i)&nbsp;the audited consolidated balance sheet of the Company as of March&nbsp;31, 2019 and March&nbsp;31, 2020 and the related audited consolidated statements of operations, comprehensive income (loss),
shareholders&#146; equity and redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest and cash flows of the Company for the years then ended, audited in accordance with the standards of the PCAOB, (ii)&nbsp;the audited
consolidated balance sheet of the Company as of March&nbsp;31, 2021 and the related audited consolidated statements of operations, comprehensive income (loss), shareholders&#146; equity and redeemable
<FONT STYLE="white-space:nowrap">non-controlling</FONT> interest and cash flows of the Company for the years then ended, audited in accordance with the standards of the PCAOB, and (iii)&nbsp;customary pro forma financial statements) or any other
filings to be made by the Company or MAAC with the SEC in connection with the transactions contemplated in this Agreement or any other Ancillary Document (the &#147;<U>Closing Company Financial Statements</U>&#148;), when delivered following the
date of this Agreement in accordance with <U>Section</U><U></U><U>&nbsp;5.17</U>, (i) will be prepared in accordance with GAAP applied on a consistent basis throughout the periods indicated (except as may be indicated in the notes thereto and
subject to, in the case of any unaudited financial statements, normal year end audit adjustments (none of which are, individually or in the aggregate, material) and the absence of notes thereto), (ii) will fairly present, in all material respects in
accordance with GAAP, the consolidated financial position, results of operations and cash flows of the Company as at the date thereof and for the period indicated therein (except as may be indicated therein and subject to, in the case of any
unaudited financial statements, normal year end audit adjustments (none of which are, individually or in the aggregate, material)), (iii) in the case of any audited financial statements, will be audited in accordance with the standards of the PCAOB
and will contain an unqualified report of the Company&#146;s auditors and (iv)&nbsp;will comply in all material respects with the applicable accounting requirements and with the rules and regulations of the SEC, the Exchange Act and the Securities
Act (including Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> or Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> as applicable) in effect as of their respective dates of delivery, at the time of filing of the Registration Statement /
Proxy Statement (in the case of the Closing Company Financial Statements included in the initial filing of the Registration Statement / Proxy Statement) and at the time of effectiveness of the Registration Statement / Proxy Statement (in the case of
all Closing Company Financial Statements). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except (i)&nbsp;as set forth on or provided for in the Company Financial Statements (and
in the notes thereto), (ii) for Liabilities incurred in the ordinary course of business since the date of the Latest Balance Sheet (none of which are Liabilities for a breach of Contract, breach of warranty, tort, infringement, Proceeding or
violation of, or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with, Law), (iii) for Liabilities incurred in connection with the negotiation, preparation or execution of this Agreement or any Ancillary Documents, the performance by any of
the Company of its covenants or agreements in this Agreement or any Ancillary Document to which it is or will be a party or the consummation of the transactions contemplated hereby or thereby (including, for the avoidance of doubt, the Company
Expenses), (iv) executory obligations under Contracts (excluding any Liabilities for a breach of Contract), (v) that are expressly permitted pursuant to or incurred in accordance with <U>Section</U><U></U><U>&nbsp;5.1(b)</U> (including as expressly
set forth in <U>Section</U><U></U><U>&nbsp;5.1(b)</U> of the Company Disclosure Schedules) and (vi)&nbsp;for Liabilities that would not have a Company Material Adverse Effect, no Group Company has any Liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) To the knowledge of the Company, the Company has established and maintains a system of internal accounting controls that are designed to
provide, in all material respects, reasonable assurance that (i)&nbsp;all transactions are executed in accordance with management&#146;s authorization and (ii)&nbsp;all transactions are recorded as necessary to permit preparation of proper and
accurate financial statements in accordance with GAAP and to maintain accountability for the Company&#146;s consolidated assets. The Company maintains and, for all periods covered by the Company Financial Statements and the Closing Company Financial
Statements, has maintained books and records of the Company in the ordinary course of business that are accurate and complete and reflect the consolidated revenues, expenses, assets and liabilities of the Company in all material respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Since January&nbsp;1, 2019, the Company has not received any written complaint, allegation, assertion or claim that there is (i)
&#147;significant deficiency&#148; in the internal controls over financial reporting of the Company or, to the knowledge of the Company, any other Group Company as it pertains to the Company&#146;s consolidated financial reporting, (ii)&nbsp;a
&#147;material weakness&#148; in the internal controls over financial reporting of the Company or, to the knowledge of the Company, any other Group Company as it pertains to the Company&#146;s consolidated financial reporting or (iii)&nbsp;fraud,
whether or not material, that involves management or other employees of the Group Companies who have a significant role in the internal controls over financial reporting of the Company or, to the knowledge of the Company, any other Group Company as
it pertains to the Company&#146;s consolidated financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.5</B> <B><U>Consents and Requisite
Governmental Approvals; No</U></B><B><U></U></B><B><U>&nbsp;Violations</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) No Consent, approval or authorization of, or
designation, declaration or filing with, any Governmental Entity is required on the part of the Company or Merger Sub with respect to the Company or Merger Sub&#146;s execution, delivery or performance of its obligations under this Agreement or the
Ancillary Documents to which the Company or Merger Sub is or will be party or the consummation of the transactions contemplated hereby or thereby, except for (i)&nbsp;compliance with and filings under the HSR Act, if applicable, or under any
applicable antitrust or other competition Laws of any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions or any other merger control or investment laws or laws that provide for review of national security or defense matters
(collectively, &#147;<U>Foreign and Domestic Approval Laws</U>&#148;), (ii) the filing with the SEC of (A)&nbsp;the Registration Statement / Proxy Statement and the declaration of the effectiveness thereof by the SEC and (B)&nbsp;such reports under
Section&nbsp;13(a) or 15(d) of the Exchange Act as may be required in connection with this Agreement, the Ancillary Documents or the transactions contemplated hereby or thereby, (iii)&nbsp;the filing of (A)&nbsp;the Certificate of Merger and
(B)&nbsp;any filings required under the Companies Act in connection with the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps or the Merger, (iv)&nbsp;such filings with and approvals of Nasdaq to permit the Company Post-Closing
Common Shares to be issued in connection with the transactions contemplated by this Agreement and the other Ancillary Documents to be listed on Nasdaq, (v)&nbsp;the approval to be obtained by Merger Sub pursuant to
<U>Section</U><U></U><U>&nbsp;5.9</U><I> </I>or (vi)&nbsp;any other consents, approvals, authorizations, designations, declarations, waivers or filings, the absence of which would not have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) None of the execution or delivery by the Company or Merger Sub of this Agreement or any Ancillary Documents to which it is or will be a
party, the performance by the Company or Merger Sub of its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obligations hereunder or thereunder or the consummation of the transactions contemplated hereby or thereby will, directly or indirectly (with or without due notice or lapse of time or
both)&nbsp;(i) result in a violation or breach of any provision of any Group Company&#146;s Governing Documents, (ii)&nbsp;result in a violation or breach of, or constitute a default or give rise to any right of termination, Consent, cancellation,
amendment, modification, suspension, revocation or acceleration under, any of the terms, conditions or provisions of (A)&nbsp;any Material Contract or (B)&nbsp;any Material Permits, (iii)&nbsp;violate, or constitute a breach under, any Order or
applicable Law to which any Group Company or any of its properties or assets are subject or bound or (iv)&nbsp;result in the creation of any Lien upon any of the assets or properties (other than any Permitted Liens) or Equity Securities of any Group
Company, except, in the case of any of <U>clauses</U><U></U><U>&nbsp;(ii)</U> through <U>(iv)</U>&nbsp;above, as would not have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.6</B> <B><U>Permits</U></B>. Except as would not have a Company Material Adverse Effect, each of the
<U>Private </U>Group Companies has all Permits (the &#147;<U>Material Permits</U>&#148;) that are required to own, lease or operate its properties and assets and to conduct its business as currently conducted. Except as would not have a Company
Material Adverse Effect, (i)&nbsp;each Material Permit is in full force and effect in accordance with its terms and (ii)&nbsp;no written notice of revocation, cancellation or termination of any Material Permit has been received by any Private Group
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.7</B> <B><U>Material Contracts</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Section</U><U></U><U>&nbsp;3.7(a)</U> of the Company Disclosure Schedules sets forth a list of the following Contracts to which a
Private Group Company or, in the case of <U>Section</U><U></U><U>&nbsp;3.7(a)(viii)(B)</U>, Datavant is, as of the date of this Agreement, a party (each Contract required to be set forth on <U>Section</U><U></U><U>&nbsp;3.7(a)</U> of the Company
Disclosure Schedules, together with each Contract entered into after the date of this Agreement that would be required to be set forth on <U>Section</U><U></U><U>&nbsp;3.7(a)</U> of the Company Disclosure Schedules if entered into prior to the
execution and delivery of this Agreement, collectively, the &#147;<U>Material Contracts</U>&#148;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) any Contract relating to
indebtedness for borrowed money to a third party of any Private Group Company in excess of $25&nbsp;million or to the placing of a Lien (other than a Permitted Lien) on any assets or properties of any Private Group Company that are material to the
business of all of the Private Group Companies, taken as a whole; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) any Contract under which any Private Group Company is lessee of
or holds or operates, in each case, any tangible property (other than real property) that is material to the business of all of the Private Group Companies, taken as a whole, owned by any other Person; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) any joint venture, profit-sharing, partnership, <FONT STYLE="white-space:nowrap">co-promotion,</FONT> commercialization or other
similar Contract, in each case, material to the business all of the Private Group Companies, taken as a whole; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) any Contract that is
material to the business of all of the Private Group Companies, taken as a whole, and (A)&nbsp;limits or purports to limit the freedom of any Private Group Company to engage or compete in any line of business or with any Person or in any area,
(B)&nbsp;contains any exclusivity, &#147;most favored nation&#148; or similar provisions, obligations or restrictions that are binding on a Private Group Company or (C)&nbsp;contains any other provisions restricting or purporting to restrict the
ability of any Private Group Company to sell, manufacture, develop, commercialize, test or research products, directly or indirectly through third parties, or to solicit any potential employee or customer; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) any Contract requiring any Private Group Company to guarantee the Liabilities of any Person (other than the Company or a Subsidiary of
the Company) in excess of $10&nbsp;million; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) any Contract entered into under which any Private Group Company has, directly or
indirectly, made or agreed to make any loan, advance or assignment of payment to any Person (other than the Company or a Subsidiary of the Company), individually or in the aggregate, in an amount in excess of $10&nbsp;million; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) any Contract required to be disclosed on <U>Section</U><U></U><U>&nbsp;3.20</U> of
the Company Disclosure Schedules; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) any Contract with any Person (A)&nbsp;pursuant to which any Private Group Company may be
required to pay milestones, royalties or other contingent payments based on any research, testing, development, regulatory filings or approval, sale, distribution, commercial manufacture or other similar occurrences, developments, activities or
events, in each case, that are material to the business of, or that are material in amount to all of, the Private Group Companies, taken as a whole, or (B)<B></B>&nbsp;under which any Private Group Company or Datavant grants to any Person any right
of first refusal, right of first negotiation, option to purchase, option to license or any other similar preferential rights with respect to any Company Product or any Company Owned Intellectual Property that is material to the business of all of
the Private Group Companies, taken as a whole; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) any Contract governing the terms of, or otherwise related to, the employment,
engagement or services of any Designated Individual; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) any Contract for the disposition of all or a material portion of the assets or
business of any Private Group Company or for the acquisition by any Private Group Company of all or a material portion of the assets or business of any other Person (in each case, whether by merger, consolidation, recapitalization, purchase or
issuance of Equity Securities, purchase of assets, tender offer or otherwise), in each case under which any Private Group Company has any continuing Liabilities (including any obligation with respect to an &#147;earn out,&#148; purchase price or
other contingent or deferred payment obligation) that are material to the business of, or material in amount to, all of the Group Companies, taken as a whole; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xi) any settlement, conciliation or similar Contract (A)&nbsp;the performance of which would be reasonably likely to involve any material
payments by any Private Group Company after the date of this Agreement or (B)&nbsp;that imposes or is reasonably likely to impose, at any time in the future, any material, <FONT STYLE="white-space:nowrap">non-monetary</FONT> obligations on any
Private Group Company (or MAAC or any of its Affiliates (other than the Group Companies) after the Closing); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xii) any other
Contract the performance of which requires <FONT STYLE="white-space:nowrap">non-contingent</FONT> payments either (A)&nbsp;on an annual basis, to or from any Private Group Company in excess of $10&nbsp;million, or (B)&nbsp;in the aggregate, to or
from any Private Group Company in excess of $25&nbsp;million over the life of the agreement and, in each case, that is not terminable by the applicable Private Group Company without penalty upon less than sixty (60)&nbsp;days&#146; prior written
notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as would not have a Company Material Adverse Effect, (i)&nbsp;each Material Contract is valid and binding on the
applicable Group Company and, to the Company&#146;s knowledge, the counterparties thereto, and is in full force and effect and enforceable in accordance with its terms against such Group Company and, to the Company&#146;s knowledge, the
counterparties thereto (subject to applicable bankruptcy, insolvency, reorganization, moratorium or other Laws affecting generally the enforcement of creditors&#146; rights and subject to general principles of equity), (ii) the applicable Group
Company and, to the Company&#146;s knowledge, the counterparties thereto are not in breach of, or default under, any Material Contract and (iii)&nbsp;no event has occurred that (with or without due notice or lapse of time or both) would result in a
breach of, or default under, any Material Contract by the applicable Group Company or, to the Company&#146;s knowledge, the counterparties thereto. The Company has made available to MAAC true and complete copies of all Material Contracts in effect
as of the date hereof (other than purchase orders, invoices, and similar confirmatory or administrative documents that are ancillary to the main contractual relationship between the parties to a particular Contract or group of Contracts and that, in
each case, do not contain any material executory or continuing terms, conditions, obligations or rights). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.8</B> <B><U>Absence of Changes</U></B>. During the period beginning on April&nbsp;1, 2020 and ending on the
date of this Agreement, (a)&nbsp;no Company Material Adverse Effect has occurred and (b)&nbsp;except (x) as expressly contemplated by this Agreement, any Ancillary Document or in connection with the transactions contemplated hereby and thereby,
(y)&nbsp;for any action taken, or omitted to be taken, by any Group Company to the extent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determined to be reasonable and advisable in response to <FONT STYLE="white-space:nowrap">COVID-19,</FONT> or (z)&nbsp;as would not reasonably be expected to be, individually or in the aggregate,
material to the Company and its Subsidiaries, taken as a whole, (i)&nbsp;the Group Companies have conducted their businesses in the ordinary course, and (ii)&nbsp;no Private Group Company has taken any action that would require the consent of MAAC
if taken during the period from the date of this Agreement until the Closing pursuant to <U>Section</U><U></U><U>&nbsp;5.1(b)(i)</U>, <U>Section</U><U></U><U>&nbsp;5.1(b)(iv)(A)</U>, <U>Section</U><U></U><U>&nbsp;5.1(b)(xii)</U> or
<U>Section</U><U></U><U>&nbsp;5.1(b)(xv)</U> (to the extent related to any of the foregoing). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.9</B>
<B><U>Litigation</U></B>. There is, and since January&nbsp;1, 2019 there has been, no Proceeding pending or, to the Company&#146;s knowledge, threatened against any Private Group Company that, if adversely decided or resolved, has been or would
reasonably be expected to be, individually or in the aggregate, material to the Group Companies, taken as a whole. Except as would not have a Company Material Adverse Effect, neither the Private Group Companies nor any of their respective properties
or assets is subject to any Order. Except as would not have a Company Material Adverse Effect, as of the date of this Agreement, there are no Proceedings by a Private Group Company against any other Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.10</B> <B><U>Compliance with Applicable Law</U></B>. Each Private Group Company (a)&nbsp;conducts (and since
January&nbsp;1, 2019 has conducted) its business in accordance with all Laws and Orders applicable to such Private Group Company and (b)&nbsp;as of the date hereof, has not received any written communications or, to the Company&#146;s knowledge, any
other communications from or on behalf of a Governmental Entity that alleges that such Private Group Company is not in compliance with any such Law or Order, except in each case of <U>clauses (a)</U>&nbsp;and <U>(b)</U>, as is not, and would not
reasonably be expected to be, individually or in the aggregate, material to the Group Companies, taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.11</B> <B><U>Merger Sub Activities</U></B>. Merger Sub was organized solely for the purpose of entering into
this Agreement, the Ancillary Documents, the performance of its covenants and agreements in this Agreement and the Ancillary Documents and consummating the transactions contemplated hereby and thereby and has not engaged in any activities or
business, other than those incident or related to, or incurred in connection with, its organization, incorporation or formation, as applicable, its continuing corporate (or similar) existence or the negotiation, preparation or execution of this
Agreement or any Ancillary Document, the performance of its covenants or agreements in this Agreement or any Ancillary Document or the consummation of the transactions contemplated hereby or thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.12</B> <B><U>Employee Plans</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) No Group Company maintains, contributes to, or has any material Liability with respect to or under: (i)&nbsp;a Multiemployer Plan;
(ii)&nbsp;a &#147;defined benefit plan&#148; (as defined in Section&nbsp;3(35) of ERISA, whether or not subject to ERISA) or a plan that is or was subject to Title IV of ERISA or Section&nbsp;412 of the Code; or (iii)&nbsp;a &#147;multiple employer
plan&#148; within the meaning of Section of 413(c) of the Code or Section&nbsp;210 of ERISA. No Private Group Company maintains, contributes to, or has any material Liability with respect to or under a &#147;multiple employer welfare
arrangement&#148; as defined in Section&nbsp;3(40) of ERISA. No Group Company has any material Liabilities to provide any retiree or post-termination health or life insurance or other welfare-type benefits to any Person other than health
continuation coverage pursuant to COBRA or similar law. No Group Company has any material Liabilities under Title IV of ERISA by reason of at any time being considered a single employer under Section&nbsp;414 of the Code with any other Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Group Companies, taken as a
whole, each Employee Benefit Plan has been established, maintained, funded and administered in accordance with its terms and in compliance with all applicable Laws, including ERISA and the Code. Each Employee Benefit Plan that is intended to be
qualified under Section&nbsp;401(a) of the Code is so qualified and has timely received a favorable determination or opinion or advisory letter from the Internal Revenue Service. Since January&nbsp;1, 2019, none of the Private Group Companies has
incurred (whether or not assessed) any material penalty or Tax under Section&nbsp;4980H, 4980B, 4980D, 6721 or 6722 of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) There are no pending or, to the Company&#146;s knowledge, threatened in writing,
material claims or Proceedings with respect to any Employee Benefit Plan (other than routine claims for benefits). With respect to each Employee Benefit Plan, (i)&nbsp;there have been no &#147;prohibited transactions&#148; within the meaning of
Section&nbsp;4975 of the Code or Sections 406 or 407 of ERISA and no breaches of fiduciary duty (as determined under ERISA), and (ii)&nbsp;all contributions, distributions, reimbursements and premium payments that are due have been timely made,
except, in each case of each of <U>clauses (i)</U>&nbsp;and <U>(ii)</U>, as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Group Companies, taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The execution and delivery of this Agreement and the consummation of the transactions contemplated by this Agreement will not (alone or in
combination with any other event)&nbsp;(i) result in any payment or benefit becoming due to or result in the forgiveness of any indebtedness of any current or former director, manager, officer, employee, individual independent contractor or other
service providers of any of the Private Group Companies under any Employee Benefit Plan or (ii)&nbsp;accelerate the time of payment, funding or vesting or increase the amount or value of, or result in the forfeiture of, any compensation or benefit
under any Employee Benefit Plan to any current or former director, manager, officer, employee, individual independent contractor or other service providers of any of the Private Group Companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Private Group Companies have no material obligations to indemnify, reimburse, make-whole or
<FONT STYLE="white-space:nowrap">&#147;gross-up&#148;</FONT> any person for any Tax or related interest or penalties incurred by such person imposed under Section&nbsp;4999 or 409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Each Foreign Benefit Plan that is required to be registered or intended to be tax exempt has been registered (and, where applicable,
accepted for registration) and is tax exempt and has been maintained in good standing in all material respects, to the extent applicable, with each Governmental Entity. No Foreign Benefit Plan is a &#147;defined benefit plan&#148; (as defined in
ERISA, whether or not subject to ERISA) or has any material unfunded or underfunded Liabilities. All material contributions required to have been made by or on behalf of any of the Private Group Companies with respect to plans or arrangements
maintained or sponsored a Governmental Entity (including severance, termination indemnities or other similar benefits maintained for employees outside of the U.S.) have been timely made or fully accrued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.13</B> <B><U>Environmental Matters</U></B>. Except as would not have a Company Material Adverse Effect: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) None of the Private Group Companies have received any written communication or, to the Company&#146;s knowledge, other communication from
any Governmental Entity or any other Person regarding any actual, alleged, or potential violation of, or Liability under, any Environmental Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) There is no Proceeding pending or, to the Company&#146;s knowledge, threatened against any Private Group Company in respect to any
Environmental Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) There has been no manufacture, release, treatment, storage, disposal, arrangement for disposal, transport or
handling of, contamination by, or exposure of any Person to, any Hazardous Substances that has given rise to any Liability pursuant to Environmental Laws for any Private Group Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.14</B> <B><U>Intellectual Property</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as would not have a Company Material Adverse Effect, (i)&nbsp;all necessary fees and filings with respect to any Company Registered
Intellectual Property have been timely submitted to the relevant intellectual property office or Governmental Entity and Internet domain name registrars to maintain such Company Registered Intellectual Property in full force and effect and
(ii)&nbsp;there are no Proceedings pending, including litigations, interference, re-examination, <I>inter partes</I> review, reissue, opposition, nullity, or cancellation proceedings, that relate to any of the Company Registered Intellectual
Property and, to the Company&#146;s knowledge, no such Proceedings are threatened in writing by any Governmental Entity or any other Person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as would not have a Company Material Adverse Effect, (i)&nbsp;a Group Company
exclusively owns all right, title and interest in and to all Company Owned Intellectual Property, free and clear of all Liens (other than Permitted Liens) and (ii)&nbsp;for all issued Patents owned by the Group Companies, each named inventor on the
Patent has assigned their rights to a Group Company. Except as would not have a Company Material Adverse Effect, (x)&nbsp;the applicable Group Company has rights under all Contracts for Company Licensed Intellectual Property to use, sell, license
and otherwise exploit, as the case may be, all Company Licensed Intellectual Property licensed pursuant to such Contracts as the same is currently used, sold, licensed and otherwise exploited by such Group Company, (y)&nbsp;the Company Owned
Intellectual Property and the Company Licensed Intellectual Property, to the Company&#146;s knowledge, constitute all of the Intellectual Property Rights used or held for use by the Group Companies in the operation of their respective businesses,
and all Intellectual Property Rights necessary and sufficient to enable the Group Companies to conduct their respective businesses as currently conducted (it being understood that this <U>Section</U><U></U><U>&nbsp;3.14(b)(y)</U> is not a
representation or warranty with respect to any infringement, misappropriation or other violations of third-party Intellectual Property Rights) and (z)&nbsp;the Company Registered Intellectual Property, to the Company&#146;s knowledge, is valid,
subsisting and enforceable (in each case, subject to applicable bankruptcy, insolvency, reorganization, moratorium or other Laws affecting generally the enforcement of creditors&#146; rights and subject to general principles of equity). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except as would not have a Company Material Adverse Effect, each Group Company&#146;s employees, consultants, advisors and independent
contractors who independently or jointly contributed to or otherwise participated in the authorship, invention, creation, improvement, modification or development of any Company Owned Intellectual Property have assigned or have agreed to a present
assignment to such Group Company of all Intellectual Property Rights authored, invented, created, improved, modified or developed by such person in the course of such person&#146;s employment or other engagement with such Group Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except as would not have a Company Material Adverse Effect, (i)&nbsp;each Group Company has taken reasonable steps to safeguard and
maintain the secrecy of any trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and other confidential information owned by each Group Company, (ii)&nbsp;without limiting the foregoing, to the knowledge of the Company, each Group Company
has not disclosed any trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> or confidential information to any other Person unless, such disclosure was under a written <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreement
containing reasonably appropriate limitations on use, reproduction and disclosure and (iii)&nbsp;to the Company&#146;s knowledge, there has been no violation or unauthorized access to or disclosure of any trade secrets, <FONT
STYLE="white-space:nowrap">know-how</FONT> or confidential information owned by a Group Company, or of any written obligations with respect to such. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) None of the Company Owned Intellectual Property and, to the Company&#146;s knowledge, none of the Company Licensed Intellectual Property
is subject to any outstanding Order that restricts in any manner the use, sale, transfer, licensing or exploitation thereof by the Group Companies or affects the validity, use or enforceability of any such Company Owned Intellectual Property, except
as would not have a Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) To the Company&#146;s knowledge, since January&nbsp;1, 2019, neither the conduct
of the business of the Group Companies nor any of the Company Products offered, marketed, licensed, provided, sold, distributed or otherwise exploited by the Group Companies nor the design, development, manufacturing, reproduction, use, marketing,
offer for sale, sale, importation, exportation, distribution, maintenance or other exploitation of any Company Product infringes, misappropriates or otherwise violates any Intellectual Property Rights of any other Person, except as would not have a
Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Except as would not have a Company Material Adverse Effect, there is no Proceeding pending nor has
any Group Company received any written communications (i)&nbsp;alleging that a Group Company has infringed, misappropriated or otherwise violated any Intellectual Property Rights of any other Person or (ii)&nbsp;challenging the validity,
enforceability, use or exclusive ownership of any Company Owned Intellectual Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Except as would not have a Company Material
Adverse Effect, (i)&nbsp;to the Company&#146;s knowledge, no Person is infringing, misappropriating, misusing, diluting or violating any Company Owned Intellectual Property </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and (ii)&nbsp;since January&nbsp;1, 2019, no Group Company has made any written claim against any Person alleging any infringement, misappropriation or other violation of any Company Owned
Intellectual Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Except as would not have a Company Material Adverse Effect, to the Company&#146;s knowledge, no event has
occurred, and no circumstance or condition exists, that (with or without notice or lapse of time or both) will, or could reasonably be expected to, result in the delivery, license or disclosure of any source code that constitutes Company Owned
Intellectual Property to any Person who is not, as of the date the event occurs or circumstance or condition comes into existence, a current employee or contractor of a Group Company subject to confidentiality obligations with respect thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) No Group Company has accessed, used, modified, linked to, created derivative works from or incorporated into any proprietary Software
included in the Company Owned Intellectual Property any Public Software, in each case in a manner that (i)&nbsp;requires such Company Owned Intellectual Property to be licensed, sold, disclosed, distributed, hosted or otherwise made available,
including in source code form and/or for the purpose of making derivative works, for any reason, (ii)&nbsp;grants, or requires any Group Company to grant, the right to decompile, disassemble, reverse engineer or otherwise derive the source code or
underlying structure of any Company Owned Intellectual Property, (iii)&nbsp;limits in any manner the ability to charge license fees or otherwise seek compensation in connection with marketing, licensing or distribution of any Company Owned
Intellectual Property or (iv)&nbsp;otherwise imposes any limitation, restriction or condition on the right or ability of any Group Company to use, hold for use, license, host, distribute or otherwise dispose of any Company Owned Intellectual
Property, other than compliance with notice and attribution requirements, in each case, except as would not have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3.15 <U>Labor Matters</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Since January&nbsp;1, 2019, except as has not and would not reasonably be expected to result in, individually or in the aggregate,
material Liability to the Group Companies, taken as a whole, (i)&nbsp;none of the Private Group Companies (A)&nbsp;has or has had any Liability for any failure to pay or delinquency in paying any wages or other compensation for services (including
salaries, wage premiums, commissions, fees or bonuses), or any penalties, fines, interest, or other sums, or (B)&nbsp;has or has had any Liability for any payment to any trust or other fund governed by or maintained by or on behalf of any
Governmental Entity with respect to unemployment compensation benefits, social security, social insurances or other benefits or obligations for any employees of any Private Group Company (other than routine payments to be made in the normal course
of business and consistent with past practice); and (ii)&nbsp;the Private Group Companies have withheld all amounts required by applicable Law or by agreement to be withheld from wages, salaries and other payments to employees or independent
contractors or other service providers of each Private Group Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Since January&nbsp;1, 2019, there has been no &#147;mass
layoff&#148; or &#147;plant closing&#148; as defined by WARN related to any Private Group Company, and the Private Group Companies have not incurred any material Liability under WARN. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) No Private Group Company is a party to or bound by any CBA and no employees of any Private Group Company are represented by any labor
union, labor organization, works council, employee delegate, representative or other employee collective group with respect to their employment. There is no duty on the part of any Private Group Company or, to the knowledge of the Company, any
Public Group Company or Datavant, to bargain with any labor union, labor organization, works council, employee delegate, representative or other employee collective group as a result of the execution and delivery of this Agreement, the Ancillary
Documents or the consummation of the transactions contemplated hereby or thereby. Since January&nbsp;1, 2019, there has been no actual or, to the Company&#146;s knowledge, threatened in writing material unfair labor practice charges, material labor
grievances, material labor arbitrations, material strikes, lockouts, work stoppages, slowdowns, picketing, handbilling or other material labor disputes against any Private Group Company. To the Company&#146;s knowledge, since January&nbsp;1, 2019,
there have been no actual, pending or threated labor organizing activities with respect to any employees of any Private Group Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) To the Company&#146;s knowledge, as of the date of this Agreement, there are no
unresolved allegations of sexual harassment, or other discrimination or retaliation, against any executive officer or director of the Company (in his or her capacity as such) that, if known to the public, would bring the Company into material
disrepute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) No material employee layoff, facility closure or shutdown (whether voluntary or by Order),
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">reduction-in-force,</FONT></FONT> furlough, temporary layoff, work schedule change or reduction in hours, or material reduction in salary or wages, or other material workforce changes
affecting employees of the Private Group Companies has occurred since the date of the Latest Balance Sheet or is currently contemplated, planned or announced, including as a result of <FONT STYLE="white-space:nowrap">COVID-19</FONT> or any Law,
Order, directive, guideline or recommendation by any Governmental Entity in connection with or in response to <FONT STYLE="white-space:nowrap">COVID-19.</FONT> As of the date of this Agreement, the Private Group Companies have not otherwise
experienced any material employment-related Liability with respect to or arising out of <FONT STYLE="white-space:nowrap">COVID-19</FONT> or any Law, Order, directive, guideline or recommendation by any Governmental Entity in connection with or in
response to <FONT STYLE="white-space:nowrap">COVID-19.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.16</B> <B><U>Insurance</U></B>. Except as
would not have a Company Material Adverse Effect, all policies of fire, liability, workers&#146; compensation, property, casualty and other forms of insurance owned or held by any Private Group Company as of the date of this Agreement, are in full
force and effect, all premiums due and payable thereon as of the date of this Agreement have been paid in full as of the date of this Agreement, and true and complete copies of all such policies have been made available to MAAC. As of the date of
this Agreement, no claim by any Private Group Company is pending under any such policies as to which coverage has been denied or disputed, or rights reserved to do so, by the underwriters thereof, except as would not have a Company Material Adverse
Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3.17 <U>Tax Matters</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Group Companies have prepared and filed all material Tax Returns required to have been filed by or with respect to such entities, all
such Tax Returns are true and complete in all material respects, and the Group Companies have paid all material Taxes required to have been paid by or with respect to such entities regardless of whether shown on any Tax Return. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Group Companies have timely withheld and paid to the appropriate Tax Authority all material amounts required to have been withheld and
paid in connection with amounts paid or owing to any employee, independent contractor, other service provider, equity interest holder, creditor or other <FONT STYLE="white-space:nowrap">third-party.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) No Group Company is currently the subject of a Tax audit or examination or has been informed in writing of the commencement or anticipated
commencement of any Tax audit or examination that has not been resolved or completed, in each case, with respect to material Taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)
No Group Company has consented to extend or waive the time in which any material Tax may be assessed or collected by any Tax Authority, other than any such extensions or waivers that are no longer in effect or that were extensions of time to file
Tax Returns obtained in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) No &#147;closing agreement&#148; as described in Section&nbsp;7121 of the
Code (or any corresponding or similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> income Tax Law), private letter rulings, technical advice memoranda or similar agreements or rulings have been entered into or issued
by any Tax Authority to a Group Company, which agreement or ruling would be effective after the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) No Group Company is or
has been a party to any &#147;listed transaction&#148; as defined in Section&nbsp;6707A of the Code and Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.6011-4</FONT> (or any corresponding or similar provision of state, local or <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> Tax Law). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) There are no Liens for material Taxes on any assets of the Group Companies other than
Liens described in <U>clause (b)</U>&nbsp;of the definition of Permitted Liens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) During the two (2)-year period ending on the date of
this Agreement, no Group Company was a distributing corporation or a controlled corporation in a transaction purported or intended to be governed by Section&nbsp;355 of the Code (or so much of Section&nbsp;356 of the Code as relates to
Section&nbsp;355 of the Code). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) No Group Company (i)&nbsp;has been a member of an affiliated group filing a consolidated U.S. federal
income Tax Return (other than a group the common parent of which was a Group Company) or (ii)&nbsp;has any material Liability for the Taxes of any Person (other than a Group Company) under Treasury Regulations
<FONT STYLE="white-space:nowrap">Section&nbsp;1.1502-6</FONT> (or any corresponding or similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Tax Law), as a transferee or successor or by Contract (other than any
customary indemnification provisions contained in any commercial Contract entered into in the ordinary course of business and the principal purpose of which does not relate to Taxes). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) No written claims have ever been made by any Tax Authority in a jurisdiction where a Group Company does not file Tax Returns that such
Group Company is or may be subject to taxation by, or required to file a Tax Return with, that jurisdiction, which claims have not been resolved or withdrawn. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) No Group Company is a party to any Tax allocation, Tax sharing or Tax indemnity or similar agreements (other than any (i)&nbsp;such
agreement with another Group Company or (ii)&nbsp;customary commercial Contract entered into in the ordinary course of business and the principal purpose of which does not relate to Taxes). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) No Group Company has taken or agreed to take any action not contemplated by this Agreement and/or any Ancillary Document that could
reasonably be expected to prevent, impair or impede the Merger from qualifying for the Intended Tax Treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) The Company believes
that it is not, and does not expect to become, a &#147;passive foreign investment company&#148; within the meaning of Section&nbsp;1297(a) of the Code (&#147;<U>PFIC</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) Notwithstanding anything to the contrary in this Agreement, Section&nbsp;3.4 (Financial Statements; Undisclosed Liabilities),
Section&nbsp;3.12 (Employee Plans), Section&nbsp;5.5(a)(i) and this <U>Section</U><U></U><U>&nbsp;3.17</U> (Tax Matters) contain the sole representations and warranties of the Group Companies concerning Taxes. Notwithstanding any representation or
warranty in this Agreement (including the representations and warranties set forth in this <U>Section</U><U></U><U>&nbsp;3.17</U> (Tax Matters)), no representation or warranty is being made as to the use or availability of any Tax attribute or
credit of any Group Company in any taxable period (or portion thereof) beginning on the day immediately after the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.18</B> <B><U>Brokers</U></B>. Except for J.P. Morgan Securities LLC, SVB Leerink LLC and Goldman
Sachs&nbsp;&amp; Co. LLC, no broker, finder, investment banker or other Person is entitled to any brokerage fee, finders&#146; fee or other commission in connection with the transactions contemplated by this Agreement based upon arrangements made by
or on behalf of the Company or any of its Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3.19 <U>Real and Personal Property</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Owned Real Property</U>. No Private Group Company owns any real property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Leased Real Property</U>. Each Real Property Lease is in full force and effect and is a valid, legal and binding obligation of the
applicable Private Group Company party thereto, enforceable in accordance with its terms against such Private Group Company and, to the Company&#146;s knowledge, each other party thereto (subject to applicable bankruptcy, insolvency, reorganization,
moratorium or other Laws affecting generally the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enforcement of creditors&#146; rights and subject to general principles of equity). There is no material breach or default by any Private Group Company or, to the Company&#146;s knowledge, any
counterparty under any Real Property Lease, and, to the Company&#146;s knowledge, no event has occurred which (with or without notice or lapse of time or both) would constitute a material breach or default under any Real Property Lease or would
permit termination of, or a material modification or acceleration thereof, by any counterparty to any Real Property Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
<U>Personal Property</U>. Each Private Group Company has good, marketable and indefeasible title to, or a valid leasehold interest in or license or right to use, all of the material tangible assets and tangible properties of the Private Group
Companies reflected in the Financial Statements or thereafter acquired by the Private Group Companies, except for assets disposed of in the ordinary course of business or otherwise as permitted by <U>Section</U><U></U><U>&nbsp;5.1(b)</U> (including
as set forth in <U>Section</U><U></U><U>&nbsp;5.1(b)</U> of the Company Disclosure Schedules) or in accordance with <U>Section</U><U></U><U>&nbsp;5.1(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.20</B> <B><U>Transactions with Affiliates</U></B>. <U>Section</U><U></U><U>&nbsp;3.20</U> of the Company
Disclosure Schedules sets forth all material Contracts between (a)&nbsp;any Private Group Company or, to the knowledge of the Company, Datavant or any Public Group Company, on the one hand, and (b)&nbsp;any officer, director, executive (including,
for the avoidance of doubt, the Designated Individuals), manager, direct or, to the Company&#146;s knowledge, indirect, equityholder of more than one percent (1.0%) of the Company Common Shares (each such direct or indirect equityholder, an
&#147;<U>Affiliated Shareholder</U>&#148;), or Affiliate, in each case, of the Company, on the other hand (each Person identified in this <U>clause</U><U></U><U>&nbsp;(b)</U>, a &#147;<U>Company Related Party</U>&#148;), other than
(i)&nbsp;Contracts solely between or among the Group Company(ies) and/or Datavant, (ii)&nbsp;with respect to or otherwise related to a Company Related Party&#146;s (A)&nbsp;employment with (including benefit plans and other ordinary course
compensation from) any of the Group Companies, (B)&nbsp;service to any of the Group Companies as a director (or member of a similar governing body) or (C)&nbsp;in the case of an individual, service to any of the Group Companies as an independent
third-party consultant or other <FONT STYLE="white-space:nowrap">non-employee</FONT> service provider (in the case of this <U>clause (C)</U>, on an arms&#146; length basis and terms), and any ordinary course compensation in connection with any of
the foregoing in the preceding <U>clauses</U><U></U><U>&nbsp;(A)</U> through <U>(C)</U>, (iii) Contracts entered into after the date of this Agreement that are either permitted pursuant to <U>Section</U><U></U><U>&nbsp;5.1(b)</U> (including as set
forth in <U>Section</U><U></U><U>&nbsp;5.1(b)</U> of the Company Disclosure Schedules) or entered into in accordance with <U>Section</U><U></U><U>&nbsp;5.1(b)</U>, (iv) Contracts relating to or entered into in connection with a Company Related
Party&#146;s status as an equityholder of such Private Group Company (including the Company Shareholders Agreements and similar Contracts), (v)&nbsp;commercial agreements entered into in the ordinary course of business on an arms&#146; length basis
and terms that are not individually material to the business of the Group Companies, taken as a whole, or (vi)&nbsp;customary director and officer indemnification agreements that have been made available to MAAC. No Company Related Party
(A)&nbsp;owns any material interest in any material asset or property used in any Private Group Company&#146;s business, (B)&nbsp;possesses, directly or indirectly, any material financial interest in, or is a director or executive officer of, any
Person which is a material supplier, vendor, partner, customer or lessor, or other material business relation, of any Private Group Company or (C)&nbsp;is a material supplier, vendor, partner, customer or lessor, or other material business relation,
of any Private Group Company. All Contracts, arrangements, understandings, interests and other matters that are required to be disclosed pursuant to this <U>Section</U><U></U><U>&nbsp;3.20</U> (including, for the avoidance of doubt, pursuant to the
second sentence of this <U>Section</U><U></U><U>&nbsp;3.20</U>) are referred to herein as &#147;<U>Company Related Party Transactions</U>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3.21 <U>Data Privacy and Security</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as would not have a Company Material Adverse Effect, each Private Group Company has implemented adequate written policies relating
to the Processing of Personal Data as and to the extent required by applicable Law (&#147;<U>Privacy and Data Security Policies</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as would not have a Company Material Adverse Effect, there is no Proceeding pending or, to the Company&#146;s knowledge, threatened
in writing, against any Private Group Company initiated by any Person (including (i)&nbsp;the United States Federal Trade Commission, any state attorney general or similar state official, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(ii)&nbsp;any other Governmental Entity, foreign or domestic or (iii)&nbsp;any regulatory or self-regulatory entity) alleging that any Processing of Personal Data by or on behalf of a Private
Group Company is or was in violation of any Privacy and Security Requirements, nor, to the Company&#146;s knowledge, is there any basis for the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Since January&nbsp;1, 2019, to the Company&#146;s knowledge, (i)&nbsp;there has been no unauthorized access to, or use, disclosure, or
Processing of Personal Data in the possession or control of any Private Group Company or any of its contractors with regard to any Personal Data obtained from or on behalf of a Private Group Company, (ii)&nbsp;there have been no unauthorized
intrusions or breaches of security into any Company IT Systems, and (iii)&nbsp;none of the Private Group Companies has notified or been required to notify any Person of any (A)&nbsp;loss, theft or damage of, or (B)&nbsp;other unauthorized or
unlawful access to, or use, disclosure or other Processing of, Personal Data, except, in each case of <U>clauses (i)</U>, <U>(ii)</U> and <U>(iii)</U>, as would not have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except as would not have a Company Material Adverse Effect, (i)&nbsp;each Private Group Company owns or has licenses to use the Company IT
Systems as necessary to operate the business of each Private Group Company as currently conducted, (ii)&nbsp;to the Company&#146;s knowledge, all Company IT Systems are free from any defect, bug, virus or programming, design or documentation error
and (iii)&nbsp;since January&nbsp;1, 2019, there have not been any failures, breakdowns or continued substandard performance of any Company IT Systems that have caused a failure or disruption of the Company IT Systems other than routine failures or
disruptions that have been remediated in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) To the knowledge of the Company, the consummation of this
Agreement and any transfers of Personal Data necessary to give effect to the Agreement will not violate any Privacy and Security Requirement, except as would not have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.22</B> <B><U>Certain Business Practices</U></B>. Except as would not have a Company Material Adverse Effect:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) None of the Private Group Companies, any of their respective officers, directors, or employees or, to the Company&#146;s knowledge,
any of their other Representatives, or any other Persons acting for or on behalf of any of the foregoing,&nbsp;since January&nbsp;1, 2019, (i) has been a Sanctioned Person, (ii)&nbsp;has transacted any business with or for the direct or knowing
indirect benefit of any Sanctioned Person in violation of applicable Sanctions or (iii)&nbsp;has otherwise violated any applicable Sanctions, <FONT STYLE="white-space:nowrap">Ex-Im</FONT> Laws, or anti-boycott Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) None of the Private Group Companies, any of their respective officers, directors or employees or, to the Company&#146;s knowledge, any of
their other Representatives, or any other Persons acting for or on behalf of any of the foregoing has, since January&nbsp;1, 2019, (i) made, offered, promised, paid or received any unlawful bribes, kickbacks, or other similar payments to or from any
Person, (ii)&nbsp;made or paid any contributions, directly or indirectly, to a domestic or foreign political party or candidate for any improper purpose or (iii)&nbsp;otherwise made, offered, received, authorized, promised or paid any improper
payment in violation of any Anti-Corruption Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Private Group Companies have instituted and maintained policies and procedures
designed to ensure compliance with the Anti-Corruption Laws, Sanctions, and <FONT STYLE="white-space:nowrap">Ex-Im</FONT> Laws in each jurisdiction in which any such entity operates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) To the Company&#146;s knowledge, no Private Group Company has, since January&nbsp;1, 2019, been the subject of any allegation, voluntary
disclosure, investigation, prosecution or enforcement action related to any Anti-Corruption Laws, Sanctions, or <FONT STYLE="white-space:nowrap">Ex-Im</FONT> Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.23</B> <B><U>Information Supplied</U></B>. None of the information of the Group Companies included or
incorporated by reference prior to the Closing in the Registration Statement / Proxy Statement will, when the Registration Statement / Proxy Statement is declared effective or when the Registration Statement / Proxy Statement is mailed to the <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> MAAC Shareholders or at the time of the MAAC Shareholders Meeting, and in the case of any amendment thereto, at the time of such amendment, contain any untrue statement of a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are made, not
misleading; <U>provided</U> that, notwithstanding the foregoing provisions of this <U>Section</U><U></U><U>&nbsp;3.23</U>, no representation or warranty is made by the Company or Merger Sub with respect to any information or statements included or
incorporated by reference in the Registration Statement / Proxy Statement supplied by or on behalf of MAAC for use therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.24</B> <B><U>Regulatory Compliance</U></B>. Except as set forth in <U>Section</U><U></U><U>&nbsp;3.24</U> of
the Company Disclosure Schedules: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each Group Company conducts (and since January&nbsp;1, 2019, has conducted) its business in
accordance with all Public Health Laws applicable to such Group Company and is not in violation of any such Public Health Law or Order, except as is not and would not reasonably be expected to be, individually or in the aggregate, material to the
Group Companies, taken as a whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) No Group Company has received, as of the date hereof, any written communication from the FDA or
other Governmental Entity, including a warning, untitled or notice of violation letter or Form <FONT STYLE="white-space:nowrap">FDA-483,</FONT> that alleges that any Group Company or the research, development, or manufacture of any Company Product
is not in compliance with any Public Health Laws, except as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Group Companies, taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) There is (and since January&nbsp;1, 2019 there has been) no Proceeding pending or, to the Company&#146;s knowledge, threatened against or
involving any Group Company related to compliance with Public Health Laws, except as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Group Companies, taken as a whole. The Group Companies do not
have, and since January&nbsp;1, 2019 have not had, any Liabilities for failure to comply with any Public Health Laws, except as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Group Companies,
taken as a whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) All preclinical studies, tests, and research being conducted by or on behalf of any Group Company or with respect
to any Company Product are being, and, in each case, at since January&nbsp;1, 2019 have been, to the extent applicable, conducted in compliance with all applicable Laws, including the good laboratory practice regulations set forth at 21 C.F.R. Part
58, except as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Group Companies, taken as a whole. Except as is not and would not reasonably be expected to be, individually or in the aggregate,
material to the Group Companies, taken as a whole, all clinical studies, tests, and research being conducted by or on behalf of the Company or with respect to any Company Product are being and, in each case, at all times have been, conducted in
compliance with all applicable Laws and with good clinical practice, as defined or recognized by FDA, such as in the guidance document E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1), and applicable provisions of the FDCA and
implementing regulations at 21 C.F.R. Parts 50, 54, 56, and 312. Except as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Group Companies, taken as a whole, no preclinical or clinical trial
conducted by or on behalf of the Company or with respect to any Company Product has been terminated or suspended prior to completion for safety, data integrity, or <FONT STYLE="white-space:nowrap">non-compliance</FONT> reasons, and neither the FDA
nor any other Governmental Entity or regulatory authority, clinical investigator or institutional review board that has or had jurisdiction over or participated in any such clinical trial has initiated or threatened in writing to initiate, any
action to terminate, delay, suspend or modify any such ongoing preclinical or clinical trial, or, to the Company&#146;s knowledge, to disqualify, restrict or debar any preclinical or clinical investigator or other person involved in any such
preclinical or clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) To the Company&#146;s knowledge, as of the date hereof, no information, condition or circumstance
exists that could reasonably be expected to materially adversely affect the acceptance, or the subsequent approval, of any filing, application or request for approval of any Company Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Except as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Group Companies, taken as a
whole, since January&nbsp;1, 2019, none of the Group Companies or, to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company&#146;s knowledge, any of their respective officers, directors, employees, agents, or suppliers, with respect to any matter relating to the Group Companies or the business of the Group
Companies, has made an untrue statement of a material fact or fraudulent statement to the FDA or other Governmental Entity, failed to disclose a material fact required to be disclosed to the FDA or any other Governmental Entity, or committed any
act, made any statement, or failed to make any statement that, at the time such disclosure was made, could reasonably be expected to provide a basis for the FDA or any other Governmental Entity to invoke its policy respecting &#147;Fraud, Untrue
Statements of Material Facts, Bribery, and Illegal Gratuities&#148; set forth in 56 Fed. Reg. 46191 (September 10, 1991) or any similar policy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Except as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Group Companies, taken as a
whole, since January&nbsp;1, 2019, (i)&nbsp;none of the Group Companies or, to the Company&#146;s knowledge, any of their respective officers, directors or employees are or has been excluded, disqualified, debarred, or suspended, or threatened with
exclusion, debarment, or suspension under the FDA&#146;s debarment authority under 21 U.S.C. &#167; 335a or for the award of a contract by any Governmental Entity or for participation in governmental programs such as Medicare or Medicaid,
(ii)&nbsp;none of the Group Companies or, to the Company&#146;s knowledge, any of their respective officers, directors or employees are or have been convicted of any crime or engaged in any conduct that could result in debarment or exclusion under
21 U.S.C. &#167; 335a or any similar Public Health Laws, (iii)&nbsp;no claims, actions, proceedings or investigations that could reasonably be expected to result in such a debarment or exclusion are pending or, to the Company&#146;s knowledge,
threatened against the Group Companies or, to the Company&#146;s knowledge, any of their respective officers, directors or employees and (iv)&nbsp;no Group Company has undergone, or is currently undergoing, any inspection related to any Company
Product&nbsp;or any other Governmental Entity investigation under any Public Health Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.25</B>
<B><U>Investment Company Act</U></B>. The Company is not required to register as an &#147;investment company&#148; within the meaning of the Investment Company Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.26</B> <B><U>SEC Filings and Matters</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each Public Group Company has timely filed or furnished all statements, forms, reports and documents required to be filed or furnished by
it prior to the date of this Agreement with the SEC pursuant to Federal Securities Laws since its initial public offering (collectively, and together with any exhibits and schedules thereto and other information incorporated therein, and as they
have been supplemented, modified or amended since the time of filing, the &#147;<U>Public Group Company SEC Reports</U>&#148;). Each of the Public Group Company SEC Reports, as of their respective dates of filing, and as of the date of any amendment
or filing that superseded the initial filing, complied in all material respects with the applicable requirements of the Federal Securities Laws (including, as applicable, the Sarbanes-Oxley Act and any rules and regulations promulgated thereunder)
applicable to the Public Group Company SEC Reports. As of their respective dates of filing, the Public Group Company SEC Reports did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein, in light of the circumstances under which they were made or will be made, as applicable, not misleading. As of the date of this Agreement, there are no outstanding or unresolved comments in comment
letters received from the SEC with respect to the Public Group Company SEC Reports. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as is not required in reliance on
exemptions from certain reporting requirements by virtue of any Public Group Company&#146;s status as an &#147;emerging growth company&#148; within the meaning of the Securities Act, as modified by the JOBS Act, or as a &#147;smaller reporting
company&#148; within the meaning of the Exchange Act,&nbsp;since the later of January&nbsp;1, 2019 or its initial public offering, (i)&nbsp;each Public Group Company has established and maintained a system of internal controls over financial
reporting (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> and Rule <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act) sufficient to provide reasonable assurance regarding the reliability of its financial
reporting and the preparation of its financial statements for external purposes in accordance with GAAP and (ii)&nbsp;each Public Group Company has established and maintained disclosure controls and procedures (as defined in Rule <FONT
STYLE="white-space:nowrap">13a-15</FONT> and Rule <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act) designed to ensure that material information </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
relating to it is made known to its principal executive officer and principal financial officer by others within such Public Group Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Since the later of January&nbsp;1, 2019 or the first filing of a registration statement in connection with its initial public offering,
none of the Public Group Companies has taken any action prohibited by Section&nbsp;402 of the Sarbanes-Oxley Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Since the later of
January&nbsp;1, 2019 or its initial public offering, each of the Public Group Companies has complied in all material respects with all applicable listing and corporate governance rules and regulations of its stock exchange. As of the date of this
Agreement, there is no material Proceeding pending or, to the Company&#146;s knowledge, threatened against any Public Group Company by its stock exchange or the SEC with respect to any intention by such entity to deregister the Equity Securities of
such Public Group Company or prohibit or terminate the listing of Equity Securities of such Public Group Company on such stock exchange. None of the Public Group Companies has, as of the date hereof, taken any action that is designed to terminate
the registration of any of its Equity Securities that are registered under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.27</B>
<B><U>No Other Representations</U></B>. In entering into this Agreement and the Ancillary Documents to which it is or will be a party, each of the Company and Merger Sub has relied solely on its own investigation and analysis and the representations
and warranties expressly set forth in <U>Article</U><U></U><U>&nbsp;4</U> and in the Ancillary Documents to which it is or will be a party and no other representations or warranties of MAAC, any MAAC <FONT STYLE="white-space:nowrap">Non-Party</FONT>
Affiliate or any other Person, either express or implied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.28</B> <B><U>EXCLUSIVITY OF REPRESENTATIONS AND
WARRANTIES</U></B>. NOTWITHSTANDING THE DELIVERY OR DISCLOSURE TO THE COMPANY OR ANY OF ITS REPRESENTATIVES OF ANY DOCUMENTATION OR OTHER INFORMATION (INCLUDING ANY FINANCIAL PROJECTIONS OR OTHER SUPPLEMENTAL DATA), EACH OF THE COMPANY AND MERGER
SUB, ON ITS OWN BEHALF AND ON BEHALF OF ITS REPRESENTATIVES, ACKNOWLEDGES, REPRESENTS, WARRANTS AND AGREES THAT, EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN <U>ARTICLE</U><U></U><U>&nbsp;4</U> OR THE ANCILLARY DOCUMENTS TO WHICH IT OR MERGER SUB, AS
APPLICABLE, IS OR WILL BE A PARTY, NONE OF MAAC, ANY MAAC <FONT STYLE="white-space:nowrap">NON-PARTY</FONT> AFFILIATE OR ANY OTHER PERSON MAKES, AND EACH OF THE COMPANY AND MERGER SUB EXPRESSLY DISCLAIMS, ANY REPRESENTATIONS OR WARRANTIES OF ANY
KIND OR NATURE, EXPRESS OR IMPLIED, IN CONNECTION WITH THIS AGREEMENT, THE ANCILLARY DOCUMENTS OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY, INCLUDING AS TO THE MATERIALS RELATING TO THE BUSINESS AND AFFAIRS OR HOLDINGS OF MAAC THAT
HAVE BEEN MADE AVAILABLE TO THE COMPANY OR ANY OF ITS REPRESENTATIVES OR IN ANY PRESENTATION OF THE BUSINESS AND AFFAIRS OF MAAC BY THE MANAGEMENT OR ON BEHALF OF MAAC OR OTHERS IN CONNECTION WITH THE TRANSACTIONS CONTEMPLATED HEREBY OR BY THE
ANCILLARY DOCUMENTS, AND NO STATEMENT CONTAINED IN ANY OF SUCH MATERIALS OR MADE IN ANY SUCH PRESENTATION SHALL BE DEEMED A REPRESENTATION OR WARRANTY HEREUNDER OR OTHERWISE OR DEEMED TO BE RELIED UPON BY THE COMPANY, MERGER SUB OR ANY COMPANY <FONT
STYLE="white-space:nowrap">NON-PARTY</FONT> AFFILIATE IN EXECUTING, DELIVERING OR PERFORMING THIS AGREEMENT, THE ANCILLARY DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. IT IS UNDERSTOOD THAT ANY COST ESTIMATES, PROJECTIONS OR OTHER
PREDICTIONS, ANY DATA OR ANY MEMORANDA OR OFFERING MATERIALS OR PRESENTATIONS, INCLUDING ANY OFFERING MEMORANDUM OR SIMILAR MATERIALS MADE AVAILABLE BY OR ON BEHALF OF MAAC ARE NOT AND SHALL NOT BE DEEMED TO BE OR TO INCLUDE REPRESENTATIONS OR
WARRANTIES OF MAAC, ANY MAAC <FONT STYLE="white-space:nowrap">NON-PARTY</FONT> AFFILIATE OR ANY OTHER PERSON, AND ARE NOT AND SHALL NOT BE DEEMED TO BE RELIED UPON BY THE COMPANY, MERGER SUB OR ANY COMPANY
<FONT STYLE="white-space:nowrap">NON-PARTY</FONT> AFFILIATE IN EXECUTING, DELIVERING OR PERFORMING THIS AGREEMENT, THE ANCILLARY DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES RELATING TO MAAC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to <U>Section</U><U></U><U>&nbsp;8.8</U>, except (a)&nbsp;as set forth on the MAAC Disclosure Schedules, or (b)&nbsp;with respect to
any of the MAAC Fundamental Representations, as set forth in any publicly available MAAC SEC Reports as of the date hereof (excluding any disclosures in any &#147;risk factors&#148; section that do not constitute statements of fact, disclosures in
any forward-looking statements disclaimers and other disclosures that are generally cautionary, predictive or forward-looking in nature), MAAC hereby represents and warrants to the Company and Merger Sub as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.1</B> <B><U>Organization and Qualification</U></B>. MAAC is a corporation duly incorporated, validly existing
and in good standing under the Laws of its jurisdiction of incorporation. The Governing Documents of MAAC are in full force and effect and MAAC is not in material breach or violation of any provision set forth in its Governing Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.2</B> <B><U>Authority</U></B>. MAAC has the requisite corporate power and authority to execute and deliver
this Agreement and each Ancillary Document to which it is or will be a party, to perform its obligations hereunder and thereunder, and to consummate the transactions contemplated hereby and thereby. Subject to the receipt of the MAAC Shareholder
Approval, the execution and delivery of this Agreement, the Ancillary Documents to which MAAC is or will be a party and the consummation of the transactions contemplated hereby and thereby have been (or, in the case of any Ancillary Document entered
into after the date of this Agreement, will be upon execution thereof) duly authorized by all necessary corporate action on the part of MAAC. This Agreement has been and each Ancillary Document to which MAAC is or will be a party will be, upon
execution thereof, duly and validly executed and delivered by MAAC and constitutes or will constitute, upon execution thereof, as applicable, a valid, legal and binding agreement of MAAC (assuming this Agreement has been and the Ancillary Documents
to which MAAC is or will be a party are or will be, upon execution thereof, as applicable, duly authorized, executed and delivered by the other Persons party hereto or thereto), enforceable against MAAC in accordance with their terms (subject to
applicable bankruptcy, insolvency, reorganization, moratorium or other Laws affecting generally the enforcement of creditors&#146; rights and subject to general principles of equity). The MAAC Shareholder Approval and the MAAC Sponsor Consent are
the only votes or consents of the holders of any class or series of Equity Securities of MAAC required to approve and adopt this Agreement, the Ancillary Documents to which MAAC is or is contemplated to be a party, the performance of the MAAC&#146;s
obligations hereunder and thereunder and the consummation of the transactions contemplated hereby (including the Merger). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.3</B> <B><U>Consents and Requisite Governmental Approvals; No Violations</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) No consent, approval or authorization of, or designation, declaration or filing with, any Governmental Entity is required on the part of
MAAC with respect to MAAC&#146;s execution, delivery or performance of its obligations under this Agreement or the Ancillary Documents to which it is or will be party or the consummation of the transactions contemplated hereby or thereby, except for
(i)&nbsp;compliance with and filings under the HSR Act and Foreign and Domestic Approval Laws, if applicable, (ii)&nbsp;the filing with the SEC of (A)&nbsp;the Registration Statement / Proxy Statement and the declaration of the effectiveness thereof
by the SEC and (B)&nbsp;such reports under Section&nbsp;13(a) or 15(d) of the Exchange Act as may be required in connection with this Agreement, the Ancillary Documents or the transactions contemplated hereby or thereby, (iii)&nbsp;such filings with
and approvals of Nasdaq to permit the Company Post-Closing Common Shares to be issued in connection with the transactions contemplated by this Agreement and the other Ancillary Documents to be listed on Nasdaq or in order to deregister the MAAC
Shares following the Closing, (iv)&nbsp;the filing of (A)&nbsp;the Certificate of Merger and (B)&nbsp;any filings required under the Companies Act in connection with the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps and the
Merger, (v)&nbsp;the MAAC Shareholder Approval, (vi)&nbsp;the MAAC Sponsor Consent or (vii)&nbsp;any other consents, approvals, authorizations, designations, declarations, waivers or filings, the absence of which would not have a MAAC Material
Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) None of the execution or delivery by MAAC of this Agreement or any Ancillary Document to
which it is or will be a party, the performance by MAAC of its obligations hereunder or thereunder or the consummation by MAAC of the transactions contemplated hereby or thereby will, directly or indirectly (with or without due notice or lapse of
time or both) (i)&nbsp;result in a violation or breach of any provision of the Governing Documents of MAAC, (ii)&nbsp;result in a violation or breach of, or constitute a default or give rise to any right of termination, Consent, cancellation,
amendment, modification, suspension, revocation or acceleration under, any of the terms, conditions or provisions of any material Contract to which MAAC is a party, (iii)&nbsp;violate, or constitute a breach under, any Order or applicable Law to
which MAAC or any of its properties or assets are subject or bound or (iv)&nbsp;result in the creation of any Lien upon any of the assets or properties (other than any Permitted Liens) of MAAC, except in the case of any of
<U>clauses</U><U></U><U>&nbsp;(ii)</U> through <U>(iv)</U>&nbsp;above, as would not have a MAAC Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.4</B> <B><U>Brokers</U></B>. Except for the Persons set forth on <U>Section</U><U></U><U>&nbsp;4.4</U> of the
MAAC Disclosure Schedules, no broker, finder, investment banker or other Person is entitled to any brokerage fee, finders&#146; fee or other commission in connection with the transactions contemplated by this Agreement based upon arrangements made
by or on behalf of MAAC or any of its Affiliates. True and complete copies of the engagement agreements in effect as of the date hereof with the Persons set forth on <U>Section</U><U></U><U>&nbsp;4.4</U> of the MAAC Disclosure Schedules have been
provided to the Company prior to the execution of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.5</B> <B><U>Information
Supplied</U></B>. None of the information supplied or to be supplied by or on behalf of MAAC expressly for inclusion or incorporation by reference&nbsp;prior to the Closing in the Registration Statement / Proxy Statement will, when the Registration
Statement / Proxy Statement is declared effective or when the Registration Statement / Proxy Statement is mailed to the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> MAAC Shareholders or at the time of the MAAC Shareholders Meeting, and in the
case of any amendment thereto, at the time of such amendment, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the
circumstances under which they are made, not misleading; <U>provided</U> that, notwithstanding the foregoing provisions of this <U>Section</U><U></U><U>&nbsp;4.5</U>, no representation or warranty is made by MAAC with respect to any other
information or statements included or incorporated by reference in the Registration Statement / Proxy Statement, including any such information or statements that were supplied by or on behalf of the Company or Merger Sub for use therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.6 <U>Capitalization of </U><U>MAAC</U></B>.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Section</U><U></U><U>&nbsp;4.6(a)</U> of the MAAC Disclosure Schedules sets forth a true and complete statement of the number and class
or series (as applicable) of the issued and outstanding MAAC Shares and the number of issued and outstanding MAAC Warrants, in each case, prior to giving effect to the PIPE Financing, the MAAC Shareholder Redemption and the transactions contemplated
by the Sponsor Support Agreement. All issued and outstanding MAAC Shares have been duly authorized and validly issued and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> All outstanding Equity Securities of MAAC
(i)&nbsp;were not issued in violation of the Governing Documents of MAAC or in violation of any other Contracts to which MAAC is a party or by which it is otherwise bound, and (ii)&nbsp;are not subject to any preemptive rights, call option, right of
first refusal, subscription rights, transfer restrictions or similar rights of any Person (other than transfer restrictions under applicable Securities Laws or under the Governing Documents of MAAC) and were not issued in violation of any preemptive
rights, call option, right of first refusal, subscription rights, transfer restrictions or similar rights of any Person. Except for the MAAC Shares and MAAC Warrants set forth on <U>Section</U><U></U><U>&nbsp;4.6(a)</U> of the MAAC Disclosure
Schedules (assuming that no MAAC Shareholder Redemptions are effected), immediately prior to Closing and before giving effect to the PIPE Financing and the transactions contemplated by the Sponsor Support Agreement, there are no other Equity
Securities of MAAC issued and outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as expressly contemplated by the PIPE Subscription Agreements or as issued, granted
or entered into, as applicable, in accordance with <U>Section</U><U></U><U>&nbsp;5.10</U> there are no outstanding (A)&nbsp;equity appreciation, phantom equity or profit participation rights or (B)&nbsp;options, restricted stock, phantom stock,
warrants, purchase </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rights, subscription rights, conversion rights, exchange rights, calls, puts, rights of first refusal or first offer or other Contracts that could require MAAC to, and there is no obligation to
MAAC to, issue, sell or otherwise cause to become outstanding or to acquire, repurchase or redeem any Equity Securities or securities convertible into or exchangeable for Equity Securities of MAAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Other than as set forth on <U>Section</U><U></U><U>&nbsp;4.6(c)</U> of the MAAC Disclosure Schedule and, except as permitted by
<U>Section</U><U></U><U>&nbsp;5.10(b)</U>, MAAC has no Subsidiaries and does not own or hold, directly or indirectly, any Equity Securities in any Person or the right to acquire any such Equity Security, and MAAC is not a partner, member or similar
participant of or in any partnership, limited liability company or similar business entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) There are no outstanding bonds,
debentures, notes or other indebtedness of MAAC having the right to vote (or convertible into, or exchangeable for, securities having the right to vote) on any matter on which holders of MAAC Shares may vote. There are no voting trusts, proxies or
other Contracts with respect to the voting or transfer of any MAAC&#146;s Equity Securities between MAAC and any other Person. MAAC is not a party to any shareholders agreement or registration rights agreement relating to MAAC Shares or any other
Equity Securities of MAAC. There are no securities issued by or to which MAAC is a party containing anti-dilution or similar provisions that will be triggered by the consummation of the transactions contemplated by this Agreement or the Ancillary
Documents, in each case, that have not been or will not be waived on or prior to the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)
<U>Section</U><U></U><U>&nbsp;4.6(e)</U> of the MAAC Disclosure Schedules sets forth a list of all indebtedness for borrowed money of MAAC as of the date of this Agreement, including the principal amount of such indebtedness, the outstanding balance
as of the date of this Agreement, and the debtor and the creditor thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) All outstanding MAAC Equity Securities have been offered,
sold and issued in compliance with applicable Law, including Securities Laws, in all material respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.7</B> <B><U>SEC Filings</U></B>. MAAC has timely filed or furnished all statements, forms, reports and
documents required to be filed or furnished by it prior to the date of this Agreement with the SEC pursuant to Federal Securities Laws since its initial public offering (collectively, and together with any exhibits and schedules thereto and other
information incorporated therein, and as they have been supplemented, modified or amended since the time of filing, the &#147;<U>MAAC SEC Reports</U>&#148;) and, as of the Closing, will have filed or furnished all other statements, forms, reports
and other documents required to be filed or furnished by it subsequent to the date of this Agreement with the SEC pursuant to Federal Securities Laws through the Closing (collectively, and together with any exhibits and schedules thereto and other
information incorporated therein, and as they have been supplemented, modified or amended since the time of filing, the &#147;<U>Additional MAAC SEC Reports</U>&#148;). Each of the MAAC SEC Reports, as of their respective dates of filing, and as of
the date of any amendment or filing that superseded the initial filing, complied and each of the Additional MAAC SEC Reports, as of their respective dates of filing, and as of the date of any amendment or filing that superseded the initial filing,
will comply, in all material respects with the applicable requirements of the Federal Securities Laws (including, as applicable, the Sarbanes-Oxley Act and any rules and regulations promulgated thereunder) applicable to the MAAC SEC Reports or the
Additional MAAC SEC Reports (for purposes of the Additional MAAC SEC Reports, assuming that all information supplied by or on behalf of Group Companies or the Company Shareholders expressly for inclusion or incorporation by reference therein, if
any, is true and correct in all material respects). As of their respective dates of filing, and as of the date of any amendment or filing that superseded the initial filing, the MAAC SEC Reports and the Additional MAAC SEC Reports did not contain
any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made or will be made, as applicable, not
misleading (for purposes of the Additional MAAC SEC Reports, assuming that all information supplied by or on behalf of Group Companies or the Company Shareholders expressly for inclusion or incorporation by reference therein, if any, is true and
correct in all material respects). As of the date of this Agreement, there are no outstanding or unresolved comments in comment letters received from the SEC with respect to the MAAC SEC Reports. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.8</B> <B><U>Trust Account</U></B>. As of the date of this
Agreement, MAAC has an amount in cash in the Trust Account equal to at least $410,794,357.31. The funds held in the Trust Account are (a)&nbsp;invested in United States &#147;government securities&#148; within the meaning of Section&nbsp;2(a)(16) of
the Investment Company Act, having a maturity of one hundred eight-five (185)&nbsp;days or less or in money market funds meeting certain conditions under Rule <FONT STYLE="white-space:nowrap">2a-7</FONT> promulgated under the Investment Company Act
which invest only in direct U.S. government treasury obligations and (b)&nbsp;held in trust pursuant to that certain Investment Management Trust Agreement, dated October&nbsp;6, 2020 (the &#147;<U>Trust Agreement</U>&#148;), between MAAC and
Continental Stock Transfer&nbsp;&amp; Trust Company, as trustee (the &#147;<U>Trustee</U>&#148;). There are no separate agreements, side letters or other agreements or understandings (whether written or unwritten, express or implied) that would
cause the description of the Trust Agreement in the MAAC SEC Reports to be inaccurate in any material respect or, to MAAC&#146;s knowledge, that would entitle any Person to any portion of the funds in the Trust Account (other than (i)&nbsp;in
respect of deferred underwriting commissions or Taxes, (ii)&nbsp;the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> MAAC Shareholders who shall have elected to redeem their MAAC Class&nbsp;A Shares pursuant to the Governing Documents of MAAC or
(iii)&nbsp;if MAAC fails to complete a business combination within the allotted time period set forth in the Governing Documents of MAAC and liquidates the Trust Account, subject to the terms of the Trust Agreement, MAAC (in limited amounts to
permit MAAC to pay the expenses of the Trust Account&#146;s liquidation, dissolution and winding up of MAAC) and then the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> MAAC Shareholders). Prior to the Closing, none of the funds held in the
Trust Account are permitted to be released, except in the circumstances described in the Governing Documents of MAAC and the Trust Agreement. As of the date of this Agreement, MAAC is not in material default, or delinquent in performance in any
material respect in connection with the Trust Agreement, and, to MAAC&#146;s knowledge, as of the date hereof, no event has occurred which (with due notice or lapse of time or both) would constitute a material default under the Trust Agreement. As
of the date of this Agreement, there are no Proceedings pending with respect to the Trust Account. Since October&nbsp;6, 2020, MAAC has not released any money from the Trust Account (other than interest income earned on the funds held in the Trust
Account as permitted by the Trust Agreement). Upon the consummation of the transactions contemplated hereby (including the distribution of assets from the Trust Account (A)&nbsp;in respect of deferred underwriting commissions or Taxes or (B)&nbsp;to
the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> MAAC Shareholders who have elected to redeem their MAAC Class&nbsp;A Shares pursuant to the Governing Documents of MAAC, each in accordance with the terms of and as set forth in the Trust
Agreement), MAAC shall have no further obligation under either the Trust Agreement or the Governing Documents of MAAC to liquidate or distribute any assets held in the Trust Account, and the Trust Agreement shall terminate in accordance with its
terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.9</B> <B><U>No MAAC Material Adverse Effect</U></B>. During the period beginning on July&nbsp;6,
2020 and ending on the date of this Agreement, no MAAC Material Adverse Effect has occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.10</B>
<B><U>Material Contracts</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Section</U><U></U><U>&nbsp;4.10(a)</U> of the MAAC Disclosure Schedules sets forth a list of all
material Contracts (other than, for the avoidance of doubt, confidentiality, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> or other similar agreements) to which MAAC is a party or by which any of its assets is bound as of the date hereof.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as would not have a MAAC Material Adverse Effect, each Contract of a type required to be listed on
<U>Section</U><U></U><U>&nbsp;4.10(a)</U> of the MAAC Disclosure Schedules (together with (x)&nbsp;each Contract entered into after the date of this Agreement that would be required to be set forth on <U>Section</U><U></U><U>&nbsp;4.10(a)</U> of the
MAAC Disclosure Schedules if entered into prior to the execution and delivery of this Agreement and (y)&nbsp;each &#147;material contract&#148; (as such term is defined in Item 601(b)(10) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> of
the SEC), each, a &#147;<U>MAAC Material Contract</U>&#148;), (i) is valid and binding on MAAC and, to MAAC&#146;s knowledge, the counterparties thereto, and is in full force and effect and enforceable in accordance with its terms against MAAC and,
to MAAC&#146;s knowledge, the counterparties thereto (subject to applicable bankruptcy, insolvency, reorganization, moratorium or other Laws affecting generally the enforcement of creditors&#146; rights and subject to general principles of equity),
(ii) MAAC and, to MAAC&#146;s knowledge, the counterparties thereto are not in material breach of, or default under, any MAAC Material Contract and (iii)&nbsp;no event has occurred that (with or without due notice or lapse of time or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
both) would result in a material breach of, or default under, any MAAC Material Contract by MAAC or, to MAAC&#146;s knowledge, the counterparties thereto. MAAC has made available to the Company
true and complete copies of all MAAC Material Contracts in effect as of the date hereof (it being understood and agreed, for the avoidance of doubt, that each MAAC Material Contract set forth in any MAAC SEC Report that is publicly available as of
the date hereof shall be deemed to have been made available to the Company pursuant to this sentence). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.11</B> <B><U>Transactions with Affiliates</U></B>. <U>Section</U><U></U><U>&nbsp;4.11</U> of the MAAC
Disclosure Schedules sets forth all Contracts between (a)&nbsp;MAAC, on the one hand, and (b)&nbsp;any officer, director, employee, partner, member, manager, direct or indirect equityholder (including the MAAC Sponsor) or Affiliate of MAAC<U> </U>or
the MAAC Sponsor or any family member of the same household of the foregoing Persons, on the other hand (each Person identified in this <U>clause</U><U></U><U>&nbsp;(b)</U>, a &#147;<U>MAAC Related Party</U>&#148;), other than (i)&nbsp;Contracts
with respect to or otherwise related to a MAAC Related Party&#146;s employment with, or the provision of services to, MAAC (including benefit plans, indemnification arrangements and other ordinary course compensation), (ii) Contracts entered into
after the date of this Agreement that are either permitted pursuant to <U>Section</U><U></U><U>&nbsp;5.10</U> or entered into in accordance with <U>Section</U><U></U><U>&nbsp;5.10</U>, (iii) Contracts with respect to a MAAC equityholder&#146;s
status as an equityholder of MAAC and (iv)&nbsp;customary director and officer indemnification agreements that have been made available to the Company. No MAAC<U> </U>Related Party (A)&nbsp;owns any interest in any material asset or property used in
the business of MAAC or (B)&nbsp;possesses, directly or indirectly, any material financial interest in, or is a director or executive officer of, any Person which is a material client, supplier, vendor, partner, customer or lessor, or other material
business relation, of MAAC. All Contracts, arrangements, understandings, interests and other matters that are required to be disclosed pursuant to this <U>Section</U><U></U><U>&nbsp;4.11</U> (including, for the avoidance of doubt, pursuant to the
second sentence of this <U>Section</U><U></U><U>&nbsp;4.11</U>) are referred to herein as &#147;<U>MAAC Related Party Transactions</U>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.12</B> <B><U>Litigation</U></B>. As of the date of this Agreement, there is (and since its organization,
incorporation or formation, as applicable, there has been) no Proceeding pending or, to MAAC&#146;s knowledge, threatened against MAAC that, if adversely decided or resolved, would be material to MAAC. As of the date of this Agreement, neither MAAC
nor any of its respective properties or assets is subject to any Order. As of the date of this Agreement, there are (and since July 6, 2020 through the date of this Agreement, there have been no) no material Proceedings by MAAC pending against any
other Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.13</B> <B><U>Compliance with Applicable Law</U></B>. (a)&nbsp;MAAC is (and since its
organization, incorporation or formation, as applicable, has been) in compliance with all applicable Laws and (b)&nbsp;as of the date hereof, has not received any written communications or, to MAAC&#146;s knowledge, any other communications from or
on behalf of a Governmental Entity that alleges that MAAC is not in compliance with any applicable Law or Order, except in each case of <U>clauses</U><U></U><U>&nbsp;(a)</U> and <U>(b)</U>, as has not had, and would not reasonably be expected to
have, a MAAC Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.14</B> <B><U>MAAC</U></B><B><U>&#146;</U></B><B><U>s Business
Activities</U></B>. Since its incorporation, MAAC has not conducted any business activities other than activities (i)&nbsp;in connection with or incident or related to its incorporation or continuing corporate (or similar) existence,
(ii)&nbsp;directed toward the accomplishment of a business combination, including those incident or related to or incurred in connection with the negotiation, preparation or execution of this Agreement or any Ancillary Documents, the performance of
its covenants or agreements in this Agreement or any Ancillary Document or the consummation of the transactions contemplated hereby or thereby or (iii)&nbsp;those that are administrative, ministerial or otherwise immaterial in nature. Except for
this Agreement or the Ancillary Documents or as set forth in MAAC&#146;s Governing Documents, there is no Contract binding upon MAAC or to which MAAC is party which has or would reasonably be expected to have the effect of prohibiting or materially
impairing any business practice of it or its Affiliates, any acquisition of property by it or its Affiliates or the conduct of business by it or its Affiliates (including, in each case, following the Closing). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.15</B> <B><U>Internal Controls; Listing; Financial
Statements</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as is not required in reliance on exemptions from various reporting requirements by virtue of MAAC&#146;s
status as an &#147;emerging growth company&#148; within the meaning of the Securities Act, as modified by the JOBS Act, or &#147;smaller reporting company&#148; within the meaning of the Exchange Act,&nbsp;since its initial public offering,
(i)&nbsp;MAAC has established and maintained a system of internal controls over financial reporting (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> and Rule <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act)
sufficient to provide reasonable assurance regarding the reliability of MAAC&#146;s financial reporting and the preparation of MAAC&#146;s financial statements for external purposes in accordance with GAAP and (ii)&nbsp;MAAC has established and
maintained disclosure controls and procedures (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> and Rule <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act) designed to ensure that material information relating to
MAAC is made known to MAAC&#146;s principal executive officer and principal financial officer by others within MAAC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) MAAC has not
taken any action prohibited by Section&nbsp;402 of the Sarbanes-Oxley Act. There are no outstanding loans or other extensions of credit made by MAAC to any executive officer (as defined in Rule <FONT STYLE="white-space:nowrap">3b-7</FONT> under the
Exchange Act) or director of MAAC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Since its initial public offering, MAAC has complied in all material respects with all applicable
listing and corporate governance rules and regulations of Nasdaq. The classes of securities representing issued and outstanding MAAC Class&nbsp;A Shares are registered pursuant to Section&nbsp;12(b) of the Exchange Act and are listed for trading on
Nasdaq. As of the date of this Agreement, there is no Proceeding pending or, to MAAC&#146;s knowledge, threatened against MAAC by Nasdaq or the SEC with respect to any intention by such entity to deregister MAAC Class&nbsp;A Shares or prohibit or
terminate the listing of MAAC Class&nbsp;A Shares on Nasdaq. As of the date hereof, MAAC has not taken any action that is designed to terminate the registration of MAAC Class&nbsp;A Shares under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The MAAC SEC Reports contain true and complete copies of the applicable MAAC Financial Statements. The MAAC Financial Statements
(i)&nbsp;fairly present in all material respects the financial position of MAAC as at the respective dates thereof, and the results of its operations, shareholders&#146; equity and cash flows for the respective periods then ended (subject, in the
case of any unaudited interim financial statements, to normal <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments (none of which is expected to be material) and the absence of notes thereto), (ii)&nbsp;were prepared in conformity with
GAAP applied on a consistent basis during the periods indicated (except, in the case of any audited financial statements, as may be indicated in the notes thereto and subject, in the case of any unaudited financial statements, to normal <FONT
STYLE="white-space:nowrap">year-end</FONT> audit adjustments (none of which is expected to be material) and the absence of notes thereto), (iii) in the case of the audited MAAC Financial Statements, were audited in accordance with the standards of
the PCAOB and (iv)&nbsp;comply in all material respects with the applicable accounting requirements and with the rules and regulations of the SEC, the Exchange Act and the Securities Act in effect as of the respective dates thereof (including
Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> or Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> as applicable). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)
MAAC has established and maintains systems of internal accounting controls that are designed to provide, in all material respects, reasonable assurance that (i)&nbsp;all transactions are executed in accordance with management&#146;s authorization
and (ii)&nbsp;all transactions are recorded as necessary to permit preparation of proper and accurate financial statements in accordance with GAAP and to maintain accountability for MAAC&#146;s and its Subsidiaries&#146; assets. MAAC maintains and,
for all periods covered by the MAAC Financial Statements, has maintained books and records of MAAC in the ordinary course of business that are accurate and complete and reflect the revenues, expenses, assets and liabilities of MAAC in all material
respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Since its incorporation, MAAC has not received any written complaint, allegation, assertion or claim that there is
(i)&nbsp;a &#147;significant deficiency&#148; in the internal controls over financial reporting of MAAC, (ii)&nbsp;a &#147;material weakness&#148; in the internal controls over financial reporting of MAAC or (iii)&nbsp;fraud, whether or not
material, that involves management or other employees of MAAC who have a significant role in the internal controls over financial reporting of MAAC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.16</B> <B><U>No Undisclosed Liabilities</U></B>. Except for
the Liabilities (a)&nbsp;set forth in <U>Section</U><U></U><U>&nbsp;4.16</U> of the MAAC Disclosure Schedules, (b)&nbsp;incurred in connection with the negotiation, preparation or execution of this Agreement or any Ancillary Document, the
performance of its covenants or agreements in this Agreement or any Ancillary Document or the consummation of the transactions contemplated hereby or thereby (including, for the avoidance of doubt, the MAAC Expenses and any Liabilities arising out
of, or related to, any Proceeding related to this Agreement, the Ancillary Documents or the transactions contemplated hereby or thereby, including any shareholder demand or other shareholder Proceedings (including derivative claims) arising out of,
or related to, any of the foregoing) (it being understood and agreed that the expected third parties that are, as of the date hereof, entitled to fees, expenses or other payments in connection with the matters described in this <U>clause
(b)</U><U></U> shall be set forth on <U>Section 4.16</U> of the MAAC Disclosure Schedules), (c) set forth or disclosed in the MAAC Financial Statements included in the MAAC SEC Reports, (d)&nbsp;that have arisen since the date of the most recent
balance sheet included in the MAAC SEC Reports and either are incurred in the ordinary course of business or immaterial and incurred in connection with activities that are administrative or ministerial in nature, (e)&nbsp;that are either permitted
pursuant to <U>Section</U><U></U><U>&nbsp;5.10</U> or incurred in accordance with <U>Section</U><U></U><U>&nbsp;5.10</U> or (f)&nbsp;that would not have a MAAC Material Adverse Effect, MAAC does not have any Liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.17</B> <B><U>Employees</U></B>. Except as set forth on <U>Section</U><U></U><U>&nbsp;4.17</U> of the MAAC
Disclosure Schedules, and other than any executive officers or directors as described in the MAAC SEC Reports, as of the date of this Agreement, (a)<U></U> MAAC has never employed any employees or retained any independent contractors, consultants or
other individual service providers and (b)<U></U> MAAC has never maintained, sponsored, contributed to or had any direct or indirect Liability under, and does not currently maintain, sponsor, contribute to or have any direct or indirect Liability
under, any &#147;employee benefit plan<U>&#148;</U> (as such term is defined in Section<U></U> 3(3) of ERISA, whether or not subject to ERISA), equity or equity-based, deferred compensation, severance, retention, bonus, incentive, retirement,
retiree or post-employment welfare, vacation, and other benefit or compensatory plan, program, policy or Contract. MAAC has no obligations to indemnify, reimburse, make-whole or <FONT STYLE="white-space:nowrap">&#147;gross-up&#148;</FONT> any person
for any Tax or related interest or penalties incurred by such person imposed under Section&nbsp;4999 or 409A of the Code. To MAAC&#146;s knowledge, as of the date of this Agreement, there are no unresolved allegations of sexual harassment, or other
discrimination or retaliation against any executive officer or director of MAAC (in his or her capacity as such) that, if known to the public, would bring MAAC into material disrepute. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.18</B> <B><U>Tax Matters</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) MAAC has prepared and filed all material Tax Returns required to have been filed by or with respect to it, all such Tax Returns are true
and complete in all material respects, and MAAC has paid all material Taxes required to have been paid by or with respect to it regardless of whether shown on any Tax Return. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) MAAC has timely withheld and paid to the appropriate Tax Authority all material amounts required to have been withheld and paid in
connection with amounts paid or owing to any employee, independent contractor, other service provider, equity interest holder, creditor or other <FONT STYLE="white-space:nowrap">third-party.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) MAAC is not currently the subject of a Tax audit or examination and has not been informed in writing of the commencement or anticipated
commencement of any Tax audit or examination that has not been resolved or completed, in each case, with respect to material Taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)
MAAC has not consented to extend or waive the time in which any material Tax may be assessed or collected by any Tax Authority, other than any such extensions or waivers that are no longer in effect or that were extensions of time to file Tax
Returns obtained in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) No &#147;closing agreement&#148; as described in Section&nbsp;7121 of the Code
(or any corresponding or similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> income Tax Law), private letter rulings, technical advice memoranda or similar agreements or rulings have been entered into or issued by
any Tax Authority to MAAC, which agreement or ruling would be effective after the Closing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) MAAC is not nor has it ever been a party to any &#147;listed transaction&#148; as
defined in Section&nbsp;6707A of the Code and Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.6011-4</FONT> (or any corresponding or similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Tax Law).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) There are no Liens for material Taxes on any assets of MAAC other than Liens described in <U>clause (b)</U>&nbsp;of the definition of
Permitted Liens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Beginning on the date of its incorporation and though the date of this Agreement, MAAC was not a distributing
corporation or a controlled corporation in a transaction purported or intended to be governed by Section&nbsp;355 of the Code (or so much of Section&nbsp;356 of the Code as relates to Section&nbsp;355 of the Code). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) MAAC (i)&nbsp;has not been a member of an affiliated group filing a consolidated U.S. federal income Tax Return (other than a group the
common parent of which was MAAC) and (ii)&nbsp;does not have any material Liability for the Taxes of any Person (other than MAAC) under Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.1502-6</FONT> (or any corresponding or
similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Tax Law), as a transferee or successor or by Contract (other than any customary indemnification provisions contained in any commercial Contract entered into in the
ordinary course of business and the principal purpose of which does not relate to Taxes). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) No written claims have ever been made by
any Tax Authority in a jurisdiction where MAAC does not file Tax Returns that MAAC is or may be subject to taxation by, or required to file a Tax Return with, that jurisdiction, which claims have not been resolved or withdrawn. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) MAAC is not a party to any Tax allocation, Tax sharing or Tax indemnity or similar agreements (other than any customary commercial
Contract entered into in the ordinary course of business and the principal purpose of which does not relate to Taxes). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) MAAC is not
aware of any fact or circumstance and has not taken or agreed to take any action not contemplated by this Agreement and/or any Ancillary Documents that could reasonably be expected to prevent, impair or impede the Merger from qualifying for the
Intended Tax Treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) Notwithstanding anything to the contrary in this Agreement, <U>Section</U><U></U><U>&nbsp;4.15(d)</U>
(Internal Controls; Listing; Financial Statements), <U>Section</U><U></U><U>&nbsp;4.16</U> (No Undisclosed Liabilities), Section<U></U> 4.17 (Employees) and <U>Section</U><U></U><U>&nbsp;4.18</U> (Tax Matters) contains the sole representations and
warranties of MAAC concerning Taxes. Notwithstanding any representation or warranty in this Agreement (including the representations and warranties set forth in this <U>Section</U><U></U><U>&nbsp;4.18</U> (Tax Matters)), no representation or
warranty is being made as to the use or availability of any Tax attribute or credit of MAAC in any taxable period (or portion thereof) beginning on the day immediately after the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.19</B> <B><U>Certain Business Practices</U></B>. Except as would not have a MAAC Material Adverse Effect: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) None of MAAC, any of its respective officers, directors or employees or, to MAAC&#146;s knowledge, any of its other Representatives, or
any other Persons acting for or on behalf of any of the foregoing,&nbsp;since July&nbsp;6, 2020, (i) has been a Sanctioned Person, (ii)&nbsp;has transacted any business with or for the direct or knowing indirect benefit of any Sanctioned Person in
violation of applicable Sanctions or (iii)&nbsp;has otherwise violated any applicable Sanctions, <FONT STYLE="white-space:nowrap">Ex-Im</FONT> Laws, or anti-boycott Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) None of MAAC, any of its respective officers, directors or employees or, to MAAC&#146;s knowledge, any of its other Representatives, or
any other Persons acting for or on behalf of any of the foregoing,&nbsp;since July&nbsp;6, 2020, (i) made, offered, promised, paid or received any unlawful bribes, kickbacks or other similar payments to or from any Person, (ii)&nbsp;made or paid any
contributions, directly or indirectly, to a domestic or foreign political party or candidate for any improper purpose or (iii)&nbsp;otherwise made, offered, received, authorized, promised or paid any improper payment in violation of any
Anti-Corruption Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To MAAC&#146;s knowledge, MAAC has not, since July&nbsp;6, 2020, been the subject of any
allegation, voluntary disclosure, investigation, prosecution or enforcement action related to any Anti-Corruption Laws, Sanctions, or <FONT STYLE="white-space:nowrap">Ex-Im</FONT> Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.20</B> <B><U>PIPE Financing</U></B>. MAAC has delivered to the Company a true and complete copy of the fully
executed PIPE Subscription Agreements as in effect as of the date hereof (the&nbsp;&#147;<U>Disclosed Subscription Agreements</U>&#148;), each of which is substantially in the form attached hereto as <U>Exhibit A</U>, pursuant to which the PIPE
Investors have collectively committed, on the terms and subject to the conditions therein, to purchase an aggregate of 20,000,000 MAAC Shares for $10.00 per share. Each of the PIPE Subscription Agreements is, as of the date hereof, in full force and
effect (assuming, with respect to each PIPE Investor, that each such PIPE Subscription Agreement has been duly authorized, executed and delivered by each applicable PIPE Investor), and as of the date hereof, none of the PIPE Subscription Agreements
has been withdrawn, rescinded or terminated or otherwise amended or modified in any respect, and, to MAAC&#146;s knowledge, no such amendment or modification is contemplated as of the date hereof. Except as has not and would not reasonably be
expected to cause any of the conditions to a PIPE Investor&#146;s obligation to purchase MAAC Shares under the applicable PIPE Subscription Agreement to not be satisfied, as of the date hereof, MAAC is not in breach of any of the representations or
warranties of MAAC or terms or conditions set forth in any of the PIPE Subscription Agreements. As of the date hereof, no event has occurred which, with or without notice, lapse of time or both, would reasonably be expected to constitute a material
breach, default or failure to satisfy any condition precedent to a PIPE Investor&#146;s obligation to purchase MAAC Shares set forth therein (assuming the accuracy of the representations and warranties of the Company set forth in this Agreement and,
with respect to each PIPE Investor, the accuracy of the representations and warranties of such PIPE Investor set forth in the applicable PIPE Subscription Agreement). As of the date hereof, assuming the accuracy of the representations and warranties
contained in <U>Article</U><U></U><U>&nbsp;3</U> in all material respects and, with respect to each PIPE Investor, the representations and warranties of such PIPE Investor in the applicable PIPE Subscription Agreement in all material respects, the
performance by the Company of its covenants, agreements and obligations to be performed at or prior to the Closing hereunder in all material respects and, with respect to each PIPE Investor, the performance by such PIPE Investor of its covenants,
agreements and obligations under the applicable PIPE Subscription Agreement in all material respects, MAAC (i)&nbsp;has no knowledge that any event has occurred that (with or without notice or lapse of time, or both) would constitute a material
breach or default under any of the PIPE Subscription Agreements, (ii)&nbsp;has no knowledge of any fact, event or other occurrence that makes any of the representations or warranties of MAAC in any of the PIPE Subscription Agreements inaccurate in
any material respect and (iii)&nbsp;has no knowledge that any of the conditions to the consummation of the transactions contemplated by the PIPE Subscription Agreements will not be satisfied when required thereunder or that the transaction proceeds
contemplated by the PIPE Subscription Agreements will not be made available when required thereunder. As of the date of this Agreement, no PIPE Investor has notified MAAC in writing of its intention to terminate all or any portion of the
Subscription Amount (as defined in the PIPE Subscription Agreements) or not provide the financing contemplated thereunder. Other than as set forth in the PIPE Subscription Agreements delivered to the Company in connection with the execution of this
Agreement, (A)&nbsp;there are no conditions precedent or contingencies to the obligations of the parties under the PIPE Subscription Agreements to make the full amount of the PIPE Financing available to MAAC on the terms therein, and (B)&nbsp;to the
knowledge of MAAC, there are no side letters or other agreements, understandings, contracts or arrangements (written, oral or otherwise) related to the PIPE Subscription Agreements or the PIPE Financing, other than those entered into with the
placement agents of the PIPE Financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.21</B> <B><U>Investigation; No Other Representations</U></B>. In
entering into this Agreement and the Ancillary Documents to which it is or will be a party, MAAC has relied solely on its own investigation and analysis and the representations and warranties expressly set forth in
<U>Article</U><U></U><U>&nbsp;3</U> and in the Ancillary Documents to which it is or will be a party and no other representations or warranties of the Company, any Company <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate or any other
Person, either express or implied. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.22</B> <B><U>EXCLUSIVITY OF REPRESENTATIONS AND
WARRANTIES</U></B>. NOTWITHSTANDING THE DELIVERY OR DISCLOSURE TO MAAC, THE MAAC SPONSOR OR ANY OF THEIR RESPECTIVE REPRESENTATIVES OF ANY DOCUMENTATION OR OTHER INFORMATION (INCLUDING ANY FINANCIAL PROJECTIONS OR OTHER SUPPLEMENTAL DATA), EXCEPT AS
OTHERWISE EXPRESSLY SET FORTH IN <U>ARTICLE</U><U></U><U>&nbsp;3</U> OR THE ANCILLARY DOCUMENTS TO WHICH IT OR THE MAAC SPONSOR, AS APPLICABLE, IS OR WILL BE A PARTY, NONE OF THE COMPANY, MERGER SUB, ANY COMPANY
<FONT STYLE="white-space:nowrap">NON-PARTY</FONT> AFFILIATE, ANY COMPANY SHAREHOLDER OR ANY OTHER PERSON MAKES, AND MAAC EXPRESSLY DISCLAIMS, ON BEHALF OF ITSELF, THE MAAC SPONSOR AND THEIR RESPECTIVE REPRESENTATIVES, ANY REPRESENTATIONS OR
WARRANTIES OF ANY KIND OR NATURE, EXPRESS OR IMPLIED, IN CONNECTION WITH THIS AGREEMENT, THE ANCILLARY DOCUMENTS OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY, INCLUDING AS TO THE MATERIALS RELATING TO THE BUSINESS AND AFFAIRS OR
HOLDINGS OF THE GROUP COMPANIES THAT HAVE BEEN MADE AVAILABLE TO MAAC, THE MAAC SPONSOR OR ANY OF THEIR RESPECTIVE REPRESENTATIVES OR IN ANY PRESENTATION OF THE BUSINESS AND AFFAIRS OF THE GROUP COMPANIES BY OR ON BEHALF OF THE MANAGEMENT OF THE
GROUP COMPANIES OR OTHERS IN CONNECTION WITH THE TRANSACTIONS CONTEMPLATED HEREBY OR BY THE ANCILLARY DOCUMENTS, AND NO STATEMENT CONTAINED IN ANY OF SUCH MATERIALS OR MADE IN ANY SUCH PRESENTATION SHALL BE DEEMED A REPRESENTATION OR WARRANTY
HEREUNDER OR OTHERWISE OR DEEMED TO BE RELIED UPON BY MAAC, THE MAAC SPONSOR, ANY MAAC <FONT STYLE="white-space:nowrap">NON-PARTY</FONT> AFFILIATE OR ANY OF THEIR RESPECTIVE REPRESENTATIVES IN EXECUTING, DELIVERING OR PERFORMING THIS AGREEMENT, THE
ANCILLARY DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. IT IS UNDERSTOOD THAT ANY COST ESTIMATES, PROJECTIONS OR OTHER PREDICTIONS, ANY DATA OR ANY MEMORANDA OR OFFERING MATERIALS OR PRESENTATIONS, INCLUDING ANY OFFERING MEMORANDUM
OR SIMILAR MATERIALS MADE AVAILABLE BY OR ON BEHALF OF ANY OF THE GROUP COMPANIES OR MERGER SUB ARE NOT AND SHALL NOT BE DEEMED TO BE OR TO INCLUDE REPRESENTATIONS OR WARRANTIES OF THE COMPANY, MERGER SUB OR ANY COMPANY <FONT
STYLE="white-space:nowrap">NON-PARTY</FONT> AFFILIATE, AND ARE NOT AND SHALL NOT BE DEEMED TO BE RELIED UPON BY MAAC, THE MAAC SPONSOR, ANY MAAC <FONT STYLE="white-space:nowrap">NON-PARTY</FONT> AFFILIATE OR ANY OF THEIR REPRESENTATIVES IN
EXECUTING, DELIVERING OR PERFORMING THIS AGREEMENT, THE ANCILLARY DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;5 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COVENANTS<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.1</B> <B><U>Conduct of Business of the Group Companies</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to <U>Section</U><U></U><U>&nbsp;5.1(c)</U>, from and after the date of this Agreement until the earlier of the Closing or the
termination of this Agreement in accordance with its terms, the Company shall, and the Company shall cause the other Private Group Companies to, except as expressly contemplated by this Agreement or any Ancillary Document, as required by applicable
Law, as set forth on <U>Section</U><U></U><U>&nbsp;5.1(a)</U> of the Company Disclosure Schedules, or as consented to in writing by MAAC (such consent not to be unreasonably withheld, conditioned or delayed), use commercially reasonable efforts to
(i)&nbsp;operate the Private Group Companies in the ordinary course of business in all material respects and (ii)&nbsp;maintain and preserve intact in all material respects the business organization, assets, properties and material business
relations of the Private Group Companies, taken as a whole; <U>provided</U> that taking any action that is permitted by an exception to <U>Section</U><U></U><U>&nbsp;5.1(b)</U> (including, for the avoidance of doubt, any exceptions in
<U>Section</U><U></U><U>&nbsp;5.1(b)</U> of the Company Disclosure Schedules) shall be deemed to not be a breach of this <U>Section</U><U></U><U>&nbsp;5.1(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Without limiting the generality of the foregoing, and subject to <U>Section</U><U></U><U>&nbsp;5.1(c)</U>, from and after the date of this
Agreement until the earlier of the Closing or the termination of this Agreement in accordance with its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
terms, the Company shall and shall cause the other Private Group Companies to, except as expressly contemplated by this Agreement or any Ancillary Document, as required by applicable Law, as set
forth on <U>Section</U><U></U><U>&nbsp;5.1(b)</U> of the Company Disclosure Schedules or as consented to in writing by MAAC (such consent not to be unreasonably withheld, conditioned or delayed), not do any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) declare, set aside, make or pay a dividend on, or make any other distribution or payment in respect of, any Equity Securities of the
Company or repurchase, redeem or otherwise acquire any outstanding Equity Securities of the Company, other than repurchases, redemptions or other acquisitions of Equity Securities as required by or, in the case of any employees of the Group
Companies following termination of his or her employment, permitted by the terms of the Contracts and Company Equity Plans that have been made available to MAAC and that are in effect on the date of this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) (A) merge, consolidate, combine or amalgamate the Company with any Person, or (B)&nbsp;purchase or otherwise acquire (whether by merging
or consolidating with, purchasing any Equity Security in or a substantial portion of the assets of, or by any other manner) any corporation, partnership, association or other business entity or organization or division thereof, except, in the case
of this <U>clause (B)</U>&nbsp;for any such transaction that would not be material to the business of all of the Group Companies, taken as a whole; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) adopt any amendments, supplements, restatements or modifications to the Company&#146;s Governing Documents or the Company Shareholders
Agreements that are material and adverse to the holders of MAAC Shares or that would adversely affect the ability of the Company to perform, or otherwise comply with, any of its covenants, agreements or obligations under this Agreement or any
Ancillary Document or any Company Shareholder to perform, or otherwise comply with, any of its covenants, agreements or obligations under the Transaction Support Agreements; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) other than in the ordinary course of business or pursuant to a Contract that is in effect as of the date hereof, (A)&nbsp;sell, assign,
abandon, lease, exclusively license or otherwise dispose (other than through an issuance or sale of Equity Securities of a Private Group Company other than the Company) of any assets or properties of the Private Group Companies that are material to
the business of all of the Group Companies, taken as a whole or (B)&nbsp;create, subject or incur any Lien (other than any Permitted Liens) on any assets or properties of the Private Group Companies that are material to the business of all of the
Group Companies, taken as a whole; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) issue or grant any equity incentive awards of any Private Group Company, other than (1)&nbsp;the
grant or issuance of any such equity incentive awards by any Private Group Company to any employees, officers, directors or other services providers in the ordinary course of business and consistent with past valuation practices pursuant to any
equity incentive plan in effect as of the date hereof up to the maximum number of shares reserved for issuance thereunder as of the date hereof, (2)&nbsp;the issuance by any Private Group Company of any of its Equity Securities upon the exercise or
settlement of, as applicable, any equity incentive awards outstanding as of the date of this Agreement (or otherwise permitted to be granted or issued hereunder) in accordance with the terms of the applicable equity incentive plan and the underlying
grant, award or similar agreement, (3)&nbsp;the grant or issuance by any Private Group Company of any of its Equity Securities pursuant to offer letters or similar Contracts with service providers entered into in the ordinary course of business and
consistent with past valuation practices and (4)&nbsp;the grant or issuance by any Private Group Company of any of its Equity Securities to any employees, officers, directors or other services providers, which grant or issuance is approved by the
board of directors (or similar governing body) of such Private Group Company, is consistent with past valuation practices and is made pursuant to any equity incentive plan in effect as of the date hereof up to the maximum number of shares reserved
for issuance thereunder as of the date hereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) issue or grant any Equity Securities (other than as permitted by
<U>Section</U><U></U><U>&nbsp;5.1(b)(v)</U>) of any Private Group Company, other than (1)&nbsp;in the case of an issuance of Equity Securities of the Company, the issuance of Equity Securities consistent with past valuation practices that represent
less than one percent (1.0%) of the issued and outstanding Equity Securities of the Company as of the date hereof, (2)&nbsp;in the case of an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issuance of Equity Securities of any Private Group Company other than the Company, if such issuance is to any Person (other than a Company Related Party) and would not be material to the business
of, or material in amount to, all of the Group Companies, taken as a whole, (3)&nbsp;Equity Securities issued pursuant to offer letters or similar Contracts in effect as of the date hereof with service providers entered into in the ordinary course
of business or pursuant to offer letters or similar Contracts entered into after the date hereof with service providers in the ordinary course of business that are not Designated Individuals or Affiliated Shareholders, (4)&nbsp;Equity Securities
granted or issued to any Person as required under any Contract to which the Private Group Companies are party as of the date of this Agreement (on the terms of such Contract as they exist as of the date of this Agreement) and (5)&nbsp;Equity
Securities issued to a Group Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) incur, create or assume any indebtedness for borrowed money to a third party in excess of
$200&nbsp;million in the aggregate; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) (A) enter into, or amend or modify in any manner that would be adverse to the MAAC
Shareholders in any material respect following the Closing (including, for the avoidance of doubt, by reason of any additional payments or consideration that occur prior to the Closing) or that would adversely affect the ability of the Company to
perform, or otherwise comply with, any of its covenants, agreements or obligations under this Agreement or any Ancillary Document, any Contract required to be or that, if existing on the date hereof, would be required to be, disclosed on
<U>Section</U><U></U><U>&nbsp;3.20</U> of the Company Disclosure Schedules or (B)&nbsp;consummate any other transaction or make any other payments that, if reflected in a Contract and existing on the date hereof, would be required to be disclosed on
disclosed on <U>Section</U><U></U><U>&nbsp;3.20</U> of the Company Disclosure Schedules; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) except (A)&nbsp;as set forth on
<U>Section</U><U></U><U>&nbsp;5.1(b)(ix)</U> of the Company Disclosure Schedules or (B)&nbsp;as approved by the board of directors (or similar governing body) of the applicable Private Group Company in an aggregate amount not to exceed
$10&nbsp;million, enter into or provide for, or amend or modify in a manner that would result in material additional payments or other amounts under (either individually or in the aggregate), any retention, transaction bonus or other similar
payments or amounts (other than, for the avoidance of doubt, the grant or issuance of any Equity Securities of any Private Company permitted by <U>Section</U><U></U><U>&nbsp;5.1(b)(v)</U> or <U>Section</U><U></U><U>&nbsp;5.1(b)(vi)</U>) to any
Person that would (either alone or combined with one or more additional circumstances, matters or events) become payable as a result of the transactions contemplated by this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) other than in the ordinary course of business, make any loans, advances or capital contributions to, or guarantees for the benefit of,
any Person in an amount in excess of $25&nbsp;million in the aggregate, other than (A)&nbsp;between the Company and any of its Subsidiaries or between any Subsidiaries of the Company and (B)&nbsp;the reimbursement of expenses of employees and other
service providers in the ordinary course of business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xi) enter into any settlement agreement or similar Contract the performance of
which would involve the payment by a Private Group Company in excess of $2&nbsp;million individually or $10&nbsp;million in the aggregate, or that imposes, or by its terms will impose at any point in the future, any material, <FONT
STYLE="white-space:nowrap">non-monetary</FONT> obligations on any Private Group Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xii) authorize, recommend, propose or announce
an intention to adopt, or otherwise effect, a plan of (A)&nbsp;complete or partial liquidation, dissolution or restructuring involving any Private Group Company (other than a Private Group Company with no material operations) or
(B)&nbsp;recapitalization, reorganization or similar transaction involving any Private Group Company (other than the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiii) change any Private Group Company&#146;s methods of accounting in any material respect, other than changes required by a change in GAAP
or Law or that are made in accordance with PCAOB standards; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiv) enter into Contract with any broker, finder, investment banker or
other Person under which such Person is or will be entitled to any brokerage fee, finders&#146; fee or other commission in connection with the transactions contemplated by this Agreement or any Ancillary Documents; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xv) enter into any Contract to take, or cause to be taken, any of the actions prohibited
by this <U>Section</U><U></U><U>&nbsp;5.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding anything in this <U>Section</U><U></U><U>&nbsp;5.1</U> or this
Agreement to the contrary, (i)&nbsp;nothing set forth in this Agreement shall give MAAC, directly or indirectly, the right to control or direct the operations of the Group Companies prior to the Closing, (ii)&nbsp;any action taken, or omitted to be
taken, by any Group Company to the extent such act or omission is reasonably determined by the Company, based on the advice of outside legal counsel, to be necessary to comply with any Law, Order, directive, pronouncement or guideline issued by a
Governmental Entity providing for business closures, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;sheltering-in-place&#148;</FONT></FONT> or other restrictions that relates to, or arises out of, <FONT
STYLE="white-space:nowrap">COVID-19</FONT> shall in no event be deemed to constitute a breach of this <U>Section</U><U></U><U>&nbsp;5.1</U>, (iii) any action taken, or omitted to be taken, by any Group Company to the extent determined by a Group
Company to be reasonable and advisable in response to <FONT STYLE="white-space:nowrap">COVID-19</FONT> shall not be deemed to constitute a breach of this <U>Section</U><U></U><U>&nbsp;5.1</U>; <U>provided</U>, <U>however</U>, that (x)&nbsp;in the
case of each of <U>clauses (ii)</U>&nbsp;and <U>(iii)</U>, the Company shall use reasonable best efforts to give MAAC prior written notice of any such act or omission, to the extent permitted by applicable Law and reasonably practicable, which
notice shall describe in reasonable detail the act or omission and the reason(s) that such act or omission is being taken, or omitted to be taken, pursuant to <U>clause (ii)</U>&nbsp;or <U>(iii)</U> and, in the event that it is permitted by
applicable Law but not reasonably practicable for the Company to give the prior written notice described in this <U>clause (x)</U>, the Company shall instead give such written notice to MAAC as promptly as practicable after such act or omission
(<U>provided</U>, <U>further</U>, <U>however</U>, that any failure by the Company to provide the prior written notice contemplated by this clause (x)&nbsp;that is not in made in bad faith shall not, in and of itself, constitute a breach or default
of this <U>clause (x)</U>&nbsp;or a failure to satisfy the condition precedent set forth in <U>Section</U><U></U><U>&nbsp;6.2(b)</U>) and (y)&nbsp;in no event shall <U>clause (ii)</U>&nbsp;or <U>(iii)</U> be applicable to any act or omission of the
type described in <U>Sections 5.1(b)(i)</U> through <U>(vi)</U>, <U>Section</U><U></U><U>&nbsp;5.1(b)(viii)</U>, <U>Section</U><U></U><U>&nbsp;5.1(b)(ix)</U>, <U>Section</U><U></U><U>&nbsp;5.1(b)(xii)</U>,
<U>Section</U><U></U><U>&nbsp;5.1(b)(xiii)</U>, and <U>Section</U><U></U><U>&nbsp;5.1(b)(xv)</U> (such covenants or agreements, the &#147;<U>Company Specified Interim Operating Covenants</U>&#148;), and
(iv)<U>&nbsp;Section</U><U></U><U>&nbsp;5.21</U> (and not this <U>Section</U><U></U><U>&nbsp;5.1</U>) shall govern and control with respect Merger Sub&#146;s activities, businesses and other actions from and after the date of this Agreement until
the earlier of the Closing or the termination of this Agreement in accordance with its terms and, in the event that this <U>Section</U><U></U><U>&nbsp;5.1</U> conflicts with <U>Section</U><U></U><U>&nbsp;5.21</U>, then
<U>Section</U><U></U><U>&nbsp;5.21</U> shall govern and control to the extent of such conflict. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) From and after the date of this
Agreement until the earlier of the Closing or the termination of this Agreement in accordance with its terms, the Company shall not, and shall cause the other Private Group Companies that may hold Equity Securities of Datavant not to, take any
action in furtherance of, approve or consent to any dividend, distribution or other payment by Datavant to any Company Related Party (including, if applicable, by voting its Equity Securities of Datavant against any proposal to make any such
dividend, distribution or other payment), except for a dividend, distribution or other payment to the direct holders of Equity Securities of Datavant that is made in accordance with the Datavant Governing Documents and applicable Contracts governing
such Equity Securities (in each case, as in effect as of the date hereof) without the prior written consent of MAAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.2</B> <B><U>Efforts to Consummate</U></B><B><U>; Transaction Litigation</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to the terms and conditions herein provided, each of the Parties shall use reasonable best efforts to take, or cause to be taken,
all actions and to do, or cause to be done, all things reasonably necessary or advisable to consummate and make effective as promptly as reasonably practicable the transactions contemplated by this Agreement (including (i)&nbsp;the satisfaction, but
not waiver, of the closing conditions set forth in <U>Article</U><U></U><U>&nbsp;6</U> and, in the case of any Ancillary Document to which such Party will be a party after the date of this Agreement, to execute and deliver such Ancillary Document
when required pursuant to this Agreement or otherwise, and (ii)&nbsp;using reasonable best efforts to obtain the PIPE Financing on the terms and subject to the conditions set forth in the PIPE Subscription Agreements). Without limiting the
generality of the foregoing, each of the Parties shall use reasonable best efforts to obtain, file with or deliver to, as applicable, any Consents of any Governmental Entities or other Persons necessary, proper or advisable to consummate the
transactions contemplated by this Agreement or the Ancillary Documents. Nothing in this <U>Section</U><U></U><U>&nbsp;5.2</U> obligates any Party or any of its Affiliates to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agree to (A)&nbsp;sell, license or otherwise dispose of, or hold separate and agree to sell, license or otherwise dispose of, any entities, assets or facilities of any Group Company or any
entity, facility or asset of such Party or any of its Affiliates, (B)&nbsp;terminate, amend or assign existing relationships and contractual rights or obligations, (C)&nbsp;amend, assign or terminate existing licenses or other agreements, or
(D)&nbsp;enter into new licenses or other agreements. No Party shall agree to any of the foregoing measures, except with MAAC&#146;s and the Company&#146;s prior written consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) MAAC shall promptly inform the Company of any communication received by MAAC from any Governmental Entity and the Company shall promptly
inform MAAC of any communication received by the Company from any Governmental Entity, in either case, regarding any of the transactions contemplated by this Agreement or any Ancillary Document. From and after the date of this Agreement until the
earlier of the Closing or termination of this Agreement in accordance with its terms, MAAC, on the one hand, and the Company and Merger Sub, on the other hand, shall give counsel for the Company (in the case of MAAC) or MAAC (in the case of the
Company), a reasonable opportunity to review in advance, and consider in good faith the views of the other in connection with, any proposed written communication to any Governmental Entity relating to the transactions contemplated by this Agreement
or the Ancillary Documents. Each of the Parties agrees not to participate in any substantive meeting or discussion, either in person or by telephone with any Governmental Entity in connection with the transactions contemplated by this Agreement,
unless it consults with, in the case of MAAC, the Company, or, in the case of the Company or Merger Sub, MAAC in advance and, to the extent not prohibited by such Governmental Entity, gives, in the case of MAAC, the Company, or, in the case of the
Company or Merger Sub, MAAC, the opportunity to attend and participate in such meeting or discussion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding anything to the
contrary in the Agreement, in the event that this <U>Section</U><U></U><U>&nbsp;5.2</U> conflicts with any other covenant or agreement in this <U>Article</U><U></U><U>&nbsp;5</U> that is intended to specifically address any subject matter, then such
other covenant or agreement shall govern and control solely to the extent of such conflict. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) From and after the date of this Agreement
until the earlier of the Closing or termination of this Agreement in accordance with its terms, MAAC, on the one hand, and the Company, on the other hand, shall each notify the other in writing promptly after learning of any shareholder demands or
other shareholder Proceedings (including derivative claims) relating to this Agreement, any Ancillary Document or any matters relating thereto (collectively, the &#147;<U>Transaction Litigation</U>&#148;) commenced against, in the case of MAAC, MAAC
or any of its Representatives (in their capacity as a Representative of MAAC) or, in the case of the Company, any Group Company or any of their respective Representatives (in their capacity as a Representative of a Group Company). MAAC and the
Company shall each (i)&nbsp;keep the other reasonably informed regarding any Transaction Litigation, (ii)&nbsp;give the other the opportunity to, at its own cost and expense, participate in the defense, settlement and compromise of any such
Transaction Litigation and reasonably cooperate with the other in connection with the defense, settlement and compromise of any such Transaction Litigation, (iii)&nbsp;consider in good faith the other&#146;s advice with respect to any such
Transaction Litigation and (iv)&nbsp;reasonably cooperate with each other; <U>provided</U> that in no event shall (x)&nbsp;MAAC or any of its Representatives settle or compromise any Transaction Litigation without the prior written consent of the
Company (not to be unreasonably withheld, conditioned or delayed), or (y)&nbsp;any Group Company or any of their respective Representatives settle or compromise any Transaction Litigation without the prior written consent of MAAC (not to be
unreasonably withheld, conditioned or delayed). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.3</B> <B><U>Confidentiality and Access to
Information</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Parties hereby acknowledge and agree that the information being provided in connection with this Agreement
and the consummation of the transactions contemplated hereby is subject to the terms of the Confidentiality Agreement, the terms of which are incorporated herein by reference. Notwithstanding the foregoing or anything to the contrary in this
Agreement, in the event that this <U>Section</U><U></U><U>&nbsp;5.3(a)</U> or the Confidentiality Agreement conflicts with any other covenant or agreement contained in this Agreement or any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Ancillary Document that contemplates the disclosure, use or provision of information or otherwise, then such other covenant or agreement contained in this Agreement or such Ancillary Document, as
applicable, shall govern and control to the extent of such conflict. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) From and after the date of this Agreement until the earlier of
the Closing Date or the termination of this Agreement in accordance with its terms, upon reasonable advance written notice, the Company shall use reasonable best efforts to provide, or cause to be provided, to MAAC and its Representatives during
normal business hours reasonable access to the directors, officers, books and records and properties of the Private Group Companies (in a manner so as to not interfere with the normal business operations of the Private Group Companies).
Notwithstanding the foregoing, none of the Private Group Companies shall be required to provide, or cause to be provided to, MAAC or any of its Representatives any information (i)&nbsp;if and to the extent doing so would (A)&nbsp;violate any Law to
which any Private Group Company is subject, (B)&nbsp;result in the disclosure of any trade secrets of third parties in breach of any Contract with such third party, (C)&nbsp;violate any legally-binding obligation of any Private Group Company with
respect to confidentiality, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> or privacy, (D)&nbsp;jeopardize protections afforded to any Private Group Company under the attorney-client privilege or the attorney work product doctrine or
(E)&nbsp;in the case of any <FONT STYLE="white-space:nowrap">in-person</FONT> access, be contrary to, or would not be reasonably practicable in light of, any action taken, or omitted to be taken, by any Group Company to the extent determined to be
reasonable and advisable in response to <FONT STYLE="white-space:nowrap">COVID-19</FONT> (<U>provided</U> that, in case of each of <U>clauses</U><U></U><U>&nbsp;(A)</U> through <U>(D)</U>, the Company shall, and shall cause the other Private Group
Companies to, use reasonable best efforts to (x)&nbsp;provide such access as can be provided (or otherwise convey such information regarding the applicable matter as can be conveyed) without violating such privilege, doctrine, Contract, obligation
or Law and (y)&nbsp;provide such information in a manner without violating such privilege, doctrine, Contract, obligation or Law), or (ii)&nbsp;if any Group Company or any Company <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate, on the
one hand, and MAAC, any MAAC <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate or any of their respective Representatives, on the other hand, are adverse parties (or would, in light of then existing facts and circumstances, reasonably be
expected to be potentially adverse parties) in a litigation or dispute and such information is or would reasonably be expected to be pertinent thereto; <U>provided</U> that the Company shall, in the case of <U>clause (i)</U>&nbsp;or <U>(ii)</U>,
provide prompt written notice of the withholding of access or information on any such basis, unless such written notice is prohibited by applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) From and after the date of this Agreement until the earlier of the Closing Date or the termination of this Agreement in accordance with
its terms, upon reasonable advance written notice, MAAC shall use reasonable best efforts to provide, or cause to be provided, to the Company and its Representatives during normal business hours reasonable access to the directors, officers, books
and records of MAAC (in a manner so as to not interfere with the normal business operations of MAAC). Notwithstanding the foregoing, MAAC shall not be required to provide, or cause to be provided to, the Company or any of its Representatives any
information (i)&nbsp;if and to the extent doing so would (A)&nbsp;violate any Law to which MAAC is subject, (B)&nbsp;result in the disclosure of any trade secrets of third parties in breach of any Contract with such third party, (C)&nbsp;violate any
legally-binding obligation of MAAC with respect to confidentiality, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> or privacy, (D)&nbsp;jeopardize protections afforded to MAAC under the attorney-client privilege or the attorney work product
doctrine or (E)&nbsp;in the case of any <FONT STYLE="white-space:nowrap">in-person</FONT> access, be contrary to, or would not be reasonably practicable in light of, any action taken, or omitted to be taken, by MAAC to the extent determined to be
reasonable and advisable in response to <FONT STYLE="white-space:nowrap">COVID-19</FONT> (<U>provided</U> that, in case of each of <U>clauses (A)</U>&nbsp;through <U>(D)</U>, MAAC shall use, and shall cause the other MAAC to use, reasonable best
efforts to (x)&nbsp;provide such access as can be provided (or otherwise convey such information regarding the applicable matter as can be conveyed) without violating such privilege, doctrine, Contract, obligation or Law and (y)&nbsp;provide such
information in a manner without violating such privilege, doctrine, Contract, obligation or Law), or (ii)&nbsp;if MAAC or any MAAC <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate, on the one hand, and any Group Company, any Company <FONT
STYLE="white-space:nowrap">Non-Party</FONT> Affiliate or any of their respective Representatives, on the other hand, are adverse parties (or would, in light of then existing facts and circumstances, reasonably be expected to be potentially adverse
parties) in a litigation or dispute and such information is or would reasonably be expected to be pertinent thereto; <U>provided</U> that MAAC shall, in the case of <U>clause (i)</U>&nbsp;or <U>(ii)</U>, provide prompt written notice of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the withholding of access or information on any such basis, unless such written notice is prohibited by applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Parties hereby acknowledge and agree that the Confidentiality Agreement shall be automatically terminated effective as of the Closing
without any further action by any Party or any other Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.4</B> <B><U>Public Announcements</U></B>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to <U>Section</U><U></U><U>&nbsp;5.4(b)</U>, <U>Section</U><U></U><U>&nbsp;5.7</U> and <U>Section</U><U></U><U>&nbsp;5.8</U>,
prior to the Closing, none of the Parties shall, and the Parties shall cause their respective controlled Affiliates and its and their respective officers and directors not to and shall use reasonable best efforts to cause their respective other
Representatives not to, issue any press releases or make any public announcements with respect to this Agreement or the transactions contemplated hereby without the prior written consent of the Company and MAAC; <U>provided</U>, <U>however</U>, that
each Party, the MAAC Sponsor and each of their respective Representatives may issue or make, as applicable, any such press release, public announcement or other communication (i)&nbsp;if such press release, public announcement or other communication
is required by applicable Law, in which case the disclosing Party or its applicable Representatives shall, to the extent reasonably practicable and, unless and to the extent prohibited by such applicable Law, (x)&nbsp;if the disclosing Person is
MAAC or a Representative of MAAC, reasonably consult with the Company in connection therewith and provide the Company with an opportunity to review and comment on such press release, public announcement or communication and shall consider any such
comments in good faith, or (y)&nbsp;if the disclosing Party is the Company, Merger Sub or a Representative of any of the foregoing, reasonably consult with MAAC in connection therewith and provide MAAC with an opportunity to review and comment on
such press release, public announcement or communication and shall consider any such comments in good faith, (ii)&nbsp;to the extent such press release, public announcements or other communications contain only information previously disclosed in a
press release, public announcement or other communication previously made in accordance with this <U>Section</U><U></U><U>&nbsp;5.4</U> and (iii)&nbsp;to Governmental Entities in connection with any Consents required to be made under this Agreement,
the Ancillary Documents or in connection with the transactions contemplated hereby or thereby. Notwithstanding anything to the contrary in this <U>Section</U><U></U><U>&nbsp;5.4</U> or otherwise in this Agreement, the Parties agree that the MAAC
Sponsor and its Representatives may provide general information about the subject matter of this Agreement and the transactions contemplated hereby to any direct or indirect former, current or prospective investor or in connection with normal fund
raising or related marketing or informational or reporting activities; <U>provided</U> that the recipients of such information are subject to customary confidentiality obligations prior to the receipt of such information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The initial press release concerning this Agreement and the transactions contemplated hereby shall be a joint press release in the form
agreed by the Company and MAAC prior to the execution of this Agreement and such initial press release (the &#147;<U>Signing Press Release</U>&#148;) shall be released as promptly as reasonably practicable after the execution of this Agreement on
the day thereof. Promptly after the execution of this Agreement, MAAC shall file a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (the &#147;<U>Signing Filing</U>&#148;) with the Signing Press Release and a description of this
Agreement as required by, and in compliance with, the Securities Laws, which Signing Filing shall be mutually agreed upon by the MAAC and the Company prior to such filing (such agreement not to be unreasonably withheld, conditioned or delayed by
either MAAC or the Company, as applicable). The Company, on the one hand, and MAAC, on the other hand, shall mutually agree upon (such agreement not to be unreasonably withheld, conditioned or delayed by either the Company or MAAC, as applicable) a
press release announcing the consummation of the transactions contemplated by this Agreement (the &#147;<U>Closing Press Release</U>&#148;) prior to the Closing, and, on the Closing Date (or such other date as may be mutually agreed to in writing by
MAAC and the Company prior to the Closing), the Parties shall cause the Closing Press Release to be released. Promptly after the Closing (but in any event within four (4)&nbsp;Business Days after the Closing), the Company shall file a current report
on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (the &#147;<U>Closing Filing</U>&#148;) with the Closing Press Release and a description of the Closing as required by Securities Laws, which Closing Filing shall be mutually agreed upon by the
Company and MAAC prior to the Closing (such agreement not to be unreasonably withheld, conditioned or delayed by either the Company or MAAC, as applicable). In connection with the preparation of each of the Signing Press Release,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Signing Filing, the Closing Press Release and the Closing Filing, each Party shall, upon written request by any other Party, furnish such other Party with all information concerning itself,
its directors, officers and equityholders, and such other matters, in each case, as may be reasonably necessary for such press release or filing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.5</B> <B><U>Tax Matters</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Tax Treatment</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)
The Parties intend that the Merger will qualify as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code, and, for the period beginning on the date hereof until and including the Closing Date, each Party shall use
commercially reasonable efforts not to take any action that would reasonably be expected to cause the Merger to fail to so qualify; <U>provided</U> that, for the avoidance of doubt, the Parties shall not be required to restructure, or otherwise
alter the terms of, the transaction as provided for in this Agreement. The Parties have no plan or intention as of the date hereof and as of the Closing Date to take any action that would reasonably be expected to cause the Mergers to fail to
qualify as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code. For two years following the Closing, (i)&nbsp;the Company shall use commercially reasonable efforts to cause MAAC not to liquidate (including a deemed
liquidation for U.S. federal income tax purposes), and (ii)&nbsp;the Company&#146;s &#147;qualified group&#148; (within the meaning of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.368-1(d)(4)(ii))</FONT> shall use
commercially reasonable efforts to use at least fifty percent (50%) of the cash and cash equivalents in the Trust Account (but not taking into account any cash acquired in connection with the PIPE Financing) as of immediately prior to the Closing
(and prior to the MAAC Shareholder Redemption) (such cash and cash equivalents, the &#147;Relevant <FONT STYLE="white-space:nowrap">Pre-Redemption</FONT> Assets&#148;) in the Company&#146;s business within the meaning of Treasury Regulations <FONT
STYLE="white-space:nowrap">Section&nbsp;1.368-1(d)</FONT> (such business, the &#147;Roivant Business&#148;); provided that if, immediately following and as a result of the MAAC Shareholder Redemption, MAAC holds less than fifty percent (50%) but at
least <FONT STYLE="white-space:nowrap">one-third</FONT> of the Relevant <FONT STYLE="white-space:nowrap">Pre-Redemption</FONT> Assets, then the Company&#146;s &#147;qualified group&#148; (within the meaning of Treasury Regulations <FONT
STYLE="white-space:nowrap">Section&nbsp;1.368-1(d)(4)(ii))</FONT> shall use commercially reasonable efforts to use one hundred percent (100%) of the cash and cash equivalents in the Trust Account (but not taking into account any cash acquired in
connection with the PIPE Financing) in the Roivant Business; <U>provided, further, that </U>if, immediately following and as a result of the MAAC Shareholder Redemption, MAAC holds less than <FONT STYLE="white-space:nowrap">one-third</FONT> of the
Relevant <FONT STYLE="white-space:nowrap">Pre-Redemption</FONT> Assets, then there shall be no limitation or requirement imposed on the Company with respect to the use of MAAC&#146;s assets under this clause (ii)); <U>provided, further, that</U>,
for purposes of this sentence, use in the Company&#146;s business or use in the Roivant Business shall include, without limitation, retention of Relevant <FONT STYLE="white-space:nowrap">Pre-Redemption</FONT> Assets for future use in the business
operations of members of the Company&#146;s &#147;qualified group&#148;, loans of Relevant <FONT STYLE="white-space:nowrap">Pre-Redemption</FONT> Assets to other members of the Company&#146;s &#147;qualified group&#148; for current or future use of
such Relevant <FONT STYLE="white-space:nowrap">Pre-Redemption</FONT> Assets in the business operations of such members, and acquisitions of operating assets or controlling interests in operating entities in exchange for Relevant <FONT
STYLE="white-space:nowrap">Pre-Redemption</FONT> Assets, in each case, by any members of the Company&#146;s &#147;qualified group&#148; (including MAAC). Each Party shall file all Tax Returns consistent with, and take no position inconsistent with
(whether in audits, Tax Returns or otherwise), such treatment unless (x)&nbsp;such Party requests that each of Kirkland&nbsp;&amp; Ellis LLP and Davis Polk&nbsp;&amp; Wardwell LLP provides written confirmation to the effect that the Merger is more
likely than not to qualify as a reorganization within the meaning of Section&nbsp;368(a) of the Code and each such law firm fails to provide such confirmation prior to the later of (A)&nbsp;thirty (30) days following such request is made and
(B)&nbsp;sixty (60) days prior to the date on which the relevant Tax Return is due (taking into account applicable extensions); <U>provided</U> that the Parties shall provide customary factual representations to such law firm; <U>provided</U>,
<U>further,</U> that, for the avoidance of doubt, the Parties shall not be required to restructure, or otherwise alter the terms of, the transaction as provided for in this Agreement; or (y)&nbsp;otherwise required by a final
&#147;determination&#148; within the meaning of Section&nbsp;1313(a) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) MAAC and the Company hereby adopt this Agreement
as a &#147;plan of reorganization&#148; within the meaning of Treasury Regulations Sections <FONT STYLE="white-space:nowrap">1.368-2(g)</FONT> and <FONT STYLE="white-space:nowrap">1.368-3(a).</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) If, in connection with the preparation and filing of the Registration Statement /
Proxy Statement, the SEC requests or requires that a tax opinion be prepared and submitted, MAAC and the Company shall deliver to Kirkland&nbsp;&amp; Ellis LLP and/or Davis Polk&nbsp;&amp; Wardwell LLP, as relevant, customary Tax representation
letters reasonably satisfactory to such counsel and reasonably acceptable to the Company, dated and executed as of the date the Registration Statement / Proxy Statement shall have been declared effective by the SEC and such other date(s) as
determined reasonably necessary by such counsel in connection with the preparation and filing of the Registration Statement / Proxy Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Tax Matters Cooperation</U>. Each of the Parties shall (and shall cause their respective Affiliates (other than in the case of the
Company, the Public Group Companies) to) cooperate fully, as and to the extent reasonably requested by another Party, in connection with the filing of relevant Tax Returns, and any audit or Tax proceeding. Such cooperation shall include the
retention and (upon the other Party&#146;s request) the provision (with the right to make copies) of records and information reasonably relevant to any Tax proceeding or audit, making employees available on a mutually convenient basis to provide
additional information and explanation of any material provided hereunder. Without limiting the generality of the foregoing, but subject to<U>&nbsp;Section</U><U></U><U>&nbsp;5.5(a)(i)</U>, following the Closing, MAAC shall, and the Company shall
cause MAAC to, (i)&nbsp;comply with the reporting requirements of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.367(a)-3(c)(6)</FONT> and the recordkeeping requirements of Treasury Regulations
<FONT STYLE="white-space:nowrap">Section&nbsp;1.368-3</FONT> and (ii)&nbsp;attach to its timely filed U.S. federal income Tax Return for the taxable year in which the Closing occurs, statements meeting the requirements specified in Treasury
Regulations Sections <FONT STYLE="white-space:nowrap">1.367(a)-3(c)(6)</FONT> and <FONT STYLE="white-space:nowrap">1.368-3(a).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
<U>QEF Election</U>. If the Company provides to any Company Shareholders information that is reasonably required in order for such Company Shareholders to make an election as contemplated by Section&nbsp;1295 of the Code (and the Treasury
Regulations promulgated thereunder) with respect to the Company for any year that the Company is considered a PFIC, including through provision of the Annual Information Statement described in Treasury Regulations
<FONT STYLE="white-space:nowrap">Section&nbsp;1.1295-1(g),</FONT> the Company shall provide the same such information to the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> MAAC Shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.6</B> <B><U>Exclusive Dealing</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) From the date of this Agreement until the earlier of the Closing or the termination of this Agreement in accordance with its terms, the
Company shall not, and shall cause the Private Group Companies and its and their respective officers and directors not to and shall use reasonable best efforts to cause its other Representatives not to, directly or indirectly: (i)&nbsp;solicit,
initiate, knowingly encourage (including by means of furnishing or disclosing information), knowingly facilitate, discuss or negotiate, directly or indirectly, any inquiry, proposal or offer (written or oral) with respect to a Company Acquisition
Proposal; (ii)&nbsp;furnish or disclose any <FONT STYLE="white-space:nowrap">non-public</FONT> information to any Person in connection with, or that would reasonably be expected to lead to, a Company Acquisition Proposal; (iii)&nbsp;enter into any
Contract or other arrangement or understanding regarding a Company Acquisition Proposal; (iv)&nbsp;make any filings with the SEC in connection with a public offering of any Equity Securities or other securities of the Company (or any successor or
parent company of the Company), other than in connection with the transactions contemplated by, and in accordance with, this Agreement and the Ancillary Documents; or (v)&nbsp;otherwise cooperate in any way with, or assist or participate in, or
knowingly facilitate or knowingly encourage any effort or attempt by any Person to do or seek to do any of the foregoing. The Company agrees to (A)&nbsp;notify MAAC promptly upon receipt of any Company Acquisition Proposal by any Group Company, and
to describe the material terms and conditions of any such Company Acquisition Proposal in reasonable detail (excluding the identity of the Persons making such Company Acquisition Proposal) and (B)&nbsp;keep MAAC reasonably informed on a current
basis of any material modifications to such offer or information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) From the date of this Agreement until the earlier of the Closing or
the termination of this Agreement in accordance with its terms, MAAC shall not, and shall cause MAAC Sponsor and its and their respective officers and directors not to and shall use reasonable best efforts to cause its other Representatives not
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to, directly or indirectly: (i)&nbsp;solicit, initiate, knowingly encourage (including by means of furnishing or disclosing information), knowingly facilitate, discuss or negotiate, directly or
indirectly, any inquiry, proposal or offer (written or oral) with respect to a MAAC Acquisition Proposal; (ii)&nbsp;furnish or disclose any <FONT STYLE="white-space:nowrap">non-public</FONT> information to any Person in connection with, or that
would reasonably be expected to lead to, a MAAC Acquisition Proposal; (iii)&nbsp;enter into any Contract or other arrangement or understanding regarding a MAAC Acquisition Proposal; or (iv)&nbsp;otherwise cooperate in any way with, or assist or
participate in, or knowingly facilitate or knowingly encourage any effort or attempt by any Person to do or seek to do any of the foregoing. MAAC agrees to (A)&nbsp;notify the Company promptly upon receipt of any MAAC Acquisition Proposal by MAAC,
and to describe the material terms and conditions of any such MAAC Acquisition Proposal in reasonable detail (excluding the identity of any person or entity making such MAAC Acquisition Proposal) and (B)&nbsp;keep the Company reasonably informed on
a current basis of any material modifications to such offer or information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, it is understood and agreed that
the covenants and agreements contained in this <U>Section</U><U></U><U>&nbsp;5.6</U> shall not prohibit the Company, MAAC or any of their respective Representatives from taking any actions in the ordinary course that are not otherwise in violation
of this <U>Section</U><U></U><U>&nbsp;5.6</U> (such as answering phone calls) or informing any Person inquiring about a possible Company Acquisition Proposal or MAAC Acquisition Proposal, as applicable, of the existence of the covenants and
agreements contained in this <U>Section</U><U></U><U>&nbsp;5.6</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.7</B> <B><U>Preparation of
Registration Statement / Proxy Statement</U></B>. As promptly as reasonably practicable following the date of this Agreement, MAAC and the Company shall prepare and mutually agree upon (such agreement not to be unreasonably withheld, conditioned or
delayed by either of MAAC or the Company, as applicable), and the Company shall file with the SEC, the Registration Statement / Proxy Statement (it being understood that the Registration Statement / Proxy Statement shall include a proxy statement of
MAAC which will be included therein and which will be used for the MAAC Shareholders Meeting to solicit the adoption and approval of the Transaction Proposals, provide its applicable shareholders with the opportunity to elect to effect the MAAC
Shareholder Redemption, and other matters reasonably related to the Transaction Proposals, all in accordance with and as required by MAAC&#146;s Governing Documents, applicable Law, and any applicable rules and regulations of the SEC and Nasdaq).
Each of MAAC and the Company shall use its reasonable best efforts to (a)&nbsp;cause the Registration Statement / Proxy Statement to comply in all material respects with the applicable rules and regulations promulgated by the SEC (including, with
respect to the Company, the provision of financial statements and pro forma financial statements, and any other information with respect to the Group Companies for all periods and in the form, required to be included in the Registration Statement /
Proxy Statement under Securities Laws (after giving effect to any waivers received), or in response to any comments or requests from the SEC); (b)&nbsp;promptly notify the others of, reasonably cooperate with each other with respect to and respond
promptly to, any comments or requests of the SEC or its staff and, in the case of the Company, provide copies of any written correspondence with the SEC; (c)&nbsp;promptly prepare and mutually agree upon (such agreement not to be unreasonably
withheld, conditioned or delayed by either of MAAC or the Company, as applicable) any amendments or supplements to the Registration Statement / Proxy Statement in order to address comments or requests from the SEC or its staff (which amendments or
supplements shall be promptly filed by the Company); (d) have the Registration Statement / Proxy Statement declared effective under the Securities Act as promptly as reasonably practicable after it is filed with the SEC; and (e)&nbsp;keep the
Registration Statement / Proxy Statement effective through the Closing in order to permit the consummation of the transactions contemplated by this Agreement. MAAC, on the one hand, and the Company and Merger Sub, on the other hand, shall promptly
furnish, or cause to be furnished, to the other all information concerning such Party and its <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates and their respective Representatives and, in the case of the Company, the Company
Equityholders, that may be required or reasonably requested in connection with any action contemplated by this <U>Section</U><U></U><U>&nbsp;5.7</U> or for inclusion in any other statement, filing, notice or application made by or on behalf of MAAC
or the Company to the SEC or Nasdaq in connection with the transactions contemplated by this Agreement or the Ancillary Documents, including delivering customary tax representation letters to counsel to enable counsel to deliver any tax opinions
requested or required by the SEC to be submitted in connection therewith as described in <U>Section</U><U></U><U>&nbsp;5.5(a)(iii)</U>. In the event there is any tax opinion, comfort letter or other opinion required to be provided in connection with
the Registration Statement / Proxy Statement, notwithstanding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
anything herein to the contrary, neither this provision nor any other provision in this Agreement shall require counsel to the Company or MAAC or their respective tax advisors to provide any
opinion regarding the qualification of the Merger as a reorganization within the meaning of Section&nbsp;368(a) of the Code or otherwise qualifies for the Intended Tax Treatment, unless required by applicable Securities Laws or regulations,
including SEC Staff Legal Bulletin No.&nbsp;19. If any Party becomes aware of any information that is, in the opinion of such Party, required or desirable to be disclosed in an amendment or supplement to the Registration Statement / Proxy Statement,
then (i)&nbsp;such Party shall promptly inform, in the case of MAAC, the Company, or, in the case of the Company or Merger Sub, MAAC, thereof, (ii)&nbsp;the Company and MAAC shall prepare and mutually agree upon (such agreement not to be
unreasonably withheld, conditioned or delayed in the case of either the Company or MAAC) an amendment or supplement to the Registration Statement / Proxy Statement, (iii)&nbsp;the Company shall file such mutually agreed upon amendment or supplement
with the SEC and (iv)&nbsp;if requested by MAAC, the Parties shall reasonably cooperate in mailing such amendment or supplement to the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> MAAC Shareholders. The Company shall as promptly as reasonably
practicable advise MAAC of effectiveness of the Registration Statement / Proxy Statement, of its becoming aware of the issuance of any stop order relating thereto or the suspension of the qualification of the Company Common Shares for offering or
sale in any jurisdiction, and MAAC and the Company shall each use its reasonable best efforts to have any such stop order or suspension lifted, reversed or otherwise terminated. Each of the Parties shall use reasonable best efforts to ensure that
none of the information related to him, her or it or any of his, her or its <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates or its or their respective Representatives or, in the case of the Company, the Company Equityholders, supplied
by or on his, her or its behalf for inclusion or incorporation by reference in the Registration Statement / Proxy Statement will, at the time the Registration Statement / Proxy Statement is initially filed with the SEC, at each time at which it is
amended, and at the time it becomes effective under the Securities Act contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the
circumstances under which they are made, not misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.8</B> <B><U>MAAC Shareholder Approval</U></B>.
As promptly as reasonably practicable following the time at which the Registration Statement / Proxy Statement is declared effective under the Securities Act, (A)&nbsp;MAAC shall duly give notice of, and use reasonable best efforts to duly convene
and hold, a meeting of its shareholders (the &#147;<U>MAAC Shareholders Meeting</U>&#148;) in accordance with the Governing Documents of MAAC (including by causing the Registration Statement / Proxy Statement to be mailed to the holders of MAAC
Shares), for the purposes of obtaining the MAAC Shareholder Approval and, if applicable, any approvals related thereto and providing its applicable shareholders with the opportunity to elect to effect a MAAC Shareholder Redemption and (B)&nbsp;use
reasonable best efforts to solicit proxies from the holders of MAAC Shares to vote in favor of each of the Transaction Proposals. Except as otherwise required by applicable Law, (i)&nbsp;MAAC shall, through unanimous approval of the MAAC Board,
recommend (the &#147;<U>MAAC Board Recommendation</U>&#148;) to its shareholders that such shareholders approve and adopt (A)&nbsp;this Agreement and the transactions contemplated hereby (including the Merger) (the &#147;<U>Business Combination
Proposal</U>&#148;); (B) the issuance of MAAC Shares to the PIPE Investors as required by Nasdaq listing requirements (the &#147;<U>Nasdaq Proposal</U>&#148;); (C) each other proposal that either the SEC or Nasdaq (or the respective staff members
thereof) indicates is necessary in its comments to the Registration Statement / Proxy Statement or in correspondence related thereto; (D)&nbsp;each other proposal reasonably agreed to by MAAC and the Company as necessary or appropriate in connection
with the consummation of the transactions contemplated by this Agreement or the Ancillary Documents; and (E)&nbsp;a proposal for the postponement or adjournment of the MAAC Shareholders Meeting, if necessary, to permit further solicitation of
proxies because there are not sufficient votes to approve and adopt any of the foregoing (such proposals in (A)&nbsp;through (E), collectively, the &#147;<U>Transaction Proposals</U>&#148;), and (ii)&nbsp;MAAC shall include the MAAC Board
Recommendation in the Registration Statement / Proxy Statement. Notwithstanding the foregoing or anything to the contrary herein, MAAC may postpone or adjourn the MAAC Shareholders Meeting (and MAAC shall adjourn the MAAC Shareholder Meeting if an
adjournment is reasonably requested by the Company in writing)&nbsp;(1) to solicit additional proxies because there are not sufficient votes to constitute the MAAC Shareholder Approval, (2)&nbsp;for the absence of a quorum, (3)&nbsp;to allow
reasonable additional time for the filing or mailing of any supplemental or amended disclosures that MAAC (or the Company) has reasonably determined, based on the advice of outside legal counsel, is reasonably likely to be required under applicable
Law and for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such supplemental or amended disclosure to be disseminated and reviewed by the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> MAAC Shareholders prior to the MAAC Shareholders Meeting or
(4)&nbsp;if the holders of MAAC Class&nbsp;A Shares have elected to redeem a number of MAAC Class&nbsp;A Shares as of such time that would reasonably be expected to result in the condition set forth in <U>Section</U><U></U><U>&nbsp;6.3(d)</U> not
being satisfied; <U>provided</U> that, without the consent of the Company, in no event shall MAAC postpone or adjourn the MAAC Shareholders Meeting for more than fifteen (15)&nbsp;Business Days later than the most recently postponed or adjourned
meeting or to a date that is beyond the date that is five (5)&nbsp;Business Days prior to the Termination Date. Except as otherwise required by applicable Law, MAAC covenants that none of the MAAC Board, MAAC or any committee of the MAAC Board shall
(i)&nbsp;change, withdraw, withhold, qualify, amend or modify, or publicly propose to change, withdraw, withhold, qualify, amend or modify, in a manner adverse to the Company, the MAAC Board Recommendation or any other recommendation by the MAAC
Board or MAAC of the proposals set forth in the Registration Statement / Proxy Statement, (ii)&nbsp;adopt, approve, recommend or declare advisable to the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> MAAC Shareholders, or publicly propose to
adopt, approve, recommend or declare advisable, any MAAC Acquisition Proposal or (iii)&nbsp;fail to include the MAAC Board Recommendation in the Registration Statement / Proxy Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.9</B> <B><U>Merger Sub</U></B><B><U> Shareholder Approval</U></B>. As promptly as reasonably practicable (and
in any event within one (1)<U></U>&nbsp;Business Day) following the date of this Agreement (the &#147;<U>Merger Sub Shareholder Approval Deadline</U>&#148;), the Company, as the sole stockholder of Merger Sub, will approve and adopt this Agreement,
the Ancillary Documents to which Merger Sub is or will be a party and the transactions contemplated hereby and thereby (including the Merger) (the &#147;<U>Merger Sub Shareholder Approval</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.10</B> <B><U>Conduct of Business</U></B><B><U> of</U></B><B><U> </U></B><B><U>MAAC</U></B>. From and after the
date of this Agreement until the earlier of the Closing or the termination of this Agreement in accordance with its terms, MAAC shall not, and shall cause its Subsidiaries not to, as applicable, except as expressly contemplated by this Agreement or
any Ancillary Document (including, for the avoidance of doubt, in connection with the PIPE Financing or the transactions contemplated by the Sponsor Support Agreement), as required by applicable Law, as set forth on
<U>Section</U><U></U><U>&nbsp;5.10</U> of the MAAC Disclosure Schedules or as consented to in writing by the Company (such consent not to be unreasonably withheld, conditioned or delayed), do any of the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) adopt any amendments, supplements, restatements or modifications to the Trust Agreement, the MAAC Warrant Agreement or the Governing
Documents of MAAC; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) create or form any Subsidiary; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) acquire (including, without limitation, by merger, consolidation, or acquisition of stock or assets or any other business combination) any
corporation, partnership, other business organization or enter into any strategic joint ventures, partnerships or alliances with any other person, or make any loans, advances or capital contributions to, or guarantees for the benefit of, or any
investments in, any Person; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) declare, set aside, make or pay a dividend on, or make any other distribution or payment in respect of,
its Equity Securities, or repurchase, redeem or otherwise acquire, or offer to repurchase, redeem or otherwise acquire, any outstanding of its Equity Securities; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) split, combine or reclassify any of its capital stock or other Equity Securities or issue any other security in respect of, in lieu of or
in substitution for shares of its capital stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) (i) incur, create or assume any indebtedness for borrowed money (other than working
capital loans from the MAAC Sponsor in an amount not to exceed $3&nbsp;million (it being agreed that no loans from the MAAC Sponsor or any of its Affiliates shall be converted into warrants)) or (ii)&nbsp;guarantee any Liability of any Person; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) make any loans or advances to, or capital contributions in, any other Person, other than to, or in, MAAC or any of its Subsidiaries; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) issue any Equity Securities or&nbsp;grant any options, warrants or stock appreciation
rights with respect to its Equity Securities; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) (i) amend, modify or renew any MAAC Related Party Transaction, other than (A)&nbsp;the
entry into any Contract with a MAAC Related Party with respect to the incurrence of indebtedness for borrowed money permitted by <U>Section</U><U></U><U>&nbsp;5.10(f)</U> or (B)&nbsp;for the avoidance of doubt, any expiration or automatic extension
or renewal of any Contract pursuant to its terms, (ii)&nbsp;enter into any Contract that would constitute a MAAC Related Party Transaction or (iii)&nbsp;make any material payment to any MAAC Related Party; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) engage in any activities or business, or incur any Liabilities, other than (i)&nbsp;any activities, businesses or Liabilities that are
contemplated by, incurred in connection with or that are otherwise incidental or attendant to this Agreement or any Ancillary Document, the performance of any covenants or agreements hereunder or thereunder or the consummation of the transactions
contemplated hereby or thereby or (ii)&nbsp;the engagement in any activities or businesses, or the incurrence of any Liabilities, permitted by another subsection of this <U>Section</U><U></U><U>&nbsp;5.10</U> (as modified, for the avoidance of
doubt, by <U>Section</U><U></U><U>&nbsp;5.10</U> of the MAAC Disclosure Schedules); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) enter into, or amend or modify any material term
of (in a manner adverse to MAAC), terminate (excluding any expiration in accordance with its terms), or waive or release any material rights, claims or benefits under, any Contract of a type required to be listed on
<U>Section</U><U></U><U>&nbsp;4.10(a)</U> of the MAAC Disclosure Schedules (or any Contract, that if existing on the date hereof, would have been required to be listed on <U>Section</U><U></U><U>&nbsp;4.10(a)</U> of the MAAC Disclosure Schedules);
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) enter into any collective bargaining agreement, except as required by Law; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) authorize, recommend, propose or announce an intention to adopt a plan of complete or partial liquidation, dissolution, restructuring,
recapitalization, reorganization or similar transaction involving MAAC; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) make, change or revoke any material election concerning
Taxes, enter into any material Tax closing agreement, settle any material Tax claim or assessment, or consent to any extension or waiver of the limitation period applicable to or relating to any material Tax claim or assessment, other than any such
extension or waiver that is obtained in the ordinary course of business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) change any methods of accounting in any material respect,
other than changes required by a change in GAAP or Law or that are made in accordance with PCAOB standards; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) enter into or amend any
Contract with any broker, finder, investment banker or other Person under which such Person is or will be entitled to any brokerage fee, finders&#146; fee or other commission in connection with the transactions contemplated by this Agreement or any
Ancillary Document; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) (i) establish, adopt, modify, amend or terminate any &#147;employee benefit plan&#148; (as such term is defined
in Section&nbsp;3(3) of ERISA, whether or not subject to ERISA), equity or equity-based, deferred compensation, severance, retention, bonus, incentive, retirement, retiree or post-employment welfare, vacation, and other benefit or compensatory plan,
program, policy, arrangement or Contract, (ii)&nbsp;grant or increase (or accelerate the timing of payment or funding of) any compensation or benefits (including, without limitation, any severance or change in control or retention payments) to any
employee or independent contractor or (iii)&nbsp;(A) hire any employee or (B)&nbsp;engage any individual independent contractor or consultant for fees (other than, in the case of this <U>clause (B)</U>, for purposes related, incidental or attendant
to this Agreement or any Ancillary Document, the performance or enforcement of, or compliance with, any covenants or agreements hereunder or thereunder or the consummation of the transactions contemplated hereby or thereby (including, for the
avoidance of doubt, purposes related, incidental or attendant to compliance with applicable Laws or applicable listing or corporate governance rules or regulations of Nasdaq or purposes related, incidental or attendant to its continuing (or similar)
existence); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) make any Transaction Payment; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s) enter into any Contract to take, or cause to be taken, any of the actions set forth in this <U>Section</U><U></U><U>&nbsp;5.10</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything in this <U>Section</U><U></U><U>&nbsp;5.10</U> or this Agreement to the contrary, (i)&nbsp;nothing set forth in this
Agreement shall give the Company, directly or indirectly, the right to control or direct the operations of MAAC, and (ii)&nbsp;nothing set forth in this Agreement shall prohibit, or otherwise restrict the ability of, MAAC from using the funds held
by MAAC outside the Trust Account to pay any MAAC Expenses or Liabilities of MAAC or from otherwise distributing or paying over any funds held by MAAC outside the Trust Account to the MAAC Sponsor or any of its Affiliates, in each case, prior to the
Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.11</B> <B><U>Nasdaq Listing</U></B><B><U>; MAAC Public Filings</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company shall use its reasonable best efforts (a)&nbsp;to cause the Company Post-Closing Common Shares issuable in accordance with
this Agreement (including, for the avoidance of doubt, the Company Post-Closing Common Shares issuable in respect of MAAC Shares converted into Company Post-Closing Common Shares in the Merger) to be approved for listing on Nasdaq, subject to
official notice of issuance thereof, and (b)&nbsp;to satisfy any applicable initial and continuing listing requirements of Nasdaq, in each case, as promptly as reasonably practicable after the date of this Agreement, and in any event prior to the
Effective Time. MAAC shall, and shall cause its Representatives to, reasonably cooperate with the Company and its Representatives in connection with the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) From and after the date hereof until the earlier of the Closing or termination of this Agreement in accordance with its terms, except as
set forth on <U>Section</U><U></U><U>&nbsp;5.11(b)</U> of the MAAC Disclosure Schedules, MAAC shall (except if, in the case of any reports to be filed or furnished in connection with the transactions contemplated by this Agreement or any Ancillary
Document, the Company&#146;s breach of its applicable covenants, agreements and obligations hereunder would result in the MAAC&#146;s inability to make such filings) use reasonable best efforts to keep current and timely file all reports required to
be filed or furnished with the SEC and otherwise comply in all material respects with its reporting obligations under applicable Securities Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.12</B> <B><U>Trust Account</U></B>. Upon satisfaction or, to the extent permitted by applicable Law, waiver of
the conditions set forth in <U>Article</U><U></U><U>&nbsp;6</U> and provision of notice thereof to the Trustee, (a)&nbsp;at the Closing, MAAC shall (i)&nbsp;cause the documents, certificates and notices required to be delivered to the Trustee
pursuant to the Trust Agreement to be so delivered, and (ii)&nbsp;make all appropriate arrangements to cause the Trustee to (A)&nbsp;pay as and when due all amounts, if any, payable to the holders of MAAC Class&nbsp;A Shares pursuant to the MAAC
Shareholder Redemption, (B)&nbsp;pay the amounts due to the underwriters of MAAC&#146;s initial public offering for their deferred underwriting commissions as set forth in the Trust Agreement and (C)&nbsp;immediately thereafter, pay all remaining
amounts then available in the Trust Account to MAAC in accordance with the Trust Agreement, and (b)&nbsp;thereafter, the Trust Account shall terminate, except as otherwise provided therein. From and after the date hereof until the earlier of the
Closing or termination of this Agreement in accordance with its terms, MAAC shall perform all material obligations required to be performed by it under the Trust Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.13</B> <B><U>Company Shareholder Approval</U></B>. Substantially concurrently with the execution hereof, the
Company has obtained and delivered to MAAC a true and correct copy of an irrevocable written consent (in the form attached hereto as <U>Exhibit F</U>) approving and adopting this Agreement, the Ancillary Documents to which the Company is or will be
a party and the transactions contemplated hereby and thereby (including the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps and the Merger) that is duly executed by the Company Shareholders that hold at least the requisite number
of issued and outstanding Company Common Shares required to approve and adopt such matters in accordance with the Companies Act, the Company&#146;s Governing Documents and the Company Shareholders Agreements (the &#147;<U>Company Shareholder Written
Consent</U>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.14</B> <B><U>MAAC Indemnification;
Directors</U></B><B><U>&#146;</U></B><B><U> and Officers</U></B><B><U>&#146;</U></B><B><U> Insurance</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each Party agrees that,
to the maximum extent permitted by applicable Law as if the Company were MAAC, (i)&nbsp;all rights to indemnification or exculpation now existing in favor of the directors and officers of MAAC, as provided in the applicable MAAC Governing Documents
or director and officer indemnification agreements, in substantially the form set forth in the MAAC SEC Reports, in either case, solely with respect to any matters occurring at or prior to the Effective Time, shall survive the transactions
contemplated by this Agreement and shall continue in full force and effect from and after the Effective Time for a period of six (6)&nbsp;years and (ii)&nbsp;the Company will perform and discharge, or cause to be performed and discharged, all
obligations to provide such indemnity and exculpation during such six (6)-year period. To the maximum extent permitted by applicable Law, during such six (6)-year period, the Company shall advance, or caused to be advanced, expenses as provided in
the applicable Governing Documents of MAAC as in effect immediately prior to the Effective Time or such indemnification agreements. The indemnification and liability limitation or exculpation provisions of the MAAC Governing Documents shall not,
during such six (6)-year period, be amended, repealed or otherwise modified following the Effective Time in any manner that would materially and adversely affect the rights thereunder of individuals who, as of immediately prior to the Effective
Time, or at any time prior to such time, were directors or officers of MAAC (the &#147;<U>MAAC D&amp;O Persons</U>&#148;) entitled to be so indemnified, have their liability limited or be exculpated with respect to any matters occurring at or prior
to the Effective Time and relating to the fact that such MAAC D&amp;O Person was a director or officer of MAAC or other person entitled to be so indemnified thereunder at or prior to the Effective Time, unless such amendment, repeal or other
modification is required by applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company shall not have any obligation under this
<U>Section</U><U></U><U>&nbsp;5.14</U> to any MAAC D&amp;O Person when and if a court of competent jurisdiction shall ultimately determine (and such determination shall have become final and <FONT STYLE="white-space:nowrap">non-appealable)</FONT>
that the indemnification of such MAAC D&amp;O Person in the manner contemplated hereby is prohibited by applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) MAAC shall
purchase, or cause to be purchased, at or prior to the Closing, and the Company shall maintain, or cause to be maintained, in effect for a period of six (6)&nbsp;years following the Effective Time, without any lapses in coverage, a &#147;tail&#148;
policy providing directors&#146; and officers&#146; liability insurance coverage for the benefit of those Persons who are currently covered (whether directly, via endorsement or otherwise) by any comparable insurance policies of MAAC in effect as of
the date of this Agreement with respect to matters occurring at or prior to the Effective Time. Such &#147;tail&#148; policy shall provide coverage on terms (with respect to coverage and amount) that are substantially the same as (and no less
favorable in the aggregate to the Persons covered thereby than) the coverage provided under MAAC&#146;s directors&#146; and officers&#146; liability insurance policies in effect as of the date of this Agreement; <U>provided</U> that MAAC shall not
pay a premium for such &#147;tail&#148; policy in excess of three-hundred percent (300%) of the most recent annual premium paid by MAAC prior to the date of this Agreement and, in such event, MAAC shall purchase or cause to be purchased the maximum
coverage available for three-hundred percent (300%) of the most recent annual premium paid by MAAC prior to the date of this Agreement. Notwithstanding the foregoing or anything to the contrary in this Agreement, if the term of MAAC&#146;s
directors&#146; and officers&#146; liability insurance policy in effect as of the date of this Agreement expires on or prior to the Closing Date, then MAAC may renew such policy or obtain, or cause to be obtained, one or more directors&#146; and
officers&#146; insurance policy(ies) that provides for coverage through October&nbsp;9, 2022 on terms (with respect to coverage and amount) that are substantially the same as the coverage provided under such MAAC&#146;s directors&#146; and
officers&#146; liability policy that so expired, and all references in this <U>clause (c)</U>&nbsp;to the directors&#146; and officers&#146; liability insurance policies shall also be deemed to refer to such policy as renewed or such new
policy(ies). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) If the Company or any of its successors or assigns (i)&nbsp;shall merge or consolidate with or merge into any other
corporation or entity and shall not be the surviving or continuing corporation or entity of such consolidation or merger or (ii)&nbsp;shall transfer all or substantially all of their respective properties and assets as an entity in one or a series
of related transactions to any Person, then in each such case, the Company shall use </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reasonable best efforts to cause the successors or assigns of the Company shall assume all of the obligations set forth in this <U>Section</U><U></U><U>&nbsp;5.14</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Persons entitled to the indemnification, liability limitation, exculpation or insurance coverage set forth in this
<U>Section</U><U></U><U>&nbsp;5.14</U> are intended to be third-party beneficiaries of this <U>Section</U><U></U><U>&nbsp;5.14</U>. This <U>Section</U><U></U><U>&nbsp;5.14</U> shall survive the consummation of the transactions contemplated by this
Agreement and shall be binding on all successors and assigns of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5.15</B> <B><U>Company Indemnification;
Directors</U></B><B><U>&#146;</U></B><B><U> and Officers</U></B><B><U>&#146;</U></B><B><U> Insurance</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each Party agrees that
(i)&nbsp;all rights to indemnification or exculpation now existing in favor of the directors and officers of the Group Companies, as provided in the Group Companies&#146; Governing Documents or otherwise in effect as of immediately prior to the
Effective Time, in either case, solely with respect to any matters occurring at or prior to the Effective Time, shall survive the transactions contemplated by this Agreement and shall continue in full force and effect from and after the Effective
Time for a period of six (6)&nbsp;years and (ii)&nbsp;the Company will cause the applicable Group Companies to perform and discharge all obligations to provide such indemnity and exculpation during such six (6)-year period. To the maximum extent
permitted by applicable Law, during such six (6)-year period, the Company shall cause the applicable Group Companies to advance expenses as provided in the applicable Governing Documents of the Group Companies or such indemnification agreements. The
indemnification and liability limitation or exculpation provisions of the Group Companies&#146; Governing Documents shall not, during such six (6)-year period, be amended, repealed or otherwise modified following the Effective Time in any manner
that would materially and adversely affect the rights thereunder of individuals who, as of the Effective Time or at any time prior to the Effective Time, were directors or officers of the Group Companies (the &#147;<U>Company D&amp;O
Persons</U>&#148;) entitled to be so indemnified, have their liability limited or be exculpated with respect to any matters occurring prior to Closing and relating to the fact that such Company D&amp;O Person was a director or officer of any Group
Company at or prior to the Effective Time, unless such amendment, repeal or other modification is required by applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) None of
the Group Companies shall have any obligation under this <U>Section</U><U></U><U>&nbsp;5.15</U> to any Company D&amp;O Person when and if a court of competent jurisdiction shall ultimately determine (and such determination shall have become final
and <FONT STYLE="white-space:nowrap">non-appealable)</FONT> that the indemnification of such Company D&amp;O Person in the manner contemplated hereby is prohibited by applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Company shall purchase, at or prior to the Closing, and the Company shall maintain, or cause to be maintained, in effect for a period
of six (6)&nbsp;years following the Effective Time, without lapses in coverage, a &#147;tail&#148; policy providing directors&#146; and officers&#146; liability insurance coverage for the benefit of those Persons who are currently covered by any
comparable insurance policies of the Group Companies in effect as of the date of this Agreement with respect to matters occurring at or prior to the Effective Time. Such &#147;tail&#148; policy shall provide coverage on terms (with respect to
coverage and amount) that are substantially the same as (and no less favorable in the aggregate to the Persons covered thereby) the coverage provided under the Group Companies&#146; directors&#146; and officers&#146; liability insurance policies as
of the date of this Agreement; <U>provided</U> that the Company shall not pay a premium for such &#147;tail&#148; policy in excess of three-hundred percent (300%) of the most recent annual premium paid by the Group Companies prior to the date of
this Agreement and, in such event, the Company shall purchase the maximum coverage available for three-hundred (300%) of the most recent annual premium paid by the Group Companies prior to the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) If the Company or any of its successors or assigns (i)&nbsp;shall merge or consolidate with or merge into any other corporation or entity
and shall not be the surviving or continuing corporation or entity of such consolidation or merger or (ii)&nbsp;shall transfer all or substantially all of their respective properties and assets as an entity in one or a series of related transactions
to any Person, then in each such case, the Company shall use reasonable best efforts to cause the successors or assigns of the Company shall assume all of the obligations set forth in this <U>Section</U><U></U><U>&nbsp;5.15</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Persons entitled to the indemnification, liability limitation, exculpation or
insurance coverage set forth in this <U>Section</U><U></U><U>&nbsp;5.15</U> are intended to be third-party beneficiaries of this <U>Section</U><U></U><U>&nbsp;5.15</U>. This <U>Section</U><U></U><U>&nbsp;5.15</U> shall survive the consummation of
the transactions contemplated by this Agreement and shall be binding on all successors and assigns of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.16</B> <B><U>Post-Closing Directors</U></B>.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company shall take, or cause to be taken, all actions within its power as may be necessary or appropriate such that effective
immediately after the Effective Time (i)&nbsp;the Company Board shall consist of a number of directors determined by the Company (upon reasonable prior consultation with MAAC) prior to the Effective Time, which shall be divided into three
(3)&nbsp;classes, designated Class&nbsp;I, II and III, with each class consisting of an approximately equal number of directors determined by the Company (upon reasonable prior consultation with MAAC) prior to the Effective Time, and (ii)&nbsp;the
members of the Company Board are the individuals determined in accordance with <U>Section</U><U></U><U>&nbsp;5.16(b)</U> and <U>Section</U><U></U><U>&nbsp;5.16(c)</U>; <U>provided</U> that, in any event, (A)&nbsp;at least a majority of such
directors that comprise the Company Board shall qualify as &#147;independent directors&#148; under the listing rules of Nasdaq immediately after the Effective Time and (B)&nbsp;no such determination by the Company shall affect the ability of the
MAAC Designee to serve on the Board in the class of directors set forth on <U>Section</U><U></U><U>&nbsp;5.16(b)</U> of the MAAC Disclosure Schedules immediately after the Effective Time or MAAC&#146;s rights under
<U>Section</U><U></U><U>&nbsp;5.16(b)</U> or the Company&#146;s obligations with respect thereto. At or prior to the Closing, the Company will provide the MAAC Designee with and, subject to the entry into the same by the MAAC Designee, will enter
into a director indemnification agreement with the MAAC Designee, in form and substance approved by the Company Board and to be offered to all directors serving on the Company Board as of immediately following the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The individual identified on <U>Section</U><U></U><U>&nbsp;5.16(b)</U> of the MAAC Disclosure Schedules shall be a director on the Company
Board immediately after the Effective Time (provided that such individual is willing to serve and is not prohibited by applicable Law or disability from so serving), with such individual being in the class of directors set forth opposite his or her
name on <U>Section</U><U></U><U>&nbsp;5.16(b)</U> of the MAAC Disclosure Schedules (the &#147;<U>MAAC Designee</U>&#148;). The MAAC Designee may be replaced by MAAC prior to the Effective Time with the prior written consent of the Company and, upon
such written consent to any such replacement individual, <U>Section</U><U></U><U>&nbsp;5.16(b)</U> of the MAAC Disclosure Schedules shall automatically be deemed amended to include such replacement individual as the MAAC Designee in lieu of, and to
serve in the same class of directors as, the individual so replaced; <U>provided</U>, <U>however</U>, that the Company shall not unreasonably withhold, condition or delay its consent to any individual proposed by MAAC prior to the Effective Time as
a replacement if the MAAC Designee (whether the initial or any subsequent MAAC Designee) is no longer able to serve on the Company Board as a result of death or disability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The individuals identified on <U>Section</U><U></U><U>&nbsp;5.16(c)</U> of the Company Disclosure Schedules shall be directors on the
Company Board immediately after the Effective Time, with each such individual being in the class of directors set forth opposite his or her name on <U>Section</U><U></U><U>&nbsp;5.16(c)</U> of the Company Disclosure Schedule (each, a
&#147;<U>Company Designee</U>&#148;). The Company may replace any Company Designee with any individual after reasonably consulting with MAAC with respect to such replacement Company Designee, by giving MAAC written notice, and, upon the Company so
giving written notice of the replacement of such Company Designee and after so reasonably consulting with MAAC with respect thereto, <U>Section</U><U></U><U>&nbsp;5.16(c)</U> of the Company Disclosure Schedules shall automatically be deemed amended
to include such replacement individual as a Company Designee in lieu of, and to serve in the same class of directors as, the individual so replaced. Notwithstanding the foregoing or anything to the contrary herein, unless otherwise agreed in writing
by MAAC, in no event shall less than at least a majority of the directors that comprise the Company Board qualify as &#147;independent directors&#148; under the listing rules of Nasdaq immediately after the Effective Time (whether as a result of the
replacement of any Company Designee as contemplated by this <U>Section</U><U></U><U>&nbsp;5.16(c)</U> or otherwise). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5.17</B> <B><U>PCAOB Financial</U></B><B><U>s</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company shall deliver to MAAC, (i)&nbsp;as promptly as reasonably practicable following the date of this Agreement, subject to, in the
case of <U>clause (C)</U>, <U>Section</U><U></U><U>&nbsp;5.17(b)</U>, (A) the audited consolidated balance sheet of the Company as of March&nbsp;31, 2019 and March&nbsp;31, 2020 and the related audited consolidated statements of operations,
comprehensive income (loss), shareholders&#146; equity and redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest and cash flows of the Company for the years then ended, audited in accordance with the standards of the PCAOB,
(B)&nbsp;the audited consolidated balance sheet of the Company as of March&nbsp;31, 2021 and the related audited consolidated statements of operations, comprehensive income (loss), shareholders&#146; equity and redeemable <FONT
STYLE="white-space:nowrap">non-controlling</FONT> interest and cash flows of the Company for the year then ended and (C)&nbsp;customary pro forma financial statements (after giving effect to the transactions contemplated hereby), and (ii)&nbsp;as
promptly as reasonably practicable following the date of the relevant financial statement or other applicable period, the other Closing Company Financial Statements. The Company will use reasonable best efforts to promptly obtain the consents of its
auditors with respect to the Closing Company Financial Statements as may be required by applicable Law or requested by the SEC. The Closing Company Financial Statements (A)&nbsp;will be prepared in accordance with GAAP applied on a consistent basis
throughout the periods indicated (except, in the case of any audited financial statements, as may be specifically indicated in the notes thereto and subject, in the case of any unaudited financial statements, to normal
<FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments (none of which is expected to be individually or in the aggregate material) and the absence of notes thereto), (B) will fairly present in all material respects the financial
position, results of operation and cash flows of the Group Companies as at the date thereof and for the period indicated therein, (C)&nbsp;in the case of any audited financial statements, will be audited in accordance with the standards of the PCAOB
and will contain an unqualified report of the Company&#146;s auditor and (D)&nbsp;will comply in all material respects with the applicable accounting requirements and with the rules and regulations of the SEC, the Exchange Act and the Securities Act
in effect as their respective dates of delivery, at the time of filing of the Registration Statement / Proxy Statement and at the time of effectiveness of the Registration Statement / Proxy Statement (including Regulation <FONT
STYLE="white-space:nowrap">S-X</FONT> or Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> as applicable). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) MAAC shall use its
reasonable best efforts to cooperate with the Company in connection with the preparation of customary pro forma financial statements that are required to be included in the Registration Statement / Proxy Statement. Without limiting the foregoing,
MAAC shall (i)&nbsp;reasonably assist the Company in causing to be prepared in a timely manner any financial information or statements (including customary pro forma financial statements) that involve financial information or statements of MAAC and
that are required to be included in the Registration Statement / Proxy Statement and any other filings to be made by the Company with the SEC in connection with the transactions contemplated by this Agreement or any Ancillary Document and
(ii)&nbsp;obtain the consents of its auditors with respect thereto as may be required by applicable Law or requested by the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.18</B> <B><U>Company Post-Closing Incentive Equity Plan; Company Post-Closing Employee Stock Purchase
Plan</U></B>. Prior to the effectiveness of the Registration Statement / Proxy Statement, the Company Board (a)<U></U>&nbsp;shall approve and adopt the Roivant Sciences Ltd. Amended and Restated 2021 Equity Incentive Plan, substantially in the form
attached hereto as <U>Exhibit G</U>, with any changes or modifications to such form as the Company and MAAC may mutually agree (such agreement not to be unreasonably withheld, conditioned or delayed by either the Company or MAAC, as applicable) (the
&#147;<U>Company Post-Closing Incentive Equity Plan</U>&#148;), in the manner prescribed under applicable Laws, effective as of one day prior to the Closing Date, and (b)&nbsp;may approve and adopt an employee stock purchase plan, with such terms
and conditions set forth on <U>Exhibit H</U> and with any changes or modifications thereto as the Company and MAAC may mutually agree (such agreement not to be unreasonably withheld, conditioned or delayed by either the Company or MAAC, as
applicable) (the &#147;<U>Company Post-Closing Employee Stock Purchase Plan</U>&#148;), in the manner prescribed under applicable Laws, effective as of one day prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.19</B> <B><U>Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps</U></B>. The Company shall, and
shall cause its Representatives to, reasonably consult with and reasonably cooperate with MAAC and its Representatives in connection with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps and otherwise keep MAAC and its Representatives apprised, in reasonable detail, of the status of the Company <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Steps. Without limiting the generality of the foregoing, (a)&nbsp;within a reasonable time prior to the Closing (and in any event ten (10)&nbsp;Business Days prior to the Closing Date), the Company shall
provide, or cause to be provided, drafts of all agreements, documents and instruments related to the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps, and give MAAC and its Representatives a reasonable amount of time to review all
such agreements, documents and instruments and shall consider in good faith all comments provided by MAAC and its Representatives and (b)&nbsp;none of the Group Companies shall enter into any agreement, document or instrument related to the Company <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Steps that is not in a form and substance reasonably satisfactory to MAAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.20</B> <B><U>Company Related Party Transactions</U></B>. The Company shall use reasonable best efforts to
take, or cause to be taken, all actions necessary or advisable to terminate at or prior to the Closing all of the agreements set forth on <U>Section</U><U></U><U>&nbsp;5.20</U> of the Company Disclosure Schedules without any further Liabilities to
the Company or any of its Affiliates (including the other Group Companies and, from and after the Effective Time, MAAC and its Affiliates). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.21</B> <B><U>Conduct of Business of Merger Sub</U></B>. From and after the date of this Agreement until the
earlier of the Closing or the termination of this Agreement in accordance with its terms, Merger Sub shall not take any action, engage in any activities or business, or incur any Liabilities or obligations, other than (a)&nbsp;those that are
incident to its organization, (b)&nbsp;the execution of this Agreement or any Ancillary Document to which it is or will be a party, (c)&nbsp;those that are contemplated by this Agreement or any Ancillary Document (including the enforcement of any of
its rights or the performance of any of its obligations under this Agreement or any Ancillary Documents and the consummation of the transactions contemplated hereby or thereby) or (d)&nbsp;those that are consented to in writing by MAAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.22</B> <B><U>Notice of Certain Events</U></B>. From and after the date of this Agreement until the earlier of
the Closing or the termination of this Agreement in accordance with its terms, each Party shall use reasonable best efforts to promptly (after having knowledge thereof) notify the other Parties of (i)&nbsp;any written notice or other communication
received by such Party or any of its Representatives (in their capacity as such) from any Governmental Entity of the type that would, if received prior to the execution and delivery of this Agreement, have been required to have been disclosed
pursuant to any section or subsection of <U>Article</U><U></U><U>&nbsp;3</U> or <U>Article</U><U></U><U>&nbsp;4</U>, as applicable, and (ii)&nbsp;the occurrence or <FONT STYLE="white-space:nowrap">non-occurrence</FONT> of any event the occurrence or
<FONT STYLE="white-space:nowrap">non-occurrence</FONT> of which, as the case may be, would reasonably be expected to cause any condition to the other Parties&#146; obligations to consummate the transactions contemplated hereby set forth in
<U>Article</U><U></U><U>&nbsp;6</U> not to be satisfied at any time from the date of this Agreement to the Effective Time; <U>provided</U>, <U>however</U>, that any failure by a Party to provide such notice that is not in made in bad faith shall
not, in and of itself, constitute a breach or default of this <U>Section</U><U></U><U>&nbsp;5.22</U> or a failure to satisfy the condition precedent set forth in <U>Section</U><U></U><U>&nbsp;6.2(b)</U> or <U>Section</U><U></U><U>&nbsp;6.3(b)</U>,
as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5.23</B> <B><U>PIPE Subscription Agreements</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) MAAC shall use its reasonable best efforts to (i)&nbsp;obtain the PIPE Financing, enforce the obligations of the PIPE Investors under the
PIPE Subscription Agreements, and consummate the purchases contemplated by the PIPE Subscription Agreements, in each case, on the terms and subject to the conditions set forth in the PIPE Subscription Agreements, (ii)&nbsp;satisfy all conditions to
the PIPE Financing set forth in the PIPE Subscription Agreements that are within its control, and (iii)&nbsp;satisfy and comply with its obligations under the PIPE Subscription Agreements; <U>provided</U>, <U>however</U>, that (a)&nbsp;MAAC shall be
deemed to have satisfied its obligations under this sentence if the PIPE Financing contemplated by any underlying PIPE Subscription Agreement has been funded or will be funded on its terms substantially concurrently with the occurrence of the
Closing and (b)&nbsp;for the avoidance of doubt, any breach, or failure to perform or comply with, any provision of a PIPE Subscription Agreement by a PIPE Investor shall not, in and of itself, be deemed to be a breach of, or failure to perform or
comply with, this sentence. The Company shall use its reasonable best efforts to, and shall use its reasonable best efforts to cause its Representatives to, cooperate with MAAC and its Representatives in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
connection with the matters specified in this <U>Section</U><U></U><U>&nbsp;5.23</U>. If reasonably requested by the Company, MAAC shall, to the extent it has such rights under the applicable
PIPE Subscription Agreement, waive any breach of any representation, warranty, covenant or agreement under a PIPE Subscription Agreement by a PIPE Investor to the extent necessary to cause the satisfaction of the conditions to closing of the PIPE
Financing set forth in the PIPE Subscription Agreements and solely for the purpose of consummating the Closing, provided that (i)&nbsp;any such waiver may (in MAAC&#146;s sole discretion) be subject to, and conditioned upon, the Closing occurring
and the substantially concurrent funding of such PIPE Financing, (ii)&nbsp;subject to, and condition upon, the Closing occurring substantially concurrent funding of the PIPE Financing, the Company also waives any such breach to the extent the
Company is a third party beneficiary of the provision that was so breached and (iii)&nbsp;any such waiver shall be subject to the rights of the placement agent, as applicable, under such PIPE Subscription Agreement with respect to such waiver. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) MAAC shall not amend, modify or waive any provisions of any PIPE Subscription Agreement without the prior written consent of the Company;
<U>provided</U> that any amendment, modification or waiver that is solely ministerial in nature or otherwise immaterial, and, in each case, that does not affect any economic or any other material term, shall not require the prior written consent of
the Company, so long as MAAC has provided to the Company no less than two (2)&nbsp;Business Days written notice of such amendment, modification or waiver, it being understood, but without limiting the foregoing, that it shall be deemed material if
any amendment, modification or waiver (i)&nbsp;reduces the amount of the PIPE Financing available under such PIPE Subscription Agreement or (ii)&nbsp;imposes new or additional conditions or otherwise expands, amends or modifies any of the conditions
to the receipt of the PIPE Financing under such PIPE Subscription Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) MAAC shall (i)&nbsp;promptly notify the Company upon
having knowledge of any material breach or default under, or termination of, any PIPE Subscription Agreement (including any refusal or repudiation by any PIPE Investor with respect to its obligation and/or ability to provide the full financing
contemplated by the applicable PIPE Subscription Agreement), (ii) prior to delivering any written notice to a PIPE Investor with respect to any PIPE Subscription Agreement, deliver such written notice to the Company for its prior review and consent
(which consent shall not be unreasonably withheld, conditioned or delayed), and (iii)&nbsp;promptly, and in any event, within two (2)&nbsp;Business Days following the Company&#146;s reasonable request, deliver the Closing Notice (as defined in the
PIPE Subscription Agreements) to the PIPE Investors if conditions to the delivery of such notice under the PIPE Subscription Agreement have been satisfied and all of the conditions to the Closing set forth in <U>Article</U><U></U><U>&nbsp;6</U> have
been satisfied or waived (other than those conditions that, by their nature, are to be satisfied at the Closing, but that would, as of such date, reasonably be expected to be satisfied if the Closing were to occur). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;6 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDITIONS TO CONSUMMATION OF THE TRANSACTIONS CONTEMPLATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BY THIS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.1</B> <B><U>Conditions to the Obligations of the Parties</U></B>. The obligations of the Parties to consummate
the transactions contemplated by this Agreement are subject to the satisfaction or, if permitted by applicable Law, waiver by MAAC and the Company of the following conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) no Order or Law issued by any court of competent jurisdiction or other Governmental Entity, in each case (x)&nbsp;in the United States or
any other jurisdiction in which the Group Companies conduct material operations or (y)&nbsp;that is otherwise material, in each case, preventing the consummation of the transactions contemplated by this Agreement, shall be in effect; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) the Registration Statement / Proxy Statement shall have become effective in accordance with the provisions of the Securities Act, no stop
order shall have been issued by the SEC and shall remain in effect with respect to the Registration Statement / Proxy Statement, and no Proceeding seeking such a stop order shall have been threatened or initiated by the SEC and remain pending; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) the Required MAAC Shareholder Approval shall have been duly obtained; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) the Company&#146;s initial listing application with Nasdaq in connection with the transactions contemplated by this Agreement shall have
been conditionally approved and, immediately following the Effective Time, the Company shall satisfy any applicable initial and continuing listing requirements of Nasdaq, and the Company shall not have received any notice of <FONT
STYLE="white-space:nowrap">non-compliance</FONT> therewith that has not been cured prior to, or would not be cured at or immediately following, the Effective Time, and the Company Post-Closing Common Shares (including the Company Post-Closing Common
Shares to be issued hereunder and under the Ancillary Documents) shall have been approved for listing on Nasdaq; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) after giving
effect to the transactions contemplated hereby (including the PIPE Financing), the Company shall have at least $5,000,001 of net tangible assets (as determined in accordance with Rule <FONT STYLE="white-space:nowrap">3a51-1(g)(1)</FONT> of the
Exchange Act) immediately after the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.2</B> <B><U>Other Conditions to the Obligations of
</U></B><B><U>MAAC</U></B>. The obligations of MAAC to consummate the transactions contemplated by this Agreement are subject to the satisfaction or, if permitted by applicable Law, waiver by MAAC of the following further conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) (i) the Company Fundamental Representations (other than the representations and warranties set forth in
<U>Section</U><U></U><U>&nbsp;3.8(a)</U>) shall be true and correct (without giving effect to any limitation as to &#147;materiality&#148; or &#147;Company Material Adverse Effect&#148; or any similar limitation set forth herein) in all material
respects as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made as of an earlier date, in which case such representation and warranty shall be true and correct
(without giving effect to any limitation as to &#147;materiality&#148; or &#147;Company Material Adverse Effect&#148; or any similar limitation set forth herein) in all material respects as of such earlier date), (ii) the representation and warranty
set forth in <U>Section</U><U></U><U>&nbsp;3.8(a)</U> shall be true and correct in all respects as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made as of an
earlier date, in which case such representation and warranty shall be true and correct in all respects as of such earlier date) (<U>provided</U>, <U>however</U>, that this <U>clause (ii)</U>&nbsp;shall be deemed to be satisfied if no Company
Material Adverse Effect is continuing as of the Closing Date), (iii) the Company Additional Capitalization Representations shall be true and correct (without giving effect to any limitation as to &#147;materiality&#148; or &#147;Company Material
Adverse Effect&#148; or any similar limitation set forth herein) as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made as of an earlier date, in which case such
representation and warranty shall be true and correct (without giving effect to any limitation as to &#147;materiality&#148; or &#147;Company Material Adverse Effect&#148; or any similar limitation set forth herein) as of such earlier date), except
where the failure of such representations and warranties to be true and correct would not be material to the Group Companies, taken as a whole, and (iv)&nbsp;the representations and warranties of the Company and Merger Sub set forth in
<U>Article</U><U></U><U>&nbsp;3</U> (other than the Company Fundamental Representations and the Company Additional Capitalization Representations) shall be true and correct (without giving effect to any limitation as to &#147;materiality&#148; or
&#147;Company Material Adverse Effect&#148; or any similar limitation set forth herein) in all respects as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made as
of an earlier date, in which case such representation and warranty shall be true and correct (without giving effect to any limitation as to &#147;materiality&#148; or &#147;Company Material Adverse Effect&#148; or any similar limitation set forth
herein) in all respects as of such earlier date), except where the failure of such representations and warranties to be true and correct would not have a Company Material Adverse Effect; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) the Company and Merger Sub shall have performed and complied in all material respects with the covenants and agreements required to be
performed or complied with by the Company and Merger Sub under this Agreement at or prior to the Closing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) since the date of this
Agreement, no Company Material Adverse Effect has occurred that is continuing; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) as of immediately after the Effective Time, the Company Board shall include the MAAC
Designee, as determined pursuant to <U>Section</U><U></U><U>&nbsp;5.16(b)</U>; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) the Company
<FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps shall have been consummated on the Closing Date prior to the Effective Time in accordance with the applicable terms of this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) the waiting period under the HSR Act with respect to the Notification and Report Form to be filed by the MAAC Sponsor as an acquiring
person (as that term is defined by 16 C.F.R. 801.2) in connection with the transactions contemplated by this Agreement shall have expired or been terminated; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) at or prior to the Closing, the Company shall have delivered, or caused to be delivered, to MAAC a certificate duly executed by an
authorized officer of the Company, dated as of the Closing Date, to the effect that the conditions specified in <U>Section</U><U></U><U>&nbsp;6.2(a)</U>, <U>Section</U><U></U><U>&nbsp;6.2(b)</U> and <U>Section</U><U></U><U>&nbsp;6.2(c)</U> are
satisfied, in a form and substance reasonably satisfactory to MAAC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.3</B> <B><U>Other Conditions to the
Obligations of </U></B><B><U>the Company</U></B>. The obligations of the Company to consummate the transactions contemplated by this Agreement are subject to the satisfaction or, if permitted by applicable Law, waiver by the Company of the following
further conditions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) (i) the MAAC Fundamental Representations shall be true and correct in all material respects as of the Closing
Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made as of an earlier date, in which case such representation and warranty shall be true and correct in all material respects as of
such earlier date) (<U>provided</U>, <U>however</U>, that the representation and warranty set forth in <U>Section</U><U></U><U>&nbsp;4.9</U> shall be deemed to be true and correct in all material respects as of the Closing Date for purposes of this
<U>clause (i)</U>&nbsp;if no MAAC Material Adverse Effect is continuing as of the Closing Date), and (ii)&nbsp;the representations and warranties of MAAC (other than the MAAC Fundamental Representations) contained in
<U>Article</U><U></U><U>&nbsp;4</U> of this Agreement shall be true and correct (without giving effect to any limitation as to &#147;materiality&#148; or &#147;MAAC Material Adverse Effect&#148; or any similar limitation set forth herein) in all
respects as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made as of an earlier date, in which case such representation and warranty shall be true and correct
(without giving effect to any limitation as to &#147;materiality&#148; or &#147;MAAC Material Adverse Effect&#148; or any similar limitation set forth herein) in all respects as of such earlier date), except where the failure of such representations
and warranties to be true and correct would not have a MAAC Material Adverse Effect; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) MAAC shall have performed and complied in all
material respects with the covenants and agreements required to be performed or complied with by it under this Agreement at or prior to the Closing; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) since the date of this Agreement, no MAAC Material Adverse Effect has occurred that is continuing; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) the Aggregate Trust Account Proceeds shall be equal to or greater than $210,000,000; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) the MAAC Sponsor shall have complied in all material respects with its covenants and agreements required to be performed or complied with
by it under the Sponsor Support Agreement at or prior to the Closing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) at or prior to the Closing, MAAC shall have delivered, or
caused to be delivered, the following documents to the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) a certificate duly executed by an authorized officer of MAAC, dated
as of the Closing Date, to the effect that the conditions specified in <U>Section</U><U></U><U>&nbsp;6.3(a)</U>, <U>Section</U><U></U><U>&nbsp;6.3(b)</U> and <U>Section</U><U></U><U>&nbsp;6.3(c)</U> are satisfied, in a form and substance reasonably
satisfactory to the Company; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) a certificate prepared in a manner consistent and in accordance with the requirements
of Treasury Regulations Sections <FONT STYLE="white-space:nowrap">1.897-2(g),</FONT> (h) and <FONT STYLE="white-space:nowrap">1.1445-2(c)(3),</FONT> certifying that no interest in MAAC is, or has been during the relevant period specified in
Section&nbsp;897(c)(1)(A)(ii) of the Code, a &#147;United States real property interest&#148; within the meaning of Section&nbsp;897(c) of the Code, and a form of notice to the Internal Revenue Service prepared in accordance with the provisions of
Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.897-2(h)(2).</FONT> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;7 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERMINATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.1</B> <B><U>Termination</U></B>. This Agreement may be terminated and the transactions contemplated by this
Agreement may be abandoned at any time prior to the Closing: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) by mutual written consent of MAAC and the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) by MAAC, if any of the representations or warranties set forth in <U>Article</U><U></U><U>&nbsp;3</U> shall not be true and correct or if
the Company or Merger Sub has failed to perform any covenant or agreement on the part of the Company or Merger Sub set forth in this Agreement (including an obligation to consummate the Closing) such that the condition to Closing set forth in either
<U>Section</U><U></U><U>&nbsp;6.2(a)</U> or <U>Section</U><U></U><U>&nbsp;6.2(b)</U> would not (assuming that the Closing occurred as of such date) be satisfied and the breach or breaches causing such representations or warranties not to be true and
correct, or the failures to perform any covenant or agreement, as applicable, is (or are) not cured or cannot be cured within the earlier of (i)&nbsp;thirty (30)&nbsp;days after written notice thereof is delivered to the Company by MAAC and
(ii)&nbsp;the Termination Date; <U>provided</U>, <U>however</U>, that MAAC is not then in breach of this Agreement so as to prevent the condition to Closing set forth in either <U>Section</U><U></U><U>&nbsp;6.3(a)</U> or
<U>Section</U><U></U><U>&nbsp;6.3(b)</U> from being satisfied (assuming that the Closing occurred as of such date); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) by the Company,
if any of the representations or warranties set forth in <U>Article</U><U></U><U>&nbsp;4</U> shall not be true and correct or if MAAC has failed to perform any covenant or agreement on the part of MAAC set forth in this Agreement (including an
obligation to consummate the Closing) such that the condition to Closing set forth in either <U>Section</U><U></U><U>&nbsp;6.3(a)</U> or <U>Section</U><U></U><U>&nbsp;6.3(b)</U> would not (assuming that the Closing occurred as of such date) be
satisfied and the breach or breaches causing such representations or warranties not to be true and correct, or the failures to perform any covenant or agreement, as applicable, is (or are) not cured or cannot be cured within the earlier of
(i)&nbsp;thirty (30) days after written notice thereof is delivered to MAAC by the Company and (ii)&nbsp;the Termination Date; <U>provided</U>, <U>however</U>, that none of the Company or Merger Sub is then in breach of this Agreement so as to
prevent the condition to Closing set forth in <U>Section</U><U></U><U>&nbsp;6.2(a)</U> or <U>Section</U><U></U><U>&nbsp;6.2(b)</U> from being satisfied (assuming that the Closing occurred as of such date); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) by either MAAC or the Company, if the transactions contemplated by this Agreement shall not have been consummated on or prior to
November&nbsp;30, 2021 (the &#147;<U>Termination Date</U>&#148;); <U>provided</U>, that (i)&nbsp;the right to terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;7.1(d)</U> shall not be available to MAAC if MAAC&#146;s breach
under this Agreement or any Ancillary Document to which it is a party shall have proximately caused the failure to consummate the transactions contemplated by this Agreement on or before the Termination Date, and (ii)&nbsp;the right to terminate
this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;7.1(d)</U> shall not be available to the Company if the Company&#146;s or Merger Sub&#146;s breach under this Agreement or any Ancillary Document to which such Person is a party shall
have proximately caused the failure to consummate the transactions contemplated by this Agreement on or before the Termination Date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)
by either MAAC or the Company, if any Governmental Entity of competent jurisdiction shall have issued an Order or taken any other action permanently enjoining, restraining or otherwise prohibiting the transactions contemplated by this Agreement and
such Order or other action shall have become final and nonappealable; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) by either MAAC or the Company if the MAAC Shareholders Meeting has been held (including
following any adjournment or postponement thereof), has concluded, MAAC&#146;s shareholders have duly voted and the Required MAAC Shareholder Approval was not obtained; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) by MAAC, if the Company does not deliver, or cause to be delivered to MAAC, the Merger Sub Shareholder Approval in accordance with
<U>Section</U><U></U><U>&nbsp;5.9</U> on or prior to the Merger Sub Shareholder Approval Deadline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.2</B>
<B><U>Effect of Termination</U></B>. Except for a termination pursuant to <U>Section</U><U></U><U>&nbsp;7.1(a)</U>, any termination of this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1</U> will be effective (subject to the cure periods
(if any) provided above) immediately upon the delivery of a valid written notice of the terminating Party to the Company (if the terminating Party is MAAC) or MAAC (if the terminating Party is the Company). In the event of the termination of this
Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1</U>, this entire Agreement shall forthwith become void (and there shall be no Liability or obligation on the part of the Parties and their respective
<FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates) with the exception of (a)<U>&nbsp;Section</U><U></U><U>&nbsp;5.3(a)</U>, this <U>Section</U><U></U><U>&nbsp;7.2</U>, <U>Article</U><U></U><U>&nbsp;8</U> and
<U>Article</U><U></U><U>&nbsp;1</U> (to the extent, with respect to <U>Article</U><U></U><U>&nbsp;1</U>, related to the foregoing), each of which shall survive such termination and remain valid and binding obligations of the Parties and (b)&nbsp;the
Confidentiality Agreement, which shall survive such termination and remain valid and binding obligations of the parties thereto in accordance with its terms. Notwithstanding the foregoing or anything to the contrary herein, the termination of this
Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1</U> shall not affect (i)&nbsp;any Liability on the part of any Party for any Willful Breach of any covenant or agreement set forth in this Agreement prior to such termination or Fraud or
(ii)&nbsp;any Person&#146;s Liability under any PIPE Subscription Agreement, the Confidentiality Agreement, any Transaction Support Agreement or the Sponsor Support Agreement to which such Person is a party to the extent arising from a claim against
such Person by another Person party to such agreement on the terms and subject to the conditions thereunder. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;8 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.1</B> <B><U><FONT STYLE="white-space:nowrap">Non-Survival</FONT></U></B>. The representations, warranties,
agreements and covenants in this Agreement shall terminate at the earlier of (a)&nbsp;the Effective Time and (b)&nbsp;the termination of this Agreement in accordance with its terms, except for (i)&nbsp;in the case of <U>clause (a)</U>, those
covenants and agreements that, by their terms, expressly contemplate performance after the Effective Time, which covenants and agreements shall so survive the Effective Time in accordance with their terms, and (ii)&nbsp;in the case of <U>clause
(b)</U>, those covenants and agreements that expressly survive termination of this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.2</B> <B><U>Entire Agreement; Assignment</U></B>. This Agreement (together with the Ancillary Documents)
constitutes the entire agreement among the Parties with respect to the subject matter hereof and supersedes all other prior agreements and understandings, both written and oral, among the Parties with respect to the subject matter hereof. This
Agreement&nbsp;may not be assigned by any Party (whether by operation of law or otherwise) without the prior written consent of MAAC and the Company; <U>provided</U>, <U>however</U>, that to the extent any such assignment following the Closing
relates to any of the Company&#146;s obligations under <U>Section</U><U></U><U>&nbsp;5.14</U>, such assignment shall, unless otherwise agreed to in writing by the MAAC Sponsor (not to be unreasonably withheld, conditioned or delayed), and except for
an assignment of the type described in <U>clause (d)</U>&nbsp;thereof in connection with a sale of all or substantially all of the Company&#146;s assets or businesses, only be effective to the extent such obligations are actually performed or
discharged. Any attempted assignment of this Agreement not in accordance with the terms of this <U>Section</U><U></U><U>&nbsp;8.2</U> shall be void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.3</B> <B><U>Amendment</U></B>. This Agreement may be amended or modified only by a written agreement executed and delivered
by MAAC and the Company; <U>provided</U>, <U>however</U>, that any such amendment or modification prior to the Closing with respect to <U>Section</U><U></U><U>&nbsp;6.2(f)</U> or following the Closing with respect to
<U>Section</U><U></U><U>&nbsp;5.14</U>, the proviso in the first sentence of <U>Section</U><U></U><U>&nbsp;8.2</U>, this <U>Section</U><U></U><U>&nbsp;8.3</U>, <U>Section</U><U></U><U>&nbsp;8.9</U>, <U>Section</U><U></U><U>&nbsp;8.13</U> or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<U>Section</U><U></U><U>&nbsp;8.14</U>, in each case, solely as and to the extent related to the MAAC Sponsor or any of the MAAC <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates
(collectively, the &#147;<U>MAAC Sponsor Specified Provisions</U>&#148;) shall also require the written consent of the MAAC Sponsor. This Agreement may not be modified or amended except as provided in the immediately preceding sentence and any
purported amendment by any Party or Parties effected in a manner which does not comply with this <U>Section</U><U></U><U>&nbsp;8.3</U> shall be void, <I>ab initio</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.4</B> <B><U>Notices</U></B>. All notices, requests, claims, demands and other communications hereunder shall
be in writing and shall be given (and shall be deemed to have been duly given) by delivery in person, by <FONT STYLE="white-space:nowrap">e-mail</FONT> (having obtained electronic delivery confirmation thereof (<I>i.e.,</I> an electronic record of
the sender that the <FONT STYLE="white-space:nowrap">e-mail</FONT> was sent to the intended recipient thereof without an &#147;error&#148; or similar message that such <FONT STYLE="white-space:nowrap">e-mail</FONT> was not received by such intended
recipient)), or by registered or certified mail (postage prepaid, return receipt requested) (upon receipt thereof) to the other Parties as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If to MAAC, to: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Montes Archimedes Acquisition Corp. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">724 Oak Grove, Suite 130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Menlo
Park, CA 94025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Maria Walker </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> &nbsp;&nbsp;&nbsp;&nbsp;maria@patientsquarecapital.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><U>with a copy (which shall not constitute notice) to</U>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Kirkland&nbsp;&amp; Ellis LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">601 Lexington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York,
NY 10022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Michael E. Weisser, P.C. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ryan Brissette </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> &nbsp;&nbsp;&nbsp;&nbsp;michael.weisser@kirkland.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ryan.brissette@kirkland.com </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If to the Company or Merger Sub, to: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Roivant Sciences Ltd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Suite 1,
3rd Floor, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">11-12</FONT> St. James&#146;s Square, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">London SW1Y 4LB, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">United
Kingdom </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Matthew Gline </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> &nbsp;&nbsp;&nbsp;&nbsp;matthew.gline@roivant.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;legalnotices@roivant.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><U>with a copy (which shall not constitute notice) to</U>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Roivant Sciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">151
West 42nd Street, 15th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, NY 10036 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-mail:&nbsp;&nbsp;&nbsp;&nbsp;</FONT> jo.chen@roivant.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">-and-</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Davis Polk&nbsp;&amp; Wardwell LLP </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">450 Lexington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York,
NY 10017 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Derek Dostal </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Brian Wolfe </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lee Hochbaum </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> &nbsp;&nbsp;&nbsp;&nbsp;derek.dostal@davispolk.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;brian.wolfe@davispolk.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;lee.hochbaum@davispolk.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address as the Party to whom notice is given may have previously furnished to the others in writing in the manner set forth above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.5</B> <B><U>Governing Law</U></B>. This Agreement shall be governed by and construed in accordance with the laws of the
State of Delaware, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the law of any jurisdiction other than the State of
Delaware (except that the Bermuda Companies Act 1981 shall also apply to the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.6</B> <B><U>Fees and Expenses</U></B>. All fees and expenses incurred in connection with this Agreement, the
Ancillary Documents and the transactions contemplated hereby and thereby, including the fees and disbursements of counsel, financial advisors and accountants, shall be paid by the Party incurring such fees or expenses; <U>provided, </U>that the
Parties intend for all unpaid fees and expenses at the Closing required to be paid by MAAC pursuant to this <U>Section</U><U></U><U>&nbsp;8.6</U> to be paid by MAAC from a bank account opened by MAAC LLC (as defined in
<U>Section</U><U></U><U>&nbsp;4.6(c)</U> of the MAAC Disclosure Schedules), assuming that MAAC LLC is formed prior to Closing and such a bank account is opened, and otherwise from a bank account specified by MAAC (it being understood and agreed that
in no event shall this proviso result in a failure of any condition to Closing set forth in <U>Article</U><U></U><U>&nbsp;6</U>); <U>provided</U> <U>further</U> that, for the avoidance of doubt, if this Agreement is terminated in accordance with its
terms, the Company shall pay, or cause to be paid, all Company Expenses and MAAC shall pay, or cause to be paid, all MAAC Expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.7</B> <B><U>Construction; Interpretation</U></B>. The term &#147;this Agreement&#148; means this Business Combination
Agreement together with the Schedules and Exhibits hereto, as the same may from time to time be amended, modified, supplemented or restated in accordance with the terms hereof. The headings set forth in this Agreement are inserted for convenience
only and shall not affect in any way the meaning or interpretation of this Agreement. The language used in this Agreement shall be deemed to be the language chosen by the Parties to express their mutual intent and the Parties acknowledge that each
Party and its counsel has reviewed and participated in the drafting of this Agreement. No Party, nor its respective counsel, shall be deemed the drafter of this Agreement for purposes of construing the provisions hereof, and all provisions of this
Agreement shall be construed according to their fair meaning and no rule of strict construction, presumption or burden of proof favoring or disfavoring a Party shall be applied against any Party. Unless otherwise indicated to the contrary herein by
the context or use thereof: (a)&nbsp;the words, &#147;hereof,&#148; &#147;herein,&#148; &#147;hereby,&#148; &#147;hereto,&#148; &#147;herewith,&#148; &#147;hereunder&#148; and words of similar import refer to this Agreement as a whole, including the
Schedules and Exhibits hereto, and not to any particular provision, section, subsection, paragraph, subparagraph or clause set forth in this Agreement; (b)&nbsp;masculine gender shall also include the feminine and neutral genders, and vice versa;
(c)&nbsp;words importing the singular shall also include the plural, and vice versa; (d)&nbsp;the words &#147;include,&#148; &#147;includes&#148; or &#147;including&#148; shall be deemed to be followed by the words &#147;without limitation&#148;;
(e) all monetary figures used herein, including references to &#147;$&#148; or &#147;dollar&#148; or &#147;US$,&#148; shall be references to United States dollars; (f)&nbsp;the word &#147;or&#148; is disjunctive but not necessarily exclusive;
(g)&nbsp;the words &#147;writing,&#148; &#147;written&#148; and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form; (h)&nbsp;the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
word &#147;day&#148; means calendar day unless Business Day is expressly specified; (i)&nbsp;any reference to a date or time shall be deemed to be such date or time in New York, New York;
(j)&nbsp;references from or through any date mean from and including or through and including such date, respectively; (k)&nbsp;the word &#147;extent&#148; in the phrase &#147;to the extent&#148; means the degree to which a subject or other thing
extends, and such phrase shall not mean simply &#147;if&#148;; (l) all references to Articles, Sections, Exhibits or Schedules are to Articles, Sections, Exhibits and Schedules of this Agreement; (m)&nbsp;the words &#147;provided,&#148; &#147;made
available,&#148; &#147;delivered&#148; or words of similar import (regardless of whether capitalized or not) shall mean, when used with reference to documents or other materials required to be provided or made available to MAAC, any documents or
other materials posted to the electronic data room located at https://wwwna.dfsvenue.com/cardhub.aspx under the project name &#147;Project Rhine&#148; as of 8:00 p.m., Eastern Time, at least one (1)&nbsp;day prior to the date of this Agreement;
(n)&nbsp;all references to any Law will be to such Law as amended, supplemented, consolidated, replaced or otherwise modified or <FONT STYLE="white-space:nowrap">re-enacted</FONT> from time to time and shall include all regulations and rules
promulgated thereunder; (o)&nbsp;all references to any Contract are to that Contract as amended or modified from time to time in accordance with the terms thereof (subject to any restrictions on amendments or modifications set forth in this
Agreement); (p) any reference to &#147;MAAC&#148; in this Agreement shall mean and refer to the &#147;Surviving Company&#148; from and after the Effective Time; (q)&nbsp;whenever any other word derived from a defined term shall be used in this
Agreement, such derived word shall have the meaning correlative to such defined term (e.g., &#147;controlled&#148; or &#147;controlling&#148; shall have the meaning correlative to &#147;control&#148;); (r) the phrase &#147;ordinary course of
business&#148; means an action taken, or omitted to be taken, by any Person in the ordinary course of such Person&#146;s business consistent with past practice, subject to, other than in the case of any action taken, or omitted to be taken, of the
type that would, if taken during the period from the date of this Agreement until the Closing (and regardless of whether taken prior to, at or after the date hereof), require the consent of MAAC pursuant to any Company Specified Interim Operating
Covenants, any action taken, or omitted to be taken, by any Group Company to the extent determined by a Group Company to be reasonable and advisable in response to <FONT STYLE="white-space:nowrap">COVID-19;</FONT> and (s)&nbsp;the phrase
&#147;consistent with past valuation practices&#148; shall mean (i)&nbsp;with respect to any equity incentive awards of any Private Group Company (other than any Company CVAR Award) that has an exercise price, an exercise price at or above fair
market value and (ii)&nbsp;with respect to all Equity Securities of the Company or any other Private Group Company (other than equity incentive awards described in the preceding <U>clause (i)</U>), an issuance or grant with a value at or above fair
market value (with such fair market value, in the case of each of <U>clause (i)</U>&nbsp;and <U>(ii)</U>, determined by reference to, among other things, the Company&#146;s most recent equity financing or third-party valuations). If any action under
this Agreement is required to be done or taken on a day that is not a Business Day, then such action shall be required to be done or taken not on such day but on the first succeeding Business Day thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.8</B> <B><U>Exhibits and Schedules</U></B>. All Exhibits and Schedules (including the Company Disclosure
Schedules and the MAAC Disclosure Schedules), or documents expressly incorporated into this Agreement, are hereby incorporated into this Agreement and are hereby made a part hereof as if set out in full in this Agreement. Any capitalized term(s)
used in any Exhibits and Schedules (including the Company Disclosure Schedules and the MAAC Disclosure Schedules) annexed hereto or referred to herein but not otherwise defined therein shall have the meaning ascribed to such term(s) in this
Agreement. The Schedules shall be arranged in sections and subsections corresponding to the numbered and lettered Sections and subsections set forth in this Agreement. Any item disclosed in the Company Disclosure Schedules or in the MAAC Disclosure
Schedules corresponding to any Section or subsection of <U>Article</U><U></U><U>&nbsp;3</U> (in the case of the Company Disclosure Schedules) or <U>Article</U><U></U><U>&nbsp;4</U> (in the case of the MAAC Disclosure Schedules) shall be deemed to
have been disclosed with respect to every other section and subsection of <U>Article</U><U></U><U>&nbsp;3</U> (in the case of the Company Disclosure Schedules) or <U>Article</U><U></U><U>&nbsp;4</U> (in the case of the MAAC Disclosure Schedules), as
applicable, where the relevance of such disclosure to such other Section or subsection is reasonably apparent. The information and disclosures set forth in the Schedules that correspond to the section or subsections of
<U>Article</U><U></U><U>&nbsp;3</U> or <U>Article</U><U></U><U>&nbsp;4</U> may not be limited to matters required to be disclosed in the Schedules, and any such additional information or disclosure is for informational purposes only and does not
necessarily include other matters of a similar nature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.9</B> <B><U>Parties in Interest</U></B>. This
Agreement shall be binding upon and inure solely to the benefit of each Party and its successors and permitted assigns and, except as provided in <U>Section</U><U></U><U>&nbsp;5.14</U>, <U>Section</U><U></U><U>&nbsp;5.15</U><U>,</U> the two
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subsequent sentences of this <U>Section</U><U></U><U>&nbsp;8.9</U> and <U>Section</U><U></U><U>&nbsp;8.13</U>, nothing in this Agreement, express or implied, is intended to or shall confer upon
any other Person any rights, benefits or remedies of any nature whatsoever under or by reason of this Agreement. The MAAC Sponsor shall be an express third-party beneficiary of <U>Section</U><U></U><U>&nbsp;5.14</U>,
<U>Section</U><U></U><U>&nbsp;6.2(f)</U>, <U>Section</U><U></U><U>&nbsp;8.2</U>, <U>Section</U><U></U><U>&nbsp;8.3</U>, <U>Section</U><U></U><U>&nbsp;8.13</U>, this <U>Section</U><U></U><U>&nbsp;8.9</U> and the last sentence of
<U>Section</U><U></U><U>&nbsp;5.4(a)</U>. Each of the <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates shall be an express third-party beneficiary of <U>Section</U><U></U><U>&nbsp;8.13</U> and this <U>Section</U><U></U><U>&nbsp;8.9</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.10</B> <B><U>Severability</U></B>. Whenever possible, each provision of this Agreement will be
interpreted in such a manner as to be effective and valid under applicable Law, but if any term or other provision of this Agreement is held to be invalid, illegal or unenforceable under applicable Law, all other provisions of this Agreement shall
remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any Party. Upon such determination that any term or other provision of this
Agreement is invalid, illegal or unenforceable under applicable Law, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner in order that
the transactions contemplated hereby are consummated as originally contemplated to the greatest extent possible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.11</B> <B><U>Counterparts; Electronic Signatures</U></B>. This Agreement and each Ancillary Document
(including any of the closing deliverables contemplated hereby) may be executed in one or more counterparts, each of which shall be deemed to be an original, but all of which shall constitute one and the same agreement. Delivery of an executed
counterpart of a signature page to this Agreement or any Ancillary Document (including any of the closing deliverables contemplated hereby) by <FONT STYLE="white-space:nowrap">e-mail,</FONT> or scanned pages shall be effective as delivery of a
manually executed counterpart to this Agreement or any such Ancillary Document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.12</B> <B><U>Knowledge of
</U></B><B><U>Company; Knowledge of </U></B><B><U>MAAC</U></B>. For all purposes of this Agreement, the phrase &#147;to the Company&#146;s knowledge&#148; and &#147;known by the Company&#148; and any derivations thereof shall mean as of the date
hereof (in the case of the representations and warranties of the Company and Merger Sub set forth in <U>Article</U><U></U><U>&nbsp;3</U>) or as of the applicable determination date (in the case of any covenants or agreements set forth herein), the
actual knowledge of the individuals set forth on <U>Section</U><U></U><U>&nbsp;8.12</U><U>(a)</U> of the Company Disclosure Schedules. For all purposes of this Agreement, the phrase &#147;to MAAC&#146;s knowledge&#148; and &#147;to the knowledge of
MAAC&#148; and any derivations thereof shall mean as of the date hereof (in the case of the representations and warranties of MAAC set forth in <U>Article</U><U></U><U>&nbsp;4</U>) or as of the applicable determination date (in the case of any
covenants or agreements set forth herein), the actual knowledge of the individuals set forth on <U>Section</U><U></U><U>&nbsp;8.12</U><U>(b)</U> of the MAAC Disclosure Schedules. <U>For </U>the avoidance of doubt, none of the individuals set forth
on <U>Section</U><U></U><U>&nbsp;8.12(a)</U> of the Company Disclosure Schedules or <U>Section</U><U></U><U>&nbsp;8.12(b)</U> of the MAAC Disclosure Schedules shall have any personal Liability or obligations regarding such knowledge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.13</B> <B><U>No Recourse</U></B>. Except for claims pursuant to any Ancillary Document by any party(ies)
thereto against any Company <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate or any MAAC <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate (each, a &#147;<U><FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate</U>&#148;)
party thereto on the terms and subject to the conditions thereunder, each Party agrees on behalf of itself and on behalf of the Company <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates, in the case of the Company, and the MAAC <FONT
STYLE="white-space:nowrap">Non-Party</FONT> Affiliates, in the case of MAAC, that (a)&nbsp;this Agreement may only be enforced against, and any action for breach of this Agreement may only be made against, the Parties, and no claims of any nature
whatsoever arising under or relating to this Agreement, the negotiation hereof or its subject matter, or the transactions contemplated hereby shall be asserted against any <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate, and
(b)&nbsp;without limiting the generality of the foregoing, none of the <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates shall have any Liability arising out of or relating to this Agreement, the negotiation hereof or its subject matter,
or the transactions contemplated hereby, including with respect to any claim (whether in tort, contract or otherwise) for breach of this Agreement or in respect of any written or oral representations made or alleged to be made in connection
herewith, except as expressly provided herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.14</B> <B><U>Extension; Waiver</U></B>. The Company may
(a)&nbsp;extend the time for the performance of any of the obligations or other acts of MAAC set forth herein, (b)&nbsp;waive any inaccuracies in the representations and warranties of MAAC set forth herein or (c)&nbsp;waive compliance by MAAC with
any of the agreements or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conditions set forth herein. MAAC may (i)&nbsp;extend the time for the performance of any of the obligations or other acts of the Company or Merger Sub set forth herein, (ii)&nbsp;waive any
inaccuracies in the representations and warranties of the Company or Merger Sub set forth herein or (iii)&nbsp;waive compliance by the Company or Merger Sub with any of the agreements or conditions set forth herein. Any agreement on the part of any
such Party to any such extension or waiver shall be valid only if set forth in a written instrument signed on behalf of such Party. Any waiver of any term or condition shall not be construed as a waiver of any subsequent breach or a subsequent
waiver of the same term or condition, or a waiver of any other term or condition of this Agreement. The failure of any Party to assert any of its rights hereunder shall not constitute a waiver of such rights. Notwithstanding the foregoing or
anything to the contrary in this Agreement, any extension or waiver following the Closing with respect to any MAAC Sponsor Specified Provision or, prior to the Closing, Section&nbsp;6.2(f) shall also require the prior written consent of the MAAC
Sponsor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.15</B> <B><U>Waiver of Jury Trial</U></B>. THE PARTIES EACH HEREBY WAIVES, TO THE FULLEST EXTENT
PERMITTED BY LAW, ANY RIGHT TO TRIAL BY JURY OF ANY PROCEEDING, CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION (I)&nbsp;ARISING UNDER THIS AGREEMENT OR UNDER ANY ANCILLARY DOCUMENT OR (II)&nbsp;IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE
DEALINGS OF THE PARTIES IN RESPECT OF THIS AGREEMENT OR ANY ANCILLARY DOCUMENT OR ANY OF THE TRANSACTIONS RELATED HERETO OR THERETO OR ANY FINANCING IN CONNECTION WITH THE TRANSACTIONS CONTEMPLATED HEREBY OR ANY OF THE TRANSACTIONS CONTEMPLATED
THEREBY, IN EACH CASE, WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY, OR OTHERWISE. THE PARTIES EACH HEREBY AGREES AND CONSENTS THAT ANY SUCH PROCEEDING, CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY
COURT TRIAL WITHOUT A JURY AND THAT THE PARTIES MAY FILE AN ORIGINAL COUNTERPART OF A COPY OF THIS AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY. EACH PARTY CERTIFIES
AND ACKNOWLEDGES THAT (A)&nbsp;NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (B)&nbsp;EACH SUCH
PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C)&nbsp;EACH SUCH PARTY MAKES THIS WAIVER VOLUNTARILY AND (D)&nbsp;EACH SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND
CERTIFICATIONS IN THIS <U>SECTION</U><U></U><U>&nbsp;8.15</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.16</B> <B><U>Submission to
Jurisdiction</U></B>. Each of the Parties irrevocably and unconditionally submits to the exclusive jurisdiction of the Chancery Court of the State of Delaware (or, if the Chancery Court of the State of Delaware declines to accept jurisdiction, any
state or federal court within State of New York, New York County), for the purposes of any Proceeding, claim, demand, action or cause of action (a)&nbsp;arising under this Agreement or under any Ancillary Document or (b)&nbsp;in any way connected
with or related or incidental to the dealings of the Parties in respect of this Agreement or any Ancillary Document or any of the transactions contemplated hereby or any of the transactions contemplated thereby, and irrevocably and unconditionally
waives any objection to the laying of venue of any such Proceeding in any such court, and further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such Proceeding has been brought in an inconvenient
forum. Each Party hereby irrevocably and unconditionally waives, and agrees not to assert, by way of motion or as a defense, counterclaim or otherwise, in any Proceeding claim, demand, action or cause of action against such Party (i)&nbsp;arising
under this Agreement or under any Ancillary Document or (ii)&nbsp;in any way connected with or related or incidental to the dealings of the Parties in respect of this Agreement or any Ancillary Document or any of the transactions contemplated hereby
or any of the transactions contemplated thereby, (A)&nbsp;any claim that such Party is not personally subject to the jurisdiction of the courts as described in this <U>Section</U><U></U><U>&nbsp;8.16</U> for any reason, (B)&nbsp;that such Party or
such Party&#146;s property is exempt or immune from the jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment,
execution of judgment or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
otherwise) and (C)&nbsp;that (x)&nbsp;the Proceeding, claim, demand, action or cause of action in any such court is brought against such Party in an inconvenient forum, (y)&nbsp;the venue of such
Proceeding, claim, demand, action or cause of action against such Party is improper or (z)&nbsp;this Agreement, or the subject matter hereof, may not be enforced against such Party in or by such courts. Each Party agrees that service of any process,
summons, notice or document by registered mail to such party&#146;s respective address set forth in <U>Section</U><U></U><U>&nbsp;8.4</U> shall be effective service of process for any such Proceeding, claim, demand, action or cause of action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.17</B> <B><U>Remedies</U></B>. Except as otherwise expressly provided herein, any and all remedies provided
herein will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy. The Parties agree
that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that the Parties do not perform their respective obligations under the provisions of this Agreement (including failing
to take such actions as are required of them hereunder to consummate the transactions contemplated by this Agreement) in accordance with their specific terms or otherwise breach such provisions. It is accordingly agreed that the Parties shall be
entitled to seek an injunction or injunctions, specific performance and other equitable relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, in each case, without posting a bond or
undertaking and without proof of damages and this being in addition to any other remedy to which they are entitled at law or in equity. Each of the Parties agrees that it will not oppose the granting of an injunction, specific performance and other
equitable relief when expressly available pursuant to the terms of this Agreement on the basis that the other parties have an adequate remedy at law or an award of specific performance is not an appropriate remedy for any reason at law or equity.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.18</B> <B><U>Trust Account Waiver</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Reference is made to the final prospectus of MAAC, filed with the SEC (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-248802)</FONT>
on October&nbsp;9, 2020 (the &#147;<U>Prospectus</U>&#148;). The Company and Merger Sub each acknowledges and agrees and understands that MAAC has established one or more trust accounts (collectively, the &#147;<U>Trust Account</U>&#148;) containing
the proceeds of its initial public offering (the &#147;<U>IPO</U>&#148;) and from certain private placements occurring simultaneously with the IPO (including interest accrued from time to time thereon) for the benefit of the holders of MAAC
Class&nbsp;A Shares, and MAAC may disburse monies from the Trust Account only in the express circumstances described in the Prospectus. For and in consideration of MAAC entering into this Agreement, and for other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the Company and Merger Sub each hereby agrees on behalf of itself and its Representatives that, notwithstanding the foregoing or anything to the contrary in this Agreement, none of the
Company, Merger Sub or any of their respective Representatives does now or shall at any time hereafter have any right, title, interest or claim of any kind in or to any monies in the Trust Account or distributions therefrom, or make any claim
against the Trust Account (including any distributions therefrom), regardless of whether such claim arises as a result of, in connection with or relating in any way to, this Agreement or any proposed or actual business relationship between MAAC or
any of its Representatives, on the one hand, and the Company, Merger Sub or any of their respective Representatives, on the other hand, or any other matter, and regardless of whether such claim arises based on contract, tort, equity or any other
theory of legal liability (any and all such claims are collectively referred to hereafter as the &#147;<U>Trust Account Released Claims</U>&#148;). The Company and Merger Sub each, on its own behalf and on behalf of its Representatives, hereby
irrevocably waives any Trust Account Released Claims that it or any of its Representatives may have against the Trust Account (including any distributions therefrom to the holders of MAAC Class&nbsp;A Shares or in respect of deferred underwriting
commissions from the IPO) now or in the future as a result of, or arising out of, any negotiations, or Contracts with MAAC or its Representatives and will not seek recourse against the Trust Account (including any distributions therefrom to the
holders of MAAC Class&nbsp;A Shares or in respect of deferred underwriting commissions from the IPO) for any reason whatsoever (including for an alleged breach of any agreement with MAAC or its Affiliates). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding <U>Section</U><U></U><U>&nbsp;8.18(a)</U>, <U>Section</U><U></U><U>&nbsp;8.18(a)</U> shall not serve to limit or prohibit
(and the Trust Account Released Claims shall not include) the Company&#146;s right to pursue a claim against (i)&nbsp;MAAC under, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on the terms and subject to the conditions in, this Agreement or under, and on the terms and subject to the conditions in, any Ancillary Document to which it and MAAC is a party or (ii)&nbsp;any
other party to an Ancillary Document to which it is a party under, and on the terms and subject to the conditions in, such Ancillary Document, in the case of either the foregoing <U>clause (i)</U>&nbsp;or <U>(ii)</U>, for legal relief against monies
or other assets held outside the Trust Account or for specific performance or other equitable relief to the extent not prohibited by this Agreement or such Ancillary Document (including a claim for MAAC to specifically perform its obligations under
this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;8.17</U>). If the terms of the Confidentiality Agreement or any Ancillary Document conflicts with the terms of this <U>Section</U><U></U><U>&nbsp;8.18(b)</U>, the terms of this
<U>Section</U><U></U><U>&nbsp;8.18(b)</U> shall govern and control to the extent of such conflict. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, each of the Parties has caused this Business Combination
Agreement to be duly executed on its behalf as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MONTES ARCHIMEDES ACQUISITION CORP.</B></TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ROIVANT SCIENCES LTD.</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>RHINE MERGER SUB, INC.</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Business Combination Agreement] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Annex A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PIPE Investors </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of PIPE Subscription Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(see attached) </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit B </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Transaction Support Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(see attached) </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit C </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Registration Rights Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(see attached) </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit D </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(see attached) </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit E </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Company Post-Closing <FONT STYLE="white-space:nowrap">Bye-Laws</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(see attached) </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit F </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Company Shareholder Written Consent </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(see attached) </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit G </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Roivant Sciences Ltd. 2021 Equity Incentive Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(see attached) </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit H </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Company Post-Closing Employee Stock Purchase Plan term Sheet </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(see attached) </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><A NAME="rom65062_39a"></A>ANNEX AA - AMENDMENT NO. 1 TO BUSINESS COMBINATION AGREEMENT
</U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Amendment No.&nbsp;1 to the Business Combination Agreement (this &#147;<U>Amendment</U>&#148;) is made as of June&nbsp;9,
2021, by and among Montes Archimedes Acquisition Corp., a Delaware corporation (&#147;<U>MAAC</U>&#148;), and Roivant Sciences Ltd., a Bermuda exempted limited company (the &#147;<U>Company</U>&#148;). Capitalized terms used, but not otherwise
defined herein, shall have the meaning given to them in the BCA (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on May&nbsp;1, 2021, (a) MAAC, the Company
and Rhine Merger Sub, Inc., a Delaware corporation and a direct wholly owned Subsidiary of the Company, entered into that certain Business Combination Agreement (as amended, amended and restated, supplemented or otherwise modified from time to time
in accordance with its terms, the &#147;<U>BCA</U>&#148;) and (b)&nbsp;the Company, MAAC, Patient Square Capital LLC, a Delaware limited liability company (the &#147;<U>MAAC Sponsor</U>&#148;), and, solely for purposes of certain provisions therein,
each of James C. Momtazee, George Barrett, Maria C. Walker and Steve Oesterle entered into that certain Sponsor Support Agreement (as amended, amended and restated, supplemented or otherwise modified from time to time in accordance with its terms,
the &#147;<U>Sponsor Support Agreement</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to Section&nbsp;8.3 of the BCA, the BCA may be amended or modified
only by a written agreement executed and delivered by MAAC and the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the date hereof (a)&nbsp;MAAC, the Company, the
MAAC Sponsor, James C. Momtazee, George Barrett, Maria C. Walker and Steve Oesterle are entering into Amendment No.&nbsp;1 to the Sponsor Support Agreement in order to provide that, among other things, (i)&nbsp;each MAAC Class&nbsp;B Share held by a
MAAC Independent Director or a MAAC Independent Director Transferee (each as defined in Section&nbsp;1 below) issued and outstanding immediately prior to the Effective Time be converted as of the Effective Time into the number of Company
Post-Closing Common Shares equal to the Sponsor Exchange Ratio, on the terms and subject to the conditions set forth in the BCA and the Sponsor Support Agreement, and (ii)&nbsp;a portion of the Company Post-Closing Common Shares that are issued to
the MAAC Independent Directors or any MAAC Independent Director Transferee upon conversion of the MAAC Class&nbsp;B Shares in the Merger be subject to the vesting provisions set forth in the Sponsor Support Agreement, and (b)&nbsp;each MAAC
Independent Director, on the one hand, and the Company, on the other hand, is entering into a <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, each of MAAC and the Company desire to amend the BCA in connection with agreements described in the preceding recital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration for the mutual promises made herein and other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, MAAC and the Company hereby agree to amend the BCA as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp; <U>Amendments to
the BCA</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp; Section&nbsp;1.1 of the BCA is hereby amended by adding the following new
definitions in the appropriate alphabetical order: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Independent Directors</U>&#148; means, collectively, George Barrett and
Steve Oesterle. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Independent Director Transferee</U>&#148; means any transferee of MAAC Class&nbsp;B Shares originally held
by a MAAC Independent Director, prior to the Effective Time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp; Section&nbsp;2.1(b)(vii) of the
BCA is hereby amended and restated in its entirety and replaced with the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">&#147;(vii) At the Effective Time, by virtue of the
Merger and without any action on the part of any Party or any other Person, (A)&nbsp;each (x) MAAC Class&nbsp;A Share and (y)&nbsp;each MAAC Class&nbsp;B Share that is not held by the MAAC Sponsor, any Affiliate of the MAAC Sponsor, any MAAC
Independent Director or any MAAC Independent Director Transferee (other than the MAAC Class&nbsp;A Shares and MAAC Class&nbsp;B Shares canceled and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
extinguished pursuant to <U>Section</U><U></U><U>&nbsp;2.1(b)(ix)</U>) issued and outstanding as of immediately prior to the Effective Time shall be automatically canceled and extinguished and
converted into one Company Post-Closing Common Share and (B)&nbsp;each MAAC Class&nbsp;B Share issued and outstanding and held by the MAAC Sponsor, any Affiliate of the MAAC Sponsor, any MAAC Independent Director or any MAAC Independent Director
Transferee as of immediately prior to the Effective Time shall be automatically canceled and extinguished and converted into the number of Company Post-Closing Common Shares equal to the Sponsor Exchange Ratio; <U>provided</U> that for the avoidance
of doubt, a number of Company Post-Closing Common Shares owned by the MAAC Sponsor, any Affiliate of the MAAC Sponsor, any MAAC Independent Director or any MAAC Independent Director Transferee, determined pursuant to the Sponsor Support Agreement,
shall become subject to the vesting and other terms and conditions set forth in the Sponsor Support Agreement at the Effective Time. As of the Effective Time, all MAAC Shares shall no longer be outstanding and shall automatically be canceled and
shall cease to exist, and shall thereafter represent the number of Company Post-Closing Common Shares into which such MAAC Shares were converted pursuant to this Agreement. From and after the Effective Time, each
<FONT STYLE="white-space:nowrap">Pre-Closing</FONT> MAAC Shareholder&#146;s certificate(s) (the &#147;<U>Certificates</U>&#148;), if any, evidencing ownership of MAAC Shares and MAAC Shares held in book-entry form issued and outstanding immediately
prior to the Effective Time shall each cease to have any rights with respect to such MAAC Shares, except as otherwise expressly provided for herein or under applicable Law.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp; Section&nbsp;2.3 of the BCA is hereby amended and restated in its entirety and replaced with the
following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Section</B><B></B><B>&nbsp;2.3 </B><B><U>Fractional Shares</U></B>. Notwithstanding the foregoing or anything to the
contrary herein, no fractional Company Post-Closing Common Shares shall be issued in connection with the transactions contemplated hereby. Except with respect to Company Equity Awards, all fractional Company Post-Closing Common Shares that each
Company Equityholder will have a right to receive in connection with the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps, as well as (a)&nbsp;all fractional Company Post-Closing Common Shares that the MAAC Sponsor and its
Affiliates as holders of MAAC Class&nbsp;B Shares will have a right to receive in connection with the Merger and (b)&nbsp;all fractional Company Post-Closing Common Shares that each MAAC Independent Director and the applicable MAAC Independent
Director Transferee(s) as holders of MAAC Class&nbsp;B Shares will have a right to receive in connection with the Merger, shall, in each case be aggregated and, if a fractional share results from such aggregation, such fractional share shall be
rounded down to the nearest whole share.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp; <U>Effect of Amendments and Modifications</U>. Except as
expressly amended hereby, the BCA shall remain unaltered and in full force and effect and the respective terms, conditions or covenants thereof are hereby in all respects confirmed. Whenever the BCA is referred to in any agreement, document or other
instrument, such reference will be to the BCA as amended by this Amendment. For the avoidance of doubt, each reference in the BCA, as amended hereby, to &#147;the date hereof&#148;, the &#147;date of this Agreement&#148; and derivations thereof and
other similar phrases shall continue to refer to May&nbsp;1, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp; <U>Miscellaneous</U>. Sections 8.5, 8.7,
8.10, 8.11, 8.15 and 8.16 of the BCA are incorporated herein by reference, <I>mutatis mutandis</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[The remainder of this page
intentionally left blank.] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AA-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have caused this Amendment to be signed as of the date
first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MONTES ARCHIMEDES ACQUISITION CORP.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Maria C. Walker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Maria C. Walker</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ROIVANT SCIENCES LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marianne Romeo</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Marianne Romeo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Head, Global Transactions&nbsp;&amp; Risk Management</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Amendment No.&nbsp;1 to the Business Combination Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><A NAME="rom65062_40"></A>ANNEX B &#150; FORM OF SUBSCRIPTION AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>FINAL FORM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SUBSCRIPTION AGREEMENT </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Montes
Archimedes Acquisition Corp. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">724 Oak Grove, Suite 130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Menlo
Park, CA 94025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
Subscription Agreement (this &#147;<U>Subscription Agreement</U>&#148;) is being entered into as of the date set forth on the signature page hereto, by and among Montes Archimedes Acquisition Corp., a Delaware corporation (&#147;<U>SPAC</U>&#148;),
the undersigned subscriber (the &#147;<U>Investor</U>&#148;) and, solely for the purposes of Sections 6, 8 and 11, Roivant Sciences Ltd., a Bermuda exempted limited company (the &#147;<U>Company</U>&#148;), in connection with the Business
Combination Agreement, dated as of the date hereof (as may be amended, supplemented or otherwise modified from time to time, the &#147;<U>BCA</U>&#148;), by and among SPAC, the Company, Rhine Merger Sub, Inc., a Delaware corporation and a direct
wholly-owned subsidiary of the Company (&#147;<U>Merger Sub</U>&#148;) and the other parties thereto, pursuant to which, among other things, Merger Sub will merge with and into SPAC (the &#147;<U>Merger</U>&#148;), with SPAC as the surviving company
in the Merger and, after giving effect to the Merger, will become a subsidiary of the Company, on the terms and subject to the conditions therein (the transactions contemplated by the BCA, including the Merger, the &#147;<U>Transaction</U>&#148;).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Transaction, SPAC is seeking commitments from interested investors to purchase, contingent upon, and immediately
prior to the closing of the Transaction, shares of SPAC&#146;s Class&nbsp;A common stock, par value $0.0001 per share (the &#147;<U>Shares</U>&#148;), in a private placement for a purchase price of $10.00 per share (the &#147;<U>Per Share Purchase
Price</U>&#148;). On or about the date of this Subscription Agreement, SPAC is entering into subscription agreements (the &#147;<U>Other Subscription Agreements</U>&#148; and, together with the Subscription Agreement, the &#147;<U>Subscription
Agreements</U>&#148;) substantially similar to this Subscription Agreement with certain other investors (the &#147;<U>Other Investors</U>&#148; and, together with the Investor, the &#147;<U>Investors</U>&#148;), pursuant to which the Investors,
severally and not jointly, have agreed to purchase on the closing date of the Transaction, inclusive of the Shares subscribed for by the Investor, an aggregate amount of up to 20,000,000 Shares, at the Per Share Purchase Price. The aggregate
purchase price to be paid by the Investor for the subscribed Shares (as set forth on the signature page hereto) is referred to herein as the &#147;<U>Subscription Amount</U>.&#148; Pursuant to the BCA, on the Closing Date (as defined herein), the
Shares so purchased will be exchanged for shares of the Company on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, as described more fully in the BCA. For the avoidance of doubt, with respect to
any obligations existing in this Subscription Agreement, following consummation of the Transaction, (i)&nbsp;the Company shall be the public issuer and (ii)&nbsp;the term &#147;Shares&#148; as defined above shall refer to the <FONT
STYLE="white-space:nowrap">as-converted</FONT> shares in the Company. Notwithstanding anything to the contrary herein, nothing in this Subscription Agreement shall be interpreted to limit the consummation of the Transaction in accordance with the
terms of the BCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection therewith, and in consideration of the foregoing and the mutual representations, warranties and
covenants, and subject to the conditions, set forth herein, and intending to be legally bound hereby, each of the Investor, the Company and SPAC acknowledges and agrees as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Subscription</U>. The Investor hereby irrevocably subscribes for and agrees to purchase from SPAC the number of Shares set forth on the
signature page of this Subscription Agreement on the terms and subject to the conditions provided for herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Closing</U>. The
closing of the sale of the Shares contemplated hereby (the &#147;<U>Closing</U>&#148;) is contingent upon the substantially concurrent consummation of the Transaction. The Closing shall occur on the date of, and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
substantially concurrently with and conditioned upon the effectiveness of, the Transaction. Upon (a)&nbsp;satisfaction or waiver of the conditions set forth in Section&nbsp;3 below and
(b)&nbsp;delivery of written notice from (or on behalf of) SPAC to the Investor (the &#147;<U>Closing Notice</U>&#148;), that SPAC reasonably expects all conditions to the closing of the Transaction to be satisfied or waived on a date that is not
less than five (5)&nbsp;business days from the date on which the Closing Notice is delivered to the Investor, the Investor shall deliver to SPAC (i)&nbsp;at least one (1)&nbsp;business day prior to the closing date specified in the Closing Notice
(the &#147;<U>Closing Date</U>&#148;), the Subscription Amount by wire transfer of United States dollars in immediately available funds to the account(s) specified by SPAC in the Closing Notice to be held in escrow until the Closing, or (ii)&nbsp;on
the Closing Date, the Subscription Amount to an account specified by SPAC otherwise mutually agreed by the Investor and SPAC due to legal reasons that apply to such Investor (the&nbsp;&#147;<U>Alternative Settlement Procedures</U>&#148;) by wire
transfer of United States dollars in immediately available funds. The Investor shall also deliver to SPAC, at least one (1)&nbsp;business day prior to the Closing Date, any other information that is reasonably requested in the Closing Notice in
order for SPAC to issue the Shares to the Investor in accordance with the Subscription Agreement, including, without limitation, the legal name of the person in whose name such Shares are to be issued and a duly executed Internal Revenue Service
Form <FONT STYLE="white-space:nowrap">W-9</FONT> or <FONT STYLE="white-space:nowrap">W-8,</FONT> as applicable. On the Closing Date, SPAC shall (1)&nbsp;issue a number of Shares to the Investor set forth on the signature page to this Subscription
Agreement and subsequently cause such Shares to be registered in book entry form in the name of the Investor (or its nominee in accordance with its delivery instructions) on SPAC&#146;s share register, free and clear of any liens or other
restrictions (other than those arising under this Subscription Agreement or applicable securities laws), and (2)&nbsp;provide evidence from the Company&#146;s transfer agent of such issuance on and as of the Closing Date. If the Closing does not
occur within three (3)&nbsp;business days following the Closing Date specified in the Closing Notice, SPAC shall promptly (but not later than one (1)&nbsp;business day thereafter) return the Subscription Amount in full to the Investor, in
immediately available funds to the account specified by the Investor in writing, and any book entries for the Shares shall be deemed cancelled. For purposes of this Subscription Agreement, &#147;business day&#148; shall mean a day other than a
Saturday, Sunday or other day on which commercial banks in New York, New York are authorized or required by law to close. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Closing
Conditions</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The obligation of the parties hereto to consummate the purchase and sale of the Shares pursuant to this Subscription
Agreement is subject to the following conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) no applicable governmental authority shall have enacted, issued,
promulgated, enforced or entered any injunction, judgment, order, law, rule or regulation (whether temporary, preliminary or permanent) which is then in effect and has the effect of making the consummation of the transactions contemplated hereby
illegal or otherwise enjoining, restraining or prohibiting consummation of the transactions contemplated hereby; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)
all conditions precedent to the closing of the Transaction under the BCA shall have been satisfied (as determined by the parties to the BCA and other than those conditions under the BCA which, by their nature, are to be fulfilled at the closing of
the Transaction, including to the extent that any such condition is dependent upon the consummation of the purchase and sale of the Shares pursuant to this Subscription Agreement or Other Subscription Agreements) or waived and the closing of the
Transaction shall be scheduled to occur concurrently with or on the same date as the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The obligation of SPAC to
consummate the issuance and sale of the Shares pursuant to this Subscription Agreement shall be subject to the satisfaction or waiver of the following conditions: (i)&nbsp;all representations and warranties of the Investor contained in this
Subscription Agreement are true and correct in all material respects (other than representations and warranties that are qualified as to materiality, which representations and warranties shall be true in all respects) at and as of the Closing Date
(except for those representations and warranties that speak as of a specified earlier date, which shall be true and correct in all material respects as of such specified earlier date&nbsp;(other than representations and warranties that are qualified
as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to materiality&nbsp;as of such specified earlier date, which representations and warranties shall be true in all respects)), and consummation of the Closing shall constitute a reaffirmation by
the Investor that each of the representations and warranties of the Investor contained in this Subscription Agreement as of the Closing Date are true and correct in all material respects (or, in the case of representations and warranties that are
qualified as to materiality, in all respects as of the Closing Date) and (ii)&nbsp;all obligations, covenants and agreements of the Investor required to be performed by it at or prior to the Closing Date shall have been performed in all material
respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The obligation of the Investor to consummate the purchase of the Shares pursuant to this Subscription Agreement shall be
subject to the satisfaction or waiver of the following conditions: (i)&nbsp;all representations and warranties of SPAC and the Company contained in this Subscription Agreement shall be true and correct in all material respects (other than
representations and warranties that are qualified as to materiality or Material Adverse Effect (as defined herein), which representations and warranties shall be true in all respects) at and as of the Closing Date, and consummation of the Closing
shall constitute a reaffirmation by SPAC and the Company that each of the representations and warranties of SPAC and the Company contained in this Subscription Agreement as of the Closing Date are true and correct in all material respects (or, in
the case of representations and warranties that are qualified as to materiality or Material Adverse Effect, in all respects) as of the Closing Date (except for those representations and warranties that speak as of a specified earlier date, which
shall be true and correct in all material respects as of such specified earlier date&nbsp;(other than representations and warranties that are qualified as to materiality&nbsp;as of such specified earlier date, which representations and warranties
shall be true in all respects)); (ii) all obligations, covenants and agreements of SPAC and the Company required by the Subscription Agreement to be performed by them at or prior to the Closing Date shall have been performed in all material
respects; and (iii)&nbsp;the BCA shall not have been amended or waived in a manner that materially and adversely affects the economic benefits that the Investor (in its capacity as such) would reasonably expect to receive under this Subscription
Agreement; provided, that, the SEC&#146;s (as defined herein) issuance of the Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (the &#147;<U>Statement</U>&#148;), made on
April&nbsp;12, 2021, and any consequences thereof or actions taken by SPAC directly in response thereto, shall not cause either of the conditions in this clause (c)&nbsp;to be deemed to not have been satisfied so long as any such consequences or
actions shall not have caused a material adverse effect on the business, financial condition or results of operations of SPAC (a &#147;<U>Material Adverse Effect</U>&#148;). For the avoidance of doubt, any restatement of the financial statements of
SPAC and any amendments to previously filed SEC reports or delays in filing SEC reports, in connection with the Statement or any subsequent related agreements or other guidance from the SEC with respect to the Statement, shall not be considered to
result in a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Further Assurances</U><U>.</U> At or prior to the Closing Date, the parties hereto shall
execute and deliver or cause to be executed and delivered such additional documents and take such additional actions as the parties reasonably may deem to be practical and necessary in order to consummate the subscription as contemplated by this
Subscription Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>SPAC Representations and Warranties</U>. SPAC represents and warrants to the Investor that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) SPAC is duly incorporated, validly existing and in good standing under the laws of the State of Delaware. SPAC has all power (corporate or
otherwise) and authority to own, lease and operate its properties and conduct its business as presently conducted and to enter into, deliver and perform its obligations under this Subscription Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) As of the Closing Date, the Shares will be duly authorized and, when issued and delivered to the Investor against full payment therefor in
accordance with the terms of this Subscription Agreement, the Shares will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and will not have been issued in violation of or subject to any preemptive or similar
rights created under SPAC&#146;s certificate of incorporation and bylaws (each as amended on the Closing Date) by contract or under the General Corporation Law of the State of Delaware. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) This Subscription Agreement has been duly authorized, executed and delivered by SPAC
and, assuming that this Subscription Agreement constitutes the valid and binding agreement of the Investor, this Subscription Agreement constitutes the valid and binding agreement of SPAC and is enforceable against SPAC in accordance with its terms,
except as may be limited or otherwise affected by (i)&nbsp;bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the rights of creditors generally, or (ii)&nbsp;principles of equity, whether
considered at law or equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The execution and delivery of, and the performance of the transactions contemplated hereby, including
the issuance and sale of the Shares and the compliance by SPAC with all of the provisions of this Subscription Agreement and the consummation of the transactions contemplated herein will be done in accordance with the Nasdaq marketplace rules
(&#147;<U>Nasdaq</U>&#148;) and will not conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any of the
property or assets of SPAC or any of its subsidiaries pursuant to the terms of (i)&nbsp;any indenture, mortgage, deed of trust, loan agreement, lease, license or other agreement or instrument to which SPAC or any of its subsidiaries is a party or by
which SPAC or any of its subsidiaries is bound or to which any of the property or assets of SPAC is subject that would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect or materially affect the validity of
the Shares or the legal authority of SPAC to comply in all material respects with the terms of this Subscription Agreement; (ii)&nbsp;result in any violation of the provisions of the organizational documents of SPAC; or (iii)&nbsp;result in any
violation of any statute or any judgment, order, rule or regulation of any court or governmental agency or body, domestic or foreign, having jurisdiction over SPAC or any of its properties that would reasonably be expected to have, individually or
in the aggregate, a Material Adverse Effect or materially affect the validity of the Shares or the legal authority of SPAC to comply in all material respects with this Subscription Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) As of their respective dates, all reports (the &#147;<U>SEC Reports</U>&#148;) required to be filed by SPAC with the SEC complied in all
material respects with the applicable requirements of the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;), and the Securities Exchange Act of 1934, as amended (the &#147;<U>Exchange Act</U>&#148;), and the rules and
regulations of the SEC promulgated thereunder, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. The financial statements of SPAC included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations
of the SEC with respect thereto as in effect at the time of filing and fairly present in all material respects the financial position of SPAC as of and for the dates thereof and the results of operations and cash flows for the periods then ended,
subject, in the case of unaudited financial statements, to normal, <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments. A copy of each SEC Report is available to the Investor via the SEC&#146;s EDGAR system. There are no material
outstanding or unresolved comments in comment letters from the staff of the Division of Corporation Finance of the SEC with respect to any of the SEC Reports. SPAC has timely filed each report, statement, schedule, prospectus, and registration
statement that SPAC was required to file with the SEC since its inception. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Other than the Other Subscription Agreements, including
any subscription agreement entered into consistent with Section&nbsp;7(b) of this Subscription Agreement, the BCA and any other agreement contemplated by the BCA, including any Ancillary Documents as defined therein, or described in the SEC Reports,
SPAC has not entered into any side letter or similar agreement with any investor in connection with such investor&#146;s direct or indirect investment in SPAC (other than any side letter or similar agreement to the extent relating to the transfer to
any investor of (i)&nbsp;securities of SPAC by existing securityholders of SPAC, which may be effectuated as a forfeiture to SPAC and reissuance, or (ii)&nbsp;securities to be issued to the direct or indirect securityholders of the Company pursuant
to the BCA). Except for any Alternative Settlement Procedures, no Other Subscription Agreement includes a lesser Per Share Purchase Price or other terms and conditions that are materially more advantageous to any such Other Investor than Investor
hereunder, and such Other Subscription Agreements have not been amended, modified or waived in any material respect, or in any respect that materially benefits the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Other Investors thereunder unless the Investor has been offered substantially similar benefits in writing, following the date of this Subscription Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) As of the date of this Subscription Agreement, the authorized capital stock of SPAC consists of (i)&nbsp;400,000,000 shares of
Class&nbsp;A common stock, (ii) 40,000,000 shares of Class&nbsp;B common stock and (iii)&nbsp;1,000,000 shares of preferred stock, each with a par value of $0.0001 per share. As of the date of this Subscription Agreement, (A) 41,071,823 shares of
Class&nbsp;A common stock of SPAC are issued and outstanding, (B) 10,267,956 shares of Class&nbsp;B common stock of SPAC are issued and outstanding, (C) 30,750,267 warrants to purchase shares of Class&nbsp;A common stock of SPAC are issued and
outstanding, and (D)&nbsp;no shares of preferred stock are issued and outstanding. All (1)&nbsp;issued and outstanding shares of Class&nbsp;A common stock and Class&nbsp;B common stock of SPAC have been duly authorized and validly issued, are fully
paid and <FONT STYLE="white-space:nowrap">are&nbsp;non-assessable&nbsp;and</FONT> (2)&nbsp;outstanding warrants have been duly authorized and validly issued. Except as set forth above and pursuant to the Other Subscription Agreements, the BCA and
the other agreements and arrangements referred to therein or in the SEC Reports, as of the date hereof, there are no outstanding options, warrants or other rights to subscribe for, purchase or acquire from SPAC any Class&nbsp;A common shares,
Class&nbsp;B common shares or other equity interests in SPAC, or securities convertible into or exchangeable or exercisable for such equity interests. As of the date hereof, SPAC has no subsidiaries and does not own, directly or indirectly,
interests or investments (whether equity or debt) in any person, whether incorporated or unincorporated. There are no shareholder agreements, voting trusts or other agreements or understandings to which SPAC is a party or by which it is bound
relating to the voting of any securities of SPAC, other than (1)&nbsp;as set forth in the SEC Reports and (2)&nbsp;as contemplated by the BCA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Assuming the accuracy of the Investor&#146;s representations and warranties set forth in Section&nbsp;7, no registration under the
Securities Act is required for the offer and sale of the Shares by SPAC to the Investor hereunder. The Shares (i)&nbsp;were not offered by any form of general solicitation or general advertising (as those terms are used in Regulation D under the
Securities Act) and (ii)&nbsp;are not being offered in a manner involving a public offering under, or in a distribution in violation of, the Securities Act, or any state securities laws, or in a manner that would otherwise adversely affect reliance
by SPAC on Section&nbsp;4(a)(2) of the Securities Act for the exemption from registration for the transactions contemplated hereby or would require registration of the Shares under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Except for such matters as have not had and would not be reasonably likely to have, individually or in the aggregate, a Material Adverse
Effect, there is no (i)&nbsp;action, suit, claim or other proceeding, in each case by or before any governmental authority pending, or, to the knowledge of SPAC, threatened against SPAC or (ii)&nbsp;judgment, decree, injunction, ruling or order of
any governmental entity or arbitrator outstanding against SPAC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) SPAC is in compliance with all applicable laws, except where such
noncompliance would not reasonably be expected to have a Material Adverse Effect. As of the date hereof, SPAC has not received any written communication from a governmental authority that alleges that SPAC is not in compliance with or is in default
or violation of any applicable law, except where such <FONT STYLE="white-space:nowrap">non-compliance,</FONT> default or violation would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. As of the date
hereof, the issued and outstanding Shares of SPAC are registered pursuant to Section&nbsp;12(b) of the Exchange Act, and are listed for trading on Nasdaq, under the symbol &#147;MAAC&#148; (it being understood that the trading symbol will be
different for the Company upon completion of the Transaction). There is no suit, action, proceeding or investigation pending or, to the knowledge of SPAC, threatened against SPAC by Nasdaq or the SEC, respectively, to prohibit or terminate the
listing of SPAC&#146;s Shares on Nasdaq or to deregister the Shares under the Exchange Act. Except as described in or contemplated by the BCA, SPAC has taken no action as of the date hereof that is designed to terminate the registration of the
Shares under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) Other than the Placement Agents (as defined below), SPAC has not engaged any broker, finder,
commission agent, placement agent or arranger in connection with the sale of the Shares, and SPAC is not under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any obligation to pay any broker&#146;s fee or commission in connection with the sale of the Shares other than to the Placement Agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) SPAC is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration
with, any court or other federal, state, local or other governmental authority, self-regulatory organization or other person in connection with the execution, delivery and performance by SPAC of this Subscription Agreement (including, without
limitation, the issuance of the Shares), other than (i)&nbsp;filings with the SEC, (ii)&nbsp;filings required by applicable state securities laws, (iii)&nbsp;filings required in accordance with Section&nbsp;13 of this Subscription Agreement,
(iv)&nbsp;filings required by Nasdaq, or such other applicable stock exchange on which SPAC&#146;s common stock is then listed, and (v)&nbsp;the failure of which to obtain would not be reasonably likely to have, individually or in the aggregate, a
Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) SPAC is not, and immediately after receipt of payment for the Shares will not be, an &#147;investment
company&#148; within the meaning of the Investment Company Act of 1940, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) SPAC acknowledges and agrees that,
notwithstanding anything herein to the contrary, the Shares may be pledged by the Investor in connection with a <I>bona fide</I> margin agreement, provided such pledge shall be (i)&nbsp;pursuant to an available exemption from the registration
requirements of the Securities Act or (ii)&nbsp;pursuant to, and in accordance with, a registration statement that is effective under the Securities Act at the time of such pledge, and the Investor effecting a pledge of Shares shall not be required
to provide SPAC with any notice thereof; provided, however, that neither SPAC, the Company or their respective counsels shall be required to take any action (or refrain from taking any action) in connection with any such pledge, other than providing
any such lender of such margin agreement, upon the prior written request of the Investor, with an acknowledgment that the Shares are not subject to a contractual prohibition on pledging or lock up pursuant to this Subscription Agreement, the form of
such acknowledgment to be subject to review and comment by SPAC in all respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Company Representations and Warranties</U>. The
Company represents and warrants to the Investor that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company is an exempted limited company duly organized, validly existing and
in good standing (or the equivalent thereto with respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof) under the laws of the Bermuda. The Company has all power (corporate or otherwise) and authority to
own, lease and operate its properties and conduct its business as presently conducted and to enter into, deliver and perform its obligations under this Subscription Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) This Subscription Agreement has been duly authorized, executed and delivered by the Company and, assuming that this Subscription Agreement
constitutes the valid and binding agreement of the Investor, this Subscription Agreement is enforceable against the Company in accordance with its terms, except as may be limited or otherwise affected by (i)&nbsp;bankruptcy, insolvency, fraudulent
conveyance, reorganization, moratorium or other laws relating to or affecting the rights of creditors generally, or (ii)&nbsp;principles of equity, whether considered at law or equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The execution and delivery of, and the performance of the transactions contemplated hereby, and the compliance by the Company with all of
the provisions of this Subscription Agreement and the consummation of the transactions contemplated herein will not conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, or result in
the creation or imposition of any lien, charge or encumbrance upon any of the property or assets of the Company or any of its subsidiaries pursuant to the terms of (i)&nbsp;any indenture, mortgage, deed of trust, loan agreement, lease, license or
other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company or any of its subsidiaries is subject that
would reasonably be expected to have a material adverse effect on the business, financial condition or results of operations of the Company and its subsidiaries, taken as a whole (a &#147;Company Material Adverse Effect&#148;) or materially affect
the legal authority of the Company to comply in all material respects with the terms of this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Subscription Agreement; (ii)&nbsp;result in any violation of the provisions of the organizational documents of the Company; or (iii)&nbsp;result in any violation of any statute or any judgment,
order, rule or regulation of any court or governmental agency or body, domestic or foreign, having jurisdiction over the Company or any of its properties that would reasonably be expected to have a Company Material Adverse Effect or materially
affect the legal authority of the Company to comply in all material respects with this Subscription Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except for such
matters as have not had and would not be reasonably expected to have, individually or in the aggregate, a Company Material Adverse Effect, as of the date hereof, there is no (i)&nbsp;action, suit, claim or other proceeding, in each case by or before
any governmental authority pending, or, to the knowledge of the Company, threatened against the Company or (ii)&nbsp;judgment, decree, injunction, ruling or order of any governmental entity or arbitrator outstanding against the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) As of the Closing Date, the issued and outstanding Company Shares will be registered pursuant to Section&nbsp;12(b) of the Exchange Act,
and will be listed for trading on Nasdaq or another national stock exchange. There is no suit, action, proceeding or investigation pending or, to the knowledge of the Company, threatened against the Company by Nasdaq or the SEC, respectively, to
prohibit the listing of the Company Shares on Nasdaq or to deregister the Company Shares under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The Company is in
compliance with all applicable laws, except where such <FONT STYLE="white-space:nowrap">non-compliance</FONT> would not reasonably be expected to have a Company Material Adverse Effect. The Company has not received any written communication from a
governmental authority that alleges that the Company is not in compliance with or is in default or violation of any applicable law, except where such <FONT STYLE="white-space:nowrap">non-compliance,</FONT> default or violation would not reasonably
be expected to have a Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Investor Representations and Warranties</U>. The Investor represents and
warrants to SPAC that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Investor, or each of the funds managed by or affiliated with the Investor for which the Investor is acting
as nominee, as applicable, (i)&nbsp;is a &#147;qualified institutional buyer&#148; (as defined in Rule 144A under the Securities Act), or an institutional &#147;accredited investor&#148; (within the meaning of Rule 501(a) under the Securities Act),
in each case, satisfying the applicable requirements set forth on <U>Schedule A</U>, (ii)&nbsp;is an &#147;institutional account&#148; (as defined in FINRA Rule 4512(c)), (iii) is acquiring the Shares only for his, her or its own account and not for
the account of others, or if the Investor is subscribing for the Shares as a fiduciary or agent for one or more investor accounts, the Investor has full investment discretion with respect to each such account, and the full power and authority to
make the acknowledgements, representations and agreements herein on behalf of each owner of each such account, and (iv)&nbsp;is not acquiring the Shares with a view to, or for offer or sale in connection with, any distribution thereof in violation
of the Securities Act (and shall provide the requested information set forth on <U>Schedule A</U>). The Investor is not an entity formed for the specific purpose of acquiring the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding anything to the contrary set&nbsp;forth herein, the Investor acknowledges and agrees that, subsequent to the date of this
Subscription Agreement and prior to the Closing, SPAC may enter into one or more additional subscription agreements with additional investors with terms and conditions that are not materially more advantageous to the investor thereunder than this
Subscription Agreement, and entry into such agreements may increase the aggregate amount of Shares being subscribed for in the private placement contemplated by this Subscription Agreement. For the avoidance of doubt, such additional agreements
shall reflect not less than the same Per Share Purchase Price and shall constitute Other Subscription Agreements for purposes of this Agreement,<I>&nbsp;mutatis mutandis</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Investor acknowledges and agrees that the Shares are being offered in a transaction not involving any public offering within the
meaning of the Securities Act and that the Shares have not been registered under the Securities Act. The Investor acknowledges and agrees that, other than with respect to any actions taken to consummate the Transaction pursuant to the BCA, the
Shares may not be offered, resold, transferred, pledged or otherwise disposed of by the Investor absent an effective registration statement under the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Securities Act except (i)&nbsp;to SPAC or an affiliate thereof, (ii)&nbsp;to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> persons pursuant to offers and sales that occur outside the United
States within the meaning of Regulation S under the Securities Act or (iii)&nbsp;pursuant to another applicable exemption from the registration requirements of the Securities Act, and in each of clauses (i)&nbsp;and (iii) in accordance with any
applicable securities laws of the states and other jurisdictions of the United States, and that any certificates representing the Shares shall contain a restrictive legend to such effect. The Investor acknowledges and agrees that the Shares will be
subject to the foregoing transfer restrictions and, as a result of these transfer restrictions, other than with respect to any actions taken to consummate the Transaction pursuant to the BCA, the Investor may not be able to readily offer, resell,
transfer, pledge or otherwise dispose of the Shares and may be required to bear the financial risk of an investment in the Shares for an indefinite period of time. The Investor acknowledges and agrees that, other than with respect to any actions
taken to consummate the Transaction pursuant to the BCA, the Shares will not immediately be eligible for offer, resale, transfer, pledge or disposition pursuant to Rule 144 promulgated under the Securities Act. The Investor acknowledges and agrees
that it has been advised to consult legal counsel and tax and accounting advisors prior to making any offer, resale, transfer, pledge or disposition of any of the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Investor acknowledges and agrees that the Investor is purchasing the Shares directly from SPAC. The Investor further acknowledges that
there have been no representations, warranties, covenants and agreements made to the Investor by or on behalf of SPAC, the Company, the Placement Agents or any of their respective affiliates or any control persons, officers, directors, employees,
partners, agents or representatives of any of the foregoing or any other person or entity, expressly or by implication, other than those representations, warranties, covenants and agreements of SPAC and the Company expressly set forth in
Section&nbsp;5 and Section&nbsp;6 of this Subscription Agreement, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Investor&#146;s acquisition and holding of the
Shares will not constitute or result in a <FONT STYLE="white-space:nowrap">non-exempt</FONT> prohibited transaction under section 406 of the Employee Retirement Income Security Act of 1974, as amended, section 4975 of the Internal Revenue Code of
1986, as amended, or any applicable similar law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The Investor acknowledges and agrees that the Investor has received such information
as the Investor deems necessary in order to make an investment decision with respect to the Shares, including, with respect to SPAC, the Transaction and the business of the Company and its subsidiaries. Without limiting the generality of the
foregoing, the Investor acknowledges that he, she or it has reviewed SPAC&#146;s filings with the SEC. The Investor acknowledges and agrees that the Investor and the Investor&#146;s professional advisor(s), if any, have had the full opportunity to
ask such questions, receive such answers and obtain such information as the Investor and such Investor&#146;s professional advisor(s), if any, have deemed necessary to make an investment decision with respect to the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) The Investor became aware of this offering of the Shares solely by means of direct contact between the Investor and SPAC, the Company or a
representative of SPAC or the Company, or by means of contact from any of the Placement Agents in their capacity as such, and the Shares were offered to the Investor solely by direct contact between the Investor and SPAC, the Company or a
representative of SPAC or the Company, or by contact between the Investor and one or more Placement Agents in their capacity as such. The Investor did not become aware of this offering of the Shares, nor were the Shares offered to the Investor, by
any other means. The Investor acknowledges that the Shares (i)&nbsp;were not offered to it by any form of general solicitation or general advertising, including methods described in section 502(c) of Regulation D under the Securities Act and
(ii)&nbsp;to its knowledge, are not being offered in a manner involving a public offering under, or in a distribution in violation of, the Securities Act, or any state securities laws. The Investor acknowledges that it is not relying upon, and has
not relied upon, any statement, representation or warranty made by any person, firm or corporation (including, without limitation, SPAC, the Company, the Placement Agents, any of their respective affiliates or any control persons, officers,
directors, employees, partners, agents or representatives of any of the foregoing), other than the representations and warranties of SPAC and the Company contained in Section&nbsp;5 and Section&nbsp;6 of this Subscription Agreement, respectively, in
making its investment or decision to invest in SPAC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) The Investor acknowledges that it is aware that there are substantial risks incident to
the purchase and ownership of the Shares, including those set forth in SPAC&#146;s filings with the SEC. The Investor has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of an
investment in the Shares, and the Investor has sought such accounting, legal and tax advice as the Investor has considered necessary to make an informed investment decision and the Investor has made its own assessment and has satisfied itself
concerning relevant tax and other economic considerations relative to its purchase of the Shares.. The Investor is able to sustain a complete loss on its investment in the Shares, has no immediate need for liquidity with respect to its investment in
the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Alone, or together with any professional advisor(s), the Investor has adequately analyzed and fully considered the risks
of an investment in the Shares and determined that the Shares are a suitable investment for the Investor and that the Investor is able at this time and in the foreseeable future to bear the economic risk of a total loss of the Investor&#146;s
investment in SPAC. The Investor acknowledges specifically that a possibility of total loss exists. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) In making its decision to
purchase the Shares, the Investor has relied solely upon independent investigation made by the Investor and SPAC&#146;s and the Company&#146;s representations and warranties expressly set forth in Section&nbsp;5 and Section&nbsp;6 of this
Subscription Agreement, respectively, and no other representations and warranties of any kind, whether express or implied, of SPAC or any other person. Without limiting the generality of the foregoing, the Investor has not relied on any statements
or other information provided by or on behalf of the Placement Agents or any of their respective affiliates or any control persons, officers, directors, employees, partners, agents or representatives of any of the foregoing concerning SPAC, the
Company, the Transaction, the BCA, this Subscription Agreement or the transactions contemplated hereby or thereby, the Shares or the offer and sale of the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) The Investor acknowledges that the Placement Agents: (i)&nbsp;are each acting solely as the SPAC&#146;s Placement Agent in connection with
the transactions contemplated by the Subscription Agreements and is not acting as an underwriter or in any other capacity and is not and shall not be construed as a fiduciary for the Investor, (ii)&nbsp;have not made or make any representation or
warranty, express or implied, of any kind or character and have not provided any advice or recommendation in connection with the transactions contemplated by the Subscription Agreements, (iii)&nbsp;will have no responsibility with respect to
(a)&nbsp;any representations, warranties or agreements made by any person or entity under or in connection with the Transaction or any of the documents furnished pursuant thereto or in connection therewith, or the execution, legality, validity or
enforceability (with respect to any person) of any thereof, or (b)&nbsp;the business, affairs, financial condition, operations, properties or prospects of, or any other matter concerning the SPAC, the Company or the Transaction, (iv)&nbsp;have not
acted as the Investor&#146;s financial advisor or fiduciary in connection with the issue and purchase of Shares, (v)&nbsp;may have acquired, or during the term of the Shares may acquire, <FONT STYLE="white-space:nowrap">non-public</FONT> information
with respect to the Company, which, subject to the requirements of applicable law, the Investor agrees need not be provided to it, (vi)&nbsp;may have existing or future business relationships with SPAC and the Company (including, but not limited to,
lending, depository, risk management, advisory and banking relationships) and will pursue actions and take steps that it deems or they deem necessary or appropriate to protect its or their interests arising therefrom without regard to the
consequences for a holder of Shares, and that certain of these actions may have material and adverse consequences for a holder of Shares; and (vii)&nbsp;shall have no liability or obligation (including without limitation, for or with respect to any
losses, claims, damages, obligations, penalties, judgments, awards, liabilities, costs, expenses or disbursements incurred by the Investor, the Company or any other person or entity), whether in contract, tort or otherwise, to the Investor, or to
any person claiming through the Investor, in respect of the Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) The Investor acknowledges that it has not relied on the
Placement Agents in connection with its determination as to the legality of its acquisition of the Shares or as to the other matters referred to herein and the Investor has not relied on any investigation that the Placement Agents, any of their
affiliates or any person acting on their behalf have conducted with respect to the Shares, SPAC or the Company. The Investor further </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
acknowledges that it has not relied on any information contained in any research reports prepared by the Placement Agents or any of their affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) The Investor acknowledges that J.P. Morgan Securities LLC and SVB Leerink LLC are each acting as financial advisors to the Company
(i)&nbsp;in connection with the Transaction and (ii)&nbsp;in connection with the Company&#146;s contemplated acquisition of all issued and outstanding shares of common stock of Immunovant, Inc. not currently owned by the Company (the
&#147;<U>Immunovant Acquisition</U>&#148;), as disclosed on Schedule 13D filed on March&nbsp;8, 2021 by the Company (it being understood and agreed by the Investor that the purchase of the Shares pursuant to this Subscription Agreement on the
Closing Date and the closing of the Transaction shall not be contingent on the consummation of the contemplated Immunovant Acquisition). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) The Investor acknowledges and agrees that no federal or state agency has passed upon or endorsed the merits of the offering of the Shares
or made any findings or determination as to the fairness of this investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) The Investor, if not an individual, has been duly formed
or incorporated and is validly existing and is in good standing under the laws of its jurisdiction of formation or incorporation, with power and authority to enter into, deliver and perform its obligations under this Subscription Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) The execution, delivery and performance by the Investor of this Subscription Agreement are within the powers of the Investor, have been
duly authorized and will not constitute or result in a breach or default under or conflict with any order, ruling or regulation of any court or other tribunal or of any governmental commission or agency, or any agreement or other undertaking, to
which the Investor is a party or by which the Investor is bound, and, if the Investor is not an individual, will not violate any provisions of the Investor&#146;s organizational documents, including, without limitation, its incorporation or
formation papers, bylaws, indenture of trust or partnership or operating agreement, as may be applicable. The signature of the Investor on this Subscription Agreement is genuine, and the signatory, if the Investor is an individual, has legal
competence and capacity to execute the same or, if the Investor is not an individual, the signatory has been duly authorized to execute the same, and, assuming that this Subscription Agreement constitutes the valid and binding obligation of SPAC,
this Subscription Agreement constitutes a legal, valid and binding obligation of the Investor, enforceable against the Investor in accordance with its terms except as may be limited or otherwise affected by (i)&nbsp;bankruptcy, insolvency,
fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the rights of creditors generally, and (ii)&nbsp;principles of equity, whether considered at law or equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) The Investor is not (i)&nbsp;a person or entity named on the List of Specially Designated Nationals and Blocked Persons administered by
the U.S. Treasury Department&#146;s Office of Foreign Assets Control (&#147;<U>OFAC</U>&#148;) or in any Executive Order issued by the President of the United States and administered by OFAC (&#147;<U>OFAC List</U>&#148;), or a person or entity
prohibited by any OFAC sanctions program; (ii)&nbsp;owned, directly or indirectly, or controlled by, or acting on behalf of, one or more persons that are named on the OFAC List; (iii)&nbsp;organized, incorporated, established, located, resident or
born in, or a citizen, national or the government, including any political subdivision, agency or instrumentality thereof, of, Cuba, Iran, North Korea, Syria, the Crimea region of Ukraine or any other country or territory embargoed or subject to
substantial trade restrictions by the United States; (iv)&nbsp;a Designated National as defined in the Cuban Assets Control Regulations, 31 C.F.R. Part 515; or (v)&nbsp;a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> shell bank or providing
banking services indirectly to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> shell bank (each, a &#147;<U>Prohibited Investor</U>&#148;). The Investor agrees to provide law enforcement agencies, if requested thereby, such records as required by
applicable law, provided that the Investor is permitted to do so under applicable law. If the Investor is a financial institution subject to the Bank Secrecy Act (31 U.S.C. Section&nbsp;5311 et seq.) (the &#147;<U>BSA</U>&#148;), as amended by the
USA PATRIOT Act of 2001 (the &#147;<U>PATRIOT Act</U>&#148;), and its implementing regulations (collectively, the &#147;<U>BSA/PATRIOT Act</U>&#148;), the Investor maintains policies and procedures reasonably designed to comply with applicable
obligations under the BSA/PATRIOT Act. To the extent required, it maintains policies and procedures reasonably designed to ensure compliance with OFAC-administered sanctions programs, including for the screening of its investors against the OFAC
sanctions programs, including the OFAC List. To the extent required </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by applicable law, the Investor maintains policies and procedures reasonably designed to ensure that the funds held by the Investor and used to purchase the Shares were legally derived and were
not obtained, directly or indirectly, from a Prohibited Investor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) The Investor acknowledges that no disclosure or offering document
has been prepared by J.P. Morgan Securities LLC, SVB Leerink LLC, Citigroup Global Markets Inc., any additional placement agent that may be engaged by SPAC, or any of their respective affiliates (collectively, the &#147;<U>Placement
Agents</U>&#148;) in connection with the offer and sale of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s) The Investor acknowledges that neither Placement Agents, nor
any of their respective affiliates nor any control persons, officers, directors, employees, partners, agents or representatives of any of the foregoing have made any independent investigation with respect to SPAC, the Company or its subsidiaries or
any of their respective businesses, or the Shares or the accuracy, completeness or adequacy of any information supplied to the Investor by SPAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(t) The Investor, when required to deliver payment to SPAC pursuant to Section&nbsp;2 above, will have, sufficient funds to pay the
Subscription Amount and consummate the purchase and sale of the Shares pursuant to this Subscription Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(u) The Investor agrees
that, from the date of this Subscription Agreement until the Closing or the earlier termination of this Subscription Agreement, none of Investor, its controlled affiliates, or any person or entity acting on behalf of the Investor or any of its
controlled affiliates or pursuant to any understanding with the Investor or any of its controlled affiliates will engage in any Short Sales with respect to securities of the SPAC. For the purposes hereof, &#147;Short Sales&#148; shall include,
without limitation, all &#147;short sales&#148; as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act, and all types of direct and indirect stock pledges (other than pledges in the ordinary course of business as part of
prime brokerage arrangements), forward sale contracts, options, puts, calls, swaps and similar arrangements (including on a total return basis), including through <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker dealers or foreign regulated
brokers. Notwithstanding the foregoing, (A)&nbsp;nothing herein shall prohibit (x)&nbsp;other entities under common management with the Investor with whom the Investor is not acting in concert with respect to any trading in securities of the SPAC,
this Subscription Agreement or the Investor&#146;s participation in this offering of the Shares including the Investor&#146;s controlled affiliates and/or affiliates, or (y)&nbsp;in the case of an Investor that is externally managed, advised or <FONT
STYLE="white-space:nowrap">sub-advised</FONT> by another person, any other person that is not directly controlled or managed by such manager, adviser or <FONT STYLE="white-space:nowrap">sub-adviser,</FONT> in each case from entering into any Short
Sale and (B)&nbsp;in the case of an Investor that is a multi-managed investment bank or vehicle whereby separate portfolio managers manage separate portions of such Investor&#146;s assets and the portfolio managers have no knowledge of the
investment decisions made by the portfolio managers managing other portions of such Investor&#146;s assets, this Section (u)&nbsp;shall apply only with respect to the portion of assets managed by the portfolio manager that made the investment
decision to purchase the Shares covered by this Subscription Agreement. For the avoidance of doubt, nothing in this Section (u)&nbsp;shall restrict any transactions with respect to securities of SPAC other than transactions that are Short Sales
including the exercise of any redemption with respect to securities of the SPAC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) Except as expressly disclosed in a Schedule 13D or
Schedule 13G (or amendments thereto) filed by such Investor with the SEC with respect to the beneficial ownership of the SPAC&#146;s common stock, the Investor is not currently (and at all times through Closing will refrain from being or becoming) a
member of a &#147;group&#148; (within the meaning of section 13(d)(3) or section 14(d)(2) of the Exchange Act) acting for the purpose of acquiring, holding or disposing of equity securities of the SPAC (within the meaning of Rule <FONT
STYLE="white-space:nowrap">13d-5(b)(1)</FONT> under the Exchange Act). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(w) No broker, finder or other financial consultant has acted on
behalf of the Investor in connection with this Subscription Agreement or the transactions contemplated hereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) The Investor acknowledges the SEC&#146;s issuance of the Statement, and the Investor
agrees that any actions taken by SPAC in connection with, or as may be necessary or advisable to address the potential implications of, such Statement or review shall not be deemed to constitute a breach of any of the representations, warranties or
covenants in this Subscription Agreement; provided, however, that any such actions may not materially and adversely affect the rights of the Investor (in its capacity as such) under this Subscription Agreement. For the avoidance of doubt, any
restatement or the financial statements of SPAC and any amendments to previously filed SEC reports or delays in filing SEC reports, in connection with the Statement or any subsequent related agreements or other guidance from the SEC with respect to
the Statement shall not be considered to materially and adversely affect the rights of the Investor (in its capacity as such) under this Subscription agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Registration Rights</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) In the event that the Shares are not registered in connection with the consummation of the Transaction, the Company agrees that, within
thirty (30)&nbsp;calendar days after the Closing Date (the &#147;<U>Filing Deadline</U>&#148;), it will file with the SEC (at its sole cost and expense) a registration statement (the &#147;Registration Statement&#148;) registering the resale of the
Shares, and it shall use its commercially reasonable efforts to have the Registration Statement declared effective as soon as practicable after the filing thereof, but no later than the earlier of (i)&nbsp;sixty (60) calendar days after the filing
thereof (or ninety (90)&nbsp;calendar days after the filing thereof if the SEC notifies the Company that it will &#147;review&#148; the Registration Statement) and (ii)&nbsp;five (5) business days after the Company is notified (orally or in writing,
whichever is earlier) by the SEC that the Registration Statement will not be &#147;reviewed&#148; or will not be subject to further review ((i) and (ii)&nbsp;collectively, the &#147;<U>Effectiveness Deadline</U>&#148;). In connection with the
foregoing and with all transactions contemplated by this Subscription Agreement, Investor shall not be required to execute any <FONT STYLE="white-space:nowrap">lock-up</FONT> or similar agreement or otherwise be subject to any contractual
restriction on the ability to transfer the Shares. The Company agrees to use commercially reasonable efforts to cause such Registration Statement, or another shelf registration statement that includes the Shares to be sold pursuant to this
Subscription Agreement, to remain effective until the earliest of (i)&nbsp;the second anniversary of the Closing, (ii)&nbsp;the date on which the Investor ceases to hold any Shares issued pursuant to this Subscription Agreement, or (iii)&nbsp;on the
first date on which the Investor is able to sell all of its Shares issued pursuant to this Subscription Agreement (or shares received in exchange therefor) under Rule 144 promulgated under the Securities Act (&#147;<U>Rule 144</U>&#148;) within
ninety (90)&nbsp;calendar days without the public information, volume or manner of sale limitations of such rule (such date, the &#147;<U>End Date</U>&#148;). Prior to the End Date, the Company will use commercially reasonable efforts to&nbsp;(1)
qualify the Shares for listing on Nasdaq or another applicable national stock exchange and (2)&nbsp;update or amend the Registration Statement as necessary to include the Shares. Subject to receipt from the Investor by the Company and its transfer
agent of customary representations and other documentation reasonably acceptable to the Company and the transfer agent in connection therewith, including, if required by the transfer agent, an opinion of the Company&#146;s counsel in a form
reasonably acceptable to the transfer agent, the Investor may request that the Company remove any legend from the book-entry position evidencing the Shares following the earliest of such time as the Shares (A)&nbsp;have been or are being sold or
transferred pursuant to an effective registration statement or (B)&nbsp;have been or are being sold pursuant to Rule 144 promulgated under the Securities Act (&#147;<U>Rule 144</U>&#148;). To the extent required by the Company&#146;s transfer agent,
the Company shall use commercially reasonable efforts to cause its legal counsel to deliver a customary opinion within two business days of the delivery of all reasonably necessary representations and other documentation from the Investor as
reasonably requested by the Company&#146;s transfer agent. If restrictive legends are no longer required for the Shares pursuant to the foregoing, the Company shall, reasonably promptly following any request therefor from the Investor as described
above (and no later than five (5)&nbsp;business days after such request), deliver to the transfer agent instructions to remove such restrictive legends from the Shares of the Investor. The Company may amend the Registration Statement so as to
convert the Registration Statement to a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> at such time after the Company becomes eligible to use such Form <FONT STYLE="white-space:nowrap">S-3.</FONT> For as long as the
Investor holds the Shares, the Company will use commercially reasonable efforts to file all reports, and provide all customary and reasonable cooperation, necessary to enable the Investor to resell the Shares pursuant to the Registration Statement
or Rule 144 of the Securities Act (when Rule 144 of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Securities Act becomes available to the Investor), as applicable. In no event shall the undersigned be identified as a statutory underwriter in the Registration Statement unless in response to a
comment or request from the staff of the SEC or another regulatory agency; provided, however, that if the SEC requests that the undersigned be identified as a statutory underwriter in the Registration Statement, the undersigned will have an
opportunity to withdraw from the Registration Statement. For purposes of clarification, any failure by the Company to file the Registration Statement by the Filing Deadline or to effect such Registration Statement by the Effectiveness Deadline shall
not otherwise relieve the Company of its obligations to file the Registration Statement or effect the registration of the Shares set forth in this Section&nbsp;8. The Investor acknowledges and agrees that the Company may suspend the use of any such
registration statement if it determines in good faith, upon advice of legal counsel (internal counsel being sufficient), that in order for such registration statement not to contain a material misstatement or omission, an amendment thereto would be
needed to include information that would at that time not otherwise be required in a current, quarterly, or annual report under the Exchange Act, provided, that, (I)&nbsp;the Company shall not so delay filing or so suspend the use of the
Registration Statement on more than three (3)&nbsp;occasions for a period of more than sixty (60)&nbsp;consecutive days or more than a total of ninety (90)&nbsp;calendar days, in each case in any three hundred sixty (360)&nbsp;day period and
(II)&nbsp;the Company shall use commercially reasonable efforts to make such Registration Statement available for the sale by the Investor of such securities as soon as practicable thereafter. The Company&#146;s obligations to include the Shares
issued pursuant to this Subscription Agreement (or shares issued in exchange therefor) for resale in the Registration Statement are contingent upon the Investor furnishing in writing to the Company such information regarding the Investor, the
securities of the Company held by the Investor and the intended method of disposition of such Shares, as shall be reasonably requested by the Company to effect the registration of such Shares, and shall execute such documents in connection with such
registration as the Company may reasonably request that are customary of a selling stockholder in similar situations. The Company shall use its commercially reasonable efforts to provide a draft of the Registration Statement to the Investor for
review at least two (2)&nbsp;business days in advance of filing the Registration Statement; provided that, for the avoidance of doubt, in no event shall the Company be required to delay or postpone the filing of such Registration Statement as a
result of or in connection with the Investor&#146;s review. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding the foregoing, if the SEC prevents the Company from
including any or all of the Shares proposed to be registered under the Registration Statement due to limitations on the use of Rule 415 of the Securities Act for the resale of Shares by the applicable stockholders or otherwise, such Registration
Statement shall register for resale such number of Shares which is equal to the maximum number of Shares as is permitted by the SEC. In such event, the number of Shares to be registered for each selling stockholder named in the Registration
Statement shall be reduced pro rata among all such selling stockholders and as promptly as practicable after being permitted to register additional Shares under Rule 415 under the Securities Act, the Company shall amend the Registration Statement or
file a new Registration Statement to register such Shares not included in the initial Registration Statement and use its commercially reasonable efforts to cause such amendment or Registration Statement to become effective as promptly as
practicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In the case of the registration, qualification, exemption or compliance effected by the Company pursuant to this
Agreement, the Company shall, upon reasonable request, inform Investor as to the status of such registration, qualification, exemption and compliance. At its expense, the Company shall use its commercially reasonable efforts to advise Investor
reasonably promptly (but within no later than 5 business days): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) when a Registration Statement or any amendment thereto
has been filed with the SEC and when a Registration Statement or any post-effective amendment thereto has become effective; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) after it shall receive notice or obtain knowledge thereof, of the issuance by the SEC of any stop order suspending the
effectiveness of any Registration Statement or the initiation of any proceedings for such purpose; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) of the receipt by
the Company of any notification with respect to the suspension of the qualification of the Shares included therein for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) subject to the provisions in this Subscription Agreement, of the
occurrence of any event that requires the making of any changes in any Registration Statement or prospectus included therein so that, as of such date, the statements therein are not misleading and do not omit to state a material fact required to be
stated therein or necessary to make the statements therein (in the case of a prospectus, in the light of the circumstances under which they were made) not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon receipt of any written notice from the Company (which notice shall not contain any material <FONT STYLE="white-space:nowrap">non-public</FONT>
information regarding the Company) of the happening any event contemplated in clauses (ii)&nbsp;through (iv) above during the period that the Registration Statement is effective or if as a result of the occurrence of such event the Registration
Statement or related prospectus contains any untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made
(in the case of the prospectus) not misleading, the undersigned Investor agrees that (1)&nbsp;it will immediately discontinue offers and sales of the Shares under the Registration Statement (excluding, for the avoidance of doubt, sales conducted
pursuant to Rule 144) until the undersigned Investor receives copies of a supplemental or amended prospectus (which Company agrees to promptly prepare) that corrects the misstatement(s) or omission(s) referred to above and receives notice that any
post-effective amendment has become effective or unless otherwise notified by Company that it may resume such offers and sales, and (2)&nbsp;it will maintain the confidentiality of any information included in such written notice delivered by Company
except (A)&nbsp;for disclosure to the Investor&#146;s employees, agents and professional advisers who need to know such information and are obligated to keep it confidential, (B)&nbsp;for disclosures to the extent required in order to comply with
reporting obligations to its limited partners who have agreed to keep such information confidential and (C)&nbsp;as required by law or subpoena. The Company shall use its commercially reasonable efforts to obtain the withdrawal of any order
suspending the effectiveness of any Registration Statement as soon as reasonably practicable. Upon the occurrence of any event contemplated in clauses (ii)&nbsp;through (iv) above, except for such times as the Company is permitted hereunder to
suspend, and has suspended, the use of a prospectus forming part of a Registration Statement, the Company shall use its commercially reasonable efforts to as soon as reasonably practicable prepare a post-effective amendment to such Registration
Statement or a supplement to the related prospectus, or file any other required document so that, as thereafter delivered to purchasers of the Shares included therein, such prospectus will not include any untrue statement of a material fact or omit
to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Indemnification</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company shall indemnify Investor (to the extent a seller under the Registration Statement), its officers, directors,
advisers and agents, and each person who controls Investor (within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act) to the fullest extent permitted by applicable law, from and against any and all losses,
claims, damages, liabilities, costs (including reasonably incurred and documented attorneys&#146; fees) and reasonably incurred and documented expenses (collectively, &#147;<U>Losses</U>&#148;) that arise out of or are based upon any untrue or
alleged untrue statement of a material fact contained or incorporated by reference in the Registration Statement pursuant to which Investor&#146;s Shares are registered, any prospectus included in the Registration Statement or any form of prospectus
or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein (in the
case of any prospectus or form of prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading, except to the extent that such untrue statements or alleged untrue statements, omissions or alleged
omissions are based upon information regarding Investor furnished in writing to the Company by Investor expressly for use therein or Investor has omitted a material fact from such information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Investor shall indemnify and hold harmless the Company, its directors, officers, agents and employees, and each person
who controls the Company (within the meaning of Section&nbsp;15 of the Securities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Act and Section&nbsp;20 of the Exchange Act), to the fullest extent permitted by applicable law, from and against all Losses arising out of or are based upon any untrue or alleged untrue
statement of a material fact contained or incorporated by reference in any Registration Statement pursuant to which Investor&#146;s Shares are registered, any prospectus included in the Registration Statement, or any form of prospectus, or in any
amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any
prospectus, or any form of prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading to the extent, but only to the extent, that such untrue statements or omissions are based upon information
regarding Investor furnished in writing to the Company by the Investor expressly for use therein. In no event shall the liability of Investor be greater in amount than the dollar amount of the net proceeds received by Investor upon the sale of the
subscribed Shares giving rise to such indemnification obligation. The Investor shall notify the Company promptly of the institution, threat or assertion of any proceeding arising from or in connection with the transactions contemplated by this
Section&nbsp;8 of which the Investor is aware. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Any person entitled to indemnification herein shall (1)&nbsp;give
prompt written notice to the indemnifying party of any claim with respect to which it seeks indemnification (provided that the failure to give prompt notice shall not impair any person&#146;s right to indemnification hereunder to the extent such
failure has not prejudiced the indemnifying party) and (2)&nbsp;permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party. If such defense is assumed, the indemnifying party
shall not be subject to any liability for any settlement made by the indemnified party without its written consent. An indemnifying party who elects not to assume the defense of a claim shall not be obligated to pay the fees and expenses of more
than one counsel for all parties indemnified by such indemnifying party with respect to such claim, unless in the reasonable judgment of legal counsel to any indemnified party a conflict of interest exists between such indemnified party and any
other of such indemnified parties with respect to such claim. No indemnifying party shall, without the consent of the indemnified party (which consent shall not be unreasonably withheld, conditioned or delayed), consent to the entry of any judgment
or enter into any settlement which cannot be settled in all respects by the payment of money (and such money is so paid by the indemnifying party pursuant to the terms of such settlement) or which settlement does not include as an unconditional term
thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) The indemnification provided for under this Subscription Agreement shall remain in full force and effect regardless of any
investigation made by or on behalf of the indemnified party or any officer, director, employee, agent, affiliate or controlling person of such indemnified party and shall survive the transfer of the Shares purchased pursuant to this Subscription
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) If the indemnification provided under this Section&nbsp;8(d) from the indemnifying party is unavailable or
insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities and expenses referred to herein, then the indemnifying party, in lieu of indemnifying the indemnified party, shall contribute to the amount
paid or payable by the indemnified party as a result of such losses, claims, damages, liabilities and expenses in such proportion as is appropriate to reflect the relative fault of the indemnifying party and the indemnified party, as well as any
other relevant equitable considerations. The relative fault of the indemnifying party and indemnified party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of
a material fact or omission or alleged omission to state a material fact, was made by, or relates to information supplied by, such indemnifying party or indemnified party, and the indemnifying party&#146;s and indemnified party&#146;s relative
intent, knowledge, access to information and opportunity to correct or prevent such action. The amount paid or payable by a party as a result of the losses or other liabilities referred to above shall be deemed to include, subject to the limitations
set forth in this Section&nbsp;8(d), any legal or other fees, charges or expenses reasonably incurred by such party in connection with any investigation or proceeding. No person guilty of fraudulent misrepresentation (within the meaning of
Section&nbsp;11(f) of the Securities Act) shall be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
entitled to contribution pursuant to this Section (8(d)(v) from any person who was not guilty of such fraudulent misrepresentation. Each indemnifying party&#146;s obligation to make a
contribution pursuant to this Section&nbsp;8(d)(v) shall be individual, not joint and several, and in no event shall the liability of any Investor hereunder be greater in amount than the dollar amount of the net proceeds received by such Investor
upon the sale of the subscribed Shares giving rise to such indemnification obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Company shall not hereafter enter into,
and is not currently a party to, any Other Subscription Agreements with respect to the Shares that is inconsistent in any material respect with, or superior to, the registration rights granted to Investor by this Subscription Agreement.
Notwithstanding any other rights and remedies Investor may have in respect of the Company or such Other Investors pursuant to this Subscription Agreement, if the Company enters into any other registration rights or similar agreement with respect to
the Shares that contains provisions that violate the preceding sentence, the terms and conditions of this Subscription Agreement shall be deemed to have been amended without further action by the Company or Investor so that Investor shall be
entitled to the benefit of any such more favorable or less restrictive terms or conditions, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Termination</U>.
This Subscription Agreement shall terminate and be void and of no further force and effect, and all rights and obligations of the parties hereunder shall terminate without any further liability on the part of any party in respect thereof, upon the
earlier to occur of (a)&nbsp;such date and time as the BCA is terminated in accordance with its terms without being consummated, (b)&nbsp;upon the mutual written agreement of each of the parties hereto to terminate this Subscription Agreement,
(c)&nbsp;December&nbsp;30, 2021, if the Closing has not occurred by such date, or (d)&nbsp;if any of the conditions to Closing set forth in Section&nbsp;3 of this Subscription Agreement are (i)&nbsp;not satisfied or waived or (ii)&nbsp;not capable
of being satisfied and, in each case of (i)&nbsp;and (ii), as a result thereof, the transactions contemplated by this Subscription Agreement will not be and are not consummated at the Closing (the termination events described in clauses (a)&#150;(d)
above, collectively, the &#147;<U>Termination Events</U>&#148;); provided that in the case of clause (d), to the extent such failure to satisfy the conditions to Closing set forth in Section&nbsp;3 of this Subscription Agreement is caused by the
Investor&#146;s failure to satisfy such conditions, termination shall instead be at the election of SPAC; provided, further, that nothing herein will relieve any party from liability for any willful breach hereof prior to the time of termination,
and each party will be entitled to any remedies at law or in equity to recover losses, liabilities or damages arising from any such willful breach. SPAC shall notify the Investor in writing of the termination of the BCA promptly after the
termination of such agreement. Upon the occurrence of any Termination Event and subject to the provisions of this Section&nbsp;9, this Subscription Agreement shall be void and of no further effect and any monies paid by the Investor to SPAC in
connection herewith shall promptly (and in any event within one (1)&nbsp;business day) following the Termination Event be returned to the Investor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Trust Account Waiver</U>. The Investor acknowledges that SPAC is a blank check company with the powers and privileges to effect a
merger, asset acquisition, reorganization or similar business combination involving SPAC and one or more businesses or assets. The Investor further acknowledges that, as described in SPAC&#146;s prospectus relating to its initial public offering
dated October&nbsp;6, 2020 (the &#147;<U>Prospectus</U>&#148;) available at www.sec.gov, substantially all of SPAC&#146;s assets consist of the cash proceeds of SPAC&#146;s initial public offering and private placement of its securities, and
substantially all of those proceeds have been deposited in a trust account (the &#147;<U>Trust Account</U>&#148;) for the benefit of SPAC, its public shareholders and the underwriters of SPAC&#146;s initial public offering. Except with respect to
interest earned on the funds held in the Trust Account that may be released to SPAC to pay its tax obligations and to fund certain of its working capital requirements, the cash in the Trust Account may be disbursed only for the purposes set forth in
the Prospectus. For and in consideration of SPAC entering into this Subscription Agreement, the receipt and sufficiency of which are hereby acknowledged, the Investor hereby irrevocably waives any and all right, title and interest, or any claim of
any kind it has or may have in the future, in or to any monies held in the Trust Account, and agrees not to seek recourse against the Trust Account as a result of, or arising out of, this Subscription Agreement; provided, however, that nothing in
this Section&nbsp;10 shall be deemed to limit the Investor&#146;s right, title, interest or claim to any monies held in the Trust Account by virtue of its record or beneficial ownership of Shares (x)&nbsp;acquired by any means other than pursuant
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to this Subscription Agreement or (y)&nbsp;currently outstanding on the date hereof, pursuant to a validly exercised redemption right with respect to any such Shares, except to the extent that
the Investor has otherwise agreed in writing with SPAC to not exercise such redemption right. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Neither this Subscription Agreement nor any rights that may accrue to the parties hereunder (other than the Shares acquired hereunder, if
any) may be transferred or assigned without the prior written consent of each of the other parties hereto; provided that (i)&nbsp;this Subscription Agreement and any of the Investor&#146;s rights and obligations hereunder may be assigned to an
affiliate or any fund or account advised or managed by the Investor or the same investment manager or investment advisor as the Investor or by an affiliate (as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act) of
such investment manager or investment advisor without the prior consent of SPAC or the Company; provided, however, the Investor shall provide notice of any such assignment to SPAC and the Company and (ii)&nbsp;the Investor&#146;s rights under
Section&nbsp;8&nbsp;may be assigned to an assignee or transferee of the Shares; provided further that prior to such assignment any such assignee shall agree in writing to be bound by the terms hereof. Upon such assignment by the Investor in
accordance with this Section (a), the assignee shall become an Investor hereunder and have the rights and obligations provided for herein to the extent of such assignment; provided, that no assignment pursuant to clause (i)&nbsp;of this
Section&nbsp;11(a) shall relieve the Investor of its obligations hereunder, except to the extent actually performed in accordance with the terms hereof, unless consented to in writing by SPAC and the Company (such consent not to be unreasonably
conditioned, delayed or withheld). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) SPAC and/or the Company may request from the Investor such additional information as they may
reasonably deem necessary to register the resale of the Shares and evaluate the eligibility of the Investor to acquire the Shares, and the Investor shall promptly provide such information as may reasonably be requested to the extent readily
available; provided, that, each of SPAC and the Company agrees to keep any such information provided by Investor confidential except (i)&nbsp;as necessary to include in any registration statement required to be filed hereunder, (ii)&nbsp;as required
by the federal securities law or pursuant to other routine proceedings of regulatory authorities or (iii)&nbsp;to the extent such disclosure is required by law, at the request of the staff of the SEC or regulatory agency or under the regulations of
any national securities exchange on which SPAC&#146;s or the Company&#146;s securities, as the case may be, are listed for trading. The Investor acknowledges and agrees that if it does not provide SPAC and/or the Company with such requested
information, the Investor&#146;s Shares may not be registered for resale pursuant to Section&nbsp;8 hereof. The Investor acknowledges that SPAC and/or the Company may file a copy of this Subscription Agreement (or a form of this Subscription
Agreement) with the SEC as an exhibit to a periodic report or a registration statement of SPAC or the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Investor
acknowledges that (i)&nbsp;SPAC and the Company will rely on the acknowledgments, understandings, agreements, representations and warranties of the Investor contained in this Subscription Agreement, including Schedule A hereto and (ii)&nbsp;the
Placement Agents will rely on the acknowledgments, understandings, agreements, representations and warranties of the Investor contained in Section&nbsp;7 of this Subscription Agreement, including Schedule A hereto. Each of SPAC and the Company
acknowledges that the Investor will rely on the acknowledgments, understandings, agreements, representations and warranties of each of SPAC and the Company contained in this Subscription Agreement. Prior to the Closing, the Investor agrees to
promptly notify SPAC and the Company if any of the acknowledgments, understandings, agreements, representations and warranties set forth in Section&nbsp;7 above are no longer accurate in any material respect (other than those acknowledgments,
understandings, agreements, representations and warranties qualified by materiality, in which case the Investor shall notify SPAC if they are no longer accurate in any respect). Investor further acknowledges and agrees that each of the Placement
Agents is a third-party beneficiary of the representations and warranties of the Investor contained in this Subscription Agreement. The Investor acknowledges and agrees that the purchase by the Investor of Shares from SPAC will constitute a
reaffirmation of the acknowledgments, understandings, agreements, representations and warranties herein (as modified by any such notice) by the Investor as of the time of such purchase. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Each of SPAC, the Company, the Investor and the Placement Agents is each entitled to
rely upon this Subscription Agreement and each is irrevocably authorized to produce this Subscription Agreement or a copy hereof to any interested party in any administrative or legal proceeding or official inquiry with respect to the matters
covered hereby; provided, however, that the foregoing clause of this Section&nbsp;11(d) shall not give the Company or the Placement Agents any rights other than those expressly set forth in this Section&nbsp;11(d) and, without limiting the
generality of the foregoing and for the avoidance of doubt, in no event shall the Company be entitled to rely on any of the representations and warranties of SPAC set forth in this Subscription Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) All of the agreements, representations and warranties made by each party hereto in this Subscription Agreement shall survive the Closing.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) This Subscription Agreement may not be amended, modified, waived or terminated (other than pursuant to the terms of Section&nbsp;9
above) except by an instrument in writing, signed by each of the parties hereto. No failure or delay of either party in exercising any right or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such
right or power, or any abandonment or discontinuance of steps to enforce such right or power, or any course of conduct, preclude any other or further exercise thereof or the exercise of any other right or power. The rights and remedies of the
parties hereunder are cumulative and are not exclusive of any rights or remedies that they would otherwise have hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) This
Subscription Agreement (including the schedule hereto) constitutes the entire agreement, and supersedes all other prior agreements, understandings, representations and warranties, both written and oral, among the parties, with respect to the subject
matter hereof. Except as expressly otherwise provided herein, this Subscription Agreement shall not confer any rights or remedies upon any person other than the parties hereto, and their respective successors and assigns, and the parties hereto
acknowledge that such persons so referenced are third party beneficiaries of this Subscription Agreement with right of enforcement for the purposes of, and to the extent of, the rights granted to them, if any, pursuant to the applicable provisions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Except as otherwise provided herein, this Subscription Agreement shall be binding upon, and inure to the benefit of the parties
hereto and their heirs, executors, administrators, successors, legal representatives, and permitted assigns, and the agreements, representations, warranties, covenants and acknowledgments contained herein shall be deemed to be made by, and be
binding upon, such heirs, executors, administrators, successors, legal representatives and permitted assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) If any provision of
this Subscription Agreement shall be adjudicated by a court of competent jurisdiction to be invalid, illegal or unenforceable, the validity, legality or enforceability of the remaining provisions of this Subscription Agreement shall not in any way
be affected or impaired thereby and shall continue in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) This Subscription Agreement may be executed in one or
more counterparts (including by facsimile or electronic mail or in .pdf) and by different parties in separate counterparts, with the same effect as if all parties hereto had signed the same document. All counterparts so executed and delivered shall
be construed together and shall constitute one and the same agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) The parties hereto acknowledge and agree that irreparable
damage would occur in the event that any of the provisions of this Subscription Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an
injunction or injunctions to prevent breaches of this Subscription Agreement, without posting a bond or undertaking and without proof of damages, to enforce specifically the terms and provisions of this Subscription Agreement, this being in addition
to any other remedy to which such party is entitled at law, in equity, in contract, in tort or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) If any change in the
number, type or classes of authorized shares of SPAC (including the Shares), other than as contemplated by the BCA or any agreement contemplated by the BCA, shall occur between the date </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
hereof and immediately prior to the Closing by reason of reclassification, recapitalization, stock split (including reverse stock split) or combination, exchange or readjustment of shares, or any
stock dividend, the number of Shares issued to the Investor and the Per Share Purchase Price shall be appropriately adjusted to reflect such change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) This Subscription Agreement shall be governed by and construed in accordance with the laws of the State of Delaware (regardless of the
laws that might otherwise govern under applicable principles of conflicts of laws thereof) as to all matters (including any action, suit, litigation, arbitration, mediation, claim, charge, complaint, inquiry, proceeding, hearing, audit,
investigation or reviews by or before any governmental entity related hereto), including matters of validity, construction, effect, performance and remedies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) Each party hereto hereby, and any person asserting rights as a third party beneficiary may do so only if he, she or it, irrevocably agrees
that any action, suit or proceeding between or among the parties hereto, whether arising in contract, tort or otherwise, arising in connection with any disagreement, dispute, controversy or claim arising out of or relating to this Subscription
Agreement or any related document or any of the transactions contemplated hereby or thereby (&#147;<U>Legal Dispute</U>&#148;) shall be brought only to the exclusive jurisdiction of the courts of the State of Delaware or the federal courts located
in the State of Delaware, and each party hereto hereby consents to the jurisdiction of such courts (and of the appropriate appellate courts therefrom) in any such suit, action or proceeding and irrevocably waives, to the fullest extent permitted by
law, any objection that it may now or hereafter have to the laying of the venue of any such suit, action or proceeding in any such court or that any such suit, action or proceeding that is brought in any such court has been brought in an
inconvenient forum. During the period a Legal Dispute that is filed in accordance with this Section&nbsp;11(n) is pending before a court, all actions, suits or proceedings with respect to such Legal Dispute or any other Legal Dispute, including any
counterclaim, cross-claim or interpleader, shall be subject to the exclusive jurisdiction of such court. Each party hereto and any person asserting rights as a third party beneficiary may do so only if he, she or it hereby waives, and shall not
assert as a defense in any Legal Dispute, that (i)&nbsp;such party is not personally subject to the jurisdiction of the above named courts for any reason, (ii)&nbsp;such action, suit or proceeding may not be brought or is not maintainable in such
court, (iii)&nbsp;such party&#146;s property is exempt or immune from execution, (iv)&nbsp;such action, suit or proceeding is brought in an inconvenient forum, or (v)&nbsp;the venue of such action, suit or proceeding is improper. A final judgment in
any action, suit or proceeding described in this Section&nbsp;11(n) following the expiration of any period permitted for appeal and subject to any stay during appeal shall be conclusive and may be enforced in other jurisdictions by suit on the
judgment or in any other manner provided by applicable laws. EACH OF THE PARTIES HERETO AND ANY PERSON ASSERTING RIGHTS AS A THIRD PARTY BENEFICIARY MAY DO SO ONLY IF HE, SHE OR IT IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT TO TRIAL BY JURY ON
ANY CLAIMS OR COUNTERCLAIMS ASSERTED IN ANY LEGAL DISPUTE RELATING TO THIS SUBSCRIPTION AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY AND FOR ANY COUNTERCLAIM RELATING THERETO. IF THE SUBJECT MATTER OF ANY SUCH LEGAL DISPUTE IS ONE IN WHICH THE
WAIVER OF JURY TRIAL IS PROHIBITED, NO PARTY HERETO NOR ANY PERSON ASSERTING RIGHTS AS A THIRD PARTY BENEFICIARY SHALL ASSERT IN SUCH LEGAL DISPUTE A NONCOMPULSORY COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS SUBSCRIPTION AGREEMENT OR THE
TRANSACTIONS CONTEMPLATED HEREBY. FURTHERMORE, NO PARTY HERETO NOR ANY PERSON ASSERTING RIGHTS AS A THIRD PARTY BENEFICIARY SHALL SEEK TO CONSOLIDATE ANY SUCH LEGAL DISPUTE WITH A SEPARATE ACTION OR OTHER LEGAL PROCEEDING IN WHICH A JURY TRIAL
CANNOT BE WAIVED. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) Any notice or communication required or permitted hereunder to be given to a party hereto shall be in writing and
either delivered personally, emailed or sent by overnight mail via a reputable overnight carrier, or sent by certified or registered mail, postage prepaid, to such address(es) or email address(es) set forth on the signature page hereto, and shall be
deemed to be given and received (i)&nbsp;when so delivered personally, (ii)&nbsp;when sent, with no mail undeliverable or other rejection notice, if sent by email, or (iii)&nbsp;three (3) business days after the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
date of mailing to the address below or to such other address or addresses as the party may hereafter designate by notice given hereunder: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(i) if to Investor, to such address(es) or email address(es) as set forth herein; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ii) if to SPAC, to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Montes
Archimedes Acquisition Corp. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">724 Oak Grove, Suite 130 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Menlo Park, CA 94025 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Maria Walker </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-mail:</FONT> maria@patientsquarecapital.com </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><U>with a copy (which shall not constitute notice) to:</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Kirkland&nbsp;&amp; Ellis LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">601 Lexington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York,
NY 10022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Michael E. Weisser, P.C. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ryan Brissette </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> &nbsp;&nbsp;&nbsp;&nbsp;michael.weisser@kirkland.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ryan.brissette@kirkland.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(iii) if to the Company, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Roivant Sciences Ltd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Suite 1,
3rd Floor, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">11-12</FONT> St. James&#146;s Square, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">London SW1Y 4LB </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">United Kingdom
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Matthew Gline </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-mail:</FONT> &nbsp;&nbsp;&nbsp;&nbsp;matthew.gline@roivant.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;legalnotices@roivant.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><U>with a copy (which shall not constitute notice) to:</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Roivant Sciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">151
West 42nd Street, 15th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, NY 10036 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-mail:</FONT> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;jo.chen@roivant.com </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">-and- </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Davis Polk&nbsp;&amp; Wardwell LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">450 Lexington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York,
NY 10017 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Derek Dostal </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Brian Wolfe </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lee Hochbaum </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;derek.dostal@davispolk.com</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;brian.wolfe@davispolk.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;lee.hochbaum@davispolk.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U><FONT STYLE="white-space:nowrap">Non-Reliance</FONT> and Exculpation</U>. The Investor acknowledges that it is not relying upon, and
has not relied upon, any statement, representation or warranty made by any person, firm or corporation (including, without limitation, the Placement Agents, any of their respective affiliates or any control persons, officers, directors,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employees, partners, agents or representatives of any of the foregoing), other than the statements, representations and warranties of SPAC and the Company expressly contained in Section&nbsp;5
and Section&nbsp;6 of this Subscription Agreement, respectively, in making its investment or decision to invest in SPAC. The Investor acknowledges and agrees that none of (i)&nbsp;any other investor pursuant to this Subscription Agreement or any
other subscription agreement related to the private placement of the Shares (including the investor&#146;s respective affiliates or any control persons, officers, directors, employees, partners, agents or representatives of any of the foregoing),
(ii) the Placement Agents, their respective affiliates or any control persons, officers, directors, employees, partners, agents or representatives of any of the foregoing, or (iii)&nbsp;any other party to the BCA or any <FONT
STYLE="white-space:nowrap">Non-Party</FONT> Affiliate (other than SPAC or the Company with respect to the previous sentence), shall have any liability to the Investor, or to any other investor, pursuant to, arising out of or relating to this
Subscription Agreement or any other subscription agreement related to the private placement of the Shares, the negotiation hereof or thereof or its subject matter, or the transactions contemplated hereby or thereby, including, without limitation,
with respect to any action heretofore or hereafter taken or omitted to be taken by any of them in connection with the purchase of the Shares or with respect to any claim (whether in tort, contract or otherwise) for breach of this Subscription
Agreement or in respect of any written or oral representations made or alleged to be made in connection herewith, as expressly provided herein, or for any actual or alleged inaccuracies, misstatements or omissions with respect to any information or
materials of any kind furnished by SPAC, the Company, the Placement Agents or any <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate concerning SPAC, the Company, the Placement Agents, any of their controlled affiliates, this Subscription
Agreement or the transactions contemplated hereby. For purposes of this Subscription Agreement, <FONT STYLE="white-space:nowrap">&#147;Non-Party</FONT> Affiliates&#148; means each former, current or future officer, director, employee, partner,
member, manager, direct or indirect equityholder or affiliate of SPAC, the Company, the Placement Agents or any of SPAC&#146;s, the Company&#146;s or the Placement Agents&#146; controlled affiliates or any family member of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Disclosure</U>. SPAC shall, by 9:00 a.m., New York City time, on the first (1st) business day immediately following the date of this
Subscription Agreement, issue one or more press releases or file with the SEC a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (collectively, the &#147;Disclosure Document&#148;) disclosing all material terms of the transactions
contemplated hereby and by the Other Subscription Agreements, the Transaction and any other material, nonpublic information that SPAC has provided to the Investor at any time prior to the filing of the Disclosure Document. Upon the issuance of the
Disclosure Document, to the actual knowledge of SPAC, the Investor shall not be in possession of any material, <FONT STYLE="white-space:nowrap">non-public</FONT> information received from SPAC or any of its officers, directors, or employees or
agents (including the Placement Agents), and the Investor shall no longer be subject to any confidentiality or similar obligations under any current agreement, whether written or oral, with SPAC or any of its affiliates, relating to the transactions
contemplated by this Subscription Agreement. Notwithstanding anything in this Subscription Agreement to the contrary, neither SPAC nor the Company shall publicly disclose the name of the Investor or any of its affiliates or advisers, or include the
name of the Investor or any of its affiliates or advisers without the prior written consent of the Investor (a)&nbsp;in any press release or marketing materials or (b)&nbsp;in any filing with the SEC or any regulatory agency or trading market except
(i)&nbsp;as required by the federal securities law or pursuant to other routine proceedings of regulatory authorities, (ii)&nbsp;to the extent such disclosure is required by law, at the request of the staff of the SEC or regulatory agency or under
the regulations of any national securities exchange on which SPAC&#146;s securities are listed for trading or (iii)&nbsp;to the extent such announcements or other communications contain only information previously disclosed in a public statement,
press release or other communication previously approved in accordance with this&nbsp;Section 13; provided that, in each case of (i), (ii), or (iii), SPAC will provide the Investor with written notice (including by
<FONT STYLE="white-space:nowrap">e-mail)</FONT> of any such disclosure and shall reasonably consult with Investor regarding such disclosure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Separate Obligations</U>. For the avoidance of doubt, all obligations of the Investor hereunder are separate and several from the
obligations of any Other Investor. The decision of Investor to purchase the Shares pursuant to this Subscription Agreement has been made by Investor independently of any Other Investor or any other investor and independently of any information,
materials, statements or opinions as to the business, affairs, operations, assets, properties, liabilities, results of operations, condition (financial or otherwise) or prospects of SPAC, the Company, or any of their respective subsidiaries which
may have been made or given by any Other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Investor or investor or by any agent or employee of any Other Investor or investor, and neither Investor nor any of its agents or employees shall have any liability to any Other Investor or
investor (or any other person) relating to or arising from any such information, materials, statements or opinions. Nothing contained herein or in any Other Subscription Agreement, and no action taken by Investor or Other Investors pursuant hereto
or thereto, shall be deemed to constitute Investor and Other Investor or other investors as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that Investor and Other Investors or other investors are
in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by this Subscription Agreement and the Other Subscription Agreements. The Investor acknowledges that no Other Investor has acted as agent
for Investor in connection with making its investment hereunder and no Other Investor will be acting as agent of Investor in connection with monitoring its investment in the Shares or enforcing its rights under this Subscription Agreement. The
Investor shall be entitled to independently protect and enforce its rights, including without limitation the rights arising out of this Subscription Agreement, and it shall not be necessary for any Other Investor or investor to be joined as an
additional party in any proceeding for such purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Massachusetts Business Trust</U>. If Investor is a Massachusetts Business
Trust, a copy of the Declaration of Trust of Investor or any affiliate thereof is on file with the Secretary of State of the Commonwealth of Massachusetts and notice is hereby given that the Subscription Agreement is executed on behalf of the
trustees of Investor or any affiliate thereof as trustees and not individually and that the obligations of the Subscription Agreement are not binding on any of the trustees, officers or stockholders of Investor or any affiliate thereof individually
but are binding only upon Investor or any affiliate thereof and its assets and property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>SIGNATURE PAGES FOLLOW</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Investor has executed or caused this Subscription Agreement
to be executed by its duly authorized representative as of the date set forth below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Investor:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">State/Country of Formation or Domicile:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name in which Shares are to be registered (if different):</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date: ________, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s EIN:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Business Address-Street:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Mailing Address-Street (if different):</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">City, State, Zip:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">City, State, Zip:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attn:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Telephone No.:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Telephone No.:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Facsimile No.:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Facsimile No.:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Number of Shares subscribed for:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Aggregate Subscription Amount: $</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Price Per Share: $10.00</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You must pay the Subscription Amount by wire transfer of United States dollars in immediately available funds
to the account specified by SPAC in the Closing Notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned has accepted this Subscription Agreement as of the date
set forth below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MONTES ARCHIMEDES ACQUISITION CORP.</TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ROIVANT SCIENCES LTD.</TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELIGIBILITY REPRESENTATIONS OF THE INVESTOR </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">QUALIFIED INSTITUTIONAL BUYER STATUS </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(Please check the applicable subparagraphs): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#9744; We are a &#147;qualified institutional buyer&#148; (as defined in Rule 144A under the Securities Act (a &#147;QIB&#148;)). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#9744; We are subscribing for the Shares as a fiduciary or agent with full investment discretion for one or more investor accounts, and each
owner of such account is a QIB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">** OR ** </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">INSTITUTIONAL ACCREDITED INVESTOR STATUS </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(Please check the applicable subparagraphs): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#9744; We are an &#147;accredited investor&#148; (within the meaning of Rule 501(a) under the Securities Act
or an entity in which all of the equity holders are accredited investors within the meaning of Rule 501(a) under the Securities Act), and have marked and initialed the appropriate box on the following page indicating the provision under which we
qualify as an &#147;accredited investor.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#9744; We are not a natural person. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rule 501(a), in relevant part, states that an &#147;accredited investor&#148; shall mean any person who comes within any of the below listed categories, or who
the issuer reasonably believes comes within any of the below listed categories, at the time of the sale of the securities to that person. The Investor has indicated, by marking and initialing the appropriate box below, the provision(s) below which
apply to the Investor and under which the Investor accordingly qualifies as an &#147;accredited investor.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#9744; Any bank,
registered broker or dealer, insurance company, registered investment company, business development company, or small business investment company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#9744; Any plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its
political subdivisions for the benefit of its employees, if such plan has total assets in excess of $5,000,000; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#9744; Any employee
benefit plan, within the meaning of the Employee Retirement Income Security Act of 1974, if a bank, insurance company, or registered investment adviser makes the investment decisions, or if the plan has total assets in excess of $5,000,000; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#9744; Any organization described in section 501(c)(3) of the Internal Revenue Code, corporation, similar business trust, or partnership, not
formed for the specific purpose of acquiring the securities offered, with total assets in excess of $5,000,000; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#9744; Any trust with
assets in excess of $5,000,000, not formed to acquire the securities offered, whose purchase is directed by a sophisticated person; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#9744; Any entity in which all of the equity owners are accredited investors meeting one or more of the above tests. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">** AND ** </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">AFFILIATE STATUS </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(Please check the applicable subparagraphs): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#9744; We are: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#9744; We are
not: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">an &#147;affiliate&#148; (as defined in Rule 144 under the Securities Act) of the SPAC or acting on behalf of an affiliate of the
SPAC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">** AND ** </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">D.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">QUALIFIED PURCHASER STATUS </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(Please check the applicable subparagraphs): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">FOR INDIVIDUALS: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#9744; A natural person who owns not less than U.S.$5,000,000 in investments. For this purpose, investments
owned by the Investor include all investments that are the Investor&#146;s separate property and any investments held jointly with the Investor&#146;s spouse, as community property or otherwise, but do not include investments that are the separate
property of the Investor&#146;s spouse unless the interest will be a joint investment of the Investor and the Investor&#146;s spouse. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#9744; A natural person who has discretionary investment authority with regard to at least U.S.$25,000,000 of
investments, including for this purpose solely the Investor&#146;s own investments and investments of third parties that are themselves accurately described by one or more paragraphs of this Section D. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(Please</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">check the applicable subparagraphs): </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">FOR ENTITIES: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#9744; A corporation, partnership, limited liability company, trust or other organization that: (i) was not
organized or reorganized and is not operated for the specific purpose of acquiring the interest or any other interest in SPAC, and less than 40% of the assets of which will consist of interests in SPAC (calculated as of the time of the
Investor&#146;s execution of this Subscription Agreement); (ii) owns not less than U.S.$5,000,000 in investments; and (iii) is owned directly or indirectly solely by or for two or more natural persons who are related as siblings or spouses
(including former spouses), or direct lineal descendants by birth or adoption, spouses of such persons, the estates of such persons, or foundations, charitable organizations, or trusts established by or for the benefit of such persons.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#9744; A trust: (i) that is not described in paragraph (3) of this Section D; (ii) that was not organized or
reorganized and is not operated for the specific purpose of acquiring the interest or any other interest in SPAC, and less than 40% of the assets of which will consist of interests in SPAC (calculated as of the time of the Investor&#146;s execution
of this Subscription Agreement); and (iii) with respect to which each of the settlors and other contributors of assets, trustees, and other authorized decision makers is a person described in paragraph (1), (2), (3) or (4) of this Section D.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#9744; An entity that: (i) was not organized or reorganized and is not operated for the specific purpose of
acquiring the interest or any other interest in SPAC, and less than 40% of the assets of which will consist of interests in SPAC (calculated as of the time of the Investor&#146;s execution of this Subscription Agreement); and (ii) has discretionary
investment authority with regard to at least U.S.$25,000,000 of investments, whether for its own account or for the account of other persons that are themselves accurately described by one or more other paragraphs of this Section D.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#9744;&nbsp;An entity, each and every beneficial owner of which is a person accurately described by one or
more of the foregoing paragraphs of this Section D or is itself an entity each and every beneficial owner of which is a person accurately described by one or more of the foregoing paragraphs of this Section D.&nbsp;<I>If the Investor is a qualified
purchaser solely for the reason described in this paragraph 6, the Investor shall, at the request of SPAC, submit to SPAC a separate qualified purchaser questionnaire for each beneficial owner of the Investor&#146;s securities.</I>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>This page should be completed by the Investor </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>and constitutes a part of the Subscription Agreement. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><A NAME="rom65062_41"></A>ANNEX C &#150; REGISTRATION RIGHTS AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ROIVANT SCIENCES LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THIRD AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS THIRD AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this &#147;<B>Agreement</B>&#148;) is made and entered into as of May&nbsp;1,
2021, by and among (i)&nbsp;Roivant Sciences Ltd., a Bermuda exempted limited company (the &#147;<B>Company</B>&#148;), (ii) the Dexxon Investors (as defined herein), (iii) the QVT Investors (as defined herein), (iv) the Viking Investors (as defined
herein), (v) SVF Investments (UK) Limited (&#147;<B>Softbank</B>&#148;), (vi) Sumitomo Dainippon Pharma Co., Ltd. (&#147;<B>Sumitomo</B>&#148;), (vii) Vivek Ramaswamy (the &#147;<B>Founder</B>&#148;), (viii) the parties listed on<B> Exhibit <FONT
STYLE="white-space:nowrap">A-1</FONT></B> hereto who signed joinder agreements in connection with the Original Registration Rights Agreement, the First Amended and Restated Registration Rights Agreement or the Second Amended and Restated
Registration Rights Agreement (each, as defined below), as the case may be (the &#147;<B>Joinder Parties</B>&#148; and together with the Dexxon Investors, the QVT Investors, the Viking Investors, Softbank, Sumitomo, the Founder and each of their
respective Permitted Transferees who, at any time, acquire securities of the Company and execute a counterpart of this Agreement or who otherwise agree to be bound by this Agreement, the &#147;<B>Investors</B>&#148;) and (ix)&nbsp;each of the other
Persons who, at any time, acquire securities of the Company or shares or rights, convertible into, exchangeable for or exercisable for, equity securities of the Company in accordance with the terms hereof, execute a counterpart of this Agreement or
otherwise agree to be bound by this Agreement and shall be listed on Exhibit <FONT STYLE="white-space:nowrap">A-2</FONT> hereto at such time as such Person entered into a joinder agreement (the &#147;<B>Other Shareholders</B>&#148;). The Other
Shareholders and the Investors are collectively referred to herein as the &#147;Shareholders.&#148; The Company, the Investors and the Other Shareholders are sometimes collectively referred to herein as the &#147;Parties&#148; and individually as a
&#147;<B>Party</B>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company, Dexxon, the QVT Investors, the Founder and the Joinder Parties were parties to that
certain Registration Rights Agreement, dated May&nbsp;5, 2014 (the &#147;<B>Original Registration Rights Agreement</B>&#148;) pursuant to which the Company undertook to grant certain registration rights to Dexxon, the QVT Investors, the Founder and
the Joinder Parties in connection with certain securities of the Company and BVC Ltd., a Bermuda exempted limited liability company (&#147;<B>BVC</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as of December&nbsp;4, 2015, the Company and BVC completed a statutory merger under Bermuda law, as a result of which BVC merged with
and into the Company, with the Company as the surviving entity and in connection with which the Company, Dexxon, the QVT Investors, the Viking Investors, the Founder and the Joinder Parties entered into that certain Amended and Restated Registration
Rights Agreement, dated December&nbsp;8, 2015 (the &#147;<B>First Amended and Restated Registration Rights Agreement</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,
the Company, the Dexxon Investors, the QVT Investors, the Viking Investors, Softbank, the Founder and the Joinder Parties entered into that certain Second Amended and Restated Registration Rights Agreement, dated September&nbsp;6, 2017 (the
&#147;<B>Second Amended and Restated Registration Rights Agreement</B>&#148;) for the purpose, among others, of providing certain registration rights to the Dexxon Investors, the QVT Investors, the Viking Investors, Softbank, the Founder and the
Joinder Parties; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company, Rhine Merger Sub, Inc., a Delaware corporation and direct wholly owned subsidiary of the Company
(the &#147;<B>Merger Sub</B>&#148;), and Montes Archimedes Acquisition Corp., a Delaware corporation (&#147;<B>SPAC</B>&#148;), have entered into a Business Combination Agreement, dated as of May&nbsp;1, 2021 (as it may be amended, supplemented or
otherwise modified from time to time, the &#147;<B>Merger Agreement</B>&#148;), pursuant to which, among other things, Merger Sub will merge with and into SPAC (the &#147;<B>Merger</B>&#148;), with SPAC as the surviving corporation in the Merger
and, after giving effect to the Merger, SPAC will become a subsidiary of the Company and the Company shall become subject to the reporting requirements of the Exchange Act and certain of the Company&#146;s Common Shares, par value $0.0000001 per
share (the &#147;<B>Common Shares</B>&#148;), shall be registered under the Securities Act (together with the Merger, the &#147;<B>Go Public Transaction</B>&#148;); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the parties executing this Agreement constitute the holders of the requisite number
of shares necessary pursuant to Section&nbsp;13D of the Second Amended and Restated Registration Rights Agreement in order to effect the amendment and restatement of such agreement effected hereby; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in connection with the Go Public Transaction, the Company and the Investors desire to enter into this Agreement for the purpose,
among others, to provide the registration rights set forth in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual covenants,
agreements and understandings contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1. <I>Demand Registrations</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Requests for Registration</I>. Subject to Section&nbsp;1(e) below and the other terms and conditions of this Agreement, at any time
beginning one hundred eighty (180)&nbsp;days following the date on which the Company completes the Go Public Transaction, each Major Holder and each Person, if any, holding at least five percent (5.0%) of the then-outstanding number of Registrable
Securities (&#147;<B>Other Demand Holders</B>&#148;) may (i)&nbsp;request registration under the Securities Act on Form <FONT STYLE="white-space:nowrap">S-1</FONT> or any similar long-form registration statement (a &#147;<B>Long-Form
Registration</B>&#148;) of all or any portion of its Investor Registrable Securities or Other Registrable Securities, as the case may be, in accordance with Section&nbsp;1(b) or (ii)&nbsp;if available, request registration under the Securities Act
on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (including a Shelf Registration) or any similar short-form registration statement (a &#147;<B>Short-Form Registration</B>&#148;) of all or any portion of its Investor Registrable Securities or
Other Registrable Securities, as the case may be, in accordance with Section&nbsp;1(c) (each such request, a &#147;<B>Demand Notice</B>&#148;). Subject to Section&nbsp;1(e) below and the other terms and conditions of this Agreement, at any time
beginning one hundred eighty (180)&nbsp;days following the date on which the Company completes the Go Public Transaction, any Other Shareholder may, if available, request Short-Form Registrations of all or any portion of its Registrable Securities
in accordance with Section&nbsp;1(c). All registrations requested pursuant to this Section&nbsp;1(a) by the holders of Registrable Securities are referred to herein as &#147;<B>Demand Registrations</B>.&#148; Each request for a Demand Registration
shall specify the intended method of distribution and the approximate number of Registrable Securities requested to be registered. No Demand Registration will be consummated (and no registration statement with respect thereto filed) if the number of
Registrable Securities requested to be registered (including pursuant to the following sentence) is fewer than (A)&nbsp;in the case of Long-Form Registrations, such number of Common Shares with a value (based on the closing price on the trading day
immediately prior to the filing of the registration statement or prospectus supplement, as applicable, for any Long-Form Registration) of $100,000,000 and (B)&nbsp;in the case of Short-Form Registrations, such number of Common Shares with a value
(based on the closing price on the trading day immediately prior to the filing of the registration statement or prospectus supplement, as applicable, for any Short-Form Registration) of $50,000,000. Within ten (10)&nbsp;days after receipt of any
such request, the Company shall give written notice of such requested registration to all other Shareholders and, subject to the terms of Section&nbsp;1(d), shall include in such registration (and in all related registrations and qualifications
under state blue sky laws and in compliance with other registration requirements and in any related underwriting) all Registrable Securities with respect to which the Company has received written requests for inclusion therein within twenty
(20)&nbsp;days after the delivery of the Company&#146;s notice; <I>provided, however</I>, that no Investor shall be required to be named an &#147;underwriter&#148; without such Investor&#146;s express prior written consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Long-Form Registrations</I>. The Major Holders shall be entitled to Long-Form Registrations under this Agreement as follows:
(i)&nbsp;the QVT Investors (acting by action of the holders of a majority of the Common Shares held by them), the Viking Investors (acting by action of the holders of a majority of the Common Shares held by them), the Dexxon Investors, Softbank and
Sumitomo shall each be entitled to three (3)&nbsp;Long-Form Registrations, and (ii)&nbsp;the Founder shall be entitled to one (1)&nbsp;Long-Form Registration. Other Shareholders shall have the right to demand Long-Form Registrations or Short-Form
Registrations only to the extent such Other Shareholders are designated as Other Demand Holders pursuant to the terms of this Agreement, provided however, that the Other Shareholders will be entitled to a maximum of two (2)&nbsp;Long-Form
Registrations if so </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
designated. The Company shall pay all Registration Expenses with respect to such Long-Form Registrations. All Long-Form Registrations shall only be made if the method of distribution to be used
in connection with such registration is an underwritten offering unless otherwise approved by the board of directors of the Company (the &#147;<B>Board</B>&#148;). The Company shall file a registration statement on Form <FONT
STYLE="white-space:nowrap">S-1</FONT> under the Securities Act covering all Registrable Securities requested to be included in such Long-Form Registration (subject to the limitations set forth herein) promptly following the Company&#146;s receipt of
a Demand Notice therefor and, in any event, within sixty (60)&nbsp;days after the date the Demand Notice is duly delivered to the Company in accordance with this Agreement. The Company shall use commercially reasonable efforts to cause such Long
Form Registration to be declared effective under the Securities Act as soon as practicable after the filing thereof, but no later than the earlier of (i)&nbsp;sixty (60) calendar days after the filing date thereof (or ninety (90)&nbsp;calendar days
after the filing thereof if the SEC notifies the Company that it will &#147;review&#148; the Long Form Registration) and (ii)&nbsp;ten (10) business days after the Company is notified (orally or in writing, whichever is earlier) by the SEC that the
Long Form Registration will not be &#147;reviewed&#148; or will not be subject to any further review. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Short-Form
Registrations</I>. In addition to the Long-Form Registrations provided pursuant to Section&nbsp;1(b), each of the Major Holders and the Other Demand Holders shall be entitled to request an unlimited number of Short-Form Registrations in which the
Company shall pay all Registration Expenses, whether or not any registration statement for such a registration has become effective. Demand Registrations shall be Short-Form Registrations whenever the Company is permitted to use any applicable short
form registration statement. After the Go Public Transaction, the Company shall use its reasonable best efforts to make Short-Form Registrations available for the sale of Registrable Securities. If the Shareholder initially requesting a Short-Form
Registration requests that such Short-Form Registration be filed pursuant to Rule 415 (a &#147;<B>Shelf Registration</B>&#148;), and the Company is qualified to do so, then the Company shall use its reasonable best efforts to promptly file and cause
the Shelf Registration to be declared effective under the Securities Act as soon as reasonably practicable after the filing thereof and the Company shall use its reasonable best efforts to keep such shelf registration continuously effective
following such registration; provided that any request for an underwritten offering using such Shelf Registration (an &#147;<B>Underwritten Takedown</B>&#148;) shall be deemed a Demand Registration. The provisions of Section&nbsp;1(a) shall apply
<I>mutatis</I> <I>mutandis</I> to each Underwritten Takedown, with references to &#147;filing of the registration statement&#148; or &#147;effective date&#148; being deemed references to filing of a prospectus or supplement for such offering and
references to &#147;registration&#148; being deemed references to the offering; <I>provided</I> that Shareholders participating in the Underwritten Takedown shall only include Shareholders whose Registrable Securities are included in such Shelf
Registration or may be included therein without the need for a post-effective amendment to such Shelf Registration (other than an automatically effective amendment). If for any reason the Company ceases to be a WKSI or becomes ineligible to utilize
Form <FONT STYLE="white-space:nowrap">S-3</FONT> or any similar applicable short form registration statement, then the Company shall prepare and file with the U.S. Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) one or more
registration statements on such form that is available for the sale of Registrable Securities. The Company shall file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act covering all Registrable
Securities requested to be included in such Short Form-Registration (subject to the limitations set forth herein) promptly following the Company&#146;s receipt of a Demand Notice therefor and, in any event, within thirty (30)&nbsp;days after the
date the Demand Notice is duly delivered to the Company in accordance with this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Priority on Demand Registrations</I>.
If a Demand Registration is for an underwritten offering and the managing underwriters advise the Company in writing that in their opinion the number of securities requested to be included in such offering exceeds the number of securities which
marketing factors permit to be sold in such offering, then the Company shall include in such registration only that number of Registrable Securities that in the opinion of such underwriters marketing factors permit to be sold in such offering, and
the Registrable Securities that are included in such offering shall be allocated pro rata among the respective holders thereof on the basis of the number of Registrable Securities owned by each such holder; provided, however, that the number of
Registrable Securities held by such holders to be included in such registration shall not be reduced unless all other securities are first entirely excluded from the registration. A registration shall not be counted as &#147;effected&#148; if, as a
result of an exercise of the underwriter&#146;s cutback provisions in this Section&nbsp;1(d), fewer than fifty percent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(50%) of the total number of Registrable Securities that holders have requested to be included in such registration statement are actually included. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Restrictions on Demand Registrations</I>. The Company shall not be obligated to effect any Demand Registration within one hundred
eighty (180)&nbsp;days after the effective date of the Go Public Transaction or within ninety (90)&nbsp;days after the effective date of a previous Long-Form Registration. The Company may postpone the filing or the effectiveness of a registration
statement or prospectus supplement, as applicable, for a Demand Registration or suspend the use of a prospectus included in any registration statement for a Demand Registration, if the Board determines in its good faith judgment that such Demand
Registration would reasonably be expected to (i)&nbsp;materially interfere with any proposal or plan that is material to the Company related to any financing, acquisition of assets or securities, recapitalization, merger, consolidation, tender
offer, reorganization or similar transaction, (ii)&nbsp;require premature disclosure of material information that the Company has a <I>bona fide</I> business purpose for preserving as confidential or (iii)&nbsp;render the Company unable to comply
with requirements under the Securities Act or Exchange Act; <I>provided</I> that in such event, the Shareholder initially requesting such Demand Registration shall be entitled to withdraw such request and, if such request is withdrawn with respect
to a Long-Form Registration, such Demand Registration shall not count against the total number of Long-Form Registrations provided for in Section&nbsp;1(b), and the Company shall pay nonetheless all Registration Expenses in connection with such
registration; <I>provided, further</I>, that the Company shall not register any securities for its own account or that of any other stockholder during such postponement or suspension period other than pursuant to: (a)&nbsp;a Resale Shelf (including
any amendments, supplements or any other filings related thereto); (b) a registration relating to the sale or grant of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, equity incentive or similar
plan; (c)&nbsp;a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (d)&nbsp;a registration in which
the only Common Shares being registered are Common Shares issuable upon conversion of debt securities that are also being registered. The Company may not delay a Demand Registration or suspend the use of a prospectus pursuant to this
Section&nbsp;1(e): (i) more than two (2)&nbsp;times in any period of twelve (12)&nbsp;consecutive months, (ii)&nbsp;the duration of any one suspension or postponement may not exceed sixty (60)&nbsp;days and (iii)&nbsp;the total duration of any
suspension or postponement period may not be more than ninety (90)&nbsp;days in any period of twelve (12)&nbsp;consecutive months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)
<I>Resale Registration Statement</I>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company shall file within 30 days of the consummation of the Go Public
Transaction, and use commercially reasonable efforts to cause to be declared effective as soon as practicable thereafter, a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (the &#147;<B>Resale <FONT
STYLE="white-space:nowrap">S-1</FONT> Shelf</B>&#148;) or, if the Company is eligible to use a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT>
(the &#147;<B>Resale <FONT STYLE="white-space:nowrap">S-3</FONT> Shelf</B>&#148; and together with the Resale <FONT STYLE="white-space:nowrap">S-1</FONT> Shelf, each a &#147;<B>Resale Shelf</B>&#148;), in each case, covering the resale of all the
Registrable Securities (determined as of two business days prior to such filing) and any other Common Shares or other securities of the Company issued in connection with the Go Public Transaction that have not been registered under the Securities
Act; provided, that the Parties acknowledge and agree that the sale of any Registrable Securities registered under such Resale Shelf may be subject to restrictions imposed by <FONT STYLE="white-space:nowrap">lock-up</FONT> or holdback restrictions
and/or applicable securities laws. Such Resale Shelf shall provide for the resale of the Registrable Securities included therein pursuant to any method or combination of methods legally available to, and requested by, any of the Investors named
therein. Notwithstanding anything to the contrary herein, to the extent there is an active Resale Shelf under this Section&nbsp;1(f) covering Registrable Securities of any Major Holder and/or the Other Demand Holders, and such Major Holder and/or
the Other Demand Holder wishes to request a Demand Registration, such Demand Registration shall reduce the number of Demand Registrations that may be made pursuant to Section&nbsp;1(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Company agrees to use commercially reasonable efforts to cause such Resale Shelf, or another shelf registration
statement that includes all Registrable Securities, including, without limitation, the PIPE Shares, to remain effective until the earliest of (i)&nbsp;the second anniversary of the consummation of the Go Public Transaction and, (ii)&nbsp;the date on
which Investors cease to hold any Registrable Securities (the &#147;<B>End</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
<B>Date</B>&#148;). Prior to the End Date, the Company will use commercially reasonable efforts to&nbsp;(1) qualify the Registrable Securities for listing on one or more of the New York Stock
Exchange, NYSE American, LLC and/or the Nasdaq Stock Market and (2)&nbsp;update or amend the Registration Statement as necessary to include the Registrable Securities. The Company shall use its commercially reasonable efforts to provide a draft of
the Resale Shelf to the Investors holding Registrable Securities for review (but not comment) at least two (2)&nbsp;Business Days in advance of filing the Resale Shelf; provided that, for the avoidance of doubt, in no event shall the Company be
required to delay or postpone the filing of such Resale Shelf as a result of or in connection with any Investor&#146;s review. Notwithstanding the foregoing, if the Securities and Exchange Commission prevents the Company from including any or all of
the Registrable Securities proposed to be registered under the Resale Shelf due to limitations on the use of Rule 415 of the Securities Act for the resale of Registrable Securities by the applicable stockholders or otherwise, such Resale Shelf shall
register for resale the maximum number of Registrable Securities as is permitted. In such event, the number of Registrable Securities to be registered for each selling stockholder named in the Resale Shelf shall be reduced pro rata among all such
selling stockholders, in each case, giving priority first to the PIPE Shares and then to the remainder of Registrable Securities, and as promptly as practicable after being permitted to register additional Registrable Securities under Rule 415 under
the Securities Act, the Company shall amend the Resale Shelf or file a new Resale Shelf to register such Registrable Securities not included in the initial Resale Shelf and use its commercially reasonable efforts to cause such amendment or Resale
Shelf to become effective as promptly as practicable. The Registration Expenses of the holders of Registrable Securities shall be paid by the Company in the Resale Shelf, whether or not any such offering is completed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Selection of Underwriters</I>. If any Demand Registration is for an underwritten offering, then the holders of a majority of the
Registrable Securities being sold in such Demand Registration shall have the right to select the investment banker(s) and manager(s) to administer such offering, subject to the prior written approval of the Board, which approval shall not be
unreasonably withheld, conditioned or delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Other Registration Rights</I>. Except as provided to the holders of Registrable
Securities in this Agreement and except in connection with the Go Public Transaction (including the filing of the Resale Shelf contemplated thereby), the Company shall not grant to any Persons the right to request the Company to register any equity
securities of the Company, or any securities, options or rights convertible or exchangeable into or exercisable for such securities, without the prior written consent of the Board; <I>provided </I>that the Company may (i)&nbsp;grant rights to
participate in any registration pursuant to Section&nbsp;2 below (a &#147;<B>Piggyback Registration</B>&#148;) so long as such rights are subordinate in priority to the rights of Parties hereto with respect to Piggyback Registrations, as provided in
Section&nbsp;2(c) and Section&nbsp;2(d), and not otherwise inconsistent with the terms and conditions hereof, and (ii)&nbsp;enter into an agreement with any holder or prospective holder of any securities of the Company related to the filing of a
Resale Shelf to register shares issued to such holder as consideration in an acquisition of a third party, if and only if such Resale Shelf does not permit underwritten offerings (provided that nothing in this clause (ii)&nbsp;shall be interpreted
to limit the rights of a holder of securities of the Company in connection with the Go Public Transaction and the Resale Shelf contemplated thereby). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Termination of Registration Rights</I>. The rights of any holder of Registrable Securities to request inclusion of such Registrable
Securities pursuant to this Section&nbsp;1 shall terminate upon the earlier to occur of (i)&nbsp;the seventh anniversary of the date of this Agreement and (ii)&nbsp;the date as of which (A)&nbsp;all of the Registrable Securities have been sold
pursuant to a Registration Statement (but in no event prior to the applicable period referred to in Section&nbsp;4(a)(3) of the Securities Act and Rule 174 thereunder (or any successor rule promulgated thereafter by the Commission)) or (B)&nbsp;all
Registrable Securities have been sold under Rule 144 under the Securities Act. The provisions of Section&nbsp;7 and Section&nbsp;9 shall survive any termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2. <I>Piggyback Registrations</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Right to Piggyback</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Other than in connection with a Resale Shelf or a request for a Demand Registration or a Shelf Registration pursuant to
Sections 1(a), 1(b) and 1(c) of this Agreement, if at any time the Company, including if the Company qualifies as a WKSI, proposes to file (A)&nbsp;a prospectus supplement to an effective shelf registration statement (a &#147;<B>Shelf Registration
Statement</B>&#148;), or (B)&nbsp;a registration statement other than a Shelf Registration Statement, in either case, for the sale of Common Shares for its own account, or for the benefit of the holders of any of its Common Shares other than the
Shareholders, to an underwriter on a firm commitment basis for reoffering to the public or in a &#147;bought deal&#148; or &#147;registered direct offering&#148; with one or more investment banks (collectively, a &#147;<B>Piggyback Underwritten
Offering</B>&#148;), then the Company shall give prompt written notice, to be delivered not less than five (5)&nbsp;business days prior to the filing of (1)&nbsp;any preliminary prospectus supplement relating to such Piggyback Underwritten Offering
pursuant to Rule 424(b) under the Securities Act, (2)&nbsp;any prospectus supplement relating to such Piggyback Underwritten Offering pursuant to Rule 424(b) under the Securities Act (if no preliminary prospectus supplement is used) or (3)&nbsp;such
registration statement, as the case may be, to all holders of Registrable Securities of the Company and such notice (a &#147;<B>Piggyback Notice</B>&#148;) shall offer the Shareholders the opportunity to include in such Piggy-Back Underwritten
Offering such number of Registrable Securities as each such Shareholder may request in writing. Each such Shareholder shall then have three (3)&nbsp;business days after receiving such notice to request in writing to the Company inclusion of
Registrable Securities in the Piggy-Back Underwritten Offering, except that such Shareholders shall have two (2)&nbsp;business days after such Shareholder confirms receipt of the notice to request inclusion of Registrable Securities in the Piggy
Back Underwritten Offering in the case of a &#147;bought deal&#148;, &#147;registered direct offering&#148; or &#147;overnight transaction&#148; where no preliminary prospectus is used. Upon receipt of any such request for inclusion from a
Shareholder received within the specified time, the Company shall use reasonable best efforts to effect the registration in any registration statement of any of the Shareholder&#146;s Registrable Securities requested to be included on the terms set
forth in this Agreement. Prior to the commencement of any &#147;road show,&#148; any Shareholder shall have the right to withdraw its request for inclusion of its Registrable Securities in any registration by giving written notice to the Company of
its request to withdraw and such withdrawal shall be irrevocable and, after making such withdrawal, such Shareholder shall no longer have any right to include Registrable Securities in the Piggyback Underwritten Offering as to which such withdrawal
was made. The Company may postpone or withdraw the filing or the effectiveness of a Shelf Registration Statement or a proposed Piggyback Underwritten Offering at any time in its sole discretion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) If the Company does not qualify as a WKSI, (A)&nbsp;the Company shall give each Shareholder five (5)&nbsp;business
days&#146; notice prior to filing a Shelf Registration Statement and, upon the written request of any Shareholder, received by the Company within three (3)&nbsp;business days of such notice to the Shareholder, the Company shall include in such Shelf
Registration Statement a number of Common Shares equal to the aggregate number of Registrable Securities requested to be included without naming any requesting Shareholder as a selling shareholder and including only a generic description of the
holder of such securities (the &#147;<B>Undesignated Registrable Securities</B>&#148;), (B) the Company shall not be required to give notice to any Shareholder in connection with a filing pursuant to Section&nbsp;2(a)(i) unless such Shareholder
provided such notice to the Company pursuant to this Section&nbsp;2(a)(ii) and included Undesignated Registrable Securities in the Shelf Registration Statement related to such filing, and (C)&nbsp;at the written request of a Shareholder given to the
Company more than two (2)&nbsp;business days before the date specified in writing by the Company as the Company&#146;s good faith estimate of a launch of a Piggyback Registration (or such shorter period to which the Company in its sole discretion
consents), the Company shall use reasonable best efforts to effect the registration of any of the Shareholders&#146; Undesignated Registrable Securities so requested to be included and shall file a post-effective amendment or, if available, a
prospectus supplement to a Shelf Registration Statement to include such Undesignated Registrable Securities as any Shareholder may request, <I>provided</I> that (1)&nbsp;the Company is actively employing its reasonable best efforts to effect such
Piggyback Registration; and (2)&nbsp;the Company shall not be required to effect a post-effective amendment more than two (2)&nbsp;times in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
any twelve (12)&nbsp;month period. In lieu of providing the notice set forth in Section&nbsp;2(a)(i), the Company may determine to include in a Shelf Registration Statement a number of
Undesignated Registrable Securities equal to the Registrable Securities held by all Shareholders. The Company shall have the right to terminate or withdraw any registration or offering initiated by it under this Section&nbsp;2(a) before the
effective date of such registration, whether or not any Shareholder has elected to include Registrable Securities in such registration or offering. The expenses of such withdrawn registration or offering shall be borne by the Company in accordance
with Section&nbsp;2(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Piggy Back Expenses</I>. The Registration Expenses of the holders of Registrable Securities shall be paid
by the Company in all Piggyback Underwritten Offerings, whether or not any such offering is completed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Priority on Primary
Piggyback Registrations</I>. If a Piggyback Registration is an underwritten primary offering on behalf of the Company and the managing underwriters advise the Company in writing that in their reasonable opinion the number of securities requested to
be included in such offering exceeds the number of Registrable Securities which marketing factors permit to be sold in such offering, then the Company shall include in such offering only that number of securities that in the opinion of such
underwriters marketing factors permit to be sold in such offering, with priority for inclusion to be determined as follows: (i)&nbsp;first, the securities the Company proposes to sell, (ii)&nbsp;second, a number of Registrable Securities requested
to be included in such registration allocated pro rata among the respective holders thereof on the basis of the number of Registrable Securities owned by each such holder, and (iii)&nbsp;third, any securities entitled to registration rights pursuant
to a private placement expected to be consummated in connection with the Merger, <I>provided, however</I>, that (i)&nbsp;the number of Registrable Securities held by such holders to be included in such offering shall not be reduced unless securities
held by persons other than the Company and Major Holders are first entirely excluded from the offering and (ii)&nbsp;the number of Registrable Securities included in the offering shall not be reduced below thirty percent (30%) of the total number of
securities included in such offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Priority on Secondary Piggyback Registrations</I>. If a Piggyback Registration is an
underwritten secondary offering on behalf of holders of the Company&#146;s securities (other than holders of Registrable Securities) and the managing underwriters advise the Company in writing that in their reasonable opinion the number of
securities requested to be included in such offering exceeds the number of securities which marketing factors permit to be sold in such offering, then the Company shall include in such offering only that number of securities which in the opinion of
such underwriters marketing factors permit to be sold in such offering, and the Registrable Securities that are included in such offering shall be allocated pro rata among the respective holders thereof on the basis of the number of Registrable
Securities owned by each such Shareholder; <I>provided, however</I>, that the number of Registrable Securities held by such holders to be included in such offering shall not be reduced unless all other securities are first entirely excluded from the
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Selection of Underwriters</I>. If any Piggyback Registration is an underwritten offering, the Board shall select the
investment banker(s) and manager(s) for such offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Other Registrations</I>. If the Company has previously filed a registration
statement with respect to Registrable Securities pursuant to Section&nbsp;1 or Section&nbsp;2, and if such previous registration has not been withdrawn or abandoned, then the Company shall not file or cause to be effected any other registration of
any of its equity securities or securities convertible or exchangeable into or exercisable for its equity securities under the Securities Act (except on Form <FONT STYLE="white-space:nowrap">S-8</FONT> or any successor form), whether on its own
behalf or at the request of any holder or holders of such securities, until a period of at least ninety (90)&nbsp;days has elapsed from the effective date of such previous registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Termination of Registration Rights</I>. The rights of any holder of Registrable Securities to request inclusion of such Registrable
Securities pursuant to this Section&nbsp;2 shall terminate upon the earlier of (i)&nbsp;the seventh anniversary of the date of this Agreement and (ii)&nbsp;the date as of which (A)&nbsp;all of the Registrable Securities have been sold pursuant to a
Registration Statement (but in no event prior to the applicable period </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
referred to in Section&nbsp;4(a)(3) of the Securities Act and Rule 174 thereunder (or any successor rule promulgated thereafter by the Commission)) or (B)&nbsp;all Registrable Securities have
been sold under Rule 144 under the Securities Act. The provisions of Section&nbsp;7 and Section&nbsp;9 shall survive any termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3. <I>Holdback Agreements</I>. Each Shareholder hereby agrees that such Shareholder shall not (i)&nbsp;lend, offer, pledge, sell,
contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, (a)&nbsp;any Common Shares that are held
by or on behalf of such Shareholder immediately prior to the consummation of the Go Public Transaction or (b)&nbsp;any securities that are held by or on behalf of such Shareholder immediately prior to the consummation of the Go Public Transaction
that are convertible into or exercisable or exchangeable (directly or indirectly) for Common Shares (including without limitation, Common Shares or other securities that may be issued after the consummation of the Go Public Transaction upon
exercise, vesting or settlement, as applicable, of any stock option, restricted stock unit, capped value appreciation right or other equity or equity-based award or interest (the securities described in this clause (b), the &#147;<B>Other
Securities</B>&#148;)) or (ii)&nbsp;enter into any swap, hedge or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any Common Shares or Other Securities, whether any such transaction
described in clause (i)&nbsp;or (ii) above is to be settled by delivery of Common Shares or Other Securities, in cash, or otherwise, and whether any such transaction is made or executed by or on behalf of someone other than the Shareholder (each, a
&#147;<B>Sale Transaction</B>&#148;) for a period of <FONT STYLE="white-space:nowrap">one-hundred</FONT> eighty (180)&nbsp;days following the consummation of the Go Public Transaction (a &#147;<B>Holdback Period</B>&#148;), <I>provided</I> that all
officers and directors of the Company and holders of at least one percent (1%) of the Company&#146;s voting securities (calculated on a fully diluted basis) are bound by and have entered into agreements that are no less restrictive than such
agreements entered into by the Shareholders (including, without limitation, any provisions relating to early release from such obligations); <I>provided</I>, further, that the term &#147;Sale Transaction&#148; shall not include a sale or other
transfer by an Upstream Equity Holder of its direct or indirect common stock or membership, partnership or other equity ownership interest in a Shareholder (whether or not for consideration). The foregoing provisions of this Section&nbsp;3 shall not
apply to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(1) the sale of any Common Shares to an underwriter pursuant to an underwriting agreement to which the Company is a party in
connection with a Shareholder&#146;s exercise of piggyback registration rights set forth in, and in accordance with the terms and conditions of, Section&nbsp;2 hereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(2) a transfer of any or all of Common Shares or Other Securities (I)&nbsp;by gift, will, intestate succession or charitable contribution,
(II)&nbsp;to any Permitted Transferee, (III)&nbsp;by operation of law or pursuant to a court order or an order of a regulatory agency, such as a qualified domestic relations order, divorce decree or separation agreement, (IV)&nbsp;to the Company
pursuant to the exercise, in each case on a &#147;cashless&#148; or &#147;net exercise&#148; basis, of any Other Securities (provided that any Common Shares received upon any such exercise will be subject to the restrictions set forth above), (V)
for purposes of satisfying any withholding taxes and/or estimated taxes due as a result of the exercise, vesting or settlement, as applicable, of any Other Securities, (VI)&nbsp;in connection with the Company&#146;s consummation of a liquidation,
merger, amalgamation, share exchange, reorganization, tender offer or other similar transaction that results in all of the Company&#146;s shareholders having the right to exchange their equity holdings in the Company for cash, securities or other
property or (VII)&nbsp;by pledging, hypothecating or otherwise granting a security interest in Common Shares or Other Securities in a <I>bona fide</I> transaction to one or more unaffiliated lending institutions as&nbsp;collateral&nbsp;or security
for any margin loan and any transfer in the event of foreclosure upon such Common Shares or Other Securities as a result of a default on such margin loan (so long as any such pledge, hypothecation or grant of security interest shall be on terms
consistent with customary margin loans, and the applicable Shareholder shall provide the Company with written notice prior to entering into such margin loan); provided, however, that in the case of any of the foregoing clauses (I), (II) or (III),
the transferee in such transfer shall agree in a writing delivered to the Company that the Common Shares or Other Securities so transferred will thereafter continue be subject to the terms set forth above; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(3) the establishment or modification of a written plan meeting the requirements of Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> of the
Exchange Act that does not provide for the sale or transfer of Common Shares during the Holdback Period; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
provided that, to the extent a public announcement or filing under the Exchange Act is required regarding the establishment or modification of such plan, such announcement or filing shall include
a statement to the effect that no sales or transfers of Common Shares may be made under such plan during the Holdback Period; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(4) any
Common Shares or Other Securities issued in connection with the private placement consummated in connection with the Go Public Transaction, including any Common Shares or other securities received in exchange for, or converted for, securities
acquired in such private placement (the &#147;<B>PIPE Shares</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Shareholder agrees to execute and deliver such other customary agreements
as may be reasonably requested by the Company or the managing underwriter in an underwritten transaction that are consistent with the foregoing or which are necessary to give further effect thereto. Any discretionary waiver or termination of the
restrictions by the Company or the underwriters of any or all of such restrictions with respect to any officer or director of the Company or a holder of 1% or more of the Company&#146;s total outstanding Common Shares (including a release of such
restrictions set forth in Section&nbsp;5 of the <FONT STYLE="white-space:nowrap">Bye-Laws,</FONT> a &#147;<B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Release</B>&#148;) shall apply pro rata to all Major Holders, based on the number of shares
subject to such restrictions (the &#147;<B>Shareholder Pro Rata Release</B>&#148;); <I>provided</I> that the prior sentence shall not apply to (a)&nbsp;waivers or terminations granted in an amount less than or equal to 1% of the Company&#146;s total
outstanding Common Shares (calculated on a fully-diluted basis immediately after the consummation of the Go Public Transaction) or (b)&nbsp;any primary or secondary public offering or sale that is underwritten and in which each holder of
Registerable Securities is offered the opportunity to participate pursuant to Section&nbsp;2 hereof. The Company may impose stop-transfer instructions with respect to the Common Shares (or other securities) subject to the foregoing restriction until
the end of said <FONT STYLE="white-space:nowrap">one-hundred</FONT> eighty <FONT STYLE="white-space:nowrap">(180)-day</FONT> period. At least two business days&#146; prior to the effective date of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Release, the Company shall provide written notice to the Major Holders stating the percentage of Common Shares held by such Major Holder to be released. The Company acknowledges that the approval of this Agreement by the Board and the approval of
any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Release triggering such Shareholder Pro Rata Release shall together constitute Board approval under Section&nbsp;5 of the <FONT STYLE="white-space:nowrap">Bye-Laws</FONT> of any Shareholder Pro
Rata Release. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4. <I>Registration Procedures</I>. Whenever the holders of Registrable Securities have requested that any
Registrable Securities be registered pursuant to this Agreement (including pursuant to a Resale Shelf), the Company shall use its reasonable best efforts to effect the registration and the sale of such Registrable Securities hereunder in accordance
with the intended method of disposition thereof, and pursuant thereto the Company shall as expeditiously as reasonably possible: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) in
accordance with the Securities Act and all applicable rules and regulations promulgated thereunder, prepare and file with the Commission a registration statement, and all amendments and supplements thereto and related prospectuses as may be
necessary to comply with applicable securities laws, with respect to such Registrable Securities and use its reasonable best efforts to cause such registration statement to become effective; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) notify each holder of Registrable Securities of (i)&nbsp;the issuance by the Commission of any stop order suspending the effectiveness of
any registration statement or the initiation of any proceedings for that purpose, (ii)&nbsp;the receipt by the Company or its counsel of any notification with respect to the suspension of the qualification of the Registrable Securities for sale in
any jurisdiction or the initiation or threatening of any proceeding for such purpose, and (iii)&nbsp;the effectiveness of each registration statement filed hereunder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) prepare and file with the Commission such amendments and supplements to such registration statement and the prospectus used in connection
therewith as may be necessary to keep such registration statement effective for a period ending when all of the securities covered by such registration statement have been disposed of in accordance with the intended methods of disposition by the
sellers thereof as set forth in such registration statement or, in the case of a Shelf Registration, if earlier, the date as of which all of the Registrable Securities included in such registration are able to be sold within a ninety (90)&nbsp;day
period in compliance with Rule 144 (but in any event not before the expiration of any longer period required under the Securities Act or, if such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
registration statement relates to an underwritten offering, such longer period as in the opinion of counsel for the underwriters a prospectus is required by law to be delivered in connection with
sales of securities thereunder by any underwriter or dealer) and comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement during such period in accordance with the
intended methods of disposition by the sellers thereof set forth in such registration statement; <I>provided</I>, that any such period shall be extended for a period of time equal to the period the holder refrains, at the request of an underwriter
of Common Stock (or other securities) of the Company, from selling any securities included in such registration statement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) furnish to
each seller of Registrable Securities thereunder such number of copies of such registration statement, each amendment and supplement thereto, the prospectus included in such registration statement (including each preliminary prospectus and any
summary prospectus), each Free-Writing Prospectus and such other documents as such seller may reasonably request in order to facilitate the disposition of the Registrable Securities owned by such seller; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) use its reasonable best efforts to register or qualify such Registrable Securities under such other securities or blue sky laws of such
jurisdictions as any seller reasonably requests and do any and all other acts and things which may be reasonably necessary or advisable to enable such seller to consummate the disposition in such jurisdictions of the Registrable Securities owned by
such seller (<I>provided</I> that the Company shall not be required to (i)&nbsp;qualify generally to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section&nbsp;4(e), (ii) subject itself to taxation
in any such jurisdiction, or (iii)&nbsp;consent to general service of process in any such jurisdiction); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) promptly notify in writing
each seller of such Registrable Securities at any time when a prospectus relating thereto is required to be delivered under the Securities Act, of the happening of any event as a result of which the prospectus included in such registration statement
contains an untrue statement of a material fact or omits any fact necessary to make the statements therein not misleading, and, at the request of any such seller, the Company promptly shall prepare, file with the Commission and furnish to each such
seller a reasonable number of copies of a supplement or amendment to such prospectus so that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus shall not contain an untrue statement of a material fact or omit
to state any fact necessary to make the statements therein not misleading; <I>provided</I>, that each selling holder of the Registrable Securities, upon receipt of any notice from the Company of any event of the kind described in this
Section&nbsp;4(f), shall forthwith discontinue disposition of the Registrable Securities pursuant to the registration statement covering such Registrable Securities until such holder is advised in writing by the Company that the use of the
prospectus may be resumed and is furnished with a supplemented or amended prospectus as contemplated by this Section&nbsp;4(f), and if so directed by the Company, such holder shall deliver to the Company (at the Company&#146;s expense) all copies,
other than permanent file copies then in such holder&#146;s possession, of the prospectus covering such Registrable Securities at the time of receipt of such notice; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) prepare and file promptly with the Commission, and notify such holders of Registrable Securities prior to the filing of, such amendments
or supplements to such registration statement or prospectus as may be necessary to correct any statements or omissions if, at the time when a prospectus relating to such securities is required to be delivered under the Securities Act, when any event
has occurred as the result of which any such prospectus or any other prospectus as then in effect would include an untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the
statements therein not misleading, and, if any such holders of Registrable Securities or any underwriter for any such holders is required to deliver a prospectus at a time when the prospectus then in circulation is not in compliance with the
Securities Act or the rules and regulations promulgated thereunder, the Company shall use its best efforts to prepare promptly upon request of any such holder or underwriter such amendments or supplements to such registration statement and
prospectus as may be necessary in order for such prospectus to comply with the requirements of the Securities Act and such rules and regulations; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) cause all such Registrable Securities to be listed on each securities exchange on which
similar securities issued by the Company are then listed; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) provide a transfer agent and registrar for all such Registrable Securities
not later than the effective date of such registration statement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) enter into and perform such customary agreements (including
underwriting agreements in customary form) and take all such other actions as the holders of a majority of the Investor Registrable Securities included in such registration, the holders of a majority of the Other Registrable Securities included in
such registration or the underwriters, if any, reasonably request in order to expedite or facilitate the disposition of such Registrable Securities (including effecting a split or combination of equity, recapitalization or reorganization and
preparing for and participating in such number of &#147;road shows,&#148; investor presentations and marketing events as the underwriters managing such offering may reasonably request); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) make available upon reasonable notice and during normal business hours for inspection by any seller of Registrable Securities, any
underwriter participating in any disposition pursuant to such registration statement and any attorney, accountant or other agent retained by any such seller or underwriter, all financial and other records, pertinent corporate and business documents
and properties of the Company, as shall be reasonably necessary to enable them to exercise their due diligence responsibility, and cause the Company&#146;s officers, managers, directors and employees to supply all information reasonably requested by
any such seller, underwriter, attorney, accountant or agent in connection with such registration statement; provided, that, unless the disclosure of such records is necessary to avoid or correct a misstatement or omission in the registration
statement or the release of such records is ordered pursuant to a subpoena or other order from a court of competent jurisdiction, the Company shall not be required to provide any information under this Section&nbsp;4(k) if the Company believes,
after consultation with counsel for the Company, that to do so would cause the Company to forfeit an attorney-client privilege that was applicable to such information; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) take all reasonable actions to ensure that any Free-Writing Prospectus prepared by or on behalf of the Company in connection with any
Demand Registration or Piggyback Registration hereunder complies in all material respects with the Securities Act, is filed in accordance with the Securities Act to the extent required thereby, is retained in accordance with the Securities Act to
the extent required thereby and, when taken together with the related prospectus, will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under
which they were made, not misleading; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) otherwise use its reasonable best efforts to comply with all applicable rules and regulations
of the Commission and make available to its security holders, as soon as reasonably practicable, an earnings statement covering the period of at least twelve (12)&nbsp;months beginning with the first day of the Company&#146;s first full calendar
quarter after the effective date of the registration statement, which earnings statement shall satisfy the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) permit any holder of Registrable Securities which holder, in its good faith judgment (based on the advice of counsel), could reasonably be
expected to be deemed to be an underwriter or a controlling Person of the Company, to participate in the preparation of such registration or comparable statement and to require the insertion therein of material, furnished to the Company in writing,
which in the reasonable judgment of such holder and its counsel should be included; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) in the event of the issuance of any stop order
suspending the effectiveness of a registration statement, or the issuance of any order suspending or preventing the use of any related prospectus or suspending the qualification of any equity securities included in such registration statement for
sale in any jurisdiction, the Company shall use its reasonable best efforts promptly to obtain the withdrawal of such order; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) obtain (i)&nbsp;a cold comfort letter from the Company&#146;s independent public
accountants in customary form and covering such matters of the type customarily covered by cold comfort letters and (ii)&nbsp;opinions of counsel from the Company&#146;s counsel in customary form and covering such matters of the type customarily
covered in a public issuance of securities, in each case, in form and substance reasonably satisfactory to the underwriters and addressed to the managing underwriters; in each case as the holders of a majority of the Registrable Securities included
in such registration reasonably request; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) otherwise use its reasonable best efforts to take all other steps necessary to effect
the registration of such Registrable Securities contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5. <I>Certain Obligations of Holders of Registrable
Securities</I>. Each holder of Registrable Securities that sells such securities pursuant to a registration under this Agreement agrees as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Such holder (if such holder is an employee or independent contractor of the Company or any of its Affiliates) shall cooperate with the
Company (as reasonably requested by the Company) in connection with the preparation of the registration statement, and, for so long as the Company is obligated to file and keep effective such registration statement, each holder of Registrable
Securities that is participating in such registration shall provide to the Company, in writing, for use in the applicable registration statement, all such information regarding such holder and its plan of distribution of such securities as may be
reasonably necessary to enable the Company to prepare the registration statement and prospectus covering such securities, to maintain the currency and effectiveness thereof and otherwise to comply with all applicable requirements of law in
connection therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) During such time as a holder of Registrable Securities may be engaged in a distribution of such securities,
such holder shall distribute such securities under the registration statement solely in the manner described in the registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Each Person that is participating in any registration under this Agreement, upon receipt of any notice from the Company of the happening
of any event of the kind described in Section&nbsp;4(f), shall immediately discontinue the disposition of its securities of the Company pursuant to the registration statement until such Person&#146;s receipt of the copies of a supplemented or
amended prospectus as contemplated by Section&nbsp;4(f). In the event the Company has given any such notice, the applicable time period set forth in Section&nbsp;4(c) during which a registration statement is to remain effective shall be extended by
the number of days during the period from and including the date of the giving of such notice pursuant to this Section&nbsp;5(c) to and including the date when each seller of Registrable Securities covered by such registration statement shall have
received the copies of the supplemented or amended prospectus contemplated by Section&nbsp;4(f). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6. <I>Registration
Expenses</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) All expenses incident to the Company&#146;s performance of or compliance with this Agreement, including all
registration, qualification and filing fees, fees and expenses of compliance with securities or blue sky laws, filing expenses, printing expenses, messenger and delivery expenses, fees and disbursements of custodians and fees and disbursements of
counsel for the Company and all independent certified public accountants, underwriters (excluding underwriting discounts and commissions) and other Persons retained by the Company (all such expenses being herein called &#147;<B>Registration
Expenses</B>&#148;), shall be borne by the Company as provided in this Agreement, and the Company also shall pay all of its internal expenses (including all salaries and expenses of its officers and employees performing legal or accounting duties),
the expense of any annual audit or quarterly review, the expense of any liability insurance and the expenses and fees for listing the securities to be registered on each securities exchange on which similar securities issued by the Company are then
listed. Notwithstanding anything to the contrary contained herein, each seller of securities pursuant to a registration under this Agreement shall bear and pay all underwriting discounts and commissions applicable to the securities sold for such
seller&#146;s account. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In connection with each Demand Registration and each Piggyback Registration, the Company
shall reimburse the holders of Registrable Securities included in such registration for the reasonable and documented fees and disbursements of one (1)&nbsp;counsel chosen by the holders of a majority of the Registrable Securities requesting
inclusion in such registration, subject to the approval of the Company of such counsel (which approval shall not be unreasonably withheld, conditioned or delayed) and for the reasonable and documented fees and disbursements of each additional
counsel retained by any holder of Registrable Securities for the purpose of rendering a legal opinion on behalf of such holder in connection with any underwritten Demand Registration or Piggyback Registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) To the extent any expenses relating to a registration hereunder are not required to be paid by the Company, each holder of securities
included (or requested to be included) in any registration hereunder shall pay those expenses allocable to the registration (or proposed registration) of such holder&#146;s securities so included (or requested to be included), and any expenses not
so allocable shall be borne by all sellers of securities requested to be included in such registration in proportion to the aggregate selling price of the securities to be so registered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7. <I>Indemnification</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company shall indemnify and hold harmless, to the fullest extent permitted by law, each holder of Registrable Securities, its
officers, directors, members, managers, partners, agents, Affiliates and employees and each Person who controls such holder (within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act) against all losses,
claims, actions, damages, liabilities and expenses (including with respect to actions or proceedings, whether commenced or threatened, and including reasonable attorney fees and expenses) caused by, resulting from, arising out of or based upon any
of the following statements, omissions or violations by the Company: (i)&nbsp;any untrue or alleged untrue statement of material fact contained in any registration statement, prospectus, preliminary prospectus or Free-Writing Prospectus, or any
amendment thereof or supplement thereto, (ii)&nbsp;any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein not misleading, or (iii)&nbsp;any violation or alleged violation by the
Company of the Securities Act, the Exchange Act or any other similar federal or state securities laws or any rule or regulation promulgated thereunder applicable to the Company and relating to action or inaction required of the Company in connection
with any such registration, qualification or compliance, and to pay to each holder of Registrable Securities, its officers, directors, members, managers, partners, agents, Affiliates and employees and each Person who controls such holder (within the
meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act), as incurred, any legal and any other expenses reasonably incurred in connection with investigating, preparing or defending any such claim, loss, damage,
liability or action, except to the extent that the same are caused by or based upon any information furnished in writing to the Company or any managing underwriter by such holder expressly for use therein. In connection with an underwritten
offering, the Company shall indemnify any underwriters or deemed underwriters, their officers and directors and each Person who controls such underwriters (within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the
Exchange Act) to the same extent as provided above with respect to the indemnification of the holders of Registrable Securities (or to such lesser extent that may be agreed to between the underwriters and the Company). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In connection with any registration in which a holder of Registrable Securities is participating, each such holder shall furnish to the
Company and the managing underwriter in writing such information and affidavits as the Company or the managing underwriter reasonably requests for use in connection with any such registration statement or prospectus relating to the Registrable
Securities, or any amendment or supplement thereto, or any preliminary prospectus or Free Writing Prospectus and, to the fullest extent permitted by law, shall indemnify the Company, its directors, officers, agents and each Person who controls the
Company (within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act) against any losses, claims, damages, liabilities and expenses resulting from any untrue or alleged untrue statement of material fact
contained in the registration statement, prospectus or preliminary prospectus or any amendment thereof or supplement thereto and any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements
therein not misleading, but only to the extent that such untrue statement or omission is contained in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any information or affidavit so furnished in writing by such holder expressly for use therein and has not been corrected in a subsequent writing prior to or concurrently with the sale of
Registrable Securities to the Person asserting the claim; <I>provided</I> that, in the event that a court of competent jurisdiction decides against any such allegations of untrue statements or omissions of a material fact, such holders shall be
reimbursed for any amounts previously paid hereunder with respect to such allegations; <I>provided</I> <I>further</I> that the obligation to indemnify shall be individual, not joint and several, for each holder and shall be limited to the net amount
of proceeds received by such holder from the sale of Registrable Securities pursuant to such registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Any Person
entitled to indemnification hereunder shall (i)&nbsp;give prompt written notice to the indemnifying party of any claim with respect to which it seeks indemnification (provided that the failure to give prompt notice shall not impair any Person&#146;s
right to indemnification hereunder to the extent such failure has not prejudiced the indemnifying party) and (ii)&nbsp;unless in such indemnified party&#146;s reasonable judgment a conflict of interest between such indemnified and indemnifying
parties may exist with respect to such claim, permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party. The indemnifying party shall not be subject to any liability for any
settlement made by the indemnified party without the consent of the indemnifying party. An indemnifying party who is not entitled to, or elects not to, assume the defense of a claim shall not be obligated to pay the fees and expenses of more than
one (1)&nbsp;counsel for all parties indemnified by such indemnifying party with respect to such claim, unless in the reasonable judgment of any indemnified party a conflict of interest may exist between such indemnified party and any other of such
indemnified parties with respect to such claim. In such instance, the conflicting indemnified parties shall have a right to retain one (1)&nbsp;separate counsel, chosen by the holders of a majority of the Registrable Securities included in the
registration by such conflicting indemnified parties, at the expense of the indemnifying party. No indemnifying party, in the defense of such claim or litigation, shall, except with the consent of each indemnified party, consent to the entry of any
judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Each party hereto agrees that, if for any reason the indemnification provisions contemplated by Section&nbsp;7(a) or Section&nbsp;7(b) are
unavailable to or insufficient to hold harmless an indemnified party in respect of or is otherwise unenforceable with respect to any losses, claims, damages, liabilities or expenses (or actions in respect thereof) referred to therein, then each
indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages, liabilities or expenses (or actions in respect thereof) in such proportion as is appropriate to reflect the
relative fault of the indemnifying party and the indemnified party as well as any other relevant equitable considerations. The relative fault of such indemnifying party and indemnified party shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by such indemnifying party or indemnified party, and the parties&#146; relative intent,
knowledge, access to information and opportunity to correct or prevent such statement or omission. The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section&nbsp;7(d) were determined by pro rata
allocation (even if the holders or any underwriters or all of them were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to in this Section&nbsp;7(d).
The amount paid or payable by an indemnified party as a result of the losses, claims, damages, liabilities or expenses (or actions in respect thereof) referred to above shall be deemed to include any legal or other fees or expenses reasonably
incurred by such indemnified party in connection with investigating or, except as provided in Section&nbsp;7(c), defending any such action or claim. No Person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the
Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. The sellers&#146; obligations in this Section&nbsp;7(d) to contribute shall be several in proportion to the amount of
securities registered by them and not joint and shall be limited for each seller to an amount equal to the net proceeds actually received by such seller from the sale of Registrable Securities effected pursuant to such registration; provided that in
no event shall the aggregate amounts payable by any such seller by way of indemnity or contribution under this Section&nbsp;7(d) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and when combined with any amounts payable under Section&nbsp;7(b) exceed the net proceeds from the offering actually received by such seller from the sale of Registrable Securities effected
pursuant to such registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The indemnification and contribution provided for under this Agreement shall be in addition to any
other rights to indemnification and contribution that any indemnified party may have pursuant to law or contract and shall remain in full force and effect regardless of any investigation made by or on behalf of the indemnified party or any officer,
director or controlling Person of such indemnified party and shall survive the transfer of securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8. <I>Participation
in Underwritten Registrations</I>. No Person may participate in any registration hereunder which is underwritten unless such Person (i)&nbsp;agrees to sell such Person&#146;s Registrable Securities on the basis provided in any underwriting
arrangements in form customary for transactions of this type approved by the holders of a majority of the Registrable Securities to be sold in the contemplated offering (including pursuant to any over-allotment or &#147;green shoe&#148; option
requested by the underwriters, provided that no holder of Registrable Securities shall be required to sell more than the number of Registrable Securities such holder has requested to include) and (ii)&nbsp;completes and executes all questionnaires,
powers of attorney, indemnities, underwriting agreements and other documents required under the terms of such underwriting arrangements; <I>provided</I> that no holder of Registrable Securities included in any underwritten registration shall be
required to make any representations or warranties to the Company or the underwriters in connection with an underwritten registration (other than representations and warranties regarding such holder, such holder&#146;s title to the securities and
such holder&#146;s intended method of distribution) or to undertake any indemnification obligations to the Company or the underwriters with respect thereto, except as otherwise specifically provided in Section&nbsp;7, or to agree to any <FONT
STYLE="white-space:nowrap">lock-up</FONT> or holdback restrictions, except as otherwise specifically provided in Section&nbsp;3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9. <I>Other Agreements.</I> At all times after the Company has filed a registration statement with the Commission pursuant to the
requirements of either the Securities Act or the Exchange Act, the Company shall use its reasonable best efforts to file all reports required to be filed by it under the Securities Act and the Exchange Act and the rules and regulations adopted by
the Commission thereunder and shall take such further action as the Investors or the Other Shareholders may reasonably request, all to the extent required to enable such Persons to sell securities pursuant to (i)&nbsp;Rule 144 or any similar rule or
regulation hereafter adopted by the Commission or (ii)&nbsp;a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> or any similar registration form hereafter adopted by the Commission. Upon reasonable request, the Company shall
deliver to the Investors and the Other Shareholders a written statement as to whether it has complied with such requirements. The Company shall at all times after it has consummated the Go Public Transaction use its reasonable best efforts to cause
the securities so registered to be listed on one or more of the New York Stock Exchange, NYSE American, LLC and/or the Nasdaq Stock Market. The foregoing agreements in this Section&nbsp;9 shall not apply to a &#147;take private&#148; or other
transaction in which the Common Shares cease to be registered under the Exchange Act, so long as such transaction is approved by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10. <I>Subsidiary Public Offering</I>. If, after an initial public offering of the capital stock or other equity securities of
one of its subsidiaries, the Company distributes securities of such subsidiary to its equity holders, then the rights of holders hereunder and the obligations of the Company pursuant to this Agreement shall apply, <I>mutatis</I> <I>mutandis</I>, to
such subsidiary, and the Company shall cause such subsidiary to comply with such subsidiary&#146;s obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11. <I>Term</I>. This Agreement shall become effective upon consummation of the Go Public Transaction and shall terminate upon
the earlier to occur of (i)&nbsp;the seventh anniversary of the date of this Agreement and (ii)&nbsp;the date as of which (A)&nbsp;all of the Registrable Securities have been sold pursuant to a Registration Statement (but in no event prior to the
applicable period referred to in Section&nbsp;4(a)(3) of the Securities Act and Rule 174 thereunder (or any successor rule promulgated thereafter by the Commission)) or (B)&nbsp;all Registrable Securities have been sold under Rule 144 under the
Securities Act. The provisions of Section&nbsp;7 and Section&nbsp;9 shall survive any termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12. <I>Definitions</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148; means, as applied to any Person, means any other Person that, directly or indirectly through one or more
intermediaries, controls, is controlled by, or is under common control with such Person, including, without limitation, any general partner, managing member, officer or director of such Person or any venture capital, private equity or other
investment fund or account now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company or investment advisor with, such Person, and the term &#147;<B>Affiliated</B>&#148;
shall have the correlative meaning. The term &#147;control&#148; means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting
securities, by contract or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Certificate of Incorporation</B>&#148; means the Memorandum of Association of the Company,
as issued by the Registrar of Companies in Bermuda, and as amended from time to time in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Dexcel</B>&#148; means Dexcel Pharma Technologies Ltd., an Israeli limited liability company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Dexxon</B>&#148; means Dexxon Holdings Ltd., an Israeli limited liability company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Dexxon Investors</B>&#148; means (i)&nbsp;Dexxon and (ii)&nbsp;Dexcel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Act</B>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated from <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time</FONT></FONT> thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Family Member</B>&#148; means
a spouse, civil partner, child (natural, step or adopted) parent, sibling or grandchild. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>FINRA</B>&#148; means the Financial
Industry Regulatory Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Free-Writing Prospectus</B>&#148; means a free-writing prospectus, as defined in Rule 405
promulgated under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Investor Registrable Securities</B>&#148; means (i)&nbsp;Common Shares issued,
distributed, issuable or distributable to the Major Holders as of the date of this Agreement or hereafter, (ii)&nbsp;any other securities issued or issuable directly or indirectly with respect to the securities described in clause (i)&nbsp;of this
definition by way of a dividend, distribution or equity split or in connection with an exchange or a combination of equity interests, recapitalization, reclassification, merger, consolidation or other reorganization (including any common shares
issued or issuable to the Investors in anticipation of a registered offering), and (iii)&nbsp;any other equity securities of the Company or its corporate successor held at any time by Persons holding securities described in clause (i)&nbsp;or (ii)
of this definition. As to any particular Investor Registrable Securities, such securities shall cease to be an Investor Registrable Security upon the earlier to occur of (x)&nbsp;a registration statement covering such Investor Registrable Security
having been declared effective by the Commission and such Investor Registrable Security having been disposed of pursuant to such effective registration statement or (y)&nbsp;such Investor Registrable Securities being able to be disposed of pursuant
to Rule 144 under the Securities Act in a single transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Major Holder</B>&#148; means each of the Founder, the Dexxon
Investors, the QVT Investors, the Viking Investors, Softbank and Sumitomo, and any of their Permitted Transferees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>MNPI</B>&#148; means material <FONT STYLE="white-space:nowrap">non-public</FONT> information within the meaning of Regulation FD
promulgated under the Exchange Act, which shall in any case include the receipt of any notice delivered by the Company under this Agreement, including pursuant to Section&nbsp;1 or Section&nbsp;2 hereof and the information contained in any such
notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Other Registrable Securities</B>&#148; means (i)&nbsp;the Common Shares issued, distributed, issuable or distributable
to the Other Shareholders, (ii)&nbsp;any other securities issued or issuable directly or indirectly with respect to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities described in clause (i)&nbsp;of this definition by way of a dividend, distribution or equity split or in connection with an exchange or a combination of equity interests,
recapitalization, reclassification, merger, consolidation or other reorganization (including any common share issued or issuable in anticipation of a registered offering), and (iii)&nbsp;any other equity securities of the Company or its corporate
successor held at any time by Persons holding securities described in clause (i)&nbsp;or (ii) of this definition. As to any particular Other Registrable Securities, such securities shall cease to be Other Registrable Securities upon the earlier to
occur of (x)&nbsp;a registration statement covering such Other Registrable Securities having been declared effective by the Commission and such Other Registrable Securities having been disposed of pursuant to such effective registration statement or
(y)&nbsp;such Other Registrable Securities being able to be disposed of pursuant to paragraph (b)(1) of Rule 144. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Permitted
Transferee</B>&#148; means (i)&nbsp;with respect to any Person, an Affiliate of such Person, (ii)&nbsp;with respect to the Founder, a transfer for <I>bona fide</I> estate planning purposes, either during his or her lifetime or on death by will or
intestacy to a Family Member or any custodian or trustee of any trust, executor or other fiduciary all of the beneficial interest in is held for the benefit of, him or her or his or her Family Members, or to a trust for the himself or herself, or a
charitable remainder trust, (iii)&nbsp;with respect to any QVT Investor, (a)&nbsp;any investor in such QVT Investor and (b)&nbsp;any entity in which one or more investors in such QVT Investor have the power to control the decisions of such entity or
at least 90% of the beneficial interest in which is held, by any such investors and any Family Member thereof, and (iv)&nbsp;with respect to Softbank, each of SVF Holdings (UK) LLP and SoftBank Vision Fund L.P., and any investor in SoftBank Vision
Fund L.P. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Person</B>&#148; means an individual, a partnership, a corporation, a limited liability company, an association, a
joint stock company, a trust, a joint venture, an unincorporated organization and a governmental entity or any department, agency or political subdivision thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Public Subsidiary</B>&#148; means any subsidiary of the Company that has a class of securities registered under the Exchange Act.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>QVT Investors</B>&#148; means, collectively, QVT Roiv Hldgs Offshore Ltd., a Cayman Islands limited company, QVT Roiv Hldgs
Onshore Ltd., a Cayman Islands limited company, QVT Financial Investment Cayman Ltd., a Cayman Islands limited company, QVT Deferred Compensation Holdings Ltd., a Cayman Islands limited company, QVT P&amp;E Roiv Hldgs Ltd., a Cayman Islands limited
company, Fourth Avenue Capital Partners LP, a Delaware limited partnership, and any Permitted Transferee of any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Registrable Securities</B>&#148; means, collectively, the Investor Registrable Securities and the Other Registrable Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Rule 144</B>,&#148; &#147;<B>Rule 158</B>,&#148; &#147;<B>Rule 405</B>&#148; and &#147;<B>Rule 415</B>&#148; mean, in each case, such
rule promulgated under the Securities Act (or any successor provision) by the Commission, as the same shall be amended from time to time, or any successor rule then in force. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Securities Act</B>&#148; means the Securities Act of 1933, as amended, and the rules and regulations promulgated from <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time</FONT></FONT> thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Upstream Equity
Holder</B>&#148; means, with respect to a Shareholder, its direct or indirect stockholders, partners, members or other equity holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Viking Investors</B>&#148; means, collectively, Viking Global Opportunities Illiquid Investments
<FONT STYLE="white-space:nowrap">Sub-Master</FONT> LP, Viking Global Equities LP, Viking Global Equities II LP, VGE III Portfolio Ltd., Viking Long Master Fund Ltd. and Viking Global Equities Master Ltd. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>WKSI</B>&#148; means a well-known seasoned issuer, as defined under Rule 405. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;13. <I>Miscellaneou</I>s. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>No Inconsistent Agreements</I>. The Company shall not hereafter enter into any agreement with respect to its securities which is
inconsistent with or violates the rights granted to the holders of Registrable Securities in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Adjustments Affecting
Registrable Securities</I>. The Company shall not take any action, or permit any change to occur, with respect to its securities that would materially and adversely affect the ability of the holders of Registrable Securities to include such
Registrable Securities in a registration undertaken pursuant to this Agreement or that would materially and adversely affect the marketability of such Registrable Securities in any such registration (including effecting a split or a combination of
securities). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Remedies</I>. Any Person having any rights under any provision of this Agreement shall be entitled to enforce such
rights specifically (without posting a bond or other security), to recover damages by reason of any breach of any provision of this Agreement and to exercise all other rights granted by law. The Parties agree and acknowledge that the Investors and
the other holders of Registrable Securities would be irreparably harmed by, and money damages would not be an adequate remedy for, any breach of the provisions of this Agreement and that, in addition to any other rights and remedies existing in its
favor, any Party shall be entitled to specific performance and/or other injunctive relief from any court of law or equity of competent jurisdiction (without posting any bond or other security) in order to enforce or prevent violation of the
provisions of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Amendments and Waivers</I>. The provisions of this Agreement may be amended, and any provision of
this Agreement may be waived, only upon the prior written consent of (i)&nbsp;the Company, (ii)&nbsp;the holders of a majority of the Registrable Securities, and (iii)&nbsp;the holders of at least 60% of the Investor Registrable Securities;
<I>provided</I> that to the extent any such amendment alters or waives any rights of the Other Shareholders in this Agreement in a manner disproportionately adverse to the Other Shareholders (as compared to the Investors), such amendment or waiver
will also require the prior written consent of the Other Shareholders holding a majority of the Registrable Securities held by the Other Shareholders; <I>provided</I><B> </B><I>further</I><B> </B>that this Agreement may not be amended, modified or
supplemented and the observance of any term hereof may not be waived with respect to any Investor (each an &#147;<B>Amendment</B>&#148;) without the written consent of such Investor, if such Amendment would (A)&nbsp;disproportionately and materially
adversely affect such Investor&#146;s rights hereunder, or (B)&nbsp;grant any rights to any Investor that are not similarly granted or offered to all other Investors. No course of dealing between or among the Parties (including the failure of any
Party to enforce any of the provisions of this Agreement) shall be deemed effective to modify, amend, waive or discharge any part of this Agreement or any rights or obligations of any Party under or by reason of this Agreement, and the failure of
any Party to enforce any of the provisions of this Agreement shall in no way be construed as a waiver of such provisions and shall not affect the right of such Party thereafter to enforce each and every provision of this Agreement in accordance with
its terms. The waiver by any Party hereto of a breach of any provision of this Agreement shall not operate or be construed as a waiver of any preceding or succeeding breach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Successors and Assigns</I>. This Agreement and all of the covenants and agreements contained herein and rights, interests or
obligations hereunder, by or on behalf of any of the Parties, shall bind and inure to the benefit of the respective successors and assigns of the Parties whether so expressed or not, provided that neither this Agreement nor any of the covenants and
agreements herein or rights, interests or obligations hereunder may be assigned or delegated by the Company except in connection with a Business Combination (as defined in the Amended and Restated <FONT STYLE="white-space:nowrap">Bye-laws</FONT> of
the Company (the &#147;<B><FONT STYLE="white-space:nowrap">Bye-Laws</FONT></B>&#148;)) in accordance with the terms and conditions set forth in the <FONT STYLE="white-space:nowrap">Bye-Laws.</FONT> Without limiting the foregoing, whether or not any
express assignment has been made, the provisions of this Agreement which are for the benefit of holders of Investor Registrable Securities or Other Registrable Securities are also for the benefit of, and enforceable by, any subsequent holder of
Investor Registrable Securities and Other Registrable Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Severability</I>. Whenever possible, each provision of this
Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement or the application of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such provision to any Person or circumstance shall be held to be prohibited by or illegal or unenforceable under applicable law in any respect by a court of competent jurisdiction, such provision
shall be ineffective only in such jurisdiction and to the extent of such prohibition or illegality or unenforceability, without invalidating the remainder of such provision or the remaining provisions of this Agreement in such jurisdiction or any
provisions of this Agreement in any other jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Counterparts</I>. This Agreement and any amendments hereto or thereto, to
the extent signed and delivered in counterparts (any one of which need not contain the signatures of more than one Party hereto or thereto, but all such counterparts together shall constitute one and the same Agreement) by means of a facsimile
machine or electronic transmission in portable document format (pdf), shall be treated in all manner and respects as an original thereof and shall be considered to have the same binding legal effects as if it were the original signed version thereof
delivered in person. At the request of any Party hereto or thereto, each other Party hereto or thereto shall <FONT STYLE="white-space:nowrap">re-execute</FONT> original forms thereof and deliver them to all other Parties hereto or thereto. No Party
hereto shall raise the use of a facsimile machine or electronic transmission in pdf to deliver a signature or the fact that any signature or document was transmitted or communicated through the use of facsimile machine or electronic transmission as
a defense to the formation of a contract, and each such Party forever waives any such defense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Descriptive Headings;
Interpretation</I>. The headings and captions used in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. The use of the word &#147;including&#148; herein shall mean
&#147;including without limitation.&#148; Any reference to the masculine, feminine or neuter gender shall be deemed to include any gender or all three as appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Governing Law; Jurisdiction; Agreement for Service</I>. All issues and questions concerning the construction, validity, enforcement and
interpretation of this Agreement shall be governed by, and construed in accordance with, the laws of the State of New York, without giving effect to any choice of law or conflict of law rules or provisions (whether of the State of New York or any
other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of New York. The Parties agree that all disputes, legal actions, suits and proceedings arising out of or relating to this Agreement must be
brought exclusively in a federal district court or a state court in New York County, New York. Each Party hereby consents and submits to the exclusive jurisdiction of such courts. Each Party hereby irrevocably waives all claims of immunity from
jurisdiction and any right to object on the basis that any dispute, action, suit or proceeding brought in such court has been brought in an improper or inconvenient forum or venue. No legal action, suit or proceeding with respect to this Agreement
may be brought in any other forum except to enforce a judgment entered in a court described in the preceding sentence. Each Party hereby irrevocably waives all claims of immunity from jurisdiction and any right to object on the basis that any
dispute, action, suit or proceeding brought in such court has been brought in an improper or inconvenient forum or venue. Each of the Company, Softbank and the Dexxon Investors (A)&nbsp;acknowledges that it has, by separate written instrument,
irrevocably designated and appointed Corporation Service Company (&#147;<B>CSC</B>&#148;), 1180 Avenue of the Americas, Suite 210, New York, NY 10036-8401 as its authorized agent upon which process may be served in any suit or proceeding arising out
of or relating to this Agreement and acknowledges that CSC has accepted such designation and (B)&nbsp;agrees that service of process upon CSC, and written notice of said service to any such Party, in the manner provided in Section&nbsp;13(k) shall
be deemed in every respect effective service of process upon such Party, as the case may be, in any such suit or proceeding. Each of the Company, Softbank and the Dexxon Investors further agrees to take any and all action, including the execution
and filing of any and all such documents and instruments, as may be necessary to continue such designation and appointment of CSC in full force and effect so long as this Agreement shall be in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>WAIVER OF TRIAL BY JURY</I>. TO THE EXTENT NOT PROHIBITED BY APPLICABLE LAW THAT CANNOT BE WAIVED, THE PARTIES HEREBY WAIVE, AND
COVENANT THAT THEY WILL NOT ASSERT (WHETHER AS PLAINTIFF, DEFENDANT OR OTHERWISE), ANY RIGHT TO TRIAL BY JURY IN ANY ACTION ARISING IN WHOLE OR IN PART UNDER OR IN CONNECTION WITH THIS </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY, WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE. THE PARTIES AGREE THAT ANY OF THEM MAY FILE A
COPY OF THIS PARAGRAPH WITH ANY COURT AS WRITTEN EVIDENCE OF THE KNOWING, VOLUNTARY AND <FONT STYLE="white-space:nowrap">BARGAINED-FOR</FONT> AGREEMENT AMONG THE PARTIES IRREVOCABLY TO WAIVE ITS RIGHT TO TRIAL BY JURY IN ANY PROCEEDING WHATSOEVER
BETWEEN THEM RELATING TO THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Notice</I>. All notices, demands or other
communications to be given or delivered under or by reason of the provisions of this Agreement will be in writing and will be deemed to have been given when (i)&nbsp;delivered personally to the recipient, (ii)&nbsp;received, if sent by confirmed
electronic mail or facsimile during normal business hours of the recipient (or, if sent outside of normal business hours, then on the next business day) or (iii)&nbsp;one (1) business day after it is sent to the recipient by reputable overnight
courier service (charges prepaid). Such notices, demands and other communications will be sent to the Company at the address set forth below and to any other Party to this Agreement at such address as indicated by the Company&#146;s records, or at
such other Party&#146;s principal place of business with copies (which shall not constitute notice) to such address or to the attention of such other person as the recipient Party has specified by prior written notice to the sending Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>To the Company</I>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Roivant
Sciences Ltd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Suite 1, 3rd Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">11-12</FONT> St. James&#146;s Square </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">London </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">SW1Y 4LB </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">United Kingdom </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention:
Marianne Romeo </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: marianne.romeo@roivant.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>with copies (which shall not constitute notice to the Company) to</I>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Davis Polk&nbsp;&amp; Wardwell LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">450 Lexington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York,
New York 10017 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Derek J. Dostal; Lee Hochbaum </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Telephone: (212) <FONT STYLE="white-space:nowrap">450-4322;</FONT> (212) <FONT STYLE="white-space:nowrap">450-4736</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: derek.dostal@davispolk.com; lee.hochbaum@davispolk.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>If to any of the Dexxon Investors at</I>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">c/o Dexxon Holdings Ltd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">1
Dexcel Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Or Akiva, 30600000, Israel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Dan Oren, President&nbsp;&amp; CEO </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Telephone: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+972-4-6364040</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Facsimile: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+972-4-6364004</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: Dan@Dexcel.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>with a copy (which shall not constitute notice to the Dexxon Investors) to</I>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Greenberg Traurig, P.A. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">333 S.E.
2nd Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Miami, FL 33131 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Robert L. Grossman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Telephone:
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-305-579-7970</FONT></FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Facsimile:
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-305-579-0717</FONT></FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: grossmanb@gtlaw.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>If to any of the QVT Investors at</I>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">c/o QVT Financial LP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">888 Seventh
Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, NY 10106 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: legalnotices@qvt.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Facsimile: (212) <FONT STYLE="white-space:nowrap">705-8820</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>with a copy (which shall not constitute notice to the QVT Investors) to</I>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Davis Graham&nbsp;&amp; Stubbs LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">1550 17th Street, Suite 500 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Denver, CO 80202 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: John
Elofson </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Telephone: (303) <FONT STYLE="white-space:nowrap">892-7335</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Facsimile: (303) <FONT STYLE="white-space:nowrap">893-1379</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: John.Elofson@dgslaw.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>If to any of the Viking Investors at</I>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">c/o Viking Global Investors LP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">55 Railroad Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Greenwich, CT
06830 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> legalnotices@vikingglobal.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>with a copy (which shall not constitute notice to the Viking Investors) to</I>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Gunderson Dettmer Stough Villeneuve Franklin&nbsp;&amp; Hachigian, LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">1250 Broadway, 23rd Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New
York, New York 10001 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Greg Volkmar </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Phone: (212) <FONT STYLE="white-space:nowrap">430-3170</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: gvolkmar@gunder.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>If to Softbank at</I>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">c/o
SB Investment Advisers (US) Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">1 Circle Star Way </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">San Carlos, CA 94070 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attn:
Akshay Naheta </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: akshay@softbank.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>with copies (which shall not constitute notice to Softbank) to</I>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">SB Investment Advisers (US) Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">1 Circle Star Way </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">San Carlos, CA
94070 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attn: Brian Wheeler, General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: bwheeler@softbank.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">-and- </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Cooley LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">3175 Hanover Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Palo Alto,
CA 94304 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attn: Matthew S. Bartus </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: mbartus@cooley.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Telephone: (650) <FONT STYLE="white-space:nowrap">843-5756</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>If to Sumitomo at</I>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">c/o
Sumitomo Dainippon Pharma Co., Ltd </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">6-8,</FONT> Doshomachi
<FONT STYLE="white-space:nowrap">2-Chome,</FONT> <FONT STYLE="white-space:nowrap">Chuo-ku</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Osaka
<FONT STYLE="white-space:nowrap">541-0045</FONT> Japan </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Shigeyuki Nishinaka, Senior Executive Officer, Global Corporate Strategy
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: <FONT STYLE="white-space:nowrap">shigeyuki-nishinaka@ds-pharma.co.jp</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>with a copy (which shall not constitute notice to Sumitomo) to</I>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Jones Day </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">3161 Michelson Drive
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Irvine, CA 92612-4412 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Jonn R. Beeson, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: jbeeson@jonesday.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)
<I>Rights Cumulative</I>. The rights and remedies of each of the Parties under this Agreement shall be cumulative and not exclusive of any rights or remedies which a Party would otherwise have hereunder at law or in equity or by statute, and no
failure or delay by either Party in exercising any right or remedy shall not impair any such right or remedy or operate as a waiver of such right or remedy, and neither shall any single or partial exercise of any power or right preclude a
Party&#146;s other or further exercise thereof or the exercise of any other power or right. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>No Strict Construction</I>. The
Parties have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the Parties, and no presumption
or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any of the provisions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Complete Agreement.</I> This Agreement and the other agreements and instruments referred to herein contain the complete agreement
between the Parties with respect to the subject matter hereof and thereof and supersede any prior understandings, agreements and representations by or between the parties hereto (whether written or oral) that may have related to the subject matter
hereof or thereof in any way. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>Aggregation of Stock</I>. All shares of Registrable Securities held or acquired by Affiliates shall
be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14. <I>MNPI Provisions</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Each Shareholder acknowledges that (i)&nbsp;the provisions of Section&nbsp;1, 2 and 4 of this Agreement may require certain communications
to be made by the Company or other Shareholders to such Shareholder that may result in such Shareholder and its Representatives (as defined below) acquiring MNPI (which may include, solely by way of illustration, the fact that an offering of the
Company&#146;s securities is pending or the number of Company securities or the identity of the selling Shareholders) (such communications, &#147;<B>RRA Communications</B>&#148;), and (ii)&nbsp;subject to the time limitations set forth in
Section&nbsp;1(e) and the qualifications in Section&nbsp;14(b), there is no limitation on the duration of time that such Shareholder and its Representatives may be in possession of MNPI included in such RRA Communications and no requirement that the
Company or other Shareholders make any public disclosure to cause information in such RRA Communications to cease to be MNPI; provided that the Company will notify each Shareholder entitled to notice or who received an RRA Communication if any
proposed registration or offering for which an RRA Communication has been delivered pursuant to this Agreement has been terminated or aborted to the extent the knowledge of such registration or offering constitutes MNPI. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each Shareholder agrees that it will maintain the confidentiality of MNPI in RRA Communications delivered to it and, to the extent such
Shareholder is not a natural person, such confidential treatment shall be in accordance with procedures adopted by it in good faith to protect confidential information of third parties delivered to such Shareholder (&#147;<B>Policies</B>&#148;);
provided that the obligation to maintain confidentiality of MNPI in RRA Communications shall cease when the information in the RRA Communications (i)&nbsp;is known or becomes known to the public in general (other than as a result of a breach of this
Section&nbsp;14(b) by such Shareholder or its Representatives), or (ii)&nbsp;is or has been made known or disclosed to the Shareholder by a third party not known by such Shareholder to be in breach of any obligation of confidentiality such third
party may have to the Company; provided further that a Shareholder may deliver or disclose MNPI in such RRA Communications to (1)&nbsp;to its affiliates, its and its affiliates&#146; respective directors, officers, employees, partners, members,
agents, attorneys, consultants and financial and other advisors, and potential sources of capital (including potential limited partners) (collectively, the &#147;<B>Representatives</B>&#148;), but solely to the extent such disclosure reasonably
relates to its evaluation of exercise of its rights under this Agreement and the sale of any Registrable Securities in connection with the subject of the notice, (2)&nbsp;to any federal, state, national, foreign or other regulatory or
self-regulatory authority having jurisdiction over such Shareholder, or (3)&nbsp;to any Person if necessary to effect compliance with any law, rule, regulation, investigation, audit, request or order applicable to such Shareholder, including in
response to any subpoena or other legal process, audit or examinations; provided further, that in the case of clause (1), the recipients of such MNPI in such RRA Communications are subject to the Policies or agree to or are otherwise obligated to
hold confidential the MNPI in a manner substantially consistent with the terms of this Section&nbsp;14 and that in the case of clauses (2)&nbsp;and (3), such Shareholder promptly notifies the Company of such disclosure to the extent such Shareholder
is legally permitted to give such notice and it is reasonably practicable; provided further, no such notice shall be required where disclosure is made (x)&nbsp;in response to a general request by a regulatory or self-regulatory authority or
(y)&nbsp;in connection with a routine audit or examination by a bank examiner or auditor and such audit or examination does not reference the Company or this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Each Shareholder, by its execution of this Agreement, hereby (i)&nbsp;acknowledges that it is aware that the U.S. securities laws prohibit
any Person who has MNPI about a company from purchasing or selling, directly or indirectly, securities of such company (including entering into hedge transactions involving such securities), or from communicating such information to any other Person
in certain circumstances, and (ii)&nbsp;agrees that it will not use or permit any third party to use, and that it will use its commercially reasonable efforts to assure that none of its Representatives will use or permit any third party to use, any
MNPI the Company provides in contravention of the U.S. securities laws and such Shareholder will cease trading in the Company&#146;s securities while in possession of such MNPI to the extent prohibited by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Each Shareholder shall have the right, at any time and from time to time (including after receiving information regarding any potential
underwritten offering), to elect not to receive RRA Communications that the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company or any other Shareholders otherwise are required to deliver pursuant to this Agreement by delivering to the Company a written statement signed by such Shareholder that it does not want to
receive any RRA Communications (an &#147;<B><FONT STYLE="white-space:nowrap">Opt-Out</FONT> Request</B>&#148;); in which case, and notwithstanding anything to the contrary in this Agreement, the Company and other Shareholders shall not be required
to, and shall not, deliver any RRA Communications for which the Shareholder has indicated in the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Request that it does not want to receive hereunder to the extent that such RRA Communications would
result in a Shareholder acquiring MNPI. An <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Request may state a date on which it expires or, if no such date is specified, shall remain in effect until the Shareholder notifies the Company that it
withdraws the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Request, and the Shareholder may, in its sole discretion, determine the scope and applicability of the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Request as set forth in the <FONT
STYLE="white-space:nowrap">Opt-Out</FONT> Request. A Shareholder who previously has given the Company an <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Request may update or revoke such request at any time, and there shall be no limit on the
ability of a Shareholder to issue, update and revoke subsequent <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Requests; provided that each Shareholder shall use commercially reasonable efforts to minimize the administrative burden on the Company
arising in connection with any such <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Requests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* &nbsp;&nbsp;* &nbsp;&nbsp;* &nbsp;&nbsp;*
&nbsp;&nbsp;* </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed or caused to be executed on their behalf this
Third Amended and Restated Registration Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">COMPANY:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">ROIVANT SCIENCES LTD.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Third Amended and Restated Registration Rights Agreement] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed or caused to be executed on their behalf this
Third Amended and Restated Registration Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SVF Investments (UK) Limited</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Third Amended and Restated Registration Rights Agreement] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed or caused to be executed on their behalf this
Third Amended and Restated Registration Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DEXXON HOLDINGS LTD</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Third Amended and Restated Registration Rights Agreement] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">DEXCEL PHARMA TECHNOLOGIES LTD</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Third Amended and Restated Registration Rights Agreement] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed or caused to be executed on their behalf this
Third Amended and Restated Registration Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">QVT INVESTORS:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">QVT Fund V LP</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By its general partner QVT Associates GP
LLC</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Third Amended and Restated Registration Rights Agreement] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">QVT Fund IV LP</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By its general
partner QVT Associates GP LLC</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Third Amended and Restated Registration Rights Agreement] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">QVT Financial LP</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By its general
partner QVT Financial LLC</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Third Amended and Restated Registration Rights Agreement] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">QVT Offshore Ltd.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Third Amended and Restated Registration Rights Agreement] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fourth Avenue Capital Partners LP</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By its general partner Fourth Avenue Capital Partners GP LLC</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Third Amended and Restated Registration Rights Agreement] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed or caused to be executed on their behalf this
Third Amended and Restated Registration Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VIKING INVESTORS:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS <FONT STYLE="white-space:nowrap">SUB-MASTER</FONT> LP</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By: Viking Global Opportunities Portfolio GP LLC, its general partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">VIKING GLOBAL EQUITIES LP <BR>By: Viking Global Performance LLC, its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">VIKING GLOBAL EQUITIES II LP <BR>By: Viking Global Performance LLC, its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Third Amended and Restated Registration Rights Agreement] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PURCHASERS (CONTINUED):</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VGE III
PORTFOLIO LTD.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By: Viking Global Performance LLC, its investment manager</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VIKING LONG FUND MASTER LTD.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By:
Viking Long Fund GP LLC, its investment manager</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Third Amended and Restated Registration Rights Agreement] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed or caused to be executed on their behalf this
Third Amended and Restated Registration Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SUMITOMO DAINIPPON PHARMA CO., LTD.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Third Amended and Restated Registration Rights Agreement] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed or caused to be executed on their behalf this
Third Amended and Restated Registration Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VIVEK RAMASWAMY</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Third Amended and Restated Registration Rights Agreement] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><A NAME="rom65062_42"></A>ANNEX D &#150; FORM OF TRANSACTION SUPPORT AGREEMENT
</U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[FORM OF] TRANSACTION SUPPORT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>TRANSACTION SUPPORT AGREEMENT</B> (this &#147;<U>Agreement</U>&#148;) is entered into as of May&nbsp;1, 2021, by and among Montes
Archimedes Acquisition Corp., a Delaware corporation (&#147;<U>MAAC</U>&#148;), Roivant Sciences Ltd., a Bermuda exempted limited company (the &#147;<U>Company</U>&#148;), and [&#149;], a [&#149;] ([collectively,] the
&#147;<U>Shareholder</U>&#148;).<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> Each of MAAC, the Company and the Shareholder are sometimes referred to herein individually as a &#147;<U>Party</U>&#148; and collectively as the
&#147;<U>Parties</U>&#148;. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Business Combination Agreement (as defined below). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,
concurrently with the execution of this Agreement, MAAC, the Company and Rhine Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (&#147;<U>Merger Sub</U>&#148;), entered into that certain Business Combination
Agreement (as amended, supplemented or otherwise modified from time to time in accordance with its terms, the &#147;<U>Business Combination Agreement</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Business Combination Agreement contemplates that, on the terms and subject to the conditions therein, (a)&nbsp;on the
Closing Date prior to the Closing, the Company will consummate the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps, and (b)&nbsp;on the Closing Date promptly following consummation of the Company
<FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps, Merger Sub will merge with and into MAAC, with MAAC as the surviving corporation in the merger and, after giving effect to such merger, becoming a wholly-owned Subsidiary of the Company;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Shareholder is, as of the date hereof, the record and beneficial owner of the number and class or series (as
applicable) of the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares set forth on <U>Schedule A</U> hereto (together with any other Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares that the
Shareholder acquires record or beneficial ownership of after the date hereof and prior to the Effective Time, collectively, the &#147;<U>Subject Company Shares</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, in consideration for the benefits to be received by the Shareholder under the terms of the Business Combination Agreement and
as a material inducement to the Company and MAAC agreeing to enter into and consummate the transactions contemplated by the Business Combination Agreement, the Shareholder agrees to enter into this Agreement and to be bound by the agreements,
covenants and obligations contained in this Agreement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Parties acknowledge and agree that the Company and MAAC
would not have entered into and agreed to consummate the transactions contemplated by the Business Combination Agreement without the Shareholder entering into this Agreement and agreeing to be bound by the agreements, covenants and obligations
contained in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the premises and the mutual promises set forth herein and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, each intending to be legally bound, hereby agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Company
Shareholder Consent and Related Matters.</U> Prior to the earlier of (A)&nbsp;the termination of this Agreement in accordance with its terms and (B)&nbsp;the Effective Time, (i)&nbsp;to the extent that it is necessary or </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With respect to institutional investors, this Agreement is to be executed by all entities that hold Company <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reasonably advisable, in each case, as mutually reasonably determined and agreed by MAAC and the Company (such determination and agreement not to be unreasonably withheld, conditioned or delayed
by either MAAC or the Company, as applicable) for matters, actions or proposals to be approved by the Shareholder in connection with, or otherwise in furtherance of, the transactions contemplated by the Business Combination Agreement and/or the
Ancillary Documents, if any, the Shareholder shall vote (or cause to be voted) the Subject Company Shares in favor of and/or consent to any such matters, actions or proposals promptly following written request thereof from MAAC and the Company, as
applicable (<I>provided</I>, <I>however</I>, that the Shareholder shall not be required to vote for, or consent to, any action that would result in any adverse economic or other material changes to the form of the Business Combination Agreement
and/or the Ancillary Documents as approved by the Board of Directors of the Company on or prior to the date hereof (any such action, an &#147;<U>Adverse Action</U>&#148;)), and (ii)&nbsp;the Shareholder shall vote (or cause to be voted) the Subject
Company Shares against and withhold consent with respect to (A)&nbsp;any Company Acquisition Proposal or (B)&nbsp;any other matter, action or proposal that would reasonably be expected to result in (x)&nbsp;a breach of any of the Company&#146;s
covenants, agreements or obligations under the Business Combination Agreement or (y)&nbsp;any of the conditions to the Closing set forth in Article VI of the Business Combination Agreement not being satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Other Covenants and Agreements</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Shareholder and the Company hereby agrees that, notwithstanding anything to the contrary in any such agreement, (i)&nbsp;each of the
agreements set forth on <U>Schedule B</U> hereto shall be automatically terminated and of no further force and effect (including any provisions of any such agreement that, by its terms, survive such termination, effective as of, and subject to and
conditioned upon the occurrence of, the Closing and (ii)&nbsp;upon such termination neither the Company nor any of its Affiliates (including the other Group Companies and, from and after the Effective Time, MAAC and its Affiliates) shall have any
further Liabilities under each such agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Shareholder acknowledges and agrees that the Shareholder is, and during the term
of this Agreement shall continue to be, bound by the confidentiality obligations set forth in the Sixth Amended and Restated Shareholders Agreement, dated June&nbsp;17, 2020, by and among the Company and the Company Shareholders party thereto (the
&#147;<U>Shareholders Agreement</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Shareholder shall not, and the Shareholder shall cause its controlled Affiliates and
its and their respective officers and directors not to, and shall use reasonable best efforts to cause its other Representatives not to, at or at any time prior to the Effective Time, issue any press releases or make any public announcements with
respect to this Agreement, the Business Combination Agreement or the transactions contemplated hereby or thereby that contain any information that is not, at the applicable time, already publicly available (other than as a result of disclosure by
the Shareholder in violation of any applicable confidentiality obligations) without the prior written consent of the Company and MAAC; <I>provided</I>, <I>however</I>, that the Shareholder and its Representatives may issue or make, as applicable,
any such press release, public announcement or other communication if such press release, public announcement or other communication is required by applicable Law or applicable rule of a stock exchange on which its or any of its Affiliates&#146;
securities are listed, in which case the Shareholder or its applicable Representatives shall, to the extent reasonably practicable and unless and to the extent prohibited by such applicable Law, reasonably consult with the Company and MAAC in
connection therewith and provide the Company and MAAC with an opportunity to review and comment on such press release, public announcement or communication and shall consider any such comments in good faith. Notwithstanding anything to the contrary
in this <U>Section</U><U></U><U>&nbsp;2(c)</U> or otherwise in this Agreement, the Shareholder and its Representatives may provide general information about the subject matter of this Agreement, the Business Combination Agreement and the
transactions contemplated hereby and thereby (1)&nbsp;to their respective affiliates, their and their affiliates&#146; respective directors, officers, employees, partners, members, agents, attorneys, consultants and financial and other advisors, and
potential sources of capital (including potential limited partners), (2) to the extent required by any federal, state, national, foreign or other regulatory or self-regulatory authority having jurisdiction over the Shareholder or its
Representatives, (3)&nbsp;to any Person if necessary to effect compliance with any law, rule, regulation, investigation, audit, request or order of a Governmental Entity of competent jurisdiction that is applicable to the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Shareholder or its Representatives, including in response to any subpoena or other legal process, audit or examinations or (4)&nbsp;to any direct or indirect former, current or prospective
investor or in connection with normal fund raising or related marketing or informational or reporting activities (so long as, in the case of this clause (4), the recipients of such information are subject to customary confidentiality obligations
prior to the receipt of such information); <I>provided</I> <I>further</I> that in the case of the foregoing clause (1), the recipients of such information are subject to policies to protect such confidential information or agree to hold confidential
the information in a manner substantially consistent with the terms of the confidentiality provisions of the Shareholders Agreement and that, in the case of the foregoing clauses (2)&nbsp;and (3), the Shareholder or its Representatives promptly
notifies the Company of such disclosure to the extent the Shareholder or its Representatives are legally permitted to give such notice and it is reasonably practicable; <I>provided</I> <I>further</I> that no such notice shall be required where
disclosure is made (x)&nbsp;in response to and required by a general request by a regulatory or self-regulatory authority of competent jurisdiction or (y)&nbsp;in connection with and required by a routine audit or examination by a bank examiner or
auditor and such audit or examination does not reference the Company, this Agreement or the Business Combination Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The
Shareholder (i)&nbsp;shall be bound by and subject to <U>Section</U><U></U><U>&nbsp;8.18</U> (Trust Account Waiver) of the Business Combination Agreement to the same extent as such provisions apply to the Company, as if the Shareholder is directly
party thereto, and (ii)&nbsp;shall vote its Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares, exercise its director appointment and termination rights, execute any documents and otherwise use its reasonable best efforts to
take, or cause to be taken, all actions, in each case, as may be necessary or appropriate so that, immediately after the Effective Time, the Company Board consists of the number of directors, and is comprised of the individuals, determined pursuant
to <U>Section</U><U></U><U>&nbsp;5.16(a)</U> (Post-Closing Directors) of the Business Combination Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) [Except with respect to
the transactions contemplated by the PIPE Subscription Agreement entered into by and among the Shareholder, the Company and MAAC on the date hereof (the &#147;<U>Shareholder PIPE
Subscription</U>&#148;),]<SUP STYLE="font-size:85%; vertical-align:top">2</SUP> if applicable, the Shareholder hereby agrees to promptly execute and deliver all additional agreements, documents or instruments, take, or cause to be taken, all actions
and provide, or cause to be provided, all additional information or other materials as may be necessary or reasonably advisable, in each case, as mutually reasonably determined and agreed to by MAAC and the Company (such determination and agreement
not to be unreasonably withheld, conditioned or delayed by either MAAC or the Company), in connection with, or otherwise in furtherance of, the transactions and the other covenants and agreements contemplated by the Business Combination Agreement or
this Agreement (<I>provided</I>, <I>however</I>, that in no event shall the Shareholder be obligated to take, approve or consent to an Adverse Action). Notwithstanding the foregoing, the Shareholder shall not be required to provide any information
which is, based on the advice of outside counsel, subject to legal privilege. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) [The Shareholder hereby acknowledges and agrees that,
in connection with the consummation of the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps on the Closing Date, all of the <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Shares held by the Shareholder as of immediately
prior to such consummation of the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps will be converted on a one for one basis into voting Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares (the &#147;<U>Share
Conversion</U>&#148;), subject to the prior expiration or termination of the applicable waiting period under the HSR Act with respect to such Share Conversion. Without limiting <U>Section</U><U></U><U>&nbsp;2(e)</U>, the Shareholder shall use
reasonable best efforts to take any actions reasonably necessary or appropriate to cause the Share Conversion to be consummated, including by (A)&nbsp;making any appropriate filings pursuant to the HSR Act with respect to the Share Conversion as
promptly as reasonably practicable (and in any event within ten (10)&nbsp;Business Days) following the date of this Agreement, (B)&nbsp;obtaining any other approvals of any Governmental Entity as may be required in connection with the Share
Conversion and (C)&nbsp;responding as promptly as reasonably practicable to any requests by any Governmental Entity for additional information and documentary material that may be requested pursuant to the HSR Act or in connection with such other
required approvals of any Governmental Entity. Without limiting the foregoing, the Shareholder and its </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Note to Draft:</B> To be included for Company shareholders that are also PIPE investors.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable Affiliates shall not extend any waiting period, review period or comparable period under the HSR Act or in connection with such other required approvals of any Governmental Entity or
enter into any agreement with any Governmental Entity not to consummate the Share Conversion except with the prior written consent of the Company and MAAC. The Shareholder shall promptly inform the Company and MAAC of any communication received by
the Shareholder from any Governmental Entity regarding the Share Conversion. The Shareholder shall give the Company and its counsel, and MAAC and its counsel, a reasonable opportunity to review in advance, and consider in good faith the views
thereof in connection with, any proposed written communication to any Governmental Entity relating to the Share Conversion. The Shareholder agrees not to participate in any substantive meeting or discussion, either in person or by telephone with any
Governmental Entity in connection with the Share Conversion unless it consults with the Company and MAAC in advance and, to the extent not prohibited by such Governmental Entity, gives the Company and MAAC the opportunity to attend and participate
in such meeting or discussion.]<SUP STYLE="font-size:85%; vertical-align:top">3</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) [Without limiting Section&nbsp;2(e), the
Shareholder shall use reasonable best efforts to consummate the Shareholder PIPE Subscription, including by (A)&nbsp;making any appropriate filings pursuant to the HSR Act with respect to the Shareholder PIPE Subscription as promptly as reasonably
practicable (and in any event within ten (10)&nbsp;Business Days) following the date of this Agreement, (B)&nbsp;obtaining any other approvals of any Governmental Entity as may be required in connection with the Shareholder PIPE Subscription and
(C)&nbsp;responding as promptly as reasonably practicable to any requests by any Governmental Entity for additional information and documentary material that may be requested pursuant to the HSR Act or in connection with such other required
approvals of any Governmental Entity. Without limiting the foregoing, the Shareholder and its applicable Affiliates shall not extend any waiting period, review period or comparable period under the HSR Act or in connection with such other required
approvals of any Governmental Entity except with the prior written consent of the Company and MAAC. Notwithstanding anything to the contrary contained herein, it is expressly understood and agreed that: (i)&nbsp;the Shareholder shall have no
obligation to litigate or contest any Proceeding in respect of such filings and approvals and (ii)&nbsp;the Shareholder shall be under no obligation to proffer, make proposals, negotiate, execute, carry out or submit to agreements or Orders
providing for (A)&nbsp;the sale, transfer, license, divestiture, encumbrance or other disposition or holding separate (through the establishment of a trust or otherwise) of any assets, categories of assets, operations or categories of operations of
the Shareholder or any of its Affiliates, (B)&nbsp;the discontinuation of any product or service of the Shareholder or any of its Affiliates, or (C)&nbsp;the imposition of any limitation or regulation on the ability of the Shareholder or any of its
Affiliates to freely conduct their business or own their respective assets. The Shareholder shall promptly inform the Company and MAAC of any communication received by the Shareholder from any Governmental Entity regarding the Shareholder PIPE
Subscription. The Shareholder shall give the Company and its counsel, and MAAC and its counsel, a reasonable opportunity to review in advance, and consider in good faith the views thereof in connection with, any proposed written communication to any
Governmental Entity relating to the Shareholder PIPE Subscription. The Shareholder agrees not to participate in any substantive meeting or discussion, either in person or by telephone with any Governmental Entity in connection with the Shareholder
PIPE Subscription unless it consults with the Company and MAAC in advance and, to the extent not prohibited by such Governmental Entity, gives the Company and MAAC the opportunity to attend and participate in such meeting or discussion. For the
avoidance of doubt, it is hereby acknowledged and agreed that nothing in this Agreement shall limit the conditions set forth in Section&nbsp;3(a) and 3(c) of the PIPE Subscription Agreement entered into in connection with the Shareholder PIPE
Subscription.]<SUP STYLE="font-size:85%; vertical-align:top">4</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) [The Shareholder agrees not to participate in any Piggyback
Registration (as defined in the Registration Rights Agreement) pursuant to Section&nbsp;2 of the Registration Rights Agreement during the Holdback Period (as defined in the Registration Rights Agreement).]<SUP
STYLE="font-size:85%; vertical-align:top">5</SUP> </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Note to Draft</B>: To be included for the Founder. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Note to Draft</B>: To be included for Shareholders whose participation in the PIPE Financing requires an HSR
filing or other governmental approvals. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">5</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Note to Draft</B>: To be included for the Founder and Matthew Gline. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The Shareholder acknowledges and agrees that MAAC and the Company are entering into the
Business Combination Agreement in reliance upon the Shareholder entering into this Agreement and agreeing to be bound by, and perform, or otherwise comply with, as applicable, the agreements, covenants and obligations contained in this Agreement
and, but for the Shareholder entering into this Agreement and agreeing to be bound by, and perform, or otherwise comply with, as applicable, the agreements, covenants and obligations contained in this Agreement, MAAC and the Company would not have
entered into or agreed to consummate the transactions contemplated by the Business Combination Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Shareholder
Representations and Warranties</U>. The Shareholder represents and warrants to MAAC as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If the Shareholder is not an
individual, the Shareholder is a corporation, limited liability company or other applicable business entity duly organized or formed, as applicable, validly existing and in good standing (or the equivalent thereof, if applicable, in each case, with
respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof) under the Laws of its jurisdiction of formation or organization (as applicable). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Shareholder (if not an individual) has the requisite corporate, limited liability company or other similar power and authority and, if
the Shareholder is an individual, legal capacity to execute and deliver this Agreement, to perform his, her or its covenants, agreements and obligations hereunder (including, for the avoidance of doubt, those covenants, agreements and obligations
hereunder that relate to the provisions of the Business Combination Agreement), and to consummate the transactions contemplated hereby. The execution and delivery of this Agreement has been duly authorized by all necessary corporate or other action
on the part of the Shareholder. This Agreement has been duly and validly executed and delivered by the Shareholder and constitutes a valid, legal and binding agreement of the Shareholder (assuming that this Agreement is duly authorized, executed and
delivered by MAAC and the Company), enforceable against the Shareholder in accordance with its terms (subject to applicable bankruptcy, insolvency, reorganization, moratorium or other Laws affecting generally the enforcement of creditors&#146;
rights and subject to general principles of equity). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) No consent, approval or authorization of, or designation, declaration or filing
with, any Governmental Entity is required on the part of the Shareholder with respect to the Shareholder&#146;s execution, delivery or performance of his, her or its covenants, agreements or obligations under this Agreement (including, for the
avoidance of doubt, those covenants, agreements and obligations under this Agreement that relate to the provisions of the Business Combination Agreement) or the consummation of the transactions contemplated hereby, except for any consents,
approvals, authorizations, designations, declarations, waivers or filings, the absence of which would not reasonably be expected to adversely affect the ability of the Shareholder to perform, or otherwise comply with, any of his, her or its
covenants, agreements or obligations hereunder in any material respect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Subject to the due execution and delivery of the Company
Shareholder Written Consent and that certain Large Lot Shareholders&#146; Consent and Waiver and Founder&#146;s Waiver relating to the transactions contemplated by the Business Combination Agreement on or prior to the date hereof, none of the
execution or delivery of this Agreement by the Shareholder, the performance by the Shareholder of any of his, her or its covenants, agreements or obligations under this Agreement (including, for the avoidance of doubt, those covenants, agreements
and obligations under this Agreement that relate to the provisions of the Business Combination Agreement) or the consummation of the transactions contemplated hereby will, directly or indirectly (with or without due notice or lapse of time or
both)&nbsp;(i) if the Shareholder is not an individual, result in any breach of any provision of the Shareholder&#146;s Governing Documents, (ii)&nbsp;result in a violation or breach of, or constitute a default or give rise to any right of
termination, Consent, cancellation, amendment, modification, suspension, revocation or acceleration under, any of the terms, conditions or provisions of any Contract to which the Shareholder is a party, (iii)&nbsp;violate, or constitute a breach
under, any Order or applicable Law to which the Shareholder or any of his, her or its properties or assets are bound or (iv)&nbsp;result in the creation of any Lien upon </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Subject Company Shares (other than as expressly provided under this Agreement), except, in the case of any of <U>clauses</U><U></U><U>&nbsp;(ii)</U> and <U>(iii)</U>&nbsp;above, as would not
reasonably be expected to adversely affect the ability of the Shareholder to perform, or otherwise comply with, any of his, her or its covenants, agreements or obligations hereunder in any material respect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Shareholder is, as of the date hereof, the record and beneficial owner of the Company
<FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares set forth on <U>Schedule A</U> hereto. The Shareholder has the sole right to vote (and provide consent in respect of, as applicable) the Subject Company Shares and, except for this
Agreement, the Business Combination Agreement and the Company Shareholders Agreement, the Shareholder is not party to or bound by (i)&nbsp;any option, warrant, purchase right or other Contract that would reasonably be expected (either alone or in
connection with one or more events, developments or events (including the satisfaction or waiver of any conditions precedent)) to require the Shareholder to Transfer any of the Subject Company Shares or (ii)&nbsp;any voting trust, proxy or other
Contract with respect to the voting or Transfer of any of the Subject Company Shares (other than the Company Shareholders Agreement and the other Governing Documents of the Company) that would reasonably be expected to adversely affect the ability
of the Shareholder to perform, or otherwise comply with, any of his, her or its covenants, agreements or obligations hereunder in any material respect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) There is no Proceeding pending or, to the Shareholder&#146;s knowledge, threatened against or involving the Shareholder or any of his, her
or its Affiliates that, if adversely decided or resolved, would reasonably be expected to adversely affect the ability of the Shareholder to perform, or otherwise comply with, any of its covenants, agreements or obligations under this Agreement in
any material respect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) The Shareholder, on his, her or its own behalf and on behalf of his, her or its Representatives, acknowledges,
represents, warrants and agrees that he, she or it has conducted his, her or its own independent review and analysis of, and, based thereon, has formed an independent judgment concerning, the business, assets, condition, operations and prospects of,
MAAC and the transactions contemplated by this Agreement, the Business Combination Agreement and the other applicable Ancillary Documents to which he, she or it is or will be a party as he, she or it and his, her or its Representatives have deemed
necessary to enable him, her or it to make an informed decision with respect to the execution, delivery and performance of this Agreement or the other Ancillary Documents to which he, she or it is or will be a party and the transactions contemplated
hereby and thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) In entering into this Agreement and the other Ancillary Documents to which he, she or it is or will be a party,
the Shareholder has relied solely on his, her or its own investigation and analysis and the representations and warranties expressly set forth in the Ancillary Documents to which he, she or it is or will be a party (including the PIPE Subscription
Agreement entered into by and among the Shareholder, the Company and MAAC on the date hereof, if applicable) and no other representations or warranties of MAAC, the Company or any other Person, either express or implied, and the Shareholder, on his,
her or its own behalf and on behalf of his, her or its Representatives, acknowledges, represents, warrants and agrees that, except for the representations and warranties expressly set forth in this Agreement or in the other Ancillary Documents to
which he, she or it is or will be a party (including the PIPE Subscription Agreement entered into by and among the Shareholder, the Company and MAAC on the date hereof, if applicable), none of MAAC, the Company or any other Person makes or has made
any representation or warranty, either express or implied, to the Shareholder in connection with or related to this Agreement, the Business Combination Agreement or the other Ancillary Documents or the transactions contemplated hereby or thereby.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Company and MAAC Acknowledgement</U>. In entering into this Agreement, the Business Combination Agreement and the other Ancillary
Documents to it is or will be a party, each of the Company and MAAC have not relied on any representations or warranties of the Shareholder, either express or implied, except for the representations and warranties of the Shareholder expressly set
forth in this Agreement or in the other Ancillary Documents to which he, she or it is or will be a party (including the PIPE Subscription Agreement entered into by and among the Shareholder, the Company and MAAC on the date hereof, if applicable).
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Transfer of Subject Securities</U>. From and after the date hereof and until the
earlier of (A)&nbsp;the termination of this Agreement in accordance with its terms and (B)<U></U> the Effective Time, the Shareholder agrees not to (a)<U></U>&nbsp;Transfer any of the Subject Company Shares, (b)<U></U>&nbsp;enter into
(i)<U></U>&nbsp;any option, warrant, purchase right, or other Contract that would reasonably be expected (either alone or in connection with one or more events, developments or events (including the satisfaction or waiver of any conditions
precedent)) to require the Shareholder to Transfer the Subject Company Shares or (ii)<U></U>&nbsp;any voting trust, proxy or other Contract with respect to the voting or Transfer of the Subject Company Shares, or (c)<U></U>&nbsp;take any actions in
furtherance of any of the matters described in the foregoing <U>clauses (a)</U><U></U>&nbsp;or <U>(b)</U>, unless, in the case of clauses (a)<U></U>&nbsp;through (c), the Shareholder causes any transferee of any such Transfer to enter into a written
agreement in form and substance reasonably satisfactory to MAAC and the Company agreeing to be bound by this Agreement (which will include, for the avoidance of doubt, all of the covenants, agreements and obligations of the Shareholder hereunder and
the making of all the representations and warranties of the Shareholder set forth in <U>Section&nbsp;3</U> with respect to such transferee and his, her or its Subject Company Shares received upon such Transfer, as applicable) prior and as a
condition to the occurrence of such Transfer; <I>provided</I> that, if the Shareholder is not an individual, a Transfer of securities in the Shareholder by an equityholder of the Shareholder shall not require the transferee to enter into such
written agreement so long as (x)<U></U>&nbsp;following such Transfer, the Shareholder continues to hold the Subject Company Shares and to have the exclusive right to vote and to take all other actions related to the ownership of the Subject Company
Shares without restriction and (y)<U></U>&nbsp;such Transfer would otherwise be permitted under the Shareholders Agreement. For purposes of this Agreement, &#147;<U>Transfer</U>&#148; means any direct or indirect sale, transfer, assignment, pledge,
mortgage, exchange, hypothecation, grant of a security interest in or disposition or encumbrance of an interest (whether with or without consideration, whether voluntarily or involuntarily or by operation of law or otherwise). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Termination</U>. This Agreement shall automatically terminate, without any notice or other action by any Party, and be void <I>ab
initio</I> upon the earlier of (a)&nbsp;the Effective Time and (b)&nbsp;the termination of the Business Combination Agreement in accordance with its terms. Upon termination of this Agreement as provided in the immediately preceding sentence, none of
the Parties shall have any further obligations or Liabilities under, or with respect to, this Agreement. Notwithstanding the foregoing or anything to the contrary in this Agreement, (i)&nbsp;the termination of this Agreement pursuant to <U>clause
(b)</U>&nbsp;of this <U>Section</U><U></U><U>&nbsp;6</U> shall not affect any Liability on the part of any Party for a Willful Breach of any covenant or agreement set forth in this Agreement prior to such termination or Fraud,
(ii)&nbsp;<U>Section&nbsp;2(b)</U>, <U>Section</U><U></U><U>&nbsp;2(c)</U> and the representations and warranties set forth in <U>Sections 3(g)</U> and <U>(h)</U>&nbsp;shall each survive any termination of this Agreement,
(iii)<U>&nbsp;Section</U><U></U><U>&nbsp;2(d)</U> (solely to the extent that it relates to <U>Section</U><U>&nbsp;8.18</U> (Trust Account Waiver) of the Business Combination Agreement) shall survive any termination of this Agreement pursuant to
<U>Section</U><U></U><U>&nbsp;6(b)</U> and (iv)&nbsp;this <U>Section</U><U></U><U>&nbsp;6</U> and <U>Sections 8</U>, <U>9</U>, <U>10</U>, <U>11</U>, <U>12</U>, <U>13</U>, <U>14</U> and <U>15</U> shall survive any termination of this Agreement. For
purposes of this <U>Section</U><U></U><U>&nbsp;6</U>, (x) &#147;<U>Willful Breach</U>&#148; means a material breach of this Agreement that is a consequence of an act or a failure to act by the breaching Party with the knowledge that the taking of
such act or such failure to act would, or would reasonably be expected to, constitute or result in a breach of this Agreement and (y) &#147;<U>Fraud</U>&#148; means an act or omission by a Party, and requires: (A)&nbsp;a false or incorrect
representation or warranty expressly set made by such Party in this Agreement, (B)&nbsp;with actual knowledge (as opposed to constructive, imputed or implied knowledge) by the Party making such representation or warranty that such representation or
warranty expressly set forth in this Agreement is false or incorrect, (C)&nbsp;an intention to deceive another Party, to induce him, her or it to enter into this Agreement, (D)&nbsp;another Party, in justifiable or reasonable reliance upon such
false or incorrect representation or warranty expressly set forth in this Agreement, causing such Party entering into this Agreement, and (E)&nbsp;another Party suffering damage by reason of such reliance. For the avoidance of doubt,
&#147;Fraud&#148; does not include any claim for equitable fraud, promissory fraud, unfair dealings fraud or any torts (including a claim for fraud or alleged fraud) based on negligence or recklessness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Fiduciary Duties</U>. Notwithstanding anything in this Agreement to the contrary, (a)<U></U>&nbsp;the Shareholder makes no agreement or
understanding herein in any capacity other than in such Shareholder&#146;s capacity as a record holder and beneficial owner of the Subject Company Shares and, (i.e., if such Shareholder is an individual, not in such Shareholder&#146;s capacity as a
director, officer or employee of any Group Company or in such Shareholder&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
capacity as a trustee or fiduciary of any Company Equity Plan, as applicable), and (b)<U></U>&nbsp;nothing herein will be construed to limit or affect any action or inaction by such Shareholder
if such Shareholder is an individual, or, if such Shareholder is not an individual, any representative of such Shareholder serving as a member of the board of directors of any Group Company or as an officer, employee or fiduciary of any Group
Company or any Company Equity Plan, in each case, acting in such person&#146;s capacity as a director, officer, employee or fiduciary of such Group Company or any Company Equity Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Notices</U>. All notices, requests, claims, demands and other communications hereunder shall be in writing and shall be given (and shall
be deemed to have been duly given) by delivery in person, by e-mail (having obtained electronic delivery confirmation thereof (i.e., an electronic record of the sender that the email was sent to the intended recipient thereof without an
&#147;error&#148; or similar message that such email was not received by such intended recipient)), or by registered or certified mail (postage prepaid, return receipt requested) (upon receipt thereof) to the other Parties as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to MAAC, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c/o Patient Square Capital </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">724 Oak Grove, Suite 130 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Menlo Park, California 94025 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: &nbsp;&nbsp;&nbsp;&nbsp;Maria Walker </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;maria@patientsquarecapital.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Kirkland&nbsp;&amp; Ellis LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">601 Lexington Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, NY 10022 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: &nbsp;&nbsp;&nbsp;&nbsp;Michael Weisser, P.C.; Ryan Brissette </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;michael.weisser@kirkland.com; ryan.brissette@kirkland.com
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to the Company, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roivant Sciences Ltd. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Suite 1, 3rd Floor, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">11-12</FONT> St. James&#146;s Square, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">London SW1Y 4LB, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">United Kingdom </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: &nbsp;&nbsp;&nbsp;&nbsp;Matthew Gline </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;matthew.gline@roivant.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;legalnotices@roivant.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Davis Polk&nbsp;&amp; Wardwell LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">450 Lexington Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, NY 10017 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: &nbsp;&nbsp;&nbsp;&nbsp;Derek Dostal; Lee Hochbaum; Brian Wolfe </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;derek.dostal@davispolk.com; lee.hochbaum@davispolk.com; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;brian.wolfe@davispolk.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to the Shareholder, to the address on the Shareholder&#146;s signature page hereto or to an address of such Shareholder in the books and
records of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address as the Party to whom notice is given may have previously furnished to the others in writing in the
manner set forth above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Entire Agreement</U>. This Agreement, the Business Combination Agreement and documents
referred to herein and therein (including the Ancillary Documents) constitute the entire agreement of the Parties with respect to the subject matter of this Agreement, and supersede all prior agreements and undertakings, both written and oral, among
the Parties with respect to the subject matter of this Agreement, except as otherwise expressly provided in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.
<U>Amendments and Waivers; Assignment</U>. Any provision of this Agreement may be amended or waived if, and only if, such amendment or waiver is in writing and signed by the Shareholder, the Company and MAAC. Notwithstanding the foregoing, no
failure or delay by any Party in exercising any right hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise of any other right hereunder. Neither this Agreement nor any of
the rights, interests or obligations hereunder shall be assignable by the Shareholder or the Company without MAAC&#146;s prior written consent (to be withheld or given in its sole discretion) or by MAAC without the Company&#146;s prior written
consent (to be withheld or given in its sole discretion). Any attempted assignment of this Agreement not in accordance with the terms of this Section<U></U>&nbsp;10 shall be null and void <I>ab initio</I><U>.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Fees and Expenses</U>. Except, in the case of MAAC and the Company, as otherwise expressly set forth in the Business Combination
Agreement, all fees and expenses incurred in connection with this Agreement and the transactions contemplated hereby, including the fees and disbursements of counsel, financial advisors and accountants, shall be paid by the Party incurring such fees
or expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>No Third Party Beneficiaries</U>. This Agreement shall be for the sole benefit of the Parties and their respective
successors and permitted assigns and is not intended, nor shall be construed, to give any Person, other than the Parties and their respective successors and permitted assigns, any legal or equitable right, benefit or remedy of any nature whatsoever
by reason this Agreement. Nothing in this Agreement, expressed or implied, is intended to, or shall be deemed to, create a joint venture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Miscellaneous</U>. <U>Sections 8.5</U> (Governing Law), <U>8.7</U> (Construction; Interpretation), <U>8.10</U> (Severability),
<U>8.11</U> (Counterparts; Electronic Signatures), <U>8.15</U> (Waiver of Jury Trial), <U>8.16</U> (Submission to Jurisdiction) and <U>8.17</U> (Remedies) of the Business Combination Agreement are incorporated herein by reference and shall apply to
this Agreement, <I>mutatis mutandis</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>No Ownership Interest</U>. Nothing contained in this Agreement will be deemed to vest in
MAAC or any MAAC <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate any direct or indirect ownership or incidents of ownership of or with respect to the Subject Company Shares. All rights, ownership and economic benefits of and relating to
the Subject Company Shares shall remain vested in and belong to the Shareholder, and MAAC (and each MAAC Non-Party Affiliate) shall have no authority to manage, direct, superintend, restrict, regulate, govern or administer any of the policies or
operations of Company or exercise any power or authority to direct Shareholder in the voting of any of the Subject Company Shares, except as otherwise expressly provided herein with respect to the Subject Company Shares. Except as otherwise set
forth in <U>Section&nbsp;1</U>, the Shareholder shall not be restricted from voting in favor of, against or abstaining with respect to any other matters presented to the stockholders of the Company. Without limiting the foregoing, nothing in this
Agreement shall obligate or require the Shareholder to exercise an option to purchase any Company Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature page follows]
</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed and delivered this Transaction Support
Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MONTES ARCHIMEDES ACQUISITION CORP.</B></TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ROIVANT SCIENCES LTD.</B></TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Transaction Support Agreement] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed and delivered this Transaction Support
Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>[SHAREHOLDER(S)]</B></TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Transaction Support Agreement] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE A<SUP STYLE="font-size:85%; vertical-align:top">6</SUP> </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Class/Series of Securities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of Shares</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT><BR>Common Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#149;]</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">6</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Note to Draft</B>: Company to complete for each Company Shareholder. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company Shareholders Agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><A NAME="rom65062_43"></A>ANNEX E &#150; SPONSOR SUPPORT AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPONSOR SUPPORT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>SPONSOR SUPPORT AGREEMENT</B> (this &#147;<U>Agreement</U>&#148;) is entered into as of May 1, 2021, by and among Roivant Sciences
Ltd., a Bermuda exempted limited company (the&nbsp;&#147;<U>Company</U>&#148;), Montes Archimedes Acquisition Corp., a Delaware corporation (&#147;<U>MAAC</U>&#148;), Patient Square Capital LLC, a Delaware limited liability company (the
&#147;<U>MAAC Sponsor</U>&#148;), and solely for purposes of <U>Sections 1(b)</U>, <U>1(d)</U>, <U>4</U>, <U>5</U>, <U>8(a)</U> and <U>(b)</U>, <U>9</U> (solely for purposes of his or her representations or warranties therein), <U>10</U> through
<U>13</U> and <U>14</U> through <U>23</U> (to the extent related to the foregoing sections) the Insiders (as defined below). Each of the Company, MAAC, the MAAC Sponsor and each of the Insiders are sometimes referred to herein individually as a
&#147;<U>Party</U>&#148; and collectively as the &#147;<U>Parties</U>.&#148; Each of the MAAC Sponsor and each of the Insiders are sometimes referred to herein individually as a &#147;<U>Shareholder</U>.&#148; Except as otherwise specified herein,
capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Business Combination Agreement (as defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, concurrently with the execution of this Agreement, MAAC, the Company and Rhine Merger Sub, Inc., a Delaware corporation and a
wholly owned subsidiary of the Company (&#147;<U>Merger Sub</U>&#148;), entered into that certain Business Combination Agreement (as amended, supplemented or otherwise modified from time to time in accordance with its terms, the &#147;<U>Business
Combination Agreement</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Business Combination Agreement contemplates that, on the terms and subject to the
conditions therein, (a)&nbsp;on the Closing Date prior to the Closing, the Company will consummate the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps, and (b)&nbsp;on the Closing Date promptly following consummation of the Company
<FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps, Merger Sub will merge with and into MAAC (the &#147;<U>Merger</U>&#148;), with MAAC as the surviving corporation in the Merger and, after giving effect to such Merger, becoming a
wholly-owned Subsidiary of the Company (collectively, and together with the other transactions contemplated by the Business Combination Agreement and the Ancillary Documents, the &#147;<U>Transactions</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, reference is hereby made to the following Contracts (collectively, the &#147;<U>Affected Agreements</U>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(A) that certain Letter Agreement dated October&nbsp;6, 2020 and delivered by the MAAC Sponsor to MAAC (the &#147;<U>Sponsor Letter</U>&#148;);
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(B) those certain Letter Agreements, dated October&nbsp;6, 2020, and delivered by each of George Barrett, James Momtazee, Maria Walker
and Stephen Oesterle (each, an &#147;<U>Insider</U>&#148; and, collectively, the &#147;<U>Insiders</U>&#148;) to MAAC (each, an &#147;<U>Insider Letter</U>&#148; and, collectively, the &#147;<U>Insider Letters</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(C) that certain Warrant Agreement dated October&nbsp;6, 2020 between MAAC and Continental Stock Transfer&nbsp;&amp; Trust Company, a New York
corporation, as warrant agent (the &#147;<U>Warrant Agent</U>&#148;) (the &#147;<U>Warrant Agreement</U>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(D) that certain
Registration and Stockholder Rights Agreement dated October&nbsp;6, 2020 (the &#147;<U>MAAC Registration Rights Agreement</U>&#148;) by and among MAAC, the MAAC Sponsor and each of the other Holders (as such term is defined therein). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, as of the date hereof, each Shareholder, in its respective capacity as such, is the holder of record and the &#147;beneficial
owner&#148; (within the meaning of Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) of (i)&nbsp;the number of MAAC Class&nbsp;A Shares, (ii)&nbsp;private placement warrants (the &#147;<U>Warrants</U>&#148;) to purchase an
aggregate number of MAAC Class&nbsp;A Shares and/or (iii)&nbsp;the number of MAAC Class&nbsp;B Shares, in each case, set forth on <U>Exhibit</U><U></U><U>&nbsp;A</U> attached hereto opposite such person&#146;s name on such Exhibit (collectively,
with respect to each Shareholder, the &#147;<U>Subject Company Securities</U>&#148;); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, as part of the Transactions, each of the MAAC Class&nbsp;A Shares and the
MAAC Class&nbsp;B Shares will be converted into Company Post-Closing Common Shares on the terms and conditions set forth in the Business Combination Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, in connection with the Transactions, and concurrently with the execution of this Agreement and the Business Combination
Agreement, (a)&nbsp;the Company and the MAAC Sponsor entered into that certain <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement (as amended, supplemented or otherwise modified from time to time in accordance with its terms, the
&#147;<U>Sponsor <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</U>&#148;), and (b)&nbsp;the Company, on the one hand, and certain Company Shareholders, on the other hand, entered into those certain
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements (as amended, supplemented or otherwise modified from time to time in accordance with their applicable terms, collectively, the &#147;<U>Significant Company Shareholder <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</U>&#148; and, together with the Sponsor <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, collectively, the &#147;<U><FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreements</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, in consideration for the benefits to be received by the MAAC Sponsor and each of the Insiders
under the terms of the Business Combination Agreement and as a material inducement to the Company and MAAC agreeing to enter into and consummate the transactions contemplated by the Business Combination Agreement, the MAAC Sponsor and each of the
Insiders agrees to enter into this Agreement and to be bound by the applicable agreements, covenants and obligations contained in this Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Parties acknowledge and agree that the Company and MAAC would not have entered into and agreed to consummate the
transactions contemplated by the Business Combination Agreement without each of the Shareholders entering into this Agreement and agreeing to be bound by the applicable agreements, covenants and obligations contained in this Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW,
THEREFORE</B>, in consideration of the premises and the mutual promises set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, each intending to be legally bound,
hereby agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Sponsor Letter and Insider Letters</U>. The Company, MAAC, the MAAC Sponsor (in the case of clauses (a),
(b), (c) and (e)) and each Insider (in the case of clauses (b)&nbsp;and (d), as it relates to the Insider Letter to which he or she is a party) hereby agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Sponsor Letter provides in Section&nbsp;1 thereof that MAAC shall not enter into a definitive agreement regarding a Business
Combination (as defined therein) without the prior written consent of the MAAC Sponsor. The Transactions constitute a Business Combination for purposes of the Sponsor Letter and the MAAC Sponsor hereby consents to entry into the Business Combination
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Sponsor Letter provides in Section&nbsp;2 thereof, and each Insider Letter provides in Section&nbsp;1 thereof, for
certain requirements of the MAAC Sponsor and the Insiders in respect of a Business Combination (in each case, as defined therein), including in respect of voting all MAAC Shares beneficially owned by the MAAC Sponsor and by the Insiders, as
applicable, in favor of such Business Combinations and forgoing redemption rights in respect thereof. The Transactions constitute a Business Combination for purposes of the Sponsor Letter and each Insider Letter and the MAAC Sponsor and each Insider
will comply with its, his or her respective obligations under Section&nbsp;2 of the Sponsor Letter or Section&nbsp;1 of its, his or her Insider Letter, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Subject to, and conditioned upon the occurrence and effective as of, the Effective Time,&nbsp;Section 6 of the Sponsor Letter shall be
amended and restated to provide in its entirety as follows: &#147;[Reserved].&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Subject to, and conditioned upon the occurrence
and effective as of, the Effective Time,&nbsp;Section 5 of each Insider Letter shall be amended and restated to provide in its entirety as follows: &#147;[Reserved].&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Section 7 of the Sponsor Letter is hereby amended and restated to provide in its
entirety as follows: &#147;[Reserved].&#148; For the avoidance of doubt, if the Business Combination Agreement is terminated in accordance with its terms, then this clause (e) (and the amendment and restatement contemplated by this clause (e)) shall
be of no further force and effect and Section&nbsp;7 shall be reinstated and effective from and after such time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U><FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Shares</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to, and conditioned upon the occurrence of and effective immediately
after the Effective Time, (i) 20% of the number of Company Post-Closing Common Shares issued to the MAAC Sponsor upon the conversion of MAAC Class&nbsp;B Shares (rounded up to the nearest whole share) shall be subject to the provisions set forth
below in this<U>&nbsp;Section</U><U></U><U>&nbsp;2</U> (such Company Post-Closing Common Shares, the &#147;<U>20% Earn</U><U><FONT STYLE="white-space:nowrap">-Out</FONT> Shares</U>&#148;), (ii) 10% of the number of Company Post-Closing Common Shares
issued to the MAAC Sponsor upon the conversion of MAAC Class&nbsp;B Shares (rounded up to the nearest whole share) shall be subject to the provisions set forth below in this<U>&nbsp;Section</U><U></U><U>&nbsp;2</U> (such Company Post-Closing Common
Shares, the &#147;<U>10% Earn</U><U><FONT STYLE="white-space:nowrap">-Out</FONT> Shares</U>&#148; and, together with the 20% <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares, the &#147;<U><FONT STYLE="white-space:nowrap">Earn-Out</FONT>
Shares</U>&#148;) and (iii)&nbsp;the remaining 70% of the number of Company Post-Closing Common Shares issued to the MAAC Sponsor upon the conversion of MAAC Class&nbsp;B Shares (rounded down to the nearest whole share) shall not be subject to the
provisions set forth below in this<U>&nbsp;Section</U><U></U><U>&nbsp;2</U> (such Company Post-Closing Common Shares, the &#147;<U>Retained Shares</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Subject to, and conditioned upon the occurrence of and effective immediately after the Effective Time, the
<FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares shall be unvested and subject to the restrictions and forfeiture provisions set forth in this <U>Section</U><U></U><U>&nbsp;2</U>. The <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares
shall vest and become free of the provisions set forth in this <U>Section</U><U></U><U>&nbsp;2</U> at such time as the Stock Price (as defined below) of Company Post-Closing Common Shares equals or exceeds (x)&nbsp;with respect to the 20% <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Shares, $15.00 per share (the &#147;<U>20% Trigger Price</U>&#148;), and (y)&nbsp;with respect to the 10% <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares, $20.00 per share (the &#147;<U>10% Trigger
Price</U>&#148; and, together with the 20% Trigger Price, the &#147;<U>Trigger Price</U>&#148;), in each case, for any 20 Trading Days within any 30 Trading Day period commencing no earlier than the Closing Date and ending no later than the fifth
(5th) anniversary of the Closing Date (the &#147;<U><FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date</U>&#148;); <U>provided</U>, <U>however</U>, that (i)&nbsp;if the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date occurs on a day
that is not a Trading Day, then the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date shall be deemed to occur on the next following Trading Day, and (ii)&nbsp;if the Company or any of its Affiliates enters into a definitive agreement with
respect to a Sale (as defined below) on or prior to the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date, then the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date shall be automatically extended and shall be deemed to occur on the
earlier of (A)&nbsp;the day after such Sale is consummated and (B)&nbsp;the termination of such definitive agreement with respect to such Sale in accordance with its terms. Any <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares that have not
vested in accordance with this <U>Section</U><U></U><U>&nbsp;2(b)</U> or <U>Section</U><U></U><U>&nbsp;2(c</U>) on or before the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date will be immediately forfeited at 11:59 p.m., New York, New
York time on the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In the event of a Sale (as defined below) on or prior to
the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date, any unvested <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares will fully vest and become free of the restrictions set forth in this <U>Section</U><U></U><U>&nbsp;2</U> as of
immediately prior to the closing of such Sale. For purposes of this Agreement, &#147;<U>Sale</U>&#148; means (A)&nbsp;a purchase, sale, exchange, merger, business combination or other transaction or series of related transactions in which
substantially all of the Company Post-Closing Common Shares are, directly or indirectly, converted into cash, securities or other property or <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration (other than, in the case of this clause (A),
any transaction in which the holders of Company Post-Closing Common Shares as of immediately prior to the consummation of such transaction continue to own all or substantially all of the equity securities of the Company (or any successor or parent
entity of the Company) immediately following the consummation of such transaction), (B) a direct or indirect sale, lease, exchange or other transfer (regardless of the form of the transaction) in one transaction or a series of related transactions
of a majority of the Company&#146;s assets, as determined on a consolidated basis, to a third party or third parties acting as a &#147;group&#148; (as defined in Section&nbsp;13(d)(3) of the Exchange Act) or (C)&nbsp;any transaction or series of
transactions that results, directly or indirectly, in the shareholders of the Company as of immediately prior to such transactions holding, in the aggregate, less than fifty percent (50%) of the voting Equity Securities of the Company (or any
successor or parent company of the Company) immediately after the consummation thereof (excluding, for the avoidance of doubt, any <FONT STYLE="white-space:nowrap">Earn-out</FONT> Shares) (in the case of each of clause (A), (B) or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(C), whether by amalgamation, merger, consolidation, arrangement, tender offer, recapitalization, purchase, issuance, sale or transfer of Equity Securities or assets or otherwise). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The MAAC Sponsor agrees that it shall not engage in any Sale Transaction (as defined in the Sponsor
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement) with respect to any <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares until such time as the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares have vested pursuant to
<U>Section</U><U></U><U>&nbsp;2(b)</U> or <U>Section</U><U></U><U>&nbsp;2(c)</U>. Notwithstanding the foregoing or anything to the contrary herein, (i)&nbsp;the MAAC Sponsor (and, for the avoidance of doubt, any permitted transferees pursuant to
this clause (i)) may transfer all or any of the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares in any transfer of the type described in Sections 1(b)(iv)(A) through (C)&nbsp;or (F) of the Sponsor
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, <U>provided</U> that, in the case of a transfer of the type described in clauses (A)&nbsp;through (C), the transferee shall, in addition to any requirements in the Sponsor <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, agree in writing that he, she or it is receiving and holding such <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares subject to the provisions of this <U>Section</U><U></U><U>&nbsp;2</U> and
(ii)&nbsp;from and after a transfer pursuant to clause (i)&nbsp;of this sentence, all references to the MAAC Sponsor in this <U>Section</U><U></U><U>&nbsp;2</U> and <U>Section</U><U></U><U>&nbsp;7</U> shall include such transferee and shall
collectively mean the MAAC Sponsor (to the extent that it then holds <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares) and each permitted transferee of <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares pursuant to clause (i)&nbsp;of
this sentence (in each case, to the extent he, she or it then holds <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares). Each transferee of <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares pursuant to clause (i)&nbsp;of the preceding
sentence shall be a third party beneficiary of this <U>Section</U><U></U><U>&nbsp;2</U> and <U>Section</U><U></U><U>&nbsp;7</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) As
used herein, &#147;<U>Stock Price</U>&#148; means, on any date on or after the Closing and on or prior to the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date, the closing sale price per share of Company Post-Closing Common Shares reported
as of 4:00 p.m., New York, New York time on such date by Bloomberg, or if not available on Bloomberg, as reported by or an authoritative source generally used for such purposes and selected by the Company, and &#147;<U>Trading Day</U>&#148; means
any day on which trading is generally conducted on Nasdaq or any other exchange on which the Company Post-Closing Common Shares are traded on or after the Closing and on or prior to the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date. The <FONT
STYLE="white-space:nowrap">Earn-out</FONT> Shares and the applicable Trigger Price (and all references to Company Post-Closing Common Shares and each of the foregoing in this Agreement) shall each be adjusted appropriately to reflect the effect of
any stock split, reverse stock split, stock dividend (including any dividend or other distribution of securities convertible into Company Post-Closing Common Shares), reorganization, recapitalization, reclassification, combination, exchange of
shares or other like change with respect to the Company Post-Closing Common Shares (or any other Equity Securities into which they are adjusted pursuant to this <U>Section</U><U></U><U>&nbsp;2(e)</U>) at any time prior to the vesting of the <FONT
STYLE="white-space:nowrap">Earn-out</FONT> Shares pursuant to this <U>Section</U><U></U><U>&nbsp;2</U> so as to provide the holders of the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares with the same economic effect as contemplated by this
<U>Section</U><U></U><U>&nbsp;2</U> prior to such event and as so adjusted shall, from and after the date of such event, be the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares and the 20% Trigger Price or the 10% Trigger Price, as
applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The Company shall use reasonable best efforts to remain listed as a public company on, and for the <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Shares to be tradable over, Nasdaq or any other nationally recognized U.S. stock exchange; <U>provided</U>, <U>however</U>, the foregoing shall not limit the Company or any of its Affiliates from
consummating a Sale or entering into a definitive agreement that contemplates a Sale. Subject to <U>Section</U><U></U><U>&nbsp;2(c)</U> and the other applicable provisions of this <U>Section</U><U></U><U>&nbsp;2</U>, upon the consummation of Sale
the Company shall have no further obligations under this <U>Section</U><U></U><U>&nbsp;2(f)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) At the time that the <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Shares become vested pursuant to this <U>Section</U><U></U><U>&nbsp;2</U>, the Company shall remove any legends, stock transfer restrictions, stop transfer orders or similar restrictions with respect to the
<FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares related to such vesting or this <U>Section</U><U></U><U>&nbsp;2</U> (other than, for the avoidance of doubt, those that relate to any applicable and then-existing
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period (as defined in the Sponsor <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement) with respect to such <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) For the avoidance of doubt, (i)&nbsp;the MAAC Sponsor shall retain all of its rights as a stockholder of the Company with respect to the <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Shares owned by it during any period of time that such shares are subject to restriction on transfer or sale hereunder, including the right to vote any such shares and the right to receive dividends and
other distributions with respect to such <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares prior to vesting (<U>provided</U> that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dividends and other distributions with respect to <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares that are subject to vesting and are unvested at the time of such dividend or distribution
shall be set aside by the Company and shall only be paid to such holders upon the vesting of such <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares (and, if any dividends or other distributions with respect to
<FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares are set aside and such <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares are subsequently forfeited pursuant to this <U>Section</U><U></U><U>&nbsp;2</U>, such set aside dividends or
distributions shall become the property of the Company)), (ii) any <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares that vest in accordance with the terms of this <U>Section</U><U></U><U>&nbsp;2</U> shall remain subject to any applicable <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period set forth in the Sponsor <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement and (iii)&nbsp;notwithstanding the expiration of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period with
respect to any <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares, such shares shall remain subject to any applicable restrictions set forth this <U>Section</U><U></U><U>&nbsp;2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The MAAC Sponsor intends to make a protective election under Section&nbsp;83(b) of the Code with respect to the <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) The Parties agree and acknowledge that the
<FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares are intended to constitute &#147;voting stock&#148; within the meaning of Section&nbsp;368(a)(1) of the Code and the Treasury Regulations promulgated thereunder received by MAAC Sponsor in
connection with the Merger, and shall file all Tax Returns consistent with, and take no position inconsistent with (whether in audits, Tax Returns or otherwise), such treatment unless (i)&nbsp;such Party requests that each of Kirkland&nbsp;&amp;
Ellis LLP and Davis Polk&nbsp;&amp; Wardwell LLP provides written confirmation to the effect that such treatment is more likely than not correct, and each such law firm fails to provide such confirmation prior to the later of (A)&nbsp;thirty (30)
days following such request is made and (B)&nbsp;sixty (60) days prior to the date on which the relevant Tax Return is due (taking into account applicable extensions); <U>provided</U> that the Parties shall provide customary factual representations
to such law firm; <U>provided</U>, <U>further</U>, that, for the avoidance of doubt, the Parties shall not be required to restructure, or otherwise alter the terms of, the transaction as provided for in this Agreement or the Business Combination
Agreement, or (ii)&nbsp;otherwise required by a final &#147;determination&#148; within the meaning of Section&nbsp;1313(a) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Sponsor Exchange Ratio</U>. For purposes of the Business Combination Agreement, the term &#147;<U>Sponsor Exchange Ratio</U>&#148; shall
mean: (i)&nbsp;one <I>minus</I> (ii)&nbsp;a number equal to (A) 0.5 <I>multiplied by</I> (B)&nbsp;a fraction equal to (x)&nbsp;the number of MAAC Class&nbsp;A Shares with respect to which a MAAC Shareholder Redemption has been exercised <I>divided
by</I> (y)&nbsp;the total number of MAAC Class&nbsp;A Shares outstanding as of the date hereof; <U>provided</U> that the number referenced in the foregoing clause (ii)&nbsp;shall not in any event be greater than 0.25. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Working Capital Loans; Related Party Agreements</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) With respect to any loan of funds made by the MAAC Sponsor or an Affiliate of the MAAC Sponsor or any of MAAC&#146;s officers or directors
(each, a &#147;<U>Lender</U>&#148;) to MAAC or any of its Subsidiaries, in each case, prior to the Closing (a &#147;<U>Working Capital Loan</U>&#148;) that is or may be convertible into warrants or other securities (derivative or otherwise) of MAAC
or the Company, MAAC, the MAAC Sponsor and the Insiders hereby agrees, and shall take such reasonably necessary or appropriate actions within its power so as to ensure, that each and any Working Capital Loan shall be repaid solely in cash, and that
no Working Capital Loan will be converted into warrants or other securities (derivative or otherwise) of MAAC or the Company, notwithstanding any applicable provisions of the Insider Letter, the Warrant Agreement, the MAAC Registration Rights
Agreement or any other Contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) MAAC and the MAAC Sponsor agree that, notwithstanding anything to the contrary in any such
agreement, (i)&nbsp;each of the agreements set forth on <U>Schedule</U><U></U><U>&nbsp;A</U> attached hereto shall be automatically terminated and of no further force and effect (including any provisions of any such agreement that, by its terms,
survive such termination), effective as of, and subject to and conditioned upon the occurrence of, the Closing and (ii)&nbsp;upon such termination, MAAC shall not have any further Liabilities under each such agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>MAAC Registration Rights Agreement</U>. Subject to, and conditioned upon the occurrence and effective as of the Effective Time, MAAC,
the MAAC Sponsor and each of the other Shareholders who are party to the MAAC Registration Rights Agreement agree that the MAAC Registration Rights Agreement is hereby terminated in its entirety, and shall be of no further force or effect from and
after such time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Anti-Dilution Adjustment Waiver</U>. Subject to, and conditioned upon the occurrence
of and effective as of immediately prior to the Effective Time, the MAAC Sponsor, which is the holder of at least a majority of the outstanding MAAC Class&nbsp;B Shares as of the date hereof, hereby waives on behalf of the holders of all MAAC
Class&nbsp;B Shares, pursuant to and in compliance with the provisions of the Amended and Restated Certificate of Incorporation of MAAC (the &#147;<U>MAAC Charter</U>&#148;), any adjustment to the conversion ratio set forth in Article Eighth of the
MAAC Charter, and any rights to other anti-dilution protections with respect to the MAAC Class&nbsp;B Shares, that may result from the PIPE Financing and/or the consummation of the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Registration Rights</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Capitalized terms used in this <U>Section</U><U></U><U>&nbsp;7</U> but not otherwise defined herein shall have the meanings ascribed to
them in the Registration Rights Agreement (as in effect as of the date hereof); <U>provided</U> that, for purposes of <U>Section</U><U></U><U>&nbsp;7</U>, (i) the term &#147;Registrable Securities&#148; shall be deemed to include the Common Shares
(including any Common Shares underlying any other securities of the Company or into which other securities of the Company are convertible into, exercisable or exchangeable for) held by or on behalf of the Shareholders as of immediately following the
Effective Time and (ii)&nbsp;the term &#147;Investor&#148; shall be deemed to include the MAAC Sponsor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company shall file within
thirty (30)&nbsp;days of the consummation of the Go Public Transaction, and use commercially reasonable efforts to cause to be declared effective as soon as practicable thereafter, a Resale <FONT STYLE="white-space:nowrap">S-1</FONT> Shelf or, if
the Company is eligible to use a Resale <FONT STYLE="white-space:nowrap">S-3</FONT> Shelf, in each case, covering the resale of all the Registrable Securities (determined as of two business days prior to such filing) and any other Common Shares or
other securities of the Company issued in connection with the Go Public Transaction (including any Common Shares underlying any other securities of the Company or into which other securities of the Company are convertible into, exercisable or
exchangeable for) the transfer or sale of which has not been registered under the Securities Act; <U>provided</U>, that the Company and the Shareholders acknowledge and agree that the sale of any Registrable Securities registered under such Resale
Shelf may be subject to restrictions imposed by the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements and/or applicable securities laws. Such Resale Shelf shall provide for the resale of the Registrable Securities included therein pursuant
to any method or combination of methods legally available to, and requested by, the MAAC Sponsor and any other Investor named therein. The MAAC Sponsor shall be entitled to the benefits of Section&nbsp;4 and the first, second and third sentences of
Section&nbsp;1(f)(ii), <I>mutatis mutandis</I>, under the Registration Rights Agreement with respect to its Common Shares or other securities of the Company and it shall not be subject to any &#147;cutback&#148; or other restriction in connection
with the inclusion of its Common Shares or other securities in any Resale Shelf. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The MAAC Sponsor will be offered an opportunity to
participate in (x)&nbsp;an offering and/or sale of Common Shares by any holder that is conducted as a block trade or underwritten basis (whether firm commitment or otherwise) without substantial marketing efforts prior to pricing, including, without
limitation, a same day trade, overnight trade or similar transaction or (y)&nbsp;an &#147;at the market&#148; or similar registered offering of the Covered Securities through a broker, sales agent or distribution agent, whether as agent or
principal. The rights of the MAAC Sponsor set forth in this <U>Section</U><U></U><U>&nbsp;7(c)</U> shall be substantially the same as those investors who are party to the Registration Rights Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Other Covenants and Agreements</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each Shareholder shall not, and each Shareholder shall cause its controlled Affiliates and its and their respective officers and directors
not to, and shall use reasonable best efforts to cause its other Representatives not to, at or at any time prior to the Effective Time, issue any press releases or make any public announcements with respect to this Agreement, the Business
Combination Agreement or the transactions contemplated hereby or thereby that contain any information that is not, at the applicable time, already publicly available (other than as a result of disclosure by the Shareholder in violation of any
applicable confidentiality obligations) without the prior written consent of the Company and MAAC, <U>provided</U>, <U>however</U>, that the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Shareholder and its Representatives may issue or make, as applicable, any such press release, public announcement or other communication to the extent such press release, public announcement or
other communication is required by applicable Law or applicable rule of a stock exchange on which its or any of its Affiliates&#146; securities are listed, in which case the Shareholder or its applicable Affiliates shall, to the extent reasonably
practicable and unless and to the extent prohibited by such applicable Law, reasonably consult with the Company and MAAC in connection therewith and provide the Company and MAAC with an opportunity to review and comment on such press release, public
announcement or communication and shall consider any such comments in good faith. Notwithstanding anything to the contrary in this Section&nbsp;8(a) or otherwise in this Agreement, each Shareholder and its Representatives may provide general
information about the subject matter of this Agreement, the Business Combination Agreement and the transactions contemplated hereby and thereby (1)&nbsp;to their respective affiliates, their and their affiliates&#146; respective directors, officers,
employees, partners, members, agents, attorneys and consultants, financial and other advisors, (2)&nbsp;to the extent required by any federal, state, national, foreign or other regulatory or self-regulatory authority having jurisdiction over the
Shareholder or its Representatives, (3)&nbsp;to any Person if necessary to effect compliance with any law, rule, regulation, investigation, audit, request or order of a Governmental Entity of competent jurisdiction that is applicable to the
Shareholder or its Representatives, including in response to any subpoena or other legal process, audit or examinations or (4)&nbsp;to any direct or indirect former, current or prospective investor or in connection with normal fund raising or
related marketing or informational or reporting activities (so long as, in the case of this clause (4), the recipients of such information are subject to customary confidentiality obligations prior to the receipt of such information); provided
further that in the case of the foregoing clause (2)&nbsp;and (3), each Shareholder or its Representatives promptly notifies the Company of such disclosure to the extent the Shareholder or its Representatives are legally permitted to give such
notice and it is reasonably practicable; provided further that no such notice shall be required where disclosure is made (x)&nbsp;in response to and required by a general request by a regulatory or self-regulatory authority of competent jurisdiction
or (y)&nbsp;in connection with and required by a routine audit or examination by a bank examiner or auditor and such audit or examination does not reference the Company, this Agreement or the Business Combination Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If applicable, prior to the Effective Time, each Shareholder hereby agrees to as promptly as practicable execute and deliver all
additional agreements, documents or instruments, take, or cause to be taken, all actions and provide, or cause to be provided, all additional information or other materials as may be necessary or reasonably advisable, in each case, as mutually
reasonably determined and agreed to by MAAC and the Company (such determination and agreement not to be unreasonably withheld, conditioned or delayed by either MAAC or the Company), in connection with, or otherwise in furtherance of, the
transactions and the other covenants and agreements contemplated by the Business Combination Agreement or this Agreement (<U>provided</U>, <U>however</U>, that in no event shall any Shareholder be obligated to take, approve or consent to any action
that would result in any adverse economic or other material change to the Business Combination Agreement, this Agreement or any other Ancillary Document to which he, she or it is or will be a party). If applicable, from and after the Effective Time,
MAAC Sponsor and the Company each hereby agrees to as promptly as practicable execute and deliver execute and deliver all additional agreements, documents or instruments, take, or cause to be taken, all actions and provide, or cause to be provided,
all additional information or other materials as may be reasonably necessary to effectuate the purpose of the covenants and agreements of this Agreement that survive the Effective Time. Notwithstanding the foregoing, no Shareholder or the Company
shall be required to provide any information which is, based on the advice of outside counsel, subject to legal privilege. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Without
limiting <U>Section</U><U></U><U>&nbsp;8(b)</U>, the MAAC Sponsor and the Company shall each (i)&nbsp;make any appropriate filings pursuant to the HSR Act with respect to the Company Post-Closing Common Shares to be received by the MAAC Sponsor
pursuant to the terms of the Business Combination Agreement as promptly as reasonably practicable (and in any event within ten (10)&nbsp;Business Days) following the date of this Agreement, (ii)&nbsp;use reasonable best efforts to obtain any other
approvals of any Governmental Entity as may be required to be obtained by the MAAC Sponsor or the Company in connection with the receipt by the MAAC Sponsor of the Company Post-Closing Common Shares to be received by the MAAC Sponsor pursuant to the
terms of the Business Combination Agreement and (iii)&nbsp;respond as promptly as reasonably practicable to any requests by any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Governmental Entity for additional information and documentary material that may be requested pursuant to the HSR Act or in connection with such other required approvals of any Governmental
Entity described in clause (ii). The MAAC Sponsor and the Company shall each pay fifty percent (50%) of the HSR Act filing fee. Without limiting the foregoing, the MAAC Sponsor and its applicable Affiliates and the Company and its applicable
Affiliates shall not (A)&nbsp;extend any waiting period, review period or comparable period under the HSR Act or in connection with such other required approvals of any Governmental Entity, (B)&nbsp;request early termination of any waiting period,
review period or comparable period under the HSR Act without the prior written consent of the MAAC Sponsor (in the case of the Company or any of its applicable Affiliates) or the Company (in the case of the MAAC Sponsor or any of its applicable
Affiliates) or (C)&nbsp;enter into any agreement with any Governmental Entity not to consummate the transactions contemplated by the Business Combination Agreement except with the prior written consent of the Company and MAAC (in the case of MAAC
Sponsor or any of its applicable Affiliates) or MAAC Sponsor (in the case of the Company or any of its applicable Affiliates). The MAAC Sponsor shall promptly inform the Company and MAAC of any communication received by the MAAC Sponsor from any
Governmental Entity relating to the matters contemplated by this <U>Section</U><U></U><U>&nbsp;8(c)</U>, and the Company shall promptly inform the MAAC Sponsor and MAAC of any communication received by any Group Company from any Governmental Entity
relating to the matters contemplated by this <U>Section</U><U></U><U>&nbsp;8(c)</U>. The MAAC Sponsor shall give the Company and its counsel, and MAAC and its counsel, a reasonable opportunity to review in advance, and consider in good faith the
views thereof in connection with, any proposed written communication to any Governmental Entity relating to the matters contemplated by this <U>Section</U><U></U><U>&nbsp;8(c)</U>, and the Company shall give MAAC Sponsor and its counsel and MAAC and
its counsel a reasonable opportunity to review in advance, and consider in good faith the views thereof in connection with, any proposed written communication to any Governmental Entity relating to the matters contemplated by this
<U>Section</U><U></U><U>&nbsp;8(c)</U>. The MAAC Sponsor and the Company each agrees not to, and to cause its Representatives not to, participate in any substantive meeting or discussion, either in person or by telephone with any Governmental Entity
in connection with the matters contemplated by this <U>Section</U><U></U><U>&nbsp;8(c)</U> unless it consults with the Company and MAAC (in the case of the MAAC Sponsor or its Representatives) or the MAAC Sponsor and MAAC (in the case of the Company
or its Representatives) in advance and, to the extent not prohibited by such Governmental Entity, gives the Company and MAAC (in the case of the MAAC Sponsor or its Representatives) or the MAAC Sponsor and MAAC (in the case of the Company or its
Representatives) the opportunity to attend and participate in such meeting or discussion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Each Shareholder acknowledges and agrees
that MAAC and the Company are entering into the Business Combination Agreement in reliance upon such Shareholder entering into this Agreement and agreeing to be bound by, and perform, or otherwise comply with, as applicable, the applicable
agreements, covenants and obligations contained in this Agreement and, but for each Shareholder entering into this Agreement and agreeing to be bound by, and perform, or otherwise comply with, as applicable, the applicable agreements, covenants and
obligations contained in this Agreement, MAAC and the Company would not have entered into or agreed to consummate the transactions contemplated by the Business Combination Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Shareholder Representations and Warranties</U>. Each Shareholder represents and warrants, as of the date hereof, solely with respect to
himself, herself or itself, and not on behalf of any other Shareholder, to the Company and MAAC as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If the Shareholder is not
an individual, the Shareholder is a corporation, limited liability company or other applicable business entity duly organized or formed, as applicable, validly existing and in good standing (or the equivalent thereof, if applicable, in each case,
with respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof) under the Laws of its jurisdiction of formation or organization (as applicable). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Shareholder (if not an individual) has the requisite corporate, limited liability company or other similar power and authority and, if
the Shareholder is an individual, legal capacity to execute and deliver this Agreement, to perform his, her or its covenants, agreements and obligations hereunder (including, for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
avoidance of doubt, those covenants, agreements and obligations hereunder that relate to the provisions of the Business Combination Agreement), and to consummate the transactions contemplated
hereby. The execution and delivery of this Agreement has been duly authorized by all necessary corporate or other action on the part of the Shareholder. This Agreement has been duly and validly executed and delivered by the Shareholder and
constitutes a valid, legal and binding agreement of the Shareholder (assuming that this Agreement is duly authorized, executed and delivered by the other parties hereto), enforceable against the Shareholder in accordance with its terms (subject to
applicable bankruptcy, insolvency, reorganization, moratorium or other Laws affecting generally the enforcement of creditors&#146; rights and subject to general principles of equity). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) No consent, approval or authorization of, or designation, declaration or filing with, any Governmental Entity is required on the part of
the Shareholder with respect to the Shareholder&#146;s execution, delivery or performance of his, her or its covenants, agreements or obligations under this Agreement (including, for the avoidance of doubt, those covenants, agreements and
obligations under this Agreement that relate to the provisions of the Business Combination Agreement) or the consummation of the transactions contemplated hereby, except for (A)&nbsp;compliance with and filings under the HSR Act, if applicable, or
under any applicable Foreign and Domestic Approval Laws, (B)&nbsp;any filings with the SEC related to his, her or its ownership of Equity Securities of MAAC or Company Post-Closing Common Shares or the transactions contemplated by the Business
Combination Agreement, this Agreement or any other Ancillary Documents to which he, she or it is a party, or (C)&nbsp;any other consents, approvals, authorizations, designations, declarations, waivers or filings, the absence of which would not
reasonably be expected to adversely affect the ability of the Shareholder to perform, or otherwise comply with, any of his, her or its covenants, agreements or obligations hereunder in any material respect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) None of the execution or delivery of this Agreement by the Shareholder, the performance by the Shareholder of any of his, her or its
covenants, agreements or obligations under this Agreement (including, for the avoidance of doubt, those covenants, agreements and obligations under this Agreement that relate to the provisions of the Business Combination Agreement) or the
consummation of the transactions contemplated hereby will, directly or indirectly (with or without due notice or lapse of time or both)&nbsp;(i) if the Shareholder is not an individual, result in any breach of any provision of the Shareholder&#146;s
Governing Documents, (ii)&nbsp;result in a violation or breach of, or constitute a default or give rise to any right of termination, Consent, cancellation, amendment, modification, suspension, revocation or acceleration under, any of the terms,
conditions or provisions of any Contract to which the Shareholder is a party, (iii)&nbsp;violate, or constitute a breach under, any Order or applicable Law to which the Shareholder or any of his, her or its properties or assets are bound or
(iv)&nbsp;other than the restrictions contemplated by this Agreement, the Business Combination Agreement or any other Ancillary Document, result in the creation of any Lien upon the Subject Company Securities (other than as expressly provided under
this Agreement), except, in the case of any of <U>clauses</U><U></U><U>&nbsp;(ii)</U> and <U>(iii)</U>&nbsp;above, as would not reasonably be expected to adversely affect the ability of the Shareholder to perform, or otherwise comply with, any of
his, her or its covenants, agreements or obligations hereunder in any material respect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Shareholder is, as of the date hereof,
the record and beneficial owner of the Subject Company Securities as set forth on <U>Exhibit A</U> hereto. The Shareholder has the sole right to vote (and provide consent in respect of, as applicable) the Subject Company Securities set forth on
<U>Exhibit A</U> hereto as of the date hereof. Except for this Agreement, the Business Combination Agreement, the other Ancillary Documents to which he, she or it is or will be a party, the Affected Agreements and the Governing Documents of MAAC,
the Shareholder is not party to or bound by (i)&nbsp;any option, warrant, purchase right or other Contract that would reasonably be expected (either alone or in connection with one or more events, developments or events (including the satisfaction
or waiver of any conditions precedent)) to require the Shareholder to Transfer any of the Subject Company Securities or (ii)&nbsp;any voting trust, proxy or other Contract with respect to the voting or Transfer of any of the Subject Company
Securities, in the case of either clause (i)&nbsp;or (ii), that would reasonably be expected to adversely affect the ability of the Shareholder to perform, or otherwise comply with, any of his, her or its covenants, agreements or obligations
hereunder in any material respect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) There is no Proceeding pending or, to the Shareholder&#146;s knowledge, threatened
against or involving the Shareholder or any of his, her or its Affiliates that, if adversely decided or resolved, would reasonably be expected to adversely affect the ability of the Shareholder to perform, or otherwise comply with, any of its
covenants, agreements or obligations under this Agreement in any material respect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) The Shareholder, on his, her or its own behalf and
on behalf of his, her or its Representatives, acknowledges, represents, warrants and agrees that he, she or it has conducted his, her or its own independent review and analysis of, and, based thereon, has formed an independent judgment concerning,
the business, assets, condition, operations and prospects of, the Company and the transactions contemplated by this Agreement, the Business Combination Agreement and the other applicable Ancillary Documents to which he, she or it is or will be a
party as he, she or it and his, her or its Representatives have deemed necessary to enable him, her or it to make an informed decision with respect to the execution, delivery and performance of this Agreement or the other Ancillary Documents to
which he, she or it is or will be a party and the transactions contemplated hereby and thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) In entering into this Agreement and
the other Ancillary Documents to which he, she or it is or will be a party, the Shareholder has relied solely on his, her or its own investigation and analysis and the representations and warranties expressly set forth in the Ancillary Documents to
which he, she or it is or will be a party and no other representations or warranties of MAAC, the Company or any other Person, either express or implied, and the Shareholder, on his, her or its own behalf and on behalf of his, her or its
Representatives, acknowledges, represents, warrants and agrees that, except for the representations and warranties expressly set forth in this Agreement or in the other Ancillary Documents to which he, she or it is or will be a party, none of MAAC,
the Company or any other Person makes or has made any representation or warranty, either express or implied, to the Shareholder in connection with or related to this Agreement, the Business Combination Agreement or the other Ancillary Documents or
the transactions contemplated hereby or thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Company and MAAC Acknowledgement</U>. In entering into this Agreement, the
Business Combination Agreement and the other Ancillary Documents to it is or will be a party, each of the Company and MAAC have not relied on any representations or warranties of the Shareholder, either express or implied, except for the
representations and warranties of the Shareholder expressly set forth in this Agreement or in the other Ancillary Documents to which he, she or it is or will be a party and to which MAAC or the Company, as applicable, is or will be a party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Transfer of Subject Company Securities</U>. From and after the date hereof and until the earlier of (A)&nbsp;the termination of this
Agreement in accordance with its terms and (B)&nbsp;the Effective Time, each Shareholder agrees not to (a)&nbsp;Transfer any of the Subject Company Securities, (b)&nbsp;enter into (i)&nbsp;any option, warrant, purchase right, or other Contract that
would reasonably be expected (either alone or in connection with one or more events, developments or events (including the satisfaction or waiver of any conditions precedent)) to require the Shareholder to Transfer the Subject Company Securities or
(ii)&nbsp;any voting trust, proxy or other Contract with respect to the voting or Transfer of the Subject Company Securities, or (c)&nbsp;take any actions in furtherance of any of the matters described in the foregoing clauses (a)&nbsp;or (b),
unless, in the case of clauses (a)&nbsp;through (c), the Shareholder causes any transferee of any such Transfer to enter into a written agreement in form and substance reasonably satisfactory to MAAC and the Company agreeing to be bound by this
Agreement (which will include, for the avoidance of doubt, all of the covenants, agreements and obligations of the Shareholder hereunder and the making of all the representations and warranties of the Shareholder set forth in
<U>Section</U><U></U><U>&nbsp;9</U> with respect to such transferee and his, her or its Subject Company Securities received upon such Transfer, as applicable) prior and as a condition to the occurrence of such Transfer; <U>provided</U> that, if the
Shareholder is not an individual, a Transfer of securities in the Shareholder by an equityholder of the Shareholder shall not require the transferee to enter into such written agreement so long as (x)&nbsp;following such Transfer, the Shareholder
continues to hold the Subject Company Securities and to have the exclusive right to vote and to take all other actions related to the ownership of the Subject Company Securities without restriction and (y)&nbsp;such Transfer would otherwise be
permitted under the Shareholders Agreement. For purposes of this Agreement, &#147;<U>Transfer</U>&#148; means any direct or indirect sale, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transfer, assignment, pledge, mortgage, exchange, hypothecation, grant of a security interest in or disposition or encumbrance of an interest (whether with or without consideration, whether
voluntarily or involuntarily or by operation of law or otherwise). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Termination</U>. This Agreement shall automatically terminate,
without any notice or other action by any Party, and be void <I>ab initio</I> upon the termination of the Business Combination Agreement in accordance with its terms. Upon termination of this Agreement as provided in the immediately preceding
sentence, none of the Parties shall have any further obligations or Liabilities under, or with respect to, this Agreement. Notwithstanding the foregoing or anything to the contrary in this Agreement, (i)&nbsp;the termination of this Agreement shall
not affect any Liability on the part of any Party for a Willful Breach of any covenant or agreement set forth in this Agreement prior to such termination or Fraud, (ii)<U>&nbsp;Section</U><U></U><U>&nbsp;10</U>, this
<U>Section</U><U></U><U>&nbsp;12</U> and the representations and warranties set forth in <U>Sections 9(g)</U> and <U>(h)</U>&nbsp;shall each survive any termination of this Agreement, and (iii)<U>&nbsp;Sections 13</U> through <U>21</U> shall survive
any termination of this Agreement. For purposes of this <U>Section</U><U></U><U>&nbsp;12</U>, (x) &#147;<U>Willful Breach</U>&#148; means a material breach of this Agreement that is a consequence of an act or a failure to act by the breaching Party
with the knowledge that the taking of such act or such failure to act would, or would reasonably be expected to, constitute or result in a breach of this Agreement and (y) &#147;<U>Fraud</U>&#148; means an act or omission by a Party, and requires:
(A)&nbsp;a false or incorrect representation or warranty expressly made by such Party in this Agreement, (B)&nbsp;with actual knowledge (as opposed to constructive, imputed or implied knowledge) by the Party making such representation or warranty
that such representation or warranty expressly set forth in this Agreement is false or incorrect, (C)&nbsp;an intention to deceive another Party, to induce him, her or it to enter into this Agreement, (D)&nbsp;another Party, in justifiable or
reasonable reliance upon such false or incorrect representation or warranty expressly set forth in this Agreement, entering into this Agreement, and (E)&nbsp;another Party suffering damage by reason of such reliance. For the avoidance of doubt,
&#147;Fraud&#148; does not include any claim for equitable fraud, promissory fraud, unfair dealings fraud or any torts (including a claim for fraud or alleged fraud) based on negligence or recklessness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Fiduciary Duties</U>. Notwithstanding anything in this Agreement to the contrary, (a)&nbsp;the Shareholder makes no agreement or
understanding herein in any capacity other than in such Shareholder&#146;s capacity as a record holder and beneficial owner of the Subject Company Securities and, (i.e., if such Shareholder is an individual, not in such Shareholder&#146;s capacity
as a director, officer or employee of MAAC), and (b)&nbsp;nothing herein will be construed to limit or affect any action or inaction by such Shareholder if such Shareholder is an individual, or, if such Shareholder is not an individual, any
representative of such Shareholder serving as a member of the board of directors of MAAC or as an officer, employee or fiduciary of MAAC, in each case, acting in such person&#146;s capacity as a director, officer, employee or fiduciary of MAAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Notices</U>. All notices, requests, claims, demands and other communications hereunder shall be in writing and shall be given (and
shall be deemed to have been duly given) by delivery in person, by <FONT STYLE="white-space:nowrap">e-mail</FONT> (having obtained electronic delivery confirmation thereof (i.e., an electronic record of the sender that the email was sent to the
intended recipient thereof without an &#147;error&#148; or similar message that such email was not received by such intended recipient)), or by registered or certified mail (postage prepaid, return receipt requested) (upon receipt thereof) to the
other Parties as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to MAAC or the MAAC Sponsor, to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">c/o Patient Square Capital </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">724
Oak Grove Ave, Suite 130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Menlo Park, California 94025 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Maria Walker </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;maria@patientsquarecapital.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Kirkland&nbsp;&amp; Ellis LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">601 Lexington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York,
NY 10022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Michael Weisser, P.C.; Ryan Brissette; Sharon Freiman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;michael.weisser@kirkland.com; ryan.brissette@kirkland.com; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;sharon.freiman@kirkland.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to the Company, to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Roivant
Sciences Ltd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Suite 1, 3rd Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">11-12</FONT> St. James&#146;s Square </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">London SW1Y 4LB </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">United Kingdom
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Matthew Gline </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-mail:</FONT> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;matthew.gline@roivant.com; legalnotices@roivant.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">with a copy
(which shall not constitute notice) to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Roivant Sciences, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">151 West 42nd Street, 15th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, NY 10036 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention:
General Counsel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;jo.chen@roivant.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Davis Polk&nbsp;&amp; Wardwell LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">450 Lexington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York,
NY 10017 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Derek Dostal; Lee Hochbaum; Brian Wolfe </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;derek.dostal@davispolk.com; lee.hochbaum@davispolk.com; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;brian.wolfe@davispolk.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">if to a Shareholder other than the MAAC Sponsor, to the address on the Shareholder&#146;s signature page hereto; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address as the Party to whom notice is given may have previously furnished to the others in writing in the manner set forth above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Entire Agreement</U>. This Agreement, the Business Combination Agreement and documents referred to herein and therein (including the
Ancillary Documents) constitute the entire agreement of the Parties with respect to the subject matter of this Agreement, and supersede all prior agreements and undertakings, both written and oral, among the Parties with respect to the subject
matter of this Agreement, except as otherwise expressly provided in this Agreement. In the event and to the extent that there shall be a conflict between the provisions of this Agreement and the provisions of any Affected Agreement, this Agreement
shall control with respect to the subject matter thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Amendments and Waivers; Assignment</U>. Any provision of this Agreement
may be amended or waived if, and only if, such amendment or waiver is in writing and signed by the Shareholders, the Company and MAAC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Notwithstanding the foregoing, no failure or delay by any Party in exercising any right hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any
other or further exercise of any other right hereunder. Subject to <U>Section</U><U></U><U>&nbsp;2(d)</U>, neither this Agreement nor any of the rights, interests or obligations hereunder shall be assignable by a Shareholder or the Company without
MAAC&#146;s prior written consent (to be withheld or given in its sole discretion) or by MAAC without the Company&#146;s prior written consent (to be withheld or given in its sole discretion). Any attempted assignment of this Agreement not in
accordance with the terms of this <U>Section</U><U></U><U>&nbsp;16</U> shall be null and void <I>ab initio</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>Fees and
Expenses</U>. Except, in the case of MAAC and the Company, as otherwise expressly set forth in the Business Combination Agreement, all fees and expenses incurred in connection with this Agreement and the transactions contemplated hereby, including
the fees and disbursements of counsel, financial advisors and accountants, shall be paid by the Party incurring such fees or expenses<U>; </U><U>provided</U>, that, any such reasonable and documented fees and expenses incurred by the Shareholders in
connection with this Agreement and the transactions contemplated hereby on or prior to the Closing shall be deemed to be fees and expenses of MAAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>No Third Party Beneficiaries</U>. Except as set forth in <U>Section</U><U></U><U>&nbsp;2(d)</U>, this Agreement shall be for the sole
benefit of the Parties and their respective successors and permitted assigns and is not intended, nor shall be construed, to give any Person, other than the Parties and their respective successors and permitted assigns, any legal or equitable right,
benefit or remedy of any nature whatsoever by reason this Agreement. Nothing in this Agreement, expressed or implied, is intended to, or shall be deemed to, create a joint venture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <U>Miscellaneous</U>. <U>Sections 8.5</U> (Governing Law), <U>8.7</U> (Construction; Interpretation), <U>8.10</U> (Severability),
<U>8.11</U> (Counterparts; Electronic Signatures), <U>8.15</U> (Waiver of Jury Trial), <U>8.16</U> (Submission to Jurisdiction) and <U>8.17</U> (Remedies) of the Business Combination Agreement are incorporated herein by reference and shall apply to
this Agreement, <I>mutatis mutandis</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <U>No Ownership Interest</U>. Nothing contained in this Agreement will be deemed to vest in
the Company, any Company <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate, or any MAAC <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate any direct or indirect ownership or incidents of ownership of or with respect to the
Subject Company Securities. All rights, ownership and economic benefits of and relating to the Subject Company Securities shall remain vested in and belong to each Shareholder, and the Company and MAAC (and each other Company <FONT
STYLE="white-space:nowrap">Non-Party</FONT> Affiliate and MAAC <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate) shall have no authority to manage, direct, superintend, restrict, regulate, govern or administer any of the policies or
operations of Company or exercise any power or authority to direct any Shareholder in the voting of any of the Subject Company Securities, except as otherwise expressly provided herein with respect to the Subject Company Securities. Except as
otherwise set forth in Section&nbsp;1, no Shareholder shall not be restricted from voting in favor of, against or abstaining with respect to any other matters presented to the stockholders of MAAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <U>Spouses and Community Property Matters</U>. Each Shareholder&#146;s spouse (if applicable) hereby represents, warrants and covenants to
MAAC and the Company that such spouse shall not assert or enforce, and does hereby waive, any rights granted under any community property statue with respect to the Subject Company Securities that would adversely affect (x)&nbsp;the covenants made
by the applicable Shareholder pursuant to this Agreement or (y)&nbsp;the transactions contemplated by the Business Combination Agreement and the Ancillary Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. <U>No Recourse</U>. Except for claims pursuant to the Business Combination Agreement or any Ancillary Document by any party(ies) thereto
against any other party(ies) on the terms and subject to the conditions therein, each Party agrees that (a)&nbsp;this Agreement may only be enforced against, and any action for breach of this Agreement may only be made against, the Parties, and no
claims of any nature whatsoever arising under or relating to this Agreement, the negotiation hereof or its subject matter, or the transactions contemplated hereby shall be asserted against any Person that is not a Party, and (b)&nbsp;without
limiting the generality of the foregoing, no Person that is not a Party shall have any Liability arising out of or relating to this Agreement, the negotiation hereof or its subject matter, or the transactions contemplated hereby, including with
respect to any claim (whether in tort, contract or otherwise) for breach of this Agreement or in respect of any written or oral </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
representations made or alleged to be made in connection herewith, except as expressly provided herein. Notwithstanding anything to the contrary in this Agreement, (i)&nbsp;in no event shall any
Shareholder have any obligations or Liabilities related to or arising out of the covenants, agreements, obligations, representations or warranties of any other Shareholder under this Agreement (including related to or arising out of the breach of
any such covenant, agreement, obligation, representation or warranty by any other Shareholder), and (ii)&nbsp;in no event shall MAAC have any obligations or Liabilities related to or arising out of the covenants, agreements, obligations,
representations or warrants of any Shareholder under this Agreement (including related to or arising out of any breach of any such covenant, agreement, obligation, representation or warranty by any such Shareholder). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23. <U><FONT STYLE="white-space:nowrap">Non-Survival</FONT></U>. The representations, warranties, agreements and covenants in this Agreement
shall terminate at the Effective Time, except for those covenants and agreements in this Agreement that, by their terms, expressly contemplate performance or survival after the Effective Time, which covenants and agreements shall so survive the
Effective Time in accordance with their terms; <I>provided </I>that the foregoing shall not limit any Party&#146;s rights in the event of another Party&#146;s Willful Breach of any agreement and covenant set forth in Section&nbsp;4(a) or
Section&nbsp;11 prior to the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature page(s) follow(s).] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed and delivered this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ROIVANT SCIENCES LTD.</B></TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Sponsor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">N WITNESS WHEREOF, the Parties have executed and delivered this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MONTES ARCHIMEDES ACQUISITION CORP.</B></TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Sponsor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed and delivered this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PATIENT SQUARE CAPITAL LLC</B></TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Name:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Title:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Sponsor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed and delivered this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INSIDERS</B></TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: George Barrett</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Sponsor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed and delivered this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INSIDERS</B></TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">James C. Momtazee</TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Sponsor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed and delivered this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INSIDERS</B></TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Maria C. Walker</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Sponsor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed and delivered this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INSIDERS</B></TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Steve Oesterle</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Sponsor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[REDACTED] </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Exhibit
A</I> <I>to Sponsor </I><I>Support </I><I>Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE A </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The letter, dated as of October&nbsp;6, 2020, regarding &#147;administrative support agreement&#148; by and
between MAAC and the MAAC Sponsor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Securities Subscription Agreement, dated as of July&nbsp;23, 2020, by and between MAAC and the MAAC
Sponsor. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Schedule </I><I>A to Sponsor </I><I>Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><A NAME="rom65062_43a"></A>ANNEX EE - AMENDMENT NO. 1 TO SPONSOR SUPPORT AGREEMENT
</U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Amendment No.&nbsp;1 to the Sponsor Support Agreement (this &#147;<U>Amendment</U>&#148;) is made as of June&nbsp;9, 2021,
by and among Roivant Sciences Ltd., a Bermuda exempted limited company (the &#147;<U>Company</U>&#148;), Montes Archimedes Acquisition Corp., a Delaware corporation (&#147;<U>MAAC</U>&#148;), Patient Square Capital LLC, a Delaware limited liability
company (the &#147;<U>MAAC Sponsor</U>&#148;), and each of James C. Momtazee, George Barrett, Maria C. Walker and Steve Oesterle (collectively, the &#147;<U>Insiders</U>&#148;, and together with the MAAC Sponsor, the
&#147;<U>Shareholders</U>&#148;). Capitalized terms used, but not otherwise defined herein, shall have the meaning given to them in the Sponsor Support Agreement (as defined below) or the Business Combination Agreement (as defined below), as the
context so requires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on May&nbsp;1, 2021 (a) the Company, MAAC, the MAAC Sponsor and, solely for purposes of certain provisions
therein, the Insiders entered into that certain Sponsor Support Agreement (as amended, amended and restated, supplemented or otherwise modified from time to time in accordance with its terms, the &#147;<U>Sponsor Support Agreement</U>&#148;), and
(b)&nbsp;MAAC, the Company and Rhine Merger Sub, Inc., a Delaware corporation and a direct wholly owned Subsidiary of the Company, entered into that certain Business Combination Agreement (as amended, amended and restated, supplemented or otherwise
modified from time to time in accordance with its terms, including, for the avoidance of doubt, as amended by Amendment No.&nbsp;1 to the Business Combination Agreement, the &#147;<U>Business Combination Agreement</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to Section&nbsp;16 of the Sponsor Support Agreement, the Sponsor Support Agreement may be amended if, and only if, such
amendment is in writing and signed by the Company, MAAC and the Shareholders; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company, MAAC and each Shareholder desires to
amend the Sponsor Support Agreement to provide that, among other things, (a)&nbsp;each MAAC Class&nbsp;B Share held by George Barrett or Steve Oesterle (each, a &#147;<U>MAAC Independent Director</U>&#148;) issued and outstanding immediately prior
to the Effective Time be converted as of the Effective Time into the number of Company Post-Closing Common Shares equal to the Sponsor Exchange Ratio, on the terms and subject to the conditions set forth in the Business Combination Agreement and the
Sponsor Support Agreement, and (b)&nbsp;a portion of the Company Post-Closing Common Shares issued upon conversion of the MAAC Class&nbsp;B Shares held by a MAAC Independent Director in the Merger be subject to the vesting provisions set forth in
the Sponsor Support Agreement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the date hereof (a)&nbsp;the Company and MAAC are entering into Amendment No.&nbsp;1 to
the Business Combination Agreement (&#147;<U>Amendment No.</U><U></U><U>&nbsp;1 to the Business Combination Agreement</U>&#148;) in connection with the amendments contemplated hereby and (b)&nbsp;each MAAC Independent Director, on the one hand, and
the Company, on the other hand, are entering into a <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement (each, a &#147;<U>MAAC Independent Director <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</U>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration for the mutual promises made herein and other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the Company, MAAC and each Shareholder hereby agree to amend the Sponsor Support Agreement as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments to the Sponsor Support Agreement</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp; Section&nbsp;2 of the Sponsor Support Agreement is hereby amended and restated in its entirety and
replaced with the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;2.&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp; Subject to, and conditioned upon the occurrence of and effective immediately after the Effective Time, (i) 20% of
the number of Company Post-Closing Common Shares issued to the MAAC Sponsor, any Affiliate of the MAAC Sponsor, any MAAC Independent Director (as defined in the BCA) or any MAAC Independent Director Transferee (as defined in the BCA) upon the
conversion of MAAC Class&nbsp;B Shares held by him, her or it immediately prior to the Effective Time (rounded up to the nearest whole share) shall be subject to </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the provisions set forth below in this<U>&nbsp;Section</U><U></U><U>&nbsp;2</U> (such Company Post-Closing Common Shares, the &#147;<U>20% <FONT STYLE="white-space:nowrap">Earn-Out</FONT>
Shares</U>&#148;), (ii) 10% of the number of Company Post-Closing Common Shares issued to the MAAC Sponsor, any Affiliate of the MAAC Sponsor, any MAAC Independent Director or any MAAC Independent Director Transferee(s) upon the conversion of MAAC
Class&nbsp;B Shares held by him, her or it immediately prior to the Effective Time (rounded up to the nearest whole share) shall be subject to the provisions set forth below in this<U>&nbsp;Section</U><U></U><U>&nbsp;2</U> (such Company Post-Closing
Common Shares, the &#147;<U>10% <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares</U>&#148; and, together with the 20% <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares, the &#147;<U><FONT STYLE="white-space:nowrap">Earn-Out</FONT>
Shares</U>&#148;) and (iii)&nbsp;the remaining 70% of the number of Company Post-Closing Common Shares issued to the MAAC Sponsor, any Affiliate of the MAAC Sponsor, any MAAC Independent Director or any MAAC Independent Director Transferee upon the
conversion of MAAC Class&nbsp;B Shares held by him, her or it immediately prior to the Effective Time (rounded down to the nearest whole share) shall not be subject to the provisions set forth below in this<U>&nbsp;Section</U><U></U><U>&nbsp;2</U>
(such Company Post-Closing Common Shares, the &#147;<U>Retained Shares</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp; Subject to, and
conditioned upon the occurrence of and effective immediately after the Effective Time, the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares shall be unvested and subject to the restrictions and forfeiture provisions set forth in this
<U>Section</U><U></U><U>&nbsp;2</U>. The <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares shall vest and become free of the provisions set forth in this <U>Section</U><U></U><U>&nbsp;2</U> at such time as the Stock Price (as defined below) of
Company Post-Closing Common Shares equals or exceeds (x)&nbsp;with respect to the 20% <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares, $15.00 per share (the &#147;<U>20% Trigger Price</U>&#148;), and (y)&nbsp;with respect to the 10% <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Shares, $20.00 per share (the &#147;<U>10% Trigger Price</U>&#148; and, together with the 20% Trigger Price, the &#147;<U>Trigger Price</U>&#148;), in each case, for any 20 Trading Days within any 30
Trading Day period commencing no earlier than the Closing Date and ending no later than the fifth (5th) anniversary of the Closing Date (the &#147;<U><FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date</U>&#148;); <U>provided</U>,
<U>however</U>, that (i)&nbsp;if the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date occurs on a day that is not a Trading Day, then the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date shall be deemed to occur on the next
following Trading Day, and (ii)&nbsp;if the Company or any of its Affiliates enters into a definitive agreement with respect to a Sale (as defined below) on or prior to the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date, then the <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> End Date shall be automatically extended and shall be deemed to occur on the earlier of (A)&nbsp;the day after such Sale is consummated and (B)&nbsp;the termination of such definitive agreement with respect
to such Sale in accordance with its terms. Any <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares that have not vested in accordance with this <U>Section</U><U></U><U>&nbsp;2(b)</U> or <U>Section</U><U></U><U>&nbsp;2(c</U>) on or before the <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> End Date will be immediately forfeited at 11:59&nbsp;p.m., New York, New York time on the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp; In the event of a Sale (as defined below) on or prior to the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End
Date, any unvested <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares will fully vest and become free of the restrictions set forth in this <U>Section</U><U></U><U>&nbsp;2</U> as of immediately prior to the closing of such Sale. For purposes of
this Agreement, &#147;<U>Sale</U>&#148; means (A)&nbsp;a purchase, sale, exchange, merger, business combination or other transaction or series of related transactions in which substantially all of the Company Post-Closing Common Shares are, directly
or indirectly, converted into cash, securities or other property or <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration (other than, in the case of this clause (A), any transaction in which the holders of Company Post-Closing Common
Shares as of immediately prior to the consummation of such transaction continue to own all or substantially all of the equity securities of the Company (or any successor or parent entity of the Company) immediately following the consummation of such
transaction), (B) a direct or indirect sale, lease, exchange or other transfer (regardless of the form of the transaction) in one transaction or a series of related transactions of a majority of the Company&#146;s assets, as determined on a
consolidated basis, to a third party or third parties acting as a &#147;group&#148; (as defined in Section&nbsp;13(d)(3) of the Exchange Act) or (C)&nbsp;any transaction or series of transactions that results, directly or indirectly, in the
shareholders of the Company as of immediately prior to such transactions holding, in the aggregate, less than fifty percent (50%) of the voting Equity Securities of the Company (or any successor or parent company of the Company) immediately after
the consummation thereof (excluding, for the avoidance of doubt, any <FONT STYLE="white-space:nowrap">Earn-out</FONT> Shares) (in the case of each of clause (A), (B) or (C), whether by amalgamation, merger, consolidation, arrangement, tender offer,
recapitalization, purchase, issuance, sale or transfer of Equity Securities or assets or otherwise). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp; Each
Shareholder agrees that he, she or it shall not engage in any Sale Transaction (as defined in the applicable <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement) with respect to any of his, her or its
<FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares until such time as the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares have vested pursuant to <U>Section</U><U></U><U>&nbsp;2(b)</U> or <U>Section</U><U></U><U>&nbsp;2(c)</U>.
Notwithstanding the foregoing or anything </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EE-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the contrary herein, (i)&nbsp;the MAAC Sponsor, any Affiliate of the MAAC Sponsor, any MAAC Independent Director or any MAAC Independent Director Transferee (and, for the avoidance of doubt,
any permitted transferees pursuant to this clause (i)) may transfer all or any of the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares held by him, her or it in any transfer of the type described in Sections 1(b)(iii)(A) through (C)&nbsp;or
(F) of the applicable <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, <U>provided</U> that, in the case of a transfer of the type described in clauses (A)&nbsp;through (C), the transferee shall, in addition to any requirements in the
applicable <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, agree in writing that he, she or it is receiving and holding such <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares subject to the provisions of this
<U>Section</U><U></U><U>&nbsp;2</U> and (ii)&nbsp;from and after a transfer pursuant to clause (i)&nbsp;of this sentence, all references to any of the MAAC Sponsor, any Affiliate of the MAAC Sponsor, any MAAC Independent Director or any MAAC
Independent Director Transferee in this <U>Section</U><U></U><U>&nbsp;2</U> and <U>Section</U><U></U><U>&nbsp;7</U> shall include such transferee and shall collectively mean the MAAC Sponsor, any Affiliate of the MAAC Sponsor, any MAAC Independent
Director or any MAAC Independent Director Transferee (to the extent that he, she or it then holds <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares) and each permitted transferee of the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares
originally held by the MAAC Sponsor, any Affiliate of the MAAC Sponsor, any MAAC Independent Director or any MAAC Independent Director Transferee pursuant to clause (i)&nbsp;of this sentence (in each case, to the extent he, she or it then holds <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Shares). Each transferee of <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares pursuant to clause (i)&nbsp;of the preceding sentence shall be a third party beneficiary of this
<U>Section</U><U></U><U>&nbsp;2</U> and <U>Section</U><U></U><U>&nbsp;7</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp; As used herein, &#147;<U>Stock
Price</U>&#148; means, on any date on or after the Closing and on or prior to the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date, the closing sale price per share of Company Post-Closing Common Shares reported as of 4:00 p.m., New York,
New York time on such date by Bloomberg, or if not available on Bloomberg, as reported by or an authoritative source generally used for such purposes and selected by the Company, and &#147;<U>Trading Day</U>&#148; means any day on which trading is
generally conducted on Nasdaq or any other exchange on which the Company Post-Closing Common Shares are traded on or after the Closing and on or prior to the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date. The <FONT
STYLE="white-space:nowrap">Earn-out</FONT> Shares and the applicable Trigger Price (and all references to Company Post-Closing Common Shares and each of the foregoing in this Agreement) shall each be adjusted appropriately to reflect the effect of
any stock split, reverse stock split, stock dividend (including any dividend or other distribution of securities convertible into Company Post-Closing Common Shares), reorganization, recapitalization, reclassification, combination, exchange of
shares or other like change with respect to the Company Post-Closing Common Shares (or any other Equity Securities into which they are adjusted pursuant to this <U>Section</U><U></U><U>&nbsp;2(e)</U>) at any time prior to the vesting of the <FONT
STYLE="white-space:nowrap">Earn-out</FONT> Shares pursuant to this <U>Section</U><U></U><U>&nbsp;2</U> so as to provide the holders of the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares with the same economic effect as contemplated by this
<U>Section</U><U></U><U>&nbsp;2</U> prior to such event and as so adjusted shall, from and after the date of such event, be the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares and the 20% Trigger Price or the 10% Trigger Price, as
applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp; The Company shall use reasonable best efforts to remain listed as a public company on, and for
the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares to be tradable over, Nasdaq or any other nationally recognized U.S. stock exchange; <U>provided</U>, <U>however</U>, the foregoing shall not limit the Company or any of its Affiliates from
consummating a Sale or entering into a definitive agreement that contemplates a Sale. Subject to <U>Section</U><U></U><U>&nbsp;2(c)</U> and the other applicable provisions of this <U>Section</U><U></U><U>&nbsp;2</U>, upon the consummation of Sale
the Company shall have no further obligations under this <U>Section</U><U></U><U>&nbsp;2(f)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp; At the time
that the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares become vested pursuant to this <U>Section</U><U></U><U>&nbsp;2</U>, the Company shall remove any legends, stock transfer restrictions, stop transfer orders or similar restrictions with
respect to the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares related to such vesting or this <U>Section</U><U></U><U>&nbsp;2</U> (other than, for the avoidance of doubt, those that relate to any applicable and then-existing <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period (as defined in the applicable <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement) with respect to such <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp; For the avoidance of doubt, (i)&nbsp;the MAAC Sponsor, any Affiliate of the MAAC Sponsor, any MAAC Independent
Director or any MAAC Independent Director Transferee shall retain all of his, her or its rights as a stockholder of the Company with respect to the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares owned by him, her or it during any period of
time that such shares are subject to restriction on transfer or sale hereunder, including the right to vote any such shares and the right to receive dividends and other distributions with respect to such
<FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EE-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prior to vesting (<U>provided</U> that dividends and other distributions with respect to <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares that are subject to vesting and are unvested at
the time of such dividend or distribution shall be set aside by the Company and shall only be paid to such holders upon the vesting of such <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares (and, if any dividends or other distributions with
respect to <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares are set aside and such <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares are subsequently forfeited pursuant to this <U>Section</U><U></U><U>&nbsp;2</U>, such set aside
dividends or distributions shall become the property of the Company)), (ii) any <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares that vest in accordance with the terms of this <U>Section</U><U></U><U>&nbsp;2</U> shall remain subject to any
applicable <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period set forth in the applicable <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement and (iii)&nbsp;notwithstanding the expiration of any
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period with respect to any <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares, such shares shall remain subject to any applicable restrictions set forth this <U>Section</U><U></U><U>&nbsp;2</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp; The MAAC Sponsor, any Affiliate of the MAAC Sponsor, any MAAC Independent Director or any MAAC Independent
Director Transferee shall determine, based on advice from its own tax advisors, whether to make an election under Section&nbsp;83(b) of the Code with respect to its <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp; The Parties agree and acknowledge that the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares are intended to
constitute &#147;voting stock&#148; within the meaning of Section&nbsp;368(a)(1) of the Code and the Treasury Regulations promulgated thereunder received by of the MAAC Sponsor, any Affiliate of the MAAC Sponsor, any MAAC Independent Director or any
MAAC Independent Director Transferee(s) in connection with the Merger, and shall file all Tax Returns consistent with, and take no position inconsistent with (whether in audits, Tax Returns or otherwise), such treatment unless (i)&nbsp;such Party
requests that each of Kirkland&nbsp;&amp; Ellis LLP and Davis Polk&nbsp;&amp; Wardwell LLP provides written confirmation to the effect that such treatment is more likely than not correct, and each such law firm fails to provide such confirmation
prior to the later of (A)&nbsp;thirty (30) days following such request is made and (B)&nbsp;sixty (60) days prior to the date on which the relevant Tax Return is due (taking into account applicable extensions); <U>provided</U> that the Parties shall
provide customary factual representations to such law firm; <U>provided</U>, <U>further</U>, that, for the avoidance of doubt, the Parties shall not be required to restructure, or otherwise alter the terms of, the transaction as provided for in this
Agreement or the Business Combination Agreement, or (ii)&nbsp;otherwise required by a final &#147;determination&#148; within the meaning of Section&nbsp;1313(a) of the Code.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp; The definition <FONT STYLE="white-space:nowrap">&#147;Lock-Up</FONT> Agreements&#148; is hereby amended, and
deemed, to include the MAAC Independent Director <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(b)
&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything in the Sponsor Support Agreement to the contrary, the Insiders acknowledge and agree that Section&nbsp;2 of the Sponsor Support Agreement shall apply to the Insiders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp; <U>Effect of Amendments and Modifications</U>. Except as expressly amended hereby, the Sponsor Support Agreement
shall remain unaltered and in full force and effect and the respective terms, conditions or covenants thereof are hereby in all respects confirmed. Whenever the Sponsor Support Agreement is referred to in any agreement, document or other instrument,
such reference will be to the Sponsor Support as amended by this Amendment. For the avoidance of doubt, each reference in the Sponsor Support Agreement, as amended hereby, to &#147;the date hereof&#148;, the &#147;date of this Agreement&#148; and
derivations thereof and other similar phrases shall continue to refer to May&nbsp;1, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;
<U>Miscellaneous</U>. Sections 8.5, 8.7, 8.10, 8.11, 8.15 and 8.16 of the Business Combination Agreement are incorporated herein by reference, <I>mutatis mutandis</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[The remainder of this page intentionally left blank.] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EE-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have caused this Amendment to be signed as of the date
first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ROIVANT SCIENCES LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marianne Romeo</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Marianne Romeo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Head, Global Transactions&nbsp;&amp; Risk Management</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Amendment No.&nbsp;1 to the Sponsor Support Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have caused this Amendment to be signed as of the date
first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MONTES ARCHIMEDES ACQUISITION CORP.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Maria C. Walker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Maria C. Walker</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Amendment No.&nbsp;1 to the Sponsor Support Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have caused this Amendment to be signed as of the date
first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PATIENT SQUARE CAPITAL LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Maria C. Walker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Maria C. Walker</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Amendment No.&nbsp;1 to the Sponsor Support Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have caused this Amendment to be signed as of the date
first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INSIDERS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ George Barrett</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>George Barrett</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6724 Perimeter Loop Road, #311 Dublin, Ohio 43017</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Amendment No.&nbsp;1 to the Sponsor Support Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have caused this Amendment to be signed as of the date
first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INSIDERS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James C. Momtazee</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>James C. Momtazee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>724 Oak Grove Ave, Suite 130 Menlo Park, California 94025</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Amendment No.&nbsp;1 to the Sponsor Support Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have caused this Amendment to be signed as of the date
first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INSIDERS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Maria C. Walker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Maria C. Walker</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8240 McDaniel Road Fort Worth,<BR>Texas 76126</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Amendment No.&nbsp;1 to the Sponsor Support Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have caused this Amendment to be signed as of the date
first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INSIDERS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Steve Oesterle</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Steve Oesterle</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>240 Oliver Ave S. Minneapolis,<BR>Minnesota 55405</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Amendment No.&nbsp;1 to the Sponsor Support Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><A NAME="rom65062_44"></A>ANNEX F &#150; FORM OF LOCK-UP AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[FORM
OF] <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B><FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT</B>
(this &#147;<U>Agreement</U>&#148;) is entered into as of May&nbsp;1, 2021, by and among Roivant Sciences Ltd., a Bermuda exempted limited company (the &#147;<U>Company</U>&#148;), and the undersigned person[s] ([collectively,] the
&#147;<U>Holder</U>&#148;). Each of the Company and the Holder are sometimes referred to herein individually as a &#147;<U>Party</U>&#148; and collectively as the &#147;<U>Parties</U>.&#148; Capitalized terms used but not otherwise defined herein
shall have the meanings ascribed to them in the Business Combination Agreement (as defined below). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, concurrently with the execution of this Agreement, the Company, Montes Archimedes Acquisition Corp., a Delaware corporation
(&#147;<U>MAAC</U>&#148;), and Rhine Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company (&#147;<U>Merger Sub</U>&#148;), are entering into that certain Business Combination Agreement (as it may be amended,
supplemented or otherwise modified from time to time in accordance with its terms, the &#147;<U>Business Combination Agreement</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Business Combination Agreement contemplates that, on the terms and subject to the conditions therein, (a)&nbsp;on the
Closing Date prior to the Closing, the Company will consummate the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps and (b)&nbsp;on the Closing Date promptly following consummation of the Company
<FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps, Merger Sub will merge with and into MAAC, with MAAC as the surviving corporation in the merger and, after giving effect to such merger, becoming a wholly-owned Subsidiary of the Company;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Holder is, as of the date hereof, a holder of Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common
Shares, MAAC Warrants and/or Company Equity Awards, as applicable; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, in connection with the consummation of the
transactions contemplated by the Business Combination Agreement, the Holder will be, as of immediately following the Effective Time, a holder of Company Post-Closing Common Shares, Company Warrants, Adjusted Options, Adjusted RSU Awards and/or
Adjusted CVAR Awards, as applicable; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[<B>WHEREAS</B>, concurrently with the execution of this Agreement, the Company, the Holder and
certain other Persons are entering into that certain Sponsor Support Agreement (as it may be amended, supplemented or otherwise modified from time to time in accordance with its terms, the &#147;<U>Sponsor Support Agreement</U>&#148;);]<SUP
STYLE="font-size:85%; vertical-align:top">1</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, in consideration for the benefits to be received by the Holder under
the terms of the Business Combination Agreement and as a material inducement to the Company and MAAC agreeing to enter into and consummate the transactions contemplated by the Business Combination Agreement, the Holder agrees to enter into this
Agreement and to be bound by the agreements, covenants and obligations contained in this Agreement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Parties
acknowledge and agree that the Company would not have entered into and agreed to consummate the transactions contemplated by the Business Combination Agreement without the Holder entering into this Agreement and agreeing to be bound by the
agreements, covenants and obligations contained in this Agreement. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be included for the MAAC Sponsor. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the premises and the mutual promises set forth
herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, each intending to be legally bound, hereby agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U><FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Provisions</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) [For the applicable <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period
(as defined below), notwithstanding anything to the contrary set forth in the Company&#146;s <FONT STYLE="white-space:nowrap">bye-laws</FONT> or any other agreement, except as set forth herein, the Holder shall not (i)&nbsp;lend, offer, pledge,
sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, (a)&nbsp;any Company Post-Closing
Common Shares that are outstanding and owned by the Holder immediately following the Effective Time (the &#147;<U>Covered Common Shares</U>&#148;) or (b)&nbsp;any securities that are outstanding and owned by the Holder immediately following the
Effective Time that are convertible into or exercisable or exchangeable (directly or indirectly) for Company Post-Closing Common Shares (including, without limitation, Company Post-Closing Common Shares or other securities that may be issued after
the Effective Time upon exercise, vesting or settlement, as applicable, of any stock option, restricted stock unit, capped value appreciation right or other equity or equity-based award or interest, including for the avoidance of doubt, Adjusted
Options, Adjusted RSU Awards and Adjusted CVAR Awards (the securities described in this clause (b), the &#147;<U>Covered Other Securities</U>&#148; and, together with the Covered Common Shares, the &#147;<U>Covered Securities</U>&#148;)), or
(ii)&nbsp;enter into any swap, hedge or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any Covered Securities, whether any such transaction described in clause (i)&nbsp;or (ii)
above is to be settled by delivery of Covered Securities, in cash or otherwise, and whether any such transaction is made or executed by or on behalf of someone other than the Holder (each, a &#147;<U>Sale Transaction</U>&#148;), in each case,
without the prior written consent of the Company. The foregoing limitations shall remain in full force and effect for a period of (A)&nbsp;with respect to 100% of the Covered Securities, six (6)&nbsp;months from and after the Closing Date,
(B)&nbsp;with respect to 75% of the Covered Securities (rounded up to the nearest whole share or other security, as the case may be), twelve (12)&nbsp;months from and after the Closing Date and (C)&nbsp;with respect to 50% of the Covered Securities
(rounded up to the nearest whole share or other security, as the case may be), <FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;months from and after the Closing Date (the periods set forth in the foregoing clauses (A)&nbsp;through (C),
as applicable, the &#147;<U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</U>&#148;), with the percentages set forth in this sentence applying to the aggregate holdings of Covered Securities held by all entities constituting the Holder, and
calculated on an aggregated basis. The Company may impose stop-transfer instructions with respect to the Covered Securities subject to the restrictions set forth in this Section&nbsp;1(a). For the avoidance of doubt, the Covered Securities shall be
measured on an <FONT STYLE="white-space:nowrap">as-exercised</FONT> or <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, as applicable.]<SUP STYLE="font-size:85%; vertical-align:top">2</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) [For the applicable <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period (as defined below), notwithstanding anything to the contrary
set forth in the Company&#146;s <FONT STYLE="white-space:nowrap">bye-laws</FONT> or any other agreement, except as set forth herein, the Holder shall not (i)&nbsp;lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Company Post-Closing Common Shares or Company Warrants (it being understood and agreed that,
for purposes of this Agreement, references to &#147;Company Warrants&#148; shall be deemed to include Company Post-Closing Common Shares underlying such Company Warrants), as applicable, that are outstanding and owned by the Holder immediately
following the Effective Time (the &#147;<U>Covered Securities</U>&#148;) or (ii)&nbsp;enter into any swap, hedge or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any Covered
Securities, whether any such transaction described in clause (i)&nbsp;or (ii) above is to be settled by delivery of Covered Securities, in cash or otherwise, and whether any such transaction is made or executed by or on behalf of someone other than
the Holder (each, a &#147;<U>Sale Transaction</U>&#148;), in each case, without the prior written </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be included for Holders other than the MAAC Sponsor. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consent of the Company. The foregoing limitations shall remain in full force and effect for a period of: (A)&nbsp;with respect to 100% of the Company Post-Closing Common Shares owned by the
Holder as of immediately following the Effective Time, six (6)&nbsp;months from and after the Closing Date, (B)&nbsp;with respect to 25% of the Company Post-Closing Common Shares owned by the Holder as of immediately following the Effective Time,
the earlier of (I)&nbsp;twelve (12) months following the date on which the applicable <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares (as such term is defined in the Sponsor Support Agreement) vest pursuant to Section&nbsp;2 of the Sponsor
Support Agreement and <FONT STYLE="white-space:nowrap">(II)&nbsp;seventy-two</FONT> (72)&nbsp;months from and after the Closing Date, (C)&nbsp;with respect to 50% of the Company Post-Closing Common Shares owned by the Holder as of immediately
following the Effective Time, <FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;months from and after the Closing Date, (D)&nbsp;with respect to 100% of the Company Warrants owned by the Holder as of immediately following the Effective
Time, six (6)&nbsp;months from and after the Closing Date, (E)&nbsp;with respect to 75% of the Company Warrants owned by the Holder as of immediately following the Effective Time, twelve (12)&nbsp;months from and after the Closing Date and
(F)&nbsp;with respect to 50% of the Company Warrants owned by the Holder as of immediately following the Effective Time, <FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;months from and after the Closing Date (the periods set forth in
the foregoing clauses (A)&nbsp;through (F), as applicable, the &#147;<U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</U>&#148;). Notwithstanding the foregoing, the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period described in clauses
(A), (B) and/or (C)&nbsp;shall apply to Covered Securities that are Company Post-Closing Common Shares (other than the <FONT STYLE="white-space:nowrap">Earn-out</FONT> Shares), the $15 <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares (as such
term is defined in the Sponsor Support Agreement) and the $20 <FONT STYLE="white-space:nowrap">Earn-out</FONT> Shares (as such term is defined in the Sponsor Support Agreement) in the manner (and in the applicable proportions) set forth on <U>Annex
A</U> hereto. The Company may impose stop-transfer instructions with respect to the Covered Securities subject to the restrictions set forth in this Section&nbsp;1(a). For the avoidance of doubt, (1)&nbsp;any
<FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares that vest pursuant to the Sponsor Support Agreement shall remain subject to any applicable <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period set forth herein and (2)&nbsp;notwithstanding
the expiration of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period with respect to any <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares, such shares shall remain subject to any applicable restrictions set forth in the Sponsor
Support Agreement. For the avoidance of doubt, the Covered Securities shall be measured on an <FONT STYLE="white-space:nowrap">as-exercised</FONT> or <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, as applicable.]<SUP
STYLE="font-size:85%; vertical-align:top">3</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The restrictions set forth in Section&nbsp;1(a) shall not apply to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) any securities issued to the Holder in connection with a PIPE Subscription Agreement, including any Covered Securities received in
exchange for, or converted for, securities acquired pursuant to a PIPE Subscription Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) [if the Holder is a party to the
Registration Rights Agreement, the sale of any Company Post-Closing Common Shares pursuant to the Holder&#146;s exercise of the piggyback registration rights set forth in, and in accordance with the terms and conditions of, the Registration Rights
Agreement, so long as such sale is consummated during the six (6)&nbsp;months from and after the Closing Date;]<SUP STYLE="font-size:85%; vertical-align:top">4</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) a transfer of any or all of the Covered Securities: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A) by gift, will, intestate succession or charitable contribution; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B) to any Permitted Transferee (as defined below); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(C) by operation of law or pursuant to a court order or an order of a regulatory agency, such as a qualified domestic relations order,
divorce decree or separation agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(D) to the Company pursuant to the exercise, in each case on a &#147;cashless&#148; or &#147;net
exercise&#148; basis, of any [Covered Other Securities]<SUP STYLE="font-size:85%; vertical-align:top">5</SUP> [Company Warrants]<SUP STYLE="font-size:85%; vertical-align:top">6</SUP> (provided that any Company Post-Closing Common Shares received by
the Holder upon any such exercise will be subject to the terms of Section&nbsp;1(a)); </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be included for the MAAC Sponsor. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be included for Holders other than the Founder, Matthew Gline and the MAAC Sponsor. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">5</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be included for Holders other than the MAAC Sponsor. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">6</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be included for the MAAC Sponsor. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(E) [for purposes of satisfying any withholding taxes and/or estimated taxes due as a
result of the exercise, vesting or settlement, as applicable, of any Covered Other Securities;]<SUP STYLE="font-size:85%; vertical-align:top">7</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(F) in connection with the Company&#146;s consummation of a liquidation, merger, amalgamation, share exchange, reorganization, tender offer
or other similar transaction that results in all of the Company&#146;s shareholders having the right to exchange their equity holdings in the Company for cash, securities or other property; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(G) by pledging, hypothecating or otherwise granting a security interest in Covered Securities in a <I>bona fide</I> transaction to one or
more unaffiliated lending institutions as&nbsp;collateral&nbsp;or security for any margin loan and any transfer in the event of foreclosure upon such Covered Securities as a result of a default on such margin loan (so long as any such pledge,
hypothecation or grant of security interest shall be on terms consistent with customary margin loans, and the Holder shall provide the Company with written notice prior to entering into such margin loan); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(H) a sale or other transfer by an Upstream Equity Holder of its direct or indirect common stock or membership, partnership or other equity
ownership interest in the Holder (whether or not for consideration); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(I) [to cover any direct or indirect tax obligations (including
satisfying any withholding taxes and/or estimated taxes due as a result of the exercise, vesting or settlement, as applicable, of any securities) that may accrue to the Holder, the Holder&#146;s direct or indirect owners or the Holder&#146;s
Permitted Transferees (so long as, in all such transfers pursuant to this clause (I), no more than 5% in the aggregate of the Holder&#146;s Covered Securities are transferred);]<SUP STYLE="font-size:85%; vertical-align:top">8</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I>, <I>however</I>, that in the case of any of the foregoing clauses (A), (B) or (C), the transferee in such transfer shall agree in a writing
delivered to the Company that the Covered Securities so transferred will thereafter continue be subject to the terms of Section&nbsp;1(a) unless released earlier in accordance with Section&nbsp;1(h) of this Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) the establishment or modification of a written plan meeting the requirements of Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> of
the Exchange Act that does not provide for the sale or transfer of Covered Securities during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period; <I>provided </I>that, to the extent a public announcement or filing under the Exchange Act is
required regarding the establishment or modification of such plan, such announcement or filing shall include a statement to the effect that no sales or transfers of Covered Securities may be made under such plan during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) As used in this Agreement, the term &#147;<U>Permitted Transferee</U>&#148; means:
(A)&nbsp;the Holder&#146;s immediate family (which shall mean, with respect to any natural person, any of the following: such person&#146;s spouse or domestic partner, the siblings of such person and his or her spouse or domestic partner, and the
direct descendants and ascendants (including adopted and step children and parents) of such person and his or her spouses or domestic partners and siblings), (B) any entities controlled by, controlling or under common control with the Holder,
(C)&nbsp;any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder, (D)&nbsp;if the Holder is a trust, the trustor or beneficiary of such trust or to the estate of a beneficiary of such trust, (E)&nbsp;if the
Holder is an entity, any direct or indirect partners, members or equity holders of the Holder, any affiliate (as defined in Rule 405 promulgated under the Securities Act) or employee of the Holder or any related investment funds or vehicles
controlled or managed by such persons or entities or their respective affiliates (including, for the avoidance of doubt, where the Holder is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such
partnership), and (F)&nbsp;a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under this Agreement. As used in this Agreement, the term &#147;<U>Upstream Equity Holder</U>&#148; means, with respect to
the Holder, its direct or indirect stockholders, partners, members or other equity holders. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">7</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be included for Holders other than the MAAC Sponsor. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">8</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be included for the MAAC Sponsor. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Holder agrees to execute and deliver such other customary agreements as may be
reasonably requested by the Company or the managing underwriter in an underwritten transaction that are consistent with this Agreement or that are necessary to give further effect thereto. Any such agreement entered into after the date hereof
(i)&nbsp;shall not be more restrictive than this Agreement and (ii)&nbsp;shall include provisions providing for the <I>pro rata</I> release of the Holder&#146;s shares that are consistent with Section&nbsp;1(h) hereof, unless the Holder agrees
otherwise in writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) If any Sale Transaction is made or attempted contrary to the provisions of this Agreement, such purported Sale
Transaction shall be null and void <I>ab initio</I>, and the Company shall refuse to recognize any such purported transferee of the applicable Covered Securities as one of its equity holders for any purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) During the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, each certificate (if any) or book entry evidencing any Covered
Securities owned by the Holder shall be stamped or otherwise imprinted or legended with a legend in substantially the following form, in addition to any other applicable legends:<SUP STYLE="font-size:85%; vertical-align:top">9</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFER SET FORTH IN A
<FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT, DATED AS OF [&#149;], 2021, BY AND AMONG ROIVANT SCIENCES LTD. (THE &#147;ISSUER&#148;) AND THE ISSUER&#146;S SECURITY HOLDER NAMED THEREIN, AS IT MAY BE AMENDED FROM TIME TO TIME. A COPY OF
SUCH <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT WILL BE FURNISHED WITHOUT CHARGE BY THE ISSUER TO THE HOLDER HEREOF UPON WRITTEN REQUEST.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) For the avoidance of any doubt, the Holder shall retain all of its rights as a shareholder of the Company during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period, including the right to vote any Covered Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Any discretionary waiver or any
amendment, modification or termination of (i)&nbsp;the restrictions set forth in Section&nbsp;1(a) of any <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement entered into on the date hereof by the Company and a holder of its securities and
(ii)&nbsp;the <FONT STYLE="white-space:nowrap">lock-up,</FONT> holdback or similar provisions, agreements or restrictions set forth in the Company&#146;s <FONT STYLE="white-space:nowrap">bye-laws,</FONT> the Registration Rights Agreement or any
other agreement entered into on the date hereof between the Company and a holder of its securities, in each case, shall waive, amend, modify or terminate the provisions of Section&nbsp;1(a) of this Agreement with respect to the Holder to the same
extent and/or in the same aggregate amount, applied <I>pro rata</I>, to release Covered Securities that are subject to the restrictions set forth in clauses (A), (B) or (C)&nbsp;of Section&nbsp;1(a) of this Agreement, respectively, based on the
number of shares held by the Holder that are subject to such restrictions[, but taking into account differences in the restrictions set forth in clause (B)&nbsp;of Section&nbsp;1(a) of this Agreement with respect to the MAAC Sponsor].<SUP
STYLE="font-size:85%; vertical-align:top">10</SUP> The Company shall use commercially reasonable efforts to, at least two (2)&nbsp;business days prior to the effective date of any waiver or release pursuant to this Section&nbsp;1(h), provide written
notice to the Holder stating the number of Covered Securities to be released. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) In the event the Holder effects a Transfer (as defined
in the Transaction Support Agreement entered into by and among the Holder, the Company and MAAC on the date hereof (as applicable, a &#147;<U>Support Agreement</U>&#148;)) of any Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common
Shares, MAAC Warrants and/or Company Equity Awards, as applicable, in accordance with the terms and conditions of the Support Agreement, the Holder shall cause the transferee of any such Transfer to enter into a written agreement in form and
substance reasonably satisfactory to the Company agreeing to be bound by this Agreement (which will include, for the avoidance of doubt, all of the covenants, agreements and obligations of the Holder hereunder) prior and as a condition to the
occurrence of such Transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Termination</U>. This Agreement shall be binding upon the Holder upon the Holder&#146;s execution and
delivery of this Agreement, but this Agreement shall only become effective upon the Closing. This Agreement shall </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">9</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be confirmed with transfer agent that it can implement these restrictions as a matter of Bermuda law.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">10</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be included for the MAAC Sponsor. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
automatically terminate, without any notice or other action by any Party, and be void <I>ab initio</I> upon the termination of the Business Combination Agreement in accordance with its terms.
This Agreement shall automatically terminate, without any notice or other action by any Party, upon the expiration of all applicable <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Periods applicable to the Holder; <I>provided</I> that such
termination shall not release the Holder from any liability for any breach of this Agreement prior to such termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.
<U>Notices</U>. All notices, requests, claims, demands and other communications hereunder shall be in writing and shall be given (and shall be deemed to have been duly given) by delivery in person, by <FONT STYLE="white-space:nowrap">e-mail</FONT>
(having obtained electronic delivery confirmation thereof (i.e., an electronic record of the sender that the email was sent to the intended recipient thereof without an &#147;error&#148; or similar message that such email was not received by such
intended recipient)), or by registered or certified mail (postage prepaid, return receipt requested) (upon receipt thereof) to the other Parties as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to the Company, to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Roivant Sciences Ltd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Suite
1, 3rd Floor, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">11-12</FONT> St. James&#146;s Square, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">London SW1Y 4LB, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">United
Kingdom </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Matthew Gline </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> matthew.gline@roivant.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">legalnotices@roivant.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with
a copy (which shall not constitute notice) to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Roivant Sciences, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">151 West 42nd Street, 15th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, NY 10036 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention:
General Counsel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> jo.chen@roivant.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">-and- </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Davis Polk&nbsp;&amp;
Wardwell LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">450 Lexington Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, NY 10017 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention:
Derek Dostal; Lee Hochbaum; Brian Wolfe </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: derek.dostal@davispolk.com; lee.hochbaum@davispolk.com; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">brian.wolfe@davispolk.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
to the Holder, to the address on the Holder&#146;s signature page hereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address as the Party to whom notice is given may have
previously furnished to the others in writing in the manner set forth above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Entire Agreement</U>. This Agreement [constitutes]
[and the Sponsor Support Agreement constitute]<SUP STYLE="font-size:85%; vertical-align:top">11</SUP> the entire agreement of the Parties with respect to the subject matter hereof, and supersede[s] all prior agreements and undertakings, both written
and oral, among the Parties with respect to the subject matter of this Agreement, except as otherwise expressly provided in this Agreement. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">11</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be included for the MAAC Sponsor. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Amendments and Waivers; Assignment</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Any provision of this Agreement may be amended or waived if, and only if, such amendment or waiver is in writing and signed by the Holder
and the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding the foregoing, no failure or delay by any Party in exercising any right hereunder shall operate as a
waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise of any other right hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assignable by the Holder without the Company&#146;s prior written consent (to be withheld or given in its sole discretion). Any attempted assignment of this
Agreement not in accordance with the terms of this Section&nbsp;5 shall be null and void <I>ab initio</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>No Third Party
Beneficiaries</U>. This Agreement shall be for the sole benefit of the Parties and their respective successors and permitted assigns and is not intended, nor shall be construed, to give any Person, other than the Parties and their respective
successors and permitted assigns, any legal or equitable right, benefit or remedy of any nature whatsoever by reason this Agreement. Nothing in this Agreement, expressed or implied, is intended to, or shall be deemed to, create a joint venture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Miscellaneous</U>. <U>Sections 8.5</U> (Governing Law), <U>8.7</U> (Construction; Interpretation), <U>8.10</U> (Severability),
<U>8.11</U> (Counterparts; Electronic Signatures), <U>8.15</U> (Waiver of Jury Trial), <U>8.16</U> (Submission to Jurisdiction) and <U>8.17</U> (Remedies) of the Business Combination Agreement are incorporated herein by reference and shall apply to
this Agreement, <I>mutatis mutandis</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature page follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed and delivered this <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ROIVANT SCIENCES LTD.</B></TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Lock-Up Agreement</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed and delivered this <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>[HOLDER]</B></TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Lock-Up Agreement</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Annex A </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN THE PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;20.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification of directors and officers. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DGCL does not limit the extent to which a company&#146;s memorandum and articles of association may provide for indemnification of officers
and directors. However, such provision may be held by the Delaware courts to be unenforceable, to the extent it seeks to indemnify or exculpate a fiduciary in respect of their actual fraud or willful default, or for the consequences of committing a
crime. MAAC&#146;s existing organizational documents provide for indemnification of officers and directors for losses, damages, costs and expenses incurred in their capacities as such, except through their own actual fraud, willful neglect or
willful default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such limitation of liability and indemnification does not affect the availability of equitable remedies. In addition,
MAAC has been advised that, in the opinion of the SEC, indemnification for liabilities arising under the Securities Act is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;21.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exhibits and Financial Statements Schedules </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>2.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521235175/d65062ds4a.htm#rom65062_39">Business Combination Agreement, dated as of May&nbsp;
1, 2021, by and among Montes Archimedes Acquisition Corp., Roivant Sciences Ltd. and Rhine Merger Sub, Inc. (included as Annex A to the joint proxy statement/prospectus which is part of this registration statement and incorporated herein by reference)
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>2.2#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex22.htm#cov">Agreement and Plan of Merger, dated as of February&nbsp;
2, 2021, by and among Roivant Sciences Ltd., Silicon Insite, Inc., Silicon TX China, Silicon Therapeutics, LLC and Silicon SWAT, Inc. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>2.3#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex23.htm#cov">Stock Purchase Agreement, dated as of November&nbsp;
6, 2020, by and among Oncopia Therapeutics, Inc., Pharmavant 5, Inc., certain selling securityholders and certain seller representative </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>2.4#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex24.htm">Amendment No. 1 to the Stock Purchase Agreement, dated as of November&nbsp;
17, 2020, by and among Oncopia Therapeutics, Inc., Pharmavant 5, Inc., certain selling securityholders and WRYP Stockholders Services, LLC </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>2.5**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000110465919059171/a19-21684_1ex7d04.htm">Transaction Agreement, dated as of October&nbsp;31, 2019, by and among Sumitomo Dainippon Pharma Co.,&nbsp;
Ltd., Vant Alliance Ltd., Roivant Sciences Ltd., Enzyvant Therapeutics Ltd., Altavant Sciences Ltd. and Spirovant Sciences Ltd. (incorporated herein by reference to Exhibit 7.04 of Roivant Sciences Ltd.&#146;s Schedule 13D/A, filed with the SEC on November&nbsp;4,
 2019) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>2.6#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex26.htm">Asset Purchase Agreement, dated as of July 10, 2018, by and among GlaxoSmithKline Intellectual Property Development Ltd., Glaxo Group Limited and
 Dermavant Sciences GmBH </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>2.7#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex27.htm">Asset Purchase Agreement, dated as of May&nbsp;29, 2012, by and between Glaxo Group Limited and Welichem Biotech Inc. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>2.8#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex28.htm">First Amendment to the Asset Purchase Agreement, dated as of August&nbsp;
31, 2012, by and between Glaxo Group Limited and Welichem Biotech, Inc. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>2.9**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521235175/d65062ds4a.htm#rom65062_39a">Amendment No. 1 to the Business Combination Agreement, dated June 9, 2021, by and among Montes Archimedes Acquisition Corp., Roivant
 Sciences Ltd. and Rhine Merger Sub, Inc. (included as Annex AA to the joint proxy statement/prospectus which is part of this registration and incorporated herein by reference) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex31.htm">Memorandum of Association of Roivant Sciences Ltd. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.2**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex32.htm">Form of Amended and Restated <FONT STYLE="white-space:nowrap">Bye-laws</FONT> of Roivant Sciences Ltd. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1819263/000104746920004991/a2242417zex-4_1.htm">Specimen Unit Certificate of Montes Archimedes Acquisition Corp. (incorporated herein by reference to Exhibit 4.1 of Montes Archimedes Acquisition
 Corp.&#146;s Amendment No.&nbsp;1 to the Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1,&nbsp;filed</FONT> with the SEC on September&nbsp;24, 2020) </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="88%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.2**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1819263/000104746920004991/a2242417zex-4_2.htm">Specimen Class&nbsp;
A Common Stock Certificate of Montes Archimedes Acquisition Corp. (incorporated herein by reference to Exhibit 4.2 of Montes Archimedes Acquisition Corp.&#146;s Amendment No.&nbsp;
1 to the Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1,&nbsp;filed</FONT> with the SEC on September&nbsp;24, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.3**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1819263/000104746920004991/a2242417zex-4_3.htm">Specimen Warrant Certificate of Montes Archimedes Acquisition Corp. (incorporated herein by reference to Exhibit 4.3 of Montes Archimedes Acquisition
 Corp.&#146;s Amendment No.&nbsp;1 to the Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1,&nbsp;filed</FONT> with the SEC on September&nbsp;24, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.4**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1819263/000110465920114035/tm2033018d1_ex4-1.htm">Warrant Agreement between Continental Stock Transfer&nbsp;
&amp; Trust Company and Montes Archimedes Acquisition Corp. (incorporated herein by reference to Exhibit 4.1 of Montes Archimedes Acquisition Corp.&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K,&nbsp;
filed</FONT> with the SEC on October&nbsp;13, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.5**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521235175/d65062dex45.htm">Specimen Ordinary Share Certificate of Roivant Sciences Ltd. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.6**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521235175/d65062dex46.htm">Specimen Warrant Certificate of Roivant Sciences Ltd. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.7**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521235175/d65062dex47.htm">Form of Warrant Assumption Agreement, by and between Montes Archimedes Acquisition Corp., Roivant Sciences Ltd. and American Stock Transfer&nbsp;&amp;
 Trust Company, LLC </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>5.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex51.htm">Opinion of Conyers Dill&nbsp;
&amp; Pearman Limited as to matters concerning the laws of Bermuda as to the validity of the Common Shares of Roivant Sciences Ltd. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>5.2**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex52.htm">Opinion of Davis Polk &amp; Wardwell LLP regarding the validity of the Roivant Warrants under New York law </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>8.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex81.htm">Opinion of Davis Polk &amp; Wardwell London LLP regarding certain U.K. tax matters </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>8.2**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521221954/d65062dex82.htm">Opinion of Davis Polk &amp; Wardwell LLP regarding certain U.S. tax matters </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>8.3**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521235175/d65062dex83.htm">Opinion of Kirkland &amp; Ellis LLP regarding certain U.S. tax matters </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521235175/d65062ds4a.htm#rom65062_41">Third Amended and Restated Registration Rights Agreement, dated as of May&nbsp;
1, 2021, by and among Roivant Sciences Ltd. and the parties thereto (included as Annex C to the joint proxy statement/prospectus which is part of this registration statement and incorporated herein by reference) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521235175/d65062ds4a.htm#rom65062_40">Form of Subscription Agreement (included as Annex B to the joint proxy statement/prospectus which is part of this registration statement
 and incorporated herein by reference) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521235175/d65062ds4a.htm#rom65062_43">Sponsor Support Agreement, dated as of May&nbsp;
1, 2021, by and among Roivant Sciences Ltd., Montes Archimedes Acquisition Corp., Patient Square Capital LLC and certain shareholders of Roivant Sciences Ltd. (included as Annex E to the joint proxy statement/prospectus which is part of this registration
 statement and incorporated herein by reference) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521235175/d65062ds4a.htm#rom65062_42">Form of Transaction Support Agreement, dated as of May&nbsp;
1, 2021, by and among Roivant Sciences Ltd., Montes Archimedes Acquisition Corp. and certain shareholders of Roivant Sciences Ltd. (included as Annex D to the joint proxy statement/prospectus which is part of this registration statement and incorporated
 herein by reference) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1819263/000110465920114035/tm2033018d1_ex10-1.htm">Investment Management Trust Agreement between Continental Stock Transfer&nbsp;
&amp; Trust Company and Montes Archimedes Acquisition Corp. (incorporated herein by reference to Exhibit 10.1 of Montes Archimedes Acquisition Corp.&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K,&nbsp;
filed</FONT> with the SEC on October&nbsp;13, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1764013/000119312519321147/d839382dex106.htm">License Agreement, dated as of December&nbsp;
19, 2017, by and between HanAll Biopharma Co., Ltd. and Roivant Sciences GmbH (incorporated herein by reference to Exhibit 10.6 of Immunovant, Inc.&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed with the SEC on December&nbsp;20,
 2019) </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="88%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex107.htm">Collaboration and License Agreement, dated as of January&nbsp;15, 2020, by and between Dermavant Sciences GmbH and Japan Tobacco
Inc.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex108.htm">Clinical Manufacturing and Supply Agreement, dated August&nbsp;
20, 2018, by and between Dermavant Sciences GmbH and GlaxoSmithKline Trading Services Limited.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex109.htm">Commercial Manufacturing and Supply Agreement, dated April&nbsp;
1, 2019, by and between Dermavant Sciences GmbH and GlaxoSmithKline Trading Services Limited. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex1010.htm">Funding Agreement, dated as of July&nbsp;
10, 2018, by and between Dermavant Sciences GmBH and NovaQuest <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Fund VIII, L.P.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex1011.htm">First Amendment to Funding Agreement, dated as of October&nbsp;11, 2018, by and between Dermavant Sciences GmBH and NovaQuest <FONT
STYLE="white-space:nowrap">Co-Investment</FONT> Fund VIII, L.P. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1012.htm">License Agreement, dated as of November&nbsp;
21, 2018, by and between Cincinnati Children&#146;s Hospital Medical Center and Aruvant Sciences GmbH </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1013.htm">Subscription Agreement, dated as of November&nbsp;
21, 2018 by and between Cincinnati Children&#146;s Hospital Medical Center and Aruvant Sciences Ltd. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1447028/000144702820000118/a2020-q210xqex103cross.htm">Cross License Agreement, dated as of April&nbsp;
11, 2018, by and between Genevant Sciences Ltd. and Arbutus Biopharma Corporation (incorporated herein by reference to Exhibit 10.3 of Arbutus Biopharma Corporation&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the Quarter
 ended June&nbsp;30, 2020, filed with the SEC on August&nbsp;7, 2020 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1447028/000144702820000118/a2020-q210xqex1041stam.htm">First Amendment to Cross License Agreement, dated as of June&nbsp;
27, 2018, by and among Genevant Sciences Ltd., Genevant Sciences GmbH and Arbutus Biopharma Corporation (incorporated herein by reference to Exhibit 10.4 of Arbutus Biopharma Corporation&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q
</FONT> for the Quarter ended June&nbsp;30, 2020, filed with the SEC on August&nbsp;7, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1447028/000144702820000118/a2020-q210xqex105secon.htm">Second Amendment to Cross License Agreement, dated as of June&nbsp;
27, 2018, by and among Genevant Sciences Ltd., Genevant Sciences GmbH and Arbutus Biopharma Corporation (incorporated herein by reference to Exhibit 10.5 of Arbutus Biopharma Corporation&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q
</FONT> for the Quarter ended June&nbsp;30, 2020, filed with the SEC on August&nbsp;7, 2020)</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.17#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1017.htm">License Agreement, dated as of November&nbsp;19, 2018, by and between iNtRON Biotechnology, Inc. and Pharmavant 1 GMBH in
Formation</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.18#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1018.htm">First Amendment to License Agreement, dated as of March&nbsp;
23, 2019, by and between iNtRON Biotechnology, Inc. and Pharmavant 1 GMBH in Formation</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.19#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1019.htm">Second Amendment to License Agreement, dated as of August&nbsp;
28, 2019, by and between iNtRON Biotechnology, Inc. and Lysovant Sciences GMBH</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.20#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1020.htm">Research Agreement, dated as of January&nbsp;
1, 2018, by and between Oncopia Therapeutics, LLC and the Regents of the University of Michigan</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.21#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1021.htm">Fifth Amendment to the Sponsored Research Agreement, dated as of November&nbsp;
19, 2020, by and between Oncopia Therapeutics, Inc. and the Regents of the University of Michigan </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.22#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1022.htm">Amended and Restated Patent License Agreement, dated as of November&nbsp;
16, 2020, by and between Oncopia Therapeutics, Inc. and the Regents of the University of Michigan </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.23#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1023.htm">Investors&#146; Rights Agreement, dated as of January&nbsp;
11, 2021, by and among Pharmavant 5, Inc., Roivant Sciences Ltd. and SK Holdings Co., Ltd. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.24**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1024.htm">Form of Indemnity Agreement </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.25**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex1025.htm">Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.26**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex1026.htm">Form of Roivant Sciences Ltd. 2021 Equity Incentive Plan </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="88%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.27**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex1027.htm">Amended and Restated Employment Agreement between Roivant Sciences, Inc. and Vivek Ramaswamy, dated as of May 14, 2021</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.28**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex1028.htm">Executive Employment Agreement between Roivant Sciences, Inc. and Matthew Gline, dated as of May 14, 2021</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.29**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex1029.htm">Executive Employment Agreement between Roivant Sciences, Inc. and Eric Venker, dated as of May 14, 2021</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.30**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex1030.htm">Executive Employment Agreement between Roivant Sciences, Inc. and Benjamin Zimmer, dated as of May 14, 2021</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.31#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1031.htm#cov">Credit Agreement by and among Dermavant Sciences Ltd., Dermavant Holdings Limited, Dermavant Sciences IRL Limited, Dermavant Sciences GmbH,
 certain subsidiaries of Dermavant Sciences Ltd., XYQ Luxco S.A.R.L. and U.S. Bank National Association, as collateral agent, dated as of May 14, 2021</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.32#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1032.htm">Revenue Interest Purchase and Sale Agreement by and among Dermavant Sciences GmbH, certain purchasers and U.S. Bank National Association as collateral
 agent, dated as of May 14, 2021 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.33**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521235175/d65062ds4a.htm#rom65062_43a">Amendment No. 1 to the Support Agreement, dated as of June 9, 2021, by and among Roivant Sciences Ltd., Montes Archimedes Acquisition
 Corp., Patient Square Capital LLC and certain shareholders of Roivant Sciences Ltd. (included as Annex EE to the joint proxy statement/prospectus which is part of this registration statement and incorporated herein by reference) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex211.htm">List of Subsidiaries of Roivant Sciences Ltd.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d65062dex231.htm">Consent of Marcum LLP, Independent Registered Public Accounting Firm of Montes Archimedes Acquisition Corp.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d65062dex232.htm">Consent of Ernst&nbsp;&amp; Young LLP, Independent Registered Public Accounting Firm of Roivant Sciences Ltd. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.3**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex51.htm">Consent of Conyers Dill&nbsp;&amp; Pearman Limited (included in Exhibit 5.1)</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.4**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex52.htm">Consent of Davis Polk &amp; Wardwell LLP (included in Exhibit 5.2) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.5**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex81.htm">Consent of Davis Polk &amp; Wardwell London LLP (included in Exhibit 8.1) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062ds4a.htm#sig">Power of Attorney (included on signature page) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1635088/000119312521221954/d65062dex991.htm">Form of Proxy Card for the MAAC Special Meeting </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.&nbsp;INS**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Instance Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Calculation Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Definition Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Label Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.PRE**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Presentation Linkbase Document</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Previously filed. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Portions of this exhibit have been omitted because they are both (i)&nbsp;not material and (ii)&nbsp;would
likely cause competitive harm to Roivant Sciences Ltd. if publicly disclosed. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;22.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Undertakings. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;The undersigned Registrant hereby undertakes: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;To file, during any period in which offers or sales are being made, a post-effective amendment to
this Registration Statement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To include any prospectus required by section 10(a)(3)
of the Securities Act of 1933; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To reflect in the prospectus any facts or events arising
after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement.
Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum
offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in
the &#147;Calculation of Registration Fee&#148; table in the effective registration statement; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;To include any material information with respect to the plan of distribution not previously
disclosed in this Registration Statement or any material change to such information in this Registration Statement; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;That, for the purpose of determining any liability under the Securities Act of 1933, each such
post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona
fide</I> offering thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;To remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the termination of the offering. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser,
each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part
of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document
incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any
statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to
any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method
used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or
sell such securities to such purchaser: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any preliminary prospectus or
prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any free writing prospectus relating to the offering prepared by or on behalf of the
undersigned registrant or used or referred to by the undersigned registrant; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;The portion of
any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;Any other communication that is an offer in the
offering made by the undersigned registrant to the purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;Insofar as indemnification for liabilities
arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such
indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses
incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being
registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by them is against public policy as
expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned registrant hereby undertakes as follows: that prior to any public reoffering of the securities registered hereunder through use of a prospectus which is a part of this registration statement, by any person or party who is deemed to be an
underwriter within the meaning of Rule 145(c), the issuer undertakes that such reoffering prospectus will contain the information called for by the applicable registration form with respect to reofferings by persons who may be deemed underwriters,
in addition to the information called for by the other items of the applicable form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;The registrant undertakes
that every prospectus: (1)&nbsp;that is filed pursuant to the immediately preceding paragraph, or (2)&nbsp;that purports to meet the requirements of Section&nbsp;10(a)(3) of the Securities Act of 1933 and is used in connection with an offering of
securities subject to Rule 415, will be filed as a part of an amendment to the registration statement and will not be used until such amendment is effective, and that, for purposes of determining any liability under the Securities Act of 1933, each
such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;The undersigned Registrant hereby undertakes to respond to requests for information that is incorporated by
reference into the prospectus pursuant to Item 4, 10(b), 11 or 13 of this Form <FONT STYLE="white-space:nowrap">S-4,</FONT> within one business day of receipt of such request, and to send the incorporated documents by first class mail or other
equally prompt means. This includes information contained in documents filed subsequent to the effective date of this Registration Statement through the date of responding to the request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;The undersigned Registrant hereby undertakes to supply by means of a post-effective amendment all information
concerning this transaction that was not the subject of and included in this Registration Statement when it became effective. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be
signed on its behalf by the undersigned, thereunto duly authorized, on the 6th day of August, 2021. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ROIVANT SCIENCES LTD.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Gline</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Matthew Gline</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Principal Executive Officer and Principal Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Matthew Gline, Jo Chen and
Marianne Romeo and each or any one of them, his true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent, with full power of substitution and resubstitution, for him and in his name,
place and stead, in any and all capacities, to sign any and all amendments to this proxy statement/prospectus, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the United States SEC, granting unto
said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in
connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents,
or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the
requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Capacity</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Matthew Gline</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" NOWRAP ALIGN="center">Principal Executive Officer and Principal Financial Officer</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" NOWRAP ALIGN="center">August 6,&nbsp;2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Matthew Gline</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Rakhi Kumar</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" NOWRAP ALIGN="center">Principal Accounting Officer</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" NOWRAP ALIGN="center">August 6, 2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Rakhi Kumar</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" NOWRAP ALIGN="center">Director</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" NOWRAP ALIGN="center">August 6, 2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Vivek Ramaswamy</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" NOWRAP ALIGN="center">Director</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" NOWRAP ALIGN="center">August 6, 2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Andrew Lo</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" NOWRAP ALIGN="center">Director</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" NOWRAP ALIGN="center">August 6, 2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Patrick Machado</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" NOWRAP ALIGN="center">Director</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" NOWRAP ALIGN="center">August 6, 2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Keith Manchester</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" NOWRAP ALIGN="center">Director</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" NOWRAP ALIGN="center">August 6, 2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ilan Oren</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" NOWRAP ALIGN="center">Director</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" NOWRAP ALIGN="center">August 6, 2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Daniel Gold</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" NOWRAP ALIGN="center">Director</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" NOWRAP ALIGN="center">August 6, 2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Masayo Tada</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Gline</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Matthew Gline</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Attorney-in-fact</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-8 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>d65062dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM&#146;S CONSENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the inclusion in this Registration Statement of Roivant Sciences Ltd. on Form <FONT STYLE="white-space:nowrap">S-4</FONT> (Amendment No.&nbsp;4)
(File <FONT STYLE="white-space:nowrap">No.&nbsp;333-256165)</FONT> of our report dated March&nbsp;22, 2021, except for the effects of the restatement discussed in Note 2 as to which the date is May&nbsp;13, 2021, with respect to our audit of the
financial statements of Montes Archimedes Acquisition Corp. as of December&nbsp;31, 2020 and for the period from July&nbsp;6, 2020 (inception) through December&nbsp;31, 2020, which report appears in the Proxy Statement and Prospectus, which is part
of this Registration Statement. We also consent to the reference to our Firm under the heading &#147;Experts&#148; in such Proxy Statement and Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Marcum <SMALL>LLP</SMALL> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marcum <SMALL>LLP</SMALL> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costa Mesa, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;6, 2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>d65062dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 23.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Experts&#148;&nbsp;and to the use of our report dated June&nbsp;30, 2021, included in the
Proxy Statement of Montes Archimedes Acquisition Corp. that is made a part of Amendment No.&nbsp;4 to the Registration Statement (Form <FONT STYLE="white-space:nowrap">S-4</FONT> <FONT STYLE="white-space:nowrap">No.&nbsp;333-256165)</FONT> and
Prospectus of Roivant Sciences Ltd. for the registration of 51,339,779 common shares and 30,750,276 warrants to purchase common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/
Ernst&nbsp;&amp; Young LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Iselin, New Jersey </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;6, 2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g65062g01t65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g01t65.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!GP(, P$1  (1 0,1 ?_$ !X
M 0 " @,! 0$            ("08'! 4* P$"_\0 2A    8#   #!@$("0(#
M!@<! @,$!08'  $("1$2$Q05%A<A(B,Q5UB6F-77&"0E)C(W07>V)T(S-%$*
M&6%DU/ V0U-B8W&AL?_$ !T! 0 !!0$! 0             ! @,%!@<$" G_
MQ !6$0 ! P,"! ,#" ,-! @%! ,!  (#! 41!B$'$A,Q%$%1%2)A%B,R<8&1
MH? ())47)3-"4E57E['!T=360V+A\28T4V-R@I*B"396<](U@Y;35*/"_]H
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M.)15VJFE):[?#O?FA6E<IBU3>9&0?3HC-L<4.B[J*))S/:"+<1[**,(&$XW
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M^TN\99'1;)'9K7D$#OHC88+LD]CS#!! &P\OM^"C5RMR=TOW7T1W+,^F'KI
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M"\4%/&RE?%%"U\4;)7S)I^<=0R:2+4-U\^UI5$6)9E"I#((?T,OMAT6OH%B
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M1[HWH6T[\B43=6U0$"AJ=8O%;(96)T:%!91[4XMZIO.*),3"* 5+CD_4 /N
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M)DJ(Q'U;_I^/NYQJJ>+VM01-:2:RDJ8VD.K"#SJ_?]%=24FK8_<L]Z-)8M6
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MG:I Q.*-W9'QM0O#,[-R@M6WNC4YI2EK>XH%1(ADJ4:U(>2I2J"AB+.(- 8
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M-;,52G0"9VFQ-$G20J&)W!C)U9.H3&9%'9)8$BT=$T*)D>DHX@EFKJ2M:$I
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M%++76BXT,;WQ,?(UU3231,Y'$%S2U\G,WE((=N"#NNAY#F!$_P"5^<IH2$H
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M$\2:KE$'B>1M=U3GVB,5H&XF#BYQQE@Y8J:-(:';VPF6Z3\XG/BBM?>)O)E
MRC9$@4-SG\QB&X^4F+$2I,]T(=0G$-X/-&A+3MIIZ(ZU':J2)M UO6Q;3(:;
M,\I(,K2U_5)=\Z,$\H?D-'NM ;EIQM!PRTM;H=#P4S+J(^'KJU^G>I>KE(6N
MN%.^GJ?:!=4?ODTLD=TF50>R 9B@;'3N?"_@K>1Z=<(?-(,H(F>V&?7$.\Y"
M$NP)<4X#GICNUO0S4#F6ZA6MK)M8T)/2Q(SBD!6M".)++6:*5%4NM%&Z&> B
M?IU%9XZ3%1,'>(+VO):X/YF,RP?-M(:.X =@BS-PJTE/:;Q99&7CP-\U:=;5
MX;?;JV<WPU=-6%T%2VJ$U/1=6DBQ0PO; P9<QK9>65N2/?.=:/[]<\D<2I/M
MSOF#MM>V!M-,)&D2F1UJ:'!D2A8$2=P FCB_W!R/":O:2TYPS_4I\]'JEXUE
MU]MI9)*V5PEYZ^!M-48FD#3&QCF#IM#@(W<KC[S #G?N7%V0K.'VG:ZNUA<:
MAMR-3KBRTUAOQCN]PBB=;Z6DGHHA00QSMCMT_0J) Z>E;&\R9DR'R3NE^C-S
MQ6[#):BE;>5)M.](U^LK."[4R^1*T9<77-S<U' ?4*EP,32)R]S:TVM.CL6I
M5B/UI4<,U0F0FI)9;J:.6CE:)>>AIS2T^9I7-$3FM8>=I<1(_E:!SO!=G<DD
M-(JH] Z>H;CI2Z4[;D*O1EAFTW9#)=KA+"VV34]/2O%;#).Z.X5/2IHP*FJ;
M)*7_ #KW.DC@=%BS9R/3K1$*\@Z,B9Z8:OMH-U10)]@2Y0O+G '9V>@&.CB:
MZB5O#-I8\K-B9' TY"<#8=J"SC3%)JBRRT43(:>!HFZ=+6>.AS43%PGYWO\
M><7Y>SF>?FW$M/F"22<93<*M)4EIT_9867CP.FM4C6-K#[]=I)Q>A5558'55
M0^J,M71]:LF)HIW/@>,=1KWND=)RY!RI4DF:;U970F7[1=%.3,[61I-.).F.
M,6,*="G;]QTTMQ]4:(T%O3^])6K1*=<5K:!84>U@(0DU26FCE97L>)N6Y.8Z
MIQ/*#F, -Z1YOFA[H)#,!WT7 LPT7J_AAI6XTNMJ.I9=NCQ J:2JU#T[U<HW
MNFHHX(X/9[FU&;<S%.SJQTO)'.W,$S7TS8X&94*A:]'8"BS-E23YG4U)]$S1
MZF$FTW?(GQ+;K[(#?\3]@!]][WYZDH?)[T'S$%;HT9AH[O@*?Q!J<2]4T?@2
M>M+R^'YN?'+SXZF?]K_"?[V22LF=#V$WZ349;<?:4FE?D:X^U[EX?V)XDU7*
MV#Q/(VNZIS[2&*T#<3!Y<XXQ'^6*FC2&AVYL)ENDW.)[XIK72B;R90,HV1(%
M#>Y?,8AN/E)B]DJ3/="'4)Q#>#S1H2R&TP]$=:CM-)$V@:T38MID=39GE)!E
M:6OZI+OG003@/R&_1;AI+3C:#AEI:W0:'IZ9EU$?#U];)IT27JY2%KZ^"2GJ
M3<"ZH_?)I9([I,J@^. 9BA;'3N?"[A+N2*=<8?-8,I(F>V&?7".\Y"$NP)<4
MX#GACNUO0S6]S ZZ6MC)M8T(_0Q(SBF\G6A&D%E*]%*2H=:*-\,].1/TZBL-
M=+BHF#C4%['DM?S\S6$L'S;2&C<@!VXLS<*M)5%IO%DD9>#0WW5IUK7AM^NS
M)W7QU735A=!4MJA-3T76I(L4,+VP, +XVMFY96Y(]<YUH_O]S25Q*D^W2^8,
MVUY8&TTPD:1*9'&IH<&1*%@1)W M-'%_N#D?HQ>TEISQG^I3K83U*\:RY);:
M622ME<)>>OIVTU1B:4-,3&.8.FT. C=RN/O, .<GNYQ=D:SA_IVNKM7W&H;<
MO$ZXLE/8+Z8[O<(HG6^FI*BBB%##'4-BM\_0J) Z>E;&\OS)L^2=TOT9N=ZV
M89+4,K;RI-IWI"OUE9P3:F7R)6C+BZYM;FDX#ZA4.!B:1.7N;6FUIS=BU*L1
M^M*C1FJ4R$U)++=31RT<S1+ST-.ZFI\S2EHB<QK#U&EQ$KN5H]]^79W))#2)
MI- :>H;CI2Z0-N0J]&6&;3EDZEVN$L+;;/3T]*\5L$D[H[A4]&FC'B:ILDI?
MB5[G21P.BQ9LY'IUIB%>0=&1,],586UJZXJ$ZP)<H7@G 79V>0&NCB:ZB5N[
M-I8\K-B9%YIR X&P[4%G&F*35%EEHHF0T\#1-TZ6K\=%FHF+A/SO?ESB_F>S
MF>?FW$M/F"22<;3<*M)4MIL%EA9>!0Z;U4-96P/OUVDG;>FU556-=4U#ZHS5
M=()JR8FCG<^%XP7M<YTCG\N0<J5))FF]69S)E^T713DS.MD:33B3ICC5C"G0
MIF[<=-+<=;C1&@MY'O25JT2G7E>:!:6>UED(2:I+31RLKV/$Q;<G,=4XGE!S
M& &]+WOFA[H)#,!WT2"T!HNU_##2MQI=;4=2RZF'B!44E5J+IWJY1O=+0QPQ
MTYM[FU&;<P"!AECI>2.=N89FOIFL@9E0J%KT5@'V9LJ2_,ZFI/HF:/4QDWP[
MY%^);=?9!;_BGL /OO6_/YE#Y/>M:V(*W1PAFBN^ I_$&JQ+U32>!)ZTO+T.
M;GQR\^.IG_:_PGH[.ZR9T/83?GZC+;B;E)I7Y&N/M:Y>'-D\3XKD%/XGD%:9
M=_:(Q68W$P>2XXQ'^6*FC2"AVUL)EVDW.2A\4UKI1-Y,H&4;(4*EO<OF,0W'
MRDQ>R51GNA#KHXAO!YHT):=M,/1'6H[321-H&M$V+:9'4V9Y2096EK^J2[YT
M$$X#\AOT6X:2TXV@X9:6MT&B*>F9=1'P^?62:=ZEZN4CFOKX)*>H]H$U'[Y-
M+)7&*.J#XX!\S"V.F<^!_"7<D4ZXP^:P921,_@,_N$=Y2()5@2XE>.>&.[6]
M#-;W(MU"M;&3:QH1^AB1'%-Y.M"-(+*5Z*5%4NM%$Z&>G(GZ=16&NDQ43!W7
M+VO):[GYF,RP?-M(:.X =@BS/PKTE46F\V61EX-#?M6G6MP#;]=63F^.JZ6M
M<Z"H;5":FHS+20@44+FP, +F-;*&2LDUF471TPB81,(F$3")A$PBHO\ $G_H
M\?TJ*JUXB@IZ'@_=$O.X+I/NUPT-OJ#4\%\P?7,51^1VGG58?+VZ?^HHM0S1
MFK)VV_WC]AC_ )?>JVYP>7&<[[[X^&?CWP<]OLVGX5'R5IRZF#S-]3Q<#ZF5
M;"Y=%9&[)$T;DXH>M^O0:5%;W]_A4B&0ZB6X]L_>XI\\"L7Y,WMG\L*'>6>_
MG_<3\<?@ K?<*E,(F$3")A%K!I_SGG_^V51_\INO"+1G-_\ 8UT]MP[7V*2W
MS$YVFUO_ %)L2AZJ4J!!U^?0!.[&ZZW_ *;.">+7WV+,-;?<KKY#Y"X0U ^J
MIM](21\.>-_V@KDW#W]4UAQEM'\6+7%KOD0\^G?]$:8D>0/Y)JZ*J'Q>)#W)
M6*Q[^Y?B/V2U%_DD%[\DUY-] 'KR"HDM#6=*X8]'$[W]MF?+MOPLDX(=>TV6
ME)$/8@%EZ+M1_,:DJ6C9M?:*:?X&6@JIH7GZ^G60CZF_!?7-;^^O JPU+CS3
M:.XE7NTY'>.@UEI^VW6D8[SY?':8NSVD^Z#*X- <YQ=.S,\N/IA%"3P_?[)Y
M_75N9]E-*W9T+3YH/S! AAMTS8$9"6'?W"3N'K8Z,C7VT(@19@=: ,(=;]Q)
M/7U+'=1]"_6'35[!\S)76&@-63ZN\='5!VYPX$9)!6A\.?F-.26L_2L5^U+9
M2/2.BOM?X4#_ '?!24Q;ZM(/8J;>:"M\3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB815,2OB7OUVZ.F%KQ7Q2K AL!>XB='HW#_P"C
MU04D/BR84X>Y&WQ[30Z0XJ(NB9F:7%(VESY2W GSQ[MI$[*S&TE.#15\S< <
M@)\SD[]OC]>W92GY:YILFC'FVYI;_4-D=06%;J^&#<'Z9QF$P&.15E@;*M9F
M1FAE?UZV-<781+/B:]?(W-,1I7(%FT1RW7M46C3BI)![ #[SY_'?M@?9\2I@
M84)A%11TOXA=BQ_H[I2OH1=$;IB/<G/%.15>3*>:K<MVL)))[!@T,M%VDG3M
MWP&//S9S=2ZUFGT?KZ)27^QG1#)FF>S5U7OD9CA[.BC/W_GOZ*L-V!QG(<>X
M';(V'<D$9^/;;N<YL#KWI-M#T!T]'YA"D//W-G8L/YE<*&/@)+D[6# $LYJJ
MKK=L=79XGQ,\LD];I58LD?8 TM;4&*:8X,U-$@0/"V4JWEGE1@8QC?&<Y[;9
M Q]6/O5RJU:C;4:MQ<5:9 WH$QZU<N6GE)4:)&E*&>I5JU)XRR$Z9.06,X\\
MX8"B2@#,,&$ =[T5*TW!Y5&)=;5B.,4D;#)V\BNZF1'KH\\-[TC)6%R2Y3QI
M#53:H4D%J0$*$YPR!CT:$H\DS8- -!L1%JJOO[#[<Z49A_;4TI3G&P$@?S:$
M8UO%S01S,\OS;'L#.S%B\ON$)97J^P@YAJ?YN^7-F_S]#;:@>GN/K:=Q'_H8
M#_R7);#^I<9N(E([87C1O#V_1#U=35FK[)4N^)Y:2C:<=@UN>X6*])_W1ZMX
M)L\7Y%"Y3JY^>WI4'[;VGMRIG&;Q].=O7EZRCIA2C$F)T9OTEGJ]>C\H;H([
M5R^9NU@JNS73UMND/PK*1T\8/J#/0Q@>A=MN=_KG0G[Y\.>,FGQ[\T%GTKK6
MEC.^'Z9U+!:*V1F<\KF6O5E;([EW<R/#O=:2V=F9Y<@3"*$G,>M1F_\ NVMP
M_9,GNV"7 V W]A:0W%2T&"X""'\P23)A!9:,/E]AG;4&;WZQCUK?M6?K>F^'
MET.[W6"XV24_]Y8[]<.D"?-PH;A1#U#>4=@%H>E/U74?$&UC9K+];KU$//IW
MNQ4'4('8--;;ZS&.[N<DY)Q-O-!6^)A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(J-?%6ZOZ:K!_L"O.>KLC7.Q]1<<2OKI5(5L!B%
M@SFZW-EG1\,)JZ#HK!(<8JPL$22MXI#9K^1')))2BI;!TC4!C3GKG$XJV@8R
M1G)Y?,8SY[?@%-?E:ZK+EW1G<E$SR=12U66B+)@KQ )Q%V!%'54;C5U,L@EY
M%"S5,U+5S4Y32DT[4A1&R O:-W?HE*(>Y29O(?SUYZHH(&&GMGN/J\QMV.?C
MYJ>>%2F$58U^>'_-[1DO4R.N[W8JTJ+NJ-QR,=60UWJ$<YFS@0TUZAIN0N],
M3\FQHDUUZ]SFG6EG@KN;,():*%G5M:271Y$A=-K4JY^?S^2J@[&.^6G+=]AO
MGMC???N/-<:2^'?)7213R$,-VLS!R-;?05>=*V32)U5JG6Q5,U@;G7DD<(9$
M;EW9"%MC]7V),:OBTFF;4Z5=)98$2N9-#',&Q!*$HHZ3F&VQR 0#G;&"!MC.
M1GU\E:%A4K6#3_G//_\ ;*H_^4W7A%HQU_L?O>%*#->S*G?)U@-18_S>W75S
M;, =""/_ -VRD5AN1VOS[!H0_MK0][S#/]R_P$]JBTU#!\74U73O S_X:EQ^
M&/BN357ZIQRLSW>ZV]\+;]3-/\N;3^J;%4L9\2V&_P!0_P R 3VR54%XX?B"
M3+G*R.>:8@T"8G%WC[Y7'4WSG*0NQR/3E")Z^)(]%&=*V+VO6RG 4:>D,T/.
M5'FF1R0E(&T+>M4?$B=/UUJ*:V5-NHH*>-[XY*:Z]:7G+>:"H>V.%@:YOTNF
M]LQ))Z<@:W#B7#]0OT2."UKUQ8M;ZJN]YK(*:NH[[P[]E6XTS)?#W:S4<M=<
MJJ2HAJ?>A%PI9;2QL;&MKZ%T]1UX6"!]X/+%X?TD^=:>O84<41$VSX0TRA5&
MU)PU.VA:J ,E>F2JS"4YBYM]\(/-:7 :=.->UF(U@R"1'[+#O-JKO:=MHZ_I
MF$U4#)3$3GD<1AP!P.9O,#R.P.9G*[ SA?)/$327R#UQJ?1XKH[FW3]VJ;?'
M7QM$?B88R'PR21-?(V&HZ3V-JH!)((*ELL0>\,YCO[,@M,4)&W^ZWB)RI(7^
M02W'R#%'PP'^$"U[HRVY"RJC_/\ ,,\EFNMF(V'[B"04$6OP^KRWZ7];X8T;
MS[S['K:LIP?..GU!9:6=C?@UT]AG=GL7''HM#B_5.)E8P>ZR]Z+HZ@^DE1I^
M\U,#W?%S8+[ W'DT9WWQ-O-!6^)A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(J@/%;H@5EQ>-3^Q(IP1:]!ULW+%4GK3MI8\TX>@?#
MU)IZN1U?U@RN+EJK'5]9R4K&XL+Y W5@>-M:%0N=D9>C/8%4T[XRX$D8+=_/
MS&V=^V^WH5E7A(75SA;//C\T\P\H/?*,!@4O.;7!E3L$=.JVP)*Z)_;.,WJF
MWXDO<F&]F542B2IU\_\ > /(O0VHW9*E"%$7A'@@[G)(^.0/0@]OJ\OJPK5<
M*E,(F$3")A%K!I_SGG_^V51_\INO"+1EU_V9U9Q8^[_ !R6]!UV,S\P=_,57
M$3@H@0OMK\J=5X! #OS]1A8=:UYYAJ[#;M9)/Y3KC39_^[2B?'IN:08_!<FU
MCFGXG\':W/*VHFU[8'.SC/C]-,O3&$G^4_30('<N:,+NNK^0Z3ZWKUWBUIUW
M%)5(4L9EC;7\K>&X WV#/<@9ST1#JQO)&RG%$$A?IO<3D@#Q(52EN1G*DIXT
MI&P5W:ST-WIWQ5=-#-(V*9M/*]OSD#Y&%H?&\8<W#@UQ&>4EK20<!?3O#CB9
MJSAK>Z:XZ=O=RMU%)<+;47JVTLY%'=Z2BJF2OIZRE?S03%\)G@9*Y@FCCGE;
M'(P2/S^<.SD-C<@<Y2D2(AL7F5+$&!^:TR<E(F:97#&PJ&R]I3I$X0$)"6N4
ML#N@*2E  !.!.$G0 ^CTZFQS^)L]MEY0QQI(8WL:  R6%HAF8    R6-[0 !
MC&/)3Q<L_L+B=KJW-E?40-U+<ZVBJ))'2R5-MNM0ZZVRI?*\N?*^IMU;2SNE
M<29#(7DGFRI4YE5SI0DO_P#NWUIPQ.A?D$KR_P!\T<XJO\(1:L"JC+%9DAPM
M>7KT>]4HE+3 %Y^1QN]@UKU#WF^Z<Q5:-X@V_P"D^"FT[J")G?!MMX%LG>T>
M7+3WYY>0/HM&>P6AZC_5=8Z N'T63U.H;!*_L#[2M!N<#''SYJBQ,#!O[SB1
MW*FWFA+?$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$7GDZ(=!VQ?%1+Y-(/!JL/J2IJJ>%TF%T$_7/)HE ]'VI*T+,JJE,K<5<%97
MDM$D;B)$:[%%6HDD"9>(&R(D6QB"58R&]W 9QL!N<#;N#_=V5C'#_1]CW.^7
MC7UL61R18$VII77!:TKD0VTG2(1UNGS&]/#2CD4DGY1C&[.ZQ(TZ4I4<,=7$
M+.E",A_+0*U",DPJ2-@=]\]\>7VE6!X4)A$PB81,(M8-/^<\_P#]LJC_ .4W
M7A%HSK7^SW?DV4@_ ..]<UJC&=K[;"FGT8GU8F$[%_H6I4S1&6+7YACT6'_7
M,-=_=?:)?^SO%*W/PJ(JBEQ]1,[?MPN2\5/U>KX6W,;.M_%;3L1?Z1WRVWW3
M;F9]))+Q"W?.7<H4PLS*ZTH(\4?W,D'7="&^1&JDZCF\EC2 /_@I:_Z%;6>_
M8_[H'[: C)D<\FS046#6P%&,YQ7JV86:$&!LGS,EXMYV\'=)Y(F^0I[BQEPC
MQ\!+43L&-AR$9SE=@XK_ +ZT7#/63??^4O#VTT%?,?IR7K1$]5HRMZO<F5U!
M9K34N<<%S:IK@T-+2Z=V9Y<?4(^\/[%K6IK-W]BZ<ZFYNGBTS7^,ED<[.9JS
MDYH=_P#;H$7L-Z]J/?X0)]G#,_)A'F_\._G[K>K2-S?-'ZIMT8_E5$5IGNM(
M,>9-7;(,#S< !OA:%Q"^8M=FNO8635VE[A(?-L$MUAM541Z?JERG#CY-+L[9
M4W,T!;ZF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M\U_B9Q&H*@O&WYS3/AS^'Y9\VK3DQVZRZ6LGI*N N:9Y@Z^TI6@'\KP:,198
MVR:SC7"/3V:3>PW\29^4,:-O:%3RL$K;T>RN-W !<X D  >H^W/GM@8)],*?
M?AK"G\*D_45 V;1O%O/\FJN2UA(FV)\2P)SAU>R^%V?$W5PCMH.:UP*:]O*Q
M_61Q]B9*8^,L3HRK8&] 4">&A>PN9Q4N\B"X@@[N^'<?9G.Q/?R.0K5<*E,(
MF$3")A%K!I_SGG_^V51_\INO"+1G=?\ 4N>EDJ!]E%?6G0-A)S?_ -#40O2O
M'5<=Y_;T^AJ*</,7GKRUO>][]/GK,-?O=MSIO.GJK?4@^G1KZ9[C_P"@.7)>
M-GS.@IKH-I+#J?0E_C=_(]DZVT_53/\ _+2LG]/B<94PLS*ZTH(A_P"G7B.#
MU_Y-EZ>Y7"/_ /B<;"YEL#8!;U_\^H@5Y%ZWY>7K0QK[^?L=>6!_ZMJ0^4=S
MM0/P=46RHP=OY1IZX?\ EB^"["?W\X%CO+5</^(I'^]!9-?V7(S_ -S'>='G
MN=IKAM](J=V9Y<>45NY(DIF_'G2L?0>OXKNFIT],>R]>9FI%%6-5*HZ(K>M;
MV$T+XRMXBAZUO8#-!'K6]AUK-PX?UK;?K?2M3)CH^W+=3U&3@>&K*AE'4\WJ
MTT\\G,/,9'FM1U]1NK]%:IIHP3+[#N$\&._B:.G?5TW+Z.\1!'RGN#@C<+>]
M<RU-/Z]@D[1[!M)-8;&):EV7OS!M-)&1"\D;!O\ U!LI:'T[_P!=>6:[<Z)]
MMN5QMTF>>@KJNB?GOSTM1) [/QS&<K8+96LN5MM]QCQR5]#25K,=N2JIXYVX
M^&)!CX+,L\*]R81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$5!W2\QOJ22)NMSHGPJ:K0:8(;95(E369^)C5M<QZ4UC<[&MC,SK6:IS8L
MQ,$PC,I;S1."",2TMXTQOI);Y' MKR4:M&QY^BK&/)WF/XISD=L>>?J4G/"T
MHUQIF)W$8^\]2BEWZ12R/M:R1SKLP7:TPFB*OFUQAS7$54\/3$K(BP4X2B-A
M\?@YXQZ:-J7,L0"UP%XC2AQSC<8\L-Y<9W[*U7"I3")A$PB81:P:?\YY_P#[
M95'_ ,INO"+5W;#$9(^0^E&PC0MJ@4M8;LBT#_Q-KX_&U[^@T7_Z&^^MA'L]
MZ^^C/3O6];UYYB[W'U;/<V#<^!J7M]>:.)TC<?'F:,?%<UXQT3KAPHXBT[,F
M0:.O]5#COUZ"W3UT'+CL[K4S.4^3L%;^A[Z7*(E%I,5L(BI%'&1]+V'R].RW
M=L2N -A\OMZ=A4:WKR^WEY>69"&02PQ2CM)&R0?4]H=_>MZM-:VYVJV7)I!;
M<+?15K2.Q;5TT<X(QM@B08^"AGVK_<R3<@7V5^1U5'44-BDE7B^Q"6 =$-;S
M0S[[X+\P$9,HF\%=C3![]F48T$F[#[0!8P86]_,RV>O&WA+K#%*[R%/<626^
M3/P$L\#R>P+ ?+([API_?6@XFZ-=[YU'P]NMRH(1CGDO6AZBEUE1]+S,C[=:
M+Q3!K?>>VJ<S/*YP=.[,\N/KKW9L1O;4YLSB5H]O=V]8V+B!?X3D:],8E5%"
M\_/7D80:,&_/6_MO+D,KX)HIXCRR0R,EC=_)?&X/8?L<T%6YHF3PRP2CFCFC
M?%(W^4R1I8\?:UQ"B'X>SFL7<:4,V.1NS7.!Q5=4CD(7V&%?3,E?*G5%F!W]
MP#+-AH@["+\6M:UY^?GY[W;B7#'%KK44L0Q%<:R.]18[&.^TE/>6$'L06UX.
M0M+X;3/DT/IZ*4YEM]))9I>^1)8ZNHL[P<[C!H2,?=MA3,S15O"81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$7G2\;2C)],W.43U3RO9
MG6T-=^.YW3]'(ZO@X+?>N<^F7::_'E-G'5< TQ]2_42&A8(TBM6&,C]((.?!
M!M2H#2VRP2PTJV^@.-QG)P"!Y9[;?'OGX!3D\/*-2)PM;M7H!#0M@\P4YT78
M]?2^ U#:C&F@T_D$Z9XN[(;GZ!DM6)7!PW7+A<L@6L:4] \;02J3'P(Z:R=K
M2.,BV(\H/8#N0._P/8?9OY>>/)6DX5*81,(F$3"+6#3_ )SS_P#VRJ/_ )3=
M>$60V!']2V!S:*B#H89-$9)'Q W]]#T\LRUNV'>M_;>A:4^6_/\ ]<LU$?6I
MYXO^UAEC_P#6QS?[UBK[0"ZV2\VMP#A<K5<* M/8BLI)J<@_ B3!6F>-9!N4
M<F<UO8Q[&H4TA61"T>_\0G%MB+4V.6Q?ZZ%[^C4^H._N'?F'?WUO/%99.K:+
M9)G)-!2AQ_WFPL:__P!S2M/X15YN?"SAW6N),DFC-.1S$]S44]JI::HS\>O#
M)D'<'8[A</M6MU]M<F] P1FT;\R.-8R5UAPR=>9Q,ZB:3<O@B@GRUO>C4TP8
MF106(.MC",H(@:V+6M9%[IG5EIN%.S/5=2R/AQW%1".M3D=]Q-'&<XVPOH;A
M1?8=-<2-%WBJ+? 0:@H*>Z!_T'V>Y2^S+Q&_<9;):ZRKC<"0"UQ!(!*VE2=D
M(+CIRJ;9;/9^X697,+GB8!6_,!)<LCK<^>[?GWL(THEPDYI8M^LHTH99FM#
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MY^FKP]C3@1T%9-C/.73VS/KC:815)^-&^.\'XX!:406G1^Q:SMRM9% IFV:
M1((D\'NYK4J7,KCH&SD>U[8M5M;B4$7NSDW*U#>N)4)#S"1=FX$T\%PUP;17
M1MJ;9=;+=::XT$N74U; V$3,CGBSA_3EC9-$[Z<4K&R1N:]H<..<<9YJ#10N
MU&]U/<[5>;74VZNBPVIHIW3&%\D$N.:,R1/?%* >66)[HY&N8XM,1O TZOZ*
MZ0E?13?>-KR:R445CU<+(\3(?APPM*IU<I>0X&I1HT*0P.UA2)* X QB /2<
MO?I]0-;S=?T@=':8TO1Z8ET_9Z2U25E3=(ZEU-U!UF0Q43H@\/D>#R.D>6D
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MU/<[7<9Z&DIG0AUII:>FJ973:ANDTT%OL],UDM//65 DZKX*:J,<X.:.?D5
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M4SZ9-]:1HIS^ES]&W^,ZFWQN5;? "=D29S3*G(M%\'+5Z)6G ("$DG?H, 8
M/V7P>X662JTDZHUGI >UI;K5.B]KTU5359H/#T?AST9'Q/9$9.N6<T;2[+G;
M@@GX^XN<4+U2ZK;!H[5N;5':Z42^R:BDJ:45W7J^N#,QDK'2B/HAX;(0T<K=
MB"%Z(^"IY,+/XXYWL"?OJR33*55LSNLA?W ) 5KLX&#4%C6*M)B4Y.SC0%E^
ML8"0>TWKV@O4,0A;^9.(MNHK3KC4]MMM/'24-'=9X::FBYNG#$ TAC.=SG<H
M). 7'&<#  "^D^'EPK;MHG35QN-0^JKJNV0RU-1)R]2:0EX+W\H:WF( R0!G
MOW*JO\2T58I>]Z,>.B9UVE ZG:>79HD@4IXGCO02&3QJQWVS4&YBGLV?\Y0E
MYL ^,S*+,D4!%8F@>E;.D=X<]NLF8T(W&-N#AI?Y_/X+=6@D$ #.03G';R Y
MMO7/G]Y4Y_#F=N?'6-6>*@+<[6MEN)?(X&2+.SUW6"U[9EHT#EMO304754;C
MCL6U*R J#7K4/*5-PE9*';J86ITD"(H<"#[V <>7+_\ \[*R+"I3")A$PB81
M:P:?\YY__ME4?_*;KPBV?A%6)XL]VETWRNH 3&GMZ?)?.H$3&'5(@--C<8?X
M1,X_8[<YRIQ!L $B<Y1%"TK<WEFE+7A2,PI,802F5JD^KZMKO!6DXB?(^:HI
MQ$\-)BBD@FCJ6OE<,<H)A :T$.>3@$ .(^;?TIM9MTAPQD#+=6UE;=;W8V6V
MJB@>^W6VOLUWH-0TU3<Z@8$3'26ML=/ U[9JN0N;$YC(YI8Y*<9]*?TL*#BM
MQ&0YWA"]R.6LSPTN"90!L4/3+LI.YN<2<%&@B>HJK5#&!O<-:V,A40O9U0S%
MS4K,%D[+<_:UOBK#"^!SBYCV.!Y2]F ]T+C].(G/*[N"',.7,)/1.$/$3]U+
M0MKU:ZT5=EGJ7S4E72U$<C::2LHRR.IJ;5/( :RURR$BGJ-RR1D])*73TLKC
M*?,JNG)A% GCO_I78G3_ "@I_JZ"L++'<-3)1?DB?HIT:J>)RA;VLH?D,:"'
M6JEM:(A]GL92-$WM"??HT,GVF!L_ZK4W2TG9M+4^,I < >"N1?.UK!WY8*L5
M<.VS6M8#W&>Q\3\ZBL?#_B.P]2;4%A&E]229YW_*S0L=+:)IZEPV$UUTY)IN
MZ'F ,LT]4\9+7AL]LSRXXF$712B,L,TC4@A\J:DCY&94RND=D+*O+]JB=F1Z
M1'MSHW*R_/7K3K42@].<'6P[V P7I$'?EO7HI*NIH*JFKJ.9]/5T<\-533QG
MEDAJ()&RPRL/DZ.1K7-/J O/5TE/7TM315D+*BDK()J6I@D'-'-!/&Z*:)X\
MVR1N<UP]"5$#CZ3/L,'-^1+%=53I.^=-M:>%R!U,]3A9//#^)6&HYP(T>@"<
M'5D1-ZVMYL>2$W1<JB)RY4=L3XEV9N^MZ2GK_ :UM<,<-NU1UG5U-"/FK5J:
MFY#>K?R[]*&>22.ZT#7$<U'6B-C<4[\:5HJKJ*$U^B[G,^:XZ8Z+:&IF.9+I
MIJIY_8U?S$ RS4[(Y+77N:'8JZ(R/=FH;F;F: M]3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBPBPK+KNI8T?,K0G$3KR)I
M521$HDDS?VR-LA*Q>;[!$D&Y.RE(DTI5F_@3D>U]J:+0O0'>@BWKWVVU7.\U
M3:&T6^LN=:]CY&TM!33550YD8YI'B*%CW\C&[N=C#=LG<+P7*Z6VSTKJZ[5]
M';:-CV1NJJZHBI8&OD/+&PRS.8SF>=FMSDG.!LL9JV_Z-N\;T73EO5O:1D;"
M@'("X#,F"5F,H'7:P+8-T+95ZP:$#@)O7!1C4A+"H$C4A*V+9)F@^N[Z;U!8
M! ;Y9+I:!5&04QN5#4T8J##R&40F>.,2&(2QEX9DM#V<V.89\MIU%8+\9Q9+
MS;+L:41FI%NKJ>K, FYQ$91!(\QB0QR!A=@.+'XSRG&W<PJS*81,(F$3")A%
MBTVG$-K:+/,XL&4L$+A\=1C7ODFD[JB961J2 WH.SEKBO.(3$Z&,0"B@",]H
M>>8602 PXP !6IYX::)\]1+'!#&TNDEE>UD;&CS<YQ 'H-]SL-UD;3:+I?KC
M2VBRVZMNUTKI1#1V^WTTM75U$A!/+%!"U\C\-!<XAN&,:Y[RUK21Y,?'/OQ+
MTE#.=W!AJ&=Q:LD\FL-95]USLDR+GV>F"T1@N3[B57N8$LJ30A5M3#W!HG$M
M(8E#WHH_3"QGMVCEZK.:+X.U''P7-E'=_DS2:<\%-!<*VV25KKI[4\6QS:>B
M%90RPT\8H&/%3.<S<[1%$&-<]W78_P!(BD_08JHS>;91\1M0Z\IYZ2]Z/T[J
M&GHH]'/T]+2RTCKOJ1MKO-OK+O+[7KZ>:RVH31V_I%U?7"H?'3Q2R\'OFRN;
M0X_3O<4O/K:I3FVQY0Q2MFA%[%P^-/TL3-,87KI2V1IH8=$-!"QN<VEK"F4J
MW1=Z68)BES5;&'1=C5_!9W"VY0::^4ETNCI*"&Z25=#U;7 Y]5-40.:*,2U7
M(6^$'O==Y<TMR000L5'^F55\=IZ[6U1PKX<T,4=8^R4%%J.T0ZKNE+0T,4-3
M%%->Y1;35 R5TTN&T--''))(V.(-P3:=_0C9_P!<?N']YMR_@V:K\GG?SGJ#
M]H3?_P!:O?NQG^C7@Y__  6E_P ZG]"-G_7'[A_>;<OX-CY/._G/4'[0F_\
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M/_=V<+?JGT9^P#'_ /39AOW3>(/_ -9:A_:=3_\ FLQ^YKH#_P"D+!^SJ?\
M_%/_ '=G"WZI]&?L Q__ $V/W3>(/_UEJ']IU/\ ^:?N:Z _^D+!^SJ?_P#%
M8U,O#(X7F,3DD4#S?6,4%(F5Q9@R>&Q)@9I8P"<$IJ8+Q&W8QM6EMSTW[,TJ
M;EAJ-460J++,,3G T(L7KH.*_$&AK:6L^5%VK12SQ3FDKZVIJ**I$;PXP54(
MFC,L$F.25@>PN82 YIP1Y:[A7H&MHZJC&F+51FI@E@%70T=/!64QD86">EF,
M4@BGBSSQ/+'M:\ ECAD'5?+WA%\L<FVP@N.OW*TI)*FMI=&IN2V&_1!_8T7Q
M71 #7-.C;8(PJBG9, G8$*P"_6D^CC]^R&,0! S&K>-.K]96:2QW**T4M'--
M#-*^V4];35$G1+BV)TDMQJ6&%Y=F1AC]XM;[P (.'TIP:TEH^\1WNW37>JJX
M8988F7*HH:BG9U@T&5K(K=3O;,P-Q&\2#EYG;'(Q:-G(UUE,(F$3")A%3OW2
M[]&4QU% ^A(G4M1WISPHHA74TWA5[]&5?S]"HM9*BPS)/')I%72Q6.1)%TN6
M,@5L>=$JALT6X-!K>!K=&T]O<R'4I&#MOGRP,_6.X^M37Y-L>Y+!C,I!;'-$
M)YJ3QA^&PQEB@EYPJ[6EY/1*7))*RCU$(B<4015RC;ZC$U.+.J3J%@G :H!^
MDIZ,\H1#^<C'^*ECA0F$76*WMF;US<UKW=L1.;P,XMI;E:]*F7.@TX-&* -R
M0XT"A<,@O>C#@IBS=E WH8]!#OSPB_HQX:2G1.R&NC<4\JTIRY(T&+4P'14B
M3CT6>L3H!&Z5G)2!B" Y064(HL>]!&,.]ZUA%V.$6L&G_.>?_P"V51_\INO"
M+9^$3"+#;#K^)6I")-7<Z:"'V)2YI4LSVV*/4'1R51K6P')SP;"<C<$*@!*Y
ML<$PRUC:XIDJ]&:2J3DF@LU%/#5P2TT[!)#,PL>P^8/F#W:YIPYCAAS7 .:0
M0"L1?[%:M3V:Y6"]TD==:KK2R4E;329 ?%)@A\;QA\4\,@9/35$9;+3U$<4\
M+V2QL<(X\[V!+8O)7GEVZ'<]WLROVH+Q7T[</2 =X4X!0%O9YELSR" R<Q8P
M2:,V>W!\S0/.D,E)V<W24@96-MU1-%*^U5KR^JIV=2GJ';>.HL\K)\_]O$<1
M53>_/RR@ELH(Y_H&^W2VW&LX:ZOJWU6H[%2BKL-[GP':STB)!!27<NP Z]6Q
MQCMVI:<9<*P07%A?3W%A9,#,PNKK +.K"#W%!I77-A,"*0Q69QMZBKTC5$E;
M/VTOZ(Q OTA5B (]O6:+&$Y*M2B+4)%A"960,!Z<H8?/54L%9!+35,;9(IHW
MQ/:0,\DC>5W*>[3V(<,$. (W 69T_J"[Z7O%NOMDK):*XVJOI+C22QN<&>)H
MIFS0=:,$,GBY@6R0R!T<L3Y(GM+'N!C5QK8LN&S33FZX'8YVO'F-S;87('];
MY@5V?6CFE-54]=!6M[$$X4XBB7:"4B+./VCL..3%$<(K99(!8RRU,Q9/;:QY
M?76M[8))';&KIG NHZT#?/7B'++N<5,4S?(+?N*=CMC:JTZ[TQ3-IM(\0*>H
MNM%1Q8,6G[_3R-CU1I1V,%@M%RDZUN#F,ZMCK[5,SFYGN4U,S:Y0F$7X((1A
M$ 8=""+6PB"+6A!$$6O+81:WYZWK>M[UO6];UO6_+> 2#D'!&X([@^J$ @@C
M(.Q![$>A4".=!;YSN::\>N8MIH"]$/ET\J*3M["F+@3D[ -LZG$9IGD$2JHY
MB\%ND?;P&*% :[F+(4#04\>4^RZ-J@?*BQ4&MX0'7&!U/8=8L;N\W**$MM-\
MD R>2]4,!BJ92&L]IT-03EU4S/.M,$Z8OE?HF8EMOG;47W2#W9Y!;I9P;K9&
M..Q?9JV9LU-&"]_LVN@ PRE=B?&<Y714PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PBUU;%K06DJ_D=FV.]%,43C"/2E<JV6-2L6*
M3S2TK:S,S<1H2MX?WMQ.3-3&S(2SESJZ*TJ%(48<< .9.S6>X7^Y4MIM<!J*
MRK?R1LR&,8QH+Y9YY789!34\37S5$\A;'#"Q\CW!K25C+Q>+?8;=576YSBGH
MZ1G-([!?(][B&1001-R^>IJ)7,AIX(PZ2:9[(V-+G!4?NL$LKQ$[HD\6GK06
MSMZ5M,CEH%KTK:_L?)%220M,O-HZ&!6IU[ \]IW,SA0K+@G(25@:%ARA+&VD
M9<@$B2&>C6=\H9*2IX8Z-J&SV6.2%^NM4Q,&=0UT)#V6^B<\$BVTKB[V?"06
M1C-TJ&NK)J9L/3.$VG:G00M7Z1/$BGD@U=41U$G [AY)-+"^VPO#X)-8W]L$
MD<K*&,Y;, Z.34%6SV+3/;9*6Y2U5H#;X>_$35 D]9I>7*7%$4B@Q:G3+(0T
MN+P2Y'%$$FNY<K7DJ96!Z&2F3E;> /87/11!)0502RBPATMFGK&RG;3-M5%T
M6DN:'0,<\.( +Q,X&;J$ #GY^?  SL%EY^-?%JHO+[_)Q#U6+G(QL3Y(KO4P
M4KH&.>]M,;; ^.VFD:^1[Q2FD-/SO<XQESB3H1!X7-=5-+GFRN1+BNGE^?.^
MC35J9HEA]H5E(E8@CV5\\U_:.Y$HE"$HP8ADI0RAL,0;,,,:E" _11I6_P"G
M]236JB98KM"_4VEV!S8++=ZJ6>:U<V,R:>O$HFNEE>, BGAJ);6_WA-;92XD
M<OUS)+K6M.H?#673^MR6.J-6Z=LM'9)KX&.R(=662S^SM.ZC8\%S9*^JM<6H
M0.3HWR%K.5VBY!V=XA?*DM+C/5=&478-?JU9+=&+V@TTD%21*0'*3O9(TC^_
M29KF$&A4E4>80Z1V.X5)&EBG8R&A_6%E:4'7*S2%?=!+7</*BGU73,:Z:;2]
M=(RTZXM\;07/Z5.!+;-2PQAN35VE]+/AS>M;*;#G+WV74O#)T$%NXG56I.%5
M\>]L+-54=M;K?A7=)7$-8]U3#/;-5:,?*XX%!=Z?4<;.1[H;U5ES(FR\1^(7
M5C F2G7Q6][<UEJ22#2Y!9]9N3[6"GVP F!/07/4I]D548VF%"TH3.3C+&HD
M](("@0"M&!!OG+[[!2O?%=:*Y6:6-SHY17T<G19(PEKV.JJ;Q%,TL<""))8W
M C=H.RZ@S@U>[NQL^A-2:)XBP2L$L$6E]1TL-Y? \!T3_DUJ%MCU ]SVEN&4
MMOJ@7$B-\C07J"$0_P#:!.69-T Y5,I@MAME>?%'5CB]QHB!2@N3NC?[P!O$
MGKJ.MJZ5A;92J3!118QL&]O:Y2XM %\?:]*E8F_78.(5IFN+J,P5+*?F?'%6
M@=42O;GEQ31-=-RRD<L)9U)'%S.:-G,[D[/<OT+N(=!HN#4D5XLE1?/#4U9<
M-+2O%O=;Z>;D=.'WRNGAMQJ+;%(9KB*@4='#'3U1@KJGIQ=>9*XGI;JY"L=I
MLX27B3ELM*>N6LP'1"R]1V5'B"AJ5"J92<H]2T<X1!0DUHQ:ULBMTM#:0M64
MY/\ "!&#3!ST<%YOTC(A'4VJBF>V.*EA!-[KR]P#&.Z?/X!LI(8(8>I6/SRE
M\+CRKDTE9PXX51ODIG6GB=K>E8Z26ZU;7/X9Z7EC!+Y**FJ!!)K6LIN5[A77
M!E)IJ-W)+%1W9C!*<=K:;!=8R52GAH5=#HA4[0J5(WKIR3,2TNFVY>(W:9Y<
MJY:A'I91TE/S3B5 ULK/="(4>ZDE*7Z>/QAIB$WKM!HG3^BZ6*36)?22AHFI
M=$VF2,7RH+QSMDOM6X2QV&"7+'2"I%1>9F.<6TD3AUA\UZGXH:UXIWBIK[57
M3WRHF=T*S7=^ZDEDI(HG%@I=.T+#"+J*4<[*6FH&4=@H^5K&3.C^8,J:5Y:@
M-/O#C/W!>_6M>$C2!2R^\[,4IWRP'@C>]C&SLIA:=.TP2&DF"V%OA,(;F./)
M" $!/2K516UIF-OVKKC>X(K;%%36?3]*\OHM/6ECJ>VP.[">H!<Z:XUS@ 9:
M^OEJ*E[R\M=&QW3%%BTE;K+/+<I)*B[W^J9R5NH+JYM1<IFDDF" AK8;=0M)
MQ'04$5/3,:&AS)'MZADOFJ+:DPB81,(F$3")A$PB81,(F$7G4\;*BK FCI*9
M\;RM9/6\/>..YW3M((ZPA1%MOG.72SM-?CZFSC*P$>)[3:L:'!88TEM.%,S]
M(H0?!!-2DML;)8)885;3V&0-P3GS'U_#?;SS\ IR>'G%I*OM/M+H5'05@<O4
MYT=9%?RR 5':3(D@\^D,[8XLZ(KGO^35>A<7(%=NEQO[BPI5+>[&(I9)#8(*
M;2EL1N4C]1Y0[R&02!N1N/@,]CC?MMZ95H^%2F$5'7=]"4O?MKV[0]05JWVI
MV[?,8K/<LN^3I"'QNX!JYA*TWPZUF2;*$VG*K96G6-L@G=-U7!'1),+(M@Q7
M,G,IKA:5]E#650.-_(>0VYO4'X8."3V![*/5IP^**ZU[?Z/=61E<.PZS\5*H
M875EHKV]O.MN+!8+>YA@U+UM%7_:<+XTQ.:55+0)5L&:3$\=E+-:,R5KFE8"
M6O!RHI'< =N4_ '9V2?JWP3GL.^R](*T:PM&K&W$)E3@!,>-"F6JS4"-0L"4
M/:8A6N(1.1Z),<?H!9ZLEN7FIRA#.+1*A@T085"TW!U$G4VU8@Y6SL+*X:KN
MI@$)8](W"3HS$>I)<NP'FKG**Q$\E2(\2@L:0#<>4 HHD[2TP9XR$Y%NW")A
M$PBJV\6"CKFM^A&=ZHU,G4RRL7IYDCF0TA7(K&71)UC;A'Y,U0=[0*TYWL%[
M8N.^:(GLL>Y@V$$)DXC5K>F:7?5=64-;66]CZ  S4KWRO#.9M2Z%\3HY602-
M(.',<>K#_MF@ 9+0Q_S/^E'HO6&K-#4E9HJ..2ZZ;K*NXU+*430ZAGM53;JB
MAN5+9:V"6-W)/33/]IVLM)NU,QD<9=-3Q4M7O'P\!7&IY%J%UNV:MD\DD@CB
M"01YZ1#,6.!,!>&]$MB#9)WD9H]/\H1-QF].KIHHDT/M"&U<-R<FY:].?OT[
MXTV>C?73LJ)9(FR1O:2YPIWM:Z%DK\_.2M:???@'<-<7N:Z1^Z< G:NEX4Z3
MJM9WBFOEQK[?!7T%9 YTL[;'5P0S6FFN587$5USAIW8JJD-8X<S*><U%3!-6
M5,V,S:[(H$=BL;Q4\@@O;\";%C@^T2A7QZ\(\T$#/<+#Y<?UA"V?(@)"=:,<
M7ZIW A/;<.)$8#?FRREF(]6Y,: > O,;Z22"^4[2Z2@:Z.NC8"75%JD<'5#0
M!]*2D<!60C_<F8/X4KLG"^KI=1T5XX2WFHB@H]830UNDJZI>&0V/B'11/ALL
MSI'9$%'J2%[],W1X:=JNW5;]K>TB<3$^,\G9&:2QYR1O+!(6IO?&-X;CP*F]
MU9W9(2O;')"I*V(M0C7(E!"I,>6+8#230&!WL(M;S.1R,E8R6-S7QR,;)&]I
M!:]CP'-<TC8M<T@@C8@@KD=9255OJZJ@K8):6MHJB>DJZ6=ACFIJJFE=#403
M1N <R6&5CXY&. +7M+2,A=KE:\Z811:ZTJ.3617[7+*P]V2WO2,B36O2;@>/
M1!2R5L:520ZP5T4A$69J,VA%E3S 9"0(XM.%.]D.9NAFM2;8-OT9>J2U7*:C
MN_,_3M_I7V:_Q-',YE'4.:Z&XPL((\7:*QD%RI7!I>74[H@0V9^=1UC9:NZ6
MV&LM/*S4-AJF7BPR./*U]93L>V:WS.!:?"W:D?/;JEI<&<L[97 NA81M&DK<
MC-[U5";9B/O!3/,F8M>)M7 V4Z1]X3'&MTBBKV1L(1)7Z*OZ-SCKVE$'6T[J
MV*RM>80Z%O$7^RU>G;Q7V:MY3/0SF,2QG,-3 ]K9:6LIW;\]-64SXJJG?GWH
M96.[DA9>PWFEU#:*"\4?,V"N@$ABD&)J:9KG15-'4-P.2HHZEDM-4,Q[LT3V
M^2VIF'673")A$PB81,(F$3")A%5S!/&%XGL:U8M3D8D\[/F4RF[77K"!77[T
MD;%,D>7DIA;235YF]^[)%+D>25[V<2 LDLS1Q^BBPCV'KEPX):]MEGK+Y5TE
MN;0T-OFN=067*!\K:6"!U3*YL8^F]L37'D:XEQ'*W)(SR:W\:M"7.[4=EI:N
MX.K:ZOAMM,'VZ=D3JJHG;30M=(?H,=*YHYW !H.78 .+1LY&NLIA$PB81,(F
M$3")A$PB81,(F$3")A%C<PF$7KZ*R";S9];8Q$HJTK7R12!X4@2-K2TMY(E"
MM:K/']@EE% WY #H1IIFP$DEF'&  +U4-#5W*LIK?04\M76UDT=/2TT#"^6:
M:5P:R-C1W))[G  RYQ#02/+6UM);J2IKZZHBI*.DADJ*FIF<&10PQ-+GR/<>
MP '89). T$D T=RZ;7-VY?<:9X2F6Q!Q:4R.6UBSOS;I2W<J5D^DGID755Q,
M:G6T3GU#9S0-85S!4#GZ]UPP*3;#D)*=1M4M'L6JKU'I:DJN'FCZN&HU'<(F
M1Z\U52N$L-OI7.#G:>M4S=G4S'L+:E[2#=ZMA?)BV4T<=1L/##1%#>H*;CMQ
M;M]1'H&T5LT?"OA[4N=2UVO=0TS1^^MPC_A(+91\[)+G7<I;9Z*1MMH>I?[A
M(^BN5I>FH%05<L%85PUFMT=8BSS3%*Y28XOTB>W$\:U^EDK>C]>^/\KDKH<I
M=Y ]K1"4N#@I.-W[,K11)>DT5%3V^FCI:9A;%'DY<2Z21[B722RO/O22RO)?
M(]V[G$]A@#UZJU3>=97RMU!?:AL]=6.8UL<,;8*.AI(&"&CMMNI&?-45MH*=
MD=+14D0$<$$;6CF=S/=M//4M=3"+@N;8VO3<N:'EO0NS2YI3T+DUN:1.O;G!
M"J+$2I1KD2HLU,K2J"1C*/3J"C"3BQ" 8 01;UNY%-+3RQSP2R0S0O;)%-$]
MT<L4C"',DCD86O8]K@'-<TAS2 000K<L44\4D$\4<T,K'1RPRL;)%+&\%KV2
M1O#F/8YI(<UP+7 D$$*#*SEFP:)4JI'Q5,VZ(LIAYZYWY?LL]T=^?WX9Y@CE
M8((J3Z62>BG=4(T\PL<0TZ00:H1&EL!$6$9X>@LU?;-1,92:]H)*V<-$<.K;
M4V&'4E.  UAN+'<E)J&!@#0X5O1N')S=.XY(:M!?I*YZ>>ZKT)7QT4)>99M*
M71TLVG)R7%S_ &<]G/5Z>G>7.<UU%UK?SEO/;2 7+QS<KVY\#\0J 7"P<[P*
M12N0W,EVRU'&3'Y*RMDHE+\)O,W7@9!.B&MID/O3BHU'%4J<W&'QMQ/(<DK*
MA3MJ M#V"Y?HF\*;)17/5%-<M04=716^JN4-37UM-/::*:.!\QK):&EM'BGP
MQX=(:>&5[P/=@#9!&6VG_P#Q%/TC=8V"V<*[K%I6NLM?-06&NDMMHJ:;5-YM
MHGB@9:Y;Q57MU"))V,B@EK#1P2U(!\?/-'-5";V+(.9[)Z#7(Y;VJ_-3I&R5
M)#G'N3Z_<%HJ68!DFA4H3+6?#2D#O>\E1" G$>G>4S56J-:4?\.AS@$8'(?'
MY-5VO34;Z+0=/-#5.8Z*IUE<HH_;U2'-+)!9Z<&2'3M)("X-= ^:ZOC<WJUT
M1!B%<>E;IJ21E9KNHAFI6O;+3:/MLDAL5.6N#XS>*AS8YM0U49#"YL[(;7'(
MU_2HI01*9VHD*)L1I&YM1I6]O0)B$2% B3E)$:)&E*"2F2)$I "R$R9.2 !1
M!!( %%% "66 ( ZUKGLDDDLCY97OEED>Z2221SGR2/>2Y[WO<2YSW.)<YSB2
MXDDDDKH,<;(F,BB8R..-K61QQM#&,8P!K6,8T!K6M: &M:      %RLH5:81
M,(F$3")A$PB81,(F$3")A%Y1ZULR1]*<^<=4,'IFTI=TSXE743K*NXV5MN-Z
M(E]'TG1Y<]E_0%,0IE8G1*OYRB;(*,1*C"&]A21I0[!?7 9RMP<GCT*(]/7\
MY\_\5<[$GE #1[NW?) #CZYR7#.1MA6C^&Z2Q0"_?$%YOIZ8R68<P4'8](M]
M4I9!/9-::2M)_-*JV_7=4$9GLO>I*_JV2*.Y$4D)\86R%RW#9#-'QH]"$S9B
M,J?S^?SYJEV^"1@G)[8R,[' P/4?8K<<*E,(H;69X>7#MRSV1VE:O+%+3ZQI
M>8W'2B:R>$M;I(G\UG:$+ U#=7,\H2A8)N96QO:D>SAB]W0HDR8OTE%!#HI#
MG#LXCZB0MCN?*'-;U;K/?3M1];.%QL.V<UJL-5%FTV1IEL<;5#+&W<:H1.P*
MGZ-LRI2T1R0K"E#XP-1QC<T."-$+9&$R<8R<>GY_'U4@L*%K!I_SGG_^V51_
M\INO"+9^$3")A$PBAKQO_<QIN+GM1^2-Y_N.5,,;2C^Y@:ML$15J5@:'>OPC
M2(6*8'Q--L&@A **GI] ![#TZPME^996VX[&W5LL<8\_"U&*NE/U-CF,0_\
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M[WO(:UH!))PK%34T]%3SU=7/%34M-%)/45$SVQPPPQ-+Y)9'N(:QC&-+G.)
M !*@1 XZ_=JS2.7I9C.XL7,L*=D\AYSJ)^2'(5UHOB(6Q-70MJ,:L #2FHKS
MTLIJ#NA.C$24PJ=OJ0IT5LR5%T:XU--H.@JM/6J>*HU77PNIM47JF>V2.T4\
M@'6TU9ZAA+3,?H7VX0NQ(\&W4[W1,G?)SNW4U1KJNIK_ '6"6GTK03-J=,V:
MH8Z.2[5$9S#J2[4[P"(1].R4$S<L81<*A@E?"R.Q#.9+I:@/<4$E_.%@OO55
M%1]RDL7D8R%?4U$1\GVJF=-B$@"?=UUHUA$ D%R1%M*#\P,Q'L2[5BZ3X>>(
M$M;&5:JZ-8[A1:IMM/H_4-3%25=*',TAJ&I=RLM\TCBX6&[38+C8ZV4GPT[N
M8V>K?U&@T4T[(^=WNWUNF+E/J[3]-)54E26OU=I^F;E]PAC:&^WK5",-%\HH
MFCQ,#<"\4C.DXMK(H)'S,@D[B%G0Z-V# 9 W2J&RYI2O<=D#2=[="YMJP'K*
M.+%O03"C2Q:&0K2*"R5B%64>B6D)U:<XDO1KC;JVTUU5;;E32T==13/IZJFF
M;RR12QG#FGN'-.SF/871R,+9(W.8YKCO%ON%%=J&EN5NJ8JNAK865%-4PGFC
MEB>,M<,@%I&[7L<&OC>',>UKVN:,LSQ+V)A$PB81,(NGD,A88BPO,IE+RUQR
M-1QK7/;^_O:Y,V,[*SMB8Q8XNCHXK#"4B% A2$FJ5:M2:60006,TP80!WO5^
MFIJFMJ8*.C@FJJNJFCIZ:FIXWS3SSS/$<4,,48<^221[FL8QC2YSB  258J:
MFGHZ>>KJYXJ:EIHI)ZFIGD;%!!!$TOEEEE>6LCCC8TN>]Q#6M!)( 6FJZZKY
MGMZ2!A]67[4-ARLQ$J<2XW#K!C$A>S4"'18EJLIL;')2L-3I F@&H-+)$ D
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MWYULEJ*XY97R9YG,=1NJ6/";DJ9P(B\/:&V/F*TYB TDY4A;3]HPKQ@VM5)
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M.PTL!=21S226+HT:1O2)4"!*G0H4*<A&B1(R"DR1&D3%!)3)4J8D("4Z=.2
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M\PS_ !NFS/?D;V'=K=ICC6+?1"X\5-,MN I*<5K8>'#:N(50B:)PRJ^5-O\
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M'GG# 424 9A@P@#O>BH4;FJZ:<U<4\/W;-::),K:IRBSMSN+:*&:3)[F&<6
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MCD7C:>+H5Z%,H.4@7R.4R0P9X0!&6HE4B<Y&I3@T7K6MDI5#F8G($+S&(DL
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M?Z'Y\CL'CEA1NP[2@)!!#=H+G*F)GL2:.[)$H.>K0K3Y:C( #MGU\MO@2=L
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M!.'V.ONW^/2B>O"\9:!MAC^G$W[225NTG4[7!,,."I ).6$H(S"-< ,'/?\
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M*7+:QDT1*8V@^=/6PS*2G(WM,V1OGR\_[L'M]_UH&@@X.<%H!W'<]\>GU[_
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$,(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g65062g02u44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g02u44.jpg
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M$0$0$0$0$0$0$0$0$0$0$0$0$4;N7[(6K^6YS^ENA+>8\1[U#N1\#[E)!"E
M1 1 1 1 1 1 1 1 14WLS=$'KYY'U:,BY*_;0L+=1>JZQJN4%K#)HE/X',O,
M.5SDCJA46J^<%DK=8UV42VP51%J:0D? QR_*[0;5T\)+!C:]>?,[0WF.=C=G
ML<6.O6&@[IM6GO<(,9C(W\+&3O/BK1@.;&9Y]R!_;[*;"Y#:2"SE[5NKL[LE
MC)&QYC:S+B1F,J/+=\4J44;76<UFI8^-7"XR.>Y*7,?,*U4OM1ZC6K@/>[MV
M17]][FV9-UW;$.:-<0\3JI"%2JE+3KKD\G3V$:]M<%+R-C?0,PJK)RLW*-&K
M6P.5#-T(&&8$31-YGDO0W+M=GJ.V>U>T%NCM)5-=]6MLVRHW&XD49#8Q<->;
M)4[4]Z:E:<ZQ8N68HX[TCBQE*K"T,/M&'_PAH-@ME\GZ.MAME*&3V.O"W'=N
M;827WYC.NR<0J9NS:@P^0I5L77R-%C*E.A3FFEQL31))D;UASI!?7Z1MPZ@_
MN-RU;.QJ4W[,;AU-!O5Y*/:DY8\:V%J5NI(SL?A)(IUGTY0'%JC.PSAQ!UYK
MCH$[+V[M3LO\S:K''/8IG ;4;-4YGV((Q_VF<V98ZQ<@W6@NFN85^2KGB]].
MC&-&^=_)C8G;7[)L/EALQG9=2=B=L<A!'5LRGCT6S6V4K:N/L[[RV.OC]HX\
M1;UTCCR&3E.\Z_JC<ZG?H)G9Z38X:U5Z0+G+27@I!M),5#%Y>%1,LV44*DZ;
MFSX-TT6\&Z:K8,BY125*8F.TQF5QF:I19'$7ZF2HSC6*U3GCL0N(TWF%\;G!
MLC"=V2)^[)$[5DC6N! \YS6#S&SN0GQ.>QE[$9*L0)J60K2U;# [7<D$<K6E
M\4@&]%,S>BF80^)[V$.,E&P6J0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0
M$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0
M$0$0$0$0$0$0$0$0$0$0$0$0$4;N7[(6K^6YS^ENA+>8\1[U#N1\#[E)!"E
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M$0$0$0$0$0$0$0$0$0$0$0$0$4;N7[(6K^6YS^ENA+>8\1[U#N1\#[E)!"E
M1 1 1 1:TV3&+KQ0Z^KV,>%B],4"?V?*EY>$2);]A+NM>T/"F/U$ET*W';2<
M$Z7-;&'+=1/!"YZ9N O_ +[>D/!T>#ZVRF$N[161])K<IFWR83"[WWK7LH0;
M1O&OS_LD;F@ AQ]4Q?[P^B7:7)Z[ES;G:3';)4SQ8]V%V:CAVEVA+#])\<F4
ML[(QNTT83%(UQ<06MSK9H?"$_(;#TO8LZFV/(*^.3F6C'K'7FPG!>6<)['HI
M7#-G)NUBXRCY70;B$NK0JF3%FW;9/Q!6]DMC=R[/G-D[WR:ST[^FN=%#T^#S
MD@^]SV'#XHK$KQJSVG4?4RT0.HMRQMZ!V-A_2&9,;6V:VZQGRRV7K,$%#IK'
MJNTVS41U&]LOM Z*>>K#'J'^Q<A'?P,Q8 :$,KA993=VXZJ=HEQ&UCB6J5EU
MS>'9O[G%:9GN]+L48GDZ2MJJMA:>)NE87PY"I.8J9BXVTQCAPDW7B'*'1D%>
M6RWIAQ>QSX,?M_C+^"R\I.X,?&<OB;]=NK79+&WHA#(ZIO@-DK6ZU;(UWO:Q
M]61FD[^YP/\ @^9STA1V\MZ*\SB]J,! -7G*SMP&=QEMX:]F'R^,G,\3+_1N
M+XKE&W:Q%N.)\L=V*36JR=IT?8/$(9.2W"W?:^U"MDKB+T<PD2EL=Q:Y^<V=
M[IL,2X,F2/<)YPMG6%<>'B\8.1&VS<]T58AMN&XC-[;EMC:B.7";,/(DK;(0
M3CU[*QGC'+M9>K/+1 ]NCSL]0E=6XAF3MW='58^==G]F_1L'5=B9:^TFVK Z
M*WM]8JDXO"2CA+#L+C;L0>ZS&[6,;69.!ML[IDPM#';S;LNTL?'1\0P9Q<4Q
M9QD9'-D64?'1[9%DQ8LVR946[1FT;$3;MFR"1"I(H(ID223*4A"E+C&,>BP0
M0UH8J]:&*O7@C9%!!!&R*&&*-H;'%%%&&LCC8T!K&,:&M: &@  +R2S9LW+$
M]NY8GM6[,LD]FS9EDGL6)Y7%\LT\TKGR2RR/<Y\DDCG/>XESG$DE9@NJP@(@
M(@(F<8SC.,XQG&<<LXSVXSC/GQG'TXR'/FG+DM<)KAY9P\J^MVC;,[TI;WZY
MWTHRA6*4IK"VO3<LG4N6LEUVD,NY<_.PXL%7<56V',?*BL\O@O@C<';V'BJV
M9LGL?D)-DLI,\S68JD+;&SV3F/-V5V?>^*H^20Z])>QS\=DW%Q<ZZ_3=/J%'
MTESW:=?#;?XJ';S"UXQ7J3W[#Z>UF&@&NZW![5QQS7HXHN!CQN7BS&&:&AK,
M=&3OC!;;]EZ X0AN(^HDUJ=19)HTVC!.7-@TG-K*G*DB9Q9SMD)/7CIRIG.<
M1NP6$6P3-G#=A99HW)4UF/;6SA7LJ;>8QN +G".+:*G))=V2MN)#6E^1=&RQ
M@Y9#Q]7S<-:%I^QP9"X='&_+Z.:6T<<E[T89IVU+6L?--LED(HL;M[0C:TO>
M(\2V62IM-#"W0&ULU9N67#66SB:#?FC8QI,1,@=--A*1SY19DA)I)M'S9R=6
M-=?\UD$RHJG,=DY_ZAV7&4%O^K4,.[BM5IRUL-B"9SHF6&B*:.0N@D^US-#'
M$F*3[R0?,?\ >N*\QFI7*S7.L5+,#63R57NF@EB:RU#]MK.+V-#9XO\ M(3I
M(S[YH78B^L9 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M'-<"""00057%+)!)'-#(^&:)[9(I8GNCDBD8X.9)&]A#F/8X!S7M(<UP!!!
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MSTV!R!.H&ZVAFHJ%MS@2 6MA)"P<AZ)O2-CJ[KIV3R>2Q[=2[*;/"OM1BFM
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MH!(!YJ_#8KV XUYX9PT@.,,K)0TG70.+'.T)T.FNFNA5CC$5Y 1 1 1 1 1
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MDW5<CHU9%T9BBU0C2N-.@YL)X\'CEQZB>''O/U:#5>L7R8+C@;6X6(M/Y/\
MN*>P-,(7.T*6>Y2$A:Y6^V/;LMB-L-\F=MR%\91UV<[-E<S$3)3_ )3,&+U!
MD[B6K)DRA4(MF@5+M=?G<_JTT[M.&GAP7H<"I0$4;N7[(6K^6YS^ENA+>8\1
M[U#N1\#[E)!"E 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 14[Q"W"=U]HG<%YJ[E)G8ZCKBX6*#=K-D'B+:5B(-Z^8KJM'1%
M6SDB;A%,YD%TSI*8QDARF+G.!RVW&4N838[:C,8Z1L-_&8'*7J<KHV2MCLU:
M<LT+W12-='(&R,:2Q[7-<!HX$'1=OZ-<+C]I/2%L3L_EHGSXO-;483%Y"%DL
MD#Y:=W(05[$;)HG,EB<Z*1P$D;FO83O-(("_F]_XTCC)^WU?_P#4&G?"!\'?
M](?TJ?QY3_H7$_W1?J'_ -$CT'_Y.9+_ /D>;_OJ];ODU.);;G$C6]K26V9Q
MA-NZM.5AC#'8P43!E;MY-A++O"*$B6K4CC*BK1#)3K8.9/!<X)G&#&QGZ9]
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MW]X":CM'F$ZUB_63#VQO[P$U':/,)UK%^LF'MC?W@)J.T>83K6+]9,/;&_O
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M<3K*_P!FR=Z;75M>*O2;V!^Z;4VG>1- TZ?@:'B%A<7K9SJ"Q:TXTJ^W7/\
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MEE[[7*-;WK2,L*2LH=L_CI-@R>)%7&='=8XCB!KR.NG;H>O3R(U"V3^2!BK
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MW+T4U9SS)/A;[FE[L?:>?G/A> Z3'6W "U7!8_2S#.T34LR"0TK9 MQ-WF2
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M''*)#KJ-6,?INR2-+&Z[S"Z^1RJZU 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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MJ<$8W_I&89-_[Q;=G<V[GF,H>[U^T!Y"7176[/X)O+"XH?\ E]0^^%9R>O*
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M.[(]I/;ZM193  _!=/*.HDIZEF['W5F(ZK3SBQ5&-CP.SUF^ZZ2>K>97B/6
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MS^ENA+>8\1[U#N1\#[E)!"E 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M]D<A...NIER,-M@=KUQQ1Z<@!P75"/&3_=VU$UW7Z4;<K7Q\![NBQIJ/+/\
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M#J\_"Z3U&KS\_A-;TT_/MY]O2AL_3V_Q[15[7RW\:9'\]L_VJCU2J>=:N?\
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MDSS+P9\*G/..7;P]:D-_[C5'.!'RMVK//:;:$_\ G62_O*GV5B_XMH?F=?\
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MP(GD\K]I+)[8R^' B>3ROVDLGMC+X<")Y/*_:2R>V,OAP(GD\K]I+)[8R^'
MB>3ROVDLGMC+X<")Y/*_:2R>V,OAP(GD\K]I+)[8R^' B>3ROVDLGMC+X<")
MY/*_:2R>V,OAP(GD\K]I+)[8R^' B>3ROVDLGMC+X<")Y/*_:2R>V,OAP(GD
M\K]I+)[8R^' B>3ROVDLGMC+X<")Y/*_:2R>V,OAP(GD\K]I+)[8R^' B>3R
MOVDLGMC+X<")Y/*_:2R>V,OAP(GD\K]I+)[8R^' B>3ROVDLGMC+X<")Y/*_
M:2R>V,OAP(GD\K]I+)[8R^' B>3ROVDLGMC+X<")Y/*_:2R>V,OAP(GD\K]I
M+)[8R^' B>3ROVDLGMC+X<")Y/*_:2R>V,OAP(GD\K]I+)[8R^' B>3ROVDL
MGMC+X<")Y/*_:2R>V,OAP(GD\K]I+)[8R^' B>3ROVDLGMC+X<")Y/*_:2R>
MV,OAP(I&7'1*4O/)NCC&.D;.,F-RQRYFSC&,9SGSYSC&,<_HP"+Z"("("("+
M5?BAO5YKJ_#UKJ@6=Q0I;B"W\TU)(;#CXFOS<U1Z]&Z?W%NF:E*['6V*GZF>
MPS;33^:3#N;+7[!$1SVUI2*L))KM&[10I'7W#7](']?5Q7:<).RK=M323&PW
MQVSE+=7=D[\U%.3\?'HQ+6V.M";\V;HTEV)%-CG9QBEW;:[0MKB/C\XC63B:
M5;1I$F"3=,A#P/U ^8U6R@*$!$!$!$!$!$!$!$!$!%Y.<0'%;MZJ\4-QJD$\
MV)4--Z&_LKJ7ZS5K7FI+I15OT\;!EXFP/=M>6]SK6UG=95@&L;7ZKGA^:J3N
MOYQ.Q7_8'E;7DH6E.RJ &G5KQZ^P=6G(\]=>?#3K7K&"I0$0$0$0$0$0$0$0
M$0$5,<0\YM"M:5V18--&I2&Q(:JRLI O]A$F'55B/$&JCM_,OHF!(21L3B*C
MT73Z-K19.O-I^11:Q;VS5]HY6E6Q2!J0.TK0:Y[LXBG-!X5[52]QL5=K[AU%
MH";H.@*]0*G+O]P7F97AIC?UUV\_DHA[(TO1%1I,Y".E++07^N,TB9=/BOIV
MX35DU[KR1(.OAV\2=.KAIW]W'7NXKU@!0@(@(@(@(@(@(@(@(@(M.M_;(W;1
M^(/@PKE4>4:-TSMC=-FUSLLCQG(RVP;&[3X;>(_9\-%Q&54&T%4Z[#R^K*_*
M/YA%S,V&Q.W!8=%O6HF.?K6EV=_P)_J4C31VNNH T[.8UU^I:M\&G%+O/:V_
MB06R)&>5USM&A<0FP=;.Y^G4J!HEK8:OWY7:129;AIFZL3RZEZ$;5UJB9C8>
M.(9.+N\Q-3=,M.L6CREO[.C OV_;]O\ VD@#ZB![^?5KX<N.I7K2"I0$0$0$
M0$0$0$0$0$0$7CTKQDWG0#[;5MVINRJ;FUU2JQ"TFU6V6CZ-I_3-:XT[9?6=
M9KN@M3[+Q'Q95=>5]F\D_P!,\_L66V%+Z=3B(Q[8[FK,YM]2@'U_^RKW==-
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M??#0=:G)"Y.=IPZE&MDPK8%:&WK,-5X-2Y$( \@>!X\1KWCRY<->.J]OP5*
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M:MU^>BJWM&J5^S.W\_ U;8\3:J_"R\G+2$9&M74K(JNBG4\OK\#VCLY#EV+
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g65062g07z79.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g07z79.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M<P\HV3<EHGJZ1TL%(@IM@<U';MW6P%PM@]KA+1JKMGX*U[0#6;U96DI)U>E
M5V:V+;;<A?2<@B](%.KE41XQN@U^9 ?*\E)Q&?=NP2;-GHF#5<X46+I'87LI
MJ*J0=!P0;Z,&,;06S,*!4@<UC*+,=L 4SXH/Y2?_ +?T-_X9*\_Q_;//JOX!
M/]2K7_F"]_<M;GRS\._^NE7_ , H_P!\V6>?;GMF>+9+1$"FA^)S">!8N;*0
MROUHVWF\G8CW#@+%5Y@\>#XLD<?IZ90';GWP]\T%:N-],O%VBZ:/G;)[8Q&;
M=J)LU:;;"5V[L6"J5S,1;9&J '9E(3/)P@& 3)&)[((9GWY)53MNK6KBJ[65
M:4H&W8 ")5<K1&%>''$<!+C68K[ICN(9B/6,/H',QD+C]BD(R89P65FI!'(U
M*W#-5,(;.Q5 0YD8D<^VQZ)R^"MSX58@AIG.[=,FSVWQC"VOE!<J,MOHA84=
MRLE#[%83B7)39)HH:P/>(-)#8"9_C2LN/=@Z=I=5-XZ[0IV6N0BR03"7.KPH
MGK6?N(U"Y4G$>HPP>??D2Y)R-CC&2Z/P*:2L%-)/&XR8-QZNA \].C YDJY'
MQ0*5.#XT-)FW&F,Z,6;T^5&B&RRV<:JOGK=#7.=U,8Y%?=J5G5*[["E/OM8F
MFHR@3LM4D[#%I&?4R!*V-*(]P 1>Z)R2FG:L)M6$5VM116#KC0"2"LIK@KK8
MZ8]  W,6H2GTDS$??,9BM(Y(5(\XEV@(QO%&AIG''4FU&/=H^WD)!B^)L02Y
MC".1R1AX-&$2#49NXU>KLF#QTDCL@V64TRR]$/&K+E19)1O&O+ \<D 8+-PJ
MY\25 QBP)D#V"9@,S!%$3CA#Y05F$MFL+105CPS\$7F!L!,MX[(:2UF8KDN^
M0 BB)@9F,-S+F+'&,S(".2&5DTPL7!&)&86;OG:0H$,>ER*C06Q<$R;O1DP1
M<.=FPT8S=D7[C"?H6;!JY>.=TFZ"JFF)[T5ERVPY2%00!+',!2X)ABM8R9R(
M]S&&*P'GDS(0&)(HB<J4/LLA5=+7MD3*%I6;62*P)C"@ @B[5K$C,N.  2(I
M@8F8RDK@4S@R447F$9,1Q&<Q(=/8>H69JL]))#"[PD/%R83E3&,/ []\'*-6
MSQ/RI*K,'.FN<Y2VYCK7:ER;,5;"GS3LLI6H4<%*+:A6;*[>/XK0!JR()]8@
MQGY\R6:5NG%:;5=J(N5EW:LM"1A]1IL!=A7/\91FI@B<>DR!1\V1+DG(V.,8
MXQDMB\#F<V:2Y]$HR8D+. Q5S.)HY%,U7:49B#,H)"NY&8W3QG#(2W+'0P]5
MXKY$M'1)FEG/G+:XS&L7:E0JH6;"D'=LC3J"PX&;%HEM<*%1/\=I*2UD#'K(
MK.?FG)->G:MC9.M7:\:58KELEA)17J@Q22>V8_B*%KU!)3Z03!CY\Q<>CDAE
MIAE'HJ",24^1V6U'A  QZ8+OMF[=9XXPT'#T7#QQZNT;N'2_H4=_0MD%EU/-
M22WWUR/>BLHWV7*KI7QWN<P%*#N* 'N8<B(]Q$(CS,<D4#',S$9C0A]EH(K)
M;8>R9A:4K-K3D1DI[5A!$7 C)3Q$\#$S/I$SF&YES%CC&.,9)8W#I5,,F<1<
M 3/9CPG0\<]FM=W/LH,H:#QU,F^\S&?0,]CL@""L+;^33UTHS1\OG+:\P/M5
MJOA>8<M/CME*?$*!\1L*:^5AS_&.$H<SB/7L6<_-.9T5;%KQ?+I8[P%PYWAC
M)>&J6J1##X]PRYZE\SZ=[!CY\QAD.4CQ@J -L7 PT#)/@Y<:[TRD['E!CI5D
M08N4\^7*;AH[06;K:9SY=%$]M?\ W<[J:MZEO28L4Y8-4P9Y%BV#!@8S\XD,
MP43\\3$YT:IB&L0X"6U+#4U9QP2V+*0,"CYB$HD9CYIB8S^F0IB.DW860"20
M,R/4PB_$F&+H:38K;)Z*X2>,7B2+ILKE-33?T:R6F_F;Z[>;Y-L<*<IZQ<AJ
MW*..0:HQ8LXB9CD3"9$HYB8YB9CF)PU+4,)+U,2T)X-30); F8B>" X@AGB8
MGB8B>)S&<R9CQQC'&,<8QQC'&,['_#+=T<TN"P/VY!:@,C'-4DVL3VMN25;'
M\")/O*(JM@Q"4+^B,GZ_2*5HAD"K/V#;#R*#W -\8=1R2-9*S'-G6A_" &X/
M5TO8[MHI@[)96?9B-B[Q:_EK,>%;+2V:^[16ELJ+QM8-E@N!0O05<C(=ZZ +
M4#M+OM=6L:LM<P:WM-^N1X5CS%:?$J#NJUC2/LPJ&!X.R.L$I-IH>+P 2[4Z
M(LSI52-SBR<<M>BW(:-]UN\!A W'73"L!BU6RSP_\ HFR#,_> NXC\)?VJ2,
MP"(%!!9T *25-12'+^K.1[5/SG<Z_JW;ZIJ[&MW M?TET@F5/$]BR-C6ZUEU
MHVGX"H?;#7+3=M+:H7+KS$6H[A,I]%TU_I34[13$[+3DJOU7U:V'(-=!<ZZS
MT9*JPJ'QFDFHS8L;3K&IA)98Y\K/:0!'WJCNY3H33J';=16% *LBE2TWWC>.
MZDM.S3$[MBONSTCIDO[%W)R&R),\*2^K;(?!(BA6:$?$!129M4K'3R;J3D&J
M:?79=([1WX3ZS9T;NQL[/:](@.SUVO53UE[IY&U5XL+10K@NKL: .LSL)<UK
M)5"WID:ZRF>VMZMU:OP9V>LO4M=6UFJZN(M;L=@VYLJ74#]6R4RQ]^P3+6OO
M$FL.OA"E*ALL0Z"L&,1]M[E\/@M(.AU_BI]$8;6=',>W_;Z;4"B_CQ*;P6[9
M"7J A%:2B,-?FX_N<WS<C<E**V%NU@# W7D7WSEZ-%-E"B7$:KK92.LM(VE:
MMW]N?2_2]/=2#PJ7-0A>T"SM[5H$OA,1JB"M?8(N--VQ'R&,F%RG:]%-?T=N
MEW:U6AJ ZGZFMZ:#0=NIMGMUC*^IJU3<B6_]*PRQ064I!M&OQW@L9;'6CXE,
M_H;L&3Z^]FZOM O/9+-Z]95GV 9S85%(==+R?4RF,B[.TII!8]+)@.%_M/@Z
MH38:_'&B0EV^BY!155B[74%MM_Z!I;G1KW?3^QURJ=>G>/8:0JC+-K4A2VLL
ML%K:EQ]:JQGLZY#O$!BEM$+(1$&(PPM"Z\NZ;=,TG4&OV#;MBY2&AN@MKK5=
MJ5S50NN&PM4T6;(+]H5)5*S!QJ(ZYS) 4RL>U]S.?#]8I&J_E4IZ<,^J<I[?
M=5I)740J-Z&9R\Q1D<KVT&S(GV%'!/,EKYT$FID4WL=S.-5YT.2)R;$EV2C3
MV+>D\V&GUL<JNUJ_51=25^E^HZ]ZULP:556XL7M>1KT9NYK +JBF30&I(TSE
M=?R\38"QQZ1-OHL(;2LV>E@Z<L]3=.OHU=8:0LMU"*.P$&;L$\63)5MJXOG<
M[K:X:_QYA!UHFM8X_P"AFE\+(G8GTLR?<T&$0DQ<)/\ K%M$&TI_;$163+PZ
M+2NO5^EKJ:_L]U8#)U'F4RC\A6AJ3$O#SS.R'L@8-I[PZSG31*;/5G@QNG37
M4ZEU#%HJWLM8RJU9K7AZK"IY[O93>55Z(M2:K23H DR@5SZ.C<2+JW2GC%IE
M18:J[T_Y4;'M1A0RK7LTIZ4*WY& 7<0%I#IJPME5X7S> QFM8YTW.$AD%A1*
M@+8DT5G7B='JQ=DX8NYJ1@8U 5,OUYF=KP-VI+L1ZD&ZC67^[3R<[%(0V<-&
M[AZ]=CT=E>2-A8ZJ2MMRXO=:RM9I_!\C8"NW [,T^/LAWE767!BM+]N7=5\P
M-.%W"$R$ $YB,CT$=+--52HS2[*Q6N?" [7DRK):T&^#K9TEK94RFQX&I$AL
M^ 5SQ*<2 D1$N.<YUW_#)UZ&%Y 3K'I>ZMPSUY\."61X.M6\-*0 Y()G-;<S
MV'F5?PJ2#FS0H(+QM0,L:>9$;C$ *L;+-VK1!A&G#'KJ/P@WAJ2O8]5CK%;S
MKRL]HWK:[JD5:NM]AU+MNNPB4U3X;"1\6&$Z'JDB)E@3[;:-!HUL<S7]*GLF
MZ/H6RA14:K*3GVK>R]MVJ55X"+%-1*I:?A2N$RA@B(@@@Z_FR?7(+XB/95"$
M#*6D5'Z2:ZTJ=0-S*K@T"1'NS2F8H^KHW<D7G-"$GXH4LX7B@BV6K."E13=P
M/8R$/*=HJ]TW4BWK>AM 5QFV1MYKZF=K*:FQ;=DP5'F0O)U5BGNE@U@B-ENL
M([BVD)FAM;S(YI8QHT];[\:B]2_4Q8VT:N'6M<NE $Z?+'1;M*]S3,-:Y*:Z
MMD(4V+@@!ZK/EBS9E0E1Q=F"KX79O5![#*\[*=J9RBP*0KKD"2>')WU<HY]7
M@^/ I7-&L$7'J6-'[0B.)4^FLFZTZS&&0[<R+D40:4["7.OPO<+-UYFOZD"W
M>T'3E.37;WKI!-+J+<!>-[JU0K@G%!^NM>6"I7Z@FK:M0IB+1;2X-_)ZE@II
M+V'39U:.^ZCMP#*NA5!.N=/:<Z*TILVAIDOSR=A5\R=JQH?-5*LN6^J&LJ3(
M2\DI9%@>CU6%^E3=.36!TIF=IQBR3'6Q]#<"H[65T1F^24?%IB(_5*1\:2(B
MVLIQ1<;82GTAK+RHDWGMC4H0P+1MI-+]DOJPIKTNK:FNL:]6^"UXC]AJ;&F6
MYDL?LI0:P85:=Q897X3V;.1\*5KSLL:J <G7-Z4&+%WI2WL:U]NB.KX:-?M:
M^X-*_#3KH<MC%C8]D("QRWNUD%XO><)CLQZ<LX@PB\=D-;,X&7D=1&%0$C(B
M$B3UG&E?%&:"W\Q9$%<.ESX,%,:1;%'!379ZSWD,+3<[:;$!N%)CJO5)63LO
M1?*XJOLU0Y"VR '8CX.R:%4@CB$N=5VY+%4]I0BW(\P!\0D6NEPJKKH=0&FV
MQK&REYJ@S!$_"$*SM R>Z7*3:U(LED=P2^I!<>(OGA1MI2\<VZ[P^WM^F$^C
M347))7-+/A9+IJ")[VX3I29I474SX77S9*9K5E#["5BO[69Q<<8*1:33Q5?>
M88Q6X! G*^SSVK_;MK61U92L$RO6J:ZVOJMRXUB]M4+<[(&7BFI&PM48L^S*
M>JL+L5Z<#%2?/O)=8@=4CV'5V?X*W*XJ?9M["J?2R63LV:FW&HUIKHCYN:%:
M[-;VE<VE9E=]R2FU_F*1.S)HBOU7=6(_8$P'5,"5)1.CT;$DSN<=1Y<PCK[2
M47+K-2S*$E()"^M4C$O(2ZK!*T(WU6L6(VRP?!8L3KR3N#\AM$/'(UH>HQHK
M-;^I'+7:V\T*XT^IZIO":VJ\HH[:[EO?H8%P=A.OL=24;.L8#;*[U<4(US7R
M*Q=.E>,&)Z<2QE;41>>5OIFT"#BQM?-L&HVG4T%A1U2UT;"OT[>K;(#5691L
M2Y^Q4C4KHO8,6@2]^1A::5:,%DI9U[/L2\Z;P8)DW%ZY[$18K(G\/*60C[7'
M$FL37>2)$ !)HRIP@SU?-6KTF!079[/UA1LW8TMB*FQ8Q=;>)-5,KCO!L7]'
M84@+2Z$^$Q961%$N<N:PD781 MQ0>M='W:],MRB;>N6L[.D<#+@TTRZO1WE=
MCSJLOQXJV#6(WPE+(LR(=XB;$C([!PNP^L%H$B<UL4/UZ;VTG,^Z0"LAPP)1
M%<Q@BV8ONK!JD2,\2FL>6I\SZ6/2;LPA!9]>8HVUELG',F,CD14@&'.F5';H
M]0ZY:ZE%F\+634Z3?L&,=N;UA9&'4:MNNE-1\;17#Z_3\W*6G:HJU<S.NA8-
M8)752]T_L&';O*TD;*+?5::"UJT]"NP0+IUNH.[%M$ZQO*;&_BG=VZW#8L+
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M6>LG5VL:+;1Z*"Q9J/I[N.(5UU5TJJEJ-]-E6[H%MGZ[VK*CT+=014$Z9-"
MNUD4K<+J;9&NB=C+U0^TQB73V\R[H:SN6VZTZ+RSM)?C5(V'LN&CO5[>!ONW
M#;Y'3L/N59.UJ7;"8U\5V^!66MJ8DM0NUM@]1XE0MYA^OL"ZQ.IE/.YL_C;1
MV-8A;(E4-I76DZ?>N'U1R,X'$&P<!?W UFGN7)AP9JU&H>U T5?>SG;Y<AM'
M3='J:SN=.W=W>H!J4NE*5@Q8;:%:WMIV^T$0V:$M:EUT-453S=<W%)EX;;(>
M((0O6>H[W3-;3;=6DI=/E;N=57:XDL%7[-74QJ=81'K'N4MJ:3-F-KRMA:A%
M<>(JL?89R> KE.@U.A<>]UW?21K./<WL=\2&>P;3+OL)M.\%O.HO6A-!RS>R
M=%5(E@0E&EH$M[AMYCN;6MANZ$Z+H[9;\[J.LW^8#JXJ?FM#[!]B'VZ2*4K_
M .F)W/B05"8BUXLV(NQYTJG@QK"%DQ.8*,::>CD>6+I(;?E=Y[>]N#W;OSD,
M_P"B/8W9,7^9K>%%>:4^4&UXQ;(27$QF\-F7+T)O"[;*VOI3KV3@4'OCPXU(
MM/HJT!I6!.Z^)51[ [&('9I'5=Y?84+C+T+'1,O%H.7C>%,FOH1;1@4]&HIJ
M%#5=::C44/8T;Q=VYINNXL4K!.FE3O+V4OT1)JOCRM&W8!SV56$(%<,HEA&N
M)B-MO[3H[;;6].XG2,IT]QT+->Y7%,7;E(];X.]AUI$S:O54&I"[*X(PJ"'"
MQ!D\S"K9EO2*&&[4E(J']+3%F .G=G/HLQ [4W.ZT/6GIV-K/6HU&,'@@-I4
M.+)&UQ[Z+^Q@+J0G)#!D6N+.8:$%)$,=S-;5ZNM*UU9MKJQ6O?U3KPL&[VK3
MOIUTZ+8>TX.Y<<6SG7LO^4CQ7BA*+DE[//LA#1B[*STE4=L;*JO2C;Z.E]@=
M<$^R[E!VPC>Z^-9(5*B0UDWUT9MEX29<Y],1]H!XDV%E8^U@>'N2OX-NS%]/
M8-#JZ[U=4BD3-PEA!XQH2J":TA(I#?RYT\S<X6D=?!+448-G#=^X6C\ >Z,8
MX%1"L4TF'($4NMUZ5O<SJFY;O]'=2+LIMG=L2O:5-NA&E%*2'BO=;KH,A(!A
M]T)-[I:<R>3XN]$GNE2"^F*E6CU?TX=9U4*=>&:RWJ7NW)-<!1+Z*MC("4&1
M(I%V(5"@B!RB=3?34=TEATK:*]68O;D TK^7,TVC.I;2F=D38#?*)$L&D04@
M$A_9>*28G%=U?>Q@;ULWK8\@P_1C&WB3H@FKBYE/53.KK58HZCL:R[YVL4F6
MSUU2A4=IB!34.!UK06:Z[/'EC3.OWPW#[[ R*YB:?Q>EE])U;(ST[7V5**5H
M8 -9L+=^TG<"QJG*8JMOJUAE;GS(-\_HCJ+[$$)'SDV[M=C* C)OLA:T2B?2
M+L!:L_[V"W46<I1>K+8>%^M+ZJ61Q-X@@QT)Z-R9V4#6 V6R%RV<&V$F>FV3
MS*!DD^QM#Z1T6[L)T.MM6>KM)K:71S1L#-G8ZP%=0!LC3(E)RN26FLPV5D"4
M).N"C&"4L,E]6[W35W;W8UJW26ZV-WJ]15BBOKMD;=">N%O?$!#.UCK"UKLN
M(2:#S:!<-8R)T_\ %,@77JCW]6551,7!,U[!WF/;21&=HX@-ED6AW81XP*TC
M1KQRZ:HFA0VL*X$MGZL;4RDST)2_9[LCNY_IMMI^#JYO-N&QV6YLN.*45>F4
M*\>65K-K2":]ON!$2E+6;&^T@BQ')RNKV<P/IFK_  AT])J#U^NT]=(S=FUU
M*]O@"NS7J[LP9J=01$,-4O7T%B<U_0(99D^V2^5,]=S?JD+D->18<*ZT$HG8
MERW&#MDV4BM='3 BL4>K?5UM"-A4K),79BNV6+1(6L\!2.*/P!;:9BY BV+9
M] 99.((T^I&(OV#9OUV:.KU3M8E=F\E3=A/474)7/$KK,%7C]G+UH.1:!RO*
M,21*^4HXG%;Z<6^C76O0'6O;79IV365J#FJUX].]/#5E5E@$VB'M ]D27UC2
MR;2W0#)[6@6*A[VA1IVK"1%OTH?=>!D*JI_'A<H95^\NTO9#3KT95M)A8. J
MR-DX9N+DP;UDB5X?^Q#ES[H(TINDUR&WQEM!NF)V*UEU:&]9;V(6&5SO!J%4
M"W:HUQT?&&=?WQJO!E$Z?_.QCS4[;D_%C,54],M^N8P>E#T:ZFN-"K TBVS;
MXZ-T[!=[P9B_V%M?%BQ&W_S,B\L.IF \+.$UDW628]6M9 7C] MY9)*?MQ_:
M:NJU!UC*P78IW.)IK7:\,@,<K=U>S44-!?LP=Q^-4PD%HDD#T-"YKM'R2TO*
MM^Q(ZAJ]12A3]T59&TU@:V)'=;&L[1!3J>>BW=??'3$UCO: OL;:6[A;I2RI
MXX#6670;&@M=.PYJ-*-FQK=F>Q*"TNOLHWAW+<49JTD:\MP*EI]GFE&JA6G8
MGQ5VY2R;+!O&5-NI(@K$$4TNH\T)Q2[YH$BFXZ1=7J\CTLJXM1=H-XL?12C,
M?M<.-8-I^&AQ: )=RI#:!-I,\ 0]\$8I'I*;(EJBL74S5VYYZGJ+L:BHZQXB
M.HKSZVQ5N->5E$S8=KFL,J3;2KL]*U]<LZLN;I@LOKJ6JXLQTTME6(CIFTRM
MMK2J\K=T]119U[-/L!KN&$)V2EA%U55M*.J7;!@VO!5N3K)>TV_"+MNF0R6S
M/?57K=-9(_L.GGMBM)*^ZN5S"Q%3.*L"9F  "\=L+%K9X0:S+$H1M&1=,MFE
M@.BNP0G5 (4@KO'A_-DNJV5:D3&_J("CM!H'7#J*_;;LAV3O*.<('1OB!5)K
MSKD=5]U(5PY>S<R8AY]:X]++LV^)T-MYWM6=X7GT[1JJULZY7FDI(EWZ!F-K
MS$;!W2O;<-LJ9KDJB? #52VTNOQ+INW5BN:0B<B!C8<XB[0 1J*<6%/#*\[(
M,S;8@0; J][30&6#HP2=$I@A:0>>4H89QW3%?%0"Y6'LD=DUD[M?5119]KV4
M.9:&P3E[2G1I*&DLTD"R=>Z<NUF6%BNJ6N;3VRC?/GE/A5IDZ[LXTK.EQFM[
M(K.2NH5<4GK+=ZXV;; <)F*:745.R%=DLM1L5W-2T4?YDQ),JC$[@O8$+%.H
MP1=,[09$Y'>EUF5>'ATEC5,GI"O9+GQ!*DGR F2P(N(<FY@GI62C>P(VG- Y
MZ)$'8:3FFR)$FPFF-H5S2.L]4-B4[H$OZLU^Q;:KV-JE$4!Z)V=(FU[JFBJK
M,[#FD^:C4V@%M=12M9U)R53W:JW3*IANF-J.E+^O55?7U3GE?+K767878IM4
M3K41K^+R(MJ=6,U6&A!L"US<\:>]'%MY$2; .O!-,W8^IVZAI>54A!@K*M3M
M TT9P.K'WPADQF@,>VLQ_>#34=U0&ZV;&)0W%B7(1<,SAXY&J>'5\1763MXN
M4T93J6*K;BXT[Z=UM5=^P\K;JU'&6O#4'+.I6>S[%<F-%PM.RR;6N72,P]D)
MTC/&O>-M0;9U%-04':75.A>O\U4MVU .P/;!X?3BXV%>Q *))*"L$="?/9\\
M<QQC+$J'_6S5_P#O$A/^)1G(.T_T;L?^!M_W=F3M7_I+7?\ '5/[PO/]12>(
M"U+)I)9XWK55^W/3+82M+B:S.<MU5(053=;58P3142+%-V^V=).BX413:QGU
MMVGYRZ:/F_GWK"=&HZB%9;>%'6U_CC12+-:0CL42$;ILE$H3!>M(A@I.YV!/
M 27/WWLQ3.WZ<)@:<FA9V$H*^XE[()G7.$YTJH&8>Z0GBZ)D,!3[SCDH'CQ8
M?RD__;^AO_#)7G^/[9Y]3? )_J5:_P#,%[^Y:W/E_P"'?_72K_X!1_OFRSS[
M<]LSQ;.S'IJXKJ5=3^\]$RN[*HI>86T4ZKDH*_MXO(@D<,HUO-+#/2M+1]&H
MO+7^B[)B_'XTT]E[:*+OVVFRB>FVZB>@=5#>K=2]'[FMJ=EMJNL5U&NX&K4A
MSU3?JT4UID'V*P2)F#.9\3F( IXF>(G?>ERHV>F^KM/9VVMU5K9-Z=93/9M>
MI#8H6KSK,0=>O9." &+XCP^)DQCF(YF-T>H49Z\LP].THT>TI<M_1 KWY=A)
MK%ZS/71" TJ(TO5ZM VA.PN:U)2.7U7%I.PE;MKL;@QP?%B+5_('H!!@S<O<
MZGU18WA-VNV(-MJM+:5T6#JEC8)U-QM9>UV,;K74W>?6BKLK%<ZPE";B3LK(
M$ \C,0S:^F:^C%6KU(EJ=INJS.LB3;KZ]VUJ*LLU6O+2["XKR#'VM=7L!8(?
M&J.778)N-(@!'FTQ+3K%25V5^>N22]8XG+?@\Z?F)6'2H^NH%#[0('[6M5_>
M4V L)OUOG24:7WC[..O"<2#4Y#K LN*FAX^*$8(P'HZ--;7/4.WU%U.KK]0V
M:WX4]4*JMG;WKMG7+1K=:O3U''4WU,K P\G@NRW:VJ6OLJ8=D+AG/=L)QT_J
M=M3=M+&@K6?P8Z8;85&IHTJVP-^QV)[>V@+>BN17F4B@SK)U=6[?KM :[*:P
MCMUW;WGT=C4ABM8AFG652HYE,_%0'VB1<51"#1="%O=9B4Z:-Q<X)Q!Y,(JP
M4+>[RD!4BA<2[1SJ-;D=T41S-%G?%J.K["+.P:?4$;.I5^#EFO6.QN)45L/*
MKZJ)E1=H*MDX7+XNQ84T9_A"")EAD5*.XZ218KZ]0Z"=9:M?"(&P86NJ-:-0
M_-,Z6%=ME8K58);X$T_+M64?P<,[8 8'Y26^>J8WI];T/BU@T(QKB>]3NID2
MB-,P6$#HKV94LB'6C49SLHTG$\S7*3LD:,E@TED+)]*Y=)PYA/04:C W+$65
MROS7TW4A]4ZNU9H[D[]+J3J:S:VMRX=GI_R%K7;-.@*I3B_(K4I3:Z#"M5K-
M5,L4]G>Q?;UL;GIL.F-G5K7=,%"[TYTW6K:JG476W_GZNQUKM^%NYY&"-K6*
M>\#LV;"FQ"FUU]BV\X"E;OZ:R#K>&I",SV.4A4@?OK3%ER:)=FXO6]S62\K!
M2)CQLC.L7@BJ@H^6,D+!9L_;;;;U%R)KK4R&/K%H@0(QP[EVVHZK1OF[>Q2?
MM]FWHS;4*]GI^Q?U5 =C%DS0A@LV33K&5$S\(OE"V]X340NTM;TX=5M^EG:)
M6IKW$:C6JZRU-^Q5W]>CM;YZ_P L /<!JUR@LA%T \49[251\53Y;5-B'65;
M'8GIS$FDGLF%J=7)/=PSI=,(R-W7K^H;'$.[_%=I8N^AQ#(T1U_J.K)#,1U1
MKO'(P\/J86*5##-P2I26LQFQ4Q UNBZIM%7H6XZBKZAG5E6PR(N[2BT-*WIV
MR%L/$;NMGL45&;. %B3V3&0YGC0JJ3(6J?LMYTM6&Q?JST]8VZ^E;5=<E2UE
MY1[I74-<JI]BM)K-<^T&MDR6Y>M6J4K\&6607+&V2O!Z7VZF2&R)G754#Z&8
M]*NI,P3B:O6Q:#WD*F\BNFGVE[3UM;1"K(\F8;VINYD6D/(1RRRS23AR#'6&
M"18D"8SF#%S:_A*BA5O;)FZ/JSJ:K-J-\-S3LIIU.T+34RUB]B^53K8&O-H'
MZ]95F@?FVL:Y7,\JFI_!M]ZU1UJ],'2G35J*TZ&:>W7;?M=8&WN#LCUR(;&Q
MDGQ6-&P8-A;!BJI2TMS+K=J>F,'[.UX5JR2=5XDS/#>Y,2C=G!A,%( (K4L\
MI]RQH6&6-&1'4VL@,2$(SM@&08-Y2_L^S@8Q_,XA8,F.0^3N]2V*.G.J[G3]
M]>QK]1V22?2ME^O:RX#[.SI;03W-NC8;U+L'V632-LF58-?KW,"K:I5TVJX2
MO+/472M3J"@S7V.G:P.#JFLC8*53--?67=80Z>K>KJZ<H)K+BX"A ;1W]@E9
MVJUU[JU@_%TO/=@>M=>4S(I#!E>MTAOL!TGZJ1V,K/*BKZ9#E+[%=IIR[N!\
M(CTI@SN+N9.C5Q1H0>$G8?7R LA\M]L+#!Z#/:TZ3?7]K71<C?(TK^K>I'V8
M'9WJC(TK>G:@:L&OKW LC7G8+(!6+9_AH;!>C#DM6=NM!2U3WU)T+]RCI/IM
M%>2U=*TN=RKJ*X6T-2+%,JY6(US!,V$K_J?"[?58"'8]U^@_6>U[T*%^O$&H
M)S3LB\1HTWL-_*NLKJPH7:%2/:SK\[$*_IV6K5)+(I!4(K+5I;(#D91.U]F/
M(D6$I*N/=!#5HKHF[N;_ %NG6K>7-T.T1T*HJ(5^H!HV]?L@V%U-J]M:T;.M
M9N38K#60FQ*;L/E9UE#%J9*-XTM30;+;L9I*>E+5OZX=%\[.@*]4V&M/7TG5
MJ6KLSK;->F-:R5ES40ZEX F%AI36CM+HAZN6Q5U01?O!)B;:IG=EYA\)UZ\-
M[$KR&V.SQ*4;_ABIUS$@4RCLCCFA%A7WM]_HLNRU2T9-MMT_2Y332S[%U%K-
MCM+'2%=9;,:'F;D[PJ-ZW0/RY:2W"1M.J/KV)6R]X*YB#F9,O7CF9SQWI[9:
M_65NK;#!UIW_ "M2-&-ZE5O!YF-U4EQ5DVD/1!A2\8^9"(@!YCF8B,[/IEV
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MY'7 ;Y'YE5!P,72OL0M6T:2*!V[ 52KT1M/$D+FZRO\ PPDHNU@R,6,]*;^
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M<NI8 @LA?$QZD?F)8,QC,B;E :P0N]2D()0A&L=7:9 69%EMK*]>\X5CK=D
M6&:Y!V+=6M993&LZX@%G#ZJFG802W0U02AT!)K])[EYU8E=1:[-BDB63LM:9
M5PV#PKU;5FNNV5E--YL"46FJ"N\6*E+3AR9/FR7I7:HTOH&CZ8HQA@PFY.2R
M\[,JCA%5"A\0MH[4:!)I:QNT]H2NP-2 2V'LO;I.+D',D=N(\$''DV:!@ATK
M]6:UBI<^6*[SJ+KU4U=G;V3#M:Q.S)9ZU.NBW!I0PF'X*["QKB+W,3)RH.S^
ME-DMOA)A;>P+;'VG6M94URPK;)VL$QV+MAY60:]4 'C,KF3RE"5N@8:<?UZ6
M]EO94C+.:X3&:1<E8X=^*-S6O0,J(E:A$-Y#9@Z)0LU+&$OG;R&1YVU/FD(2
M$D"B )R@8TPH.63<[9YZLZ?\1"QORSS"Z#0:FI>?66O:-)&O.S;36.K3&V\2
M0J;;D1+AE4\,B1S#^"F_\-[2H0N*[+RC6ZW238-FL4+[X5JK;(6;A54$+VQ4
M4^824-CE<P602J>O=M76V)/:[CHP@Q&&0<:4?GYI!H(P(2R3Z/U(W#(^^GLE
MC+243>0)BB2H6%QM8M*2B3)RJQ$+II;;8F;+>:S4DL+SV ;%.L0":ERX85J\
MA#[;PI5[!5J:98$-MV(567)C!MB9XR'K=)LML+"HH68+:FO)OMTZ8'9L0R:]
M5)W'UQL6WPIDIJHEEAD 4BN8B9R:W-UR_8K477^=2"5:NIM>0"7R]:!M/<MR
ME!X]&K EE=(-#CL581:8-I2X,PXFH4%'*]C@L.XV=1CVZ^F<6FL>CD35;WVM
ML]W316[:FG?5JQ=+S8S<?8HU;\DD&4552K"JTN%L3>>QL0-CP0J6:CWR]KH_
M96LTMQUF"M[=%FU-,?*%%1"+MFC N-=UMH;!-JLEBVTD+47=7\8[=:VA&L/-
MAS7\L2H?];-7_P"\2$_XE&<@[3_1NQ_X&W_=V9.U?^DM=_QU3^\+S_4=FY!N
MUL.FV:IX.-6)')<DU$/X2]D1.1*-H65<JMP<I;[8:P)<>AHJ0>D'VN=#C%%4
M&CMA1SG17\^-<HCU6_8-:PX4UJ!&]6Q7434@]@@!.S2.)/9BTI%2U*GFLPHL
ME':',??VQ:*]MT^N;-=).LWQ!#=<RVZU(:YYD%:Z$]FL)0Q+6-9Z65C-89Y/
MB?%/_*3_ /;^AO\ PR5Y_C^V>?5/P"?ZE6O_ #!>_N6MSY<^'?\ UTJ_^ 4?
M[YLL\^W/;,\6QQC,U'9)(H@:'R2)GC47D0E;+D4?CI1\%-#'&4]TLKCRHU=L
M^9+92443RJV73WRFIOIYWF[;8SB?71:2=>RE5A#8[6H>L')8/,3VFM@D!QS$
M3P0S',1/S9E0]]5H/K.;7>J>Y;D,-35EQ,=P,60F$\3,<B43Q,Q[IS::NZ1G
M?:6$7+<)>SV+Z>0N>TK%GI.X+'  6TD2M$;:2*;LG/K'DK#*Q8>_KT"'&#O6
M7BJS0T[(.]QX8"^>M]<O[>GTY;U6K5KC"E;I;:P"]70>\J\ZYFN*172H5S[5
M&%YS6,[0B#4(#!M< %L5'4W.H:FTV;-@!W*ES55S9M+R4B^-@O8#!,NWK <L
M6=)*EK[CF0:1EV*29CRM^DMOJ#&;A44PA3D%&Y 9M)Y:\UKFO([#'0.\YI12
MS?!(U+4E]L(3**>[KQD2:,#N9'ZZFP%/0N1I=_TCJ[5PPQAAVQ=80K7!K:E^
M\^V+M/4W,%X:JTCZU+/CB:S8GR_;)L!L,4',])[.5A,K"H2J[F[ ME;HT45"
M3M[>GD?$;9@O2U6E! P0=X_? +-7AM.0U_T'MHO)9:&LO8!6B$/9]C&[MD4F
ML#VEYV1==*\E<KEK2%1-23)E)L#8'P0\ 4DD82)B<MWI,D%=%TH\;]GX;O6F
ML57JMU_C[";1Z*1-=2[Y5*-[>K5JIV[,5Y74<:',<NO8E;>X%K<*I>GOSTNC
M=DVQ95?E-"*H[P2!ENG-IS]'1LV;(U:TV(9;2#D@EEBO#%<&9J)L);V8]WT2
MN@FY47AXL-@4Y>M8['64WL*K8M,)=-$:BKNX"\5BD:VFCEQ(B>T:L4*0"("-
MW>[Y!VQ%.O4Y4XP!YW'K+4K&(M,;+! GO.G1V-FK5J3M+VK59LV/*#"%Q8HM
M!TM@.T@-@0=<?&SH71^U9,E66KPR(4H"W=U]>U:M1K*.T;6K5_-$3V>7O*8H
M524F) LNVQ/@Y69OJE<4=K,I:I9A$D  ")P.=2,+I84'<3V-Q"TG8-M6YX]7
MS<\I,!S&:(R,(4#[+"/2ZA2@TL038L2HI9[8)ZDU3]@O6K.S+W6;M-#9HW!I
MV+6N%Q7TINDF*K#J$AJF\-X\9;%+DS6R @-Z<VB*#-BP*PH36IW'JB]4*XBM
ML22-!SJ0NFTL+8O4U4DKGP6+:< #%R<D"5WV7L*B\[,K"5+U5'(_*K"$U"2O
M /Z[[J0)R^UF$TCM-/Y9Z]@;'%6QARY>-X^W=N&XXX_%(OVHTDNA'=>Z?H[B
M.^C"MD]]>BS:+T[>SS-T0FM4?M0K=GB6()0B,O(1(T@V0)BQ+.FCOKVGY"]+
M=<A-BZO6,VZO$\M3(_-6T:H[/?X=>1:1'"!(A6XUP8K80Y0YT.[' #+6/N <
M(?%\RY_") U"VO69C6 GQL0/V$[TLAV/E2[*!CD8!$Y5-%S$E<CQ3(!%Y&N0
M=LW(0DU;8T]9Z%Z2>+K@*\JNX@FZW8*FZAEI-$9H"=:#NLF[9K5(57$V&ZRB
M $A<LBR-Z.WJ6@DDU#;-DZCA5LJ#?).75=>*+Y!9(*812KV+<ML$"P17>1D!
M)8(\&?=6G4 L#J_7RLA:2PGV"B$.E#A2$%XC(Q[9687)/JS'#XE(FL@]US67
M8J)#2[=<H9#ILBI=P&/Y$*C'F4>]+J,;M'J*[""K+TEJU6&+BK2#**NJI; V
M6D$GS"NUEIBB%:FR:E"U/BPP>>ESITJ5WI^D3QLLW5:K8F:C*SP'S6UNT%A6
M>+_+N[EUEM$F-5 ,:2G>%*SXFXCKYVRKR$2,G"IVK!(%*P2TG-Q@??<5B9^0
M5CI9+RF7,WE]=AIRD1=Q$5,M58^<)$![L<S1]HD$U'$?'%B3.(W=]-7K:%VZ
M<7+M9T5TV#TMFRE.PF@.U&G5O-IR VFU>')6!@PR\,)B'FI92U:7J2E4>RI<
MFG3LI*PZN&YKUG.U\7RU96[-)5N#*LNU$I<PP( 'O9S*%M8'"LGH-<<*L6W(
M. ?PJ8,ZWL^UZRC!+$W@X Y;9"G]=7\PS7D+?RA<T?,! ;D<Z/QP1L5>BS[O
M>$-UB<N:+">=J'6FJMT-9<>%NJ5_7:W86%^4MO3K VGR*OGK85Q4A3G"8I>V
M%@Q Q<*%UBAF=;_1FTJ7MG32=2T-#8;&A79YNHEVR/61WVO)5#L2US4ID">A
M7B&MQS4&661)>8'7HO>N@]$J2=5" 'Z0Z!3XXXD5Z5(%S#8K:0X&6KHC-FSZ
M7).XJO,ATC"O (HNW;EWK5]H[U88:I.%TL\]8:>3E:QVCCFU=I)%&GV3?-V=
M<;EW@J$%:0L#58AP.:LI4!A(2?=(Q.'\$-Q 0QA:Q(15IW'2_<:U4U:^Q6EM
M$[8G9@JY6@>DDJ8(M(3@NSM@B&/?!Q>B6+ :/Q,0$R:MG=N-)# BEDU^TL!Q
MO0S,F2M]<##]I'L:.LH.-"FG[Q\.;+-##8,7S&%CB@Q\FAG_  JT\^2(&VFU
M[XZPD75Z^\=$8W)+#5PZU"/"2=QCDK #*"43518A,,"9P?@ON(\Z)JJK?0+9
MB^FR_2&[/L8&,VA)JR_Q7!36EIF2Q(60IOEY=*S@;%LKI66C!T3'HK)1SA4Q
M.9E#1AVP)' Z_CAQY%:]Z\S/<."<%I5@DYE>CF]6K9P)<CFK=^/U$N(X\,NT
MY,S 0-?U:JPEK[-<QA5.K;8BDBY=>D+%[>5/%="ZWAC6D=.1"P6$0'XHO%0S
M7)\Z_P!*,KN4BL\")URU56ZZ^G20XJU+26I4DFV(,K,%N &5$ B8>&2#:46
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M9YR<=UNZD>B9/2 WH=#-C;N#9K"BW<N;"0/5J=?7:N56(,0V#;!+&J+FE:
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MNN4R5<#B>X$E,DH9A<S,C.>#_GV)GR!ERT%;/[$+1!6/AA)G^X=E(626T*L
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MN3)L:;)@'F ")=1ZGJ 5A!+87:OV2%(9,S,@;+S(C#M.0TAW.@S6;P:=SX$
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MLQ XZ?A$;-OO=E8II<GJ([_M&C#&J'PKU]>S[*[QY8HZ]Q%=J6$+(F4P+5L
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M=RR^T=IJ2L15$U53.NB%T4JKTE"I91'930A*D=\F8"L9DR/DY@XJPY^"6&.
MDYF(9P$;$F89<5)C0Y80T,K[.3#48JT>H[L&Q9SMLX)(--DDGR^VRKK553.=
MLS&4:3H8+:=5HN)9MAE=)PTU1VJ)D$$P9+'Y*R+F0CT&8C(B[UU,K)-RTHE"
MP5$NPT)4+9DFBN1.) 6%,DR!X@YF9*)G,(*.FP1=J?"&"H8ZQ<Y>,C8H@['%
MV;O/G>5TU)-%D7C=SGS]_*NBMHK_ #MOYW\[/ES,2ERB0Y2VI,>PTL6+%&'\
MDEE$@0^D?)F)CT]V85N<EHN2UBG 7<#5F0-$O7Y0L&8,2]9]8F)]9]<XQ B0
M+OWA0J^>$R9%RL]($2#E=Z_?/'*FRKAV\=N=U7#ERNKMLHLNNINJJIMMOOOM
MMG.<]@ % *U@*U@,   ,   ,<"(B,0(B,1$0,1$1$<1'&=3,VF;&&3&&4F9F
M4F9F4\D1D4R1$4S,R4S,S,\S/.9O6;S30<!#Z2^4:"(L1R8C O4^5U'1POE;
MUC)0"QP[PV$$<N/Z?+X>DW<Y6_I?2^?_ #N89IU)8YLU:\MLK\*PR4*ECU<=
MOAN/M[FK[?3L.2'CTXXS-%NW"TJBS8A5=GBUU0YGAH;,]TL2'=VJ9)?*[P@2
MY]>><Q HN5!$F1D&3(!C URF\'%A3UR.),':.WG).F3YHJBZ:N4MOYR:Z"J:
MNFW[]=L9_?S*U2W+-3E@U3!D6+: L68S[Q,"B1(9^>"B8GZ,Q+:U+ :EC%-6
M4$#5F0, H]Q 8S!"4?-,3$Q].?PH4)FR+TN:(ORY8DY5>$2A1XX($7[M?;.Z
M[IZ]=J*N73E;?.=U5UU5%5-LYVWVSG.<\+6M( I2P4I8P(+6(@ #$<0( ,0(
MC$>D1$1$1[HPQC',-KF&UK"DC8PR-AE/O(S*9(BGYYF9F?GG,EO+I6H&%1S>
M3R'>/ GZI4("W-$M@P8HOMMNL2%"\N<L1[];?;;=5XT01<*;;;;;J9SG.>8_
M*UO%:_RZ/'<$*<[PE^*U<1Q"VL[>]@1'I %,C$>D1F2;5F5+1-A\H2<L2F6L
ME2F3ZRQ:^[L6<SZR8Q!3\\YD]K(L3>0NY=O/9IM+'[)4:^D^TI.;2%Z.6;:L
MUF#LUE]DDY9*L]-&JK59SN@HVUU0W3REKC7&/R%&$#6BE4\L!PP*_ED^ #!+
MN@Q5V>&)P7RH*!@H+UB>?7._G[WCE9\Y;\R82L['F'>.:Y'LD";W^(02$0,C
M)2,C\F8X],E!6\[/,5P&JMU*BJ</$EY:;<,VI$D@M)'TT<1YV6S+5-7N4Y&D
M@ZC UP,3(H*^H+Y=*I[;*.,[:QU:?7JONV0UUS::JJF"(%E" J"\%>6CLY1)
M#88+) H[X[8F(@?62S;[!M%6N*RR*JF66R FP9>=HDFWS,P?#X@D 2X9$]D]
MTQZSD,9SB:CT3;=A,)2Q;R8>V$2-!G("S9&0"F:&&K08;21=Z:%1[5KKJV;,
MG^KAL@AC"*26J>,:\EG3J,))'5K&5<R:@C0HB0PR[B8F9&969%\HC#M*2]9F
M9R(-RV$.$+5D!L *GP+VC#UC':*W1!1#0$?DB!]PQ'I$<9\%)A+5H^VB:TID
M:L69Y<9:1I0V3WC[7+MV@0=9;!MG61R&7+]LV>N,I-M?3.VZ#E3SEDD]]>8J
MU8>5F*R(LGV]UB$KAY=HR ]S8'Q)[0(@'DIX$I&.(F8SB;5F4#6FP^:P]W;7
MES)0/<0F7:J2\..XQ$RX&.2$2GUB)R.\SY@QQC'&,<8S_3/^6-X>OT;=>OMI
M'?PG/S_^,'K?ZU;S[0L??S[X^+_HGZK:7]!3]W'RQO#U^C;KU]M([^$X^,'K
M?ZU;S[0L??Q\7_1/U6TOZ"G[N/EC>'K]&W7K[:1W\)Q\8/6_UJWGVA8^_CXO
M^B?JMI?T%/W<?+&\/7Z-NO7VTCOX3CXP>M_K5O/M"Q]_'Q?]$_5;2_H*?NX^
M6-X>OT;=>OMI'?PG'Q@];_6K>?:%C[^/B_Z)^JVE_04_=Q\L;P]?HVZ]?;2.
M_A./C!ZW^M6\^T+'W\?%_P!$_5;2_H*?NX^6-X>OT;=>OMI'?PG'Q@];_6K>
M?:%C[^/B_P"B?JMI?T%/W<?+&\/7Z-NO7VTCOX3CXP>M_K5O/M"Q]_'Q?]$_
M5;2_H*?NX^6-X>OT;=>OMI'?PG'Q@];_ %JWGVA8^_CXO^B?JMI?T%/W<?+&
M\/7Z-NO7VTCOX3CXP>M_K5O/M"Q]_'Q?]$_5;2_H*?NX^6-X>OT;=>OMI'?P
MG'Q@];_6K>?:%C[^/B_Z)^JVE_04_=Q\L;P]?HVZ]?;2._A./C!ZW^M6\^T+
M'W\?%_T3]5M+^@I^[CY8WAZ_1MUZ^VD=_"<?&#UO]:MY]H6/OX^+_HGZK:7]
M!3]W'RQO#U^C;KU]M([^$X^,'K?ZU;S[0L??Q\7_ $3]5M+^@I^[CY8WAZ_1
MMUZ^VD=_"<?&#UO]:MY]H6/OX^+_ *)^JVE_04_=Q\L;P]?HVZ]?;2._A./C
M!ZW^M6\^T+'W\?%_T3]5M+^@I^[CY8WAZ_1MUZ^VD=_"<?&#UO\ 6K>?:%C[
M^/B_Z)^JVE_04_=Q\L;P]?HVZ]?;2._A./C!ZW^M6\^T+'W\?%_T3]5M+^@I
M^[CY8WAZ_1MUZ^VD=_"<?&#UO]:MY]H6/OX^+_HGZK:7]!3]W'RQO#U^C;KU
M]M([^$X^,'K?ZU;S[0L??Q\7_1/U6TOZ"G[N/EC>'K]&W7K[:1W\)Q\8/6_U
MJWGVA8^_CXO^B?JMI?T%/W<?+&\/7Z-NO7VTCOX3CXP>M_K5O/M"Q]_'Q?\
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M1_6#=_:M_P#>,?@STY]7])]E4/W?'PD=4OIDZ]_9>N/TWQ^$W4?U@W?VK?\
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MQ\0<-9MSP\8ZAY>H.O4TZRG>P,0M>[4XE#D;$$N;#K&+5[*(<5864<:!XE*
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MDPQNBU92HZMMMYFT:OJFG;@57)&G9](F3GBNPOI%D^B^??VMF(CW093GR_\
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M)789R=;;Z[:Z[^<B0TSG?77;.<[:XSBKL[W=7!D+6UV#EE'!+.V[PIC\JX.
MG^<<FKI5%3$KK($H]Q0H.Z/S%,24?TYN!RIR3CC&.,9K//>E_4.T2+DS8G6"
M@IB;>;[*.SQZI8*_/N5-\YVWW7.J@\EE=MMLYVVVW>9SG;.=L_O_ '\A-UVO
M?,DZE484SS)'75)S/TR4CW3_ #SFZ:KX1_A T:0KZCK?JO75E1$+JU-_M%5
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M]_77._M;0_CK7_UK7[MG/CU_]NK?TL_8X^ SOY](UN?\S7OZZX]K:'\=:_\
MK6OW;'CU_P#;JW]+/V./@,[^?2-;G_,U[^NN/:VA_'6O_K6OW;'CU_\ ;JW]
M+/V./@,[^?2-;G_,U[^NN/:VA_'6O_K6OW;'CU_]NK?TL_8X^ SOY](UN?\
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M?PG@=_9\KC(&U[_9FQ\/SW?Y&WV>R_"G9=W@,[?9_C<I\[SQY7Q?X/Q^SO\
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2,8XQCC&.,8XQCC&.,8XQG__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g65062g12a21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g12a21.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2$>4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0'2?KA         *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M #^    X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         ".$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             #
MJ@  !5,          0                         !              53
M   #J@                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   #J@    !29VAT;&]N9P  !5,    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   ZH     4F=H=&QO
M;F<   53     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    #.$))300,     !:'     0   *    !N   !X   SD   !9K !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !N * # 2(
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MAVN-8#&;=EFUY=]-WJ+L;OJ+TN^JJFY[WLH!# 8[H]/U2PJ*&8]5KVU5_1;
M[ZI*>?HRLZS%;;9A^E<7%II+P8 _PF\*9OS107_9@;MVT5^H(V_Z3?'_ $5T
M0^K=($"]\? )_P#F[5_IW_<$E.#0^][";ZQ6X&(:[<"$1;7_ #>J'^'?]P2_
MYO5_Z=_W!)3BI:K:_P";U7^G?]P2_P";U?\ IW_<$E.("9B-/%5J[NHNN:+,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                     /_A1DQH
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB
M[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE
M=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-
M4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR
M-R @(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W
M+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z
M9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @
M(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(" @
M(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^<VQI9&4R-&)G<F%P
M:&EC/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @
M/"]D8SIT:71L93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS
M.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @(" @(" @
M(#QX;7 Z365T861A=&%$871E/C(P,C$M,#4M,314,#(Z,3,Z,#<K,#4Z,S \
M+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR
M,#(Q+3 U+3$T5# R.C$S.C W*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @
M(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C$M,#4M,3-4,30Z-#0Z-34M,#0Z
M,# \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L
M/D%D;V)E($EL;'5S=')A=&]R(#(U+C(@*$UA8VEN=&]S:"D\+WAM<#I#<F5A
M=&]R5&]O;#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM
M<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @
M(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V
M96YT(R(^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z,$(R
M,4(R0C0Q.4(T14(Q,4)$-SDY.$4S.#4Q,$4V,C$\+WAM<$U-.DEN<W1A;F-E
M240^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z,#DR,4(R
M0C0Q.4(T14(Q,4)$-SDY.$4S.#4Q,$4V,C$\+WAM<$U-.D1O8W5M96YT240^
M"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P
M.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO>&UP34TZ3W)I9VEN86Q$
M;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ4F5N9&ET:6]N0VQA<W,^9&5F
M875L=#PO>&UP34TZ4F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#QX;7!-33I$
M97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z,$$R,4(R0C0Q.4(T14(Q
M,4)$-SDY.$4S.#4Q,$4V,C$\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @
M(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z,#DR,4(R0C0Q.4(T14(Q
M,4)$-SDY.$4S.#4Q,$4V,C$\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @
M(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS
M0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO<W12968Z;W)I9VEN86Q$;V-U;65N
M=$E$/@H@(" @(" @(" @(" \<W12968Z<F5N9&ET:6]N0VQA<W,^9&5F875L
M=#PO<W12968Z<F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#PO>&UP34TZ1&5R
M:79E9$9R;VT^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @
M(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.FEN<W1A;F-E240^>&UP+FEI9#HY.38U,C,P,"TT.&8R+31F,C$M.6$T
M-BUF,S5B,# S,3,V8V0\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,#,M,CE4,3$Z,3 Z,#8M,#0Z,# \
M+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R
M94%G96YT/D%D;V)E($EL;'5S=')A=&]R(#(U+C(@*$UA8VEN=&]S:"D\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.C X,C%",D(T,3E"-$5",3%"1#<Y.3A%,S@U,3!%
M-C(Q/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(Q+3 U+3$T5# R.C$S.C T*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T
M:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M
M(&EM86=E+VIP96<@=&\@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO
M<#PO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M
M971E<G,^8V]N=F5R=&5D(&9R;VT@:6UA9V4O:G!E9R!T;R!A<'!L:6-A=&EO
M;B]V;F0N861O8F4N<&AO=&]S:&]P/"]S=$5V=#IP87)A;65T97)S/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HP.3(Q0C)"-#$Y0C1%
M0C$Q0D0W.3DX13,X-3$P138R,3PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP-2TQ-%0P,CHQ,SHP-"LP
M-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.C!!,C%",D(T,3E"-$5",3%"1#<Y.3A%,S@U,3!%
M-C(Q/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(Q+3 U+3$T5# R.C$S.C W*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T
M:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M
M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S
M9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M
M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H
M;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HP0C(Q0C)"-#$Y0C1%
M0C$Q0D0W.3DX13,X-3$P138R,3PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP-2TQ-%0P,CHQ,SHP-RLP
M-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ
M2&ES=&]R>3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.FEL
M;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL;'5S=')A=&]R+S$N
M,"\B/@H@(" @(" @(" \:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^4')I
M;G0\+VEL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/@H@(" @(" @(" \:6QL
M=7-T<F%T;W(Z0W)E871O<E-U8E1O;VP^061O8F4@26QL=7-T<F%T;W(\+VEL
M;'5S=')A=&]R.D-R96%T;W)3=6)4;V]L/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q
M+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R
M>2 Q-2XP,#PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @
M(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H
M;W1O<VAO<"\Q+C O(CX*(" @(" @(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^
M-#PO<&AO=&]S:&]P.D-O;&]R36]D93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1
M" $1 8T# 1$  A$! Q$!_\0 'P !  $$ P$! 0            @"!@<) 0,%
M! H+_\0 31    8" 0,"!0(#! <%!@,) 0(#! 4&!Q$ "!(A$S$)%!4B0191
M%S)A(T)Q@1@9)"4F)U(T-4:1H0HV1&)RL3=#94559':5I<'4\/_$ !P! 0$
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MYULU.^,BU>^DE\XW*DY]-/U>PL#KKF,L< ' !P < ' !P < ' !P < ' !P
M< ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' #6HYP+/
MVOJ@OV.K'6)0V GALAYU1F5F2AJ^_N^7\90.&']8:.CIBS5E& K96N#QL)Q7
M:J6.,>"0HN$U3_2DWT>)IBOL8TIK]?05=1&P2R*0W!I[.1=-REH(^,FG,5,-
M*BPE91W49,DFDM <);M@^PXTKW(^WF$O!]FIZ5&1#4T1G^TU%F4ZHBR9&XDS
M(LD9XLQ]C+,[W%2=KR%4;,7))^I/H[H3AI]*D5));&O3A?L<0$A<U$O1,Y+7
MYJ:2R+?EY'M^F_1)0LH*YF0^OS:V%I3-VJHE=,BG6EIK6,Y*^V;2V5GJ2!92
M&X9'DDG(89.N@);_ /T[9HV^$EE@=9F/+5%[1]ISWCW^J8QPJ-1QX#\="GC+
M&20M92'S5_UX%<6<;CKIV.TH=>A.^H'#5ZO.,D87JCCZ_6T<;6B^_IO)-BZG
M;S8F$P[I\-$2<G"RMRH+R+&D7I=@V9,FR;@Z$Y%$DD72Z98F\F>C3]S!@V:G
MM+./R3LHL#WFMCZ8@QULHF//-M/-0IZ'??H*5K6M1I)3#IMJ01I@D=B<Z*\]
M')%@2&RCNO\ 9R%V+RTK-I"%*0IUDT]B^9$22SA:.(C5GGIVQAFT.G3#U/EG
M%.A,>%Q*%=NF(+_B^8D+X[7<M9IL]BGT^^N;")9$<E<L4U6DI29$OIIN06,N
M1V0Z.BU%:4G_ )';S&DS'[#]6]XA6]?:,MP$)0IA2'41VX;CKAHX7#);4UL\
MFGA))H/B[D"-+*!%96;2&/=>S=BOQUJ?,S)9&E2S=2DLY+*5,J[\Y(]HM,:I
M;Z!A[IH:XNJ4S0+#G3#\+T:9.A7M4>T.7K60UFQ)D^4%H23CX=W(/JLDGF>1
M=6-)L\3G32C.6;/7B"@.E/4+EP["XU,JUF,V$:BN'M95C[<M$]J37I5V)5:7
MVW'D-MRC.E;1&-2#8[);*D(,N M<3;K$6O*.VMAR;%14OH-I3"VWS(UG)-"D
MI,U-$4M1N8/CXB61J+GUV_'M)"Q]8>/:/B>W36:8RW8FJ73S<(&D6*6:T-_!
MX5Q(A6%(S(S.-=0>,PJCQ%.>MCJ4F*[]:@!:MC'FR)%8(6)83CC:0L)UM$9I
M78EM+U#$?FQFE3VW[FW5*)RN<=2_9^]H4<>(AIF3V$CC61,FHW%5YAGM+-AF
M,ZN6ER,W!=0RM9,J1#BDWA\DFB/V9D2W#6MOC;P7[\<)>^[Q;?U<QW)Q98FS
M!E9YU1,K13KC!].]CLMC+C5.VPSVLO(GJ-7N,71:SCJ-HB"E?M%(D#MUD&J4
M]$_IF8E9-NX>==%I *GAIC.QOTI&EUQ)D-_44:-&.R.*\B2A[3B8;L^38N3U
M%(BSFR42EG'>]Z9::4E&1QGSENFXEPI)V).,NH@+=<]W)U"FN"P-U++<=+">
MS<97@R(EI[-:E$:IK=4M8R!E&2P_B*CHI1\=*75+)5YMD_6)>R45A!XG68V&
M K%C:1TM7"R"MLO2U8,WABV*.<NXZ$F'(E7:M'"1_%Z6E5]6W<6\Y1N.-03K
M(,2/*:C3W'[8G(\B5&6XU)-LHD%,KB>..XE#K[*2PM:3+;V+;\A46,R1)2I[
MWAYUQM;C*41C2M#:R2ILE&Z\;>$&XG*4+/<B,A$2;Q+FF#83V!)A"PR$:;JN
MP/FVFY&Q739B"@X"M9$R>68R2WK24FYO3"M.,;6QE,VE1O+24LDP86-I+N&_
MTH1;-_7,6U*^Y'OV51FW"TI?4DRNM9K+\B1)KJM3-:J2;:8+DI-E$<8BDMII
MI3CD=;*5=J7$K5N19:"7"43BD_J<*8T_&96A#;;\GCD$V2C?2V<=PEN&2UKX
M4K)9EPY(I"8[Q=;\7=5RSR\R.2LT0ELQU*L\49<MCIS,*XP.W>Q+R\XTL3.O
MQT94(<EL&.A[# V\\)$/9@(M>KNG3URS:BX\]8VL2TTH2(+=;2O1;%I=M41$
M(9*S)2'40;*.M]QV8][IVCT=^&3SR&>U*4E+:5*X>\Q&=CV1F\J1+0XPHHTI
MU2E^[_N2I^.XE"4LH[4TH<;=X$J62.R,S-)&<].>#&Y#@ X : \H0M)ZCLRS
MC"OXZP37<DY"S%U(1EF&WW#.(T]'#W1V_<8QM^0>IO$.-\NXMIV1)?(5Z:TJ
M)JWZP8+1D7C.RQCV7<6L8@D4KEC!9/.V,=VYEG;8\8WSX[;"=_PZZ[L>8W+=
M.604\L=/V$,H)5QI3TLAXFQ[=$ZI'Z&.KB=EJD5+DA8PP-V@'BXTKL&D:H#5
MJ"C%)NH#9#N](F(I;_7Z'@9!N5SJ..ZO-W:^V>!IE.K;(\E8;3:)5E!U^#CD
MS$(H^EI>26;L8]HF8Y"G<.ETDB"8H&.&PX 8!I?6_P!&V2+3"T?'W55T]7>Y
MV-W\A7ZI5,OT.?L,V]!)5?Y2*AXR=<OW[GT$5EO1:H*J>FDH?M[2&$+@_ _D
M8"4?( PMF?J$Q1T_QT-)Y1GY2)1GUY1.,;0--NU\E5&<#''F+).NH2@UVS3$
M=5:M$D&2M-LD6+6MUQF=NK,RC,7;0J[&>NO[ 6]@_JBQ=U /IB+I*5ZB9*+@
MX*X,F&0<>6_'CJTT"TK2#>L9#IR5MBHPUDIDZO%ODFLI']ZS11- DLSC3/XX
M';KKK'@ D5P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P
M A!U/=2EDQ/D3'V,X*Z=/>( NM5L]G+D_J8G92*IK][ 2<)&(T:F1;"<IR-F
MMQT99:=EVKB[0SB*A6[1RRC)LCQXK#TOC\"ZQZ[@+EZ4.H.:SFCE".F)G$5Z
M-C.UQ5<0RI@.=D;!B6[#*UUC.N6<4YD'$H,9::JLZ&.ME?:66U-8WYF'7&:!
MW(.HJ,&6/KMWE@!+KD . #@ X . #@ X . #@ X 6+(XSH\M?H#)\G (OKS5
MHE["5R<<NY%4(5A)?,E?C'1AG@P[9^Z1>NVBTNG'A+&8.5X_Y[Y%4[<>^W9S
MF:^15M2#;@RGD/R6$H;+MG&^$V^T=)';*;2:$+)DW.Q[1*7.#C(E#A5'96\B
M0I!*>;2:6UF:CX"5G/"G/ 2C)1D:^'BX3-/%@\#UH2H5NN2MKFX2*0CY6\3#
M6?M;Q(ZYE)F890D77&KYR5551--5&$A8N/*5L1%(4F:9C)F5,HH?A?F29+45
MA]U3C4%E4>*@R21,LK?=DJ;29$1F1OO.N&:C4>5F1'C!%DAIM"G%H225/*);
MA[Y6I*$MD9Y/N0A*=L%@O'(N3G6'(' !P < ' !P < /SU]8]2R=AW*N:K'D
MK(G2M.XXS^^]$M#I& <"S?55D"H,7R3ZKX_L&,LD&@G_ %#MZLDQ8()OFN2'
M$I($C4EFU# ^FZ>:3+PW[]S(O7)&?CX=_P #G7C]N7K\\C>CB-TX?8JQH]=A
M+@Y=T&H.7 3],_AQ.E67@(]10LSC[M)^AI0IS"#^H=A?TVZ!6' H?)ZYAUUR
M%%K]1^1H3$F"LIY%LE7;W2 K%/E'4O5GR[%G$3;!T0L:X9V*1DV[R-B:H)'H
MJVR;D63UC"5M.5EGC)XW9J-E:6Y[<^X!#'%.=\CX<?=/N)[77>EEWC*\2U?Q
M%CB+P3U'WO*>0ZTV2KC]S7G*$7D*@1#S(U.@8N!.G9;&ULD?)5^"1^OFBI%@
MR=I-Q]_/.3SMU@\B?$L?G/C],>(V<\@H@-UI6!C#7+IM:1$#2ULIS-MO+7'U
MKRCEN9P]BV,8(55%>[TZY2<)7[6O?R7Z(!HC'XE7KSEO:?H#RP&D84U-*_)?
M'KHNL +<Z59]1]U)9FA;W!XR4RW%8GQ0*4U@[+\WDW%%/Q>@^LD'7L;Q=1F:
MG3389E%)J$EK2M!H,9O];(//JPV'Y6NL8*%'R(^[S[S[_7U_/-U]_P"OD-CG
M( A,^ZRY;^*F4<15CI&ZI;U8\22$*VLC^NCTU1D-(15G:NWM3ME<_774E39J
M7J=G;1\F6)F0A6Y D8B<@9!%A88&;B8^X[\D6?7\$ F!7)5W.U^$FG]?F:F]
MEXF/DGE7L9H4]@KCEZT2<KP<V>N3%AKYY:*54,QD#0<_-1!G:"HQTK(-!1=*
MP!A;J0S9(8-I5?FH.NU^RV:Z9 JF-*HRN=V+C:BM[%;5796#RZWP:_;%JU"Z
M8K,VJS*KS\C+6%Y!UV.C5'DRBJB]0&#<,]4&;K/E^G8ZS;A>F8H+E:I9)MM#
MK$1D>6M65:DQQ;/P]?E'65:M)4>K,6%>MBDL5Y5;56I&5BR*C&P[XIW<RU<)
M7^OK\>M^6 $].0 X . #@ X . 'B6*S5NH1#JP6RP0E7@6($,]F[%*L(2(9E
M4.":8NI*2<-F;<#J&*0@K+$ QS 4NS" < /EJMSI][BRSE'ME:N4(94Z!9BJ
MSL788LRZ8%%1$LA$.GC052 <HG3!83E Q1,4 ,&P"Y> $<,H=8'2YA6S_HK*
MV?,746WD:M7[JLSUMBVTY&1[X@JLI&;C2+J.X*->)%.LTD)E)BS<HIJK(KG3
M24,6D1GR(P&=Z_88"V0<19ZK-Q%EK<_'M)>"L,!),YB$FHI^B1PQDXF5CEG+
M"1CWC=0B[5XS76;N$3D524.0P&& /45]7TE/0$@+>F?TA5 PI@KVCZ8J 40,
M)._7>!1 PEWH=ZX :!SY,S-V#C!.W]80?$'"*!L!#YCZ=!Z=!RO\D"AI$:$2
M_C5OX!_6.YP$/_#<,MCC\/3"'#(  H&6"SW8^O/R[^[ECYD9SY\_3X;X_P![
MQO[#>@WK>@WKVW^=?TWS$40KZ]'2L5A%E9)"V15<H%7O<#,97B)3-K_IT'(-
M"/&ST.-%C,PQ;N-D*M+/;?*U*=9QZ$O"IW8*\K0'TLRC;2\4Y2Y_UGZ (F]
M-RQ[D;,LW-X!<H8^QK7<<ST?D/$\MU9/NH"TV6VS5BJ)Z)=$\>+7;($;C>'K
M<;"7>-4MK&:BWEU<6=O&R$4^3@FKM@/8L&6_H1<MMC[^N><B>?7VSW\O[&X?
MD%&M'K\DUX61H\CE ,N.NF3Z%-M[/'83M.+JG.FR<,K$+UMU=7=]LE1LSRKI
MUY&:2A&N.IL[@LRH^4M46Y:#".F-+O\ [^/\_#X&ZZ]?\&0N@]U:'](N4@W5
MR$&#G4_%?P&9Y<G\;6;(C* 0@VZ%K*YE\82U@C5:BM9B++5-"TSTG>FZAIPL
MT9I%&K[%N/Y'X;[8]3ZV#KK\B=G( < ' !P < ' !P < (NY$L]GQYU(89E7
M4W(J8KRU"V3$4O"KN#_0Z]DR/1<WN@6-%$>Y-LZLT3%W*I/EO[(KERG66YA.
MH"0!Y:QE2J[4M*\M]PZFV8DU#S*E'V$>S;)<Z!(263)*Y334N(M6")2BCI,S
M/&/KFF:FHU-[+==0V8$5.L-&3ZK6L*>VVG]0L])R5M:=U)5K7LIUFIF3**YC
MM_O-II5JX1)2:\Q?9Y"RED^1H:,3DFSTZL=6F>LC?I:>AUVP253P#A^BS 0<
M?0?J35XQ@I[+KFI&N*E@3:N'[:&LSIRT(5\R:N6WE46%K:.0$LV<N%%U=?67
MNLAE2>UB:?IH+W8MP.T0IN,_;JB'+5())N):D&I)=HE*D_6W],Z1TC&U$N;I
M6IO+;V,>SK2_ZO73FWCBW/M(UOJ&"=A)U'[J\Q(L:[1+5T5&BL4\U&=GU++3
MZE1WWFG9!.HVT=,D/DZU,LF6#+%19U*(FX3'>8,@Q:<Y7)]*8/&2\^MF&Y/T
MW,7CUPS>LG4RA8D)U6'6BGSFO*K+.DJ\[]"MN5I=FSE(M)%O$1#9?8KKBP;]
MYCR"?[%V0JXF.$IJO4A:%/)D)>-I32U1S-2NP7\T9EU/M8G:3IY&E*W1MV_=
M38$_4^B--3%5]I7+A)E0JU&AZ*.MJ9J9I]B0S!<JW*Y$Y$R.U9H;0RNS9PQ"
M=>LW-1-X:PE Q[D*YU2^8,ID07&.77$_CVVDSM/OZY".V5WDJ#$N&3BO248^
M3G4#UYVT%%-)RTD%"JJ)(:6/KY]YF<AFOK[&;%GTD-C]+MEO5\PKQUQEE;<U
MV T;9QW&EI?(V%(,L+2O&2+WD_\ _P Z0($S3ST_4FI=-45SISVA7LX]6:*:
MK=34JO9W6Q[2P9D4$74<QJ0U9Q)<==<XFR9>XU+:?C(-*%N2TQ!E.S72<R11
M,@5*(I^0<7RE?;336M61U;*M,0MMA"S=;L$%,R$!5Y/TG1$Y*.?1\E!LW3"1
MB712'=M%6KI7UU-;2IS]G L(C4.QJGHZ'TQI"Y41YF6P4B-(CO.,1G,+3VC;
MC3C*5-N-*W4E25'\9UMH^IH:_2VHM-W4V[TUJZ)9NP'K6J9IK>#.I9YU]I66
M,&-96\3M&5+BRH\J+8/,R(LUDU)9>0\RB,4XYO5.SM082*SK;;]DV2R%-7/,
M51*Y:-,08[Z;5R61=N$W6#$<L*2ZBH\E9BZC-N98ELN-F:R<LJJ]@SRS=AY9
M]<^%?5[#5]+L+1VQ>FW,/C0W35VFS*0K_P!B-A:(*VFBBM0WEO>\RY*7'E&M
ME3I(^LU[6G;SV>ZCL)GL]I=-Z3B::@T6A[KLGGM;:G]JC:JEMWW"V)34F^9F
M256TRZKVH2J6CJ7HD)M$>P3"=DV'4.IRQ9.ZB)V6C<AQ$;BBQ]-.9)+$M'83
MC ))Z^J-PH#6%R/.M2.Q<H6FX,WMCE*K!*HIOHBB-6+U9NA(R,Z@UZ,35$BT
MOY3S=BPU52--W#E/!1(;[5;D27!2Q8OI)9J3+F)5(>B,&DG&8*6UFDG''B3Z
M*[]DU9I/V8U\.5IF;*UE5^U;0\36>H)%?)]TCL75)J1Z?I>N>4R33E12/,5D
M.XL$K5'FZB=DL(<<BQ:YQW*'2GGS+D["=-U/R[28MM_%CIY8WNJ7YID!S:[+
M87=.@: 6>>7V&<U6'0AY2UH6]G9F9XR?L14!4<Q\DJ1Z4QPVND[^XD,:;AV\
M%I)6VG6Y\2P18*E2I*X<>O)]V>RN*REER8F8B6@VWWS1Q*;=/M,F7D?;%[.=
M%UUA[4[O15]+=_\ #?:;(T[<:<?TVU3U58S>6.I55S&G9S5Q.<G0Z=RC?J7B
MEUU6;A(:DQ$*CF1"?G/H _. < ' #0<XZ/YK)^5.I/J#Z;,5Q-6:R.:,KP<X
MLZZT^L_$M_SE>L?6^6J^2I 0P_<&-+QI$N;["6&N4QFO$VIO]/BV4LX80D:\
M;QC3+)E@N1=^2(]N9=V_C\=O.&6>\_38_N7>-R?3[::]><#85NM13L2-5M^)
M\>6>N(6^<E;/;$(.>J43*12%GLLZ^E)JP6!%DZ12F9N6DY&2E9$CE\]?.W"Z
MCA3$^9_CE\!1[&7,C5;$F-KAD6ZH2#VM5B(4=2,;$QOUB6F3.ED8YA Q,4)D
MR2,I/23QG#1S-=5!LX>OD$W3ANW,JNF 0+J=DA:/DG&CAYT1V7HO)?<DQ==3
MR?#5?I(GF]UD9F+G#1F,\B.<67&Z7.IH7*1%,R$]%L%VR,['1T6\M4:G+'3>
M7'@>?GUR+?U^(F^?+KNQ^1LZY!1&+J6R'48%A4L:3.#97J3LV5'<V2LX=C8G
M'C]K+L:BQ;R-DL=@>Y8GZQ08>OUQ&1C$G+N4ECR+A_,1K"%BI-VY,DF^G7S#
MHACGICL\4WR1<L:I8,L'2E(Q&/ZM9TL"JUK!2%)E6,E9+2Q<94JEOPG*V-O+
M/WKINC5+# S\O&.8<L/#OVU;1+-*RLA3+;Q+)EG?HO$OB'W$X^0!"J6ZJ;Q)
MSER2Q!TFYLS'4:;:+/0)G)=5LN :NPD;/19=_7;G&4Z"R7ENH6FQ?I"SL9>O
MN7+^&A8J0G(R20@G4LU*1XXN/,OK_ "0F$;6RO6',67..M$Q=F5IQ]49UO;[
M%"Q];L%E+)P3%T,U/5V)8QL7 S4B=4SF6AHZ/8L8Q^HX9-6B""!$BP!X.?LE
M5G&M)9+V*A3F5GEQM4%1J?C"N1=<E)F]W*74</XF%:$N<O7Z='IM4(A_//IF
MU3\+"Q$?#.Y!=^19!NBL 8.HF8+)9^H6F163,'Y)Z<+A8L?WEO!-;-_ .\0>
M78FL2%>D312^0L;6N\VZO2F.OK3^;BJH_<UN!F$;789!N:?=11Q87NY^'CG<
MM_+R/T(3Y=?;NZW$X.041BO76KTA8QMTS0<C=36#*-=ZZHU1GZE:\G5""L4,
MJ]9(2+,DG$24JW?,C.F#IL];@X03]9LNDLGW)J%,-P?@?R$SZ_(QG*CWNEY,
MJD/>L=VNOW>F6%!9S!6JK2S*<@)ANW=.&*Z\;*QRSAD\22>-7+511!8Y2+H*
MI"('3, 047.JJF@DHLL<J:2*9U55#B!2)IIE$YSG,/@I2% 3&$?   B/ #6R
M;XEE6=1[ZSPG3=U*2&/JWC^*S==K](0&.J_"USIWL99!:KYR8L97)*<[:JS8
M(Z"M4ZWJD#%N<FQD%49UW/TB(>JU^-GKCN[\XQY]=_C\3)UUT0V4E,4Y2F*(
M&*8 ,4P#L#%$-@(#^0$! 0']N0!KUZ\OX8PJ^#\@Y S%TWXWDZ38KB>G5?JM
M38O,2W^0G:\VCI(Z+1S88!TQO-58D!U6K1'DG%X6-EK)'JPBZ$^=XQI9WQGS
MQ]OCUD3_ 'KT^^!;O0ZYQ=<LEY?RA2\Q=(MUL\O3\>U6S4;H^;,6]6@8^"EK
MI(PUHOK]*QRTA9K3,JS,C$Q$F\A:XC&0T,K&M4Y(RCA= 98QL9>OX+K/D&<_
MV1E]QLMY!1I3RQE/)F,>H7,%7Z5E\O3$MEW,#.)EX@V <4W>A36?8[#E3F;5
M5*?E>W9NP^[K3F'Q!68^XRZF1F-@I;=W$SE?I\R\FDOT4AD6^,F6Q'X[;]^W
MB?+Y^<^/?MW>'YVZR>P;HJ;T]KTSXX0I*MN5C2+7@9PE]CH&&N3+(A\BVU3+
M$58H:J %2AI.'RB:X12T/43*U**!F5A5W#F!;Q[A6'S_ (^_QY^8HE"X HH+
M =0R)!24 ZQ#^F=(HD,!E"*>>PR8;,4_]T0 WXY 'YR?F.EY7$9NF9/K%^%F
M% ^@FI09K180)>HHI$]M#W[QD4T%_'TK@@SJF4/KH&#(_=>AK(+A]#'+!YSP
MGG.>_G\O'Z;>8GY\C/G\/Z+D/T=!X   =^ \_OX]_P#/F(HA?UO';-:-BZ3C
M%,A'RI#9I@Y7!D7C.GTV_62<R8VH^0BO(U6HY#GJG2Y:&3QBKD>5F#SENJAX
MII&&FX*?8V>-A/4I?#X]=<@$8ND+(UXS#U!5/(^;SY&/+RN$\HATTS<SB/'F
M'J?>,:+7?%Q<HSJU8@LIY7R;#6=.388U<1E>R:_J92UZ3<R<=6!E?K!8898V
M].?/YX+8\^1^6PF2_ONZY_+<;;N04:RNMZ3Q31\K8LR1<LS]'],M[.C7&KU_
M'_6&DQ7K\M#R<W7I&4MF.GJEBBI*LV%DYCV<18W[2$L3:;B7,:P=?2CQZ"SJ
MD6>XS]/\,.OOUW>HOCH0)C:49YEOF/\ +73GD9W>KG /[9!=*S=BPQ'1Y6)J
MS*(:(@T:V&P.']SL+%LG(V:SR P[B;;MX1F2%;(0B3AV/.V2,O7U_L3KOS]>
MOF,O]06<K]B^U86Q]C#&$%DR\9LL%T@H9&U9#7QM6( M)H\I>G\E-SC*D7^2
M.W<L8E>/:H1U>=N!D7#,%"IM#N7341<S[BQY\^N\R%&O* ^(G:PS_4\H71VX
MJ?25=.C/'E[EJ,^CX.1DL>9KM,9U&Y1(^4ML='I2<JT?T?IUO5-*W5<A$2,V
MC5E8N/92,LJBZN-O//TP7ASYERR8?WUX"8_P]\D9NRC@24G^HB1;OLK1V8\Q
MUFP,VD;%Q;2LD@+U*,F-+:I1+-DB\;4QJ!*RA*NDE).62C"R,FX7>N5E!Q/R
MZ_T!.3@ X . #@ X 8JS3B&MYSQY,8YM+Z=B&$HYB)!K/59\A%V>OS$#+,YJ
M)F:_)N&C])C),WK%+L6.T7(=NHX;*I'174*.INZ>-?5SU;*6^RVZMEQ$B*M+
M<F.]'=0\T]'<4AQ*'$+01$9H41I-23(R,R/V&@];6OL^U-!U141Z^;)B-38S
MU=;QW)=19P;&$_ FP+*(V]'7)B/QY"^)LGFU)<2VZA:5MI47AW/I]H5OH5%H
M+<\Y3&V*W%>?8NL-*DBP]FQ_)5:'6KT,^@'CAL_8J G NGD*]CIF-E8>5BWK
MME)QSM%71>";IVOF5\"O2<B$FJ5'75R8+I,RJ]R*R<=E;#AI6@\,*6RXV\VZ
MRZVM27&U$98V%%[2M14FH]0ZD=37WKNKV[./JZLOHIS:G4L6WG-V<Z/9,-NQ
MI"#78LL3X\J#*ASH4MAE^)*96C)XOD^C6GVF+N9L@9$R;D*]W-G4(U3)UC=T
MY*RUN,H5L8WJJ1-5@X.FQ&/XR(96Z.:SLE&KTU\WLKTFK&64;IMD&^J=T7#E
MLS/U&RM+&?,1$;.TDKB%(C-0):)T5F)'9AM0&F42VT/NM*B.)DN$9R.T+A)/
MK8GMSO*B71%IK3.D],Z>HG[N4G2=6S>KJK27J*FD:>N)MQ83[V;J27.?I93U
M=%E-7D9RJCJ__P"7[FXIUQW&^4NC2:EFTE-5S)N2[5D"^9)Z;I2]6Z?F:3#2
M497\,Y!<3@6"H-8&FP5>@IB'@I>0*RBF4.I$OW#!BLO$NI1U+/)366NBY#J5
MOQK2SF6,^STV[/F2'8##K4>GG*>.3#0Q"CQV'F6'5\#2&3:4IM"NR4XIQ3GJ
M=(^W2##=BP+32>E*?36G-*^U.)IZEK8-_.BR[/7>FFJ\ZV[>L;VQLK"#.L8,
M8Y$M^:F;';DR$-S68C,-B)*[%F(H_&1[;*K6FTWZYWV582]SO5S4@@G)M>(B
MFT)"LR,:M!5FLP\1#1;8K:.C(2!CVQ#K/'C@'+]Z[=+>MJ:=NK.6\J5*L)M@
MZV]-GS38[=]3+26&$$W%8C1F66&D<+33##:2-2UJXEK4H_CFK]:R=6)IH:*B
MGTY1:<AR(5%IZB38?I]>W-F.SY[YR+BPMK:=-GRW3=E2["RE.J2AAAHVH[#+
M*,0T'I,3QW9[!88?.N9G[*XW61O-XK$XCB"2A[M(2JXG?1MFD#XF);'\*9EV
M0K1D2RH'BX)%O$Q2[)FW033U%?I$JZ3(?9O;AQN;-<G3XSZ*AUJ>MU7_ "-2
MW557O;C*F\,I04A)M,$332D(21%[;4?MF7J:IK:R=[/-"1WZ.ABZ?T_;UZ];
MQ9U!&AMDF/*J8Q:S52QYY/\ %/??.I<3+L''9DMM]]U:U76?I1P<G?VN1H>B
M5NL3;/']KQ\U;UFKU.%C4&EN>P[I[8DDFD 1RG:F*,2:,BY9-V0K:*EIEDHV
M7(^,).TK25%[^5@S BQ7DU\NO2F+$ALMI3+6TI<E)(CDI,MM+1M-.DK"6G74
M&E1+,:=/MD]H*]-O:7G:BM;:O?U)3ZE==MK>YGREO4K$UEBL6MZR-I=/(<FI
MES(2F3-V9"@OI=;5'+BN"J8%J-05P<K&R-A7-@+&DEBRH ]=1Z@2-?E(BEPR
M[RP^C&-Q=2Q&M&B3I+QXQC0J[A^8[(Y%6Z;;LQ*")".B-MV0H]/UCE3#XU-G
MVD=QF$P:Y'"VGB>)$%HR4WV:.)3AFC!I).LN/:+=W:?: B5&K6R]H^JXFL+O
ML&9*3C64.;?SFF:SM);G8PE/:BFI6W)][>-MJ,1/I4AQ3N;N;P>!&-\KY-B,
M1TUY=9QC(R,<R>1[-1K%%;&>&4D71&J1B [<-D>PAS@93N5*/: ]H&'QP BF
M/Q L8AL?T=>A /SZ5?#?[^\WOQ^XZ\"'Y\  0UE770U+3MFLA\9=241(V^TV
M:ZS[>I]2F?*3".K1<)M]9+/+-:O3\]0=:B59F=DY"5>(1$2P:&>.UU2-R"<0
MYD2E%R/Z%_ F"/F1'\!)RA]:.",;TVIXWI&.;U!T^@UF"I]4A@6C'Q(FMUN+
M:Q$)&D>R=E?2;PK&-9MFP.9!VZ>K^GZKIPLL8ZIL<Y,_G\^C%'VVSK6P7?:Q
M/4NZ8OLMHJ5JB7\%8Z[.1U9D8B:AY) [5]'2+%Q,*(N&KI!0Z:B:A1 0'8"4
MP ( $?*+<>BK'-LK]X@<0YBDK%45G#BGN+[EC(F58ZENW;%U&*OZ? 9.RS<*
M_4Y'Z6_>QB,C7HN.?-HYXZ8-W"31PLB>F9GS/K;GX\BY@)3_ .G_ (SWK]'7
MH=CH-)0(^??6OK7OKS^W]>0!B3+O4=TPYTBHF%R?B>^S:=<E1GJU*QLRK3[5
M5YD6CB/5DZM=:7<J]<*T]<Q[MTP=N(*<CSO6+A9F[,LV4,D+/7\^(#S<0YVZ
M4\&N+#(8XQ5DII.6\D:E9K7:;;,Y(N\\UA1?*0T;*WC)5^MEO=1$.I*2:L3#
MK31HN-6DGZ[)F@J^<G5IF9]8^WE^" 9M#K_QF;?_  =>@$/.C)0(?X__ +:U
ML/SYU_7D 14N=DZ)+[:;';YO#V8&,O<7PR-Q;4O+>2,;UBW2:B"+=S(VREX\
MRU5J;8Y!^@@BE*OIJ!>NI8A +)K.P$=L@)+U_K=PO4X"$J]8QQ:("MUR*CH"
MOP4/'UIA$PL+$,TH^*BHUBVETVS*/CV+=!HS:MDRHMVZ:229"D*   6QDWJF
MZ=<S5%]1<EXHM5LK#MU'2!F#LT8S<,Y2)=IR$1-PTO&6-A,P,Y$/D$GD5.PD
MA'R\8Z(1=B\04#O!DRY'@!C?%64ND;#UG<W:D8IRVYN:L,O7"6V_Y'N>6[+&
MU]XZ8NWT% SV6<FW:3KL/(O(R,<R<;!.HUG)KQL<J^1<G8M#)4S,_P#"+[ )
M$#U\XW#6J9>C";V $H#?L'N'UK7YUL!'V'\<@"S&O5M@)K?Y;*#3&-P:7R=J
ML139VPMQBVZ\S6J_)2LM 1\PT3L1(Z1-!OIJ;4AW[UFO(Q:4S*M&+M!I(O$%
M@==?(7D'7SC7P'Z-O)0^[7]E >>W]@":'W_'G_U]P#D.OC&I@-_P==Q !T(>
MG #L!]QU]9WVZV(^!\ ._;@!@Q3+_2";%C3!QL'68N)&<VG/M\=I/"I5<KE*
MRJ6U**/'(VXB*]33FU!4)1UQ5IA8TJ4"$!] 11C$[D^??T0#.@]?&-0#?Z/O
M(@/MVI0 A^/S]: /S_\ ;]PY %FW;JSP)DEE!,;EC*YS2%8MU9O=?.*L>P>P
M=OITFC,5^;C9&+LC*09NFCI$4'!$7)&TM%.I&"E47\)*R4>[=?,!>/\ I[XT
M* ZIMX 0$ $"HP&_?7G4S^/?SX]]#X'@!5_I\8V'VIUY'0 (_P!E ^-^VQ^M
M?_;? #&K;J;Z<6$YDVR1N++M$SV8F<8SR5)0KU.(=6<T+!KUJ,DG!HNU-"L+
M"V@%R0X6>)+'V-6/80K9>553@84(\ ]RA=76!L74VO8_H.+[75J=5(]*)K\%
M'HPORS%FD)U3;57GEW;IRX746>/Y!\X<OY)\X<OW[IT\<KKJ %VAU\XU\[I]
MX  ]Q]. $-?@0U-;$!#SO6@#R(_C@!9%+ZMNG_'A+(UI.,+=7VMMMT]?IUFQ
M^F&8.K;9U47-CF&K%>PKLXI6<?)'EY-K$HL6+Z;=RDXNV/,2\H]=@%ZEZ^\:
M&$=4Z\AH/?TH'0C^P#]:T/\ 0=ZX#\BR[QU9X!R='145=\77&>9P%F@+E""L
M,8R=0UIJ[TLA!SD5)1UC9R$?(,ERG1,JS=H_-L'3Z*>E<QD@^9N #I)U5]/B
M.2G&7OX8W53)#BG)X_+97+AH\694].6&>6A(ABYLZT/!H2<N5H^G5X=@Q>V%
M6+@@G'$BG 09&#KKY +['KZQJ Z_1UY'W]DH'\?N'UG8:]Q_8/W'QP LFS]6
MF +G.T2TV/&-PD;%C*>>V:BS95(YE)5V7E("4K$F=JZC[&T5<,96!F9".E89
M\+J'DDSMU7L>X<,&"S8 O8.O?&@ '_!UX*!O801@  ?V'_OD-@/@ \;W^ #S
MP N7'F8\0]164*>Y3I-A2N6,&-HM=,G9E=)NA"FFXPE.GQ1;Q4VJ@]7D8>;5
M9=DDR=H()F47;_+NB)*@ 7,KT7],3BL)TUUB:(>5A*-Q##DB'LO9WK<L;@>V
M6*\8J:=[J<67%.KV6V61Z8PJB>>:S#R'LIYB%.6/*S_'TQ]@&<Z=1*G0&LZR
MJ,02';66W6F]S:2;I\[!];+I+N9ZS2YC/W3HZ)Y26=N'9VK8R+%L904F;5L@
M4B10"[N #@ X . #@!B!IG7&<EF-? \384)C(T?4Y2Y3D9%BD];5R,BY*!C!
M9SSQ)821\V\5L+)RTAQ(H\!@11Z]39H+QQGVX716;5,F^>CJ9KG);4-AUTE(
M5)==:?=XXZ#3EQA!1UI6\1DCM#)"#6I+G9]4ID=4HX27"5(2TIU:$[DVE*D)
MPLR/"5GVB3)'_;A_<9$1I,[/KW5#CZT3Z$-#PN0G,=+GM;6F7+]&O@I>0Y6E
MMY!U/0])F2JF/)OBH1$JI$J.V<='6(D<Z4KS^43(0Y^Y(TO818ZGGGZY#C)1
M%387OK?OM<U-4VB.].9P1--FIYDG20MQV.;J"D-M'G'$W8L..$A"'S2OM2:>
M[%78O*9)1N(:7S4HN%7#E*4N<)]FI1$.NG]3]0MV1H_%AZ/EVHVR1KDK;DTK
MSC]_6F+:N0ZA&[N8?O7+E0K%B=\JE'-7+@A$74@H5HB<RI5 )9FEYD2M<M2G
M5$N(U):B&J#8-R5JDO%Q)9;0E)<;A-D;JTI,U(;(UJ(BQDU8M.R$QNQE-.J;
M4Z1/,*;23:#P:U&9GPIS^TC/8U;%OD7QBW.&-\T.KXCC>=3LS+'EH2J$U.,/
M36@GLR>&CII4(*21642EV39"31:K/T !J=ZBX3:J.4$R.%.C:4=E2I@'9,'&
M7813F,L.92^ADGG&2]X:,B-E:S:-:6U&:R0I)K)*C-)<L:9'EF][NLG$L.=D
MM:=T&O@2LR0HCPHB)1$9EMG.,EN,M\U [0Q=FW,5'Z?<29#S7DA\Y84C&=6E
M;9856#47\HX:1B J)1D-'%42-)SLR[%O$P4815-22EWK)BF<AW!3 Y 19V(1
M]LW7AAB Z:L5=4L9$Y&O%%S/8<;4^@5FDU=I)9&D[GE.?0J==ISBKR,U$(,+
M*RMBQZS8(MS*D5B)QJ\8JF44;GX^O7R&7">3+8C(C,_#;TSUS'V8@ZUJ'E7+
M">#IK&&>\'93D:9-9"JU5SOC0]*&\5"L2<'#VJ6ITY&3%EK,R>L2-GKJ,[%!
M-(33).:8.QCE&9U'"<S\/(#29%G8RSC8^77^XR0F/RC$0[Z[Y)&(Z;K;)N3
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MV Z^T!\CL X#KKKZ#K%TB'\QPV'@1,(=HB&PV ![>=[#0F_(B #O@!61=(P
M8IMEV)0T8H_;Y ?("(@'@H;WKW_R"?UX_3KY9'<30!K0:,;7D>[93!HNA$2C
M["8!#QO>QWK@45)IID(<I#"4H;'9MZ'N'^8 $!$"@ AH2^VQ\:#? ==?WW_
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MV@EC^9)H-@4 ^L5L0$-[ 1'0['QX[0 - .A]WD?X,OR W <H!P < ' !P <
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M_<  0\_C0Z ?(  ,>6W/&VWP_P!W/R >R"93(F J9/!!*)1 0#0>-=OGR)A
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MW>WXX ?()2B/@ [>[MWH1V(![Z\"&M:UK0_TWP'7H.Q-, +Y ='UH?81T/\
M4/(#OWT AK0@'@1 .E1MW*E$0 WC[0T81V : !T&S" AK8 (;'Q^1X < W
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M2._._(!^P:T'C@!]R/P[9QN)O1R-!D PAL KSWR ;\?]X:\@([\>=CP [O\
M5ZV$1*)LDPFR@ =P5]]OQH?89 0\Z#Q[>-\ *P^'Q80U_P R87\]W_#[T0$?
M.A !?^X;\B.]_P"' "O_ %?=AV'_ #(A1*'L P#X1 ?([#_;_P B8V__ *A#
MVUH X'X?5B'0_P 1X/Q^/T\][1\[\_[?L0#W]_?^@:$ $^'U8BZ$<D0AC  Z
M-^GWP"!M_:/B0]M?S!^?QK@!5_J_+&!NX,E0W@  H# /A  \;U_O#QO7[#X'
M\\ *O]7_ &710#),(( &ON@'XZ'MT!@U(@'=[B(B C^V@X 5#T 6/0 7),*
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M2CG$-U-?:$^?L4?[%P^AIQ1=+YHVE7,2X5BUQ.V["D[L34%E"AH@LK:-AO\
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M,A:!=;%)8LL=;DIJ=@W=A@(R2)0\AVB>@%IR.9+_ $U66A6S8SOM:.56JPF
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MESI+VMT/M*@2YMS;7ZKIC45[";]H$1$B5'4N&M*HU5J-,=)DR][A8FRDI+O
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M>NZ8/"M))BY;@Z9.7#1P"8*MUU43D4-!1GG@ X . #@ X . #@ X . #@ X
M. #@ X . #@ X 19ZR7SV.P3/.F#QTP<DF:V4KEFX5:KD*>60*<"K(G(<H&*
M(E, &T8!T;8#P TVFN%I)L!M-A$1T.CSDF!A !T "'S7D=^W;O8:\>0X <#<
M[2)/%JL!A >X?]]R0>X^ #_;-F   !   ?<->-\  6^U"  %HL(^/?ZY([V/
MD?'S0Z]M?D1 1#_  I-<;9L0&TV 0'?@)N1*/L("(?[4 ]W[?@1\_C@!R6WV
ML=]MHL0_;[_6Y+P(>!WIUL-[_P#MKSY  X"X6L![?U18C!H T,Y)ZW^1 0=
M(^-^P[']O(< *@N%L$3;L]A I0]AFY01T.@T/^TCK_S 0_<-#P K&XVP=!^I
M['OQL?K<D "&]@  #C[1 /&];]MC[; .0MUL\A^J+%H!#[OKDEL0$?(!W.1#
M?CQ__GVX #6^UF#?ZIL0>PB'UF2$-!XUOYG7D0#SXUP Y)<;4(#NS6(!_ A.
MR(Z']Q+\QY#\:  \ZUYX !MUMT(C:;![^ ^MR>_V[@ ' @! W]P^Q? " ;X
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M(U/]#Y]XY=^B!PLH'%(7"J@$]7TR"?LUW=I.[?:   ;%> #@ X . #@ X .
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MAW: #^2!H.TOCM'8B/YT&OW\;'?@.!1R4P !P[A$!#1@ ==P^= (:\@  /\
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M7+&+:YERC3]"M;!*0A+#&N8Y\V63()3I.$Q*!BF$-IJ$/VJIJ%'N(H0IR:.
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M]T![0UH #0AP K(EVB8H%\:*83CH1 H (" >=^>X/ ^??^FP#D=;$! @B8/
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MR&K4/)3TLM+5Y9&-BF:[YZJDWE4%5SD;MR**F*DF43J& NB% 3&$ #@!J5'
M^:C!VABR]AL0#8U>5#7DH[#;4>W7D!']MAH> 'SFP'FDW\V*[\(A[:K,N&AW
ML1 0:A[^/'X_'CQP ZR]/^8P$=XGO@[V.S5:6,81 0\"86@B&O(E$1'>Q#\;
M&;?+KF K)@',I1$?X4WLH[]PJLM[>=  ?*"/L(;$!_ \H#G^ 6:#]_=BJ^"
M"80W59;[@ 1$  !:B B(B(@(A[^ _''1>0#I-T]9A-]XXGO/Y*!1JDJ8??8C
MY:B(!XU_4=>=;W,?YW?U\ '>GT_YC()>W%%[(&_ !6)4 \_]0@S$ T(!K0;#
MQOE^X#O' ^:M@'\++V("(CL*O+!X_8=-?.P_(^_Y#QP [0P-F71@+BV^!XT
M_IB6 1#N#QY; &@*.A ?M,)?QK0@%(8(S-]P_P *[[WB4/(5B7[=CKN\"T#P
M >-?O["(>P _@1F@"A_RLO@F[Q_\,2P^-Z ?^RZUX\^/(:_/ #DN"<T" _\
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MWZQ]!E+@4. #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X .
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M4F 2+QY<E;_4(JV+4ZZT%24,_ U4R'$LX.WQGR,D[C@&5C&$G,-6Q7Q6@2#
M4I%QZT:[:+G!%14Z*8!>O ##/4#F%K@;%%AR:Y@U+*I%R5,KT5!%EXZNMY*Q
MY!O%;QW5D)2R2X_2ZS !9+5%*6.S2!56==@22,TX;N$F)D%'7R 1BQ_U=YIE
M,FXXJN6^FACAZIY4R+=<.55Z[R\C9<B*Y Q_2K7<YJP%H*5"AH^4PQ-H4:S-
MJAD.%N+Z5D61JQ8)>F0<593&A[@O'.V?KCK8.C_KKX[#8'R ' !P < ' !P
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M:46U561KV1K3 /<?6"ML%7+-&2QTO&GI"LJV=OD+,2!3LZ$A((S";YP 9LX
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MDG:;0J@.56[DA"HBIWF**1A, " " ^><HZ@A<I\1J!3$"FQ9+;'S_P"]+,-
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M\:2UABXI"#+/A&O(%9BRF)"+:Q[2:D8YNBYF_IL<K*&=.&I%0!X[];;?G?\
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M045< ' !P < ' #'N4<J4+#-,E;_ )(L3*M5B(*F"[UV8QUG+I<X)-(V,9)
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M3.GV&*JY2V3[0 OWB J:[K]_L'77=]3&PFU9MQ_4%7#:9LT:R<-0$5DG;I!
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MO$"XT*;D5"&$O88A4  V]B!RB50"".O.NX#" &\#HVG\]>'/[GW@/=:2[)Z
M&24[R@8$N[7VE$V]>2[_ " ?N(@8@ZT.P'W>/<??MG<^6Q9^O(![W>30 !S
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MN_7RZR?,-FOP\#%,SRR) T'S5+V'X >RU_G0>=  B&S:]A'>PY0&R7@ X .
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M .T2F#L\AKM*4>T0,47777X =X;, E VA ODHAL0 I@[= .]ALO@=!]VS"
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M940/W@(@;M >XQ]'*("()&'8@'84 *IOL 3*3GGF7=_9<P'7]23 @" ID$@
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MWF'0E,8N]"&P*.@#0'$P@8/M$>T $=!]FQ$!V NOY <CHY1$QOQW=I?'V@4
M'[NW8@H(& -CK8!K7N#KQ =A ,/=W;WON#QW" ![@ B7M#N O=X^S[BAY'[C
M.B <@(_=LYQ YOM'M+L@%,(!LH%[][, _:  4H;^W>Q=?P'77T%0& 1[=#L
M$I2E,(@8=B E#M\#ON#M\!O0" :$ XZ].OX =OJ;'M$@EWLH[ PD[@ "B'?W
MB'@0,/N  (&'0@(Z .>\H[ 0[C .RE^X%!-K^98P' =%$4P'V#0]O<)O' #I
M$XF.':(B(&$-J=HE'N,.RD-H0$VA[.T2^2@4!$0,8! *BBIKPH(ET4/[3QX'
MO\ (Z* >?M$0$!^WR(& @.B 5=QB"!ME#[1(&QT ".M;#8_<!BZ["@;[C&V;
M9Q 0#9M\.X1%MEO8F$1<4<PB.NT>Y*V&^P    FQ'6OM_;^H!LHX . #@ X
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M7X=V%SH>BE;<KME- 'S24]5%%A$!$0$2.J2Y:#X$2B7Y;L$! 1*)DTS$==8
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MP < ' !P < ' !P < ' !P < ' !P < ' !P < (@]:V/;'D3%-9;0U'5RQ
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MW,76G,9-LYL%6B[B215JKZ=C4CF<1S>P)1,DK%'<D3^<29K*I 9,H&$ O7@
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M#,B(CXS,O*>S_P!HOL\I'/:%85&C*G31R/97=U,>GU->3]75NJ;B3J;2$J)
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MV&J9:62!Q(V?M"N2E(1\0.%&1D1%W9+P\-_B>0^?77?\-AM0YB*' !P < '
M!P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P ;#]PX .
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M\^[EZ!UU_(Y((&'8=H@(=FM_R@)ME'QY,7P!];$!UVFWOEWSRV\<_CE]?3O
M?HSP_P#_ (2XNWO8X[I.][WO]-1GOOSR@,B\ ' !P < ' !P < ' !P < '
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M #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@
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M$Q  #&*.PA\OZS]"#OVZ^.W\#ZB8>RN30_POR!X\#_P79/81]@U'ZUH []B
MCVAOV#D\<]^V"(S]=\>I8VQSYF+_ 'WEX>?1]VXI-B#*G<.\7Y#'O*)?%)L0
M 30['S]-\]P@ B/G9AV8!$-\OXY==>0@X)A[+!NW>,<A$UW@(!2K('<&S=OG
MZ:&Q+L??0_\ U!YX[^7R_)?;&3%[ON7SQU\^[-1L/97 Y#%QCD+[ *(&_15B
M[@$1*(!L(P1T4-@(!H!'8#KMV$,ML?C8_7.2^??ON!8SX==V"^G+&WF.#X?R
MN<Y>W&.0_ ]PG&EV0? ZT!0&.  T ^P#H#:$?M*3=SSY]^#P?\?+Q\S#\;?Y
MY?;O'T#B+*XF* XQR$&PT?\ X+L@Z -?_IP@/<7N =&V&M (^ X^1'CXY+PS
MW%W<^?S9Z\_'U'8.)<L%)HF,LAB)3&\?HNQAW:,)@ -QH^#>//D=  ")M>1D
M1D9>OID]\^8@%Q'E<-=V-,@!W!]PA2K-H![?Y=)Q@CYT %$ T!NW9@\B$Q\-
ML%ODO+GC?G\.8"H,297 P@&-,@!LFC"%-L>OR.]FC=@/]! ?<??R W&^_+?[
MYSS^7AC;'(!P.),L!K6,\@F'>A$:98S#H!_&X[6][\^V]_=H>/OO@\9Q\L\M
MO7 #J'$V60$O_+'(&A$# 8*79.XH!^!#Z;X$0#QKP(A[>?#?Q/Z;[>GCZ>?F
M&_S%35TQQ?C=D^;KM'K.A4]J\:.D5&[EJZ;UZ.2<-W""I2*H+HJD.FLBJ0BB
M:A3$.4IBB 4M@%^\ ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < '
M !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P
K< ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' #__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g65062g13m19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g13m19.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[25N4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )5*^E50X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M ! #O_XU  (  0.__C4  @ !.$))300F       .             #^    X
M0DE-! T       0   !:.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         !.$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@             #=@  !V0
M         0                         !              =D   #=@
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #=@
M  !29VAT;&]N9P  !V0    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    %
M.$))300,     !K&     0   *    !+   !X   C*   !JJ !@  ?_8_^(,
M6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )
M  8 ,0  86-S<$U31E0     245#('-21T(               $  /;6  $
M    TRU(4" @
M               18W!R=    5     S9&5S8P   80   !L=W1P=    ?
M   48FMP=    @0    4<EA96@   A@    49UA96@   BP    48EA96@
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M14,V,3DV-BTR+C$
M                     %A96B        #S40 !     1;,6%E:(
M              !865H@        ;Z(  #CU   #D%A96B        !BF0
MMX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T
M<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N
M8V@
M    9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO
M=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N,2!$969A
M=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M     &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I
M;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#
M;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M      !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@
M      !,"58 4    %<?YVUE87,          0
M  */     G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 >
M ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L
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M=IMV^'=6=[-X$7AN
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MI2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*E+KHMDCK+J$22(
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M-<V=K>1F*[MXKB,Y]65%?&>94D90_P"LI!'0U=AGFMVXX)7A8'.4<@$<]P"
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MDC$L[N[%F=B2S$DG-<75=6J:4II2FE*:4II2FE*M-Q?_ /@_.)0.?]\3AO\
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M;'&[J-T8_M*,$\2[^IRDVYA<H)I+LE ,*J1.N3[#I*]$.F4Y>TI@-N E, "
M\AYZ\_\ A[CG]]=1GH>?W_O'6JOTJ::4II2FE*:4II2FE*:4II2FE*:4II2F
ME*:4II2FE*:4II2FE*:4II2FE*QQNG&%PI8YRK#8,OW$?A*F9DL*L:A#8QLV
M3*C"W=^XFA3+"-DZZ_ED)(CJ;,LB6%:K-TW$N99(L<FY%0@&4KL<E\57#/AF
M]5#&.6\_8>QID6_^;#2Z1><AU:L6BRD>O%8UBK%0LQ)M'SE!_)(K1K!P5$$'
MTDDI'M%%GA#(@I5;9-S!BS"\/#V#+60:CCF$L-J@:- R=QG6$"SFKE:'!VM>
MJ\6J_61*_G9E=-4D?&MNM=. 164(F*:*IR*50V8.*[ACX?9ZJU?.G$#AW$%C
MO!MJE!9'R)5:?*V!/SCS07,:QG91DX78@[_@8R'5@Q*[$&HN 7$$Q4J_Q#D4
M(51,Q3D.4IR'(8#$.0P 8IBF*(@8I@$!*8!$! 0$!V'2E1:4II2FE*:4II2F
ME*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2I:JR2)>DJH1,OB<P%#V;B
M&X^@.>E*Z9Q/M$MP1*=P;Q#][3_Z1@$WQ$$/3I3Y\/G[:Z1>:?K[@0X($'N1
M+]EMS[5#],V_I)T.S4^[X_/WYJG<\SCQ ^S<_ACGX8SU)NFH;I'.8YQ[3'.(
MF'U\]^7QZCQ\_GVTX1[?=GPY[;Y\^6>E )W_ )AW_P#6V^?\^E,+CEL3TWY\
M^6=MO8.F^*BZOZ]GYA\?1\NE3\/#SWV\L;C'NJ+J_1O\8]G;V"'UV'L';3V_
M/SUJ.(8SG'EY'E[_ &9',>8B FW,0$-N>^P!^C^O<=]/G\J$@[9!S[A\<$>?
MCRK&K,5XAV3>94FG*J50J,<6:MRC5;JW+U)1<&T16H]0.192T2@I1K;[(HHM
M?/7P&*#,VMEI&EW6M:C:Z;:*#+<R</$02L: %I9I,<HXHU9VWW"\('$PSI^T
M&N679O1[[6K]L064)<("!)/*Q"06T6< RSS,L:YV4L6;"*2-+M^O$WD>V2]O
MGSI@]E%B]2R; *<?#QK8A6\9"12&_1;1<2R319,T2\^K2ZU45%U5E3_5VE:9
M::-I]MIUDG!!;1A>(XXY9">*2>4@#,LKDNYY GA4!%51\$Z_KE_VCU:]UC4I
M>\N;R4OP@GNH(AZL-M K$E(((PL<:DEB%XW+2,[M1VMA6GII2FE*:4II2FE*
M:4II2K2\7_\ X/SB4]&1.&__ -X[G\7S]OHUQ':G_._9O_8UO_P;"O=OH:_Y
MGVN_V= Q_O\ 5*\V.L:O6??^_P"SKUP*:4QYD9\.6=_S]YQUII4TTJ.GV;_)
M^_VTTJ,>/+S.1[\CQWSS/7PII4_//QS[_P##;E32GVD;_?CW<Z:4ZYY;<O,^
M/CRP/?[NT@YN8K,U$V.O2;Z%GH&28S,),1CE5G(Q4M&.4GL?(L':!B+-7C)V
MBDY;.$CE4163(H0P&* A2Z)(CQR*KHZLCHP!5E8$,K [$$$@@\Q4JQ0AE)5E
M(*LIPRE=PVV,$$?9@^ ]SWDU..%CQ+XHA,DNUF;6[,G[&D9\KS4$&Z4=D0[,
MRT=?6,<@)2L*UE)FW<2S8J:#=DPM3*RPK45"-D3&\/[1:.VC:@T:AC:3AI;5
MSD^IGUHF8[<<!/"V3ED,;G!< >B:7?B_M5<D">+"3+L/6QM( /XL@R1M@'B&
M/5K=$DJ19--5,P&34(4Y# .X"4P (" ]_(=:&MH#FIFE*:4II2FE*:4II2FE
M*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2O)[Y1S%_"?G_B"S/Y/7A5Q
MSC1OQ'<1.1L=YKX[>+S(D^G)Q_#+7Z[,P,XU0K%JN<R^DH_*=DC8IK%0&+J*
MYAH-A!S+]NHP9(/Y=Y71WV./#D!MCR&_R>=5,Q;&0HX0%'"B)L  ,\*CB. ,
MLV6)R2222<9>-VMXYG\A_LCZ1S,UKT]><<X6X*66$)BZECY"QUVL^]&%7@'=
M#D)1,SJ.3FK@-84EW5>40&0FGR*3DQEWI"JJIK(+RK7#\_D^'OR7?%IE.^98
MG<OKYF\GCC);'L[;GA<7T:4F*U)6+)MDBJ,DFDW/D*YV2.8M[+9Y=Q(/ CH1
MA&,$V2971W4YV P-NO4^VJV<,J*$5>#B]8#UGXFSZYSOPCU5P!@5-\J]B>5K
M7$WY1G)IJ#P\<3L'F#R=\7#2#"_9DQU6LD\$S&CQDJT+D9.@6="1N3JJ6&5\
MUMU5?4)LC,S>1B,81N=DX62?.8WY_;X$\O#P)YYV./*G!(+8/""%+8. 6XBH
M)Y D*V!U"DCD:WI>2C?7*2\FOP/OK\J_7L[CALQ:=PXE#+*2+B+"M,R5MP\4
M<"+A5=>M%B%CK+B9943]8H8QS"(JBM@>E*:4II2FE*:4II2FE*:4II2FE*:4
MII2FE*:4II2FE*:4J!11-(O24.1,O^,<P%#U;F$ W]&E*ZE>;:);@D!W!N[H
M!T2;^DY]A_Z)3:5&>?D,YZ?/LS73KS+U;<$Q(W(/9T-A.(=^YS@/L$@%$-*$
M_EL,_'W;X^^NI/UBINF<QU##VF.)CF'_ )1Q-^?LTJ!CD2,C<_CUS]PP0.5
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M$#($0!(P%W'8!(.VX[:U#22,<L[L1R+,Q(]Y)/05T*11QCACC1!MLB*HVY;
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M:<Z#(WY8Y=<;Y^1N!@5^E#PMW UV@&-O,("6_4?&V1";;[&->,?UJSKJ%$0
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MF-O'&?NY>(J+H>L/#<?GVW#M^;T[@J.+ER.?#?[,YY??Y8/T$]^[?QY"(_.
M?)Z=N[2F3DY./#D >0Z@>W8\N1J/J^SEMZ^B&^WKYC]=N>E1OOO[<D[9]FWF
M-^7/K475=X@'/M[1]//EMZMQ] :4!VV/+D,$G..8W&<]=O:*C*B/=OL/9R .
MP?7W\]M_2.E02-N>1C8[;GJ2,';&YP<[>VH@1[N79R^RW#Y@'MY?GTID<\<S
MOD'.^_7;P(P<CSWS&"0<N_;M  [?:;?O[.?9ZM*G?)VP#@C R!YX&1R'ASQR
MJ,"!OV#W]H_H[?;Z?1I3A.X&!G&=SD^/CX^7,>RK+Y?("@4YOV$7NE63. !V
M@:<8=+<1[0$-^6E2HP2#SV_''3Y]U>>.\N#N[M<G:AA,HZMEC<G,/:8Z\R]5
M,([\]Q,<1YZ^Q-.01Z?81C8)8VB@> 6WC 'V5^=FLR&76-5E)),FI7TA)YDO
M=2L2?,DY-4MK,K6TTI32E-*4TI5Q, 1Z4OQ-\/\ 'N  R/PCQ4B)3 !BF5A$
MW,TWW >7)>-3V$0W 0 0YZY#MU*8NS.IE<@M;M&2.?#(0C>S9_AFO2?HL@6;
MMEHH89"W:2 $#&8D,PY^#)GVXQN*]-FOEZOM^FE*T)RWDH,^Y!\HG"<1.9.)
MIMD? ^-;]2LUXG2E\>1!,V5V2J%WRO::OP_-<@MYU-6.QG3Y#(!I%Y8DX%>6
MNM>"'IKY%B,(K,.&.NWPWP/\3CP\/&<#A!X@22P*>MQ* %(8DJ%PW$0N&+ H
MW$J@H6J>=\DWF//^0<?MN.#BV1XB<$82:<0C'&,#7<7EQ!F2U-.(BL2M(F$<
MN9,IUK1B7/O/ITPZAH<^/ZA3O=UP5M)RQ&Q431RSW_=^7SCVYBNRPWY'"%X7
M>(+*>?.&;.=^J$E)\-,;A3!\'D:U9+R[&XRML:VL+-I9K2VM^0'#+(M(AFTE
M$%JF-9%JRAZDM&NG$$NS6DE3D# Z'GO@XVV&!ML=N?+RJL&/"\2.6#Y<B10&
M3JJ@Q,4?GZY9Q_U9QO2^?/)I<=N9N*G%/%,3C8PFI.X3QO6*MC"GY!X7Y*]T
MJE7\*W$MLDY?KM4'+</6V-[NUJ1F)*-FEHEY(U2O.86OQKPQX!E( VR.>,;C
M(W.>8VVVVWSOOY5 *93*L0,=X X!;UB3P'@(3*84<0DPP+[@A!Q+_P"2OXN7
M>9N-&^8CXM\#4VD<;<K"/\AUC(G"6EEV=@RQF-VV.G 0$O*Y2AHI,R[49&02
M16A#-@7<-2+D5!KTE!QMM\=]_$;#'V^VA*^KPAAZN'RP;B;))*@*O"N,#A)8
M@@GB.0!M@X3.'F&X3>&K"G#=7[),7")PUC^"HS6T3Q"(R<\:*;[.I-9FFLY2
MC4'3Q1PHPB$7+E"'8"UBT'+A)H18ZJ:R&TI7D:_9-5?9-LA<'-L23 )&6JF:
M:Z\5 "@91E7Y;'$G&$,/VYBH+V:5.4HB)2BN82@ G-OZ+V"<\5_'T#6[CVMW
M@/QX5^%<EVH08M'ZY=#SY94\_CYUYT,04]AD/+6+<?RKEVRB[UD>CTV2>1YD
M2OVD?:+/%P;QTQ,Y1<-RO&[9\HJV,X;KH N0@JHJI@9,WHEU*T%K<SJ 6A@F
ME4-GA+1QLX#8(."0 <$''(BN8A02311G(625$)!W =@"1D$9&=N8^ZLD'7#+
M3[DSEW6);W&.)2L5DTE8*JZML?>.E+=5>YTC6)N+6J8XCY0B=/I#J8EHZ%K\
M])P'G"#YZ9:OMK7+TS7C4986074+*DL@6.01F+U3W*9>(R3LI[V4*I=T#@$*
M.,QI+EFSCDXS;R F)26C9PYX@9#ZKJD:'**S$*&*[9V+%/H\((QRLZ>3OT>Z
M2B'=CKK..1AK% RDS;JLRRV>=;(^ZT(Z]SX"+7Q!/N6TL^9E<SJ3J*B!CH*9
M5GTZK'UL&**D# L(Y&8O&ZI%(UJ%)X7'%(?2HP4#83#.6=0G>R;!@&8R @%T
M X75C(BS,P]93A!W+$,1ZXP  2>'DS7!#:X6(F9)2[5Q9U$0U@5]Q 333F'E
MHJ1+4K9JR@Q-)"X(ZC25&23&*723R$DX4_LOCJ'90UM?5N%UF)F0=S( TB#B
MSE1'+W?!(3C&"95W&8<?LSL6C623IL@S^L4D(6"\+!BREPR@8YX1C_*VWC4!
ML4-Q#<-#_!AWKOWQQDVR;WRT4UU'LG(OGM>5BYJQL81"7=':1#X[F5CZW(/4
M'LG5:HTFTD3R%6;S$8F]7CK]CJ"WF%[MD;N8Y0S  2<21LY50S@!6D48624H
M3PR%&P&L7-HUN.+B#J97CVSE.%W"AB0NY"$[JO$ "H()QBR(@ ;CR -;*L-O
M:>GO/EUS[<CR\/=!PX\5>/, \*_#A>,CVN&J<*_X7L!1[*0G5G2CFP2<-B^M
MQ[YC6H.*:25DLSE@1!L20-"1+UK&'6;EE7+(JQ#&\8?0M5UW7M5@TFRDNBM_
M=&1T"I!"&GD(,L\A2&($\6 S M@\(."*]"CO[2QTZR>[F6'-M"%7=I'(C4'@
MC4,S\]R%(&=SOFC/RU_#*O+ Q5F[XS;"J4@R\AC10L"4HF$!6%6+LDM9!1 -
MC;EJQG E'DV X=$-\WT6=J5C,@&FR-C/<+>,)#Y<3PI#DG;_ "P'B0 36".U
M6EE^$^E(,_Y0Q IOR)"R,_GCN\^7/.S;#/$=C?-< QL=*M-?LT)(*BV:SE>D
M2OXT[XB1%E8UV4Y$'\/,(I*)JN(2;91LPW142678IIJIF-PVHZ9J&DW+6FI6
MDUG<+OW<R%>-<D!XV&4EC)!Q)&S(<'#'%;VVN[>[B$MM,D\9..)",J< \+J<
M%6'56"L-LCK60?;V:P:R:^;ASYAR#<>?8'/F/@'(>?H'PTI3I%^Q^R#[+D7F
M'V0[".Q?'D CRWY (]FE*^B(!VB ;CL&_>/AZ]*5\ Q1WV$!V$0'80'80[0'
M;L$.\!YAI2@"!@ Q1 0$-P$! 0$![! 0Y" ^(:4K[I2FE*:4II2FE*".P"(]
M@<QTI6"G%%F0U&K<]96*X%DV"WO3HQ $I@]^<HT44=38IFZ15"5*#\XDDQ.F
MHD$PZA2' HG X==V)T#](-<AAF3-C9@7=]S]>*-@$@R.1N)&2(C*L(C*ZG*;
M^>_29VK/9+LQ=7-O)P:I?GZOTOD6CGE1C+=!3G:T@$DJL59/2/1XW'#(*T>&
M,<YSJ*'.HHH<RBBBAC'444.(F.<YS")CG.81,8QA$3&$1$1$1U]1
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MA P" [" Z\GY@'[.OE^6W+%=J  3MS&1]QQX=*K[HCX#OZN7QZ5(QTQ[J^]
M?5\NWK_J^+2IKZ!![Q^3</S<_5V>W2E1=7L'?X;B/1_,/?W>&^X\MP5&1T.?
M9O[>7S[3M40)AS$  >>W>/M#M\?ZMP#2HXAD#???P\=CGYY;U'U>W9O[ #]/
MU].E1Q;C( YC?(Z^/#R^3BOO0[/EY]OR?G]O?I3BY]-O#('/P)\]\#//EM40
M)[]V_IV]'Q;^'+XQTJ,GS&-R,#\2#CWXY\@*CZ'/;EOZP^+8.[8 [=]_9I4=
M,YVZ[$YP>8)QOOT(/4;U$"0]P=G@4?BW';Q'?GZ^W2FX.Y_:(R/O)R"-B!C[
M-JCZD?3W\Q^QY!ZNEM^C2H'/)\AA>O+P^W'7&*BZKD/9_P"L;T]H"'+;LW#U
M]VE5 C/+GOOPCRZ@9)(SL1O[ZC!( V_0 >T1[>8<O#T>*HW(.01GF2>F_+(
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M%> J.14K_%*D%2.A!%5[K#J]32E-*4TI32E6CRH^;$)7XUX?HL'$H1_*AOL
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MY.Q"E"=+[8),+@V67ZKP/[B(S &VY]4*H=^VNE[(ACKEMP\N"8O_ +/=G_\
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M+"W4'($-G;)%;H1RX^ R$?M.:L-KH*U]-*4TI32E-*5QW#9%R0R:I"G(8-C
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M7I]@ ,9L[.WMV(Y>LT4:,Q\2Q).3XFM9=:A?7QS>WEU='.?X1<2S ;YV$CL
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MZS@I%;1QL>%ROHK2-&Y$BLKL>]8/QJP8;C!WJXMTZ$D*HXFF9@O$H(G"!U'
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MJ_/\6E34@SPX]IP#;T[]_@'=W;^@._49'S\^_P!F_*E<8SH [5-_1OX<^?\
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MB1 /".\*I2G9[4DDA=98QW-W+(F;Z[8K ]V)RQXHV$LDD:!&CDXEC>1F$K<
M+Y"X(I&4*337<)DB3&>E@G%7$:_4M=@NDB,0:(AD#$EYZQ-V"CE^>8;S#@"Q
M<3#1 ,UVBR,2Q=K/4"\QVBO]+O[Z.YTJW-O#Z.JRQBSMK&/OA-.<P6]JT@6,
M6[P+^NGFF[Q'#32HL;'>:-::A:6CPW\O?2=\61C<SW3]V8HE(DFN A=^^69A
MP1Q1]VR,(HV9U%R+)6E9^*<L'#901.0>J.7<#IJ!S(<ARF Q#E-L8IP-N4P
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MW<@9>&3!*YP.)&#1O@!T8 8TTYYX);YB]G)W?'KI;+>)F1CK/+%"QJS>V4E
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M/IP(EO(Y91_YBV(GE)SC!X#P1G_M73XD [*VTF_NB."!D0\Y)?U:#V<0#/\
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M:#O4?;*\JA.$(Y@'!/X@$>W<??N.>!4JQ4\0"DX(]958>L"/V6##(!.#CU6
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M'"[A9PW2;HHHIIHN#+G4;]7V<[-QZY'<RRW3P+ Z1JL<:NS,REB268  #
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M?6C@)A:RPFG*;:(?V)SD&%:2KIPEUZ+6-=252:H/EU4 %9)%J=551(!4*4Q
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M:41:)"1 WN>QKLD>HE93;U]T#^9M8Q9TNZ ANH(?HCM0.Q.F%G0:PQ>)6:5
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M95TCA96'BK*Y!'F#0]I+E"5>SC5EV*LSJP/F",CV>!'OXKS]D:98C5_-9#A
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MJ'ALW'FWE18P\/"*LDV%;PK,P?##DW [-SB>1;SKIZ9K8+#>HNUR#I*&I+R
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M,X]5N)GD5B2#@@%&JUUQJ5R1MEVED,?99J"5MFE[&C:H>#-)6Z+6-D>8OKB
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M^KQ>./Y/R-^5#^1PP2(=(U$QB<0*4H;T.LB/1(4"$*&\9V%*4I2AV%*   ;
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M^8VWA_S>'\OMY4_<;<#_ 'AXO_F%6/U7J?KK6/Z6U'^NW/\ >5'H%A_,;?\
MJ\7_  T_<;L#_>'B_P#F%6/U7J/KK6/Z6U$?_G;GX?Y0_(YU/H%A_,;;_<0_
ME3]QNP/]X>+_ .858_5FGUUK']*ZC_7;C^\J/0+#^8VW]7B_X:?N-V!_O#Q?
M_,*L?JS3ZZUC^E=1_KMS_>4] L/YC;_U>+_AJ(/(X8( #%"BXQ #; 8 H=9V
M, #N4#![F  ["&X;[[#S -PT^NM8V_Y5U'G_ #VYV\_\I[:>@6'\QM_ZO%_P
MU#^XW8'^\/%_\PZQ^J]3]=:Q_2VH'V7ES^,E/0+#^8VW]7B_X:?N-V!_O#Q?
M_,*L?JO4?76L?TKJ/]=N?[RI] L/YC;?[B'\JKG&_DG\(8^NM>N;"DXY:R5=
MDF\I'/6%)KC5\R>M3@HW=,W2,<19LZ1. '1<(G(JDH '(8IB@(42:MJDT;Q2
MZE?21R*5>.2[N'1U.0596D*LIZ@Y!&U5)962,KI9VZ,IRK"")64CD00,@CH1
MN.=;9VZ)6Z"*!/M44B)%W\"% H?-K7UE_/SRJ=I2FE*:4II2FE*:4II2FE*:
M4II2FE*:4II2H3D*H0Q#AN4Y1*8![RF 0$/: Z4._P"ZM?.1\7\(2UPF2W++
MN,JW94G(A+0LSD*HQ,HP<G*"W5/(Y_,-G;502*$4ZM=$AQ(<IMNB8HZVT'9_
M7;J%+BVT35KF"9>*.>#3;R:*1<D<4<L<+(Z\QE6(V(SG-:^75M,@D:*;4M/A
MEC;A>*6]MXY$.QX61Y RMR." >7/G5#_  4\#GX></\ ]*=&_7_Q_GU<_1;M
M'O\ _1W7/[)U#^X]N/"J/KS2/Z7TS^T;;^\]E/@IX'/P\X?_ *4Z-^O]3^B_
M:3_1[7/[)U#^X^/CUJ/KO2/Z6TO^T;7^\I\%/ YM_?YP_P#TIT;Y_=[?3]%N
MT?/]'=<_LG4/;_T%3]>:1_2^F8'+_E&U]G_2[>'E3X*>!SG_ &^</_TIT;]?
M\O9J/T6[1_Z.ZYC_ -DZA]OZC?W^?C3Z\TC^E],_M&V_O/93X*>!S\/.'_Z4
MZ,/_ /W_ )>_3]%NT?\ H[KG]DZAU_\ Z'P\.E/KS2?Z7TS^T;;^\KY\%/ Y
M^'C#_+L_MIT;M]/]GOE'?U:G]%NT?^CNN;_^J;_[/X/MSZ4^O-('_I?3!X_\
MH6O+Q_ROSXT^"G@<_#QA_P /[Z=&]O\ A[XA[?5I^BW:/_1W7/[)U#I_^7Y>
M7*GUYI']+Z9U_P#2%K_>]>OXT^"G@<_#QA_O_P#K3HWZ^_U=VGZ+=H_]'=<_
MLF__ /E_CX]:?7FD?TOIG]H6O][\^5?1Q3P.?AYP_P#TIT8/FG^6GZ+=H_\
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ML@C D:.Y$JSQ=^&P@[?_ $<6.FZ?IUAK<Z+IEU%=VSW&GZQ([R>D22W1FD]
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M0<:5$M?\U(UAD:[ ^Y)$T"C&K0L6Y9BBY8MED[\OTS=C);9;67LYK3VZ337
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MBH1%B@AC2-0(XTB1(U55 JJT\#\82,:SBTK*Q1(R3A&Y)%*#(E9'3&MN6+N
MBI:V$J1;1.0<.YC(Q2.@IJ8?P[7W.CR),2ILFI$L,_2YV%:5Y3V;UQBYG;NS
M):FU22Y21+B:&T.JFT@GF2642SP0QS/WLI9R9'+71V [2J@1=6TM0HC7B'I
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*I32E-*4TI7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g65062g13o68.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g13o68.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1QD4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '$B^<D X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M ! #O_XU  (  @.__C4  @ ".$))300F       .             #^    X
M0DE-! T       0    >.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         !.$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@             $"P  !V0
M         0                         !              =D   $"P
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   $"P
M  !29VAT;&]N9P  !V0    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    %
M.$))300,     !&?     0   *    !8   !X   I0   !&# !@  ?_8_^T
M#$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*
M"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,
M# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !8 * # 2(  A$! Q$!
M_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$!
M 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#
M!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#
M)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6
MIK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A,1($
M05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$
MDU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#O<;ZL8>-<R^K(R?498+&N=9NT
M&[?29;[J;=WZ3\_^6M#$<X^L'$NVVN G6!S"HX_UHZ/D7MHKL<'NL]$%S'-;
MZAW!E3K'#8VRS8_TZW?SBNX1!]<C7],\?= 24TKNL=(]5[!U:L/I<XW5L?6[
MTPP[+/7VM<ZFJIWLLLO_ $=?^$0,O/Z?DL;;B]8#-H>W[566V5-(?C[A<ZN,
M3U/?76SU_P!)^M+1O&<Y[=N-CV-98'--ECI $_I&CT';+57Z@.HN:W;BX^0=
MKIQG.!W'=5MBVUM>SV>J]WZ%_P#-U)\JK^V* -?]]SAD4C:#]82-8>V&23&C
M&;_>W;^=^>IFW%]"@CJ]WJ$G9D$/-;G>L]NZQO\ ,>EZF_&]_P"C]/TO^!1@
MSJX%8'2L0 2![P-@V\;0QWT_H?HU-PZL:!6[#Q8+!-9 +&DW?S9][?:W%_D?
MTC_MI,7-8.J9U"TGJE^C[G^FYMFQ@_2NV,,^GM9Z%[&;M_J?9[?0]-,ZW&L8
MRH=<M=:3.RN'3 +=NVIOVC9NN_TW[B+;5U1L6#!PO5L%PRGD-&[Z+6V-E[7?
MIJOYRNQ__&6JTW]KN+&'$QRUK027NV>YP_2[?3;D;?SO_4B2FY@@C#IFTWRT
M.%IY<#[FG7^2K"S^F/ZD/T69172RMC0STN =K=S&^Y_L:_U-G_!>FM!)"DDD
MDE*225#KG2SU?IEW3QD.QA<(<]@:Z1^Y8Q_TZG?X5GL]3^;24WBYHY('^Q.N
M0P_JN;_6OJR1B=1&19<):VUU(<YIH;;4+74V>LZBO-L?;^D?;Z?^B77I*4F)
M !), :DE.@67;RZJIOJ.X<3]!O\ 7=^]_P &U(!!-)*K:KJVW4O;958 YEC"
M'-<#PYKF^US5-"Q:!CX]= ((K;M&UH8(' :QOM:BI%+_ /_0]3].O]T>/ Y"
M#B<W_P#'._[ZLZC)^M!R0<G#QVXWJ['-K?+_ $W%WZ9MCG-:[T6^GZC/1WV?
MX-:&'/Z>?],_^"2F%XQ=X]07DEXC;ZI&[Q]OM:U9_6/V<&L&17E:L<&74AYL
M:"^DV /UN9^E9C?U]_\ QJO.Q^K%[RW,K#';O3;Z,%LGV;W>J[UMGT=OZ'?^
M^Q"MQ.N%H]//K%FLGT8;RW9[/4?^;ZWY_P#H?W/TCCM\U^&J!O\ +7CHY-5/
M17W4X^W/;8\[2'&P#?&W]/L.SV^[9_VG40
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!2P)= P$1  (1 0,1 ?_$ !X
M 0 " @(# 0             '" 8)! 4" PH!_\0 51    8" 0($ @8' P<(
M!0T  0(#! 4&  <($1()$Q0A%188(C%8E=<7(S1!47BV&3)A"B1"<8&7U24G
M,T-7D:&Q*%)BUO V2%-4561EE):8I<'%_\0 ' $!  (# 0$!
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M@*4H"8QC" %*4 ZB(B/L  'N(C[!CS( [DD #YDGL /Q)[!02 "20 !LD]@
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MA1(J@MT;0XBA+(MZTLX3G5V1TW*4>=%5(YR+"@Y^\*C1MOF$^3VFUHVARL!
MVMTWND4X+%3]H-*$K]?\M!519]/2QH.:!I"1R;N4.,1)]6A08.O*(HVOOB$Z
ML9[7XJ:HTY+ZUV\]Y1&E)V'LJ6U(^"K<1K^$E&,*ZG8MU'0-K6M5DEY=>4B*
MO4VZ,8$C+UFPQ\G,PBD<L8I%(G,#F+4^(M9K$I+4NZ[!L5QL4%#0]>J<+**Q
M\=&25PJ5/E;;<[>G&/:_2ZW"/[G!-B.)E<CR=F9.,@H-D\=.UE63^M%BVP^;
M++7?)*+TG)T1$::%AU[2;7LIU<FD;(5^W[0HVTMA5=5G2%X90)BE,('5,N2V
M6Q6T12L,[D43-(6580\^]8$5AM [6>;PU97MKJ59S486\*2TW2&#]THO*RFN
MUY=\2@VZ5:JL6)X9Y=ZHG%6\L <KE:%:S3:.=O%WJ#D"-[\D5(]G^(/L6@27
M*J<B.,!+CIWA_:RUO:M^1WC6*Y:%V[76M(VC.2=8U_8*FU:RJD;7KPR29Q:M
MV9N)E^T59LU0=.&Z!BCY_+7K]&OQ_@LDV]X@@:\G-E5JJ:?>WF;I;CATPKK5
M_=$*6C;9+F+<YVF5=J\7=UB94JI*J[ATG4NLY;2AW:;TR)4&1VAC+$)U_5^O
M7T/U"E#4G*>Y6'=JW'?>NBY'1.SY+7\EM"@G:WV"V?1-B4ZOS<17;7\!MT3&
M5YVTLM4E+!!#,UJ8KC%R$9+LI5BY>M!6,B3\_GZ_BL\LG).K5O=%HU:^39LH
M#5VD5MY[KV/+RZ4;7M:UV3EY*,I+!Z!FRQ'+ZQM*EL2POSN'<<C 0%/!ZMZL
M9IDFG'?]'YN_K>OS#:E=-!<Y>'5E@+_:X3DSI5]5]6!#GV'9 V!7F\%4VMBE
M?@4!(RTL[>H,$8><F^L/#S1%U(F3E2GCV3U=V0Z)93UW[+M:;S)XG;%@K]9M
M>\CM+WR!U;75+;L:4IFQ:O:&M*K22#]R::LAX.2?#%1YD8N0,DX=%3*L+-P1
M'S#IF+CUZ_6HV/J/UJL%-\1]KLK4>O[S0M&7!WL+<7(O8/';5.HK7/,J9,2$
MKKKYQEIVUWZ7?Q+H=?Q$92Z/.66?CO@MDFH=V5K7$&DK(N 5*4J0:+SDC;.G
MJ)>RZXE:*6[[VV)Q7V0TD)YA+NM/\B*8G)JP-2DW,8T&,LE4OHUZ6:5RZ1KQ
MH"C^;U^U5A"J6E\6OD5\\(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"*@=
MP\-#BE>>08<CYVM6T;8YN=1V78J:QOEE8:DN>S:"V4:TK8MQUJW>EKLY;:VB
MH(,'RR";58PN%9%D]5D)-1Z1<C6OAM<5]3<@W?)*FUFT-KJ$]>[=6JU(7:P2
M>L]?7+:+=)ILBW:]H#IT>"JM@NK1+TDV[9)"CZ,_I(]LQ;(-4FY%W^Q.!NEM
MH*;NDK3*;"4MN\;OJJ^R5\86-@RN- F-'JQ#W4[/6$B2#,SK<+29B*<3T=&/
MXZ<3>35@LCV9/)_%E$TR>OU*>-"Z1HO'#4%%TCK1O)-Z5KZ(-$PPS,@>5F'9
MG+YW*R<I+R)R)>LE9B8D)"6DETT&S<[UZOZ5JU;>4W2(H@Y9_MW%3^;S5G].
MW["*WF$3")A%7F7XQ:UFY63F7LKMLCR6D'DDZ(QWIN.-9$<OG"CI<K./87=N
MQ8-2JJF!NR9H(-&J($0;(I(ID3+:H.8Y>O!#6C@P1C@BCA89>-<?FD+(FAC3
M)++C7R2OTT%\DCG2/=M[W.<23S^W[-..7+=F[+<Y@V:W8FLRM@Y[S6M V2>1
MTL@@K09Z.O7A#GD1001QPPLZ8XF,C:UHZ=UQ'U2[:N&JDQN3L<H+('$V^]S+
MAV+)F3-W(NKNNV6+VF'JDX1604#ZBJ2A!,4?=G.<W&]KVU^/;8YKAKB_'F]V
MN#A\3,:U[>X[.:X.:>[2" 5BR^RGC$L<D3KW-.F1CF'?M!YM(-.:6DEDN>DB
M?V)VV1CXW>3V.:2TQI$\7=@3S75]%VE<*TXUCI5 Z--6UP%MI&P+&HUKSFIP
M;BQ3T;,-%*X#&$>+GD4*H] )J0[1=*D9BHW/MY^9XNM)FLGA<?;9F>1.#L@,
MO[ADL54:^VR_994JS5Y!;\2U&P0NO1GW:+88TR 2"M5/9EG[T7&,'RC,XV3C
M/"XRS#OXV,O@N09%\6/EQ-*3(9"I=@?C1#1F>ZS'B9P+MC7BO;%MAE+Z)VK/
M_MC<O_[@-V_^_F:;^6^:\_=^/;^O\EN.?^5JS_S5\8UKW[FVOH/:)SL?NY#^
MOZ_-9G1-%4C7<X-AKTAL5P_%DX8"E9ML;+N$6*#DZ*BAAAK3:I>),X R!/)=
M&9BX0 3@@HGYA^N!D^2Y++5A5M18ED0E;+NG@\/0FZF!P %BE2@G##U$N8).
MA^AU-.AK<8/@^%X_=^T*%GD<L_@25^C*<MY/FJOAR%CG$TLMEKE0R QMZ)C"
M98_B\-[>IVXKD=/W5SSNJ&_4FS ==PW$W8>H'KPS](),MTL>WM9W.,;IQ8AY
MZC \)5Y915^4WE(N$T6Y@[UR#E?5P6M>2X><QIS?E/LD["IK5&D<\4^0ZJT+
MM*DU+3CO5JUTGG$>\IVD:G18.:?;@0K-A1D-AVO:5CEI68F(^RN(>;GG=D:
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M5RY4_:L;<PC:_'VFK6RO_!O@K-S'%>/JZ_:)LW[UNQ29O5$': =OH=_PUO\
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M@!F@6DGXQT[(NO-UZOF\5/7Z!H.&,DMP%W \41-&LA35=!R(TJ3U1TQ1$IW
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MS^?]7H?58_%67E!$\'ME<^HGE]N-]?=76/D9=E]1W1#5DOHJS5#3&\MC5D:
MYA4];Q]UC49JC5!.*93$=?49>/G5T9%NY$@>CQO??6MZ]?/]*^B>HDZ _ #0
M[=NP_'S\]?F6RKEOMZTPNFM70^NI1Y3KYR;VIJ3251LJ9$3R-&3V6Y-+W"SM
M".$U4?C]7UM"W20KYE6[A!.T-8A1RV6:D63,4*'7O/>[PE^MD8/'H5M(:TY5
MTWB#;=KK[8:J6L;K>7E%AJY9X;7:M0.K,UIK+["JS&S.'MQCY1L>06<QC2;*
MP?"F_;_7^X)_5Y_L_BN+5O$CCY_;T=K%]!<;XQHZNJU4>2[+G;Q\L%E8M6TB
MNS<R!-;QRQ;.]E$$4#N%:NB(2J:I5&)Q!PD<<'MY]OS^OQ"D@M)#@6D>8(((
M^?<'OY=U#^B>9FT.2?-.W1M+V13JYH^\\5-BS?&*JR'PR57F;!6-EU>MP.ZK
MM#HNV-A.YN0.K!.URBD?QCHFI6,),OF["8FY0T>4+(./U@WDGR=W3Q&V)O;?
M$^T>\8T+(SO>VJQ3*/:)S;!+:^IUXV;Q?>TBJPS$VIH).4@5E8FPKR$C7)U[
M51CFSB*D)!Z](KQ<,-OV?>7&K6NP+TDS2V!Y=JI&Q/AR0H1KC8>JKO9-67M_
M&-Q]VT9)VRFS$C'-NI@;LG2"('."?>)%:'")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$49[CT[K??^M;3J#;M91N.N;JU9L[/6G#^6BT95M'RC&:9I'?
MP;^+E6X(R<:R=E,S?MSF.@4AS'1,HF=YHM%?*/P N/%WO/'"4XRZ[UOJFDTW
M9"4UR'@;'<MMOWFR]=%E:JNK68!5:2M)V4@:*86=H"Z3ZMG\R7;C\3#RRJM"
M+LN2.J^3M%Y4:_JGAV\TZ7JF#K?%]M6C\=]V3U[GM%4>D:]F8G33>PU9V:(O
MM0+<8F20K,3\-GD6EO;3T:]=.I*68V&;C!V@PV2=CSDVU9#5%N.B/^F=/+5=
M=CZ(/\JZ)U9CI1,&&/I'9W?O@G(TQ;]R,S?']W=9(_YML;)Q6=U2_P"3#Q,X
M1^&7!_5OMYZOUX:/ QOP&T;,4>7NAMD[2V/<Y#9.V[Z#=9LTF;7)-&C(K&'3
M="9^:%BFS410=21O7R<F^EY==%B$@G&LM7Z[K.45T_@GLS96Y.>V]N24Q7F5
MOY$Z]M/%W0;:L2*UB3U+QG=P$C%MG1E74?%@VMMMEY).SV6*:*.6K.58NBM)
M15O+*D1>O6OZD]?F57^!?AJ<L-1\C>.^S^1LQI-A3^'W'JVZ#U@EJB<M,[-;
M*"R6&XO4K-:49^N0;>";-(BZ2!%&J2R[E:19,%"M$R+O%$WKUZ_6H'K\?Q_C
MV_9I?01A2F$3")A$PB81,(F$3")]F$5>;_O=LPGW.M-6P*NT]L FF#RO1;HK
M6N4M)SU!&5V1:A(LRK#$@ 94D80KRRR0%(E'1!P7(X+:<7QETU5F8S5IN$P1
M+O#MSQE]O(N9]Z#$4=MDNR$_"9CX=.'9=+..DM//\]SF.O?DXWQ>@[E/+ T>
M-CJLS8L=A6R;#;7),KIT&,@ VYM4";)6=-97J.\1L@@_7O'+<T5"ZGUU<Y?5
M7Z/]676)V"C.U5K92W>:E8>2D)]E#';2;=.+CV_QF150EK"5^[DIN(*JDJP:
M.I!ZJ:P93E/'9K&<RV.K9L93-8^?%NK77TOLZO#8BBK26 ^!QFE?[O$'05/"
MCAK3D.;*]D4;13<!P#FE6GQ7CN9N\7/'^+YFIGV7L6S)C-W+5.Q8O04S%9C;
M5@C-RPYEO(>/+8NU&N8^".6>5YOMG-EW),(F$3")A$PB81:6++XH]]5\06R\
M+]?4CCZXAZ?LC6%"D[#LC?C:@["L86R KMAN2NOZ$\A%RVR6JK>5D8]E#-)(
MKB8EV#:.0$7+LR:)%T&N?%VN5NVK7#R_'EJTXW[BNO)+6W'R_P )=%938EMM
M_&V#>S4@:STL\,DPB(K88Q4C%5(L;*R#]I+%(WD4E6Y#/%([^N_KZGY:[?BB
MX'&WQ:-B\B:97H:#UGK1SO+8^ZM/ZZUS'U.T3UGUP-6OFIJMO?:$_9I [:,F
M4I3CSKZ3G(79,>Q,!2; 0@(1+TWQ@446_KV_AZ_4BWJ /4.O_P !_ADHJA\L
MQ#U_%0.H=?I>:L]NOO\ _)V_?N^W"*WN$3")A$Z 'V!TR-#Z!$R44.T[C[I?
M7VQ[[MVEZYK5=V1L[T_SS;8YF9.2G/3F(H;N[U#MV /G*:3^8"+09!.2:24I
M,@^D4DW1=U>Y'G,EB\=A;^3M6L7B>OW"G*\&*OU@M'DT/E\-A,4'C.D]WB)A
M@\.(EAT]/ 8:AD;V6IX^O7R.2Z??;4;2))M$$Z!)9%XC@))_":SQY6MEF\21
MH<)BS2Z!\QM;A,(H;<Z1JSKD##<CE)"="[0>GK)I1I%D<L K*E6M%SJUY?OG
M#08XTF><2EJE'(-'*<LDQ(P6>)*QZRZB+E BJ6U\-G7#"[1UG9;BWFVJT#R2
M7Y75S5"$GKA"B16X)&V2%OG))V\2UJ2_V:(EGLU8(\D1;;M.-X6,G7A($T:]
M:0[Z,(H<XM^&8>LZ=UI!<A]G;4M4_2:9MV!K.LSVFH2.M-/SVY(^VU*VVG7Z
M\;2(ZP2TXI2K7,QD$>\V"X1-52L<XU@8MDDLB1N1624\/[3ZFL-TZH&R;#"O
M;UJ^FJG;'82E>"7CX[1]"I^O*HM +_+'I&SQ_#4J+<SJC]E)(N9)=\LP0CFR
MB#1N]>O-%B*_AMZY/>7-J:;DWI%5H_)=CRW9:NC)/6[>D,MVH7)K=G\XY>&U
MHK?+##2DDG(-AK-HNDU"Q+.8=G@6L9(,8%_#O6_FG[/7K]:S!?@3KEIJ[2FO
M:=L3;&OK%QXM=SN&I-O5:4J!]BUR1V"ZM2ERCW:=@I<Y1I^OV!A<)2(D82;I
M;YFLR0BUP DE'HO\>O6D62:FX3:KT_9=:7*!GK]-VW7?Z=)!_9+7-1<K,;(M
MO(F8I\[LJ\;"=(03$']C>/Z5$%BBP*=>A(ECWQC:'] WCF[)Z_CV0?K_ #KF
M;_XA5S>UNC=@,=I[>TK>4:!8=26"U:>F:M%R=RU59Y!O+2=(GR6^H7-BDW;R
MK<\E V"":0ULKKQ[)*P\ZU!\N42'\^O7KUV7HMG#*@V2C(ZRC+SM:A:_K](T
M_4-95:A6AA",M026CYU6=H]]U\X<04A((7+S$XB,GEK&[L4#/0L!'1LC!*HK
M2@R)/+UY?F78:VXJLM7U/=36*VUM"R;7WRHL]O._;BXJ+W8YI=M5$:;57L0P
MK]4K-#A6=%AFR 52#BZ@TAVKL'#QZT?.'KU1<BCM'P^=1Q5VU78ZI9KU4:IK
M.OZ+@'&L8=>M+5.[AQIL%LMFEI.SR$K6Y&WI2=8M%SF9R57@;)#A;7I6(V,K
MXJ+@KPBD?D5Q4CN05KU)?&^W]O:7N^F!OA:C:=0O:*UDCMMC1D+$65I*)7RA
MWR.<-U6,$V2;^G8M5D16<&,JH)D_*(L"IW '4U1&DR2MTVQ<+G5>29.5D]L2
MZV6&F;ELG:R.L[!J-JI=G2%9CXDM;CZ1/$BXR J</5FL<2%B :F3(60)($U\
M_7R_@HVB_#!UTA"*Z\L6_P#DQ=-#N;K/WE]QVF[=08[4\L_L=]DMER4+.DJ>
MM*Y>9NJ+7"5=2B]>D;LNR?AY;.4!\P [50I.B20 T'^BW>A]=$DN[^9^+S\M
M#LK%\N=/VC;&KH-;7"4:?:FH-F:ZWAJEI*NOA\/)V[6E@0DE*M(O **;%C=J
MHM9:,H^5**$8%C"25+V,QPH73NN&^MIFN7N%>RMY:(;,Y.4CEK/I_$H 7D=L
M:DS^M;-&0#!5.$<-25,[_5\"WDF:@OY)9NZEBM)]$R[-=H16#/JW62BRKE37
M5$.X7,N==P>HU\RRQG('!R9548\5%#. 44!<3F,*P*'!3N YNI%6)7P\^)0;
M1=[3BM.46K2#W3EPTJXKU-I5*I]="!O+LAY^RM K=<C)R-O*\0+ZK(V:,FVC
ME"M2TI&%3$'0JE(NLUWQ!)H*3F=OQ.P=S\E]MTS2\OJ?3$?N:V4@I*Q3R*L)
MQ&C0S^O5"C1YG5LG:[54+-?KN>PVM\UA(SUTZ=%LX(Z>O6_6O)%,G%#2KSCS
MQ[UIJ:7ET;!9J_%2,I=[ V(HFTGMAW.?EKQL2;8I*E(LE'RMXLD^_CTEBE62
M9.$$U@\TIQ$BL/A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%Q'[CT
MK1=?IW>6F8W3^/0/L_V_9]H?Z\>?8?/]'[?DH)T-^O7H]ME?.]:_#PH$]S)6
MWPLTUH2'<;4C)]SJ<^MB'H4M1SP;Q:T*SD62534D=K3-\=DL36Z"\2BVY6+5
M1U ODO-BAZA![2KD''1@@W(&48Z2!N3&0_QR*YXS!6$,GA%L>+BI-,#Z?097
M.<[IF8?R@I$O#H)<L<F75/#-ULCJ9J UWUS$X3&1G7MUV2RX2MGZ@QH:WJC<
M/@'T.Q;L7S%NY$.@J)D,(?O 1* C_P"/4/\ 9G+U>!Z]>OS#R7/PB81,(F$3
M")A$PB81,(F$6+W*ZU/7M>D+7=9^-K5>BTP4>RLHX(W;I]P]J2*8#U5<NG"@
ME1:,FJ:SMXN<C=J@LL<B9LRAC[V5MQ4<=5FN6YW=,4$#"][M=W./DUD;!MTD
MCRV.-@+WN:T$C69C,XK 8^QE<U?K8W'56]4]NU((XV[.F,;O;I9I':9#!$U\
MTTA;'%&^1S6FM@O]P<B![(0;#HO2SGV-8%T0C=S; 8G >U6OLG":Q=;5U\D<
M#I2DDB>XNT>Q1JPAB*@MEN\+ \4[V/=>3<A9Y56.\;CV*D&MBU(QS3F+<9!#
MH(7#'L=L/EL%O2N<^/R_V@GII'(<&X9)V.0>SW;F>?A(/Q8^&1KV\:Q\P(+;
M=ECLQ*P-=%7IM>7&PU"UW2]85]O5Z+7V->AD#G7.@T(<SA\\6[?42,H_7.J^
MEI1T)2F=24DY=/G)@#SES@4H!5<GE<AF;;[N3M2V[#P&ATA 9'&W?3#!$T-B
M@@9LB.&%C(F GI:-E= P/'L-QG'QXO!8^#'4V.=(8X6DOGF?KQ+-J>0OGMVI
M= RV;,DL\A ZWG0UFN:];E,(F$3")A$PB81,(M)O(3P]^3>^=U.HF4L7%^/X
MVR?)_6?)0]YAM>+5/E'!DU^B@HK0FTA6:LUKEI>OW:1F3395ILKFU-8EPLF[
M(]031BP(L7X]>%]OW5N_=((V_8FIY3BKQ5W7R'W?I-I (6L-Q6*3WD@Z2BZQ
M?VKZ-;U&.CZ0O*2,@67@Y1^YEURE;F8M4'91C(U_5^SU_#NBD?D_P&W+O:V;
MOV##'UW".FR^HJ-H/6S:R3M/J\_IB$V-3]K\B(S8-AK%:7D:K:.0\W#FJ<Q(
MP,=-&2J53K+"3<.4):932E/7K\ZOCPKU#L?0O%G2^H-N6MO==B42IC#V2P,Y
M27G&"BII61>Q\3'3$^W:3,I&5J(=Q]9C7\DT:.G3&(;K*-6_>")"*,.6>NZ8
M&SN*NT@@F_S\/)75E,&R><\]4-8^&WZ5^$^G]1Z'R?B  Y\WTOJ>_P"KY_E_
M4PBOCA$PB81,(O$QR$(8YS%*0H"8QS" %*4H=1,8P^P   (B(CT  $1R0"2
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M43_W54E$Q,0<AG/>0,>QX&&VQ[7C_P!',".[2".[<<UP\O-KFN'FUP.B,=_
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MB+=.=4WS:][KVTY&FT6/V,K?]D7'EK\S:>:R#5EL1GN&LV&CZXU.9Y!V,*%
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M.^O,JI]W\";P\K:*AX>B7[72RG<(JTK9MF6 IA$1[B-KPM=&9.G4.A2-@)T
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ME7?+G+V*JCY8$)0L_C>:W+;KN>QF;DF+0ULDU"P*\432>F&LV*$5H(&=^B*
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M0<,%:6]K[US%M(INV.W42Y]6Y?G+.6@QL]6M+BY[S*#^+^X5VT6P2S"M[E%
M(1+%8B:0R.RUXM-F8)'2$[W;9N/XV&A);BGFCO15C9;G#:F=9,K(S+[S)*9"
MR2%^B7PD&NZ)SF-8&D:OIQROEDVGQ^T?LRXQA(:V;!U)KNZV:*31.W283UGJ
M43-2S9%NH)E6Z"3YZN"#=4QE4$NQ)414(8<J.;J08_,Y:C5D\:M3R5ZK7D)#
MB^&O9EBC<7  .)8T;( !.RM]C+$MS&X^W.P1S6:56Q,P#09+- R1[0-G0#G$
M ;.A\U,V:Q9R81,(F$3")A$PB81,(F$50^6?[=Q4_F\U9_3M^PBMYA$PB810
M7)J\EPDI (9CHTT.#UU\*-)R=]+)&CO/4]$,@1K%':E>BV\H716QSH N*@)&
M%,"B)%URCGE0DFHJ:/T$8J9#J&*G(['54,!"B80(FG#F.H<0#H4A"F.<W0I0
M$1 ,(J3:?W!RRG=R6%1>C/F;78JB1&[:^UW8$;0ZB:OQKE1IZ%RBP57B"/6C
M8[5<RB8IR$DNW6==BQ_,!Z]>2*[GG<J?_J''_P#%-B?\(PBRRFJ;Q-,"&PFN
MJD8#TBX@>FOK<XF/7=R?IP%.;CV[+T@D\[SC>:"P&\OL*(=V$6E[<M:G*]O'
M;OAJ1#24)2^=V[:AOV%DF":Z;.L:)M:4O9^:\"1Z0!:,O66/53R,0:&(0AGG
M)&,\LBJACB$:^7E]/F.VOU?F'YQW3^OUI1->^0_(UCRIVM#-=WU36MUH/,#7
MFJ]/Z2L.\;C!$G-*.7E%:0T+&<0*;Q_O#S:L#M*HREAEU-KM+FD]JTFX4D22
M]/@J(]:+OW?+\VOIK]G]R>M+)]$-K[J2!XU[/J^ZMK"TW/X@'-G4-LU:^LK=
MSJ-*C+3?,^SMFT/2@CB-H^=87'6T3:TK4#E6PK2$A+,'4@K!'91+&5'T_.?G
M^?Z_N'[0%C%1Y!OIC7?'Q/DES#V;QGII/#)TGN;6MMJ-JCJA([6WI-GL;?8L
MP87#(P[;ME-8Q>OQB]-%%ZUG/G!9=:MR!W[=PV* ?K]/TGN1Y G\-:\]]E&*
MVZ=KUV9"LM=D_HLU#LGF5S=GK]?KCN.4X?(V'8D&PU6[I%,M6UHO7&QY'7$B
M]C9>YVQ.C&8UQ.QRM=5A5IY3X*:!F"^M^OZO7T*V>UBZ; V%X/\ LVW;.ND7
ML>URG%[D@0;]#I6 C2XUV/A]CQE-L)G-GHFM)26>R519PB\A8BT> B[.^,XL
M4&V6A91@[<$'KT=*@G'G9K:X\E/#T58<EM \LWL!JW:%64H^@Z0PJEKX^L)G
M08J/[SM*Q0%UV(E.Q#!2O--;.(6S.Z4@XLUH8S4?'24S'H-&3UZTHWOR(/?Y
M:\M?/O\ 7UYKQX8;DT?I"R>'G9]^;'USK&I27A-V" C9K9MC@JS"O["MO35,
MBC#LG=A<M6CJ75C8Z3=I,4#'=G:-'BI$Q225$!!'<@^>O+Y_,?Q_:OMS'L!+
MV.8 ]T9+FEH#VZZF$D#3V['4T]QL; VME?AMEB9-OR_V%K:+5B^/FT.6%MN>
M@2DBW$) SU;/KW6\+=;I38UPV: A3;AM2'NLK#.FK5!A**&?2[-,R#XJZQ?.
MM>OT*E>DCWF_:U\-NDM]K[-UDMR5VWS-M_).3UG8S5"YV^[QC?:=[L<-)3Z;
M5>2BEHN^PY80Z[$&LM&0T2$-&NHPJ:!VT:]=_P!OU[?5/IZ]>OT912VG,C;&
MCM6R=+LG)G8[JHV?D=K"=N%%Y+Z:TU(S:.K>2FT]=5%[>&E_T]>7-JM1J?5H
M=%]9(YQ%HNU$55'C)5\LLZ5GY>?Z/G^?RUZ\E.ATAW4TDN(+/BZ@ !\1/3T:
M))  <7 M=U-:.DNKSXC5>Y927'9&'VWHO=$_IK3VK86V(V:1W7H>ZR4EOV:V
M&:/3L.XI9G8];RMLB-;U!R@PH\=4]9K1[FUVT;%*%\^EPKU,H4L<P-^<7-C[
M&V/Q*F)[3W%Z];RKNG;+SKV5O+8^OHJST6!90T(_JVFZ(U6MDM$W'=2==:L6
M:<O4G3G6VM8U^:V_&YBV2D6Q=1_?]=^NVE&Q\]#]/EOS _9]/D5L-UVL>'\2
M'D# 5A0QZK:.)?'/8-Y11,*S-'9"%_W11JY+K*=3%++S^NJXQCG:IC"N]BZA
M!]XBDR1$)]>O7]L^O7KY+8!A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PBZ*S6BM4N!E+3<+!"U:M0;15_,V"PR;*&AHIBB'55W(2<@LW9LVZ8?W
MEG"R:8"( )NH@&>T%>>U-'7K0RV)Y7!D4,$;Y99''R:R-@<]SC]&@E><LL4$
M;YIY(X8HP7/EE>V.-C1YESW$-:!]20%H(Y5>.W2HF<-J3@]1)#D+M&4>DAHF
MVKPLXM1CRBQC)@WJE;C?2W+83XBA3)IE:(P,.L/ENX^4G&@F3-U[C_LEM2P_
M:/*[;,+CXV&62LV6(6PP?.S8?U5:+2""2YTTK>[7LB=W7/<OSZ!DGN>!KNR5
MM[O#9,62&N7GMJ&)FI[+@>V@(F'LYCY&]C7G6WA3<U^>%MC=S^)'N:U5. .=
M9U$:P8/HYS=F+!R8JP,8N":-W&O-41[D@I"JBUCIBQ+ D9&<AX^1#U1=U=]H
M7%>)5I,7P?%U[,N@V6_(R1M1SV]NN2=SFW<E(T]6BY\4+-@PROC/2==6XCG.
M03-O<FO2PQD;95:6.L-:='3(V@U:;7>9 8^7Y21L?LKZ%N/'%70/%6J!4-%:
MUK]&8+)H%EI1H@9Y:+(LW+VD=V:TR!G,[.N ,)SI!(/EF[05#IL4&J @D'&L
MUR',<AL&SE[\UMX+C'&X]%> ..^F"NSIAA&M EC YV@7N<>ZZ-C<3CL3#X./
MJQUVD#K>!U32D>3I9G;DD/<D=3B&[(:&CLK"9IEL4PB81,(F$3")A$PBQVUV
MZLT:!D+/;YR-KM?BD?/?RTLZ2:,VY!$"D**BA@[UECB5)NW2 [ARL<B#=)58
MY"&RJ5&YDK45*A6FMVIW=,4$#'22//F3H#LUHVY[W:8QH+GN:T$C7Y3*XW"4
M+&3R]ZMCL?49XEBW;E;##&W8 !<XC;WN(9'&T.DD>YL<;7/<UIK.,WMWD.'E
M5$T[I'33D! ]V>M/0;;OC$W7L5I<.^25"@5]^C^L0L<^V-9W+=5%>-AXP3>H
M+</=L%Q0]5\5>1\@9Y8V*3Q<#C)!YMR-B)S3E+<3AIU2J\4V.#FS6)M=!YM[
M[RWV@_#B#>X5PV7L[-SQ&OR[/0$G3\+3L1N& Q]B/3X\E?B=DY(WL?6IU2?%
M%@->ZUI.K(!.M4:!:0<;YQW;LR8J.)"6D5NGJ96;E'1UI&9EG9@ SF1DG+EV
ML(%*97RR$(6KY3+Y'-6C<R5J2S-TAC.K38H(F_<@K0,#8J\#!V9#"QD;>Y#=
MDDWWC_&\+Q>@W&X.A%1K=;II2SJDL6[#]>+;NVI7/LW;<I ,MFS++,_0!?TM
M:!G6:U;Q,(F$3")A%Q7S%E*,GD;)-&TA'2#5PQ?L'J"3IF]9.DCH.FCMLN4Z
M+ALY04.BN@L0Z2R1SIJ%,0P@/TQSF.:]CG,>QS7L>PEKF/:0YKFN!!:YK@"U
MP(((!!!"AS6N:YKFAS7 M<UP!:YI&BUP.P002""-$=BJ'(>&]QZ3.T@W$ONJ
M4T]'R+>4C^-TQN:\27'IDNS>$DF+,FN7,B=%S7&$BFD]94N0D7E*;*I)$3KP
M-TRH!;3S?-'JF;'BH\F^,QOSD6+JQYI[7-+'N-YK 1.]A+'VF1MM.:3N;J/4
MJ^.,XT=,9?>=28X.9BWW9W8UI:[K:/=B[O&UVBV!SW0#0 BT %?A---),B21
M")I)D*FFF0H$(0A  I2$*4 *4I2@ %*       =,J!))))V3W)/F3]2K#Y>2
M\\(F$3")A$PB81,(F$3")A%4/EG^W<5/YO-6?T[?L(K>81,(F$3")A$PB81,
M(O29LW,NFZ,W1,Z23422<F23%=))82&5236$HJ$35,FF*A"F IQ3()@$2%Z$
M7&4BHQ601EE8Y@I*-T3MF\DHS;GD$&ZG7S$$7ADQ<)(J=QN](BA2&[A[BCU'
M"+S"/8 1(@,68$0<*ND" V1 B+I?SO.<I%[.B;A;U#CS5B "BGGK=YA\T_<1
M>A6%AG";!)>)C5DHM5)>,358M5$XY9 O8BLQ(=(2M%$2")$E&X)F3*/:00#V
MPB_74-#OFR[%[$QCQFY7]4Y:.F+5PV<.1.53U"[=5(Z2JXJ$*?SE"&4[RE-W
M=Q0$"+FF00.@9L=%([8Z0HG;F3(9 R)BB0R)DA 4S)&((D%,2B02B)1#I[81
M<-C#Q,8"@1L7'1X+=/.!BR;- 5[>O;Y@-TD^_MZCT[NO3J/3[1PB]"U>@')&
MY'$'#N",TP1:$6C&2I&J0#U!)N51 P()@( ($2 I0'WZ=<(NW "E  * %*
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MM?E8T#^8V6@]>>K3MVQ'8I"DZ93^P)1C6S&.=Y7I!/M&."_NR?L^]F[70XN
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M'U.*5#D:\+AV_P ;S,KZV"J-:[37B;)B5I/:%Q!"Z_T7*?8O7UTC2N/M=<@
MBTAB);/V<5(0Z&25EGR+*@0;DW41[V<9;2HCT%-R8P 8/3Q.%XK_ "<.2Y3;
M:1^4L$X7#=0[[;!$Z3*V6?3Q)J!=_2C V%C>#[4.0_Y>SA?9_CI #X-)K>3\
MG#==V26[#(<!2D)WWAJY8, ^&4GN.[K_ !?U7'2;>QVQG,;:N#8W>C;=MR[B
M\238X"!B#&1T@4M:@BHF 1;E@H*-\KJ(@(G$3CCVN99N:!].E)!@\>_LZA@H
M&8V%X^8FFB)N6>K^D;5J;JT >PTLW'^S+B]:U'D<K%<Y7F(SU,RW++;\W9C/
MR]VKV W&T6L_YMM&C6#.Y'Q$N-A"E203*0A2)))$ I2E I$TR$+T*4I0Z%*4
MI0      *'0/8,JQ)<22223LD]R2?,D^9)/ZUT !K6@ !K6@   !K6@:  '8
M #R'D JM3NW+=M68D:)QU,R,VC72L9<]X2;3U]*J3A,PINXBFM1,1.^W1N'0
MQDVYQJ\(H9$9>0<KF-&A=*V"H86O%D^6"4/FC;-CN-0R>%D;[':,=C(2#9Q>
M.?\ )SA[[9 =[O$QH$RI-G/9#.6)L7Q+PBR%[H<CR6>/Q<;0>-A]?',V!E,B
MSS+6'W*N2WQYG.=X2EC6&HJGJI@_)"%?2M@GG!9"W7:Q.AE+A<94"F 9"?F%
M"$47[ ,8C./;$;1<:B(H1S)LD)BCH\SG;V;EB-DQ05*K/!H8VHSP<?CX/^BJ
MUP2&[\Y)7E\TSOBED>[NM[A<#1P<4K:PEGM6G^+?R5N0SY#(3_.6U8< YVMG
MPXF!D,0/3%&P$[E'-,MTF$3")A$PB81,(F$726&RURI13N=M4_#5J#8)BL^F
M9^490\4R2*'4RKN0D%V[1NF >XG66(7_ !SWK5;-R9E>G7GM6)#TQP5H9)YI
M''R#(HFN>XGZ-:2O&Q9KU(GSVIX:T$8ZI)K$K(8F ?-\DCFL:/Q)"IL_Y_Z8
MFGKF$T1!;,Y2V-LX,U69Z"I3VRUAFM[E*I*;3G5JUJ9@T!7M(LM\\+K) 8#@
MU4 0 ;M'[.\Y!&VQR"?%<2JN;UB3D5^.K:>WS(BQ-<6LQ(_6RUIH,:[1'6-'
M50?SS#3/?!@X<ER>RQQ8Z/ TGV*S'?63)V'5L4QF] N]]<X;WTD+A ]\0;;0
MD,TB-)\2:L\[2G/.NWG(+<C1#H F.2-AU*OJ6(>* /0@'G+RW;G[N]-P4A05
M]/#]G&&^_/G>96V;^&!C.-X-[OD#+,+>9F8T_,04'.'D6D_#\!_/<J1TPX;B
ME5Q;LSO?GLPUNMNU'":V*A>>S1N:ZUO<_%H=7N;\!=;VM5*0Y&;!V]RGDRG(
MY&/V]='".N6K[N$ZJ\7J*C(5+7""*AA["(2<!,G21*5('!OKF/#O:)E*;71<
M9QN%XE$06^+A:#79-\?]%LV9R#KF2<YNM]45B#;N_2.P$MX)CK1;)R'(9;D\
MH/4&9:XYN/9(3MSHL51;4H-!\@V2&8AH#0[6]W#J%(IFOX1K6J)4JU2ZZQ(5
M-G!56#C*_$-2%*!0*A&Q+5HS2#M  ^HB7K^_*5=OWLE8?:R%RU>LR';[%RQ+
M9G>3W^*69[WG]+E;JE*GCX&UJ-2M2KL[,@J015X6_+X8XFL8/+Y-649B+)3"
M)D:'T"*,KII?4NQ.XUWUQ3+,N8![7TK7HQQ))"/4>]O*"W"1;GZB(@=!TF8#
M?6 0-T'-SC^0YW$_Z-R^1I-^<<%N9D+A]'P=9A>-#6GL(UV6FR/'<%EM_:6(
MQUQ_REGJ0NG;^+)^@3,.SO;'@[[^:K)4^/&T89KK/5[U36[?4^I=C-K] VZ,
M7G#;'G&\1+R4U#0[Z%5B48:*DW;AZ#"UV!O/OOC$69TFC'HJ/W )W&]RK"V'
MYC-1C,.SN=Q$F*M4)FUAB*SK$$5>Q8BL-G=9G@8V,2T*CZT7NTX872N;$WJI
MM'B>:KLPV%E=AVX/!9AF5JY"%UDY>RRO/-8KUY*YKMK03O?+X5VTRS)X\/6&
MQ-=(Y7HSFRZ6F$3")A$PB81,(F$3")A$PBJ'RS_;N*G\WFK/Z=OV$5O,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M1IM_<.MM#:]L6T]M6R+I=&JS07<M-RBA@( F,";9BQ:HD5>2<M(.#)M(R)CF
M[F1D7BJ35FV664*0<[&XV]E[L&/QU:2U;L.Z8H8QLG0VY[W'38XV-!=)(]S6
M,:"YS@%C7+E:A7DM7)F001#;Y'G0V>P:T>;GN/9C&@N<X@-!*^6&\[*Y5^.C
MNM;5^I&TUI[A;09QHO89>62$K0"(&,X:3MX]"Z%M;=A2*!16JVO(M\XAZWWM
MWKUV4J3VUJ]_J4./>R;%#(9)T63Y1<B<(8XS\9)'2Z&GU@.JTHS\-B[(QDMC
M18UNRRNN33VLOSV\:E,24L'7D'BO>- :TX/L%KB)K1UN*LUQ9%L$NUU3GZ6^
M+G%;3G$'5D7JC3==)$Q+82/)Z=>>2YM%UL H)H.[-;)9-! TE+.RIE(4I$F\
M?&M2I1L.QCXQNW:)<-S_ "#)\DR$F1R<WB2.VV&%FVUZD/42V"M$2X1QMWL[
M+GR.W)*]\CG./4,5B:6&J-J4HNA@TZ21VC-/)H RS/ '6]VOD QHTUC6L :+
M'9I%LDPB81!$  1$>@![B(_8 ?Q'"*!K=R4U'4Y4]91L"]UNH?52HNN(Q]>[
M8HL)A*""\=7D7B,0<1 >JL\[B6I *)E'! #J-FH\1SMZ 7'5&X[''N<GEYHL
M91#=;ZFRVW1NG&O)M6.=Y)&F%47+>T?B>*M.QK,A)FLR.S<'QRK/G<LY^R!'
M)7QS)F4W;!VZ_+4B: 2^1H&UBOS+R=V+T&JTJJZ-KRPB!9O9SHMUOJJ!S=4W
M+.BU&11KL4MY?7JG.7-XJDH( M&#T$N9GNG#L5OWW(WN26V^=;#,^SL8UX'=
MDF3O1.MSMW\ZV.8US1MLW<:U@R7M+Y#_ *+PN+X/CWD:N\FE&:SKXG=Q)%@<
M189CZD@;_0O9J5[7'3ZPZ2#[VO%RIS:Z,EN.T7+>DJDH1P1O?Y0A*8T<@/<<
M\;KJOH0]-13,;IT+)1<NX*0I""[/TZC\OYG>K-=%@*6/XU"X%I=BX2<B]GD!
M-EK;K&0<0/\ H9X&$DGH&U]1>S#$W7QV.8Y/,<ZM,<V01\@M-;A8I022ZMQS
M'LJ89C23H-LU;;P !XIUM6,BXF*@V#:+A8V/B(QDF5%G'1C-NP8M4BAT*DV:
M-$TFZ"90]BD23(4 ]@  RJ33S697SV)I9YI'%TDTTCY99''S<^1Y<]SC\RXD
ME=#JU:M*"*K2K5ZE6%H9#6JPQUX(F#R9%#$UD<;1\FL: /D%V&>2R%BUSNU4
MU[79"UW2<85ZOQB93O)*05\M,ICF B*"*1"G<.WCE42HM&31%=X[7.1!L@JJ
M<I!S<?CKV5MQ4<=5EN6YR1'#"W;B -N>XDAD<;&@NDED<V.-H+GN &UA9#(T
M<54EO9&S%4J0@&2:9VF@DZ:UH +Y)'NTV..-KI)'$-8USB JU%A]B<EQ!Q;$
M)[5>A5_K-*7YRL/LG:;,W:8J]T<M5 <TJFODS=I*LR<(V66;BK\;=1S59)D>
MWFQBN'_!1=5S?*&;#\B6ML8?!R D%N.8\%F2R,7?=V5CJ<#^GW9DKPZ1M/\
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MY&6*>.Y+3I4;V1MQT&!UJ6.G6?,RM YS)(XY;4C6PL?(UP'42UCW]+31^?\
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MQ7]W.N>/#-OQ_H/DJ?\ 3QKN=BW,_MR:9JD$4555MAQAEDQ,(-6X&["Q_*[
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M"%-V^6_52D[ (IIG6FE#AUS&N<KL&M)C<'5AX]BI6]$U>@YQNWF: !R>3?\
MXU<) .XFNAJ_$0VN!I9N+]GE,78<WRS(6N9\@@?XM:WEF1LQ>*D))(P>!BWC
M\<!\.IWMLWR6-<^XXA6,   .@!T#*HNB+]PB81,(F$6.VNVUJC0$E:;?-1]>
MKT0@+B1EI-<K=JV3 0*4!,;ZRJRR@E1;MD2J.'*YTT&Z2JRA"&RJ5&YDK4-*
MA6FMV[#PR&"!A?(]WF3H=FM: 7/>XAC&@N<X-!*Q+UZGC:LUV_9BJ5*[2^6>
M9P8Q@\@-GNYSCIK&-#GO<0UC7.(!K'Z?8G)D>]X%AU-H!8?U; #.(/:.W&(]
M!!60,0P/-?T*22. $8D,WN,ZT[_5C",7:::MQZ\5P_M'[IG>4MWN4AMG!X&4
M?T8@?@RN4A<.\C@_'UI/\F+,L9+:;TY;F6C)[W@^*N\HOBK9K/Q?64@^)B\5
M.TC\D.C(68^KK->*1H-HJU6:_3H.-K56AX^ @(AL1G&1,6V3:,6;=/KVIHH)
M%*4!,83'44$!465,=54YU3G.:FV[EJ_9FN7;$MJU8>9)K$[W22R./S<YQ)T!
MV:/NM: UH#0 +I3IU<?6AITJ\56K78(X8(&-CBC:/DUK0!LDESG';G.)<XEQ
M)/:.WC1@V7>/G3=DT;)&6<NG:R;=LW1('4ZJRZQB)))D !$QSF*4H>XB&>#&
M/D<UD;'/>\AK6,:7O<X]@&M:"23] "5[O>R-KGO<UC&@N<][@UK6CS+G$@ #
MYDD *G%IY\\;XB9=U&CV2=WU?FA_)&A<>:K,[?G/4@)@,V>2E6;N*9 *I 0Y
MEAM%J@D42D,954@%'I=JGL\Y1- RY?JU^/8UXW]H\EN086N&ZV',AMN;?L-.
MP&^Z4[!<2 T$JHVN=<=AF?4I6)\[?;V]PX_5FRTY=WVU\M9KJ4!;HEQM6H T
M DD:6.CL'GAMD/\ F^TIK7C36W G EEY"V@VQ=AG:*]/)>,=5:ED2UV/<E(/
M>+2P[5(LFH'EKL?8Q<R/LWV?8<_\I9[*\HM-&S5XU4&,QH>-[CDR^9B-F5NQ
MKKJXGI<#MLGEO'^T.<97_1^&QW'*SM]-GD%DW\@6'[KV8O%2>!$_I[F.SDPY
MKM-<P]]>0<(G%_$7')OD1NW?Q%Q$[VDHV FG-/JFZ?42_1]J<M<=R35 >OE(
M6NU6<%/8SD5U [\G^7C<=MO%>-8'CA;VCOFL<YFVCYN^TLQ[RR)[Q]YU2G5+
M?)G2-[?R+=?^+DG(,UG@[?72;.,/B#OR'N&*]W?(UOR%JW9WYNZCW5H]9:7U
M'IB'" U-K6D:YB1*0JS2GUJ*@@>"3[%9!9@U1<23D>HB=T_6<N5#")U%3F$1
M&I97.9G.3>\9G*7\I,"2U]ZU-8Z-^8B;(YS(F_1D36- [ !6;&X;$X>'P,5C
M:6/B[=3:E:*#K(_I2.C:'2.^KY'.<?F2I,S5K9)A$PB81,(F$3")A$PB81,(
MF$3")A$PBCS:&V-<Z6I\E?=HVZ'IE5BB +F4EUS$\U8P#Y+&/9H$6?RLFZ$!
M(TC(QJ[D'9_J-VRI@$,S\;C+^7MQT<;5EMVI3\,43=Z&QM\CW$,BB9O;Y9'-
MC8.[G!:C.9[#\;QTV5SF0KXVA !USV'$=3COIBAC:'2V)WZ(C@@CDFD/9C'%
M?/\ [NYB\BO$=G)GCCQ#UT_BM52!V[:XVR?;-V[^2B2/B*IR%JFU?61%%K*B
MS9)XWBV!WUNF/1^2U57567KP]QPW%,![/X8>0<JR#)<G'U.J58'.=''*6%IC
MK0CHFO60UQ8^60,J0]>W!H:+"_*7)O:%R[VPV;/#O9_B)8,%-T,R%ZTQC)IZ
MXE!;/D+3O$KXFCU,;*R"$RY"SX73$Y[G/I';VO\ 2SME8L6GYZGTRHNI+7SN
MN)<BXR\-[<P5L#B!;,',XGJY2 J4R@]?/%))=NB>2+&Q3CT:YOB;<BC$_*FC
MB]6S7RL%N[:9%?98/'Y:1J2"NV=SVP')B>W"YC&MC:XB,R2MZV[C)#U^@'_R
M^OT;G'[6/QF.EFQ,E-O,(,FW(0FV^HR)]MN#-3&V62R2NF>QAF$->3PW?EXP
M8S9;75&A=8T"DZXK@+A7Z%4Z]3H471RJ.C1=;BFD.Q.Z4(1,BCE1LS3.X4(F
M0JBQCG*0H"!0K^0NS9*_=R%C7CWK5BY-T[#?%LROF>&@DD-#GD-!)(&NY5RP
M^+JX/$XO"T@X4\3CZ>-JAY!?[O2KQUH2\@ %Y9&TO( !<20!Y+,LQ%LDPB81
M,(F$3")A$PB81,(JA\L_V[BI_-YJS^G;]A%;S")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A%IG\3'Q7JEQ&:.M-Z9+'[&Y13R"#
M-G!MTSR\)K097RB,)&VMV9O-D+*]*N12NTAL?USD5&TE. RBEXY"<Z;P7V>6
M>2.;D\F7TL!$2YTI(BEO]'47LK.>-,@;TD3VW?"WXF0]<@>8J5RCEL.&::5+
MILY60 -C ZXZO7KH=,UI!=*_?Y*!NR>SY UA:)*V>';X45LFKF',_P 04[Z_
M[LM4B2W5W6]S4)+F@9!4"'8VC92"Q#LWEF;))-_E^DI$&#I;-%B1ZV&8;-XB
MK[WFOM#K15CQ?AO13Q5=AK3WJH,0F8W8?7QY!#F5RXN\:T?RUIQ?TN\,F6?5
M\;XC*^;[;Y$76;TSO&CJSD/Z''[LUH$$.ET&F.N/R< #>IO6UL<'T3J*)()'
M55.FBBD0RBBBABIIIID 3'.<YA I"%* F,8P@!0 1$0#.+ %Q#6@ESB T ;)
M)\@ .Y)^0'<KI#G-8USWN#6M!<YSB&M:UHV7.)T   222  -E5EEN10VB2>U
M7C[5E=P6-DX,QE+.D\^#ZDJCH#&(?X]?%$5T9=RV'HJI"4QI89-0I#HK"Q/V
MFRWP<4]SACN\INMP%21HD@INC]XSMZ/L1[KBVN:ZNQX[-LY!]6$$AS?$&PN:
MVO:%]IV9L7P#%OY?D(9#!:R;9O<N)8J79:??\\YDC+<D1^)U'"PY&TX!S'^
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M+GO>XN>YQ.RYSG$EQ)[DDDD^:M[&,C:UD;6L8P!K6,:&M:T=@UK6@  #L
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MAZMAS05"K$;7&"JQG3P6B9U7\F]/[*/YB5='<2DS(*_]8^E'CMV<.A3+"4
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M#-6MJF$3")A$PB81,(F$3")A$PB81,(F$3"+\$0 .HB  '41$1Z  ![B/7_
M/<<(HSM.Y]44I04+1L*J13SJ)0CE)AHXECF#J':E$,U'$FJ;J'3M2:',(] Z
M=1PBPKZ0#>9  U[J_;&P 4Z@WD6M3-3Z^H?]P&FM@NJJF*?3H(JM6[LH%$!
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MRL+K!%E)1-8KFQ+-5E'25@MZS24<N9I\]!!TA#NWC-R]>OTHN/H+PL-HZGY
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MUEKYNGJ$9?MXA86PL)VU@.R;897%NTPB81,(F$7X(@ "(B   "(B/\ #J/\
MW![X14TWESPX]:-73@Y"SGNU[>OB1,1K_7S<UHLLG,*G!-.*228"HV"1\PY
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M>@ 1 XXU"4 1OMHV3LX3"!C-[G>9@(CN^TW2NUL]>KPD,/\ U:L8J4 ^K[@
M="*3:MK?7](3\NGTJK5H!Z=QX:#C8]=00#IW+.6[<CA<_P#$ZRJAQ_>8<>O7
M]B+-?L_PPBUG\R?$UT]Q@+(TVL"WVIN=,JC8E/AG@?!:L],7M24O$XAYA&*J
M1S <:Y&@[L"XE(F[1AFSI&2+T/B7LZRW)#';L]6,PYT[WN5FY[3-]Q2@=HO:
M0"/>9>BNWN6.F>TQKC/M$]M''N$B;'4NC.\C:',^SZ\H%6A)KL[*6V]0C<TG
MJ-* 27'?"V1M6.1M@:_M8\*.57B!6Z-WAS5M\_1M<',9[5Z T2^$3J\0] CA
M-G5:JY*[8T&!<D!!-:9GD'UNF$6R9W+5WYS2>)><ES#C/!JDF&X?5@NY#LRS
M>>?%@$K-M+[5IA9)>G:=ZA@,=2(N(:YFGP'D^%]FW.O:QD(>3>T?(6\7AR3)
M1Q;&^[VGUY0'"/'4'^)%B:CQTAUFVV;(66L:Y\<O5'<&^K5>HM;:2I\?0M65
M"'IE6C0[DHZ);B4[IR9,B:LC*/EC+2$Q*N2II^KE91T[D'0D+Y[E3M+TXED\
MID,Q;DO9.U+<M2><DKMAK026QQ, $<,323T11,9&W9Z6A?J;!<?PW&<=%BL%
MCZ^-HP]Q# TATDA #IK$SRZ:S8>&M\2Q8DDF?H=3R -2/F MPF$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB815#Y9_MW%3^;S5G].W["*WF$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$706>TUNEPCZR6V<BZY QB0K/Y>8>H,&#
M9,/L\QPX.FGWG-T(DD BHLH)4TB'4,4HY-.G;R%F.G1K36[4QZ8J]>-TLKS^
M#&@G0&R7'36@$N( )6!DLICL-2GR66O5<=0K,ZY[=R:."")OD.J21S6[<=-:
MT$N>XAK07$ ZJ=B[$V'S2Y#0&KN/;:$I-4T+76^R[OL[>.NG]MKTNXV:25K^
MN1I&H7TM57$[)F8URWRT39;9)1D=%L5%';>'=.W$8HMT^I4AX+@[EC+S&SD.
M0/;CXJ6#R+(+5./'2,L7X+>7A989"'234V6JU1LKGEK(W3@>,UG*WOJ^T_+8
MJ[3J6(L-QF6U=K2<@Q9-',SY"LVM2RE;#W!%--#7A%W[-MW!7=XDLT[:_2VN
M^?5!NOPQN1N\^>=7X\[5VSKYEJR5HTYO%O:-=U):D-'-1A[1%5VX15=UVY?V
M)K&7E*>L\5Y4<>=>U"$C;"I8(S]8M)5IQ?JGM+Q]3AC\K5I7I+E6U!AS4NVO
M>W.MR5I9:MFW>:V%\\)K0/:9C"RU*:XKR=@V=:&I[*ZF/Y59BKMI5VY)MC)N
MLUZ[8/ IFQ$+./Q]8!S*<#;4K9A4C>:S'V73;.Q /IQT-H/57&G6=?U)IRJ,
M:E3:^CT3;-B^8_EI%0B97T_8))0!=S4_*'3*K(RKU11=8Q4T2>4U0;-T?SYE
M\QD,[?FR63L.LVICW<>S(V DLAAC'PQ0Q@Z9&W0'<G;BXGNF/Q]3%U8Z=*%L
M,$8\AW<]QUU22//Q/D>1MSW'9\AH  3'FL6:F$3")A%PY"1CXEDYD91\TC8]
MFD==V^?N46C-J@F'4ZSARX.FB@D0/<RBIRD+^\P9]Q123R,AAC?-+(X-9%$Q
MTDCW'R:QC 7.<?D "3\@O.66*"-\T\L<,4;2Z265[8XV-'<N>]Y#6M \RX@#
MYE5AF.4$?-I2*6DJH_VH$81R,I>5GJ-.TY7"-2"=T[F-D3R:;&109H_YTNG4
M65C,9 A@%1 ?K!<8.'253$[DEZ+!>,6^#C1&Z_R"WUG3&5\16)DA=([X&F_+
M4 <1V=Y&FS<RCM^+'QJA-G3$'>-D2]M#C]7I&WNGR]EHCF#&_&6T([9+1K;>
MY% Y"W\@^9<B]K&HK2UN]0(Y7C;/M9FTL%&XDUHR1A1?Q=43;/&.TN3]C:_6
M$H-9RN:K2>%;%E'[ENJNP-T:*OQG@D<=K)T'8Z\6-FJ8NP^KD^;6@0#'-:#F
M287B%5^QOJK6\P6%YA:R1H>*'*[DG-I7UJ>1;?IA[HK=VJVSC>&UM'3X:Y:]
MF8Y588.^A8JXL2=(E+HW.8KP\;.$FG^.*PVEDV<7[;CYB+*:VW<6D8>R"U4^
MNM"U.-C6C.OZ^J95!.#>L4^.C68I=@2:TJZ(+P_/.5<^SO*?\5GD%##LD$D&
M'IR3>[=;>S9[DTTDEG)7- %UJ[+*X.WX+(6GH70>,\(PO&0)X(O>\FYG1+E+
M,<0GZ3W=#4AB8ROCZNR>FO4CC!;H3/F<T/5Q<I"N*81,(F$3")A$PB81,(F$
M3")]GVX11O:MPZLI BG:K_589R!NP&#F99GDSG_]1*+;J+2*Q_\ V4FIS#]@
M (^V$6"?2#83( &O=:[6V("@B5"0C:@M5H Z@#]AIV_N*JU%+I[@LT(\((>Y
M>X.H@1!EN2]CZ&C:CK#6C13ZO=;+#,7R=2 0]U/AE7:P4(53]X)_,CDA3 ("
M90H]P$7X.GK_ #X]]ZWW?711]S1FOV,#KB*#J("9(KA@SE;,9(>G0!-9 6[1
M']8'OU(NUBN..EXMV216HT=8Y8HE.,S=G,C>94ZH#U%87MM>3*I%3#[B9$4P
M ?[A2AT#"*7PB8L(]2)"-8!%+-U6BT:#-N#!5JLF9%9LHS\OTYVZJ)C)*HF3
M%-1,QB&*)1$,(L=A-<Z]K3\DI7*)38"33351)(PE8A(I\1)8O:LD5VP8H."I
MJE "JD!0"J   8!  PBS+")A%@&S=IZ\TW4)*^;.ML/3:I$D 74M,./*(=4_
M4$&3%LD55[)R+HP"FSC8UL[?NU/U;9LJ?VS.QV,OY>W'1QM66W:E/P11-V0!
MYOD>2&11M'=\LCF1M'=S@M3F\[B..8^;*YN_7QU" #KL6'Z!<?N111M#I9YY
M"-1P0,DFD/9C''LM"FU^=_)[G5<G^BN#-0L=4I:@^GL6Q%#A#V5>)554;J2D
MQ9"JG8:UK:Y.Y1!!HX7N,J5$$&;@CEPO7C]MQ?"N-\+J,S7-+=>U<;\5>@ 9
M:S90 X1PUB!)DK#3V<YS13BZNI[>EK; _+.>]J'-O:AD9>+^S&A<H8YWPV\L
M3[O>?7+BUUBU=V8L'2<-N8R-[LC8Z0V)XD<^BZ\_#;POM2\;31MZOHL]L[H3
M%-[\Q2C45*O4I$>XYQID,\()C/4E#] M$T1:9443!U'(5\%W#,U+Y9[1\IR#
MQ*5'KQ>'.V>!&[5JU'OL+DS#H,(_]FA(A );(ZQTM>.G^SOV)8#AQ@RF5\+/
M<D9J06YH]T,=,>Y^S:T@),K20!?LAU@N:)*\=+K?$=H8  >P!T#^ 9SA=M3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"*H?+/]NXJ?S>:L_IV_816
M\PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+Q.<B93'.8I"$ 3&.80*4I2
M@(B8PCT    $1$?8  1'V# !)T!LGL /,GZ*"0 22  "22=  =R23V  \RJ)
M;YYWZPU;!3CZNS=7D6\$Z/&3VQ;5-? -05.4 0*$>^LR*;J1NMB*)@.C2-;1
MUELKT"*)"1@8HJ!T#"\!O6WP29?WBA'.P35L96A%C/9"([/7!1<6,H5G:T<A
ME9*E5A(<WQAV/*LS[38))+./X75@Y#=K2.KW<U8G-3B.%G!Z2R]EFM>_)6F$
MAWV5@HKUR0![7NK$=0^>_9OB1[FY+[,0H7#S7ELY$;>47=?!MDV^G)N*Y3.A
MA1^-ZATBNNZJ5)8,P!%5'8^Y74]. B*:LG$UYV4?+[)5XQC,!C7R9BS6XSAB
MUHL4J=LF_D6]OR>9SP8RW==)MP.-Q#*U79(C=.S2Y_'6M9G)P7;LECFO(HWF
M6I8NU!%@L(\GL_C_ !HNEI5/#;H#*Y=]W(O#0][ZYVUNP?A=P?\ $OXXR=VY
M"6'=^JMD;FW*W@6^RM1[AFKQ-1+^+A"/7,$[=;@KR,R[AKI6#R+V)CHV%J%C
MI3>*D))DB_=I?#'##G?*.5<$S<=3#0XK)4<9BW3.H9+&14XI(WS%HF8W&3.B
M;+4L!C9)));,-MTK(WF-I#VOZKA,%RC&NL9&2]3LWKH8+-.[)8DC<R,.,1==
MB:]T<\1<6-;'#- UCGM#G@,+=E6C]'[C-N&?Y*<EK#0GNTG="+JBBT74Y9Y;
M76L]>KSS2TSR2,Y:FL?/VZW7"?CH9S8)]U#P+-NS@8J+BXI-!)9=>C97+8T8
MR'!8*&XW'MN'(V[F1,+;U^Z(75X28:[GP5JU:&25L,+99GN=-)))(20!9J%"
M[[[)E,I)6=;-?W.O7I^(:U6L9&S2:DF:V6:>>5D9ED+(F!L4;6Q]B3<[*PMV
MF$3"+$KG?*9KN&6L-XLT+5H9 >TS^:?H,4E%1_N-VY53@J[=*#T!%HU36<K&
M$"I(G,/3,['XS(9:PVKC:=B]8=W\*M$Z5P:/-[RT%L;&_P!*1Y:QOFYP"P<A
MD\?B:[K>2N5Z5=O8RV)6QM+ODQ@<>J20^38XPY[CV:TE0-^F3:6S>J&B=9K,
MX)?_ *+;&XD)&JU-5'ZI@=5RDI@C?+019,QA:KO&E5C#J%^M(&3[14LW\G\+
MAOBY-F&OLMWU8+C[XKU\.';HMY(]6+HEIUXC8WWI@#VB!WJL#D&:S/P\9P[F
M57C;<[GVRT:):=$/J8T!N3O!S=]#I&4H21WF+2-UJV],:HUY9H>M;@G+WS*Y
M'32:<E2>/-:9,EV*:@'*5*9+K2-6;4>BU5J4PF=7?:TFZ129-W"C:3D'I/2+
M6?"_;.1ISV>/U<;P+B\)=#?Y/8D>+#FD.+H'9F9KLCD+C_Z-##0Q;E>QKXHX
MR'MKF5@Q%*W!!R&WD.=<EFU+1X]#&SW5CM_#,S#P%N/HU6#N^]EY)B(V.<V6
M1X+#ET+Q:V3O]6.L/,Z8B"TMF9LZK/$/6+YRVTQ I-S)KQH;5FTTF,GN:PQQ
MDVWF1ZZ<5K9@\:F&-K4DBIZQ763\LQ?'1+7X/#.Z_('LM\URS&R9RR7]0E.(
M@<9(L)6E#GZE!FRDD;QXMJ)PZ!N(>+Y'.F*?F$L+:,98ZIQ'%O<S#UVMTZ,9
M69H9)E[$>F@QZBQT;VN\*O*UW4;_ ,;&1T-'LHF'8,HJ*C6J#*.C8YJ@R8,&
M39,J+9HR9MB)-VK5NB0B2#=!--)),I2)D*4  .=RRRSR23322332O=)++*]T
MDDDCR7/?(]Y+GO<XDN<XESB2222K['%'#&R&&-D443&QQQ1L;''&QH#6L8QH
M#6,:  UK0     %SL\U]IA$PB81,(F$3")A%U\C+1<.V.\EI)A%LTP[E'<B\
M;LFQ #[1.NY422* ?Q$X?N_B&$4,ON2FFT'*D?$6L]TE2&$@1>OH6<O;LZH#
MT\KOJ\=)LT3=?;N=.D$R_P"D<H81<(-J[5L ]M*T%9FZ"GU4Y;9MCKM%9IB/
M;VJGBF+BTV4Z?01,*9XALKT#M,"9PZ81 K?)"Q>TWL>@:_;& 0,VU_3WEEE0
M*;W$I9Z[/0CRG+_=\PM3_=U*4H]!Q^S\40..=9E?>_W+9^S.X0.=I:[Q)LX0
M5.H"8P5RI?+4&8@B'0J3ABX(4OMT'[<(I)JNL-<T8@%I]&JM;-_I+Q$'',W:
M@].G<L]2;@\7.(?:=9=0PCU$1$1$<(LZPB81,(F$3")A$$>GN.$6M#F3XFNG
M>,!9*F5DS?:>Z$P.V+3H9X7X+5GAB]$U;S.(>:FP42,('&NQWJK N()I.T89
MLZ2E"=#XG[.LMR,Q6[(=C,.?C][E9^6M,&]BE 1MX.O\XDZ(!W+'3/:8CQCV
MB>VCCW"1-CJ)CSO)&[9]G5Y1[K0D([.REINQ$6G1-.'KMN/2)6U8Y&V!KXUE
MPKY6^(/;H[=W-*VS]$UJ8QGE7HK9'X1-N(AWV.$V=0JCHCME0X-PF*2:T[8&
M[ZV3"#=)1=J_\]O/)WK(\OXQP6I)AN(58;N1^[9NN=XL+9F@M+[=MA8^].T[
M+8*[F587$AKX^ET!Y/A?9OSKVLY"'DWM'OV\7AB3)1QK6""T^O(0]L6-Q[Q)
M'B:CQTAUNXR6_98QA='/ULN-WV:HT]K31U.84+55/AZ95X_ZY&$4@8%7CHQ"
M)JR4M(+G6D9F5<$33!U*2CIV_< 0@*N#%(0"\2R>5R.9MR7LG;FN69.QDE=L
M,8"2(XHV@1PQ-));%$UC&DG31LK]38'CV%XQCHL5@L=7QM&+XA% T]4DA #I
MK$SR^:S8>&M#Y[$DDS] .>0 !)6:];E,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$50^6?[=Q4_F\U9_3M^PBMYA$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(JT[YY8:>X^1L@I;[ U=S[%A\1/5X]]')/FK,P@4DC8)*2=LH.H
MPW<8HGE[-)1C4Y1[&7K71DFJMJX_P_,<A+9:\0JX\R>&[)6A(VN7CSBK1QLD
ML7K'R%>E#/(#KQ!&SJ>VC<H]H."XQ+]GDS9C/R1^)7X]B1'/D7,.M3W'O?'4
MQ5(;#GW<G8JP!N_#=*_IC=\VO)CQ=]A;]M!=3\?J?*;8EYUZ:-@Z+4HZT*4-
MZJ<#]A)%G&)16PMQ/FIA(==%5.C:_;.F .S0]RACBX7[O@^!XGC5<W[$S*3H
M6]<^;R)K"_'K6S3CD=-C\*QW?HE=[_DG-?TB:E*.D<;RE_D7-9A#G9"^A,[4
M'#L%+9;C)&[+FLSF0C;!DL_,SL):M<8[$"2)KC#>A+B^2-#^"]R*Y,3D)M;Q
M$=JS4#&-6R24)IRI/84]ABX8JA5T8(JL,V/KO5T$)^Y12MT6(D53D74%16O2
MOFF"O9KVI8C#LGI</HLLSR/<ZQEK8F,4LQ[&9WC.]^R,V@-3W)6 %HT)HM!7
M_#>SZS.RL[,2,HTZ[&QUL529!$((&Z+88F5VBG1AV"3#5B/GV\)^]?1AHWCO
MI3C93T*)I#7%:UY7$Q(HY0A&8_$)=TF0$PD+#./%'4W8I,4RE(:2G)%^]%,I
M4@7!(A"%XGELUE,Y9-O+7I[LYV&NE=\$32=]$$+ V&"/??PX6,9OOK9)74:&
M-HXR$5Z%6*M%YD1M^)Y_UI9'$R2O^75(YSM=MZ"FC-6LU,(F$45[$W5K35OI
M6]OLS9M,R(@2'JT8@[G;=-K& ?+1AZM"H/IQ^90P=@*HL1;)F'JNND0#'#=8
MKCV8S76['TWOKPC=B],Z.MCZS1YNL7;#HJT0;V):Z4/(^ZUQ[+29;D6'PG0W
M(76,L2]H*4+9+5^RX[Z6P4J[9;,O41H.;'T _><T=U%GS%R.VMT+4JVQT!3U
MQZ?,^P6S.S[0>-C=!*O#T&.>JURM+" &3[K=,R;M(3%4/7A[>T=W[KQ+"=[U
MN7E-]G_L6*?)2PK'@$%MC*2QMN7&@D.U0KPL=HM%H;VM+[WR[-]J-.+BN/<.
M]W+,CNYJ1IT0ZOBX975*;O-I-^Q,]N^HU=C2]+_7&@M!1LANK<EJ2EI.N("Z
MD]O[ML*$Q(191$ 31A/B!4(6NF45$48Z+J,/&N'*J@-6Z#E=4"GAN:Y+R22/
MC^#J>ZU[3NF+ \=JNK0SGYNL^&76;F@.J6:_8F:T-ZW.8UNQ]#!<;X\U^>S5
MHW+59H=)G.0V1:FA[CI;6$@;6I[=VBBHUX7N+NAH>XZ,.AL3DARY_P TTDRF
M>-''UYU(XWO=H$J.Z=BQBAA_7:8UK-(G3HT,^0)U:W[9;'XLJT?MWT!3"KH>
MK+M?LSC'#/BSSX.4\DC.V\>H6"<%C)0-ZSF4@(.0GC>1UX[%R&$/C?'9NECN
MDX7VAR+EGP85L_&\ _8=G;D &9R,1WWPV.F!]RAD:-MOY%@E+)&25JO4TN%G
M](<=M4\?(5_&:YKYT92?<A)7*[SSUS8]A7^;'N,O/7BZ2IW$Y8I1PJ=583.W
M/HF9EE$HQFQ:B5N6J9[DN8Y)/'-D[(=%7;X=&A7C;5QF-@[!M?'T(0VO5A:T
M-;\#3(\-:99)'#J5EPG'L5Q^&2+'5R)9W"2Y>L/=8R&0G[ET]ZY*3-8E<YSG
M?$X1L+G")D;3TJ<,T*W:81,(F$7'7=M&I1.Y<MVQ"AU,==9-$H!_$3*&* !_
MK'"+#93:&M80##,;!I,7V=>X']I@VAB]!Z#U(N^(;[?;[/MPBCB:Y3\?X5H\
M<J;2JL@9H@LL+:$?A-.%Q1(8WDHEC"NBF45,4$D^\Y""H8H"H4!$P$4:ZLY>
MH;0JJ$C ZJV%8K2DY<M)F$J<:S<PL,MZA88XKNUS\C 0Z?K8\&[H2><9RB<Z
MQ3-O+3*HH121\=Y)V0 &*H>N=;MC )15N]JD;G,%Z]!!0L/36L?%$$ Z]4SV
ME4.X/<W;["]%%^CJ79<_T->-^7+RS!U/%ZVAJ_KV.*8>G<F5\+6PV<Z0!U*!
MOCZ2@_WNI>O:5Z]>OW=RYT=QLTPS=$D9&FH6^6*(&-,7^1EK[(JJ@!>JQUK8
M^EDR*")0-^H21(4?[A"![8130QCV$6V39QK%I'M$B@5)JQ;(M&R10#H!4T$"
M)I)E    *0H  >P!A%S,(F$3")A$PB81,(F$7J661;(JN'"J:"""9UEEUCE2
M2122*)U%55#B4B::9"F.<YA I2@)C"  (Y(!<0UH+G.(#6@$DDG0  [DD]@!
MW)4.<UC7/>X-:T%SG.(:UK6C9<XG0  !))(  V5"%KY.<>:3"2%ALNY]<1\7
M&UUI;%U$[9$/W;BN2#YU&1TM&1L<Z=R4PTDI-D[C8TT2T>FD)!!1DS*LY#R\
MW-;CN>N3,@K8C(22R6'U&CW65C6V(V-EDBDDD:R.%\<;V22>*]@CC<'O+6]U
M6+_-N(XRM+;N\DPT,,-./(.(OUY9'TII9((;,$$+Y)[,<\\4D$!KQR^-,QT4
M0>\=*TE;7YX\GN=%RD-%<&*C8ZM3%/\ -K#L4YAAK*XB55CMU):6L8*BQUK6
MER=5$$6KA6XRA$@19N$G;A:OF[#C.$\<X74CS7-+=>S<'Q08\?EJS90 X10U
MM"3(V&_=+GM%.(GJ>TL:VP/S7G?:ES;VGY*;B_LPQ]RCCC\%O+;]WON@<XL,
M]FZ'&'"47C;FMCD=DI^CHBD$KGTC>3AOX7NI>-YHV][ ,TVWNA,R3X+#*-!4
MJU2D.HJF&G0ST@F4?(JFZ!:9HBTPJ=,KJ.;5_P Y=H:F<M]I&4Y"'TJ(?BL1
MHL\")VK5IG8?XY,P]F. _P UA(A );(ZQIKQTWV=^Q' <.,.4RQCS_(VELHM
MSL+J./F\S]G5I!\<K7'_ #^RTV"YOB01T^M\9VBYS==O3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB815#Y9_MW%3^;S5G].W["*WF$3")A$
MPB81,(F$3")A$PB81,(F$3"*-]H;>UMI>L.[ALZWP]0@&A5!%W*..U5R=,G>
M9"/9)%5?2+@"?7,@Q;KJD3 RJA2)$.<NTQ&%RF>MMI8FE-<L'1<(V@1Q-)UU
MSS/+88(^_P!^9[&DZ )<0#HN0<FP7%J7O^=R,%"!SO#A:_KDLVIC]V"E4A;)
M:N3N^4-:&636W%H:"X?-KR\\==]8W[K6G$NO3#MQ)JA$L;&U057L,N_77%!%
MM&&8%>';"Z[BE2:5M&1E'@&)Z*T0SH3(D[[QOV2XW%QMO\DF@R%F,&5]8DMQ
M55K6]1=*7F-]QS""2Z8P56G[\%EHV>&9KGW*N5N-7#,M\/PDI\,6 V*7EV0:
M3K4(;[Q4P,<K3H:%W)[;\+J3W;;%&BO"-YE\S91AL+F?=YG26LWDH>=3U\4P
M.MB2IG1.Y1\A67"KV*J<B[25,U6LU_6G;X;R1)+03U(Z+HWIG_:C@,&'5>/P
MLS%^.,0-M:$>.KL;H-B;)&V,S1,UU"M09#2V=QS-(+5N.,>S*9D>YX_LBI+,
MZS8:7.GRE^=_=UFW-.Z6:2S)L]=J_-8L^;3&6=.OI&XR\,N.7$.M!7M&ZXB*
MVZ<-$&L[<'A"RU[M(H]#"K8K6\(>3>)G7[G)(Q!1I!LEE#_#(IBD()!PG.\G
MS?))_&RUZ2=K7%T-9GY*G7WVU!6:?#80/A,C@Z9P \21Y[KL>+PF,PT7AT*K
M(G%H;).X==B;7SEF=\;@3MW0.F-I)Z&-!TK1YH%M4PBBK;.Z-?:3A&<[?Y99
M@A)O1CHEBQ8NY25E7A$%'2R3)BS244%-JV24</'C@S=BS1 #NG2/F) IL:&+
MMY)MN2NU@@Q]9UN]9FD;%!5@#@QKI'N[N?+(YL4$$39)YY'!D,3SO6NR&4J8
MUU..PY[K&0LMJ4:T,;I9[,Y:YY:Q@TUD<4;72SSS.CKP1M+YI6-T3$A^9^DI
M",8+TF1F]C6*504694FH0CQ:S-Q265;J_,))0L9%5)!!9$_FO+/*1391#M=,
ME'C=5NHMOHN$YK7O%XT<5C.F.1N8R%V&/'S131LFB?3=$Z6>^9(GM<V.G!,\
M.)9*V-S7AM?EYQA=^[T6W\KD^J6,X?'TII,A#+#*^&5EQLHB@H".6-S7/N3P
ML<T"2(R,<PNP:5N]YOG<;8V[=;\;Z<J8>^J4B[U>=VHY0[?K-IJ_22JD!75N
MI04.E4822<D*84D[#["<?7WOB6$_S"G+RG(,\KN6CDIX5CO]:#$Q2-N6QW(!
MOV(6'74:GD%Y^Z<NSG>_<BXK0?W]RQ+X[N;>T]NFQEI6.IU#L=1%&M,\ ](M
M>97>4.[<.-4*/%:7:*FXG9$3?&;,T5F;W<YY8>AU59FTD1GI^4.LIU5\I9\9
ML50P^G03*)2AI<MR',9KPV7[DCZ\/:O1A:RMCZK?(-K4:[8JL(:WX0YL7B%H
M^)SCLG=8GCN'PGB/Q]-C+$W>Q>F<^SD+3B=N=9O6'2692YWQ%KI.@.)+6M\E
MBNQN<<2[@Y2/XN4B<Y%;$:O_ ((YCX>.G8FIT>04*8"/M@R:D2I.-6C<0.I\
M(K\'+33TS=5MY<<4X/4O;&8FEX\4G);5W!XU\?CQR#%7+%S(QC1,>,88HJCW
MO! $]FU!7CZVOZI-%A^,CE;?@R1\>K5,UD&R>#(PY*I!5H/.QXF1<)9+36-(
M.X*]::P\M<T-C^^(;H&M9^?MT3N#DEK;=_)+<<4OZ^JQ\I3:S2=%:D=J?K/*
MU1K>TW1!-J_;@9)L>^W$D[=I#T;=T1]$&[FA=WD>9B"G/A.(4?Y-X28>';E;
M+XV?S3!VWF,HUK'&)YZG_9](5Z,9D>PLF;IRU./XFZ6U%E^4W!G\O$0^M$Z/
MPL+B7'OTXK&N+F"1OPM-^V9KDGALD#H7;:KMALK=CL0^'<<9-NF;KV*6/9]$
MBN@=/854H=:RKI]1]A*5)00]AZC[Y1%=%^C+\G7_ -9K2=+UT@@(@68OEOGU
MR]0]@,2*I48B82C[& KGM-_HG /?"+Q&(Y/O^H.+OI:ND$ #K%4*X3RQ $?<
M2J2EWC$C'#[.HM@(;V'M*/7"+]-K?=KWVDN13]F0W7O)5M94F*Z /3_HU9PE
MI7((#UZ"*I_80 0$0ZX^?K^[]B)^@N9=!UE]^;T?G'KW@SL=9KJ9NH]1[2UZ
MH1JJ0=>O:!%P H>P>P>Y%Y?1MU^Z+TGIC:%IZ@(#\P;;V,Y(;K]O<W:6-BTZ
M"/\ H@@!?W 7^)%[6_&#03<W>?6%<?GZB85)HKV?4,(_:)CS;N0,?J/N;N$>
MX?<>HX19I%:@U1!B4T-K.@QAR>Y5&-0K[94HCT$1!5*/*</< 'V-]H=<(N7<
MM:TJ^U60I5DA$EZW*"T%]'QZ[J%\X&3Q!^V+ZF&78NB$(Z;(*&3(L5-7L BI
M3D$2B18WJW1.L=,*32FNH%S!FL)&!)8%9R=EDW(1AG9F0@E+R3Y)$Z(OG0>8
M@1-0Y5>TYC%*4 (I>PB81,(F$3")A$PB81,(O ZB:1#**'(FF4!,8YS%(0I0
M]Q,8QA H  >XB(@ 8\R  220  -DD]AV"@D $D@ =R2= #ZDGR5:]C\R.+6I
MC*I7S>NNHAZ@!A5B&<^WL,\02=.XHU^M_%YL#!U >WT'4?W98<?Q/DN4 =1P
MF0F8[RF? ZO =^7^,6/"A[GMV>53<Q[1.#8$EN5Y3AZ\K20:\=MENV"/,>YT
MO>+6QH[_ "/R/T*H=L;QK>+-6,X;46O[(V>Y3[O(?,H5G4J\L)>H?K'MI?,K
M @ B =#!55@Z>_3[.MVQ_L?Y+9#779\=C6G[T;YGVK 'X,JL? X^7;WH=SKL
MN79C_"1X/1+V8NIFLV\;Z9HJT>/IG6]]4M^6*VT=NQ%!X/UUW5?8SQ!-K<P+
M+6M<6GB?,1W%^[6ZJ0&RIR-2VE9'J$%)V*,:QWJK?4V=7BDHMU-J1:,[&.(M
M^REX95]%/$E&;M8V;R7@N,XI7L9"MRB)_)*=2S/CX)3BZ[#/'7D?)TU+3[4I
ME9 )'02MEC=%,&2L/6T!5*+VL9SV@W*>&O\  [$7",ED,?4S5F!N>O2"K8N0
MQP"3(XZ*C R&6V8&VJ[X)XK-4S5YFF*1[E:;F97-([8TI<Z$AJ6F.[93=D:\
MTKHGX(T3!^YGKDVJKY-.IC6V\2K"1<97)N>>*1YWCNM(-JXM-R""Z+,K1*F<
M&RN8JY^6P;]R&HR"[D,ZZ>4NCDAK0.D=);;9$@?*ZR:\(<![RY\XCC>UTNUT
M[VK\?XU>XA!4;A\;8R,UK%X?BL=:N&31VLA:C@9#CWTC$8H8Z0MV2USO<8XZ
MKK$\3V0:6QK5&GM::.I["AZJI\/3*O'_ %R1\4@8%7;HR9$U9&6D%SK2,S*N
M")I@ZE95T\D'/80%G!RD(!:?D\KD<S;?>RER:Y9D[&25PTQH)(CBC:&QPQ-V
M>F*)C(V_)H))/2L#Q["\8QT6*P6.KXVC%\0B@:>J20@!TUB9Y?-9L/#6A\]B
M229^@'/(  DK->MRF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$4"V
M3DYHVI[WUYQFFK]&I;RVC#V*P4_7[1K)R4JYA:O%NYF5DY9>-9.HZM-#1\?(
M*QBEC>1039V#U"']<NU733(HGJ_B'<-[EN>V\?Z]N^!>;1I(W1*=AUXBU1L,
M+O7#4SZ_QT/=).!9TJR2E,9)K/+)%UVP2C^+:-7KARW(BQ>'0(N#3/$5XF;!
MUO);3J&PI66K<=?M<ZS!@I0-@1%OD[CMXM><:MCH&D3E9C+9.M[]%6J$L%8D
MXN(=1DC7'*\X1V6/CY%9J]>O7]:*\'VX15#Y9_MW%3^;S5G].W["*WF$3")A
M$PB81,(F$3")A$PB81,(NOEI>+@8U[,3<BQB(F.;J.Y"3DG:#%@R:I!U5<.W
M;I1)NW13#W.JJH0A0^T0SUA@FLRQP5XI)YY7!D4,+'22R//DUD; 7.<?D&@E
M>%FU6I5Y;5RQ#5JP,,D]BS*R&"&-OWGRRR.;'&P?-SG #ZK0=S2\=O3^ICR=
M#XRLV^Y+^F8[%2VB"I*!#.Q$R)@:*@";JQNTE0,"9FA 8 N5/KZY!7V[5Q7V
M/6[0CN<HE?CZ^B]N,KO8;L@&B/>9_CAJL(^]&SQ9]=37&N\=0X]GO:=9M=53
MA]>/H.@[D.5@E%4-.^HXK%ET%N_(!KHLW'4J ZF30#)Q=4:UT:XX">(UXGEG
M:[7Y0W&9U'JV54;O$)"[LW2$R_B1."Z+>C:L*LQ=IL^U0RS!]:5J_$(D=&>0
MH2:(&9'N.4YYP_A-1V)X_6@MSQ$@4L:YK:D<H'27WL@?$\:3L0\L-FP[I#)'
M1]B-'A/9YE,S=^VLQ/:EN3L ES>8/CY*6)Q+O!HU0V&&C5)<2RO4AH4VAW6R
M*1Q=U?1?Q&\.CBUPRCVRNK**E)WWTAFLIMBZ"WL&PI/S2E*Z*WE#MD&5;8N
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ME7E+%*J&'H1*+K\6B\F) YS"!0%LR43*(]5#D* F#Z#7'R!U]?K^ ^9(UL@
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M@^X^Y_W.[V_XC_\ '_E'\WOL_P#]L6?[XPG_  4_GD]LG;_U93>?E_)CE?\
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M''6.S:.'SYTDBFHY<*'(NXYM\G-=:.T7HO5G(S56U9'C!R"UVUHNVMY:VD;
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M=LV0;'?/ 01;"]?*)$(9TY!LW;MQ<N!.KY""*0G\M(A2D7,(<BA"J)G*<AP
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MN_U5ZYKV;I$=9@O8RLIKUHV8R5;UK#4.' SJK$%M+HP2[-26=K.USJCD?/\
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MB81,(F$3"*+[9I34M[OVO-I7'7M6LFQ-3*3*NM;E+1:#N>I2EA;)-)H\ ^4
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=1,HQ6D8B,>*(C]4R[%N<?=,,(K/X1,(F$3"+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g65062g14w92.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g14w92.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1> 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %V2^68@X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M ! #O_XU  (  0.__C4  @ !.$))300F       .             #^    X
M0DE- _(       H  /_______P  .$))300-       $    6CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))300>       $     #A"24T$&@     #
M-0    8              M<   =D          $
M     0             '9    M<                      0
M               0     0       &YU;&P    "    !F)O=6YD<T]B:F,
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M;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   +7     %)G:'1L;VYG   '9     -U<FQ415A4     0       &YU
M;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%0
M   !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0
M   !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '
M9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@
M  =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R
M5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S
M971L;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U
M='-E=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M     0$ .$))3004       $    !3A"24T$#      ,V0    $   "@
M/0   >   ')@   ,O0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M     ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04
M#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,_\  $0@ /0"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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M-*+ONQ^J#<UE+GM#B6/.8\/@?1T^S^SU-N]S'JX
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M0G)SD]/A-$-58H*4LO$6-51C=**SPP<DE<+BH[34%T1D@R5%A*3_V@ , P$
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MT/92R%^%#Y[[^4LK+:MH.CL'C$M8CK%ME0'>[:1NKM,S,69>R+=<B8RX78D
MC+;'4C+G9O*+UEFM0S2<JJY7,Z@0 VI:IWHKM>[%WE>],Q)X$%3@MEG-%"\2
MO6ZB6YN;%LFG=BV]BDFF:_9[88#F:05K0F9()%FJ40L#9"-ERH@_12(W.&,Z
M,P^$LXHK<:Z]L%4+VKUJ#;Q5BV;R%[=I72ZMQP%4W0A4_"/*M6EK$W+MRP,H
M57)+961@5:S<=5,,Q!4JI).4M(.4"14;I?:!MC%[W@5LFZZLE5"O':4B@Z9;
M]SZQ%!&1VO#]SB5@8<U>'UG\:<$3 $"(KKYN-;RD_$:+BQJ'EF%J%/7NX.T;
M.$2WA7^&LX M=M8;$,Y:^EHW"N(;$>3EBS&$-I5D]7F4@-2W<N3==KOQ+N("
MH[VPF5'N*@*+:ZR H&N<D_&U&AUV.W;LE9H@:R K F 8J6OVQFK+'*$!+5J^
MQ'=T;2H5AF;/)6FRTH?&-UT76:L(M%9D'0@&+>+'5P :TNQC<*P6"?>G#A53
M/<9EN7BV(0,UK$6UPMB\BX=;=N\Q5VN.UNX$=S:2X[6P5*(\JN0'R@!@@%MH
M#VF:XR$W2S(.R  5E1F(4-Q,]'=M+9TX BX.4#6T0(SA >1 7L.--3,/2^S_
M '+=, U"O05TO1VJ3(?JD. T41+)M.@+'DZZ0AK +AF\FZ*L!S:%Z^7G,";)
M6$&-M85E-E\EXW0+I)0JI#VRF4YY2?*[D!NK0+L06YV7NALX)0)*02,PAI#=
MGM1ZO=N6Q'S=>B*S2PBB\N93#5G/$T0]7T@M&,S'$V.T.#YY<<^J3'C0:D.]
MEMM6*I$;?8P(6+:U3I,IJ#H_1-M$9OA7"@751%)Q%Y2B]BUF56 !+7#UN&MW
M%M([-;  D,4QRQE!)-MF:1:1AKF:"1J(7LW"N8@!SO4SIW:GV9MA%?C0J]7:
MP"O%J9U9#*ULS,)VABQE>S6;WS"NE4G%P:@!.J3%@\#:RJ<&3*.@CXRRJ6*=
MA9&D>?$]&V<.E\"[=:[:LM?U1%3*N-7!FTX#%ENC/F>"0CHUOM3F72W?>X4.
M10C,%W):3;+AAH 5D$#34$,"(AO=%!AF!](J,.PSR90['K@=LQ/->A^MI!+$
M!C,W)#,"+"B*E(D9<:=6U&;RXI'ENY<=4XZOQJZZEO"E.%*<*4X4IPI3A2OS
MBQN_<%;LV_\ 89V1L$YKW5^R;%3*\!5C15?U+(\K%3  (1ZPH%3]VB61AFTX
M-V.SN1)8L8-@39JVB$&+@;+]PX3#/;P=A%LI?Q%BW==QY6^)_G'<HF<85B5M
MY4MZ,S$"5)+#CZRZIO.2S(CLJJ>J6WP !8 W!!,DQI!F140L/;5V"&V>4A$Q
M$&""UF\?@;"JM2DP[9 LT^EZ][1]S,XIEL)  921@EC7].@N,/#QSP2R"C==
M>2[EB?)F[6^B;#X96#DO?"-8NW ;907;^ LIUMM7=1E-^Z1#-G1D<'50,'QC
MK>RQV48AU49LV6WB;A*,0"<PMH.Y@R\S4TN';J/:[4:&VS5];)G1"75,9U_L
MM^TUPXY#!:UV&6%A3DRC@GY1\7J"VW?8BA*A2'9HO6TI^,O$"P1)L#&UT0M_
M*UO$7%1M^NL"W<0%[]A'=!=>+;XJW9L9LVC7P#JA#:OC#;G-;5B!^8^920J.
MP#%0 1;9W@[BW.@818SO:A<L K49X4,.TX+;]D4A)*PG:R6:HYC66PL6%%#E
MC+Z;"#ZU(*VV._1Y;XX1/>(@S)QNMK??DXRN5@.C\C8E&9+KVK%Z+:.O6IB+
M&3K@UE6+A;1ZT9F 5U0O $@7.(E;; %0]RV"Q'8-MS"D.84E@5V.A.DQ58Q^
MV5;PMEV'!>"5*ZUFL72^3FC*[E'KA=^B5[:]8U0P$H@0?5RL6\6"$;-2HS69
M1D7B?8(T6IOSF21:-(B=!Z+M-;L$/=M7+EFRI7JBZB\^'N8DM>9G4VD*(I("
MME0F[&52#08I@7$*X%Q]<P4Y5NK:A  <Q!)U)U("S)T_2#CPJ[J<*4X4IPI3
MA2G"E.%*<*4X4IPI3A2G"E.%*<*4X4IPI3A2G"E.%*<*4X4IPI3A2G"E.%*<
M*4X4IPI3A2M2?!BK."-5H[$20"6$21!F8"W7V$S11:&] (Q%/1G6)+*9,20\
MSEV.\R^WA>5M.MN82O%D=K;I<0Y71E=&T,,I#*8((,$ Z@CF*AE#*RL)5@58
M<P1!'I!JDAW9;TF+#DPS%<L4KULJLY>/F-F;1L%ZA(I<YTG4HX'8QZYDK]68
M5;(R9DT+!KMD%PA\D@3=C,-J*$,R>MND,6S*Q=!EZR$6QATLGK5"W2]A+2V;
MAN* '-RVQ8*H).41EU%J&&4]K+KG?,,OQ<C9LR1N A74D[DSJB/8][.Q9IF.
M0H$A^$T$? N#,7;8+ B>Q*$68#++&1$>U-#3MOF![E:8$R]FHL^ZRV#D_P!)
M/NK=PM-EZ3QRF5O0V<.&ZJSF4AK;A58V\R6U:U;*VE(M HL((J#A;#  I("Y
M8+.000021FAF(9@6(+&3KJ:X+1H7LX4:E6NSVX+(&UZOA;!:+5=35ZV#.LT&
M#!?I5I(V65>9=GE73UP"5J>AO@3K9I1ZM0Z8"&5F8.@PF8>9M8S'7;MNW:?,
M]QTMV[*VK(MLS"[;6V+(MBUE?RF\'0IEN-==G#,Q-5:SAT1G=8"JS,[.Y8"4
M9CG+%P1U:$$-*Y%"P !596?:78Q;J=DTU8+;/1!U!5J3N*VU\<;VO)V#2LG;
M8P1IA Q8JU.D;)QM$M<I<.>S77#4K9),L4@390V2HQ#=E]"8;I4W+>*2T)Q5
MR[A;5QEPPL7LELK=54N 6/)UM J;F48=54@,,IBC7<+E>R7_ "2+==0;AN(&
M;LG,IZSK"VPS=86(.YJ4ZPU_V2=B4^KWJB 8C@)\NZ$$NG)5[J]@8ME$M(99
M4+8 -PF";1&NX2XZK'NV>#9QZ;+)-5PC*/(EO33#T[+$7>DK%VY9O.<X4.P0
M6KELV[UMLKH]H-;-I[6((MM;.0*ZA(A0+VQAGMHR1DG*N;,K9D8@J0\/G5D.
M8-VI4SQJ6S=/]FM\^%MLA(:*5Q9@UH@/Q-E6(4,/64IL*Q;9JDXN&@6V("N+
M^=@G+1::9%/#S$:#,(EVJU'C07)$7&8Q./R-: <KD="#AT9D1;%O#W0KFT7M
M 6%MV[N1ED!2Y)@U)3#EE<E9E2"+A"L2YN(2H8*YSYF20=9R\:D.TS^CPJW;
M9L4@->F"&(6D9BX<DH3)BHG:,N6OJK&K)(/7G9$N U=;0/HC*2<V"TX.CQ,3
MVB X9ZTD+SPZ8M@+=A7 ;-BUD!58X&U?N&XK. &-JV;VBDR25@ME%6N/:4YG
M*R(MG751>9  0#(#L$UCD=IJ&6S5?9A,+G$3<,<;5*H1:++J@:\6F;$MM5K=
M5-4J=+<UP!LWJJ[G!-8?*5:)8GJ\7M4)IB,,AE69 P<B)M;Q'2"0J%DB\I%Q
M[5L&W<N7%O*!?>WFM(]P+=*!UML27*G,2:-;PS23E:48%0[$.J@J2;:ME=E
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M[07E$2N:>6H3Q(L2*&YA(O/FU4Z8'$IA.7+D%'B,DL1<E&5^L,#C<47S];#
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M8]H5&C;*UUM,5K8N]3;G7(9UZN[3U\(MM,7=0^2425":68H)T*%2\A+,\9(
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M.&P]*ERI+J&(\:-';4Z_(D/.*2VRRRTA;CKKBDH;;2I:U83C.<2 20 "22
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M"G5Y0EF2GT>,1BDY$0D\MIH8],6\TE>)Z ]RP2Q=.'M+;Q3HF'+XK&(;SO\
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M.X8ELQ!9"6RAGS;R9$R>W:9I:'YQI3Z63+)'#3J?)3+;0WGCA?#7'ERQN $
M@ H@)_-8E+@,[A75Q(, #2NH0C*N8%R,T'XYB 6&8DP#W@\":D4-#3;,IJ2)
M#NM"G&T2HY 5##2(3;J?.-.LS6'"("<\XAS#B4Q7AB6,N)\\N,ZYAOCF%C-*
M^16+I0_D[F'6RX!)[5IP+UFZY&;XK6PIT=D.@WSP#-UE !#,')X2,XE651(W
M#$C4 U]2,BWDL+P]-C.9PE<;!48\?80E;J6<+BF(;DB0A:GE(:9]$LB$M.J0
MTPVA2DIX@I;S=I,3;=)[.*P]W$A-SV<2G6LK: @+C $B B@P!)(A7ME3L5=5
MS &/R?9D3O-LAM\W/6$C)0*WC,$B2EMMJ;3EMZNDYD-"G%(SC#TXY-@*2E2%
MI3F1-N"&FG'.B/SJ8RME:XI5;/7W2VBIU%]PQU/QKY#-WEKY"C3* "!B[9 6
M+(JB.T640 8U4,H T@_%G<\#7'ES:LIA,Q^?2 ,1SS*FD<Y3DG*'>K/ERG,%
M1J%R,N--HPRJ<A.>;K;C^'$LHZTZUM;EM03^:)8]^@C4 ; MEW)!KG<XK1A<
MM(G P59IG+OUBB3EX:ZQO%64.;G-0(;91YJ011':3.?83A#+LK",>?6RC#,?
M"6LN>5Y'\0:_.\LY;;SGR<:@:"9/(S'$0!MN1I]DQ74F?*H>"\#,1L3 G@!O
MMH-.&]=W/U^O[W=CPXF)Y;3(UUUY1WZZ<8UU%@(]O;U[\ZQ]?KW_ .GA&TQI
MQ](B3&_=QG3?2?;VV_A3A X"!WCOUTCB.?#8;TK/R=._O^OAP//?E''3F/2!
M $$DQQJ._7;;VXUCB-N7'2)GA .FFPU'=RJ:L&E%EX<6)?7Y2%)6_#\K/5&4
M<LOM8SG/5"L9PXA.,=%8>SUY\L<N)00+@YY3MJ#)4Z<H(GD5'"K6S!*SIN.[
M:1RUD$#Q)WDV/QR5M3A2G"E.%*<*4X4IPI3A2G"E.%*<*4X4IPI3A2J8&_[^
M!;^P9W_QH;Q<?DV_3M_X;E9D=M?[9_P^W'[!14+L/Z\>W?NK?5I?19KKL*\5
MZ\Z\7/2<D!=6F*[J"K:O@%4TR98Y5"MECA2@$VP#;$5JS1. @DV+8>2B$W*<
M],]+WQA,+@K8ZNS9M/9OA<@?$H^)N8@H;P07K=LAPC6UN93E+$=J!S^1VC>N
M7V[5QG#VR<Q6VPMK;!"9LC,(D,5S"8F*\C4OX*@Q5% "$G;-"*FQ%OC65]>=
M03XX93<CL^'M"V# <2]L:<W6Y\Q,\/> ;8)<"L5@T&A#!57;$CA;43T[WNC6
M[UBC#7E1[90 XD%M,<F-MAFZ@&XHRM:?/FN7%8LUW,S3SV^CBA5C=4L&!/P9
M"F;!L.54N0C,.T,L*L!0L16I,_!"Y+,6*(O=,%Y)S68JFLE)]-M;QH:8A:+I
M&C9?FT0]J0*Q.I<@=3E6&-6RE9G3H<XBS#0:5@..GMW7W3Y2C>2'L8AKQ47;
M81D.,O8P;X<W!>#7C;-Q;@!4$Y)<BLST2"&4WB<UH6YRM(/46[!_/*E(3-E*
M[F)$ U:ES^#*$6$[;R(BS:Z'"+:;[33GLX5U1*FC 58[1-!UM5<!@2JW?*<0
M%S:N7UZ\361$$!*R0VW6&#!0"(O8,KYK7N@=+=I6MWBUI.CQUBXF&>Y@+V(N
M9WZRU=5A<2_E"NK!6MH3G49*V;HY2SE60*_E(RFWHJXA+0A<K*05:T#(()#'
M8ZU90#L0601V2[AV=G-QY]KR-ZSLK7NSH=3<P_K.WB+97[S2IL=DC82-FN+]
M?M%=8)$#EMMT^RV%! A GEL0/18S'._2Z-TE:QPPHZI;/D][#M<TQ%IK3V;J
MDJBI:%RVY4):MJB0K*H:6K1<&PPK8<WCG+EUNA=;;9@ZD2Q+%2/C,23QFJ,$
M_!-5X-3LTB-M14P-#O5M(5[UQ34%'J_JPSHG<^J*SK"/E^PX],CU&U;SNM_C
M%I2LXF8F9!Y@1?XD39[']TEQ[PO'#!6ZJV+F2[E#XE<9A<3<Q&B=DW;>#LV2
MHVRYP?S:P'1:K;:T+IC,V25!RVS9NVE3>3E:\[AB9DQJ*LO6'P>*:'>:'L:9
M<:2[::?M;5NP7957UEBMX? ZZ[+17LY2:.+D.6<H0%BC\XEB\O>5+EPV9#;P
MYT;*>D8)M88CISKK-ZP+-T6[N&Q.' N7^L(:_P!(KCUO-%M59T"]3\4$CM K
M&6M4P(6XETLH=;MJZ2B0#U>&.'* DE@AG.!) (B# K]->/GZ]"G"E.%*<*50
M6LOYR+E^S5L^[_'\[W=/O<^-+WY6[K_.W-.7:K*WM;_5)]E:R'_,D3Q_C6/_
M (%'N^O3Y^?I1Q_K&!WR=X[AZ-29%9C8> J@NT-M"R:TKK,NL.@H$U0JSG)1
MFSP9$\)$@5^%$8S'4U'*!LXF^GG1YQ7G9[;2P%>L2,Y86I$Z%C=<IL(T;M%9
MT B -!Q](%2!//<: B=3_"#L->->?)G:AV@-LA0' A4Z_ W(=BJM%OM9!EF:
M]<[^1'5LA0+'EUBSFA\/7PXP_;=?7.5#+D?2K,%CRAQ03AV2'C9FZ^L@,((#
M $!C&AWV!T:--!KI4@"!N#,E3J0.(\3H0(VX:U,%[OV\6I]R;&1*V#N-!UB>
MVD:+3JH8*UTB-)5T1;=8CA0OVE$RE).PY%OKAN<DS(=AGM>&'&H+3!.&VS/6
M7#(D J"22 =P"!&^TCD"HJ"(@ZD&! /K)Y1H=MC'":G6T=KV_7%);E9)A7;:
M%=&/S)!FFS!0+8V9<:00>K=";?NC&?:!B"E3[P^"0M-@F9&RH &MEBDMAB/)
M=E4&9)@F0(>>"B>7""21 4D14 2=C&L:G3A)TT'@ (DS!JH8O::V0]'@/+Q2
M,O2 T:R+C(#$TK7<GI%:9>[,#6%VGRT[;BM&2#RR2VO66,0$*<U\EMD@INHO
M/S ,<N,@=7$@9@#,G6 !&YJQ7O._/A$Y]B0L@C3GHVP%\!=G7+VQ8 6&"!RP
M1WM9M414"&R",10T71\K< ,RJ;-<RJ?.84#G B:4PH$24HMB8PB+ZHQ'(:*S
M!@"1!<KQ$#(&D'3O&P&G<(J-8.L99TYELL0)VWWD#AO7H3C6"8D1W@[:</J(
MV$C?6IJ>Z^A0GAQ1QV)&=<49E<UNL-.+SC#;.,<U*1G.>6.G?W<O#EQP8C\L
M_P#9_P "UI;G+Z_7F:>^OS[[='P?)3?=W!=H#2NYIW9]W96J*O6D^SP*\H[#
M,TA=D1983,9J&9K\X!81)EV4['-PI<G$T?+?%38:V<,O,^WT1TXF P]S!8O"
M+C<&][RA;1<6V2_DZLDDHX=&6)0@0P# [@\&-Z/;$W%OV;QL8A;9M9\I<&V6
M#: ,I# S!!@@D$<:O/LP]B6J=G#1NP]31+:9G6+<EDN=VVGL*H1D:Z(2[=>H
MC0XI-H8X3)(8H \2.CQHM9A#)\EP(ZTN=#DM2'4X9X>E>D[G2F(2ZRFW:L6;
M>&P]HN;C)9MSE#W"%-RXQ)+N54L8TTKHP>%7"6V4$,URXUVZP7(&=HG*LG*H
MB%4$P.-7/7.SS1*W5Z/3X\BP30>NC=2/U&+,G064"IE*8DQ@3++ D6+A(@-,
MRE-OPFHK;+V&V<^2C*.:O,KKJ]>%*CI6WU,%(3$.6BNAI:F\/)BE38T=(4TK
M.<)=2Q,DLNY;5E*L87A.4YSC.,9YXSQV8?H[I#%H;F%P.,Q-L$J;F'PM^\@8
M;J6MHR@CB)FN+$=)='81Q:Q6/P6&N%0PMXC%6++E3(#!+EQ6RD@@&(,'72M9
M\96NOU_4KZ5 OX?QO[R],_T3TG_<,5^ZK#W\Z%_ICHO_ -0PG[ZGQE:Z_7]2
MOI4"_A_#WEZ9_HGI/^X8K]U3W\Z%_ICHO_U#"?OJ?&5KK]?U*^E0+^'\/>7I
MG^B>D_[ABOW5/?SH7^F.B_\ U#"?OJ?&5KK]?U*^E0+^'\/>7IG^B>D_[ABO
MW5/?SH7^F.B__4,)^^I\96NOU_4KZ5 OX?P]Y>F?Z)Z3_N&*_=4]_.A?Z8Z+
M_P#4,)^^I\96NOU_4KZ5 OX?P]Y>F?Z)Z3_N&*_=4]_.A?Z8Z+_]0PG[ZGQE
M:Z_7]2OI4"_A_#WEZ9_HGI/^X8K]U3W\Z%_ICHO_ -0PG[ZGQE:Z_7]2OI4"
M_A_#WEZ9_HGI/^X8K]U3W\Z%_ICHO_U#"?OJ?&5KK]?U*^E0+^'\/>7IG^B>
MD_[ABOW5/?SH7^F.B_\ U#"?OJ[H^\4HM+:@"KA5R<Y_*L,0A]@$S9;V4IRI
M6&HT:6X\YE*<94K"$9Y)QG.>F,YXSO=%])X>VUV_T=C[%I(S7;V$Q%JVLF!F
M=[:J).@DC6M;/2O1>(N+9P_26 OW7D):LXS#W;C$ DA42XS- !)@& ":E''!
M7?6G*?RN?^S^^GBR\?T3[>T5F?C'])/MJO,D\ CL(FXO"(4KS8HLK.<X0B/(
M=SZ#,5UY<H,YS"5*SR0U#G3GEY_.8X-^;^B/K-67B#._V#B-)YU;?%:M3A2J
MCO3R\GX;&<_G,"7',8]RE2VTYSW].>$X\.OWN75AOS]_S=M_SMOJY:Z[5D^X
M[B?J7U^.A&U1/Z_7YN.S@8!WG4Y8VY1H)\-]=II[>WC6>_\ =\>>?KW_ '^(
MWG2) ,$G7>=1MOKIQ(.\U&WU<-/;;U4^O/P_<^?ZXX<-)Y1W0.!!UWTTD:ZU
M/M[?1[&L?7Z_7]WB3'A$;#6)(\"(G3AQ!VI[>WM]59^OS_?_ &NG @$3I)$S
MSG33CQ[XD"#4>WAZOIUJI-^5HU<M&[DJ-;@^LK#:-77VO AV78['IY@Q5R@X
M=#\],?BQ&O29DAEGSDF3'81Y?E//M(PI>.[HN_:PW2?1^(O,4LX?&X:]=<!B
M%2W>1[A"JK,V4*3 5CO , '*^K/8NH@EFMN%V@DJ8W([N(]'"BK!H2:!DS[!
M"'0;/8";YN1%"4_6=&@ZF'H=$@!R!Y36=PNZW'BMA]3Q_3+H-L\4SYB,X*DD
M!(9;<.9Z6%Z34A;+N^'L@60;E_&XOWP)1[US/:QV$PA"I9-PD8>YAGMDLMP6
M[MU0Z>#TIT?=N]5<6R<3>MKB<B)A<)?P<W%LCJ\1@\7B;18W>K 2]9O6GMJ+
MB-=MV[K+<^\Z[M+P*PC"&KDM[+-7B'9 ^QALRL3!];A.%Q1,3F#8Y12):X[&
MN 3&:?%%,B&%'60;:8\=<"PS'D:#&X9;MFY;Q[-T?:P;6+F =+ZW+["S<MW5
M>P$?#,>D+_\ YIKIO-U#7I+"Y813Q'H_%-8OV[G1H'2=[&+B+?2-M\.UNPAO
MV[EKJ\0UQ,4JX##@8-;2V%-];&BFWB'<:[&J=KN)*E9@P,]*W'-J-@NPF0TT
M8C5 X"VI7K8$9L<*998P^T1:W0Y1:CE<UYZ'@S!I=<BH4MMUB0U=ND.CXMVE
MN7@O1B8BQ@[B,UML38O='XC#7FLL,.US#-?QR6L;:6\K=2^-Q):""&H.B^DY
MNWGM6F?I9\-B,=;=5NC"W[/2.'Q-E;ZMB%MXI</@6NX&XUAE-VW@L*HD$,O0
MA:%L\Z=B)9*TPU'-.-JN*JO('URKQRK>T]5E7B.NX$$KDK6Q+E=J;UJ@+4XB
MPQ;&V4(S)"[!+0])LW2]E!FP]]R;1 POE*OB,2UH]'=*VNJQ]Q[(LXFX+V+7
M"W 4%A\-U=M;:X=65:)T'B+C9,3AE O9CC/)BF'PRW3TCT5<ZS 6TNF[AK9L
M8-L4A+>4)B1<N,[8A@SRW-)V,[9LE;[4F+X.#F#T##C35;(Q[#/<I%*#T_;#
MU0G$PHU3\- NRB#8%N1!EC"U@(. &7 K;!)OG.)P8P_5X+$-A+EZS8?;$(V'
M08O&7,5T8,2MN[<RN;F&OVKW;2[9L6QB&&(SVJZ3@ND#B!<QV%&.2S?Q";6+
MB8AC@L%;P?2K85KMJV606L38O6 4>U?Q%PX=#8"7:DLZLDB&FQ@*QT" -+,E
M+/&%C@&N*=8XE6@NEK&P#(1Z5.LIX,,D%Z^_%9EL"#A6$,EEY,1V7&$^?=8P
M2];'2;7L/C+MRV;=A[ER_CL5AKF(?JK#7[9Q:6+-QA;Q <HURS:>XEA656O9
M0W3<P]UNB+>'OX"W:N"[B$M6\/@,+B4P]LW<0+-P8-\1>M(U[#E1<5+MQ+;W
MG5F6UF*WA0X1$;1J4-,0LCBX^HUJ"5'9(.%U0"<4)!CSX.2STB8\5S$F-O1\
MDWI<IXAEO,MV2^X\IU7F8MDN8O%/;;/;N8C$/;<6Q:SH;K%+@M(J+:!0@]4J
M($G($  4>W@DN6L%A+=U3;NV\+ATNH;AO9+B6D5U-YF=KI5@5-QG<O&<LQ))
ME7U[N.<_4>,$;D<QN8T.Q'<2.KVWK/U^]]SYOW^&ACA!($S&@W/A]$'6H]O7
MZ?'[*QP\03 \3KH/7&H[X@:S-.&W G>3X;;\=B8W.T\%/K^_P$3$09&GTC;;
M:3ZI@0'M]E=\.\MD^ \C.<>=)995R\4+@3E9Q[N7-&.F?V^7&-_6VQ[UYSO&
ML[^/>1K%2OQE]/JC7OY?:=JOGC@K>OE*TJRM.,]4*\E6/'&<XPK'W,XSCEGY
M_=PI7UPI77D241L-\TK<<><\TPRUA&7'7/-K=RE/G%MMX\EIIQQ2EN(3A*,]
M?*RG&;*I8G4 *,S$S $A9, D]IE&@)DCA4%@(W))@ ;DP3Q@; G4@:5P^EO_
M &-G?VP_^'\3D7SJ>JY^[JN9O-OZ[?[RGI;_ -C9W]L/_A_#(OG4]5S]W3,W
MFW]=O]Y3TM_[&SO[8?\ P_AD7SB>JY^[IF;S;^NW^\IZ6_\ 8V=_;#_X?PR+
MYU/5<_=TS-YM_7;_ 'E/2W_L;._MA_\ #^&1?.IZKG[NF9O-OZ[?[RGI;_V-
MG?VP_P#A_#(OG4]5S]W3,WFW]=O]Y3TM_P"QL[^V'_P_AD7SJ>JY^[]H\*9F
M\V_KM_O*Y8\I+ZG&\MNL/->1E;+V&_.80YY7FW,9:<=;4VYE"TI4E>?SS:T*
MQA2<XQ#+E ,AE,PRS$B)&H!!$B01L01((-2&F=""(D&)UV.A((W&AW!KL\5J
MU.%*I@;_ +^!;^P9W_QH;Q<?DV_3M_X;E4/QT\'_ /;7YS2NQ]M:_P#;$[0&
MZY!=.OJW6]VZ]N%,*L5FS+V!L>N@.SE1@1*FUJXQ[V,KD'61RUN%Q5K"S*.>
M?G$H)1+$R*^^V]$^D'2>&L=%X/"A3>N7,)>M75-RWU%AWQMUUNW+1LM<.(2W
ME:VXNH I601(/G'"7;F+N7BV1$O(Z&&+NHLHI16%P*+;-(92C$D'N(\\56Q?
M"9Z\HFE:#K"A[/'N4OLO4VI205LK%)-5*3=879$,%X99PC.I+!L=:1F^!@>H
MR8=BVE,CR##"X9VL!ZV6@%27;<3H"_>Q5[$7L.PN](7;H>U<NI=6TW2:J4RB
M[D:VV#9K@:WAP54REQ[BLJ\ZMTBB6DMI<E,.JD.J,A<88G,6*YLXO@+^4(:>
MTH':-B!.T)VTY<3;C5'7O;9,6FW7=6L@;-CU'JJ#M0'9"792TY?-$2[]6 -6
M #!$5G9=AM$]^?*'Q(:&3 N!<(_H^8@Z/@V"Z)G"F]Y'AS=M86^YMXK$G#O;
M7I+$V<8MFX]RXS'R=+:@9B>PS6S,M5UOXR+W5F]<"/?MKGM6^L!.%MO8SJJ*
M!\,6U@#4!M"!7I7LRVSMNF.T5;1F](5B@:RBA; N)#G5.L0J=B+B-0E:_*5N
MR"JL'*9M1'#UO<N(>5;;@VB>Z0CO :+&!@4&^'I"UT0F!M-@RC8@NDD7+ANS
M-_KEN6WNNO5K%KJG%JUV<ISWB[E-\,^-;$.+X(M ,0"JY=D"%6"*<Q[1<9W$
MD@*F49O*]/[*/:=H87<O:,I=DGZ\V?#NW:P]DJC4M93C>R+V+O7:$,2ZP:OR
MK5?Y].O(830X2#>N( _7;)4/!(BIL&);)8QFM6#T+G271]YL+@;UM;^'-KH[
MK;EV^MNQ9:S@E%Q+/56!=LL]XY;[-?96*L"UM6-Q,?)<2AO8A'*7<V)"*B%W
M</?)MLY>X4<*@E +88 Z!F&4S2%L7X2&8,U4ZNN;5$F90 6V(AJJ6KK""NUU
M9WX:%6=?:!-3=<4(YKFBN:&8!6*IN!JGJVR8D$"#9?$VXCHX.7F;'0(;$@/A
MW0.Q9C=Q-M[-HX)&M^1(M^\E^\,:7MW0]S$I"J5*VF+@+G2!%HY;@8J(&2V4
M=^O96%\]6C6TZG*RE5MG74%@5/,:5VZ L$5L^9%VA?;VYK[M@,L#8%#U.),:
MZ=SO#6%=U$'J4E&LRKV?6>L0Y2\(BGQ=YGVM4"5(9#F)+(8*W5?>9V;#J</9
MM"_T7VFNXIUOCR2^^*>[.(4:8AEM$HUE;>8#,HS-5V\M51<^%N-DQ/9"V@4/
M76ULA1D,GJ@7[2N6,Z20M:J@;!^$;=OVE(5N%[9/5&>:M5>O PAKS7U4CR:T
MC;.TQPFZVVT(U;-CS)$74Z=<E9E?93HZ9/5&:<KB[)9#1VNC+7K/0?4XMK38
M:W=5;;V66_?N$7/)\,SVK5LX@$ XGKT%P^5JH/;ZM$6X:VWZ0ZVR&%PH2RO*
M6TE.LN!79A;.O5]62OP), J"685(.RJ8[<U9V5V8J/?*Q?6M2KT;K8??:_[#
MT.C5+7YN)I++UAF$9T.CEW34EK9T-H.H",OVMK #FSHT*#KDY31\JPS:]))T
M1<P_2%ZQ<LG$C&7VL/UUZ]=OHV+ 0!6O($'D[%LYL7T<*2;R7"$6<*V-6YA[
M=Q7ZOJ;8N#*JJC"S+$ME;--R00'ML"0.K*#,?V1X^6KUJ<*50>L,952KCA..
M:LF[7C&.77.?6$[EC..7R]W&M[\I<_6W/\7MW:Z5E;^+;_5I]E:$-,CSQ4"7
M%<2ZR[&:QA2<\_)<:3AI]I>/Z%UAY#C+R,_GFW4+0K&,ISCCT 94,#(:"#O
M.H(X3'")S=^AS&FG%="/;G&G,5RRQT">^-DS8<:5(#S7"0IY]E#CHZ>Z.GB'
M9D):L95&DN"BI(:MUK*5K@SYD56<LR'4*91I.\SP,:Q/#0SKI&41H0*D:;>W
M'7GKKXUYL[3NU=FZGC:A*:TJ*KPDSL^</OU>CP)$XO+UR!U)M*_6/-9S'6C#
M5J;S3(.:S%?_ (B>-8A5?RF7#C<AG&ZY7*54;D,,NX )D2---8.O=QJ0 <TF
M(&D[22  >!F?1,QIK%>S[O+>FP8-6SL+2_J )-T?3+X]L5@H70U8+D7IE.-E
M03%+75$+#)44-G6&HS-B+S8V ^(Z8C[SRTQH2X[""D J"6G<D"-A @\--)CC
M4LH&QGM$;#@3J=>,3/VQ5.ZQ[0O:5.5;4!<T-J5IEE]H;(IEW?K=9L#(JSN
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M)(WU&PDP>.L; <QJHX2!0;\O#?[/KJ=SJ+*9+^I1TI9&4[.L,F*YF$XPRNE
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MOA5:MVLBQX/$ $^U1H+59724V"1_M<&2S<B5'&.PH0W$:5,DQVYT',E2/O\
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MI;^2V_RKI,C7;-'T1]C.BNT;GOW-(_O/6N?W<^I^>?\ +U[^)\IO?*7YEO\
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MI.,X^_Q^"U_00^_Z?NKID\<TY^;OZ=.[WYQQ9>/Z)JAW/Z2_4?'VX55YOO\
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MJU&(>S)B*5H]-HYB<]2K7-!; K_DRW&QU[I]1*O9>C09(TA4VP5AW&C:'13
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M6]?@J['@B@[XLO M*-0\%>SFTU.NA!.6-=!IXT+R N59$DGM9F!*[]J-(T(
M.IS%M(M+3G8RTYI^+1 VOS]FD0-0;=8V<+@S30LO)9LJ>RU$[-3(>QRD#D2G
M6W]=3H5L>POT0E*L$^.6\_ZHF-0%76VJY8(.4SI)),;F#&;+IL!'"26JQNAE
M ZFVI%H6RX-X,S"Z;O7$&ZRBYEBS 5;75">J%Z;IU<KLC&7MCF[F VI9=;OC
M=MW7;NOCM0'4DT0CO;?U]6ZALJJV(+?Z=:Q$F*@]6IUI#EXJ&Y7D6OU5Y+"
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MLEY/)/LZU$PEVWYD_P C\5!L]DGC([TK'&=V<@F(SK(WD9M=@-#R VF30;^
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MFZXV"JXQ21>52QM0)/6!59BFC*%8D:5+=-]+KJUE%!07!.'N =62%#B6^++
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M2#:[N>&VJ>R)JK&+ X;E-1)-(M-?DE# 8()DVD(1KP::6)PIC$<;J E9^*P
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M;7'0Y-Z-=H]B(QK+&R357G)$<0?0P0+H&D:_*VM]%X#)@\-C;&$O/GPEK%V
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M8_V&;LZXSS]B=??0\+R^]Z#RX>_?3']*](?WN_\ CIY#@O\ 8L/^QL_=6<_
MT=G;.>?L1KWNY<L4X)R^?EZ#RY_+W_<Z</?OIC^E>D/[W?[]/CZC6GD."_V+
M#_L;7W>WA7U_L-/9VY8Q[#Z[Z?\ R8#Y_=SZ!SX>_?3/]*](?WN_^.GD."_V
M+#_L;7V"OG/P,_9VS_T)U[CQZ4X)C]R#^UW</?OIG^E>D/[YB/WE/(<%_L6'
M_8VONK"_@9^SJO'+-)U\G_L4X(G/W\0>?#W[Z9_I7I#^]W_QT\AP7^Q8?3_<
M6?NK"?@9>SJG_H5K]7+^JIX57W^<'K]WA[]],_TKTAZ,7?'_ '*>0X(?_LL-
MK_N+/W<.%6-J[X*70FM+P O JFT2(6KL]HB-FP*B%C3H<MG.<MR(<IN$EV-(
M;YY\V^TI#K?/.4+QG//&=[I;I3$6VLWND<;=M.(>W<Q-YT=>*LK.0P/(@CF#
M5TPF$1E=,)8MNIE76U;#*>X@2.XC7OK]5&FTLM-LH_E&D(;3_P!E"<)Q^UCC
MSZZ:U93^5S_V?W\?>_?^YQ9>/Z)]O:?M&9W_ +2_5_GIZ>=578$2GUL08'D^
ML"3Z(,'RL<TH?>PO*I"T_P!$U!CH?GOIQRRIB,XG&<9SCB&_-_1'UGV/IJ4W
M/HC^'#EMPBK<$BX@49!$P491$'QFHK.%9\IQ26DX3EUU>>KC[RO*=?=5S6Z\
MM;B\Y4K.<Q5ZV'"E4]><9]I(N>?3U,KI\OIB?WOW_?QUX7\_D"A._#,?:?KB
MLG.H$<]?0N_K'T5&..P?9L?1Z/4(^FJ4X@:[<>/KY$:SN1O.F^BO'^V.R#6=
MP;SA[6LY]]RKR-+VC5EJUY@;AR/82T\3L2HU*X9+YG)3$=JM"WEOFM.C%BI>
M2N;\/G8(0/9U,<ADUL/<DG0@J1N) ,$Z1,$Z;CGK22 =-9!!GG$CP) VC4;$
MQ-# O@^[0#15#2]TC#E\&"M7NW"QE]>RLP[I=0%^[5=\VE;5C8EU8DBE7TEV
MK+.^"'^M2*:G*KXM,F18(+[L-BG4$ $,<\RQ)!!UD #0B3FU),R! @DZ%DR*
M C"X'N9FSKU;6F2V+2K;%L,K6V6X7<W66X&0+;M&VS7=S![!YRJVG5EXHVR*
M?$L&KM :>T'#%VS5\BQ4TL*UU1MS48Y8)((=>*Z_')F8NU!\@,VV0<0)& #=
M6F.$H%S>G W4ZJ0=@ 1(.@4CN@D'0[<2*%K>;\G<R&XS$=:N;JRR%4#]5 <
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M@%]&@1M6[JUB.L9:4[1S<J>U>QUEK<I\O5I204=5.GQ[C#62S,58 ,2#OXB
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M&7K;#*AN.SFY<1;:);5KCO<9$1 79@H)K=,W3?C^&UM;,*JCR7 ;(Z=G9X-
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ME;76CIC$=*FX$%C(KLN(?"EE0$* RZ,;==8?>C LS%+1($)YQN)6VY;9:PV
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MMA.C,/AR+JW#<7JR2%5UR=BS:,$L#JQ'9VUKIPRXG#N7.+OW"5*@.=%)*DD
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M[8*R@T.)M @$L)S1*L)RYIB1)U4@$ Z^(J1A;Q$J%_-D!E[.8*!))@1F4QI
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M,'JYZ6E&1<2[R61$LGZ D(/*&5:\M$<,U/),,SUQ(KK#V8Y(:]+'%6@"1F,
MF IX!C$Q D*8YZ<=*+A+TA6RC,P$LX,"5$QH2!GEAOQ XC?6SM&U*BW-59MH
MTZ(%9J-;LN+$D0=)HQ)L4+99U0UT<("SU0XP&J:DNEBL!@A+AQX3,%F TQ+F
M/Y2V;$HK965@,BM,$ZL"8T!V"DDSP@ U(PSNA92I.=DRA@" I !DGB6$  Z'
M7:NH2[5NGP\Z8+GRKDR5&)5DT+1KB^29H)](FYV'T,TU%KSN!\Q=:U]<+*S'
M?5E3P$0V3:RJ.6!*)CB;0D'/(W&1I&Y,Z< I)[A/$5 PMT@$!-=1\(H#25$@
MSJ)8#7B8&VDCM.^Z/2;64JUH2=&I@ 1QN,9CUT\6$DE3@MXLKHB/+%"Y;*"\
M:OZ_L9;$%3F7W8T1./);>DCVIUFOHK%6D !3F@D',&(&@T,*8'&H7#NR!ERF
M2P*D@$964<3JH+@"!RUVJ*Y[76A4Q')KEQRU&:"X.+=<#E\-8BKN6=>-MI?Q
M$RPXIZY(57V9;;JQ3\Q"U,DG&$./(J<39'$S$QE//+'+?B#'?5O)+\1E'$1F
M!_-S:P00([ITUU(J.0.VAJ&;-GX](,+$-2Y$<*1& +,;FGF(6LPFU21!D**
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MP),:"L;=H.N;.%[84B&9AF5B# T);*0@ UTGA4KH5JS>*=7;9ZKDALGQS1!
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M#UDFA8A<DPH;- @03"D\]8WX:^F!!M+:L %QAT12Q$,F#?4_7I'DRI"*RE<
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MKHYI+N$MJ\Y8V;1_,&FVIG91O,[(HGN[S-1?NZ$.==] 1NS:S'%FX:3!&T<
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M>WFN%%9E<'- NDP1JBZ@B0 -.(TT6[A64@=4%MAV :V0$DV<H*D]MP 0<LZ
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M.._W\N[GC/=C'52"9DCN[M_"3XQ!UX4Y<L^_ER]_?GEUSW]_/.,8[NO=W\*
M'F#PX^.NI)CAJ/ITSRQRZ^[IS[L=_=USCNQTY<\^.>?/A3QU\1X[;[@; 3SF
ML<O^UCESSSS[\YZ8QCKX]^<8Y?)GGCA2(XG37QGT:ZZ1O]%,9QRSGITYXQWY
MY8STQSY\^_IW8_?X4$:GAK!UB--ID;Z=\:"*SGIS^_GO[L<L<L^_EUSGK\^.
M7"A\=CP!/KUUC6==^' XZ\\<NN?'/SX^;&?#./?C'R],*<M9)W/H/*(V,'<:
MCB:9QTY\\\NF>?+EXY^;KUZ>_GGOZ<E(&^H!C4:$R?X\?I.SE\O7GGEGGSSG
MEGOSSZ=.N/EY9QC/+/50#4B=>>A)&P/HU![_ !USXY]V?W\]WBGGC.>N,]_?
MGOSPI&IU\# T))^G4;[\-S6,],?<Z]_?G&<YZYY]>O/OQGOQUX4XS&G?,CCQ
MTTD\1N1PK/+ECGG/+ESZ<L9SGOSXYSCGG_+R\>%1$;D'6(WD[@:DZG?NX1)-
M9SC'7NQC..[IX9[_ /5R[_#/"K:=PTT]!TF8VTTT@GPJCMY_H52__P P0/=W
M?[@1_?YX^Y]W/)COY*_Z=OZS7;T>!Y0.81QPYCEMK/T^->T('\Q1/ZV9_P &
MGCPJ]RNWPI7Y&_#D_P#%N[F_LDU'_P"JE2X^F]R'^OL+^KQ7_P!K=/IKR.G?
M]5XCQL_]>WZO8<:]5?!X?\!+LA?]W?4__DX5QYO3?^N.D_\ CL3_ -5J[,!_
M(<'_ ,-8_P"FM>QL)3A2EX2G"E83A2L8QA2L)Y^3A2N7/.$^4KR<9SRQY6>7
M?GCRZZZ\;;4V3?Q*=CA(VKM=6*J4VVT>:<%$)""OK6@V>-831<R^+)YKT"1<
M2%H&CH@H*/;L$I$LJ@A'C6LNI CA3V]O85I7=M4FRZCH%C"!=307M@W '2K7
M9+53)+FMJ 211W[Q&GG1Q-RI3CPK,6LU.LU"3(-5UHJ6-4QUJ3 <1'"H4J#5
MGM'2;F9&NOC=(' *+11ZF@&.$.$+!LEZ[;DV#K"?LG6AIVS2H2J@N$)E;5A0
M?9NRJFU,D96];E-O.'<QK[<>_CWZ5.GAO]6WCW_15F6'M!ZZ'3X&N@6K!]D/
M5>U6L17Z:EZHBXM=):\*1!T(PS'DH=168TZ)/=*5R:S ;DY@,/\ HB%+<0A<
MU%5UK'M,AMR[=#Z[7JZFQJT6]*CP%$1D$H3Q49U0V&1$/25X?S$'S2HZN(A$
MJRL4[%@#"#Z6RQ1@FA$-4QOQB-CS]H\>//>Q>T]7;7J>^7'5=!$1"]&N^IJD
M CE*YDN-FP=CVK7H"OG!@Z$]4%E%,!YPZ6-BA3S8.:Z$ Y"6XD(Q"(-J@1Q^
MBJY8V*0U3=B]VL]+H6LKO'JE4EVKUW&N!,C=Z78MDVFE#8VO*A V*:%ZFBM5
MW7-0L-D'@8VPY*#=HJ8,\+1/@1Y4Q3V]OIJ<ZXW9K(BO<NQ?BG#C2&JP16U:
MRECJK/JN;GIN<6MD4+8ZF4M8\."+/VTP-/'YA^E^E#'P5VJD-Z60)SEL25/3
MO[:^W"MG6^U1K=0F#FJ:O!BXN)5<KP\<^:I])7%NQDU7EI&K FXP:PC*T&)7
M1,@C:7J\S+'6)DT&F5N'94>@R%*C,7M?ZCL5HI29.B2#K.PY%=#";/+ @R\I
MV+;8.LRY1N6Z)'F(L>'!(;]KJ9"B)R&+/9E6Z<+F39#@2+;(/#2=?5WT]O;V
M^VI=L+=X6OWMO75 U53UVL';:+JP.>.P@V88@5(M6F7#K,>NC'(%@@UT2,VK
M7)E5<Q.&AYUE'O\ EHB-PPR[!-/;V]/L*DL;;J']K;7BS*K15.5.M[&FQIL8
M2F1>QV=/,:\EP'+;,>G-*FP+4YL=\K48#303U6/#K?:)%%&UOB%*T%9[0>GR
M@3;IY_6 <9-T>+CR)#7J4*A\S%L:"M&9P"=:@/L(;.N4M5:5""3["YF#'&U6
M=G-H%E*>'4J*1.U95KQ%C62D:<K1.T.VNN4#&+.7J8<],-F]GTVJV<</'E61
M]S<KB63R"K%J6%PALN/S'/5B+.@N0U1IIZ?X_5'C%3_ _=]!K557MJ:WGG8M
M8KVE34R<=&URZAA(2J#8;N%[&H-9V>!&.SX:B5>G6@E959:.3Y92N(8G,!9\
M1@XZQZ:J:$=_I]8](TX3]E;(CVXM-$+#$88UB6L<%4ARQ4VWNAH*!)4G(Q88
M-9N$ X2@(#B@)\169,MFXN&D$(0*7"G*&/A8YF:'5%>J-62P6U=;1C!^E4]F
M-.,7($\!C1@Y\$F#4+N3J8YEN2VW)&E&?0J<#=])C8S!><@0G833$:+"9CJ5
M:<2N5X?G&8 $-"RGT7*<Q!<&-E.87E^A9QEEA'+T3SCGHO+^9_.+\UY'E*YJ
M5Q^RU8]((S/9P#Z67>S(+2O5 _T@I(R/=$9?(O\ H_G9KV1+[XS+LE3J\CWG
M87E>C.+:4I7:?"AY4]LI)$C)!-J.J&T1?@179[<1:9"%Q6Y;C2I"(ZDRY:5,
M)<PTI,J1C*<X><PI2M*W0*(TB&VU2JDTV/&2 D!MNMAD(@AI:W')0B&E,+"8
MPR2X\\Y(@,X1$>6ZXIQI2EJSE2MFNM5QQE<=P $<CNLN1W&%BH*F7&'D$VGF
M%M*8RA;+K9HPVXVI.4+06)H4G*9\K#JE</LE5?5Z!/LS7_53<7$%L9ZF'>KV
MX6!ZA.(:(7HWHR(N!2UC<1TM8:P/6J'A'HRLMY4KO20H>:_F5,$C9<G+:&<R
M),"*^_EIM@C%;:RZZTMS+:(I@O&0C*O)2P4(LIQAN=)2ZI7%%KX&"ZI^$$$0
MWUS7"2WHHV%'=41=:E,.SU.,LH6J:ZQ.FLN2LYR^MJ9*;4YE$A["U*C)O5NM
M[$P0CF:-5IJ2K,B.1>R$@,3);$N9,(2VG9\9EF=E$R<0(RI:<2,8E/D)[C_G
M%39675*D,>L5N)'8B1*\#BQ8K,>-&C1Q,!F/'CP_0/1([#+<=+;+,7U4+]':
M;2EMCU; \TE/H<?S:E=-BCTJ*+DA(M/J\8+,CR(DL0Q7Q+(N5$EX9Q+BR8#<
M1,1^/*Q&CXD,NM*;>PPSAQ*L-(\E2M]$@PH"%-08<6$VKS/E-Q([,9"O1XS$
M)CRD,H0G/F(<6-$9YX_B<:.PPCR6F6T)4KKF?T'*_L;._P 5=XTL_E;7ZQ/\
M0JES\G<_0;_":\[=DK'+3H3_ +:_?[L>.>_W\_N>'&?$\9,^PX> J]>A3_Z!
M&OV)(_XF]QMA_P"46/UUK_&M97_R-[]5<_P-5"GI5GCD:DV @1)P^98GHUL<
ME+0RH;7<5X])01B.9E,KS+Q86 ,-#+4,FJ0S-?;<8ALY=+C?H&+2F4 @MVYX
M+!U&N\QL#Z-Z^=6(N9C!RCJQS:1H=-B,VLZ>(BJ/NM(VE9MUP2X*S%:Q20%=
MUC/9?:L-D:&3B@^_W$G?@B*>,,PZX=DV2H10-<GD;8/GM@XA6(4!(<(P'6\9
M7$NM=4HY15"DZF##$D900"2($L- 9&H%;6GM+9.:VKLS. - 0,HRMF(+!<TD
M!3OIM-5/(V#VIJZ+'N6D0PJ5(EZO&E9@BD1)$2'$NY/4HTZ3"QV;7*=FV</9
M;3L:JPZJ\[*::#5H)9I\EW*TKM>#7,2@U$_%!(00 V74=HDL"6&6"-)UV.RV
ML*YA2(AH!<S*YP0940D92&TU)!TF-R M7:T+OH@F:Z/KK\EVO1GYV:T-?A"@
M<HYJJ*_8H[J;A-;EV2:$*[:FF:TI<N)5YE>#L87-BQX,R_V#8HD K$E03E4A
M5.49@<QDZL6&P@ =]63" ,<P8@-EAR&+#-*Z*(6,H#:DZG;:#5*Q]L<)76XY
M"KSC!Y#=20U)-P!Y!ZPF6Z;J,?>L&7&[/$&U8:'FYV:3!/A(T$7:3XF/EMM;
M\Y#=NH#BU6,I)X$@-)A00>UV0.T1$:[DB:LRX-S\=0H ^*2,HER"(4R?B@R9
M45?#YS?(^G/(GPFY9F+L!D7-L(6LPY9-5!D5>.658 ]/4>7&(D(]OE)J*XBY
MWG&@C4LZJ+*DPLJE;YK_ %<D'/G@D*"V4B9 F"<W9F-%EHD36.6QUNC=@H8!
M8@9PT07RDCL]J(U.DCA6R+!OZEZYJ<XZV5^-+9VX+0U8!$<>F],U<=G7^PCX
M.O5$:NQ1A$.O1B%*K<!N2B?&BJ'SB9.=CUT1E%E9%L0EM20>LN7&D1F@96*J
M!F( D#;AWR:U"X9[C!2.JMVDRD$KF.8 LW9DF"9[Q&@ %0VX6KMF&I5@BP*7
M)"#AKQY<-H"J(E925FC;H%# B2.)PTCD),L_Q0EF384NX09<GY)K,5YV,?K%
M3JS8MB1E*@'\T#7LL(!D$B<ID$\YT(%D7!*%.<,2! )DY0Z$F(B<H801K$09
M!J8B[?VQ)\0Q)(T^MAIPQHT58',#T%&RA0?)'9C4J+,DD >$#)[#SV(MBC8+
M(=;3+RT;=D82R/N'Q9!E0").@!,Z=G6!E[P9B=>-59,&"!UA(( D-! UAS .
MO"( Y#761::/]H]DQ,";'"3"@D=2#4R,8F#1 \C-MT&8':@CW'(L]D3.24D/
MV=$*7%(PF'QPT=Z:'KL1H?9;U:TU_,RNIRA#!8#5@=-9$SKQV VU8TNKALH-
MMEDL 0I,!8,Z1P$$R#K)DD15;MW+MB'ZE<8)2I2J^3? VF)2)X #"DD31693
MJ])A.EI! ]57*:@.:)6-(8@J Q(>FAXT539J3 CIN>8;%LI#*5)F,JK)D :D
ML,L:E2!.@F>.A3"JP*NK $2"Q@03($*V:8 (,<:D5ELO:]"&2+->JH>R1VI,
M<=%.S6G(<8NF&=V7D2K%>B$BD0<P6'YIC9XFRT%\EEQC,XX*8<3, 2QQ2L8&
M83 8@:@%X[,P =,Q !VU!JH7",!+93#$B9RDY01F(),:P-=#L=JV$@QVM9IZ
MOLX"!PD9,C85;*'8T-DE#<@UP-6\ +GZ@7:FX;"MAVP:?? 0)B"!&N5F? 8E
MO1I4DJV_).*D'* =5, ,# T:,T L1Z 1K%2!A((!F<K;PPS;B0IT52"=>T1S
MVTX':6Z[ZG>--RRS#MX34MU?&BJY&'QWZGL*1.L0FD"8=FBV0@O)0F'BBCCD
M<S'%R(!=V6J'+?@,^:'2ERZ_6J=&5#  C*\D!09).D:F#K(TBH>U9MFR^F0W
M!VF;XRD#,2L   S,2#&NIFN4[3^TM3X8B+2BLZUM!K/)VI.'S+S8GO/!J^*J
M8=O2T6S7A5NL%N7?G%7FPXR;E !@$PZ#99+C80Z/Z=4KB550&+D-UAU.J@ =
M7+2229)&P, 5/681BY8!)'5KH-R6/6PH4  90I$D@\]M;6 N^'=A,QB>-I.4
MXK?BLVX$9]EGA<P:_-K&Y6XX0</Q;S[6&XLPI1,Q+)K8C5*\MR-6W%TL%91Q
M9Z,07RT-UN4N226*Z$7-/C'^I!2%VE0:.U@(8-H,$A84,"0;<,8 (DA@5<$_
M&[41.XI50W37K?IF82)W\O"D (Q*Z5P[8+49 UTI9Y%U+6>&]<G-F_R6?H3$
MZI5<,*N=*MJ#,4=!F5\BP4FV0S7)1+RO:EG8$ L"S$ G-FDYH.490 5,F?1#
MW++)>"BV&!(0A5S& N4Y<D@.0Q)#*1.P  )U?:@JDJSNCGB9T,1NMOFH5,"1
M;2=@P29_=2JPH+%E6V%';!1HM7T8 0"@11T0<$O-CL,]<><T0.@8G%*7W89V
M@D*Q@YR(&9871! &@8F)!J8PKY-5!ZM9&8J- @:3E,DRYGB5"SJ*G-2+]IF3
M>@KEM@ 8E.E&I:#0J$$BJ6,&NDMR08Z8M@Q8G)$E$*#6]3%<2E"\N3G;@22M
MAEE3<4'HIQ!92P4*2,R@#0$7)@R28(0@\9Y;9L,+E(0RP!*MF/:8!".SEB26
M>1H!EGD35IFY]KJOXM$*L4^9:&V+1:Y@*8=$P([CN,W39DL15V9+)8@]/KCU
M,9UQ*'&9,43'\N<6"O6FOEFHP(?D7Q2DA59AG:"0-LS0)UE2H!!@1,2!%:*F
M$8 LX4E%! .YRK)B  Q;,2 3IK#;UN6;UVO<F14+V"#."EWLQ"(E9+&8.5 T
M$J,V.C(@LYG*BQ%!)VPI;Y',]X7&(!@J8=\L2EM"[-.?%;9-)(G*)X0-# $3
MKP, D\63!B.W)R@Y9G74DG221II$G>-:B50,=M<!0@?^UB&:L0ZE#V)8>V*9
MG3S5N<UWM.5+GE+,Y;7<QU1[M7=6CU18;+ ]U%I-)YH:E-3J_6V<8J:K) $!
M]2Q*O)+%I$$+H!K.@UJUSR)GT8!3,E- H#(  N6#(+22= )Y V7;;OVG(&G*
MT8J]*B%=H2S%NQ-%^B<XRPXYNUO4E!!$R,*D09%B3$JR";DD-7F5+ES8\I=!
MD2V/5FC/B1:0JLW"2#V1MJ%)$R)T)@<. WR1,,;SAGA%5(,\3&;*0#/&!KX&
M#')9PV^R]&K@\.;LT2R%-I[(I5P,-/#!),)JFV6RY#PUZ#,LN,P7BU-",TTK
M59+27)S4)4G&6E27I3*C"^;: %\Y=U<Z*0K%H81'Q1!'+ZB-AQ<8LJ%.KMLH
M@M+JH++Q,L9S#;8Z<:V&V3MNAD-.II(4V6,54T=E##9)MT;'O P5=*[&KL.9
M$D*A" $I=2UG:H"GBHK,V??K0WYDB]F;(J= V+'YH8D$ZZZ@%8F1E'9##F6.
M\Q6C+@V/QXRD+(T,$AIB-3!8'33*#&DU96I3W:2G[(BO[(KK<*@%JCF-B9$<
MRM]FSC+-L!8=<L3-8"OA8A2GY$.GB;86)-G'FJM$R' Q7YD1%[+8@W)N*0A'
M(#49HTW4$1)C4Y1I)K.ZN&"?!,"X.FO Y)$Z@F8@'8$Q.E:^QBMO1C+PM1+:
M\],[=DPD"M@V?#P(K=%:"ZXGJ<* :VR/R=A8((M%2JU:+1T5GS,X_9KHT<*B
M0[I(PNR1-PS>,,# "0A)R@B1.8*"8U),D5*M9B8M+%I0R:R7EAHQF-"K,P[6
MP$#;V9G/7'+GRSUZ<\Y[NO+]SIGIR\.[CKKCG8@;P=-=>(/CH/7-,XYY\.G/
M&.G?RY]_+EW?)[^F.F>2HC6-.7B./+N((&A,#C6<XY]^.73OQGEGW9Y\^_\
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MR+'A(X4W+C;,G5#V0;'NEK+%CDK,PN.04JQT48M5@ DDF"2K20 #F);0:'+
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MJ2:W#1GMD9+B8V:NTL1[;%4%"LJ3K]IQX#DG1TB\9"0Y;SD"L("2-@*<9C6
ME;$SX :6FSSDY0"*LV,VR_G,)A-=H.X(7?7>8UYR%P>AS3"J8FX==03,&6V.
MT03IO$3J$+MN5V@@FDPTD+.*I0Z$^(M)FL&\E[2K7FTUSR9JQS#Q$H[.CWD3
MJ6(QB&5B"'?7IMV6S*ANS)X"J#&+;(@9@- Q5I)5I).8D96"P!H2=HFIN'!-
M<!URDDDJKJ1#(   HT*EI.\#?:K*MAKM3QM.UR15:Q(([569M^2$14[7T5UL
M3"3:W*/@WF?A%>F)+X9JS!S()NNRWL/R'FUU!Q;T2'HS8GJDRK-PL9^((&N7
M,#(Y21'#;6LE7"]<X9NP%4KJY!8_&B!,@ P3.DC6ONT4W>AFBUP,+/V^$=G[
M4V/5[J7S9!0PW!TU<[;=(L.V Y(67"@MG*K7UTTM37HZ6K"%B,O0V8T:>N7%
MX%+[6U$MGSW%8E@/@W8]K0ZY0%RB9WCE1;EA;CDJN3J[;* I(ZQ%'9,J8DDA
MN!TG36JW&?FX@C33C(: 7,%:J7+D&"IRLS:Y'OL$7=:Y!%J1(*))#*\1C5C5
MED#HKTV'%:/6ZWNV&).7*(/ : 8Q=@"6!)!RM# %1)+"- I !B3KJ2*T/D3@
MS( *@%94P2&D *9(+,"3)C;<$V5J1?::5LB//V6,D,T$E4U#W\9(U=\K"LHR
MS[ D!I9: -ELBF($RIR!#)LE61(XJ3.N4M+XR&-@V2./O9\HZR;@.1E _-D$
M9HD F 1OE DD: 35+WDO51:(#J?ZT0Q60"0->(S$P)XQ70L-2W$R8DC6%[7-
M126ZYIT;<1M\"08]3H21.M)ZUR*W&LE58/L2B\*T5BN5>9!D5X2.E62R6,$?
MFH#C+09+H)'PC W2P8.HRK"<)$ZRH4PH$F.97LY03U0BR%*%3#-F;\XJT0"I
M+#4F ".'LKIW9SG'3'?GESSGIW?)RZ^[//&<YQQUUQ\#IZSH3![]8V/AN8D9
M\,9QW]W+KCN\4_<SWYQRY=/?C*DZ C28'HYCPF9(B-^ K'3'?\N/#ICISY]W
M7.,9Y9[^7/OSPIIIN  =N&@WY&)WUU.H,4\,YY<O#/?SQRZ\^?S=.O3GC&>G
M+A0<=#,P1]O?H1]$0!-9SSYY\<8Y\N?7GGEGW9Z]>?/'+ICO\,84UDS.FQY^
MH\P21&T3L*QGICECGTYXZXSRY?/C'/O^7EGKX<L<*@C0#4[ZP=MB) ,SORG7
M:!3GTSTQC'^7GCIR^[USG'7/?R[U)D'0#@1OJ3'#GKO&O&)-9[^77IRQUSGI
MS\/=G'?SZ\N?+'3'?PJ>/<1SD3/ \.[GZ!6/'QSR^7&,=^?FQW8YYQS\.7+E
MCHJ.,0=!P) U^V! UB=!$$C'+EW\^N.F/'Y<=>G3/W\YQG'"D#O ,@  C>>>
MDSL-!Q&].F>7/W9Y=^,<^>>[GRQUZ<OO9\.%-/1!B/&=# '+C .AF:I'>?Z%
M4OIRY[  9]W_ "!+Z_-][')C_P"2M^LM_6:[^C_Y1M'88_3RVD<8WD5[0@?S
M%$_K9G_!IX\*O<&PBNWPI7Y&_#D_\6[N;^R34?\ ZJ5+CZ;W(?Z^PNWY/%;\
M?_+7=/\ +7E7C]/?ZLQ'Z5GT?#6_\O37JKX/#_@)=D+_ +N^I_\ R<*X\WIO
M_7'2?_'8G_JM7;@/Y#@_^&L?]-:@':1[$Q;>NV36UH&P703RM?:4J8JG29EJ
M32+0_JS;-YV,9#[8K8,X+'7>EVD?;(HF*.FLNS:\3@K,PG7&WI(^;Y4>W?[;
M?Y1V QIWGQUC8[C;[ZU.GNP_?*,]M5JS]HBX3X6P+#$GS$UN'74N7$6R:V.3
M(Q-EQ+36S\(@Y9QMZ'5ZRSPR85UGCZ@*9;V"R&9!5VL30F>$>'H]/TU2 SX,
M:W#--#*1&V758ET#(TT(1.A!2*JJ?INK]4P-?%JH8%F,&66!UNMD*+MJ>V@2
M09Q<A85QUEV2.@EX2H]O;VVK)3X-?:1<T;*6#<50NK;T+6[,)JTU@NXY9I6L
MMFZ)O8.7?Y:9\LP>FO!M76VHOEBYJR%8[-Y(3Q\B'$F3PF53(Y?3W>'I'U\I
M CX-JVL$WSHK<B*W9GV :VK>#B6%NQ"S:+[O\U:K*/D+-M^48-47:E%I#;[K
MN%I':X@#G7<!VAD2&C[/HH"(VG??A,:C3NKJ!?@W;W'HXBO&-OBI!@".V(Y7
M'X,$[%$U:WV<QV<YM?M%=@PIHR*-F"&]+VTC(R/&CWL&]DE)OG)I1^Q'[%$<
M^_ZQZ>&WHU%)[A[3]_T"KKQV,; -[/N-+ C- ;9&=H:Z[@:#S AUNA["J-GV
M);;I#H.RA(XC&GO1X42T0H;BQ\B5 5.IU;DJA2(J)$3B?;[Z3]4?1'M[&JRL
M7P<ART5ZVP"^Q*ZNP7279XQDVP$M;L+-7+=C%[LW ZS%''[?8BN U=V1,G[8
MA#RED,/*S)RU+*SK!EXX[!$[\^?H^K@*21[=\SXZ#T5I@7P<=^P6LSMEVT&D
MUNTS]8NSZL'@G(8Q5:JFR--70OKU:F9,*7-J86N:S/:_H22THID96[A)BPX5
M<BO62)9YI/=P^_N[Y] UJ9L]A?9\3:NL[K$VM5LU?7%UO5GA 7*Z005R)N6W
M]UWF5463B93I)H$_4-G5BJ2AT&>+$YQ1E,S!1B.3#OU.!Q]O7[>@12>[E]$=
M\:D3M7Z)T0&_6*33JS+8"19=>JM?!R8M:8GQ:[&D"1,. \P BE9A$I&",N,*
M;%,$I\Z>S!3';F3),A+CRYJ*E?"E.%*<*4X4IPI3Z_>[^%*<*5C*DXQY6<XP
MGOYYSC&.7OY]W"E9X4I]?K][/"E.%*^?+1RRKRD^2GOSY6.6/GSSY8^[PI7U
MSQ[\=W/[GO\ FX4IPI3A2G"E,9QGKC.,XZ]<=>[/+/WL],_+PI3A2G"E:TS^
M@Y7]C9W^*N\:6?RMK]8G^(52Y^3N?H-_A->=NR3TTZ$_[:_N=,=,Y\<X]_%#
MQ'(GA'T</"K^WMZZ]"G_ - C7[$D?\3>XUP_\HL?KK7^-:RO_D;WZJY_@:J%
M/$C@\C4XX@-DM$+V%X=8'\+RU@$&2 .D<&LN<_-+PDM %"O1EX\X_DKS9SAQ
MK&./H&+ H LRT-_5$$YIVT( @[S UKYP*I#DF"JYD'RFS %8XR&)G<0=>5)W
M*)O$ONB-$I1MP%KX16M8&"#L]<!@*1EN7ZYKO8AF*_KRQ2K"2*4L0($*9BW.
MH.59106<9S)?DI2O%Q=:Z C%5"*3\DG.<P(RF25&@S+&^M;VS8%DYUS%G8:?
M& RJ5@YE"@$_):0 (BO/,*]=I8@)55@@_:S][M "DCC%G/5(>'!Z\V#YQ139
M"1#-@U?7JDH/%#"[&&JA<9<]G4R>28J&79R"%C9F67 /?U51=+, "S* J/N\
M2JJ% D"&8;'0UN4PX[;&TJH20%;M.D0N;*S,26()!4,-M0*MV[[FW<)KNI#E
M7U$0)%[8 *R+S1W*U:")<+;XD82PS7&ST5T?6ZV'9-/ET2K98I<N.1$08Y*L
M"SC#KJF]'O7@MHK;DLISJ5:0XTC30"9WW $;UDEBRS70UV K (0P@J9.8S\:
M%RC: 3!T$",&=V=H*(TXFMT;VK>Q6;#/&ONZ2VY4&#TV$%V1.@EEQC1^1(JK
M$$[6Z;67**==7;+;[4^T%?FPQC\!M53?O@2+>;0Q\'<&: 3.IT@@#+.LR"-*
MLN'P\P;A62)^%0E22O9T':S ELP&@!$&MT,V1VCBPKM"B2%*C#CE'K5E9UJ:
M#5"SBW+#81TBT#0T\7$L[QRN6=NR1!(:WB8(8P3; ^NHM5L&"DE/K"5=;E\B
M\&0 H#D(4R2) (!D-([0 XZ:SI!M6%Z@AR1<89P6D*(!()!E0"<C'CJ=*[I7
M8^WZUJT.:! C]I+R[5LB/ DV?6]M*6,G71$ZW2M;#3-1JL*J&*Q.N4(> $>U
MYP5"%5YN0P2LHMZ80;;5&>ZEM2 S$LX!="6*@G(&"P07&F8C3B-:CJ[+W6#$
M* J$A' 4,0N<AFD$*9.53KIJ=#4P,E-S$=;23$=UH#:T;389CBP5/E/$?BY'
M[-9 ^KGV31,VE^<7K,99PK:XP^-$]13I'J<0+?1$L3%\UUK0;XCYP("R<HN!
M2(8\1))^3L.-4"6$O9/CJ;9 9GTS=7G!TR\84+,!HDC:JY[0NV=^UBT3ZGJ2
MED)\)Z@6(DW:D:OMUN2*L,:E;!L(N8.*BB/LX6>R:JE>JR:=.&LEY)2UC'X;
MA),A@:Y2]=O*Y6VA(R3FR,=88R#\4P0!ECCOM6EBS89!<N/#9P"N=1I*K!$
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MPG0CV]MJ>CV]OJJZ=3:Z[2U9V: +W6RUV92'!&P%6X0,.SG!V3=AV)?+4'E
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MPR32I/M]M3?6&B=^U?8NO=B'K-1XL"H5^!JN9K\(@W*A/:N=$DBLJ0,-R)4
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M$B4L.3JY#OGIH:]SF?T'*_L;._Q5WC2S^5M?K$_Q"L[GY.Y^@W^$UYU[)/\
MO.A/^VO/7'+OQC/^OY>GAQGN3MN1I[>KNWBKUZ&/_H$:\/Y$DO\ $WN-L-_*
M+''X:UI_;6LK_P"1O<?@KG^ U0I\D=@D:HP'#I*PRM@=@6)_*\L^HPJ:^<GX
M,X<SGS:U(,P1 ST92%N2,%<Y;\WYM3B/H&+ H%$@M#=RY29GQ $<9X;U\Z I
M6X6(!597C+2HRD03J"VHB!N:\H]HD]VB!-DM\;4[5HD!S.FX0&N. ZT/+IKF
MRIY6]FIMRB298N8VN<(IM66+8'D53Q+UK.T"$X'==,X;F<]]KP8BV&(:WED
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MV@A[6[HZ_P#L;1[OYZ<]WNY^H^[Y,<L?)P]\DTFP_CUH^@=7]OJJ/>QC_/\
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M 'DYY]_?SY]>_O>^2>8?]J-]/]W]_#QJ/>PS^7]&0\?[4^GG)WUI[7;HZ?\
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1X4IPI3A2G"E.%*<*4X4K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g65062g15a20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g15a20.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M^9@,189L,'+RH8^Q-$&HS,>+EB*V6>:6;1Y)P&E5]1!*F/WP)"P5O>F=%9E
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MI9)W)C5%YDAR3&@)Y8 PH"MV&.@.*RM=%M8K/PMTD5V6N);IV:$1H)I3UY*
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MN<#JG8R=^]6M&U/L9N_:6B]+5G95ZV0Y8RNSZ1?':0*U_"C"=8&99/Y0%/\
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MWHS)=BC&RQJ7,GFK&;Q#%PUN/2I<>!%]+65M(TEO'(YRQ4EB!U.">RJ/4.@
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M(2K.$NH2ZAMU*',8PM*7&T.8QG&%H2K&4XDU+KY\4J]O^#<_SLVCO^2-W_\
MQ-:^0=1^M7_"3Z0JOU3ZSD_"C^F*_I:\YVN7IQ2H39?QUG\U1^N>Y1:I]7C_
M +(?3>M+_#_)7]K5'>5E8TXI3BE.*5QYD.(0B2H$^+&G0)T9^'-A3&&I,29$
MDM*9DQ949Y*V9$:0RM;3[#J%M.M+4VXE2%9QG)69&5T9D=&#(ZDJRLI!5E8$
M%64@$$$$$ @YI7F/[^9.5WNYW8 Z\A5$0'!^$+8J"@N;&F#X VB0KZF'+A5.
M$#;:BPRL9E,*.'C2&VP[,5#S+K:4)93C[KPA)'+PMPM)>27,DLGLIV4D<BN'
M9[MK,LKW#3$LR,2Q=E)D+$$')-8[L>KH<_/Z>@/IQ^[TFV[QET6E1NF/4K9,
M>G5R'?S?6#5@$C=&@0YFV$:S@5'-PPDP^F,DK*"HGRUDHX]Z4N&F0[B2VUA>
M4JQ\[XZO;N3B;B*R:ZG>RCUZ_N$M3,YMTN"YB:98=W+64HHC9PH<@8)[UZ#N
MZ^O/WN_7IV_OQFK"N<97M527#JQW*V[W#N5[M6S=)Z]ZDPF6P8#6@#7JK5L#
M:HZ2 &,E3.P"DQX4R%,I*9(0!I.*<+1E H<,=/I[K:E2%WN@\8\3:+<FV1X+
MG05S&^FWX%Q%/&X!E%N 6DM@Q:0 \U8^86>6SG!RW5ZMIOL57'!EHD.E:_+[
M(\Q\5+Q';:@=.M=&N(;B7PL<,05TOT6%())(VM$G#G-OJ\#+RTG^E>H%<ZDR
M;:SI;06IV8=T8.LF[#3 8.NV><V;=C/9B$I$WU)KH.$_%P[!J45]P! PZZB!
M[HE?HQUT3>Q_?LMW9O+PG?>,M;R:W$$LMI));-(VVWDMD<6ZDRG:ZB!8RH,=
MJ/-G@-<XG]DS5T@M.(]8ON,;*SM)+.R:]OBTD".B1B26*=PLUQM3$L\HFN+@
M$B>[?IC*.SM@[^ Q+3)UQU@/;6/S+$V8J(LM;-84>K_#GZ&!JLF#:SY>T2RT
M<BT;D'B"\CZR8BS*W"2.R3B294>.FAT#2K.2YUF#B3C+2K32>9'::1)8V^J7
MUR-,"Z7?RAK5=/@5@^J)JI59YPZ/-;R;6C3"R=5O+86W#TVB:+J(U)+6:?7_
M !36\*'6/':U;V\EM*+J;:BZ*VA1LT2JN^.Y& Y9GK$J/BFWQM\_>[GV,N.F
MM6 ;1#S#JFDM44*-8@X",QE*![MH*J?K@R82<8:2Y8VA[1R,9)O.$HI,9A.(
MBN ]E/V-_8LU>^M==]BX<1<$<=6=[)?_ --=(O)-,BGN96=W?VG@DA=6#2-R
MKJQGT6[525NC? ]/OGL6_P#B.]DGA;2WX7]D&#2?9-X$N+2.QGX6XJ07]S':
MHJIRH-8N([LM$51<VVI6^KVJ!56UCLR-U66='^O5MZPT(_J<W7-3#*X'(CWZ
MC8-8@604VV1GV9:9\Z\)1$@225AB>R@,8)$(\B:\RXIMTL4PTEYNMX?U#V3;
MYKY?9+UZVXFN[9K>/2=:B>3GW-F5DYL=U"R01020E8B%AMHU9I)&:6Y;,E<Y
M[)<OL0WESI6H^Q-H>L<+P7T-V_$'#FI,DMIIM^LD)@;2IUENI);6X5[@D2W;
MF/EQJEM9H1#5=7F%\1&PO(#>-6;DTQL*EU?85$J3VNSE=V3(/CZN<JJ3I*QB
MB(PS7 5FG#38LD<-M2XD@')BF(<R'G! 8X)]F2^Y<#<>6W#.GZAI-_:3S6MW
M<>,AGM!&TT4YACAD22.62)7B=(HBK+(&C97RCB3*?/\ 2[F.ROX[J4.R*%#!
M "V%8L"H9E![G.6'HJE"]3/&OTFI=KZ%[LMNY[[V62<A3MJ=@=0QBQ'2NG]B
M-,,9#5MJB%+]6,7\13X<A4.Z36J.0L[GOY9 J1#L$*'7*[U#\#\6<<6;<0V"
M:?8Z?<Q2-IMC?RE+^\A!(YQ>.VEC@Y[+[PLEPB$;68B-A,_T#2?9ION'.*--
MU&WM(YM,T_;;SV#PVO/N+9R/$_\ QS0O<V\[$+)&().3&T:(\<ZF82[H:T8T
MGXA(U&[@=E-PU/;4>^UXA&ZX43KA(?N)[94"RB6L3+][U;6J*+&U077"6&Y,
MIZ2_$Q*.P6VYSI-$,41^/\*>Q5Q%Q+Q3>"*..T?2A-%=O>\Z*&RF<F%H[AEA
M=S<,%E2*WBC=G\TC,D<;-7VOV:?_ !/Z#QK[',? W#6CZM;)JEY87>LWNK+8
MQ'D:=,+R&SL(;2\O>:)+V.VFEO)I+?EQVYA6VD-P7AOWZ+=]]$>0;5)#:>CW
M[%!;KIS-9N=,N@Z$*N%0.*B-3XS!.*-)&!<J 4A.IEB"XHK.@3FT28ZG(Y,>
M3'PK+BSA'5N#M033]5$+F:+GVMU;.TEM<Q;BC&-G2-U>-AMDCDC1T)5L%'1V
M_']O<1W"%TR,'#*>ZGT9]!!'8C(]'<$5NOSEZWUX3@W\\A&_ZDKO_P#TPYSM
MG_V0?_\ 7C_IQ5 OUX/QD?\ -KW8\XFK^O"EVR_G9K]__*^J?M36^=M:_P"R
MH_Q5_HM5#+]>-_;#Z0KW6\XFKZG%*<4IQ2LL<["I%.*4XI3BE.*4XI3BE.*4
MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5PR!$>)@RB96=#&#8+*Y,
MT@0DL0H,..WCUG'Y4N2MMB.RVG\*W77$(1C\*E8QP 3T R?4*] ). "2>P'4
MG^ZOXX6XG6W]N;3>9<0\R]L>\.M.M+2XVZVY9BBVW&W$9RE:%ISA2%ISE*DY
MQG&<XSC/.N3X*_@C]@KM(_J:?@+^P5CCF59UO3XX^X0SHGVKJ?8XQ19^QX-:
MJFRJVY51IV/7)<MR^T(_3&9:"LH87990-=-(GNM9@N*DMQU1T+94YAU&FXB,
M\31AMN2IR1GX+!NV1WQ4>Z@-Q"8@P4EE.2,CRL#C&1WQ4+Z)]EH'3OMQH[LR
M4J4R]0-0VQ^R2:C +,@IAQ#P(N'Q$8+R()-F"M*R:7\O.0).,I94CV?I7A2?
M9XS-$\8.TN,9(SCJ#VZ>JLKB(S0R1 A2ZXR1D#J#G'I[5MW%\F0"-6?'\ SJ
M0PM?2KN?L+M86DXMT+"=@#KONJL;89I@]KX#G-?FCHU?<"N&I*RK$A^4F:D<
MTVUF.O5X<YN#O'OT A Q\$B-DW'KU[YQ]\9K2;4EKD[Q[_ L(Z'RE8RFX]>N
M<YQT[=ZR^0\KFA=J ]NU3LCU7N.QJR]WKVUWLZ\Q:CN2-1"%1LNUK*0/E=3[
M/GJI!UNUT%YR3'>)DZ]$ 65]Y$R..E#$/Q)0_#PLB%#%*%/(2"3<FX$(  ZC
M<,-Z@21Z\^G6+.1"C12JI\.EO+E"V0B@!T\PPW3H#T[$Y[5IGV<[L5_L#Y%C
M_>?.H(#E;,[DUIM.3I*ZEH]B$'!M!8IK,ZD68JR(BQB :U-55^"34D-ZF!Q5
MUE<21ZBL.[HX3';B#?U",F]1@@MGS 9[C.1U[BM\4!CM1;[SN$;H)%&""V[#
M 9[KNR.O<>BK(>SOFNU5O;7.R=;LZ-[!V@#?NQFGNP\<-N?M#..5BG0]?V-T
MH9T1K$1KJG:]):CU(V'<6*ILFD6!FWBY\A9R>6D288]B/&BLW1E;?&I6-X_>
MXL$EA@2,6+!W)ZMN&TXP!UJ+%8/&ROS(@5B>+,<(!;<N!(Y8L)'SU8,,'MZ3
M72=G/-#KK=.I:/I^!I3>FS*H&[%T??A"/VG[*2]CV.A!:>\\Z]IO26V:13*%
MNJN@RS3_ +BC9%KV%9MA#8;&?]JG29;DAGV.S9'9RZ(3&T8Y484,6^S=&+(<
M?:*JJ?D].45BR.[\R-"8FC]YBV*Q;IODC9FC..^Q55"?5Z97N'SQ-D@>CAVH
M=:[FM)73_:.H=FP]@[=;I";TL%)C5:--AO:0UK;1VNJK>L4,Y!(R1A&UWZUV
MZ\NC/:,OS94N1B=%\2QP9-[( \1BQ$A0-G_U&4L5W @$!0%S6*:=@R%W10\)
MB(@0QAL_^HZEF7<",A555SZ .E0CL=YI 6SK3IBTZ_I7:>:[1>W5![:VH)V"
M[B7?:E0C9H%H@6T/H[6%%@AZ_0Z_0AI>*\Z%N-FJUEOXMA[ ]B=@;C,3F4=F
M5#JQB&Z)H@8X55O,""[,26+$'J 0M916)59%=HO-"T(,<"HWF!4R.V2Q8@]5
M!"GN>O6NXH_EXZUZZ[&]F=V:[T_W#U _V&VY%WI*MVH.V$6NWC%K(SC)^[:]
MN-%L5!M>A+OJLW9CT\A7G3.MY&P:A&>FPHUL(1R#;0[QK21HHXV>)^6FS:\6
M5P,!65@PD5PH&<-M8XZ#&3XUG*\4,;/ _*3E[7A)7  "LK!A(K  !@&VL<$K
MTZUK[G[S'MC>0DGY :1KFJ:PLK6]Z7O2IZ['*R0K@<Q0"==)A8Q>5&B!<FYA
MJ76HY*YE68(E1\V3-DVXD!4[#+4A( MOR&8N-C(6/0D-D''4XQG &3@ #-2H
M[<);"V9V<<MHV<]"0P(..IQ@'"C)P !DXJP;N-Y?-4=MJZ_43NONXKM2VANV
MK[5WA3KQW4MUPHH"FARK-@-Z8T'K^-7P%% 5TL<89G +3?ZW;RU"Q':CUD6S
M$;@1AFB&T:(Y#0Y1"D96%58L1@/(V2Q('0A2H;TG.<QH;)X3N#P[DC*1LL"J
MQ8@@22MDL6 )!",H?H6.<YC_ &;\P=![.PM13S_5()2K?U*W[2+IT](4>TQA
M0FA]=:6_2TQ>N5_B+KK\BV15-4V*5B7*$\-?$G'4MC L0-[\/)>QVC1E\2EA
M*C+-N&2TAW>^+UZ'+'*GN.Y)ZCV&R:(OB8L)HV6<,"=TC;O?%.>A\Q!!SD>G
M/;.0[S@:G#;/[;OU35?:?5NI>W-[J6\["2TYV4%:]WU0MY"I)%=QDU2[P-?R
M0DS6=Y%/BJ],J)D2],'1A2BL8HY/EM-C\/!,5BRT3O$K( \9:-D/P<KN!#*<
MG<#USC&!UUFP<I#EXG>%6C DB+QM&1Y<J6!#*<G<.^>O08K3;>?E&A;IU-WU
MUH[K"[CL]P=H]>KE4B=MW=<]O%M;570651QU9L5OV7DY=]@3R\%#&<$Y9P=#
M$R/7C#!<8.P/&Q-J6VQX&W*>2DBD!%0,9.Y 7"KW/3'WR3DUOCM.6]NV]3R$
ME5@L:H',GI 3"KC[Q)])SDU/=3>6ZMZU[)^-/?3^DCA:'T%ZNDNO)FM,W>!$
MD[*G3Z-M*H8M PDNMOM5J*V[L1B=D7*AF'E-BG6,3<*E(=8\>T+QW,?, Y\H
MD!VYVX*'&,C).W&>E8O9L\5U'S /$2B0':3M 9&P1GK\'OT[_)6>>G?G!UGU
M<U?U5JN=";I^-== FQ:K9*?JS?XK66@MU8V"@^R]M/:FN6-:EREXVH'A&U0P
MRK#9)($:22JT1T9FQQ0T;A-9M*\S;TQ*58,\>Z1"ISL5]PPAQUP,D=/63KFL
M'E>9N9'B4JRL\6^2/:00B/N&U#CK@9QT[$DX-T/Y<:II:)T*@KTC83[/2_2O
M<#4<YQ-W&CW;\YV=D&'!9N(G-;E) (J"":,3X+V2BC"V5YCR8&%XPG*2T+F<
M[P.<\+CRYV\K&0>O7/H]5;9+-G-P0X'.D@D&5/EY(&0>O7=CH>F,]C6Q=2[.
M-]6O!>:UC:]A:4LV^]WF;OK/K,)I&QZ]=]M:JZN=B,:]NW8L==Z^!F2I.NPU
MG,T&4'DB#BH1QZR6/&'H:6!ZDN8&,RWH<+((T"M(64JCRQ%ECVD_"*ALY'0
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MK,8C"(Q9$>0PVXVI.--Q;FW* NKAUWJR9*E2>A!].>X(Z8K1<VS6S("Z2"1
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M.<8QC&<YSZ,<] )( !))   R23T  '4DGH .]>,RJK,S!54%F9B JJ!DLQ.
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ME#33;:5+<<<4E"$ISE2L8QS!Y$B1Y)'6..-6>21V"(B("SN[L0J(J@LS,0H
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ME<C<VY\J,DXZ9&>N1.S?FE#1=[=6=JTK1V]"56ZZ[<LFYS-2WIWJW/O<Y>[
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M 6OQ@6RVB32X,-NO4<>:6ZU[H4F%8$?T3(7MI&F4J+4QLI<EEE",&++Z"V0
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MQDC/4Y;+'&YNS*!%$O*MDP%C'V6.S.>[,>^"3@]22V6-NG(E0Z<4K^-SN?\
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MY8M/LUGFTZ-&N(8XXO&7D+7/-LA%)#:QBXC,MO+)+<PR.L30PM+7,UU(LBS
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MA??,$LQSD69@DXN7F1<-/ L<)FDVO C,C="I;<ICSWVC&,9[=.U2+E[FW6.
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M%P,3HQ&+K?$=I-IZ</\ #ME+I>@QSK<S^)E6;4]8NT7;'=:I/&JQ8B4GP]G
M/#0,6<&1]C)*TC0;J*^?7-=O(]1UIXC;P\B-HM.TJU<[GMM.A<M(3*V.?=S'
MQ$ZA4(10P??3G'UU-,XQG'HSC&<9_EQG\.,__CBE8;OFJ(=K5[PA;,M>&XJW
M8%K;)7L)(6/V  OK;4>GV@XY2F"#BAA(6(L3XG)JHYEB'*X0@#PK0MZ/;MJ&
MES^)TJ\NK=Q#J&]DN[TWCR7DZRM!#<27@2*UF@DO;1X' BBAFM[>W,%G ;=J
MNZT\S/S8Y"LFT+[Z9;J(H+R*[91:SS^$#N$DA2<QF6W#Q\ETCCY;8QK_ %P%
M!G+ T. 4ZNQCYW=%ND/A 10>>R6WBIID\J%?,74I>J;:H[,/VMDL.OB58%G7
M90]02 !P%C-MS]2XBXJUF%K>\OI^6-(T^PCC>016CP6"R1:;8745C-&\SZ4N
M66ZVDL9^9#-S Y$1=+E;G(W)CBF;47;D12PRD:CA=@NUNGN[:XA529KFSD@2
M5F4Q)"8P!M$/&QQC2F8ZYKB5+POUIY(D5=3ZK#$9*&WRDN8^VWEJ,TI;3;J6
MG)&7I:T9DR9#KD.*%(3*4,IYLAE;FSSS[6*(A6+GR2<F+$:D0Q;(@Y>0)S))
M&:[CC$:[07(];R/(< *H\TC,PZ*"1G!;<Q\S$GL.;:V4XI6CQ'JD5!=V:SVG
MU>=@U81;*>=JG86L9:7EN\YA#&6J67B1F_0S\7S-9&)*35N,9CL5L>\RB2Z1
M+(E=1'KT4O#-QH5]"T\L%Q%<:1/GK;;G/B(V8]>6$:0QJ 0QE920$CVUKV4@
MU&&]@<(C(\=VA&>:-OO>!V!W!<MGH$'0Y;.\/.7JRIQ2G%*<4IQ2G%*<4JF7
M^#3_ ,U+J[^T[=/[=S^=]J/UT_X*?1%7&J?7DGX,?T!5^7(-5].*5YBQ737R
M>:ST?N72>MM=@10J-Y*"_9B-:J/O6@UG86^NONQ;-<#5IKVM;'8JH75U_P!@
M55^%1)T6T%789^<V5+L YX=8-V/:+(S6S.CLQ/\ \-RL&,E8Y% "E@&',!\W
M0=.@SG/2U,UH[I(S$GPHBVO&Q6.5 H4N%8<Q6\W0 @8!(.>D/HWBK[@)JH@)
M<->@FDR_-/U][W'!]DWX[N<CCK]7Z?,&W>-9MB71J+9MA7X&^Z@<?<+P&I5O
MGORIHGWD;EM>/6NHLDAB?_@Y(!B/8.86RI"J<*I]&.P !K)KR')*L<^ DMQB
M/8.:6!4JB^55/<8/0  @&N'Y#=FYZK=[.^!FM7KJP7E=M^AH.N7BJ=CMGF-,
M6+5<"J5:SU&$:U[&.44H!WZ(ND%Z3B)JW7E@5:K%>69 XM\GH@1Z?.]MUYL$
M *R@13DJ8D#ALD,0Q# QD$_#;H%ZC.>GELG-@MP5F AN"RM$@D#[BIPQ# QE
M3W=EVA<$9)Q6%M4>/'MX;T[TH[+:=I%LV' O7B]I?6RVZVKW9.1U;MU4G33Q
M78%>-6,U,"SV+EIZSBK-%3;-?Q'(1N1,:^*L*6M,9I>;7$(>>*1@NVZ:4,8^
M:#@!2 ,C#C'1NWH/2LWN(0UQ#(P7%VTRN8A,K#&T@#/E=<>5NWHQW-6#U'Q]
M]E-"]A^EMFUWJ#6.Q-7U#Q\6CI5MP26VU.S6]7%[9=7+Q/,Y1:QJ+KM77<!R
M6NMPQ(QH78RX=E_WA==]2(V]':>.2.8%V5C<"9#L&6 7;CH<(WI)ZC/K]&AK
MF*2*X#.ZNURLZ$1C+@#;U .U6/<Y)&?7DXA?CLZ&]Z>N7:/4I=P%9>OO66B5
M+9X7;VHB_;'_ $E](W"::%+A4*'U6H]DK3FR=*A(5E2/M=BD7:VOF"(T;$!.
MN.Y8EH,Y7$\$D3CI)*Q4HXBY3K@@MS2#M<XRHVC )S][VYN+>6%P,22LRE'$
M(B=0""W.96VR$C*KM7 ))]5;3>1_KOW@W3O?6,G2$.=:.O,G2NP:%;ZQ2.P#
M?6"WA]K6<FG FW; V8$K179=CTP@%B'$+Z^UT28*SIL2=,DP9251XL_5;R0(
MC\PXDWJP)CYH*#NJJ2%#Y^R88 K3;20)&^\[9>8C*S1\U2B@Y54)VB3/9G&.
MPR.I& >B/CJ[+Z1VIXR;CM&H58:-ZJ]0.P6F=F.Q;>!.R@]]O.PS!&KN $0G
M75E(16M35//$8.4^X,SW1\W#3WMVL;)[B-TN54M[[+&ZY!&550#G[Q';TXSZ
MJV7%S%(ET%8DS3QR(-I&55<'/3H03V/J/R9PQI#QP=W^KE7\=^Y:?J?76VMJ
M]/=C]WHMQZ_D=K@J;%,43M1:3;M=MM'V+*%&JP'.U@2_%F&8$N(N3,B26A<1
M'MX\C',GN(93<(S,BS+!B0(3AH@,AER,@D=".W?[VV2ZMY3<QL[HDZ08D"%B
M&A R&7()!(P#Z#U/HJS;Q/=9-\]8]9]I(/8>L4>H77=O>+?/8L8!US9$6BH0
M:MM$=0G8$<,0]Q%2VH$0H',P!\0F*%DT#8D)^8.A+D8CMQ[J5)6BY98A($C)
M8;22I;/3)]!'I/7/6HEW+'*\1C+%4@CB)9=K$INR2,D=00>A/WS5I_(M1*<4
MJ@;PC_[Y/,I_U1]_?M&;Y.O/@6?XK'^P587WP++\3A_95_/(-5]1"_7^D:KI
M=EV+LFU@:-1*<)E';3;;03BAP((3#1Z\B<2(S7&H\=I/I2A&%+]=YY;4=A#C
M[K;:\E5G8*H+,QP% R2?4 *R56=@J@LS' 4#))]0 KS@V;:G:/SM6@SJ_K@1
MNW5SQ8!B\P!M+L:_ D@-L=L61\A<0U3-5#R#*'P]'(*;>'SW9+.8K<3,AR]Y
MG3E/:GY8A(K$!Y-LMT1E(P05B)[%R/LAW]?VN!YZLU2+3P'E"RW9 *1="D/I
M#.0>K#N,'/VN/AU?SUQZUZ4ZF:EK6D= T,1K[7E79SB*+&-J<F%"+J&DS[#9
M"\C+A*QV4LIEMTH=+R91"8I#3:GDQX\9AFODD>5R\C%F/I/H'H '8 >@"JZ6
M5YG:21BS-Z3V ]  ] 'H K.G,*UTXI3BE.*4XI3BE4/^0W9U[L_>O2.A*S'[
MJV.AT'KG>MP;,IG1R]DJ+?#9:_7&#2M?O7 E#V!KR%\! RJ<3ELJG%9DJ$HU
MG$(<Y'+37DJ5@;6^W.TF@KEU=JG9[:]XK:](Z9[H]PMGU+:^Z2<R;)U8:-#=
M4=7-<=@=C5MLXB[$1=K.NOJG2A%OF,FI@R- !3"P9H-A2LO#?+CNR'K;M@4.
MZ>H1_8VC(_6&'01E?#[OU\&MEZ[-VCY/@M=EJ_NZG4._*F"827+%!M4$1 "6
MH#A!,;'C1'HSLA2K!^I?9;<^WMU]M=*;EI&M:Z6ZVFM.P(Q[5EALUBKI23M:
MA2KU/JLN=:! 25..T2-@3#*F(8T9!*.ED9;##%Q5MNJ57A6>_';R%N'L*XT(
MUGL9G97>!'1#JE1)9T_7Z92;)J<42)["V#:"L2MY(D:>P.F2R%MF1?B=M/6V
M"FNUYD?6P8_U5*LLZ:=EKUOE&_J=M6L4VO[*ZW;K+Z9N)76I<P9UO:I<*O@K
M)&-5F388<,T,?9C'<#3U>)YFR@Y&%G*R#J9B6(JE5L:$[W[OL[^K(6FJO7[8
M6[@WONQO^06WSMK8A>J:<T=I^TPJ#2#HC#$(R0KU(,$P[[XJ@5T9%"(>6XS
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MT1 !DY/3)QU R.G4D $BPSJEXV=U=EMO@N_/EMEBK[N6'E)+0O4:)E$W2'6
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MIQP;9*R>AMSA!H3);EP9T9STX]=IUO.?5<;<2MF1'=PB1%D-NQI+34AIQM'
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M=,;I&=X=SWR3U^VM@#9_(+UUV'7+-'I4]^MS-;:^;W73KK<%EVDY9CC6';X
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M4:;$=&84JUSI/TY?";\[2=JNP6O53=VG^P1X!I:Y750TU81^E*!KVMZIJ%X
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M$LLN)6V^T ,EY##C:VWF6W/0G,A+&Z<;A$0/1N*J3^22"/[P*E)I]W(NX1$
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M(VN)YKMIG:=XN4A=5C) '? P".@ P3U8Y[^O5$]Q>M<2-<21<I#(B1DA0>I
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M+7C'IJ6+6JVEFNFZG;VVZ]CFADEN>=<LFZ.*2$^'9BF9$P\ZWKIG0,.-V;[
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M7G8&VV4O#=!V@SUFVA.*2&+%==.VR*41,"0S:\X?:M%6861FP<L>VR.(C;7
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M+OXK_,B_CI[6WOQ/^9%_W*??%?B&^E 5^H;L+]EO'@+OXK_,B_CI[6WOQ/\
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MJ?#4SF?5N&&=GELP3F2\TICN8!5'FC4,ZJ%$B7$2J]KNIJ?M#H[= FF$:-?
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M8X50([<7Z_+>ZMJ$][XB[UK2[C1KZ6:&(@Z?<B,2001JB16R@1((^2B"/J5
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MCEML8 C$XPH" A/+6LO.JKDZ<4IQ2G%*L,\6W_C,U[_Z#?\ ]BS7/F_LL?\
MDC4OQC3O^N@KZ;[$/_GK3?Q;4O\ H9Z]5G/R/7[#IQ2H39?QUG\U1^N>Y1:I
M]7C_ +(?3>M+_#_)7]K5&(\=B*PS&BL,QHT=M#+$>.VAEAAEM.$-M,M-I2VV
MVVG&$H0A*4I3C&$XQC&,<KG=Y':21V=W)9W=BSLQ.2S,Q)8D]2222>]:U545
M4151% 544!550,!54   #H   !VKZ\QK*N--FPQL21/(RXT"##97(ES9K[46
M)%8:3E3C\B2^MMEAEM.,J6XZM*$)QG*E8QCT\]56=@J*S,QPJJ"S$GL !DDG
MU 4J/#[U2"TEF$*N-5)S)*LHCQ!]A$39+Z\)4K*66(TQUUU6$I4K*4(5GU4J
MSZ/1C.>;GMKF-2SV\Z*!DL\4BJ!VR25  SZZ\R,XR,^K(S\U=Y/*#!;;;I,C
M!'-.K]DTY/EQX;;CGJY7[-M<AQM*U^JE2O43G*O5QG/H]&,YYK2.20D1QO(0
M,D(K,0/60H.!7C.B#+NJ#MEF"C/?&20.U<-%DKKGH]F>"N>G^3U"D%?I_P#+
MU7\\S\-<?U>;]%)Z>WV-:C=6H[W, ^_-&/\ [J[A*DK2E:%)6A:<*0M.<*2I
M*L>E*DJQG.%)5C.,XSC.<9QGTXSZ.:B""00002"",$$=""#U!![BMP((!!!!
M ((.00>H((Z$$=01WKXRY<6!%D3ITF/"A0V'9,N9+>;C18L9A"G'I$B0\I#3
M##+:5..NNK2VVA*E+5A.,YX569@JJ69B JJ"68DX  &223T '4FO:CD"^48K
M)8AC+G5"4N2O#4:+ L0B9)D.*]/JML,1YCCKJ\^C/H0VE2L^C/HQS<UK<H"S
MV\Z*!DLT,B@#UDE0 /E->$@'!(!]1/7YJ[V>3&BVD/$R$$<RXYAEMV?+8AM.
M.Y2I>&D.2'&TJ<RA"U80G.592A2L8]"<YQK2.20D1H\A R0BLQ [9(4$XR0,
M_+7C.B#+LJCMEF"C/JR2*X:++7'?1[,^%<]/\GJ%8*_3_P"7JOY]/-GAKG^K
MS^OZE)V]?P:U&ZMAWN(!]^:,?_=7<(6AQ"'&UI<;<2E:%H5A2%H5C"DK0I.<
MI4E2<XRE6,YQG&<9QG.,\TD$$@@@@X((P0?40>H-;@0P#*0RD @@@@@]B".A
M!]!%?*3)C0HTB9,D,1(D1EV3*E276V(T:.PA3K\B0^ZI#3+++:5..NN*2VVA
M*EK5A.,YP +$*H+,Q 50"223@  =22>@ ZDU[49@WZB$Y#$0;=:D0ERG$,QH
ML&QAY<B0\YGU4-,,QYCCCSBU?Q4(;2I2L_@QC.>;FM;I 6>VG10"2S0R* !W
M))4  >DFO,C.,C/JR,_-4@G$APMI,@G/A#F%N)90].E,1&EO*2I:6DN2'&T*
M<4E"U)1A6592A2L8]"<YQK2.20D1H\A R0BLQ [9(4$XR0,_+7C.B#+LJCME
MF"C/JR2*X2++7'?1[,^%<]/\GJ%8*_3_ .7JOY]/-GAKG^KS^OZE)V]?P:U&
MZMAWN(!]^:,?_=7<(<0ZA#C2T.-N)2MMQ"L+0M"L84E:%ISE*DJ3G&4J3G.,
MXSC.,YQGFD@J2K @@X((((([@@]01ZC6Y65@&5@RL,AE(((/8@C((/K%?A]]
MB*P]*E/-1HT9IQ^1(?<0RPPPRA3CKSSKBDMM---I4MQQ:DH0A*E*5A.,YX )
M( !))   R23T  '4DGH .]>U%H6P*&2D,11UVJ,^5*=;8C1H5D#2I$AYU6$-
M,L,L37''77%YPEMMM*EK5G"4XSG.,<W-:W2 LUM.H )):&0  =R25  'I)Z5
MX2 <$@'U$@'_ -ZD4XB/&,XDDIT,?'RXEK#\Z2Q$9RZO"LI;PZ^MM&7%82K*
M485ZV<)5G&,XQGT:DC>0[8T=VQG"*6./7A03CJ.ORUXS*HRS*H];$ ?.<"N
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M@4,S'NS8W,>@R3@ 8 Q?V/T13NSNB-K=?[\N<Q4ML4PO3RTP6\I@F+R09],
MR.7A24*G!2;4(M$8D8<A29$)N/.8D0W7V')&E:C/I&HV6IVP4S65PDZ*XRC[
M3YHW].V1"R,1A@&)4@@&IJ.4=7'=3G[_ *P?D(Z&O)3TM\;NN"0GLSU6+#3&
MK/)SU,LCUMUI?Q]TL4&O;0JX\K!L&O[P""32&1@^$0PZ*%K*P8L*0"'V.E61
MS#I9)N$C[?KO%EU')I&M*\=YPAK<?(N[9K>)I;*9T:.YMY) H=V0AI-CEA(T
M5Q"N$,;5!O(A<<S82LP!>(@X\P(.#\N?+D=CU]'6Y21*D>3'I;$GRH+H3M%U
M^-RH5UI3K2ATIK8U>B/#;*%?$.>RS"AWT?&>F!FUMM)%6:+D$J9[(064YQ]N
M1P3Q,%W"30]8C4V]R"'7P<KAX91(,[FM78+(1GF0-S0N7CQS^IVYUW2)508O
M[,N>7V+2HI5T*GL)E!*=>DBA2V%<5)-8=:M2;>T35+MHRO2 MXDF@@*[#3]I
M*RL4R;&D,,6UMN%,=]$E4/#C!.$Q+4F1)K\C+C2%%\LQ,SY^)=3T;6[BUUN=
M9;%;>XGLY+>UC7QBLK-; NH.T.5,3L@*K.H!(BW-7%S\*Z=KVC17.B0&/43=
M06]VMQ=2D69#A;HB-B YC5Q*JL0S6Y)4&;:E6T5*M0*=60=6%Y>5  C(HV,Y
M(7EQ]U$9O"%/O*_D]J^YZ[SB482VA2\H:0AM*$)^5WMW)?7=Q>3;1)<RO*P4
M852QR%4>I1A03DG&22237U/3;"'2["TT^W+&&S@2!&<Y=@@P78_;.V6(&%!.
M%   $&WSIBG]BM+[0T5?T3E4W;%(L%&L#@R2J&3BP3X]Z%F>-DI].&B YUQJ
M?"4ZAZ-F5&:3*CR(RG6',]-OY]+O[/4;8KS[*XBN(@XW(6B8-M8>E7 *MC!P
M3@@X(GJQ1E9>ZD$?W>OY/77D6Z:>,[5;\WM+TRN<(MKCR,];2\JZ:4VN/N%E
M%5K:E)8GCSE#N@<"^1>%P6'5K%P2<V#':(@Q%H"$FFG;& L'LON6N<7WJ#1=
M?@*77"FK*(-1LF@ADFLYRK17-N\@4.Q WLBL=LDD4B$B*2*H5[$MT9 ,K*5W
MQG./,/W'RY'WP?35S Z80\E72Z4!LD5VO]K^NM@6-NU4EX2.E(V;58D\1/9F
MC<Y:;C0-A#623<;UD1XH>W,2X+;RX0.3F5QR;.">)DFB;FZ!K$0:WN%\X\'.
MRR(5< [FM)"A;&6DMF5L!I!MH-1MSKNE3P+Y;^T)(C)QF9 R[2/5,NY5/99!
MZ0ISV^I>MFI]N:!"6W3-8DA-G,EP];O 6P6@PM%1-0IT6-:\I@SG%96AMA?Q
M:#'F*4_D,^XTG#QJ/B$JQNN)=2T;79+;5[E9=+:">YLY8+:+-W&T;M; N@Z$
MN#$[( O- )Q"V\<3)PMI^NZ(+C1[<QZJ+B&VNH[BZE"VKB55N6Y;'KM0B55?
MJ8BP :90AMLI54@4:I@*B,6Z[" #6![3[^<Y>DJ;QE3\IW&5*PA<J0MV0II&
M<--9<RTRE+2$)Q\LU"]DU&]N;Z4*LES*TA51A5!Z*@]81 JY/5L;F)))KZAI
M6G0Z3IUGIMN6:*TA6)6<Y9R,L[MZC)(S.5'E7=M4!0!4=W+JBI;VU+LO2U]8
MER*5M:C6C7UI:'RW(!#(.V!Y84BN!-:_CQ)S4:8X[$D8PK#4A#:U(<2G*%>6
M%[/IU[:7]L5$]G<0W,)90R\R%UD4,IZ%25PP]()JQ5BK*P[J01]\'/7Y/77D
M&Z>^,+3C-Q[5]%MG1"M#[Y:4?F7KKMNF%:[,)K6T]?*=AE:1:8-;R0DAVG(S
MZ1[5@4,864&";"_[FVJQ4HW,1]SUOB^_%OHG$=FT=SPU?A;;5=/:"&2:RN<,
MEQ"TNT.VX%S%O(1WC ;$4\8J+>QK=;U!*2,"T?7LX.>IQG&0.N,X.0,XJY>K
MS3'D>Z9'-:7YEVN]M^M]CP+N==GJ;@R5;+J$4L%C$",5*T1T#MA"\&ALA['L
MH0NV()/1D*'"HWO?''9P9Q)!?6WOW#^LPAH)D&Y19W#1RLJ,03OM'Y<BC.^2
MWV!L,YV\_>P'7-+GM3Y;^S8L%) S,BN$#>C;,NY">ROEAD+UYVF>MNJML=?H
MMBU15)@7<@@D,JEWK]BM)=MNLV0>1B1;,_D?-6I2&7(>7RH^-+4K+49;\+UI
M)4>Y$7:7G$NI:/KO)U2Y671Y8I+JTFMK:)FN8'C9K9>8H[[]L;L@&6VMY8WW
M#AWX7T_6]$DETJV*ZU'-#;7,-Q=2JMM*LR+</L/HY>Z1%?.%W*-\B;#;?0:=
M U_3:]31KKK\0 .;AXDO9S[64^I:Y$V6M.5+PWF7->D2<,I5EMC#N&6O0VVG
M&/EFI7TFIW]U?RJ%>YE+[%[(H 2- <#.R-53<1EL;CU)KZ?H^F0Z/IEGIL#,
M\=I$$WL3ND=F:260@D[>9*[N$!VH&"+Y5%2_D&K*G%*<4K+'.PJ13BE.*4XI
M3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5Y.+=X_
M>X9"UV<A#TB=?ASK":F1'TG::E+T:22DO,.I2NR)6G#C2T+QA:4JQC/H4G&?
M3C'Z_LO9%X+BL[2*37K=7CMH$=3;WI*ND2*RDBU(."".A(]1K\:WWL:\<2WM
MY+'H%PT<MU<2(WB; ;D>5V5L&Z!&5(." 1Z0#4>^YX]S/R&'OT]2_P!Y>2?=
M)X(_W_;_ .'OO]+47W,>._N>N/\ $Z?_ *NGW/'N9^0P]^GJ7^\O'ND\$?[_
M +?_  ]]_I:>YCQW]SUQ_B=/_P!73[GCW,_(8>_3U+_>7CW2>"/]_P!O_A[[
M_2T]S'CO[GKC_$Z?_JZ?<\>YGY##WZ>I?[R\>Z3P1_O^W_P]]_I:>YCQW]SU
MQ_B=/_U=/N>/<S\AA[]/4O\ >7CW2>"/]_V_^'OO]+3W,>._N>N/\3I_^KI]
MSQ[F?D,/?IZE_O+Q[I/!'^_[?_#WW^EI[F/'?W/7'^)T_P#U=/N>/<S\AA[]
M/4O]Y>/=)X(_W_;_ .'OO]+3W,>._N>N/\3I_P#JZV'@:@\IHP911$*HVIJ#
MK0(4K=(PI6HGY8,"9%/ YXE!&1)=(SH*Q+[L",P4ES4CV%82/]URA"D\U)K/
ML2RRZA/)>6C2:I/#=7_^V52XN()EGCF,2J(HY!,HD=HDC,C?5-X)!Z>/0_9@
MAAT^".RO%CTJWEM+ ;M$9[>VGA:WDA$K.99(^2S1HLSR<I3B+9@8AH3K!Y(J
MV)HH2OT&Z!AVM+(3MU&:&G-?PWZ]83.&TE2,6<R;1/?S/;;2S)BS9,J$['4[
M'5&]@\\VN=/Q7[&-U-J%Q<ZC8SRZI:Q6=^9;?4G6YMH,F&)HV@,:\LG<KQHC
MA@&W;E4B!;\(^RG:PZ?;VVFWT$6E74M[IXBN=,1K6ZGP)I4E6X$K<P *Z2.\
M;+E2FTD'E;6ZV>2?=J@WSFZ]L]D8KV)_P4>W+U>!$#72CR)!27&"UHD'$I($
MGVVW2!%4)4^:MM&9,EWU$^C#2.*/8OT(3^U6I6EJUSR^?(4U6XFE6%2L2-/=
M133&.)21'%S.7&"=BC)K/6>%/95U\P>VVF7=TMMS.1&)-'MH8FF8/,ZP6DL$
M/-E8 RRF,R2$#>YP*D6NM,^4S4U3?H^O:Q=ZY5W9$Z6P.9)ZQG."91-I;)"5
M7")4E.*5>1,0XZJ0_7)HMUQUUU]2\ONN.*C:GKGL3:Q>+?ZE=6%U=A8T:5HM
M5C$R1,&C2YBABCANU0@!5N8Y0%"KC: !*TO0?9?T:R;3],M+^UM&:1UB$VD2
M&%Y05D>UEFFDEM&<,Q9K62%BS%B=Q)/55SK[Y-:GG6^:_1[:/5J)-Y3KI>)N
MKY2ZWC969"KQEI<TC)6058%2I"I"RZB"X^7,Y@JBYPGT;KGB/V++SVS%S?V<
M@UDV!U(;-6077M7M%AD)$HC%L$4*(>6&  D#UIM>&O99LO:KPVGWD7M(-0&F
M'F:.YM?;3<;_  9)6,IN2[%C.92N?>]E=:-ZS>2,/C5>!NN[1%QI*06E:N]6
M=K)?R2?.D\&"KD;VI1SW_,PDG$I23'Q%+:L>HREMK_5\VR\4^QC-[;\W4K5_
M;U84U;*:J/&+;Q<B$-B(<K9%Y 8.42.K$GK6J+A/V5(/:?E:9=I[0-.^D8ET
M@^":YEYTQ3=,>9OE\YY_-"GHNT=*^F>MGDKQ%KD-JC76(U4;P7V16EP#6O!T
ML/=STG$LN?B3X!F/.3)FOX]=R.N0N"C&5-LQ6VE*1G'^D_L7;[ES?V+M>6$&
MEW0D@U*5)K"W79#;O') T>V->@8*)"0"SD@&O?Z*>RL$M473[Z-;+4)]4M#%
M<:7$\%_<MOGN4DCN%DW2-U*EC&!T5 I(KF;:Z]>3/>;8AC:=%MEHB 79DD4/
MQ-U>#&1IA#*<SB*A=<(AQ\DI+]7'O!27&?(.X4YA<G.'',*QT?B3V+- ,S:3
M?V=H]P$6:3EZK/*Z1YY<0EN8II%B3/EB1EB7 PG08SUKACV6.(5@36-.O+N.
MV9WABYFCV\*22_5)>3:RP1-,_P!G,Z-*V3ESDYPK]SQ[F?D,/?IZE_O+R\]T
MG@C_ '_;_P"'OO\ 2U0^YCQW]SUQ_B=/_P!73[GCW,_(8>_3U+_>7CW2>"/]
M_P!O_A[[_2T]S'CO[GKC_$Z?_JZ?<\>YGY##WZ>I?[R\>Z3P1_O^W_P]]_I:
M>YCQW]SUQ_B=/_U=/N>/<S\AA[]/4O\ >7CW2>"/]_V_^'OO]+3W,>._N>N/
M\3I_^KI]SQ[F?D,/?IZE_O+Q[I/!'^_[?_#WW^EI[F/'?W/7'^)T_P#U=/N>
M/<S\AA[]/4O]Y>/=)X(_W_;_ .'OO]+3W,>._N>N/\3I_P#JZ?<\>YGY##WZ
M>I?[R\>Z3P1_O^W_ ,/??Z6GN8\=_<]<?XG3_P#5UNEX_NGO9+479^F7K8VK
M"U7J8P/<8\XS*+5J4S'>)58I @MJ8&FYLM69$M]EE.6XZTI4O"G,H1A2L</[
M(O&G#&L\*7VGZ9JT-W>2S631P)#=(S+%=PR2$-+!&@VHK,<L"<8&3TKO/8VX
M'XJT3BVQU'5-'FM+**"^22=Y[1U5I;26.,%8KB1SN=E484@$Y.!UKT+<_-]?
MIBG%*A-E_'6?S5'ZY[E%JGU>/^R'TWK2_P /\E?VM4=Y65C3BE.*53KY*M*W
M'6=TUKY)>O@S+NW>N24C]O5V'Z[#6U- 2''DV(>92PV[[T[5(LP@^N6MA3T*
MNSR!CVRI51K[+7>\(7]O>07?"6J-BQU;+6$I&XV>J#!A:/)&!,RH  ?-*B1X
M"SRDP;W?&@N8AEH<LX^V3'F'J[=^G0=1U%0VW7P;I"]5/R-]=8+UKT!V>K<2
M-NNEP76H*&;E)CO_  "RRVV4R(H<W@^U($V-]QEU4&TQK# ?DN3+EG+=K96;
M:Q:W'!FL.+?5]%F9]+NG&\FV!4S0J<AI(C"1)" 0'@:%QY;?KSVHW)TJ5-<M
M$,UG<ILO(5. )"#RWR,A#S.C$CH^]?A2BM].EVLK+3Z">V%>FDC;SN\^]L8]
M78D?(X56V"KDN:*&1A"?0W FJ9)/RR*<H1);]XB#)GKOBLNN<SQ;J-O=WEO8
M61YEGHT L8+ACOEN&0(LCM*>KH#&J1]2OE>1,"7 W\+Z=-:6US?78V7>KS^-
MF@4;(H%8NT4:Q]D<B1FDZ X9(VR8\G<CG)UU%.*54%Y--%7.JF]:^1#KW!S\
M^W5KUG;N(B)<1C:&AW')*[;6C*&$+<E-UV%/,3O6QA#S-;*VA]A;I2  3'[O
M@[4;>=+OA;5&_P#EVLC;;.W7P>I8 @ECR<*976-1Z#,D(.$:3,*]#J@N(OAP
M>8C[9/LA][&<_)G S6/K5?Q.LK?0/)KUR'R+#I3L'71X3L-1(+K45;)Q["H8
MP_-;:P_"&V,988RJ\?EY;]DQ:!SS/O,CY:$)*[>SLWU&VNN"-8=8-2TJ9IM'
MNW4G,71GB7.&>%X6YT0'>!P<#PR"N>U&Y;3I(M=M4:6UF4QWT*G'4^57/=58
M2 *2>G,&,^^DUO9TKUU9@=-M.V[W'0)NN_#V=@E*U"9S %UT9.=G30L-L6GT
M(8(26BLF?,=>PJ=["3!B$%9(1)CCO-\7:A;SW-KI=F>9::)#X*.X<[Y9Y5")
M*QD/5D4Q*B >3<'9/(R@;.%M.F@BO-3NQLN]9F%V\"C9'#%EWA41CHLC<UG<
MGS[3&C^=&)W2YR-=53BE5(>3CKY<H[NN.^O7N)AGL7U,><,D(T5MSVFR=*)5
M*?NE*+-Q_5?(,"H$TR28C)<2\L"4N4"$ATJ1%^P[K@[5+8^*X9U5LZ5K8$:L
M3]:7YP+>=">BEV5$)Q@2I S817S#O%D"">+X<)W[?ME&2P/I[9S\F<=:Q99]
MA":K8-7^4KKF-D%M7[DKXVK]F-?0'FFI"'W5-"V#!!"$9B1K+7C\-NNE9V4L
MLK."Q#S3CT"TF)CUQ:63W<5]P)K,BQ7VGRO<:'>,I(P/.8U.0S0RQ,943J>6
M\H(#P1*.>U&X:Q:'7[13);NHBU"!3@E2=N_J" RN I)Z!PGV+N:WEZ4T2SL5
MRY;TO41L+;^PAQ-Y>J\%I4(8!K[SLZ6!1F G"$J(D&B<@@],DX=G.0Y$)4QQ
M))TIE[G>+KZW>:ST:S8S6NAPFT%RYWR33@(LWOAR>6G+5 JX0.K[1L$>/>%K
M">-+W5[M>5<ZS-XCPZC9'# &=H?(,#?()&<LPWE"FX[S)G=WG'UUE.*55!Y.
M>N%R-#M>=U>OD?$3LWU&F.VL2J(RM<B_ZJ:4_*N] ),Q\M2"T=F ^3)P1N75
MKE#9MN 0&%3;2A:.WX.U6W22ZX>U4[M'UQ>0X9@%MKTX%O<H6R(R6"(SXPKK
M!*QVPFH=XKB,S1?5(?.,=V"]2/EZ ]/2,CTUA:Q[&%LS=1^5GKH-?F5'8 (9
M3>T^N8+[7O:HJEQ0[LLDE"6V<6&J&8D4#)GN):9DR!M/+LMY"D2TN1=VED\J
M:AP%K#JMQ;2/<Z!>N"0&PT@5#WY,\3&4(,D*]Q&<2I&J\_J%PUJ8->M%+Q=(
MM1@4]2APN?5N1@!D],B,]%+$[P]*:99IHR]=BKQ!0 LW80PW:XM4@HS$&AJI
MAR2_7WGHJ$,HDDBC,QR=DA);<ER8+D:>\[B<5*)5S_%U[;JUEH-FW.MM#B,#
M7+G?)+<E56=5<Y*QQE FQ2%#@H!LBCQCPO8SYOM<NQRKC69!,MNF5CBMU+&%
MF4 !I)-Q;>P+%"K9#229WGYQM==3BE.*4XI66.=A4BG%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2M=]_=L^N?5IJJO
M]@=LUG5S=X=,L5/Y0_$5.'7*\V-=-X@M#8$]U:1C9@6J6M:$(;]^CX];.7,8
MXI7SJ';GK3L 9JHQ1]S4FV#=WV([4M5R0!!PIBX6:KCI9>Q@X+<1AQZ(1!#(
M,J:6C%&X"X##:5R<-^U9PXI6QG%*<4KH(=JK!"Q&JA L(6;:ZW #%;%6XA.%
M). 1MC4217IYH4R\N:+B'5!B^ S\YEALG\*(YA*?Q"DY:4KO^*4XI7X==;8:
M<>><0TRRVMUUUQ6$-MMMIRMQQQ:LX2A"$XRI2E9QA*<9SG.,8XI4%UAM"@[H
MH=<V?JZS0;E0;=%D3:W9QB)2!YB'%G2AKTF)B;'BR5,IFPI3*7%L(2[[+VK6
M5LK;<4I4]XI6)BV]].@+E;=?G]C58%:Z%086TKL.-$FQ,>IZ]($)HJ%:["8(
M8CA!(I^<.G-)<FD67<(BNR%M)C8P]E2LIQY#,N.Q*C.)>CR66I$=Y&?2AUEY
M"7&G$9_XI<0I*DY_XXSC/%*^W%*<4K$%-W]I?8$<?*J&RJF9:+WJVZR"8;)M
MQ'C]]HF26;C5Z[&(8B2; 3KC08O)*(#-3FHT(61G*=S#A27VU*[_ %AM37NZ
M*;!V#JVU#;K2B<\Z,'601[QD;.FUDX1K1UF([)8CJ?2..B20QYYM"F%28;V&
M77$)PK*E)6U->PMG"-,2;4.;VB=IQ38(JE_[2LO*I04K"!D[)ZK;"X[ R*7(
M0AV7I,AG+LN0AEE#BL*]52L@<4K6LAW#ZR"9K@XGN:GP9;6]8_65QN5(F,MI
MWS)B-3F]99D+AXC_ "A3%?8<D8P[[C$R^RU*F,NO-H4I7*V#VUZX:JQMA6P]
MMU>JIT9'U[*VWDBHAG%%:VO)5$UU@SF-!D8P];'TJP+C1?>9*FDYD/,LQ\>U
MXI7/T/VCZ]=G1APOH';M+VE#K,N+!L:*P3P^0 29R'W("3(B2W%+#&R"(LO(
MZ1,A,QY^8<Q,-UY4.3AI2L]\4IQ2G%*<4J$V7\=9_-4?KGN46J?5X_[(?3>M
M+_#_ "5_:U1WE96-.*4XI7'EQ(L^+)@SHT>;"FQWHDR'+9;DQ9<62VIF1&DQ
MWDK9?COLK6T\RZA;;K:U(6E259QGU69&5U)5E(964D,K*<@@CJ"" 01U!ZUX
M0""#U!&"/6#5?O4'J]=>L]W[!:M2H87ZL'3@>]:9#E'4$IP C9')[EIJ;<5_
M+ZFQ8!P>/9SB?A:9B,!2T1Q9*=8?9]=Q!KEKK-KI%\.9%KT,<EKJ,D8,:RI"
M$$$^Y2/?)0[GRXV^^1G")%FJL[.6VGO(6"OI\FR6!'PVUW)YB8.?*NT$@C!)
M5E\Q>K"N<A5M3BE.*5\WF69#+L>0TV_'?;<9?8>;2ZR\RZG*'6G6EX4AQMQ"
ME(<;6G*5ISE*L9QG..>@D$$$@@@@@X((Z@@CJ"#U!':G?O5>O4_JU<NM&T^P
M^O1J1,_J9=)0B_ZPKQ!QN:_6K18WYK-II\$:[EW#842P.CMO>_-K:DCLU%V(
M_()?*7V77Z]KEKK.GZ/>$R1\06JR6E[,F4$T$*J8+AG&"9)&=B-I!#^(#!4Y
M.:FSLY;:XNXB%>PE"R1(V&"R.S;XPI^Q 'F!&".7C)WU8=_)_)SCZMJ<4IQ2
MORM"'$*;<2E:%I4A:%IPI"T*QE*DJ2K&<*2K&<X4G.,XSC.<9QZ,\ D'(.".
MH([@^NE5X]7NJ]OZU[N[#5"OMB)'4;9+ [8-*JLU34G-6OQV8]"LM3&"G/6;
M;!1AT%S,G,B.J.X(5284=Z3,@&U8[#6]=MM9TO2+B4RKQ#9,]I<3H2.?:1*'
MAN)).AYK._EVMN$GB68!6C J;6SEM[J[CPC:?.JR*CX.V5B0T:IC&W:#NR,%
M>6!DAJL/QC"<82G&,)QC&,8QC&,8QC'HQC&,?@QC&/P8QC\&,<X_OWJV[=J_
MWBE.*4SC&<9QG&,XSCT9QG\.,XS_ "XSC_CC/%*KOZX=5K=UQ[$[_$5-L.YU
M'VX*C[!$U"7EIY-5VB6(Y@'ZT'#J]+#0!X4S.D2?3&3#^#N5 *WEYP+(6KL-
M7UVVU?1M)DG,HXATZ4VCW"DCGV*)OBGDD!SS1(4"X.[F"XD.!( *FVLY;>]N
ME4(VGW$?,V-@[9R0K(%ZC:4#%LC!7EJ,E35AR$(;0EMM*4(0E*$(0G"4(0G&
M$I2E*<8PE*<8QA*<8QC&,8QC'HQSCR222222<DGJ23W)/I)JV  & , = !V
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M3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI6B_;7O71>KEUTGJ2. C[,W9OJS?
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M"K]9-FW76^F*C4=VVK1]?M=^W+J5D'?3U31!1.E!B VX3(@F:LA(GCG*;8I
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E4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g65062g15b23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g15b23.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2/04&AO=&]S:&]P(#,N,  X0DE-! 0
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M<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M      IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O
M;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I
M;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M     %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB
M;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!O
MX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M      !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M          !2<VQT56YT1B-0>&Q </TO(         IV96-T;W)$871A8F]O
M; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L
M=                %1O<"!5;G1&(U)L=                %-C;"!5;G1&
M(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P
M4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M#6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M        /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))
M30/S       )           ! #A"24TG$       "@ !          (X0DE-
M _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $
M,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M '   /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z   .$))300(       0     0   D
M  )      #A"24T$'@      !      X0DE-!!H      S4    &
M      -_   &L@         !                          $
M    !K(   -_                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   -_     %)G:'1L;VYG   &L@    9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #?P    !2
M9VAT;&]N9P  !K(    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     0X0DE-! P     &3\    !    H    %0   '@  "=@
M&2, &  !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="
M(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M     0  ]M8  0    #3+4A0("
M                             !%C<')T   !4    #-D97-C   !A
M &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "
M+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D
M   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T
M96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/
M" QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@
M0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M     !)S4D="($E%0S8Q.38V+3(N,0
M                                    6%E:(        /-1  $    !
M%LQ865H@                     %A96B        !OH@  ./4   .06%E:
M(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P
M.B\O=W=W+FEE8RYC:
M                  !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U
M;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                    9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@
M0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                     '9I97<      !.D_@ 47RX $,\4  /MS  $$PL
M UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                 H\    "<VEG(     !#4E0@8W5R=@        0
M!0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R
M '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .
MY0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6 !9P%N
M 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!\@'Z @,"# (4 AT"
M)@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@ NL"]0,
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MJ4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M             /_A0!%H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_
M>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK
M8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z
M>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q
M,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z
M<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M
M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q
M+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!8W)O8F%T($1I<W1I;&QE
M<B Q,"XQ+C$V("A7:6YD;W=S*3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(CX*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y04V-R
M:7!T-2YD;&P@5F5R<VEO;B U+C(N,CPO>&UP.D-R96%T;W)4;V]L/@H@(" @
M(" @(" \>&UP.DUO9&EF>41A=&4^,C R,2TP-BTR-U0P-3HT.3HU."LP-3HS
M,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR
M,#(Q+3 V+3(W5# U.C$V.C,Q*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @
M(" @(" @/'AM<#I-971A9&%T841A=&4^,C R,2TP-BTR-U0P-3HT.3HU."LP
M-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @
M(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O
M,2XQ+R(^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!
M;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L
M="(^36EC<F]S;V9T(%=O<F0@+2!2;VEV86YT("T@4RTT("T@06UE;F1M96YT
M($YO(#$N9&]C>#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @
M(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD8SIC<F5A=&]R/@H@(" @
M(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3YR<C(Y
M,S<T.#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @
M(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F
M/"]D8SIF;W)M870^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @
M(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z
M<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O
M=7)C95)E9B,B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED
M.C1$.#4T03DW.4%$-D5",3%!-4,R.#=&,S)$134R,#$P/"]X;7!-33I);G-T
M86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C1"
M.#4T03DW.4%$-D5",3%!-4,R.#=&,S)$134R,#$P/"]X;7!-33I$;V-U;65N
M=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD
M:60Z-$(X-31!.3<Y040V14(Q,4$U0S(X-T8S,D1%-3(P,3 \+WAM<$U-.D]R
M:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @
M(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C1".#4T03DW.4%$-D5"
M,3%!-4,R.#=&,S)$134R,#$P/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 V+3(W5# U.C0Y.C4U*S U
M.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F
M='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z-$,X-31!.3<Y040V14(Q,4$U0S(X-T8S,D1%-3(P
M,3 \+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,C$M,#8M,C=4,#4Z-#DZ-3@K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@
M87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F
M/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE
M=&5R<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO
M=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C1$.#4T03DW.4%$-D5"
M,3%!-4,R.#=&,S)$134R,#$P/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 V+3(W5# U.C0Y.C4X*S U
M.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F
M='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(
M:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)
M1#YX;7 N:6ED.C1#.#4T03DW.4%$-D5",3%!-4,R.#=&,S)$134R,#$P/"]S
M=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)
M1#YX;7 N9&ED.C1".#4T03DW.4%$-D5",3%!-4,R.#=&,S)$134R,#$P/"]S
M=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$
M;V-U;65N=$E$/GAM<"YD:60Z-$(X-31!.3<Y040V14(Q,4$U0S(X-T8S,D1%
M-3(P,3 \+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X
M;7!-33I$97)I=F5D1G)O;3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H
M;W O,2XP+R(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H
M;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!/ )=
M P$1  (1 0,1 ?_$ !\  0 " @(# 0$            &!P$%! @" PD*"__$
M '80  $#!  " @@/!PL,#0D'!04#! 8  0('"!$2(0D3%!46,5'1%QE!4EAA
M<8&1DI:AL=+6(B-35I.7P1@:)#=&5%=B==/P)28R-#9$@H:5HK/B"B@S-4-(
M8W24LM35X2="1U5VA[2UPF9G<J.DQO%S=X.XQ/_$ !P! 0$! 0$! 0$!
M       ! @,$!0<&"/_$ %81  $# P$#!P@%"@0%  D#!0$  A$#$B$Q!$%1
M$R)A<9&AT044,E*!L<'P0E.2T^$&%18S5&*"DZ+2(U5C\4-RE*.R!R0U1'-T
MA,+BL[3#-&5U@Z3_V@ , P$  A$#$0 _ /W\5SS=Z0UTGITA$JD&[TAJ,3'L
MCYE$J.F3S@.B8W(E2#ZX^T42@D$<X'(Q,ZF-$7X9-_\ 99>R!P_?&[8C&^(@
MN,CL5V]LJ-@!J<,UJM@/"@IH;%BF."SJ&N'*V+1BU0;XJN%UEU,4[9K*J*7R
MSR_>O)WY)?D]7\G[#6J^3F.JUMCV6K4=RVTBY]2@Q[W0*P EQ)@  3@ +]>V
M#\G/(M78MCJ/V&FZI4V79WU'&IM$N>^BQ[G8K@9<XF  !H!"J3TXCLCOLE37
MR(U=]AZ]GZ&_DW_EC/Y^U??+U_HQY#_R^E_,VG[]/3B.R.^R5-?(C5WV'I^A
MOY-_Y8S^?M7WR?HQY#_R^E_,VG[]/3B.R.^R5-?(C5WV'I^AOY-_Y8S^?M7W
MR?HQY#_R^E_,VC[]/3B.R.^R5-?(C5OV'I^AOY-_Y8S^?M7WR?HQY#_R^E_,
MVG[]/3B.R.^/]4J:Y>7P(U=ZOB_</ZM/T-_)O_+&?S]J^^3]&/(?[!2_F;1]
M^GIQ'9'/9*FOD1J[[#T_0W\F_P#+&?S]J^^3]&/(?[!2_F;1]^GIQ'9'?9*F
MOD1J[[#T_0W\F_\ +&?S]J^^3]&/(?\ E]+^9M'WZ>G$=D=]DJ:^1&KOL/3]
M#?R;_P L9_/VK[Y/T8\A_P"7TOYFT??IZ<1V1WV2IKY$:N^P]/T-_)O_ "QG
M\_:OOD_1CR'_ )?2_F;1]^GIQ'9'?9*FOD1J[[#T_0W\F_\ +&?S]J^^3]&/
M(?\ E]+^9M'WZ>G$=D=]DJ:^1&KOL/3]#?R;_P L9_/VK[Y/T8\A_P"7TOYF
MT??IZ<1V1WV2IKY$:N^P]/T-_)O_ "QG\_:OOD_1CR'_ )?2_F;1]^GIQ'9'
M?9*FOD1J[[#T_0W\F_\ +&?S]J^^3]&/(?\ E]+^9M'WZ>G$=D=]DJ:^1&KO
ML/3]#?R;_P L9_/VK[Y/T8\A_P"7TOYFT??IZ<1V1WV2IKY$:N^P]/T-_)O_
M "QG\_:OOD_1CR'_ )?2_F;1]^GIQ'9'?9*FOD1J[[#T_0W\F_\ +&?S]J^^
M3]&/(?\ E]+^9M'WZ>G$=D=]DJ:^1&KOL/3]#?R;_P L9_/VK[Y/T8\A_P"7
MTOYFT??JPM2=EN[(5(]K:QCIKB,,O0Y[84+"EF>4+UFEB[&%9(,8OVV2B$+1
M73Q7:KJI741525PMG?)-3#.ULK>;;?R1_)ZEL>U5*?DU@J4]GK/8[E]IYKFT
MW%I -8@P0#EIT7#:OR:\BT]FVA[-@IM>RA6>TBI7D.;3<YIS6<,$ Y!'0OW9
MX\[XVO?KO>UN=_+?E7X.-!\=?:OQU,O['+E?E?E?K\G5XZ(OP/<9'9?NR+ZR
MXNN*/6\'XDS(*%P#B'W/"XB$2A6LG:0>-1?8LC" Q:;I_"W3YS@P&,FK7%=X
MY<.E<4K9N%U5<L\\O[;9/)6P5-DV9[]G#GOV>B][B^H"7/IM<XP'QDD[E_:[
M)Y+V&KLNS5'T 7/H4G.-QRXL:23TDR3NF8PNN%NS:]D_OSY<5!WGU<N<"U/Y
M>5_W!V\MO4KTCR-Y./\ [L-T2^KQ U#QOZ%Z/S1Y/_9QUR[QCN7CZ=MV4#V5
M!WY!:G^P=3\S^3OV9OVZOWBOYH\G_LS?M._N7E?LVO9/^=^7%0=Y6Y_N"U/X
M[6Z_W"?IJ_F?R=)'FS<3F^KN$_6)^:/)_P"SM^T[Q7CZ=MV4#V5!WY!:G^P=
M3\T>3?V9OVZOWB'R1Y/_ &=H]KOB2E^S;=D_]E0=MY><"U/]@Z?F?R=^RB?^
M>KOTCG].^9PGYG\GP3YN".,NQW^]/3MNR?\ J<5!V]O:@6I[^IY? /U/5\E7
M\S^3M/-1[7U9_P#,#7H4_,_D_P"H':5Y6[-KV3^_/_;3G>?5RYP+4_5UVM?]
MP?M^2@\C>3OV8;B)?5WD#4/''@GYH\G_ +..N7>,=RQ?LVO90+?\:@[\@M3^
M6]OQ#]JA\C^3A_[LW[=7B1]9T*_FCR?^SM/\3O@0ENS:]E O_P :@[ZO[@M3
M^I;G^(=!Y'\G'_W9N_Z=7<)^L0^2/)_[.T>UWQ)6/3MNR?\ LJ#OR"U/]@ZG
MYG\F_LP]M2IW0\=\J?F?R?\ 4#M*>G;=E ]E0=^06I_L'5_-'DW?LS?MU3__
M "!7\T>3_P!G:>LN^!"\K]FU[)_:UO\ ;4'>=[6O_<%J?[!^YR]^A\C>3A'_
M *LW(F+ZOWGSE3\S^3_J!VGQ6+=FU[)_>]O]M0=\=OW!:G^P=!Y'\G$@>;-R
M8].K]XK^:/)_[,W[3O[DOV;7LH%O^-0=Y]?B@6I^7CO;\0_:\M#Y'\G#_P!V
M;_,JQJ1Z\ZCC[%/S1Y/_ &<=4N\9[TMV;7LG][VM^JH.VYV_$+4]_+_]@[>2
M@\C>320/-AGB^H?<\)^9_)_U [2L>G;=E ]E0=^06I_L'4_-'DW]E;]NK]XG
MYH\G_LX[7>*>G;=E ]E0=^06I_L'3\T>3OV5OVZOWBOYH\G_ +.T]9=\"%(8
MCV:GLFQ*5Q@<]XHSB[-_(0K)VC>":JPLLV=$FR"Z5\DX+AGC91)3/"^6&6.=
MK7YXY6RM:]LO\D^3@QY\V:"&N(Y]4Y )^L&^%A_DGR>&/<-G;(:XC+HD ],]
MZ_HH8<^C;G?G?E;G?^EK5_! R)XSKUE?PB\JJ+^?_P ?O9A^R.Z=XV>*?5FN
M>)@[&H%K_>>Q(G$(^A"M8O40T?"2)ZQ&#DGA.%/"+G!JV232Q6>O'+G.V/25
M64SOEE?[FS[)L]2C2>ZF"YU-CB2YPRYH)TZ97]%L^R[*^A2<Z@USC387$N<)
M)8TDX.\F5U#]/1[*C[+*1?('4?V!KOYALWU0^V]=O,]C_9V_:?XIZ>CV5'V6
M4B^0.H_L#3S#9OJA]MZ>9['^SM^T_P 4]/1[*C[+*1?('4?V!IYALWU0^V]/
M,]C_ &=OVG^*>GH]E1]EE(OD#J/[ T\PV;ZH?;>GF>Q_L[?M/\4]/1[*C[+*
M1?('4?V!IYALWU0^V]/,]C_9V_:?XIZ>CV5'V64B^0.H_L#3S#9OJA]MZ>9[
M'^SM^T_Q6?3S^RI7Z[<6,CY>7P U)]@:>8[-]4/MN5\RV0Z;,/M/\4]/0[*C
M[+*1_(#4?V!IYALWU0^V]/,MD_9A]I_BL>GH=E1MX^+*16_Q U']@:>8;-]4
M/MO4\SV/]G;]I_BGIZ/94?992+Y ZC^P-/,-F^J'VWIYGL?[.W[3_%/3T>RH
M^RRD7R!U']@:>8;-]4/MO3S/8_V=OVG^*>GH]E1]EE(OD#J/[ T\PV;ZH?;>
MGF>Q_L[?M/\ %/3T>RH^RRD7R!U']@:>8;-]4/MO3S/8_P!G;]I_BGIZ/94?
M992+Y ZC^P-/,-F^J'VWIYGL?[.W[3_%/3T>RH^RRD7R!U']@:>8;-]4/MO3
MS/8_V=OVG^*>GH]E1]EE(OD#J/[ T\PV;ZH?;>GF>Q_L[?M/\4]/1[*C[+*1
M?('4?V!IYALWU0^V]/,]C_9V_:?XIZ>CV5'V64B^0.H_L#3S#9OJA]MZ>9['
M^SM^T_Q3T]'LJ/LLI%\@=1_8&GF&S?5#[;T\SV/]G;]I_BGIZ'94?992+Y :
MC^P-/,-F^J'VWIYGL?[.W[3_ !3T]'LJ/LLI%\@-1_8&GF.S1^J;]MWOB4\S
MV/\ 9V_:?X_/9#T]'LJ/LLI%\@=1_8&GF.S#_A#[;C[PGF>Q_L[?M/\ %?H;
M_P!CV]D"XO.,S;'$9'N)/<A+9P:$Z]AAF,,7\<A@3$63*2,FQ?.DU8O' BZ^
M3AJ@BEDF[572PLG;)/##.^667S/*6STZ+:7)ML+BZ3<XC$1).G1\Q\[RE0H4
MJ=)U*F*9<]P,%QD!H(U)XK]4-?*@^N/M%?(2J)D<\'.ETHNM9[BBUQ$>(D=P
MYR][X.R>2PP%+(<7(+(I!9"Z,&9"'SC&#C/H69'<% >*X]-QG=$O9W=HW53?
MI-VSV&J&U.3=@D CAK!U]GPG)7847NI<JT2 2"!J -_5QX03HNRE:<'23= Z
MR%Q2C9S)!TWS&J*BY!Q,:'BCDNSD6S8V)<@6)@F81=*NK9L&$?EG@*9=+]!M
MG:R0^7?U!<7QOE>S[[G&V6'W=8-2D'$%P#A),SN)!/" 01\A=!1JN@AA-Q &
MF26WC?ZN>I5W^KRX/_X?8+_T@C_W?6>6V>9Y1LS.IU6_-J_U9[6^*?J\N#_^
M'V"_]((_]WT-;9R9-1O:4\VK_5GM;XI^KRX/_P"'V"_]((_]WTY79_7;VE/-
MJ_U9[6^*?J\N#_\ A]@O_2"/_=].6H8BHW4;S\_BGFU?ZL]K?%?S].(TL-/<
M0V^CH=XB0$&MT[3+"G[>^5T'PTE.CSU@\1OECCE=%TU7272OECCE?!3&]\;7
MZJ_U!Y(,^2?)A&A\G[$1_P!-27[IY-!;Y/V($$$;'LH(/$;/2"IJOH+VI1$H
MBWL;!Y2 LB/R=8,&F"+Q^4)*)W63&B!C18@4?Y(XY)Y.5&S)NMFV9)J8+D7G
M<X]ME=RZ1QRY5JG),+@+G2&L;,7/<;6-F# +B+G00ULN,-!<,5'V-+H),@!H
MU+G$-:!@ZN(DQ#6RXX!5[P6-; G-L,=68,==Q7OXTB@P\^+I!STDDCVV&3,+
MB=9HYRZ8R=XDLS7>1R',7(P0FZ9N\@8EJ]P=._G;34V;9\[9=M5>PUG4V4[V
M4J8(!J<FXBC1I@BQM:LYM2I!8*CRTM'CK5:-'&T36J!G*NIM;<QC6DB_DR>3
MI,;) J57 F+;W.PM+L%MMC5TBO$]P,%9#V]OW7@/E)"TE:OQUG;L<H[CTF2=
MN2(E9H28/ASO,*48OQAD:0!'FB;MB5#VZ;,=CVND:^PGD3,%U)II.:^T. JT
MB VHTM<UP#PYCV.;4I.+7,>MT#LVT4Q4V4A@! -@-,AT!T/IP+@6O#A>"UP+
M7L):X.-62D*S%.6+L2NX= #S#$N#7=]KN]3:Y.7+)T.)=IP22N2$DF;P<Z53
M202?8MT2K9L@S(-D[>RB]SPYKP!5I.LJ 3!-K7->V23948YKVR26W&F7.<QQ
M/HI.+@0Z ]AM> "&SJ'-!S8YI#@)=;):7.+3$8KLNB41*(E$2B)1$HB41*(E
M$5E:9?LQ6X-4%"+A-H/&[*@C]^Z5O>R39DSE(IPZ<*7QM?*R:"":BN=[6O>V
M.-^5KWZJ\?E$QY/VXG0;)M!/0!2>2?8 O/M@G9-J U.S5_\ ])^/;H.E?T)<
M>/+@_MCC;T?8+XK?WP1\G\GU_ET;11@34;._KW[E^#>;5_JSVM\4RX\>#^^.
M5O1]@O7:]O[8(^3^3Z><4?K&IYM7^K/:WQ7\Y7CD/AI5QI\74GCI! L D?$S
MO4Z$*-;Y9-B0DML^3OQS]O?/'#.Z#MHX1<)7RQQRZ"F//'&_.UOTO8"#L.QD
M:'9=G_\ TF+^_P!A:6[%LK2((V>D"#N-C975S'Q^YR_ZUJ]K<GJB/M#Q*]2Q
M?JO>WDO>H<$C@2BS?KO>WMY7^;_PJG)(Z7'N_!%N(Z"=R4RQ"LE$$57BBEU7
M3O/)-D/9-4%7A(J05PP4R1&BA[=T2(KXIJ9-V+5PM9//M?1ODD-:YQT:-!J3
MHT#$2XD *.<&@DYC<-YW#0Q)Q,*7O)NB RS&:[0L$8-[Y)7E"S5OX:G<\>6.
M9%P5R[H6C2+C.RBC4#&G#1LQ:9MVA1_(R+3,Z[R&D@%_.)@V3S&\( YKS$2Y
MUTF8#1A8#"Z#4(<=8'HMZ,')&A)SQ7M9SR=/F[UV;LYV "88-^_*$O;/)*Q9
MI/<[-6_3-+9]^(THZ7RQ0;O@QD*_S5OBD@ZO?++#)8T$013)!@LM:8 YT-BU
MY#1EI:Z6D1N(&FR0!S''#;=V9PT8/$B.S5:24@AS)(3((]D[4B\CQ=W'8OU$
MUWX@H-R:6-1DB[10:MGSX/9^/<ID&[9JF3#%@Q-5@*=O7 AAMADEKASV%N0"
M 02"' $ <[G2,EI!&@!6FN)D.PYIC_F&YP'3!D"0#C@H;?GY>?C\7NW_ $_3
M:AGC.NG6?C[PM);YONOAM;GYJ#NYW:!/@BQ3)^> \ B5-$6;VY<K^6UOHMSK
M1$0>('N$HEO';EX^=N50:B-9$(E^?5S]OZ;_ *>=#.)Z?>?C*+-K=>/+U>?/
MW.NWT<_FHW) ^8W]R+QJ(E$4FA2Z3:91)ROGBD@WDP%==7+GT4D4BK3-13+E
M:]^CAAC?++E:]^5K\K7OU5BI^KJ?\CO<5BIFF\?N.]Q7].G'CRX/^5O_ "^P
M7JM;^^"%_4MY!]Z_*Q7H@ &HW?QXGB%^<^;5Q_PSVM\5G]7EP?\ \/L%_P"D
M$?\ N^KYQ1^L;W^">;5_JSVM\5_-J[))) 4SX^>+^51<FV,QV1<0>SRX0LTO
MG=J1&OI.^<-'C?+/##.Z2Z.>.>%\L,<N5[<[6OSM7]5L3AYK1<#(Y*G!&\6C
M(Z#..HK^CV9I;0I!P@\FR1O!#0,]D]4+I)7L79*(E$2B+-[<K\J@,B46;8WR
MY<NN][]&UNN][W]RUKT+@-=PGOA%V67@4H@$2>G8Y&!Y<D&7<-)E+"%@)AY&
M2 UV*9%A\6B+]RZ>8AXX:,#(](]F7!/F'A<LB#CAD-@EBYDOGN#GP3K!#8.1
M)U< &@D D,)]$23.$#FY$B> T.L2XP 7"76S<1.)@*'"I)NTP_"#T'<MDV<C
M=8L 84\S<R@*:74<]I[E:!)(V(@GN&+KFGGA9GFBWSQSMGVNV&5[:(I"<01F
M9 ZI(.@W9[58'[H DF)EN(SOD P /;HO?LF 9BT7)3 .QCQH7@$6E4=#&F4D
MCG>^3,\'T<F,,.#"1MJ^BY?!3!B11P,%D AU1HBW++(G&X<"IU,AI)(,VDB#
M(/H.! (<(, Q@2=R#G0,XP"Z1,?1((!#IXXZ=%>N@>'G29G14MXE.)"=;+C.
MLQ.Y(9H2.A-.Q6.R>9E9K*HK))R3D!125G08<9%XG%XWDMDS0L_+R<J3;CF>
M8A)JX?YXJUJC:HI4@USBPU#<2  '-: "&G)+ADX ))T7)[W7BG3:'/+#4<7$
MAH:'!H AI-SB1DX DP=VP2X!-C2>&239VLI;!93!;H[HE&IA<B+WA&W=U:IT
M2^>I;!V5$=7O\7ZS-A'!XXD],!"\@:FK+!)$R -I%F%<JW':FAP8X$'_  P\
MM!<VD^H(:US@<R<AP$1TIR[+K'-<"+&O< 7,I/J#FL<^8,G1P$01,:BU)5V)
M+B3B6$F2>S/A^(&XHZVR'(Q4/M)1Y)'$LTOKA+<,XA(YCG'4$'<F9ZN6QFJ"
M=W:0C ?_ %*)F!LH41 J\QMK'%N*@#BR"60T![BUI)U@N$8S@P#J,#::1+8;
M5AQ9!+"!:]]@.I,7<TXD&01*\<.Q)\2BK=OVF8: 4+NGC,$C&<=I9XR+PT-:
MA0WM%(%=BI'L$?"N7ZOS=2,&C9UD'0L->,) 8!$%!S9^\^IDS%0-P9L %MUC
MC).@?@[\XF$.U4C,-J0!,\F8@/Y,NDN]$/YI,8*UX[L2_%R_8ZH?7&0-AAMA
M(0JTP+RU84G"KR744FWG%,9Z1>AD0PRTDUM$#QIHN$)R)F'<L^\TL<QTNI@R
MOH[;3!?Z4,,8;)(#PQQ:))YKG";@)&F<)YU0!>"7&R9AIS#@PP-<.(&0)$Q.
M%&@?8\9M<QJ'PAVGHYT'VYL6%1V'@XMM$=Z(.PX!*MVX:-QV?K$#)109M((P
M\EC<NF%NZ<M3[@:-<2E>,X1-!<OB.U&'VL?+&ON)8;6O:POM>0"6N&\8$P,*
MFNT!YLJ L:298ZUKA3OM>1):X B=1)M)"L36_8L]GSHS&Y(K(HTEIUYQ(P?1
MTP?""ZI784)$SC?5]$CY 48X!\80L6L>QQR4C;&7/9$U1>#"Y*/,0!!$A67;
M8&@C-XINJ"0 QQ;3-0@?2 QJ=TQ)4=M-,7"TW"D:C9!#7Q2Y4@2;A@9F!$@$
MN7'9]C%F4[-Q8!K;8.O@CXGI64[L+7W%+D8@W5A\1VQNW7Y^3B'0D,;9#XO'
M!VH\7LE?2MV'R'$"[5)-1= B.MD\[M!<YKB+PP!C;C+F4R 1@DDN(%N#QPJ-
MH8&DO#L/:P6-<Z2YC'!I&\FZ &DR9X*B=T< W$'H?2D4WU/1(!&%2C* X+-A
MA5ZZ/1:^U8B0G>M\I*T<B60ZUI;$QCLLW\'RT@R!Y61$RW&/'7386KTI[53J
M5#3:2"+M0(-AAT&01K](1B=(G;*U*H]S&'(#M9B6.L=&01#M[NM4YO/5 W4+
MK5X-(D_>R23:5UULR;LWN#;!$$:V8P<S0 &'60QLKW+AKDQ!2+GNW+)WB7)%
M$[WQ;IMT\.M*IRA?B 'N:WC#8!)ZW3I.!KN&FNO#C %KW-W\X-(:7>UUP&F!
M.]4;;QVY>6U=#H9X%5+^._/RWH-!&D"$6*J+]-G^QGMUZITKN/BA);4FX6$,
M3FM((Q$N3*BZ:;YVUE!9=P@CVA!?*^:2.>*F=KVM:ULK==^NOB>67,:VA>X-
M:7.UG)C="^=Y2IOJ4J08TNMJ.)B, M $R1J5^P3]7EP?_P /L%_Z01_[OKX7
M*[/Z[>TKX_FU?ZL]K?%/U>7!_P#P^P7_ *01_P"[Z<MLX^FWM*>;5_JSVM\5
M\"^R>;:U[M_B*CLNU9,!LO!,=51D,H9"*N+H-C+&3S1\LTLHJDW5Q<MVY!BX
MO?&UNC9=.^.?2Y\O'M#F5*@+3< W<8R"-_3\Y7T=F8YE*UX+3<<&-#U$KO5V
M/WLD6$@[PZ-XA#&*9^_<PB";,)+VQ3/YWOBBQCTR=*WMBD;ROT6XR0K*62,Y
M9)-"MTRW1?%NM"N2 RMN@-=.IT <>/ D@9@Y7FVG98FI3&,ES1[V@#361NU'
M ?<+Q^*O< !H%X%^:/BHYWE^^;^36G$!_P#[T96M7S:GZQX_<?W[1^"^M0RQ
MAZ6#LV=L+Y)UR7J2B)1$K+OH_P#,/BB^7TK_ +J9-_[0F_\ YFZK_6'D;_V/
MY*__ ,;L/_[6DOU_8_\ ^DV;_P"!2_\ !JT%?27I2B)1%.X=TL@NS4T\^2RL
M"0LFG;EVQ;%#8,#=NL4K<KY9W18MW;E;'#KQ:(.5<_O*:M[>;:/UFR$Z#:'3
MT3LVT!IWCT[6C&2X#>N%:;Z!P0*ID' @T:K9)G&2&C0R8G*LX0#1VUK&'Q8%
M)X>!EFNG\LL\B\VF$7U\)D@>3OV!-*6 Y',RP*+O)&W7PO'9$%=%&9E4&'B+
ML*B9;-S. +RU7G8MLK5JM*O5H[2RDT5J%"KM+Z3Z0<PT:E*@RI7%$@"K2>&&
MF*CZP<6%S+_.YQV:O4J/I57TZS:0Y2C2?6<QU-KV\DZG1:]XI&34IN#+0]U8
M5',/)A\YX@4I(IJ73;4M)(QL96&OY2 DTTAAAE)A<9-.A4/#1O6A60#U'#8L
MZ%1"!M"X>2,73J,2!$D5%14F7RAQ]QAY_)SJ7GNW%E*KLW+BE5HT:[#3=6IA
M^TOJ[4VFX TQ4K5W,-,@5*1:Q]8,.T,:>6Q<F-IVDMIU* JBFYE*JUU-U5LU
M'OVAK7 %I=5JVOI.BHQS&&HUIJ4VB*Z+#CCD]X6H_(F#(L%/\1PU@2"DVR3I
MH5CI:2ZB$/&KYHXQS2>""5TC Y1!5/)LODD10RME>ZUJ[;>]S*'E>I3<6/I^
M3'%M1I(+*S*6VO:00014;--P/ L.FO3:W.90\H/8YS'LV)Q8\$@->&[2X$'<
M\7,<2-):=(7V$E?#U'#4C?-MP</FO]$S!GQ"\3T5T^."Z?BVN76QM"0_AUW+
M+T)&^@)()<#+!4=E4>U_A'MC91I1UW4==9##.1!%HZ8_Q5+R@^G2'F7E/:-N
MH.\F^2JFV.J;75V@;-M];RIL=+DF;0RH*E)U2C5VGE-FY6(;+Z=I(7\O3VZH
MRF#LVV5MMHNV'R?5VDNVFIM H;;5V_9:1IMK!X?3=4IOK7T+XBF+V%IA4VMV
M-O3SECP_' [K;F0J> Y&M( ADJB V%L.8 ^'I]N45!]81L]J46'[;,CPM:+
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M$\ 9PH=GI 00!S'-@N(-M_*NU()%TDZC!/2L'NR <70-W#HS)"$<$3'3#5_
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M;)9513)9?*^5[K*Y9Y9745O?+*]U,[WSO?+*]\NN]  (@ 0($ "!C X# P.
MX) U@3I,;N'<%Z:JJ41*(E$2B*R]+L69/<6IAI%LB\'D=F0-@^9N,+9H.F;R
M4BF[INMA?JS2704S34POU9897M?JO7C\HP?)^W Y!V3: 1T&B\'N*\VV2-DV
MHC!\VKP>!Y)Z_H<6X).$CE;_ &O6K?%;]R[+ZM?Y=%"B0":;9@'37KX^U?@W
MG%;ZQW=X)EP2<)'*_P#M>M6^*_[EV7D__#0T*)_X;.R/<GG%;ZQW=X+^<)QT
M Q$9XU^+V-Q\<U$ 0'$YO<*%$L4L4&0P2+V?*&0X>S0Q^Y1:LVB"+=NEC]RF
MDGAA;JM:OTO8 &[#L8&@V79P/Y+.$+] V$EVQ[(YQ))V>B23J2:;2NK./C]S
ME]-K?IKVMR1T1'VAXKU+&7CO[M_IJ.U/6?>B7MUW_P +YN=(R1PGN!1;B/G'
MD;,,#3'%%1=BM?/)LZ3NLR?M5DU&SX800MEAW4,*,5G(XDTRRM@[8.G#93[A
M7*U9(!:0=^A&H(R".D.APZ0%' .!!T*F#N&LI IF2U^];/6CCI*YQ4F48,98
M#4SMT[#,$'ZS+"6H896428DXWW:Y=MDD7)@1'WKQ(90.+</#@0,/:"6$=+@(
M:8$NNM .DA8#RW%3!W. ):>F8YIX@B)T($3EG I6S1<8'7C>"AG/:+%,Y,3[
MTYK)-U<%4<\8REFM)CUDW':[H8B@).Z*V5E\^YT$EG2*YA(MEY$$6MNB?2%Q
MYC1@3<1NUWB]LB 7N&@#9(GB2(;.)DC"T\H/,'^ H#'DWC>+1Q-RF+L^Q21?
MDWY!1#,S)2C=LLNU:DS.35BAW*W7<X#0PL*&S?E5!F15Y6-,N+HN=%UN@$P&
M D D-!.8$DN,<XJM:1<707.UC0#<T3PWG>9UU457=.7&6&3ARNXR3MRPR654
M4OA;GXL+YY998VORM?E:]K>_SJZ:>Z)R=8B9!Z\E;  T$=2\E7CMRLJY<.G"
M[A?'+%==99519?'H8X<EE<\LLU;7QQQQO;/++GCCC;Q8VM9 ,8'-D@0(;&00
M(@&=XRI @"! T$"!&D#="8OGF*:".+MS9%JHHJV2LNI9-NJM?#MJB&'2Z*.:
MO:\.V9IVPRSZ&'2ROT;<I@S($D03 DQI.,@;AN@'<EK9)M;)B3 DQI)Z-RED
M#V%,-:2^&SR$GG(24Z_DXF9P\EBBT?IA9.%?M28TLB-*-GHIPLW?,FB^23UD
MY;.>TX)ND5T>:=SZ=*JQ[*@!;4I\F_4%S2"'-)$&((C.X++Z3*C7L>T$5&EC
M\02TX(D9[U'C1DG("3LP8>K$"1!PLZ=N5NCTLU5U,EL^AAACBFBE;-3+M:".
M":"./)-%--/''&UAK6M:T   8 C< #TF(DF3C<M!H: &@ "-.@1)Z>*U5O';
MGXO5J#43IO56;\O4OS__ )O^CE5,;C/^Y^$(O.UK?<>WSY]7J_\ \U0&DM$G
M.O7NW<47KK*)1%)H2BDXF<2;KIXJH+R< BLEG;I8*I*E6F"B>=K^/#/#*^.5
MO5M>]JQ4_5U, \Q^#TM*Q4_5O_Y'>XK^G[CP2<)/1MSX>M6WORYWO>+LNOGU
M^MK\L;1I1/)M!))TXDK\X\XK?6.[5G]1)PD>QZU;\EV7U:O(41_PV=D^]/.*
MWUCN[P7\UGLE$=!Q/C\XP8Q&1;,)'P/$+M$2&$#T<&[$:.8RA^@T9-$,+6P1
M;MT<,4DD\>K'#&UK=5?U.Q0W9:( #0*5* - "P0!&X>W5?TFSN+MGHEV3R;3
M)U,M!S[20%TAKV+LE$2B)1$O:]K\KT!!R$7E:][<K^I:_E]7E4,&0=2.XX5'
M3G!':(5OOL6>R'.,F%EQX78"F:;B2"3)1H":2$Q;HYK2R.'B2S00V($UT\W\
M@ E" Q=,VOD\B>11H1S"1CEEG-(EIP'', 8@MS(B8.GK95F!.2(()&8D:$'5
MNX0(WRI9+2/$;L4>."[(E4O,A0F2?>YQL>:IMPJ-DLGMVV;<]+"[=B1Q:7*%
M%1]DB#V[;OJ5S'XX7)O>Z<!M-AEMLG<&9,'@.K.FD%1K6@RT-!(@M:,Q,YWC
MCJ)@*N394(! JPZ,/K&LB#ML^E<H30=M&A?-A96XL*"0?MVA/"/,%EE7[I<F
MT8.CA7N%=P)9I@1JJ^V@O-SA S:,8SF8WG>>C5.DC&0&S.).9 C48WZY@KZ]
M=C#XT^&#A]TG/=*\2SHTZA6UM\Q"63F.BHT5.6=PO7NNI;*HL0ODU'O&BB^&
M[8YK(5DQMEW=@Q*/"5\$QS-\Y2\FUT*U2H'T@+F4W $XRXM:0,;V$G@(.03"
M\NT4*U1S7TH!93<T&<W/>T'=]67$1(D9B5V.>]D$X*-K[6E.W=MOHJYDDL.\
M-4DW@XG7#DGM<EO35L0X48'!-M</NO"1V/D7.L90IN,/)UVTQLZ@XLJB]#GV
M\ZLF 8-7''D*[&AC00V'!@;5#;'FJ7-J&"+P60".=&1:"[F\O-J[&AC 0 *@
MIAM6T4W.K.<Q[HMO!9 +1?F19))%-0_C"['ZF%UE$-B:QA)_74(A/ &0>QL5
MHN/-I@2V-KR9*X\469B=8107()?=_!E$6)A&1R1>.3ULT[@8]N<NG"^?0TMH
MEY:YS7.=M&34<1:[]40"2UH))RV"W!W9ZFCM O<UY#GFN+C4= 8\'DH -K3=
M!EH);(,B)5K$..O@R:>C5"H](]>APLX!\*! [)QG#Y@L V\5U+Q 2F93T0X%
M,-':_P PTBQU2>#1P8>]#.#"W"X'M>+QR8:HR8_@4:QM)8]T&K:TU/1#Z8:T
M@FHX07!Q().IP!(7/D*Q-,D/+F\J '5#++Z;0"#RKY%X)BYQ@YQS!XC^+#L=
M J/PA _(]5;)CSKBXD>VMD0A_P 'K09.A>G'&URY/7^LX/-&^LA;<K'P+ JU
MV+L6\WEI<G+!PAOJP,P:@$G(8XY#:27 -<P\DUC7<I(+PT7.>+C!)$- : T&
MZ=Z<AM)+B+F.%(,815)!>& .<YI=@D@M; :&@R3$%?*7C^V;I/:FY0)[2",9
M<B1^MHL"E\JB42\"0\YG#)R8<$I)8#AKG4*%GN MZ% O2:&KX/@66"=VJ!UE
MU%BY/V;*U[6N#YFXD F2UIB&GG.S,GTG1I*]-%KV4RU\@WN+6D@EK=S20Y^A
MD@7.B2"2<KHW7J719O:_*W/Q>IUTX]_8/A"IG?\ .!\(2W/KY>3K]RH8Q/''
M6HG*_+GZEJOS\]JL'7YW>(6+>.W+Q^I0Z&=-ZB7\=^?C]6@T$:;D2B+].O\
ML973^KMO[EXHQVT()&YTQ#:S@;P4UD@Y$BBP=.92617<-L%K7LDJJEA@GGGC
MUY88VM?JM7QO+#&/;0#VAT.<0")S;V:3'#VKYWE.H^G2I%CBTFH\&-_-:OV'
M_J).$CV/6K?DNR^K7PN0H_5L[%\;SBM]8[N\$_42<)'L>M6_)=E]6KR%'ZMG
M8GG%;ZQW=X+X =E!U5 ]6\2$:B6K84&B <AJJ+D[@HP-Q:-G9I_*IJQ4=8LV
MV-[K/G2+)BUYX8W45Q;H)8VO?'&U>#:&MIU(8T"6S &I)$:<>&B^CLKG.I%S
MW$DN.7;HP/GJ"[Z=C^[&^G#+@]X<0 A->7VLW*PC7)!'!5O$\_N5F9^5-U+9
MIKR?#[E<<&5PR1CN=L'+[',]BFB$[4-F_P")4 G5K=0TZ21H3C2=VB\^T[3,
MTZ9QHYWO#=_03OT&,G[7U[8R3QCN7@2LWYB-\:],<$2E^8C?&O3'!$H7P2(T
MZ?P1*G*='?\ @B4NN($;QOX9Z$7XA]\]AW[()-MY[IF<<THS?1V7;:V1* #[
M+8^M&V3T)()D:+"G>39W+$'3;)PP>-ULD'**2Z-\[IJIX9XY8V_<_)WY9_D[
M0V#8J%3;BVI1V39J3VC9MJ=#Z=%C'"11@P6D2)' D97ZWL7Y3^1:&Q[)2?M<
M/I[+L]-XY':3#V46,<)% C#FD8)' D954>DH]D=_@*9?G.U;]L:]GZ<?DS_F
M!_Z7:ON5Z?TL\A?MG_8VK[A/24>R._P%,OSG:M^V-/TX_)G_ # _]+M7W*?I
M9Y"_;/\ L;5]PGI*/9'?X"F7YSM6_;&GZ<?DR=/*!/\ ]+M?W*?I9Y"_;/\
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M6(MWSK#/&+(Y-,TS6<)8ZI #I=)  :U]0RX#+M8S(DY P8TU726N=S0279,
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M25QM?'!<]I#7&J'-<7VDF0\R"Z"9#B-8C$0LAS_1EX(<3!&0^ "XB/2(SVP
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MJU0W$P)SB'?W;U8/KO\ M)X"PK\4X_\ Y,;_ %:@;()@"-T.SWI!.KGG^)/
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MJ$$G<?GJE+Y6M;QV]^_F]KG2&DB+NG3YUA!)W'N^!*STL?76^&U.;ON[DS,
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M.H8 ?[_,2B8J9;*9O>]+/N\?'JR:=&8:&E["\ &H0*A;R0#B< -)<]PCG$,
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MH\YYU6TF,>0(=_A-(O#G,+N5<2V7N/HM8#K%Q.);&7MIAKPT GF Y +9<]Q
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M#@.<ZUHRV22X8@1OF!)Y,UX]==LR\UU_!6+HMLX.$25BS$RYCN DM)7\LUG
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MO,/#[90&7("2+%*:Q6;2^UC<BB4LQ,QDBMS;+"KL<U&N1NT5&FX'/-() P6
MAA;B6EH) ((<!O$(USAF9/-@DLD%K;6$2##FC0ZC$1"X>&D^&-/(GFGK&2X*
M&!T@%$5K,MG]O7:2D-+X^=OBO=]=9N\?"Y_-T;$6V:)!JO*SSYFZ;OR3ESF.
MT5#'..((]'!:6EI@- (%K<'<T#$(7OQSM(B+8$$$0 ,00%R3NH.'&1%%S3^
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M726$&X@F009RUIS)P(B IPUC6E&<-F^OFL!-IPS9#9^RFH"\7F:C0ZR)0\3
M';1;/-.[ALVRAH(/'4$6*S5-F-'-4FF*%TL<ZR:KRYKKC<V(.,0XN&(C#B3F
M9)4N<2'%TD9:;FB,EPZ^<2[.9)RH ST=PTM$98DK 9^65G8&81B7D9*^W-*C
M,A"3^.P")2YD0-R4V5+*W,1O5T%"Y.,7F+EDP X-QJS/!Z2L\UYQ4YN8M+2V
MT-: 6EQ$AK0")>[<"9R28*I>\VRX"V+8+!!!>X&-#E[C!D&<A>M327#RB;=R
MP7")FA*N^9J0A'15+<)^.1Z1F]E1[=#PB*A;R0HQT<R=[<B4:GQ0.$;!F9,R
M+Q[;DDDNM:[EZA :3( (,!@+@6EF383-A+0XDD#&\H'/T+A&ART$B+(+H)]$
MD9F 3QS&0'#=P\--;#]>2J,SB4XJ%=A2*8%V8K9$(RG9[;A7$ULW"2#X<1&)
ME(E*'B3%CX"FW)J.L8X#C<?Q;N&8%AGCH[34O+V\TBT-&'6A@AL%P)D#)<""
M72[?"I>\NN!$\T"2UT!F&P7"00!,ZDDDG,"9WTUP[6[]70AVS&69HY>28K#C
M6[QJ\;,*2=_-'+B +,) W4UL@_E)4D9*CX#E'!Q9=XJB3:.V=L&^&>7?C3 C
MT69$!H#I9SB&BV728  C,PN>3J#KK9G$2[$.(& 2,;HPK@AA. :\B4<@L,CD
ME!12)!V "/B$8I*W*8\2,;X-6;6SEZV<O7.2:*>-E'3URY=N5.DNY767444R
MPY[GN+B3<XRXS$GJ$ =6G !0\XESLDDDFYHDDR2I-Z(@;]Y2KY'2+_L%9D\3
MVE2!P_K;X+CN]@AUFKI'!C*<E%6ZZ6&-XA(<+7S42RQQM?+)A:UK7O>UN=^J
MW/G?JYTGC)X9.#W^U,3P.,W#W@?[=RMO4S%T-UY%V+Y!1LZ;C$$UT%<;XJ)Y
MVPMTL<L;]=KVOU7KUT@0P XP.X =\2O'7(-1T&58M=%Q2B)2!P1*(E$2B)2!
MK&>*)1$J0!H $2JB5(' =@1*0. [ B4@:0(X0B4@<!V(E(' =@1*0. [ B4@
M:0(X0B4@<!V(E(' =@1*0. [ B4@<!V(E(' =B)2!P'8$2D#@.Q$I .H!]B)
M2!P'8$2D#@.P(E(' =B)2!P'8B4@#0 (E<Y-VI]*.]$I)NU/I1WHE'$W')[>
MA$K,GB>THE::3<,G?OZ"B]>2*65[WR23RO?QWOAC>]_?Y<ZC<N$YUUZOGJ5D
MC0D>U>/<Z'X%+W\,;_3;JJ$Y.Z"1@ >Y)/$]I3N=#Q]I3^)C]'+E2=V.P>^)
M23Q/:4[G0\?:4_B8_1RY5IF3! B. Z-^J2>)[2L]H0_ I?D\/-1@!)D3CXA)
M/$]I3M"'X%+\GAYJPDGB>TIVA#\"E^3P\U$D\3VE8[G0_ I_$Q\U;;D.P,#&
M!T]'O23Q/:5GM"'X%+\GCYJC<W3'HDZ!)/$]I3M"%_\ @4OB8V^BU9F/]@?>
MDGB>TIVA#\"E^3P\U:^A_%\$D\3VE.T(>/M*7Q,?HY<JNK"3DSJ==V])/$]I
M3M"'X%+\GA]6L))XGM*=H0_ I?D\/-1)/$]I6.YT/P*?Q,?-6_5P,DS@<>I)
M/$]I6>T(7_X%+XF-OHM72!I CA"2>)[2G:$+?\"E\3&_TVKFW)@Q$:0(W9C2
M>E)/$]I3N="WB12M_P#X\/JUT@<!V!)/$]I3M"'X%+\GCYJ0. [ DGB>TIVA
M#\"E^3P\U(' =@23Q/:4N@A:U[]I2ZO^3P\U+1P'9"2>)[2JV>YJ6=NK6SSQ
MM9RO:UL<LK6MC97.V-K6ME;E:UN5N5NOE:UO4KS&9D3F9'3C3!C3>(UTE>QM
MH !B0!,ZY'$ZKC7S4Y=2BG/_ /'G?Z<K6H9&A)[/@)/L26'AV1[PL]//\(I^
M4S^M0AQ SG?I\ DLZ.S\$Z>?X13\IG]:@#AJ[LS[PDLZ.S\$Z>?X13\IG]:@
M!DRX]'R1[DEG1]G\%$G>PH.PD3>(/IS%F4L=]K[DB[N3B6TB<]NMS1[G"K/L
M"2W;;=:?:VV73MUX\[5>2K.::C0XL'TP'%HZR!;UKFZOL[:@I.JT6U3I3+F!
MYG@TF3V*675RQM?+)7.V.-KWRRNKE:V-K6YWO>]\N5K6MUWO?Q6\=9()B'=.
MH^ T77F\!]GNTUZ%Z&KY!\W1>,GJ;QHXPLH@Z:NK.&ZZ=_$HBNBIFDKA?E?E
MEAEEC?EU7I:\""<S\[IF4-H,$ $:@MR.O"]^2N6.-\LE<\<<;7RRRR5RMCCC
M:W.][WOERM:UNN][]5K==ZH!&KCKT'WA0%AP "> ;^"X HT-/#FA@&79F1)!
M&SA@4%$42(YZAE>^-EVCYFLLV<HWRQRM91%7/"][7M;+G:]2UX<0XP0><#((
MZP1CHD*D-:8<VT\"T@B-Q!$@]!6PZ:GX13\IG^G*J00,$GKCX">S*DLZ.S\$
MMFI^$4]]3/\ 1ERH).I(ZH^(GM26='9^"Q?-3\(K[RF7Z<O_ !H;AH9F=?P
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MR N<YPIAC@RHUKV@"72 ZT.+@"Z<6Y5Z]C.V?Q3;BU;*I]Q!2K64H$.]G;E
M1U6)A).+E3(I#]P3.)D&!#(@4=1_&'#FX9)A#68X>@7;B6[3O\^)$KNWB_'R
MC2V:C5;3HLJ-(I4G.#WMMA]*F\$0 Z\EQ+KG1,VM;$+EY0I;/1JMIT&O;%.D
M2'.:6D.IM<"(%UQNYSB2#$- R5]+;96Z^OGU]75>WO>+K]VOG"-+>\C(U/1\
M%X#\Y_WA9OE:W+GSZ_%]SEYJO-TM'VOCH@F#IV^,=P*7SQMX^?Q<O-3'JC[4
M^Y "> ]OC"X9'*UQ[V]N=_V(YY=5[?\  J6]7E4UF !@SF9B#IKN5WYC=O\
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M4D7>CF1F8]L?,HE'$ F6STR1*)5809@1IOGBB5;Q,9UCYRB4O$QG6/G*)0O
M,9^?:B5+QP/=XHE4/!,9^?:B4#P3&?GVHE0O )&<=7BB4O' ]WBB50X$P)1*
M!P)@2B5+QP/=XHE+QP/=XHE4.!!.<(E X&=<"42I>.![O%$JWB)SK'SE$I<(
M)S _#Q1*EXX'N\42EXX'N\42K<,:YT[81*TB5D.!,"42M(E$2B+&7BO[E_HH
MBJ]YS[K=\K_WTYY>+E:_;L_:YUXG$$P= 3U^_>>@+WMT'4/<N/ROU==_;Y\O
MT6\O*A<"(/LQ&>TJIROY;_-YJ7 @ [N@_P!R)ROY;_-YJ!P&GN__ "10?9.M
M8+M^#236VRXR+F,'EHY06?CIE"RS)\URSP63RM?'H+M7C-TD@^'$6:J#\80;
M-2 ]RV>MD%TZU]I+FD@F02)$M=AP](X<)!$002#@KI1K5=GJTZ]!YIUJ+Q4I
M5&F"U[3((P1J-""#O!71D'P!'(=@5B<'XD)_'].&25B#_6C@(P,Y7M?*UU6R
M!]R4101LOCRLLKB O9WDDVS)HD54$U;?EWD;_P!'WE'\F]KK-\A?E?MVQ^0Z
MU=]=WD7:/)VR[=39>27-H5Z]0"B8@<K3V9KW  UA6< 5^W?E+_Z7_(WY:>3Z
M+_RK_P#1UY+\H_E/L^S-V>G^4FR>6=M\E/J6#FNVK8MFV8NVAH=<[D*NW.IL
M+WC9CL[20>W6O-#:WU- 3^OM<@6T9&2AU)#$A?HIXN"I^3RM//$U*#SW.V"Q
M4P[O='#IJY)H-6+1B)'(L1+!BR;?J/*//)WN+^2:QK;H'-8! YL ;YM $DF-
MP_#I >ZHVFQA<\O+&E]H+G7$ N+GQN%SG. U<3)/0O5'8XMGP350SAOFO&3)
M]F\+B$ E&L3.E76CM5QA0Q#I+'S8?%DGL4=9[-!CX0_+I'V!1)ZX>7?#6R"N
M>3;-3&WT*OE"D^J=H9LC:6T7BJ*W+57Q4#KI+"0PM.A$;S&8*]]7;F/J':&[
M*RGM)>VH*HJU'0]CFGT#:""&VD2!F=5.]>\!<O'S/31_>'$U*M]1OAN%F&>A
MHB3UW$X3:.EB<<4AK273XZ!>.WFRI8"B:JHH.2<-8ZV0<K.3"S%<D[<+9X?M
MS+*PH;,R@[:"TUG"H]X<T.N+&-= IL<[)$ND0!$2,U-M!95;1V=E!VT$&O4%
M1[[@'%Y8QK@+&N<9.2=TB HK$NQ>PB%PS1T: [-D TQK;2TOX;]H28: :L,]
M]Z*FS0ZF2A4J&)%\L I,"4-WD,&E+5Z3>1<NBK?-F58/566&W>4WO=7+Z;2*
MM=NT4VDDBA69;#VXR"&VN;B6DP00":_R@][Z[G4FEM2JS:*32XGD:],MA[3'
M.#FM#:C3:'#$@@$;G2O +L'6^R>&R73OB?>[4A_"7#9I M*PB^FXI!GS".2^
M%C8'VF52T$?=9R5V,CX0*BB[P BLW+ECD[7Q[>Z<W4S5VZG4I[0QFS"D[:GL
M?6?RKGBYCW/%K'-$ EQ)!<0) &&B57;&/IUV4]F%-VTO:^J_E7OYS7E\M:X8
M!<XB+L QG$2/6G8Z-7:]-\5SU>42,\!XG@<JA3..=I;BD].:ZGAB=2V;0K7[
M]%9W=)E()YL>42]5SFS:V1>9"6N31PD*255E3RC4J#9H8UK]G<UY=EQK5*88
MUE1^F13IL9;)YL\Z22LU-NJ/;LPM:';.6O+B2[E:C+0Q]0$"2&,:PR3B3JXE
M5K%.QP3YJ1U<GL?BJ?;&B>C-([6T1J"/(:3B4)?QZ*[2UVPUJX>2,^%DKCPL
M)! 08)DW4[TAL7SIAFLOVG-XYRRV[RBR*O);,*3ZU:G7JNY5U2Y[*G*0T.'-
M#G$F)QIE=';<P"IR6RBF^M5IUJKC6<\$TWFI #F@M#G$@Y) /0(NC#@<$8:W
MX&==6V&2R;\$DPUS+A)7P=:V6V$KKW71[7R+(BT[[=KCJ9-([F456:KELFJC
M;%I@FOBK=?#F=O/*;94%,#SQE5K@239RE5M3'&+8SQ/"5Q.UN-3;*G)MG;&U
M6.%QAC:E5K^;Q( (ST0>,NX7^%Z2\,A'88,7N8C,-,R>83F<PG5YB#@!Y#79
MS8<S?S>2883\>\N5E(W(J6*8#F9,4TR9H._OCATHEAG7/:-J;M')N-$,K,8Q
MCZH>XBHVFP4V_P"&2 PV@%Q#C)F !@3:-H&T!CG4@RJUK&.J->XBHUC QLL(
MAI@ D@F<Z"%V_P"5_+?YO-7EEHW=Q_O7E3E?RW^;S52X$R=1T?\ Y(G*_EO\
MWFH7 Z^[_P#)%PR//N![UW_M1UY/P"E_)[50D$0!H#Q$21TF==_X(MCI+]JV
M&?R*T_T6->BA^J;\\%YMH_6>S_[G*U*[+@E$2H2 0.*)51*(E$2I(D#>?Q\$
M2A,"42H'!TQ..*)6C@$\$2L7C@>[Q1*7C@>[Q1*MP@G,#\/%$I>()SB._P!J
M)4O' ]WBB4O' ]WBB5;A .8/X^")2\1.=8^<HE2\<#W>*)2\<#W>*)5+@ #G
M*)2\0#G,]WM1*EXX'N\42J7@&,_/M1*%P!@RB5+QP/=XHE \$@9SU>*)5N$Q
M!F8^<HE"\ QGY]J)0.#IB<<42LW&Z-TQ'MCK1*7&Z)Q,=\(E1SB"0#W#@B5+
MW<>X>")6FN)(!.J)1KB7"3@SCV(E0N=)SOX!$J7NX]P\$2M,<22#P1*-<2<G
M=T=")6;W<>X(E+W<>X>")6FN)#IW#'?X(E&N)F<P">Q$K-[N/</!$K5QMG?,
M3W]2)0.-A.\'7L\42LWNX]P\$2E[N/</!$K5QAO2<^PPB5T1*YM<2<G=T=")
M71$HB41+\N5^?BY=?N4^?F457/>7=;O_ )VXZ//R]N4Y<^5>1VHUB'3$3&.*
M][?1;U#W*J=C;GU1J2PRVRY_%X7D93(.!J!XH@S<O&(C!!4T42:WRNYL%!)N
MFBIXWFE@(!HNFRQ9ZS272SSZ!CZDV-<XMS(@@$@@ ])S U.L1E:#7$$@$QK$
M?$B2=P&5.5CX-N"5D[@P+0C2 K,ZM(%7[5,(B$3:7(*&%"N2MF& K!A:[W,A
MDO9IBTQR<W6[3:^=N9N$, -P@1C)FVT3](NP 8SA3.D&>$9GA''='%>(>0!)
M!B^S"$V93 :]Q'/U&:V*Z;9]DP8E,6RBF'/"ZMQY-@[M;#+*W:72.7/[KE9)
M;A\R<C33.=VO:F1J"-".D'0XGQ&^%[D3(M<L_ HOFZI@6/&%B [#/FZ9CC3@
MLU%/%T^7W"+]P",(MLKWYJ9CG5K6^]WJRX9(,$PW3LC!D2$]GMXZ3[QK'0L#
M#0LTFZ6%/4'Z+(D1#NU6V=E,$"@AXJ/)L%,K=5G+!\@LU<IVYW27143O]UA>
MUL$N!.X:C RTZ'JW93C@XCA&?;NWS!Z-%R7KYD-9.R)%VV'CQ[5P]?OGRZ31
MFR9M$LUW3MVZ7R30;MFR":BSA=53!)%+#-13/'#&^5M%Q,6SOQ ),<!DX]AC
M.DP6NO) -KQ_D68YVEBETHUDFO@K@<4L(>'N0W-.^6#G&X8>\)643O=.[5NH
MI;.]N7-SH.XM.9C F((UF>CP3.<:8/0>$:S@X /2O.\A!VD%HI<JQ\);A\I#
M8'W0GWSL#Q>XC;E;M>?;<6/=^5F>+C+&R>3BV2>-[Y89VQ!QMN(,3$QB8F.N
M,]29U@Q,3NG6.N,QP"W'/^G*_5[OD]^L![I$G&_ 18YVY7\G*_P>K_2WM>6U
M;+A&A@Z$1NSQ/>BUI<R(CXY<L<)L PMI=#%R1*/&[!DADY<(M&V*KIVHDAAD
MX=+H-D,<L[76<+)()VR54PQR-=. '$Y.@G>3\3C<.A._J[?<"4%&!1UGD_$/
MD"++!\4&Y.6V=U$K/PA1X%*M>E:UN:S JP>L'&-N=L'#97#G?HVO<XP8(<#$
M;M#''Y"=8CL]FAWK9<^5KWOXK>3W+>>@=.,G/1@3C\=443,3J%QM\U%'92!$
ME'JP%NU&/BC1 @NM*#[:*QRR;'-6SJ^)R2ND 8O/M70>E,[M$,LU<%,<-"X@
MFUT"<P- ),]0SU1JK#HD-)''$8UR2-/G>I9;VO5Z^7CO>_J^7VO%[=<KB#B8
M$#($P-WO4S/#3KG,]'SU+-:+\B)@:XZ46F=2$&R."(R[*L6\A/,#!0*&5<)X
M$28V/*"D3C]DUO>RJ[02J<#)$%\,;IME"C!-7+'-TCCG27$%S08!@G&IT'6<
MQQ3=,8D#M_V/8N82Y][WW+]YNO\ 0*?IY5'>B+O2S':.'1\RJ-1UCYRMCI+]
MJV&?R*T_T6-=J'ZIOSP7EVC]9[/_ +G*U*[+@E$2LN)!;TG/<B5I$HB41*R2
M;@-Q'CX(E5Q@$A$K+"3,GA\42M' )X HE<KW<>X>")2]W'N'@B5H.-I,Y!Z.
MA$H'&''>(CVHE9O=Q[AX(E+W<>X>")6BXV@SDGHZ42EQMG?,3W]2)6;W<>X>
M")2]W'N'@B5ISB V#J,Z=")0N,-.\S/L1*S>[CW!$K3G$$@'1$H]Q!P=W1TH
ME9O=Q[AX(E4.=(SOX!$JW&Z)Q,=\(E'.() .B)5829D\/BB5J!,P)X[T2D#6
M!/&$2D#@.Q$I X#L")2 - ![$2D#6!/&$2D#@.Q$I X#L")2 -  B4@#0 >Q
M$I X#L")2!P'8$2D#@$2D : !$I X#L")2!$0(X;D2D"(@1PW(E(' =@1*0.
M [ B58'#31$HB5( T 'L1*J)1$HBQEXK^Y?Z*(JO>VOW8[Y97M^R7'*W+'ES
M[;GY<;W\?MUX71)R=3..S?GN7T&GFC TZ?@5U"V+KG=(_<4MVCJ85K"4+3W3
M$5U/>^R)+(([GKPC$9/L*0(2$>T"PN68RT#([; 2SDL:Q>1%XY=PB.HV+K(/
M[O(_V8^D6-94+@&/-3F@&Z0V6Y(M,M$'(@DR(@] YA:&N! #R^&B;I#!$EP@
M\P03=J<:+YY@.!/<DBUO*(4D&BK$2.4FFKQ9^=RZ6CYELS5$1@\:X98_##<<
MQAA(/!X3(XK!"&ZP[D8ZD;%Q,7, D34 W7>&"#/U.VBF'!Q+I(:\M:!:RH7.
MJET@BYP<^W0&T&':!=N6:'!TW3#B&AIL<YSJEP=(EPN#2,8D&0 KZ%\"\T)R
M5J4GA&,$0J6Q01MH#&RN7ILXS!&NX=Z;;.1B.,DA@YBAB7%S'56F732R;9H^
MU9&9 !<*IAWZH(KR.TL AL@\F6DEH)+^3IL#B=QN;4?C1SIU.,&L+2 #ECFS
M:W6UK&N.=0 3.MQ]HA(_@CWO<+KB%S49J+8$.8R.!%9WDXV-,0LA&1^#:WUZ
MP2@^MB"VL#V0&-&-J>B<=.W'*1XJ]@>$7AC%^*1,EU FQM-,EQ:7L<6N#>8"
M"Y[G2]W/U#+0T . /.S: 7*,YQ:7-=#@WF-()<YQ+G O]*T@-R0'9.@7*D_!
M_OAC#I+.7$T;6VV,Q>FPDAAY6824Y%6J6NMUSHO;7(186Q[HDACB-VTN/P$M
M4!^4AU4!!"G3ZRZ#**M:*].0VV68#FNM$F]E/G&?1%%DSCG&2<$K0J4Y#;.;
MH03 =SZ8%QX6,).,$F -3N-6Z%GT\X;>+H VUN)UF1WFTOKJ 0F2']D-P%H8
M)U9'8F0D+Y:?P,%.@9B4S@ILTZ[,%]9BC)<FX82HF.-+/U#I7-2HQM2B2\O%
M/G.< PF^\D !KG-(#+1AQ B)G"CGAKZ?.O#!+G0V2XDD 0XB&B! <0#(!@ +
MER3@HVDBBL^A"\&'OS*NTVTK%VELC%MGT3D^\]?%=<PH&[4B9T2-":XX>HU*
M(.*#$8J5ARAR6FF9"*$Q!\Z]=AM-/0W?\."6@BYM,W/(D&7UB'F"'0(#M%!5
M;]('1L$Q-UCKS R"ZH020X&W (.5,-)<*.\]=:QW,)(S^.BMGS'3Q;6VLY.!
M)O7X^ D7,ZX@=@!7S3-K#H<@*&1PCN0$$$LXY&1K)D$@PC$:&')-68Q&5*])
M[V.#7<F*H<\$ %PMI-CTG<Z*9<29YSSK%RCZC"YA:UUK7W.#M=*;?6S :=7"
M;B#.BH&3\)F^3\S,P8- H%%8!(8)L(H+ H;)V([UYJ2:2N)ZPU;#)X+/IPI@
MYV%M*/K1;8^S2 CO;$N1D]&CWA,TF&"LO(;%:D&AQ>YSPYH)+&AU1C75*C@1
M/-8X&FTGG8!$$ -6Q58T7$ESI8)M:"\-+W%L$PT26M!,DB0 0(%@!."+>CN;
MR\E.]DV, Y3L!PZD95*=NTS4YUTXXAHMMMB()MP>L8H?$K1C7D#!ZG AR6PI
MFS$BY1-FL8(QH,Y41.0[13#6EK1(;+6E@AK^3MD%SW @N<YY-C=&2)F)RK !
M:P"T<W$@.#"W4N."YSG38"8:2-PBV/ CNDC+"1"1,]2$(6YE<'</(+A*7V$>
MD<>BO$)'=GHV=,L=1HDT6T>@T)C$0A<;E<DV G'A9*8Q&/&8S&7[?!5YU3#0
MT%P<&O%UH,%U(LW/()+R7.+6L#@&DR5>6;$<ZZ'PX#,NIN:))?$R><0ULF'&
M8SR[<$G$MG&;@EIK#;S2\848WW7:>SC*7((G.&174<BUV("^"6*(F(Y;DD$L
MW>H4L;<8%BB81=>,-9#DB4CE\YHW2 ;00>3M ;S:UX<7$R\\F&L@M!B8)CG3
ME673!#;IL#6QBK>TG(EUK6MR,<2 ;IG)^"S9V,P%Y0G*$,8$RW4K/!8=[.):
MFA&HTJ.TO%R7;0ZT2+NRLM-@M;R&6LY?&)9 )]&MER0B[M.S0&:3EN]P-I:0
M;KKN3#9M;+R"]PD@XASX((<US  6@M:1!5;:9DN++28&3SS@S@2^"""TM YH
M< 3/-J<(AK:G$@3VD?CVN#,)6OJ9-1J4*EDS$E!ZLA^]WK"'GQC>-9-TQ3O<
M.Q8/)"N7?T@Q.1Z),69$5ED)2'D<MVAK*09+@[GDV@0#4=3)()(F*;7- @"7
M:021&U;:=HD.YXD1 O+07;C(IM+0)U)R 55T=X']H1F.0ER;P@6YY-&E8='3
MD:GVP)L,B<G@T,X<(?J\2.(DK1*3J*L/1=CS[;!F,KQI=B;?NQ!=V_7.1*/H
M([=M+'%P%S ZX@M:TD%]8U#:)Q_A_P"%)B /1()NT:K23%S&DW-( D$U'/.)
M'.+3:'28$@@C6*3#AHXJH;KE^(?S;PN$0Y\,E/A=&97M$KL_9!)CH36W#JW
M.HM'XB4D$<C[P'CM&0R@M&CL[F+8L88S.. "LH9V:*:;6H.=($$MBUP8&,FJ
M^L2"2&N()8&W!K>:9P56OIEP-L7&TM=:6@%Y>3)@$X:,D" 6DQ!'"UWP:;!V
M6,*[$.PZ-:KR,28B^U=K]<U-VJNI0$HWI 6T\+Q\<4C84A&"[O16C->R76S=
M4%&R@><R@ZS)1^ 9V=94?7IL(8'&H UMSP&B\MI.#0;2=*CR'<XB&L,NC%=5
M (;)?$2[F@/(IN@F"Z9<]T@&,#)U/V((VO9@^O:]_P"TW7W/5RY]H4]JU[]=
MO+Y;^/KKP8SU8P>(S,DCW;IW+S", @:Y.?&%L])?M6PS^16G^BQKT4/U3?G@
MO+M'ZSV?_<Y6I79<$HB41*(E$2B)1$HB4@#00B41*D#@.P(E(' =@1*0(B!'
M#<B4@< B4@<!V!$I X#L")2!I CA")2!$0(X;D2D#@.P(E(' =@1*0. [$2D
M#@$2D#@.P(E(!U /L1*$ Z@'K1*0. [ B4@<!V(E(&L">,(E(!U /L1*0!H
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M/Q)C)U.]C)H\00-#&#'-3'(G9)N%5Q#C !;D-/TAD@S!(T/1CMU9!;DD$P3
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MDQP#M,UT4&M-9E[W6@A]-M-C#-K&\QN2' @V,+20X$7;PJ:@+GFV6N8*8:<
M- :(,&8M;;ATYF=9TK_L<&BR#_!\I(=DIW38%D<;=W05X2Q,'M5RK4YJ2IS
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MCLTJ[C!"6-%XU*9(3(IXQB4QUN04[BR*(/51S%5",KN8VT-:?UD%TDMY40^
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MU7ES'XN8  <F2'EY)+BXF2<YW*!9=CNX?DH]*XT,5G(5C+$BS598<=%J/ S
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MZ4[ZXR%AB[;LI 2G)4QL)%"P/O9GM!\OLF;ME9&Z'N1MA<D-!\ .(LN6:/\
M/G-3'HD"HU\1@V6VM(]46M(&!(!W"+RS],1>'Q S%O-.ZWF-P - 1D2N'#N!
MN :T)8R/7TWV3'Y'D9DIPTL%=:ZA[.9X2975SI_%#3:&ZP#LXQ%%E]/0Q#-/
M6PZ&E\!MBPW,BZ&O^X$Z=I<\6O8PC%LWDLMO%PEY+G0]P!>79(.(E1U5Q$$-
M(QB"2(N /.=DAKR.<2,-(B,\W6'!MKX%!#@_8H"+R?8DPV)/-N$I>D+9FW$
MF\X+$WXWT)B<M%OWL:;:X'/68B&$$6+)6[H>XDK@4T)G2C?(_:'7@L)#&M8P
M-)(N:T?3 .2XDETDC00(1U5Q(+26M#6M#=Q#0!+@")+HETZR9"WH#@WU9%%C
MKN,%IT (&(,=U^S)"S8QN]C 4W"],0#!>-*7!9X,R(6,Z$UVR"J/DR3)*S,I
MB08$D"KA"H=I>Z)#2 X/(,P2'5'9@C%U5Y@1KC  4-1SL&TBX.(@P<N,&23J
M\F009C.%K];\'X#398>9UGL>=!E\,68XXR>B]:*@B<=PV.6V26#AXV"U_' <
M%2-/31&/.6\!8QD(D!==U8@U90T82%M7;1R@(>QL'((+K@;"P$N<YQ? ,@N)
M,[XP*ZH7B' 0)( NU++ 22YSG$8,DDF-59<VX>()/\-TX2%U(5/1X@L=UM-L
MVKY@BHC"HVVDS9H"!9J"UKL&SNTSE2Q#)UWP657./,VZC7&R&".&UW-Y, -B
MF\O:(Q<2"2[.?1:-P :,*![A9%O,)<)'TB1DP1D0. P-PA:N'<+VKH=-2D]Q
M;$I*?)KSYU;*79!S+0:ZV5LXOM24.12%@S7-HNL6?B8^S4NLKDTB,.B(FW;'
M(UV1(UU=[FAGH@1Z&)#6"F 9DQ:,[Y)/TC,+W$ 3$!HYLB0UH;!DG!R3OESC
M.57\CX%='R-X]DBGA0'V:4FD\FY;= !Y'QVW23O8,,FFNB85>991IPLA&P\$
MFJ\5B@P>T99QL7'(AD-=)O0*3M;0VJH( BT-:T,,FF+7-<"&R,W-N,DRXDF=
M%H57C$@MM#;(YL APQK,B9G)GB0I-&^"WABB1@F0 Z:U^R%$1>MF*4,M#XOG
M# Y35#J=KP^8@PF8:]QLW:MM@F!3B3)NLGV8IB%:M^Y<F2JKK)VBJX9>Z9>2
MZXW$/#0YI,Q:0T<V(F2!DA3E:IUJ..7$F2";HD2",2)B-Y"B@_@GB@F/Q, +
MW'OAA:#1,AK>)%&\B@O=\?U04C0"*/-9B&RFN5 8T0J,BX%;*7L0[?;"A,:W
M(K[$5<8\[T[22233ID.(<X0Z'/!+KSS]9) 'H!IMM@!4U"3):R26N.'9<UQ<
M''G9,F /1 W+:)<%.F6@#",L;2AH#2!;3C"0Q JPP;XQS;^P89/Y<$O?(*LI
MDPMC 8S!A5E+J+CX S4#76</U>^^-&TONN,3+73&;F-<UIDG7G.<3JYQ!T@(
M*KAG!(M@D;V->UI.1)%Y=J!=D@Z*LHEP!1M:%PYEM;9NQYA.  TRX4,C"<;%
MAX[*)T[.RS92\&;X0M AB)D.SI!AL%JM,7$F/M34/@B6!1$("5!/-.VHASBQ
MC&M= C)):T!C Z'%LAC8P (>Z6R95-8DDM:&@D$@@SS;;9S!+6BV0 !<_&<;
MMMV//1C:682NQ.;JW;.LU1H56\!LR'L5I9K^6.@61U'7Z4[. %+:Z%15B*E4
MP/MXY!2IZ(Q.P 0Z8HCH=LJ%MI:PS!)Y\D@.;I?:)N)<6@%SN<3=E.6>! CK
MSJ+H,3:"+B1#1F#J%>6O^'B(:WV'*-E 3DM=&I@QDC0XQ,.P+T2LXDVS)7M!
MP4;]JCK4NR?,"<O?1Y@FU+I#5(J-CS J/*$ ; LGS=6<]C6%K8:001((BF*>
M\D20"22"9<Z" 86'/<YH:0V!$0';F!D$7000-(QF-2J:9\!NMF4<:0]/8NX<
MHLD'AS$D%[\01!(^;UP/=CM=38P09Z[;&KRJ%87"/AO>TF.CA0U$HZ>E4=D)
MG N^,;.U/)FUDRX@P9 >9>T9 @R1D$M:YP;$R-\JXDFULDN(]+FAWI!HN@ Z
M9D@$@$2M2X['#PWW0C@L4-+ (M%59"@%A3$=KTE%1T;E^$ 6EL/"L)3 I"ZB
M@>1F=>,9(1+0Q]')NB<D4P6%RT<R.Y,&VO/*V28),9)<'2VX-)(<+H:ZV' M
MM YLB5>7JYYPDZNYP)(N@X< 8#B((+8@1S6D3\QP::T*B.]*4BG0RUADS$W=
M(*PDLFX:;'VFMMW82)6/RJ#R&'2)G-I.H@UD(>21HP =!APQN@);/F*)+' V
MEX,VL)QDAP,AEC2"UP((;I! !DC4SCE'SN(Q@@_18&- (<"  )$$022())-B
MQ>"B=8J\/6N0#HL^"P<4M%13PZ]L1,N1X*.L1K-<F]Q1;IKNU$4,+K9-VS1I
MAG?M;-HT:XHMT\7%]8/( )>7$ 8S.@W:],GK7.I+F57&)(T&-3/<![=5W*KT
M%QD\TGM\%X$H'&1S2.WP1*MQF+3KK\=$2A<08M)Z?D(E 29D$=?^R)6.==]*
M+NF(GW(E7G7;XGIB)[$2HZZ3%T=$\$2IS_WN]$JMND3='3/!$JMNN$S&=9C3
ML1*ANDQ=J>*)4Y_[W>B5IMTYG3?/1Q1*-NG,Z;YZ.*)6>?\ O=Z)3G_O=Z)6
MFW0Z9TQ,].B)1MV9G0Q,Z]")6>?^]WHE:YUN^9Z9B.U$H+K3K,XUG=[42L\_
M][O1*<_][O1*USH;KKGMW^SM1*Z(E<VW3F=-\]'%$KHB41*(E$55R75C62$U
M25Y3,!%U;6MDT"R!^.9]+KZ2EF[=;!.RF=[WOEG;'GE?KO?G>]<#1!,W'\?#
MH,RNS:Q:T"T&-_0.B/PZ%'O0,:\NJ?;'M_C<6O\ 2XJ>;M/TG>[W%:\X.]C3
MVCW0GH&-/Q]V/\KR_P#VBKR#?6*><.]5O8/!/0-:7_=[L?Y7E[?0XIR#1](^
M_P!Z><.'T6^_WA8] QK^/VQO:_KN+=7P.;7O[]04!)RX?'72?@GG!]1OSUR!
M[(3T#&O5_7]L;J\?]=Q?K]K^V?/[57S=OK.W?/X=LIYP[/-;GH]RSZ!K2W[O
M=C_*\O?Z7%.0:?I'W>Y/.''Z+?=[@L^@:TY\_#W8_P KRW+X.Z.53S=L1<[X
M]LRGG#HBUOQ[8E8] QKZL^V/?_&XM;YK.*C: C5PSOS[T\X=N8T=_OE/0-:]
M7]?VQN7J_P!=Q;K\G7W1S\]7S=NMSOGHF$\X/JMGYW:?.(6?0-:6_=[L?WY>
M6O\ 2XH=G:?I.]WN*><.]5OS[$] UI^/NQ_E>6_[13S=OK.^?:AVAQ^BWYZ@
M$] UI?\ =[L;Y7%K?0XJ\@WUG>W/SVE/.'>JWY]BQZ!K6]_[OMC<O)X7%K=?
MEYV<<_>J>;M'TG>_WE/."/HCKU[CCX].Y9] UI^/NQ_E>6_[13S=OK.^?:GG
M#O5;\^Q8] QIRO:T^V/;GZOA>6O]+BKR#?6*><&9+6G7H[8"6T8TY?W>['OY
M?Z[R_P#VCJ]ZG(-]8IYP[U6]GX>]+:,:VO?^O[8_M6\+BW5_^HIR#3](^[W(
M=H)'H-^?9V=\ZIZ!C7G_ '>[&^5Q>W__ $\OFIR#?6*><.]5O8/!8OHQK?\
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M<F\DL#7O):"TD"FYPWZ.M !!,R(.5GDVBH6.)+0TN)'-) :YT ATZ-U:2,@
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MW<+-R >0LHN/C0,9=5P$)CXL, #V:S./,F3.FIM =,U 8@G-V,D&00"TDDD
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MX@,&9/\ %BDVN]3"ALG-U5!(_-O.6J-#8J$B9]*#,W3DF,DQP!(WJ![Q$.=
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..>K'KJN241*(E$2B+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g65062g15q63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g15q63.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2LN4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *Q*^$0)CA"24T$!       #QP!6@ #&R5'' (   (    X0DE-!"4
M   !#-S_I]J,>^"05P=JZO!<-..$))300Z      #S    $     $
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M]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L
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M5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M   %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M      $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6
MQO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4F
MEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M  $ $L     0 ! 2P    !  $X0DE-!"8       X             /X   #
MA"24T#\@      "@  ________   X0DE-! T       0   !:.$))3009
M     $    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M         !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *
M&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M !.$))30/X      !P  #_____________________________ ^@     __
M___________________________P/H     /________________________
M____\#Z     #_____________________________ ^@  #A"24T$"
M  $     $   )    "0      X0DE-!!X       0     .$))300:
M,U    !@             $B   !H0          0
M     !              :$   $B                      !
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M5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$585
M    $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585
M    $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
M=D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M  !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W
M)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='
M-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W
M5T<V5T;&]N9P      .$))300H       ,     C_P        .$))3001
M     ! 0 X0DE-!!0       0    %.$))300,     ""'     0   *
M!O   !X   T"   "!K !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F
M\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('
M-21T(               $  /;6  $     TRU(4" @
M                                             18W!R=    5
M S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A
M@    49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD9
M   L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;6
M5A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P
M@,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&
M5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C
M8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                   %A96B
M    #S40 !     1;,6%E:(                     !865H@        ;Z
M(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /A
M  ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M   !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                  9&5S8P         N245#(#8Q.3
M8V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M     N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2
M!S4D="                             &1E<V,         +%)E9F5R96
MYC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M   "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,B
MXQ                                  !V:65W       3I/X %%\N !
M#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M       0                        */     G-I9R      0U)4(&-U<G
M8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5
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M<#TP/@ ^P#^00&!!,$( 0M!#L$2 15!&,$<01^!(P$F@2H!+8$Q 33!.$$\
M3^!0T%' 4K!3H%2058!6<%=P6&!98%I@6U!<4%U07E!?8&!@86!B<&-P9(!E
MD&:@9[!HP&G0:O!L &T0;C!O4'!P<9!RL'/0=/!V$'= >&!YD'K >_!]('Y0
M?X" L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)$ DE"3H)3PED"7D)CPFD";
MH)SPGE"?L*$0HG"CT*5 IJ"H$*F JN"L4*W KS"PL+(@LY"U$+:0N "Y@+L
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M(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T? 2
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M>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^T #$%D;V)E7T--
M+_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q
M,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"P
MT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M/7^L;$=Q.T_O6=WA4+L_ZG?Z-_93NSV9]]/[O,_R]5^>#.3X^_8'L;78W_\
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MS\+A>;22*=V>S/OI_=YGG^MZK\\&<GQ]^P.G[&UV.'[QN&)[B=I_>L_"H?\
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MS.I'J #'6.N):;<=5?*TA;BLHNK*A)4;#B; V'$Z5RC+2GG&FD9<SBT-BZK
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M7-S8%@<JB2 *8!@[.*^Z#CSDGH\/C(?4Q!:2[-D!2\F5A"RE)2W8E9.91ND
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M+DQZ^I,692.+*<?P1;C32<5@E;^;HDB2U=612D'^%8=\E21F(S%)";D&KR\
MQI*'7%X7-#;.3I%] X0G,E*A8!))NE:2<N;*E0*K#2HGOEE@S#995L;;LP%F
M[A6A63!M/=HL3.HVO80?$*6L@M;6WF*BJ"3SVXQ4EH<T0& M;*E22E>G3"I)
MZYE0L1@8BEQ4"6Q+2RH(=+#B7,BC?+FRG0*L<JOI56.4FQK%FX=.PU3:9T5^
M(74J4T'FU("P+7M< $I*@%)N"BZ0H FL\\G^1O+#=/)M=[.+F?OQ<^T4-M=>
MEBM *"W%NFN?JEY\B86)T;%YB16YMZJBJM8[F)3@*U)))(H.$1&L:0TF+8SB
M47%HF$X;!C2WI4-R5FD2%,!(;<6E2;A"A]*D$<23;A6[PK!L-DX3+Q7$ILF(
MS%EHB96(Z'\V="%(44DA6]=C;0 7KH,X/)ZQ>UD2RDW8RFW-F&9*V><L9@TV
MH8G.VCC$KP5RZ#R%!&G1C"")%#LL?"7%S<2DS.N:2?\ 1"HDPNA,<E4M3@X7
M,)QUV2[BD7%(S.'2<(Z%4I:9*78G1/MJ=0YTY"0WE0DJ6E9[T$$D$*2FWBV!
M-QFL*DX7(>Q"/BW2HBMJC*:E=*RX&U)Z$9U+"E&R"D&Q&J2"E1Q3O7DJS:Y<
MRXH=>_+S=:VJ><.E#'$54CB3B0CD+\;3U94?;%:<I0G4/Y]']4(8P-I=3RZ:
MS"D=5%%=5.RAXQA>(=*(4^+(+*2MT-NI);0-[B@2"&QN+EL@.A56LFX1BF']
M"9<"3&#RPVT5M'(XX1?HTD7NX>""0HV)MH2/JO-D>S?Y=X:W7#OCEPNY;"$.
MBQ(W)9/+H<Z-;,2Y+RC#D+:XK#"1H9W):66:*9 []@K%%11Y9)%1A!M-$0\:
MPF>\J/"Q"))?0"HM-/(6LI2;%20#WZ0=ZD9DBXN=154S!\5@,ID3</E1V5*
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M%P9Q#ZC%4&F) CV0B0HHR(>#BUE*7"%](2H=]K6*_BP.#;5(&(I5(E8TE4=
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MN&X[Z[[<!5 T/9KQL-VFHWBQ%B=;ZZ7(->&W/S 'AX\^HZ!J C[NN%3NTX\
M-UK[QOUL+B_FO>F@<![_  UX<?!T;:: .NF^V%+#<>W=?=O\7+2U@;VUTH
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M]CC[ ._TE(_,1:^)_LB?9YK4C][8]^7U>5KK?4>3<+CGKB#P< $/AU ->/>
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M #6J^MIMS<_';0>@-0X\VX\,*GS6TX<=^ECR%QOX:G=3@'1KH'@'3UAY@V
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MKAJ([;!IT;=_3OAQWUUPINN3IH+<M.VW:-^M[UQU]SB(:!N''774 X:Z!IJ
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MWX\^/GWFGS.7/5Q\RQ>+CJ.D55:;!WJM=QT#00'GP[J-GO?B#^.33N8VAO\
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MH!UU92W&C9BKJS-\VA T<*1(F;2MO3XF*L2,2P_$(I9=AO-(AQE.-(CI:Z0
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MY7A*/@X_2U7M9,?NJ;OWM4_QKT8=-!\#=^%G]!3HY7A*/@X_2T[63'[JF_\
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M'IMWQUZ0#'WSN6V=]YX7XK]=?!QM3M$?][S/%GU!OYM+C>=V\#6]/FMW*5*
MZR=G,O;64=_4C:*I(6-)A9GT%= _Z#':JD1I$._IQQ2O9;9X(41A$('*JWT+
M=IH=_P ]5-[4;0J6@'%Y@!6D$9]""1?6Q[1X]#7$OE2.4,@I=$*A^;>\4?BD
M2HICD;8FZ04%(&9B9@!N:FM$3V)4):1 A((3)Z!$1I**II&H=-1P<(V;P%_"
ML->=PJ&MUV#$=<6INZEK6PVI2E&^I*B23Q)K/Q?:3'F<5Q)EG%)3;3,V2VA"
M5Z(0EY:4)2+'1*; >+EOYCRN7*6A_MS[W\W]T9?/X4GK]&H8V'<ML[[T0OQ7
MZZUQVIVA'^]YG#^&./C]/*XK^Z/D3[Z7(S"<G=9.X5X)L^W$N4Y.%U2)'+I*
MI!8\NM#9>">-;/2K4!06!@(&-&VMR;Z !I2I":!UZG7'Q3;")&@[03HT1EN/
M';$3(RV,J$YX;"U$#_F6I2CVD\Z^T;(2Y,[9^#)EO./R'3+SNN&ZEA$Q]M.M
MAHE"4I%^ ';;;#CF:Z6F%*84IA2F%*84IA2F%*84IA2F%*M!K^O*6]]NBH_]
MU[#\@>UC.>^L(/\ *S!Z8Y^>L5KZ[E:_<XQ\6CWJJ[\8-95,*4PI3"E,*4PI
M4:F_95H])Z/WU<\7/N8^^7\356Q]45^#\E=25BW5RN-?TE7XM7N#A2HWMM]2
ME_IR</>UIQ6O0(\2_2ZX:MHWJ_ ^2*UEOV9A#EXF-W[.1*]>0=:WR"ZMQ)-0
MXWKS%.5N)S;J3W,D[A)9;'+@VZ06^E:&>4,,H?'-*Q=1/K?J%4<I9HNY%ME;
M94^+**KU\>_]5;+[)6\06BLS:2U+4\G2-LMG;."0!ND*D":3WU##HNUQY*\'
M4)ZJTQ9CF0W4+:BTU=2<L3NMD")--&%34GX4IA2F%*84IA2F%*84IA2F%*84
MIA2H!S-VX@]R;,3M'.8VW25-'8K*Y0QE.%)P@UR%MBKV6@=DE1)I-9:Q+0I/
MI),ZH0IZ[4.FN@@I7SY5K?0RWEAK:HH5'T$>2R*&P^7/A2 #@!TDKS#X_0Z/
M2NHXTVLQ<NI1I@4&#4 5]9H'J0'414K(;"E,*4PI3"E,*4PI3"E,*4PI3"E,
M*4PI5I3SZS9-WF=:/K%"/Y,9N&ZSX@_\]OY0K&F?6LC^27\5747]3H_$I]P,
M859-<\*4PI3"E,*4PI3"E,*4PI3"E,*5KBY6@?\ 4]\U_0-B;H;\WUGNW$.<
M!#7&ZV=O[O8-R]U(/GZPBWSUIMH;>XF,<_<R;YN@7\7SUY@.NO-KKP]0!T$0
M[XAL/1IOMCTM7FV]^%[[O(#8D=I&AY6UTKZT%:(M136X$JCTP /]31*2DIW5
M@(=;$#CDRLOJ-0'JZ>L!4/-50'''E(DK94F(ZPR\2 %R&7'V\IN%#HVWXZBJ
MVX]* .*5;JR(BXZ'@N6V^ZR!HB,\AAS.",EG'&9",MP<PZ($[KI%?>_+D#FY
M*5Z%(L25+#U"I30J6%*P Y0=4:($"2C2"452%8@%!G7:Q#3^J<0QBX5%E08;
M,22_'?$9IEAA;##K!+3+:6P70Y)D!3AR@E2"VGD@5E8I*BSIKTN-'?85)<=>
M>2](0^ ZZX5D-%N/'*$ *T2O.HBUUZFND'?0-=_<YN CN.H[[ZZAMJ(8V5:P
MZV%]?BX;B=3<ZZWN-+D5Z(OD=\=>37M!OJ';B[&@='[,4]W]7\F//NW5^ZC$
MOO8//P&/;L^>OO\ L/\ :SAIYF?_ /L)(^(5O7QR-=;3"E,*4PI3"E,*4PI3
M"E,*4PI3"E6DV?7E*^^UQ4?^\_A^3&:[]80_Y>;\46L9OZZD_P E&\NK_P#I
M5VXPJR:84IA2F%*84IA2HU-^RK1Z3T?OJYXN?<QK_"<\NC7MI5L?5%?@_$NI
M*Q;JY7&OZ2K\6KW!PI4;VV^I2_TY.'O:TXK5N1]ZO3=;Z*YI5"=ZM;_2]O\
M!'^O#?6"M\LW-S(6X7%:4U>4$^'M$Z5VH)5/]P;[S65=T"Z,K)52Q2"UEOLO
M$A!Y?&Z&IEDFF$68Y6K2,C"C7J'Q_:D!*A<315=9HY=X:SV[R_V.@$>E9<\8
M(/:"VL19)P4:4>3,FB.0UF9VZ5$G)SU2<PF0(T9+L34G4J"!+5T]9/-+ZFNI
M2ICPI3"E,*4PI3"E,*4PI3"E,*5@]RC^8Z9Y3<EU];]VW+CY\_M]&VMRBJ:4
MH%+HPG+UDI86<VER;T;@U*51((G%55102X)JJ3@*,&NJFBHNO<[/P&,4QB#
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M[:7&\"Y(TUTW<@ >?H]7?OZ][34=Q$!X!A50'/EY=;<1XM^\D&UA5-^/M<0
M0X!Q#AN :!QZ1#451KO]&\ C<-XW:@6&_F1<UWZ!Z!';P[=(#X/4#3"IUY'D
M3IX].8/B\@M7HA>1W@_U-BT'^&+K^U>*?>WOP_)P\_;=?;1B/WL$[^<"/OT\
MWE%??=A]-F<-\<\?_P#0D^W+T5O8QR%=;3"E,*4PI3"E,*4PI3"E,*4PI3"E
M6FW[323=]DBP^LHD@#^33U?5S7?K")_.)OR8E8R/KJ1VLQC^5('S5=F,*LFF
M%*84IA2F%*84J-3?LJT>D]'[ZN>+GW,??+_[56Q]45^#\E=25BW5RN-?TE7X
MM7N#A2HWMM]2E_IR</>YIQ6O<C[U7&_W5RK:-Z_P?DBM5:.XT*MC(KR,4NY3
MR-Y=EY=^;[R$^UA*C*J[$Q)ND-T93($)BY=.8')9.E6N3>O(>7)O>W@Q2TJE
MIZ"HA"6FI2$45<K-&_$;G]U,ML$KLNALIF7<SZ8!+25-\#SQMU=:,TL)BFJ7
MT-,!H:8=(WE]%6WRB-,KF2V6X,<#B%Y5;-4WLBY I6.^6B2--W[R*X!>6#Y=
MHY=JT3$FFR2"0BT#Q$+J6U<$[VV(&]V*N9';C7*M[4SJRC5+:X,<0FZE>X)5
M="-Y3=ICG! I4K/&_#DW-MO5/;.X!]M"7!\C34GD1+X$3+6N3@]HB6J)+)IV
ME?S84WS=Q%-$ELJ1-U;NTIWBLQA.(?:VTVE2M8EO[_W3>TL#6R*[[O1-8Z=E
MJC<5BZ1YCIK)>!7*\WUS+(7I>$XIFY*%VH\9!HDB"-3I"B:RJ(\0V7;H8XL?
M)C4J=2I(C=X+IV#G***WVFC[<AK894CI?WB".R=X*-E\AMU#$"A$]52H(2I3
MLS<*F07C=K2QA/*7=B-NK;1H@">3-$86DH5*VKX4IA2F%*84IA2M.W+L;<FU
MF('HCC%_#>,?!CI]COMEPG=]7=\G[F>UY_Z:5S>UVFSN+?S='H?;X=G'QBO-
MLUV - 'UPTUX:<_'0=0  Y@QZ)KSO?0"P/G%K[K<=]C< #@*J/,&H#S;:AN'
M/L.FVPZ#ZF%2> N"=W'>..^VFAL?)3O[]&G ==M!Z-=- 'AMKKSAA2VM[GE;
MC?2QY7M;D+7ORH(Z!OQT$ Z1VYQ >;7?7GW#"A( UO>UAS.G'7A?6_&Y KTK
M>1"^UP9;/2/5[_/./..UOVQXO_.C^;17HK97[7\(_FG_ /M5;;L<[70TPI3"
ME,*4PI3"E,*4PI3"E,*5:DZ#6&R@/^ W+_-C,9F'_7T3^<-?+%8TS6+(_D7/
MDFKF3CJ00/226/\ W*<8JA92AR41Z:R$[AXA\5?KBFIIA2F%*84IA2F%*84I
MA2F%*84K7%RM&OS/C-?^X3<_P_6>[::8W.SOV>P;^DX/^(1Y/;QUI=H?L)C'
M/W+F?F'/+7F Z=(\= T'<1$.&OK#X>G@ >EZ\WD#B;7MH===XOYB.WGNLWUU
M[X[!Q$0 .8?  AIJ.^W3A4:WOVG0;R0!P/B!%KG73G3;40#H'0! -QW#G[X
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M\ X][547T !UOIO%]=+[KWX[AO[+AW$=Q > !SZZ /J<P#IX==QPH=2=2#N
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MQZ*KSR>-]#S .N^VFN[?H;^*J:= ;\^NP[\^NP!WMM>.W'146Y#7C?0Z\;Z
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MAD1];T5N!Y8E%FFIRS*B2S:U!/.X)AT/$I:VI^)Q\)B,1GI3TEY/2+6EG+]
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M337?7U]MQZ=PYAUYL* FU[6OK?SZ:GGJ.!OPH ;  Z:B.O..O?$..^@CIPV
M!PH!H ;7)OQ-^TC?K8FV[0 T$-AVZ> [!L&VP!S &PAITCA0C0Z<]QT&@TT
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M"E,*4PI3"E67<.;MUN(7()L[)E2Q!'4-2]0D0]9[,4T4F%E]:3 H-))$T1,
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M^Y&ESIR]=AO]- VT#01U'O\ /KIKJ',&@;CKZV%#K<W L.SA:]K'B;G06\]
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MG*A-PE ))"0+DFY/:X9A\?"</AX;$"Q&@QVHS/2*SN%#20D*<589EK(*EJ
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M*N4PI3"E,*4PI3"E,*5\JM82B)$XX1ZD!I *:.I&NH:A -*::JJ0'374=PT
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M\O-HWLV_8,:O\N.O\7?+4<+GVT\>ZUR=U]_S,AX&P\_S#V'F>;1O7SV,:O\
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MB680_P!T_.^OM-WA^6^)*B3\79SM;=N\G WUIDYGE^O]6ZN=.=&]PA]'8IH
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MYM?R4K^#Y!_8[M'^D'#JNQGA?Y4WU4ZUM=X(/[$7])3S:_DI7\'R#^QW:/\
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D94\OCKZ"R2B0ZDHN@NGHHI"D/6  PJ0 +VX[_;RU^F%37__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g65062g16a22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g16a22.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1D04&AO=&]S:&]P(#,N,  X0DE-! 0
M    &/2^8X@X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M ! #O_XU  (  0.__C4  @ !.$))300F       .             #^    X
M0DE- _(       H  /_______P  .$))300-       $    6CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))300>       $     #A"24T$&@     #
M-0    8              YP   =D          $
M     0             '9    YP                      0
M               0     0       &YU;&P    "    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P   YP     4F=H=&QO;F<   =D    !G-L:6-E
M<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO
M;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53
M;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53
M;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   .<     %)G:'1L;VYG   '9     -U<FQ415A4     0       &YU
M;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%0
M   !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0
M   !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '
M9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@
M  =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R
M5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S
M971L;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U
M='-E=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M     0$ .$))3004       $    !3A"24T$#      .:@    $   "@
M3@   >   ))    .3@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M     ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04
M#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,_\  $0@ 3@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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M'[$<!P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M    _^%(]&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T
M(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*
M/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB
M061O8F4@6$U0($-O<F4@-2XS+6,P,3$@-C8N,30U-C8Q+" R,#$R+S R+S V
M+3$T.C4V.C(W(" @(" @(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT
M=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B/@H@
M(" @(" @(" \>&UP.D-R96%T941A=&4^,C R,2TP,2TQ,E0R,SHQ.#HS-%H\
M+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R
M,2TP-2TP.%0Q-#HR.#HP."LP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @
M(" @(#QX;7 Z365T861A=&%$871E/C(P,C$M,#4M,#A4,30Z,C@Z,#@K,#4Z
M,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O
M;VP^061O8F4@4&AO=&]S:&]P(#(R+C$@*$UA8VEN=&]S:"D\+WAM<#I#<F5A
M=&]R5&]O;#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D
M9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP
M9&8Z4')O9'5C97(^;6%C3U,@5F5R<VEO;B Q,"XQ-2XW("A"=6EL9" Q.4@Q
M-2D@475A<G1Z(%!$1D-O;G1E>'0\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E
M;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(^"B @(" @(" @(#QX
M;7!-33I);G-T86YC94E$/GAM<"YI:60Z,$4Y-$0T.#A$-T%&14(Q,3DQ,S5&
M138U0S4X,$4V.$,\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-
M33I$;V-U;65N=$E$/GAM<"YD:60Z,$,Y-$0T.#A$-T%&14(Q,3DQ,S5&138U
M0S4X,$4V.$,\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I/
M<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#IC.38Q,S=D,BUE,V8W+30X-F$M
M8C0V,"TU.6$P9F4T,64X.# \+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*
M(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N
M8V5)1#YX;7 N:6ED.F,Y-C$S-V0R+64S9C<M-#@V82UB-#8P+34Y83!F930Q
M93@X,#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.G=H96X^,C R,2TP,2TQ,E0Q.#HR-#HP,RTP-CHP,#PO<W1%=G0Z=VAE
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O
M8F4@4&AO=&]S:&]P(#(R+C$@*$UA8VEN=&]S:"D\+W-T179T.G-O9G1W87)E
M06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T
M179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O
M;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @
M=&\@:6UA9V4O:G!E9SPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z,F1D-3=E964M,39B,2TT9#1B+6)C
M-3 M9#DP-6-A-64V9C4S/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 Q+3$R5#$X.C(T.C S+3 V.C P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C(N,2 H36%C:6YT;W-H*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z,$(Y-$0T.#A$-T%&14(Q,3DQ,S5&138U0S4X,$4V
M.$,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,C$M,#4M,#A4,30Z,C@K,#4Z,S \+W-T179T.G=H96X^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N
M9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@:6UA
M9V4O:G!E9R!T;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P/"]S
M=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R
M<SYC;VYV97)T960@9G)O;2!I;6%G92]J<&5G('1O(&%P<&QI8V%T:6]N+W9N
M9"YA9&]B92YP:&]T;W-H;W \+W-T179T.G!A<F%M971E<G,^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C!#.31$-#@X1#=!1D5",3$Y
M,3,U1D4V-4,U.#!%-CA#/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 U+3 X5#$T.C(X*S U.C,P/"]S
M=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!
M9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z,$0Y-$0T.#A$-T%&14(Q,3DQ,S5&138U0S4X,$4V.$,\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,C$M,#4M,#A4,30Z,C@Z,#@K,#4Z,S \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC
M871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V
M=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC
M;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P
M('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C!%.31$-#@X1#=!1D5",3$Y,3,U
M1D4V-4,U.#!%-CA#/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 U+3 X5#$T.C(X.C X*S U.C,P/"]S
M=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!
M9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y
M/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N
M:6ED.C!$.31$-#@X1#=!1D5",3$Y,3,U1D4V-4,U.#!%-CA#/"]S=%)E9CII
M;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N
M9&ED.C!#.31$-#@X1#=!1D5",3$Y,3,U1D4V-4,U.#!%-CA#/"]S=%)E9CID
M;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N
M=$E$/GAM<"YD:60Z8SDV,3,W9#(M93-F-RTT.#9A+6(T-C M-3EA,&9E-#%E
M.#@P/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#PO>&UP
M34TZ1&5R:79E9$9R;VT^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@
M(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @(" @(" @(#QP
M:&]T;W-H;W Z3&5G86-Y25!40T1I9V5S=#Y%.$8Q-4-&,S)&0S$Q.$$Q03(W
M0C8W041#-38T1#5"03PO<&AO=&]S:&]P.DQE9V%C>4E05$-$:6=E<W0^"B @
M(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO
M<DUO9&4^"B @(" @(" @(#QP:&]T;W-H;W Z1&]C=6UE;G1!;F-E<W1O<G,^
M"B @(" @(" @(" @(#QR9&8Z0F%G/@H@(" @(" @(" @(" @(" \<F1F.FQI
M/F%D;V)E.F1O8VED.G!H;W1O<VAO<#HV-CEB,3$U,2UF.3DW+3)F-&(M8F1F
M.2TT83AD8F%E-&(R.#,\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z0F%G
M/@H@(" @(" @(" \+W!H;W1O<VAO<#I$;V-U;65N=$%N8V5S=&]R<SX*(" @
M(" @(" @/'!H;W1O<VAO<#I(:7-T;W)Y/C(P,C$M,#$M,3)4,3<Z,SDZ-#0M
M,#8Z,# F(W@Y.T9I;&4@1$U65"!3,2!2;W5N9" R($EM86=E<R!T;R!#;VYV
M97)T('1O($AI9V@@4F5S7T)(=C%?,2XQ,BXR,#(Q+3$Y+G!D9B!O<&5N960F
M(WA!.S(P,C$M,#$M,3)4,3@Z,C0Z,#,M,#8Z,# F(W@Y.T9I;&4@4&%G95\Q
M.2YJ<&<@<V%V960F(WA!.SPO<&AO=&]S:&]P.DAI<W1O<GD^"B @(" @(#PO
M<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD
M/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$!_\  $0@!* )= P$1  (1 0,1 ?_$ !\  0 !!0$! 0$!
M       & 00%!P@# @D*"__$ '(0  $$ 0(!!@@'!PX("@< $P0" P4& 0 '
M$0@2%"$QE!,5%D%15%7487&!E=+5\ D75I&AL=,B)#(T-3924W62D[/!T2,E
M1$5VM.'Q&#-"0U=D972$A29B<I:RMK<G1W."HF:CI<+$"ADW1F.'M</%_\0
M'0$! 0$! 0$! 0$!          $" P0%!@<("?_$ %01  $# @0"" 0#!@,$
M!P4&!P$" Q$ (002,5%!8043<8&1H='P%"+!X08RL14C4E.2\0="TC-B<I,6
M%R0T0U2"1&-SHK(U@Y2SPM/B-G1UA+7#_]H # ,!  (1 Q$ /P#^_C2E-*4T
MI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5&)>ZT
M^ =DV9RT0,0]#1\/*R[4E*A!.1D98)$^(@I Y!#S:A0YB4BY*.C2'L(:,- +
M&84MT=U*?4S@L9B T6,+B'@^X\RR6VEK#KN&;;>Q#;92DYULM/-..I3*D(<0
MI0 4"?.[BL,R7 ]B&6BTAIQWK'$(ZM#[BVF5KS$94NNMN-MJ,!:T*2DDI('E
MY>4GIF([RMKG3\V7-,P'XY Z3FVX@%6K-:PSX?PGCS%:2J>S&<WIF(A*I#P/
M1L9<T^!QF3K?A<1U?POQW6=4O)\'\1\)\5FRQ\/\41A^MG)UQZO-GM3XO"Y^
MK^(9S_$?"Y.L1F^)#!Q18B9ZX88%_J_S=2"Y&2]>*-Q:"XVTZBYUA;;X5IDF
M5IFX[*'8^CR(\3<C6U8(X+%JTH6+'S[Z>+<280R.:IEUQ"<Z/1^/!4DX/% I
M<P;2AU#DI<Z0:6]@6S\MEXQI"W,,DW>0E2FPH FLC&X,Q&*PYE&)<'[YN[>"
M<0UC%CYORX5U:&\0K1E:TI<*20*/;BT(93R2+G6&5#A562?P[-QR,LQ]YEBH
M*F&NX41CF"VJ:!,B:^^K@W+2 KX@*GGVEHP3T=CUA)3@\2H+<QC22&7"%.]'
MLHQ&/;$)NO!L.(>Q*1=EM:5N!*2#5.-PB20<2P"E&&<(+J)#>-=4SA%D9I"<
M2\A;3"M'7$J0@J4"*]<7VD9-1'8MU<R>Y9G*6V'B9 Z2NW-0#MJ=K*6?#^$S
M.-UIAZ?7%X3TQ,0TY(9:Z,G+F)\!C<A=^$Q'5C"C'%?4N91@E8D8,8HJRQ\.
M<6I.&#OY.O(;S9S%/C,)G#?Q+&=6(.$2CK49CBDL'%'#A,R7AADJ?+8&<,I+
MA&0$UXHW&H#C2'V[I5ULN1=HG$.HG(Y3:X:D2(D1<91*\$93D"KRL@#'3Y6,
M^!BC2QAC5LNO-I5H]'8\**3@L4%![!X<I+#@(?Z0:6_@62,L]9BV6W'<.C\S
MS:%*0% $U!CL$4YAB\.4]7B7LP>;CJL&XEG%N3FC)AG5H;?5HTXI*%E*B!7J
M_N!1ADOK(M]:90*FLK)4[-1Z$L)NDAB)J*G<J(QAM-FDU)CX+*N&)0S.!P_"
MNYPG64X#'+*0G"8A14<6$A+*R5' M==C0(3<X5G][B(_V2/F7 O55C,(D$JQ
M+  ^'DEQ$#XMSJL*3>PQ#O[MD_\ B+^5$JM54WZD*-:CDVZN*/?LQ%,9"3,@
M9*=MPL"1:":RVQA_+BYUBMB%3ST6E.3&XD9^04S@9I;F(<#C0A3IPF(#:<(G
M'J<ZES(G!+Q",(C%E67*,.K%+1AP\3U9>6EK-G4 7QF$*TMC$L=8K$JP:4=:
MC,K%H87BE89*<TE].&0O$%H#.&4*<*<@)JS^^=MS@!F4\NJGXM(K4]<AS_'\
M9T-ZI59P!JR65HCI/@G(.!=E(UN6DTJR& L\-)+S:B&L*Z?LSI'K%,_ XLNI
MQ6&P*FQAW2M.,Q@<.%PI3ED8C$!ETLM$9W VLI20E49^.P61+GQ>'ZM6'?Q:
M5]<WE5A<,6QB,0#F@LL%UL.N#Y&RX@*(S";XR]4N/<,:/ME=#<CWJV.<V3,
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MB,_48K.%9?AWNK7U3LY',BLJCE,9;-XIJ2B@E6JOI,"L0=0,%S+@X(%M4A#
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MT:2*%?8$<=<:6G&_V9TCF"?@<7F.(Q6$">H=DXK!-H=QF'C+/785IQMQ]O\
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M*3@<A3F^*"E)26(ZR5 9;BN8Z0P):Z\8S#%CX48[K@^V6_@E)*QB\X5E^'*
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M=UU'P9#I>P2DN8=2DA04%,*;2H @ 9?F!$U'0_NNO+/ -!D@[75F#8V;M-D
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M<=7Y4_@_H=+;;*3C VU@WL V@8I4)P>(Q#N*?8!RYBES$/.NE1)6"LA*DI
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M&L*7$OD#X<X88LPH.AME3CBBT%UZ#_B)^/&'D!24MXA+[F-0A70K"' _B?\
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M6UO-N8'^$O\ A_A&\,HHQ3#19QF"PBE],XA"%M=,,OLXO#LJ6Z X<:QB'D
MK<*5DLE*@DC?_69^-<2IY(>P[J\[&*?">B<*LI5T<ZVZR\X$L#(,,ZTTLJ4
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M$L'=]GF?]HFYL>R0=;&"8'^CU1_WI5_^2Q/ZI.O^7Z?RI_X4Z6X"O^@QU/\
MQ*_4S40WD2ERIMM.)2XT[*A(<;6G"VW$9ROBE:%8RE2<\,<<*QG&NS(!=0"
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MBTR5)44M-J+:R@J;ZQ#+2'0@I#J4)2L*$@T]'X0D$MD0DICK' E0S.+&=(6
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MXM.'&)6ID(4EHM^E70'13F(=Q*\,HNO.-NN XK%=4'4OX+$EUO#AX,,NN/\
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M/*# ;6 $DMK^(Z06\O\ VC?SN-O8'(N%6:*9'5@'Y3F&Q[F(=6TXMI.=2@=
ML=7@PVG\BB$(4WB0M,B5.2)"C&7 Y,.\2'XXVY[Y&[FD0^^6U6YM<$=9W#H\
M77*[3[:Y*V>&-CB=S]QHZYE'PC^&(40\"&A0Y0)D_(C1G0#X;!Z4P4+2UA$8
M<.8/$8=PA6'>6M;K82VL*&'84T L2LI4I928F)"NB<'B$E)7B''\KZ'8(>;
M2 0I.7K' X"(@*A((DB2"G5#O(:L<'<*!9J6!M_6P =Y+[N';8^'<E8T"M11
M6]>S<[4"Z-7HZL.!R4V=R<]HI39FWQCJH!LF2W3O,BB2E(RRV0>5]7[;9<:>
M;>=><)PC##144*+BA@\2AU+RUNC(A./Q0Q;2@%D)P[280IMLI\HZ,<0ZVMMM
M"4E]UUQ*4E 3F?86E:$I;A2OAF#AUI.7,75E2E9E$]I\G2NVZK;#;/5R[L'#
MVJ$VYJ49-!2)'3I*+*$AA&D0TG()<>3(2<*PEF*D3TOOI-.#?+P^_AWPR_CX
M]YAS&XI;*VRTM]Q2"F$I4"HG,E,_*E1E24\ 0+1%?3PC;C>%80ZE?6);2%@C
M,H&(A1 @D#Y5*@9H)&M;FRVYGKRVO^:KX?MV<.STZ\F='\2?ZAZUZ((X*B>"
M3]$Z;'C?:G@W/XM?'MQP3GMS\GY,8QG\6F='\2?ZAZT@['8RE6E^4GCJ3V7I
MX-SA_P 6OS_\G/#S?!Q_'\'7U:9T?Q)_J'K2#LKA_E5)\NS3G:JY;<QU^#7U
M]GZE6>'GX=F,>?AG'#T]6,9QIG1_$G^H>M(/%*OZ57X;$S:09!TXBK6E(4W"
MDH<2IM6;3>E82YCF*YJ[Q87&U\U6,9PE:%)<0KL6E25ISE.<9S]O"OLIP[8+
MS22,T@N(!C.J/\VL01;2!SKX.+:>5B75!EQ0)L0TL@C*D#1-XTF=)$3K+>./
MX2?-_P K'G^7\?HUZ?B,/_/9,?\ O6Y_^H"N'4O?R'@+VZI?;_#Q/"8CPIQQ
MG/[)..'_ *R>&?QY_MQ^;3XC#_SV?^:WV_Q4ZA_^2^3OU2[#LRP;Z_853]3Z
M4^;AUI^WG^3\>GQ&'_GL_P#-1_JJ=1B.#+VI_P#"=D\+_+;>QVM-J<<>G'X\
M?C[?/U?;L?$8?^>S_P U'^JKU+\_[!X__=+O>Q_)-N//017$>-J]_P ZX6F3
M@KV]3P,[FS,L4E^0>Z+: 9+<*F&!R:PAX\E4H#%["-%[?@B^-XGP5JB6$XR
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M^XCGX@DS3CCJZT_SD_W]7RZOQ&'_ )[/_-1_JJ=0_P#R'A)N.J<GQRZ;QP@
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M;9<XK>"1C-J-YZ),XN3MMCZO8C+O.TF;IPI5*EK-N  R -XAE8VTS>)%V8+
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MV^K#2104DD09DQ_ZC80"=C8$PH0=#1W#.M.%LH<_,$I)2).8J"00A2T!PY%
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M"2X;)4@!*NK;!/&:?+'?=:;<<PN8$"^@ 5<FV\F3$ ;=M:#*E*2D)6I;D9
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MC;2EDR=LLA] K3\X4W8Y*=L*XZ-;+,BXV#@$SBBY63:8;?%C :U$NR+2FU^
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M'4-[6C._B_I=*5S-N7LR-?\ >K;3=<?<:&B@J*W$-EP+K11#IF(6Q.V/"A'
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M@F#K<\-2;\HO--K'M]BJ_C^WYOR?%J$FT$DW.ND>6_:.&ZF@[8.@B=])F-R
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MNN=O_P!S9X?[-2;Z\9M.L1:3-YOI/ [4_P"7_A^IV][U>^?\O]G5]O/I/.?
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M'A03L6I!B;PSTS;C<+<3.XK1&)7H6:&.92!=NU!KKN7'K3,Y*S:&,AM0)V^
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M68:&RZ '?<D1)@:S>18R8T )M%4!2R0$K592B!\T)2"I2K)L$I2HJ.@2"20
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M>#'R)(\'#R2'[0@!Z>8?D@(:'3)$JDG620HUH%<CAQAR+;)%MN!T /TU*C<
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MIW6V*"OEEE[I6K57*C;9"N5"+&F50SY!C4Q3+Y%W&(GC)"#LU9E#W0Q@'88
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MDXV]#Q?WU7$3&8P'<TR?8A31-E[X4J;?B&HB#Z/!A6DV"E+'% /M#!)',YK
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M;LKTS3>+F7<E@Y=4I*U.9B597E:/!X2K*\R/.RI/@6>;G.>./!-\.',3P3R
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MXEI:%J2AQ*U!=NJ40X0DMJ"U)04MJ*$.%*EH"OT.U*Q32E-*4TI32E07;O\
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M*4TI32E-*5RS+[Z6*.Y2E=V@:8JSL#,'@P3\0MLY-^;;.VSW$W&SN6P1B7P
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MS>]^TI3F'>L"]S>[>_?D_+I2G,.]8$[F][_I2G,-]8%[F][]I2K0]!O03>)
MN<=#)XXP&[C.?\"OCPST[/#C\6>';UZ4K"T']Y=9_D8#_5T:=M0?4_J:M+JI
M*":<M:DH2FV1^5*5G"4IQX-_CE2LYQC&.';G.>&KP/:/K3B.P_JFIATX+UP7
MO#7T]2K7,?*'Y/\ %[^?J2;M)5M#.SV]FVPGB&T6NN.JE-UTT!($O*/4^T5Q
MV;@X3%,(S(U6567&3>9 =3R&E!8RXI[][URK=.1+O;/@[G@P_*R-CU7J\R=H
MB#I",0096F"_OF$0Q W0B@64S%8<O%<C(PYEM$^W';?5]R(MM>;!KL75TB+
M1OJ3IW""#$"8)!)K94 G*E"1(^92OG69ZLD F$H2%H*D%"$N!*UMK<<21'O/
M\B?=8^R%ST'RA(2"()L%=EBY=B*G";+.N5.XVBV1-@L$A*6>5%392!K.97#G
M*T'7&Q1EX+@S(J)Q(U.:3:.9O;B!RX0=21R%YF89$IBX6M15\MPH( 'Y<_RY
M2;K4GYI0A!*RN0(Y%=J) '<,WM#B;K"0H\%7MR*UBXLVULMRS;9R-FW!E7I;
M<"2#>OEXAJ58A;!F-'C83!EQ-QT,QMV9?G*2"9X$V @6))B0 )CC$;" !6UK
M2XX5%,-E:CD1U;:PA2U+*<[;2&\P"BE*@R$I  2V$)2VGJ/DV[9SFR^VC-+M
M^XJ;]+^/):6Q*.98%% %/4.EF(BQ6TCL#@LJ'<.4V,$$ST^0.7X!;BW"B(8]
M9KF8M (M>2#)O)$ 0-+&3K<S;?G30O6Q?3^V&NST_L]*E5Z:'ZV-_3M?3U)&
MX\:53IP7K@O>&OIZM*KTT/UL7O#7T]*53IP7K@O>&OIZ4ITT+UL7T?MAKM]'
M[/2E.FA>MB]X:^GI2G3@O7!>\-?3TI5>FA^MB]X:^GI2J=."]<%[PU]/2E.F
MA>MB]X:^GI(WI3IP7K@O>&OIZ4ITX+UP7O#7T]*4Z<%ZX+WAKZ>E*=."]<%[
MPU]/2E.FA>MB]X:^GI(WI4*K)8J+%N,I1+"4N6B*4WE3S:4K3BBU%&<HSE6,
M+3A:5)SE/'&%84G/7C.-*5->G!>N"]X:^GI2G3@O7!>\-?3TI3IP7K@O>&OI
MZ4ITX+UP7O#7T]*5SMRCMI9'>BO5B-K5OB*C/5BQ'SD19WS+>Q*5@^2IUHIR
M++67:;=*CG-BA![024$%8TSM:EA\F1,E%MI.1(A 1!XR.6XY':+0><2#H$!*
MP1.8  _+:% S)25"P(^12#>ZBF4JPEXV69OUON!,RN )"*M')TW#J%HEFXZ6
M-@YG:*X.R\K7@ EO-DQF<QX)C\7,"Y:0V7N-9,)1G#!+1MS"PB)208405W*@
M5 DBQRV  (2/\WS5U#J<B4!'5CJ5M.J:<=2K$DN*>;4^%K<;(;6&1D:0TA2&
M&U%/7YGC -\=@;YN!8+7;X.W5D,VP[;6B@'Q$:?:X_-J%E:SN?4*I"6AB3N9
ME*Q6*N9N-';CD2H%1;N#%BJ9 4428#-]"82"  +:S(,R!-P 8D2+F)C62KFL
MH*4I2E2<I)))022I#:5"4MI5ESI4I 4I00E0"0%=8MWM]DH1IEII9[#JFVT-
MJ=<(9Y[JD)PE3B_U?[)><94K_P!;.=2L5Z=-"];%]/[8:[/3^STI3IP7K@O>
M&OIZ4ITX+UP7O#7T]*4Z<%ZX+WAKZ>E*Q<88'A4EQ+&QQE",XXOM8XXRVQPS
MCBKKQGS9QU9\VE*RG3@O7!>\-?3TI3IH7K8O5V_KAKZ>DC?72E5Z:'QX=+%X
M^CI#7'_X]21$R(WX4JG3@O7!>\-?3U:5J_<G;^O[A&;>R1+T"W*[=W^"NT/)
MG!B'FA>+7%HDQ(DE;B'HLB8!<7'D&#KPI0JW6'D.L.N-J6]*HRWS FQB"!"N
M!,@R)U @G<:US5<>3;8[CN?;[/Y8P,7#SU_$G<D&,9E37:><#R79 X*&4S*A
M*AK;#V7DS-AQQ+X;\.U#7 6:;6;-198+NLP ! 2"D03J%75)4%9DR 0D0$@!
M(,9B5'N'PD-Y&6D*;3E4J"ZA\YGB77V7R\T70EU+2"T&6T(:2KJE/K<>5'Y[
MDN79ZT;G7 ?<&'..W3D:Y(FQPIL^,) SYLUL%B=LL:/,6<^( :H0FSLA.4[,
M)%@V"==FXZ$L!SZ*O&G%PE-P =0;F8B;: 3!%XU$B)@96MK*M+3;B0IQ*DJ6
MZ%$)27@$J"4-H4HH6V"LB0IM93E2Z4)_07IP7K@O>&OIZE<:=."]<%[PU]/2
ME5Z:'ZV+WAKT<?X?HZ_BTD;^]/UM2J=."]<%[PU]/2E.G!>N"]X:^GI2H1MZ
M4*W R"7"1T*S>-SE8PMYM.>:YN3;%MJX*5C/-6A25HSV*3G"DYSC.,Z4J;].
M"]<%[PU]/2E.G!>N"]X:^GI2G3@O7!>\-?3TI3IH7K8O>&OI_!G2E:FO6W,%
M<MP=E-PLE0(TSL_;K/.LG$!"E2Q<+:=LKQ1)*O1TIX9M^*&+DK+!STAA/AAS
MLUH1A\;+R1"15*YI&Y-UOSN#/VYBV5*/07N(78WR949Z7DIT*!W4GM[]NBXL
ML&6"<A4L2EPSM;=0I$<HF1IE(BO$KH*'!754$ R1:\Z:&QU! ,:&)!N+@&NK
M+@;62H%22E:% 9)*' 4*_P!HVXD*"2K(K+F;<"'4%*T)C/2NQ%M?W.F[SBPT
MS#=HN6SJVVZX&=#>(:QM?NO9-X39:2;EK++,^.Y]$Q*T*0:IH<2-9#[7*W*S
MBDJ/('A4C2-KR21 TV@ZZ2+"=XI:2F B\H/6*4I2P$HR% NE'5DPI(*"M 2E
M <("LW:/3@O7!>\-?3U*YTZ<%ZX+WAKZ>E*=."]<%[PU]/2E.FA>MB^C]L-=
MOH_9Z4JO30_6Q>OL_7#77_\ AZ2-Z5C(8T-,/%8R6-C.(P#&<9?:QG&<"M8S
MC.,KXXSC/5UZ4K)=-"];%[PU]/2E.FA>MB]X:^GI(WI3IP7K@O>&OIZ4ITT+
M/86+G_Q#7T]) U,4KF^5V:*D=^X+=;RN@6JU#S0-S5#YCW56AZUQNV.X&TK,
M6F=\:I 12G8#< N>7&9BE'LVB-2^DMT60<;$L@B-;6OI)'"]M=(N9FT5O.%(
M"%!1R)(;A9A*E+2HDI4%""C,G*CJR5*2LJ.4I7J#;SDX76LV2G69^XU%A=+G
M)"R^#D B)&<LMPC:IN=M4',2<X!.#LYJUSJU^=W%F818.)H&_N/*>D"62'_
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MZ.Y.V_T-RAJC-VF(B50BH&S9K4A&JD4S'@"'*[7K0-_C08(6+/<Q&64%HHF
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M$6:0D9,\>&%@9.D0 ;7$V()%R+@$E)MHH D00(()VIM2$MJ)00ZDK2$N-K4
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MI3F'>LB=R>]_TI3F'>LB=R>]_P!*4YAWK(G<GO?]*58R1;4>-@B8E(4$)90
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ME\Y2$\WBA&4HRIS*<K4I4XYAWK(G<GO?]*4YAWK(G<GO?]*4YAWK(G<GO?\
M2E.8=ZR)W)[W_2E8@_$<P=$KE"JXS)G%JCX)9X;#9QAS89DHH&)41(8((+;
M D9%0P>5O)##,+RWAD9]Q#Z:U0E1"B 2$C,H@$A*<P3*B-!F4E,FV90&I%8
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M$0\ _,D R<M<C<2@-LG01USEHL]ZDY.7>;JT?&PT%HD&($$  F29CC?38 0
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M5997PQC&'>.<Y\V,=>=*DC<5CZ#^\NL_R,!_JZ-4_0?I[^]!IWJ_4UA]Q?\
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M[(MIRKL/J?U-8R_,*)S5!TKPVIZT -X<4C+F$94V_CG9;PMO*L8]&'$_'JR
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M+;0I:0PTO$*0G*L-YQCCI,\ =3_F[SKXUH-%7Y0M4 DP)@)2I:C86 2E2B=
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M/EZ4\E2?/*,?-KGUEI/"!&L7Y\^?D*9!N?+TJ/UF.-GHXDYPT4=3%@MD+AM
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M=,L1!M]!KI!+?1^)Z/ZDY'^DNC<<EP*;SMM]'M=+-=4H%G*\XZ.DYZU8 3U
M26U(6E+<[(Y).Z& !8J/WPK@HY!60K7).Q]V+F;G&)OFU]W*M<]DC<5R+7N'
M9VMO#JS9BPXX.#?B;4=ED!0XN(PK(7""C*F"0<T)S@A*Q 5EG*<Y*@9)RH@C
M*#7$8P)PJL(&&BE2VW.N4VRK%(+3.+;ZMO$=2%AAU>+6Z^TO.I99PP2XVIA*
MS%'>0A:FL6-0&]L8T1/U&-KI):8Z6&-,7#[B7.XQ8L@]Y1F %PD="V82M1\5
M)Q,S#(9$+9FH&Q5PXJLD8D<]!Q' 1MI/D(-[C@5MD*!"R"EL  MCYD-%)*CU
M9.4+A02(*D I6HK(<3^AVWL674J#2*K/V@:T3M9J-;K\S9LMI!S896&APXZ0
MG,A.&GN"9E2QG3LC.&F+8R_EM13ZDY=5*XU,.FA^MC?T[7T]*4Z:'ZV-_3M?
M3TI3IH?K8W].U]/2E.FA^MC?T[7T]*4Z:'ZV-_3M?3TI3IH?K8W].U]/2E.F
MA^MC?T[7T]*4Z:'ZV-_3M?3TI3IH?K8W].U]/2E.FA^MC?T[7T]*4Z:'ZV-_
M3M?3TI3IH?K8W].U]/2E.FA^MC?T[7T]*4Z:'ZV-_3M?3TI3IH?K8W].U]/2
ME.FA^MC?T[7T]*5"JP4,FQ;C*40PE*[1%*;RIUM*5IQ1:BC.4*RK&%XPM*DY
MRG.<85C*<]>,XTI4UZ:'ZV-_3M?3TI3IH?K8W].U]/2E.FA^MC?T[7T]*4Z:
M'ZV-_3M?3TI7,O*7V/+WUBJ>S 7QFF3%3E+$2/(9*G<,H9M-/FZ@2>TU6[)6
MR")6$3+HE8T&5)D*W+I',@;!$EQLN\\+08G6>!!B#(,Z7M(X7(,V@[2I*<Q(
M5G@=4M*\A;<"T*SF 2KY M  4@A2DKS')D5;7G9-F_W"W%3*Z\0&3:N3MN)3
MK/+#Q\N? 36T=O>E9>OQP;CS1,9E<6&:N+F17&\-$[C69'@U-LDL'"9 $ 0(
MD3)N3)DD2)BP @"TR35K"DM)#;:"V@I*T9\SI+BUYW<RU)SI"PV,B6T]6A$I
M*\RU:GWTY,5PW)NEGW#"N%8*/E=O[)3@*[X.2$%R3+T;=G;B!R0@VP$UH4>(
M%W5Q;92Y,UTC<=IR"E:E RV:E9R*\T,< >_L$\-Y[HVDY5D^7(% VS%2@J?E
M1(2 E.6%]8025?*I"8!2I2^]V216F6FE'L/*;;0VIU;[7/=4A.$Y<7^K_9+S
MC*E?#G.I6:].FA^MC?T[7T]*4Z:'ZV-_3M?3TI3IH?K8W].U]/2E.FA^MC?T
M[7T]*5BXPL3"I+B2/CC*$YQQ>;QQQEMCAG'%77C/FSCJSI2LITT/UL;^G:^G
MI2G30_6QOZ=KZ>E*=-#];&_IVOIZ4ITT/UL;^G:^GI2N<=\MFBMVI^BRL;;X
M6"%@1CX*PLG1[DB657Y+<':/<4DFO$CR@*(RQL2&T$9& &&,FB"LS9<GEAPJ
M,%%+H,;=XD>!M:;5MMQ3:@I(2H R4.(2XV3E4D%3:PI"BD*.4E)*293!O6J;
MAR:[%<=T+?:,W&!BX:>OPTXMXL94J<_3S@>2X>>!$.,RP"H6UQ-EY,C(D>4^
M&5#MPMN%EV\F3444&Y<T982FP(-B<TDW4%$B0" ,H A(,9I4=AW*6E(992IM
M"D*)2IT/E2G#UKR'UNMAQ*7$M)#2&FPAIM?5]?UCSF.M7)FN<M/7.S8N=1+/
MN!XIK"(N/*ARX*<MT]R<7;Q8E29DZ8HH2G#;!"SE!!:93).$'AQ)Y6<P@TB8
M)3$ $<R09NKE:Q @&)$\1%=6R4E++:T#,#F6M"U*"5O%))#25));6TE24+#:
ME-*6I)SH#/>O30_6QOZ=KZ>LUPITT/UL;^G:^GI2G30_6QOZ=KZ>E*=-#];&
M_IVOIZ4ITT/UL;^G:^GI2H/MZ2,W R"7"&$*\N-SE<U;K:5<US<FV+0K@I6,
M\U:%)6C/8I"DJQG.,XSI2IQTT/UL;^G:^GI2G30_6QOZ=KZ>E*=-#];&_IVO
MIZ4ITT/UL;^G:^GI2M$;F;:R=[OFV=C!LM8B(2E6*'LLFE8$DY9SB8 HP@6/
M8-&L(M?DH62&D3@'HZT5Z937RG\6FLN@V<://!H, Z\>,"XC3CX]M=$+2E*@
M0M4A0 #A2B2DI"E) E123F S $@!0*9!T2-R;;AG<"?MC%NJD:T9N(39"2)(
M-^7D9X& W5G]\=N2HTH&9C50N!9FX+VQNH<B.:_*4RE16(9Z/PZ._D#?EH0(
MTB#;28XQ,WUJI=4%#,HY" E:4A(S("0@@!25("^KD)64E05"P<PFO-CDP6")
MW)L-T&NL<<%9]SJ98(>+"60 '0Z]&;T2>_\ >BUYD9D\F3/N%B?D*P@<+G]%
M<N$X=CHU8-8KE63:(V,\=+WV)O$6WWR5C)D2A(E2%%:OF<E*"E20H90&U*)5
MERR(2"I64E7>/30_6QOZ=KZ>I6*=-#];&_IVOIZ4ITT/UL;^G:^GI2G30_6Q
MOZ=KZ>E*=-#];&_IVOIZ4K&PQ8B8>*PHH?&<1H&,XR\WC.,X%:XXSC*N.,X\
M^,Z4K)=-#];&_IVOIZ4ITT/UL;^G:^GI2G30_6QOZ=KZ>E*=-#];&_IVOIZ4
MKG"4V9?D=^8+=7RM@VJ[$3@-U7#>+G%65^V1NU]^VC&CL3V)1(2:8Y7K^;..
M1:HI1[5GCVB&SEB'/,CVT:&;WFW")$<+Z$3(V,[EO)!0K/"OG"P$DE2"DE!0
M20E(<20%)S%2%2.K4ES4.WO)MN%9L=-LK]PJ3#M+GI"SY0?'/R,W9;A&U+<W
M:@";DIL&<$:\F;A4]P"=P)J#4$F8"O[SRG)-\=XA":2DDG+EDDPDP!)!@!68
MP!($DG0DF#/5;F'<<4LX?JL[BUY,.XI+3:5N)4&VTO!]>5MOK&D%;JU$%I2U
M*+:P]=[<\FVP;?6?:-Y=IKTQ&;=V&+5F2"95#*71:#LGN5M+4@I(-V0D'I:_
MV@_<UN>M4T/@"!=#JC0Z1ARAXI)D)!T! VF0.S;S.DDQ7-Q:50$)6E*9A"G.
ML"<QDA'R)RB9UDGB29)[BZ:'ZV-_3M?3U*YTZ:'ZV-_3M?3TI3IH?K8W].U]
M/2E.FA^MC?T[7T]*5:'F"9!-Q@H;.<B$XQC#S><YSEE?#&,85QSGX,=>=*5A
M*#^\NL_R,!_JZ-/M[[^%0:=ZOU-6UR_;=-_TMCOZM_X?M^3-X'M3]>7OS#B.
MP_JFIQJ5:YAW]WFF=M)RLP@-IVSV[CI:D[D7,R][M"21M5690G*>V'21&8NT
M50EF8GAK-(S:C6BY<T6&JTHJ.K$TZMUR.VE(5K-BF8B0DGYE7M  @R0)4"2*
M]6&82]F*NL4$+9"TM% 6EE2E%Y\E<("&D(RE2U-MI6ZVIQU*1E7IF=Y>T7$J
MMR0]LI";S3VKA,R: K6 V0'6*"+O479LS09$2@N NZF-B[,Y!T:082LYNP4U
M4M.5_IU@Q69EN +Z?E$ZQ:+7!,1_%::YI947$H$N"&E++"2Z4AWJQ 3*05I4
MXELH*D@O?N\\D$QUG[H=#1DZNGV:H0RK2FU7JFO-P-P,5#PTW7MQ[)4(=ZSS
M,Q5 (J$JC,)$!S-XLRI(F6JBEGD.TIZ(88/=D6GQUMH)-HO.]<PDE)4GYLH)
M6$A7R *2C,LD90DJ4 "%&Y ,$I!GU?Y8I$C0;U=Y&M4MGQ)O#%;75SH&Y,>3
M3TCRVV5/OXUAN&X>8W,-$19BYV0#A9(0(D2;<(J8+"6"YW+K$(C7D?$2/*H4
MJ284"DPE4&QRK2%I/8I*@H;@@BQ%:^H?W0P:X^(8-C;(LNWR($4HT9,VN "&
M+&ITI;+<:6/*Q)9($7D6"E#:/B++MN+'$J ?ECZX26RP]8M/9;B9FXY6N>8K
M60A!62D04 )486H.!PA:$Q*D)ZLA2A8*4@?YK>5M^Z-1M AWY.\;5/5]U;,R
MY$L9NN91B2>K=/8W FPED15/+)"*Q5#X_$6XJ/?CB9]$R%+GP->BV;9) +W.
M46N0="0)  O D\+ Q> :A *DAU?4I.5692'%$H4M*2I"4))5E25+N4)4$*2E
M164)5:%\O.T!V8>)(I].;CL[A2E2,<8G229-H!O>3<C;BOHCVC7X8$ZS2T-1
M43DS%FF0P=:#=)G6#;&#_BT1%N/^;A(L ?*^;80:TEL*0DA+N8E^2E&9!#32
M'$A.AE)*B\9(;;*%Y3!"NR>3WO=%;_[=L7R,CD1"DRIT+)Q31Y,JS'R038I*
MQFI0B(A,224B'AK6:&"N*?>6XJ(D)>+Z)*FB()!U%CR(U$Z'ND<ZPXV6EJ;4
M4YT$I6$F0E224J3F'RJ((_,@J0=4J(O6\-2L4TI32E-*4TI32E-*4TI32E-*
M4TI32E-*5"*O^^3<G_2F)^7_ -!*AI2IOI2FE*:4II2N6N57O=9MBZK4;'7&
MZOE@ZTR+-J>LF(LPMFI0=%N%JDDT^OR.XFVCEJN99L%%A1,!'3I4@2*1)$,1
M)F1>+= GB!$3,Z$@38&PF_E)@5T;;SYB5I0E 05*4'" %.(;S'JT+("2L*,@
M$@$("G"E"OK<?>:^5Z<LXM2A*J9%5.\\G.H2V;(]-!RB0]V;P##VV;C!P&WF
MI3 4+8*Z%7!"7(4=F;:L\A)21[,,- 2*#;0R";7( )!D#0VF_"#H:%I02VH%
M*^L0MP)0H+6A*%+2KK$I)4V0&U+A8!ZHI<_(H&M9;V<JFT;<[F3%=KV*/+5>
M/VTL%DC6T)!L%@D[C4:ENU?;"!-KB]RHV8IE03![8.5X6RO[>S\?Y;&9A'Y)
MHMQH-H1 !YG4'9)!TC0\">P6DILH;0I25)4I2Q<* RA#*T$ MA/S)<S AQ9*
M2DE#:2A3O=;+N'V6GDI6A+S3;N$N)YKB<.(PO"5IZ^:M.,\%)XYX*QG&I7.O
M72E-*4TI32E8J+_92?\ *I/]6QI2LKI2FE*:4II2N7>4%OE8-I++MM#PHU;>
M9MF3"C&9YH]V0L#@>XNSU&:IE0R))QS;%KEPMSY2?C2"&)Q&$U)X9<(X(49*
MQ&DA)L3!X$DY18Z@)43)B(YSK([LI965(=5U9,Y'5+4EI$(<)ZQ+>'Q#JRI?
M5A 0E(_,%J2%=8WK/<CE46^J;G2=0B(NI,Q$'N"+3/ SHTH].V\AK_@P+)@:
MVZ+-QPX=FFA>45(GP"'HZ8PD3;UTAV,- GB)"O G22!-P9D ?,(4$A2@HE-@
M0#'S1E(-:0P"E!<<;:2X I+Q67&FT_\ :$Y'T89#[S3SBV3U3:T)640Z4=2X
MAT6$YRN++';@;B1D8Q0YRI5!W)H(4<LTFT.5J+D.3=X6;)DF)YV,.1N%$;UV
M-[;U(L."+DJKQ*NG6!B3DDQ4*2-;'8ZZD'L@I((,'2 1>N;C*VA+L-J.C:I#
MA&=UM9( (1U;C*D+0X4.9BG*DIS*3W[J5RII2FE*:4II2H+MW^]^0_TZW1_^
MIENTI4ZTI32E-*4TI6D+Y;-PHW=C:*ETXJI.1-NS9I>Y@3=:EC9@"F4T<',]
M8(BPAW2'!#(5-6.E5<&,(J\XM1=C7,.O=!BR1%T1>?IJ=.[B8!VM,UM 3"U+
MF (2$E )<4#EG,<V1,%2RE"I(2V2V74N)T65RH)U&Y]9JN)S:6)CY[<C<6N^
M24X28)=FJ'MC:9>CVN[RDV;9HB#KHH\O5Y:5KK2(2S'W-,W#P(<3#B0EEN@X
M)41($B8$:DP28&I@7,"$VDB16D,/.)"VT*6"YU:0F"M:PA2U!#8/6.!M(!=4
MVE26LS76E'6MA?A#<J:UFWZR0;HE+D82"W*@J@9%PS4GFT5N-GN4':.3S#-V
M,IR;*#5+69T2 W7@'L0\4TY3A[#%-QTAA4;:<TY<HB0J85)F00+@!(  (,RH
MDYDP+*-;6,,6&U-%:7@LI=0XYGS@H00XTE.'0AM*7 ZE06^XLA;02CY7%'NK
M6:\]-*4TI32E-*5C(7]QHG^3 /\ 56M*5D]*4TI32E-*5RW+;X66/Y25>VA9
M'J[L#+G PY$0ID[R]:$,VTW#W!7N:T2F8P#B@B3%,CMMG!E5IQ2[3-^'59V'
M&6(0JP8F\7GE! WW(UC45UZI9;#J4J4@!160!E0$J0@DD*)'S.M YDH@N(C-
MF%:NHO*QLMCW'I$/-MT2'JUR*=RJ$?0>!>(.K2E-W-O\%N)+&FV+,>-6HI-.
M@-K+*.NO>!SN3+'*'L0:&1*^[HIN1J1(^6% D*"=0=#-B 9,1(,CH<,0IQ"5
M=<MLJ3_V?(^VI0Q"&$D.-N$EIPK'5N!!#BE-I0E27.L3<[.<J2YWR=V^"G8R
MG/@7VU1E<+16V9,8JC2]CV;W!W;Q0Y]\R<F$&WG;?[VIM>O361(/)RKC 234
M+6EQ94;*9(CS[+;$&]<5H* DF9)6"1E*)0HI/5N)4H."1=0@;%0O7=FI6*:4
MII2FE*M)#]H'<>SH9/\ 4KTI4;H'[RZS_(P'^KHTJ#ZG]35G=>=DFGX1E*5Y
MMD?S5+3E:<9\&_PRI*5HRK&/1A:>/IQI>"!N+]D\/<4XCL/TX]WN*F',.]9$
M[D][_J7W'A]ZU;8^/VKQ>$?)PW@A4<_AIYLAK#T:MW#3[*N<T^WA9RL(>:5^
MJ;<3P6A76E6,Z7W'A]Z6V/C]J^.@+XO9YL7Q(6IQ_/BO/%]Q;.!UN/9Z;Q=6
MH=*6%+7SE*93AK.<HQA.K4KXS%I4MQQ3,/EQY"VW5YB,96ZV[E_+B'%9,YRT
M.9))RM*LY2O)#^58SEUSG2^X\/O5ML?'[5]YCU9:<9RB*RR[X/PK68O.6G/
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M:E.8=ZR)W)[W_2_K;[^M+>E_MZ4YAWK(G<GO?]+^Q]Z6]G[4YAWK(G<GO?\
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MM=6@;R9VBT<]_$<ZI4@LMH (<2XZI:OERE"DLAL"V:0I#A5)@!2<L$J-9Y-
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M%K4M9HV6*%='=/B'JT-+NDPBWT#33S \>8T6*^\&0[XUUG;2P.N@X3J0+U0
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M!"A@DH9<R61A0F,LBX00.O)#F$M82^RK*N:XC*D"=9TCA-MR($:WG6-:9E2
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M!1A)EAMF9@.8AX^2#E!C2%*S\CNUMBP%27C+XP7&[I1;$E2WA0<3 %EA)-R
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MR_1G_:)G\R/]QTI3HS_M$S^9'^XZ4IT9_P!HF?S(_P!QTI5J>,]@$S/C S/
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M3GGUM",H8;6^[D;&77E(;QEQS.,96O*E9QC.=2N=7G3&OX!7<3?=]*4Z8U_
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F_;[%\D"$/'!C "H\&,(RV.RCMYK;2<(3C.?/GAC''/GTJCQK_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g65062g16a35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g16a35.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1JF4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &HJ^9Y0X0DE-! 0      %4< 5H  QLE1QP"   "   < E  "')R,CDS
M-S0X' (% #1-:6-R;W-O9G0@5V]R9" M(%)O:79A;G0@+2!3+30@+2!!;65N
M9&UE;G0@3F\@,2YD;V-X #A"24T$)0      $$&DNW82W!*%P)FV<TN1=.<X
M0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0    !0
M<W138F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R:6YT
M4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $       ]P
M<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M      IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O
M;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I
M;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M     %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB
M;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!O
MX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M      !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M          !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O
M; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L
M=                %1O<"!5;G1&(U)L=                %-C;"!5;G1&
M(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P
M4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M#6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M        /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))
M30/S       )           ! #A"24TG$       "@ !          (X0DE-
M _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $
M,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M '   /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z   .$))300(       0     0   D
M  )      #A"24T$'@      !      X0DE-!!H      S4    &
M      0]   '9          !                          $
M    !V0   0]                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   0]     %)G:'1L;VYG   '9     9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   $/0    !2
M9VAT;&]N9P  !V0    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     <X0DE-! P     $!4    !    H    %P   '@  "L@
M#_D &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( %P
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MECG6/:'28;(G0?\ F7N4<Q[:JC;_ (1H)9VU
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M@:&QMR4F-3=#4V)R<Y'7"C0X1%)68W5XDY:CL[2VPL/_Q  < 0$  04! 0
M            ! $" P4&!PC_Q !6$0 " @(! P($ @<%! 4) !,! @,$  41
M!A(A$S$4(D%1!V$5(S)Q@9'P0E*AL<$6)#-B"'*"T>$E-$-38Y*BLL(F-U1S
M\365M=+31556=':#D]3B_]H # ,!  (1 Q$ /P#^_C&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,JKNUTE^;<0[)T2OMA.SU!Y5T.Z0C4FRZ3&N2]6J,Q.1K<@
M.P^*\0$LT!E);+)0SKK&W$-OLK5IQ,W6UX[>QH5)2PBLW:M>0H0'$<T\<;E2
M0P#=K'M)! /!(/MC/-:K_JNPPU>I %HX/V:[6W<%XMP_0K+S2*Y\S1V>I^4?
M(*QT?GU<K@EKZ;$V%UJQ2DZ[7VMNB.A5PAA+MAF!0"(\^0ZV;HF1I;#0[/7U
MX/4W4E2*W):-DTM-?FJ6IIC!3>)3#'%ZI^8-*.1#&S!T2@)X'@_^/ /U/Y\?
MO]\D4Q^K-S.+K8DT/P/O\U+BTSNMXO53BQ.7:F.:Q'C?T!KGG6_ZI+D.F P9
M:X.3<V9'JJ\I8$S0JA60=*.)T*WBCZ(N/,T9V>KCC-G6U:T[M=[+DFWJFW0]
M!4IO*/50=K^LD7IL"6^0=QKY\>#Y_=X_Q_RYR?T[]2OF-JG8VKR/*NQTFR2_
M8^#\F A+7'TA!JA?)*GV*\\GOY"X.[S80U9EZ_5Y-Z4C5%JML"5ID&3K[)FW
MV1XMCI&Y!&TR7:%B%*&SO-) ]CM#:B>*M>J@2UHV,T<LR!'[?0E7ETE*\$TY
M_K^?_=F#LOZH7.XAEM-;XAW+H,FI/D^6_$543G+1$?"^)=X#I/4K!($6+H,$
M$S&*62N8KR&""I.5%:;C]1S,V:'&O98NCK3DF;9:VJG.F423M;[7DWE9K%*)
M1%4E8OX].4E0D;$N7,2LX$_D3_+_ %(S(R?ZG_&!C&9*(Y[V&S<OB(?A$MU#
ML43!U9NE\@5Y'Q<#-\OCKB#)V\"X2)S\3::W)6?5+K5H&JX<V N0(V\MUAJU
M.CM@5*26J$-UY-G'3U\DDYL7_P!$/+'=>NR5WKHJO!,D/Q$T#3M$P1>."7/Y
M']_]>?\ #,Q&?J1<HF7EP\7S[JDC=8.%\C9OH]!#!J"K1RMGQKL+%3L@UU2_
M;QX<5^Y6$^)!H+P4L9'RC,HS)29L/'#'DBXGZ3O1@2/:I)7DDU,=6TS6/1NG
M<0F>%JW;7:1A7B61K0:-'0H4C61V16$\?R)^GT_C^?TY_EE?4_\ 5<Y=?H&%
M)IG&^M6^YS_<SO'R,Y_4)WA]I+-O(_,2>K"% 7B#ZX9RV1K9E?&=$>F KP]^
MU2@YHTH.,@)QU4NQT3=JRR+8OT8*\6M7:O:GCV4*K6-P4F5JTE!;J3+*P81M
M6'>C*T;,6 QS^1_P^W/WXS+<*_4.-\B/(OC?.J%QVV \FZGXTVWMA5OL>ZX'
M9*M/5OI9G.2XN;C1[B0AF#B)V!E:N>N*!GI21LDY7C 4#UD28E6\>RZ575:J
M_;L["!KU+;P:X5X?5:&>*:FMM9(G-=>9)(I$G3O:)%ABF5N9FC3'/Y?;_7_+
MCZ<^^>G><?E<8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,BUZ
MIT+T2DW'G]C02Y7KS5;#3IY ;^Q3%PMFB#(240*4E*U#$J!.?TP_I"MLN[2Y
MI*MI];S5K$E6Q7M1<"6M-%8B+#N7U(9%D3N7QR.Y1R/J/&,U.A?T_P#QZ@!4
M"1X5O2RW;/&NZ)T]:'G5:F_%&I0-*Y*OY;%U_P!&&@ZW&(L _KXS927R'%,;
M>VG6[DZGVLK%F:#DP;>MX@4?JMW/+8O >?#&29S$WO&" .>,#Q_7O^_.DK].
M_P <5;NV]@W'W?Z9Y#T2P_\ MJ>_O@/)^[C= ZF@/_HG_12R+$*TY!$I^>X8
M32A6T/:5\\N_VJVW^[_-!_NMC568OU(\2Z:L:M+N^;YE6(D2*?$C<,>,?U_7
M\L^[9^GOP&V:L!*W^BU^?FI#@$R#;JK=S(2T5.?\:8"5J_+I^I23(SB(R5"@
MIV8CY=U\8YB50>\ZX.T^AAUI!U1LX/2 %66*-=I&T$U=9(9X]Q+'-=CG0D=Z
M-)%&R %2A0 $CD%G+3_T^?'>CBB"08UY6V%4?(2DM.S%WE9P]V$\FY^-LO4U
M'2DKHN3DY0R4BA78N7DC"Y +6WU/OFOONO*I8ZHVMEF:5J_+6-79(CKQQJ)-
M/"\%+M1.U$18Y&#QHJHWC@* !C^OZY\_S\Y@7_TU?&1Z5JI>A>B#04'7N0UV
MT4$+HD^'SWKK7!(N+B.0R77ZF,ZU'W27I(D+$I"*<^R9D=1H+$Z-*!B#C-Y1
MU=N DX[JK2RRWY8;35(6MT3M'=[Z4)V!:O'9:1^Y1W%.YC&49F)?S_G_ *>W
M^'OYR6V?P"\9;=,^3U@F*:=N6\NZ[ 5KL18<[( K)!K@C8X1%9T,M&JV<64-
M'S$R^#[;FIF, .DV25-.(=P0]3[B"/311V%[-%++-KU:)&"M*Q+";N!]955G
MCC#>8XW=4*\\X^_Y_P!?U]\QW/OT_>%\[M-?NP4GTZQVRO\ 5 NT(GKE>BK!
M(2O1 ^4F\:5,R[KP3.GQBJ4<L9<,*D.'"(&!_: 8T$-@!-UKJC9VX9:[+3A@
MEI-KC%7K+$B5&O)L/3C 8\%;*=WJ'ND8,WJ.[,6+^O\ #C^N?]!F7YAX+\2X
M[<N17GGQ70(*8XY2K_SN%8;N1;L59Z9T2XR_0):"O,<X-MF?$C+E-G6&"TC8
M*PY!(+A*SDQD>D:RYU'L;]>]6M"K)'?L5;4A]!0\,]2NE6.2NX/,3-7C6*3G
MN[E[N.TNQ+-RLT&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QGEWUOSSZWS6\
M>4C\5P&L7+BWB++T0;J=G'ZJ5#='(@K=0JM>Y*>J]'+HA,!*ZK<?825$ %7:
M,?.9C'-CK2\^AM'H>LZ-UE^GTZLFZL5=MU/%<;75VUJRT!-6NV:4<%BXMQ9X
MC.\"]KK4D56D (X!(Y6YO[E6?;,FOBFHZ:2!;<PMF.R8Y:T%EY(JYKM&XB28
M\J;"E@AX\D+FR#?G'XR.7&2HZ>A$[EXIN=03(?T9>MU%V9J]*_Q&LE0C[TFM
MJIDK>H*D>[')TJ,G2[,*"EQ*XS[EIT=&A_V0Z@^%CM_ KZ4IA[4^+I_$B*Q;
M^ @LR4_B/BXJ<US]1';DA6NSD<2=I!.S_3NK]9X/B3WIZ@+>A8]$R10?%2PI
M8]+T'L1U_P!:\"2-,%Y^3D$"N%_J<>&S<,-8%= N/[097S[B&;KB7;MME4B*
M>AF)2]LIUSSY[HT<N=C_ +JWK2BOHULC29!:A7THG#\/^J3*T'P57U4G2HZ?
MI;4\I<D$ICI$_'<?&2""3LJ@F<\#Y &7F.>I]*(UE-F81O&TRL:-X P)Z??8
M_P#-N1 OJIS.0(O/ASP<G(/G?XURM>G;'#V6[3**_;H*D&5^(XWV&0O!,Y::
MTJZ5A<501J*Y<I6%L5/0JT0MD A'X"0@]:D!Y)3+C6UPWZ/WT<\,$L%2(SU9
MK:3R[75I36&O8^$L>K=:X*L4L%K_ '>6!YEFCF_5M&&!XSKOM8\3RQRSR".6
M.%HTI76L&2:(SQ=M<5_79)8098Y%C,;1_,&XSF \[_%:4K,K;P.HH(@HBJ<Q
MNSSZ:I=4&&USL=C)IW/38.)<KB)6P/S=M#*K!$="!'R4).L.1DZ)&E:^GL_1
MW4<=B.J^N(FEL["H!\14*I/JX%M7DFE$_I0"&JRV%DF=(YH2)(6D7SE%W^I:
M)YEM\QI#4G)$-@LT5Z4PUFC3TN^7U)E,16-6:.0%) C>,X)3SS\88.4OT5.W
M>?@G.<5N\6^=/FN8]0BX.3KG-)D.O7Z5I4\=3F(?H(]4FSPXZ6_HDV>6V\^E
M;*7V$K>36/HWJ&:.E+#4@F%^Q3JPI#L-=+-'/L(6GI1VX4M-+1:S"K/%\8D
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M((/9+C;>T:?+?<6A@,$;ZBDHV0:4ZR,S\E:3I;FEKVE"5*UAU&KL[K8U=94
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M\I^P4LLJ8X_&UCG7(P;LO2$Q_0[] B,2%BDX]UG6F#U5X5M@4@UGV,Z-.1I
M3C@YGIOR+\8["5NGNE=-;$<>X-K8;66FIY>A0F)BKK)R2R"TQ+*AX8-7D5QR
M@)]I_!;4S1;+J';Q)(NMF@K4XI77L6Q8[Q8=57@ FHO*L0 H%A.WGD\>M@K_
M /4W;"B@O@Y%\NI<C6)(M#FG6GKAT8ZJV1^%^.M>QY"KU:IU^5-TO>_K ]$B
MOI;UMLA.O$6'PVD5'Y$NTNQ6HD(X*T]=';K+/S_:CM6K=B%./:36S<^"I/N0
M_7[0NO\ PZ%22N[ \AK%UZTYB('L\$%:&1N?=+D?']K+@S3YLL8QE173E7[S
M86^@4BQE<\Z6R -$D6,(!F7A+9" .&$1U;Z+5'WPQ[9!QQ9YA420-(P-NKSA
MLFU5[9!"3D^-*Y%DX'8X[TY)"D\%2>.2C<$J3P ?!4^.Y20"+@WC@CD?;ZC\
MP?I_B#]1D1D;WWZG1XSMGY;SVU)5)0T)J7H_3).+4>=.S0,#&F/5>VTAA, *
M^;(B[)$9N5J=!:VYM)A^D?+=2(3Y5W7V\,@/'/O\ROYX^_:O/VRO"'V8C\BO
M/^(/G^0SN$@>0]W^<=(G4;BD ^RILR2I4L;T_HI"7%?Q"R%HIU3I=.,;1KX*
M,/K/2FG$J<T.,$_IDQIS"OD!Y6Y\!P(T_B%9V<?D#'^9]QE/D'MRQ_, #^0)
M)_=R,M.E4BL\]@&*U4X[<?&-$FGD+?,-E)25EI0IPZ7G9Z;E2#9B?L$R>\^?
M,SLR<=+2ASSI1Q;[ZU+W8S,YY8\G@#V   '      '@   #V&4))/)_K\@/8
M#\ADLRW*9^;UK>MZWK6];UO6];U[UO6_QO6];_&];U_.L>^/;VS5GFG%^0RY
MU1LULYU3['V/@4/KB\1=K'7H^5M==A*YM+T(9!GR Y"H7^K*\=$VM1,,MIY3
M4[N/(*VX,0*SI-?2J,L'K0QRW=4@UZR2+W/&M< PRHK<HC30-%.)$'>!+V=_
M@J.\ZGW6X2?8-2OVJNCZQE/4[5*LS15;$VQ9OCJLPC*O,NLV4=S6&*?Y"]/U
MUB[9(Y'M8SC'-RY-V917=1<D_IY+Y,#)2U?^OHEIU@GZK$,<",O9#+[[1"ML
M_)]M]Y+JEZ<7K?8-N]E)4>A/8%JI(AC>"Y#!;4QL "G=8CD?M\#@=WRD KP0
M./,$U&OAN1["O":MR*19HYZDTU5EE0\AP()(U[N?<]OS>S<@G*M=\+?&,^[@
M]&L?*8N]7**T%J(F.DS%GZ7J&_;=/ZC%0T;?9NQ1,2Y%I)?1&/1P ST<TYMD
M);#24(3(BZEW5;7IJZ=TT*$<8A6OKH*VO4Q  "-GIPP2.G  96<AO[0)S-)K
MJDUN6]8C:U;GD>:6>U))89Y7(+N1*[KW,0"2%]P"/89D^P5_FW/XNT]+CJY5
MJ[TNTP!7-XRXC !1<F2_;'!V6G)DUAMK9L3 *";M4V::DE4/7*]+26W& @RE
M9Y]=TVHK7+.ZJZRE#O[]:35KL(8(XK=GXMT?ML2H%:RD;Q+9D:7U'CB@D92%
M# ^E].[[?;"+7]/;+<[*QT;H[L/4MS56;,T^NI0ZA).YJL,A=*<MI+#ZRLD)
MABL7;]>%PTDD9%^PHL<%#Q(4.IE<2'&@BQ:AW$/,*CQQ6F0MLO(4I#K6QD-[
M;<0I25H]*3O>MZWG1(BQHD:CA4544<D\*H"@<GR> !Y/G.'L3RVK$]J=N^:S
M-+/,_P#>EF=I)&_[3L3_ !S)Y=F'&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC*T(MTM9RB(KG
M38;[ I#@DK>Y-IPBL1I SVV30(,9AX=^W38KJ%C$(#)$K\64@EF1FURT<17W
MV/Z_K^.9ZN4N)KCQ$EI9DS8SV&V)6USKK1M@DFFE;<0,LEM@<:/C&WUN$#P4
M*)&0 1#S[P,6,X^\I;&5VY6[3S7<@U2H!J\\V/682_S5!49'V&M.GJVHX2A$
MSI4?69.LFO./D?T79)2!8@U$G)@K%^RIB:>!NULU=D8VNV6H[*,(J[,I+)!9
M$?\ PWOK722U%9C4*HNUHK#3A4]>MZWJW'UC0S5 ZUX!:IN'+4@8TEB+^76L
M9F2!X7)8FM,\2Q]S>G-Z?9 OGA;_ -.[]."Z6MZU3GCWUF -++63+U2MTWR4
M@JF4;[4\\QJ%J$4NN-C-KWO6F:@6Q"N:3Z%VZRK6U^DU?Q(_$NI36I#U'J;,
M:(%AMVKO3,]M4Y"JS3W)199B./FNHTXYY?AO;@I>@N@9+1M'0WJ\C/W/7@J[
MR&L']V5(:\9KQI\W;VU66 @<1^!F[?.4"BTJ-YMXT<X%Y-S.M*,KH-DFJVW5
MHN"2!(%ASC-3YJ6D>V2=H&E&#D&D7V)J4:N2(_?W2;AK148=P-Z46+DVTZBV
MAW.RL.9):]>R;4LTJ\*@N;)>:D5;M"A%U\UR3TT]!5I@QS)VM1/2KQT=10_1
MM*% D<TT KI&A/GX>DW%AYB>2S6XZZ=S>J38/=&VP%1J<12H$2OPR25##N%%
M$FGD*,E)>5DBGI"7G)DY>DN'S$S)$DR,F:YI.R"R'5I0VW\&T:*W;FNSO8F*
MAF"HJ1J$BABC41PP0QCQ'##&JQQ(/V44#DGDG:5Z\=:)8H^X@<LSN>Z261B6
MDEE;W>21R7=C[L3P . )+D;,^,8QC&0/H_\ X/ ?^/7+O_6;4<8R>8QC&,8Q
MC&,KJTT^3?F&;I2SQ(>YB@MQ9:)%#KE>M\&.\24- 6AH9*BVT DF&E5^> TN
M2KAIIKC8\G%2,S!2T*>M(91:JNL=D((V#@F&S$K,RQ3]H[QVLS&&5.7@9W(6
M2-Y89-_K=K62J^HW$$MO423M9B:NRK?U5R1(XY+VM:0B)C-'##'>HSE:^PAA
MA5I*UJO3NU8W6^U RT,#+35*Z# HD6?N8Y^/J$]?(6:CU>_MYR%F:#'6).H.
M3;^)<0NR!UB<*CWARBH !3OT4VB]V'MLU+<#CD?JZ\MR)^ .626FDW"$_L^N
ML$I Y,2^V9FZ<$_$NJW6CV%=AW<V=I2T-N'N/RPV:>^L:]C8"\&3]'R[&FK<
MJEV7CG,N[U)@Q*6:M2NC6:2<4A*!7Z38*2"RAS?QT69.=%!J41H-E6]*);CB
M927TUI2@X@UW265T-\/XKU;L\AXX5JLU1 #_ &FFNI7B[1]0C22<<]L;'QA>
MFGA)?9[CI_75UYYDCW-#<SNR^\45+03[2T96'(C:Q'6J=W FMPJ2X[-<J,R_
M.)NU\+ .L[0I(,%#PZB':U2HXQ2=F#Q+QC IDS-R*&V&)>U'!Q[Q8P[8<5#P
M(+L@,?=#6D,OQ5MD>P%9(8XBQ@JHQ^81%PK22R#@2V&1"RJ$CCA0NKXK^TJ)
M3.GTD4\&M>2.:[:MB-=CN+$(/HO;2%Y8JE.N6=ZFL@FG2*5VFLV[TZ5Y8/DF
MD&UY]^5YN2)#//.O$GT\_;R*3-/OO:?)>;'&:??J<L2YMYQ<Q #J%)**(.G8
M"P%;9<8G9S^9VM7$"P/%1;XQ<%9XQIMZ7JTQIIJ5"9>6MI@\=3#KPDO"EN-.
M("G(D@R-?=;?#6^Q)"' BL9+L8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&=4XX*,"+D9$L8"/!'>+-.
M,?;&$$%';4Z^220\I#3##+25..NN+2AM"=J4K6M;WC&5BD>6Z=_M3T2->YTO
MWMB)6DF+L=Y9W]1.G9S2M,GU^I$)VAYJ#3]G/SC>FT3ZHR)6=7Y9E/?\A_G[
M?R_=_IX-HBBC!##AACL"!B,M#"BBM-CC##L(2TR..PTE#3+++:4MM--I2VVA
M*4(3I.M:TRN<^,8QC&,96@FOZ9Z1(!^FFHGHX6IP57OX[3=:V$'%S(ZU+WK2
MG9NICP1D<&/[VE-2LI[R=;>4M3']?U_AEEXQC&,8QC&,@?1__!X#_P >N7?^
MLVHXQD\QC&,8QC&,97O2C"-P(]9CBE"3-\DV*?&OM*4V0*P>.498Y(1Q"D[:
M,AJE'S\N"XK>D;/"$9W[4\A*F/Z^V3L448$48(-AH40-AD449A"6F!QAVTM,
M,,MHUI+;332$MMH3K24(3I*=:UK6L8SGQC&,8QC(Q9ZG&6E@7[I94?*QCCI,
M%8HIQ L[7S76_I++BRUM/-Z^JWZ:, ,8+B94;Y R\>> XZ*XQF#A;3) 2HU1
MO*!!9TO;R:_.A-K&@+HV.VZ^ZW'MOO/N15D%#967(U@D@AQ0K;\E"&RT>)**
MBF/W_P!?U_1.=FV]1YG0'Q1KWT6BTHDYM3P0]MMU?KCY;2%?!3HK4Q(!N$-I
M5_:I;25ITK\;WK?XRY4=_P!A&?CP>U2W!^W@'*A6/LI/[@3_ )9+(R4C)L 2
M5AI$"7BSV4$ R486.> :.YKVA\0P5QT<AE>ORAUEQ:%:_.E;RA!!((((]P1P
M1^\'*9WLIC&,8QC&,8QC&,91T%Y'\;LNNQ:AK>V6]P0F>%ZF'N*F6#ZVJMHE
M5RKZ B(]HJ7#;W"2S0YL*U("FO@OL".O.Z2A73VNC>HJ1Z=^)UYC7JM*DFBE
M$]9X;HNFN($,J2LE>0BU7:2.RT3Q)*K2!5Y(XNC^(72.R_VM%/;"5^AI;T74
M\1J78YM<=<+7Q3B&2NDEN%31MK'-26Q%,\#I$SMP#9=,M\!T"I5N\54Q<C6K
M="1MB@3W!2P5F1,L*T: 2L,YD8T53PSS;FV"AV2&MJ^#K2%ZVG6EV6OMZG87
M=7?C$-W7VIZ=N(21RB.Q7D:*5!)$SQR!71@'C=D;CE6(\YT>HVM'>ZK7;K63
M&QKMK2K;"C.T4L#35+D*3UY&AG2.:(O$ZL8Y8TD0GM=%8$"39"S8XQC*JI_:
M^:WK_$C5>L/U5\CL,O5^A-R$=*0[M=EH-IU^0^NW*AAJ)CT,L$.CRP.B8PQ
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MZW\M^_6O6_?KUE>U@>TJW</!'!YY/L...?..Y>.>X<>?/(X\>_G\OKD6:O\
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MMM&O24-I2A"=?SZ2E.M)UKW^?6M:RA)8DL22?)))))^Y)\G*@!0 H"@>P
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MA&6QAT:UKUK2664H;3KUK6O6DZUZUZQC@?;(M>?_ '% _P#'3FW_ *Q:KO\
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M],M!Z0_$#K.WUKT,9NHMYN.G.MK/5$1DVVHZ8T^MV$.LJ79J\O3^KUUN_O\
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M*K)2V'46WN4Y8!6EK6+4DD,L2ND@$J,2)).^-&,S]TQ95)D/ XU&L_#7\/\
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M:'4.7L>2UKMK5U5Y0_U?"]4Z%TS@>H66NP4>,%+\NIG.*@+:C*[3XNGS#\9
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MVK6M@CEBH1BP)!4*2P(Y)!''(( //[C]LH98@H<RQA" P<NH4J2 "&)X()(
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ML+6TI*M\'N)89+ICK2K-6IPUZ->5 PCF6I"D,EB-6 98[EA9KBJP#+\1PP#
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MUOUG,R_MN/4,H#, _)^<<GAO))'=[\<_7/0H./1C8PBN612T7"CTSVCE#V@
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M*NJB^6=]N52E[N7!NWJ#Z7:*%70KX>&@XFOQ]*Y\U5XB.WIA.I ./LD+-R9
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M@.J$%3ZI"5>;$254V)X%A2OJE$L,:4[K(FMNNU5$@):XC25AWQCU40=S,.7
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M7^NTGI5_]6MB)_\ 3EIUK?24']Z$?_4<I\)_[3_X?_\ K.RGJ\;OU\XHY/\
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MZ%"D9':?DW!2U2LI7_R0*W;X*=DU_P#+X1L>6K>_\M:W_/\ &V,QF_QO>O\
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M!42&G#A'-Z2<!7Y&QC3DA'Z4A9X,<0&VXAQY*]6NP168^RJS'\PJEB!]B0"
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MG3UW7[6_J:X?:R:Z18K$VOKV)HED**SKXC[U]-RT3%U7YT<#P,ML4Y8;$U=
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M(L$(_;9I2 $5SR?3Y''(/ X.6'3_  !KF^V\+W,^*XR:2/\ I7M#W5)O-/\
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MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC/*KG7E3YJ]WO\
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MXCT]N:W6/JV+4TLDCM,4GDE=VD50W*R%G-%K(I![F/#.W]D#F1.QO"J !Q[
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M7QKUHQ60ZUMM(TSH9>1ZTOP?IGX07#RWJ*.\!?U@3UI *35[35DC]3N*^Z>
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MTEAH89YU&3T9O_52>460?(W_  W8(C^W[#.RJK?LLQ"@DD#(_P 75'O9K_\
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MAE5%2$'M,\\L5> M]466=XTD<#R8XR\@'GMXR-+;@A<1LS/*0&]**.2:4*?
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M\8K3:-[2WI.MYSU_IG77;,NPA>]J=G,J++LM-=FU]B<Q*$A:[%&6H[1H$^2
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MMIIIM.D-MM-HTE#;:$:TE"$:TE*=:2G6M:UK(Q))))Y)\DGW)^YS9
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MF>;7"/O5/B-6-SHAD91[#26Y$.)=F;+]L3JHW$$@E"D:(A@QB(^\N-LDF[H
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M6Y8< YW7X<V]#K.JJ6ZZCF5-=H8K.Y2KV-)-LK]&(OK=?74*R>M->,$G,Y2
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M*;]199[EB!'MJ9-;\-"PJV #+8M21UXH99"J29Y.O-Y% 9I.F2@?31=00/\
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MTC;CKSFLL,SZ_<,S02+^GJC1O4C]*HS20[DRM4C].(1UY D12,1QE8Q K(O
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MVUJ3/ZL;2U+,3U;L".(VEK2,CGL<JRI-#-'%:KNZ.BV8(6DCDC#1MK]E3>Y
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M@V((.#>CC7XPIUM;P+Q8!#X)+@JVEOB/.CN[4RXM&\ 9E#*&8*X =02 P!#
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7QC&,8QC&,8QC&,8QC&,8QC&,8QC/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g65062g16b45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g16b45.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1I\4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M      IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O
M;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I
M;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M     %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB
M;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!O
MX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M      !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M          !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O
M; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L
M=                %1O<"!5;G1&(U)L=                %-C;"!5;G1&
M(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P
M4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M#6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M        /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))
M30/S       )           ! #A"24TG$       "@ !          (X0DE-
M _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $
M,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M '   /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z   .$))300(       0     0   D
M  )      #A"24T$'@      !      X0DE-!!H      S4    &
M      .O   '9          !                          $
M    !V0   .O                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   .O     %)G:'1L;VYG   '9     9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #KP    !2
M9VAT;&]N9P  !V0    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     4X0DE-! P     #^L    !    H    %    '@  "6
M#\\ &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( %
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M/H,8SV?X
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M  (1 0,1 ?_$ !X  0 " @(# 0             &!P4(! D! @,*_\0 6A
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MAU;YS^">(/>/V^2G=EPO]G3/T^@'B/3.4.K?.?P3Q![Q^WR4[LN%_LZ9^GT
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MJWSG\$\0>\?M\E.[+A?[.F?I] /$>F<H=6^<_@GB#WC]ODIW9<+_ &=,_3Z
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M]_Q%%%&R]5557;1A5----.VM]ZBE]]*6V666TK=??=6EMMM*W75I2E:Z&O2
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M'2593GA$C;0](&+G MJ .-RU^->%5<KC+2KZ&W[E"6U.-RD)'+(=>L7-%\H
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M?46OW6D#4-P3+?SG=X\4Z&#^:AOJ+7[K2!J&X)EOYSN\>*=#!_-0WU%K]UI
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MJ+WT18YX[?-[[+6HM5_9=;6MRB;IHA2R[C^2VMKE5.Z[CI\O';2M*?NX^/\
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M?\.*KFHZ6EHE*F1XE2XA& *,D<'#K:EQ:GA!@9O#9@N5=T_X0]")R=9W<DF
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MCR<9>AL98HQ4RBP)-@);JM(8K&L1 FK\2V<MGJS0J=',RH]HL/M'6[5I)]I
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M*I0S*F1A8RHDE55!NG;>FI-YN_-<C<LY5X,83[2<?SV:%5V1N#2@F6"9"7Y
MR[DJ4Y+D%)0*E,]+!<4.+R\)EL9AL3(0=K#[<=IP88(&L(*&( 75(^\)-SCR
M0O#+H\R/OQEZXSM!T X[,![U0\C "!ACKU_G[*SDMBN-D7P]\G)9=;>---#;
M=/C >#\,TW;I[PJ(5X@E+J-U9XDG'%:676WW12RVSET-6VEZ#P]D.!VW7>]
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M1#"X!;B3%\:F!EW)5&\NLN.2:CV)NGD8="05TKAQ]@UZ0-)]N&O%7(:)DZ2
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MPA@(Z%,AWDOD@6/QQP89]9X3$G<W4LB9ZZ:-NV[7[;\;M0^BA DW8-G4)OO
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M$ZM&RB;AQ1-*^V^J7:SO*D'5C@LD^G\"%HL7).9Q(<W)QLO,AR[Z0AV:3^(
M&XYV=E+-1P\3L<QP*U,"7)8XC=>,&MR@]9XZ13>MKE4NYQW]O#Z*P=1W+C!<
MEXVD;"(E8]/H2=%S]X_'04D&E((FPFA 4R+DRC&*.V+]=O(G@T< .D'[80H\
M79L@A=TYL20&O%$4NYQWI!U&['8HH4W$;?P<K.0,WF_$ ><QEB])R2&%,DPL
M?*X^-&@.M9$B;CKLTB7%,6$7K22O7;]F@@U 5Z974L'?^)TDZSO_ #VZD@ZC
M^?EVM7#;6RZE+J<FM+J<=*_)\M*_NXOX\=.*M/\ I6FDNUG>5%Y_T?\ I_\
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MFXQB=O!()F[ 2>R[B-ZQTXR-!L<1 C/)G(6(>*"UAS5P5HFY)56(&##*.A1
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M'0&)&C-TT7:V6LG$63N:A$4S#BQA>/:;YDG3HB(P%T3*F4"(.D'?DB/BF?=
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M/3UOZ.\[[:0SG.[H\Z<YD'FD7[<<_@>GK?T=YWVTAG.=W1YTYS(/-(OVXY_
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M@)G(:P1Q^-6"Y$@3L,1F"P9H>NF(!H&6?/'E6Z<%Y@8ZM7:IDF";H%TS<3C
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MP3-5.;[V\4ZQ"/G7/LLI[EIE?^V$8.PU88)FJG-][>*=80_SCGV63]RTRO\
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MIMUG$^C=S>_(#[HN#XN9N!CTY1YDB<$4([%U.@!B#HF>; W#Q64EA YLN]>
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MZ=3=BHZP&DG3<>T84I]-WH;^'B:U5UJ-@K-IU'U+1;J=G=9\@6@V$FI:&LH
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M*2DVR(=\6T=Q[(LO1;)&18ACT>^@<TC\<2ES>%Q9N\4EV)\CB"%0#4$9C[X
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MX]&NTGS!=W'2[<T,<6M':*2[9JJA<R;7V4YLV1MXZ5_F-A_^./07H>WU+?\
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M6>5.55^D^%GE3]FKLB]!(S_,<C_G'3E5?I/A9Y4Y57Z3X6>5/V:NR+T$C/\
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MBIIRJOTGPL\J<JM'2? SRKT_9N[&Z5K2N$ U*VJT0NIUUR)QVKW6VW6HU_\
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MI/@9Y5]OV:NR+T$C/\QR/^<=.55^D^%GE3E5?I/A9Y4_9J[(O02,_P QR/\
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MNRL:;J;FFG-+]$L8Z)+G$D.:14(+C_\ 8'0# N#0(I+)QPCN0[C2A6-9Y!
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MEX.-QH@2?D)E/9 S:FAZ,51,W-D#VN$B1JG& ;HOO,!:81!FH&P 8<'2XAP
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M[+.3EO!&67S0M S8IE@>ZJ32_EM::C)<_);>2"0UQ&3Z0L@!)J/ ::F7-"T
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M2WL@V/[G!%N6,%WA'(D2"CSST2+Q\^/$%PC::*$Q91JS&Z=EUX(DW7#?^&Y
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M(=>85(1_!V7I?. 1[.\D$RVS')\V0QV48,T![MN*+*1#_P $9; F\4'+EZ=
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MD5N;\HS7(ZP6;PM@8=AYBVBZ<PZ(%JG>=)\Y8JFFK,8J_N9-RI?))@7QM(@
M7&[5*AT5VC#Q+?#0F1RZLFCN'J;@RK$-T#4981FN;BQ!(7,4%Z&WU!9"!P&8
M90@C5.B+Z\LA/WI2QT&JSZ/>V<-D^^>)'^4+[W1=,?#A[3 )VRJ]@6R&01_'
M3B(3#+ B4R!N^VEB 4H$8X5C#=GCC:%-HK,(:#) W$ZD7/IC*[A$A0E4N8%@
MPBB\C:JBX6S9 ;!Q,3(W:,($#29UZ(3*$@Q<)NQO,WZ-8W+G;A]C:&?,V#\N
M+9(6B[2D;Q/!Y/%VT61)5F$ Q])LQRF400L95.LZVQC)3_)D<L/L+!E_@4X
MUI>H_M,5L%3\_/S<C7  B-JUW'<%#4?CY@-LW$2M3*K2'*XP6FU0).V!N<6*
M;<$-L=877$?7R\:DGU.8"Y=4G;)+G-V2!S>276<TY0FEU^ZZ= %\G9-VLW)E
MC5=,X[2?SWE;6QO:Y.WC/-YG+>5(I+<D9@P8%V]-3< Q>6QW"XC (PVR0J"6
M1AQ[*63#1J2*'LIR8J=)NITU9$&C<(*&"P7,WKTE/\=G']M04RL+L'%QTDDQ
M.@:E2HO@U(\,=QPC9. ]"8R4$)%(BC?&[%J2F"+G/>U#-;(68>TDBJZ[<<TV
MPV0Q&YZH1LYK,^DDF[9./4%&@ $8W77&#@+S=!B "-() B9'051+BYKKVN R
M7Y)#BQ[09+7>KE.!>V 7L!8'-+@YM -^"%E2 J'"J;B8KX",WP*KBC;!I451
M:_'<$VLPH0[&K!\UL"::Y2FV 66/BI$4E$0>$I+802BR):,CB3JP+[]%UV)U
M8W>_MUYRQJQVX7FX;^W 3<I7;P41)J((#6F8<?.NDX#.L0J(2# -30,7CR=L
MFH9P= !*Y7:)C,U@PP8*F#R/<[=!4'KV;JJ0.YC+$1X%=KT$87'AHOQ%ZF7<
M!!NPOC#";K]MV&];E8"V?@\"Y(-Y##'V+YS(H_D40<0;Q-F&(FWT[W Y SF@
M;.FFI)=4N^"63UQ%4[WK119W:T6+V.65""@M$8FX0-4S?IO@8F2+KA<23>:]
MP=&2' 0V<IP<<H,:'$$-: US\IS6Q+&D-+GD%YW*U%S31$T1-$31$T1-$31$
MT1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$
M31$T1-$31$T1-$31$T15SF#&@G,V*<D8D//R0L)DR$2>"ER0>YK:68#I2'=A
MGCP;<^;/&=KYNW>**M:NFCEO1:VRJJ"MG*LJQ5:<D@C$*B5]EN(G$Y.9(5;J
M7S@WN*C6XV^4WAXO?(6)V,Q*)0]I#6)VX'4NE"G3&(MG3MA<]N?7/")*J3])
M!5)%)^?]+1>3=_3D_P">V+NR%$I]L@9Y(R1D?(TDS9DAP[G-(CT".N$8Z=TQ
M7;CV10Z=P9EC4J1A[TH""B<E06/Y$,A%'#IA-Y(U3K-$SH]H+9CGY^?FN\('
MP  ,-IO.!)&N"1L"Q O8@H$FP2>"]Q&5;3(%ED=X,1)1_%)H8&R%EZ33N69(
MRO&1I2!NF4:GDD(3UZ*H5&HVU&0T4/A@ZB !_)FQ\+O>1L)Q(V_@5+P?^(T:
M= P&T#;[96P&VW J.W3'E<?-YN?R%9>;('W$HE@R--967*&+&RIHO*3$>$"7
M$ODIPJD[-G9;);B4D,$2"][XDLBDU203^?FO?<%@F3A%T+8#11-$31$UV9^D
M>WZE%J=E+&>[V1S4F7Q1NHQ_C&#N$1]HJ&GMM3;(I,:L@P;HD55Y:IEN*WD;
M7Y!-R^12J$:T8HN+&5+W%$.<*ZRZ N?1<]VEPJEH.J&AAB! QO7=C[.&@5*+
MWNOES:N2#?=ZN08@78WQ.E5YXE^$#[<^)^YDS^/NF<L_5W>.?(MYRR=7J>/_
M *)XE^$#[<^)^YDS^/NF<L_5W>.?(F<LG5ZGC_Z)XE^$#[<^)^YDS^/NF<L_
M5W>.?(F<LG5ZGC_Z)XEN$#[<^)^YDS^/NF<L_5W>.?(F<LG5ZGC_ .B>)?A
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MX^Z9RS]7=XY\B9RR=7J>/_HGB7X0/MSXG[F3/X^Z9RS]7=XY\B9RR=7J>/\
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M133&3>4U%OQ3 :>CKPV4>1LP(6*E:OUQQ%UYNV]OMWE:#W#3-P%^S#\_PKT
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MP+'- ,[!C[%R\,;NX]O<S-$=\F4D'H? _!L[2;L@3ABY:*LQJ^\'(4==4G#
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MYMA2# QTR8[2(N]\S .J]ZMXNBZ+X%V,F2=9PB=I6R.UJ;[ZY%/8H2W%B"(
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MJ9+)J 1\K2CX '+0@MD@0W+!UTXY+I]8,Q!O$X$:+[@#=-WNG7(;$$BZ8@C
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M$9DUAM@19_;!CPH\BE:2XG:;FYDTN7)MG;) !-R08G1VC7':JZC&^?;',C0
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MK-P>0/FQAC<I9.N2VML91FUF=H@0<"((B1!$"_3A-XU@"(5%3),M+@<<H&'
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M.'1]&W<.]"G61)S)C9D>#*W)2%@YFQ!44 T$CM@[<;SC=V>Y,L3(!&G$;!A
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M+,S T:X!#<F?W5#9LX.6;OD6S+ <]8"K)9C)UA+))2<F6 ]1IC=U!-O>.U:
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M.@^:],Y9^KN\<^1/$7OC[>@#ND0+X@:30Z#YKTSEGZN[QSY$\1>^/MZ .Z1
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M(&DT.@^:],Y9^KN\<^1/$7OC[>@#ND0+X@:30Z#YKTSEGZN[QSY$\1>^/MZ
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42XEC2QMT-+LJ+K_6@3)OPNP7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g65062g19f83.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g19f83.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "X ET# 1$
M A$! Q$!_\0 'P !  $%  ,! 0            8%!P@)"@(#! $+_\0 41
M 00#  $"! $%"@H&" < ! (#!08  0<($A,)$105(187.%FW&2(Q.E=XEIC1
MU HC,D%6=79WM+88)#4V4=@:)2B!D967U4)28:&QUM?_Q  > 0$   <! 0$
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M1O/.:R5$,S%A9@U-!6(DX*LV4*&L\+/R]&M1D:#*GB53H,/%'T>T$BQ,NZQ
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M<Z "9J>FI!6$2PLY\YU=5UIH$0Q@Q'6$R1/LTEN@P84)#16&.8-?/D.<>7%
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MFL7Q/M2(#LU0HX8,@DUC:^PNX:0''@/K'MK'1I[!U$1C2M<"/&&@>XKA2DF
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MW7GWG8H1QUYYUS:G'775J4MQQ:E+6M6U*WO>][QDS)/C&,8QC&4^6_[*D_\
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M:1F@Q+;<HVRS%8@G=N_6S,93MPB;,8)I+:FMM0ZK)!Z+]QQM6MR0_MI<_?\
MH8R-43LW+^G2DW"4*YQ%GE:Y'"RTX#';)V]&QQMWZ5S<4LC3X[*=-/7GC_3*
MTCT*6K[A3I;6TZ9T.Z^R/"IZ_3_4B_[E3(?R_P GN)=GL!M:YG;9"T2(#,R^
M\4S2+_&UYUNORR8.7V!;9JKQM4E%B2JMA^U&31;KZVB%C(>9&(<:9#+^XQC&
M,8QC&,_GP^3WZ2OD-_ORZU_S]8,X*V;[(]@_ANU_I\C/=SPW_6[T+_8O5OQ'
M!RQN63,TQC&,8QC&;1/@X?I^\H_V?Z?^SFRYLSPA^SNK^Y[+\7R,YL^%K^L;
ML_W?K?X_K\[3,[$SR"QC&,8QC&8^U'Q@X]1O(3K7E#7(*0$[%VZ J-9Z'//3
MTN7'RD11XJ+AJZP) D%.1$4X+'PX#3S\>(P\6MI3I"W''7%*9#A.57Z??_%F
M06,CC&,8QGI9)')TYL<ADC3+JF7=LNMNZ:>1\O6RYZ%*]#J/GKU-J^2T_/7S
MUKYZQC,*^G>5$U'3P]=YM7HY;*+?-U4RZW3>V:H^=5 6B[**&V)*@2+(D6Z6
M&U(V$E*H\4;9) XQNDM+WG%9J@21W2K.21%="CS!P8*=<Q!S"]$1[U>$@G/,
MUI'BBL7ND5&-<\?4O&(V&QF8=L>N /A)9HI)DQ>F*KXH^J2QJ-*PK6B<X;22
M')T,17.:TG3ZY!\?Z_6.RUC5@KJGFR 7& +#'.LD;1$3>Q6B"8YF14PT#+--
M:=2MHZ.=>9=86RXYIAQSV4X[<T\JEEK&DHBH]%)'(BM13 ZE:PKA=2D YW"H
MX16M>UR.;Z\<K>ZJUC6T;S$?J16*C#L5%X$;I1SQH3A&%1O*<$&KFN:K5Y3G
MA+KY:<N>,8QC&<DW+.H>=SW^$*WRL25*X^U;'N?KY7?+(S3KRBG,^(T-8*QT
M:,Z7" JZ(^8%?+1&1U6K(1Y4W-5J,NMA5#&0#VQ'_89+3GK]R<K[^/7T^GW_
M &OH^UG6).SL-6(64L5BE (2!A "I28EY,EH./C8X)I3Y1AA3ZD-,#L,H4XX
MXM6DI3K_ ,?EK*>7+BU\61.G2 Q(<0))$J5((P((X M5Y3&*]6L&,;&JYSG*
MB(B*JKE? @3K6=$K*R)(GV$^0*)"A1!//)E23O080 "-'$*4I'-8QC6JKE5$
M1,PQH?Q!. 7>WV"NO29E1@(ZP'5FO=&M;T/'T6WS$<ZMIT *61)ON0ATBAIX
M^N!6<:'(L<4R\5&I<?8(#9UA2^,FGW-G+@=X]=$'.+75]W8.B"J+:8!RM?'C
M2&22/BR#=+RP060H9;&.QYH;2J,HQ[MV/X.WB%KU) M?+QK:>:L!;VNMU39I
M[^BKY T(V7*B$B"'-BQ>I@+234FG!JY;V!F.&P@C$PV\L_+&K'VRZ51^_F62
MKU:SU)"*OS< .WU8FKB11\K9YJUS\6YL7<K&3C<:&1"'SL+H0;;R66B2&%OM
M=/:XM=!A FAC./+2%8%F3&"E%- ,AAB"WD8WQHL9(BED..]"%<Y.$1OR1NY+
MO4GS)98A3H&*LJ$.)%<2,,4T2B>0KOEO;(D'62@@M"Q6#:BHJ\^I&YH^''3[
M7=P+37I)IMRHU)N,_(XUPHF>E&H^6*E7V(&4MB%-1<R_ 1S,>&U[((YC;.T)
M*4I3?MM6_<ZR'")#E!=^FYO=68QK&QPN()@$62&$J*:.R41Y"?*>K'.1W;:U
MO'-=JMA*ELE1RM_2T/MI%>Y[CE097&5H"RD5!F?'&UC/DL1R-5.MSE]$S;S"
M,R[(U<;A6N?UB:N5PF H"M5\-1TM+2#R6! Q]+0TC;CB]ZUZWGW6AV$:^:G7
MW6FD:VM:=;H;.S@4\"59V<H,*!"$II,J0]!B"-%1O+G.5$3J<YK&I[W/<UJ(
MJJB9=*6EM-BM8-)2PCV-I8F2/#A1AN(8Y5:YZHQC45>&#8\A'>Y@V/>Y4:U5
MS3K&?%.O4H='20E"Y,;5'F ;7/"QMZF";/3ZB[(RP1%<F_JXZ.CR+ZZ#%/3C
M*XQHF&"8V!#R#.I><!::YHB^/UY*[,\5#KY:9>Q/G.#<RGS*JN(60UU;+>2(
M&,385BQWV/9C]R-'"@8TC@\Z,N=G2_@IZS#236&VC:P; Q)%=6LDT, <"[LV
M AO'=0!AFR)@]6;,ECJW%E]J7)/YF7&>L2NE*NY&:M-8K8;$A8K' P !2TMC
M'34O'Q09#BT^M"&"3B&&7EK1O2TI;6I2D[]6M;U^.=5QXTB8[IB1S2G(WK5L
M<1#NZ%]SN!-<O2O*?*]WK[\X8D'#$3F4849.I6<R","G6G/+.2*WY2<+RWWI
MPOIE3$/!/2XL$T0U#2]-.J$)9)2TYMM#NFW%,K7I"]M.-N:0K>E;;6A>M>E2
M=[EO8]BHCV.8JIRB/:K55.53E.43E.45.4].45/FS[:]C^58YKD1>%Z7([A>
M$7A>%7A>%1>/H5,LMY(>./)_+'D-DX9VV#-L?-[83 ES<1'S<M72R7ZU/1UD
MB%-RT&6#)#:8EXH)]:6"6TOH;4P]I;+BT*^<BJ(OHN7HC@!HJ/ BPD;;#C0Q
M0!&U+4XIL8-A ["%.+VI;FTM-H3M:U;4K>O4K>][WO&1RPUL\K_'*B6L^CW'
MK]/KEKBY>+@Y*%E3'AB@)"9 :D@-&*4/[ X*@GF7B99UY,3'J>:9D#17W$-;
MPJS\1M&IK$M3:[/4P+$$J/"/$E2.T4,B4!DD*%ZF](Q* HB$D.<D<*$8TY1N
M>UJ[(IO"#Q-V&HCWU)I=W:5$J%+L(TZ'':8,B+"DDB2%"C2=9#I($48HC&++
MD]LCXP"L8YR9!H6AU"'&UI<;<2E;;B%:6A:%ZTI"T*3O:5)4G>E)4G>]*UO6
M];WK>9HBHJ(J*BHJ(J*B\HJ+ZHJ*GHJ*GJBI[\UPYKFN5KD5KFJK7-<BHYKD
M7A45%]45%]%1?5%]%SRR.0RGRW_94G_J\W_AG<D2O\VD?]0;_ANRIA?YY$^Z
M0?\ %9G"_GC=GZ!\O,CO70] BQY#M8D1X^*KT7&[E:54Y1V-75:XU4(*8!<.
MAWU,3X57&CX-<NGYEFBP\$](+*.@XDL/+$W6][(@/=7'8"-!C1UDU%9(='6M
M@-JH4H+C17JR:*M&"&LI.2F'%AO,I#0XQ18*[PZUI9!I(VVT8DF99RY20[ZY
MB,E-N+-]U8P9#8\T:$KCVY9,]L)?T$!IU@R,@8]A,"?[F.R=>:"JUG'>8;CJ
M+(UJ*BYAJKPN@OND%34U.!!F2-1OL2QOY#1+<.IN2V^^;%1R7"-NO,[(R>/;
M-I8&ML1O8V/2R*^-&E-KH:"\S"J?9D(,MZ1^B47V-&;$5LCK>:-'17]3V*_)
M!-&THDBWJ2L(^5L,6UERX+[><I_)V-ZMS8R((UE=R$#XP3736OB]L<>9)5HN
MACT'E5LO5>XU<^MCSP3=0>J%CK<E7(K5)A( :,G./V:_ZAFFP&XH=LARM6.[
M74.39+00X<:0MJ=V<2$RMJHL-DW&N-7CFA;5NJ["!(KXWLB'!''F:M8W?E6M
M V,-I%@6%O;BD-(A'&*]6S%,035;256GZ!;Q[0M>=]V.ZJ[2+9RUOK"R++K]
MWJM;6<]TATPCQMM:N@H3Q'A<)L< VNKTCB.1KOID++W_ )37Z[&VNK/1=;%:
M!CJT)>^>0LE' 2==E++9 '!VK#"E-#V>'+OL^2ZP:G[AL&9:&E1"(]J/:9FG
MG[OK,& "RK71H VACUXKJBAR8X9-?)L)X7,9/B%:.QB%NIQ',*G?4,MHY(B
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M D6.CR(8<@3S-/)(CB%8@^#."=C&C4:D:T+T(K51$6Q_E#Y&]0C)6)5<A"J
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M[ORZVJNAR;&U(0$C-=S,%IFJ6ZQ9I"3OO2INRT"TQ%G.B%L1&JT.>'.O-E3
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MF\]+%541<WA>AP$W4 KA6CQ9.+DQ/JQ2=K2A S: 29 A,@PIQIT8L5@0AIP
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MU[Q^(-20;G,>RMVM['L<K7L>W4;YS7-<U45KFJB*UR*BHJ(J+RF6O_-WS_\
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M!>SA0G,8P^DA2.=2?%'5?-2IOQ<HUE3HA8$P[JN$XDJ$>.*)(BR%<%4*&1$
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MX0?9_5_P7MO_ '/OLCF4V3,8QC&,8QC&,C7%?TN.A_S<N;?M,Z?DBG^RF?\
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M2:A(QE@@JC,=+J&QK,J<D!W$DR$K#PUJA*^U'(LL.EN2 #+K94<(.\X6Q./
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MU>$C5QP]UIU9Z9"#1I=5*H6RK18K"F%9F8F:D:U4I]D.?1.?G3E?7YN/?_\
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M_P"G3_LU_MY]?&!GS 3^4(G_ ,M<\/W??RF_4S^5/_SOHO\ Y9<>R5_TZ?\
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M%+>-&Z>P]7ZV?I;P\I7V';#["M+&$?9'A/3Z_F]WO]WT_4O\R<^O&QR/T?H
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MP6:EM3]Y<L(_-JL[U"8Y=3ZO%S?19"N&056$M&JV^;8W!H?V=/'1;D@QPO\
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M<CV05.?Y_P"=%3\N5*M>!]0?Z-'](Z^70>I%"@WEAVHL\E"K-#8/LU7\;*3
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g65062g19q45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g19q45.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1@J4&AO=&]S:&]P(#,N,  X0DE-! 0
M    & Z^85@X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   (    X
M0DE-!"4      !#'71?E=+5N]=N^.93 Z7E<.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0&JX]<         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE- _(
M      H  /_______P  .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             D4   5$          $                          0
M           %1    D4                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   D4     4F=H=&QO;F<   5$    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   )%
M     %)G:'1L;VYG   %1     -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !SA"24T$#      -V0    $   "@    10   >
M (%@   -O0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ 10"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M.$:^A7'&TRU6/L?33KMG^T__ ,DF^Q]-
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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MF .!X '-=D0>4W4%I$R#;DI*%P@54J!ET2K&(*A414("IB ( )RIB;K$@"(
M)@ 0 1#D=3O-F-X3PD3W9I!B8,<=%:]UNL+0JA8[M->D7,-5X62GI)*!B9&Q
MS*S"*:J/'18J!A&[V7F7PHI&!O'1;1T]=*"5)N@JJ8I!C>;Z3>\?%-UV6Z9.
M0@ZY=ZJ4+8(V=BH>79J*I(3L4QF8]K(-UHV3\SD&B3Q$KF,>E1?-'*:2Q"NF
MCA!)PT6 Z#A,BI#%"=YLQ(G.)$QG/<FZZ"=TP#!,& >!.A5D8>S)0L[4A#(F
M-Y1Q+U5Q-V>O)/G<:^B51E:?89*K3Z LY)%NZ C6:B7S9-<4@1<D2*N@=1%0
MBADB)D1QTMFA!%B"#P(@J2TW394@*).$%$S&,0#IK)G()RB(&(!BF$HF*("!
MB@/(" @(!P.DCB.\)!R@SPA=9WS,B(.!<H"B(@!5"JD,0XB(E I#%,(&,8WR
M2E+R(F^2 ";NTWF^D.\)NNX'N*QP1W>8-<;<9/=<G9)$<)1$=-2SZRC7)T'R
M3& L;JJR:I:\+$)Q449IFY;$328G4633!PB51$Y#F @B001Q!!'>D.F"TAW
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M0Y$D^T4(3K54$"D3()A#K4.80*0A>3&,( 4!$=22!F0.L@( 3, F+F!D.)7
MN&X&*05T0,<ICD**I ,<A Y.8I1-R8I $!,8 $"@/(B&DCB.\)!X'N76H\;$
M[O.$!./6($[8G4)4ND51 I1,8>S Q1/P7@G47J$ $-)'$=X2'<#W'X*Q,;Y8
MQ[ERFQN0L=VJ*M%*F7DRPB+&P5,6.DG$#.R5;D?,E7)43.$4YB(D&R"Y"=B\
M*@5PT.NV525-&\WTF]X3==P/<5?QW+8BA$CN$"JJ 84TC*D*HIT%$QN@@FZC
M])0$QND!Z2@(CW!IO-])O>$@\#W%6#0<L8]R?%SDU1K5%6&*KENL%$F9!DJ<
MK-G;*J^&,L$-V[@B*:[B+DBJ,'"C8RS872*J22R@IFX;S8G>;'&1'>FZZ8+7
M Y@%IN.(M<=2]>1\B5_%M-E+U9DIUU!Q"L6DZ2K%=FK;-'-+R[&%:BS@:ZRD
M9=Z0CR00.[.U:*D9,RN'SHR31LNLG,B)D1QD1WJ.4&9CQX]:O,'" F*05DBJ
M'ZNE,5"=8]''7P7J$1Z.HHFXYZ0,7GCD--YLQO">$B>Y+YP>T$>U=_CX:E$T
M1-$31%22I_KXHKV*H<Q22?G FY1, /%S=B!>GN5+U=8FZ^\ABAT!P BU\>SQ
MRU15;1$T1-$31%%-XS3C_'=[Q)C:TRKEE;LX35FK^.8]*,D'B,Q*5&LN[=.(
M.7S5NJTBB-H-DNY36D56Z;A0H-T#*+F*F,$@$ D2<AJ4@G(3&?(**HK>?@*9
MO)<=LK0_-:3YUMFW'S16N3J+8F5Z31S9&L<(=^JP(S*R95,@OR3@K!$.%?U(
M@[4< *88BNV0"0#($VB=;S[K<86O1/B1!@3;/L'/LX+XS[O/PAMNL](IF0W%
MZD+5D6(G9VHP..\9WO)TI)Q%:6C&\T_%E0X&?<MVS%278=HJX233Z%RJ ;H*
M8Q==YN4@G@""3U!9AI.D 9DS ZSHKGL.Z#%-1P1';C;6YM%:QI)*59$BT_2;
M5#6AFM<K9&TFOH2=*DHIM:(MPZL,O'-E6\A&-EFJ#@'CDB38IE %P%S8<[#.
M,S [,^209@7/*_L4_>>-02%<SEN1(H&$ZAED@3)TFZ#@=3KZ $AP$A^3?).
ME'O[M3(B9$<=$@DP 9X09X^Q?1G34H)F,Y0*57@$C&63 %1$.0!,1, 'Y 0$
M.GGD!Y#0D#,@3E)"0>!M8V.?!?2BZ")#*K+)))E !,HHH0A"@/@)CF,!0 ?4
M(B #H2!<D <20% !)@"3P%ROD[IJF3M%'*!""4# <ZR92=(F*4#=1C '2)C%
M* \\"8Q0 >1#EO-XCO"F#P/<5V'433(*BBA")E 3&4.<I2%* <B83F$"@
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M>1;>B$9Q\Q5FE2N48PKI1HX*FWF\1WA-UWHD=8(S-M-;QXB^?.VG/'G3?GM
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M"7]]_6ML3_$U[O\ 6T+1#M*F6.K$-<&]OIUSQ:JVE)"*BY)V]15;!1J _4,
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M=2FNW-UC.DUB-S7"VRQ1UM/;(F00MK6<M3P*5 VYEDQP[/&/'JR+E=1*@I5
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M\FL8#/(E8B* )PUCA4)W3&\(.D;H!]86KWM+-T._PXC]:>K@<O:M^H!P ![
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M$T1-$31$T1-$31$T1-$5* GZ^'4[%4.8I(G;]8=@/#M8W8@GT<@J7GK$XJ"
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M,BW8;W'7-BI+WC;8;^^VA[;MON!!L$Q,8AS)M4;QUID48N7EX*K8JL,0W=Y
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M$LR;SS\?3=UX?MUC3CZOZW?\?(_/I\VL7][/*;]_LO\ A2GZ4]A?H<^2[/\
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MSG"FWZK 22&MF\-F!)F )NJAHJ)HBI14^)M17LC]\6B3M^OE,>':YNQ!/IY
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MQXVH,&9P:%I&UWX(1!G9RJNC1E:M-,A6!W"A2$*=P9HS2%<Y"$(=3J,4A0$
M"S0&U-T9='/_ ,T=7JGFJ$33WC,](-?U9]7=R6412E*)A .!,/)OG'@ _0
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M&*18&WFTD%T1S[H*J=I85C@[";%P#0&AO_*Z^*Q3R,B\TGU&M+B8\X4A3$P
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M]MZ%ZU4,@Z:1NXS-6/,&SSILX((';N6\!D"46;KIB"J2R9#(B"H$$()B+3)
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M]JA]TZ>=XJ[4-E$-LN6?+1WJF.U)'*\NRO>*8K%]IP]+71:>0;IXZ(K$L[Q
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M2,LYT%A<"#J?8%G5K59J!W'^$[$?Y![%^G(-6^SO^K6(^V=_T8]H^*U_P/\
M:^QGXV[5/&MEDFB)HBX$>/'@ ]8B/'&HO:W7?+XHHNQF4)CX47Q004^&DXJI
M#*\D4*%,@.UA*J9HN4A15C)I!N]NK+JZND;>XX,(&  TJMB*<F0T;W)S@'.
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M?.7-<T'@>.6G%0<XX'<Y$#X\X'L7 ^KC[H-7'5?\8\Z?_$![EI/]S&G2S_\
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M#J-I9K)4"JUAVC(HJ*%>)K%7[13M.T-YM0 'E/?POGE8G+(B5ZE,DMOG;2W
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MT9W._P!LK5(J4%58I[-VBW3<;7:_$LT8U$ZKF1EY=RRCV:) X$RCEPD0/ 1
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MH6&>5Z(!=>%6D5TL?TN7._3FH4L@K\MB,9294?4JU:8K5+5&TV.?.Z26M+B
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MRKCFYT"=!&0JV1:=8*?,E3$BZ+R!MD,[AI$J9@ZDU"N(]^L"9@Y*8#E, \"
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MD2B/0\.W,Y+R8A##PJ'(E*(\B #JNZ. [A\)]?5 17$4I2@!2@!2@' %*
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M[\AJ8,3:R>,]?'@634B3I-HRGCEEQ[]4\>(349W)SN>_E[X3QX\7XIW>_O\
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M?.F NWEB:VK)9J.G9#*2%6)*5:7<'2,Z,K!QVA>X;N5W &,HUOE:8S_',L:
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M>80(]--TN9D9R-D6.M(MS*.I%=55U+J^8X@N)(,ZDDW/$ZWZ^9U79!%@0!I
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M:-]<>XJ;XSR FW;J:.;)F#*\E(-HP8X[B"B,9U]NZ,*1$0?KM9"EV=49 I"
M .2O2F.03(K]JB<2!/0"_G=7NFW7U<U'3GT1WE;E,(8D@\$XII.(JS)34M7Z
M'#I04.^L+ADZF%6""BBB)':L='Q,> ( J*+=%C&LFC5JFBV;-DD42$#5C=P1
M,WE9/<7F2(ZE*NKJJ:(FB*WK9WUR7_>AOT'(.J53%-Y_5=ZQ"O2']ZS]IOJ,
M^+]G''#Z?LY\?L]6O+/5:W9E,?C.=[KU59N1;4I1<?7N[(LTY%6G4RT6I*/5
M6,W3?*UZ#?2R;,ZY4U3(D<J-"HG5*F<4RG,8"'XZ#3G,$:QSXVTMD8&0L#E2
MH2 (,7 [UJ#VV>5Y:9'82[G,>,F=:>.*!@BY4&%Q4ODRQVV]6'/%IEJ=7<90
M5+RKBS#\O.V1I--(X'5OJ"UFQ0+>61,I=FI&JRZH"=">6H&8TC0\=(N5B7.'
MYQ'/3MOKV&Q.2N^W>5SIB,Y(QV.<*9+N$9"1V$'\Q,24<M#/F$ODW=<&UZXX
M^5J231W,?#^ASS"R VBB*N$+'8X1W7VYVS1-&>?W:!!D P> F-._K/6I!=?S
MCI?CQ]G&>JTY</M\.'6.V]SN@7C+ZA18^S2U+EX![ QT3<Z_;Z[>9''5DK]B
M;S$]'U:#6K]IB9-E*2LE;&]=23:"LE-+@X9E<'  \,K:]K9 @P+\NZ"YQ(AQ
M'LOSX^K29SA9]Y4C DC&&1H<1D.=MDQMMD-T]*9RU)EHNM2V'6^/9>Z$R!,6
M%L,@G$U./F(Q&@6 R;=[8F5UD6$/'U^4*];.E:F.%Y(DFT]X,:D$VF9O> ]V
M9>8T /'LDD=68SSBU<E^5<Q-28^XUF%KDQ,YEJ>,ZSDE*K2I48>KV%C(R^+(
MZ?2BI4J[VTLT(A+*44ZCW]AIT(QLB39Z-?<R*;-ZLVT#00+ R)TG(YF,[=O)
M6WG<3F!F?5?C:^7MRAS?O5POM\R[BG#&1C6EK9\Q25?AZG(QT2S<0 2EKL*]
M6KC!VX<RS*5=N9">;':.4Z]$3HP""S23LWH:)?L7[G,P".$\""!;MR&>M[ J
MLU(/GY<^N>JT:'LNH.J7E4-N%UC85S U;.CF=MZ6*'F.Z*IC%=&ZY-A<RQ-Z
MG*?8:/%J3 -7T(,7C'(#R2?2DE$ T;U=XY1(Y:NXM>0$-&7#7KB1SMR!F;"0
MI!J3=QCC/(9C49\./!=]=W_*R&"]D^<)C' ,&&ZF?D(^R0K*0E)*0HD5&X?R
MWE1=W#M$H0LA9),4\8DB20ZC"/=*&F%#E$SMJDW5EH!BW7P.D$Y:3!X@BRG>
M=.9B^ON[8STTUC(_ED-M[B0JKN-JF1EJ$NRSX[R7>%V4,LWQ6I@*D4.]S363
M85J6LS6RJS$5D2M$0) 3BRC!V_1C'9#3)EXIC+@ ,HX1 X]5N.=IZP+G18G/
MB9R]1X \N,*2JCY5#;1?E()I28G+MNE)2'RA/S455Z,VLKFC16'3ULM[?6YW
M 3TC#)-& 7"JG8.Z_)S[.8&?C6\6NX>*G:IU\T3:^8GN@BUP9D1E,2%2:AOO
MGB(+N'5RR/MSJN!?*)8YW,9=Q_0L20CYW6K36<]NK/-3[J.;S54N&#Y3"#=:
MM)-*^_LM;FFDS%9G82AI>)L[E!H+5)D8#O#/V[$(S%KVGJ,$Z6.=LH[9WG@'
MSB2!G)@\YUM$<\UL/#D0]G>/S_R<>/L[O5\VH.9 ORO?(D6C+J%AE*VIDELF
MYDYVZAK[>]7A1?OF8_N77K_^55]O'J]0?QZVP_V@U_\ M=ZO!A9XG[,^/SFK
M(+7H+STT1-$31%2BA^OB@\-_[E)=X&_5?]MK< 8G5R#</^(;H !5[0.H1[@(
MJKHB:(FB)HB:(NM;CL5>2]8=DIR3N^6'2/R>_N^5X=_=WZ(M0FREQ.V>W7[#
ML^WR7]S]M0KG5GM5F)K)[2-Q>V6''9HVEJ2-BAH5)2T+,[9;J_%S54EHY:.)
MCR<D(=D:&EH5^AR4'%U2H#EPTDP>TQ.=\UU5@!386QO6AUKP#<$7BP.9(L-%
MFZWV;X!;U:'I85:><UF ;/(R(BG^1<C2*;&N24;'Q$K2T5W]J<N@H<RPB(EO
M-485AJDN6,8'D(=R=H@).HM!BPL9'+QGUKF#G<<Q!]7(>)M)5T*E!/<U#)D
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MZ0)HNKP,178T7>'VB[H8^%CV\:R%RN2\I$67%LV2%94B293J=1@3)U 4) @
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46#NUU+D31$T1-$31$T1-$31%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g65062g20e67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g20e67.jpg
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M"B(,#MR\>#[68>272&M-:ZHV/&-N>8.[E/#4$7&^()FN(Q/'32-ZB\>C=_\
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M/L.-%\)"*E"A!ZZ*18I( Q)^7#,,CIB%'(H:DS!' 1)21<4DW9HDK\_._?\
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M=#\UU[] ^1XKR=#\UU[] ^1XKR=#\UU[] ^1XKR=#\UU[] ^1XKR=#\UU[]
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M+&///A;= H% H% H% H% H%!CE?\69?Z<4_W(>@R- H% H% H% H% H% H%
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MB$.)D@9I0WK04H=&D# 7 $ .[3A026FCLACG9)8I#1<4(&GTZF,94;2.'PU
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M3F=1?6T8(3&9$E!8 :L+:++MQI4T^<D3I=A'P(@2#!,29PZ</'RHP&"!!!I
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M*/HL^L3^U ]-91]%GUB?VH'IK*/HL^L3^U ]-91]%GUB?VH'IK*/HL^L3^U
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%"@4'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g65062g22m63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g22m63.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1;T4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %MB^6$@X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!H_%_
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              E(   .@          $
M                 0             #H    E(
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   E(     4F=H=&QO;F<   .@
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   )2     %)G:'1L;VYG   #H     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !#A"24T$#      ,P0
M  $   "@    9@   >   +]    ,I0 8  '_V/_M  Q!9&]B95]#30 "_^X
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M -KC_@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M$04A,08205$34F%Q@9'1\*&Q!Q0B,C.BP>$C0G*2LA5B@O$6TB0E-$-S_]H
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MRQF, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M=H NW55;K@FL4%D%545 ,DH<AG1LZJ#><N2N<J<E553XDAY<J, 8 P!@# &
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M9-LUK<6BS(CF</W$[[<5T1.*ZEI4L]>W/]/T+@9J9C & , 8 P!@# & , 8
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M+>/CZFT H=T  /@_)\/[_C^#K\ >S+E#S@# & , 8 P!@# & , 8 P!@# &
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M<BHYCE:BHYJYHJ&;IF[Y -X>/7V>/L$0_P"6=D=4F>BHO:FB]Q[X P!@# &
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M18=14&%T\^'QX;)2T='2LIXZ>6%E35)+*S<<Z:K=.Y]7*Y]0_<=(L;+*I?\
M=EZE$@^/WH].H>(_%X>/M_+GL<^*W7WWGB$M9+);7YY_$^F"1@# & , 8 P!
M@# & :\.U1137X3[#*IU$J=]X\K@ #TZG;\C-4+)@(@ CT\H0HB =.H!T$P!
MUS&:^YV7^-TM^IK#]].Y?3]38>/L'Z/Y^$/WA].;&1KXT5JR"AN>O-C<*%F;
M'L5UK.@*4_IB<56V+AG$4^J2$I'6U5]';!L\_+$EG-E?0Q7-BIFN_($@4F,8
MQG6K8L\_P:G\:1<M$OW+GPXWUOKWW-7+_!C1=$5;9+Q6R6X:(FAL'S<R& ,
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M4T[&))*V5R;K'.;7B3YPV2-9ZW4?:^KKDMI>6$BKT+-*'BY=O!W^.H24E1Y
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M%:C&L3?&^MJHZ..5T3$CC5M%14]! C6)DF[3TL35YJBJN:F=9V1TXP!@# &
M, 8 P!@# & :WNUL_ (W)_K_ $E_OYUGF$Z_P'.XHU%1>2JJ9Z?H;4_XS/\
ME_BXV0C[!^C\?_+Q_-XYN8E;-9C(I;[Y(-'*LL>/,XU)(1Q'J^QUXM/SNFNF
M;TL0%FC6VOFHJ.(T%7['6<G(]U82O;BBPF7R*;FB*MU2_%+<N-URRS3.UM<U
MT531WW(^]]URYIXY=O,LET  Z  =!]H= Z#\'L^CPRYF>O<)_P#A#P'K_/Q_
M0/@&!9.1#_(>LTFYZ#W53MDV!6I:[M.J;_7;U:45V[9:N4^9JTI'6.<2<NV[
MQJW4BHAP\?%7<M7*"1D 4605(4Q#0J(J67-%&AENM(J#@M<T&$K$D>8K4-2Z
MO%5Z754154E(*.@V+.(D3JMTT4%3/H]%NY,HDDDF<RHF(F0@E*$A,S-L 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@$>;3:;3>T>:;Z7F:/ ;&4\P]7
MY78T)-V*GM>Y(-3R7I:'KTS 2[ORT6#Q!IYI+-11>J-UU?*HI'2/#D545$6R
M\%Y!-<[V[->/[<?WIYZK]J/_ &P\(/\ !'=?_P#LP?GS-K9$5%5]T1<TYH6^
MSPWO@3OK&(Y8M*9>&^X[IHB=O[E%<-<R>NJ+>JY4XMQZ,6*U-<(FP7>?EI=(
MDR+==R2(E8DZL859LF=-T9-P34KX_+T/KLZ)Y5O*126^G+GHR"V,@DP]T25V
M)1[Q8J?)KDB"IR0U"&K]TK\O$I+3PG<LPEY>5,C%]QJL*KH!<C5R*J6:MERS
M_0E+<;^'[D">J_:C_P!L/"#_  0W6/[]SY5K7HMW/WDY$KN\-Z_;8N)JUKM%
ME1X5MN:8I$]L=,'WK%*ZZA9NNTYT8TB[-&C#P]BF)^79E2B3,47@.Y=WY5^F
MZ71%)!5-%/0J8OR%V4346HKG?@*"KV%C#)PK7N*J'?6*353BZ\P320(HLJ=W
M,O&2/DTR',8AS]"CT\/.;6XZS9O9W$\9=*R)])"Q*=9&=*U]5/+'3TT:Q)]J
M3?EE:FZW-4NO ]9L+LT_;#:W!-G4NV*OJT6MF21L24^&4C'UF)U+IGJC(4AH
M8)W-D<YJ))N9YV772WY/;:G-34R(:6F<E-H1N]S:\N4E2:W!-;):*N]JUHM-
M?DH.LW./9Q[-:1:M6J20.&S8%EH5YY%53RA0/\>AVXVBJL(PRE@Q&>LQE-KF
M8;BD]#0TE),_!TII*EKHZ7$$:C)ZB)6+#N-1TBL=9;(M_O[OHVV1IMKL1KEP
MV@I-D:_8E=H-GX<:Q2MFPG#:Z/$J'"JAF+8G@\DM<Y(*A97OCIW/>JUD3+-8
MF\V1-)[^V18);31KK<FP0%S0WX8'$PS@(J7=HTAW7O59O;$F9$8V*ML:W5F"
MS,7'JIE(F(*+MQ63[R7:[,[7XY/48"_%*YR87BC-KT@EQ%:"":-,+=2MH(L3
M6E1&,K$Z21ZQR.:Y>C54:N\Y$\SMKL+LQ1TNV#\#PN9M3@E3]'#'+3?ZE)30
M38_25K\63"UQ!5J*G"JR6&FEHZRH9TDC)6LA5MG])D-4Y&2DSH"N/[)?I*G7
MF6U^O<)794A07<G48R(;V*0;KNV[]!BVJ:DX[C6@M8J+4>BX4=KL%O,'GG!$
M5^TI=K)ZC8VFGKZZMPK%$PF&JK<0;AJU=,L:OJ%2:"1Z)"LTL,+UBW517R.B
M7=<B-0ZO$-@J:D^D*NAPW $QK9ZEQZGPF/9G_6DH,7=/4X>LT3)XG2/Q-E%'
M4-?)65O1K%2QQ21NEB5UT@*R\E.1-?C-=+K6=5)N:$FKM,.G%=JY)8U'5VC$
M5NJS=_CA34(@JXJ;U<TI7Z6FE8V<J**ZK9L1-9,/'U>UFU5%%A3F8G/B,;\+
M3%(:FEPF%V]056*4])3+B].YZ;ZPT;G.JW4O\6&I?O.8B+9?HF&_1Y]'U?-C
MB)A3IH8ZE<)@?2XGBTM%'CT&S%3B55AF!5<+>EG:S$8FM9B&+HM#+$UR->K;
M.67M6;KW9>=B6&'86*#DE[#![E?0%6EF9&,?0GFMMH1-(@U'KV*;C-/F\C#/
MW,B[0D3'7=22"2+-=HU54.3U6S^TFTM7B]=$Z)J/=1XO/%@]0K%CH?J>/1X?
M"^.2-C73LEIFK4(Z1ZK_ !MQJHQEF^+VHV)V1PK9G#:YV&UU.N&8CL/%B.)T
M]=*]V/T^U&S.)8EBD=,VI=)30U>&55'3LCEI&) C:A%F19%NMB='W39.P.-E
M.MX/(B6V9-5A=;TE-IJL(-Q*^EGS0CETWB4>^FV;MVX*BU:$ ZXD(@*Y!5,Y
M+ZW97$<7Q'8O!,1E?'+BE1AL$M0^145RU"JB2+(C6HB+NW6R?S):Z9J> VXP
M?9_ OI%QO!(Z:OHMGJ#$Z=GU7I&38A'1R4T,[X63R(K7U"/>YJR.NU$LJMLE
MBMK/F%;J?KG3SZ;J[_8%NM] F[O:GK(7\:B$?!VM& 52B&4/7II!6265>I"W
M2?GAHU!%NFD[E4W#YJ53P[/I'K<+PG9]M?2355=6TE15UDRY-=!'B3J9WU=6
MI9]6K%1&,5$;9&W6^9]'J/HDP?'MH-JGX5BC=G]GL.QBFP;"8ZYD,M0E1682
MF(P+5LJ\3P^2*%.A<Q\S%J7(Z5=V%6M5I-$->-SO]W[2IA7M9,R2U37;GK:%
M73?MV;5:9LEAC47=I>BU&4%XLC'D5D&;,HM&J146K7OJD6=*^GI,8VGGVIQ_
M#E;1I3-V<PW$\'A?=%B2JK\2A8ZINF]]9=3PL2=$LQ)(VM:NJGCJ_ =E*;83
M9G&DI,3?4NVMQ/!MI*ME3%TDRTE!ATRPX9&W>B;2LDGEZ%[VO<Y7*Y[G-W4;
M*G%.Z6K86A:/;KM((RMIDUK<C+OV[1)BW<*Q-YLL,@*#1$ 300(SCVZ21/OC
MBF0IE3J*B=0W;;!XGB&,;*87B&*O9)7S+7LJ7QVW'.IL3K:5BI;+\.!B+QO>
M^=SJ/I3P+"]F]NL9P;!8GP8730X+-212R=-(QE?@.%XB]'R77>>LM6]76R15
M5$1$1$2PV>O/GPP!@# & , 8 P!@# & :WNUL_ (W)_K_27^_G66<>?*G<O)
MK5^+3:G_ !F?\O\ %QL@'V#] _S\/[ASD&"Z+W*5DI;--CRGWFH5JDFI/:QT
M=(*.TX=)J=<8R3VI&"W<S)KU*+RRJ!")'1;)Z\J3:+05'I8K<X=KMZU1/ON3
MA9//GR[^_CPNY?X3.*[UDSUX\N/;VV[;.9<J, Z&TA8AK5@"H(P3FUC"R85I
MO:%GS>M+SWF:WHE&P+QC9Y)(PJC[R!)-5@T=/$V8K';-UE@(F8#F0Y9,L3&%
MFR1Z<R$>S"63B3KJ12<EYNGY\G&*.DD'2D>1UY4K,[E%)P=N"9EDDU!,0 3W
M[6YV6 , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#"[WZ
M@I0S9_L?U73@(N;@WS1W;CQB,4PL023=M7'**\N<C1"6]+N6J$.H4Y70R"Z"
M;01<*$ >+5T='6QLBK:>"HCCFBJ8V5$;)&,GIWI)!,ULB.:DD,B(^-Z)O,>B
M.:J*B*<NCKJ^@DEDP^JJ:26>FJ*.9]+-)"^6DJHUAJJ:1T2HY\%1$YT<T3KL
MD8JM>BM54(TMLSQEK-A>VJ\R^EZ_:(2:KK61G[3)TZ*F8JQ##R3FJ-GTC)N$
M'3&7& >RZT$DX43=GBG,@HP S55P8>')A&#/JUQ";#Z"2MZ2&;ZW)30/J.EI
MV.BIY>F5BR=)#&YT<3][>C8Y6M5$4YT6.8_'0?Z5#BV*1X9T4T*8?'65+*/H
M9Y(Y)XOJ[9$BZ.:2*&25B,W7OB8YZ*YK53$;8MPM=,XMA='_ !U&/N\@ZNT(
MC8)/7R36URCXY6#VT1(O7)$IAT^.W*R>2S,5Q=&2\U764$IDPX4VS.RU3%)!
M/@F#RPSU,M9+$^@I'1RU4_XU3(QT2M?-+GTDKD5[\]YRYG8T.V6VF&RLGH-I
M=H:*:&C@PZ.6FQ6NADCP^FNM-1,<R9KF4L&\JPT[52.*_P##:ET)OE]>:UGJ
MH2KS=-I\E26[%LDG /X2(<UM*-8^0<,R$CEFYXY)DT\U06;E*F5%'R"2A *"
M9#%[";",*GP^+"IJ"CDPR*.&*+#WT\+J)D=/E QE,YBPHV'_ /6UK-V/^5$.
MLHMH,=P_%W8]0XOB=%CKGU#W8Q35U3#B;I*QJMJW+6QR-J5=4M7=J'=(JRI]
MEZN1"-*SKKBW:489G3J?I:Q-JD5C9H-M78JGRJ, G:#>D8R;9)QJ3@C%">/&
M^?L7I2D2DSL2NFYUS-0.3KV[*;+HVD8W ,%6.@DFFHF?Z=1JE)-4.:^>2G3H
MK0NG<C7RNC1JO<UJO53M)-N=M7RU]1)M7M&Z?%:1E!B4SL7KUDKZ*)CXHZ2L
M>L^]44\<;WQLAE5S&L<]J-1'*BRK$:XH$!.SEGA*558BQV4IB6"=C8*-92TV
M0R@*F+*2#=LFZ>@=4 5.#A50#J !S=XP=<Y]'@F#X?5U&(4.%8=1UU6CDJJR
MEHZ>"JJ$<YKW)-/'&V65'/:USM]R[SFHY<T13JJS'L<Q##Z/":_%\2K<+P]$
M;08=55M3/0T:(U6(E-2RR.@@LQ5:G1L;9OV=,CN(6LUVMQ+* K\'%0D)')G2
MCXF+8-F,<R34.HH=-JS;)IH($.=54YBI$* F4.(AU,/7F4M)2T4+*>CIH*6"
M-J-9!3Q,AB8U%14:V.-K6-1%1%LB(F2<D.'6UU9B-5)78A5U-=6RO266KJYI
M*BIDD:B-21\\KGRN>C41J.<Y7(B(B+9##I'2VHI9E7HZ3UC1)!A4U#JUED[J
MT,NV@#JJE75&)149F38@JN4JRI&Y4R**E*HH4QRE,'!FP'!*B.DBJ,(PV>*@
M?TE#'+14TC*.3?Z3?IF/C5L#^D^WO1(U=[[5[YG<P;8;64U1B573[38]!58P
MUC,6J(<6KXY\2;''T4;:^5DZ/JT9&JQM2=7HUBJQ+(JHN8HUFNMYMQ94(.)1
ML+R+;PCN;38-B2KF':.7#QK%K/BI@Y48-W;MRY1:G4,BFLNLH0@'4,8>6RAH
MHZN6O924S*Z:%M/-6-@C2JE@9(^5L,DZ-Z5\399))&QN<K$>]ST3><JKTSJZ
MM=2Q4#JNI=0PU$E7%1K/(M-%53,CCEJ(X%<L3)Y8XHV22M:DCVQL:YRHU$3Z
M0%>@:K$MH&LPT9 0K(SH[.)AV+>.CFIGKM=^[,W9M$TFZ0N7KIR[7%-,OE7*
MZRQ^JBAA&:.BH\.IV4E!2T]%2QNE='34L,=/!&Z:5\\SF11-9&U99I))9%1J
M*^21[W7<Y56*NLJZ^H?5UU345E5(D:25%5-)//(D4;(8D?+*YSW)'%&R)B*Y
M=V-C6)9K41$A88**D(:)DIB,82EB<N64!'/'S5L]FWC)BO)O&L2U65(O(N&L
M<U<OW*#0BRJ#)NLZ5(5!(Z@<HXWOW[_6WK(6. B7\+%2DS%Q\G9'+IE7H]Z_
M:M7LX\9,UI%XUB6JZR:\BX:Q[==\X1:)K*(,T57*I2)$,<!%];9JG#Y'"?72
MHQ;F89R5E@H]U7H4EDGV[Z68-%X2NJ'>IISTLDX<)GCX50\;(E)*.BI,3&8/
M0*N(M5^Y"JB:JA*(JYHBV73+7N/#:[T]Z>L)LK/7WA[JQ<2E0*VF8Y<UIC&;
M5N^=R->!-R89EDV9/&CM=S'><HI-G39=0Y4EDS&D+ES\O?NYDIU"ID$YQ I0
M*)C&,)0 I0#J8QC"( !2AU$1Z]  .O7 ,'B]H:YG8&7M,%>JC.5N 5>H3D]#
M6.'E(B(7C2]]^WDI!B\7:LEV9?OG"+A5-1(! 3E+WB]:(]J\??A<MN.35JIQ
MS,FCYR&EG4LRC91@^>P+Q*.FVC1XW<.8A^NQ:2:#.2014.HQ=+1K]D_20<E3
M549NVSDI!172.:Y4[7 & , 8!KJ[5YJ5WP.W0F<QBE3D]0.0[OM,=IN[7#DA
M!Z^PAS) 0X^T"F'N_?=,QG^[;FNF5E[_ -NW@;TWXT?>OADN>B^AL5'V#U\
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M/ .GQ= \, = ^(/S8 Z!\0?F^/VX%D31+'GH'Q!@'CH'Q!^; '0/9T#I\73
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M H%N>R9D"F3G*HV8N23E5U37PXHGPUMJG%%NEBR?=7EEYKRR[.:97+)98J,
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M^W:]^%],N:K\S)^XB_P]Y6Y?>M>]\]$1,B>\N5& , 8 P!@# & , 8 P!@#
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M$,1,LHED3N]\5^:DZDBY(& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MF)S%MTK.:\."Y7\/?"Y7=<EU5.%]4]V^)LNS0@8 P!@# & , 8 P!@# & ,
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2 P!@# & , 8 P!@# & , __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g65062g22r19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g22r19.jpg
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M 0$! 0$! ?_  !$( 7(!" ,!$0 "$0$#$0'_Q  >  $  @(# 0$!
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M:)J-ECTR6@T5;FM4==X"UT%-JV5&;OR:ZZN:^K.RFE:MQ5!%U)0]#;&"&3B
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M+),JRK$BJ^54\O&."* :%O9K4\!X(6.<CI7M=/)++)IIIGGD,DF.1 'LJ%&
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MK[/5.(IXY9I;=\:=;/I/J*QM&^=;MTQMQMUIX=Q>A7D_W4>X4I5:%8Y6?E+
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M#THZ-F3<-VWBQ86Y<M_>D24+#<DZFY]G[4\5\1@\U[3*B9Z\Y!V<.7X\XH-
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MBJT=7OW7QKK2RR >;[=%_P"C(UH?M,:&G?F>62;STX@ZJ\M..DM)9BY4'!Y
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M'<ONN8ID2U2<GQ:TA]GVE*F2(Y_5RA6(##SS@]\,NNN[6EK$L4AK7$ \*S&
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M]I;*P3=HW7%=^\T,;%PA9\+RC<#*  A#R4^UDFG@G)').VVQ!-H=>@7$5K.
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ML%D2U,*ZK, 0&XQQS%5;R$A;!Y#6Z_O^UVZ;CHP$?"CG!36GO?:5ENE.^_\
M=6 ^ZJR0-M8UGF9[\V5#9%&]R\(GD.R?O*?>ONH!Y>'S+9& >Q"X^*G.<_#'
MO&^_3\!ZC_V=6(M*M4SR6!)[*2\%F$!CX9.:["0R<^Q94\/&6$@^;OG]$^W6
M3J1<#ZCZ_EIYN^?T3[=-.!]1]?RT\W?/Z)]NFG ^H^OY:>;OG]$^W33@?4?7
M\M/-WS^B?;IIP/J/K^6GF[Y_1/MTTX'U'U_+7"R"".5TT<$#)G(Y'2LAC;*Y
M'O61Z.D1J.5'R*LCD5>SGJKE[N^/52S$ $D@>0).![NP\O+7@0*K,ZI&KOW=
M@H#,>PRS 9;L .Y/D-<WF[Y_1/MU37O@?4?7\M/-WS^B?;IIP/J/K^6GF[Y_
M1/MTTX'U'U_+3S=\_HGVZ:<#ZCZ_EIYN^?T3[=-.!]1]?RUU.Z?-/ZITUL.!
M]1]?RT[I\T_JG33@?4?7\M.Z?-/ZITTX'U'U_+3NGS3^J=-.!]1]?RT[I\T_
MJG33@?4?7\M.Z?-/ZITTX'U'U_+3NGS3^J=-.!]1]?RT[I\T_JG33@?4?7\M
M.Z?-/ZITTX'U'U_+3NGS3^J=-.!]1]?RT[I\T_JG33@?4?7\M.Z?-/ZITTX'
MU'U_+3NGS3^J=-.!]1]?RUQN(@8]L;YHF2/_ ,D;I&->_P#]K5<CG?[(O5<'
M&<''KCMJG CL2N3Y#/G]-<G=/FG]4ZIJO ^H^OY:=T^:?U3IIP/J/K^6JXUS
M>4X?:BVI$V:SZ\5$\.XCW'8,A-9>$WE9H=JL6.8^0OW.8F,BUM[RQ,CB] .L
MESP2A*6?-8)I8QN W^T6@A_1[;;4X60&$IE2:UBODMQ+!I))78858S"O'DY?
M74;O^QY^QW8DBW3<VZT@ZWZB,^PF2N=O3;[6U["6WKM#XT<<D=.CMU2!V\2>
MXFZ6/O @K)6.6X0MDG"M1#CEEM+%0-*L<LCE<:T^N"@LK*'U7>;Y'V43EL(H
M46,520)I?"6R;YW]MF,B3!W+2"9F()[@,!C&?=D'L.P/Q.OF;[.=SDW"INR6
MK1EO?I.6V\,KDND-B.$<HPQ)\/QUE5E4<8V*Y ,BYE^_OZ_-U9-K8/<L4*-9
M"/#X.*-+E7P&!$C>]C7DDRJV./S?'#&BNF(EA&BFFCV$DB1(TCD*JC)/^0]2
M?(#WG4[W&[6VJE/?NRK%7KH78Y]ICY)'&IQRDD8A$7(RQ&2!DBKS[$R:U9?V
M$*DG3:2HOSQPY&*OI5]G73M!"<4X2&3W*KKX*\6290T+45DY'H2D3.2,"V'O
M+9DSQ#@X'<J@!"@#U [GU.3[]?.:]1?>>JX.H+ZN(DO0SF*+#M%6APL4488H
M&:.-5R<H'?D^ 6(UD*6[C!U%9H[=K117:&XL[%ZR)(VK'O8;J*+U941&R#U;
M[0:$TQ5BBC"@(.5L<47I)?K64.XM,QXK*652W]GE@)GW#R )\AG6VV'J"H_6
M\F[VSX%>_/:C1Y6 %9;"F.L9F!XA554BD;/! Q<X5<BT$AX,+QHYC1(I#%["
M1R$PL>4O9J]AFN>CIU[.:O:)'+V<U?U3O(LCMW'?R[^?X>NOH \05!DC!?\
M8!8 O_P@]V\QY9UVNZ?-/ZIU77O@?4?7\M.Z?-/ZITTX'U'U_+4+;J[!Y1P'
M-."XUOX+'7Q8G79.*QKICHJBHV-S17=37U;]:*.ZGAOZBS9$^[JP;&>]S#9
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M&")@S'"GE(!C'AN5D_LC6U7O%7M@R>SWRAPI/QSJM5K+WD&6_P CR1#[04=
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MW3+X_B)A)H8@:>*O\929!U:5# J3W;:J3R/)*,Q0@$J>P9VY%0W\ "LS#/N
M/LDZY$2,@$X'XXSGR'\SZ=^V.V=5"AUU/:#$VD.IK[06&25IEHE]!8Q,FC\W
M3>^6"ESIZ[?3D=,I$WJ)X/=(O\+E22F$1X!B$?887PPF!Y#"A0 /<,#&O.4Q
MG*8SC/;&?3/KK9<ARFE!8D$4FF$LQJ>=&Z"B'N!S1FQ-=_XD8H-I$L=98O8B
MH.7Z<!4<[(6S+.*DPDUBS22Q'AX@C.N8IN'%LXRIY8'./RR"2.))7!PPKE3G
MB5RO8X([8]S8_P ^X'EC5VI;&MMJD;0TU@'9!P,:>.?7$PF"E .:UYC(IQWO
MCG9,&KI8HTD\%*B$E=_\IO: [G4\>K-$ZD2("Z!AAEDCR<=^XY8*'X$ZD/2^
MZ-MN\4Y@^()Y$K61GV3#.57DW?'ZIBDP/GA,#LQSKUSJL2243B3=C15]]<P$
M545/'H:H32K(<'(B( !(5[][Z@\BDC> TCT1K9D8YB=UY\Q@SX32(KN"H7Q
M)#D']D9Y$@9/8'&,Z[C:LT)"VV37X(+-R.2".%;<4-UO$B;)KIS$WBJA,B,B
MDKQYCL,Z@8BEFS1Q-"2.)#*,V,J&8 9HH5B$4^5L-A# U7^[222P3PEAR222
MBE0R(DI LH9I4=LUWKR<&)8$95SYL/?GXCR/\O<1KYCZIZ=M=.;FU6=S8AF!
MGJ6R"/O$18@\P2>,\;>S,F3@E7&4D0G0=QHQZ: <:8R -"_)7R3SQC^;$<C&
M1,<]S>ZR/54<UJ]W(U&_DY46M:M-89A%%)*47DPC1I"H[>T0H) &0,GL,^><
M:A&Y2R!5@BY\I%9Y"@)81@A<=@<!B3R/HI![$ZAB;65) SS1[>NE#258%+B.
M&D&29$15@]=DKHFRHG9?3\_-$5/A\4[W[,;4?^V(U0@ _P#6@8#AB0I_6A,A
MCD ]N1&!W';4U:%V[,M6G2MV[)5G%>M7FL3LBJ2["*&-Y"J DLP7"@%CV&M-
ML>6\OC6I>E:BK&04R$)D4!;; TZP(8^4>E#JZY2K*VM+".*1!*:N%*LCD8Y!
M!97M3M;A:*ZS15G2RX8(R0.LKJYSA2$+%6[' (SV/;L=9<FU;YMTM1K.U[C1
M:RAFJFY3L5([, *J\L;6(XDDK@L@>4'PE+#DPR-3((7O^6 130IB.+,*:R L
M8T:>NL.4;N)KV30$@SP/L<_QU"DT+)1RD?I=BX>='-AX[TE>R2*RZ/7D*.KK
M-&>ZLKQF-O,9!XOG!\B%'_&IU*()S3DBL02.+4922.2-WB$$@PRLDB%)7=2>
MQ4QH&'8RH=3+Q]QN;6 S180:ZIJRW,?;V6BLM;J$GT5@2R..>^L;$JT/T^OM
MRH6#/2\N))&VHD<7AH'LCB3K.@BOSX9I7C1@&Y.>[ C(*H,'OGW\1Z>[/4MA
MVG[0=W2.TV\6]KHV )A8L3GQ9DDPPDBJQGQ'Y*0R&8P1NF"DA7&;2489-74@
M@&V,]N6+#Z<]B0US)27J]S_)6R3DS(R-')%%[P462L4;%)+*(60B3<)&%558
MEV  +'L6(\S@' SKM5&"6K4KUY[4EV:&)(Y;<JJLEAU&&D=5R%+'W98@8Y,[
M98Y7S3Y+]/OUZX+Z?4_GK*T\T^2_3[]."^GU/YZ:>:?)?I]^G!?3ZG\]-/-/
MDOT^_3@OI]3^>FGFGR7Z??IP7T^I_/33S3Y+]/OTX+Z?4_GIIYI\E^GWZ<%]
M/J?STT\T^2_3[]."^GU/YZ:>:?)?I]^G!?3ZG\]-=7S7Y)]?OUXRWJ/FNLCP
MOX?K_KIYK\D^OWZ9;U'S73POX?K_ *Z>:_)/K]^F6]1\UT\+^'Z_ZZ>:_)/K
M]^F6]1\UT\+^'Z_ZZ>:_)/K]^F6]1\UT\+^'Z_ZZ>:_)/K]^F6]1\UT\+^'Z
M_P"NGFOR3Z_?IEO4?-=/"_A^O^NGFOR3Z_?IEO4?-=/"_A^O^NGFOR3Z_?IE
MO4?-=/"_A^O^NGFOR3Z_?IEO4?-=/"_A^O\ KIYK\D^OWZ9;U'S73POX?K_K
MKY!<Y+(_LB*Y]< L;556HYT)%EY(KNSE1.\\2*O9WBB]_%?R65=.L3':!.2'
MC/;!P"KCW?@=<H^TR/@^SN!W9+R^?8\35(&>_P"\?PUYN>T-8<QV^TMQ :*V
M"?>4V>KZ$M\PHHN,:$<?%:S#R^J/(8%8D/DO9+:-LYT5O34;:Q\D%? Z3JNR
M1T#61IB"(Y)S/'@M]YY1IX:GSX$+F$CV0(Y68^T6 Y(WBEFX@Y)4*_EP&>YP
MQ!P1R.0#APN/4Q[N@KZLUFANL+DY3(-1GHQC:\(08$&LUDS83W&#0%S#5SZ@
M*R;)65B#NF8W*N-!-_#";*<4G,HJ&K5Z]Z7B:M@\92?$:6L.2 DKR<2>$(W(
M;C^OY,,]FU[F#>(S1(2&7)48"B0X.0"0  ^<8R. (;!8@_6FK[^HM,EJ*?/E
M7FE_=%0-]!61>Z1V>A>&\(BY@L)G1PEG'W42;R<Z264S]Y3VLE&A$KUED\UE
M4Q6JDK"*N+7B4G9@X6N9!(L# 9D58XG:MCAAHXDP3R[5D!Y1NJEFX 2X[!F
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MY_1/MTTX'U'U_+3S=\_HGVZ:<#ZCZ_EIYN^?T3[=-.!]1]?RT\W?/Z)]NFG
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M2:5[Y97/D>YRU"<0%5< #  & !\!K)KU8:D$5:K!'7KP((X888Q'%&@\E1%
M51[^P[DDGN2==KNGS3^J=5P?0_(ZO8/H?D=.Z?-/ZITP?0_(Z8/H?D=.Z?-/
MZITP?0_(Z8/H?D=.Z?-/ZITP?0_(Z8/H?D=.Z?-/ZITP?0_(Z8/H?D=.Z?-/
MZITP?0_(Z8/H?D=.Z?-/ZITP?0_(Z8/H?D=.Z?-/ZITP?0_(Z8/H?D=.Z?-/
MZITP?0_(Z8/H?D==;S;\_HOVZ]<3^Z/F?^;6;P7T^I_/3S;\_HOVZ<3^Z/F?
M^;3@OI]3^>GFWY_1?MTXG]T?,_\ -IP7T^I_/3S;\_HOVZ<3^Z/F?^;3@OI]
M3^>GFWY_1?MTXG]T?,_\VG!?3ZG\]/-OS^B_;IQ/[H^9_P";3@OI]3^>GFWY
M_1?MTXG]T?,_\VG!?3ZG\]/-OS^B_;IQ/[H^9_YM."^GU/YZ>;?G]%^W3B?W
M1\S_ ,VG!?3ZG\]/-OS^B_;IQ/[H^9_YM."^GU/YZ>;?G]%^W3B?W1\S_P V
MG!?3ZG\]/-OS^B_;IQ/[H^9_YM."^GU/YZ>;?G]%^W3B?W1\S_S:<%]/J?SU
MPS0BD(U"((9T:O=J30LE1J_-OFUW9?YIVZ]*9$.4RI]5=E/T8:\200RJ5EB2
M13YK(H=3^(;(.N)0J]4\5#%5O^E1HE;_ &^'CW_GV[]7C9N%>)GG*GS4SR$$
M>F/$\OAY:P5V39EE$Z[5MRS Y$RTJPE!]1((PX/QSKMHYJ)V1>R)\$1$7LB?
M+\NL?BW[H^9_YM;'@OI]3^>M!KGM_P"*.Q^/_P"P>-OT7_\ R+E;^76(BG[_
M &?9'_9*7O/_ *;</XM2*TJ_[);)V_\ SBZH]Y_^3.C_ (ZVZUKPKFO)K3FN
M>,4QK7^#G1RQOC>V6">"1J>41 T\<9 \K?XHIHHY$^+4ZR7CYJR,@*L"I&?<
M?_%Y^A]Q[ZB5_;ZFY4[-"Y$)JMN)X9HR6')'&,JP(*NIPR.I#(ZJRD, =<=+
M5!T5;!5A.F?! \F7U"'(^:6<PJ<TJ:5S(XXT?,43-*K8HHH8_/PABCB:QC:1
MQ")%C1 %48&22?YGEJUM>U4]GV^MME%&2K40I$KNTCX9VD=F<]V9Y'9B< 9.
M    *_[^H?I;_09QME#4CW=L$)8V),:RC#TXV3KK6YC(8A CTA.JZ\NN?*PH
M=T'OB3I,Q(U<F) %&^U&>!IQ%X<HA1L%Y(^31 963/ZWAE2K<OV<$'&OGG[2
M.FWZJZVM;*-SK[-6FVB&:_N5N$SUJNV5JTD^X&91;HLB2UDE@-@7*[5C*+ E
M4QC4;[3-4Q-N+;45DS#+2!541#*6W(T\VLXIJSJZEI-2(RN!L8S)2EE6J<#8
MD..;&&"8ZS$B$D(FZ U5;]5H+\#7IY6G-:U)!'2;;M[F2:S9V^4V)8U\!<>.
MW!!$S22".(2LA3C7772_3UG>*FX[->K=$4=FH[2NZ;?LF]W.KKG6OV+[7:VK
MI_I[K_96V';-VM2[Q+(\6R5X=PMV+ IU*T]^X:4,C366XW$'!KK2$31AWHD-
MK,&D5>,0*%6&!L:PV",<DPYX\Q$CV$D002QA>;T)AB?.4489#%H6:*I%863+
MHLT7B#C^ID&4*88Y0X)!SV.5P""-?7?V<Q;=%L]ZKMG5$?5-7;MXO;4TT60N
MV6]O\."WM3 S3NDU>4<Y8RX0&56B0*_.21O-OS^B_;JO$_NCYG_FUT#@OI]3
M^>O*BC_:/VYW+/*N&?Q45:4L^^R^/]F4_P!PUV'$Y7"9RB+P3R5=S;C6TC\C
MI*?)\CV68T#+WC9NA!APFYH(#()=&(5 53T]D=SZG!_#O_GJ,1[\6M68/NA=
M#8CAVYL30+94612LN9I4,4B16&C?G7\11#/&"/$&&TW-_M4UNS?QLWCRCI<?
M8U&8NZ&OLM6"%;A4O(V5]AF_QNEY-U11D=+QKF*27VM[&;774F?TM=/3Y8TB
ML-&*S)@^G?\ A'?XGS[>??X_UC5F/J02'F:R)"RQ.BO,%94L1;+)#)8E9@E>
M)/TJQF<QR*4B8J08V$FT8S]JOE.0+..BS'#.HFO3J[A26GKK+645>AEES;K.
M <E0OG(0,E&Y$4WVA<\U=C4QW<!)N1V]=-65\H^8EU-,Y..([_C^>KL/4D$[
M!(J<I=EI\ TJJ&:Y+1B0YP?U(:_'^N4."T4Z\%(B\6;/9G]O3(^TGR=-QA78
MJSR%LG#N1Y@$6QO0+PJ>MT.;XTOK.O-@H RJNEDI">3Z>GACMKT6_N) #[>'
M,B4$]3:651W\E'S/YZS=NWF#<;)K+ T3?=(K:\I [%9(ZSLK! 53@;*(.3AW
M*LPC$?!VOKYM^?T7[=5XG]T?,_\ -K=\%]/J?ST\V_/Z+]NG$_NCYG_FTX+Z
M?4_GIYM^?T7[=.)_='S/_-IP7T^I_/3S;\_HOVZ<3^Z/F?\ FTX+Z?4_GIYM
M^?T7[=.)_='S/_-IP7T^I_/3S;\_HOVZ<3^Z/F?^;3@OI]3^>NIYI\E_N7JN
M3^ZW]YM7^!]1_=&GFGR7^Y>F3^ZW]YM.!]1_=&GFGR7^Y>F3^ZW]YM.!]1_=
M&GFGR7^Y>F3^ZW]YM.!]1_=&GFGR7^Y>F3^ZW]YM.!]1_=&GFGR7^Y>F3^ZW
M]YM.!]1_=&GFGR7^Y>F3^ZW]YM.!]1_=&GFGR7^Y>F3^ZW]YM.!]1_=&GFGR
M7^Y>F3^ZW]YM.!]1_=&GFGR7^Y>F3^ZW]YM.!]1_=&GFGR7^Y>F3^ZW]YM.!
M]1_=&GFGR7^Y>F3^ZW]YM.!]1_=&GFGR7^Y>F3^ZW]YM.!]1_=&GFGR7^Y>F
M3^ZW]YM.!]1_=&GFGR7^Y>F3^ZW]YM.!]1_=&GFGR7^Y>F3^ZW]YM.!]1_=&
MH8IMUCR^=]UBAM#63Z\+CW 3F9N,M'7(HH=ON3""R 4_QX@HA]+0O4Q[&BJZ
MW!B;*Z4AD:ZN*Y7;>+E195-E*5)FKASXJJLMMF=D_:"!9X#R(X_K$ .6QJ<W
MNGMZA^SWI_?9=MM1[-/U+U''#NC0$4999Z73\$,,=@_JVG>7:MR40JQFQ2L.
M4"1%A,_FGR7^Y>MID_NM_>;4&X'U']T:>:?)?[EZ9/[K?WFTX'U']T:T(G'2
M$Z2RN7FCN".%(5@<P:$N98D4\%#Y3ME>HQ5>P&*61XDL7D3.2K))&00^,UF.
M+P[JW/UA*J@"*S(P*L&RLH]I3V[%>ZDY![8U"[?1B6NH=RWUK<3#<-@FV;[G
M8HQ6H$>=!"TTT4SF"W7,*\9*4L7AS%G$CE&XZC RDV>>LQLQG=.(-;6>9JY1
M[JP.I:JH8[.3D#FTN:PX]18_@49(,T-Q8&CQ& $.">,D [O4GAF<5K;K,3W;
ME&9Z\%VP'K0QV9K!%Q \5BYNC31?>2DJM!%$YCD4/XG)^R-P;=>F?M$Z;W"I
MT5T=UOMFV]2[ST=L,E#J/>+73VV;"K='7'J;ML?2'V85MIW'_9Z&YM5N#>-U
MW&BEW;':I'26O3<M:AP:[.\$2YGRMI>Z"XI]E;@D5:YFFJLPK[QR1+/<$BV0
MBP5E"M5;FQV%J>%9RERCMM?0%D=-)DC;ZS&JM^&K4K6=NK3+.MVQ/="UA^S
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M/+>OY=_TSYX[^I^.K\/2'WVI4,7VB?: ]S<K%J&/;);'V?),"IW6*::S_P#
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MLJ5;+-^S]WF7OY9=&1/PR[*!\2/?IJWM^]KK(!C?B^$$Y\J)^<;22 4@\O\
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MUZDM57-5?_M++"\PY$[.:YU<&8R*1OISNA<J=\^YO>W4AAYQ-(1D15RLK_\
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MZJH&-&*R<9]:RHQGLW8<4RL,&RPI5.>VL]F7($PF4$].2"9?:6.MF#K)JZN
MKK%?I.BT;1BQ;4,B(&#0ADX0;975D80AHV";7 08RA5I)0A5"J+Z19BA@RV:
MSV8&,/L1LY1U-"/86LL$]H?!4 #U\1EE,,.(-,>5&.V<R4<06"0A\CXAX8U;
M&UJ2Q1B**.(%F$4:1AG(+L$4*"Q 4%B!EB  3G 'EKGM+"FJVB%6]B!4^\G!
M5(!AA\-9)-9VI40==6 ER3#R./LS)(1 PQY?>#2)(QX8Y9'M8MZ&6>)B8'D1
ML$MX98951DE@.Q4 9/($ =SK7;O!LEB"*/?(]M>O+8AJP?I+[N$>W;D6"O!7
M:P1_UJS*Z0P1Q$332,L<89F .:B,LQ^WH6$CVM3LR$V.,N)$_7RD_P $^157
MXHKSG*GY?Y41J;*+>[L8P_A3#U=.+#^<90?-3J%W_LJZ5N-S@CN;:Q))%.R6
MC.?6.VEGB,^01D \@,:XR)C#>R'%+-&CFO\ =88VCA^;%[L<L:+)/*C51')&
M25/$DB-E2-)&1N9;L[M;LH8R4BC;LPB# L#YAF9F.#[PO$$=B"-9VP_9WTYL
M-A+D44]ZY$0T,]^1)1 X_MPPQQQ0JX/=9'1Y$/=&4]]? =;(>5-.%"- O9@Q
M=K+ CW2(.Z1S1(D8Z*4ST'R2-=Y3QCB22R(UTI#)QDN4-IDMJ)96,4']G R\
MG?N4![*O\9!R?)2,D8'6'V@;?TU/)4HUXK^],BK,,A8:JC+1+;E3$DCCFSI6
M1E*J[,[Q<UYQ]S#PSQOSK@]+PUM[K\4JM-&%#:U#3:5+)J5MD%<1R00Q!H6*
M1!,#')%/&ULL"IZGDJ(O>21;+!7"6(Z\ZA<\9RTO'N"O[0Q&<@D=AWUP/K+J
MG=>NMAW/IK?EH3[/NJPK9J+315 @M0VHS%*6-B.1)8$*2K,'0C(;.MU!R5=A
M*6MI,]6557DZ8:"MK*REK1:<.B!A1(AH(JT".&OB C^#'.!'$B%5S7*&T;UR
M(-)N&SM&KV()))<9>5)"&DQYLZN,%\=RP(R%!.6\M=>Z"^T';Y!1Z;L;9M^Q
MQ1QQU-K7:X5J;6@4!8::4U'"F#V6$1L8F<A D9(SWNH]KM&G337'+##,C4FB
MCE1KD>U)&-?XO1%1'M\D7Q>B*J(YO9R=U[+U[21XVY1N\;?O(Q5OFI!U9L5J
M]N)H;4$-F%^S13Q)-&WN]I)%93V]1KFA(L!>WNU@1XI\?1,<MA"YWZK(\ARF
M]NWP1D)L+$5$5$_S>6S@WF[%@.RSJ/=(HY8^#KQ;/Q;E^&H'NGV8]*[ER>&K
M+MDS9/B4)2D?(^6:TPE@"C]V)(B?WAKOI>6B-\%' >Y4_P#S"2$1-:OS]S\9
M5>B?+WYG?YIUL!U N.]1N7H)Q@^G?PLCY'4.;[%QXGL=0D19_M;9F0#TR+P5
MC_%A1_#[M8Z>4HV1DITZ3+$[RA@BC6 2%_96^JR%9)7OF5O;_$(GG6-5>HR#
MMDD8[5W-TL7!P.(HLY,:9]K'<<V/=L>X *N<$J2 1/NF>A-DZ9;[Q LES<.)
M7[]:XEXPPPXK1*!' &&06'.4J60RE"5TZUNIKITTUCK"QC ;$WTWD%$N<P42
M)6I),YB(Z21SG*C(!H&JUQ!,BHR/RCB8DI,XP\UV*%YFXKY#NS'R4>I_R [G
MW>_&-:M15(_$E)[G"(O=G;T \@ .Y)P!^) .)]ZOG_Q)/4#H[X^A[@:9Z7?_
M -'O7XF#Z_;_ .Y[F-Y?GZ3?RZSQ1B ]II&/J"JCY%7^/]K6B;>[!)X0PJON
M#<W(_%@Z _W1JHWM#<+\B<I<E<):?'ZRVXY/Q:<@!:GDO 1THFP9B=/1AAE8
MFI#U+KNHFGN[H:JM![.R#*BH5IYSZYH]LHSI[\4,<,<Z >,) C)%-G@)(VRK
MLR%6[*77  !SACQSCE?7O3FZ]7=1]%;IM>\7^DK6R'?J^Z=2;&M)]V.R;K1B
MAFV:K'N*6JW*Y=BIV4LST[0HM4>Q6$5KPV:V.*J JC'4F;BO+_6C4U6/1SW6
MS.=<:BV]T@:/+-J#9QA9#;<AG9UA*2)#(0^199(NTG=VIE#K*Q9!&Q;EQ0<5
M7)R.&"0%']G!(]#KLNR4XJ.T;?M\=^_NT=.I%4_2&[6?ONYW1"@C,VXVC'&;
M%N4#E/(T:&1R6903KO.HYH/A6V+QXOR:*= MD-"W\^P[O>!#F_Q=^S9CB(8V
M*D4$,,;6-;D)=D7LZB3XYXL?Q(!!_'CD^9).<^9MFK2$M$S0D^X>V@/P4D$?
M@&XCR   U\)4V[U\9K82.-?@YX54Z(KM^?>*0RP/&C=W[(OJB$M5O=$1'*CD
M]M?[>S$ ?5GY#Y!4/UU838U#9DL%E_=2,(W]XNX_\IUA[O-<=ZVBL,1I0<YI
MZ2XF'6WH+MX5O#;D@F"G#.LA"WS.-F', #FB;.U_I.$'8QK(X(XV8Q>QS\8F
M0,!V<!EX@C'LD !1@D=L#N?75Z_L^R;KMT^R[G1H[CMMDQ?>=ON1Q6:]@PSQ
MV(O'AEY+*4GABD7F&P\:'^R!KI[#E+-XC9\68>[AM?Q/EZ]T&;RYHHP\E0-;
M9W)VVQ(&NBY3()@U/JJ4^*K]V%->4=&T=[(&.69/"1,Z2NN,0JK.">_%G" J
M,=\,PSDCS]_EK#WCJG;=CWGI;8[J6OO75]_<-MVN:**-JD=O;MIM[S)'=E>:
M-X?'J4K"U?#BG,LZB-@BGF.@3P9PT>,$,3QEB21JV8@FNB?05SHPB">1*?EL
MF<3M#_@32\H9ZCWTDD2M>NLJ*^[5??Q8IFV\?U_7]#W:W!H4750:M=E4DK^K
M4@$V4N$CMV/WN..QD?\ ?(LG[0!U@@?9C]GJLXWFX>K^&>.P^+9K0:\=@A\Q
M6QY>.X#8#&'9CU384&$.%CK08AB160RP1#1QQ.:SNU6O"[5MRUC36E66H7$G
MW<1*(@ZA0KA,85@$4 C!   [:XG^RW[.$D5X.[@[BYHVD0IMX)'BZ*$2Q8=E
M]9BCHIA(@V#)";E=YMJ(R"**.$H#6Z..=DCKFP>13 [_ !^7IY?AJAVK;")!
M]PJ8ESX@$$85N44T# @+C#0V)XV  !6:0'/-L[YC>+.-^.[#3VN%P^8R5EM+
M!+35G4-0'6E7QS2[,]DMC,-$Q\[(K"ZNK"$=50>&PNK@Z*)A5J?,1761!4K5
MFE>O!%"\[<IFC0*9&!=@6('?#22,!Y!G=@,NQ.^]-9&G333IIITTTZ::=--<
M@@IMBB/#CC8,OY'$JY(GHO?^,6!B>J8UOP7S5XH\K53T2I%\O#<U-FGG423-
M]WC894,O*1@?(\,CB#[BQ!QW"D$$\UZE^TW9]CFDI4XVW:]$Q25895BJP..Q
M22SQDYR*>S)#&X4@J\B."HA[VD>"+'FOA;=<=#6=;#=W59'-D[>0$P27,[.J
M,'M,GK BQ[="1C,U>B!7$*CO9+/[HX57K$1)&_:Q;+'!*DL=B3*GVU9%*R(1
MAXSCC@.I*D^U@'(!(UQCKWKF;KCI'?.FK6SUJ\U^LK[5N$%J=;&S[S4FCM[3
MN\!_5NT^VWX8+<8CFKM(8C&7X2,K<?#O$Y_$518U6@Y!Y(Y*U=\9%=:+4<CZ
M-;J4^P8(.%.N7KA( :#-9V)T;4%HJ*L :(R2!UC'(5,V>71[C6F@D420Q1Q8
M(B, /AD9SAF;VS)Z\SD_V?9&NO?96NVQ[1:$'574O5.[6ITN;S:ZJO\ WB\E
MIH4A(IT(5BV[;-M]C$%7:X$K*,"5Y)^3F!+<?VA+OVPJ^^X\QUK2\64.,EXV
MY'L^0M<E?F-U(9,+LJ/0<09.K;>N709*,FT M=/>Q4=?=-.)SLR/+S\/G?V^
MM!:1()'!=I/' C3VHXD!6199.V!+[*HHY%&(?L"=0/K;>NO=H^T.QU-L6S6:
M?3&T[ >F-ZFZBW?P=KZBO798-SVB]TALU3[\S7=F>>S%N&Y7EV^&[!)9V]BT
MNW1G5M^3M>N4I1,]2]P[:S$5J20R*KJBL;_@S$1RHOJJ:1)YC 3+XN1["SEE
M]81D1'1-IHK.XD=1]W@*J$Q[+L![,>/+@@ +CT*IC#$CE4LTMB62>=VDGF=I
M9I';D[R2,7=V8]V9F))/F22=5:1C6HU&IX^#VR,5JJUS)&/21DK'-5',E9(B
M2,D:J/;(B/:Y'(B]2L]\@X((P00,$>6"/(C';&,8[8U;U9GB/6VF@BM*"^F6
MS]R%@F$+):V0B<.5T@Q(9[U1$)6+_P .L1$Z2$E,FG0J65\7J21G=Z<4'AS0
MJ$65G5T'[(888%0?V0P)!485>(X@ X%5+*592592"K X(92""".X(."#ZZVR
M%CHFO@<YS_=B"A&R/5722,$)F&CED<OQ=+)'$V21WY+(YRHB(J)URB]"L%N>
M)>RJ^5 \@K@.JC_A# ?RU]D=+;E)N_3VT;C,<S6*<?CM^_/$3#,_PYRQN^/=
MG&N7K$UO].FFG333IIITTTZ::^7/8SQ\WM;YN1C/)R-\GJBJC&]U3R<J(JHU
M.ZJB+V3X=-4) QD@9.!D@9)S@#/F>Q[#OV.M1;,V8JSM)G(D<4TX,#G?_IPZ
MN22 GNB=T:LMA&;.Y[>[I8/=&R?&!C&;FK'PA0 >U)ASZGE^P/P"XP/<2V//
M.HCNDYEMR#/L0_JE'N'']L^F2^1GW@*#Y:\PMERWLMI<%6;KVXK:R6=[ZRE
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MM6;=,0^+N8D*\A!#))D^2LV(U/Q/MMCT[GW:U8KP4Z\=:K#%7KHS<((46.-
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M+:QQQRO&DD:UC212()83JNQC8R"TJR1+ =K8R$8RL$XG5LJ8Y8VX30L06BD
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M@I>[6Z&JA;G+)SGCYRPS^'-&\,AM0*6) %F!?^_11@2(/_68E&%/_?1@0/\
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MJ,K2&; V)FFKHI)<?9D2&[*H@8Z1U&9,Y7D[:F@8CG>A*Y5EV=3$WQ*8CM2
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MAY8:T)L38.9+TYQ=EJ-'1U;0AJ;CK3$RL='[VXNWE6"4V2PG&;3MY_U_7?\
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M98I8&#2QR1.A5CXY!HXQY&.:K7P,9$Y%C:UJ->/#C((*)@^8XK@Y&#D8P<@
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MU4C8QY#U'CF=*KEGF;%_$Y[&N1-TNX[Q7EJ[A)+8D:-'BJRVU>:+PB&#1H9
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M9E>"1SV"). F')[ 21QAB0JEF(&M3N72]ZA&T\3I<@0%G:-625%&27:$E_8
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MEC9(Q55DC4<U5:YJ]G)W3NUZ-<U?FUS4<U>Z.1%14Z$$$@C!'8@^8/H=4!!
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M,>P)4XQ@Y'F=2!+E4[A;!#<J\4$'C>#*T8.99946PJ&)<%XUE3Q RR1@. 5
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M\Y*K9^[OGWE%4P2$GDTD+2$!9$SG;^@N-!U#"!X.]&5[BH %K;Y"(SNU<J
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M#98@I]S&0J%\N^!JV^=QB0UT#)_-7(SX+/)%-.C5<KF1RD0C"1$R0L5L4A+
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M"Q?]7N9I+Y$__I[_ !=__>G4&ZN3$].3'[4,J9_X'5L?R\3ZZZ/T.^:EZ/\
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M265.1X@OQ#,JYP"P5>1 [A5SY#&Q,,?,N%7F54,Z@<BJEBH+8SA2[84]@6;
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233IIITTTZ::=--.FFG337__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g65062g23k88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g23k88.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1PH4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ' R^<8 X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!J6(M
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              FL   4Q          $
M                 0             %,0   FL
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   FL     4F=H=&QO;F<   4Q
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   )K     %)G:'1L;VYG   %,0    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !SA"24T$#      1]0
M  $   "@    2P   >   (R@   1V0 8  '_V/_M  Q!9&]B95]#30 "_^X
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M>5M!DBU],:&6N'I5NL<]GYGZ1B5*LO\ _]#U+T:?W&_<$O1I_<;]P0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! ?_  !$( 1H"70,!$0 "$0$#$0'_Q  ?   " 04! 0$!
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MK[M=:7Q_]&Z%GQX]'O?5!FB=@ D>*-T\'E4ND "J%*8RH;UPE*:<Q]/Y?/\
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MJU"I<3N-\ED;F"X*B5 1%!$S)* DS--S'E\?RY_GXB&<IS1!E(J12M^"7,D
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M7 T-5/4!,T0 7%$6Z?6A"F04HA8Z8Z]??\?T_3S^.>(0:(\F&_:52@W&]BC
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MC-9BE2@)EC<N!-%I)J?RX\?/]/?]'7[W!, DKP9W(0)XE!D2JR:02HHA7 '
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MH7O1;DQWID5SEU&3K/M>O&KQF.SJZ\B:/(,"!H',$@Z3(V<>^8<5<[C1HL.
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M1,,TR,MD'T,;.!#X85<>"J+Z.-C,,0E1NY;REJ8OH%+ICQ-;V/6BSO>:C@O
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MMV]'@O%Y[6.@EXF0>O-\DVH-F#4_4Q>=SYDWO+R]NM;^'_W7_P _\F.M1%]
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M1Y#MCV>,[$ >AETC1.C)4> >%Z4((R(H9,=ML-]V40%TR)G0R)W88R2K0O\
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MUCQ9KH"^>$P >HHJ2,%D.O$_4Q>=WYDWOQZUO\/\[OC_ #_1PU$7T#V>+-=
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M.@RVIB^AW;<?:+B&:^!\(Z<0CP& -)Z*E*2,D0,J/U,7G=^91_\ 'K6WT_\
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MP/SC8EB&@]<G9\B.E-:23A!L/*G(.%HHA1#/(^/@6CD8EP%YTAY2H723RI3
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MVIJ\5C)W;FHV]GXJ!,?:C-$N>O+"Y9Z1<0,85/F"24L.4KQ:'/%'81$0: G
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MY']M B+<@] &A3%<(42O#VA!Z7CV+FRY"K4S(C]N,@!6:;MO'U-=-Z00U,U
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M;2I;CCF<)0G&5*STQG@Q1B&U#-LK$E-;7&L 5]%QCYEU-;).$ZFRQ<#<F,R
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M=TJM X^@D;EJ"9E N$PJ9S1IJ'!\X)2JBJBV WAE\F2(W16Q!]ZKHQ+58/\
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M+<]>4TV?LX*F4W6Z-GV?F*H%:S0-7%!55E''JO7:(2M50V><-3KRN'87@+
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MW-YF,--%ED=A"D*5 %YV4;/:^R*6B&(.DX^HBQZNU0#<A[AV=-L$ @0M^O\
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MUQU]WJJN>7UY\<X^&<XXW\H!!R:@$[ XLOUD9L5B"FWBH%N./P4)17BK-OC
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MIO.H "50T) O$D%P$Y3*4DV;$YB>>2XAKB1C56UT'UG03>YJBJ7K-J=)K4&
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M7M+L'LYSC7#.581+SC'ME QA;K3J416L9S ^T],:RI[*U^$;IW2TK5G&<M3
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M.9=3GJFF# Z0?W']]'C1%K-46X\A]\F<,@3[Y526?==ZS8]@84WCY.FL(4]
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MS;&2TE2=:-+=]%?<RUBY0>F)3<SN6(O>Y'XQV7X?[-S(PG*6E?L52,KSASC
M[!LZ#[H>$@)NO8"9\JXJ#?WG28L52D$FJ7<9)5LE5BO^''$IUVTMM,B8AMWV
MO@I[R,S'PY#D91F!G*%37\YCJ8SG*XN,=\O+J<]GB:J"BZ\W>\?O*'WRRK2>
M3>FF]<X;Y'LN2OBMS><6/8.>SUURTGM>K^UGVP@J[OTC&<D,]/0,=Y@=G&$H
MZ91F;UZHPSC'C=5 Z0=F@]B@GIFM;T6;33?7W,[5XIVY4;S[2;#[M2LZV9P[
MAB2M+7MF/SA3[4E#<>/WF('9QB5&RN1E[..RPI&&5I4I?:3-5 ^'/[CZYR+X
MIVW7 W2>] [UZZ=E^37<V&_X<SCY/&>[Q)<;[S%O@YSZ.F+EUN5V/0L9ZNRN
MD7T?&<K;3GTA2LI_6^&J@)[N\O[-].O2]3--[T#Q=M[&R1QR[R<KQ/HS0_LL
M15ISBT1)6%O.I=S)8QW<-.<8B*0WC#V<82_AW&4)3E"TXY>AP@B17GJKY+P0
M22KU\[Y)-J'C-77ALGC[&GG'FW;4RK&,XQG/CGR\,^/G][W9X,:O!C'!C'!C
M'!C'!C'!C*+8?[^-(^7[_#OG_HOV#^F/CGC79/P>WU]S=[8T+@Y-EC>[6?\
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MC*L^6/'/U?'^?@QJ^?!C'!C'!C44K"<94K.,83C.<YSG&,8QCQSG.<^&/O\
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MP*BSG@F4SHC(AHF.DQYC YB+]Z%RI87($&&>3H;T:' ?A1(Q>=(B/%S1AQ=
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M,5$(1Y/-4ZB/V'7$-ZLE[*^0%W;7A=\*+&/LG7Q\D05B..$6U#T\F(/0?P5
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M5=VW"1C"MG;$7U0.6I;.5]JSY[QQW*LXG/+[3Y).$^L')793G'7.XH][!O\
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M1ICTB"0*RQ<X<E<-% %YPW3F.HK2Z2S:$ODC0&C*8!52BBN!!&]3)&=DS?\
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M<2X2H0U\A/\ 7XZJ#1X\C+6*=WK6_C*C>9<B%/*?SF:A,5S27B.BN46D[V
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M=HD/<+1F&Y,@4B9%61CQ75=EJ0]!0ZJ2U'<5C.&WEM);5E/1*NN.#.../%M
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M#&.#&.#&.#&.#&.#&46PL_MXTE_GX=Q]_&KM@Y_#CIGZ?AX\:[*0+/;IB<,
M8^[053'9UR;-&'VZSR]^?]#_ +/5-&4MZY<%WB^;"(N6,A7Z[L)&E+6X3 +&
M9LM=V7HBYHL5=(PXQX*;"$@Y^!'!02D2;#7B*BO2$(0ZHVF0/R.D@!,!V3;T
M>AAXDWE;MU>Y1LQ:SCDSUYW&LF,V2YJ3JS 3 1>9(+O"'J'=U'WO$R7S@%A+
MN7;30A0R3Z&B%V@,J>RUW1!QD@R::EV4S*X[_'.@9?&_L<^C["0V#()RRZAF
MP)%Z)R!4:NZSCR0QW81=-@-EHEMS0W;N91$->D3P@6W62Q@(7ITH?*&$!"(
MZ#5QWTQ7CJHT>@.O.EU2%!%\MDZA3[&9H?E#HHC1VU=&MG3#8G<$*R0[/80U
M?UY42<'-DKT:L./5\+3Z8"IHY8X9#CYA=_6YN79:7))-9!3J\9+?Q@W3L(.N
M!T&B32J%:9F9G,]3;>'RT0R!(&4V9LN[;B=  [[6(L2\AM9PADJM;&% 0UB!
M$QM'H51BD("X8%KN._;S)RY-F8E2)4?++#13*DL@-M$JTU(55*]TD";Y[<&C
MNCN2W4^B)8:6"FV>VK 5NSU<3G8$H39Y,>%:=H6+:LJ8X2?#M$Y)>*9LDH9'
M)R)CDIX3'C>L%S269!%^>ING88=..T;/4 &D6]-,7#:%ZTM8*IL$GK>/KZ;L
M!XV<KS-?E6-R+;:BNO1(@R#:JQ::]*95)7WTWTZ$T[&[F-+ANY>8[M8%)M7G
M \ER+3/80T2#<E6O:A6AH"@6N\4N56KO4[]2[! D5XL3JAJHZ@$Z/CL1F+#7
MRHHJ-+T$=+@FXYP>1?DS#9.?$E07TCU0:"1QN;DP@;SV]5?!M*+Y%J4!P,C
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M$K+B4;-HBE-9PEW"=4DU9;5E*5XPYC&T^J,Y0M*L85TSE*DYQCIG&<M;R?\
MF^U_+87\IHEHNM#G[CU^_/P8R#W$E2$*V=1$K7UPA&=4D\*7E..JNPG.T^JN
MF/'.,=>F/'/#6\G_ )OM?RV%_*8EHZ1#_<>NK>WOU!N7IU^4JC=/C\E!3QZY
M\/\ "GT^C'#6\G_F^U_+87\IKHVGI#GQ;WBU/4&Y<?X2Z-]'W*"GC_\ 5/\
M3Q\N&MY/_-]K^6POY3-&T](<^+>W7M7U!N7IU^4JC=,>>?DG*]/#KUZY^5+Z
M,]?JX:WD_P#-]K^6POY3$M'2'/W'KZ7M3U!N7&?'9=&^/3Y)RN.OC_I3\N&M
MY._-UK^6POY+-&T](<^+>\6LR!&W8K2GY.TJ!&93G&%/2-6$66DYSUZ84XYM
M1*,9STSTQG./+/PX:WD_\WVOY;"_E,T;1TASXM[?>WEH9MIY+2F=J:^=2^I2
M65-ZN(+2ZI&%96EK*-JYPXI&$*RK">N4X0K.<8PG/#6\G_F^U_+87\IHEHZ1
M#_<>\6]9$[=PE*\[2H&$*>PQA>=6D<)4_E?=X93G.U.F7>\Z-X;QU7V\X1T[
M6>F&LY/_ #=:_EL+^4S[?+[IAS_0,ZT\K';X7O4&Y<].FRZ-XXZX^Y.5SUQX
M>./NI>/UX\/'AK>3_P WVOY;"_E-=&T](<^+>\6ID!N7P^Z71L>6>F=3E.OC
M_P#%/\O3IY].O%UO)WYNMGRV#_):):9):(= 4U;Q/^KQR5O7L_N;YRJ/CZ/D
MG*_]J6?=X_'IY\36\G_F^U_+87\IB6CI$/9H/+)<^+\O" >XG<9[K9U#<Z+6
MWU1JDFO&%MJRAQ&>SM//VZ%I4E:<]%(4G*58QG&>&MY._-UK^6POY+$M$_NB
M'7X-[?[[;AX^_9_<V.O795'QT\_N3E?#Z_NI<-;R?^;[7\MA?RFNC:.D.?%O
M>+6G NX64+==V?0FVFTJ<<<<U420VAM&.JUK6K:F$I0G'7*E9SC"<>.<^'BU
MO)WYNM?RV%_):)::<XAD_LWLKM+C._TL'N)I&77=G4-MK&.UEQS5)-",8\\J
MRM6T\)[/3W]>F/?GQQPUO)_YNM?RV%_*81:!6TPQ=-QZO7LDUS%>W/\ .32/
MXIBOX/[Z7\O#6\G_ )OM?RV%_*:Z-IZ0Y\6]XL>SNY_G)I'\4Q7_ +4OI_/U
MX:WD_P#-]K^6POY3-&T](<^+>\6]IKVZO/&S:*G'PSJ4MUQX_'&TL^'$,2PG
MS;)'<R>CNOGK=@H5VRHW)<M"DZYT['#/_,&6.O .WW).R$Q-B4J.XG91I$E3
MNL"LC+\I(L%EZ2UV-EL9BLNH4UA,97I"T=VK.9"DN)2G?;8EB3DY++%"<GNJ
ML0.J]K8TPL$KBM'MRM@LCEJ/]H#7N?AQ25!JH2 @/B> )4)?<R_9[<_OV32,
M_'[DQ7Q^]\J7& 1.3T"\GVHE I%KA.@G$.F$KH-SIF*%OHZ-H$N<.2_0>\2Q
M[/;G^<FD?Q3%?^U+[WP^_P 76\G_ )OM?RV%_*9HVCI#GQ;WBQ[.[G^<FC_Q
M3%?=Y_X4O?\ ]W#6\G?F^U_+87\KCO:-IZ0Y\6]XL>SNY_G)I'WM3%?^U+/#
M6\G_ )OM?RV%_*9HVGI#GQ;WBU<5W=/7PV71D]<>:M2ELXZ?#/3:7GGW>7 Q
M+!+1L-J</I/6N&^-FB[!4'/ZFA<M!K'<(N AO#_R#;D4&V@QW_KB\U(EVNZ]
M']!UZ0%89[.%]]WF'KZ3[_O>K78[.6>Z["\9PYV\91P7[+[V#%=Q^V*N'XH4
M:.N1@JQ'3@CNW$G*C7;KMS6&M\,9O]]JM-Q*BNS8N+(9A"%2HC#\6*_(C)FN
MLJD-,R9L-AU;.%X0])8;5T6XG&<%HM=FLI==M$9V$7G7G@'E*NNE'C(&A(K6
MY6^]R5]C_+W+H>/(O(O*W*X<>=<B/<F\G6NVN0WWW'XCCD1^S08CL-]YQQ]]
MUU\NO%UTD! V$+W;I\W8H=2"[.HQ>SD!C!J  %V820+314F$T3CSXL*)*>?D
M1GQK[!%IQI"L.#WFYJ>L9:7<]0[39XK[D.'&AO/ONA]QT/!7G7G=($*B@ND/
M;"M&]K1]C'V262Q6CE*U<@<LV?D^R6GF=JML;DRV0[-9[7I/.<WC1GH(<AQM
M-QYPPWW@\'W2Z0'I-2+N_3\VZ.ZYB;+I<B^LK>:<IS5@'+L:9$=A4F1%]4X?
M],S,CQDYD2(:6LRF(^4/.LH;6A2N>>67G!LFOA\X=\Z%I>4"@(!/FJ000%4W
M4+2+]C'V1P.2('+T?D+E>#R+:1I0>5(O)UJAV)^&8T&SNQ=>_"#CL"):+1 L
M\*.^78,6/%AP83[\5X.F)[3YD=3:PAV>*3N]1=NE=K!>RHU^]918ZTE$#@DT
MS$@,#9+OIS4HLB)AN C,1;TA*U/1V'T-KQCSM7*%ELHCB)$=$2 X'GX9)!&D
M0'9HATB0 A-5H%;;R+]A?V2\O.6.U6+D7E:)R5:+= L;_*T+D^U1+#",6/"L
MSSYCNPQ"><@QH\)R,\']&$\^Z[$><+P;;D=\:EJC=::O>Q*;22MI&0B0H/9[
M(+%3WV)R6NPXRW-?CK>BIDNXB)G80F*Y([+*7<NJPC-B\H62SH+5:+/9HF@7
MWG'XK@0.AUXE50^2^Z4$_* 15;PL7V(_9)RF;:>1N0^6>6;/8(\6!:+3R?R9
M;+9"A/PM(O.17[/!B"&^ZXZ7RX^0^')E1-M^6W#JL";BUDUL*HB[%,B9GQ@4
MXY CEW8&(,PFJ?@<X\F6F"F .G2ES%M)C(9BO*4[CL9QQT+=9#$>A.VB&]$=
MA.QWG7'M,B$\"77SHKY+P!+MY 4!)MGLOV.?9!;K(;=8^1>5+38Q%YOSJ#8;
M3$@<XUKD#F^L=AETQ]=$APS!!UH??==+H)#6JSNC4UT+D %0V+4+.:%1DS"0
ML"<@EIL*(IQMGTF0Q!=>6W'2^ZVPX]G'=M/+2RZI#F>SP@VVRVA]UR#&<??>
M<>B!V;KQ<<*/O(\ 4=,BM&O*7V-?9#R/98-NY6Y$Y5Y-L4=]^%!M5NL-ILMG
M?C0W-8] $:-#<<YQJUB.V<O",^X"^XX\Z"1J1_,+HLL8E5X9MS7LXY"F('R1
M,6U"'I[4YR3B"F)Z,B5EU;^)RDP'&D)4IJ>MN$[A$IQ#2O-SE*PQ'G7'+3#>
M>>\T E3Y6C-0@\J4T;7&^PO[+[/9H=LC_8O]D$&S189BN1HG(]O<<,(03:=:
M\39P7(;UG!CN1'PZY$@I$<+SA!-JZSH1.V:((#Y+$V!-NIB5#F17$O1Y49_5
MFP'&)$=Y"LMO,/(4EQIUO*D.(4E:%*0K&<_:LH/-[?/\6[@0AC034+49M^3M
M<*+ M<.!'A1(,:#'B08T&,X]"BPHL,1''X<2&^'7W'W'W2Z\Z\ 0000SG3Y8
M^K'YN,3M!L'<WLWS.C/;8,<SW,?9,M[&L&O-0[!J:1\,)OBPU8.,B">7O5]_
M>K3.GX .2(MK9ZPEICDO,TS#3.6>?0^RMJ-AM^MX^6'R4.B 0JROF 24IA@D
MBUBD<[]QE636(>XN:=)"=E0=06J39*40+,"Z $VP"V?-8J%EE%3A&+(M \E1
M($<18%OA(ME9G%&\5 ._"BJEU*3JE)HJUF$/%S<F,0:!,9H$*%95I?ABS-Y9
MN9+9',-;23OH6NAVM@E.!&Y,@4V<(V$\2M5CV&+$/AR63*@L,)$@4>/+>R["
M*2"KAA6(T@<B"GTTE=J4V^%/!NG(CSSR( H)KM"8SO6E$;DJL6[F8#UN]<P@
M"5L>:$UM<><.RW&?L7;4$WJZ[4S6)C>0FF4>KZPC329RNR81\!28>2S;-07#
M%U\P^W,G^LVX\D0+E*< ]M#]7+KT1T/%YT@:52AE,XY(;^PL\I'-MN:M&9,&
MW,Z7=DU:Y:2I5@IH=JSP;E=7=Y+K\F#:-?X(V:5AFO4:%;(\8AB8%-9MLBB[
M#FM3:>S!8AQR5F)$"\=Z< X,UKTE $E)XQE@9[%4([F]WSM5CE^@5^P:B@63
M9$_0>Q&"M+19R%4KP;9HK;#);7>PQN;0LC8W8#E2CEH:H1:H*-R(4X9(A!<B
M4EYE2DZ@=9H#M'"39K2HE>BR22A50=A0+6YF*USI[0)#0E.*5.K#;[L@*7=I
M1((LXD*_&UO8=F5_?AE'I4IR9&521U!%GP#:Y'3$O8=/$37YC[<F3(B2X[\I
M=;76E405/""Y01DBFK+@1]D V!4TZ[&O"0%_!MTUL(?PB,39NI.\5OE"G<PQ
M-;MC(V*$LB<)E!<0--#U_65A"Q89^$5DW]LW(76(P@20\ !>-F+36F2I3;EA
M=NWWV]T<UNZA$!J7C9^DR4&#I[?EQ-P=3NV6'(*R1^B@]^I@=!:192$RLV /
M*E3R(XJ)*E7C05R&?4# K>CPT$SZB-UXP/<DYM<<)* #?F3+<@&*$HW9.E.8
M6U;+V"8$EB&K!8%=AW=5@E!CRS6-PB7M)[$9H#UA.I<F2PY0+:V\9LG=)%5A
MRN#S529:G6G)MV1 )-,T;IV)12DKP:HJ+VJ46<V[)5G[7.?HSG\G$;V62W5;
MAZZ%K73]$HV?5)Y-G.I]T738=L#P'<I9M6MA>UKP-V0&GL8PK,M$.E&#EJ$1
ML)RI5HK=?>QA?<]VO3;)6EU;K/"=-\S A9B=^&+98:ZE\A"L8OSDKNL)PPE.
MBS$VYEO/.1LC75*,;>KY&OV!G:4?<&\*-5K7%(DX0_16J8U7JE*6!RNU:_KU
M;&;!'MQ-@FK#/LI4Y!*WV-#"T*X8;?\ 5V<A )U7LVXB8;K6FJ()4S696D\Z
M]NRO7.=MFOP)>TY->J,VE@=@;=KE5JX:?:11*>UK_3EPM+Q>_F<SI8F<&619
M&K<8B5QK .&-FGT.39:X<6(22Y@)+!<]S-:3< 3+>"B3J9J1=E,M/HG.S9*W
M<[-1KY/U"2C5,+LV<_LZL32(>D&R=4UC0MD@PL)HM8#30\NS%LYEFP#<V(N]
M('"X!F"N!Z9,&P*@6LL>J64S-3U,$5["[*94WR6B2&-\VVFDN<.^[$W16*);
M0M(!URZ@&7:S@*B69)3#\?5M1V,6B.GQ5L.8$D(23!M$^IW:C4=<$3$#$1-M
MMCY-$',/$UX+=.Q%6A3 ;<Z279>T&M/-GN&HE-TLU$722 ;5$??NR;%[:O6T
MT6, =6["%U[-3K4B"9@Q*ZZ3$S9+T*?(8+# $R.S&37YD:0[F-&FF02 %!(J
MEY1.I)#L9-R>;O?VG#FS$.1PVR")*Z<RM\5-M!1L#5A]/TMLS.N0VMZWBZ;?
MK0.F]Y#9Q.,VD*FP( L/")Q6AV4@6G$VJAG27:F&>56"*<*IMF)8+1**;@A#
M-;97-MN(I4[23K-KTMKA2-DS:<*JQM!<EM2KPZ#O>A:]L1JSQFSZ*^2"GPQB
M<1*):9JR:L(.5M< ]8WS#<Z"0("M20AE[+UJTUQJFP8^N96:E9R"-8K7.CL2
M! /*8:HC@^@VK&#(6V%;"2OVT8MVYI=K:@A#=93'#$9H=( 0JA%4+BRA=O9)
M%B ZGQXU>@18YB03ZKU4A.QFM(!D"ETE1!.1I]>3;LESYW2=5:H_2P^M"ES/
MT!-E+A7CT'+U>.*WK5=3Y%M"S5TI<0B2R-+'9@NJEK?5I]AL@ED%"-0WGNZ6
M 7A,!G>=X##&(N"&]":$K?>@3!9MT/4-G/[CUORW;"D.BUSC>T'(A-0:"9&#
MFC5?%[(K1QE@;84X*P<QC >;&<B/R"+#+[3C< T<'XC&9VRQH!;A<++% ZX:
M-S:*P$D=<YWE&9 RG;VC\Q%ANI+:P2=R^3==# H#4#=1BQSP?83!1M\A;7[B
ME>9DR%)&H?BI'.=IG*I;241HJH"I,[&HP3#B^4L&]@Z]I:1>EZ.XKVH98)@S
MSF=YZ*_EIM3KJ6EJ;:0O#:W5X3G.&TN*Z):4O]REQ6<);5G"L^&.(WHWPOUX
M"OFL%'I^G=:7-VQ5O4=U<+G2G+O:=;[GI<Z*>J)==3N%\C*SK;FJ/V#$(TT,
M,U\"6.^E091V$9G9..^GWCZ^#VMX$/AXD 3DLC>236@D"H&YG@:W)O*RV>VF
M'IO,;3M0R;EMC&L2-$T>1DWHH9%4S0CFK:^0J]JH<LH/IYPL2W 0A3K6,K8,
MF6B)'6>V!HL6)#?(,<<>S;FF;57T*."_"9"B8#U!AC13-M+;MG\T\0!<7@<K
M?$C8\>YFHFQJY(UBU U[0-<1]Z"100MK2QC];6DC83$C3SSA!A5'@[C(2(+]
MC.E1D&S!PPA:2":F\)Z_!BQ)>2#(H56LUGL%4G0$!M>'VCS?1[)HZ0;>VJ=$
M%2D&"L ,H1T&^9!2]W6(0JP6*R&-**@DI$/6* 2CXC9 GEVGIKD9JY@"+EF+
MRQ8V;^^?9WHPF),:*A*K51@N-X5#@)-#@L#F'W=+I=3VE'W!:1M3WCK.U$#9
MNDX 5B:0BUC;LHE (TZV:CKR@*@)X73G2H\38MH:]&29X-^J[$>FRU.-4))=
M_K%-VV]*</:V91+Q,2[3B=RD 39H4J[;QVS?.7EJT5S::AM%B\L$V_/VG6M@
MJ42)N-FO\R [<Y-B23KHA)&+$4J@QB102J54\.21BA,A2)6''Y=U>MNM%[2A
MDB8\Z8*&9QVSOOHS+W/>>8,5L;;L*E2=PJMPZ*KY":76-<#SFI+17E:EE$)A
MJYV\I7L"(A:/LG!&-Z'*NXTZW)&U<<+KA 8<G>LK+'Z_9V]HZ)B*4=I=Y-)Y
MK=MG2YEU'.\R5Q-0P%*OO,2UJV25FNLW^SZS&U'8KAB#HJ\V T!>BV;6P=V/
M6(VQQM&;%E)%3B9FFBIRI!R\T8Q&;9G''K];18A!1U"0<*SO7%4/76<3G;+Y
MA*=+TV"VILK?(L!LHIJ,K:C5:UJ,,7=@W9>6O>-UV!3*P'K6MBDJ,&";!I=2
MDSAXVM$R]7;<=C2ID:!*?=C66:2VTG65<MAQ\SK5H0B7B5;UI(@8KN$)>LO.
MG7&$V4F#O%8E7V=426U[*"K)M%BS9AO+=KB'6&FQE-U+NF3%CS[)'/-V.,#I
M3X6%:A4>N3SHJ \_&FN.P7>N_<U2*J'R1B2) &5^:4S%5.>XKFO"62VV6$$O
MIC;9,D,NQ+$K7C9"N@IL_D=C"WR6OWR018864SLP4? /UV!8Y<A!<:%KAAG,
M8XVV=G''J];5X11>LS(()5),MHI5+D#-R 6YD+K8)P2F[!Y@X.HXT;9).J7X
M_KX95]AFR8?6E'(# I:';-:C9K(:-L&::2"?F5000/.1RX2+)(!H<=>;)<![
M!(IWIM5I]M5"*S11A4J=DB4D@2;.[:ETVI'H_+H3.%-L4L%9*A((;E/:EU_+
MM5^%WQRCAYM;"O5J'3[F1$A9UC?L."CC%;4W&*P @@C*A#9\AN0&?'U5X5O1
MXOR1T$7@D5!!%45:2)V*$,+Y8M<;*FQ>8_8.W8=H"[?V?2-3#B910L/!G0"*
M>7:DOV&'3)D<7)2B.)OI*PQDC6"!H(.,CUQV6GI+$U^7&.Z6D\\\$* !43WT
MY4NPKFR Y>-<[ZHT+7FN:QG86KZ@)K%;/G':_KFGP"-A,B.6/29Q%?L$DA5A
ML6?F3L\A;11+$J:--$'QA*LOGH3K,J3'ZE>3N P[2LL\6\R[%!(<=*&?G#;4
ME,DS62J-GIH]O^V7/EZ*[1E[O)BZ1OU$0I:'ZG81H4WFW<NVQ1KL@K6B>F*!
M::T"AWK \4=45C6&F5<A;7H0K8DV$AO(>7ILG/+'K]B-TZ8A 5T]><QYTJ#J
M*9M^]0-^D]Y;D#5 M?\ 7E.F'KJ<A66C4^N,NV&97^6GE^S2VY)XM3S:"[6;
MY(M4)E]W,B9-6$E57$I0X7ZNC)8KP/:-RMTK^"BH*@7$H%(NVR4211,]GU3:
M.R_[$$Y@K?*7:8M*O1Z\6&GB1T4J#L933D5>!DYLT!-#@F"%I7Z)Z&\/:D..
MLN#&76NVZTN-4(3$ YW @5)JHDE\D,T-$W=S7.5P/72(3:;&RS!*J6YY<74Y
MC &#22/)-DR7C/V!-956(,QOF78DQ'*Z^3]J(AO+ QT>P%<;:XHEG[0>[ZFY
M)?>"(A,E45O%9JF"7HV]%.\V=3(1STJ[[POK(4OJ%U58G4^DH8/L773IPKLN
M,I$6C@W%I$7B$*;#M.%($&KEG$#)3_HLR2RN2SN]LNZF;-&*"NEI8 7JMY-T
MOK:":AN?-QL4_6:J;L6[ZM4[%=]3/G;9(JTIH^*#E]/\QI;80YLW>M!ZQCC8
MR;S4=6CR;<2DNCZT:*Q!M<./M&8REW?AQNE3%H=,HCMZE"%"*%\DWSWBE&ZD
MC3=_VK0'*TP1/W^K[!M=SJ@7<=B"5T5"MD.MIK-S<.S24"=6YHNN.$9XP%B8
M10#B(AS)K"H'H3CS&,1NW@\\Z$.B;P0N2;[MK<?&:5S1;-H>LZKL&5:K^];)
M'*W=3[&V]2BK/3:O;X>WK@.N+1BF5V#K]$X'&J@RM$;. *&XF6$Y:+N38.";
MRUT)W>N5U=HH9MYEV*" NDN! ,IWU3(&IW::'RT;7D78!4(PB1K/9-2YE+YL
M@-:M7T$E2N7T'*'\OL@=J:UT^N0IA*%'IUR=%#@.WJH5L,\C.M1"W!'YJF)U
M>*2$EJ!.4BB"^^N^]6@,;1(T5F5F"9W5E-< E:MB9UWS2<P%/9H<'4\C7%C%
M[:YCN8$]\H%IL='"5S:!*\V,#I"17K*'HUP8O<6LV-5CV/!@(C#XA*("I!J0
M3B12T9B2EWRW2I?N[VY(C/"'Y "$EX%X#WURDFDT6B83[ZV5M+>^=!:GWOKN
M@VK-U8CB9NP=%/!U8/$95NK)*IOUU;4V(F;&71MG%:[8)IF.M$5VH@3\UOTJ
M%+CN8@XSR;W?T]$:(\HA*B1FJS 3#-,FY(N.PN=JJ;.14Z8G95Q-UI@U4'GC
MU5E.4JYRX'+>9+@KAW8_4@VDB@UEW7#$8:,9W*1/9(39=?FU@"#0UB%9+]=P
M[B> WBL7 CSKQC,R,DSVEI?*V)M!*0R8=^YQG-7K%W!PM=<Z"BIV2O;L:M45
MVH4T=7W=9-EU4N7.EWN5-GF*:+JB;8/'5Q-U<K^,-YC>JF5987%)"?4G>2IT
MGI7-A'%[!*U^1LRFOT]6U+O6ZN#U_58,&Z6>3S87YF!'LD!-6*^MO7&M$09L
MZ.#)-22T,MBSX)SY3C!9;'LS:$Q$/DSI=4@!1.LR)+G)$;7+1=N:(_S 603M
M9NQ1J['1MU5G#$0=@;JP58Z^C8.IEU Q,U54*^C$VHYENI:KVR-H*/P'I!2P
M8 EH"&UW'NK>.%RS:.:S2&D)3OR.:U2XD+/$H&PUWF ; <Q52KQ7=+@T2$^R
M#W/V:)T@<7"7JX$+R*EZ6K.'[+1)T:U5@_3[21*":^ D.PS$QV:.=>=0&DAH
M"XA<Z5+5X/!\O.NZ5PF$K/89 $RJ6T&WKAS.W@WMJDM5O;<JGDP&ZJI)J\^H
MG)0MC(!X7G6\D0F%INMUP6V9CC9TNMR &T-BSSPR;V[-@(67##PW;Q7)HC[R
M***547@%)&8W(N3?<A/ECK\,?FXC>[5X,8X,92:P_NAM#W_=3L'G] BN_F]W
MT>'&_E#S>3/\ Y_N1FPV/SK?=]W'MA0N^_.;2B\;'UYK(7&-[)OE-U\%F3FQ
M<0O=[.$J@R42=9?DM#X\\[.@1'ISL>+)?;B-NJ?6S'?<2WE#2U)P-N;* WBE
MVG$7-9MM;L6)PABP05 S8TJF: E27H<8Y#5!DOXE!Y,N/(BL$V,N07I,=]AM
M]3K3B$Q1CU3X&=&-)LK3CKUSTZ8QG/AGPQGK]'T9Z_#W].*QJY6G'GG\F?YO
M#],^_'!C:Z>:$"O1/690>.]/GQ1<'TZ6Q$]-)SE=B$.B=^XWZ3/F+QV8L-GM
MR)"OM6FUY\.#&V6,XSC&<>.,XQG&?HSY<&-R[:=823W,EK^^SZXT0!5K3.R@
MC9MST9>!%HL-MUA)AL1,.OYG,S9X4.?3B9$9PG,)N9"D2,)EY9D?.M$ Q>4(
M,9^'K;/"LMHA 'RB3%>==+NB4"&&H,Y!4HC?L;#]D!LGV!\K\@6:UQ[+:>5?
MLAY)Y1M4*!:;19X=KL]AL-O<T(H@ON0XD-VTQX#VJ?4:3H,JE%TS1=@K6J]#
M H%,;#V.H\P-BNAV/%6-8=$!"Y[:;2SN9$:3EE;;H6P"H2&HCKLK Z4R/S&P
MQ'4PQ\]WDY^%"L0@V)QPN<HO//$/IH6-[7:7E 3TG'W1JS<0%50?UEO^S"R\
MH?9)]E=MM_*D>W6?E#["G>2K'K78KSS[]FY.Y*<LED=<>.@YH6JR/ 1"[I!Y
MS7//EXEXQ(?0KPO4M$Y=EZ;L4&_5R\U F4VL^R ]BO3:S=85K.[G@V=!E16<
M>M;$0C,P'0+S9YANP2Q9Z,P'>)E'<VHBVBRPK#S.+9[>(T)^):G4$*&+/'$<
MQ!:22\7X[L-T !W2#SR$ !1]J+RUR1!^R3EC[.'?LNLCW)%LY$Y1A0OL8@QK
M7"Y7M9Y0Y+=Y/L_V,Q.3H5F-B@6&S6A]UZU6EU\61VQ65Z/92[;.;NMAW>E7
M49I[F!TH]H>T;'N.PS>YRHFT#6:Z[4;NB_$3YRFGS5B)EXDH24HT2< KK@DE
M#1/@^RT)FH1R$) U7'5LAQW;#RGR>_R>_;;3:@=22'##B_; \#$M$1YT0GG7
M"B@F(KH+@/DIWR-RCR9&^RW[!OLU@?9G8^0>1_L==^QT6_D^,_:8O*=B')MF
M@6;E2QV+DR%9XL&W0+?%LT:.Y%?=$%]VWQ';:0\X^3B'=9;(J5UVB1FB-WF8
M>SPM-2%9UD)TN>$3AXC7X2J2M?6Q>QZV8G <0#0\N0;>F3H])>@V21(:6@MZ
MZ2_EM%BM#MIM\9^S6^%SQQV%#%DAV*TND\WAPTB"U$NPT?<4$>20\I0R/OR;
M]D'(O*?(_P!CUFL\3[#[.]R':.53;HOV26[[*K*8,>V\L1;<_P#9!8H/(_*E
MDAVVTQ+*8$(66'"YT(EF+CY?A&"7&10-"6.IA]MQ<566X2(\LFK-8U@B1-#3
MQ>83K5/V%!G5SVC9B \D4#B1@?$62DB@\,MEYF9F*TG"T,[K'8;3#B<I/6AV
M*\7^3N3[)9WH@LP?+T"%:'8P6$'??Q'2I"!Y= .@D#Y'+7V;\G<IVG[#HQMN
ME LG_P#1/LH^R;E6%9H5NLUF%FMW*O(46QVN#R=&M4>'9G8UGL-H?%F<B//A
M4BQ(CZ/#:V+1-G>J&CZS2!#=((UW2VQM=RSHM4:*BCS;-JF,%%*[$.0E[NH]
MIC0IJO5/I#:YPYB8_P!IS#3N>G^3XNKY/A.V8EZ#9;6X]$<?<<+D2-"=<#ND
M$>(+[@FODHKI )7Y%B^R^QNVW[,;;RG:'^4'>4OLAY&Y9A62-$M#PM,3D[[(
M7;9IPH,0Q86D]R:_:+/$#SH>T8XAJ7 ^Z8$1KUBM(GEJI0KEBL=6(:DVCK4I
M8R,^/4X=6H JK.(&G'J:;BG)+MEA%(RW4,)"P<-/!5/S#.!Y9,<9)S/.Q(T.
MP6-SD6*X;&] =C17S"=A0W8;H"0X@B//QKP"@.@4>(0!OT<&T6+DRU?9WRS:
M_P#^@6;E&!]D_('+\.P6.!&M]HY0Y5M_*4*(.3H?*=FBPX4/DTV9V*-(18CX
MA1(8APG2X2\.U;NTABW:+9:3A#35Y-H0A*,-I0E.K]A82A*,8QA*$8QV4XQC
M"4IQX)QCPQ^UL>B+-;0Z Z!!= =P&N@JAI6HJ34FK?P"T:1M$ ODO/O17GB2
MKSQ+P?>)+Q))K,DDFMR,Y4^6/JQ^;C([0;!W-I9;7/8FIM1H21OMQHVO$V62
MZ_B99306M*/2X+ X>\_WY"1$63D0HC@J&ZYVGW(L3T)E66V$,IQ6Y>>#J+?(
M25<FYZL^W>7B'"#UC76M 6^F=G76Q@IE7TY'TP4'S+94P"[>?D6]^YW6D5+!
M&"+::FYR2+2#+[K\5R/%=2XE[%F955N"80"G124@)E%N !V55$ 4-AZZYN]
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M\!4XCTIW"6Y%BM!:$!KP7'9PI69Q4L3A0(C*L8SEV2CMY0C/:XJ%%N87G72
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M8KXY8F7FI:8!V(%609Z/,I=>-NP:\2$E*C.-,2(H]%Y9WC=>+NX9M0[%$@5
M)296M IOS6K:6F\DI42(LL_?T88FC :'S',U]X:_$L=AU])V5:*A8*_8JN!H
M=&JH"!9JV&'67+.:/41J1)1Y46OQ)+)"1)D 22!H$U2;MZ=J7F0V!H8)>4EX
MJ\,3(RQ\*"<BK.JEZ@W7L;DINT"SFU5[F$Y@ [ERM,[*I()J!.GQ@D -5E,$
M!A&36V':%7@U<+1IP*?D01(F')H68O,B"["2GFE<%' SK-KH1=2\ZHTR2CU
MBR4XH,-DILH1/(K="8PW%M0<2^(F5+F+15JE9K'32L6H7/85/T]7**7$#M>Z
MRUW2JWE@O2;78)&:\ <6$(F/7T>9+.F2'HI3@;U4B68"I.G;@C5E"A?)0Z*D
M  I+2"E0J4DBY+#=R\JFXH57NUGF4JKVJU5\%S%V^5MP=:BLW95M&WKEHOM!
MK>MX@%@*X1D*KEB-B T/+99;:!H$84!LI)%C,%OI331).,L",5SVA6Y#D:@
M-#)0* H%*U"40*0B39@-<IVSG#3=Q7I[64G7S\XME'*V_=DM4N(3GZTJ]1C[
M/4255\A/:+!8,5:=')")D,!C'M&B;[69EP50O'T94T5!EB)@&BUK.: M-7%$
M_?":*05&9E?M$U%S8 [D1VB18<&[,)5?8V(6KMF@(90P;)2U3-@GM \LNMZI
M:78TZ,MQN1#M^K+R205DK?(BTS1AIE62\UW,4I0>3.:T2@&-:I*N]NW8;Q/E
MJE0AO4)(S 0D<!GY4>6_9 75W-Q2(BP%2N&\$O$*KL,04=S,EF3.CJ;2)LRP
MN0X,,M DC+N".DLD&'YDV4P<46BN1ISK[*(I-0;S=7KXR;T#@=#VB"#)%Q&!
MG(@IUJT-UYRG6%C<="V<7UEK;7=4J.QF[,)UD$,,62)4DQ-,6BDD+6$D(!#1
M\<Y:[=.JLJ=#&1XN,0::(L$^0[879+#(DDCR4%\Q*0G6:]>UN(;CXTM,";V1
MHA6E].\2GG[*Y0;K;;SLS858F@ZM?;7NENQ578K$^6FSUG7+O+,K5,B!'>:9
M1(9PS?'GS[E<C26X,Q#;)5]])!#6&6D11V^JBB)*9E/ 'L;IZ&#>1.:(F.4A
M*>4@&6&HN57?VHYM3N0L)"GS:A<*-/F4 EL>DP!-C;":IV_KP_9QKU#TO0PL
M$B0);%KTR01L4$[:;4*J;&3LV'/'"6':'CZ.[R3<BK@LTV7JGF8<0&4P$0$W
M*OI$)=44.+>:!R-7:.>U>G95/UN=$0V>7TGM";@NHGD].U=J7<5*.U^5"EA8
M\BQP46>V4LT,D$GTL3HPYQR9#:D#V6'HIP.WR?%>KP;T==*#24%)@33$#;<0
M*8K/04_DTY@HUYB68U#HXB,JPZR,66.'-@XHDF4HO-#KC;THJ)B"*.-LI*.F
MF@;)'%$=EV^Y6YPM-4/7,$CI*W'Z'J*Z9']&85<>^=U&\M7%4FY2DP>N:?5B
M0&IGD[W03BK'6;5^LI16M\N)/5= O(>[1X!CY1;%JLC3B^P[S)55<'#[@QZ1
M&J],&XGY@5\-@Q8'&YQDD.9!13+R3_E\1QO+''(SHT2!,5!"8*A[CV3;<[2Y
M1M@BZ7?;L'P+&WB4;YA3=CLU:58B]N-Z]MVKR0>L4]MFN#G[,7C.62('==KH
M9B4_ <:<(@HLPWAMN04GWIJ;QF@$^+LQAQ$J#,A%*D'O&VFRC$Y91VP9>I^;
MPSJ+7-=U.7O-\EKT>#6H_ HT*<QH?5M58L<))JJU>=@!'O8X[*GH&U># G$Q
MI1J$Y,>=>)2*5%72, H/;0[^UO4")HD/ ND@@265*@DW_4C+J=R);+UX-ATF
MI$@V\]62)W+U8S=5V7, 4YU1K0!\2-3&[-9J.!QYR[ZY98A&RMA9D2YI:EAV
MK!+(#RLUV-%-SKQWN\3ND6\A"BNA%=>5Y3=),T^J^XO4GRX7:=RK"M7RZQ33
M%C"[K!;:#Z^GF4RJD"JPGF+A[6AZR%V">(>:1& T)+U&%RO4[(Y*6D0F&(P9
M:.ZJY$Y2VSF-ETYAO4B(7<Z%")R,YYD*II<:MSM8.2+<TC))Z%!JJY11%$F6
M$H,/UQ!NU0*=NW<]RG40A[:4&W )@XI7-@4LW%S8@Q@"^7H;-?+#V8GH11@3
M?HG&>B<<T-U;V\!"C"?DK*0**BU2\R%9;I[49R'7)=+M35I%P;)9EZRHE7HN
M9]^"O6&I.#]Y[3V-:P >PMZOA4H=#;IMMK-:@#/DV<HYF&+Q0SX.71FG<R@>
ME-TG>)3.=XVA<6&"^5TE5!3LWB\HJ=G2]+T=M>%RQT36)GV9@VZN;EH]S<9#
M/11@]BDUGF&#;'5!D^H!H\$D^NE0'8Y*%6@P>JO&7'8(F /#K;2V!H2Z;I*[
MC?=2M9FIFWJZX^(8=5"I53B2;I*5-)4:G*CRT&-!2*D_+'5T>\KEMU31=AN
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M\RF7^'6+!F5G-XK<O YA4V E9NE)34=5>+E:O.O3T>PSO))Q3 W;V1G]BSS
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M[3TF'.BP'M_X\+PJM3V2W)C./NNUO&>GS6-]>F/+I^W7RQX\-;8.AQ_EKO\
M2,U5IZ3#R(@/?U!;UBI[EZ=/E<KF<?#Y+&^F>ON_?KT\<^/EY\-;8.A1_ECO
M](S5VB^TN82@D3K?&,T8]E=R8\?E<K>/?U^2U'CX=.O7VV\O+[W3'7AK+ B<
MRCIASQU/^(UU5HZ0Z;O<3(_&]B-7V5W+\[E<_BM1][^&WEY]/^_AK+!T*/\
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M*348]LL>LS =2AK395V/---V)@WH'D F"4G.DJD51<S<BJ W!I;F"YPKQ$,
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MJ-A7O8UPIU4MAZG*$P]K:<B61X^W2#(DHAP41  !-<!V"GEWX/<"WQ<=$PN
MN[<1.1X2:-=6]54*$(H*@RFH(*C'*<E;9QN0&R5.5 IE?OZM@Z8,.\OTRZ5_
M:D:IM%$R=#6T!%AQ14*A:]JX0N/LNJHTJL&7[&U+.SY==J[9,Q/B9><AE"TP
M[,9378OK"$\ 0H0S.90A;T*)0D5:0ZIY,]C:WV$&)R[N*L]+I_,=!V'3G"DD
MF];HVHPO*SL'1=6J!N4[%=08L=8(VP.-9+2)JW#%8!-EBLUT^^^R\4\3DB;#
M+)IJ3*8DLE.->+YH)AMYL3E5OUAUD1JX_-8.%7.;0]OQD=*N=NHD0A5"5X-V
M:*#5;ZJ+EV, ;3!)L,.R1<5U#<AIYMF5W"TKP5/7/J3!%S:ZHGK/41,==:9&
M]I#/Y:=@W;3-DUQ.N!W3[):K["JOL15]A?+-2[$FWA)4"$9N-JVUKAS:+N8$
MZ8I] :LVFNQ&(\5MI,A]$AQI!5K4+/%2L^W:U#CX" Z*D$TK>;T!D$&&#0-[
MEUYA7]G-<PZH6J<;,:2Y5OD^]L+)FG9I[FM':CDM[88HZ2/M"FUN>O/0\U+T
M=RM8R$403/5Z:@"A4!/5+QGV45IJWS,O+(A!++9GWSDSSUMRZS==E^7!^/.$
MS8VF])6?6%E():=BD; 5)P=70AI**REMW"H+6*04SEJ9+P]$8E0F6\/]',M%
MXIUX[V[$-T3(4WE3GZBC=9>7$;THWE?[A7^2K\V>#1ZAV'N95:9_>6[_ )[[
M4_UHW#C1;OPH?LX/_'A-XV;W(;3WEFOQG;W:)WVIQ;[2+A1Y\B5$@7*KV"JS
MI<)SNIL6'81,P1*D0W<]<-RF6)BW(Z\XSA+J49SCPX-R\"1(H5XX[Z-\]-D<
MK_,3N?5]9U5=I&I*_#U=KG8H&L62KF[+)?OUULNBKWHFNE"@235AZ-?59@+?
M2QTV&@E;E,440-'PY3HZ"^].JC"['*OK[D;R,-]Y%>".F4L#EED,\BR<EEB%
MW,S8J52M+6FER3TR= T[<,R0-#<=-Z/HFL9EMF0AE2.P&[((,5":MAM A]PI
M7;&9QDN,*/-]"S5!=LH!2B2N1%K)IJ2LD""2;#FJJ;THC0.P\B.VC0*PU=G&
MGADY]S>Q=&T!,BQ0K1=&MO:[M=1":QL0I\).FBZ!2"-I&NP%R+E;%J$ZWH3;
M IJ9'=<AEN24[D.4Y]^]FK?QPE(H0A6:+-5Q,VUVTN3W9(\!8R^0]-EQZJ<V
M?<9]CJ4*Q6C8^_!5\VH&O<77NR*L+K+!275(8>(JNVN$+*WDD5&P8ZZG6^][
ML&^7QWK?X4[5AA/+)$1);$69&,M^TP&KZ,NEV+ GQ6MB6J,;FYA-G0[H$"T*
M^@:@CE/,536\[8$(G(L5/J"ZF6M=TU< &5F':P=:L!;-CLL\'7%"B!&4S5&'
M;4();TK<IDPPW@, +@@O,ZFB[TF;Q]OFD(;:;;;2E"$-H0A"<8PE*$IPE*4X
MQX82G&,8QC'AC&.F..6T!$"40#J:YP:LHMI_W7T[_I9&_P#5"Y\;;!YMO_PD
M;_5#;):?/L_[>'_Y;^)7LW>,3:VUIB/.EBB,89*3!(R(,IF!-6C#B(DUQAQ$
M64MO/7MICOJ;>RCIGM=CICSZX-'@2" 47CBK?'K4G)WOI)*AC-IYMDZJPK)0
MW]PPB6PA"0NQ2(&K;6CV2W-PJL1<+6"*7/'*O@D1LTX2=M@V3&%6*J.0*TRM
M-453#9(7]BXS;PU;YD2H,S<9FA(0F2B5%DV4CE>YEX=;L5?P$*%=ARJG' :=
MV\[NPJ&C:3##:W9P/J&5B 3EV0K,>G28YEE<4.<@V3)D<S:B<+-/@K;+MRG2
MLL438W(@D=EY),SB4$I7][5*\LFXR!8Y-8TV=;TL1KAD()Y<U[E@,3A6T)M)
M@"(VZ%FVK4^%BP,$&98M4&'89)B)-D.;+9 O6R7*1D#C3"<LYR5)#MSZ,)XF
M[(DY&J%4)G3$4;7!^3+?KE4MD6QM2UF@6F2XS4OHVQYT2)7]IQ:SIV#4BH]@
M88C0X,D03J=G2.)O-9;&M/RDQ\MLFI.)!=M3NHE$GU7;&@A/3OI>*BJ@'#$W
ME9M).5[!>1S7PQCP\L3/5:G\T$3<U]]KCI"+:K"6W)07==JL]-)9CRJD3BUR
M(:AU>*=&"UMA8<V'1LE*)&'%YDXXV-TX/*T3-!.>4S0&9D5O4$ MKJ[RY<Q^
MO6[K4J=KV5$!70E6H4(@,V2$@AJ][,\VNS-MFK<]!?,X(IQ;]5WD"&CLC(CI
M:7/K+X0_$'CT0)DNRP]L^R61HU+CZE")Y"0DAQF0DSB29*<T?R6[9@#!Y:.T
M28O<:@Z]G8+N[-.S,HV^%WM+L9JRJ:>/N0GY\;5[B0<<@MG+2P+KU0C=!KKT
M%;OXGWX)*K<:DJ:J1Z1QDLTP2:$ MA!>4K>QHMK859 1@17A>*>-YBYTG;$R
M<CF$LD'8@$R;V+'0,/9)1A:JO M4>;$*I ERT"[,4UX(X#KL1N.)]LZG':P0
M4(,ZK4B1))"+G.6(6X=';YY=[U=]BVFZ5./+2\ U_P MHO3[[5S)"8X"UTO=
M=ZLFS)K(MLK&A-RI- (5P:\0(1W7#0M4VNI>7%D$(S\;V><"%!.ZI[%;DNF<
MJ/-.%Q%=NB+9=H\&> <W6!^46L#!7,8J)<9!(G.%)CSVITI>8ZVC2%WTO2<S
M1*G-9D1\^O=R] H*>L&^?%<-S>1AOI,B<I 5JM=N&(N;.SRT<URK+39:*T_
MA5F\42P4J2UL1DZ5HFO6-[V*V6'7I>PV"YO9@N M6D!593"HM1(1KA&:4 .W
MB<'#B8C)4*@7^M?"B2VM#!)$SA><,CB22M33.XGDGVT) :&=S5GK,1JM4Y;C
MNT1TS8[\Z8:V_39-W'7ZSL3#YY<.47'C[.-?021+BLDA MD3!6[@:+@M@E]%
M'%<%::EYT26A!G43214X#8&Y[:UWO=\Q7M'B2QI7,^QDZ/E[19V)9F950KO]
MA^0KP($8#YQB8U6 6R9$!8^]1!Y"DR+-+C6$"?)7B<8&PZ#UA4.2(!Q[6Y>A
M/&BWR$D4C B8!OI>"$#=,TODVVN6=EQ+@(MD*A9KNUU!:2<V(&A-";J8I&N@
M]4+QQ>O3#PZ$TX?$V"?#<]H"Z8IB"BYO10IXPZO/+=.PGP"LEQR" ^<4G/JG
M>6WRWZ0WY0M^KM]U&$9(4M5"S%SL]HND&QRI!:0'I30:+4IH X-GE1WIX<FJ
M;7]C4<HFDN>F8HEW='EY3!"F_CN[K@W<,1'7BZ?,$P!HR6:+6J[MH3Z7<1O=
MC@QC@QC@QC@QC@QC@QC@QC@QC@QC@QC@QC@QC@QC@QC@QC@QC@QC@QC@QE)K
M#^Z&T//^^G8/=_BBN_DZ>_[_ -'&_E#S>3/\ Y_N1FPV,>5;_P#'$U_50O7=
MC)N=]R\G [>G,B(VE=+'>1M &:$-ZM?#ZVW3N'3=@+&#-[&6)]LY+U+:J7(.
MUA8>))C*A%3$EMJ:ZE; ]"\JEI^?HC@F\KBVX[4;E.\_8SB,:Q7BU:3#Z5H]
MA<WX!N&KBY(--?>K&F*K]CE%<H-<UF4=AB\%)-?'["'8.2*?&+8"SJ?C$AR:
M@VK,1/!A.$2 5$!F4D@4+-,VD^.-QX3F)/V*OF-?K5J;(QM/RB)2P:ML-;",
MW2J#&*Z:J&G-H:KL!KU:%Y2Q>ABK!'%O#LNU:Q\NEB@EJ>AZ"X6%V8,-./\
MCJ7I)4%9I(W)7-569ZJW0&C/L=F^-=\S-'V[>[M2K7% WD?LLS= <T?6RN7_
M .QQCZ7):V TJ#JIFQ1Z@T>0]+#0I^[I%'@TM ^#C7'M- B&(_HZX^Z\%((G
M/=()Z_K8W5!#4',K:^<,?LJ_@=4V/E^H!-E[2P2#LJS!C%*(3:FZ)LVT[/0T
M:NE#+YM28_/)UBM.D-@P:[3*5(<R$'-V,B9+3_<$A0"BA#F%!0[P#M#=.OON
MA]UUYYUV*Z'(@#Q ?<#[D0.O 'RG1$AN/Z)EI..O(H!;Z!IQG"4XSYX3C&<_
M3C'3B-RUF1&CRF78\EEI]A]IQAYEYM+C3K+J%-N-.MKQE#C;B%*0M"L92I*E
M)SC.,YQQ7277G7W277W""Z\"CSI!!!!$P00"")@AH0'@72 0\"""%!!"$$7@
MBHO97 ]&ZDKIK-A$:_K40SWW?MD,0$/OQW<+PYAR+Z3EY$1Q#N,+;7&2TIOI
MA*,IPG'&^)RORE&A/08EOM+\)\:+SABO:+XP> /E#(JV%SDOD]R([%<L=G=B
M.E77Q"=TG3B"04.83K"LUNRG&<9PG&.GEX>7U?S\?/2:F9Q,_J;< !1C*4Y\
M<IQG/GUSCKGPSUQX_1P:M3+:,^:<>_'X<=,]/AX>'AP08,;UC&,>6.G!C5X,
M8X,91;#\+OI'Q_AX=QT^/75VP>GA^'K]'EQKLGX/;Y?BP0?_ 'X*^I&RQO=K
M/_?,_P#L?EO]3-Q/ECZL?FXQNT&P=S:FKQ6,<&,<&,<&,<&,<&,<&,<&,<&,
M<&-Y7^X5_DJ_-G@T>H=A[F56F?WEN_Y[[4_UHW#C1;OPH?LX/_'A-XV?W(;7
MN\LU^,[>['!C'!C'!C'!C'!C4PE..G3&/#'3'ACPQ\,?#'T>7!C5\N#&.#&4
M.U,XP6T]G/EC; [.?JQ3[IG/&ZP>;;_\)&_U0^,VR6HH]9R:".X>QY?4WN#O
M;4Q+<9?E_@W45)W$!J$.^F*(WB5DK J4Z6Q!C&'G,Q\0,M*DRH:%QT2US&D3
M(C[L=#$AIQ6%M(?=) Q[\.QFL^\F.RZ\O&<H:;6XK">G7.$)RK.,=<XQUSC&
M<8ZYQCKT\<<&I(="EN**AST:[,0J,?O=-N>F:9LRFSKU1;WL8EKANKF@(Y@-
M+?<F2*Q?+'/K3ZH1X=(:19AXEIS+F8G?XGX;BN5#W]E=C>>M=7.AZT"8SZF<
M$?FCY=97I_=;EUWT$@5V8HIVSBV$#@+4,=/DDIBWI#:([,*"6%3""'%)?&Q2
M,*1/;C,R65KC417)^4 F.'%<&TKG-UR]OP9\BM[.IEM)0(,V>L "M-;27<8&
M$8HPHA6"I49!B21LB8PN;$(38DEF.XU(RUEJ1&4[0%XXWX7LUKF*RJ+\/7?W
MALZ?S4:(CK>1$V-4## TV^'M$J%:*XW'J;$4'<STDV95/*PU.AF(]"LC#D@2
MDD]B0-GYPQF.*,/CR&E\[Q=59R88KHQXPQNIBU[^REY<4 UVC.Y-=H MFGJ\
MX6S9Q?HC9=@0@^_$6O$C.<=U7ELGG7^GHS8-UHLMY(]29&2$^TIW[6FLA@JL
MS7%0*'</%&W-IW[JRG,5(O8+4#'5*Y5R=:1-VF'J_!K60L>158T&9Z1.*QIL
MR,;>N 5 V6,@SH6%2F$3I$-<\<F;$]?8U,1U<5 /AMGU5:/Q>;7EGFL$)$3=
M^MGV!(])0HXFU"4I'0<GAM56[.RY)1F,N/9# <%-8>PF1!*%AD*:TP_/BH=,
M$5P^^#;&O\S_ "\VF:@;6]QZ^-$'%#VTPA]E&ORLO%;,*IL&-W&'\.8EN6P\
M$KKD+*<2XQ@R*@2669!"(AY5FM<](9Y92O;,+\Q^B !R/63>V**+L$HDL0P'
MG6(;'GK)-GY-57%RPM_"FUHLL-\ I;O=MH,)2.6M,MUII9/#C!FL=FBE!=O^
MN2U:VKF3T&GVH[6VZ%CV*<0S9L>T8Q2A+KICV<;;<2F1E3[B['^UU*(F)"U'
ML>I\)]893'S4XXX-!-FM<Q[O'KPJ4#6X',SR_$W:TR.W!K^:Y<)#T2LIBV88
M_@Q(9,2*\MJ-EJ0I.%9L464 :P]EOOC<=\2QWD]IR.F,UCFR=^,O4:X-J6.:
MG199V$S4]B4^XN2#]= SL ;96%8$ILZR;0\K,5/+PDR!V'0Y&.OU9F?,7*A3
M(D>(])A36H]&V[+MF$H6&*X*&_@C'A6BEJYU^7*K"XY]-]!6*ON2&H,LQ6#
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M!</IU^CI&Z=/'S_!GCYXBQD'VV)2GE$#(9-KU;A]Z&/9FN?\QBL__:N'[O\
M]&^'A]7X>+K(OPL3J>9JW/1#4]FJY_S(+_\ E43_ &;AK8WPT3_,S5N>B&K[
M-5W/_B07]\7#_P!FX:R+\+$ZGF:MST0Q[-5WP_M(+^C^U</_ &;P\?'Z^&MB
M_#1/\S-6YZ(8]FJ[G_Q&+S].1<3PS\?^38^'YN&LB_"Q.IYFK<]$,>S-=_YD
M%_#^Y</Z_P#\F_3Z^&MB_#1/\S-6YZ(8]FJ[_P R"_+_ )KA^7P_Y-^3AK(O
MPL3J>9JW/1#'LU7?^9!?A\!<3[_3]C>_Z.&MB_#1/\S-6YZ(8]FJ[_S&+_\
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M2LXQB/C.<],=>G7'P\^F.&MBBL6)NTE]?<UU;@]Z&Y2UYS1Z)V Y55/U.QT
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M?:F83EY25%\..*2HT$)W1 2:;E1-H6IP(;V-Y"?5H4<,BSZ7!E0P'*B#43'
M/1I;#?+_  3,"S/1'&H[+F%V:.76V*0I:,-H[]H@O#+F4*JY"[L\;VY,$7($
M1$QX**2)"X-:UQR8;)A6G4Y[9YW6)F%JN'H$!'$ QQV=&.!M%:OYCJ#%*RVS
M\5#,8T<*[J#6)F"TVN*$2$F04DR3R8L^47U=B^*[6""\H+SVD A(Q2JXK+>
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M3- +[O&ISG5LPE]C<O9URT"#>RZ[/'V"+?BJ;?W-MASDVJ_:8E:HGP\ZK$%
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MU<+IKBN@[E&J8/8P+0>L3FEX>SPE?MHZXE"]OR-V09[N]FY86$'BV8$@9(
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ME;I$KXQJ[50]9H%H725U,@]...&&YRY<5M+D;MYTF=]!D%5=N_P; .\N6]K
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M?6OXX_QMQE/)G)OE?>^P^;T2S_I?JVS\[M?2;1\=$^DU/EMW/\[NS_Q^M?\
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K"PP]1J[%9'%UJZ%F@NJFK1=%P*BE%;59K3:7M/2M$=Y-%%BQ"GG45YO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g65062g24x49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g24x49.jpg
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M^U>[ BDF:_TO:8/8M_BID(>7>D5RE7CZ\.>(!&/PI,=($]R\BR3X8KC7B?\
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M)Q(#88=%FXS/UWM#F2\*%!(8UP#2,TUSU9VC%+?U=1J?LS=6[(;81O1-U+Z
MOVUFV;);9X/8EXWZO9.I)<J03: )^SAPE+P;!"27M!!=<?FWXX7+,>\<_C-U
M#(J:%0FYF1I5+BR;,J:%6).GDP)>$^2E*/TC4836& ^# =%FLV,Z'F%L80@]
MUWAH5I K$(P(,.-,S+8QID[*1H]GQ'MC19K;I=Y.>'Q V%G-#LZ[,\@6!*T9
M\]77Y=.$3A%>3LPO_P 23H<^OP#[$W7GDVS/^YS?C>1_]*:7ZG)#]K._\I&\
M^$OZ3G-4%Z>OY6>S_C=W9]>F[_VKW#FZ.QO^Y&3W_E(OVN87D64?[;J'_P!U
MG_HPUA?/VZPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+:=7-P=%N
M[=,=+5<ZH;5N.BSG2= W&E2M*UK0XJSA[XH4O=YC8$ #7;<7;8)O6-L;-FSZ
M[8I";AIN/*"R',QY#1>'0V//X],RHI53K\:@R]-FX644:6FF34]-Q(#J1-PY
M6%)QG1I9LO%,_+ED-L: R%$A/:[.A/:YMG.SK)FF34M(LGHDS"?(,B0G0H,)
ML1LU"=%=%:&1#$;M#[N+'ES7 BQ!!T3IJGKWT#3=':VB<VO<%9!U3H;J,TQ-
M]'@4"S-ZEWS.[A*O^:K?KG<V;%#0RW(UFYP!MR.G*,1/HDJ%&YJHBAWVT-XF
MH9(5B:JL]$Z7IL=]1J]%J<+*5T8PJC2(--;*=,2<K*F#$BV>9:,R6;!FFPBR
M<?TP_.!(NX%6DX<K ;GS$,2\K.2SJ>&!\";=,&)M<6)$SFLPSVF*7PR_.AC:
MQ:RYBR]J'#)I^VZW2MI;F@DRNI^SXI>KA8TF;AQ*S+:$'@F=\YB\!S3::VU/
MH'EQL&1R6G;@"2H*1[A"%L<^4'(**9FG1IJGTR+M=1RRF9]SQ"B.CPZN8II!
MB9T,F.81,-V:^XEG@/8,YMU5$KC-KCLA1YEH= I,. &ES0QTJ6]-YMG#,SQ<
M7;C$!S3\$V5O$=<&AZ["4OJ4;W9M>@:ZD^T-ZO=VL:NHM99.,W;43H;6Y@U"
MV)"-7*%9KZ;-F7<!$)L04Y6W1Y&UN&+9.$"R5^<]RM7CQIJAFE4^<G8>1N3E
M+=4)N.6MI4RR+.-,W)1C+13&VC:PY[8#X48%DN&W8YP&0-4E&,A3HF8\*"ZK
M3\R($)@)FH>9!_LHS-L:&9^=@7AS+%][.M>JL1U[]+4/TJG:GC9_9C,M9=.:
MR@WJ-/1NP+-&4_8=+W_7=H6&/A#9#:+^KX.@MQ89Z-:BTO4D59$*<*S=K3@G
M HI7Z"+D?7XE?;4'P9$PX-3GHHFH3Y.!$F9*9I$:0@OBM9("?C3AB.89YTU4
M(D$V;TK #<]PL&U61;(&7$2,'/EH+-J<V,]L.-#FF1WAI,8P&PK [2(4NU^)
MVQ^AJQ^>[2^H6/:?5]>)[8&U)438'5MTJ;3Z?"96 :N;U+U/HG;NT;R3&!52
MTSX\!%XA@;;$GQ%(4<!#3,J])LD'Q[CY,@K[0<A9F!3\FY6#)2$-TID[E#(5
MEK(YE1,U&K4^0E6Q'S$O"=&B;:^7B,B308^)"AB&0QX 8*75J&^/48KXT=PC
M3\A&DR6;;M<O*QX\0@0XC@QN:(C2(5VM>XNQ!)<I/O/:*=+4IMFMV2(N6UHJ
MQS>ANIC4TUN^CQ&RD0VE[1N22K1M&V3J#5VTMPW&S5:QQ[,79@-DLT>YUL-T
M&U^*I.%G1^'W;&4R*K\.GQX$26I\2!"J]#J,*ES<61VVJ2]-AQVS<C4I^0ID
MO F(#S$@ND3-RT9P?+GI@-8\ ?:+6)!TPQ[8L=KWRL] =-0F1LV6B3#F.A1I
M>!&CQ'L>,UXBB%$8+/\ [/$745;2[1ZC-:[W96-3[+W$YM*4TAT9:@@^H%X,
M^G7[<<_HG8%]L>QMAVB2C[)(V&NJD:U:XNGPV)6=E[#.5R &$GS<>I?#;R%/
MR)FC.TN/49"FBGPZKE-4HM':]DS)TR#5I.4@24G 8^##@Q\R-+Q)F+M<*'!A
M1XSG0F?!#S;QZQ"$*99+QY@QS*TZ7;-V=#BS+Y6-%?&C/<'E[+LB-AMSW.>]
MC 'G'-$-KZSM)Q_:LW+K$%C;.5I^Q7Z_344<# 1S5XK"[QKV9J49L*(KTB<U
M&N6NE6699NT>*3(-+(D(I#C!HL@L<QC)^YBJ/V/I7)ISX#*E!DY.%$8^,XRL
M?I2<A3$23BQF-<[I>:@PG2SW-80UD3%CF L-OU2E17HE1 >9=\6*YK@P;:S;
M(+H;8S6$@9\-[A% )!);<$.LI\)[1O7M+JQM!KN\M[[1M,+T4=0NF$]2$W'S
MU3N>QMI[-V5#W?5P!8K]RGK2'6M0Q.+#$UNTV&P%R\:98K U$ QT22PE_$-R
M)G)F8;-QJ329"7C944:I]1(3X,Q*R-/D9&+*U![7"6@R[X]2B;3$CP($%L.(
MV#!,1T2(UQ%V:Q!AL="9-34Q$;39N6$ZYKX<6-,1XS(L &\1T0,EVA[61'O+
MFE[PT!I"AKLX.M+3_37KO8U*OATE1K1,;?U%MF%O\;7=G61J9AM<#61@ZAR8
M&I-UZ+L))"#)D:;K49:;#8=8RY;DJ+<ZWGPQ9[&2RWR7J5<G9*:E&,FY>'3:
MC3HLG$CR, PHLZZ"YDW#?4:958+6EL,PH\27@P)^&T0W2T?]=AMJ-4I:3@1H
M45SH41TS+S#8K61WYS8(<'0B)>9EGD@N#V->]T!QSA$8?@E39KGM2JO7)+IB
M>?O.U:M7]>J[0$G8M/J*)^'J@N=[1ERQT\Q4#61[?(A/Q5%D)R-;AX]Z1D4Z
M\'&1B(D#%B))=Q<[D#,1H=<:).GS$:;]QS9.9F3!BS#A27RW5F)&CF78\1)I
MD)YBO#&&=<3MC&YV:+F!7(;'R1,6.QD(U4QH;,]K!TT(AE&M8(A!$(N :+NV
MG^Z3:ZX&K]>^FIFB0U EMK[?T[>YOHCU%H^6ZE:G7)2PWBC;+U_U)WS<URCV
M\QULKMLF*SLR L,=&S=@B; ,<_+,,(D@30/6+Q]IC)&IPIN-.0Z=3:E*0LJ:
MC58=#F(\.#*3<C.4.3IDJ\Y\O&EX4>0C07OA08D%S6PR3#>Q^:J6567?"9!=
M,3$O%?3)>6=.L8]\6%'A3D68B#X,1D1S(S'AKWM=<NT@BZD[37:#=*E!%OID
MKM7J+M)UQO?5&]9T[0B;+.'WR.V[K!JD4BZ*KFOMG4_2\/(&G->T=E.7#7&R
M+0XZ/%B5,B+2@J91CZGD;E!-NE&PZ=19=LM*4%L#J?$@0F2CZ=4#-S4L(\[(
M3-3B,8P[7)"6G9*7LZ(^.V)\&$OO+U>GPA%+H\Y$=$BSN>8[7N,5L>#M4.+F
M08L.6:2;F+MD&-$P#6%H^$HHL'6?$W>#TF1T\;GZ@([<$9!]'E$UST>@0$9&
MZ5@=HZ'DJ^R_/%6&1LI,7)0=HFXA<U7!Z[#UZR'3UF):MY&8[U3+V1@Y+Q)6
M+5!6J92'TU\;*2;G<I'QHCZI&D*M#BEL%L&'!;$9%EX43:XSH\2- 9"EVNEF
MA^:X6[ZDR*R5,G,S;9D,I\*#3FL:V69'E7-N\Q'.S2V(YH<P,:QY<\B(<VX4
M3]K?L#7?OS5OI^TR,Q$ZWTXW=+G-P@<K%38L=NWJ%M9.U]I1#<M!.O0\@W11
MY*H:L']&\5B/10G(]1;[C+J\Y'8YDYSJ7&K%3<8D[4NE96%%?#B0G/I=&EVT
M^0B&'& BLZ;=#F9\YP;GF;#PT @*WR@C0>F62DL V#+[9%>T.:\-FIN(8\=N
M>V[7;4'0X ()MM6;>X*U,\]$6 3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A$X15#ZJO_ -!__P H_P#^=YKWL\?^%?\ ]<__ ,=>B9 _[6__ "'_ /<7
M]CSFO:_:)PB<(G"*,=V8[]-;;QWYQWZQON._'\^.^JROPX_^>/\ DX4C2.$+
MK,],_8$]$VQNF_I^V%/6[J09G+WI'5-RF68O9\&)&-2UGHD#-R+4<*Y1"'!@
M6S#GD"#K(?6R/AMM3SJDY6KT*6RSRK@2TO @U^H0X,&!"A0H;3 S8<.'#:QC
M&W@$YK6@-%R388DK\Y&IM-?&BO?(2SGOBQ'.<6Q+N<YQ+G'^T&))).&DJ;OO
M=?H1^>74]^E> _A]S[^[C+#NBJ/'+^P7SZETOM=*_)B>T3[W7Z$?GEU/?I7@
M/X?<>[C+#NBJ/'+^P3J72^UTK\F)[1/O=?H1^>74]^E> _A]Q[N,L.Z*H\<O
M[!.I=+[72OR8GM$^]U^A'YY=3WZ5X#^'W'NXRP[HJCQR_L$ZETOM=*_)B>T3
M[W7Z$?GEU/?I7@/X?<>[C+#NBJ/'+^P3J72^UTK\F)[1/O=?H1^>74]^E> _
MA]Q[N,L.Z*H\<O[!.I=+[72OR8GM$^]U^A'YY=3WZ5X#^'W'NXRP[HJCQR_L
M$ZETOM=*_)B>T3[W7Z$?GEU/?I7@/X?<>[C+#NBJ/'+^P3J72^UTK\F)[1/O
M=?H1^>74]^E> _A]Q[N,L.Z*H\<O[!.I=+[72OR8GM$^]U^A'YY=3WZ5X#^'
MW'NXRP[HJCQR_L$ZETOM=*_)B>T3[W7Z$?GEU/?I7@/X?<>[C+#NBJ/'+^P3
MJ72^UTK\F)[1/O=?H1^>74]^E> _A]Q[N,L.Z*H\<O[!.I=+[72OR8GM$^]U
M^A'YY=3WZ5X#^'W'NXRP[HJCQR_L$ZETOM=*_)B>T3[W7Z$?GEU/?I7@/X?<
M>[C+#NBJ/'+^P3J72^UTK\F)[18:YV2'3#T4]1G0MN;4=BW3)VQ?6)1J@H6^
MWJ*L4%[*G==[5),<Q'AU2&>]:AR+&]._ZSP-)4]A3*_'C*<-7<I<H*M)"5J=
M7FYV6V^'%VF.819MC \,?\"$QV<T.<!C;$X*^D)&2EX[HDO*0($3:W-SX8<'
M9I<V[?A/<+$@7POAITKL\<_'K,+0S:/]SI] MKM-JMIMCZE I"WVBR6Z3%B]
MK0XT:S+6F;.GY5( SM%(<'$S(R)*AV%OO*9:4EO+B_#XL_J9'+;*JF2D&1D*
MW-RTI+M+($"'M.9#:7.>0W.A.=8N<XXDXE8Z/2*9,Q7QX\E BQHA!?$<'YSB
M &@FSP+V & &A<'][:]G[\[>J+]+L)_#_EW[XF6O=%/?4>Q7RZA4;M=+_6?C
M3[VU[/WYV]47Z783^'_'OB9:]T4]]1[%.H5&[72_UGXT^]M>S]^=O5%^EV$_
MA_Q[XF6O=%/?4>Q3J%1NUTO]9^-/O;7L_?G;U1?I=A/X?\>^)EKW13WU'L4Z
MA4;M=+_6?C7!6C_<[/9RTVLV*WV*\]3\?7ZK!2]DG3W-N0F4!0\''D2DF6O&
M*!WY0,$*^\K&/ASA&>/?$RU[HI[ZCV*=0:.?]G2_UGXU0>[]GSV+>O=;ZXVC
M9[GUR"5_:'2K-]9, "W;(1V? TK$%:OCA#;#%^Y-&8FQ6:9V_28*L02WWG9&
M8-+"=($4&XI3WQ,M1_XBGN*![%5>Y^D7(ZG2^#LT]<TX_P"_HP*D/;/94]D+
MK&-TV=7KCUF=0!F_;1;JEJV"Z:-E4W<TM9I.@5J6M=X=%S7*]B*4!4HJ&-3/
M%-RCN #O)"<1YSG<E[XF6O=%/?4>Q4=0*/C_ -G2XMIOMG)GWU[BC^G=FKV6
M=PNP=.Q5NT#JSI9.P(1L:Y[7TS [ *N.K]<KVC>:I7]&Y)*WC=BZY7O1QDN=
M1=?64$"V2@4&0XAMB8D(E[XF6O=%/<4#V*=0*/IZGRQ\47=MK?8>-1Q&]$O9
M(V%->:J]5[0Z:D;5K'1^PX*,=VCIN").F.HNR:;@=5:N']T!$:D_84@+U Z>
ML-F'A_:=;I4+?:\]9+&$Z9Y3;WQ,M>Z*>XH'L5/4"C]KY;21_P!YJOC@_1@;
M;JOUHGL&NSBWWK<+8T%(=8=7:7:=DT69K-KVW2?;U=N6H]DVW4M^@SGZW6;%
M79!,3>*180 Y>!G9:&F01QI6,/(",97E[XF6O=%/?4>Q5)H-''^SI?ZS7B/[
M_/6I?^]M>S]^=O5%^EV$_A_Q[XF6O=%/?4>Q3J%1NUTO]9^-/O;7L_?G;U1?
MI=A/X?\ 'OB9:]T4]]1[%.H5&[72_P!9^-/O;7L_?G;U1?I=A/X?\>^)EKW1
M3WU'L4ZA4;M=+_6?C3[VU[/WYV]47Z783^'_ ![XF6O=%/?4>Q3J%1NUTO\
M6?C3[VU[/WYV]47Z783^'_'OB9:]T4]]1[%.H5&[72_UGXT^]M>S]^=O5%^E
MV$_A_P >^)EKW13WU'L4ZA4;M=+_ %GXT^]M>S]^=O5%^EV$_A_Q[XF6O=%/
M?4>Q3J%1NUTO]9^-/O;7L_?G;U1?I=A/X?\ 'OB9:]T4]]1[%.H5&[72_P!9
M^-/O;7L_?G;U1?I=A/X?\>^)EKW13WU'L4ZA4;M=+_6?C3[VU[/WYV]47Z78
M3^'_ ![XF6O=%/?4>Q3J%1NUTO\ 6?C3[VU[/WYV]47Z783^'_'OB9:]T4]]
M1[%.H5&[72_UGXT^]M>S]^=O5%^EV$_A_P >^)EKW13WU'L4ZA4;M=+_ %GX
MT^]M>S]^=O5%^EV$_A_Q[XF6O=%/?4>Q3J%1NUTO]9^-42L/99=E]7^J1CI%
MS0NT^F=H$@ V)F4@\PIE"50RK+"4\O9B[4] "H9U["V.>%C)BR/!-LC.CR"V
M626@G5\>^)EKW13WU'L5/4"CVOU/EMS_ +S3\M2;>NR*[$K76LI_<=DZL]D*
MUM6+;#4";M,!U*4:V !7RPR@L/#4MSW+TV7=Q9S3S6$JAU-X+!"27+22 X>/
MD#Q7OB9:]T4]]1[%.H%(O;J; OIM:)JQ_P >\O/;78]]CCIV@[NV!/[]WQ8F
M.GB <G]L5*@;\HMSV%5F\O(# BI"EQ%5<F09V:D76(N%C)1F/=D)%]H5M6%*
MSE+WQ,M>Z*>^H]B@H%') ZG2^.B^V <>>LOLG8:]E[5=V:KZ?Y:X=72=C;<H
M>S]E0 8VS8 B,AZ=J-ZCAVV6MDFFE89@V?:6PZU%Q*E))1)GO%M-+2@)YW#W
MQ,M>Z*>^H]BHZ@T>U^ITO8$#_O-)O;_O-XJNVC.S?[$OJ!M6OZ93]T=4<#8M
MI:BI>Z:!&[ V[3*85:ZGL6XW^FT>/@1)6M8-F+99'M;66PQ]8BAC9+-3]F3C
MZ&&I(=K+WQ,M>Z*>XH'L5)H%(&FFP,"0<(F%K7_O[ZY_3_9.]E_O7:4[K?6]
M2[2N8A:YLK:NIY3=;ID*)HEJWZ;F++6[JRSL)VN>64 S9JK)UN,.'C'&Y.96
M&(PG&",.(>^)EKW13W% ]BAH%'&FGRV@&W]I>QT?W[;^G0KL?>VO9^_.WJB_
M2["?P_X]\3+7NBGOJ/8J.H5&[72_UGXT^]M>S]^=O5%^EV$_A_Q[XF6O=%/?
M4>Q3J%1NUTO]9^-/O;7L_?G;U1?I=A/X?\>^)EKW13WU'L4ZA4;M=+_6?C3[
MVU[/WYV]47Z783^'_'OB9:]T4]]1[%.H5&[72_UGXT^]M>S]^=O5%^EV$_A_
MQ[XF6O=%/?4>Q3J%1NUTO]9^-/O;7L_?G;U1?I=A/X?\>^)EKW13WU'L4ZA4
M;M=+_6?C3[VU[/WYV]47Z783^'_'OB9:]T4]]1[%.H5&[72_UGXT^]M>S]^=
MO5%^EV$_A_Q[XF6O=%/?4>Q3J%1NUTO]9^-/O;7L_?G;U1?I=A/X?\>^)EKW
M13WU'L4ZA4;M=+_6?C3[VU[/WYV]47Z783^'_'OB9:]T4]]1[%.H5&[72_UG
MXU0WJ.[,CLB>E_8T]K>_$]H783:/J"*WYM*QZQ*3L.JZCU!+V*V5MB];&,K]
M%?E(:''*HUJD#?10\H4-"PILJH;(K*U8>^)EKW13WU'L5(H%'(OU.EMP7VS$
M[@^'OCC4O?[SAV/0DE=![)OG>=&@:5)T"$=O=]ZB-;U"AV2:V33 [_6H>HV2
M:KPH\U*+JTE&29(/E#$89DPG!&S&7%.H>^)EKW13WU'L4Z@4?M=+\43=M_C7
MZCL>>Q;S?=HZT)ZI-JQEOTN/3W]FA3?453((&IN7J-L4U70#IN8I(4*]*/0U
M6F)<^,#/)-AHYL8J78":-%RZ]\3+7NBGOJ/8IU H^'_9LOCHPB8Z-'P]\*+R
M.S)[%:-V;5]6V+=?4O492ZV7;U9JMFMF[]>05"FW]*>]J+;)(&W&P:(UR,D9
M[:M8JE3SG*9&R65F:CP8[RXQ9+CWQ,M>Z*>^H]B@H%(()%-E\+:HFO1_?5I9
M3L#.RKA'Y 69WON2(*B9ERN2HTIU'4(!^,L+55=O3L%(,EU%IP.9;I##UQ<B
MR4MG(JK+MA4QB(;69A[XF6O=%/?4>Q4=0:/VNE^*)^-5[USV4W8M;6CV+/2-
M^]0LAK5W6)VVW=OR.[*C7-81]0#V/,:L:?F+)8Z?$NPQ4G:J].HB42<>((<!
M%%%(,2KR67GOB9:]T4]]1[%3U HXTTZ7OAA_:7Q%QAG\[J7Y;L/NQ\@82NV6
M<ZH;_"URX1B9JI3\MU5:NCH2T0RY".B42U=E3*VR#-QBY67B8Q)\8^4*J0E(
MX+#N231FW7OB9:]T4]]1[%.H-'[6P.*)^-9-?NP)[*W5047);0WKN76\=.2C
M,)"GW[J,H=/"EYHE.5#Q$658:A',2$H^E*E,QXCCQ;J<9RAE6,9X]\3+7NBG
MOJ/8J.H-'[72_%$_&H9J_8Y]D[=^J2_](U-N_5S:-G:IH<!?=F2,-MJD$T^C
ML6DPP6!K4W(JKK<SFV'-!+/>C8ZOGAQ01,=[:DHTN4CQ"7OB9:]T4]]1[%3U
M H]@[J=+V)L.N:O^=1,UV;_8P.ZXTKM7.P>M)FG;\$ZA)B@&O7:%;><JG3)5
M[_<MGW699]QV<1=3:KVNY(Z E%N.JF?;=59;'9>FVT,O?$RU[HI[ZCV*=0*/
MC_V=+X6O^OK-K?KZ=Y??/]F9V-$7H+6O4-7=B]8.T:WMBY:WUM4*7J/9]-V%
MLYW9VT8=J=@-:2E2@:Z]B'OD=&N./V:MGR3)T#@4K):?"UA2GOB9:]T4]]1[
M%.H%'O;J=+BUS<B):PU_K\6ZK.Z@[ /L_MNTH6Z9B>O+5^"CI %-4V_<H*EW
M5G$>_P"1ZTJ Q4)10X)JN]R/><)PLEE/G8:2VI"EO?$RU[HI[ZCV*CJ#1NUT
MOQ1/QJ4/O;7L_?G;U1?I=A/X?\>^)EKW13WU'L4ZA4;M=+_6?C6-6+_<PG9K
MVWT?NCE>IF6]G^H]'ZG;T3CT_JO(]1X/*HC?_M?3,>+Q>+_V:>[N^'OPM8RB
MK=?Z7ZL5&//]*;=TMMVU_P!EM^U;=FYC&=<VF%G7O^H+6QO>R<G*4_;.DI>%
M+[=F;9F!WP]KS\R^<YWZN>^UK?K%=B?F%5RG")PB<(HRW7\36V_JROOV5E>%
M+=(X1RJJ713\C;I*_%ET-^RRJ<SL/K</O&^:%B8G7(G?N\XJS7*U0G")PB<(
MG")PB<(G")PB<(G")PB<(G"*E76!^&70G^/;JW]F>Y^6D[UD=^WD<KF5ZX[O
M#YS5LUYBE?IPB<(G")PB<(JZ]7>H+AU!=+O4!HBA6Z/H5KW-J6\ZMC+G* ER
M05:;OL ;6).74$"^,8^^)$R9RP\#D,.(-].YAYOP97@I!L02+V-[:+^-:A]J
M]AO2\V/8I73/C1VE*?;M:])^M!Z2;K21F(*PQ.@]]$]0&Q5;+$B9B%<LR=R3
MU6U#4IUL8T+.:I595LI;SYC#>2JS\,02<<;F^(MQC$W-].]CGU"['. L&W:]
MLKJHD]9;:K*9SJHV]/ZBJ=5L-1H$3OKJ8LNEA6Y6EC8G5&,U&@:JTT#41O:K
MRIFR6>PV*XEMQ>95^*23/(%AAH&[@+FQ\9\@ M;'955NC;ICI,ZW9*IJ"N04
MJQ7?<N&H$B:1'QT:JDQVMB"8J%7*KA8FPG4"(C:=*6Z-CQ;7*UX-F+DIHH7&
M6\E3<[I7%6#H:Z3K.8S(2VE*QD\2&IT  =&%S\"7%1M 53%5'$,3 S$:]#'1
M"=<:Z8Q+Q:PY8X37M$"DCC!*=7&8TESN\^=^,[I5AJ32*AK>IP5%H5;AZC3Z
MR W&0%<@0F8Z*BPFU+<\H85A*484Z\XZ22^OQOEEO/EE.O$OO.K*";XE93PB
M<(G")PB<(G")PB<(G")PB<(G")PBUV[7Z'9[;^T^MO84QM)5:=ZF>B^M=&VK
M9.NQ96;'IFOM#[ID+E;/-</$8EY.8N&U(J<!'!?BW6F*>&,]()=>8?"*H.MF
MBWZKL[A.'J\I5((CLBMG$*K%HM-OZ;1+!$;>Z#9>2U?0]46&OZ/+T[T-,;!7
M7X?,:7-GS4CL6X6/8AEF.G9-I<8#%5RO:^PR3$>T)PDF<-PZ'8WO<N%L<-S#
MAQWEA=0[&+>!%MGK/N'J'U_=2+F9HZ*OQ$%3[7!>ZVG4+K*$ZKMO=U><GR*C
M5)K=SU5H\+)1U+AJ_6(5\69=+ L11QTU,N=^7C4YPU C3;&]L+#4+VQT[VH6
M5R>L?LRZ[UB[?VOM;8J=:6M3W1G*=/73G WVI%V,'4FX)^PWRQS&ZS4*)0V4
M[ZF2UV&(#%MCGI"J<@A1J%237DN?/GZ5 =8 8VO<XVOHPT<.[IT*LM=[';8$
M#=HN-3LW3+NE@I#L^QV$JUE..;KJ]'[/&K4,VCTBDWQ=AQ&PPFV=L5N:L-WE
M&XIHZOUV9D1([W02<Z^_$%.?ITW.=?&X.=NX X G6<;:,5=GH.[.#3_1M2J7
M,&U^K6SJ::A;1C:>]XP.9 /O=JOUE/MUWE&8Z1E3F@0I*8D%-C-J;R6V",.T
MX]E2GO&4%Q.G1J'!@,=)6QWA4IPB<(G")PB<(G")PB<(G"+3EOCL^.IC<.[.
MM:5@]]:HH6DNN+7VG-*;#(SK>UVG>E/TAKFDV"MVVD:\FG[G#4*&E-@&7_9S
MF+)+UVPHKC%L8/8A9*3B1\K*H.  N";$G387-M5CHL.%0%M[L;MH6N&L,?K7
M;NK:7-SN^MW;0KUY,KFRW+?JVN7VFZPTSKR!AT@7IND[.KE7T+JFO42]ZGVM
M2)FG[ *\!C4[71AGQI(ISL=&%@"#:QMB<+"UW8@C$8Z;V4R1792&2G4N;L[:
M4WIN]:C>ZQ6^K)^F*UOZ2<L[U4Z2Q>F[3M%LP.?%4$0NJ)I)NP85B/"S'E3!
M+I60!'G\,"E&<;?\N;P?"SK^/TG@5>9_L7MV3<?881[=&AY(+:6A=_Z0VA-6
MO44_9[+!RG5OU-;)WYO_ '!JM]ZR!1T5><U^QTS7U)%EQ'66?<T//'RHS<4+
M#2959^Y? @Z;7#0  ;;PTW.YOJ9(OLJMQC;<O-J-WAKMVB.[&ZR=O:U#71[)
M*7879'49T_UOILU9.[ D92R.0L^)I'5(,Q4A(^-  >G1G&Y)Z0:?DW08=SY[
MJISL+6W <=(!).D:S8^+6H\K78X;+K-0H1 M_P!%DW?42^@4:C4F3HMJD=*V
M&L=%6O-GP9-.OH/M42?+#O>SMQV[<OMD9@HAB]PE2F96,E"AR<H*2^]]..=P
MW<1KW+  VMA=>DGL2)Z8H&R*M:=N:\GYO8&B;-JL21;UN3%P%!G>H3J^N?4M
MU9RVN*WF6DD4NOV>JV2'U7K.*B3L'PD?6FI"8DG?:9@_"9Y!PP%[[^#;"^_K
M)W<196ZZ[NS_ -A]4.PX:[ZYO&H8,<OI?W;TG3<+N;6LILB,H%8WE)5 B=V]
MJ&+C[#"1X6U(J&K+M=;%G6\Q,Q&D1[!,D$''F 2Y0#;#?!X@?7XL=U9WT\]"
MTMTY5KJ_=J-UA3-H;^, "USL$^'>S)4NHZ_Z<M;:)U#$VPQK+9T_(0\C02;U
M:C@%!MS,U8Y$AIA!?B(<*";VOJO??N;GU>):\9KL$*9":]@*;HZP:MU%/B]G
MO<NCFV; B]?&+L=YV3MDC5M>VGO"T*$DPG)AZ3UK4[]#14*^8R^F7V+)//'C
MAX>2Z5>V$FY%_A!VG1:]@,-&B_!H4HQW8[.W_:%4O747+Z1G:(_NN&VQLCI^
MU-0;)1]1&A:BZ79KILZ?(&K!D6$N8;-K+MILVP[5-29J%EFOP-4C!$Q%<:,.
M*,^VB^BP)TXFYX]!WN$WW/ZTUG0].4:OZUUC68^G46K#DBU^MQ7G^@BV#3RY
M0M#&2GB"%>HD3C"W5.ON+6\0XK*OA[L%03?%9UPB<(G")PB<(G"*,MU_$UMO
MZLK[]E97A2W2.$<JJET4_(VZ2OQ9=#?LLJG,[#ZW#[QOFA8F)UR)W[O.*LUR
MM4)PB<(G")PB<(G")PB<(G")PB<(G")PBI5U@?AET)_CVZM_9GN?EI.]9'?M
MY'*YE>N.[P^<U;->8I7Z<(G")PB<(J.]<U_N,)!=/>F:)-S-2G.K'J7I?3[(
MWBMG$Q-EIM"S2MC;EVM*5::$6T7 6R6U=IZX4^JV0!]J5JU@L\?:8E:9&$&4
MDI&LX8"]CKQ MY;K6/L+>]OU5=^V#OW5!UL;5J?3WT]U'0NG->3.H(>'I\GJ
MVR;)B)':,G3]7P\L5;A;/N4JJ[#TG0V]HVR0-M!,_,S4VW(T"'8CPZP5=KY@
M %R2;'6!88XZ,#N*1M1=3.[-+]EM5MW5;8M'Z@MM;MZ@*_2>FJ.MNVI/J0K-
M<:ZA>J2)U7KK3=QWG7;$S-[HEM+0L_)1]ZN =H)(<G:I/Q 4S+1T((8:4$#.
ML;@ &^&:38$X Z+ZL,=-A>RKL5VMW6A2(JYW*;I_3QN.J5JA]HW=(H'76NMH
M4&3F*9T:;YJ'3_0-U2\I*[BV:S7:'>;W:)-BQU0>%G3HNJ4B<N =Y4X<BO1!
M3FMW2/U-=_UA<C1N#>QP.ZI/J_:<=35MN,1I:E73I V?+374H9KP#JZI6OMD
M%=,TKIRB]),YU%=0%HK-1 WW.2-HLFCK8FJ:[)D8K<[E8LQUA&BCFJA/X/1&
M%&:+$V(  -B1>][;F M<Z-ZZI1LGM#>NKJ"I\%#P.W]?:<O6Y^@[HK9J^K-?
MP=BI5N*WQVB_4H!K>K[-I-F>V+*W:#8UGK*N!W)V1"8L 5(!V"]7WBB;,3%6
MC)5!H!.%P'.QQM9HO8Z =S5?>"L#M7M>^IO4M(B7Y&5Z8B2HWJ0ZK-4R]S H
M%@D9BY:ZT-M6LZ1HUOUUT\6GJQI5\N@]BVF]=JI?#]:;.W->X$: K\W :CM'
MNF?1%% 8"==K [V(O:X!%[6(O;6+A;>^D6^72Z[F[00.6FY:P:^I75;6ZAK<
MN2DY"3CX@D#I5Z<2=J5*HJD77%B52 VR7;EX %PV&%;)*W"-MM/L$L,E0;6;
MNVQXS;7N6U#"RO3PH3A$X1.$3A$X1.$3A$X1.$3A%0[J1NUYL/5%TE]+],L<
MM3(N\0F[NHW8UBABY*-/E*MTWNZKAJMK]9\1(1$IBOVC;&ZM?SEXCXR4!>LM
M+I<U19,E$!<Y5M\I P)X /'?T K39-]4T]JWHBZD=N]7/6AN2Q2^Q.T>V3I[
M0TMKB]5KIB=VU$:2FA].QVJ:;:<'^QNF[25AONM-@6K8.R8*VPT[7J8P5)3=
M]G["82BT.#GZE7:Y :!^J"<";7Q).LD7&%K7T!7ILG4GU!=-O2MV<] C=RZ=
MW3O+>$,TC8W49=(JQ;+UJ3J;6?31L'>VU=X0C51NNM9._M!Q]7JH-7F3;/!,
M7K%A$DI8B-/G$D"E38$N-B ,0+@:7 6O:PP)U:E3>G=K=UHIH\!+[0A>E.G$
M7C6?9R3<KL:1J6R:SJKI>M?7'(;/D9&2W6].;C(<N%6J^MJ'7+8T(Q8M0^Q[
M?LFLZ^FK,6(A%SDXU\\.'%59@N0+G%]@,2X-M:V&O'&QM:]M2\[5VO'5R1J.
MUVG7L9TV.G:EZ<^K_J L>T)C6.U)F@[YKFJ>H<;0O27.Z4HT?NN"G:I7^JJ4
MB;:^"_8+Q?6 0F1['6I.Q@!"Q=EE,T7 -[$M&D89PN<=[1H7%7CJPZT=L]3U
MQU%6^HW6]#,QVB&EM-5^D1,%8@6-2ZRZ7>F*5ZM^I&R[ 56MH0EGN>O+I97F
M]83L3(2%.1M4.NE1P=FK%;DD0<1'%O>GA4 - N<?@DGA)S0-!&&G^H6::L[7
M?J-N]\[/NJV4?IYK['5!1]!R]ZCJ_5).UWHJU;TM=M-KK(NN2^HZK[0U%0K!
MI:'K]XKNR8S7G4S48:QRLU%;"E:I!5I^7,GGR\_$5):/A6O\$G3O#=M8D' Z
M,,1=;7>SHO=OV7TNQUTMTW-V9J8W5U5XH5FL<F;,3-@TX!U2[CC=*2I$G(/$
MEGB$:I$J"80UTA_UL W%&H=4@A.>%2X6/B%^&POY;J\G"I3A$X1.$3A$X1.$
M3A$X1.$3A%UTNI_;O55LKI(ZB]_:>ZC+=I*V;AZWE]&.F:Y7XOVM*@T:J=4"
M^B>MP^O/:4PU#ZWO=OV)G8NY[YLP.MS.PRX-<)3H>7@!:95I"&*L 7 M>S<X
MX[V<;Z."U_*5)TWO"'OW;"T/I]TKUAW5JRZ?'C)??^J;9NN)#URNI1NFKFD?
M0NK=$I6-)[HVG;)65B=U[;W!/"3QFFHFH!0@5R%D)I5,"<^>KGOI8YMR,#H-
MCIOI)T:B ->YA=>G<7:,=50G5%:=:ZD(Z;8'3<'U46[IK%G=B:UV7;[<W#:>
MZ*'NJ#J,W')R5?W71(-V'U#:'X:E1E/&@PE7DL]Z%*N=,-$3+%DS1;&][ X'
M==8"UM)&.G#?."A"H=K]U56%O2#,Y7.FZH;&L=![/FQ%].,A7K^7N3JFDNM"
M4CS+E*].3?OH +U[2]*4$XNP3\O/57=8H$[6[7#VN3KH$0F3*)FC&Q) +A?0
M!;1?3IW,#N7)7";$[6KK&9U3M+:U>QT\0M.GNE#K\ZC]/( UK>CKE0J=HCJ!
MK6CNERX76P36W2Z=;3=W*LKI1<2/3*_"P;D4BY9)F(;,G1A"D-!MITM!N1K:
M2[5?X) Y-*]VE>LCJ\UWU )E;'O;5V]-2V#J TGT63CDI$7Q^.L3'3OT(6/J
M.ZHNH_5!D-L^7J= CV;$:;FV2K-3V:[LDB/C&,$5P>OQ@[Q00T@D7O8NU8#.
M#0-&.&YK.Y=<QIOM).HGJ=H-?7-V+7T;M*"Z[N@'78,%T^BN-4N2@MK; 9MV
MWZD-M:G]0N]Z/OBC_<X1ESM11F/>VM<"%&%2>P=.U0I$"G!,VQ.!MFN..G"X
M!L0+8V\MB5NZZ6-1733U(O49L*V3=RM%PWGNN_\ M:?N$Y>#FJ?8-@S(^K(Q
M<S/(9('=CM31E%'DH&/&%K]=FDRD+7&<080#CA4GT#DQ5E^%"<(G")PB<(G"
M)PB<(HRW7\36V_JROOV5E>%+=(X1RJJ713\C;I*_%ET-^RRJ<SL/K</O&^:%
MB8G7(G?N\XJS7*U0G")PB<(G")PB<(G")PB<(G")PB<(G"*E76!^&70G^/;J
MW]F>Y^6D[UD=^WD<KF5ZX[O#YS5LUYBE?J-@MLTN4>4W$.V.98Q*/0Z96%H]
MVF(!\X:<B*X5@6Q1M?*@RQ0Y>988,D!I!V/$9!L!Q)30-8L9,647!\6&@H-M
M:L%)&4U&[!3@ML!UK!&J-GBJ0F2%IA8^"$E5!E0CC;5\@TFM%89<C2 K<)()
M%*H5X9KQ3?G8K\QM>KY;2[B-V'X5#I)QC.IMI87Y:PF9#"5-9I^'$/X8?0A0
MRT)(27AV/4U@YEX9!1?AXCP[G/1I0G:]7%24MV-V$K 8YY+V&-3;1*4IN."M
M9Y"1D#4]U9C[C%-ET!#")>(DC"JR!'M%'7.HCS93?G8K!MB>]-?Y"E.W2LW^
M3D-2[&8V13# M>;8:7"7BJC;'J29@$R'KB&I(<B($N\1Y/FF15A@+%$.,MGQ
MEXJ3\T2_#Y>>KDWEF3U\I)2G R*];B$FF-^>A_4>PG!R"_5#1C9!*W*AD=6$
M.+8_OU]7E-@M*.R\F/&=(;*+^GR:4$V#2G&XT(>!N3+"WXYP!A>H]C""B/GF
MTQ@1Y>'J>T/&J8*O\*\8\1Z;V6T)<#3UBCT*]/UXI7J'V12$H&>'K]W9P0(S
MAGNT[LL=U LFS 2GIWFE4QMT7Q^Z:/6<(0AI8Q[$Z*>TR?6K&S%E%^'B*]+5
M_H$:$RP+6+B*#'B&^D$"TQLA+0HN0Y$XQ@,,:E?R/4LQA2,B#M8<-+<!!;:>
M-E(T<LE^'B/JY^,+S*O=!%(=.=K%M67$COAI*'TYL0LIH6%7>",#1[PM,>>(
M':=U_/NQC("G6C'CJ<J+20YL.A9LA+[QXN'U<FZOTRZT-:V$$UJUNN1,B4\
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MZ=/-#LU8(KD"V?0VF*X; 5Z.J<O/P]"A<DF%RK1A.J(>;B==SRTRYCIIF9.
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MOI60IO*\8*/D#,(RGULC(%><:_2I& W5EW"E.$3A$X14*ZUA2B2-<>F$G2?
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M.[&,8^#&,8Q\&,8Q_-CE2A?O"+'Y*IU69)R;+UFORIF4(:R7)0T<<3EMOO\
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MIL'?"X3<7&[CKP^:7U^]?=5[*@3(/$_?H7?MMG_2$NH2ZV6G93,Y1I)Q))#
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M14JZP/PRZ$_Q[=6_LSW/RTG>LCOV\CE<RO7'=X?.:MFO,4K]1MJ0=H6AQ;+
MK(;:9*TJ2./'B1;2,NVV<=6M(05/H8S:GEK4\XXBKA+)<<44\9./O.3TF0;V
M_P N/E4D\(G")PB<(G")PB<(G")PB<(G"+'DVZIKBI2=19Z\N$@WSA9N93-1
MJHJ'*BU^"3&E)#!.1(]^.7_(.9+>9<$7_)(2WGX.$7.#D,%L,%"OLDC$LMD#
M$CN(>8(8>0EQE]AYM2FW676U)<;<;4I"T*2I*LISC/"+V\(HVVV.DJBR#*A<
M&85,5!7IU -2>%9:N4 [A?HWJ1L1M>6<HP_AW-3,4-EO!2)&N.,ILL04'1NZ
M.7@//<TJ2>%*<(L<N+:':C:FG&D/-NUR<;6RX.T6V\A<84E33@K\/86"4.8S
ME"AWH"<:>3G+;D/)H5D)\G"O&F-H9I]39;:0PVU6H)M##8[(C;*$18J4M-B#
MPU=8%0VG&$('8K\$RRG&&VX:,0E(3!!H"R7A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X11Q?ATORVK59&P1D;8[1"5Y :-R(K%)N[/J<.N4FWYCL]SV6/7LR-!
M=QA_(F+LVV6Y5K24'5P\]1]'"I'X4IPBCK:K#1-,>:>&9+;S8Z(O+#X LFWE
M;-[K;S3OI#*C>&,K'=;00T1FNN.A.M(-&EZP2.U9X<H/J\G/_32I%X4IPB<(
MG")PB<(G")PB<(G")PB<(G")PB<(M??7)"-3!.M,N5UN>].Q;L)RY2XZW>E\
MURM]^,*/Z/>JO('G>7C.<-/4;U/E8RMJQ^G2N#*D@:[\5_05L$X52<(G")PB
MC+=?Q-;;^K*^_965X4MTCA'*JI=%/R-NDK\670W[+*IS.P^MP^\;YH6)B=<B
M=^[SBK-<K5"<(G")PB<(G")PB<(G")PBKWU*[JD=%T(.U1$#%6"3DIQ^'%'G
M9E^ A!DQ]2M=T-(DI,:.E7Q\$1U0,BH_P!KPJ8DHW#O>SYB%T1'EC;@7QMB;
M 6!=<GQ6X2JFMSC:]O%<Z0-%QNWX =.A1?=NK9RO;(I%)C*[6QXFSZW"O$G:
MKQ:RZU#0DG8HW8#U=KDB?&5ZQ)B\@R.OS&;?*G#9$@H\]!CJ4NBH&.I,2S@
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MLOX5G&?R'Z4FQA>^TY2WQQZDRM\=/^T=>M?OOT)]F7_XC(W&U_\ MR=U:/\
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MY)):[>:ZK;-;/^R=^41<_J:L'VUU_P V>Z$[LC5GP+J7WWDZM+^CG[$^3O\
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M<6ZX\M=<A%J>=?>)==4J,%RIUPDF1F""'',YRI;[\O*/.JSEQV1.6I1+I2-
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M5\Y^(7I*[!/8P_%_O#Z8U3]22/-V>A3_ &'E=\:T[[)&7-OHZ/WER!^(ZO\
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MTL,Y(P+43 !2$F@L\I(T630Y^:YHM>]KF]K7<&BPUXG'18 G>536W!-[6O;
MXV!=IT# 'U+!-Q=5TCJF9VG!HU/+39NOXK2\G ^984MKOZ-NSVR(1;D+$U2
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M"BVF6V6FTR=JSA [ 0S6,KMTZM64LQ\9$")4I:E*<4@!IQQS*G"'2R%NF/E
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M7G_HNB'_ &*..F8_\0\3?4FT0?X8^5$_&GW"FRO\I%UY_P"BZ(?]BCCIF/\
MQ#Q-]2;1!_ACY43\:?<*;*_RD77G_HNB'_8HXZ9C_P 0\3?4FT0?X8^5$_&G
MW"FRO\I%UY_Z+HA_V*..F8_\0\3?4FT0?X8^5$_&GW"FRO\ *1=>?^BZ(?\
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M6E_T1Q>4/H,]*8*2V^?)ZEXC42;'P-A>U]CE^G4"IS)*->]Y> WJ2ZZ@GT]
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MU*DU.?GP+KN.VQTJIBP7JNZ]B) ZH4LP.P.XD,K?!&*H-O?$:\.#'@ X3B<
MMAG"I3A$X1.$3A$X1>I]YH9EXA]>&V6&G'GG,XSG"&FD9<<7G"<9SG"4)RK.
M,8SGNQ\&,YX14?Z-.N_7G6U-]1 NM:=?:W7="[%K-"&GM@U^5ILEL$.T:]KN
MPHJYQ5-L4;%6>OUJ7B[$*56U6$(60G8%^,L6 P1Y5D1HI+2VU]8ONVQ(U<'H
MTJ\O"A.$3A%4GJQZE+UT[0U3(UWTU;0ZCIZT.VXLT6ER-8I],H=9HE7+MEBL
MNR-FW<^.J-,')#%3&5,&3(P7;)Y[$9'X1E@E]DI O?$"V[R"W,!2ATZ;QJ?4
MSH;3_4)10IR-IVY]=U39%<CK,$W'V"/B;9#BRXH,P(P08*W(!H*].2L$TZ/?
M<;R_'G&A.CE.D(L2#J)'$IFX4)PB<(M>9'7TN(ZU*;TAVSIVVK4H[9T]?:EJ
MS<4Q*4?V7>9[6FND;+M4V%K@:?>V0#J?$6@ZN0^VBX3%:E+L Y7O+%2\P>LJ
MLW"]QND;@)MIT7WMSQK89PJ4X1.$3A$X1.$3A$X1.$5%NGSKUUQU*=3?49TX
MZ_J-\%3TYURA3$KL6UUZ7J<!>S;E9-B5609H<588R-F)JMUN<US+Q&;NVW[
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M<I4]KV;J*.EJT[(B98:NS6A [+99:]2"SXJ0G[,<U%@R8C!83,^TY\_(J@0
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M;MU03%34WFMQ$BQL&JNA2<_@:,-]C@DHE5,DR&09N$.2,TM3J@9J'-2G(LJ
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M2U]'->M<Z3*D;!MX,>!?)+;5%A! :PIFF[2E;I4=AD654@3#O2-EC&+=3A9
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-)PB<(G")PB<(G"+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g65062g29a02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g29a02.jpg
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M6I3A$X1.$3A$X1.$3A%*=&?W[:=_VIU]_6T1S7Y;_-63_P##[O\ =I5D5/\
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ME]$>.[>C543\[%AVQKC;S-\Z^7S?GMGR>7R>7R>7/D_4\O'A,VY^<$_LN/\
MA$ZNX7R"/[2;WJZOJE_#+]D:.^\2V?C;CPF;<_."?V7'_")U=POD$?VDWO4^
MJ7\,OV1H[[Q+9^-N/"9MS\X)_9<?\(G5W"^01_:3>]5DDGA>^%1#0124R_K+
M HK&0;10@;D4DMFR@8(.P1\GIGI0N3GK4>/:)>7'I'+MPBCIY<>=OCRXX\)F
MW/S@G]EQ_P (G5W#>01_^>;WJQVO_#M\'NV!KLQ5E'5!98@>ZPQ?E:_O2;S(
M:R>[)X6U9NWT<L<DU;.MDLX5PW65T5RGG&^-/-SC/'A,VY^<$_LN/^$3J[AA
MSH1C_P#O/[Q9[]4OX9?LC1WWB6S\;<>$S;GYP3^RX_X1.KN%\@C^TF]ZNEOX
M4'AANTL+M.IL6<HYW53PLWLFU5DLJ(*[H+IX43F^VF=T5TE$5=?+YR:J>Z>^
M-=]-M</"9MS\X)_9<?\ ")U=POD$?VDWO5W?5+^&7[(T=]XEL_&W'A,VY^<$
M_LN/^$3J[A?((_M)O>I]4OX9?LC1WWB6S\;<>$S;GYP3^RX_X1.KN%\@C^TF
M]ZN6GA+>&7MOIK]$:.X\[;77R_A#MC/D\N<8\OD^>WX_)^Y^WQX3-N?G!/[+
MC_A$ZNX7R"/[2;WJY*^$IX9B:JB?T1X[GT:F^GE_"';&/+YNV=?+Y/GMGR>7
MR>7R>7\7'A,VY^<$_LN/^$3J[A?((_M)O>KK^J7\,OV1H[[Q+9^-N/"9MS\X
M)_9<?\(G5W"^01_:3>]3ZI?PR_9&COO$MGXVX\)FW/S@G]EQ_P (G5W"^01_
M:3>]3ZI?PR_9&COO$MGXVX\)FW/S@G]EQ_PB=7<+Y!']I-[U/JE_#+]D:.^\
M2V?C;CPF;<_."?V7'_")U=POD$?VDWO4^J7\,OV1H[[Q+9^-N/"9MS\X)_9<
M?\(G5W"^01_:3>]3ZI?PR_9&COO$MGXVX\)FW/S@G]EQ_P (G5W"^01_:3>]
M3ZI?PR_9&COO$MGXVX\)FW/S@G]EQ_PB=7<+Y!']I-[U/JE_#+]D:.^\2V?C
M;CPF;<_."?V7'_")U=POD$?VDWO5=@'A6>&\".A38;JC'V!@,6'%13[2P+35
MW9$ASQ%VQ=ZI+S)1!79LZ126U36342WSIC533?3.=<T2_I(VVFBDAEST[XI8
MWQ2,-6@ YDC2Q[214! <TD:@@\>!!53=G\.QS7MHQAS'!S2'S:AS2"#_ )3L
M(!7J]SAUN$X1><MY^'=T5N^U)7:-O]<@LYL:4J"-Y'*G<TL,4X*[B0 H",V4
M8!)2.%M_D846.'ZX:LT<*:--5E<;KJ*J;];C=NMJ\/2@QV-S$M6E6$@@@;7I
MO;&)97SR:.EK22'>ED>\[SSH7$#0  :NQA<9:F?8L5&2S2;N^\OE!=NM#&ZA
ML@'!K0. '+QJ)?JE_#+]D:.^\2V?C;F=X3-N?G!/[+C_ (16>KN%\@C^TF]Z
MGU2_AE^R-'?>);/QMQX3-N?G!/[+C_A$ZNX7R"/[2;WJ?5+^&7[(T=]XEL_&
MW'A,VY^<$_LN/^$3J[A?((_M)O>I]4OX9?LC1WWB6S\;<>$S;GYP3^RX_P"$
M3J[A?((_M)O>I]4OX9?LC1WWB6S\;<>$S;GYP3^RX_X1.KN%\@C^TF]ZGU2_
MAE^R-'?>);/QMQX3-N?G!/[+C_A$ZNX7R"/[2;WJ?5+^&7[(T=]XEL_&W'A,
MVY^<$_LN/^$3J[A?((_M)O>I]4OX9?LC1WWB6S\;<>$S;GYP3^RX_P"$3J[A
M?((_M)O>I]4OX9?LC1WWB6S\;<>$S;GYP3^RX_X1.KN%\@C^TF]ZNY?PD_#,
M14\SZ(\=V_M:._E_"';&O[*BFKY/)\]L_K?/\WR_^UY/.SC&<^3#PF;<_."?
MV7'_  B=7<+Y!']I-[U=/U2_AE^R-'?>);/QMQX3-N?G!/[+C_A$ZNX7R"/[
M2;WJ?5+^&7[(T=]XEL_&W'A,VY^<$_LN/^$3J[A?((_M)O>I]4OX9?LC1WWB
M6S\;<>$S;GYP3^RX_P"$3J[A?((_M)O>I]4OX9?LC1WWB6S\;<>$S;GYP3^R
MX_X1.KN%\@C^TF]ZGU2_AE^R-'?>);/QMQX3-N?G!/[+C_A$ZNX7R"/[2;WJ
M?5+^&7[(T=]XEL_&W'A,VY^<$_LN/^$3J[A?((_M)O>I]4OX9?LC1WWB6S\;
M<>$S;GYP3^RX_P"$3J[A?((_M)O>I]4OX9?LC1WWB6S\;<>$S;GYP3^RX_X1
M.KN%\@C^TF]ZGU2_AE^R-'?>);/QMQX3-N?G!/[+C_A$ZNX7R"/[2;WJ?5+^
M&7[(T=]XEL_&W'A,VY^<$_LN/^$3J[A?((_M)O>KNT\)/PS-D5E?HCQW'HLI
M8\W\(=L9\[TF=L?J_/;^Q\GF_N9\OE_:X\)FW/S@G]EQ_P (G5W"^01_:3>]
M73]4OX9?LC1WWB6S\;<>$S;GYP3^RX_X1.KN%\@C^TF]ZGU2_AE^R-'?>);/
MQMQX3-N?G!/[+C_A$ZNX7R"/[2;WJ?5+^&7[(T=]XEL_&W'A,VY^<$_LN/\
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MJY(0]%&V&5&:@E+13.^":GU\_P!XT*W+X4+EI^OU_A:_RXX1=[W\L=_QE?\
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MR0*Q:X)K0->UM-9&9C4D6JVMJFJ>ED/G18X?06=A0(I<3J(:N;$L9N@6*O\
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MVZ">B***>B:>FNFNNN"*KX1<M/U^O\+7^7'"+O>_ECO^,K_I=^$5-PB<(K0
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M)<YSG$ESG.))<YQ))))))))U5UK6L:UC&M8QK0UK6@-:UK1HUK6C0!H
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MH:>,GC^"UI)=V.RFR5B6YO%:Y@=7==[;ZH4E=E+R6,R,]:A64WQ!^MTYM<@
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M"*HGL)'S4TXSJYM/4#9<.E+3%C,0F,1F.2;T>SZ*!79Y"-JBU)3(E"12#IV
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MUEHF?VM-RILXRM?BO39&_?[C-TXR"X^*2.@<@YQLN$K8V6;+MUSH8G69I##
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MSB&M:UHU<YSCH T $DD@ #4\%IT'[^=8I%"KKLJ.3E:15U1)T+%)/-P(ET7
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M,I*S8SNTY(+CTD-;.W@UB0!#VX<JB?$!R )XZ\AKV^A1"0Z1W-#QH2,PJIY
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MG-G\GB\D;H<^U$^]'BH+)NRWG=-#$ZOD>GATI.O7,B^Q=S<UM^\Z*&M3J,?
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MU8W>'_,C_P"9-1?'W.ZZ][*>=?\ <<E\&N-ZF;2^;?\ ?*'Q2?5C=X?\R/\
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?G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g65062g33c40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g33c40.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X7*P:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(Q+3 U+3 X5#$T.C0Q.C4T*S U.C,P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!)
M;&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(Q+3 U+3 X5#$T.C0Q.C4T*S U
M.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,2TP-2TP.%0Q-#HT,3HU-"LP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C$R,#PO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @
M(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G
M14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!
M04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=4
M04%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+
M0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C
M2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF+SA!04519T%E045!07=%4B8C>$$[04%)4D%135)!
M9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W
M14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!
M04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%
M54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-0
M0TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y
M-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N
M9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[
M<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#
M04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T
M4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H
M9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&19
M5U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ
M2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$W.35O.#)1861&-C U;BMQ
M=D]B4R8C>$$[,G1R3F$S3C%/<$EC2U149VEK8V%R.%)05'1Y>6-/17DR2%!N
M=GE$:#9N56I'3$XQ9$%$;5-O-EI&;R]N1%%8=71-=F14,#94;3!5:B8C>$$[
M3&0S0WI1>DM!4W)+,&IO9G1!+TQW=S5"3$9+<$%(-$QG>5)Z431O:VHY0F5#
M*V,Y82]-;GET-6AU9$AU+TU7;T\P5DAH;$9Z2E(T;B8C>$$[,U)V=%IT8T5-
M5U-.:4EC5$QK>5%.17!*+W=!<D4X*V8Y5$)Q2"]35$PO>E9L,S5B2"].1%8K
M6GED-W8K5FEE9E K<&<Q1"]P2FPO-28C>$$[<7@O3%DO-6]8.'IK-S-F.')%
M."MF.51"<4@O4U1,+WI6:BM7>"]Z478U;DHS=2\U5THU."]W0W!G,40O04M3
M6F8K87-F>3)0*V%&+R8C>$$[335/.3,O2WA04&XO049-1V]F.$%35$PO04TQ
M62]L<V8X,$PK6GED-W8K5FEE9E K<&<Q1"]P2FPO=T-A<V9Y,E K848O335/
M.39,*R8C>$$[5F0W-3EV<%<Q+U5D53%'-S R,E!#1S!A85(O6&1J=THT<V5,
M2VQA-SDX=W141$AF0T%!-4=,3$]R2F5N87@U=3%05'!W:5=C.31N1B8C>$$[
M5TIG5&LS>$U146]#.%1X-#%.5TA59E)R>D5$;S5-6GE05D$S4#5I,S%U,&9Q
M85IF0D-36G!04TA'3D%!4U1T=69I-EI';SEZ25-L,R8C>$$[<6QZ*UE&+V)Z
M4$4R;&%I,T-1>#@Q9U%Q858K245(8U9'2&A(8V]L3'9#:% K6E8U04EW*VU8
M>7E4=4DT23)J4E,W535%1#-!,V]-1B8C>$$[4C=L0FPS;W104%8K67I+8D,X
M0VE&-6Q8,&9J8FA-,%%52U9!<7ER>D<O,F-00T\U2$9,=E%%9C5M-G!)<$LV
M2G%)24M,4F]12VQG>"8C>$$[2D<R-G)X-BM/0V@S37)L+T]29'8K648W3&9X
M5W P-CEI5UEQ<5134DMO-7-Q=%1E;E)35#$W665'4&-G>6Q83D-X9FUB<44X
M57=T.28C>$$[278S=6]F=%=Z>&]H0DI!44UD*U!)1V].3VTK0V@S2G5896EO
M+W=!=TPV4U=.0G!L*VEV=S5Y4U%Q<6](<#ER,T9D.%!$2'52>%,W,28C>$$[
M1F9Z2G9M:CE585)Q4FI+;&Q944MA9T$P-F1M23)0,#1+2&-T>3=W<F8X<D%V
M0VMB4C9B9GE&,DMS<7=P>5%G23%(1F1V:&Q"*SAD428C>$$[8U!$2'58:6PS
M<4U8-6M8,&A#<G!6*WI&>6A!:%5G9494,C9I=FAG;V1Y,TQV6'(U+W="6F5.
M-4DY3'5E16-58G9Z1D=$>6]R*VYX0R8C>$$[36511%50=C@X945D>3A5=3E7
M;C@K86A%:5 X06]Y+VM$0U5N:$-V=RMM<D]O26)I875Q-U4V9$1V:#12,TDT
M<&0V;$(K670S3T5A4"8C>$$[5$Y184XR54(O4E-L1TMG3C$V9D98-D1J564U
M2FQ,=D1L+TU/.4U58FI48C5I-%IM4DEL67)X5DA)4&%T2#9E27!J564U94M8
M9750-28C>$$[9U@V>E)W='!E;T5V16MP9$E66D(V:$$T,4Y#5T9D>%1(:$AC
M=D9,=E5:4'I),4)):$PK:#E39%-+.%9G57-F:4,O0T\O=T1N-#1+2"8C>$$[
M8W1Y-W=R4V9M1&5+:79(<'0Y37)2:51K:U-&4E9M5&I513E#=3E/,BM';SEY
M.%5U.5%8.'EB.3!$4C969GE!>'1*>5=*94Y6<G1Y.28C>$$[-E5'0V@S3&-U
M.59M."]A>$<Y,7@P=35K:6=L94=+5E9Q<VYP,55S84EE2S@V0W4O8R]S;D1W
M:G58:6PS<&I:96%.4G59=%!N355L=B8C>$$[.6%U16AL9W5%-'5&644Y=W!Y
M331I<EI9-45Y;VQ6=F9+*VYE671':G-R;5-7,G5D4'5P1$9C5S=C2EEP:V-N
M:T-2*S)P1&9)9S5:2"8C>$$[36-C<DA53E=85%)Z46\R0T1Z2$U&:DYL9"\X
M04MU+TUK3VA03$IE-DIR0CEE3U)L<E!$3WA%8DUZ2T%(1$5#=F-F.$%%<VE5
M9DAH>"8C>$$[8W!28TM%=GEM45DW36]4*UE0-E=!+VYV<CET2"M9*VYV86A:
M2CE+=#1X8V=H5U5S6D=K-$AK1T(K13<Q1U@V0T)-0T0Q8CE63W!G.28C>$$[
M>511+VU(-4]E.6YU=%,X;C(Y-#!Z>'-V-W=2;%%Q='E(=W!X,UIH,C9F255V
M3VUN5D-D35!Z34-B35522BM:6&M+83<Y969Y3F)/:"8C>$$[6&5-4W%N>&-T
M:E99;')24&@O2$%.3FM!;U139%1J4$]+,D0X>F9+3G9Q3VU83G(U4F=G=#='
M4S1E83-$>'8V=VYJ36%";6%+=C=S8R8C>$$[978V.%1P6FM%1V9.4G%O06EO
M<G(W.#!V2W0Y2DUB<GEH8E-233AB,CAF3E4Y2V=I5C9E;D=G4$E216EO;T-E
M;$-W3$A3>DA+87DQ528C>$$[1'II=W9Z3G)&:G$R;U(S3FQ9<G X0U<X34@Q
M9$-P1EE50T8V<7%63%5Q9'-Y<U5$15548FI:6FE2<T-K6#5(.&\S6&UF5S0W
M3D%6="8C>$$[56\Y-4]".6E-2&8V5#!'43%'8F=(;75,2'A(>693<U5E;C9,
M<&-535-E;%HR<7!%:4E#84%K24YH=61Z.#@Q04)K9DYY>55H.# S;B8C>$$[
M;"M$5W)6.5)L=4E*-UI%;5-A1D]38U=D;%5-5D10,4)04V<K;DMP5F)D04=T
M:VE-+VQX=41282]Q65)Q.#1W-VMR+V5Y045N655#<R8C>$$[3SE2:V1U.6Y2
M-V=I:VPX=7=Z,G1W;71A;$M'6#9W<V)M5C!-8THY5C-D4T(Q5T)V-EED=3E'
M+V-%2W,O;$=35DQF.$%4*W!M9$MV-B8C>$$[;DM25'AI0D1G;F=+:F)T9S(W
M,"MR=4,K-G5F2V=H36IE64Y44DI'6GEW;&M"54]%:EIJ>4@R43-3;G942&)V
M44),=4--=&TX=%(S1B8C>$$[=48Q:E5(86%D+U-:;6,X-4%):TU:*T=P-3A"
M5'-E4G Q1TA:0C1U-$E!5"M466%F5G19,4LQ9U-74TEI1G!!<&MT,6ID+S)3
M854S."8C>$$[3W9B0G-Y.5AC151B>2M68G5X36M/<C-X:5IF5$YX5C%:,7-O
M2&MD:GE8:WDX6#<Y-E5W-TDY439)9#5F3%AR4WIN6&166F='.5=21"8C>$$[
M2E%"5F5T94MF<S<P-V5'1&)V5'8S0FQI*V,O3'I8>3)3,T1.8TY-8F-!4E,P
M16]:531L=4Y".%1G5C9:4&E$5#1:<3%+4'HW-6%K8R8C>$$[;W,W,7%O2#=Q
M4V@U1D%/9R]W0TQ2,7@T=VYW:3)F4%AL=U-V17,W=$I'<&1W23,R0W%Z3G51
M0E5C0T-02$AJ0RM'6%1E961#:$ML+R8C>$$[5SE&;#5F5T)%>%%%8S9Q,S=1
M8CDR,C%-94U,-%I84F5D9$%M-"MH2DI,>65.3F\S6"LY:V%*5#A96&)K:')4
M='9J>&AF1$MJ2BM94"8C>$$[;&50;%<T8VQ:4%-+*VLY86=G13=G8D1L:GAH
M9D-K=6TX+V5767)23'!R:'I(2U=73E)&24=*5E5D:%%Q2U575E1V:GAH9D-+
M*V)Z=B8C>$$[;T5-14US:VMG13A1;FI14D]82TTO<&EI9U9*-3=B9GA'4$=&
M.$UR1#4K.'1H<&QE85)$8G%';3524#A!0U-'8FHP,TY&4%1B2&I#*R8C>$$[
M15A$>C<U84YO;'E:,U9(9C!W1$<U25ED:E%%5G X6%AP:GAH9D-+,69Z0CAS
M3DDV0V518T5,.&I%.4-O579T=%@W27(P>#1W=FA35"8C>$$[5%-.93 W5FA-
M,6DW3W-"54]75FLK,'9)16-Q2&-946)9>6E2>E9,+T%0,W$P>B]M3FDO53)1
M>3AM>D(Y5$ER=E1P5W50<F1L4#E6=28C>$$[:4%*87)Z:FQ!-D-22W(P-TU#
M1#E'56E7,49Y5$AE=VMM<C)V-6@S551W,DYZ<'1K,C1J=F94;&QK54AQ5E)J
M>$@S;DI2;$5D4'0O628C>$$[9WAK978R9G1E5UA0+T]/1W8S5GA,8S-/=GAZ
M6$TW1C5P;FEC<WI(8VMN;FUW:#)I26EH2#=F,D]*3%$S+T8Y;C=64"]!2T9N
M,6(O<28C>$$[.7=F.&E7+S5R>5@X<68P9G0O67@O:R\K;#EN-UAF.$%1<RMR
M9CE8=40O:U,S+TYE4#AQ9C!F="]9=CA!2B\X05,K>CER=CA!;U=F5B8C>$$[
M=BMR,T(O>4IB+VUV2"M64#90,B]S6"M4+W=#;#EN-U9#.2\U>'HQ1WIT,FYM
M,75%271+;C!7-S=F>C12,FYF.% R+W-23%$P3V8R9B8C>$$[=%-V+T%*57$S
M+U8Y9R\U178O>E9K=C522&0Y=C='=CAM9G=(<&9K;E).0SAR85%,2T<T5U<T
M8S@W;34T:T8R4#,W1'1M2FMZ.%IS;"8C>$$[=D=%9U5!>4@Y3&%D+W8T9F-F
M-EI8>&AF1&PS2DIR8U5U;UAC8C(R=$=Y=&Q10F]5:DI*8TU4>C5B93(R4DUG
M97):1TI(4D%W-F9Q>28C>$$[26]K.'EI46=*>7)A>#!B:7@U03=D-'IX<CE/
M0R].3F8P5E0V<'%B5U5K13-M1EI:1S5$;3%Q;$-R249:0TMF6D\U>'9Z6&@O
M;W%C928C>$$[;F%M25I9-69-4WDX-"]4571B3%%F64)*2%)Q:%<K,5AR:F9M
M=$@K875J<TY25U)#9DUF2D%%5U--,C9K37%X0F%!;71+=E9S8C@Q;R8C>$$[
M+W=!,5EU;6%L=UI(.'EE<GA59E8R83)7<V)R36IH>"]-46EC9"LK*TXK83!F
M-7%R1EIA:W-A2R]M34UW;#5S,S%:4&E4:7=#14YY-B8C>$$[:S=N<C<T,S5R
M4B]M<51A9'%S:4=+6'I'1V=D:3 X671L6&U#=D5O5'925#-P-&Y'+TYA+V]O
M;4\R=E)A4U%Y*UE+>79):G)-='9'3R8C>$$[2TQ7<3!+<T1Y3DLQ*U='>#-O
M-%0O3E5H86%W16E!.'AJ,59D,VMN3G5'-4)U1D5#3E5$9%1V6&(V8T8K865(
M*VDV,W-B.4ER:&)N6"8C>$$[>&-T2W-A>&XP9E-+1D=6:7=-9DAC,% X9'1S
M8C@Q;R]Z5GAT=%5D:V,K64%G06E$>')!1%AJ1T9K+V5':F9%=TQ6.2]F1R].
M94@K:28C>$$[,TIB87!)>CAV35@W<&Y$0TU7-$AW.&Q01V\S-D$O9FAV>EAH
M+V]Q53ET<F$X,W0O34M-=T-R16HR-F]$4BM82C)#=G92:C!'0R].928C>$$[
M2"MI<5AL<&9Z;38Y3%AL9T4X-GE1;&)F94]%0B]W0C-7;W%F:4AX9&1S2DDW
M,454,T]U<F)66DQI4G)F>D=)8F0U1V1)1&%O=U9#=R8C>$$[;VQA8FA61DU3
M9DY22"MI<VUS.5IK4D8O>$M"=U9&,G150DI65S5S5%-T5UIH,'!3;4,O3F5(
M*VDR.6AQ4')U.%AM4&A%,&Y)4D<R4B8C>$$[<4IY<GA$3E@Y;C1C8C@Q;R]W
M03%2;3!V57)H6C%L,39.63=H6D),071S<DMX8T92>4I!-5579W)3=$YU;4XK
M86%0.$%.5G!,1%50428C>$$[5DE034EI:T%64W=T,4ML5G!T-EI(16)$<TXX
M8C@P568U<6Y.66$R,'AK:C@P1TU$;GA55S9J-U1.>'(O041C5EE!5GAV>E=V
M-DME=R8C>$$[>DLW85!B0S1.-6-X6$5*;6TT.%-X5E1Y8V=!06(T2GE&2GA2
M26QD23=Z5C5O*V]P2$E9-3=I3V$T3FY9,DYO>%-7-6U5,&-T25!I4B8C>$$[
M16-C448S2CA18W-W-&5,=3574V5J6'%D4G=#-DIS,$%/<%$K:U=0;')Z:F]C
M,#A6=F,V8D]S:C(Q>45M;&EN:6U3:%E&;%EC:CA13R8C>$$[-'<U1%!&2W)"
M6$)/1V%&:30Y4$U&-$(U-FDX,RM64$UL>F\X,G18<W%2,&MT-2]8;4A/2CDQ
M8C=86'-F9DYV<'I$2D<V1&A:94]";R8C>$$[:W!"+VEJ>DXO=T)893DO-E-*
M9BMA<W4X2TAC1W)X6CDU9"]I:GI.+S%D-S,O<$EL+W=#87-F0V@S0F9&;C-L
M,RM+4$TS+U8S=F8X028C>$$[<$EL+S5Q>#A+2&-&.%=F95=V.$%&2&UB+W$W
M,W8O4U),+WI6:C153S1,-',K.'4O>% U;"]W0W)T968Y2D5V+T%$5FHT54\T
M3#1S*R8C>$$[.'4O>% U;"\V=3$U+W="2D5V.$%Z5FHT54\T3#1S*SAV4R]Y
M;# O>FAD>DAZ1%!E6%4Y=F)(:F%7,# X;D-:;5!&,E!);&5+06YT,28C>$$[
M>D(Q2FAF04%",S=/5FE-=TQ*3#%,5CED.#-7.2]&1'!U;DQE5VIQ<&MU5VM3
M4&EX3&AL2VYF<VTT2&,U<E1$>6-Q3U$Q=55';FUF>B8C>$$[-#E&8E$Q:4IA
M;DUZ>'-!;T\W14-N56(P=V-0:WDT+S932UAZ1#5T3%%6,&]C2&LT5$XV<4%Q
M;DMN4&I4*U59.%!K:FHX,$I*-7(X."8C>$$[.&E)9$)R-F)32R]/9$9R>$%+
M1E!H,U9G=S,Y:4UE2'E4>"\P;%9033-N9WA3=$IO:7))<UIA3TU815I$3T=!
M-#AQ94(X365(>5)X+R8C>$$[,&UL.# K9$=M2T11>496,59M339!55!%<W=0
M2&5G63E01$AH.&PT+S934#!J6%!-9#%024PK=RMO=VAE551'4DI'2C5S=$-&
M2#AQ:"8C>$$[=F%T34EG3S5%<VA(27!P.6-U9C4O=T%"+U1*94='2&EY-S-F
M6$QN*V8X0B]42'=W=FEY-S-F6$QN*V8X0B]42'=W=FEY-S-F6$QN*R8C>$$[
M9CA"+U1(=W=V:7DW,V983&XK9CA"+U1(=W=V:7DW,V983&XK9CA"+U1(=W=V
M:7DW,V983&XK9CA"+U1(=W=V:7DW,V983&XK9CA"+R8C>$$[5$AW=W9I>3<S
M9EA,;BMF.$(O5$AW=W9I>3<S9EA,;BMF.$(O5$AW=W9I>3<S9EA,;BMF.$(O
M5$AW=W9I>3<S9EA,;BMF.$(O5$AW=R8C>$$[=FEY-S-F6$QN*V8X0B]42'=W
M=FEY-S-F6$QN*V8X0B]42'=W=FEY-S%'9E9R>4,T<VQ69U)08W!#-$E(,E="
M<E-N9F)+.&M103(T<"8C>$$[:VYD8F0K5V1+.'<V3W5N6"]Q4GI71G<O1U=&
M=44P56ES4W)Q84=N2D=$0V\W:DI2>E-X>7-D47AY865/5U!$3&]E;DU&:D9R
M3$PK6"8C>$$[+VUI1%)B8U0S,F<V=BLK5E-H95=#66M2<S-.44$T-F-V069J
M:VME4$1I3S!O+V$T55-D3&Q%0F-O5"MW<T$O3WIZ4G!Y+VUH<'-I=R8C>$$[
M<F5P;V%1:3AG2E5P27=L37!I3E$T-D=H<4UU,$]-;D=2>71U,4]10UE08VQH
M+TUZ>6-B>'!Z-5!T>6QW.'AV67I);C<Q2DIL:VI!228C>$$[:4A$,'=L3G5V
M9F),+W=!<D]V<EDO;6]F>E5G.#1E6G9,,G,R;&\R;F%21G!T.%-$96U*47%"
M63!#4F]L3V\S66LP1S-%1W!7=5A98R8C>$$[56]K,F)$5&UY>&M"46]S5GI)
M8V0R2W5X5FMF:U1Y:&,K6G1B:G1&0E=Z:DEE.&U!*WEG4%0U;DUF55HK06)C
M>3(T<V9%8E!*.4M2-B8C>$$[4EIX85A(<'-!83-T;VQ262]34$9G27E#2TXY
M2%A.4TI58F-S-W-C.#)R94A60G=I,4@V<5E)>DQ.<#="4T=5>D910GAQ5%%M
M=2\X028C>$$[3&Q5=6)D:C5D17-+3F,S0S-#4F$U2$Q$1$9$*SAB:4A6=C-"
M2DE$8VTO,UE2,'(T2$DO3FPX:TTP2$ME1&Y(-6=,8S5G6%9Y94DO=28C>$$[
M-FLP.%)Y5VY8<C=9+TY.*S5K=BM",4XQ2F-T<D=O;5-50E<O9D%#9T)',4)T
M,7)K*T)R.%1Y0W)D*U15=4QI3V(Y2S,X66HT9G4P;28C>$$[255L2T-V4W13
M1G!J=TE'5'E7>653=W=O3E@Q0E-9;&A,0V(T:7%I;E=L9F8W+TA(9U0T;FM&
M,7@U3FAN9W4T5S%+.45D,TLX,4))4"8C>$$[9TQH9U93<6XT85-(8DAG44UN
M:W%R-59#,D)S5C%#-E-%3W-K4E(K3$E6:DUF04XO=G5L1'@X8V5&95!E-E$Y
M>#5):6UA4G8P<G%#1R8C>$$[44)7-'IK03!61C95<'8V9C1N2&=336YK,"]K
M94HS9&TQ8E5E36=93D8V-31F2#1,5'0R1U!!=FEE461E95)O<G$T86,V='%%
M6EEK."8C>$$[1FXK14%S5TMG14=I-SE01$5W55I+-DYJ>4YB1S-71U158C)8
M:39V-G)Y0G!.:TM5-4U$,4)/4$%V:653-C(X;'<R.$9X1D9Q5C9V,28C>$$[
M;FU88U-!3GEE4DA,-T-N3#1/3F8U8V5"0GEE5%DX;5%H:51Q9"MA<W)533-:
M2S!1-V)R.%A1-#A#*THU2U(X:7<X6E%.6#%)97-!1R8C>$$[<E!8<'AR445D
M*T<K4$%N>%!)3C-8:W W:3=K;4]S6'EW4VML-V-39D-!54M&5C=!9EI05'1J
M=TM-;FLV8GE02$Q/2G8P=&9O5E5O:28C>$$[<DQ12T-X8F)B8G)G-$8X5'E8
M,VYK=4LU;&EK+U-M;U(K:7%Q9U-C:EI3>#8P<G9Y;V9B0UE)1U1Y8FXX;5)Z
M6$UK>#%3+U9:5TQ.0R8C>$$[2GIW,TE*04A98EDX0VI*-4Y7;FMU3S-7169P
M5R]K14DT9U!.549E3$Q1:6Q$.7(X0FIW2V-N:VY/;3)!<V)23%E44WIH2R]V
M6C(U=28C>$$[83<W=&MG2UEK,G1V+W=$97)44"M9,DPY5%I8;#5.;40V:R]V
M.4IE5V8V-5I80G,W-VE%855+2%-25DY1<W%(-U%(63=%9&IL26QT6"8C>$$[
M4GE41&5X<U5H,7)4+W=!>F(V1U<Q<SE3,#=4-#-Q;W4T;UI7;31K52M%3S=+
M<#DX:TI22%)":DDY9FLX,6LO-7AT,4M75C5P=&)75R8C>$$[859I.&MJ<7A:
M;4\U2DIZ3F@R9UEI9T$T.'1&16YC;&(O=T)#,#-V+T%&94DO=T1G1&MV-51L
M,T)J*U%J,VPS+T%%3%1E+SA!5C1J+R8C>$$[04]!3U X<'DW9W8U0U!E6&8Y
M0S S=CA!,65)+RM!3U X<'DW9W8U0U!E55!F+SA!3T\P.6QA=F-Z87=N<'!3
M=$DR4%AB=&A(855U-"8C>$$[26QO66IQ56TO=T-64%<S+T%&95(O=T%I2F8X
M06UN2F9Y:64T35!Y9G9E:RM3.4\X=F573DE7>6AM36MZ2&YC6$AO>4%U>"\R
M4%1-5R8C>$$[969I3FMT9W=Y06]"3V)V6&)5=TU,4V-,4%9E3%-24VQA8VAY
M<4%T9G,Q=U)Y4G9D5&EL,TI:<E=S-G5B9U!O.3-B<D)W;S!D>$1-5"8C>$$[
M>C-.4598<'-"5#4U07HW:7IJ:3=W:'!.8CAZ0S-223=M>DUW5#0U5VEN<7IN
M63!!44%5-FIB0G@K869#.&EO;EA03V19=CA!4TY0228C>$$[1'0V9SE'-4AW
M52M(.6LY*W502#5P.$ED>%9$<G9M>C!N26YS9E9.06EM2S4T9V-(<61L-C@K
M4#EM4$=J=V@S1E)G,2]Z:D5T3&U3>B8C>$$[;6(P.6UI:6U!.5%%:CEO3#%Q
M1# W63AA9D-(8U979E<O3FAK-5%85FM%16<K1F]B:6AJ24YF,DLX9V%5,TAF
M2&HX,&5%3S1Q<38Q-28C>$$[;$]P<3!L,5IJ5#%D<7%K3GAZ84]V=S%Q;7I5
M.$142&HX,3A,8FM7-UA89DU2=4EF<F,Y;71T4B]8355.>5I#8594:GE(14=U
M>"LO,B8C>$$[=SAF;7!X95)1.&UR*V%'35)I=DDP54MG;$1X:VMS1#AD2U%E
M2"LP3VU$:C@P*T8U3W9.9C@S=&-31WEK<UDW8U-/27A.1F-&:D='8R8C>$$[
M251X6'%6-&YR:5IQ35$W:7%X-C4U;T%N-3-&:7I(,'I"*S5U84ME4RMO1#A.
M4T]02VYV:G@K85!#.&EP4S8Q-78Y4D1(9%=0144X=R8C>$$[66)J8U9)1S-(
M<G@S-FIF2&HX,"M%3S1Q-F$W-6E$<5AN=$-P=#(Y465L4'1C8W!/4$@T4',P
M.5!R-S0X85!#.&EQ84YR975,8TE.5R8C>$$[=4Q:-V5J*V]967!U4E!W*VYX
M<6\Y-C=94E!V2WEX9'=+969P-U,O.2MT+WE,:R\U<'E81T=V=W!D>G8P.7!F
M*R]7+S5&>68X,#0X628C>$$[6'=P9'IV,#EP9CA!=C%V*U)C;B]!1%1J>&AF
M0VPS3R]4,FPO-SEB+T%*1GEF.# T.%E8=W!D>G8P.7!F*R]7+S5&>68X,#0X
M65AW<"8C>$$[9'IV,#EP9BLO5R\U1GEF.# T.%E8=W!D>G8P.7!F.$%V,78K
M4F-N+T%$5&IX:&9#;#-+5#9J85AL.7!S5G-Z4T],=4YY4%1C555"<28C>$$[
M:VMQ0FQE4U%)8F--0T1U<F5B4$Y"<V]O<%1B>EAI6%9Y8DQ4=$]G:TU*;FQ5
M;$AE5U%6251L.$MR,%!5,7(X3G5(1'AD86]75#-.5R8C>$$[<#%004%A=7I1
M2&564%$W5'EP-3(P0U=:.4I';GI*3$IB6$M256EL:6U506YJ3$=%-6)/1'50
M;WAY;65+5EAA-F%C33!,03149$AY3"8C>$$[-2LO34A2.64X<&5:6CE+9E5B
M:5=%05,R<S-Q4T1N12]4=C%(435T.5!/3U-.,$A$>D-C2E9:63,K;618+W=#
M5S8T+S5'=CA!,7I)-"8C>$$[23EZ5C1K=3AU+U1/<B\X04QD8V8X:E@O04LT
M.$5E-69%;#-L,S9:,68O;'5U4#A!:V$O.6-E0U!C=FE3-WDW.4UA=B]!370Q
M>"]Y3B8C>$$[9BMU4$)(=5AX2F0U9"MM3E@O-6)R:B]K82\X05A"=U(W;#A3
M6&589G!J5B\K5S8T+W=#4G(O,7@T23EY*TI,=DPQ4#AM.4LQ5F)S928C>$$[
M84Y5=356<TQA<3)Y>G4U4C)C1D]:-4=L0GDV-7)T6$E34$)%93EY.$5P4DA%
M4SEI=B]/96YA9D])3#(U=#=A57 V9U=4-&9G<E1L=28C>$$[96UA-#0T:'EX
M;&UE4554-2]W0D5!471F5WE#4VY!=5-T86EO*S!2,7=C164Y9D5N,TY(.'=D
M0D1&9C!J6FQG=DQI2$)*2'-!9"]O>"8C>$$[-$DY-BM*4'56<&9/,FQ22D\X
M;#5A<4Q9,&XK2591:SAA159R,3)W*TA(=EAX6CEY>"]096EO=U=3+W1%9&Q$
M:$=C2S-&:SE25%%M=28C>$$[-C<T3T-0979I5#=N4V5E=$A25EDS='%1+TUR
M>&)L55(X=68R4V9S.$=R.'-E0U!E=FE4-VY,-3<P6FM$<F97<%1913AU:%I3
M>3AT.28C>$$[<7%.<30X164Y9D5N,TYJ>GIP0E0Q0F4R=D1N-F90:TMC<59P
M5W9H,W@T23DV*TQ0=6%B>C-O-G%#,3=A9TUA1&8U2'@V9D5.+V9(9R8C>$$[
M:C-R-&LK-71V4%=I;T9:=%%S,41%:%-:1D930T%F,G9&:#DK4$)(=EAX6CEY
M,&5F=$1,1E)Q1FY507,S>&EG07%D>E=L84M45#)0:"8C>$$[:G=2-S$X4V9C
M=F9Z>'!#349A.7115'AP.%%P.&%H,3-R,U9G9G!(:FIW4C<Q.%=F8S%,-3<P
M5TM6-'!D47,P;&E*5U)':U5&4W T<R8C>$$[1%9T<4A(9VHS<C1S*S5(=V$R
M,#A-8SA":6MH;%502$EU-G-R0V])25!1:DIE14=*>GE8+T%+5G50-44K-"\Q
M>#A)3#0X;F9P5S0O:R8C>$$[5#=J+T%&>#A)3#0X;F9P5S0O:U0W:B]82'=G
M=FIY9"ML8FHK4E!U4#EC9D-#*U!*,S96=5 U12LT+S%X.$E,-#AN9G!7-"]K
M5#=J+R8C>$$[049X.$E,-#AN9G!7-"]K5#=J+UA(=V=V:GE5<'1D;FAN=$5-
M4TU,:61)5%-O235!-SDO1$E49T%'>DAL36I3:% U93!F>D)P1#96<28C>$$[
M:U)C,DYW-'%P2U-)=UES:G%2,#5X<T0Y3U1'5U5*8U5E<D-E0T=74$1)8VEX
M>4=+-SAI95IR8E1.2W1B=2LX=F%O03AK0V\P<'0U828C>$$[:$=D2$A8<U=5
M.7-Y0U)M9UI3244T+V$T55%D3FM%64%Y>'DK4$-F>'IE869N:#5Q='!0>DES
M>EIC6FTP4TM/3V,O0S9'5#%$27E%128C>$$[34YG84=O>DDP1TTX0D(V=&UQ
M>59-161%1D8K6G9K>&\U4F9E4S=E-V4T9C%*,SE94FML4DE%<'AJ,F]*0B]M
M1G!C9$Q0<$]K9FUO2"8C>$$[;D8Q<"M:4&MI,5I'5'E:05-*;6QC97%T1T%N
M.5-%9C-7,W!*.%!V,S(R>$]M>4@K3E)Q640K1D1A>#4O.')A<&\X.74O;"M/
M,W99,28C>$$[;4YL2V]J97-K+T9+=7=61T%I5&MY:F5R8V9$1$14>FI+*TQ:
M13E20U$U8G90.'I80V1I<DIV25AK*S0X>F$S2&(P2S)C4D0S8W1.9R8C>$$[
M9U!4-6Y-6%4U*T%54'%,9&AX,W5E5#9087AJ<SE+:G1,1S%35DE"1VM6<S%!
M<$-S3W!.96<S<FUR:'HS3&Q&2R]-<U=P4&-Q8F91-R8C>$$[8E9O9E0S95IK
M5C%B-'9H2$E(86QE;C@R5GDY>EI#=2MK='998C%B:&M4>6AB>D-)>4QA>6,T
M*TI736YG9G-F0E=G22LT6D4K-6M++R8C>$$[;DQ*-U<W:5):;#AO5WIS5UE0
M1W!J3$MO5TYG9&@X6'AS-#)(8D@T2D(O<$MS:6%S-&5/5'EJ8G5K+T]76G95
M:4DU9SAH>490:4I+.28C>$$[=F)(9G52=#-R>%DS:G4U;CAR,FIY3D9%95EA
M34%N9VE.1V1I9C-A=31(63 R=S$U3%DW,7-C3W!!46ME5F):9E5:-%I51%)R
M-F-5;B8C>$$[14UE44)Q0TAC14%9+T)B2&5P3D1R4$-61SAP5VY!37I!:#1Q
M4#9A<W-8=VEV16M5.&%93BLU3FIV5F)E,79)-452+TLX0U)85D)+<28C>$$[
M<VI,1WET27$Q041,44DU,V]/<"M72#1)2DAE<'<R,G%K0C502TYO2FQ73&EF
M56E(,FI1.5%A96U+2#-P=#)W8CEY4U(S;V%'>C%H3"8C>$$[54M02G1Q5R]E
M4SA(=45E:W(P3D9$:EI35D=W3D%.<V%08W1J*V-I3%=06$IB2U)P9DML<$1)
M-T]*;VDV15!64GA.05!I2EE!1W V628C>$$[-SEY;74Y=31'='101U8X;U=S
M:%5Q=VMK;&EQ=$EK555*6%ER.6UV=#EZ=C-,="]/6&DP=DHU2E=U4$M.<7%Y
M;5HU2W9%-T\Q3U$U8B8C>$$[1"LX6E8X8TYE4TQ(96DT.5<X>G<R,$M79FPQ
M5F=11D9G.5I5-'%Q07)3;T9">7%+15DR935(1$AV5C=J5W9.158X.$LV1C9T
M<4A+>"8C>$$[5')/=%=535%'2S K1W%I=34Y<TYN=5%)>')M<VDQ9GIK-W%J
M-DQ(1G9V2C8V<U!S03E0:"]A3D]U3FYU5'=X-S!1,2\U;F%+,VQ3=R8C>$$[
M:FHU9VUE26M/-FMC3TY0:FI'+TIV;%0V36)+2VHS;V(Y3"MC,6II639.2$MX
M4W-Q:552,&(Q5U=G<5@V4C!B1WHS2C19.38K,#$S>B8C>$$[3$IQ0S(Q>F]:
M9VA:;W=:>$U(54)X5GI65G X4$4O:#!R:4-E-4)J1W5B27-K,75X5D(S+T%0
M=E9P;B]-8D8K<'-R>3AM-T(Y4V9A<"8C>$$[;SAL>DET,5I85#).*VDX5FY1
M0FQ:97EY4FXT6$$W5C9D<W!%<6-O>'9D:2MT84@K86UO2DIA5RMV,DYH8G5#
M<&YG9V-80E4K0DI)428C>$$[+TQ*0UE(4FE913E3."\X02MH87)S:W,R<W$W
M<U-Z=7EK:VLW:VMK6FU2-U%L155!1VE7:6EE<&(O=T-H87)N+T%+=D-F.$-F
M-EI,*R8C>$$[534Y=UDO:UED-60O,$Q68R]W1%8T5"]G5"]42"M5-3EW6#AJ
M1'9,=BMH87)N+W$X2B]W2B]P:B]!0VY0=4,O:UED-55B<B]N2$<U9R8C>$$[
M:$UV-E9%;$MF0VMB360O64%N161P5#=G9S9'4%,O<U%0+TMH8FXO;'5K+S92
M-78K84UL+TM-=DPW5T@U265F,E!2+TIV;&4P.',V4R8C>$$[=&Q"1DY*2U1Y
M;FXY0U5&;5 K>#9::E-Z0U)S;F1S.$=11D%B2GID>$,V9V%&:W551$94>6II
M;%9H>%E.<V5/,U1'3UE!,G!W>3=K<28C>$$[,79Y,T9Q<S=Z3DYF5WI016M*
M3455:4AI:FPO=&-#,B],8U9P,'ES>6EE<D]-2D1O:%@X;WI03D=7,5!65$)'
M1%=-3$U'6FI)-VMS=R8C>$$[54-L2'!4:C)'3FIV5'=Y-VQ+8GE-<W-3;V14
M,6UQ<S<X<7I%;FY462]",%AT5$)C93E.4S=G:6\O2VEX>G!-=#=Q;DI6;%9T
M<&9I.28C>$$[554U365'-THK>6-01DAV4G=Y-VQ',SAL<$))-VI53E=B;$,X
M4$4K<T9!9%=7;T%18G)Y<79H:F-E.51'6&-'-5!+3GA*8WE3='%U<28C>$$[
M*VTU3DEW<V]O2T%+2SAA8F(Y=2\S:7@S<G=Y-VPY=#52:6AT,W1Z96%P3$4X
M;G%T-FYR36$X5T)&4VYF;%@U-&)J,W)W>C=M>C54528C>$$[>FEB-CEQ=DI:
M4DMQ+W9A8D1D86-/:'AU4&5V1$QU0S@K5T,Q*SDT8B]687-(06A(<D--8S%D
M4E)1;C=03V\Y.&5+4&5J9VQ824EE5"8C>$$[>5E#25)&<4=Q4F5K=D9Y<7DO
M2%=2-4-Z9D(Y<CDT45!$8D)C93E01$QU8R]K=$=$<BMK9%A%8F]S9G O=F5)
M;V%L9U!4-CEF=GAU4"8C>$$[979$3'5$2E5B9V]665IG<6=!1#!:96<O,D]4
M.%-,6#1-=35V,40O=FUF.$$U17DO.# T*TI&9D)L,T\Y42\W-6XO-45Y+SA!
M3D]0:28C>$$[4EAW6F1Z=E50*RM:+W=$:U1,+WI4:C1K5CA'6&,W,40O=FUF
M+VM43"]W03 T*TI&9D)L,T\Y42\W-6XO04]2378O3D]0:5)8=UID>B8C>$$[
M=E50*RM:+RM2378O0414:C1K5CA'6&,W,40O=FUF.$$U17DO.# T*TI&9D)L
M,T\Y42\W-6XO-45Y+SA!3D]0:5)8=UID>G954"LK6B8C>$$[+W=$:U1,+WI4
M:C1K5CA'6&-O5%$S1GAD-F5);TI4-F0Q2$I)5VID04951W!Q=T%Y1U-926)-
M5TUG-V]F>F8U:FMT23=E45<S,30S="8C>$$[,&),5&10850P;UAD1S1T3$\S
M4FAZ1D95+T149C5864U6,W960WEF,4Y/<3%"9T)T>&-2;T1L.#%U9U=F;&)Z
M=C5C;4]O84AB45!(328C>$$[.7!C>$EQ2&I*1E$Q:FQ103 K24AB.&-C<&YH
M;G1).38V855-.$Q-84E.2#1E8G=B>E0K5S%Z<%@U:'<K5F]*85$V:$Q'3E!U
M6F%K928C>$$[;D\S1F560G9W3E%A6G1-3W%%<UIK96II>C Y5#1E.4582#5+
M*V(T-49%8E<X:U5G4F]P0WIO5#9K:7A+:DEY.&MF;316;% R92M),28C>$$[
M<T=2,%5V2D=39FM0-6]T,61R=39T;V5(<$Q1178X8VY+;S)(4F506&]A*TE)
M>4DQ.$1Y1$PX:DQQ56YV4'EP.'DR*W%4-F5S;'1,2B8C>$$[0VQZ2W)I47%(
M:71'5DI(54]!86,S-&9-3C)5;DQ)-G5*1C<Y4'192%-3=71K:CAZ*U=.5#AT
M-FUD3C%,,"]R25AN*S9B;71/4EAR428C>$$[9#%/6%ES;VU,1%1L>$=";W!2
M;&I7-T98<T@U32M54'%,3#5V,5-K2U(W860V;7<K4#1$2V$Y3W1".2MA,U8U
M94TX06-Z0DAG.5A6-B8C>$$[+V4K8W)+>'5H8EAL-49B>D9&:T%K2$9E3$U5
M6#1J.$\W03=6>E='15$U9WE42S!E94Y-6FE&,4-":49,,4)"0D%6;DY#3FI2
M63)/,R8C>$$[:&IW4EAX2G12965D2VQR-E=P5WIK2S=K0FQ*-'AG<S5P,2M%
M03%X-$ER-&LQ<2MF9$AC=48Q3S)*:4E%;$=8-&%G<TLO44-C94=+."8C>$$[
M8S%2=D\R;4EW5G13=&Q::U=5075L9E1B-TQD96AX-$ER-&LR:S@X-E<W27%A
M:F)L-48U;W9*86QE4%!P+W$W-#A%5CA38F-8;F942B8C>$$[4T%M;S(U63AG
M1DQ+1%=-8VY&1"]!0VIR-%DX158X4V)59FYF4S5:5FAJ,4LR859Y07-99$-X
M2C951F-E0TLK2DY:1C4Y,&E:-#0T="8C>$$[4W0R:VQD66\P0DA*;F8W2V=D
M82]Q>#1)<GAZ5D<X-V%9:WAH9E5B9$IL9&]J1WI+<F,Q3D-T1'8Q1U!"1F9%
M;71J.#EA5$I+26LQ2R8C>$$[,DUR4T=&535Q1TUI:T%R43EW5T=00D9F16TR
M4%!';&QM56%J8D9K:T5,04UU,&A.3T]00D9F16TP+VYR4U5K94XY5'1L6D%#
M.5A1028C>$$[8VA58C%P,$YC94-+*TI.<5AZ,W!-24Q3-FIB<79%34A*2$9G
M854T=#!B<4]M4$)&94]B<%!0=6IX;'<K<#)Y=$=81&]754U$1V%-3R8C>$$[
M4%A9-#A%5C0U=4AN,U(R24,V<&%S4U%!<75R2#1J>$=W4&E-94-+.&,Q<2MF
M.49E-&$R6%9,67IO,T)K-7)8:TLO1#@Y:FIW>%AJ;28C>$$[=E!N;E1&:T52
M=C11-598;V%$-%A(244K1S(K4$)&9D5M-79096MR1SAH,4LS.4]09TI(-4QX
M0F9K5G%F.6<S,UDX158X4V)2.#DV428C>$$[1S1N53=92&%L5U5!,5!%54HR
M3RLR,E!"1F5/8F%E961,93E7>%158F0W=&IX14MS<D=T4TMB9$1557!J=U)8
M>$HX,&1,<G0Q1%!A228C>$$[>6@Q=4HP9U!A;DU(9CA-131!0FQI>4=2;W)*
M3D,P8EA.3&PP8E9O0D],3UIU55I*5FQ*3$=+4E-P0DA*1S=E-#=(0TUK;U,T
M;SE55"8C>$$[=U%Y>#1*:399>CE2,5!Y6#5R=#=8>2]96$XS-60Q2E$Q,5IQ
M1VM30U%%25AJ:TI99S!O4T=/+S9S;FE'84)->4)-9F$T47AY,"M51"8C>$$[
M1T-C8W59-VYM4#4P*UI.2#%0.$%-<3%H87,Q:G!+4C(Q,TI'-5%L:35E44MW
M1$5&3UA96FLV2$A)45!M>C%--&U9=FMG:S!N.'%,=28C>$$[-FI,95ER;E19
M1SEC>6]%;&UO>51*-DQC:6QF:E)M2CDQ<G0P>3-J>D%F4T-P:FE**W%L4T1Y
M;BM85C-A5SAS6&UY5EHW;%95>'E!1"8C>$$[,'!3<%IG+TU2+T)'1%5T,S9,
M=61K-6-O4#!Q35=-:C9I=TA58C97935)5S1M;71O03!.;5IM2EIB9FMX5F9B
M-U)*03=K-6QX:E$U3R8C>$$[2$]:2C5O4FY::E9I5U!I5%A*<T-B87A6;"\U
M8F536F9-,G1+6FQ),'4Q264W9G!Y,S)J2'4S-G-X9%9N-$)1-6QU=S0W,U!*
M.4E*828C>$$[5WDR-E=W:5@V=D=&5DEQ1&E!;$]/,U1A;6%O1VY+4U!Z1%E8
M='IE>"MJ1G W27EO3V0T=DM4-$1)>' T<75X02ME46M'>4)!2%9*-R8C>$$[
M9E%F34U&=5%,5%)F5C5/2VE-9T)34V="04%"2E%U=BM:>4Y(>5IM43@Q>#!F
M6&Q73#9L839)6D1(24QP,E%K+W9&25960V=F1#9B1"8C>$$[;#1G+U1J4CAL
M-&@U<6PU;RMQ0RLU861B-E1B5W1W>71D3$EG36IR>%%C5W!65%9Y9G9'2D-"
M259V835D2#%&-U9L;G-T2F)55D%7428C>$$[<6<Y35)C5T5A04@T<6@Q53<W
M9F1H<&5)96%H1#5E,7$P9&XK<F%.=U1E249'0EAL=7<U2&5L6&9R9S14-4HT
M9V4Y55A1=DY405-I,B8C>$$[,&-Y=%%/5$5X5VA1<DIX;T-A:V=,,396>&\K
M4T]+4&UP,C-L=GI*16AE4%0Y2&EL64TV:&\S67%X,T%*<68R:65H;T)J=VQ*
M;4\X="8C>$$[;GEV-6=517A796IX>59K9$I%:%E&6&]05$E066<X="\V63A*
M6&I(;7$V:C56,64W4UEF5G1.16HS6')2>D=.*UE10GE'6FQ+,69K4B8C>$$[
M6'0Q<415,4II54-92&4P3D(X>#)P5F]B1%-P9VAA85%E;GAE4V)I0T-U>7%P
M6C8W-#A*6&E(;7,Q2'ER<F,P,3!9<DA2,FIN1$%-."8C>$$[56EY16Q.>5=5
M,3-D;5!T-#<W07A+:5DX,C=N45!.52]Q3SEN;W-K:VQ7:TQW=6540W%P6'(P
M5&IJ=VYY55-J-6]H9$$Q;50Q27(R>28C>$$[,#)A2#!M5S-#4C!%8VEO;VA.
M1T(K0E1Y0CEQ665%<GA$<&%';3AS-B]*>DPR3VM34T]'<35I22M.-D9N,T)R
M53$V-$]%<#1X-75T+R8C>$$[3&5V=% V13%N<'-%9D-.;799655.5U9Q;&5$
M8C=F-F\W54E/4$-6-'@U<6M8;&I7230U;BMP-EA*8W-694IN:4%P3#9G-7-X
M4D9Q0R8C>$$[:%!(=4M$<F@T4VIJ2&TT*U=.9&LU3SA7;5)Z2V5+37-)6E=J
M5D]#:'53<S-4<4LT.$I8:DAM,&YL;EAF<3DR2DQ84S5*6C59,U)':28C>$$[
M*T1I<7E"<3A653%"8V-383DO2$AH2SA9.#%1*U@Y849X1R\Q1%-M9U8V>4M)
M:C9H551H+V=9,$%00W1+.3AE17)X:G9+<$AO1W-R<B8C>$$[279"6393:U)U
M0S!K:7=T.5EA2#%59%-7+W="*V17<G5++V9J4G1(14LV<"]F+S<Q85HO>D=X
M9G%B0FPU2G=F57E3*S!U0S5K4S1%:B8C>$$[,C$S14M*9%%K2S18<GAA;TMS
M=BM3=TEY:U-)8W%5460K<D9T5S!Z54Y5:6YS>C5Z149S,59D8F1B6DIG3S9M
M46)J=TY!37-"23,T9B8C>$$[=EEC24\S1CEZ0W8K5D%E4V%K;EAP0U-A:VU3
M26MK.5-C>5)R8V]&0699,4A367DW+VQ12&MN+W$O4#A!.$A&:W9Z,F)U*WA(
M-5!'-R8C>$$[+VQ12&MN+W$O4#A!.$A&:BME>F0S,DPK5'AU+S550C5*+S9V
M>B\X04)X62]N<S-D.6DO:SAA:&4O:U0U3'0W9'!6,6U75FA3:4DP5"8C>$$[
M2&8R1TDQ,E@X0D5T2D-T=G93<B]!2E9"-54O-6)R>B]!249-;BME>69G3F8U
M460S,G,X.'-W840U93!Q4%1R1DIF5%%L;F1L2$HR4"8C>$$[5FUP;5!,25I'
M>F)0=U-.9VTX97,R,&IH230U6&1V<W%Q5DHK9TA).&$K1$I!878U9C!R5C4O
M6'8Y3'4U6E!4.4MV0U)2=T)9,&]#0B8C>$$[*S)C9UI23$]-2FIK:$@X:RM7
M;E-25&]T,2LY;&%A46A:9U,W14=P,S=5,CA.+T4T3&EN:'E,<G)Y9&]6>DPV
M<VUL,V=K-'!'6%9:428C>$$[945A;VY(<C!:26=R94EX36]Q27IB6'EF-697
M1U=%85)D*VY/:7AZ1&I..%-R24I2=E@K6E)H-&]R=S5&:653=DQ38W5/:3-0
M>$=-;28C>$$[<51(94MN2'%F.&Y"8U8T8VIP9DI0;&U7-&MN9E)B;WE3=5I(
M4$=A:%EK:S=C='9T2%E9,T9E2$EN3FA"2%E7,S%A,7-,=$EE5'9X328C>$$[
M8G0X56I&,DY46'%Z2$I$2D5-5&EK55(Y6FTO-5ER<B]!2D5T:#A123A#5'9R
M33,O04-X6%@O26QS9D5#*T)*,S%M8B]!2EER<B]K4R8C>$$[,E!I0F9!:S<V
M>DXO>7A86"]);'-F14,K0DHS,6UB+VQI=78K4DQ9*TE&.$-4=G)-,R],1F1F
M.$%);'-F14,K0DHS,6UB+VQI=78X028C>$$[:U,R4&E"9D%K-S9Z3B]Y>%A8
M+TEL<V9%0RM"2C,Q;6(O;&EU=BM23%DK248X0U1V<DTS+T%#>%A8+TEL<V9%
M0RM"2C,Q;6(O04I9<B8C>$$[<B]K4S)0:4)F06LW-GI.+WEX6%@O26QS9D5#
M*T)*,S%M8B]L:75V*U),62M)1CA#5'9R33,O3$9D9CA!26QS9D5#*T)*4VM3
M-W5R>B8C>$$[5#%J=$QH4DAD4GE333A:5E%Q9S%*2BME46Y-14YM3$=9;7EH
M9D]F;5-A>70W934K<E)86G9R<S)E;E=T>7=3,5AG4W)45#%O1TQ-4"8C>$$[
M:'%A0F%(63%R9F=X8U))=7%&;G9C8E8V9W=!3EAX4V]8>3DU4E!L;34P;GIZ
M-6%L8E8Y2W1Y67!:3%-E24)8:G%G0C523TYW2U Q0B8C>$$[>4]A37--+U-F
M3FYP8V\Q1T\U4C5'=C=#*V0O>DPX:TXU5C@R4V%88D(U8E<T5EIR06M66FMC
M:V-D=7!6:%1.=G!D4C1K3%!.=W,R128C>$$[=VQ4135)-4DS36-I;$A5,%I'
M0D)".7=C>6=79VEL4G)/-U9#-U%30D%O8W-664%+,S)45VY1.7-(14=8064U
M8D1B,T4S3#!9;FLT1"8C>$$[:R]"4S%"-&UM2DE#0D5N:S9E,G5,9'=K.%1W
M=5)53$EP53 V5F]C45%E4VU*2$Y9>7-J1DA"5FQ*1$M246=J<4--2T=S5F5X
M+VLQ-28C>$$[44]N1F9.=7 P9T-#;&@V;$%!2E!G36AR,')Y;TTQ;7%Y.%HT
M0GEC>D1(9S,V=EAR<GI:8E=K-U%83C=(1DUS9G)'3G%"=E0K3#1G2R8C>$$[
M8B]94#-:<FI#3&QJ2DUO6B]0.$%P0U$K="MK;VUJ<GA,24]D0T9$,%E+0U8R
M4&9"=WA4>'IA8GHO<$MX*V\Q*V=8:GI&56%R3'E#5B8C>$$[5F5.5TA.=4\S
M96\W2$AH:79(3F9"-3<P>31#;4,O4U506&E557-.:'DS25AB8G!8<FIW>%AJ
M;3 S;C-2,4-L.55T-'<T5FAZ2W X328C>$$[:6AL2C55<%5(=FIW>%AJ;7%*
M-3(P>#18;5A5-V-X4CA$22]*049%:&]H2CA'-UEE0TM/3V%W*V4Y24A/=7$R
M=SE0:'HK2DYJ2G5G*R8C>$$[6CA-2$1&4$A.5U!M*WI(<$@V.49X;EAN17=+
M;%=55C-$9% R5&@T26\X4V%J3#4V,&U'<&LQ4S-507-P4$I+06]1<D%K9$M%
M-$]'2R8C>$$[94]A-69/,FU-<W),<61U5F@S;&)M;$9"2W)7=FAY9%)8>$](
M9VEJ:FUP+S0O=T)%-6-F,'1B8W5Y.#!Q83EW3S0Y>&<T67 T.&IC,R8C>$$[
M;GI3;VHX96]X154U1FQ(3F%C*T@R;$)(,G8V.4UE1TLX8S)P9E R;'=Q1$QF
M<6Y,:G-9,C5$;GDT:W)X<4%E0C-/4$1&94]B63@Y-B8C>$$[65DR;$8X:E)O
M:&M:,5%L47$W2&-,,4AH,7@T67)X>E@O=T-.=$XK<W)A:E5O1$]Z8T%I;%0X
M44Y/2DDR0G(R3TAH:6IJ;71K.#@V8B8C>$$[2$EQ1R]J3$]N<7!W575#9UEO
M5T)516)-:E8X2T4Y0F<T67 T-7%N*TTY4#1)-3%'04-24%9J<7EG;$)Y*TE!
M-S K02]D:#1);SA38B8C>$$[4C@V-F-0.$%P67=%:551559L62MQ,4M*459.
M5%59.$56-#5R6E!03VU2>%%Z4S9H1DA&4'HY1C5+24=%6#)Z.%%'=W=C354X
M8S$P;B8C>$$[;F)423)+=G%D<W)#;%%84W9X25A8-S%&4F@T26\T-7%L:#5S
M=&(Y=4YL9E)81#A22551<5=#;F]3=E5D92M):$5Q8VMX>E)%;758528C>$$[
M13EO:D%33&-4<$%2<TMC=V0Y:#=:1V-!07IX6D-44EA,<%=L87)95#9.<3%S
M;'=,5UIQ=WED94I9=$1+<$)"*TI$,4AF:TUE3U54>"8C>$$[4DMN2$=C5$=1
M=&IC=6QA=C55.#%7;SAS-F),4&]/;TM0,&AA2S%9;S5&25@Q14Q'<4YX;U18
M6G8Q6D%N2$Q!.%HY435/1V-5.$]5928C>$$[1D@Y,TQM3V<X,VQF-71E9EE:
M4'I0<W11,&XP<FME6&A%<5-%;&\U2FMK36I+849A9T4P,D]:96IW6&I)4%9/
M;WI6345D175L+T]R>B8C>$$[0DU#,#)N861,8TUR:5,V849J2WI0-EI::3-,
M+T%)<7!4<%$P-D%:8TY&1613=R]/>3=G:4PW.#EV358V:GA485I996DT:%%W
M0DIF5"8C>$$[.4]'45-C3T)K<%)V<VXR=U(P15(Q2U1R4V5G46M(-7DK65E,
M>5<Y:7-R2T<V;7-$<#=Y=U)T0V0R3"MT*S=:85-C;3=B93)33VEI4B8C>$$[
M5FYN84)R2F1W8G8O04TU=DU&+TA+=#%95TUS:W939#0S859"-D%H<$A)6#5+
M2VIM86135#)*1TUD1D5C:59/<VME9UEB<FUR5#9X<B8C>$$[1C=Q<S9,2%!F
M5%!026EC=4EA4G520SAI>'!V='9M5&IH=WA!2%)X<VLK2U),2E!Y,#AK4V5:
M3EI6-3!),'DQ264U8G-X0C)19E!-8B8C>$$[5EHK16-)-6QS=S0W,U!*.4=R
M83)Y,C97=VE8,$5#<6M204MG2E1J=#=5>E=$6GE3>&YZ33-$5C!9>397:79$
M1W),9D%E<7E"<$)*428C>$$[:C1Q56%I-SDR>7583G1H>39P4$9E:4M#6697
M=$-8,30Q649+065P27-9;%!C55I1.40T-4<O8WIR,W%#>GEX>7A7>7EE6%=K
M,D%1<28C>$$[9#-"9FAX*UA*2S V9&4K4'E46'9236AV;W9Q,%-,;V%Z<U!3
M045-;$)/-T5%3'@R2V-$=69N:CAK9DY:0C8Y,TU&5U111UE44GA1:"8C>$$[
M5E!08C19.6IU5#A0=VHX8V9K=DQV4C!U:F5:-VUY-"]O,U1)6G!A1S134TY7
M4FU2,C0Q-&QY4G@T;&0O=7<P56-593AQ6CAQ*UEY-28C>$$[:V$P,&1P6%)L
M95%23E4Q84YG4TMC5'5L9#$O:FIW;&5-96%:,BMI-GEL=W!K=$Y/14M80T]N
M1EAQ<UA/45!X<G1Y.4UP5&]+,4]':28C>$$[>$UH-6]"4$HK<DY,16)U1%1R
M:T9L:W5M35%J-4AL>F-$9VQA:SAG4V1I2V)6<F<T4WDX465A;U!,,VU&66)G
M2EDV46MK<&Q)2WA.>"8C>$$[66,P85!K4$@Y,E!P03A":#13:FI(;79K.'9A
M,&LQ=SA&;G!G4FUH15-P2'@K0E%X9&IY5G1W95!$-F$K0F5%<GAJ>E5)+TQ(
M;4=',R8C>$$[149R0EE,131R2W,V;#(Y451-.6$P66-#<F),,CA"9S13;FI(
M;3%,-68X>5(R>&Q85&1);&U25W!#:U!X3GE+9VIK+T56;W8X,4YS928C>$$[
M17)X>#=Y<5AE9V5::4A&<F%A4W%T-FMA.#1J55)&,4M$655Q0EA#66Q!;5!.
M<%!,+VUK4RMU8E12:$]+=C9Y47-(36IT5GI59S!Q028C>$$[365%<GAX.#%3
M5%%F35)A84)B4%-M<T=,<D1#,%IQ27A5>')10VQ/5'-31#1N>'AO<GA$>E=N
M45!-<DUH93 P;5)656=P-E1+04=P>28C>$$[5DM#;RLR.6$Y-F4K4$-6-'@U
M=#(R:&5:>&-H-3=84U%I>D-D94UB9D,V0F5,1%E(;#A06#9F1$=I<&Q(>E9,
M9GDY<D)U;TDW=7DP<"8C>$$[.5!$35IK5TYY>6E115 V66%O6&QX4W500U9-
M>#5P.4IO3VEY:VU3>&=9;6Q363%Q84QX1F1U>6UM4S11,3A25DQ,4V1,<U=,
M5V1P1B8C>$$[8G-W;WAI4E9*2&AS34E!57E*-718+SA!=E9P;B]-8D8K<'-R
M>3AM>D(Y5$ET4S!I,W9U1&PU3&4U:7%)<G%"=45Q9SE26'5$,U4W6B8C>$$[
M4TI%3U9+24Q(3F(X:RM9.5EH93!U4$Y6,T19>59$4E<X54U4<W)#:%9P14%*
M1DUK36QB9T)I8V0X>5=*1"]N1S-Y>5 K;&AC*TI.1B8C>$$[,T]:161D:T%O
M53%N4S1Z>D1V.$%O5S=Y>B\Q8TQN-VQW+WEH;%(K5'@Y>G8K:&)V3% X03%C
M3&XW;'@O;$1+=C502#-/+S9&=3AS+R8C>$$[.5A#-2LU8V8U47ER*U1X.7E(
M,40O;DAJ>3=A,FIZ>#-6-6-/=$M24G%P8S%.3FA565(R:&LW+W-19$A$;U!T
M4TPO;%1';68X<V5R+R8C>$$[05!)<4PO<7!K=C51;C,O63$O:W@S9F%Z=GDS
M<#9E6#E,:C V>#!856935&1N84M0:WI(<50X9553>C)B4$YN*UA0:VUN-E1V
M=BMR3B8C>$$[<4@O27!0.$%Q<&<X54PK6&MG9%%T8EA52E9L=F9,9#502W$X
M1F1O:S5C9#EQ:51P=F=/4TI:1$9-8VES+U(R;59"+W=P4'-!;R\P5R8C>$$[
M1%I61D%".%=W04=02$AU6'=P.39X=$LP=&QD9CA+,T%%:6Q(-#(X4S%5.5(X
M3&IW=V-C5CA/9F5J2D-S<V=K:SAU,VIY2S-Q0FI"128C>$$[5'DO;7)Z-C1F
M16EJ=UID-D9H,#-4;V)H8FE,>71C<$UT3TQR8GA#:$1+=U R*V]:06$T.&-5
M*T90=E1,.4HS,R]6;3%$+VM5;B]65"8C>$$[1#1O62]L-4\O4V0Y+W="5V)5
M4"M24V8Y5DUF1D,O;#5/+U-D.2\Q6G11+S5&2B\Q57@X54PK6&LW.4HS,R]6
M;3%$+VM5;B]65$AX428C>$$[=C5E5'8P;F9F.5=B55 X06M5;B]!1E5X.%5,
M*UAK-SE*,S,O049:=%$O-49*+S%5>#A53"M8:S<Y2C,S+U9M,40O:U5N+U94
M2'A1=B8C>$$[-654=C!N9F8Y5V)54"M24V8Y5DUF1D,O;#5/+U-D.2\Q6G11
M+W=#4E-F.$%65$AX478U951V,&YF9CA!5FTQ1"]K56XO5E1(>%%V-28C>$$[
M951V,&YF9CE78E50*U)39CE6369&0R]L-4\O4V0Y+S%:=%$O-49*+S%5>#A5
M3"M8:S<Y2C,S+U9M,40O04I&2B]W0E9-9D9#+VPU3R8C>$$[+U-D.2]W0E=B
M55 K4E-F.59-9D9#+VPU3R]39#DO,5IT42\U1DHO,55X.%5,*UAK-SE*,S,O
M5FTQ1"]K56XO5E1(>%%V-653,%-A:"8C>$$[93,R;F].3'9)1FIU56QK;&U2
M1E%+;TYA:T\S:FM*>D)$6FIX1TIS=B\Y:ST\+WAM<$=);6<Z:6UA9V4^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^
M"B @(" @(" @(#PO>&UP.E1H=6UB;F%I;',^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F
M+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/DUI8W)O<V]F=,*N(%!O
M=V5R4&]I;G3"KB R,#$V/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L
M96UE;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @
M(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^36%H97-H(%1H
M86YA<'!A;CPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @
M(" @(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @
M(" @(" @(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]S5'EP92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%10
M9SI-87A086=E4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(#QS=$1I;3IW/C<R,"XP,# P,# \+W-T1&EM.G<^"B @(" @(" @
M(" @(#QS=$1I;3IH/C0P-2XP,# P,# \+W-T1&EM.F@^"B @(" @(" @(" @
M(#QS=$1I;3IU;FET/E!O:6YT<SPO<W1$:6TZ=6YI=#X*(" @(" @(" @/"]X
M;7!44&<Z36%X4&%G95-I>F4^"B @(" @(" @(#QX;7!44&<Z3E!A9V5S/C$\
M+WAM<%109SI.4&%G97,^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L951R
M86YS<&%R96YC>3Y4<G5E/"]X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC
M>3X*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/D9A;'-E
M/"]X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#X*(" @(" @(" @/'AM<%10
M9SI&;VYT<SX*(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z9F]N=$YA;64^07)I86Q-5#PO<W1&;G0Z9F]N=$YA
M;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D%R:6%L
M/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=$9A8V4^4F5G=6QA<CPO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IF;VYT5'EP93Y/<&5N(%1Y<&4\+W-T1FYT.F9O;G14
M>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SY6
M97)S:6]N(#<N,# \+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET
M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93YA<FEA
M;"YT=&8\+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^
M07)I86PM0F]L9$U4/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.F9O;G1&86UI;'D^07)I86P\+W-T1FYT.F9O;G1&86UI;'D^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y";VQD/"]S=$9N
M=#IF;VYT1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E
M/D]P96X@5'EP93PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @
M(#QS=$9N=#IV97)S:6]N4W1R:6YG/E9E<G-I;VX@-RXP,#PO<W1&;G0Z=F5R
M<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET
M93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z9F]N=$9I;&5.86UE/F%R:6%L8F0N='1F/"]S=$9N=#IF;VYT1FEL
M94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.F9O;G1.86UE/E=I;F=D:6YG<RU296=U;&%R/"]S
M=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&
M86UI;'D^5VEN9V1I;F=S/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^4F5G=6QA<CPO<W1&;G0Z9F]N=$9A
M8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y/<&5N(%1Y
M<&4\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M=F5R<VEO;E-T<FEN9SY697)S:6]N(#4N,#$\+W-T1FYT.G9E<G-I;VY3=')I
M;F<^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\
M+W-T1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G1&:6QE3F%M93YW:6YG9&EN9RYT=&8\+W-T1FYT.F9O;G1&:6QE3F%M93X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D)A
M9SX*(" @(" @(" @/"]X;7!44&<Z1F]N=',^"B @(" @(" @(#QX;7!44&<Z
M4&QA=&5.86UE<SX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI/DUA9V5N=&$\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y9
M96QL;W<\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y";&%C:SPO
M<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP
M5%!G.E!L871E3F%M97,^"B @(" @(" @(#QX;7!44&<Z4W=A=&-H1W)O=7!S
M/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C:"!'<F]U<#PO>&UP1SIG
M<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P5'EP93XP
M/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4W=A=&-H
M1W)O=7!S/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP
M34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @
M(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E
M;G0C(CX*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^
M>&UP+FEI9#HW,T4S,D8P-D0S049%0C$Q.$8X144Y.#-%13A"0D1",SPO<W12
M968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^
M>&UP+F1I9#HW,T4S,D8P-D0S049%0C$Q.$8X144Y.#-%13A"0D1",SPO<W12
M968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C
M=6UE;G1)1#YX;7 N9&ED.C<S13,R1C V1#-!1D5",3$X1CA%13DX,T5%.$)"
M1$(S/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(" @(#QS
M=%)E9CIR96YD:71I;VY#;&%S<SYD969A=6QT/"]S=%)E9CIR96YD:71I;VY#
M;&%S<SX*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @
M/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HW-$4S,D8P-D0S049%0C$Q.$8X
M144Y.#-%13A"0D1",SPO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM
M<$U-.DEN<W1A;F-E240^>&UP+FEI9#HW-$4S,D8P-D0S049%0C$Q.$8X144Y
M.#-%13A"0D1",SPO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-
M.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C<S13,R1C V1#-!1D5",3$X
M1CA%13DX,T5%.$)"1$(S/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @
M(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T
M179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E
M240^>&UP+FEI9#HW,T4S,D8P-D0S049%0C$Q.$8X144Y.#-%13A"0D1",SPO
M<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H
M96X^,C R,2TP-2TP.%0Q-#HT,3HT-BLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL
M=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA
M;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-S1%
M,S)&,#9$,T%&14(Q,3A&.$5%.3@S144X0D)$0C,\+W-T179T.FEN<W1A;F-E
M240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,#4M,#A4
M,30Z-#$Z-30K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @
M(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.E)E;F1I=&EO
M;D-L87-S/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @(" \
M+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M,9\KP]VV;Y\/S9C0\FQXQC_QQMRA+X<_^.,X_P#+J#\A_1GT;GOH_?-MY_\
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MX4/YC3XVZ_\ V%O_ '(?YWIU%6?7I_YY/PM/.O;?95GA0_F-/C;K_P#86_\
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M]M]E6>%#^8T^-NO_ -A;_P!R'^=Z=15GUZ?^>3\+3SKVWV59X4/YC3XVZ_\
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M'AE^( BFR+'4R!E4RK(<UIFQ$D<0;(%6903K8E[J6D!-HUUH<1<M3K%WM%D
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MSD&[K""R<F0!RZ-CJG13@X=O%V%S83P3=8-!I<JH=1*Q520JLT[Q"UR J22
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M-,)?,S-JU,E62S[1KF3).X6!6-5;*\8[!"O9[]II)(E"=@9C)"6)QQ!/(E6
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M9S*_8@TUB3'85 Z5M*H1!C6\>.!XHFL^YQNJD;58/K:*_,:%5D%*H+.0J!I
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M!3BJJFAF2H>*%K<-S% TDAXI*K" I,K,JQABP&N9!M.Y5-134L=%4":KF,$
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M7,'HM(F'N&B =R@!5\&LF37!&)[*ECV2K#D<0;FUB1D4G)BC60LKQ\2/*3!
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M<B+&ZXLK:B30L0IC1;=A651)';)% 5U2V!:0*20JAL@>XG6DE+5(K,LTC?\
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MM,1B(721&:2-ESY%6C!<K(;( 0@8]G%AV2!G(*KUI8+ "MKJ)>$-XOFP82D
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M=)3-I\C"8@!%#%P.9"KWFP5;V"CN4<R38"Y[^X:@R.R+&2,59G L 2SV#,S
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MQA&8$L&O);8P0>,,,9(6,*0OTU\S3QIZ"EB!(L2A4*8\FQ/:D<D@&QN920+
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M'E-))-'-NF\HI (AW>JIZ2*B/,2[?ME-71GAUV*]16N/!C&/ZL=>Z    =P
M _<.6NC$W))[R2?XZ^]3J-.FFG333IIITTTZ::=--.FFG333IIITTTZ::O%?
M0L[,X7HE ^Q+!D1H/!'KC.<8SMG^7+)G&,YUAATQM++OX,^+IKMG&,Y\&,_/
MW7=*/9MOJMRKI.'34L9D<BQ=V^C'%$I(SEF<K'$EQD[ $@7(Y5#15&X54-'2
MIG-.^*CN51WL[GGBD:@N[6-E!L"; ^L+X,_LH XXK*ZZ6,#&QTL490VQ$'BR
M$$R:XVE,EUWU\.-M\XUUAU\;;R4.L<6-LXTQMG\J;KNM;TEW6?=ZZZ\3L4L
M.24E*K'A4Z7 !"@DR-8<29I); MKUP0T^TT46UT9OAVJB:P#33,!Q)&MZ6(
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MDF8F_'8913"-$)2(!FL#-V)=6Q$^[C"XJRH>CWU2"!'PDS;RI*Z3%,NC%?\
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MS8!7N42FJ'52CJZYW"@3:\<<<N'MA8,R]2VL=I"?6)YALH<,=]QEL::8A6'
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M TPI0I$>LD,T,VFT<D<FFV,Z[:;:[9UVUSC.,XSG&<=2K,K!E)5E(964D,K
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M38V,.,X\/E<ZYUVVR/1NO?M4<^U[C$?HR46ZT#.P]!-)//3[A"#Z!44D+?\
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M&Z%[9T+:5GB>[-L.0!:C@9>I$KW(QPHKH=NRWW8)(2YU.B]AMD/,U;E<EC4
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M+"X//T:O!MZLL<DC.0X&28JMN)333Q,KK(]^40)5T1K,#:Q!.5;5S3:*SI1
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M]$,?9B[\STZBK/KT_P#/)^%IYU[;[*L\*'\QIZR\9?1#'V8N_,].HJSZ]/\
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M=3@UF&06ZFUB,F5;BXR8#O(U4'6BLJUQC=G8D2Y2NF''8-#FZ\1<#.7H)()
M8:01&,-,5&>#(/'/+IO/H:)M%KMJ3#G<64 DLH L"20 ";$ DFPN"+?O'KU"
MQR,P54=F8$JJJQ8@$@D "Y *D&W<0;]QU&JYRK0+0(B,6699%K:(E<U;&:$P
MJ&#[1O64-N#PI7,=QCCI?05F3E$0#P;S"[%8A(CCDTVUZJLL;A2&':MB#V2U
MT5Q8&Q/9920!ROSU=Z>:,N&C;YO(2%1D$QD>(Y,MPO;C=020#:XN+'5S'Y!H
M1?H_S6[U GTLUG1*O-[*FF])NQ<PX)3K_)F[>>M1\D08G7C>4+AS/#B2'7RF
MGC2)(S:TB&[8BS+S8=ZCGS;F.0Y\]08)AE>&48J':\;C%#>SMRY*;&S'D;'G
MRU86O,O%JB*"2>]UDK8LQHN%@5-@VY!#)-6V-N8+M8ULQ/DC8:^J,88A)S#F
M37 \.F=B# XIZF>)>^1.\CDP))52Y%A?F%!-O_M(U9:6H8D"&06"L<E* *\B
MQ*UVMR,C!;B_I/<K$2H"X5%J<6L66FN,F0!VJPY> [6&'!LMQS2]%Y8@Y4A
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MGF$I&8<CDS1$C22U$T1!(D2PRO=@+8L48\R.086OW$VL3<:T--4 @&"6YPL
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M$816ST$:<M9J*1-L5!IF2/&=<ZYRXT5R.(EQC>[ ?3!*\R;'( D6//4^35
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M#2LR2SX\W#@R3/B.+;3;:>,A8*H9B51KJI*A7)"DL!8 V)_8!?5332A#(V"
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M")F,@XV-F#.M-X0XM9MII=((9LQ:Q&![3UXT5V!=05MD&(%KLRB][=Y4@?\
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MR6=-^CO1_;Z_;MUCCVZ<O)6#<EC>5J]$7LTLN"O()H!EY*@^:D#N $F+&?\
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M@@LES'UJAQYP,084301C_P#94M%XMMS-W/N;A+++"K-Y16)O1B@=N]/B$F;
MJYA86>BK-:R,@9C DBP!#=DQPN6-\>2F8+8 L;7 /,#5MMF)/"/$"AB25*]H
M35$2IRS%V%.S9,4120K,"5+38'G]>V Y)>*JH](0T;BJO<K)3B\CKYKTFL6G
M(A($B2"7:2,1>:%1825QK(@<Z3#C&K%.L\TTR;H*@,)2J,5CB652;#B*_$(Q
M![@1'<$D'M<U6W/,T;*T"-(@>:I>F<"Y$+QF -F?25,UF"@KV>R[7[,LIW,%
M=N3010,N?+"C@7A()+,*#14>;4C5RF[)P&(I9.DS"HNV<*=GF:(80TR!ANA)
M;BJV1 ETF5R  P)#6N.1*$!U!OS*,<3ZR#C< D92TSQ*7+(P!0$*2642*S1.
M00++*BEU[R 5S"EE!Q:9W9T95 Y=N4MA55$*NTVSIWIT:T"1^DMX%V=0.1!&
M;  >);A%3\L%PV['>S-R#MTH]:C>!2+I,O*T 9BK! J.K&PR5P[!@"0 +)<
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ME45N[C2+&D3E?O)3>23=PSQQ'Z\7>#8X<G,8P2^SNUZ]?KGT>O ,T#"%@&"
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M8 M@.-,P#; &C,]!AAF$1(H\$,=CNVV,XD,LN:BP(2I46N&L54!2"0+@@WL
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MGZ07W/\ _=_[3/N3R5_%?I^A#HQ^LM^\?;_]-T_2CO?N.U>'5_G-/T@ON?\
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M!FZ9S<&)YF$C/808OC.2?1EH9R[$P2 %FLD,"-7@"3BB7TCG%ABB,#%D+1V
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M=U8MJE'6:\4BME(-&SHG">&/GP\"V*T,)CB!:O,/N-(M8UN\2DICHXD2I9Y
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M0BJS0RY8XV8'A@ A>_LNQ8EN_LBU_IL+**5)H3'((, XD)2W'+,I8\CQ(T5
MJD '-LL1\VK%G/+GKF:^=ITTTZ::=--.FFG333IIITTTZ::=--.FFG333III
MTTTZ::=--.FFG333IIK&G-'\SO+'_#2]_P#*S7KC5O\ P=7_ ':?_*?7-VW_
M )C0?WVE_P ^/7*+M>_F1HG^Y O_ &\?70->N-WG]Y_\ZH>"I\!7?N9JT_\
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M\]NA_P#:;8_\2I/Q=/-CI'^H]U^PU'X>GQ+<O_LPOOW4=_DNGGMT/_M-L?\
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M B.K7I</CPY\D-QX^BU^?]?AQH+KC/\ 7\_ZOZ/!UHN[;<GT7<?_ )IQ_P"
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M;-NJB44\=5$^XON])+1D&HIPL\R4HD,3.K*$1T4M'R;+=$Y7[-Z]PKPM.XY
MX#8WQ!<.R'E-8W34GCRDVVH68#FVM..XD&115.'$]T6$U5*>U%LC*V\OVH&\
MJ%T3>FTNO*5&-=_FUFW=)IMTW414>\)1S4W2K;WBDJZVKIJF!]JGBV5A)4;G
M+2NM1*D;01TVVTSTDC\.JJII)3;G4U;L<5!0&2IVUJF.?8*Q'CIZ6GF@E2OA
M?<U*0T,=0AAC:02O/6S"H1<X((T07^7?F3M ;V[#WDBZ=KE^M[FV]^[VHVKC
M/C10@4*>%;OP78PN"*OR=H/Q_5M6_)T_+I>S*M%6,:QW-,?-*T9VC:=G"<1-
M)MG26.GX5#2](*.FBINA\533U]?+-+)NE)NT#;O44!:LJ#'0#;4$<ZPM!32H
M!''3A8RHB>NV22;B5<^T5,\DW2*2":EI(XD2@GV^5=OAJP*:$-5FM.<1E66=
M&8LTUV!-53.ZGM=KW(G$O()=ZXU(?U&[_!,AYL32M V%M7J;QOPN^IW</E;.
MS0L2E\%/,)7Q/9EF(S@'02=TFWRW3JSQ*U71_?YJ+<:):2N$-11_**W CJ&A
MCFJJ[=(JG9<UCF17:I17,0>Z/$\L4HX4LB-:#>-HBJJ.J-12&2&?H<O%>)97
MB@IJ&6#<\"\;,H@++Q2EF5U1T[:(PAMS-XC+[8^X?N>O51XFL/)/%E\YZX X
MKMM0XQJH/&/.;+N9<K65$Y"2G!5-!6+-8^":Z-SB4"2.F(,3305';$PFZP'P
M\FE7<EW[9=@I*K<H:'<*3:-XW"FJ=PJ'K]ICV**1*RBE1JF:>"#=YVVE74RA
M)0:GDPD?6$[41VG<]WJ(:.6KHZC<=MHYH*2%:/<&W5T:GJ8W6&.*:7;XQN!4
MJA,9$-B,5UQ\[ KKVZUSBH<2X6+MLJ5[A[DZ\ZYTG[C>. ;[)=>T&&L+(W5+
MXID:4:[>9VB1]%:9&BNJ9K=U;DG5.<![H*LDP/\ 9Z8TF]3[@S4T.^5-(VQS
M1;2-DKGHQ2])#42&*JW$1U=+G3B$TXCDJ!/2Q*E2'A+2"_S.C=1MD5&%GEVJ
M"H&ZQ2;@=TI5J#/LHA02049>GJ+3&02EDAX4[LT++)BAQR3%S=V;1\6@<:UM
M)PDOI5@[1N]_9AFR\94X_E0+EWXS.77G:LJ;<BEUPV[A716@WI&B'=;98QYX
MC(!FY!<(H.@'!;:NDYW!ZZ>7=9*J#I'T3X? KZE-O;;?(=MAZ0R14*SI2-2R
M3"K,P> L"I:)5+/GRQ7['Y(M+$E E/+LN_Y<6E@:L6M\KK9-H1ZIHFJ%G2/R
M<1X2@$, Y8!0O1]UZMKS_3IIITTTZ::=--.FFNPOL/[4G?.5_4-25\NZ@8S3
M<+RD6=H=LP[?YUE+C;P:YB@SC,8GA\/C3XWGQC&88-I/%?E-Z7,,NBVURGBS
M*.N*B-N<4+ ,M K*;YS*0U5:V,)6$EN+*J>@=$MF6-.O:Y.Q&3U?$P^G(IL:
MH@_U8R"L-P;N&EY"-&;V7<3<:).+J@JK2<6*#0,2".7?2/73:636/7&VVV=<
M?/G.<>'PYSG_ /!UY%!$(T  '\+7/K_^T=W/G;N.OO5$S3RM(QN23;]@ORU9
M*+S #<KW>*  O;-YZ&V,5NK@MK[8*D#GQ^2(TK\=A9:ZJG%A6CEC@O1*Z>TG
M6NAV0S,!/'!#F;L-=L\E%04&X220Q+N$*2P4DM1"]<\9R7RDTT7ST--*R-)3
MR5,<2RPM$T,DY9BOQJ7<DJ:NJHT220TDC1RU*0R+2JXL1#QI (Y9D5E658'D
M*2!U=(PHO:.<>0;I22Z*%30#&&S\BURN(5-8$MKW"^NULASC*E,;;:?$5-M+
M%KK)! >6P(USJ.  01)CP==GD=.&$!.1:X"9M94+=E2Z7-QZR?4"=??I((IA
M,96"X"/$M)PTR>14[;B*6P -[E0H[V8#6*T?=H9(I5:,:,38&^:^CU9LZGZ4
MS6SKFXXM#Y6@#3L-%KRN[HBT)PPT.JZZ62VY>$85)JQ9A-(79>2U?9%TR-E!
M9+XEVA$P -F7$J0.3LV1LJMWGDOMH#-:81KF^*RE.((DJ&IB67)'S#J2<HHX
M@@R>2,W07.R=U0PE!M+U2@P/852(_(4!I!6X0]FA5<M2Y#- 9+Z[8/)*FW$S
M85FL9+$#Z+$NXK!:F8@GB#2U5:-F"V8 V!)L&M-W@A6Y&%K@JK>@A2"!2/;R
M9HD9[QO(@)6V7#9J87!4NEV6J0JRLZ'O5G4J3?JCW"-V-C3UJSU,$#TO<+O6
M]; J8N"E VB;DOD2@UB"?;-=F"!;--Z+C4F&Q.JW$W+80XI>MB+A<I:_9*AB
MX1T N\BY L5&,LD: ]FP8\/GDRW)[&1R5:2T:JC.DA.,4+X,$#7>"":2W;!9
M5XW(HCXA3Q>&,'>T%]P5RKUXN:!Q4E+=:-;6B:M2+7V5F%RM?-Q16%>[P@Y7
M-DAA8+ERPED/FBT'5UFNCMC9"6$RH>!W4U#K(ZLBD!RJD-:P!B09$@W+/*M[
M !5#$DD -84<3Q1NLK*>&K2!DO=CY3(V #<E2*F8+<EI)"HQ4,2ESB[C71U@
MAK"CC>$QM$T&K3:0BZP"*Q+099^6:I",O-CKID[-%"PXA=DG.) 5[$4%HJTU
MKT[>-JI73Y2Q;!8KL&"-VP%#%IDY'$DK>%B38$ CLY7 CR)%CXCSE5(+K:(E
MC&(Z:2[ N KD52!5!9258\0)BS7ESSU)"-Q"S05R5GKR[2A;*E3L#8%6PQ+Z
MQ\1HT^K9S%HSP",OUY*S.U\R5-I981)]PM)9X(!3K&HY0E5OQHPZJ3:V30JM
MVYV XO.RMR!MS !JM'<U*NX4TTIC=E!:X2.I=\5..1/D]ENR $B_(DKC(?N]
M-C'<L#N.RBAHYY34X".=ZU9QH$/&5!O%Q]+;JZRU$C;!,KM$LK\TV55<:#Z2
M3O'=7@7S'F9"L-B3$2.94*68XK$DCY64@,"]E[E8<R5L2=SMH)11. 2+,7P5
M<WJ)X8L<I%)5EA+2 92)_420L%$KC[CGA;X56OH6DLCUU9*_50#+%$%Y_FLO
M;ND*>NF6BLO9&.3/0G.\*@=<Y+C"D7E2D8-((5!W\I)8*(_I,ZI=@+X,ZEF/
M/$?-L<0K&Q!O<E1EY$@3-IK!4C>0K&6QXB0N%0%AF0)D!8L@R# #$!VE%<Y_
MB>\>6&]D5653*IGI<:U+*XP=*UUY%04Q]3H=R%ZJ<J-J5B\*E3!*G5V$_P!,
M0SKZUI:B)UFC"ZU&4;2%+8E %RO?B*C)W+?(\0 JH8Y7"9DB]'H\)TAX@;(2
MEF"V"\&25)/I, 5'!9E=VC7 AI#$ V,-![L B!LMC*5.NKZN,N&TM2[!HOD4
M-!7_ "U6MH!%SY,D(E6Q-.(7.Y["R;5$Q: V4D%J-"8FX*S-:L$7P(50<R6
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M(\+8;<D/6LSW8F15I/NT@3.8XT4X5638K&Q+,RH6N@)1RC%B5Y ,+C',D7N
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MS#E6'M55'N'4H'(H&@RS9:O4DG+3L"64E1.L=&P*NX)X1Y*TC DK9%$3$C)
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M$AZD)N/K8R>-C&:UR08<CT4U8II95QZKC-K(58$6C).4%48O+,=X0@<=3QX
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MMG3:DM:W<!U L(H%9+-B0%5VHVI61$5%$L3J!917&H !HNA4M)3*,L58\,$
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MP5N(06M$4X2DOB@&-L=<@^N1KAZQIS1_,[RQ_P -+W_RLUZXU;_P=7_=I_\
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M#F*6/MW+%69F"W("EDX;']I*EA?E8,1;DI&[5\I$6(17C14,F(+.JR\95/(
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M+)Q,BQPP!-RUBQ=BQ)(-V/9"JH474 BP7.2I+PB$(J*9>*P6P6XC6- BA05
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M'5Q *A56(\DM7]I>L=YXQ(<Z:GO)@E0L(JM,$ "-C23>"'@JRY @D$ *0!8
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MCB0%W/>0,5!8JI]:W"3E;R9Q^AM#:IK06!B\3)F^B394*89YO'YV6$M*+9$
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M<YQC&/#GJ&945G=@JJ"S,Q"JJJ+EF)L   222  +G4@%B%4%F8@*H!)))L
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M$,IR4=QTZNP$ADDYQ"H#(H4&\<54\;+=BY5FIKG*) R,,')N1)P.Z5<T8U>
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M.4#HH#A!=6/99HGDM8KS%D()N""0+'FVHJ*.*-9&BE=C%Q&(= ,D2>.#O5B
MP:0<K,& 9B4[*G)=5YI$L_*+7C>-'-!H*ONIZM_'.RG$8_%]9Z]4+./)).A!
M1[3CN[% -%'7;':)0I 6(-GBK3F#55+HDX:4Q8D<I"&YD'ANJ/SQ"_28 8LY
M%B'",+:PDI3'3K/F#=HE9+*"O&C>6,V#E[%$).<<8-U,9D0YZP#4N;><VM6I
M-C:KD:U'R"#0A-+D^J.$J.JV.[-D\(^01!N0V1]L2%K2SQ%93""IZZ6*>K#R
ME,-')H2SCI/.R1N0H601C-DQ5'=@.0XA+J02 3C9L1SR(',EI*19)HU9R\#3
M'AK)D\B1(Q-R8%6-PP4L 9.QQ+ 8 M46+N:L=5BPJCCWM+JG7EUGDB8/C:XZ
MEKN-*HKICJPRE)T)%@A16>19?E1B9T<PUJ;.%0TS)JL,R0L6RU4R"WTF20F6
MT3W6% C,2JE[-:0%6)"-8]QN CH$D[7]&DL*\ -/%9JB1I4C 9PA>/*%E=0O
M%0LOTULS9EY,Y\5<9.QA62(QC7/5CUF865?*65%%&1$_V5K@8P5)ZK!S.9#N
M.OQ9W]2A=D,! ZC)9V0[8!;M+4")@"I*89%Q<]^5@  1<XV&3)D2 F9N!Q8*
M1IT)5P',G#6,X@FQ3)CDRMBH>YX:2E I,HC4JS6C?N!-";D)FM-61%(2>/M+
M?LIOBQW&L&Y4L(5;I>R/6!4.0\8>>&QDV-0R@K):Q=D4Y-FRPN:]EO'E!#%2
M@NO#SQD#6$K!4QY L;F[*0MA8J7R7*WD8*AUE8K()S%E$R9&G0O*'NQ""PLC
M*9 S75^&4?&UT/N:WN3ZE)"N/FR;%O659C(7$4U<#IMKO5FMVK$!3""K"UR7
M.U>7P:NM?6& P%R9N$I L*U:R=CUCJLVC!C*YA#>Y;'B(TB7L@7Z([7:!#&P
M# %A::@X23.)E;A/(H!"J7X4J0R$*9"X^<8X]@@H S%&=4-)=N?[/IOJEIM=
M4AGN;OFI5UV[<;E:Y'K//- X0Y -:H1%>TBPC1I=X2*?X#V@[$#3=LWU62Q"
MHFR2H;D$4 M)@K,;\DJ(X)"5 Y&[W3F01S:QLK3%1QD%I78A(N(Z(H!O)1S5
M< 5RQR&,1$MU4J2%3($NLRGY-LT/+&M=WD10U33D;'&DR^8$G5W_ #%%\S;7
M3#K9MH+&#J7!BJ85[)=H?! 8?LVR1C4.*YE;BA>SAQ>$00<OZ S9AKVM>R6Q
MMR)O?D,A!'Y.9.WQ.!QPP88?\6*7A%,+Y6O)EGZ0,;<S0\D\K<@5CDU%2:K7
M*NW 9BTV7RK=RP5G3GV1S<%Q(>\L"MB,"L%#KD)VS2.!B=#)Y8>),?DB',$2
MS2+*D:*I#8=Y()+%Q;N(  6][$]X"G5H*>&2!Y9))%93+R5%8!8UA(-BRDL3
M(1B2JGD2XL0:;C;N56\DV=(B7TZP+@':Y/O&W,'9[1".FW&E=Y4RN((PDCK4
M@<%?L8P."0[24ZE<PR8VK,*281Y.BJ1*R@(P#!;,;\F:))K$XA;8N!<.6+ ]
MG&S:3T+0([-+&S(S]D%;E$J'IBP&?$#&1";&()@?Z3,%!'F7=3NDCL#=SQV7
M#5:U .R9,@++ Q=;IV-FY$IRF<.OX3C1DLBWG&KB6=9Z9CB%2'J3=&!+24Q&
M%0U>.3&,X( 20UVL6E067'F<HFN,K!2I!))477;\^&JS#B2DJJF,A<EC@E8%
M\B0H2=0&PN7#"P6SFWL>Z)X6G91(Z)A99$^V"'&+*<X5+!%'GG&\6AR8=_6:
MR\L)<L/)*O20 E77889@CI1&+,<JLR66#5,5.,=F',Y$@8WBYKDBEC:4<B%Y
M@V)NN5EV],E+S7C>V/#".Q:T_9<I)(D8O3MV@SGF 54B01[6.[D<,5)Y:H%N
MI&@ @VI ))86TEJ)HXU_U4$;;I2ZNLBV0E#;;0S7&:RP3%@E2U;%?.%?2C5@
M6[!:X Y$CM%!)B>10=D@D%\KD'#$AM.KB<[2A<6;DP4_-K,8"X[8D8Y@\Q$(
MR 1Q,P4UR<H-MGN=?D;&*]$K *P6VL,UT+#+46%G3[0WJI\@++8);(:O+*3R
M& SSK5Y.PD\."0A2,20Z<J-\U)(Q(9T(O<71BIL;"X)%P2 ;=X!UP9HQ$^(;
M-2D<BL5Q)66-9%R6[ , P# ,PN#8D<]33J^LM8TYH_F=Y8_X:7O_ )6:]<:M
M_P"#J_[M/_E/KF[;_P QH/[[2_Y\>N47:]_,C1/]R!?^WCZZ!KUQN\_O/_G5
M!P7/@*]=S54G_D&+.:X+*+'M\VY-?N_&/'K4)GKK^OS>1^-:TT>^?FV(0EXQ
M\VO78-Y'$H>CE4O-'V=Z5CZ%J*+<]PC>,_\ J%.]+,1Z%G2_,G73>C!X.[=-
MJ!^4D/22*OC![WH]UV+9YXYP/J&MCW&E!]+TDG<+:RKR1QCQ]S!46=#Y/J".
M[U!OC3SY$_"T,$WEASG8<L?;/BD L!-\YD"9 3#, I?\Z(3#)C&_7S=NW*OV
MFKCKMMJYJ*KBOA/ Y1@#])&'-9(VM9XY%:-QR=6'+7W-ZV/:.D>W3[3OFW4N
MZ;=46XM+5Q"2,LMRDB'D\4T9.44\3)-$W:C=6YZX'[?!&=A^BJT+@>(2P2+*
MK,60.,WF\-&58R5KX86%9P\?M  V0,^L1 I1@)^VWD\BE8) G*$G[N/E6Z<&
M6FD?=D=:>5)&A\BHHHZG$\XZG@P12/&ZW5E1X^_)<9%5U\I/^SW\E(IZZ"+H
M[)$];!) M3UKNL\]#GS66B\JK)XHYHG"O'))%,3CPY.)"\D;]/E/N/<%\#/W
M"RT6\Q,N0NV7D1E*=!*%'M&MLBN'> ;>VU+0B;86O\DUT600>S5J<K09L/J,
M(63,!/6+,%ZU5TFP_*]L K:(Q[?TDV^,(0Y!DII2&84M45&51MM0X=J:H52T
M3%G11(M33/\ G;;MQZ7?[-O3!MJW59]XZ#[Q.TJM$"(*V!2J'<-O#L8Z/>Z.
M,QI7T+2!*A D<CM"U!71>G7C7DJC\OT>N\C\<6("U4VU+XV*9RNDSM%-%MG:
M.8<B'?&A +$$C24)DM,B@.6GP$!&CP$P2Q:_F[<MNK=IK:C;MQIY*6LI9#'-
M#(.8/>K*PNKQNI#QR(621&5T9E8$_N#9=ZVOI%M='O.S5D-?MM?")J:IA-U9
M3<,CJ0'BFB<-'/!(J2PRH\4J*ZLHZ._\HZORRL]AJ6GRSQ>FN0^::8$L#VWU
MQ+* A"=-&YD6N<^-OJ')LLCD\7'\G)L?ASC&?G[W\F<#-NNXU-CA!MJP@V-C
M-5;A1*D?<1<P1U4@!]$+&W(VZ-\I,JL.BM"I!DFW^:ND7^LE'MFQ[N\LUOJB
MLGVZG8]P-4MSS /D6[2>647 O<?P-S1:5[=K7>+N3J;>':Q#&%,[.65UP*Q+
M%51,#5P$ATT,&^@^A9P8^TNVN)2(M?#OC]0;QMLV[=&]QVJ!XXYZ_:ZBDBDF
M+B)))X61&D*+(X0%AD55FMW GEKR3;JZ+;]\I-PE5Y(J2OCJ'6(*9&2*7(A
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M/#: 5&--12!^"RQS5+J#))@_$*#JMZ]!UU#3IIITTUFO@CAQYS/>%M<6B$3
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MASROP",YF,E P#8[ >/Z:F*XGMX+_6>LDTDD%G<\D4Z%FE!33W6C'KG=J\Q
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M<,9-=\V,$..)^B&RYN?I"/@W))OR4X]_?^W68JJC/($9%,.S&H[/&\JL%"V
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M8# DDELVR;((&#&_,$1I>_,XW))))T>MG<!6*%0JA5X:8K@9"K*N-E*F:3$
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M.,:;/J..\>;:-&D4F9O+SC P:;1 @!"02((P00#V22MV8A26S:UR?I-S;UV
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MGF&8!A#(NR:#1<D637H$P937UM>F\:M695(9'%QKQ!QTT:[35SDQ*7EQO'Q
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MWMXQ_P#HIM_[N"O<Z=9[9]9O!;X=.H=]^M']I34W1\Z<65L; B2D\@+A\?\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g65062g34f97.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g34f97.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2+*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (JZ^B'@X0DE-! 0      "(< 5H  QLE1QP"   "?_<< @4 #G-L:61E
M-C-G<F%P:&EC.$))300E       05DB_^ )QPSBL_C4GSN%9<#A"24T$.@
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M36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M     $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C
M:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M    1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R
M9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M %)S;'15;G1&(U!X;$!RMV!         "G9E8W1O<D1A=&%B;V]L 0    !0
M9U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M        5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M           08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T
M=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E
M8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@             _
M@   .$))300-       $    'CA"24T$&0      !    !XX0DE- _,
M  D           $ .$))32<0       *  $          CA"24T#]0
M2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M    !@       0 U     0 M    !@       3A"24T#^       <   ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #-0    8              XP
M  /[          $                          0             #^P
M XP                      0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M XP     4F=H=&QO;F<   /[    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M- ;6UY;N_6:[F?I/2L]*OUOY"T>I9[,)M.^IUPOL->U@+G MKMR=S:VAV_\
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M378UMCMU'Z#V9-F7O]"RG]'3^M?JJU\LV?:<0-:"SU"=Q0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MDO 4(T)B<8&AT@A3L<'A%3*B\206,S070W*"&"54<X.D_]H # ,!  (1 Q$
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M48)C6XG2)G /(E%<L >1( /772U*[^@:=?7P3TAL[2XN0G/US#$\@4XY@,5
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MXG>Z;2;R."&ZF93--:W%K!=VXN'.WTMQ$LQBDD"@R!%=LNS$YDO;.&_1K/\
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MG*!3*H@=,HF!2O3$0 !$1   !$1$>@  >\1$1]P  >\1'\F*4 0, &*(&*8
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MV!K'5^?SFF.WD>7+&2,YP.1Y]??R_'JJQ<3R@W9)EUAR,5V<YL>TJUQ)])+
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M,JM68R7D;!'5V"CYZ8*4LO-LHB/:R\H4@E$A9&20;IO'I2B4HE*Y65 HE 0
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ME_UM-_JO&!WC]?*FT>VO@_[:>OYCX'LO^MIO]5XP.\?KY4VCVU\'_;3U_,?
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M-ZA<D(^6;,K?#$%5T;6VP^CIR,C5)%R<YX^0\!64J,FL,K#J>"K)QTE7_'_
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MO)_ Y/NY\Q_GM=61\Y'R>ZMB7)J*8I7X43(J0R:I"*)F#H8BA0.0P=>O0Q3
M("'4 'H(#[\4KK^KV'G@D_)-/60-A9!(>61\\#,5 6%H#OL\P#850!44/$\(
M5  _9W!UQ2NWBE1]M!S%Y/Z8* ^X^FN0 &_Y@%LX^F#_ +OPB@/4/?[NGY!'
MJI4@L4IBE4A-D6A'J=G:>.9DF1<MI8($?.S.HU-DJ=&5CHB,C9![)V-DZ:Q[
M)%-$4/,0:\@DJ#QRRAD4>"0&-A,N=H#>F4!FW(%)#K&B,SRJRJH QF-G!W%8
MP.[;E;B,VC[1(Q0V<C&- DID :&6::6*.&UD1Y9&+!MMPD178CSLU7 (" "
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M+;OG9_Y&,GW> \J;ONKX4]D0^);=\[/_ ",9/N\!Y4W?=7PI[(A\2V[YV?\
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M\9G2TBZE8R</=#'#MP!+96M] JZS/;2<XS-'<6&MZS'.J]?IX= 63=O6 +M
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M!\0RO^UOW\BKWG H&_VB1<NG';T*'1/Q?#+[Q*4!,;K&<_\ 0']*@G//E^0
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M7"2Q)-*J"1KW9WZQ^F*4Q2F*4Q2N#&*0ICG,!2D*)C&,( 4I2AU,8PC[@
M1$1]P![QSY9E16=V5$52S,Q"JJJ,LS,< * "220 !D\JD D@ $DD  #))/(
M <R2>0 ZZA30VX[WW;-[(D"BYH^NURQ%/;J$,9F^DD3G4;/0(<.PQDS":;6'
MM*J15>'34[DT>W-">CFW_P#Y%]/NO]*FII]+Z/.BZZ70^!;:56>RU#5H)'DM
MM11'&QWC).OS$JLL<USH,3EH[8J;VXAE_P#I[P'8<+VQ]%Q!Q-&;W7)58":W
MM9%59;<E>8##&GIS*,D=\ZX:3-37S?BJ(IBE,4K\**)HIJ++*$222(=1550Y
M2)IID*)CJ*',(%(0A0$QSF$"E* B(@ ".0S*BL[L%5069F(5551DLQ.   "2
M20 !DU]*K.RHBL[NP5$4%F9F("JJ@$LS$@  $DD #-8^]C;2U;R&+/Q>N)=\
M38VL#N;-2Y11@M'-]@04,J"=A?Z]E3B 6>+BY)LY0\S'"90LK%IKM"*QSQ-X
MMI5_$-8\/]+_  Q?W_!=Q<Q=(?1F\O%'">HPP/;3Z]I^ENLNLQ\.W@(?48;>
M6V:>W:VS(-4TZ VZM!<F9]D.%^$N+NC5M-O.)[*W/#'%@BTK7+1+A+F7AS4+
M]-VF6_$MFH)TF[O+:6)Q%<X4V=VT<S)=0- DN-.[!1V70(2S=R02)DACYUND
M( #::9 5-X4" (^&FY 4G[=,1$2-7:)1$3 .7UT'=)<'2QT;</\ %H:)=3>)
MM-XAMH2 MIKVGA8KY-@SZ*.Z!AU&VC))2TO;<$DYJF>-N&WX5XCO]*PYM0XN
M=/D?KEL+C+0'=]MHB'MI6Y S02$ #%7/RW*Q.F*4Q2F*4Q2F*4Q2F*4Q2L"O
M)'<O.#<>DX*N[$]$A3MY!.[*V/%SFL+G>8%^R@*Y3V]4^CO8<>Z>$,HUE+>$
M_;$&Z\8JVDHA."6*5PF1^8#/GYQSJ>7?^7C_ (\?=7C^C9;[YU;NV*HJOHBJ
M!PQUO=8^?+=MQP%W862QHEAX.2F8"(>O'KB0LLK'2<^S81Z; \B=BR5>>>!
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MM)4Q&@ZTK,&9,J,@JQ3EID#="J&EY0A'3LBOO]YVH&38E$?_ ,MJF']V9)T
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M]_:;XCYU[<?&1L2AY6+CV4:U[S*^6CVB#-#Q#@ '4\%NFFGWF I0,?M[C 4
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ME@L^%.#))[*66+3=:U3C6$H+GC"4JMU8SZ9<1/-"G"]L[%;.TBED6[D2274
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M6!3CF6EFD+SSR232.Y\S?MKJ,WJ"\1S.PP[QVK&ME6[9%Z@HJJJTE&#PI4R
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MY?6:0JI,C)F!8#BD=2LQF*4Q2K2;MT[7M[45"@6>1F8J*;["TYL@CN!58HR
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MMF^[,8/N\1YTVGO7XT_=3VTC_P#*+?\ 4VS?=F,'W>(\Z;3WK\:?NI[:1_\
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MJ,06-M%;0C .!B.)1@<AU"JBNYI+R[N;N4J9+JXFN)#O7F\\C2N>OM9C7?\
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M.Z.J=."?SCEVJZJT:U2$]9:*-TI-R\54<'+H_P!*_2-P]Q=K?^E-:%]+M_\
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M >1R[^1:*K).XV9*O N16,R54;KMF*KM\*R!C*,9@X)-#*H++/ ^S<V;E3)
M[,&C;)6-BK(I;<I8YW)+CT9]7U2S^JWJGKI!=Q*RQ7C1JR21LJ/,BLDF$=&5
M2 4DB 613D-@*0R\QY""U[C4T4H6-DF"+46Y4DG-Y/8/--8R0638LWJ]L9V)
MV5.2AW:RTX[:N$I4\DRCF[>0%L59V/&L\";0KWB@>B!!D67U41]RYG,K'=(0
M&;(D= &WHR[6YW625G::/3Y2_ISN6V-J5>9H\2*MD;9 8U0F*-E:!&=P8G#
MK'+9%OV;LN6)H]J[CWXI*MW%AD&C=)-T",6HX4[YYZR=(PYC+%-&OWD<QCHU
MNQF2I1J3AWW$\+1K^('BW4^F#C31?X<N!KV22![JTU'I)UJWCWQ:9:6#QS2V
M-PT+^AD6RD,=Y<0GT2R:J=)TWTD=P;B-+GX'TC3^%-+O.D'5K3T,@2XAT"R:
M<E9S<Y6*2!98S/&TB!X$D>2X8VIN;G9L",\C8*;V=6(6*K\30:>,=#L&T:S
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MF-R]X\:8/7CE\_/N/(TP2!UD4 )ZA\]=,9'>/GY_KW4P>[YZ_P"E,9![??\
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M\/N13QN_2.DS>8\SXW]N%V#O\W))2[C\FC@[?$D$$G'X/;VB3PR=J)C)B!P
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M\Y]=^>3N/VNTC/XT4B-R*^+XFDM)F\8'8*_VX78.\'TBE*NNO31P=/%D$$G
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62F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g65062g40x97.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g40x97.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1+ 4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M    $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO
M;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG
M:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M$ .__C4  @ ! [_^-0 "  $X0DE-!"8       X             /X   #A"
M24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M       ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F
M  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M      $ -0    $ +0    8       $X0DE- _@      '   /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z   .$))300(       0     0   D    )      #A"24T$
M'@      !      X0DE-!!H      S4    &              $=   '9
M       !                          $             !V0   $=
M                  $                         $     $       !N
M=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   $=
M %)G:'1L;VYG   '9     9S;&EC97-6;$QS     4]B:F,    !       %
M<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M       &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R
M871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   !'0    !29VAT;&]N9P  !V0
M   #=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$58
M5     $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,
M8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T
M   /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU
M;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP
M965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S
M971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T
M<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@
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M# P,# P,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M         /_A1DQH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A
M8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED
M(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP
M=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q,B\P
M,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F
M/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C
M(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @
M(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q
M+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M
M870^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!;'0^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^
M07)U=F%N=%!I<&5L:6YE/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L
M=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @
M(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+R(^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C$M,#8M,CA4,38Z
M,C<Z,#4M,#<Z,# \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z
M36]D:69Y1&%T93XR,#(Q+3 V+3(X5#$V.C(W.C U+3 W.C P/"]X;7 Z36]D
M:69Y1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C$M,#8M,CA4
M,38Z,#@Z,C$M,#0Z,# \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP
M.D-R96%T;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R(#(U+C,@*$UA8VEN=&]S
M:"D\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @
M(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M;6TO(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @
M>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP
M92]297-O=7)C945V96YT(R(^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$
M/GAM<"YI:60Z0C=%0T4V04$V-T0X14(Q,4(V-#-&.3,Q1#$Q,C0R,$4\+WAM
M<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM
M<"YD:60Z0C-%0T4V04$V-T0X14(Q,4(V-#-&.3,Q1#$Q,C0R,$4\+WAM<$U-
M.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT
M240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO>&UP
M34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ4F5N9&ET
M:6]N0VQA<W,^9&5F875L=#PO>&UP34TZ4F5N9&ET:6]N0VQA<W,^"B @(" @
M(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z0C9%
M0T4V04$V-T0X14(Q,4(V-#-&.3,Q1#$Q,C0R,$4\+W-T4F5F.FEN<W1A;F-E
M240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z0C-%
M0T4V04$V-T0X14(Q,4(V-#-&.3,Q1#$Q,C0R,$4\+W-T4F5F.F1O8W5M96YT
M240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I
M9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO<W12968Z;W)I
M9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z<F5N9&ET:6]N
M0VQA<W,^9&5F875L=#PO<W12968Z<F5N9&ET:6]N0VQA<W,^"B @(" @(" @
M(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y
M/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HQ8C5C,S4Y,2UA
M.#@P+31B9F(M.#@R82UE.3 Q9F9A.&9E.#0\+W-T179T.FEN<W1A;F-E240^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,#8M,354,34Z
M,C8Z,S0M,#0Z,# \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R(#(U+C(@*$UA
M8VEN=&]S:"D\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D(R14-%-D%!-C=$.$5",3%"
M-C0S1CDS,40Q,3(T,C!%/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 V+3(X5#$V.C(V.C0P+3 W.C P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R
M86UE=&5R<SYF<F]M(&EM86=E+VIP96<@=&\@87!P;&EC871I;VXO=FYD+F%D
M;V)E+G!H;W1O<VAO<#PO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@:6UA9V4O:G!E9R!T
M;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P/"]S=$5V=#IP87)A
M;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I"
M,T5#139!038W1#A%0C$Q0C8T,T8Y,S%$,3$R-#(P13PO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP-BTR
M.%0Q-CHR-CHT,"TP-SHP,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D(V14-%-D%!-C=$.$5",3%"
M-C0S1CDS,40Q,3(T,C!%/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 V+3(X5#$V.C(W.C U+3 W.C P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R
M86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @
M=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO
M=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A
M;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I"
M-T5#139!038W1#A%0C$Q0C8T,T8Y,S%$,3$R-#(P13PO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP-BTR
M.%0Q-CHR-SHP-2TP-SHP,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @
M(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @
M(" @('AM;&YS.FEL;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL
M;'5S=')A=&]R+S$N,"\B/@H@(" @(" @(" \:6QL=7-T<F%T;W(Z4W1A<G1U
M<%!R;V9I;&4^4')I;G0\+VEL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/@H@
M(" @(" @(" \:6QL=7-T<F%T;W(Z0W)E871O<E-U8E1O;VP^061O8F4@26QL
M=7-T<F%T;W(\+VEL;'5S=')A=&]R.D-R96%T;W)3=6)4;V]L/@H@(" @(" \
M+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O
M8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B
M92!01$8@;&EB<F%R>2 Q-2XP,#PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N
M861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @(" @/'!H;W1O<VAO
M<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D93X*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0]
M(G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0'_P  1" !; ET# 1$  A$! Q$!_\0 '@ !  (# 0$! 0$
M      8'!0@)! H# @'_Q  [$  !! ("  $("@(!! (#   & P0%!P((  $)
M%AA76)27U-<1$A,4%1D:5I;5%Y(A"B4QUB(C)"91_\0 ' $! 0 " P$!
M          $#!@(%!P@$_\0 11$  0(!!P<(!P@#  $%      $$ P(1$U%5
MD=0%%%22D]/P!A(6%U*4H=$A,59A8I7A%4%QHK'!TN('(H$C,C-$8_'_V@ ,
M P$  A$#$0 _ /OXX X X!P!\82R]I8W9[0:D-;BC:EGA< KMW+E(3J,:T2
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MN8\BM];)6"HS;EWJD[*ZNF,Q!L,#(F53$<\DH:5L4K=DN4[DV%6(%,8YJ3>
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MO:^QMDG40UD9-\41),C!RN%<-6,:G7-93R5@/1Z:DNW#EL!N1EX]=PUS3_\
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M]"HGNG,D.1*D(J2HLN+.OH66D-%3W)1R)"3?BBK[RV>8C(. ?-%XQ^EN^GB
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M&ZLVQ:NGK;)=OEBDMTDKGVGT!59?6&S%A;,RVRE!4!<6N%?$KVA0&=$WC*M
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MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
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M0N%%IXL&XA8;FI.&4@<8K$IS[M- [^S A%M0GB;B@;:!Y4IIL42'U@.=[T'
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MI2,P<DWE9\9AIUZ01$;]K(2$8U:MW"B(&SW ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M='M6[%@P8MTFC)BR:)8-VK-FU;X)H-FK9!--%NW13P212PP33PQPQQQZ ]7
M(<VKNOV1I(60S!0YI8DM%HPDJ>MAF$0-).%;]I9-XB0*4F.$X\BT,D$,D6#E
M\HT2[12[P2Q[3P^@"8\ AQG7=?V,TC8^P@4./&$-+-9Z(9&8Q"%#2*G&76?3
M*9C6TVQ?(L99ITHITUD6N"3QOTIGTDMA];+Z0)CUUUUU]'77T==?\===?^.N
)O_YP!P!P#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g65062g42i82.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g42i82.jpg
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M 0$! 0$! 0$! 0$!_\  $0@ C@(3 P$1  (1 0,1 ?_$ !\   $$ @,! 0
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M; ;'\(OGT>J/;@E^E?R5?JO7X_)R+\]>(>T7J0'DO2(_HFJ./V.#^W)@_P!
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M+ZQYBNS7TOTS7U-:*S8B639S('DD<!C6#CD00@^2,JGME=?K._<.[L"C,/\
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MQ,O7MGS_ %RUK4/3FQG%-)=9,+4.LAKU$(CA6^9/RQ=MD&172-?=ZH#]TL;
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M@B+R&*>>!YXY9)%6OW):> P,HB9PQCC:42>)QR50Q\'OQF_U%5W_  \\!?\
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M5SE7RJJJJJJJKY5?E>M!B2223R3YDGU)^9SZG@         <  >0  \@ /(
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M&-,<Q&N>002A8GJ*G4:ZJT[[C5/' .;=9Q9JCT+NBLKQ _ R1LP7S \01\D
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M7W,>0/W(87,PI[2=RUB]#IXG/@TE6>R ?)[4J<HI^!\&!@0?@TSJ1RN?73Z
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MY\FGNLUI<_\ >QD8U2S<ZS)M5S6JD?U*K^L@P=?I9@2OU#I:>V"#@3]D2O\
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M1K&-17.<J(B*JHG5"0 22  "22>  /,DD^0 'J< $G@#DGR 'J3\L^E$4!2
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MHCUD T:NBA1?2"-%"%GAK$3K578VWOW[MUR>ZU9FGX/\T22,RJ/L12% 'D
M!GZ4.@^EZW1/172G2-146'ISI_4Z<%!P)9:-*&"Q88_SI+-A);$KGS>65W/F
MQR)NO%DLPZ8R<^Y[_;(<^?ZX^2?^N%OU<=O_ *:['_?MG_GGR#>S'_4WZ"_X
M'=-_]#T\@SJW9.<.F,[!>U[H_?\ <]GW&>][7I]WVO4GN>WZ_P 'N>CSZ/5^
M'U>/5\>>@XY'//'/GQZ\?'C[<XOW]C>'V]_:W9W\]G?P>WN[?/MYX[N//CGC
MSR_7)_/8M?VQTV4E9PL7CJTY.Y2I^*LF*Q8].,%XXR_;JS$3PR?I!#MIYL[>
M[J!MI#(]<S6Z/?Z+:S([;MT?VY+<V(GU$<)B*U7N74IP!N14]UBU8KL#P [&
M*2PM@@()Y;,MAE$A'&!.F.@GT_M,M[6+8I+U%6Z8Z7N=5[9ZQ4]4#J/:>T0[
MN!X_%=JD";"AHI])&9+!U.NT&NTL,AI"3NH#U&LS[ATQF4#['/ER3Q)]H#PJ
MOU3H]/R8>ZXDT FO5B38^TK2LS\9WSZ7-9N8&3E^ER.1RQ4:WTO5KVRWH>ZU
M+J2A];B.V9*4H_I"=#X0_P X6$_HS6'Z8?24?5GL!ZT_DA)<Z:2EU;0<KW>#
M)IK*G82#X@G1V-M#R"./%Y/*@@[['6Q>?!W#IC.HQAQPFD&=Z @$0Q7JBJC!
MB8KR.5&HKE]+6JOAJ*J^/"(J_'3&?(TF/,C@EQ#BDQ9(AGCR $:4)PE:CQE$
M5BN80;V*CF/:JM<BHJ+XZ8QIUG^6;;3S'?+:JLH:$'\!F*V9=V"I_!3BL*A'
MI_",-?U7IE?@/+YGGY_C@YC]^U@Y#/CNUHV:A'<*7R9M<]E3H-WH+]SUZ2]9
M9/:Y/#D$\]!70)+6JGN!L'">CA$(BZ__ $DMX^J]G3T(G*R]0;:CK7"GAO=8
M1+LK# ^O87I002 >JS]I!4MFU?T.NFH]Y[78]I/&'AZ4T.SW$98=R>^V3#IJ
MJD'D=ZILK-B(G\UZP=2'53FL'U\]\^LF<F(Q7M0CG-8KFH]S&H][6>4]3FL<
M\:/<B>5:U2,1RHB*]J+ZDJ..1W$A>1R0 2!SYD E02!Z L 3Y<CURC=W:>T
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M;#IC#IC)S[GO]LASY_KCY)_ZX6_5QV_^FNQ_W[9_YY\@WLQ_U-^@O^!W3?\
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MG/,MBQ*W+S3RM]:21R68^7DH '9//)8D,DA!/ 55 "I&B^2QQH/JI&@\E50
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M*1EYY5)%*^( ""6B8B50".60953P?,D @@\>9X(XY ^)'YP'S SJXHC<63:
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MLSU1K QH<2&60<KW*C6C$-[W*J(B*J]<DK6)&"1P3.['A42)V9B?0!54DG[
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MN7X1>O)?MI0I6KDG'96@DF()X[BBDJ@^UVX11\68#/32JO=MUJD8/?8FCB!
MY[0[ ,Y_R47EV/P52<S?PX@($2+!BC046%&!$C"3\A@CB:$(T_DP;&M3^2=:
MVR2-+(\KGEY':1S\V=BS'])).;"1HL:)&@X2-%1!\E0!5'Z  ,:F6_RVRUUY
M^8YMZM5"=^:.A9N..J+X7]4^^VWBHJ?A]+D\>5\JO#.P_#]?Z_E^CC'GTRF'
M3&'3&,F[7[ETM+HOW8-DQF5NW_W1?4R%/G)I5^$1D>U+)J_*KX1U^UZ^&C<Y
M&/Q^/W_HQ#YNXAQ_/W$7(O"^^B+,R')>2N,E=,&C%DQ0VD5XH]I7O(US0VM-
M-^FMZB5Z56)9P8DEOXA)U[]7LK.HV-+9TV[+-&Q%8B)Y[6,; F-P/6.5>Z.1
M?YT;LI\CG1:KQVZ\U:8<QSQM&_IR PX##GD!E/#*>/)@#\,_-$[E.WW>]K7-
M_(?!/),)T;3X"^D5CIC E#!T%.1&R\_J:?W?+R4VEICPKFM<Y5*./,;'DM%+
M!("/>/1[BGO]52VU%NZ"Y"LG:2"\,H^K-7EX])8)0\3_  ++W+RI4G"-ZG-K
M[<U28</$Y /! =#YI(O/JKKPP^7/!\P1D&=7;/)ATQE^\?09M.&^']-H+6@B
M\1XC+<B;O?,DTE;OI5OS?L.4I/&<7%LQ?]87',ZRT;.,*+C/9U=5(TE>VJS,
M71:V.R7%+8@+#[,TYV>SKPQS-LK5BE4IE97IK%JJVO6^UHVO<KJ) ;\UZK)(
M(',D[0UCPP0B\Q(GNM:1S'[M%'/--W(LW=:DL& 1>%XT!:3P$@E52X[8^]QR
M"1G5_65VG?\ D ?_ '2('_\ VMU7W'J+_7#_ /,3?_\ *X]XUW]!/_AH_P#]
MIG8XG$O)U;<4G!DJ%5<N542%JL+%;P9&XLO+ZUSU]339-3D-D'N>Y#^DU8JG
M[QO*JO\ V:D2;M*:13U)Q7DVK:6G&RH212[8-)K9':M;;\K-?BACGAE19+-;
M\@4NZN9>R&1_'58C*LL@,2.17FO85DJ%$LJ!+#Q4%=W:-U8K%+[_ #<2=O+J
M.PENTJI#$97?N5'5MYQY"D5:50EM+2%?7<"B-!/24>RT5-67V]S506L>6M=6
MY?;6.@SL%*\I8+(U8-D0CX[1O6]:(R?DFFK^(1'&\,+RAUEEJP2R0TYY!(!)
MWV*B0S,7 <F0EAR3GAV 47)RO:.YE=@G!59'17E1>TE>U)6=!VGCA?+RR#>K
MMGCPZ8S/9]@IV/S>?^Y$/<;LJ=[^(^W&SB7%::6!5A:?F/VF2\A417/:C#IC
M&O%N+4@".? L(V1C2@NCWGE,1>USJI=1I#I*T@&QW<;1R!3]>#6<E;,C<>GO
M1!J(&\G1K)4\Q9+NDM6;=WWV13[O2(921Y26>.8U'/KX0/BMQ^:WA@_G9N\Z
M.X2BIYEBT7U,EC61ZZ&B^'S[285D2L@L^47U2YQ@ 5R?N->XCO#6.5-5,REG
MW.5'W%25U6XOU!XX%?-E>/"S+&21\JRFN3PGATR>>3*<GCX<54Z8/G^/EZ8M
M=,8=,9UF"*0(H#,:4)QO"83T]3""(U6$8]%^%:]CE:Y%_-%5.F,:.*.4$"1F
MYA'/GY.0E.]Y%\DE5;1M+0V"JOR3ZNI='8<OER+81IXE<YX7^&/Q_;^W]F8$
M?M\.S*9R9QIG>['!U+IFKX=KGYWDV+#"I)EEQ9*FEFP+Y6#1Q"_L'>S9IIJ,
M8OMT.BM;.68<.@^,9^T;1-;J1;FLA::BICMJHY+TRQ99?+S/NTC,6X'^+E=V
M(6+/H7] SVRP]-=2[#V4;VV(=5UC978],RS.%AK=4Q0+#/0Y8A5_+U&"".$L
MWUK^NJ5HD::_FH/UA//KKATQB[G]1ILE-6SRNBO<S9*-0K89^WL*::HG*BN$
MLNND1CJ-51%5GN>E51%5/*)UV1330-WPRR0OQQW1.T;<?+N0@\?ISP[#5ZS;
M0BMM==0V=<,'%?85*]V$./(,(K,<D88#T;MY^W'U_7SSE_PS<K_](FO_ /O'
M7H_*.P_V=<_SF?\ Z^6+_ /H?_V,Z4_^7=1_W/#^OGG+_AFY7_Z1-?\ _>.G
MY1V'^SKG^<S_ /7Q_@'T/_[&=*?_ "[J/^YYX+/F7E^ZA2*RXY5Y)MJV6-P9
M5?9[G3SX4D3T5'BD1)5H4!AN151S"#<UR*J*BIUQ:]==2CW+3HPX96L3,K#Y
M%2Y!'WC.^MT;TA3FCLT^E>FZMB)@\5BMH]7!-$X\PT<L55)$8'T96!'P.1OU
MY<DF'3&=@0FD&%'CB(<YR,"  6.*8QBN1@Q"&Q'/(0CW-8QC&JY[E1K4551.
M@!)  ))/  \R2?0 ?$G.+ND:/)(ZQQQJSN[L%1$4%F=V8A555!+,2  "20!F
M_!]E#V<'[/.U>BJ-57-A<M\H2 \A\HL(QJ3*B?/AB%GL69Z)ZD_9"D]J-.C^
MLH1::=I#12OCR1N78WH[1G2:>))D[;MLBS<Y'UD9AQ% 3Z_R$? 8>8$K2\$@
M\Y\&/I5^V*/VP>U*]<U5DS])=,1OT]TNRMS#;KP3,^PW2#T/Y7O=\L$A"NVM
MAUJ2JLD3 7^EK]][&# 9^.!D0_?$]?S8^]LXYX=/$=^CG0ZTMC8G&OE1/E4Y
M_"*X;NI7FM/S^WR_C_ 8]NF4PZ8PZ8QH[*+)^[8]S $\]EF)PKV* 2>2RX\<
M9H]O7C1/EQ9]+)L(T=G[JS'QGJBJ-.F!^_YXX@FA6T 1Q*"=7641A1JK6EC2
MX4P*.:JL>BM($X")Y8]JM>QZM<WPJIUQ95=61U5T92K*P#*RL.&5E/(*D$@@
M@@@\'RSDCO&ZR1LT<D;*Z.C%'1U(965E(965@"K @@@$$$9J+][7;A.[:^<M
M#F8T,K,)I#2-1QS/5KW1RYR?)>YU-[[O4CIV8EN)32V/>L@@ P+(@QBLX_J^
M8_M:Z#FZ!ZOO:^.)QIK[/L=%,02C4)G)-7O//,VOE+5)03WLB0V&55L1\_:3
MV"^U"O[4_9_K=K+.C=0ZM(M1U/7Y D3:5XE O>'Y$5]M"%O0LH\)9)+%5&9Z
MDO%0^L8YFK#IC#\ORZ8R6R\B9_4,&3D['R]-=!$,2[',:0>/UUJP3&B"FHE3
M<_K:'0F")OA;8N>AZ>>15?<:&R] 4%)6WE+8*IZ@U<FPM(H7\J:^^-9L[(4=
MJ#8RS4MG3O,JCSLM1BV,Q\[5Z?A L,3IG9:@LO2>ZAU-%W9_R)M=6^[TM,NQ
M>3\DPP;+3;#6(['RIILYM374!:6LJ\N7Y1N0,EE'I.XXP\VIT;%1T/5;73Q=
MK:T!V_N3\M"K\OCZ&LLV>5='L[:IT-A5R$%8T4FIM8T6<&L>ZUFM/C:+3RUK
MP\XMCMMA'MK-)Q^;/KHH-?JZ=>RH/*6+-:]-7D"3TI*MB..9:2]-[K< U^J.
MH*]S5MY3:?0ZF;0U-C&?SJ^WGL[?=[&W4;R$M2G<UE:W$7J["*[3EFKR1,8Q
M9!2R)!2'.<CS&,9[BE,4KE>0I2/5SR$(]SGO>]RN>Y5<Y5557J-LS.S.[,[N
MQ9W8EF9F)+,S$DLS$DDDDDDDGG)DB)&B1QHL<<:JD<:*$1$0!51%4!555 "J
M      !G7UQSEATQEG>T3MYM>Y7FW,8((9#,Q%,R_P!_:A1S6U6/K3A=8HAV
MHJ"G6[WAI*I41[FV%@&0\:QHTEX\@^S+H>SU]U;K]*B2#7QNMW=64Y K:JNZ
M&QPX_,FM$K4K$<D3SHY4QQR$8G]M/M+I^ROH+:]1.\3;:9&UO3E-R";F[M1R
M"L3&2"]>DJR7[GFH-:L\2L)98E;<%BQ:ZDK(\.(&-6U-1!#%C1Q-9'AP*Z!'
M:((1M3TC!&BQA-8QJ>E@A#1$\-;U]0X88J\,5>"-(H((TAABC4+'%%$H2.-%
M' 5$10JJ  %  \AGQ-L6)[=B>U:EDGLV9I;%B>5B\LT\SM)++([<L\DDC,[L
M22S,2?,XV\:PDN-8::2-XSZF;]XQQE:K21Z, F1*".YCD1PW$KQ,LCA<B.#-
MLI;%\JGGKLSJ/R^7X)_'PXQY=,IATQATQC)LU^Y-95W*_AK]$ 68M'?DP5D$
MIY>;E$7\FM,2195#GJGDDF?5B5R(UJ=,K\/W?Q_A^W$OES  Y*PESF7>VR>\
M;9U)))X1L6ZA(XD)[G*B^@4CR2#)>B.<V)+D*Q%?Z>KQH=JVGV=>Z.3$"8K*
M#^?7DX$@X^)3RE0?&2-.?+G+1N]8NVUMBH>!(0)*[G^98CY,9Y^ ;SB<\$B.
M1^//C,-<Z#+K)LNNL(Y8DZ!)/#F13M5AHTJ,1P3@*Q?EI!%8YCT_1S5ZV%BE
MCFCCFB=9(I462-U/*NC@,K*?B&4@C[\P1)&\4CQ2*4DC=HY$8<,CH2K*P^!4
M@@_:,\O7/.&'3&'3&,6_XXRNCM'7<P=[77!(H(,JRRVPV&+F6,2*\I(<>V-C
M[VC=;C@ND25@):?5K 25*2&H&R3H3N2Q+&O8O8R<E@LL,,P4GCDJ)D?L[N!W
M=O'=P.>>!E0Q'R_2H/KQSQR#QSP.>/D,2/ZH,K_YYY1_Z;>9?^WG7/WN7^A6
M_P RI_\ 897N/R7_ (B?]7%S.\?9C+V!K>O%<S;<T-U<EMIM7JME:1JXAA23
MU]?8:ZZO)=7 E28\:1-A5IHL:;(B0SRQ'-$CO%PDGDD4*Q0*#W=L<44*E@"
MS+$B*S $A68$J"P! 8\T))]>/T #Y^?D!Y^9\_M./7KIRF'3&7J[/^,BDE3.
M3[6.K01V2:C+(1GCWI!44-O:"\HB^B.%7U8"-5S"$D60U\/C(O6,NO\ <J$C
MTL#@LY2>[P?S54AJ\#?#EFXG8'S4)"?1LR)T-J"TDFWF7ZJ!X*?(]7;E9YE^
MQ%YA4CD$O*#P4&7>U%N6FII,F(QIK.0X5=31G+\2KBP(V+7!<GROLI((PTIZ
M(OLPQ2)#D] G*F+,R9GKHJH5'3UM0%[BM@1 QW'?_G))FM\R)9?E?)I<A2R3
M+Y_$4KU_7I@^>*O3&'3&'3&>&SKHEO7S:N>/W8<^,6+(8BJURC*Q6JX;T_$,
MK%5'A*Q4>(K6$8J/:U48],0,O9RWI)SUT7UZ"B00Y!G-1GWQ6D5[:V_ U/PJ
MV<,3ASF#\MB6H9L;P@V@>5E3^/[/Q]F8GOM<OLQ*WOLXWB[KC@%;4=R_&=5)
M%C;"2\,&'R%FFD-.D<;Z&P)Z!QWNE%D3L=<3'_2TUS*F1)9(E5>V4^'DKV==
M=R=)WFJ72\FCOR*;2*"[4YR BWH4'FP"@)9C4=TL2JRAI(HT:-]0Z-=M )(>
MU;L"GPF/D)4\R8'/PY/G&Q\D8GGA68C0OUN1U&"T]]B]KG[?*ZW+VDNET6<O
MH$BLN*:V@%<"9 L8$L8Y$:2 K5:\9&(JIX<WU,<UR[;UK->Y7AM59H[%:Q&L
ML,\+K)%+&XY5T=20P(^1^P^8.8EDCDAD>*5&CDC8JZ."K*P\B"#Y@_\ YQN]
M=^<,.F,.F,.F,.F,.F,NAV.=C?,/?;S! XUXTKRU^=KRPYW)'),Z&8V9X\S)
MC.:2PL"M<)DZ[G,%(!FLR"0.?>SQO1'PZJ';6U9&.J^J];TEK7O7G#SN&2C1
M1@)[LX'DB \E(D)4SSE2D*$>32-'&]SU6JL[:R(85*QJ09YR.4A3YGTY<^81
M >6/R4,P_0_[<.WGC3M8X:Q7!W$U1]U8_%5J11%/[1+:^MI#ED76GT$P0@I/
MO[^Q>:PLI*"$%I"MB08\2NC0X<?3/=;F]O\ 9VMKL9?$LVG[B!R(X8QY100J
M2>R&% $C7DG@=S%G9F.8Z5."A6BJUU[8HEX'])F/FSN?B[MRS'YG@   ![1'
M?M9H&V;5]>=S$B0&J=^8K?1(TL.=9L\_A+#I1/D5L$J>6&L#V)F^4AQ"OM6>
MOX??Z_C\?#S]<??3*8=,8=,8=,8RM*$]1-C;& $AE@1U@Z*&!CB&GYU2.,IP
MB:BN-.H3O)8Q!M12&B%M886N/,#X97[/U?C[?[//C'%)C5&DIY$*9'K[NAOJ
MTT67$E!!85=O46<5P9$:3'*TL:; GPSO$8)6$!(CE<Q[7C>J+Q=5=61U5T=2
MKHP#*RL"&5E/(*L"001P0>#G;6LV*=B"W4GFJVJLT5FM9KR/#/7L0.LL,\$T
M962*:*15DCD1E='564A@#FD-]JI]F-H^SO;V'*7%]3877;-L;9Q:N8!IYQ^*
M;BQ.KFXK3&7W#-IGG?[6/T,MRMFQE#26<E]Y'9)M\ ]8=)2Z.PURFC2:J=R4
M8<L:;L?*"4^9\,D\02M^<.$<^( 7^V_T6/I-:[VP:2OTMU1;KT_:7IZ@6U#(
M8X(^JJ== #NM8@[4-U47OW&NA ,,G?=JQ"C(T=/#GU!\W#PZ8PZ8PZ8PZ8PZ
M8PZ8S9O^QF^RUM)MQF.\/N+S9:^GJWQ;[@KCV\B*.9<V3?1(K.4-%7R6(^+4
M5Z^B;A8$D;9-K/2/JG,!50J4EYECH7I%V>+>;.+MC7MDUU:0?6=O5;<JGT1?
M(UU(Y=N)CPBQ^)\S?ID_2BJPT]G['_9WL5L7+0EH=<]0TI0T-.L>8[/3&NL1
ML1+;L><.\L1L8ZM?Q-4#):GNK1VC=#=LHJ]9#0NF3Y)AP:BM&Y&FL[23ZDBP
MQJOGT,56N-*.J*R'"#)F&\! 14S!GRQ'ZLXYNF?2UOLR3-EV<V0:RNIS6JU)
MMM,5KY16-<JN'&$C1Q((55?IZ^-%CHJH)%5@XO=,8=,8=,8=,8Q*=W[+W#\P
M=?13VI94_)F7X& KU?*M,TYR_#7Q7N-8U _CW*PDB(%J,J'*YE3YCGX_'^W^
M!^W[\A[NO[9,GW2\73,3=N%5Z.M>:UPFL0/NR,WH$#[;5(C4]V12VC&LA7M>
MB^),;VI0498P*Z3'Q][2?9]K?:+T[+J;96M?@+6=/LNSN>A="\#N ^M)4L "
M*Y #]>/MD3B>&!TRM['?:ON/9'U;!OJ >WJ[2I3ZATWB=D6TUI?N(7GZD=^F
MQ:?7V2.8I>^)RU6S9BEU+N4^*]SPQM[KCWD2CDT.EI#JPP"HKXLZ*]SOI+:I
MF(U V-18#:IH,^.KA&9ZF.]LXS!'\U.H^G-QTIM[>CWE-Z=^H_#(W)CFB)/A
M6:TO 6>K.H[H9DY5ARI[75T7[)](=7]/]=:"CU+TSL(MCJK\?<DB$+-7F4#Q
MJ=R#DO5NUF(2Q7DX=&X8=T;H[1YU8\DV'3&'3&'3&'3&'3&/;COCK9\K[&DP
M6 H9NCU.@E-BU];"9Y\)^\>9,.]6@@UT(*.DV%A+(&)"BC)(D%&-BNZNVCT6
MUZDVE33:6G+?V-V01P01#]+RRN>$A@A7F2>>5EBAC5GD95!.6'J;J?1]':2_
MU%U'L8-9J-;"9K-J=N.3Z1P01CF2Q:L/Q%6K0J\T\S+'$C.P&;8O9YVJ9OM5
MXR%FXI(UON="L6TY!U8A*S[VMA">V/6UZE:TX\_1-.>+4A*@WF>69:'""59'
M /Z3^R[V<4/9QT^M",QVMQ>\.QN]DJD>\VE4A*\!8!UHTPSQUD8*79I;+HDE
MAT7XY>VWVO[3VO\ 5;[699:73^M$M3IO3NX;W.F[*9;5D(3&VRV#)'+<="RH
MJ05(Y)(JL<CSWH7KH[)F-BJKH36@FZ^0Q5] JMZ^N-0^IJIXE:!S%;)'Y]0J
M1DQ[T8^;!>_)>8;]//\ 5^/X_,??CY1$:B-:B(U$1$1$1$1$3PB(B?"(B?"(
MGPB=,IGWIC#IC#IC$VXJHMW63:J:C_IYH7"<\3O08+T5'ADQR(BJ*3%.P<F,
M9OX@R!#*W\3$Z8Q(S%O*ECDU%PK&Z.B<.-:-:U!CG">COH;R&S_R&V"-Q6HW
MRV+,'-KW*I8;U5@_9E6NY?@4VG0_(.,AJ6_CA:NAIXS/);J-'&C66,(;4\DM
M8H6-&>.U%?811L4"+, @IN1.CNJ%I=NJV,G;59C[I8<_5K.QY,,A/I [$E7/
ME$Y/=_)MW1P+JSIMK8;9T(^ZRJ@VH$'G811QXL8'FTZ* &3UE0#M_E%"R8YE
M16JK7(J.15145%145%\*BHORBHOPJ+\HO67 01R#R#Y@CT(^>8LSYTQATQAT
MQATQATQATQDV\*\,W'*]ZSU,/ R=:=BWMTC/2BHGI)]UUKGM5AK.2Q41?"/'
M!"])4E'>8\>5&^H^HJ^BK'@K+>F4^[5^?O'C3 'E84//R,C#L0CZSI(-!H9]
MU9'(:.E$P]YL<<>7D?!B)'#3./O$2GO<'ZB/EKJ:JNHJR#3U,0,"LK(H8<*(
M!OI$",!B,&Q/*JYR^$\O(]SB$>KB$<Y[G.7!$\\MF:6Q/(TLTSM))(QY9G8\
MDGX#S] . !P   !F:X(8JT,4$"".&%%CC1?144< >?F?(>9)))Y))))QJ5;O
MVJO4T'[U!1.E0\Y^H[*S>U\6TT+/[KXP!*:HJ"IY0HR6LMBO!*B$ZZL[OX_C
MC]Q_!Q]],IATQATQATQATQC;T%&6R^EL:R0R!H:E2$JISVN> C2HSZJKLAL5
M'GJ;%HQLE":ON!*./.C*V7$ Y&,[*'0!N6R(Q@/K;NN5@[>EDO:Z3!*]%]!1
MO:C63:Z5Z7/@60$6/+$BI_92!R(X65(X^W[<QO\ V@WV57 '?M5/O[8:\9\Z
M5M>V'GN8LW7 D398(XU9#IM[2>["#M*$"(UD5#S(-]4,:T=/>0X3YE?-GG1W
MM W'2,@AC/OVI=RTVLG<JBECRTM27AC5F/JW"M%(?.6)F[76P[C04]LI9AX%
MI1PEE .X\>BRKY"5/+@<D.O\U@.0=,;NZ^S"[O\ LSGV4KDCC6?I..X9"NB\
MO<>!FZKCV1#:Y4')M;"+$98X\I$3T_1[*MHC$(TGT7UL=K))-FNG.O.F^IDC
M6E>2"ZP ;6W2M>X'/JL:,Q2R!_2JO, ..[M;E1C38Z+9:TL9H&DA!/%B$&2(
MCX%B!W1_=(J^?(!/KF/CJ999\.F,.F,4*FHM;ZS@TM%66%U<6<D4.MJ:F%)L
M;.PF'<C Q8,"&(TJ7),]4:($<1"D<J-8Q5^.N$DD<,;RS2)%%&I9Y)'5(T4>
MK.[$*JCXDD ?$YR56=@B*SNQX55!9F/R"@$D_8!F>'L@^P1[C^>YU/LNY$5E
MVX\2O>"6:IM8P7<R:>$JM>Z+59*4TH\4T[4( MGN!Q[.O(HI ,?<QW^I,2=5
M>UW2:A9:VD*;K8CE1)&Q&L@?T[I+"D&UQY$)5)C<<@V8CDLU?25VV5EO=U.O
MR#V'CWF1?DJ'D1?+F4=P]1&1YYN/]O?;EPWVL\:5'$W!V*K<5CJGR<H8J.D6
MM[;%$(4S0::YD*2QO[^>@1))L[$YBM"*/"BI&KXD.)'UJW.ZV>_O2;':VI+5
MF3R!;@1Q1@DK#!$O"0PIR>V- !R2S=SLS')%.E6H0+7JQ+%$OGP.2S,?5W8\
ML[GXLQ/P X  #SL)\G629%#0R"@J(Y71M)HXSU9^XOI/0T1V_P"<LB?(;*R"
MJCIA*\(GNM7(V':L]?I_?^_\?M&/6)$BP(L>%" *+$B!''C1@L08@ "Q&"$-
MC?"-8QC4:U$_1.F4ST=,8=,8=,8=,8=,9'KT)A)!C,8\N)EF(>0,3'$)D91W
MJ0\@8F(KG9J25SC2!B:JT<AY#M8M44OW:ROK]_[_ ._]_P!_JY-!G\SN,W:9
MO34]-J\GIJL];<4MQ#B7%'>4]B!1R(DZ%*8>'/@RP$5KQE8016.1?"HJ+UUR
MQ13QO#-&DL4JLDD<BAT=&'#*ZL"&4CR(((.>S6[+8:>_3VNIO6M;L]?8BMT;
M]&>6K<IVH'#PV*UB%DEAEC<!D=&5E(\CFKGWT?8)WD*=<<D=D\D5O4'>>?.X
M(TUL.-;5:N<XCP\>ZVW.R):P6^KQ'H-;.AV,40G)'T=V<X( <2=0^SEPSVM"
MP9#RS:Z9^'3XD5IW/#K\HYF5@!Y2N2%'U!]AOT\J4T%/IOVU1/4MQK'7@ZZU
ME1I:EH !0_4.IJ(9:L_E_*7]3!-7E9@9-=31))WUQ-]QSO\ BO2SL;R7B]1@
M=76N5L[.ZZCL<_;@3U.:PJP;./&.^,96.='E#8^-)&B% 4@U:Y<6V:MFG*T%
MNO-6F7\Z*>-XW'V]K@'@_ CR(\P2,^C.AZCT'5.M@W/36ZU>^U5D<P;#47JV
MPJ2'@$H)ZTDB+(G($D3%9(VY61%8$!F==&7G#IC#IC)KX0[<><^Y#3#R7"'&
M&LY%N%*(<MU%6O6GIFG7P.1HM'+=%S^;A.7X2;>V=?%5RHQ"J]S6K[]?J]AM
M9A!KZDUI^0&,:_R<?/H996XBB7_*D=1]O.0KK?VC=#>SC6-MNM^I]3T[3[':
M%;UE??+IC'+1Z[6PB78;*8#UAHUK$H')*!02-J#L"^PWP_"\^DY8[K95%RIR
M3 ?'LJ+C2O8Z=QED)PU:8$F])- %^^NXCT8K(\F'%RL"0AT2%HG,@VH,O]-^
MS^O0:.YN#'<M+PT=51W5(&'F#)W >\2+Y>140J>?JR_5<?+7V^?3@WG6D%WI
M3V5Q7^E>FYUDK7NI)V$'4VX@8%'CHK [C04IAW=SQ32[6Q&4YGUP:>J^?BWN
M*Z@@K-GD406O''C@"-Q94R45?1&@0(@D4LJ9(<GHCQ@,<]R^5\-8U[FY*SY_
M^9/)/))\R3ZD_$D_O.(=)53YD_\ :?1"05FX) 4]0A&&#FZXRM4@E(Q7"/<S
MT:-UK-&KAC:P==">Z*$AYC']W/W^?]OX^#QZ93#IC#IC#IC#IC$JZIX=[7EK
MYJ$:Q[AF!(CO44N#, ]"Q)\(Z(KH\R(=K# *U%1'M]+VO&Y[',#RQ$I;R6"8
MS-Z91BO6L>ZOGL9[,#3PP(BNFP$558&P"/PZUI_4I8C_ %2(R&KGB.C&1'W&
M]KG%/<]E6Y_D.I<.UKV'7,[*I]F-I\S),B*]T&8\1&2:\[VL6=33QR*V9Z6%
M4(IH(DR-!>N_9YTW[0=:*.\K%;,"O^3]K6[8]AKY'X),,K*PDA<@>-5F5X)>
M W:LJQRQY.]F'M;ZQ]D^W.RZ:NAJ=EHQMM'<[Y=3MHHS]46(%=6BLQJ6%>]6
M:*U!RR"1X))H)=<SN+^SPY_X#DS[2)12.3>/@.*0&SQ<&3--%AM57(32YH2R
M;>@(,:(^5)1MA1A\HUMV5ZN8W17KKV'=:]%R36(J;]0:1"S)M=3#)*\<0Y/=
M?UZ^)9I,JCNDD GIIR +;'D#Z=^S'Z2_LX]HL5:I-L(NE.I)%59-%O;$4"33
MG@%=5M7$5+8J[GMAB)K;!^"3010&-#E14545/"I\*B_FB_P7K#>;#^OIATQA
MTQATQEW>W?L![@>X*3!L(^<D<?X*0X9#[O;0Y5;#-#<J.4N=IRM#;:4A!^M8
MI800TQ#,]F5=057UIESH?V*];=;/#/'1?2Z60JS[G;1201/$>"6HU6"V=@S+
MR8VB5:C,.R2W"3SF _:9]([V;^S:*Q6EV<?4G448=8^GM#/#:GCG7D!-G>0O
M2U2J_:)DG=[RHWB0T+ '&;&O;/VE\4=K>;?5X>N?8Z:S )FGWER,!=)?O8K2
M+'0HVH.II1F:CXE)7^B*/T"-,)86"$GFWJZ ]FG3?L[H&OIX#/L+"*NPW-I4
M:_=(X8IW =M:HK@&*G!Q&O"O*9YPTS_,/VJ^V3K'VM[1;?4%E:VJJ2.VIZ=H
MM(FKUJL"HD[&/?<O.A*S7[/=,W<Z0+6K%*R3C>7\EDI,]GF!F:20)I'J5'/@
M4$,JJU+6Y5BM5K/".^@KFO9*M3M]L7M162YL7(68GQ5HJ6-104B (628I22[
M"PDJUTRSL)"HZ5/F$:C6N,9R(C6,:T,<# Q8XQ1@!$QC%CIC#IC#IC#IC#IC
M&QH*21,)%N*8PH>CJFD;!D&]219\0KFODTMJ@T4A*Z8HV.0C4<:!+8&=&:YX
MB!.RH/S]#^.?O']H^.>FBOXUX([4$6!:0'M!;TTM6I.K)+F^I&%:U58:,=J*
M6%/ KXDX"H:.1R>MK&4_'X_'WY7OF+MFH.0"R=!F"QLUK"JXLA5&Y*6Z,ORK
M[  &.)#F$=\OL8@R*55>^7$E&>AF37I_K*UJ@E6XKW*"\*@[A[S64>7$+,0L
MD8'I#(R@>021%':8?O>DJNS+V:A6I=;EF\O]#V&/F3*J@E)"?65 >?,O&[$,
M,>&SXXVO'\M8FKH)M:U2*,$_V_J*N9X\JBQ+('N0SJYJ>M1(5) VJB&")_EJ
M99UVWUVUC$E&U',>.6BY[)X_F)(7XD7@^7=V]C$<JS#@YB^_JK^LD[+M:2+D
M\+)QW0R>O'ARKS&Q('/;W=X'YRJ?+&1U<LM^'3&'3&>N# G6<H,&MA2[";)>
M@X\.#'-+E'>OY,#' PA2N7_"QCE_EUURRQ01M+-)'%$@Y>25U1% ^+.Q"@?:
M3G...29UCBC>61SPD<:,[L?DJJ"S'[ "<M]Q9VEW]T6-;\C/)G:=%:5M" C'
M7T]J*CD'*>SW 5 ")X]:.<:P]/K$Z/"(K3M@.[Z[JUU>#4 6['FIM.I%6+YF
M,'AIV!]/)8O1@\@^J9QINBK-@I/M2:L'DPK*0;,GR#D<K I\B?-I>.5*1MPP
MR$T=%49JJATE#7QJNJ@"0,6%$&@Q#;Y57.7\WE*5ZN(<Y7/.<KGF,0A7N>N*
M+-FQ<GDLVI7GGE;NDDD/+,?@/D% X"JH"JH"J H &3J]:"I#'7K1)##$O:D:
M#A0/B3\68GDLS$LS$LQ+$G&K-EFVAS4U08@<R$CX]_>QWN&MFX;E8>@HCL5'
M.:YR.!<VP7>B,/W*^"1T]YS5O1GH]/7] _B?X#]/IZOL  10!C1@CCQXXA@
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MVH\.USVODU=Q=*U45&VMW+:Q51?**YE5]V->GG\VN16.3X<U4547SS]<]03
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MP^-Z*S#+A\'9*FLK_<:V\WVVY&Y/X$Q7/-F!N#X>[>+@]B.BR%[?R["3D,^
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M&G.^XA6\O22&55=0GCSF,[>%>]>5S'RM!Q</C)\#%W5UN\K2[J!=Z"ZBGO\
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M\G29P7,E?4I6 DR6P:+'[>BS=#8UG<'A.X+"T/'@*?F6#KL/QUE[7$LRY,W
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M'6"XKY*K;;$R-/=IEN/=YJ]S5S^-[X.MS\?%ZB>3;Z*NGVEG2ZN,R2#(:"+
M%+R38=PQG??=JE/J>"Z[@S2757?4(>;J;ENY6XR8+*IT%76]R@>X&9BK#/2[
M8L8L6TC#?BSV$B5*"C2NNR5!V>:5S&1+*^STQ!:?1<<5VBB9_@Z[U_,NEA<>
MT&1B5=Q0UO/7!6PX=Y"S<'8 MD27$99["?L,G.M*";.S4/T8<#Y.;K<ZRB8R
MSG&>-YSJ+YUORYS'F=U!@Y<6;J*#$<8%X[JYU@Z9&E6&XU;K7<<@6%CII(8,
B:#70**;G,W3QY5X]]9:GLX#Z-C)SZ8PZ8PZ8PZ8PZ8S_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g65062g46g30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g46g30.jpg
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M 0$! 0$! 0$!_\  $0@!HP([ P$1  (1 0,1 ?_$ !\  0$  00# 0$
M      0 " 4&!PD#"@L" ?_$ &P0   % @,$!00+"PD$! @,!P$#! 4& @<
M"!$A06'P"3%1<;&1H<'A$A,4%188.5F!T?$*%QE7>)>8M[C6UQHD6&)YB)75
MV"(E)Y0C)CB6,E5DA(6&D[1$149'5%9C969G@X>2LS2V=[7'_\0 '0$! 0 #
M  ,! 0            ,! @0%!@<("?_$ %X1  $" P0'!00$!PP&" 4$ P$
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M /%>DB_SG!->-M\&_)7Q2_N57\69_P#BO21?YS@FO&V^#?DKXI?W*K^+,_\
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M;<.U%U'YY*@MK9PV/DDN$9.E;$E2QI-*UB QN;(B8:]JW$XPY>E(;$8*"U(
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M?8+8/DAMD\2:Z2J!5P&X4P>%#](448]S3MD44RVM60@$D4H0Z@&V\XDFXW;
M-U5QK,\X^=ZT9^:VW%5S+V,<OCF6/+Q>:WBK-7'LDLHNE!)=/LSK9:%\=ZXU
ME-1&V\20"8QMQJ-20N<+'F6M2EO5*FIX:"U1'M!"&W7#^5>TNH:"M/K7U%>&
M%Q63-P[T9N,N,GSE1XG,).+\QW*!&,D>;AW7SVWEE4\\DMC+@36_#9FNM355
M;"UT&8JVY%;>S+Q/[;N+1%4DX:9(01'3I$[,QHD5D !I<!4D9XT%,3M/!=@F
M2Z[DXS!Q"ZM]G:1$NUK+B7MGJ?+.U)F]F2H&^Q%O#45KV"4$.3>@)=G\B[LL
MALQO$U.KVX.)@1.=1E"V4(&Y&2GJ+4BE!F!?Q-_@+N-<5U99:(OD:6]%.^W)
MSFL\%5RPE?<-^SHS9:133?UOS8LUQWXR9)BI(QB7=EMO4R7!1)FFT#<P+TTR
M2)TT(;(&30WU,959;&H>-7=J[*$;[J$8Y;\U[!;:<6H;D"@FA:62>B2G%%N1
M2HAQH+-(+K+H7D+J:5I*VFFH*512RFE46>!E"BD#J:P M$W!%8(L=<X'_9+S
M1?DZWM_5I)L$6BY&_P#L4Y/OR6\OWZIHE@LNQ/$\UE)@L*P16"*P16"*P16"
M+X]G2>_*3](+^6SFG_7C.<%VP_L-X+Z*OW.'\C'DV_O#?M5WRP7-%_*.[/NA
M;-SVV*S&W?Z5C*N=861Q:VE2+);F$:WRZMS<ORJ_]LVTM?<BWM5466,!\IA#
M"GE3R2 +68QQD8F D;G"BEH7)SSJTY&D!AK4_6%P-*W'&XW=F*P]NMEUE_1[
MHLL&4F67XSTL62J 95[_ ,@9+P9-(W<V-2Z?Y\YE>1=.4D=FK;E]9I2ZQ2(U
MQ^5.ZRS]N'HXJW2UV*%KD#H^4MSJ:H+(.M4T;K%PN=AJTOQ/><<[J56-3ZT]
M(3$;N.-\W]+F60Y_[F=!]#S(20RM%PG&,O=_XO)[E)9U#5S*PL2^VS1<6-6E
M0IKK(;7/@-:1/F"? =6!B.F$H;VM<6?JW 4U1$-2:5I]6E3C0WBNP7X+>EN)
M7GKDEB9:W0._&;ARM^_YQ^CGB4;E:=VS9/MTX4EEDH-;LSWO5=+,5:V"3V1P
MTUI51]?<&,+65ZMK;V1HW5N))HCCG4AJ+%&@W@5#7G*A(%6W \<;RN4Y@\9L
MK5)[BVIG5U<^5.2VW?2MR2&7-O!&I%?:<YDH]E3<<NL<E$*2,EUXZAD%]'*S
M07P<:FR13&(*W%X;$HTQ\A\**4'(S277$!NL6 @74UM:AN-U:8#,[2;PYCKW
MYM;"VBRKW(RW7 SSS6/YUK97;Z.^W+7F^=38_=V(W_N-<Q<YY6<RCE&$!B,Q
MKD(10+@I&2<2!H0W%=K<QV!/,]I<'JLU260 $FM/JC6^K@0!]85OJ<-H^U?1
M>TU;>(J(!;R"017)I'-5<+AL9BBJ93!U6ODLEJF/,J)I/DTG>G)2L<':0/IJ
M2MT>7%:K4JEKBJ4*#SS3#*JZBD<3DMZ8(K!%8(K!%8(K!%8(K!%8(K!%8(K!
M%8(K!%8(K!%8(K!%8(K!%8(NM)Y^6)MS_9I7I_:CL'C&8X'FU;?R/ZWDD=,
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M);6*'JYLZ0-.6I5WDN9;PE<YFO369[%*V&*@I3GDFFUET@;460"N8&&-<Z[
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MNR71Z..;:TOIM J)$Q,:M*16Y-;>806#7.NZM>LUJ5T2[-YB[<7(*L%F+LC
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MQC<2A2?,IDUEV9JZ:9<L+;U"*IH(:B4=IHK,G=8C2%+8 ]"RDGN"!$I1)<K
M)N%2;W5&-S@ :;_.A6;G1VQ:3%9>J+VW%9#X_=G-W,Y%FKN.R+:O;'&,FW6*
M;:K:V_7F#1094JM38]FM=:U2!@:BJAJ@[V!0G5$T%AV-!@+A3.F?::GM75S!
MXAFYDO1N/?1L-^2J^<1N)<>)7ALA*+WW(=+$,]@H+#+Q7 G-,@N52X-EZ'RY
M<GJ8()+SG5AC;';,UZ>)(2C;SJ&M")[L06]0'!U0:$&@J#44NO;3QPKG1>Q
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MR[BV&KFAS2IG!N55I:CD:P@I01709134!9#7C"HX$#S6^PZ7[H\0  "^KP
M   !8G,4   ;   "TN@  ;  .K!8U';/$?-?W\+_ -'E^/5Y_,3F*_A+@FH[
M9XCYJ_"_]'E^/5Y_,3F*_A+@FH[9XCYJ_"_]'E^/5Y_,3F*_A+@FH[9XCYJ_
M"_\ 1Y?CU>?S$YBOX2X)J.V>(^:X3S+=*QD0FV7*_P##(M>5^=Y-+K)W5C$<
M:2;&Y@R3G1]?X(_-30W%&JK5$)BC5K@K3IBS%!Y)%%9H5'&EEA56!-1VSQ'S
M6?N29(J09,\HZ%<F4(EJ++'81(L1JR3$RI(J36JBA*A,I3G4T'$*"#J*RCB3
M:*#"C**J*Z::J1 "P[$\3S63F"PK!%8(K!%8(K!%8(OCV=)[\I/T@OY;.:?]
M>,YP7;#^PW@OHJ_<X?R,>3;^\-^U7?+!<T7\H[L^Z%UR7>Z#/+9.^F+C"YZO
MUF[*F%U;,WOSPNUQ6ZX5KTLVCU[+;YA+!LD,IAZZJRYS4RP]B27'<JFUC,9E
MJMNJ8XPG;G9&W-AZ%<6P>?=D74J&X94/C=CYKVUBJ*BRBRZS3#ZZ"Z**CC0*
M TZJFD*:C3 )+)) PP0&NL"BBB@J$0++HHTI HK]X(K!%ZRW2/PF173N_P!*
M*^18NR"*,VBR46(8KU*;[$^Z[G_!IF(NU=\IVRE2H$PHK&.!\??7IK:[ARA!
M/&)POTR1U>EB[2? G-:]NNK[E1I U:U^U6[#*YVW# "M#G6@[$\\\LB-R;6Y
M,$[U429:V6YR\H!E\(A,S$1E:"(RQ,ZR:W<;NXRJCE"=,2[7="TJ58TR*BI
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M?YR)_P )_P EY SIV*JZG:0?3'%^'X_?9U^>VG79^"IFOR\5D6W(&X/B7?\
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MY K8/:=HXA>0,S%JZNI>[C_Z&58?CV]GOY[:/[+F?DM@0<,^/7:OW\92UO\
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M6 R%U,3D!L'IC@+JD[M;7S/D/,^6***!J$/,'I'AX^+8 . V;S_2^[QPJ!@
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M8+'\V?TQ]UR[,\%HK!%8(K!%8(K!%8(K!%8(K!%ZV]Z*!JO5>/L^^U<OZ?\
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M )++WC]G ./'D=]@ NR'Q;SNV#/@K-;7S/D/,^6+**.H1#9N#GD?'(&-]_\
M*=Y#J[N J!@ ."510(CQW!V<1Y\^-P*7!6:VG',IE%'DWCV\^;Q*K6YGL'F=
MVP9\*IA9?5L[@[.(\^?!5P2Z:=P=>\>=W/7@J-;2\XY#9Z\N."BR]>=HC]7/
M:. '=UX]855FMKCAEO\ D!F>P7IE-.G?SL#&<;AARVD^9] J@4ZZH!D/-)++
MWC]G ./'D=VMK</L^+C\NL<,IM%&F@B'<'9W\>>OJL!D+J8G(#8/3' 75)W:
MVOF?(>9\L444#4(>8/2/#Q\6P <!LWG^E]WCA4#  )Y984AJ/7SM'T!N[\9
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M[-R]1_\ 79]V<]7C_/OVV?[3M*/TK(_Y#9:^8:0#^.)W>8%?[-!7'U%'LM
M-G/(^4<?*UXIK:7G'(;/7EQPPF>6ZC,AFC4Q-TI!;9?*<=&WM[:*P]FV3G,;
M(VPN0QE(Z4?[9#@U6>AJQKDM" P::!F<P9E2HHTV.DTT?1)>(=$]#V3L'^#M
M_35LW+R\<71;.T5E8IE9Q\$W.A1[<GV1I0Q "?H$C'8QP$TZOG(7^A2 BMNF
MK0#VM=_*A23':CRW-KIF*US-8 _P4)X!&NLZRRQK'AOYY\1#YVO'K4** I -
MG<'I'CX> "MP6S6UX9E)IITVCU[@[/7X=_5O< ;[LSM_HMZWFY5 R&'/TY\,
M<').W4Y;,S\0GS)3[WVES825/;FZ3(2'M;4P7^K;#S[8W+2): J+2*[CHVM;
M;B8F$%IBW9^I@3BMK/<!4'&_09.(=*]$IZS9C^$MK0V5=:ECQW&L:8T;$5K;
M6LE[S?$99;XK+4D0YSC!ES:,*&&P]5H\M")G).)!=0S$DSWL!]/K&6UJ18).
M)]T7"+#!^RWW@J*"F?%%'D\>?4'#Y^!3]+,Y-'SZPQX0 !0)-%'LM-FS<';Z
MN>[)( H,?$GK$]@OK2C6UO.&0V^G/ABNFG3OYV!C+6TO./+KT"L!7AF=B466
M(CQ\. <>T=WCLJ@=V6_>?(9<: .II"D-G//GQD DT"HUM;SAXD[!YGU(\U%
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M ;-YZ]"733N#JWCSOYZL"<;ZUQ.W<-VT^@)(HHUV!U><1^OGL#&0*4)%^0R
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M[(?%O.[8,^"LUM?,^0\SY8LHHZA$-FX.>1\<@8WW_P IWD.KNX"H&  X)5%
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MG75 ,AYI)9>\?LX!QX\CNUM;A]GQ<?EUCAE-HHTT$0[@[._CSU]5@,A=3$Y
M;!Z8X"ZI.[6U\SY#S/EBBB@:A#S!Z1X>/BV #@-F\_TON\<*@8 !/++"D-1Z
M^=H^@-W?C(&0_K.RIL&[GP5VMI<,>:511U"(;=P<\AX"0!NR'Q;SNV#/@J-;
M7S/D/,^6+"R]X_;P#AX^&M[CS/SW*H&0_P AM*;11IILV[@[,9NI089G-Q^7
M+$WT"JUO=][>=VP=I2BR]?2/H#GB.X,:F]5:VO#,IU% 4AH'7SL#G;C(%>&9
MV*P%+@D4TZ=_AZ^>_8G(89#;O/D,\3=0+=K:WG#GUUN111Y?#GU!QUPXYGR'
MF<\KL:I=!?D\?5SUZCC")I9>O/5Z^P.0W I2ZKC@-F\]>A+IIW!U;QYW\]6!
M.-]:XG;N&[:?0$D44:[ ZO.(_7SV!C(%*$B_(9 ;3U6N_"K6TO./+KK>XLOZ
M-/-P#CVCR.X%-Y.)V]9!;@5N"911KILV;@[>=X\AE6:VG',IY175L^SZO'R!
M@MDVFG30 #41\HC@B2  6'];>/9P#CVCY,%1K<SAS]-@SQ.01S#-/0'I'G@&
M\<4:VEYQR&SUY<<.EK:7G'(;/7EQPT\PS7T!Z1YX!O'%FMKPS*Z&,)._(;-Y
MZ\4$TWK !U$?/ZO'J#9B[6UW 8KL8SNS.WKPYDJJTXB//DQO]JX7-'CUZG)7
M P '!#--]CKMV[Q[.?4'"K6UW ==ZZ(</U/D.O(+33#-=H_0';SYMW&X%+@N
MEK:W"X#P1JJNL1YX!C=K:WG#(;?3GPQL  *!#,,UUVZ '.@>GM[L5 K<%9C,
M"1?D.NAR)77O'JW!Z1YV>-FMIQS*ZF,[\SLZ\>0:ZQJ'ASYOM';C9=   H$8
MPS38'V^KQ[L4:VEYQR&SUY<<+-;2\XY#9Z\N.!1'K$1Q17:VMYPR&WTY\,=W
M6YJUGT0 =[^W:!V![HHYYV>UZ#BFE^CE<3:TG=L'O1CO.S+$KQ>DC/\ 5^V"
M<?P?,T&S^#./7CAV-8_:J_-ZL$5@BL$5@B^/9TGORD_2"_ELYI_UXSG!=L/[
M#>"^BK]SA_(QY-O[PW[5=\L%S1?RCNS[H61<K^6-L1_9K9J/VG<H&"Q_-G],
M?=<NS/!:*P16"*P16"*P16"*P16"*P1>NM=PL:[PW?[/OLW-U'_UY?N>1$/Y
M]^VS_:=I/^E9'_(;+7SRV_\ I2:XPO\ V(2V910%(!L[@](\?#P^5@5N"\8U
MM>&96$2173ETS9O2-W'W#:7.&L:G6.NE8B4U1O,O&&!.PN\:65CHF1FW?@;(
MQNC 8;716YRJ&/;>508O=4E)WT1T,Z3Z%P'P?X2V=!V1H$U";]:--Z*3<PZ9
M@S4,4UWBQ+1F(\&9 !$*3GI>*XB'!?3R^K],D&%@K'L\.:YN+HDF]Y>UXS(E
MXKG->!A#B-=]EI6=Y98B.H_9Q'CV!R'SPFOD.L^:X #6[',_#Z\N.#**/)X\
M^H.&X%/TLSDT?/K#&H  H$FBCV6FS9N#M]7/=DD 4&/B3UB>P7UI1K:WG#(;
M?3GPQP<N<KHS"YF[=6/8A!= <N+^P7WORZD_[: 9^A3J#[$6I]OI&LLUWH=S
MZKM2%#46/O>V1B) ?648_I:1^@V1!.C6BMIV_,_4M+2>6F-'M'X+KH@LV(YK
M=(+7U;B()@M%C2T0$"+%FIS5#FRSBO+0&_1Y6)'<*1)EKH$ &ET,_EXU#E3^
M"8<RY^32L^"RQ$>/AP#CVCN\?05R =V6_>?(9<: .II"D-G//GQD DT"HUM;
MSAXD[!YGU(\U% U"'F#TCP\?&ES1NS.9.P=7<:D5 ZV#8.K^X!Q9>G/7ZNP.
M1F37AD-BV [\AYGK>;L64TZ=_AZ^>\!7AF=BHUN9O)\>LAVF^@"2R]X_9P#C
MQY'?8 +LA\6\[M@SX*S6U\SY#S/EBRBCJ$0V;@YY'QR!C??_ "G>0ZN[@*@8
M #@E44"(\=P=G$>?/C<"EP5FMIQS*911Y-X]O/F\2JUN9[!YG=L&?"J867U;
M.X.SB//GP5<$NFG<'7O'G=SUX*C6TO..0V>O+C@HLO7G:(_5SVC@!W=>/6%5
M9K:XX9;_ ) 9GL%Z933IW\[ QG&X8<MI/F?0*H%.NJ 9#S22R]X_9P#CQY'=
MK:W#[/BX_+K'#*;11IH(AW!V=_'GKZK 9"ZF)R V#TQP%U2=VMKYGR'F?+%%
M% U"'F#TCP\?%L ' ;-Y_I?=XX5 P ">66%(:CU\[1] ;N_&0,A_6=E38-W/
M@KM;2X8\TJBCJ$0V[@YY#P$@#=D/BWG=L&?!4:VOF?(>9\L6%E[Q^W@'#Q\-
M;W'F?GN50,A_D-I3:*---FW<'9C-U*##,YN/RY8F^@56M[OO;SNV#M*467KZ
M1] <\1W!C4WJK6UX9E.HH"D- Z^=@<[<9 KPS.Q6 I<$BFG3O\/7SW[$Y##(
M;=Y\AGB;J!;M;6\X<^NMR**/+X<^H..N'',^0\SGE=C5+H+\GCZN>O4<81-+
M+UYZO7V!R&X%*75<<!LWGKT)=-.X.K>/._GJP)QOK7$[=PW;3Z DBBC78'5Y
MQ'Z^>P,9 I0D7Y#(#:>JUWX5:VEYQY==;W%E_1IYN <>T>1W IO)Q.WK(+<"
MMP3**-=-FS<';SO'D,JS6TXYE/**ZMGV?5X^0,%LFTTZ:  :B/E$<$20 "P_
MK;Q[. <>T?)@J-;F<.?IL&>)R".89IZ ](\\ WCBC6TO..0V>O+CATM;2\XY
M#9Z\N.&GF&:^@/2// -XXLUM>&970QA)WY#9O/7B@FF]8 .HCY_5X]0;,7:V
MNX#%=C&=V9V]>',E56G$1Y\F-_M7"YH\>O4Y*X&  X(9IOL==NW>/9SZ@X5:
MVNX#KO71#A^I\AUY!::89KM'Z [>?-NXW I<%TM;6X7 >"-55UB// ,;M;6\
MX9#;Z<^&-@ !0(9AFNNW0 YT#T]O=BH%;@K,9@2+\AUT.1*Z]X]6X/2/.SQL
MUM..974QG?F=G7CR#76-0\.?-]H[<;+H  % C&&:; ^WU>/=BC6TO..0V>O+
MCA9K:7G'(;/7EQP*(]8B.**[6UO.&0V^G/AB8PS3:/T!V<^?=PV IO<<!LWG
M?NRQ*Z6,P)%^0ZZ'+==MJQJN##QU_P#E V_^\4^CR!U8]LT(;32W1W,FUI.I
M_P!ZWK>O%:3-U=';9V_@^8O_ *A79-C]I+\SJP16"*P16"+X]G2>_*3](+^6
MSFG_ %XSG!=L/[#>"^BK]SA_(QY-O[PW[5=\L%S1?RCNS[H61<K^6-L1_9K9
MJ/VG<H&"Q_-G],?=<NS/!:*P16"*P16"*P16"*P16"*P1>O%=>D/ON7=J_\
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M;#AL:Y\1S6@E>2E)2/-160):$^-%B&C60VESG$"IN&  J7.-&L:"YQ !*VM
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MQ# A@M:"Y[G;@5Y$CD-IVGRQY5HH&H0\P>D>'CX^)V #@-F\_P!+[O'"H&
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MQPJ!@ $\LL*0U'KYVCZ W=^,@9#^L[*FP;N?!7:VEPQYI5%'4(AMW!SR'@)
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M<&5<VK5"#VZJLT$"D\Y&!IAI@$!6:8-?EK.MRU;($1EFSD26;&_*0PV%%87
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M;U5K:\,RG44!2&@=?.P.=N,@5X9G8K 4N"133IW^'KY[]B<AAD-N\^0SQ-U
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MRN='<4A[.II*(,Z9@@5I??YT(XKK6S).M<ON$NS41.?W.LW8>X/2XV'?X3F
M@]LJ9*]IX[;'HU;A6?FEZ8M#IO;.X;0[Q!VN"C&V#?*'NWKZROOO"+DT^W)#
MF-VJ+([#]6A!RJ[/"\5KCCOJ%VI9=92LOS!+EPRS/21WXNI.&MVB#RHN=.\N
MUD8V^P!G5>^Q/P?8X_\ %AM%"'Y#*:V]76O5NC%)GIKK0E"B7-12@*%)8N!%
M0. ./B:+!^'9=<PV4[)OT<#KF-FLTFK)EDS Y<II=^WA4)@+P3E[A#1:"]MJ
M'LY,X689U[E/HS#9U=" 2>225P<):,?9(@IE-*\IN0.RVDLU!+J#&H':=^%U
MUU#?OHN&)['G&<YGC,YP36\-H<D\USYW%4K+P6YC[ZR/J:,F]'Q92P*&\B!<
M?%W:00*V\^O#:N86M,O&V,B*NIE>"G%OD;&S2]!*RBSE2@+J8<'.)PN)I2XU
M\*#MXZ/]5="99;Y)6\S.<F- WWO.GLE=F:P]H9[GW.L.AGC@7;N?3IH>8JS4
M.KS)6VE22DF+O%6M\G481L$Z<:#W"0G.2PM#2O.F%=W6*P?ER54CG=R4RYQ.
M=EA%T;GE*7-00D2GKC:+@2.FM2:G0$)D1-9HA[.HM*0232(Z4%TT@ !^ O;0
M"?:;I,!\5D?\ALM>JS[:SL8G"K.)/NV8=7;<2-&HH&H0\P>D>'CX_,;FC=F<
MR=@ZNXU(YP.M@V#J_N <67ISU^KL#D9DUX9#8M@._(>9ZWF[%E-.G?X>OGO
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MP&0NIB<@-@],<!=4G=K:^9\AYGRQ110-0AY@](\/'Q; !P&S>?Z7W>.%0,
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MIH&K4:::JZA - &JH0U$M%^L$5@BL$5@BL$5@BL$70]/:/97*NH/_P";-U-
M_P#W"DFT>'/?^!?;10>TO28X?6LFIS/\167</GEE?4CUJ>_^;C'>W[C>N@M"
M++TYZ_5V!R/RHFO#(;%R@=^0\SUO-V+*:=._P]?/> KPS.Q4:W,WD^/60[3?
M0!)9>\?LX!QX\COL %V0^+>=VP9\%9K:^9\AYGRQ911U"(;-P<\CXY QOO\
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M,A=3$Y ;!Z8X"ZI.[6U\SY#S/EBBB@:A#S!Z1X>/BV #@-F\_P!+[O'"H&
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M ;-YZ]"733N#JWCSOYZL"<;ZUQ.W<-VT^@)(HHUV!U><1^OGL#&0*4)%^0R
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M(PS3GJ#Z^>P,;@5N"ZV0^[GZ=8U*$89O'JW!V\1]/9XV:VG',KJ:VO#GZ=<
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M5F,P)%^0ZZ'(E=>\>K<'I'G9XV:VG',KJ8SOS.SKQY!KK&H>'/F^T=N-ET
M"@1C#--@?;ZO'NQ1K:7G'(;/7EQPLUM+SCD-GKRXX%$>L1'%%=K:WG#(;?3G
MPQ,89IM'Z [.?/NX; 4WN. V;SOW98E=+&8$B_(==#D*NO741ZO'U^&*-;3>
M3B5TM;3CF40PSR^8 ^OGJT#%6M[_ +N\[]@[2KM9F<<AUGUC@.JK7N\>>>%
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MUN9PY^FP9XG((YAFGH#TCSP#>.*-;2\XY#9Z\N.'2UM+SCD-GKRXX:>89KZ
M](\\ WCBS6UX9E=#&$G?D-F\]>*":;U@ ZB/G]7CU!LQ=K:[@,5V,9W9G;UX
M<QUUZ<1'S<[@Q0#6N%S1X^G6.%P, !P0S30 !V]X]OJ\>H-F*M;7<!U<NB'#
M]3Y#KR"TXPS7:/T!V\^;=QL!2X+I:VMPN \$:JKK$>> 8W:VMYPR&WTY\,;
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MNZ\>L*JS6UQPRW_(#,]@O3*:=._G8&,XW##EM)\SZ!5 IUU0#(>:267O'[.
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MP%-[C@-F\[]V6)72QF!(OR'70Y"KKUU$>KQ]?ABC6TWDXE=+6TXYE$,,\OF
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M+^Y;OCDDCLQ8FJ41%_993&7U$2XLDBCCJA?&)Y;U%/LB%[4[MAZIO<$1]/\
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M=>=/7VCR&X':3U_D/-=+69G#(=9=88A,,W!SQ'T!]([L5:VEYQY==;ZHU50
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M2])OTK)_Y%9BYG-^NYQW4[AX]</*67KSM$?JY[1Q\O [NO'K"JV:VN.&6_Y
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M\BPXT68AV/9,K.1'PFZC-:<E9*#-. ;1I88NH6M:' AK0MY2S9>6<'06Q&D
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M11IH(AW!V=_'GKZK 9"ZF)R V#TQP%U2=VMKYGR'F?+%%% U"'F#TCP\?%L
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MRQ33IH !J(^41QXU420 "P_K;Q[. <>T?)@J-;F<.?IL&>)R".89IZ ](\\
MWCBC6TO..0V>O+CATM;2\XY#9Z\N.&GF&:^@/2// -XXLUM>&970QA)WY#9O
M/7B@FF]8 .HCY_5X]0;,7:VNX#%=C&=V9V]>',==>G$1\W.X,4 UKA<T>/IU
MCA<#  <$(TT*0';WCV^KQZ@Q5K:[@.J!=$.'ZGR'7D%IYAFNT?H#MY\V[C8"
MEP72UM;A<!X(U576(\\ QNUM;SAD-OISX8V  % AF&:Z[= #G0/3V]V*@5N"
MLQF!(OR'70Y$KKWCU;@](\[/&S6TXYE=3&=^9V=>/(-=8U#PY\WVCMQLN@
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MT4L2<T)F;2LB-8<K:LC:<:WY*2M"=M>0A&!K,DC9EKUG&3,Z\N#XL&%,3$K
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M=H_0';SYMW&P%+@NEK:W"X#P1JJNL1YX!C=K:WG#(;?3GPQL  *!#,,UUVZ
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MZP =1'S^KQZ@V8NUM=P&*[&,[LSMZ\.8ZZ].(CYN=P8H!K7"YH\?3K'"X&
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M>H>T<4T"TN _\ M+_P#CO7L"8_0R_G(K!%8(K!%8(OCV=)[\I/T@OY;.:?\
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M*IPBK871&UT($\>;A1D/DP]YW]:"Q.2I_G%*Y"W^6&E]@63.V)*6AI5%MZ+
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M2OADKC5#+##'<F8/%;ZUTM43-CZ0%[\5)7"I4"1AK9$(@M=RW0U+4W)!!2M
MDD0J'I$G-F++0!*S)C3@A&3@B!%,6:$P_P!W ,M#U=>.(S_J0C"#A$?]5FL;
MDUV4<[6;JLKKG6%&ZHJ[6-:-U1>:TH,5KK ]L<H96B1QAX:I''9 W(GAB?V)
MP2.[*]M+DG+5MSHTNC><H0N+:O2&E*42U&><F4IS2SB#3"ZZ:QG'@1I:-%EI
MF#%EYB!$?!CP(\-\*-!BPW%D2%%A1 U\.)#>"U['M#FN!:X @A9:0X!S2'-<
M 6N!!!!%001<01>#6E+\$=-,X:HE;E TDMC*J=L[.BD#Q#4[ZUGRMI8',\U*
MW/3A'2E53PA:'!20>F1.:E&4C5'DFDD'&&%U4TT=)S;)6'//E9ELE&C/EX4X
MZ!%;*Q8\)H=$@PY@M$)\6&US7/AM>7M:07  K=I87%FLTO #BS6&OJDW.+:Z
MP82+B11Q[ @IK@0IQF#[;UOE<?6SJ,-+0_2&'IG9$?(V1E?ZU13(ZNK06=4N
M1(74Q"KH0*3R:"E(D& 555IJ-39\Y"E(%H196.R2F8L6!+S3X3VR\:- #3&A
MPHI 9$B0@]A>UI)9K#6H<.ACH9>Z'KM,1C6N=#J-9K75U7.;B :&E=FW!"20
M,KLJ=436\-;FM8UE+>](T#@D6*F=?606IH1.R=,<8:WJZTQI2BA,KH).J(-+
M-IH$NNFH<NEX\-L)\6#%A0XS/>07Q(;V-C0P2TOA.< (C=8%NLPEH((K4475
M#:'$T(+FFA (.J:5^L!@:$&AOO&9"\QIO6 #J(^?U>/4&S&S6UW 8KM8SNS.
MWKPYCKKTXB/FYW!B@&M<+FCQ].L<+@8 #@A&FA2 [>\>WU>/4&*M;7<!U0+H
MAP_4^0Z\@M/,,UVC] =O/FW<; 4N"Z6MK<+@/!&JJZQ'G@&-VMK><,AM].?#
M&P  H$,PS77;H <Z!Z>WNQ4"MP5F,P)%^0ZZ'(E=>\>K<'I'G9XV:VG',KJ8
MSOS.SKQY!KK&H>'/F^T=N-ET  "@1C#--@?;ZO'NQ1K:7G'(;/7EQPLUM+SC
MD-GKRXX$JJTVCM$?/BBNUM;SAD-OISX8G,,TVC] =G/GW<-@*;W' ;-YW[LL
M2NEC,"1?D.NAR%77KJ(]7CZ_#%&MIO)Q*Z6MIQS*(89Y?, ?7SU:!BK6]_W=
MYW[!VE7:S,XY#K/K' =56O=X\\\* 4ZQWE=#6TO./+KK>8PS38'V^KQ[L4:V
MOF=GKRXX5:VO#,HE56FHB//U>&*@9#L5@,AV(9AFNHB.SQYW!](\*M;2\X\N
MNM]F,[^77H-XC#-.>H/KY[ QN!6X+K9#[N?IUC4H1AF\>K<';Q'T]GC9K:<<
MRNIK:\.?IUP"89KJ(CL\>=P?2/"K6UO.'/KK=<#,X#Q^0&9[!>@&FZ]W#?P#
MAVCO[M-:J@&9[!LXCD,N))1!$1'4<9 S.&0V^FT^:JUM;SASZZW> PP  >SQ
M]7:/(T:TDU..0V;+N0\U9K:W##D@&&:ZB([/'G<'TCPZ&MU;S>XX#9UF>P;^
MEC.[GUZ#<(PS77G3U]H\AN!VD]?Y#S72UF9PR'676&(3#-P<\1] ?2.[%6MI
M><>776^J-54 !J/V\[QQNJM9F<<AUGUC@,PS741'9X\[@^D>&[6UO.'/KK=T
ML9W\NO0;QUF>7P]?/5H&*KH I<.T[=PZNP%]2!&&:; VB/G]7CW8HUM+SCD.
ML^6)W4:VNX#J@0JZ^O;MWCV<^;PW [^KAU?W =+&8779#;UX\QF&;@^WB/#A
MR%&MKYGR'F?+'H:VOF?(>9\L15UZZ[=F\>WAW>/4&SKJ!2X*[6UW ==Z+55K
MP .=1P5@*7!&,,W!]O$>'#D-FMKPS*JQF!(OR'70Y<LY>:_^.MIPUVC.H_J/
M_GQ6SZ]P=6//:.BEN64!=_IL#NUQ5>H>TEE/9]ICG_J_:53_ /COIX_/A["V
M/T OYLJP16"*P16"+X]G2>_*3](+^6SFG_7C.<%VP_L-X+Z*OW.'\C'DV_O#
M?M5WRP7-%_*.[/NA9%ROY8VQ']FMFH_:=R@8+'\V?TQ]UR[,\%HK!%8(K!%8
M(K!%8(K!%8(K!%U3F4:R&?CVW8O!WC_Q2E^P.';SI^#O;(*^TG24?TK*[/XC
MLR\KR<L*PF?UNSZSKRO&Z,C0_MBUD?FIN>V=T3&(W)H=T*5R;'!(<'L34JY
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MD0M !B,#7N#6AQ(:T#DID9&J/-:!D9&]*UM+8F*1M[<A)H(2HTQ-/L2R22J
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M&X?7<8C8A<\/N! U:7K[TR*71XT$M $)L)P=F[W@<3792E N%X)TA5K&&V$
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MMJ2$GKF%[0)*/;%*QH<DJ<L:J* ,/4(SBB:!K,JIHH]D972'LJZJ:*=?95B
M!CI@4AQ8;W?R8C'$XT <"<,339P&_$PQT27CPV"KGP8K&BH%7.8YK14D 5)%
MY( S*Z>6JUV9AUR3LN6)URZR&.R2%#;Q8ED2N?VM7M,C-9+SQV2NB1"F;9<H
M5(C$K 8X.=1J\2B#"VH],368L4(TYWTF)/V%#THB6[#MJ#'@37TUKH+9.?9%
M@"-9D> QSS$EFM=K1M2'1E2#$#B UKB/BLO8VEL?0&!HE&T6FI6;D/P2]DR^
MTK&B0)HRUOR<W&9#;"GGOAEDM[V-6+JM(@N8TF(^&UW$LFM5-;Q3[-Y!X'91
MN?)#(\V$6K2W^-=HHA56I2Q<Z)2%U RAQ.(E=!9372JJ;Z8\"RAQJ?'1.826
MK2IB5_D9>?E;.E-')J;M-\*#!T>CAUCB%,N;:#I@3,%E\,&7OB%NO[[5+/=,
M<"6N<6>,FK"M&WK2TXLVS='H4U-36FTCJ:3.CR4-]B,DS9\W,5$5[9T!L'6]
MU]$$013,QVN#7,:V+R[,LNMY"7F62\VU(7"86[/B^WOJMF:]Q+V<_MTXP=L8
M&Z0HB79U]Y3%C2Y H.3LD@-0*S0]T"8G++VF>/EK9LTPY>6$_P#0XK]$X5EB
M>$*8I)SK)M\9\!YAP_>AD2'JAT:"'M:=6A)K3V*>T1T@;,3T^;$_"TM!]ILS
MI$;',S(5M6R(MF092%-0FQX_T8Q($;7<R7FG0GDAU6M%YR:R4VTF=KHI>=/,
M;>([6_#;,'.;A1>%-SHP.R%EB,D88=2U(4JB-G&MA1+<<A6M(IB2TM!9C=6*
M9-2@K2''>&TFG9:>CV8Z7G'3YE;'E).-,OAQH;XLS!BS'O'N;' B%SPYL76)
M=<_ZSM<.#?>/9O8EHV/):0MM"R8=B"T=*K2M63LZ#'E8\*7D)N6D/<0H;Y-S
MH $)T.) +&A@:Z$XL9[HPR[!G+_E8O?#Y-E\5A:*16ZEUM;D2U[N+="0W6C\
MEA[Y;J0/,B4.,5BEO$$MD]+0\/S&O;6PQU:6*.^UJTZA:YGJCE8K"/:;7MZS
M)F!:[?PC!G9>=DI:%)2$&0C0)F%.P8<%K)B8G'2T Q(<**R(\0XD:-5KFMAA
MK1JGYYHCH+I/9\]HE$&C\Y9$_8ULVA,VO;<Y;LI.V=-6/.3,X^-(2%D0I^=$
M"8FY:- @F/ E9.D1CXL5T1T0Q&]DF9&V3S=FW@1^/*B"'=M>T3\B3JS1(2N5
M21(X(C$)QX4UTDU5DN!AR8PRGVKW2050;44776<5\[@.U'ZQO%""=E:8;:4O
MIV;_ %;]VW^Y_P!)_P!T7[%CH=H9:$I*:2V'I19FE]ER=HS#I2SK<BV=9]KV
M9&L>9FPV(V5?%EK9C34E,1H;I?Z?*2T&8?+2\:)-P.&<KEB9I;%VD,GF?N9M
M/<6JED1LJ5<0X5U%U+4RT]>L.1UFHZ!HJ2$DHZ"CSS*J3U8F@0 4 =>+$:\
M#(U)(\/GV+\Z_P#Z>G[COVI^P/233/3_ -J7T"PYRV]'FZ*65HK(6M*6S%=
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MM'Z [>?-NXV I<%TM;6X7 >"-55UB// ,;M;6\X9#;Z<^&-@ !0(9AFNNW0
MYT#T]O=BH%;@K,9@2+\AUT.6@.K\RLU;:6\.[6U5O+B2SLY3DX)$-;J[J2S3
M4[6W4JC2JESB>40>82B2@:I,+)-K+*JI+K$.J#+Q8@B&%"B1?=0S%C&&QSQ"
MA-(#HD0M!U(;2YH+W4:"0"14!= +&%H>]C#$<&-UG!NL\U(8P$C6<:&C14FA
M-*"[0AFD2.EIT"HE,=KG*=@+E9\,H>VVJ5DQ<Y?4U$R0V.@I%W+8#72BIN+=
MZT8-]:^FI)2H%0 EA8RDT)43IEHXDG1S+-FS!B"6=,AGO3+B/J^Z,80R(AA!
MVN&'6+=6]6$6"(IEQ%A^_$,1C!]XWWPA%VH(IAUU_=E_U=?5U=;ZH-;E^)5+
M(S"6%SE$PD3%$XRS$ J>)%)79 Q,34F$TLD%#D[NBA*@0IQ.-*) U2H*HJ-,
M++"KV5=(#O*RDQ-QH<O*P(TS,Q7:L&7EX3XT:(ZA=1D*&USWN !-&M) !)PN
ML]\*7ANCS$2'!A0QK/B17MAPX;:TUGO>0UHJ0*N( )VK1I9/(7!8FX3V92I@
MC,+:D:=P<I6]NJ-NCZ)"K.3ITBM0ZJ3BT1292>J2DISJCO:SC%!-!0U5&T!5
M:5DIN=FH<E*2T>9G(KW,ART&&Y\=[VASG-;#:"XN:UKBX4^J&DF@!58D:!+P
M73,Q&A09=C0YT:*]K(36N(#7.>XAH:2X $FA)&T5<ZR%D9B$:IW>6IJ3.*U$
MV-Q[DX)$)"YQ<J_:VYO1FJCBJ%2Y>9_L(DA%5:A77_L$%UCL#6' C1'.;"@Q
M(L1C'Q'MAL<\PX<.]\1X:#JM8+W.=1K!>XA=>M#AACHD1C ]S60R][6ASWFC
M&M+B Y[S]EHJ3D"<!@_,Q[NI82W=L-?4:(AR5LA:])6[I6Y4:80F7J6VDT5A
M"-0<4:20J,)I(-,+,++,JJHJ -Q BLA-CNA1!">]T-L8L<(3HC0"YC8A&JYS
M007-!+@""0 0NIKH8>80>PQ6M#W0PYI>UCB0UQ976#200'$ $@WW4"3#/+Y@
M#Z^>K0,9:WO^[O._8.TKJ:S,XY#K/K' ==>O=X\1Y]5 *7#U)^:Z6MIQY>O7
M$IAFX/MXCPX<A5K>_,[-PW[3DJM;7S/D/,^6):JM-1$>?J\,4 R'8J@9#L0S
M#-=1$=GCSN#Z1X5:VEYQY==;[,9W\NO0;Q&&:=^X.SZQ'UCLQ0 DT"ZV0^[G
MZ=8U*#77UB/'0.?./J#%@ !S.U=36UX<_3K@(PS741'9X\[@^D>%&MK><.?7
M6ZX&9P'C\@,SV"] --U[N&_@'#M'?W::U5 ,SV#9Q'(9<22B"(B.HXR!F<,A
MM]-I\U5K:WG#GUUN\!A@  ]GCZNT>1HUI)J<<ALV7<AYJS6UN&') ,,UU$1V
M>/.X/I'AT-;JWF]QP&SK,]@W]+&=W/KT&X1AFNO.GK[1Y#<#M)Z_R'FNEK,S
MAD.LNL,0F&;@YXCZ ^D=V*M;2\X\NNM]4:JH #4?MYWCC=5:S,XY#K/K' 9A
MFNHB.SQYW!](\-VMK><.?76[I8SOY=>@WZ"C:6AJ.<E#6U-K:H>5M3D[GH$*
M5&<Z.-911%3@Y&IRBZURZH@@DFI4JJ-/J*)*+$SV!=%(=#XD1X8U\1[VPF>[
MAA[G.$-@)(8P$D,94DZK:"I)I4E;P9:! ,5T"#"A.CQ#&F'PH;(;H\8M:TQ(
MI8 8D0M:UIB/+G:K0VMUWE,,TV!M$?/ZO'NQEK:7G'(=9\L3NZ6MKN ZH$*N
MOKV[=X]G/F\-P._JX=7]P'2QF%UV0V]>/,9AFX/MXCPX<A1K:^9\AYGRQZ&M
MKYGR'F?+$5=>NNW9O'MX=WCU!LZZ@4N"NUM=P'7>BU5:\ #G4<%8"EP1C#-P
M?;Q'APY#9K:\,RJL9@2+\AUT.0C#--=NHCSH'I[._%@*7!=3&=^9V=>/(=56
M\>O<'.[GKP [NO'K"JZ6MR'6\HU=>FT>OP#ZN>T<5:W,]@V;SOZV 7:VEPQY
MKE_+E7[*_=H]NSX?1SZ1]\"O-V!R'FK _P"FK+_^]@??"]*]IS:>SK30Y_O=
MM/L_T9_7+?[&6/O*_F*K!%8(K!%8(OCV=)[\I/T@OY;.:?\ 7C.<%VP_L-X+
MZ*OW.'\C'DV_O#?M5WRP7-%_*.[/NA9%ROY8VQ']FMFH_:=R@8+'\V?TQ]UR
M[,\%HK!%8(K!%8(K!%8(K!%8(K!%T%YK,YMH\GB9[=[C4/SR\2Z\-\4T8B<5
M2HE;VYEM=U)0+HXF5.2]L;T#4W"N0EJ52E8!QARPDI$E5UTG@3^)O:98<Y;7
MM-TI9+>[9#@&QS&C1G.;#9KV'9VHP:K7N<]^JXM ;0!I+BVZOW;V.>QS2SVO
M1YN4T=,A)REDPH<2T[6M6+&A24LZ:BQQ*R[1+0)F8CS4P($=T.%#@ZC607NC
MQ8(,/7WYE@S0VOS8V],N';$]U)3H'0UCD$?D*0A#(8X\%$$*@1N*9(K7HS2E
M2120J0KT"Y6B5$UUETG4+$RU(F^6VM9<W9$P)6::RKF")"?"<7PHK"2-9I+6
MNN<"TL>UKM85(U2TNY_:3[+])O97I VP-)F2CXD>59/2$_9\:)'L^T9-\2)"
M][+Q(L&7C,?"C0HD*/ F($&/">UKM1T&+ C1=.M%?Q[N+F6S;6,6L#6W-674
MZQ93$^)5"LQQD(79MXLF;D+L0:(IDWO2K34HD7N, ]N3U55GZFZ"/F+8T>@6
M9HQHA;S)B+%C:2BWC,0'M8(<M^"+1AR4/W+F_6=[YCR^)KUHX -^J37YS#BN
M?&F(5&@0?=AI%;]=I-_"EU%P9;CI$K3-EFK.RV]\\CSM/;MM%S7R-I+'6QO6
M[L<Q16ZG[E$G(B(1MZC2Z<4+FQ.4D]]DKTG3U&FM[^^HO8QI("POV"T_9O:T
M6V[9D["L^8@V?8\:RX$TZWK5L2#'DXEI6?"FX1FYJ!,PY$PXSG.]RZ YU!$@
M2\3_ $E^H9,G(8APW17ASX@>YONH<0AP8\M.JT@NJ+J@C:1<*KD1KSI0&57%
MM Y0ZY]K3["7#L)=*]*QU=V6X:2;5MEN')(C='Q"ZU($\+C[!%PH=TLQ:);[
MDE*=Q0F$HTH E4A3POT(M"3LZV(<[9=J#2"SK?LJQ(<&#'L]\B(MI0WOA0(D
M$/=.S$Q-5A/DHTIKRKH3P7OJ]BW$RQSX>K$AF$^$^)4A^L0PT)!IJ-#;]8.^
MM4&@N6Q[0](%&\P>;N#6ALZJJ<[3OM@)E<UV<91;Z=0R5J7IMED=;8NZL!LM
M3,1;C"WQB=%*Q$X(F=>F<#*:@+<B#TBA(5Y"V/9],Z.Z(3UL6RWW5K0=().R
MX<.5M"1G95L"))S,6:@QQ*.CF%.P)B$QD2&^-#=#;C"<US7'6'-"+,-AP[X9
M@N>26/:[6#VAI&M2K7--00#6ZAQ7\G.?M_M]GW8,JSW;YFHM.[J;:Q-9=,'=
M=2]--P[NQN8/%OFI0UB0+>8@?W>(*8V4/MI9Q:I62J$^L?8(C=K/T E[0T#C
MZ50;0C&UH+;2FX=E&"PP(EG61-2<&T(S8NM[P1)>#.-F2"""UKFT!K$;L9HP
MYQLNY@U'>[;[RIJU\5KRP4PHXL+<:U(IL6JV?SYOUVL]<_RQM, 9B+3Q9JN.
MDCUSO?5<8^R:76E7P9CGA)#7[4#;2PMTHE+K'4RP@X^I6I8SCZ5 5 H1DK6T
M#E[)T&D-)8L_&=:LU%LY\Q9GNF"!+2EK0YZ/(N=%K[PS$65E84PYCFM#&1VM
MU::KW4A3;HLW$EPP>[:(FK$J:N="<QKQ2E-4.>16N+2NS^BC739LW!V\[QY#
MYLO*-;3CF4\HKJV?9]7CY P6R;33IH !J(^41P1)  +#^MO'LX!Q[1\F"HUN
M9PY^FP9XG((YAFGH#TCSP#>.*-;2\XY#9Z\N.'2UM+SCD-GKRXX:>89KZ ](
M\\ WCBS6UX9E=#&$G?D-F\]>*":;U@ ZB/G]7CU!LQ=K:[@,5V,9W9G;UX<Q
MUUZ<1'S<[@Q0#6N%S1X^G6.%P, !P0C30I =O>/;ZO'J#%6MKN ZH%T0X?J?
M(=>06GF&:[1^@.WGS;N-@*7!=+6UN%P'@C55=8CSP#&[6UO.&0V^G/AC8  4
M"&89KKMT .= ]/;W8J!6X*S&8$B_(==#D2NO>/5N#TCSL\;-;3CF5U,9WYG9
MUX\NK_I(7YFCKSD/?Y&[MC PL^>JU+B[/;TO2-30U-Z6+SPU4N<7)<<0C0HT
MY5-1AZE4<4227356:932 B'T70&#&F(6FD&7A1(\:+H9:<.%!@L=%BQ'NF9(
M-9#AL#GO<XW!K023< 5X#21\.#$T??$>R'#9;TLY\2(X,8UH@3!+GN<0UH O
M))  W+''-7F3?&"].8N<V,G,*5HF/HV$]P(1<*(,UNY4I^$R/,*_QE0J0SRA
MG=U[PTHO<)Z*N-J'E?&$KLF4*O><MW+.4![!HSH_!C618$G;,E-M?&]H#I*;
MD9N+/RS1+OL.!,-:^2,6%#A17Z[7B8;!9,.AN:WWIA$-7!:MI1(4[:<Q(3$
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MO^1V9<//NVU]CL__ .4@_P"\_P#=>M9H+\GCZN>O4<?,%V)I9>O/5Z^P.0W
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M #&?_:<U_B3\+SW_ 'D/_A-^:W6&7Q93M"]5T@'JU][;0^FUFSZ,/Q'^S_\
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M/V7*_P"%>,>CRMV/7=>\FW_[>U_\+\;?O#T<_-YC^UQOFMA[;O:$,+0D+O\
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M!%8(K!%8(K!%8(K!%8(OX(@ "(B   "(B(Z  !M$1$=@  =8X(N.+=7DM#>
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MPPBDW5_!)\)0=!B(Q\/</OT%Q?<H I"5 !8&+-E#LVFM?6^E-RWH4,3^].A
M*HZ.;S\/:H]M !;:KETK?C[*@5!2&V1A'OP?M(ZZ:)?O(>QZF$*<%G/=[O;_
M $;_ ._B-M5[(F"FK!%8(NI^96<A\(Z7;+#=)M/E+G-KN98<\%$I=)++Y'(D
MB)EA<FR4IHK$X>QNCB>PPF*,IKY(70MEB[8UDKWR1/CV[UN+HX&*@+:OU:9
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MZV.?P]479GT6?N;XK#O\'?<_WKQS1YU_O%>X/:_>;[Q/QN+S_>K^#/M7_0_
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M&(W@TU,DIK+&MCC>T-X4+2>RX]ZXG8.BVSCV8EV5*Z5A[BY8E]P,MUY^DAN
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MN4TB;(LUR)5,KJ7RM3&G)/*7EP4D1BB+.<BK<26)_5&@D3MX&'$IM(&XUKW
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M5]^?W^P349\+?U1\E?A->DC^<&SO_I7WY_?[!-1GPM_5'R5^$UZ2/YP;._\
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7DJ4KW!<H/5JU!R@XPRHM@ +@*#8%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g65062g48l79.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g48l79.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[22:4&AO=&]S:&]P(#,N,  X0DE-! 0
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M;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/
M8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R9%15
M;G1&(U)L=                $)L9"!5;G1&(U)L=                %)S
M;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S
M96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M    5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M       08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M
M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12
M:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M   0 [_^-0 "  $#O_XU  (  3A"24T$)@      #@             _@
M.$))300-       $    'CA"24T$&0      !    !XX0DE- _,       D
M          $ .$))32<0       *  $          3A"24T#]0      2  O
M9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M!@       0 U     0 M    !@       3A"24T#^       <   ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H   X0DE-! @      !     !   "0    D      .$))
M300>       $     #A"24T$&@     #-0    8              BH   =D
M          $                          0             '9    BH
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   BH
M    4F=H=&QO;F<   =D    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$$0       0$ .$))3004       $
M SA"24T$#      9W     $   "@    +P   >   %@@   9P  8  '_V/_B
M#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  (
M"0 & #$  &%C<W!-4T94     $E%0R!S4D="               !  #VU@ !
M     -,M2% @(
M                $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P
M    %&)K<'0   ($    %')865H   (8    %&=865H   (L    %&)865H
M  )     %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,    AG9I
M97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P
M#')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0
M0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D
M97-C         !)S4D="($E%0S8Q.38V+3(N,0              $G-21T(@
M245#-C$Y-C8M,BXQ
M                      !865H@        \U$  0    $6S%A96B
M                6%E:(        &^B   X]0   Y!865H@        8ID
M +>%   8VEA96B         DH   #X0  +;/9&5S8P         6245#(&AT
M=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N:65C
M+F-H
M     &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L
M;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@1&5F
M875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M      !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@
M:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I;F<@
M0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M        =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:
M(       3 E6 %    !7'^=M96%S          $
M   "CP    )S:6<@     $-25"!C=7)V        !      %  H #P 4 !D
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MK@K%"MP*\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS
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M+UA]6,M9&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                          #_X49.:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60]
M(E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS
M.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U
M+C,M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @
M("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O
M,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P
M.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF
M;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/D1E<FUA=F%N=%!I<&5L:6YE/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT
M:71L93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @(" @(" @(#QX;7 Z
M365T861A=&%$871E/C(P,C$M,#8M,CE4,38Z,S@Z-3<M,#<Z,# \+WAM<#I-
M971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(Q+3 V
M+3(Y5#$V.C,X.C4W+3 W.C P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @
M/'AM<#I#<F5A=&5$871E/C(P,C$M,#8M,CA4,38Z,#4Z,#DM,#0Z,# \+WAM
M<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E
M($EL;'5S=')A=&]R(#(U+C,@*$UA8VEN=&]S:"D\+WAM<#I#<F5A=&]R5&]O
M;#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X
M;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E
M+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(^
M"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z,S)#0C4U.#DS
M,D0Y14(Q,3A$,D9!13,S,C<Q-#9!.3(\+WAM<$U-.DEN<W1A;F-E240^"B @
M(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z,D5#0C4U.#DS,D0Y
M14(Q,3A$,D9!13,S,C<Q-#9!.3(\+WAM<$U-.D1O8W5M96YT240^"B @(" @
M(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS
M0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N
M=$E$/@H@(" @(" @(" \>&UP34TZ4F5N9&ET:6]N0VQA<W,^9&5F875L=#PO
M>&UP34TZ4F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#QX;7!-33I$97)I=F5D
M1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS
M=%)E9CII;G-T86YC94E$/GAM<"YI:60Z,S%#0C4U.#DS,D0Y14(Q,3A$,D9!
M13,S,C<Q-#9!.3(\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS
M=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z,D5#0C4U.#DS,D0Y14(Q,3A$,D9!
M13,S,C<Q-#9!.3(\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS
M=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q
M.3$T03@U.3!$,S$U,#A#.#PO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@
M(" @(" @(" @(" \<W12968Z<F5N9&ET:6]N0VQA<W,^9&5F875L=#PO<W12
M968Z<F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R
M;VT^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F
M.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN
M<W1A;F-E240^>&UP+FEI9#HQ8C5C,S4Y,2UA.#@P+31B9F(M.#@R82UE.3 Q
M9F9A.&9E.#0\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IW:&5N/C(P,C$M,#8M,354,34Z,C8Z,S0M,#0Z,# \+W-T179T
M.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT
M/D%D;V)E($EL;'5S=')A=&]R(#(U+C(@*$UA8VEN=&]S:"D\+W-T179T.G-O
M9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D
M/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)
M1#YX;7 N:6ED.C)$0T(U-3@Y,S)$.45",3$X1#)&044S,S(W,30V03DR/"]S
M=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE
M;CXR,#(Q+3 V+3(Y5#$V.C,X.C,W+3 W.C P/"]S=$5V=#IW:&5N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E
M9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&EM86=E
M+VIP96<@=&\@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<#PO<W1%
M=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^
M8V]N=F5R=&5D(&9R;VT@:6UA9V4O:G!E9R!T;R!A<'!L:6-A=&EO;B]V;F0N
M861O8F4N<&AO=&]S:&]P/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA
M8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HR14-"-34X.3,R1#E%0C$Q.$0R
M1D%%,S,R-S$T-D$Y,CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.G=H96X^,C R,2TP-BTR.50Q-CHS.#HS-RTP-SHP,#PO
M<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E
M06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O
M9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D
M/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)
M1#YX;7 N:6ED.C,Q0T(U-3@Y,S)$.45",3$X1#)&044S,S(W,30V03DR/"]S
M=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE
M;CXR,#(Q+3 V+3(Y5#$V.C,X.C4W+3 W.C P/"]S=$5V=#IW:&5N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E
M9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI
M8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%
M=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^
M8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO
M<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA
M8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HS,D-"-34X.3,R1#E%0C$Q.$0R
M1D%%,S,R-S$T-D$Y,CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.G=H96X^,C R,2TP-BTR.50Q-CHS.#HU-RTP-SHP,#PO
M<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E
M06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O
M9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D
M/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R
M>3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.FEL;'5S=')A
M=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL;'5S=')A=&]R+S$N,"\B/@H@
M(" @(" @(" \:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^4')I;G0\+VEL
M;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/@H@(" @(" @(" \:6QL=7-T<F%T
M;W(Z0W)E871O<E-U8E1O;VP^061O8F4@26QL=7-T<F%T;W(\+VEL;'5S=')A
M=&]R.D-R96%T;W)3=6)4;V]L/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*
M(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @
M(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*
M(" @(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q-2XP
M,#PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @
M(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @
M>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO
M<"\Q+C O(CX*(" @(" @(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO
M=&]S:&]P.D-O;&]R36]D93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "Q ET#
M 1$  A$! Q$!_\0 '@ !  $$ P$!              <%!@@) P0* @'_Q !.
M$  !! $#  $1!08% @8!! ,% P0&!P(  0@)$1(3%!<8&1I65UB5EI?4UM<5
M%E73U2$BD9*4T0I24U32,9,C)"5!46$F,S0V@4)QH?_$ !T! 0 !!0$! 0
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MW9ZD[>[#74>5 EX3T[]V2?D#PUBT>C_']2 7D.X5"KC@S@=)F<VKV7\M./\
MC=:JC2PY#9\:46: <2(C,(SA]&VQ',HWL\4F]CQ"4*CXXN!"\#_Q!_*U[2]S
MF)O7_'[NRB27&K>#,XI'WI:K(/$K\M\C5Y&P3U@1SDA-Z]M>"1]5!FTCQ)S9
M_'\^9E"JS*01N,A<%"[8#;=5G,1[R=Z*^<W]R7MG#AWOD1L.NYKR"H23 .T0
M#&)6PXKQA9, .#2=YLH*C+DV[)@43<&I@2KDD2.))R+M@*SD*8'8Z$>V+ LW
MC-=8.R;3D%R':8YC\@:=&S@O9CR]@SB(Q]_'S\0#PCD*4;#CM]14$ E#(;A9
M<D"QX^^-HFPCX$P3!MME -R&@&@&@&@&@&@&@&@&@&@+/L-TZ8P"<OF3A=H]
M9PZ3.FCMLKFBY:NFX5ZLW<-UD]\5$ET%<,%4E<,L<TU,<<\=]LMMM] >&'C%
MTH_/^BA/ P1R%,VY=IN&\)N8?."-&U)C*W(/EU3LJXK)675D9ME\H]?.I9/*
M&M.,SR,%WQML2(#(]]VY&,3W<O\ 9T\ SM7Z>OE[$>)\^O\ ,U[QALF55C<-
M1PUI"H.H4;D;^CUT4P2L)2/U8"@5WWP3B\^I9^/5F$O<RMT0$S*F$5I$U&0D
M\FJ-P SVZ/\ Y:<EKOZ1.VX;:G(CC]8U3%.CWX<7Q7<+IT3(@L;(G[/<3!>5
MSRJ4Y-,3)LM%TBS4J.EQ<TT>D%!9*H6:B<2(,33$\!K"XV\N>6ISFM'8YRPM
MNZX5P3\)AS]J2F+ B5PGVA6WN2,)LPNXIKCU=,@;G&T@B?'QC%4RT5J6KQSM
MJ"FD]C^0@\U<QG[-8I 291W3S<T+5K.Y+E4H^B7L3JRJ(;RHD,4!;.%YQ :.
M%\B4*UNRNCX<3><JEAR>QFILS5@A;)+0&LPS22P:6QDS5ZZ*@=PX S;O[F9?
M5V="!S-YFA"N=+D91&[NE?%>5580E,.G0BA1=@YQJEI\5.;FEB;"P)C%QOWT
M=/P"P=@D.D0MLS'M\DEU' &@F)\]>>Y>[PXZ:WG=S2.\2^&'2$</;.!)VC80
M(-<_*OACQFNZ<2:[) J(D0\F5F:K0W3AUK/%7*<J9'NM*BBK5^P;N\ ,TL^E
MCY5\=I390N-F&\T?6Y9_#^(QB37X>D5@UC1XMST9=?WY+1XT5*+AJION:LV8
M)$%]E"-K1S(@4<R64/L97).QC2(&0D5Z<GE!)>1O$2"R.ON/E;UER!B/%%C(
M<!SC"[SXNT.2<>)9X,W9RN+V1DD( +R;[$4K!RI2D_BTRBKM<J>LB*X8JN6(
M&.M$=,US8BG%VI6LTNCAL2LQ>H^;W)29W)R)1EHH),LJ!N9>/#>(@!A%[%C;
M<?R$(($UI&T0PWP2C51&*P0%UL9=8N2!8#,4+TPW,F26J#DJ%0TI&Z PY,\
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ME9.0-</6Y.O B\"BJPB!DFF_5:$(8-4%9,HN];;_ +6[L&BQ71W_ &IJ8[Z
MO4_'@$J%.0,H!AY(#>Y-LG@8^,9&!3O)F[0?L\G(XB@X9KY-'S5L\;;JHY[H
M.VZ#A+?!9)//$"L: : : : : : : HSV.1XD8"2$B"#/S\:Q)XQPX]%L71@!
MB:;I-#.(0FN@H]%8EFJ"+8GLQ70V?MT4D76RJ:>&.P%*.5_ Y.N3=26$Q&0N
MC01K&3+DY&PQ9<M&V)%8PRCY-9^R<*/PC,LX7*-13K)5@W(KK/D6^#E3-7("
MB)TS3Z4C)S!*J:V3EIMVX?F92G!8OA(R[YV(6C[MX3-XB]B;]VY .7 1PX=N
ME5EA"ZPU3/)DKFCD!3$^/]#I052KTJ3J-.LU26QE6NTZWAN$%4,8KX.L2JD1
MQ#; ,R6+I--SL^R'[NMET\%ME>R88Y; 7-+JTKFP ["/3R 0F; !3A%X+!RZ
M*@I('&NVS59BW=,!AE@]9,W"#)PNS17;H)JI-5UF^&6*2N>&0%9C,6C,+",8
MS#HZ"B<;%XKXC(_&1 \"$'8N7*SQSBQ$BV[5@TQ</'#AVOLW;I[*N5UEU-LE
M5<\\@*[H!H!H!H!H!H"CF(['Y#L,V/@PYS8(792 -L8&,B>P@\-[+L.-C-GJ
M"_:!=ALNMLR)->Q/6O9E>P+)]DSZH'7+Q**R!\Q)GHS'S9(6Q-#!A N%&DGP
MX;)&Z#21#V+MXV67:,3S1JV:FFC=1-N4;MT$7R:Z:*>.(%G;4=2NQ<3(-J@J
M[8\!&1\(#-[5_$]BX8-$G*;R*B!)+83VX.&1EVDDZC[!FLBT#.4TUQR397#'
M+8#]8TA2XL7- 8RH:O'!;(<N'EB!V, BC07/7;OLG;3J:#VXE-I*7+GLJO;"
MYQ%\JMV53LF677Y=4"ZF,*AHN)HP(9$HR.@S<1E'V\+8@132)H ,T,FN8-&.
M-VB8=(1FVSS;Y#<&>++)#/)'=#=/+?'<#DBD0B<#CXV)P>+QV&14,EDW$1J*
M!1L=CXI#-7-;-$:&$-F8YBEFLJHMDFU;)89*J9J;X[YYY;[@7%H!H!H!H!H!
MH!H!H!H!H#C52272407336163S2615PQ42524QWP4343SVWP434PWWQSPRVW
MQRQWWQRVWVWWVT!:36NZ_8Y1;-E!8<SS@PQZ%A6;6,!&^4/#DFB0\B)BV2+'
M#>/C'[!!%D]8"=VC5TT12;+I*(IX8; 4*.TG3,12#H1.HZQC"$=)FC4?1CL"
MBH5($9DC7M&1%@Z8T2VP&$S[+;9F:?LL4'15KMVN^572_<T!WH_4U5Q,H+.1
M6M*_C)L''%X>%,1^&QP,4#Q)R3R-.8L+(#AK9V/CC@SGF67"-%D1BI//)^HU
MR=9;J[@<[FL*T>"EP3RO(,Z!NI*K,W(9S$@"XIQ,%GV1-:5KCE1^31:2JDLL
MB"IU1'(HH^RR=Y.MU]]U- 0C=_#NF;OJNVZFS9&*A$WMGMM;DIH-T-J>P9ZT
M<9YIG!\FF  1N1,M92*<$(_(U"/;3Y\%*D6R+QJNO@Y2 F..5+6T4JV,TD&A
M<?PJ>(0N/UV @3X:W+1MG"HJ(9 @,=4&E<'B#T<.$CF3-))[BXZ]-NGDKOGG
MMOEN!]K5+53A9XY<5E7R[@@ZDKU^NM#(XJL^>S,6B$F#MXKF-RS<NI6&;-Q$
ME<+99JG1:"+ IFZ:)8)8@=0Q2U.2$*8C1^IJS.1V0JA%CX Q XL3"G%HRS:C
MXVJ8%/12[$FK'Q[%DQ"*/4%\A+-FU;,-VZ+=+# #ON:JJ]Y*X[.W=;P)U.(>
M-R#1*9.8?'EY7%Q&22J&0J.R)4=D7"#<D%UT<F(QXU:[I+*I[I=8IGMN!175
M#4:^9_9[VF*H>,/OHYLGM%U740<,^Z(]SQ5>3[M94/FC]]':F&"CF4]9]N+Y
MX8YJO\\L=M]@+H7KZ NGSHFZA$0<DGT@#2UZ07C059\\E4<;I,X])G3M1EDN
MXD %HW0:AC*RF9$6W1208N4$D\,<0/F,UW7\*(R8Q#8+#HD6FA/<W,2D9C 0
M"1EAG?LG5+R9Z*8M')XGOV97JORBKIWOV53_ ,7]_+J@7CH!H!H!H!H!H!H#
M%N24Q?I:0&RH3F!.HJ&(E7[X5&6544F39Q\>Z=*K- S4B8ACLJ^;C4,TVB3L
MDZ</G&"6*KI91;+//>Z9?0Z,LHU!NVVD1$5I7S]%:5$H5I41XB(J_JJ(B(B_
MHB)\B@T[>JTJLQ#3**OR9JW:T?:E6:5_Y^=M)"C!O*"D@2B0SI/61&5+$%1*
M,981KBL\D"I5#-1)88D&;QI0DH01525359X-MW*>::F&:>V6&6VWJOA<!=^/
M$>814O\ "6_"=<)<V\#MG%I*'^_2(F=F,'6<MIH\WKSC7LTB#AFWQ=NV\H<;
MQ#L,?6:M,\73E(MFT40;Y8KJXXI;[9;OS$+@+OQXCS!5/\):\)UPE%$AYN?%
MJFP727[&@J!8<!6+B8AQ=(BT3AA9)N)"JD&<76:)EBCA9% <.S6V>/5E4DFR
M*N:F&.[\Q"X"[\>)\P53_"6O"=<)6FT#MEZW&O&?2(F7;0P><Q40Z;5YQJ7;
ME9.SR>X.XX-72B&:3X\US&D<7(=KDJ00R8/<56^.[5?9-^8A<!=^/$>8*I_A
M+7A.N$[2=:W,L[D8]+I!I&J_AR3=:7,DZTXX9NXJB\99$FBLC;8PW=8&DZ'8
M9OVZA/!KBNRQR=);Y(8[J;*^%P%WX\1Y@JG^$M>$ZX2AQ".6#8+AXU@723KS
M=T.1P<D&T0A7&&2N&#=3/L:;AXB&BKU1JCFI^Y@JOC@GEG^[CEOE^S2OA<!=
M^/$>8*I_A+7A.N$Z849,I*PDY6.])HD?&0GLWWS(A8GQ:*L(CVOBKFO]YWC&
M,+MP'8,$%\UOM51IV/%%7+/K=D\]]E?"X"[\>(\P53_"6O"=<)5(=$;,L/%_
MG7_2.OYS@*R;XE,X=!.,LFQ&Y.]EMVF+_(+$GNS/)ULW<;M]G&Z>Z^R"VZ6V
M6R6?6OS$+@+OQXCS!5/T_6):3_\ 4ZX3JR:/3^%&&<>F724*Q(^110<CP<FA
MG& "8?MW3A5HV<,QA6*M'KI%RZ07;(*H(9IK.$544\LE$\\=E?"X"[\>(\P5
M3_"6O"=<)?\ M1')'?;J[<W[$WVW_;MOM3=!=3?;_P"?_P"":5\+@+OQXCS!
M5/\ "6O"=<)\*47R.23S55YQ6"DDEADHHHI3E 8)IIX8[Y9YYYY03;'###';
M?++++?;''';????;;;2OA<!=^/$>8*I_A+7A.N$Z["EN095BR*"^=<Y)#"31
ML_'$6%1\?'C%^Q>(X.&CUD[;P=1NZ:.FZB:[9R@HHBNBI@JEGEAECENKX7 7
M?CQ'F"J?X2UX3KA/AS3=_LW8Y@\YWS9H^+K+MQ+)S4O'I!V47:M5GSI <V5A
M&"SU9LR;KO%TVV"N:+5!9PICBBEGGBKX7 7?CQ'F"J?X2UX3KA.]W!^2/IO6
M)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$
MM>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*
M^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^
M2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y
M@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ
M"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$Z
MX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%
MWX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO
M6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^
M$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-
M*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!
M^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1
MY@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[F
MJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$
MZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P
M%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/I
MO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG
M^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1
M-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W
M!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\
M1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[
MFJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>
M$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%
MP%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/
MIO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@J
MG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^
M1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1
MW!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX
M\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)
M[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M
M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^
M%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2
M/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@
MJG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"
M^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX
M1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%W
MX\1Y@JG^$M>$ZX1W!^2/IO6)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX1W!^2/IO6
M)[FJ"^1-*^%P%WX\1Y@JG^$M>$ZX26*PKZSH;L;VGE\26W-R.XW<5N<A%=Q7
M[O[--G_;NS7:&1\/L_\ M7=RTW6W)=L;MOLY+9IV+MAUV6D]>.F[FKAV7-%-
MU0\>MW5-%'_NTM%%"_I^M/S_ &*CMEMFF[>J\IHHI989HHIIHN42FGY?K3^G
MRH)F_P"NJ!4//R0XLU5Q_P"E"YA\K0'!:-GHM6O 2K[7K A7?'$*[>2ODB'L
MOD%(9DWJLB"ARN[N^Y8.SB[$T^CRBDT?(% 69991HHURT!I1B_%OI-./]&\V
MP-Q\8IY(G?2C\!>2LKL=Q54@EM\&7'-M!*>VX(,V%$@]>B,:5+3.!V@^I<-#
M6;^4#2,DKR.B64A?$UL$<P,K95T0=NT73<,O-@UB4KLRT[@Z+ "<HGBCQ6=4
M)"(5#*9Y&PZ>2VPK$@@276 1E]E!F1$C]^+++?8>PL*+)Y/F:#=93M,3;_;+
M\T("X_\ $_G'QNM;A_,'=3W3+>,%C=)KR Y:VY#MX!+BTUX[655$PY608;)1
MT39!=S#:M.0E)R*OC01VLW5;/Y;&&RK!W_\ F(A @(]^_>4N7CI37245=<%I
M<NKCXHS,>%Z5:D^5D7N\3$3TTL>=PN9S:)S:S>*.=D4TUK\>1IE"LXPP:\=\
M$R<@E2:#J3I;''4?(9XC\@(DJ?HV.:=<PH, $4[O#;6NGH7957/'6>\=^.S/
MCO\ 9=SRV%P4O:=#<WY*(Q7,9W@H)C^(JNK6LN21,$7E3XVNX9#9EOVDT D^
M\N.VUQP26NN 71QW[Q/#5WT4G+FF.3@8SQN.4>2N>P9U74:$4[10N.(BVA/D
M-8\7GH8S+'$Z"LI0T5143S3E;]Z70:9@>CSHP>&Q7B)2:;62IT5M)Y_':X*$
MNXYQ/@W%LL.2$Q))/:/V,C#S!=U8<D$D")+KI%(LF)%LY<DL-V22KUSON!C%
MRGX46OREY[7Y@):TI&:RE/!>AJS(3Z^.)Z_(AF[(/[/Y4X2054IPA95>1R)3
MB-!9")*F<7;69[98&HF[(AF[5-#$D'OWL,3IX2Z0^EK=O&I:#(\N[/%1*M)5
M ZT>O(C(Q8NNX# ZJK\?')8-;RZMI5QZNR4&, L@=U;)Z_N(#<IZU9'N)M"G
MWP(87:BP]^_Y)O@HGE3:EM,XM#;7YTL^((>66A*83,;-BDE@MJV!O&:2JHKM
M7T]4LVM0-AYU6ZN)W(V\8WET: R.6KHS6+!BI.#HCNJ!BI7EF](P.FG&$(%C
MG,&$N8K$N/4#GD24K69E89M#7_!,,I))*$@"=*0/C:"%CK_((#L6DSO0C; Z
MS0Q((89P"M6F;$*%OO);M/V%ROI"CE<,DD=^71:30XG;ZXF]2=+SV929J<-\
M)[-;[F()4O(2L*@LF)F0%G(@]BD-PG$U@A:;'$HA45B&T55XL@'OW[4W+=&!
M++JE-%S;&[&-M;D0%PR,+#93;3BPLW4YA>T8AI)"10UE<U1TQ=XF%I2(C(P3
M,9;D7+2AN:#G?LV92:'91EVF]H#9%H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H
M!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H"++BNZIN/T.WL&YYX KJ&;&!
M$?VD,C<*-V.9P\YV9!A26Z22ZRS\F[WV;LVR*6:BRO[N&.^^@,>2W2/<&@(6
M-2(YR8K00$F&,G4C9 D0?,D2K>%N0K.6/$MG ]-1%A'W4C!(%"#G!!DU4*L\
M5'&W9=M 3P5Y"48%'5"8)VW7S<1?Y\)%J1+[2H0X%6L?DH1[)(\,@9)LZ692
M5<V"'/"@K(8NX1?-$ME&RBFZJ.R@$PZ : : : : M*,3R&S1[,AL4D8H^_KV
M5JP6;M!KG%PM&)@B" R=6.E\,=NJU*)Q^3QXODVRZN6S(NQ6_P"BVV@.4/-H
MG()#+XF%D PG)8"Z#,9H%:.,52$:=R$,VD(1N60V_>:JDPCQJ49XY?M59KIJ
M[?LRT!6"Q4<"%DC9=XB/$AQ[PJ4?N<NL;L1P]NH[>O%\]MM^M1;-D55E<NIO
MUN&&6_4WZF@+8?V1!!E=.;;(2@4TK5I#LK!<S)9;+$*C"\ _W@SDF;C;#?+8
M9B%_]2W6['OEVM^_UG5_9H"]<,\5,,<\,MLL,\<<\,MO^F6.6VV6.6W_ -;[
M;[;[: ^M - - - 4%*4QE>3O84C(0BTQ&@QLG(Q5(HR4D3"-F7Y06(/O0N"^
MY%H&*DPAH>-)KMTV;YZ(*-6JRJP]W@B!UIK,XI7,0E$_G1\;%87"@!:4RR2F
M7&+02 CH)BN2,&"3K/\ =;L1S!LN[=+9?L312SSW_9MH"YMM]LMMLMM^KMOM
MMOMOM_TWVWVZNV^W_P#O;0%MEYC%P)Z)Q<P;8#I!.GA8?$!+E7?!Y('H(,[D
M)=L.3VQWV55'A&#PDYVWWQZQJW4SVWWWVZFX'X)F<4/'Y;%@Q\:2D4#="&,R
M#M7&*KZ-O#P9K(0S<LCM^UJJ2"/6A1KCG^U5FX26V_=RVT!CT*YS<.S@>QI
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ME:5&8IN%2!BX94A'3#U]6/JJX6X>/7+-S_0MTMW2GRH1?VQ"?$@QLY)";DV
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M]:C< ,HN3G,CG;P<B.3+OY17+8GR$Z-SEAR=C\E4J:G8\2H"U*/K>.SV+6-
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MYSW!M5[>!6%SSY-\?B"T<2;T!G-&T[4!U6'B[YZ2,OH^I'$6$F&BQ<M2+8'
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MIH]_0.<\\LDV,\H.@ZALRA<_BT]H %+*\%1<1"R8X#,D$@",)@N]80\@T%[
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M4T]ECGP.GY^!PV$TESQCHZ4,!C-&?\!\;UU8.V_4W@LRVWV_Z[;Q@WMOM_\
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MUB8&51;+,9ECF-SRCYU@_$[YC\\,,V.6[3?=IEACDANGOCMOL!4G\*AI44*
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M<ZC;33DPXOIXCQKC]JOA&^>RU#X4CBE)WT &%"78[<W78Q,J[5:I*R1LD!S
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M&#&6CII"8)+C\IK9,RBZ=EX+G+FS0F>#C'+@L'C3I=BR<@;(] - - - - -
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M_P#W$%:;X>OS_P V7\V_]]<<G4(Z_/\ S9?S;_WT Z_/_-E_-O\ WT Z_/\
MS9?S;_WT Z_/_-E_-O\ WT Z_/\ S9?S;_WT Z_/_-E_-O\ WT Z_/\ S9?S
M;_WT Z_/_-E_-O\ WT Z_/\ S9?S;_WT Z_/_-E_-O\ WT Z_/\ S9?S;_WT
M Z_/_-E_-O\ WT Z_/\ S9?S;_WT Z_/_-E_-O\ WT Z_/\ S9?S;_WT!(-2
MYY]U.MOWLO\ ^>Q#_P#RW\H!_P#]ZE/U3^Z?]GAY_P"C7]CTFZKED1_8%7PJ
MT,(9A-12A7& 6!%[0BNR9$B.^SIK#5G#B/%5-QSIKN]39*NE\LQS[M@<ZVSV
MQ=M5L<<=M@*!8%$UC:$F$S":@%RI\)7-JU.->)&30[!""W7A$$[&$9-1S]JU
M65.8P2,;(DED5"8G<?GN(=L=WCW=P!B@SZ+3AFP*-'S>#3?86/./I2/A65T7
M#O7;*5F:??4)))4A ]IOC%_O'*:E)/X?(3*@U1\_:/7SS99(F0?O70'>2Z,W
MBTBAF[21NE.=*2%:0YW-AR/O?&]LLW$-'5ZN"RN7&P-K"4B"\)$C(^M$E#V<
M?538-"JC#(^V1+)@2';_  :X]79 :1K25B9\"B7',P!D%-MJRN*V*G*0PU%H
MPZAT;*-I%74RC<A(/P<>?/68QX7)OW+59VX?IJ[$%<W6X%DO.C=XQDY,*EIA
M.Z3AD<<IR6/5#W)&^S3>6S:@3@X]4LZL%L3L-TG84PB3D0,:('9GL;=/Q@]B
MP*;O46339$"];PX+\=.0\W2L&RH_,%9 JSK\=(DHE:5E0 #/F%3S1Q8E7L[(
MC,*E((!/D*_FKT@?BN$I'D_LMT2?I)[Y,W2K;<")T>BLX:HCB@?:)61F'>0N
M<5R%#K7S=BHB 0:P9]$+2/QJL1><\W8UTQ2L*!1&5AEXDW%$0I($.P'/4&+5
M!HF!(-7]']QLJ"S(Y;,,%6-M*X8<M:10QO(;IMR61.(%;R=OBMO.([")),B<
M2&[V ?)/))(=TP^ZC@]FD01S0R:M,$ ,U= - - - - - - - - - - - - -
M - - - - - :P;SYS=&7/+=PX57Y,H-/96K9\6KEY%)G5LSE]2"[K,-,7L0K
ML_9ZT+(TV"M!Z@0PQ%Q,Q,6<CP=/4Q^[)(@YP:YWTG2G*,D1'YN2XZ*D^*1A
MIVD1"/GCA]5MT7;%8[:9:N6J$NF::%H2G]"TC(&"E%RL-'PD/&0ZM,MJYB7+
M#]TK;%-RU</&6F;IFE:%HI2E:#$6#6]T"]DECPJ%495QM*,L[2?G)*GP4N%G
M 6+6EQ$I-V4IE8Y"BVD"5WC3.%R5+)-O(U5"90=]B!\"!EVQ8N?O=?)Z8U2]
MK.+\T^3U2FOB](VKH3RBCQ+D#_A[YI'YU)Q-;T(/$5W3C_D'(<Y=PYL:!O75
M+BW8IB1L2(BYM3,?)S^/,W)T/@LX@K21*[8DF:VR.2*V*FG7R>F-4O:SB_-'
M5*:^+TC:NA/*+JBMF] C,8;/IT*J[CNR$U>9J\)/!4KXI2R#3B.N+IEPJ"5>
M_<US-*J 3]Q'IC+30\*,E+&-NHW@Y46S=E6R#1TJBZ^3TQJE[6<7YHZI37Q>
MD;5T)Y1,DJAW0S0FSC5.2>C>-0JQX];-$T<7CF?'KMC)K:7)<22-TG%MB;2"
MN [A6;"Q!%RD3;$%@P7M?=&1$1"ZB*2CKY/3&J7M9Q?FCJE-?%Z1M70OE%Q<
MGJEZ'SAE#(O8/)JC>+%40Z9V#'*LC1PU2P5^W)3F5ID%PH?9(#%2SIJDJU%$
MGKTL]0;A1#!DY?%B#%JGDMIU\GIC3+VLXOS1U2FOB](VKH3RB![_ )IT&O&"
MW&U%71Q[K*.V@1W0P"QT)P8MN?(219:.82Y1M%)!7U(2B-RMXPC>>Y8NSCI<
MFZ"M476Y9)EFS=8(NOD],:I>UG%^:.J4U\7I&U=">47'#R7093RV871D;JSB
M\O:EB3Z]:NA<3)<>EH^XD%@<:R&PJZ8JS(2" "Q&)6'/NO1Q1</T<9#LDNK%
M\S2*"JF#KY/3&F7M9Q?^'JCJE-?%Z1M70GE$=$+F_P /Z+@JEDNJZXY90].K
MP%S?:+/BG+2+I:N91>CGC4 /-0H^J71MXL3NQHO"&X-J.6D';&.)?,7@ 52*
MYNOD],:9>UG%^:.J4U\7I&L_^G0GE;?T,B^,E9]#]S!83E]0/';C_*5ZS.CH
MU8 "0\:7M9S&'ES(A$\%0/PBT*^ALN'-S0=?$@&(+A<1Q5O@ODP=.-VSC9)U
M\GIC5+VLXOS1U2FOB](VKH3RB];GXZ=%#QYRJ_"Y.._%Z#97-:L7I.M=B-,Q
MYUM);+F6#[..QU/<7&GVPW!]B.=;*FC&X\ /SV03)%&F;MIBLZ^3TQJE[6<7
MYHZI37Q>D;5T)Y1>H;ACT9\AD$^BP;C)Q;?GZN+!@-@C4ZJA>"T4,2&-!Y@%
M'%<U0R:*3DA&9 $,H)X*J?\ DR;3+/?#-7;#3KY/3&J7M9Q?FCJE-?%Z1M70
MGE%WY]'IP P4P1RXB<:MEU,<\DT.Y1!^S*XX8=DSW21^RNR*=:GU,]^LQRZF
M.^V7_3?;?3KY/3&J7M9Q?FCJE-?%Z1M70GE%M0SA!T<\^C$8ET<XB\?MQ$P"
M,I$"2-T4$BIQ84_;IND%'T7E$9#R4,ZQ15P[:'&!+ BQ4WW1>M4%L<D]G7R>
MF-,O:SB_-'5*:^+TC:NA/*,4[3;]"U2UC3*L+)XYU&!/5OC&%+)/-^&=@2&L
M:W;S$0T/1]Y8=Q1JH#%40=@Z#/FA-R_E,S%,A3%;9T678HX*9X.OD],:9>UG
M%^:.J4U\7I&U=">49G)]'OT?BN^.R7$CC,KODVP>X[)U7!<]\F:FVV^#O';$
M7OONVSVWVWP7VZJ66V^V^V>_5TZ^3TQJE[6<7YHZI37Q>D;5T)Y1\^#YZ/KJ
MX[=Z5QDZN>ZNV&W<M@G5RW0VSW7VQV^S/WMT=DU-U=MNKV/9//?/J=;EU'7R
M>F-4O:SB_-'5*:^+TC:NA/*/OP>W1^_^6W[T?C/U'O4V9[]RN"_^;WWQVSVV
M;?\ I?\ X_5PWVRV[%U_5QWVR_Z;]73KY/3&J7M9Q?FCJE-?%Z1M70GE$ .:
M8Z(IIC@NXX_\9<!BDD4AN$@VHD?G%LIDE=[?CAE$-I2G#\H]M*<KJ=)09./[
MDMBJKOLI5)KF!06*INOD],:I>UG%^:.J4U\7I&U="^42W#^$/1S3H(P/Q_B+
MQ^[0)N335DB;HD+%RRRL?,/P13+<#)HP(.)()D!KK9LY5'IMB#+M<H/5=#'K
M-VNZ^3TQJE[6<7YHZI37Q>D;5T)Y1=W@Z.!7H=\<?='"_P!(TZ^3TQJE[6<7
MYHZI37Q>D;5T)Y0\'1P*]#OCC[HX7^D:=?)Z8U2]K.+\T=4IKXO2-JZ$\H>#
MHX%>AWQQ]T<+_2-.OD],:I>UG%^:.J4U\7I&U=">4/!T<"O0[XX^Z.%_I&G7
MR>F-4O:SB_-'5*:^+TC:NA/*'@Z.!7H=\<?='"_TC3KY/3&J7M9Q?FCJE-?%
MZ1M70GE#P=' KT.^./NCA?Z1IU\GIC5+VLXOS1U2FOB](VKH3RAX.C@5Z'?'
M'W1PO](TZ^3TQJE[6<7YHZI37Q>D;5T)Y0\'1P*]#OCC[HX7^D:=?)Z8U2]K
M.+\T=4IKXO2-JZ$\H>#HX%>AWQQ]T<+_ $C3KY/3&J7M9Q?FCJE-?%Z1M70G
ME%S13@WPW@I3(W#.+]%Q8OFU58YDP-9Q08^R9KYI*+-<G+08DKN@JH@CFHEO
MEUF622>^^V^^.W4L)2G/.*6(=(259;E.485'C+Y(>,C'\0Y1ZPC3+#Q';UMI
ME&V66VT9:HI1&FD1?FI>0,AR-)CY8F3I*D^!B%8:=*^A(1Q#O5=M*RTTPK;I
MAEI6&E9956::%5E%5/DA(_>^49YHZ\]DPWPFO@T)8F1#Z]VWVFLY=X[WRC/-
M'7GLF&^$TH2Q,B"[;[36<N\=[Y1GFCKSV3#?":4)8F1!=M]IK.7>.]\HSS1U
MY[)AOA-*$L3(@NV^TUG+O'>^49YHZ\]DPWPFE"6)D07;?::SEWCO?*,\T=>>
MR8;X32A+$R(+MOM-9R[QWOE&>:.O/9,-\)I0EB9$%VWVFLY=X[WRC/-'7GLF
M&^$TH2Q,B"[;[36<N\=[Y1GFCKSV3#?":4)8F1!=M]IK.7>.]\HSS1UY[)AO
MA-*$L3(@NV^TUG+O'>^49YHZ\]DPWPFE"6)D07;?::SEWCO?*,\T=>>R8;X3
M2A+$R(+MOM-9R[QWOE&>:.O/9,-\)I0EB9$%VWVFLY=X[WRC/-'7GLF&^$TH
M2Q,B"[;[36<N\=[Y1GFCKSV3#?":4)8F1!=M]IK.7>.]\HSS1UY[)AOA-*$L
M3(@NV^TUG+O.TRHFEQKQH1'U9 V3]@Y0>,GC:,"47+5VU5Q6;N4%L&N.:2R"
MV&"B2F&^V6&>..6.^V^VV^E"6)D0*TTOR5II4L55WDKZD\C0#0#0#0#0#0#0
M#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0&AVG>-72%<:+;N*E*P
MJ/C)/^/-Z=(-->9)+D[:DR>%C,0K:UY0,F\[KM[0;0,+.R"YHZ1'.0-<V(TG
MJ49;(* RY)DUR&*CL ,&N+'1G\XJ7@]OU+):(F2ZT_C?.$".LAMTELW=48WV
MY #KH>0-QOPKWBZE=(.LG4TCH4HZP+IKL3J[ZPE%/M)%5OF!9\BZ$KF#$*EF
M$&C)%QR">W#T4+'BJ/<WE?IZ1%^(U^,Q$*<R^#4RO('BL;PX]VD4CC=KFW&!
MLSD3?1X.BQ()0_-09D!/'(3HXN>_-!:^KYG=9TOQ^M=CQBXQT'0]*MKP=6@/
MGY/CURLAW*LQ)K)L<37,6%QA&4.8BE 8>P:!3J@3(F1*EWJ#3/;94#ELOA#T
MB5LSNRN8K_CQ5<5MZ5<_NCUY'1_C!WQHDQ@E6W":OY3'3>QR[$(&VC;4U/C)
M_#[):CHJ3R"L<-U7J+M5/=-4$^6W:E!>',S@%SYZ6F>UVPO\%5?!JF*IIRZQ
M3..X2 'S-6F5KW8+=5@_.8L&V%),H^ZBE4/2KB(2U5-X4BLF-NUQ#5=SGB^9
M 9&U_P 4.:LL+]"E.[_8P]S9'"$E?+'E"<8S1H6^W$S7&>?T/!IO'UL6R2DA
M)3I^\C4DD3'%-JN%<&"FR^V>S+?=0#7H>Z$#DC:=S36920O'*Q?";HZ3KD!Q
MZN"-RQ A*:HN6\^5517GQ.GS84U22=9X["H4='V",Q4V4:@BA:.K9Y*EL%DP
M,>LNA*Z0#O70U>O8M7K^P&/!VCZ6)C@=R-XGL\L^!=*21Y<R@:%F;)@HYCC5
M6J'.+@+,&B&:H^29ILVR.[QKCGN!N@Z)SASR7XU6;S*LF[(ZK7D/Y!'J=*PJ
MN9CR/-<Q+@:GJ_A+V)RF4S;D=*(I%Y0>!F&?W?'PZ%%5#:<1;B27:#EBB0S3
M> 2'S?X#VESIN PSD%KDZ<I"&\;Y#7U<.XJ+@LKD1^V+C/++V','#*81XYG"
MGE?1^!5FR@<MCV8Z7H.Y)-]A!86VS6^T ,($.!?*0W:;R[KSX?4)<[B9SVFK
M=O\ J5E.*^;QN[9:/X9-./\ )6;QO* >P(]E5MXB"MO1$382JT9?A[%=2$8_
M;V/&TFC@",*,X)\AVEO/:P/4W$C-L58]Z/0NWYBO9TH^?<>HW61_.Q; K*K'
MTF"(S:;#B5<#75%I.XRL-83!B2W;6>V&QQHV8N@,D>(O *_J0EM$J6U0-4VY
M,(R#XI;!>1YRS=D))Q<C5.TL!K^U*CA386BWFIM"22T3-9>"0CC].OYN_N$T
MG:+10=&^TCX$ZW=2?,G.T.D'C52T974SA'-N)0&'QNUYO<(N,Q^N<4:!:4W)
MR\OKYO%Y!+),V!NLWIIJ&#;(9R))LB+[>%8O5"30/?\ 8P1-]$ORF'6I:^88
M@6EBCT;>#>"7NO8-+1I0[7,MX?2:B:XIB7;*4J6Y&DV@J5DP;-[7Y"W6=)#&
M@,?:HIZG,QC..9 9%2/H>Z_<2Y\N%X]4MA%14EZ/AO"FRC<3MF'@M8VD;D?,
M84UP5;YK-4[5BTED+6<M]E-\[D2,D1LL4*HNE<,@,6[EZ+KE^4W&Q"OZDJ].
M-5\8ESWCY)0$BJD>2J4&WY\7A>L7BB)2PXI+Y)6<>%46<JD57@_C>SK\[D8;
M/858,Y81&-QY)@)_M9_CYEXR;HK+A6QG#,5QFH][%XO<LBL&)PK8] V@*VV>
M?2@0CE@/?[L5P&(R+&"7&9(Y3^^,E9;Y--@>,17=_=0DSRVCY[=E&WYV4$+N
MV(7-7_1S<JH3R"XTV8C7$*?&H), SF3SR43.MYK$XM7K;D[?-ER8>&%D84PO
M.O[!5K>SL$(P]IFS\J]G1HJU!W)#U T<<*DY!Z0] - - - - - - - - - -
M - - - - - - - - - - - - - - - - - 0)R(Y @N.<0C<I,PV>6"]F5B1
M"K8G#:V91Q]*C\PF[IPT!LFF$LD\/C[=#)1LMDY=D3[)%!/'J]7/+?;'0&,T
M:Z4'BX[FR=;V:6.<<9RU-V3%Y2!Y$+PFMD85**S TE*W\?/29::DH<]?2:)\
M@:WDD,5BLBD8\X,>E,=WK1^(=LL0,N5;^HE">9U8O=53(V<F*5.J5TK8T/3G
M6 1$3N?6,9Q+,QL?Q%I MMS2C_(?LUP$;;DLE=F6VZ^@+;[[#BU]R=K+[Y2@
MNYQO(MXAM/\ NPUY]RMY9BUQ?;QC:4_>+[#^\.S+/!YN%[>^T=FF6+G=MV#+
M;/<#LW)?0FHA4&=CX'9%PG;,D.\;@L/IX*'D!@ZX2C)N8O2:QB0R&*0:/1UC
M&X^1?JGY3+@8QTXW'!QCA^<,"1CT"TZNYH<8K: 5 7CURP(.8O2,"Y56U>32
M51Z'VD>8E5'C7!HWKPV4;2=P2:DAA80[;,6#Q/[2$D4&J[K!KDKN!*,EO&E8
M7- =;S&WZNBEB2;[-^[<"DL_B@*9R#8R[=CP^X2+E"S4X5V+/V#YB-W8L5]G
M[QFZ:M=U5VZJ> %EO>7/%$:F[5(<G./;!)A)]X2^5>717#5-G,]F^#O>).LU
MY)ABWDVS53!SN"6WP*;(9XK;M=D]]LM 6L-YQ\2WKNW6A"_ZIB7<.MW*C+$=
M3F>Q.&L1-EXQD1*ON^B[D)E@DZ6S8%5FB.6&^.[@N E(U#!1Q'2FR $LNKVI
M!C-&M;OKCJMG8;T!G*V<#=6%$F\S=Q9(>X+*21M&%B^!M<"F*:.R>9A)CD/Q
M'M7+W=QLV055P CAGS"X]GY5346@-CQ>U=[QF\UKV)2*JI+%Y_%&$I@-<'K3
MD Z2G8Z<>-1*R<6C[I1!#'9T[S=NAZ:K9%N[V=8@=XKRSX^1-]*A]EVS6]1*
MQ>>DZ[3SM&RZVB&$C-" ,(/D%H]@]E^;A5LU1L"-LW#,HB*/-7CUMF[#(,"8
M1\4 ORU[MJ2CHI]];;LB#UW'%<E6XTE,Y;'8JU.$L&+DBB%!.9"3&-2IIZT:
M.%&(QHNHZ=8IYY)X;IX9YX@1M7_,;C7846K"1MKAKR+$;9IJ+WY&(%.)S#8S
M8Z%8RN%(V"UD1B&NS^11BQ&Q?-P1-O\ #!P*&HCB;A0AFT8KN<0) F-_437;
M-T1L"ZJE@S!DQC9-X^F%C0^--&@V9*%DH@1<N#1EDB@QE2H ZG&W:N>+<YF%
M+8#%'60UYLB!8*O,'CJ,)6.UE=IPJ A*R+UZ$+3F?2^)Q* FWUH09C8<.PBD
MM,'6XHYB3C1!%TENDJEFOE@ODSP=-DMW.X%]]\'0GWQ%UWW;ZA[H!MD@2#0;
MNE0S[X%Q[D&G)VS\9&?MK[:?LW$:62D*#EJR516!*IET\\A^>+C<"U ?+[B9
M)BH@%&^4''>0FY <9Q@"'!W56Q8H;DI!%)RPCX@>PDKAV2-OFZZ"S,4R26?.
M4UDLT4,\5,-\@*YOR7XX[8SS/?D!2>V%6/F0RSL\K5@NV%=$B1G".#A\[RW/
M;8Q%Z_D*B8%DU/[CUW1K/$4AAF^WV0T!:D=YB\9YE:]=4Q"KFKZ:S>V*VFML
M5\E#Y;'9,(E$,@$D$161/0QD.3>,2;I(N4=IMF(]1TNX;QB8.>MP2C!7) #)
MC0#0#0#0#0#0#0#0&LCI;.4UM</>([JXJ6?!!\U2L>%1G!P?"-SX_P"RCFQ?
M=_AN/<YX);K9=IH=B6Z[KDNIEU-M^NWUL+\,IN29.F<[,E2LP^;A%@(N(5EP
M^:<-UCFJN%NV45:$NUI3]_D8;/N7(Z;T@MRC)RNDB68N&<HKYW6L7#U6T;_H
MNF?G_2E"T_(\NOA_^D5\JJL]UH;XG715Y*8F#REK%[PFE+[$[.W)VA?[1X?_
M *17RJJSW6AOB=+R4Q,'E+6+WA%]B=G;D[0O]H\/_P!(KY559[K0WQ.EY*8F
M#REK%[PB^Q.SMR=H7^T>'_Z17RJJSW6AOB=+R4Q,'E+6+WA%]B=G;D[0O]H\
M/_TBOE55GNM#?$Z7DIB8/*6L7O"+[$[.W)VA?[3XWZ?WI%O_ &EM7[?_ %M5
MH/?J?Q6WW_COOOI>2F)@\I:Q>\(OL3L[<G:%_M'A_>D6\KJO]U@+\W2\E,3!
MY2UB]X1?8G9VY.T+_:/#^](MY75?[K 7YNEY*8F#REK%[PB^Q.SMR=H7^T>'
M]Z1;RNJ_W6 OS=+R4Q,'E+6+WA%]B=G;D[0O]H\/[TBWE=5_NL!?FZ7DIB8/
M*6L7O"+[$[.W)VA?[1X?WI%O*ZK_ '6 OS=+R4Q,'E+6+WA%]B=G;D[0O]H\
M/[TBWE=5_NL!?FZ7DIB8/*6L7O"+[$[.W)VA?[1X?WI%O*ZK_=8"_-TO)3$P
M>4M8O>$7V)V=N3M"_P!H\/[TBWE=5_NL!?FZ7DIB8/*6L7O"+[$[.W)VA?[1
MX?WI%O*ZK_=8"_-TO)3$P>4M8O>$7V)V=N3M"_VCP_O2+>5U7^ZP%^;I>2F)
M@\I:Q>\(OL3L[<G:%_M'A_>D6\KJO]U@+\W2\E,3!Y2UB]X1?8G9VY.T+_:/
M#^](MY75?[K 7YNEY*8F#REK%[PB^Q.SMR=H7^TS4X1],=S9O.<R\#8$B@#P
M<&B>!=C@.K\4,4P>Y&&#/?)15NKURF'8'"FW8\OW>NWVR_Z[;:U3^+4P)NS/
MD>3(V1744P_BI36%>K$13<0RKK\J_>T,LM(ERU=NV?ZD_:E/W-B_AO/&69T2
MI'PDJ+"JYAX#\P[_ "[BI:K/S#EU_4U=M4LW+;7RH3YT+3\C99W^7(+\2B_L
MRT_-UH2[6Q-N\W'4L??*._RY!?B47]F6GYNEVMB;=XJ6/OE'?Y<@OQ*+^S+3
M\W2[6Q-N\5+'WRCO\N07XE%_9EI^;I=K8FW>*EC[Y1W^7(+\2B_LRT_-TNUL
M3;O%2Q]\H[_+D%^)1?V9:?FZ7:V)MWBI8^^4=_ER"_$HO[,M/S=+M;$V[Q4L
M??*._P N07XE%_9EI^;I=K8FW>*EC[Y1W^7(+\2B_LRT_-TNUL3;O%2Q]\H[
M_+D%^)1?V9:?FZ7:V)MWBI8^^4=_ER"_$HO[,M/S=+M;$V[Q4L??*._RY!?B
M47]F6GYNEVMB;=XJ6/OE'?Y<@OQ*+^S+3\W2[6Q-N\5+'WRCO\N07XE%_9EI
M^;I=K8FW>*EC[Y1W^7(+\2B_LRT_-TNUL3;O%2Q]\H[_ "Y!?B47]F6GYNEV
MMB;=XJ6/OE'?Y<@OQ*+^S+3\W2[6Q-N\5+'WRCO\N07XE%_9EI^;I=K8FW>*
MEC[Y1W^7(+\2B_LRT_-TNUL3;O%2Q]\H[_+D%^)1?V9:?FZ7:V)MWBI8^^4=
M_ER"_$HO[,M/S=+M;$V[Q4L??*._RY!?B47]F6GYNEVMB;=XJ6/OE'?Y<@OQ
M*+^S+3\W2[6Q-N\5+'WRCO\ +D%^)1?V9:?FZ7:V)MWBI8^^4=_ER"_$HO[,
MM/S=+M;$V[Q4L??*._RY!?B47]F6GYNEVMB;=XJ6/OE+M@/-J]9#.H8 )$8W
MD.-RJ/B'^*,<:I*Y,R)9HS<XI*[*[[IJ;HK9[8*;;;[X9=3+;;J[:E&U543Y
M?-4MWGEMTPRRJI32B6FY?50MC$OF#QC;<K(;5\#*/4&L<B=]U=:DL:J%I*!=
MFHS!'[]X3""#42>#3HLN0V=)8LGC0D/V3WPSV4=IXY?O 8ZS?HT:LPE49>T[
M$Z_A43%4?S,@IP:<:&).?D=G<I -+1AI8QF2'\SYP\0'QVKWL=D)@Z7>G5XZ
MZ% F*BHIMDS1 P<PZ(SDP_F<15DELTL<A<..G#39H^[HJ4:/,I+P9E7$%P!D
M](Q)A!XJ?*#GDI5D!ZU#\].658D38MH<W+5FWV[-B!TF_1%<F4TXK+'5JQ D
M?A$OGBL6JQY>O(!$6PB,^I> 52_</>4(B,B+ZE)02K7[+[ CL^!S- ?7)<W6
M.4R60<LY*/ SML_B5R<#<+.-_$;C195>Q-G7$2KBL[C./Y!:=?$)A5L$@Z,?
M?PZKID.SM>?UPG*R[$:T>G79N0S01!,"(0)+VDF?MI@+ Q>EW1E<BI59E52
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M5\QJ9K+[ AMB5S'3'&.=SI8G/KW:.$I/0/&6NZ *0^-U"%,@ZPE(.1N*\P?
M9Y,W[=_'H=*3\+-5Y+FNS=SD'OW\SMI=#M;$=BE;DQUT#I]9].W,6=0K(Q.;
M3I]!_P :8M1Q'CA059/;3K-,E/ ,QK2OE<I.6/M@9\-)Y;-K;&9C6;&<?;8X
M"Z*IZ*RZ./1RH[ K22T#-Y)3X8+&Q%;V"WL\=5Q$4^XTQNC92\9&";JUIM&R
M,;+1_=S!]G^<V5?U^6D,*)D@F9O[4&@1E1_1DW]&7TSX].'5:,J?@]F\$Y<K
M?9*+R0%:4Q)<6:5J(KB%J04@B3!(U<4G,>>5ZV;D)>F\K"*+3P S:3)U(>RB
M@)IB?1,R2-5C#H9A):K2/1;C!T65%['6  @AU)%P0Y'D[QL^0L5]A>#Q$?9+
M-VU9QK??;!_L;;8NCZ;9'!-;8"**EZ&2Q(0/C$2E<Z@$MC=9=PV*QH[()M>4
M\*V- ZXYU<=.6,N6DT F99Q657.Y-&J&S!NXC%!,W'G)])WDAPET3CJQ./$0
M]^_?\YLT9P:L6D^6JM^,9!6Y2&2&2\U%I#'DT3@P^#CW):RJBM>(NHULB)7%
M$#@B05@Z$RY@^7$LLVDF=&AA1^]04'O -HN@&@&@&@&@&@&@&@->'.>AZBZ0
M*J"7%/'D%$H7*6TW$25^VC[V,S.7,'D+R(I/A3N&[2<21;YI9O%,'^:V::K#
M-#?%5#????;'+9E3K;F;+:2R[@F)0:2$B(7\NV_:AT5']Q2W6,NGRTLW'R9N
M/G3^J4&.SIF\Q.>2FI+>13<(RT_<OZYATCYI%<JTJ,W#3;M*&KKYK=?*C]%-
M'V_^'MX[[!\I%OTA0?[OX'_NIF<^YD'^Q\)1UFRGW:R)]UCM+$_UF^V?V-NO
ML1ZW?;+M;J;]76W_ (A(K%:'UL]]/-:WF(3O^(T!WS1V'?\ AX:!81IM,WW2
M #V</>O<QS.5NH-"V\;=D$UW351@V.*VK@,7>INF+UOFU2=9KX+LW2.2>RC=
M;'!\0D7BM#ZV>>GB\Q"=_P 1H#OFCJ13_#X<<YV15#P?I#0DR+HM%'ZPN*0Z
M"R(BDQ15105>JL1%L/'*;1)9RW14<YI;(X*KHIY9[9JX;9/B$BL5H?6SWT\7
MF(3O^(T!WS14L?\ #KT7G(W,.PY\-LY<R355>17& 0_*1M$D&FS]=1R#VM3<
MF@FBQRQ>JYJM<,4VF6SC/?9'?;/3XA(O%:'UL\]/%YB$[_B- =\T<K+_  Z-
M(DHJO.AW/)-_"&K5\^=3%E7L1=15LR%[K8DWB\A0M)00BU'9-U]GSA1YBDTW
M16V<9I[IY]:^(2+Q6A];//3Q>8A._P"(T!WS157W^&NK4:(<2$AS8(CX^U8Y
M%')M]4P!L(;#,4NV,B#@HO:"3))CBAOV;)VHK@WV2W[)NIUG[VGQ"1>*T/K9
MYR!*?@Q!]_1*_P#\+KF#EW_PTU>[$\ N_-(ML9S8J%,!.]0A-B>8Q)PFT5(X
M,-[0[:R8INED6RCO9+=O@X531R4V4SQQW?$)%XK0^MGGIXO,0??T3H+KF#O>
M+)1#TP9)[E1?U,T^(2+Q6A];//3Q>8@^_HG077,#Q9*(>F#)/<J+^IFGQ"1>
M*T/K9YZ>+S$'W]$Z"ZY@IJ/^&KKAQD6Q;\UB2^0%QNS.XHU&"5R"N]F#4KNU
M+;86CEN.<;#'S(CN@\V15V8/&KSK>UW"2F;XA(K%:'UL\]/%YB#[^B=!=<P<
M6_\ ALJRQ;AGF_-Q[LTD:S5O'G6]3Q_9N></F:Q!D@&7WM+L119XP;KOFJ3'
M)?-PS06<HXYHI9YXOB$B\5H?6SST\7F(/OZ)T%US!5_%DHAZ8,D]RHOZF:?$
M)%XK0^MGGIXO,0??T3H+KF#I/_\ #25^+217)\T2XY!P]8#6ZS^H C-)<B5>
M(CAC!%1Q9Z>"KTD0<MV+!KAODN\>.$6S=-1=5/#)\0D5BM#ZV>^GB\Q!]_1.
M@NN8.[XLE$/3!DGN5%_4S3XA(O%:'UL\]/%YB#[^B=!=<P/%DHAZ8,D]RHOZ
MF:?$)%XK0^MGGIXO,0??T3H+KF!XLE$/3!DGN5%_4S3XA(O%:'UL\]/%YB#[
M^B=!=<P/%DHAZ8,D]RHOZF:?$)%XK0^MGGIXO,0??T3H+KF!XLE$/3!DGN5%
M_4S3XA(O%:'UL\]/%YB#[^B=!=<P9)<:.@;C/'*3R"2MN2QV6Y'@.(/)FO5P
M\+BUQQ(-7_;.*Z<Y)[K;[[MMDNQ;I)[=3/?/LG[O6[X)/[\3'T^I.@I/>20Z
MDUF#C5C$>L1K<4KQ:AZXJU9:AG",I0\5JZNFEI1$H^=)E\SIBN9H1L5&N91>
MQS45"_E5=O(=ARC"5SM[=HTR]>*JTN[FA41*%II^1F=X-L+YV2GLBT_7]:JJ
M_OL_DV'7KV4RJ/!MA?.R4]D6GZ_I5_?9_(KU[*95'@VPOG9*>R+3]?TJ_OL_
MD5Z]E,JCP;87SLE/9%I^OZ5?WV?R*]>RF51X-L+YV2GLBT_7]*O[[/Y%>O93
M*H\&V%\[)3V1:?K^E7]]G\BO7LIE4>#;"^=DI[(M/U_2K^^S^17KV4RJ/!MA
M?.R4]D6GZ_I5_?9_(KU[*95'@VPOG9*>R+3]?TJ_OL_D5Z]E,JCP;87SLE/9
M%I^OZ5?WV?R*]>RF51X-L+YV2GLBT_7]*O[[/Y%>O93*H\&V%\[)3V1:?K^E
M7]]G\BO7LIE4>#;"^=DI[(M/U_2K^^S^17KV4RJ/!MA?.R4]D6GZ_I5_?9_(
MKU[*95'@VPOG9*>R+3]?TJ_OL_D5Z]E,JCP;87SLE/9%I^OZ5?WV?R*]>RF5
M1X-L+YV2GLBT_7]*O[[/Y%>O93*H\&V%\[)3V1:?K^E7]]G\BO7LIE4>#;"^
M=DI[(M/U_2K^^S^17KV4RJ/!MA?.R4]D6GZ_I5_?9_(KU[*95'@VPOG9*>R+
M3]?TJ_OL_D5Z]E,JCP;87SLE/9%I^OZ5?WV?R*]>RF51X-L+YV2GLBT_7]*O
M[[/Y%>O93*H\&V%\[)3V1:?K^E7]]G\BO7LIE4>#;"^=DI[(M/U_2K^^S^17
MKV4RJ/!MA?.R4]D6GZ_I5_?9_(KU[*95*_%>CX#Q>3QR2IV@2>9QXZ)-X-,X
MJU1P=9"G[=]BWR6Q.*;I8K;H;)[J;)J;X;9==MAEOMUNY&*%1:?T^W\D-/E:
M145E*%L4V*ZJ%$: : : : : : : : : : : : : : : : : : : : : : :
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M9S&!%7V?54-.0"9BVX^//IK'JRLBZN/K%N]CO<VDHE5<R@3 W,Z : : : :
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M)492BE:?V,I/"(4WY,V)ZLC_ ,RZUW=I8NS>9K4-VLY5W#PB%-^3-B>K(_\
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M'*2YGLTKGEVYDT7@7*PR#E<0Y2RRTFCGCM9Y<G([\A0=C$([535:,PW>(%"
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MRR))4+(<JNI0?P\JK$/G;MU$NE8<_E(AW=JL0X=,JEVVRS0RJK\_TH^9L_\
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M9/T]W>^8&L%?IU.DM2J1Q!>Z@#[NKCE<YM9E/]ZGK+L:/ )E9)OCNYCOW?\
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M=E'VILE#+0D"HQ_M@!L<T T T T T T T T T T T T T T T T T T T T
MT T T T T T T T T T T T T T T T T T T T T T T T T T T T T T
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M4LU=B%)"'.-Y&Y"B<"[42/$&S70#0#0#0#0#0#0#0#0#0#0#0&D[I^@Q<[P
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MQ %BU@,,@<<W1%O9E+2[XXY N9?*CLD+'9G))$7<;/, ,P- - - - - - -
M- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
M- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
A- - - - - - - - - - - - - - - - - - - - ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g65062g48q33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g48q33.jpg
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MU_$G,U-BDL'_Q  = 0$   <! 0               0(#! 4&!P@)_\0 71$
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M7>JJ9K@#$F+=Z';2,>:Z9A1FY4.9DC,PS=:V4>4X\3!V(-9&\,.%?)+(?O\
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M.?L^/J?<?3L0/?V^7OS*3M=U:E]A;8+AO/D&*-L/K3VHZE[.FA9P^$>IU:[
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MJS!;#V.V')V1=5%;*6VI8*(^+&ER]A@A(U"T_K$G-'3ASES-6XJ+>)DV0)Y
M[#W?J''V_;R3W].!VR(K;X8MAO>Q[3=[;V1)&QY@GNYX*((TZZ%I@D%N?:]6
MVC]-R$G]X&=?PX%&34AM1KZ-:ZRU;$,AU2"]V@6>VOO'W6.>W''[\$?TGU)^
M7 [9=&Y_#J.[#*=C#5'WH,HI#L[4]Z:VV!BRZAQL2".UUO6@ZAI9>)58;>R:
M7@== $C4Z"PNSD73%?(L66:,/T0HZ("%(;(@\<?+@C@\>A)_IR0N[O2>R]P
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MI;9'ZU?YC ?Z1QC'TMLC]:O\Q@/](XQCZ6V1^M7^8P'^D<8Q]+;(_6K_ #&
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MAB3EZ5->(UYPH07APNRISRMXR;13;.Z#<IPI#I6O+)>JQQJJ1P6D9%U"LB*
MJHLLD=F-54(D=I(D'$9XZ3M/5#J&FB*5R]FD5AD9CRSQ$$P2,3W)*JT9))+-
M$6)Y;-NH;<>JK,"LUEJ>P:G<@U-'O$[-+IAN#;U"(;$.7/RJ3%K;Q27E]Z+
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M=[NM_5(C#I!8O+A#8Q2\E8C059J9 >AQQRYS<N=$1,XQD@W[JYJ/95HL%PM
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M6P[DN[7S554%,1]1;E#+G5K;)4J-K^SJTDGKA+MTH#Z095P;9JLR2KQF4@=
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MTM"M=>-A R6KLW8F]4'3ET)D+!3;!B^U>/6[EB!=R@P-+-5^X5T>[G)$I6K
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M RDUS7$376O*K;*&Z?"YUS>RUFF[;/&;("KJ)I77U<D/4@C7H=KS:S(V.Q[
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MVTN_,)K( NHL)A$VO3"^"C1Q+"$Y$N*7Y+_"%H:/1\1;;:7(ILW:%.[K-=%
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ML1I ^ AN-)E.LH3"B)2C&(S.$,9</S47_A*!_GD?_><8Q\U%_P"$H'^>1_\
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MG:.$HS<-VSM+6_$35)-?W!/833&E_*66^I);$;<"IIR,"D5>/NC2JODQ'J5
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MN-LLLMK=>>=6EMIIIM.5N...+SA#;;:,94M:LX2E.,J5G&,9SR0 D@ $DD
M#DDGL  .Y)/H,G) !)(  Y)/8 #U)/N S63V.[T>'AU;(US:MUOE3/6^U&)D
M44UIZ<S?;#,?C16_FQPP(J)A0IB)#CS(R)14]EI^4_+CL0?CI>?;1C-+\!=)
MUC=XW=1V1%6W56,EMM7(MZ1YDTB-!)/8B$U:E=MR)*RM-8KSSL&ZF?D Y+?\
M1%H:.NG7-PI)I19($K*T5XQCDND<;1I/9@B'06"(Z1J >!QR,HE.\:_PU+E[
M3378INMS7/3ZX5RUOM6M88RK\F'BLZE8KWEC/GA2FC#J$^7FI6,9QG/1;/A]
MO"MR7T2S(H_C5W@L _8(I6?_ .'-?@W=MNQP$UBFI/H)G,!__6"#]>95TWO1
MTNV#EINF]L.NQV4]Z<(&Q=PT)LSC*O\ DI<"2CL<NRI7Y,)>A-JSG&<8QYXS
MC&!L:%K53GVG2=2@ ]6DI6%7_+,?2?N.9>'4:%@<P7:DW_Y=B)S^A7)_5D&^
M)?6RFQ>I[YRDY'V =5;6"OQ&5#)P517:O %6 ;-(P)7O_#3T1G#,62IN*ZZ\
M[%;D+C-OO-H9<\Y?A(Z'J&L>&=Y:<08Z1J=+6+ZNZQO'0IQ6X[4B+(R!WB]H
M1_*!#LJMT!F 4^F?P6-=TS1?%>FNHS-"-;TB]H=!DB>59-1N6*,]6%S&K&-)
MA4DC65AY:2-'YC(A+KV^LG8_KKKKJMIJQ6HEKK1,:SC34-JNKF"QK]B.TPO)
MJ%ELT0</AQ)YA\M*#QR9*:D<^]%62APIDIYS$=U_?? :E-O#PYV_J&UMK-3B
MDK2+=J:953R5O5;4^FV+D\L$,,1FU"6B]HO*!,P8JS2&)G///PBKB[0\4]SZ
M?NS=IU"9+4,M&YJUN3S_ &"_3KZM5H01V9YY5@TR+44IJD+&$% Z)%YPC%UE
M/$GZ6",JP_N;$M:?R)$Z_P!HF4KS^;"'Q=)EQLXS^967DH_/E>,9YW:+PSWQ
M-QTZ#*H/_C6]/@X^T2VT8?9QS\L\^3>)6R(.>O7H6(]T56_/S]AAJN/U\#WG
M-;GB3=S.MO:?J/M?2VN2^P2=[-0Q9*D2$";520+Q\(8A3T0C\B3."*G"2@UH
MB-6/,BRHG$F9%G21Z9$&+,B;-H'A;NZGJ^F:A:JU(8J5VO9D5M0B+E(I S "
M#S58E00 QX)(^T6M?QCV51M0S^TW["12*S"O0EZB!_)$Y@[_ &E?ASW[Y3>&
M;V&UU7.F.CM=;%V+J.M635M#K.NE0V-@PTE"CE5#Q!<UR35;## 6@5.A$F)0
MU>$C2 @W'C1;$ +2AIAF-"TS<FW-?JZ_JT5C2K0)NS3)+#&\]>2*PQGB=;$:
M>4?R;CJ'5RC!D;AE91MM;=>@Z[$-6HWX?9[KRRI'.\<-F/B5T:.6!G+JZLI!
MX!5NS1LZ,K-C-W[\<H9U'W$-U)K/1S.X4KIHFVE+H=NQ.AAEJ-S2D6' K<!-
M(/23T2.V*>^-/?%PX7QZGQD5F0Z/EOXV':OAI9W%3GMV-1CT[RIS (!"+,IX
M16+2=,\8B!ZAT*>IB 2> 1FM[AWS5T.>"%*<UT31&43*_DQ#ARO2K.C&1AQR
MW   *GD\YK9V7^R*KWLVB6Z@%NIM'B"+?7R@"7*9VY8ED1V",5QA@J+DMT>(
MJ(7$R%,DA,YKTO0242+,86AYE"D[2W@G$R,LFOMP002*(''P()LG@@]Q]V:\
M/%6,$%=&D/!]]M?Z(#]XR2-;>,1W#*"A=K.&ZP1CFH#TQ%>D5FL18$%$N1EV
M'AB9 KT,L_F+$2AE#TB8M,K"U2'6?4I"&^;2;1>O9M03W9@U>W;K=#543J6O
M9EACEXZ^H"6-%E Y(X<<$C@G?8->CL5ZUB.MREBO7G^K+U!3-"DC(&"\,8V8
MH3P.2IY"GTV#53Q >PUNJ@>P,B),+)L8W*;RR%HKK;*WD*3A^(HB6A/2(V58
M]^&]*'1_B8^6GEQDH<PG.N3U4AFEA]K@)C=DYZ9^?JDCD],+KS\0&8 \CDYF
M4D+JC^5( RAN"4![CGCNX/ZA]F8S'?$![E#S!* WN2,-1"F2(J89C6FL'2+>
M&'%-I7)7%!,QLJ?2G#Z/A\.L>VXCV9,IO*9#F:K;=AFKPRM>L2&2-7+0K (^
M6')"AX&?ZI^J>KAN0>54\J->MZ]/!8FA6K&JQN5'FF3K('HQZ7"\-ZCCD$$$
M$CN;B#^)GVF'CH\0E;:*?F-9>]XK-I8F')E>X^XXWAR.)E0(#?L-+1'1[$5K
MUMM)6[ZWE..+NUVW5 X,UMC\2803]RP =OLRU.XK7/:"N/EQ*?\ _9G7,>)-
MVQ-+@,!KI5PKJ)&<., *17)DXM[OH0U";R>8/M,NY7]F%1X>5J<<PE:7$^2<
M4YMN5A&S+:L0=*EC(XA9%X'/4X,0^J/4\,IX]^58=P67D1#6A?J8+TIY@<\G
MCA>78<GW<@_8<VY]9\=C &B-8+FZGUHJR6:HA;U>2%GW3<@]I-; O,!BU78S
M9Q*.OY)L0<(60J1=F HY"9!KN,-U\6]@4+@MMZ[6BTP01&6WJ"3-&C3*NFUW
M E90T@#MJL;, Y(#&-"0!]1?S1GY9-0$D@CJ4VC#L$8WY5+("0A*C3W"DKP2
MH=@#V#-ZG29X@/<[QH-9=F;C3M.:@N5:U:,@UU5-D:BT3-[ U:Q0Y8$=+)&'
MMDE=4S7II;!U\H/F"<"*LH*U"BPW TG.$GS76-J;?\.KVDQSZMJ_]?-+*)8[
M5R/3)(U5B(U%99I1TE &#B:4,2?K*0471=P:QO:I?\K3-(BDJ^3&PDCADNJT
MA!+CSN:Y!4]NDPH1Z_6!!.J3;W>'Q*-U']-ZJ[6P[?-I![=M/BC]>[%ZL4P*
M OMM$6$+!^F)H$[J6.S;94)VP0&'JW[4IUF67&K<BIEOCUXVU-J>'E:&W9T_
M4#Y\-&>?S8-8D9HH61D\TM&_*1.3Y9D)"-U%.?K<9C:6XO$EINJ'1VZ$<)8E
MATZ4F",L!*6=9F\KA2>HGC@>N>G;Q4=T[%T<6Z+GM3;V.Z^)D>Z6@J)L'2E4
M8HQ0GN[3=_V)6@]W'JKIT61MTW(<6.DA@;=&<'3II2V?*DNR2<H,RCS8TBJ1
MU'NWHH!9F^/"@$D#D<GC@<]R,ZVHYZN1R.&[DD<$ D=^>/T_;FT2AV&S6@*X
M8M%$):[??GOI%UTX9!F+#@,EF/F+./HK4LJ"$$Y4A4O"@PT_86XL1J(](*)F
M2I(T?%26')4KW/ )!/'N)XY )^ )X^//82D '@$'YCGCG[_7[<JT2K5F ?+6
MN#70<.T'XT&&<LD43 8/&88M&6QD0H7:820GQ1S:E(@QI4AUF)A:\,(;]:O.
M/2H)8 !CV)X') ] 3ZGC(<GTY[#T'PY]<KW(XQQC'&,<8QQC'&,<8QQC'&,Q
MTW%U$ZP[_1(_#%HG6=[G24*0L\5JPYFUMI5C*58BW :U!M,+U8S]\PS#&<YP
ME7GZD)SC8=(W9N702OT1KFI444\B"*U(:I(//UJ<A>J__GA;U(]">;&UIFGW
M>?:J=>9C_'>)?,^Z50)!]S#-3^Y?V/?U'N_Q<W4ERV9I(H][F8T!!!C8U.BY
M5YY1YB+0IBUO80KRQC"KZC&6\>G./5^V8ZGH_C[NRET)JU/3=:B7CJD,;:=<
M?CU_+5NJHO(^% ]^_IV.MV]DZ9-R:TMBHQ]%#">(?^23B0_YX9J=W+^Q^>XU
M$^*FZKL.M-XBVO7F+#&F5T*WR$HSG/FZ&N7P]98RM'EE"&;S+7E?J1Z?LA3G
M5-'\>MH7NE-4KZEHDIXZGDA%^HO/'I-3ZK+<'GDFD@X //<@:U:V3JD/)K25
M[BCT"OY,I_\ ++Q&/\\<PHJ_A6>(-;+5*J$'J[L8:0@O(9EDK0R)JE51A7W4
M]%N%B*#:R69;3C*EY"E22\^6$-H6XI"%;G9\4-@U:JVWW/ITD;@E(ZS2V[1^
M3U*\4EF(GT FBC'Q('?,3'MS6Y)#$-.G5AQRTG1'&/F)798VX]_0S'Y<]LV8
MZ:_8Z.[[!\+.WIN^@ZWAN90Z\$H@HKL6P8;^V5Q)4L@NF@1\I6?-/Q$*78HS
M6/2YA,C/FWCFVL?A":+!U)HFBW]1<<@37I8M.K\^YT2,7)Y$XX/2Z5V/<?5]
M<S]38MM^&N6X8%/<I"K3R?XI+>4BGY@R ?/-L>FO LZ&ZN^$F6JL7/=IJ/E#
MN9FR[9*:$IDI\LJ4S6J4U4Q+\3.<9PF$<;.HPC/D\X^K&%XY9K'C?OG4^I*M
MFGHL+<CHTVHIE*^X&S=:W*K_ !> P'D?5"CD9LM39^C5N#)'+;<>^Q(>GGY1
MQ"-"/DX?YDYM)USI[4VGQ6 FJ-9T+6PGT(0N!1JD"JT=_#>,>E<I 6##^+=S
MG'J6_*R\\XYG+CCBUJ4K/,=1U?5=7E\[5-2OZC+R2)+UN>TR\^Y3-(_0/<%7
MA0.P ';-B@JUJJ]%:O# O '3#&D8/'IST <GYGD^_)'YCLKXXQCC&.,8XQCC
M&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8
MXQCC&.,8XQF@[Q"NL,3KBQ?NZ%0VG]&B8U\ VDM7%QTA\5TJ:GJ5*/"#+9=3
MAR<[<7H<L=7F *933)8FB.[+:C(97Y(\2? C<ZZY?WIX8V-5O:]J>X=*U"/:
MVE566=;<DK+9NPV(K($L:WIDMRI-6BAJUY;<TTX@B8Y[:\)?PA=LV=!T[P_\
M4:>DT]#TO;6JT)-UZM=1JTU.K77V;3[-66H/9V?2HI*:S17)IKMFO2ABK^T3
MKDC=1?&GUIV_V2K2^N-"[B([%33\62&OXK6PFN%?D\8<U;ICLJPWL5,"!QY,
M@S\J]44J<)"W$R7@D&>VZ,3[EL[$W'HNW=(UC<OT?IMNY7J#4M/BGDMOI^HS
M5UDFIK)7BDBL>7()HQ+%(8CY8/F$,I/@T;GVYJ>X-:TO;=FUJ="C<MC3M0FK
M&J-0TV.R\56YY4Q22%I8?*D>*5$D4N0$/2>-R@&2:F!Q\JQ"H8,V_'2X1$0"
MRCL0?(5E6?AFBRAPG,[T(]'N/)'QT>[E:&\.MH2\YJ;A [!&+H#]5F7H+#XE
M>ING[.HYEQR0.1P?> >>/ESP.?T9WY4N+!C/S)TF/#AQFU/294IYN/&CLHQY
MK=??>4AIIM&/NI;BDI3C[YSC'"JSLJ(K.[$!54%F8GT"J 22?< .3D&944N[
M*JJ"69B%50.Y))X  'J2>!F*UX[T]1]>/JBV'>])E2VW<,/PZ<Z2V+,AO>KT
MY:GQ->C[1('K3G[K3-;CY0G\9>$I\L\VJAL7=VIKUU- U#HXZ@]F-:*,..>4
M>\]99 1Z=!;GW<G-6U#?&TM,;HMZ]0#@])2O(UV13SQPZ4DL,G'OZPO [G)N
MF;1IC-("[!'FH9JLV>&+FU8D-?0]%L#!N)\>*='O_P#)4S+A><OW<X\VXR'7
M%(RI&6\\J\0-V:?X<:1<U3<"2Q25K8TV+3^T=JSJCF4)17KX6-P(9Y)G?D10
M032!7**C[IHU9M>,+:<ZV()JZW%L1_7B]D8(PG!7\Y6$B! ..IG5>1SR(DKW
M9&+,N0^J66L. 634QH>),1R7S&-\=*6EJ#&(-+A0U,-S'5(8:F,K?0F0ZTEY
MEIG+DAOS7M'\*^CJV]M-VANC:4NVX=>O1:9HVMU]6^E*JZE;D$-&GJ<+Z?1D
MKI<G9*T5Z%YXQ9FA$]>"N9+470[/AT[:%9UG2M46^]"![-RC)6]GE]GB4O/+
M7<33"1H$#2/#(L;&-&*.TG3$U%[<='NNO=VLUFM;_J,X[BE$").GG01\K6K'
M6Y)F/%C&40"0Q]M+\$LS '_,19.,0&2GQHV6Y$S+'PWV/;&A[BU;;L\MC2;7
ML[SQB*93''+'*BDLH=)%8<HQ)5APR\D \$@\@U31].UF!:^HUEL1H_F1@LZ,
MC\%2R.C*RDJ2#P>XS1U%\ WJ'M786RAFL=J]E:K4*@*K8\<?,B@\ZMSM@-V[
M:E;V&!$D;'K&KXM<*J9J%88?D5P]/C0II.6W**R%2HK43I;>*6Y]/J4I+<>D
MV;-AYW>'A/-2H:]&:G+)'5LEJ[3^T3L%F1&=(U*QJ Q;1AL';EVS:2NE^O7A
M2)5E1YPK6?.MQ68T>U$Z2B'R81S$656<]3-U "-;E^QF3J/>>H';T/-QGU>R
M*N6F)@WR_P";AX\%V25POS^V%916T>G_ )6$J\_3B]K^-,W %S08F[=VKW64
M'[(Y8'X'/QD.6LWA94)YJZM9B^'G01RD'X]4;0_S#[<SCU+TMQT-Z&[6T9M+
MN [++F &V=BQ]?#IFM*]29TJ16&?@ZO5HM^JAC8TD7/)UV/+**KIZN(G'#!5
MT>,'$9DJ=.XSXPVI-_[6WU)0VC):%C:FKUHQ3AU2U<-B+2[,E?MITL<#V&G"
M&)'K2N_"(WFKP@[%X.M!LC?/AW[=NF*HM3=VA233:A/IM6J*LVL5X[;N;Z22
MQ5TK22J\@LHL2@R*T; MD%Z$ZX:'[(:-HI^_]IA.NK+3BENJ,$"2L.ME0&*B
M[8IMJ8:A"ISX(Q'E/6"R'B&2I H72^B<J(AA,6' ;AZY^"5N+?.R/".AHMK8
MU^'RM1U?I@NZ3K5"Z"]^:=9IQ/&Q<,)RBA884*1H5/5YC29_\,C;NQ-]>,M[
M7*6]M/L+/I&B&2?3M8T?4*/5%IT-0P0M!*51D6K&\G5-*_F._5POEHF00CPZ
M^BZ5-I+]Q9Q-]2DI2T'V=HP2T\XK.,)1AF57#TG/J5GTI0W)PO.<XQA><_E]
M'S^*&_CR8=J0PKQZR:5K,I4#U/(L1+\SRO ^&>7X?"[82D>=N:>8\^D>J:3$
MK'X<>1*WP]&!R7=C^%YU9HVI-F6UF?LTA/K6N;I8QI<C;&9/P4L/621.$22.
MKXVM12?PKT9J2F$ZZU'F^WAAU:6W5*YK3>+N\II419=/K]4BJ5BH)VY8 CFP
MU@CUXY/)'KZC-IK>$.RT:,/6O6064'SK\HZ@2/4UUAXY'\GCY9BUX2'=WKGI
M#P^=0K[*=@Z+0KY=+GN<ZH+;SK#9QV,QLVPBVY<0?&]\A(!Y;A--Q"JAT" N
M6F8*C)6\,D9S8;OTS7]>W3J]BOIMRX\;5$F-:-[$<9%2'H3S$C1 >@ A HX!
M';@@GH5VOM[:)BT>J:6CT*\:K4K26>.S 22N9+#F65WED9Y)'9V9V)9C[I"W
M)X@7ATR+?BXW/;77GM7K]R6XM=)O%#!VC96JVYZF,$)FIS1RF8&6:IK=:;GE
M:&?EP+)&5\=-K5M-Y9#T)6$@VOOFH7-32M;CCD/,B0K-"W8>[H9 X'\E^X'/
M23R%S&R:]MJ3@3:KI#%>RE[-9QW/H>6/2?F/AW^.67JWN'X0S=KOM^OM@ZBA
MFC[<"GU:D >N95+8(#0;SM+(VR$)6:(3ASC-X"V<)/FO#H(IEF(.&QWD/J:;
MQ'V&]MO>7D5:E33=PR&$O8GM2S/S++;JT>N%%Y1DBJRP2(H=Y"6=R"._5BJN
MNZ#YUFQ9U71D$G3!# DL("1U[%SHE8F1E:2PDJ,W0J *J @]N(<A6;4NP9)V
MZ !^K6J\>N%VEU159$ A8.13V[@<BT^>*@^C&8\,A68XF>SA*&FUXD>ZTPPV
MM#+>@20ZHDDL=N&XEB.66.9)4FZU=)&5@X;D]7;N2>Y[YM:S5&5'AF@:)D1X
MV1XRK*RA@RD'@@@\@CMP01VRT#VZ8P@M-%C +96./=Q&S-^<)AMNNH0C+F&&
MF1D].6$95Z$.9>3ESTY4EO",H4K*U= >Q!'-)8\EI 6$?DER%Y('43)']8\<
MD<'CD=^>0,/;UV.M.\*US*$X!?S0@)X!/2 C\@>G/(YX[#C@FB*WJXO/FNF1
ME9\O+S585*SY?H\\U[.?+EQ^+A'I>(__ *?_ /?RU_&-3ZTN?_;C_8Y^)WFC
M&<9=ID=#6,^;BFSJ5K2C'W5E"%@F4*5A/GE*5NM)SGRPIQ&/-6!VXW!XN\GW
M P$ GW D3,0.?4@$CW ^F1&XD) -(@$@$B92?N!B4$_(D?:,FB-8A#S#$IF$
M92EYEM]O_P!E;#Z\)=;PM.,Y;%*3Y^E6,9]"U)S]_2I6/+.=?:M,K,C/ 2K%
M3_75?CD'@^LH/J/> ?EFP+/&5#!90& (_K>;G@CD>D>5?>7CRIZLS-;:C+=7
M+1>-B#M+ZF/;1?L5H,:-B!+O::,%/%05?K=BUO<CI(4.<F^S@O+<A17'\.QA
M[A6/&P3D=!VKX:7]RZ5'J;:G3I+(P58E47&Y"(S>88)PD+@OTF%F,L9!654<
M%1I^O[YH:%=%)Z5VP_09"X3V=>!+)$.D6%1I 3&Q61%,3J5>-W5@<QQLW[)>
M)F*W81 ;IXY72Y4&6&BK SV,^*>!$IT"1%@F&HN=#Q\271DIUJ:VQE]G#RV,
M-Y>;]7K3M4'@Q9CFADDUNK-''+&\D)HRJ)41PS1EO:#P'4%2>#P#SP?3-?E\
M4:#Q2(FG7HW>-U202P$QNRD*X'(Y*DAN.1SQZYK\W3XG*>RFV.D;M:T:6US%
MZ^]G*]NHFL[ONP;/,;!M1&[:\(S9$HT9H B8%D_!U<B)BR5*,MQ(-AEQV8J(
MK;D65ET\-[=6OK4MK4:%HVM(DI0+'IPK)26(B5'B1&9&*A.GA1$S=1+2'D\W
M>C^*6E45GJ1Z/>E-\&(RRVXW=99V4-*S2"5V[\'IZAV  (STL^+J.'HK/10N
MB!"25D>*CX>(Y\FF*PD@^/B;Q3)B07IN&\27(<63-F2(\5;JF&7Y<EUM"7'W
M5+\Y\#GG@<\<<^_CX<_#N<Z<OJ?\5_\ Y&S;OR.2XXQCC&.,8XQCC&.,8XQC
MC&.,8XQCC&<,F3'AQI$R6^U&BQ6'9,F2^XEIB/'8;4Z\^\ZO.$-M--H4XXXO
M.$H0G*E9QC&<\IRRQ012SSR)%##&\LTLC!(XHHU+R2.[$*J(BEF8D!5!)/ R
MI%%+/+'!#&\LTTB1111J7DDED8)'&B*"S.[$*JJ"68@ $G$>0Q+CL2XKS4B-
M*9:D1I#*TNLOL/(2XR\TXC.4.-.MJ2MM:<Y2M"L*3G.,XSQ%+%/%'/#(DL,T
M:2Q2QL'CDBD4/'(CJ2K(ZD,K*2&4@@D'(2Q20R20S(\4L3O%+%(I1XY(V*.C
MJP#*Z,"K*0"K @CD91OJ")-CGL5YR*>* 5R8<@5'G,QUX+L,9=;%R)+F%-0W
M7E^EG+SJ5-LJROU^>6G$IL/I."Q%J7T6T.IW--::"6E%8CC;VZ.,NM.65^4K
MO(W$9=P5C);J[HP%_P#1D]>73OI-9M-IZBL,\5R6O)(OL4D@1KD42$/.B+RX
M1"&D 7I[.I-:CK=<89<?9^'?6TVMZ/[B7O8=4A*G&?=1C"'?:7G*/<3C"5^G
MU)QC&<<R$;.T<;2)Y4C(C21]0?RW*@LG6H ?H8E>H !N.0.#EA(J+)(L;^;&
MKNL<G24\Q Q"OT,24ZU ;I))7G@GD9TXY./)(D1;;<Q,@8W"<D..PI+,-Q,]
M#SC.(DQUI,::I"6%8DIC..YC*4A#WH6O">4(KD4MJU359Q+36N\K/7FC@<65
MD:/R+#H(;!41L)1"[F%BJR=+,!E>6I+%5JVV> Q6VL+$B6(9)T-9D63SX$<R
MUPQD4Q&9$$RAFCZE4G*CRZRUQQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'
M&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC-7_?[Q5^O?1(=
M+K1&1C9^^I,!N4#TS6"+#,V F6PE\>5V(>PU-BT0%(:<8D1TRHL^REXSS4D%
M7"4#$N?#W#:VRM7W3*&K1^S:>K],^HSJ1"O!^LD*]C/*/3H0A0>SNF:[KVY]
M,V_"6M2^99928:<1!GE/N)'I%'SZR/P./S0QX!\P(*G^(GXX^X_J W/5"U;6
M3#K"K!-CDJ_U]TU&?QC,P94@R7I+]MN^8#J$/QX\D[=2"7QR+580=;<A38'9
MY+&T/"^EY,*BYK,L?=04>_8)'9II..FI6Y]% 4$ ]"2/R3S)(-R^(%@2SEM/
MT5'Y0<,(  >/R2GI:W-P.#(W$:'GCI_,.YOIGUUIOAA]U(FD(\>-:1.Z*?7P
MD+;UD!BT70I/*PXKC#8\C&86_7*X2V(!(@%4D;,>@J;76BAN07*C6S4CP?O/
MQQWW8\>:FT=UV*Z;)W#0K_BK1KUDCBIW9("B2O8 \^S8GU""U0D\Z1U59Z[Q
MQPJ3U>ZMJ^"&PY_P=;6\]H5; WQMB_<?=EJ:W++)>IUK!DE@]F9Q6@@KZ/;I
MZG%)##&Y>O;B9Y.0$RI\0+:G>:N;.KM'Z\5W8,;7I>H0I>;+K77*[N2*V1\D
M69,CBY_%=L?TB@7"CB'83<=(&4XU+E3_ )M-94J.*]=>'>D[ M:;:O;GN4O;
MX;;*M2_J!I11UEBC,4D4*S0&V97:4/R9E!14\I2.J3Q-XA:KOZKJ-6CM>G;-
M&>H&>W1H"Y*]DR2"2.29HI5J".-8RAXB9@[.)6'*QX'Q>@G?KL!)8(;4<GQ6
M''$R&)^^-KR[ MAKS\_4/"BI>PBHIQ.//V1\@6$PVK"4J3'1G"T] ?Q#\.=N
M*8]&JI*X!4KHVE)7Y/\ AV+"TUE!/YSK)*3W/UCV//U\/?$;<3"36;CPHQ#
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M ^.5'@\;=M<\'CG480.?=R14) Y]3P?LR(\#K?(YW#7 Y')%"4D#X@>TCD_
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M_P!4!WC)0'[\GU[#[>W!X^'\_P ,C+77>S?FEATQ6Z:[.V1'LEJ/0 4DL8%
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M.0?ELPH"8NQZ%N#Q1T.M)5KZ+K-^*24S ZGHFK7)8G955A%-Q'($8*I\MV=
MP+(JEGZM7UW0/##7+,=JUK&CTY8HO)/T=K6F4XY$4LR^9$&>,NO4W#JJ.P(5
MRP5 NM;KKH?1FTO%'V_H.K;"M-DZ[ZST]7;QK:R""]-+1+YLAC&KBQ]L1L8-
M"6+.B #-J)Q%AQ8UV<\3&6EF;(&,5%*C&QZSO;?U#;5>]J&E04I+ENU4G:;3
M;L#P0>7T1++!.5$+3L9&AD,A\P+PJ]L4/#KPNL)5?2]:CU'4UG:;V6KN&G:G
M2* ]2N]6!"_0&4,S^G25!_.[;-/%W_<1T._^:[X?/^VJ)SS_ )UM?4_XK_\
MR-FVOC)<<8QQC'&,<8QQC'&,<8QQC'&,<8RGEBHP$+(FC4^(+$"84DD3)3WV
MXT*! A,KD2YDN0ZI+3$>.PVMUYUQ24H0E2E9QC')))$B1Y976..-6>21V"HB
M*"S,S$@*JJ"220  2<K5Z\]N>&K6ADL6;$J0P01(TDLTTK!(XXT4%G=W(55
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M=AB1XM0I+1VQ$(#ZAN:8[.NMP-VXG$,+E6C>FZMEF6\O#Z6!"LG#@C@\#O\
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M>U<CI5V9G;AN2A[JJAVX!HZ%O#1+<[4HO:I;$AEL!TTZ3H8DKS%!7@:U.%0
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MCL$6AZ0L$&;82U(OS[;(>7.B!B6M=T#MP4YVH$7&'8%TD,6)^=(G"(N"#Y:
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M($X:J3T*>+/T^W'\0+#:1SH\ R2%F]CUV!O:LU=B-2;J>A5P$.UM0F1<D_4
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G'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g65062g48r17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g48r17.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
M0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M_\  $0@ L () P$1  (1 0,1 ?_$ !X  0 " @,! 0$            ("08'
M! 4* P(!_\0 2!   00" @$!!0,(" ('"0  !0,$!@<! @ ("1$2$Q05(187
MUR(C,3=!69BW&#(Y459V>9<S0@HD)B=288$9)30V8V1QL=7_Q  ; 0$  @,!
M 0               0(#! 4&!__$ $P1  $$ 0(#! <#"@('!@<   $  @,$
M$04A$C%!!A-1810B<8&1H? R4K$'%4)B<I*RP='2(^$6)#,T0U/Q)41S@J*S
M5(.$E)6CU/_:  P# 0 "$0,1 #\ ]_'")PBKR\FMHV34_6W4W4,FNF,6.:G(
M:*Q)S2%7I6>97.&P<F1$+SE-2K;E4AM31DNF/G-C2L=7QX\Y 156$QIB_D,R
M&"WY2W<[X]YQ\\C?Y>*J]LSL-Y!@M@W,-;6'V)-5VK(J\4)6)5O6LNQ:T57^
MA.-AUM8=7L[ZJ/9%-9?:;C=*3JF@<KN,)#8:^F:9$-&G+,"<8%;;;EUV)Y^1
M.1MSQ]D[[9Y+,*1[*^7)U:)!)Y1QFV9OFGT2<_HZT6[+KI2<!D.L,Z<.X*8@
M%V:4^=V/2.8&)IVM<2^+8D$RT0+PO(/=K"M8BT'NR8;XX&>8&3UYC/D,$8Y\
ME9IX^^VTX[B5)8LSLJI0]*SZJ^P]S==IC!P,]VLH0WDU+R%*+GGP^6[1B(_,
M&CHOJ]3;YT#)IY0;IKIK*ZKXQH57  X!SL#N,<P#XGQ\5E,TGEN#^\-%UR&<
M%]:4DE$75)9NV1CC)T%5G,>DE=-(8J^E*@E9^*?)CBLAPR$MS3)N43V<+KL7
MFS))1OZZG1TF3L5K>HS-B.LUM<T:M2<;+VS"E8KZ@^X&51,V.5ADB@XY70O=
M&0T->P/(=S)9;+=5J0M+O17U+3Y0& L[UCX!%F3A):>%S\-#P';D@XVF%SR*
MZ2<(G")PB<(G")PB<(M*=E9#,XCUSOZ5UPH]1L.,4I:DA@:PT6@;(I3,+!3Q
M*+J, KIF1:EWNAQLQV:BW(]^@_7PFT69NDU=D-^SV<KT[?:'0:NHAAT^SK.E
MU[PDE=#&:<UZ".R))FOC=$PP.>'2MDC=&W+P]I <-6Z^6.E;DAR)HZMA\1:T
M.<)6Q/='AI#@X\0&&D$$[$'DNRH,W*Y-15+22=J.U9Q(*FKDW,E7X]$0^4E9
M:'AG\A4>BFS5BW&.]R[AYLX'H,6:+);.[9)JWT2U1TQZY#5K:WK%>B&"E!JN
MH0TPR0RL%6*W,RN&2N<]TC!$UG#(Y[R\8<7.)R;5'2/J57S9[U]>%TO$T-=W
MCHVE^6@ -/$3EH  .V!R6V><I;"<(G")PB<(G")PB<(H?55/+<-=R.V\!E#@
MNI4$&@W6@C5#=U'&3 .W-R\39B]D;"9*B(:OI"NLZ$1O))H]+E4PF^C9-J@.
MU?*Z.?6ZI1TJ'LAV4OUFQ#5KM[M)'JCFV'R3.AJ2Z8-.$M8RN97:&S6>[<R&
M(S@N+W2< +>=!+8=J6H1/+O1XH:3H 6 -#Y!/W_"\-!>?5CX@7.X-L!O$<S!
MYY)=%.$3A$X10[[ES*XH6 Z_N*9WD&A"0]N^N4/L#,>CB$D5VJ*23I!A8^A5
M%<46P( [ MM\%Y"GHQ6#-O5TD48;8]]CUO9"GI%R?7FZP(#'7[)]H;=#TBPZ
ML!JU>BY^G&(MEB[Z<3X[JN2]LSO5,4G)<[4I;,3*9K<>7ZC2BFX&!Y]&?,!/
MQ M=PLX,\3Q@L&X<WFIB<\DNBJGN_,C[35;:,6LVB9Q>1J+QKK=VLMTS1\1B
M,&D-=3BRNOD1ALQJ&OC3_%2R.QF*5QF"AV*&PP"<"Y%)F2&&T#< 3+)=ZH5V
MAIV.!N-R>0)P>N-N?^2T)+?(=WN@,\NJNI1UBP[<UXUBPJ/SF%T-<DKBA L>
MDE#"&DX;H)V$P92R"G6MH6 IL(^UT$+1'-7.U]#T[<8FP:O2C QG/CG< ]<<
M\[[=,\\;;9U/"?(EY,BS27'%^O 10F_C,-M<?7$FHB\!F\$ O^M73";$JR&2
M,>X%J'2Q>U;?O.+Z/S+<O)(O)*LF+<D(=#QK&+"8Z_'^7]?DA '7/,;$'.Y&
M>>VPSYY'+FLQDWDO\@D6+S..[]+5CY6#U]V;>M" VK;E0C]HR>D#_:X!%97$
M7C4H><QV-S5[1-5_!U\5;'BIAA=PHD(LQ)PXKH+9\I@;;\\=1U S[,$G/ACE
MS(DC3W9SNR8[)V[#+1KX2O#ZXI"[G,-C<.JF>Q05=%J5?<),,!,1:?2M_(6@
M%O*8$O$FC>+/"YK1V\++R00[=L?5!D3 P#GF=_+W<_/Y>:KRDG=_R>]C7+6'
M=?&N(7+Y(63Z_$I#$*,EX$#3]D26K>K?:\?9$[B=[!BTECV8G 5^QU 8<R!=
M"(2N4%(5(VPMH]<LA[<I ;S/3!Y[G=P(&.I.#SV&=RKK.@%BW;<G6L#<U^@Y
M/#)O;,UM&<":UF,>3B\BJVMG]A2)A54$*B,CAI! DPKT;'"A7)I)P6P7,$$G
M#URDDAOPJG&=N0Q[SU/Q^NJFGPH3A$X1.$3A%11WGZ-WWV/[)V?+Z^IZ 1L(
MZZV3"OXK=*-CLP\YLV:2R"% 1&"VCNJ.*R0/1N@-9:!AH#%D$@B\TEQ>XY6F
M5>QT PP5@< ;]<D?S]OAN,;C?)6BH+XPNXX:U:QE\6-P*A7(A[,C=<V5'7<8
MGIWI5"#$_P#(S*&5 UY7QF.Z12;1EW'^U/7&/O0;%P/K=VG1SAB4:+B8)5R3
MZ!]?$X^ PIXAC!ST]_V=R>8Q@[^!P,9<5,OQYSWMFQ[@^0KJWV<[/O.TS'KF
M$Z>&:[FA"G*HIIZQS=T,MF4RYLL%JT&,;O==U0$?:)*EB!79+05[YCJPR^?)
MKRH., @8R7#GGD&_U5P/"JOPHHFDGNJKOHDDEILHHHIMKHFFGIKG;????;.-
M=---<9VVVVSC777&<YSC&.2 20 "22  !DDG8  ;DD\@G+FM?51)3$T@ "9&
M4T$=I;J2DP1!%ONU4;PT\7?E($@0;J;J;I&DH2ZC^A_3.WLZF\$,::)I^RGK
MOZI6BIW[%.(EWHACK3$N#@;D$4<5XQN  =";K+!@.-X>[R2=UAKO=+"R5V!W
MG%(T8QB)[BZ($;^L(BSC_6RMB<YZS)PB<(G")PB<(G")PB<(G")PB<(G")PB
M<(G"*GTUY!K8O*^BE&=%9!X_I?N':$7S&16WVF*R.0V*D"VPWD^877-!0R=:
MAV<<((OVCW>83T=+5FS-8[I 4HW\(8?E; &[N(>P=?#<CXX/OW5@E RWL5(P
MQMAV4IV#U;- #MDV:E:MM3>U*TGC-RBONH7C#XY$:\G@%5DJAJF3!2^$,?AL
MNV?RD[(],/5F10<="2/,8/R)'S]P6_N%"<(G"*H[P_?J][S_ .JOY!OYWO\
MA6=S'[+/X&JW'A53A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$74L  (40.%A842-*R=XT(R0FP',V9"0D& M
MB#8OSCQNBFY+/&848-$-'3]1PNW%CV(]'?1HT013(NVX1.$3A$X1.$3A$X1.
M$51/4;^UN\PW^2?&O_**[>%8_8;^T[\&*W;A56F+U45(PQM7S13=,C;Y\=6"
M64M]D5] 1U!\1L-VT=8SC#0B*JT-.# AQMG./FX]@CKKNJLGIMV-$ CN.ON
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M$X1.$3A$X1.$3A$X15$]1O[6[S#?Y)\:_P#**[>%8_8;^T[\&*W;A56E6O\
MVMO,D\Q^=#T_$DP"&VOYQLI/K(RP.G$5TU/H@6B<%#1!9@Y1U]O85:15OLKC
M111+/9=_JFB1LY2ZM:,[AR>*&G<<$!:1]J&U=FMA[7;=[ID3@,@%:H_Q+;CS
M;6CX!X=]/A[L_K,B;'@C]&=P\5NKG&6TG")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G"*B?RZ/):/N[I^ZJ4U?$,N92#]F&0"95/V&ZQ]88QM!EB- NIM$9
MC8796L+*&2<R7+,82;B=<1ILT>$&D:E$O?-GB,.1>B"NW&#G!Y;$.)Z[^J1[
M\^(5I_4I:8N.MM.KV"6D!V:*0UEM(R\JL" 6I(B!+WSC"K@O8E61V)5Y+GFV
MN-,;EXE&PPA;&-=$66FZ:FVQ5/,^T^/\]_CNLPN2]:AZ]Q1";W3/P%=Q9V63
M!,RQ]=71-\84&%3FP]@V:HN7KYPV @CL@?ZM&RV!L>!&SS_+80((O6Q "=@M
M3F.]G3X#BP,D^Q%9)?=<I&$9OAN?T(;"UIB[3'QQ)GH.3=[2!4@05T'[)QO!
M?=D_]ID0U:.DU$M2<)VVYY^2V%!.RE!V?/CM7UW;4'FD]C<=%2TQ&XX<;%'C
M>-FAL;,L#*"S791D19;"9G#23M0:Z=Y&LIA$W)+5HE)0FSXHQU^OK_/P5?OA
M^_5[WG_U5_(-_.]_PK.YC]EG\#5;4Y=-F2"KIXX0:-4-?;6<N5DT$$=/7&/;
M565VT33U]<XQ[6^V,>N<8]?KRS6N>X-8USW..&M:"YQ/@  23Y *A( R2 !S
M). />5I,GV:Z^A[4CE)$[A@+.U9;'2LKCT+6D3'YH2!!E=$GKO3?539D@KGU
M<+,6#IT@1*M!AMZ+:/&@$RNP[,?9O7YM+L:U%I%]^EU+$56Q<%=_=1SS EC"
M" ]P^R'R-8Z.)\D+)7L?/"U^LZ]4;895=9B%B1CI&1%XXG,80''P!WR&DAS@
MUY:"&/+=T,2# FAAT->M"#7;;;35RQ<HNT,[Z9]-],+(;J)YVTS]-M<;>NN?
MIG&.<=\<D3N"1CXW8!X7M<QV#R.' '!Z;+9!#AD$$>(((^(4(G?D8ZM!3S2.
MS&9K5^0S-+Z@Q[>=Z"HTQAA3KS-8C )8\ECYZ8^&8"Y1([%K1"MEV:A!U-D+
M'ARP]FG\Q7T9T5^$]-]@=M^>3\L'/A@KE,/(EU-,&)[&PMJQ@O*(!,(;%'<9
M9RB%:&)*RG2M*H@)W"DGLH:-I+7KC>_JXTUDK1UIH[5*_"BVI%VX$MRA1@^!
M^L_T/P*YKGR&]-D3XP,UO^M# YZ,L(D2FH29Q<I!8KO6Y"L!145*I(V,[-Q1
MDZ_M^#-H8PPDXWEBI31,1NNHJRT>$X7>!Z=/'./P/P6VK%[)5+7-)MNP#B0X
MF5<&<0-&%$*WT2F[JR"MJR6/0RK@5>I!G"K63%+"ELLC0"+Y;O4QKIX9:.'9
M!D-U<OFY,$G'7?Y;GX+#(_W-H=UI"QMB27;K[8,])2 1'J@[";BJPM)Z_C9U
MQ''N1\=)EG#21B'Y1#5"-RF(E9%$I;\2TQ%SQ=5?5/!,'GS'B-Q_E["L'<^2
MGH<W*Q@9IVJI5ZC+&,X)CSXZ> 'T19,*ZC,3F4I<GI:W?;QX#HTB\XBIYGJ5
M(ME"P@PB3&:.V"#MRW)@^!^"R1YWSZF_%"A<9NN"6&?*2^FH=B,5W)X_*I,/
M<WM-H9 8&:*A&971\RCFQVP(GL<*;);Y",S+%1VW^(>L6KHG"? C8G?;D"3\
M@I?<*$X1.$3A$X1.$3A%U!\^#BH,Q)I,8&Q^.Q\:],G3IEZW&B0XD:W4=D"9
M,@[42:LF+)JDJX=.G"J:*"*>ZBF^NNN<XRP0369HJU:*2>Q/(R&""%CI)9I9
M'!D<44; 7OD>\AK&-!<YQ  )*J][8VN>]S6,8TN>]Q#6M:T9<YSC@   DDG
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MAYZYDH@%K K9W9([4 HE>1ES6,JM!C,QQ0Q?KZY5YD0S-YC%#UM1[?89>$H
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MD%'O29\@T153;BHXV<@]")!XWW>2 2P;.G'" 9./K\0JTKK\HE\5O>-PT^V
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MK!8NT#+/]C1MRX>&Y7(U4,-G$FEQIQN0D)Y9OA1?#1)Z165P-%IK*- (9$:
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MI;$TL\[W2S3R/FFD><ODEE<7R/<>KGO<7./4DE9FM:QK6, :UC0UK0,!K6C
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M"O!&UD->%I<XMBB8Q@<YSL<3G$YXXF1-X6#&3Q.))<][CS<][B7/<>KG$DX
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M(%<]#S"H"5!=2#?=#4K'S"2:_P  68*;:.F2RK9VU]^EIH]9O&FZ[58J*O\
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M();Q @.:'.9Q,/)[.)CFA[26DM(!."K6*MFI)W5J":O+@G@FC?&X@/=&7 /
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<QVLJ7.!XA^L"W/08=D>0R1M\5?APL:<(G"+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g65062g48y51.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g48y51.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1HR4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &A:^9G@X0DE-! 0      !D< 5H  QLE1QP"   "   < @4 !5!R:6YT
M #A"24T$)0      $'&R'N^RK%WYEXQ?IGQ&?D$X0DE-!#H      0L    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585    !0 0P!A &X ;P!N "  5 !3 #4 ,0 P
M #  ( !S &4 <@!I &4 <P      #W!R:6YT4')O;V93971U<$]B:F,    ,
M %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !
M $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7
M $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B
M;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M  !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M          !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
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M8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M    "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#
MO_XU  (  3A"24T$)@      #@             _@   .$))300-       $
M    'CA"24T$&0      !    !XX0DE- _,       D           $ .$))
M32<0       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M     0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M 0 M    !@       3A"24T#^       <   ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M   X0DE-! @      !     !   "0    D      .$))300>       $
M #A"24T$&@     #-0    8              H0   =D          $
M                     0             '9    H0
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   H0     4F=H=&QO;F<
M  =D    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   *$     %)G:'1L;VYG   '9     -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M     #A"24T$$0       0$ .$))3004       $     CA"24T$#      /
M@     $   "@    -@   >   &5    /9  8  '_V/_M  Q!9&]B95]#30 "
M_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3
M%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-
M#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,_\  $0@ -@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M1^XI.^I?UC]NS&#8/NGJ%KI'_;3=B](@^*0!\90^\S[#_G?]\G@#YP/J9]8
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M$85';YN+[8R>+NZ)U.H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                              #_X49":'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E
M:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E
M.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V
M-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR
M9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R
M,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO
M<F<O9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^:6UA
M9V4O97!S9CPO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET;&4^"B @(" @
M(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL
M86YG/2)X+61E9F%U;'0B/E!R:6YT/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B
M"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+R(^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C$M,#8M
M,CA4,38Z-#(Z-# M,#<Z,# \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @
M(#QX;7 Z36]D:69Y1&%T93XR,#(Q+3 V+3(X5#$V.C0R.C0P+3 W.C P/"]X
M;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C$M
M,#8M,CA4,#DZ-3$Z,C(M,#0Z,# \+WAM<#I#<F5A=&5$871E/@H@(" @(" @
M(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R(#(U+C,@*$UA
M8VEN=&]S:"D\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @
M(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]S5'EP92]297-O=7)C945V96YT(R(^"B @(" @(" @(#QX;7!-33I);G-T
M86YC94E$/GAM<"YI:60Z13 U-4(Q.#8V040X14(Q,4(V-#-&.3,Q1#$Q,C0R
M,$4\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I$;V-U;65N
M=$E$/GAM<"YD:60Z0D8Q-#0V,C4V.40X14(Q,4(V-#-&.3,Q1#$Q,C0R,$4\
M+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O
M8W5M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#
M.#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ
M4F5N9&ET:6]N0VQA<W,^9&5F875L=#PO>&UP34TZ4F5N9&ET:6]N0VQA<W,^
M"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI
M:60Z0S,Q-#0V,C4V.40X14(Q,4(V-#-&.3,Q1#$Q,C0R,$4\+W-T4F5F.FEN
M<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD
M:60Z0D8Q-#0V,C4V.40X14(Q,4(V-#-&.3,Q1#$Q,C0R,$4\+W-T4F5F.F1O
M8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT
M240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO<W12
M968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z<F5N
M9&ET:6]N0VQA<W,^9&5F875L=#PO<W12968Z<F5N9&ET:6]N0VQA<W,^"B @
M(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @(#QX;7!-33I(
M:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HV-CDP
M.30X92TW93$Y+30T.6(M.#AD.2TX,#DT,SDX934W.60\+W-T179T.FEN<W1A
M;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,#8M
M,CA4,#DZ-#0Z,3 M,#0Z,# \+W-T179T.G=H96X^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R(#(U
M+C,@*$UA8VEN=&]S:"D\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D)%,30T-C(U-CE$
M.$5",3%"-C0S1CDS,40Q,3(T,C!%/"]S=$5V=#II;G-T86YC94E$/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 V+3(X5#$V.C0Q.C4U
M+3 W.C P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO
M<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O
M;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<&%R86UE=&5R<SYF<F]M(&EM86=E+VIP96<@=&\@87!P;&EC871I;VXO
M=FYD+F%D;V)E+G!H;W1O<VAO<#PO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@:6UA9V4O
M:G!E9R!T;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P/"]S=$5V
M=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP
M+FEI9#I"1C$T-#8R-38Y1#A%0C$Q0C8T,T8Y,S%$,3$R-#(P13PO<W1%=G0Z
M:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R
M,2TP-BTR.%0Q-CHT,3HU-2TP-SHP,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P
M($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D,S,30T-C(U-CE$
M.$5",3%"-C0S1CDS,40Q,3(T,C!%/"]S=$5V=#II;G-T86YC94E$/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 V+3(X5#$V.C0R.C0P
M+3 W.C P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO
M<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O
M;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T
M;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC
M871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V
M=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP
M+FEI9#I%,#4U0C$X-C9!1#A%0C$Q0C8T,T8Y,S%$,3$R-#(P13PO<W1%=G0Z
M:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R
M,2TP-BTR.%0Q-CHT,CHT,"TP-SHP,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P
M($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^
M"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.FEL;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N
M8V]M+VEL;'5S=')A=&]R+S$N,"\B/@H@(" @(" @(" \:6QL=7-T<F%T;W(Z
M4W1A<G1U<%!R;V9I;&4^4')I;G0\+VEL;'5S=')A=&]R.E-T87)T=7!0<F]F
M:6QE/@H@(" @(" @(" \:6QL=7-T<F%T;W(Z0W)E871O<E-U8E1O;VP^061O
M8F4@26QL=7-T<F%T;W(\+VEL;'5S=')A=&]R.D-R96%T;W)3=6)4;V]L/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O
M;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E
M<CY!9&]B92!01$8@;&EB<F%R>2 Q,"XP,3PO<&1F.E!R;V1U8V5R/@H@(" @
M(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H='1P
M.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @(" @/'!H
M;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D93X*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE
M=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME
M="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0'_P  1" #. ET# 1$  A$! Q$!_\0 'P !  (" @,!
M 0            D*!P@%!@,$"P(!_\0 :A    8! @(""P<,# H&!PD  0(#
M! 4&!P ($1()$Q05(3A36'>5EK;5%A<9,3=VU H8&B(U5727L[2WUB,S-CE!
M4597<W5XM3(T86)QE+&RT=(D4E22D],E)B>1I,770D9997*!F,3B_\0 '@$!
M  (" P$! 0            <(!@D#! 4" 0K_Q !N$0  !0(" @81#@L#!PH#
M"0   0(#! 4&!Q$2(0@3-C=VM106%S$U0515<W1UDY2RL[31%1@B,S115E=R
MDK'3U/ C,E)A<9&5EK;2U5.!H1DD)6*%P<0)0D-%8V2$I,/AHM;Q)F5F@H.C
MI<7B_]H # ,!  (1 Q$ /P"_QH JH=/MNZW-[=]PV%:W@[.&0\70,[AE2<F(
MFG3[F)92,N%WLK )%TBC]JJZ!FU;MNM'[;J44R?$4-6 PAMRA5JCU5ZJTJ'/
M=9J26FG)+).+0V<5E9H29\Y.D9JR]\S/IC [NJ,Z%*B(B2G6$K86I:6U9$I1
M.&1&>H]>6H0.?">](1XWV<O31]J6^4.S?@W2O!DC$O5ZL]<9/SR] ?">](1X
MWV<O31]IRAV;\&Z5X,D/5ZL]<9/SR] ?">](1XWV<O31]IRAV;\&Z5X,D/5Z
ML]<9/SR] ?">](1XWV<O31]IRAV;\&Z5X,D/5ZL]<9/SR] ?">](1XWV<O31
M]IRAV;\&Z5X,D/5ZL]<9/SR] ?">](1XWV<O31]IRAV;\&Z5X,D/5ZL]<9/S
MR] ?">](1XWV<O31]IRAV;\&Z5X,D/5ZL]<9/SR] ?">](1XWV<O31]IRAV;
M\&Z5X,D/5ZL]<9/SR] ?">](1XWV<O31]IRAV;\&Z5X,D/5ZL]<9/SR] ?">
M](1XWV<O31]IRAV;\&Z5X,D/5ZL]<9/SR] ?">](1XWV<O31]IRAV;\&Z5X,
MD/5ZL]<9/SR] ?">](1XWV<O31]IRAV;\&Z5X,D/5ZL]<9/SR] ?">](1XWV
M<O31]IRAV;\&Z5X,D/5ZL]<9/SR] ?">](1XWV<O31]IRAV;\&Z5X,D/5ZL]
M<9/SR] [%7ND.Z32W*ND*GN6W*6==BB5P]1KTU89I5F@<PD(NZ3C6KD[=$YP
M$A5%0(0Q@$H&$0X:X'[,L6,23DT.AQR6>B@WVV6B4HM9I2;BDDH\M>19F.1N
MLUYXS)J9-=-)9J)O269$?.ST4GEGEJSY_2'".>DTZ1!DY<,WF[;/+1VT65;.
MFKFWR2#ELX0.9-9!P@J4BJ*R*A3)JI*%*=,Y3$.4# (!S)L6RUI2M%NTA2%$
M2DJ3'0I*DF69*2HC,C(RUD9&9&6LA\'7:TDS2JH2DJ(S(R-61D9<\C(RS(RZ
M9&/!\)[TA'C?9R]-'VOWE#LWX-TKP9(_/5ZL]<9/SR] ?">](1XWV<O31]IR
MAV;\&Z5X,D/5ZL]<9/SR] ?">](1XWV<O31]IRAV;\&Z5X,D/5ZL]<9/SR]
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M#LWX-TKP9(>KU9ZXR?GEZ ^$]Z0CQOLY>FC[3E#LWX-TKP9(>KU9ZXR?GEZ
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MC)A9D9&69&1D[D9&6LC+49#^?7<;JQ*)PW%9F$I1*43>[R=Y0,8#"4HCV3P
M3 0XE 1XB!3"''E'@YM&*&1GRX5;(C(C/31D1GF9$9[7EF9$>1=/(_>,/6^X
M+YD7,^M[,R,R+D=>9D61&9%MN9D1F1&?2S+/GD/Y]=UNI\8S,OI[._2=?G-I
MQ0^&%5[XW]6/WUOF#'Q>V_X.Y]:/9>;K=VL<Y592&X'-S%X@8"KM'EVL39RB
M8Q2G*55!=<BJ9A(8IP Y"B)3%,'<$!UR.XR8JL.*:?NRLLNH,B6T[HMN(,R(
MR)2%M$I)F1D9$9%J,CYQCB8P#P2DM(?C6';4AAPC-MYALW6G"(S29H<;>4A1
M$HC(S29D1D9<\C'K?7=;J?&,S+Z>SOTG7'S:<4/AA5>^-_5CE];Y@Q\7MO\
M@[GUH?7=;J?&,S+Z>SOTG3FTXH?#"J]\;^K#UOF#'Q>V_P"#N?6A]=UNI\8S
M,OI[._2=.;3BA\,*KWQOZL/6^8,?%[;_ (.Y]:.W8]W9[H761,=,WFX/+KUD
M^R'18]\R>7>9<M'C%_;(=F]:.FZK@R:S=TU75062.42G34,40X#K);-Q<Q&J
M5UVY FW75'XDRLT^/)94X@DNLNR6TN-J,D$>BM)FD\C(\C/6,4OO K".EV5=
ME1@6'08TV#;M8E1)"(ZM-B0Q ?<9=1I.&6FVM*5),R/(R(Q;[ULB&GX- #0
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M 1-1VG5QW5O\C-+9;6ODEU*5$AQ*%D1()*2TDD1Y'H%HY",#6>C'@T - #0
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M'/KK!:R_#_=O:?=^E^=M#"<2M[V]^"M>XMDB[]K;2-$H: &@!H : &@!H :
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M?H_=OH>G-SH_6.I=_B^D.4>7U='[VYZ0^QG=P?C(X;]'[M]#TYN='ZQU+O\
M%](<H\OJZ/WMSTA]C.[@_&1PWZ/W;Z'IS<Z/UCJ7?XOI#E'E]71^]N>D/L9W
M<'XR.&_1^[?0].;G1^L=2[_%](<H\OJZ/WMSTCR)?4T6XA!5-=#<MA]%9%0B
MJ*R4%>$U4E4S =-1-0C0#IJ)G #$.40,4P 8H@( .OP\<J,9&1T*HF1D9&1O
M13(R/49&1GD9&6HR/GC]*R)B3(RGL$9:R,FW2,C]\CSU'[Q](<A,?4W&YVQ/
MU)2P;J<7SLFL5,BTC,1V09-^J1$@)HD4>/45W!RI)E*FF4R@@0@ 4H 4 #7P
MUC;0F$$VS;TYELC,R;:<AMH(S/,S)*,DD9GK/(M9ZS'TY9DYU6D[467%?E+0
MZI7Z,S,SR+I%GJYQ#B_L9W<'XR.&_1^[?0]<G-SH_6.I=_B^D?'*/+ZNC][<
M](?8SNX/QD<-^C]V^AZ<W.C]8ZEW^+Z0Y1Y?5T?O;GI#[&=W!^,CAOT?NWT/
M3FYT?K'4N_Q?2'*/+ZNC][<](?8SNX/QD<-^C]V^AZ<W.C]8ZEW^+Z0Y1Y?5
MT?O;GI#[&=W!^,CAOT?NWT/3FYT?K'4N_P 7TARCR^KH_>W/2'V,[N#\9'#?
MH_=OH>G-SH_6.I=_B^D.4>7U='[VYZ0^QG=P?C(X;]'[M]#TYN='ZQU+O\7T
MARCR^KH_>W/2'V,[N#\9'#?H_=OH>G-SH_6.I=_B^D.4>7U='[VYZ0^QG=P?
MC(X;]'[M]#TYN='ZQU+O\7TARCR^KH_>W/2'V,[N#\9'#?H_=OH>G-SH_6.I
M=_B^D.4>7U='[VYZ0^QG=P?C(X;]'[M]#TYN='ZQU+O\7TARCR^KH_>W/2'V
M,[N#\9'#?H_=OH>G-SH_6.I=_B^D.4>7U='[VYZ0^QG=P?C(X;]'[M]#TYN=
M'ZQU+O\ %](<H\OJZ/WMSTA]C.[@_&1PWZ/W;Z'IS<Z/UCJ7?XOI#E'E]71^
M]N>D6G-I.%Y;;KMHPG@V>F8ZPS.+<?05.DIN(2<H1DH[B4!15>,47A2.DVZH
M]U,BY2J '^$''4!W%5&ZU7*I5FFELM3YCLE#3AI4MM+AYDE1I]B9ETS+4,\I
M\94.%%BJ42U1V4-&M)&25&@LLR(]9$?YQW?.%0E\@X5R_0J_V)V^N^+L@5"$
M[/7,V8]M[+4Y:&C>S')$ES-VG9CU'LA<J*QDD>=0J2@E @XA7(;U1HE8I\?0
MV^=2JA#8VQ6BC;I,1YAO341&:4::TZ2B(\BS/(^<,KM2IQZ+=%MUB63AQ*37
MZ/4Y1,I);IQX%1C2GR:0:DDMPVVE$A)J22E9$:B(\RKB_!.[QOO9BK\8CK]5
M-41]:W?_ %?0/"Y'V8;-/7I84];[K_9L3^H!\$[O&^]F*OQB.OU4T]:W?_5]
M \+D?9@]>EA3UONO]FQ/Z@'P3N\;[V8J_&(Z_533UK=_]7T#PN1]F#UZ6%/6
M^Z_V;$_J ?!.[QOO9BK\8CK]5-/6MW_U?0/"Y'V8/7I84];[K_9L3^H!\$[O
M&^]F*OQB.OU4T]:W?_5] \+D?9@]>EA3UONO]FQ/Z@'P3N\;[V8J_&(Z_533
MUK=_]7T#PN1]F#UZ6%/6^Z_V;$_J ?!.[QOO9BK\8CK]5-/6MW_U?0/"Y'V8
M/7I84];[K_9L3^H!\$[O&^]F*OQB.OU4T]:W?_5] \+D?9@]>EA3UONO]FQ/
MZ@'P3N\;[V8J_&(Z_533UK=_]7T#PN1]F#UZ6%/6^Z_V;$_J ?!.[QOO9BK\
M8CK]5-/6MW_U?0/"Y'V8/7I84];[K_9L3^H!\$[O&^]F*OQB.OU4T]:W?_5]
M \+D?9@]>EA3UONO]FQ/Z@'P3N\;[V8J_&(Z_533UK=_]7T#PN1]F#UZ6%/6
M^Z_V;$_J ?!.[QOO9BK\8CK]5-/6MW_U?0/"Y'V8/7I84];[K_9L3^H!\$[O
M&^]F*OQB.OU4T]:W?_5] \+D?9@]>EA3UONO]FQ/Z@'P3N\;[V8J_&(Z_533
MUK=_]7T#PN1]F#UZ6%/6^Z_V;$_J ?!.[QOO9BK\8CK]5-/6MW_U?0/"Y'V8
M/7I84];[K_9L3^H!\$[O&^]F*OQB.OU4T]:W?_5] \+D?9@]>EA3UONO]FQ/
MZ@.0<]%GO;>LV<>\][IVPC@.6/8N<HR:[-B53AS@S;*UDZ+4#\ YP0(0#< X
M\> :YW-C+B.ZTTP[5J.ZRP1DPRY4):VF25^,33:F#0V1Y%F2"+/+6.LULQL'
M6'WY+%%N)F1),CDR&J-3VWY!IST3?=1-)QTTYGD;BE99GESQQ_P3N\;[V8J_
M&(Z_537!ZUN_^KZ!X7(^S#L^O2PIZWW7^S8G]0#X)W>-][,5?C$=?JIIZUN_
M^KZ!X7(^S!Z]+"GK?=?[-B?U =FI/17;N(:[T>;DV&+THR"NU0G9)1"_.G"Y
M(^$L<9*O10;^Y=+KU^Q6BO4I"HF"BO*05" (F#W;8V-]\46XJ)5Y,RAKCTVJ
M0ICR&I3YN*:COH<62"5'(C5HI/(C,B,]68QV[MEYAC7K5N.B1(5SMRJM1*G3
MHRWJ=%)I+\R&\PT;JDSE*2V3BTZ:B2HTIS,DGED=F75YAK.#0 T - #0 T -
M #0 T - #0 T - #0 T - #0 T :X[OMR58V>[8LX[G;C%N9ZOX4QY/7EU7V
M3]G%/+&[C4 3AZVTE) #,8YU89E>/AF[YV11NT6?$7525(F*9@#0;!G3/;;\
M@P,O*Y;9KXD[%SFVP/7+/1Y*3W+X5O=A>1N*%4YJJ9UPM4IBAGKS&RYBJ5!G
M)>:7AXF+NAG\462>$C9)PR /+5NFOVB6";<!*FO=(II7608>)F+;CO)[>ZW2
M>JF:AP=46V/<7Q./Y>PW6-R?98#)DA774,[4F(J,QI9_=)78QU!W)"F@&3Y#
MI@>C^: ;M?F6=LX&H(Y&:.*IAK-D]#OX13;M-;KV,6VL[/'AJJG<I3 ->F,A
ML*,\G&EM/',5F2\0WE2]@B <MD+I&ZU2-N>U3/K' F>+$YW=V;!=1H>/#4]>
MNS=&F\[V:F5>";Y@EYHJ,31@B9&Z,&RZ9!F'D^Z;N3U)I.PR#R<9@$CN@!H
M: &@!H : &@!H : &@!H : &@!H : &@!H : (VND-Z1VE[ "X596&N5.R3F
M;)+)J4*G><TTC!-5B8;$]%5NUGDWUSO:#J-=2+M1:!K%;K;%LK*S]CLD6Q9E
MYCCQ ,83'33;0ZOAJ3R1;8W-D!D&"V[U;<+-;?W&%<E>^6FQM,=A]5.B0LBZ
MK#&@V:YPT[GG%-8L3>%MSF/@)*UHK33R/9Q<\M% '?:9TL^T"=OBF-+7>QH]
MSD<L3F+JK$.ZODV1[)-%7\<.LIJ^2/O=1T+B8+!FN,MN*(%I=Y-DSF+=4I9A
M$3,BY;2#:- .)CNF+V4V];%++%<]E7*DGF++6#\4U".KN!<U0SA4N?(FYVFE
M9".6Z4.M&=XV/2<;9$MZMJAR2C)6'ITPZ0YV;9=XB 9IF-YKZ WTTO9;*80M
MB3?(5%M-UJF7&MNI4FR=LJ978Z>L,Y*8\BY)[=*SCAK)2K'';3(5H1AD)?*2
MQ:I$0CYB9.P* &\F@!H : &@!H : &@!H : &@!H : &@!H : &@!H : (>,
MD],%C3'>^"3V9!CU"T/:UD['6*;=/P.5:DZR1#R]^Q*3,CVVQVWI)BMD>R8Q
MQ]4G+%>_WV*.:+A3KKI(I/7S-1@8 \U^Z;K916*["V*I2>2;ZQEHS<1(2+\F
M'LOU")H([;L4P.4K@3)Q[1CYI8:<A))WO%E;AES5>267ELEUH>Q# MU*@!E]
MITL>QWLBRPDIEMVE<*5.URFV6LUW&.:+DL^O,_DLN%3UG&CB"QHJKF0T3F$K
MC'<K(XT8V%O&S:'&7)&(*%. !W3;STB6WW=7EF5Q7@A/(MT3AL 4;<*[OSG'
M%OJ5&-7,CV2PUJIU5.3N43 .F]Y>KU2?=KP,JRC!31C9%NV7>OX"V-*Z <EL
MFWD+;P8K.*LAAZPX;L.!LV2^#K=7YFX4Z_-@MD)5JK9YJ*):J&]DJNM9J@K:
M4ZGD""AY.;CZQ=(F7A6=CGT&Q)%4 W<T - #0 T - #0 T - #0 T - #0 T
M - #0 T - &'2;@\(*-6[TN4Z4#5XUF7S-<\XT33>,J_&'F9AXT,H<G931G%
M)+2 N4.L17:H.%FQUBMUA3 ,AUNU5NX1X2U6FXVP18]B<DA$NDGK)0'T7'S3
M,R3E QT52N(J5CGR1TSF*9!VB;CQ$0  Y_0 T - #0 T - &'<\X)QYN1QL]
MQ-E5@^EJ-)V?'MJE8AC(KQG;1[C+(-8R;6V+]=N'6KPRMGJ$,,U&")4)B+([
MBG?,S>+D. :^;A>CLVP[GLS8?SMEBM6"2O.$#5?W%(Q5HD8FKJHTW*=5S)7V
ME@JR'/$3;)K>J?$OG31PW*WE&G6,I5-ZDC'"P ->'W0G;$92E'I$K5\B2S1H
M:F#5YN6R1.2MDHI*#=<Z7FMHT^1D"N48]!!_N0RY&/4WC.1"4A;&FWD>R7L9
M'R#< [J^Z(C9,_JT]2U:7;R5RPER@#UFGD&RBY3-EK;)6]G]C7;RRKI68[,C
M\!UAG3JZ_</W+Z+,_FY0SEU(R[Q<X!ME9-LF,KA5]O-2M0V>?C-LUXQ[D?':
M\G8G;B2>W#&%2FZA4IBYO>4I[2LU;SKF;<D>E(FZLS6.FCE*X9)%T ;"Z &@
M!H : &@!H : &@!H QO/Y@Q?5GTW&V.]5N%?5M%@O/-Y&11;&B4Y0&IH_LXR
M@@F@HZ3?-'":)C];V*NF[,0K815  Y>O9"H]L?OXNLVN#G9&+>2["19Q<@@[
M<,GD"M'-YANX31.8R9V"TO&$7YOM0%\W$@F*H Z .XZ &@!H : &@!H : ,.
M3F",=V3.5'W#3D>]DLBXXQM?\64U5T_56@82M9-L= L]S<M8(X&9!/RLAC*G
MMQFQ#LQ"-CCL$C%1<K<P!H?9.AMV36B_YZR<]@LE-+GN+D9&6OLM%Y.L3([*
M2E<RXPS^^>5(I3'"O*K94Q%3I\_5"X(=FU4KARGK:,9$QH!YW70X['G=LJEZ
M-4;PC;JK#W2)[?M\AV!&3LBMUR-EC+CF;MCL%!6FK!#Y)S=DJWPTF8Z!S2<\
MB2;3FF4/#-& !DFI=&7M7HESQ9?*C"W6 L&&K;BJVT%2/O$PDRBAPUMT<[6J
M36UH_B+5Y4VV)9"98/X9PF8'LU8+#-BX3=3<B5< R'C_ &2XDQMNMR]O'@+#
MEQSEW.$%#UN_LYO)]CEL>O(:M-F;.J,(^AKJA"1K:IMF[LE:;H)]CPZL]97C
M5(K^P2CIR ;@: &@!H : &@!H : &@#@;/:*]3(1W8[5,,8&"8'9I.Y216!!
MJBK(OFT8P1,<0$3+/9%XT8M42 91=TY102*910I1 .CAG/#@O!CQR73"/2R,
M=$G:J3K%)9*0ET7R\:V7(HJ44#N^U<DW2,MR)]GQ[V-,<L@U7:D ,G,W;=^T
M:OFBH+-'K=!VU6*!BE5;N4BK(J@4Y2G*"B9RG #E*8 '@8H#Q#0![&@!H :
M&@!H : &@#4QWLGP$_QONHQ6^@)IU6-YEBR99\\+#8Y1O8+!(Y7IT+0;0G%6
M%DJVE8%@C4Z["0\(QCW!$(IK'($1*<O6 < U-BNA9V00U?A*PPA\I)1$4MD@
M\BW#*,^0MN;9:NV',A7R*MJ:)4F\I#3-FP/C=48M%!DS:QL*6#;))0Y6C%H
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MY[1T >PV8(-#F424>G,8O((.9*1>$X"(#Q*F\=+IE-Q /MRE X!Q*!N4Q@$
M]W0 T - #0 T - #0 T 82NFY;;OCBT-:3D#.>):5;W@I@C6;3D&JP<V7KB
MHW,YCI&4;N69'13%[$4>)H$=F$"-S*G'ET 9G;N&[QN@[:+HNFKI%-PV<MU2
M+MW#=8A5$5T%DC&35153,51-5,QB*$,4Q3"40'0!YM #0 T - #0 T - #0
MT - #0 T - #0 T - #0 T - #0 T - #0 T - #0 T - #0 T - #0 T -
M#0 T - #0 T - #0 T - #0 T - #0 T - #0 T - #0 T - #0 T - #0 T
M - #0 T - #0 T - #0 T - #0 T - #0!%K/YBA-M^Y+,U;G6LAE6DY3E,;
MW&>K]6@<10D5AM*^3!L<@M*MY.VPEQRK.6VW13N4GH6M5:P348S(UDW*;Z7G
MNI?/[_?^_P#=SOI 2<0T+#UV*CX*OQ,;!0<2T1814-#,&L9%1C%L0$V[*/CF
M22#1DT03*":+9LBDBD0 *0A2@ : .2T - #0 T - #0 T - #0 T - #0 T
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MZ1TY QB#P$4HF573$> #]HL@R424#N_&0Y@X\0X\0$- 'C[<-/ RGF.:]GZ
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MIYA..8QT=&3KHLF2*[IRR3 -LU#E23.H8#B4A3',"::BJ@@4.(@1)(IU5#<
M[A$R&.8>X4HB(!H X[MPT\#*>8YKV?H =N&G@93S'->S] #MPT\#*>8YKV?H
M =N&G@93S'->S] #MPT\#*>8YKV?H =N&G@93S'->S] #MPT\#*>8YKV?H =
MN&G@93S'->S] #MPT\#*>8YKV?H =N&G@93S'->S] #MPT\#*>8YKV?H =N&
MG@93S'->S] #MPT\#*>8YKV?H =N&G@93S'->S] #MPT\#*>8YKV?H =N&G@
M93S'->S] #MPT\#*>8YKV?H Y!)0JR9%2 H!3AS "J2J"@!_GHKD353'_-.0
MIO\ )H \F@##V?,J+85Q)<\D-*S+W"1KL4JO&5Z'CIB0.^D5 ZMJ>3-!QDP^
MC(!D<1?6"9+'N"Q<0V>.BHKKD1;K &KSS>%>#C.2E>QU"3\!79B---M4YI['
M6F#K[^[7['C%&>A91LS?1L_9)2HQ=DK34C!V^4A;$BP?0**+-Q9BOH ;I4&W
MQE\I\%:XAZE(,Y5J<#ND6+Z-1._8.5XR6328R90?-DV\JS>MR$<"H;E2 Q%W
M"9B+J '/J2C9)0Z9DI$3$,)3"G$2RR8B \!$BJ+(Z2A?XCIG,0P=T#"&@#\=
MN&G@93S'->S] #MPT\#*>8YKV?H =N&G@93S'->S] #MPT\#*>8YKV?H =N&
MG@93S'->S] #MPT\#*>8YKV?H =N&G@93S'->S] #MPT\#*>8YKV?H =N&G@
M93S'->S] #MPT\#*>8YKV?H =N&G@93S'->S] #MPT\#*>8YKV?H =N&G@93
MS'->S] #MPT\#*>8YKV?H =N&G@93S'->S] '0K;F;'5&>-6%JFW,.[>-A>-
MD'$!8C&5; J='K2BC%*% O6IG)W1 >)1[G#@.O7IU!JM6;<>@1=O;:7M:U;=
M':R7HDK1R==;4?L3(\R(RUY9YYCRI];IE+<0U.D[0XXC;$)VI]S-&D:<\VFU
MD7LDF61F1ZN=D.J?7.X1_ED;T>L_L;7H\IER=;O_ #4+[0.ARW6_U?\ ^6E_
M4#,,%8HJRL&4I#JN7,?(LT7[)VK&R3)%PT<%(=%5,[YHV >L(<IBDX]9RB)N
M3@4PACLAAV*^[&?1H/,.+:=1FE6BX@S2I.D@U)/(R,M)*C2?2,\R'OL/M266
MI#*M-E]M#K2\E)TD+(E)5HJ)*BS(R/)1$9=,B'-ZX1RAH : &@!H : &@!H
MBEWG;CLXXRW'8MQMC[*F**%6;%'8YG5(NW6''$?8[-(/K[9JG,5KM7;GA+ M
M#SY']8D#/JXS*[[4U"VQL#($MS^'8/@"5K0!XQ11$Y5!23%0G6<AQ3*)R=;P
MZWE-PYB]9REZS@(<_*'-QX!H _*+9LW$XH-T$!5ZOK!1232%3JDR(I<XD*43
M]6BF1)/FX\B9")EX%*   >;0 T - #0 T - #0 T - #0 T - #0 T - #0
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M&5\44S(M&;K/+VA'UPVDUA0S$- #0 T - #0 T - #0 T - #0 T - #0 T
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MT<J?;2_]WW](Q?SG_P"L;_O#_P =>YD7O%^HAXHFTJS>5&L5P2R38"C Q @
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M.-[6;A.&6UF19Z1(1S\^=HZO?,9)['EOOFU\V&^GZ\<>L'8\M]\VOFPWT_0
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M*,INA4B:CE16CY>H5J48+&3.D95E(0S)VU5,DJ4BJ8J(*IG%-0I3D$>4Y2F
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M?K:U38)I+,N15ESR+63RCZ9_G(1H_"1;+OYZ$_0'*'ZDZD_E?K'49]^C?7#
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MB(B+\/(/(BR_Y_HR'+;DE$U<U791(Y%$S*PG*=,Q3D-PK4, \#%$2CP$! >
M]P0$/C#66V;N;IOZ)/GD@1U=NZ&H_IB^91A@W63C'!+MMZ>LTL-45-5VV3.6
M.>@8AUTB'*(S$B( 8IC@(<0$![H?$(#J +M,N6*J:R]N;Z?_ '=D3A:W0"G=
MC=\X>$:N9CD4ROD$Y#%.0UKF#%.0P&*8HNS\!*8!$! ?X! 1 =3+;G0&D]HQ
M_$(1-7^C54[=?\<QC/7M#R!.'7I&/)7H/G?,R\D-&\W,Z0#EY6*'-QXG[G#@
M/'C\7#59Y9D<N21'F9R7B(BYYGMJBRRY^>?2%B8VJ+'S_L&O)I'!CEG%P"(#
MD6D<0[@_^M$+]-UWO4&MG_U14O I'U8Z7JW1R_ZUI_AC'U@_1<KXP.8I"Y$I
M)C&,!2E"T0HB8QAX   #WB(B(@ !_".OPZ%6B(S.DU(B(C,S.%(R(BUF9_@^
M<1#]*MT<S(BJE/,S,B(BEL9F9ZB+\?ICE+7/)1M6LLBPD69'S" F7K(X+-E1
M([:QSE=L<$CB<B@E63(/5G(8I^'*8I@$0'J0&VWIT-ES)3;LN.TXG,R-2''D
M(4G,C(RS(S+,C(RZ6L=F:XMF'+>;/)QJ+(<0>1'DM#2U)/(]1Y*(CR/4?3$8
M?UT.:OY5(>88'V=J;.4JW.H5>%2OKA#_ "WU_JQ/@T;ZH9%Q+N$RE9LCU."L
M%D;KPTE)&0?HC$PS4%$0:N%. N$622J7VY"#S$4(/<X<> B ^/7[5H<&CSY<
M:(IM]ADEMK.1(425;8@L]%;II/49ZC(R'K4*Y:S-JT*+(E$MAYU27$$PPDU$
M3:U$6DELE%K27.,O>$BW;&/_ .W,_P#64/\ GU$&9>^7ZR$J!VQC_P#MS/\
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M2&?,%XF>9US2[<TF+5<NLLY&<.%3*OP,JNO<)E5500*\*4!.H8QA I2E 1X
M !P#5*J[LI<?J56ZQ3*?B56(T"FU6H0(49$.BJ1'B0Y;T>,PA2Z6M9I:9;0V
MDUJ4HR21J49YF>T^S]BU@#5[2M:JU'#2C2JA4[<HE0GRG)=:2N3-FTR+)E2%
MDBIH02WGW7'%$A*4$:C)*4ED18TB\"XA))QQRT:* Q7[0Q1ZZ1[ABN$Q >Z]
M_@$..O-;V6.R(6XVA>*%:4A:T(4DX5#R-*E$2B/*E9ZR,RU#W)&Q-V.[;#[B
M,+J(E;;+BT**97,TJ2A2DGKJIEJ,B/61E[XO^II))<>J333YN''JR%)QX?%Q
MY0#CPXCPX_%QU?L:>!Y- #0!AR?P#BJSS-HGYN DW<K<CQJM@<)W*[L4W2T3
M'I0\>X:,X^QM64.Z0ATU8<SJ&;Q[A>(D9N+<**L)^;;R !S9,18Y3N4;D!.L
MMT[=$*N5HV7(]E""T,ZK;6HG*FQ*^"-%!&N-"1C%L=F9O&IN)%>.2:NI:47>
M &1S%*8!*8 ,4P"!BF ! 0'N" @/<$!#N" ]P= %/+ZHPQG=+=N<P:]J=8>2
MK)M@<K5RLQ(V(FFZ#(-P6%(X'52$3]4JF?B!1#E,'=_@"4[#Q@PRPZI\VEWO
M>='MNH3IO)\2+4G74.OP]H:C\D-DVRX1M[>RZWF9D>DA6KIC\5@_B;B.15.Q
M[,K%RP(!G!F2J:VRMJ/+/*04=PW'FSVS:76W,B(RT5I//6*]'O$9>_D),_\
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M'M>[?*6X,0=,K\MN*O)8?UMGM8MLJ-V%O<&D\:5 9OL&=P-X<+T\2TX0]:K
M+NBY-M$[UO;[Y(:%ZNL-;3<+][FR.#%&\Q9&C3&C?<Q)X:W'QI)&Q6L[$9#0
MW<I\CM=\JEN_OF[ZS[#SHO+[GK\XCC!K]Z%Q.WT^;R!JMA?Y6,>?.V%_/$]2
M3<70*K=H2?)J$>T/HS3.W8_E$C</=%3]R5EL2JV"K,UK3 -MN?H20/*0DO8F
MLG>9E]C<]%C8-M$Y,QT-?NRR+&QC7KF[[>-H),L@F9FGV;^RUX$]C61.K[V9
M>MV_$#!') 1V0KQ?(V:M5PM4%36N/JH_RZZM<:YQ]DRHEL>24&%NPZPM=//(
MJQ=@E*+;[%CM2OLX-@TE&Z(!E#$#'<'-9HQ"OE6JY7JDM0JBK%Y1O#6UOI;%
MN6;C$5"U4=1E"U9K86M;K^.95VFWRXC/254->)FZ25.AA0KT= S"3P'O_?\
M5^K_ !$D>@#'V/?VJX^4&V?GB>@"(K<_:[$CNJBV6.6^X-9C69R@K2\4$1OV
M]R>0[?/Y'5;6RMP=CHEDK>&JE5Z;5C1UD/87T%>JC*(/G$+V*9K&.8Y4/P\L
M^G_CE_AJ_6)MM!^C12:6W7NIMG6&%CF(MS*/<A1L;:VM%KRE31;KV?)+5C.6
M1)9G*.89O5JLECF1HK0)=)S8WKA="4]U)@EBMP#+^W6QY;EX:=B\PP<VTL,.
M-<61L4FQ:1+&PHR4 W Y(^(9,46\6^: Q1DK,P;2UF9,;'/R$>SFDDV8P<,
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M[CGK.R7BK3E_8+ER\G5LGG/Q[O-QZOEX!PYN(\+C[%#VN]_ET#Q:N-=FSO\
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M*"4.Z!#<. @%<WIBSNSYLQ:+M!N@H&+! I6[I1T4Q/=;8/MC'4:-!*;CQ#E
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ML[<[I->*L2?7>@]1[5=^@?.2U=@0J)?.@H,N7I+L)"V2266"NY?Y4UECMTS
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M+E%)PW62<-W"2:R"Z*A%45D52 HDLDJF)B*)*$,4Z:A#&(<A@,41 0'0!Y=
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M,J]?M+E,U5/ZWS-F*6!(*W6NJ'<V7);FE+0SJQ>YI1$LU4&1:R[+-1#X717
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M8F .W: *Z73*?+?BSR5#ZW6'5%ME1NPM[@TGC2H#9YL&=P%X<,"XEIHA\U6
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M:5BN@8X@TZS0:VVIU>2<N'B4+774C%1J;IV8#NG!&;1XDB59P<I3+* 0#',
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M]8M '/P-?C*VS58Q1'145WCJ07.]D'\H[</7JG6N7#A])N7;Q=14_=$55S\
M  +P* !H UFL6S;&=FRV7-3ZZY\:79)THJU"'SWE&'KT?'N9&'E9"MQU:86-
M"'85.5?P$.YEZPU:IPLFHP;F>,UA2()0#;/0 T - #0!ABU8*I5NRK3,PR79
MR5NI#1%C'*-D80R;AHU5F'#)!1\]AGD_%IHKSTJ9VG6IJ").-W/:VQ%EXM--
MD4 S/H : ,(6+!D38+.WLI;?<8<GOD1V496NQYZNYK=ALD-5Z55(4DW'3=8E
MU'#&%:4>.E(@B#IL[C;(Z<6)H\2EX^NNH0 S?H : -;G.WC&D=DBE91>S<LS
MGZS8+,YKZ3Y[74VCB8O5BR'8GD<R=.X3MVQ!X_R38&JD96YB*&R1[& C[*G/
MH0;8N@#8=H^9/R+*,7C5Z1NZ<L5SM'"3@B#UDL9N\9K&1.<$W31<AT'+<XE5
M06(9)4A#E$H '"6EDE/PLU5$K/)5:2L$-)1C28KKV.:VF'%\S<MPF( TBTD6
MR4I'AUCM@X<1KYNBX;%55;+$2.00#$>.=MM QG:8J[0KVV/;3'5.9I[N1D[
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MA462;QS9;5;GJZ9XR'CI*3<NIVY3:W9MDD)U\R8&8PT:Y91+%!F !F;0!_!
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M?M':52QR[Z5>K2$A(SCZ#AH-"7EG[YPX>2,R]9JRTH\77>2;UXZ5.L8 R%H
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< - #0 T - #0 T - #0 T - #0 T - #0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g65062g49g49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g49g49.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1@V4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &!J^87 X0DE-! 0      !D< 5H  QLE1QP"   "   < @4 !5!R:6YT
M #A"24T$)0      $'&R'N^RK%WYEXQ?IGQ&?D$X0DE-!#H      0L    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585    !0 0P!A &X ;P!N "  5 !3 #4 ,0 P
M #  ( !S &4 <@!I &4 <P      #W!R:6YT4')O;V93971U<$]B:F,    ,
M %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !
M $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7
M $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B
M;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M  !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M          !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
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M8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M    "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#
MO_XU  (  3A"24T$)@      #@             _@   .$))300-       $
M    'CA"24T$&0      !    !XX0DE- _,       D           $ .$))
M32<0       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M     0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M 0 M    !@       3A"24T#^       <   ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M   X0DE-! @      !     !   "0    D      .$))300>       $
M #A"24T$&@     #-0    8              UD   =D          $
M                     0             '9    UD
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   UD     4F=H=&QO;F<
M  =D    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   -9     %)G:'1L;VYG   '9     -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M     #A"24T$$0       0$ .$))3004       $     CA"24T$#      -
MA     $   "@    2    >   (<    -:  8  '_V/_M  Q!9&]B95]#30 "
M_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3
M%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-
M#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,_\  $0@ 2 "@ P$B  (1 0,1 ?_=  0 "O_$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MUNO\Y=23PW]RMK?I;TO;Y?N/\95S_D'H#_C.Z1)C
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MTI4<RRH&LLS)Y573Q0=443AC/(<R;-##"Y9"9Y7N 3J@!0 H 4 * % "@!0
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M=3*24@ZA,]:S-H"*X7 G$@%,< VDH 4 * % "@!0 H 4 * % "@!0 H 4 *
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ME/GHZP?+4S^A9:]0DY_=U2\OMV'T!A/2GST=8/EJ9_0LM>H2<_NZI>7V[#Z
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MI+J1B2\AF!C*:?L-Q&9DB?3#88I4R,3.%3J8JEB2FFGR)TN8)GT]1)E3Q$X
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M\:8* % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 7-J,_[?YL_XK/_ /\
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MJP_XTO#_ %MJ_1RP/_!EG/\ 3&/]U#X/M#^NJA]__P"Q TBJWC3!0 H 4 *
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MU[P)EB["E9ZTTB X12:;4ZRF%.GURGJ)R+"J<9F)$CR*;4IE/SQR*IUE#$^
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MMF1/&KVJ9%:#:188;31,IILNW4J6D,P9*F$\THC@I<Z2&21AULR0MCQYT=#
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M>YTI/E74?1$;V@/?_=@6A\AJ-Z<G>S0_%7I/UQ*/9 M[\I[G2D^5=1]$1O:
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M?+?(.)-(KA(F<42997)%E ,JI DU ^3P.!#6*'C9?BS @!<= "@!0 H 4 *
M% "@!0 H 4 * % "@!0 O?>M>_Y;[UM_>M^>_P#\/_.@#1&&-3SUU2RNOI\5
MM!R1K#<'N=<9\Q.*46I=.>CPE5',J"8:B5FH61\<FE)#;+^#74['\(:4Q#.*
MD@MI"3@1S*TJ)ELJ="C4&GLKJ$EB;4JHPU)IK,"03D6/3W$H<349+I()3CCZ
ML<>/#)+>' \^ZLR)IM>MCS%S7EDRA;3$9:VI"GFS2XX^DS2;+:3.XD(*Y:WK
MU$K$E""(\:D[W54QL@H 4 * % "@!0 H 4 * % %":E-1+,TLQ4IS%(2(^%I
MG(BHB)BSR!;>3I5TO%?404@BIFTL,V4'\%8*9HD2,F"]QQ@ASI7' L+82]\=
MM1*-*KU0;IL-V*U)=;=<:SM\H[;ALH-Q;:7#2I.4R:5K22L)&2%?"*[EBS);
M<)A4AU+JFT*22LD@W%)QJ))*-)&1FG$9$=UYE>7)=>.;3\K30Z63RYFY,2F<
MOO<R&X4**4PO84Q%+6-%0;)#2<SCR%R$=3VXBUE%WJ(!9-2$Y:.&$!%)"D$G
M!6558;ID>5FE+<<DLQ4FR[4'%7%4)"5'E9##-UT>+B^!&0:ENK:2EYU1+<-M
MOF*J0MHG)"4MK<^&EA/*;"#+X+:UW_&.7<KBB(DDHS0@C).-5ZUJ1)"@!0 H
M 4 * *-DW].$_P"ZP?\ 5&ZIUHOEC/X9/YKH] LG^KW_ ,8O\A@5S6@%H"@!
M0 H 4 * *AEN7"L5E6_A=KN5U+3R4Q6XT4U")8"E3[J$+W&2T=44LQ+8(P:E
M; <2Q\4N8 +%"*@:&QMB5X E7M-:=JS;<(CIU0J,NJR%0:8Q#:)3;U14C''B
MR9"E71$OW+5EU-N);:9?=4FYNY5UL98MZU[M2457I-(@4.*BIUF349!H>CTA
M#A(F3HD5*#5.5%Q-I..AQMQUY^,T@[W<29ZU0',70B.+P/IJ@Y!,1#"H*C%!
M"207',BYC^#DP,<04T*23<!,2)<X<SVP\&7L<,A@BCY ![FFHJ"(3)55^._/
M42G)"HK1M16UN*->;QTK4IQ3,<C)E#KIY5Y*,JX2%+-":[5W*4Y4)!T2/*C4
MM)I:B(G/)?FNMM(2WG,M;:4,HD2E).0ZPPG(1U.&PTIQ#9.+D-3QK H 4 *
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MMH" G]SOT!J:,FMXWI8@6Z*C)CB2$I/+LM#) )Y!UO),D5?#*;%@7S!&/O\
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M2\M);2 -M)\[+>?"[]+RTEM( VTGSLMY\+OTO+26T@#;2?.RWGPN_2\M);2
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M OZ*O-/H'&4;YQ'G)Z0XP/Z3#^+'^=,"_HJ\T^@,HWSB/.3TAQ@?TF'\6/\
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ML( \"HW1*9U K[*EQ:"V$ >!4;HE,Z@5]E2XM!;" / J-T2F=0*^RI<6@MA
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MO%](9K&U=C<M]4-E+<W \R'W:9=_GG=XOI#-8VKL;EOJALI;FX'F0^[3+O\
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M$W61P9ZC@6P_GD57'E+)IS8OTKK)D DWI+@TSJ*;;Q:T.1/"*3FRR.GATLZ
M@5"/7&^6C)D6GG<J(YQ-%7E$&1#KW9X!NKN=^E[6-%ST7I!UE3'(DAK9"#8.
MCM@(9J=G:]&4GK!9MC9S(J+C0P%1VJXGN*LI+-3;R.NMXZX57-/759/4\!7.
MXCBP >ME "@!0 H 4 * % "@!0 H 4 * % "]M^U[;][;]M[?M^>W_G;?W[;
M_P#^E &FVGK2LM17(LDRY*\LN&>Y(<BJN-Z.'0\29($_%<'C+QI=1(S1MB#
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M1PP4T@U<L?;CJ74HZ4R ,E3XN N]B ;!4 * % "@!0 H 4 * % "@!0 H 4
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M_P"\;;,BPD\=YI-T_P"TM*2)+=^3O6:36J\ZU0D!0 H 4 * % %&R;^G"?\
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M&4K;FN[X4<M[0ZWGJHR&7G(_JH=[X..DP@$W*R.3+P)CH+E.-PB1)MT T'U
M[D)N@L@ZM)]=[8:*?GI^D?7@P];)-(SD6/RQA9?T/S>WVLT5?$B9=H)HB47]
M/4K2<[#Z>H% !@U.&4-*- !KZVWR"@_G^?Y_R 2!^;EAK%<T+JD5-'2FC,S4
M,V(;W11LZ@-7F$GQ#B)N@I[45%DN-*)&ODM%7=C)KAS<LAO%@28N?A$(;&0(
MC-1^71VXH'0,B E 'URM(@:2VJV4P\'8$ZG-]&(' K9X"6"-%$TL7,!V$"RS
M"$M@*'GC;,//+#/>X6&66-[7N 2"@!0 H 4 * % "@!0 H 4 * % "@!0 H
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MT -H<W1"%VB4/A>@!M#FZ(0NT2A\+T -H<W1"%VB4/A>@!M#FZ(0NT2A\+T
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M4Q\J:1J0-ZCLF\]%.,E^.TL\189A!T[*;@8RXF+ZZHR 07PSUD%L(">6<"V
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M+YJ)D;C1,@#=G?M\]OWVH ;]OGM^^U #?M\]OWVH ;]OGM^^U #?M\]OWVH
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M5YHQ3\51KS>X-1[8/NI'RD/)(D(TVYI=CI?* +(!%SY)!YQ+) CQ".?'3\@
MW=RHT(M(F@$&W#"HD%FF_4616C8K,$W\<T5=NM=[LA&;S3,BR.(9;49$F?)+
M^;&,/H@Q&*AD)W+J899PQ0\*%< X1MR>T #BGLA8 *Y$E&,3L2&D'Y0Y7LU.
M2JE"86F]24RS0Q?5FP1D51@@$.*CTNDD@O*IMG<-+'>0F PV0@!?*MHWTUKK
M$G2-%>,$]09&I1<3W--"(86W3EB[W$CLIB1\C+@1^RYBJ-I616O&+#+(Q]I'
M4(TDJ;93W$GBEG'QZJ, 4\3W+_1 27(]<GR.'SZ[&QA-.)BFM2M,J^9=QY$D
MI5F1 /S%=;D$_A/!]NRPN*TBMTY-6#],H+O/CK20(3-WQSQ /TI;F#H>4T5M
MH6<+C)P#-;<<M1FJC>DN6VNZF<CQ,YI&=S Y)O1N/Q*=S:54)9ER2K9+Z*MD
M5Y52'DM-U94E!OF,4P,'\_SL'51]RTT*-U)9:(W81S;Y"/%9CK+/\!R7+B2<
M2#4=L)]1<V"WA,@_"ZD>1L([DM],U<;ZD;.(;M0'(H$'8G+05P;! &/SW)W0
M!F(;OEI_*W)'8S-1,,@VD*5K-3!KGX5 TXJ"J5:&+ZLV",CJ,$E@8J4)>)))
M>53K-QS2C+R%#&'R$ )#)>YDZ))?45=3D&&15L9QO@*0G65 DF6$-(>3B!:D
M7LJP+U0F^^DI%>+9$;L+Q@5'9+E(*C-,&FB25AD+-6-*9X\ ;YT * % "@!0
M H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % %&R;^G"?]U@_
MZHW5.M%\L9_#)_-='H%D_P!7O_C%_D,"N:T M 4 * % "@!0 H 4 * % "@!
M0 H 4 9 ;]&$?VI0_P !"LZ_DS/WK_[K C-_*I'W4;_=\8^L DA0 H 4 * %
M '4.$"*A@$$?)%#P0!DL= #.%@3. )PF-B8*&PL!L,\0S)4?# 8L/A:PH V&
M(@6>.>-LK8G6&7R2E]EIY*'&WD)=;2XE#K2B6TZDED9$XVLB6VLB)2%$2DF1
MD1C,Q)D1E+7&?>CK<:=86IAU;2EL/H-MYE:FU)-33S:E-NMF9H<0HT+(TF9#
MMUE&$* % "@!0 H 4 73%_Z.4_VT/_(QJW6<^3R/OD_N$*':WY7%_#J_,4)L
M.W4 R,(8,HB2..+E?,489/*""B97_/EGGF%?++*_]M\KWO5B%3'5!;C3,8<:
M71$ </A9X<8"GD!<.&'GD&)CP\ LL>$&)CEAGCO[^.>.6.5K96O:@#EY+-FW
MYV^B_E_);_HPE^6_S?\ N: %VLV;?ENWT6UOGNF$O8T .2S9\GT7T82]C0 Y
M+-GR?1?R_F_Z,)?E_P#X: ')9L^3Z+Z,)>QH <EFSY/HOHPE[&@!R6;/D^B^
MC"7L: ')9L^3Z+Z,)>QH 7:S9M^6[?1;6^>Z82]C0 Y+-FWYV^BV_L_1A+\_
MS?\ N: ')9L^3Z+Z,)>QH <EFSY/HOHPE[&@!R6;/D^B^C"7L: ')9L^3Z+Z
M,)>QH <EFSY/HOHPE[&@!R6;/D^B^C"7L: ')9L^3Z+Z,)>QH <EFSY/HOHP
ME[&@!R6;/D^B^C"7L: ')9L^3Z+Z,)>QH <EFSY/HOHPE[&@!R6;/D^B^C"7
ML: ')9L^3Z+Z,)>QH <EFSY/HOHPE[&@!R6;/D^B^C"7L: ')9L^3Z+Z,)>Q
MH <EFSY/HOHPE[&@!R6;/D^B^C"7L: ')9L^3Z+Z,)>QH <EFSY/HOHPE[&@
M!R6;/D^B^C"7L: ')9L^3Z+Z,)>QH <EFSY/HOHPE[&@!R6;/D^B^C"7L: '
M)9L^3Z+Z,)>QH <EFSY/HOHPE[&@!R6;/D^B^C"7L: ')9L^3Z+Z,)>QH <E
MFSY/HOHPE[&@!R6;/D^B^C"7L: ')9L^3Z+Z,)>QH <EFSY/HOHPE[&@!R6;
M/D^B^C"7L: *9D5'2"BR5#*I:>6#R30L\L "9<+"^=S)JU\KXX!XVOE>UK6O
ME>V_O6M;?WK6JIUYYYJ6T3;KB"..DS)*U)(SRCI7W$=U]Q%L%ZLO&CO07U.L
M-.**6M)*6VE1DDF63(B-1&=UYF=WBO,](@.PDN9E>KA=RM'G<K6'MXOI%DS&
M'JL?<M]4-A)<S*]7"[E,[E:P]O%](9C#U6/N6^J&PDN9E>KA=RF=RM8>WB^D
M,QAZK'W+?5#827,RO5PNY3.Y6L/;Q?2&8P]5C[EOJAL)+F97JX7<IG<K6'MX
MOI#,8>JQ]RWU0V$ES,KU<+N4SN5K#V\7TAF,/58^Y;ZH;"2YF5ZN%W*9W*UA
M[>+Z0S&'JL?<M]4-A)<S*]7"[E,[E:P]O%](9C#U6/N6^J&PDN9E>KA=RF=R
MM8>WB^D,QAZK'W+?5#827,RO5PNY3.Y6L/;Q?2&8P]5C[EOJAL)+F97JX7<I
MG<K6'MXOI#,8>JQ]RWU0V$ES,KU<+N4SN5K#V\7TAF,/58^Y;ZH;"2YF5ZN%
MW*9W*UA[>+Z0S&'JL?<M]4-A)<S*]7"[E,[E:P]O%](9C#U6/N6^J.\*G$+)
MY/.Q$I;/,R>MEE8L#PLK88$N#:]^!OWMCPLMZW]G"O\ />LRI4DF&E9=Z\W7
MB,\HJ\R)+%Q>/Q%>=W^9Z1'1"B')D%FK%Q-1S(LDBXC,W[S(L/C.XKS^>XM!
M#H["2YF5ZN%W*PYW*UA[>+Z1(S&'JL?<M]4-A)<S*]7"[E,[E:P]O%](9C#U
M6/N6^J&PDN9E>KA=RF=RM8>WB^D,QAZK'W+?5#827,RO5PNY3.Y6L/;Q?2&8
MP]5C[EOJAL)+F97JX7<IG<K6'MXOI#,8>JQ]RWU0V$ES,KU<+N4SN5K#V\7T
MAF,/58^Y;ZH;"2YF5ZN%W*9W*UA[>+Z0S&'JL?<M]4=4KX$.Y&L2?@LWD1-9
MD3N)79#&1,Z&&$*(3-6"X=RYH,(< 7,N-; ; ,8+/+"V(F%[XVZBX\;A-35.
MFRXIEXFY&,VGDI2I33A)4>!Q*5H4IM5RB2I)F5RBOS.TEI@F3?IR62D,ID1S
M=BDV3\=2EH2^R:T))UE2VW$)=1B0:D+22C-*B+M;"2YF5ZN%W*R9W*UA[>+Z
M1AS&'JL?<M]4-A)<S*]7"[E,[E:P]O%](9C#U6/N6^J&PDN9E>KA=RF=RM8>
MWB^D,QAZK'W+?5#827,RO5PNY3.Y6L/;Q?2&8P]5C[EOJAL)+F97JX7<IG<K
M6'MXOI#,8>JQ]RWU0V$ES,KU<+N4SN5K#V\7TAF,/58^Y;ZHNZ*P 0DU4L$"
M$%:YX.][!AX86O?B,;;][8VM:]][\F_>K30'7'6'S<6MPR=(B-:C49%@([BO
M,[A2;4LM,R8R6FT-D;"C,D)2@C/***\R217G=R"D-T#BN8IOT5:EHDT_K.2'
M,+_BEQMUC&@W(99HAU1.!!W-MX)W$_\ G+7%=:3@H-<)PAYA71A%C%1R'+X%
M\AP]^*N/GT>4?ZE-.\@MM[:8-+^HC0)IUU#S]I3@H_I7A%9TU%YH>ZJS83UE
MNZ;I):"(&]'] \?"NHJ!#K8Y3*#Q076_5"-K.!3%3%TVEFSP!WT'39NOH*R2
M?$CI$E/:=%=9TUR>HNLTXM/R]&S276?N?.I:,73@T4L<T!=FR8D:AW"Q@G$9
M9:"GM=0'<IY30%$VVE1<W@#/2YIZW9Q8C2?&;F]I@FM+>3#F:/45ER48TOK#
M8<2:[= 3 <R&IG4GDNB$A5*VN$Z^6.E!*@EDA-;:>&DC)5F48S5% '\_Y#+2
M02W:=<<FH\]&2/K&8+6.:BFT78;65%O1V["Y?3"A%7F77EN)5W%_-YP!R2^9
M)5&.L8,A?+-=+8T&-LTB@/=WO,VIV/ %G1?"^ZC.S7!HP>6JHM*ST;4-2DC/
M9Q.]%/Z>VQIU1F6K;FJ]8N<ATXQ&LYU"3\)O/ZL'>^PW,52Q7/'A9"<2,(@*
MIQOI[=%2 "P932=UBS?^K?D=?4IG@*_#QB.5!IN[2$1B,[IMO,\$F4M TZ(;
MO2S;\3]4F,! SFFW797.-UAE7X8Q&5C:]D;8YIN %9I\7;LT[5:/,E25M0T?
M,HHX(83RQ<-;TP"R+C$COUWR>A2$<FTR2;KF:RI-<=Z#EAEK*T<9.0[:R=B>
MGGDX-V/I,,Y9@&.;L0[M(Z,(>#>LS:@F?@36X,8TC<F5S3:6$., S'^JT&9W
MRIC#-19&%>@;F2=,Q/%52,@12AA<.JK?2KG1%I33 "M3"%_M"AU/>1PVXW\1
M=AG1FV\6^11DW32*S!9@%TC1F64B8*F*\DT^WYN)ZP;R(KJ!W!DK;$--;#-.
M 6,6><0044'\_P _S_D+5U-P3NGZD%K$AEOG=2,[M52C5R-[3PX'0Y='ZC!;
MQ80L-L )#3I/;+I:1!_N'4"9GP.0CQXP&BM)G!M@5"%%7#+9*6:Q@ QYF,-U
M?E/50M82<T97STY)6L+3Y*+50G<[X+64!M(<0ZZTE?&7&.O,U2;SC--(;38"
M3<-T%69J"HXERUVZK8/=]I2FZ'" ;4ZP6/NMIN=)V3=)T@[##AB!WG-\-.!3
M,QQM1?4:'%A^&&SI>#3W&F"BX,T5RF"NII.<SCL(B8ODF U5M4NUA327@ :Y
M1>W-V,#6H. E-7U2K$=#+3G"(\CE'1XPI);"@+-[ S3C&J4VY5R6$YRQF6A,
M.10D$=@W<;V,9&2Y19023SP;CE+ %3Z<XAW9:)D'3I&Y3\(LD69UHU2K'W<^
M=,SGC;E.#JO?ZQJP7]2B@=5EB4W:Q'GII/-?'3P/'>1QR%'>*<%5R3?6KY';
M 'M]N=S+U'LO29%N.KI\/][ZCW*D@NB6;R"H,E0.-1TGRI4H99J!>/TA*;9=
MMHP*>"(4" S5S(I\ZIG32T?$-6XH!^,[O%\PW<H 4 * % "@!0 H 4 * % "
M@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@"C9-_3A/^ZP?]4;JG6B^
M6,_AD_FNCT"R?ZO?_&+_ "&!7-: 6@* % "@!0 H 4 * % "@!0 H 4 * ,@
M-^C"/[4H?X"%9U_)F?O7_P!U@1F_E4C[J-_N^,?6 20H 4 * % "@"JY;;<E
M.=!()\8OH)AJN2N7"6E 9,(J-C+9.!#$EC$G<R1-F":V0 'LJ(1@H(5QR4R8
M!<Z-8F,+F'6[3P*_483+%GJR5&DG*0F4^J.R^2X#J5M2B:-QEU;4ME*RD0W&
MC;(Y#2$.JR2E&FWV,JEEJ349,FUEGEVBAE"=7!C-RI$4VJJPM#\(WR:D,MOP
M)#C>:5!IY+IE$><<81ET()4R:;50V2WTULMTG8DE)8%@@<,A,QS)@7*]Q#)]
M0-BWR,'U,^8R$.**B:$%-GC@PQHR*(,+GE?:TRFPZ1"8I\%K)1HZ,*2,S6XX
MH^5QY]U5ZWI#ZS4Z^^X:G'G5*<6HU*,QHZQ6*A7JE*JM3?R\R6YC69)2VTT@
MB)+4>,P@B:C1(S1(8BQF4H9CL(0TTA*$)(I%4\:P* % "@!0 H NF+_T<I_M
MH?\ D8U;K.?)Y'WR?W"%#M;\KB_AU?F*$P/J*N1Q-F,D](P3R@8HXAXZOYD@
MPBH&%Q!3)GAHXH18((/'(07/,?(,/#&^>6=L;7O:Q"IB!QW+S5E] $=43.N+
MI0:X2B<1Q7)'<GHSU00U9/OAB?2Q%AM$5-/P42-Q [&R61BQDM<3"PP6'#QW
MP":&U=:3RI@\?34(D2)@B&39PVY\RQ4J7!PN(,8,&!D/ $ $(/'+,047/$,/
M#&^665L;7O0!V-K<O0B5V@,>X: (>D2:BN!<-ME!78Z6W(GXK&9]O)$BIJDN
M$L6ZL8MYP9&TDFG#'RV*$OYX(:QD,7PLF+&>*8=N =RL!< F&UN7H1*[0&/<
M- &&2'<(X<U<- R:*YFWUDTW%_!(>@*EFAN$B"5,G4)7Q)) ]TU9)ESI(P:2
MSM@#Q<$V5%% P#,!99@&9VMR]")7: Q[AH ;6Y>A$KM 8]PT -K<O0B5V@,>
MX: &UN7H1*[0&/<- &%L[\[N+)H6S:%W9@BX.3-KV>@-W%BW1#PB8&O9(G@C
MPEBBB*00J?@J7+6(Y'@Q"F(]S&&0=@#]$7:*J*JXA)F3145ML"IX#E1R+S!-
MJK>'5B(:FE@KB>72!#:2*I)HH2BGAGP2^9PB*&;+V$+YXB7 ,QM;EZ$2NT!C
MW#0!$&K)B.^K#W9*Y';QL5))RB9NU9%37#8NGK&9X-(/CW2$XY8$DJYI:G@G
M&A." >S3CV)806Y0Q8, E^UN7H1*[0&/<- '6.*ZRG%#2@H)R"1($2PYPZ>.
M.?,J4)E"H60YDT:,CH> )<L7!PS&''&SP"""PR$$RQPQO>P!UT=QGG"D):^@
M -E<0EQ.(K"(MH[NQ4TA82%,L$=351+4B2,.34$Y0)C@FR)XH,,6-EA@AP!1
M A,,[@'9R5UK V"0S34+$\8+F#@!+)SYXFQRA,4J";- EKH=AA"Y48\2",#X
M89! "G"H8N6.9@*V8!V-K<O0B5V@,>X: &UN7H1*[0&/<- #:W+T(E=H#'N&
M@!M;EZ$2NT!CW#0 VMR]")7: Q[AH ;6Y>A$KM 8]PT -K<O0B5V@,>X: &U
MN7H1*[0&/<- #:W+T(E=H#'N&@!M;EZ$2NT!CW#0 VMR]")7: Q[AH ;6Y>A
M$KM 8]PT -K<O0B5V@,>X: &UN7H1*[0&/<- #:W+T(E=H#'N&@!M;EZ$2NT
M!CW#0 VMR]")7: Q[AH ;6Y>A$KM 8]PT -K<O0B5V@,>X: &UN7H1*[0&/<
M- #:W+T(E=H#'N&@!M;EZ$2NT!CW#0 VMR]")7: Q[AH ;6Y>A$KM 8]PT -
MK<O0B5V@,>X: &UN7H1*[0&/<- %,R*.KYK)6YE.) ">#0K6P"5!3&-\-I-;
MV5\\DPO>U[WOE:^/ O:UK6OPK[^]:IUY+)RVLHXX@\W3<2&B<(RRCO*9FZW<
M=]Y77'R$1W\MQ7FS"I"8+Q-,MN)SM=YK?4T9'D6.3"3+A&5UQWXBY3,KN2\X
M!QA[FA?KF?V.M'@B\^]PR.TBR92;JK'%J[*'&'N:%^N9_8Z8(O/O<,CM(92;
MJK'%J[*'&'N:%^N9_8Z8(O/O<,CM(92;JK'%J[*'&'N:%^N9_8Z8(O/O<,CM
M(92;JK'%J[*'&'N:%^N9_8Z8(O/O<,CM(92;JK'%J[*'&'N:%^N9_8Z8(O/O
M<,CM(92;JK'%J[*'&'N:%^N9_8Z8(O/O<,CM(92;JK'%J[*'&'N:%^N9_8Z8
M(O/O<,CM(92;JK'%J[*'&'N:%^N9_8Z8(O/O<,CM(92;JK'%J[*'&'N:%^N9
M_8Z8(O/O<,CM(92;JK'%J[*'&'N:%^N9_8Z8(O/O<,CM(92;JK'%J[*'&'N:
M%^N9_8Z8(O/O<,CM(92;JK'%J[*'&'N:%^N9_8Z8(O/O<,CM(92;JK'%J[*'
M&'N:%^N9_8Z8(O/O<,CM(92;JK'%J[*.\,*H>#B5KDRUL;&3U\<MNSO>][X$
MN%:^.Q6MC;'>QWK\++A<*_Y,>#^7,I,;(-?'.W91ZX\W3>9X6;R,LXY+N2X[
MSOO/D*[ECH<F9R^91F3,VH]Y9THB(KW[KCS;EOY;RN*ZXN4[^3H\8>YH7ZYG
M]CK#@B\^]PR.TB1E)NJL<6KLH<8>YH7ZYG]CI@B\^]PR.TAE)NJL<6KLH<8>
MYH7ZYG]CI@B\^]PR.TAE)NJL<6KLH<8>YH7ZYG]CI@B\^]PR.TAE)NJL<6KL
MH<8>YH7ZYG]CI@B\^]PR.TAE)NJL<6KLH<8>YH7ZYG]CI@B\^]PR.TAE)NJL
M<6KLH<8>YH7ZYG]CI@B\^]PR.TAE)NJL<6KLH<8>YH7ZYG]CI@B\^]PR.TAE
M)NJL<6KLH<8>YH7ZYG]CI@B\^]PR.TAE)NJL<6KLH<8>YH7ZYG]CI@B\^]PR
M.TAE)NJL<6KLH<8>YH7ZYG]CI@B\^]PR.TAE)NJL<6KLH<8>YH7ZYG]CI@B\
M^]PR.TAE)NJL<6KLH<8>YH7ZYG]CI@B\^]PR.TAE)NJL<6KLH<8>YH7ZYG]C
MI@B\^]PR.TAE)NJL<6KLHO"*LA\DU4N,$&'?;@]ZV V0MKVV?'\M[W!#WK[_
M .3>WK_/OU:: 39,/Y-:UEE2O-;9-F1X"Y"(G'+_ /.\O\A2;4*=5)C99M#9
MY!5Q(=-TC+**Y3,VV[CO^:X]-_S"E]?>G]YZJ=&&I/3M'CE36D]I=BIR,YMK
M*V.IE6_=2/@X"!HSE,HP8RL6:[FP S;3F,)Q8Z< 05=1% ('Q,+$A]^*P/&K
M43HRW1Z4X[$4M.4*09H-5UB7,EETQAIBU!N*.'P^4Q$T_#Q]';[D68HR;\;H
MBKBP9+V,\WV822CB& RDY&5'4T)$5TOD29 ,%J3W,/7_ #.Q=120?F)_O=4F
M,#5.FGVRM:K)428X6&^,]=.+[TPI#<8Y59+,N.10E)CS 6/&VRV4$8@1=MVZ
MY#!MHG\$D@ 8W4)N?6ZD.&&) +PC*$HHLN2#J&U&O1&/+>O;4@&:B>,L$Y:&
MTD-QIB$9.36<(F-<^OJH+_**J0X_"YL%O"+* Y0B9!5:0#^S[/\ ;E_\1AIC
MW.;=) QI[6(=## 6Y94-2V;;46CJKD"!UMD*TUZPTZ7TF2RRE%BVT#:VYD*+
M@U>Q)J*JS@SSKI-IQ!UDUQODC:0H ':,:!]V,S=DMG&;J$D%F-I;@$9FQD2=
M^LF17HJIR<!"D:-%,BYR+.9%23@Y<O)C??3K.ZF6JRVZ\03KG$=>#V4;*@S"
M1 #:2*=$VL:/-#>KN,V@75HXE>9M:6,]-%I8:JGZX7\J0"<7X"'>D2J.K(<)
M0D9O2.]XR83]C<.1MM4EI 554B> =8A>P;F# *_,:-MT_-2-"JXAO5Y,E!;R
M9#021B=UYS'("?";-:,@2DL3G&<E-E6;R80U7/.;HU7&&ST&5'W@K+,=KA+C
M$ERDP6.CNAV/Y_GQ@*:0-S8W4UHL!N'$+4E-YV5\(XC]$<9ASZWYQ=2!FZG%
MN?$VQG/A\LEN1X*:#D8/ZP#T)/-H*MDRQEHX-\9T, 1K!@J950 7C*_Q?.,X
M[-SBW5!!#D >"M4$LHJ^XP)3;B*I2-K&G!])1)FNO2'#18D7)ISJ<;M!;;H/
M:O4N8E9(?2*EXN]A)3A3%%MJB<VB:8A$0#.(6YZ[I^IQLX,%?4;*C9?;;TW3
M*@0.E"ZP9E%(-J57E,Z^>:Z<_EM(7%@^[CY""UE8:38>[[/S"?B]2740XD.)
MPK<?-9PIX!U9#T-;I.L9"*L:)ZTQ4%8B-NQB*R7+KYGB091:K="U:.>4%( C
M.Y1>8,@K+J+1P=1"P(:E(QI$*HUS;)&=;O2TTNB*H<\EWVW_ /*[^?L%Z:8M
M%6Z%Q[I=UM(KJD],;NKV>]..GIEQ[,YN0#KK5?ELBW26WX?<;U<;R#35!<+F
MC,@I!@V3>8I!3<&8!@)U9D1%4/(I<.!4!C17NIIV4M,SC8SU?<,PZQ7A8^I1
M:N:])CG%T,C'&:&2ZG$XY%?#N PPFA%=T7)KM9B;&SP+3$C-DL<\$(HC9'=Y
MQV,9_/\ ]O\ E_-_* L#2IHHU2:/]*.M7%=*6)R*X="K.8L8WBEQ'EQX7E&+
M6=J<-YXMG) +EUD%:"5I"9]VF:2KW4CBMGE9/Q#-%0[Y@%80+H6W2UT*\9N-
M\S-,L3QH$:?S_3& MZSITDYT->1#>F"'$=A.:1' J*"$ZWZR5C5(V'9*AB"G
M(,=:#62#Q]NJC8+HSI7V9@ 0$SN?6ZMJT56:2\]'VK,<\>2D]Y04J;HA.*D\
M'F^,],,@QT[)NSU(#)P3P3XM7Y_7F9)PFFD,P$RQ4ENG3^;3+CG<F&* 9ME:
M&-V%8\2,Z!6#)R='I%G1R7":\E%=1KG%2VJJ ;E4R=+K<BU/899NG-B;#1U7
M--;D\)8)6.)**J.!&DIM-]3<P:MF0 -K]*VBG44Q]9D!:DI#8;Y;C0:D%:FX
M:--IUZ]9DU+...B[W?T9/F/#3D//T4H6D8DLY(D@IQI!&,.X%N&#L?K!I:.F
M&*T2K0!_.C_P'NA0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4
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M%J69.I(C4HU&18".XKQ2;4LM,R8R6FT-D;"C,D)))&>445YW>/D%J5OQ5PH
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M*.*Z18:R4JFDXH84DRQG'@&+)YX8',T2L/A_N#6+"A<;C_NY\*WY* ,K0 H
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M?_5TP1M8<X<O7!E)>JM\3_!#B$WI ?T?_5TP1M8<X<O7!E)>JM\3_!#B$WI
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M:>B&F0LI+J;04"BRHDDID:$ZUD$5UJ2B1';DQ9&%)1Y#J#6M&S=>A#R@* %
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M;RS?<4MZYPI0:9#7/)@J,<2[&DT9R N[,J8-GQ<;N$NX@G874,1,S5Q@^(<
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MA^V]$,=M5<*N-#;MBRT23;I1(Z855M3N3*9DT]/'R*@*BD=*ESIPDE)Y905
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M ",:MUG/D\C[Y/[A"AVM^5Q?PZOS%"SZL0J84 * % "@!0 H 4 * % "@!0
MH 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * %
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#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g65062g52a40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g52a40.jpg
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M0J$D,C17<7*!E]4S-9&QLK/!\"524W-T=2<V-V)W@J*TM;?1X?'_Q  = 0$
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ME.[:[L/1UEUKNPJ!"2>SOS!/>U[30]5NQ 'XD_7VR]3'J1: <.(1-1Z_T_\
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M,3[2R#G7RO;?L5TI*'!O4*YZ;/YMTR]U>57L0[$>V (@7VL#:?KBCBZ?^?\
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M"K6"[[4FV3[7<[+70D=AQV'//S]?C]>./IJ,FP>R'B":RU?HAFK;(["*VEV
MVR0ZIAZOVSUCUFH>PF]B;LTM2UC=]Z^J-&K0$A:]==5MW";%.)M&*O '3JM<
M;"\09OE&KM1.H:Y<+R>P( ZNQ;T!/8_+J';Y@CGMK\'AGB6Z>+[\ TZT]X#%
M<+]I>V=K:O%3UKH?9%W+3)>N]>2>FXZI,W77$BMKT-:CC-O&[6F"13<>G3JW
M3:W),:]!3[))D-4]T\<\>@'J?ASU$\?'Y>@X^9U]!K'B>:_M>\Y%P)=O@\/8
M792@WG;9K0VO]-[4)U>K%^B5+;"#.KL78%'LX(G1F.U-?*:YVA 1$L\VKU"I
MZ_GY; 2[ALW8=D:'I[<<?HGY^H8^O'?]'T]/7Z<:]]HL/BZ6]VUU+9U4V;/U
M[;/#\M8BYUJOZGTL=K$COZ:ZFE'9^OH+KHLJ<,=<9U@D^T653%*C9'8Y]5 :
MMA#4><BG6GN\]OUCQW(]WGL?AP?]CSQ\=?'9#/B,VG6':+5IVF=C#!YS3=EK
MFJ-6"])=<C/5!VBP-6Z<<UK/9.F:\B\EMODKPO88T_26R5K@19^)\$K1J[3P
MU9,X:IV]WTY)[GD\^I!Y[\#MQ_L?75IV:^]^^M]T(ZPJ&V]L+N_;/Q >UG7F
MC@-PB=4$R%9J^V[76[WISMQII,NEQ2MOU]HC3U-V!)LH3.+3211"UBP,^KC(
MH$>+&T_'_M^/X_YQJO _!0>WTX'!^7)/<_#U^FNGII&6VVV\N+=RVA",NN^C
MVCN4IPG+CGH0VCUKSCU+]"$(]6<^E"<>6,5UPU^^--.--.--.--.--.--.--
M.--.--.--.--?AQQ+3;CJL+REM"G%8;;<><RE"<JSAMII*W75YQC.$MM(6XM
M7DE"5*SC&6FM7P;Q>.I=B8EL H6[B]KC;/$:B;UN.T[9YFQY-QL6JK_N6N1/
ME*/AR>-26H^L;G+?C'LB"U7G"'A]X%U=Y+F6VN720.>.W'/J/3GC]_<CT^>L
M#[][M]'.ULWK%KM6B6>UE:V=MOK.,B6:[ZS.QZ#JIKM=K0G<ZG*=M96OO_"M
MB%=0EHY8A1U_#&I]7LN =B*QI))D-,:<,O)Y(([>I![$?P!_B-2L"]\]15'L
MA>>H4W6EOU]$U;>.NVBZ'8Q];]-"LMKW5KFS7>IU@##&0HT&L :[6:>]"BO9
M><BNICR&F(8^-!8][:<$CGGGL3]> ?7^OX:BHGNWX7\[>U4[!@]%6BV[]N+&
MK4A]M5/K2<L-PP=W,,V-J_3HTA8QPYUR#>+\/UI<=85V?)=P4C (_P &+%A%
M*5+D1VJ\-Z<@>O8D#TX)_=Z']QX[ZD_6/%3ZBW&?K2/7C>Q)XC8\+3;TBX(U
M9<TTO6);L)9"%,TQ5-OV50W$"@VF_P!R&2JP+&$%O(A$E#WC<D4+,A2)!JG2
M>_TY_?QW/'W#O]VKUJ/B&=?[CU<D=P84/:HO3#YZLUBH2K!J^S"K;LTW=SM4
MJ%(B:UIKD=9ZV-W*\W(/2*U.BQ6AY.PIG>RE8$0G2W&J<'GCX]^?IQW/X <]
MOZZM1_Q0^JHS9FI].VJ9LZA;(VR[4(<2I[!U5<*68I!?8NQK/J37 ;8D _ A
M2Z_,V!L6GGZ[49,1@L(*L,C;0DFU3;#7+&6:KTGO^\_?P 3^ ()!X(^_G40M
M4>.!J>?0X%_W_1)6K!MBHG54[4(55+.W:;8+GV1UYN79$BG)?*#:B(@?+ 33
M9? F9/*1I=QGRHX,*-=LDP0&*-.D_#OZ\_#@ \$_[ZW<@#<&R@@MC&8EX&GQ
M(TV/P0@314_$$K#9G1,319)B*1&R\1WV_>8$^+&FPWO7'E,,OMN-I:XZJW&F
MG&FG&FG&FK+OE&';"!I %"]L"QDSH\_$RFVDU4"^78R'FT,J+ I4.<J&O#ZE
M/Q,O>P>6AI;B%*:1G#36&?Z*U,_SA]@/]_.R_P#C_&FG]%:F?YP^P'^_G9?_
M !_C33^BM3/\X?8#_?SLO_C_ !II_16IG^</L!_OYV7_ ,?XTT_HK4S_ #A]
M@/\ ?SLO_C_&FL5E.B54*[=JNQW]F;7R.J0F,S"'R;[:"MHDF&B1"6I;=W*%
M9)D(#Q&D,LJ%A,Q9$AYR8^@A"4XKV[34[4IPE*4X\\X3C"<94I2E>6,>6/4I
M6<J5G^*E9RK.?KG.<YSGC37]XTTXTTXTU&SN7M^S]?.H?:;?-)BA9URTKUVW
M3MBIPK)%F3J[,LNO-<V.V@XIZ$.("9\L.^3$1FB<:"5&RWX2WFHT^&\I$AMJ
MJCE@#\2!^)U!LKXMU(!?K'K"=$[DN^U-*!-F'-N4"@B1ALW6 E$G:/BU6W9%
MQ2$HH]6=P"=^TZ]4CW*(1+LT83>2DT>[+J$V#(:KT^G) !_S\1\?W:L%_P 8
M:OK&P=E@M8W"YT>3H1.PYNNJ ( ;!MP*S-]H<]=BI8_L"B[ LD,74JVIMVQ6
MJOO:S5;ZJ";=(6=(6R0B=!A-4Z3SQZ=N>_(^'/RY_AQ]>.^I!["\0 RG0/2_
M?&EM6P[Z/[8=@M,ZAF!'[Y1"*J8'V%//P[))9L56MQ"HFSX697)P*.W L,J,
M/++6HY$:DCIX5#50O<@GC@$_>1\!_7[M1/TQXREA(ZEID_;O6F\$-P70=J2;
M1Q&N2>OAM;VS^NKM"<ZLU-RK(L6QI[U*3$OD02F:S?C,!4@/.R>R[ ;PZ-BO
M\_S[]"OR/Q([@_ <_ ?>/W?+64KMXQ^N]<#MB'[KU\W"&JM*9[*A EE09UB3
MB7C:/4"*VOL!K<:.&7.4<"NUPC'L0RLVT^+@UFX.50O+B2X,6=67#[3I^HY[
M=N_H?0^GU'UX([>O%W[A\6*@:ML^W:8(T?M+8UETH<[*?.T&O&-=!([.O^J6
MG-#[AVQL&"1N%L PYS4>#V(H($%56'%V,L19L$K$6-"&M.3'^?Y_XT"D\=QW
M('Q]22!Z _(ZI?63Q+[!MWL*8TU>-0EA=6O78*]ZGT9LT&_760S:*=U1U7V=
M<J-_#2;F2M3]J17[-<'I-M$ (%2<4S7 <2*[-^*$6FJE>/W $^OQ/'RXXY^?
M?5GGO%;&AO%A#]&5$]3)U&_$#:<+$GC#^-O,]I[12"VX ;42"@SD:O5#5)@A
M==S9&0#A#]<5O%A%&HN8<@8Z_P __/\ #\=4Z>5)[\CO]..>/QY_AJ(@+Q<>
MX.L^N>G=[;I#]<]IK[/=+=E]E=7@=;T'8>J5:>NM"N>DZ:T'VY,.[>VPFW:J
MEKW>,*D+J$8H)0>FJFH.1CF"$::/:Y%%ZB!SV8 GD'MP3\AW['MZ?7MSJ:M]
M[*=T=56#7G7$YN'I7>-Z[N[)4O3=5VO4Z!?QH33=8L6A]F;R,SMR]>).Z2YA
M-Q),ZN+5W2,"-N\0/V1%,P3Q-H.H#/&G&N( /)[\ <D<CGU ['@_/D]OAK8K
MUNM=_M^IQ<[:=STAL#88FP7BHVRV=>"!:7K J4IMU/5=680\X1-E:I9HC IF
M%?*-,L-E<I5WCV"LHL1AD:W.=:H>.>W/'U]?\^O;GUX'IK.W&J:<::\). T5
M&D!;STR.R2@RX#L@?+?@3V&IC#D=QZ#.C+;DPIC27,KC2X[B'XSR4/-+2XA*
ML--1S_HK4S_.'V _W\[+_P"/\::?T5J9_G#[ ?[^=E_\?XTT_HK4S_.'V _W
M\[+_ ./\::?T5J9_G#[ ?[^=E_\ '^--/Z*U,_SA]@/]_.R_^/\ &FL7;9Z*
MU;90$0 8V=MN'&8LHXL4<L^P[=?&'!D.*1;?8&![&9D"HAEYV2PB(8>8?4/9
MS*4F/)PXJ.ZTU,&D5"!0JH#J N>>*0 ,%N#&GV8U.L!N2VWG.<.3BI!QQ]Y?
MFK*6VF\,Q(C.&XD&-%ALL1VVFKJXTTXTTXTTXTUYY;V8\62^GR\V([SV/-/K
MQYMMJ7CS3ZD>K'FGZI]://[/4GS\\--:8NN7BYCMG0NN0:RZ?OAF3M,7U$#7
M7;X&!2:;10U_[?:O+7_73,77!':=UNT(:_* D1IZ'#-V]JJID0%XL5C0IQ[#
M7(KP3Z>K#CGD^Z3SWX _IS\OAK-!3Q"3E0[C;.ZXW73DYBC ML]4M*:]V(%/
M Y$HQ<.R%'OET63LHJ291,A@QB*<\/A,PA>)B'(4MZ4Y)R3'LQVG'8'GU!/W
M<'C_ 'YUA@3XS51M<RG1J#U>W7=6;>[H$6B:/LFHQ,<39^SEYW)K73P"=\R7
MD.Z[\8N&F3;9PM!1)&5T%,;+RGGGV61<]JO0?7D#]+Y_Z?7T'W?CJYJ7XPNK
M+TU0C0?1VX<48FSUMA[?NLB9KAN'HZU=K]GFM-:AK1@&JZ8LE\S(V #?BV<Q
MKX4<' 0<\690LBXX2&BVJ=)_]W[^GGG^G;Y_ASENI^(T%/\ 2S^FP9T1LVJ4
M^QVFBU/4U"G'-=$+MM";M&^TO4NNY\1T;:WJS4!5FV==(X##UP.BI@D,/DV@
MQ!A0GHL9UIT]^.1Z$GY#@$GX?(:LF1XJE5#[QUEU[M777=038]I<HT798X9+
MUW>8VG)6S=S7O1='?,3*'<+''M :7;-=G[!9"M?<4NDT%<,_9X, JR;K85IT
MG@GGL#Q\N?0_'[Q]_P /KAWI9WQVIV?USMS:FRZ1I]-QTKTOT-V%H1$'42[+
M@R[[LIN_25W@)DF;0;)1:U(5JBLQ(T$3/&$50'2D<F7)^VAK@-590&Z03QU<
M?N[?]]85C^-#;K]TXIG8C6E5 C;),T_VCF%&[73WY]>MFY.N'0^P=ES>8(*'
MM0+<=::Y1L0;'@AF[5%L%JOU&0Q.&1JZ#L];V%):='!(/S'Q[\$\?+U_#C^&
MKU:\7:XT(U=RVV:D-.56CDNV*LU365,4BT60'HH9T857?=+3:MKPA(<\HOVB
ML+<V#(K9(;9X;8KT%J0[6Y*KA0?'Z'_8'_?3I[#CX]([GTZNKX >G;]WR//;
M+5S\8RJ4D-L=,[K%N>9?]) >U5SW;KZ)9]/HD:^HG4E&M<WRT,6>;?8M<N7Q
M96X*!D"#JDLB<=9D6%QV%AP+"8.5U0+SZ'U( Y^)/P_=W[^GI\];@@95HZ$#
MG&&G&&#(H>599>RG+K+1&(S+;:=RC*D9<;0]A"\H5E/JQGTYSCRSQKCK^20(
M.86&'Y@85+.A&)\8,:DCH;Y83&*I804CC"3K*YD!@DB+&3/:BO--S$QV$R$N
M89;PEIJJ\::<::<::<::<::<::<::<::<::<::<::<::\!49!-C"08HQB4-+
MP)@PC%RXZUB3!GQW(LMC+K"VGF\/1W7&\N,N-NHPKU-K0O&%8::@'IWPN^GV
MBR5-+T&GW1LC0#5..U*18MJ[%M?P>7K[4NTM%TV-%9L%CGL-B@.J]Q7:JQ1*
M&DCGDR8!J;'E6* V74UR+$_'UY^ ^)ZC\/F/]O32I>%UT\HMBU78ZG3KP$<T
MZG2#]0 PMO[1;IKYWKI5,4+4%PM5-^:_EJX7.IT5+=.;LMD&$21  Q%B$G9:
MX<1YAJA8GGD\\\G\3R?N[]^!VU?&TN@777;VP[7M2T0MBC;S<#VH[:2-4K;F
MQZ,["NFD(Y<9KVZ@&JK8Q;0"U#:Z=+U269%)C2"-<GR1\GU*=6_EIR?\_P _
MP]]4/7_AL]1=7LUB/3* :'-4\MH8T!Q)OUW*KBD.M1O8EAU"\^^4/3'YWR^4
MVI='YV)KLCY@229;.Y((@0L,-"2?C\_XC@_PU2:]X7W3FJF]?&@-%MHYG7>=
M</1:Q'VMLUJC7 CIJVF;WIXULVD-VI-8V0<U=;SY(]2RMO&%)8V7D>AYR7&"
MA&!S3J)^/^'L?NY'K\]9?>Z9]?WNL%?Z?9JI9G1U2#T\35 \*X6L?9JR[KVQ
MB;A0SX&]P#$:XC+34+:""V0#8HIELI#+C(DCWAQ*5MK:<GGGX]_X^OXZQF"\
M-OJU7;_KK:(\1LYR_:Z;%8^:"&\-O$RNPI("]6_9P"?MV5.N3[NSY82_7^Y6
M,=FVJ(1VOC\H"['>JL<>!AM.H\<<]OEP/H/]A^&K3=\*3IIB@2-:#:E?Z_5I
M57U92I<>N[BV<'?GU73E7NU,I($NY$LZ6CHR-6]B6R"0AG6"4<E*G0C<EO)\
M&"*#6G4?PY^ ^)Y^6IXT&BU35]$I6LZ((:K]'UW4JY1::!8?ERF0E4J0>& K
MPAF3/D2YTAH:('PX;;\V5)EO(9PY)D//*6XIJGKJ[>--.--.--.--.--.--.
M--.--.--.--.--.--.--.--.--6Q=J75-D4VV:\O@ 9:Z1>ZV<I]QJYJ,F8'
ML=7LHR2&/@BL1?[$H:6%3)4";'7^R]&D.MJ^BL\: \'D>H[C42:]T$T-&N_:
M&];"%)W).[7-Z[!7L/L*NT==<":ZU!'E-:KUS6AE<JH!?PFD2)CI,=8C\D[=
MY!6($(3+*[(K@)<!JO)X ^7/'[_75UN=$^G;U<9J;G7/5BP485D/'BYK4;WE
MB-F_KVLJ6R4QG!5HZO9CKM_79D34V-=O==L"RJB;KDE33D^O)Y^?\/Z=M7W.
MZP=>R.KZ=I67I^BJU3KTU7;)1Z*R$CQ -5L54+*/ #P2/$PPN":@F7)!-11E
MU,Z9,F$'Y[\I9"=F0U3D_/5)B=0^L<#-3S#T=KN-FB,U&-3LM5^,CY;8H6R,
M[@IC0KR_R5%:VAG-Z$I1](ECSD@C^LXU7D_/Y_Q['5-(=*NI!:V[-O93KGJ$
MC;MS5VSU/:)V;20LF9=J_=X<&!=AYO#T9;#R;I#%BV+?(:::F6A(L9D[(GJ'
M0U,-.3\_E_#T_#GM\M1/[%^$'U-WSKZOZQ A4:*J(D]L&PEH&L*%IDLNS%MH
M46N:XN!^=+VQK+9$T3=9%6J5?8@7BMR0UC:(#8Q4G++SHT-V*U4,1W]?3U)^
M'W$=OH>VIK4SK!H*@3*R4JNK:H,-5"S3KL /)'I<-P[H5UF-TX8MWQ%S*I#M
MB,:P$#J63*.*4_,!Q6XCN<IQY\:IR?F>_KW]=>]_KEHJ2%)5Z1JJF.AC&WX^
M_P G"6(9RF7NR):1]VB;1<>_RC%UB6D4,,13J'D38TB!%;9<1&8;92TY/S^'
M'[N../PUC75_0WIAI:!<1>K^L.E:>/V#4).OKO%'T($^W::!-]IF=137Q"),
M5.ID]3JUSZL\I0*:YG#LJ \XA"DM"Q/J2?CZ_'Y_?]=? 7T%Z6AM5']("^LN
MGH>J[391MSL-/;IPU4(K< K42."M4F6XVLIFQUZ+ A0JZ;;GH)U^!$C0 TF#
M#8:82T+$^I)]?C\_74@M:ZRUYINC5S66J*56M>:^J,)8^M4ZH"(8.OAHKLE^
M;(1"&P&F8[;DR?*ED9\G*522!&7+(37GYDJ0^XU35\\::<::<::<::<::<::
M<::<::<::<::<::<::<::<::_*T(<0MMQ.%H<2I"T*QYI4A>,I4G./WX5C.<
M9Q_#/&FH[5GJ-UEID4#"JND-> 8E7G:L)UZ.- 1H[0<AI /*K^HY<%*?HP_K
MP+.EC*NM/U&0Y#K37[*L\:J23ZD_'^/K^/QUY]C]/.K^W;'9;?LO1VOKE:+A
M&I$:S'C01M\H83K8F^7H<B5+0MMWXA59LF1D.4:4V2BQ'WAV)>1SBXN6@)'I
M\-*QT[ZM4ID5&J.AM:5N,#EZRG!HP:LPA\87*TP>M5GU0] CQT(9BYU]8+Q;
MBU62RA"!4RPDW(Z4^\9QAIR?F?C\?GZ_C\?GJF1.D/4.!:-;W6'URU(Q:]0Q
MX476QY%.%9(5)D4;+V4(D:\IE7J57;&?.6"L.2TR7:P<,$RP!8V?.DR'&G)X
M(Y/!]?\ /K\?G\=9"D=>='3-+JZZS-54B9HQ0)NM?JKE@H<FF(!L3$$8L!L,
M^VY':1")-LDQ[S6$21Y./&(PGF)L9A]MIR>>>3S\_CK&PCHOT[ E-7F@W6[4
M0TOIC*%:R(Q:<,;F55]JT$KS'F1W\->N?/AWHT9O, B7R0G0+L8+6^%(8L9*
M:3?:<GYG\=7[1.M6@]8!S]?U]J:DU +::16]:V(8##,0H9FA4^)8H%7J<]IO
M]E\*"A6ZS1AT-7[$=DV00GZ/JXTY)[DGGUYY^/SU9CW27J5(C2X3W7S6"X<^
MM/4^;$^6HJ8LNMR=/KZ_RA4B.CTM.L2M)+QJV4XM&9$BDLQ +SRX4*(VPTZC
MZ<G_  \_U[_C\SKUD^FO5<U\1^+:&UL0P6S<<D\2J]&=Q.SL'.NLW;,CS_Y3
MYGSJ/6>3'G_E?R17O7_S>UQIR?F?A\?EZ?AR>/OU&/N'X5/7'N-"BCK(Z2UO
M#E&-KF;IBATO3)6;=R.ZPE6KFP3DHQLW6&P#56N,\13@<<=<:*1K)B!(B123
MJYI0-6IH-JJL5]/H>Y/'8\^@(^OK\SK92/@11<"",@M88@CH<:!#8PI2\,Q8
M;*(\=K"EJ4M6&V6T(PI:E*5Z?-2LYSG.6N.O7QIIQIIQIIQIIQIIQIIQIIQI
MIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQI
MIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQI
MIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQI
MIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQI
MIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQI
MIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQI
MIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQI
MIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQI
MIQIIQIIQIIQIIQIIQIIQIIQIJF+-AFC#%><+C&S\J ^4C USXB#$D9&>;C22
M+ Q3N)KT"/(>:8?F-L*CM/.MM..)6M*<TZEZ@O4.H@L%Y'45! ) ]2 2 3QP
M"1KM$,QA:P(I3 LBQ-.(V,*RLI98VDXZ!(RJS*A8,5!(! .JGRNNK3C33C33
MC33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33
MC33C37C(D1XB!,*EI\,6+'1GII D1E,0H$&'&;4[(ES)DE;4>+&8:2IQY]]Q
M#33:5+6M*<9SBA(4%F(50"220  /4DGL /B3KG'')+(D42/++(P2..-6>1W8
M\*B(H+,S$@!5!))X YU]8LJ--C1YL*0Q+ARV&I427%=;D1I4:0VEUB1'?:4M
MIYAYI:'&G6UJ;<;4E:%*2K&<@00"""" 00>00>X(([$$>AU1E9&9'5D=&*NC
M JRLI(964@%64@@@@$$$$<Z^_*ZXZ<::<::<::<::<::<::<::<::<::<::<
M::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::C
MONKMIUKZZ3A8G=NZ*)KHT;A8)B@!TPC-AG"\R7H>"S%?@HF&5"53(\F*DIF"
MF J3&E,)D9=C/I;SN(VQN#/K*^&P]_(QPMT2RUJ[O#&Y4-Y;2\",2=)#>7U=
M?20W3P03C[N6QN.*+>O5JK2#J1)I51V4'CJ"$]17GMU<=/((Y['5WZGWSI3>
MPJ0:TSM;7^SQT/+22+M)M0:PO"7'O5[*.:A#I;TX+*7A*LIB%8T.3Y)SGV7+
M3)8;+8:809;&WL=*>2J7*TU<N!ZM&9$59%_:C++]==U6[3O)YE.U7M(/5H)4
ME"GY-T,2I^C<'Z:RSS&ZNM6S<KI4==U@S=;Y9@5-J%=A.$3MFLQ6$%!B(3>4
MI5)GDR#S$2,WE:D-HRZZG+KSC;+>%NN(0JXJU;-ZQ%4IUYK5J=Q'#7KQO--*
M[>B1QQAG9C\@#VY)[ ZZY9HH(WFGD2&*-2TDDC*B(H]2S,0 /J3K178.^?:G
MQ ]I6O1WAHLA=>ZUI#4)>Q.TVQ("H\A,4F],CP4U8"5#&70+)S XLBOLRZP4
MN1K$-T@XWKN*-D$'=SQ['VYL/&U,SXC"Q=R-[K..VKCY I/EA2SWK22)R(B\
M?FB.9(HRP3_FV;RU@KY_)[AM34=L>5!5K\"UF+*\@%N>E:T)5B2W2W271F8>
M\1" &;;MU>UAMO4&G0-&W=NTAV OX^:7E$-B$@30&0_#(SG)<$*EG$XE-GL!
M6G,Q&2I6>^1FI^JTQ8S<:%&U7N+(8S*96Q<P^'CP5&18EBQ\5A[*QF.,(\GF
M.J<-,PZV1%"(3P.H\LTOQE:W4IQ07KK9"RI<O::)82P9BRKT*3V0$*&)+,!R
M>/02$YA-7^G&FG&FM?FU-C]T:;==K.ZRU^)O5/'6[,NHC;#4B!"64KJZEU(
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M?D[*DN^T?<TQD9ZUJ_<LTZ:X^I/9FEKT4E>=:D,CEHZZS2 /((E(0.P!/'/
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MG&FG&FG&FG&FM;/=[PO-!=XK %OER,76A;- @(]6C7.DS1JT%:["G$B0X/9
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M<<#MG%5(8]T?\3XS,3133>SPUZ;52@FE2 P.\;F4="H)2TT1\WK!$:E6-O\
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MB,5,4BCYCNVXFX>5_1Z\+C]&-/T974\R-R@(129.:VWW@/2XC?O./>)SK?\
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MX]65+6JVH2AO"<94IS.<X2G'GY9QS7O_ ,#<P2 -S;6)/;CVV?GGY#_E^_\
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MY$A]Q#+###*,N.O/.N92VTTTVE2W'%J2A"$Y4K.$XSGE0"Q"J"6)   )))/
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M7G97FC=7@)[1?LW]NY6G1ISR/.]#(K*D5,N>IU@LPK)S7!)\N.2)3"O">9(
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MA QRSH>L,Z"7S!+30:0IB6$5!+$!Q,7QW=)/B;*9W>&S+>-VZU9J-G_A-*5
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M[-M^PN_LT^"IYM=TG$PW+2VL(+$B@3SQ&R*]11T3=$<#7&N"6G5N-?;RS5N
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M-[;$VKB:T&(V[A=IY1_L:G5LM9M(ZJU:E/<R-H1A[F5Z+YOSA)+$E1!"LEW
MM::&!]S]/6+0U8U#5*"R33<!=@'ZPUTR$I9:W#!'ZU(9&0E#8\/=[:Y1F(+Y
MF"_7BP.4?A,U<<N',E2SN)K[&VWC]M9"_D=LQQ;FHRWUK+':OU[!DM-&*]VE
M06+R37C22)O^G()(ZTQDFC9F1,YD/&[Q'S6YZ.WJ?B-DK6R<S7P29);B8ZS
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M;#O)^^_T7MNW_9X#:@BZ$JS5Y*AL&V5.J!:Q^JV,4#5-^V!:Q'DD53&DD@Q
M@.L+L-)&.;PDSE+<.)CW?@\;B8;ZS08]<'8I*+U;&RI+<ZXHI)I*UHPVE\F6
M=7C(Z(UY,+*9CL;;&U\MX<[DSWAAO;*;KN[>^S;F[JVY,5D:[;?O;FBEJ8EZ
MMIXX*F7QR7:#QWXZ7D64DZ[;J8;:2K-$1HL_M/=U#>[8E>N^U+%IB')V'K>O
MAWI*]B4P\^>J\D?;(XMD34WDUG)2N#)<CXU$-!9-C"5><S";+!A\Z':[B_X#
MOQ5EQ&+R463J64L1OD;$$J1P]+!V6-)IGZS((2K<*@*<DDA1KHV3D/&+;D>8
M]OS]2';.X*,F)R:8B&RB9"8<F.M+8?'4X0$K2W5=%DDF,4\D858I)2=1?B':
M(V/WD[JA3O0W9 B\V&G1H76_M= +3I((-U]Q7;/=GQ%U4Z?^%2;?7IL[.QZX
M7&Z[:L+,>Y4>8*2[\<)DV8>G\_BAG\BC8ZPDLE8K2R"EB%J%'=U<]14N#S*K
M+$&]^/@'J)X]J^$V^4\*-CVH-\8.6I2S0;=.SY?)$DNX_-KU(9:J- )5KRQJ
M,?/%)?:N33NB7@0)$S[=*<=T-T,TN6ZS:1Q'VMNG4&H+%MIC188VPO<NWBF$
M/EC=DE0(<0N2<-7 VZY/=AB0I>>-$OQHE6J\P5!"!UR>$TL/4./IA9K%2H]A
M:2.OM5CI!+.5[MU2OZD*>.1TJ5"C6C,DFYO$G<*;QW(\F+PVX,_6P\^YK-:4
M8'#!RD459928XE@Q]4*JAYHE<HS6+"2/-,/A1NJ_5_N%5:_V9[!]+*O6MO[9
M!BBMUJFTA! Q8@LX-'^61^9D4Z-KSD:5+ !PV&B,RH5:SDJ]&K4.TBH4L-%%
MBZP4:.0C3(6\7'%:M1QM-'90/,A0%55^H#NJ\#GH5BO2& ( %,CNW=FRK=K:
M.V]_7;N!P=RW#CKF&M&#'V4GD$\TU?R99AY<D[.Q1;-B!)VG>O*ZRM++G.[]
M)NJNR-TA.PEYTI4+-M@".=%Q; 4:GO#B##D:9#:DV2H8FIIML*P8L^2P+,V<
M 7+#$>ZY@3(ZAHQ4*=U-V[CHX>? T\O;KXJS*LTM6-E'#JRM^:GZ#9KHS(ID
MC@FCCDX/F*P9^K3\V&QEB['D9J4,ER)&C29@3[K CWX^?*D(!(5I$9D!]TCM
MK0I^D :@UKK^O]7C.O\ 75&HSDPUML:7?IU1 5EPFE<'7LJ V2<"0(*YJ8N8
MTQ41,G+N&,OR,M>C+SGKWM^3]DKMO);C@MW;5H+1H21+9L33B/IL3JY02NP3
MGS%#=/'/ YYX'&O?$FI7AJ8R2&O#"39L([11)&6ZHD8!BBCJXZ3QSSQWX^.N
M7N^-.O4VR(9QG*_A,MSRQ]N6VD>U=QC^/]4A?T_?]G[^>F;()KR\?J$_N'<_
MP!UJJN0)XN?3S%_$G@?QXU!SD>U(M.--.--.--96TTTZY=65MXSE# T@Z]Y?
M9AK*6V<95_+VSS6/K_:SC]_+R@";"\>@5R?NXX_J1Z_UU97R!7//J74#[^Y_
MH#J77,YK":Z6_!T[*]?-PZH#>'5V/U]4+C(@6JUW/38Z]U4/;Z;;VY$HWL,T
M$D0C,.?&@W2ND)=Q/#9<B.B*3KDJ0.C269D!R*5\N^,>U\]ALS/O_ W+5:"S
M!6K92:E9EK6Z4OEQ4$<O"Z.U2TB5XVZ2>B<>^.EU9=N;'R^.O48]N9&"*62%
MY9:J3Q)+#.G6]@CI=6 FA9I&'(]Z/T/(8'J)999CLM1X[3;###:&6&&4):99
M9:3A#;33:,)0VVVA*4(0A.$H3C"4XQC&,<\U$DDDDDDDDD\DD]R23W))[DGU
MUM0  < < =@!Z ?+7TY337'YL3_[4-N?_C'M[_\ LJT\::QI:O\ ZL6/_P"0
MF/\ ^/D<::[.PO\ S,)_^60/_P!JUQIJ.G=/>9#K1U/W_O8-#A$#^M-964_6
M81-"W1DBU9B9@59LHRTXTZ\,S8)HW)%AIYEUZ%A]IIYIQ:7$V61M-2H6[2@,
M\$$CH#^B7"\)U?->HCD @D<@=]2C9.!CW/N[;NWYI'B@RN6J5;,D1 E2JTH:
MR8B0567V=9/+9@55^DD$ @_YI5/1C/L\J\LYSE&%9]*$8SG.<^>?2A*4(QG[
M?2A*4X^Q*<8QC'-".22Q)'))//P_\#[O0>G&OKM50(JH/1%"CDD]E"J.222>
MWJ22?F=2ZH3",Y9^F/KZ?W?SQ]O[O[O^GG6W8J/4#@\?,\]^WX]OKV^MY.2$
M/'R/^W_?4Y->0F%X9\TI^Q.///V?[/\ HQ_U_P"GC\O7OZ]O7^/?DC\?340R
M;L.0.3W/\./3YCZ>FIF5BM094'U+RVG*4>K]KRQYY\O/R^OE]<_3&/K]>54<
MD]_F.0?Z_,'^/?Y=X7:M21R<#D@D#M^'X_[>G'KK%5^$16,/(1A/TPKZX\O/
M[?[_ /;]N?+/^BAYX[]^#QSQSQQQQZ^@/)^_M]><K1F=BAY/P^[T]/\ N>WI
MVU!K845M.7_+"<>7K^WR^OU_OS]?_P#F?KP>W/?T([_'GOR?Q']/EJ=47)53
MR1V^?U_[@\?[$]H671I.%NY_UO[L9_\ /T\O]O.8]5^?2"3SZ\C^O;]XY^0U
MEI1R/OY'T[_Y_763N@%_[>4GM=6@'1X^# [YVO7+5KD3BRQZK( %02(+>PC
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MU[:]FGDN6]QU99$D]HK5(IY#7K05K*SUZRXJ'%1*IMRWC48XV1?=?B[,Q.D
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MNH<3C-4JYB0R..'<#@?%5]0#\B3W(^';GOV&$NSB5PB'E(^>_P &8^I'T''
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MVGN>@-@6+T^6,^7RD(=M7K\L_P#L_@WM//\ =Z//]WGRPSB=>(R*^O%29O\
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M%*?)Y!ZM^$XS'^9+D<Q>R%Z>*:FL4,BS3F-9TC>O%7625'UEZUZZ;Z[5E[-
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MQVV=AF[W)W"!"GJ?9:+7KQ:-/S:GD<>HFS@V0T^JTH+*>B%Z588A%LC:V8F
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M]XNS3?9*O:T%U@[+U&%UD*H5 M>U@4 5[E9]G%6#!$IM\75C$269KH8T)K(
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M7M$:I:YO6K1I:ES,M#C@PAL+0&QAMD,M:ZJUM"%(YH40L>N;W6UJ;@)I"1$
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M[8QN/Q+ZP<Z/:N[+Z4[*PM>6^)4Z+IW8W7#7[^NX5LJEWG)>'6N75JU9(1E
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M@JXW(9&F^ JXF2$4XJTU.U1R J&-KMI,@)I1*WJ/VSNFCJ_N 52]C@J4O;@
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M]0?W>FKP:N:\)^KO_P"K&/\ Q_V?[.4X/R7]XYY_#^/;_L.T2 _7CY'G[O\
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MN5/F+2F/#C(7(DN-,H4O$ML6JU55>U8@K(\B1(\\L<*M+(>F.-6D90SNQ 5
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M*0&Q6\SI;H%FN98"_2W2)">D\<:PCX:W5"\]).G.K>M>PMA"]EV'7\BYN?,
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M,+X(P(E/DS9M-GQ9[)%J6U9:9-*%YE-N*7L6VIRS1R37C8U\T5<EM5!(]/\
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MQIIQIIQIJW5G_0M2?=//TJ4GS]OY>?ISG'GY>QSY>?E_'EP(.0#U>HY_1_\
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EO;_U'?\ L9YUR_\ 3;]W_N&NR+_J+^__ -IU>?+/5YIQIK__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g65062g55g55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g55g55.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X3^3:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/F<U-6<U-3PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @
M(" @(#QD8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE
M($YA;64Z(" @(" @(" @(" @(" @9S4U9S4U+F%I)B-X03M5<V5R;F%M93H@
M(" @(" @(" @(" @(')R,S<U,#<T)B-X03M,;V-A;"!4:6UE.B @(" @(" @
M(" @(" P."U-87DM,C R,2 Q-3HQ-SHT-R8C>$$[15-4(%1I;64Z(" @(" @
M(" @(" @(" P."U-87DM,C R,2 P-3HT-SHT-R8C>$$[4V-R:7!T(%9E<G-I
M;VXZ(" @(" @(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q
M-BXP+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[
M)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A
M<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O
M8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R
M97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($)L86-K)B-X
M03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&<U-6<U
M-2YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C$Q-C Q-"8C>$$[
M3&]C86P@5&EM93H@(" @(" @(" @(" @,C@M2G5N+3(P,C$@,3<Z,#(Z,#<F
M(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,C@M2G5N+3(P,C$@,C Z,#(Z
M,#<F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T
M<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @
M(" @(" @($)A<B!#:&%R="8C>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H
M96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@
M87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O
M;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C
M>$$[(" @(" @(" @($)L86-K)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SID97-C<FEP
M=&EO;CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL
M;G,Z>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG
M+R(^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C$M,#8M,CA4,3<Z
M,#(Z,3,M,#<Z,# \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z
M36]D:69Y1&%T93XR,#(Q+3 V+3(X5#$W.C R.C$S+3 W.C P/"]X;7 Z36]D
M:69Y1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C$M,#8M,CA4
M,3<Z,#(Z,3,M,#<Z,# \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP
M.D-R96%T;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\
M+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@
M(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX
M;7!'26UG.G=I9'1H/C(U-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @
M(" @(" @/'AM<$=);6<Z:&5I9VAT/C$S,CPO>&UP1TEM9SIH96EG:'0^"B @
M(" @(" @(" @(" @(" @(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG
M.F9O<FUA=#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ
M+S1!05%3:UI*4F=!0D%G14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU
M34%!-%%K;$Y!*S!!04%!04%"04%304%!04%%028C>$$[05%"24%!04%!44%"
M+RLT041K1FMB,DIL04=404%!04%!9B]B04E104)G445"055%0F=51D)G:T="
M45E*0W=G1T)G9TQ$06]+0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$
M0DU41D)15$5X=V)'>'-C2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H
M55)&4F]F2'@X9B8C>$$[2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF+SA!04519T%H045!07=%
M4B8C>$$[04%)4D%135)!9B]%06%)04%!04A!445"05%%04%!04%!04%!04%1
M1D%W24=!44%(0T%K2T-W14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!
M0T%W449"9V-)0U%O3$5!04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&
M25))>%%614=%,D5I8UE%54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y
M9W9%;%%Z4E1K<4MY63-00TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH
M2E)&4G%3,%9T3E9+0G)Y-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H
M<&%M='-B5S5V63-2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#
M:S535FQP95EM6B8C>$$[<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!
M24-!44E$0E%514)1645#04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%
M>28C>$$[;V)(=T9-2%(T4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-0
M4TYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0
M>FA*4VMT3515-5!2;&195U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N
M9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP
M=6-N6C9F:W%/:W!A86YQ2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y
M4&%V669P1%-R,G<Y47<O6$E*628C>$$[4%=!-4905E%P>4$R<E-T8U933%%V
M24]N5TAL2%103&PW4$QE4C9A1'=N:&5A>DQ%<W@V47E"=4DU,$%,2$968CAU
M2G!P+WDX.')Z>B8C>$$[>4Y,3DQP1F<X<W)K<WI-,71'5UIM3S5*4%4T<7E,
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1B8C>$$[6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E9S<W-5351Y>75S8U5A
M;#5*2$E65E9256MK-T%!67%P,E8Y6E@Y<6PS63-%5C%A>3$Y3R8C>$$[-&=D
M6DDR;U-P-'5P24Y#2UEQ:T@U6F8K4S(X<"]W1&)',"\O04MH63A66DQI<G-6
M9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<28C>$$[5F5:9DY8;"]Y>'!W
M,4Q88GAB1WA-:7=I9'=Z1&UW2E9F9T1(9FEC5E-04E!Z9R],8EA.570Y2S!R
M6$EB<E5,;VQB93-62E%72W%73B8C>$$[0WE!9$909D95,VLX-2M7;W14=71.
M;G920F,R5&5N8W9-:VM50W8V361X=RMS3W%W1G93;5(K265T1#@X5E)(*TIV
M3&134#!R6C%$:28C>$$[26HV>$9T27=*0V9A*S!1<#)X5F9"<C)J6$8U0EHR
M,35&4&-83G4Y-4%S5&-W.79'-GAT24=7<3AE56=!,S,W9$1I<G17,7I43DIJ
M:B8C>$$[92MK9&963$-.631P6FY00E,W2&A#<G1X5E)5=%-G>%9,,C@Y*U=!
M.$5A,TUS,&QX>#E.24Q7-FU91C-K4E$T:FEF9U,Q=DE+3E$O0R8C>$$[8U96
M3')Z;&].<F9Z869/.7=T,T%%3%)#>G4R-65Q>DMG:EI9:7-P8C S;T5*,E9J
M,$)X5G%Y.#8K5V(R86%+,W5Z>6=H:W5P1VMH;28C>$$[:5%W=VQ2239V26EO
M-%%U=DQI5%-U2W$K:RMA9$(Q85999%!U:$Y/66UM34I34DA616M-3&,Q9%9:
M0TI&26\Q1&EQ831Q-T9867$W1B8C>$$[6%EQ-T97<$8U;WEC:79)16-L-FEV
M8V4K2W!+,VMR>71.;S%H;SDO<&QT<61J<'-A4E=I6#A-5GIX-$E%-2]V1DDU
M<T(X4D$S>%9#+R8C>$$[;&PO-4QB>6XO=T)S8E0O*V]74$974S1Q-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ."LO4$8O27EE4VQ0;E=/-FPP8C8S
M1B8C>$$[4F),85@Q=4PX3S8O1%-U2W9+=GET=5 K8V5M."]A479L:3(Q9$YD
M36HO55=U5"LU1&5K+TQN.%HO67)I;#9N<3%V.$%L-4PU:S%1828C>$$[:F18
M3G1E2F525%-Z=3!K5G1$<45D<&%V1S!-;$)(-B\Q9$E305-A-V=$9'-+14MN
M;#<X;D9T63=A3%9)16=T,%,P54IE9V9U+W)%<R8C>$$[>5)S,TMR07ES,4LY
M94E(>E9:5D9F*U=*9%,P:4=*;FMA-'-P8F942D92>F)Y45-H6&1224)W3&-B
M44AR<U X05=&47%'.'<V5C56<R8C>$$[3%,P=#-I=7)D:DI+,7-M;"MT.5E)
M84]K.4)$5BM0<"]A*VEN>&-C2W!D0F4K43=A-C0R:TXQ3%!E,V]V6D5I:6UK
M-#-,*W1"-F(W2"8C>$$[:#AC37A+9GIC:C,S5E9D569Y:D9Q8VQG64PK,S%#
M,U,Q5S$K<7A42W<T3F,K:CE764-J37EY6$9E,T5.6%E9<6PR;C)N-5=81C5D
M4B8C>$$[<DA,-CET6C-%,3@Y,'-Y=3%V1WE'43-"8V5O5VE,:FHV;GAI<E4O
M87A1;F9L0V9Y:3DS2$1P36QW.3=&0F-.24QH6E)*4C=O*W0V<"8C>$$[:U5F
M=E!75' Q07 R<&EL;#)"6%EQ-T9867$W1EA9<6PO=T1I3%%F4G5*:S%#,VMJ
M=%EN=4QG>'E,255I:D988VA#>&]-5E=76&UF428C>$$[3'I38F)6;W(R3DY/
M=D%48E1Z,71W.4-2<W-W:F(Y:SES5E,S.'-V+T%#5S-L4#A!-UDR;B]W1%5,
M2&ER2F-69&ER<U9D:7)S5F1I<B8C>$$[<U9D:7)S5F1I<G-69&ER<U99>"M9
M1VTV2G%U;E=/;&%V;S4Q=4<Y=7=K3FU*0D5"3$A"3$YZ3$8T.6=K5&0K*TMS
M83!(.'902E=G-B8C>$$[-W K;S)V:V]A6&1R3G=T-SA826LY3C-6;')X17(Q
M<4MJ<&A65C%7-3AH1'I4<6DV<G!T-4A+8BM'0CE14V%D-&XQ15=D<$Q&-DU%
M128C>$$[<&MJ;3E%=W%R>'A!:W%26"M92VA)-79Y4&$P:&EH5FAA47A,2$0V
M4V%I<696>F-334M-9T%A2#$R97)B<'EO1#!80W)*;V8X2UA(;28C>$$[2%1R
M=&)7-$5S=6IY=&)88WAN:'1L<UEN:E9O<$E*5U)E5&5U1U!+3W1!3U(R6$%Q
M13%P+WDK5%)%83)T;V)J5%EX9'I+9$EL14-H;R8C>$$[8E9P2FPU,G)X8G9%
M=D5R6&9A=4953U!-=C595V0Y3D=K8W%V3F1Z,VQX271T9&Q0<E9U<V-,:VIH
M56IH3E@T5DUF,FTY>7%O6$AM,R8C>$$[.&XU<DPV>#8W43)Q2D=S8S%R0F8R
M-&HK<7I01VEW=$%K9D(Q:W585VE566AT+VAX5EIB6'8U47-S-T<P55$R5%-7
M.%1Y45A-9VQ1>"8C>$$[4EA":VI5<7AC04]05&%L979P-TYU<6DW3'IB*UA'
M:7AT*VI$3SDQ84)O9E%-5C8X.6)P>F-/2$TV:S$U9W,W3V9G-DU2,'A6;C)"
M6"8C>$$[67$W1EA9<3=&6%EQ.#$O3$-X,#8X9GI*159H=61.13AT:EI+2DQI
M9%):97),1W%,2DYY:C134DEH4'!33E@Y<6YW:D-R3G),>7@U9B8C>$$[<SE+
M9S!Q1WAI87=T:7I1=WI!>C!:,EHS8W1-6%IM6FY9;&EA:VY!<5AF;&PO=T-3
M,CAP+SES8E0O=T1Q1FIX5FMU2W5X5C)+=7A6,B8C>$$[2W5X5C)+=7A6,DMU
M>%8R2W5X5C)+<$8U<EEN.4914C)I,V0Q8UAH:G1E9'I,6FE*>&%Z>4Y*-G-+
M4U O04AA3VQ!3BM72V]'2S(Q4R8C>$$[,79R2C<O5#1X0S V;W)R<3$W9&Q(
M64AI,V]Z47AO,5!C-%938E9T83AM>&5:=%1H,4QY+TA,2DQD>#9B2F9"235P
M<FDW83!T6C0P128C>$$[9$]1<6LP2T(V+V%55G!12$95379M=CA!2T\U=%EM
M1VQ+.6]I2DQB2#9J4D)!6C565U-086=15',T.6U05$9755)E6DQ".5DP<4I.
M3R8C>$$[9%!R1FDX.%9Y+T535SEU=S5/2DEX5FM1;4=-16UL5TMG5F\S14MH
M+TTK=F55-VI3575B=3!H,6EY:49Z3V=D561693!T;FUC9G9",28C>$$[6D%6
M*U(S,G=Q:V0S-7$O3&QD4CE/8E)'9FE,=U!C3F))5DA$,#%N,DIQ5F18<69:
M8U5)52MB9GEF+U)41CE)03 T1UHS1#)935ED6B8C>$$[47,O26UQ.'58>$U3
M9'A5,4]+;VE,6'9Y<F8V,4I*;V-58V--.#-P<V)24#,O<5<P56IY<71/:VM4
M<6]R,4%X5E-U9DUV-51),#!%5R8C>$$[:5)Y,W-$=V-R65=A;S1D54E7<D55
M2&]Q0W)(=#<T<3E1=TID:7)S5F1I<G-69&ER>6YY1DQ9<#5S.#!E65@Q1C4Q
M<&1Y5W1P2&1M-B8C>$$[1GA:+U=$371W:U%33F9G1D9J-$TT0T]O2D)0>$97
M8C)V;F92<'1"=&1A:U,V=#=E-V0T,6AA,VML;FIK:61K9$I9-V-41D=6;S)$
M5B8C>$$[-DA9-S1&569Y>2\X;'0U5"]W0S).<"\O049#>#1Q>5A&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&54IQ96MA6G%K56-7;R8C>$$[5WE8
M36-4*W)%<V=R>&9I>6-H-$AI-T0V8U91;'(U5#AU5W1Z2&,R*VYX4GIX2&Q&
M24%A<6%5<4MN,WA66&XP1%%P-3=I-&XP,C%L;B8C>$$[=3!%9#%-.$UB4$MG
M<%):1TLQ669!=7@X0FER<%!,*V=Y2VEY86)A=7-:1%)Q,$U:0VM->D%R5F1Q
M3DEX*UI0:FEQ<61,,'<S<V0X8B8C>$$[3T$S,$ME;$1D1TY05E-09C1&96Y)
M3#A2,D(W-'$S9C9:<'5O4G)&9C)K3C-%:D-216YJ5U968V)"9TA"04\O6$96
M3CE$,%8S1'9P.28C>$$[<WIJ;4%X:&I*+V5#:C=K9G1!8BM/2W%8*T=F3&8Q
M8C9R*VER4#9Q0U-)4'$X6' Q2C5%.&5.3V]R:7):.'0K6%-X63966FQI,&IL
M=B8C>$$[<3A6954T-'ET.6YR24)2=DAV:7)8*T=F3&1+9F]Q>G!73G8Y-31U
M<U-L67HY;G%I;6DK0399<6U72W5X5C)+=7A6,DMU>%8U-2M89"8C>$$[>3$Y
M-6PX-#)D>F(R;C%7=W5V<6QM<TYM3&,O5C)K;59K9&EI*W%$-EE";U=',64Y
M059:-UI75FQ9,G-D<%I7.&1R85%J:D1B=V]S8R8C>$$[84PT2VEG2T(X<T-P
M0BM76"]K='9+9CA!,GAT4"]W0V]74$974S1Q-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1B8C>$$[6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ.'4O3%,Y0V594% R<')96&%7,S%H6C!J84,X5V5B:3EY
M-3E/2S1J:DI99R8C>$$[:6EP,U!';7=,1E=685(U=S%(55!+,FXV,T8U9G9:
M-VDX3&E85%E$8GAZ46-(6D1Z*W5Y,EE)<6Q.=7958F(T1EAF;&PO=T-3,CAP
M+R8C>$$[.7-B5"]W1'%&:GA6:W5+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R
M2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=28C>$$[>%8R
M2W5X5C)+<T<O3#(Q.'1W95E03G P=3EH=3<K5RM:.5572T<V:&5*>E!C1E5K
M33AS<U0X5TQR>6A206%%:T=U2W,U>%9J6#5:9B8C>$$[*U,R.' O.$%B1S O
M+W%&:GA6:W5+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU
M>%8R2W5X5C)+=7A6,DMU>%8R2R8C>$$[=7A6,DMU>%8R2W5X5C)+=DQ0>74Q
M935U-S=Z>DQ&9%=T,TY(9$Y,1S%P3F,S,T(U2'5(5D-S<3)Y37%R>$5F<%5$
M<E1F0W),9$HQ4"8C>$$[>G9C959T4'5Z<'1P3')5=DE8='9D>E1A8VEQ1UE+
M-FA93#%W5T%5.%=59&4S5$%R9C5:9BM3,CAP+SA!8D<P+R]Q1FIX5FMU2W5X
M5B8C>$$[,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W9.9GEX,4)M."8C>$$[,RMB
M<F$X=6MA*VQU-4=3,%,T;751<7=4>4-1:&YT-$EH=RMS4G!25UIG=D97-#A2
M:%8V5F=6:E@U6F8K4S(X<"]W1&)',"\O04MH628C>$$[.%9:3&ER<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5F1I<B8C>$$[2&),>6]M:G9R9#E9,V0U8S-E<&E2
M-&]:2DEA47,P:S O0S),4FA6<DQC36%Y.'8R4CEL44U653E(<R]/<VYL6%1O
M-W$O4WDQ,5%49B8C>$$[4&-1>#-F5FUO;C=M4TI$>$90:DA7;31"3TMT+VQL
M+S5,8GEN+W="<V)4+RMO5U!&5U,T<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M628C>$$[<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ>'(X<W8O2F)E52\X071J868O=T)1<V5+<R8C>$$[;'A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5F),2"8C>$$[-FM4>#AM5&UP6&UH
M;W=Q2U95.6II<5%A9C5F,7DS.',V6G!F-F%M=#<K>FI23&TK:D-81'I&5F]E
M5%A34T4Q3SE4=FEQ;BM76"]K="8C>$$[=DMF+T%'>'10+S9H63A66DQI<G-6
M9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-6
M9&ER<U9D:7%N8R8C>$$[6$5&=&)Y,T9X27-514M.2DQ+-6]Q;V]Q>DU4,$%!
M>%9$84YR5VQA,W!D=G%U:S-+6&UN,U-L<F4U:DY664%L5#$S<4="0D(V2$95
M8B8C>$$[:7)S5F1I<G-68U-!2VY91$97:VM34D$X8D(P8F1753%"*U)'2W-B
M+T%#>2\X;'0U5"\W63)N+SE1<V5+<G9-=C5H955V3%8O0EEA>B8C>$$[92]6
M<G$U=#=I-VA4,#5(<D1A4FU75G%O<D%55E-13RM+;S-Y;C5P,&YZ5C5E<SEF
M,&@S9E0W-5=-2FM5;S1-8G1'-G-P-W$V165(:"8C>$$[=&EQ8EEQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T95=C%8>D1O96M3,F-7<#,X1FY,
M<45W=')&2FY#1U=5.4512'%F-R8C>$$[4$A&57=X5C)+=7A6,DMU>%8R2W!,
M-3(O-5%Z6"]W1'1N6&8O04-99D98>C4K479N,UAR4%4O2B]L9#<Q269,5#96
M9C-L,4,V4D%E;R8C>$$[=#5E3C9J5$U/86=E;5 R<5EP3#9A9VYG;FA384-2
M6EE:04=J;%%H;%I4,$MS3FE-54PX5F1I<G-6475R869(<5=L,VUN4W4P8V0W
M0B8C>$$[2F)U-E4U2W-Q1D-6<C-&8U938E1F2D=N,G9L:7HP0V$U=6UH=$AA
M5517;'IC864W3S=U-4A+,&QI9FA753!1<U(P-FM6>%92=&9Y,"8C>$$[.'-7
M;'1&83)S=7)7.7)B;W-51457=&%U:V%2;T]+;VER9$%+<6=504=+<% U;R]+
M=CAU;71:3E<Q:7IV.5)E>FAK4EAN,5A5-7!"1B8C>$$[2T-K:V%T2F1':75R
M14U+,$EX5S),=V%F*UAN;'I48D<Y=$<Q84139%%H='IP;6A7;7%A;$,Q;D9.
M2DDQ>&-/27)S2W-43U%84%%%5B8C>$$[-S16=#9(+WER=GDO>34O5V19-455
M3&9P>E=+,$AA=C%V07)F+TMV=$(O-6%T6B\W:FUS9CEL94MU+S56.6]0+T%#
M,6%Z+S-(3EDO-R8C>$$[2SA69"]W07$K,$@O04IA=%HO-VIM<V8Y;&5+=2]W
M0U9F840O04UT5W,O.$%C8S%J+W-R>%8S+TMV=$(O-6%T6B]W0S0U<D@O04=6
M-"8C>$$[<6LS;6Y29DMV;#)W:G9B<5A86F\U2&1!<U=U879Y2'!W4S-"*S%E
M1#EM06HU-'%L561L-5AS=DXP4&QE-3%,5SE1=G11;FYA3U=,5R8C>$$[9%97
M2S!J5TPQ631*;2MU06QI0G1S4V$W-'%Y-R]L6#)G+SA!3%9R4"]C8S%J+W-R
M>%8S+T%#<C=19CA!;'$Q;B]U3V%X+S)6-'$W+R8C>$$[04I6.6]0.$%Y,6%Z
M+W=">'I74"MY=D989CAQ*S!(+VQQ,6XO04QJ;7-F.$%:6&ER=BM69F%$+WDQ
M87HO04YX>E=0.$%S<GA6,R]+=B8C>$$[=$(O-6%T6B\W:FUS9CEL94MS1C%Z
M>40K6$=P-FIQ=6M'3SET9%4P6DAV;V17=713,4-:3&554G=Y=&-O2'5M4$I2
M2W!,53=F3$-Q2B8C>$$[<TPS>5)E95I,9E%%+W=!4E(S3GIC5%=S57HV,W%N
M<&QO64=U5F)A*TQC6DEK67%A949A5D="8EIJ+WER-U%F*U=R5V8K-#5R2"]:
M6"8C>$$[:7)V*U9F840O=T%T5W,O.7AZ5U K>79&6&8X04MV=$(O=T-7<E=F
M*S0U<D@O6EAI<G8X06Q8,F<O=T1,5G)0+T%(2$Y9+S=+.%974R8C>$$[+VQT
M-6%M2T=78E9P1$5W:VE,-C-Q-V-804E$3%<W,D\O6$961SDO2W9Y9F9Q<3,S
M-E1U;%5-1E=F5TY7:T%$<55E;DLV4#)L2E4K228C>$$[>%8U+UHO;'(K5"MP
M5U@Q>E1D4'5.3D]K-F<R;5-23F4S<E-3;T=,3F%W05A*-&ED-51X<%0T<316
M=%!02T=G*U).4G8Q<S=#>#%R5"8C>$$[2$=M,G0Y02\V6C%"5DYV9'%*4%-(
M;S-R1E1'>E5:5%1F9F]63$)75R]W1$MV=$(O-6%T6B]W0S0U<D@O04=6-'$W
M+VQ8,F<O.'17<R8C>$$[+W=$8V,Q:B]!3$LX5F0O>7(W468K5W)79BLT-7)(
M+UI8:7)*8U9D:7)S5E5R<C9R.5AF-C-W*W(P+V4K<E1H5"]+-6)9<6LQ="]G
M4"8C>$$[-F=0<3,V3"MO9EA&<#98,68P9G(R,T@W4'<K=#!P*S%I<699<3=&
M6%EQ-T9867$W1E5&<3,V1BMQ+S=L+W$S,50T=CDV+U0Y4"LW8B8C>$$[;B]E
M9D0O9#@V+S5.93)+;V%Z+W=N-FUM+U4O<4AQ96Y**VE04CE'=G!5+V4O5G50
M-TY0=&-.=DA&53)X5C)+=7A6,DMU>%8R2W!08R8C>$$[+W=#15 P>$0Y82]2
M+W=#;795+S!F,692*W1E<'=8-TA,.35Y-&-/;3E+67%Q;B]$6#989W(Y4R]4
M1EIV<3%F4RMS,31R-B]$+V1N,B8C>$$[95!/;F%L8U944$9867$W1EA9<3=&
M6%EQ:RMM+S10.$$P=$XK:E P9BML*T1F5U!Q,V]F5V94-6IN>C1F2'@U,')8
M=FEQ<G!N*T=F<B8C>$$[<S,V32MP9EAF4F<Y9C9T-EAQ*VAX+S!F;G<K3# K
M4#DS6&%N5$95>GA6,DMU>%8O+SEK/3PO>&UP1TEM9SII;6%G93X*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @
M(" @(" @/"]X;7 Z5&AU;6)N86EL<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @
M(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @
M(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]297-O=7)C945V96YT(R(^"B @(" @(" @(#QX;7!-33I);G-T86YC
M94E$/GAM<"YI:60Z035&1$4Q-D,V0T0X14(Q,3DV-45$.3,W130Q-44X,3,\
M+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$
M/GAM<"YD:60Z035&1$4Q-D,V0T0X14(Q,3DV-45$.3,W130Q-44X,3,\+WAM
M<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M
M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO
M>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ4F5N
M9&ET:6]N0VQA<W,^9&5F875L=#PO>&UP34TZ4F5N9&ET:6]N0VQA<W,^"B @
M(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z
M031&1$4Q-D,V0T0X14(Q,3DV-45$.3,W130Q-44X,3,\+W-T4F5F.FEN<W1A
M;F-E240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z
M031&1$4Q-D,V0T0X14(Q,3DV-45$.3,W130Q-44X,3,\+W-T4F5F.F1O8W5M
M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^
M=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO<W12968Z
M;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z<F5N9&ET
M:6]N0VQA<W,^9&5F875L=#PO<W12968Z<F5N9&ET:6]N0VQA<W,^"B @(" @
M(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @(#QX;7!-33I(:7-T
M;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I#1#=#-38W
M-D-#049%0C$Q0CE"04-".#!%0C,R,4(Y-3PO<W1%=G0Z:6YS=&%N8V5)1#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP-2TP.%0Q-3HQ
M-SHT,"LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD
M;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z035&1$4Q-D,V0T0X14(Q,3DV-45$
M.3,W130Q-44X,3,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IW:&5N/C(P,C$M,#8M,CA4,3<Z,#(Z,3,M,#<Z,# \+W-T
M179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G
M96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O
M9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D
M/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R
M>3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.FEL;'5S=')A
M=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL;'5S=')A=&]R+S$N,"\B/@H@
M(" @(" @(" \:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^4')I;G0\+VEL
M;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z>&UP5%!G/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O="]P9R\B"B @(" @(" @(" @('AM;&YS.G-T1&EM/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS:6]N<R,B"B @(" @
M(" @(" @('AM;&YS.GAM<$<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]G+R(^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#Y4
M<G5E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#X*(" @(" @(" @/'AM
M<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/D9A;'-E/"]X;7!44&<Z2&%S
M5FES:6)L951R86YS<&%R96YC>3X*(" @(" @(" @/'AM<%109SI.4&%G97,^
M,3PO>&UP5%!G.DY086=E<SX*(" @(" @(" @/'AM<%109SI-87A086=E4VEZ
M92!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=$1I
M;3IW/C8Q,BXP,# P,# \+W-T1&EM.G<^"B @(" @(" @(" @(#QS=$1I;3IH
M/C<Y,BXP,# P,# \+W-T1&EM.F@^"B @(" @(" @(" @(#QS=$1I;3IU;FET
M/E!O:6YT<SPO<W1$:6TZ=6YI=#X*(" @(" @(" @/"]X;7!44&<Z36%X4&%G
M95-I>F4^"B @(" @(" @(#QX;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @
M(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^0FQA8VL\+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%10
M9SI0;&%T94YA;65S/@H@(" @(" @(" \>&UP5%!G.E-W871C:$=R;W5P<SX*
M(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M>&UP1SIG<F]U<$YA;64^1&5F875L="!3=V%T8V@@1W)O=7 \+WAM<$<Z9W)O
M=7!.86UE/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<%1Y<&4^,#PO
M>&UP1SIG<F]U<%1Y<&4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E-W871C:$=R
M;W5P<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z
M4')O9'5C97(^061O8F4@4$1&(&QI8G)A<GD@,3 N,#$\+W!D9CI0<F]D=6-E
M<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X
M.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N
M9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! ?_  !$( -4!J ,!$0 "$0$#$0'_Q  >  $  04! 0$!
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M:$.&+]-'??=F\Y8/V+[AJXX37]T>M'/J>Q<H[[A[,!@,!@,!@,!@,!@,"/\
M[^53)[?"T%!X25O^+2*:WS%X*2L&B[HOVHN*RK9R.*V+:TSF'-+3J'!"OOL*
MJTA7<!+6@TD$=C-C6!&M1S-1\<5%&S8FKTTXQ$]*N)XZ\K;)7K$[ZED1%#.N
M]R06DI@U/M79246)3!"]Q)*,I#"C=R!;1AE;50.1Y1R47$$4Y$K)2.J#88\'
M[A7&Y35^/$5QB_.D?'1&.7-%N]7D:$WQ:4.N&?ZPSI"NO,X+5#NF "HI:+7I
MR-')PE]9-K+HNF&FJFKDES+5=2&RFN^K!EPGZFY>*O!@J*SQY7?\4NN',P&
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MZZ=]<S,!/'(R"C4%/<$D48\4@6A*32>5,0(RRSJHF.?'3K?&=^#"-4]/NR<
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M;?888# 8# 8# 8# 8# 8# CCZ]?F0^2#].>B/[3OC"Y^#!UQ_:D<P@P& P&
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M2>*@05*#:]<U\:L094)\_'%I<3+"E[B;#45!EGIQOCPX7O-Z767#7H,PDP&
MP& P& P& P((XS=[TOY;+:J^3=DHXRUBELQ..P6CCW?%W7LK=A7W5NO)DZ8Q
MOI2#I\]'[4!*GCIH\WD)JV8U(%WRAMX0'Z:1,:W(%U^RXB><^&XC/^5Y=*^:
M=S"# CCZ]?F0^2#].>B/[3OC"Y^#!UQ_:D<P@P& P& P& P& P& P& P& P&
M P& P& P&!@BU[/GD4F%=0"MH)$9M*)^PG!CCF<6,9K< )$P9.->_P"_VF!K
M*TR+XB]7E#!-HR^PV;;A)!VLL23WT107-B.,_G6^FRB_>CM]_J-ZW?YJ[/\
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M_:D<P@P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M4W9KK:I[\\%XHK!@C+7'I,3_ !XQ,PEWPYF P& P& P& P& P& P& P& P&
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M7#F8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M[#$<?7K\R'R0?IST1_:=\87/P8.N/[4CF$& P& P& P& P& P& P& P& P&
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M-#3PO9TUW]FY;:D!3EVTY<-E/[BZ/"W*B._]U377;\,,7#@,!@,!@,".;O\
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M5X\/EV;_ %.NC^1L%SO/>6)9AX9O$%!X#(CTSZDUF#KF###\^D2Q&169S'@
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g65062g58k78.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g58k78.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X3/^:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(Q+3 V+3(W5# W.C Y.C0X*S U.C,P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!)
M;&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(Q+3 V+3(W5# W.C Y.C0Y*S U
M.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,2TP-BTR-U0P-SHP.3HT.2LP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C(P/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @
M/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%
M05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!
M04)!05-!04%!045!)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!1U1!
M04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#
M=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(
M>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&8O.$%!15%G049!14%!=T52)B-X03M!04E205%-4D%F
M+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%
M04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!
M0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC6455
M37!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#
M3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT
M+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD
M-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ
M8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!
M341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C13
M3D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG
M6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E7
M5G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A9
M84AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+
M;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X03E29EAR3"]L;VDO-$YF-C1Q
M>%!Z)B-X03M&-40X<6$Y<G)A-618,'-/<&96<F5Z:6UT-V=2;4]+,VYK;E!#
M;C=5:E,P6FI59T1A;%=Q<7AY-2]*4'EZ8WI757,O;6962DAS9E%%)B-X03MB
M3F1X;&U%15%I2VQY=DQJ26\K24$T5E)C=C5395AP3E1T8C,O16PK<U9R8TIC
M<EEI-&@Y0FEL4&A:94@R87)7;FIV:7(P5#8Y6F8X)B-X03MT15@O04%A+S%W
M2S<V.5IF.'1%6"]"<B]!1GA6279.=FQR>7@U<6=S3&)6-6A*8E=&,DPU255L
M0V@U1FAL:%5043%+:C%U6$AO4T%$)B-X03M686=Q<TU4.&Q.0VE8,')F>FAR
M149Q1D-R8E(S:U-O;U=/5TYE2'=C;' V-TA9.69O;U9:>&]7:39,;S%X3F-1
M6'I45%A&=&%7,#!K)B-X03LX<74W+U5K84Y*1V)Q6%I7*TEN<F=63U!R,6PO
M>3!29CA'=CEC5F0Y97-V*U=I3"]!24YF-C1Q:UAM,WDQ-5DX,5%71G1Q.'=K
M=')#)B-X03LW1CAK2U-H43AI=WEW<4AO86Q2-C-,:C!*04)Q=%%65T=**U-M
M:%),-E9V-7<Q:4,Q0VA6=&\W>4I554Q(3$=V1#1/4S Y9&IS978P)B-X03M5
M2W-U.'1E5TY',$A5-S8O:#%.<G%7*V=T3%IZ3SA28FI:4F5M<DY);U8U2&5T
M5UIY4V9U=TMY3#8Y6F8X=$58+T)R+T%&>%8S,39Y)B-X03LO=T-7:4PO9S$O
M<FEQ42MB4$Q(;&YZ4W1G=7%81E8P-F,S5G5S8W=4.3<V8DER3E$W.$,S241P
M56)G:F)&5T9J.&M.05=75F]F3T]T)B-X03M1>$]S:4IB<&9)230P:U-607%$
M:C!15&9$6'-+659:;C5D.'0V1F]7<#9P<59V9FUE-3%68EI,:'!N:4IP85)T
M1VA,2W%S-TAM4WI/)B-X03M35&=64"]R,6PO>3!29CA!0G(O6$989EAR3"]L
M;VDO-$YF-C1Q-S8Y6F8X04Q21B]W82\Q>%8S,39Y+S5A278K1%@K=4MP9C5G
M<V1')B-X03LQ,U)R<E-,>3968E<X54I-635&5BM024A9.75M2W-(:"]*>GDQ
M13A"+W=!4S9L2DAB,TU6,FM%=#-(2D=8:$U,24-R3"].8F=N>'%C)B-X03M+
M='DO;$AO2S-3,T9J-6MV<E%--6$T:$9W<%(P:V5->DM!0VA"94])>&=K;FER
M1V<V55958G8X04I,>69C87)Q=7!J6'(V1S8Q5G)H)B-X03LS361X0W9O;35N
M:W5$-E!W5E5+.'I5,WA6<"]Y5CAV3DIF>6IZ6G$V>3,W.'!*4F5X*V]Q9WES
M<4LU6&Q25&-.,2]I8U9::C57.'8V)B-X03M6-61..39/<E0S:3-R>$U)-W4T
M16EX0T=&659726)C45%L5#0T1E0S-CE:9CAT15@O0G(O049X5C,Q-GDO=T-7
M:4PO9S$O<FER=G(Q)B-X03ML+WDP4F8X04)R+UA&5T-F;41:96)K93A':5AU
M;F%68EA&=&%,65A.,C!-9G S559X2S%Y3TQX4'E%,$1X-SAT=4A4975304HU
M24I!)B-X03LU<%!A,FYM3T]E865B>F9P:VI.0DYB=WA.2F%E:W!8:$9"3U97
M0D-:2%)8;&-6-&AZ441I35!"3'5,2&IJ,VA2*W%E8FLQ3C5O+TXK)B-X03ML
M1WIK4$PP6&QS,D-5.5!K:2]U069J24I"<CA)<4XV,7@T2F1X6&IJ,VAL56UO
M=W U9W9,:4A5=$IL,' W6&IA5S!K.$,X8FM#<6LX)B-X03M6<GA*0G)V,S<Y
M1F5#6&-6-#0Y-T@T<G9Z<$A#25 P-S5A:VMH-$ML,TDP6DTS16]R4$I';U%,
M>5AM>DMP2%E!-#A%=31R>'@W,UA.)B-X03MZ-7)U9$]L4G1B,$<R=D1C4E!!
M,$5S3D9G.4]53VI&;#-)8WAM=$]X,C=-.$5U-')X>#<Q2T,K."]&03 K<RM7
M16UQ84MR4G1%1DUQ)B-X03M&95EO2%EQ;DU(:7=Q2V1'<6-E0UAC5C0T.39*
M=')R>F-:2E!R5W4K6%!35V]I.4IO9WI+4E%&<7%A34]U,C%F8DAG;#-&94]0
M97EF)B-X03MY-7$R;')O='%U=C9H<$0V=490,7 W95-%4D4X:GAO0V8U858Y
M.&5#6&-6-#0Y-EIF<&IY9"]Y,C9D+WE.9R]R:G=3-VEN:FHS=2]4)B-X03M(
M:S<O04IB9$\O-4=W9C%X-$ID>%AJ:C-U+U1(:S<O;'0P-R]!2D=W9C%X-$ID
M>%AJ:C-Q:U=O*U9*4U)&9%=%:$A8:3A,52LT-45G)B-X03MJ;6M%2&MQ9E=F
M3&XK+V)0+V=O<VIB2VDW-GHU8R\S-UHO.$%"4EDR=$8S,6YY-2]V,GHO04]#
M:7AT84QV<E!L>B]F=&XO=U573G)2)B-X03MD.5HX=68W.7,O.$%G;W-B5VDW
M-GHU8R\S-UHO.$9&:F$P5FLY-35C:'1,;3=:<EIO3%-*-3=G>&A*0W-C83AM
M8FEN23=!66)24U1,)B-X03LU.2],:&YD1G8W56Q&4B\W<S=I4FQ63U!W+T57
M3&I98C164F-(;6IY3DYC9E9K=DQ0-G@V8E1'2F=Q<TDP47E->F-G2T%+<D=V
M*U,S)B-X03LX<&]&46LO;G8X=F)C>&EE-FAH.5IG:U!Q44]N36U32TPT86]+
M,&4T44AW,U!113165DQF>FXU1FYT<$QV,6]O8D]/3EIV<E4P2FEI)B-X03MA
M3B]3,U)N54)Q1S1J0DAI=T=+<6IE8B]!0T%T958Y6G)X65)N:T%0:DMS+T56
M1S4T<61V:T]P1TMU="].,VM3-'5L=$E,;3-K=D=K)B-X03M72#9Q26HV=V1I
M5D%A37)Y559(5FA4<#1I<7$R1'IF-4IU27)M4S)D2C)T24)D6$U-9'4U;%-*
M;%)G>E(X3V$W4T$W:G@X1&EQ,C(X)B-X03LT951B;#=D645-9W5M:E=&>&%Y
M8U0V<V=J47-3;G=H;61.,B]M1TMS:2MO,E@O3%!&+W=#+W="34-U*V\R6"],
M4$8O=T,O,'A6,S%')B-X03MY+S5:-'8X06=&+W!I<G9Q3FPO>7IX9CA!=CA!
M5$9722]M;B]!25@O04546B]W0TEF<E@Q8C$O,U Q4&AY-3A$.7)N,G!M4G K
M2R]3)B-X03LT*V\T83E4>E0O:T0S+V$T+W=#4T]:6#<S>6-4.7HU=2]W0U%0
M9CA!830O-4DT+W9F2F8S4&TW+T%*03DO=T)R:B]K:FHK.3AL+V,K)B-X03MB
M=CA!:T0S+T%'=5 K4T]0-S-Y6#EZ-74O=T-14&8X06$T+S5)-"]V9DIF,U!M
M-R]!2D$Y+W="<FHO:VIJ*SDX;"]C*V)V.$%K1#,O)B-X03M!1W50*U-/4#<S
M>5@Y>C5U+W=#45!F.$%A-"\U230O=F9*9C-0;3<O04I!.2]W0G)J+VMJ:BLY
M.&PO8RMB=CA!:T0S+T%'=5 K4T]0)B-X03LW,WE8.7HU=2]W0U%09CA!830O
M-4DT+W9F2F8S4&UN2&PW+VQ6+W%4+U5V,'!7:3@O5CE,,W!3;5EM<31Q2$8Y
M:FUA5&AS.$-D+SA!)B-X03M/:"\X=B\X07E4>D0R8S,Q3R\U,% O;"\O=T-3
M94]Y*W S+T]H+SA!3"\X03AK.&1L.51V*V1$+T%/6"]!4#5*-#=,-FYF.$%/
M:"\X)B-X03MV+SA!>51X,E@Q3R\U,% O04IF+T%0:VYJ<W9Q5&IY-2]G-G0O
M=T-J-G9O9E98*W4O6&5(;R]6.795-61Q538Q,G!K;S!X;F96<R\X)B-X03MQ
M9SE:869O6#%V,V9$:CE8-612-F1+8BM&36TQ;S(R+S56=CEB4&\O;W8V-39F
M>%8Y2#%F5#E"<3AQ+T9X.4AN5W9B;"]L67%P6&XO)B-X03M!0W$S-FYA9EAF
M,%(Y5C,K<&974%$T,7 X6$1N,W Q>%8P9B]!0W$O,&15.5 Y1F96*U@K-6%N
M;RMN>3E19C-N-TYF5C0Q+WEQ9#A6)B-X03M1,%@O04-Q5&YC.% P6"]E:C%U
M6' X4%4K<G14:'DK2"LU-699,C8Y.$MO<7<O-59L*VML*V\O;W8Y2F5S3U!P
M96PV,W)686Y4-'$Q)B-X03MR5#908D955&0O-$0K;UA(<B]54'%F<&HV>%0P
M-F5N>6IP>30W,#5E;BM'2V]/,2\U5F8K:S=F-G K:G9R+W%X+U9V4C1C=E8U
M4RML)B-X03MX-&4O<6-F<#=9<7DW07)S5F1I<G-69B\R43T]/"]X;7!'26UG
M.FEM86=E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z06QT/@H@(" @(" @(" \+WAM<#I4:'5M8FYA:6QS/@H@(" @(" \
M+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O
M8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B
M92!01$8@;&EB<F%R>2 Q,"XP,3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^,C V/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @(" @
M/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @
M(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@3F%M
M93H@(" @(" @(" @(" @(" R,3$N86DF(WA!.U5S97)N86UE.B @(" @(" @
M(" @(" @4E(U,# P-S@F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @(#(W
M+4IU;BTR,#(Q(# V.C,Q.C Q)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @
M(#(V+4IU;BTR,#(Q(#(Q.C Q.C Q)B-X03M38W)I<'0@5F5R<VEO;CH@(" @
M(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N,"8C
M>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF(WA!.^*
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M !L! 0$  P$! 0             ! @8' P4$_\0 0!$  0("!0D%!@4#! ,
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M(CE8E19:D2@P@1V5!8#LC]( (L$5=5(D:Y,-&M2)EB0W ,&)51!2A,9@L83
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M<6'(62(P"?M$DTA<H5.97)GWV7CD8A\J1Z\',4ED+_)O_AUE965>M<G1]_\
M$(4QZ_\ X_#B0OQ4R2"Q,3R8/^RR<NI2?MB)8Y.6ZFQ+>W-Z50N7KUS/J4D1
M(420H9ZI8L5'ZQED)DJ8@LPY0H., 424 9A@P@"(6#B0OQ1C,W8*TH!$C+78
M<RFK>D)MRRHQA:I;,R. *],IBPX<D>"\JV_+O'=;W%OPM2X.*RI294>G(P:7
MDTL.!A\IQ(7XHQF;L%<"NIY:WN[/'U^\E^(GZ0EN9T?9%:'4-,[OA+*4G/>3
M6=M.UG M<RVDE6D.<S$1)X4!2I.8JR4 XO(CB0OQ1C,W8*K]0]F=LG9/N_JA
MX8.'$A?BC&9NP3J'LSMD[)]W]4/#!PXD+\48S-V"=0]F=LG9/N_JAX8.'$A?
MBC&9NP6-INV-=9.3*S61TC]E5\[R7S_9QJF[UI1$W)_]$>2F,^Q4+]KH@5.O
MHU*A.G'ZB4?YAYY)0O(8: (CB0OQ1C,\!@LD]0]EY_ZW)V3[OZG^&#AQ(7XH
MQF;L%!'1]AEGDIC-T-C0*5(3AITXV34P)YX$^ 9/&24+6+!AH2,&E9.$ (L%
MX,!Y^0^>'RG$A?BC&9NP4;J'LSMD[)]W]4/#!PXD+\48S-V"=0]F=LG9/N_J
MAX8.'$A?BC&9NP5/54Y-T*QL;EN[>P:-P>CU"9F0JFO4=.L=E*-&>XJT[8F-
MUE >O/2MZ52N4%)0&F$(TYZHT(2"C!A.)"_%&,S=@JAU#V9VR=D^[^J'A@X<
M2%^*,9F[!.H>S.V3LGW?U0\,'#B0OQ1C,W8)U#V9VR=D^[^J'A@X<2%^*,9F
M[!.H>S.V3LGW?U0\,'#B0OQ1C,W8)U#V9VR=D^[^J'A@X<2%^*,9F[!.H>S.
MV3LGW?U0\,'#B0OQ1C,W8)U#V9VR=D^[^J'A@X<2%^*,9F[!.H>S.V3LGW?U
M0\,'#B0OQ1C,W8)U#V9VR=D^[^J'A@X<2%^*,9F[!.H>S.V3LGW?U0\,'#B0
MOQ1C,W8)U#V9VR=D^[^J'A@X<2%^*,9F[!.H>S.V3LGW?U0\,'#B0OQ1C,W8
M)U#V9VR=D^[^J'A@X<2%^*,9F[!.H>S.V3LGW?U0\,'#B0OQ1C,W8)U#V9VR
M=D^[^J'A@X<2%^*,9F[!.H>S.V3LGW?U0\,'#B0OQ1C,W8)U#V9VR=D^[^J'
MA@X<2%^*,9F[!.H>S.V3LGW?U0\,'#B0OQ1C,W8)U#V9VR=D^[^J'A@X<2%^
M*,9F[!.H>S.V3LGW?U0\,'#B0OQ1C,W8)U#V9VR=D^[^J'A@X<2%^*,9F[!.
MH>S.V3LGW?U0\,'#B0OQ1C,W8)U#V9VR=D^[^J'A@X<2%^*,9F[!.H>S.V3L
MGW?U0\,'#B0OQ1C,W8)U#V9VR=D^[^J'A@X<2%^*,9F[!.H>S.V3LGW?U0\,
M'#B0OQ1C,W8)U#V9VR=D^[^J'A@X<2%^*,9F[!.H>S.V3LGW?U0\,'#B0OQ1
MC,W8)U#V9VR=D^[^J'A@X<2%^*,9F[!.H>S.V3LGW?U0\,'#B0OQ1C,W8)U#
MV9VR=D^[^J'A@X<2%^*,9F[!.H>S.V3LGW?U0\,'#B0OQ1C,W8)U#V9VR=D^
M[^J'A@X<2%^*,9F[!.H>S.V3LGW?U0\,'#B0OQ1C,W8)U#V9VR=D^[^J'A@X
M<2%^*,9F[!.H>S.V3LGW?U0\,'#B0OQ1C,W8)U#V9VR=D^[^J'A@X<2%^*,9
MF[!.H>S.V3LGW?U0\,'#B0OQ1C,W8)U#V9VR=D^[^J'A@X<2%^*,9F[!.H>S
M.V3LGW?U0\,'#B0OQ1C,W8)U#V9VR=D^[^J'A@X<2%^*,9F[!.H>S.V3LGW?
MU0\,'#B0OQ1C,W8)U#V9VR=D^[^J'A@X<2%^*,9F[!.H>S.V3LGW?U0\,'#B
M0OQ1C,W8)U#V9VR=D^[^J'A@X<2%^*,9F[!.H>S.V3LGW?U0\,'#B0OQ1C,W
M8)U#V9VR=D^[^J'A@X<2%^*,9F[!.H>S.V3LGW?U0\,'#B0OQ1C,W8)U#V9V
MR=D^[^J'A@X<2%^*,9F[!.H>S.V3LGW?U0\,'#B0OQ1C,W8)U#V9VR=D^[^J
M'A@X<2%^*,9F[!.H>S.V3LGW?U0\,'#B0OQ1C,W8)U#V9VR=D^[^J'A@X<2%
M^*,9F[!.H>S.V3LGW?U0\,'#B0OQ1C,W8)U#V9VR=D^[^J'A@X<2%^*,9F[!
M.H>S.V3LGW?U0\,'#B0OQ1C,W8)U#V9VR=D^[^J'A@X<2%^*,9F[!;+9_P X
MS_[9Y%5\ZE8:[[>K>BYKO1*T=&9D1)*7@]-#&^)-G*1B1TPD-76_#)=A32\R
MA$\E+C$+1CI* R=UVXV.R-E>KGV*$L,R7$-[OZ%1)U&ZN_\ =EF2,HQ VF+4
M[ NS@VN]?U960MTAZ1)MUG36E5D29V/=*JML+KFM")K%>-?6"UY'0FQM/ME*
MV LV8G=#-T;I::7 F>U*:W'&3-![D[/S=4]>MZUZ=Y<G+++JH,+M9"0 6<AP
M7J!+^$ZRS.NA2?0_JQMCHL6:L86R.]/Z<5_=%?SZ1KLQY*XX3NU%,D"A3TO;
M5Z@+M(7.22EO5KW$YO(<S43BL4N2\9 #LJ1%CE?U>+7%4G9G2Z];E:];Y39+
MW76P]RT9OUKU<D%ET9@1E((:LU]8KJJ:5V4A#')%;<_:93-&F,0EY-4S)$I;
MY*^M+@?%8W'&XM<[IW\@+.U0((.MZC_=O!8TVJT)M2_$723RQIKZ%M\_L:%U
M?36JJ0U?%VI-*JKAQ<%NNUBW->W>F*C;M?ES+)? )8MEI:=:Y,D!@:I\\R.I
M$:@9!%_3(5G^5V !I5LQ*QFDZ/.UIK JWLJ54@WQJX&_I=6'="*5\[3>(.#C
M0-$2796L9I8J<U3')2XUBLG"J$5\IDST7"G.3. 3)&]Q>,O"X;T^IG-<KE:@
M:LECXD M>?!=CMH82HLG7BXX"F@JFS1S"!/T?-@""8I( ZRQ&YI1)E[,R3!Q
M(/:&.0*4(U'L^H?<)XZ<]!0))"O;610O<$I8BT+6C4-INF(RRT72?UU9R^.S
MU\K1IC]@6I$]:X=?3@>QQ2:@DKM;Z>@I$U5Z_0"($-T+B$"D;3&$%AK7=^>&
M]PBCA#&AGF9Y"WA]';PMUZY,VM8?V7H/:^PMB'C9^OT$2+%JTYUB7KQ7;TS@
M<9S:C2SHC99L2;7DV+M..1.MSM@HQ/WC79018T7<@A7U<RR<>6-G5(7I65!#
M-.WP^8:MF<,=;3"M:11'>R='1NO\LU]P]GC\BL)AGU@-]N1./ F49E_2+:T2
MIB=X4\QJRCIH3F/:9LUP%-[JO:XX]Q^/N[K!VDDN3J3V+)*L*O _2UAXZZE9
M;O3W2'LLPNS$8D]QN!+85>@8,65,EBZ/3"MT;FB-USB4=F<^VT>4**SRHFA8
M&ITE8J#K:2NDO:IX=:UG/*"4(YC,'_?^+?YX(XJLU?\ 9LLMJ<VV5,JW;C%O
MK,I(X6#"8;L"R(Q7)83_ %_52^RF&/M2J+&0361) T<R=*\V3B7L"E5RF*VT
MO:#)"SWY7C$B>YX785&N,A?XJ882H>-5?$S\&=F,C:K]WXHNXK,N,AV@\:O]
MTB$CU/M6G75PH=OU&>%"F1RZ6,"Q%')BBVJ-"D11]P:DZTW+M##65S)& 99\
MA;\9)&$D) E400[ZGDL(NM<=)D&>1H4#8I!7+NR1!WAIHFZRG.24"VX#H!*8
M]#7)E;9'?9K *+M6XPHB$AE<=9I-;*<3 LELCN91#'8F/N9''S^E8#BHU"MG
ML+:JE-V+1.T;NZL,[HFO]KH9+8]4&T<$@#I>6R#79$CBEA6'6=%J&QY5(UUX
M/2;,<?7B SN.1D$@F$F96RV\LTQ2(()"38U)D!'%=ALLJL?PJ-8U6>*KD9HK
M?-Z1O&$TZNF/%,=>;=R"D"9=/Y-#T3'=2J':J-VMB.RT)^SVQ\YLB"%V"W["
M2E*QVK8TV:"DRI\:WV/MD-60F-F$>&6L/-G+M8)6-^Z@PJA-UI*U-K!*Y9LH
MS00V6R9Q6M)UIRBM9RC/3:TS9O0#-G+=N%L%9CE&7"[U$%-3M15JM3"7*V%S
M<FN*IZX=SU3P0D/4W\\& NUSK7ZZ5%OS$&1.*+E73.U>:[:Y"[)7J^D*I_.M
MF2ZE6!%K'*C\DE4O<118H%S&1-<QQR-#8H&Q2<P+A""8HUG*WI 0D%C\W%@
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$.$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g65062g59s49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g59s49.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2>V4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )YJ^$!.#A"24T$!       (1P!6@ #&R5'' %:  ,;)4<< @   @  '
M(%  50<FEN=  X0DE-!"4      !#XK,2A+1_^O$((&3,(ZB/^.$))300Z
M    $9    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;V
MP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96
MY":71B;V]L      MP<FEN=&5R3F%M951%6%0    ; $( <@!O '0 : !E '
M( ( !- $8 0P M $P ,@ W #4 , !$ %< ( !S &4 <@!I &4 <P      #W
M!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M      "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F
M]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<F
MEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M      4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&
M)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;V
MP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&
M_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M       $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M           %)S;'15;G1&(U!X;$!UX           "G9E8W1O<D1A=&%B;V
M]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4F
MQT                5&]P(%5N=$8C4FQT                4V-L(%5N=$
M8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W
M!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M  .$))30/M       0 5X    !  $!7@    $  3A"24T$)@      #@
M         _@   .$))30/R       *  #_______\  #A"24T$#0      !
M   !XX0DE-!!D       0    >.$))30/S       )           ! #A"24
MTG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8
M    $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0
M$ +0    8       $X0DE- _@      '   /________________________
M____\#Z     #_____________________________ ^@     __________
M___________________P/H     /____________________________\#Z
M  .$))300(       0     0   D    )      #A"24T$'@      !
M X0DE-!!H      S4    &              .[   'L0         !
M                    $             ![$   .[
M    $                         $     $       !N=6QL     @
M9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M    !,969T;&]N9P          0G1O;6QO;F<   .[     %)G:'1L;VYG
M 'L0    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M  !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9V
MEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7
M!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P
M$       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M       $)T;VUL;VYG   #NP    !29VAT;&]N9P  ![$    #=7)L5$585
M    $       !N=6QL5$585     $       !-<V=E5$585     $
M9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V
M5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&
M]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V
M5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115
M-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M    IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M     +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M     X0DE-!!$       $! #A"24T$%       !     HX0DE-! P     '-
M<    !    H    $X   '@  "20   '+L &  !_]C_X@Q824-#7U!23T9)3$
M4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35
M-&5     !)14,@<U)'0@               0  ]M8  0    #3+4A0("
M                                                           !
M%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!
M   !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD
M "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6
MUI   #^    !1M96%S   $#    "1T96-H   $,     QR5%)#   $/   "
MQG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8R
MD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U
M)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M
M      6%E:(        /-1  $    !%LQ865H@                     %
MA96B        !OH@  ./4   .06%E:(        &*9  "WA0  &-I865H@
M      )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8R
MYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                                !D97-C
M   "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('
M-21T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&
M]U<B!S<&%C92 M('-21T(                             9&5S8P
M     L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3
M(N,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B
M!)14,V,3DV-BTR+C$                                  '9I97<
M   !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B       $P)5@!0
M  5Q_G;65A<P         !                         H\    "<VEG(
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M>K)]PH#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K BLV*VDKG2O1+
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MR<B9SWG62=TIY GJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                        _^%&16AT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR
M95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM
M971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-2XS+6,P,3$@-C8N,30U
M-C8Q+" R,#$R+S R+S V+3$T.C4V.C(W(" @(" @(" B/@H@(" \<F1F.E)$
M1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F
M+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C
M+V5L96UE;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P
M<V8\+V1C.F9O<FUA=#X*(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @
M(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB
M>"UD969A=6QT(CY0<FEN=#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!
M;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @
M(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"\B/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(Q+3 V+3(Y5#$P
M.C0S.C$R+3 W.C P/"]X;7 Z365T861A=&%$871E/@H@(" @(" @(" \>&UP
M.DUO9&EF>41A=&4^,C R,2TP-BTR.50Q,#HT,SHQ,BTP-SHP,#PO>&UP.DUO
M9&EF>41A=&4^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(Q+3 V+3(Y
M5#$R.C(S.C,P+3 T.C P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM
M<#I#<F5A=&]R5&]O;#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO
M>&UP.D-R96%T;W)4;V]L/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @
M(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @
M>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B
M"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN
M<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E
M<V]U<F-E179E;G0C(CX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP
M+FEI9#I!1C0S.#8W.3 Q1#E%0C$Q0D,V-3@S,$5&.34X,C V-CPO>&UP34TZ
M26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I
M9#HT,S@P8C=F8RUA8V5F+31E8C(M8C1A-RTP-3-C93AC.&8S934\+WAM<$U-
M.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT
M240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO>&UP
M34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ4F5N9&ET
M:6]N0VQA<W,^9&5F875L=#PO>&UP34TZ4F5N9&ET:6]N0VQA<W,^"B @(" @
M(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z1$$R
M0C8Y,#0P,$0Y14(Q,4)#-C4X,S!%1CDU.#(P-C8\+W-T4F5F.FEN<W1A;F-E
M240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z-#,X
M,&(W9F,M86-E9BTT96(R+6(T83<M,#4S8V4X8SAF,V4U/"]S=%)E9CID;V-U
M;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$
M/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+W-T4F5F
M.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I
M=&EO;D-L87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @
M(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \>&UP34TZ2&ES
M=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z,#$Q9#$Q
M83@M-V5A9BTT9C W+3AC,S4M-3AC,3EF.&,S8V8Y/"]S=$5V=#II;G-T86YC
M94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 V+3(Y
M5#$R.C(R.C(V+3 T.C P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B R-2XS
M("A-86-I;G1O<V@I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I&.4(X,T)$,T9"1#A%
M0C$Q0D,V-3@S,$5&.34X,C V-CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP-BTR.50Q,#HS,CHT-BTP
M-SHP,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV
M97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G!A<F%M971E<G,^9G)O;2!I;6%G92]J<&5G('1O(&%P<&QI8V%T:6]N+W9N
M9"YA9&]B92YP:&]T;W-H;W \+W-T179T.G!A<F%M971E<G,^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&EM86=E+VIP
M96<@=&\@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<#PO<W1%=G0Z
M<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z1# R0C8Y,#0P,$0Y14(Q,4)#-C4X,S!%1CDU.#(P-C8\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M
M,#8M,CE4,3 Z,S(Z-#8M,#<Z,# \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I$03)"-CDP-# P1#E%
M0C$Q0D,V-3@S,$5&.34X,C V-CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP-BTR.50Q,#HT,SHQ,BTP
M-SHP,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV
M97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S
M:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T
M:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z
M<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z048T,S@V-SDP,40Y14(Q,4)#-C4X,S!%1CDU.#(P-C8\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M
M,#8M,CE4,3 Z-#,Z,3(M,#<Z,# \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@
M(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @
M(" @(" @("!X;6QN<SII;&QU<W1R871O<CTB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]I;&QU<W1R871O<B\Q+C O(CX*(" @(" @(" @/&EL;'5S=')A=&]R.E-T
M87)T=7!0<F]F:6QE/E!R:6YT/"]I;&QU<W1R871O<CI3=&%R='5P4')O9FEL
M93X*(" @(" @(" @/&EL;'5S=')A=&]R.D-R96%T;W)3=6)4;V]L/D%D;V)E
M($EL;'5S=')A=&]R/"]I;&QU<W1R871O<CI#<F5A=&]R4W5B5&]O;#X*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^
M061O8F4@4$1&(&QI8G)A<GD@,3 N,#$\+W!D9CI0<F]D=6-E<CX*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @(" @(" @(#QP:&]T
M;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@
M96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$!_\  $0@!!@(< P$1  (1 0,1 ?_$ !\  0 " @(# 0$
M           '" 8)! 4! PH""__$ %<0  $$ @(  0<&"@4'" D% 04#! 8'
M 0( " D1$A,45I?4%187&1I8&"$X=Y.4MM76USE35W:6"B(C,3>UMR0F07%U
M>+&T)3(U-E%A<G2X)S-&LK/!_\0 ' $! 0 " P$!              $"! ,%
M!@<(_\0 4A$  0(#! 4) P4-!P,$ P$  0 " P01$B$Q404&0:'1$Q9A<8&1
ME+'P(L'3%%-4TN$'%R,R-392='6SM-3Q%3,T0E5B<T-RLC>"M<0DDJ)$_]H
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M"M"OVAOQ(O:FIO=2'^+Y[CF!J]\W-^*=]58VSD-_%/M#?B1>U-3>ZD/\7QS
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MCVECPYH+' 6APH<QTTQZJ;2:"\9K%&'5?L(0GDGK1*K3[67PL*RDLM;%UPX
M)&XP5T&J!929F1PF.AC"+R'0R'WC,D<2#0')M2XG8 _)8),<K\KM*:/; A3)
MFH9@QGNA0G-#WOB16EP?"9!8UT9T5A8\1(8AVX=A_*-;9=1?@ :[<!3IJ2!3
MIK0[*KLP/3WLU)#<YCHVG92D4K(W'X]8FIK81&&$(*2Q@4)Q764&9,3$!@K"
M3,A#M:/&7[]$*;V5%H#"#IP=")$<7Z7T;#9 B.G(5B99$B2Y8'Q#&;"+6Q>3
M;"8]SW0RX"(QK2]E'%S0&/+5#^B;L<!2ZM]2-G8N2AU4MQPT=QM.MK0^F1G>
M*E(JU]O$V23?62MHD2DKJ/Y?+GTCF9OK\FK*-8^E&%1KX/KN0;2#=SEL/<PZ
M4E0X1#,2WR,R(G1,<HXGDS&;"#Z"&6<B2ZAB&('-B4:8=*N;+\C^-9I2_"N>
M-:C"AV&Y<$[U$[*QR3U[#2=/2O>2VLY+,*]&B-1LCS)B4>V2UDXEJ\CA JP:
MF8EA9):9!B3ID5A[931W)V8EKMA;F3-+:.B0IB,V;A<E*M8Z8<^U#Y)L2O)O
M<(C6.+(M"(+VAS(I]F&YYN5H<C?>-M>JE=]/-8G:G7^XJ2:1@E:$&(181-]C
M>(6=V?!3,>F"<;P(P==Q:0QTF7"2$<+5.C&CHH(?O!VI!5P-U=;/QY%LTY96
M?DYUT5LK';%?!##&99B,B0>4M\F(L.(QCX;G<F\ACVM=9 =2RYA<O&((KAA?
MAA0G,>JJ'>;:)PB<(G")PB^[WPJF*A+P4:K9)1<K,U%I!/\ .L;";/M29#T7
M:"0KYV;9&LW[W&&&J623CT+17&6S-;"N4T<J*Z?!->?SFTA_V2/\!++F9^*.
MWS*TW?Y3%^6_4W_=ABG_ !/MGGN_N<_D::_:47^&E5@_$=7O*^=/GT!8)PB<
M(G")PB<(KS]=Z'ZP6_ ;).S"W+YB,PIVHS=PSX+&Z3KZ4QI<$+L2&P) ;#Y
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MQM-^TV$S26BY:1@Q00YS7L;I!L0N:*.#6_*81Q]KVJ7M2MX_VDDW8_BTI@,
M1C<<;E;$AVNZR,C@848GN9I5\R[+U_9\Z!4UUGC/7>2-()"<S-RR,6)+HYL
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MQ!LA2X4JVC@;L;1)%Q_1(%"1M)N"Z*]N_D;M.KZ^D&D78R6_I78J<F['C9\
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MF/ODI#^8O'/C5KZ>_P '.? 2P[+>.*?40>*-]W)C[Y*0_F+QSXU:^GO\'.?
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MA@OLUPKJ*88:M&+I]Z!$B6$L]U7Z'!,Z^Z @P(D27CQ9J.UIY* V7CPB]_\
ME#HD:&QC6 T+G5+@VI:UQHTPL<;J4!K4U%W9MW=87VTZC$(=<5"P81*5V0('
M2]F!V<0<?*:RT@;1MW4(H:;7<H-,B,KQUKG9LIL^<M7BVY[;8<W72U?9;_#H
MD1T6)$BNI:B/=$=2X6GN+C095-U_E?SKY;_%'\$+MW:';.S+XZU  -KPJYCN
M\S(!UYI%8?*(7)'K1MH?'OT9F5CXPH'=D4EGX1^().W:;=UN/(CFN6"3XC]8
MU:UST5*Z*EY'2+XDM&DV<BUX@Q(T*-##CR9:8+7N:]K2&O:]K6DBTUQM%K>(
ML-21>":XWU[J4NS6N+ZB#Q1ONY,??)2'\Q>>@Y\:M?3W^#G/@*6'9;QQ3ZB#
MQ1ONY,??)2'\Q>.?&K7T]_@YSX"6'9;QQ3ZB#Q1ONY,??)2'\Q>.?&K7T]_@
MYSX"6'9;QQ3ZB#Q1ONY,??)2'\Q>.?&K7T]_@YSX"6'9;QQ3ZB#Q1ONY,??)
M2'\Q>.?&K7T]_@YSX"6'9;QQ3ZB#Q1ONY,??)2'\Q>.?&K7T]_@YSX"6'9;Q
MQ3ZB#Q1ONY,??)2'\Q>.?&K7T]_@YSX"6'9;QQ3ZB#Q1ONY,??)2'\Q>.?&K
M7T]_@YSX"6'9;QQ3ZB#Q1ONY,??)2'\Q>.?&K7T]_@YSX"6'9;QQ3ZB#Q1ON
MY,??)2'\Q>.?&K7T]_@YSX"6'9;QQ3ZB#Q1ONY,??)2'\Q>.?&K7T]_@YSX"
M6'9;QQ7N1\"GQ3VWIO5^O3=OZP@HU<>ANFDTO3ME?-]*W6]'8^OI4%?-U](C
MOYR>_FZ^=KGR8\D.N^K)I6><:&HK)SAH1@1^ N(S2P[+RXKT_40>*-]W)C[Y
M*0_F+R\^-6OI[_!SGP$L.RWCBGU$'BC?=R8^^2D/YB\<^-6OI[_!SGP$L.RW
MCBGU$'BC?=R8^^2D/YB\<^-6OI[_  <Y\!+#LMXXI]1!XHWW<F/ODI#^8O'/
MC5KZ>_P<Y\!+#LMXXI]1!XHWW<F/ODI#^8O'/C5KZ>_P<Y\!+#LMXXKNH[X!
MGB<FS@P21I2,1)@_>(MG<ED-O5:X"A4%=\:J$"2$8E4CD*S1MKG*BR8<$5?[
MZZYPW9+J>33.$37K5MC'.;-Q8KFM)$-DI,A[R!<UIB0X<,$X O>UN;@$L.RW
MA?=%U5HIKUDZX4O030QM(L537\?B3N09;[,]3A9BTUW-F$66RJ^S%J2,+/GC
M1ANX<;LFJR+79POLCE7?XKI.=.DM(3D\6<G\JCQ(HAUK8:X^PPF@M%K T%U!
M4@F@K1<H% !6M!2N?K)6 YHJJ-B5RU &9%29>UJV%#@4S1K@V0(SF,,60>PW
M&C-5"!E'3DHD@/F:Z9!@HC%G:B)Q71\SVT8[:N4<[E0"2  220  *DDW  "\
MDFX 8J2>%%T,FE47A05U))E) ,2CK%1FD^/R8P/ A6:I%\V&#TW10JX:,6ZC
M\D\:#V>BR^FSI\Z;-$,;N%TD]B+ON$70D95%PYJ/1LO) (N12Y0FC$P)$P/8
MFI.J$8Y)F4H\+<N$GQI00-QD@3T&H.=F#'&7;K"2&/2<(N^X1="SE48(2$U$
MF$C OI7&V0@E(HRS,#W,A CI!Z]\@OS05%QN2%LC?R82^2'3YL@@2^3WWJ:B
MWJCCT9%WW"+"9_9=<U1'MY;:4_A5;15)TW8J2:?2H%#H^F]=^?AJSW,R%^.'
M:NG/HU/5V^7.%EO,W]'IMYNWD(NP5FL-0B"E@K2V,HP)$#O*EINJ>%)Q!*,)
MLLDE)&I)=W> V@%,=KL0W,;/<#]&6,NMG&$,94X1=F,-!S27IPY8861R@R=8
M6&/VK]++8DT2?CG'I&JJNGH'[%9%ZR5\OHW315)PALHBIIODBX<HE<7A )_*
M)I) $1C(O#?).12@P.  AV';M!@UR_+E7+0>TPY?.FS-OEPX3PL[<(-T_.66
M3TV(N_X1.$3A$X1.$3A%!O9'+O%,2[+'YL8=>GBWH_GC@'F.>3YY1[TGRAB2
M8R%\[T7G^H^N8\[Y1]4]5_Y9ZOPBG+A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$4&27+O\ "(J;S/FQZEFL[C]9]=P"
M^=WK'RW5'JOR#ES_ ,XL!O-]8^</R3GY+RY^0OECRK_)/"*<^$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1?*R*Z4=MJU[RV+W7,U=*;HI
MF->*):<E$=6"  :]RQ@MMUG6\40[X56GL=12DTY@I@<(#,A!88\("8K&)2_B
M.@LX3<%$"RJ"*75ICVDT]^R_$J'VY3Q6J7K3N!>'9"[KLJ1_2$+=W1NZM.5"
MHY1EA795_8U*?1:L:JDI.W7[!_"KAH\1(JMS :_@<>K@VQEL/9R'1*QA&$'Y
M+B0 .BMVT4K0 88WGN6PZR:H[4=@/!<-_.D?.[/[(]E)56W8MQ '3UP0+0D'
M8W9^ W(%JD Q+.4DP0.FZFV&QW8$CNW;L5(R6631]874UW(*!PK2@NS&&/34
MJM,IJOQ@PQ>:S6H)EV8>V!8,E\6*,LHY/; 8%:MA\0'NB93HL_BL:E+U2*1$
MF6>[YUKR4.O]/C#IB&D+YG$&#88R)5M*4_1P%_3ZN&W''I)%17=2Q7%)R^G*
M_P#$"'$( )[ZIU_)^X]DPDS;D(G5A=#FD)A!,&=8DU);"(T:OK#L;$U)U*2Z
MNDEU?'HWO'(.Z"LVY4EHH:UP+O9H!0NJ!F*!I)(;>2*&EH]%::_BQ6E74_DT
M6CO>NJV"*G11N$CCUH]WD$@WB5$6I&^Q&Y(+6M\0BYHO%9)<>8D5E)VK3#R?
M$B;>,G3T*+0=X8<MB@LBF!QV=(NPH32M^^X+NU:\\4';8U/Y)7':*(CY16WA
MB#.PK:H9U"R?96002"">QB/8L)6MCLU8RZ-66..%ZG)3?,><#9.H)(FAD?>N
M7ZK]9R2[K-^S;=2[++IZ*KJI%4'C!2FGY*3<37N=&9- ^GUT33KP$#V<.&3X
M]:;'M@7>=;8CV#S&B+B/3BX$NN;L8C/1#QPY&&4-=&LM7?'1Z^$B>ST7D5QP
M(O%,* X;5LQ\1"K9B1O_ */=BI+UEE?<>A:3!]@@5KT7"HO"I_*!$[M6+00=
M75KC:OG)H&#G.(ZI'Y9$WV$7"Q2*-9DH<'MMV^""J!0'&^AN]5%X[.U4-FW5
M[N%-JXG,<@5&W=U%J2/>%3<CJINFU2W F=JC3MA-+#OYM'(#+DF.Z :72@A
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MV'K=A!66V#&WT '"(ME<U7C0P C+$G,DR":Z[$Z\%IZXV5*D"H )-0W$ 7D
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M(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+3=XF_B(V3TUD"
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M!GC +H\,Q89@1'1&V6O+#:+H;*&HP%;LE/55553QA>IR5CJ5=L-MWYRI3?>
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M8[%&J34L\:(-'N2XO&Y5FEJOODH,UV(MM7#/&5^;,*<DX\6) @34M&CP*F+
MAQ8;XL*PX0R70VDN;8>1#) _!O-@EKKDP^P\%U+N#3,'$(U9#D2Z8Q63&I %
MCA[1TTQET9B2,?=FT-&R+G8DRV8(R@"JFZ=M6S=WE]C ]=RHV=ZM\VS$")'C
M2K7M='@PX<2-"LN-F'',5L,DEMAUHP8H+6N<6V3;#:BLZ>SOK]JE5;K[*4J2
M<7<*G4!/"D748'RJ(1\V;>S"-_/0F<91EO(,8CZ,26)D7,:<O7,3%2PO+PK!
M847.1X<R=ZN4=0:2AG2+='OEYF'$<V.^#,18<-L"+\G9#=&,(\J8X8UL9K6S
M#X$.7B.$2'#C.<VAM+NW#/JS-^7:II5Z(7<WF#&)S.90"%/!E=5A+WY>72*2
M[BX<ZM&;.:_@5:DE0,8D))E-MY@W=BWXYB.<Q^-J,RK@J>8H#GBB?7C6/1[H
M#H\O FIAKYN=EV,@08(B3 DY9LU-3C!$C0FOE_DY:]KWO$6,'0PR&XO 2E+^
MVO3_ %!'955I"TU<QZ>2B%Q"!S:53N#&WH^3#H<%+2(H"*BSWR"Z</5 :#S=
MKH@?\UG@DIOHW];W3SJX\NVNW.VB3\C#EX4S'FI>#+3,-KH42/$9"9%AQ(7*
M@-$0MM5A>U8 ) V8*;<>WWKNW%!=E&1@7&'E07(Q/6%H7<"P3R$3!F3END=W
M];/+)#W Y)R5U!94U?%E-DE=1B2Z+]YE!%PDNIQ#2>BW0WQFS\@Z'*E@?$;,
MR[F0#%NA"TUY#.4I9AAIH\@M;4@@6^_?VYK]JT#<^8]-'IZ*RP.[K!2,M'T-
M/@Y(UE+9M+HW+Y^F[8Q]P-RX8AQ\-A,CF1M^ZU8LF85MJ34WW16PIK1I*0Y2
M V''@1!.<LYD>%%@N@N= C2\L0Z*U]'/?,3$*7AM!<3%-@4((2^[IP\O<NPA
M'7B\)B=*AM@$DB&X.-$Y<1*S(9)P8IHE'*IDMO F*KS ISL@9D<!BI4C!VZJ
M2>I-KA-RW<-Q.'#]#"8TKH^6A,B<M!C")%; 8R7? BQ'&+.P9"*X-MBL.%,Q
MF,F7 FRZH(=$HTNLT'NKLW[UE:4_[2M B_6IE&"PTMJ 29/XT*J0$+N!Q$Q3
MQK:*0DE(!\3;V<Y",G MC,56[LGMY& QFY<[[!V3=)+A,KH<Q1I=T6$]G*ES
M([YZ(^0$>('21B,A/CF3$5P<Z "U@ <YP $1Q)@NPQQKU>MR@;$)L=A*04#S
M&I6.F$@< -@$4<#B(TV1<S!JSVC2C(6Y3;N=MY$Q)L%!2VJ6N"#%\U50W4;.
M$M]NR^42SH,29$: ^!#$7E8X?#?#8V7<[EK<0%P A/8X/!/LN:X$6@0K>+OZ
M9?8I"M2A[1J6VC]'NLZR^8QF.L";]O7S@E)AJ@,G!A]FD<L%6[-%5\,#Q]^J
M0-ND&NPM+ \@13<.!R.I!36D](RD[)0M(L)@P(T1S6NFFL@/Y1DT^29;#G&R
M]\5H9":YW*>VQE&O):%^%^5/<O? .OEUSR1H1I(#(8KHK$W!G8U+QDF#QYM'
MG=?2RTP*#A_H*=^C;3B+PL^_B"7H-F<ARU4=-U/4$7CYMC,Z4D):$8KHT*-2
M,(8AP'0(L5T434"2B$-+VU=+1IB$V.ZU:A AI]IS6N7CRQW'@5U3&DNQ3QF=
M9#ZNMUPRC(MF2D;!M$I;NB$%%Q*LB8KE&6C'S62)$%JN?;ZKI:9<A]5BVFN[
M'51QC)VD-%M=#+IV0#HKW,A.,>!6)$AQ!"<&.M7N;$(A$@W/I#K:(:EX_KU]
MV)NZ5!_-]1.$3A%YQC.V<8QC.<Y_%C&/QY_'^+E%:BF.Q%]K7A=QGLY%NL,>
M8=DWN<YV]65JX :0=?/Z,P#+77Y/&S1XNKG.-]_*FK'PCI#)B.ALHCBSK13T
M ,#\!UQC:'C:8BNT2V[VA.Q89:):--6O:?+M PQ$6('<G%B5=#;2L2(6QWGE
M$4!2APTT[)T^U4-&V[U:K+J5; 6S)-0 400.U#JZ(E7^3+=1J2$[+-T1#?0"
M3U=HE"F^Y$5EMJB3>N**?>$7P[>)Q^7AV/\ [WB/V,C//T/JC^;NA_\ @?\
MQ,9%OR\1;^B9&?W.ZV_[V@O/FNJWY[1/^?2_[N91:\? 7_*)N'\S&_[;Q3GJ
M/ND?DF0_:/\ ]:,KL/6/)RUM=V?RT.S'Y_+(_; ESU6@/R#HC]F2?\.Q7_,W
M_P!OD%]&WC:_D2QW\\4!_9>:\^6_<^_.&-^H3?[V L5%'@'?[%+W_.F%_9%G
MS=^Z5_CM%_J<7]^5=@ZSY-6@][^6<\_[S[G_ (KJ<^E,_(;?V.W^ "BW(?Y0
M#_[4ZL?_ &%Q_P#F*RYX'[F?XFF?^[1_E.*[#UCR<K5>!I^1S,OSYS/]C*^Y
MTWW1?R[+_LR7_B9Q#@WJ]Y7SC],?RP>LWY^ZI_;@)SZMIW\AZ8_9D[^X>CL3
MUGS6SKQZ_P H&E_S.*_MM(N>/^YM^2](_K[/X=BBV#^&W_11E?[M]C?]Y3+G
MF=:_STA_\NB?_"74=@>H^2T[^#'^71#O[CV+^S:_/=Z^_FY-?K4I^^56;^.1
M^68"_,9!_P!J)_S5^YY^0(G[2F?W$HBO.1_H#]/[CCO_ ,D6O/.M_P#4D_K#
M_P#XER*EO@5?E>3;\P<M_;FM^=_]T7\A2_[3E_X:<10KXPGY?%M_]BUE_P -
M(ISL-1OS9D?^6=_BHJ+ZC^B7Y%_5C\PU8?LD+Y\>UC_+^F?VE.?OWHK7\Z5$
MX11O";BJBRI#8D3KVR(3-I/4<C2A]H1^+240<,5_*5V>K](!+QXYVX<@2N[7
M.^^K(BF@MYZ#M#.N'#-VDB10I>'9*10*S(?1U14R5O:Y91"Y!9[J.I3".5W%
MH96\;+BHVO)I9-9(F]U;/#TC-M0,/CX4&:)&W;0X[>?(X4*0*)O7!6EU=GO]
M>L%'D*\2'JG(AL/3F$US4D^DI9_&#%76 /63EL!F(2W)+01^/S9]&]9!$@S<
M5=$3.UWI+-Y)M#"AO CY*/NVTECZI(E#Y[A7;T7K/$^]749PRF;U&Z(RNU@9
M$.+-82'2)98D_/3!]7P!&#,DPF[NS?EF>"B,,#K5NA*T"$I8N0+)58HCLUP4
M7OJWN91-U7*O358F74O):TM'[S1EPT6XWAKV-'9U,ZXW"Z%E$]%6DOCLD@QP
M=*(\7:C7P5YKL'5T4-#)&,"*;;K^D5V[,=GEF*Y%A#0^K:$@4MLMWVJ>Q:M@
M>R:DMH*MJ1;9:A^Y_$TZPUQ +!D\,E3*Y)?!RL;CS"OXI@JW=RPS*[5#THT=
MQZ0+@7@PY# =BFT([-)M$$Y8(C)!%<*MJ[D[@9'R- J:7=I Z,30<,3<JQCG
MFR+()I^,YK!>0![3RT#&I)- *N)#02+ V)VKH>F'4."W-/ ->RJ8@AASY!<I
MES6H,80)#8_\L28H("KM8O$$Y.6;1Q"9S#$<C;HJIZIJ]3=85;)18FE30U )
MH2*$C82*FE1B*FF%2H@L_P 2'J15[U^&7L3662839\(JHC&X6%+FB*1V6W/#
MJ).OQB^K%$9*!=73R;BAEJYB#\^1AQ+.D7?C\S,F%CA-2N7:0,2-I]9W7JM8
M7FR+(-WX[VL%Y 'M/+1B02:T#:N-&M<1PWEV]0^QT1BQVTI+'T$JLN^N'>D2
M4L$ZB''6MO/"@.E=I0PBQ$5'[ 8.Y:%TDT:%2=C(X>"ET;3D#IJSDE>;E 0]
M=</+#LP1P#3[+K0(:;5DB\M!<*&_V7$M)%QI47%6#J#LW078!A(R-264 FK*
M)- Y8]NV2(C]V8&0M7S^,2U!L;8#7!&%REF+*.XE-A:+R)REN*)K1XR23'O-
MD2Q59JY[X%9LPA5JF^ML_A75VT8R;FD!OU])8@:=)0$9##EA [%LZKPKA>55
MK7\ZB(%R3B9ER[/$FSHO&0LV PPV=T'MIUT[OM5IC>+O5W5_2J[&JN[QV72^
MC1EE=;IW2,%[28(I=<IU(Y7!Y"M)";2!';5&Q2R(G&R#@G54OE-9Q>1S".B5
MG4H';)1\J /&P,LU'@B%2F-X-%.QOMIUIBI!Z&D%QP@"4&_3)L_&DB&S%XTQ
MU]$#)%=&Z[99!-1/6OP!L0?.[[:XUP%*,2S39TP=).-RBI]+?%DH&%DGPHR'
MD>51$AC#$R7'8U*1<;&)1W3*=+TY$L=8MEL_*@*2AG\RDD+W8I'AP]+>,-\/
MI.V(,V3N[Q7NK7=YK*PZS;NH33\9MJM";V5M@4%:EM,+[Q69U/$0ZM-GC<@Y
MLR--H$2C0@F*F.SM_DH2EQ6R9Q5/T<8KO01F>M9HWFD /1C(1X$1,K2UHYAR
M8K$B:[L=YY;_ +/6"E#Z[_*_J68V#W!KH%1<(O&KT%;O&6S.8/651B8D2'A=
M)C/)_,M((*$D#4GW&LX@U"'="6LS6.HIE8[J",C< W\F0;1]W5%(77:]0O8>
MMLSX4#*11^)F]F5?-(@9="R!*)6/3MA26KK"CJI,([?""[0=+XF7U$&ASG9J
M;"[CB^B33UW+1 GKO4Y\(H-[(N';6F)>NQ.B(TZT7BV$S1UNLZ%,\;S&/Z*:
MND&X@\MOEVEMNR;YT%.O,=.4%-LMM--G2!%.7"*.[>_V36A^;N;?LT3YMR'^
M.DOUN6_?,1?SRM?]6/\ JQ_X<_3SL3UGS1>>1$X1.$5PNK?<"4=7!T];QR.L
MCQ*3.8N;BI1\04:;0.6Q[Y;#N9&-0T9.O7%C<$ETRAK]MZ9CKLW-MWRBRVPM
M%HMTFE]!P-,.EC&BNA,@B-#C,:P.$S B\G$$%YM-+1#FH$O,-< XUAN: +9<
MJ.D5]>NE3>KXB:BXVV8=M4 YO6%NR!@R,P5C*$D=0]/@*=^B.(UI'C;B(NW@
ME_%DQT5E0^8,T4=G)F,HMR %TQ(/4MM :KM#Y&8_M!YG9"$]T.:= ),2?BS_
M ,NCS<:&V.UL1D8OCP'P'$TAQB616N8PI7H];?LRO4+71VH#6Y3<.K=:M=$)
M5&=X0GM8YTO'#\A:BH3$'L3UCH$PQ@$<G*T?.8<M"KD=84\L34&H*'C(UN,'
MHZ:Z;\AH=\C/3$TV<+H,83%)2%#C0H3GS$=D?EHL-TU%EA%AD/:UTI+2O*<H
MY\:VXE/1RZ/>H_E?:F\II2\6H213^2D:ZBCMVLU%N9%(W.I(?LA%D0,>,-79
M=P*=QV$YBC->%"TQK=( X?E54-M\N4\(;$'0^CI>?CZ2A2L%DW':T&(V%";8
M=6,8L6&6PP\19GEG"8>7GE U@H+-\4GUUVZ&U#5X^*UW5R32<)R" 2<F<E4Q
M(S6N%)57,K^=(FP 54&Q>[>.V(8T;B8Y(#S24+#=XZ-68AP8C4JZPEJS>A73
MTXZ/-3A=+F%,P60H$NV6FQ!FH'(/E8D]#?6+*,K$C0H1@A_*O#HD1_)MK?7'
MO]P[98QXAK,Z_%ISNBXV^CB$&JP(8%P8]K!"9>8U!9SJT8K(_EK,9D.K:/+E
M'CX01B:HY\YU'F#+MC)6I)RBNCI<V70V/,MI*,R,9F=BPWS,+Y2R' GY-LE&
MA<GRT(NBM8UD1D>TT6X<-KH3FBA;>B@&%3GGA7#[56(+V,+,G/8TF3!IOC'8
MI=@^+O&)146W D$KEC-P$E6S7U-[N_;/W4?5"I-=W33+1)_J]V7=9:>J..WB
M:,AO;HMC8A;#T4'MAM<RV8K#H^+(,:XAS0QS6Q!$+@' EMD 5M *;03D*^>[
M)6_AG=B&V#++%C]F!64&@UMRSMC*9*3)R23O\(CNQH^!;-(8V,Q6!R$W'7$>
M(5Z,31FJ,-E[1ZW=JL2,'2&J.=\=%'U?C2L&4BR<5\Q,R,#0D&"UD* VKM$N
MF;4PZ',3,&'%$5DT^U+_ "B YKFA[)DO#0E;QMNI?09[NWJ(NIU=P=SX0,NJ
M#F*J 8E<&@9^#NY*HZ*&F0^T@$<Z_5]1Y*&)*'03.1LH_@,/M$,U/G!?RN6'
M3U=^[ CU$]V;CDD- S#M'S$.=BB!,3,*9;!#&0WNDHL;2DUI)DP>3BNA.B\H
MZ2>8<)Y9#?*AK8CJAP$]7=U]FW&@PN7*)^)Y,G\P@<X;UX/&GX2\[ %=W:!]
M-UJ;,6K&I/"JP<O&A&-/!V6-$PPV/B\?%N6+UJ?$BE6SCY)2)+Z(XLU0EFP)
MF6=-O?"F!HM@:8)')PY*+"F)P-+(S76M)3$-T:*\.8Z$^("+=@577TVG;N)Q
MOIE]BK4CV4"H]I&G:'6N5D3*!YM8[F),)F['"'=N),=7[N2:$6@5(DTB9*P,
M;R]]"T<Y6W&N'423DB;)75^GVYT4\Z'=H?Y6##,(R;8[I=KWMD"XM$&PZ)8=
M'9+4@-F#=::(W)6A9,]>O6*_,C[5FW/9$GV<B,2"!)K(4GY \'DZRL\CFTLD
MT7<1R:EPS<FBP>BA951^2)1\,H]?+Q#UM$>-,+M!S'",A:'A-T3#T1'CQ(LO
M!+60GP1\EBB!!CMC2S(A87M>]@:QD6( T3%FV]@<]P-PZ=WD>"[27=N2$D[0
M03LHPKZ-1E>&(5BP7A(3?5H*D N"1L1%S0TD^0'H9]7EH=D0";^0<ID1&'8\
M!K@BF(U=.\(&A&0=#S&B'346,)CY8X3$0%SX,2:C/C0WL:7&I@1',B4M_A(S
M7Q/8+Z-;=OOZ?Z=E580CXFTC=2>LI*/K$>)6K24VX=9I)27#S8H*E4<G\2I>
M-/<OXRX:*#J#C5BG (/#QB_2D0GS&*S4,EOMSK&:HP&P)R$Z=?$$Y D83JP;
M-B) C2L?2$9MB*"':3C2L.+$LO:83_:M177IZX;S?WWK&P_?D"D2LPU)Z2;R
MI>UGHB7S.,E)/'2=>R"S$X4ZBLHE#J*R>L9*N!:28LX^=VF8$:A\S#NU'H%M
M.5@*S!J)YHFK3RR3AP=(F ))L2!+Q608S9J%)F9$>#!;'@3<%L5T)@$ F9AQ
MX$1H;%=+"+;+UWH4W]]_5V:VL8\F,8\N<^3&,>7/D\N?_GGR8QCRY_Z?)C&/
M_ESU)O).9*B\\B+SKKG;.-=<9SMG/DQC'X\YSG_5C&/^G.?^C'* 3@B^F3PM
M_"^Q&,1[LKV0CWEDV?53565@:;>7$<Q_F.!\VF(]QKC_ )Q>7S'4; .D_( Q
MZ(N22^7\LFX'Y-KCKARO*Z(T3%_ WPYZ<AN_OMCY>7<#_<XMBQ1?%O8P\E:,
M0OH3Y\O1.$4&25PZU[$5,VT.B&K-:L[B5<1U=NON;+KH&ZHU;$QKK4.NW08!
MM%G")1%4X-4<*EAVR0\IJ@JL-(ISX1?#MXG'Y>'8_P#O>(_8R,\_0^J/YNZ'
M_P"!_P#$QD6_+Q%OZ)D9_<[K;_O:"\^:ZK?GM$_Y]+_NYE%KQ\!?\HFX?S,;
M_MO%.>H^Z1^29#]H_P#UHRNP]8\G+6UW9_+0[,?G\LC]L"7/5: _(.B/V9)_
MP[%?\S?_ &^07T;>-K^1+'?SQ0']EYKSY;]S[\X8WZA-_O8"Q44> =_L4O?\
MZ87]D6?-W[I7^.T7^IQ?WY5V#K/DU:#WOY9SS_O/N?\ BNISZ4S\AM_8[?X
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MGO"M^,B?4E]V?ZFI?\?K_P /<?? U>_2GO"M^,B?4E]V?ZFI?\?K_P /<??
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M@@"N>N>RA*TM3D6I2RIK2NPPK'56PH8'"R;1I<P!Y%Q,4L(E8 8W+1B<[*T
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M0\ZT"LB5Z!LOOK=AM\J'I62U;X7-"52_F10/*K)(OIT O..F]54:IBP=NS[
MU[0-:33("*5K5D&B,;T&QSKA /FL/" 60D6]<2%PZ'DM2#9)@2O0/53[_)=!
M*_"ZZ\/T9"P+VK<@$7./7Q H8WEL $X"223UI4-8F"<.)+P#)O:2G0%"P,EH
MU?DS3-D;'$WP(4.;OG+/5Z]>MO4J2"T"R 02;7M6B#2C34V:-()%&@U<;1<
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MY_'Q0]'_ .OVHF.E-9ZN]G^#DKP^W1PWW>XS',.]V^NWGZH;.,1_TVR.-_\
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MBB?@:U_[3S3]8 _N+B_,=QXHGX&M?^T\T_6 /[BXOS'<>*)^!K7_ +3S3]8
M_N+B_,=QXHGX&M?^T\T_6 /[BXOS'<>*+SCIM7V,XSM)IIMKC.,YQZR!QY<>
M7\>,9^0<^3.<>7&,^3/D_P!?DS_JXOS'=]J*T@ &.C047'Q".6XP.R;L&26V
A^RN^J#=/">N5%=\YW55W\F=U5=LYV44VWWV_'MGE1?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g65062g59y90.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g59y90.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1LL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &Q"^:2@X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!PINF
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              \P   :0          $
M                 0             &D    \P
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   \P     4F=H=&QO;F<   :0
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   /,     %)G:'1L;VYG   &D     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      0J0
M  $   "@    70   >   *Y@   0C0 8  '_V/_M  Q!9&]B95]#30 "_^X
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MY8PN'TVT-9^DL:S_ $SW,9^XJO4>F-KH=E8;W.96-UM9=N(:##K*GPQWZ/\
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M7,JAG@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M+3\8^N7\>_[^_!\#30)IF3R(9;V/_I/UPFLQ9Q?I*I%_)0'G]Q@XWS#U2?\
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MN0;8.HGD ?F/;L2<_O@C.>^,=^VW"%!DV]/LF?S_ %PN^P]8&]YX'4XV&>5
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MV_0WWMS'.%*YL1OMOO')L+WW(M.^#K4YX$;G;<DGVR-PDY&Y]@-^&% ',&3
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M20)W) 'Z'U@^41C:FZ&_4L#N,X4#W[;9[]\^?/?@[@SL/D)_/#%*3)A1)$2
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M0+1I.T3)D<_E^DQ":03)@D7$GI'3<6VG<SMC1ZV,XV.Y[$@]S^I]AD=M\@9
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M8GZ]?G[8.-.K)&^"<;$# [>=R1Y.V>_G;B,S8&XDD7,VG:P,_2('GB209ZB
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MEB)YX^?!CK\\3!$>).V\@@^8'G%CL"3!XNJ1-1=+J6;%+D*6CI0)!20%]/\
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MMB3^NY(QV&<_K_3MC@PG2;$<WL![]?+T-H&A06,@']-OKV/^1Q]>#!)@">D
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M?=K4GN9U.@I7W2DK0D)2VDK+RU)#;:A^FO9W.F^TG9O(<_H4+ SG+*:K827
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M/3((0WA+2P@/I:')TC#V9U]#E=,XV:VLJ&VFDJ::NM]T+1J?-#1.)4 I#Q;
M6SI4X0Z$G0G.S.LILIRZLS.K*&J:F8?<U.*7W2G&F'%I;4E%65:5EM2-25)=
M.BS:R"3V+Y \LJRJN7M61*FP$FX:D5:(# ^2:F/S7%-/R ^VVI,]YFN>46GG
MU*5F4%MMOK;/'V#0Y(SE:V4H6AHTE&VU4+0 &WG$)3H<=05E2ED)&T)1&A*H
M*0CXYR:G=75U^:*2H.9Q55-94,(0&T.U-94N/O/%0U%;B0HH"RJX@ $!(QUH
MJX3-=7Q(3'J^E'8;;1ZZUN.X2D !:G#U9';IPD) "4I2 $BFM16M2C$J))@
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M'0Y?WE91LU-6H)<7J2XVDE+86VXMI10%$$)4I!4D$$I20"203AI4E*E(;;F
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MS*@-5E]$I!?>RM3I;=?6I#+JREI[NETR%KIVJBK2U3E;B%*;<P:!,U-34*2
MEMIP)<<D(2[ (2 5!)*DDA5E%""I< B1S9YLZCD6M[;2Y<AN1(D3)#CSS9RA
MQQ2U%2T'()"B203ON"=\\??W9;+:?*\FRN@I6UML4M'3M-(7 6A"&PE"5CA0
M $@;&1M;'!U#BGGUK6H>)Q2E0#<DF_Z@WM!WL:TV<GK<5N._;)V/OG. <[YW
MVSW''8LH\K]8.PWVN>GTYQ3><BPL!QQT&J;;;]9OO.&XXZ5$E1R2>^0=S[C;
M&"<?7V][:4@?=XYO>W.UKG%36HZ@J"9@D1MTL3 MMM@N5D#<G/T)Q]//;AQ
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MZ9VMS-=,FLHE.N9>FB;J6UM..53*4.JI*:I?*&E;&4OI0X$*&L.%/\L$ N.
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ML(=;8-2AQRF<8^'2%M,4R2T'2ZM*-"$R2LI X:CK7\DS3+<T/>G_ $^N#NM
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M![@]L_7M]#X^O%C]/WG$*I*A:.D_.]OGTYPM14)\D'R.VY]OJ?([C' -OO\
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M8*LK+RO[\IQL?00<)4  ,.+0L;95M@1%VF: A)>6!:!X/_M$?H1Y#F=+;BA
MTM#:]U\[@6!-XO*>#N,!N@TY 47;"2Y9RU$E2I+RU)*\?FPRA0"LD?F2M;IP
M-]APAJ*ERS:.[1L E,&-A"CM?< )C8SB1-,W<DZS?\1E(MN1^'SO[^:'9*==
M"TU_RC; ) :92H 8R-R$A .XV*3@]R<D\3MP(+FLJ-R3^UR?I?I@("0-DCH
M>-[CP] (OTO?#(")<Z6F''9?ERGG/3:C1T.2'G7"<!+3386M2B1@)0DD^WM<
M4I#:"M2DH0$E2EJ(2D 7)*C  'G%S&(PA:U)0A*EJ5 2E"2HJ)VA*1)-^DXL
M+HGX>==W3;;UAZ.DH;^%+DV22_9K;4,]#-8RM#C1_P#M<V1#6 .KI4>.:K^T
MV74Q*6M58XFP#1TLI5>272""/-M*QY].AHNS>85$*>":1!@RY=T@]&@002.%
ME"B8D&^):U5R=Y":/Y?7<BQU\F1S(K4/.?A5K>0WIQ97'+D.=#TA4LFV7%0^
MD-R5/L3FDMN]3BTXZN,)K/L_K*QH-48;H'%0'&65A)4" I"JIU7=24F4A)0H
MD0 -L=#2=G*!BH1WR%U8TZSWJO#JU7EM(0-KZ5%6T$&0<5KUO\9G*&%I65H-
MO05S5V,ZOK)4.W=K:K3M,BQBXZI$"0EQ]^76K<2XE$LL,-/%!2@E0(.Q2=D\
MW>>36&N:=;2M:7&PZY4/:%'9Q! "'(@E.I2D@@G><;["&*9Y*F&FT!!.G0TE
M(*3)@$ 0"-O?<SBF/,?XV^8KZA$T[<Z0B-%GTUOTE'827& A 0GKL=4I")<A
M0R77(U,Q&2L$L..I4D\=;EW8W+TC54,U2S((2^^VD*G<ANF)*$BT:GRHVU $
M1AUU&(\)VB3Z;@$]?P]-Q.*N:OYJ<P[2.F?J7F!,LD2'$J_"&M5>HXM"SMFN
MK'%P8[0!RI*T-)0!T] 40GCIJ3+,N:)134#;13([Y5*0 =Y[QT!PF=C)/G%\
M.3<@ +'0E)TV')L)M!L=HV&&HQJY3;2K&(='P9*6U'U;(_B]DYMGT_DI;$^O
M6I?8#Y#;)ZE#OQ952I)#:S6+3,D-0RV!.^M"FW(%O_$D[#H9$I@@&";G8&=@
M!!$=>/0[X;=MJ2%<QUW%G>M_C12E":JOTO"@,!*%_E29=>JN@L?D)/J-075@
MD)*5X&)6VNX5W+3)[@$DNN5*W";;Z7.\68/"G (O(G#P0-X$^@]XFVY%K&/(
M03:U?539C*+M>JC3)9Z7(L2]9E2O7"ATNM*GPC$0WT[%KT.K/Y@[W3PQ:%MH
M46?A0\392F"E$1<'0X%$VF=1Z1A>\2".>%6V',;?0\\\R/I'7N@JN3*B1X.G
MFZ]20ZU8<RM)R-7V(D$$*:C'3<ZJ88CH"4J"7XSW4M9.^,<9]4Q5.I2M3SX<
M_"49=5)I&RD'=0?0Z2KS"P !&YPG>P3;PGT-Q N(V-XVBY,##/N=5LRKFP>A
MR*5Z,I3?I.Z?JG:*M6G\Y :K7F8[C"DYZ5=0<)VRZX1U<7V&D!EL*[XJ ,A]
MT/N#B[@5!F.('D-L+*%B8@](28VC8P/SF9Q^J[Q^=V/)\#@P8'!@P.#!@<&#
M&#C:'4+;=0EQM:2E:%I"D+21@I4D@@@C8@C'"@D&02"-B+$>^$(!!!$@[CKB
MD'.+X7US&TVW+UJ.4L.EQW3CR$I0$/+1\T:Q[*3'<>07_5 4@/-O.1I/S$12
M66>KRSM $DM5Y4=28#X@FUTAP?U 6TVL0%)TKE1YK,<CUCO*,)M.IA0L0J-0
M0=P57GK)2HE, 5XU5RMCZ?U*](?I9.GYBH\8M>@RDP9,GT?E528C;K;:67"V
MZRE]++C,3J=?93#65R8SS5T=)F%,0!3U&HN(6*A"7TJ8<*N\IG0K4HLKU. )
M\6D*-B@Z<8KU NDJ_B:8N4=0.[6A22H2MM6I"T. I<;6AQ*%MK2L!I0A#9$M
MF#]1<A9LY4VQT>[6Q7VY+OSFGBZ_$:2M!6D/U2I[38BQG7V7DM0I2E1TH_YA
MJP2AUJ&S\\]LOX+UC#RJ[LH6ZFC>!=<R:J4V'&%*!649?4*!;=;)5)8J-"T!
M:T)+I4-/T/V/_BRV^TW0]K0&:IN&DYM2I<4TX$E0U5S,)=2X8" \R"A>@*4&
M@(PT:CX;.<>IGRN8_I"B@L-1VGY,FR:ES'_S!MEQN%IV*\HH'S"F@B3,C*;6
MTEXRN@E''(Y5_"KMK5.N%_+:3)TZA4T]1F3[;[K=0XW2N5"E):6^I2W%,$.J
M-.@NIE#RGRAIP;]=_$'LDPA*FJJLS!>A(=IZ-@H1H4Y4I#8==6$RVE3*I"BG
M4Z5(@H6%VIY<?"#54;LFUFNVNI]35\5MUF;*98!CNMJ<1*8JXKR9**54G,I*
M)Z8TJY6I0<59-NI95Q[!V7_AEV=[-5",PS%P9WF#R0E3U6D"D9<TI)<9I?&7
M2A=TJJ*EQ" J&V41;S'M!VYS[/F%T5(/](H4I"E-42O^*?4%.:@JK*=;"7$$
M)4W3I1*6TA2BHK6Y>W2G)^LK$)5(2VS7/QFG!3L-N,EM]U!,E4QPE*WI#J%J
M9EE84'\N>J%^HO/>NUY"=#20DI41KL00#(TC@!7B29E)@@VQRC&7--R2 E"O
M%W:04C4J2LJN94HDZC_5)D2;37'CLQ&&8T9M#+##:&F6FTA*&VT )2E*1@
M   <9JE%1*E$E2B22;DDW).-( ) 2D     ; #88+V=C#J8,BQL)+4.)&0E3
MLA_/I-E:TM-=03E2NMUQMM*4@J6I:4I_,1Q4K:VDRZDJ*ZNJ&J6DI6U/5%0\
MK2TRVG=:U< 6'4D@"Y&)$(6XM+:$E:UD)2E.ZB>!YXY8:JMWM8:BO["7&A//
M3;%:[/1=BVY%DU=O&PP]843T6CU(AN/8EI,ATM2$*E25.R5SY"%I7QXCV#H#
MG_:+-^V%;293WKKI:[_*B0AX,A*6*M*N]=*E.MIAW^8O6I"5%< H&_F#GPE)
M3T:%._AU .7$*)*D%)"?PD^$P(!V)@XB'5+89FML*?%%$9+,..E^WE)82\_Z
M;4QF>EFS0HLH?6YA:*B0I4=*5%E*%#I] S3-&<OH,XS^H#M33T+"T-M,-(;J
M5%1[E#-,ZL,N%Y:UI2VVU5!2W%)2G2Y$9[#2G5L4J("UG49U*2(\94I*=0*0
M$DG4B !)E(.*_P#,.YB*+=.Y'@4-O6)=A?B%7*<;K;6,Z^^_$<>+2A)474K6
MM*W&DM/I;;"8\Q0=^5XC^'N05-95JS:HJJUWX]\NTU/74P[RC;4XHI:)A1*B
MEP.)4AQ]W6M1UC4EQ6AF=2EM 90$!* "5(4/$= !'0)20$QX$@#8Q&*^:\OW
M=*Z.U'%U?0P5V]M4Q)]-;S(Z$6:H\A+B(2H5@R%(GUC[#KZT*#JXTDICO,,0
MC'4PKW#LOE.8=KOXAY'4T-:V<G[,YA5T%2S1OBIIEN4BTNU"JQ"M'=50<13]
MVT&6C1R\VI3RJ@NC$J'&Z3+7DK"@]5(2XG6G2H!8A(3$RD#7*M1[P!)&C21C
ME)JNS4MYY75C*E;'Z[]P#DC(\'MY[<?=]*U"4^GM'ETMQ&YQQ"EBY/R/$[?+
MJ.AWN,16\\I2U$^<DCOOG;Z#SV_TXUDH$ ^D';?Y$_H/K16HDE(@@IY'-H(Z
M[WXZB]]&4D  9SM]0#GS@]N'>O6_]_UYPRP2 1,D"3^(3O[02(D>N"[J",])
M^_T/G;!_J>_!)._W\OL<6Q(F+#CB-H-]YM/D!.QF;.F-H6YD:3K=:(>@"JL]
M9O:&894\^)R;=FLK[5;[S0BJ837F/91TI>3)7(+R'4F*E"4.+JFM:35.T92X
M76Z,5JB G06BXMN$G4%%S4THD%(3!'BDD!Y0=*2"(U]V 9G5 ,G@@2(_*-Y[
MG_"5S#H=4ZOTQJ*]T51IT78Z@BV>H)$[4,Z@EUNGM#W?,-W4=,[2Z9M+.SH[
M+3E#*<K%L57XDN<ZQ FUD%]N:(F(WVIR]^EI*FG9K'C6-L+:ITHIT/H<J*UF
M@%.\'JEIMIYJH>2'072V$!2T..)*-<RJ9Q*U))0D-%6I4J*2$H4X5 A)*DZ0
M8M))@@$P&7)T9S6Y=:LN:&A=M)L_3SNF/5M=&KMI-:^SK2-73-(2FENQ(,V,
M-1L6U=^'PK2!76J94D5\ZOB633\-JXBLRO,*5E]\-MHJ$U,-58:0ZDT2G$5B
M% +6A1IU-N=XMIQQHI27$.+;*5F.'VU%*23I*+ID@ZX*#) (U2(D!0F#!D"R
M6B==?'8XO2T#3QYD^EJ2\K*'3<JRBS(D!^UN;*105ZD6-B6(L6/)M8TVK-H\
M\S"$R+,A.2@^P^TGCLU[._PTJ55SV8Y=D%0XE**^N"J6D?=<5ES::AIUU(:6
MMY^E:4V[3@ZGF4*;6V$H4DF^S4YFD(2A3Z090@A:PG^82DB280E1G5L%$&9,
M#",=>?&!K]:JVWU;JREJ%IUJARTF+FL4Z;71FG=6:HLZ=YV"'Q'M)S>C[Z+
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M]/R[LMD.1.K[0YP5U^9H;IW*)L(?J$!]6E@-LTU)3ON+*G%M!MQ;:TH!4I2
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MNB18CY'?SN8\[>V$[Z"921Q?U,\<6&#B)(([Y/TW)SG(QWQ@=_/#2B.D"^P
M'0@]3/T\YPNH+F"-I%XD[&1^4GIQ!QK4Z"2%*&1D]Q]1YP"?<;X.WOEVD$ @
M&YY^Y WY]C:(]4'Q*!@6BQW.TQ>T;&/+<EE. [IQG.V1N?U R"0/!W]AOP\"
M/8#T]//W$^9X24V@W,[CVD1>3[>0G&"W\[8'5_U>/L=OT.W"X8)F$SUB?3K
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M.C_"0N2XI#)*1C9O\X P0<9XN%JDI@$J6DJO8W6;_P"T2H>\#H>B!3JQ*4A
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M'EEHT!0;JD-!22A02M1!0I:5J0I*B0L$I '6%%(STXZE=5CX^JF2Z29!N!N
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M3U!=;H'6VZEEBF=<)-3,BZXTYJ[MW0?$0%E80'$EM:>\F4*2-(>2$]X)25+
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MGJZE)235+0IP-IL=##"R4*<\,BH>U=W'@0I2B$M4X5I2 HS)F)3,0-[7L8
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M&V.X\YW\8/W%955%BJ_4#S_<;^W.&2J)F3ZD&+_<&.N!$L73ZA#A&>C/G?\
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M+ETY,T]*N+[4\Q^TU@:_0S;U;K#3,-BGD,6L.\.J[",^[;*HY@-A 939:9_
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MK)]C_J=QG&>W;VX89Y%O\S/EQZS@D)N8M!L1;FXWZ6MY8/)'4.^<@]L '/\
MH/KG;A)VD?VL?\3AREI@&WF=X^A\QZD';'GH=*NK'L/H"?(^IV.?U\[$CKU/
MMZ<1M?D1OB J"I*9(!%NHWGVV)N.A,W QD C;S[=_P!?U\^W?8,P8WXQ&5'>
M2-N8^^?K&-H2GQ@#L,$@Y\;'R!]\_3MPR2" 9')L#;V&Q^GGA0;2/%N38'ZD
M]-]L6DY<RXG.S24#D1JB2RWK.H$EWD%JN:XVTMNTDNKER>3UQ.?4E"=.:PE.
M//:1=?<0UI[6TA#*76JO45HICFLQ0O)JMS/*9*O@W0D9[2H!,M) 0G-V4)&K
MXBD 2*L)!-11))(+M.R%7&2*A'PZH#@GX91.Q(_Y"B2/ O=!N$.0-E8J_,K)
ME;+DPIL=^)-@R'X<N%*:7'DQ949U3,B,^RXE#C#[#R7&WFG$I6AQ*D*3U @=
M,AU+B4K;.M"TI4AQ!U)6A8E*DE)(4A28((D$1MS14(,$1I,$*M<2(-@;7X\H
M/!=/5VQOGL1DCOW[]NWD^3OV<8B9MZQ\C_<8C(O;Y1($GD7 @;\B/E8327.P
M2**OY?<Y*!7-'ES!08],F1,$+7W+]EW93O+O6;K,J761F5'UUZ3N&;;1LYQ*
MBY31ICB;%G JLFA]ROR>H&6YBOQ/E*"NAKU#89A1A24.J-TBI94S6-C9]38+
M:K:*DZ0U4H[YG9,G^:R)_P#"<W2!N4JU(/0&XTZYY*FJH3S#Y;WZ.9'*I;[+
M,C4,*&8.H-&S)9/H4?,?3 >E2M,695_<1;-#LS2UXXDFBNYJ_5CQWT.;]X__
M *?F3)RW- "I-.XX%L5B$B"_EM20E%4T/Q+:*453 CXAE$!2D<IAI+S2R\Q)
M&H)A;9_%I=2"="CMJ!T*_I-QB&4LYVQC&!GMO[8R,[^-L >XSQN6'E,GZ7.T
M\?=L5P"; &UR9-[BP$@#I&X$\V&_Y8_X2"0/ \_MMGL?UQPT+3M!'R _/"EI
M5R2+#Y[V&T3;I<XS#1QA76>GO@ =L'<Y\?3'UQPZ1U%]K_+YX828(X!C:YC@
MGH#Z3,[VQF&T8R0H@C;<C/[]P?8G&_;?AJE18&#-[3]_4X<A*E7(U".I!O:-
MP?J!!,G&Q325#I4$_F_^9&1@$Y![@CZ8[\0%RT@F;Q/ZW^?M.XQ; Z>@ZW_?
M_.^)+7#&E="7\/UWX]C>.0JV4I*+&&5-NMMS[""<V,-F9^',H9BRF9-5,BHD
M6*GU*ZV*6:?+T5">U7;+*:T-(<RW(6:ROIU*50U25.E3M#153;B*%]3!KEJ?
MJF%,9FA[N,O0TIMA:\TI%>M/T![)=A:ZC?<2,V[6/T+:V '6WJ:AI4MUK[;S
M3KA6E:"MAKQT5$LHJR[3U.8T%2RXW +S:7E'_P"2@Q2/4W*.ONH().#TG!4X
MH_X<G8E(X]7U@#JM0]=C<QP;C83<S>^/,$LP8%DB9-Y-I/)O8^9ZP(PFLRT2
MWW;*9M70R41VE]GW$@$-]/8-HV4[@8/Y&1G*L,<"DI#:#+B]U _A!F_)DW@S
MO)WN;+("E D0A)-MIBP,<G:W6!$ 8T+L)=W.0TTA;K[RREAA&, 8\]DH2$@%
M2R4H0@*RKI3PPI0PW)("1^)1F9CZ^7)) @\Z"4E9 BVP2.#.YG]^A@"<.=E3
M%&41H*!::B?'0%-)4ZB*5#=$48RDIW#DA02M8"@CH;ZL5#J?E:SW5.DWDP5"
MT3UO_3Q:9-S9TAH !(4X?PI!O,[S<Z1M.\] )!65!@5BC8ZJE?B5BK=NJ:<)
MC,J_B")#B5*]4@X*F6B&R0?46\"27!Q;G\JD1W;=Y=(A1ZD2+3P3)Z:2(PY+
M D.OG6H[)X2!%DIV('$6_P!Q)OC>VS<ZA:;F63RM/Z<0G_EVV6PV_*90,^G
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M-#:4@ 6$ #A" 05&!&VD&03:W)#77/?7]^S/9MM9VUO^)-+;L;*>&V[:>RM
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MEY/:'^';G9JGFOHE3_\ ;7EQ3\L=9S-;Z-^7(;>&K=-M4YMM,%MQ26%?CD6
M3(<:C#^^=;;6Q[,\O8IVZM^OI&Z9Z.ZJ%U#*67NG=.:M+AB_@*K2=KX?+* #
M(@Q?4(,[P28O;8](OBW&KO@VKN7?_#NK/B/U73<S=+?$.GXZ;WX6]2<N]3Q#
M2PJ6AJN3[&O&V)FC;+3T35==K47SPBO&;:!GY%2(XIDR")*JE)GBW,].7M*I
MW* Y,C,6ZAHZU+<75]S(=2X6E,]W<:4SJN5D2G AS4YI3I"0V%@S,RJ(%P(-
MC:_G%A77F-\*?Q5\I(NB)G,_X<^=W+V-S*FPZO0+VL>5^L]/#6-M8%M-?3:<
M%I3QE6EW-#S*HM-$#UF^E]E;4-:'FU*UV,\RZK[Y-+7T+YIDJ54=U4LN%E*9
MU+<TJ(2A,$E9A (()WQ*E:%;+0J)U *!@ 7)A4@3S[<3AE3.3O.NM7S+9L^4
M7,^ ]R7<B,\XFYF@-5Q7>4[LZR-+"9YF(?J6U:%<F7&:J*WJE-4N39Y@M)7)
M!9X=\?2K%.15TZA62:0I?;/Q02G6?AR%GOPE'B/=ZX3<VQ*EU$"X\7X8(\0
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MD^^/;_L>^>'&3MMUW!!^A'78QMOAI)M D<S:/G'K>V-H<4/)!W^W;;(QOO\
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M@M84&,>D@?F<"R%%IKM1K"T4Y"&&TJ4XZ+%01)4 ;0($=5<0(EZ6S92YDF!
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MG^%_.%B[V9HZ^AS'NDT-5394U35"3_J35 JIIZAQX.=Q1UM*.^JJ=1E2BZ-
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MVFI;<.0G).-M@/OX_3[]_= \1:\>Q_,?KABDVN$CDS];C<&??C>1X*<-DE*
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MWM^F#6@J]J;;3G7UI;5'KW_EW'%A"$R9"DMA2BK.,H]5*E 9'7OWXCKEZ$(
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M9Q]M\GN??V/%Y$""-OS_ "^^"+8"";$@&T)^GMZ7WPWI<<_F)&0!L4YSOO\
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MC+:O-LRJ<CI%4&7/U;SM'2+6'#3L+65!MLZ4D-IF&6U%:FVM+:G75I[Q2>D
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M<=]22_U>P4.7-TY*Y6_4N"'ZIXZG'";J$3I;;G9IH)0A(2D#2E,984IRP "
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M0E"U\9F'\3:?+72G)G\R[1/ .J57YE65=+0I*5J;!1E5&UE[;C;B4]ZE+K:
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M9--NN.*26?@V1)92'J6N=J\P99-2$?RRIP4J*6J2G4TW7! IY:=*L64TS)@
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M(60Q:%A*"4("2#H4V%$+ BZB5*!6) 5IT@6\"2<0*\X%'?;'D@D'S]-\CCU
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M,2(!*0.MOO[B,;E1/4Q^4*3XR#]MQ@_R\[]\<(%Q(F(XD7YM?\X_/#BV!!D
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M6A)6VKU8T5;A2?[P,(;5A.<XN89<Q7H>2N6G7FOAUNH )4UI=04*28"P$/U
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M&0#P 9V!'7;?H/+RY&"2H:VM^DC&WDX[?O@>WD=QP\K!N"#])M:..+G\R<*
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M^2NG*Q4.EM/PM0MEPH<;<[K##2T\-J.H)+>I90HK(!HS4$J24  A0!2B3WB
MH I(G"-1_"O7&Z70Z@L%1)4C057&IYK6I=/UU9<<U-<:CUE5\O'*N9="*BWT
MC;U6F/QH1:LOV]A6O,RX"BB2A*)'^T[A:%13MA:4UKJGD&FJ%N-970TU&[F
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MOO//J6MQQ2EN+6I2B5$GB&O=32Y96K2$MMT]#4K 2 E*$-4ZR D"P2 D6
M%HP]D%3[<R5+=0-YDJ6)-]B29.\D<G=<YTV2+SG/S;NV%!<>XYEZ[LHZDG(4
MQ-U1:265 [Y"FW$G/D;Y\<0Y,TIC)\J94(4SEM"TH=%-TK2"/FG"U!U5#ZI,
M*>=5?S62/OJ<,J IT$#\P3DG))\ _MW/MOCOQ?6!!D>7W][3AB29 !]N,.R$
MIQ02.^21]<=OY[8[_H.*3H$6XO'WY$F?;C%MJ 2=XMT_7B(/7I)C"[Z*G5!'
M\+;*$]:]NY&XSV/^1!)^M8F+[]!Z?D.I^NV+:4ZIM$R?/D<F;^P$_/7(*4M*
M"4]+3:>EL?\ 4M7D^YWS]03P@DP;#VV$FWF3 !Z=,60(%K1:/+]B=[[^HPH\
MM=9)Y>\R]#:Y6CU&-,:II;.='4E*TS*MF<U^+P7$J_*MN=5JF0W6U9"VGU(5
M^4GBGF5)\?E];1BRJFF?:0JX*'2A0:6(OJ;="5@C8IGULM'2I"B8@@G?;I'I
M;KUG#-YRZ.;T!S8Y@Z)97ZT+3.K[ZLK9 R6YE,Q8/JI9[15E18GU1AS65*'4
M6GT$[GBSE-6:[*Z&M4(744C+CB>4/+;'?(5$C4VYK01, @C?>4(TN*'^U1@P
M8Y,\1:.@$[BQQ%#<5=C8LQ&P5+D/MM#8?EZUX*N_9*25'<; ^.- K#;2EG^E
M*E>I$P/> /7%E"5*6A(V,"W$Q/68$GCU.'1S)E(@5T#3\7\B"A#CB1C9IE(;
M:00,'L"KSU9!VQQ2R])<=4\N\$@$DR5*,J/3Y&TQ!MB_4*AL( C5!CG0DPD&
M;R#TZQ&.AGPLP:[X;OA:Y@_$!J4Q&;+4E<_=U<:P<1&9D1:L2JK1-.MYQ2.A
M6I=1SB.OU$-&-8P'2I :6XGSWM4\YG_:6BR.G"E-TJPTXI *BE;NAVL="1,B
MG8; B"90L &1.[DM*4LA1L:A0)@72V)"3]2KG<;;X^:+7.HK+4NJ=2ZBN;A_
M4%O?7MM<65[)2I#]S-L)TB5(LW4+)4VJ<\ZJ26MPR' V,)2 />*-AMBFIV&F
MDL-LLM--LI(*6D(2E(;!&^@#2#_5^(=<=.D $ " +>8 F+[=)BT0),WC&7JB
M;5UEU50O3;3=MLLS'\'YCY9A3I$5M60$(?4O^]V)* >V0H:*:9#CC#RY/<E2
MD)GPZC!UD#<I@Q\_6VRF5#8 0;#:#)V'22>M@?*'M9PXM4Y&BM2#(E>CUS5!
M64!U:DE"$  =(2G(&23CI*L$[SN/K6V9&E)5I2+B4CDWW,D\B,/=<!1-@";6
MXB))\[WV)VWO#-P^4E>2",9)';Z@>>YV_IQRN8&'%)U3L3: "3L+SMZ3SC(?
M<L22>ABWH)^<=3OB+IY0A3CA)4I1.YVQGVVR3VW[[_OSE21XB.;WB_M?D#[-
M\HI 45\F9]R)@#H).&)8+4^XI"/X4')((RKMW[;#<=SG<_;*69-OGM/4_I[;
MXC4=1WV,CRC]>?6+';"2ZI+22<_P@DG!SD G;&_8;#_,X$:MN9\HG_$Q,8(V
M )GGB_T_M\\%FU>L I((Z\[J!!/<[COMN3W';([YKD@CRY,=(M>+GK\K['$\
MR?7[]8ZB>#248'2.Y[YP>Q';'8?Z$;D<(5;'?IN.#O\ 3H8-O-4@D]!R8GV@
M[X,(;*B D9R<;;J)]L8\^#V\?3B*?OI[[V]?7%M#8 3,#8^4&]QO?D_47PX:
MZ IQQIOI2'7EH;0%*"0@K6$I*B=A@D!2CL/<D'B)QT &Y\R.8_/J>L$B<6(M
M '4$G@3)$3[<3$S$'$T<UN4>J^1W-/F!R>UXQ!CZSY9:NOM$ZF:K9B;"N3<Z
M>L'JZ<8,]"&TS(2WXZEQ9(;;]9A3;G0A2B$Y]/4HJZ=FH9)[IYM#J"I.E4+
M5)'!N1 , ^F'-E+B$N))TK"5"9!@B;;CUZ$&=IPYN4/-77W)K4T?5F@K9-=.
M :9GP)L.+:45["9DM2D0+RBGMO5]I#1*99DL)D,EV%+::GU[T6?'CR6\?/,G
MR[/*15%7I<*9*FGZ=Y;%53.$ %;%0V0MN19Q!UM.I\#K;C94@Z5-5U=&XEVE
M?73K\(U(5'>:5)6D+204+"5)"H4D@*"5"% $=Q_BJT1RJ^+W0WPLZ[D/'EEK
MP_"3RIJ8E_IMT67*QBT9O]<NWE5J?3<@S=5T[/\ :ZRL8$?442VL^A<>QB*B
MZEU&S%H7?*LAK,TR!_/F*93684U+G^9BLHZQ*F<UK5-M4:T5[%<$M4A=51Z%
M/)=:53DFF+[N34DUC_9M9,C/LO=S1ZJ4,U=><>U%2/@^ZT-A+2VM*7*8]]W@
M0_WBV%J<4A:DO):9J.)MUHVZTCJ"XTMJ.N?J[S3]C*JK6!(&'8\V&ZMIYM2A
MD.-]2.MIUM19>94AYEQ;2TJ/IU/7L5U,Q64KJ7:>I:2ZRZDV*%P1;^DI_"M*
M@%(6"E0"DD8X=UAYMYQNH0IMQI:D+;78I4E1!&D@;7O,$7V(Q8C1_P ,>N]6
M:4TYJ*FL-(KM-85^K+;1VA9ER]7ZTU75Z),K^T4JABS*]FBER(X@3A74:M0-
M:BO78JXU#36<MZ)'DUG<P;2XM!"]+90EQP"6VU.1I"M*M8-QJ5I*4R=2@ 3B
M(O(0HI(4 DI"EZ92"L#3J,R!<3  &Y, G$CSOA,YM<OILZ/J^FB0(3]3R\=C
MRH,Y%NQ=Q.;;4M.DI% JN0]^+J8MJNPI;IB*%2*?4-394DME-C"?811>S)IU
M*"R-;B%K7IB"GN3"PH*, J29038I4%3I.)&WVG(A1 )<221&DMQJU=  I*O-
M)!&XQHYI<B-5<C];76A;JAC6=S1-5,ERYJ[.-?TST:]HX&H:N? =K>N*_'F5
M%I#L(CRGG6W8KS4D)Z%835;S%-2C4M[NI)"F2G0HZ5E'XEP2"002D @RBQ!Q
M*TM+B$N-DE*I@F00I$@I4G<*2H$$&1L1((E)T57J16OJ*W$ER4HY1$$PY"$@
MI6EU(0P4DDCH)4X%97CI1Q'4O2L"$R$C=P-\GY]-@!'))P\),<;FT:NG0&/I
M/MC]2#CSC'FF!P8,#@P8'!@P.#!@<&# X,&!P8,#@P8'!@P3L'2Q G/)<994
MS#DNI=D$!AHMLK6''RI;20R@CJ<)<; 0%96@?F$%4X&J:H=+C3(;8=<+SQ 9
M:"&U*[QXE;8#3<:G"5H&@&5IW#D#4I(@F5)$)_$9($"QN=A8WXQQ;U/;NBJG
M--W$UJ-&G)C?@]O=I18Z??=>FN+K&FVN8*)#PB*0[%AH54PG)S)8E?)SCZCK
M?GO\/5*'9?*77JFFU..5M2I^B0DTB3K6I:PI*GDEEM1*VU_$*[QL ]ZL*"SJ
M9H/^,=2E"[);0$J)U$P ("@"%+W5X82H_AM&&G8D#2\,(_%I"6Z]Q:C;E34R
M*XZLNN I4ELN^HI?K)ZD$^FZ@$DI*N.Z_@P%.(;J77*/77Y[FCXJJ/\ G-9D
M@+>"7'U=]4Z*U)"DO!-2ZAMP*0A02D)3G9^84M*4J ;IV4:%$ M638#2CP ;
M$H22 2I,DDT3YI'I<1^5:3Z:B XKJ2>IQ1)0/&?/G/D<?7N6\R0?$ "!>T"%
M?<6^?&.62)Y"C!W!/'KOMQ[XJ->JRXOJ&=SY\XVV'C?Z$=SWXZED0E1X@V\N
M>HFQWWYQ1<),'K,F8/&T?N+884EM"W5Y&<$>>VP\9[9'[^QXM)48$<^6_N1)
M^N_.(ATZ1]\?E&$"9""^K&,@X!QDX\ _IG<YW[>>+"'(@#:)CIZ<B_3CU$M*
M9)(,$$$])Z_?[X0'Z]0&Z<C!]\CN!OW![_;B=+@X/G$[^W/&W[0@)'XA VML
M/EUGCGTM,4;F,K3?(FRY<P%ZOB6&JM1/6%DS,BT4C15C2EIIAQ^O5)KS=1KI
MEZOA,JDQ998"6WQEM?0E'DE7V$5G?\7*'MO6([./T/9[)&Z'+W:6KSMCM329
MGWCCR6*Y#%9_HU3E+C5;5/!FHITU&M;-G&Y)-2@"D:PDD*LZ0VL00 IDITR#
M^%SO K=)3$16]Y*@0/S$ =\>3WSMC.V>WG?/'L>!$>AVM.W6+CU)$;8T?3_?
M^_?'!'/W_;#Q/4'\QZQ^PQZ-_'?Z>,G'O_K]/'"FW^>;3]_4X";6(O8;??Y^
MAVP<;2DI'Y0,]R1G/UR!_E_GPF(2HGD_?W]S@TTVDG&WGOC?M[[# \;^",@#
MA"8BTR8].D^_WU. 3)DGI-@(]-[^7&V#'RR"" !W[YSG88.X._V^WC'#=2N1
M'E!_.;;$W%@.</DV@6$@'<D;=#'N/+&E;#:,X"-OT/U!.-_K[>X\."B;&;<'
M_/D9Z;<875O>8&Q$$'I8==^EM\:5$#/4=@" ?;V]MQY]^W"XCU$;$^]\8)D*
M0<MN$'?L2%=B" ?J,C]3OCA"D&Q -^1/Z<0/EB1+B@8%E&1()%B((,7N)!XC
M>V'30ZDUC5!"=/6>I:P!U;B#33+.'_?O_*AU:3 <;/JO&'##ASU.&+'ZB?1;
M"<;,<G[/UZU.YKEN45J]#:%+S"DHZ@AMCX@MH*JEM9[MKXNJ*$DPW\2^4Z>]
M7JT*7,<WIV^XH:S,*=M;BEAJEJ:EI"G' VE9T,*2"MP,M!4R5=TV%60F)D>Y
MR<][B"G2&H-03-40Y4)];5;K>GH=5.I8"'V7GV7]4UMC,C26.A\"2B0B9'6T
MI:5(<2E0X9K^'_\ #++ZE6?95E-+DU2S4,I76=G*W,,E2726G&V5(R6JI6'&
MG2XU+0;4P\EP)4%()&.A&==KZH(RFJJ7JQ+[1=13YFU2U8#1"FU/%=>VXIM3
M<+!=4L.-:%*E)3J$0-:>LBPW(;C];*X1L2M+K9].()$B*I:TE04%(=BNH<0$
MJ4@A.0"M(5WIS6CU*0I[245 I8*'/&\66:A*4D)(4%-/MJ2HP#*H/A5&*,ES
M$J2E+&HEDOF'6@$MI=J&3K*EINEVE?04B5:T!!&I:4J57*)Q@32'6755QCMS
M&OS^HA;RG6E*:'26GHZ7&T]+R5_F;DQE)3E3B6XV<Q0Z:<%I:4UB75TRS&E;
M;;;3@2N3K;>*7%RVI!@L.@JLDJ;694JG:?4AT.+H5,L9@T0H+8J77ZIH!L@%
M+S %.VOODK E]I(1.K202PE"B<#? QW_ /&XSC?)'GN;Q48L")'R].MN<8\S
M )L.?L7MM;F^#89Z@!_4 [[=B1G']??B.3<DP-SOSO(%B8MY>AC$@0%?A$F>
M+_VB_I\L:'*_\V02G?<8V[GW/?[;<.2X>8/IO]./43UC"E"A%I &Y$QZ1N?(
M]/3!Z.V48 &>WC? ()P,'';S]?<<-5%Y-B3Z7G?8Q_G:^%:$CI ))M8SR#Y?
MEQ&'"RVDY_*-L_?W[_H>_P"W%>8^G[#\\!/)/WO]@8W_ "X5OC!/L>V^,=OI
MVQ]]^$U"_E^T[[?,X.+F)V!W\HL1?B??&QN.I!&,C^>_U. -MO;M]<@WFUN9
MY',1?\NM\-G@!4]2(^=OTC\\+$0A(*23V! _49QY\[CV^O#2"0+"1(VX@_?2
M=C&XDI!4"5#\,7,[@P!OY&?SPOMLH6D I!/MC[G;OW&,^ =]N(=13?;>T[^?
MWL#.^)2E*E%)!@B9(@ \B8_J@W)@1TQ@_6MD9Z>GOOW3V\Y./?;;/;&^2Y+I
M/0^7EZVWQ$6X-A DP21%X L9!D]#<"9Z(C\$I!'21WQ@;??&Y\_?R//$P(.Q
M]OO]/VQ&1 N")N/+GU(/0Q'G?!1,,Y_*D^#@#'MVW/8X\;C/CA<-CZ1]R#YV
M_0X4V(:ATDCW&X[8&V^>WU'GWQ@(5 3?;B?G_CY]<."23L8Z_?'S\IP>]$!&
MW\6-L$X[;8R23_//MPP+O$VZG?Z"/O<8738\F\@7'IN#:W7T.)V^&&O;B<X*
M?6LU#:ZOE/5:AYM6:WD@M(_L!3R;NF;6#^59L-4-4%4RV1AZ3/9:!*G #@]I
MUZ\G>HT$AW-G:?*6@-S\>\EAXR-@W2E]U1$Z4MDD6Q9HAIJ4N&-+"5O*X_Y2
M2I/S7I'F3OB!@VIYUU]Y2UO/.*===6<K<=<65N**CN2I:E*43DDG?OOODA"4
MA,0   -@D"!$=(C%8 DF9WOM<SZ="=OR.#;382?X,#;).Y.>WCL?'N!DC&>&
M*,Q?V L/W/W.% B=I_#,_,QQ'F>!R8*Y$>;04IVR!D>1MVSX^N!L-OUIN)4?
M%')D>9OZ_/R N;VV2((-N1?<6!WWC:1)$F8L<+J9"%,=^GJ5VVR0 !G?&23G
M[^=N*Y!D]8&]HN>D';S'GBZ@B>."+^NW/RX^>"\Y(0A#0)( "E8/=1VQ['!S
MC/N#VQPB3,FT[>UL68"H-I DQU-Q];P?\LJX_N&D#NHA2U?_ $VZ1]RD#;<C
M)_25 U*B+&T[2=C[#VGB; R01%KV(MP=HX,_MYXE#XCY2+>;REYAH)<7S#Y'
MZ#ESW\9]:^T.U/Y3WKSJ^RI4F?H!=C*(PHN3NM8!<WRL@1W:,TH9CX#.:Y"
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M'IR-J6+6W%Y9Z0MSI?3-!34-5(H(5S!TRVBDC+=DTE1 #C8EB2)+^^2E*EM
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MK:$J )'UW^OZ?0;'W..)3.TVZ_E^9ZCU&(4I!$Q]?:?+GS\\'FHZE;I! &"
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M_O\ 7AA<4>-(XD@F/RPH&JY,\6\N/N/RQFN*T4D=(&Q[ 9[;=L=_/O\ ??A
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M%+C*DPILRWK"J0U&DA],CW:*A:I7ZQ*7GV6A2+3W*4J<>35M=^%-(4M*B66
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M9*L#IP 1MC;W &,Y ^V,?7/%1Q9%@;G:-QOS8B)($_+$Z0"=H2+ 6_%M,7M
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M:RAJE%-(N.^K*U+3#S=*V]3I;<0'&5H>4VA;BAAQ(4;NK=  "5NE6J+D =X
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MN%*M3;E'W[M.ME3J$:)TJ2]4NA.LH#E2ZL""@(::IX -A4*0D-E<*0YI2L*
M)DB9" ;7"$B]YAK6&H9^L-7:DUA80H%;.U5=V.H9T&L8<CUK$ZXENSYOR,=U
MUY<:*Y)?><98#JFV$.!EKI:0V@;-(PU24=/1H<<<;I66Z="W"%.E#* A <4
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M6\N"$.+7/?/M!YI#:W98Y:U#UHY"JX7*.VUO06D&F5.@2[+KKHTZ7,F1+B7
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M;1E/,L'1_$_)ASKJBBNOG.5.?A-/6(*S^9:4I<4I2E%1_7#_ -GE^LJOX79
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M#60=G64IJJ)(HJE(H*R'U(/>!44U2DJ2II0)>1!LA6C2@#2,CM!)J*H^!?\
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M3]8_OZ85>V]YZWBXPH-- IRK.<['ML-QVW/\L_OPPD"]Y,VXXF9D>T&.>(8
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MIRM33%HNA8JZA# 2EK,&DI9-?W!(6_2DEFH[DK#;J H=X"[BR4(E)""N0/\
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M@ZFL+#].[7:$MM4N9J#3C#JEOM,K75H=<6OXQ=0%**4H*N+K.THHG*NIS7)
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M,-K6?_T(ZGP[(CD4-JH/Q6R](9*83R@ZVRE2"\6R LL]:?52E394 K/&/VA
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M SZI4GU9.6J?J*9:W%)#(?2V@73#G=WL;!(!2!SJDQ$'3; 44K' 4#-Y)WD
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MW9>IT*=I([BXL%Q7X,PLOTSR45HP@ N)8'3TK!!;<1Z+/YTJ5T;]1]%_@E4
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MG"D [WO;R\K1C,(*3N ,G/<]_IC?.-_Z[YX=@E(FX%[^I^_UQM2#M@$>V_\
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M1H1DCM@91T%1))/2-MLGAOX4I\7:!9,J+M$".-ZT_G,;"/GCTQ@#0-IA-ST
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M'J+^<6QFB*"0 G![; X [9W(QPNM77Z#G$:@V),$6$&Y-AL!(O:YD[=#C?\
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MI;:2"KFLA[/9EVWS!OM)G:BW3)<*J:D&E6G20 IP:M6L6&F9T@:P>) 5-%:
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MPB>3Y>7TXXQ]R?'HN/"L#@P8'!@P.#!@<&# X,&!P8,#@P8'!@P.#!CP@D$
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M4+);5TE/2,%U-0NF2JI1I>E:5@@)V4H!40!"H)$6(,B1&,Y:3/(D$D1/)%I
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M],I;3?I,K8HG4+:6ZHHI?A05J206^_<J=1 2GQ!;B@"#&D !((DPN/EQ"B0
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M=?._TP46MIM"G7WF(S2!^=^2\VPRC.!^=YY2$)R?^I0&>'*6AL$J4$A(N20
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M;7D)AOI;C6=E,F-)2_(<4<JIH:52EE=.THK4I:]3:3J4XA+2U&URIM"$*/*
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MM\;H\AZ&\Q+B/O1I45YN1'DL.*9>8?96EQEYEU"DK:=:<2A;;B%!2%@*2H$
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MS'^#C1!$)'E(!FT\>=A]G%S?A[9=YE?#)SXY6QPE^R74ZF:I$J 7Z$_4FF9
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M/N)Z2 "H9(_F!V\G[8QL-N/0*9<@>8!$QO\ 8\]Q;&>X)CH(!(X,<CION+1
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M@OHY^(08)DDG?PITJ F.),']#OE]H5-HR/,E.J "V"V@&/$XI20T$@[J*],
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MZXG#KG6*1EU^H=;98:25N..*"$(2.2HP!:T&^H@ $J3B)Q26P5+*4(3<J)
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M7VXYX]^F*\GJ;^?'V?KC40CWW/G.=_?]?_'!\H/G_DC[L8C#9WWMY?O;&HG
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MRFU)P4[E.!CN.,-P:0H7L#?8GS])/N;W@XG$!$7D6),BXCH=XMT-YPX8) .
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MC_.+2%0M"@1, $[V%[S;GYSTPER*MF6]-4Y@"(TMP[ %:7% M@^3T84%#<[
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M.Q!-O[>6V)MM[7E;S;K+&ZGFLY2<U(<*5/EB#72$\L.8KL1A;[HCUM7&E2=
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MTDO#5E7/$%(ZG6@EZ,I84EB<Q$E8*F .*V=98SG- _0ND#O$A3+D26GTR6G
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M*9@RC9(-T^(*BR@+E)V@[];&;F,5W$H 042"4G4%7&H;$7F#\K"0 <'&&"%
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M2^?32&U.AI'IN+(;"0IWH/6XL@J<5E2BI2M\QY 200GPBWD)!MN;>P%_*SQ
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MK=:IVG*BH=0RPRA3CKKB@AMM"!*EK4J$I2D2221&%"5K(0@%2U$)2D2223
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MEVGRFFU?Z;3N)NEQ]2PAS,JALB4./MML-J\;5*E8"P+J&V4E-,E29&E3ZO\
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M!T^<]N_TWV[9[C;^A)QJA.\;#KYV)O)O[$&1?%A),"3]=Q%_E)'UYP^JY_\
MAP3X4!@#/;?&Q\Y(R,'![Y'&14(5<>_U\IVO]VQ92HF+=-5]T[R1>P%MS/01
M&'K7O[ 9QC<*^FV._8 X'D=L\9+Z9@Q,?WG]/;RG%A)\0%H5,CDD$ GV)%]_
M/#QANG*2-]QG!)!R #M^A\@YR?!XR7D[CR,3Y7OY7\K6MB4F)!@B)$SQQZD=
M#Y[G#M@/?FP20%8PD]L]\C/GOV!SMGQQCO)$&1%B8 (( V]HM?U%R<-1O//
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MI;[Q?<*<J$M!Q!0K2I3+J05P3I0%$I)A2B)*=9I:U(4M30:?4VH#Q@()@@W
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MVE ?B0(25D08"DI ,3JV4_(T6-&89CQ6VV&([26666DA#2&T )0A"0,!*4I
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MW.R[7D'/4L3N;997]4^BE!&Q3C(*?Z+F"I[WM1G:A.S;62L6/ T91-NI)(G
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MEI9*TV<A/>!"(<V2'PAT$._$4J%"!W:M30T2H6!4HI!D;_A!,:C$^MJ<H,E
M0@=#BE#OU*!.,XQ_"#N,Y&^V1GCZKRRHER-2U!QL*23^'@&+V,1(@>7&.)>3
MX!MX; 3ZGSX!V\CSBLE_!Z''$E("=\$YV.3L/L=NWZX''6L.6$&^]IW']O2#
M/.U.>0">% >4W%I\@?L1991<.*3@8(SW.,9Z<D;^P)[;[\:B%2F/7:.-HC:)
MCRXOL$0#(M>P L).TC?KYS&&O(8&58P4$Y\Y&^ ._P!\>",]CD<2A7E)'2+R
M1OOY7YPWD)5>9 -I/TWMQ\CA!DQMBH#([[> ,G;^?VQC<'BPA4B\7Z^<7GRW
MG?GC#%'2H 3'6-O?:-^/48176@-M^^QQ@;GL#X[C.=OKMQ*/OJ?7"$"2=P9L
M)$^@,CB(@[;X(MICQID61(@1K*.P^AYZOF.3&XLYM*TJ<BR'8$J%.;8D >F\
MJ',C20E9+#[3G2XEQ*UI4A*U-K4"$N(""M!(/C2'$+;*D[@+0I,QJ2H2,,L%
M"VJX.G86.QTE)B+ S.]^1/.JN3^E[RU?%#$.DFHUMI:@BTU!$F7CEBY;Z,8U
MS?7MG::TU[!A5D*CJ6;AP!,J.PI$>&W)4TA4VTC8E)G-6PVGOUBLU-53ZGGU
MML=V&:TT+##35%0+6ZM]XLC\*E J6420VT9W:9I9E([LRVG2@%6K6WWBE$N.
MA*0A,F/"+)DP2K#>OOAU@4J;6.[KAYZU2QK.QTY';TPCY"RJM%<N-(\T9[]S
M8-ZA=<IY4O3FK&XT*)6P-0LJN(#L=R:W"?:G\2L]HG:@M*%"E+6JC;J%&I\;
M3M;F-7EB$M-_#I[Y"*FE*UK<73GN7 H(UI4WA#2)0%#O#/\ ,*1HW2VTV\2H
MZ_"2ES2  OQ)(U&QP<D?#_2,1ID-FXL;*&B_K94;7T.#2MQ96C%Z8U5/E6\*
MKF:YC4_X:]:4S#6;6XK=1PY#3U5*J(URT]3.L1G[Q*%J9;;4IAQM5 MQ\J16
MBII$):6XFB6\'0T^I7\IERG6"'4.J9*7@II$<*)&I)[T!(EO0LD@%P I*DC\
M1"Q&G0%2DJDWX;JBML7M'1=22YNLF7=34<^5;4X@Z5B6]'SWIN4<:PJK&%>.
M3RTZU.%A,C6E4^F/&?<<2E;RHXC1([1ONM"L53(11$4S[2&WBY5*:?R)[-UM
MNMKIPB04=VA33HU+ !@!6IQHTA10%$NC4E2BG2W*:E+ *?$3LJ?$-I@[0A5G
M(/3]@FNL'-=WD&BM[&BI*URPT$U&U!^,W6K[[1:?GJ)>L2U%IX]G2*E&T9MI
MCK\54V*W %I6OPESNY]4-AUL4+#C[+;[S@;KRJG[EFD8K/!4"D"E/*;?">Z+
M* E>A17W3@6!-,F4JUJ"2I"4DM@+"U.*;A2.\("043JU&02(! &*Y3HJX,V7
M!=4E;L*3(B.E!)07(SJV5E!(!Z.I!*<@$@C*1G''1(5K0AQ.RTI4 =P% *O$
MW@QR)%IQ5)T'21<3,3!X$$^8ON(@C? ;PL);6  !D%(!)R>Q4<XQWRDYQ],G
M@5(N"9/'UF/+SG>=[X>DA7AB)/(N2+QOR=R(/F,9_+HZP$;#))!R3VSW !\>
M<]^^W"&Z23.PX@3?J;W,G86&  )) '6^XOP/EY^N#*6BWN4?8X.!G&^1C<GZ
M[\1XF$'8QO:PZV((-AY2)DP,>OA13M@D!6,#Z8(W/M]>  3)YB=]OOIA$FQB
M;>A_(#ZVMOA#=!4"<9./L<C]O\_L-^)P('&YV]8O<WMY1TQ55^(^7KY;?/TW
M],)[S.=P<G<D8V^N//\ V[>W$J5F;QP)&\\?8V.&&8BY%S'',\&YG:WYX27H
MP5DC;8Y_KG??OO\ MMQ82O8'R'W ](_/#"FQ(VBX$$_.>HO'38XQK:8V<T1#
M-@P.I"G#(GK?1'0A)!6I2H\>2YE*%*60&U80VM6_2 :&;YHC**)=<NDK*U*%
MMM"GH&V7*A:W5=VVE*7WZ9KQN%+8*G4@K6@3>1I9+D]1GE>G+Z5VF9=4Q4U)
M<JG%-,I9HZ=RKJ5J4AMU7\NF9==("%$I;4 "8!DNNY9::6PU(MN9U)7-.H2H
M&)37%CNJ-!D])$A-7A0381FB-CZY=:.[#RD>8UG\3\]#RZ?*OX<YY7N(44Q5
M9IE%"3_/K60H"G=S,Z%)R]Y\*B33JIW-,OM)5Z$G^%:V6/B,R[3Y/1-207$(
MJ76Y"J-M0[U\4;<A^M13_BTEYBL2%::1]:%:5R\Y/0SZ4CGNVEW<+0QRYOI8
M "W$?_$C63J<*]/K2>H%3:VG .EQ)XCHNWG\4*]M3C'\'5-H(\"ZKMUE-/*B
MVVL2V[EC;ATESNUZ0I*76WF]6I%\NM[)]D<M?;:J^WC+Q\*UHH<DJ:DALK6G
M_FLU;K25J0CO$!P@]VZTO04J,;G&/AWT_#*1J#66MYB,.-_A^EXU"VX^([S8
M0N;<V3I88]=U$@8J9P08C"%L/)7)$FN$_P ;,\JRMVB[-=D:10+:T.9W59RM
M+)J&7)0QE]'3!Q\,-.,EP9A2J)JWUI<;[ND^&U*?-?X;9+2LML4-9V@JV'14
MIJ*JB99#E0EI](#OQ)*%4H><IW/A7:6H8*:-"5,K^*K2_&EWS <EJF0]+U4;
M2-+*08[D>$Z9-O+AAMID1[*]6TQ)D-K9881(C0F*R!+]%MZ9"D2@N0YW.2]B
MJ:@-/69Q6/\ :'-F5!T5=8@-4;%3K<=4_096A:Z>G6'77%M//+JZNG"NY8JV
MZ9MEAKFL^[=9QG:%TC6C+,K,(%%2*5J<;0VEE"*FJ4 _4!*$JU));:==<J*E
MQI55553[^&G=+ZPOHBYM'I;4=W7M240W)U326=C#:EN+C-MQ5RHD9UEN2X[-
MAMHCE?JJ<EQDI;*I#07U-154;"@A^JIV7"DK2AU]IM:D *)6$+4%%("%DJ B
M$*D@))'(MI<5^!"E"8D))$\"0+&XMY[$F\GU')G7-U4ILHS%;&DKGW4!%#9S
MDUNHE.:<EU4*_<-7-;:4VFHD7,(3677$34-F2ZB(MN)(6WF/9U1,NEM1=4D(
M86:AIOO:>*E+JZ<=Z@F2\EE>A0!03I!6"M(-A-,M29  NH:%'2L:"G7X8"@$
ME:20;^5CC";R6Y@UVHT:6FUT6/;.ZT5H5"5V43Y-5N(D.R3-3/2X8:M/NU<^
M+:LWR'C6NUCHG-O*C?G*MYU0.TQJD.+4R*/XXD-JUAK6MK06XUBH#K:VBP1W
M@=!00%6P*8<2H(4D:N\[O<&# 4#.V@@A05,$0=L1W?4=EIVZN-/6\<Q;6BLY
M]19Q^H+]"?6RG8<QGK22EP-OLN("T$I6D=25%*LG1IWVWV6:AE6MI]IMYM41
MJ;<2%H5!N)2H&"+'<2,0N-E*E(4(6@J21/*3!'IY^8PV9#:\_ESC)/??'^_]
M._%L&0/KZ\XA((WP42XI!R"3V[CWVQY[^_"X3"@P\%'O].V_O]MMNW#5 D1%
M_P CT_/CUC"B 0>)Z?>UIO\ /"]%6<#/D'.3Y'DY/^IQQ7'XB+P1/N(V]HG#
MU 1(XZ=#_?;8<8/@XW\_T_W]>&3( X OM/WP/D=\+I ))W)MN>?:_)OZ;'&I
MS'2=]\']C[[CV_WX5-P8M L!OMN3N=[<814RD&\G>//8?(=3A-<;SN#C&Y_[
M?[V_HY*IWW&_W]/7UPNQV.UMK1/4C8;>_),YMDI]_N1W&W[_ .\?048BXN8(
M/(/7H, $S/!,$<&9/I-NO,1A22=AG'\__/;B,C2?+B#]^F%!U#SYD??KC%S!
M!&#@]NVQWQOWS]?Z<-^_R]O3$B%%/(W!VZ=-^/F0)Z8)K>0P")"5.LKR'$YW
MZ3L5@=NI/?I[*QTD[YX8M,CPV4(CI:#'[=#C087I(Z*-]S,SXA WFWI\\)#\
M634J5.K%)EUKWYGV% K86@]PM RIM:1D=8 6T0 H%'4"V0X.[<!2L?A4;$<
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MWS<+5;#5F;:%I2M:L-/K0C1LY#]G'EZ:?AV#T8YKU/ )\]CU^=[GF>!P</\
M]*8T+2I;Q0I#;8)4T=#;2G5MH;)9)3I6ZHI< [Y/A*7)2"('CNE2E%6,J))
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M://B-\/5/K?7W)[XF>6_PUZBY?<K.?%'K/0VL[#F;(J$:>UGROYNQ=$"NU'
MFQK4&-26.G*=Y%HPNIL+B#^:>B%?8O3FE+0G,%L4]9EM1F3=154+C+[":8++
MC-52%[4VI)1=:75C2=:4&R2%CQI3J("DE4E-Q&X*9_7'9ODKJ3FGJ_ECI74G
M.KEK5\GN9MJS9/ZGY:T^MX?,B!I12+FR8J82-;5]52P;Z1(HFJNQGO0ZR/'B
MSYDF R7T1$R7N/K&Z5FI=;HZE593(*0U4K853*=\"2M7<*6M38"RI*0I1)2D
M*(!,"%02%$)5J2-E$1-KVXOB"_BPHU-P]/:K:DRZYAI;U+;RX46/9-NM._\
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M$5XY '6OI4EE8(VZE%LG.5-'"0J0MJ5,*[QOEL_B OQ:?,@ Q:"!)L!:'+.
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M0HOY>ZEEP^+NE'4R3P4D$K;X,:5CH$P8[/+^UU6T@,YDT:A&PJ&DA+L1'B1
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MOS(I(+,2#J"C-;51*R.AM3;Y3 5 ,9B-*7#B?+I9BN,2_$R08(C>\SMSO8
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MKZ D:4@D'> F#$00"D&#J'G<8&\T<2MA:F6U)8I?A%(5JTNLJDJ"KV40HR1
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M0JWR/SY^A\KQ@H5*_P 0SN-]_P"N>_#RN+:8^GZ8:$3?5O[_ +8"59V.<_\
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M(4<J1@; '! [_3VQWWQ[8X:G5>9\A[^9GRW _/"J5$09G?;]/G^6-P@LJ3_
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B(!\D-@3:YC&>]GF7TVE+C%0HJU04H;/X8WFH3U\_7@?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g65062g64e05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g64e05.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1P"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &^:^<4(X0DE-! 0      !D< 5H  QLE1QP"   "N X< @4 !5!R:6YT
M #A"24T$)0      $($T$W8M)'Q"O;6DFEX6OXPX0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q >3Q6          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ ._
M_C4  @ " [_^-0 "  (X0DE-!"8       X             /X   #A"24T$
M#0      !    !XX0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              "S   )\@
M   !                          $             "?(   "S
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   "S     %)G
M:'1L;VYG   )\@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG    LP    !29VAT;&]N9P  "?(    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
M   "/_         X0DE-!!$       $! #A"24T$%       !     ,X0DE-
M! P     $74    !    H     L   '@   4H   $5D &  !_]C_X@Q824-#
M7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q
M  !A8W-P35-&5     !)14,@<U)'0@               0  ]M8  0    #3
M+4A0("
M         !%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B
M:W!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0
M !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W   #
MU    "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,     QR5%)#
M   $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'ER
M:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P
M       2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q
M.38V+3(N,0
M                6%E:(        /-1  $    !%LQ865H@
M         %A96B        !OH@  ./4   .06%E:(        &*9  "WA0
M&-I865H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O
M=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                                          !D
M97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S
M<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@
M4D="(&-O;&]U<B!S<&%C92 M('-21T(
M9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I
M=&EO;B!I;B!)14,V,3DV-BTR+C$
M '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B
M $P)5@!0    5Q_G;65A<P         !                         H\
M   "<VEG(     !#4E0@8W5R=@        0     !0 *  \ %  9 !X (P H
M "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4
MF@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .  Y0#K /  ]@#[ 0$!!P$-
M 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6 !9P%N 74!? &# 8L!D@&: :$!
MJ0&Q ;D!P0') =$!V0'A >D!\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G
M G$">@*$ HX"F *B JP"M@+! LL"U0+@ NL"]0,  PL#%@,A RT#. -# T\#
M6@-F W(#?@.* Y8#H@.N [H#QP/3
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M+RLQ^TII)K,1]YY6/E(/WOL>\XR/*0OM>Q[7L\/?/43V>'MY?V>''C\>/"W
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M2$!%C=^YN$BC&GQ>^^_0&0SP_P"05^63.])T/9-K["DBFS2(WF-,D=%$[)C
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G'&UK6OEE>^5[\/C>][W^-[T!OH!0"@% * 4 H!0"@% * 4 H#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g65062g65x96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g65x96.jpg
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M!@<"  $("1=8EM<2$Q05%A@95V>FUN81&B$B:)BHYPHF,C0C)3-!0D-$_\0
M&P$! 0$  P$!              $" P0%!@?_Q !'$0 ! @(## <#"0@" P
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M2X*ROGHG;,GHN>R2?5=P/G]*<DY03G)J60Z"3(+4O'$!'(\,%N3CR+AWDAE
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M8P%?RB1"X&=@J%6^8;S>5-?02CK-T1H<G[Q>=Z%P ]ID'GZJ.U7<_2$V5)D
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MI\FG'?Y/\-TI88@YP<"4-'CX<V>)1&<\[JXLZ.NHA97&2,V%$GJ[-T\B\Y-
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M.!#HU$92T,(E&D\O2=GL=[[5$5AE);%YF)UQ<LEI]G6EAVW*,'X9A&HO7H6
M@73??>JY#:AQV6F%BW)&P91ID%CSO!GOB(B[AD3S:!L4#VSSUNV)7DM)_ 27
M?=_(V6,^/E?\A:9E571.#32$C)ZR)VW"IS/I3*<YO%QI6HJTK^J(%+H07D=@
M6.9-L1#=JTF+PNS?I-@H&&3$@=Q6!D FU?D=+L9+&\ATBMA @=HBI14)T!:,
M*Y*\;J7;L&546W,*MCPNWV_%E2:#YE<(!MO7OM=&'ET3D:,(;26/C<EQ404=
M@'6SO-$V5;W$UAY/>KLM\UD]R:N2ZZHF%=MZ_7J(B,F4@@<6C-7&0,SE%R7+
M)3,UQ:V(/B2H24Q<%6,7K*M-L)R8L<R'L\2W05,.I2#AH:+MG\O*-*_EL%D\
MIO2JDY,K!0WESR"F Z/DU"''2'";HI*9<C:VDTV#S8)':.JJL[>K:+S_ #N=
M[E82B%CG6%7VN"EPK,.\I $M*XY(HZ7)!@BZ4G&E6&4AVO.21)JQ6+3)E,8E
MREY#D@W$ J:KF!81^][TL"MYC.7B,R@[PE!1C.Z"M0SNNZB-+G9!'-[>B->1
MFQ%V4\F[MQ!@4@3 J,Y25(9/X^0@3R 9;'<Y'6QW1931$T1-$31$T1-$31$T
M1-$7S^=-9T8_Q Y70!KKMZI.K*/6 +]&ZMO;WUW[3DHL[\_Y[V^A?JWT'U-Y
MOS7FG_I/I/E^<;^9\E7ZO]F_ENB(.MP_-OG';Q]"7[;LKCLQT@;_ ,72W3W>
M1FOO+EZ/I+@$,[EZV^XK1]_3;_XS?].W^^FOI?IG_+?[S_56^W^QK?E3^FW_
M ,9O^G;_ 'TT^F?\M_O/]5.W^QK?E3^FW_QF_P"G;_?33Z9_RW^\_P!5.W^Q
MK?E3^FW_ ,9O^G;_ 'TT^F?\M_O/]5.W^QK?E5^>,70 ]4%[UW9'O9^T7LJ3
M(//4W4/ZI]/])!%1WF_6/7,3]%\CTWSWE^@N/*\WYOR<?+\O#R/E_P#:2E/D
MCKO4/F78?..C@A[7YQVMQ<]-T?2/V?8='=/<,UW"SN\F/+T'6NSZ6"/LWN2[
M73/(W[D^Y;M_<,^JOV-^X:_*J-[[9\Q>G2WA]KRT]PSZJ_8W[AI1O?;/F)2W
MA]KRT]PSZJ_8W[AI1O?;/F)2WA]KRT]PSZJ_8W[AI1O?;/F)2WA]KRT]PSZJ
M_8W[AI1O?;/F)2WA]KRT]PSZJ_8W[AI1O?;/F)2WA]KRT]PSZJ_8W[AI1O?;
M/F)2WA]KRT]PSZJ_8W[AI1O?;/F)2WA]KRT]PSZJ_8W[AI1O?;/F)2WA]KRT
M]PSZJ_8W[AI1O?;/F)2WA]KRT]PSZJ_8W[AI1O?;/F)2WA]KRT]PSZJ_8W[A
MI1O?;/F)2WA]KRT]PSZJ_8W[AI1O?;/F)2WA]KRT]PSZJ_8W[AI1O?;/F)2W
MA]KRT]PSZJ_8W[AI1O?;/F)2WA]KRT]PSZJ_8W[AI1O?;/F)2WA]KRT]PSZJ
M_8W[AI1O?;/F)2WA]KRT]PSZJ_8W[AI1O?;/F)2WA]KRT]PSZJ_8W[AI1O?;
M/F)2WA]KRT]PSZJ_8W[AI1O?;/F)2WA]KRT]PSZJ_8W[AI1O?;/F)2WA]KRT
M]PSZJ_8W[AI1O?;/F)2WA]KRT]PSZJ_8W[AI1O?;/F)2WA]KRT]PSZJ_8W[A
MI1O?;/F)2WA]KRT]PSZJ_8W[AI1O?;/F)2WA]KRT]PSZJ_8W[AI1O?;/F)2W
MA]KRT]PSZJ_8W[AI1O?;/F)2WA]KRT]PSZJ_8W[AI1O?;/F)2WA]KRT]PSZJ
M_8W[AI1O?;/F)2WA]KRT]PSZJ_8W[AI1O?;/F)2WA]KRT]PSZJ_8W[AI1O?;
M/F)2WA]KRT]PSZJ_8W[AI1O?;/F)2WA]KRT]PSZJ_8W[AI1O?;/F)2WA]KRT
M]PSZJ_8W[AI1O?;/F)2WA]KRT]PSZJ_8W[AI1O?;/F)2WA]KRT]PSZJ_8W[A
MI1O?;/F)2WA]KRT]PSZJ_8W[AI1O?;/F)2WA]KRT]PSZJ_8W[AI1O?;/F)2W
MA]KRT]PSZJ_8W[AI1O?;/F)2WA]KRUL.XR5=U0UG[)>O/:'_ )A*E/6'JSU3
M_P!ZFRP\QZ)ZP)_^EZ/_ #YWTG^_Y?\ 'F\/)_G+T^J=#V'17%U=O%%$]S<U
ML&9XK+5Y77.G^<=-VES</!"+FZNJGF[0^Y>Q_P 8J,)R":2E] T5SUAC;+$3
M%_N>E.&1D=<,:K"(6.VS;I',&C+:2QVF:T&J*#D&:PW&,)N0R@YX4-N"7975
M<_'KO*BCOA9QI>D !16NG";N-%C)L7Z'.K''-<R!^7UO/B>1<>/ES9A(FBDS
MJ&N)&T&2%L4&#"D6:.!C1GNY([/".?;^GNEY24>&\!N+ @?L+'P25(,6XB%1
M\,EE=-Y+YQ$!6UCQRVZ^!0%RXLE5S7@6$6%$H](HJ*@RT>8 <QV(P8W;!G+P
M<X(YR>P:93]5(A7"[C:#/1R0AZ_>CG$7>Q4JP$-; LM*'$3<%+O3T(D4M@&T
MQ]AIW)X8:>^M(G)IO'9"?C;T< <!B+)2-1[<61S\-8WN#*?0CCW3==#VXF(0
M8>.%M:9KKCW@.=OC)UBK3=3H2MM 8,[:'R11!^/!MYQ*D%'S[!P9-(EU4SY(
MI@W9[-R.=+^I4.@_$#CY79 &7C<,,*F8R9BIN/&Y39%H3XX&4@L6G4+A(<<:
MGDSDA1K#HA'+.L)E&8$D[QA )Q,9 5&1]J7(KO\ (CGXE\?I8N^T.)-"7))2
M,KL"(FB)(^$$QF9L0MCV?"XK9<:!.7SD3&[<@T)F4=A5OQ]CZT*LT0MG1^6#
M=Q!4J#S:YA2;]@X(Y'Z#18J;*.%O&*9K&',FJ@86<'@E]QPJNJ<EB*S@1R=2
M10O!LFJT/H9M%9JV1S:X/F63=_%VCXPTAKJ/-SAA)\0$BHM,'U%2J)3B109F
MQE+1(1 RK(G,T V4_"HV/9S.L"]D1; 9C'+$.THRF3>G#T^"+ P)$;,S,$?2
M1J9C\>.ID]C( ._9&O\ WGW5(YMR96L>MLB]$YXI479%@(V=+XJ<?2[ M5)Y
MSF.L>SHY&S!VCICM8%2FI+!8U,A$&E)>"2_%(R")22.%7J6;=HT677'M&K1(
MCD59=(8S\E$Q_!KC&*S%*,((?;Y1XY&#L5VVMBXE,(5['(3%E'HS DE9^HG
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@L63=$<,P9$>O+\?<KNZ*)HB:(FB)HB:(FB)HB:(O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>g65062g67t12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g67t12.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[25(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )2R^E18X0DE-! 0      !\< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   @   #A"24T$)0      $-/)GTL]C>HHA4@U:H05G"LX0DE-!#H
M /,    0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
M    26YT965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I
M=&)O;VP     "W!R:6YT97).86UE5$585     @ 2P!Y &\ 8P!E '( 80
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 [_^-0 "  $#O_XU  (  3A"24T$)@
M#@             _@   .$))300-       $    6CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !H    !
M   "0    D     "  !GG@$   _R 3A"24T$'@      !      X0DE-!!H
M     S4    &              /0   '9          !
M          $             !V0   /0                      $
M                    $     $       !N=6QL     @    9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   /0     %)G:'1L;VYG   '9     9S
M;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E
M241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M  Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M  I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   #T     !29VAT;&]N9P  !V0    #=7)L5$585     $
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M!!$       $! #A"24T$%       !    !,X0DE-! P     &IX    !
MH    %,   '@  ";H   &H( &  !_]C_X@Q824-#7U!23T9)3$4  0$   Q(
M3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)
M14,@<U)'0@               0  ]M8  0    #3+4A0("
M                                                 !%C<')T   !
M4    #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:
M   "&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D
M;61D   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^
M !1M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $
M/   " QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(
M97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V
M,3DV-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                        6%E:
M(        /-1  $    !%LQ865H@                     %A96B
M  !OH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*
M  ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M        %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                      !D97-C         "Y)14,@
M-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C
M92 M('-21T(                             9&5S8P         L4F5F
M97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M        +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV
M-BTR+C$                                  '9I97<      !.D_@ 4
M7RX $,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A
M<P         !                         H\    "<VEG(     !#4E0@
M8W5R=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H
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M\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $X ET# 1$  A$! Q$!_\0 'P
M 0,% 0$!              0&" $#!0<* @D+_\0 9!   @$# @0# @4." <+
M"P,% 0(#!!$2!08 !Q,A""(Q%$$8(S)1E D50E)55E=A<9*3TM35%A<S-'2!
MD;$D)28U-K+P)T-B<W:AL[2UP>$W1$548V1R@J+1\76#E5-E9H6'_\0 '0$
M 00# 0$               $" P4$!@<("?_$ %(1 0 " 0,"! (%!PH$ @D
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M<.HW>LXR2?,(\8RQJ6^X_"'S/Y.>+OGIK&W_  ]>-S>7)34^3WA#Y;\HM?\
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MZU+0MV:C1:A+M?2ZBCH_H[XEX?X7U.Y+K-K?E/=WNEVX=9TV[#;_ #?8AO\
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M.'W[G^IHXOZ\ONA^'1[-/]T:S\S3_P!AX.4?Z.'W[G^IHXOZ\ONA^'1[-/\
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MSE>$\M]Y/U:UU_J/#O!8>-;<-GP/P;<G+:^%#9_DSHC:E/<%C*<3;C$8V\I
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M,)I$[L<CB.6-Q>-UZ&KLTU151&25*AIX8 X,"Y$K(DID=0W34*C $+;!T$@
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M-EMN;ON^K&BV#(BE&89,R]12 25QMC'(@+.; "^):V ;\2A62J[J7[E'%_\
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MOJ5]^/7Y7[9/GIRL:<>X1+?M?3U^6>U]VL@)"N; WP)M9K-8][>H+&]_DCL
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M5O&-I3>FQXYDL<@I'!%!$,R:4Y(%.LYR!GECVG4TSED6GU;4HBY9%\RU3ED
MPL!C(X178$2.?*3YQZR^C:[O@'ADTY7TFW"\XXC :P<JBV_(Y/IKYY?3DCL_
M2SQR RB'7[L^T06:3E'LJ/-HN[?*6,M2*C=' @7L"I()8#W*4)%E"F,H$#6(
M\T8!R4CBZ8L4:;+I:,XS5E -]VPMQ3K5OB1E%[4M(*UC^J(^EI&E +O1(B@
MQEKW*28FT>(LH!+8FSJ$#=V) :ZF^7"B\JD5G(YS++7Z0AZ-/R]CL7&\#F.!
MC'!RIJI8\UN1;,,KL8SC:,%F>0.6CNJ9*HRO*R@KFKJ%[.9!Y@%!O<I$_5JK
M>_R^RPLM1/5+TO(8HV352(U05=JYI07VJHBUJ4W@I6_B@Y-.77([L<%%R .&
MD:F&.+  ,)&DR92R6'35OBT)@WA-J?>JL:,\D3U[<:[7=WWMU9^%H]=TRH2Y
MI5OZ,91QFE9,BGL'J<5ZA^*S6]:11_YQJOZ%0?\ 3ZEQ(_\ "A_YF[_T[.FG
MUY?U8_QGI;Q'IVN4?QFQ2MXH>>F)94&^J\')69%+Q0.'\A=N[,5 P-U?L,@%
M.R=&GYOLR0E4&K,X822-W9650+D4ZY'XX2_E3Q#BI>^C0R/,3I:IM2J&2!F-
M ZBN(08^Y=F.2'RF[R !NQ-@H^5<%BR+&O3^6U\N7I>,B,?0[/E*&2UZ9&\^
M;5,1B84;$25>9^M&1*1]6$;M$JB):AJY!!FL=VDNQ( "IB LF(1STUD4(K
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MGCW.YA];QFSL.XK-;-I)3_R]?_28_P#J5+P^7U=O^H__ '-S33O+^MG]V/\
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M0J-A=%TI0<0MXI&.:,A8E0L8[JP10'$9(,@=L5*#L3Z@$790KJH&,8>T\4!
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MS"F62:*.:411UQ2*6D25CC"IQ9+@NK11M(8V:0A(UF('$&Y$82OS>98PF<6
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MJ]V.?JU5WEO.LZ,^5QCLU.X\1'A+':YAR$L7&0LY8TY:$U"@1QK&E,G46-Y
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M.IG(B#YD8D:$!2ED\J8\@Y4FHQ2'SD2,058!BD:AE-T4,I +"UD!%\1,%(!
M4C,#C&S.:(V71@O/+MWD<C-KRE+5-.I2IE3&EQ9:!<$Q3CRO'/U! EJL65XB
MH41A2P965R 6+ @!4#( K&SV/2;WLG=)L<C\BW MU(NPOS<A7BR0[-Z2!*XN
M:"4B@DQ$>*"#WAQJ1R-L0;#7B:.108XD8,755:48LI!'9E)+"7RDEB19F!*M
M[Y(R[2[6Y6T(O=LQ@D#BT'#>F(Y@7)J(?5MD6$6*<N7+W6Q[VUJG2%U!NA(9
MQ)&Q*FX!+,IDN067(#S )B<FNMEC*VS[(W]:A\OE[QY'E&55EIJM(X*?+ZW'
M,>RMRY MC)(B9#LUK6/.?3%U7EQNVB9'P?0:Z3$.0'>*$R%0N5BD+HCAR% :
M[CL+\8?5[?Q.GWHK?Q-N<>TJXL)F6\<C'&5YLON-CX9OO3]?T>Y$3X>]MS^L
M6,=R-D2@0]$]!PJ2C\J-A4:ONNK2075J>$]B5#QI2F1PV78L)2Z1, 0UHP%=
M#*K>=O%%.BE%*8[DRNU,9)?R4[X,]L5KW3]&I$_$H[OI/9V\.2I0,'HF .S7
MKBV:6T)!%I\%.PG,HJH<BQ(S$A>))DZ@/4257,D4BE\ X2- J!>.=]8MR1H1
MKB9RMA<6WO[HWZZ[CT<I!'(Q"NZX&-Y+JRN1BQRF-;U@H--6BFJ3301Y*H7J
M "0WMUE R0.JC (H/E7)L\68FDW8\I5V*RM@U0JL4##]^.^KOI^IG&<8,I2C
MDL*K%Q$,Y5%3,L88FO%)34<>".8&BF1A"^752-4$,<0+JUA-+$'B67HFGR+-
MEDN/$/F%C$05;'VSVRF!>V16[J\V6[)E_P Q7<  +1L1!1HE=QQ'+J3WAI\/
MM7S]U;=6D4>[].VI'M/1Z75J=:ZB.JU&IK4U512JT,<U90R)14\E(QU74UJ)
M5HVJ*1(Z!A576\\$\&_EG<ZB$NICT[L;9.Y;;.<V5Q:BSAY(,?/*U%CAY7K2
MOI=]+7Z,;71;KX;N]:]9OSVMPCOFS#9-N$)R.4=K<><C<_F-MA'GQGRW?YNM
M:5U-H*"6LI3/23I1S3444E/4-44D[TE3/U:JCJ8@!+!/&E0]-421132PE*A5
M*-(12SAPW9[?*$OAR8$H291EQ96QNF0U<5[EO:ZOS?EO;&UNNWN;;N$=UC.,
M8SB3A"H[D;EQE!8LB,F,9$H]^.M*;R;JRV=&/N6)062&,D 70L6ZULPQD<D$
M N%6Z<9?37+=$.V$R-R*##Z=_7MYLNJGJI!M,F06,I/JH*M@5"3QS7JTO?6L
M>42TTW-V!A#TB=)U.LA):QD>6HIHKW)0LP$3GLWGC ^0TF1]!?DSVV,.N0+C
M#:BMF+Y*CWM?4;/2RQ\=?EZWN;X3M\FG?W]Q*::C +,%'(Q(KN-)9] J2)PB
M/*BI&SF141K@$,0$;S&QCQ*$NT:J&#V;%<NO"5&-2LBF0M\D4I#ZW?!<F49<
MG/F\UI(94QID(#)B/)PBJ!1<ID0'!+627XP(ZD&Q<2'ILQ .+9!<39CTRS ]
M@^"J"&MPS-R%Q[CQ]9"+8X7O$1,5WTJ_5P".1%KZJ,>PV<L21,*XO5^0W4QH
M %1C%(65+*<C96>-%14*E\22K*I)LW<\+$BRY(BG*+%;"U/K/<6*UD[8'3V4
MJX\B5-2&)3**"+ /2R*XE30R'2:25XCE;W!&,?3+L&N,S;LMR!W)4]5@AM<,
M)3BF)<7S-,9=J>(5?FB>@4'I7=MI:1S57%!&\N4*>V45QA36^?#(#\(CD:S!
M;-S1V4\C @WD;7J +8GO;N<?>5!!"DY-C]2GP-X7S<)U'&+B^M%OO7=7*&+/
MPDE_*712"H?G6Q<JR_SD0PWA]P.Q=/?JMXUW75])8_YY4_\ $TO^M4\.?J1_
MK2_A#2>K]A_&6E7#=+HX-&C@T:.#1IBZX;;WV3^.CW0/_IT7_P#/Y.'?HORE
M'_IF?XZ1[GIA_C'^/;3ZX;I='!HTPMC_ ,OO4?-O*K_[(T7\O]Y_+PKVC]C_
M !=-CZ_LS[X/L_@=]/WA-.T<&C1P:-?G^[SD_P L=XK9<ANK<(4%@0V.J5:J
MEK @@=P.]LC[Q<72)$N\1@T8,U;1^VBL_:YT^;;+ ^:56YJZH]L6N5'3:'Q\
M@E,K*ZA0L?J@\I<WR9196MW6XR]W>Q7L-'EE7)/>RT:PTWZ9QG&H_KR'E2':
M_FN;KU^TO[]+HP<L@P1%Z9[@L2HNHNMV-KGS*%/<DVM:Z2KVP->GW%XO&&[[
M6ZDBO=JZLN[6W.+S08;;;[4*U+=>1@INC+8'S9 A2"@)"% N2WL+6( OQ&UQ
MB7WQ=8Q8>IWP^MUC#2Z*LEK(X+>S<K+QDY&,&:K5UI,B+J0PRQQ%BB&Q (([
M$FX &-P2!V!/#*Q+)Z7ERWAOMVLS]K3D7D6/'NXH[&%P'=LL&\557I*T4O=F
M%@H41NZMGWO=<+A?>5OZVL20."*!FWOBZS5'SS??Y&DD2SA/JU*2@]^12@T=
MO7*-:QDT+1]?$ AXV*9FY#H"0%122+78@]R"&]!WXDJXWRIM#C;>%O..Z'>B
MJ&],+))4>6*9-O(NT/7+=^BU=%ZA7S.")NC3YV0N5J9B Z8@!:2=OE7LC1 %
ME?S,6502";\:G]+B_!NHC=>?:'/_ ,PKT]\64W\K-=$_)R\?I+TJA?P^H#VO
MX4L?/B.*^WVTNY8;?6L74GB'Q\>3PAXXN@9!902Y1L'B%E95NS9,]D#V7CO7
M];+;-H'D!$E??U>]7V'[3+@QZ\^B,GI]V4)'\W.=-9J+*+=>N(Q'T'LCG3VA
MT*KU;5JB"KJ6,\<2I#C42^W/&7EJ&-1'*V<DM0T+=65EG$;A(1A&8TBI=Z#N
MH_$*G59\W%&0>N6E'L-'R/5/@/B'3^']#TAL[-;<FY#MGP(M;>U<)QC0;?,J
M%PYQ93!J3+<.B5E320U5/AC*E"?;8YNF\L@$I""-QU9G=I'CC)7R2"1DE1"K
M21QHS5C=F7G]9(WVQE].U(O9M-EO8GM]/(E!A/?X;/PB1&*G\Y%@\",2,9S1
MICPC*+(E&$G"^_*#3* U%9UZ2GGJ:$2FL7K+-6M+,BQQID;L9IA'WB:8DF[E
MPTG$<W],)1A)N;(M91O"=_>[+H1L&JZ?A\SJ.!/;GNANQVI;4^$=K9G\.A%:
MN) CQ2'-(0@<HP<9KFY![#(=/I87]G,@D=7>25W,G3CJ5$JHI]H9G"I&SI&!
M3J]F+-*[>([>WY*LOZO=:;K^M:T"61:;5R^G@SFG4[F[$W@X'&," 1OX5PE-
MXQ-N%RD#*][+1';VIRLETW1=*CU*N>.FUSHI2QT=5/)&(34><F2%I8@LDC-B
MR!49((X2(BS2*^M>(=/O[VZ0C&48D:GWJ4LO:5/+*!42.*&V]"^E$^JZC=W-
MK;);O0SG\0W(0C(F0P<=R$)<X4<B7*5LI#/B18Y'G'SNI-1Y$:+R<I-L4$FI
MTV\=4WAJV[DE22<JE'KD<44-"M+ _M2Q:I#15M?)6]&GH=,HJ;V9Q,A@V?H9
MQ/!]GH#8C .K)QW)9GNBRD2X\1)_H,KXD.,0XRHX1X]X/N;'CO5>-SZG<-F?
M1? VNDD(PCMQA%N?.1\-8_&AML>4]V>[,E4%E\Y.4U(-2U6MK^D%2;4ZB90O
MG4EI/][ '>,@$*Q(! 0J22+^DOHYM?!\(\.VL!^;;;7MS_G+S@S+)?9?M/"?
MTWWOSGZ2>,;_ '/S[=@4+_PGX5X2P-L>XG:V\S-CBZ<$8MG&F++V-R1V8$+V
M7(&]EOWNQNO&Q#B(>:3?(D( /F,C6;^28,76EY+I:R#[^@X:[>UHC>KW1B4L
MTBLZ ^5C=0F7H223=B%&)#9*<?.;&ZC.FJCE0?5H$K+=XSZQ[7G0\0IY(8)1
M"S,GMV;$:RW1=8U]&OJ43,?';R7.)"M1\SELTA+*$Y5;VMV9B6R/<GS!;@"U
M^T'5E;&X-6<%J\W,,^@7Z8]._?5EX6KUFS)NI?%.Z]MK<?7WQYLY*L[/8=Q3
M:VO22G_EZ_\ I,?_ %*EX?+ZNW_4?_N;FFG>?];_ /=CI7PS3M<CGB84OXD.
M>021W8\W.8@&+,@*C<NIDK8H0#'TN[D,I:)UQ?('C:.EE?3;3QJMN K=5$B>
MGFLY'KGF<:O7)?$XCXGUAR6^JZA 2VYR>+BJ\EYL&,B45.1IV+*5$MB&P7R.
M]V4JUELH+KD0V+!/F+*5N"TJQ+E(4KB(9<"U9''*\^E=ANL4NP&,<VDOT9*@
MT,CEQ_1%)%@Y!50QM"Q,S+F,Q&28E1RGE%L)1'=CVO>P9D )-KL=P0P#Y3!6
M'L+D21>.]]ZIJ6.WP59<OK5?%+M.PQM3L@G%*NQEZDNSETD^.NUT5A(P7Y"!
M5+%#Y"JCJ,% ,9+,1YP;4JPB49CR;MY2/JTC]6T)=Z/*WBF1S)I,281KC<;L
M5*CYT'C?=J5RG8QJ_4DB=2L;2+%<7 4J5"EER-BK-%<  %0?4.LT9Q:G%)3Q
M('YK+V/JE]UE@)=DB2(I)C(8P5BU7>)&/O*U7M$ ,1&T6L*E925<#RCI]%P6
M/3+L3$T8 )95LPS 8D"0QDD(Q*\8Z)Z?I<L\@0*Q0HB V6KQC<3,Y*/U65Q2
ME*:O.>218M2"L%"\5=?)75M-*49D$4G4H*^MB9$#.9!1UL\%W*W47C&-B0K
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MV67$'5278WHX0VYJXOZLL%1<CAN6*<FK;P>%>(]"MB]7L--]_B1KU $NBLV
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M*V_+)5,W#;RPWA$.(>;RQ!;Y5R8@1N*-M5:1#T"*J&92"!=G*,9+,!WPZMF
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MH:J5 'FC17N&7$-]JU[8_)-BOV9#7 O?!ZS;Y]+U$*7GM;L0S>8-4]_7V/\
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MPI3]!MBH5WNRFI!R8Q/T4.6/TDC?,K,JVL JL[DQO&H8J!,RDD9=.X);$@H
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M]$\W=R1.4;JEXID;S$]+LJ/<"^-  .M_^%T!/$5R/!D=6/-38X8.19C]?*(
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M.H%02![ DK<EA<W+!E)QL4 O<^'%Q):6VJ7]E_5'.,UBO?2,T/*7ASQH!O\
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MK!@5))L.RMY+@'RGA]A<>5IWNK*!*:!Y6!FZ:'S-M"XDN(1>W&VW(B+8 %V
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M%BU$(MVE%7Z,1J,;VWH6I3RPT<<\)1<'RP#37"F);7ZDMV&3N8U4@(&"%V;
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MRC$JK+XUI8LT:R,J-UBRE'[ -YRYQ+WL<5^U4]R%[FV#9 "(W==\2<71@RV
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M'XHN34HE4NFZ" A15 D^L^J65P,"YQ8C,@E;@ V:W#-X?AS3(GJ(XI<+BK'
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M_FX5[1^Q_P"J7^_MTT^M+_Z?X:< MV-_7OW-[6]W<]['\7;O[['A-._W_O\
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MG\7Y3<7_ /SZ]ZK71/\ ?^_MTD0_X;4?-[+2'OV_WVL-K_UD6_J/$C_PH?\
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M6:,I(RQ%<B@4-E(2JJY# /B9+F_RFNXL"+,W#TL:Q()5=HR9UBT?5R$4RAJ
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M/:E BX$:L>W>@[/DL4#(;FX8+9K(P)&2W\MF*G%VNMKDA<E&*/UE(T,B^WE
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MK6!!L;Y6[WN"#P]@!)*J_6V[S?IV<=VZL?:*S%VK>![4?W+\@?3MK*";,1*
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M6/5$#.*JE]<A05JH1<F.]F?D=\>_S3&KRR1@$$,_O5B64^G<ELK 6(^QNQ
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MX4EP*!'8QQA4 8DHL91 H'(>I26[-<).2@M8EF_:ZN^_R[)Z7Z2/'IX D9,
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M.C^(;DBIR/\ NG;,9RY'=SN"BLOH<V-@3<V'?S7!OB]5G8W\?^[D!F@(VH&
M/LHS\C5QX4AXAT/RZK99=K7G$!0!:^:]OFO4#TX#?_%##T%^EIQ[_C'7^?U]
MY[6XUZY__$'[V[^'74Z/Z*O;$/Q:#' #;ZT$GYNEIWY>UJG\G]7]?"7/_P"(
M_P#VMT_C#1Y6OYOWPD,=O3E\_P#>->T2$.MM+:(@@B7I4(,?_"O',7 'SJ"W
MK8>G!)E3>^2*^KRW&[]*8A^Q_;I:B/\ PP[9J&+Q[W_^<7K($?COZ^MOZ_Q
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MX!FM>K?R-#TWT>CN+(.HZSJ6NWU9;<+$SGC*[M<UG7T*+"NF%; B34<H8AW
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M ,C7AITGT1Z*9$C+JOC=3.7H_%WI$94GZA&O4"E*T\^O3?7C7]5FA&$]7#3
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M*,M>164,^%R@?$9(I09 A#Y5+7(/8G<%5237&(>7ZJ211K,R+;GMW;TR%3B
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MV9;N\$;5D1".7S>G_-??MDRYQJJZT.GZ>>Y-XQV_-*0G:N33[%=N_K5 Z4[
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MUS$9D:6B]F:J+]O8,KZ578EQ7ZV?1P:-'!HUR#>)SI+XD.?-I#DW-_F%D/*
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M(%ITD NT0(#V#"W$ORL=&'4>'=9Q".[M;FUZ#RV)DZE(PO'=./N'>BWUE_\
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ME_S1HOK^/Y^%>T?L?XO^_P!KIIW7YF/;!_N_7&GYPFG:.#1HX-&OSZ-].O\
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M,<NT0$DBA$SGC16&L#WJ(6<?*TA6E"!F)!\Q)64*18BS8V5Q"% 4)=P6Q!L
M2&(X:M1[H)Q"F.#MBUML.79JY/;2H,O3D>8*)6XO* @<K+,K1Z:\HK=225@
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MZ7"U/%V2*'#'C@Q>7!6*1.K3BOUO^C@T:.#1KDI\9P)\5O/M6[(-_:G<DHP
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M?(R@"UU\Q9E**+@N#8 JJDEV:[GZM+@(X2QLNA+,!07*S( :87R'AFY.$7"
MMT^:SEVIQZWKT1*Y 3J-'@UTE*$L[* $01RJP*=T !!#7![ #AL95;]6I(M-
MV=HW*+&0#&W)54O?2I+ZI<KCRI"EE%%\LQME?'))L$R&KH+QM)@N(98T!8NS
M#&-201Y@QP!NQ4A<+$YOW:I_S-QL**&U3EV#EBL-/M1I2,LX,R!]&N+W/58R
MRY!*LM=77@+ 89,5+$JC7A2*XQ<*5*,RV[74@,3Z$9<(S<WB7%XA0JV]\N>1
M78:/UBGL'%.+2=9XT1!8T2:(O?S>_971G- &.HT%V1VA&J3!C\7AF*6K* ),
MJW9PCJ S=-D0*!?UT?\ *.RE]&MUC%>/5;)GN03<B-<3RJ^I;)2\%=D_('M[
M;]/]G;W9P@2\-ZI%DD9SVY[,Z$&7*HJ5=1+QK4'.ZO-3RJUU*6+X^%M-G2E+
M(WM"TVIT,\L9P<HQZ4=D#G'-EM8BZ^;_  MCT_BFQO;L248S2318,4OVQ=EW
MD+S6O=OC/1SWO!^KAM3C&6[T_DD6#(;(T@G+(UV'-@WLO0=P"1*"9%+4^HT5
M*8DG'3:.)XU8@DJ_=2V3*2"S"S"W?BMZC;W:>)*X]Z]4KT[4!AN_87LWIS;C
M%>=2C.3AM6WW2BL=D.XMWK);8J7I=8YAU!C<K'NRELK1LEXQM;0 &.:CUME:
M,D,".[=PL6R+M<9B$HIFL6R]_P")\GLZCZU?B=++;8R>*]\)SJC[6RWV_1<Z
MUGSPEU'=.T/K514[9U&Z=F1 .MECIWW;HTE:]P6*M344<M1(0IB7&Y+$,HGZ
M+<ATG4F[2GYKUL23FY;O0[^S$JQ//.->S]CJ3K.EEUFQ';FD5W^AWF)(91CT
MW7]-U,NQ2,=I/1>T0L=;@U_5J8M2QI(2%@2$H4<#)4 )C<=I"M@;*2/R7'&-
M&'/;"OJOEE*Z3!C#?;%>I15ZDZ26YM3W))7Q+Y C930X[93T^^[1\NX8EU/<
M56C!G2HH8LB2I;HP&H[K:U\JB0 !6NS!3C;-?2_Y*MCC]'-Q"W=Z[=&\?5VM
MDBF*[*UCU;L!\0?_ *0G5._]-=B+VV?"MC@%M\^IZF3C[(1+<Y**N4=R)(Y=
MG4X!I%?(.6'43,,02F!7)0N(( Q 8 ,K<=+7 4$KJ2]WLF%O!RD*9RT]WA,8
MW*5*1"XEW$63>0[,J*LI]/:DA,AZC=LF!# L8\C$<GRL;$/YD%W0.0"IL%+A
MHHS33;FQMO-TEQ>TBTL*TDKRI];-QL*1,AGO?_*M(8PD6-G*DE X9LUOB&!%
MBX48$I87&(LR!F#$W55LI*4:3NOHQ,]T/+)&Q.U(I$6F6)73@!RQLP472"9+
MO.I$^$Q0WB7Y!2JRD-S;V+D#?U3<5#EBARQQ=X[*A4*6#^A8'$ZJG8WL?^ZG
M5=OJM9\N:,M-@&K;P2_Y2\/R5^=;/R?^)"[&_5*"FVWVUU_<:QKL.C@T:.#1
MHX-&C@T:.#1IC:Y_IOLGT_F6Z/7_ .'1O3\?#OT7^M'^$_\ ?_;37N?8_P 8
M_P"'_?&GSPW3M'!HTP]C_P XWK_RRK/^R-%X5[1^S_%TTQ?[/X'^^^GYPFG:
M.#1HX-&H_P _A.\+=5435=3X;^1%155,TE145,_*384L\]1,[22SS2OH+223
M2R,SR2.Q=W8LQ))/#N4OUI?>_P">HO@;%W\':OO?PX7?OV^1]VK;>$GPK,06
M\-?(5B/0MRBV"2/=VOH!]W!SG^O+]Y_ST? V/Z':_LX?Y:J/"5X5P+#PV<A@
M+$6'*/8(%B+$6&@>A'8CWCMP<Y_KR_>?\])^;[']!L_V</PZJ?"7X6#V/AMY
M#$6M8\H]A>E[V_S!Z7[V^?@Y2_6E][_GI?@;';X.U7M\.'O?M[Y^W5/@E>%<
MDD^&SD,218G^*/8-R!>P)^L'<"Y_M/!SG^O+]Y_STGYOT_\ 0;/M_P *';V^
MKH/A*\+!]?#9R&/Y>4>P?W!^(<'.?Z\OWGT[>NC\VZ?^@V?[*'X=>AX3?"TO
MR?#=R(7\G*380^?YM!_&?[3P<Y_KR_>?\]'YOL?T&S_9P_#KQ\$GPK7R^#7R
M%RO?+^*+8-[GM>_U@O?N1?U[\+\3<K_B3JL^:55]_;2?FO3?_#[']CM_AUXD
M\(OA2E1HY?#/R"E1Q9TDY0<OW1@?4,K;?(8'\8/!\2?Z\_WG_/1^;=,=NGV3
MUQM0,]KQ'O7KJWH_@_\ ";MZ:2HT#PQ^'_1*B643RSZ3R=Y?:=+), JB622C
MV]"[R!549L2UE O8#C ZOP[P_KY1EUW0])UDHQXQEU73[/4,8VO&+NPFA:M&
M+;U;]!XMXIX5MSV?#/$NO\.V=R?Q-S:Z'J^HZ3;W)T1YSAL;FW&4N(1Y2%H"
MZ-."L\-?AVU";VBOY#\G*VHZ0@Z]5RTV;/+T%9G6'J2Z,S])79G$=\ S%@+D
MGC$/ / HE1\&\*#V/#^D#[C:^1]VLW_TH^DN'_T@\;L;'^5.NP]K/Y_O6-6?
M@R>&_P")_P!P'DO_ (/(98/]S#95X965D:2(_67XMV1V0NEF*,RDV)'"?^CW
M@/?^1?";<+_)_29/;_@Z>_2SZ4-W])/'FRF_%^O;/9_\1D^W7CX+_AK$DDP\
M/W)42S&\LHY7;)$DA[=Y'^LF3FP NQ/8 >@X=_(/@E5_(_A=>WYATM?_ &M$
M/I9]*=O$/I)X] [U#Q?Q".??'4&KC>&7PXM#[.W(+DPU/:W0;ECLLQ6^;IG1
M<+?BM;AO_H]X!_\ R3PG.7_U=TG?W_X.C_TL^E+)D_23QYD]Y?ROU_)^U_.+
MU?D\-WAYF2..7D3R>DCAL8HY.6NSG2+$67IHVC%4L.PQ L.PX#Z/^ G;P7PD
M^SP_I#MV_P#=:/\ TM^E1=?27Q[S7R_];^(>:^]_^(S?K>FIJ'@R\(.KUZZK
MJOA9\.VI:FD7034:_DORYK*Y(<F?I+55&W))UCS=VP#A<F8VN3Q8=+TG2]#"
M6WT73;'1PE+E*'2[.WL1E( ),=J,1D %I>#51U_6]9XKN1W?$^KZGQ'<A'A#
M<Z[?W>KG"%KPC+?EN2C&U>(A;=7JU-X+/!W4J$J/"GX<9T%P$FY)\MI%L?48
MOMLCO;OVXR_B;CWG-_\ JE_GJO.FZ>/;8V3_ /MP_P M9?1?"7X6-MPFFV[X
M;>0^@TY:1C!H_*386F0EIC>5C%1:#"EY#WD.-W/=K\5N_P"%>%]5NRWNI\.Z
M'J-Z>9[N]TFQN[DD &4Y[<I. ,OIJ^Z7Z0>/=#T^UT?1>->+=)TFR)L]-TWB
M/5['3[0K)^'L[6]';A<I2D\8EJO==.#;OAXY!;0W50;YVGR1Y2[9WKI4-53:
M9N_0.76T='W-IU/6TU71UD%#KNGZ13ZI20U=)7UU+4Q054:34];5PR*T=1*K
MS]-TG2]%MRVNCZ?8Z7:G+G/;Z?:ALPE.B/.4-N,8RE48G)%J(70:P>LZSJ_$
M=Z/4^(=5U'7=1"'PX;_5[VYU.]&%R>$=W>E.9&Y2>)(+DXRZW%QD:QM'!HT<
M&C6F]4\.GA^US4]1UK6N1W*'5]8U>MJ=1U75=3Y<;/K]1U/4*V62>LKJ^MJM
M'EJ:RLJIII9JFIJ)))II99'D=F=B9#>W0 W=P# $Y &, -'8[>QK%ET/13E*
M<^DZ:4I292E+9VV4I-W*2QMDVVN6V^[I"?##X;3:_A_Y*G$66_*[9)L"0Q _
MQ)V!8!K#M< ^HX/C;W]+N?OR_P _F_?IKX?T#5]%TK11_,;7:Q_5]P^X]C5?
M@Q^&XVOR Y+&WI_N7[)[?D_Q)VX7XV]_3;O]I/WOW]\_;G1_)_0U7YGTM>WP
M-JO;MQ]L:]?!F\./I_$%R8M>]OXL-E>M[W_S+ZW[_E[^O"?%W?Z3<_?E_GIW
MYCT7_P )TW[=C;_#]_OZZ]KX:O#J@LG(;DV@^9>6>S%'S>@T4#T _LX3XNY_
M23]_KR[^_?0=#T04=)TP?^1M?AU4^&OP[$6/(?DX0?4'EGLRQ_J^LUN#XD_U
MY^WUGM[=]+^9]'_\+TW>_P#@;7?&?J=\&?D>VO'P:/#G<G^(3DS=C=C_ !8[
M+NQRRN3]9;DY>:Y[Y=_7OPOQ=VJ^)N5[<Y5]UUI/S'HK9?FG36HW\#:NQLSQ
M]UU3X,_AP'IR#Y,>OX,=E?*/K_Z%]>P_'VX#>W3MN[A]DY'^.D_,.A_^#Z7^
MPVF\5GRYQ[]K??0?#/X<2 #R$Y,6'R0>6.RK ^G8?67M\W;\G!\7=_I=S/?S
MRS_?H_,>BJOS/IJ/_D;7X=8>L\(WA2U"H-7J'AHY!5M65B7VFKY0<OZBH*PL
M6A7JS;?>3&)BS1C*R,25 )/&)U'2]+U;&75=/L=3*!47?VMO>E&+Z1=R,F(^
MH4.K7H.NZWPN&YM^&=7U/A^WNR)[L.BW]WI8[DPHG..Q.!.08)2%# UHI_"+
MX4Z7J^R^&CD'3==VDFZ'*'8$75D<!7>3I[?7-V555F:Y(4 D@#C%EX/X3,(R
M\,Z"0=B72;"'V#MH?LU80^D?TAVYNYM^.^,0G)&4X>)=9&<D %E'>%0 +< 5
MVU;J_"!X3:Y(HZ[PR>'^KCAFBJ(4JN3W+Z=(IX'$D,T2R[?94EBD4/'(H#HX
M#*00#PT\%\'C?'PKPXO#71=.6>S6WI[]*/I*X?I!XVC=CXIUSW[]]_U]=7V\
M)/A6?$MX:^0K8BR%N46P6Q%P;+?0#87 -A87 /"_R-X1G_U7X?GO_P"#Z?/V
M_P WG38_2;Z1Q^KX_P",Q]?+XGUIGWQOZ3-X//"4U=%J;>&'P^MJ4%/+2PUY
MY.<O3614LSQ234\=2=O=9()7@@>2)7".\,3,I,:D+_)'A1!V_P"3>@^'*49L
M/S3I^#.!(C)C\.F42<R+5A.0?6;4^D_TD+KZ0>-EMM>*=<6TEM;^4%!<@IZN
ME4GA*\*\I!E\-G(:0@  R<H]@N0!Z %M -@/<.$_D;PCO_)?A]^_YGT_^GI?
M_2CZ2TQ_](?&^,L,?Y5ZZD[TGQZ<YSKW0>$[PMZ5U?K9X;^1&G==LY_8>4NP
MJ7K/W\TO0T%,V[GNUSW/&?L[<.FCPZ>$-B"VPV8FU%:"^,")= 75T!V#5'U:
M^(;AO=<O6[H,3=ZM>HW"+-FQ)[W.0,UG5UR5JUO)GPT^'0WOR%Y-&]KWY9;,
M-[>E_P#$ON]W$WQ)_KS]_K/?W[ZQ?S+HZK\TZ:NU? VOP:\_!F\.(].07)@?
M_P#,-E?B_P#[+^(?V#YN#XFY_23SW\\O\_F_?IOYAT/_ ,'TW]AM_AUEM"Y"
M\CMKZM0Z_MKDWRMV]KNF3&ITW6=$V!M72M5H*AD:,ST6H4.E05=+,8W>,R02
MHY1V4G%B".Y.5W.;?>Y+?VVY_;I\.DZ7;D2V^FV(2C?&4-G;BQOV2(GMCTQV
MUMGAFLC1P:-'!HUJ'7/#[R&W-J]?N#<?)7E/K^O:I4-5:GK6M<O-I:GJVHU3
MVRJ:[4:W2)ZNJG:PREGFDD-A=C;B4W]Z(1CO;I$J@W)@5VH&BO3VUA[GAW0;
MLY;F[T72[DYJSG/I]J4I+W92E%6_6UUC!X9/#>"".0')8$  $<K]DW %P /\
M2=@ 38#L+GY^#X^__3;O]I/\6F_R9X:=N@Z/_P#YMG\&O9\,_AR8 -R#Y,L
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M71>Q_P!O=^+AWZ+_ %H_PGIKW/L>_P#6C_?[?9I]<-T[1P:-,/8_\XWK\_\
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MB$NGGU4WIB/#AM$W;CPV9[\=J!U&YL;=1=O9W-XG/;@A44J.W&MN&+T9OQV
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MLO\ +1\,7PS?A<V]]&UO]U<'"7O#^TV_Q:.<?G^[+_+1\,7PS?A<V]]&UO\
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MY+?>Q3?HHOU.$_:_W?Y:7/RO['[^_P#V^6CX)?);[V*;]%%^IPNC/^>/^_\
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M\EOO8IOT47ZG"Z/]^I_"G2V@\+/)O3JF.JAVM1F2)@ZYQ1$74W'V'S]^W?\
M&.#2?[/]]G[M;YTO2=.T6CBH-,I(:.EA4+'#"@10 +"]@+FP]3P:6O\ N^_V
'ZR/!HU__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>g65062g69h00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g69h00.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1@B4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M      IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O
M;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I
M;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M     %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB
M;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!O
MX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M      !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M          !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O
M; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L
M=                %1O<"!5;G1&(U)L=                %-C;"!5;G1&
M(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P
M4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M#6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M        /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))
M30/S       )           ! #A"24TG$       "@ !          (X0DE-
M _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $
M,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M '   /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z   .$))300(       0     0   D
M  )      #A"24T$'@      !      X0DE-!!H      S4    &
M      ,C   '9          !                          $
M    !V0   ,C                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   ,C     %)G:'1L;VYG   '9     9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #(P    !2
M9VAT;&]N9P  !V0    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     4X0DE-! P     #9$    !    H    $0   '@  !_@
M#74 &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( $0
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MW8>FU[B<W+_G!J_:R?H[O_ UYU@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M6#*P-<G+9+KS5WLD94JXQ8U^M,).;D5W\[,,&9$8]@Y7ZK )4C].@X)"C)V
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MB NHYG&Y'+;; ._I.-NW;OQ@0N>[D#N0#N,_EYM^X5CJ&[4[C]#F4B]QNWM
MLY]J[JHZ<7"1%HO+"&INJ-\3>AH_9EUF(6N%:U"NVBR1K1,%9,H(,'KEX@5T
M\81$A*(XZQ1SV\HCD3L"1J)QL"1\/("LF!B 5W!16WVW(SI'><'V^RIXIVF7
M$II+7J+F+9<:^AKZ-VU(2T_.ZOV'&U>75T=<6E$V=$4VP+5SVNNL[6K))P[%
M2*JZTHY>*3,:BQ*X=K*MD&M=]R,9SD$#;G@]N-O/W9K'5/@$8.2.T9&1D$@[
M@$;[]F]4-G[3_BC1HJ"DKU*;0I#J7>6E*1KELTKM*"M5-BJ4ZKK.SVR[U]_5
MDI"NTV*<6RNIGM#A)2)=&D3$CW#L\=+ECVM=N8SG((P1CF2.[ECOSRQG#J7.
M<8..T,,'/8#VGS;5/^1N\7T9:ZQH&F:A:;\G=IZ>W=L*?H:]@BH!G+Z[HT%"
MP",*22G4PKIE]@WK8%.J22DP^:1C*"<V297.Y4CF<>_D3N%TABP8XSC;;&<[
M;DXWQMDG;%$3(+EM 5E /G)S[6 /=Q77# ]I=(:5U,2D:XXCZSC!T_)<BF4O
M4-7[:1;:69:LXLT[7-UVC/:HMS;5S!*SS",IM!"DMX,*W%1:E]@;8F^LXE:J
M+'AU@ QHW4L"%/DX3!.#IW]D0.7+S8JPPZCDNQU!2"1Y67) U#.PVSMG;W\X
M;F[3NX:,M]P;7#CLW>4A+4FP=N:W<US;4/-[#G:K3DJ@VJ]OV'2X^N.8[6%
MVS9[>C4J1-/[/,3R<M$R 258*;TJ#(7TG==M)88.^!C!(QL&SMDY^"L+"I \
MO!U!3L,;D@@'.Y&-_/63]$\];%L39=,U7LK5D50+-+;7W]QYM9J_<G-QAH;=
MVDJ=4=IL8R%E'E:K"\S4[SJN>G)]E+.XN)?P\W6E8%RP=@^0?$D&R<$8(+*2
M"2-0P>[<$'8[#.V^^(M$ I8$G96&1@Z6)7?N((]SSUV5Y*J:8I3%*8I3%*8I
M3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I5BD)U*/=>Q!:N'"GH$W
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MLT L[F(-U=6NQWDS..I^H3AV]PDKTU&QS=HJ85:1L2CM]#6$TK6G)H4,&-"
M-P%&!N,XSGF0=\Y\H8.>W&U9$[@DX!+'4<YQG&#R(VQWYQMC';>K/V4O%RUV
MJ(N;\VPF\_'VG8%CDWC.P0??LK/9&WY3>,[5)59[57SJ,KS6^S,JM$NJ>XJ]
MM;PDE(UYW:'L3(/VSK.A2>WF3S!YG..7(')&,'?GSH)W  \G   &.6!I';OM
MWYWWYU-+3V;_ !SNL C6;*G>)*&1)R8 C8+.FR5(MRJV/%[6V$\2>1\6T>-W
ML)<X6-?41RV71/ I-$TWP3)P%7!13GGCRL;_ $1R2?O#S^:@F<<L?.]F_D#
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M+3Y]5P!_67[0K[KFT?A#QZR]O]>N,_Q_QC\;3U_NG?UF\%G^JOH3_4M/GU7
M']9?M"ONN;1^$/'K+V_UZXS_ !_QC\;3U_NG?UF\%G^JOH3_ %+3Y]5P!_67
M[0K[KFT?A#QZR]O]>N,_Q_QC\;3U_NG?UF\%G^JOH3_4M/GU7 ']9?M"ONN;
M1^$/'K+V_P!>N,_Q_P 8_&T]?[IW]9O!9_JKZ$_U+3Y]5P!_67[0K[KFT?A#
MQZR]O]>N,_Q_QC\;3U_NG?UF\%G^JOH3_4M/GU7 ']9?M"ONN;1^$/'K+V_U
MZXS_ !_QC\;3U_NG?UF\%G^JOH3_ %+3Y]5P!_67[0K[KFT?A#QZR]O]>N,_
MQ_QC\;3U_NG?UF\%G^JOH3_4M/GU7 ']9?M"ONN;1^$/'K+V_P!>N,_Q_P 8
M_&T]?[IW]9O!9_JKZ$_U+3Y]5P!_67[0K[KFT?A#QZR]O]>N,_Q_QC\;3U_N
MG?UF\%G^JOH3_4M/GU7 ']9?M"ONN;1^$/'K+V_UZXS_ !_QC\;3U_NG?UF\
M%G^JOH3_ %+3Y]5P!_67[0K[KFT?A#QZR]O]>N,_Q_QC\;3U_NG?UF\%G^JO
MH3_4M/GU7 ']9?M"ONN;1^$/'K+V_P!>N,_Q_P 8_&T]?[IW]9O!9_JKZ$_U
M+3Y]5P!_67[0K[KFT?A#QZR]O]>N,_Q_QC\;3U_NG?UF\%G^JOH3_4M/GU7
M']9?M"ONN;1^$/'K+V_UZXS_ !_QC\;3U_NG?UF\%G^JOH3_ %+5Z@>V0X#3
MS\&"6GNT&;F]"HL*BG+>UG*!4^Z AW2;#ZB(B8.GD >(_!EL/@2MYGT#CG&
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MH_IPHR> >##M_P#99T&[.W])JK2=H'PC/Y4#G>'7RZ\K[Q[W7]<#,_F<,?\
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M(75RACE="K.)9"D,,32R $"29XHT:5P&;RI"QRS$Y))K#S2.-+$8R"<*JEB
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M'36IYV)BHL"N42**,_3]SNE%4W= #5MP6^+J$BD$;2/)(JS0@9*GD0P?=L'
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MCW]T?3G_ )RX/_W-!7W?PE_\$_Q/7_RUTZ_\?<5K>+/95\(IBE,4IBE0*?\
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MA0=G9*):_46,D<B((A<OPRUT:E@$0FDN8%9PY;6)R&;6< B,N2P -5+&CJP
M77U$9&2@ RZ D$G.O+9;MTDGSUG;LL-F\STMA;:U[S/J&YHJ6W+ L.5NLY+9
M+^&L,'4T[9+!#;"TW3Y"MV.TLJC3J0L[I3JBT*PK5FT,V<C9EW-1CBMUU5=;
MB\5B8HI;)[<B!S9RK"&5G"#,<\@94+R2>6))$U1DA<.<U&Y2-<:"I,;&)@O:
M5Y,3R8G#992RG PQR*Z-_FKCK^.!XF]//\1R]=.OEU]VK//0]#OF:\_R\?\
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M2F*4Q2F*5\-Y#\0_)BLCG[3? :[7^&FW]<:1VZG==H596SU\]1L,&T,UAD[
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MA"&8C;G@><G&#CN&<^C>O7.FFFD0B21")))D*FFFF4I$TTR !2$(0H 4A"%
M"E*4 *4H      9\^]_T[GVSVUJU%;1YLOB<?*AE%QR3TO\  E*P9V9?Z![1
M/[6W/_I*N>>1\'?]QO!?L+W_ +RO*^W_ !4G_#SX0/\ .>!?^%^!UOAGM:^
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MWBC U35!18J2$6T75(D<P=X"S4FJ< +W@)WC%#H'7IU$?'P\M94#BY& 2TC
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M4Y27JR2PR\E)V&$;,XE%-626]LVBQ6HMU/2A]$/"N( J#;-EPS+AHSE5#,S
MAR-("MEN65(SD$5\&\7FV&@^5RW7?&Y[?A[01S&*N4OVD/".O-*T_L/(*JU]
MC;HV3F8-Y/1EKA6RL+"SAJW+3<@O)U]JG!0L?-E&/=2\Z:-C4E.BAG0(""HX
M7AE\VL+;LQ0A6"LC'4RAU50&)9BIR%7)[.>U/%YM_(Y;<UYD9 Y[[=WHY@UN
MPV<MWC=!VT71<M7**;ALY;J$60706("B2R*R9C)JI*IF*=-1,QB'(8#%,)1
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MF<+NC*5(*J000RJ00)YFC6U6CO'']%1SY_QB:3_Z#JQGC>CW]T?3G_G+@_\
MW-!7W?PE_P#!/\3U_P#+73K_ ,?<5K>+/95\(IBE,4IBE0*?_-L_[6,OX5(Y
MD\E]'WS6W!\K^W;^2E6S,5;7T $?(!'P$?#W@\Q^(/7BE8_NEP=UI5F1FWCG
MA%?2 Z%9X!UDE2CT]C^Q&RZ:Z(@0 4!PKZ1(W? @%*8@@;HVEDLX8R,Z$>Q
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M3$II*39U& CZ^VD) Q1,4SUXC'D<.S%$2BNHH("(#G$FD,TLLI 4RR/(578
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MDD\COMO@G;EOMO4NH]7D*XC*,W*C=R15TW6;+-E>I52 DJ14134 BB?<-W/
MY>A@$3$,8"B.:E[<1W)C= 05#!@PQC?*[Y(.V2,>?T5&20.RG!&Q!!YC<;GS
M>V>7IJ:?Q> _&'F'V,T:CG/*F*5^3%*<ATSE*<BA#)G(<H&(<ARB0Y#E, E,
M4Y1$IBB @8HB @(#F02""#@@@@CF"-P?:I^7^_VJC:]/KJT:XC$HQHU2<>E,
M"Z:0*.D%E!$Q5TG"QCN %(_=[J0*@F*1?0=T$C& =A;RX$BR&1F*X&DG"D
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M;3(I8O&$D <:VDX+*LR@WB.8G-V*CT_H6\>&\&LHFU3  *1!%W.5"3DC(ID
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MJ'KZ>/\ 2_'X<?F=N*_LC=)!Z;]B/:Q9_#C[U5GXH3AP!/K&> S89_N+O_\
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MSQ\W-S./W+YQ4?S6/!^WXG_P)8/+^Q&[Y9QO^CY_(>>JHG)"J''I^+MVB8>
M>6^J!Y^L/&@?Z?\ LS!^)TXL ,^$?I(,]HOF][\Z''MYK'YK+@__ /C_ .!'
M_1&\_K^I-3M_<7H>V1%[O]&Y'<@[96G/LNK2G(';K+8K.K/>H* ]KU84;1E2
MCWR2A2K-GWM$H]8KD(NQ<-UB%.&U:_$ZQ0W4%Y?<?GX[=VY#6LO'KBZX@MLV
MWE06Y6.V1\[AS$S*PU*P(!KF<:^*YZ3WO![[@'1[H[T9\'/!^)QF#B]IX.>
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M(H8#+>>+SDJ+EH442S\I*=<Y(U*0,D>P\R9R<# &7TML#C&IML]62/TH=/\
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M*8I3%*8I3%*8I3%*8I3%*8I42M'FR^)Q\J&47')/2_P)2L^Y?7/IU#W\4IU
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M0I'7SY#'< _)MB1R',]E/%X!G,48QMN2#DXP,%L[Y&._-4;OMU.UOCQ;E?\
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M!U;I HJ'/UZB()ZT(4!$?4   >H SKP=%>C[1Q,W#T)8 D]?=;G /T_M)_\
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M8RQR-SY1(&2< ;;;5O;G/JFF*5X@/FK?]$#Q-_Q.7K_;5GGO^AWS->?Y>/\
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M:H(8*C889S@X(&Q.,'W?<\U3P@@)""!C& 2E$#&#H8P" "!C    "8.@CT
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MK7JK#LX*&;.'SHZCIXLA&L&R2KIRHHNX4(998YU#F,.C+(TTCRN07D=G8@
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MJ"K,P(Q@(QRN>6P[<G/:<G.<U8(KB=RD3,45.-^^"?1EZ]_4E]+TZ%Z#UZP
M=/'W\[)Z1='\#]'.#^RS^F5GRR3].[JX5Q:739TVUP<YQB&0_1?XOG'NUE")
MXM\F$^YZ3CUNXGTOT^K+P7R\_.##^?EDO5'T?R3\?.$8P-_CE9^?]N\]<&]X
M=?R-Y%E=MA@=K>4[9^PW]JLE1?&OD4GW?2:&W*3H4 'O:RNA>@^'@/6%\!^#
M-;U0<!U#]&^$=O\ ?*S[2W+Y-O[5<B;A7%&;*\.OB/)_6L_8=]M&>RM]^!>F
M-P5#DYK.=MFJ]BUF$8HW$KV8GZ78X>+9F<T&SLVP.G\A&MVJ N':Z#5 %52^
ME<+)(D[RBA"CY'IUQK@]WT6XG;VO%>'7,\C6FB&"]MII7TW]N[:8XY&=M* L
MV <*"QP 374Z-<-XA!QVQFGL;N&)%N0\LMO+&BZK.9%U,Z #+$*,G<D <Q7H
MHS\\5]9IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE
M,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4J!3_YMG_:QE_"
MI',GDOH^^:VX/E?V[?R4JV9BK:QEN::D:]JR\S$2<Z4BT@7)6JZ?>!5L=T=-
MF=TD8H@8BS1)P=RDH _E:B13CX%'.ST>MH;OC?#;>< PO<H75L:7" R"-@=B
MLC($([0Q';7*XW/+;<)OIH21*L#!&7FA<B,N",$% Q8$<B >RNE3/T/7Q2IW
MK.)@+!>JQ7;(UDW4;8IJ*@1&)DV\4\:+R\BU8I/@7=1<LDLFU!<ZAV?L=(7(
M@4H.D.G>'G\5FN+;A]W=6KQ++:P37&)HFE1UAB>0QZ4EA92Y4 /J.G<Z&Y5M
MV,4,]Y;P3B0QSS1PGJG6-U,LBH'RT<H(7))72"VWE#&^1H[3K"S]^9B9%Q 0
MCF2DDV48_*M/.T(BO24)$SSI[86T?$124B965,[B8M9HV4>D(1J*I%EV1WO*
MEXY+: 031)<W"Q1&26(K;H9KF*>>W1+9Y99FCQ#HFF5V6,G7C2KB/=BX8EP.
MMCD:&)G?0DA,SB*!X(IG>94BC#ZI@T<912_L0<LA>81W'!LK-K&<S;OW.IW1
M:O\ L99LE'3B\-[HY:N-I!LHJ9?TBAWL6J0[@(LD:L4BIFSHZZ*[-OHR=)W$
M"Z+=/&38>,APYD@6;Q6&Z:)@N-A',N%ZXRJ2 ZA2LC[2<#5IB3,WBXNS#I("
M3-#XQ+;B13Y7E:HF&>K$9P=+%E9%@]/H=1E-4O[M,ED5IH+!889D@A+R,<T
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M@M43QVV504A19(3"_7*NB9S,I?2[F5(NKTX7))KK=0O6!#%AE?)4H%.E48R
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M./EWO^\*[E]%ZW<:@U)1M:NY5&;<5"'&+5EF[4[)%\87CIUZ9-JHLX.@7HX
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M2#UZ$15Z'%01[PE " '>'.G8Q(Z'7&C99MW7?2 /8MGL9AV9YY/(5R[Z1DD
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M/F %*4?^*&2+9.0 HSD*N< [<LDG?',DGS["JUCPK*226&"QQDC?'(#ED@C
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MZ6G8:(KC(U),M%Z[FB:<8%V95#N'"]TD[-,2B4I$"W;MEMNPZ.&96Q=JH#@
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M(UE,L/2+,5UTR>SH>2CI9GWS![)C)!D_1[[5V@JHQ^7O9J1U#!*, 02I( U
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M=LV*HN5A'O7@D!NT7434SYC[WX:XI66BH&.=S$Y)QT+$QZ0N'\I+/6T=',D
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M:YE@@$5\TUMQP0S7'$K<0PR6]O(+.(:D6)I9)&9(+MG179(IX%!89M:ZXY-
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M+AI'M);)CAB ##-'$Y*C ZSJHUDQK5%!P,QYQZZ%,4IBE,4IBE,4IBE0*?\
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MMW64T]:HY"F738;G85:J+'8(F7.Q?P!M;O0:[*EV*D[!S0IS:8&+&1F0Y)
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ML:"V1/"MJK,R5.@&WNSF).R,*A:I2+;W60=K1;*HQ\''^V4@S=6=.RD@Y]"
M7@I+Y=X2HK24<"%[*(X1/?[$NHD8BV4*70$H "7+' (33J74&&KT!6-KOB@D
M8*NBUYY )U3#!(!QCGG(Y8R,Y'8!N_D?SEEMMWE?2=<VW%:1+"U-FRD(70[>
MSR-:K;#:6HJEM+8%4/*4FQNKGN*'5=;TB(O6P!9X>1IE1@=A0]+EV3Z,E;-\
M@@M;!8(Q.T+7&I\@W&D,YAG>*-M+II@8>+,TN4*N[QLX(8)]+1+<)A]Y<^3\
MD"KR<Z77&0#\C.L.NDZE.HD:<V\#-H<ZKYL38+#EK3YBJQ3+6>LI0L:[H<?5
MZO6=ER3,PS]>U_:6;<JM^BGT85.<LSA:9M1:M95#U]*0ARE"&)1Q&'A\<49L
MW5R991J#EF:($:7D4G$9#'0@TIJ0:L$G-5RK$ .K(/E$<\D@9W.Y [M@,@ X
MWS7:/G(JBM7;?%[3C?Q6EJRK>'<E;718#7C1">9/HZ'2:U)S9I.SMS2;PC>K
M#*RZDC2XDJXIH,Y./KRXH-FT@M(!Z>TEX5*>$+<BR2*T4S\1=H'CEF+W8MHK
M9Q'&6N^IA$5[-I)+Q27*Y9HUCKC7"7L8X@T'C+27!$5HHE5TC"P&9YU,C!;<
MR2%[9 =E=(3A5<O6$BUWEUZ)T#YQ<EFPP<8F=O'VVH(2:S CS7AF47'NC2R)
M&]V8^QM@J6B=6=),I2/>-&[>8DW L4F_;-ST1RG5K9J_C$I!DM+QHU<IQ$22
MR 0MJLGU<.6U@"%XI$9V@B7K"_+$/']+:S<$=4@Q'<6X<H'LRB(3(,72 7G7
MRDA)%8!9'.@+OO7B2R<##)SZB:TX2*CR3"R/<!%64*T1+(*(@0"D!([L%C)@
M0 *!1#N@ = SP=P83/,;<$0&60PALY$1<]6"3N2$T@YWSGGS/J8NL$4?6X,O
M5IUA'+K-(UX\VK.*O&4U93%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I0?$!#W\4K%<KI'5,Y"UNO2U(A7\+44W"%=
MCW"2ID8UJ\]%[.8E$%05<1TAZ!O[8QSM1=C(BW;B^;N!02[G4BXWQ6":YN(;
MZ>.>[*M<2*PU2.F=$FX(62/4W5R(%>/)ZME!(.B_#;&6*&&2UB>*W!$"$'$:
MMC6HP02CX'6(Q9'P-:L0,40:&U:A**S4;5F41)NIYE8'SN- $3/7+*5<SHLS
MD5*NDTBG\P[<24K&QJ;%M*/%E5GI5C++"I/X^\4:)89+IYHT@>WC67RNK1X5
MMPP(P6ECA18HI)"[1( L>D 8C\:[$.9$MTC=I5E=D&-3+*9BN#D*CRLTDBH%
M$C$E\DG-&''#1I8=& #6E:&(;RXSB3(S50Q"R QR$.(BH945CLAB&K:*&*.J
M:*]K&Z$?["]AHIH%GZHN-]<T_P <[H2M%U+.''ROK&FV&,!^N=I>M $O6LTF
MO6Q8X^-'#!&(O$H.K$G6A=)QK*+'GGDKU:K'U9/5]6H31I&*E\-J^@UR=LMG
MK]7BH>Q6TJX3TNS0$CI\+E=1VY'Q,9)N#M\J=^^*U31(_?C[->E7==%<U)N)
MW]Q!;6UQ=2S6]H0;>%VRB:5"+V9;0@$<9<L8XQH0JNU7Q65K#+-/# D<UQGK
M9%&&;+%CSR%U.2[!0 [G6P+;UBZH<4]+56J0E75J;2=4AF,0S/8)0RP3TB:'
MC9**16</F:K8[=)RTFIM-[&,/8L0[]NI;T[ _M@[]+U+SI5QJ[N[BZ%V\ GD
MF<6\6GJ(A-+'*RHCAM15X8"DLFJ9.HATR#JTQHVW N&V]O%!XNLIB2->ND)Z
MY^JC>,%G4KI#++*'C0+&W6RZD(=LR@O'G2Y06*.OH-1-PR;1ZR"Y73AJ=JTK
M04YN06KAPJV]*G6"DAQ<@D#I1JBW%18ZK9NJEJ>J#C.Q^.$X*NT@92BOJ>Y\
M<;RU4,5-T3-H)*!V;"@,P-XX3PT9_.<)#*J,I#%2JP>+ :2V,]0!%J #%57)
MRJD7-OI'5;5JLS1ID9Z%TR+'NS*G=N'#UL6Q)6T0?/'#E5V^7/8T4I=5V[76
M=JNDR"HN8A0)D&XWQ1G#F\E#*_6+I"(J/XL;3*(JA(P+9FA"HJJ$) 4'!%B\
M.L54H+9"I70V2S,PZ[QCRG9B['KODA9F+%N9(VJE::%U$QE&\TTI$6A(MI7V
M[25(H]]#[9EEUI]!RJR,Z%BN#&<<N)B+07;*-HF4<+OXQ%HZ645-)^/<7DB,
M+WTS1M%U!'D B(PK;LBN%#KK@58965@TT2K'*SHH407A?#UD$JVL8=9#*#E\
M%^L:8,R%M#:)6:6,,I$<C,\85B367LY%="F*4Q2F*4Q2F*4Q2H%/_FV?]K&7
M\*D<R>2^C[YK;@^5_;M_)2K9F*MIBE,4KZ!C%Z]T1#KY]!$.OQ]//[.,GOK!
M /,9]/Y;>?O[:^B8P^9C#X=/$P^7AX>?EX!X>7@'O!BF!OMSY_E^6*^"8P]>
MIA'KY]1$>OEY^_Y!^X'O8R>^F!W#;S5][QO^,;SZ^8^?7KU^/KX]?/KBLX'<
M.6/:[O17SO&#R,8/#IX&$ Z>/@( /00\1\_?'W\5C [ASS[=.\;S[QNOB/7J
M(#U-YCUZ]>H]/$?7BF >S\AR]KS<J 8P=>AA#KY]!$.OQ]!\?L^OQQDCD2*%
M0>8^&G>-X?1#X#W@\1\#>^'O#\/GBFD'L'Y?ERIWC>/T1O'J(_1#XB("41$.
MO01$HB B/CT$0\AQD]Y]W\N\^Z:%0>8_+\NROO>-X_1&'O!T'J81ZA[P^/B'
MP#X8R>\TTKW#8Y&PV/>.[VJ_/41Z=1$>@  =1$>@!Y!X^H.H] \@Q6< <ABF
M*4Q2HE:/-E\3CY4,HN.2>E_@2E9]R^N?7SNE$>HE 1]_H'7%*=TO_%#SZ^0>
M?O\ QXI7W%*8I73OVF/8\:V[3"\:QO%YW'>=9.]8U69JC!E4H*OR[>4;3,NC
M+JNGAYD0417052!),J B0R9A$WT0!G<X5QR7A4<L<<$<HE=7)=F4@JNG T^[
MO6S#<]2C*$#,S:M18\L8TZ0._?.?-BNO^E_,O.A:9(*R#?E)N!\94B9!27J%
M*2*'HS"8![R8B(]>\("'A[X#G?M.G=W:.76PMG)  #22@#&=]N?/\NRXW[F-
MX^K7#C!.3D#MQZ=L^C;%;2UGL'-0UGT?L??.RG/H^[T]+7JL3KW>G3Z0H]/+
MX?7G?3PM<10 #A%B<=IGN/1Z.5>9O^$0W^O7+)&'!'D!3C//<@Y]RNQ7BCPQ
MJW%!S;7%<N<_;#6YE$,G19ME'- :$AUGZR1T/8 !WS+"_.50%/ H)D[OB)L\
MKTHZ8772B.SCN+.WM19O-(AA>5BYF6,,&ZPD #JP1@=IJC@_ 8>#27,D4\LQ
MN5B5A(J*%ZLN01IW.K6<YY8&*W.  #R  ^+PSQ]=ZF*4Q2F*4Q2F*4Q2F*4Q
M2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q
M2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2H%/_FV?]K&7\*D<R>2^
MC[YK;@^5_;M_)2K9F*MIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE1*T
M>;+XG'RH91<<D]+_  )2L^^67USZT:8]I=P.DJ[=K8TY/ZR- :ZAVMBN+Y9_
M(M#0]?>6MA149X&3N-0?R,*%QE(VM.)6*:OF#.8?M&3MP@LX2*;?/"^(!HT\
M5EU2L50 *=3!#)IR"0&T*S $@D XS5W43;>0?*V&XYXSCGMMOOV9[JG\QS<X
MF5^YRVOIO?>O(RX0-DU=4)J%=RYDU(NR[K8+2FJHAZ[% 8]NZN\<@J]A14=@
MDHW*"BZB ')WH+P^]9!(MM*49974A>:P$"9@,Y(C) ; V.U1ZJ3&=!P=1'GT
M>RP.>V:SO3K]3M@-YYU3+ PL+>KVVR4.P*L#*F+%6^GR2L19H!UZ5-,2OX:3
M159O"D Z95B"!%#EZ&'6DCDB*B12I9%D7.-T<95AC.S#<5 J5QD8R P\X/(U
M+\A6*\<_S3%R#WWIK?W%:+U!N_;^J8R=U?;7TW&ZVV7=*,PF'J%T8MD'<HSK
M$U%MI!TBV$6Z2[M-55-$QDB'*0PE'W/1*UMKB"Z,]O!,5GC"F:*.0@%,D#6K
M8!/,#GVUT^'JKY#*K>6!N =L9QN.1[>^M*^/G*KE#*I1_MIR0WW)=\A!/[/W
M!L)YWA%-,1$WLBQ*=X1$1'J/7Q'/O%EP'@;6JLW!N%,W5G=N'VC';.,DPD_A
M[:\)TON+BW><6\\L &"!#(\6/+4;:"N-B1MV5[%M7<DJ+1-9\2:ILV?MBMUW
M92*/&5^:6JMXM$9)6:1B(INV2MM[80TI 5V4L<L[39Q)[;-QKF>D5%BLA=&0
M='2_-_2"R(X[Q];:***"UXE>@11F*)8XDN) %BA!7R(U&ZQH0B@;#8'L\%ZV
M?A'#YG=I':PM7D=WU2.S0(S.Q8EG8G+,=SOD\ZHIKM&N(]?MLE2)?8THTL<3
MLLFJGK0VO=BG03L(6*QTUU,%D$JJ=@K08NYT^TT^9V,DY/1XBS0$G#R$\W=-
M^Z;FCAEX4$@B!4Q=:")(]UT+)IQKR)"CHZQ8ULK@A3O74$$A ( P5U>R'+ (
M[>9!!"\R-\5G#0')#4/)ZGO[WIBR.K-6HR;+ .WCZNV2KN2/'%?@+=%N$XRT
MQ,-)+Q-@J%KJ]MK<R@T4BYZMV")EXQVY:.R'RBYM9K201SIH<KJ U*VP9D()
M0L RNCHZYRKJRL 0147C:,Z7&"1G&0>TCL)P0001WBLX*J)HIJ+*G*FDD0RB
MBAS 0A"$ 3&.<QA I2E* B8QA "@ B(@ 90 6( !))   R22<  =I/8*ARYU
MB)7>^L$8&J6<UA.>#NLPYA*Z_1BIAPD[<LY1:&<NERH,%%(^(0D$006F9$C6
M,2!PT44=%2<HG-UAP+BC3W=L+8">RA6>XC::!2B/$LRJNJ0"29HVU+!&6E;2
MX"$JP'//%+$16\YF/57,ACA<1RD,5<QLS (2D8<8,D@5!E26P15OKG(O4MKD
MX*(@K$Z=O[&Z.TC$E*]9&9!4&/:RK%5ZN\B$$(QK.1CYF^KCR14:MK"W=(&A
MU7AE +EEST=XO:17$T]LB1VRAI2+BV<XZQH9!&J2LTKP2H\=RD0=K=E83!,5
M&'BW#[AXHXIRSS$K&##.H)"*ZEF:,*BRHZ-"SE5F5E,9;-9PSB5TJ8I3%*8I
M3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I
M3%*8I6@?:6[=Y6Z0XKV&_<,-<J[4WHSME,CXBH(T6<V*=S R<N5M8WH5BNO6
M$FX!C'B9<72;DJ3/IZ98IRATSI<*ALY[Q8[^40VY1RSF18L,!E1K8$#)VP!D
MBKH%C>33*VE<'?(&_9N=JQ3I/=_()UK;A1OKE51]A4JT3NL=SQ&]JE3=7;*<
MIUG8,Y,T]>B)V'5U;8VJTQ22\/4YU**D92.=MHY_))LO9S1:Q,T7>[);6K'B
M=I9/ Y6>TDM7EG@0O BRB;J[B5HXSY4L99 P+*,X;JR1>8XFZ^.'3D-!U9=T
MW"JPE*NVD>4Q#:1N!L-6G-8+JD=NVMO./3VUH;\G-@(TGC8V=T.4C-[L7[9R
M:P^S+E+0.U:A+6#4319)E*NFFZJ1O"I-9B2802[-];(V%?5EVPZ4C6<@O1$;
M)+<S<1*S*UD5*A-,*O:S+'=$:D#6DUG*R*SAEB:190VRW5,)@@A"!IB&!AQC
M3A0R,%D.XS&\3'!((74#GO&SQU<FM!^?VW.5>H:/K*5XGZZ4V/:)W9S>"NL<
MG1YR]>U5(4JUF?K2YF4&^8+QH$G6,(S]LG*BC8OLOV**?I7*9R^HZ)V'!.(<
M1DAX]=BSLQ;NZR&XCMLS"2-57K)%8'*LYT@9.G.=JKN#(MI<R0@-/'&&A0C5
MK?4 0$!!;8DX!SM559'EYL3C3LY>65AB7<KI%C(VV/95'<TC$1M_?KU]W+1J
MT3K"2:/(F4:'4D4$4)U=PH@U26;I]Y4ASYT[5+*W7C$%@\$JQ<:>.UD:[X-%
M-)8(LZQ2"7BD;I+$^(V)@5<L0QV(%><N3<ROP^2Y6:,OPX-.D=OQ*2-;MC T
MB%+&1621<N%$K,0H8#)!(FKV_P"U)F6B:I64[#"N L5WC9^<=Z[ECL8N&1V9
M'1])<M7LS&(Q+U=UKU5R^%=-R\3 3I2,F0QTSMS:"</X5##-=W+6\R^+V$MO
M G$81)+*W#99+]6CAD,R*O$ L>"B'8QQ'!#5M/=7TDB01++&W772RS-:2:8X
MQ>HEJRM*BQ.6M"6R"PR=;@XQ6/S;BVX@\I;&<E;)!(V1-@%G=(ZDE',G7+H:
MF[$G9RC5N-&(=JV*(B)*O5Q,LLW93*GL-PZ44GW"<LR<1?0'!^$LEZ\$=M.U
ML7\50\7B6*XLO'.'007]S+UJ"VEECN+DF)WA&M%46ZF&19M/XXWZM;)*TT(G
M*"=OC?(SPW!M;V::U@01MUT43P0CK567R&.9FZQ6CR/IS8&\;+>31NQJZC7V
M?M1*N)6')%3:+:&<M@@2PBD=,*UPD0\&2!U)JNTO=I/*.!,4C1E%*0<JBMS^
M,V' [:Q$G#;HW#B6)8INM@+3JYGZX2PBYZY>JT1A&\1MPN,O),)X67<X==<3
MFN"E["(1U<ADC$<H6)E,/5&.4PB-NL#.7'C,Q.0%2,Q2!MLL\G7=IBE,4IBE
M,4IBE6=_"-9!P#I55RDJ")$!%!0I"F33.HH0#%.FH B4ZJ@@(=!$#=!Z] Z8
MQYR/R\^:FLC(,#&,YY?EW51^YAE^FI#_ #Z7WOC![S[WX*EUS^;W*>YAE^FI
M#_/I?>^,'O/O?@IUS^;W*>YAE^FI#_/I?>^,'O/O?@IUS^;W*>YAE^FI#_/I
M?>^,'O/O?@IUS^;W*>YAE^FI#_/I?>^,'O/O?@IUS^;W*>YAE^FI#_/I?>^,
M'O/O?@IUS^;W*>YAE^FI#_/I?>^,'O/O?@IUS^;W*>YAE^FI#_/I?>^,'O/O
M?@IUS^;W*>YAE^FI#_/I?>^,'O/O?@IUS^;W*>YAE^FI#_/I?>^,'O/O?@IU
MS^;W*>YAE^FI#_/I?>^,'O/O?@IUS^;W*>YAE^FI#_/I?>^,'O/O?@IUS^;W
M*>YAE^FI#_/I?>^,'O/O?@IUS^;W*>YAE^FI#_/I?>^,'O/O?@IUS^;W*>YA
ME^FI#_/I?>^,'O/O?@IUS^;W*>YAE^FI#_/I?>^,'O/O?@IUS^;W*I7-+B'?
M<]DG>K>C[W<[SGN]WO=.]T]$1/KU[I?INO3IX=.H]14'GD]V>SW,4ZY_-[GY
M=]2T?(?B')#8CTBJJ\_L-V)K)#B$75MHNJEVWX_B8&BO9VU7V]3.HJIJTW*F
MF[]O5/UI5UXU+W*(W"(IL8A)+(0)73ZS-TS*/6D<X<KF]$W'2;TS*G5VX+R!
M5CC$[S>*/;Q/*X/E=67(7RO)C/(M6X;D"3* Z -7L0KF0QXR<,V0KDA6SDH
MVE6.D82H_81;)4AHVM[MVA0=FQ]KL?'=UNV4!W:V4];X#2-@Y P(%BGH5Y-5
MM.I:8O>I:Y77ZB[51G8JA+NS.&R2$:]>[#]((0S/!%)$56Z$"@(5C,Z6S#/E
M[J9XYV91D%77F2P$S=)@%0P8&7"E5T@.L6DY#9.9!)J72,+I.IRS!>Y+@#QN
MVEQ:TA-ZYW'L>/VW>Y7;^U-@2.Q&2#IJZM32[6AQ*QLQ8&KEHT!M:W[(4GEF
M0:>RV"<RN[!F_?(=UPIP^(W,-W.LL$9AC$$48C)R$,:X95/,H#LA(!TXR 0:
MU9I%D8%5T@(%T]V,[#<Y&^V=_-6[V:%55XB?FJO]$;Q"_P 4MS_VZ89] Z&_
M,]W_ )Q%_(KJ\-YM]F/@K0[C9_68W]@3_P"$GGZ&L/F1?\FU?/.FOLY_:'MZ
MTV]X^Y7M5HO&&L;NT]Q&V))778M5N&I],,"ZZ7J]@2;0,!8+=1&T&\N"U<=L
M';-]9V46X<1D=-%4:RC"'?3,,Q?-8^P3B,A^8>D-V]OTAZ11K'$Z3<7O.LUJ
M2S*EU(P0,""$)P67=2P5B"57'>X#(4X+PQ<*5:PL]0(W.($VSS [QW@$@X%)
M'LO^+<U9G-OG&FPY>P/KZ2^/WKN_S %?"M;[;L2:IKANW!! :'9MAWRX7:?K
MZ::9G,U/.D&KYG"H,(EIR1Q:[5 BF,*(S& (QMY"1B0?MBQ1QQJQSA4&0223
MUNOD  !4 # PH[@H/I   SV5L9QLXP:JXI4B1H&I&L^W@).993+D;)8']ED0
M&&IU3UW6XQ%_(&,LE$5:@T2GU""9AU,C$0#11XL]DUG\@[UKJ[FO)!).5+*I
M4:%"#=WD<D#FSR2.[$_/,<87 $))&D(+8R,\ACF22<<LDDDXQDFLYS4/&V&(
ME(&9:E?1$U'O(J49'.JF1W'OT%&KQL<Z)TE2D7;JJ)'%-0A^Z8>Z8!\<JAFD
MMYHIX6*2PR)+$X )22-@R, P()5@",@C(Y53+&DT<D4BAXY4:-U.0&1P5920
M0<$$C8@UA#\;9KTS>*C%%+":!@I=2:AX49^14;MG3V<DK#--W"ZZRSQXPG9%
M\V&2:+.!*="(C44SI@#PSOMCI)Q &60"W$\\(@FF%O&&9$@BMH&55"HDD$4;
M")@NS2R,024T<T\'M"(T/7&.&0R1QF9V +RO-*I9BS,DTCJ9%+8(BC QABRK
M\9=75"6@)J&:S97M==(N6@NIQZ[1=!'13.#K[:225,)7K6KQ4<Q:5](_=%I[
M&(NN=TZ,JNHNNDO%+R*XAF>#1<JROH@1"G63//<-$1[!KJ621[@[ZM150B!5
M"#@UC;O"\:RZH""NJ5F#!8TBA5P=F6".-%A!W72&8LV6.P6<"NK3%*8I3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I7SH'O!^YBE.@>\'[F*5]Q2@@ ^8 /QXI3H'O!BE?.@>\'[@8I5*NP8
MN5V;ERS:N',<LJXCW"S=)59BNLV69K+LU3D,=LLJS<.&JJB)B'4;+K(',*2I
MR&D'=0ZJ[!9%"NH8@.JLKA7 .&4.JN <@,JL!D U$JK%254E"2A(!*DJ5)4G
M=259E)&"5)'(FJKH'O!^YD:E7W%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I
M3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*\D'S1K_9VXQ?XMK5_M@QSV
MO1?Y3-_EX_@KIV')OLU^"M2]!?2,?B+_ !9]KMOE2_8K]^O%]+.;>AOAKV8\
M>O[!6H/\7-0_^2,\_.W'_P!/.+_\XWG^W>NEPK]+;#_-+?\ V2UF+.16_3%*
M8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*
M8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*
D8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>g65062g74i25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g74i25.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1D\4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M #^    X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         ".$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
M-@  !-@          0                         !              38
M   "-@                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "-@    !29VAT;&]N9P  !-@    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   C8     4F=H=&QO
M;F<   38     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    $.$))300,      ZF     0   *    !)   !X   B.    Z* !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !) * # 2(
M A$! Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+
M 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,
M,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C
M<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E
M]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "
M$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#
M!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&
MEJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#TIV3TW/.1TYN15=8&
M.9D4,>USVM=^C?ZE;3O9]+\Y85OU!Z?:'@Y>1#VEL?HS'LKJUW5'?_->_P#T
MK/0IL_18F-Z1?JRWTNI]5P6C]7P;6C&!+K"T6#==^L6>J_?<]GJ9#/7_ )W^
M<KJ0LWK7UOJR,MF-TIME53[!CV07;V-%?I60+6;W>YWL;_/[_P#!68UZ2G7P
MZS3U?+I;98ZO[/CV;;+'V .<_*8]S/5<_P!/>VJO^;6BLS"?>_K68;JA41C8
MVT!V^1OS-?HMV^Y::2E))))*4DDDDI22222E(..;2U_JF3O<&ZS[08;^;6@.
MS['M%5# <IY<&L.[:UK7%GKW;FUN]/V_]=^@S]]C=(PZL2FYM9L<;+[+;'6\
ME[C[W,]K=M?[J;Q612_AJ)O>Q3=)@$^"KXV<S(MOJ;5;6:'["ZQA:UVF_=4X
M_38K!, F)CL$#'R;[;;668SZ6UNVL>XM(>-K7[QM=N;]+8B;L:_@M!B 019.
MQ_=<FWZUU4Y3L-^)<Z]MGI!K((+P_8YF^STF?T>W%RF>[^;RJ_4])-7]<NG/
MLI:*K2V]VQK@ 2"7,97NJGU:VN:_?^E97O\ ^TWVE)WUI](Y)NQ7EN/;=7^B
M(<6BI_HUNOW;'5_:W[/0]O\ X%^D47_6^H$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M%A@A%R(Q6)C6.4%1>+8C)'$E4@H9)C(X1&&W\?_$ !P! 0 !!0$!
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M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+QG&,_P >$3QC'_\ N?\
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M;=M_GIOJ\J5U.$3A%%'>G=#0.AZ+/729O-?MI<(6Q&(IE(L=;G+?(2Q!61,
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M%N3*GW]_1%S]=>GUNK6U6ZSHI.DB:G9CNNW0!/8J5"D:[]UG]XZD[Z==-K[
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MA'#$,('='9<\+;*;(:7[,1]_'MD ",[=NO&) ;A6*N+&<4L<T1&\U>8MQR1
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MHF'<#@ B#-MLI(MQ;&H%7VOKV]ZMO )$G2]E4VT4"WQHDE)0Q4A5[C"'5VP
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M"W"RQA6T)RI:R'VF4(3C]<J6IQ:4I3C'ZYSG.,8_SSRL1(GT(D3_ *"SN_\
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>PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>g65062g75k22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g75k22.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[14F4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M #^    X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         ".$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             !
M[@  !J@          0                         !              :H
M   ![@                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   ![@    !29VAT;&]N9P  !J@    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   >X     4F=H=&QO
M;F<   :H     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    $.$))300,      J0     0   *     N   !X   5D    IT !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  N * # 2(
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M!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M'6_M#V3$NZO[XR^ONN+>[F;"\X)4F;WJ#>C/Y6IV0NJMQTCD5?P(OJ$(HN;
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M<O?6ZNG:M84D.M^DYO#XM0T7+@.VO:,;8ZT/[93]([+8T2@+"Y:H<NZHJ>7
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M-2V-LH4@,ULU69IBS\DAQ*,#)V[C3:&)R7;48_+-4VS]XU P12O?3L3+NO\
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M%>OY/H2:(0R:".U'>DG,*XD$*%R=,_#:&,]D2?<6[I%;NA;&P%F_B@UN[K\
M\"/$QY<W*(<QQKJ4)8TY/MAG?GSQY WNX]L8Y0. . . . . . . . . . .
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MK2P:U6&"97^=<QBJQ^@-[L-(/)G'OI%%W"9-34#>_P  < < < < < < < <
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MFX8D%TT<-!9/?=8R11*I[.VKP8UPT60V=ING2*/+:6W8:?#,43FCF]-7X??
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M1=Z:#WZN,[_2H.MW?R7&$,H* ?C]/]*.RM\S#J]K5OPICG13NA7UO0&279W
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MU]?T'[?TZ*>5/2WWQ[KZ+;K./1]OZ9)'Y7GT)_,USG; %4X X X X X X X
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MJX=B(ZW4))1/J\"CU<+C7&C)-!N:=L-Y2\7:NFI-RHP8"-$@)H\ < < < <
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MF:&!B+9!BII]0WT9HIH-\ZNMLN<JIII:Z:8^?NKLMOMC7&=]U-M]O.VV<YY
MHD/8RH<!;-9H='R.0:+OMG188)_!&:Z"KU=1BEH/PY=82W;,MD&ZF^%<_-42
MV4SC.VV=MJXFBA93(*FTU\$RVWIQCU?0?M82:Z9W\-]\>ZJ6^SE;&OVQ]7II
M\OWU0]2><YY 53@#@#@#@#@#@#@#@#@&G[M>&J^$]A+-L[LEU0!]LX ;J"$I
M04N5==;3R-) P#\Z+FX(Y%NQMEUZ,@T8E\C+AS*]G@=G8XN_>HQV7OAN8U&]
M'@%>D5<'!?PU(# YMU9"]Z"61P1R-HIK8D4, 1H$Q)29Z"-V%M2Y9=F384M#
MB *-LI^#W?&BR,?2+QW+G#W1;+6M? ,-?"88?ALZM]+4*G"&;J.#' BL6+*B
MY0-@+),SJDL+3NV.WC;]]V2X45V1PIO8+2)QAKJWQN,$MB&WR]@(;2Z*-0_:
MP21&]+F71E%:TD#1%08\ZO6R2ND6O+-T-Y(I4]E7E!*VK#26+HKO%Y5$X!/)
MUXSLHU>)G$L(( 3W^*S&AYAS B3GHV+O5P) $,:=GR-B0ZN<T/J]+)M&X1%R
M^G%<RJ5_C#Q9(AM#U9K&8<5SMJ@2)[NEL-5&M?H%N0J3RNO_ (=41+Q_N="^
MJ<C#VB^;N;=LFF^L#$1--\ZG-]JO%P*KYY9< T*G\9;+!#(8[-[1>9C*C@J&
M,+NB#928]M>/OY$F?A\V[=-LCK->VN8MN1L!*D:0B4TG@&N8W").@Y1,*/C%
M=AV5%=;KD;M\[)M<&/Y4ZH'"5/ [>$'#[38J^VH(=4YV*[%.NPT)KP=W+/=X
M(6ZLL*+E$TZZUI2,0@D4!;F4='S.Q2I>C"E=OQ ]OKNRE.*P[4JVVJW46WB-
M<;E-4M4@,\?$?KJQ3\TII[';F[#JC;&*J55&^M%4/Z^B<&F$J'1B>V2<EL^E
MLIL.HU"#/:(1=Z.VB1F:E@I7<<Q;LX>04=E72($ONN$/:UMU0CT0FL9 TP.!
MQV8M3H/495L#!1(6\-R!=9\NUJ&0D:W$)K,G>##U^#D6^RZ[I8F8>('%R.$@
M,+=#JOA->BF8>N.RO7?L!$X# !-<([TY5U31B1C<"OPEL,=2N75I,3^'BBK(
M(JD[%NA8](@0WU)[;:KLOEJ 4&Y:VK"0=JS,A#]J>M<)M&9P^NX*3J"S:^J2
MTYTNM"R<L(AG,=;2B= YD&W+(S7=#<&/';CE5F[<H@VW(/72ZX%?[XV_,Z>(
MUD7)V7/Z=H!\QEB$YL"H/Y ][$0L))Y&5(*!>Z=@4RPA*$% >TU<$7$-BIZ2
M_C@\-J^=! GU&Y$#*?2";V98=3&Y1/)$;F<9>3TLE2\VF/\ )7I8<PJE )'-
M&IR?HTJZ7K9 YO-OSLR&Z@FP9VI$F4;7D0(7)%2R' )D< < < < < < < <
M< < ^#K195LX2;K?3KJ(+)H./1A3Y"VZ>VJ2WR\^V_RM\Z[^C/MMZ?&?;/ /
MSW5Q743$?S8*13ZM1.L^Y 2UH*5D/=%S->MN%K,-53.!C[L=8T0L(39[OL/<
MABX@HF9Q>1U\6@FA%HXFSX'9+,"*C[A9,-8ZUT,C?%8BS(M/8P7_ )CHF=D6
MD(%,&_=<A/8#$%:X5=R$_LRKE*.E+*J8U9>K-;5<_B(2N= H*JI(-=T=23U0
MD@D!GB.A=#'PNA0 GUYQWA46 HCW=&E(]UVJW2TB*%M?*W?K!JYD\THR))QE
M^E^>4WL=DQ\LWTCNA;YKFP-U6W (J?#1$:C+)O9'^2]"*B75/R34=UL8I=?K
M#&A4FAT,@3B2EZ*WG9E[39V>47;A-@4RC4$JQHDEE1V.9DT!B2H&&.K\63CG
M="K\,.JK+HH-;2C5-_00=]UPNCZYP39O' QV]+RZ\&AZDD$\.FY/(GK]2RA%
M7?&-6QAZT<K+J 2(O;L/V(A78*Q8I6/<XUV&;:S)\BGUZZX5M2;:T:-:*D%-
M-X5*YC+:*MVJG)./I;ZH9<W7;M /E$6VVCI1^4523=@9F[UW1;M66?$,5SW7
M"0EX4A S?/4 -7$1E-URU_L]):9GH0\$I7LM,1HPEMZ!&Z3RG_R-H\#.5\3(
M.A@@LW ^W8;6WIYT6K6U)%=?:VC#8#8:_GL4B^*-%7+9A2:3$?!HE"I=*Z\,
M0&"PUBF;."U%34,F=>M6 -?ZZ:NAKH>7:M@,R]'ZO)TU3EI,[(A"50Z$Y$_/
MG#<F2I865/-E8VR;$IG-)?55ASO\S$--$-T7LIL"69E.4&FB:J_X<W:K\:_%
M!CRUK\8TOH35$&K88-C]9]F>O%_Q*N*_&5PEK4E850!EHU,9^%-!+R7S:NIG
M(5WJZC0(LD09OQK/)DEM^*NE]GC/;YH%'JZL:Q9=GI\2KOM7UJEIJ3W"<MB2
MU"A7E1RVY []XW8HG R,Z93M6?C\-,A]E$"!$"Y<@4_FL&:+42R9#V8$<[W[
M*W'#K<L^!%KSNZ$7QO+9(VZ\4S7B/25>F)E&MEE]JB6/*6DZ6L]7:3,%Q&UF
M_F28U^5:&%#C6&,F@1*.%B0&[H/L5W$"MSJ;)(WN-8[&$AVZJ@](KLV2R038
M*+XPLHRT=Y6U:[K8PKNAC393&-\YQP"H\ < < < < < _-Y-Z2?!/B]Q)&GH
M11:0419$,GLU!C"U??RNM64H%"9E*;2/-)O:S6?:,7Q1[8*.5X+6YH:DN*AH
M@?X=R21%H@!^D/@%,W"!E"Z4@W$#-SR#%08@;W8-=BZ(U57"ZH](EE++Q-BH
MOC"RC31;"&ZN,*;)YWQC;@$'J^(V4)IKMN2IT0./V>R[!]@EX4'*[)ZL7YO2
M1(_(25PLY9(**8T^:HV07=MD'#K1%!==-)3??'Y/KNU]4V/H_J.U]$V&SWGU
M;9[KM+6X[#:M*QM-NE_%/BM6+-II2[%FU;LV;=M6;-II-GUOT-NOTKOOUC].
M;K];[]O7IOTEM_4]UV?KV_;G9M6MXW?T^T__ %+=C@V6WVEFR[7!9VNTV>QV
MNTV6QM;3:[/9V[=BS9>9^J9^_)+2T>+]E(ZPC%I+NRVC\<Q1:M%-Q*3W?0.]
M)#V+IXS'$G3;&=EV;=;771/5%51NU755;)?F_1^\_46]^A;MMOJG==GNGJ]J
MWMEM-E8LV-G:>Q5MK8[3:[+9V[=C9;6W9_Y6++225ENS8M.U97T?^L/IW^G/
MI7UWZGN7^E?JF\^K_2&SV.Y6MVWK>+>VVUFSOEO=[+W[8;KO.\;'8;?>MUV6
MVIL]OM;#;M/:6+.TVVSL6-K;D;SZ@_EXX X X!2Q^/#HW^SC7U$TL^<:--/7
M_4XG'JVV;;;+*YQXQI\Q_C1WC&N$]-?HDV>VP%2WTT4TV34UUWTWUVTWTWUQ
MMIOIMC.NVNVNV,XVUVQG.-M<XSC.,YQG'C/ /GELVV;_ $FS=#9I\K"'TV4D
M\M_D8U]&$?DYU^7\K&F,:83]/HQKCT^GQ[< PY,H7)]6D9AM6H1R"Q)Z8>OY
MD5'#1NCH8V272+8;B8ZHS_"B.9.^^I8&%E\:;MD7&76NJ^WJ3VLIR[4MQ2M^
M%];E<#,#5ZS?:;J,7;9XDDNLU54:KI.-$W+93*3AOONCOOKHNW5UV261VSA1
M)37.F^NNV,XY >G@%+:8\$RV?3KCS]!^UA-IKG;PWV_OE$=LNE/'VQ]9KKZ,
M?LM_4GYSQK6L053@#@#@#@#@#@#@#@#@&@3NS**JA_>M@'E\L2+$Y4,J&U=J
MDWZQWM9$PL0_2K&?*5-78FR*_BLMCZM.9M G%K0F,:'1N1R4!+HKE[H/5WDC
M;=@!L@ZOTVW3Z-Q>F2) HV3EM=SX.97<U[+JJ6!.++*2L@:&!*VF>@>90R.1
MAU)G8B%QXUH.)L(L,"(YV;XPGOK'VY3R_ +DZR];Y70*/X<;GU=3(6UB@>+B
M](AU\AE-ET] ^&R23PL4B1I\B6T5;ML:[CM!@YDDYV^I0T2QKJCB@P)/*@@F
MG9A]9(SL]UWBI[L"4A"X.N[#K*JY_,)8_K@,PAR[>MI+(YR+E;K"R0C5%45'
M&#P:#,X=/VHW0R],NR9 SEW%K&'VS"8NUD=MP"I%Z?G0.]/S!8@&)3**L&,>
M$RB*[NY9%)D=!Q]:.JZ2IXEJ8,K9;"2J#,@-4:'F0PD/ Q3/J>%V#T6GHV/!
MNMO;^2-X?/[%HE1&D:J+U">LEM&9 W@9&.P98E+("\,:/G;H,@>U,:)OLDGC
M5Z[:LG+[3<"A?#QHZ.5#_*@J%I^W*L5DK2&8(I6I0G2RE-2VS#\Q[:H"-NHL
M;!8D>P[9^MJ1TFRQ%N,PZ:YC:FGUYC=8",P[J/&(WW4?F&O4<I!(="[QJ\C3
M$DH;J3T#:5%B'L@%=FW$EE\^EL17["A#HRQ-YJG*3D)=!2@8*/%NX'MH7;:O
M-@)H=II1";&F:77DGTMCG<\E$8]&;</1ZPOY"M(1"6DJ(32)1,NR1NH@IN1E
M)+,7F371>-QUTB*&)KHECH_<LU9/ ,4V41HN7?#UW;5_4KBF(:QM")PZ)4C!
MX52J#(!>\-[3!HN+@#J)X/-: -Q4O?P5,;+7+B5M83(@!$L9Q)&+IXD1;@6S
MU%:7!KVQ;O>U4/#P>[%.O5BM*R:5U J@B,$/U<A8=/*3]Q)'T'N"WYJ2E@&2
MJUXG'VDB> (HR&'I(K&&I$DZ/[L (;VV*GBL.[+IBH8L^Z O+0[#DKFLEQ5W
M7 C?(_*5I3)2\#<*/G[S$FG2</F:$H:P<W*ZC?VLQ#@Q:D>''B[*,NGX$].\
MC:<+W90[CKV!2F79,?6MMK1Z.3&(UO,*T;U2X/U<VF\@+I619=4DA4K2D.84
M,"/()*'!IT/(&FLD#. _R'C&:IYKVCKT!DCX>+1)E![P2-CR8.WE.P)QU?L:
M5 0",1:/6J[K:KW&S2OPM8RB;0]O$B,$4@\@^>E+C\B?2$R?>S)XC*URS!G0
M;!. . . . . . . . . . >5]IJHR>:;*+(Z[M5]=E6^-LN$M=DML;*H8TQM
MO\Y/&<[I>G7;;YF-?3KMGQC('Y:.K3.IK&?U[7$.ECBP)'!YUU/J!6:0_I'V
MBC#ZK*EZNV>\M8>Y5=EH65%0&Z+OM4HY+WC.Y,?B\9&BRCPVLB:<#FZRL[:_
M&%WL#?SV@ZV.>PZ=1NQ<Q!0T_4%C.["".I16H.V8\26(5_-J\>C"<0D9,8,W
MQL.FSIZT*Z*X)#7C)#+%5'5=S\R@R3#8=M ZG802:RB+.UMT7L<=R !%!E5
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MO5":Q)XUK6-X+BA["T++^&PL.CM+@6BLIFTH2%4:&C/7J1L&'69SV=*[MH?
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MK48\D/+5WS0F%VOIWJ!VZ%Q%2Q7X52;5L[>DJVF)2%*2]("[()H)D1IV)2D
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M]EMS"=%62I']&JAS0#KN)3>^O#/<AJ18Y:Z.<I[:J80V6QKA3T;8V]&<^,\
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M'SCP\74.$OQ0ZKJJ6>M,D5,;,1SAYN/$M4&@X4U9#F3-HA9;Q(DE<C)_(4<
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M\TLEX\?G=EX\^?& CC'VSC/G_&?W]OW>/]^=0N4]+[[UC?7,DW<KJW73'CG
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K(=%24RL@XM(I#([\>%)6=-R_=N_#+D!S1NP1$BV3\#<SP!P!P!P!P#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>g65062g75q31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g75q31.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1K:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &KZ^:$8X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!PQ5PP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              \L   :<          $
M                 0             &G    \L
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   \L     4F=H=&QO;F<   :<
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   /+     %)G:'1L;VYG   &G     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      06
M  $   "@    7    >   *R    0/  8  '_V/_M  Q!9&]B95]#30 "_^X
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M^R&L!X$)$$T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M$HEE#S<A;3K3#_NZT/NL-(6@<9G!V1V&XS_HE>XRWP&L?#O!^(/U.5[\2X\
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M_+?@D7,&3RN=!I]^L2)%\$*) L1U)C?:/0\M#>V#C4AQ%R4W^]N]^X.+=_3
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MS*6\EYEN32ZS'ASW:1*+Y]PG0YU0A2L;BW"3Q!5+4,U#E+64:U%MQ&4H?8<
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MSWR6U=R'.[2MPI4Z4I4&TJ<4"0VE2\HQ8HF345#3<$C.D'+&:";Q, PF2)(
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M ( ";:GI!.OSUY G&CWJ2 5*0I23D8W'8X)\L@6-[DC&%A&EAY'_ !O,6.)
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M#\MB4N.Z%GI)?D'H)0KH2V6TG:X[24W$Z7C/#ZC(XESAZI;JVTKI6'0@*:<
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MO,1Z^>F,T>R;K!L 5CFO[,VG%6^)NK>T1RO?=;-KE+C=#KU87U#-TI2M5Q8
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MCN2.T)%X(&NUO:=NL;8>J2F9V)M:9TYV'+W.%>.BZ4_$+G.2,;C';&+7&3C
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M83:QO>-^N I*LD%)%@#\)/UN<^?KC<VX=,\Q\ZC36]OKAGS^^N"RTJZ00D9
M-B+>=[_^D^IQC;A#J+;P8F>EQ%N>WKA1O?:0#!'L9ORT/.T8+J2J^ /I@?K^
MOWL[#=!)G7>\;WB8'+:/+&05\5[6(.<X/H3CZ>>WJ#GY^V$4K^D SE,Q?7_/
MH(UPH17P#D%-R+;>N;W'<C\O3ABQ:>4??^]_[8>BT)-XDZ<QN+SI;R.%AMQ
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M1;<;E"K6-E$Y-NI0 7Q E?=JA8@:3_MYV,3Y"($Z?EQ"_3$@P8.NUQ,#>TZ
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MZ56-C:W$;K:7FG&5B4.MK;6.:5I*5#U!.)&G5LNMO-F'&G$.H.L+;4%I,=%
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MM!2%+Z7@J@UQ6G*VTI2W7TSJY6"M245E,7$)!-V4H1#A\66,WBB!"T9KPF&
M]T+(CH45)0VH%*0@6;ZP%NO7N7@2;)%P=QQXNF.[0<H5X4@I2D&85=M *4RX
MF<SDD#+>2,?2"E#.<OA&8E)4H@B0?$J\)3J$0F9 M@3Z:S6H4JFS2DPYC3T>
M6VKH>0_XW4EGH*U$.H#9 3=?2GJZ+&]^)$*4E:5((0J?$9E*U_\ HA)3*EH!
M&0B2$*L?"($:PE22DA2@H0!$*2F/YF8$#*J)5IXDW%QB%-0M2JS1_P#2M"K,
M+_5V@8WBZ8I5<J4>E5)J'3'6I*V*+4JP["8D4NH0%EJ93X-2\)J>@.2H:?!@
M2./1J2IH>*<)9IE4;RN)CPI<33KJDNJ#JLZ' QWA*FD%1FH90D(0@(>C.A-!
MQJF-*IAAL#B%,26$M-E"ZALN9R 4I'> M*6H^(J06Y)B)V4NL/2ESX\UQ J;
M" Q48,@-1I3+P6R\T'&E=#Y2DNH<9<*REQ"T.A900H\MQ!HL$-,TM0EYII:G
M*TLH;+@-2V&UA;B%+404!)2G(ML94A1058HMN HAU:4K#@FF*UYVU=THJ26P
MI !@A0*I"@2J)C&U,QAV2\$R%+>0V"\WX,9Y25!Y]\*<2I"U24E376I_Q0EM
M"RA?B)/%0%2E.@97" M3A=994ZH)=4\YG3*RZ92D.%)24MR@@IC  G*DF4F4
M@!"W D>'(G*1&7*%2F9!60K,#?&IFH,$I2W.J7091:*J<TI;:4.W<<#370RR
MX!X33BO_ *?P@TA*0X>BZH[Y692*A]+1?A::5H*90EXAU::5HH *U%"2H#(4
M(2;*2"<.4$) *T-E0:\!6L!:BGP@N+!)@!7)4DQ($#$Z<@94EK6&HZ@7*G+A
M0>6O-)^>I;3ST,-.Z!U!&4"A0\1U'O\ .BD,N,I6^IWHMU.I"].C+CG^J-FI
MXA4!7!N*%2$9>'H<[Z@JU.%-4<O<N!YQI32Q&9:T^'*!CF^TI0CA*B&:<%53
M2I2G.7B2FJ92A)0+D%M"PH0=)F<6IY6+9=U%R]IB*KK9HKI9DKT= =EO1)"%
MTAUU8ISK=>1,BTPN+,QT&F 1H(;86^X@E4CNG^[7V>X*E]*JYQ'&:];#'"DK
M1WZZ9%:EM=*67W''*=M65=4MMU:5N+>![I,H1YA3W>>4A*6TFG9!6XJ4M!2F
MR>]*D@=Y:$A0! "3"B03S!]MX/5?VD=2P:?%<?ENOQ8+$&$VY*>=F.K#+42,
MTA*WI#RGE)CLMH2IUU?0E(6HV/Z"?P^[UGL?PE5=W#+XHF5U(;4H4[3@927>
M[4Z<W<I4%9%+)/=@%1!QPG$,IJW,A4H9R$S!4I.8Y20)&8ZD<S88JD_2JA3)
M2X=2A3*?+9(#T2=&>B26B#;I<8?0AU"CV"T)X[)+K;H2XVM"T7RJ0I*P21<@
MI,$#2Q-QUQ2(*3!!!@6.OK^T2,'&PE(22<@WM;UO8_/R[>O#@F0#N 1'0W G
MR(_MB!1 4J8\7,WL!I]#<'!L6=Z1;Z8)&V/7&U[8-_,<,(C6UI_S.F_^+X;?
M, #(UTUFPUYD7\HQ/_+KEE$?HD#5^H:6:A'K=0J-/TU3W5O-PIBZ*J$BIS)0
MCJ;>D)9D366&8P>::7X4I;P?(98<^6_XH?Q#XT[VCXAV8X/Q![A/#N",TBN)
M5%,[^&JJZIJT+=+"*@$/-LT[*0EPTX4M3JVDDI#G>->[?PT["<+XI1'C?&DL
MU" XH,4;CD-]VA1!<<;0I*UA92M("22,H&56<*2;Y[<WJU6ZTSI?3E1B0M+:
M;TIIC1S2*-!AP_&_!:!#@56.W46HK-0=@*J/O\="?>2U(8_B+K+I*NK_ (8?
MPSX/_I%!VD[0<+4]QJK>?KF&*VH?=89IU51=H'WZ,J33U-8MMMBM+]6T\ZAQ
M;:TAIU"0CENV/:ZM:K^)\%X'7JI^"-N.4X:I3E2M)GOF4OI'>*92N&PD*2@A
MOPRC*,5B0FP(-P0+# O8]OF<;6\KG?CWL"YFT3>"-#J"( CF?;'F'B4H;WC4
MP(,[6C746C;0;DBXVL3VMMZ 9\O[XXE\_@]A\WPCD9@$D6WGKN>8_87.#C+:
ME=( )/8>IW/88/?%K;CB%:A/E/V_2^%3)  N03H?S&# ^LDZ GV7(K2D)V/Q
M858WS@XL<GS'??89KJ,F9V_?I^]]^4Q$)(W,2-;VL/3IZP,+[-DG8]KD_*PO
M8_GY>MN&*T/R9M'K_B\860%  "PN>0CG[7P9&YL!VS?)^WUMPT)T!)MME,=9
MM!Y3;ZX12M8 TB01/[VP";"_]<?VX3+,R;Z3Z:\I!L>@YWPH4 D1[3UY_6^"
MP 2HB_?;[D;^EOT1Q*3,<@!^D_.7KB$@$P1U^WSJ,9IO?'K_ $['L?(\(;7.
MV%%[#?&Q%P3<6QCR%C][B^,^N<<-L;:WO[:GE8>]K7P[Q SH(/K>P'K<ZVYC
M!U NBQ)N/,7(^Q)(/EZ;7X43%^GVU]?@!G"&)L!8GYZ:;^9$8]+8.QO_ $^?
M<?<<!//>=>0YZ_6+'GA.5R(Y1\$>>OT+.-*! "C@&^]O2W]/IZ<+\Y820-3%
MS&E[?0;>F\W+D$ _%>YL?[ &V?Z]CP?-_P!<,(5(-B1 YC_'41SMC>TIP$6M
M@]P;CU/VM_4@\)8]1[S'EK_;0XD (U_-II$ V(D[;^LVTP>0ZL84G%A:^",Y
M].^V<G'"%(/,<XWP@).NOT]+SISQL#R=B#? ^1.^/EC<[_+AA21)V!MY=?FO
M3#T@$@2;C2^L&PB;STY3C);K-L]0.>_YG)V/Y\1^*=H_2_I.GG?$R4Y9ZB""
M9TM/2^YB^EL$W'T)R@GOE5P+[]P1Y6P#CX>'@$Q8QY3\^_+#S"=)G0@CUF\Q
M!CSVYX\#CP'B/.AEOMMUK'H% V'J;$]DD&_ <HD 9CYVY@6]COORP\)4;JA(
MB=/<B1KIY],'XZYDZS45HH9__5=)2D]B25?$LDWQ8X[)%N(E%+9)4KQ;I$$_
MVMUV@G#TI_VIU_J5&E]!!/('>=]9<+,&+";#LI25K%CUJ4GH'R3>_P!5%1Q@
M#M74\I2LJ!]+DVM)&\[;:XD#0F][3MI8B3-@-?.+80*C6&R[T1@IU1PGPT%9
MS_VA*5*P>XM<"_5:_$B4$"5F-]N7[:D\M,2 "T J,?72;#7_ !?"*69,I14^
M\&$DFX=<L;8_^V@*/K99&38D=WA219(F=(&OF3Y];:<L*6E02KPCJ1;8P/WY
MVB3C:/PJ*05SW9"D@8:*4-WML2DN*5;S !&+VSPA4X8 2 #(O<VG:POUVP@;
M0)E4F?TB"((W)O&N%:#4FWU=,6G/R@<=2"XI(OYN$I;3C?JZ?/ABP0/$Z$\\
MV\<@1)WTGISQ(EI!$!)-S),'323F(OITO@]*?CPVDW6&IA4GI90]XR +GJ*R
M%*0", C))-A>Q/#$E2C<DI,@DB"1I;0_/+#BS%P)$$2;&1'[G21;33">]4H+
MY+<IGPEG9^,L-K!]4V*5D'>X%QL>_#LBT0001,Y5"8%YZWN>G3 @(5:XZD"^
M^HT/VM@@J3(A$KCR1,BG*D*'Q!)&RVS<$>=NKY)&>%_,+IA730#601%Q'MJ-
M"7E!%Q<;;GYUPH4RNM(4XY&(:N$A;(-FB3U82G9!QD#!L?A'#7$9H"@3K<V/
M.\"\GE>W+");!!!C6_0DW@VY>1&%INM0W%!11[N[?^)!LD^9LD@I/R%O,<1%
M"Q:<R>NH'ZZ:1ZVP=S%P3/L1I&ENO[X<L6?%FH#,I+<EM0L+V*DWQU(4+%*K
M8/3:]@2DW($"D*0<R"4GX;@CV-XYZ0I"@,I 4!_5H0-MHL8F(.-[5*5!7[U1
MY)Z".I45S(.>JP0"FQSNV4WO\39))X:IP.#*\FYGQ@1Y'2\:G:]C@"U)$ YD
MS<';6,IM'K_E6933YX+DQDM/H"4KZ7%(*M[7*%ME73;'4"H ]KVXA4IUJR5%
M23,2)CG:\3K_ (P\(8=\1 UV!'TY_3D<?2[[2/*/4_-G2NC'-"UJ@4;7W*WF
MEHOF_HD:O@3:EHRLUW1STYES3FK(],<;J<>E5RBU>KP8M<IHE3]*UURCZLC4
MNMN4,46H?*N-/'.KG][$GME<\^6_,73K7,K1>B:CS!YPUKF%2M,.<]>;O,J)
MRGAS>3R]'4J5R\YF\S.4VHI, 4SF=)G\QV]!TCE)I.DT2-+8I'+75_+>K4N#
MJ1)@Q(#_ .SLU'K+7LC5',?7E+Z'H_/ZKTW4^DWZDUK[1O,KF4Y[&%8Y<\RM
M)SJA2&X#&I- :O\ 9CK>HW')77#EN52A0),&JTN;7Z>T84D':-(OH (Q$K7[
M,WVA]><K=*<N^;/M#:&T_(TAH'VA_<JKRTT([6HCW/+VD.?6L^;==YLTBFZW
M0VYHZH<N:8O1-/Y7S:=/JE<H<^J\PVG9SD633Y4XPF+*\L?9;]H&#S(UKK[F
M9KK3,+7.OZ/1Y<KGWROU?7)/,C1,O_1O+BDUOE/HKE=S3Y:ZSY,KY61=5:4U
M56Z'6JS3GJ@8>JW)'^B:5K5RK:SJ1@PT*7[%G/>%SGYKZU1S#T_%T=KOG'RH
MYD@5'6VJ]4ZOU#'T'S#J^HZDBH>%H71]/T?"DZ1GM:;B:'%0YCT=$A#<73^H
M=#:'IE)T1&,&(NY3?LMJ_P ON7VD^7.I=6Z:YET=K2_L%TO5KW,'4G,37LB!
M']F2?2E\WN5FB4ZT76X\+D9KHTV9JK0FC&F*#$T_JC56JZ;,IS&E7]-T[2Y@
MGY[?L,*M&_9S\^8-2U3HZ3[0= D<HI_M#<K^:5#JE4TY)U7S&F<L.0G+NCTO
MD=RJUU3]0,KTYJJ7H[7E*T[.JNKYU4D3]547EII2IUR-+U'J;4RHQ@Q?KV2>
M3FL?9[Y!Z&Y'ZQU=!UV.5;=6T7HG5$2,_!E3>5=&K,^/RKI]=@NMAN-J'36@
M?P#2M85$?F0YTJB*JC,G_KE,,&#%D>#!@<&# X,&-,B/'F1WXDMAJ3%E,NQY
M,9]M#K$B.^A3;S#S3@4AUIUM2FW&UI4A:%*2H$$CA" H$$ @B"#<$'4$84$@
M@@D$$$$&""+@@BX(-P1IBB&H_P!GIR==5-KG+?5G-ODIKZ/5W-1:3U]ROULN
MF5K2=46Q,:?C(IM3@573VL-/5)$MQFK::Y@TG5E+G,!#;;<5UMI]J.C911U"
MW_'4I4TED4]4M3S+32! 13@D+9(2 E*T+"TI&5*@@E)ZA[M?QBM89H^(+IJZ
MD; 2MFJ820] RH6ZXC(Z'6TR&W6UH6B29,F>"/M8#G!S6TG0-7:PFT'FQ+<I
MD5_6DO5D*!#K7OT!HM)72J-3I-$IU%I1CEY/X9I1N&_$FR9,MIAUYU4IKYI_
M@?\ Q.['5W\5^T?$_P"(7:3MCV2[4IXF:/LC6<->4.R[/"'3W;O ^(H%%6Y"
MIT(SJKT)HW6VTN*?9K4=X]];]I>R/$.'=FVNRW9#@U&_P-%*E566F5+XF[7A
M"74\8;JBXA3M2%$E)4IS^6K\,IIRC461S:Y.<_-6\E=9+30YS4OETY4793NC
M:I75.1X]1 3&EHITZ=!FQ&Y"F@@*,AM<DHCLQYJWWF&9O'Z)]H_X><,[7(H^
M.+- [V@9IDM47:&DIDL&NHB2Y3-5Z&5N!QHI6HH?:5E;65.L-I9=52(^:>(\
M*J'V5T[CB45+2E-J44]WF4A64HJ&@595"(*D"4J$A,'*.U'*_P!K7E)S2G4<
M1ZSIS2%?DFEP13:_4&DR_%5X:7D18STJ)'JS;4D*6TNEPY,9+;B77TL%83Q\
MV_Q [']I^SO N/O<2X8[7,.)"0]2I"J=#*U94/-O-ALBI22CND5#],YF 4D@
MMA)YA/#JJDJ6.^96VA!)#R/&THQ^53B0H(0J\YD D)*<M[31S9KIJ-03[C7M
M/UAEM$MEE)?CM/P'@\6I%/+31<>=BL30^IAQ+S""TX"AM0_B\T_A'2!FOXJM
M%'6\-"JV.ZJUN/NNJ:;RE9?"0@..PE2TA2W$?E+JS"S%QE<M,#,A9[LJ)3 3
M"B2DA)\5@J- "8\(OBL/.";,@\N=-L3X-.Z7Y53E0I].1'2I'4[X<N'+6PZZ
MZ5!Q*%LLS7%N)9#;S7@MO%AOZ#_@HV:C^(7\0JM+JZ=QL4%)5T"E.EM19013
M5;(=44K4IO,:AQD-_P UU3+J5K:2ZO"XP0.'\-0/&,JW LP/S$*4D_[4R0$I
M,R!G! 44CG+J:H^(^ZHFZ0HI!W[DG;!R=]A87''URPB .>OOM/VM,3ICE;F;
M1>!)VG72/I?RQ&4V0D@Y S\QL3OV-LD=KXSDZ#:23?3VG8FT'0 0=9O8G"D@
M6!!5%Y(\]AM$F-K=2E*?42<^NY MYVOY_KRL!(&@L9U'V/+G\EH-[P#OY#?D
M-=)@3KKC2IRXRJXW &<_[\*!>P$FV P!*K^EB8^O(3:(WO@JM(7<V\_UV^_S
M._#P %0>0UBUI.WIB%4QF&LDE/28M]^>EM<)<ACN/]_7]=M^V)4J((F9'K(O
M:>NI]XPPBQY&YZ'F+;;@_OA.(*20?UV^FVW$X,B<1D08^'RQTI_9PZMI\+F#
M6-(U:*]4(FHJ<XRS3V'G6G)<M/26&T^"_%4HDD@!3[;85TN+44H*3X)_X@N"
MM<3[&/O5#B$45"\BKX@TYX154:6WFUTH?_%4@I%+==:6BI6M:6BU);42%)Z#
M@#Y;JD)23WC@+;9%\BB4G,4Y5YAE!E( )FRA<&_-8E/Z*U[H_5M25I]^HZ%U
M-$J4VDT)B%$G+5'D-O+IL^:S'D0Y;4B--D+4S4*\IYU$9+EF'"VD_%=>JMJ.
MS'#:IMIIKBW#7&Z==(^A+K5"_1+15K754YJ0:A;5!3+88;0XNK2]6MELE2UY
M>E6E#?$ OQ_AU@N!P&RDK&5&101X5%XI65!/=PA4V&$/7^F3I36-9HC*EIIG
MBHJ6FG2'&C+TU6&FJA1)REE"DEU^ER8R'@@J\-\/,*5UL+ \?K:=JG>4EAT.
M4BLKU ZE*VDGA]6 _25*I;D.O4[B)4?&DE3:@%)4!]#\*KQQ*BI:LC^8\T/Q
M"3!BJ;&2I:@* "6W4J,6$!*AX2G#);1UO!#9(!;7_$+-LA*[);*"A*>IQ-RI
M)O\ $?$38\52TL(2I*2,Q(050.Y";QD("2' /$8U()$VQI9X5J"$B3&KAYE4
MS* 3EO\ E  MAC:STPB9#=J-%@1'-11T+,9^2'%H>:<;<9]TD&*A$A3#Z5%#
MRD*;>4T"MEQ#K:2G5X-Q:JX75TU52N%ON"X0!E) ?!;@A20E7A4J,P@S*52
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MT[4H#G$WJ:B98XTEZI3^#IG::JKJABDI_%5*:=:H&$J.1HFI2@K&0D\5VIK
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M5E2"9R^6Y.@'[".=HP](*C N9DF=!O/+47/UG#F3"CP&_$?<:<DE(42X3X3
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M$F4)'(F\;3IS,<].@,XW>($@C'5; /:]KXSO@;^A/#5$D6!B;VZ_!YZXE2D
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M\NY)L;7D_O&"E:KRY[OO;\JG-%+8;98@QT--H0DJ4EL(9 )_B(\1SJ5<Y(2
M$QO/  J_$-&TI2G,HDSHH0>>MC'(8''03FSHY0A.D20+$\_S*!Z[8;)K1!_C
MR0+W'S\A_7/GVXH&M7KF(V]1 M?H)Y1MM!WU]XM:WWZX-PZ_;Q?B_P"SOT_]
M_KG^WUX4<0-_%,=?/F?FF$[_ /P )]9^GKTQ^L-Q\5XXC X,&!P8,>$@ DD
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M:8G*0V,SRB1LDDJ)Z!,@^>PN3-\)"A7]7$OO/(I%%2.GWB0I;<;PTGI"6FT
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M(%]@-"9Q44^)@D'HDV&OOI8]>DX:DK465 *-[_/Y_/>^WS]<I=8I6J@!ZB3
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M3>=]K:]>EQ?&Q.2+ 9MVQ]?2WY<(H$D#0<QJ.G3YRPX&$DSK,2?MUG7&\+*
M,YML>_SW^A^?"E(.OOOA$+*--#J#H?FA.T^6-J7 KS%]K]\XV_QY&_FEQK<#
M??S/R=\.E*X L2=(!.E[VC:# TZ8VDWM@8%OZ_Y_,\* +[R9'3R/VY;8+I)(
M.A\4@S8"09&D3J3(L).NR++G4]Y+\"9(AO(-T.1WELJ"KW!N@C-^^_$:VFW
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MUO<P-P!<[BT=3J346Y:#;3R^"+P-QKNUY55*C9*K_4$7[#89[[?(]^*2WR3
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MS7%;IFI*K295-6XIB'H[0]$=+K2FE^^4'2E'H]02E*B26TS(3R6G!8.MA+@
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MAQ>9]%0/Q2F<U0I+B$MQG2IE:PIM*\ZB3(()Q?XH!E'%Z-"/^[^%4X\"6U*
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M\&&WY <H_P ?J<>)Z;'J P?,W(^7IZ=N#"B-YUVC['[Z;:X!;&X-_MV.]_\
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MFX&Y)D>7OAMS'DK)LL%!&P.23:]]A>^UAY?6HMRW(F=8,6V\Y%SMIS#%Y?\
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M9G3" H6<6 DJZR DA-KDB^!O;?SQQ](<+; 8:$@PA-X@F1,P+3TB3'IC =4
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MG^T9I][<B-MZT*82Y?!SO^O7Z]]AMTI3%P8/6(/OIUU-IN;FJ"0-N0V-NIM
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MVBVL]=#?R%AZ^>+*4:3J?8:1U)YVCSPJM-7L$[8MTW'W(MC'R\MN$M&NG/\
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MV.TT? HD531( =F>]2''%)OU66VXTV.GJ!4E* !U#)O?B%:E*/\ WE B;)R
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MN)TT.E];#I;"!S*3F)5<7@6D'337?0;"V,'XR5"QL?AP>YS?/R[;CSOPDV)
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MI[WFG-"+-,6L2(:/>%Y?%^"<(X]2FBXSPZCXE2SG#-8RAY"%P4YT9@2VO*2
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M5!(^)(R2-[WM;\_]C;OQ*AR))(C00;$G<ZQ8;]9Z*3F$:*\M=;<_??"*]'4
MJR2E5MQL;V)[@=_UBU@*"M#/P_L<+*A94$:<]/0SSZVOK@@6W4W!02-[VO\
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ME0Z7_P":XV^RTXP$,+*UH( PY?9EP!4*\24!P)(<&9N"HJS% 2F# 4DG,5*
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ME)496K(24DF2"O+O)E0!%?J?09U0K$6AQ(CGXI+F"GHBJ96E]$CQ/#<;=:4
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M[]CZ>9^^,<3R51) O8\OH+Z'TB<,O/,'TCGI.O7EUC#AY?ZQ=Y?:E-?;@.5
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M4PQI3$V#1Z8(].<;D-R&(1;"W4F2TU&B-168\EA'A,+)9;]Z_@=VE?HN,U7
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MTV\OJ =OEV%O+)^0B6D*L#?>X^LVMR$1;3"B0)(V!3:WN+B>I@WG7"HV\TZ
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M;K4MJ2R%=X:< TU0W5-I_$4]34):*T!,5+2:8AZG(S([UDYB%XMN4RD%25*
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M58#CSGAP_$?Q#>5$_APX$SL442*:;1^52RJPVWQUO"A#+%XA"U7_ .2U&/\
M\;7'$6!2]9S*;J/0$4H:IM/9=U=.<6E1CVAPWX+L@&Z"Y($>J+9;2%GPU-OH
M2TXZ4J3ZNX]1H=I^(*DK6H4B$R 1F6%I M9.9L*/.4G,E-CO(&4 $C\UI$02
M! T,D[3%QTQ7:I:7E_C1I554N$V(DN<A\=)\5AEQ3#;[742 VMRSGQ)"BR,
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M2J#&4TPRS2Z,F<(+#;#26P4N5.;4JC(>>*2[(D39\E]UU:CUI;#;:-"G8+*
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MN.R X\Z[(>4H(1TAQ3P"&+*#:$(2%*-E<:C=*FG8J"F%9W"Z!E"0F   )D2
M#*MY-AIABB0"9 T5OIJ== =^L$:88',-V'17Y%)ID54=J538CDEIU:O%C2%%
MP.)=2JY+CK#;+EB1T^*5Y*SQR#JEN@K<4%$.*"5  !0  ,$=20+7BYG6DXJ
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M]0!:Y+20^IE.&T8?XCP;AC3Z#4I=575B*JC?K.(L?Z@TEA#*'0$TM E7!O\
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M,<SAN/4'?&0<_/\ Y\C>WSX0Z@VB+#0 &P//ERZ;D*+V]>>DV ]>>%1A]*0
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MC*2#<6'1MD]R=Q\P,_7A[:AL3H!/+R%Q>-.>XQ;2(C<P4[;V%CKY:#Z G0Y
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M2#F5FL3%A-[:GE$T5-E(RJ(])CQ$S,W$" "2;#F<0U*C1EQ2"%^*2I9<_E0
MYT!  Q?H(6;C^%5]K$8=5F"U&$Q)D 7-K'>)-AN9&]A&4@(W]-;;&\3,F"+Z
MS-L-"8U8@6*@% "YVLDI^PW[]_IFQ!\[Q^OU@]+&3B*((DB!?T%]])F-I/77
M7'8R#@W).1:P[#[#U/?)VB,"8Y@>=C-O<6M<1&\H$B= ;ZSK>VNNV@/OA?BL
M7 ^'O@VV W/E\M^W#3\^6Q,D6G]NL"W+EMI;3#FB1P   .I9V];FPQ\QC-LG
MOQ6<.7,3>(L-)$G[^4D"3?%A(A,P9O/UBQWPYV82F@@+0M!-B.I"DFW<@$#O
M:UQ^0XR75E:BH&]]M8G:]])OK.&?F43$\@)WTF_+4Z>>[CIGC17VWV%J;6VK
MJP5 +%^H @6ZD*(LI)-K"WH,MZ%YDD6, R1Y#['32QG#_*"8B?K>-K@Z"=XD
M8EUF@)U! 9K(DT^"(Y#$]^9/;;4A#:4>*M$%;KDZ40X\E#7NK#RG!=(!*"4X
MJWE,+4P$N+F5-Y4%4S^4%<!"1 )5F(BQ&H.)D)-S('J)&X,3/70S$;XF7ESR
MW@:^GZ8T3H>C:WUQJW5==9I4&A:8I\:16*A.*!X#,>$EB6MI@),F2I;CWAM1
MVGI<M<=EE:D9%2]5)<<4>X0AMLJ27"LH@DE4J2H!1!@:;0GGAZC3M-EQU:D@
M E:I2,L3)@BR0#(@DD@Q:V)$?Y>S-!\QM2\NW*C01*TS6)M'JZJ3J&!JV,N?
M =4ST-U_39D4JI(:EI$9QRF/.14/K=:<Z>EWHS:AXJ9#K@)4H),Y<B4YA<I2
MLD@ &1F)^@)DIRE82ILGNU@*3G2I+A!$C,"$E!]!:3><.G3HJ% U!2JFV'4H
MI]3:>3)07V9,8./*LZAY94EQAUA+:G6%NJZ+I*" .CC'X@TBKHJBG('\UE2,
MI"2A2@GPRD1E(5,$1(O8WQ< .;G?J")O$F9%YO8;6  LAS7H08KE+GTZS\.5
MI>?57&6T%+;\*>S)6TAU+*$)4XB:0%ELI2X&@GI*D*4/$NS6>GXZY3.2B*H!
M)-O$") DD62" ""1?G&+JCG9%[I(0JP&G.+P;7DV)BV+1^R7R\J5"T5J'7U:
M81'+$EU%/COI9;:99CQB9*VD+!+LQ"'W5);ZE%MSI:4 [UA,7\3./H#M/PFF
M62X\ E60E2E+6=\IL D!,V_.3,C PC,L2#E3<D@;:3TG<Z@3&(SJ5377M8U&
M7&0VAI_W9YMNJNA+[$1$Q;P"DATN,ID.J+:$*65-H2A*0X$K2-/LQP=5#P]I
MZI2"^H%20E(A,H !D@',!!)WN3:#ASJLZI$P)@'>_2Q"1H)MO)MBU6FH=$UC
MR[YC\UG9(\+16D9]%K%$:2J2[5-=:@AR]+T"1'@):D-2@IJ34-55-^$[ ?@M
MTR4[-B>$ZVHV&VJRGIZKA)<2RU^*I'::J!<2L<+%:Q6N4PB4@M?ADT9+D_R%
M-E*QEA72M<><5PXT#=&ZY4K;=0Z60M3":5+2L]2^V4+;&0Y 5I6TOO%)E)0)
M52J&U63 0M-384Y'>;\&4^E!4B,ME3?4B0^P74*84TAI">KQ$MJ;2R/"1\.V
MM29,I,D$$ VL=QF N"=C-YZ<X(M:XU DB9F;1M!VW.DXD[1L^H2J<Y'CI<GO
MPW.B5+=E26_%\92W&NE39\1PI_>)*G@3TA'2L@E#=%[*5DG,!H  +1KN+&Q'
MKA5DB#X!,FY,\[^^/LEX] QXM@<&# X,&!P8,#@P8'!@P.#!@<&#$0\\N07)
MCVEN7=8Y3\^>6VE.:?+VN>&Y.TUJVF-5"*U,C]1A5>E2?W<^AUZFK6IZDZ@H
MLNGUJDR;2:=/BOI#@,&.>T3V7_;U]DDD>QU[1%$]I'DU3D__ "WV7?;>JVH9
M6IM.4QA(4BA\K?:XTU K^O8<5AAINF:?HO.#1?,J'3V?";>U/&8;*TF#%DO9
MX]J;F?S3JVK-%\^?8^YZ^R?J_1>F'=2UJMZUJ7+S7G):LPFI#,:2C0'.CEUJ
MJL4VOS(S;_X@Y3JWI[25;8I[,B7(I+(CNH2Y"5*6A*$YU*4E*4@25*) "0-Y
M) C><* 20 ))( &LDFPCKCYC^=,#E'IO6=3UA[.?M_\ ,"NU0U214V6.;G+C
MF4&:A*$B2]TU#65/HM3-><?LA176]!HB3E.EZ8II(</'NF7C-;7<-H>.?PMX
M;6\--(L/<9H^+<#[WA;J%MI13L<+JW&JD)6DJ<+M'Q&6,N1*%J(!]#90^[2%
MNNX4R$E*$]TPIL%28_.$YP$*219(<UB-,.?D)^T;JCBZC2N>6EZI'GQ67Z>O
M56AH.GD4BMO*?)]ZJ-#\6B1U-E#77[Y1Y3P+SB5MTAE"UK'(]I/X0KJ./]G^
M,<!70JI>%556Z_P_BZZINK:35L9>^X7Q%AM\J4DAMM5+5M,33E]#E6M2PV,^
MH[/G\/5IHEK;54);*6'K)2$F<N8@9A"B1G!*5!!43$B8=3>V![/54>ZW^8)I
MCCL?H4*AIVO4]#:BV04KE)ICM/24C^)1F%.R@HCXN/1.!\#XG0T+33]*E"V5
M+S 533R0GO"H*![S-DC\J2 0($ Q/%5G9CC:7''$T1<1 .=#K*KQJ4AP&9&H
M%SK&I9TR7 K,&%6*1,CU&E5.(S.I]0ANH?BS84MI#T:5'>02EUE]E:'&UI-E
M)4+;\=2S8D$01K((@C7I YBPF;QCDGVEM%3;B"AQM2VW$*$*2XDCPD1(((@C
MF(&LX93R2E9%O/YX)WW\O/C0293,Z>V@CTW-_6+8K7][\]?GG@DXC<6N+?(W
ML/7;/_/ )$:W UV %]!KRY[BUW^%6MC-XWGE])PE2&2JQL;IW'G>Q%ML@7O^
M5B>)D*V,1SB+CG?G/EIAI$3&T#78SY=!&"7A**2+=MCN#;Y[YWM:^PXD&@ M
MZ'UUCT_MA%:WOY$?IRW&^"Z63U8N1Y$7SW^WD!]!8W))T]_(W&GGJ/*;P0!K
MI]8(D$W'L#YD8=6E.7>NM=S1 T9H_4^K)A6$>[Z?H=2K"T*4; N^X1WTLHWN
MMXH0@ E2@ 3Q4J^(T5 CO*RKIJ1 _JJ'VF-OZ>\4G,=/RS,VG#T-+<,(2I7+
M*DJ'K ,>NF\8FYCV9JAIL"1SEYA:"Y.QFP%/4FK5AK5^O'$*/241M!Z)76ZO
M&E7-O!U&_IQM&2](:0%*&*KM*BJ\/!N'\0XPM4@.M,FDH00#=?$*[N65(L)-
M.FI.P23;$XI0B?Q#C;,$6)SN'3_TFP5@BT9\@G>V#K/,/DORO 3RHY>RM<ZI
M8/[CF3SFBP)L6'(00/?-.<K*<]-T[#4E:?>(<G557U8\T5()A,N((+3P[C/$
M[\6XBBAI5#Q<-X,MQ#BDF)14\4=#=0H?TK32,T8,&%J"L'>L-2&6^\4#9U\!
M0%C^5I,I!Y%:G#>X$897*'F7,T1S4CZKJ<I]N%J.?(9U,]3@U2R4U1]3DIR.
MW"9:C0DK4ZL):BL-,,-DMLMM-A*4TNVW9L]HNRG$>#T9916_@EHX:[4*>4EE
M]+1;:4MULFI2E29;<<;7W_=J5XBI1F?AM5W%6VZN2CO 7$I";@F3"5>"9 *0
M;2.5L7^U[!]V@3/=)*:;I74J3(TG#A4%B349\*-^%NK?>D,S%/7C2$L28\FL
MU@N)3^'MP*>ZT\I;7PVKAC50W6]F:FF<;5P2NKT]GDU;R%FI704SU%4LNK0Y
M4OM.TU0^L*<6E+S1<IW$(*FRD=VXXXC+6,+!6ZT@5*TYAD+R\X6D )20M" ,
MH*@84"JX@O5:0YS3IS5>90%\V*'3T-:]TXBG5.#*U3"B)6B-K*@19K:')4Y4
M",TWJ>FM%VH%;"ZTJ.I;E3\+SCBG#7W'WF@@N<2H(H5-//K?J^.(X=1TRG^+
M--Y&W!5-+46^,TR>\=0XU^*,I<<*?0^R?:-E#+'#:UY*&'"I5+4D)2W3]ZZJ
M*)Y1D98O1NKA)2ON; -@PG-BJ8<2\A(""GI6E(( "E=2VRH*"TA2K)N$%0(P
M,6''D9EPIQ6<*5WBB5)SIA(7D 5 3*L@6@$G+(F#CT]*4I"; 0G,B/Z2K0JM
M!( "BDG*)&X!PB5J'%ET";!J%/\ >F)R@PXRV@D*#J/WBDMA7P!"38+5=+AZ
M ;9XFIB^V^%L-*>="0$--(6I24JRH<>"$F4K2%!MIX%22L2M-\5:[NW*=27'
M ELJ\2W% "TJ2@J((()&9:+&%0",4GU'[*6A=0#QJ>V*1UJ\5QY#[C?B/*/2
MW$2VIU?2ZL'Q.LGH*DK2I8VX[OA?\2>UG!F4(HNTW$J-IMIY(81Q:JIU-(IU
M!*6A2L.(25@R,F57> *@&"!SR^$MK4 TAP$J1XVPH()6"HJ*Y/ABQ(%C$ZC$
M&<Q/8PJ:* ](TO4U2)3+4M;K+WO+P*VNE#:6V_=5.J\5M:@@EUIM"NCJZK@#
MU[LC_P")'M-PU[\+VA=9X_PY2.\6MY'X:N90H=V335;:,K@S*D"L;=[R,G>,
MJ.85'^'/)04H45 G*$*7*@H@F22"1 D$)*A,$ ZE+]BSV3^8NE->R=?<QF)+
MFF:96(I134N364ZF2U5(Y@Z>H[3C(>7$6IUQVKRTMH99BLN18SYG*:XE_B1V
M_P"%=LFN%=W3N57"6777J2BJG:=CB'%*ZI+=-W%$W^*4VBDI4N0^_P!YE!+F
M?\C,\G5UE1PP.MLJ6*S(22/$FF;!*RMP08,)EM$9ED@@0(/>.FIJM=J4>J5:
M5+HVM=>JAZBCZII1J$JEPVDT^!3IM->C1%17V*70V(1B%5+0RN XE427$?A!
M$@<)1*J.!<.=XIQ"JK'>*<25W- AQJE?C.XIIVN134*FFQ2M4IIR,]0$HH*1
MAQ3++ZGD*Y!*14.!*$'NT'/4$J4E1(*E);*UYB5J6I9D)4KO'%)E20DX87MD
M<QT1J1ISDI0ZV]5F8P;GUI[W1BF(8:2 IMAR!#>?C-/+65N/N-*'O#J_&4GJ
M6I2OJ#^!W9)WAG#E\>K7N*/5%2A5'3CB69A18IZFJ+-0BC2\ZPA=2'E/_B0$
M/U#"Z=+R4!M#2.:X]6!:^Y0EI*4PH]V0J5J2C,"YE2HY0D)R72"%921XL450
ME"4=";!*0 ,;6%O/ML+;;9X]Z5),DW\HYDZ[#F=>=CCEL:EV'S[>1MY[?GYG
M'#P-@3;RG<;C2QVY08P8PZE>?Z_W[\*0(,QZF-YUY3@$[?3'O61M>_>_]+>5
M_*WY7X0:;3%KD@#Z>X)(GD8P8S#RAV!MMOCA"A)VCT-YYS]9OIH!@QZ7R>UO
MUC>_^WK;@R"VOJ-=.EO:XG;!@)?5?XMO3<?KOYXVX120>AM;?<>0^UM1,X+^
MGS^WMC>E06+C/IPP@I^=-#Z>A]\&,TH^0'^<C^O>V]AY<),VGR&@WT^OITC!
M@P%! &!COW/V[_3;AL$&1,;R?H/<Q)B==I"; 6M^NLX\7(O<V ]3V^M_^.UN
M%2(@:F(_>/E]\!,W/S3U]/87P7,GMU [7Q?;S&_S('KVP_(;3:?I<:[>7MK;
M!B0^4FF&-><S=":5EGIIU9U128]7<!Z?=Z&W*;DUR4;;)B4=F;)4=PEI5AVX
MSN+U2J#AE=5)@N,TKRF0084^4%+"+@3G>*$#SQ(P@./MH/\ 4I(5SR RKV2"
M?3"=S#U8_KO7>KM9R4AM>IM156L(C#"(<6;,==A4]D !+<>GPRQ!C-(LAF/'
M;:0 A"0'\/I$T%#2423(IJ=EDJW6IM 2MQ7-3B\RU$W*E$FYPUU?>N..005J
M41(T!)( &P%@!:P&&VPM&+6QC/GC)OOC>U_MQ;/Z'37T//3E],1I$&\%1N9&
MUOI\C"VP01<6L  +>>2?7]'Y\1*U.LR=>L?WQ*()3:T1ZBY_OYG 2$F0$J%^
MINPV(N,[6M@7\L';ABI"3$:DDWGEM;D 3K:YQ.B) (FUK"/4:?3"76TIM<V*
M2DV  \AY=K@^O].%9)N(%M#RY_?X-+1%Y$ &+G;8V'6 1I.O2.9*BRLK;)!%
MP,D7%_/';)]?KQ>_-8@;&W4#KSGT\[O"B-+&!,&!?6_+4[V&"U)J,EZMTR,5
M#PW)T9"AG*2ZD$6_6]_G&\D):=,7"%;]#SM[X>P27D#^DJ3>#S&W.#TY]"V=
M>QO_ .9*D!O=H#:W_E)L ";][_/TX6C7_(0#:YO;G-]1\VUQJ$#.9BP3:^F0
M:"?H1IB;-!51&G-#:<6Y'0^Q/FU%,ULH!4Y',J<A92">A2@$LBSEPI"2VH)"
MNI./6H[^K?A652$HRF;!61$7%]U7 U@Z#%AMOO! M8D?^XF+Q/3IJ9Q-'MMZ
M;;U1["W+.+I=MD0*5JFC5=JY<0U'IU%TGK]R2VD*27$J_=F*TT1;QEMM7M8C
MFNR[_P"&[:<274%16[3NMD  DK>J*+*9F  #F49N!.LSUO#1##&: 0T$VB K
M, ?J(Z3MMSJFU7DE19%+Y05%E"Y5/TE)T[5*S2TN,N5617TO2W:>NH-I8,F8
MY'?IB$("@/>4I8*_>VE-M]FEOC+R7.*MDA#E2E]MI9"N[2P0D.9%9@E 4EPJ
M,72"J"D@G4*5SF!,YH@S$ !, ZW@Z'3S(/.5WEW"K6O-3Z1;JR8T>DR-1QJ=
M-L'/Q!VE5%<* @$721*NVZM0%BD$)*2M*D]R[Q!3/#Z>K+147D4Y6@6[L.MA
M:R?_ &F0 ;Z$]7R$IF\*('.\GT@")%@;BQG%6:U'6VM:7$E-B1D$7&""D$"Z
M2+E*L@@@@9!XSN()'B5,S<&^WGZ2(L>M\0N 3KI];B#?Z>NL6CR>PZVD+(4E
M*P5(.0#;X"K]9MG;CEZM(UC63TD7OUW\CBFM)2I),P28W!U$^=_\8;3B%+LD
MY)(!.23V!.VUO+MBXR<AP95$VZ7MM(]_FN&%,G:_0[3:U^4G>T;2988N4#L<
M8^?^#CY>H/%=6IVF3<$?)^1H)T)F$@Q8 Z01H+\^L=1S+FAQ@2 D"VU]L 9^
MIS;;YVX:3 )GTOUCYU\\60D)ZZ>]QUV._GATPXOQI5D$*246QGMYFP.?/Y<4
M'E$ BT$$1S$2>FNFWUP*)VZR"-.4[#U,;B</JGRNL^!5 N9$> 2I2U=<F,;6
M0_'=5D*0KXEM%7AN)'2JQLH9#J(\:/ H3;1*K$E*@-CI-B)GI@3-P1R/[1[<
M[0.N%2/35KFIAPU(E]3H##C8*4NI4+I)"PDMV2?C"K!M257-DW.>M<)*E@I@
M>(&+0;6'4$"-B/+$@2)L-=[><QY:]=3BX'LW^S7K_G8WJ5Z%^%:,Y>:84RO7
MO-[7DE5#Y:Z&8=;5T?C=<>;7[]5WDE*J-I73S%3U769"D"F4F4A*W&\#B%2V
MRIM0.=?]#:(4XL3)RIF8U"EJRH&A,P"/5#;, YEN+LVTW"G%D204IG\H_J4H
MI0(NH#%RG=?<NN4NCM0\GO92D3(\34--E47F?[0M>#U YD\V*<4#WFDZ80PW
M,9Y7\L9SGC-_Z;I=7_'-0PDQW-9:@DAQRA1.?>>==6EU])E)'=L@)4EN9NH9
MDE3B1)DIL9RI38X<U1K>*7JPI5!!;IT$EEHD64HY8>=$@9S"$$JR";XI^G2$
MVCP"8KJ65R:DE!"9;"UQD16@\42:BP[[H$LN.-N1RRXM<M'3*#3'2$&-52A:
MH6"0$Z!) 45'*"A!&>XF=DF4R;'%]+9 E.I,S(M%S<0#!T@<H$VQ-FGO<=3P
MY%/JM0;->#"6X\Y*Y#D60MQ;P+(4\I;7B=3L="&RTVVE9):=*#X;>)4E3"@M
M*"EK52( 4D "%>$ 18DJDF") -\6/$1!$D3)G0&^YN->=HC%\M%<D>==3Y50
MM0NTNGPZ0W/HT)$ZNRHT!Q^B)47I4EEFHJ:;DI0SX[C,9)#:W'!XB@0I"?">
MV'&.#4W&T*H'G7.()2ZM**1"G#^(((*?!)"9 *ED#*08D2<6&_S9"1E,%<S
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M\(K;+]14Q[J'7$1 0PEQ8:ZN*#=33.]X:0G\,W5UU.P5.!XJ9I*Q^F;4'@E
M>2I#(*7\B>]3#B0,Q&,/B#*&*VH;04J2E86"DH4 '$A< M^ A.:V0Y;0D1!P
M0I&G]1!MTPHL]()3X@C^(BY!6$E80I./XN@F]Q<@VX0K022HIGEK&OWY;0/2
MH2F!/D)%[:[?/3'VD<>AX\1P.#!@<&# X,&!P8,4G]OK7G-7E]R+H]3Y.577
M%)UG7N=/)#0R'.6C7*IS7\^E:YYDT#2]2HVDG>=E"U'RQAUFLM5---8J&JZ2
M_!@HDN24N1WFVWVS!BF/*3]H]KO3>EO9JT9KO1U5YR:WYGT*AZNU5JU,HZ;U
M+0-'<Q_:"U=RCT+IJNTW3'*N#RYJ7/OEG"I,"A^T-I:9)Y*46#S%I]0HVA:9
M/GU>%IRGF#"GK+]J%JK3?+:+KNF:,Y$5RI:HYF1-#4_1S'/RGPM0\E&':+S8
MK2X/M1M:CHNFJ5RMUM*=Y7+TM3M.O5HQWM<3Z_IQ%1?5H],O4I@PX](_M']=
M:UYG0N7T/EUR9H-:J5<Y(Z/A\LJESV8KW.V16^>?L[<O^=D35--TKI#2U8H&
MHN6G+2K:UDT;7NK--ZBJL!_1NF-5:^HLM::$Q0*X8,,/EY^TSYCCEAR JNN:
M+R#KFM=5<G>3^OM>Q:/S4J-$JO,74_,+7]1Y:5[EC[/FE7=)S%ZOYRZ#J=%=
MJFO^7LN9 &G:QJ?1.CE366]1#4E.,'S[?O\ ?%]N5G,357-GDES>U?SLGZ6Y
M8:5>U;[0&AJ=/TM/J^G:CH[E[RVUUKKE6[K"OZPU)+]U8K]0CZ3E:UCU6#2Z
M12M/QI\*.D5,P5U278I.^%73&G8%2^*ADLTY;4\'W0XDMLEI/B=2XH!"FTW6
M"4C7#V\W>-Y$YUYTE*,N?.J04IRC\TF 4[S&/E%Y[^SS[#W*^(XWRS]NWF3S
M+EL/N^%IBG\KI%=4S":!;8::U34!3--REIN@!;;S$9QEIY;#87X3"O=VN-?Q
M!>K>',T_8=@4U4MW_4.)U7:2EHV.'H0$J"OPBFZSB#[KZU$--,L+0CNU]^ZW
M*"KT*C>XL\ESO*(4Y"1W86Z0E2C,V4'"A*?55QE2HR<4BT;R6YJ<TWG&]$\O
M=3:EIWODIBG:A_"4TIJ0&5*5X,RH,F)IN'+;9Z%/QC,+B%)*@I25IX[6N[2<
M%X$:5KC_ !>CI'ZIQNG88<J Z^[4.I20AMM" ^I!4<J7.Z0D^#/E*@G&DJMI
MZ9)_'5#84VWF6E*^\6!(E65"0K*/Z?""0)C7&CF#["GM82J:_&IO+6HHDN@H
M9(U9H]@J(>;7E:=1'I/AI<0LGIZ@0DX5BK6\4X?Q.F7_ *=Q!"\BEMF!4M#,
ME22H26@"1=)(/K .,&L[1<&LE-?!B0"S5 E)TG^21-C<G>,=/^6FA:IRYY2<
MN]"UM2#6M+:.H-&JP:=2^TBIPX#+<]EIY)*76F)1>9;=20E;:$K3\)XE8("6
MP#F2A*&PH",Z4(2D*BT9HS:6F;X\FXF^FJK:VH;)[MU]:FR1!*00$JR&X*A!
M5,'Q>N)&T#J70^D]1)GZ]Y9T[F=1%= >H\S4>I-,2&NE9)7%GT"<RFZP;+;F
MPIC:NE/2&P7.LXA35U4P44/$G.&/3*7D4]-5),@64V^@S!T*%H,3J(QF-*;0
MH%QH.IW25*01Y%*N<R"#MI.+6\UN<WL4:JT/I.GZ2Y 5^@U6)4Y;]:@42K4?
M2%68:3#2TP7M8.4+6<C4E/<<<>"(LD4]YIUM$EQJY0$\KPK@W;6EKZIRKX^P
M^TII*67'V7ZME1SDJRT8>HD4[@ $K1W@4E12%:XNNU%"MM"44RDD*)4$J"%"
MUO&4K*A//*1&E[5S<U9[,XRWR5YEOF]PF5SJIGAGY^[<K([@'GTK!\MN.B%)
MVEF#QGAH'-'!79U_Y<54)]//:(>\I-0R[(-IJ!)] S)G36W.,:T\S.0\&ZJ?
M[,E-GN)!\->J^:^O:FV5?RJ>9T^[I)+@!L2VA384+I)%R> \-X\NR^TSK8W%
M)PJ@:,:P#4"K@QO$WGEA.]IP)%(%7L7'7#?:<I1.\S;;'G_Q#R*<GHT=R8Y!
M:,=0>IB?&Y<,ZMJ<<IN4+;F\RZEK<^,C!#@;2H+^)-B  ?\ EX.&:SC/'JT?
MU-KXDJD:5-R"CAC=#8\ITUG7#A4I \+#"#-B&>\.^[I<T &D6FVV&KJCV@.=
MVKXAIM=YEZK51U I-"I%05IS3J@0!8Z=TZBE4.UC:WX> !8"PXM4O ."T2PX
MQPRD[X7[]YH5-1S_ /F:DNOWU_[G4:G$2ZEYRRG%E,0$)5E3.QRI"4^XG[8B
M1+)62M1ZE*N2<J423DJ.+F]SWWR>-8F+ 3RBW^(YQ'EB,*@D& .7*+R($&3_
M &QN]W !'GW\MQW/GM8#??@$QK)/(P-9V'EK.$*@3I[@$^W/U\Q@N_$0I*FU
MGX%CMNDYLKME)MG>Y^A=?7Z_+>FG2, /B!2(@: Q)^>9M[7.]GWG='DTUSEG
MKJ=,34V(#\'0%?5.#*:5,DE*&765R$/,LRD.)C+1)4A3K;4=*&5,/>!)8^>/
MXN_PU_&I5VLX"RPQ5<,HN*U;S+*767C7N)[Q/$&.X4&"[E75JKA44M2NL!9
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MBPZPTAI+33:6FFX ;;2&T)$$$!*(2(V @6)$D3BTD)0 E 2E(E("4A( DS
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M>ELTQQ;/N$@A,6H=)6N.RX0$*3<EIQMI2T*25I);:4+]=@. LH>2I8!S)U1
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M0XZMU2G%J6L!:U+4HE2E%9)4M1*R22KXKGA[P@P+"+1 CF ($=!81$$:XF4
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M8;64H;;"0MP))5T!*A@FUR;XXQZJ4(<7^8I0M0&IG*2.M]X&VF)6B2J-A?0
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MTONBDJ*BDK<22)*"XM*5)M("<@"QUS"Q5#2KO)=ZE<GZ?K1,*I#4$1FBZEU
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MQ&5:ILB*IM3S);#[:76B2"'&RD%)"@;7(-R-QC;O$_"@O*1!S >FHZ1)ZSY
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M.FA(B+&UKN>(T 4V-@M75D7 />UP1WV/?RN.,UP3&FD:2+;D>OTG6^ :BVA
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MZG#XH$Y#+9:DJ79M0>BN)4H*C2D'J2ILI/4CJ( V*0L)401<C(J!/J"+1<;
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M$[>N&E(D3)M[G34D7Z8+ *!L;V'E>WZO:^//RXE)! TDW/RU^FFO0X:D$[D
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MRVVE#*FUA=?(3.14Z253.EI\/2=!KJ=G%/*!Z$G;6)W^&^/K!X]QQX'@<&#
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M#[#Z\^>-"ED&PQ;<FWZMP[ 3'T^ML:"YG8GUOO\ +>^V_"Q()UC;>V_VBW/
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M.4.(4(KPPA>0MM..N*0L%25E=)4TZ)3H2VX\AY)5,*;"DPM*2'MN]T51()2
M"#$0XA2MIN$D6-YC2<2#%]H;W*=)J[>G8]5J3E&<HA:U%#I%9ILJG)YLQ]>P
MZ9-B3XDAO\.AZ>CC3$),=#;]*0&#2'8342*&<U79U2VPS^(4TT'P_FIG'674
MK/"E4"W$.-K2>\6^LU2\Y4ETYN]"U+7FF_%A)*LH42G+X@E22 \'0#(/A" $
M"!*004P!;=IOGU3*1JFAS)U*KNHM+0J[4:Y6*?5ZFPY7*A4$ZVJ.LM-5]%2\
M)QE.HZ+)F>#)FEI(J<657*<LQX=9?Z"IX"Z[2OH;=8IJI;#;#3C31##;9HFZ
M2HIRWF"OPSJ42A /\I:&'!F6RF434@+1F2I2 I1(41F4KO"XA4ZYDJ-U:*N+
M!5T&'S:H,71'_AVK0T!VAOZ+J-#FULSJTG4CNHI\QC4Z:VAA%:1ICHBZMIU$
M:2X[0G*H]I2EHI*YZ%O*4B9?"7U5O^HBN<#Z:UM]# 0Q^&%.V@TQ8*BR:F5T
MCCZH2^EM-6[WP00D#"=Z@-]T&QE+925RKO,RE!PK'BR2'$I )3F[M.6023BO
MRFE"Y O\LX^?Z_MQT*52![:WGRY'IIIH,5I(B=/]W7J-OTTZXT6SZXN=K[9[
MC%MOO@\/^<_GP3A=?FFHGGSQO0Z4X.4_F/EPTI!&T\_O,8((T]9W]A8_3I-\
M&%/)6U\S8@GR%\@;_P"V=^(LD*FT_P" +ZC_ #!MAZ3$@Z1;E/EZ"^,PTER(
M1N$K)&=@JUP,6V%\^>_#3^:TBVD::W)@1N(Q.E7ABTDWTB-1S\XOK;"JJ(E:
MY"K6ZZ8DC)W_ '1/RW.W<^N*I59(F?YD&1_[HY[>W.UM)I1D>0,>H/IO_?#/
MEP4OTUM73=QEUQ N+>(V""4WQ\: 0!>]Q:VQO*E4.$&1(DB]C>^DP8/3%R00
M=QIZG:-]==M#K9NLZ>9JR78:5=$D)\5@@E)4 ;*'D5))%P;W!O;!XD4\686-
M-"-=>8UV,=;[8< @V5/F">EH%O4XC6LT>=29*V9"% =2@E8%T* -O47MFP)S
MD$B_%UIU+J0I)ON.77J#L?< X9!2JYD$'*HZF;@$].7WPM4^I0ZQ$;HU:):>
M;0&Z?4SE2.D]+3$A1R0DV2A:B00>A2DD77 XVII7?,W%RMOZE0'(WD"X-Q;2
MPVO,G*KTF-_8VUG<&"-\$GZ3/HLM'5XB%(6'8TIDJ2%EL]2'674FZ'$$!>"%
MMJ (& >)$O(=01$S*5),&T000=CUV.NV%R9/$-KVF1!D:P1!B(C:29&.GW++
MF%I;VGN74_EGS-ID&H:GIM+6W),UMM8J\949VF?ZA@7+;D:H(9E*CU5N.XVK
MKD>.TXTQ)\*+Y/QKA=5V8X@CB?#G'$4CKOA")_D+"@Y^'7$A394G,R5 @!.4
MA2DROON!<117I+#ABH;0,XD@.MCP]X.OY<XV)"DV5 Y+UCE[7.1VOYU#YG"1
M6= Z8G5;14"H1Y#LAS2@U$IO4>F*HEQJ.)]-9K#4)VH4F3%Z U,8J[S3:78]
M0A2?16J]CC="A_AV5FNJ$-5BT* 2*KN :>I;NKNW%-%80ZA>J%-!4A2%IW\B
MF5PJZ)(!@R-")C8@1.EC$ 8I/K=JG3JY.GTQZ7(;ER)#KSLUMI#K[Y>>"Y02
MS^Z2B8D(F>$FX86^M@*<2V'%]A1%U%.AMT)!0E*805$)$)(3)$RBZ"3^8)"B
M!,!P6"HB(Y6B;D3R$D'?VTQ'4R*IZP<%^D%(-@%8. 3F]AA-[FUP2<VDJ&N\
M00-1<?+:;[8?FL J"+@DB3?6>END#0B9PV%TYMIYPA5EO"_056!*?YTI/\V"
M" ;&QQBW'.UK*U-@E!R(.4J"3;6Q.\6U@BPY8186M"8$A)@$#8WB=-I]^8QZ
MF-961\1(!%K7!!(^1SWMM?UXY*J8-Q][;Q?36-;B<5LOBG=.MM=M=+>NV%6/
M&44I"0L%*B;&_D,_(&]AL 3@'C(6V$JD#F3 ,:Z\K_H.F'(!S: R!,W-N@M.
MGKIKAT0VBCH&;8ZLC'<^G89MG-CQFOH,J)$QOTZR28CS]IQ,!!)(UWW.I!(U
M&HGZ:8<K#@ZT*%AU=QF]L;BV,YP;G('&)5(&F_M,SKKZ7]L-)A4#>)&P)Y?0
M^_I)^DZZS 2]3ZBR)E'GI=1+9)<#C+ZHSC4>8R4.-W<CO*8>LH+!#/P)"K'C
MG:Q@N95H.5UL@)F(*9!4#((DIS & #FA1RF<76%A(4A0E"XS&+C*2?"=!'K(
M-A.DGT[07XLI,G3U?HTJ&XAEQ+<Z4J-*CKDV#$>2A+#B65%X.1E2I'NT5#S0
M,A4=+S15@OUBFREMRE?4XHNB&D!?A940I<%25%)3E<"$=XLI7X LH5%YNE4L
MYF%AU-U!,PY -ADF<QB-(FV:;&0J-R5YA3IK%)ATJ)*KCSK+*: U5('XREQ]
M0Z0(:WT&2IL*ZWVX2Y3T=H*=?;;;0XM&0]Q&F*''0BJ+2 K^<FF>+:H @)(0
M3*P#W6<(#A@(S$B1=*^E'?EM7=*N5D@!(V*A_0))DKR@09B^)7T[R2I[M5@T
MRL:_I-.D>](_$V54JM)93 C*\2I*@5(0GD*D,169*P:A#@QD*:N\\ALA1YRK
MK.(&AJ:ZGX2^IMEI:KO4Q<;4;-J?IP\E>25))2TMQ:H*49E2$ZB.#5.4**V<
M@3G6K/ 2@05*N+A*9(4+*RD2#K/M&UY1>5\JG5+33G+!=&BK><9C1:-R_P!;
M5M]"&'E)8,JHP*Y7D.3B40W)-7+:8Y<4OK$8+9&72HIGVJ@U'^K+XLAL]R[4
M,\3I*,5$@(4IEUIGAY0TKQE+*G XV(2DO +5IN#@;+ 4DAQ:1+?=/OMU!<3X
MD*#K#C;C2@H)!.9(3$H(,XA>M<PM3ZQZ16)=.3'+GBJ@T2@:?TQ3EN$E0<=I
MVFJ52(3ZT&_AN/,.+;)5T*2"01]A(6MU:WG5D 9GGWG@F 0 VEUQ:6P94"&D
MI"I,B=<)50^XT$+>><0@IRI<=<<T$"5.%14H28*LQ$F+J).B&NQ N18^0MN+
M?4DBWU^?&>ZD3,<]A<QJ2=@#<\^HPT"2) YGRWOY#_.'A2E)>"XBB 7@/")L
M E] /0#Y!9'AY\P3QG/-V)D38WUU] 3H8G:(YR))D&-+;6TYF8%N>IOMA0B*
M 2L*58@I'>QWVL1Y6R3V]>*1 !N-0"+$R/\ [0M,\\3*BP$6M(WZ_">>]_L8
MX]FQ\^X'!@P.#!@<&# X,&!P8,#@P8'!@P.#!@<&# X,&!P8,,/F=2%5O0>I
M833;RY**<[,B*C$"8U(@$2T.P2IMT>^I2RH1FU(\-]Q0CO*2RZXH<UVPH%\2
M[-<7I6J>FJJC\(M^E:JU*0R*JF(?8<[Q *VG&UMA;3B(4EP)\21*A:HG U5,
MK*E)3G"5E-R4+\*A!(!!!@@VC'*34:FJI!CK=G1]02HLMYMJ F D55UQ8#T-
MA^7T:LK35WH[JWHD^;176RXIB4U$AR(38SVBGCO9=HYG'%<0X*6_^@6 KOT,
MRD(*26^\[U*4E'C0H@H *,Q-@@T]:=$ANH!_F@F$DP3L0,BB0J0=X! P_:D@
MSZ3%?4$-^]TUI[P([GO+:GFVTAU1>*U.=(((;*[*4D_&D*QQU7\+N*?BJ+@C
MZW*BI=50KX=5/UK9IJP/T2RRHOM%*<[BRTG^; +R5!P@%1&,[B[/=NU"82E/
M>!Q.2%(RN F$D&+9CX03&DF#BM.LX1-UW4HA*DFZ0D"Q-@DC"K BW8;F^>/H
M;AZX"@( 2K8R8(!!(VO/2PCKR[L @&23^4G218;<]8YW WKQ6H?0XO&%W4FP
MV4D$6[6!/RS<=N.E87:!H;&9N)MY<O2+3B!0F)U%S<:VC3RTVPR)#1-S8YSM
MW[C!\^WGWSQ?!) ]?+Y:)N="1B,65F$F8T,[W]--.N$-Y%NJ^.WTN;'^XX7$
MZ3)U,QYR)WZC^^YPB2@5 [#(^8/H3;'G?[]^)6S!Z_?7ZQRM&UL0O'IYSL8V
M]-]_;"#); N ,$';>^Y \P3Z;8VMQ93<3S/ZQ]O?$&$E]*DH^(_RWZ;]L6^V
M<;$C..)$FX!])Y^\?>^&0"H*&DWMO\W&FN")!&;$ Y'R.W$NEO[GU^E^N' C
M29(UQN2"M P" >FWR S]R;F_?8#A#8Z['EZWN3 C:\"3ALY5:V(),\SR]A_F
M,:SU)^60#;?]8QMCOP"#S!W]+6V(GEN9L8ATB8WQB;&UQD;GS^?YW\^ B1UU
M!C0S/S]<.28/3?'G$=["(OK$'W]<2VNJ201Z1Y85J?4Y$)#K:%O +4RH*9D.
MQUH+:E7*%-DD%25*3C /22%!/2<SB?"6:]3+A[M"V45*1GIVGT*#[81*VW(!
M#:TH<M<Y2,R<V;%_AO%%</#R"S^(9?53*<;+JVC%-4(>*4K1)3WJ ME1 LEP
MJ@D %=>UGJ!;:H[53FIC/0T17V7G0^%W8##ZDJ<"UH\8742A25!2E'JN;\9-
M+V1X.RL.O4-*X^U7/5=,ZAM3!:2JH+[+2DH6$+[@D(2%@HR)2D)  &+=9QZM
M?2$,NO,-&C9IWF\Z5I<6EONG' 2G,DO )*E).8KS**B28/\ ^OZDTU'C*B46
M6S&89:8$FEM+6TE#*$EL*24=/0KK0%(/Q)^(GXCQ1/87AU2[5U"WN+4;M35/
MN.?A>)N!#X4Z5H>6%)<!*P$J*524+$ 0E)Q8/:2IITTJ*<TE0ENE;2>_HD!;
M#A0IMUA*DY)1DL%),*0L@G-F&$B7JM^4.G\+HS'[LM LPB"EL@!2$I6\XV$F
MP-NBU[7V'&C2]DJ2E6%_ZEQEX]\*@AZN!*GSG_F*6VTTZ5^-R?&)SN2#F4#6
M>[0USS:VNXHD-K8%,I**=13W">Z*6PAQQ;:0DL,00C, TV 0$I 0W)3LCH+A
M19L=*$(;::2A/4I72E+:4 )*E*5MNHD[\;[-(S3%SNPN75]XX5..N*<6&T-]
MXI3BE^+(VA*B)LD:[8[U0]4=WWJPH,MAIH!*$!MH+4L-I"$I&4+6L@7C,8MC
M$K(P1G>PV^I\QG86XL91K<V$@#W@W!/WTMB#!=;A5BYP?EY]A_SP]*0.7IOH
M9\[<XY8,:N%Y1'/T]CK^^#&EQP!.+[C? MF]\\+@/G&"Q=20?U^6/+S_ -SK
M;R^'_.V^$'SGM?\ QSVC OC<6W[?+Y_;^G"QRN;C?G/U@1]IU0P+Q.H\^FM_
M8Z&TXQ0M/58^>XN/KY^GT^G 1\];P=Q^^]SA-(L$\]-S%N0WY21.YP:2H8(S
MG/;_ !]CCRW/"8?T_P XW@]Q]-O[_P!-[\(3$<MSRY?+#"$3$W$\C]QI\%L'
M&00@&]^_H,_YW]>&+.D38GZ0=]0),>L6PVQ49Y1!&O7]NF%!"_A_F_MC(^WU
M M<<,U,V_;?SBV$G*(,S?J/,?MSUP2?<[FYO8#&//OM>W^UN')$F1:/K:-/?
MST$;!%H.OYE'I)Y:QRT$6PGE?3YY\O3SV\_7B7KSPZ JYDS<7-L9(<Z?B!&U
MB/GV^^W#2-M1!L8-YMK!L"=]!SPBD@"TQRG3K?7RGZWPH-+!%_/\B+[_ *^^
M_#/RD@B9&_,7'F#;E/2",-()$?[?60=/:,9K2+!0[_K;/YV\^&GRB?GZX<+R
M"9B0;&=3O/\ C&HI!L" ?*X!_1]=^%S*YZ_/GIR&%RI%]/4C]<>&,%"X(2;"
M^=L;6/IY6_RH4H:Z7MI<W_SRGRP!0DB#J8W&NOO/3KC262@YN;?,$?/TWR#V
M]>'!6:T>_IIK<<HOK; J8\/P=/AP9CJ/[QJ]PH=C_,, ]MTDW%MO+?B-S0&T
MB9D<AH"=?$-9-R-</;,1O(B!]!KMI?\ 6<*8D$/,MFW[R&8YVW+8(OFU^I %
ML9S:]N*ZFP4DWG/FWN)OKS%ST]<:#3@B"=!%[WB.IWD81'%J_#9;6RF9@=3C
M(2I 3=)'_LOC!OD7OP[+#B%1JB-M9O/+4:W.+:7+* @ZZ6!(,F?J=OKAO(+K
M3R),>XD,K#B2+$+%P%)*>X4DD*'D20,7X>I(4E23$$1RCY:,2M+*EI!,@F+@
M VOL;C7WWN1C4FVJJE]YIL/,/%2Y,15E.,/'^-QK((2I5E*Z2DA944J"B>J)
MLJ:(!UV,:W)$[2!J+"(QH90H$6-[<[ _MSM?UC&HTGW194@%3-\*L+IOL%@
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MYO?''U#P]W^8F"@!UL$0942+VB9'B-K'D<<=4)\(NJ4W$Q$=(DC2P\L5NK\
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M0<C FW/_ #RP?#TF0/J,8I6"$@V/Y6 [[XL<=[^? 4_F(.H_R/7I@QL==(2
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M43]/W]<'#>UMP.X&_K_OWWX84D#2VLB2//X!@"DR3<$\[CYY^F,?+;?L3?\
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MZ/\ M^O/OPGB$Z$3Z^5O8:DG;D\D[7CSO?\ ;S\AON;<[* PDBY-A:V!MO\
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M<W1$<4DI.P\K;6-C\\YN!WN+')Q7VB 9!CEJ+B\W&GKUO<.VGY\^#0X=,.0
M0#O?!^=M]P">W_%LAU!!@2;F.>A&DCF-+&9@W&)42#KM(O\ WMN#Y8>E,D E
M *\^1M<_7UVP<;VWXI.-222+00;;Z"+;]><XL($:I/0VT];\]M]\/&,0HBY(
M&,@6L21VML;[D8\LV.:\U8P+W%Q:W3X.HQ/ @$;&YCE>;S$?6=-L..*YT !-
MS< DFPOFUQ;%_09%\<8[S4$Z[[<]C;TZ&=<(03$V3>/2=C>8D:>^'!%D'X03
M>U@.WG@^O;?T%[VXR7VB,T:0>I!C;K/F?>0H,$ @:DYN<SO:9M?RWG#BB2B
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MZS<T-I1RFPH\F,U6FZ5,K!55W79<5R)!]T@O /L-3'/&*$^!TJ*T]2RLQJ#
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M@UN*</ID<-XA^+IV6S1U%!W%0Q0T5%+*ZCN7UTPIJA^H>IUMW2JK.91"5?\
M<"THD6E.18('A*,I"4IWA1$$DB!N3>.6)7]FWG#4:AR'U?J33GM%^UIK/]L
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MXAU94WWA07!G<7W@"4KVP\VP]E_[[)0LH7,N(_W K<4#!@9B)C01)3-8T?\
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M?+U?5]45QIJJ-<KF5.TZGU?4K;<Y^CI\1E,>2T_)C%Y;Q3-><2Z$O4MM;E.
M5JRK>!4I2EJDI$0I8DI!TO&I!G"H+B6JLNH0THHIB4(2E(@NF5%+9@*@:1.D
MZSB*^3-=YHU/F!H1U_F54:%SG5KR:WS#T56*GS6FS95'CS*@_6Z#4-"HTJ[R
M\T]0TTUIO\!K,26Q CN"$IR<IY;G@,0XI9;#JU*E9SA:W%$)$@@H("$6(R*$
M;7L0+2T-I0X6FDI1D!;<2EH)*B 0K.#G5?\ .""1R$C"]6^<$MS0+W*VO:AU
MG'YQP/:UCMU!A]>I!.C:$JW,GQ(Z7:NXHM-:4>IDR+!I\=<Q,.0S(8BPV7HY
M7X<94MD$M+5"725)!4%)2E5B2(@*$")()L183(E,K!4E/=J8 'Y2"L(OD GQ
M@R51! B]L*VD]2UO2?M,/TNF:YUEKVHU/7NN(;L&E5OF#13I*C069QBTG6O+
M2NT5&CYND:;X:6*17Z=4(SE1?]VJ#3,@J+(L-N-/O)#Y6X%.+(/>+3W<I)@M
MQER"T+!!!())$@(XV4,9FLJ0E*)24H4I9$24K2<Q69,@SN!%HZ-0:[0:VX@U
M#KTY647+50BJ<1$4\!BZDVD05DW ZBZVC^=Q%[<6G*9YE)+1#S1U0J"J#;<9
M5B+G0[ &1B!NH2N$N"%#?16@ DD[':(WGF\7)M=B,I%6AP]5TM:?@DJ#9D*:
M(M=$UA*@O&>IQ#CBB22>*65I2CW94PX#=-\LZF4'2YT%HY1&+@D73"TD1: H
MCE'Y5#F #U P@/4G0M6*@VY,T]*."S,CA; 6>R7VBIL))P"ZVR3OT\2AZK:N
M8>2))(,DCF4J@S_[2>6^&%+2C=)2J;W*3;24W -]O3&VDZ3U309)J6CZZT\J
MWQF!)0XAYL$+#<J-=;4A -B6GF%HO\2=@>&5#M+5([JMIY&V=)!23NA>J3M*
M5"1/3%FFJ*BB7WE+4J843!N0@\@I,*0L3IF38W$'$GZ>KS53J$EGFOIXU2#*
MA?AUC2D5"D*#SOB29%1ISQ><6I1;9*'(C#Q;6CK;CMJ"5IYZKX8MM"5\(J"V
MM"N\"2YW;HBP2TZF!&LA:DVB5$F_9<-[2^#N:]M*2?\ [RP04JM_ZC1.8&=5
M("I-B@1)6-4^S1HC7T.!.T?6([0IHM!IU71(KM(1'4/_ /6*?1+@ZGIT8_"E
MJ.[4Y;-- !B4UH@I5GL\;KN'K<;K&%RY)6M&5APD?^H!D73NJW*@V"[!SN&;
M]33UC%0G.RZT\GFA844R/ZR/$@WD!0D3<6@54U)[)W,Z'/J+C6BFH5"AA+KM
M8H$^;J:FVNI*?<D.IC3H32DI!>1J(Q0FREL2S8,*W&^T'#G&VPNJ*WW+):>0
MAAPVDYX*D.$&8_#YM0%)$YL6>]:*DI*@%+)A)LI4#8:FQ_MK$$S*$[I^2_16
MU4JOOJ79I<)A]U:%J 2MI7B-0:C'D(*ATX?C.G$9QUL^-Q;*>\1WJ4J93J0N
M$VU!"DJ4"($SF"@1>#&)D**!E"0<Q N 57UN(4+";'7RDM-ZBO1GW&)D9^,^
MB_B,2&G6'T7R"4.H"P,D@*%R,GSXY^JH4JS+&5:5$D*01)&QD2")N2=YWOB$
MHDW$^VO0F9MY'V.%-6G*C%CMS7(CJ8KP24R.A#K"@JUNIQ!6A))-B%$&YL1<
MVXPETE12DN,E3858J&528GPA0,C<@$BQ-B3AZ>\;\0S)!$2!*3H;C0@<X,;:
MX7J?2IY0IY$%UUL W=0PXI*4C!/4@$ "V_8C..,6I;6O-W@;6I1DJ*$))-M2
MD"==IO$[8D$J_,!8R2E.N^P$<OKRPZJ,Y&B*6N5"3,2L )"K(*;>=T+N"+7
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M_=V?^S_\E?\ [W!F5S^@_;$L (! @S^^#:(L<B_AB][84H8L/)0X,RN?VQ'
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MM@XJ.R46Z,8&ZMBD'S\\\19U<_H/VP[*,T1;+.IUG"1*BL W#=CD84L=[?\
M=Y<66UJ)3?43])Q&0"!(U$_4X)*8:"00C-U?S*[)N/YO/B;.K-$VRSH-9\L1
ME(G3_;N=S!QK++=R.G8^:NQ^? 5$ZGZ#;$>-:V6R#=.P'=7<D'OY<+F//Z#]
ML*+D>8P7#+?4?AMOL5#LGR/J>$"U'4[G8;$QMA,8K:1<BV,8NH=OG^OH.#,>
M?7_//RTQ($C+,7@\]IQM9CM$7*2=OYU^9_\ 5Z?;'"YE<_GSZWUPP@ #YLD_
MJ<;2PT ?@['^97_[W"2?UT'UY^N$QI5':N1T>8_B5MMOU7VX7,KG]!^V'$0$
MD:F?H;8U*BL $A'_ .:_0?\ =P9U<_H/VP)N0/73SWUQK]W9_P"S_P#)7_[W
M!F5K/SRTP\@!2;:YIWFW7'HCL_\ 9V/\R_(_^K/UX,RN?VPPJ()@[D<]^N-B
M(S-@KHL=[A:QL?\ W<,4XL&)ME)T'(],*I1!(!^@Y8WRFD!E+@!"PD?$%K!V
M&X"K$9.""!<^?# 3F(VE5H'7%Q)(*2"1X9M_].VF,?<(CK2'ELCQ@.L.I4MM
M:57.4J;4DI]0" >XX9G4!8[@&0#,G>09UWQ?3< G6]]_?7UQ@Y ARJ<V^^PE
MQXA=W+J0HV( )Z%)N;=SD]SPP+4ATI2HA(T&VYW\AB=%TP;B?GW.&FB'&ZB/
M"!LH 7*C87(M_%MQ86HQ,WF-!UQ*V?$1M$QU),G#MI<5CQ&8Q;26)'BAYHDE
M*PAE2DG))20I((4DI5C>U^*E03W95_4F"DP)$J /TV-L2TZCWB4R8,DC:0DP
M?GEIABU*%&8J+X9:\,(7U(Z%N I))N4D+N#@;$9N=R3Q(E1*1)GVV)C%X $S
MO -I%S,Z<\+5'J4Y4MF(Y)6_'6$A3<D)E8(-P%R$NK2/1*@.(W6T9"O* J]T
MRGEKE(!B;3IAX)!(!V&M]2=S)Q)%0T[17F$K<IT=2BD$FRTY)R;)6 +^@XST
MO.I,!:@!/V3^Y\]\3"%3F ,*($@&UL-!R(W34N& Y+B!))"&)\Y#6%&UV1(\
M)6W\R#Q:0KO"D.!"["ZD()U&Y3._/#5^$^&0+6!('Y4F(%HDDQSP5H]?JLJ:
M(\F0V^U<#I=APG%$=5LK5'+AQN2JYW.>)%L-)05!)!OHM8Y;!4;G%;.O_<<3
M)3:73I"4K>A1EJ*22?"2D=NR D=SV[\8K[BTSE6H>I/+G//%Q"E1,[].0]\.
MN-IZB*0":;&)ZK?PJVP/^[U/KQ64\X%'QJ]^=_UQ8"U2!-BD$Z:VO.N-=1H]
M*B-E<>GQ4* N"64K-[G_ /4"_(>G"(<<44A2U$&)N1-ND8<M2AF(,$&Q$<X^
MQUQ ^IM15J--3&BSW(C*#=*8C;$50MT@#Q([3;A%L$%9!&"".-RGH*-U!4[3
MMN*),E8*]R/ZB1[8K*XQQ2E6E-/7U3*;^%#JDI_JVF-AMA>TGS(UM#=3&8KK
MO@K0A*TO0Z=)4H%0!NY)AO.7MBX7>V+VXS>)< X0XDJ51)S)E2<KKZ #$R A
MU(WY8U:/M-QQ:VTKKUK&8?F9IE$Q(NHLE1TW)Q;/2E<JLZ/%7*E%U3B25GP8
MZ+GK4,!MI 2+ 6"0 +8&_'E?&J.F8J%H::"$I%AF6J+#_<HDZ[SCT^AJZAYI
MI3CF91223D0FX)']*1L--#OB8J8VAT)+@ZKI%\D?R!78COGCD:@ )L.7U/7R
M&-ELDI!)O;IL.6"-=D/0X[JXR_#4D I/2A=C>U_WB5"]O/BLVRVX0%H!O&I%
MHZ$>^N&N.+1&54:; \^8.(#U-K34L66PABHA"5,%1!@TY>0XM-[N1%$8 V-N
I^_':<)X50.4Q4M@E1()/?/B;='0,<W5\5KVEA**C*+V[ID\N;9Q__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>g65062g75y58.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g75y58.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[22"4&AO=&]S:&]P(#,N,  X0DE-! 0
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M;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/
M8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R9%15
M;G1&(U)L=                $)L9"!5;G1&(U)L=                %)S
M;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S
M96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M    5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M       08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M
M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12
M:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M   0 [_^-0 "  $#O_XU  (  3A"24T$)@      #@             _@
M.$))300-       $    'CA"24T$&0      !    !XX0DE- _,       D
M          $ .$))32<0       *  $          3A"24T#]0      2  O
M9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M!@       0 U     0 M    !@       3A"24T#^       <   ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H   X0DE-! @      !     !   "0    D      .$))
M300>       $     #A"24T$&@     #-0    8              Z4   :_
M          $                          0             &OP   Z4
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   Z4
M    4F=H=&QO;F<   :_    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$$0       0$ .$))3004       $
M CA"24T$#      9PP    $   "@    5@   >   *%    9IP 8  '_V/_B
M#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  (
M"0 & #$  &%C<W!-4T94     $E%0R!S4D="               !  #VU@ !
M     -,M2% @(
M                $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P
M    %&)K<'0   ($    %')865H   (8    %&=865H   (L    %&)865H
M  )     %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,    AG9I
M97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P
M#')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0
M0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D
M97-C         !)S4D="($E%0S8Q.38V+3(N,0              $G-21T(@
M245#-C$Y-C8M,BXQ
M                      !865H@        \U$  0    $6S%A96B
M                6%E:(        &^B   X]0   Y!865H@        8ID
M +>%   8VEA96B         DH   #X0  +;/9&5S8P         6245#(&AT
M=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N:65C
M+F-H
M     &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L
M;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@1&5F
M875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M      !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@
M:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I;F<@
M0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M        =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:
M(       3 E6 %    !7'^=M96%S          $
M   "CP    )S:6<@     $-25"!C=7)V        !      %  H #P 4 !D
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MK@K%"MP*\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS
M#-D,\PT-#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/
M)0]!#UX/>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J
M$<D1Z!('$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E% 84)Q1)%&H4
MBQ2M%,X4\!42%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)
M%ZX7TA?W&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:
M[!L4&SL;8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ
M'I0>OA[I'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B
M52*"(J\BW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97
M)H<FMR;H)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJ
MSRL"*S8K:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LMX2X6+DPN@BZW+NXO)"]:
M+Y$OQR_^,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;,M0S#3-&,W\SN#/Q-"LT
M932>--@U$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.% XC#C(.04Y0CE_
M.;PY^3HV.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _
M(3]A/Z(_XD C0&1 ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.
M11)%546:1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+
M#$M32YI+XDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%0
M49M1YE(Q4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8
M+UA]6,M9&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$!_\  $0@!*P(I P$1  (1 0,1 ?_$ !\  0 !! (# 0
M           )!08'" 0* 0(#"__$ %(0   & @$"! $'!P<&"PD    " P0%
M!@$'" D1$A,4(146&2(Q69C7"A<8-T%1=R,R<7BVM[@D-CAA>8$E,U57D926
ML='3U1HH-4)25I.7H?_$ !P! 0 " P$! 0             ! @,%!@0'"/_$
M $@1  $%  $!! 8%"04&!@,!   ! @,$!081!Q(3(10Q05%BD15A<8'P(C(V
M=J&QM<'1%B-"<N$(-9.VTO$D4E16E=07,[*B_]H # ,!  (1 Q$ /P#O\
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MG,G-)OCR:CI \<=J5)4T*O3]G[5Z%FHBHOKZHCE]G3HB=?M]9(*)*@
M
M                                              !&?U,BF-$\&LE*
M;."=2WAV8^<8SG!"YMLR3!C9Q[%+DYBE[Y[8\1BE^O.,9A?5][?WH79ZW?Y'
M_N4DP$E
M
M C=ZD_\ \!X7?[1[AO\ W@.!"^K[V_O0LWUK_E?_ /PXDB$E0
M
M                                          C5ZF*ADJYPM,3.,9SU
M)>%J>>^._P!%;91DC_[_  '-VS^S/;/[!"^K[V_O0EOK^YW_ /*DE0D@L#96
MS:IJ:M9MERQ:,PQ7[6-S\D*!?=DR_JGN%<H=JWKBM6RR9:]D3^>_Q$Y8M<^#
M#IRCE5+!P,6Z'Y:Z*Y,9?FTO8K7:6<:G*'<S$CJ7;](KIUH2;5K<TP966_4.
MKU^2F(B>0=14G"1TDZEV#QF^3=,4O0N\H@;(@
M
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M,HH[-$T<UQ#N6S-Q$X;L\HI8C'#-JNPP3TJK9!1(R17V JX
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M>O:DN_=N895LY*S6: ;I
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M5FT^]?T&5M#FFLIZ$2LIBKRC56Q,GT?A1!'RO-8NRX5R=NH7 &]0
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M<YSG-7?X?\R%V?XO\C_W*2@BQ0
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M[Q=HEJ>[6LS%AB$LZ295)-)J7+ADN4JALJ)%,!,0
M                                                C,ZHGZO.)O\
MM%^#O]]L**N_P_YD_F79ZW?Y'_N4DS%B@
M
M                 !&1N/J;0="V):=8ZAX@<X.6$]0IMW7+Y.Z%T,[/KJLS
M\:IY4K!)['V9-Z[J5JF8M3^2?-*3(V1%LX*=HNZ3=I*H$?C\?C_4;'\7>6]&
MY4Q5J4K]"WCJ6XT)S#M+YJ_D%J"X:BOU75GTI%6%7,SL3'$'9(J4)$2>&<]2
MYZRPBBC%PB>037+A+(&U     (VNIR@FMK7C"H?&<F:]0G@RNCG&<XQA0V_Z
MHVSG.,?SL>4Y5QVS[=\X-]9<"KD]7U.1?V]/YEV>MW^1_P"Y2246*
M
M                                      '58ZL6MXK5?*^C0U+DN44[
M<^3$!LS;DE+W;J]7K@AQTJ1:)*TV#?4C7Q)&,L=;>6=UFU,IA*CP*$:M'P:#
MJ720>M</E8\3UZ>[[T1?WD]/ =I(L.'VB6DL8QY)&I.".SFY"J\KC&4^/S)L
M9SR(68QJNU/H&+VL!V+?*6/^"O!G$=@QA!M\    "-OJ=K$;ZMXUK*=\$)U
M^"W?MCOGZ7(FF%QVQ_2; A?YI^]"[/\ %_D=^U"2024
M
M                            .J=U;RQVTN7VL]AVO6](UC%:&HNU]//K
M'S[Z>^ZN5/%N_P ;;;94;!&W^DW34:EJH5.RS)5E,Q\];'U,LR3"7D6,NW(S
M4RT0#\?CR_J3[<"R0).(.BBUBP<=+5 XJ*^8V?XEUA.E\=9!',[+F.;5U43D
MYC$!#(+95:OHT\BY7;SR$L5QY*_F() ;=@    C0ZI/ZH^.'^T#X)_XC:2(7
MU?>W]Z%F_P"+_*O\B2\25
M
M      .J-S5N?!UAR9WRTN/./KMT39S6Y3!);7_&=?E*IJ" L)&J)DX?5#2O
M:9FJ"K!$4\GX:BSGGD$HY.H5=YY.5LE G#Z7<AR#E>GYQ4DN5+.R,-_/M61[
MK8:%TBDX2[*.EI*3/!O;M$$32/'W22J^8.0MS9TBC()V-U)?$T49'+I,H&^P
M    (T.J3^J/CA_M ^"?^(VDB%]7WM_>A9O^+_*O\B2\25
M
M                               (J-T<(G$[NZ:D]-=2SEIQ7O>U%I:\
M2>E:MM36VP:?,X.Y31L-HH>JMY4^_P I3VIG[A+XA\A'4;4V3]S@Q(9LX<=S
M ;7<7.+*/&>*M>)#>W(GD3=;TZB'=KV+R*V4I>)Q?$$E(I1<=6X"*BZU0J)"
M-<RTBKF*I51@TGJSG"TLI(K-FBJ &U(    (U^J&CYNH./)_%X?3\_.":W;M
MW\?_ +RE#1\/?OCP_P#'>+O[_P WMV]^^(7^:?O0NQ.O>_R.7Y)U_D24"2@
M
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MBFYEF9SN7F5JJG7HON5/WIU7W^K[B[%_.]7YK_/V^KR3U]/7]7M^Q27D6*
M>I3D/C.2&*?&#&+G)38-C!B&R0Y<YQG./$0Y3%-CZRFQDN<8SC. ![
M
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MU?-%3K[NJ>:>?S7U?=]R':;$F,
M
M      Z>O5/Y :CD>=\-0M\\B.EVUV9HG.PIK7U?Y?\ '3DKL:M:SU]8<:LE
M*7#62)BMAQ^N9?;THH^E[ G83U.29R-6PP-7EH@\7)ED@.Q[T\]W2G(_A=Q^
MW;,2-4EW]_IBTD>4HM!GM7TR0;,I^9AF#NKT.SS$_.5V"681K4\:V?3#_P!2
MURF_;*X9NVZ9 -S0    1H=4_P#4AHC^OKP._P 4&N0+-_Q?Y5_D27@5
M
M                                         ((^I_,;1T]RFT)OMIH_
M>VUM''XZ\C-,V=WQ(K&F)3?,3M?9!Z>WI+V??;)<Q<_B@04&PF[/6C5^26AX
M79\%6IVT1CUNR8-G ?C\?Z$@G3B7WXXX-\:#\H91"9WT36S%OL:03DZW-.SR
MC1_(-8]O.RM/46J[ZV,(%&*87)>#54CS6MM,X0-G&,Y &[     (UNJ4@HMH
M[1YR>'PM^=_ Y=3OGMGP?I2ZT1^CCMGOGQK$]N^/;OGO[ 6;_B_RK_(DI J
M
M                                            06=6SI+VOJ'["U7L
MR!E-)6 ^G=866&J^L.04/>)37[O8GYV-4;,A9-R:ER**[6!O$#0K'J+9JOPU
M[+)T>VJN:^4TJV0.V D"Z=O&RV</^%''?C5>I.F2UMU+1?D].N]=LY)G1TWC
MB;EYKX=6,32+:;>Q,.E*)1#>9G&Z,W/>A--S"9).0=%P!NB    ".+J@?J*T
M[_7CX'?XK]5 6;_B_P J_P B1T"H
M
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M/Q^/W VY
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MTY8RRKA58Q4DT2$,H=4Q4RER;.,9 R@
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M;('V
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M2T?'*OV[*2;N8]9XU259^N:NVI%S+M7":;\?C[09G
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M /#&^?V7E!/,_P!$.4_J]L_P^P.SW]/>$_K9Q[^+5"_!M3GRL#8&O
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M3)6&H8F&UA^2\R]8H.9*OFG6;9HSF%(=VJK'J23-NDT>*-S+MBY0.F;(%R
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M>^]/U)[?_AC?/[+R@GF?Z(<I_5[9_A]@=GOZ>\)_6SCW\6J%^#:G/E8&P->
M     !&?U8O]%FJ?UNN#G^+C3HJ_\U?N_>A=GK7[/YH28"Q0
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M%EFE;I==B*M M5G!L&75;P\&S8QR"BYL8,L=)N4RIL8,?)L^X NP
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M)[?_ (8WS^R\H.:YG^B'*?U>V?X?8.P[/?T]X3^MG'OXM4+\&U.?*P-@:\
M    "./JI%+GBC&YSC&<EY3<&S%SG&,Y*;],K1A>^._U9\)LX[X]^V<X^K.1
M#O4OV*2WUI]J$C@D@                                         #6
MKD9P]XT\N$M>-N2>I*[N".U5;4[W1(6W.)EQ7H:W)%031G7%=:2C2#G'B""&
M6K?Y01\JB@S=23))(C65DT78'&C.&'%Z#Y,S',B#T[6H3DU8ZUBGV3;D*O-1
M,_9*R6.CXDD18V<?*MH&?;$80\,DGF7B'BR:D+#.2*E=1,<LV V>
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M)]OX_P!?J)(//1S]2R7_ .0G_B)(/J
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M:G[(A?JQ_1C_ +A8\QY
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M\                       *'/UFMVMHU86BOPED8L9:)GF3*>BF,NT9SD
M_0E8*9:MY!!PBA*PLHU;243()$([CG[=!XT61<))J%#JJ>I>GL^[W%<
M             4.OUBMU)BM&56OPE:C7$G+33B/@(IC#L5YB>D7,O.2RS2/0
M;H*24S+/'<G*OCIF=2$@Z<O7:JSE=54P?CY>HK@                H:]8K
M3JQ1UO<UZ$<6R(BI*#B;.O%,5;#&0DRXCW<Q#Q\TH@:191<J[B8IU)1[9RFT
M?.(R/6=)*J,VQDP*X
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M"[>.'*KA2-BI!_%M\*8+&O7;+R'"@&QH
M                  Q7O3]2>W_X8WS^R\H.:YG^B'*?U>V?X?8.P[/?T]X3
M^MG'OXM4+\&U.?*P-@:\     XKYBRE&3R-DF;61CI!JX8OV#YNB[9/F3M(Z
M#IF\:N"*(.6KE!11%PW63.DLD<Z:A#$-DN0+>I%#H^LZQ%TG7%-JM ID(1=.
M&J5*K\35JS$IN7*SQR2,@H-HQBV)'#QPX=+E:M4L*N5UEU,&54.8P%U@
M          LC8&L]<;8@,57:5 I6R:OA^RE<5R_5:#N$#B4C5,JQ\EB(L+&0
MC\/V*AC*,W?I_4-CF,9%0F<YSD"]$DDT$TT44R(HHD(DDDD0J::2:9<$3333
M)C!2$(7&"D(7&"E+C&,8QC&, #W              !19^MUVUQWPBT0,+9(G
MUT7)_"Y^+8S$=\2A))K,PLAZ*10<MO71$NQ8RL6[\KSV$DS:OFBB3INBJ0"B
M0NMM=UNVVN_5VA4R!O5[+&EN]SAJO"1=KN!8=#+:(+:;"Q8H2]@+%M\Y0CL2
MSQWADCG*3;RR?1 %Z@               #&5LTIIJ^1EIA;QJ76=RA[Q*14Y
M=8JTT2K6".M\U!,V4="3%H92T4[;3\I#Q\;',(N0E4G;N/9,&;5HLB@U0(F!
MD9JU;,6S=DR;H,V;-!%JT:-44V[9JV;IE20;MT$BD20002(1)%%(A4TTRE(0
MI2EQC 'W                                              &*]Z?J
M3V__  QOG]EY0<US/]$.4_J]L_P^P=AV>_I[PG];./?Q:H7X-J<^5@; UX
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M ,,;Y_9>4'-<S_1#E/ZO;/\ #[!V'9[^GO"?ULX]_%JA?@VISY6!L#7@
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M_4'YWM3?\Z&N_P#MK6O_ %,/[5<8_P#<>#_\QG__ &!_8KF7_M+DW_P.K_\
M4,9[JVIK!]IW:S%CL>A/'KS7%V:M&C6X5YPZ=.G%;DDD&S9NC(G57775.1)%
M%(AE%%#%(0IC&QC/.\OY+QR;BG)88>08DLLN#KQQ11:M"2221]"=K(XV-G5S
MWO<J-:UJ*YSE1$154ZS@?$.65^<<.L6.+\B@@@Y1@S3SS8NE%##%'J57R2RR
M/K-9''&QJO>][D:QJ*YRHB*IG@=@?/2L#8&O
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M&,>V,?[@!Y
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M]&!Z#S'D
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8=&RUUD5R^.ULG7JA=@VAI@      /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>g65062g77d58.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g77d58.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1YZ4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'EZ^=W0X0DE-! 0      !D< 5H  QLE1QP"   "   < @4 !5!R:6YT
M #A"24T$)0      $'&R'N^RK%WYEXQ?IGQ&?D$X0DE-!#H      1D    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'7@           *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             #^@
M![4          0                         !              >U   #
M^@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #
M^@    !29VAT;&]N9P  ![4    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   _H     4F=H=&QO;F<
M  >U     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#"S>HY9SLHG,NGU[9_3/\
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M[2?I/V^E_P!-6*NK_5^UH]$-?^FK:P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M V!V9[>16:*]-[D0@:<W75KY%[M  EM*ULI8L4TMAK5,D5&Z@[#=P/)#US0
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M2;J*[C-5-5UOFK&O_<XM_J=?^*E7/;J',/4M-[Q\O]*%>_\ )VFO['H3S,_
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M6$WL+']+2N3?_P"2+'EOR6MS9SV5\1" O[1/SU* S-)D7[*=I[P09[.@GIJ
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M"'%R#%D^$-,$@\=+,2+\8\QG8H^9[J^H-$7>[-A529IZB&6#C'8Q38G$V7C
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MTU13 RQATK&S#0;(Q^@UDC2TNM6O: VX-PUPO8&Q))N <CEEG93"6\1&!&[
MA4I9RCM' 2<5ZRAZ%4M&/NJ[D,K*DP=Q3&P7166U6\?QRMK!@DQ!R5LP7KHX
M3'-(.2'#?6LI)D@B+TGQ&\'YV031&/#)V2XB^O\ DL@J(XFM?20P-9%5-;+4
M4\\,D9<*AC7&=KG:;8M,L;KXT99N%FV!ROKW:C?S6SUW7YMXB57$]+3A8H%9
M%!025V3!;4CTDI.$TVZD).4 JECU86.M+ZO?8B%:A,VX2C;2Q=]H(_',H!)G
MQ5BT%RX<_55Y?!^I;\EF?)35\\5//2R1ULU8(VQ/JY*FF$-4TS5+_D;974P$
M[7&>)K7%T+V@*<8T@BQ;F#=H&9M8W!L,]>6U8V^P=IZW9<]AVBGI)DFLN.Y=
MC4IE(M)9*D0[%FT$!43\B2'"$"Q1$2/9).W+86P:84TRDS:HM4TM,>AH*7Y'
M1T]*3&3#'HN,,?%1%Y)>\QQESRQI>YQ +G'.Y)))6TXZ3B<\]^9W*'.<M1.$
M3A$X1.$3A%_2LZPM4E:E\,EUM'2Y%5IU4 82D+-RLD)C>'%$UMHHF8;:#'23
MK<WC7#8;E8F+R@LV6W3T?YVV22^:L:_]SBW^IU_XJ5<]NH<P]2TY?'R_TH5[
M_P G::_L>A/,S\!OHU1?O*S\7,N+-^F>8+#;SURVDX1.$3A$X171=G.Q;N\9
M\RD,<<RZ/1=M3]"UHK&R)E7T=5W4]'5]5AYYZ"P>*#LCSIB(/S#-';7U7+)^
MCAZGJZ]7TQUN&X>*&!T<G%22FLKJD2,9F!55L]2P:3@':3&2M83O:;966M[]
M(Y$VL!T:_,5<D9[B4L[.V!?P^)V?CLA9?7%_01B,/-HMI30$M(Z7'T)+[.$R
M% EO+RFA2#H$R8:MWT39-(_)RVBN\V+BA38>XZYF$5@CIZ!TM-^;Z;$!7,E;
MQORQ[(ZQU=#3.B+!"S1F+6OJ6S.=)&T_X#7/+EJTVYNL=(MT;9$7M8&^1U;+
M*N=_$<A+>P7<O;5I*"(HQ=*<S/A'9<4+=/*Z/]2WG5N=@6!9MJ4];)8Y&&S9
MJ-E?07C%@OZW+.DU=TEFV=GP?F-,V U$37LHN)8\,<X-J(\6&*0/<PZ.G$',
M8R1NDUSAI 6!!02 :@<W7.H6&B6Y'//.^Q1S".W%,4.TIR!T['K1F-;QN]3M
MOW 4LUM$XS*9Q')A7V:<DE7QV.Q@U* P@;M5AJ<B'4B?R1TYDA:4).E@\?8B
M&S-3D3X565QK)ZN2FAJ)*%E)2,IC++%!)#4&LCJ9)9612.=\J9 \1MC B9&0
M'R.>7('M;8#2(TB3>P.8T;"U]E]H]JJ.Y/$2'V'45GP2,P0I'99([N=/*[E+
M]V+(-8=U9:&H+,HG2CX;NDN@0(1^;U379?5SA#8(NV:&&>[;9%WHCG:H^#[J
M>KIIY9VR11T0;41-#FNFQ-S)X9:P.N"&R0550RUQ('%C@01=4RW! %CI?-)S
MLW(V-[[0,M1VWMG&$([KOY:3MH+VI1+S>"7538^G9 2JR-5G7\PB+>-6;&;=
MATG !@D:C42DCL1,(SHD2%'<#US88H[9>R,?EF/V1Y4V#-B;2OPS0@GHZQU7
M&VJDJ9X93)32TDT4CWRR31M?%*2US-(,>T$1NTG Z1(3?3S!;HW  (SZ]OLL
MKFNL%]]>4;AZK4-7S">L:-KJ4]F[,GDVMHQ$H=-)U*;3H5Y#GK1JWC[L['($
M,&1J$!0,>Q@_)7KXX6=$7.^N^[,;IUN)4->:/%*ZH= ZMJ(<,IX(*1DTT,$5
M-7LF!)D:R2=[I)GR2?,C:&-#0+7<M3'#28T7#1I$EU@22T[M5MF>U6,W!;M5
M+TI7W7NDF5A.8;&;*GUQR27VBTC8F3'9C.XW!(@V!C8[%2LA%"([$X_ VR>A
M'<^](R@L9($7+ "U:CA2/=4E)5"MJ*^M=3B:2G@HXHJ4RNBCA@EGF+W22MC>
M^262<G1XL")C&M#I"7.6AQ;HAK0; DW-KYV&Q6H<[1:$X1.$3A$X1;__ /R>
M?_1K0C^=&VOZS9Y@OA]](YOX6C_Z0N9%_EM\_P#R*L_\4#P'[2[3=CY-V/ZW
M6+70AY9FHIY8,(M)])0C=A)!(=B"W.1@['HY+<NF1IB-8N'P8@-8;CRFCYVU
M)/6Q%)@+[;@UPXIL,P^+#L1IZA[:;2;3S4K8WET;WN?Q<D<DD5G,<YP:]KR'
M-L"UI;I/.82;C;KOT9:]FS?SK&O^C5]_/GWU<^\.R/W.<]%XQ<!^PQ3T:F^-
M4T#O'7V)^C5]_/GWU<^\.R/W.<>,7 ?L,4]&IOC4T#O'7V)^C5]_/GWU<^\.
MR/W.<>,7 ?L,4]&IOC4T#O'7V)^C5]_/GWU<^\.R/W.<>,7 ?L,4]&IOC4T#
MO'7V)^C5]_/GWU<^\.R/W.<>,7 ?L,4]&IOC4T#O'7V)^C5]_/GWU<^\.R/W
M.<>,7 ?L,4]&IOC4T#O'7V)^C5]_/GWU<^\.R/W.<>,7 ?L,4]&IOC4T#O'7
MV)^C5]_/GWU<^\.R/W.<>,7 ?L,4]&IOC4T#O'7V)^C5]_/GWU<^\.R/W.<>
M,7 ?L,4]&IOC4T#O'7V)^C5]_/GWU<^\.R/W.<>,7 ?L,4]&IOC4T#O'7V)^
MC5]_/GWU<^\.R/W.<>,7 ?L,4]&IOC4T#O'7V)^C5]^_GWU<^\*R/W.<>,7
M?L,4]&IOC4XL\G?S)^C5]^_GWU<^\*R/W.<>,7 ?L,4]&IOC4XL\G7V)^C5]
M_/GWU<^\.R/W.<>,7 ?L,4]&IOC4T#O'7V)^C5]_/GWU<^\.R/W.<>,7 ?L,
M4]&IOC4T#O'7V)^C5]_/GWU<^\.R/W.<>,7 ?L,4]&IOC4T#O'7V)^C5]_/G
MWU<^\.R/W.<>,7 ?L,4]&IOC4T#O'7V+T@__ ":3O0Z*,&YNS.LH@0JZ1T)$
MV4QL<P\9,]M\8<.&HO:JAFA!PDGYVR+10DP374QJGN\;Z[95TTO_ "BX(&.,
M=-B3W@'1:Z&F8UQV O%6\M!VD,=;<=2:#MXZ^Q;20[KQ">H7A[,^O0:323,6
MJVOT!3R8CAK=61DRQ&3Z'I+(VH94X+:ME#DH+E"*8KU_32&-7V&:;YSJUTV6
MQ+BF(2XKB%5B$K6L?4R:>@TW$;&M;''&'$#2T(V,:76&D076%[#< L -=MJM
M \8/PEY#XAOM<V)4\[C<+N&M@Y&)X83G!1*'2Z)$"/KNW:.BP0<9*@2H(FL1
M<,7"(4HU(HE7+5VFUV1;.M/2<$^%,> ?**>J@DFHZA[9=*#1,T4S6Z!(8]S&
M/9(T-#@7M+2P%I-R#HDCT[9V(ZU@5_1J._OS\ZM_>'9/[G.>X\8N _88IZ-3
M?&K9XA^]O2>Q/T:CO[\_.K?WAV3^YSCQBX#]ABGHU-\:G$/WMZ3V)^C4=_?G
MYU;^\.R?W.<>,7 ?L,4]&IOC4XA^]O2>Q/T:CO[\_.K?WAV3^YSCQBX#]ABG
MHU-\:G$/WMZ3V)^C4=_?GYU;^\.R?W.<>,7 ?L,4]&IOC4XA^]O2>Q/T:CO[
M\_.K?WAV3^YSCQBX#]ABGHU-\:G$/WMZ3V)^C4=_?GYU;^\.R?W.<>,7 ?L,
M4]&IOC4XA^]O2>Q/T:CO[\_.K?WAV3^YSCQBX#]ABGHU-\:G$/WMZ3V)^C4=
M_?GYU;^\.R?W.<>,7 ?L,4]&IOC4XA^]O2>Q/T:CO[\_.K?WAV3^YSCQBX#]
MABGHU-\:G$/WMZ3V)^C4=_?GYU;^\.R?W.<>,7 ?L,4]&IOC4XA^]O2>Q/T:
MCO[\_.K?WAV3^YSCQBX#]ABGHU-\:G$/WMZ3V)^C4=_?GYU;^\.R?W.<>,7
M?L,4]&IOC4XA^]O2>Q/T:CO[\_.K?WAV3^YSCQBX#]ABGHU-\:G$/WMZ3V)^
MC4=_?GYU;^\.R?W.<>,7 ?L,4]&IOC4XA^]O2>Q/T:CO[\_.K?WAV3^YSCQB
MX#]ABGHU-\:G$/WMZ3V)^C4=_?GYU;^\.R?W.<>,7 ?L,4]&IOC4XA^]O2>Q
M/T:CO[\_.K?WAV3^YSCQBX#]ABGHU-\:G$/WMZ3V)^C4=_?GYU;^\.R?W.<>
M,7 ?L,4]&IOC4XA^]O2>Q/T:CO[\_.K?WAV3^YSCQBX#]ABGHU-\:G$/WMZ3
MV)^C4=_?GYU;^\.R?W.<>,7 ?L,4]&IOC4XA^]O2>Q/T:CO[\_.K?WAV3^YS
MCQBX#]ABGHU-\:G$/WMZ3V)^C4=_?GYU;^\.R?W.<>,7 ?L,4]&IOC4XA^]O
M2>Q/T:CO[\_.K?WAV3^YSCQBX#]ABGHU-\:G$/WMZ3V)^C4=_?GYU;^\.R?W
M.<>,7 ?L,4]&IOC4XA^]O2>Q5K7G_)F>WI&8 VMHV]0,6@>[Y#,E,0P[.9?*
MFXO7?7+G4$!*U[%!;PBJGC9-OD@>8M4=]L+*Y6U3RW5V:C\HV$MA>:6DKY9P
MT\6R>."&(NV:<C*B9X:-9T6$G4+7N*(';7 #DN?6 ML_V'1&LI]U&K2//CPP
M1!8'/H5"P:2*3X<]C\1@D3!M$Y"35*,ETG H4R9[,%4A!7+YUNX]6R-QC"JN
M'IYI*F>:HE(,L\LDTA L#)*]SWD#8"YQL-BY.I89_%I\$>PNZMX)=CNOMAP6
M.S8_'P,>L&(6:X/"0A%6,,M1(>2@9#' $G=(O-@B \20"O@VK;; Q!^V*:*+
MKM,^]X+<,H,'HCA]?3S201R/D@FI@Q\C1*[2?&^.22)I&F7/:]KP?G%I:; K
M9DC+R"+ ZC?;NU K$G^C4=_?GYU;^\.R?W.<]5XQ<!^PQ3T:F^-6WQ#][>D]
MB?HU'?WY^=6_O#LG]SG'C%P'[#%/1J;XU.(?O;TGL3]&H[^_/SJW]X=D_N<X
M\8N _88IZ-3?&IQ#][>D]B?HU'?WY^=6_O#LG]SG'C%P'[#%/1J;XU.(?O;T
MGL3]&H[^_/SJW]X=D_N<X\8N _88IZ-3?&IQ#][>D]B?HU'?WY^=6_O#LG]S
MG'C%P'[#%/1J;XU.(?O;TGL3]&H[^_/SJW]X=D_N<X\8N _88IZ-3?&IQ#][
M>D]B?HU'?WY^=6_O#LG]SG'C%P'[#%/1J;XU.(?O;TGL3]&H[^_/SJW]X=D_
MN<X\8N _88IZ-3?&IQ#][>D]B?HU'?WY^=6_O#LG]SG'C%P'[#%/1J;XU.(?
MO;TGL3]&H[^_/SJW]X=D_N<X\8N _88IZ-3?&IQ#][>D]B?HU'?WY^=6_O#L
MG]SG'C%P'[#%/1J;XU.(?O;TGL3]&H[^_/SJW]X=D_N<X\8N _88IZ-3?&IQ
M#][>D]B?HU'?WY^=6_O#LG]SG'C%P'[#%/1J;XU.(?O;TGL3]&H[^_/SJW]X
M=D_N<X\8N _88IZ-3?&IQ#][>D]B?HU'?WY^=6_O#LG]SG'C%P'[#%/1J;XU
M.(?O;TGL3]&H[^_/SJW]X=D_N<X\8N _88IZ-3?&IQ#][>D]B[+/_DTG?15T
MW2>V+U>9M%%M-7+I.=V4Z4;HYVQA171MBH$<K[Z:^7.J7JR6%-L8URIIC.=L
M1WY1<" );3XF3;(&GIF@G=?Y8;<]BG$.WMZ^Q;<_1+J0 Z0=8J[Z[@CZ\M6B
MJ98G)9:NS];<R66R4HZ-'R;<9Z2[P-':NW?H AAETY6;"63%-TZ=O,.'2V*L
M;Q63&L2J,0DC$0E+&QQ!VEQ<,30R-I=9ND[1&D]U@"]SK -L!R&MT6AHV?W/
M6KON=2M2MM<]P.LK4B&#*W-#=S<CNJ3]=(^!;.W+P\;NR$K;H3&O!(-FT7*D
M#44W3VVD:C1FJ."HYT<D7K=NHFKL17)<(J LFU*\IZ/-)79TM$0N./Y/$H6S
M+FE5$6;B53R1CHE#P:>Z::NV7T@DI<:''Z9UQJH\>(Z;[Z:[9VP3OT*O^$5"
MF;-@,>GT)JXU*10VP;'%RXU!HFY5WU+285 DPJLQ?#$L)[)JH1Y.1!-R&=U$
M\IZDFV=-=_.V\TBKKA%1 &R(-)YE/:^ 2-@3F=7[QE.?1]OAQA[&-YD'V/Q?
M4AZHBFAG)D/IL_:>CK+X]0QGU7*>_P#@<(JWX16^]@>U?77JL' '>PENQ"K&
M$J?OAL8TD3Q;).1.Q;/UQ+Z P8UN_-E4@P_S7YITQ'KM0S+=-T37:(*IJ;%0
M"=2JMQ>E/(4XIV$UL:*O:1TAWM@XLX232-1%>%99X(8DK,H(].2?"]F>?5]5
MV6%\[:^7&NN=\9UP4MG;;J54Q6?P><KREK#);'92Y@\DWATR0 %V156+2U,*
M&D2L9/Z,UEMA)Y %(@15P)>X1?-V1=@NLAIJY3SL1=>P['@]3Q9Q-;%D;"*1
M5J4C@5P:)>K^B)%)=(A42C;+;T9%=7U4M(S8H2V\B6=/27J65=DTO/4U)WZ%
M6W")PB<(G")PB<(H0[(NW+"C[$=M)*SA[E ,ANE)7Z!)RS$[9*,-?2%T! LT
M24TVQME#&K04]4QLKKG*6-,;J:$4W\(G")PB<(G")PB^<[Z8VQKG;7&V?X-<
M[8QMGX?)\&,Y\N?A^#X/]?"+ZX1/+C'D\N<8\N?)C_KSY,Y\F/X\^3&<_P#T
MQG/^KA$\N/+G'EQY<?PX_P!>/+_!Y?\ Z\(OS;;73'EVVUUQ_'MG&,?^.?)C
MA%^>?I\&?.U\FWPZY\['PX\N,>7'P_#\.<8^#_7G&/\ 7CA%]<(OS&<9_@SC
M/PYQ\&?+\.,^3./_ *XS\&<?ZL\(F<XQCRYSC&,?PYSGR8_\<\(OGU1/_P"?
M3^EK_P#?A%]\(G"+\QG&?+Y,XSY,^3/DSY?)G^+/\6?^KA%^\(OS;;737;??
M;73377.VVVV<:ZZZZX\NVVVV?)C&N,8SG.<YQC&,>7/P<(OW&<9QY<9\N,_#
MC./X,X_CX1.$3A$X1.$3A%!\X=N4;MHEHG)68QL\96OLYC:R!)1W*,M@ +=!
M1FNV%NAR&H+;?=VYP2*"ME='.FK'0@KA5)$BG#A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$6MO67AJ=L:#[@3+O# $&\LG$^[G]P0\CK.
M42J%$PD8Z@=CY7[(XO<--J%%&S.&VM%).S:2N6QY8JW,6%''[R$DEQJ+-LDL
M6JXM:ULM?*+VZB0K)_<G]V.D/6ZW;PO.6R\=;E7G>N\ZJ)!E:,HMT9VB[:55
M;4JEI!\VA<-82.4)HW[7[\Y6+\K,"$8('-9J."R6$#&L'#'ER97WC/+(6!Y3
MEET;M:R[R_I!?#_PS^M?7MJNI.[]#79U2OB[RDEE#?14A-1_92%=@.PA%(V;
M=ZZ.6H<BI,$HT-T6RJJ*&B@XU#SM6Z'"EQ<[LP/."!_56,J^%WWP$5\16K&1
MFH+<ED]?N^<+MZ3O.P,C5;2"23CMS$+#ZV1=%=M)#"<;;$*#&RR(#I'#Q33%
M?.9.\4([MRCARHJ5N,KZLM8SU6/F&X\F1S7J6AX;O;.SX V&U/1 WJJFA3GB
M(Q"%P=_VM/W"3@1Z^8%1 JK,J2LF1?)0WV62R 2YPM':S?EX=#FZK20OWC<[
M(C;9)W[]^E3*XVVM?+SD>S/U*B^PG0OQ(>P#*YYJ0K.20U_/+FI^;1.K0_92
MNY0U% X7U,1IXCI*XJ94"06:,G-@M-RCYH-LNMS\-=DTYW"3$L/BTT5"H(%]
M6HB_+GGJOJ-NB_)(LIZ#>(0:)%9%8,6%6K"%I1T3.6EUPAG9&70H!>@.HNH,
MHJFVHK%["E4G>RT:,BUYEH[.4!]DR%EFT$(Y@F?/$"J399X2XZK G9F3?^HU
M9VNHU->%CX@!FNW+F1&3,@MR#=2Z5CU#DF79"2[XKFZ(UW9LFU]X]@\_D0-6
M3%ZMZVRN.UHA8\H'N4#Z0I^-%/'.CG.RQ+B^_,WRS.0]MSKRZ%EM[;T_V1CW
M;VA^ZG7NHXWV36K^B;HZ^R:DI%9@6J28C6SI' 9B'LV%2:4"2L:V<:.X,I$I
MP/<[,"J\<)L5A'KKLU=,,._-WYOZP:K;R/;VK'[:?AM=L;2%=A9C((%6<0M9
MUX<L%J3KS$^O-BGZSHF =FBBU^,;-;06#J2<:Q$M&D7L".A6$REPS9NJX>EB
M07<>X\[+4K<9?M$YZ[9=>2MZN;PL.[>9;V,VK&NE',$G_=6?]@C B.WZ/CZU
MXQ*QJ,TC\!4RP,2@.S!EZ)MG,K.%$).Z%^FJ3]I((HC)EJ_ ,-B7%AO MT7]
M=[:CJ-]=U.3[PQ>W;V,=AI3)GQ^:]@"N_AI1NH9V1OTF_P!EHQ3"/6E;MD^V
M4R_B8'4M)257R14O(3$+CYZP=6"2S1@TT.+#UB \ULS:VVQM?IL-RF?H#U%[
MMU)W]M2^[MB;6'5C8M?WT!E#.,W"ZFT/D4_*=@0<SJR6#P<FFTOGI%!:L5"C
M-M(I>Y8E@+]0W$1T+@T2; D390D6MMRS\QO[!RVN5GUX43A$X1.$3A%"'9%-
MVK1]B)L&,=).]@Z&$&,M=BV$<<[^NC#.="KPT1$BT&^-<;;Z[O"+5/*VJ6N%
M,J;::;$4W\(G")PB<(G")PBPC=Q8OUC>=U;0,=INODEN0>4Z3TL I5]'.N%F
M71)FL[86QVG=RH15\PKZ!RAU6]@[-S$$<)%FT@B!)HNYCI?UU:I,$GS,J+Z@
M0+'7>UKCL'>X4(Q"UO$?A@2"5U*Y;=;[M!%P5#UYBGF]/!933\Y@:O3B%FK@
MOB17>K6I5-Y8P3L.O8[;4EM<(:/+2:&QB +P$I[+4R<F=_;[>X5RYAG?/,9Y
M6&>RVP[><>%/NP5NWA8'6.5'IAV;K>KZOE_5HY)[1B?5V5H2^!67,.G'B)Q>
M_P L.C4QHB1[OV3N4/*L@4O+/(%)XC7Y(TEE@@!)X6=ID&HZKD';RCEUZSR\
MJH3:W_$#C+EY/5Q-@0'>V7](:W';2D&/PR4X&1WK[+=Z]?.@PWJGVR2@9.?$
MVP8C8HMO0#IM%IJHA6+EY7S\XU;:E,KY^O(9ZLR+Z]AWFY5P7;HCVOM[IGU_
M3[*4I320=2>=.IA.96I#+B['MS1U10"1LIU:_25E4-82P5!19)T97)Q5O9CT
MXB@V:LBHV/.E'+0834<B?,;=8OR;%:E X7< /:K_ &*U49(0R,V%V.904N'Z
MW3FN*A+P2==Y_"'F")*L^MUL"9(=H>#!6J-NC(A%I"0..4GU4SBYX1(- B[)
M\%*Y9\MCKOGHNV[[V/GMR*YU*X>_T7C$!,R:SK^(@+;@<9EUQ2%.AH 1D?6\
M,/[5Q&OY>3JJ.QNE,O%ROM*R(D5)"Y^"M<@T:AW-AC0GH(HDT5*<ENO+;M.7
M7;I5Y'11>ZHWT^*$*^C*]L30QVI[B'QR_8XI(NM9N8PF5=L[L/A+#D#<31DD
M?!2\I /PLD9!VM2Q@01:F<.V#..,,-!W"&U_,-6>P<OM5Q=D+R"4=7KM?]K^
MN%82MC'HM*I6ZHN'2<KV1CMCAH"$:S@"QV:RFFJR<D921E 7+83%T(48PD18
M R#$J[(/<,1Q-HL2.75;K6,(KX:-,H4#TLZTR7K?5Q:<W):*TK['62)J<!E.
ML!Q"+&[WOH77A5 'OI54?FDLB<5Z\0)J(6%OHS SHW0"^3D4;9&$BH<;DWV9
M9Z]@Y[7OTJX/Q"[MLBHK,IVNJRMNW:D9&^L/;6<Q6.TA1X2Y"T[N&J"W7 12
ML.*B'E66>\%15=>P)$-68CD(BA(7;\:"5F =TL,PO+YG< #Z^Q0;=7G-NSL&
MU8\^P-]>(+9[GL962*-]1A&74KW+@)2OHQ!MMM(G+(;UDE<EKK2"JCNL"VH9
MC/I_%-Q5<SS;MG8DFM0++7RP&OH$<5!I0>]^U4 6OE<6RWW.VYV;<AT9K]FM
M[]ZX&YFB-'.IN"KP[*;@EL#M,E3!B.R>Y;)'5GUM3J]K8\<@G1B[R4I7E+9_
M*"3^/[PRBCT_((FH\-M>*[0%,"P*6YMVL;SGKY+<QORJ4>QYGOS+*3[%Y<6#
M?3A:R@?B25LVJN&5C#$Q<*#U5%9,<HYW71L34B-F.BLN> -X8(/EI.74FL=E
M7J49:-9>@"DC0@L".2W:>C5YE(4+)79VDOJYNJ]N6/V0F?6BV:^GHD7* L0=
M4P7A\0&MZT?P@[)7+OJ_5CJ)269CUBFXR412Z[1$V2I)#[5_3U6: G82*$RL
M-^WKY>G+=O6;.LH&PJVNH-6PLS)I&/@D4 Q-I(9H84D$O/(@AK<=@U*#BB3?
M)60%<M\OR[[1LT0</W"ZC9FT;Y2;)%%7/")PB<(G")PB@^<)O-KLHE1%C'%V
MB3*U_37Q%X+1D3#.X %JVQ&FCHBV)O$W:F-TS>PH<2U;-=&VY#9DCNDJH13A
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PBPE=S^SUG=
M6^]"-M)GIM(Z'@?52$!I[2PPH2<1TS+KFFW8T964J%1=-3<>K8IVXZPIREPQ
M=-MZ?D;9KMGNINVUUT3*@7'3NV6]A)ROS9*R6!^(CV;ZKTT/KV8V5&+DLZL;
M([$N+=/6LTV/GI@/"=^K;H9DU$2Z7WS4F8]'4!D/,"X<&KJ*7Q)X]JT"-G]>
M@(B-&8DA4B][ VRMK.L7MJ.?G4KP_P 2#LM Y,'K 8$CLT'BI]+";\M:<FA"
M4KM4?8/B%]CZ2;0Z$2>QNQU5'16E;P^# (]%TH15W8!PH=+1:+E0<.$I@]9"
M[]^_L2PZAD/V0;ZMI.O+?FKXNYG=VS>O]JS6*Q(E3(0;65'U;<8V$V4(/O[
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M&S#.-Y@9H.XX%K+EUGDRV;#FJ?Z_PNJYG".QV\M"R$M.(;2<BG<$=HE]1L8
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MU\Z4QLN[=KJN%]U%5-M\ZG/>\@O>YY#6L!<XN(8QH8Q@))LUC0&M:,FM
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M5(2]I^W!Q!] ZV9#YI!'M$W-X:4"OIVB07B!A]B-2ZT&':61-&:P]8;)*G
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M<ZPS<23F5%A%\5WLMV)K7N?-XG7=ZV[!8NSBT <M([$+%ED<"-G#Z+,'+Q=
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M:7836PZ[ZKS&U;3+$Y]8H=R/M^/5G+[C]AB+2'RT2%T%AA3N'P@_JBVV<^N
M,NN@Y2>N%U]^RFQ'$ZFD;B=)B#J>EJ\:@HJ*-E+22!U#+5P4'R@NJ())-.1[
M:BHBN0-"2,$%H #(D#S7Z.4\NHBZAKKA2=6S>ZZV2M!L%(PFY=IFXA]=5E9P
M@H5BCYDDL\'"+(U3-$IW$@XQFHIN-2*Y1DDF5&HI9(:(;$R"788KB-;3X?6?
M(C(RIP\4XJ*NLHY&,G:XAKY*2\;::>1Y%G%EXH0^^@3H-(C;;(ZO/T$VZ/;<
M#UQZ,UO/J8K"5S9UH5DD]NZAT#A(!/8ZDA%*ML0I.02D(U#-3F[_ !/Y"\!
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M!W+2X^.A\J'8C(+!ZZ"645DV#8:6RDYOCV&$%MMO58;3K YM>K4H#N*0=G+
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M@.DO?3< YUR+I<]'?S^?9DN-272=4N5D"LH/*'CB)-N;-J&R.Y<RW--U6AE
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M$"*C8<@JMGSW"+A%2<'Z3C9;2U4H<*2D#K/E</\ [><RR!AMQDEO_P"+ YY
M1;IE)4E7'7JN(_5E6 $0$4CR'FIZ>758D6(+:Z9('CQ#"::A0X55TPN_?JZZ
M^=G";=LDV8MVK5#Y^Q'$:O%:N6MK93+/*<]C(V"^C%$VY#(F V:T<KG%SG.<
M2ECG!10!8&@O:_.O.[IB87)Z,+C]:GK-TV2$,==HY'L$-3+90<X<.MG:.$DQ
MN6Q =ANOHKLOJ]UWU32(I_X1.$6E=XNGQ_[P_P!FK+^RB$<^@> GT8P_]NM_
M&U"+9/\ "Q^(-UV_W'+_ .TF9\Q+PS^DV*_O8?PL"IU^9OJ"UH?%E^/_ 'Y_
MWU=_V4P;F7N!'T8PSFJOQM2HM@7P8/B,1/\ E[8O_'L\QA^4#Z1S?PM)_P!9
M1:]/BJ?'][$?[W@_]EL&YE'@5]&,*_8J?QM2BV)?!L^(=7O\KK+_ *Z%>8KX
M??26J_<4GX=BIU-YO:5KE^*'\??L?_*:,_V=P[F5N!GT9PK]U-^*G0Z_,WU!
M;(O@\_$%J7_?MH?VE2GF)N'GTGKOW='^#@46"+QHOCRR7^;VN_\ A"O,D_D^
M^CD7\75?\VHL]GA"_P"C]I#_ &ZU/[7IWS&G#KZ48C^S1?@:9%@ \93X]]@?
MR0K;^IXWF3N 'T;IOXBK_P"]R+,[X''Q,S?\^$W_ *M03F/_ ,HOT@9_I]-_
MV5"+"SXQGQ]+,_DS6?\ 4,'S(7 +Z,T?[ZL_$R*G4WF]I6;CP1_B5;?SO3S_
M -E&>8[_ "B?2$_P--_RE46)_P ='XX<1_F#AO\ 76R>>W_)Q_Z&?_4ZC\/2
M*G4WF]I66[P4OB1#?YT+ _\ 5%<\-^4+Z1/_ (.E]3U%ENYX=$X1.$3A%9E:
MU\72O>KKKMUO@-:2>:1"J(U<]ER6X9K)X=$0,<GDIF<0KF+A$H?#9D9,R69%
M*WG[AX1509"H@)CJ3UP@?>F&0K4G?M43UMXH%$S-.#B9+&[-ALX-.H''+&$-
M(+)YI#*:GM@W1.>M\?C$XM&/!MHDW:&;XK>85]'CVRC9$IEBTD#MD(".U'34
MK8]^:_J[W7JB?%"ZJG8&I8HA]9;V//Y;'(5!=M:KF*"]KG94UF9(.WK/=VP;
MCY#NF%KN;R"0M'#\83A4>CKDU-F$='O!*Y ECZ[\EM_?VJN^O/>"N.S%J3Z#
M5J%DCF&PZFZ>MX?9Y,45#@SJ-I';3 $8RX'F!8]W'SD*(UF]%%V117!'V0-Y
M>!=C1CR$$<NB6MW[C;WR5NEP>*G7PRMAYNA8-/9_/YS(Z.'U&*FU;67#HM84
M$O&VHY506ZHP_P!8PY*RRMV3X^U50V!,L&"I(S!1>[84UL&+EWI ,\\M>[*U
M^7DVV5VMV=QJ>Z\RZ)0NT?9PR>2=2$(.9*$KV6&H'&E;%F.U?P[,BE[0=L(:
M;')<DN/PP9."98,R2]?I&P$1]5N56**#99XEM2C]HEB#5]<T^:S*ZJ[J2/R-
M"KIV#A,G'3&SE*M.SV$S%_'% LK Q4^U=-DDFR[123+N ;D&JO'#S"1[E;>J
M_5=>$'[M=-K+@E375<Z<)]ED#>PV11XP0A$B-H5_([(Z]FKM<3NNRTKB(F3,
MXDA3 >>DBT[3"A5&0^'30*42:%P9 6F2QSU[NL>VV6:N"J+NY0EU0NU)M$BT
MG',Z8CS67V&$F$/.Q24A(@4CQ651^4>L)9LDZ<AI&%!&UA*R'GKX?!3(,DV'
MG1!,8T(01K[V5IS#Q&9E"A\:L+L'%.OD#K^=T#,NR(RMHSV+"%^T,!K:-5E)
M;9#D954LH$1'-@^R".1,T&+JU*\/HPZ9-]V&F99$1\@G0,EM=KVWD6Z]04WU
M[V7[!#;-HF%]CZ?K2"A^T+.3IU8]K*RS\Z+PR;1B $[66K6SFAZ#1!D\>OJ]
MCTL)MIG#W3L(F<BI  N+U0(!3;\EM=KY<FSIWKWY7XAO5:$FR\9DD[(#Y*$&
M7X3(1_,6D"Q=/W.4H81*=#4V2+'=54V;)$FKJM0^F,O[)#95,1% FP156U)8
M^KKU*UDEXK;(:9<!&]-2F68%RVE@CX[!Q$Y.#B[6W>S=X]=]A,5%KPH<;*3,
M"XIW+IJ+RVU824XZDS :_2 Q!:2$R6]O0 #ZN^:F77Q+J.V/#D6[>:&!LE%0
MH5%(C'JTLLM=*]K'[ [,5X?KH]7J<4T1"/(Y(^L<]CSU50VJH+/ 3ZDD3"1M
M(-("Y+'OYNWU6O=5E:?=F.BNOE/7E4+,$?&7S8D+K>&FK:*&*E@\)(2MT<:O
M2]NDR$?('8>A'WL;*1?8*L#P2+6(YCT)36'KG-"C0EM?(+[^_+N%]RE_JCV#
M&=HJ,C-QBV0H?J5/V1#BC>/2'271C:25/9LPJ:5/8A+$V G$IA9220DJ4ALC
MW$B5CD7>"2;D4-<NE6+<H<N_?^BN+X109V7>>M]%V,\]DI6'^CAD-_9*$2=+
ME1/E*C]?2&23)\,=;J[>=ZCG"+YOMZFKOG.^=<9TV(ISX1?F<8VQG7;&,ZYQ
MG&<9QC.,XSCR9QG&?@SC./@SC/P9QPB\3V,1KYO _JEA^S\W..E^UD_G=VHG
ML8C7S>!_5+#]GXXZ7[63^=W:B>QB-?-X']4L/V?CCI?M9/YW=J)[&(U\W@?U
M2P_9^..E^UD_G=VHGL8C7S>!_5+#]GXXZ7[63^=W:B>QB-?-X']4L/V?CCI?
MM9/YW=J)[&(U\W@?U2P_9^..E^UD_G=VHGL8C7S>!_5+#]GXXZ7[63^=W:B>
MQB-?-X']4L/V?CCI?M9/YW=J)[&(U\W@?U2P_9^..E^UD_G=VHGL8C7S>!_5
M+#]GXXZ7[63^=W:B>QB-?-X']4L/V?CCI?M9/YW=J)[&(U\W@?U2P_9^..E^
MUD_G=VHGL8C7S>!_5+#]GXXZ7[63^=W:B>QB-?-X']4L/V?CCI?M9/YW=J)[
M&(U\W@?U2P_9^..E^UD_G=VHGL8C7S>!_5+#]GXXZ7[63^=W:B>QB-?-X']4
ML/V?CCI?M9/YW=J)[&(U\W@?U2P_9^..E^UD_G=VHGL8C7S>!_5+#]GXXZ7[
M63^=W:B>QB-?-X']4L/V?CCI?M9/YW=J+4I*]'["[C>(CV7C$7;;QBM8U=LO
MWL"?Y98]:8R+W..-M!0E+R)MR,H)(:;Z!PR6V-4]<;$"&6XUNHKMF]G".EP#
M@KA$TQ$U7-AT'R6ETOGS/XL7DD.99"PD&20YD_-;=Y 5.OS#U!;3=)TG7'7N
MN %659'T(_%(^AYJ:>OFJD"I!773T\Z=?^9HJ4.%%=,+/WZV,9WSA-!!-NS;
MMFR.&<0Q"KQ2KEK:V4RSRFY)R8Q@_1BB;J9$P9-:-69)+B28I7YPD3A%!<[>
M>HWC0C/V2E1GIK*V\^QMJBZW%R?T:/@E/5"RJ3Y!JCN"\_TH?AVQ?Y46<JZM
M]FF^-U%"*=.$3A%I7>+I\?\ O#_9JR_LHA'/H'@)]&,/_;K?QM0BV3_"Q^(-
MUV_W'+_[29GS$O#/Z38K^]A_"P*G7YF^H+6A\67X_P#?G_?5W_93!N9>X$?1
MC#.:J_&U*BV!?!@^(Q$_Y>V+_P >SS&'Y0/I'-_"TG_646O3XJGQ_>Q'^]X/
M_9;!N91X%?1C"OV*G\;4HMB7P;/B'5[_ "NLO^NA7F*^'WTEJOW%)^'8J=3>
M;VE:Y?BA_'W['_RFC/\ 9W#N96X&?1G"OW4WXJ=#K\S?4%LB^#S\06I?]^VA
M_:5*>8FX>?2>N_=T?X.!18(O&B^/+)?YO:[_ .$*\R3^3[Z.1?Q=5_S:BSV>
M$+_H_:0_VZU/[7IWS&G#KZ48C^S1?@:9%@ \93X]]@?R0K;^IXWF3N 'T;IO
MXBK_ .]R+,[X''Q,S?\ /A-_ZM03F/\ \HOT@9_I]-_V5"+"SXQGQ]+,_DS6
M?]0P?,A< OHS1_OJS\3(J=3>;VE9N/!'^)5M_.]//_91GF._RB?2$_P--_RE
M46)_QT?CAQ'^8.&_UULGGM_R<?\ H9_]3J/P](J=3>;VE9;O!2^)$-_G0L#_
M -45SPWY0OI$_P#@Z7U/466[GAT3A$X1.$5L%O=7AEF3\=;,3MJW:$M%O#%*
MW,SFG'T U(2^OO75T='Q65!K/KVS8D02CALB8+Q(XWCS*4Q=\=/X#G6S(Z79
M/2M_/S_TMW\RC<%X>G7^+QPE%(ZI/!(4LPZO,WJ6DG0(/G+KJC=<B[ 0D\\,
M&!)(P4DLVLF5GBUK'B[\@1EV2#ERU6"EEW!18ILMS]=NQ04]\(;K2X5.2 Y,
M[,,R]U)()+A,]DPZAC!:/E*Z'V>%#D#@XI2*T,N$R_C5P3R-26:]AXQ;T]-B
M"+)9W+-30@:8;E;\UMVS?YLP-5@KE>O'42HZ,,.Y'64SF)\8\J*-4%*0)8O"
MSL7D?M63NRSR,D,IB8D/=CIZ/DUEV4&.C(Z3 0AJB6<AM8$/5""=19+WZ;[>
MCFR"C>)^&O3D:Q!TB%B77-&=3(4H"IAC+)#"E4:EKVAK>A5UPNLHPL"KX$],
MQA[*ZY@H^3F)ZZF-@F(S%@XO6:M'""I!=WZ$)SOJOK\]]]]ZZ?:+HIUP[ WC
M$[%M.SI)$)Y)@E?PJ-19B1IM-Q*?:1F\@N$ G!7%B5O+["CQ1J7./W\Z;5+)
MXNC,(Z/%-)JR*#12?E)<VMW[VRZ5ZC;PZX"R'"@#*\NR#.)PJ7Q>84]#$)A!
MO8E2[F*6VQN1@.AH):MEF4C:;2$<UCZ!*V4[)DP*":*Q.*GP#)X04=DOR#EU
MYW\_JL-X7XQ\,CJ\WTAS<H.F4E80_J86Z:8&'9&AN.D=4%!)J.:%Y(V%B1>J
M]B"(O+K"BP.7"LB%!T?LF<#DV.VA9OLQ)<F_*;J2>M?2NK>LP&P   K(YTWL
MME'PTIWFH>L!+5U'8P%?@1(+$;JBN:RAB^BC,L76/'"$:?2R5/2;A>32 MH@
M.18E._?O91"R\.JDHVC"4[*MVY+*I:F LF"UC3EPRROW=7US')/7$OIMR)<2
M0?7T:M*9B!-76!+8*!0M>T)PDP$&UEEMGAI!B4:E;].TYW.W?OS4K57TRC=<
M3>!3B17)>MV.*?CYJ,4D%N*10LN&J49(!J( J[!;Q& 0LY+)2O%D?8BG.+2-
M3^9MHRY*CVYY-2021T8)?F&_EZ\L]V7)JM04Y\,_K-8=X2/L#(FLVWG<INB@
M[U+(-)&T0CNTPZ[Q8]$8B.0%;A5MT8I)1L@<KV(!P[VTEQ%H/=N'#;U!1-<E
MSJOL(\QUKG ^'/3$;EX"6B9G;:&@,U#9(M&=SD-6CIZ05[V%M3LG"RQC"L#V
M.Z+@)K=-C@TD IT.Q?P\]HP+M"!L6+D#,E[]^2WL'1SKOQOP\:,B]I!K<'&;
M(4DX*S"UK,VSL\!5#;R4S:7;:W7;=PU3BJ+K<1K*.YUL-T&NCY-UH&&0AIN]
M4=""[Z0$)OWYA[%7CSI_!_<\".N$?F]E1.+@9 M)!<D$OX@2DF[QU-BLZ>#C
MXF5PN15Q,XR_(F7X\A%9G 3X!V+W;;JL,F1X\PU)?D'?KZ/4I<I&FXA0-8QN
MJ8/L57!1Y0^05)GG3=Z?D4DE\E,32:RV0.F;,:P6D$PF<B/RDYN,&"Q6"I=W
MJ+%#!^&S!N44K<(H0[(JNT*/L15B2CX=WH'0RB2E3-F0C[3;)1AC*A1F0%FF
M;A#.N=D]=' MYIA7=/;U/&VN%-"*;^$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A%X("+1R*IE4HX$&A=#AXQ*#/K<U2;;%I$?=[OC
M!HBIIKA1X1?N=_.6=.-E%?4DT&VFVC9NW13W99I9RPRR/D,<4<,>F2="&)H;
M'&P:FL:!DT6%[N-W$DN_0O>YM(G")PB@^<*N]+LHE)(G'VS59E:_I8T@S9K'
MRF4P /9OM'7BPMT\9)L=\[JF=6105JZ;*M]'6A#31-)$BG#A$X1:5WBZ?'_O
M#_9JR_LHA'/H'@)]&,/_ &ZW\;4(MD_PL?B#==O]QR_^TF9\Q+PS^DV*_O8?
MPL"IU^8>H+6A\67X_P#?G_?5W_93!N9>X$?1C#.:J_&U*BV!?!@^(Q$_Y>V+
M_P >SS&'Y0/I'-_"TG_646O3XJGQ_>Q'^]X/_9;!N91X%?1C"OV*G\;4HMB7
MP;/B'5[_ "NLO^NA7F*^'WTEJOW%)^'8J=G-[2M<OQ0_C[]C_P"4T9_L[AW,
MK<#?HSA7[J;\5.AU^9OJ"V1?!Y^(+4O^_;0_M*E/,3<//I/7?NZ/\' HL$7C
M1?'EDO\ -[7?_"%>9)_)]]'(OXNJ_P";46>SPA?]'[2'^W6I_:].^8TX=?2C
M$?V:+\#3(L 'C*?'OL#^2%;?U/&\R=P ^C=-_$5?_>Y%F=\#CXF9O^?";_U:
M@G,?_E%^D#/]/IO^RH186?&,^/I9G\F:S_J&#YD+@%]&:/\ ?5GXF14ZF\WM
M*S<>"/\ $JV_G>GG_LHSS'?Y1/I"?X&F_P"4JBQ/^.C\<.(_S!PW^NMD\]O^
M3C_T,_\ J=1^'I%3J;S>TK+=X*7Q(AO\Z%@?^J*YX;\H7TB?_!TOJ>HLMW/#
MHG")PB<(L4W<:#]J)A<TE?5-.>P,.B$8@?3GV&(5041'1TI*Y?VPF,7[%/R3
M)R(*,I(2C/7QPR?OF!9%X'!#G(^5*BU3(H"2%E1;;R^K+KW>?)6B25KWYC&E
M@1;4IW"(D(=I= ;I$3CC<I)QLHM$3VHN$? ,]J)/@8]P;K%:D=:*T%R2Z'R,
M2-0!>PC6A@A9"0TCH[]^Y5RMNSSYLM7.;G+,<RZ-VTWW,E=9S;$B*]IILULL
M'W&+6#!V90NZ:!-*D[\T\4ZPL:UCP9FS?1TH5ZXH3U>.#H]ODM9L=T54+)R
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ME4.#CI$) GYKO*W2 E8EC_3SV]?>R]0-XJO4:_XVXAH.NI]<;V?%81"Q%*M
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MBNP*Y<E\B;@["=PW6OO5V_>3K_;EB2[K?)Q]36A>BT"ZX]I*\.OZFN@%2LC
MW'9S?KG[6\P?&G%B5,N[!Z'J^DYE=V%V*;1 H/#S%E%US06/(:E-A'*.J_\
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M5GCRC0B:1CKQ\W/MG!/6-JQP@.?D OVZ[#.^0SV=J]&[/$QFL(I6WIJE116
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MP;E.HSQ$+@ AF@N/Q"L@;EM+ ,S4)CQ\Q2P_.1NVU;A'/2,>S-<Q!V_<FUU
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M-\/^/TV^#^'_ !I._!_]?^G\6&X= 43VR;&^'_'Z;?!\.?\ &D[\&/@^'/\
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M_%X1/<JT[\DE_K\E^+PB>Y5IWY)+_7Y+\7A$]RK3OR07^OR7P_\ 5_\ U?\
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2X1.$3A$X1.$3A$X1.$3A%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>g65062g78m56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g78m56.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2/24&AO=&]S:&]P(#,N,  X0DE-! 0
M    ([:^D4(X0DE-! 0      #H< 5H  QLE1QP"   "   < @4 )D-O;7!U
M=&%T:6]N86Q$:7-C;W9E<GE$96=R861E<E!I<&5L:6YE.$))300E       0
M,>K>O:F53)2?Q<W@D!,,Y#A"24T$.@     !"P   !     !       +<')I
M;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E
M     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA
M;65415A4    % !# &$ ;@!O &X ( !4 %, -0 Q #  ,  @ ', 90!R &D
M90!S       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "
M4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,
M8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M 0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B
M;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M  !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L("!D
M;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD(%5N
M=$8C4FQT                4G-L=%5N=$8C4'AL0'+            *=F5C
M=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,
M969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M  !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O
M;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L
M;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14
M;W!L;VYG       X0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))300F
M       .             #^    X0DE-! T       0    >.$))3009
M   $    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M       !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9
MF@ &       ! #(    ! %H    &       ! #4    ! "T    &       !
M.$))30/X      !P  #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@  #A"24T$"
M$     $   )    "0      X0DE-!!X       0     .$))300:      ,U
M    !@             #P   !V0          0
M   !              =D   #P                      !
M             !     !        ;G5L;     (    &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG   #P     !29VAT;&]N9P  !V0    &<VQI8V5S
M5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N
M9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L
M:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L
M:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   \      4F=H=&QO;F<   =D     W5R;%1%6%0    !        ;G5L
M;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$585
M  $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585
M  $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D
M969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M!V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4
M>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E
M=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T
M<V5T;&]N9P      .$))300H       ,     C_P        .$))3001
M   ! 0 X0DE-!!0       0    ".$))300,     !C_     0   *    !1
M   !X   E^   !CC !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"
M$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-2
M1T(               $  /;6  $     TRU(4" @
M                                           18W!R=    5     S
M9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@
M   49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD9
M L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A
M<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,
M8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T
M="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M
M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                 %A96B
M  #S40 !     1;,6%E:(                     !865H@        ;Z(
M #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /A
MML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                9&5S8P         N245#(#8Q.38V
M+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M   N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S
M4D="                             &1E<V,         +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                                  !V:65W       3I/X %%\N !#/
M%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M     0                        */     G-I9R      0U)4(&-U<G8
M       $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9
M %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8
MRP#0 -4 VP#@ .4 ZP#P /8 ^P$! 0<!#0$3 1D!'P$E 2L!,@$X 3X!10%,
M 5(!60%@ 6<!;@%U 7P!@P&+ 9(!F@&A :D!L0&Y <$!R0'1 =D!X0'I ?(!
M^@(# @P"% (= B8"+P(X D$"2P)4 ET"9P)Q GH"A *. I@"H@*L K8"P0++
M M4"X +K O4#  ,+ Q8#(0,M S@#0P-/ UH#9@-R WX#B@.6 Z(#K@.Z \<#
MTP/@ ^P#^00&!!,$( 0M!#L$2 15!&,$<01^!(P$F@2H!+8$Q 33!.$$\ 3^
M!0T%' 4K!3H%2058!6<%=P6&!98%I@6U!<4%U07E!?8&!@86!B<&-P9(!ED&
M:@9[!HP&G0:O!L &T0;C!O4'!P<9!RL'/0=/!V$'= >&!YD'K >_!]('Y0?X
M" L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)$ DE"3H)3PED"7D)CPFD";H)
MSPGE"?L*$0HG"CT*5 IJ"H$*F JN"L4*W KS"PL+(@LY"U$+:0N "Y@+L O(
M"^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-)@U #5H-= V.#:D-PPW>#?@.
M$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0"1 F$$,081!^
M$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,3
M0Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7@5FQ6]%> 6 Q8F
M%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA &&48BABO&-48^AD@&449
M:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:' (<*AQ2''L<HQS,
M'/4='AU''7 =F1W#'>P>%AY 'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!(&P@
MF"#$(/ A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D321\
M)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G&"=))WHGJR?<* TH/RAQ**(H
MU"D&*3@I:RF=*= J BHU*F@JFRK/*P(K-BMI*YTKT2P%+#DL;BRB+-<M#"U!
M+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R
M*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43-4TUAS7"-?TV-S9R-JXVZ3<D
M-V WG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\
MI#SC/2(]83VA/> ^(#Y@/J ^X#\A/V$_HC_B0"- 9$"F0.=!*4%J0:Q![D(P
M0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T? 2 5(
M2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,<@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^%0[VAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M P$1  (1 0,1 ?_$ !X  0 " 04! 0             " P0!!08'" D*_\0
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M)738+%K[QLJ#+44=K!:/A*^1T:J4[-;/4"KI<]EK<@4UM:@A#!>19=A2"6Y
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M )V#YGD7P?\ ZN?Y6T[WC7PQY5R?#&CYFY'$_'7D/,?CSH<GK:7Y'=#T/?\
M@;:\Q>5O*7^S>8TZ'/<Y@^%N?7RFQY4H1S:JE#;N='QYNY+89SE6U=R.BX9%
MN10UXQ[&RGQ[59#BJM>2***>;@N[9#<UJ;EOB%?3@.1NLQ*CR=>80FPHPXFL
M!7"*O([)+G?$[]-'R-F=>^$/]5+\O];,\:=-H];XB\B]=W?BCQ-;VK-N;H^&
M./L][XR_)W\S_+>S>Y_B[5?7N]?X(\'\+XM\<:%%/54*S=777D:2:6RN_HV-
MN1T?!5KD"7U)5=>%]._8*KL/ H 9QQ"9.19=:"4.@NU^$@3*S%IVP"NJJSZ'
MJY"M72GD@#C8Y9O3T&P='4[2J?ZL/Y"]7B^/:WEN?$?@EUGI_ 'D#J.RY"[U
M:>8XOCW?AOWGYG^7N-\D#L.Z/8UZO-9-#PUA='1YI6#JZ=7RC9Y3&M6-7/J[
MFOI;HN*CV]COY "9-25V!.=MGO\ 5T^AZ2H55+L;W0N& [/-@%)48'%K7EPY
MV?#8H5@-EN\M*,FM $DN1O8V@)&CH<;K?ZZ'FK_Y>?C?L5L7\7NX\@>?^T"W
MF<KPFO?;3#QGT'E[QYX?X7"NV]/S '\?S%H:'1]%T7>\QRMCRWL>*,\.9J=C
MQ%:L_=WLK,^SU'=RU+9E56+7IK+5&^ZM%M]K "@;H"HJU/9V%O/-J[#\*F?<
M4Y6#=@%8\D@?M!&<D +Y3P I;@'\\3Z";1F_ZJ_Y,5-_N.[U.U\9=?C<3WOY
M!Z(9U.]'*>)?%/!]!^7?B?\ "?P87Y%/HU-/HLSF>)5E^8_R"Z2W>UL+H4X4
MT3NWIS;U>QBCT;%*U5BNY&LJQ1L@O=?:N!=U#)7%V0C/9RQ\:L!77GO0V--)
MQ:M*O%U+)6-D;=W%+W6=OP%);:( -C9\>1H]N:/^L)^3NCSM^[P'C/P)TI\-
MBWMW:[5H^15</YQQ^L_,C%_%/\>^@\$UE;_W\W!\W-5VG09.CT6MTM"K6Q%[
M&7H]%AB!Z.D=$Q0P%EN2IL8**QVNYCLF"V9E+DDKHMC@UHRJJ$EBK!&],!B5
M[^)K!R.@OP\DXTFVP.=:W7X!UHDG6@?3]'WKR\YT>D1Z1/SI_P"H'^4/YEWO
MRP\B^ _PZ\C7.<Z_/K?C3XL\>\V5#)N86GY:L\E^1?Y>^5[6B=RM8:0Z'ASP
M]X\\<Z@2U?TL[R'\Z4*>X++_ %'3</ &%5DYU(="<NZY]L&6@/B85  ! \9%
M]EH^IJ/DC8'0HJI%2V7*"#W&8^>03E54FOE^V[,/7?'^!\:YW^IEW7FVU2ZK
MR!^7/E+\3^7\C^,/S&_)_P /</S#^$5Y6ZH5>4^2\$_BIX+Y?E.BXCLF]K>#
M5\4>9.JN\IC9EK=V]/H)2ZPC.8DJEX])KQ^258-6:]-V!B7VMW30GZE\G,R7
ML2RL5J5OQT#NP50O@;WO<<94\+2MI5J:W8\N ^!GM<D$<1IT&R= #YZ._4WY
M<?Z@OY.<K^/GX;^./)M#L?PP\[^0.Z\79/F[R_Y6[[Q#^/?CWM*7,^!NN[OS
M<OQKY&LU_-R>,JGY"H<MS'VNK\4*:O2Z7)Q,C&MQ?*Y0IX73,2S*S[:2N?C5
M5W-CT459&5<A?*KJQ^[4/=BY[1L?27$:1F+>-'73CU-9<5*W5JK]M5#NRDN
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M4^0=@CD#H@^A&B/K/0B4IK)57KJ6BO74M*$) 5)2E00M2E+"!!:U@(@  ,"
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M'I  P-?%W-\"/2PSV!X>\H;?E#+UM#;\9=EXR=FVZU9.?V5*S2M:(/03CLU
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M3"X[SW^*W#^(?,FAS72^!/%NY4WN4\J8FPBI4QNN\9>8.Z\8]5XXW=O(N['
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MIZ0\2Y=N6/LT+3X"KCA6MS@OL9Z=G/DU](ZI^V4($*M5.XDY8& ) (!(!UL
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M8;+KTJG'$&74[,+JU:IN4BQF2=]MNM:$<XT2A3^LE"9?F\\%F:N$3UJV])J
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M9 [0\SV+X;Z'S)T.7K/\R<)C<)J(MUEY-/&U:NJJ[4.N1V7N;5V-@5&JQ J
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M>EEQEG9%\54HDGU.@-3!K[6>EQ5]<%-9B,>"[-FZIN*\E1KIEBLJ@+J=VO#
MG6>T+H/S!5-1B)85;<EYF.M1&O-JTQ:)QV$P*C*"TTZQ/_J1!NJZ0LO.M0D!
MM5F#0&M6)?W31-5UMN/A^35I'[69\O\ ;D&OY5I1(:0!^],_A*]8_3JS)^6*
M"X^ @NS/S>D3'"GT<*6+-S.-PHI U@X+ !EE6A\U]XJ_M'*UW,W_  *Z)8R:
M5G_V!.MC_A>D2QM7?('PG9H*8:-H*YGBL:*+%IJRP7,"-9<O7CI%JKZ(-,[)
ML!JVY,+E;$2Z*^Q]B3G4IS5_HRZ*_P#*.&QF?QAJQ0FQ_1D9M1NP6O\ T?KP
M$T2C&^C\@_U91,=-3H1!$/VL]S K886###8D7VJEAQ]#86$[#90K:K$A&?6D
MW%AM2=AEC8AT(4B:S4Z"0F!VL^&?#=&#G#9(P]N@#J#I#^Q'[73S891L)]\3
M=LF-\75!":1HDF5=V6,)>Q0!1-T"4LL9ADM+JJUYJS9&L$,.C;AEFRV 7%])
MC6%=(ES8-$L"MLP8RS4I&N+%0S <DP(JRZ7Q7$0?],_:VU>_S$V/:45$?X9(
MLE_E^D3&&GT<*4)[F:3AJY"W-'!8(-MUK\NV[(*G:*5)U<[]4J5:6,+(L1-Y
MEC4&?IPB6LJ[Q+<*MB@MI5MP$,/%-@*M6[8LY^PQ<:JY<K%I0570K0Q4[CRB
MVM^.(_6)$F5;:FS+!U:0U?Z#'17G(838S2QQK*HS9_IQ$V5[<%K%?^"!92F,
MB*2S'^I*)%57=%=>':]!C 7D19,,9BA>RL1SM&M<ZK)KCJC(#27)NG)D9(ST
M_=[11*BI]%*Y@-S.%DI,8.<)A##YT8>#I7_9&96&9^\\D^^).S,:/RB,?1E$
MM*KN3]GVZ]$??&I%7]X["^N5B$_R9;^M4?LQFR#YMQ'P?TX<N G/^&9:B3&O
MLP\#+4I%6BZEIHC),6'0'+*N^G#_ .F4!8;KR.DN[\)"FH,YDU&F7]"$2A53
MH137%VWGM>%3#79:&&Q0/NU+9,Z"TM,[#9KHVJ<C5SZDM<6&X9M,M:XE]:$3
M4ZG02#8#:SQ82=L4F6(PQ4^U?%V"XPC7"6ACYT'1OI@USM62B^MN2(S2)$L*
MMMRXR#6HBB;MEH)G(,F!1/-A%6I+OZ@P;Z^K^]%MSXA&S5G^;%1!Q]^43157
M='XOEUZ#/;.9+O9C,5\HH40ZL!^]5GQ3HND65)GY/YH#*CC0DOD%$K*IT,KB
M!V\\6?7K!)SA,(9LKOPZT_X_[ S"[&=^Z*D>^9K6?\^7/&/I>D21U-^8L>S9
MSPDU;(UI+$8<(=:8DL)K8_KC]@,A0/7>4,HG9)RV+9E0F5M1+YKZ_P!@#C3I
MQ6C1AS$3EG+3S/Y)UYH#8_HQ 6IV9#4C0E!A%(9R?HRP_P"F*)BUZG1 JN-G
M;SGN"K@KLL5A,K@^Y3>P^BLJ5.R^:Z=M!*3G598\L)BS<RSLPR$K1)-J= 2V
MBG:SU-)6F*6'AL:*W/T!=E--<;"Y:&=FP5"VJ&+G2LE&@#,\1^D2)85;<DVR
M&M1$"?>-(%CL(E5VU!7GI,XU1^5E*Y!6K#X%<74E%04U"'[)(FH5MJ#7+-6D
M:Q=2)H#D&!,0JJ2[ZA/^F?QG<N2-E#I XI)&:I*MR7V11*%5.B%:8;MYS&#7
MRP>8835"VS7T)=KO!<[+)2K2S?U1J5Y-LYEF/OF_1&?I0B:MJ="0/A.UGJ8=
M?="N9X;&BBU;L*/GK# C87+U8E87(T*\&F=QC0L+?CPJ4-1,F:^O]B3C3IQ6
M_I&^$3EG+(RIR"K!G?8_HQ$VAVI'5G2^'V%2&<GZ F7],43'34Z$13#MK/:0
MIQ1?(8;%0Y]5C9WG+&=AOPAL+)(4$S+9Q24;&-UH; +1!U.AE9PO:SP9*+ +
M,L-AB%@[_P U9Q+C8"36C._P6H@PFQ9_SX<@?\+TB:LJ[Y$V5[.>L2+4E(EB
M,9*QL* <@3*-</EG-=#&6R@5QI@8J <Z0^0T2\:^O#5D6E3E0W$M:N,LQ-E(
M<Z4/J"W^C,+>[3_5]=OXS%-6)SIJM*?O0B8BZ?2"I(MW<UCAKX0/:& Q8.LU
M- G="]:IVF2E>UF2-#/1+'3AV1G08[8$OHB^_OTB6LJ[TIL"O8H \ZVV%9IX
MK& BU:M"S!L-3&LN;"L>I!5K]>&HG::465OR8'ZY(DBK;DO,QUJ(UYO6&K3.
M.9,#//+BO6I$[^H,'81K_O29>A0#8J3_ #(II./Z/I$RJ2M!0C%^[7N%%:HL
MB11*E$VEJD;MB!*Y;_2K39%B*WNF:@1*RL6IGY(1,[TB/2(](CTB/2(](CTB
M/2(](GD;\F.5_,GHM+DV?BWY,\9\#EU:.H'7H[[*C1L:5]MBF62[-*>*ZOXD
MUZX70L#\M/W&U4_&[]>X/<^R&;[ XE6</;/H_6>J7/90<!NEWBE::U6P7K<#
MU#"Y,[&LH>-F@K>5WH_&_P 4ND_C;U+)Z.WX2^U/LG[.XM5&8O6J_:3";*LR
MLA[*#A/B%>B]5X)56N0MH+T\F=#Q?6U\QCXR_P!7'W#[_P B_P <Y'W1[HCF
M8_<C^X]T1_\ <>C_ ,_K]_K_ ,Q_Y_\ H^O8'K/X&:.O9+VNWHZWFKK?R_\
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MKW56<JTL68QK)O*UP/.R <#:]VLXV]$G:NBJTM$N+-T2N?9'H=(*_P#5F_\
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M;)WM UA=1:-$UL>%NK*RYHLSC(<V'#5LW9C::U35W@O1%=%M67^\^43"5B[
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MM;=6U=A%H8%JVIH\E5"E=HU9KTO$<]LM@#>FSL[XAY,_#'RGF?B_^+'@*_\
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M<=VN?1P.UYG4R+[]4"Z+(G/8F'=;5AE#3T,RS;R+U&K9H9;LW9S=.*MQ&6Q
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M7WLQ-5X[E_#^]S:;\+,YD_(VA/SQGUY0Q;O9GA^UZ93]C1@/C)EB(*J51?\
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M=A\L?T0"I>\S16E(@B:GSU)BS7-K=@318KS(=)T"V0%F_P#T6$# TQ8MX/\
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M^)FY^-1KTY1^LJF8RE=GIN%[CB4T&RRRQ::4L+76VH+*ZU1A3W3NNK8/!%5
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MXD$B=2(^"B5:O,JEK[_N]/XQ+3YO&.P=HZA2]E^UIF?VKD?N[=RHQ++O9%B
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M011EP$1%""**L*_<_M$A_M;F?B%'^WL3X0KC4!7\NE\850OCJA7$/@]HH'3
M-$51$!%X!M0/SC!PB3/F><9\_P F#CG]D=<;/OS:9?./02J=T7?M,_(.S*$3
MJP?[B_*53:AOL'](EO\ !PXL#<C'S(MCHKV!L_1J_8'63D_P%:<.^+Y(OKP_
M_3A;@OL!E_X LBK_ -7I$QD\IS%<$JK\[AH77J8%!"TY5%8)H\I<?H\Q34((
M@5U>=OV;-W$0$0K+MV'6*0H:TS)$F_F.;M*8BS@8MA#JVO3:EV92:IE3H+J=
M+=K, TD)U]G1KHOZB2B5W[B56;0M<L3A$F7.X!O.T6)DE99:MWF6)SZDO.[?
MSUY5VV;95[RLW,M2LZR^2EKZ*PJ-(D"(0B:KY[!5\/Q8N4OZ[,]J(7GU A+<
ME$ULMBH%4?&>=6F:]$@_15$S\2)6'_'TB4!RG+J4M"^<PUI37I5%)#*HBI57
M-T/ZV=76N$0((H:G_LJ:AB K7O\ +2(/_P"STB6.YGG+"["GX.,Y5M&W5M+;
MF4V!9K=(U;^BKO$TS#4[KTI=L*."#2:I;+@N(!F$2V,'#BS-R,?+BW.E.Q-J
M*%6+$ZTXH\Y.G+H5\DZ$\^(X<W/=]C^0(YWR?4B$PB4)Y?FJP(57Y_%0NK6P
MJ59:<NDL*]/E[#K?-54B"(%5?G[=FQ9Q4A KR[#VNI"AC#*407+\V02HN?Q2
M7*+M:5SF4I":^EH!K:*)&4_J4W]1:]&XJ8]EF\ 6G";Q@X1)GS?/-8US,+(8
MUS=![FGFTS8UVM571U&L,DR1LT:2E5+QE,E;K+!#Y8L!&$3R_P!G^6WX?^+O
MR(YO\7?(7DWQ[X]\Z]9R7/>2^,Y+KDAS0=1CV]#H^*PK/.=-ITZO,Z/15W\G
MLY-7GJ^S_N95!*IJ9IT' ?JW7@9EN*^95CV68U=AJLL0<N#JJ.>:J2ZKQ=3S
M*\/.N6YM%-K5FU4+(K%68>=$ $[ \@:8>=:_/Q/30<IRPJ2E?.80I15QZ2%A
ME484JES]^=7 J* 40*ZV+IE.CDI"(5GW9FU4%3I]_JI-4M9S/..4Y+<'':FQ
M6W:;U,S:9K=4ZBV.ATM5H$F197Z"\ 7-I)1*]2T V+HN:,%"),N>P3LS=+%R
MBN%H,UBM3GU)L3J.QQYYVC+I5\DWFX CB,MR7SGDC&>3)J1"O2)%7-\\A==2
M,+(2JHO(556K-IK765SY$6"M  F!2O%(S+*!<".?)E-6%24_M$J+E>8-<J/G
M<0E2DZ\K++I$$UST8V#1(RB8E)ZT1IFN8]A7XBY,38B&>D2XN<Y\_L^_#R"^
MY&H-OW9U2?M#MPD=F+'[3_W1K16KQI0SW1=A"8L_)\8?I$G&!A#8"V.-EC:7
M>3IKLC0JP\-&OEEAU[XMA7O&XC&,LE5F"AR\TBH@<5IE7I$QU<MS*$UZZ.>Q
M$HJ4\+/JI5E4056H<O;*_P U20L40":O/WC*YBUUP*LNT4V*0);,GZ1-3Y?F
MS!JCY_%-;T;=9RRS*1 ZOTN@.MT:&A*9$T[VH :.RLHD-.\(VKD.?$'"):7/
M8)N.R>+DE89=LZ1O+/J$X]"YFQC6[QLE4F5RSD1&78LS,N=GQ%-AE7CX_30^
MD2*N;YY'Q?#A9"?@G,)'QYM,/A+%42,>5>U,>R<I)$G.D?U-)9$%;XQF8](E
M9<MS)KA1\]BDJ*]:I"RRZ4A%6G?_ *M2O 2GVPBKI_\ L:ZHCV)O?Y2Q%_\
MS](DCYCG&18AF!C'%I6TBU!YE,HLIZ1J'="E\2F8<K==6KMUP9[AT6(2=R'$
MH)%$OG"Q9L+MSD9LVE:,;"[,T:WV%ZPY!<_&F#OC^0=",(SQHN"46(RC+/\
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M.=0F 3$*3@L>]F.L/:&:;FE3A,L*91!\OS;%FIG/XK%-18K,6>92(&5K=_\
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MN_--9,M^Y-*<V;?R2'O^S.=,T)?[OEFE,U??\$_'Z1(!F9J@!:\ZBM:PHK6
M5*X M>8?R9JP$5Q AGL_YT1&(&H?_*O"R_\ /I$T+*RS&0/-H&!+8DA*G7(9
M4ZQ%MJI&5S$K;:&++ F/:=B(<42R(+TB3G.SYDRFA2DF39)A351,L*X +MD<
MRO\ 93:6L LR7[EX  M]PC$0B(SZ$&#(HTX8#EV .*R8,+":\TTO O9[A<JH
M155MB8-=>90)0J9'TB0'*RP 5AFT 6"J20 :=<0!.<\K.>H1A<"*J%DSL4EQ
M$#5>9-1"V%)2B#R\Q@&MF=0-;%WE, Z=<@-6H\;6FLQ)<B2]&R 6+P%$C;>
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MB2W6/MM60RO]2#;7^2P)CVG8_P"XHEG_ "](@LS-.3DL^B4LFU+)*I7*3F\
MKNR<RN9*;@"(6IG]S8 1%OOB(B$2R*-*"$XIU8,'!8 XKI@AL+K?36\2@/V+
MEU)FJ#8F#"M/P"4*_P"/I$I')R@ %AF9X@I=%2P&E6$%JR[$W,Q8#"X@%YUN
M9M40&(&I8F7UX6V9+TB2+,S3!BSSZ)+<N\EH%400-5IMAVDI@RN1->@Z(;>
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M0^#3R;V X>?\GY6NMV3H0Z+-VO6TPIV:V*] H4*YOM;)J]T[&65K[]7N:E$
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M/2)!O8<HA9M=T>*I05K5PV,TJ@@%2EI!C7+)%+8@45M9@9KVS, J\0U3F'3
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MQ>PRL40T,TQND$5RADHE".KYBR*3K]!CO"R.(=<E:-4Q>'204\^2I%LPP=N
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M-H:_:$O7?TN_P5H:Y;.K]:!HP<+J-FO9_J!UB]0KPK<9AI/+,G4,8L@^)"S
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MJ6TEB]@J%MMSV=V\5XDX?A/&5/Q'CY<V.+1CZ>-=I:;(M/VU;QW7]%:V' "
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M7.P=-"<7.\69>?'^X]N332\-;F[T7!!+ONPXF9FKT>L^R_Y(=HBY:KC&A73
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M:A]5XRW=JN!=GF<^1U.B5EYIC:E$U;T=%*G..IO$**VS:,5<QT3VDO"O!GW
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MY%FPK4,*9(F,GI:#U*:%3H!%U3$N"+N7Z2NT5=!==0I+:E^4MJ;=9R#9MT7
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MWA&PC"L +N9Z*NT5]"\Z]$7I?F+;6?5-9'NUK *L<TB0L]"K,KL6TD0?1T0
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M5@]GJ6NL[[0#^/3_ -M!2R:&SM=!FY 39T/M.4?,K#(V<7 IL8K1@66UW7
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M3,NLZ@;[:[%<5Y%&-C]H*"3DA]Z0@^+O_INOS]__ &?FA_\ U"1__KO7T'_
M7\,?_2E3_P"R;/\ YD^&_P".3^D;_P#ALO\ _>_#_P#XLWBU^5OYUJ.R*/P.
MOV!5CY%U!?[]0/SZ5U&0S1S8B:$_J<UMW15+?_/R_P Z2]HPS_C73V)_#9@A
M?\3*D+9&16P_1=AXTUM>*;O\IY%RUU,%_P!'O#_5E^_\7/Z0-;7"K^CQ?:J8
M&#D5L/:O%7N9F15@OEX>O=CKW-[\NON>EGNFU [@$]8^#O)GFGO;>HGRIX5=
MXJKU46V4'MV@UOOM3>17KJ_0)5"_L56.MQ/_ )]L*]G_ )_?[]>']HND= Z:
MM)Z-[0+UIG9!8%QVH[8-;,Q\L=\7"I^>]_D/LOL+[3>VGM![S_A9[$O[(]H7
M&D/U"O.[Y3(%=0!1$"]VG=_^S^QY()GE;D>/X;\C=+\@.H\W]WT>;TG!^6O(
MW"86;3[C0XY/C#D>*WV4^7W\K.JW*E=5S212K[C-J_7M5]!\)M0HO^MA?+UM
MJKS^MY'4NHOBKTR^HU"S)]UQ\;"MZ=CY*9K%BB.EIOOJ9R]F*'QFK9%S:,H#
MWIK;J;C%ILRDNY=FK&P[K*K2Z,4%AKH8/=;:W*U&M5K!5>M:$8QI$[0\,>2O
M)FG^#^YWU_:N[/D'F^*\R!S?4VJ*[6EMGPFAV&9QVY;IW4/7IZ#JV+FS:9=K
MV)V+26V[@6#N-EG2Z)U&SJ_2.G=4LH..<_$JRD4HU7<HN!;&RA2[.U"YN.:L
MQ,=W=J%O%)=RG(W+:/=;KL7WA<HXMUN,V0A5EM:BQJG8.@"6Z9"O>K5*[B.[
M774CK6O7E;\O.MGM<6OR=WFO*N3O^-?Q=RZV<G;R<7$S?*7FGK.RQ=34VNFP
M>>Z"_2]E.AC7+N"%.Q]2DHW9^6JPZ1L=2:YQCIOSH[O=Q><H\SS7*\%NV+_A
MC_<U[4[.OH:K&]A^1U_Q1OY/CKG=3CC1VN=&9Q'3AL:=IV%H8F?T5'2II'0Q
MSEK[^_[HFX<#^>&VJUXRP^NY2-+.ZOGK5^[U]KH$7>DO[=G0\@_RL"GSW#\(
MK'I:+D\:JGG+Z-?&5MD+C+-.VXLNP[2??\HD=/\ .'K!S/&/>MS./##L5.X[
M3JN'\<=OG>1-77Y*O^./8>7.7Y_?N7.5Q[O&]32T\FHG15462&G1>\;=G+-M
M8GW]^OW]/2)D=1_J![_)Y5QNAXXX;0M\[TSLWJ][G/*&CTG!U\(.#YCR$.EB
M:.1P-KK=NS4S>G5E=+&;QMVCR=ZC-S6L_2TJ$2B;KJ?Z@%BGK^5JM+QC2MY/
M#Z&EA8.C;[*SE.LZN7Y*X;QD>GV-6]RBQYWD;=_N4]$&WD/Z9N9SF18=LTJ-
MK3SDDW_7Y^_YQ.0<W^3W99?XU_D#Y@[!^-T'4<5Y6\H\-PV7RC$[V-;U$='3
MY3QUR^#?S</(N=32=T&IG4:NF[&':U*C9L6D'8_:QC\_L??Y^D3I_&_.#R#F
M>'T<[JQC['FS)T?,_,=+V?>(M^&LJ%>.^-+ON<[!?*;7&,N4]SM.4V.?M\UR
M>ESF72OZ%/;A[DT*1D<Q-CM_F_Y4U,;QZ&>W"Q?H8NU4[:^&SSY^0NPW\;\/
M-SS5:V4\3?XF_C\QRMCJ+V!:Q=RG9M ZYCLIV\1N+JEG0_=$Y/6_-/R3@:VO
MI=EGT]/ Y3K^P4O Y'3RG]#O<US?XBCYNK5NEJWN)2:K&EJ_'=JZG.WL%0;-
MC3RR39Y_FQ5T+[^_YQ.=-_.'MR^W@9?C#@-WL,Z[U@7+V-Y8T-#QP_-YOPY2
M\U0[(ZNMX]9>T=:,2X7/:.06)571W@KN/2_G7?EJHG O*'^H%O,R.WR^!Q,;
M&MGXFZ/I^7ZJOL7-G;YGKL/QSS'D6Q0W>>WN&J<M=&M2ZBO1D<K:Z)"GI0^]
M\97CSZ")VG^4/D7\C*'E'@^ \#7NL;J[?A?ONV#$Y3#\1:"K_58?1\1CX-OK
MKWE-E&,_B5'T3ZVY_M71#H?=;J,HTVBI[Z[Z?>XEMW\N_)F6^[E:'CGQO1MJ
M\NW/!6?T/0>4-/G>69VO,\%:[[K-OH;A<+HKYWG+%*M&1RE5-K9U=3;9->R%
M2J 6G/W_ '_W1.*Y7^H4W=T>3+/\9Y%#)Z*WXPQWYW0>0?YW<QI>2>#N=^O9
MP.:5REI'0</D4ZDXI=)&IG,OZ_R_%G)KI.?4$Z!/T&XF56_.[I:]SP<G?\<\
M52+S!E^,>D?C9?D'IM3H.=YGS%M'A\7>;-GQCE<[8N5W(M6=:@6^JPT*MI>>
M#$HB^Z8F/QWYW]ST3^0N:?AOE\WGNG3X3TWV:?E"W<U,_(\[V>MP^1@*VCP6
M-F.T*&]QFJ[?^SK4:%+'L42K6KEF;)(1/0'XK?DG9_(K$ZJYK<SE\?N\Q<PY
MM8&=MZO0$C,Z7*G5Q[-C5M\SA8U^'@JVNKH<SH=!CZ=>N-]-RL%A=:$3U;Z1
M'I$>D1Z1'I$>D1Z1'I$>D1Z1'I$>D1Z1'I$^:GY%?F/YB\+?EKQ/A?B/#UKS
M/RO6>,<'J+V!S%:ZKM\W3N]7V>-;U*.J$V,@,M5+&H'9K;E.M4@TD<[>8#6L
M](GT;R;MG1R\[0N95["MW:5:U9Q=1F<W2RGO2#&Y]YN/?U,IENH92BP>=I7Z
M1- IK6WJD6$B;AZ1'I$>D1Z1'I$>D1Z1'I$>D1Z1'I$>D1Z1'I$>D1Z1'I$>
MD1Z1'I$>D1Z1'I$>D1Z1'I$>D1Z1'I$>D1Z1'I$>D1Z1'I$>D1Z1-D9I:@0Z
M0YV^V5_UOC@;N./S_0@9S_9+- (#^Y,D-/Y?9]20F=3Z42,RB6#H:)6@06%=
M!!7E52N3;RI4%4\AF@S2)0WILS73HB.$:!25TKK!MKKGE"=X43&7JZYK29\Q
MHJ-E?!:Q17\,BKNU- JFM5,EZ1+-G,U(C4T&*-B+]8XKXK-*]!581.C^^_'_
M ,2>0]ZUV76>&1V>G91T8MWJ6[_!L]!.%;31PJ.[&+TN13WSU\X!?E,Z$+J,
M[+3&9J-SB]E&>;U#HW1NK/BV=6Z/TGJMF$Q;#LZGTS!Z@^(S'DWNSYE%S4@N
M Y%9138JV$<U5A !1G:M[:FL3MVFFZVGO5Z8=N[M.@NKTS );S4!FT/B.^Z:
M ?Q*M3!QN0_GX>5$XV74S2PZ.73Q\[&4S.FCGIMI&IFDX1P*=%==3:K4PUE5
M&9[+4],DL2S$EB2222223LDD^23ZDGY_6  H"J %       &@ !X  \ #P!-
MHR.>PLA0ULGQID8E>UIY.Q:3G9_*4DAKV!.Q9U["J+0!VCB6  'W@%MM[F"W
M-9: 38,292W%R;$T;MCQ9G-NYM4#SI=3X]MK.9=W1==ITK!6BBJ:VJ5TEHZ[
M0KV&"LEM=K!"!1+YP\>M<J[-;QKF3L8E#HJ^+>12Y1.G317M3%7-R[Y/6W/3
MU4/?<0M;Z]6O$MC;FE89 &B69^#BY5B*N7XZR\RI_?MM^UGT.8IUQ/3YUUK2
MZ7X*S5V/?=N&?*WIA']>W9>5EJ&X9,O0B;<CD^8=C9N6[Q+@U\VJ_"VZV"S)
MXUE'*VM6](ZUA%5+&9ZM7F@F='1T*<3-\2]N+:TK?[5Z??W_ %1,BQC93&[E
MYGB_/LW>@S-"IO..IR)6NAK4+PT,_(U[#;4%I(U,\CTJ:M!C:52F)5+Y5+Q#
M4E$SD9F?0KCE4> IU\JEI/M4JU6OS5;/&SFU46\S5JT@L+"N^U;$:=%LI5<I
MV:\6+$5:T*L2B5W\7)VGC.QX[SM&;&EBVK%G3I\Q?]MBOG.).L[YW.:U^ <S
ME*:(LN 3Y/-AE*6.A$PAPL=C@TF>+,P=(LC'J$XZ7'G>"JUMS&=B%;&R4S7P
M<:S8>U(N+/;F7GY^65JPU].43)_DYM2U:UJGC>C_ %3K;#2N5ZO*(T+K<(/X
M>%3*Z5E3)9OXEJT&2RPX:^9E18SM=N8;AJ,1+*>!B94IR<OQWE4<JMJZ%>O.
M?0YFGGHK:6"=S1V4T4L2Q2-.Z9\U=0%8=&U:,K-JJ>,17I1,%'-<^UD:#O%6
M-7T-"CSZ-!C,WCV7!3<KGFWLZY:2YGVE<OG3-:T"W/JVJ3)JXDWP]RH1-]98
MM0X-(>,>S21G6ZZ'18YZ+P(+4KJG+5;/0&5JO)0G9E<.&G\592K)!HK57A$P
M-+*SM6EJY>GX[HZV9<NZEVW0OUN7MT-FY276;1OV:=NP:'6=EHBJJ^\J+%5E
M2#T2J+A!DB=7[G@?@^F\HX'D_:Y7J+>U@7L(<VFSL73QE)N1@Z:\WH(Y"-HL
MP#Q2T;.-%2I26%C0:G7+,N? .J")V+_$R+K,F_<\79L7\O)YZOF,M4^0L6\5
M%O4_S<6A9"R[ZB>6BI3V+2Z31H68^O&&=^^B4K1,J<^G53!5?'54CJU;K*J*
MZ>604,Y72E?*TJY%:6I)Z*KMW6P#DUU\1?VEZ+,J_8%#43)QLVAS96Z'.\+3
MP:%G9N-L,Q:_.Y=2\9Y87SWWUJ+T,:=[0DL8I>B=.;BYMV4CG2%PD3=%Z>H<
M)D^<OJEG\CY(*]C%*/OB4Z'OE>@4'_#F(&Y\4G]N2B<O[L1,PB5SK:_QP<<O
MHR<UU-E7]##@H<>A]0ZLE_3^/Y$T_P#VAL@I05;_ !UM.]_C>D2QNGJ@+Y7S
M=]Q*7LFH0O8PS9/.)<9JERS1 5ET$&942=*UTX44:QT")<&B71?T)LBF<.Y"
M"T0IE<FWE_$%,L?^@6M*XNS8FL&C_P"A*N*9OS=_S!JEE?YWI$Q4ZNNQ2#;R
M^C78VK@/:D[^&9UGZMQU?7IL).FQ;&\Q66K0T6I-E:^BP"<-VG;!R%HDG:FL
MM)L7S6@]@HUFB@+^*!L;0OJJY]83;H@H6;=1C-.FPV"FK72:--E*Z2JQHEA:
M6F+FK'GKQK79N)6^+N1 /17H+M5K@ 5^&@J_;,\Q*F@%A-E1/MI11)=DD22]
M#1.5P>#=5!MH 9%<RBA06J\NMN*%WCDAS'?XE@5P;+#9^2B-FO\ MOI$Q@UM
M@EK,^6TEF=;/<:BT,(C2^WHS4MTS(-,EDW+IQ&K9:LSKV*T_7HMLWOW6](EK
M-/4!;B#G+[36C=:M8WL82L-R[()RJP$S1  9TB2*WGFTEIHJ62]IF=8(%$B6
M?T-'[<H_@W8K_P!,J47?N97PS1C$'2C8^*+TV?JEJ3/.Q6E/]&+XS=FI&/(Z
M$HE*=358I!LYK0KFU&$UJ67L4SK-U+!JU:S"3I,6QG-*$;.@:38F\M@KQ6:+
MQ-0HFAZNL($0\QHF4(MMA<7\2")M?1"I7K01:4!#+U,BU4G)0A-8)KVFHOR-
M642QFEI@QHASM]H+/1%;!NXXB\:=93J; %F@)@.LXSJ5A:('7:DV7QJUR6TT
M2M3GQ>^W_MAR;5D\_/M:'S8WV(SQI6+\,>Y=R;+J>7H6+&?%4?D;]RTZU30R
MFQMJ430-;7)*6'R^BMC*N*]B"T,,C0_1OS5TJ9F&F2C;S]2(TKS5&=:[7*$9
M+K]V)K0B39J:H)<P.:T&L6C>:I WL43L-R[PU<JL!LT14#.EJS.EGFTP31KC
M*-MF;<D:\OO[^_[DMG0THLFF,"Z21T&U!MQ<RH4RH&..@&H*RO18BN[1(L$*
MYJ&\-T)N,K!E2-XD2"=+48""9SM^N30QR:MEW',JQ:'N_HK82=!@,+!_4?=)
M),"W[H_E%>_1?I$J+6UX7[HY?1(_K_+\<:&'!0[^C%3ZONG2@/D^G,ZOR07P
M?6&:_P OWYBK*):6EJ1]C]<[?+X1UY3^KN/'VIH2B,\5>[0CXYW88V:<V/B&
MI]=G]2:4FGY$2R-#1^R"?X5V$EH*J%;FWE?$NF>25]FH2XO38FLG0$<0ZX**
M\5PXMKK'F05T43&3JZ[%(8SE]%#&U.?L-0=_#,ZUC5MFC7HL-6FQ1NYBN(WM
M%J395OI8*L-^G:$T"B2;J:RUN-?-:#S6C::M07\4">W.T J9M8";H@L#Z"H1
M:E%C2!-.LLJ^NRA>D*I(EI:.D+S4//WC4-NT@;,7,B%LKHS0N(O"!7X<*;ET
MBR5*-8VE6@*Q82JA(VB1(JTM,_A^3G;Z?D+,%OONXY?7&Z@FW39\>@?O'(;
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M2JII8*9?7Q*<+LY5PE(/?>9U'U,$ BTQ$DVUT0K;*<7,:T4;))!F\]0-L5M
M$X26,C#;*5:V;++VB\5M+%M .>E&PLYO@_A]_?[OWQ+3L[L/,0R<\J\6[2UN
M+9<#3I!G ZI:)$9!"#[&I)T'5(<85:@CHC;LL.<\$2*K.^7P_-D9R_<6;#_9
MMN;\0/01:I+_ 'C*^8L^Q IIB7PQIK*7L+.(?A)$K^WTGQ 7\3+^:45#-?\
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M_>[48,$VMI0-:HJW5F;8OO\ MB7&?2?*V K8<IBQ?A!'=OPV:@TUEF$T(SY
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MSQK[:#YQK<K&-.3;C>F-9<] \5RY;37C6VX]62,M,>VVA<E65UN%-C5\TL4
M75DKJN_BOO"!;BJ&PJ.FL'L?/'1=;D]'XXQ_*/,YS^+_ !9\.])?[CQYTJ)Q
M=UO7]A'EO9H<SU].FO0L\SAZ>6W4[!=2SA3854^72T*BC7/4F$XUU???EMUF
M7Q_+]30[[-8S0\.VACE?$VNN.XM8?Y.7J'=ZO4]'E5"7X\7E>/\ E^3WYS8?
MF9N[E]'J>RK?S=!09;[_ -WWZ?RB;EX^\G_EOS.WX@YM?$='=P=3F-'^ARK.
M)Z-$U-ENAY':5_JNGZ3G[=5&<M]3E2^8?)G/:F96L"D.0Z->I3M)C[]/O^SY
M^D2LN_\ RHZ#+\8]AD97D;L^ZY<O(FQ=P^C\0ZGBW"I=O9_&KM'_ .R+BAOT
M8Z_F,CR6>?D8FKHYN96M:;:.;1ZCHKICK5IB1Z?SG^8F;RY:W+4NQZC%I=JZ
MGC;%[P9T'-=_W='_ &+S.F_)+D_]B;M+$J97<V^CP*5O9Q^,J]55HIKU^[QF
MT6ZVLB<AV/-7YHAT'F\*G)7*&=SSM .?R5^-NAV-' YD/(O"Y&7UO+65<NKG
M.YV3\::7:=7:YFOVO6W-#;S:M6GCYB<ZYEZ*)R7DMSSC@_B[YYO8F5Y%ZSRK
MV'F/R5C>+6=%R^OS716ZO>]-0Q.3[%V#J5L__:G/Y-'39U+HLU\C'QZF=9"4
MYX!]9;[,3INKTGY6\%XD#PI?YORKS@\WM^6N9/LZW+V_,_7[/,;/#NZGPICS
MT>)7OT[TW]K6TN*Z7L,M2CP;/-Y*+>CSUG2^X*)Q^[M_E+K4/'?/;&1Y2"QQ
M',:B:O(T_'O4JQ[N)_\ 27](O&Z/H_(-)46=KI=WRII:.!?YFWL!>H;]#,!6
M9G:M=-W1CU^H]?\ ?_=_+]\3EM#<_*;GNFV[./@]_P!MT6)UW4[W(\_T_-=/
M6Y7*SG_AH5OD<_-U_P!T,JWEW/)U5_*VLBUIV?BWZ0NMQG=)TAZ=N8G-ZOE#
M\O\ >K,H<[;Z[^#&AW3,GR-N>#)YSJ-E.#X5J==4R[W$;>551D5P\K#<XK)U
MG8]<NBI_)2I1=OH3L/C]_P#W_P!0^7G^?TB=;^4?+7Y>=O0[WE*_&^0J&5N^
M(-^K8R\_QQT.1:R.MCQ3S'3Y=[EM[.YYCB=J=;:Z#&JDWO+^B3Z-G'?QF!;J
M5-#3F)WU^3WB#RUY@\N\#S_#7;7/Y8^"_(<6>NT=GR3B8/+=<[J> K8FS4?P
M&UA?=[K.J/U+N!E[ETL^S41K,L5VK1/M??W_ %1-MV^Q_*OF$;;M#I>N#D,[
MS5;\:NW\7PPKL.IP_&W/<$S4S/)&9SU/-T=7K;/;]TS/YS0U HZV/D9S'O11
MBU%C4JHG5<_E'^4%+LN#YSLEKY+KMK7\-X-SQ]F\%4U,J]2['QOK]+U.MJ]!
M+]&YR_:!UF>692XFQH!:K82?MIS-%;';=6#OSKZ>/3U^GG[]?2)RP/+GYB8N
ME^/E6_4ZW>M];SWB?JO)R"\0E2PL[_?G1#F=OS97,7F-9N;>\>9LJM6D;>SQ
M%W-FRC1LV.K4YN/G3$TXGR5^;SF\5J='&O91>K> -/H,"UX=314#?)M_M<+R
M-CV+%1-70J)\<U^=P>DM2I];0IW-^1U[*L>Q0H*1/0WX>>0_-W>8':K\W96T
MC7PMC(1F[6AR=[D<S6^[DP_7J8E#8Y'A=OZ^1HJ);D:'/W/Y\VU45==U9*=>
M4B>QO2(](CTB/2(](CTB/2(](CTB/2(](CTB/2(](GS*_(KS;^8G$_E[R/!?
MC[XY7Y6X+3\4<SN=9S.O17E\_F:=KL.YH6]8O(,_37S&B_-SL] !HW-&BY=5
M9)P;=HOV:)])LIVC8S<]^Q2K9NJZG6;I9U*^>I4HWF* K-2MI,I9IWTUW2:E
MVRSZ<V!&&S63[O9")G^D1Z1'I$>D1Z1'I$>D1Z1'I$>D1Z1'I$>D1Z1'I$>D
M1Z1'I$>D1Z1'I$>D1Z1'I$>D1Z1'I$>D1Z1'I$>D1Z1'I$>D1Z1'I$>D1Z1'
MI$>D3J+M/ ?ACR+NCTW;^->3Z/?BHG/?JZ&6HK>AG5B,J^;L,5*O[>;7EC81
MGZ\7::1<\%H$'M$ZF5@8&<^+9G8&#FV8%WO.#9F8>-E6863H#WC#?(JL;%OT
M!^NH-=G@?%X$P-:,7)4;LK[5FO'=JV3VK=:[E6V)[;\DV2>.S.UJM6M1K5Z5
M*NBG3J(55J5*J5UZU6LA8J17KH4(*2A*@%:E+ 5K6(@ B(Q$7"222222222=
MDD^223Y))]3,P !H#0'@ >@'TE_J(CTB/2(](CTB/2(](CTB/2(](CTB/2(]
M(CTB<3L<%PUOJZ?=V^,Y6UV^?5FC0[&QSV2[J:5*0>N:E3?94+5K5I79LK^!
M-L%_'8>'M]KF02)RSTB/2(](CTB/2(](CTB/2(](CTB/2(](CTB/2(](CTB/
M2(](CTB/2(](CTB/2(](CTB/2(](CTB/2(](CTB/2(](CTB/2(](CTB/2(](
3CTB/2(](CTB/2(](CTB/2)__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>g65062g80i80.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g80i80.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[27(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ):R^ED0X0DE-! 0      "(< 5H  QLE1QP"   "S( < @4 #G-L:61E
M,S!G<F%P:&EC.$))300E       0N?\+?^N$"/M_4<!7!Y'W&CA"24T$.@
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M36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M     $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C
M:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M    1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R
M9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !0
M9U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M        5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M           08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T
M=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E
M8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@             _
M@   .$))300-       $    'CA"24T$&0      !    !XX0DE- _,
M  D           $ .$))32<0       *  $          CA"24T#]0
M2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M    !@       0 U     0 M    !@       3A"24T#^       <   ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #-0    8              L$
M  4-          $                          0             %#0
M L$                      0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M L$     4F=H=&QO;F<   4-    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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MU@ !     -,M2% @(
M                    $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0
M  'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L    %&)8
M65H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,
MAG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P
M    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0
M    0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY
M  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0              $G-2
M1T(@245#-C$Y-C8M,BXQ
M                          !865H@        \U$  0    $6S%A96B
M                    6%E:(        &^B   X]0   Y!865H@
M8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P         6245#
M(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N
M:65C+F-H
M         &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@
M8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M          !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I
M;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I
M;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M            =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !
M6%E:(       3 E6 %    !7'^=M96%S          $
M       "CP    )S:6<@     $-25"!C=7)V        !      %  H #P 4
M !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($
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M 7YB?L)_(W^$?^6
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( .(!G@,!$0 "$0$#$0'_Q  ?  $
M @(" P$!            " D&!P4* @,$"P'_Q !:$   !@(! 0('"0P%!PD)
M 0 " P0%!@<  0@1$K4)$R$V-W5V%!47(C$T.'1X%AA16'-WE[*SMK?7&2,R
M-4$S5Y6TN-76*%1587&!EIC3)"4F0U:4I['!T?_$ !T! 0 !!0$! 0
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MO+2@FE7W/"H/6E?QB6U2\&Q]65'36QAJQC ).\(9&0YA>)8UO '"./ZAC+#
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MY(=.S<?:,K;!*(LDC"10TG(RC46UJ;:XT/JD?@_N.LBC5,1-]%*3#Z,Y'O\
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MQ;0KM(U@=!#K2@DSH'6O)H,\P& P(J\<?2)S3^U4E_V6N,6!*K 8# 8# 8#
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MV*$+$"=/'49J5M+<IC)'ER9=%R:22PYU"XVB7$YWI"G'90_@E1[I5=?.)TG
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M1H4&B]P&/%55_9T;=:MB2M%+XO(JVA3\M8X^\O38L(<1,H5^AM EKP'86P&
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M?76MX'%T#Z"*4_-)6_[G,V!%KF%YU1'V?5=XF8$/\!@,"Z.+^;,=]1-'=Z?
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M$YP.H1=@TF(M!9@>T'>PB[(P[UU#O8=].NM[UY<"*G,+SJB/L^J[Q,P(?X#
M8%T<7\V8[ZB:.[T^!SN P& P& P& P.J?X<GZ6L ^SS$?XC6QG7.T'W'YE\I
M<9Z+R9S=MP]TV!\A87TAF:F?-WM4&![D_P X(_+%?KAR*MZ>">1-._'#'*_0
MY1?,TGU8C]D#/S;N=<N<>KG2[EH]Y3Q:>2'TY0J,!@,"/')+D(AXY1"-RI;
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MZ<H5& P& P& P(R\9#0');V&#KV=<F[E*WUUTWVR'A&09_W>,+%TW_CKIO\
MQP,WY >AZ;?4F_OIMP*HL!@,"P7A]YGRKVE+[K28$N\!@59<J/3$\>JF'NTG
M,SR7L"WQ[O/EI39MV_Q'@,+YFE'3+JQ(P.>BOG/'/7S/W@GSY7^L7O!7.94]
M6![-P?C6'\]0NZS7CHXP(@\^G9U8N&_(-W9'-P9G9! %:A"Z-2U2WN*(\*]
M'1R1:D,)4IC=:$+6C"30#UK>]:%TWO,TVN[-G$;-MCEG$6K=^S<S&BFY:O6Z
M;MJY3U.Y.K7;KBJBJ-,1.BJ)C<8OLUNW+.Q7/+MFY7:N48&N:+ENNJBNB=:C
M=IKIF*J9^.)B73*^':[_ //):OZ0Y=_OC.W?R?R']291_MN"_DN4/;C-OUIF
M/UW$_P UC[G?-Y!>HT -SVN$)BEST8$-BR_03-!:E(@Z&'3QT%H(M:$'0M;U
MH6M;UTWY<L^/R+(Z<SR*BG)\JIIN8C'173&782*:XIR^_53%<19T5135$51K
M1.B8B8W5UP6;9I.6YU55F6/F:+&#FFJ<9B)FG3CK,533/5-,:8TQ.C1IC<G<
M9!\.UW_YY+5_2'+O]\9>/R?R']291_MN"_DK5[<9M^M,Q^NXG^:[&/@1)I,9
MI6][*9C+)-+%"&;Q0A$?)7YT?3D9)K"O,-)2FNBI4-.48,.AF%E"  8]:$+6
M]ZUO.:=OC X' YEL>IP6#PN#IN8'&U7*<+A[.'IKJIOVHIFN+-%$53$3,1-6
MF8B9B&^-J'%8K%9=G%6*Q.(Q-5&-P\458B]<O33$V)F8IFY55-,3.[,1HB97
MA9H1M\P& P& P-/\AO0#>/3Y?@?LS]RWO R.JBMIZOK<C8NULF!0\K8M:Z:%
MLN/-P.UTZ[Z=>SUZ==].OR[P(><PO.J(^SZKO$S A_@,!@71Q?S9COJ)H[O3
MX'.X'I4J4Z-.>K5GDI4B4DU2I4J30$)TR<@ C3CSSC1!+)))+"(PTTP00%@"
M(8Q:#K>]3$35,4TQ-554Q%-,1,S,S.B(B(W9F9W(B-V94UUT6Z:JZZJ:***:
MJZZZZHIIHHIB9JJJJF8BFFF(F:JIF(B(F9G0PSX3ZT_SAP;_ ,6L'^\,]'L/
M&?Y7$_L+O\"W^W.3_K7+?KV%_FN/7W+4+4-O Y6E7B(;LX%-+8%3,HZ4)>YG
M$*%)2%+H3CK9RHQ.D5' )!U&(M.:/6N@!;U$X3%QHTX;$1IG1&FS<C3,Z=$1
MIIW9W)W(W=R55.;957K31F>7U113-=>KC<-5J41,1-=6BY.K3$S$35.B(F8C
M3IF'(?"?6G^<.#?^+6#_ 'AD^PL9_E,3^PN_P*?;G)_UKEOU["_S7-,TKBTC
M&>5'I*P/QB4 #%);,\-SH-. S8@EC/ A4GB) 8((@@$9H.A["+0=[WK?3YW+
M%ZUHF[9NVHF9B)N6ZZ-,QNS$:T1IF(F)G1WWHP^.P6+FJ,+C,+B9HB)KC#XB
MU>FB)TQ$U1;KJFF)F)B)G1IT3HWG/Y\GJ,#JG^')^EK /L\Q'^(UL9USM!]Q
M^9?*7&>B\F<W;</=-@?(6%](9FIGS=[5!@>Y/\X(_+%?KAR*MZ>">1-._'#'
M*_0Y1?,TGU8C]D#/S;N=<N<>KG2[EH]Y3Q:>2'TY0J,!@,!@,!@1;XL_,+Y^
MU)>?[REX&P>0'H>FWU)O[Z;<"J+ 8# L%X?>9\J]I2^ZTF!+O 8%67*CTQ/'
MJIA[M)S,\E[ M\>[SY:4V;=O\1X#"^9I1TRZL2,#GHKYSQSU\S]X)\^5_K%[
MP5SF5/5@>S<'XUA_/4+NLUXZ.,"&/A#_ *$_([\W:SO!NS.-K7N[V,^4J/-7
M6*;.>Y'/O$*^?0Z0N=X.0G%*F)D7*REZUG:EBXCQ?B%JIO2*%9/BA;&5XI2<
M2,XOQ8Q"$7V!A[ A;$'IO>]Y;\1E.58O$6\9BLLR_$XNSJ=1Q6(P>&O8BUU.
MJ:[?4[]RW5=HU*YFJC5JC5JF:J=$S,O;8S/,L-8KPN&S#'8?#7=?JN'L8N_:
ML7->F*:^J6;=RFW7KTQ$5:U,ZT1$3IB-#E<N#Q.S!X!_T87_ .WD1_=YPSES
M^T%VTV.>(8[]XLN@MIKM;G7CV'_=ZE]&<]-S& P& P&!I_D+Z ;Q_,_9G[EO
M>!E-9^C>OO8B*=PH,"&W,+SJB/L^J[Q,P(?X# 8%T<7\V8[ZB:.[T^!SN!A=
MD>CN>^Q<I[C79Z,)V7A?&+/G*5OS;M5F?D_&_NUU2WFP'.[1]OM5@.[G7)D-
MBK2_I8M-4,P<SG&5 CYFP(6E_:O>Y*0)F<_'&G;=RE 5 S"B@!*,+$#8MAWO
MSWZ;E4VM2BFJ*+D7)TUZN]35&B/S:M.F:HG3N?"N>7UX2W1B_9.(N6JK^&KP
M]%-%B;L?GUVJ]>J>J4:(C4F-6(F9TQ.F&[]==ZUUUTWTUUUUZ]-_XZZ^3KT_
M#TUUST+8FQPO_OR=^JF7_6UV8]L@ZWAN/<YM+8VUYV1FG@<-S[RP',8;2,#J
MG^')^EK /L\Q'^(UL9USM!]Q^9?*7&>B\F<W;</=-@?(6%](9FIGS=[5!@>Y
M/\X(_+%?KAR*MZ>">1-._'#'*_0Y1?,TGU8C]D#/S;N=<N<>KG2[EH]Y3Q:>
M2'TY0J,!@,!@,!@1HXQ_W3<_VE[V_?57@9IR ]#TV^I-_?3;@518# 8%@O#[
MS/E7M*7W6DP)=X# JRY4>F)X]5,/=I.9GDO8%OCW>?+2FS;M_B/ 87S-*.F7
M5B1@<]%?.>.>OF?O!/GRO]8O>"N<RIZL#V;@_&L/YZA=UFO'1Q@0Q\(?]"?D
M=^;M9W@W9G&UKW=[&?*5'FKK%-G/<CGWB%?/H=(7.\'(1@,#LP> ?]&%_P#M
MY$?W><,Y<_M!=M-CGB&._>++H+::[6YUX]A_W>I?1G/3<Q@,!@?(8X("EB=N
M-6I"G!66<<D0F*20+%12?6MGFITPAZ/.+(T(.SAE@$$O6];'L/76 &O0EK26
MT:U(!Q4$&*2$ U)(5IR8D00&J"4NQZ/,(*$((3#0%B+ (0="%K>]:P-5<A?0
M#>/YG[,_<M[P,IK/T;U][$13N%!@0VYA>=41]GU7>)F!#_ 8# NCB_FS'?43
M1W>GP.=P,+LCT=SWV+E/<:[/1A.R\+XQ9\Y2M^;=JLS\GXW]VNJ6\V YW,!@
M37X7_P!^3OU4R_ZVNS'MD'6\-Q[G-I;&VO.R,T\#AN?>6 YC#:1@=4_PY/TM
M8!]GF(_Q&MC.N=H/N/S+Y2XST7DSF[;A[IL#Y"POI#,U,^;O:H,#W)_G!'Y8
MK]<.15O3P3R)IWXX8Y7Z'*+YFD^K$?L@9^;=SKESCU<Z7<M'O*>+3R0^G*%1
M@,!@,!@,"-'&/^Z;G^TO>W[[*\#-.0'H>FWU)O[Z;<"J+ 8# L%X?>9\J]I2
M^ZTF!+O 8%67*CTQ/'JIA[M)S,\E[ M\>[SY:4V;=O\ $> POF:4=,NK$C Y
MZ*^<\<]?,_>"?/E?ZQ>\%<YE3U8'LW!^-8?SU"[K->.CC ACX0_Z$_([\W:S
MO!NS.-K7N[V,^4J/-76*;.>Y'/O$*^?0Z0N=X.0C 8'9@\ _Z,+_ /;R(_N\
MX9RY_:"[:;'/$,=^\6706TUVMSKQ[#_N]2^C.>FYC 8# J2O6HYH]\O3'I)4
MDFDLJD%I<*I;5%XH8PB6Q^KJKJ&<N+O?T.7S\P>E4'->(S]W*)1'RQ$#GX+8
M0-2(IW(+?M,I.YWO@GZ=W=^;<^AC$A@,VGG*I!81="V27*9Y=O%2VZNMZ01$
M#293M"P6NRFZWZSELF-4&JH0\*')-9K2X5IX_0Y,NNA$N3$.:<N0*V0A8?RJ
MA]CSWC]:L4JN0IX_+7F!S- E"?&")68_E+HB^H=1=&B4O+&4@7/:M4C3IG@2
MLW: P/7W(?HW>RPUQ":IY9-\,B*!1R8B+<>AC# C/;S^.K<<<A.3-20DQ&<=
MJT0Z--2C (@PW00Z,&#8]!UK?3 Q"P>*-^V6N0.$DY2L6E#:D&C3>]W'UK2E
M^),.V>+Q@1V4?L0^V+?06A!UH/DZ?XX&O_O![9_&F1?H':/YAX#[P>V?QID7
MZ!VC^8> ^\'MG\:9%^@=H_F'@2,0U3RG;T21 1RDAWB$25.D)\9QR;A#\4F*
M 27VQ:M(.A#[  ]H6M:UO?7?37R8&$+8OS:(M6-Q)-?4.401SKZ;2)YFWWN2
M70&B6L<C@#9&8ML.K2\1L<B9Y%+'8.Q[T<$,7'HKX@C<#,'BH.43XT.K*MY2
M1#2)X;5S6KV3QS;BSO<K@E-2*/%&;M$>@&^*.'XL>P"T$?06PBUKINNW75;N
M47*=&M;KIKIT[L:U%451IC<TQIC=W7RQ%FC$V+V'N:>IW[5RS<U9T5:EVBJB
MK5G1.B=6J=$Z)T3NZ)1Q_H_;5_&H2_H(9OY@Y=?;S&_Z/[.?XV(_D)D??QOU
MBC^2?T?MJ_C4)?T$,W\P<>WF-_T?V<_QGY"9'W\;]8H_DG]'[:OXU"7]!#-_
M,''MYC?]']G/\9^0F1]_&_6*/Y+9%<\4+]JY2Z*XSRF8A&NY"9.K]\N/K4K#
MHM*8:85XK1=DI]@%VC1]K>]BUO737373KGDQ>/OXR**;VIHMS,TZE,T[M41$
MZ=V=.\N^4;'\!DM=^O!S?TXBFBFYU:Y%R-%N:IIU=%%&B=-4Z=_3N.8M>+<V
M(C5ME2R!7Y#IQ.HQ )C(87"@<<D@1R^6,L=<7*.1< D]I[/"*0/"9&TA$3_6
MZVKULOX_9SQ+XST%;<KA  (7**&!$((=B#][@W_%%O6M[#Z4_P##?76!!GDU
MX*F6\L9ZU6-:G*E27(6>)((6CU%Z38VAOVS-KP_/:?9R91.7$8UGNV1.&C#]
M'A"(G2<O10=E"&//]BNV3LBV'9=>RS**,NJPU_&W,?7.+PUR]<ZO=L8?#U13
M51B+411U/"VM%,TS,5:TZTQ,1&';(=@^2;)L;:Q^93C8OV<+1A*/8^(HM4=2
MMW;]ZG3359N3->OB+FFK3$3&K&C<TS';^@+8?QK)9^BB.?\ %.9-[NFS;_#R
M3ZA?_&K%[DNQ3]+-/KEO\,?T!;#^-9+/T41S_BG'NZ;-O\/)/J%_\:>Y+L4_
M2S3ZY;_#/('@#6( PC#RLEG4 @BUUJB.=.H=ZWKK_P#%/R==8G;TV;3$QU/)
M-W_L+_XTC:EV*1,3K9IN?]Y;_#+;"ZQY5%%EE!Y20WLE@"6'KQQ;][[( Z#K
MKOX4M==]-:Z^37E_PS3<S-4S5._,S,\,SI;-B-$1$;T1$?0YJI W^SV=9,1M
MF3-,^A3?!*HD<$G337@:_+4RF12"X&RPHF:23*)*G<QQQIBM</ 30B1G)=2[
ML'!/ <1LJ$I'8# 8%6/A')<9&W>NT\NL:P*MJLZF^3;TT2.O9S-:]=7/D['V
MJMS./D7+=(*Y-;E)WMP;EUJ.4/K1R$[LDZDK.C3*8O)%S<W(@!HSF5=#^JCT
M(+E-JS> NT7XH\@S-:K"8R^$*S/")1^*4 _U!6:[4-7LXIG-#&^831TA%+OP
M'J,SX1[CIPB;^-F3$HW].G3?%R[>&4.$(0@5JDS%-%T53!5+=H0N*-GE"EH!
MH]5MLVI3@7IF]U&(WW#M80!443[GVI*T9XT(03HJFN73*VV8!??T>BXG.\+9
M>DQ#GQY0*3'A"YRI2>DDJ3>[-)\2VOY71P0)]:-T2G- #1QGRZ#:$KH[DU,H
M^Y1IXY2Q33:ZEE%*MI..K:0H[!*DE4#Q1HK/-"#?C2 =K>RQ=0]K7DWOKH-%
M?>#VS^-,B_0.T?S#P'W@]L_C3(OT#M'\P\!]X/;/XTR+] [1_,/ VO7W&SD3
M6C>N;(WRECFTS@L"N4>^''IL5&>/"06GUXL8+,(T$'BRP]0["+XW7?7R],#T
MVU&>;L0KR22. 7Q#IS+VPA"8S10'')*$3N:>ZH4BHO0D]I^.U[F0J%2W?8\O
M1-O6_B]<#8OP:<K/QI(9_P"7!O\ YIX&CYSPSN^P9"HDS_RG:=.2DA*G,T@H
M%I3)O%HR0D$]DH=C'"T+L!UV][,WVA==ZUKY,N.&S3%86U%FUU/4IFJ8UJ)F
M=-4Z9W=:/A^)C>9;%<KS7%UXS%3B>K5TT43U*]311HMTQ33HIFW5.G1&[N[L
ML0_H_;5_&H2_H(9OY@Y]_;S&_P"C^SG^-X/R$R/OXWZQ1_)/Z/VU?QJ$OZ"&
M;^8./;S&_P"C^SG^,_(3(^_C?K%'\E]2'@3;;>M1KT_*=%X]"J3K"/&4.SB!
MXY,< XOMAU80=B!VP![0="UO>NNM;U\N4U9UC*Z:J)ZCHJIFF=%N=.BJ)B?[
MW>E7:V$9+:N6[M$XS6M5T7*=-^F8UJ*HJC3'4HTQIB-,:8W$E?@UY6?C20S_
M ,N#?_-/+2S!KJ.1GFZY6)9,;>+XAS3#XRFA)L,E>^.2789<<^MKFJDQ( CM
M/Q(?N<6I42,7B?+O:S6S?C=G _EN<9.0UTUM,*KF7*:/ B\W:#&1Z$S\>VM"
MYZ1FG$G"]QJS;+5ED'=LD&M#&G-UK7:UV.N];U<\FS;%9%FF"S?!1:G%X"]%
M^Q%^B;EJ:XIJICJE%-=$U4Z*IW(KIW?A>',\NP^;8#%9;B^J>Q\9:FS>ZE5%
M%S4F8F=2J::HIG3$;LTSP*U/Z MA_&LEGZ*(Y_Q3FTO=TV;?X>2?4+_XUK_W
M)=BGZ6:?7+?X8_H"V'\:R6?HHCG_ !3CW=-FW^'DGU"_^-/<EV*?I9I]<M_A
MC^@+8?QK)9^BB.?\4X]W39K_ (>2?4+_ .-/<EV*?I9I]<M_ADS>+O@][2XB
M,DK8*GY4)C$,Q=$#N[[E5$LSR?I6VI#42;20Q/8#;H@KQ)P_& $ W8A]!:$'
M6NF\'V6;-,XV9W\'B,XIP=->!M7+-B,'8KL4ZEVNFNN:XKO7IJJTTQHF)B(C
MX/A99L=V+Y9L8LXFQEDXF:,5=HO7?9-VF[5KT4313JS3;MZ(T3NQHG3/PL>Y
MN27PFE!U3'YCQG>XIR9G;E835&G:!IN/1B0QIB*R-RQT7R[9C3: U(@('EF8
M6;8!Z\1L3^$0M^,"7K>),B6U8# 8# 8# 8# I@3P+D]:O,+DH]5W():R,58<
MT:.:2)\\<M;Q;(C%JG8N/7$FQK.JQFX?I&=[HZ:I)RWR6<HRY(ZG,+NGDM@K
MGX+DA6Q= >K=/C%:G&KD-:[Q42S0>43^C,EG"%[?;+G$-Y,7QR]D=86BEL:G
MFTNRKYBLP3!>>)BXEADTK;7%EIAW6DM;"9/I8#2=36#*N"3._.C>TSH7->#5
ML<<WC=XLI$H639FA5F,R!HDS)R8E?,.GU('6 1AR7H:EY!V,SM]G2-$G7[/<
M);$IPYR99!)*[J&EI>O>4]$VMY"S# @=R^F%W1FWN%#;1Q3&[/<JN&T6Q\B$
MRL*5UO 98RM_&^W'P*27O42A5B+5!#2XMJ-_9$*F'.R4R1-C69L;<:66XI@K
M(:_"#<L*ID*>OG]DKY0^N-Q<@G U/+Y.=,$MAOH^<UL5-JAZ8F<UL*G9:J15
MO#6AB*CFXA3]FR4A#(X*-16,?C:(U$Z!E)7A4+:)BJMZ4S/CJ_FNJ%U(=E<+
MA+J!+QPE23DPS4Q&XG<JJ:<A([# .EAPQQ>I1'7&>6!1[$WN<*>EIBA[87!I
M3&AKV%>$ Y'3V<PF</;C''LM_@=;K8_1T/3RZ)F2R2PGDSS&J68R>*?<S;DA
MT[ D*6KH$1*H^J-L:')3II VTY0Y%($3A, EC)^4M@63X/#FK9#;?543F9PG
MCI))8Q3SC0R3JOPUI*GBG5DK/B2I[7SJ=%?=W!7?>CM*V*6-\E94:EG!*XM&
M7GQ!SJZ=.GJ3&_&G>TQI<Q>?)"16A:?'6=\'KICUV(*OAG(>=V15M5SI@ET4
MNY/#3^/*1VJ=\/9W)<TH;!^Y"?2%_JQ8N,3J6Z=ACY2LXF-O3^%20@[4PN5_
M+MK/<*>FUGG29PXD53+*[LJ7<O>0M*MU03.P>2O.IN:;!D-)Q=HD\/O-P+C\
M*@Y#Y$;1:-%B9H,R0P9B=M<#3FYWNG3_ (^<[';T)6EBSL/:D0ER9@7BVL)#
MM,,2LEN-WM22 L6]IQ;.#XTL(![V5OIH(OBZW@=>LBZ>8ZOCCQ/<++GA=1,D
MO\'I:4E3W)6MC6S=EB.TBU7?'_:"U;=@*VKX0<GD$;)D#A)W-U9);.WR/B=)
M<Y-3R!0B"[K0]5=WL%8G:(;*KREL?XND\CXTRWG>=9<V+.ONFF]G?J G[Y$8
MO$>:,LU%KSJUBD=K1Z&ZM1F=9WXZ"2%^AD599JULEDK&O3IH$XY/;D-A_"$Z
MQ:RONRY#544Y0T>A;KNLF9N)YXZHUS,J1GFP45N.Z@IZL&GD4272B*E6/*W^
M0&R^"D.(WV4R-K--<E8:AO/E1,%W(TR^.,%NE7?QWJ_BN<]7!7=528B>QN3Q
MUSLV5L,QG<$+C"Y>@,N.H"VY@E:=,B$)U?X8VRN'%EC=7A@$F#1G&^/<N[_E
M[Q(X=.9^4OASUP,4CMB7<O+X;&.)QQ1Q'XF6A;T>^]63-L@IZVU-A:?YR<YN
M\P-9W1?*IRO<5;PWK&HAS$3WN#UR[$V$& P&!_-A"+IVM:WTWH6NNNO06O+K
M?3?^.M^76_EUORZP&PAW\NM;\NA>77R"U\F]?@WK\/\ V_AQHT]/F]8_N P&
M!5KS?:[6FG)CC!7%=(YI)&UXI[E'*7R'1KEE=O$5I6NT7D7&YNC4F>YO2"=P
M>I KC8)6]I&F-/36M9S2I Z+1A\<E 2H'?X8^#U]-/S*Q#K*Y%4[R-40&SN1
M@)Y>%96SP-B+HS-7+2XVJP)VQO5?T&&XFNI>%)32GI>YF"8FO4Q,DL_E:6+R
M! )9*)F6F;GI@1@P)9<+K?=5_+I'%5EU2BY768AY!J9.%MY 64^O\3*9I64Y
M,K+R3X564VK8]Q170@L)4&A,GJ!Y8&F8.(TJ1U8UR>2)ST87IX# I+?K:Y;H
MU=U;:@,*ZI6?PHE#00N9FW58J2WVF(.O(+C$T.E=1BNR:Q618Z /:=]7QMT;
MQVRSMRB-R:4"4,B@.S&EV#2=?^%8Y!2UOAQ\L>>,]4-LSFM/L<SF\T:"%C)Q
MS56&V7 LD5>V(TQGDFZG%2UB,K]I1MR^R7:FG],Y%2,<LJYH:U+8>WASS1X4
MB^)1/*:@B<-21YYG2RN8>_M2V"*2U#HHM,4P;8U;\+2OO(..V&K@CQMOADOC
M"%DJ^;Q+3;(-PJ07"GF#DFVQ!@U'^$%N5'$FKW^O"C(ZE>8)7CP^\E+>;+)F
M=:+YW'.(M#SM14Y<537DA;F&S9U+93-DCJG@:] H<W"M)^<FK9UL)V-$A'K6
M.6AR<A5.<QJ/%=%V1BH:UFW$2V7;3?/YP& P9ZL8BTJ$VTFDMLR5L2=1*V]@
M<),0V!7H"9(A9U+RG&0E 8X$Z&_\:MANOGE3#U=;,4GGUFRRN+VY\<FE-:6.
MC=GC2J#ME:3SE1$7OCC,W=$I"I6P9:RQ6&613^W4P])LMLF46"%(WPB%DJ F
MMX-NM^2Z9NJBX+"?9(V5A-N*,%.>XS,^5UV\I)!9-NR=/!90@MOW-<C*6"EO
M<,?+E;>ZPN$R1Q8G=;,4Y9K>0&(-ZY;&[TY-_?\ L&XKUFO(QGYOTI%*,;8=
M+D#KQ4Y#R&30BSK7F]8U^:L9;<XSMK/*PBA]96P%UF+.0_.;0S!71I$),RR"
M1[3OB?QAC>XIZ;WK[^\?!TZ?=\ZH*-\AK!;V#C)-9S?U@2*=BHCAJM)JH/)*
MUJENYVD<C-;EDLE%)U.O:WNHN>Q=BJG4R/SMNLYEW(XXM9GIH;WUD5A;CT<]
M.3Z. 3QX[6=#'NS8 ?9/(ZZRN:KOR#N6*V-QU8[+E3\RM41:'NRT[%'97QG7
M.CC JYI9E@#="9+'[P:H/')&_JM1)S^$EY.G2]$_/AWOG]7?')6GRLC,*/\
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4DT$P(1AUKR!&$(M=!:UO0>W _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>g65062g86u75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g86u75.jpg
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M6)*6U-8F,4%7U3(S0D115&0U-D-&9@HG*#2!_\0 '0$!  $% 0$!
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M<0/X_P#-;F>*JIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2M5GU/1U2(PM
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MI:L=@N@],:[:\UX2MM*J-0JK%\NMHF;:L-,LDT=2;T &8V)!.@APQ"0&D-D
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M[5.V&1,O%3-2"WBIBQ(5QQXC%K4"+8Q1R?+4).F->.N-"0#W=^=>!QGGPJ-
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M]3V)[FWP_P 2O5\WC[/&F+[;LY1WUVO&%4?)U>?E8C/@NN._:B=O3X\36?\
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MM@B;\:@Q,K]K((RU'1@WDOA*,JB1/3NC_'V>6[X<]V^.1]GOIV)[FC]X_AI
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ML3W-'[Q]7S?^/&B;];5?;C7BLIS1??L*Q;!&<9N_[!8[1_\ LL_M9_\ #?\
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MC(0?>_??1Y]=V\WVWV:'W\'K\>/T;[_1_&K;.^>W_I/WUL/YZ5\-.*4XI4&
MRF"%IVI'Q:)EAR'OL86H?*#>U-4[.=>T(G\7@2O CWZ&M)+%GR9[N=IEEEB/
M'^J? CQ7\XU=H?\ 8C7^\KT<-!SY^<X[JROE-?53BE.*4XI3BE.*4XI4(]2E
MVL.M^G_<=]J1JLUNT5/7=I.5^P7.&7GU$(8@BI#H\K9HX*"3)X!P).&Y120P
M/EM0H;3TR8PN%'D8Y(XCSBJ'%%+:U @$))!() /CC]#OTK4'6/J:[;I 2&4M
M2*CML'7/QHU7":\<HHD\:*:?USIJ]52N4.\Z>?O6H=BC&6MES"-KMX&'5B J
MM0CZC-'#G-8&85WJ*?1PY]Y(R<X(X>/GUKY@^H#)PH#K,Y*03NI00 I 4E0!
M4<D8( .4Y3Y4[BOJ7; LS].@U7I_HI66?(T$ 3(/;^D)KK1K9747<NFVLR*X
M4#:@L#YFO-V6MP;$?EE(%=L 09*,!EUB6=#-,$HW1S/?W:Z#)[_158D$[N$
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MVLK )"4[R4K "MXA*LXR,#N''AG('"K3<BO2G%*<4IQ2G%*<4IQ2G%*X1(C
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M[9ZT;*VB-8K&R^S!8??E+7+>1)FRIDKJDO2YC[;,9IQ]34>-' 8C1F41XS"
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MP@P%E],3$[O+PSX9&<_?RY50'\9WDC.58(.,[KA1J,$Z#&HWLZZ#A7/$_52
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M!>;YL[*D3K+=)%JFR6^HE+89A2&Y# /6-(>C7"),B.%EU2UL.J8ZUGK'VVW
MQ*E-OW, BM2],^J1H9PX UWK6EL+;>/W:S0QD!N69*OSB)BQ6BQ38[,@U9;$
M4F%"I(A+Q(*G"DF0O*GY/AS<V6<AJ/$C)0VPPTQ&BQ&=UJ/%B,):8889;!#;
M$:,TAMM(&&VFQDX!-?&\_NEV1+DJ6X^^Z_)E2WLNR)<M]3KS[[SA!<D2I+JW
M'%$[SCKA.,JQ54NN/7ECZB-"!#N@Y$#8CKYBK36VJ>?"OQ;U1472JV<E&!61
M,] 29GUU2&2H6'B; >8ZTY&(D(0YV;*;^6ZPI<BV7JV-.BWSIMIN<".](0ZE
M+$F9!?CMA\(0IYMMSK>J<<0VMUE#A>;0M:$H5[VR9$C76QW9UGX1@P+M;9\A
MF,MI:I$:+-8D++!4M++KC19#S;2W$-/.-I:<<0A:EIUL=/.IRVL=L@-F;-#V
MVM :!*64"5ZV6%$^S&K$N):YL0* J<LU,)5"DPK)=#-]-ERK(R40/0:R##PB
M%3=0H!B&Q]AVIA")*VMGVYQ^U6]^U66W6Q$974M/M0X;MQNL^*TAF7*3;(#%
MLALMN20&'9,F2MF;OJF99MGM%LG)5,B[(P+@VS=KA'NU\N-S<DCKGF%S9C=N
MM4"6\M^)$-TN#]TFO+:C9?;C1HR7X>XF'<)WH\J_4W:)VQY5<B!:Z53&CK*V
M$=)4S9(D)#*H4=BIQYT>%8! I_UC</-A<R-AJ?<P&;<\<G#.>$H#D=Y;,=R3
M#4I4.2Y'8=E0E+(*U0I3C:I$-2R 5JC.-*60"O)P:U\VA]UN4TW(E,1)H0F;
M&;DR68L]*  VF9$:=0Q-0V"0@2D.)0"=P#-6RDZ'VT"CMYJ&U1I=[+ ^++B6
M\$['B2V12HF1ZW78[QUM+\9$&&QZN(,A%7F(K#<@L]A&.U&\#Q![]0>><^O/
M>3_"O7J'4CR'0K0#"TX&G#4;W( Z D<34J5G5Y60U$E[0-P;3,BS4$XE<##6
M@U'&D6W/.;GY&--MR+"30]W?1/L"Y#;#N4.1($:0UB2N"1W#'GXGW>CTYKT2
MT3CK5!1!R$I&$ YSG&/*.>\YQW 5-/(KWIQ2G%*IQU<:P>V0WKSRNED+U+>S
M+M_B]XW0G4/PKW%-6[>G\1(?\A^1^ASYW;SO:?86N_E^Y_?]&^_T?QJVSOGM
M_P"D_?4.=50^QE=\62O.;TJ=4AK%UNYU(+/VE;JW.J]@>A5O752GEQ8<<L17
MQ=./'+ALZ,Y*)H^>%B08#/A9@0URV>9.DEBX2=M)\)6V-MMK1BV^[6R(]M)=
M+>];IRVH-AMCTJ-$CF+!C6J;,NFT+:G9*?AJ5(B07F>I:+J.P.B&1:X?1Y:[
MFCH^O-X?$NZ6*]3H^R-FNL:[VQ#]TVGO,>%+FR4S;E,O=NM]DV3>2S%5\784
M6=<8[_:'DLN;*MR.5YK4.U7;<@DY5&];WERSMAF8L@PNO(K!11I J/.8E0GR
M2AN).(+,R-(B.2LM(D,.LJ6VKH#:M4%.RVTJKH)"K8FP7A5Q3$0VY+,$6Z29
M8C-O(<97(,?K RAUM;:G-U*T*22D\L[#IN2]M-D$V545-X5M1L^FTJG+>:A)
MN1NT00%3'([C3[<42BT9"V'6WD,A:FW$+"5"CO11<&I-ODU!^T;F)R&==D9@
MT%>]RTS;=9$#:W<(-<<0T]6JG6Y<$RB'(KT@;/<>(""4 J9@#I<QP')E*T]T
M1W1+ET<M:[CM9(<18GW8\.\[5VC:>W1H\"Z,P%!"[?;+>ZS*#3D%<=Y2GXTA
MF1,88<=5"<<._NGBRK:LS=Y;M.PT1I>TT9B5<-GMAKYL9=9LJZ661=$J6BZ7
MBZ,2(*GV[FW*C(1&FQ)$2!(E,,)N#3*;<!"_N=IVG&^7*L_L=\C"/;% O9\4
M7Q:^H9;XBB9Y:/DJ5^Z_+???$[X56M0+S/U)Y;>^E_.]'K_7#T5S?#_L1KGR
ME>CAI_'TUE7*:^JG%*<4IQ2HRM.ZM.4>>H3=-LZTJ)5&,*6,LUZJX(BE*L8R
MG*H)0I%E8QG&<9QG+7;M]O\ E]O+3-OUCMJ^KN%YM4%P8RW,N$2,YKP\AYU"
MM?-5]M^R^TMW:#]JV>OER8.</0+3/F,Z<?ZV.PXCNQ\[CIQKO:EL*@W]A^51
M+Q3[K%C92F3)J5E"V1B.I7_3A]X/-FMM95VSX<.*3G/;[.?3#N5ON*"Y;Y\.
M<V,97#E,24#/#*F5K SXFOCN-GN]H6EJ[6NXVMQ>=UNXP9,):L<=U$EII1QW
MX!Q68<^VK=70VBK5J[UTU4+E7PMKJED'2@]@K5C&0C0(V*FM*9F#2PDBS(@D
M(,EI2FWXLIAUEU&<X6C..*@@$$$ @C!!X$5RL!AK07%>A1&!@=H7@-$@C6&(
M44>-1$]"Q$'QF6L1HC$2+A#,5AIG###;;;:&L-HPCBF!C' 8QIW#PJ P'2EI
M>KT[6M&K]8BA 6M'$/,)"#@ *7<)'X([II:1*O$H(%'*,39M2OAV3*GPDBIJ
MC?I9C4AJ(B1 DR23GQ]^=*H#2 $I P$<. SY"D>5@#.0HYX:ZUA\3HOU^E92
M6;NVR[48*ZT,:C>.&IU+8GLT4I#HT**,88K]&!B<20:*)$?&D71KTU^4<L#I
METJAX4T(9\!QSP\_LUX?\YCJDZY4HY3NG.[PP !HD<,>TYR, <TAT=Z\($CL
MART[!:"VVQN6NXU-F?5L [0;8VG?MQU^3.DNU%VQCT5:[[#*2Q+  ^';FP1-
M?@63!UF)/]S9\WZ 'M J>J3DZJP3DC(P3O%8SIG0G3!&<#.<5@T3Z?>G(R"^
M'35C*OF1,&!+G':EHLV160C(I")IU\@2T[(F$)!GX+"41!DWIM/:48.>U5L8
MGV)()DG]''FX\/T*I#"-<DG(QDA'AKJDGNX$D:G &F)X$]/])'#M/BR$^Q6M
MO2T,O$KC]OFC3THSDT#? R9-E5)$I:E/,0W7%#FA3(:$.RAJ-#B-#8[,%N.?
MC_W580D!(U(3PSC7.FNGCIC%1FQT8:];:H@B5<=AEZ5K]^HS@U"..T,P"P3I
M;<1D;-A%IU"=NU2CDFQPY%G :_ME0J]F1'F,EPDABRW)JR3G_OO]Q](SZA5/
M5)TU40G! TQD<,'&\GQ"2 =0003F3M<Z/:UY$]LSL[:=S!P*;&H%6 V\S75B
M*C5HF$-1X\"-6JK6E6 RW#CCAR;9>W;=:T0!K;39E#I2QOG&? ?K]=V![*J2
MC=_O*4,;J02/)3R& ,G@,JR< :YR3 0GZ>VF1:ZZM9NV%_CI*3*8BF@6G2 ;
M(B2]19+E6$5E>J4UBB 53*%#GJ3K,-2BBB5AMQ/W/!$PQ*'B<]P]OCKQU.O?
M5'4)TRI1P>\(\-,;F!\W7=QQ.,9TS^-T9:::US9]:RV3Q8?9:Q+JK9\I*#R+
M17(4_2M0T-.EUJ<V#8'PB,RETD/)D/3!9".LZN9*]+@>XP+CLG(/+WD_QJKJ
MD[I2<G3 .F0-T(TTQP X@Z^&E>B=T8ZEG[+,;0<?,LF2]WKVQ%0V!6O$XA6N
MOW/7=Y]7%L[E$=V&Y +&-;"V206?<YHE \R?CC(8Y:P;P)DCU8[_ !\?']:Y
M@LI*BK7.\%8PGB"D\=W>XIX;V-3C&F.E>Z#]'R[@8MQ%LN6S92%T*64*9%Z]
M+1#,V\D=BSR2TG9]$D7@#'B(V66@0H56M@*(N$)!8),D)6#TH\R< <N'L/WC
M]:8CJ$9)UUSD>2<YWLZE.\/G< H#09SKGHFOI]:BC 2H*)<]JMXL4BER;9/E
MF:@:>MZZ9KVPT+'R@4>HY2L&5629:[%LJS.RP"W9NUBCMQA*'K:CP663X>[4
M<._NQX#2G4(QQ5W9)().$E.H((.<E1R-5'/A5GM0ZFKNEZ<U2:Q.-D1;1"82
M]58)$"217)G>5Y_C<&C143R^[*<H2B&C*<Y5W5G&<83'&O1" @$ D@G.OF _
MA4H<553BE.*4XI7&FPH9*'+'$(K$V!/BR(4Z%*:0_%EPY32V),62PYA3;S$A
MEQ;3S3B5(<;6I"L93G..4K0AU"VW$I6VXE2%H4 I*T+!2I*@="E2200=""0:
MK:=<9<;>96IIUI:'6G$**5MN-J"T+0H8*5(4 I*@000"-16GG:/2[LC4Y*4W
M5:Z>V)K9+B\UXI7([]@MM>'=_P!% 6:MQLOV,T\/;RF' L5?A'5E8C&)5@8$
MD/$Z0Y%VVZ'+Y:YTB7LW%<NUH><6ZU'8._/@A:BKLZV5'K)+;>=UIUGK%E
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MEC4^O';*3K[18L5>#"YDAY4QE$@'7'ZQKZ:\U.(2I*5'4D8T)QDX!)P0G).
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M38D[9V'0?55NC2+*<)6VX5PHR/ES"<:8I@\1]XY>?33U5!<9U!QID?,5@^4
M0/)\H[Q3D#)R1WD5PZQU+:5E:NI.UQVIH%;K-AZF;#H6 @J &U*;79],ONPM
M+XOY8<9!""5=:8#5@NZZ%*CQ=@  S$JND<1%M$&%,:X\,^S- XC="MW +A1P
M X$HWB,#&@.G$#3PKJXW5OT"#*U6S$%@=#%U<O)+TH- Z:]GM6$.^1I)K:>;
MQ3J1%U5BT1*Z>H5</W2#L4$$;K1T,$+3HA^7D;-PQ.%9\>_4>;&<^;2HZUC
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MNXI3BE.*4XI3BE4WZN=5KV8WKSP=)L;JA]D7;^_J-X?@:^#>Y)JW;P?K$?\
M)/DWH,^+_MO9_CZ?^S]T^_Z-]_H_C5MG?/;_ -)^^HSZ@=;DMC]05ZA4>D;U
MLPJ,U5X.YAM0/Z:K]3L+I^F#8*(L";L*=%M,5)*C-# I^;7E>F<3$>C0L0RK
M4J8[S=MO8)%^VXO+-GM&V=PBH1;F-K(]KF[)P;9/5-M,=D-,O7QYJYMID69$
M>'.>@GJU!I;;/524..KZTZ-]J(NR_1OL^_?[_P!'MIF.KNTC8:7>K;MS<KS;
M$6Z^2GR])8V:CO6ATQ=H%RI]M8N0ZY)>0Z_U\-;+"-EFPW;*S0+R]3!T,Q<&
MJ?9G:H)(I;6/*65L+-6"'3D.K;:7#FE,18TE#KC;:F75I6M"<Y5CH"^JN"+)
M>%VEAJ5=46JX*MD5\)+$FX)B/&$P\%J2DM/20VVX%*2DH4H%0&2.6-FD6IS:
M/9]N^RGX5D7>[4B\38I4F3$M2I[ N$J.I"5+#\>(7G6BA*E!Q"2E). :2=(T
M+,#8!9NH:E+Z_I3VI:LSL I8]""=(SR>YA9%#$UP5B(/&R3D,O!E&B)@;#;E
MU:KRXHQJO/,(+2D/:AZ+VBS>Y(M>S,FQVA>S-N1?)$[8J+L@_(VMC/A#RHW5
M,1US6I3+LM^4PR';;;G6XZ8*T"2Z%[ZZ9WQ)V<AJO6V4+:2_(VRNZ]FXMLZ1
M9FWT>)L++C*<83,+TF4S;WH4AF!%A2GE,W>[LNRUW-#AA,J;LR$+>Y6G:4;Y
M<BS^QWR,)P,2!]FS1>^OZ&6^(KF>4W\E6OW3Y;[]XGO"FUI!>;^H_*;W:OYW
MH]?ZX>BM 0_[$:\%*]&N<'[_ #&LJY37U4XI7C.<8QG.<XQC&,YSG.>V,8Q]
MN<YSG[,8QC[<YS_EQPXTX\*U#;^ZI#VSIQ<+1K),J6GA:I3#A\,1=#F=B-1/
M'B::<L,5YB8#H*LMN*$LB94.591[>"Y0FH 30$7RITD]+,^=,DV/9>6N);6%
MK8DW*,HIDW!Q)*7$QGDX4Q$"@4I6T0Y( W^L#2P@]>=&G1%;[1$BWG:>$W<+
M[)2AYBV2VDO1+0E8"FD/15A2)-S((+HD)6U#60TVSVEHOB"ZCJG8I8*V2H^G
MSF*Y)3F7 E>*GT]LNEWNYF4/$62P 2[B).58=8GD!L"$1:<1,ASI4=U#ZM;1
M-@]JKDQVT0MP.CK$&9(;9?>WAO!>XXHN#?SD*="-[.]D@YK9%PV\V4MTDPY5
MZ:6^T>J=3&9ES&HQ1Y.XMZ,PZQY&-U3;#CJVRDH6A*ANUBF(GEFG9+L(Q5;M
M5IRQ[\A"YE:N]4)H:8DKCL%QDB.4'J>BR(TIB4+(K'%QDN--A2B F<P_(L.;
MSLU<B$.2[5<XBQY3+JF7D$X(*5MJPMM8P005-N((/E)-7_-MOEM2"(=WM$]K
M?"'6VY<&4V2I!*F7D*05(6E2%)<;2\PZA2%I;=00G9+TM=3)FUEH^I]ISFIU
ML>BR7Z3<\L1H*KK&'1ERR(0W$B-1X$>Z#(#+Y5#@R/%@V(+%)3XXT<^#)8D]
M3]%O2:O:C_W'?%-HOC+17'DI ;1=&6QEPEL80B8TD=8XEO"'6]YQ"$=6L5RG
MTL=%K.S2#M'LZAP61QU+<^ I2WE6AYY02RZTZLJ<7;7W%)927E+=C2%-LK==
M2^R4W V.%N5CH5O Z\NS>MKT7KY,?4[\[6AUR;IYZ3&<:'6!=4+2(HRP)&25
M(DY%3Y#429X/*?7AM6<9W76AU D$).Z2#A6 <'G@Z''*N_%Q"44&.@EB:31B
M,*B1"9A,)D8DN29AMLS":1S#CK Y,^4ER5B$RZXS$P[Y#;BT-I5E4C.!DY.-
M3PR>>*U7"= ]6Z=2U&B32]IAQH8?3E#DU:/:=<N":O4J;HWI^R3+A5.(DX=L
M8G=U:V6MHE*G%GYS2GL8BSJO,"I542,Y'B=<ZZG^&/\ NOE"'=P).= A.,IT
M 0WDCQ"PO77S$8QV=TU!U3.VP.?]!L*R)J1DW'KEBIUKTP+V*^)'ENN<+K^0
M8/6P@';,#AE0V%T_NSHA9^1)<R0)/2AQ DYL.'.9&/1WY_RGT9(/ZQ4E#N\#
MY1 R 04;W%X)R21G 4V=3STSD5P)>J.LT/*MQX;BS1;58A\9J2_KDCK%FK3G
MAVX-ZV4@AJNE[]KE\:1LPN[T$S$L\<@R61$@%,7#!V7&F4JTO)\W_0\#WYJ
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M,>$XXI*<V2S])>Q5[DIAPKVRF4XH):9F-2()=43A*6G)333+BU' 2VEPN*)
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M,GI+_9.S_P [V'^JX^3CT6?5=R^V9_YE/E8=,_US:?L"V?DT_)D])?[)V?\
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M]5W+[9G_ )E/E8=,_P!<VG[ MGY-/R9/27^R=G_G>P_U7'R<>BSZKN7VS/\
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M!%/R4XQJ/'PX>\?]5XHDA1/DDCR=P#&\K(659WBE(W=Q7?W8XZ5)I#ZI&@F
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M<4IQ2G%*<4IQ2G%*<4IQ2G%*<4KPK&5)5C&?#G.,XQG'VYQG..W?MG[,]O\
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MHT27 E, DE*')K4EM]*<\-X0V5$#3.3@$Y.D?Z1$&.A_92YI2D2Y3-XM[R@
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MM(B2D0X<[QSJ!W'7/CCO\?-4!E!! 63C>2HC<R?FY2<)P"-Q(T&=,'PV*":
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M#>/B6I:2\]V8Q!%9CKEI>P2F/CB#,2#E'JI#L&8VRTM<5]*%*Q[9&W]::BB
M)NQ[>,J[5IN%&H5=:E8E2IQ>U[)O=7UE3!<(:-C32+J"UYNE7 .D?2X%"'3$
M:8;G#AJ7YC2I )X<B?0!D^P5F,:P@)K!25#.!Y<4'*FPC<F,3A/L!YHY&'2$
M0H\T^ML?*@-JPY-CRU,NQ49PM]"$YQGBHKB)N-15%CS4VFN*ARS/QV++2<&9
MBR;!EY<? */(Q*\IXSZAMQCVMM:IOG-K:\CQI4G"E=71MDT+9D:Q3=?VT';X
ME2N-DU_9)(*<U/8#76GSU"[16IKK6<H;*@B*%P24;&59CR4+95GQH5C"E9OQ
M2G%*<4IQ2HDV:M<4_IHCA2D,1-I-1I*D8^]X3=%O *.E2\XRE+3DXE%:<2K&
M,KRXA+:L.^#NI5-^H3KFL6N=JV35^NM8 ;XQ0$!XFPR%EN<VIN23A^OB[4W4
M*JU"K-@;]5&J5@ %I=B++0-3-,1PK,!U<<F0'8'M?TD;-[$3[5;;PBY2)%S8
M$QPVYIAQ-NMZI+T1N4^'GFE2'7'XTDIA-%M89:ZY3P+K+;FQ=BNB[:;;RVW:
MZV9VVQH]L?5"93<79#2KE<41F9;D5A3+#J8[*&9,8*FNAQ'7NEE+*NJ><;K_
M *BL(W8/2@<F#<J2.)5XN8'BY8,:Y9,9B$$$&8<[#>7GH) -+8\D\AF2MP<]
M'4TMQS#L9$O/2$Y!0XAYM24N-/-$J:>9<2%M/-*(!4T\VI+C:B!O(4DX&<5K
MK"P5)<;6RZVM;;S+@ =8>:46WF'4@J"7674K:<2"=U:5#)Q6TK1!_-FTWK4P
MM],EYZH!XLM]/;'F3A49(J?E6$_=PYB;"?2YC';&',*QA*?^G$4J6>*4XI3B
ME.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI6![,V;1=.4@WLC95@8JM(K
MGMN3M@E12$R*,07+P 4%^4T+B3IB(JB9.$S(EXC9C0&75SI[L:!'DR65.-5\
MC=>W2//)F@@K<@LV9KNV-DZ.-B:_6[O828[:>GT5M>S*H_!"5F?*\VGIN%9P
M5*MM+!>,U";C%)#BU)0J=T\NX'NX'./N-272NIG0>Q[4U2Z)M6I6JQR!9PS&
MA!IRY<>9 K=]L6L#BH19#/L\V4.OE3L==?'Q9[Q',D1*DMQ7!^&Y:U,'^'Z'
M&IA:-!GW'FF2PQYV.0R(D-M3XKCC!7#6'\C'D(=RIHAAC.'LPEX3)PUG#GE>
M#[>*BL8KVSM>6VQW"H5>YURP677[===NH805BSYE81;163M:R91'<<3#4:">
M O 0ZO"WAKT:;A.(TJ,XZI7&SMO6&+6 HV+_ %)=MM-0M5^KH%HZ/=G&*51R
ME?"VZSP4-/K0\&KY6U5^ 2FI7Y3$@DTC*L^5(RRIC3/=P]><?<:R9VT5EA##
MCUB!,MR82249;I<>VB0.5%ESDSV%+D82["5!@3IB93>5,9BPI<C#GDQWEH4K
ME-FPKTMN T7%NSWF5R&83<^(N6[';9C2''VXR7<O+91'FPWUNI1E"69<9U2L
M(?:4M2O2U8Z\^D4ID\&>2>4\@&IHI!<297'2I<A K*'\X(J80A2WDP\O9:2E
M2EX3C&<X4KDP2PLFW*>&DAY!J%*D09CL&9&EMQ)L3.,2X<I;#CB8\J+G.,2(
M[N4/,YSC#B$]\<4KBMV6N.H'.-'PCC9?+.!+C96"M!3,A:FV,#EI?RF;E]Q"
MT,^FR[YBT*2CQ*3G&%*PJB;HU7LNEIV)2;R!,TO+Y"*X>7)4+BQ7QAN?7)C<
M]HRV/ECLH-"YT%G,^/&3+6QYL/+\=UEYQ4D$'!K/$&@[DU0ULL,610TX^N B
M?%5-2RRU#?>>5%2[E]+33)$>\XYEO"&VIT-Q6<(E,96J*]<>P 9:1BXAL1)0
M;Q(R&7')0GDE\1$+=EY&*;>5B?B*VVMR1F+EWR$(6MWPI3G.%*Y(\F-+,>J%
M$()*+XO!ZD?+8F,>/P(<\'G1G'&_%Y;C;GA\7?P.(5V\*TYRI7%8L("4V.>C
M' \AHO(?B"76"<)ULI+BX?S)BCEMOJ3-D1\1I.7V8V77&<1W\N)3Y3GA4I&L
M(":^F-#.!Y<E>9.$1XQ.$^^K,-J(_+PEII];BLQ6)\%Z3V3GR&IL1QWPHDLJ
M6I7-@SX).(Q/&S8A"#*1YD:;!D,RXDAOOE/F,28ZW&7D>).<>-M:D]\9QW[X
MSQ2N7Q2J]=6)\K6>FW<Q8)(D0BF**7&Q2,1Q34L5[ZA )XQ%>3E*F9(>.2=)
ML/8SCR78B'?MPGMS&-M)C\#9/:*9&4I,AFT35-+3D*;6IE2 ZDC@IK>ZQ)[B
MD'NK-.CJ!&N6W6RD*8A+D9V]P5/-+ *'T,O!_LZPK12)!:#"DGYR7".)K3?I
M38@G2MLL96=2BQ\18*I5Z^-?J:0.2=;S5YUCDK@*@G3 %C 8PR<A82X+F./L
MRPT=$Z$[$S%E#^/M@=J[5L[\(-W)IX*EJ:6B4RV'E -A8+2T[P6$J*M\%.05
M?.&?*';72#LG<]JF+;\'S([:H+TI3T:6XZVV]VE,<)?0MIIX%UKJ5A274C*'
M26U[V\A?5; O1#:5^(7N6#<K,' (35P .7(A2S+0H5/,E%D;!)&ORQJ"A":<
M?;2,'3RD 9#A1E,DY,F=.PBU;:[3,[2W%EZ*RMF)$9+#)="0\[O+*UN+2DJ"
M 20E* I6 ,DY40+IL7LPK96T*A/242I<B2N7*6SOB,VM3;3*&8_6)0XM*$-!
M2GEMM*<6LIZM*6T%5W_IREIR++ORK)<5[*U#U3=&XV,JRVU8;%C8-9,3?MQE
M*7)X>AU:-G"<X[X$85E.<JSGF]/Z/4V0[;=HX"U*,:)+@26 3Y*'9K4I$@)Y
M%0B,DXT[^)-<_P#]):!&;D[(7-*4B9*8O4!]0QO+C6]RVR(H/,-NW.9@G)_K
M,9P *VE\Z)KEVG%*<4IQ2G%*<4J M1]4&CMZVO8]'U9='[-:M1&$5_8XAVI7
M:O.54VZTS):%3I%HK@6$].=A2H1)J/!DRW'!) 860E0TG E25,>W6I]XI3BE
M.*4XI3BE.*5H(^H/>\/=0UUKI*0?;(0Z)7:=4&00(R<?&BYHZ(;,VEMH7%D(
MAHCF+VTX4D+=CR2$.LQVXK<YX,AEKD3IM,ZX[9)CE;:(=KM<-#0D2&H[)<EB
M3*7N=:I.\[(4WU&\D* 4VTEQ3:<&NW.@<V^T;!Q)(;<>E7:\W&9*2Q'=D.K3
M#?C0$H=+3:]UF,RE+X0LY DR%LH6I:TF)PVV$RJO4L:^U+6P+C94K=@%QEB
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MV2VT!^F]W1IEGJ9>'M3915.LK'N$II,G7ZUY.HP\>-5I#)/2-1KL^V#;&J=
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M&\$/(*-]!.<.-DA;:O[JTI5W5=;'>)FS]XME[@*2)=KFQYK 7DMK4PX%EET
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M.4U3[N<UZB6QZGMT>-YXP+=9=7:KM2K>R+/MJR&6X]X2]UK:0VF<RD.EU*0
MDRFBI*^L"1A3S167?)*VM_?<7A=WV4$IY<F XVRMPE3C+F0V5'BI"D@[F3J4
ME.,YP1PK *_TO]5][F-C<T,!H\4XO#1*X;*M-8N1H:PK/WY=7H.KSMH&6B9A
M.,H:CV/85%BQU+1,=412PH7+NDO;2S,-DQC(G/8\AM+2H[6]W=:Z\$K2G_\
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MVQMPQ[=IJ[A =DCD<+(CR8@\'#F(&3;+;4W#92X=MA;KK;J0W+B.*(:DM Y
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MA2,D6QSJH:W%K%S6GL.M>9A7B>BOY4UYB)",(4M*E29T]6!VSZ3UL6?[9?\
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MIQ2G%*<4IQ2G%*<4IQ2G%*JCO37B=I[1U'7X4QD?+K<*TV@Z14Q&E21M=>D
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*\4IQ2G%*<4K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>g65062g86u89.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g86u89.jpg
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M 0$! 0$! ?_  !$( &@ _P,!$0 "$0$#$0'_Q  >  $  00# 0$
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M _BCS[?%MJ'-K\:'BR5384FK[._")V/F-*DR7,VJB'4%,Z]?^Z6]&X=T1F3
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M.KG9TO,K=CV]V(U;>)F]2J-P%D:9@@6.TH60%Q4"9RWCI5[(A<DXVYL.=3+
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M2+.0"QR?@YY& W!Y@IK&W\P=%9D@FRK997$!?FBL:_\ @'5TG)6K9.UP2_\
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MN<QH%P4"I0)&IP4H("'& A65.E0>1G_70_9=*BG2H/(S_KH?LNE*=*@\C/\
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M2G(W^,L\TCU]*4Y&_P 99YI'KZ4IR-_C+/-(]?2E7W7/<GPE+Z'*C(^XU?\
MX@2L!Y.:'E_V19SR_DTI5OS/\:'K\[_Z1>E*MC2E-*4TI32E-*5K3@**]]R<
M&L6^6?<O,:=?$UGW=%JCA#8SP-34D+8Z5M"85@V%6LP/,56R2:J):K@RQ^L
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MV(0^Q!@@[,P B9[>0)W2/ILP<FW,?YYKAAQ>9"?'D: 0&TO(S37$("M5M[2
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MD/O]R]3[;T:&D!E#W3="DOH^A)&=>J3MF=C+<E&\6"!EVL=/HR[E,7C@B_\
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MV>=@.48<?A:[%GRT]-Q*$I.1D=%@^0:/8]*/D5I#A&;MLFX(9R99FS%!<O"
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AH8 <[<XP XZ3]R@L@!$U ,;A"FQJF#8!3 ([2@'*%?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>g65062g87g13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g87g13.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[3(&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ,>J^$G>#A"24T$!       )AP!6@ #&R5'' (   (  !P"!0 226UM=6
MYO=F%N=%!I<&5L:6YE.$))300E       0N\5R>7PHAR[*7W^+9N6^H3A"24
MT$/0     /X (    @;FE7 0   $, 80!N &\ ;@ @ %0 4P U #$ ,  P "
M  <P!E '( :0!E ',                                    !! H,W
M#4#@/?@0,!  $ Z@IO"&0  0 4 ?W_ @ !     0 ! $P 90!T '0 90!R
M
M                                       0    (    !     0
M                    #4#@  0DI$30H,        D H  -D   #9
M         !    5E0  "1M   L 0  @ (  &!/   $:@  + $  ( "  !@3P
M  !&H  %94   D;0  + $  ( "  !V @  ] $  &!/   $:@  + $  ( "
M!V @  ] $  "P!  "  @  =@(  /0!  !@3P  !&H  %@"6 (8
M
M
M
M
M
M
M
M                                 0)P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                 "     P    ,          @ !
M             "  ,
M
M
M
M
M
M
M
M
M
M
M
M   0 !     P    ,    "                          0    !     P
M   !0!   #          $                               ,    "
M   0         !              !D     0   %94   D;0   0    $
M!65   )&T   $    "          $    !     0
M                    "3              ! #@   0    $    !
M                    $    !    __\                   H
M                   0                         !
M                       0        #__P                   @
M                $          0                              5E
M0  "1M         0   '\   !_    ?P   '\          0
M  YP,  /\                                               $
M
M                           0              "@
M        #G P                                             %
M   0         "          (    !
M#H P        $          0               @
M$         !                0    $
M               0    $    !                          $
M                  !    &0
M       0         $                         $, 80!N &\ ;@ @ %
M0 4P U #$ ,  P "  <P!E '( :0!E ',
M         !! H,W #4#@/?@0,!  $ Z@IO"&0  0 4 ?W_ @ !     0 ! $
MP 90!T '0 90!R
M                                                       0
M(    !     0                        !G,Q*O 0 !
M                              .$))300Z      $+    $     $
M    MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
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M]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M  0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&
M)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M   P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M  0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M!";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M    IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U
M!#     $QE9G15;G1&(U)L=$!/P            %1O<"!5;G1&(U)L=$!T>
M           %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G
M1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<   ,"    #&-R;W!296
M-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG   "00    MC<F
M]P4F5C=%1O<&QO;F<      #A"24T#[0      $ $L     0 ! 2P    !
M$X0DE-!"8       X  #]AQQQ D8XY/X   #A"24T$#0      !    !XX0D
ME-!!D       0    >.$))30/S       )           ! #A"24TG$
M  "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V
M9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0
M8       $X0DE- _@      '   /____________________________\#Z
M    #_____________________________ ^@     __________________
M___________P/H     /____________________________\#Z   .$))30
M0(       0     0   D    )      #A"24T$'@      !      X0DE-!!
MH      S4    &              'C   '2P         !
M            $             !TL   'C                      $
M                      $     $       !N=6QL     @    9B;W5N9'
M-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,96
M9T;&]N9P          0G1O;6QO;F<   'C     %)G:'1L;VYG   '2P
M9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6
M-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M!28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $
M)T;VUL;VYG   !XP    !29VAT;&]N9P  !TL    #=7)L5$585     $
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ME-!!$       $! #A"24T$%       !     (X0DE-! P     %UL    !
M  H    "D   '@  !,X   %S\ &  !_]C_X@Q824-#7U!23T9)3$4  0$
MQ(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5
M!)14,@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! ?_  !$( )L"50,!$0 "$0$#$0'_Q  ?  $  00# 0$!
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M?S9T+'&9VMAMAOJ*Y$;VM FQ4?O#6)L-1<&,2RMM9_-B<-1EK98< 9.&,-O
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MPPL'<)WTZ3U4!=(7UH(KA52.+)99)WBTLJEU=1:X#(4%4!1!\0X$I'F65*M
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MGVPW#'9)G.9KM!D208:Z<DHR[],LV>A)"+Q0*$FL^$7;BRC!DOB1N3H% H%
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M]TC&8CP9@A5?<:FH.)4(7*FETX85!#0N0G\/P_QT^++6@4&N/<GBCZRZ,/\
M;4;S:#(XKB=;/!>Z7=FM4DO)]D4=:6$'"QHR974K,$YSY$.WN!B")C8&X(G*
MWN)?#'MNC^A>>=):KEJWFW_:?T<A6)JU/_<9><E2_J1D\GE9U:,9.G;1U<I1
MZ;8Z;8LZ$FE$>N?\L0_M#_#_ /1)V[.4GOC7.\U.E7]M[92^PFO1O\)W'VA_
MA_\ HD[=G*3WQIS4Z5?VWME+[!KT;_"=Q]H?X?\ Z).W9RD]\:<U.E7]M[92
M^P:]&_PG<?:'^'_Z).W9RD]\:<U.E7]M[92^P:]&_P )W'VA_A_^B3MV<I/?
M&G-3I5_;>V4OL&O1O\)W'VA_A_\ HD[=G*3WQIS4Z5?VWME+[!KT;_"=SYR_
MXB'0&W\B4[Y?^T=H]O\ \^,\K?\ ]>&KS4Z57YLC\ZY3_:KR:U'K1'YQ/[1+
MY^T1:!>@3QV=HW?.G-1I5?FSME/AUUJ/6C"E])]HBT"] GCL[1N^=.:C2J_-
MG;*?#FM1ZT84OI/M$6@7H$\=G:-WSIS4:57YL[93X<UJ/6C"E])]HBT"] GC
ML[1N^=.:C2J_-G;*?#FM1ZT84OI/M$6@7H$\=G:-WSIS4:57YL[93X<UJ/6C
M"E])]HBT"] GCL[1N^=.:C2J_-G;*?#FM1ZT84OI/M$6@7H$\=G:-WSIS4:5
M7YL[93X<UJ/6C"E])]HBT"] GCL[1N^=.:C2J_-G;*?#FM1ZT84OI/M$6@7H
M$\=G:-WSIS4:57YL[93X<UJ/6C"E])]HBT"] GCL[1N^=.:C2J_-G;*?#FM1
MZT84OI/M$6@7H$\=G:-WSIS4:57YL[93X<UJ/6C"E])]HBT"] GCL[1N^=.:
MC2J_-G;*?#FM1ZT84OI/M$6@7H$\=G:-WSIS4:57YL[93X<UJ/6C"E])]HBT
M"] GCL[1N^=.:C2J_-G;*?#FM1ZT84OI/M$6@7H$\=G:-WSIS4:57YL[93X<
MUJ/6C"E])]HBT"] GCL[1N^=.:C2J_-G;*?#FM1ZT84OI/M$6@7H$\=G:-WS
MIS4:57YL[93X<UJ/6C"E])]HBT"] GCL[1N^=.:C2J_-G;*?#FM1ZT84OI/M
M$6@7H$\=G:-WSIS4:57YL[93X<UJ/6C"E])]HBT"] GCL[1N^=.:C2J_-G;*
M?#FM1ZT84OI/M$6@7H$\=G:-WSIS4:57YL[93X<UJ/6C"E])]HBT"] GCL[1
MN^=.:C2J_-G;*?#FM1ZT84OI/M$6@7H$\=G:-WSIS4:57YL[93X<UJ/6C"E]
M)]HBT"] GCL[1N^=.:C2J_-G;*?#FM1ZT84OI/M$6@7H$\=G:-WSIS4:57YL
M[93X<UJ/6C"E])]HBT"] GCL[1N^=.:C2J_-G;*?#FM1ZT84OI9_Q[O_  /)
MC':L@-P)[X(3P1"*^DXJ+?*ECV)%0!Q'+V-EPU8? $>V&5N4#P&%QQR\-K9Y
M6_C70,X5'+YLKU:S?6=3_<5/+Y2KY;^G2FG0_J9.E-&EJ4IBC-*C;'1,Q%L>
MR%_B?TGICP7CTQHA_H=7L8#YC6S#IC1#_0ZO8P'S&@=,:(?Z'5[& ^8T#IC1
M#_0ZO8P'S&@=,:(?Z'5[& ^8T#IC1#_0ZO8P'S&@=,:(?Z'5[& ^8T#IC1#_
M $.KV,!\QH'3&B'^AU>Q@/F- Z8T0_T.KV,!\QH'3&B'^AU>Q@/F- Z8T0_T
M.KV,!\QH'3&B'^AU>Q@/F- Z8T0_T.KV,!\QH'3&B'^AU>Q@/F- Z8T0_P!#
MJ]C ?,:!TQHA_H=7L8#YC0<Y7;Z)3AHL4!P='*FAP2P7CHX../*#B8A8>-E9
M0OX,?&RMXU_!?P6\-_!>@REH% H-:$R<0Q/U[D^>&U(C*,+S5CM>AAN,P9L+
M,>,DR*=D2,7C(:\:?;]G"4HTBE")%<6D(G-S$XYD)05U(X20TTBNJIT*P006
M7XT40%;'72X8W=R7&CX"UW$UP6U)UPFRCTLVG: #>Q GTP?DJ8F:T8[NUV03
M-CGA7VOME/%-%BZ*F*2PY5M&13 9>N7:11D[4^.]G=:G=$C*8#]()KT<4N;'
MEE&[(AV*@$==4W4ZW,SD%Z,@P[EY'5T@FS+-LC)S42\%%7,."SM.I2'8FLA@
M\U.(]M N-AO2DNQC&#084?7TU1IT:"XV9&3I&?"IN!,=HQ2'5%UUERI D3H#
M8:2]'TLE6C([-?KJ<(#G58Y4CC.76WDX%(>?/J39'6V6XJ@_Y[CE5C6"YD?$
M:Q"WGZ(TX>6'*RVW#4K.QWCIR3KE+$T.]>>K9?;H3F (%)CD=C0:3(7DINI0
MV5X=$S>+"Q6@F:-=TL1M"]8]N91:AY1=\]17K2M QM$Z>&9.N*6MBDUDE$!B
M,0J[7$3)E"IUX/  @4/N]VD4M#10AU=RN(J03SRC@'1BCB%LJ8IJ0X!:T(SR
M7D8,![B2R36$J-RB3 (S <IQH+923%H"3#9!3&.+^",$W<HM%D8NX4QS)"\F
M##(H"T>20L15XM.K23/#Z@#*SN4W,Q5N5&8*>03$=KAAP2-#,;+TJOQAH<=)
MT@CS0$=*-AKN,HCNMP1FA1TX72CF&JCO(VLFDLLH//GS(LE&XOL2/DF"BQG#
MTMOB3E"0W3&!9D-)=UX?I1'5FO$R5,ZB[%Y^,2?ER+A68EL16NJ*^*'("DZR
MQY'5VS]7,7+9.3CX2#J=Q(&;/3&UK378V5]'GF9TV)4YQ,U#1  $,@NOS45N
M[9+,AHECKH53Q>$"Z LB-E*<"B?/+0;PS),\X3,*F69K,(VVMWKV%U6E-SC+
M#5AE]1VDLR>))+0LSPG><G1%@^$]?7?)EMC9 DG!Q#LAGM%URZV4Z$4U@*<7
M%S8A]VI"RBR,XU$BL-<F%OJVU>T[+-34AOU9TNCQ_0JW8=D"8MG%M@20'&2'
M"$F,>25YB-$C%.$O%Y!?S\*2ZUG''R67+3,D$3I!SDWD@L\9PK(D?COU_3HW
M6^(NIK[B;@FGGI[A($;0XP!MDRT4A*.KO,7RXMC$Y(78N*O&<Y@4':$Y4IN1
M<Q('=1_%LJ#9>T7K([CS)$T<:0&X^'FV&IF&W*@4"@4"@4'EHXZNBVV6TNR4
M4/. 887Y);"!!Y%L*ZNDJC7(@$5X)^/A5$3A EQ=2C.8N*>J$#-\P@! +X&<
M,;"W$QSPP]J_TTTFS%F3,]>J^=,XY*IY;*YRIY;)Y.G0R].:62FJU;)Q3B<E
MDJ<1&O0IT;)F)MHST66,=.C,ST1[/P_%I(\SYQ)^JF]/>&/>^%>C<OM$-MU?
MY-;X=IU*5WC&\\SYQ)^JF]/>&/>^%.7VB&VZO\FM\.:E*[QC>>9\XD_53>GO
M#'O?"G+[1#;=7^36^'-2E=XQO/,^<2?JIO3WACWOA3E]HAMNK_)K?#FI2N\8
MWGF?.)/U4WI[PQ[WPIR^T0VW5_DUOAS4I7>,;SS/G$GZJ;T]X8][X4Y?:(;;
MJ_R:WPYJ4KO&-[\OP?>)/;^>J;U_^'!'U_\ ]/"].7VB&VZO\FM\.:E*[QC>
M_/,_<2;JIO;V\P.]].7VB&VZO\FM\.:E*[QC>>9^XDW53>WMY@=[Z<OM$-MU
M?Y-;X<U*5WC&\\S]Q)NJF]O;S [WTY?:(;;J_P FM\.:E*[QC>>9^XDW53>W
MMY@=[Z<OM$-MU?Y-;X<U*5WC&\\S]Q)NJF]O;S [WTY?:(;;J_R:WPYJ4KO&
M-YYG[B3=5-[>WF!WOIR^T0VW5_DUOAS4I7>,;SS/W$FZJ;V]O,#O?3E]HAMN
MK_)K?#FI2N\8WGF?N)-U4WM[>8'>^G+[1#;=7^36^'-2E=XQO/,_<2;JIO;V
M\P.]].7VB&VZO\FM\.:E*[QC>>9^XDW53>WMY@=[Z<OM$-MU?Y-;X<U*5WC&
M\\S]Q)NJF]O;S [WTY?:(;;J_P FM\.:E*[QC>>9^XDW53>WMY@=[Z<OM$-M
MU?Y-;X<U*5WC&\\S]Q)NJF]O;S [WTY?:(;;J_R:WPYJ4KO&-YYG[B3=5-[>
MWF!WOIR^T0VW5_DUOAS4I7>,;SS/W$FZJ;V]O,#O?3E]HAMNK_)K?#FI2N\8
MWGF?N)-U4WM[>8'>^G+[1#;=7^36^'-2E=XQO/,_<2;JIO;V\P.]].7VB&VZ
MO\FM\.:E*[QC>>9^XDW53>WMY@=[Z<OM$-MU?Y-;X<U*5WC&\\S]Q)NJF]O;
MS [WTY?:(;;J_P FM\.:E*[QC>>9^XDW53>WMY@=[Z<OM$-MU?Y-;X<U*5WC
M&\\S]Q)NJF]O;S [WTY?:(;;J_R:WPYJ4KO&-YYG[B3=5-[>WF!WOIR^T0VW
M5_DUOAS4I7>,;SS/W$FZJ;V]O,#O?3E]HAMNK_)K?#FI2N\8WGF?N)-U4WM[
M>8'>^G+[1#;=7^36^'-2E=XQO/,_<2;JIO;V\P.]].7VB&VZO\FM\.:E*[QC
M>>9^XDW53>WMY@=[Z<OM$-MU?Y-;X<U*5WC&]Z2]9]2MBF5K]#[2=,7+*.XF
M\P6\E+268/H @Q!0*$0PC)47,LKC 9YA"6OCED$*)A>]O^7.]OXU\UZ35JKU
M[2#/%<JN4C+5:LYPK.6R&5HQ2B,IDZ>4F:-.(I11I1$QTV4J,3?#-[(_"*,8
M1$)RZ.,V?@!3]<1_F5<&'1QFS\ *?KB/\RH'1QFS\ *?KB/\RH'1QFS\ *?K
MB/\ ,J!T<9L_ "GZXC_,J!T<9L_ "GZXC_,J!T<9L_ "GZXC_,J!T<9L_ "G
MZXC_ #*@='&;/P I^N(_S*@='&;/P I^N(_S*@='&;/P I^N(_S*@='&;/P
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MUQV.*[R:^)RRP(043\1M\LNLQ$C@U,"N*YT];DH1H($;L.6B$@)!]R KRS?
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M""PJ_2,?8MPR3<I^)8_.N0CF66%!L)BB;.%\0S[H% H% H% H% H% H% H%
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M Y ?[D7_ !Y_M0.0'^Y%_P >?[4#D!_N1?\ 'G^U!5D$ :RZB^$$7_ZLG?\
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M>Z%T(ZJN%[GG(2N>!&(IP:46+)A?PAF%0*!0*!0*!0*!0*!0< I8L/E;(8
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MGJH;B2A#%[XF/I(J5",F<R/(9##"9AJ[X@AOR$;&;/L*,)00X^/1OK_JPY8
M9K@V3V729[4'!DZYI<SM2=66>W' OI\G2:\#)-/0@R+_ "3B0C2\=:*(Y")M
MH#'R-@ETG)#*-O*8/)Q++_'XB@/%3.(L=Q2D3!)BDXA(5RV;91)[M]^1 7=1
M]C%(/3=>S$BG%X^X&P7;J&F)X2TAJ)=S$&Z/</4#0*!0*!0*!0*!0*#R#?\
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M5DP9Z*I351^.ECDU3:EJQ:KLQY$',\I0>6J;A+(KG(WC0@V+KS>0W.6'-*2
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M5LKJ?T A)W/S?*A%KRU/TG2$:*8Y=D>,]O%1FS%6N$)D0W"Y6VXB2/!2<Z9
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MP(2-$,*1E [8.-&+&U=N(ZJX55VK@IM9<#H7W*ZURX'TNYW6[7:JKKL=;B4
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M9%@]I1(=0#*0WG4H'&A(KC3 S%@F\C-$,@7R>K?*EE9Z/1(1PJTX\-V2YTV
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FFX&#B&GA*P1X/'#(;$7$6Q@?E S&H% H% H% H% H% H% H/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>g65062g90l00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g90l00.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1744&AO=&]S:&]P(#,N,  X0DE-! 0
M    %;B^56 X0DE-! 0      !D< 5H  QLE1QP"   "   < @4 !5!R:6YT
M #A"24T$)0      $'&R'N^RK%WYEXQ?IGQ&?D$X0DE-!#H      0L    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585    !0 0P!A &X ;P!N "  5 !3 #4 ,0 P
M #  ( !S &4 <@!I &4 <P      #W!R:6YT4')O;V93971U<$]B:F,    ,
M %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !
M $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7
M $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B
M;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M  !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M          !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M         $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!R
MP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M     %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C
M4FQT                4V-L(%5N=$8C4')C0%D            08W)O<%=H
M96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,
M8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M    "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#
MO_XU  (  3A"24T$)@      #@             _@   .$))300-       $
M    'CA"24T$&0      !    !XX0DE- _,       D           $ .$))
M32<0       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M     0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M 0 M    !@       3A"24T#^       <   ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M   X0DE-! @      !     !   "0    D      .$))300>       $
M #A"24T$&@     #-0    8              H<   =D          $
M                     0             '9    H<
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   H<     4F=H=&QO;F<
M  =D    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   *'     %)G:'1L;VYG   '9     -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
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M# P,# P,# P,# P,# P,_\  $0@ -P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MQ__:  P# 0 "$0,1 #\ ])/6>D D'.QP08(]5FA';Z2;]M='_P"YV
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ SP)= P$1  (1 0,1 ?_$ !X
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M[) A!FD[!XQ-SHJ&(JJ-B31!)H^<-B+$..;Z/W0'+P#R5Q3/G5(9+&1\0;9
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MUW?,$/8.>00'#.S=/4.KJW#XJ:JP_"H*BHJ*"KEHINXA='GE8Z>)S8G-%Y-
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M]1/WZ>\?^MGN8]>^4OVJT_HQV:_N]@?^4T'^W3\3Q+^T:[_%U'^HG[]/>/\
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M;*W75LMK7AK;;6M:VVUK^7@IP4X?R\'#HBXZ(KX;9/\ Q);>_P"_#$__ *]
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MM!H415:L4F[52Q*]\0!.7KFZEZE]:JN%U5*\/!6[@I2E/PM?<+';X5G>[XT
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M890 OH\,K,3%-5":22*JAJ*D&*2"*:,34T(BBCRPNGF!)=*X][)*^3U*2.0
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M6L_^ILB_[=HB=JC*7BUG_P!39%_V[1$[5&4O%K/_ *FR+_MVB)VJ,I>+6?\
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M=\O\J[[=+#<.011FZBE7"'#??_+)?[UW=V_\]00 #8#8?#@BAWJ*<:[^'?\
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M5$TE\D,,;I97Y6E[LK&-<YUFM<XV!LT$G0%'O9&TOD>UC!:[WN#&BY %W.(
MN2 +G4D :E3WE%.^7^5=]NLK#<.05E)!DJ FB,A#AY"+*%HD0:BI0-'DVSQ_
M'2CX6Q.,QQMHW647%O708F.+-VKVQ%98<_9O$[+F[A)2_62GEB9#++ ^..I8
MZ2GD?&YK)XV2/A>^)S@!(QLL;XW.82!(QS"<S2!4.:XN:US26$-> 02QQ:'
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MO*R 4%N./U(&0A>.QX(>%(P 9$D,+LBK=9\N5@:DB06F[F7D0Z$A:$F#.X:
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M3QTT%.Z)[&M!E8R6=K[/H*EKPZ*0AK&L+7=_.96AD4@D@;&X.9(V>5V=TCY
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M-;UV-MUE%HNC9F#"1*/F89E_(H'-[TY.QC^03]]")N"<WH#=OQ^/H2$&[',
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MC'"+T631(7-72-UUMM]%DEDDR*GV&-<C%';E@,@$U(OF3DNS>,V$5.O';1V
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M@X3LIA^!8IB<%55TM),ZCHX*JHGK'13"D8*. U$L/I#8W1>D&/+DB<YI<Y[
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M9!I:9=N@\PC5<BK1,L$'H.TT3X-USA=EQ5&EI%DLXVOXP,LUX^K J0/'BHC
M*>,MT-#4E=IY1E>1)-CL'+1UB1@]? CMZ0^338NJ!BPT22A585<D==<FB1JL
M12"';$PKE %%IA3) Z?S%]B>RY-.,VH7X\$37<%.,0%3!X,Y<H.U65@F-A#"
M3M]8U;(KGFS;C4L<MG-Q%& ]3X&'#?6Z\]DL*FZB0XA0:<A#%O+(O(29_)@(
M;;+XT/*%"C,$?2QS:?C[^K1F*7%2-FF2D@Y=,3?)5_OIO^2*9I[,<:2EC&$P
M2LGC+ ^&Q-)&A(D'*%95*;#FV&2Y9.#(.W9DG0XQ9()5'UA":#&/%B XZW,,
M1:CU()4*2?9^_@BH$ELTQP"2D_/LD2]\Z!79/*-D[(<@#0O!8ID&.F!QD91.
M$&I@3(W3*=.&=6J@ZUN-,!5:KJK-'%.2(OD:VZ8U%[ML^ 9F$<#L%X&*S!^0
M#9!D2\&M+,7)BV-8V +2U1RV<M&TC*&A)D&6YQ1R<BK&\A9==<ZK=4BJIKLG
MB480S*5-K2B;C(V&W!*PTN &VK08<*B>*QL[Q1+91)F1A!PU(389*PTFBX^C
M9P,)("7#56PHV=N[Q9%Q,[(\6A"Y8>-R!,C!&.2.:C56AR+"680I9C#-^.<5
M21-RN*E%I1%N;0R&V>#*-;T'+:HAU59S9<10M'/O[^_TU+[%MF^-B4ZBS%22
M%7+XA+X<1)Q=V!4I#>Q&4[DI3@NH1)^SE[267N$+0;4SRMI%LXJT5684)<[K
M833(D0V4P!0?B^2E'^094RR/!<@O4 (F/*!GZ\U%X/D^2P@J,LR=[(M)$V),
M/4>S<1ZDF"R%=(98[,B%RU0=I%+([L:ADI,S4 (F<^46A,6B*Y,XI%1*H1&9
M2_&!O*3(<HW%%2IA ):P'LP*!0LS"#7I1=Y7KRU?6!P1PBJ*2;-,=OEDT(NT
MFXX:K>/-!&J(5T;R)D(<CMXCF2% V/&JIQ(%(5I)('1&C*YJ+57:.&YVUDX(
MMQ38(H_E][/O@BM?,-H$'B0B9UOR%*7DC%H9?=QUA6,"&S1O7$>/<=9%+!II
M6D@<.1<CL0FS^)%APVU]8'DP)SRRRJ-JC?1%@!HB:(FB)HB]$W4<OZ#\I?WK
M?Z0CVM(_'Y?59R>'S^BV]:T6::(FB)HBI68SF&X]#7R&<R@%$@B=ZJ=Q20$F
MHMGRB#%X4<)V+.U4[5+VXP<1)N+$^-<@.'OGZM+&C-RLE!(&I0 G8JJU*)HB
M:(I8&-!Y$,:&H^6&G [^R]1B6$/FQ(:]335O1O4:/F:JS5RG:LFHE=>BK?;2
M^RZWAX;:THN#L**8*6<HG>GP\''LNLX>#AX.-;6WAX/BX>#AX>#AIHBU11'8
M5D=;!. \;H;D,62T%@W$#C$6*3[[;0_?BB&-)9B-?%1\C*H\2SX18GYJ]C]@
M!]'92*7C0\38G*PI&-R #-GC$;3+<#UK^ T\"+'^7';POF )T.IN=?$&X\/D
M>NWY#>I/XYBF;XYE5YDZ22Z*1PM(4*8HE$>$DHT?QZ?!('^U]*7*KRY,\V9;
MD"$XW))&'0FBRDHFKV-U8V#&G/GC(+[=-W\_Y(7D@^%[:C3[TL-O@MD"IS&&
M*64;B*Q2&8^'KH7M(G'E'0F.-5T&Y$2,4;A!UU[5-7@+R,(PJDT2NO5)G!S;
M@O>$6]BUKANE[?\ 7[^PJV)UU/%5-V2Q_GX054P.M*24<_+ !U[I*Q\8&"K1
MUY-^/:WW6KN6H^TN*YZLG96QM4BSHM6RYPE2Y<::[=GR46^GGL7=3),%23L.
MF[1O)L&(\D\94NX5V[ JN3:CG:MG^ZB\<!BJ*%W#_"O8N*?%Q/CFX\K_ "3[
M^^:E41ET8GT9"S.%G1DGB<D8(E8_(@KI-\'-BW-*W-28I\C6YN_'/$Z469/F
MUZC5XVO3<M556ZJ:EX$'4(00;%34:28&&#0H+=)/1S]"QRS=H75N1<MU:<9-
M9*ZM*<9-2W@NLNI3@NMK2M.&E:5U (.H\4((-BH2AH2B99QU4BS3.D!A(TP$
MWKV6OW@D.Z%,2Q%JVNK11=F->'0K9\NG;=8U6+#DUZV7/&]%)OK;YI]_?)3/
M1$T1-$31$T1-$49O_.$/TR7Z]NH=L/P/Z(H=_P"/=_:N_P ZZE%QT1-$31$T
M1-$31%1##)6/R;<@[:3&/5;"[C'/UW!-JR3;(@#CJ,F'UUSU1OQQ;&0,7@94
MLGQQEQ%LLU2=J*IW6TZG458PL:ZFFO)W>0-C<XN=-$V>-GJ@VD?"]DHB-I Q
MP<6@$*@EC-SG;IFO=P%@UQ8XF_@' M)V7!%[KOW3>%V/>MM\OB]A'@1NZWW'
MQ-KWBN65Y%O=S6KNB_ N/34?HUY/@5967NK.,A;<I2GHM5D[ST:?N]1G[F3)
M=K@QPS9<NCR&'71Q#3KHISL!L7MONS"^H)&E[[ 3\ 2N"4[@ZZ*KA&9119!%
M=HU662D0A1%)R_<N&3!NJI8\K8FN]>-'31HC==11RY;.$$;;U45++9-)5 @&
MFJ 2'. ,,@):QH>]P!;<AC'-<XC1K7!QL""H$D9V/8=0-'-VDEH&W:2" /$@
M@:@KB2GD.$BY :=R,7</BEUR<C48.*%5PZ]BU6]6KUD+H\?)/:N+;D+67-JN
M[UK;DK$;E+:VT,I*F22&)L,@?4 & /;W8E!%PYCY,K"RVN?-EMK>R&1C0YQ<
M+,_:MZQ!W$-N;\+7X+&;.6 L![AS#'(F0CL'/A(AB[+F(FO7MO#)-&8^3RR[
MQV^5EJ3PW:\:")E&+88Q3!*IJ-W%B)]WQK[:+(\?W<*Q?%\&B?14457#+4U^
M&XD[N755/43,PYE<P4Y;%E=)33^EO=*"'#- T@&QMR5%+353VS2ECVQPU%.,
MPC>QIJ'0$ONX$-D9W30TW&CS?:%KVW&['G0^!'7&!\RP6JQJ%Y'A&1I)/YO'
M@0\'CT[M_P .X+/VMQS?&V3$R]EENW\+(#=S"Z*2=BZ3,AP9YMSJ^]E]C@G:
MMKJR$8OAE61%54-70P4=)-+)-608QB>+P9GNKZ$QD_C,L,6<5-.]ICDF@=8!
MWEU>&98'BFGC&:&>&:2:1C0R%]'34CM!!-FMZ(Q[P.[<'9FAXOZN5F%\4;9A
M<Z!RD!F>/S5]'9%F:0.A[ZT%:&>F<[FX0U?"7CEQ;R%I>-G</49"PM[E0\V?
M-GR)%JFX&)\G\]B>(8Z^DFIYL,FI63P87"'M[[O6Q81%5EDC0#?N9X<3SOE#
M>Y>US3&XM>;^A!#2-D:]DXD<TU!L2S*34R1$@Z?ML=3!H;?,""'"[=,]([/X
M5+4G*T<E 4M:S5-I.K&SY'ET*1R0E8H9<*M5;DW-C%E(09874C5+F#A=BM<U
M<KH\16[Y.>DJJ8M$\$L>81%I<TY3W\,=1$ X7;F?#+')DOG#7C,T&X7>V1C[
MY7--BX&QU&5[F.TVV#VN;?82#8J(TGD&?TON8S.*/;4DU%5;FDB#N:)I(I$%
MU5+ZHO+Z6)I(""JRE]W!;8D,(*75I8R<W)0ZDJV6STU0VY &:&1MR2P "[1<
MDRQ@#Q,C!M>VX21G8]A^#FGVN/NN_P"5VXVEC_*F-Q9!D+?S>--GC_L@Y"VX
MJUN03K%+!E\CH^>IJ7LAE0_7H18]M).&E4EBC!#@JNZ03ONR@K9&.D92SN:S
MN;VC=<^DF009&D!\G>]U)D[MKKB-YV-)$&6($-+V@G/XC3N\N>YV-RYFWN1;
M,!XJ<=FL-ZXW".RV,]=K;D[+A?7X5UQMO6:+/T;;F7.^<TN58MUWJ=M4J54:
M(K.;:513OOMS]&J<G>^CS]UK_6=U)DT<&'U\N71Y##KHXANT@*V=E\N=N;V<
MPOJ"1I>^H!/P!.P%<0LUB4D)/A$?D(HT0&B AYX@,=I/;4PLD<G&8(I8X;UO
M;+LB;N-'VS5=NLK9<N)?)75MO1NMTEI:B!C9)H9(F/EEA:9&EA,L#87S1EKK
M.#HVSPN<"!I(T^*->QQ(:X.(:U^AOZKRX-=<:$$L<!;V2JHU@K)HB:(FB)HB
M:(JQC'\@Z_2I_J5UD_:/A]2M(_'Y?5>2W?'B;)YK=OGHL'@<K(C'\\?K,W[(
M,^7:ND+FK.VBB*R25UBJ=U;:TI=;6M*\%::HM%BI3">8J4NMIC:;4MOX.-;0
M 2I2[@KPTXU*(\%W!7XZ</#P5^.FB+[7"N9*TK2N.)O6E>)PTJ")5I7DZ<5/
MAI5'@KQ+?X-G#^+3XK>"FB)3"F8Z<-:8WF]*UI6E> "2IPTNKPW4KP(_'2ZO
MQUI7XJU_#HB=I3,?!2G:XF_!3AX*=827!3AKPUX*<CP4X:_'7@_#7X_PZ(OE
M,)YBMX*VXVFUM;:\:E: "5."ZGX+J<"/Q5I^>GQZ(OE<)9AK^'&TUKPUK6O"
M (UX:U_#7XT?PU_+7\-?RZ(OO:3S'6VVRN-YMQ+:UK;;UA)<6VMW!QJVV\CP
M4K=P4X:TI2M>"G#^#1%/8UCG<!#Y(#E\:A,]$R2-F!L@"%4(^]478& [] F-
M?66.&JR"JC1^V0=66.$E4;E$K>43OMX:5(I2XPYFITX<.G&.YPHX=*7*N%:@
M2-*JJ7W\I===2U"EO!Q_X5+:4I;;6E.+2E*4I0B@]I7,G#;7M<3?ALX.)7K$
M2X;.+PUMXO\ $_P>+6M:TX.#@X:\&B+YVDLQ5_#C:;?E_P#@!+_>_#_Y/Y?R
M_G_+HB783S%=6ZMV-YM=6[@K=6X"2K6ZM/P5NK5&M:\'Y.'\&B)VE,Q\%:=K
M>;<%>"M:=827!6M*5MI6M.1X*\%MUU*?FI6M*?%6NB)VD\Q>+:;?E_\ @)+\
MM:5K_P"3^6M*5K_SI2OY-$3M)YB\6\V^@27Y^'O/Y_C_ .OQZ(N5,*YDIQ.#
M',XIR?#Q. $3IQ.-PUNXG\3_  >&M:UKP<'#PUX=$7RF%,QTX>#&\WIQN#C<
M $E3C<7\7A_B?CX/R</X/R:(G:5S)PVU[7$WX;.+Q*]827#;Q?BMXM>1X;>+
M3XK>#@X/R<&B+YVDLQ>+:;?'P\/^P"7^]^'_ ,G\OY?S_ET1<>TAF#Q:33ZO
MD?8:(G:0S!XM)I]7R/L-$3M(9@\6DT^KY'V&B)VD,P>+2:?5\C[#1%OZZDC#
M)9%,,9+926.EP3MSD_G3=L58KLEEF_8H!2Y=-->RRZ]+E4[T^/;2MO'LNMX>
M&E=780+W-MGU6<GA\_HMKG-'/>%/)KK2XWCF%FG-'/>%/)KI<;QS")S1SWA3
MR:Z7&\<PB<T<]X4\FNEQO',(L8MQFVF[<,M!!IDLZ&Q0"O(+9"Q:TXA!RW.6
M!D'+D.K>V<HHDGL?8R/'[U57F_%B.0Y75-913BL'M76=;U@!K?56:0+Z7.EO
MOER6#)OJ1\>1ALE3C\X4)S]<&BSBCU_%XY"P00@UQM(<;O+QB\<!F'\:4GS-
M2!&\GG6[*0$YA(H0L]*M7PF3DX\E4M'M"_R ^_OQTL'Z[-->/Z_/GP4VQ)U)
MB#Q@@,E&1S;22F'_ #$M,H0#CJ+#&%Y5SEL1FR20Z/QNJC./(8G7FH9-0?#Z
MPT>WOJ6E+XBDM89%"8P#1XN'PTWJ"_=LM;7;_P!?F5<C)O4[VV0LQ6SYQ)&R
MD>D>5V^09NDK'0#"8719MBB5XT*8L2D[6/.CLOA,V82- $3#'I"*"12#,7P8
M&$(%#CLPA) O^T-N_P -VW4>&T6'Q3-IJ/#F;[>!&_6Y^ 6/]W4;@0X9C>*Q
M_)C>R*1=G?'Y0D3Q;#'3J1Q9SB-+'KYJ29+,W;*3E64A"Q29XW=R195GB8N+
M>O [ ^X*D+7491[0\NNJ9]NFNGB;?KIX:#;XJZ8OJ3>-!CJ1DKY]."AHQ*R<
MN%FSB"<C) S:V38'DH-)DEY*_-5NGHF^*2"+KS,=0,Z)1V<EFM&#*K!A6V<K
M?:'EU^/-,YW?=C_U5,,>I"P\#(%I%'LH'45&\_Q;.@@<K# 9,(/OPR^R>K &
M"K!1W1@LZ&Q_)Y" ."*8Y$:ZA@]BNO&EIRT%S87&4>#APO;SU^GR4Y]X^-C]
M_JLB-PO4_8)N;D@R891**DY$.@+"#).*Q.//FC&EL(SQ$39>/MS")%>/NC[S
M-Z$I=)L7E>3.8PQRO59>H6V^MB ?_,-@W>%^/%5#K>&_SM^EOYJQLBZE #F'
M-W$MS-+I*3')S 0)?%(;%U>:1:6BFS:HU1.ZM]59 *DR;_)@Z8V7HDVF2CQP
M\S;M1;IO'VE<H]H>753GVZ;O'=]\M#=44VZCR&D4(!L,C9;.*S15F]5G*L&C
M3.*PJ6&I16-/YD].A!#L.^EQ)S(P5),/E$A>T*NY,QBI60,R8F,LHK<RCVAY
M=5.?AIX>"R?S/U/2"9KECN82"1'4BK>+1J(Q"]V&"R2^%C(E),82P(L+<2-
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M6(+*JE4AKX?5_;K%)77D@P\L+&1R1L94PMD#(JR&^:"JBEB);6S$^CR0@:,
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M]:UPV63L(NR=Q+D6-1P7+3<6>L8\;OCJ8HC5=@XM>WRP$K)H]8BW:NUW?&*
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>g65062g92p74.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g92p74.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[3 44&AO=&]S:&]P(#,N,  X0DE-! 0
M    +_B^$B@#A"24T$!       +!P!6@ #&R5'' (   (  !P"-P (,C R,3
M U,S$< CP "S$S,3<R-BLP,# P.$))300E       0$:\NPOTZ< 0^2 =6D0
MAJ>#A"24T$.@     !&0   !     !       +<')I;G1/=71P=70    %
M   %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<'
M)I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4    &P!" '
M( ;P!T &@ 90!R "  30!& $, +0!, #( -P U #  1 !7 "  <P!E '( :0
M!E ',       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 (
M!3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
MQB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M  0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V
M)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M   $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M!29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&
M1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@56
MYT1B-2;'0               !2<VQT56YT1B-0>&Q ;(            IV96
M-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $
MQE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M   %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V
M]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&
MQO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%
M1O<&QO;F<      #A"24T#[0      $ #D     0 ! .0    !  $X0DE-!"
M8       X             /X   #A"24T$#0      !    !XX0DE-!!D
M    0    >.$))30/S       )           ! #A"24TG$       "@ !
M        $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9
MF:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M$X0DE- _@      '   /____________________________\#Z     #___
M__________________________ ^@     __________________________
M___P/H     /____________________________\#Z   .$))300(
M 0     0   D    )      #A"24T$'@      !      X0DE-!!H      S
M4    &              */   #D          !
M    $              Y    */                      $
M              $     $       !N=6QL     @    9B;W5N9'-/8FIC
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MQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M  !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;V
MYG   "CP    !29VAT;&]N9P   Y     #=7)L5$585     $       !N=6
MQL5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M   0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
M   0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V
M1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E
M1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V
M5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=7
M1S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M    $! #A"24T$%       !     4X0DE-! P     %(D    !    H    '
M,   '@  #7H   %&T &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@
M    '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0
MP,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4%
MX.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,#
MP,#/_  !$( ', H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M7[.R.X;,BM^4_?76U[QM9M;N!KV;O>]SW;_P"9K_TNQ/7ZP.1>ZK=D$AHIW
M0W:QWI>H_V-?KNM_EHQPLK[;5ZQ;8_98]@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
M0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M_\  $0@!% &  P$1  (1 0,1 ?_$ !X  0 " @,! 0$            &" <)
M 00% @,*_\0 9Q    8! @,$ @P("08'"PT  0(#! 4&!P 1""$Q$A,400E1
M%18B-E5687&!EM36%W5VD96AM? C)"8R-;&SML$E,S0W4M$8&2=$993A.4)#
M14935&)TIO%78V9R<W>%DI.HLKC5_\0 ' $!  (# 0$!              $"
M P4&! <(_\0 3Q$  0,# P$& P4&! ,%!@0' 0(#$0 $(042,4$&$R)187&!
MD? 4,J&QP0<5(T+1X3-28O$6)'(T-4-3@A=5<Y*4TR5TM<(V9(63HK/4_]H
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MN^/O $(,"$2"%$CKO0I39Z[5*23M414 J"VRE0 0HJ4G,N"("29^[,$@@@D
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MRT@XMQ-NVCY^TBT7;TZ:2CUPSC)!RD@41.9%FX. =E,XAEMV+B[<+5LRX^Z
M5=VTA2U;1$F$@F!(DQ D4J6T^X5B_P!7@KK2YV+L]3L\:VF:]885VD_B9F*>
MD!5G(1SU QD731RD(*)+)&,10H@8HB @.L:DJ0M2%I*5))!2K"@1R".A'!ZB
M.*5)-12N!#<!#?;?S_?U]-003$&,TK4S@K$]5CO2E<7\VW=6U1S6<98:N$*R
M>WJY2$$QGLP!?37UVC7'LZM! G)F@8H6;,T>9E!@W,$&WCO$+]YUVI/N+[':
M"@AD)_>.K-J(MV$N+;MT6BF4*>2A+RMJ[AQ4J6J9VG 3#&?Z\?#Z_*MLX= \
M]<B.!["E-32J3>DB#?@+XM=_+!E]'\T.O^_[[ZV_9\%6NZ-!VG]Y6>TQ,*[]
M !B1($R4R-W$B:?7SJRF'PVQ-C#I_J]I?3;XMQGJZ^O?Y=:MW_&?,1+SJO\
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MVKY4RCZ<B\$%.%X;>$S#+9QOV'5SO#FWR;0HC[DYE*O?9IEN ?SRJ02QM_\
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MX@R<8X]H\IBJJ5ST37"O;.,SB9P[31R/A]CB3%?#Q;\:VK'U^G0M=:LUU'(
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M KZ'V<[,Z7V9LD6FGLG<  ]<O*+EU<J!)WOO8*S))@;423X9K-QDRF  '<
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M&$,S0[ZEQLQ&QT?#YQA+-+LZ1)A+S]C5E;#3AJZOLC8VR\*TG64S%NDZM F
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M[(R".[69DP"5>&L@Z).208C/$>G,'W!$S-4+>-;/Z!/BH]DFQ)B6]$]Q570
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M,PS22?I5MO8'TE-(12*KD4VZ4G(/'A ()5G"I@[8^&X2VW</MM]Z&T.K2@/
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MA)VD@D$H22,2/"5%!$DRDGB*P-DG<8@%2H/F HI!^(2%#T4)S-9EY^7]6_\
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M[+:WHR"]=6+KELF%"ZM@;AD@P4F6_$D$'E:0/>LB7$*P%"?(D _C^/EUJP7
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M5 E)!2<I(4(((D=8K*#(D<'(JL>8!#_A/<'_ #_YUG<?H_!JESUM+(C]UZN
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M2;UKNT*;0B])<4Z@H4""MT[=RC!)4DS K+=B_"5+94H^0&=BC/#5*(EX@II
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MWA4'*:9VJY ,=JNLCV5!ZE?96ZO=-TU LDE-L+L(;4XA"DAY[O8(69RI2R,
M@$2,",06B5DSZ >@X,R9GX5EEIZ5'AM=; /$!*MC#S[+JFY'2#;_ .U"HG1
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MQB0#U/6ME"""+9!-NW22102(5-)%(A$DDDDR@":2:9.R0A"E  *0@ 4A=@
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M!/OF! F /*N=A]7S[#MT ?E\Q$>?ZO/42//VD3R1Z= !C\>E1(\_:1/)'IT
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MB(B.N[/OO_OS3W@XO>_>(#JQR4N86D^A!VDF!R",5H^TD#1-3XW&U<$#_*0
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M ']R?G7&X!MY" [\Q$>0\A'?SWZ\OG]>I@F>H(C  R,@1TCC/MY5.V9\B(P
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M"_+;97('/YJN4-P'H&_[\^0^JT44V&I"-TBR3M"5$E275$@ )VF HDE2TB!
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M1+TZ[[;COTVV\M>*)4?^H\$$_$8@_P!1UQ3;.<B23!PHCV.!Y\\$&OO?GOR
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M^#6$IR" 0(:4D$[H0=H X*1)DYSM 2/( ><"Z@"VD?YBI)3S]Y*Q,]9*H(Q
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MD*V6^Y3S4A0)2L$IA!$Q.[Q0/.8!BVPYJKU$KJ\338:XU(6BQX]-E(%8SJ"
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M4,'!24P.2/$@><3 /.*RIN&5F4+:*2#!#C?'P61Q&1//E6'N(1!XOBFRBU?
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MS654,7UZ=L=ODY)S-+.23+1F&\FJ=/N@K%;<D$Q%R*]I0AUSIE.([D0*FB4
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MNQD_[YY]ZX-ARG@ C_E3EN.POB;>8^;?Y?ZO+3]Z7B9(<2#$24B!Z_#^U 2
M , 3$8YYJB<Y;\W1TS+Q\;P67F7CF$D]9L)4F6(A(DDS;.%46S\B2-0>)I%>
M(D(Y!,KIP!.\[(JJ" F'I6&[!YEMQ[M);-.K0DK;^Q%P(/\ E*RZF3 $D!,&
M1F)-23/!/XS\9_3\*\KV]Y\#KP.7OU?ZW(SU"'Q'_?;U<M9A;Z62 >U%L/\
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MS:$A*/EXV#@V4I/2T7&//'<VUS9K0W=V[]LXZ%%M%PRXRMP)PK8EQ*2J"0#
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MB?N-FS#@$DYETS*@HS@&,5N?;F,9,G:WW$@&'?8!Y[==N7GSU:?$H8@*4![
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ME.R4>I0_,&E*YTI32E<" #MN #MTW#?;YM*5SL = VTI32E-*5\]@G^P7_\
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5B(I$+OOL1-,I2%#?GL4 #?GI2O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>g65062g97g79.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g97g79.jpg
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M 0$! ?_  !$( -0!J ,!$0 "$0$#$0'_Q  ?  $  04! 0$! 0
M" 8'"0H+!00# @'_Q !-$  !! ("  ("#P0%" H#   % P0&!P " 0@)$1,4
M"A(5%A@A-SE9>'J5M;?8%R(C-C%!479W&1HD5UB6E[0E,C,T.$-YF-;74G&!
M_\0 & $! 0$! 0                $" P3_Q  U$0$  @ #! @% P0# 0
M     1$"(3%!46&A Q)Q@9'!T? R0G*QU"(SLA-2X?$C<Z+2_]H # ,!  (1
M Q$ /P#?XP,%'C,=7.Q_8Z1]6WU$5J>GR=<IVH0U=Q\A"4MX_:!2444_KA8R
MO.)Q#MZW!.@\7L+UN^JV;2"W:SW;IC(>V9M9H:Y?&\$Q%W.N59YQG>G=43E-
MYY)>=C)!VOI:>U;/!=_P@Q5-@]IJ+JIU4;RAV3<N.A-JV&&B1-HA9J=A*NW!
M4<Q?+K-"N\42]*O[3E1IIQK\9(J8F*SB)F[W<-&1O#)@1'"=N8DD_L!G8PYI
M DXSVM:]5HBY2D',@UF9XO%(/)H\>=:+!8_Q&O=#>8*,'HCA0Z@+U%ZO.3KS
MA_ZNS+5Z9Y7.RO5+C"& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P(*]]OY1ZU_7JZ;_G=&L-8?F^F?).K#
M)@:0/C-SB%S!U7K:)3"+RAP!\<+1B<;QV0"3:P9ZC2=,"E699(8[=;CG21,,
M8'*-WFJ*VC\429[:<.&+I-(Z]'$QU[B8OHL4Q>V,L^QN_8<C 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8$
M%>^W\H]:_KU=-_SNC6&L/S?3/DG5ADP.8Q='R@7O]H1.?C=@8>C\=TY\/.8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# ^(F3&A1I R9(,1(@2Q=DRI4F[08#1@U@
M@HZ?$"#YTHDU9,635)5R[=N54T&Z":BRRFB>FVW 1P^&QTS_ -KCK'_Q[JO_
M .5X6IW3X2K"#=ENN5GGTHI6E_TG8<I7;.7J$:@UJP26GUF;+3A1X[2# #Q
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M)$Y6'MG@K?E[OWSI\M+]EH]/:8&V_8[R"U@((R^:1(8>6G;=Q7<Q;1>72*.
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M2KQ'*G:UPQF]?Q2?6"1)LFAE$*/C[O86*C+N>1ZOV\Q/S,"G)8OI$29F0II
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M:E4G73<G"[\U(WY!]ML]72TV28MU4!0U'5-B)8,!Z#=HD)F9U[%S\(8# 8#
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M[*;_ ,#!AV[^K-Y>=^3+5ADP.8Q='R@7O]H1.?C=@8>C\=TY\/.8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MZ/E O?[0B<_&[ P]'X[ISX><P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P&!K$0JJPE0^,<(;12*6X3E+67 ZF6
M>SN]?$:L:ZIQ1"E+\VOM>1ZVYO:9;K?).N\5L]5Q7>],2T5(4=9<!W>-3;67
MN <:V.ESU:N*JZZN&*FZK2[F(NXILY*H(+\I<K(I+<HJZKH\JIZ*<HK:<<\:
M+)<[Z\^C5UXVVXU4T\M]>.>?+GCSYPYH-=]OY1ZU_7JZ;_G=&L-8?F^F?).K
M#)@<QBZ/E O?[0B<_&[ P]'X[ISX><P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P&!K%R6-;]7N_5RR\#UG[K]T
M:R@5F.>RIN10CL!W">CJ#ES>E8^S+:NZSOF3A>MO9^3,HUN_=1%I6EAR^RP
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3&XH6 8""W[\/3W<I"X0P&!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>g65062g97p21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g97p21.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1WN4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '=*^=C0X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B
M:F,    !        4D="0P    ,     4F0@(&1O=6) ;^            !'
M<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D5%5N
M=$8C4FQT                0FQD(%5N=$8C4FQT                4G-L
M=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E
M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M ! #O_XU  (  0.__C4  @ !.$))300F       .             #^    X
M0DE- _(       H  /_______P  .$))300-       $    6CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))300>       $     #A"24T$&@     #
M-0    8             !)0   :#          $
M     0             &@P  !)0                      0
M               0     0       &YU;&P    "    !F)O=6YD<T]B:F,
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M;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   24     %)G:'1L;VYG   &@P    -U<FQ415A4     0       &YU
M;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%0
M   !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0
M   !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '
M9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@
M  =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R
M5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S
M971L;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U
M='-E=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M     0$ .$))3004       $    !3A"24T$#      32     $   "@
M<    >   -(    3+  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M     ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04
M#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,_\  $0@ < "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
M      ,  0($!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+
M$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52
MP6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S
M1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  ("
M 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A
M<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%
MM)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1
M #\ L_7CZR=>P.O.QL+-LQZ16"&,#8DN=K[V/6!_SR^M7_EI=]U?_I-=%]=/
MJK]8.I]>?E8&'Z]&QK=_J5MUESHVVO8[NL/_ )A_6_\ \KC_ -O4_P#I56L?
MM\ OAOQIKS]SB-<5>%H?^>7UJ_\ +2[[J_\ TFE_SR^M7_EI=]U?_I-&_P"8
M?UO_ /*X_P#;U/\ Z52_YA_6_P#\KC_V]3_Z53OU7]3_ )JW];_6_P"<A_YY
M?6K_ ,M+ONK_ /2:T<'ZR=4OII.7]8K<2U[G^K+:W-8QOLJ<Z*=^^VUU7^D_
M0^O9Z3*ZO553_F'];_\ RN/_ &]3_P"E4O\ F'];_P#RN/\ V]3_ .E4#[1Z
MQ'^*D'*#M(_XS=?]8NK54,L?U^YSS5NLJK=C.<+!7<]X9L98UU?KU4T5>_U7
M^MZGZ+^;4;?K%UAK\EC?K%8T5-I-#G"EP?O:]]X?Z+?I5/8QFVAUVSU?^MJI
M_P P_K?_ .5Q_P"WJ?\ TJE_S#^M_P#Y7'_MZG_TJE6/O'_FIXLG[LO^<V,K
MZP?6''HM>SZQ^M;6-S:6-K)=K&S>SU&>KI_@_59_PJM7]7ZO]I->/]:FBH%K
M0^TT$DEUK-X]+:W9L93;_P!>_P"#6?5]1/K6+:S;TTFH.:; +J9+9]X_GOW5
M:'U2^M@+0WI(:!OGW8KM75LH8Z'/_P ':VW*V?OV('@[Q_YB09]1(?XZOV]U
MMM4O^LWO+6O]@J( +=[V;'-8ZRUOT/I5J#NN_6)N1Z/_ #E8YGH.O=<WT]FY
MIVC';O:S?;9^9_Y[_/4\?ZG_ %BJQQ4_HN^WWCUW6X[H#W,?OV>I[G5>DQK?
MY'VC_3*K9]1?K:ZU[F=,+&.<YS6>M1H"9:W^=_-:D/;[Q_YBB9T-)?\ /;E7
M7^JO;?O^LKZK*[K:J@\4P]K"&5Y'L;9MKN]:A[-GJ?S6=_H4._KW7Z<>VQOU
ME%UK 3757Z<NVO=6YFK/IN8/5_\ /?VC]#ZE7_F'];__ "N/_;U/_I5-_P P
M_K?_ .5Q_P"WJ?\ TJC6/]Z/_-1Q9/W9?\Y/=]9^O,PS?5UNZRR:0UA./N)L
MK]7)W8[0Z]C<>W]%ZOT/\']/U?2I_P#/+ZU?^6=WW5_^DT;_ )A_6_\ \KC_
M -O4_P#I5+_F'];_ /RN/_;U/_I5$>UWC_S5I.4])#_&0_\ /+ZU?^6EWW5_
M^DTO^>7UJ_\ +2[[J_\ TFC?\P_K?_Y7'_MZG_TJE_S#^M__ )7'_MZG_P!*
MI?JOZG_-5^M_K?\ .0_\\OK5_P"6EWW5_P#I-=#]1?K'UWJ'7?L^=FV9%)J)
MV/#8G<-?8QJQ/^8?UO\ _*X_]O4_^E5O?4CZK?6#IG7!D]0Q#12:RT/]2M^L
MM,14][DW)[? :X;\*78_<XA?%7C;_]#U)G\Y9\OR(>8S+?4!B6MILW E
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                             /_A2/IH='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I
M9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL
M;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E
M(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @
M(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R
M9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(CX*(" @(" @(" @/'AM<#I#
M<F5A=&5$871E/C(P,C$M,#$M,3)4,C,Z,3@Z,S1:/"]X;7 Z0W)E871E1&%T
M93X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C$M,#4M,#A4,30Z,#(Z
M-#@K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D
M871A1&%T93XR,#(Q+3 U+3 X5#$T.C R.C0X*S U.C,P/"]X;7 Z365T861A
M=&%$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E(%!H;W1O
M<VAO<" R,BXQ("A-86-I;G1O<V@I/"]X;7 Z0W)E871O<E1O;VP^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA
M9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/FUA
M8T]3(%9E<G-I;VX@,3 N,34N-R H0G5I;&0@,3E(,34I(%%U87)T>B!01$9#
M;VYT97AT/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @
M(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]297-O=7)C95)E9B,B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)
M1#YX;7 N:6ED.C!!.31$-#@X1#=!1D5",3$Y,3,U1D4V-4,U.#!%-CA#/"]X
M;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX
M;7 N9&ED.C X.31$-#@X1#=!1D5",3$Y,3,U1D4V-4,U.#!%-CA#/"]X;7!-
M33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N
M=$E$/GAM<"YD:60Z8F0R-C(P,34M,S<U8RTT,#)C+6)D9# M,#0X-#(V-30Y
M-#=F/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-
M33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#IB
M9#(V,C Q-2TS-S5C+30P,F,M8F1D,"TP-#@T,C8U-#DT-V8\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M
M,#$M,3)4,3@Z,C,Z,C4M,#8Z,# \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R
M,BXQ("A-86-I;G1O<V@I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!A
M<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+VIP96<\
M+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)
M1#YX;7 N:6ED.C-A.38Y965B+3,Q8F8M-#8U-"TY8C8V+3=D9#9E,#%A,S4T
M-#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.G=H96X^,C R,2TP,2TQ,E0Q.#HR,SHR-2TP-CHP,#PO<W1%=G0Z=VAE;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@
M4&AO=&]S:&]P(#(R+C$@*$UA8VEN=&]S:"D\+W-T179T.G-O9G1W87)E06=E
M;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T
M.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED
M.C W.31$-#@X1#=!1D5",3$Y,3,U1D4V-4,U.#!%-CA#/"]S=$5V=#II;G-T
M86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 U
M+3 X5#$T.C R.C,S*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&EM86=E+VIP96<@=&\@
M87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<#PO<W1%=G0Z<&%R86UE
M=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D
M(&9R;VT@:6UA9V4O:G!E9R!T;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO
M=&]S:&]P/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN
M<W1A;F-E240^>&UP+FEI9#HP.#DT1#0X.$0W049%0C$Q.3$S-49%-C5#-3@P
M138X0SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.G=H96X^,C R,2TP-2TP.%0Q-#HP,CHS,RLP-3HS,#PO<W1%=G0Z=VAE
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O
M8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E
M;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T
M.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED
M.C Y.31$-#@X1#=!1D5",3$Y,3,U1D4V-4,U.#!%-CA#/"]S=$5V=#II;G-T
M86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 U
M+3 X5#$T.C R.C0X*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N
M9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE
M=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D
M(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G
M92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN
M<W1A;F-E240^>&UP+FEI9#HP03DT1#0X.$0W049%0C$Q.3$S-49%-C5#-3@P
M138X0SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.G=H96X^,C R,2TP-2TP.%0Q-#HP,CHT."LP-3HS,#PO<W1%=G0Z=VAE
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O
M8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E
M;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T
M.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @
M(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HP.3DT
M1#0X.$0W049%0C$Q.3$S-49%-C5#-3@P138X0SPO<W12968Z:6YS=&%N8V5)
M1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HP.#DT
M1#0X.$0W049%0C$Q.3$S-49%-C5#-3@P138X0SPO<W12968Z9&]C=6UE;G1)
M1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N
M9&ED.F)D,C8R,#$U+3,W-6,M-# R8RUB9&0P+3 T.#0R-C4T.30W9CPO<W12
M968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV
M961&<F]M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,]
M(FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @
M/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(#PO<F1F
M.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA
M9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \<&AO=&]S:&]P
M.DQE9V%C>4E05$-$:6=E<W0^13A&,35#1C,R1D,Q,3A!,4$R-T(V-T%$0S4V
M-$0U0D$\+W!H;W1O<VAO<#I,96=A8WE)4%1#1&EG97-T/@H@(" @(" @(" \
M<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@
M(" @(" @(" \<&AO=&]S:&]P.D1O8W5M96YT06YC97-T;W)S/@H@(" @(" @
M(" @(" \<F1F.D)A9SX*(" @(" @(" @(" @(" @/')D9CIL:3YA9&]B93ID
M;V-I9#IP:&]T;W-H;W Z-C9C931C,C8M-&-A."TW9C0U+6)E,CDM-S8P8F-F
M8F%A.#@Q/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D)A9SX*(" @(" @
M(" @/"]P:&]T;W-H;W Z1&]C=6UE;G1!;F-E<W1O<G,^"B @(" @(" @(#QP
M:&]T;W-H;W Z2&ES=&]R>3XR,#(Q+3 Q+3$R5#$W.C,Y.C0T+3 V.C P)B-X
M.3M&:6QE($1-5E0@4S$@4F]U;F0@,B!);6%G97,@=&\@0V]N=F5R="!T;R!(
M:6=H(%)E<U]"2'8Q7S$N,3(N,C R,2TQ."YP9&8@;W!E;F5D)B-X03LR,#(Q
M+3 Q+3$R5#$X.C(S.C(U+3 V.C P)B-X.3M&:6QE(%!A9V5?,3@N:G!G('-A
M=F5D)B-X03L\+W!H;W1O<VAO<#I(:7-T;W)Y/@H@(" @(" \+W)D9CI$97-C
M<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_;
M $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M ?_  !$( 7<"%0,!$0 "$0$#$0'_Q  ?  $  00" P$              08'
M" D%"P(#! K_Q !_$   ! 4" @,$#!0-#0H,!P$!! 4&  (#!Q$((3%!"5%A
M$A9Q@1,4%1<8&561DZ'1\!HB)S,U-C<Y4E165W-VDK&RL\'2"B8R0D9R=Y:U
MT]7A\2,D)31'6&9T=927MK<H.$-B9(.&I:;"1$539X*%AY6BHZ?4*4AC982T
MUGC_Q  < 0$  04! 0               0(#! 4&" ?_Q !B$0 ! P(#! ,(
M"@P*"0,# P4! @,$ !$%(3$&$D%1$V%Q%!4658&1H? '(C(VE+&SP='A(R0T
M-5)3<G-TD[33%R4S1%1B=</4\4)#9(.$DK+"TD5CI"9E@I6BH^)6A;7$_]H
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MT#7X5Z\J@;;;,^-%]?VGB'I^U<AD?1GSCX(=Z/<=PO&H=?S*;OY[=N\'<<>
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M9G08HJ_7#G^C[6'S\?(^"'NCW^O"?[?B57?V_P"P/:'OQEX#;4>+$_#8&?\
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M;4^+$_#H%_-W5YN>>=/#;9CQFO*_\SQ#SG[5X7UTMU T']$/]'MMB\2@.?\
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M\A_3U/ ;:GQ6D_\ '0/\5ZW[*>&VS'C1?+.'/S[/M4>37YB^"'NCW /FPJ
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M(N!G?K%^KK/7J0;#*IV .6.(![8#XQY  \MNM4Y <+:@>D'RG@ >&7./!C.
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M.%!)2DW2GVP6L;G29:MFL-<9G-0,:$S$,.@'$) 990K#W&TH0MQMB4AU04M
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MCCY\QIE?.Y'$  6J<CU\>& X;\-QQGB' !VZPQ"ISYZ\AI8Z9Y:7X Y<Q:O
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MC[#$+%!!=FP#@V'RVG79[;+<EI4A70@+=0T0$*2BQ2D(6JY]NM6X&(X6G:/
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M=T%0*BJX2E1Z.#B4&).V=AR<3AR)>'8?BB)F(]TMJCI,A-X\42UJ"75-A 0
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MA/,D)#QH@7DJUZ]2^B#*DQMI9;;&+.+DX2(B.Z<,9P\S'$I"D!F%';0ZXXR
MIH+Z-04%%(4; 59<G18TG9J(Z_A+2(^+&6ON?$GIXB-$*2HO39"U-M-/%27.
MCZ1-BD**1F:L/<Z_%CU#2SK4;Q"\MJ3J^ZNG).W::Z&4N(T#2PY+4SJ:;4EN
M<@IE%8G.+%O9Z4E2I*\T^B8;8R4YY@4NYD$0S(L*:G$L'<5$E)0UL6F*ZLQW
M@EN4$K^UEJ*-U$C3["HAS,>UK#E3H2L-Q=M,R*7'=LC*;0'V2IR*5(/=*$[]
MUQ[7/3)!;M?VV1MD>X-8%JG%TFO2_*JWJ?MTLV2?>@"XC"M&I*%YFN<M8\G(
M-K;1E41H6X.UG'4:;A<%58K/*DGHC8J&U2NK5W0%$O4/5E?NL!O"I3>SNR:4
M8;(1,8QV._+2F(XF2RWW3**W9"0V'6VP@-%3C@"0@-7(2$5GKQ6*YM%M4M>)
M1UPG\$>9BJ5,;,5USN6*$M1R72TXO?Z:R&[J*R[8%6_5[+?:M=/9MM:+]2UL
MKAZ/6R@V#T5H]KW83O+JCN>S7S;5W-5H+J [;7S:2FDN44^YY-WF3I4NC.&B
MT%M3<4\M)4E\OTD!I2F,-_"YX<QC#I+&+.KG8PN2T8F&QG69#3KJ'&I/?5U!
M5%+022MLO(2V/:Y=([;,CXKAY:PG$8[^$M(@X2B,[W7B4EI^,ZTRM#L;O6TL
M(DAPE*4K#2U+R4+]&U?\P^@J:U:QKGL;7NM=E=TXVO.7*-'UFY[,=AEB*K#+
MS$5DXBT4U[23R&&>3/JP);:..:K4IR(B4IFU T8H42]4Q3^CXX)*<&G"+%;Q
M"2F. B,\T'T/D*0%E3)N'E)1O.I:%RM:0E()(%?.,#,5>-0C)E.8?&5(4I<A
MEXLJ8NE:DA+UP64J5NMJ=-@A"EJ)RN-\VKB[-GV/H(N1;QN78TQMZXS=UZVU
MO$FM&SFL9>U)W)<#'&>9+K755GB[WHN.!>>ZI7[H^Y4]@$R%-OHDA10<".DG
M5$Y+/Q.%193^.QI#D7$G([F!R(:G9>$MX=&;>!WA%2RTRAMMA(R;5(*^D7=*
M%K2D5V^*RHC&"/QVY6'-OMXY'E)9B8LYB$A;%P@R5NNNK<6ZLW4XAA*0VWNE
M:4J42=:G3K*"(\]>3WO*R+Y6JO9:^\*,SW#;B>U]U4FXX-%%1F"S&PJ);C3D
M<V;+,H^HN1)5U,HC^2A.?+59E*K+3KUJU.7H=BDK9P-B(]!E0I,1;R) DQEQ
M^E6M]YQ*VRM*2\D-J0E2\]TC=!L!?G=M%H>QIZ6U,C3(LM#*HXC2D2.B0AAE
MM:5I;40RI3B5J";^V!WC8D@[ ]-FM^QK6Z%)UJ;BN.P26KVP%O=1NE"RK*4'
M@W2MTCS#U+O"V:FJ.AM,TR>E<RHF(*<;IT"Z^FD*I)+),U:+3UZ8EJXT]%B&
M#37-L&DMQWSA,]_#\4F/):<,9+^&LR4(:<>2GHT+<6DJ+:E74IY!L;B^\P_&
M8;6Q[JG'V$XM!8GX;#94\V)*F9[T=2G&F2H.J0A*@-] (2&5@GVN7WZB=<VG
M-8Z(VT3H(/5CNW4_?IM:2M.&H^VY%Z(!ZY86]TD/*X3@G7W<SZ1ZHXDDH\Y4
MT"E975")8BLI[P0I9#%6E*6EFC#\%Q!&U4ILLO-8;!=Q7$</D%E?<W3XJS';
M+;3I ;46=[>"$J)0IERX!)-53\:P]6RT5P/,NXE-;PO#\0CAYM4D,86\^LK=
M9"BXE+H21O+2 M+R,R+"LIM6FK6PARGK U-VTN5HV<MM+^:3:=N6[*X-3]U'
M->%\%7,ST-OTK3>A!*+II%MH[FJJE39XFKRLY.)H4TPJBN83JRZ[SI/5X5A<
MX'"<-DQ\7;D0,4,ASH\-BM1&2VZMPRN^RFPN0RZDI!075%SW*0H(:!V>*8I!
M(Q7$8\C"7(\W#.YVRO$Y+DI[I&TH$7O4'"W'=:4"I*@TD(S4LI*W5#Z&-JWT
M]&4#1YJ:MA<+1VVVY8S10C6P=!&\FJ*Z#2?-N'4UV>LM]UVEFTC--=HI]RRC
MG,'2Q9&7Z+06C[@J245:3R]30FF)D]A4\+Q;#I+&+..3<97):,/#(SK$AIQU
M#C4H8JZB\930!*FR\@-YH]J5N6J8Q2 IO"L1COX4VB%A*([HEXE):?CO-M*;
M=B=ZFE;DA+A4 EP-+4X;*&\$-7HS3SKLTFH&B'05I-==R;;L)8U$V6U867>U
M[VE=%MI]P-%U5U.P55GRNJG0/BM,9LOU6,H(J5=RJK8+&$YLD5(W5-)9(V;(
MWL0P7%',9QS%&H\A]&'S,+F,PG8SBH^,!IK==Z*Z=Q]UA <W VETA3JDI 4H
M!5B#C>%HP?!<,<DQV%SX>)Q'IC4EM+^$%QS?:Z4!6^PT^HHWBXMH%+:5&Z4D
MI_(6]6P;MX^G2T1<#;<!UENA70@=3#<J>Z&DM5T)3,$Z:\T78AFC"8N(:A.6
ME/HBTFFJE X4JEC=&I\/B7ZHRZ)#+3O1N-I>:0OHGVU-.H"T@[CK2P%(6F^Z
MM"A=*@0;FOECS1CONM%QMPLN+1TK#@<964+("VG4JW%H41O(6E1O<*N;FVUZ
M^C]MZ\>B,Z.VSZ%<BW9ZY[>O[J&,NUDSOILR.=F)[J=9\$)<>Z/45/-)I(2G
M3,4S99;<!4@FUB8S'*9F:A*-0.8AL2&MJ\?EKCR!&<@0 T]T#I;>4TTG?0RL
M)W77$D$%#94H*RM?*NGFO,.[*X#$1(CJD-3IQ=9+[0<92XZL-N/)*@IIM05O
M!;B0DC,&MD-\+$V6TXZ"71IUT1ZZ^CFKUWE;PZ\-8EV%35,RZ]_]0*HV$\VM
M2V5M,UFZ4<4B6Q3%4D)%O-ZBXJ2H[#BG(BGZ)291<!YQ<_"G2\0QQO$,9P7:
M !J0EG"8J<,>$& ATA'=LIU9;WGP%;SCA;*6DI*P560&]],@PX&!NP,'QO +
MO,*>Q:2O$F3.G*;25]R1FFPX$LJ(W4(#F\Z5!!MO+*_RHAL #N(AF7''':&V
M!V#M]:/IE?-!D <R1=-M;=8RL<AU^:ISL& 'AG8,;CCLW]OAN XV5-\A8'2^
M0MF;=6?ITS!MDWWX;CU#U9  QCA@>'/J$84SSTS/(\K@"UM+'3CR)H'/ECF
M!P#@&1X[<.S&^\*#C;*W$#@-!<ZFVGD-S>@=F=ML\A'(B&0 . >+&1 ><*#R
MY7SYDDG.PT!US%KD'C0,;#G;CU;B @.XX''/._ >J%!;(WRUY9D$',V-N-\]
M#RJ '@.P;X'?/'F(YVZOO[;0J =#D,['.^O$F^7+X\LJD-\Y#EN'#(\QZM]^
MS8-^I4C.]QPS&ESQ/+//JR&?*0  R/'MP "&1'(B(\PY]6.$*D "YUZ[ $7)
MN23Q''E;2H#;;.1#GS#,O(/%P#E"H&5Q>Y&AU(N/J.0O4@/'@ 9VWSN/KA[^
M$*D'70"^6=\SYQZZ5 =HCMMQX!C<1WZ\[[X$.. A4#K)RRO?A;CGSOGG8C6P
MH("(\A#CC.,XV'/;G'+&V-H4()/ C6U[7MD;]=[<+96RIR'  & X;#CAQ'(<
M<#D!ZMQY0IP-@!8:9&VFIN-;&X/+,\*;[AGAX<\!QG&0$!VY;[[9A3/,7T[;
MZ&U[7!!RX9YY7IQ# =4O#MSL/';LSX\0I:XL#P&G7?CGEU<N-C7Z:NAC^4)M
M8YNQ<SX?->?&W@]^\? MOO?+*_,1/V=%?>-@_>Y%_/S;9<.Z5_/ZY5^WFW7R
MII7^+T_P)>4<;P'9\Y]<\_):NR&JO)Z_Y99\R:PMUU_*:;'_ )--ZWP_'U_7
MQ \.SYSY_3Z*#57;\PKKQ^D$_P!\FXAR'R$1![=I3?$.KCRSG&PA'W;V//>Z
MG]-E?W=?#?9!]\!SM:#&OSR+OHS/ Y\]*PG#M#(XR(=@YV'D/, #EZXQW-<0
M.L7-KD=1OD>!X@#AYS4;AL&P#U8V'CMS';KQMPY!"H-[G6QY6-C:^7$Y<[9:
M<!0>K(B.0VV\(AUXQS'K#(\8?Y\/7R?-4GE>YN+C+RCG;MYBYM>G'F&X\=A#
M/(.W&1QGAN..&%1KQ&9UR(OP'7:YM?3,VTLQCC@!WP&1P/M9'M .0 &,#"EK
M:V!SL+FQ]%SU@< !:QISVVX"' >(XSS'&.KM#(!B%..66A&AU-K\3:W+K%P+
M4VQMN(=@YR < X@ [;^  'KAZ^OU4%K9 $BVM[W &0U%\L[<@#SIXP$ R/+D
M&PACV\^( VA3KR(%SPX"P(MYC?R 94QQV ./'\O/ X$>H<!PR.5"-;6SOJ+>
M<ZV-B>1MPSO.P>  WV';&-N([#SVW#P9%4Y#L SR.5K9:G(\<LQV7/CQX8P(
M"&XXX<>&<AC@(#@, '((53KI:Q!&9MIKI>XMH0;"P' 5Y<\\. 8R/'<0SCPA
MSQN(;\U5<;Z:"USKF1>W:.-LR,^,<-Q#N1X!G(\MQ\?#(#D<  ;!"HTS(W3H
M+W/#,^72X-S8 9"@!@=Q#8>08Y>L&W'&>W@ @H!8YD9'@+</,,M;7Z] 1/;P
MYCOG( '+'A[/7Q"IZ].)SO< <+=O5Y[5 \-L"'/CU /5U!X0Y#G,*@Z96(XZ
M\@>7(=HX&]Z@!'& $,[<=N0!CKVZP\6XCA4 FU@1?+7+@!;GES'DS)MY=O4(
M^/B'BWQML&0VY0JKKY$^74>3.V60N,N% W$=]@V'8>(YSQ^]@<;=8A"@S)SR
M&1R.IO?7XK&V7,BHF'<>L-_6W#8.7MAOL 9&%0HYGF,_-F,AP](SR N:8WX;
M<N6.(;APX<,\@ !#([J6STRX<+:C,:::7X  BYS;!CAV#D.WCOOD<YP'7U0H
M;9:=1N.O7/.YO>PSN=2*G<,X#K'?AQXYSMQSPSMCD$*G,7L!Q.>FNI-\M;Z7
ML+7RKQQP'@ B&0QCK#MV\/'(Y'A"J;:'0$BXM;F.O+MUN;G2O+F&-PXAC'#8
M/'Q'GMV[!"JN(MF-1:VF0\NIXY=>0KQ\ _KN';N(8#?&>.<AG(\ Q"J3U'_2
MTZ\R+#.U]=1>YT%JGUAVWX]6-M@P 9$!P&W/GA4^8Y9Z\K99"P%R#89<>-HS
M@1Y\PX8QD1#,W6/$,Y]<<@J+V)X\1I:UR1=7,ZB]_.;C(,WI:OL2F?M,RQIJ
M9FU5IF_>ZYI.JO-@L?8%O72?;:<A'702-+- TFN!0,O%K!(R9J4[UHTUPE4,
MH%*64V);!&)0CT%GKB5*7#C$-NE+\AM+BEI;4$$*0D,N_9K]"2A0#A-KYYPZ
M<GI]YC.+$;FR 5M!4>.ZIM*%.)*PI+BBZW9FW3 *25-VWB,@TCHN-:ZZV3#S
M2;>VX-M8CYB@I+P:G-+%).2*KCHF:Z$46C%>]-&5%/JM,F=$BG*_E,]7G)':
M4A8:I0Q3I:]>TN#H=#*GY =._NM][<3*E!L@+* (9WTIWDW4BZ0%)-[$7ST;
M-XRMHO(88+:=W><.(X9NHZ3>*$K/=@"5&QW4N;IN% )N"!QK%Z,[61<PPI$V
M&P;?.0ZD*+I3#I%/U(:91/RUF2)WOJ,ER1B\%$T?1T:FFGS1E?(4#2',0)&5
M NHUR-&H8EK?VBPB,$%Y^0VE:&EI4K#L2W;/VZ(%0B$)4YO)"4*LO>4$E(4;
M52SL[B\FX8886I!=24IQ##2H="5=+8&6"I"-VY<2E2+ J"B+FL<;UV"N=I\7
MTILW2(-1/6%I(!=3J#3N9;*YY29,$X:(25C:I:YXO)*3C FR1B25/4CI0^-.
M0#(%1+5:-:?80YT:>VIV*IU2$++:B['DQCO!*56")+3*U"RA[9*2F^5[@@:^
M9!DP5I;DI:2M2=] 9D1Y"=VY *E1GG4).\DC=44D:VL0:FV^GR\=W61=^X]N
M&,=<[*L&V4UX7<72RBB$R[,;JP=,IZ:HFBRFJ$3RF!DV3-@!5#**9ZG1*F3=
M8M3*EZM:1(GQ(CT2/(>2V].<4S$;*5J+SB$A2D@I2I*; C-PI220 23:D>#+
ME,RI$=@N,P6@[*6%("66U**4J(4M)4-Y)N$)4JP*K )-O.S>G>\VH(;B#:!B
MG7C0M-;M?NO<8[34D)%3&DP&Q3DJK3@5%1Q*J.FA*7IS@)=-+FJZRI]Q7D3$
M\X-"L%.)<^) [G[K>2T94AN+'24K6IV0Z;(;2AM*U9G51 0G+>4+BIB0)<_N
MCN1@O=RL*DR#OMH2TPV!O.*4M:$9"UDA1<6+A*2 ;<NFZ6[[*J&R7$28E69+
MN1:VY]Z6)-.N-N4^Z+:V:,N0K<9R)J-YL"LRTV_,SW55E3CA HIJY)"45!#)
M*)&EY8FI5B4)"WFU/@+CR8L-\;CFZW(F!LQVU+W-R[G3-#>"BE"G$I64J-JJ
M3ALU2&'$L>UD1I,QDEQLJ<CPRL2'$H"]\!'1.V24I*TI4IL%-S6/X[9$=N'/
MF \ $<8VV$>&X]0YSJP3E<G+3CQ!T!-K99$Z9GD;N0@.X;CD,9P&_5@=_7R
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MW'.]^.HJ R.> \0SMN/ .6W7X^K:%0+F^AU%\LSH.&7/R\LJ9^&X@ >V.!\
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M Y#,T' 9XAZXB&PCG/BP.!'AN.."AL+ZCSDC(F]_)8V)TS-M&/7 1'CC<0[
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M&>/'.\W6'7D.L.,/"C9[QQ!_7)IX+;16L,(E^1''6^9YCG<<QK3TN+7;@?\
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M/N^WQX]>SPHV>\<0?UR:#9;:*^>$S#P/M+=>7T]O'2/2X==HYSI7O%QSNUC
M\AY=URSORVVAX4;/>.(/ZY-1X+;1&]\)F:WS0#P/#JOGPRRJ?2XM=N0_W*UX
M<=C5,@'7]%GCN/7MVP\*-GO'$']<FI\%]HKC^*)=NIL <^=]<SSRZZ>EQ:[<
M?[U:\/@%JF1 /%W7K=6^_*'A1L]XX@_KDT\%]HK?>>7V%%P/)?S<L\^% Z.+
M7: _[U>\7'ZEC'YVW6. R(]FT/"C9[QQ!_7"@V7VB!^]$S7\ ?3Y[#,^:@='
M#KMYZ5[PB/'(M8SQQV3<L!G?>'A1L]XX@_KA0;+;1<<(EDZW*.-NH\+"^>=!
MZ.+7;_>KWA'?@+5,CU '&;EQX[P\*-GO'$']<FAV6VB\42SGH6[\@-3PUUSH
M/1PZ[1Q_N5KQ<?J6,]G'X;J#?&>OPO"C9[QQ!_7)J#LMM";?Q/,U_ [-<^0L
M;7SS[0='#KL#AI7O%U?*L9V#&/HL<@'AV8AX4;/>.(/ZY-2-EMHAIA$SE[C0
M6MSMP!TZK4]+BUV_WJ]XO$UC. V#KF$<9X &W(=H>%&SWCB#^N%/!?:+Q1,\
MB,AD.=S:^@&7 Y4'HXM=H_\ Y5[Q<?J6,^O^J#F&>O<>&=GA1L]XX@_KDT.R
M^T1_](F:_@>G4<1?GF=+Y/2X==NW^Y7O%VAWK&<8QP_5;>+;/+&,/"C9[QQ!
M_7)IX+;19?Q1,SU!1PMI:^7DX\+6M/I<.NS;_<KWAVSQ:QD1'.<AQY\X>%&S
MWCB#^N34^"VT.7\42\KZHN3>]QIQXU'I<.NWGI7O$(YW_2L9Z^7PVW(=NJ'A
M1L]XX@_KDU'@MM%QPB83?/VG7PSRX'+E4#T<.NW^]7O$/']BQ@>. YS=F_CX
M;0\*-GO'$']<FH\%MHN&$3#K_H G.WX1ZL_+I4^EQ:[<_P"]7O#P^I8SR\,P
M]8]?+/#=X4;/>.(/ZY-3X+[17^],O3\#EVD\SSX7TS#T<.NWEI6O%X0:QG "
M/_I;< $ WV# 0\*-GO'$']<FAV6VBT[SR^T(TTZ\K$ \<A:@]'#KMY:5[Q;C
MD0!JF-^H=QY8]?VGA1L]XX@_KDT.R^T7#")>9N0&QY->SRFOT1=$=I;O);ID
M(R5<AB.%D.)/<JP9/(+A(5"*D5H&5&8R3K5J,W=#+(:+C)7HCGX:G4EF\/QC
M;65&FXZ])AOMR&'8\;<=:.\@E#0;4 >)2I)!Z[C6OL>QD.5!P%B-,8<CR$/2
M2MIT64 MY2TDBYMO)4".)K]>[))52#;32U:499Y*%,! =A#X27ERWV\0QRIO
MD#D0,_.3\_KI74)S*CS/Q7'/EV5SBD0*GRM:D:HR5I!IS[3R@/"41YQ'I'$<
MZDB_40#8\JL_;!H-^9-<0U$TM/,#N5P"8:<N<!03P .'+'OWBXOW+/YL_*NU
M0!=3F9'MQH?_ &T?35RN\YM^I17V.7W(M_YZ55N]:O/Z^NE.\YM^I17V.7W(
M5-NL^<^OKSSIWG-OU**^QR^Y"HW>M7G]?H]-W><V_4HK['+[D*;O6KS_ %?5
MRIWG-OU**^QR?FPIN_UE>>G><V_4HK[')^;"F[_65YZ=YS;]2BOL<ON0INZY
MJSZ_BX^N=Z=YS;]2BOL<ON0IN_UE>?U]-.\YM^I17V.3\V%-W^LKST[SFWZE
M%?8Y?<A3=_K*\_U4[SVWZE%?8Y/S84W>M7GIWG-OU**^QR^Y"F[UJ\_U=7;K
M>G><V_4HK['+[D*FW6?/IYOGIWG-OU**^QR?FPJ-WK5V7/\ GZ:=YS;]2BOL
M<ON?T\X4MUJ\_P!7QZ<+4[SFWZE%?8Y/S84W>M7GIWG-OU**^QR^Y"IMUGRD
M^OKG?*G><V]O[%%MMOC<ON0I;7,YF^OQ9:>O.G><V_4HK['+[D*C=_K*\_U4
M[SFWZE%?8Y/S84W>M7GIWG-OU**^QR?FPIN_UE>>G><V_4HK['+[D*;O]97G
MIWG-OU**]?QN7W/:X0J;=9T UY?.>)IWG-OU**^QR?FPJ-WK5YZ=YS;]2BOL
M<ON0IN_UE>>G><V_4HK[')^;"F[UJ\].\YM^I17V.3\V%-WK5YSZY?YWIWG-
MOU**^QR?FPIN]:O/3O.;?J45]CD_-A3=_K*\].\YM^I17V.3\V%-WK5YZ=Y[
M;]2BOL<GYL/GZO7S4W?ZRO/3O.;?J45]CE]R%-W+57;?.G><V_4HK[')^;"F
M[_65YZ=YS;]2BOL<ON0IN_UE>?ZJ=YS;]2BOL<ON0IN]:O/ZW\MZ=YS;]2BO
ML<ON0IN]:O/Z^ODL[SFWZE%?8Y?<A3=ZU>>_QWIWG-OU**^QR^Y"F[UJ\_D[
M/1>_&G><V_4HK['+[D*;O]97G]?72G><V_4HK[')^;"F[UJ\].\YM^I17V.7
MW(4W>M7G]'KGUZ4[SFWZE%?8Y/S84W?ZRO/3O.;?J45]CD_-A3=ZU>>G><V_
M4HK['+[D*;O6KS_5ZZZT[SFWZE%?8Y?<A4VZSYSZ^>].\YM^I17V.7W(5!3U
MJ'EIWG-OU**^QR^Y"F[UJX<>7I%^-K4[SFWZE%?8Y?<A3=_K*\_TT[SFWZE%
M?8Y?<A3=_K*\_KZ:=YS;]2BOL<ON0IN_UE>?U]%.\YM^I17V.7W(4W?ZRO/Z
M^BG><V_4HK['+[D+\/F'QZTW>M7G]1ZWUIWGMOU**^QR?FPIN_UE>>G><V_4
MHK[')^;"F[UJ\YR]>N].\YM^I17V.7W(4W?ZRO/3O.;?J45]CE]R%-WK5Y_7
MT4[SFWZE%?8Y?<A3=ZU<>//Z.%.\YMA_XJ*^QRC]\(5-NL^<#XAZ^:G><V_4
MHK[')^;"HW>M7GIWG-OU**^QR^Y"F[UJX<>7T\:=YS;]2BOL<GYL*;O6KSFG
M><V_4HK['+[D*FW6?/\ 1KY;T[SFWZE%?8Y?<A4;O6KS_1:K=-UK(="Y#RJ4
MB!>3R.5'&64*<H8$4@GD0VZ]^6,]L5J.3>G\GI;_ -QP7\MOCJD @D7/N]>=
MD)-B;\O/5ZI9990"64 EEE#   8  #D 115RO"K\:J_8Y_P1A4'0WY5;BU_R
M,<7VWK'X@A%Q?N6?S9^5=JE.KGY8^315RXMU72%*0I5N+G71;UJD5+55PLK*
MIUPKY-JM9MM\N3,K[H<9PDHJLJ4E2*1]*2:,Q5$1EMP*BBLJR4C(Z B*ZPJJ
M1,@0,5Y%*MD4U3VZ-K[60ID:XB>#BI,6DHJRTR5)#36(X+F@H2L)G/\ I*\Q
M-9;SJ<AI.G3RZ>"0<+)Y]0;U!:.IG?4V)U=2OJM-J>MM>>LCE&;1<H**R!HY
M33%5+*DSA%OTV0P+AD'4HA14C9<NB+36NM;4VFRR&*RS3-O(BE*J0F*:6Y2B
M&I614*4A2D*4A2D*4A2D*4A2D*4A2D*4A2D*4A2D*4A2D*4A2D*4A2D*4A2D
M*4A2D*4A2D*4A2D*4A2D*4A2D*4A2D*4A2D*4A2D*4A2ORX._4O>2AK%6^E
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M"E(4I"E(4I"E(4I"E(4JDU6C6F=C2KR4JDU*D6<=.O5EDFFITPJEB TPJ3@
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M;R$;JU)2+WKFL.VC1B&+S,,[G+3;(>[CE%S>3-[E<2S*W$[@ Z-Q0W=U:RI
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M[N^I1 7:YX:CM/E\KTI#GT?:QQN?=9TW3U5:H]<=O+QVM67^ZEFWIMB,)&N
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M;385-(4I"E(4I"E(4I"E(4I"E(4I"E6BO]+=FI9.ZA>PY5'-7F.,9Q)]L97
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M,/X'&_=T[C:_&2?A3_[RG>6F^J;I_?8X/Y0AWP=_$P_@<;]W3N-K\9)^%/\
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M5)J4]2G3GGHS#/1GGDEFFI3S234YIZ4P@(TYIJ<\\@S2B C)--*(]S,(#()
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M4-MFRAO7OJL9Q+&6<8PAAMH1,,=Q:+%4]TB%O8@'$)6L!L EF.BZVSO6<<6
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M6P,TK="DH;59*B3O;NOC;1%$R7"QEF)ACD2,U*4\F>A^.4.K* VI:VF%-O7
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M5"=7/RQ\FBK<ZB+<7/>QNR;IM)7M_*[;/W6/7 D(7*JN$NW%4BJ6BNG:XT5
MTV2*BIEE N%QI%(K4 L-&>4C6H5)Y/)@S;JNK;:)[&W=TYV[2[3/1&L&0:B
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M,_3]'&NM]V[ F'/'<=PR.WM9'P8Z_1%>>LNH$\\SF+G++3F>RW-QQGB(9QN
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MXT%=#2%*0I2%*0I2%*0I2%*0I2%*0I5(,GY%'PZG,Z@#'# .%1X1FS_Y9O\
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M7[A2D*4A2D*4A2M%WZ(:SZ6K>80]4K4^$?BQL#[P9QQW'AU]=L+[Z,,[)O\
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M # ^'.VP8'?.XQZ"KX#I:YXY7UL!8]M\LA8YWS-1Q$!WW#F&!' @(#C._(/
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M7K@RLL6XIIZ:?7'VV6^Z3!PC.55ERV]$N8=1>JFR3 ;3"E&C6JSIYXQ//*=
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M@-AED=#V"^6AN<[\<]!S  /MYR/;MN/# 8R/+(  \1W4!]-[GKRS.EA:YX7
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MM]#B/6.!QQQG&^=AY?#=>P9$8]#UYZ&IYFQMK:]L[Y'A[;GD+DTP''.P@/8
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M(4I"E4B^WLA6Z::P\W+4,TD1#HT*Y^<F7$T9"0P;+DJ?D)>6:6:K-Y.:I!,
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M5FX;[(FVCV)0&7<>E+:=G1&G$*9B +;<?;2M)(C @%)(-C< Y'C7NM]JGO\
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MQ:=W_P#2VL_>\I[P_A VC_'1?@C?TT.P.SIU8D_"G?BXU'P-_P!&3]25WO\
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M;221J!8UC@.@RP.<^5':'@<M3M_Y)VQW/\*NUWX^#\!;^FN _@?V*M;N:?\
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MU00 E9*?=+"4YUJ9F*+B3(L,0)4A4PK2PZTY$2VI33:G7@0]);6GHVTE1*D
M*]R@J5E54&];6E%.*W"/*M\F0C$;5BW9W\=7#1U$)H!)VO&G;YN+,QI6)$RZ
MBW%9[U9&N6<R144&_P";'=$ZJG3J23]S;&#8HHQTHA/+5*Z0,!L!9<4TR7W$
M (*BEQ#(Z4M*W7-S/=L15U6+X:D/E<QE C='TY65(" ZZ&&UW4D!3:WCT8<0
M5(W_ &N]>J'*]('IJ.K)PV7N8PPM4DVN7KCN&ZQQXIR:2;-9N721[2JK=<32
M4*)9T(=9/<ZT5*JBHK%")1*.3T$\]2I535*I%XX#B*4)28S_ '4N2B.W%#*E
M%P.1ERD.-NI);7O-H)0A!*EINI)(!%6!CF'E:B)#'<S<=;[LDNI2&BW)3%4V
MXTH!Q!2XH!2E !)]JJQ(JJ*6NW2)604)STK[,V9ON%QJ;2)JW]EP)D'"C+*:
MWE1/<]29+ 68)):6$=.K&G>"&2\L*R8$IF:50*35K?>3%M];?<+W2-M)>*?:
MW4VM"G$J;]M]FNA"U -;ZK(5E[4VN]^<+*$.=VM;CCBF@KV]DN(6E"DNG=^P
M[JU)22[N"ZDB_MA?ZEC7!I-033X(*=\V724;;O(I;EY)A>JHJ"HDW".G7 1+
M,.DF)R>:/JSSGG:KA-SM=%+J*Y02$NNNUR--%FHJ%2$8+BK@8*83Q3(95(94
M0E*%QTI;47RI2@E#-G6QTJRE&\H(WM_VM2O&,,07@J8UO1W1'>2-Y2D/J+@#
M&ZE)4IX]$X>B0%+W4E>[N64:%8^NVV=UM4C;TYVE%&N"C+%@4O4 =NLD.H)D
M*1ON565$MK);;32Z$=HN8R<E2YSRT;G7T6DA4#R>7DHJBB"F22[S^"28N&.8
MA+WXZT3E0$Q5M?9-]M"5.K<45I+0!5NH'1K*RE1)0G<4NRSC,>5B+<&+N/H5
M!1.,I#GV/HW%K0TEL!"@X3N%2SOH" I-M]6\E-O7)TF=LVK;^^3^7K5W9;]*
MQE]B-A5M!=99G-9645U1MN@W4(N.>NJNRFCMEN*;472TR2#K4T=:.+!A);]=
M))+JP63I,AO9R2Z_"8;E17#-A*G(6T7G4I0F0N,IL!#16XXEU!W^B2I"4A;F
M^6T%56%[0QVV)CZXTEL0IJ8*T.]"TM2U1VY*7+J=W&T*:<3N!Q:%E92V4I6H
M)K*^T.H!K7G2'H\&PEK)&W#24!2"C\7:5%.2G2HI*<!M[BA%AJ5#55+8BJ-9
MH+BQ6"F4J/!&=*,1\L2-^L<,:N7 =AK99=4@R'4[Y802I;25JLQOFP 4^BSS
M:!GT*VEJMT@ V46<W+0ZZVE:8[2MP/K 2AQ2$W>W![HI97=I:R "ZAU ]P2<
M0FYTG3$5B#-=;@L=>EC6SO#;JZUS-/5Q7'+;JLFWG0[1L16N<LDD]"0WXK.E
MD+#DM\B*CP9!2X".WJ*\ADJ\]4TG*$GF<.U<V;?0IYIN;#?D1'XL>?';[H"H
M:Y;Z8R"I;C"&WT-OK2T\8ZG"VM0R4GVU:MO:%E0:<<ARV8\MB3(@R'.YRF6B
M*PJ2L)0A];C*G&$*=9#Z6PX@$DI5[6KS:=-:+=OX[R5O52U5S;-/E>LRV=0K
M,1;AS,-3*/FSCJ/%4LF[VXN6Z>KV2I*J6JJ"8GN%NKU=$<:165DJK43*I0[(
M8#$Q#!W(+1D)E1I;*);D!Y<?ITJ8F-)*E,N(D,LJ(4E*E-N-A;:PE0"@4D5E
MP,6;FNAA4:1$?7$;G-(?Z!0>B.J"0ZVN.\\CVJRE*VUE#B2I)W2% UF?&GK;
M4A2D*4A2D*5PCE6@;C>7' ) ZJ2HB4?5ITY."C,?.TT\M4-5"Q*4Q6H4)S56
MG2FEH25:U*6>H,L@SRYS&5"C=VS(L,/-,&5(:CAY\J#+2GEI;2MTH2M0;25
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ME U(<I5JHU**PE3^1RRUYQI]&O9F<DO[BV7DM8=AF(LJ9Z5?=B<7<CLPHL9
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M)C!F.&X?@Y,4F,I*T-)D*2\F,8\T/NNI6N6 TE@!(K*&G/Y)3DJ  RA/)+.
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M"["J::KT?*Y@P1+KQ _2*5C!?)<Q4H24YJ] 1HU1GI",@U,2I,4J5&D/QU*
M"E,.N-%0!N HMJ22 <P#>QS&=0_&CR0$R&&7TI-TI>:0Z$DY$@+2H D9&VHR
M.5<XKM%J.#REYO-AO+?F:55"*=YKHJ:I>4"2VFU$=:)DO+I:MY5*JZ16JI2H
M7H>1T5!-JU")N2L5GFI#0AUUN_1N.(WBE2MQ:D[RD*WT*-B+E"P%))S2KVPL
M<ZK4TVNV^VA>Z%!.\A*MT+24+ N#8*02E0&2DDI-P;5;--TZ69;YQA5V@P6T
MQ"%NGJKW&0&\Q$)%:#;KOA89"Y;JLY5E'0DXD7550JTG$K)9&N9R-"6N7JS!
M4J)R;,4R58A,<#_3/NOJD,(C../N+=<#"'VY ;0M:B4I+K2%$#6Q&04J^,F!
M$06"TRVRF.\N0AME"6FR\ME;!<6E"0%J#3BT@G2XUW4VO;&%692%*0I2%*0I
M2%*0I2%*0I2%*X&BVDBBLG5T"M.H>/5R9R::M3HUI"RB33C","F2[ND-0HH&
M4<P"4;,4JLHUB%"D7Q+(-?R;+5-D*C-1-\AII+K8"2I)6RZ\B3T#ME;KC*)*
M.Z&T*3[5Y:EW)W=W#3 BIE/3.C2IYY;3I*TI4$/M,+B]T-725-ON15]S.N)4
M"MA"&[!.]O<N5*E2)4L2)%J!,D3H42I0H5HTRY4J5+TY:)<L6+T99*5"A0I2
M24J-&E)+3I4Y99))9990 ,=QQ;KBW75K<=<6IQQQQ16XXM9*EK6M1*E+4HE2
ME*)*B222362VVVRVVTTVAIII"6VFFTI0VVVA(2AMM"0$H0A("4I2 E*0
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M\B?G'<F?8Y.?_.]GNPW3ZWUY::_-GI>F^.OU\M.^-/\ H3/L<G\;#=/,<>?
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M:@!+-@0R @ 339#EGKB/7U]>VI"@<M#R.M4(A?-$>WV-&_@DE_-%2M&_S?\
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MOEU=G(BW&QIZ^OK];'#'5CP>_P!_#>FW'*U^?#A?,'2_#>.=Q2F.OWXX>_E
M7[>)N--;W[=3QR%LQ2O@0/FB<OE9+X_]X*'MXSMZPYB",S?UTZ@;^07U[;B=
M!:_NL\NKJX7MGY\J][]^6]E<?CJMX/D,?Y<?'MPYQ''R'UX\QY]1K4KT/D^/
M_/T^7Z ZN?/??AC/+/A]X5'.V?5RL;Z]0(]((&0%K5/=Z^?'W=O> 9WMD<O)
M<V-LQ;4>D7I3;L]^!]?<!#KB=!Q)R'6.-@#R( .ODO3/UY<?GH'Y1^_GM\/N
M1 SN<AE;0Y7[!\?8;TJ<9]_B_+#3/+3C:]P;9"]^&=[WSYTI"^=^? ]>1L=
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M[[>26Y&TPBWE%-./$TEI%,Z[2ZD80BA\F6*U3-6WLV[@L)B1-E8DU%QC>4B
M'X,R8U"%D[TS<894VM\[RPR%+*6BD+4@J.Z+FT36,RWH\.-ASLK"2D+G]!-A
MQ'9:PH[L3>?>0MN.-U"GUH3=T++84D D[9K8R&J5MK>TSS"HVK.TV.TY#EL"
MY]&5J%N#4B"GRF&$75&W/5;RE0:%4)V_2/H-2HBG)$^4PESS$:E 8Y25NF3(
M*9!E ONVE$*29(Z1=I!2Y9Q'3?RA2X-\;UEV-=-'OT#%V!&/0M7C!2%".>C3
M=@*;^QJZ$_8]Y%T*W;I)20:KCP?SAU??\75%BYO>_+/3/4WL+YY]O7:KWKZ^
MBG#D._5ZV_M>\!Q.1L<LSF+D ^7SVMV:Y%4^'W[[>_VQA;,]=SQ&6F9O?.V?
M :WM<%3^GG[Q[?O1%]1UWSOJ.7$'7,D9:YZ/7U]>RHWWVZL9]OUN7;X,Q-M-
M";D\+'3+D<^&5L\C<4]?7+UY\I]XCP]_A")Y&UOP1;JOF.O4$7XYY9*>_G^3
MW^/$1J+<O2+>2^9OGH/,5<,DC\4@A]KTW_\ ?K>_LBDVOEZ_3VY7Y5<1Q_\
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MXRC>\/J[R]J)WLS;('*WDMY^NIW.OT#Z:!K]9/ +770W'Z3;W,0 >*[VYP.
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M$K[#3]SW]<*9\QYOKIYP%M/4$K[#3]R%,^8\Q^F@6 MIZ@E1_P"9I_>Q"F?
MCS?75>MEDMUI4YZ:(0I% G# ]Q*$NW/8/?X]X9?%Z.= "-3?R <_I];VK@D'
MYHCW_:(O\$$?6\'.*U>Y;_(/RCE4#W9_*U_W:>%7*BBKE>%4,TJ@!Q&G.'KR
MC"GKZZ5^63I#==G2E::=1KB8VE-@-5<LU63$I9**ZTQ4MPFJKG4)3$J]0\OF
MG$FF/(J %B82T1*!)2[H1EGJ#--CO-GXFR$C#D+QR669J774;G3/-V9"MYLE
M*$*3<E2\[WYC*N%QZ9M='Q!2,$AI?A*9:7TBF6G/LQ!2X-Y3J38!*<@-3<7%
M8+#TO73I<?.PMX&V_P 2E#]?=X<>'/ 8'<>>[[V>QQXP/PJ3^ZK3=\_9$\6H
MOQ^UF.S\>!RXV OF:>F]=.D']R^W8_\ LJ1 Z]_EO\'K8WXP[V>QQXP/PJ3^
MZIWS]D77O:@\_M9D'S=-V'CQ&=/3>NG2Q\S"W@;<[4H?:&?EPVZQX]00[V>Q
MQXP/PJ3^ZIWS]D3Q:B_Z,QSL,P_ES.N6A-/3>NG2^MA;OL^)2B=N?V8;]8<.
MW ;0[V>QQXP/PJ3^ZIWS]D7Q:CJ^UF?+_K^RQ-NNUJ>F]=.EO\2^W?9\2E$S
MCB'[,,=0#V9P/ 1=[/8X\8'X5)_=5'?/V1<SWM1U#N9F^>G^OX97\O5>?3>N
MG1W^)?;L>& \ZE$#P_LO'\L.]GL<>,#\*D_NJJ[Y^R(/_34'E]K,^6YZ8V]<
MZ>F]].C]:^WG^BE$' \_V8!PY_TP[V>QQXP/PJ2/[JH[Y^R)E_%J,Q?[F8-C
M^O&GGS%A3TWKITM_B7V[#_V4HG_^Q' >+ASSP=[/8X\8'X5)_=4[Y^R+G_%J
M/@S&=_\ ?\]>0USO:/3>NG2S\R^W@!VVI0_6V>&>WCV>!WM]CCQ@?A4G]U3O
MI[(A_P#3$@=<9CYGSY.>E3Z;UTZ.!^)A;S;_ ,U*'OX?TX &/6';CO#O9[''
MC _"I/[JI[Y^R)G_ !:C+3[68_?@>2]\J>F]=.C]:^WG+^Y2B;]>/TX\NT/'
MSAWM]CCQ@?A4G]U4=\_9$\6IRM_-F!?G:[_H(ZKYU ]+UTZ.<>=?;L.H?.I1
M-^/+OP\ _?ZH=[/8X\8'X5)_=4[Y^R)?[VH YF*SU\.GUT\ESEH'IO73HY^9
M?;P0Y_$I1.S;Y<<]H^U#O;[''C _"I/[JG?/V1+_ 'M1;GW,QQM:WVQUYGJI
MZ;UTZ6=K7V\QGZU*)Z_RW@/BSG/,8=[/8X\8GX5)_=T[Y^R)XM1;]&9OPSMT
MXYZ:\1>I]-ZZ=+ZU]NP[!M2B]77WX=?M;YY0[V>QQXQ/PJ3^[RIWS]D348:C
ML,9F^E_Q_/MZC?*H'I>NG1^MA;S_ $4(G9R%X=6<[^ (=[/8X\8'X5)_=4[Y
M^R)XN1\%9YCAT_;\U/3>NG2^M?;SA]:E#$>?^& !G&!'?&0VS#O9[''C _"I
M/[JG?/V1?%J-+_<S!U.G\N,[6OGEGKPGTWKIT?K7V\Y9S:E$]<,/'KXAZW:[
MV>QQXP/PJ3^ZIWS]D3Q:CK^UF.7"TCAQ''.U[4]-ZZ='ZU]NPW^M2B\/WX!@
M?7AWL]CCQ@?A4G]U4]\_9$\6HUM]S,Z=O3"W'F-,Z>F]=.CO\2^WG9\2E$]?
MY;_'PVWX[!#O9[''C _"I/[JG?/V1/%J/@[',\2]Z]=Q0>EZZ=+?%K[><-OB
M4HG'/:\.KPAV<A=[/8X\8'X5)_=5!Q/V1.&&HTR^U6>?'[.+>IRR!@.EZZ=(
M.-L+=B.-OB4HG6/^&'+;/N\7>SV./&!^%2?W5.^?LBYWPU'5:,SK<C\?<\#E
MPJ?3>NG1^M?;OQVI1.O;8'APY\=^&W)WL]CCQ@?A4G]U4]\_9$\6H^#L?$'\
M\L]<]+#A'IO73I?6PMWUABU*)PZOEP'QB&=Q# X"'>SV./&!^%2?W50,3]D7
MCAJ/@S/I^SY>2^N5[&GIO73I?6PMWQV#SJ43A^^\!''+AVC#O9[''C _"I/[
MJG?/V1?%K>O]&9R'ZX7] ZZD.EZZ='G:^WG^BE$[=A_3C][UQAWM]CCQ@?A4
MG]U08G[(G'#4?!6?W]SUVRZZCTWKITM_B7V\[/B4H@>/Y;Q#(^ .(]D.]GL<
M>,#\*D_NJ=\_9$S_ (M1J;#N9D9#_?'7+EG4^F]=.E]:^WG;\2E$R..&/TX8
MWYY'UN .]GL<>,3\*D?NZ=\_9$\6HXW^UF03RM]G^?EQ-J>F]=.CGYE]O,?N
M4HF1_P"V&WK\N6\.]GL<>,#\*D_NJGOG[(GBU%K7^YF+GD+=/KY^P7H'2]=.
MC]:^W8[[_$I1/:_3AP#MW'CU +O9[''C _"I/[JH[Y^R)XM1U_:S';D.GX:<
M[WRRL0=+UTZ/UL+>9S]:E$P #P_9@ CP$.6_*'>SV./&!^%2?W53WS]D3Q:B
M]_Z,Q;2_X\'JX9Y6J/3>NG2R.+7V\#<,?$I0]@Z_EPY\=^H><.]GL<>,#\*D
M_NJI[Y^R+G_%B-1_-F#E^OUSO;@+\:>F]=.EC:U]NQX8'SJ43?;?]F > /;Z
MX=[/8X\8'X5)_=5/?/V1<[8:WEI]K,"^6?\ K^>GJ:GTWKIT=_B7V\[,6I1-
M_7>'KY#U^$.]GL<>,#\*D_NJ=\_9$%_XM0>5HS&>O_O^?EUW%1Z;UTZ7UK[=
MAU?$I1,#X0[\,]NP[9#CO#O9[''C _"I/[JG?/V1<_XM1U'N9GAU=-?/7RC6
MQJ?3>NG1X>=A;SP^=2A\L;_+@.WBZN'-WL]CCQ@?A4G]U4C$_9$R_BU.=_YL
MP-./\OE?.U_\WIO73I</.OMYGK\ZE$Q_KARX>WOC=WL]CCQ@?A4G]U4=\_9$
M\6H[>YF>W3I[VX'MOPM3TWKIT?K7V\\/G4H>?]< #JY#S\,.]GL<>,#\*D_N
MJGOG[(GBU'P9CKYOCS 'RW%1Z;UTZ0<;86['_P!E*)ZWRX!QR&!]XN]GL<>,
M#\*D_NJCOG[(HUPU'DC,]>7\OQX'ZKO3>NG2^M?;SP>=2B;!GF/?AQQ][Q"[
MV>QQXQ/PJ1V?B_772G?/V1?%J/@S&EQJ>GUM?(<>O*GIO73I?6OMV.WUJ47C
M^_  \6WK9$'>SV./&!^%2?W5.^?LB^+4?!F<CY7QR.67 7SO4^F]=.CM\2^W
M@\<_$I0\\\?LPY[=7#MP#O9[''C$_"I/[JG?/V1/%J",R?M9@'TOZ_1IF*!T
MO73HX^9?;P?_ &4H>X=@]]X?>X]F\.]GL<>,#\*D_NJGOG[(GBU'P9C/L)>'
MIXY<0:CTWKIT?K8V\#@ ?$H1/_\ 8<1'W]3O9[''C _"I/[JG?/V1/%R/@K/
ME_U_,9>36XIZ;UTZ7UK[=\^%J40,=7%X#PY\>/ <;N]GL<>,3G_M4C]WEY:C
MOG[(OBU'P9D=FKWGM<\@;9O3>NG2S\R^WF.?Q*43/@^7#EPSMMGB.(=[/8X\
M8'X5)_=4[Y^R+KWM1;*_VLQ?K%NGOY;>?C(]+UTZ/*U]O W^M2B<.OY;Q\4.
M]GL<>,#\*D_NJ=\_9$\6HUXQF=.)MTWF\_ V>F]=.C]:^WG/^Y2B<>7[,. X
MZ^>,[9AWL]CCQ@?A4G]U3OG[(GBU''^;,ZWL/]?:W'7RY7J/3>NG2^M?;SC]
M:E#W#/VX<@\''AMF'>SV./&!^%2?W5.^?LB9_P 6HU%OM=C0FWX_@,_FYSZ;
MWTZ7UKK>?Z*43QC\N'#'#;/7C@+O9[''C _"I/[JG?/V1<OXL1;]'8\I_E[V
MMIE<^8&/3>NG2P'Q+[>9P.WG4HG'.W[, VQU>W#O9[''C _"I/[JG?/V1;?>
MU%^7<S&MSQZ>UK#GRUO3TWKITOK7V\#_ -E*)L&_^&.X\ 'VNN'>SV./&!^%
M2?W5.^?LB>+4:_T9C+M^SY\-,L[@D T#I>NG2R/Q+[>8Y!YU*']_OPY<]AY]
MF7>SV./&!^%2?W5.^?LBW/\ %J+#_9F/CZ?AQL#Q X7!TO73I<[7V\X_6I1.
M&_\ AAX.W?G#O9[''C _"I/[J@Q/V1>.&HUL/M9@99W)!?ZO3QTH'2]=.ESM
M?;OAO\2I$[/\+]O;#P;0[V>QQXP/PJ3^ZIWS]D7CAJ/@S/D'\MEUZ\LJ>F]=
M.EO\2^W@\OF4H8#GP]^.V<\PX!PZW>SV./&!^%2?W5.^?LB>+4'_ (9@7X:]
MT<3GV>>@=+UTZ6 S;"W>?W*$3_\ V(>#8/=AWL]CCQ@?A4G]U3OG[(O'#D?!
M63;_ .1GY.W3.I]-ZZ=+ZV%N^7]RE$[/\+^O//AMMG(.]GL<>,3\*D_NZ=\_
M9$\6HZ_M9GL_'9YY]GGJ/3>NG2#C;"W?8/G4H@".X8_9?CL''6$.]GL<>,#\
M*D_NJ#$_9%XX:WQM]K,C^^R[<^JI]-ZZ='ZV%O.6XVI0^O[;^/5MB'>SV./&
M!^%2?W5#B?LB<,-3\&9MKGF'N6F5JCTWKITN(6OMWC'#SJ43?GL/?AX@\8]4
M.]GL<>,#\*D_NJ'$_9%U[VHRX=S,$DVX6?[!?MY5(]+UTZ/UL+>!N&/B4HF_
M7^S >7@X=7!WL]CCQ@?A4G]U4]\_9$S_ (M1PUC,?O[WMPRS[:F7I>.G3G$)
M9+76\&8<!*'G4HF1'([!^G ..W5XN3O9[''C _"I(^-JH.*>R)G_ !:BX&G<
MS.N?$/:9"QX]7#](G19W;U*WRL6%RM63>3VS>9:6UJ@KIB6C%4$E*C)QV8DW
M#%-.)J"G0I3&$F@7J3SRFQ&K,(U)Y))A&6."Q]K"VL2<;P9WIL/0TR&G"M:R
M5J25NC>6$J-EJ4,P+6MH!7<X$[B;V'M.8PUT$]3KQ<;"4H 0E12V=U"E)%T!
M)R)UX"];08TM;J@AD! > [#"E8T7(TR,FY"I,J*U&G-6GR(]U((CD1$1W 0V
M$1SZ_CDY]6GU]G9\54BXRM>VG V^D>3AUU;/T#%L?I:E]S/[7PW'P^UG:G/F
M-.7'SZ?%UVS7/X/9F/4>FGH&+8_2U+[F?\X.S;VX9\QYOKJ;G\$^<:^?T^BG
MH&+8[?UM2^XGX<\?#=?;$\\^S+CUYU%U?@^D4] Q;'Z7I?<3^/\ 7>'P=N=H
MSYCCP\W'S\^JEU?@^D4] Q;'Z6I?<SC_ -X.WU_$,^7_ /;;_N/KEQN%U?@^
MD4] Q;'Z7I?<3_?[O\F_#;C$9VU%^S+X_7RY+J_!](IZ!BV/TM2^YG_.AG?(
MBWY.?_54W/X//B/)YZ>@8MC]+4ON9_SO 'OQ#/F/-]?KIPN5S^"?./IIZ!BV
M/TM2^YG\?Z[;VX9YYCJR^//LJ+G\'TCUU^GJH.A>V.^"]+QR3^W\/$CK/;8?
M72ZOP?3]5/0+VQY%J7W$X>WW0\89\3Z+^C>'GOY*75^#Z13T#%LOI:CR_6S^
M/]=X<0YY]F7;:^>7#GQI=67M>W,94] O;'.Y:C]Q/G/W?5ZW;C<>H^<?-?Y\
M^KA-S;W.?*XZN/KI3T#%L=OZWI=OPD_M?#PY^C+X\ZBY_!](IZ!>V.^2U(0Y
M?"3^W\/R]OLAGS]%_1<?'2ZOP?2*!H8MCS+TL=DD_P"?X89\/BO\XI<_@^D=
M?;U4] Q;'Z6I<OUL_C_7>M$9\QYOK[:FY_!/G'/MY9T] Q;'Z6I<L_"S^/\
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G22RT90E#X67N0      #/ ,?SQ/KZ^IJ>L^0<O+KGY.RK@0J:__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>58
<FILENAME>g65062g98g89.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g98g89.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %= ET# 1$
M A$! Q$!_\0 '@ !  (" P$! 0            <(!@D$!0H# @'_Q !+$  "
M @(#   % @$%#0<!!@<$!0,& @<  0@)$A,4%1$6%Q@A-SEW(B,Q.%=VE9BT
MM;;5UQDD059SM[AA"B4F<9/4*%%5<G21H?_$ !P! 0$  04!
M   ! @,$!08'"/_$ $L1  $$ 0(#! <$" 4$ 0,"!P$  @,$$04A$C%!!A-1
M810B<8&1H? 'L<'1%2,R-G6SX?$U-W2TM19"<[)2)#-B%R4T0W*"DJ+2_]H
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MDDDD<Y\DCWDN>][W$N<]SB7.<XDN))))*-:UC6L8UK&,:&L8T!K6M:,!K6@
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MF:5P@(P8 Y[W$0D;&,'@(V+5(ZU:)I;%7@C:9!*6QQ1L:91N)"&M [P'D_\
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M78*2I67#TLFM\#G?^OKYBYO<;[80(0$E:CBJ^M]=_E]IM6>O(FF(\[A7?A[
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MIY<XEJ9<M-7$Y$DF-DRUD5 SOD 9Q[.N?K?P6-V=U[7ME.V)=)]'ZB1U5_\
M".6B&Z<L_H:V!W11>#@;DQF^^<5K3S*F]D"!Y,$?0X3>#&:6(8N2V*XBR1%I
M788P3@.YX&,;9.,Y\#@KL/0-TWXDH_LT6_>)T[=5U\+2CBM&6KMQTG9ARUQ&
M'Z2PPK)8>RD>JWSM$ERZ,9LFX6;ICCW6Q9DZ6RLF ^ I,#;? XC@D8\,DX)Q
MC\]UD&[/2/G6RF>Y:&VLZO4FPLOA[:K^YT?Z.2-:0DK?0.7I@_\ #B5BT=H:
M;83$N$RT<%EKU[8$GW?TVB1@S71R32D /JG&1Q;'S&,^8VWW'+?Q5KMO;(V'
M1;!["-0V.VHT]"\Q>>;OK\RE1K[H*KL;RP[N6.V=2UXRKEN7!B.!Z4@7,()U
M;@6-4J(;CY SE$,,2@Z<N9Y[=!S^:FFT^L:MKUYZ"%NL-?AK>@QM*2,&"6^I
M#;D9)N3+L)?C;ZC8 :8GU_E SS$Q59%7)OA9%A$K&&-5/#&KG)C.//R^O>NT
MN7KW3U,+V\K)//:.M'6G3U.V$G"FK:J98[WH8G#U]'&QN%BK"#,<_)Z!.820
MX&C$@[GRZ^M(/+%B3'X_)<RP^GJ@IGV0O4IFEB;ZJVWJ'3=L7#.*:%G!9]S'
MT02N$PY&67&6):$/L6N,66;0=85(/D? J%9&KC!HBGX_7X++C_0&K5<UM@8M
M;&'E2-DU#45CDGUUL? 8;8%\'K)522@&=U+[1\*YBN=5QBL*"=I6AB'RT0YP
M,41C#PB[3^-NIHBG0;"^UY!.@V&LU*QZM1>51CSV6[7KFJ.DJR+/&H'>V!XM
M;JSD@*.5C(X&/$E6_=8S8=]DQ^?BL7N7IK2M*FK YMY0N)[3O9#YL@AK3I&[
ME3[EL4,Q =(L<8[3'-,\&'BZ(8J"<?S(4$XTLBWO">/+LK@_+/N6(3^N==EM
MZBIJ*VQ73.R>F+)Y7:%)A1\!ZCL.G5^R6.TEO/N2,)>T:@.KGPRDB1S3R$2C
M98CXB93%0DQ[ML[_ %UZ+HD_I6_V$K6>*[3N(P=W]3[;\]-IB[9EA*EK6IP=
MLS%[*&B;5^NYL^G)FIV<,->7X&XB#&XR8.F!@N:^0F!X] ?>>GN_!3-I &W@
MU)UA=;CE=VN>R=I]!M<E<RGL) %L&Q*D"+H:9PZREQ3*UXP6)F),/176'4N0
MD,O<F4A13#PB<(G")PB<(G"+Q[_!U_Q^UG^9^TO]@[Y]B_;+^X,_^MTO^:O"
M.P?[SL_\%W_U7J?]#[LKGG?3MSV_:24,"NI"K\HX+)8XZFM:M7#=>B2HL7\R
MYM" P>-F0:I3F0#D'(R+%B/)7@YDL1/CI>[@$\AGV+N-*;1&W7JJC[6"J[^G
M WI)"_7U^S'TYLU&7DRS8@&=.=>VJ\4=VK<!QP.D+RJVU\E=(6"UH$?G&7UA
M@0[+"_0N7I(5/6V?FK"@L[&O,M>3NK;$AF'K]BQFUW;L*3$P?AGCM4:879.-
M0_<<Z(,YYBB)-9+QV'XF:MV(J,=<^[Z^OF(9JZ7W>QW+GG;KK2$>G,H8G 7:
M:L5C)AAG$Q4LRJ@Y4$&OW&$I ^.%8 ;*;:3!BL[O;<PZ%Q/0.P2;8\_K&-_H
M@=,K(-/LT%=\N2&[7486]:#8]Y_NT!'K]Y;@&D@^U-F2.\AJ:$-;F$2HN.$^
M.,9C,?"..1& <T(SF^K.6)QUW]V?DL0] ['THBUUJUVPU>K<T\S.RG(JO:#K
M%I&658HHAK5G4TE./K8G=Z=W!#'E6T>KG0(57NI4T:I@;&-'UGB5&_CR/3\#
M]_3FH#,WEX,C3M,9-+V/I/#_  Z)F=X8UD"&-BP =8:R3PVV?: 4B$I33?S8
MR@8ING54.OA=:O/(KE@"6T",LL$8W&//ECV8(YX]IP1GFK05C<^I"V?FBF5/
M7JU6AO?6T&^OD3@Q:BM=704ROV=>=:D&N (7,YM><!F$I9QBF"-TJ@N"<22O
M3'RMUB0IX^[Y[X^O#Q7&VK:M0IV6GE8.KZM%*T/LY]5QO)[SSN#$0IM>KPCZ
MJO6M*B,?;WUPL+^HND^O6B:.NW*>D9-2"9&=82XY$P=_+PW^86,ZSV90K"=K
MT.I^>4"O5;.G[8:U5A-V[8V15FNONI)=D((M25W6]ES&PZWI:4RYP3DYCQ4E
MZ_L-OR&%4*U>3(KT)SOGIUSGK\?CYE0]:]SZT"/)8W'SSK6.VU^&R%BUP?<;
MR=C;&$&SM_)1<ZI5\-;@&;#-76^J[(L+ OJN%.:$IV.:=6Q64]BLRW$I\<>S
MIU_#;V9.P64I-QZ2F;Z98J?.,(EUL7\<&"Q7!D?6&0CQ027 ^3UGNT5RI!WD
MX\W],K&D>=5UIHZ&*9?=D-*M-;8U543?QVY<^GL&=A_9;!]:L5;?7- ;(U.*
M!*TI-58IT6&?4F"56:B )7J<),<<,9,5PDL(>.>.&'674/676./7?Z=$/,Y\
M5FW"B<(G")PB<(G")PB<(G")PB<(NC86:N*FZ.O,WZ1?8+1^3ZK"$YLO#<V3
M)*)B>XQ0K"2(C&^2H+/ QET!#/T +GB07W##EUGPBKM6-SOMDV;11RE>32*#
MLS6FXKE9*M=%JB6]195!MKY)7>H[!3[TZKB&'*.V,&QOV9-AE)&_&1?=I3(C
M(L2N-C[0/CG\E2&D>A?.VJF/@Q]M3:-& MC?P/N6TIKKM.\='LW,^$_F-S9I
M9]C6<I\^*),,'L?1D<1;5EG],\01>5E%T#V3!/Q \-SG'XJG>M_B.:[25/Q7
M8:X)L)ODN^%GN&PPR)SM8:QUET?7L?.P'W:S8'IP+5AS8D)I32 "FZ%#:JH,
MT@@$!46O\99X8YY^7USQ^"R+3ZW_ /5C'/QSRY8VR#OX*L^L/77HRSUKSQ::
MMJUU9:TO^"[LV1/%7]?;_O\ U;;4-UJ8.6M0[VU!5*C645Y+Z6)\<_V)0+,L
MH)>6*QK>)+"W#FK=5+1ON/V\;D X'%DX.XZ;D\]L=5G$/M?=*2AH>G'C#TCF
MT'^"ZR9X6&FL?1+],.Z[7),<*L2FV'H^!7'L""4;L\N\L5MQA%$($",N#\'Z
M_7'U]?7]7""XCB&.,C?'B>H).#CR\?;VC#XF&M:]ULAYMO4OI[1MJ_[)+6CH
MQ[L+2"X-N$<.3?9LL@KFK>4NSL9VCP^&!)# OI2=RU4G,.AZ]*IC@'*<).P(
M/K%HQR)\1CIY\L+TFZ>M2.]ZDU;=ZP20;6KEKFD6JO&%A3+2RT=AK*QNI)*7
M$FLB ")P#!Y9@B&)\PLN>4$II4D>4\A8<E(W")PB<(G"+Q[>R_ZX%A_;SYU_
MW%JKGV)V+_R>B_@/:+_<:JO!^T'[]O\ XEI7\JDO7'=+4LHM/M-U=2QPJ*E7
MG%C922SPBX=!)5Y#$CKL@G.."'O.(?+##.;/&/K/+'YN^NN?':]X4<>?][5W
MT5KR#8U9JNPZ:#(U8)"$.S*I-4[((Q5]#_>Q]C?<L%K" >0CH(DQ*U9B!.16
MU<8S!V-$]4+2I&%G&Q=@5K5E,>W^XS,1JU7(1B&Q*I(XL)@\!9PJZ.?I6A!8
ML<Q82#(9&!O0WV*A?B4W;$@J03CARBKC8O>7F.N&(PI+RP;R69XLK" I#3[:
MR3-+(RLEXJ,J&"QXIHJ[&T0636]U3W(4EK!E1CT1 UP[233"X3E>$^'G[MM_
M?D8\>BY&L+54+9L?U$RFBQ;)QR=3B61#,JS>LEAW\-P#2ZZ\KB^!J5T[ C-&
MZ8)>A221Y<^NLHLNOTR[*'SZ_P!EC#RR>=R//[EIK?7ZT6CD[#UFFQ7!@7+S
M6!E;V&]:_7J\\SMX%;KSY/'5]A$86,ILE&,*'R!FQ[BR_(]1$$;CI@<^F.GT
M/;L55Q'MWX>Q%49'2ZE?@(S=/UAE:U_4#)NGK^KB+U7L8H8!!+B1$,GBW)"L
M@+_;2Z(NV6><C8HP[ZJ6 R[,BR/%X\M]CY9Z>7+IC8>"L*DVWH5-16F%#UPS
M(5D^EZE4;$IL-B'%=6/>PF-<N)QZED=8K*PV'<Z\PK:)@X;0,"*^]8+&=Q:7
M"6DK+?>0"ASMOT^ SCIR'E[E(FV3=,J53"(+7ZX>P6#9ZY84[QDL&@(([]V#
M;V6%I<;G5J4SE=U, !:T\5JKQ3HE\?9H:ECF4/>),"R9/X;[[>&ZARH[*U.S
ML2I?0M!UWN-MLT,.YFLK5'F"BM&.F]FJUD@PU62WM7:)3O-E#'M("$$@96VJ
M^WM>O1.C9+TRL0Y/RV\_K?X87]:W;5^5^85UCIVJ5H5-<9.U5AAVVVUD ZJZ
MK7GGHAF >O*1TH2.1G0[9HY>)HMV3/4;6327@EAD!QHR=C8"8/X>/,GES\/(
M^'BH9IFX/*=DU,GN.?F_]NR]/%JZ&O=]VU*P&K:OS,AOY4/[@?5ZHM<^G6F1
MQ:-UKQ@(*IV^R["ASDLVO;1'?RRH!Z'E_P#];<O/?KCGX+9GIYXGL5,):I*J
M?2AL[]ML(ZO,R%Y1X]B4[8NJFV,"IU+)NMRD?6D%P_\ D!9%C0XL\88I?ECZ
MPQ*'\OAT^2E'A1?SOOK'KO++OK'''KOO++OOKKKKKKK]>^^^^_YNNNNOY^^^
M_P";KKA%$S2_D$;+H^N5:M6VKM\U_LRX&W .WF G*QZ(VU[7L@4ZY6D*P9S-
M#-C Y8LXK4BF48+39H<"BNAX^R*E]1V>FU73_(6Q;PVM-E(C\-;%<YQ&.&UX
MV3L:XNR_([(>MU^2R-C+!>-A7=^7^*K27-D2R=NV(2P3O'J2+&,G,^WW!53U
M.AWIZA4^1*U>ZN!IORM=_AL7I#:J8T8,1O2MY#/%\WJ+;6WY*.8VK:THMR5%
MHX(LZX^+VA"DQ<9XN:,_;BPUHLMFDX.2#L>FQY^?W;J:J'2:'ISSE0ZS1:L)
M5JA7/ABVR<=+6E!IL_?7==HYAQ/0:^ ]V_=,2<YC#2<L&3QVQGE)(D-/)SSD
M*$Y)/4G/Q40;L]:4^LX;;U56%SR];2S^$VMV$GU]4:G=;+>L/O0KL*K&M56$
MKH05$7S]'@R%L;]:ZC(!,:O",$'F9 9$%0,XS@#B()S[/P'G^>/[CZ]T;D5^
MN3NB-;>9M=6CX7M"F.666MY;0W4GMID/H@DP,NO 6%90:C-.%G;5I0^=RVA"
MDPZ428]LF9Q>-;)L .N''PP>77?/3H%Q/7OC/9VQDGQ!J[>O2VW=D!6'X?FF
MQ&0#MMJ"KUAZZK+OTDZF+_9JSSD]2U /-E7S6H,Z+LNQQ$&S"R6#J0D%K72
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MQ8^KGRXO/]G(]I']^9PMZ6MB;09KN@EWA('6;J52ZL3;ZVNA%&7U^T3HP9;
MD '!=V4(<-4VR+ %A#L=@%B@'PC'=M8L<#YRQ^OKDLTX1.$3A$X1>/;V7_7
ML/[>?.O^XM5<^Q.Q?^3T7\![1?[C55X/V@_?M_\ $M*_E4EZHO1B$&S:#W,D
M9+C7 9FLKKW(I70,S"VD@M?/-'7Q+5#BOGNL321X1ID$3I;%8())$I9489Y'
MZ_':]X4&_#H".7^,M*#,?R7W7V-R([Z;=D=G80&;&N!@<>?95KO)/8\8A$&
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M,>QX2).L1Y.6TK1[.K^D,J$.LQ&C'!7/ TV9[^H5=.@A$LCXXHB9;3"7R.#
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ML?G\/F%-?E&4^;3(\K4,=<TSV9O[\FO#.S9B L>M^[-Q.#%92!+9&(PQ74L
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M9WTD;7EK3Q%K27< <[AX6N(VEV_4TZ V;LPKP!S6&5S7N:US\AH=P-<6AQ&
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M&6H7DX!#=A@>J/R^[ 5\_P"3CKW_ ,P[Y_UJ/3W_ %?X6.3Y? ?DG\G'7O\
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M?%)C*LH,FAO6N!]80HWY:[+S[;<6,PSZ9I )%]KEECVKZ^JG8QQ,;!FG2L9
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M,+:3O'OL563B0#D63(\]O(]?<OAA[ U%+(=% LW$1(NO8^NS<8-![GER&L)
MH1F&!&.%'[R@PQ&8"S9"3XQ.<HI8IHE4D) LDY,CS^!_)??KUKJS+*/#I)NG
M]9;K-1,?_P"'[=?\SB".:3.7O_\  OZ]B_+#EUU%CUDTZ_7YLUF.&$N<9 X'
MQZ]#T]W]5^(O7.JI9 8^DFZL<F%Q8TF#YO/VZNNORRS _.>7O]*-WWF/EBOF
M^4>#J9O%^OZEJQL1S<A29'T#]=/K(7S4^P=/O,EG2X';I'3:X66D#28:'W+)
M%B]J<[@5U#++%2)(_F%*1G"D!Q92M@"8Y1VRU?,$SP!)GV_ _EM[\+FK_6&J
MV6=>P&5;@_6S.[$@7?/H?<G771M9_(_D<IODI&??TN_QD_TL1^B"8^^_T-'$
M['.Z$*<0\]_(_7]POPK]9ZH;Y57$59M[K*X%V()1U+H?<O7?<U8^[_)=3=1T
MB3]>O^Y3?2Q%^ZEQ_P !48V4<_4)7/M^'US\?#GC(7PK_KW3]G'J!:<7:Y0M
MW'L)2(F+1NX2()8:S+W$RRSE$I1.$G76?6747879F/ZX_+/E!GWCCD3/3?X'
M[\87V4>MM3._VO\ 9+MN_I;DKIZJRST3N3+'[%%(-$=W+W!2)_GS^8K#N/,+
MHP;].NOK$0Y$!XDDR//EG&#]$^019ZVU(UP0R"@[:^6QUAG;EW>6BMR9?JH4
MYB1F9Y]PT>;K//K(R/Y,Q>R0^^OT^<O#L@/HDF1] _77ZP5\%GK_ $XX!1LE
MT&U"P;#0YMCJBA]';A)'*K$,84WW<) M)G@)QFB/@D')#D)6S1Y8YXG_ "$!
M]DDR//QY'\ER,/6FILXQI<0-M]XE4.78L7Z:)W)EWW7(NH>\Y/[BD98Y3_I/
MA^G>&687^#OLWKK.+N0F1Y\L\COR_,>SJOB9Z\T\ &8>:/M441?K[O9IA!&C
M=Q00CU7&.:60J>>:DX00911P29RRSR1 1X=929G=1X298$R,XW^O+G[\8\\J
MQ2)R#8T::PK.R.UKY4N<K^RQ"0"^P6@D)PG90)L4!@1'8\\?<PA<,)(TGS0S
MQ1RX9X=%5VO")PB<(OYWUUEUWCEUUECEUWUECWUUWUWUWU^G?7?7?\W?7?7\
MW?7?\W?7'+DB\ON]?A)/VOO2N5&@JRU7G3:Y3'8[-^M'^4'7*%2:)-?:;%+U
MAE (=D<Q"#H<&<647VMD50?(5!7WA,'U'H/VN5HNP5FYJ$K)>T>DLCTV.O*[
M,FIV)6.%"Z1D.?'P1O??<'<0?5F=EAL5VN\<U+L/*_M-%7JL<S2KQ?;?*P8;
M4B8]IM5P<$-=Q/:VL",<,T8]812$>F>L5E#3*XAJ-65B)*U6$ZY @3@Q_2#5
MIU(D0*X$;#]>^\8118(H</FRRS[ZP^;/++/O++OYCM6K%VS8N6Y7SV;4TMBQ
M-(<OEFF>9))''Q<]Q)P -\  ;+UZ&&*O#%!"QL<,,;(HHVC#61QM#6-:.@:T
M !=YS06JG"+"]A[ K&K::[OEQ*+$KR"(7,V1>L8NF,\[ \52L7K5"@4QDR9-
M&IX*U>$&--,087!%CCUUEWEB15$IOI/1L6[=KV>78:@:OVS76AF%>;EP-!0V
M\.8>PFF70>9 $?>4T"QTD++&RQQ($P:"=$Q122]8=%<'P/NW4W?RJO/'^5BK
M?_K&?_M.$P? _ I_*J\\?Y6*M_\ K&?_ +3A,'P/P*XIGKCS6OBPG8;DI@,$
MA0(,<QATPT4AK,T=:M#PDF'PPR*8,2Q0 1\<NYBS21Q1\))YHX\B8/@?@5^A
M_3_FX3N?L79U.&[)GD*)['ZGA[(*E_3ZI,_<86/U9Y/EZ^I-)\TF?Z=?-EW^
MG7"<)\#\"H9O-F\7[ RJ^;O92F*2I;,_BRK(!>-<#\+=F*8-/+ U+%,:I0I^
MR^B_H5@Y%*(>($6O(#F'Z[R*%A/0\\\O9Y>0Y* \!]&50VC85SV\97!P/0MJ
MV]$J+G#SQ?E6A79IRJA%.<%.Z>D1 F'Y$2.&KB!@B$;=DIL299FHQ0M=YC?P
MQS_'?V'P752":YZ8ZZ.-WOYFMI-1VUL;89SMEJNPU2TQ+[U+<3L5Z9W5[1]3
M$P5G9\2\9>XEV0A8P;$<R:90*.63@=D'!V)Z'.^>OOY8_KA]9;LJL=I;Z._]
M<S1TC8&X[5931=M6=SW*%?N[9,EC DV?I;8#F,F+MV'&UR_(%PDDXDSR#9GR
M86(8G"_/(XW^?/;'B=LDCQZ+!-;;!N]&(\NQ%7FB]C:T9[X,M40-B5L%8.-X
MR<R5_-BG76C7(=CR*R.CD%CPP.Z4SR9$R9"=_<#2E UP_P"WQ/+RW.-NOR)&
MVRP6H;')5,/,I-IHVM#'U1JV\0+<0D74%!BN+=81_M+O.YI+PQ/A+DB[PS%,
M"ZKI,,\A XV+#*1A/@5X7;$M)(SG;.^V#T\/AMS6(:]WG<*G%YP^@+9JZ35=
M);A0O\@]FMVD7Y-EFKR1XS+KC'>T-7FD[#7?:UDU3/DRDP+G '&R!'_'ECAX
M R"",\\;Y.>OSY>W.RRW7'Q#=R:]"TQ5S&#"PPPZ'M+=O7;-4.[ ^>6] 4O'
M"R8GIXD-B7?2S8+!".CY<CQI&XW;F)R<5 5PJ _ VZ$=",]!S&^/O^$W*?BR
MWJ(=1B\\[,SR\==DL'V2<>[+(LMCQ?SCI5PY=7<R"J".AR<>X)269<?<T&>+
M*3&']#" N)'J['K[.?\ ;Z&3#?%QQQ!@R,\O[6(/SI^!TG:J%](#U>\L<>NZ
MGGD=2@YX5/4GS=S6.+H[.#KKY(5!W77ULB9=_P#$^6XW^O>N8)\7NK$,L4O?
MFO>4KJ2I@LHU2]$S-8?N\Z><6*NS!YUX4H>N2E#S#"WC.'L<HB F&))\X^?7
M9,G&>$\O+G]>_?DLJB^++KN6*7+KSKZ?PER A'719:T([Z.N/]\^\KF<D1,F
M(2\?K(/*&QS]=QDXSR_.L&S@BP**YY\]AG[^7FLA_P"U3T[G$7)#IGT[)W@)
M#TKBRTXVAS<.\>YNV2.+.4K& #)9AC#)FT93"K"\9).@R)LHH\2"9/@>7E^?
MU\,_?_M5-#RF,P0]:>D#BQ @"UXD.FW41KB0J4Z(D>,8PD7M3B%VO*^4Y_FJ
M7-,ABXTQ;"4;+#(F>>01CZZ9782?%%T1U*;B-KOT>=%AF'@DF'TE9X>K)E)E
M\K7H#!E]ADL[0_W61G[E_"=,,<?_ +@[;Y9PXRDSSV.QQR^'Q_OA=M_VF_G7
M/HOL>M[^)ZP(#@4]1Z'V##W8HYOH_DBEO1BL7\?"B^KGVPBM'[>--Z@D_;HC
MWO,;J<F>>QV\OF/'[_)?W_M.O,\LA\8*_=[',)H LBQ$T5LC#([$R%802='&
M:C#E60JX&L$Q2^PX)7Y\.'U:^F=1EK<CB$^1/U]?6<<K#XF'FO/*?K$'=W6&
M#0($67/0VT(L&()7V/4ST;&6NX2C  =G8]$+6T:VU%_0D[3UQIC,!D83.Y&#
ML0/C^75<Z+XDGF2;*7KJ;;V&.#:!?%G)H?;L>)*Z; 7.2QQ]95#J2%8+V3\L
MRPW 2X2=PR9AU<J*060DF?(\P.7CU]BYHOQ&O+9GU/H/=B9?2=Y)Y.N]*[<Z
MRCAPAPGR=31_LWZHZ[K#/#]0R,(K'C\V.>:'&++&3LK^9&_EX>/BN5C\0[S%
MW]']7>Q<,9FY"SK++2VW/TQ&@Z)[Z>9?+3,LLE4_8N6,4,?4CO#N3#LA/!C&
M1E 4R/GCWIA\1#R]GD+C^XK_ -?=-CE?S=Z8V[WU#@!@?GDRE^6E992!3?CY
M.HX!<2'$7<F/9BH7"$W(0F?;S(]X_LK)ZEVW2MVTZ*^4 IF;6YV[U) 2V1-Z
MZ7(;76I29C^BUX&"PCBQ,$FPPRF&CDQRQS@(C',@)&@(#G/D<*3.%4X1.$3A
M$X1.$3A$X1.$3A%U#6OH'LR<AVC4."*\UC>H)VJT)A,C>0BE@PN4\I<$V:QK
M$$><'&Q"R@+C%-+'QFZB(FPS(H?O^O\ 9MBW9H&]5;8/5=USKO\ BC_%&B=]
MF?KL/]V54-12_EQACR$S_:KJ$AKW]]G']/J;YA/GF[RQX13OPB<(JF['U'O!
M]NVL7JH;3F7Z['?Z@,>T\FPN$1"E/2B-I$[ !K,"-"6J=P[*RL6NA; JNW30
M0U95VT0A:%Y%1;+3"O\ 7Z^N6<JV7"B<(J5?P6]-S>H(-J0[R5(M'B7C%JPU
M!'%8[//<JG'I^Q4X *8]D4J&H)ZV_O.[6<EKW3FG6>%;4&LZE+;ZD]<['*[8
M\_=XCW\OA[]KJ\*)PBI'2=&^D$7INP;4?;OZ:Z::6*]F+M3RMK*TZ5(7=?KX
M2$&+(P8."6:"Q+2; ""668EU[%-9%=6#:=;!(,II4D;>SGR_O[=B?<KN<*)P
MBHUH71'J>@;WN&P-P>D@-M:Z?U2XKUE,6UUM3Q%MF?;1DMM=:85N=S8E8^%1
MH\N5 !/P=DL248J8 K"615.V;%21@8&#_0?7E[]KR\*+^9==]XY=8Y?+EWCW
MUCE^G67R]]]=_IE^G?\ -W^G?\_Z=_S=_I^G?"*BGCS0?J#3!#V3T)Z%ZW=T
MQ0KPA9OJN\\^VPYTN69Y(K6*(44J*# DV5LOZC)==VC]M&!A5_7%+^Y+(D'D
M,>_Z^*O9PL5PF0G1ZX\'O*;#HT(H3O,8XY61CT1!)#WE S62P,ETV/S_ *Q'
M+YX3A,^L2!)8YXX\\2*K_FC3VWM3&7:#9>QR;^G8HM5+:K(5<KC9R>FU:J4P
MNQ[0S!N,!,B-S=KH<<TFQ26 Y4<E&0=&*PK,%8K!;BI/EX_/X?65:WA11IN2
ML7&Z:JV#4M>V>2EW:QU1RGK-JA,,6D(FQPDD S 9JN@+.4%P]Y]_:N! F!"@
MGN)E$M8YB] D$^OKDHQ\O:OWKJJJVY1OK=2S=[UQ< W-9=*ZB331ZS5H-?T:
MM]5/%;._?1$?;V"O/G<S6#,/)V<\-?&AB,&Q8(94XVP,;>.<[GR"LSPHH8]#
M4G8FQ=-7FF:FN\NN=B.P5\=8N49S%9TH,#=K&)&$YZ>"=P($T #+3GS*.H&N
M(3 C\:<M-[@8#$',9Y=5CGF76FW=545]6]S;2QV[8B;]9WB6T_;D!2051G]A
MVK4R+L\8EZ>,<J%D8#7$ @R"JK#P:NMD;8)\W[<J?A]>9*L5PHJ[^C=9;3V=
M7$2[5>SS=<,%I-TS=P1$S KK<ML&I]@T]0H9,5J\IXNZ67*PU>RBLE9$4JK)
M-*V@#8. $N$!/K^RQOR1J;?6H*5;$7H+='>\;,UN\[Q):,^F,>0->SKM=5Q*
M< S\,,%$.+%6>=^'7]E Q%&ELHC/G;2+EI4XZ#'S5K.%$X1.$3A$X1.$3A$X
M1=)9*S7+DA:U:WH$MJK#T.5<[KMC5 NT3A?/U^DX+12S@) 8!S====2C%CRP
MR===?-AW^G"*'O0=*V_8=+MZ?YKM]?U5L;#*LC5*P,!88$2%8K<K,SA8QHJU
M:!H1L$@Q PZ["NDCG18=)/K)83NW2PJ,9WY>2GSA1.$58_46OMZW^IHQ]"W9
M'5[&J/L13!5;"A5M6?YST>S04DXYM#KK8-C7L*7M#]C6T&1!$HF[!6N<HS8G
ML==8*R*?ZN(Y K5=!L;#MM80D2@1ZT[S&D[9.1UX\+1AW(&J0B2=F'83D=YB
MHTPV?U/F@5+HN\0X2+O>$5)?5^L?76PVB27S1L[7^LH55&NL/3>[8YNIA]AM
M?L0*TR75G^'3^,:$9!/9@R+9%;!W"8U@KE6UYBIALR6W%1CK]#X_+PSOG<78
MQ^;Y<?G^7Y_EZ^?Y?U^7YOTZ^;Y?U_7OY?U_7]/U[_7]/T_7^?A1?KA%1[T5
MJWU]<]RZSM6B-HT*D:UJP*J2XUZWR2'GV1QA;8"#Y4P8^MFQE;RAJ/; $MF%
M><.[B.?G4#T]=7=SV4DJ,8.1[_K;Y=2?)7AX43A%1/96I_9K[TW6MA47<NMD
M6AU#W4D9%%)1R#7*.E)Y[87NQ/TWEJ5DR:';+)/IV&.,;ZO*8PJ;6^H0TCQ#
M-8;&5V\/'Z]VZO9PHG"*AD&H_:.'L$K9DVYM=Y>997/S1:]@6Y07G.L84&!<
M*C/)RHDWW8J^\]M6X0$-W#P^L[)LY!TT@H].R*[8ZY^7,_AA7SX43A%3Y)JC
MT.H]'_OZ39*]AIUN[OC&P5DMT+F^&135>O*M9TE:!CJK"1D@36KN]7DT@[8
M#&OG/EZ5%*Q3=6*%^3Z^M_KR5P>$3A%13SGJ?V72-J.K!O/<FN+OK1HHV3EU
M6:NDS#LLUP=7.FDT.RNGG51KF+C!-KU(VJN0,G4&->P_'KUTKY9F-F@*G'3.
M<]?#?^BO7PHG"*A/D+4?M;6=@L9'I[=>N]KH&R C[&.IJ<EC@>U=VYF4$<RR
M'I-/7M),*=*$ TL.4,)C4K !7@D7 5@9B[*G'08^?U];^%]N%%'6W4-YM&KM
M@5[6-MRH>QF]1>A46W]1KY84%ME7S_@#C<&:*S#?B\6?0T;;+!&P-C62%R+(
MXF6(A$)%J=V#YE^+L793R-6>O=/5&HD&NS1TA F TV!C6S/7)C&7[;0;*/N5
MSFQQ;RB]SRY(Y#<JWTQL<:7"U/2R!;U!^O?]> 6Z?A8IPB<(G")PB<(G")PB
M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PBI_P"A=8>H[ILW5%CT3NE;K6DU
MU5<P]AH6?41&3=@X'!$KCI2IEI=A7N6:B&5O)%A:&65<7$1@D_M=T?-$P3%=
ML'QZ?%1#5-8?$75H;F'LO?VNMB0E:6F3HX:=7UU*MTVUY;0,Q8M W0=.K"]7
M$33\G-6K;7 U9 I-GKK Y-TS4M+2X)MG;.-N?SV'Y_TECRWKCT_KE@[5>@=J
MQ;95!ZLTL@K5BZF'R(+MZ,:Y_P 2C#8(4]?FS,(:'K.HGQZZ9G8JYC5L'#$Z
MPI'AIA#CIRR<#Z_/Q5QN%$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%!GH^G;<OFHWE:T;>X-<;)
M*>40U3:"BLPA(DZ:^UIQ<E!1D""R&C1V*E@V!!A*O6X&]$,H<86"OK+-@,0>
M>ZJD@U-\295:*J8Q]/ZJ>U&';J)K<*^?2%/16>EP(%W;.I5QL)K8-GE9&1,K
MR,Q@]8EFD@C5S$&T(F&+Q@S*[8Y;XY\]_E_3S78T34WM5)MY?:K)N'IQK)MO
M/:;]U1#&89O2#7\F9PNO<EV7:F,[M*S4=O89Z9C8F8B!D[UHV@6#,:I:C92;
M>W;V8^MLGV^.5L/X43A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$5$MQ;RV-JGTL,3(9"=Y[J^GJ@\VXCZ7"YL*I
M#<[]=J]CMX)C$/\ E)5M*DKJB&Y*LR) !Z6>]M$0W1E>^4OONC:#INK=F'-#
M',[16M9N5]'G[Q_=VW4M/HV?T/)&YW=-DNBS,:4P:V1UZ."J7%EGU.M7]2MT
MM8:2X.TJ&A!+>CX&ET L6K$/I[7AO>%E<Q1BPSB+6UW2S!O%%ZV"A[[W-3*!
M4]]&3L-MTEQ>MQ:@L-#7#U98RBM$WH*\4+0-DK;2();AV,U;0U;4MFA.-($P
M">UZY8PXD);&2XY"3L_HEW4KG9^,1Z/>AT_1M9K:A*^W+$:H[.T-0[0U;,)?
M*>.*$V]8JF.-KS)7LTN+AGK-AVS=4U"O5@U-Q=>K/LZA0EK,;"QXF.J6:NES
M12!K/5?((*$P<YS0V6*QC,4SI)=N&V3M2Z:ME,O&XJ\S].X:8V5L4,<894%/
M^=%J]PM<'[2K^2_&">JU*9,:NK_;@8U@:EKD9-BG9,I6!!'#TM'CUC6ZEZAH
MMF+LJ=;TO37N>Z5[?1WVZ50^F6!(7-MW&SQR6>Y<R..>R6UFQ1"-K=]8O.H:
M?/7LZA"_61I]RVP 1M/>-AL3M[B$L =! 8W,B[QKG/CAS*7O+R8WUK8]Q'4*
MT61;>/1Y=WRTD]>5/OT95]&572\E_,1A95R:5O1J%6K!U%B_,&F&B+<] 9H^
MF4IN$TT4'?7):G6T9FH5*TE#LTVC^G*\%L=FK6O6];&GLGD]):(;^H6J^?1V
M.#BR'O!/W086M+EM*DVH/JS2LL:L;/Z.DD@.K0:;#IYM.C;W1[RM6AE([UP+
M0Z0,,?&79("P;/?NR=2H-CDO+9N+.\+]0-K KUOZ:H-# S[NH=DJ=<SO%,V#
MIQ4HH=DH%<)M<,M_JP#UPP""F0,5<U<"G/R+WP[/Z9J]C3&05-%]!EUB&O+J
M?9?4+\@]!?6MV11NZ=K,TVH5M0M-J.;I]N2O#&^1MB*5ME[8PS;'5+E&*XZ2
M>^;+:,DL=36:M5A](;-!#Z37M:?''6FJPF=IM0MDD>UIB<PQ-+LSI965_P#.
M=JTZXMF\[3LZH;$N+.A[# V"FU\M@33X:YO-_AOM+FI-0JI:(5)+121W=>9D
MV%9W5SYSHY!VB;,YEP56+3^TE368:>@U=+N:;2BU#3I-.FU&5TS3J5'3W:?>
M%ZY;9.^<7V/@LQ,KR^EQMC(=#.(XN2E?:TF:@^?4I[L%NP^M:;:CJ,$9]$LV
MA:KFM7@=&V,UBV2)YE9W+RX8?'Q/Y^Y]SV1K0M;[%T!>Z.=02]UZ8JMWL<$$
MK]JW4VS?.K]<L*O5L,L.DR_\@#:7F-@?L,BS5HP4("19TP;XV"N:>BZ)6AOZ
MGIO:&A?CU%FAZW;HUG.;7AAEI]G]5U*.U;(/?R=V^K :U>/@9(][I)Y>[A]&
MLYW]0EDK5+6EVJSJKM1T^"S,T&5\C)]3I5'PP?\ \MG&R:42RN+G,#0R-@>_
MO8<7^()L_>.K-8:N/\]'"C[)M7H+7%(7K#PU1B^U"NP[,1G4#NVPA,88EB-6
M@ 3GAR+V V.?S#- /FSGQW7V>:5H6K:KJL?:*-SM,J=G=3OR2QOF9)4? ^JT
M7(^Y>PO?6CDDD;&\21N(]:*3 :=#M5=U*E2I.TI[6W)]5J5F,<V-S9Q*V8]P
M[O&D-;*]C&ES2QX!]61G,57J?Q,AI#M[;(FC,L=/D=>5:'JS6C@M-3\:1LG9
MM6NV>PZW<K9(DF.305]]4G.5F9M0WG8/X#/I*N[@-BCE[7<^S!X9H.FM+*UP
M0=K-0U;5(63W?3M,TNU1&G6:5-LXCG=8KVX16BB?!Q^D?KY>*,D<+!VQ&=2N
M$.EKF31*M*G(Z.OZ-;N06#;BL3F,NC$4L$IF?(V7A[K$;<. ,]57W^;L3K7-
M>UOH]A:]F7!CMF%_4Y=@ITM=KR?3A":"Q/45Z-19B702P_N-%G1?MDZ<=U@=
MEFW-K<(TLW.OVOL]9IWZ2LZGKL=32Z<6DNKW!ITT]FS-K+9C6KST([ ?2?6-
M><7^.>9\!C ACLN>&KDX.U#K?HD5/3G3VYW71+!Z7''%#'0,8EEBLNC+;#9>
M]C]&Q'$).(F1T(!*CVV_%% J^JM8;<_@^O*17G6\.S7:2?<M7$NB5++<3:G*
M)7::.@966TSAX S-B7+A72*=E'WTM$M!36 T47DJ?V6/MZKJND?IF5D]#4G:
M9!.-$MOI3S-I,MA]FZZQ'5J->9&PM@AFO70?UKZK(G1N?M+';-L%*G>_1['1
MV:@N21G4(6V(XS8= 6Q5Q$^:<C@<\R2,K5R/4$Q>' ? OUONZ?86S45A5]UF
MJU3W7HG0E18U%O6)3#:U<R*]B6DL8CVI.YI@7RUH+87;$&<!P-&ZSKR,].4G
MR:%5G9#0QIVF3UI1:MV^PFO:_<BN0VVL9:I-L<$]=]>Y UKZ\T3ZT,;Q)"XP
M"S/%,V81,'7=1-JY'*SN88.TNFZ9 ^"2$N=#8=$'1RME@D);(QXED>TLD'>&
M*)\9CXS(?_:.5817E.XUJY#?TVJ^@[5O6JA6(5BTU /H5WU5>@9L\TX,%C-V
M%:2TZVI_KD@&^S99-3)\( Y(L^.__3:T^7$.IPOKW;?9VIH-N2L^*+67:_!Z
M69&@32.K1Z=49-+;_P#XAQ?$(8VESP1NO^K(6LS)3>V6O#JLVI0-F:]] :9+
MW :?U;1,ZW.Z-D'_ -IO"\R/< T@RYY3]="^ERKLF)I,-,?TM?3WDF"BX"[
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MZALF(S.BS+(86EY[ESRYF#@KDG:#IS[$EES)^.6W4O/9Z3-W)MTN'N)Q#Q\
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MLY&EP4*-DZX-=3T=FL[7ZPT)LSU*R$$?D!+I7,=KM-["Z4B?EDCH9KE)7IR
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MQ:TR16! 3/\ 73ZZ'D)EB@++C<!MGEP\\8WY^>!MCJ-N2U?[C^ 5F'>J-<-
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M9WZCILMI'F+1]2I";Q%?G)XNZMJ:;\T[PIT?K,J;-6KKRNQM::+BIKM;A.@
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M^:Q^ALY_/FM(D@]?UPXL#&ODOU-LN&W)&,O;-/W2495>U1L-"&-82DB[%-5
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M<;"K#0*,9FMBNIQ^U[*V-))BCJ#)C<ESTM(N+CG?U=AXG?)V/+G@<MCTWSL
M1><$@3RSN\J]61F9>[DFR55@MA;W;]AE4)0:I]7%8UMI2UG1'+%BAFR%Q6L7
MR])%E%)A$R^:,8,F/OR.OARSRSCW*?5=,2+)&<F>)3?-G:R;GCD_)R==JW9
M\ F&2/L[J7M0*%!!U&O&"^GB%C,1U!WAU/)UV5Q^?BLKX1.$3A$X1.$3A$X1
M.$3A$X1.$3A%CRFWU-_*- BL]==3FI0K&'"I=+64I=>9QP3+7PT89,V<Z5A$
M2-*$TBZS!+C(@S@GDQEC[R(NZ%*%.%&-")@,#,@A*$+%FC(%*%(CQF@)&(AR
MSBG@GBSPEAFBSRCECRQSPRRQRZ[[(OR.:&6' Q$+&*7E#1&C'#SQ3!D!S18S
MPEP%1YY02C3098S13QYY12198R89]X=]=]D42[IKC&]4U(BK>01C+^)NB[KA
M!F<+!U/7*!O+6EWL[ ?.63K&? *OIRR(\8N\NR2,Q!(?FG,'PS(I<B*%GE*A
M@)@FF"FP'-BBFCDE$GD'A+C@*CPRRS'FS%)')PCEZPSR'GAFQQ[CEPRR(OD8
MQ7KNALF!P8.)A@R\3(PF 7HH\R3Z0@(W<^>'4YA4O?48PT7S33R=_)%AEE_-
MPB#L5Y9)@8IP9):[.*-@*.3!,2#G/AW)!@9!'GE*+G-'UW)%C/CAW)AUWEAU
MWCUWWPB_*QHL= CM$S$!LL+QRS%8K"QSP2<,),XL\ARQ9)1YL<)8\X\LHY,N
ML9,,\.^^LL>^NB+G<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(M;OQ
M<OZOG??_ *FJO_>C7?/2?LB_S"T#V:K_ ,+J*ZEVY_=?4_;2_P"0JJGOP$?Z
M#-X_VL+?^#UG.X_;[_CNA?PF7_>2K@?LS_P[4O\ 6Q_R&K>NRR.Q7'Y+,(9&
M6(162^,COOH?,[J"3L3"?OK./OJ'(CJ/&7OK/#OK#O+],\?\/7@J]+51?&&D
M+IIBFWDG8M;I]8O>T[\;M"X 4:[LKHBRM%E5K)+#)@0QH%"G'GQ=1G1?78Y7
M>PGAQA9/-@V/L8+H(J??Y9\%:>U6VJT5 RM=VLU?IU63QQ3-[+:G*ZO(%44Y
M,(<$K)RW)#7 QS%D#BQ9DDQ8R$SPP8=]RRX8Y%%CEGV[JBDS"#7/9^O*B0>,
M$8#!9[K6T$QH;)B*G7%"1-68F9(Q[8T)6%/#CG$4Q+%"@SD)(BBS)@GD%J*^
M*'#>]F^:_>?\G9HN>VVX>0?&C37K=5^S;"G>*F/H+>[28Y=/:2\:@<L<53LV
M49M(3+U@&1&T2=%LHET4I9 AO"7<@79Y^ \,GZWV6F_<WPD/8'I.Y?$%8;^O
MK2_V.QI_',].8/WEYODL3]8(OCLQB;3>F!==ZYZ_%B8,P%8O85O456OL')D0
MV#<LA_@^OKDJ)>$#  +<Y  .<\O6.3[=A\,+<[6/A,U,:P>H!'DQ1]2V];/.
M+U54,<:]3],9Q:E5)X#Y*GK6HQ,(:',MA&-5!8*%=8Q,,C"83?D,NL60Q8$N
M)YXQC!Z\\G<;^6_B>BV55GSA0*G->^TD&28>]7"HW(KNO005]L.?38TN:R N
MQ ==.WT$S))$V.S=%ES%FFLLYY).SB<I"@&,^[V[8VSU&WWJ< E"E;.Q*7*U
MP!+@OH]L0$$,+.T.ZAB&Z-8S011R&E]#PPP=$DY2S=0Q11?/\D>&/15=CPB<
M(G")PB<(G")PB<(G")PB<(G")PBBC;NZJ!HY,AL.QF1:A-8K+A4@6 ZTQC!"
MYGK]AL0N#'L..7M>&4+6S1(V!/6 43"<&$N<>(C(B(F,_>M3R+3?C/7-2+N2
M_8.[8EVMPT&H<D3]M0:E*+8GI_>JZ $N'MZ^GUT-UJ /8.OGE,<P,P*S4:Z5
MJZZKV!\#0<UB60)Y8&>?B>6_CSQN/<OB3K3RC$,^K05X]%BV&A 61[><U!.N
MV-U,J_RGV-UL:QRKARV,B[7TU7_)59S'V(Y>80U<^@+M@5:W5K.S$W/AOR^8
MP,^)/QWR,'%A;;I71;8P-,/MR]0(M3U71"VSRQI8WP%JHK6"P:BJU-K=B3UC
MLRVR7MI3&-6>T6O%/ZM$_L=FSQIV%TL@4ZPID_$G?SV\]NF_S4)IM8^%IRU1
MJ/U?9&QM2BV*-U/7NZD=\@;,8,UV3+^"UM+U"37)UO<-*LX><#$*V5JMJ5;-
MG9=8(ER8F<') .=]_KZ]AWRW5V/CNCB2.4_JO8!*^:IV0U$_O4M6+.9I;BB;
MUS-UK?\ ,:ZP:9]18Y=,H"*DIP$MIP55#8]68!)^(Q*G)V(!(\.?/?./KJ.>
M5P<-"^-$J]0*V]"WR=!6 DGHU<Y*F388,]?7(5L"N#JFP1J+W9"M;=KK#@"L
MK=2LN92&"PR]Y%9'6XF:<IGR&VW+V\_/VK)Z#5_+U:V]3MH5[TA<GKHC#6Z.
MWK[2 S(;[.9'@.!-;KWT(%1KTWYK85YM FY00)5^9+QI4_S]$5JZ-E>/N2IS
MRQC&?OWWZ^',^'--1=^)?-MQ=V/+<SE;)IU<7IGM)?ATN"*MLU[Z6LBLQ\D%
M2%EEO;>0"P4^F2&,,+ QUV"SKU7294NO_,,4))Z>>P^MOR\<K:L&8(Q$%8+R
MAS@#AH# C1)HR!3!"HL9QBAB(<LXIQR(<\)89HL\HY8\\<\,LL<NN^RBY/")
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(M)_QL]A;@J?GKJG)JE7'.E=IE
M(*_<;7W&W[M5*MM<MBF[H<.^X3>E.2:SQU[$ ><@#/(4H)@/.1C.Q48\]M^Q
M'3M&M]H3<FMV8=;TIMBQ3J9A]$O4[-2:C.1F,S=_5-@R/:V0<3)(G-:6Q3$>
M>?:':OP:7Z/'!%)I]TQ13SX?WU>>&>.Q$#AW 8YA%P@EGJN:X%V7,!I[\##8
M6X/W1?\ 554J5;(U/T=%?=EWMM@WR:IS95':*M5E!T*:.MD9/BP<RL<3X)>H
M%:UV9^N<@XPT_<?MUT[1O1-/U:W;LMU;@.GZ90A,(AF8)A/:LV..-THBKL?P
MDQN'%++79@![GMX'[.+5_O[5*""$T>(6;EF02<<;BPQPPQ<+@POE<TN]8'#&
M2.W(:T^G+GS"O84X18!M+6U<W!KZTZSMTCF.KW)=^(?8(')R!D6KS(@G,7=,
MUTD1. +2&'):W#^;(9JH*.5'13@FD0R$58>_AW^4\Q%X<M!.DB76J]7"++NT
M6"*6=ML]T*]V'"=(.?#V:EMI<3(8U 1UFF7*+"]2U\).I*'#$*Y/W#V8Y8\%
MF^OJ-2JKZ6W<LK%0JM<6'Z$\O9G+$*!2H!,D66_TXB72%AKQ!QR,@$:=.E!S
MFCSR%5*%RZ#N,, 6&(AW&^^YY^>/H^U6FX43A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A%B]NI%/OZF5!>*PBMJ,B!L*0GL2P1NL(&?5YS4G8TX)T4PTX
M[:L6)\@8PRQYQ%J&[$"?',<N:/(BK_Z,,U9K#7.9M@U#E?%-ENE:P*KE;3]Y
M,2G2)<O<*G$<XD'><#=6OUE7Q*QE(2O[96)/3:V.Q$+*6YX$5-Y]L:;Q5''O
MO!]PP)=5L6\]J9J^J:M++"04_5XU43J?##%C;S>[-9[!=:7)-@L.IS+:UR>&
M/(\'<%@*@'QQ[_#',YV\CRSA2_)ZMU^4/O MAH-U%:=."ZE[L-?S#"(9.V^&
MQB<:1 )T&LF*A2UR_L&=IK%E, P%R!D.M_8RKKHS" GAO@9^'+/R/X*L=BEU
MNV35FZQ>'NY *GL79:2NTX*1O4I#ZZ0/JK&4_NNP5N4$YHU67"SVI>J@8!JU
M]BICQ^%.Q:EM&0I7<YWYD [\^?,YY#\5GO6T]%*'::I_R"K.'CDSK%11F"52
MH0XH$S!%.0@8"2$%@'5<,Q+-@CI62W(;\KLZ&P4P<Q6Z3_F#BF_4^.^2<\L\
MLYZ+OMC[5U+!LJQH7?CD^\=4&F'5"KFKT@9KABLI-EL]6SH@RD@/ *",N 1+
M?JZA^\G^IJ0K/9AOT!U2I5*5W\?,^7(Y^[WC&Y7%FWAJ5.P:V\7Q,]'?46MT
M>TN&$J1"M)0Q5@]#5ZYA)+*'^N;^E3YKSZC"/!.[[UC-G8ZS%ATZGK)A!DXW
MYG'///G\<_'GU5\"= :*LH[0YAJ6FSY7!TONSN0RL#!LV%G@S9' 6!CEG .P
M@L8$[YO-"=)W"S +8FY820SR2=\+%31##"/#$./%'!!!'A#!!#AC'%##%CUA
M'%%'AUCA'''ACCAAAAUUCACUUCCUUUUUUPB^G")PB<(G")PB<(G")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(HTW%J>G;SUA==37X#IA5;PC*3,H\>L/N1,Y/EF7MUTDF$F
M$#9(RA$;J2>\,^AF00L_>&?4?>/?)Z-J]S0M4I:OI\G=VZ,[9HR<\+P,MDAD
M (+H9XG/AF:".**1[<C.5L[]&#4J=BC9;Q068W1OQCB:3NR1A((#XWALC#@X
M>UIP<84->,O*54\>Z33ZL0%0NW<Q9-@O5OZ"Z"GM=J/ZCPG,[@[EGD'7K@H
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#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>59
<FILENAME>g65062g98u77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g98u77.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1(D4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M    $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO
M;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG
M:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M$ .__C4  @ ! [_^-0 "  $X0DE-!"8       X             /X   #A"
M24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M       ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F
M  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M      $ -0    $ +0    8       $X0DE- _@      '   /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z   .$))300(       0     0   D    )      #A"24T$
M'@      !      X0DE-!!H      S4    &              #B   '9
M       !                          $             !V0   #B
M                  $                         $     $       !N
M=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   #B
M %)G:'1L;VYG   '9     9S;&EC97-6;$QS     4]B:F,    !       %
M<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M       &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R
M871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG    X@    !29VAT;&]N9P  !V0
M   #=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$58
M5     $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,
M8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T
M   /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU
M;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP
M965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S
M971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T
M<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@
M  P    "/_         X0DE-!!$       $! #A"24T$%       !     (X
M0DE-! P     !V<    !    H    !,   '@   CH   !TL &  !_]C_[0 ,
M061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+
M$14/# P/%1@3$Q43$Q@1# P,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M  (1 0,1 ?_$ !X  0 !!0$! 0$            '! 4&" D#"@(!_\0 .A
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M0 8;K@&[$YUX>Y EFCA#XM-5:%:RPTX")H=$3*G3)E10E\>3O1)Y^0.\G '
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MOKLZHY2LED5:'Q3(*O4/I<G/K]W.7I3AKXD;(BBWLQB49&WB<P!69(R?C ^
M14;H+I$HG$OLM1J9KVIG]@"D@IO+U53PQ2^RS$RCRB*RXM_7GM!AKH3*H\K5
M-<C(5Y,(>R%)XW,M2<<8:("SG=.70E35K922G3S7154S-,3[";( JJ:'*8VE
MG*I(6WK):%">U&!,?US622T+W,X1BI<RD$,RLPYK)*2  D:[=1-6]DX_$(I?
M^OE07%%Z_&<.#1VQ(%')2R1$1Z)*VFYCC6ZH%")GP)O1)$/FH2"0A2)B4X,!
M) $& )BA,)B%;0Z+U[7\:9(9!H2P-45B$2C;<F:(_&8VQ(B6UF8F1J1%E)&Y
MJ:V].0C0HDQ19"9,2624 ( !Q@#*. . . . . . 86SUS H]-9I9#%#XZT3Z
MQT<5;I[,6]I1I9',4$&3.B.&HY&[$E!6.R>,)7MX3L92PTT#:2YK2TN"PJ3<
M" BUWU)U??R<IGW7ZH7I,)UMQ\&F=8#&W%,8\7ZG5)+M<C$ZMO.),66LF6JR
M)\>8 0Y.4I. [94A,%C($2&],_I[G0@-;&Z7ZVC@87]OE6(KFI(=AH_J9M8R
MHRFD DX6O'G/(XZ24Q+G$0LJW1I#Z@YFK$N1%9 E9+J%JNAMZ-W\AUUI=#=<
M.C*&&Q.T4-<11'-8Y%VMI''VID97U,UE+6U$U1XPR/-04IA0VV/F&L:$9#48
M-(("YOFKNN$FNZ-;*R*BZI>]@8<TB8HK<KI!HZMLA@:<EJB0(VR6J$ WA*!.
M0O7IT9A:K!R),X+TZ0P@A:J+- GC@#@#@#@#@#@#@#@#@#@#@#@$&SC637>S
M$MJHK$I*L)NCO-!#6JY$LIAC$^)[/;J\$<.!HYN2X(CRY&1#AJ#C(V!S"HPS
M&&",0>@'GSN 8/)M&--9G.K!L^5ZO47(+$MB,K899<U=*TBJJ2SF+N:9,B=6
M23.YC;E8[(GA B1MSR!4:8-W;4B5N<AJD*<I. "H6:2:?KW=&_*M9Z2&\-UE
M0^Y&YP!7,8(4-]K5^RD1N%V&ARG;B@HY=&V!*D9FM\3A+7)VU&C1X.R0D3@*
M D*2Z^T;,UUFN<MJ.O),X73"6FMK;5OL39G0^R8 PA? ,D-F@UJ0[,ACC1B2
MR#].:7+UA(CR\N(DY18E1N1 1('1C5^/R%SLFJ:9JZF;WS5JFIX=?\"K&O@6
ME7;"7$\0V.J8LZ/T:>FX:F*,B=M0-"9[;'5K/:6E!'79"X1PL;4,"IU/TSIS
M4+66/ZK0)&NDU?-R27XDZV;%LZ]ZL1XL-W=WZ?OTR+:6EG8E2N5NCZYB6H6]
MF;VA*WFD-#>@3-J1,G+ N;1I/J$P+VMU8]::3:'-E%7(VEP;JYC"18W#J&!.
MU65:)(I(;@'$BKZMWYZ@T0R >,L,6=%S*W>@0J321 6MTT-TL>X0[UL[:L40
MX0)]C5=PYVB:JM(L:R+(O46'3%6L@D0FWT92&O,/;QB&ED8*%'0NC@%J$FPK
M/P,"HQHOID&7U;/R]6*#)F=),K'':CDA%60Y.Z5VQQ<1QD7:XHH):2\M*.,'
M*5"F-E)L!PP*U"A6T>IJ3S31@8Z[].G0N0-R-H?=.]<7EK;[-D-RH6YTJ*%+
MT22T9<:WG2J:ITRIH-**>9(8TM0GTP ,$NOZ6W87$GA0I<% 2X=K+KPI>12%
M12E8GO@[1(NT;J;#6,Q<*WTT-Q7:>RA'B1Y&*:$P/&(>7(,YRXACF,-&#_4L
M>AX!XT=J]KCK,FE:37FC:KI1-.7D,@F!%90B/PTN1NY830)U;L%C0H\*\(BU
M"@MN3F>5*VE*%!: A, \T(P)WX X X X X X X X!K1+:MV)>9*\ND6VE.AL
M>6K!'M,7#2L D.&5)D ,!18>G-2!>XX ((Q^L*@X-%Y_DSCR8QSU,/89EEE&
MX2W:1/\ Z;IWC-LN&U1+"?HA9:8>JTJLOD99_)FC1JQ_ZK262+U\;NQJE#9"
M'3J!1AMFCV0)2S1!?4%,HY0[I@9R$2AL8%#N6[+R BQD(C4J0TO&<9QD6,XY
M530F1<R]J(M'^4)JF>H_I$9NY4ZI&)-U (RH?'!8[MR!F(I^F3G5:X1\1@7Y
M"D;BW<2Q2L9!%&A=TI)(SVT19F%@"<@%Y%-"9%S+VH4;_'IJ6>HM"TJSVUF*
MD;CU'("@CQ[Q_3Q+\MK*C4K,<_\ G !^AE.A[\6A,>//,+!^F /RM\XP ?0>
M40<94\)D7,O:A1O\>FI9ZC(3(7?9*[]+.WT8RG/UAH2?IQE+T^!=ZU( 'F,*
M;U03IA1ZP]EI5(V@GT?I'("<\2,)P23,A4T)D7,O:A1O\>FI9ZBL45YL4D<#
MFE7O.W)75.T&R!0V**.J4EP(82#LICWLY$8XA4E-!*C&4YKD,L*(L[&2AG8,
MQD/%-"9%S+VH4;_'IJ6>HLI4?N@_UW)'4%BIV&Y@3RQPR545+F>H196E*7))
M*M\QX%ZJP*41Q*M.\G^C;CDII2@M2(HP(\J:$R+F7M0HW^/34L]17EPN^SBH
M\>5OHR&D2[. Q0XNEZ?&5)Q93"6X#'C NF0/6<HP#5XPVY4Y]6"(_P#_ "#D
M>%-"9%S+VH4;_'IJ6>HMV6*Y0R3,,%U"(EB88/ ES%,U)2V))A282%0!/EBR
M\_JF#QD# > GU7T@B1A,P'(!8%E3PF1<R]J%&_QZ:EGJ,L55+L^A3*%JW=3U
M-&D)-4JE:J@JN3IDR<@ C#E"@\Y: HDDDL(C#33!A++ $0ABP'&<\4\)D7,O
M:A1O\>FI9ZC$6]EN-VBBF=M?4*B+E!T05 UDR;ZFI59%$@$@\%JQJ9$G>3&@
M@*4>< 4"-6 P2/. F9#G/DXIX3(N9>U"C?X]-2SU%Q9(;?,E3,ZV.;[,3^CD
M2%6YQ]6R4Q3SJF?6U 8G)7.#.>@=3RG-"B.5I"E:M$,].G,5)P'& $<7@2GA
M,BYE[4*-_CTU+/44J^-W8U%NASIU 8PVE,>!B>C5]04RC+9PEKB&P>70:AW+
M"WX Y*4S>/*O). KE!"3/D/-++$IH3(N9>U"C?X]-2SU%U8*^V'E3<6\1?>E
MLDC0<,PLET8*0J1X;C3"L^::66N;G)0F&,L7]C A-R(&?["QC/%-"9%S+VH4
M;_'IJ6>H_:VN=C&TMT.<=Y4" IC1EN#T:MHVIDI;.@-">,I<Z#/<2PMZ,T*5
M2(M2KR22,*<\01YP29D*GA,BYE[4*-_CTU+/45+=5NR[P@2.K3NT2Z-B].6J
M0N3=0U5K4"U*<' RE*18F7&IU*<T&<"+.),&6,.<""+.,^7BFA,BYE[4*-_C
MTU+/4?ELJ_95Z0IW1FW<3NS8K"(:1Q;*'JI>A5  8,H8TZM*O-3G! :6,L0B
MS!8"8 8,YP(.<84T)D7,O:A1O\>FI9ZBO]C>U'QEG_;Y67B^*:$R+F7M0HW^
M/34L]0]C>U'QEG_;Y67B^*:$R+F7M0HW^/34L]12)*JV:< GC0;L%K0)E:E
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M&]J/C+/^WRLO%\4T)D7,O:A1O\>FI9ZA[&]J/C+/^WRLO%\4T)D7,O:A1O\
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MVW]H=QD"^I9#X?BY7 YVB]G<]0O^9U=WTW][RCY!(U7]8BQY_)1L2JFX2W%
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M&#<B,"'SAXSCR8SGR8_MRME;*6?&P6&V;5I4LV?:I_@FWE12. . . . . .
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M?^W%HN%.-0IT^5=*#LX)EWEQGY,Z_P#;BT7"G&H4Z?*NE!V<$R[RXS\F=?\
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MLZ!R1JW.-K'5K2O;8D?4"<XQ4TJ7%F6HW5"2N*(,5-RM,M("8F.+,$!>^ .
M. ?%Y.]SMZZMVUMF)OUDV4_:P7CUQ:GU\JJ8MTH?@KZ,D=97=1[O/:,=UV7$
M&&^E[MI&5O9K7'21?H8'6"REK,; $2%:<H OU3=3'9A[W0NC8.6.>Q[9H]O
MFV;U_P!3WJ1LKFRZ]PN14Y!%!^L%@4_)L.YB?$QO<ZL;L524M,V(%9S\\PW*
M9:X 0F#1/>$'/;4#>_J&SJ8].6I9[?UZ'L]&V=62:Y)HKG<L&JV!:]]Z-ENT
M-(MMCO*AU$LFN:[AD.D+"WI7;)Z)N3D)/0 R9_\ +D%J_']/=CP.MG2=ZDS)
M#YC &S=_=1MCB2P.F'T]IK!D>Q-UIVTF7VK+))L8ELJ31TN</I07F:/Y**%$
M2QS1>G=5Y::/EN)I@2D6, 8K6.\-BR#.HNM!>S4W==L8CU2=\VG8BHLV(_J+
M;:-?X*T[?O42*LF/C<!/@*F8VP=4JXH>\%YBF I8P%C,,-;2 )GOW9!RLTKZ
M@>_D@FW30J:W-B+MQ#Z;V'UXL2\[/D%CR<T5X5=O*RUY:E61"QWM2YB4RZ-0
M1F8KT:52&1&JT*-&W(D16,IT@BR@-SJZZF>W*N4;L7'9CML_ :#Z@^I^YTZT
M>=IZT/$4KNJYS1=>6#,->D^OTH$Y#$C6V3KNRGV)(UK:GCYBRR&E$H;R7!0<
M6OX!L=T)MI[7L?;QIKJ3;$+[KB4PZ=D)M.0Q^*;@V%NO%HQ<35.8<WR.3VR_
M6:W-+MKG;CZWR@3=BEXOA[BQ@4[]D;OD^/H G![]K^9V$ZEIUF.MCZ&5S79%
M@OQ-D7M:;7+('7VQMAZN*9PT1W6>W9@A1.]IUFM12-$WL;XQMTE+; C,2NJU
MI3HE /,.R((&J2_<S8+0B'3RD+]GM4+[/8:VJZU*19K&L.66;+GHJ^=UK>KQ
M/4 +(E3G"YC?2JEZ7(K-C52@+"FE(GOT\@E;F]-JU*H. PNE=T]WU$3:V.&3
MFF%;)&9_K= 7!YN:O[)LZ?R-WV[W*O>B0/2F1M-SP1*F9ZE:XU&7QF8LM2U3
M)TZ%1%SGN-)!I7=,!D[;U2=D"L*"Y(\:SM<JK9[KR(K*F4P^9-U@[>O$DW(M
MO5R5.6O:=7;XE,*3LC76R-[1-.&*Z#DTR=%;3(W!KCI"5S4 64'5+VKB,!@D
MHLURUY*5W]3$'LNK\QJII@C+@;V_[.Q6C%$3?LS/8R.Q*:*GR,2DA\9GB4V'
M0T18):G,0/DF4M!R,*D#^4]U+MZKXC$ZF%;-&NCNDH6@)K=D[BB>OWZ0R:[S
M:_VSVGI!5&JS?83LA*(!"ULKK?7U'(FA8BD=RQX4X=@I6:0O\3=4;FB#]3;6
MT=F);>'35MO8]);3-KW#+.F0#Z'N!O;[!8DK-KRX73&(77LVL>21M4LF,&8;
MCB:97(I3;4:3QM33E9V0EF7H&ER@JYX,>_[_ .M .>T=ZB,PU^@LR@=83N++
M90.[GML)<9+L+^_2@V]MCVN;99+TRT/LA=MS:KN![?\ J(&F13Z(73<"R:05
M2_O:&O(C)VYP0%1\/:$PUEU.]L;7B\5L]7(=6*:JFPK:U8HT,IE]=SM]:*<=
M[QT'JO<V26=/9:IO2',#O&U$LF)M!UY%SBX?@R4S:$.3Q,W%2A'')0![)^J5
M=4A+=3 S_5*1E(;!KBED-5P9@M9FLB^HW8]!LME.NV5)/KU93%)V.GVAS?7M
MV9T8(#*$0H)5=@K4]O'/7Z<X-0&O#MU.-C1MNLLY;I96HEM82FSUI^FL<46.
M9?\ ;S5771LV#V&8)18$G>[0DS]-*IFUEN$>=VQ Y0%V5Y<F^K)&983_ #9&
MY%'@3/<O5<V+K%L?T$1M'3:[VR+.44>'&_ZUCJ5-!GEHD-+32RGFMXA!Y_MW
M"8Y*K"KY;&F&43!*SW\?-3:=G<?<XU5#Y)R'+! &-NW5DN6 S!0X-0JO25<\
M7A*%DC_J)%-)E92B,KG6@VIG*CU<V5L'74U8H\8CL!U1G(:7B-LR&+3!=&"%
M=!,Z!6Y*I$%BKPT_@?3+_P#? ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M ' ' ' ' ' ' /G#EFHVY9S=MBX1(B_88Z-P>HU;FO+-6MTR"N&:17Y.]N'6
MP=>Y.Z-$,G3 VRQ6Z0<XQ8U,D_*<(><SO2Y!*F8:C)!"4"TO>L>YJ+8QSM=/
M7U[.<EDUK.+6RS!LM4\J,L]2QWK,KKI_1I&P"L8EK1,#WJ2_)G.-E8B+GYT1
M1NL<$%"X)\M"@2GC@7^RV./NP0U#=>^H!.3<.%YU+M<OB#>]Z86U*X *Z)J>
M^CMNJMN8W([B_I>2N6VTE22Q\9ZE=W9Q)DE=QO76KI:!B0+(/5Z%XB$9$W"#
M8^LZCZ@#2X5$DEK!LZ;;:-^U+/KFPD5S@3:^UK4L=F+4JVRB=]P$FSTK3,IS
M*(PFL@HAQ?*\GSF_)Y?52&#2%A<H@X+(Z!M?TWZ2V@IX,),N1XNYP53/1'61
MSMG-SW!+;=2(MQ4CC8A5O80)I7-93_2S@4T*8BD?6R#"9H:N1H&D20H]>F.5
M9#W[]_[T)1ZD[A6_%*DB%J0K;;UR-KM0WC;=78FRK^JB]K;.0K;BDWZPK<U]
M316XU2F*5G'JK;[UDRE+&4=<Q+#0]4[B*P-)8%;I11L3^N#_ !\#H7L%J'=5
M[;O3R1Q^R9)2]-RS2"$TU))FPP*I)\;+78RW+C<9!#D*>T6*7)F%T:8S)V]T
M*=<1E8A-_5R0'A793#2 $&E/[(]F-95%@ONJ4;OXY>DV&MN'Q2)-^PKLPQN6
M:VQWI;F5S3ZPYC?Y(X5FVR5QV9@59-B*T7>"++!02U"@<'%7B)$&DA#!^FC\
M?A_G_P!($=*<ZE^:RG+>UQ[<$EI36@QS"NXLDF=GIQ/@7*@G2/N+;(#'3J(.
MFPL>8R[5:RUB)V#?ZN-QZ:J6J?R"AUD6>5"="!N/K;6O4?3[QL,QO-5:S5%1
M3^9/DP A>ULJI0VC'&C#FZ!UQ^OJMFB8&N=XO:*EC$K4133J-6>OFD=?9,Y3
MU3 Y$M4O($PDQJ<3SJ,-13_J+:E74;3MOO\ :\#M:(Q2K1QB\[]D%$OE7/MY
MW'.0V*7-FB&L4"?'*LX'#6>#.#W)'\+7))B[(V)I8X^D URVPH/=:>[,.KU
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M_D9[J.L7J*J1HVY54EKJ6]N!@MO0J(?79R-"6%,8B"!&F,FXB$H,(S34F D
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MRS:_=AV5^\7="C_R'6_Y7Q= FKG!O8XSR!>A]OGT=#?<LVOW8=E?O%W0H_\
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M;F!*_"&O<R0N 4[FO*4 ;9< < < < < < < < < < < < < < < < < < <
*< < < < < __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>60
<FILENAME>g65062g99z87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g99z87.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X5%):'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/G-L:61E,S-G<F%P:&EC/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L
M93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z
M>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^
M"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C$M,#4M,#A4,30Z-3@Z
M,C<K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z36]D
M:69Y1&%T93XR,#(Q+3 U+3 X5#$T.C4X.C(W*S U.C,P/"]X;7 Z36]D:69Y
M1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C$M,#4M,#A4,30Z
M-3@Z,C<K,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R
M96%T;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+WAM
M<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @
M(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'
M26UG.G=I9'1H/C(U-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @
M(" @/'AM<$=);6<Z:&5I9VAT/C@X/"]X;7!'26UG.FAE:6=H=#X*(" @(" @
M(" @(" @(" @(" @/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R
M;6%T/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!
M45-K6DI29T%"06=%05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T
M46ML3D$K,$%!04%!04)!05-!04%!045!)B-X03M!44))04%!04%104(O*S1!
M1&M&:V(R2FQ!1U1!04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#
M=V='0F=G3$1!;TM#=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&
M0E%417AW8D=X<V-(>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92
M;V9(>#AF)B-X03M(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&8O.$%!15%G05=!14%!=T52)B-X
M03M!04E205%-4D%F+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)
M1T%104A#06M+0W=%04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=1
M1D)G8TE#46],14%!0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX
M459%1T4R16EC645537!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L
M47I25&MQ2WE9,U!#3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92
M<5,P5G1.5DM"<GDT+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT
M<V)7-799,U(Q9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6
M;'!E66U:)B-X03MQ8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1
M241"455%0E%914-!341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X
M03MO8DAW1DU(4C133D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*
M16=X9%5K=V=*0VAG6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3
M:W1-5%4U4%)L9%E75G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58
M<#=F2#$K9C-/16A984AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:
M-F9K<4]K<&%A;G%+;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X03E21RMS
M:$=K:'5):$A*1UIO,S5R)B-X03MX84Y11TQQ83=Q05%A-'%T+U-7;F-&9C8Q
M1'=E;D)V55=H-45Q2T=U.5-+67%I8U972E!$23AI4GE+-WA%3$MQ:T5Q4TMG
M34(P,DYC)B-X03M685,U=&YN:V=35D=N:6]:66=W3'%'1E)Y6'%+-'$V5S9T
M;W!)-#5:56IK;$Y):UIG<%EG9V9#1#$V:D965$9867$W1EA9<6QM=65:)B-X
M03MV3"MH465T<3DO1%IO4E9223-X="]Q24MU,RMX1U=9.$TU;6]I,DUP06,S
M;F5S+S@U12M6<EEL3DQS<FY55T(K,C-',VI0>4QC,RLY)B-X03M-,D=0<W%:
M*V]G9F$P>3%-4GE9=&-F.$%/4G9M95=1:7@P:3!J0BMY:VYQ>DXO=W)25BLW
M36MD;%%(36QR+TUN;T9N+T%#=E@X>D]8)B-X03MR9F]M,3E,:#EN-G)C.%!(
M;%@Q83E096U(*U1C4&5F;5 Q23AE9F-V="\X06Y),WI01$E"9C9285-5*S!S
M9G%W="]W-U,P*S=!97EO)B-X03M(:U-V-6LY47EF4B\K8VEV3$9Y>7!Q;&AC
M-F5X-G5H5S1J2'I)-% Y>5IJ6D]Y<&HV4T0Y:EI(57A03C9,;UAM:GDY<C!0
M<F%29G<S)B-X03MI9U9:63(K3E(O;'AM:G(Y27I!>5E:=RMO53-X:T1Y5%1+
M;51S5F1I<GIZ>G8U63 S56(W5TY48E=,=3).:'!Z;E5R0S!"<3!4>$YX)B-X
M03M*2$I&8VQ),T-G*U!B1DQ";W1&.&<V;F98-DPU='9G,3$V9C%I1#!P;4YX
M2%E30GA,5D,O<4HX2F)K,WA!1&QS2S%64FYO959,0T-.)B-X03LT4$YU<6TR
M6513>%)W4C-%87$Q6D]01TYM4FHK*V1U4$5(-"M98SEE2W%D,F1H-60X>&59
M.5%U9$XX>EA&-7$P,71F1WAS-6A-23=2)B-X03MR;5 P:39-9FA89TA#:F@Q
M54-N:5959DHK544P='4X379M8E5P0DMS<51"<%I#<DLX0U%O<%5Y531X;%=9
M5G)53E0S>%<P5'!N-5<S)B-X03M.;'%I-FI*-6LQ0S9M5U,S665O>#-3,W5'
M;CE*:4<K2D=%:F]19'1Y8U91-2]+<E9:3'DT.69Z3F9Y,F-W6C O97EI4DI$
M8T-644M0)B-X03M49W%'4F5U+U R1TLR-C$O2T-7,%%#,#AY-FAB3UIM;FYE
M1FEN<3%K16=$:FU14W!R=C<K,DLR:79,;C59,VUJ87A:-FTS;5,K=DAT)B-X
M03LK675O-65L>4=1;V=L<7I6.4U(-&$Q.7%9<7IV1D1S5F1I<G=Q4%$O>6]L
M=%E65'I494]I5U%T-#92>D5H26XT4$QX.4QA<7(V8F)5)B-X03MO4&)&2T@P
M>E-V>7)U25DU1S$O54QC=UAS8VM)=4E3:D5S;DY2149J86EN;#$V,38Y4FEQ
M9&57669Y.$HQ1S!T4$Y&.4Q*3G Y>D%:)B-X03MP4WDO-D\P8U8Q2E!'46Q"
M-F%T4VI!2')T5&-Q<DQQ,"],>3(X=DTP3W9A<CE69S%'33,Q-6))-GER3$I!
M26HV<&5*9C=T3&1M86<U)B-X03M*=4MB9UEQ<R]2+S5:45=E<%=P.'I8.# Y
M,49B5SAS-G!-8F=',E%.*S=94F(X;S!)8G-Q;6@W67%P84A$*U<Q<'%D='$X
M,VU7+V%A)B-X03LR;6]L=F52=7IE<&%U<7E%;$599D8V2W,R.5%#3U9-5F5V
M87@U:#!44FQT,C%3.&IT1G5P0D1!6D11335&9F]!-W-D:&M:5$5E8EA0)B-X
M03M*1U!-,&U#<W)+1U5G<5)516)G9S5*;7 S5C%B5VQV2F,S37%W,CA+;#5:
M6D-&5E9'-4I*-D1$1TI*;TM3.%(X-V9N<F8S='ED2CAL)B-X03MX36958C!H
M9CA#.#!H3S%)26E$4W99<TLK=WIC-F9S,$%C5U0U9G)C5$IQ3VM70W@K5G W
M<E5(:SAX,S@Y>G%K;GA3861::C8W9D4O)B-X03LX6%-&=E-H.2MB;&@S6$UY
M5V-22'!!164X-T0T9#=535I*,S5S=# S>6)*1'A.;F]L:%E+2U5N,4YM,4\V
M*UI196YA+SA*;4)K,3!E)B-X03MS<%,Y,W!(-C(K3TAY02LQ:T5':C8X<6-'
M.'<S54-(+T%(6' P5G99<#=F1$9(;4Q,5G@V44AX<W1V:&YV5G8P4G%8+T%&
M35=S+SA!)B-X03M363,Y36@K82]O=RM3941Z2VI.;RMU<V=24$U6,T]G+S-8
M<45D=F9*+W=!1$Q(:S0V;V191#17165'93EJ*W K5'!:451D-DIP*W!,)B-X
M03LO=CA!,#1T<&0Q.'=G-3)P*VQ->7-E=6HO3VQ(,RMO9G)A<%EF24@W1TI3
M*U9:3%<O4U1Y+V9Z,F5Q>&YL1' Q-R]O9#559C<T;4(Y)B-X03M'8C(T<W)(
M<W5:.&,T:U!505DY-#-(>#9H;T]/:G1Z6G8U32]05%9.3W5X<$AN4T9Y23(Y
M2C<W9U5N:4DR<%!&46-Q9'E">2ME66UO)B-X03LW3VI)8U=0-69Q8EEA9VIA
M5#(K>G9,4SET67)U,&U3-'1P;$1X5%)S1U)L4&-%6G!:4DE.2&TU64YQ,D)5
M<#%M-C%.8DA6,6DP-6)H)B-X03M98E%V84)Y2D9U6D=2*V-2:$AX54A&4E0Y
M<FQ167$X*W1B<E5)-WI54DHU0G,W>3%T26Q.<&1P671:=DY':G%Q<6M4>%A$
M5DI:5T-6)B-X03M"5E9056EM2U8Y<G%U;UA-17-6>"M7,$1I2TU3>D9O=E13
M56Q25EEO,W173$YT4VA08G0P>%95,"]W07HV:6AG,4Q29DEC35140G%Y)B-X
M03MX0VI34G1V>5=E1S-+8T=:86ID:3-G2V<T<3E1>%$W1EA9<3=&6%EQ-T98
M67$W1EAM=79A3&8V8F-A5F1A5#54<W!:8C%41G)';F]V)B-X03MR=W!':G%"
M1D5X4DEO*U-44VMT=U5%+V%R,$ML0S9E9%AN;&4R=5!)1FIA4G5K,#A-;W1O
M>7%3>#(S3TES0V\U3S Q5B]:3D-",DI+)B-X03MQ>$Y1,2LR;&UK<W9Y.'1B
M8C!V55%-='5V3U=)<C9:4F5#3%-Q:$50545E=WA615$V:'(T<U5S>BM8.7%U
M;E-E:DLQ;7-A:$9D,D5,)B-X03LQ:CE0:'E73F5V.$%,5'1I<D]"-5 X<$%+
M;S!3=T%1:&M(,5=':6Q2445F1'118D1&1&PX;F555D9&,%!4=TM5;TQ714-H
M3$=N,F9&)B-X03LR*S@K3TMO2'IT-4,P6'IB6G)&96AO<G5%2#9R95(O8FI,
M9%%6-DUP<'5$*T=6-4U1:S!A:E1X>6EI.&MG.# K9'9Y,S%:4$QD.5!&)B-X
M03ME865(:6M19C-P5S--;GAE;'9Y5&MQ<T],1&)Q4$A-551L:DY/<T=B2G U
M8T(S2#9%<R]-:GHO<5!N9E=7,&936E!3,$<R67-R3694)B-X03M345(O875*
M:65I3#%52#=U5V1F<$Y-34UE2U@Q2#A52$UY-41-,$]32SAP955793)R871*
M6F%F271*8BMN0SEU,4DS0TAR8G=.-$0T)B-X03MM2#)V86I687=!,7IL.6<O
M5U=Z1FDK5$]D3S!V5#E.='AB,DYU;'9#4#)51DLK-TAQ5#=N3E1K>5-M8FMB
M8VU-44]32WET3'-69&EQ)B-X03M!,6DX3G9B9W!.-DQ636IS;T1V-E5136MN
M1E-$56Q6<#E/4T%*3W=T;D%!."]H-S%7=VYE6EI3>FE21FM):6Q5535+44=(
M5&)A=D@V)B-X03M-<F=9,7-E2EIX35120D(X,CE1,#)W,4<R83)V;T5U24<V
M;S1R.4DW9RLT>3)'4U5$8U1287I%2&UW9GI:-5-:3%=T=UIB-U199T)()B-X
M03MD53E3*W,Q1W=!66ME=D%0-4=.5B]:23-R='1,<DQ.8W!F668Q1G@X;4PU
M9F%G4'DW."MA;C5(,7!D3C%#43-8;"LV25IV5$IE3E9C)B-X03LO1&-W93,X
M>3EE>$A)6F)R-%DU431Y94=1-R]U84E:=D10<4]Z3V17+T\R+S%'+UA49DIM
M;%!E>6QH*R]L4FU,04AF:$5U-$@K57@K)B-X03MJ3U=L<4-455%W;C)G6D=S
M631M9F%Z3&1N4DYB;6)54'%5:F%A6%-&>7%M>&8P6D-:5VMH1%-D931R5&HX
M3UI19&U'24QQ=FU7-F-Y)B-X03LR2&TW5')2-3=G=610;FM2:6EY37)I3F9R
M14-45E9:04M&4C)&1D]&2T)N=69/9#EA>#AF4%=L4E0R<WEZ4$I(8U)#33A)
M=WI#<5%1)B-X03MH:TAQ06M.>55G9TAD0WIQ<S0P5'I(;W1N<$YV8F%N-6=S
M6C<V1F5.,4UB=4IQ=5=),UEL3RLS,E(X<U5*:F)E6B],;'DT:F@Q3S)A)B-X
M03M6<%!25TPQ541M5&MY:%%P25DX:6IC9'9I<%561TMP;FER<U9D:7)S5F1I
M<G-69&ER1W1C.'(V>F971FI$8F$Q3$9E5W16=4QX,%=S)B-X03LV17)*.%5C
M9G!P6#%):S9$-U!)9G19<6LV950O04UX0F%X2V9.:D,U<BLY9C!W>6="4T5#
M9VHT<44W,2LQ,S99<&%B>6PK67%*>FHX)B-X03MZ<SAZ;4=-<'=(0T]-;FI-
M=S5$-&U#54MK:F-J,WA6369,=FQF>EA986MT,W%7=G1F4C%0<3(T5VEY9D%Y
M,4YE;GAC5T%(5' P>%9L)B-X03MU2TA9<3=&6&Q0-2\K8C,P,U%99$)T6#0S
M3W$Q3GE2,49S;E5F.#E',BM127IA9&U93TM816559G9C9E54;U8S=E X07E(
M-593-5!')B-X03LT54<P9UI*3#=B*RMN<'IJ='EF-4E147IR,V,P3F%$36Y8
M86YH1S--.'9)9"]W069U65EC8C%$3D4U8G-69&ER<U9D:7%!:UI9.5AJ)B-X
M03M-6FID-6Q+5'%35$EO56-K2VEU>3EE5S-7;4$K:UAV4DDO2#0R6GA!3FIR
M5F]U850P;VU:44-62'=+5'A"63=+=&4Q5'1K9T5!5VAT)B-X03M9,65Z,&UX
M93EU,DMW;U98659*3$=G04@T-4-C>$575VY,;$5).%(U34XQ3#AX<GDY;BMP
M95<W3C4U;3)%-W%74'I7369R8C=S>#5A)B-X03MG;F%)9&9K,35K94A%3$Q&
M.5<X;F$S6E<X33DO>%9R<FUS16-D0W%42#0Q:EE+3TDY6#1G=DAB;%1-,U-A
M5'@U6&QK9'9U.2]K,&Y2)B-X03M43RM1=E10*V-D+TU.<F-A6F9A2SA585@Q
M<S,Q:%I65E9E5T9Z43AI0E9V5&9U97I!6FTV+U)X>%590V]L>CE*46I196EA
M-4QP559N)B-X03MR,&LR;E-/57-G,3=+:4=),TU94U1J1W,V,%II9S5D1#A(
M3#-Z6'57.'IF5F9Y,&AS-7)E-S!.+U-G=E5P4&$S:EA54FMG:5!#84=7)B-X
M03M6-"M817HY1T%69V$W;C1C57%5='@K5D4X56UN,C)M-G9"96@T<$)01DU0
M6$UK;S5*3U!6=4AJ3$5D,E=Q.'5X-DMQ:6$O.$%L2F$S)B-X03M%.7<R:3-J
M<G T:6HK=65O5UIP1V0O:#1#8TM0<V-V;E5%2V1I<7(R971F;%)A86A$0D)O
M;#%#9$YE3SET2$UX6&I--41H:C9L=W%K)B-X03MC46IF17@R<GE#:%-C5F5O
M95=T96<Q-U(T=%9G:F%+1V0U;&I2+W1C67!N:4)99&DS0W1/,U1&0UHT<3=&
M6%EQ-T9867$W1EA9<3=&)B-X03M867$W1EA9<3=&6%EQ*UHO>F9V>&8O;6QC
M>'IF=F)85&QH:C1(<#9C55%N;%AF.$%Y;69/:3!-94A!3S@O=T)J9S5J8R]C
M>G9Y;EEM)B-X03MZ.'974T]A>E-X:64T8SE7;&TO94]39FTR85A65#1S:%!W
M*U1L-'A546TK63=.,DMU>%8R2W5X5FIS,G54,CDQ9F968D9P87E)<7,U)B-X
M03M+1C5U6'!S=C)44F5+5E4Q3F9L:W!9:5DK:S!F;BMN*WA-4T%D>&%+,6)1
M;W18;C V9#5I:TYP34QI4T)E45=:;$@W<T]66E!S3CA1)B-X03MR6&9*=WE'
M24E9.$E6.6,P1%1T871K=#<U5UI),C5P=UEQ43%+5C(R4%AV;5!01TIC,G9.
M9VIK1E-884QO;&AO.6UT<EIR4E%35VM9)B-X03M,>F%P2BM*;$,Q<%=G=W=G
M26EG;D9H:FI&0E,X>C)(,3=13#)!5D5O:DUK1$1Q<W-8>'AK9C=*4FU4<' X
M3U%&;$U70S@Y+TMN55 P)B-X03MF*V%6:58O9'=A:4A2;S$R05,U:#E73E!O
M9FIM.#%S3TQ!9DPY1&A9:E4O92MH=%HO5$56:G%K,$8S8G@X<F-,64=596MS
M171'1%-Y)B-X03MY;&U$3%5Q,4])<%0S>FY(4%E4.5@O3G53=U9,3%8W0S1Q
M66MS<&=Y;C%9-$%/535C3%9M:UI+<W134&E)>%-R-G)&*V-99#=7,VMT)B-X
M03MP64QH1$1(9%%L165.=E1).58K4VII1#$K1W U9$YT<U9D640X,DIR4T)R
M969467ER<4QM06-&.5!C.&\R4D5K-'5!951J;#-&3RM+)B-X03MT9F\S.#9$
M8U)Z0R]S57!%=DY72EI05E!!3U-G461L4%$K3DXX5EIJ-5I4>D5M:V]V;4(T
M<$Y316MN2C10<T9/6CE0<W4O1VU+13%X)B-X03M6,DMU>%8R2W5X5C)+<$MF
M3W9L35%1>FY68F(P<FE&<FU).'A5>$MG:TQ5-FHT1T)O9#A65T1Z,S502W=S
M3E=T>4QH9VM!-6)S>DU5)B-X03M#9V1A.&Q/,DLP;557<V%23'DY2RMT-4]#
M1U8K37%.>&I8<35O9&Q(:FEQ2&<X>BM8<#)L5TQ58F1J1$E)6%!Q2T(V:DER
M:%%X241()B-X03MI-$\R2W)P9DUE9U)016MM;S(T85IM5TUE<6AQ558S871$
M<T%S3#=N=T]+<C1D93!784M75T\K9TUC0F-435I&6&@V57)1=5=Q4E%#)B-X
M03M21U=V5&)&54YD96)V3$9R23AC*W R-G9'05A(34Y3<D)!3G$W.&HP-C1Q
M*V,O>D]34S,O0412,71:0E)P47=12'8V,6U!;%!N>4=D)B-X03M,;SDX169X
M,6-$3#E:+TA2-FYP57E485A:>DI4:$Q"1S8P-E5:05)N4%I256E03GIO;7=X
M5%4W:3-L,4,O:#%+86$S,4MZ:T@V3V$P)B-X03ML:VAM;6=M04U3>'%H-'EF
M2'E6=5-T=4XX8F]$=6)!1#!665!.3C-O3DQF>E!-2EEN0BMR86I%:$IA4F0R
M=#5%:D9$24%D:6DP3RMW)B-X03MP=D---'I*168T96$X0F](=E0W4TYD=#E4
M865.25IR864R2RMR0F-"5FM!:T)+3596;G!8:61J=C=95$=M2D-:6D9#4RM9
M-V9Z3%!#)B-X03M9=$<Y0E1)9T145%A%:T1)=V17<6]J:&TU5E5%9%)J:F=0
M1FI/4E!$1R]4,S=(>C9C*W)->B]D;4E'-38Y>40O045B<7)L,VTK<G=T)B-X
M03M1;#!%.&@T<WDP3D-9;'%.>G915G(P>$%O5GA&2$9U1%-Y0T1Z>$=82U$R
M8W-4=3=X1C<R9$<T=4111F9Q<C!/.65U47DT0DQH<6-O)B-X03LX23,R-2\W
M2FQJ>6-.,T5'+W,K>%!T26HQ0U!4;U4Q1&=B=T$K<UDS859A.&I3:G-S8DAB
M+TI'5WEQ>EA*<6E#0G5I.&EL1#9J26M7)B-X03MN,U5R;6E*13=-9EE+4V-N
M:D9Y03@Q4$HU2"M8541Z+T%*;#9!:UAX37)W3S(S45)7-&0K;&5N134P;7%.
M65IF:G$V+T@Y62](4CE))B-X03LS<#!5>6$P=%AN=7AA>&Y58EI*0WI#17)*
M-EA'3U)V4U%S02]3;&4O8D]99&<X>65W+TMY4V1P<G978C9X:VQH:&I30S1+
M,&I54DI()B-X03M'>4UK8F]R8F\U*TQA;31#-'!7>6%8*UAD=$%S,&9M5R]K
M=#%H8WDR+V]U,'-K87=G<'0V4V9U=G-S=G%!;S%+03 U67%J3$AY-RM7)B-X
M03MM;S-F,4LQ.'=8-C9J<3=5:E1M23-*9RM/44E20W%D5C-.86-L,C-81EAP
M2&QR>2]$;T]L<G P1GA.8WA*2DI)<VQW5EHO,VIL>4MQ)B-X03M&<G5C54IP
M:7%596)D8FTP5%%:.5-H:E-74THT27=S<D9)>#8P-E%L;EE"<4MO:S5(8G1L
M=41'2GEO+VI::DM60S)(=R]N2$9&87I8)B-X03M';S9.9$I(0S!13%<T16=P
M3D9#-FXT+U10>$=6=4\R-$$X8WEZ;TQ.0U$O1G-01C=W;49P*V%6;&-Z,R]!
M0C V-%,Q<TQ75S5E5FUI)B-X03LY4GI$26M:45)H:GAP-F=,1GE/4&5M46QO
M:4%.>%I+4FM3.79Z<C!Q0EI0<E=M6%EB9UIO9E-#3W)2<S9O;%A$8V522C-P
M5F5M-7)K)B-X03LO=T-4-4AK46IX47)Z+VY,;S%U>2MT<&PX<4U:>'E+24XW
M9%!586=,:6]+<VA"-F9&,3)W1%%34%5+8V]48GEJ*UEM;"M:<C9E>71B)B-X
M03M7-70U8F5,,5=A6E8T16,K4'=U:DU$,2]8-%I6;C!S<UES:TUO>D)E83(X
M=C506$9U;F\V3'%J9U=95&E!3U%T-$IM*TEN,6%C=5-.)B-X03LS-45#;5ER
M66AD4'8O=T%Q5W16:W9D0C%',D)V67I'4DXV-&51>#%(2FA)=$]0,E=7;B]'
M,49+8F573#<X<35P8BMX=$Y)=F]5=4Q#)B-X03LT5FDW3S=35W9O>%AC=U!X
M;&QK3&9:0VLY3V]R44M'-VDV+TQR+T1!=C=8>2]F>C9863,X9E!L27$O1S!A
M;5=33FA*2C9V<'A7<4AR)B-X03M2<6II,C5/2W!F8W0K5'$R+V]J4CE4;5AN
M4T5M57%K,',P8VHX=WAN<%=K=E=N:'A",WA69G K<B]L46UN,VQN*VAD4FE4
M54),1F-W)B-X03MW>71/;G!X,TQ3.&=X;%AR-F%N;%-H<'A5=%)S5F5G9CAQ
M9CAJ1&I3,6U(0U%3<B]!2U).<S(U4%9U:D5M;S9B-')B>F(O;DE4434W)B-X
M03M,>D1P,VU+,U=K9'EG:6MF<THT1'E5;B]!1FM)<"]Q-79/>3AG341!.4A#
M,4UA26MI9GDT,7%'-C!N.4@X=C-L;4MW06UP83-C:V]F)B-X03MC;V%O,4\T
M>D0W47=M32M,=BLO.&)T,D-6:6Q,>G).1F8V:$)P5FM6:#%7,5$S4#962F14
M84M19&Q-6D):-4%P*T$W8U)59S=:<C5:)B-X03M2:FI:,SAV>#!$;'=G4T-E
M:D).6# W>DY(64YR9C$V0RMS3D9U4D9$8TY(474P:%9::6]536IQ2E@T1GE0
M:7 T8EIB:45414-U16M+)B-X03M.:E$U33,P1%5P9DQU:W%D43!A-FAI8TI.
M95AY>4ID4V,S049:,4%I;$)504Q263EQ57EU5U=%<$=.-VHT9G-164=G96I,
M<DQ5<D,K)B-X03MS,79B4V1*<E9X>45Y;C1A1')8=W S<C!X24E934LX,"]M
M+V]/;$TQ='!T3E1V1C)::V%K0T@S8U8U9DIF=GDK1T%N;G-Y149B>7@K)B-X
M03MB4&QV5U-K1C1W,#(K2D%62FE$17A0.$%*2G-0;V%N,#1*-$-/5S9M0D1/
M3W4T>6AG-T9867%X5#AX3F%I<SE'87A$56QV9U9K-&YD)B-X03MB9&8W,78X
M05I$-$9R,4IZ4#=0=VU5*TQP2#<K:E1M;%%P:3,U4V%J<$=L835E*V$Y8FQ%
M54YQ<E(R<V%5-7E83G=A15)Q96]34&QY)B-X03LS;TMI<'I,-U@Q16-E35(W
M+W="1&E9.&M917EK6'4W+T%*9RM1,U)K9E<W2FM914UP;%5G9S=%14A.1#1S
M93EY=GI/4"MC4&UK:C-N)B-X03LU3'9Q3&%G.#)L4&-T0TQC.&U2;R]45F=W
M2'!(.3-51E(X6$=U,UA(>%DY-F9Z3U K8U!M=5,O+T%#6%5Y,&PP9W!.=S52
M3C944D0P)B-X03MU9D1H1S%54VYQ=69H03-9;G9J-'-E.69Z3U K8U!M:6]0
M35@U4S(X.%9X0F,V4D900GDY0U9&:%8P-59,8T=!<71E4G)42'A9.38O)B-X
M03MM8V8X-&9.35 K5FEE4F8K<C=:+SAJ5G@X5U!E:CAZ:B]N1#5U+S572C5&
M+S9V=&XO=T%J5G@X5U!E=C5N2"]/2'I63')Z2W0Y;V1Z)B-X03ME*U9P2617
M=5E(:E%*1U))3C-8,4YU8U975TEL9W9-5C96>3=!65-L=61M67E#475*=&HV
M83<K6F1P1F%#-# Q3'$K=C<R5&YA:%9%)B-X03MD=F),2$=1:7EO-%=N278X
M8D5N,GI-.%!#8F\P05!M5G530TAM:C@R<#(K<DA1-')A-&I70U,U94Y1-%97
M=4-R:%=E6&=X.4IF<VEV)B-X03M7=%)T:R]"=T1F:78K>C--94MF8W)7;74O
M;3)K-BMT;W-C<U9,5TYG>&I7;CDT6C,U2DI7<DQW2DE7:6Y92C-W4WA92S)L
M,R]!22]()B-X03MZ5&-U-4)79FTO.$%-6%4Q4EID0FAM='120U=Y,F1X1$I(
M1U-$3S%W>F-I,W<K;6EO95IO4U9P*S!-;DQ":&HO04)B:CEL245P2&]I)B-X
M03MR8E=V>E!T56ES<DQY>F%7='!(8G,P64-#3D5D05-)>$A&3S9Q2#)!,S(W
M-44T.$HS37E4*U!*24UU-4Y033EP-7)T-&)/-S V5S%8)B-X03M6-5%5=G!,
M9C!R5#$U5DLK:%@V=TIM:VEJ2$U'4#%!4U=&1T=A-751549Z*V)S<V-->4I9
M3E5S=#!Q<VIG8U%2*S9)8T1L56)"='$Y)B-X03MA67$V,5 U>7)(3VMN-DYA
M6EIE8UA+<D%X>5-K;&%H9W=65DIP=%=G03-.8U94+WEK+VYH<&)Z+T%"36QS
M:V9'1#9I8F)R6&DS<F,O)B-X03MI8F5V2#AA8EEO6D9I<G-695DV-RME;6UA
M4G).-W!C;6QZ4W9:5%!!,&EY24%X43!Q05)M3DQ556%P,2M8=$--2D=*0C)9
M=#5X+T]$)B-X03MY-35O.'8S3VHS5VM4;TIG1V=N.5)'355Q-V\T1D(P-RM)
M<4UT,"]A0GAZ16=';69A34I#<4QZ4%%T6'9.2'5%=4QD=C-S4C522'12)B-X
M03MT;FIC9G1)-"LT,$DY.6IM-UIX6D)2:5=I1W5%96ED5"M:=$]V3E%V<FTX
M*W1F5C<K5T]A5WIG355F.$%D4G)'<4=A:E,P050Y9W(Q)B-X03M/878X,D%B
M03-Q=G=(3%!A<T-+369U6D)P;FUZ4W1:9B]$43!T;SE)=5E28GAX>$-R4CEI
M84PP56)(;#%",WAH<6E:37-084A(3V=#)B-X03MI6B\P<&]';7E7;7 R575Q
M=W)),#A/<%<V;5@Q6E=B:T=U;V=3-F-E.4%64'1G>39B:6M$12MN;G<Y-3DO
M8S=N2'=31DAB>C=M3V%H)B-X03M*-5=K45%386I,4$)Q8C Q*TLS36ES<WHW
M<&-)<7%+;$=01G=625E(<%92;6)(2DUZ<FAQ:'HV935P>%EU0THY6$5B-F]0
M>E9P4&UV)B-X03MY;D9(23%I;74V3%I226QL8T%!=F)"065:6F5,<VY0-U1-
M<#9H9FEP5E1D0UEL-49K0T-J3D8X=&%L-7=S2E1D95AR6'DO<&QY<U%T)B-X
M03MR:F=O=4565T1S64EW:49F53-Q>D5#:#9(0DQ*=SEB57EP-F9O96DR96DV
M6$)P=&U:1&(R-&]H;&-Y3G9U9'HW.6A194%Z2&Q+>F)7)B-X03M484]Y2T5S
M,3=Z1%DV3F$K<D]F56YE;W0W5E W>5)H,D$W060R-D1,<T]%>D\S26-Z,TU:
M>D52=3AG=G!T8C@Q83-&83(V1S1V-SDQ)B-X03M126QE27!5<D=L9G-X>&IC
M;GAQ>#=:=4Y*<71/05)!+U-,+TAM-C-X:&QL43-,,CEV>4\X='EE5F)04WEF
M5#%3,5AK,G!O3C5*1TY8)B-X03M$<G1Y5'-V8T0V83905VYX-6U2*TAU8VY*
M;S14:4%E639Q,R]!0V]N>4@O2F1F.$%)-RMZ36(X=$9J+THK3'4K,3,O2VEF
M268X;#$O)B-X03MY3R]S>"],4E@K5#A89#ER=BM612M1+S5,<B]K9"]::BM7
M:78X;C1U-S=89CAQ2CAH+WE86"])-RMZ2#AT1F8U4'AD,S)U+S555#5$)B-X
M03LO:W5V*U(S.6U0-6%++WEF:3=V=&0O>6]N>4@O04-86"])-RMZ2#AT1F8U
M4'AD,S)P.6\O:TQ2.40P930P>E-B;39S67)Q84]:-VE/)B-X03M69E=$;WDW
M2WI+=V\S1&E25&-%-61H:4U:,D8K.79X64DT>%5D:UHU>&=J;CAT,W-5;#)L
M:7!65#EB;'%547$V<T,Q0T11:U4V-69P)B-X03MZ57AT8EI,:W=M8GE&8V$Q
M93-M<6IZ0F)X6$=O:5 P,G1%6F5,:T-+46IN27IF1D-Z;V\O>7$O4$U'<$5!
M23A*,C<O>#-S1$,Y-U1*)B-X03LO2E=L,T]K6#A';6%P1F%75W!/,3%%='5&
M5D=J.4].665B<5))>7A/:DYS,41Y4$Q++WI%:$E'47-J6E!"<W!.*UA.:616
M*W12-F]K)B-X03M%8GHS>GI7,$I+1VQX1UDQ4D=2,4LX530X.70O8G)H+TYN
M:'%U-S=&-$XR8F%,6FUY,&5W<WI+2FIB5SA52FU(4B]444QY2%AR4W59)B-X
M03ME4U9Y2C=Y>D$R64@U=F9Y9BMH=$-7-VPQ1U-W:U5R6C-Q8S5':E5444XV
M,7HV-45R2GE65BM*5W)8658T-4)K>$M#=R],:3)U8C9W)B-X03M/=39M;')$
M-E(Y6EEN.4985U)L64HV44PO135D5S5*43$R-FI!;$U.0VTX:#9:<4,S8W9M
M4R]U8BMW2U!C4G)B,UA&4WI!9T921WI!)B-X03M(:7ET53E88GAW;UIO9GIA
M.&MP3C95.3%,8FMW:61':VAK-'5V>#AW<%5.57AM4&DS875W2C-O<E1,3%,W
M=#=Y,&AU-UIX2F(S16%Y)B-X03MW>4-O1$DT1$LR.41U1&EH5GA6,DMU>%9H
M=C5J+VQR<'9N1W="0E<R,6DS1DQ3.7 R-BMN3%1C;V9V53=J=41M8516;D5E
M*TQ6;'A#)B-X03M19E!D,T(U:3AO-G%T:G)%13%R4&(Q*W)816)59%5*-G=Y
M8G)*151U54\S6#=*2D]B,&-'84YJ8T9W-VQ!-W,P.'8X06YI2V%2-7)I)B-X
M03LR5SEK2T):3#9Z5"]!16IG=%-05W1I9E5!6'%X:C5*6$Y6;3=/04YX,CDO
M-B]W0F)K47EI-W!L;6TK64Y&,4U$-FIE>%1S9CDQ:'%/)B-X03M0;6AO=RMK
M6F<U344T9E5+8C1Z0C5),F%#1V5*;UHT,6QI8U5E3G='5F@T14A9-55Z6#1%
M3WA606%J<C)I-F%P3CEE>%%%9G--=S5N)B-X03LU24MS9F]'5S0X134O4T-5
M4VU">DQ'3F,O34)O26E,84PV:VA&5G5R,$9:1T)&45EB569V2'%0<W,S1F9%
M-6XT97HW*V\S-40Y2F%:)B-X03LU<5E,8G U:#@R-G$Q:F\X13$S8S-&4')&
M=S5R27E6-GE0<VM-45 W03(V03AJ5$YP54U-8D]W2#0K2F-7>DTP2'!J+T%*
M0C9P6F%:)B-X03MB6&5L87=6.'<R-#5Y57)(15@X25I&*TY+9$MT,2]Y8S5$
M4&=":U1$6G)L,F17.$15:WHX;"]M3#5X='9-1G0U53@Q-F),2F5Z3C9C)B-X
M03M.,'%H6DM!9F)E;G=324M63'%E;FIK365745!$2G-W86Y)2F-'46(Y-S%F
M37 R3'-69&ER<U9D:7)S5E$R;S9B639L6G9:,S!+,T9R)B-X03M)55HT;C9%
M>'5(6' T36]/4VA->$YJ;6=I,4Q83DAT9%HP<30P>3=,3&(S2VA:1$=11V]#
M1S(U0F@Q2&-98V51=VM*1&]P1FAI>"]+)B-X03M,>7,Q>71W.&QY,&EY45,W
M1T9&3%=Y;$DO:&II440T4V$P.&9L5$LO4%1Q='8W9FEW.$E)9&9Y53AO3#90
M1U<X0FA1278W>4UG.$16)B-X03M35DUF16M52&%H+V%R:"]L1$HU23A)3#,O
M2F9Y9SAZ>4\Y,F5:;4I14V]"+W!#.$A!25%.4VY49D@K54UN:W9H0FPK:394
M8392<%9T)B-X03MP;'%73G9A;TDT>35"66=B,4I!02]$351*37IK6DAQ,D%5
M16PQ.#8Y3EEA6F-J4V)393A2<$I,;7AM43-F<$]L=DI);G!45FDT<S!K)B-X
M03MA>#@K0BLQ,#(S9VQI63%$>DQ:=UA!8CAV<D\T.4(Q5T9B6D9I1#%:,35+
M<&IF6E8U9"\R=F,T<%A387(U:'-O3'$U=5!),7!,2S!*)B-X03MM:VYH:31C
M,E934VIQ63-A;UI/5F562V10:4EX5G-8,VUD<#)L8GE(6DY#.$EC;UDV4VMQ
M:VE-:&-X;7!:04958V5H;V5U>7(P-D]/)B-X03M/2TY9;VQ#4F]!<4EO0596
M06]!04]G1TM&,DMU>%8R2W5X5D%A,V]':F$U6DY:871A4C-L<V0K16<S52M+
M<TM-<#DQ3F-S>#5:44YX)B-X03M.1D5O9S@S:C-M8B]!2G@R;%-1,U!L:E5+
M52M*8E,W2D1!:F8T2FM(,U98-F,R=4AT6'!-9DIX6C9B*V%W;E9T02]-:E-'
M6F1A,%HW)B-X03LK2E-/53@X0S-9;TYH+W!59DM64E1S2D)M8D1,:&XY37$K
M>C='<WAM3UET3#=F>FM)1'=.=&17:6I9>%=..6-1<5!K<R]W0F%Y571+)B-X
M03M$,T@S>$@V2U%-=&8R;S<O04I71&%5<'@Q<B]U2U<O+T%'45I6*U-(.40O
M4VXO:6LK3V90-2]S454O;DU4349&=&1886LP14XW9C-%)B-X03MQ;C))9RMQ
M.69A;5=X,&](8U!D169P=$)Y,R]A:F1),% X>#E62R]O4%):3$=.:E9,:4-!
M5W98<B]P8W1*0U K96U2;FMW>"MQ5B]B)B-X03LY;C=&06UE47!M+VQR+VY(
M935L;$8Q-6\Q0VQ4>64P=%-79&ED>GIM8V)E.490>GI$>F1Q06)12'IB639B
M*V-8<T=H95AD13!'>49L)B-X03MP1FY(85<T,TE19D5X.%AC,5IZ-W-C,4]4
M3$M:=5)T>6]X035*:FQA5G)24DTV4TUI=$I(6&<U04I7=7AO93%C858T>'%8
M;%12.41I)B-X03MS<GEY.'=A:$@Y6G9P-%9F5%DP:G%9,TAQ<$EV<5)&=4Q1
M1W S3&)51W=X4V@W>&1';61)+W=$2&5P4C9815EO<&\U0F5&-6%)3U)2)B-X
M03M1>%IV561V:C5R=%5D9&II<4EG:#AS,DQU13@W86TO<'-Z+V\K15A-5DAO
M.'9%<7I+0GA.6D%'239.>35D;%4Y,&I33D$X>"M9-R]5)B-X03MD4#A!3D8W
M9#-::74R=&]0,S9F56AE2UE42D8V;DAI>55O=$MD0G155DMQ3G-V>7!L:3%U
M>3%3-SAW6&PY.5)K:FQT-V%E<F]P44IY)B-X03M#;#-D:'E-43<Y2V1A5DMT
M<55F-55A=$=6-&5C=%A&16\O-S91.&XT3W)35DUH;WI&-C=F<C-X5G$Q+TM+
M-F=V:F1F-' Q3G5A47A4)B-X03M$,5I!>GAW>4=49WII5&QW674Y4C)R=#-Q
M<F$K1#AQ.5AI:'1&+WAJ<7I35WI%>5-E<DI35F955U)66E1)=TA':D%5.&9A
M;4MV47-5)B-X03M/>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R
M2W5X5D0S5VTV9&0P3C-A=S-"2%0Q63%E;$LO=T%W4&IK;WI)-49A45 K)B-X
M03M%4$MF+U9L<U K:U=(+VUN2BM0:R]N2#5S945D>4YT9$TP,GI*3G!A43(U
M4%5X4G%N+T5136A+8VIZ2V%23U)3-T9867$W1EA9<7A8)B-X03MZ1G%V;4<S
M=#=/-G1T2%=3*U=A-59),FIA-UI1<75):7)W;&93*W-504Q(6F58>&1-57-.
M='1:85,X5EEV>31&=C955$Q.0WE30TU2)B-X03MS-&-F=6QT=E0U33A58CAU
M2F(T96Y41E51=7!Y8VQU8FHX=44Y4RML,E-1<7IH;2]D,#1Y,C162RMM1UI5
M-V9(,7)I<68K56(V-4]S)B-X03MV2"]H2U!2<F5A26XV+T1'67IT4G938TY"
M0WA"67-A;6XK<C-X5FUU2TA9<3=&6%EQ-T9867$W1EA9<2\O.6L]/"]X;7!'
M26UG.FEM86=E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z06QT/@H@(" @(" @(" \+WAM<#I4:'5M8FYA:6QS/@H@(" @
M(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T
M4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R
M8V52968C(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(CX*(" @(" @
M(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HV034R.4)"141&049%0C$Q
M.$8X144Y.#-%13A"0D1",SPO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @
M/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HV034R.4)"141&049%0C$Q.$8X
M144Y.#-%13A"0D1",SPO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM
M<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y
M,31!.#4Y,$0S,34P.$,X/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @
M(" @(" @(#QX;7!-33I296YD:71I;VY#;&%S<SYD969A=6QT/"]X;7!-33I2
M96YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN
M<W1A;F-E240^>&UP+FEI9#HW-T4S,D8P-D0S049%0C$Q.$8X144Y.#-%13A"
M0D1",SPO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O
M8W5M96YT240^>&UP+F1I9#HW-T4S,D8P-D0S049%0C$Q.$8X144Y.#-%13A"
M0D1",SPO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R
M:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y
M,$0S,34P.$,X/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @
M(" @(#QS=%)E9CIR96YD:71I;VY#;&%S<SYD969A=6QT/"]S=%)E9CIR96YD
M:71I;VY#;&%S<SX*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @
M(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)
M1#YX;7 N:6ED.CDY-C4R,S P+30X9C(M-&8R,2TY830V+68S-6(P,#,Q,S9C
M9#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.G=H96X^,C R,2TP,RTR.50Q,3HQ,#HP-BTP-#HP,#PO<W1%=G0Z=VAE;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@
M26QL=7-T<F%T;W(@,C4N,B H36%C:6YT;W-H*3PO<W1%=G0Z<V]F='=A<F5!
M9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%
M=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z-D$U,CE"0D5$1D%&14(Q,3A&.$5%.3@S144X0D)$0C,\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M
M,#4M,#A4,30Z-3@Z,C<K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R
M($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^
M"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.FEL;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N
M8V]M+VEL;'5S=')A=&]R+S$N,"\B/@H@(" @(" @(" \:6QL=7-T<F%T;W(Z
M4W1A<G1U<%!R;V9I;&4^4')I;G0\+VEL;'5S=')A=&]R.E-T87)T=7!0<F]F
M:6QE/@H@(" @(" @(" \:6QL=7-T<F%T;W(Z0W)E871O<E-U8E1O;VP^04E2
M;V)I;CPO:6QL=7-T<F%T;W(Z0W)E871O<E-U8E1O;VP^"B @(" @(#PO<F1F
M.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS
M(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE3W9E
M<G!R:6YT/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#X*(" @
M(" @(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/E1R=64\+WAM
M<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@(" @(" @(" \>&UP5%!G
M.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@(" @(" @(" \>&UP5%!G.DUA
M>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @/'-T1&EM.G<^-#8U+C P,# P,#PO<W1$:6TZ=SX*(" @(" @(" @(" @
M/'-T1&EM.F@^,3<W+C P,# P,#PO<W1$:6TZ:#X*(" @(" @(" @(" @/'-T
M1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@(" @(" @(" \+WAM<%10
M9SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%109SI0;&%T94YA;65S/@H@
M(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y#
M>6%N/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^36%G96YT83PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/EEE;&QO=SPO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4&QA=&5.86UE
M<SX*(" @(" @(" @/'AM<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.
M86UE/D1E9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @
M(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4
M>7!E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI3=V%T8VA'<F]U<',^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA
M9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%D
M;V)E(%!$1B!L:6)R87)Y(#$U+C P/"]P9&8Z4')O9'5C97(^"B @(" @(#PO
M<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#
M  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MP  1" #& D(# 1$  A$! Q$!_\0 'P !  (" P$! 0$           <(!@D$
M!0H# 0(+_\0 3A   00" @ $! ,& @8%" L!!0(#! 8!!P ("1$2$Q05%B$7
M(C$:(T%8E]8*&!DD,D)1824S5933-4-25W&!EM5'5&)D97)SA)&3H:+_Q  =
M 0$  @(# 0$             !@<$!0(#" $)_\0 7!$  @(" 0,!!0('#0,'
M" 8+ 0(#!  %$082(1,'%"(Q05%A%1<C,G&!TQ8D,T)2559B<I&4E=0(4Z$E
M0T1C@I*3)C14<Z*QLM$U9'2CP<)%=H.$L[2UTM7A\?_:  P# 0 "$0,1 #\
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M_?G]J'2E/T[*<+5M_,4:'UO.!TBQHAI59IQ (HU%)12,F;*DL9#&RC>Y+MV
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MDR'EJ<>???=4MUYYUQ2EN.N*4MQ:E*4K*LYSRU%5454151% 554!550. JJ
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M+0>1$(QV,^)?H&:;#[* 4G=[=8&[K%V:O[7^;:R8M$PD");ZW9O:N-TV1B[
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MSDDMF6ZO*LL9_5?IO7+:J;\3$:]H-C]S8(NN[!DD=>1HCI38&@"[ VL9*_/
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MQMNT*WT6G3*YN*Q6V<-LAV#?M5[?H=@IM),#Q$N\:6G;AA;2A5\-4;/79 V
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M'+4#IY'ZDW-FV/2K*3+B 8B!7A%AJ9F!#!C&APZ+/KS-=%LKDO%8;Q%]C)>
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MW@]\8(U9KQ$K#!"Y69IA*U+?RCU/0:N"P_'FV<UAO*(<9V-!C>\7*BH<N_\
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MUE[1;@%M*;S&:#7S. RS2O*K^F4/'9;L1-88*@U]2&-))<WZ2;#J(>Z:R/\
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MWE,&*Y:'VB7O@I05D^F ,@VQ@^.@1HB&,MMQC'&,<8QQC'&,<8QQC-47BO\
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M#PKP>'0R"4A@#VJ1G:>6^.T^S_\ Z2-Z;9M3W_XY=K5/0A?_ .]DQA4!+O\
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MC\R6)?'$-=.#)(2? /'"KSX+LH/ Y(V^61X-X@NXZWIK50^13_#AZ<KBU:E
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M=Q0>>!\)Y' X!X# CDDGAN?(^6<*4:MYN\Y-AG8@IAMV5$F2(9.M$F0T8-$
MH<09\JK89$T?\88F.EWQ!$+->A2(,/!T1&%/R'-".DNCX-N.J;72^B?JD55K
M)U-^!Z_X>-619HO03;LM;81Q>@@@CB=YH$C$H:%TD"C9G<;O\'?@5-OL1I3+
MZ[:GWZP-;ZP82"4T>YJS/Z@]0OZ:OW]K!@1SEK,9PK&%)SA258QE*L9QG&<9
MQYXSC./MG&<??&<?;..=V8.=4R !QRSY]@,+8.2HZHDHPS BM%)4568RE1Y,
M]#293[.<PXF?;==6G'PS'EC'M(\NPS3-&L+2R-$I[EB+L8U;XO*H3VJ?B;R
M#\1^TY\[5!+  ,?!( Y/R^9^OR&=MSKS[CC&.,8XQCC&.,91+Q(Z,U=NI&PW
ML,X=GTJ37[P,SE/J]EP06CPBCN,_JG.*X5-I]6/_ $O)7Y<YSRT?8YM#K.O]
M0I;MBV26]7/YX[A8KO) OW\W8*IX^[D>> 8YU77%C26CQRU<Q6$^XQR!7/\
MX3R?_CFG3Q'Y>;K;>M&]EYQ(([[Z?:/M]K(8SZOCK[3AY74=N6XO/GE3V)6O
M(SBO5G*TMOLI6K*TJSSU+[.U]RJ=2:,?#'HNK=W4JQGQV4+DD6VJ  < *4V#
M <  D,0 ",K??'UI=?</EKNKJ2R-_*FB#5I2?OYA!\^>",OA_AU[T\&[6;;H
M#CV6X%XT?,,):]6?2^:I5RK'R_&4^>,94V)LMB6E7WRG&%8Q]EJSB#?[0=%9
MNEM3? YDI;M(>?Y,-VG:]3S]\M:N./K\_H,W/0TW9LK4!/B:H7X^A>&6/CQ]
MRR/Q^O[<]BI ? +0)PHK"B$AA.')'D1T^.S+@SX$UE<:9"FQ)"'&)425'<<8
MDQWVULOLN+:<0I"E)SY"RTLQ776MZ!J*F ]=:NIU=H%$K3,F. J53%1 @$2U
M-G2B<W$(;!:9CLJFDILTC,<2CW)<Z7)ER%N2'W7%,93[_(/0TKBW5JS$F]^1
M=_+["?C1[!54ARQR;](-SJ^JEYL_R%-<E:KF2M"X;0ZDBSKQQ.$SU$6_>4QG
M\9Z*"\ZL5K'\1YV&%=2RW5;)C%8C^[B"5)H)*NOP7SOT?&,J1[> GQ/LN>?N
M9)ISCTY8SE3.CHN6.WA SL6<C&ZM;]J-=R7L5J.I5>8[/[.LNRIQ2.G)G'S%
MRGOV-8F-$<5#0;:AHF//C5NYCML9C]TZ+O6<-:*.2V#\_P!*$;GLO;<75+5;
M17+>1V+L>E6^OFQ,S<6#I>/"HD@]=K!:QP^/K7-C$&)<&/(M9:LC55V8QD:Z
M4ZX=@;MLF5M'?CAVK8IHKJJ/I0@P"U9#L9]_K^2WZ9,1I</6>UMD5IN&;_%P
M.UBUR[0(FECT0^^QKJE5]D/#?8SO-(=,+0(HS%M3/GZBVP,[&V#=6I ]Y'5W
M9<?4NOAX+8VK-::2M8>BW6"#L%5 ZGV3=4MAZELA.*T>N<A8JYEG R)T]C)%
M)],KH;=M$0YOZ0; [?E:W+[_ &"6M!F+%<S6N#3)*-G79T;:!H[6 $V'@A:4
M1$%*UL>=#JH2$L,=&VMXE:IS&8T%\/\ ='66P&W]L0H0TO?-9WI5?H^M&Z '
ML9;7/9;7'8QJR;+K0:[/:\LNRI[VN\4AO8%)H6KUH&6RTF#H&S$YL=,5C.F*
M>'2]9:N$UW:MSH*ZXUQITWIG3 "/K.'#+54&O;&C-MTTE?#LJX$XFR9M6*:
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M;;3E:L(3A2UY2G&5+4E"?//W4K"<>><XQSZ 2> "3]@\G&5)V]NSL=J^XDU
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MC$@75XSB,YQCU)\E)SE&4\]J],#UNI/:!=7S&V\U>O4_3OUW3NL]8<_U9;+
M_8><J/8_!K]'"3\0IV9R/L%B]8*']:QC^[+>> : =,=_1Y%M&5HJFH-DGGU8
MQYX::DI!U=*U9_W<9>LC+?GG_><QC^/(E[=IQ#T')&3P;6WUT"C[2OKVN/\
MNUB?U9L^C$+;H-QSZ=6PY^X'LCY_OD _7GM^YXLRW,<8RJ3/9SIPO9Q8:SMW
M3*MN28$.CG(Z3(/ZU?$@C%A<'UDFK_RFX*%G9]I<A#Y*\PHQ*8;6PA+[\S*F
M,RFK]<^KZJ=+@U#2NF\46^YJ-IEQ E$JK=?LJ:_):L5#+99BC4Q)3%=F.MF:
M@I"?8!27LS J8;KRUK8S(+%UVT);H%:%6G3&L+$+IS!>)5AIFCUPC  0K!)C
MS#P\7#E#G8\0<;FPX4XL.;;Q"(SH,"9,CO28,5UEC/B_U[U!&,-7&KZYU_4=
MDB:OBK5#9 FB51RTTZ+#K<BI@7PLF8*>;QFN@9"@PN/(0Y':!9>K^4?)94F"
MZQF L=>>N="TO1-/;) 4FX4H3:V4"Y&T0E4F?4&U=D60JN>>1$P*@@X=PV%;
M[J?2[%KPP7%E.VB>!'0&!,W([+&9V#U9UYNE>@6.O:[U38:O;PR"0XJ,J=9E
MB#X&PUZEB42HSK,#,:8-+5>AZ_&8RGU,20M0JL+.%0P8QJ,QG;W'16E]AL%8
M]ZU3KZW-'+##MICZ@J00HX1M(^N1J="L4MZ7"=>=-QJC#C55LHISXW%::2!R
M]D5E43+&?!G0&C8ULKU[BZ?UI%N51&B0]6LL6DUV,8KPL .D!P$$--8'MNCF
M  >7,$ DQ<M9#"IDP:-S%A2I##C&2[QC'&,<8QQC'&,H%V7WQV-K'8_0_7CK
MU!TG@IMB@[7NY0YN8=>IX^!C7#U62S"@?1!X5(:R0;/O8<7(ASL86TTI.6TI
M6AR>=-Z+IZST[O>H-^^Y]+57]52C@T\E&.23\(BUR[^^P2J?3,"\!73P3SR>
M"--?N7H[U.C16IW68+4S/:69E7W<Q<*/1=2.[U#R2&^0_7&.K._MEMA+5M9V
M"$H]#NL??'9?K[O*N#H]NM467;>NFN2-Z)3]2GF%#V(0LB/;%'?5=8+ZW!DF
M4$AJ=*-L$'MEM.@ZU2/9V=?-=O4FT?3>_P!)8D:I5=*G4.QCHQQ[:NWJ,\L<
MAE@_>4B@2*L[@1%HUQJ^ZDD:O'.D4,PN;"E;C422AI*,#3LU9P5"J5[7_*J2
M5)0?%P3(H3Q*^O\ 9JG3[;6ZOOL\SLF?,B:M C-)71^T[2B!*^FR6^P:_!JB
MMR+%5Z/"SF-:K$PI J&2PB!"DD7I$7#^OG]G&^K6K=6S9T4!UR(^TGEW5):N
MK>><UZE>_/WE:]J\X[JM=@97BYD=8U5^WO3?TI(XI(X[C^\%A71:DOJ6 D?J
M2O"G ,D<(\22#X W"@L2.>_L'B)=;!,.DD ,[86RH5UUJ/W)E_5FL;E>E5#5
M1,JX"BWF^1! Q<^LC/G,8@+>'R8KMA8F"BC+H5.83N<=%?V?=1RO=CG37ZUZ
M>RDT_&TV5.B+>TBB$[T:+RRA+,GHM'*)%9:[)+$1,>\9V/O*"B(H9[ EKK:Y
MKUYIO2K,_8)I@J]T:EPR]I'?RC#M\9WO7_MPSOC>W9C3\37MKK@_0-CK]?'6
MXH',LB;>@D"'E91!4V8.A01CLYPFS*JPE#LV0<J3<>WLRLP"K$>+T;_I1M'H
M^F]N]^K8DWU:Q8DJ130M+4,<\D21A$D=Y @C*VI2$6"V6J,OJ1,S<J6S%VY?
MJB"6-:3HBRLK!)>Y%<MR5 4GN!C7R7BXE!X;@?-OO)I\S?;/K:JP]A%B8,Y?
M*)%OV-:VU>G)^T->!)QBS4!O8C4+ =1L.F!*C3,N.Q1C\V+(&P"T@A[3#GUN
MB=O!0K[*T^OACF@HWVH'95!N$UE^9(:U\Z\OZOHS&163@/*J,LDD*Q\L V]5
MII*\8G9D>:$3>[R^ZFQ I:2'U^WL[T[2&\A>X%0Q;@&#-:>)QK!6E=,7;<L,
M]%NUUTO7-U[28U7KZXVREZ@I=A,R@$6WW:=%R;DU>JOE(4UJ.J7-*E<1A\XB
M]%P.9^*SN]E[-=G^&=S2T[P-2I;FQIM8VTOTZMS;7*\*6&J4HW]%;5I8G0L$
M2*+ND2,-ZC=N8=?J"N:E26T'$TU2.W8%>"62&K$[E!+,P[_3C+ @=S,W +$=
MHYRPUF[K:?J6V .I3(G:+$NSW,#K>OWW\-;(C51K8=H IL5=IHB^R([ DL5+
MCG&<1I8S$P$W*>3%EEXSK<C#$?K=&[:WJI]K#+K&2M3GV,]'\)5CM(=?5G]W
ML7):"LTL444G/<DO9.54ND+ KW9TFVJQ64K.MCF25($F]!_=WGDC]1(EF(",
MS+QP5Y3N/:6!!XX]>[T]?[4*UD5 E+843M6G[>O0,8/I9XC81%>T8X[#V,[:
M*X.C2S8<@+.-?3$ /B!**G+,XT%$0YDM>4XY6.B-]5EV44\56(ZNYJ*,\CW(
M(X)K&\ ?7"K8D9(9HY8#[S)-ZBQ05@9I711GQ-Q2D6NR-*WO,5J9%6%VD1*9
M(L>I& 71E<>F%[2SR?"H)S$(?B,]>%5K91X[$VO2BVKI&M8AS7URU;9PNRB\
MK<<F1"U9$J=.]B20L,V[SHDF(+@Q,XFQ'&''#<<5&3E_F8_L\Z@]YUL$#ZJ[
M%M%V+P7Z>TK3:V)=0BR;1K5SN6.NE)&5Y7?X'# 0M*Q[<ZAO:/ISNXLQ-7,
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M;1XIMD"5JKD1FM*65,W/J-TNWF*3*MY ;6P.R.WVUUZNC@KB::'$G0]!I"I
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MRAK)2&MJ1[B5^VQFMA@UM\1<M95<]8=NR.P[F_="TJ ?B;IF3]; ZFCK/4+
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MU$;5V#7]G=W'+@?2T3T7X=U&-;HOB7%_]&']DA)(Y^KTM#RLXBO3[7M!6NJ
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M9QG&<9QG&<>>,XSC[9QG'WQG'VSCE59)<_>,8XQF*_0M(S;<7[-.JOUU@?\
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MS JA;TN$!<@@$"1IG<7?U/TU9MH;7Z[ZQU\^Y"U43UL_,[-UMVC61G:<U$?
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M2)LV0Q$AQ&'9,J7*>;CQHT9A"G7Y$A]U2&F6&6TJ<==<6EMM"5+6K"<9SC5
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MTKYYN?IZ*(6*H)^)*6?2+2Y!*RUEO'J>D3==N.J>G68(VG"U+J[[DBR#_3C
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M;/M>(WSI*52J@[740HHGWL-&DRUR'B Y36&G&,KS1-)4#M)NKO84&&+96 @
MNUU\@LR8PA4BK[S$AM;$-L;9K0Q+A(9(#6B)J[K<@= )OI>(S*);7BPV BV3
M$R6,L)=.G5WVN;&6S;.^&[%91P>S@8[%;UC&JE/$B;!LOJSL=D=60$NZV8Y
MB1YO61&2&;!;[7/)&=BGRD:>)$" M7:8RT.O-8L4"S;KLC)ATFO<NTH>SI,1
MR$B*D _#U)JO5. [#R9+^2+3C&KV#>9KC<1:7C+L'X;*(2)4EC)2XQCC&.,8
BXQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQG_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
